(lp0
(dp1
S'line'
p2
VOur results demonstrated that hsa-miR-483-5p, hsa-miR-675, hsa-miR-139-3p, hsa-miR-598, hsa-miR-625 and hsa-miR-187 could serve as prognostic and predictive markers for survival of BDC patients and could potentially be provided as targets for future therapy.
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I104
sS'lengthInWords'
p8
I1
sS'lengthInChars'
p9
I11
sS'uniprot'
p10
S''
p11
sS'name'
p12
Vhsa-miR-187
p13
sa(dp14
g7
I75
sg8
I1
sg9
I11
sg10
g11
sg12
Vhsa-miR-598
p15
sa(dp16
g7
I46
sg8
I1
sg9
I11
sg10
g11
sg12
Vhsa-miR-675
p17
sa(dp18
g7
I30
sg8
I1
sg9
I14
sg10
g11
sg12
Vhsa-miR-483-5p
p19
sa(dp20
g7
I88
sg8
I1
sg9
I11
sg10
g11
sg12
Vhsa-miR-625
p21
sa(dp22
g7
I59
sg8
I1
sg9
I14
sg10
g11
sg12
Vhsa-miR-139-3p
p23
sasS'diseases'
p24
(lp25
(dp26
g7
I30
sg8
I1
sg9
I3
sS'cui'
p27
VC0393754
p28
sg12
Vhsa
p29
sa(dp30
g7
I30
sg8
I1
sg9
I3
sg27
VC0393754
p31
sg12
Vhsa
p32
sa(dp33
g7
I30
sg8
I1
sg9
I3
sg27
VC0393754
p34
sg12
Vhsa
p35
sa(dp36
g7
I181
sg8
I1
sg9
I3
sg27
VC1266044
p37
sg12
VBDC
p38
sa(dp39
g7
I30
sg8
I1
sg9
I3
sg27
VC0393754
p40
sg12
Vhsa
p41
sa(dp42
g7
I30
sg8
I1
sg9
I3
sg27
VC0393754
p43
sg12
Vhsa
p44
sa(dp45
g7
I30
sg8
I1
sg9
I3
sg27
VC0393754
p46
sg12
Vhsa
p47
sasa(dp48
g2
VTargeting the centromeres of chromosomes 3, 7, 17 (CEP3, 7, 17) and the 9p21-locus (LSI9p21) for diagnosing bladder cancer (BC) is time- and cost-intensive and requires a manual investigation of the sample by a well-trained investigator thus overall limiting its use in clinical diagnostics and large-scaled epidemiological studies.
p49
sg4
(lp50
sg24
(lp51
(dp52
g7
I108
sg8
I2
sg9
I14
sg27
VC0699885
p53
sg12
Vbladder cancer
p54
sa(dp55
g7
I124
sg8
I1
sg9
I2
sg27
VC0699885
p56
sg12
VBC
p57
sasa(dp58
g2
VOssification of the ligamentum flavum (OLF) causing compressive cervical myelopathy or radiculopathy is rare.
p59
sg4
(lp60
sg24
(lp61
(dp62
g7
I87
sg8
I1
sg9
I13
sg27
VC0700594
p63
sg12
Vradiculopathy
p64
sa(dp65
g7
I64
sg8
I2
sg9
I19
sg27
VC0149645
p66
sg12
Vcervical myelopathy
p67
sasa(dp68
g2
VHowever, thoracic OLF rarely causes radiculopathy.
p69
sg4
(lp70
sg24
(lp71
(dp72
g7
I36
sg8
I1
sg9
I13
sg27
VC0700594
p73
sg12
Vradiculopathy
p74
sa(dp75
g7
I9
sg8
I1
sg9
I8
sg27
VC0729233
p76
sg12
Vthoracic
p77
sasa(dp78
g2
VWe report a rare case of thoracic radiculopathy caused by OLF.
p79
sg4
(lp80
sg24
(lp81
(dp82
g7
I25
sg8
I2
sg9
I22
sg27
VC0154737
p83
sg12
Vthoracic radiculopathy
p84
sasa(dp85
g2
VThoracic radiculopathy caused by OLF was suspected.
p86
sg4
(lp87
sg24
(lp88
(dp89
g7
I0
sg8
I2
sg9
I22
sg27
VC0154737
p90
sg12
VThoracic radiculopathy
p91
sasa(dp92
g2
VThoracic OLF rarely causes radiculopathy, but it should be considered as a differential diagnosis of thoracic radicular pain.
p93
sg4
(lp94
sg24
(lp95
(dp96
g7
I101
sg8
I1
sg9
I8
sg27
VC0729233
p97
sg12
Vthoracic
p98
sa(dp99
g7
I0
sg8
I1
sg9
I8
sg27
VC0729233
p100
sg12
VThoracic
p101
sa(dp102
g7
I27
sg8
I1
sg9
I13
sg27
VC0700594
p103
sg12
Vradiculopathy
p104
sa(dp105
g7
I110
sg8
I2
sg9
I14
sg27
VC0278147
p106
sg12
Vradicular pain
p107
sasa(dp108
g2
VOLF should be kept in mind if a patient presents with radiculopathy, particularly in the cervical region, for which surgical intervention is contemplated.
p109
sg4
(lp110
(dp111
g7
I0
sg8
I1
sg9
I3
sg10
g11
sg12
VOLF
p112
sasg24
(lp113
(dp114
g7
I54
sg8
I1
sg9
I13
sg27
VC0700594
p115
sg12
Vradiculopathy
p116
sasa(dp117
g2
VRadiculopathy resulting from ossification of the ligamentum flavum (OLF) is extremely rare and concerns only intercostal neuralgias.
p118
sg4
(lp119
sg24
(lp120
(dp121
g7
I121
sg8
I1
sg9
I10
sg27
VC0027796
p122
sg12
Vneuralgias
p123
sa(dp124
g7
I0
sg8
I1
sg9
I13
sg27
VC0700594
p125
sg12
VRadiculopathy
p126
sasa(dp127
g2
VWe describe a 37-year-old Caucasian woman with a lumbar radiculopathy revealing an OLF.
p128
sg4
(lp129
sg24
(lp130
(dp131
g7
I49
sg8
I2
sg9
I20
sg27
VC1263855
p132
sg12
Vlumbar radiculopathy
p133
sasa(dp134
g2
VPancreatitis was induced in C57Bl/6 wild-type (control), cathepsin B-knockout, and cathepsin L-knockout mice by partial pancreatic duct ligation with supramaximal caerulein injection, or by repetitive supramaximal caerulein injections alone.
p135
sg4
(lp136
(dp137
g7
I57
sg8
I2
sg9
I11
sg10
VP07858
p138
sg12
Vcathepsin B
p139
sa(dp140
g7
I83
sg8
I2
sg9
I11
sg10
VP07711
p141
sg12
Vcathepsin L
p142
sasg24
(lp143
(dp144
g7
I0
sg8
I1
sg9
I12
sg27
VC0030305
p145
sg12
VPancreatitis
p146
sasa(dp147
g2
VTrypsinogen became activated in macrophages cultured with purified trypsinogen or co-cultured with pancreatic acini and in pancreata of mice with pancreatitis; trypsinogen activation required macrophage endocytosis and expression and activity of cathepsin B, and was sensitive to pH.
p148
sg4
(lp149
(dp150
g7
I67
sg8
I1
sg9
I11
sg10
VP07478
p151
sg12
Vtrypsinogen
p152
sa(dp153
g7
I246
sg8
I2
sg9
I11
sg10
VP07858
p154
sg12
Vcathepsin B
p155
sa(dp156
g7
I67
sg8
I1
sg9
I11
sg10
VP07478
p157
sg12
Vtrypsinogen
p158
sa(dp159
g7
I0
sg8
I1
sg9
I11
sg10
VP07478
p160
sg12
VTrypsinogen
p161
sasg24
(lp162
(dp163
g7
I146
sg8
I1
sg9
I12
sg27
VC0030305
p164
sg12
Vpancreatitis
p165
sasa(dp166
g2
VActivation of trypsinogen in macrophages resulted in translocation of NF-kB and production of inflammatory cytokines; mice without trypsinogen activation (cathepsin B-knockout mice) in macrophages developed less severe pancreatitis compared with control mice.
p167
sg4
(lp168
(dp169
g7
I131
sg8
I2
sg9
I22
sg10
VP07478
p170
sg12
Vtrypsinogen activation
p171
sa(dp172
g7
I14
sg8
I1
sg9
I11
sg10
VP07478
p173
sg12
Vtrypsinogen
p174
sa(dp175
g7
I155
sg8
I2
sg9
I11
sg10
VP07858
p176
sg12
Vcathepsin B
p177
sasg24
(lp178
(dp179
g7
I53
sg8
I1
sg9
I13
sg27
VC0040715
p180
sg12
Vtranslocation
p181
sa(dp182
g7
I219
sg8
I1
sg9
I12
sg27
VC0030305
p183
sg12
Vpancreatitis
p184
sasa(dp185
g2
VTransfer of macrophage from control mice to cathepsin B-knockout mice increased the severity of pancreatitis.
p186
sg4
(lp187
(dp188
g7
I44
sg8
I2
sg9
I11
sg10
VP07858
p189
sg12
Vcathepsin B
p190
sasg24
(lp191
(dp192
g7
I96
sg8
I1
sg9
I12
sg27
VC0030305
p193
sg12
Vpancreatitis
p194
sasa(dp195
g2
VExperimental studies in acute pancreatitis (AP) suggest a strong association of acinar cell injury with cathepsin B-dependent intracellular activation of trypsin.
p196
sg4
(lp197
(dp198
g7
I154
sg8
I1
sg9
I7
sg10
VP35030
p199
sg12
Vtrypsin
p200
sasg24
(lp201
(dp202
g7
I44
sg8
I1
sg9
I2
sg27
VC0001339
p203
sg12
VAP
p204
sa(dp205
g7
I87
sg8
I2
sg9
I11
sg27
VC0599732
p206
sg12
Vcell injury
p207
sa(dp208
g7
I24
sg8
I2
sg9
I18
sg27
VC0001339
p209
sg12
Vacute pancreatitis
p210
sasa(dp211
g2
VPancreas, lung, and serum was harvested up to 48 h after pancreatitis induction and used for histopathology, amylase, lipase, cathepsin B, trypsin, and elastase activity measurements, myeloperoxidase (MPO) content and cytokine concentrations.
p212
sg4
(lp213
(dp214
g7
I126
sg8
I2
sg9
I11
sg10
VP07858
p215
sg12
Vcathepsin B
p216
sa(dp217
g7
I152
sg8
I1
sg9
I8
sg10
VP30740
p218
sg12
Velastase
p219
sa(dp220
g7
I184
sg8
I1
sg9
I15
sg10
VP05164
p221
sg12
Vmyeloperoxidase
p222
sa(dp223
g7
I118
sg8
I1
sg9
I6
sg10
VP04118
p224
sg12
Vlipase
p225
sa(dp226
g7
I201
sg8
I1
sg9
I3
sg10
VP05164
p227
sg12
VMPO
p228
sa(dp229
g7
I109
sg8
I1
sg9
I7
sg10
VP04746
p230
sg12
Vamylase
p231
sa(dp232
g7
I139
sg8
I1
sg9
I7
sg10
VP35030
p233
sg12
Vtrypsin
p234
sasg24
(lp235
(dp236
g7
I57
sg8
I1
sg9
I12
sg27
VC0030305
p237
sg12
Vpancreatitis
p238
sasa(dp239
g2
VIn taurocholate-pancreatitis AZD8309 reduced cathepsin B activity and MPO.
p240
sg4
(lp241
(dp242
g7
I45
sg8
I2
sg9
I11
sg10
VP07858
p243
sg12
Vcathepsin B
p244
sa(dp245
g7
I70
sg8
I1
sg9
I3
sg10
VP05164
p246
sg12
VMPO
p247
sasg24
(lp248
(dp249
g7
I16
sg8
I1
sg9
I12
sg27
VC0030305
p250
sg12
Vpancreatitis
p251
sasa(dp252
g2
VThe lysosomal hydrolase cathepsin B (CTSB) is a known activator of trypsinogen, and its deletion reduces disease severity in experimental pancreatitis.
p253
sg4
(lp254
(dp255
g7
I4
sg8
I4
sg9
I31
sg10
VP07858
p256
sg12
Vlysosomal hydrolase cathepsin B
p257
sa(dp258
g7
I37
sg8
I1
sg9
I4
sg10
VP07858
p259
sg12
VCTSB
p260
sa(dp261
g7
I67
sg8
I1
sg9
I11
sg10
VP07478
p262
sg12
Vtrypsinogen
p263
sasg24
(lp264
(dp265
g7
I138
sg8
I1
sg9
I12
sg27
VC0030305
p266
sg12
Vpancreatitis
p267
sasa(dp268
g2
VIn summary, CTSB in pancreatitis undergoes activation in a secretory, vesicular, and acidic compartment where it activates trypsinogen.
p269
sg4
(lp270
(dp271
g7
I123
sg8
I1
sg9
I11
sg10
VP07478
p272
sg12
Vtrypsinogen
p273
sasg24
(lp274
(dp275
g7
I20
sg8
I1
sg9
I12
sg27
VC0030305
p276
sg12
Vpancreatitis
p277
sasa(dp278
g2
VC3F was also significantly increased in 20 chronic renal failure (CRF) patients as compared to 196 controls; this would support the existence of functional differences between C3F and C3S alleles.
p279
sg4
(lp280
(dp281
g7
I0
sg8
I1
sg9
I3
sg10
g11
sg12
VC3F
p282
sa(dp283
g7
I0
sg8
I1
sg9
I3
sg10
g11
sg12
VC3F
p284
sasg24
(lp285
(dp286
g7
I66
sg8
I1
sg9
I3
sg27
VC0022661
p287
sg12
VCRF
p288
sa(dp289
g7
I43
sg8
I3
sg9
I21
sg27
VC0022661
p290
sg12
Vchronic renal failure
p291
sasa(dp292
g2
VEctopic expression of Fgfr2c, a gene implicated in craniosynostosis in mice and humans, and that of Runx2 was detected within the affected sutures of Bcl11b(-/-) mice.
p293
sg4
(lp294
(dp295
g7
I150
sg8
I1
sg9
I11
sg10
g11
sg12
VBcl11b(-/-)
p296
sa(dp297
g7
I100
sg8
I1
sg9
I5
sg10
g11
sg12
VRunx2
p298
sasg24
(lp299
(dp300
g7
I51
sg8
I1
sg9
I16
sg27
VC0010278
p301
sg12
Vcraniosynostosis
p302
sasa(dp303
g2
VThese data suggest that ectopic expression of Fgfr2c in the sutural mesenchyme, without concomitant changes in the expression of FGF ligands, appears to induce the RUNX2-dependent osteogenic program and craniosynostosis in Bcl11b(-/-) mice.
p304
sg4
(lp305
(dp306
g7
I223
sg8
I1
sg9
I11
sg10
g11
sg12
VBcl11b(-/-)
p307
sa(dp308
g7
I129
sg8
I2
sg9
I11
sg10
g11
sg12
VFGF ligands
p309
sa(dp310
g7
I164
sg8
I1
sg9
I5
sg10
g11
sg12
VRUNX2
p311
sasg24
(lp312
(dp313
g7
I203
sg8
I1
sg9
I16
sg27
VC0010278
p314
sg12
Vcraniosynostosis
p315
sasa(dp316
g2
V(2) An analysis of all published HLA data for patients of European origin indicated a weak association of pernicious anemia with HLA-B7.
p317
sg4
(lp318
(dp319
g7
I129
sg8
I1
sg9
I6
sg10
VP30486
p320
sg12
VHLA-B7
p321
sa(dp322
g7
I33
sg8
I1
sg9
I3
sg10
VP30486
p323
sg12
VHLA
p324
sasg24
(lp325
(dp326
g7
I106
sg8
I2
sg9
I17
sg27
VC0002892
p327
sg12
Vpernicious anemia
p328
sasa(dp329
g2
VSpecifically, studies have demonstrated miR-221/-222 function as oncogenes, and promote PCa cell proliferation and the development of castration-resistant prostate cancer (CRPC).
p330
sg4
(lp331
sg24
(lp332
(dp333
g7
I88
sg8
I1
sg9
I3
sg27
VC0268398
p334
sg12
VPCa
p335
sa(dp336
g7
I155
sg8
I2
sg9
I15
sg27
VC0600139
p337
sg12
Vprostate cancer
p338
sa(dp339
g7
I97
sg8
I1
sg9
I13
sg27
VC0334094
p340
sg12
Vproliferation
p341
sasa(dp342
g2
VSOCS3 was found significantly declined, while microRNA-221 (miR-221) obviously up-regulated in bladder cancer tissue.
p343
sg4
(lp344
(dp345
g7
I0
sg8
I1
sg9
I5
sg10
g11
sg12
VSOCS3
p346
sasg24
(lp347
(dp348
g7
I95
sg8
I2
sg9
I14
sg27
VC0699885
p349
sg12
Vbladder cancer
p350
sasa(dp351
g2
VThis study investigated the role of miR-221 in regulating SOCS3/JAK-STAT3 signaling pathway and bladder cancer cell proliferation and apoptosis.
p352
sg4
(lp353
(dp354
g7
I68
sg8
I1
sg9
I5
sg10
VP40763
p355
sg12
VSTAT3
p356
sa(dp357
g7
I58
sg8
I1
sg9
I5
sg10
g11
sg12
VSOCS3
p358
sa(dp359
g7
I36
sg8
I1
sg9
I7
sg10
g11
sg12
VmiR-221
p360
sasg24
(lp361
(dp362
g7
I96
sg8
I2
sg9
I14
sg27
VC0699885
p363
sg12
Vbladder cancer
p364
sa(dp365
g7
I116
sg8
I1
sg9
I13
sg27
VC0334094
p366
sg12
Vproliferation
p367
sasa(dp368
g2
VBladder cancer tumor tissue and para-carcinoma tissue were collected from patients to test miR-221 and SOCS3 expressions.
p369
sg4
(lp370
(dp371
g7
I91
sg8
I1
sg9
I7
sg10
g11
sg12
VmiR-221
p372
sa(dp373
g7
I103
sg8
I1
sg9
I5
sg10
g11
sg12
VSOCS3
p374
sasg24
(lp375
(dp376
g7
I0
sg8
I2
sg9
I14
sg27
VC0699885
p377
sg12
VBladder cancer
p378
sa(dp379
g7
I15
sg8
I1
sg9
I5
sg27
VC0027651
p380
sg12
Vtumor
p381
sa(dp382
g7
I37
sg8
I1
sg9
I9
sg27
VC0007097
p383
sg12
Vcarcinoma
p384
sasa(dp385
g2
VMiR-221 significantly increased, while SOCS3 obviously reduced in bladder cancer tissue compared with para-carcinoma tissue.
p386
sg4
(lp387
(dp388
g7
I0
sg8
I1
sg9
I7
sg10
g11
sg12
VMiR-221
p389
sa(dp390
g7
I39
sg8
I1
sg9
I5
sg10
g11
sg12
VSOCS3
p391
sasg24
(lp392
(dp393
g7
I107
sg8
I1
sg9
I9
sg27
VC0007097
p394
sg12
Vcarcinoma
p395
sa(dp396
g7
I66
sg8
I2
sg9
I14
sg27
VC0699885
p397
sg12
Vbladder cancer
p398
sasa(dp399
g2
VMiR-221 elevated, while SOCS3 reduced in bladder cancer tissue.
p400
sg4
(lp401
(dp402
g7
I0
sg8
I4
sg9
I29
sg10
g11
sg12
VMiR-221 elevated, while SOCS3
p403
sasg24
(lp404
(dp405
g7
I41
sg8
I2
sg9
I14
sg27
VC0699885
p406
sg12
Vbladder cancer
p407
sasa(dp408
g2
VAs miR-221 targets several regulators of the PI3K-AKT-mTOR pathway and a link between this pathway and CD44 has been previously shown in prostate cancer, we considered miR-221 regulation of CD44 may be through this pathway.
p409
sg4
(lp410
(dp411
g7
I54
sg8
I1
sg9
I4
sg10
VP42345
p412
sg12
VmTOR
p413
sa(dp414
g7
I50
sg8
I1
sg9
I3
sg10
g11
sg12
VAKT
p415
sa(dp416
g7
I45
sg8
I1
sg9
I4
sg10
VP42336
p417
sg12
VPI3K
p418
sasg24
(lp419
(dp420
g7
I137
sg8
I2
sg9
I15
sg27
VC0600139
p421
sg12
Vprostate cancer
p422
sasa(dp423
g2
VThe aim of our study was to evaluate the relationship of TMPRSS2-ERG fusion gene status, tumor tissue prostate-specific antigen (PSA), prostate cancer antigen 3 (PCA3), miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy.
p424
sg4
(lp425
(dp426
g7
I249
sg8
I2
sg9
I9
sg10
VP55786
p427
sg12
Vserum PSA
p428
sa(dp429
g7
I190
sg8
I1
sg9
I7
sg10
g11
sg12
VmiR-221
p430
sa(dp431
g7
I65
sg8
I1
sg9
I3
sg10
VP11308
p432
sg12
VERG
p433
sa(dp434
g7
I162
sg8
I1
sg9
I4
sg10
VP78358
p435
sg12
VPCA3
p436
sa(dp437
g7
I129
sg8
I1
sg9
I3
sg10
VP55786
p438
sg12
VPSA
p439
sa(dp440
g7
I89
sg8
I4
sg9
I38
sg10
VP07288
p441
sg12
Vtumor tissue prostate-specific antigen
p442
sa(dp443
g7
I135
sg8
I4
sg9
I25
sg10
VP78358
p444
sg12
Vprostate cancer antigen 3
p445
sa(dp446
g7
I178
sg8
I1
sg9
I7
sg10
g11
sg12
VmiR-26a
p447
sa(dp448
g7
I57
sg8
I1
sg9
I7
sg10
g11
sg12
VTMPRSS2
p449
sa(dp450
g7
I169
sg8
I1
sg9
I7
sg10
g11
sg12
VmiR-23b
p451
sasg24
(lp452
(dp453
g7
I280
sg8
I1
sg9
I3
sg27
VC0268398
p454
sg12
VPCa
p455
sa(dp456
g7
I89
sg8
I1
sg9
I5
sg27
VC0027651
p457
sg12
Vtumor
p458
sa(dp459
g7
I284
sg8
I1
sg9
I10
sg27
VC1458156
p460
sg12
Vrecurrence
p461
sa(dp462
g7
I135
sg8
I2
sg9
I15
sg27
VC0600139
p463
sg12
Vprostate cancer
p464
sa(dp465
g7
I129
sg8
I1
sg9
I3
sg27
VC1519176
p466
sg12
VPSA
p467
sa(dp468
g7
I102
sg8
I2
sg9
I25
sg27
VC1519176
p469
sg12
Vprostate-specific antigen
p470
sa(dp471
g7
I129
sg8
I1
sg9
I3
sg27
VC1519176
p472
sg12
VPSA
p473
sasa(dp474
g2
VOnly 5 genes were significantly up-regulated in MS patients vs control subjects; namely TNF-AIP6, IL-1RA, OASL, CLC and DOCK4 (p &lt; 0.05).
p475
sg4
(lp476
(dp477
g7
I88
sg8
I1
sg9
I8
sg10
VP01375
p478
sg12
VTNF-AIP6
p479
sa(dp480
g7
I120
sg8
I1
sg9
I5
sg10
g11
sg12
VDOCK4
p481
sa(dp482
g7
I106
sg8
I1
sg9
I4
sg10
g11
sg12
VOASL
p483
sa(dp484
g7
I112
sg8
I1
sg9
I3
sg10
g11
sg12
VCLC
p485
sa(dp486
g7
I98
sg8
I1
sg9
I6
sg10
VP18510
p487
sg12
VIL-1RA
p488
sasg24
(lp489
sa(dp490
g2
VAnalysis of the effector molecules of the up-regulated genes revealed that 83 MS patients had positive serum level of OASL, 87 MS patients had positive serum levels of IL-1RA, and none of the 88 MS patients showed detectable serum levels of TNF-AIP6, CLC or DOCK4.
p491
sg4
(lp492
(dp493
g7
I258
sg8
I1
sg9
I5
sg10
g11
sg12
VDOCK4
p494
sa(dp495
g7
I168
sg8
I1
sg9
I6
sg10
VP18510
p496
sg12
VIL-1RA
p497
sa(dp498
g7
I241
sg8
I1
sg9
I3
sg10
VP01375
p499
sg12
VTNF
p500
sa(dp501
g7
I251
sg8
I1
sg9
I3
sg10
g11
sg12
VCLC
p502
sasg24
(lp503
sa(dp504
g2
VOASL and IL-1RA genes were strongly expressed in MS patients and that their effector molecules may be considered as biomarkers associated with the inflammatory process of the disease and possibly treatment response.
p505
sg4
(lp506
(dp507
g7
I0
sg8
I1
sg9
I4
sg10
g11
sg12
VOASL
p508
sa(dp509
g7
I9
sg8
I2
sg9
I12
sg10
VP18510
p510
sg12
VIL-1RA genes
p511
sasg24
(lp512
sa(dp513
g2
VHowever, IRF1, IFNK and viral restriction factors (IFIT1, 2, 3, 5, OASL, CD74, RTP4) were up-regulated.
p514
sg4
(lp515
(dp516
g7
I73
sg8
I1
sg9
I4
sg10
VP04233
p517
sg12
VCD74
p518
sa(dp519
g7
I51
sg8
I1
sg9
I5
sg10
VP09914
p520
sg12
VIFIT1
p521
sa(dp522
g7
I9
sg8
I1
sg9
I4
sg10
VP10914
p523
sg12
VIRF1
p524
sa(dp525
g7
I79
sg8
I1
sg9
I4
sg10
g11
sg12
VRTP4
p526
sa(dp527
g7
I67
sg8
I1
sg9
I4
sg10
g11
sg12
VOASL
p528
sa(dp529
g7
I24
sg8
I3
sg9
I25
sg10
VP19883
p530
sg12
Vviral restriction factors
p531
sa(dp532
g7
I15
sg8
I1
sg9
I4
sg10
g11
sg12
VIFNK
p533
sasg24
(lp534
sa(dp535
g2
VThe signature's genes are: Interferon Stimulated Gene 15 (ISG15), Interleukin 16 (IL16), 2',5'-Oligoadenylate Synthetase Like (OASL), and Adhesion G Protein Coupled Receptor E5 (ADGRE5).
p536
sg4
(lp537
(dp538
g7
I127
sg8
I1
sg9
I4
sg10
g11
sg12
VOASL
p539
sa(dp540
g7
I66
sg8
I2
sg9
I14
sg10
g11
sg12
VInterleukin 16
p541
sa(dp542
g7
I89
sg8
I3
sg9
I36
sg10
g11
sg12
V2',5'-Oligoadenylate Synthetase Like
p543
sa(dp544
g7
I82
sg8
I1
sg9
I4
sg10
g11
sg12
VIL16
p545
sa(dp546
g7
I27
sg8
I4
sg9
I29
sg10
g11
sg12
VInterferon Stimulated Gene 15
p547
sa(dp548
g7
I58
sg8
I1
sg9
I5
sg10
VP05161
p549
sg12
VISG15
p550
sasg24
(lp551
(dp552
g7
I138
sg8
I1
sg9
I8
sg27
VC0001511
p553
sg12
VAdhesion
p554
sasa(dp555
g2
VPrevious work has identified that following viral infection, type I IFN signaling induces the production of the 2'-5'-oligoadenylate synthetase (OAS) family, which include OAS1, OAS2, OAS3, and OAS-like (OASL) protein.
p556
sg4
(lp557
(dp558
g7
I68
sg8
I1
sg9
I3
sg10
VP01562
p559
sg12
VIFN
p560
sa(dp561
g7
I194
sg8
I1
sg9
I8
sg10
g11
sg12
VOAS-like
p562
sa(dp563
g7
I112
sg8
I2
sg9
I31
sg10
g11
sg12
V2'-5'-oligoadenylate synthetase
p564
sa(dp565
g7
I204
sg8
I1
sg9
I4
sg10
g11
sg12
VOASL
p566
sa(dp567
g7
I184
sg8
I1
sg9
I4
sg10
g11
sg12
VOAS3
p568
sa(dp569
g7
I178
sg8
I1
sg9
I4
sg10
VP29728
p570
sg12
VOAS2
p571
sa(dp572
g7
I145
sg8
I1
sg9
I3
sg10
g11
sg12
VOAS
p573
sasg24
(lp574
(dp575
g7
I145
sg8
I1
sg9
I3
sg27
VC0599973
p576
sg12
VOAS
p577
sa(dp578
g7
I112
sg8
I2
sg9
I31
sg27
VC0599973
p579
sg12
V2'-5'-oligoadenylate synthetase
p580
sa(dp581
g7
I145
sg8
I1
sg9
I3
sg27
VC0599973
p582
sg12
VOAS
p583
sa(dp584
g7
I44
sg8
I2
sg9
I15
sg27
VC0042769
p585
sg12
Vviral infection
p586
sasa(dp587
g2
VOASL was identified to be strongly induced following viral infection through engaging the RNA sensor RIG-I and increasing signaling through this pathway to enhance the anti-viral type I IFN response.
p588
sg4
(lp589
(dp590
g7
I0
sg8
I1
sg9
I4
sg10
g11
sg12
VOASL
p591
sa(dp592
g7
I101
sg8
I1
sg9
I5
sg10
g11
sg12
VRIG-I
p593
sa(dp594
g7
I186
sg8
I1
sg9
I3
sg10
VP01562
p595
sg12
VIFN
p596
sasg24
(lp597
(dp598
g7
I53
sg8
I2
sg9
I15
sg27
VC0042769
p599
sg12
Vviral infection
p600
sasa(dp601
g2
VSurprisingly, infection with viral dsDNA revealed an IFN inhibitory role and therefore pro-viral function of OASL through the inhibition of the cGAS cytosolic DNA sensing mechanism.
p602
sg4
(lp603
(dp604
g7
I53
sg8
I1
sg9
I3
sg10
VP01562
p605
sg12
VIFN
p606
sa(dp607
g7
I109
sg8
I1
sg9
I4
sg10
g11
sg12
VOASL
p608
sasg24
(lp609
(dp610
g7
I14
sg8
I1
sg9
I9
sg27
VC0009450
p611
sg12
Vinfection
p612
sasa(dp613
g2
VIntracellular bacteria are able to activate the cytosolic DNA sensing pathway, however the role of OASL during bacterial infection is largely unknown.
p614
sg4
(lp615
(dp616
g7
I99
sg8
I1
sg9
I4
sg10
g11
sg12
VOASL
p617
sasg24
(lp618
(dp619
g7
I111
sg8
I2
sg9
I19
sg27
VC0004623
p620
sg12
Vbacterial infection
p621
sasa(dp622
g2
VVacuolar pathogenic microbes such as mycobacteria induce OASL early post infection, where it functions in a prosurvival fashion by inhibiting autophagic mechanisms and antimicrobial peptide expression.
p623
sg4
(lp624
(dp625
g7
I57
sg8
I1
sg9
I4
sg10
g11
sg12
VOASL
p626
sasg24
(lp627
(dp628
g7
I73
sg8
I1
sg9
I9
sg27
VC0009450
p629
sg12
Vinfection
p630
sasa(dp631
g2
VThis suggests an underestimated role of OASL in the innate immune response to infection with a variety of pathogens and points to OASL-associated modulation of the type I IFN response.
p632
sg4
(lp633
(dp634
g7
I40
sg8
I1
sg9
I4
sg10
g11
sg12
VOASL
p635
sa(dp636
g7
I40
sg8
I1
sg9
I4
sg10
g11
sg12
VOASL
p637
sa(dp638
g7
I164
sg8
I3
sg9
I10
sg10
VP01562
p639
sg12
Vtype I IFN
p640
sasg24
(lp641
(dp642
g7
I78
sg8
I1
sg9
I9
sg27
VC0009450
p643
sg12
Vinfection
p644
sa(dp645
g7
I52
sg8
I3
sg9
I22
sg27
VC1155265
p646
sg12
Vinnate immune response
p647
sasa(dp648
g2
VOASL may therefore play a critical role in defining the outcome of infection.
p649
sg4
(lp650
(dp651
g7
I0
sg8
I1
sg9
I4
sg10
g11
sg12
VOASL
p652
sasg24
(lp653
(dp654
g7
I67
sg8
I1
sg9
I9
sg27
VC0009450
p655
sg12
Vinfection
p656
sasa(dp657
g2
VWe earlier nominated 16 genes (IRF7, IFIT1, IFIT5, OASL, CLC, GBP-1, PSMB9, HERC5, CCR1, CD36, MS4A4A, BIRC4BP, PLSCR1, DEFA1/DEFA3, DEFA4, and COL9A2) as predictors of response to remission induction therapy against MPA.
p658
sg4
(lp659
(dp660
g7
I120
sg8
I1
sg9
I5
sg10
VP59665
p661
sg12
VDEFA1
p662
sa(dp663
g7
I31
sg8
I1
sg9
I4
sg10
g11
sg12
VIRF7
p664
sa(dp665
g7
I57
sg8
I1
sg9
I3
sg10
g11
sg12
VCLC
p666
sa(dp667
g7
I83
sg8
I1
sg9
I4
sg10
VP32246
p668
sg12
VCCR1
p669
sa(dp670
g7
I144
sg8
I1
sg9
I6
sg10
g11
sg12
VCOL9A2
p671
sa(dp672
g7
I112
sg8
I1
sg9
I6
sg10
g11
sg12
VPLSCR1
p673
sa(dp674
g7
I133
sg8
I1
sg9
I5
sg10
VP12838
p675
sg12
VDEFA4
p676
sa(dp677
g7
I103
sg8
I1
sg9
I7
sg10
g11
sg12
VBIRC4BP
p678
sa(dp679
g7
I126
sg8
I1
sg9
I5
sg10
VP59665
p680
sg12
VDEFA3
p681
sa(dp682
g7
I76
sg8
I1
sg9
I5
sg10
g11
sg12
VHERC5
p683
sa(dp684
g7
I37
sg8
I1
sg9
I5
sg10
VP09914
p685
sg12
VIFIT1
p686
sa(dp687
g7
I51
sg8
I1
sg9
I4
sg10
g11
sg12
VOASL
p688
sa(dp689
g7
I44
sg8
I1
sg9
I5
sg10
g11
sg12
VIFIT5
p690
sa(dp691
g7
I69
sg8
I1
sg9
I5
sg10
VP28065
p692
sg12
VPSMB9
p693
sa(dp694
g7
I62
sg8
I1
sg9
I5
sg10
VP32455
p695
sg12
VGBP-1
p696
sa(dp697
g7
I95
sg8
I1
sg9
I6
sg10
g11
sg12
VMS4A4A
p698
sasg24
(lp699
(dp700
g7
I181
sg8
I1
sg9
I9
sg27
VC0687702
p701
sg12
Vremission
p702
sasa(dp703
g2
VThe 2'5'-oligoadenylate synthetase (OAS) is an interferon (IFN)-induced protein that plays an important role in the antiviral action of IFN, with OAS3 being one of the four OAS classes (OAS1, OAS2, OAS3, OASL).
p704
sg4
(lp705
(dp706
g7
I146
sg8
I1
sg9
I4
sg10
g11
sg12
VOAS3
p707
sa(dp708
g7
I4
sg8
I2
sg9
I30
sg10
g11
sg12
V2'5'-oligoadenylate synthetase
p709
sa(dp710
g7
I47
sg8
I1
sg9
I10
sg10
VP01563
p711
sg12
Vinterferon
p712
sa(dp713
g7
I59
sg8
I1
sg9
I3
sg10
VP01562
p714
sg12
VIFN
p715
sa(dp716
g7
I146
sg8
I1
sg9
I4
sg10
g11
sg12
VOAS3
p717
sa(dp718
g7
I204
sg8
I1
sg9
I4
sg10
g11
sg12
VOASL
p719
sa(dp720
g7
I36
sg8
I1
sg9
I3
sg10
g11
sg12
VOAS
p721
sa(dp722
g7
I192
sg8
I1
sg9
I4
sg10
VP29728
p723
sg12
VOAS2
p724
sa(dp725
g7
I59
sg8
I1
sg9
I3
sg10
VP01562
p726
sg12
VIFN
p727
sa(dp728
g7
I36
sg8
I1
sg9
I3
sg10
g11
sg12
VOAS
p729
sasg24
(lp730
(dp731
g7
I36
sg8
I1
sg9
I3
sg27
VC0599973
p732
sg12
VOAS
p733
sa(dp734
g7
I4
sg8
I2
sg9
I30
sg27
VC0599973
p735
sg12
V2'5'-oligoadenylate synthetase
p736
sa(dp737
g7
I36
sg8
I1
sg9
I3
sg27
VC0599973
p738
sg12
VOAS
p739
sasa(dp740
g2
VIn a pooled analysis of 105 candidate genes and two genome-wide association studies, we observed associations of single nucleotide polymorphisms from nine genes (EIF2AK2, IFNAR2, ITPA, MBL2, MX1, OASL, SPP1, TGFB1, TNK2) with response to interferon-based therapy.
p741
sg4
(lp742
(dp743
g7
I191
sg8
I1
sg9
I3
sg10
VP20591
p744
sg12
VMX1
p745
sa(dp746
g7
I196
sg8
I1
sg9
I4
sg10
g11
sg12
VOASL
p747
sa(dp748
g7
I208
sg8
I1
sg9
I5
sg10
VP01137
p749
sg12
VTGFB1
p750
sa(dp751
g7
I202
sg8
I1
sg9
I4
sg10
VP10451
p752
sg12
VSPP1
p753
sa(dp754
g7
I215
sg8
I1
sg9
I4
sg10
g11
sg12
VTNK2
p755
sa(dp756
g7
I162
sg8
I1
sg9
I7
sg10
VP19525
p757
sg12
VEIF2AK2
p758
sa(dp759
g7
I185
sg8
I1
sg9
I4
sg10
VP11226
p760
sg12
VMBL2
p761
sa(dp762
g7
I179
sg8
I1
sg9
I4
sg10
g11
sg12
VITPA
p763
sa(dp764
g7
I171
sg8
I1
sg9
I6
sg10
VP48551
p765
sg12
VIFNAR2
p766
sa(dp767
g7
I238
sg8
I1
sg9
I10
sg10
VP01563
p768
sg12
Vinterferon
p769
sasg24
(lp770
sa(dp771
g2
VSingle nucleotide polymorphisms in the OAS1 (rs1131476), OAS2 (rs1293747), OAS3 (rs2072136), OASL (rs10849829) and IL28B (rs12979860, rs12980275 and rs8099917) genes were studied to examine their associations with responses to IFN treatment in paediatric patients.
p772
sg4
(lp773
(dp774
g7
I93
sg8
I2
sg9
I17
sg10
g11
sg12
VOASL (rs10849829)
p775
sa(dp776
g7
I57
sg8
I1
sg9
I4
sg10
VP29728
p777
sg12
VOAS2
p778
sa(dp779
g7
I75
sg8
I1
sg9
I4
sg10
g11
sg12
VOAS3
p780
sa(dp781
g7
I227
sg8
I1
sg9
I3
sg10
VP01562
p782
sg12
VIFN
p783
sa(dp784
g7
I115
sg8
I1
sg9
I5
sg10
g11
sg12
VIL28B
p785
sasg24
(lp786
sa(dp787
g2
VThe association analysis for CR showed that the TT genotype of IL28B rs12979860 was present only in the no-CR group (P = 0.033) and the AA genotype of OASL rs10849829 was significantly more frequent in the no-CR group (P = 0.044, OR = 0.26, 95%CI: 0.07-0.88).
p788
sg4
(lp789
(dp790
g7
I151
sg8
I2
sg9
I15
sg10
g11
sg12
VOASL rs10849829
p791
sa(dp792
g7
I63
sg8
I2
sg9
I16
sg10
g11
sg12
VIL28B rs12979860
p793
sasg24
(lp794
sa(dp795
g2
VThe aim of the present study was to evaluate agreement between three pairs formed by one of three mania scales (Young Mania Rating Scale [YMRS], Bech-Rafaelsen Mania Scale [BRMS], or the Clinician-Administered Rating Scale for Mania [CARS-M]) and a single depression scale (21-item Hamilton Depression Rating Scale [21-HAM-D]) for evaluation of response to mood stabilizers in patients with mixed bipolar disorder.
p796
sg4
(lp797
sg24
(lp798
(dp799
g7
I118
sg8
I1
sg9
I5
sg27
VC0338831
p800
sg12
VMania
p801
sa(dp802
g7
I118
sg8
I1
sg9
I5
sg27
VC0338831
p803
sg12
VMania
p804
sa(dp805
g7
I391
sg8
I3
sg9
I22
sg27
VC2937260
p806
sg12
Vmixed bipolar disorder
p807
sa(dp808
g7
I319
sg8
I1
sg9
I3
sg27
VC0030481
p809
sg12
VHAM
p810
sa(dp811
g7
I256
sg8
I1
sg9
I10
sg27
VC0011581
p812
sg12
Vdepression
p813
sa(dp814
g7
I291
sg8
I1
sg9
I10
sg27
VC0011581
p815
sg12
VDepression
p816
sa(dp817
g7
I98
sg8
I1
sg9
I5
sg27
VC0338831
p818
sg12
Vmania
p819
sa(dp820
g7
I118
sg8
I1
sg9
I5
sg27
VC0338831
p821
sg12
VMania
p822
sasa(dp823
g2
VThe present study suggests that any one of the three tested mania rating scales (YMRS, BRMS, and CARS-M) can be combined with the 21-HAM-D to assess treatment response in patients with mixed bipolar disorder.
p824
sg4
(lp825
(dp826
g7
I97
sg8
I1
sg9
I6
sg10
VP49589
p827
sg12
VCARS-M
p828
sasg24
(lp829
(dp830
g7
I133
sg8
I1
sg9
I3
sg27
VC0030481
p831
sg12
VHAM
p832
sa(dp833
g7
I60
sg8
I1
sg9
I5
sg27
VC0338831
p834
sg12
Vmania
p835
sa(dp836
g7
I185
sg8
I3
sg9
I22
sg27
VC2937260
p837
sg12
Vmixed bipolar disorder
p838
sasa(dp839
g2
VOlder adults and patients with dementia often have disrupted circadian activity rhythms (CARs).
p840
sg4
(lp841
sg24
(lp842
(dp843
g7
I31
sg8
I1
sg9
I8
sg27
VC0497327
p844
sg12
Vdementia
p845
sasa(dp846
g2
VClinically, decreased levels of cGAS are associated with poor prognosis for patients with breast cancer harbouring high levels of miR-25/93.
p847
sg4
(lp848
(dp849
g7
I130
sg8
I1
sg9
I6
sg10
g11
sg12
VmiR-25
p850
sa(dp851
g7
I32
sg8
I1
sg9
I4
sg10
VP10645
p852
sg12
VcGAS
p853
sasg24
(lp854
(dp855
g7
I90
sg8
I2
sg9
I13
sg27
VC0678222
p856
sg12
Vbreast cancer
p857
sasa(dp858
g2
VIn our analysis, we found that increased expression of 12 mature miRNAs-hsa-miR-320a, hsa-miR-361-5p, hsa-miR-103a-3p, hsa-miR-21-5p, hsa-miR-374b-5p, hsa-miR-140-3p, hsa-miR-25-3p, hsa-miR-651-5p, hsa-miR-200c-3p, hsa-miR-30a-5p, hsa-miR-30c-5p, and hsa-let-7i-5p -each predicted improved breast cancer survival.
p859
sg4
(lp860
(dp861
g7
I134
sg8
I1
sg9
I15
sg10
g11
sg12
Vhsa-miR-374b-5p
p862
sa(dp863
g7
I151
sg8
I1
sg9
I14
sg10
g11
sg12
Vhsa-miR-140-3p
p864
sa(dp865
g7
I86
sg8
I1
sg9
I14
sg10
g11
sg12
Vhsa-miR-361-5p
p866
sa(dp867
g7
I182
sg8
I1
sg9
I14
sg10
g11
sg12
Vhsa-miR-651-5p
p868
sa(dp869
g7
I215
sg8
I1
sg9
I14
sg10
g11
sg12
Vhsa-miR-30a-5p
p870
sa(dp871
g7
I102
sg8
I1
sg9
I15
sg10
g11
sg12
Vhsa-miR-103a-3p
p872
sa(dp873
g7
I198
sg8
I1
sg9
I15
sg10
g11
sg12
Vhsa-miR-200c-3p
p874
sa(dp875
g7
I119
sg8
I1
sg9
I13
sg10
g11
sg12
Vhsa-miR-21-5p
p876
sa(dp877
g7
I65
sg8
I1
sg9
I3
sg10
g11
sg12
VmiR
p878
sa(dp879
g7
I251
sg8
I1
sg9
I13
sg10
g11
sg12
Vhsa-let-7i-5p
p880
sa(dp881
g7
I231
sg8
I1
sg9
I14
sg10
g11
sg12
Vhsa-miR-30c-5p
p882
sa(dp883
g7
I167
sg8
I1
sg9
I13
sg10
g11
sg12
Vhsa-miR-25-3p
p884
sa(dp885
g7
I72
sg8
I1
sg9
I3
sg10
g11
sg12
Vhsa
p886
sasg24
(lp887
(dp888
g7
I72
sg8
I1
sg9
I3
sg27
VC0393754
p889
sg12
Vhsa
p890
sa(dp891
g7
I72
sg8
I1
sg9
I3
sg27
VC0393754
p892
sg12
Vhsa
p893
sa(dp894
g7
I72
sg8
I1
sg9
I3
sg27
VC0393754
p895
sg12
Vhsa
p896
sa(dp897
g7
I72
sg8
I1
sg9
I3
sg27
VC0393754
p898
sg12
Vhsa
p899
sa(dp900
g7
I290
sg8
I2
sg9
I13
sg27
VC0678222
p901
sg12
Vbreast cancer
p902
sa(dp903
g7
I72
sg8
I1
sg9
I3
sg27
VC0393754
p904
sg12
Vhsa
p905
sa(dp906
g7
I72
sg8
I1
sg9
I3
sg27
VC0393754
p907
sg12
Vhsa
p908
sa(dp909
g7
I72
sg8
I1
sg9
I3
sg27
VC0393754
p910
sg12
Vhsa
p911
sa(dp912
g7
I72
sg8
I1
sg9
I3
sg27
VC0393754
p913
sg12
Vhsa
p914
sa(dp915
g7
I72
sg8
I1
sg9
I3
sg27
VC0393754
p916
sg12
Vhsa
p917
sa(dp918
g7
I72
sg8
I1
sg9
I3
sg27
VC0393754
p919
sg12
Vhsa
p920
sa(dp921
g7
I72
sg8
I1
sg9
I3
sg27
VC0393754
p922
sg12
Vhsa
p923
sa(dp924
g7
I72
sg8
I1
sg9
I3
sg27
VC0393754
p925
sg12
Vhsa
p926
sasa(dp927
g2
VHere, we report a novel function of isoliquiritigenin (ISL) as a natural inhibitor of autophagy-related miR-25 in killing drug-resistant breast cancer cells.
p928
sg4
(lp929
(dp930
g7
I104
sg8
I1
sg9
I6
sg10
g11
sg12
VmiR-25
p931
sasg24
(lp932
(dp933
g7
I137
sg8
I2
sg9
I13
sg27
VC0678222
p934
sg12
Vbreast cancer
p935
sasa(dp936
g2
VOverall, our results not only indicate that ISL acts as a natural autophagy inducer to increase breast cancer chemosensitivity, but also reveal that miR-25 functions as a novel regulator of autophagy by targeting ULK1.
p937
sg4
(lp938
(dp939
g7
I149
sg8
I1
sg9
I6
sg10
g11
sg12
VmiR-25
p940
sa(dp941
g7
I213
sg8
I1
sg9
I4
sg10
g11
sg12
VULK1
p942
sa(dp943
g7
I44
sg8
I1
sg9
I3
sg10
g11
sg12
VISL
p944
sasg24
(lp945
(dp946
g7
I96
sg8
I2
sg9
I13
sg27
VC0678222
p947
sg12
Vbreast cancer
p948
sasa(dp949
g2
VExpression of a panel of seven microRNAs (hsa-miR-34a, hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, hsa-miR-326, and hsa-miR-375) and seven target genes ( E2F3, PI3KCA, TOM34, WNT5A, PDCD4, DFFA, and EGFR) in 43 glioblastoma multiforme specimens were profiled compared to non-cancer tissues via quantitative reverse transcription-polymerase chain reaction.
p950
sg4
(lp951
(dp952
g7
I67
sg8
I1
sg9
I10
sg10
g11
sg12
Vhsa-miR-17
p953
sa(dp954
g7
I42
sg8
I1
sg9
I3
sg10
g11
sg12
Vhsa
p955
sa(dp956
g7
I194
sg8
I3
sg9
I14
sg10
g11
sg12
VDFFA, and EGFR
p957
sa(dp958
g7
I46
sg8
I1
sg9
I3
sg10
g11
sg12
VmiR
p959
sa(dp960
g7
I91
sg8
I1
sg9
I11
sg10
g11
sg12
Vhsa-miR-221
p961
sa(dp962
g7
I187
sg8
I1
sg9
I5
sg10
g11
sg12
VPDCD4
p963
sa(dp964
g7
I180
sg8
I1
sg9
I5
sg10
VP41221
p965
sg12
VWNT5A
p966
sa(dp967
g7
I55
sg8
I1
sg9
I10
sg10
g11
sg12
Vhsa-miR-16
p968
sa(dp969
g7
I42
sg8
I1
sg9
I3
sg10
g11
sg12
Vhsa
p970
sa(dp971
g7
I104
sg8
I1
sg9
I11
sg10
g11
sg12
Vhsa-miR-326
p972
sa(dp973
g7
I42
sg8
I1
sg9
I3
sg10
g11
sg12
Vhsa
p974
sa(dp975
g7
I173
sg8
I1
sg9
I5
sg10
g11
sg12
VTOM34
p976
sa(dp977
g7
I159
sg8
I1
sg9
I4
sg10
g11
sg12
VE2F3
p978
sasg24
(lp979
(dp980
g7
I42
sg8
I1
sg9
I3
sg27
VC0393754
p981
sg12
Vhsa
p982
sa(dp983
g7
I280
sg8
I1
sg9
I6
sg27
VC0006826
p984
sg12
Vcancer
p985
sa(dp986
g7
I42
sg8
I1
sg9
I3
sg27
VC0393754
p987
sg12
Vhsa
p988
sa(dp989
g7
I216
sg8
I2
sg9
I23
sg27
VC1621958
p990
sg12
Vglioblastoma multiforme
p991
sa(dp992
g7
I42
sg8
I1
sg9
I3
sg27
VC0393754
p993
sg12
Vhsa
p994
sa(dp995
g7
I42
sg8
I1
sg9
I3
sg27
VC0393754
p996
sg12
Vhsa
p997
sa(dp998
g7
I42
sg8
I1
sg9
I3
sg27
VC0393754
p999
sg12
Vhsa
p1000
sa(dp1001
g7
I42
sg8
I1
sg9
I3
sg27
VC0393754
p1002
sg12
Vhsa
p1003
sa(dp1004
g7
I42
sg8
I1
sg9
I3
sg27
VC0393754
p1005
sg12
Vhsa
p1006
sasa(dp1007
g2
VThe present study examined whether it could be possible to quantify the expression of TOMM34 and RNF43 in colorectal cancer and liver metastasis samples prepared from paraffin blocks.
p1008
sg4
(lp1009
(dp1010
g7
I97
sg8
I1
sg9
I5
sg10
g11
sg12
VRNF43
p1011
sa(dp1012
g7
I86
sg8
I1
sg9
I6
sg10
g11
sg12
VTOMM34
p1013
sasg24
(lp1014
(dp1015
g7
I106
sg8
I2
sg9
I17
sg27
VC1527249
p1016
sg12
Vcolorectal cancer
p1017
sa(dp1018
g7
I128
sg8
I2
sg9
I16
sg27
VC0494165
p1019
sg12
Vliver metastasis
p1020
sasa(dp1021
g2
VQuantification of TOMM34 and RNF43 gene expression in several-year-old paraffin-embedded colorectal cancer specimens was possible by qPCR using the Universal ProbeLibrary.
p1022
sg4
(lp1023
(dp1024
g7
I18
sg8
I1
sg9
I6
sg10
g11
sg12
VTOMM34
p1025
sa(dp1026
g7
I29
sg8
I2
sg9
I10
sg10
g11
sg12
VRNF43 gene
p1027
sasg24
(lp1028
(dp1029
g7
I89
sg8
I2
sg9
I17
sg27
VC1527249
p1030
sg12
Vcolorectal cancer
p1031
sasa(dp1032
g2
VThe mRNA levels of seven TAAs, Wilms' tumor gene (WT1), kinetochore associated-2 (KNTC2), cell division cycle associated-1 (CDCA1), M phase phosphoprotein-1 (MPHOSPH1), DEP domain-containing 1 (DEPDC1), 34-kDa translocase of the outer mitochondrial membrane (TOMM34) and ring finger protein-43 (RNF43), were analyzed using quantitative real-time reverse transcription-polymerase chain reaction, and their relationships with clinicopathological factors and the cell cycle were analyzed.
p1033
sg4
(lp1034
(dp1035
g7
I82
sg8
I1
sg9
I5
sg10
g11
sg12
VKNTC2
p1036
sa(dp1037
g7
I203
sg8
I8
sg9
I63
sg10
g11
sg12
V34-kDa translocase of the outer mitochondrial membrane (TOMM34)
p1038
sa(dp1039
g7
I132
sg8
I3
sg9
I24
sg10
g11
sg12
VM phase phosphoprotein-1
p1040
sa(dp1041
g7
I169
sg8
I3
sg9
I23
sg10
g11
sg12
VDEP domain-containing 1
p1042
sa(dp1043
g7
I271
sg8
I3
sg9
I22
sg10
VP62877
p1044
sg12
Vring finger protein-43
p1045
sa(dp1046
g7
I194
sg8
I1
sg9
I6
sg10
g11
sg12
VDEPDC1
p1047
sa(dp1048
g7
I295
sg8
I1
sg9
I5
sg10
g11
sg12
VRNF43
p1049
sa(dp1050
g7
I158
sg8
I1
sg9
I8
sg10
g11
sg12
VMPHOSPH1
p1051
sa(dp1052
g7
I31
sg8
I6
sg9
I49
sg10
g11
sg12
VWilms' tumor gene (WT1), kinetochore associated-2
p1053
sasg24
(lp1054
(dp1055
g7
I31
sg8
I2
sg9
I12
sg27
VC0027708
p1056
sg12
VWilms' tumor
p1057
sa(dp1058
g7
I50
sg8
I1
sg9
I3
sg27
VC0027708
p1059
sg12
VWT1
p1060
sasa(dp1061
g2
VThese antigenic peptides were derived from 5 proteins identified as cancer-testis antigens(ring finger protein 43 [RNF43], translocase of outer mitochondrial membrane 34[TOMM34], maternal embryonic leucine zipper kinase[MELK], forkhead box M1[FOXM1], and holliday junction recognition protein[HJURP])and 2 vascular endothelial growth factor receptors(VEGFR1 and VEGFR2).
p1062
sg4
(lp1063
(dp1064
g7
I255
sg8
I4
sg9
I37
sg10
g11
sg12
Vholliday junction recognition protein
p1065
sa(dp1066
g7
I293
sg8
I1
sg9
I5
sg10
g11
sg12
VHJURP
p1067
sa(dp1068
g7
I240
sg8
I1
sg9
I9
sg10
g11
sg12
VM1[FOXM1]
p1069
sa(dp1070
g7
I351
sg8
I1
sg9
I6
sg10
VP17948
p1071
sg12
VVEGFR1
p1072
sa(dp1073
g7
I306
sg8
I5
sg9
I44
sg10
g11
sg12
Vvascular endothelial growth factor receptors
p1074
sa(dp1075
g7
I220
sg8
I1
sg9
I4
sg10
g11
sg12
VMELK
p1076
sa(dp1077
g7
I362
sg8
I1
sg9
I6
sg10
VP35968
p1078
sg12
VVEGFR2
p1079
sa(dp1080
g7
I91
sg8
I4
sg9
I22
sg10
g11
sg12
Vring finger protein 43
p1081
sa(dp1082
g7
I179
sg8
I5
sg9
I40
sg10
VP30740
p1083
sg12
Vmaternal embryonic leucine zipper kinase
p1084
sa(dp1085
g7
I68
sg8
I2
sg9
I22
sg10
VP15735
p1086
sg12
Vcancer-testis antigens
p1087
sasg24
(lp1088
(dp1089
g7
I68
sg8
I1
sg9
I6
sg27
VC0006826
p1090
sg12
Vcancer
p1091
sasa(dp1092
g2
VTo evaluate the safety of combination vaccine treatment of multiple peptides, phase I clinical trial was conducted for patients with advanced colorectal cancer using five novel HLA-A*2402-restricted peptides, three peptides derived from oncoantigens, ring finger protein 43 (RNF43), 34 kDa-translocase of the outer mitochondrial membrane (TOMM34), and insulin-like growth factor-II mRNA binding protein 3 (KOC1), and the remaining two from angiogenesis factors, vascular endothelial growth factor receptor 1 (VEGFR1) and VEGFR2.
p1093
sg4
(lp1094
(dp1095
g7
I406
sg8
I1
sg9
I4
sg10
g11
sg12
VKOC1
p1096
sa(dp1097
g7
I251
sg8
I4
sg9
I22
sg10
g11
sg12
Vring finger protein 43
p1098
sa(dp1099
g7
I352
sg8
I7
sg9
I52
sg10
VP01308
p1100
sg12
Vinsulin-like growth factor-II mRNA binding protein 3
p1101
sa(dp1102
g7
I339
sg8
I1
sg9
I6
sg10
g11
sg12
VTOMM34
p1103
sa(dp1104
g7
I509
sg8
I1
sg9
I6
sg10
VP17948
p1105
sg12
VVEGFR1
p1106
sa(dp1107
g7
I177
sg8
I1
sg9
I10
sg10
VP30447
p1108
sg12
VHLA-A*2402
p1109
sa(dp1110
g7
I462
sg8
I6
sg9
I45
sg10
VP17948
p1111
sg12
Vvascular endothelial growth factor receptor 1
p1112
sa(dp1113
g7
I275
sg8
I1
sg9
I5
sg10
g11
sg12
VRNF43
p1114
sa(dp1115
g7
I521
sg8
I1
sg9
I6
sg10
VP35968
p1116
sg12
VVEGFR2
p1117
sasg24
(lp1118
(dp1119
g7
I142
sg8
I2
sg9
I17
sg27
VC1527249
p1120
sg12
Vcolorectal cancer
p1121
sasa(dp1122
g2
VThese antigenic peptides were derived from 2 different cancer-testis antigens, ring finger protein 43 (RNF43) and translocase of outer mitochondrial membrane 34( TOMM34).
p1123
sg4
(lp1124
(dp1125
g7
I114
sg8
I6
sg9
I46
sg10
g11
sg12
Vtranslocase of outer mitochondrial membrane 34
p1126
sa(dp1127
g7
I55
sg8
I2
sg9
I22
sg10
VP15735
p1128
sg12
Vcancer-testis antigens
p1129
sa(dp1130
g7
I79
sg8
I4
sg9
I22
sg10
g11
sg12
Vring finger protein 43
p1131
sa(dp1132
g7
I103
sg8
I1
sg9
I5
sg10
g11
sg12
VRNF43
p1133
sa(dp1134
g7
I162
sg8
I1
sg9
I6
sg10
g11
sg12
VTOMM34
p1135
sasg24
(lp1136
(dp1137
g7
I55
sg8
I1
sg9
I6
sg27
VC0006826
p1138
sg12
Vcancer
p1139
sasa(dp1140
g2
VWe conducted a clinical trial of colorectal cancer-specific peptide( RNF43, TOMM34) vaccines with uracil/tegafur( UFT)+Leucovorin( LV) for the treatment of advanced or recurrent colorectal cancer.
p1141
sg4
(lp1142
(dp1143
g7
I69
sg8
I1
sg9
I5
sg10
g11
sg12
VRNF43
p1144
sa(dp1145
g7
I33
sg8
I3
sg9
I34
sg10
VP31749
p1146
sg12
Vcolorectal cancer-specific peptide
p1147
sa(dp1148
g7
I76
sg8
I1
sg9
I6
sg10
g11
sg12
VTOMM34
p1149
sasg24
(lp1150
(dp1151
g7
I168
sg8
I3
sg9
I27
sg27
VC0854750
p1152
sg12
Vrecurrent colorectal cancer
p1153
sa(dp1154
g7
I33
sg8
I2
sg9
I17
sg27
VC1527249
p1155
sg12
Vcolorectal cancer
p1156
sasa(dp1157
g2
VWe started a clinical trial of vaccines against multiple peptides (RNF43, TOMM34, forkhead box protein M1 [FOXM1], maternal embryonic leucine zipper kinase [MELK], holliday junction recognition protein[HJURP], vascular endothelial growth factor receptor 1[VEGFR1], and VEGFR2) for the treatment of advanced or recurrent colorectal cancer.
p1158
sg4
(lp1159
(dp1160
g7
I164
sg8
I4
sg9
I37
sg10
g11
sg12
Vholliday junction recognition protein
p1161
sa(dp1162
g7
I82
sg8
I5
sg9
I31
sg10
g11
sg12
Vforkhead box protein M1 [FOXM1]
p1163
sa(dp1164
g7
I157
sg8
I1
sg9
I4
sg10
g11
sg12
VMELK
p1165
sa(dp1166
g7
I202
sg8
I1
sg9
I5
sg10
g11
sg12
VHJURP
p1167
sa(dp1168
g7
I210
sg8
I8
sg9
I65
sg10
VP17948
p1169
sg12
Vvascular endothelial growth factor receptor 1[VEGFR1], and VEGFR2
p1170
sa(dp1171
g7
I67
sg8
I1
sg9
I5
sg10
g11
sg12
VRNF43
p1172
sa(dp1173
g7
I74
sg8
I1
sg9
I6
sg10
g11
sg12
VTOMM34
p1174
sa(dp1175
g7
I115
sg8
I5
sg9
I40
sg10
VP30740
p1176
sg12
Vmaternal embryonic leucine zipper kinase
p1177
sasg24
(lp1178
(dp1179
g7
I310
sg8
I3
sg9
I27
sg27
VC0854750
p1180
sg12
Vrecurrent colorectal cancer
p1181
sasa(dp1182
g2
VRecently, analysis of tumor antigens using micro-arrays has revealed upregulation             of cancer-testis antigens RNF43 and TOMM34 and vascular endothelial growth factor             receptors VEGFR1 and VEGFR2 in colorectal cancer.
p1183
sg4
(lp1184
(dp1185
g7
I130
sg8
I1
sg9
I6
sg10
g11
sg12
VTOMM34
p1186
sa(dp1187
g7
I120
sg8
I1
sg9
I5
sg10
g11
sg12
VRNF43
p1188
sa(dp1189
g7
I141
sg8
I20
sg9
I74
sg10
VP17948
p1190
sg12
Vvascular endothelial growth factor             receptors VEGFR1 and VEGFR2
p1191
sasg24
(lp1192
(dp1193
g7
I97
sg8
I1
sg9
I6
sg27
VC0006826
p1194
sg12
Vcancer
p1195
sa(dp1196
g7
I22
sg8
I1
sg9
I5
sg27
VC0027651
p1197
sg12
Vtumor
p1198
sa(dp1199
g7
I219
sg8
I2
sg9
I17
sg27
VC1527249
p1200
sg12
Vcolorectal cancer
p1201
sasa(dp1202
g2
VOur aim was to analyze the dynamic modulation, determined by ADT, of the expression of selected genes involved in the pathogenesis and progression of prostate cancer (TMPRSS2:ERG, WNT11, SPINK1, CHGA, AR, and SPDEF) using real-time polymerase chain reaction in a series of 59 surgical samples of prostate carcinomas, including 37 cases preoperatively treated with ADT and 22 untreated cases, and in 43 corresponding biopsies.
p1203
sg4
(lp1204
(dp1205
g7
I187
sg8
I1
sg9
I6
sg10
VP00995
p1206
sg12
VSPINK1
p1207
sa(dp1208
g7
I209
sg8
I1
sg9
I5
sg10
g11
sg12
VSPDEF
p1209
sa(dp1210
g7
I175
sg8
I1
sg9
I3
sg10
VP11308
p1211
sg12
VERG
p1212
sa(dp1213
g7
I195
sg8
I1
sg9
I4
sg10
VP10645
p1214
sg12
VCHGA
p1215
sa(dp1216
g7
I180
sg8
I1
sg9
I5
sg10
g11
sg12
VWNT11
p1217
sasg24
(lp1218
(dp1219
g7
I305
sg8
I1
sg9
I10
sg27
VC0007097
p1220
sg12
Vcarcinomas
p1221
sa(dp1222
g7
I118
sg8
I1
sg9
I12
sg27
VC0699748
p1223
sg12
Vpathogenesis
p1224
sa(dp1225
g7
I135
sg8
I4
sg9
I30
sg27
VC1739135
p1226
sg12
Vprogression of prostate cancer
p1227
sasa(dp1228
g2
VHowever, Wnt-11 expression in cervical cancer has not been well investigated.
p1229
sg4
(lp1230
sg24
(lp1231
(dp1232
g7
I30
sg8
I2
sg9
I15
sg27
VC0302592
p1233
sg12
Vcervical cancer
p1234
sasa(dp1235
g2
VWnt-11 and HR-HPV E6 expression increased in a manner that corresponded with the progression of cervical cancer and was significantly correlated with the International Federation of Gynecology and Obstetrics cancer stage, lymph node metastasis, tumor size, and HPV infection.
p1236
sg4
(lp1237
sg24
(lp1238
(dp1239
g7
I96
sg8
I2
sg9
I15
sg27
VC0302592
p1240
sg12
Vcervical cancer
p1241
sa(dp1242
g7
I245
sg8
I1
sg9
I5
sg27
VC0027651
p1243
sg12
Vtumor
p1244
sa(dp1245
g7
I222
sg8
I3
sg9
I21
sg27
VC0686619
p1246
sg12
Vlymph node metastasis
p1247
sa(dp1248
g7
I105
sg8
I1
sg9
I6
sg27
VC0006826
p1249
sg12
Vcancer
p1250
sa(dp1251
g7
I265
sg8
I1
sg9
I9
sg27
VC0009450
p1252
sg12
Vinfection
p1253
sasa(dp1254
g2
VWnt-11 protein expression was positively associated with HR-HPV E6 protein expression in all 78 cervical cancer samples (P &lt; 0.001).
p1255
sg4
(lp1256
sg24
(lp1257
(dp1258
g7
I96
sg8
I2
sg9
I15
sg27
VC0302592
p1259
sg12
Vcervical cancer
p1260
sasa(dp1261
g2
VFurthermore, Wnt-11 was positively associated with P-JNK1 expression and promoted cervical cancer cell proliferation and invasion.
p1262
sg4
(lp1263
(dp1264
g7
I53
sg8
I1
sg9
I4
sg10
VP45983
p1265
sg12
VJNK1
p1266
sasg24
(lp1267
(dp1268
g7
I103
sg8
I1
sg9
I13
sg27
VC0334094
p1269
sg12
Vproliferation
p1270
sa(dp1271
g7
I121
sg8
I1
sg9
I8
sg27
VC2699153
p1272
sg12
Vinvasion
p1273
sa(dp1274
g7
I82
sg8
I2
sg9
I15
sg27
VC0302592
p1275
sg12
Vcervical cancer
p1276
sasa(dp1277
g2
VThese observations suggest that the increased Wnt-11 expression observed in cervical cancer cells may lead to the phosphorylation and activation of JNK-1 and significantly promote tumor cell proliferation and cell migration/invasion through activation of the Wnt/JNK pathway.
p1278
sg4
(lp1279
(dp1280
g7
I148
sg8
I1
sg9
I5
sg10
VP53779
p1281
sg12
VJNK-1
p1282
sa(dp1283
g7
I148
sg8
I1
sg9
I3
sg10
VP53779
p1284
sg12
VJNK
p1285
sasg24
(lp1286
(dp1287
g7
I191
sg8
I1
sg9
I13
sg27
VC0334094
p1288
sg12
Vproliferation
p1289
sa(dp1290
g7
I180
sg8
I1
sg9
I5
sg27
VC0027651
p1291
sg12
Vtumor
p1292
sa(dp1293
g7
I76
sg8
I2
sg9
I15
sg27
VC0302592
p1294
sg12
Vcervical cancer
p1295
sa(dp1296
g7
I224
sg8
I1
sg9
I8
sg27
VC2699153
p1297
sg12
Vinvasion
p1298
sasa(dp1299
g2
VConsequently, Wnt-11 may serve as a novel target for cervical cancer therapy.
p1300
sg4
(lp1301
sg24
(lp1302
(dp1303
g7
I53
sg8
I2
sg9
I15
sg27
VC0302592
p1304
sg12
Vcervical cancer
p1305
sasa(dp1306
g2
VIn this study, we aimed to explore the association among gene variants of five cytokines, tumor necrosis factor alpha (TNF-Alfa), transforming growth factor beta-1 (TGF-Beta1), interferon gamma (IFN-Gamma), interleukin-6 (IL-6), and interleukin-10 (IL-10), and clinical parameters and prognosis in patients with multiple myeloma (MM) treated with novel therapeutic drugs in Turkish population for the first time except TNF-Alfa.
p1307
sg4
(lp1308
(dp1309
g7
I249
sg8
I1
sg9
I5
sg10
VP22301
p1310
sg12
VIL-10
p1311
sa(dp1312
g7
I207
sg8
I1
sg9
I13
sg10
VP05231
p1313
sg12
Vinterleukin-6
p1314
sa(dp1315
g7
I130
sg8
I4
sg9
I33
sg10
VP01137
p1316
sg12
Vtransforming growth factor beta-1
p1317
sa(dp1318
g7
I119
sg8
I1
sg9
I8
sg10
VP01375
p1319
sg12
VTNF-Alfa
p1320
sa(dp1321
g7
I90
sg8
I4
sg9
I27
sg10
VP01375
p1322
sg12
Vtumor necrosis factor alpha
p1323
sa(dp1324
g7
I165
sg8
I1
sg9
I9
sg10
VP01137
p1325
sg12
VTGF-Beta1
p1326
sa(dp1327
g7
I195
sg8
I1
sg9
I9
sg10
VP01579
p1328
sg12
VIFN-Gamma
p1329
sa(dp1330
g7
I177
sg8
I2
sg9
I16
sg10
VP01579
p1331
sg12
Vinterferon gamma
p1332
sa(dp1333
g7
I222
sg8
I1
sg9
I4
sg10
VP05231
p1334
sg12
VIL-6
p1335
sa(dp1336
g7
I233
sg8
I1
sg9
I14
sg10
VP22301
p1337
sg12
Vinterleukin-10
p1338
sasg24
(lp1339
(dp1340
g7
I312
sg8
I2
sg9
I16
sg27
VC0026764
p1341
sg12
Vmultiple myeloma
p1342
sa(dp1343
g7
I90
sg8
I2
sg9
I14
sg27
VC0333516
p1344
sg12
Vtumor necrosis
p1345
sasa(dp1346
g2
VUsing absolute value of log2 fold-change &gt; 2 or extremely small P value (10-20) as a criterion, we identified nine significant genes (HBA1, HBB, HIST1H2AC, GSTT1, MYL7, NPPA, NPPB, PDK4, PLA2G2A) in LVH, also found in published data set for ischemic and dilated cardiomyopathy in heart failure.
p1347
sg4
(lp1348
(dp1349
g7
I166
sg8
I1
sg9
I4
sg10
g11
sg12
VMYL7
p1350
sa(dp1351
g7
I159
sg8
I1
sg9
I5
sg10
VP30711
p1352
sg12
VGSTT1
p1353
sa(dp1354
g7
I137
sg8
I1
sg9
I4
sg10
VP69905
p1355
sg12
VHBA1
p1356
sa(dp1357
g7
I143
sg8
I1
sg9
I3
sg10
VP02042
p1358
sg12
VHBB
p1359
sa(dp1360
g7
I172
sg8
I1
sg9
I4
sg10
VP01160
p1361
sg12
VNPPA
p1362
sa(dp1363
g7
I178
sg8
I1
sg9
I4
sg10
VP16860
p1364
sg12
VNPPB
p1365
sa(dp1366
g7
I148
sg8
I1
sg9
I9
sg10
g11
sg12
VHIST1H2AC
p1367
sa(dp1368
g7
I184
sg8
I1
sg9
I4
sg10
g11
sg12
VPDK4
p1369
sa(dp1370
g7
I190
sg8
I1
sg9
I7
sg10
VP14555
p1371
sg12
VPLA2G2A
p1372
sasg24
(lp1373
(dp1374
g7
I257
sg8
I2
sg9
I22
sg27
VC0007193
p1375
sg12
Vdilated cardiomyopathy
p1376
sa(dp1377
g7
I202
sg8
I1
sg9
I3
sg27
VC0149721
p1378
sg12
VLVH
p1379
sa(dp1380
g7
I283
sg8
I2
sg9
I13
sg27
VC0018802
p1381
sg12
Vheart failure
p1382
sasa(dp1383
g2
VTolerized cow's milk protein (CMP)-sensitive atopic dermatitis had, in particular, decreased kappa-casein-specific IgG(1) levels, compared with clinically reactive patients.
p1384
sg4
(lp1385
(dp1386
g7
I93
sg8
I2
sg9
I28
sg10
VP07498
p1387
sg12
Vkappa-casein-specific IgG(1)
p1388
sasg24
(lp1389
(dp1390
g7
I45
sg8
I2
sg9
I17
sg27
VC0011615
p1391
sg12
Vatopic dermatitis
p1392
sasa(dp1393
g2
VTolerised patients, particularly those with atopic dermatitis, had decreased responses to kappa-casein which were restored after Treg depletion.
p1394
sg4
(lp1395
(dp1396
g7
I90
sg8
I1
sg9
I12
sg10
VP07498
p1397
sg12
Vkappa-casein
p1398
sasg24
(lp1399
(dp1400
g7
I44
sg8
I2
sg9
I17
sg27
VC0011615
p1401
sg12
Vatopic dermatitis
p1402
sasa(dp1403
g2
VA markedly decreased proliferative response to kappa-casein in tolerised IgE-mediated CMA patients with atopic dermatitis, which was abrogated by Treg depletion, suggested a role for kappa-casein in tolerance induction.
p1404
sg4
(lp1405
(dp1406
g7
I47
sg8
I1
sg9
I12
sg10
VP07498
p1407
sg12
Vkappa-casein
p1408
sa(dp1409
g7
I73
sg8
I1
sg9
I3
sg10
VP01854
p1410
sg12
VIgE
p1411
sa(dp1412
g7
I47
sg8
I1
sg9
I12
sg10
VP07498
p1413
sg12
Vkappa-casein
p1414
sasg24
(lp1415
(dp1416
g7
I21
sg8
I1
sg9
I13
sg27
VC0334094
p1417
sg12
Vproliferative
p1418
sa(dp1419
g7
I73
sg8
I1
sg9
I3
sg27
VC0270850
p1420
sg12
VIgE
p1421
sa(dp1422
g7
I104
sg8
I2
sg9
I17
sg27
VC0011615
p1423
sg12
Vatopic dermatitis
p1424
sa(dp1425
g7
I199
sg8
I1
sg9
I9
sg27
VC0020963
p1426
sg12
Vtolerance
p1427
sasa(dp1428
g2
VIn order to investigate the role of food antigen-specific T cells circulating in the blood of patients with food allergy, we compared T cell response to three casein components (alpha s-, beta- and, kappa-casein) with specificities of IgG and IgE binding to the casein components in four milk-allergic patients (P1-4) with atopic dermatitis.
p1429
sg4
(lp1430
(dp1431
g7
I243
sg8
I1
sg9
I3
sg10
VP01854
p1432
sg12
VIgE
p1433
sasg24
(lp1434
(dp1435
g7
I323
sg8
I2
sg9
I17
sg27
VC0011615
p1436
sg12
Vatopic dermatitis
p1437
sa(dp1438
g7
I108
sg8
I2
sg9
I12
sg27
VC0016470
p1439
sg12
Vfood allergy
p1440
sa(dp1441
g7
I243
sg8
I1
sg9
I3
sg27
VC0270850
p1442
sg12
VIgE
p1443
sasa(dp1444
g2
VStudies have identified that PKM2 is related to the development of glucose intolerance and insulin resistance in rodents and humans.
p1445
sg4
(lp1446
(dp1447
g7
I91
sg8
I1
sg9
I7
sg10
VP01308
p1448
sg12
Vinsulin
p1449
sasg24
(lp1450
(dp1451
g7
I91
sg8
I2
sg9
I18
sg27
VC0021655
p1452
sg12
Vinsulin resistance
p1453
sa(dp1454
g7
I67
sg8
I2
sg9
I19
sg27
VC0271650
p1455
sg12
Vglucose intolerance
p1456
sasa(dp1457
g2
VMechanistically, we showed that hyperglycemia and diabetes decreased PKM2 tetramer formation and activity by sulfenylation in mouse glomeruli and cultured podocytes.
p1458
sg4
(lp1459
sg24
(lp1460
(dp1461
g7
I50
sg8
I1
sg9
I8
sg27
VC0011849
p1462
sg12
Vdiabetes
p1463
sa(dp1464
g7
I32
sg8
I1
sg9
I13
sg27
VC0020456
p1465
sg12
Vhyperglycemia
p1466
sasa(dp1467
g2
VPodocyte-specific Pkm2-knockout (KO) mice with diabetes developed worse albuminuria and glomerular pathology.
p1468
sg4
(lp1469
sg24
(lp1470
(dp1471
g7
I47
sg8
I1
sg9
I8
sg27
VC0011849
p1472
sg12
Vdiabetes
p1473
sa(dp1474
g7
I99
sg8
I1
sg9
I9
sg27
VC0677042
p1475
sg12
Vpathology
p1476
sasa(dp1477
g2
VConversely, we found that pharmacological activation of PKM2 by a small-molecule PKM2 activator, TEPP-46, reversed hyperglycemia-induced elevation in toxic glucose metabolites and mitochondrial dysfunction, partially by increasing glycolytic flux and PGC-1Alfa mRNA in cultured podocytes.
p1478
sg4
(lp1479
(dp1480
g7
I251
sg8
I2
sg9
I14
sg10
VP20142
p1481
sg12
VPGC-1Alfa mRNA
p1482
sa(dp1483
g7
I97
sg8
I1
sg9
I7
sg10
g11
sg12
VTEPP-46
p1484
sa(dp1485
g7
I66
sg8
I3
sg9
I29
sg10
VP05154
p1486
sg12
Vsmall-molecule PKM2 activator
p1487
sasg24
(lp1488
(dp1489
g7
I115
sg8
I1
sg9
I13
sg27
VC0020456
p1490
sg12
Vhyperglycemia
p1491
sasa(dp1492
g2
VTo identify the miR-155 targets relevant for B-cell lymphoma, we performed RNA immunoprecipitation of Argonaute 2 in Hodgkin lymphoma (HL) cells upon miR-155 inhibition and in BL cells upon ectopic expression of miR-155.
p1493
sg4
(lp1494
(dp1495
g7
I16
sg8
I1
sg9
I7
sg10
g11
sg12
VmiR-155
p1496
sasg24
(lp1497
(dp1498
g7
I117
sg8
I2
sg9
I16
sg27
VC0019829
p1499
sg12
VHodgkin lymphoma
p1500
sa(dp1501
g7
I45
sg8
I2
sg9
I15
sg27
VC0079731
p1502
sg12
VB-cell lymphoma
p1503
sa(dp1504
g7
I135
sg8
I1
sg9
I2
sg27
VC0019829
p1505
sg12
VHL
p1506
sasa(dp1507
g2
VFurther research suggested that METTL13 negatively regulates cell proliferation in bladder cancer and reinstates G1/S checkpoint via the coordinated downregulation of CDK6, CDK4 and CCND1, decreased phosphorylation of Rb and subsequent delayed cell cycle progression.
p1508
sg4
(lp1509
(dp1510
g7
I182
sg8
I1
sg9
I5
sg10
VP24385
p1511
sg12
VCCND1
p1512
sa(dp1513
g7
I173
sg8
I1
sg9
I4
sg10
VP11802
p1514
sg12
VCDK4
p1515
sa(dp1516
g7
I167
sg8
I1
sg9
I4
sg10
g11
sg12
VCDK6
p1517
sasg24
(lp1518
(dp1519
g7
I66
sg8
I1
sg9
I13
sg27
VC0334094
p1520
sg12
Vproliferation
p1521
sa(dp1522
g7
I83
sg8
I2
sg9
I14
sg27
VC0699885
p1523
sg12
Vbladder cancer
p1524
sasa(dp1525
g2
VmiR-29c could inhibit the proliferation, migration and invasion of bladder cancer cells via regulating CDK6.
p1526
sg4
(lp1527
(dp1528
g7
I103
sg8
I1
sg9
I4
sg10
g11
sg12
VCDK6
p1529
sa(dp1530
g7
I0
sg8
I1
sg9
I7
sg10
g11
sg12
VmiR-29c
p1531
sasg24
(lp1532
(dp1533
g7
I67
sg8
I2
sg9
I14
sg27
VC0699885
p1534
sg12
Vbladder cancer
p1535
sa(dp1536
g7
I55
sg8
I1
sg9
I8
sg27
VC2699153
p1537
sg12
Vinvasion
p1538
sa(dp1539
g7
I26
sg8
I1
sg9
I13
sg27
VC0334094
p1540
sg12
Vproliferation
p1541
sasa(dp1542
g2
Vp34cdc2, collapsin response mediator protein 4 (CRMP4), doublecortin (DCX), HuD, and NeuN expression was assessed in tuber (n = 16) and subependymal giant cell astrocytoma (SEGA; n = 6) specimens in tuberous sclerosis complex to define the developmental phenotype and lineage of giant cells (CGs) in these lesions.
p1543
sg4
(lp1544
(dp1545
g7
I85
sg8
I1
sg9
I4
sg10
g11
sg12
VNeuN
p1546
sa(dp1547
g7
I48
sg8
I1
sg9
I5
sg10
g11
sg12
VCRMP4
p1548
sa(dp1549
g7
I70
sg8
I1
sg9
I3
sg10
g11
sg12
VDCX
p1550
sa(dp1551
g7
I9
sg8
I5
sg9
I37
sg10
g11
sg12
Vcollapsin response mediator protein 4
p1552
sa(dp1553
g7
I76
sg8
I1
sg9
I3
sg10
VP26378
p1554
sg12
VHuD
p1555
sa(dp1556
g7
I0
sg8
I1
sg9
I7
sg10
VP06493
p1557
sg12
Vp34cdc2
p1558
sa(dp1559
g7
I56
sg8
I1
sg9
I12
sg10
g11
sg12
Vdoublecortin
p1560
sasg24
(lp1561
(dp1562
g7
I199
sg8
I3
sg9
I26
sg27
VC0041341
p1563
sg12
Vtuberous sclerosis complex
p1564
sa(dp1565
g7
I136
sg8
I4
sg9
I35
sg27
VC0205768
p1566
sg12
Vsubependymal giant cell astrocytoma
p1567
sa(dp1568
g7
I149
sg8
I1
sg9
I5
sg27
VC0017547
p1569
sg12
Vgiant
p1570
sa(dp1571
g7
I173
sg8
I1
sg9
I4
sg27
VC0205768
p1572
sg12
VSEGA
p1573
sasa(dp1574
g2
VFirst, logistic regression analysis in two human prostate gene expression datasets revealed that expression levels of five genes (CXCL14, ITGAX, LPCAT2, RNASEH2A, and ZNF322) were positively correlated with aggressive prostate cancer and two genes (CCL19 and HIST1H1A) were protective for aggressive prostate cancer.
p1575
sg4
(lp1576
(dp1577
g7
I153
sg8
I1
sg9
I8
sg10
g11
sg12
VRNASEH2A
p1578
sa(dp1579
g7
I130
sg8
I1
sg9
I6
sg10
g11
sg12
VCXCL14
p1580
sa(dp1581
g7
I167
sg8
I1
sg9
I6
sg10
g11
sg12
VZNF322
p1582
sa(dp1583
g7
I138
sg8
I1
sg9
I5
sg10
VP20702
p1584
sg12
VITGAX
p1585
sa(dp1586
g7
I145
sg8
I1
sg9
I6
sg10
g11
sg12
VLPCAT2
p1587
sa(dp1588
g7
I259
sg8
I1
sg9
I8
sg10
g11
sg12
VHIST1H1A
p1589
sa(dp1590
g7
I249
sg8
I1
sg9
I5
sg10
g11
sg12
VCCL19
p1591
sasg24
(lp1592
(dp1593
g7
I218
sg8
I2
sg9
I15
sg27
VC0600139
p1594
sg12
Vprostate cancer
p1595
sa(dp1596
g7
I207
sg8
I1
sg9
I10
sg27
VC0001807
p1597
sg12
Vaggressive
p1598
sa(dp1599
g7
I218
sg8
I2
sg9
I15
sg27
VC0600139
p1600
sg12
Vprostate cancer
p1601
sa(dp1602
g7
I207
sg8
I1
sg9
I10
sg27
VC0001807
p1603
sg12
Vaggressive
p1604
sasa(dp1605
g2
VSecond generation H1 antihistamines (H1A) are currently recommended as first choice medications for allergic rhinitis and rhinoconjunctivitis.
p1606
sg4
(lp1607
(dp1608
g7
I18
sg8
I2
sg9
I17
sg10
VP08620
p1609
sg12
VH1 antihistamines
p1610
sa(dp1611
g7
I37
sg8
I1
sg9
I3
sg10
g11
sg12
VH1A
p1612
sasg24
(lp1613
(dp1614
g7
I122
sg8
I1
sg9
I19
sg27
VC0861155
p1615
sg12
Vrhinoconjunctivitis
p1616
sa(dp1617
g7
I100
sg8
I2
sg9
I17
sg27
VC2607914
p1618
sg12
Vallergic rhinitis
p1619
sasa(dp1620
g2
VConsecutive patients suffering from allergic rhinitis or rhinoconjunctivitis were included and followed prospectively for 30 days from the prescription of a second generation H1A in monotherapy.
p1621
sg4
(lp1622
(dp1623
g7
I175
sg8
I1
sg9
I3
sg10
g11
sg12
VH1A
p1624
sasg24
(lp1625
(dp1626
g7
I57
sg8
I1
sg9
I19
sg27
VC0861155
p1627
sg12
Vrhinoconjunctivitis
p1628
sa(dp1629
g7
I21
sg8
I1
sg9
I9
sg27
VC0683278
p1630
sg12
Vsuffering
p1631
sa(dp1632
g7
I36
sg8
I2
sg9
I17
sg27
VC2607914
p1633
sg12
Vallergic rhinitis
p1634
sasa(dp1635
g2
VAntibody 3.1 potently neutralizes influenza viruses from the H1a clade (i.e., H1, H2, H5, H6) but has little neutralizing activity against the H1b clade.
p1636
sg4
(lp1637
(dp1638
g7
I143
sg8
I1
sg9
I3
sg10
VP16401
p1639
sg12
VH1b
p1640
sasg24
(lp1641
(dp1642
g7
I34
sg8
I1
sg9
I9
sg27
VC0021400
p1643
sg12
Vinfluenza
p1644
sasa(dp1645
g2
VWe have overexpressed OTX2 in retinal pigmented epithelial cells before their transplantation in the eye of a model of retinitis pigmentosa carrying a mutation in Mertk, a gene specifically expressed by retinal pigmented epithelial cells.
p1646
sg4
(lp1647
(dp1648
g7
I22
sg8
I1
sg9
I4
sg10
VP32243
p1649
sg12
VOTX2
p1650
sa(dp1651
g7
I163
sg8
I1
sg9
I5
sg10
g11
sg12
VMertk
p1652
sasg24
(lp1653
(dp1654
g7
I119
sg8
I2
sg9
I20
sg27
VC0035334
p1655
sg12
Vretinitis pigmentosa
p1656
sasa(dp1657
g2
VTransplantation of OTX2-genetically modified cells may be medically effective for other retinal diseases involving the retinal pigmented epithelium as age-related macular degeneration.
p1658
sg4
(lp1659
(dp1660
g7
I19
sg8
I1
sg9
I4
sg10
VP32243
p1661
sg12
VOTX2
p1662
sasg24
(lp1663
(dp1664
g7
I88
sg8
I2
sg9
I16
sg27
VC0035309
p1665
sg12
Vretinal diseases
p1666
sa(dp1667
g7
I151
sg8
I3
sg9
I32
sg27
VC0242383
p1668
sg12
Vage-related macular degeneration
p1669
sasa(dp1670
g2
VTherapeutic restoration of OTX2 expression might help revive RPE and visual function in retinal diseases such as AMD.
p1671
sg4
(lp1672
(dp1673
g7
I27
sg8
I1
sg9
I4
sg10
VP32243
p1674
sg12
VOTX2
p1675
sasg24
(lp1676
(dp1677
g7
I88
sg8
I2
sg9
I16
sg27
VC0035309
p1678
sg12
Vretinal diseases
p1679
sa(dp1680
g7
I113
sg8
I1
sg9
I3
sg27
VC0242383
p1681
sg12
VAMD
p1682
sasa(dp1683
g2
VThe retinal disease resembles conditional mice models that show slow photoreceptor degeneration secondary to loss of Otx2 function in the adult RPE.
p1684
sg4
(lp1685
(dp1686
g7
I117
sg8
I1
sg9
I4
sg10
VP32243
p1687
sg12
VOtx2
p1688
sasg24
(lp1689
(dp1690
g7
I83
sg8
I2
sg9
I22
sg27
VC0043020
p1691
sg12
Vdegeneration secondary
p1692
sa(dp1693
g7
I4
sg8
I2
sg9
I15
sg27
VC0035309
p1694
sg12
Vretinal disease
p1695
sa(dp1696
g7
I69
sg8
I2
sg9
I26
sg27
VC1998028
p1697
sg12
Vphotoreceptor degeneration
p1698
sasa(dp1699
g2
VWhen the beads were coated with amelogenin gene splice products (A+4 or A-4), the expression of osteo-chondrogenic markers (RP59, Sox9, or BSP) was also observed.
p1700
sg4
(lp1701
(dp1702
g7
I32
sg8
I4
sg9
I31
sg10
g11
sg12
Vamelogenin gene splice products
p1703
sa(dp1704
g7
I130
sg8
I1
sg9
I4
sg10
VP48436
p1705
sg12
VSox9
p1706
sasg24
(lp1707
(dp1708
g7
I124
sg8
I1
sg9
I4
sg27
VC3151227
p1709
sg12
VRP59
p1710
sasa(dp1711
g2
VThis study has provided evidence that the regulation of the SVCT2 transporter plays an important role not only in T1D osteoporosis but also in other oxidative stress-related musculoskeletal complications.
p1712
sg4
(lp1713
(dp1714
g7
I60
sg8
I2
sg9
I17
sg10
g11
sg12
VSVCT2 transporter
p1715
sasg24
(lp1716
(dp1717
g7
I118
sg8
I1
sg9
I12
sg27
VC0029456
p1718
sg12
Vosteoporosis
p1719
sa(dp1720
g7
I149
sg8
I2
sg9
I16
sg27
VC0242606
p1721
sg12
Voxidative stress
p1722
sasa(dp1723
g2
VAutosomal recessive HMG-CoA synthase deficiency (HMGCS2D) is characterized by hypoketotic hypoglycemia, vomiting, lethargy, and hepatomegaly after periods of prolonged fasting or illness.
p1724
sg4
(lp1725
(dp1726
g7
I20
sg8
I2
sg9
I16
sg10
VP54868
p1727
sg12
VHMG-CoA synthase
p1728
sasg24
(lp1729
(dp1730
g7
I90
sg8
I1
sg9
I12
sg27
VC0020615
p1731
sg12
Vhypoglycemia
p1732
sa(dp1733
g7
I104
sg8
I1
sg9
I8
sg27
VC0042963
p1734
sg12
Vvomiting
p1735
sa(dp1736
g7
I128
sg8
I1
sg9
I12
sg27
VC0019209
p1737
sg12
Vhepatomegaly
p1738
sa(dp1739
g7
I24
sg8
I1
sg9
I3
sg27
VC2678439
p1740
sg12
VCoA
p1741
sa(dp1742
g7
I114
sg8
I1
sg9
I8
sg27
VC0023380
p1743
sg12
Vlethargy
p1744
sasa(dp1745
g2
VMost frequent disease presentation in our patients was characterized with early and prominent oromandibular dystonia (OMD), followed by severe generalized dystonia and early loss of mobility within the first five years of prolonged disease duration (18.7 +/- 10.0 years).
p1746
sg4
(lp1747
sg24
(lp1748
(dp1749
g7
I94
sg8
I2
sg9
I22
sg27
VC2242577
p1750
sg12
Voromandibular dystonia
p1751
sa(dp1752
g7
I118
sg8
I1
sg9
I3
sg27
VC3150833
p1753
sg12
VOMD
p1754
sa(dp1755
g7
I143
sg8
I2
sg9
I20
sg27
VC1848954
p1756
sg12
Vgeneralized dystonia
p1757
sasa(dp1758
g2
VEight out of 9 patients reached 7 significant clinical milestones (OMD, generalized dystonia, dysarthria, dysphagia, postural instability, gait difficulties, ADL dependency) in the first 4.6 years of disease course.
p1759
sg4
(lp1760
sg24
(lp1761
(dp1762
g7
I72
sg8
I2
sg9
I20
sg27
VC1848954
p1763
sg12
Vgeneralized dystonia
p1764
sa(dp1765
g7
I139
sg8
I2
sg9
I17
sg27
VC0575081
p1766
sg12
Vgait difficulties
p1767
sa(dp1768
g7
I67
sg8
I1
sg9
I3
sg27
VC3150833
p1769
sg12
VOMD
p1770
sa(dp1771
g7
I106
sg8
I1
sg9
I9
sg27
VC0011168
p1772
sg12
Vdysphagia
p1773
sa(dp1774
g7
I94
sg8
I1
sg9
I10
sg27
VC0013362
p1775
sg12
Vdysarthria
p1776
sasa(dp1777
g2
VA smoothelin-deficient mouse model may help to establish the role of smoothelin-A in intestinal contraction and provide a model for myogenic chronic intestinal pseudo-obstruction.
p1778
sg4
(lp1779
sg24
(lp1780
(dp1781
g7
I96
sg8
I1
sg9
I11
sg27
VC1140999
p1782
sg12
Vcontraction
p1783
sa(dp1784
g7
I141
sg8
I3
sg9
I37
sg27
VC0238062
p1785
sg12
Vchronic intestinal pseudo-obstruction
p1786
sasa(dp1787
g2
VThe pathology of mice lacking smoothelin-A is reminiscent of that seen in patients with chronic intestinal pseudo-obstruction.
p1788
sg4
(lp1789
sg24
(lp1790
(dp1791
g7
I4
sg8
I1
sg9
I9
sg27
VC0677042
p1792
sg12
Vpathology
p1793
sa(dp1794
g7
I88
sg8
I3
sg9
I37
sg27
VC0238062
p1795
sg12
Vchronic intestinal pseudo-obstruction
p1796
sasa(dp1797
g2
VHereditary tyrosinemia type 1 (HT1) is characterized by severe progressive liver disease and renal tubular dysfunction.
p1798
sg4
(lp1799
sg24
(lp1800
(dp1801
g7
I0
sg8
I2
sg9
I22
sg27
VC0268483
p1802
sg12
VHereditary tyrosinemia
p1803
sa(dp1804
g7
I93
sg8
I3
sg9
I25
sg27
VC0151747
p1805
sg12
Vrenal tubular dysfunction
p1806
sa(dp1807
g7
I75
sg8
I2
sg9
I13
sg27
VC0023895
p1808
sg12
Vliver disease
p1809
sasa(dp1810
g2
VIf left untreated this deficiency of functional FAH leads to a buildup of toxic metabolites that can cause liver disease, kidney dysfunction and high mortality.
p1811
sg4
(lp1812
(dp1813
g7
I48
sg8
I1
sg9
I3
sg10
VP16930
p1814
sg12
VFAH
p1815
sasg24
(lp1816
(dp1817
g7
I113
sg8
I2
sg9
I15
sg27
VC0022658
p1818
sg12
Vdisease, kidney
p1819
sa(dp1820
g7
I122
sg8
I2
sg9
I18
sg27
VC0151746
p1821
sg12
Vkidney dysfunction
p1822
sasa(dp1823
g2
VIn this study, we investigated whether fumarylacetoacetate hydrolase deficient (FAH-/-) pigs, a novel large-animal model of HT1, develop fibrosis and cirrhosis characteristic of the human disease.
p1824
sg4
(lp1825
(dp1826
g7
I39
sg8
I2
sg9
I29
sg10
VP16930
p1827
sg12
Vfumarylacetoacetate hydrolase
p1828
sasg24
(lp1829
(dp1830
g7
I150
sg8
I1
sg9
I9
sg27
VC0023890
p1831
sg12
Vcirrhosis
p1832
sa(dp1833
g7
I137
sg8
I1
sg9
I8
sg27
VC0016059
p1834
sg12
Vfibrosis
p1835
sasa(dp1836
g2
VUnder conditions of low-dose NTBC, FAH-/- pigs developed liver fibrosis and portal hypertension, and thus may serve as a large-animal model of chronic liver disease.
p1837
sg4
(lp1838
sg24
(lp1839
(dp1840
g7
I57
sg8
I2
sg9
I14
sg27
VC0239946
p1841
sg12
Vliver fibrosis
p1842
sa(dp1843
g7
I76
sg8
I2
sg9
I19
sg27
VC0020541
p1844
sg12
Vportal hypertension
p1845
sa(dp1846
g7
I143
sg8
I3
sg9
I21
sg27
VC0341439
p1847
sg12
Vchronic liver disease
p1848
sasa(dp1849
g2
VFah-deficient mice and pigs are phenotypically analogous to human HT1, but do not recapitulate all the chronic features of the human disorder, especially liver fibrosis and cirrhosis.
p1850
sg4
(lp1851
(dp1852
g7
I0
sg8
I1
sg9
I3
sg10
VP16930
p1853
sg12
VFah
p1854
sasg24
(lp1855
(dp1856
g7
I154
sg8
I2
sg9
I14
sg27
VC0239946
p1857
sg12
Vliver fibrosis
p1858
sa(dp1859
g7
I173
sg8
I1
sg9
I9
sg27
VC0023890
p1860
sg12
Vcirrhosis
p1861
sasa(dp1862
g2
VMore importantly, the Fah(-/-) rats developed remarkable liver fibrosis and cirrhosis, which have not been observed in Fah mutant mice or pigs.
p1863
sg4
(lp1864
(dp1865
g7
I22
sg8
I1
sg9
I8
sg10
VP16930
p1866
sg12
VFah(-/-)
p1867
sa(dp1868
g7
I119
sg8
I2
sg9
I10
sg10
VP16930
p1869
sg12
VFah mutant
p1870
sasg24
(lp1871
(dp1872
g7
I57
sg8
I2
sg9
I14
sg27
VC0239946
p1873
sg12
Vliver fibrosis
p1874
sa(dp1875
g7
I76
sg8
I1
sg9
I9
sg27
VC0023890
p1876
sg12
Vcirrhosis
p1877
sa(dp1878
g7
I123
sg8
I1
sg9
I6
sg27
VC0596988
p1879
sg12
Vmutant
p1880
sasa(dp1881
g2
VMoreover, the highly efficient repopulation of hepatocytes in Fah(-/-) livers prevented the progression of liver fibrosis to cirrhosis and in turn restored liver architecture.
p1882
sg4
(lp1883
(dp1884
g7
I62
sg8
I1
sg9
I8
sg10
VP16930
p1885
sg12
VFah(-/-)
p1886
sasg24
(lp1887
(dp1888
g7
I125
sg8
I1
sg9
I9
sg27
VC0023890
p1889
sg12
Vcirrhosis
p1890
sa(dp1891
g7
I107
sg8
I2
sg9
I14
sg27
VC0239946
p1892
sg12
Vliver fibrosis
p1893
sasa(dp1894
g2
VThese results indicate that Fah(-/-) rats may be used as an animal model of HT1 with liver cirrhosis.
p1895
sg4
(lp1896
(dp1897
g7
I28
sg8
I1
sg9
I3
sg10
VP16930
p1898
sg12
VFah
p1899
sasg24
(lp1900
(dp1901
g7
I85
sg8
I2
sg9
I15
sg27
VC0023890
p1902
sg12
Vliver cirrhosis
p1903
sasa(dp1904
g2
VRecent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).
p1905
sg4
(lp1906
(dp1907
g7
I178
sg8
I1
sg9
I8
sg10
g11
sg12
VARHGEF12
p1908
sa(dp1909
g7
I268
sg8
I1
sg9
I5
sg10
g11
sg12
VGLIS3
p1910
sa(dp1911
g7
I201
sg8
I1
sg9
I5
sg10
g11
sg12
VATXN2
p1912
sa(dp1913
g7
I150
sg8
I1
sg9
I4
sg10
g11
sg12
VGMDS
p1914
sa(dp1915
g7
I255
sg8
I1
sg9
I5
sg10
g11
sg12
VEPDR1
p1916
sa(dp1917
g7
I194
sg8
I1
sg9
I5
sg10
g11
sg12
VFOXC1
p1918
sa(dp1919
g7
I162
sg8
I1
sg9
I6
sg10
g11
sg12
VTGFBR3
p1920
sa(dp1921
g7
I283
sg8
I1
sg9
I11
sg10
g11
sg12
VDPM2-FAM102
p1922
sa(dp1923
g7
I275
sg8
I1
sg9
I6
sg10
g11
sg12
VFERMT2
p1924
sa(dp1925
g7
I156
sg8
I1
sg9
I4
sg10
g11
sg12
VPMM2
p1926
sa(dp1927
g7
I188
sg8
I1
sg9
I4
sg10
g11
sg12
VGAS7
p1928
sa(dp1929
g7
I262
sg8
I1
sg9
I4
sg10
VP28329
p1930
sg12
VCHAT
p1931
sa(dp1932
g7
I143
sg8
I1
sg9
I5
sg10
g11
sg12
VAFAP1
p1933
sasg24
(lp1934
(dp1935
g7
I60
sg8
I1
sg9
I8
sg27
VC0017601
p1936
sg12
Vglaucoma
p1937
sa(dp1938
g7
I114
sg8
I2
sg9
I19
sg27
VC0017612
p1939
sg12
Vopen-angle glaucoma
p1940
sa(dp1941
g7
I323
sg8
I1
sg9
I3
sg27
VC0206368
p1942
sg12
VXFS
p1943
sa(dp1944
g7
I100
sg8
I1
sg9
I4
sg27
VC0339573
p1945
sg12
VPOAG
p1946
sa(dp1947
g7
I301
sg8
I2
sg9
I20
sg27
VC0206368
p1948
sg12
Vexfoliation syndrome
p1949
sa(dp1950
g7
I223
sg8
I3
sg9
I30
sg27
VC0017606
p1951
sg12
Vprimary angle-closure glaucoma
p1952
sa(dp1953
g7
I60
sg8
I1
sg9
I8
sg27
VC0017601
p1954
sg12
Vglaucoma
p1955
sasa(dp1956
g2
VRecently, a genome-wide association study identified genetic variations in ITGA4 and HLA-DRB1 that affect the LMR levels and were widely believed to be susceptibility genes for autoimmune diseases, including rheumatoid arthritis (RA).
p1957
sg4
(lp1958
(dp1959
g7
I85
sg8
I1
sg9
I3
sg10
VP30486
p1960
sg12
VHLA
p1961
sa(dp1962
g7
I89
sg8
I1
sg9
I4
sg10
g11
sg12
VDRB1
p1963
sa(dp1964
g7
I75
sg8
I1
sg9
I5
sg10
VP13612
p1965
sg12
VITGA4
p1966
sasg24
(lp1967
(dp1968
g7
I208
sg8
I2
sg9
I20
sg27
VC0003873
p1969
sg12
Vrheumatoid arthritis
p1970
sa(dp1971
g7
I230
sg8
I1
sg9
I2
sg27
VC0003873
p1972
sg12
VRA
p1973
sa(dp1974
g7
I177
sg8
I2
sg9
I19
sg27
VC0004364
p1975
sg12
Vautoimmune diseases
p1976
sasa(dp1977
g2
VTo evaluate serum levels of fractalkine (FKN), a mediator of leukocyte transmigration, C-reactive protein (CRP) and expression of integrins CD11a and CD49d on peripheral blood lymphocytes in systemic sclerosis (SSc) and to investigate whether they are modulated by intravenous prostaglandin E1 (PGE1).
p1978
sg4
(lp1979
(dp1980
g7
I140
sg8
I1
sg9
I5
sg10
VP20701
p1981
sg12
VCD11a
p1982
sa(dp1983
g7
I150
sg8
I1
sg9
I5
sg10
VP13612
p1984
sg12
VCD49d
p1985
sa(dp1986
g7
I107
sg8
I1
sg9
I3
sg10
VP02741
p1987
sg12
VCRP
p1988
sa(dp1989
g7
I87
sg8
I2
sg9
I18
sg10
VP02741
p1990
sg12
VC-reactive protein
p1991
sasg24
(lp1992
(dp1993
g7
I211
sg8
I1
sg9
I3
sg27
VC0036421
p1994
sg12
VSSc
p1995
sa(dp1996
g7
I191
sg8
I2
sg9
I18
sg27
VC0036421
p1997
sg12
Vsystemic sclerosis
p1998
sasa(dp1999
g2
VProstaglandin E1 down-regulates serum fractalkine level, as well as CD11a and CD49d expression on peripheral blood lymphocytes, which suggests additional mechanisms in which this vasodilatatory agent exerts its efficacy in systemic sclerosis.
p2000
sg4
(lp2001
(dp2002
g7
I78
sg8
I1
sg9
I5
sg10
VP13612
p2003
sg12
VCD49d
p2004
sa(dp2005
g7
I68
sg8
I1
sg9
I5
sg10
VP20701
p2006
sg12
VCD11a
p2007
sasg24
(lp2008
(dp2009
g7
I223
sg8
I2
sg9
I18
sg27
VC0036421
p2010
sg12
Vsystemic sclerosis
p2011
sasa(dp2012
g2
VMR-1S directly phosphorylates and activates the MEK-ERK-RSK pathway to accelerate cancer growth and facilitates metastasis by activating the MLC2-FAK-AKT pathway.
p2013
sg4
(lp2014
(dp2015
g7
I141
sg8
I1
sg9
I4
sg10
VP24844
p2016
sg12
VMLC2
p2017
sa(dp2018
g7
I150
sg8
I1
sg9
I3
sg10
g11
sg12
VAKT
p2019
sa(dp2020
g7
I48
sg8
I1
sg9
I3
sg10
VP45985
p2021
sg12
VMEK
p2022
sa(dp2023
g7
I52
sg8
I1
sg9
I3
sg10
VP29323
p2024
sg12
VERK
p2025
sa(dp2026
g7
I146
sg8
I1
sg9
I3
sg10
g11
sg12
VFAK
p2027
sa(dp2028
g7
I0
sg8
I1
sg9
I5
sg10
VP08235
p2029
sg12
VMR-1S
p2030
sa(dp2031
g7
I56
sg8
I1
sg9
I3
sg10
VP51812
p2032
sg12
VRSK
p2033
sasg24
(lp2034
(dp2035
g7
I112
sg8
I1
sg9
I10
sg27
VC0027627
p2036
sg12
Vmetastasis
p2037
sa(dp2038
g7
I82
sg8
I1
sg9
I6
sg27
VC0006826
p2039
sg12
Vcancer
p2040
sasa(dp2041
g2
VAfter overexpressing TMEM17, levels of p-ERK and its downstream molecules, p-P90RSK and Snail, were down-regulated, while levels of Occludin and Zo-1 were up-regulated, which result in the inhibition of invasion and migration ability of lung cancer cells.
p2042
sg4
(lp2043
(dp2044
g7
I132
sg8
I1
sg9
I8
sg10
g11
sg12
VOccludin
p2045
sa(dp2046
g7
I41
sg8
I1
sg9
I3
sg10
VP29323
p2047
sg12
VERK
p2048
sa(dp2049
g7
I145
sg8
I1
sg9
I4
sg10
g11
sg12
VZo-1
p2050
sa(dp2051
g7
I21
sg8
I1
sg9
I6
sg10
g11
sg12
VTMEM17
p2052
sasg24
(lp2053
(dp2054
g7
I203
sg8
I1
sg9
I8
sg27
VC2699153
p2055
sg12
Vinvasion
p2056
sa(dp2057
g7
I237
sg8
I2
sg9
I11
sg27
VC0684249
p2058
sg12
Vlung cancer
p2059
sasa(dp2060
g2
VHerein, to understand the underlying relationship between obesity and brain tumors, we investigated the effect of leptin, alone or in combination with sPLA2-IIA on astrocytoma cell functions.
p2061
sg4
(lp2062
(dp2063
g7
I114
sg8
I1
sg9
I6
sg10
VP41159
p2064
sg12
Vleptin
p2065
sa(dp2066
g7
I151
sg8
I1
sg9
I9
sg10
VP14555
p2067
sg12
VsPLA2-IIA
p2068
sasg24
(lp2069
(dp2070
g7
I164
sg8
I1
sg9
I11
sg27
VC0004114
p2071
sg12
Vastrocytoma
p2072
sa(dp2073
g7
I70
sg8
I2
sg9
I12
sg27
VC0006118
p2074
sg12
Vbrain tumors
p2075
sa(dp2076
g7
I58
sg8
I1
sg9
I7
sg27
VC0028754
p2077
sg12
Vobesity
p2078
sasa(dp2079
g2
VPLA2g2a was elevated with hypothyroidism and high fat diets which may contribute to the low grade inflammation associated with hypothyroidism and diet induced obesity.
p2080
sg4
(lp2081
(dp2082
g7
I0
sg8
I1
sg9
I7
sg10
VP14555
p2083
sg12
VPLA2g2a
p2084
sasg24
(lp2085
(dp2086
g7
I26
sg8
I1
sg9
I14
sg27
VC0020676
p2087
sg12
Vhypothyroidism
p2088
sa(dp2089
g7
I26
sg8
I1
sg9
I14
sg27
VC0020676
p2090
sg12
Vhypothyroidism
p2091
sa(dp2092
g7
I98
sg8
I1
sg9
I12
sg27
VC0021368
p2093
sg12
Vinflammation
p2094
sa(dp2095
g7
I159
sg8
I1
sg9
I7
sg27
VC0028754
p2096
sg12
Vobesity
p2097
sasa(dp2098
g2
VThere were significant correlations between age, visceral obesity, MPO, sPLA2, and SAA (r = 0.43; p = 0.00; r = 0.30; p = 0.00; r = 0.28; p = 0.00 and r = 0.53; p = 0.00).
p2099
sg4
(lp2100
(dp2101
g7
I67
sg8
I1
sg9
I3
sg10
VP05164
p2102
sg12
VMPO
p2103
sa(dp2104
g7
I72
sg8
I1
sg9
I5
sg10
VP14555
p2105
sg12
VsPLA2
p2106
sasg24
(lp2107
(dp2108
g7
I49
sg8
I2
sg9
I16
sg27
VC2936179
p2109
sg12
Vvisceral obesity
p2110
sasa(dp2111
g2
VWe suggest that pla2g2a may have a causal relationship with chronic adiposity and metabolic syndrome and that its inhibition in vivo may be a valuable new approach to treat obesity, type 2 diabetes, and metabolic dysfunction in humans.
p2112
sg4
(lp2113
(dp2114
g7
I16
sg8
I1
sg9
I7
sg10
VP14555
p2115
sg12
Vpla2g2a
p2116
sasg24
(lp2117
(dp2118
g7
I182
sg8
I3
sg9
I15
sg27
VC0011860
p2119
sg12
Vtype 2 diabetes
p2120
sa(dp2121
g7
I68
sg8
I1
sg9
I9
sg27
VC0028754
p2122
sg12
Vadiposity
p2123
sa(dp2124
g7
I173
sg8
I1
sg9
I7
sg27
VC0028754
p2125
sg12
Vobesity
p2126
sa(dp2127
g7
I82
sg8
I2
sg9
I18
sg27
VC0524620
p2128
sg12
Vmetabolic syndrome
p2129
sasa(dp2130
g2
VTrypanosoma brucei, protozoan parasites that cause human African trypanosomiasis (HAT), depend on ornithine uptake and metabolism by ornithine decarboxylase (ODC) for survival.
p2131
sg4
(lp2132
(dp2133
g7
I133
sg8
I2
sg9
I23
sg10
VP11926
p2134
sg12
Vornithine decarboxylase
p2135
sa(dp2136
g7
I158
sg8
I1
sg9
I3
sg10
VP11926
p2137
sg12
VODC
p2138
sa(dp2139
g7
I82
sg8
I1
sg9
I3
sg10
g11
sg12
VHAT
p2140
sa(dp2141
g7
I51
sg8
I3
sg9
I29
sg10
g11
sg12
Vhuman African trypanosomiasis
p2142
sasg24
(lp2143
(dp2144
g7
I57
sg8
I2
sg9
I23
sg27
VC0041228
p2145
sg12
VAfrican trypanosomiasis
p2146
sasa(dp2147
g2
VFurthermore, the molecular dynamics simulation work reveals that ZINC67909154 could be a potent inhibitor and this compound can be used to combat VL disease Conclusion: This study concludes that ZINC67909154 has the great potential to inhibit L. donovani ODC and would add to the drug discovery process against visceral leishmaniasis.
p2148
sg4
(lp2149
sg24
(lp2150
(dp2151
g7
I311
sg8
I2
sg9
I22
sg27
VC0023290
p2152
sg12
Vvisceral leishmaniasis
p2153
sa(dp2154
g7
I269
sg8
I1
sg9
I3
sg27
VC0004269
p2155
sg12
Vadd
p2156
sasa(dp2157
g2
Varginase (ARG), ornithine decarboxylase (ODC), S-adenosylmethionine decarboxylase (AdoMetDC), spermidine synthase (SpdS), trypanothione synthetase (TryS or TSA), trypanothione reductase (TryR or TR), tryparedoxin peroxidase (TXNPx), deoxyhypusine synthase (DHS) and deoxyhypusine hydroxylase (DOHH) are promising targets for the development of new drugs against leishmaniasis.
p2158
sg4
(lp2159
(dp2160
g7
I0
sg8
I4
sg9
I39
sg10
VP11926
p2161
sg12
Varginase (ARG), ornithine decarboxylase
p2162
sa(dp2163
g7
I266
sg8
I2
sg9
I25
sg10
g11
sg12
Vdeoxyhypusine hydroxylase
p2164
sa(dp2165
g7
I115
sg8
I1
sg9
I4
sg10
VP35453
p2166
sg12
VSpdS
p2167
sa(dp2168
g7
I225
sg8
I1
sg9
I5
sg10
VP30041
p2169
sg12
VTXNPx
p2170
sa(dp2171
g7
I83
sg8
I1
sg9
I8
sg10
VP17707
p2172
sg12
VAdoMetDC
p2173
sa(dp2174
g7
I156
sg8
I1
sg9
I3
sg10
VP32119
p2175
sg12
VTSA
p2176
sa(dp2177
g7
I94
sg8
I2
sg9
I19
sg10
VP19623
p2178
sg12
Vspermidine synthase
p2179
sa(dp2180
g7
I257
sg8
I1
sg9
I3
sg10
VP49366
p2181
sg12
VDHS
p2182
sa(dp2183
g7
I41
sg8
I1
sg9
I3
sg10
VP11926
p2184
sg12
VODC
p2185
sa(dp2186
g7
I162
sg8
I2
sg9
I23
sg10
g11
sg12
Vtrypanothione reductase
p2187
sa(dp2188
g7
I200
sg8
I2
sg9
I23
sg10
VP30041
p2189
sg12
Vtryparedoxin peroxidase
p2190
sa(dp2191
g7
I293
sg8
I1
sg9
I4
sg10
g11
sg12
VDOHH
p2192
sa(dp2193
g7
I47
sg8
I2
sg9
I34
sg10
VP17707
p2194
sg12
VS-adenosylmethionine decarboxylase
p2195
sa(dp2196
g7
I233
sg8
I2
sg9
I22
sg10
VP49366
p2197
sg12
Vdeoxyhypusine synthase
p2198
sasg24
(lp2199
(dp2200
g7
I257
sg8
I1
sg9
I3
sg27
VC0272051
p2201
sg12
VDHS
p2202
sa(dp2203
g7
I362
sg8
I1
sg9
I13
sg27
VC0023281
p2204
sg12
Vleishmaniasis
p2205
sasa(dp2206
g2
VThe plasma levels of arginase I, ornithine decarboxylase (ODC), transforming growth factor Beta (TGF-Beta), and prostaglandin E2 (PGE2) were higher in patients with DCL, compared with patients with localized cutaneous leishmaniasis (LCL) or with controls from an area of endemicity.
p2207
sg4
(lp2208
(dp2209
g7
I33
sg8
I2
sg9
I23
sg10
VP11926
p2210
sg12
Vornithine decarboxylase
p2211
sa(dp2212
g7
I21
sg8
I2
sg9
I10
sg10
VP05089
p2213
sg12
Varginase I
p2214
sa(dp2215
g7
I64
sg8
I4
sg9
I31
sg10
VP18075
p2216
sg12
Vtransforming growth factor Beta
p2217
sa(dp2218
g7
I58
sg8
I1
sg9
I3
sg10
VP11926
p2219
sg12
VODC
p2220
sa(dp2221
g7
I97
sg8
I1
sg9
I8
sg10
VP18075
p2222
sg12
VTGF-Beta
p2223
sasg24
(lp2224
(dp2225
g7
I208
sg8
I2
sg9
I23
sg27
VC0023283
p2226
sg12
Vcutaneous leishmaniasis
p2227
sasa(dp2228
g2
VImmunohistochemistry confirmed that arginase I, ODC, and cyclooxygenase2 expression was higher in lesion biopsy specimens from patients with DCL than in those from patients with LCL.
p2229
sg4
(lp2230
(dp2231
g7
I48
sg8
I1
sg9
I3
sg10
VP11926
p2232
sg12
VODC
p2233
sa(dp2234
g7
I36
sg8
I2
sg9
I10
sg10
VP05089
p2235
sg12
Varginase I
p2236
sasg24
(lp2237
sa(dp2238
g2
VOur data implicate arginase I, ODC, PGE2, and TGF-Beta in the failure to mount an efficient immune response and suggest perspectives in the development of new strategies for therapeutic intervention for patients with DCL.
p2239
sg4
(lp2240
(dp2241
g7
I31
sg8
I1
sg9
I3
sg10
VP11926
p2242
sg12
VODC
p2243
sa(dp2244
g7
I19
sg8
I2
sg9
I10
sg10
VP05089
p2245
sg12
Varginase I
p2246
sa(dp2247
g7
I46
sg8
I1
sg9
I8
sg10
VP18075
p2248
sg12
VTGF-Beta
p2249
sasg24
(lp2250
sa(dp2251
g2
VThe active form of vitamin B6, pyridoxal 5-phosphate, is, besides its antioxidative properties, a cofactor for a variety of essential enzymes present in the malaria parasite which includes the ornithine decarboxylase (ODC, synthesis of polyamines), the aspartate aminotransferase (AspAT, involved in the protein biosynthesis), and the serine hydroxymethyltransferase (SHMT, a key enzyme within the folate metabolism).
p2252
sg4
(lp2253
(dp2254
g7
I335
sg8
I2
sg9
I31
sg10
VP34896
p2255
sg12
Vserine hydroxymethyltransferase
p2256
sa(dp2257
g7
I281
sg8
I1
sg9
I5
sg10
VP17174
p2258
sg12
VAspAT
p2259
sa(dp2260
g7
I218
sg8
I1
sg9
I3
sg10
VP11926
p2261
sg12
VODC
p2262
sa(dp2263
g7
I193
sg8
I2
sg9
I23
sg10
VP11926
p2264
sg12
Vornithine decarboxylase
p2265
sa(dp2266
g7
I253
sg8
I2
sg9
I26
sg10
VP17174
p2267
sg12
Vaspartate aminotransferase
p2268
sa(dp2269
g7
I368
sg8
I1
sg9
I4
sg10
VP34896
p2270
sg12
VSHMT
p2271
sasg24
(lp2272
(dp2273
g7
I157
sg8
I1
sg9
I7
sg27
VC0024530
p2274
sg12
Vmalaria
p2275
sasa(dp2276
g2
VAlfa-Difluoromethylornithine (DFMO), a potent drug used for the treatment of African sleeping sickness is an irreversible inhibitor of ornithine decarboxylase (ODC), the first rate limiting enzyme of polyamine biosynthesis.
p2277
sg4
(lp2278
(dp2279
g7
I135
sg8
I2
sg9
I23
sg10
VP11926
p2280
sg12
Vornithine decarboxylase
p2281
sa(dp2282
g7
I160
sg8
I1
sg9
I3
sg10
VP11926
p2283
sg12
VODC
p2284
sasg24
(lp2285
(dp2286
g7
I77
sg8
I3
sg9
I25
sg27
VC0041228
p2287
sg12
VAfrican sleeping sickness
p2288
sasa(dp2289
g2
VThis is the first study from north India reporting CYP1B1 mutations in Axenfeld-Rieger syndrome with bilateral buphthalmos and early onset glaucoma.
p2290
sg4
(lp2291
(dp2292
g7
I35
sg8
I3
sg9
I22
sg10
g11
sg12
VIndia reporting CYP1B1
p2293
sasg24
(lp2294
(dp2295
g7
I71
sg8
I2
sg9
I24
sg27
VC0265341
p2296
sg12
VAxenfeld-Rieger syndrome
p2297
sa(dp2298
g7
I139
sg8
I1
sg9
I8
sg27
VC0017601
p2299
sg12
Vglaucoma
p2300
sa(dp2301
g7
I111
sg8
I1
sg9
I11
sg27
VC0020302
p2302
sg12
Vbuphthalmos
p2303
sasa(dp2304
g2
VPurported BS2 cases may be divided into: (1) Bardet-Biedl syndrome with fortuitous coloboma or aniridia, (2) BS2 sensu stricto, a recessively inherited syndrome of sexual infantilism, short stature, coloboma, and preaxial polydactyly without obesity, only known from the original report, (3) a "new" dominantly inherited form of colobomatous microphthalmia occasionally associated with obesity, hypogonadism, and mental retardation, to which our observations belong.
p2305
sg4
(lp2306
sg24
(lp2307
(dp2308
g7
I58
sg8
I1
sg9
I8
sg27
VC0039082
p2309
sg12
Vsyndrome
p2310
sa(dp2311
g7
I213
sg8
I2
sg9
I20
sg27
VC0345354
p2312
sg12
Vpreaxial polydactyly
p2313
sa(dp2314
g7
I184
sg8
I2
sg9
I13
sg27
VC0013336
p2315
sg12
Vshort stature
p2316
sa(dp2317
g7
I164
sg8
I2
sg9
I18
sg27
VC0242341
p2318
sg12
Vsexual infantilism
p2319
sa(dp2320
g7
I45
sg8
I2
sg9
I21
sg27
VC0752166
p2321
sg12
VBardet-Biedl syndrome
p2322
sa(dp2323
g7
I95
sg8
I1
sg9
I8
sg27
VC0003076
p2324
sg12
Vaniridia
p2325
sa(dp2326
g7
I413
sg8
I2
sg9
I18
sg27
VC0025362
p2327
sg12
Vmental retardation
p2328
sa(dp2329
g7
I83
sg8
I1
sg9
I8
sg27
VC0009363
p2330
sg12
Vcoloboma
p2331
sa(dp2332
g7
I83
sg8
I1
sg9
I8
sg27
VC0009363
p2333
sg12
Vcoloboma
p2334
sa(dp2335
g7
I242
sg8
I1
sg9
I7
sg27
VC0028754
p2336
sg12
Vobesity
p2337
sa(dp2338
g7
I329
sg8
I2
sg9
I27
sg27
VC2931500
p2339
sg12
Vcolobomatous microphthalmia
p2340
sa(dp2341
g7
I395
sg8
I1
sg9
I12
sg27
VC0020619
p2342
sg12
Vhypogonadism
p2343
sa(dp2344
g7
I242
sg8
I1
sg9
I7
sg27
VC0028754
p2345
sg12
Vobesity
p2346
sasa(dp2347
g2
VGanglioneuromas (GNs) are benign tumors resulting from neural crest tissue.
p2348
sg4
(lp2349
sg24
(lp2350
(dp2351
g7
I17
sg8
I1
sg9
I3
sg27
VC0017075
p2352
sg12
VGNs
p2353
sa(dp2354
g7
I26
sg8
I2
sg9
I13
sg27
VC0086692
p2355
sg12
Vbenign tumors
p2356
sa(dp2357
g7
I0
sg8
I1
sg9
I15
sg27
VC0017075
p2358
sg12
VGanglioneuromas
p2359
sa(dp2360
g7
I62
sg8
I1
sg9
I5
sg27
VC0206138
p2361
sg12
Vcrest
p2362
sasa(dp2363
g2
VAdrenal ganglioneuromas (GNs) constitute rare, differentiated tumors which originate from neural crest cells.
p2364
sg4
(lp2365
sg24
(lp2366
(dp2367
g7
I62
sg8
I1
sg9
I6
sg27
VC0027651
p2368
sg12
Vtumors
p2369
sa(dp2370
g7
I97
sg8
I1
sg9
I5
sg27
VC0206138
p2371
sg12
Vcrest
p2372
sa(dp2373
g7
I8
sg8
I1
sg9
I15
sg27
VC0017075
p2374
sg12
Vganglioneuromas
p2375
sa(dp2376
g7
I25
sg8
I1
sg9
I3
sg27
VC0017075
p2377
sg12
VGNs
p2378
sasa(dp2379
g2
VGanglioneuromas (GNs) are hamartomatous tumors derived from the autonomic nervous system.
p2380
sg4
(lp2381
sg24
(lp2382
(dp2383
g7
I74
sg8
I1
sg9
I7
sg27
VC0027769
p2384
sg12
Vnervous
p2385
sa(dp2386
g7
I17
sg8
I1
sg9
I3
sg27
VC0017075
p2387
sg12
VGNs
p2388
sa(dp2389
g7
I0
sg8
I1
sg9
I15
sg27
VC0017075
p2390
sg12
VGanglioneuromas
p2391
sa(dp2392
g7
I40
sg8
I1
sg9
I6
sg27
VC0027651
p2393
sg12
Vtumors
p2394
sa(dp2395
g7
I26
sg8
I1
sg9
I13
sg27
VC0018552
p2396
sg12
Vhamartomatous
p2397
sasa(dp2398
g2
VGNs are categorized into three different morphological subtypes, namely, polypoid GN, ganglioneuromatous polyposis, and diffuse ganglioneuromatosis.
p2399
sg4
(lp2400
(dp2401
g7
I0
sg8
I1
sg9
I3
sg10
VP15586
p2402
sg12
VGNs
p2403
sasg24
(lp2404
(dp2405
g7
I105
sg8
I1
sg9
I9
sg27
VC0334108
p2406
sg12
Vpolyposis
p2407
sa(dp2408
g7
I128
sg8
I1
sg9
I19
sg27
VC0334595
p2409
sg12
Vganglioneuromatosis
p2410
sasa(dp2411
g2
VGanglioneuromas (GNs) arising from neural crest sympathogonia are rare benign neurogenic tumors.
p2412
sg4
(lp2413
sg24
(lp2414
(dp2415
g7
I89
sg8
I1
sg9
I6
sg27
VC0027651
p2416
sg12
Vtumors
p2417
sa(dp2418
g7
I17
sg8
I1
sg9
I3
sg27
VC0017075
p2419
sg12
VGNs
p2420
sa(dp2421
g7
I0
sg8
I1
sg9
I15
sg27
VC0017075
p2422
sg12
VGanglioneuromas
p2423
sa(dp2424
g7
I42
sg8
I1
sg9
I5
sg27
VC0206138
p2425
sg12
Vcrest
p2426
sasa(dp2427
g2
VGanglioneuromas (GNs) are neural crest cell-derived tumors and rarely occur in the adrenal gland.
p2428
sg4
(lp2429
sg24
(lp2430
(dp2431
g7
I17
sg8
I1
sg9
I3
sg27
VC0017075
p2432
sg12
VGNs
p2433
sa(dp2434
g7
I0
sg8
I1
sg9
I15
sg27
VC0017075
p2435
sg12
VGanglioneuromas
p2436
sa(dp2437
g7
I52
sg8
I1
sg9
I6
sg27
VC0027651
p2438
sg12
Vtumors
p2439
sa(dp2440
g7
I33
sg8
I1
sg9
I5
sg27
VC0206138
p2441
sg12
Vcrest
p2442
sasa(dp2443
g2
VGanglioneuromas (GNs) are the rarest and most benign of the neuroblastic tumors.
p2444
sg4
(lp2445
sg24
(lp2446
(dp2447
g7
I17
sg8
I1
sg9
I3
sg27
VC0017075
p2448
sg12
VGNs
p2449
sa(dp2450
g7
I0
sg8
I1
sg9
I15
sg27
VC0017075
p2451
sg12
VGanglioneuromas
p2452
sa(dp2453
g7
I73
sg8
I1
sg9
I6
sg27
VC0027651
p2454
sg12
Vtumors
p2455
sasa(dp2456
g2
VGanglioneuromas (GNs) are rare benign tumors and their association with neurofibromatosis type 1 (NF-1) is especially uncommon.
p2457
sg4
(lp2458
(dp2459
g7
I72
sg8
I3
sg9
I24
sg10
VP21359
p2460
sg12
Vneurofibromatosis type 1
p2461
sa(dp2462
g7
I98
sg8
I1
sg9
I4
sg10
VP21359
p2463
sg12
VNF-1
p2464
sasg24
(lp2465
(dp2466
g7
I72
sg8
I3
sg9
I24
sg27
VC0027831
p2467
sg12
Vneurofibromatosis type 1
p2468
sa(dp2469
g7
I17
sg8
I1
sg9
I3
sg27
VC0017075
p2470
sg12
VGNs
p2471
sa(dp2472
g7
I98
sg8
I1
sg9
I4
sg27
VC0027831
p2473
sg12
VNF-1
p2474
sa(dp2475
g7
I31
sg8
I2
sg9
I13
sg27
VC0086692
p2476
sg12
Vbenign tumors
p2477
sa(dp2478
g7
I0
sg8
I1
sg9
I15
sg27
VC0017075
p2479
sg12
VGanglioneuromas
p2480
sasa(dp2481
g2
VFour of eight T1D-specific regions contained known type 2 diabetes (T2D) candidate genes (COBL, GLIS3, RNLS and BCAR1), suggesting a shared cellular etiology.
p2482
sg4
(lp2483
(dp2484
g7
I103
sg8
I1
sg9
I4
sg10
g11
sg12
VRNLS
p2485
sa(dp2486
g7
I90
sg8
I1
sg9
I4
sg10
g11
sg12
VCOBL
p2487
sa(dp2488
g7
I96
sg8
I1
sg9
I5
sg10
g11
sg12
VGLIS3
p2489
sa(dp2490
g7
I112
sg8
I1
sg9
I5
sg10
VP56945
p2491
sg12
VBCAR1
p2492
sasg24
(lp2493
(dp2494
g7
I68
sg8
I1
sg9
I3
sg27
VC0011860
p2495
sg12
VT2D
p2496
sa(dp2497
g7
I51
sg8
I3
sg9
I15
sg27
VC0011860
p2498
sg12
Vtype 2 diabetes
p2499
sasa(dp2500
g2
VAutoantibodies to insulin (IAA), GAD (GADA), insulinoma-associated antigen-2 (IA-2A) and zinc transporter 8 (ZnT8A) were measured in follow-up sera, and genotyping for type 1 diabetes susceptibility genes (HLA-DR/HLA-DQ, INS variable number of tandem repeats [VNTR] and single nucleotide polymorphisms at PTPN22, PTPN2, ERBB3, IL2, SH2B3, CTLA4, IFIH1, KIAA0350 [also known as CLEC16A], CD25, IL18RAP, IL10, COBL) was performed on the DNA samples of children born to a parent with type 1 diabetes and prospectively followed from birth for up to 22 years.
p2501
sg4
(lp2502
(dp2503
g7
I353
sg8
I1
sg9
I8
sg10
g11
sg12
VKIAA0350
p2504
sa(dp2505
g7
I206
sg8
I1
sg9
I6
sg10
VP30486
p2506
sg12
VHLA-DR
p2507
sa(dp2508
g7
I393
sg8
I1
sg9
I7
sg10
g11
sg12
VIL18RAP
p2509
sa(dp2510
g7
I320
sg8
I1
sg9
I5
sg10
VP21860
p2511
sg12
VERBB3
p2512
sa(dp2513
g7
I89
sg8
I3
sg9
I18
sg10
g11
sg12
Vzinc transporter 8
p2514
sa(dp2515
g7
I305
sg8
I1
sg9
I5
sg10
VP17706
p2516
sg12
VPTPN2
p2517
sa(dp2518
g7
I206
sg8
I1
sg9
I3
sg10
VP30486
p2519
sg12
VHLA
p2520
sa(dp2521
g7
I305
sg8
I1
sg9
I6
sg10
g11
sg12
VPTPN22
p2522
sa(dp2523
g7
I377
sg8
I1
sg9
I7
sg10
g11
sg12
VCLEC16A
p2524
sa(dp2525
g7
I339
sg8
I1
sg9
I5
sg10
VP16410
p2526
sg12
VCTLA4
p2527
sa(dp2528
g7
I402
sg8
I1
sg9
I4
sg10
VP22301
p2529
sg12
VIL10
p2530
sa(dp2531
g7
I408
sg8
I1
sg9
I4
sg10
g11
sg12
VCOBL
p2532
sa(dp2533
g7
I332
sg8
I1
sg9
I5
sg10
g11
sg12
VSH2B3
p2534
sa(dp2535
g7
I346
sg8
I1
sg9
I5
sg10
g11
sg12
VIFIH1
p2536
sa(dp2537
g7
I387
sg8
I1
sg9
I4
sg10
VP01589
p2538
sg12
VCD25
p2539
sa(dp2540
g7
I327
sg8
I1
sg9
I3
sg10
VP60568
p2541
sg12
VIL2
p2542
sa(dp2543
g7
I18
sg8
I1
sg9
I7
sg10
VP01308
p2544
sg12
Vinsulin
p2545
sasg24
(lp2546
(dp2547
g7
I33
sg8
I1
sg9
I3
sg27
VC0270549
p2548
sg12
VGAD
p2549
sa(dp2550
g7
I45
sg8
I1
sg9
I10
sg27
VC0021670
p2551
sg12
Vinsulinoma
p2552
sa(dp2553
g7
I221
sg8
I1
sg9
I3
sg27
VC1533172
p2554
sg12
VINS
p2555
sa(dp2556
g7
I168
sg8
I3
sg9
I15
sg27
VC0011854
p2557
sg12
Vtype 1 diabetes
p2558
sa(dp2559
g7
I168
sg8
I3
sg9
I15
sg27
VC0011854
p2560
sg12
Vtype 1 diabetes
p2561
sasa(dp2562
g2
VChildren of parents with type 1 diabetes and prospectively followed from birth for the development of islet autoantibodies and diabetes were genotyped for single-nucleotide polymorphisms at 12 type 1 diabetes susceptibility genes (ERBB3, PTPN2, IFIH1, PTPN22, KIAA0350, CD25, CTLA4, SH2B3, IL2, IL18RAP, IL10 and COBL).
p2563
sg4
(lp2564
(dp2565
g7
I290
sg8
I1
sg9
I3
sg10
VP60568
p2566
sg12
VIL2
p2567
sa(dp2568
g7
I260
sg8
I1
sg9
I8
sg10
g11
sg12
VKIAA0350
p2569
sa(dp2570
g7
I231
sg8
I1
sg9
I5
sg10
VP21860
p2571
sg12
VERBB3
p2572
sa(dp2573
g7
I313
sg8
I1
sg9
I4
sg10
g11
sg12
VCOBL
p2574
sa(dp2575
g7
I276
sg8
I1
sg9
I5
sg10
VP16410
p2576
sg12
VCTLA4
p2577
sa(dp2578
g7
I295
sg8
I1
sg9
I7
sg10
g11
sg12
VIL18RAP
p2579
sa(dp2580
g7
I252
sg8
I1
sg9
I6
sg10
g11
sg12
VPTPN22
p2581
sa(dp2582
g7
I245
sg8
I1
sg9
I5
sg10
g11
sg12
VIFIH1
p2583
sa(dp2584
g7
I283
sg8
I1
sg9
I5
sg10
g11
sg12
VSH2B3
p2585
sa(dp2586
g7
I238
sg8
I1
sg9
I5
sg10
VP17706
p2587
sg12
VPTPN2
p2588
sa(dp2589
g7
I270
sg8
I1
sg9
I4
sg10
VP01589
p2590
sg12
VCD25
p2591
sa(dp2592
g7
I304
sg8
I1
sg9
I4
sg10
VP22301
p2593
sg12
VIL10
p2594
sasg24
(lp2595
(dp2596
g7
I25
sg8
I3
sg9
I15
sg27
VC0011854
p2597
sg12
Vtype 1 diabetes
p2598
sa(dp2599
g7
I25
sg8
I3
sg9
I15
sg27
VC0011854
p2600
sg12
Vtype 1 diabetes
p2601
sa(dp2602
g7
I32
sg8
I1
sg9
I8
sg27
VC0011849
p2603
sg12
Vdiabetes
p2604
sasa(dp2605
g2
VThe greatest diabetes discrimination was obtained by the sum of risk alleles for eight genes (IFIH1, CTLA4, PTPN22, IL18RAP, SH2B3, KIAA0350, COBL and ERBB3) in the HLA-risk children.
p2606
sg4
(lp2607
(dp2608
g7
I165
sg8
I1
sg9
I3
sg10
VP30486
p2609
sg12
VHLA
p2610
sa(dp2611
g7
I101
sg8
I1
sg9
I5
sg10
VP16410
p2612
sg12
VCTLA4
p2613
sa(dp2614
g7
I116
sg8
I1
sg9
I7
sg10
g11
sg12
VIL18RAP
p2615
sa(dp2616
g7
I108
sg8
I1
sg9
I6
sg10
g11
sg12
VPTPN22
p2617
sa(dp2618
g7
I142
sg8
I1
sg9
I4
sg10
g11
sg12
VCOBL
p2619
sa(dp2620
g7
I94
sg8
I1
sg9
I5
sg10
g11
sg12
VIFIH1
p2621
sa(dp2622
g7
I125
sg8
I1
sg9
I5
sg10
g11
sg12
VSH2B3
p2623
sa(dp2624
g7
I132
sg8
I1
sg9
I8
sg10
g11
sg12
VKIAA0350
p2625
sa(dp2626
g7
I151
sg8
I1
sg9
I5
sg10
VP21860
p2627
sg12
VERBB3
p2628
sasg24
(lp2629
(dp2630
g7
I13
sg8
I1
sg9
I8
sg27
VC0011849
p2631
sg12
Vdiabetes
p2632
sasa(dp2633
g2
VHowever, all of the eosinophil-activating cytokines, such as IL-5, IL-3, and GM-CSF, are typically present in atopic diseases, including allergic asthma.
p2634
sg4
(lp2635
(dp2636
g7
I61
sg8
I1
sg9
I4
sg10
VP05113
p2637
sg12
VIL-5
p2638
sa(dp2639
g7
I67
sg8
I1
sg9
I4
sg10
VP08700
p2640
sg12
VIL-3
p2641
sa(dp2642
g7
I77
sg8
I1
sg9
I6
sg10
VP04141
p2643
sg12
VGM-CSF
p2644
sasg24
(lp2645
(dp2646
g7
I137
sg8
I2
sg9
I15
sg27
VC0155877
p2647
sg12
Vallergic asthma
p2648
sa(dp2649
g7
I110
sg8
I1
sg9
I6
sg27
VC0392707
p2650
sg12
Vatopic
p2651
sasa(dp2652
g2
VIn a murine model of allergic asthma, we found that Tyk-2((-/-)) asthmatic mice have induced peribronchial collagen deposition, mucosal type mast cells in the lung, IRF4 and hyperproliferative lung Th2 CD4(+) effector T cells over-expressing IL-3, IL-4, IL-5, IL-10 and IL-13.
p2653
sg4
(lp2654
(dp2655
g7
I254
sg8
I1
sg9
I4
sg10
VP05113
p2656
sg12
VIL-5
p2657
sa(dp2658
g7
I165
sg8
I1
sg9
I4
sg10
g11
sg12
VIRF4
p2659
sa(dp2660
g7
I242
sg8
I1
sg9
I4
sg10
VP08700
p2661
sg12
VIL-3
p2662
sa(dp2663
g7
I248
sg8
I1
sg9
I4
sg10
VP05112
p2664
sg12
VIL-4
p2665
sa(dp2666
g7
I174
sg8
I4
sg9
I31
sg10
VP01730
p2667
sg12
Vhyperproliferative lung Th2 CD4
p2668
sa(dp2669
g7
I270
sg8
I1
sg9
I5
sg10
VP35225
p2670
sg12
VIL-13
p2671
sasg24
(lp2672
(dp2673
g7
I21
sg8
I2
sg9
I15
sg27
VC0155877
p2674
sg12
Vallergic asthma
p2675
sa(dp2676
g7
I65
sg8
I1
sg9
I9
sg27
VC0004096
p2677
sg12
Vasthmatic
p2678
sasa(dp2679
g2
VHeterologous or homologous Nrf2 deletion (Nrf2+/- or Nrf2-/-) rescued the pancreatic phenotypes, weight loss and hypoglycemia in KC::Keap1 mice, suggesting that Nrf2 is a major downstream target of Keap1.
p2680
sg4
(lp2681
(dp2682
g7
I27
sg8
I1
sg9
I4
sg10
g11
sg12
VNrf2
p2683
sa(dp2684
g7
I27
sg8
I1
sg9
I4
sg10
g11
sg12
VNrf2
p2685
sa(dp2686
g7
I133
sg8
I1
sg9
I5
sg10
g11
sg12
VKeap1
p2687
sa(dp2688
g7
I133
sg8
I1
sg9
I5
sg10
g11
sg12
VKeap1
p2689
sasg24
(lp2690
(dp2691
g7
I113
sg8
I1
sg9
I12
sg27
VC0020615
p2692
sg12
Vhypoglycemia
p2693
sasa(dp2694
g2
VDisrupting the Keap1-Nrf2 pathway enhances Nrf2 activity, which has been identified as an important approach for the prevention of different chronic diseases in which oxidative stress and inflammation are present, such as cancer, diabetes, Alzheimer's and Parkinson's.
p2695
sg4
(lp2696
(dp2697
g7
I21
sg8
I1
sg9
I4
sg10
g11
sg12
VNrf2
p2698
sa(dp2699
g7
I21
sg8
I1
sg9
I4
sg10
g11
sg12
VNrf2
p2700
sa(dp2701
g7
I15
sg8
I1
sg9
I5
sg10
g11
sg12
VKeap1
p2702
sasg24
(lp2703
(dp2704
g7
I222
sg8
I1
sg9
I6
sg27
VC0006826
p2705
sg12
Vcancer
p2706
sa(dp2707
g7
I230
sg8
I1
sg9
I8
sg27
VC0011849
p2708
sg12
Vdiabetes
p2709
sa(dp2710
g7
I167
sg8
I2
sg9
I16
sg27
VC0242606
p2711
sg12
Voxidative stress
p2712
sa(dp2713
g7
I188
sg8
I1
sg9
I12
sg27
VC0021368
p2714
sg12
Vinflammation
p2715
sa(dp2716
g7
I141
sg8
I2
sg9
I16
sg27
VC0008679
p2717
sg12
Vchronic diseases
p2718
sasa(dp2719
g2
VThis study investigates the role of ACSVL3 in the maintenance of glioblastoma multiforme (GBM) stem cell self-renewal and the capacity of GBM stem cells to initiate tumor xenograft formation.
p2720
sg4
(lp2721
sg24
(lp2722
(dp2723
g7
I90
sg8
I1
sg9
I3
sg27
VC1621958
p2724
sg12
VGBM
p2725
sa(dp2726
g7
I90
sg8
I1
sg9
I3
sg27
VC1621958
p2727
sg12
VGBM
p2728
sa(dp2729
g7
I65
sg8
I2
sg9
I23
sg27
VC1621958
p2730
sg12
Vglioblastoma multiforme
p2731
sa(dp2732
g7
I165
sg8
I1
sg9
I5
sg27
VC0027651
p2733
sg12
Vtumor
p2734
sasa(dp2735
g2
VWe examined ACSVL3 expression during differentiation of several GBM stem cell enriched neurosphere cultures.
p2736
sg4
(lp2737
sg24
(lp2738
(dp2739
g7
I64
sg8
I1
sg9
I3
sg27
VC0017636
p2740
sg12
VGBM
p2741
sasa(dp2742
g2
VACSVL3 expression levels were substantially increased in GBM stem cell enriched neurosphere cultures and decreased after differentiation of the neurospheres.
p2743
sg4
(lp2744
sg24
(lp2745
(dp2746
g7
I57
sg8
I1
sg9
I3
sg27
VC0017636
p2747
sg12
VGBM
p2748
sasa(dp2749
g2
VFurthermore, ACSVL3 knockdown reduced anchorage-independent neurosphere cell growth, neurosphere-forming capacity as well as self-renewal of these GBM stem cell enriched neurosphere cultures.
p2750
sg4
(lp2751
sg24
(lp2752
(dp2753
g7
I147
sg8
I1
sg9
I3
sg27
VC0017636
p2754
sg12
VGBM
p2755
sasa(dp2756
g2
VA link between ACSVL3 and cancer stem cell phenotype was further established by the findings that ACSVL3 expression was regulated by receptor tyrosine kinase pathways that support GBM stem cell self-renewal and tumor initiation, including EGFR and HGF/c-Met pathways.
p2757
sg4
(lp2758
(dp2759
g7
I133
sg8
I3
sg9
I24
sg10
VP29401
p2760
sg12
Vreceptor tyrosine kinase
p2761
sa(dp2762
g7
I252
sg8
I1
sg9
I5
sg10
VP08581
p2763
sg12
Vc-Met
p2764
sa(dp2765
g7
I248
sg8
I1
sg9
I3
sg10
VP05231
p2766
sg12
VHGF
p2767
sasg24
(lp2768
(dp2769
g7
I180
sg8
I1
sg9
I3
sg27
VC0017636
p2770
sg12
VGBM
p2771
sa(dp2772
g7
I26
sg8
I1
sg9
I6
sg27
VC0006826
p2773
sg12
Vcancer
p2774
sa(dp2775
g7
I248
sg8
I1
sg9
I3
sg27
VC0399440
p2776
sg12
VHGF
p2777
sa(dp2778
g7
I211
sg8
I2
sg9
I16
sg27
VC0598935
p2779
sg12
Vtumor initiation
p2780
sasa(dp2781
g2
VOur findings indicate that the lipid metabolism enzyme ACSVL3 is involved in GBM stem cell maintenance and the tumor-initiating capacity of GBM stem cell enriched-neurospheres in animals.
p2782
sg4
(lp2783
sg24
(lp2784
(dp2785
g7
I77
sg8
I1
sg9
I3
sg27
VC0017636
p2786
sg12
VGBM
p2787
sa(dp2788
g7
I111
sg8
I1
sg9
I5
sg27
VC0027651
p2789
sg12
Vtumor
p2790
sa(dp2791
g7
I77
sg8
I1
sg9
I3
sg27
VC0017636
p2792
sg12
VGBM
p2793
sasa(dp2794
g2
VA significant association was detected between TLR9 genotypes and some of the disease manifestations as myositis (p = 0.032), psychosis (p = 0.014), photosensitivity (p = 0.002), and pleurisy (p = &lt;0.001).
p2795
sg4
(lp2796
(dp2797
g7
I47
sg8
I2
sg9
I14
sg10
g11
sg12
VTLR9 genotypes
p2798
sasg24
(lp2799
(dp2800
g7
I149
sg8
I1
sg9
I16
sg27
VC0393720
p2801
sg12
Vphotosensitivity
p2802
sa(dp2803
g7
I183
sg8
I1
sg9
I8
sg27
VC0497354
p2804
sg12
Vpleurisy
p2805
sa(dp2806
g7
I104
sg8
I1
sg9
I8
sg27
VC0027121
p2807
sg12
Vmyositis
p2808
sa(dp2809
g7
I126
sg8
I1
sg9
I9
sg27
VC0349204
p2810
sg12
Vpsychosis
p2811
sasa(dp2812
g2
VIn addition, rLj-HMGB2 could induce the generation of proinflammatory mediators in the activated human acute monocytic leukemia cell line (THP1), which suggested that Lj-HMGB2 may participate in the immune response of the lampreys.
p2813
sg4
(lp2814
(dp2815
g7
I139
sg8
I1
sg9
I4
sg10
VP10070
p2816
sg12
VTHP1
p2817
sa(dp2818
g7
I13
sg8
I1
sg9
I9
sg10
VP26583
p2819
sg12
VrLj-HMGB2
p2820
sa(dp2821
g7
I14
sg8
I1
sg9
I8
sg10
VP26583
p2822
sg12
VLj-HMGB2
p2823
sasg24
(lp2824
(dp2825
g7
I103
sg8
I3
sg9
I24
sg27
VC1318544
p2826
sg12
Vacute monocytic leukemia
p2827
sasa(dp2828
g2
VNut consumption was independently associated with a decreased risk of overall and vascular-disease mortality, particularly in women.
p2829
sg4
(lp2830
(dp2831
g7
I0
sg8
I1
sg9
I3
sg10
g11
sg12
VNut
p2832
sasg24
(lp2833
sa(dp2834
g2
VNut consumption has been inconsistently associated with risk of stroke.
p2835
sg4
(lp2836
(dp2837
g7
I0
sg8
I1
sg9
I3
sg10
g11
sg12
VNut
p2838
sasg24
(lp2839
(dp2840
g7
I64
sg8
I1
sg9
I6
sg27
VC0038454
p2841
sg12
Vstroke
p2842
sasa(dp2843
g2
VUlcerative colitis patients display increased numbers of circulating pro-inflammatory monocyte human leukocyte antigen-DR [HLA-DRhi] monocytes expressing high levels of the gut-homing C-C chemokine receptor 9 [CCR9] and tumour necrosis factor [TNF]-Alfa.
p2844
sg4
(lp2845
(dp2846
g7
I86
sg8
I4
sg9
I35
sg10
VP05534
p2847
sg12
Vmonocyte human leukocyte antigen-DR
p2848
sa(dp2849
g7
I123
sg8
I1
sg9
I3
sg10
VP30486
p2850
sg12
VHLA
p2851
sa(dp2852
g7
I220
sg8
I4
sg9
I33
sg10
VP01375
p2853
sg12
Vtumour necrosis factor [TNF]-Alfa
p2854
sa(dp2855
g7
I173
sg8
I6
sg9
I42
sg10
g11
sg12
Vgut-homing C-C chemokine receptor 9 [CCR9]
p2856
sasg24
(lp2857
(dp2858
g7
I0
sg8
I2
sg9
I18
sg27
VC0009324
p2859
sg12
VUlcerative colitis
p2860
sa(dp2861
g7
I220
sg8
I2
sg9
I15
sg27
VC0333516
p2862
sg12
Vtumour necrosis
p2863
sasa(dp2864
g2
VThe aim of this first-in-human, double-blind, randomised, placebo-controlled trial was to evaluate selective removal of circulating CCR9-expressing monocytes by leukapheresis in patients with moderate to severe ulcerative colitis, with regards to safety, tolerability, and immunological response.
p2865
sg4
(lp2866
(dp2867
g7
I132
sg8
I1
sg9
I4
sg10
VP51686
p2868
sg12
VCCR9
p2869
sasg24
(lp2870
(dp2871
g7
I211
sg8
I2
sg9
I18
sg27
VC0009324
p2872
sg12
Vulcerative colitis
p2873
sa(dp2874
g7
I39
sg8
I1
sg9
I5
sg27
VC0456909
p2875
sg12
Vblind
p2876
sasa(dp2877
g2
VPatients with ulcerative colitis were treated every second day with leukapheresis during five sessions with a C-C chemokine ligand 25 [CCL25; CCR9 ligand] column or a placebo column.
p2878
sg4
(lp2879
(dp2880
g7
I110
sg8
I4
sg9
I23
sg10
VP55773
p2881
sg12
VC-C chemokine ligand 25
p2882
sa(dp2883
g7
I142
sg8
I1
sg9
I4
sg10
VP51686
p2884
sg12
VCCR9
p2885
sa(dp2886
g7
I135
sg8
I1
sg9
I5
sg10
g11
sg12
VCCL25
p2887
sasg24
(lp2888
(dp2889
g7
I14
sg8
I2
sg9
I18
sg27
VC0009324
p2890
sg12
Vulcerative colitis
p2891
sasa(dp2892
g2
VCC chemokine receptor type 9 (CCR9) activation by CCL25 plays a key role in leukocyte recruitment to the gut and represents a therapeutic target in inflammatory bowel disease.
p2893
sg4
(lp2894
(dp2895
g7
I0
sg8
I5
sg9
I28
sg10
g11
sg12
VCC chemokine receptor type 9
p2896
sa(dp2897
g7
I30
sg8
I1
sg9
I4
sg10
VP51686
p2898
sg12
VCCR9
p2899
sa(dp2900
g7
I50
sg8
I1
sg9
I5
sg10
g11
sg12
VCCL25
p2901
sasg24
(lp2902
(dp2903
g7
I148
sg8
I3
sg9
I26
sg27
VC0021390
p2904
sg12
Vinflammatory bowel disease
p2905
sa(dp2906
g7
I86
sg8
I1
sg9
I11
sg27
VC0271510
p2907
sg12
Vrecruitment
p2908
sasa(dp2909
g2
VThe selective CCR9 antagonist vercirnon progressed to phase 3 clinical trials in Crohn's disease but efficacy was limited, with the need for very high doses to block receptor activation.
p2910
sg4
(lp2911
(dp2912
g7
I14
sg8
I1
sg9
I4
sg10
VP51686
p2913
sg12
VCCR9
p2914
sasg24
(lp2915
(dp2916
g7
I81
sg8
I2
sg9
I15
sg27
VC0010346
p2917
sg12
VCrohn's disease
p2918
sasa(dp2919
g2
VTo investigate whether Imiquimod (IMQ) as TLR7 ligand protects mice from colonic inflammation and the mechanisms underlying in such immunoregulatory conditions.#\u3000METHODS: Murine colitis was induced to Balb/c mice by administration of trinitrobenzene sulfonic acid (TNBS) with or without daily intraperitoneal administration of IMQ.#\u3000Colitis was evaluated by body weight decreases and by histological score.#\u3000Also colonic mRNA expression was measured by RT-PCR.#\u3000To confirm the induction of Regulatory T cells (Tregs) by type-1 IFN from pDCs, we generated mouse bone marrow-derived pDCs and co-cultured these with CD4+ T cells isolated from mouse spleen with or without IMQ stimulation.#\u3000Cytokine production in the culture supernatant was measured by ELISA and the number of Tregs were analyzed by flow cytometry.#\u3000Spleen and mesenteric lymph nodes (MLN) from IMQ-treated mice were collected, and mRNA expressions of cytokine were measured by RT-PCR and cytokine productions were measured by ELISA.#\u3000Tregs and chemokine expressions were analyzed in colon of TNBS-induced colitis mouse by immunohistochemistry.#\u3000RESULTS: Administration of IMQ significantly suppressed colonic inflammation of TNBS-induced colitis.#\u3000In the colons of IMQ-treated mice, mRNA expression of TNF-Alfa was decreased, and strong expressions of IL-6, IFN-Beta and TGF-Beta were detected.#\u3000IL-10 and TGF-Beta productions were increased in the supernatant of co-cultured cells stimulated with IMQ, although we were unable to detect Treg differentiaton in IMQ-stimulated co-cultured cells.#\u3000In MLN of IMQ-treated mice, strong expressions of TLR7, IFN-Beta, TGF-Beta and Foxp3 mRNA were detected.#\u3000IL-10 production from MLN cells was also increased in the IMQ-treated group.#\u3000Finally, Tregs in the inflamed colon and CCR9 in MLN of IMQ-treated mice were detected.#\u3000CONCLUSION: These results suggest that IMQ protects mice from TNBS colitis through induction of CCR9, which regulates accumulation of Tregs in the inflamed colon.
p2920
sg4
(lp2921
(dp2922
g7
I613
sg8
I1
sg9
I4
sg10
VP01730
p2923
sg12
VCD4+
p2924
sa(dp2925
g7
I1267
sg8
I1
sg9
I8
sg10
VP01375
p2926
sg12
VTNF-Alfa
p2927
sa(dp2928
g7
I849
sg8
I1
sg9
I3
sg10
VP12872
p2929
sg12
VMLN
p2930
sa(dp2931
g7
I520
sg8
I2
sg9
I10
sg10
VP01562
p2932
sg12
Vtype-1 IFN
p2933
sa(dp2934
g7
I1336
sg8
I1
sg9
I8
sg10
VP18075
p2935
sg12
VTGF-Beta
p2936
sa(dp2937
g7
I1785
sg8
I1
sg9
I4
sg10
VP51686
p2938
sg12
VCCR9
p2939
sa(dp2940
g7
I1323
sg8
I1
sg9
I8
sg10
VP01574
p2941
sg12
VIFN-Beta
p2942
sa(dp2943
g7
I1639
sg8
I2
sg9
I10
sg10
g11
sg12
VFoxp3 mRNA
p2944
sa(dp2945
g7
I1317
sg8
I1
sg9
I4
sg10
VP05231
p2946
sg12
VIL-6
p2947
sa(dp2948
g7
I42
sg8
I2
sg9
I11
sg10
g11
sg12
VTLR7 ligand
p2949
sa(dp2950
g7
I825
sg8
I3
sg9
I22
sg10
VP12872
p2951
sg12
Vmesenteric lymph nodes
p2952
sa(dp2953
g7
I1336
sg8
I1
sg9
I8
sg10
VP18075
p2954
sg12
VTGF-Beta
p2955
sa(dp2956
g7
I1336
sg8
I1
sg9
I8
sg10
VP18075
p2957
sg12
VTGF-Beta
p2958
sa(dp2959
g7
I1785
sg8
I1
sg9
I4
sg10
VP51686
p2960
sg12
VCCR9
p2961
sa(dp2962
g7
I42
sg8
I1
sg9
I4
sg10
g11
sg12
VTLR7
p2963
sa(dp2964
g7
I1323
sg8
I1
sg9
I8
sg10
VP01574
p2965
sg12
VIFN-Beta
p2966
sasg24
(lp2967
(dp2968
g7
I178
sg8
I1
sg9
I7
sg27
VC0009319
p2969
sg12
Vcolitis
p2970
sa(dp2971
g7
I178
sg8
I1
sg9
I7
sg27
VC0009319
p2972
sg12
Vcolitis
p2973
sa(dp2974
g7
I81
sg8
I1
sg9
I12
sg27
VC0021368
p2975
sg12
Vinflammation
p2976
sa(dp2977
g7
I332
sg8
I1
sg9
I8
sg27
VC0009319
p2978
sg12
V\u3000Colitis
p2979
sa(dp2980
g7
I178
sg8
I1
sg9
I7
sg27
VC0009319
p2981
sg12
Vcolitis
p2982
sa(dp2983
g7
I178
sg8
I1
sg9
I7
sg27
VC0009319
p2984
sg12
Vcolitis
p2985
sa(dp2986
g7
I81
sg8
I1
sg9
I12
sg27
VC0021368
p2987
sg12
Vinflammation
p2988
sasa(dp2989
g2
VWe here showed that CCR9+ CD11b+ macrophages play an important role during the course of Concanavalin A-induced murine acute liver injury as well as human acute hepatitis via the production of inflammatory cytokines and the Th1 induction.
p2990
sg4
(lp2991
(dp2992
g7
I20
sg8
I2
sg9
I12
sg10
VP51686
p2993
sg12
VCCR9+ CD11b+
p2994
sasg24
(lp2995
(dp2996
g7
I155
sg8
I2
sg9
I15
sg27
VC0267797
p2997
sg12
Vacute hepatitis
p2998
sasa(dp2999
g2
VWe found 54 single-nucleotide polymorphisms (SNPs) in 5 genes associated with celiac disease (TAGAP, IL18R1, RGS21, PLEK, and CCR9) in time to celiac disease analyses (10-4&gt;P&gt;5.8x10-6).
p3000
sg4
(lp3001
(dp3002
g7
I126
sg8
I1
sg9
I4
sg10
VP51686
p3003
sg12
VCCR9
p3004
sa(dp3005
g7
I109
sg8
I1
sg9
I5
sg10
g11
sg12
VRGS21
p3006
sa(dp3007
g7
I116
sg8
I1
sg9
I4
sg10
VP08567
p3008
sg12
VPLEK
p3009
sa(dp3010
g7
I101
sg8
I1
sg9
I6
sg10
g11
sg12
VIL18R1
p3011
sa(dp3012
g7
I94
sg8
I1
sg9
I5
sg10
g11
sg12
VTAGAP
p3013
sasg24
(lp3014
(dp3015
g7
I78
sg8
I2
sg9
I14
sg27
VC0007570
p3016
sg12
Vceliac disease
p3017
sa(dp3018
g7
I78
sg8
I2
sg9
I14
sg27
VC0007570
p3019
sg12
Vceliac disease
p3020
sasa(dp3021
g2
VIncluding chemokines [C-C motif ligand (CCL) 19, CCL20, CCL21, C-X-C motif ligand (CXCL) 6, CXCL10, and CXCL11] and soluble cytokine and chemokine receptors [soluble (s) interleukin (IL) 6 receptor (R), soluble tumor necrosis factor receptor (sTNFR) 1, sTNFR2, and sIL-R2], ten inflammation-related markers, were nominally associated with diabetes (P&lt;0.05).
p3022
sg4
(lp3023
(dp3024
g7
I56
sg8
I1
sg9
I5
sg10
g11
sg12
VCCL21
p3025
sa(dp3026
g7
I92
sg8
I1
sg9
I6
sg10
VP02778
p3027
sg12
VCXCL10
p3028
sa(dp3029
g7
I211
sg8
I6
sg9
I40
sg10
VP01375
p3030
sg12
Vtumor necrosis factor receptor (sTNFR) 1
p3031
sa(dp3032
g7
I265
sg8
I1
sg9
I6
sg10
VP40967
p3033
sg12
VsIL-R2
p3034
sa(dp3035
g7
I104
sg8
I1
sg9
I6
sg10
g11
sg12
VCXCL11
p3036
sa(dp3037
g7
I49
sg8
I1
sg9
I5
sg10
VP78556
p3038
sg12
VCCL20
p3039
sasg24
(lp3040
(dp3041
g7
I339
sg8
I1
sg9
I8
sg27
VC0011849
p3042
sg12
Vdiabetes
p3043
sa(dp3044
g7
I21
sg8
I3
sg9
I17
sg27
VC1852438
p3045
sg12
V[C-C motif ligand
p3046
sa(dp3047
g7
I40
sg8
I1
sg9
I3
sg27
VC1852438
p3048
sg12
VCCL
p3049
sa(dp3050
g7
I265
sg8
I1
sg9
I3
sg27
VC0333873
p3051
sg12
VsIL
p3052
sa(dp3053
g7
I278
sg8
I1
sg9
I12
sg27
VC0021368
p3054
sg12
Vinflammation
p3055
sa(dp3056
g7
I211
sg8
I2
sg9
I14
sg27
VC0333516
p3057
sg12
Vtumor necrosis
p3058
sasa(dp3059
g2
VWe identified mutations in melanoma-associated antigen D2 in all study participants and showed, in vivo and in vitro, reduced expression of the furosemide and thiazide sensitive transporters sodium-potassium-2-chloride cotransporter and sodium chloride cotransporter, respectively.
p3060
sg4
(lp3061
(dp3062
g7
I27
sg8
I3
sg9
I30
sg10
g11
sg12
Vmelanoma-associated antigen D2
p3063
sasg24
(lp3064
(dp3065
g7
I27
sg8
I1
sg9
I8
sg27
VC0025202
p3066
sg12
Vmelanoma
p3067
sasa(dp3068
g2
VMAGED2 mutations caused X-linked polyhydramnios with prematurity and a severe but transient form of antenatal Bartter's syndrome.We distinguish two types of hereditary NDI: a 'pure' type with loss of water only and a complex type with loss of water and ions.
p3069
sg4
(lp3070
(dp3071
g7
I0
sg8
I1
sg9
I6
sg10
g11
sg12
VMAGED2
p3072
sasg24
(lp3073
(dp3074
g7
I33
sg8
I1
sg9
I14
sg27
VC0020224
p3075
sg12
Vpolyhydramnios
p3076
sa(dp3077
g7
I168
sg8
I1
sg9
I3
sg27
VC1563705
p3078
sg12
VNDI
p3079
sa(dp3080
g7
I110
sg8
I2
sg9
I18
sg27
VC0004775
p3081
sg12
VBartter's syndrome
p3082
sasa(dp3083
g2
VA new variant of this was recently identified: seven families were described with transient antenatal Bartter's syndrome, polyhydramnios and MAGED2 mutations.Multiple compounds have been identified experimentally that may stimulate urinary concentration independently of the vasopressin V2 receptor.
p3084
sg4
(lp3085
(dp3086
g7
I275
sg8
I3
sg9
I23
sg10
VP30518
p3087
sg12
Vvasopressin V2 receptor
p3088
sa(dp3089
g7
I141
sg8
I1
sg9
I6
sg10
g11
sg12
VMAGED2
p3090
sasg24
(lp3091
(dp3092
g7
I122
sg8
I1
sg9
I14
sg27
VC0020224
p3093
sg12
Vpolyhydramnios
p3094
sa(dp3095
g7
I102
sg8
I2
sg9
I18
sg27
VC0004775
p3096
sg12
VBartter's syndrome
p3097
sasa(dp3098
g2
VFluorescent and radio conjugates of 11B6, an antibody targeting free hK2, are internalized and noninvasively report AR pathway activity in metastatic and genetically engineered models of cancer development and treatment.
p3099
sg4
(lp3100
(dp3101
g7
I69
sg8
I1
sg9
I3
sg10
VP20151
p3102
sg12
VhK2
p3103
sasg24
(lp3104
(dp3105
g7
I187
sg8
I1
sg9
I6
sg27
VC0006826
p3106
sg12
Vcancer
p3107
sasa(dp3108
g2
VHumanized 11B6, which has undergone toxicological tests in nonhuman primates, has the potential to improve patient management in these cancers.
p3109
sg4
(lp3110
(dp3111
g7
I0
sg8
I2
sg9
I14
sg10
g11
sg12
VHumanized 11B6
p3112
sasg24
(lp3113
(dp3114
g7
I135
sg8
I1
sg9
I7
sg27
VC0006826
p3115
sg12
Vcancers
p3116
sasa(dp3117
g2
VMAGE-D2 is new gene found to cause severe polyhydramnios and transient postnatal Bartter-like syndrome.
p3118
sg4
(lp3119
(dp3120
g7
I0
sg8
I1
sg9
I7
sg10
g11
sg12
VMAGE-D2
p3121
sasg24
(lp3122
(dp3123
g7
I42
sg8
I1
sg9
I14
sg27
VC0020224
p3124
sg12
Vpolyhydramnios
p3125
sa(dp3126
g7
I94
sg8
I1
sg9
I8
sg27
VC0039082
p3127
sg12
Vsyndrome
p3128
sasa(dp3129
g2
VThese women were divided into two after breast cancer groups (BCG1 and BCG2) and a control group (CG).
p3130
sg4
(lp3131
(dp3132
g7
I62
sg8
I1
sg9
I4
sg10
g11
sg12
VBCG1
p3133
sasg24
(lp3134
(dp3135
g7
I40
sg8
I2
sg9
I13
sg27
VC0678222
p3136
sg12
Vbreast cancer
p3137
sasa(dp3138
g2
VGroup BCG1 consisted of women who had undergone breast cancer surgery within the last 18months and BCG2 those whose postoperative periods were more than 18months.
p3139
sg4
(lp3140
sg24
(lp3141
(dp3142
g7
I48
sg8
I2
sg9
I13
sg27
VC0678222
p3143
sg12
Vbreast cancer
p3144
sasa(dp3145
g2
VThe indices in millisecond, RMSSD (BCG1=19.83; BCG2=14.99; CG=31.46), SD1 (BCG1=14.03; BCG2=10.61; CG=22.27), SD2 (BCG1=39.17; BCG2=35.28; CG=61.16), SDNN (BCG1=29.58; BCG2=26.12; CG=46.36) and HF in milliseconds squared (BCG1=194.2; BCG2=91.07; CG=449.4) showed statistically significant reductions in the breast cancer groups compared to the CG (p&lt;=0.0001).
p3146
sg4
(lp3147
sg24
(lp3148
(dp3149
g7
I307
sg8
I2
sg9
I13
sg27
VC0678222
p3150
sg12
Vbreast cancer
p3151
sa(dp3152
g7
I70
sg8
I1
sg9
I3
sg27
VC1861380
p3153
sg12
VSD1
p3154
sasa(dp3155
g2
VThe discovery that mutations in MAGED2 cause a rare and transient form of antenatal Bartter's Syndrome may have implications beyond the very small number of affected families.
p3156
sg4
(lp3157
(dp3158
g7
I32
sg8
I1
sg9
I6
sg10
g11
sg12
VMAGED2
p3159
sasg24
(lp3160
(dp3161
g7
I84
sg8
I2
sg9
I18
sg27
VC0004775
p3162
sg12
VBartter's Syndrome
p3163
sasa(dp3164
g2
VWe identified a mutation in MAGED2 in each of the 13 infants in our analysis who had transient antenatal Bartter's syndrome.
p3165
sg4
(lp3166
(dp3167
g7
I28
sg8
I1
sg9
I6
sg10
g11
sg12
VMAGED2
p3168
sasg24
(lp3169
(dp3170
g7
I105
sg8
I2
sg9
I18
sg27
VC0004775
p3171
sg12
VBartter's syndrome
p3172
sasa(dp3173
g2
VMAGED2 encodes melanoma-associated antigen D2 (MAGE-D2) and maps to the X chromosome.
p3174
sg4
(lp3175
(dp3176
g7
I0
sg8
I1
sg9
I6
sg10
g11
sg12
VMAGED2
p3177
sa(dp3178
g7
I47
sg8
I1
sg9
I7
sg10
g11
sg12
VMAGE-D2
p3179
sa(dp3180
g7
I15
sg8
I3
sg9
I30
sg10
g11
sg12
Vmelanoma-associated antigen D2
p3181
sasg24
(lp3182
(dp3183
g7
I15
sg8
I1
sg9
I8
sg27
VC0025202
p3184
sg12
Vmelanoma
p3185
sasa(dp3186
g2
VWe also identified two different MAGED2 mutations in two families with idiopathic polyhydramnios.
p3187
sg4
(lp3188
(dp3189
g7
I33
sg8
I2
sg9
I16
sg10
g11
sg12
VMAGED2 mutations
p3190
sasg24
(lp3191
(dp3192
g7
I82
sg8
I1
sg9
I14
sg27
VC0020224
p3193
sg12
Vpolyhydramnios
p3194
sasa(dp3195
g2
VWe found that MAGED2 mutations caused X-linked polyhydramnios with prematurity and a severe but transient form of antenatal Bartter's syndrome.
p3196
sg4
(lp3197
(dp3198
g7
I14
sg8
I1
sg9
I6
sg10
g11
sg12
VMAGED2
p3199
sasg24
(lp3200
(dp3201
g7
I124
sg8
I2
sg9
I18
sg27
VC0004775
p3202
sg12
VBartter's syndrome
p3203
sa(dp3204
g7
I47
sg8
I1
sg9
I14
sg27
VC0020224
p3205
sg12
Vpolyhydramnios
p3206
sasa(dp3207
g2
VVirulence factors profiling showed that most of MRSA isolates in our center carried the virulence factor pattern of cna-clfA-clfB-eno-fib-icaA-icaD-sea-psmAlfa-lukED-hlg-hlgv-hla-hld (214/239, 89.54%).
p3208
sg4
(lp3209
(dp3210
g7
I116
sg8
I1
sg9
I66
sg10
g11
sg12
Vcna-clfA-clfB-eno-fib-icaA-icaD-sea-psmAlfa-lukED-hlg-hlgv-hla-hld
p3211
sasg24
(lp3212
(dp3213
g7
I48
sg8
I1
sg9
I4
sg27
VC0343401
p3214
sg12
VMRSA
p3215
sasa(dp3216
g2
VThe main virulence genes in these strains were hlg (33.3%), scn (23.3%), cna (20%), hlb (20%), and clfA (18.3%), others including icaA, fnbA, tst, seb, hld, eta and sea.
p3217
sg4
(lp3218
(dp3219
g7
I152
sg8
I1
sg9
I3
sg10
VP35670
p3220
sg12
Vhld
p3221
sa(dp3222
g7
I142
sg8
I1
sg9
I3
sg10
g11
sg12
Vtst
p3223
sa(dp3224
g7
I157
sg8
I1
sg9
I3
sg10
VP25101
p3225
sg12
Veta
p3226
sa(dp3227
g7
I147
sg8
I1
sg9
I3
sg10
g11
sg12
Vseb
p3228
sasg24
(lp3229
sa(dp3230
g2
VOther virulence genes detected were (number of strains): tsst-1 (6), hla (15), hlb (9), hld (15), hlg (6), hlgv (9), cna (2), aur (14), and egc-like cluster (3).
p3231
sg4
(lp3232
sg24
(lp3233
sa(dp3234
g2
VSearch terms and synonyms for "aerobic exercise" and "Down syndrome" were used within the following databases: CENTRAL (2007, Issue 1); MEDLINE via PUBMED (1966 to March 2007); EMBASE (2005 to April 2007); CINAHL (1982 to March 2007); LILACS (1982 to March 2007); PsycINFO (1887 to March 2007); ERIC (1966 to March 2007); CCT (March 2007); Academic Search Elite (to March 2007), C2- SPECTR (to March 2007 ), NRR (2007 Issue 1), ClinicalTrials.gov (accessed March 2007) and within supplements of Medicine and Science in Sports and Exercise.
p3235
sg4
(lp3236
sg24
(lp3237
(dp3238
g7
I322
sg8
I1
sg9
I3
sg27
VC2752078
p3239
sg12
VCCT
p3240
sa(dp3241
g7
I54
sg8
I2
sg9
I13
sg27
VC0013080
p3242
sg12
VDown syndrome
p3243
sasa(dp3244
g2
VSearch terms and synonyms for "aerobic exercise" and "Down syndrome" were used within the following databases:CENTRAL (2005, Issue 2); MEDLINE (1966 to March 2005); EMBASE (2005 to April 2005); CINAHL (1982 to March 2005); LILACS (1982 to March 2005); PsycINFO (1887 to March 2005); ERIC (1966 to March 2005); CCT (March 2005); Academic Search Elite (to March 2005), C2- SPECTR (to March 2005 ), NRR (2005 Issue 1), ClinicalTrials.gov (accessed March 2005)and within supplements of Medicine and Science in Sports and Exercise.
p3245
sg4
(lp3246
sg24
(lp3247
(dp3248
g7
I54
sg8
I2
sg9
I13
sg27
VC0013080
p3249
sg12
VDown syndrome
p3250
sa(dp3251
g7
I310
sg8
I1
sg9
I3
sg27
VC2752078
p3252
sg12
VCCT
p3253
sasa(dp3254
g2
VFMT in inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS) and metabolic syndrome should only be performed in research settings.
p3255
sg4
(lp3256
(dp3257
g7
I0
sg8
I1
sg9
I3
sg10
g11
sg12
VFMT
p3258
sasg24
(lp3259
(dp3260
g7
I36
sg8
I1
sg9
I3
sg27
VC0021390
p3261
sg12
VIBD
p3262
sa(dp3263
g7
I68
sg8
I1
sg9
I3
sg27
VC0022104
p3264
sg12
VIBS
p3265
sa(dp3266
g7
I42
sg8
I3
sg9
I24
sg27
VC0022104
p3267
sg12
Virritable bowel syndrome
p3268
sa(dp3269
g7
I77
sg8
I2
sg9
I18
sg27
VC0524620
p3270
sg12
Vmetabolic syndrome
p3271
sa(dp3272
g7
I7
sg8
I3
sg9
I27
sg27
VC0021390
p3273
sg12
Vinflammatory bowel diseases
p3274
sasa(dp3275
g2
VBlockade of CD69-Myl9/12 interaction ameliorates allergic airway inflammation in ovalbumin-induced and house dust mite-induced mouse models of asthma.
p3276
sg4
(lp3277
(dp3278
g7
I12
sg8
I1
sg9
I4
sg10
g11
sg12
VCD69
p3279
sa(dp3280
g7
I17
sg8
I1
sg9
I4
sg10
VP24844
p3281
sg12
VMyl9
p3282
sasg24
(lp3283
(dp3284
g7
I143
sg8
I1
sg9
I6
sg27
VC0004096
p3285
sg12
Vasthma
p3286
sa(dp3287
g7
I65
sg8
I1
sg9
I12
sg27
VC0021368
p3288
sg12
Vinflammation
p3289
sasa(dp3290
g2
VA greater activation of myosin, via increased phosphorylation of its regulatory light chain (LC20) by myosin light chain kinase, correlates with an increased Vmax in models of AH and in human asthmatic bronchial SM cells.
p3291
sg4
(lp3292
(dp3293
g7
I24
sg8
I1
sg9
I6
sg10
VP13535
p3294
sg12
Vmyosin
p3295
sa(dp3296
g7
I102
sg8
I4
sg9
I25
sg10
g11
sg12
Vmyosin light chain kinase
p3297
sasg24
(lp3298
(dp3299
g7
I192
sg8
I1
sg9
I9
sg27
VC0004096
p3300
sg12
Vasthmatic
p3301
sasa(dp3302
g2
VSome of the differentially expressed lncRNAs that were upregulated, such as AK124776, lincRNA-RAB12-1, KRT8P25, RP11-474J18.4, AC000110.1, KRT8P13, KRT8P10, BC072678, and downregulated, such as nc-HOXB9-206, RP11-160A10.2, nc-HOXA11-86, nc-HOXD10-7, nc-HOXB9-205, CES4, nc-HOXD12-3, systematic research on these lncRNAs will help clarify the mechanisms of urothelial carcinoma of the bladder and guide the early diagnosis and treatment of this cancer in the future.
p3303
sg4
(lp3304
(dp3305
g7
I223
sg8
I1
sg9
I12
sg10
VP31270
p3306
sg12
Vnc-HOXA11-86
p3307
sa(dp3308
g7
I112
sg8
I2
sg9
I25
sg10
g11
sg12
VRP11-474J18.4, AC000110.1
p3309
sa(dp3310
g7
I250
sg8
I1
sg9
I12
sg10
VP17482
p3311
sg12
Vnc-HOXB9-205
p3312
sa(dp3313
g7
I197
sg8
I1
sg9
I9
sg10
VP17482
p3314
sg12
VHOXB9-206
p3315
sa(dp3316
g7
I86
sg8
I1
sg9
I15
sg10
g11
sg12
VlincRNA-RAB12-1
p3317
sa(dp3318
g7
I208
sg8
I1
sg9
I13
sg10
g11
sg12
VRP11-160A10.2
p3319
sa(dp3320
g7
I237
sg8
I1
sg9
I11
sg10
VP28358
p3321
sg12
Vnc-HOXD10-7
p3322
sa(dp3323
g7
I270
sg8
I1
sg9
I11
sg10
VP35452
p3324
sg12
Vnc-HOXD12-3
p3325
sa(dp3326
g7
I264
sg8
I1
sg9
I4
sg10
g11
sg12
VCES4
p3327
sasg24
(lp3328
(dp3329
g7
I112
sg8
I1
sg9
I4
sg27
VC1838601
p3330
sg12
VRP11
p3331
sa(dp3332
g7
I367
sg8
I4
sg9
I24
sg27
VC0699885
p3333
sg12
Vcarcinoma of the bladder
p3334
sa(dp3335
g7
I444
sg8
I1
sg9
I6
sg27
VC0006826
p3336
sg12
Vcancer
p3337
sa(dp3338
g7
I112
sg8
I1
sg9
I4
sg27
VC1838601
p3339
sg12
VRP11
p3340
sasa(dp3341
g2
VProteins labeled with LCA were Rab-3, Rab-12, Rab-16, and M-Ras.
p3342
sg4
(lp3343
(dp3344
g7
I46
sg8
I1
sg9
I6
sg10
VP52594
p3345
sg12
VRab-16
p3346
sa(dp3347
g7
I38
sg8
I1
sg9
I6
sg10
VP52594
p3348
sg12
VRab-12
p3349
sa(dp3350
g7
I31
sg8
I1
sg9
I5
sg10
VP52594
p3351
sg12
VRab-3
p3352
sa(dp3353
g7
I58
sg8
I1
sg9
I5
sg10
g11
sg12
VM-Ras
p3354
sasg24
(lp3355
(dp3356
g7
I22
sg8
I1
sg9
I3
sg27
VC0339527
p3357
sg12
VLCA
p3358
sasa(dp3359
g2
VMoreover, the ANT2 precursors were observed to change in oncocytomas.
p3360
sg4
(lp3361
(dp3362
g7
I14
sg8
I2
sg9
I15
sg10
VP05141
p3363
sg12
VANT2 precursors
p3364
sasg24
(lp3365
(dp3366
g7
I57
sg8
I1
sg9
I11
sg27
VC0949541
p3367
sg12
Voncocytomas
p3368
sasa(dp3369
g2
VIn particular, a high transcript level for the adenine nucleotide translocator isoform 2(ANT2) gene, which is usually not expressed in differentiated cells, was observed in oncocytoma and malignant urothelial renal tumor.
p3370
sg4
(lp3371
(dp3372
g7
I89
sg8
I1
sg9
I4
sg10
VP05141
p3373
sg12
VANT2
p3374
sa(dp3375
g7
I47
sg8
I5
sg9
I41
sg10
g11
sg12
Vadenine nucleotide translocator isoform 2
p3376
sasg24
(lp3377
(dp3378
g7
I173
sg8
I1
sg9
I10
sg27
VC0949541
p3379
sg12
Voncocytoma
p3380
sa(dp3381
g7
I209
sg8
I2
sg9
I11
sg27
VC0022665
p3382
sg12
Vrenal tumor
p3383
sasa(dp3384
g2
VThis study aimed to assess inflammatory, cardiac, renal and hematological markers in 56 breast cancer patients (BCP) before, during and after termination of chemotherapy with CYP and DOX.
p3385
sg4
(lp3386
sg24
(lp3387
(dp3388
g7
I88
sg8
I2
sg9
I13
sg27
VC0678222
p3389
sg12
Vbreast cancer
p3390
sasa(dp3391
g2
VBased on the results, we conclude that breast cancer and co-treatment of CYP and DOX interfere with various biological markers, thereby, showing the physiological imbalance.
p3392
sg4
(lp3393
sg24
(lp3394
(dp3395
g7
I39
sg8
I2
sg9
I13
sg27
VC0678222
p3396
sg12
Vbreast cancer
p3397
sa(dp3398
g7
I163
sg8
I1
sg9
I9
sg27
VC1397014
p3399
sg12
Vimbalance
p3400
sasa(dp3401
g2
VEpoxyeicosatrienoic acid (EET) production via cytochrome P450 (CYP) epoxygenases closely correlates with the progression of breast cancer.
p3402
sg4
(lp3403
(dp3404
g7
I46
sg8
I2
sg9
I15
sg10
VP20853
p3405
sg12
Vcytochrome P450
p3406
sa(dp3407
g7
I63
sg8
I1
sg9
I3
sg10
VP20853
p3408
sg12
VCYP
p3409
sasg24
(lp3410
(dp3411
g7
I124
sg8
I2
sg9
I13
sg27
VC0678222
p3412
sg12
Vbreast cancer
p3413
sasa(dp3414
g2
VHere, we found that CYP3A4 expression and its epoxy-product, 11,12-epoxyeicosatrienoic acid (11,12-EET) was enhanced in tamoxifen (TAM)-resistant MCF-7 (TAMR-MCF-7) breast cancer cells compared to control MCF-7 cells.
p3415
sg4
(lp3416
(dp3417
g7
I20
sg8
I1
sg9
I6
sg10
VP08684
p3418
sg12
VCYP3A4
p3419
sasg24
(lp3420
(dp3421
g7
I165
sg8
I2
sg9
I13
sg27
VC0678222
p3422
sg12
Vbreast cancer
p3423
sa(dp3424
g7
I131
sg8
I1
sg9
I3
sg27
VC1834582
p3425
sg12
VTAM
p3426
sa(dp3427
g7
I120
sg8
I1
sg9
I9
sg27
VC1834582
p3428
sg12
Vtamoxifen
p3429
sasa(dp3430
g2
VOur findings suggest that the CYP3A4-mediated EET pathway represents a potential therapeutic target for the treatment of tamoxifen-resistant breast cancer.
p3431
sg4
(lp3432
(dp3433
g7
I30
sg8
I1
sg9
I6
sg10
VP08684
p3434
sg12
VCYP3A4
p3435
sasg24
(lp3436
(dp3437
g7
I141
sg8
I2
sg9
I13
sg27
VC0678222
p3438
sg12
Vbreast cancer
p3439
sasa(dp3440
g2
VCYP3A4 was unexpectedly associated with breast cancer mitochondria and synthesized arachidonic acid (AA)-derived epoxyeicosatrienoic acids (EETs), which promoted the electron transport chain/respiration and inhibited AMPKAlfa.
p3441
sg4
(lp3442
(dp3443
g7
I0
sg8
I1
sg9
I6
sg10
VP08684
p3444
sg12
VCYP3A4
p3445
sasg24
(lp3446
(dp3447
g7
I40
sg8
I2
sg9
I13
sg27
VC0678222
p3448
sg12
Vbreast cancer
p3449
sasa(dp3450
g2
VCYP3A4 knockdown activated AMPKAlfa, promoted autophagy, and prevented mammary tumor formation.
p3451
sg4
(lp3452
(dp3453
g7
I0
sg8
I1
sg9
I6
sg10
VP08684
p3454
sg12
VCYP3A4
p3455
sasg24
(lp3456
(dp3457
g7
I71
sg8
I2
sg9
I13
sg27
VC1458155
p3458
sg12
Vmammary tumor
p3459
sasa(dp3460
g2
VComprehensive genotyping of CYP enzymes and transporters was performed using the iPLEX ADME PGx Pro Panel in 302 tamoxifen-treated breast cancer patients.
p3461
sg4
(lp3462
(dp3463
g7
I28
sg8
I2
sg9
I11
sg10
g11
sg12
VCYP enzymes
p3464
sasg24
(lp3465
(dp3466
g7
I131
sg8
I2
sg9
I13
sg27
VC0678222
p3467
sg12
Vbreast cancer
p3468
sasa(dp3469
g2
VIt has been recently reported that CD38 was highly expressed in adipose tissues from obese people and CD38-deficient mice were resistant to high-fat diet (HFD)-induced obesity.
p3470
sg4
(lp3471
(dp3472
g7
I35
sg8
I1
sg9
I4
sg10
VP28907
p3473
sg12
VCD38
p3474
sa(dp3475
g7
I35
sg8
I1
sg9
I4
sg10
VP28907
p3476
sg12
VCD38
p3477
sasg24
(lp3478
(dp3479
g7
I168
sg8
I1
sg9
I7
sg27
VC0028754
p3480
sg12
Vobesity
p3481
sa(dp3482
g7
I85
sg8
I1
sg9
I5
sg27
VC0028754
p3483
sg12
Vobese
p3484
sasa(dp3485
g2
VIn this study, to explore the roles of CD38 in adipogenesis and lipogenesis in vivo and in vitro, obesity models were generated with male CD38-/- and WT mice fed with HFD.
p3486
sg4
(lp3487
(dp3488
g7
I39
sg8
I1
sg9
I4
sg10
VP28907
p3489
sg12
VCD38
p3490
sa(dp3491
g7
I39
sg8
I1
sg9
I4
sg10
VP28907
p3492
sg12
VCD38
p3493
sasg24
(lp3494
(dp3495
g7
I98
sg8
I1
sg9
I7
sg27
VC0028754
p3496
sg12
Vobesity
p3497
sasa(dp3498
g2
VThe results showed that CD38-/- male mice were significantly resistant to HFD-induced obesity.
p3499
sg4
(lp3500
(dp3501
g7
I24
sg8
I1
sg9
I4
sg10
VP28907
p3502
sg12
VCD38
p3503
sasg24
(lp3504
(dp3505
g7
I86
sg8
I1
sg9
I7
sg27
VC0028754
p3506
sg12
Vobesity
p3507
sasa(dp3508
g2
VThese results suggest that CD38 deficiency impairs adipogenesis and lipogenesis through activating Sirt1/PPARGamma-FASN signalling pathway during the development of obesity.
p3509
sg4
(lp3510
(dp3511
g7
I27
sg8
I1
sg9
I4
sg10
VP28907
p3512
sg12
VCD38
p3513
sa(dp3514
g7
I99
sg8
I1
sg9
I5
sg10
g11
sg12
VSirt1
p3515
sasg24
(lp3516
(dp3517
g7
I165
sg8
I1
sg9
I7
sg27
VC0028754
p3518
sg12
Vobesity
p3519
sasa(dp3520
g2
VWe also found that obesity development was associated with an increase in the number of CD38+ adipose progenitors, this effect being more pronounced in intra-abdominal than in subcutaneous fat, suggesting a higher rate of adipocyte commitment in visceral depots.
p3521
sg4
(lp3522
(dp3523
g7
I88
sg8
I1
sg9
I5
sg10
VP28907
p3524
sg12
VCD38+
p3525
sasg24
(lp3526
(dp3527
g7
I19
sg8
I1
sg9
I7
sg27
VC0028754
p3528
sg12
Vobesity
p3529
sasa(dp3530
g2
VIn this study, we show that CD45RO+CD38+ Beta cell Ag-specific CD4+ T cells were present at higher frequencies in type 1 diabetes subjects compared with those in healthy subjects.
p3531
sg4
(lp3532
(dp3533
g7
I28
sg8
I4
sg9
I25
sg10
VP28907
p3534
sg12
VCD45RO+CD38+ Beta cell Ag
p3535
sa(dp3536
g7
I63
sg8
I1
sg9
I4
sg10
VP01730
p3537
sg12
VCD4+
p3538
sasg24
(lp3539
(dp3540
g7
I114
sg8
I3
sg9
I15
sg27
VC0011854
p3541
sg12
Vtype 1 diabetes
p3542
sasa(dp3543
g2
VRegulation of the SIRT/NAD system was associated with early (SIRT4, SIRT7, NAPRT1 and NMNAT2) and late phases (NMNAT3, NMRK2, ABCA1 and CD38) of glucose intolerance.
p3544
sg4
(lp3545
(dp3546
g7
I86
sg8
I1
sg9
I6
sg10
g11
sg12
VNMNAT2
p3547
sa(dp3548
g7
I68
sg8
I1
sg9
I5
sg10
g11
sg12
VSIRT7
p3549
sa(dp3550
g7
I136
sg8
I1
sg9
I4
sg10
VP28907
p3551
sg12
VCD38
p3552
sa(dp3553
g7
I61
sg8
I1
sg9
I5
sg10
g11
sg12
VSIRT4
p3554
sa(dp3555
g7
I111
sg8
I1
sg9
I6
sg10
g11
sg12
VNMNAT3
p3556
sa(dp3557
g7
I75
sg8
I1
sg9
I6
sg10
g11
sg12
VNAPRT1
p3558
sasg24
(lp3559
(dp3560
g7
I145
sg8
I2
sg9
I19
sg27
VC0271650
p3561
sg12
Vglucose intolerance
p3562
sa(dp3563
g7
I23
sg8
I1
sg9
I3
sg27
VC1850380
p3564
sg12
VNAD
p3565
sasa(dp3566
g2
VA total of eleven of genes were differently expressed in celiac patients compared with disease controls of which CD36, CD38, FOXP1, SELL, PPARA, PPARG, AGT previously associated with type 2 diabetes and AKAP6, NTNG1 with anorexia nervosa remained significant after correction for multiple testing.
p3567
sg4
(lp3568
(dp3569
g7
I152
sg8
I1
sg9
I3
sg10
VP21549
p3570
sg12
VAGT
p3571
sa(dp3572
g7
I119
sg8
I1
sg9
I4
sg10
VP28907
p3573
sg12
VCD38
p3574
sa(dp3575
g7
I145
sg8
I1
sg9
I5
sg10
g11
sg12
VPPARG
p3576
sa(dp3577
g7
I132
sg8
I1
sg9
I4
sg10
VP14151
p3578
sg12
VSELL
p3579
sa(dp3580
g7
I138
sg8
I1
sg9
I5
sg10
g11
sg12
VPPARA
p3581
sa(dp3582
g7
I210
sg8
I1
sg9
I5
sg10
g11
sg12
VNTNG1
p3583
sa(dp3584
g7
I125
sg8
I1
sg9
I5
sg10
g11
sg12
VFOXP1
p3585
sa(dp3586
g7
I203
sg8
I1
sg9
I5
sg10
g11
sg12
VAKAP6
p3587
sasg24
(lp3588
(dp3589
g7
I183
sg8
I3
sg9
I15
sg27
VC0011860
p3590
sg12
Vtype 2 diabetes
p3591
sa(dp3592
g7
I221
sg8
I2
sg9
I16
sg27
VC0003125
p3593
sg12
Vanorexia nervosa
p3594
sasa(dp3595
g2
VPF significantly increased the expression of nuclear factor-YA (NF-YA), which strongly upregulated the molecules involved in the proteolytic machinery [molecular chaperones, carboxyl terminus of Hsc70-interacting protein and transcription factor EB], which thus mitigated the behavioral and pathological impairments in an SBMA mouse model through the upregulation of pathogenic androgen receptor protein clearance in motor neurons and muscles.
p3596
sg4
(lp3597
(dp3598
g7
I195
sg8
I2
sg9
I25
sg10
VP50502
p3599
sg12
VHsc70-interacting protein
p3600
sa(dp3601
g7
I378
sg8
I3
sg9
I25
sg10
VP10275
p3602
sg12
Vandrogen receptor protein
p3603
sa(dp3604
g7
I45
sg8
I2
sg9
I17
sg10
VP01160
p3605
sg12
Vnuclear factor-YA
p3606
sa(dp3607
g7
I225
sg8
I3
sg9
I23
sg10
VP19484
p3608
sg12
Vtranscription factor EB
p3609
sa(dp3610
g7
I64
sg8
I1
sg9
I5
sg10
VP23511
p3611
sg12
VNF-YA
p3612
sasg24
(lp3613
(dp3614
g7
I322
sg8
I1
sg9
I4
sg27
VC1839259
p3615
sg12
VSBMA
p3616
sasa(dp3617
g2
VOne hundred and seven patients (49.3%) had no significant change in BP; 30.9% had intradialytic hypertension (IDHT) while 19.8% had intradialytic hypotension (IDH).
p3618
sg4
(lp3619
sg24
(lp3620
(dp3621
g7
I96
sg8
I1
sg9
I12
sg27
VC0020538
p3622
sg12
Vhypertension
p3623
sasa(dp3624
g2
VThis week's articles describe ways to treat arthritis caused by chikungunya virus, IDH-mutant cancers, and hypertension.
p3625
sg4
(lp3626
sg24
(lp3627
(dp3628
g7
I94
sg8
I1
sg9
I7
sg27
VC0006826
p3629
sg12
Vcancers
p3630
sa(dp3631
g7
I107
sg8
I1
sg9
I12
sg27
VC0020538
p3632
sg12
Vhypertension
p3633
sa(dp3634
g7
I64
sg8
I1
sg9
I11
sg27
VC0008055
p3635
sg12
Vchikungunya
p3636
sa(dp3637
g7
I87
sg8
I1
sg9
I6
sg27
VC0596988
p3638
sg12
Vmutant
p3639
sa(dp3640
g7
I44
sg8
I1
sg9
I9
sg27
VC0003864
p3641
sg12
Varthritis
p3642
sasa(dp3643
g2
VOn univariate analysis, diabetes mellitus, hypertension (HTN), cerebrovascular accident (CVA), left ventricular dysfunction (LVD), peripheral vascular disease (PVD), smoking, hepatitis C, inadequate dialysis, intradialytic hypotension (IDH), interdialytic weight gain, low serum creatinine &lt;4 mg/dL, and anemia (Hb &lt;10 g/dL) were found to be statistically significantly different between frail and nonfrail groups On multivariate regression analysis, only HTN, PVD, CVA, anemia, smoking, and IDH were found to be significant.
p3644
sg4
(lp3645
(dp3646
g7
I57
sg8
I1
sg9
I3
sg10
VP24821
p3647
sg12
VHTN
p3648
sa(dp3649
g7
I209
sg8
I2
sg9
I25
sg10
VP48735
p3650
sg12
Vintradialytic hypotension
p3651
sa(dp3652
g7
I43
sg8
I1
sg9
I12
sg10
VP24821
p3653
sg12
Vhypertension
p3654
sa(dp3655
g7
I236
sg8
I1
sg9
I3
sg10
VP48735
p3656
sg12
VIDH
p3657
sasg24
(lp3658
(dp3659
g7
I160
sg8
I1
sg9
I3
sg27
VC0085096
p3660
sg12
VPVD
p3661
sa(dp3662
g7
I43
sg8
I1
sg9
I12
sg27
VC0020538
p3663
sg12
Vhypertension
p3664
sa(dp3665
g7
I89
sg8
I1
sg9
I3
sg27
VC0038454
p3666
sg12
VCVA
p3667
sa(dp3668
g7
I57
sg8
I1
sg9
I3
sg27
VC0020538
p3669
sg12
VHTN
p3670
sa(dp3671
g7
I125
sg8
I1
sg9
I3
sg27
VC0242698
p3672
sg12
VLVD
p3673
sa(dp3674
g7
I95
sg8
I3
sg9
I28
sg27
VC0242698
p3675
sg12
Vleft ventricular dysfunction
p3676
sa(dp3677
g7
I160
sg8
I1
sg9
I3
sg27
VC0085096
p3678
sg12
VPVD
p3679
sa(dp3680
g7
I307
sg8
I1
sg9
I6
sg27
VC0002871
p3681
sg12
Vanemia
p3682
sa(dp3683
g7
I63
sg8
I2
sg9
I24
sg27
VC0038454
p3684
sg12
Vcerebrovascular accident
p3685
sa(dp3686
g7
I307
sg8
I1
sg9
I6
sg27
VC0002871
p3687
sg12
Vanemia
p3688
sa(dp3689
g7
I57
sg8
I1
sg9
I3
sg27
VC0020538
p3690
sg12
VHTN
p3691
sa(dp3692
g7
I24
sg8
I2
sg9
I17
sg27
VC0011849
p3693
sg12
Vdiabetes mellitus
p3694
sa(dp3695
g7
I131
sg8
I3
sg9
I27
sg27
VC0085096
p3696
sg12
Vperipheral vascular disease
p3697
sa(dp3698
g7
I175
sg8
I2
sg9
I11
sg27
VC0019196
p3699
sg12
Vhepatitis C
p3700
sa(dp3701
g7
I89
sg8
I1
sg9
I3
sg27
VC0038454
p3702
sg12
VCVA
p3703
sasa(dp3704
g2
VFactors predicting frailty include HTN, smoking, LVD, PVD, CVA, smoking, anemia, and IDH.
p3705
sg4
(lp3706
(dp3707
g7
I85
sg8
I1
sg9
I3
sg10
VP48735
p3708
sg12
VIDH
p3709
sasg24
(lp3710
(dp3711
g7
I59
sg8
I1
sg9
I3
sg27
VC0038454
p3712
sg12
VCVA
p3713
sa(dp3714
g7
I73
sg8
I1
sg9
I6
sg27
VC0002871
p3715
sg12
Vanemia
p3716
sa(dp3717
g7
I35
sg8
I1
sg9
I3
sg27
VC0020538
p3718
sg12
VHTN
p3719
sa(dp3720
g7
I54
sg8
I1
sg9
I3
sg27
VC0085096
p3721
sg12
VPVD
p3722
sasa(dp3723
g2
VIntradialytic hypertension (IDH) increases morbidity and mortality.
p3724
sg4
(lp3725
sg24
(lp3726
(dp3727
g7
I14
sg8
I1
sg9
I12
sg27
VC0020538
p3728
sg12
Vhypertension
p3729
sasa(dp3730
g2
VIntradialytic hypertension (ID-HTN) is an increasingly recognized phenomenon and although less common than IDH, portends poor cardiovascular prognosis as well as reflects higher hypertension burden in the dialysis population.
p3731
sg4
(lp3732
sg24
(lp3733
(dp3734
g7
I31
sg8
I1
sg9
I3
sg27
VC0020538
p3735
sg12
VHTN
p3736
sa(dp3737
g7
I14
sg8
I1
sg9
I12
sg27
VC0020538
p3738
sg12
Vhypertension
p3739
sa(dp3740
g7
I14
sg8
I1
sg9
I12
sg27
VC0020538
p3741
sg12
Vhypertension
p3742
sasa(dp3743
g2
VDry weight, hypertension, and phosphorus levels are modifiable risk factors to possibly reduce the rate of IDH episodes.
p3744
sg4
(lp3745
sg24
(lp3746
(dp3747
g7
I12
sg8
I1
sg9
I12
sg27
VC0020538
p3748
sg12
Vhypertension
p3749
sasa(dp3750
g2
VWe believe that all hypertension guidelines should follow the National Institute for Health and Excellence (NICE) and make IDP and CTD first choice 'thiazide-like diuretics.'
p3751
sg4
(lp3752
sg24
(lp3753
(dp3754
g7
I20
sg8
I1
sg9
I12
sg27
VC0020538
p3755
sg12
Vhypertension
p3756
sasa(dp3757
g2
VImmunohistochemical analysis with the anti-SOX6 antibody showed that all the glioma tissues analyzed (14 glioblastomas, 14 anaplastic astrocytomas, 3 anaplastic oligoastrocytomas, 5 diffuse astrocytomas, 1 oligodendroglioma, and 1 pilocytic astrocytoma) expressed SOX6 in tumor cells, but only a few SOX6-positive cells were detected in nonneoplastic tissues from the cerebral cortex.
p3758
sg4
(lp3759
(dp3760
g7
I43
sg8
I1
sg9
I4
sg10
VP35712
p3761
sg12
VSOX6
p3762
sa(dp3763
g7
I38
sg8
I2
sg9
I18
sg10
VP35712
p3764
sg12
Vanti-SOX6 antibody
p3765
sa(dp3766
g7
I43
sg8
I1
sg9
I4
sg10
VP35712
p3767
sg12
VSOX6
p3768
sasg24
(lp3769
(dp3770
g7
I134
sg8
I1
sg9
I12
sg27
VC0004114
p3771
sg12
Vastrocytomas
p3772
sa(dp3773
g7
I77
sg8
I1
sg9
I6
sg27
VC0017638
p3774
sg12
Vglioma
p3775
sa(dp3776
g7
I272
sg8
I1
sg9
I5
sg27
VC0027651
p3777
sg12
Vtumor
p3778
sa(dp3779
g7
I105
sg8
I1
sg9
I13
sg27
VC0017636
p3780
sg12
Vglioblastomas
p3781
sa(dp3782
g7
I231
sg8
I2
sg9
I21
sg27
VC0334583
p3783
sg12
Vpilocytic astrocytoma
p3784
sa(dp3785
g7
I206
sg8
I1
sg9
I17
sg27
VC0028945
p3786
sg12
Voligodendroglioma
p3787
sa(dp3788
g7
I123
sg8
I2
sg9
I23
sg27
VC0334579
p3789
sg12
Vanaplastic astrocytomas
p3790
sasa(dp3791
g2
VTo address these issues, we analyzed the production of proinflammatory mediators in mouse thyroid organs and demonstrate consistency with in vitro studies performed previously that Il1alpha, Il1beta, Il6, and Tnfalpha and the enzyme Cox2 are produced by RP3-transgenic thyroid tissue, but absent from nontransgenic thyroids.
p3792
sg4
(lp3793
(dp3794
g7
I200
sg8
I1
sg9
I3
sg10
VP05231
p3795
sg12
VIl6
p3796
sa(dp3797
g7
I233
sg8
I1
sg9
I4
sg10
VP35354
p3798
sg12
VCox2
p3799
sa(dp3800
g7
I209
sg8
I1
sg9
I8
sg10
VP01375
p3801
sg12
VTnfalpha
p3802
sa(dp3803
g7
I181
sg8
I1
sg9
I8
sg10
VP01583
p3804
sg12
VIl1alpha
p3805
sa(dp3806
g7
I254
sg8
I1
sg9
I3
sg10
VP51808
p3807
sg12
VRP3
p3808
sa(dp3809
g7
I191
sg8
I1
sg9
I7
sg10
VP01584
p3810
sg12
VIl1beta
p3811
sasg24
(lp3812
(dp3813
g7
I254
sg8
I1
sg9
I3
sg27
VC1845667
p3814
sg12
VRP3
p3815
sasa(dp3816
g2
VWith a few exceptions, higher circulating levels of endostatin seem to reflect vascular and myocardial damage, and a worsened prognosis for cardiovascular events or mortality in individuals with hypertension, diabetes, kidney disease, cardiovascular disease, as well as in the general population.
p3817
sg4
(lp3818
sg24
(lp3819
(dp3820
g7
I226
sg8
I2
sg9
I23
sg27
VC0007222
p3821
sg12
Vdisease, cardiovascular
p3822
sa(dp3823
g7
I209
sg8
I1
sg9
I8
sg27
VC0011849
p3824
sg12
Vdiabetes
p3825
sa(dp3826
g7
I195
sg8
I1
sg9
I12
sg27
VC0020538
p3827
sg12
Vhypertension
p3828
sasa(dp3829
g2
VEndostatin is one of the main angiostatic mediators, and inhibits angiogenesis and prevents progression of atherosclerosis.
p3830
sg4
(lp3831
sg24
(lp3832
(dp3833
g7
I107
sg8
I1
sg9
I15
sg27
VC0004153
p3834
sg12
Vatherosclerosis
p3835
sasa(dp3836
g2
VFor ischemic versus hemorrhagic strokes comparison, NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) &gt;4.9 (odds ratio, 2.40; 95% confidence interval, 1.55-3.71; P&lt;0.0001) and endostatin &gt;4.7 (odds ratio, 2.02; 95% confidence interval, 1.19-3.45; P=0.010), together with age, sex, blood pressure, stroke severity, atrial fibrillation, and hypertension, were included in the model.
p3837
sg4
(lp3838
sg24
(lp3839
(dp3840
g7
I20
sg8
I2
sg9
I19
sg27
VC0553692
p3841
sg12
Vhemorrhagic strokes
p3842
sa(dp3843
g7
I32
sg8
I1
sg9
I6
sg27
VC0038454
p3844
sg12
Vstroke
p3845
sa(dp3846
g7
I352
sg8
I1
sg9
I12
sg27
VC0020538
p3847
sg12
Vhypertension
p3848
sa(dp3849
g7
I327
sg8
I2
sg9
I19
sg27
VC0004238
p3850
sg12
Vatrial fibrillation
p3851
sasa(dp3852
g2
VIn patients with coronary heart disease, the count of endothelial progenitor cells was lower by 4 times, the level of VEGF was higher by 52%, and the level of endostatin was lower by 13% than in healthy volunteers.
p3853
sg4
(lp3854
sg24
(lp3855
(dp3856
g7
I17
sg8
I3
sg9
I22
sg27
VC0010054
p3857
sg12
Vcoronary heart disease
p3858
sasa(dp3859
g2
VTo examine the association between the serum endostatin levels and subclinical atherosclerosis independent of traditional risk factors in a healthy Japanese population.
p3860
sg4
(lp3861
(dp3862
g7
I39
sg8
I2
sg9
I16
sg10
VP39059
p3863
sg12
Vserum endostatin
p3864
sasg24
(lp3865
(dp3866
g7
I79
sg8
I1
sg9
I15
sg27
VC0004153
p3867
sg12
Vatherosclerosis
p3868
sasa(dp3869
g2
VA higher serum endostatin level reflected subclinical atherosclerosis in this Japanese population.
p3870
sg4
(lp3871
sg24
(lp3872
(dp3873
g7
I54
sg8
I1
sg9
I15
sg27
VC0004153
p3874
sg12
Vatherosclerosis
p3875
sasa(dp3876
g2
VThe most common diseases among humanitarian cases were benign tumors (29%, 5/17), cranioplasty (23%, 4/17), obstructive hydrocephalus (11%, 2/17), nonobstructive hydrocephalus (11%, 2/17), hemifacial spasm (11%, 2/17), and cerebral angiography (11%, 2/17).
p3877
sg4
(lp3878
sg24
(lp3879
(dp3880
g7
I200
sg8
I1
sg9
I5
sg27
VC0037763
p3881
sg12
Vspasm
p3882
sa(dp3883
g7
I108
sg8
I2
sg9
I25
sg27
VC0549423
p3884
sg12
Vobstructive hydrocephalus
p3885
sa(dp3886
g7
I55
sg8
I2
sg9
I13
sg27
VC0086692
p3887
sg12
Vbenign tumors
p3888
sa(dp3889
g7
I120
sg8
I1
sg9
I13
sg27
VC0020255
p3890
sg12
Vhydrocephalus
p3891
sasa(dp3892
g2
VTwenty-seven (33.8%) patients developed ARE, 5 (6%) developed hydrocephalus, 10 (12.5%) reported new ataxia, 17 (21%) developed trigeminal dysfunction, 3 (3.75%) had facial weakness, and 1 patient developed hemifacial spasm.
p3893
sg4
(lp3894
sg24
(lp3895
(dp3896
g7
I101
sg8
I1
sg9
I6
sg27
VC0004134
p3897
sg12
Vataxia
p3898
sa(dp3899
g7
I166
sg8
I2
sg9
I15
sg27
VC0427055
p3900
sg12
Vfacial weakness
p3901
sa(dp3902
g7
I62
sg8
I1
sg9
I13
sg27
VC0020255
p3903
sg12
Vhydrocephalus
p3904
sa(dp3905
g7
I218
sg8
I1
sg9
I5
sg27
VC0037763
p3906
sg12
Vspasm
p3907
sasa(dp3908
g2
VTwelve factors, including gender, hypertension, intracranial aneurysm, cerebral vascular spasm, hydrocephalus and conscious disturbance during hospitalization, smoking, age, WFNS (World Federation of Neurological Surgeons) scale, Fisher grade, white blood cell count and blood glucose level at admission, were analyzed by using Chi-square test, t test, and Logistic multiple regression analysis.
p3909
sg4
(lp3910
sg24
(lp3911
(dp3912
g7
I61
sg8
I2
sg9
I18
sg27
VC0917996
p3913
sg12
Vaneurysm, cerebral
p3914
sa(dp3915
g7
I34
sg8
I2
sg9
I26
sg27
VC0151740
p3916
sg12
Vhypertension, intracranial
p3917
sa(dp3918
g7
I96
sg8
I1
sg9
I13
sg27
VC0020255
p3919
sg12
Vhydrocephalus
p3920
sa(dp3921
g7
I80
sg8
I2
sg9
I14
sg27
VC0085616
p3922
sg12
Vvascular spasm
p3923
sasa(dp3924
g2
VWe studied 37 patients with spasm, trisomy 21, prematurity, epilepsy, psychomotor retardation, and/or hydrocephalus (study group) and 67 control patients, all between 14 months and 14 years of age.
p3925
sg4
(lp3926
sg24
(lp3927
(dp3928
g7
I60
sg8
I2
sg9
I21
sg27
VC0085417
p3929
sg12
Vepilepsy, psychomotor
p3930
sa(dp3931
g7
I102
sg8
I1
sg9
I13
sg27
VC0020255
p3932
sg12
Vhydrocephalus
p3933
sa(dp3934
g7
I28
sg8
I1
sg9
I5
sg27
VC0037763
p3935
sg12
Vspasm
p3936
sa(dp3937
g7
I35
sg8
I2
sg9
I10
sg27
VC0013080
p3938
sg12
Vtrisomy 21
p3939
sasa(dp3940
g2
VSurgical treatment after radiosurgery or radiotherapy may be necessary for tumors that continue to grow, or for patients who develop brainstem compressive symptoms, disabling hemifacial spasm, or hydrocephalus.
p3941
sg4
(lp3942
sg24
(lp3943
(dp3944
g7
I186
sg8
I1
sg9
I5
sg27
VC0037763
p3945
sg12
Vspasm
p3946
sa(dp3947
g7
I75
sg8
I1
sg9
I6
sg27
VC0027651
p3948
sg12
Vtumors
p3949
sa(dp3950
g7
I196
sg8
I1
sg9
I13
sg27
VC0020255
p3951
sg12
Vhydrocephalus
p3952
sasa(dp3953
g2
VAmong these, 236 differentially expressed genes (DEGs) were statistically significant, including many DEGs that were novel in cervical cancer, including gastrulation brain homeobox 2,5-hydroxytryptamine receptor 1D and endothelin 3.
p3954
sg4
(lp3955
(dp3956
g7
I49
sg8
I1
sg9
I4
sg10
g11
sg12
VDEGs
p3957
sa(dp3958
g7
I219
sg8
I2
sg9
I12
sg10
VP14138
p3959
sg12
Vendothelin 3
p3960
sa(dp3961
g7
I166
sg8
I5
sg9
I48
sg10
VP52954
p3962
sg12
Vbrain homeobox 2,5-hydroxytryptamine receptor 1D
p3963
sa(dp3964
g7
I17
sg8
I3
sg9
I30
sg10
g11
sg12
Vdifferentially expressed genes
p3965
sasg24
(lp3966
(dp3967
g7
I126
sg8
I2
sg9
I15
sg27
VC0302592
p3968
sg12
Vcervical cancer
p3969
sasa(dp3970
g2
VA total of 5 overlapping genes [dipeptidyl peptidase 4 (DPP4); endothelin 3 (EDN3); fibroblast growth factor 14 (FGF14); tachykinin, precursor 1 (TAC1); and wingless-type MMTV integration site family, member 16 (WNT16)] between the 561 overlapping differentially methylated genes and the 242 DEGs were identified, which were downregulated and hypermethylated simultaneously in cervical cancer samples.
p3971
sg4
(lp3972
(dp3973
g7
I121
sg8
I3
sg9
I23
sg10
VP29401
p3974
sg12
Vtachykinin, precursor 1
p3975
sa(dp3976
g7
I157
sg8
I7
sg9
I53
sg10
g11
sg12
Vwingless-type MMTV integration site family, member 16
p3977
sa(dp3978
g7
I31
sg8
I3
sg9
I23
sg10
VP27487
p3979
sg12
V[dipeptidyl peptidase 4
p3980
sa(dp3981
g7
I56
sg8
I1
sg9
I4
sg10
VP27487
p3982
sg12
VDPP4
p3983
sa(dp3984
g7
I84
sg8
I4
sg9
I27
sg10
g11
sg12
Vfibroblast growth factor 14
p3985
sa(dp3986
g7
I212
sg8
I1
sg9
I5
sg10
g11
sg12
VWNT16
p3987
sa(dp3988
g7
I113
sg8
I1
sg9
I5
sg10
g11
sg12
VFGF14
p3989
sa(dp3990
g7
I63
sg8
I2
sg9
I12
sg10
VP14138
p3991
sg12
Vendothelin 3
p3992
sa(dp3993
g7
I77
sg8
I1
sg9
I4
sg10
VP14138
p3994
sg12
VEDN3
p3995
sasg24
(lp3996
(dp3997
g7
I377
sg8
I2
sg9
I15
sg27
VC0302592
p3998
sg12
Vcervical cancer
p3999
sasa(dp4000
g2
VEmploying functions of several bioinformatics tools, we selected 143 differentially expressed genes (DEGs) associated with the cervical cancer.
p4001
sg4
(lp4002
(dp4003
g7
I101
sg8
I1
sg9
I4
sg10
g11
sg12
VDEGs
p4004
sa(dp4005
g7
I69
sg8
I3
sg9
I30
sg10
g11
sg12
Vdifferentially expressed genes
p4006
sasg24
(lp4007
(dp4008
g7
I127
sg8
I2
sg9
I15
sg27
VC0302592
p4009
sg12
Vcervical cancer
p4010
sasa(dp4011
g2
VThe results of bioinformatics analysis show that these DEGs play important roles in the development of cervical cancer.
p4012
sg4
(lp4013
(dp4014
g7
I55
sg8
I1
sg9
I4
sg10
g11
sg12
VDEGs
p4015
sasg24
(lp4016
(dp4017
g7
I103
sg8
I2
sg9
I15
sg27
VC0302592
p4018
sg12
Vcervical cancer
p4019
sasa(dp4020
g2
VA total of 1,160 and 756 DEGs were identified in the pre-invasive and invasive stages of cervical cancer, respectively.
p4021
sg4
(lp4022
sg24
(lp4023
(dp4024
g7
I89
sg8
I2
sg9
I15
sg27
VC0302592
p4025
sg12
Vcervical cancer
p4026
sasa(dp4027
g2
VSurvival analysis then revealed a five-PcG gene signature one protective gene (enhancer of zeste homolog 1) and four risky genes (EZH2, PHD finger protein 19, DNMT3A and DNMT3B), which may identify patients with high risk of poor prognosis of glioma.
p4028
sg4
(lp4029
(dp4030
g7
I170
sg8
I1
sg9
I6
sg10
g11
sg12
VDNMT3B
p4031
sa(dp4032
g7
I91
sg8
I3
sg9
I15
sg10
g11
sg12
Vzeste homolog 1
p4033
sa(dp4034
g7
I159
sg8
I1
sg9
I6
sg10
g11
sg12
VDNMT3A
p4035
sa(dp4036
g7
I136
sg8
I4
sg9
I21
sg10
g11
sg12
VPHD finger protein 19
p4037
sa(dp4038
g7
I130
sg8
I1
sg9
I4
sg10
g11
sg12
VEZH2
p4039
sasg24
(lp4040
(dp4041
g7
I243
sg8
I1
sg9
I6
sg27
VC0017638
p4042
sg12
Vglioma
p4043
sasa(dp4044
g2
VIn this study, we exploited this platform to evaluate the behavior of two biodegradable formulations, poly-Epsilon-caprolactone (PCL3) and poly lactic-acid (PLA8), respectively, in cellular and animal models of triple-negative breast cancer (TNBC).
p4045
sg4
(lp4046
(dp4047
g7
I129
sg8
I1
sg9
I4
sg10
g11
sg12
VPCL3
p4048
sa(dp4049
g7
I102
sg8
I1
sg9
I25
sg10
g11
sg12
Vpoly-Epsilon-caprolactone
p4050
sasg24
(lp4051
(dp4052
g7
I227
sg8
I2
sg9
I13
sg27
VC0678222
p4053
sg12
Vbreast cancer
p4054
sasa(dp4055
g2
VInterestingly, changes in EZH2, PHF19, CBX7, CBX6 and EZH1 occurred progressively as astrocytoma grade increased.
p4056
sg4
(lp4057
(dp4058
g7
I26
sg8
I1
sg9
I4
sg10
g11
sg12
VEZH2
p4059
sa(dp4060
g7
I39
sg8
I1
sg9
I4
sg10
g11
sg12
VCBX7
p4061
sa(dp4062
g7
I54
sg8
I1
sg9
I4
sg10
g11
sg12
VEZH1
p4063
sa(dp4064
g7
I45
sg8
I1
sg9
I4
sg10
g11
sg12
VCBX6
p4065
sa(dp4066
g7
I32
sg8
I1
sg9
I5
sg10
g11
sg12
VPHF19
p4067
sasg24
(lp4068
(dp4069
g7
I85
sg8
I1
sg9
I11
sg27
VC0004114
p4070
sg12
Vastrocytoma
p4071
sasa(dp4072
g2
VIn this report, we show that PHF19 silencing reduces the cell proliferation rate and increases the transendothelial migration capacities of melanoma cell lines.
p4073
sg4
(lp4074
(dp4075
g7
I29
sg8
I1
sg9
I5
sg10
g11
sg12
VPHF19
p4076
sasg24
(lp4077
(dp4078
g7
I140
sg8
I1
sg9
I8
sg27
VC0025202
p4079
sg12
Vmelanoma
p4080
sa(dp4081
g7
I62
sg8
I1
sg9
I13
sg27
VC0334094
p4082
sg12
Vproliferation
p4083
sasa(dp4084
g2
VOur data therefore indicate the role of PHF19 and its upstream regulator, Akt, in the phenotype switch of melanoma cells from proliferative to invasive states.
p4085
sg4
(lp4086
(dp4087
g7
I40
sg8
I1
sg9
I5
sg10
g11
sg12
VPHF19
p4088
sa(dp4089
g7
I74
sg8
I1
sg9
I3
sg10
g11
sg12
VAkt
p4090
sasg24
(lp4091
(dp4092
g7
I106
sg8
I1
sg9
I8
sg27
VC0025202
p4093
sg12
Vmelanoma
p4094
sa(dp4095
g7
I126
sg8
I1
sg9
I13
sg27
VC0334094
p4096
sg12
Vproliferative
p4097
sasa(dp4098
g2
VInterestingly, the products of the hPCL3 gene, particularly the short form, hPCL3S, are markedly overexpressed in many types of cancers, including colon, skin, lung, rectal, cervical, uterus, and liver cancers.
p4099
sg4
(lp4100
(dp4101
g7
I76
sg8
I1
sg9
I6
sg10
g11
sg12
VhPCL3S
p4102
sa(dp4103
g7
I35
sg8
I2
sg9
I10
sg10
g11
sg12
VhPCL3 gene
p4104
sasg24
(lp4105
(dp4106
g7
I128
sg8
I1
sg9
I7
sg27
VC0006826
p4107
sg12
Vcancers
p4108
sa(dp4109
g7
I196
sg8
I2
sg9
I13
sg27
VC0345904
p4110
sg12
Vliver cancers
p4111
sasa(dp4112
g2
VBoth hPCL3S and hPCL3L messages were increased dramatically in most cell lines derived from various stages of melanoma and glioma tumor progression.
p4113
sg4
(lp4114
(dp4115
g7
I5
sg8
I1
sg9
I6
sg10
g11
sg12
VhPCL3S
p4116
sasg24
(lp4117
(dp4118
g7
I123
sg8
I1
sg9
I6
sg27
VC0017638
p4119
sg12
Vglioma
p4120
sa(dp4121
g7
I110
sg8
I1
sg9
I8
sg27
VC0025202
p4122
sg12
Vmelanoma
p4123
sa(dp4124
g7
I130
sg8
I2
sg9
I17
sg27
VC0178874
p4125
sg12
Vtumor progression
p4126
sasa(dp4127
g2
VFifty patients (19 males and 31 females, mean age 52.4 y) showed sagging posterior layer TLF, and 32 of them developed &gt;=1 junctional problems, such as retrolistheses (n=25), compression fractures (n=5), spondylolistheses (n=4), progressive scoliosis (n=4), and segmental instability with bone marrow change (n=2).
p4128
sg4
(lp4129
sg24
(lp4130
(dp4131
g7
I244
sg8
I1
sg9
I9
sg27
VC0700208
p4132
sg12
Vscoliosis
p4133
sa(dp4134
g7
I178
sg8
I2
sg9
I21
sg27
VC0521169
p4135
sg12
Vcompression fractures
p4136
sa(dp4137
g7
I207
sg8
I1
sg9
I17
sg27
VC0038016
p4138
sg12
Vspondylolistheses
p4139
sasa(dp4140
g2
VHowever, the patients with thoracolumbar fracture (TLF) had significantly more MSCs than those with degenerative disc disease (DDD), but not for NCs.
p4141
sg4
(lp4142
sg24
(lp4143
(dp4144
g7
I127
sg8
I1
sg9
I3
sg27
VC0406811
p4145
sg12
VDDD
p4146
sa(dp4147
g7
I100
sg8
I3
sg9
I25
sg27
VC0158266
p4148
sg12
Vdegenerative disc disease
p4149
sasa(dp4150
g2
VCommon physiological pathways are involved in several ARCA, such as DNA repair deficiency (AOA1, ataxia telangiectasia [AT]...), RNA termination disorder (AOA2), mitochondrial defect (FRDA, sensory ataxic neuropathy with dysarthria and ophthalmoplegia [Sando]...), lipoprotein assembly defects (AVED, abetalipoproteinemia [ABL]), chaperon protein disorders (ARSACS, Marinesco-Sjoegren syndrome [MSS]) or peroxysomal diseases (Refsum disease [RD]).
p4151
sg4
(lp4152
(dp4153
g7
I184
sg8
I1
sg9
I4
sg10
g11
sg12
VFRDA
p4154
sasg24
(lp4155
(dp4156
g7
I236
sg8
I1
sg9
I15
sg27
VC0029089
p4157
sg12
Vophthalmoplegia
p4158
sa(dp4159
g7
I323
sg8
I1
sg9
I3
sg27
VC0000744
p4160
sg12
VABL
p4161
sa(dp4162
g7
I385
sg8
I1
sg9
I8
sg27
VC0039082
p4163
sg12
Vsyndrome
p4164
sa(dp4165
g7
I301
sg8
I1
sg9
I20
sg27
VC0000744
p4166
sg12
Vabetalipoproteinemia
p4167
sa(dp4168
g7
I184
sg8
I1
sg9
I4
sg27
VC1856689
p4169
sg12
VFRDA
p4170
sa(dp4171
g7
I221
sg8
I1
sg9
I10
sg27
VC0013362
p4172
sg12
Vdysarthria
p4173
sa(dp4174
g7
I155
sg8
I1
sg9
I4
sg27
VC1853761
p4175
sg12
VAOA2
p4176
sa(dp4177
g7
I253
sg8
I1
sg9
I5
sg27
VC1843851
p4178
sg12
VSando
p4179
sa(dp4180
g7
I205
sg8
I1
sg9
I10
sg27
VC0442874
p4181
sg12
Vneuropathy
p4182
sa(dp4183
g7
I358
sg8
I1
sg9
I6
sg27
VC1849140
p4184
sg12
VARSACS
p4185
sa(dp4186
g7
I97
sg8
I2
sg9
I21
sg27
VC0004135
p4187
sg12
Vataxia telangiectasia
p4188
sa(dp4189
g7
I198
sg8
I1
sg9
I6
sg27
VC0234366
p4190
sg12
Vataxic
p4191
sa(dp4192
g7
I91
sg8
I1
sg9
I4
sg27
VC1859598
p4193
sg12
VAOA1
p4194
sa(dp4195
g7
I426
sg8
I2
sg9
I14
sg27
VC0034960
p4196
sg12
VRefsum disease
p4197
sa(dp4198
g7
I68
sg8
I3
sg9
I21
sg27
VC0268134
p4199
sg12
VDNA repair deficiency
p4200
sa(dp4201
g7
I295
sg8
I1
sg9
I4
sg27
VC1848533
p4202
sg12
VAVED
p4203
sa(dp4204
g7
I395
sg8
I1
sg9
I3
sg27
VC0024814
p4205
sg12
VMSS
p4206
sasa(dp4207
g2
VWhile Friedreich's ataxia (FRDA) and ataxia telangiectasia (AT) are known to be the two most frequent forms of autosomal recessive cerebellar ataxia (ARCA), knowledge on the other forms of ARCA has been obtained only recently, and they appear to be rarer.
p4208
sg4
(lp4209
sg24
(lp4210
(dp4211
g7
I60
sg8
I1
sg9
I2
sg27
VC0004135
p4212
sg12
VAT
p4213
sa(dp4214
g7
I37
sg8
I2
sg9
I21
sg27
VC0004135
p4215
sg12
Vataxia telangiectasia
p4216
sa(dp4217
g7
I6
sg8
I2
sg9
I19
sg27
VC0016719
p4218
sg12
VFriedreich's ataxia
p4219
sa(dp4220
g7
I111
sg8
I4
sg9
I37
sg27
VC0007758
p4221
sg12
Vautosomal recessive cerebellar ataxia
p4222
sa(dp4223
g7
I27
sg8
I1
sg9
I4
sg27
VC1856689
p4224
sg12
VFRDA
p4225
sa(dp4226
g7
I150
sg8
I1
sg9
I4
sg27
VC0007758
p4227
sg12
VARCA
p4228
sa(dp4229
g7
I150
sg8
I1
sg9
I4
sg27
VC0007758
p4230
sg12
VARCA
p4231
sasa(dp4232
g2
VTranscription factor MEF2C regulates multiple genes linked to autism spectrum disorder (ASD), and human MEF2C haploinsufficiency results in ASD, intellectual disability, and epilepsy.
p4233
sg4
(lp4234
(dp4235
g7
I0
sg8
I3
sg9
I26
sg10
VP35398
p4236
sg12
VTranscription factor MEF2C
p4237
sa(dp4238
g7
I98
sg8
I2
sg9
I11
sg10
g11
sg12
Vhuman MEF2C
p4239
sasg24
(lp4240
(dp4241
g7
I174
sg8
I1
sg9
I8
sg27
VC0014544
p4242
sg12
Vepilepsy
p4243
sa(dp4244
g7
I88
sg8
I1
sg9
I3
sg27
VC1510586
p4245
sg12
VASD
p4246
sa(dp4247
g7
I145
sg8
I2
sg9
I23
sg27
VC0025362
p4248
sg12
Vintellectual disability
p4249
sa(dp4250
g7
I88
sg8
I1
sg9
I3
sg27
VC1510586
p4251
sg12
VASD
p4252
sa(dp4253
g7
I62
sg8
I3
sg9
I24
sg27
VC1510586
p4254
sg12
Vautism spectrum disorder
p4255
sasa(dp4256
g2
VThe microRNAs target a group of genes enriched for synaptic signaling and epilepsy risk, including SLC12A5, SYT1, GRIN2A, GRIN2B, KCNB1, SCN2A, TSC1, and MEF2C.
p4257
sg4
(lp4258
(dp4259
g7
I108
sg8
I1
sg9
I4
sg10
VP21579
p4260
sg12
VSYT1
p4261
sa(dp4262
g7
I122
sg8
I1
sg9
I6
sg10
g11
sg12
VGRIN2B
p4263
sa(dp4264
g7
I99
sg8
I1
sg9
I7
sg10
g11
sg12
VSLC12A5
p4265
sa(dp4266
g7
I137
sg8
I1
sg9
I5
sg10
g11
sg12
VSCN2A
p4267
sa(dp4268
g7
I154
sg8
I1
sg9
I5
sg10
g11
sg12
VMEF2C
p4269
sa(dp4270
g7
I114
sg8
I1
sg9
I6
sg10
g11
sg12
VGRIN2A
p4271
sa(dp4272
g7
I130
sg8
I1
sg9
I5
sg10
g11
sg12
VKCNB1
p4273
sa(dp4274
g7
I144
sg8
I1
sg9
I4
sg10
g11
sg12
VTSC1
p4275
sasg24
(lp4276
(dp4277
g7
I144
sg8
I1
sg9
I4
sg27
VC1854465
p4278
sg12
VTSC1
p4279
sa(dp4280
g7
I74
sg8
I1
sg9
I8
sg27
VC0014544
p4281
sg12
Vepilepsy
p4282
sasa(dp4283
g2
VGenome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB1, HLA-DRB4, INPP5D, MEF2C, MS4A4A, MS4A4E, MS4A6E, NME8, PICALM, PLD3, PTK2B, RIN3, SLC24A4, SORL1, and ZCWPW1 genes.
p4284
sg4
(lp4285
(dp4286
g7
I292
sg8
I1
sg9
I6
sg10
g11
sg12
VPICALM
p4287
sa(dp4288
g7
I176
sg8
I1
sg9
I5
sg10
g11
sg12
VCD2AP
p4289
sa(dp4290
g7
I270
sg8
I1
sg9
I6
sg10
g11
sg12
VMS4A4E
p4291
sa(dp4292
g7
I255
sg8
I1
sg9
I5
sg10
g11
sg12
VMEF2C
p4293
sa(dp4294
g7
I227
sg8
I1
sg9
I3
sg10
VP30486
p4295
sg12
VHLA
p4296
sa(dp4297
g7
I206
sg8
I1
sg9
I4
sg10
g11
sg12
VDSG2
p4298
sa(dp4299
g7
I189
sg8
I1
sg9
I5
sg10
g11
sg12
VCELF1
p4300
sa(dp4301
g7
I157
sg8
I1
sg9
I4
sg10
VP02649
p4302
sg12
VAPOE
p4303
sa(dp4304
g7
I150
sg8
I1
sg9
I5
sg10
g11
sg12
VABCA7
p4305
sa(dp4306
g7
I313
sg8
I1
sg9
I4
sg10
g11
sg12
VRIN3
p4307
sa(dp4308
g7
I328
sg8
I1
sg9
I5
sg10
g11
sg12
VSORL1
p4309
sa(dp4310
g7
I319
sg8
I1
sg9
I7
sg10
g11
sg12
VSLC24A4
p4311
sa(dp4312
g7
I247
sg8
I1
sg9
I6
sg10
g11
sg12
VINPP5D
p4313
sa(dp4314
g7
I262
sg8
I1
sg9
I6
sg10
g11
sg12
VMS4A4A
p4315
sa(dp4316
g7
I183
sg8
I1
sg9
I4
sg10
VP20138
p4317
sg12
VCD33
p4318
sa(dp4319
g7
I300
sg8
I1
sg9
I4
sg10
g11
sg12
VPLD3
p4320
sa(dp4321
g7
I219
sg8
I1
sg9
I6
sg10
g11
sg12
VFERMT2
p4322
sa(dp4323
g7
I169
sg8
I1
sg9
I5
sg10
g11
sg12
VCASS4
p4324
sa(dp4325
g7
I196
sg8
I1
sg9
I3
sg10
VP10909
p4326
sg12
VCLU
p4327
sa(dp4328
g7
I306
sg8
I1
sg9
I5
sg10
g11
sg12
VPTK2B
p4329
sa(dp4330
g7
I212
sg8
I1
sg9
I5
sg10
VP21709
p4331
sg12
VEPHA1
p4332
sa(dp4333
g7
I278
sg8
I1
sg9
I6
sg10
g11
sg12
VMS4A6E
p4334
sa(dp4335
g7
I227
sg8
I1
sg9
I3
sg10
VP30486
p4336
sg12
VHLA
p4337
sa(dp4338
g7
I201
sg8
I1
sg9
I3
sg10
VP17927
p4339
sg12
VCR1
p4340
sa(dp4341
g7
I339
sg8
I2
sg9
I12
sg10
g11
sg12
VZCWPW1 genes
p4342
sa(dp4343
g7
I286
sg8
I1
sg9
I4
sg10
g11
sg12
VNME8
p4344
sa(dp4345
g7
I231
sg8
I1
sg9
I4
sg10
g11
sg12
VDRB1
p4346
sasg24
(lp4347
(dp4348
g7
I95
sg8
I2
sg9
I20
sg27
VC0002395
p4349
sg12
VAlzheimer's diseases
p4350
sa(dp4351
g7
I117
sg8
I1
sg9
I2
sg27
VC0002395
p4352
sg12
VAD
p4353
sasa(dp4354
g2
VEpilepsy-causing SIK1 sequence variations resulted in abnormalities in the MEF2C-ARC pathway of neuronal development and synapse activity response.
p4355
sg4
(lp4356
(dp4357
g7
I17
sg8
I2
sg9
I13
sg10
VP57059
p4358
sg12
VSIK1 sequence
p4359
sa(dp4360
g7
I81
sg8
I1
sg9
I3
sg10
g11
sg12
VARC
p4361
sa(dp4362
g7
I75
sg8
I1
sg9
I5
sg10
g11
sg12
VMEF2C
p4363
sasg24
(lp4364
(dp4365
g7
I81
sg8
I1
sg9
I3
sg27
VC0001857
p4366
sg12
VARC
p4367
sa(dp4368
g7
I0
sg8
I1
sg9
I8
sg27
VC0014544
p4369
sg12
VEpilepsy
p4370
sasa(dp4371
g2
VThis work provides the first insights into the mechanisms of pathogenesis in SIK1 syndrome, and extends the ARX-MEF2C pathway in the pathogenesis of developmental epilepsy.
p4372
sg4
(lp4373
(dp4374
g7
I112
sg8
I1
sg9
I5
sg10
g11
sg12
VMEF2C
p4375
sa(dp4376
g7
I108
sg8
I1
sg9
I3
sg10
g11
sg12
VARX
p4377
sasg24
(lp4378
(dp4379
g7
I61
sg8
I1
sg9
I12
sg27
VC0699748
p4380
sg12
Vpathogenesis
p4381
sa(dp4382
g7
I82
sg8
I1
sg9
I8
sg27
VC0039082
p4383
sg12
Vsyndrome
p4384
sa(dp4385
g7
I163
sg8
I1
sg9
I8
sg27
VC0014544
p4386
sg12
Vepilepsy
p4387
sa(dp4388
g7
I61
sg8
I1
sg9
I12
sg27
VC0699748
p4389
sg12
Vpathogenesis
p4390
sasa(dp4391
g2
VA common single nucleotide polymorphism (SNP, rs190982) in MEF2C gene was identified to be related to late-onset Alzheimer's disease (LOAD) in Caucasians in a large meta-analysis of genome-wide association studies (GWAS).
p4392
sg4
(lp4393
(dp4394
g7
I59
sg8
I2
sg9
I10
sg10
g11
sg12
VMEF2C gene
p4395
sasg24
(lp4396
(dp4397
g7
I113
sg8
I2
sg9
I19
sg27
VC1521724
p4398
sg12
VAlzheimer's disease
p4399
sasa(dp4400
g2
VA key factor protecting from oxidative stress in gestational diabetes mellitus (GDM) and in type 2 diabetes (T2D) is paraoxonase-1 (PON1).
p4401
sg4
(lp4402
(dp4403
g7
I132
sg8
I1
sg9
I4
sg10
VP27169
p4404
sg12
VPON1
p4405
sa(dp4406
g7
I117
sg8
I1
sg9
I13
sg10
VP14222
p4407
sg12
Vparaoxonase-1
p4408
sasg24
(lp4409
(dp4410
g7
I49
sg8
I3
sg9
I29
sg27
VC0085207
p4411
sg12
Vgestational diabetes mellitus
p4412
sa(dp4413
g7
I80
sg8
I1
sg9
I3
sg27
VC0085207
p4414
sg12
VGDM
p4415
sa(dp4416
g7
I109
sg8
I1
sg9
I3
sg27
VC0011860
p4417
sg12
VT2D
p4418
sa(dp4419
g7
I29
sg8
I2
sg9
I16
sg27
VC0242606
p4420
sg12
Voxidative stress
p4421
sa(dp4422
g7
I92
sg8
I3
sg9
I15
sg27
VC0011860
p4423
sg12
Vtype 2 diabetes
p4424
sasa(dp4425
g2
VIn this study our aim was to evaluate paraoxonase (PON1) activity and free sulfhydryl groups (-SH) as antioxidative parameters and lipid hydroperoxide (LOOH) as oxidative parameter in the serum of women with gestational diabetes mellitus (GDM) and determine their relation with the degree of subclinical atherosclerosis.
p4426
sg4
(lp4427
(dp4428
g7
I38
sg8
I1
sg9
I11
sg10
VP14222
p4429
sg12
Vparaoxonase
p4430
sa(dp4431
g7
I51
sg8
I1
sg9
I4
sg10
VP27169
p4432
sg12
VPON1
p4433
sasg24
(lp4434
(dp4435
g7
I304
sg8
I1
sg9
I15
sg27
VC0004153
p4436
sg12
Vatherosclerosis
p4437
sa(dp4438
g7
I208
sg8
I3
sg9
I29
sg27
VC0085207
p4439
sg12
Vgestational diabetes mellitus
p4440
sa(dp4441
g7
I239
sg8
I1
sg9
I3
sg27
VC0085207
p4442
sg12
VGDM
p4443
sasa(dp4444
g2
VTo clarify the levels of protein oxidation markers such as protein carbonyl (PCO), protein hydroperoxides (P-OOH), advanced oxidation protein products (AOPP) and nitrotyrosine (NT), as well as antioxidative enzymes such as paraoxonase (PON-1) in women with and without gestational diabetes mellitus (GDM).
p4445
sg4
(lp4446
(dp4447
g7
I223
sg8
I1
sg9
I11
sg10
VP14222
p4448
sg12
Vparaoxonase
p4449
sa(dp4450
g7
I236
sg8
I1
sg9
I5
sg10
VP27169
p4451
sg12
VPON-1
p4452
sasg24
(lp4453
(dp4454
g7
I269
sg8
I3
sg9
I29
sg27
VC0085207
p4455
sg12
Vgestational diabetes mellitus
p4456
sa(dp4457
g7
I59
sg8
I2
sg9
I16
sg27
VC0032460
p4458
sg12
Vprotein carbonyl
p4459
sa(dp4460
g7
I300
sg8
I1
sg9
I3
sg27
VC0085207
p4461
sg12
VGDM
p4462
sa(dp4463
g7
I77
sg8
I1
sg9
I3
sg27
VC0032460
p4464
sg12
VPCO
p4465
sasa(dp4466
g2
VRecently, numerous new antibodies defining the characteristic clinical phenotype have been described as anti-MDA5 antibodies associated with interstitial lung disease and amyopathic dermatomyositis or anti-TIF1Gamma antibodies as markers for paraneoplastic dermatomyositis.
p4467
sg4
(lp4468
(dp4469
g7
I104
sg8
I2
sg9
I20
sg10
g11
sg12
Vanti-MDA5 antibodies
p4470
sa(dp4471
g7
I201
sg8
I2
sg9
I25
sg10
g11
sg12
Vanti-TIF1Gamma antibodies
p4472
sasg24
(lp4473
(dp4474
g7
I242
sg8
I2
sg9
I30
sg27
VC1735598
p4475
sg12
Vparaneoplastic dermatomyositis
p4476
sa(dp4477
g7
I171
sg8
I2
sg9
I26
sg27
VC0406645
p4478
sg12
Vamyopathic dermatomyositis
p4479
sa(dp4480
g7
I141
sg8
I3
sg9
I25
sg27
VC0206062
p4481
sg12
Vinterstitial lung disease
p4482
sasa(dp4483
g2
VPM is associated with anti-synthetase antibodies (anti-Jo-1, PL-7, PL-12, OJ, and EJ) and DM with anti-Mi-2, anti-SAE, anti-TIF-1-Gamma and anti-NXP2 (both associated with cancer) or anti-MDA5 antibodies (associated with interstitial lung disease).
p4484
sg4
(lp4485
(dp4486
g7
I98
sg8
I1
sg9
I9
sg10
g11
sg12
Vanti-Mi-2
p4487
sa(dp4488
g7
I140
sg8
I1
sg9
I9
sg10
g11
sg12
Vanti-NXP2
p4489
sa(dp4490
g7
I183
sg8
I2
sg9
I20
sg10
g11
sg12
Vanti-MDA5 antibodies
p4491
sa(dp4492
g7
I119
sg8
I1
sg9
I16
sg10
g11
sg12
Vanti-TIF-1-Gamma
p4493
sasg24
(lp4494
(dp4495
g7
I172
sg8
I1
sg9
I6
sg27
VC0006826
p4496
sg12
Vcancer
p4497
sa(dp4498
g7
I221
sg8
I3
sg9
I25
sg27
VC0206062
p4499
sg12
Vinterstitial lung disease
p4500
sasa(dp4501
g2
VTwenty-six (43.3%) PM/DM-ILD patients were anti-aminoacyl tRNA-synthetase antibody-positive (anti-ARS-positive), 15 (25.0%) were anti-melanoma differentiation-associated gene 5 antibody-positive (anti-MDA5-positive), 3 (5%) were anti-signal recognition particle antibody-positive, 1 (1.7%) was anti-transcriptional intermediary factor 1-gamma antibody-positive, and 15 (25%) were MSA-negative.
p4502
sg4
(lp4503
(dp4504
g7
I196
sg8
I1
sg9
I9
sg10
g11
sg12
Vanti-MDA5
p4505
sa(dp4506
g7
I129
sg8
I5
sg9
I56
sg10
g11
sg12
Vanti-melanoma differentiation-associated gene 5 antibody
p4507
sa(dp4508
g7
I229
sg8
I4
sg9
I41
sg10
VP61011
p4509
sg12
Vanti-signal recognition particle antibody
p4510
sa(dp4511
g7
I294
sg8
I5
sg9
I57
sg10
g11
sg12
Vanti-transcriptional intermediary factor 1-gamma antibody
p4512
sasg24
(lp4513
(dp4514
g7
I134
sg8
I1
sg9
I8
sg27
VC0025202
p4515
sg12
Vmelanoma
p4516
sa(dp4517
g7
I380
sg8
I1
sg9
I3
sg27
VC0393571
p4518
sg12
VMSA
p4519
sasa(dp4520
g2
VAntibodies to transcription intermediary factor 1Gamma/Alfa (TIF1Gamma/Alfa, p155/140) are frequently found in DM associated with malignancy while anti-melanoma differentiation-associated gene 5 (MDA5; CADM140) are associated with clinically amyopathic DM (CADM) complicated by rapidly progressive ILD.
p4521
sg4
(lp4522
(dp4523
g7
I61
sg8
I1
sg9
I9
sg10
g11
sg12
VTIF1Gamma
p4524
sa(dp4525
g7
I147
sg8
I4
sg9
I47
sg10
g11
sg12
Vanti-melanoma differentiation-associated gene 5
p4526
sa(dp4527
g7
I14
sg8
I4
sg9
I40
sg10
g11
sg12
Vtranscription intermediary factor 1Gamma
p4528
sa(dp4529
g7
I77
sg8
I1
sg9
I8
sg10
g11
sg12
Vp155/140
p4530
sa(dp4531
g7
I196
sg8
I1
sg9
I4
sg10
g11
sg12
VMDA5
p4532
sasg24
(lp4533
(dp4534
g7
I130
sg8
I1
sg9
I10
sg27
VC0006826
p4535
sg12
Vmalignancy
p4536
sa(dp4537
g7
I152
sg8
I1
sg9
I8
sg27
VC0025202
p4538
sg12
Vmelanoma
p4539
sasa(dp4540
g2
VAnti-TIF-1Gamma positive patients were less likely to have systemic features including interstitial lung disease, Raynaud phenomenon, and arthritis/arthralgia.
p4541
sg4
(lp4542
(dp4543
g7
I0
sg8
I1
sg9
I15
sg10
g11
sg12
VAnti-TIF-1Gamma
p4544
sasg24
(lp4545
(dp4546
g7
I114
sg8
I2
sg9
I18
sg27
VC0034735
p4547
sg12
VRaynaud phenomenon
p4548
sa(dp4549
g7
I148
sg8
I1
sg9
I10
sg27
VC0003862
p4550
sg12
Varthralgia
p4551
sa(dp4552
g7
I138
sg8
I1
sg9
I9
sg27
VC0003864
p4553
sg12
Varthritis
p4554
sa(dp4555
g7
I87
sg8
I3
sg9
I25
sg27
VC0206062
p4556
sg12
Vinterstitial lung disease
p4557
sasa(dp4558
g2
VThe frequency of pulmonary fibrosis during the disease progression was 2/12, 1/4 and 1/4 in anti-TIF1Gamma, anti-NXP2 and anti-SAE, respectively.
p4559
sg4
(lp4560
(dp4561
g7
I108
sg8
I1
sg9
I9
sg10
g11
sg12
Vanti-NXP2
p4562
sa(dp4563
g7
I92
sg8
I1
sg9
I14
sg10
g11
sg12
Vanti-TIF1Gamma
p4564
sasg24
(lp4565
(dp4566
g7
I47
sg8
I2
sg9
I19
sg27
VC0242656
p4567
sg12
Vdisease progression
p4568
sa(dp4569
g7
I17
sg8
I2
sg9
I18
sg27
VC0034069
p4570
sg12
Vpulmonary fibrosis
p4571
sasa(dp4572
g2
VEach of the identified mutations altered the equilibrium between alternative GR conformations distinctively, indicating that the Hsp90 dependence of SRs may correlate with differences in the conformational dynamics of these receptors.
p4573
sg4
(lp4574
(dp4575
g7
I129
sg8
I1
sg9
I5
sg10
VP07900
p4576
sg12
VHsp90
p4577
sa(dp4578
g7
I149
sg8
I1
sg9
I3
sg10
VP35270
p4579
sg12
VSRs
p4580
sa(dp4581
g7
I77
sg8
I1
sg9
I2
sg10
VP00390
p4582
sg12
VGR
p4583
sasg24
(lp4584
(dp4585
g7
I135
sg8
I1
sg9
I10
sg27
VC0439857
p4586
sg12
Vdependence
p4587
sa(dp4588
g7
I149
sg8
I1
sg9
I3
sg27
VC0175693
p4589
sg12
VSRs
p4590
sasa(dp4591
g2
VThe ubiquitous heat shock protein 90 (hsp90) has been shown to participate directly in the function of a wide variety of cellular signal transduction components, including steroid receptors (SRs).
p4592
sg4
(lp4593
(dp4594
g7
I172
sg8
I2
sg9
I17
sg10
VP52788
p4595
sg12
Vsteroid receptors
p4596
sa(dp4597
g7
I15
sg8
I4
sg9
I21
sg10
VP07900
p4598
sg12
Vheat shock protein 90
p4599
sa(dp4600
g7
I38
sg8
I1
sg9
I5
sg10
VP07900
p4601
sg12
Vhsp90
p4602
sa(dp4603
g7
I191
sg8
I1
sg9
I3
sg10
VP35270
p4604
sg12
VSRs
p4605
sasg24
(lp4606
(dp4607
g7
I172
sg8
I2
sg9
I17
sg27
VC0175693
p4608
sg12
Vsteroid receptors
p4609
sa(dp4610
g7
I191
sg8
I1
sg9
I3
sg27
VC0175693
p4611
sg12
VSRs
p4612
sasa(dp4613
g2
VHowever, there is still no direct evidence for an in vivo association of SRs with hsp90.
p4614
sg4
(lp4615
(dp4616
g7
I82
sg8
I1
sg9
I5
sg10
VP07900
p4617
sg12
Vhsp90
p4618
sa(dp4619
g7
I73
sg8
I1
sg9
I3
sg10
VP35270
p4620
sg12
VSRs
p4621
sasg24
(lp4622
(dp4623
g7
I73
sg8
I1
sg9
I3
sg27
VC0175693
p4624
sg12
VSRs
p4625
sasa(dp4626
g2
VThe results suggest that the interaction of SRs with the hsp90 is minimal when compared to a bona fide type of interaction with the co-factors.
p4627
sg4
(lp4628
(dp4629
g7
I57
sg8
I1
sg9
I5
sg10
VP07900
p4630
sg12
Vhsp90
p4631
sa(dp4632
g7
I44
sg8
I1
sg9
I3
sg10
VP35270
p4633
sg12
VSRs
p4634
sasg24
(lp4635
(dp4636
g7
I44
sg8
I1
sg9
I3
sg27
VC0175693
p4637
sg12
VSRs
p4638
sasa(dp4639
g2
VTo address the role of endothelial Cx43 in this process, we analyzed Cx43 regulation in human umbilical vein endothelial cells in the proximity of Cx43high (DU-145 and MAT-LyLu) and Cx43low prostate cancer cells (PC-3 and AT-2).
p4640
sg4
(lp4641
(dp4642
g7
I168
sg8
I1
sg9
I8
sg10
VP24752
p4643
sg12
VMAT-LyLu
p4644
sa(dp4645
g7
I35
sg8
I1
sg9
I4
sg10
VP17302
p4646
sg12
VCx43
p4647
sa(dp4648
g7
I35
sg8
I1
sg9
I4
sg10
VP17302
p4649
sg12
VCx43
p4650
sa(dp4651
g7
I213
sg8
I1
sg9
I4
sg10
g11
sg12
VPC-3
p4652
sasg24
(lp4653
(dp4654
g7
I190
sg8
I2
sg9
I15
sg27
VC0600139
p4655
sg12
Vprostate cancer
p4656
sasa(dp4657
g2
VThe data on the nature of AT2-R expression in prostate tissue of prostate cancer patients may be considered as a tool for predicting biochemical recurrence after combined hormone and radiation therapy.
p4658
sg4
(lp4659
(dp4660
g7
I26
sg8
I1
sg9
I5
sg10
VP50052
p4661
sg12
VAT2-R
p4662
sasg24
(lp4663
(dp4664
g7
I145
sg8
I1
sg9
I10
sg27
VC1458156
p4665
sg12
Vrecurrence
p4666
sa(dp4667
g7
I65
sg8
I2
sg9
I15
sg27
VC0600139
p4668
sg12
Vprostate cancer
p4669
sasa(dp4670
g2
VThe present study found that, similarly to 5-fluorouracil, low concentrations (1-10 myM) of 9-aminoacridine (9-AAA) inhibited the growth of the two rat prostate cancer AT-2 and Mat-LyLu cell lines and the human melanoma A375 cell line.
p4671
sg4
(lp4672
(dp4673
g7
I177
sg8
I1
sg9
I3
sg10
VP24752
p4674
sg12
VMat
p4675
sa(dp4676
g7
I148
sg8
I4
sg9
I24
sg10
g11
sg12
Vrat prostate cancer AT-2
p4677
sasg24
(lp4678
(dp4679
g7
I211
sg8
I1
sg9
I8
sg27
VC0025202
p4680
sg12
Vmelanoma
p4681
sa(dp4682
g7
I111
sg8
I1
sg9
I3
sg27
VC0162871
p4683
sg12
VAAA
p4684
sa(dp4685
g7
I152
sg8
I2
sg9
I15
sg27
VC0600139
p4686
sg12
Vprostate cancer
p4687
sasa(dp4688
g2
VFurthermore, our previous studies indicate that increased expression of Ang II type 2 receptor (AT2R) alone induced apoptosis in human prostate cancer lines, an effect that did not require Ang II.
p4689
sg4
(lp4690
(dp4691
g7
I72
sg8
I5
sg9
I22
sg10
VP01019
p4692
sg12
VAng II type 2 receptor
p4693
sa(dp4694
g7
I72
sg8
I2
sg9
I6
sg10
VP01019
p4695
sg12
VAng II
p4696
sa(dp4697
g7
I96
sg8
I1
sg9
I4
sg10
VP50052
p4698
sg12
VAT2R
p4699
sasg24
(lp4700
(dp4701
g7
I135
sg8
I2
sg9
I15
sg27
VC0600139
p4702
sg12
Vprostate cancer
p4703
sasa(dp4704
g2
VHuman prostate cancer DU145 xenograft mouse model was used to assess the effect of AT2R on tumor growth in vivo.
p4705
sg4
(lp4706
(dp4707
g7
I83
sg8
I1
sg9
I4
sg10
VP50052
p4708
sg12
VAT2R
p4709
sasg24
(lp4710
(dp4711
g7
I91
sg8
I2
sg9
I12
sg27
VC0598934
p4712
sg12
Vtumor growth
p4713
sa(dp4714
g7
I6
sg8
I2
sg9
I15
sg27
VC0600139
p4715
sg12
Vprostate cancer
p4716
sasa(dp4717
g2
VThe results showed that AT2R overexpression can inhibit tumor growth of prostate cancer in vivo by inhibiting proliferation and inducing apoptosis of tumor cells.
p4718
sg4
(lp4719
(dp4720
g7
I24
sg8
I1
sg9
I4
sg10
VP50052
p4721
sg12
VAT2R
p4722
sasg24
(lp4723
(dp4724
g7
I56
sg8
I2
sg9
I12
sg27
VC0598934
p4725
sg12
Vtumor growth
p4726
sa(dp4727
g7
I110
sg8
I1
sg9
I13
sg27
VC0334094
p4728
sg12
Vproliferation
p4729
sa(dp4730
g7
I72
sg8
I2
sg9
I15
sg27
VC0600139
p4731
sg12
Vprostate cancer
p4732
sa(dp4733
g7
I56
sg8
I1
sg9
I5
sg27
VC0027651
p4734
sg12
Vtumor
p4735
sasa(dp4736
g2
VThe aim of the present study was the evaluation of AT1 and AT2 expressions in human prostate cancers.
p4737
sg4
(lp4738
(dp4739
g7
I51
sg8
I1
sg9
I3
sg10
VP30556
p4740
sg12
VAT1
p4741
sa(dp4742
g7
I59
sg8
I1
sg9
I3
sg10
VP50052
p4743
sg12
VAT2
p4744
sasg24
(lp4745
(dp4746
g7
I51
sg8
I1
sg9
I3
sg27
VC0004135
p4747
sg12
VAT1
p4748
sa(dp4749
g7
I84
sg8
I2
sg9
I16
sg27
VC0376358
p4750
sg12
Vprostate cancers
p4751
sasa(dp4752
g2
VThe data on AT1 and AT2 receptor expressions may suggest the involvement of RAS in prostate cancerogenesis.
p4753
sg4
(lp4754
(dp4755
g7
I76
sg8
I1
sg9
I3
sg10
VP01116
p4756
sg12
VRAS
p4757
sa(dp4758
g7
I20
sg8
I2
sg9
I12
sg10
VP50052
p4759
sg12
VAT2 receptor
p4760
sa(dp4761
g7
I12
sg8
I1
sg9
I3
sg10
VP30556
p4762
sg12
VAT1
p4763
sasg24
(lp4764
(dp4765
g7
I12
sg8
I1
sg9
I3
sg27
VC0004135
p4766
sg12
VAT1
p4767
sasa(dp4768
g2
Vsartanes) and/or AT2 agonists in prostate cancer prophylaxis and/or treatment.
p4769
sg4
(lp4770
sg24
(lp4771
(dp4772
g7
I33
sg8
I2
sg9
I15
sg27
VC0600139
p4773
sg12
Vprostate cancer
p4774
sasa(dp4775
g2
VThe results indicate that CEGA using the new circular stapling device in surgery of the esophageal carcinoma is a very effective procedure to improve the anastomotic technique from a traditional hand-sewn anastomosis to a stapled anastomosis and can reduce the incidence of complications.
p4776
sg4
(lp4777
sg24
(lp4778
(dp4779
g7
I205
sg8
I1
sg9
I11
sg27
VC0332853
p4780
sg12
Vanastomosis
p4781
sa(dp4782
g7
I88
sg8
I2
sg9
I20
sg27
VC0152018
p4783
sg12
Vesophageal carcinoma
p4784
sa(dp4785
g7
I205
sg8
I1
sg9
I11
sg27
VC0332853
p4786
sg12
Vanastomosis
p4787
sasa(dp4788
g2
VAn unusual retinal pigment epitheliopathy resembling ophthalmomyiasis interna posterior (OMI) is endemic to Guam.
p4789
sg4
(lp4790
sg24
(lp4791
(dp4792
g7
I11
sg8
I3
sg9
I30
sg27
VC0860552
p4793
sg12
Vretinal pigment epitheliopathy
p4794
sa(dp4795
g7
I53
sg8
I1
sg9
I16
sg27
VC0027034
p4796
sg12
Vophthalmomyiasis
p4797
sasa(dp4798
g2
VToxicity, such as mucositis, leukocytopenia and neutropenia, was higher in ConcCRTx than in CTx followed by RTx.
p4799
sg4
(lp4800
sg24
(lp4801
(dp4802
g7
I92
sg8
I1
sg9
I3
sg27
VC0238052
p4803
sg12
VCTx
p4804
sa(dp4805
g7
I29
sg8
I1
sg9
I14
sg27
VC0023530
p4806
sg12
Vleukocytopenia
p4807
sa(dp4808
g7
I18
sg8
I1
sg9
I9
sg27
VC0333355
p4809
sg12
Vmucositis
p4810
sasa(dp4811
g2
VAt the 4th dose level (Ctx 1400 mg/m2, Epidx 100 mg/m2, 5-Fu 600 mg/m2), two patients had dose-limiting mucositis and one patient developed dose-limiting neutropenia.
p4812
sg4
(lp4813
sg24
(lp4814
(dp4815
g7
I104
sg8
I1
sg9
I9
sg27
VC0333355
p4816
sg12
Vmucositis
p4817
sa(dp4818
g7
I23
sg8
I1
sg9
I3
sg27
VC0238052
p4819
sg12
VCtx
p4820
sasa(dp4821
g2
VTherefore, the effect of CKD on the disposition of CYP1A2-metabolized, CYP2C8-metabolized, CYP2C9-metabolized, CYP2C19-metabolized, and organic anion-transporting polypeptide (OATP)-transported drugs was investigated.
p4822
sg4
(lp4823
(dp4824
g7
I91
sg8
I1
sg9
I6
sg10
VP11712
p4825
sg12
VCYP2C9
p4826
sa(dp4827
g7
I111
sg8
I1
sg9
I7
sg10
VP33261
p4828
sg12
VCYP2C19
p4829
sa(dp4830
g7
I71
sg8
I1
sg9
I6
sg10
VP10632
p4831
sg12
VCYP2C8
p4832
sa(dp4833
g7
I51
sg8
I1
sg9
I6
sg10
VP05177
p4834
sg12
VCYP1A2
p4835
sasg24
(lp4836
sa(dp4837
g2
VWe identified dedicated CKD studies with 6, 5, 6, 4, and 12 "model" substrates for CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP, respectively.
p4838
sg4
(lp4839
(dp4840
g7
I99
sg8
I1
sg9
I6
sg10
VP11712
p4841
sg12
VCYP2C9
p4842
sa(dp4843
g7
I83
sg8
I1
sg9
I6
sg10
VP05177
p4844
sg12
VCYP1A2
p4845
sa(dp4846
g7
I107
sg8
I1
sg9
I7
sg10
VP33261
p4847
sg12
VCYP2C19
p4848
sa(dp4849
g7
I91
sg8
I1
sg9
I6
sg10
VP10632
p4850
sg12
VCYP2C8
p4851
sasg24
(lp4852
sa(dp4853
g2
VIn contrast, the effect of CKD on CYP1A2, CYP2C9, and CYP2C19 was variable and modest compared to CYP2C8 and OATP.
p4854
sg4
(lp4855
(dp4856
g7
I54
sg8
I1
sg9
I7
sg10
VP33261
p4857
sg12
VCYP2C19
p4858
sa(dp4859
g7
I42
sg8
I1
sg9
I6
sg10
VP11712
p4860
sg12
VCYP2C9
p4861
sa(dp4862
g7
I109
sg8
I1
sg9
I4
sg10
VP46721
p4863
sg12
VOATP
p4864
sa(dp4865
g7
I34
sg8
I1
sg9
I6
sg10
VP05177
p4866
sg12
VCYP1A2
p4867
sa(dp4868
g7
I98
sg8
I1
sg9
I6
sg10
VP10632
p4869
sg12
VCYP2C8
p4870
sasg24
(lp4871
sa(dp4872
g2
VTo investigate the impact of genetic variants in CYP2C9, CYP2C19, CYP3A4, GSTT1, GSTM1 and GSTP1 on the efficacy of cyclophosphamide (CYC) therapy in patients with lupus nephritis.
p4873
sg4
(lp4874
(dp4875
g7
I74
sg8
I1
sg9
I5
sg10
VP30711
p4876
sg12
VGSTT1
p4877
sa(dp4878
g7
I81
sg8
I1
sg9
I5
sg10
VP09488
p4879
sg12
VGSTM1
p4880
sa(dp4881
g7
I49
sg8
I1
sg9
I6
sg10
VP11712
p4882
sg12
VCYP2C9
p4883
sa(dp4884
g7
I91
sg8
I1
sg9
I5
sg10
VP09211
p4885
sg12
VGSTP1
p4886
sa(dp4887
g7
I57
sg8
I1
sg9
I7
sg10
VP33261
p4888
sg12
VCYP2C19
p4889
sa(dp4890
g7
I66
sg8
I1
sg9
I6
sg10
VP08684
p4891
sg12
VCYP3A4
p4892
sasg24
(lp4893
(dp4894
g7
I164
sg8
I2
sg9
I15
sg27
VC0024143
p4895
sg12
Vlupus nephritis
p4896
sasa(dp4897
g2
VChronic kidney disease (CKD) complicates warfarin anticoagulation partially through its effect on CYP2C9 activity.
p4898
sg4
(lp4899
(dp4900
g7
I98
sg8
I1
sg9
I6
sg10
VP11712
p4901
sg12
VCYP2C9
p4902
sasg24
(lp4903
(dp4904
g7
I0
sg8
I3
sg9
I22
sg27
VC1561643
p4905
sg12
VChronic kidney disease
p4906
sa(dp4907
g7
I24
sg8
I1
sg9
I3
sg27
VC1561643
p4908
sg12
VCKD
p4909
sasa(dp4910
g2
VCKD increased the effect of CYP2C9 genetic variation on (S)-warfarin and (R,S)-warfarin metabolism.
p4911
sg4
(lp4912
(dp4913
g7
I28
sg8
I1
sg9
I6
sg10
VP11712
p4914
sg12
VCYP2C9
p4915
sasg24
(lp4916
sa(dp4917
g2
VTecarfarin exposure was similar between the HVs and the CKD subjects regardless of CYP2C9 genotype.
p4918
sg4
(lp4919
(dp4920
g7
I83
sg8
I2
sg9
I15
sg10
VP11712
p4921
sg12
VCYP2C9 genotype
p4922
sasg24
(lp4923
sa(dp4924
g2
VThe CYP2C9 pathway (4-hydroxyflurbiprofen formation clearance) was similar in all the patients with CKD and was concordant with previous reports of patients with end-stage renal disease (ESRD) and healthy controls.
p4925
sg4
(lp4926
(dp4927
g7
I4
sg8
I1
sg9
I6
sg10
VP11712
p4928
sg12
VCYP2C9
p4929
sasg24
(lp4930
(dp4931
g7
I187
sg8
I1
sg9
I4
sg27
VC0022661
p4932
sg12
VESRD
p4933
sa(dp4934
g7
I162
sg8
I3
sg9
I23
sg27
VC0022661
p4935
sg12
Vend-stage renal disease
p4936
sasa(dp4937
g2
VFor flurbiprofen, patients with glomerulonephritis had higher oral clearance than those with nonglomerular CKD, suggesting higher unbound fraction and enhanced metabolism through other (non-CYP2C9) routes.
p4938
sg4
(lp4939
(dp4940
g7
I190
sg8
I1
sg9
I6
sg10
VP11712
p4941
sg12
VCYP2C9
p4942
sasg24
(lp4943
(dp4944
g7
I32
sg8
I1
sg9
I18
sg27
VC0017658
p4945
sg12
Vglomerulonephritis
p4946
sasa(dp4947
g2
VThe current study suggests no statistically significant differences in the in vivo activity of CYP2C9 and CYP3A4 in patients with either glomerulonephritis or nonglomerular CKD.
p4948
sg4
(lp4949
(dp4950
g7
I95
sg8
I3
sg9
I17
sg10
VP08684
p4951
sg12
VCYP2C9 and CYP3A4
p4952
sasg24
(lp4953
(dp4954
g7
I137
sg8
I1
sg9
I18
sg27
VC0017658
p4955
sg12
Vglomerulonephritis
p4956
sasa(dp4957
g2
VWe examined whether the renin inhibitor, aliskiren, provides similar or greater protection than ACE inhibition from non-proliferative diabetic retinopathy and from the proliferative neoangiogenesis of oxygen-induced retinopathy.
p4958
sg4
(lp4959
(dp4960
g7
I24
sg8
I1
sg9
I5
sg10
VP00797
p4961
sg12
Vrenin
p4962
sa(dp4963
g7
I96
sg8
I1
sg9
I3
sg10
VP12821
p4964
sg12
VACE
p4965
sasg24
(lp4966
(dp4967
g7
I182
sg8
I1
sg9
I15
sg27
VC0027686
p4968
sg12
Vneoangiogenesis
p4969
sa(dp4970
g7
I143
sg8
I1
sg9
I11
sg27
VC0035309
p4971
sg12
Vretinopathy
p4972
sa(dp4973
g7
I120
sg8
I1
sg9
I13
sg27
VC0334094
p4974
sg12
Vproliferative
p4975
sa(dp4976
g7
I116
sg8
I3
sg9
I38
sg27
VC0004606
p4977
sg12
Vnon-proliferative diabetic retinopathy
p4978
sasa(dp4979
g2
VTo assess angiotensin-converting enzyme (ACE) levels in aqueous humor and plasma of patients with nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) as another potent ischemia-induced angiogenic factor.
p4980
sg4
(lp4981
(dp4982
g7
I41
sg8
I1
sg9
I3
sg10
VP12821
p4983
sg12
VACE
p4984
sa(dp4985
g7
I223
sg8
I2
sg9
I17
sg10
g11
sg12
Vangiogenic factor
p4986
sa(dp4987
g7
I10
sg8
I2
sg9
I29
sg10
VP12821
p4988
sg12
Vangiotensin-converting enzyme
p4989
sasg24
(lp4990
(dp4991
g7
I98
sg8
I3
sg9
I37
sg27
VC0004606
p4992
sg12
Vnonproliferative diabetic retinopathy
p4993
sa(dp4994
g7
I56
sg8
I2
sg9
I13
sg27
VC0595936
p4995
sg12
Vaqueous humor
p4996
sa(dp4997
g7
I137
sg8
I1
sg9
I4
sg27
VC0004606
p4998
sg12
VNPDR
p4999
sa(dp5000
g7
I138
sg8
I1
sg9
I3
sg27
VC0154830
p5001
sg12
VPDR
p5002
sa(dp5003
g7
I206
sg8
I1
sg9
I8
sg27
VC0022116
p5004
sg12
Vischemia
p5005
sa(dp5006
g7
I101
sg8
I3
sg9
I34
sg27
VC0154830
p5007
sg12
Vproliferative diabetic retinopathy
p5008
sasa(dp5009
g2
VWe observed significantly elevated ACE level in aqueous humor of patients with PDR compared with the patients with NPDR and normal subjects (P = 0.023), but no significant difference was detected between nonproliferative diabetics and control group (P = 0.239).
p5010
sg4
(lp5011
(dp5012
g7
I35
sg8
I1
sg9
I3
sg10
VP12821
p5013
sg12
VACE
p5014
sasg24
(lp5015
(dp5016
g7
I79
sg8
I1
sg9
I3
sg27
VC1845050
p5017
sg12
VPDR
p5018
sa(dp5019
g7
I48
sg8
I2
sg9
I13
sg27
VC0595936
p5020
sg12
Vaqueous humor
p5021
sasa(dp5022
g2
VStudies exploring the association between ACE I/D polymorphism and BDR or PDR may help us better understand the genetics of DR.
p5023
sg4
(lp5024
(dp5025
g7
I42
sg8
I2
sg9
I7
sg10
VP12821
p5026
sg12
VACE I/D
p5027
sasg24
(lp5028
(dp5029
g7
I74
sg8
I1
sg9
I3
sg27
VC1845050
p5030
sg12
VPDR
p5031
sasa(dp5032
g2
VTo evaluate the effects of angiotensin-converting enzyme inhibitors (ACE-I) in retarding progression of severe non-proliferative diabetic retinopathy (NPDR) in normotensive type 2 diabetic patients.
p5033
sg4
(lp5034
(dp5035
g7
I69
sg8
I1
sg9
I5
sg10
VP12821
p5036
sg12
VACE-I
p5037
sa(dp5038
g7
I27
sg8
I3
sg9
I40
sg10
VP12821
p5039
sg12
Vangiotensin-converting enzyme inhibitors
p5040
sasg24
(lp5041
(dp5042
g7
I111
sg8
I3
sg9
I38
sg27
VC0004606
p5043
sg12
Vnon-proliferative diabetic retinopathy
p5044
sa(dp5045
g7
I151
sg8
I1
sg9
I4
sg27
VC0004606
p5046
sg12
VNPDR
p5047
sasa(dp5048
g2
VThis was a retrospective case control study of 128 patients with normotensive type 2 diabetes with lower than +1 dipstick proteinuria and severe NPDR who were classified into either an ACE-I treated group (Enalapril maleate 10 mg, n=12 , Ramipril 5 mg, n=17) or an ACE-I untreated group (n=99).
p5049
sg4
(lp5050
(dp5051
g7
I185
sg8
I1
sg9
I5
sg10
VP12821
p5052
sg12
VACE-I
p5053
sa(dp5054
g7
I185
sg8
I1
sg9
I5
sg10
VP12821
p5055
sg12
VACE-I
p5056
sasg24
(lp5057
(dp5058
g7
I78
sg8
I3
sg9
I15
sg27
VC0011860
p5059
sg12
Vtype 2 diabetes
p5060
sa(dp5061
g7
I138
sg8
I2
sg9
I11
sg27
VC0730278
p5062
sg12
Vsevere NPDR
p5063
sasa(dp5064
g2
VSmall doses of ACE-I did not yield any beneficial effects in retarding the progression of severe NPDR.
p5065
sg4
(lp5066
(dp5067
g7
I15
sg8
I1
sg9
I5
sg10
VP12821
p5068
sg12
VACE-I
p5069
sasg24
(lp5070
(dp5071
g7
I90
sg8
I2
sg9
I11
sg27
VC0730278
p5072
sg12
Vsevere NPDR
p5073
sasa(dp5074
g2
VA7730C variant which showed a high mutation frequency in cervical cancer was predicted to be a binding site for the cellular transcription factor PHOX2A.
p5075
sg4
(lp5076
(dp5077
g7
I146
sg8
I1
sg9
I6
sg10
g11
sg12
VPHOX2A
p5078
sasg24
(lp5079
(dp5080
g7
I57
sg8
I2
sg9
I15
sg27
VC0302592
p5081
sg12
Vcervical cancer
p5082
sasa(dp5083
g2
VmiR-326 regulates cell proliferation and migration in lung cancer by targeting Phox2a and is regulated by HOTAIR.
p5084
sg4
(lp5085
(dp5086
g7
I0
sg8
I1
sg9
I3
sg10
g11
sg12
VmiR
p5087
sa(dp5088
g7
I79
sg8
I1
sg9
I6
sg10
g11
sg12
VPhox2a
p5089
sasg24
(lp5090
(dp5091
g7
I54
sg8
I2
sg9
I11
sg27
VC0684249
p5092
sg12
Vlung cancer
p5093
sa(dp5094
g7
I23
sg8
I1
sg9
I13
sg27
VC0334094
p5095
sg12
Vproliferation
p5096
sasa(dp5097
g2
VPHOX2B and its paralogue gene PHOX2A are two homeodomain proteins in the network regulating the development of autonomic ganglia that have been associated with the pathogenesis of neuroblastoma (NB), because of their over-expression in different NB cell lines and tumour samples.
p5098
sg4
(lp5099
(dp5100
g7
I0
sg8
I1
sg9
I6
sg10
g11
sg12
VPHOX2B
p5101
sa(dp5102
g7
I30
sg8
I1
sg9
I6
sg10
g11
sg12
VPHOX2A
p5103
sa(dp5104
g7
I45
sg8
I2
sg9
I20
sg10
g11
sg12
Vhomeodomain proteins
p5105
sasg24
(lp5106
(dp5107
g7
I195
sg8
I1
sg9
I2
sg27
VC0027819
p5108
sg12
VNB
p5109
sa(dp5110
g7
I195
sg8
I1
sg9
I2
sg27
VC0027819
p5111
sg12
VNB
p5112
sa(dp5113
g7
I264
sg8
I1
sg9
I6
sg27
VC0027651
p5114
sg12
Vtumour
p5115
sa(dp5116
g7
I164
sg8
I1
sg9
I12
sg27
VC0699748
p5117
sg12
Vpathogenesis
p5118
sa(dp5119
g7
I180
sg8
I1
sg9
I13
sg27
VC0027819
p5120
sg12
Vneuroblastoma
p5121
sasa(dp5122
g2
VTo identify novel abnormally methylated genes in early stage non-small cell lung cancer (NSCLC), we analyzed the methylation status of 13 genes (ALX1, BCL2, FOXL2, HPP1, MYF6, OC2, PDGFRA, PHOX2A, PITX2, RARB, SIX6, SMPD3 and SOX1) in cancer tissues from 101 cases of stage I NSCLC patients and lung tissues from 30 cases of non-cancerous lung disease controls, using methylation-specific PCR (MSP).
p5123
sg4
(lp5124
(dp5125
g7
I189
sg8
I1
sg9
I6
sg10
g11
sg12
VPHOX2A
p5126
sa(dp5127
g7
I176
sg8
I1
sg9
I3
sg10
VP43235
p5128
sg12
VOC2
p5129
sa(dp5130
g7
I197
sg8
I1
sg9
I5
sg10
g11
sg12
VPITX2
p5131
sa(dp5132
g7
I170
sg8
I1
sg9
I4
sg10
VP23409
p5133
sg12
VMYF6
p5134
sa(dp5135
g7
I181
sg8
I1
sg9
I6
sg10
VP16234
p5136
sg12
VPDGFRA
p5137
sa(dp5138
g7
I226
sg8
I1
sg9
I4
sg10
g11
sg12
VSOX1
p5139
sa(dp5140
g7
I216
sg8
I1
sg9
I5
sg10
g11
sg12
VSMPD3
p5141
sa(dp5142
g7
I204
sg8
I1
sg9
I4
sg10
VP10826
p5143
sg12
VRARB
p5144
sa(dp5145
g7
I164
sg8
I1
sg9
I4
sg10
g11
sg12
VHPP1
p5146
sa(dp5147
g7
I145
sg8
I1
sg9
I4
sg10
g11
sg12
VALX1
p5148
sa(dp5149
g7
I210
sg8
I1
sg9
I4
sg10
g11
sg12
VSIX6
p5150
sa(dp5151
g7
I151
sg8
I1
sg9
I4
sg10
VP10415
p5152
sg12
VBCL2
p5153
sa(dp5154
g7
I157
sg8
I1
sg9
I5
sg10
VP58012
p5155
sg12
VFOXL2
p5156
sasg24
(lp5157
(dp5158
g7
I89
sg8
I1
sg9
I5
sg27
VC0007131
p5159
sg12
VNSCLC
p5160
sa(dp5161
g7
I81
sg8
I1
sg9
I6
sg27
VC0006826
p5162
sg12
Vcancer
p5163
sa(dp5164
g7
I61
sg8
I4
sg9
I26
sg27
VC0007131
p5165
sg12
Vnon-small cell lung cancer
p5166
sa(dp5167
g7
I339
sg8
I2
sg9
I12
sg27
VC0024115
p5168
sg12
Vlung disease
p5169
sa(dp5170
g7
I268
sg8
I3
sg9
I13
sg27
VC0278504
p5171
sg12
Vstage I NSCLC
p5172
sasa(dp5173
g2
VThe methylation frequencies (29.70-64.36%) of 7 genes (MYF6, SIX6, SOX1, RARB, BCL2, PHOX2A and FOLX2) in stage I NSCLC were significantly higher compared with those in non-cancerous lung disease controls (P&lt;0.05).
p5174
sg4
(lp5175
(dp5176
g7
I85
sg8
I1
sg9
I6
sg10
g11
sg12
VPHOX2A
p5177
sa(dp5178
g7
I55
sg8
I1
sg9
I4
sg10
VP23409
p5179
sg12
VMYF6
p5180
sa(dp5181
g7
I61
sg8
I1
sg9
I4
sg10
g11
sg12
VSIX6
p5182
sa(dp5183
g7
I79
sg8
I1
sg9
I4
sg10
VP10415
p5184
sg12
VBCL2
p5185
sa(dp5186
g7
I67
sg8
I1
sg9
I4
sg10
g11
sg12
VSOX1
p5187
sa(dp5188
g7
I73
sg8
I1
sg9
I4
sg10
VP10826
p5189
sg12
VRARB
p5190
sasg24
(lp5191
(dp5192
g7
I106
sg8
I3
sg9
I13
sg27
VC0278504
p5193
sg12
Vstage I NSCLC
p5194
sa(dp5195
g7
I183
sg8
I2
sg9
I12
sg27
VC0024115
p5196
sg12
Vlung disease
p5197
sasa(dp5198
g2
VFurthermore, we also detected the expression of 8 pathological markers (VEGF, HER-2, P53, P21, EGFR, CHGA, SYN and EMA) in cancer tissues of stage I NSCLC by immunohistochemistry, and found that high expression levels of p53 and CHGA were associated with the methylation of BCL2 (P=0.025) and PHOX2A (P=0.023), respectively.
p5199
sg4
(lp5200
(dp5201
g7
I90
sg8
I1
sg9
I3
sg10
VP42857
p5202
sg12
VP21
p5203
sa(dp5204
g7
I101
sg8
I1
sg9
I4
sg10
VP10645
p5205
sg12
VCHGA
p5206
sa(dp5207
g7
I274
sg8
I1
sg9
I4
sg10
VP10415
p5208
sg12
VBCL2
p5209
sa(dp5210
g7
I101
sg8
I1
sg9
I4
sg10
VP10645
p5211
sg12
VCHGA
p5212
sa(dp5213
g7
I107
sg8
I1
sg9
I3
sg10
VP17600
p5214
sg12
VSYN
p5215
sa(dp5216
g7
I293
sg8
I1
sg9
I6
sg10
g11
sg12
VPHOX2A
p5217
sa(dp5218
g7
I221
sg8
I1
sg9
I3
sg10
VP42771
p5219
sg12
Vp53
p5220
sa(dp5221
g7
I85
sg8
I1
sg9
I3
sg10
VP42771
p5222
sg12
VP53
p5223
sa(dp5224
g7
I78
sg8
I1
sg9
I5
sg10
VP04626
p5225
sg12
VHER-2
p5226
sa(dp5227
g7
I115
sg8
I1
sg9
I3
sg10
VP13804
p5228
sg12
VEMA
p5229
sasg24
(lp5230
(dp5231
g7
I141
sg8
I3
sg9
I13
sg27
VC0278504
p5232
sg12
Vstage I NSCLC
p5233
sa(dp5234
g7
I123
sg8
I1
sg9
I6
sg27
VC0006826
p5235
sg12
Vcancer
p5236
sa(dp5237
g7
I115
sg8
I1
sg9
I3
sg27
VC0268596
p5238
sg12
VEMA
p5239
sasa(dp5240
g2
VIn this study, among the 7 genes which demonstrated hypermethylation in stage I NSCLC compared with non-cancerous lung diseases, 5 genes (MYF6, SIX6, PHOX2A, FOLX2 and SOX1) were found for the first time to be abonormally methylated in NSCLC.
p5241
sg4
(lp5242
(dp5243
g7
I168
sg8
I1
sg9
I4
sg10
g11
sg12
VSOX1
p5244
sa(dp5245
g7
I138
sg8
I1
sg9
I4
sg10
VP23409
p5246
sg12
VMYF6
p5247
sa(dp5248
g7
I144
sg8
I1
sg9
I4
sg10
g11
sg12
VSIX6
p5249
sa(dp5250
g7
I150
sg8
I1
sg9
I6
sg10
g11
sg12
VPHOX2A
p5251
sasg24
(lp5252
(dp5253
g7
I72
sg8
I3
sg9
I13
sg27
VC0278504
p5254
sg12
Vstage I NSCLC
p5255
sa(dp5256
g7
I114
sg8
I2
sg9
I13
sg27
VC0024115
p5257
sg12
Vlung diseases
p5258
sa(dp5259
g7
I80
sg8
I1
sg9
I5
sg27
VC0007131
p5260
sg12
VNSCLC
p5261
sasa(dp5262
g2
VHeteroplasmic m.3697G&gt;A has been reported in patients with Leber's hereditary optic neuropathy, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes and Stuve-Wiedemann syndrome.
p5263
sg4
(lp5264
sg24
(lp5265
(dp5266
g7
I132
sg8
I2
sg9
I15
sg27
VC0001125
p5267
sg12
Vlactic acidosis
p5268
sa(dp5269
g7
I177
sg8
I2
sg9
I24
sg27
VC0796176
p5270
sg12
VStuve-Wiedemann syndrome
p5271
sa(dp5272
g7
I99
sg8
I2
sg9
I31
sg27
VC0162666
p5273
sg12
Vmitochondrial encephalomyopathy
p5274
sa(dp5275
g7
I152
sg8
I1
sg9
I6
sg27
VC0038454
p5276
sg12
Vstroke
p5277
sa(dp5278
g7
I62
sg8
I4
sg9
I35
sg27
VC0917796
p5279
sg12
VLeber's hereditary optic neuropathy
p5280
sasa(dp5281
g2
VThese can be grouped into disorders with reduced papillae (Machado-Joseph disease, Stuve-Wiedemann syndrome, familial dysautonomia, dystonia musculorum, and Behcet's disease) and those with taste defects only (Alzheimer's disease, Huntington's disease, hereditary sensory and autonomic neuropathy type IV, and diabetes mellitus).
p5282
sg4
(lp5283
sg24
(lp5284
(dp5285
g7
I310
sg8
I2
sg9
I17
sg27
VC0011849
p5286
sg12
Vdiabetes mellitus
p5287
sa(dp5288
g7
I132
sg8
I1
sg9
I8
sg27
VC0393593
p5289
sg12
Vdystonia
p5290
sa(dp5291
g7
I210
sg8
I2
sg9
I19
sg27
VC1521724
p5292
sg12
VAlzheimer's disease
p5293
sa(dp5294
g7
I253
sg8
I7
sg9
I51
sg27
VC0020074
p5295
sg12
Vhereditary sensory and autonomic neuropathy type IV
p5296
sa(dp5297
g7
I109
sg8
I2
sg9
I21
sg27
VC0013364
p5298
sg12
Vfamilial dysautonomia
p5299
sa(dp5300
g7
I59
sg8
I2
sg9
I22
sg27
VC0024408
p5301
sg12
VMachado-Joseph disease
p5302
sa(dp5303
g7
I231
sg8
I2
sg9
I20
sg27
VC0020179
p5304
sg12
VHuntington's disease
p5305
sa(dp5306
g7
I83
sg8
I2
sg9
I24
sg27
VC0796176
p5307
sg12
VStuve-Wiedemann syndrome
p5308
sa(dp5309
g7
I157
sg8
I2
sg9
I16
sg27
VC0004943
p5310
sg12
VBehcet's disease
p5311
sasa(dp5312
g2
VWe used in-situ hybridization to analyze the expression patterns of three known members (a, b and c) of the RGM ("repulsive guidance molecule") gene family and of the RGMa receptor neogenin in a glaucoma mouse model (DBA/2J strain) and the C57BL/6J strain, which served as a control.
p5313
sg4
(lp5314
(dp5315
g7
I167
sg8
I3
sg9
I22
sg10
g11
sg12
VRGMa receptor neogenin
p5316
sasg24
(lp5317
(dp5318
g7
I195
sg8
I1
sg9
I8
sg27
VC0017601
p5319
sg12
Vglaucoma
p5320
sa(dp5321
g7
I217
sg8
I1
sg9
I3
sg27
VC0398550
p5322
sg12
VDBA
p5323
sasa(dp5324
g2
VIn order to understand the role of the RGMs and neogenin in glaucoma, we characterized their expression patterns in the developing and mature mouse retina and in the optic nerve.
p5325
sg4
(lp5326
(dp5327
g7
I39
sg8
I3
sg9
I17
sg10
g11
sg12
VRGMs and neogenin
p5328
sasg24
(lp5329
(dp5330
g7
I60
sg8
I1
sg9
I8
sg27
VC0017601
p5331
sg12
Vglaucoma
p5332
sasa(dp5333
g2
VInterestingly, we found a higher expression of RGMa, RGMb and neogenin in the retinas of all glaucoma-affected mice than in the age-matched control strain.
p5334
sg4
(lp5335
(dp5336
g7
I53
sg8
I3
sg9
I17
sg10
g11
sg12
VRGMb and neogenin
p5337
sa(dp5338
g7
I47
sg8
I1
sg9
I4
sg10
g11
sg12
VRGMa
p5339
sasg24
(lp5340
(dp5341
g7
I93
sg8
I1
sg9
I8
sg27
VC0017601
p5342
sg12
Vglaucoma
p5343
sasa(dp5344
g2
VA tool developed for their use--DeAR GP (Dementia Assessment Referral to GP)--empowers care home staff, makes more efficient use of GPs' and specialist memory nurses' time, and improves diagnosis of dementia.
p5345
sg4
(lp5346
(dp5347
g7
I132
sg8
I1
sg9
I3
sg10
g11
sg12
VGPs
p5348
sasg24
(lp5349
(dp5350
g7
I41
sg8
I1
sg9
I8
sg27
VC0497327
p5351
sg12
VDementia
p5352
sa(dp5353
g7
I199
sg8
I1
sg9
I8
sg27
VC0497327
p5354
sg12
Vdementia
p5355
sa(dp5356
g7
I132
sg8
I1
sg9
I3
sg27
VC0272302
p5357
sg12
VGPs
p5358
sasa(dp5359
g2
VUsing homozygous mice for an autosomal dominant hypophosphatemic rickets-FGF23 mutation or animals treated with a furin inhibitor, we showed that cFGF23 and iFGF23 levels increased equivalently after PTH injection.
p5360
sg4
(lp5361
(dp5362
g7
I114
sg8
I1
sg9
I5
sg10
VP09958
p5363
sg12
Vfurin
p5364
sa(dp5365
g7
I73
sg8
I1
sg9
I5
sg10
g11
sg12
VFGF23
p5366
sa(dp5367
g7
I200
sg8
I1
sg9
I3
sg10
VP01270
p5368
sg12
VPTH
p5369
sasg24
(lp5370
(dp5371
g7
I29
sg8
I4
sg9
I43
sg27
VC0342642
p5372
sg12
Vautosomal dominant hypophosphatemic rickets
p5373
sasa(dp5374
g2
VWe discuss in this review the current implications of GRx and/or glutathionylation in the inflammatory response and in diseases associated with chronic inflammation, namely diabetes, atherosclerosis, inflammatory lung disease, cancer, and Alzheimer's disease, and in viral infections.
p5375
sg4
(lp5376
sg24
(lp5377
(dp5378
g7
I239
sg8
I2
sg9
I19
sg27
VC1521724
p5379
sg12
VAlzheimer's disease
p5380
sa(dp5381
g7
I90
sg8
I2
sg9
I21
sg27
VC1155266
p5382
sg12
Vinflammatory response
p5383
sa(dp5384
g7
I144
sg8
I2
sg9
I20
sg27
VC0021376
p5385
sg12
Vchronic inflammation
p5386
sa(dp5387
g7
I183
sg8
I1
sg9
I15
sg27
VC0004153
p5388
sg12
Vatherosclerosis
p5389
sa(dp5390
g7
I213
sg8
I2
sg9
I12
sg27
VC0024115
p5391
sg12
Vlung disease
p5392
sa(dp5393
g7
I267
sg8
I2
sg9
I16
sg27
VC0042769
p5394
sg12
Vviral infections
p5395
sa(dp5396
g7
I173
sg8
I1
sg9
I8
sg27
VC0011849
p5397
sg12
Vdiabetes
p5398
sa(dp5399
g7
I227
sg8
I1
sg9
I6
sg27
VC0006826
p5400
sg12
Vcancer
p5401
sasa(dp5402
g2
VIn addition to arising from the procedure per se, a genetic or cytogenetic abnormality in offspring of an ICSI pregnancy could arise as result of offspring inheriting the mutant gene or chromosomal abnormality conferring paternal infertility: Y deletions (DAZ) in oligospermia males, cystic fibrosis in offspring of males with congenital bilateral absence vas deferens (CBAVD), and sex chromosomal abnormalities in offspring of Klinefelter syndrome (47,XXY) males.
p5403
sg4
(lp5404
sg24
(lp5405
(dp5406
g7
I284
sg8
I2
sg9
I15
sg27
VC0010674
p5407
sg12
Vcystic fibrosis
p5408
sa(dp5409
g7
I186
sg8
I2
sg9
I23
sg27
VC0008625
p5410
sg12
Vchromosomal abnormality
p5411
sa(dp5412
g7
I428
sg8
I2
sg9
I20
sg27
VC0022735
p5413
sg12
VKlinefelter syndrome
p5414
sa(dp5415
g7
I382
sg8
I3
sg9
I29
sg27
VC0036868
p5416
sg12
Vsex chromosomal abnormalities
p5417
sa(dp5418
g7
I370
sg8
I1
sg9
I5
sg27
VC0403814
p5419
sg12
VCBAVD
p5420
sa(dp5421
g7
I230
sg8
I1
sg9
I11
sg27
VC0021359
p5422
sg12
Vinfertility
p5423
sa(dp5424
g7
I171
sg8
I1
sg9
I6
sg27
VC0596988
p5425
sg12
Vmutant
p5426
sa(dp5427
g7
I327
sg8
I5
sg9
I41
sg27
VC0403814
p5428
sg12
Vcongenital bilateral absence vas deferens
p5429
sa(dp5430
g7
I264
sg8
I1
sg9
I12
sg27
VC0028960
p5431
sg12
Voligospermia
p5432
sa(dp5433
g7
I63
sg8
I2
sg9
I23
sg27
VC0008625
p5434
sg12
Vcytogenetic abnormality
p5435
sasa(dp5436
g2
VTwo recent candidate genes, ErbB3 and Fgfr1, are growth factors whose mRNA levels have been found to be altered in the leukocytes of patients that are affected by bipolar disorder in a depressive state.
p5437
sg4
(lp5438
(dp5439
g7
I28
sg8
I1
sg9
I5
sg10
VP21860
p5440
sg12
VErbB3
p5441
sa(dp5442
g7
I38
sg8
I1
sg9
I5
sg10
VP20930
p5443
sg12
VFgfr1
p5444
sasg24
(lp5445
(dp5446
g7
I163
sg8
I2
sg9
I16
sg27
VC0005586
p5447
sg12
Vbipolar disorder
p5448
sa(dp5449
g7
I185
sg8
I2
sg9
I16
sg27
VC0011570
p5450
sg12
Vdepressive state
p5451
sasa(dp5452
g2
VMolecular genetics and developmental studies have identified 21 genes in this region (ADRA1A, ARHGEF10, CHRNA2, CHRNA6, CHRNB3, DKK4, DPYSL2, EGR3, FGF17, FGF20, FGFR1, FZD3, LDL, NAT2, NEF3, NRG1, PCM1, PLAT, PPP3CC, SFRP1 and VMAT1/SLC18A1) that are most likely to contribute to neuropsychiatric disorders (schizophrenia, autism, bipolar disorder and depression), neurodegenerative disorders (Parkinson's and Alzheimer's disease) and cancer.
p5453
sg4
(lp5454
(dp5455
g7
I94
sg8
I1
sg9
I8
sg10
g11
sg12
VARHGEF10
p5456
sa(dp5457
g7
I186
sg8
I1
sg9
I4
sg10
VP07197
p5458
sg12
VNEF3
p5459
sa(dp5460
g7
I210
sg8
I1
sg9
I6
sg10
VP48454
p5461
sg12
VPPP3CC
p5462
sa(dp5463
g7
I142
sg8
I1
sg9
I4
sg10
g11
sg12
VEGR3
p5464
sa(dp5465
g7
I120
sg8
I1
sg9
I6
sg10
g11
sg12
VCHRNB3
p5466
sa(dp5467
g7
I86
sg8
I1
sg9
I6
sg10
VP25100
p5468
sg12
VADRA1A
p5469
sa(dp5470
g7
I234
sg8
I1
sg9
I7
sg10
VP54219
p5471
sg12
VSLC18A1
p5472
sa(dp5473
g7
I228
sg8
I1
sg9
I5
sg10
VP54219
p5474
sg12
VVMAT1
p5475
sa(dp5476
g7
I180
sg8
I1
sg9
I4
sg10
VP18440
p5477
sg12
VNAT2
p5478
sa(dp5479
g7
I128
sg8
I1
sg9
I4
sg10
g11
sg12
VDKK4
p5480
sa(dp5481
g7
I162
sg8
I1
sg9
I5
sg10
VP20930
p5482
sg12
VFGFR1
p5483
sa(dp5484
g7
I104
sg8
I1
sg9
I6
sg10
g11
sg12
VCHRNA2
p5485
sa(dp5486
g7
I134
sg8
I1
sg9
I6
sg10
g11
sg12
VDPYSL2
p5487
sa(dp5488
g7
I169
sg8
I1
sg9
I4
sg10
g11
sg12
VFZD3
p5489
sa(dp5490
g7
I148
sg8
I1
sg9
I5
sg10
g11
sg12
VFGF17
p5491
sa(dp5492
g7
I155
sg8
I1
sg9
I5
sg10
g11
sg12
VFGF20
p5493
sa(dp5494
g7
I218
sg8
I1
sg9
I5
sg10
g11
sg12
VSFRP1
p5495
sa(dp5496
g7
I198
sg8
I1
sg9
I4
sg10
g11
sg12
VPCM1
p5497
sa(dp5498
g7
I112
sg8
I1
sg9
I6
sg10
g11
sg12
VCHRNA6
p5499
sasg24
(lp5500
(dp5501
g7
I436
sg8
I1
sg9
I6
sg27
VC0006826
p5502
sg12
Vcancer
p5503
sa(dp5504
g7
I309
sg8
I1
sg9
I13
sg27
VC0036341
p5505
sg12
Vschizophrenia
p5506
sa(dp5507
g7
I332
sg8
I2
sg9
I16
sg27
VC0005586
p5508
sg12
Vbipolar disorder
p5509
sa(dp5510
g7
I324
sg8
I1
sg9
I6
sg27
VC0004352
p5511
sg12
Vautism
p5512
sa(dp5513
g7
I366
sg8
I2
sg9
I27
sg27
VC0524851
p5514
sg12
Vneurodegenerative disorders
p5515
sa(dp5516
g7
I353
sg8
I1
sg9
I10
sg27
VC0011581
p5517
sg12
Vdepression
p5518
sa(dp5519
g7
I411
sg8
I2
sg9
I19
sg27
VC1521724
p5520
sg12
VAlzheimer's disease
p5521
sasa(dp5522
g2
VThe region on chromosome 3p13-p14 known to contain several chromosomal translocation breakpoints in families with "pure familial renal cell carcinoma" is quite proximal to the VHL locus in 3p25-p26 we have identified.
p5523
sg4
(lp5524
(dp5525
g7
I176
sg8
I2
sg9
I9
sg10
VP40337
p5526
sg12
VVHL locus
p5527
sa(dp5528
g7
I30
sg8
I1
sg9
I3
sg10
VP03971
p5529
sg12
Vp14
p5530
sasg24
(lp5531
(dp5532
g7
I176
sg8
I1
sg9
I3
sg27
VC0019562
p5533
sg12
VVHL
p5534
sa(dp5535
g7
I120
sg8
I4
sg9
I29
sg27
VC2931352
p5536
sg12
Vfamilial renal cell carcinoma
p5537
sa(dp5538
g7
I59
sg8
I2
sg9
I25
sg27
VC0040715
p5539
sg12
Vchromosomal translocation
p5540
sasa(dp5541
g2
VImmunohistochemical studies and TCR gamma gene rearrangement analysis using a polymerase chain reaction with primers specific for V gamma 1-8 and V gamma 9 gene segments in combination with denaturing gradient gel electrophoresis (PCR/ DGGE) were performed on frozen material of 11 pseudo-T-cell lymphomas and 17 CTCLs, including 9 cases of mycosis fungoides (MF) and 8 pleomorphic CTCLs.
p5542
sg4
(lp5543
(dp5544
g7
I130
sg8
I9
sg9
I39
sg10
g11
sg12
VV gamma 1-8 and V gamma 9 gene segments
p5545
sasg24
(lp5546
(dp5547
g7
I341
sg8
I2
sg9
I17
sg27
VC0026948
p5548
sg12
Vmycosis fungoides
p5549
sa(dp5550
g7
I289
sg8
I2
sg9
I16
sg27
VC0079772
p5551
sg12
VT-cell lymphomas
p5552
sa(dp5553
g7
I360
sg8
I1
sg9
I2
sg27
VC0026948
p5554
sg12
VMF
p5555
sasa(dp5556
g2
VUnclassifiable cutaneous T-cell lymphoma was also diagnosed in the second patient: it was associated with a monoclonal proliferation of T-cell receptor V gamma 9, delta + large granular T lymphocytes and finally developed into frank, acute pre-T lymphatic leukemia.
p5557
sg4
(lp5558
(dp5559
g7
I136
sg8
I6
sg9
I32
sg10
g11
sg12
VT-cell receptor V gamma 9, delta
p5560
sasg24
(lp5561
(dp5562
g7
I119
sg8
I1
sg9
I13
sg27
VC0334094
p5563
sg12
Vproliferation
p5564
sa(dp5565
g7
I15
sg8
I3
sg9
I25
sg27
VC0079773
p5566
sg12
Vcutaneous T-cell lymphoma
p5567
sa(dp5568
g7
I246
sg8
I2
sg9
I18
sg27
VC0023448
p5569
sg12
Vlymphatic leukemia
p5570
sasa(dp5571
g2
VIn addition to providing insight into Pol I transcription and ES control, Pol I transcription inhibitors potentially also provide new approaches to treat trypanosomiasis.
p5572
sg4
(lp5573
(dp5574
g7
I38
sg8
I2
sg9
I5
sg10
VP10266
p5575
sg12
VPol I
p5576
sa(dp5577
g7
I38
sg8
I2
sg9
I5
sg10
VP10266
p5578
sg12
VPol I
p5579
sasg24
(lp5580
(dp5581
g7
I154
sg8
I1
sg9
I15
sg27
VC0041227
p5582
sg12
Vtrypanosomiasis
p5583
sasa(dp5584
g2
VIn the unicellular parasite Trypanosoma brucei, which causes African sleeping sickness, TbISWI down-regulates RNA polymerase I (Pol I)-transcribed variant surface glycoprotein (VSG) gene expression sites (ESs), which are monoallelically expressed.
p5585
sg4
(lp5586
(dp5587
g7
I110
sg8
I3
sg9
I16
sg10
VP24928
p5588
sg12
VRNA polymerase I
p5589
sa(dp5590
g7
I128
sg8
I2
sg9
I5
sg10
VP10266
p5591
sg12
VPol I
p5592
sasg24
(lp5593
(dp5594
g7
I61
sg8
I3
sg9
I25
sg27
VC0041228
p5595
sg12
VAfrican sleeping sickness
p5596
sasa(dp5597
g2
VA significant association was found between the perilipin rs1052700 polymorphism and T2D, and between the FTO rs3751812 polymorphism and obesity (P = 0.03 and 0.003, respectively); however, no significant relationship was found between rs3751812 and T2D.
p5598
sg4
(lp5599
(dp5600
g7
I48
sg8
I2
sg9
I19
sg10
g11
sg12
Vperilipin rs1052700
p5601
sasg24
(lp5602
(dp5603
g7
I85
sg8
I1
sg9
I3
sg27
VC0011860
p5604
sg12
VT2D
p5605
sa(dp5606
g7
I85
sg8
I1
sg9
I3
sg27
VC0011860
p5607
sg12
VT2D
p5608
sa(dp5609
g7
I137
sg8
I1
sg9
I7
sg27
VC0028754
p5610
sg12
Vobesity
p5611
sasa(dp5612
g2
VThe perilipin rs1052700 polymorphism is related to T2D but not obesity.
p5613
sg4
(lp5614
(dp5615
g7
I51
sg8
I1
sg9
I3
sg10
g11
sg12
VT2D
p5616
sa(dp5617
g7
I4
sg8
I2
sg9
I19
sg10
g11
sg12
Vperilipin rs1052700
p5618
sasg24
(lp5619
(dp5620
g7
I51
sg8
I1
sg9
I3
sg27
VC0011860
p5621
sg12
VT2D
p5622
sa(dp5623
g7
I63
sg8
I1
sg9
I7
sg27
VC0028754
p5624
sg12
Vobesity
p5625
sasa(dp5626
g2
VThis prospective study recruited 22 patients with ESRD who underwent a first living kidney allograft transplantation, comprising 12 patients with CYP3A5*1 allele (CYP3A5*1/*1 or *1/*3) and 10 patients without CYP3A5*1 allele (CYP3A5*3/*3).
p5627
sg4
(lp5628
(dp5629
g7
I146
sg8
I1
sg9
I8
sg10
VP20815
p5630
sg12
VCYP3A5*1
p5631
sa(dp5632
g7
I226
sg8
I1
sg9
I11
sg10
VP20815
p5633
sg12
VCYP3A5*3/*3
p5634
sa(dp5635
g7
I146
sg8
I2
sg9
I15
sg10
VP20815
p5636
sg12
VCYP3A5*1 allele
p5637
sa(dp5638
g7
I146
sg8
I2
sg9
I15
sg10
VP20815
p5639
sg12
VCYP3A5*1 allele
p5640
sasg24
(lp5641
(dp5642
g7
I50
sg8
I1
sg9
I4
sg27
VC0022661
p5643
sg12
VESRD
p5644
sasa(dp5645
g2
VNineteen SNPs in the ABCB1, NR1I2, UGT1A1, SLCO1B1 and CYP3A5 genes were examined in case patients with atazanavir/ritonavir-induced nephrolithiasis (n = 31) and controls (n = 47).
p5646
sg4
(lp5647
(dp5648
g7
I35
sg8
I1
sg9
I6
sg10
VP35504
p5649
sg12
VUGT1A1
p5650
sa(dp5651
g7
I55
sg8
I2
sg9
I12
sg10
VP20815
p5652
sg12
VCYP3A5 genes
p5653
sa(dp5654
g7
I21
sg8
I1
sg9
I5
sg10
VP08183
p5655
sg12
VABCB1
p5656
sa(dp5657
g7
I43
sg8
I1
sg9
I7
sg10
g11
sg12
VSLCO1B1
p5658
sasg24
(lp5659
(dp5660
g7
I133
sg8
I1
sg9
I15
sg27
VC0392525
p5661
sg12
Vnephrolithiasis
p5662
sasa(dp5663
g2
VCalcineurin inhibitor (CNI) use is considered to play a major role in the development of CKD after LT. We studied the influence of single-nucleotide polymorphisms (SNPs) in the genes of the donor and recipient CNI-metabolizing enzyme CYP3A5 and the CNI-transporting ABCB1 on the development of CKD after LT. Tacrolimus (Tac) predose concentrations at different time-points after transplantation and the CYP3A5 6986A&gt;G and ABCB1 3435C&gt;T SNPs were determined in 125 LT recipients and their respective donors to study the influence of Tac predose levels and genetics on the development of CKD.
p5664
sg4
(lp5665
(dp5666
g7
I425
sg8
I2
sg9
I11
sg10
VP08183
p5667
sg12
VABCB1 3435C
p5668
sa(dp5669
g7
I249
sg8
I2
sg9
I22
sg10
g11
sg12
VCNI-transporting ABCB1
p5670
sa(dp5671
g7
I210
sg8
I3
sg9
I30
sg10
g11
sg12
VCNI-metabolizing enzyme CYP3A5
p5672
sa(dp5673
g7
I23
sg8
I1
sg9
I3
sg10
g11
sg12
VCNI
p5674
sa(dp5675
g7
I0
sg8
I2
sg9
I21
sg10
g11
sg12
VCalcineurin inhibitor
p5676
sa(dp5677
g7
I440
sg8
I2
sg9
I6
sg10
g11
sg12
VT SNPs
p5678
sa(dp5679
g7
I403
sg8
I2
sg9
I12
sg10
VP20815
p5680
sg12
VCYP3A5 6986A
p5681
sasg24
(lp5682
sa(dp5683
g2
VNeither did we find a correlation between the investigated SNPs in either donor or recipient ABCB1 and CYP3A5 genes (or combinations thereof) and the development of CKD.
p5684
sg4
(lp5685
(dp5686
g7
I93
sg8
I1
sg9
I5
sg10
VP08183
p5687
sg12
VABCB1
p5688
sa(dp5689
g7
I103
sg8
I2
sg9
I12
sg10
VP20815
p5690
sg12
VCYP3A5 genes
p5691
sasg24
(lp5692
sa(dp5693
g2
VAn individual's risk of developing CKD after LT is not associated with genetic variation in either recipient or donor CYP3A5 or ABCB1 genotype status.
p5694
sg4
(lp5695
(dp5696
g7
I118
sg8
I1
sg9
I6
sg10
VP20815
p5697
sg12
VCYP3A5
p5698
sa(dp5699
g7
I128
sg8
I2
sg9
I14
sg10
VP08183
p5700
sg12
VABCB1 genotype
p5701
sasg24
(lp5702
sa(dp5703
g2
VIn conclusion, these results suggest that CYP3A5 polymorphism and plasma concentration of 3-INDS may account for the interindividual variability of CYP3A activity, and that plasma concentration of 3-INDS may partially explain the gap in CYP3A activity that cannot be explained by genetic contribution in patients with renal failure.
p5704
sg4
(lp5705
(dp5706
g7
I42
sg8
I1
sg9
I5
sg10
VP08684
p5707
sg12
VCYP3A
p5708
sa(dp5709
g7
I42
sg8
I1
sg9
I6
sg10
VP20815
p5710
sg12
VCYP3A5
p5711
sa(dp5712
g7
I42
sg8
I1
sg9
I5
sg10
VP08684
p5713
sg12
VCYP3A
p5714
sasg24
(lp5715
(dp5716
g7
I318
sg8
I2
sg9
I13
sg27
VC0035078
p5717
sg12
Vrenal failure
p5718
sasa(dp5719
g2
V#\u76ee#\u7684#\uff1a #\u63a2#\u8ba8FGD6  (faciogenital dysplasia) #\u57fa#\u56e0#\u5bf9#\u809d#\u5e72#\u7ec6#\u80de#\u5206#\u5316#\u8c03#\u63a7#\u7684#\u4f5c#\u7528#\u3002 #\u65b9#\u6cd5#\uff1a #\u9009#\u53d6FGD6#\u57fa#\u56e0#\u5e72#\u6270#\u9776#\u5e8f#\u5217, #\u4f7f#\u7528AdEasy#\u7cfb#\u7edf#\u6784#\u5efa#\u817a#\u75c5#\u6bd2#\u8f7d#\u4f53, #\u5305#\u88c5#\u5e76#\u6269#\u589e#\u91cd#\u7ec4#\u817a#\u75c5#\u6bd2#\u8f7d#\u4f53pSES-FGD6-siRNA, #\u611f#\u67d3HP14.5#\u7ec6#\u80de#\u3002#\u7ec6#\u80de#\u514d#\u75ab#\u8367#\u5149#\u68c0#\u6d4bFGD6#\u86cb#\u767d#\u5728HP14.5#\u7ec6#\u80de#\u4e2d#\u7684#\u8868#\u8fbe#\u6c34#\u5e73, #\u5b9e#\u65f6#\u8367#\u5149#\u5b9a#\u91cfPCR#\u68c0#\u6d4bFGD6#\u3001#\u7532#\u80ce#\u86cb#\u767d (AFP) #\u53ca#\u767d#\u86cb#\u767d (Alb) #\u7684mRNA#\u6c34#\u5e73, Western blot#\u68c0#\u6d4bFGD6#\u3001AFP#\u53caAlb#\u7684#\u86cb#\u767d#\u8868#\u8fbe#\u6c34#\u5e73#\u3002#\u6bcf#\u7ec4#\u7ec6#\u80de#\u5747#\u8bbe#\u7f6epSES-Ad-RFP#\u817a#\u75c5#\u6bd2#\u7a7a#\u8f7d#\u4f53#\u611f#\u67d3#\u8fdb#\u884c#\u5bf9#\u7167#\u3002#\u6240#\u6709#\u6570#\u636e#\u7528#\u5747#\u6570+/-#\u6807#\u51c6#\u5dee (x+/-s) #\u8868#\u793a, #\u91c7#\u7528#\u5355#\u56e0#\u7d20#\u65b9#\u5dee#\u5206#\u6790#\u3002 #\u7ed3#\u679c#\uff1a FGD6#\u86cb#\u767d#\u4e3b#\u8981#\u8868#\u8fbe#\u4e8eHP14.5#\u7ec6#\u80de#\u80de#\u6838#\u4e2d#\u3002#\u6210#\u529f#\u6784#\u5efa#\u817a#\u75c5#\u6bd2#\u8f7d#\u4f53pSES-FGD6-siRNA#\u3002#\u4e0b#\u8c03FGD6#\u57fa#\u56e0#\u5728HP14.5#\u7ec6#\u80de#\u4e2d#\u7684#\u8868#\u8fbe, #\u53ef#\u964d#\u4f4eAFP#\u7684mRNA#\u53ca#\u86cb#\u767d#\u7684#\u8868#\u8fbe, #\u800c#\u5347#\u9ad8Alb#\u7684mRNA#\u53ca#\u86cb#\u767d#\u7684#\u8868#\u8fbe (P&lt;0.01) #\u3002 #\u7ed3#\u8bba#\uff1a #\u6291#\u5236FGD6#\u57fa#\u56e0#\u5728HP14.5#\u7ec6#\u80de#\u4e2d#\u7684#\u8868#\u8fbe, #\u53ef#\u4f7fHP14.5#\u7ec6#\u80de#\u5411#\u809d#\u7ec6#\u80de#\u65b9#\u5411#\u5206#\u5316, #\u56e0#\u6b64, FGD6#\u57fa#\u56e0#\u5bf9#\u809d#\u5e72#\u7ec6#\u80de#\u5206#\u5316#\u8c03#\u63a7#\u53ef#\u80fd#\u8d77#\u7740#\u91cd#\u8981#\u4f5c#\u7528#\u3002.
p5720
sg4
(lp5721
(dp5722
g7
I11
sg8
I1
sg9
I4
sg10
g11
sg12
VFGD6
p5723
sa(dp5724
g7
I376
sg8
I1
sg9
I3
sg10
VP25090
p5725
sg12
VRFP
p5726
sa(dp5727
g7
I11
sg8
I1
sg9
I4
sg10
g11
sg12
VFGD6
p5728
sa(dp5729
g7
I329
sg8
I1
sg9
I4
sg10
VP02771
p5730
sg12
V\u3001AFP
p5731
sa(dp5732
g7
I11
sg8
I1
sg9
I4
sg10
g11
sg12
VFGD6
p5733
sa(dp5734
g7
I11
sg8
I1
sg9
I4
sg10
g11
sg12
VFGD6
p5735
sasg24
(lp5736
(dp5737
g7
I18
sg8
I2
sg9
I22
sg27
VC0175701
p5738
sg12
Vfaciogenital dysplasia
p5739
sasa(dp5740
g2
VFiltered albumin has been suggested to be a cause of the glomerular and tubular injuries observed at advanced stages of Alport syndrome.
p5741
sg4
(lp5742
(dp5743
g7
I9
sg8
I1
sg9
I7
sg10
VP00441
p5744
sg12
Valbumin
p5745
sasg24
(lp5746
(dp5747
g7
I120
sg8
I2
sg9
I15
sg27
VC1567741
p5748
sg12
VAlport syndrome
p5749
sasa(dp5750
g2
VTo directly investigate the role that albumin plays in the progression of disease in Alport syndrome, we generated albumin knockout (Alb(-/-)) mice to use as a tool for removing albuminuria as a component of kidney disease.
p5751
sg4
(lp5752
(dp5753
g7
I38
sg8
I1
sg9
I7
sg10
VP00441
p5754
sg12
Valbumin
p5755
sa(dp5756
g7
I38
sg8
I1
sg9
I7
sg10
VP00441
p5757
sg12
Valbumin
p5758
sa(dp5759
g7
I133
sg8
I1
sg9
I3
sg10
g11
sg12
VAlb
p5760
sasg24
(lp5761
(dp5762
g7
I85
sg8
I2
sg9
I15
sg27
VC1567741
p5763
sg12
VAlport syndrome
p5764
sa(dp5765
g7
I208
sg8
I2
sg9
I14
sg27
VC0022658
p5766
sg12
Vkidney disease
p5767
sasa(dp5768
g2
VAlb mutant mice were bred to collagen-Alfa3(IV) knockout (Col4a3(-/-)) mice, which are a model for human Alport syndrome.
p5769
sg4
(lp5770
(dp5771
g7
I0
sg8
I1
sg9
I3
sg10
g11
sg12
VAlb
p5772
sasg24
(lp5773
(dp5774
g7
I105
sg8
I2
sg9
I15
sg27
VC1567741
p5775
sg12
VAlport syndrome
p5776
sa(dp5777
g7
I4
sg8
I1
sg9
I6
sg27
VC0596988
p5778
sg12
Vmutant
p5779
sasa(dp5780
g2
VWe conclude that filtered albumin is injurious to kidney cells in Alport syndrome and perhaps in other proteinuric kidney diseases, including diabetic nephropathy.
p5781
sg4
(lp5782
(dp5783
g7
I26
sg8
I1
sg9
I7
sg10
VP00441
p5784
sg12
Valbumin
p5785
sasg24
(lp5786
(dp5787
g7
I142
sg8
I2
sg9
I20
sg27
VC0011881
p5788
sg12
Vdiabetic nephropathy
p5789
sa(dp5790
g7
I115
sg8
I2
sg9
I15
sg27
VC0022658
p5791
sg12
Vkidney diseases
p5792
sa(dp5793
g7
I66
sg8
I2
sg9
I15
sg27
VC1567741
p5794
sg12
VAlport syndrome
p5795
sasa(dp5796
g2
VOn the other hand, we believe that tumor depth of invasion (&gt;=4 mm), POI, and VEGF-C expression all need to be considered in the preoperative and postoperative planning stages for tongue cancer treatment.
p5797
sg4
(lp5798
(dp5799
g7
I81
sg8
I1
sg9
I6
sg10
VP49767
p5800
sg12
VVEGF-C
p5801
sasg24
(lp5802
(dp5803
g7
I183
sg8
I2
sg9
I13
sg27
VC0558353
p5804
sg12
Vtongue cancer
p5805
sa(dp5806
g7
I35
sg8
I1
sg9
I5
sg27
VC0027651
p5807
sg12
Vtumor
p5808
sa(dp5809
g7
I50
sg8
I1
sg9
I8
sg27
VC2699153
p5810
sg12
Vinvasion
p5811
sasa(dp5812
g2
VThe use of a therapeutic approach which blocks lymphangiogenic factors, such as VEGF-C and VEGF-D, may be beneficial in suppressing the lymphatic spread of tongue cancer with intense intranodal lymphangiogenesis.
p5813
sg4
(lp5814
(dp5815
g7
I80
sg8
I1
sg9
I6
sg10
VP49767
p5816
sg12
VVEGF-C
p5817
sa(dp5818
g7
I91
sg8
I1
sg9
I6
sg10
g11
sg12
VVEGF-D
p5819
sasg24
(lp5820
(dp5821
g7
I156
sg8
I2
sg9
I13
sg27
VC0558353
p5822
sg12
Vtongue cancer
p5823
sasa(dp5824
g2
VVEGF, VEGF-C, VEGF-D and MIA expression levels of metastatic tongue cancer HSC-3 cells were higher than those with no metastatic HSC-4 cells, and VEGF, VEGF-C and VEGF-D expression levels were decreased by MIA siRNA treatment in both cells.
p5825
sg4
(lp5826
(dp5827
g7
I14
sg8
I1
sg9
I6
sg10
g11
sg12
VVEGF-D
p5828
sa(dp5829
g7
I6
sg8
I1
sg9
I6
sg10
VP49767
p5830
sg12
VVEGF-C
p5831
sa(dp5832
g7
I206
sg8
I2
sg9
I9
sg10
g11
sg12
VMIA siRNA
p5833
sa(dp5834
g7
I25
sg8
I1
sg9
I3
sg10
g11
sg12
VMIA
p5835
sa(dp5836
g7
I14
sg8
I1
sg9
I6
sg10
g11
sg12
VVEGF-D
p5837
sa(dp5838
g7
I6
sg8
I1
sg9
I6
sg10
VP49767
p5839
sg12
VVEGF-C
p5840
sasg24
(lp5841
(dp5842
g7
I61
sg8
I2
sg9
I13
sg27
VC0558353
p5843
sg12
Vtongue cancer
p5844
sasa(dp5845
g2
VVascular endothelial growth factor and Notch1 expression are significantly related to cervical lymph node metastasis and depth of invasion in tongue cancer patients.
p5846
sg4
(lp5847
(dp5848
g7
I0
sg8
I4
sg9
I34
sg10
g11
sg12
VVascular endothelial growth factor
p5849
sa(dp5850
g7
I39
sg8
I1
sg9
I6
sg10
VP46531
p5851
sg12
VNotch1
p5852
sasg24
(lp5853
(dp5854
g7
I130
sg8
I1
sg9
I8
sg27
VC2699153
p5855
sg12
Vinvasion
p5856
sa(dp5857
g7
I95
sg8
I3
sg9
I21
sg27
VC0686619
p5858
sg12
Vlymph node metastasis
p5859
sa(dp5860
g7
I142
sg8
I2
sg9
I13
sg27
VC0558353
p5861
sg12
Vtongue cancer
p5862
sasa(dp5863
g2
VMutant-type p53 and VEGF are known to be related to angiogenesis, and maspin is a potent angiogenic inhibitor but its role in tongue cancer has scarcely been examined.
p5864
sg4
(lp5865
(dp5866
g7
I12
sg8
I1
sg9
I3
sg10
VP42771
p5867
sg12
Vp53
p5868
sasg24
(lp5869
(dp5870
g7
I0
sg8
I1
sg9
I6
sg27
VC0596988
p5871
sg12
VMutant
p5872
sa(dp5873
g7
I126
sg8
I2
sg9
I13
sg27
VC0558353
p5874
sg12
Vtongue cancer
p5875
sasa(dp5876
g2
VWe observed the expression of maspin, mutant-type p53 and VEGF by immunohistochemistry in 33 patients with stages I and II oral tongue cancer.
p5877
sg4
(lp5878
(dp5879
g7
I30
sg8
I1
sg9
I6
sg10
VP36952
p5880
sg12
Vmaspin
p5881
sa(dp5882
g7
I38
sg8
I2
sg9
I15
sg10
VP42771
p5883
sg12
Vmutant-type p53
p5884
sasg24
(lp5885
(dp5886
g7
I128
sg8
I2
sg9
I13
sg27
VC0558353
p5887
sg12
Vtongue cancer
p5888
sa(dp5889
g7
I38
sg8
I1
sg9
I6
sg27
VC0596988
p5890
sg12
Vmutant
p5891
sasa(dp5892
g2
VIn an experimental autoimmune encephalomyelitis model of CNS autoimmunity, we found activation-induced cytidine deaminase, a GC-defining enzyme, in meningeal ELT (mELT) densely populated by B and T cells.
p5893
sg4
(lp5894
(dp5895
g7
I103
sg8
I2
sg9
I18
sg10
VP32320
p5896
sg12
Vcytidine deaminase
p5897
sasg24
(lp5898
(dp5899
g7
I30
sg8
I1
sg9
I17
sg27
VC0014070
p5900
sg12
Vencephalomyelitis
p5901
sa(dp5902
g7
I61
sg8
I1
sg9
I12
sg27
VC0004368
p5903
sg12
Vautoimmunity
p5904
sa(dp5905
g7
I19
sg8
I1
sg9
I10
sg27
VC0443146
p5906
sg12
Vautoimmune
p5907
sasa(dp5908
g2
VA prospective randomized survey of 113 abortions carried out by 1 operator using a single technique among women in the 7th-10th week of amenorrhea was undertaken to test the effectiveness of systemically administered oxytocins to reduce bleeding during therapeutic abortion by suction.
p5909
sg4
(lp5910
sg24
(lp5911
(dp5912
g7
I136
sg8
I1
sg9
I10
sg27
VC0002453
p5913
sg12
Vamenorrhea
p5914
sa(dp5915
g7
I237
sg8
I1
sg9
I8
sg27
VC0019080
p5916
sg12
Vbleeding
p5917
sasa(dp5918
g2
VThis cross-sectional study includes 304 patients with type 2 diabetes treated with oral antidiabetic drugs (ADOs) and a glomerular filtration rate (estimated GFR) &amp;lt;60ml/min/1.73m2.
p5919
sg4
(lp5920
sg24
(lp5921
(dp5922
g7
I54
sg8
I3
sg9
I15
sg27
VC0011860
p5923
sg12
Vtype 2 diabetes
p5924
sasa(dp5925
g2
VThe purpose of this study was to evaluate the hypothesis that acute hyperglycaemia in hearts of rats without diabetes alters coronary vascular responses to nitric oxide (NO), adenosine (ADO) and phenylephrine (PHE).
p5926
sg4
(lp5927
sg24
(lp5928
(dp5929
g7
I62
sg8
I2
sg9
I20
sg27
VC0342301
p5930
sg12
Vacute hyperglycaemia
p5931
sa(dp5932
g7
I109
sg8
I1
sg9
I8
sg27
VC0011849
p5933
sg12
Vdiabetes
p5934
sasa(dp5935
g2
VIn conclusion, STZ-diabetes mellitus enhances the antiphosphaturic effect of ADO by mechanisms unrelated to ADO A1 receptor stimulation.
p5936
sg4
(lp5937
(dp5938
g7
I108
sg8
I3
sg9
I15
sg10
g11
sg12
VADO A1 receptor
p5939
sasg24
(lp5940
(dp5941
g7
I19
sg8
I2
sg9
I17
sg27
VC0011849
p5942
sg12
Vdiabetes mellitus
p5943
sasa(dp5944
g2
VBradykinin type 1 receptor antagonism could represent a promising therapeutic tool in combination with TZD for the treatment of T2D, obesity and insulin resistance.
p5945
sg4
(lp5946
(dp5947
g7
I0
sg8
I4
sg9
I26
sg10
VP01042
p5948
sg12
VBradykinin type 1 receptor
p5949
sa(dp5950
g7
I145
sg8
I1
sg9
I7
sg10
VP01308
p5951
sg12
Vinsulin
p5952
sasg24
(lp5953
(dp5954
g7
I133
sg8
I1
sg9
I7
sg27
VC0028754
p5955
sg12
Vobesity
p5956
sa(dp5957
g7
I145
sg8
I2
sg9
I18
sg27
VC0021655
p5958
sg12
Vinsulin resistance
p5959
sa(dp5960
g7
I128
sg8
I1
sg9
I3
sg27
VC0011860
p5961
sg12
VT2D
p5962
sasa(dp5963
g2
VThe aim of this study was to analyze the acute responses of bradykinin, insulin, and glycemia to exercise performed above and below lactate threshold (LT) in individuals with type 2 diabetes mellitus (T2D).
p5964
sg4
(lp5965
(dp5966
g7
I60
sg8
I1
sg9
I10
sg10
VP01042
p5967
sg12
Vbradykinin
p5968
sa(dp5969
g7
I72
sg8
I1
sg9
I7
sg10
VP01308
p5970
sg12
Vinsulin
p5971
sasg24
(lp5972
(dp5973
g7
I175
sg8
I4
sg9
I24
sg27
VC0011860
p5974
sg12
Vtype 2 diabetes mellitus
p5975
sa(dp5976
g7
I201
sg8
I1
sg9
I3
sg27
VC0011860
p5977
sg12
VT2D
p5978
sasa(dp5979
g2
VTo examine the association of bradykinin and related peptides with the development of diabetic nephropathy lesions in 243 participants with type 1 diabetes (T1D) from the Renin-Angiotensin System Study who, at baseline, were normoalbuminuric, normotensive and had normal or increased glomerular filtration rate (GFR).
p5980
sg4
(lp5981
(dp5982
g7
I30
sg8
I1
sg9
I10
sg10
VP01042
p5983
sg12
Vbradykinin
p5984
sa(dp5985
g7
I171
sg8
I1
sg9
I5
sg10
VP00797
p5986
sg12
VRenin
p5987
sa(dp5988
g7
I177
sg8
I1
sg9
I11
sg10
VP21549
p5989
sg12
VAngiotensin
p5990
sasg24
(lp5991
(dp5992
g7
I86
sg8
I2
sg9
I20
sg27
VC0011881
p5993
sg12
Vdiabetic nephropathy
p5994
sa(dp5995
g7
I157
sg8
I1
sg9
I3
sg27
VC0011854
p5996
sg12
VT1D
p5997
sa(dp5998
g7
I140
sg8
I3
sg9
I15
sg27
VC0011854
p5999
sg12
Vtype 1 diabetes
p6000
sasa(dp6001
g2
VHeterozygosity for missense mutations in Seipin, namely N88S and S90L, leads to a broad spectrum of motor neuropathy, while a number of loss-of-function mutations in Seipin are associated with the Berardinelli-Seip congenital generalized lipodystrophy type 2 (CGL2, BSCL2), a condition that is characterized by severe lipoatrophy, insulin resistance, and intellectual impairment.
p6002
sg4
(lp6003
(dp6004
g7
I331
sg8
I1
sg9
I7
sg10
VP01308
p6005
sg12
Vinsulin
p6006
sa(dp6007
g7
I266
sg8
I1
sg9
I5
sg10
g11
sg12
VBSCL2
p6008
sa(dp6009
g7
I260
sg8
I1
sg9
I4
sg10
VP20718
p6010
sg12
VCGL2
p6011
sa(dp6012
g7
I41
sg8
I1
sg9
I6
sg10
g11
sg12
VSeipin
p6013
sa(dp6014
g7
I215
sg8
I5
sg9
I43
sg10
VP20718
p6015
sg12
Vcongenital generalized lipodystrophy type 2
p6016
sa(dp6017
g7
I41
sg8
I1
sg9
I6
sg10
g11
sg12
VSeipin
p6018
sasg24
(lp6019
(dp6020
g7
I318
sg8
I1
sg9
I11
sg27
VC1280433
p6021
sg12
Vlipoatrophy
p6022
sa(dp6023
g7
I331
sg8
I2
sg9
I18
sg27
VC0021655
p6024
sg12
Vinsulin resistance
p6025
sa(dp6026
g7
I276
sg8
I1
sg9
I9
sg27
VC0012634
p6027
sg12
Vcondition
p6028
sa(dp6029
g7
I100
sg8
I2
sg9
I16
sg27
VC0235025
p6030
sg12
Vmotor neuropathy
p6031
sa(dp6032
g7
I260
sg8
I1
sg9
I4
sg27
VC1720863
p6033
sg12
VCGL2
p6034
sa(dp6035
g7
I215
sg8
I5
sg9
I43
sg27
VC1720863
p6036
sg12
Vcongenital generalized lipodystrophy type 2
p6037
sa(dp6038
g7
I355
sg8
I2
sg9
I23
sg27
VC0683322
p6039
sg12
Vintellectual impairment
p6040
sasa(dp6041
g2
VIn comparison to liver biopsies of patients with non-viral liver disease, liver biopsies of patients with HCV showed significantly increased mRNA expression of IL-28A and IL-29.
p6042
sg4
(lp6043
(dp6044
g7
I171
sg8
I1
sg9
I5
sg10
g11
sg12
VIL-29
p6045
sasg24
(lp6046
(dp6047
g7
I65
sg8
I2
sg9
I14
sg27
VC0023895
p6048
sg12
Vdisease, liver
p6049
sasa(dp6050
g2
VHere, we demonstrate a key regulatory role of IL-28A in T-cell-mediated hepatitis.
p6051
sg4
(lp6052
sg24
(lp6053
(dp6054
g7
I72
sg8
I1
sg9
I9
sg27
VC0019159
p6055
sg12
Vhepatitis
p6056
sasa(dp6057
g2
VIL-28A induced TH1 cytokine production by CD4+ T lymphocytes in a T-bet-dependent manner and was up-regulated in a murine model of T-cell-mediated hepatitis upon Con A administration.
p6058
sg4
(lp6059
(dp6060
g7
I42
sg8
I1
sg9
I4
sg10
VP01730
p6061
sg12
VCD4+
p6062
sa(dp6063
g7
I15
sg8
I2
sg9
I12
sg10
VP13236
p6064
sg12
VTH1 cytokine
p6065
sasg24
(lp6066
(dp6067
g7
I147
sg8
I1
sg9
I9
sg27
VC0019159
p6068
sg12
Vhepatitis
p6069
sasa(dp6070
g2
VIn addition, IL-28A-transgenic mice showed markedly augmented Con A-induced hepatitis with up-regulated interferon-gamma cytokine production, as compared with wild-type mice.
p6071
sg4
(lp6072
(dp6073
g7
I104
sg8
I1
sg9
I16
sg10
VP01579
p6074
sg12
Vinterferon-gamma
p6075
sasg24
(lp6076
(dp6077
g7
I76
sg8
I1
sg9
I9
sg27
VC0019159
p6078
sg12
Vhepatitis
p6079
sasa(dp6080
g2
VIn addition, in vivo blockade of interferon-gamma but not IL-4 suppressed augmented liver inflammation in transgenic mice, suggesting that IL-28A induces the T-bet signaling pathway in T-cell-induced hepatitis.
p6081
sg4
(lp6082
(dp6083
g7
I58
sg8
I1
sg9
I4
sg10
VP05112
p6084
sg12
VIL-4
p6085
sa(dp6086
g7
I158
sg8
I1
sg9
I5
sg10
g11
sg12
VT-bet
p6087
sa(dp6088
g7
I33
sg8
I1
sg9
I16
sg10
VP01579
p6089
sg12
Vinterferon-gamma
p6090
sasg24
(lp6091
(dp6092
g7
I90
sg8
I1
sg9
I12
sg27
VC0021368
p6093
sg12
Vinflammation
p6094
sa(dp6095
g7
I200
sg8
I1
sg9
I9
sg27
VC0019159
p6096
sg12
Vhepatitis
p6097
sasa(dp6098
g2
VThus, targeting of IL-28A represents a potential novel approach for therapy of Th1-mediated inflammatory diseases such as T-cell-mediated hepatitis.
p6099
sg4
(lp6100
sg24
(lp6101
(dp6102
g7
I138
sg8
I1
sg9
I9
sg27
VC0019159
p6103
sg12
Vhepatitis
p6104
sasa(dp6105
g2
VThe present study therefore indicated that NOD receptor and TLR9 may modulate the inflammatory response and further impact upon intestinal injury of SAP, via the regulation of NF-KB expression and the oxidation/antioxidation balance, suggesting therapeutically targeting NOD receptor and TLR9 might be a useful approach for the treatment of severe acute pancreatitis.
p6106
sg4
(lp6107
(dp6108
g7
I60
sg8
I1
sg9
I4
sg10
g11
sg12
VTLR9
p6109
sa(dp6110
g7
I60
sg8
I1
sg9
I4
sg10
g11
sg12
VTLR9
p6111
sa(dp6112
g7
I43
sg8
I2
sg9
I12
sg10
VP54259
p6113
sg12
VNOD receptor
p6114
sa(dp6115
g7
I43
sg8
I2
sg9
I12
sg10
VP54259
p6116
sg12
VNOD receptor
p6117
sasg24
(lp6118
(dp6119
g7
I82
sg8
I2
sg9
I21
sg27
VC1155266
p6120
sg12
Vinflammatory response
p6121
sa(dp6122
g7
I43
sg8
I1
sg9
I3
sg27
VC0751781
p6123
sg12
VNOD
p6124
sa(dp6125
g7
I348
sg8
I2
sg9
I18
sg27
VC0001339
p6126
sg12
Vacute pancreatitis
p6127
sa(dp6128
g7
I43
sg8
I1
sg9
I3
sg27
VC0751781
p6129
sg12
VNOD
p6130
sasa(dp6131
g2
VIt also has efficacy in limiting TLR9-mediated sterile inflammation in in vivo models of acute liver injury and acute pancreatitis.
p6132
sg4
(lp6133
(dp6134
g7
I33
sg8
I1
sg9
I4
sg10
g11
sg12
VTLR9
p6135
sasg24
(lp6136
(dp6137
g7
I47
sg8
I1
sg9
I7
sg27
VC0678108
p6138
sg12
Vsterile
p6139
sa(dp6140
g7
I55
sg8
I1
sg9
I12
sg27
VC0021368
p6141
sg12
Vinflammation
p6142
sa(dp6143
g7
I112
sg8
I2
sg9
I18
sg27
VC0001339
p6144
sg12
Vacute pancreatitis
p6145
sasa(dp6146
g2
VGenetic deletion and pharmacologic antagonism demonstrate that specific DAMP receptors, including Toll-like receptor (TLR) 4, TLR9, and P2X7, are also required for inflammation in experimental acute pancreatitis.
p6147
sg4
(lp6148
(dp6149
g7
I63
sg8
I3
sg9
I23
sg10
g11
sg12
Vspecific DAMP receptors
p6150
sa(dp6151
g7
I98
sg8
I4
sg9
I26
sg10
g11
sg12
VToll-like receptor (TLR) 4
p6152
sa(dp6153
g7
I126
sg8
I1
sg9
I4
sg10
g11
sg12
VTLR9
p6154
sa(dp6155
g7
I136
sg8
I1
sg9
I4
sg10
g11
sg12
VP2X7
p6156
sasg24
(lp6157
(dp6158
g7
I164
sg8
I1
sg9
I12
sg27
VC0021368
p6159
sg12
Vinflammation
p6160
sa(dp6161
g7
I193
sg8
I2
sg9
I18
sg27
VC0001339
p6162
sg12
Vacute pancreatitis
p6163
sasa(dp6164
g2
VAcute pancreatitis was induced by caerulein stimulation in wild-type mice and mice deficient in components of the inflammasome (apoptosis-associated speck-like protein containing a caspase recruitment domain [ASC], NLRP3, caspase-1), Toll-like receptor 9 (TLR9), or the purinergic receptor P2X(7).
p6165
sg4
(lp6166
(dp6167
g7
I256
sg8
I1
sg9
I4
sg10
g11
sg12
VTLR9
p6168
sa(dp6169
g7
I270
sg8
I3
sg9
I26
sg10
VP51575
p6170
sg12
Vpurinergic receptor P2X(7)
p6171
sa(dp6172
g7
I234
sg8
I3
sg9
I20
sg10
g11
sg12
VToll-like receptor 9
p6173
sa(dp6174
g7
I181
sg8
I1
sg9
I7
sg10
VP39880
p6175
sg12
Vcaspase
p6176
sa(dp6177
g7
I222
sg8
I1
sg9
I9
sg10
VP29466
p6178
sg12
Vcaspase-1
p6179
sasg24
(lp6180
(dp6181
g7
I189
sg8
I1
sg9
I11
sg27
VC0271510
p6182
sg12
Vrecruitment
p6183
sa(dp6184
g7
I0
sg8
I2
sg9
I18
sg27
VC0001339
p6185
sg12
VAcute pancreatitis
p6186
sasa(dp6187
g2
VAdditionally, wild-type mice were pretreated with a TLR9 antagonist before induction of acute pancreatitis by caerulein or retrograde bile duct infusion of taurolithocholic acid 3-sulfate.
p6188
sg4
(lp6189
(dp6190
g7
I52
sg8
I1
sg9
I4
sg10
g11
sg12
VTLR9
p6191
sasg24
(lp6192
(dp6193
g7
I88
sg8
I2
sg9
I18
sg27
VC0001339
p6194
sg12
Vacute pancreatitis
p6195
sasa(dp6196
g2
VTLR9 and P2X(7) are important DAMP receptors upstream of inflammasome activation, and their antagonism could provide a new therapeutic strategy for treating acute pancreatitis.
p6197
sg4
(lp6198
(dp6199
g7
I0
sg8
I1
sg9
I4
sg10
g11
sg12
VTLR9
p6200
sa(dp6201
g7
I9
sg8
I1
sg9
I6
sg10
VP51575
p6202
sg12
VP2X(7)
p6203
sasg24
(lp6204
(dp6205
g7
I157
sg8
I2
sg9
I18
sg27
VC0001339
p6206
sg12
Vacute pancreatitis
p6207
sasa(dp6208
g2
VWe are currently screening the 113 candidate DFNB79 genes for mutations and have excluded CACNA1B, EDF1, PTGDS, EHMT1, QSOX2, NOTCH1, MIR126 and MIR602.
p6209
sg4
(lp6210
(dp6211
g7
I112
sg8
I1
sg9
I5
sg10
g11
sg12
VEHMT1
p6212
sa(dp6213
g7
I90
sg8
I1
sg9
I7
sg10
g11
sg12
VCACNA1B
p6214
sa(dp6215
g7
I119
sg8
I1
sg9
I5
sg10
g11
sg12
VQSOX2
p6216
sa(dp6217
g7
I99
sg8
I1
sg9
I4
sg10
g11
sg12
VEDF1
p6218
sa(dp6219
g7
I45
sg8
I2
sg9
I12
sg10
g11
sg12
VDFNB79 genes
p6220
sa(dp6221
g7
I126
sg8
I1
sg9
I6
sg10
VP46531
p6222
sg12
VNOTCH1
p6223
sa(dp6224
g7
I105
sg8
I1
sg9
I5
sg10
VP41222
p6225
sg12
VPTGDS
p6226
sasg24
(lp6227
(dp6228
g7
I45
sg8
I1
sg9
I6
sg27
VC2750082
p6229
sg12
VDFNB79
p6230
sasa(dp6231
g2
VExposure to bone morphogenetic protein (BMP)-4 was found to enhance a TrkAhigh/CD15-/CD184- neuroblastoma cellular subset, accompanied by a reduction in doublecortin-positive neuroblasts and of NMYC protein expression in SH-SY5Y cells.
p6232
sg4
(lp6233
(dp6234
g7
I79
sg8
I1
sg9
I4
sg10
VP22083
p6235
sg12
VCD15
p6236
sa(dp6237
g7
I194
sg8
I2
sg9
I12
sg10
VP04198
p6238
sg12
VNMYC protein
p6239
sa(dp6240
g7
I17
sg8
I3
sg9
I29
sg10
VP18075
p6241
sg12
Vmorphogenetic protein (BMP)-4
p6242
sa(dp6243
g7
I85
sg8
I1
sg9
I5
sg10
VP61073
p6244
sg12
VCD184
p6245
sasg24
(lp6246
(dp6247
g7
I92
sg8
I1
sg9
I13
sg27
VC0027819
p6248
sg12
Vneuroblastoma
p6249
sasa(dp6250
g2
VRecent studies indicate that C-X-C motif chemokine receptor 4 (CXCR4) and its ligand, C-X-C motif chemokine ligand 12 (CXCL12), stimulate expression of the cell cycle regulatory protein Cyclin D1 in neurofibromatosis 1-associated malignant peripheral nerve sheath tumor (MPNST) cells and promote their proliferation.
p6251
sg4
(lp6252
(dp6253
g7
I29
sg8
I5
sg9
I32
sg10
VP51679
p6254
sg12
VC-X-C motif chemokine receptor 4
p6255
sa(dp6256
g7
I119
sg8
I1
sg9
I6
sg10
VP48061
p6257
sg12
VCXCL12
p6258
sa(dp6259
g7
I63
sg8
I1
sg9
I5
sg10
VP61073
p6260
sg12
VCXCR4
p6261
sa(dp6262
g7
I86
sg8
I5
sg9
I31
sg10
VP55773
p6263
sg12
VC-X-C motif chemokine ligand 12
p6264
sa(dp6265
g7
I186
sg8
I2
sg9
I9
sg10
VP24385
p6266
sg12
VCyclin D1
p6267
sasg24
(lp6268
(dp6269
g7
I230
sg8
I5
sg9
I39
sg27
VC0751690
p6270
sg12
Vmalignant peripheral nerve sheath tumor
p6271
sa(dp6272
g7
I199
sg8
I2
sg9
I19
sg27
VC0027831
p6273
sg12
Vneurofibromatosis 1
p6274
sa(dp6275
g7
I302
sg8
I1
sg9
I13
sg27
VC0334094
p6276
sg12
Vproliferation
p6277
sa(dp6278
g7
I271
sg8
I1
sg9
I5
sg27
VC0751690
p6279
sg12
VMPNST
p6280
sasa(dp6281
g2
VWestern blot analysis revealed the expression of multiple CXCR4 isoforms in neuroblastoma cells.
p6282
sg4
(lp6283
(dp6284
g7
I58
sg8
I2
sg9
I14
sg10
VP61073
p6285
sg12
VCXCR4 isoforms
p6286
sasg24
(lp6287
(dp6288
g7
I76
sg8
I1
sg9
I13
sg27
VC0027819
p6289
sg12
Vneuroblastoma
p6290
sasa(dp6291
g2
VOur data suggest a modulatory role of the MSC secretome on the expression of the 47 kDa CXCR4 isoform and invasion potential of the neuroblastoma cells to the bone marrow.
p6292
sg4
(lp6293
(dp6294
g7
I81
sg8
I4
sg9
I20
sg10
VP61073
p6295
sg12
V47 kDa CXCR4 isoform
p6296
sasg24
(lp6297
(dp6298
g7
I132
sg8
I1
sg9
I13
sg27
VC0027819
p6299
sg12
Vneuroblastoma
p6300
sa(dp6301
g7
I106
sg8
I1
sg9
I8
sg27
VC2699153
p6302
sg12
Vinvasion
p6303
sasa(dp6304
g2
VIn this study, we investigated the role of NF-KB signaling pathway in the regulation of CXC chemokine receptor-4 (CXCR4) in neuroblastoma metastasis.
p6305
sg4
(lp6306
(dp6307
g7
I114
sg8
I1
sg9
I5
sg10
VP61073
p6308
sg12
VCXCR4
p6309
sa(dp6310
g7
I88
sg8
I3
sg9
I24
sg10
VP61073
p6311
sg12
VCXC chemokine receptor-4
p6312
sasg24
(lp6313
(dp6314
g7
I124
sg8
I1
sg9
I13
sg27
VC0027819
p6315
sg12
Vneuroblastoma
p6316
sa(dp6317
g7
I138
sg8
I1
sg9
I10
sg27
VC0027627
p6318
sg12
Vmetastasis
p6319
sasa(dp6320
g2
VTargeting NF-KB signalling pathways and ultimately CXCR4 could be a strategy in neuroblastoma therapy.
p6321
sg4
(lp6322
(dp6323
g7
I51
sg8
I1
sg9
I5
sg10
VP61073
p6324
sg12
VCXCR4
p6325
sasg24
(lp6326
(dp6327
g7
I80
sg8
I1
sg9
I13
sg27
VC0027819
p6328
sg12
Vneuroblastoma
p6329
sasa(dp6330
g2
VThe FAM3C interleukin-like epithelial-to-mesenchymal-transition (EMT) inducer (ILEI) has been shown to be strongly up-regulated in several cancers and to be essential for tumor formation and metastasis in epithelial cells, correlating with a significant decrease in overall survival in colon and breast cancer patients.
p6331
sg4
(lp6332
(dp6333
g7
I79
sg8
I1
sg9
I4
sg10
g11
sg12
VILEI
p6334
sa(dp6335
g7
I4
sg8
I1
sg9
I5
sg10
g11
sg12
VFAM3C
p6336
sa(dp6337
g7
I10
sg8
I1
sg9
I16
sg10
VP60568
p6338
sg12
Vinterleukin-like
p6339
sasg24
(lp6340
(dp6341
g7
I139
sg8
I1
sg9
I7
sg27
VC0006826
p6342
sg12
Vcancers
p6343
sa(dp6344
g7
I296
sg8
I2
sg9
I13
sg27
VC0678222
p6345
sg12
Vbreast cancer
p6346
sa(dp6347
g7
I171
sg8
I1
sg9
I5
sg27
VC0027651
p6348
sg12
Vtumor
p6349
sa(dp6350
g7
I53
sg8
I1
sg9
I10
sg27
VC0599156
p6351
sg12
Vtransition
p6352
sa(dp6353
g7
I191
sg8
I1
sg9
I10
sg27
VC0027627
p6354
sg12
Vmetastasis
p6355
sasa(dp6356
g2
VInterleukin-like epithelial-to-mesenchymal transition inducer (ILEI) is an essential cytokine in tumor progression that is upregulated in several cancers, and its altered subcellular localization is a predictor of poor survival in human breast cancer.
p6357
sg4
(lp6358
(dp6359
g7
I0
sg8
I1
sg9
I16
sg10
VP60568
p6360
sg12
VInterleukin-like
p6361
sasg24
(lp6362
(dp6363
g7
I237
sg8
I2
sg9
I13
sg27
VC0678222
p6364
sg12
Vbreast cancer
p6365
sa(dp6366
g7
I97
sg8
I2
sg9
I17
sg27
VC0178874
p6367
sg12
Vtumor progression
p6368
sa(dp6369
g7
I43
sg8
I1
sg9
I10
sg27
VC0599156
p6370
sg12
Vtransition
p6371
sa(dp6372
g7
I146
sg8
I1
sg9
I7
sg27
VC0006826
p6373
sg12
Vcancers
p6374
sasa(dp6375
g2
VMurine mammary tumor and metastasis models of EpC40 and 4T1 cells overexpressing different mutant forms of ILEI were used-extended with in vivo aprotinin treatment for the inhibition of ILEI-processing proteases-to test the in vivo relevance of proteolytic cleavage.
p6376
sg4
(lp6377
(dp6378
g7
I107
sg8
I1
sg9
I4
sg10
g11
sg12
VILEI
p6379
sa(dp6380
g7
I107
sg8
I1
sg9
I4
sg10
g11
sg12
VILEI
p6381
sasg24
(lp6382
(dp6383
g7
I25
sg8
I1
sg9
I10
sg27
VC0027627
p6384
sg12
Vmetastasis
p6385
sa(dp6386
g7
I91
sg8
I1
sg9
I6
sg27
VC0596988
p6387
sg12
Vmutant
p6388
sa(dp6389
g7
I7
sg8
I2
sg9
I13
sg27
VC1458155
p6390
sg12
Vmammary tumor
p6391
sasa(dp6392
g2
VImmunohistochemistry for ILEI localization and uPAR expression was performed on two human breast cancer arrays, and ILEI and uPAR scores were correlated with the metastasis-free survival of patients.
p6393
sg4
(lp6394
(dp6395
g7
I25
sg8
I1
sg9
I4
sg10
g11
sg12
VILEI
p6396
sa(dp6397
g7
I25
sg8
I1
sg9
I4
sg10
g11
sg12
VILEI
p6398
sasg24
(lp6399
(dp6400
g7
I162
sg8
I1
sg9
I10
sg27
VC0027627
p6401
sg12
Vmetastasis
p6402
sa(dp6403
g7
I90
sg8
I2
sg9
I13
sg27
VC0678222
p6404
sg12
Vbreast cancer
p6405
sasa(dp6406
g2
VMoreover, altered subcellular ILEI localization strongly correlates with high tumor cell-associated uPAR protein expression, as well as with poor survival, in human breast cancer.
p6407
sg4
(lp6408
sg24
(lp6409
(dp6410
g7
I78
sg8
I1
sg9
I5
sg27
VC0027651
p6411
sg12
Vtumor
p6412
sa(dp6413
g7
I165
sg8
I2
sg9
I13
sg27
VC0678222
p6414
sg12
Vbreast cancer
p6415
sasa(dp6416
g2
VOur findings point out extracellular serine proteases, in particular plasmin, and uPAR as valuable therapeutic targets against ILEI-driven tumor progression and emphasize the prognostic relevance of ILEI localization and a combined ILEI-uPAR marker analysis in human breast cancer.
p6417
sg4
(lp6418
(dp6419
g7
I127
sg8
I1
sg9
I4
sg10
g11
sg12
VILEI
p6420
sa(dp6421
g7
I23
sg8
I3
sg9
I30
sg10
VP30740
p6422
sg12
Vextracellular serine proteases
p6423
sa(dp6424
g7
I69
sg8
I1
sg9
I7
sg10
VP00747
p6425
sg12
Vplasmin
p6426
sa(dp6427
g7
I127
sg8
I1
sg9
I4
sg10
g11
sg12
VILEI
p6428
sa(dp6429
g7
I127
sg8
I1
sg9
I4
sg10
g11
sg12
VILEI
p6430
sasg24
(lp6431
(dp6432
g7
I139
sg8
I2
sg9
I17
sg27
VC0178874
p6433
sg12
Vtumor progression
p6434
sa(dp6435
g7
I267
sg8
I2
sg9
I13
sg27
VC0678222
p6436
sg12
Vbreast cancer
p6437
sasa(dp6438
g2
VILEI is overexpressed and/or altered in intracellular localization in multiple human tumors, an event strongly correlated to invasion/EMT, metastasis formation, and survival in human colon and breast cancer.
p6439
sg4
(lp6440
(dp6441
g7
I134
sg8
I1
sg9
I3
sg10
g11
sg12
VEMT
p6442
sa(dp6443
g7
I0
sg8
I1
sg9
I4
sg10
g11
sg12
VILEI
p6444
sasg24
(lp6445
(dp6446
g7
I139
sg8
I1
sg9
I10
sg27
VC0027627
p6447
sg12
Vmetastasis
p6448
sa(dp6449
g7
I125
sg8
I1
sg9
I8
sg27
VC2699153
p6450
sg12
Vinvasion
p6451
sa(dp6452
g7
I85
sg8
I1
sg9
I6
sg27
VC0027651
p6453
sg12
Vtumors
p6454
sa(dp6455
g7
I193
sg8
I2
sg9
I13
sg27
VC0678222
p6456
sg12
Vbreast cancer
p6457
sasa(dp6458
g2
VKeeping in view the fact that molecular basis of Burkitt's lymphoma (BL) is poorly understood, we attempted to explore the small interfering RNA (siRNA) mediated c-myc gene regulation using BL-derived EB-3 cell line as archetype cellular model.
p6459
sg4
(lp6460
(dp6461
g7
I162
sg8
I2
sg9
I10
sg10
VP12524
p6462
sg12
Vc-myc gene
p6463
sasg24
(lp6464
(dp6465
g7
I49
sg8
I2
sg9
I18
sg27
VC0006413
p6466
sg12
VBurkitt's lymphoma
p6467
sa(dp6468
g7
I69
sg8
I1
sg9
I2
sg27
VC0006413
p6469
sg12
VBL
p6470
sa(dp6471
g7
I69
sg8
I1
sg9
I2
sg27
VC0006413
p6472
sg12
VBL
p6473
sasa(dp6474
g2
VWith other procedures, as anti-complement immunoperoxidase (ACIP) and anti-IgG immunoperoxidase (AIIP) the Epstein-Barr Nuclear Antigen (EBNA) was detected precisely in EB3, Jijoye and Raji lymphocytes using anti-EBNA antibodies from patients with nasopharyngeal carcinoma or Burkitt lymphoma, in dilution 1:10-1:5120.
p6475
sg4
(lp6476
(dp6477
g7
I169
sg8
I1
sg9
I3
sg10
g11
sg12
VEB3
p6478
sa(dp6479
g7
I60
sg8
I1
sg9
I4
sg10
g11
sg12
VACIP
p6480
sa(dp6481
g7
I26
sg8
I2
sg9
I32
sg10
g11
sg12
Vanti-complement immunoperoxidase
p6482
sa(dp6483
g7
I70
sg8
I7
sg9
I65
sg10
VP14209
p6484
sg12
Vanti-IgG immunoperoxidase (AIIP) the Epstein-Barr Nuclear Antigen
p6485
sasg24
(lp6486
(dp6487
g7
I248
sg8
I2
sg9
I24
sg27
VC2931822
p6488
sg12
Vnasopharyngeal carcinoma
p6489
sa(dp6490
g7
I276
sg8
I2
sg9
I16
sg27
VC0006413
p6491
sg12
VBurkitt lymphoma
p6492
sasa(dp6493
g2
VThe virus in the EB-3 cell line derived from a Burkitt lymphoma was partially purified by digestion with proteolytic enzyme and by density-gradient centrifugation on potassium tartrate.
p6494
sg4
(lp6495
sg24
(lp6496
(dp6497
g7
I47
sg8
I2
sg9
I16
sg27
VC0006413
p6498
sg12
VBurkitt lymphoma
p6499
sasa(dp6500
g2
VThis conjugate proved to be a potent cytotoxin for surface Ig positive Burkitt lymphoma EB-3 cells, growing in vitro and produced 50% inhibition of protein synthesis at level of 1.4 x 10(-9) M. When tested for cytotoxic action on target cells, the composite conjugate molecule was at least 100 times more effective than antibodies alone, ricin A-chain alone or a conjugate ricin A-chain--normal rabbit IgG.
p6501
sg4
(lp6502
(dp6503
g7
I395
sg8
I2
sg9
I10
sg10
g11
sg12
Vrabbit IgG
p6504
sa(dp6505
g7
I338
sg8
I2
sg9
I13
sg10
g11
sg12
Vricin A-chain
p6506
sasg24
(lp6507
(dp6508
g7
I71
sg8
I2
sg9
I16
sg27
VC0006413
p6509
sg12
VBurkitt lymphoma
p6510
sasa(dp6511
g2
VThe interaction of poly- and monoclonal antibodies against the L-chain of human Ig with Burkitt lymphoma EB-3 cells was studied using a fluorescent lipid probe, anthrylvinyl-labelled sphingomyelin, incorporated into the cell plasma membrane.
p6512
sg4
(lp6513
sg24
(lp6514
(dp6515
g7
I88
sg8
I2
sg9
I16
sg27
VC0006413
p6516
sg12
VBurkitt lymphoma
p6517
sasa(dp6518
g2
VThe only gangliosides in Burkitt's lymphoma EB-3 cells is GM3.
p6519
sg4
(lp6520
sg24
(lp6521
(dp6522
g7
I25
sg8
I2
sg9
I18
sg27
VC0006413
p6523
sg12
VBurkitt's lymphoma
p6524
sasa(dp6525
g2
VTreatment of Burkitt's lymphoma EB-3 cells with gangliosides GM1 or GM3 results in their binding to and partial incorporation into the cell membrane.
p6526
sg4
(lp6527
sg24
(lp6528
(dp6529
g7
I13
sg8
I2
sg9
I18
sg27
VC0006413
p6530
sg12
VBurkitt's lymphoma
p6531
sasa(dp6532
g2
VWe sought to investigate the renoprotection of CIRP in a rat model of deep hypothermic circulatory arrest.
p6533
sg4
(lp6534
(dp6535
g7
I47
sg8
I1
sg9
I4
sg10
g11
sg12
VCIRP
p6536
sasg24
(lp6537
(dp6538
g7
I87
sg8
I2
sg9
I18
sg27
VC0444720
p6539
sg12
Vcirculatory arrest
p6540
sasa(dp6541
g2
VOverexpression and knockdown of CIRP were achieved in vivo by directly injecting lentivirus vectors containing packaging lentivirus (pL)/internal ribosome entry site (IRES)/green fluorescent protein (GFP)-CIRP or pL/short hairpin RNA (shRNA)/F-cold inducible RNA binding protein (F-CIRP)-A into the renal parenchyma of rats 7 days before deep hypothermic circulatory arrest under the ultrasound guidance.
p6542
sg4
(lp6543
(dp6544
g7
I173
sg8
I3
sg9
I25
sg10
g11
sg12
Vgreen fluorescent protein
p6545
sa(dp6546
g7
I241
sg8
I5
sg9
I37
sg10
g11
sg12
V/F-cold inducible RNA binding protein
p6547
sa(dp6548
g7
I280
sg8
I1
sg9
I6
sg10
g11
sg12
VF-CIRP
p6549
sa(dp6550
g7
I32
sg8
I1
sg9
I4
sg10
g11
sg12
VCIRP
p6551
sasg24
(lp6552
(dp6553
g7
I244
sg8
I1
sg9
I4
sg27
VC0024117
p6554
sg12
Vcold
p6555
sa(dp6556
g7
I355
sg8
I2
sg9
I18
sg27
VC0444720
p6557
sg12
Vcirculatory arrest
p6558
sasa(dp6559
g2
VOur findings suggest that the CIRP exerts a robust renoprotective effect by inhibiting apoptosis in the rat model of deep hypothermic circulatory arrest.
p6560
sg4
(lp6561
(dp6562
g7
I30
sg8
I1
sg9
I4
sg10
g11
sg12
VCIRP
p6563
sasg24
(lp6564
(dp6565
g7
I134
sg8
I2
sg9
I18
sg27
VC0444720
p6566
sg12
Vcirculatory arrest
p6567
sasa(dp6568
g2
VCompared with baseline, rats resuscitated from cardiac arrest showed increased expression of CIRP, Bax, Caspase 9, and Caspase 3 and decreased expression of Bcl-2 in hippocampus (P &lt; 0.05).
p6569
sg4
(lp6570
(dp6571
g7
I157
sg8
I1
sg9
I5
sg10
VP10415
p6572
sg12
VBcl-2
p6573
sa(dp6574
g7
I119
sg8
I2
sg9
I9
sg10
VP42574
p6575
sg12
VCaspase 3
p6576
sa(dp6577
g7
I93
sg8
I1
sg9
I4
sg10
g11
sg12
VCIRP
p6578
sa(dp6579
g7
I104
sg8
I2
sg9
I9
sg10
VP55211
p6580
sg12
VCaspase 9
p6581
sasg24
(lp6582
(dp6583
g7
I47
sg8
I2
sg9
I14
sg27
VC0018790
p6584
sg12
Vcardiac arrest
p6585
sasa(dp6586
g2
VOur findings suggest that 32 C therapeutic hypothermia exerts an important neuroprotective effects by up-regulating CIRP expression and inhibiting mitochondrial apoptosis factor production in the cardiac arrest rat model.
p6587
sg4
(lp6588
(dp6589
g7
I116
sg8
I1
sg9
I4
sg10
g11
sg12
VCIRP
p6590
sasg24
(lp6591
(dp6592
g7
I196
sg8
I2
sg9
I14
sg27
VC0018790
p6593
sg12
Vcardiac arrest
p6594
sasa(dp6595
g2
VA previously reported expression signature of three genes (IGFBP3, F3 and VGLL3) was shown to have potential prognostic value in estimating overall and cancer-specific survivals at diagnosis of prostate cancer in a pilot cohort study using freshly frozen Fine Needle Aspiration (FNA) samples.
p6596
sg4
(lp6597
(dp6598
g7
I74
sg8
I1
sg9
I5
sg10
g11
sg12
VVGLL3
p6599
sa(dp6600
g7
I59
sg8
I1
sg9
I6
sg10
VP17936
p6601
sg12
VIGFBP3
p6602
sasg24
(lp6603
(dp6604
g7
I194
sg8
I2
sg9
I15
sg27
VC0600139
p6605
sg12
Vprostate cancer
p6606
sa(dp6607
g7
I267
sg8
I1
sg9
I10
sg27
VC0700198
p6608
sg12
VAspiration
p6609
sa(dp6610
g7
I152
sg8
I1
sg9
I6
sg27
VC0006826
p6611
sg12
Vcancer
p6612
sasa(dp6613
g2
VMultiple biopsy samples from 43 patients were evaluated using a previously reported gene signature of IGFBP3, F3 and VGLL3 with potential prognostic value in estimating overall survival at diagnosis of prostate cancer.
p6614
sg4
(lp6615
(dp6616
g7
I117
sg8
I1
sg9
I5
sg10
g11
sg12
VVGLL3
p6617
sa(dp6618
g7
I102
sg8
I1
sg9
I6
sg10
VP17936
p6619
sg12
VIGFBP3
p6620
sasg24
(lp6621
(dp6622
g7
I202
sg8
I2
sg9
I15
sg27
VC0600139
p6623
sg12
Vprostate cancer
p6624
sasa(dp6625
g2
VThe gene expression levels of IGFBP3 and F3 in prostate cancer epithelial cell-containing tissue representing the primary and secondary Gleason patterns were high and consistent, while the low expressed VGLL3 showed more variation in its expression levels.
p6626
sg4
(lp6627
(dp6628
g7
I203
sg8
I1
sg9
I5
sg10
g11
sg12
VVGLL3
p6629
sa(dp6630
g7
I30
sg8
I1
sg9
I6
sg10
VP17936
p6631
sg12
VIGFBP3
p6632
sasg24
(lp6633
(dp6634
g7
I47
sg8
I2
sg9
I15
sg27
VC0600139
p6635
sg12
Vprostate cancer
p6636
sasa(dp6637
g2
VPrevious studies have implicated vestigial like 3 (VGLL3), a chromosome 3p12.3 gene that encodes a putative transcription co-factor, as a candidate tumor suppressor gene (TSG) in high-grade serous ovarian carcinomas (HGSC), the most common type of epithelial ovarian cancer.
p6638
sg4
(lp6639
(dp6640
g7
I171
sg8
I1
sg9
I3
sg10
g11
sg12
VTSG
p6641
sa(dp6642
g7
I33
sg8
I3
sg9
I16
sg10
g11
sg12
Vvestigial like 3
p6643
sa(dp6644
g7
I148
sg8
I3
sg9
I21
sg10
VP25054
p6645
sg12
Vtumor suppressor gene
p6646
sa(dp6647
g7
I51
sg8
I1
sg9
I5
sg10
g11
sg12
VVGLL3
p6648
sasg24
(lp6649
(dp6650
g7
I248
sg8
I3
sg9
I25
sg27
VC0677886
p6651
sg12
Vepithelial ovarian cancer
p6652
sa(dp6653
g7
I148
sg8
I1
sg9
I5
sg27
VC0027651
p6654
sg12
Vtumor
p6655
sa(dp6656
g7
I197
sg8
I2
sg9
I18
sg27
VC0029925
p6657
sg12
Vovarian carcinomas
p6658
sasa(dp6659
g2
VA complementation analysis based on microcell-mediated chromosome transfer (MMCT) using a centric fragment of chromosome 3 (der3p12-q12.1) into the OV-90 ovarian cancer cell line haploinsufficient for 3p and lacking VGLL3 expression was performed to assess the effect on tumorigenic potential and growth characteristics.
p6660
sg4
(lp6661
(dp6662
g7
I216
sg8
I1
sg9
I5
sg10
g11
sg12
VVGLL3
p6663
sasg24
(lp6664
(dp6665
g7
I154
sg8
I2
sg9
I14
sg27
VC1140680
p6666
sg12
Vovarian cancer
p6667
sasa(dp6668
g2
VInterestingly, underexpression of VGLL3 and ZNF654 were observed in malignant ovarian tumor samples as compared with primary cultures of normal ovarian surface epithelial cells or benign ovarian tumors, and this occurred regardless of allelic content of 3p12.3-pcen.
p6669
sg4
(lp6670
(dp6671
g7
I44
sg8
I1
sg9
I6
sg10
g11
sg12
VZNF654
p6672
sa(dp6673
g7
I34
sg8
I1
sg9
I5
sg10
g11
sg12
VVGLL3
p6674
sasg24
(lp6675
(dp6676
g7
I68
sg8
I3
sg9
I23
sg27
VC1140680
p6677
sg12
Vmalignant ovarian tumor
p6678
sa(dp6679
g7
I180
sg8
I3
sg9
I21
sg27
VC0004997
p6680
sg12
Vbenign ovarian tumors
p6681
sasa(dp6682
g2
VWe tested the effects of the MEK inhibitor RDEA119, the Akt inhibitor perifosine, and the HDAC inhibitor SAHA on NIS expression in thirteen human cancer cell lines derived from melanoma, hepatic carcinoma, gastric carcinoma, colon carcinoma, breast carcinoma, and brain cancers.
p6683
sg4
(lp6684
(dp6685
g7
I90
sg8
I1
sg9
I4
sg10
VP56524
p6686
sg12
VHDAC
p6687
sa(dp6688
g7
I29
sg8
I1
sg9
I3
sg10
VP45985
p6689
sg12
VMEK
p6690
sa(dp6691
g7
I56
sg8
I1
sg9
I3
sg10
g11
sg12
VAkt
p6692
sasg24
(lp6693
(dp6694
g7
I206
sg8
I2
sg9
I17
sg27
VC0699791
p6695
sg12
Vgastric carcinoma
p6696
sa(dp6697
g7
I187
sg8
I2
sg9
I17
sg27
VC2239176
p6698
sg12
Vhepatic carcinoma
p6699
sa(dp6700
g7
I146
sg8
I1
sg9
I6
sg27
VC0006826
p6701
sg12
Vcancer
p6702
sa(dp6703
g7
I225
sg8
I2
sg9
I15
sg27
VC0699790
p6704
sg12
Vcolon carcinoma
p6705
sa(dp6706
g7
I177
sg8
I1
sg9
I8
sg27
VC0025202
p6707
sg12
Vmelanoma
p6708
sa(dp6709
g7
I264
sg8
I2
sg9
I13
sg27
VC0153633
p6710
sg12
Vbrain cancers
p6711
sa(dp6712
g7
I242
sg8
I2
sg9
I16
sg27
VC0678222
p6713
sg12
Vbreast carcinoma
p6714
sasa(dp6715
g2
VHere, we report that escape of human T-cell acute lymphoblastic leukemia (T-ALL) cells or colorectal cancer cells from dormancy is associated with Dll4 expression in the tumor microenvironment and increased Notch3 signaling in tumor cells.
p6716
sg4
(lp6717
(dp6718
g7
I207
sg8
I1
sg9
I6
sg10
g11
sg12
VNotch3
p6719
sa(dp6720
g7
I147
sg8
I1
sg9
I4
sg10
g11
sg12
VDll4
p6721
sasg24
(lp6722
(dp6723
g7
I170
sg8
I1
sg9
I5
sg27
VC0027651
p6724
sg12
Vtumor
p6725
sa(dp6726
g7
I37
sg8
I4
sg9
I35
sg27
VC1961099
p6727
sg12
VT-cell acute lymphoblastic leukemia
p6728
sa(dp6729
g7
I170
sg8
I1
sg9
I5
sg27
VC0027651
p6730
sg12
Vtumor
p6731
sa(dp6732
g7
I90
sg8
I2
sg9
I17
sg27
VC1527249
p6733
sg12
Vcolorectal cancer
p6734
sa(dp6735
g7
I74
sg8
I1
sg9
I5
sg27
VC1961099
p6736
sg12
VT-ALL
p6737
sasa(dp6738
g2
VAPOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.
p6739
sg4
(lp6740
(dp6741
g7
I0
sg8
I1
sg9
I7
sg10
VP41238
p6742
sg12
VAPOBEC1
p6743
sasg24
(lp6744
(dp6745
g7
I142
sg8
I1
sg9
I9
sg27
VC0012634
p6746
sg12
Vcondition
p6747
sa(dp6748
g7
I74
sg8
I1
sg9
I14
sg27
VC0596263
p6749
sg12
Vcarcinogenesis
p6750
sa(dp6751
g7
I29
sg8
I1
sg9
I6
sg27
VC0006826
p6752
sg12
Vcancer
p6753
sa(dp6754
g7
I174
sg8
I2
sg9
I25
sg27
VC0279628
p6755
sg12
Vesophageal adenocarcinoma
p6756
sa(dp6757
g7
I119
sg8
I2
sg9
I19
sg27
VC0004763
p6758
sg12
VBarrett's esophagus
p6759
sasa(dp6760
g2
VThe differential diagnosis includes Klippel-Trenaunay-Weber syndrome, neurofibromatosis, Milroy disease, and Proteus syndrome.
p6761
sg4
(lp6762
sg24
(lp6763
(dp6764
g7
I109
sg8
I2
sg9
I16
sg27
VC0085261
p6765
sg12
VProteus syndrome
p6766
sa(dp6767
g7
I60
sg8
I2
sg9
I27
sg27
VC0162678
p6768
sg12
Vsyndrome, neurofibromatosis
p6769
sa(dp6770
g7
I89
sg8
I2
sg9
I14
sg27
VC1704423
p6771
sg12
VMilroy disease
p6772
sa(dp6773
g7
I36
sg8
I2
sg9
I32
sg27
VC0022739
p6774
sg12
VKlippel-Trenaunay-Weber syndrome
p6775
sasa(dp6776
g2
VNotably, new experimental data have shown protective immune responses of bee venom group III sPLA2 against a wide range of diseases including asthma, Parkinson's disease, and drug-induced organ inflammation.
p6777
sg4
(lp6778
sg24
(lp6779
(dp6780
g7
I194
sg8
I1
sg9
I12
sg27
VC0021368
p6781
sg12
Vinflammation
p6782
sa(dp6783
g7
I142
sg8
I1
sg9
I6
sg27
VC0004096
p6784
sg12
Vasthma
p6785
sa(dp6786
g7
I150
sg8
I2
sg9
I19
sg27
VC0030567
p6787
sg12
VParkinson's disease
p6788
sasa(dp6789
g2
VSnake venom are known containing PLA2s (svPLA2s) which exhibit a wide variety of pharmacological effects including neurotoxicity, cardiotoxicity, myotoxicity and hemorrhage.
p6790
sg4
(lp6791
(dp6792
g7
I33
sg8
I1
sg9
I5
sg10
VP04054
p6793
sg12
VPLA2s
p6794
sasg24
(lp6795
(dp6796
g7
I162
sg8
I1
sg9
I10
sg27
VC0019080
p6797
sg12
Vhemorrhage
p6798
sasa(dp6799
g2
VThis study was aimed to assess regulation of surface-membrane enzymes such as Delta-6-desaturase (FADS2), secretory Phospholipase A2(sPLA2) by hemp seed and evening primrose oils as well as Hot-natured dietary intervention in relapsing remitting multiple sclerosis (RRMS) patients.
p6800
sg4
(lp6801
(dp6802
g7
I78
sg8
I1
sg9
I18
sg10
g11
sg12
VDelta-6-desaturase
p6803
sa(dp6804
g7
I116
sg8
I2
sg9
I16
sg10
VP04054
p6805
sg12
VPhospholipase A2
p6806
sa(dp6807
g7
I133
sg8
I1
sg9
I5
sg10
VP14555
p6808
sg12
VsPLA2
p6809
sa(dp6810
g7
I98
sg8
I1
sg9
I5
sg10
g11
sg12
VFADS2
p6811
sasg24
(lp6812
(dp6813
g7
I266
sg8
I1
sg9
I4
sg27
VC0751967
p6814
sg12
VRRMS
p6815
sa(dp6816
g7
I226
sg8
I4
sg9
I38
sg27
VC0751967
p6817
sg12
Vrelapsing remitting multiple sclerosis
p6818
sasa(dp6819
g2
VPhospholipases A2 (PLA2s) are enzymes responsible for inflammatory effects, edema formation, myotoxicity, neurotoxicity and other manifestations from envenoming.
p6820
sg4
(lp6821
(dp6822
g7
I0
sg8
I2
sg9
I17
sg10
VP04054
p6823
sg12
VPhospholipases A2
p6824
sa(dp6825
g7
I19
sg8
I1
sg9
I5
sg10
VP04054
p6826
sg12
VPLA2s
p6827
sasg24
(lp6828
(dp6829
g7
I76
sg8
I1
sg9
I5
sg27
VC0013604
p6830
sg12
Vedema
p6831
sasa(dp6832
g2
VDefects of CIB2, calcium- and integrin-binding protein 2, have been reported to cause isolated deafness, DFNB48 and Usher syndrome type-IJ, characterized by congenital profound deafness, balance defects and blindness.
p6833
sg4
(lp6834
(dp6835
g7
I30
sg8
I3
sg9
I26
sg10
g11
sg12
Vintegrin-binding protein 2
p6836
sa(dp6837
g7
I11
sg8
I1
sg9
I4
sg10
g11
sg12
VCIB2
p6838
sasg24
(lp6839
(dp6840
g7
I116
sg8
I2
sg9
I14
sg27
VC0271097
p6841
sg12
VUsher syndrome
p6842
sa(dp6843
g7
I207
sg8
I1
sg9
I9
sg27
VC0456909
p6844
sg12
Vblindness
p6845
sa(dp6846
g7
I95
sg8
I1
sg9
I8
sg27
VC0011053
p6847
sg12
Vdeafness
p6848
sa(dp6849
g7
I105
sg8
I1
sg9
I6
sg27
VC1836199
p6850
sg12
VDFNB48
p6851
sa(dp6852
g7
I95
sg8
I1
sg9
I8
sg27
VC0011053
p6853
sg12
Vdeafness
p6854
sasa(dp6855
g2
VHere, we report that mutations in CIB2, which encodes a calcium- and integrin-binding protein, are associated with nonsyndromic deafness (DFNB48) and Usher syndrome type 1J (USH1J).
p6856
sg4
(lp6857
(dp6858
g7
I34
sg8
I1
sg9
I4
sg10
g11
sg12
VCIB2
p6859
sa(dp6860
g7
I69
sg8
I2
sg9
I24
sg10
g11
sg12
Vintegrin-binding protein
p6861
sasg24
(lp6862
(dp6863
g7
I150
sg8
I2
sg9
I14
sg27
VC0271097
p6864
sg12
VUsher syndrome
p6865
sa(dp6866
g7
I138
sg8
I1
sg9
I6
sg27
VC1836199
p6867
sg12
VDFNB48
p6868
sa(dp6869
g7
I128
sg8
I1
sg9
I8
sg27
VC0011053
p6870
sg12
Vdeafness
p6871
sasa(dp6872
g2
VIn polymyositis and inclusion body myositis, KIF4 cells were mainly located around individual muscle fibers, whereas in dermatomyositis, they were also near blood vessels.
p6873
sg4
(lp6874
(dp6875
g7
I45
sg8
I1
sg9
I4
sg10
g11
sg12
VKIF4
p6876
sasg24
(lp6877
(dp6878
g7
I3
sg8
I1
sg9
I12
sg27
VC0085655
p6879
sg12
Vpolymyositis
p6880
sa(dp6881
g7
I120
sg8
I1
sg9
I15
sg27
VC0221056
p6882
sg12
Vdermatomyositis
p6883
sa(dp6884
g7
I20
sg8
I3
sg9
I23
sg27
VC0238190
p6885
sg12
Vinclusion body myositis
p6886
sasa(dp6887
g2
VCD9 expression obviously increased bortezomib sensitivity through inducing apoptosis, significantly inhibiting U266 cells' adhesion to HS-5 and primary bone marrow stromal cells, but increasing U266 cells' adhesion to fibronectin.
p6888
sg4
(lp6889
(dp6890
g7
I0
sg8
I1
sg9
I3
sg10
VP21926
p6891
sg12
VCD9
p6892
sasg24
(lp6893
(dp6894
g7
I123
sg8
I1
sg9
I8
sg27
VC0001511
p6895
sg12
Vadhesion
p6896
sa(dp6897
g7
I123
sg8
I1
sg9
I8
sg27
VC0001511
p6898
sg12
Vadhesion
p6899
sasa(dp6900
g2
VThe immunoprofiles of MOLP-6 and MOLP-7 correspond to that seen typically in primary MM cells: positive for cytoplasmic immunoglobulin (Ig) chains, a heavy and kappa light chains, CD9, CD28, CD40, CD44, CD45, CD56, and PCA-1; the cells were negative for surface Igs and various other B-cell, T-cell and myelomonocyte associated markers.
p6901
sg4
(lp6902
(dp6903
g7
I203
sg8
I1
sg9
I4
sg10
VP08575
p6904
sg12
VCD45
p6905
sa(dp6906
g7
I219
sg8
I1
sg9
I5
sg10
g11
sg12
VPCA-1
p6907
sa(dp6908
g7
I180
sg8
I1
sg9
I3
sg10
VP21926
p6909
sg12
VCD9
p6910
sa(dp6911
g7
I191
sg8
I1
sg9
I4
sg10
VP25942
p6912
sg12
VCD40
p6913
sa(dp6914
g7
I150
sg8
I5
sg9
I28
sg10
g11
sg12
Vheavy and kappa light chains
p6915
sa(dp6916
g7
I185
sg8
I1
sg9
I4
sg10
VP33681
p6917
sg12
VCD28
p6918
sa(dp6919
g7
I262
sg8
I1
sg9
I3
sg10
g11
sg12
VIgs
p6920
sa(dp6921
g7
I108
sg8
I4
sg9
I38
sg10
g11
sg12
Vcytoplasmic immunoglobulin (Ig) chains
p6922
sasg24
(lp6923
(dp6924
g7
I262
sg8
I1
sg9
I3
sg27
VC1306856
p6925
sg12
VIgs
p6926
sa(dp6927
g7
I219
sg8
I1
sg9
I3
sg27
VC0268398
p6928
sg12
VPCA
p6929
sasa(dp6930
g2
VThe univariate analysis showed that five parameters had an adverse effect on both complete remission (CR) and survival: advanced age (greater than 60 years), anemia (hemoglobin concentration (Hb) less than 10g/dl), the expression of the antigens detected by the anti-megakaryocytic antibodies (CDw41/CDw42), the monocytic antibodies (CD14), and the CD9 (FMC56, FMC8) antigen.
p6931
sg4
(lp6932
(dp6933
g7
I166
sg8
I1
sg9
I10
sg10
g11
sg12
Vhemoglobin
p6934
sa(dp6935
g7
I349
sg8
I1
sg9
I3
sg10
VP21926
p6936
sg12
VCD9
p6937
sa(dp6938
g7
I334
sg8
I1
sg9
I4
sg10
VP08571
p6939
sg12
VCD14
p6940
sasg24
(lp6941
(dp6942
g7
I59
sg8
I2
sg9
I14
sg27
VC0879626
p6943
sg12
Vadverse effect
p6944
sa(dp6945
g7
I158
sg8
I1
sg9
I6
sg27
VC0002871
p6946
sg12
Vanemia
p6947
sa(dp6948
g7
I91
sg8
I1
sg9
I9
sg27
VC0687702
p6949
sg12
Vremission
p6950
sasa(dp6951
g2
VIn this review, we consider the following paraneoplastic hormonal syndromes: malign hypercalcaemia, hyponatraemia (inappropiate secretion of the antidiuretic hormone), ectopic Cushing's syndrome, ectopic acromegaly, hypoglycaemia due to tumours different from those of the islet cells and paraneoplastic gynaecomastia; we make a brief final reference to other hormones (calcitonin, somatostatin, and VIP).
p6952
sg4
(lp6953
(dp6954
g7
I382
sg8
I1
sg9
I12
sg10
VP61278
p6955
sg12
Vsomatostatin
p6956
sa(dp6957
g7
I370
sg8
I1
sg9
I10
sg10
VP06881
p6958
sg12
Vcalcitonin
p6959
sa(dp6960
g7
I400
sg8
I1
sg9
I3
sg10
VP01282
p6961
sg12
VVIP
p6962
sasg24
(lp6963
(dp6964
g7
I216
sg8
I1
sg9
I13
sg27
VC0020615
p6965
sg12
Vhypoglycaemia
p6966
sa(dp6967
g7
I176
sg8
I2
sg9
I18
sg27
VC0010481
p6968
sg12
VCushing's syndrome
p6969
sa(dp6970
g7
I204
sg8
I1
sg9
I10
sg27
VC0001206
p6971
sg12
Vacromegaly
p6972
sa(dp6973
g7
I84
sg8
I1
sg9
I14
sg27
VC0020437
p6974
sg12
Vhypercalcaemia
p6975
sa(dp6976
g7
I66
sg8
I1
sg9
I9
sg27
VC0039082
p6977
sg12
Vsyndromes
p6978
sa(dp6979
g7
I237
sg8
I1
sg9
I7
sg27
VC0027651
p6980
sg12
Vtumours
p6981
sa(dp6982
g7
I304
sg8
I1
sg9
I13
sg27
VC0018418
p6983
sg12
Vgynaecomastia
p6984
sasa(dp6985
g2
VProtrudin was found to interact with other HSP-related proteins including myelin proteolipid protein 1 (SPG2), atlastin-1 (SPG3A), REEP1 (SPG31), REEP5 (similar to REEP1), Kif5A (SPG10), Kif5B, Kif5C, and reticulon 1, 3, and 4 (similar to reticulon 2, SPG12).
p6986
sg4
(lp6987
(dp6988
g7
I138
sg8
I1
sg9
I5
sg10
g11
sg12
VSPG31
p6989
sa(dp6990
g7
I187
sg8
I1
sg9
I5
sg10
VP33176
p6991
sg12
VKif5B
p6992
sa(dp6993
g7
I146
sg8
I1
sg9
I5
sg10
g11
sg12
VREEP5
p6994
sa(dp6995
g7
I111
sg8
I1
sg9
I10
sg10
g11
sg12
Vatlastin-1
p6996
sa(dp6997
g7
I74
sg8
I4
sg9
I28
sg10
VP60201
p6998
sg12
Vmyelin proteolipid protein 1
p6999
sa(dp7000
g7
I43
sg8
I2
sg9
I20
sg10
g11
sg12
VHSP-related proteins
p7001
sa(dp7002
g7
I131
sg8
I1
sg9
I5
sg10
g11
sg12
VREEP1
p7003
sa(dp7004
g7
I179
sg8
I1
sg9
I5
sg10
g11
sg12
VSPG10
p7005
sa(dp7006
g7
I172
sg8
I1
sg9
I5
sg10
g11
sg12
VKif5A
p7007
sa(dp7008
g7
I123
sg8
I1
sg9
I5
sg10
g11
sg12
VSPG3A
p7009
sa(dp7010
g7
I131
sg8
I1
sg9
I5
sg10
g11
sg12
VREEP1
p7011
sa(dp7012
g7
I194
sg8
I1
sg9
I5
sg10
g11
sg12
VKif5C
p7013
sa(dp7014
g7
I104
sg8
I1
sg9
I4
sg10
VP60201
p7015
sg12
VSPG2
p7016
sasg24
(lp7017
(dp7018
g7
I138
sg8
I1
sg9
I5
sg27
VC1853247
p7019
sg12
VSPG31
p7020
sa(dp7021
g7
I179
sg8
I1
sg9
I5
sg27
VC1858712
p7022
sg12
VSPG10
p7023
sa(dp7024
g7
I123
sg8
I1
sg9
I5
sg27
VC2931355
p7025
sg12
VSPG3A
p7026
sa(dp7027
g7
I104
sg8
I1
sg9
I4
sg27
VC1839264
p7028
sg12
VSPG2
p7029
sa(dp7030
g7
I43
sg8
I1
sg9
I3
sg27
VC0034152
p7031
sg12
VHSP
p7032
sa(dp7033
g7
I252
sg8
I1
sg9
I5
sg27
VC1858106
p7034
sg12
VSPG12
p7035
sasa(dp7036
g2
VDownregulation of ACE2 is always associated with the ALI or ARDS induced by avian influenza virus, severe acute respiratory syndrome-coronavirus, respiratory syncytial virus and sepsis.
p7037
sg4
(lp7038
(dp7039
g7
I18
sg8
I1
sg9
I4
sg10
g11
sg12
VACE2
p7040
sasg24
(lp7041
(dp7042
g7
I178
sg8
I1
sg9
I6
sg27
VC0243026
p7043
sg12
Vsepsis
p7044
sa(dp7045
g7
I60
sg8
I1
sg9
I4
sg27
VC0035222
p7046
sg12
VARDS
p7047
sa(dp7048
g7
I99
sg8
I4
sg9
I33
sg27
VC1175175
p7049
sg12
Vsevere acute respiratory syndrome
p7050
sa(dp7051
g7
I76
sg8
I2
sg9
I15
sg27
VC0016627
p7052
sg12
Vavian influenza
p7053
sasa(dp7054
g2
VA virus infection assay showed that rWIV1-DeltaX replicated as efficiently as rWIV1 in Vero E6, Calu-3, and HeLa-hACE2 cells.
p7055
sg4
(lp7056
(dp7057
g7
I96
sg8
I1
sg9
I6
sg10
g11
sg12
VCalu-3
p7058
sasg24
(lp7059
(dp7060
g7
I2
sg8
I2
sg9
I15
sg27
VC0042769
p7061
sg12
Vvirus infection
p7062
sasa(dp7063
g2
VResults show that 106 cases of tetanus occurred in Aceh, with a case fatality ratio (CFR) of 18.9%; 71 cases occurred in Yogyakarta, with CFR of 36.6%.
p7064
sg4
(lp7065
sg24
(lp7066
(dp7067
g7
I31
sg8
I1
sg9
I7
sg27
VC0039614
p7068
sg12
Vtetanus
p7069
sasa(dp7070
g2
VTreatment of (DR-BB x WF)F1 x WF animals (all lyp+/+) using a standard induction protocol caused type 1 diabetes in 58% of progeny.
p7071
sg4
(lp7072
sg24
(lp7073
(dp7074
g7
I97
sg8
I3
sg9
I15
sg27
VC0011854
p7075
sg12
Vtype 1 diabetes
p7076
sasa(dp7077
g2
VAll genetic analyses of BB rat diabetes to date have backcrossed to the DP-BB strain or used (DP-BB x non-BB)F2 animals to ensure that a fraction of progeny are homozygous for lyp.
p7078
sg4
(lp7079
(dp7080
g7
I176
sg8
I1
sg9
I3
sg10
g11
sg12
Vlyp
p7081
sasg24
(lp7082
(dp7083
g7
I31
sg8
I1
sg9
I8
sg27
VC0011849
p7084
sg12
Vdiabetes
p7085
sa(dp7086
g7
I176
sg8
I1
sg9
I3
sg27
VC1868674
p7087
sg12
Vlyp
p7088
sasa(dp7089
g2
VSince, type 1 diabetes is characterised by hyperglycaemia we analysed 22 diabetic and 43 non-diabetic [(BB x SHR)FI x BB] backcross hybrids (28M:37F) which were already homozygous for Iddml and Iddm2 to search for quantitative trait loci (QTLs) affecting blood glucose in BB/OK rats.
p7090
sg4
(lp7091
(dp7092
g7
I194
sg8
I1
sg9
I5
sg10
VP01308
p7093
sg12
VIddm2
p7094
sasg24
(lp7095
(dp7096
g7
I43
sg8
I1
sg9
I14
sg27
VC0020456
p7097
sg12
Vhyperglycaemia
p7098
sa(dp7099
g7
I7
sg8
I3
sg9
I15
sg27
VC0011854
p7100
sg12
Vtype 1 diabetes
p7101
sa(dp7102
g7
I194
sg8
I1
sg9
I5
sg27
VC1852092
p7103
sg12
VIddm2
p7104
sasa(dp7105
g2
VThis prompted us to investigate the inheritance of IDDM in two subpopulations of BB rats (BB/OK and BB/PhiK) by crossing studies with the production of (diabetic BB x LEW 1.A) F1, F2 generations and of first backcross hybrids onto BB (B1BB) and LEW.1A (B1A) rats respectively.
p7106
sg4
(lp7107
sg24
(lp7108
(dp7109
g7
I51
sg8
I1
sg9
I4
sg27
VC0011854
p7110
sg12
VIDDM
p7111
sasa(dp7112
g2
VLRRK2 selectively interacts with three Beta-tubulin isoforms: TUBB, TUBB4, and TUBB6, one of which (TUBB4) is mutated in the movement disorder dystonia type 4 (DYT4).
p7113
sg4
(lp7114
(dp7115
g7
I79
sg8
I1
sg9
I5
sg10
g11
sg12
VTUBB6
p7116
sa(dp7117
g7
I0
sg8
I1
sg9
I5
sg10
g11
sg12
VLRRK2
p7118
sa(dp7119
g7
I39
sg8
I2
sg9
I21
sg10
VP68371
p7120
sg12
VBeta-tubulin isoforms
p7121
sa(dp7122
g7
I68
sg8
I1
sg9
I5
sg10
VP04350
p7123
sg12
VTUBB4
p7124
sa(dp7125
g7
I62
sg8
I1
sg9
I4
sg10
VP04350
p7126
sg12
VTUBB
p7127
sa(dp7128
g7
I68
sg8
I1
sg9
I5
sg10
VP04350
p7129
sg12
VTUBB4
p7130
sasg24
(lp7131
(dp7132
g7
I125
sg8
I2
sg9
I17
sg27
VC0026650
p7133
sg12
Vmovement disorder
p7134
sa(dp7135
g7
I160
sg8
I1
sg9
I4
sg27
VC1851943
p7136
sg12
VDYT4
p7137
sa(dp7138
g7
I143
sg8
I3
sg9
I15
sg27
VC1851943
p7139
sg12
Vdystonia type 4
p7140
sasa(dp7141
g2
VIn this study, we aimed to analyze pairwise interactions that are associated with Body Mass Index (BMI) between SNPs from twelve genes robustly associated with obesity (BDNF, ETV5, FAIM2, FTO, GNPDA2, KCTD15, MC4R, MTCH2, NEGR1, SEC16B, SH2B1, and TMEM18).
p7142
sg4
(lp7143
(dp7144
g7
I209
sg8
I1
sg9
I4
sg10
VP32245
p7145
sg12
VMC4R
p7146
sa(dp7147
g7
I188
sg8
I1
sg9
I3
sg10
g11
sg12
VFTO
p7148
sa(dp7149
g7
I222
sg8
I1
sg9
I5
sg10
g11
sg12
VNEGR1
p7150
sa(dp7151
g7
I175
sg8
I1
sg9
I4
sg10
VP41161
p7152
sg12
VETV5
p7153
sa(dp7154
g7
I229
sg8
I1
sg9
I6
sg10
g11
sg12
VSEC16B
p7155
sa(dp7156
g7
I181
sg8
I1
sg9
I5
sg10
g11
sg12
VFAIM2
p7157
sa(dp7158
g7
I193
sg8
I1
sg9
I6
sg10
g11
sg12
VGNPDA2
p7159
sa(dp7160
g7
I237
sg8
I1
sg9
I5
sg10
g11
sg12
VSH2B1
p7161
sa(dp7162
g7
I248
sg8
I1
sg9
I6
sg10
g11
sg12
VTMEM18
p7163
sa(dp7164
g7
I201
sg8
I1
sg9
I6
sg10
g11
sg12
VKCTD15
p7165
sa(dp7166
g7
I215
sg8
I1
sg9
I5
sg10
g11
sg12
VMTCH2
p7167
sasg24
(lp7168
(dp7169
g7
I160
sg8
I1
sg9
I7
sg27
VC0028754
p7170
sg12
Vobesity
p7171
sasa(dp7172
g2
VIn total, 15 loci reached genome-wide significance (P-value &lt; 5 x 10(-8)) in the joint discovery and replication analysis, of which 12 are previously identified loci in or close to ADCY3, GNPDA2, TMEM18, SEC16B, FAIM2, FTO, TFAP2B, TNNI3K, MC4R, GPR61, LMX1B and OLFM4 associated with adult body mass index or childhood obesity.
p7173
sg4
(lp7174
(dp7175
g7
I256
sg8
I1
sg9
I5
sg10
g11
sg12
VLMX1B
p7176
sa(dp7177
g7
I222
sg8
I1
sg9
I3
sg10
g11
sg12
VFTO
p7178
sa(dp7179
g7
I199
sg8
I1
sg9
I6
sg10
g11
sg12
VTMEM18
p7180
sa(dp7181
g7
I215
sg8
I1
sg9
I5
sg10
g11
sg12
VFAIM2
p7182
sa(dp7183
g7
I266
sg8
I1
sg9
I5
sg10
g11
sg12
VOLFM4
p7184
sa(dp7185
g7
I227
sg8
I1
sg9
I6
sg10
g11
sg12
VTFAP2B
p7186
sa(dp7187
g7
I243
sg8
I1
sg9
I4
sg10
VP32245
p7188
sg12
VMC4R
p7189
sa(dp7190
g7
I191
sg8
I1
sg9
I6
sg10
g11
sg12
VGNPDA2
p7191
sa(dp7192
g7
I207
sg8
I1
sg9
I6
sg10
g11
sg12
VSEC16B
p7193
sa(dp7194
g7
I184
sg8
I1
sg9
I5
sg10
VP40145
p7195
sg12
VADCY3
p7196
sa(dp7197
g7
I249
sg8
I1
sg9
I5
sg10
g11
sg12
VGPR61
p7198
sa(dp7199
g7
I235
sg8
I1
sg9
I6
sg10
g11
sg12
VTNNI3K
p7200
sasg24
(lp7201
(dp7202
g7
I313
sg8
I2
sg9
I17
sg27
VC2362324
p7203
sg12
Vchildhood obesity
p7204
sasa(dp7205
g2
VAn obesity-related gene, Fas apoptotic inhibitory molecule 2 (FAIM2), is regulated by nutritional state and the methylation levels of the FAIM2 promoter are significantly associated with obesity.
p7206
sg4
(lp7207
(dp7208
g7
I25
sg8
I5
sg9
I35
sg10
g11
sg12
VFas apoptotic inhibitory molecule 2
p7209
sa(dp7210
g7
I138
sg8
I2
sg9
I14
sg10
g11
sg12
VFAIM2 promoter
p7211
sa(dp7212
g7
I62
sg8
I1
sg9
I5
sg10
g11
sg12
VFAIM2
p7213
sasg24
(lp7214
(dp7215
g7
I3
sg8
I1
sg9
I7
sg27
VC0028754
p7216
sg12
Vobesity
p7217
sa(dp7218
g7
I3
sg8
I1
sg9
I7
sg27
VC0028754
p7219
sg12
Vobesity
p7220
sa(dp7221
g7
I25
sg8
I1
sg9
I3
sg27
VC0015923
p7222
sg12
VFas
p7223
sasa(dp7224
g2
VWhether the molecular mechanisms by which FAIM2 affects obesity are involved in lifestyle is unclear.
p7225
sg4
(lp7226
(dp7227
g7
I42
sg8
I1
sg9
I5
sg10
g11
sg12
VFAIM2
p7228
sasg24
(lp7229
(dp7230
g7
I56
sg8
I1
sg9
I7
sg27
VC0028754
p7231
sg12
Vobesity
p7232
sasa(dp7233
g2
VOur results suggest that lifestyle may possibly be mediating the process of the FAIM2 involved in obesity.
p7234
sg4
(lp7235
(dp7236
g7
I80
sg8
I1
sg9
I5
sg10
g11
sg12
VFAIM2
p7237
sasg24
(lp7238
(dp7239
g7
I98
sg8
I1
sg9
I7
sg27
VC0028754
p7240
sg12
Vobesity
p7241
sasa(dp7242
g2
VFas apoptotic inhibitory molecule 2 (FAIM2) is an obesity-related gene, but the mechanisms by which FAIM2 is involved in obesity are not understood.
p7243
sg4
(lp7244
(dp7245
g7
I37
sg8
I1
sg9
I5
sg10
g11
sg12
VFAIM2
p7246
sa(dp7247
g7
I37
sg8
I1
sg9
I5
sg10
g11
sg12
VFAIM2
p7248
sa(dp7249
g7
I0
sg8
I5
sg9
I35
sg10
g11
sg12
VFas apoptotic inhibitory molecule 2
p7250
sasg24
(lp7251
(dp7252
g7
I0
sg8
I1
sg9
I3
sg27
VC0015923
p7253
sg12
VFas
p7254
sa(dp7255
g7
I50
sg8
I1
sg9
I7
sg27
VC0028754
p7256
sg12
Vobesity
p7257
sa(dp7258
g7
I50
sg8
I1
sg9
I7
sg27
VC0028754
p7259
sg12
Vobesity
p7260
sasa(dp7261
g2
VThe purpose of this study was to investigate the potential associations of FAIM2 promoter methylation with obesity and components of dyslipidaemia in Chinese children.
p7262
sg4
(lp7263
(dp7264
g7
I75
sg8
I2
sg9
I14
sg10
g11
sg12
VFAIM2 promoter
p7265
sasg24
(lp7266
(dp7267
g7
I107
sg8
I1
sg9
I7
sg27
VC0028754
p7268
sg12
Vobesity
p7269
sa(dp7270
g7
I133
sg8
I1
sg9
I13
sg27
VC0242339
p7271
sg12
Vdyslipidaemia
p7272
sasa(dp7273
g2
VThis study provides the first evidence that the methylation levels of the FAIM2 promoter are significantly associated with obesity and are independently associated with dyslipidaemia and its components in Chinese children.
p7274
sg4
(lp7275
(dp7276
g7
I74
sg8
I2
sg9
I14
sg10
g11
sg12
VFAIM2 promoter
p7277
sasg24
(lp7278
(dp7279
g7
I169
sg8
I1
sg9
I13
sg27
VC0242339
p7280
sg12
Vdyslipidaemia
p7281
sa(dp7282
g7
I123
sg8
I1
sg9
I7
sg27
VC0028754
p7283
sg12
Vobesity
p7284
sasa(dp7285
g2
VThe association of FTO rs9939609-A, MC4R rs17782313-C, GNPDA2 rs10938397-G, and FAIM2 rs7138803-A with higher BMI, fat mass percentage, waist circumference, and waist-to height ratio and risk of obesity, and BDNF rs6265-G allele may increase BMI and obesity risk in Chinese children.
p7286
sg4
(lp7287
(dp7288
g7
I80
sg8
I2
sg9
I17
sg10
g11
sg12
VFAIM2 rs7138803-A
p7289
sa(dp7290
g7
I36
sg8
I2
sg9
I17
sg10
VP32245
p7291
sg12
VMC4R rs17782313-C
p7292
sa(dp7293
g7
I55
sg8
I2
sg9
I19
sg10
g11
sg12
VGNPDA2 rs10938397-G
p7294
sa(dp7295
g7
I19
sg8
I2
sg9
I15
sg10
g11
sg12
VFTO rs9939609-A
p7296
sasg24
(lp7297
(dp7298
g7
I195
sg8
I1
sg9
I7
sg27
VC0028754
p7299
sg12
Vobesity
p7300
sa(dp7301
g7
I195
sg8
I1
sg9
I7
sg27
VC0028754
p7302
sg12
Vobesity
p7303
sasa(dp7304
g2
VHere we aim to see whether variants in obesity-associated genes--NEGR1, FTO, MTCH2, MC4R, LRRN6C, MAP2K5, FAIM2, SEC16B, ETV5, BDNF-AS, ATXN2L, ATP2A1, KCTD15, and TNN13K--are associated with white matter microstructural properties, assessed by high angular resolution diffusion imaging (HARDI) in young healthy adults between 20 and 30 years of age from the Queensland Twin Imaging study (QTIM).
p7305
sg4
(lp7306
(dp7307
g7
I65
sg8
I1
sg9
I5
sg10
g11
sg12
VNEGR1
p7308
sa(dp7309
g7
I144
sg8
I1
sg9
I6
sg10
g11
sg12
VATP2A1
p7310
sa(dp7311
g7
I72
sg8
I1
sg9
I3
sg10
g11
sg12
VFTO
p7312
sa(dp7313
g7
I98
sg8
I1
sg9
I6
sg10
g11
sg12
VMAP2K5
p7314
sa(dp7315
g7
I106
sg8
I1
sg9
I5
sg10
g11
sg12
VFAIM2
p7316
sa(dp7317
g7
I113
sg8
I1
sg9
I6
sg10
g11
sg12
VSEC16B
p7318
sa(dp7319
g7
I152
sg8
I1
sg9
I6
sg10
g11
sg12
VKCTD15
p7320
sa(dp7321
g7
I121
sg8
I1
sg9
I4
sg10
VP41161
p7322
sg12
VETV5
p7323
sa(dp7324
g7
I77
sg8
I1
sg9
I5
sg10
g11
sg12
VMTCH2
p7325
sa(dp7326
g7
I84
sg8
I1
sg9
I4
sg10
VP32245
p7327
sg12
VMC4R
p7328
sa(dp7329
g7
I90
sg8
I1
sg9
I6
sg10
g11
sg12
VLRRN6C
p7330
sasg24
(lp7331
(dp7332
g7
I39
sg8
I1
sg9
I7
sg27
VC0028754
p7333
sg12
Vobesity
p7334
sasa(dp7335
g2
VOur results reflect an epigenetic regulation of Rbl2/p130 expression in breast cancer.
p7336
sg4
(lp7337
(dp7338
g7
I48
sg8
I1
sg9
I4
sg10
g11
sg12
VRbl2
p7339
sa(dp7340
g7
I53
sg8
I1
sg9
I4
sg10
g11
sg12
Vp130
p7341
sasg24
(lp7342
(dp7343
g7
I72
sg8
I2
sg9
I13
sg27
VC0678222
p7344
sg12
Vbreast cancer
p7345
sasa(dp7346
g2
VThis highlights the importance of Rbl2/p130 promoter methylation in breast cancer pathogenesis.
p7347
sg4
(lp7348
(dp7349
g7
I39
sg8
I1
sg9
I4
sg10
g11
sg12
Vp130
p7350
sa(dp7351
g7
I34
sg8
I1
sg9
I4
sg10
g11
sg12
VRbl2
p7352
sasg24
(lp7353
(dp7354
g7
I68
sg8
I2
sg9
I13
sg27
VC0678222
p7355
sg12
Vbreast cancer
p7356
sa(dp7357
g7
I82
sg8
I1
sg9
I12
sg27
VC0699748
p7358
sg12
Vpathogenesis
p7359
sasa(dp7360
g2
VHere, we report that ER-beta and pRb2/p130 proteins co-immunoprecipitate in both nucleus and cytoplasm of MCF-7 breast cancer cells.
p7361
sg4
(lp7362
(dp7363
g7
I38
sg8
I1
sg9
I4
sg10
g11
sg12
Vp130
p7364
sa(dp7365
g7
I33
sg8
I1
sg9
I4
sg10
VP02812
p7366
sg12
VpRb2
p7367
sasg24
(lp7368
(dp7369
g7
I112
sg8
I2
sg9
I13
sg27
VC0678222
p7370
sg12
Vbreast cancer
p7371
sasa(dp7372
g2
VHere we show a new molecular mechanism of ER-alpha gene inactivation mediated by pRb2/p130 in ER-negative breast cancer cells.
p7373
sg4
(lp7374
(dp7375
g7
I81
sg8
I1
sg9
I4
sg10
VP02812
p7376
sg12
VpRb2
p7377
sa(dp7378
g7
I42
sg8
I2
sg9
I13
sg10
g11
sg12
VER-alpha gene
p7379
sa(dp7380
g7
I86
sg8
I1
sg9
I4
sg10
g11
sg12
Vp130
p7381
sasg24
(lp7382
(dp7383
g7
I106
sg8
I2
sg9
I13
sg27
VC0678222
p7384
sg12
Vbreast cancer
p7385
sa(dp7386
g7
I56
sg8
I1
sg9
I12
sg27
VC0544461
p7387
sg12
Vinactivation
p7388
sasa(dp7389
g2
VThese findings suggest that pRb2/p130-multimolecular complexes can be key elements in the regulation of ER-alpha gene expression and may be viewed as promising targets for the development of novel therapeutic strategies in the treatment of breast cancer, especially for those tumors that are ER negative.
p7390
sg4
(lp7391
(dp7392
g7
I33
sg8
I1
sg9
I4
sg10
g11
sg12
Vp130
p7393
sa(dp7394
g7
I104
sg8
I2
sg9
I13
sg10
g11
sg12
VER-alpha gene
p7395
sa(dp7396
g7
I28
sg8
I1
sg9
I4
sg10
VP02812
p7397
sg12
VpRb2
p7398
sasg24
(lp7399
(dp7400
g7
I240
sg8
I2
sg9
I13
sg27
VC0678222
p7401
sg12
Vbreast cancer
p7402
sa(dp7403
g7
I276
sg8
I1
sg9
I6
sg27
VC0027651
p7404
sg12
Vtumors
p7405
sasa(dp7406
g2
VIn order to further analyze the role of CEACAM1 in the development of breast cancer, we performed Western-blot analysis and immunohistochemistry with highly specific monoclonal antibodies in a cohort of 68 mammary carcinomas which had also been analyzed for expression of cell-cycle regulatory proteins cyclin D1, cyclin E, p16, p21, p27, Rb, and Rb2, as well as for steroid hormone receptor status, Ki67, and HER2/neu immunoreactivity.
p7407
sg4
(lp7408
(dp7409
g7
I347
sg8
I1
sg9
I3
sg10
g11
sg12
VRb2
p7410
sa(dp7411
g7
I324
sg8
I1
sg9
I3
sg10
VP42771
p7412
sg12
Vp16
p7413
sa(dp7414
g7
I334
sg8
I1
sg9
I3
sg10
VP40305
p7415
sg12
Vp27
p7416
sa(dp7417
g7
I415
sg8
I1
sg9
I3
sg10
VP04626
p7418
sg12
Vneu
p7419
sa(dp7420
g7
I40
sg8
I1
sg9
I7
sg10
VP13688
p7421
sg12
VCEACAM1
p7422
sa(dp7423
g7
I329
sg8
I1
sg9
I3
sg10
VP42857
p7424
sg12
Vp21
p7425
sa(dp7426
g7
I314
sg8
I2
sg9
I8
sg10
VP24864
p7427
sg12
Vcyclin E
p7428
sa(dp7429
g7
I410
sg8
I1
sg9
I4
sg10
VP04626
p7430
sg12
VHER2
p7431
sa(dp7432
g7
I303
sg8
I2
sg9
I9
sg10
VP24385
p7433
sg12
Vcyclin D1
p7434
sa(dp7435
g7
I367
sg8
I3
sg9
I24
sg10
VP22736
p7436
sg12
Vsteroid hormone receptor
p7437
sasg24
(lp7438
(dp7439
g7
I70
sg8
I2
sg9
I13
sg27
VC0678222
p7440
sg12
Vbreast cancer
p7441
sa(dp7442
g7
I214
sg8
I1
sg9
I10
sg27
VC0007097
p7443
sg12
Vcarcinomas
p7444
sasa(dp7445
g2
VWeak or absent Rb2 expression was more often found in endometrial (59%) than in mammary carcinomas (24%).
p7446
sg4
(lp7447
(dp7448
g7
I15
sg8
I1
sg9
I3
sg10
g11
sg12
VRb2
p7449
sasg24
(lp7450
(dp7451
g7
I88
sg8
I1
sg9
I10
sg27
VC0007097
p7452
sg12
Vcarcinomas
p7453
sasa(dp7454
g2
VWe found significant positive correlations of Rb2 expression with Rb, ER, and PR-B in breast cancer samples, and of Rb2 with Rb, PR-A, PR-B, and younger age in endometrial carcinomas.
p7455
sg4
(lp7456
(dp7457
g7
I46
sg8
I1
sg9
I3
sg10
g11
sg12
VRb2
p7458
sa(dp7459
g7
I46
sg8
I1
sg9
I3
sg10
g11
sg12
VRb2
p7460
sasg24
(lp7461
(dp7462
g7
I86
sg8
I2
sg9
I13
sg27
VC0678222
p7463
sg12
Vbreast cancer
p7464
sa(dp7465
g7
I160
sg8
I2
sg9
I22
sg27
VC0476089
p7466
sg12
Vendometrial carcinomas
p7467
sasa(dp7468
g2
VOur results indicate that loss of Rb2 expression, mostly by transcriptional down-regulation, may be associated with the development and dedifferentiation of most endometrial and a subset of mammary carcinomas.
p7469
sg4
(lp7470
(dp7471
g7
I34
sg8
I1
sg9
I3
sg10
g11
sg12
VRb2
p7472
sasg24
(lp7473
(dp7474
g7
I198
sg8
I1
sg9
I10
sg27
VC0007097
p7475
sg12
Vcarcinomas
p7476
sa(dp7477
g7
I136
sg8
I1
sg9
I17
sg27
VC0002793
p7478
sg12
Vdedifferentiation
p7479
sasa(dp7480
g2
VWe have developed a novel glycocancer biomarker, fucosylated haptoglobin (Fuc-Hpt), and have investigated its usefulness for the diagnosis of pancreatic cancer over approximately 10 years.
p7481
sg4
(lp7482
(dp7483
g7
I74
sg8
I1
sg9
I7
sg10
VP00738
p7484
sg12
VFuc-Hpt
p7485
sa(dp7486
g7
I49
sg8
I2
sg9
I23
sg10
VP00738
p7487
sg12
Vfucosylated haptoglobin
p7488
sasg24
(lp7489
(dp7490
g7
I142
sg8
I2
sg9
I17
sg27
VC0235974
p7491
sg12
Vpancreatic cancer
p7492
sasa(dp7493
g2
VIn this review, we provide a historical summary of our research on Fuc-Hpt as a cancer biomarker, and discuss a potential early detection system for pancreatic cancer.
p7494
sg4
(lp7495
(dp7496
g7
I67
sg8
I1
sg9
I7
sg10
VP00738
p7497
sg12
VFuc-Hpt
p7498
sasg24
(lp7499
(dp7500
g7
I80
sg8
I1
sg9
I6
sg27
VC0006826
p7501
sg12
Vcancer
p7502
sa(dp7503
g7
I149
sg8
I2
sg9
I17
sg27
VC0235974
p7504
sg12
Vpancreatic cancer
p7505
sasa(dp7506
g2
VWe developed a lectin-antibody ELISA kit using PhoSL to determine core-Fuc-Hpt levels in sera from colorectal or pancreatic cancer patients.
p7507
sg4
(lp7508
(dp7509
g7
I66
sg8
I1
sg9
I12
sg10
VP00738
p7510
sg12
Vcore-Fuc-Hpt
p7511
sa(dp7512
g7
I15
sg8
I1
sg9
I15
sg10
g11
sg12
Vlectin-antibody
p7513
sasg24
(lp7514
(dp7515
g7
I113
sg8
I2
sg9
I17
sg27
VC0235974
p7516
sg12
Vpancreatic cancer
p7517
sasa(dp7518
g2
VSerum levels of AAL-reactive Hpt are higher in pancreatic cancer patients, whereas those of PhoSL-reactive Hpt are higher in colorectal cancer patients.
p7519
sg4
(lp7520
(dp7521
g7
I92
sg8
I2
sg9
I18
sg10
VP00738
p7522
sg12
VPhoSL-reactive Hpt
p7523
sa(dp7524
g7
I16
sg8
I2
sg9
I16
sg10
VP00738
p7525
sg12
VAAL-reactive Hpt
p7526
sasg24
(lp7527
(dp7528
g7
I47
sg8
I2
sg9
I17
sg27
VC0235974
p7529
sg12
Vpancreatic cancer
p7530
sa(dp7531
g7
I125
sg8
I2
sg9
I17
sg27
VC1527249
p7532
sg12
Vcolorectal cancer
p7533
sasa(dp7534
g2
VFucosylated haptoglobin (Fuc-Hpt) has been identified as a novel biomarker for pancreatic cancer.
p7535
sg4
(lp7536
(dp7537
g7
I25
sg8
I1
sg9
I7
sg10
VP00738
p7538
sg12
VFuc-Hpt
p7539
sa(dp7540
g7
I0
sg8
I2
sg9
I23
sg10
VP00738
p7541
sg12
VFucosylated haptoglobin
p7542
sasg24
(lp7543
(dp7544
g7
I79
sg8
I2
sg9
I17
sg27
VC0235974
p7545
sg12
Vpancreatic cancer
p7546
sasa(dp7547
g2
VWe previously found that the level of Fuc-Hpt is increased in the sera of patients with pancreatic cancer, and established a lectin antibody ELISA using Aleuria aurantia lectin, which specifically binds to fucosylated residues on oligosaccharides.
p7548
sg4
(lp7549
(dp7550
g7
I38
sg8
I1
sg9
I7
sg10
VP00738
p7551
sg12
VFuc-Hpt
p7552
sa(dp7553
g7
I153
sg8
I3
sg9
I23
sg10
g11
sg12
VAleuria aurantia lectin
p7554
sa(dp7555
g7
I125
sg8
I2
sg9
I15
sg10
g11
sg12
Vlectin antibody
p7556
sasg24
(lp7557
(dp7558
g7
I88
sg8
I2
sg9
I17
sg27
VC0235974
p7559
sg12
Vpancreatic cancer
p7560
sasa(dp7561
g2
VUsing the model checking method, we verified several Alzheimer's disease and cancer-related properties, and also identified important proteins (NFKB, ATF4, ASK1 and TRAF2) in the ER-Golgi network, which might be responsible for the pathogenesis of cancer and AD.
p7562
sg4
(lp7563
(dp7564
g7
I156
sg8
I1
sg9
I4
sg10
g11
sg12
VASK1
p7565
sa(dp7566
g7
I144
sg8
I1
sg9
I4
sg10
g11
sg12
VNFKB
p7567
sa(dp7568
g7
I165
sg8
I1
sg9
I5
sg10
g11
sg12
VTRAF2
p7569
sa(dp7570
g7
I150
sg8
I1
sg9
I4
sg10
VP18848
p7571
sg12
VATF4
p7572
sasg24
(lp7573
(dp7574
g7
I77
sg8
I1
sg9
I6
sg27
VC0006826
p7575
sg12
Vcancer
p7576
sa(dp7577
g7
I53
sg8
I2
sg9
I19
sg27
VC1521724
p7578
sg12
VAlzheimer's disease
p7579
sa(dp7580
g7
I232
sg8
I1
sg9
I12
sg27
VC0699748
p7581
sg12
Vpathogenesis
p7582
sa(dp7583
g7
I77
sg8
I1
sg9
I6
sg27
VC0006826
p7584
sg12
Vcancer
p7585
sasa(dp7586
g2
VWe genotyped 107 AIH-1 children and up to 326 healthy subjects for TNFA G-308A, TNFA G-238A, LTA A+252G, LTA A+80C, NFKBIL1 T-63A, BAT1 C-348T, BAT1 G-22C, MICA, and HLA-B polymorphisms.
p7587
sg4
(lp7588
(dp7589
g7
I105
sg8
I2
sg9
I9
sg10
VP10515
p7590
sg12
VLTA A+80C
p7591
sa(dp7592
g7
I166
sg8
I1
sg9
I5
sg10
VP30461
p7593
sg12
VHLA-B
p7594
sa(dp7595
g7
I131
sg8
I2
sg9
I11
sg10
VP82251
p7596
sg12
VBAT1 C-348T
p7597
sa(dp7598
g7
I144
sg8
I2
sg9
I10
sg10
VP82251
p7599
sg12
VBAT1 G-22C
p7600
sa(dp7601
g7
I93
sg8
I2
sg9
I10
sg10
VP10515
p7602
sg12
VLTA A+252G
p7603
sa(dp7604
g7
I67
sg8
I2
sg9
I11
sg10
VP01375
p7605
sg12
VTNFA G-308A
p7606
sa(dp7607
g7
I116
sg8
I2
sg9
I13
sg10
g11
sg12
VNFKBIL1 T-63A
p7608
sa(dp7609
g7
I80
sg8
I2
sg9
I11
sg10
VP01375
p7610
sg12
VTNFA G-238A
p7611
sasg24
(lp7612
(dp7613
g7
I156
sg8
I1
sg9
I4
sg27
VC0700319
p7614
sg12
VMICA
p7615
sasa(dp7616
g2
VTandem repeats of a novel, putative, zinc-binding motif (MYM) have been described within the products of two, highly homologous genes: ZNF198/RAMP/FIM and ZNF261/DXS6673E.
p7617
sg4
(lp7618
(dp7619
g7
I155
sg8
I1
sg9
I6
sg10
g11
sg12
VZNF261
p7620
sa(dp7621
g7
I142
sg8
I1
sg9
I4
sg10
g11
sg12
VRAMP
p7622
sa(dp7623
g7
I147
sg8
I1
sg9
I3
sg10
VP28329
p7624
sg12
VFIM
p7625
sa(dp7626
g7
I162
sg8
I1
sg9
I8
sg10
g11
sg12
VDXS6673E
p7627
sasg24
(lp7628
(dp7629
g7
I147
sg8
I1
sg9
I3
sg27
VC0393929
p7630
sg12
VFIM
p7631
sasa(dp7632
g2
VFrom 2005 to 2010, our unit performed testing for IL2RG, JAK3, IL7R, RAG1, RAG2, DCLRE1C, LIG4, AK2, and ZAP70 mutations in 42 Chinese and Southeast Asian infants with SCID adopting a candidate gene approach, based on patient's gender, immune phenotype, and inheritance pattern.
p7633
sg4
(lp7634
(dp7635
g7
I50
sg8
I1
sg9
I5
sg10
VP31785
p7636
sg12
VIL2RG
p7637
sa(dp7638
g7
I96
sg8
I1
sg9
I3
sg10
g11
sg12
VAK2
p7639
sa(dp7640
g7
I105
sg8
I2
sg9
I15
sg10
VP43403
p7641
sg12
VZAP70 mutations
p7642
sa(dp7643
g7
I69
sg8
I1
sg9
I4
sg10
VP15918
p7644
sg12
VRAG1
p7645
sa(dp7646
g7
I75
sg8
I1
sg9
I4
sg10
VP55895
p7647
sg12
VRAG2
p7648
sa(dp7649
g7
I57
sg8
I1
sg9
I4
sg10
VP52333
p7650
sg12
VJAK3
p7651
sa(dp7652
g7
I90
sg8
I1
sg9
I4
sg10
VP49917
p7653
sg12
VLIG4
p7654
sasg24
(lp7655
(dp7656
g7
I168
sg8
I1
sg9
I4
sg27
VC0085110
p7657
sg12
VSCID
p7658
sasa(dp7659
g2
VMutations were identified in 26 patients, including IL2RG (n = 19), IL7R (n = 2), JAK3 (n = 2), RAG1 (n = 1), RAG2 (n = 1), and DCLRE1C (n = 1).
p7660
sg4
(lp7661
(dp7662
g7
I82
sg8
I1
sg9
I4
sg10
VP52333
p7663
sg12
VJAK3
p7664
sa(dp7665
g7
I52
sg8
I1
sg9
I5
sg10
VP31785
p7666
sg12
VIL2RG
p7667
sa(dp7668
g7
I110
sg8
I1
sg9
I4
sg10
VP55895
p7669
sg12
VRAG2
p7670
sa(dp7671
g7
I96
sg8
I1
sg9
I4
sg10
VP15918
p7672
sg12
VRAG1
p7673
sasg24
(lp7674
sa(dp7675
g2
VMutations in any of eight known genes: IL2RG, ARTEMIS, RAG1, RAG2, ADA, CD45, JAK3, and IL7R cause SCID.
p7676
sg4
(lp7677
(dp7678
g7
I39
sg8
I1
sg9
I5
sg10
VP31785
p7679
sg12
VIL2RG
p7680
sa(dp7681
g7
I78
sg8
I1
sg9
I4
sg10
VP52333
p7682
sg12
VJAK3
p7683
sa(dp7684
g7
I55
sg8
I1
sg9
I4
sg10
VP15918
p7685
sg12
VRAG1
p7686
sa(dp7687
g7
I72
sg8
I1
sg9
I4
sg10
VP08575
p7688
sg12
VCD45
p7689
sa(dp7690
g7
I67
sg8
I1
sg9
I3
sg10
VP00813
p7691
sg12
VADA
p7692
sa(dp7693
g7
I61
sg8
I1
sg9
I4
sg10
VP55895
p7694
sg12
VRAG2
p7695
sasg24
(lp7696
(dp7697
g7
I99
sg8
I1
sg9
I4
sg27
VC0085110
p7698
sg12
VSCID
p7699
sasa(dp7700
g2
VPrevious studies have reported that Nit2, a member of the nitrilase superfamily, is a potential tumor suppressor, although its function remains elusive in colon cancer.
p7701
sg4
(lp7702
(dp7703
g7
I36
sg8
I1
sg9
I4
sg10
g11
sg12
VNit2
p7704
sasg24
(lp7705
(dp7706
g7
I155
sg8
I2
sg9
I12
sg27
VC0699790
p7707
sg12
Vcolon cancer
p7708
sa(dp7709
g7
I96
sg8
I1
sg9
I5
sg27
VC0027651
p7710
sg12
Vtumor
p7711
sasa(dp7712
g2
VIn the present study, we employed an RNA interference lentivirus system to silence endogenous NIT2 expression in the colon cancer cell line, HCT116.
p7713
sg4
(lp7714
(dp7715
g7
I94
sg8
I1
sg9
I4
sg10
g11
sg12
VNIT2
p7716
sasg24
(lp7717
(dp7718
g7
I75
sg8
I1
sg9
I7
sg27
VC0858952
p7719
sg12
Vsilence
p7720
sa(dp7721
g7
I117
sg8
I2
sg9
I12
sg27
VC0699790
p7722
sg12
Vcolon cancer
p7723
sasa(dp7724
g2
VThe depletion of NIT2 markedly inhibited colon cancer cell proliferation and colony formation and induced cell cycle arrest in the G0/G1 phase, as shown by MTT assay, colony formation assay and flow cytometric analysis, respectively.
p7725
sg4
(lp7726
(dp7727
g7
I17
sg8
I1
sg9
I4
sg10
g11
sg12
VNIT2
p7728
sasg24
(lp7729
(dp7730
g7
I59
sg8
I1
sg9
I13
sg27
VC0334094
p7731
sg12
Vproliferation
p7732
sa(dp7733
g7
I41
sg8
I2
sg9
I12
sg27
VC0699790
p7734
sg12
Vcolon cancer
p7735
sasa(dp7736
g2
VFurther investigation with an intracellular signaling array demonstrated that the depletion of NIT2 triggered the apoptosis of colon cancer cells through the caspase-3 and poly(ADP-ribose) polymerase (PARP) pathways.
p7737
sg4
(lp7738
(dp7739
g7
I95
sg8
I1
sg9
I4
sg10
g11
sg12
VNIT2
p7740
sa(dp7741
g7
I201
sg8
I1
sg9
I4
sg10
VP09874
p7742
sg12
VPARP
p7743
sa(dp7744
g7
I158
sg8
I1
sg9
I9
sg10
VP42574
p7745
sg12
Vcaspase-3
p7746
sa(dp7747
g7
I172
sg8
I2
sg9
I27
sg10
VP09874
p7748
sg12
Vpoly(ADP-ribose) polymerase
p7749
sasg24
(lp7750
(dp7751
g7
I127
sg8
I2
sg9
I12
sg27
VC0699790
p7752
sg12
Vcolon cancer
p7753
sasa(dp7754
g2
VOur findings suggest that NIT2 may be an oncogene in human colon cancer and may thus serve as a promising therapeutic target for the treatment of colon cancer.
p7755
sg4
(lp7756
(dp7757
g7
I26
sg8
I1
sg9
I4
sg10
g11
sg12
VNIT2
p7758
sasg24
(lp7759
(dp7760
g7
I59
sg8
I2
sg9
I12
sg27
VC0699790
p7761
sg12
Vcolon cancer
p7762
sa(dp7763
g7
I59
sg8
I2
sg9
I12
sg27
VC0699790
p7764
sg12
Vcolon cancer
p7765
sasa(dp7766
g2
VOur report may provide clues regarding the nature of the biological amidase substrate(s) of Nit1 (another member of the Nit family), which is a well-established tumor suppressor protein), and emphasizes a) the crucial role of Nit2 in nitrogen and sulfur metabolism, and b) the possible link of Nit2 to cancer biology.
p7767
sg4
(lp7768
(dp7769
g7
I226
sg8
I1
sg9
I4
sg10
g11
sg12
VNit2
p7770
sa(dp7771
g7
I92
sg8
I1
sg9
I4
sg10
g11
sg12
VNit1
p7772
sa(dp7773
g7
I226
sg8
I1
sg9
I4
sg10
g11
sg12
VNit2
p7774
sasg24
(lp7775
(dp7776
g7
I161
sg8
I1
sg9
I5
sg27
VC0027651
p7777
sg12
Vtumor
p7778
sa(dp7779
g7
I302
sg8
I1
sg9
I6
sg27
VC0006826
p7780
sg12
Vcancer
p7781
sasa(dp7782
g2
VThe purpose of this study was to retrospectively characterize benign and malignant prostate peripheral zone tissue by using endorectal MRI and 3D 1H MRS. Fifty-two men with untreated biopsy-proven prostate cancer underwent combined endorectal MRI and MRSI.
p7783
sg4
(lp7784
sg24
(lp7785
(dp7786
g7
I197
sg8
I2
sg9
I15
sg27
VC0600139
p7787
sg12
Vprostate cancer
p7788
sa(dp7789
g7
I149
sg8
I1
sg9
I3
sg27
VC0025235
p7790
sg12
VMRS
p7791
sasa(dp7792
g2
VThe addition of 3D1H MRSI to MRI can improve diagnosis of prostate cancer contributing indirectly to improve local staging.
p7793
sg4
(lp7794
sg24
(lp7795
(dp7796
g7
I58
sg8
I2
sg9
I15
sg27
VC0600139
p7797
sg12
Vprostate cancer
p7798
sasa(dp7799
g2
VIn addition, the correlation between metabolic 3D1H MRSI data with pathological Gleason grade may offer a non-invasive means to better predict prostate cancer aggressiveness.
p7800
sg4
(lp7801
sg24
(lp7802
(dp7803
g7
I143
sg8
I3
sg9
I30
sg27
VC1853195
p7804
sg12
Vprostate cancer aggressiveness
p7805
sasa(dp7806
g2
VThe objective of our study was to establish the sensitivity and specificity for prostate cancer detection using a combined 1H MR spectroscopy and diffusion-weighted MRI approach.
p7807
sg4
(lp7808
sg24
(lp7809
(dp7810
g7
I80
sg8
I2
sg9
I15
sg27
VC0600139
p7811
sg12
Vprostate cancer
p7812
sasa(dp7813
g2
VMRI, dynamic MRI, and 1H-MR spectroscopic imaging were performed in 10 patients with prostate cancer on 1.5T and 3T whole-body scanners.
p7814
sg4
(lp7815
sg24
(lp7816
(dp7817
g7
I85
sg8
I2
sg9
I15
sg27
VC0600139
p7818
sg12
Vprostate cancer
p7819
sasa(dp7820
g2
VInitial results of endorectal 3T 1H-MR spectroscopic imaging in prostate cancer patients showed potential advantages: the increase in spatial, temporal, and spectral resolution at higher field strength may result in an improved accuracy in delineating and staging prostate cancer.
p7821
sg4
(lp7822
sg24
(lp7823
(dp7824
g7
I64
sg8
I2
sg9
I15
sg27
VC0600139
p7825
sg12
Vprostate cancer
p7826
sa(dp7827
g7
I64
sg8
I2
sg9
I15
sg27
VC0600139
p7828
sg12
Vprostate cancer
p7829
sasa(dp7830
g2
VTo establish an experimental setting for monitoring perfusion and metabolism in orthotopic prostate cancer at 1.5 T using dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) and 1H-MR spectroscopy (MRS).
p7831
sg4
(lp7832
sg24
(lp7833
(dp7834
g7
I91
sg8
I2
sg9
I15
sg27
VC0600139
p7835
sg12
Vprostate cancer
p7836
sa(dp7837
g7
I209
sg8
I1
sg9
I3
sg27
VC0025235
p7838
sg12
VMRS
p7839
sa(dp7840
g7
I189
sg8
I2
sg9
I18
sg27
VC0025235
p7841
sg12
V1H-MR spectroscopy
p7842
sasa(dp7843
g2
VDCE MRI and 1H-MRS has potential to characterize orthotopic Dunning prostate cancer in rats, which is a promising model similar to human prostate carcinomas.
p7844
sg4
(lp7845
sg24
(lp7846
(dp7847
g7
I15
sg8
I1
sg9
I3
sg27
VC0025235
p7848
sg12
VMRS
p7849
sa(dp7850
g7
I68
sg8
I2
sg9
I15
sg27
VC0600139
p7851
sg12
Vprostate cancer
p7852
sa(dp7853
g7
I146
sg8
I1
sg9
I10
sg27
VC0007097
p7854
sg12
Vcarcinomas
p7855
sasa(dp7856
g2
VWe recently characterized a stress and glucocorticoid-regulated gene, down-regulated in renal cell carcinoma - DRR1 (Fam107A).
p7857
sg4
(lp7858
(dp7859
g7
I117
sg8
I1
sg9
I7
sg10
g11
sg12
VFam107A
p7860
sa(dp7861
g7
I111
sg8
I1
sg9
I4
sg10
g11
sg12
VDRR1
p7862
sa(dp7863
g7
I39
sg8
I2
sg9
I29
sg10
VP48506
p7864
sg12
Vglucocorticoid-regulated gene
p7865
sasg24
(lp7866
(dp7867
g7
I88
sg8
I3
sg9
I20
sg27
VC0007134
p7868
sg12
Vrenal cell carcinoma
p7869
sasa(dp7870
g2
VTU3A, located on 3p21.1, was originally identified as a candidate tumor suppressor gene in renal cell carcinoma (RCC).
p7871
sg4
(lp7872
(dp7873
g7
I0
sg8
I1
sg9
I4
sg10
g11
sg12
VTU3A
p7874
sasg24
(lp7875
(dp7876
g7
I91
sg8
I3
sg9
I20
sg27
VC0007134
p7877
sg12
Vrenal cell carcinoma
p7878
sa(dp7879
g7
I66
sg8
I1
sg9
I5
sg27
VC0027651
p7880
sg12
Vtumor
p7881
sa(dp7882
g7
I113
sg8
I1
sg9
I3
sg27
VC0007134
p7883
sg12
VRCC
p7884
sasa(dp7885
g2
VIn our search for tumor suppressor genes from this region, we have cloned a gene that we have called DRR 1 (downregulated in renal cell carcinoma).
p7886
sg4
(lp7887
(dp7888
g7
I101
sg8
I2
sg9
I5
sg10
g11
sg12
VDRR 1
p7889
sasg24
(lp7890
(dp7891
g7
I18
sg8
I1
sg9
I5
sg27
VC0027651
p7892
sg12
Vtumor
p7893
sa(dp7894
g7
I125
sg8
I3
sg9
I20
sg27
VC0007134
p7895
sg12
Vrenal cell carcinoma
p7896
sasa(dp7897
g2
VOur results suggest that loss of expression of the DRR 1 gene may play an important role in the development of renal cell carcinoma and possibly other tumors.
p7898
sg4
(lp7899
(dp7900
g7
I51
sg8
I3
sg9
I10
sg10
g11
sg12
VDRR 1 gene
p7901
sasg24
(lp7902
(dp7903
g7
I151
sg8
I1
sg9
I6
sg27
VC0027651
p7904
sg12
Vtumors
p7905
sa(dp7906
g7
I111
sg8
I3
sg9
I20
sg27
VC0007134
p7907
sg12
Vrenal cell carcinoma
p7908
sasa(dp7909
g2
VE2F5 was identified as one of the most deregulated genes in prostate cancer tissues, predominantly in samples with Gleason-score 6.
p7910
sg4
(lp7911
(dp7912
g7
I0
sg8
I1
sg9
I4
sg10
g11
sg12
VE2F5
p7913
sasg24
(lp7914
(dp7915
g7
I60
sg8
I2
sg9
I15
sg27
VC0600139
p7916
sg12
Vprostate cancer
p7917
sasa(dp7918
g2
VFunction of E2F5 and p38 in prostate cancer was investigated using siRNA-treatment of PC3 cell-line followed by analyses of associated components and cell cycle.
p7919
sg4
(lp7920
(dp7921
g7
I21
sg8
I1
sg9
I3
sg10
VP46108
p7922
sg12
Vp38
p7923
sa(dp7924
g7
I12
sg8
I1
sg9
I4
sg10
g11
sg12
VE2F5
p7925
sasg24
(lp7926
(dp7927
g7
I28
sg8
I2
sg9
I15
sg27
VC0600139
p7928
sg12
Vprostate cancer
p7929
sasa(dp7930
g2
VOur findings unearthed that E2F5/p38 axis played a cardinal role in uncontrolled cellular proliferation in prostate cancer through pSMAD3L activation.
p7931
sg4
(lp7932
(dp7933
g7
I33
sg8
I1
sg9
I3
sg10
VP46108
p7934
sg12
Vp38
p7935
sa(dp7936
g7
I28
sg8
I1
sg9
I4
sg10
g11
sg12
VE2F5
p7937
sasg24
(lp7938
(dp7939
g7
I81
sg8
I2
sg9
I22
sg27
VC0020507
p7940
sg12
Vcellular proliferation
p7941
sa(dp7942
g7
I107
sg8
I2
sg9
I15
sg27
VC0600139
p7943
sg12
Vprostate cancer
p7944
sasa(dp7945
g2
VIt also underscores a strong potential for E2F5 to be incorporated as a tool in early detection of prostate cancer.
p7946
sg4
(lp7947
(dp7948
g7
I43
sg8
I1
sg9
I4
sg10
g11
sg12
VE2F5
p7949
sasg24
(lp7950
(dp7951
g7
I99
sg8
I2
sg9
I15
sg27
VC0600139
p7952
sg12
Vprostate cancer
p7953
sasa(dp7954
g2
VWe report the coexistence of otitis media and epididymo-orchitis owing to Hemophilus influenzae, type b in 2 children.
p7955
sg4
(lp7956
sg24
(lp7957
(dp7958
g7
I29
sg8
I2
sg9
I12
sg27
VC0029882
p7959
sg12
Votitis media
p7960
sa(dp7961
g7
I46
sg8
I1
sg9
I18
sg27
VC0149881
p7962
sg12
Vepididymo-orchitis
p7963
sasa(dp7964
g2
VOverexpression of tau rescued the Nogo-66-induced inhibition of neurite outgrowth in neuroblastoma 2a (N2a) cells and primary cortical neurons.
p7965
sg4
(lp7966
sg24
(lp7967
(dp7968
g7
I85
sg8
I1
sg9
I13
sg27
VC0027819
p7969
sg12
Vneuroblastoma
p7970
sasa(dp7971
g2
VTaken together, we suggest that Nogo-A is closely involved in the neuronal response to hypoxic and oxidative stress, an observation that may be of relevance not only in stroke-induced ischaemia, but also in neuroblastoma formation.
p7972
sg4
(lp7973
sg24
(lp7974
(dp7975
g7
I99
sg8
I2
sg9
I16
sg27
VC0242606
p7976
sg12
Voxidative stress
p7977
sa(dp7978
g7
I184
sg8
I1
sg9
I9
sg27
VC0022116
p7979
sg12
Vischaemia
p7980
sa(dp7981
g7
I87
sg8
I1
sg9
I7
sg27
VC0242184
p7982
sg12
Vhypoxic
p7983
sa(dp7984
g7
I169
sg8
I1
sg9
I6
sg27
VC0038454
p7985
sg12
Vstroke
p7986
sa(dp7987
g7
I207
sg8
I1
sg9
I13
sg27
VC0027819
p7988
sg12
Vneuroblastoma
p7989
sasa(dp7990
g2
VIn the present study, we report on the role of GSK-3Beta signaling on Nogo-66-treated mouse neuroblastoma N2a cells.
p7991
sg4
(lp7992
(dp7993
g7
I47
sg8
I1
sg9
I9
sg10
VP49841
p7994
sg12
VGSK-3Beta
p7995
sasg24
(lp7996
(dp7997
g7
I86
sg8
I2
sg9
I19
sg27
VC1524043
p7998
sg12
Vmouse neuroblastoma
p7999
sasa(dp8000
g2
VBrain-derived neurotrophic factor stimulates the phosphorylation, suppressing Nogo-dependent inhibition of neurite outgrowth from neuroblastoma-derived neural cells.
p8001
sg4
(lp8002
(dp8003
g7
I0
sg8
I3
sg9
I33
sg10
g11
sg12
VBrain-derived neurotrophic factor
p8004
sasg24
(lp8005
(dp8006
g7
I130
sg8
I1
sg9
I13
sg27
VC0027819
p8007
sg12
Vneuroblastoma
p8008
sasa(dp8009
g2
VIn our per-SNP analysis, eight myopia gene associations were replicated successfully: GJD2, RASGRF1, BICC1, KCNQ5, CD55, CYP26A1, LRRC4C, and B4GALNT2.Seven additional gene associations were replicated in our gene-based analyses: GRIA4, BMP2, QKI, BMP4, SFRP1, SH3GL2, and EHBP1L1.
p8010
sg4
(lp8011
(dp8012
g7
I254
sg8
I1
sg9
I5
sg10
g11
sg12
VSFRP1
p8013
sa(dp8014
g7
I261
sg8
I1
sg9
I6
sg10
g11
sg12
VSH3GL2
p8015
sa(dp8016
g7
I130
sg8
I1
sg9
I6
sg10
g11
sg12
VLRRC4C
p8017
sa(dp8018
g7
I237
sg8
I1
sg9
I4
sg10
VP12643
p8019
sg12
VBMP2
p8020
sa(dp8021
g7
I86
sg8
I1
sg9
I4
sg10
g11
sg12
VGJD2
p8022
sa(dp8023
g7
I121
sg8
I1
sg9
I7
sg10
g11
sg12
VCYP26A1
p8024
sa(dp8025
g7
I273
sg8
I1
sg9
I7
sg10
g11
sg12
VEHBP1L1
p8026
sa(dp8027
g7
I108
sg8
I1
sg9
I5
sg10
g11
sg12
VKCNQ5
p8028
sa(dp8029
g7
I101
sg8
I1
sg9
I5
sg10
g11
sg12
VBICC1
p8030
sa(dp8031
g7
I115
sg8
I1
sg9
I4
sg10
VP08174
p8032
sg12
VCD55
p8033
sa(dp8034
g7
I230
sg8
I1
sg9
I5
sg10
VP48058
p8035
sg12
VGRIA4
p8036
sa(dp8037
g7
I248
sg8
I1
sg9
I4
sg10
VP12644
p8038
sg12
VBMP4
p8039
sa(dp8040
g7
I142
sg8
I1
sg9
I8
sg10
g11
sg12
VB4GALNT2
p8041
sa(dp8042
g7
I92
sg8
I1
sg9
I7
sg10
g11
sg12
VRASGRF1
p8043
sasg24
(lp8044
(dp8045
g7
I31
sg8
I1
sg9
I6
sg27
VC0027092
p8046
sg12
Vmyopia
p8047
sasa(dp8048
g2
VThe aims of the present study were to immunohistochemically examine S100A10 expression in surgically resected lung adenocarcinomas, and evaluate any relationships with clinicopathological parameters and prognosis of patients.
p8049
sg4
(lp8050
(dp8051
g7
I68
sg8
I1
sg9
I7
sg10
VP60903
p8052
sg12
VS100A10
p8053
sasg24
(lp8054
(dp8055
g7
I115
sg8
I1
sg9
I15
sg27
VC0001418
p8056
sg12
Vadenocarcinomas
p8057
sasa(dp8058
g2
VS100A10 expression was immunohistochemically studied in 202 consecutive resected lung adenocarcinomas, and its associations with clinicopathological parameters were evaluated.
p8059
sg4
(lp8060
(dp8061
g7
I0
sg8
I1
sg9
I7
sg10
VP60903
p8062
sg12
VS100A10
p8063
sasg24
(lp8064
(dp8065
g7
I86
sg8
I1
sg9
I15
sg27
VC0001418
p8066
sg12
Vadenocarcinomas
p8067
sasa(dp8068
g2
VS100A10 expression was detected in 65 of the 202 (32.2%) lung adenocarcinomas, being significantly correlated with poorer differentiation (P =0.015), a higher pathological TNM stage (stages II and III) (P=0.004), more frequent and severe intratumoral vascular invasion (P=0.001), and a poorer prognosis (P=0.030).
p8069
sg4
(lp8070
(dp8071
g7
I0
sg8
I1
sg9
I7
sg10
VP60903
p8072
sg12
VS100A10
p8073
sasg24
(lp8074
(dp8075
g7
I62
sg8
I1
sg9
I15
sg27
VC0001418
p8076
sg12
Vadenocarcinomas
p8077
sa(dp8078
g7
I260
sg8
I1
sg9
I8
sg27
VC2699153
p8079
sg12
Vinvasion
p8080
sasa(dp8081
g2
VThe present study reveals that S100A10 is expressed in a subset of lung adenocarcinomas, and this is related to some clinicopathological parameters, although further studies are required to confirm the correlation between S100A10 expression and prognosis of lung adenocarcinoma patients.
p8082
sg4
(lp8083
(dp8084
g7
I31
sg8
I1
sg9
I7
sg10
VP60903
p8085
sg12
VS100A10
p8086
sa(dp8087
g7
I31
sg8
I1
sg9
I7
sg10
VP60903
p8088
sg12
VS100A10
p8089
sasg24
(lp8090
(dp8091
g7
I72
sg8
I1
sg9
I15
sg27
VC0001418
p8092
sg12
Vadenocarcinomas
p8093
sa(dp8094
g7
I67
sg8
I2
sg9
I19
sg27
VC0152013
p8095
sg12
Vlung adenocarcinoma
p8096
sasa(dp8097
g2
VUsing mass spectrometry for protein identification and validating the results by immunohistochemistry on an independent validation set, we could identify two of 60 differentially expressed m/z species between Barrett's adenocarcinoma and the precursor lesion: COX7A2 and S100-A10.
p8098
sg4
(lp8099
(dp8100
g7
I260
sg8
I1
sg9
I6
sg10
VP14406
p8101
sg12
VCOX7A2
p8102
sa(dp8103
g7
I271
sg8
I1
sg9
I4
sg10
VP04271
p8104
sg12
VS100
p8105
sasg24
(lp8106
(dp8107
g7
I209
sg8
I2
sg9
I24
sg27
VC1332460
p8108
sg12
VBarrett's adenocarcinoma
p8109
sasa(dp8110
g2
VIn the validation set, we found a correlation of the expression levels of COX7A2 and TAGLN2 with a poor prognosis while S100-A10 was confirmed by multivariate analysis as a novel independent prognostic factor in Barrett's adenocarcinoma.
p8111
sg4
(lp8112
(dp8113
g7
I74
sg8
I1
sg9
I6
sg10
VP14406
p8114
sg12
VCOX7A2
p8115
sa(dp8116
g7
I85
sg8
I1
sg9
I6
sg10
VP37802
p8117
sg12
VTAGLN2
p8118
sasg24
(lp8119
(dp8120
g7
I212
sg8
I2
sg9
I24
sg27
VC1332460
p8121
sg12
VBarrett's adenocarcinoma
p8122
sasa(dp8123
g2
VS100A10, a member of the S100 family, forms a heterotetramer with annexin IIH and promotes carcinoma invasion and metastasis by plasminogen activation.
p8124
sg4
(lp8125
(dp8126
g7
I25
sg8
I2
sg9
I11
sg10
VP04271
p8127
sg12
VS100 family
p8128
sa(dp8129
g7
I0
sg8
I1
sg9
I7
sg10
VP60903
p8130
sg12
VS100A10
p8131
sa(dp8132
g7
I128
sg8
I1
sg9
I11
sg10
VP00747
p8133
sg12
Vplasminogen
p8134
sasg24
(lp8135
(dp8136
g7
I101
sg8
I1
sg9
I8
sg27
VC2699153
p8137
sg12
Vinvasion
p8138
sa(dp8139
g7
I114
sg8
I1
sg9
I10
sg27
VC0027627
p8140
sg12
Vmetastasis
p8141
sa(dp8142
g7
I91
sg8
I1
sg9
I9
sg27
VC0007097
p8143
sg12
Vcarcinoma
p8144
sasa(dp8145
g2
VCells stained positively in 14.6% and 20.8% of follicular carcinomas for S100A10 and annexin II, respectively, but their expression levels were always low.
p8146
sg4
(lp8147
(dp8148
g7
I85
sg8
I2
sg9
I10
sg10
VP07355
p8149
sg12
Vannexin II
p8150
sa(dp8151
g7
I73
sg8
I1
sg9
I7
sg10
VP60903
p8152
sg12
VS100A10
p8153
sasg24
(lp8154
(dp8155
g7
I58
sg8
I1
sg9
I10
sg27
VC0007097
p8156
sg12
Vcarcinomas
p8157
sasa(dp8158
g2
VS100A10 and annexin II were expressed in all papillary carcinomas, but 88.2% and 82.8% ofpapillary carcinomas were classified in the low group.
p8159
sg4
(lp8160
(dp8161
g7
I12
sg8
I2
sg9
I10
sg10
VP07355
p8162
sg12
Vannexin II
p8163
sa(dp8164
g7
I0
sg8
I1
sg9
I7
sg10
VP60903
p8165
sg12
VS100A10
p8166
sasg24
(lp8167
(dp8168
g7
I45
sg8
I2
sg9
I20
sg27
VC0007133
p8169
sg12
Vpapillary carcinomas
p8170
sa(dp8171
g7
I55
sg8
I1
sg9
I10
sg27
VC0007097
p8172
sg12
Vcarcinomas
p8173
sasa(dp8174
g2
VThese findings suggest that S100A10 and annexin II contribute to the aggressive characteristics of anaplastic carcinoma, while playing a constitutive role in papillary carcinoma.
p8175
sg4
(lp8176
(dp8177
g7
I40
sg8
I2
sg9
I10
sg10
VP07355
p8178
sg12
Vannexin II
p8179
sa(dp8180
g7
I28
sg8
I1
sg9
I7
sg10
VP60903
p8181
sg12
VS100A10
p8182
sasg24
(lp8183
(dp8184
g7
I69
sg8
I1
sg9
I10
sg27
VC0001807
p8185
sg12
Vaggressive
p8186
sa(dp8187
g7
I99
sg8
I2
sg9
I20
sg27
VC0205698
p8188
sg12
Vanaplastic carcinoma
p8189
sa(dp8190
g7
I158
sg8
I2
sg9
I19
sg27
VC0007133
p8191
sg12
Vpapillary carcinoma
p8192
sasa(dp8193
g2
VThe spin-labeled derivative of podophyllotoxin, N'-podophyllic acid-N-[3-(2,2,5,5-tetramethyl pyrrolinenyloxy)] semicarbazide (GP-11), was synthesized and tested for its antitumor activity against mouse transplantable tumors, Sarcoma-180, Hepatoma-A, P388 leukemia and Ehrlich ascites carcinoma.
p8194
sg4
(lp8195
sg24
(lp8196
(dp8197
g7
I239
sg8
I1
sg9
I8
sg27
VC0023903
p8198
sg12
VHepatoma
p8199
sa(dp8200
g7
I285
sg8
I1
sg9
I9
sg27
VC0007097
p8201
sg12
Vcarcinoma
p8202
sa(dp8203
g7
I226
sg8
I1
sg9
I7
sg27
VC1261473
p8204
sg12
VSarcoma
p8205
sa(dp8206
g7
I256
sg8
I1
sg9
I8
sg27
VC0023418
p8207
sg12
Vleukemia
p8208
sa(dp8209
g7
I218
sg8
I1
sg9
I6
sg27
VC0027651
p8210
sg12
Vtumors
p8211
sasa(dp8212
g2
VRemote parenchymal hemorrhage (rPH) after intravenous thrombolysis with recombinant tissue-type plasminogen activator may be associated with cerebral amyloid angiopathy, although supportive data are limited.
p8213
sg4
(lp8214
(dp8215
g7
I84
sg8
I3
sg9
I33
sg10
VP00747
p8216
sg12
Vtissue-type plasminogen activator
p8217
sasg24
(lp8218
(dp8219
g7
I141
sg8
I3
sg9
I27
sg27
VC0085220
p8220
sg12
Vcerebral amyloid angiopathy
p8221
sa(dp8222
g7
I7
sg8
I2
sg9
I22
sg27
VC0747264
p8223
sg12
Vparenchymal hemorrhage
p8224
sasa(dp8225
g2
VWe here review the data with respect to the activation of tPA by fibrin and its multiple other cofactors, in relation to tPA's role in pathophysiology, notably fibrinolysis and amyloidosis, with emphasis on Alzheimer's disease.
p8226
sg4
(lp8227
(dp8228
g7
I65
sg8
I1
sg9
I6
sg10
VP22087
p8229
sg12
Vfibrin
p8230
sasg24
(lp8231
(dp8232
g7
I177
sg8
I1
sg9
I11
sg27
VC0002726
p8233
sg12
Vamyloidosis
p8234
sa(dp8235
g7
I207
sg8
I2
sg9
I19
sg27
VC1521724
p8236
sg12
VAlzheimer's disease
p8237
sasa(dp8238
g2
VCerebral amyloid angiopathy (CAA) may be an important predisposing factor for the hemorrhagic complications of recombinant tissue-type plasminogen activator (rt-PA) therapy.
p8239
sg4
(lp8240
(dp8241
g7
I158
sg8
I1
sg9
I5
sg10
VP00747
p8242
sg12
Vrt-PA
p8243
sa(dp8244
g7
I111
sg8
I4
sg9
I45
sg10
VP00747
p8245
sg12
Vrecombinant tissue-type plasminogen activator
p8246
sasg24
(lp8247
(dp8248
g7
I29
sg8
I1
sg9
I3
sg27
VC1842937
p8249
sg12
VCAA
p8250
sa(dp8251
g7
I0
sg8
I3
sg9
I27
sg27
VC0085220
p8252
sg12
VCerebral amyloid angiopathy
p8253
sasa(dp8254
g2
VThe purpose of this study was to investigate the potential of intranasal immunization with non-ionic surfactant vesicles (NISV) containing either the secretory recombinant form of glycoprotein B (gBs) of herpes simplex virus type 1 or a related polylysine reach peptides (DTK) for induction of protective immunity against genital herpes infection in mice.
p8255
sg4
(lp8256
(dp8257
g7
I180
sg8
I2
sg9
I14
sg10
VP36222
p8258
sg12
Vglycoprotein B
p8259
sa(dp8260
g7
I196
sg8
I1
sg9
I3
sg10
g11
sg12
VgBs
p8261
sasg24
(lp8262
(dp8263
g7
I196
sg8
I1
sg9
I3
sg27
VC1841700
p8264
sg12
VgBs
p8265
sa(dp8266
g7
I112
sg8
I1
sg9
I8
sg27
VC0333262
p8267
sg12
Vvesicles
p8268
sa(dp8269
g7
I330
sg8
I2
sg9
I16
sg27
VC0019372
p8270
sg12
Vherpes infection
p8271
sa(dp8272
g7
I204
sg8
I2
sg9
I14
sg27
VC0019348
p8273
sg12
Vherpes simplex
p8274
sasa(dp8275
g2
VSeventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules.
p8276
sg4
(lp8277
(dp8278
g7
I57
sg8
I3
sg9
I36
sg10
VP35398
p8279
sg12
VT-cell-specific transcription factor
p8280
sa(dp8281
g7
I276
sg8
I3
sg9
I18
sg10
VP11473
p8282
sg12
Vvitamin D receptor
p8283
sa(dp8284
g7
I109
sg8
I3
sg9
I39
sg10
VP00519
p8285
sg12
V"proto-oncogene tyrosine-protein kinase
p8286
sa(dp8287
g7
I399
sg8
I6
sg9
I31
sg10
g11
sg12
VPR domain zinc finger protein 1
p8288
sa(dp8289
g7
I322
sg8
I1
sg9
I3
sg10
VP29323
p8290
sg12
VERK
p8291
sa(dp8292
g7
I362
sg8
I4
sg9
I35
sg10
VP20823
p8293
sg12
Vrunt-related transcription factor 1
p8294
sa(dp8295
g7
I477
sg8
I2
sg9
I13
sg10
VP01584
p8296
sg12
Vinterleukin 1
p8297
sa(dp8298
g7
I152
sg8
I1
sg9
I8
sg10
VP12931
p8299
sg12
Vsarcoma"
p8300
sa(dp8301
g7
I163
sg8
I4
sg9
I30
sg10
VP10914
p8302
sg12
Vinterferon regulatory factor 1
p8303
sa(dp8304
g7
I227
sg8
I4
sg9
I31
sg10
VP49336
p8305
sg12
Vcyclin-dependent kinase (CDK) 4
p8306
sa(dp8307
g7
I296
sg8
I2
sg9
I19
sg10
VP56524
p8308
sg12
Vhistone deacetylase
p8309
sa(dp8310
g7
I95
sg8
I1
sg9
I3
sg10
VP12931
p8311
sg12
VSrc
p8312
sa(dp8313
g7
I217
sg8
I2
sg9
I8
sg10
VP14635
p8314
sg12
Vcyclin B
p8315
sa(dp8316
g7
I334
sg8
I3
sg9
I26
sg10
VP10415
p8317
sg12
Vbcl-2-associated X protein
p8318
sa(dp8319
g7
I317
sg8
I1
sg9
I4
sg10
VP53779
p8320
sg12
VMAPK
p8321
sa(dp8322
g7
I432
sg8
I4
sg9
I39
sg10
VP09619
p8323
sg12
Vplatelet-derived growth factor receptor
p8324
sa(dp8325
g7
I265
sg8
I1
sg9
I9
sg10
VP29466
p8326
sg12
Vcaspase-1
p8327
sa(dp8328
g7
I195
sg8
I2
sg9
I20
sg10
VP04818
p8329
sg12
Vthymidylate synthase
p8330
sa(dp8331
g7
I252
sg8
I1
sg9
I3
sg10
VP24941
p8332
sg12
VCDK
p8333
sasg24
(lp8334
(dp8335
g7
I152
sg8
I1
sg9
I7
sg27
VC1261473
p8336
sg12
Vsarcoma
p8337
sa(dp8338
g7
I362
sg8
I1
sg9
I4
sg27
VC0013336
p8339
sg12
Vrunt
p8340
sasa(dp8341
g2
VThe IRF-1 priming of TEXs enhances antitumour immune response.British Journal of Cancer advance online publication, 7 November 2017; doi:10.1038/bjc.2017.389 www.bjcancer.com.
p8342
sg4
(lp8343
(dp8344
g7
I4
sg8
I1
sg9
I5
sg10
VP10914
p8345
sg12
VIRF-1
p8346
sasg24
(lp8347
(dp8348
g7
I81
sg8
I1
sg9
I6
sg27
VC0006826
p8349
sg12
VCancer
p8350
sasa(dp8351
g2
VInterferon regulatory factor 1 (IRF1) has been suggested to act as a tumor suppressor in human cancers.
p8352
sg4
(lp8353
(dp8354
g7
I0
sg8
I4
sg9
I30
sg10
VP10914
p8355
sg12
VInterferon regulatory factor 1
p8356
sa(dp8357
g7
I32
sg8
I1
sg9
I4
sg10
VP10914
p8358
sg12
VIRF1
p8359
sasg24
(lp8360
(dp8361
g7
I69
sg8
I1
sg9
I5
sg27
VC0027651
p8362
sg12
Vtumor
p8363
sa(dp8364
g7
I95
sg8
I1
sg9
I7
sg27
VC0006826
p8365
sg12
Vcancers
p8366
sasa(dp8367
g2
VHowever, the clinical significance and biological function of IRF1 in cholangiocarcinoma is poorly understood.
p8368
sg4
(lp8369
(dp8370
g7
I62
sg8
I1
sg9
I4
sg10
VP10914
p8371
sg12
VIRF1
p8372
sasg24
(lp8373
(dp8374
g7
I70
sg8
I1
sg9
I18
sg27
VC0206698
p8375
sg12
Vcholangiocarcinoma
p8376
sasa(dp8377
g2
VIn our results, IRF1 mRNA and protein expressions were decreased in cholangiocarcinoma tissues and cell lines compared with paired normal hepatic tissues and intrahepatic bile duct epithelial cell line.
p8378
sg4
(lp8379
(dp8380
g7
I16
sg8
I2
sg9
I9
sg10
VP10914
p8381
sg12
VIRF1 mRNA
p8382
sasg24
(lp8383
(dp8384
g7
I68
sg8
I1
sg9
I18
sg27
VC0206698
p8385
sg12
Vcholangiocarcinoma
p8386
sasa(dp8387
g2
VIRF1 protein low-expression was associated with tumor stage, tumor size, vascular invasion and metastasis and served as a poor independent prognostic parameter in cholangiocarcinoma patients.
p8388
sg4
(lp8389
(dp8390
g7
I0
sg8
I1
sg9
I4
sg10
VP10914
p8391
sg12
VIRF1
p8392
sasg24
(lp8393
(dp8394
g7
I95
sg8
I1
sg9
I10
sg27
VC0027627
p8395
sg12
Vmetastasis
p8396
sa(dp8397
g7
I163
sg8
I1
sg9
I18
sg27
VC0206698
p8398
sg12
Vcholangiocarcinoma
p8399
sa(dp8400
g7
I48
sg8
I1
sg9
I5
sg27
VC0027651
p8401
sg12
Vtumor
p8402
sa(dp8403
g7
I82
sg8
I1
sg9
I8
sg27
VC2699153
p8404
sg12
Vinvasion
p8405
sa(dp8406
g7
I48
sg8
I1
sg9
I5
sg27
VC0027651
p8407
sg12
Vtumor
p8408
sasa(dp8409
g2
VUp-regulation of IRF1 expression suppressed cholangiocarcinoma cells proliferation, migration and invasion, and blocked cell cycle progression, but has no effect on apoptosis.
p8410
sg4
(lp8411
(dp8412
g7
I17
sg8
I1
sg9
I4
sg10
VP10914
p8413
sg12
VIRF1
p8414
sasg24
(lp8415
(dp8416
g7
I44
sg8
I1
sg9
I18
sg27
VC0206698
p8417
sg12
Vcholangiocarcinoma
p8418
sa(dp8419
g7
I69
sg8
I1
sg9
I13
sg27
VC0334094
p8420
sg12
Vproliferation
p8421
sa(dp8422
g7
I98
sg8
I1
sg9
I8
sg27
VC2699153
p8423
sg12
Vinvasion
p8424
sasa(dp8425
g2
VIn conclusion, IRF1 is low-expressed in cholangiocarcinoma tissues and cell lines, and correlated with malignant status and prognosis in cholangiocarcinoma patients.
p8426
sg4
(lp8427
(dp8428
g7
I15
sg8
I1
sg9
I4
sg10
VP10914
p8429
sg12
VIRF1
p8430
sasg24
(lp8431
(dp8432
g7
I40
sg8
I1
sg9
I18
sg27
VC0206698
p8433
sg12
Vcholangiocarcinoma
p8434
sa(dp8435
g7
I40
sg8
I1
sg9
I18
sg27
VC0206698
p8436
sg12
Vcholangiocarcinoma
p8437
sasa(dp8438
g2
VIRF1 served as tumor suppressor in the regulation of cholangiocarcinoma cells proliferation, cell cycle, migration and invasion.
p8439
sg4
(lp8440
(dp8441
g7
I0
sg8
I1
sg9
I4
sg10
VP10914
p8442
sg12
VIRF1
p8443
sasg24
(lp8444
(dp8445
g7
I119
sg8
I1
sg9
I8
sg27
VC2699153
p8446
sg12
Vinvasion
p8447
sa(dp8448
g7
I15
sg8
I1
sg9
I5
sg27
VC0027651
p8449
sg12
Vtumor
p8450
sa(dp8451
g7
I53
sg8
I1
sg9
I18
sg27
VC0206698
p8452
sg12
Vcholangiocarcinoma
p8453
sa(dp8454
g7
I78
sg8
I1
sg9
I13
sg27
VC0334094
p8455
sg12
Vproliferation
p8456
sasa(dp8457
g2
VTo examine genetic defects of the IFNGamma-IRF1 pathway in non-small cell lung cancer (NSCLC), we analyzed The Cancer Genome Atlas (TCGA) lung adenocarcinoma (LuAd) and lung squamous cell carcinoma (LuSc) data.
p8458
sg4
(lp8459
(dp8460
g7
I43
sg8
I1
sg9
I4
sg10
VP10914
p8461
sg12
VIRF1
p8462
sasg24
(lp8463
(dp8464
g7
I111
sg8
I1
sg9
I6
sg27
VC0006826
p8465
sg12
VCancer
p8466
sa(dp8467
g7
I59
sg8
I4
sg9
I26
sg27
VC0007131
p8468
sg12
Vnon-small cell lung cancer
p8469
sa(dp8470
g7
I169
sg8
I4
sg9
I28
sg27
VC0149782
p8471
sg12
Vlung squamous cell carcinoma
p8472
sa(dp8473
g7
I199
sg8
I1
sg9
I4
sg27
VC0149782
p8474
sg12
VLuSc
p8475
sa(dp8476
g7
I138
sg8
I2
sg9
I19
sg27
VC0152013
p8477
sg12
Vlung adenocarcinoma
p8478
sa(dp8479
g7
I87
sg8
I1
sg9
I5
sg27
VC0007131
p8480
sg12
VNSCLC
p8481
sa(dp8482
g7
I159
sg8
I1
sg9
I4
sg27
VC0152013
p8483
sg12
VLuAd
p8484
sasa(dp8485
g2
VIRF1 expression was correlated with immune cytolytic activity markers GZMA and PRF1 in NSCLC.
p8486
sg4
(lp8487
(dp8488
g7
I79
sg8
I1
sg9
I4
sg10
VP14222
p8489
sg12
VPRF1
p8490
sa(dp8491
g7
I70
sg8
I1
sg9
I4
sg10
VP12544
p8492
sg12
VGZMA
p8493
sa(dp8494
g7
I0
sg8
I1
sg9
I4
sg10
VP10914
p8495
sg12
VIRF1
p8496
sasg24
(lp8497
(dp8498
g7
I87
sg8
I1
sg9
I5
sg27
VC0007131
p8499
sg12
VNSCLC
p8500
sasa(dp8501
g2
VDeletion of JAK2 or inhibition of the JAK2 kinase activity resulted in loss of IFNGamma-induced IRF1 and cell surface HLA-ABC in JAK2 wildtype NSCLC cells, whereas expression of exogenous JAK2 in H1573 cells restored the IFNGamma responses.
p8502
sg4
(lp8503
(dp8504
g7
I12
sg8
I1
sg9
I4
sg10
g11
sg12
VJAK2
p8505
sa(dp8506
g7
I96
sg8
I1
sg9
I4
sg10
VP10914
p8507
sg12
VIRF1
p8508
sa(dp8509
g7
I12
sg8
I1
sg9
I4
sg10
g11
sg12
VJAK2
p8510
sa(dp8511
g7
I118
sg8
I1
sg9
I7
sg10
VP30486
p8512
sg12
VHLA-ABC
p8513
sa(dp8514
g7
I12
sg8
I1
sg9
I4
sg10
g11
sg12
VJAK2
p8515
sa(dp8516
g7
I38
sg8
I2
sg9
I11
sg10
g11
sg12
VJAK2 kinase
p8517
sasg24
(lp8518
(dp8519
g7
I143
sg8
I1
sg9
I5
sg27
VC0007131
p8520
sg12
VNSCLC
p8521
sasa(dp8522
g2
VThese findings show that JAK2 deficiency is the major mechanism of genetic defects of the IFNGamma-IRF1 pathway in NSCLC and reveal a previously unrecognized significance of chromosome 9p deletion in NSCLC.
p8523
sg4
(lp8524
(dp8525
g7
I25
sg8
I1
sg9
I4
sg10
g11
sg12
VJAK2
p8526
sa(dp8527
g7
I90
sg8
I1
sg9
I13
sg10
VP10914
p8528
sg12
VIFNGamma-IRF1
p8529
sasg24
(lp8530
(dp8531
g7
I115
sg8
I1
sg9
I5
sg27
VC0007131
p8532
sg12
VNSCLC
p8533
sa(dp8534
g7
I115
sg8
I1
sg9
I5
sg27
VC0007131
p8535
sg12
VNSCLC
p8536
sasa(dp8537
g2
VPerformance of the investigational use only-labeled GeneXpert(R) (Cepheid, Sunnyvale, CA) Bladder Cancer Assay, an assay for detection of the five mRNAs (ABL1, CRH, IGF2, ANXA10, and UPK1B), was evaluated in an independent test cohort (n=450).
p8538
sg4
(lp8539
(dp8540
g7
I171
sg8
I1
sg9
I6
sg10
g11
sg12
VANXA10
p8541
sa(dp8542
g7
I160
sg8
I1
sg9
I3
sg10
VP06850
p8543
sg12
VCRH
p8544
sa(dp8545
g7
I165
sg8
I1
sg9
I4
sg10
VP01344
p8546
sg12
VIGF2
p8547
sa(dp8548
g7
I183
sg8
I1
sg9
I5
sg10
g11
sg12
VUPK1B
p8549
sa(dp8550
g7
I154
sg8
I1
sg9
I4
sg10
VP00519
p8551
sg12
VABL1
p8552
sasg24
(lp8553
(dp8554
g7
I90
sg8
I2
sg9
I14
sg27
VC0699885
p8555
sg12
VBladder Cancer
p8556
sasa(dp8557
g2
VOur previous mass spectrometry-based proteomics study revealed that annexin A10 (ANXA10) was uniquely overexpressed in pancreatic CD24+ adenocarcinoma cells that were dissected from clinical PDAC tissues but was absent in CD24- adjacent normal cells.
p8558
sg4
(lp8559
(dp8560
g7
I81
sg8
I1
sg9
I6
sg10
g11
sg12
VANXA10
p8561
sa(dp8562
g7
I68
sg8
I2
sg9
I11
sg10
g11
sg12
Vannexin A10
p8563
sa(dp8564
g7
I130
sg8
I1
sg9
I4
sg10
VP25063
p8565
sg12
VCD24
p8566
sasg24
(lp8567
(dp8568
g7
I136
sg8
I1
sg9
I14
sg27
VC0001418
p8569
sg12
Vadenocarcinoma
p8570
sasa(dp8571
g2
VThe correlation between ANXA10 expression and the progression of pancreatic cancer remains unknown.
p8572
sg4
(lp8573
(dp8574
g7
I24
sg8
I1
sg9
I6
sg10
g11
sg12
VANXA10
p8575
sasg24
(lp8576
(dp8577
g7
I65
sg8
I2
sg9
I17
sg27
VC0235974
p8578
sg12
Vpancreatic cancer
p8579
sasa(dp8580
g2
VIn this study, we performed an immunostaining assay to evaluate ANXA10 expression in 155 primary human tissue specimens, including normal pancreas, chronic pancreatitis (CP), pancreatic adenocarcinoma (PDAC), pancreatic intraepithelial neoplasia (PanIN, the most important precursor of PDAC), and intraductal papillary mucinous neoplasm (IPMN).
p8581
sg4
(lp8582
(dp8583
g7
I64
sg8
I1
sg9
I6
sg10
g11
sg12
VANXA10
p8584
sasg24
(lp8585
(dp8586
g7
I209
sg8
I3
sg9
I36
sg27
VC1301034
p8587
sg12
Vpancreatic intraepithelial neoplasia
p8588
sa(dp8589
g7
I297
sg8
I4
sg9
I39
sg27
VC3160815
p8590
sg12
Vintraductal papillary mucinous neoplasm
p8591
sa(dp8592
g7
I175
sg8
I2
sg9
I25
sg27
VC0281361
p8593
sg12
Vpancreatic adenocarcinoma
p8594
sa(dp8595
g7
I148
sg8
I2
sg9
I20
sg27
VC0149521
p8596
sg12
Vchronic pancreatitis
p8597
sa(dp8598
g7
I202
sg8
I1
sg9
I4
sg27
VC0281361
p8599
sg12
VPDAC
p8600
sa(dp8601
g7
I202
sg8
I1
sg9
I4
sg27
VC0281361
p8602
sg12
VPDAC
p8603
sa(dp8604
g7
I170
sg8
I1
sg9
I2
sg27
VC0149521
p8605
sg12
VCP
p8606
sa(dp8607
g7
I247
sg8
I1
sg9
I5
sg27
VC1301034
p8608
sg12
VPanIN
p8609
sa(dp8610
g7
I338
sg8
I1
sg9
I4
sg27
VC3160815
p8611
sg12
VIPMN
p8612
sasa(dp8613
g2
VSince PDAC develops through a series of PanINs which in turn arise from pancreatic ducts, the consistent overexpression of ANXA10 in ductal epithelial cells in PanINs and PDACs but negative in normal pancreatic ducts suggests that ANXA10 could serve as a potential marker indicating the presence of PDAC at its earliest precancerous stages.
p8614
sg4
(lp8615
(dp8616
g7
I123
sg8
I1
sg9
I6
sg10
g11
sg12
VANXA10
p8617
sa(dp8618
g7
I123
sg8
I1
sg9
I6
sg10
g11
sg12
VANXA10
p8619
sasg24
(lp8620
sa(dp8621
g2
VIn this study, we evaluated the effects of simvastatin on ANXA10 signaling in androgen-independent prostate cancer cells.
p8622
sg4
(lp8623
(dp8624
g7
I58
sg8
I1
sg9
I6
sg10
g11
sg12
VANXA10
p8625
sa(dp8626
g7
I43
sg8
I1
sg9
I11
sg10
g11
sg12
Vsimvastatin
p8627
sasg24
(lp8628
(dp8629
g7
I99
sg8
I2
sg9
I15
sg27
VC0600139
p8630
sg12
Vprostate cancer
p8631
sasa(dp8632
g2
VIn human prostate biopsy samples, ANXA10 mRNA expression was significantly lower in the prostate cancer group than in the BPH group.
p8633
sg4
(lp8634
(dp8635
g7
I34
sg8
I2
sg9
I11
sg10
g11
sg12
VANXA10 mRNA
p8636
sasg24
(lp8637
(dp8638
g7
I122
sg8
I1
sg9
I3
sg27
VC0005001
p8639
sg12
VBPH
p8640
sa(dp8641
g7
I88
sg8
I2
sg9
I15
sg27
VC0600139
p8642
sg12
Vprostate cancer
p8643
sasa(dp8644
g2
VNext, we found that up-regulation of ANXA10 in PC-3 resulted in down-regulation of S100 calcium binding protein A4 (S100A4), which is reportedly correlated with aggressiveness and a worse prognosis for patients with different types of carcinomas.
p8645
sg4
(lp8646
(dp8647
g7
I116
sg8
I1
sg9
I6
sg10
VP26447
p8648
sg12
VS100A4
p8649
sa(dp8650
g7
I83
sg8
I5
sg9
I31
sg10
VP26447
p8651
sg12
VS100 calcium binding protein A4
p8652
sa(dp8653
g7
I47
sg8
I1
sg9
I4
sg10
g11
sg12
VPC-3
p8654
sa(dp8655
g7
I37
sg8
I1
sg9
I6
sg10
g11
sg12
VANXA10
p8656
sasg24
(lp8657
(dp8658
g7
I235
sg8
I1
sg9
I10
sg27
VC0007097
p8659
sg12
Vcarcinomas
p8660
sa(dp8661
g7
I161
sg8
I1
sg9
I14
sg27
VC0001807
p8662
sg12
Vaggressiveness
p8663
sasa(dp8664
g2
VOur results suggest that statins inhibit the proliferation, migration, and invasion of androgen-independent prostate cancer cells by up-regulation of ANXA10.
p8665
sg4
(lp8666
(dp8667
g7
I150
sg8
I1
sg9
I6
sg10
g11
sg12
VANXA10
p8668
sasg24
(lp8669
(dp8670
g7
I75
sg8
I1
sg9
I8
sg27
VC2699153
p8671
sg12
Vinvasion
p8672
sa(dp8673
g7
I108
sg8
I2
sg9
I15
sg27
VC0600139
p8674
sg12
Vprostate cancer
p8675
sa(dp8676
g7
I45
sg8
I1
sg9
I13
sg27
VC0334094
p8677
sg12
Vproliferation
p8678
sasa(dp8679
g2
VImmunohistochemistry for 7 gastric-type markers (ANXA10, VSIG1, CLDN18, CTSE, TFF2, MUC5AC, and MUC6) and 2 intestinal-type markers (CDX2 and CK20) was performed in 36 normal gastric/colorectal mucosa tissues, 163 colorectal polyps, and 175 microsatellite-unstable colorectal carcinomas (MSI-H CRCs).
p8680
sg4
(lp8681
(dp8682
g7
I133
sg8
I1
sg9
I4
sg10
g11
sg12
VCDX2
p8683
sa(dp8684
g7
I57
sg8
I1
sg9
I5
sg10
g11
sg12
VVSIG1
p8685
sa(dp8686
g7
I64
sg8
I1
sg9
I6
sg10
VP56856
p8687
sg12
VCLDN18
p8688
sa(dp8689
g7
I142
sg8
I1
sg9
I4
sg10
VP35900
p8690
sg12
VCK20
p8691
sa(dp8692
g7
I78
sg8
I1
sg9
I4
sg10
g11
sg12
VTFF2
p8693
sa(dp8694
g7
I72
sg8
I1
sg9
I4
sg10
VP14091
p8695
sg12
VCTSE
p8696
sa(dp8697
g7
I96
sg8
I1
sg9
I4
sg10
g11
sg12
VMUC6
p8698
sa(dp8699
g7
I49
sg8
I1
sg9
I6
sg10
g11
sg12
VANXA10
p8700
sasg24
(lp8701
(dp8702
g7
I265
sg8
I2
sg9
I21
sg27
VC0009402
p8703
sg12
Vcolorectal carcinomas
p8704
sa(dp8705
g7
I214
sg8
I2
sg9
I17
sg27
VC0949059
p8706
sg12
Vcolorectal polyps
p8707
sa(dp8708
g7
I288
sg8
I1
sg9
I3
sg27
VC0920269
p8709
sg12
VMSI
p8710
sasa(dp8711
g2
VTwo decades ago, Galectin-8 was described as a prostate carcinoma biomarker since it is only expressed in the neoplastic prostate, but not in the healthy tissue.
p8712
sg4
(lp8713
(dp8714
g7
I17
sg8
I1
sg9
I10
sg10
VP09382
p8715
sg12
VGalectin-8
p8716
sasg24
(lp8717
(dp8718
g7
I47
sg8
I2
sg9
I18
sg27
VC0600139
p8719
sg12
Vprostate carcinoma
p8720
sasa(dp8721
g2
VIn this study we silenced Galectin-8 in two human prostate cancer cell lines, PC3 and IGR-CaP1, and designed a pre-clinical experimental model that allows monitoring the pathology from its early steps to the long-term metastatic stages.
p8722
sg4
(lp8723
(dp8724
g7
I26
sg8
I1
sg9
I10
sg10
VP09382
p8725
sg12
VGalectin-8
p8726
sa(dp8727
g7
I78
sg8
I1
sg9
I3
sg10
VP42025
p8728
sg12
VPC3
p8729
sa(dp8730
g7
I86
sg8
I1
sg9
I8
sg10
g11
sg12
VIGR-CaP1
p8731
sasg24
(lp8732
(dp8733
g7
I170
sg8
I1
sg9
I9
sg27
VC0677042
p8734
sg12
Vpathology
p8735
sa(dp8736
g7
I50
sg8
I2
sg9
I15
sg27
VC0600139
p8737
sg12
Vprostate cancer
p8738
sasa(dp8739
g2
VWe show for the first time that the natural and conserved expression of Gal-8 in tumour cells is responsible for the metastatic evolution of prostate cancer.
p8740
sg4
(lp8741
(dp8742
g7
I72
sg8
I1
sg9
I5
sg10
VP16278
p8743
sg12
VGal-8
p8744
sasg24
(lp8745
(dp8746
g7
I81
sg8
I1
sg9
I6
sg27
VC0027651
p8747
sg12
Vtumour
p8748
sa(dp8749
g7
I141
sg8
I2
sg9
I15
sg27
VC0600139
p8750
sg12
Vprostate cancer
p8751
sasa(dp8752
g2
VCollectively, our results highlight Galectin-8 as a potential target for anti-metastatic therapy against prostate cancer.
p8753
sg4
(lp8754
(dp8755
g7
I36
sg8
I1
sg9
I10
sg10
VP09382
p8756
sg12
VGalectin-8
p8757
sasg24
(lp8758
(dp8759
g7
I105
sg8
I2
sg9
I15
sg27
VC0600139
p8760
sg12
Vprostate cancer
p8761
sasa(dp8762
g2
VImmunocytochemistry for prostate carcinoma tumour antigen (PCTA-1) was performed for culture purity evaluation.
p8763
sg4
(lp8764
(dp8765
g7
I24
sg8
I4
sg9
I33
sg10
VP49221
p8766
sg12
Vprostate carcinoma tumour antigen
p8767
sasg24
(lp8768
(dp8769
g7
I24
sg8
I2
sg9
I18
sg27
VC0600139
p8770
sg12
Vprostate carcinoma
p8771
sa(dp8772
g7
I43
sg8
I1
sg9
I6
sg27
VC0027651
p8773
sg12
Vtumour
p8774
sasa(dp8775
g2
VGalectin-8 levels of expression positively correlate with certain human neoplasms, prostate cancer being the best example studied thus far.
p8776
sg4
(lp8777
(dp8778
g7
I0
sg8
I1
sg9
I10
sg10
VP09382
p8779
sg12
VGalectin-8
p8780
sasg24
(lp8781
(dp8782
g7
I72
sg8
I2
sg9
I19
sg27
VC0033578
p8783
sg12
Vneoplasms, prostate
p8784
sa(dp8785
g7
I92
sg8
I1
sg9
I6
sg27
VC0006826
p8786
sg12
Vcancer
p8787
sasa(dp8788
g2
VThe Prostate Carcinoma Tumor Antigen-1 (PCTA-1) is located at the prostate cancer susceptibility locus on chromosome 1q42.2-43 (PCaP).
p8789
sg4
(lp8790
(dp8791
g7
I13
sg8
I3
sg9
I25
sg10
VP14209
p8792
sg12
VCarcinoma Tumor Antigen-1
p8793
sa(dp8794
g7
I66
sg8
I3
sg9
I30
sg10
g11
sg12
Vprostate cancer susceptibility
p8795
sasg24
(lp8796
(dp8797
g7
I66
sg8
I7
sg9
I60
sg27
VC1864472
p8798
sg12
Vprostate cancer susceptibility locus on chromosome 1q42.2-43
p8799
sa(dp8800
g7
I23
sg8
I1
sg9
I5
sg27
VC0027651
p8801
sg12
VTumor
p8802
sa(dp8803
g7
I4
sg8
I2
sg9
I18
sg27
VC0600139
p8804
sg12
VProstate Carcinoma
p8805
sa(dp8806
g7
I128
sg8
I1
sg9
I4
sg27
VC1864472
p8807
sg12
VPCaP
p8808
sasa(dp8809
g2
VSeventy-seven familial prostate cancer cases from 36 German and French pedigrees were screened for germline mutations in the PCTA-1 gene using enzymatic mutation detection (EMD).
p8810
sg4
(lp8811
sg24
(lp8812
(dp8813
g7
I143
sg8
I3
sg9
I28
sg27
VC0340861
p8814
sg12
Venzymatic mutation detection
p8815
sa(dp8816
g7
I173
sg8
I1
sg9
I3
sg27
VC0340861
p8817
sg12
VEMD
p8818
sa(dp8819
g7
I23
sg8
I2
sg9
I15
sg27
VC0600139
p8820
sg12
Vprostate cancer
p8821
sasa(dp8822
g2
VPCTA-1 is not a classical high risk gene with deleterious mutations predisposing to hereditary prostate cancer.
p8823
sg4
(lp8824
sg24
(lp8825
(dp8826
g7
I84
sg8
I3
sg9
I26
sg27
VC2931456
p8827
sg12
Vhereditary prostate cancer
p8828
sasa(dp8829
g2
VThe isolation of Prostate Carcinoma Tumor Antigen-1 (PCTA-1), a cDNA closely related to rat and human Galectin-8, as a surface marker associated with prostate cancer was achieved using a previously described immunological subtraction approach, Surface Epitope Masking (SEM) approach, in combination with expression screening.
p8830
sg4
(lp8831
(dp8832
g7
I26
sg8
I3
sg9
I25
sg10
VP14209
p8833
sg12
VCarcinoma Tumor Antigen-1
p8834
sa(dp8835
g7
I102
sg8
I1
sg9
I10
sg10
VP09382
p8836
sg12
VGalectin-8
p8837
sasg24
(lp8838
(dp8839
g7
I36
sg8
I1
sg9
I5
sg27
VC0027651
p8840
sg12
VTumor
p8841
sa(dp8842
g7
I150
sg8
I2
sg9
I15
sg27
VC0600139
p8843
sg12
Vprostate cancer
p8844
sa(dp8845
g7
I244
sg8
I3
sg9
I23
sg27
VC0432222
p8846
sg12
VSurface Epitope Masking
p8847
sa(dp8848
g7
I17
sg8
I2
sg9
I18
sg27
VC0600139
p8849
sg12
VProstate Carcinoma
p8850
sa(dp8851
g7
I269
sg8
I1
sg9
I3
sg27
VC0432222
p8852
sg12
VSEM
p8853
sasa(dp8854
g2
VPCTA-1 maps to 1q42-43, a locus associated with predisposition to prostate cancer.
p8855
sg4
(lp8856
sg24
(lp8857
(dp8858
g7
I66
sg8
I2
sg9
I15
sg27
VC0600139
p8859
sg12
Vprostate cancer
p8860
sasa(dp8861
g2
VScreening a human LNCaP prostate cancer cDNA expression library with the Pro 1.5 mAb identifies a gene, prostate carcinoma tumor antigen-1 (PCTA-1).
p8862
sg4
(lp8863
(dp8864
g7
I73
sg8
I3
sg9
I11
sg10
VP63125
p8865
sg12
VPro 1.5 mAb
p8866
sa(dp8867
g7
I104
sg8
I4
sg9
I34
sg10
VP49221
p8868
sg12
Vprostate carcinoma tumor antigen-1
p8869
sa(dp8870
g7
I140
sg8
I1
sg9
I6
sg10
VP49221
p8871
sg12
VPCTA-1
p8872
sasg24
(lp8873
(dp8874
g7
I24
sg8
I2
sg9
I15
sg27
VC0600139
p8875
sg12
Vprostate cancer
p8876
sa(dp8877
g7
I123
sg8
I1
sg9
I5
sg27
VC0027651
p8878
sg12
Vtumor
p8879
sa(dp8880
g7
I104
sg8
I2
sg9
I18
sg27
VC0600139
p8881
sg12
Vprostate carcinoma
p8882
sasa(dp8883
g2
VPrimer pairs within the 3' untranslated region of PCTA-1 and reverse transcription-PCR demonstrate selective expression of PCTA-1 by prostate carcinomas versus normal prostate and benign prostatic hypertrophy.
p8884
sg4
(lp8885
sg24
(lp8886
(dp8887
g7
I142
sg8
I1
sg9
I10
sg27
VC0007097
p8888
sg12
Vcarcinomas
p8889
sa(dp8890
g7
I180
sg8
I3
sg9
I28
sg27
VC0005001
p8891
sg12
Vbenign prostatic hypertrophy
p8892
sasa(dp8893
g2
VMoreover, Foxp3 could interact with LMO2 and affect the expression level of TAL1, which was in accordance with the findings in T-cell acute lymphoblastic leukemia.
p8894
sg4
(lp8895
(dp8896
g7
I76
sg8
I1
sg9
I4
sg10
VP17542
p8897
sg12
VTAL1
p8898
sa(dp8899
g7
I36
sg8
I1
sg9
I4
sg10
VP25791
p8900
sg12
VLMO2
p8901
sa(dp8902
g7
I10
sg8
I1
sg9
I5
sg10
g11
sg12
VFoxp3
p8903
sasg24
(lp8904
(dp8905
g7
I127
sg8
I4
sg9
I35
sg27
VC1961099
p8906
sg12
VT-cell acute lymphoblastic leukemia
p8907
sasa(dp8908
g2
VOverexpression of LMO2 is known to be one of the causes of T-cell acute lymphoblastic leukemia (T-ALL) development; however, the mechanisms behind its oncogenic activity are incompletely understood.
p8909
sg4
(lp8910
(dp8911
g7
I18
sg8
I1
sg9
I4
sg10
VP25791
p8912
sg12
VLMO2
p8913
sasg24
(lp8914
(dp8915
g7
I96
sg8
I1
sg9
I5
sg27
VC1961099
p8916
sg12
VT-ALL
p8917
sa(dp8918
g7
I59
sg8
I4
sg9
I35
sg27
VC1961099
p8919
sg12
VT-cell acute lymphoblastic leukemia
p8920
sasa(dp8921
g2
VExpression of LMO2 has been evaluated in B-cell lymphoma, T-cell acute lymphoblastic leukemia and acute myeloid leukemia; however, information concerning its role in breakpoint cluster region/Abelson murine leukemia viral oncogene homolog 1 (BCR/ABL) negative B-cell acute lymphoblastic leukemia (B-ALL) remains limited.
p8922
sg4
(lp8923
(dp8924
g7
I14
sg8
I1
sg9
I4
sg10
VP25791
p8925
sg12
VLMO2
p8926
sa(dp8927
g7
I246
sg8
I1
sg9
I3
sg10
VP55157
p8928
sg12
VABL
p8929
sa(dp8930
g7
I242
sg8
I1
sg9
I3
sg10
VP11274
p8931
sg12
VBCR
p8932
sa(dp8933
g7
I207
sg8
I5
sg9
I33
sg10
VP35125
p8934
sg12
Vleukemia viral oncogene homolog 1
p8935
sasg24
(lp8936
(dp8937
g7
I98
sg8
I3
sg9
I22
sg27
VC0023467
p8938
sg12
Vacute myeloid leukemia
p8939
sa(dp8940
g7
I85
sg8
I1
sg9
I8
sg27
VC0023418
p8941
sg12
Vleukemia
p8942
sa(dp8943
g7
I246
sg8
I1
sg9
I3
sg27
VC0000744
p8944
sg12
VABL
p8945
sa(dp8946
g7
I297
sg8
I1
sg9
I5
sg27
VC0006413
p8947
sg12
VB-ALL
p8948
sa(dp8949
g7
I260
sg8
I4
sg9
I35
sg27
VC1292769
p8950
sg12
VB-cell acute lymphoblastic leukemia
p8951
sa(dp8952
g7
I58
sg8
I4
sg9
I35
sg27
VC1961099
p8953
sg12
VT-cell acute lymphoblastic leukemia
p8954
sasa(dp8955
g2
VOncogenic transcription factors are commonly activated in acute leukemias and subvert normal gene expression networks to reprogram hematopoietic progenitors into preleukemic stem cells, as exemplified by LIM-only 2 (LMO2) in T-cell acute lymphoblastic leukemia (T-ALL).
p8956
sg4
(lp8957
(dp8958
g7
I216
sg8
I1
sg9
I4
sg10
VP25791
p8959
sg12
VLMO2
p8960
sa(dp8961
g7
I204
sg8
I2
sg9
I10
sg10
g11
sg12
VLIM-only 2
p8962
sasg24
(lp8963
(dp8964
g7
I58
sg8
I2
sg9
I15
sg27
VC0085669
p8965
sg12
Vacute leukemias
p8966
sa(dp8967
g7
I262
sg8
I1
sg9
I5
sg27
VC1961099
p8968
sg12
VT-ALL
p8969
sa(dp8970
g7
I225
sg8
I4
sg9
I35
sg27
VC1961099
p8971
sg12
VT-cell acute lymphoblastic leukemia
p8972
sasa(dp8973
g2
VT-cell acute lymphoblastic leukemia (T-ALL) frequently involves aberrant expression of TAL1 (T-cell acute lymphocytic leukemia 1) and LMO2, oncogenic members of the TAL1 transcriptional complex.
p8974
sg4
(lp8975
(dp8976
g7
I93
sg8
I5
sg9
I35
sg10
VP17542
p8977
sg12
VT-cell acute lymphocytic leukemia 1
p8978
sa(dp8979
g7
I134
sg8
I1
sg9
I4
sg10
VP25791
p8980
sg12
VLMO2
p8981
sa(dp8982
g7
I0
sg8
I2
sg9
I12
sg10
g11
sg12
VT-cell acute
p8983
sa(dp8984
g7
I87
sg8
I1
sg9
I4
sg10
VP17542
p8985
sg12
VTAL1
p8986
sa(dp8987
g7
I165
sg8
I3
sg9
I28
sg10
VP17542
p8988
sg12
VTAL1 transcriptional complex
p8989
sasg24
(lp8990
(dp8991
g7
I0
sg8
I4
sg9
I35
sg27
VC1961099
p8992
sg12
VT-cell acute lymphoblastic leukemia
p8993
sa(dp8994
g7
I37
sg8
I1
sg9
I5
sg27
VC1961099
p8995
sg12
VT-ALL
p8996
sa(dp8997
g7
I93
sg8
I4
sg9
I33
sg27
VC1961099
p8998
sg12
VT-cell acute lymphocytic leukemia
p8999
sasa(dp9000
g2
VLmo2 is an oncogenic transcription factor that is frequently overexpressed in T-cell acute leukemias, in particular poor prognosis early T-cell precursor-like (ETP-) acute lymphoblastic leukemia (ALL).
p9001
sg4
(lp9002
(dp9003
g7
I160
sg8
I1
sg9
I3
sg10
g11
sg12
VETP
p9004
sa(dp9005
g7
I137
sg8
I2
sg9
I21
sg10
VP01275
p9006
sg12
VT-cell precursor-like
p9007
sa(dp9008
g7
I0
sg8
I1
sg9
I4
sg10
VP25791
p9009
sg12
VLmo2
p9010
sasg24
(lp9011
(dp9012
g7
I85
sg8
I2
sg9
I15
sg27
VC0085669
p9013
sg12
Vacute leukemias
p9014
sa(dp9015
g7
I196
sg8
I1
sg9
I3
sg27
VC1961102
p9016
sg12
VALL
p9017
sa(dp9018
g7
I166
sg8
I3
sg9
I28
sg27
VC1961102
p9019
sg12
Vacute lymphoblastic leukemia
p9020
sasa(dp9021
g2
VParticipants (N = 4,901) were from Look AHEAD, a randomized controlled trial that compared ILI to diabetes support and education (DSE).
p9022
sg4
(lp9023
sg24
(lp9024
(dp9025
g7
I98
sg8
I1
sg9
I8
sg27
VC0011849
p9026
sg12
Vdiabetes
p9027
sasa(dp9028
g2
VA multidomain intensive lifestyle intervention (ILI) to induce weight loss and increase physical activity for 8 to 11 years or diabetes support and education (DSE), a control condition.
p9029
sg4
(lp9030
sg24
(lp9031
(dp9032
g7
I175
sg8
I1
sg9
I9
sg27
VC0012634
p9033
sg12
Vcondition
p9034
sa(dp9035
g7
I127
sg8
I1
sg9
I8
sg27
VC0011849
p9036
sg12
Vdiabetes
p9037
sasa(dp9038
g2
VOverweight and obese (BMI &gt;=25 kg/m 2) middle-aged and older adults (aged 45-76 years at enrollment) with type 2 diabetes enrolled in Look AHEAD, a trial evaluating an intensive lifestyle intervention (ILI) designed to achieve weight loss through caloric restriction and increased physical activity compared to diabetes support and education (DSE), underwent standardized assessments of performance-based physical function including a 4- and 400-m walk, lower extremity physical performance (expanded Short Physical Performance Battery, SPPBexp), and grip strength approximately 11 years post-randomization and 1.5 years after the intervention was stopped (n=3,783).
p9039
sg4
(lp9040
sg24
(lp9041
(dp9042
g7
I116
sg8
I1
sg9
I8
sg27
VC0011849
p9043
sg12
Vdiabetes
p9044
sa(dp9045
g7
I15
sg8
I1
sg9
I5
sg27
VC0028754
p9046
sg12
Vobese
p9047
sa(dp9048
g7
I0
sg8
I1
sg9
I10
sg27
VC0497406
p9049
sg12
VOverweight
p9050
sa(dp9051
g7
I109
sg8
I3
sg9
I15
sg27
VC0011860
p9052
sg12
Vtype 2 diabetes
p9053
sasa(dp9054
g2
VTo address the unique nature of prions, our group targets epitopes, termed disease specific epitopes (DSEs), whose exposure for antibody binding depends on disease-associated misfolding of PrPC into PrPSc.
p9055
sg4
(lp9056
(dp9057
g7
I189
sg8
I1
sg9
I4
sg10
VP48637
p9058
sg12
VPrPC
p9059
sasg24
(lp9060
sa(dp9061
g2
VDuring 5 years spanning the end of intervention and post-intervention follow-up, repeated cognitive assessments were obtained in 1,091 individuals who had been assigned to ILI or a control condition of diabetes support and education (DSE).
p9062
sg4
(lp9063
sg24
(lp9064
(dp9065
g7
I189
sg8
I1
sg9
I9
sg27
VC0012634
p9066
sg12
Vcondition
p9067
sa(dp9068
g7
I202
sg8
I1
sg9
I8
sg27
VC0011849
p9069
sg12
Vdiabetes
p9070
sasa(dp9071
g2
VA total of 5145 persons aged 45 to 76 years with DM were randomized to either an intensive lifestyle intervention (ILI) with reduced calorie consumption and increased physical activity designed to achieve and maintain &gt;=7% weight loss or to diabetes support and education intervention (DSE).
p9072
sg4
(lp9073
sg24
(lp9074
(dp9075
g7
I244
sg8
I1
sg9
I8
sg27
VC0011849
p9076
sg12
Vdiabetes
p9077
sasa(dp9078
g2
VThe purpose of this study was to assess range of motion (ROM), pain, and incidence of radiographic degenerative joint disease (DJD) after volar radioscapholunate (RSL) arthrodesis and distal scaphoidectomy (DSE) following malunited distal radius fractures (DRF).
p9079
sg4
(lp9080
sg24
(lp9081
(dp9082
g7
I127
sg8
I1
sg9
I3
sg27
VC0029408
p9083
sg12
VDJD
p9084
sa(dp9085
g7
I99
sg8
I3
sg9
I26
sg27
VC0029408
p9086
sg12
Vdegenerative joint disease
p9087
sasa(dp9088
g2
VFourteen patients with malunited DRF and DJD limited to the radiocarpal joint underwent RSL arthrodesis and DSE between 2006 and 2014.
p9089
sg4
(lp9090
sg24
(lp9091
sa(dp9092
g2
VThe impact of a static electric field (EF) on amyloid peptide aggregation has been much less studied, although EFs may have some applications to treat Parkinson's disease symptoms.
p9093
sg4
(lp9094
sg24
(lp9095
(dp9096
g7
I46
sg8
I1
sg9
I7
sg27
VC0011560
p9097
sg12
Vamyloid
p9098
sa(dp9099
g7
I151
sg8
I2
sg9
I19
sg27
VC0030567
p9100
sg12
VParkinson's disease
p9101
sasa(dp9102
g2
VCognitive impairments occur frequently and early in multiple sclerosis (MS) and contribute significantly to a reduced quality of life of patients with MS. Executive functions (EFs) play a pivotal role for the behavioral adaption to the environment and are also crucial for compensatory processes of cognitive impairments.
p9103
sg4
(lp9104
sg24
(lp9105
(dp9106
g7
I299
sg8
I2
sg9
I21
sg27
VC0338656
p9107
sg12
Vcognitive impairments
p9108
sa(dp9109
g7
I72
sg8
I1
sg9
I2
sg27
VC0036429
p9110
sg12
VMS
p9111
sa(dp9112
g7
I72
sg8
I1
sg9
I2
sg27
VC0036429
p9113
sg12
VMS
p9114
sa(dp9115
g7
I0
sg8
I2
sg9
I21
sg27
VC0338656
p9116
sg12
VCognitive impairments
p9117
sa(dp9118
g7
I52
sg8
I2
sg9
I18
sg27
VC0026769
p9119
sg12
Vmultiple sclerosis
p9120
sasa(dp9121
g2
VSeveral recent studies have pointed out that early impairment of executive functions (EFs) in Parkinson's Disease (PD) may be a crucial marker to detect patients at risk for developing dementia.
p9122
sg4
(lp9123
sg24
(lp9124
(dp9125
g7
I51
sg8
I1
sg9
I10
sg27
VC0684336
p9126
sg12
Vimpairment
p9127
sa(dp9128
g7
I94
sg8
I2
sg9
I19
sg27
VC0030567
p9129
sg12
VParkinson's Disease
p9130
sa(dp9131
g7
I115
sg8
I1
sg9
I2
sg27
VC0030567
p9132
sg12
VPD
p9133
sa(dp9134
g7
I185
sg8
I1
sg9
I8
sg27
VC0497327
p9135
sg12
Vdementia
p9136
sasa(dp9137
g2
VImportantly, analysis of circulating EVs from plasma of alcoholic hepatitis patients revealed increased numbers of EVs that contained high levels of miR-27a as compared with healthy controls.
p9138
sg4
(lp9139
(dp9140
g7
I149
sg8
I1
sg9
I7
sg10
g11
sg12
VmiR-27a
p9141
sasg24
(lp9142
(dp9143
g7
I56
sg8
I2
sg9
I19
sg27
VC0019187
p9144
sg12
Valcoholic hepatitis
p9145
sasa(dp9146
g2
VThe following associations were found: auto-immune thyroid disease (4.3% of DH patients and 6.0% of CD patients), insulin dependent diabetes (1.0% DH and 5.5% CD), lupus erythematosus (1.3% DH and 0.3% CD), Sjoegren's syndrome (1.0% DH and 2.9% CD), sarcoidosis (1.3% DH and 1.8% CD), and vitiligo or alopecia areata (1.6% DH and 0% CD).
p9147
sg4
(lp9148
(dp9149
g7
I114
sg8
I1
sg9
I7
sg10
VP01308
p9150
sg12
Vinsulin
p9151
sasg24
(lp9152
(dp9153
g7
I51
sg8
I2
sg9
I15
sg27
VC0040128
p9154
sg12
Vthyroid disease
p9155
sa(dp9156
g7
I114
sg8
I3
sg9
I26
sg27
VC0011854
p9157
sg12
Vinsulin dependent diabetes
p9158
sa(dp9159
g7
I164
sg8
I2
sg9
I19
sg27
VC0409974
p9160
sg12
Vlupus erythematosus
p9161
sa(dp9162
g7
I250
sg8
I1
sg9
I11
sg27
VC0036202
p9163
sg12
Vsarcoidosis
p9164
sa(dp9165
g7
I301
sg8
I2
sg9
I15
sg27
VC0002171
p9166
sg12
Valopecia areata
p9167
sa(dp9168
g7
I207
sg8
I2
sg9
I19
sg27
VC1527336
p9169
sg12
VSjoegren's syndrome
p9170
sa(dp9171
g7
I289
sg8
I1
sg9
I8
sg27
VC0042900
p9172
sg12
Vvitiligo
p9173
sasa(dp9174
g2
VRarely, an association of parkinsonism with PN may be encountered in other neurodegenerative diseases such as fragile X-associated tremor and ataxia syndrome related to premutation CGG repeat expansion in the fragile X mental retardation (FMR1) gene, Machado-Joseph disease related to an abnormal CAG repeat expansion in ataxin-3 (ATXN3) gene, Kufor-Rakeb syndrome caused by mutations in ATP13A2 gene, or in hereditary systemic disorders such as Gaucher disease due to mutations in the Beta-glucocerebrosidase (GBA) gene and Chediak-Higashi syndrome due to LYST gene mutations.
p9175
sg4
(lp9176
(dp9177
g7
I331
sg8
I1
sg9
I5
sg10
g11
sg12
VATXN3
p9178
sa(dp9179
g7
I511
sg8
I1
sg9
I3
sg10
VP04062
p9180
sg12
VGBA
p9181
sa(dp9182
g7
I486
sg8
I1
sg9
I23
sg10
VP02774
p9183
sg12
VBeta-glucocerebrosidase
p9184
sa(dp9185
g7
I557
sg8
I2
sg9
I9
sg10
g11
sg12
VLYST gene
p9186
sa(dp9187
g7
I388
sg8
I2
sg9
I12
sg10
g11
sg12
VATP13A2 gene
p9188
sa(dp9189
g7
I321
sg8
I1
sg9
I8
sg10
g11
sg12
Vataxin-3
p9190
sasg24
(lp9191
(dp9192
g7
I344
sg8
I2
sg9
I20
sg27
VC1847640
p9193
sg12
VKufor-Rakeb syndrome
p9194
sa(dp9195
g7
I75
sg8
I2
sg9
I26
sg27
VC0524851
p9196
sg12
Vneurodegenerative diseases
p9197
sa(dp9198
g7
I525
sg8
I2
sg9
I24
sg27
VC0007965
p9199
sg12
VChediak-Higashi syndrome
p9200
sa(dp9201
g7
I149
sg8
I1
sg9
I8
sg27
VC0039082
p9202
sg12
Vsyndrome
p9203
sa(dp9204
g7
I219
sg8
I2
sg9
I18
sg27
VC0025362
p9205
sg12
Vmental retardation
p9206
sa(dp9207
g7
I142
sg8
I1
sg9
I6
sg27
VC0004134
p9208
sg12
Vataxia
p9209
sa(dp9210
g7
I26
sg8
I1
sg9
I12
sg27
VC0242422
p9211
sg12
Vparkinsonism
p9212
sa(dp9213
g7
I131
sg8
I1
sg9
I6
sg27
VC0040822
p9214
sg12
Vtremor
p9215
sa(dp9216
g7
I251
sg8
I2
sg9
I22
sg27
VC0024408
p9217
sg12
VMachado-Joseph disease
p9218
sa(dp9219
g7
I446
sg8
I2
sg9
I15
sg27
VC0017205
p9220
sg12
VGaucher disease
p9221
sasa(dp9222
g2
VWe also identified the mutation of the LYST gene, that is causative gene for Chediak-Higashi syndrome, for the autosomal recessive complicated spastic paraplegia with cerebellar ataxia and neuropathy.
p9223
sg4
(lp9224
(dp9225
g7
I39
sg8
I2
sg9
I9
sg10
g11
sg12
VLYST gene
p9226
sasg24
(lp9227
(dp9228
g7
I167
sg8
I2
sg9
I17
sg27
VC0007758
p9229
sg12
Vcerebellar ataxia
p9230
sa(dp9231
g7
I189
sg8
I1
sg9
I10
sg27
VC0442874
p9232
sg12
Vneuropathy
p9233
sa(dp9234
g7
I143
sg8
I2
sg9
I18
sg27
VC0037772
p9235
sg12
Vspastic paraplegia
p9236
sa(dp9237
g7
I77
sg8
I2
sg9
I24
sg27
VC0007965
p9238
sg12
VChediak-Higashi syndrome
p9239
sasa(dp9240
g2
VTo our knowledge, this is the first study on spina bifida to determine the nucleotide sequences of breakpoints for trisomy 2p24.3-pter and monosomy 5p14.3-pter.
p9241
sg4
(lp9242
sg24
(lp9243
(dp9244
g7
I45
sg8
I2
sg9
I12
sg27
VC0080178
p9245
sg12
Vspina bifida
p9246
sa(dp9247
g7
I139
sg8
I1
sg9
I8
sg27
VC0026499
p9248
sg12
Vmonosomy
p9249
sa(dp9250
g7
I115
sg8
I1
sg9
I7
sg27
VC0041107
p9251
sg12
Vtrisomy
p9252
sasa(dp9253
g2
VOur report serves to emphasize the consistency in the prenatal sonographic feature of spina bifida in consecutive pregnancies with fetuses associated with partial trisomy 3q (3q26.1-qter) and partial monosomy 5p (5p13.33-pter).
p9254
sg4
(lp9255
sg24
(lp9256
(dp9257
g7
I155
sg8
I2
sg9
I15
sg27
VC1297882
p9258
sg12
Vpartial trisomy
p9259
sa(dp9260
g7
I163
sg8
I2
sg9
I10
sg27
VC0795809
p9261
sg12
Vtrisomy 3q
p9262
sa(dp9263
g7
I192
sg8
I2
sg9
I16
sg27
VC0008628
p9264
sg12
Vpartial monosomy
p9265
sa(dp9266
g7
I86
sg8
I2
sg9
I12
sg27
VC0080178
p9267
sg12
Vspina bifida
p9268
sasa(dp9269
g2
VThese are classified into ten different types (NDNC1-10), which are described in OMIM.1 The genes described for isolated nail disorders include PLCD1 (MIM 602142), RSPO4 (MIM 610573), FZD6 (MIM 603409), COL7A1 (MIM 120120), HPGD (MIM 601688) and SLCO2A1 (MIM 601460).
p9270
sg4
(lp9271
(dp9272
g7
I151
sg8
I2
sg9
I10
sg10
g11
sg12
VMIM 602142
p9273
sa(dp9274
g7
I255
sg8
I2
sg9
I10
sg10
g11
sg12
VMIM 601460
p9275
sa(dp9276
g7
I203
sg8
I1
sg9
I6
sg10
g11
sg12
VCOL7A1
p9277
sa(dp9278
g7
I190
sg8
I2
sg9
I10
sg10
g11
sg12
VMIM 603409
p9279
sa(dp9280
g7
I184
sg8
I1
sg9
I4
sg10
g11
sg12
VFZD6
p9281
sa(dp9282
g7
I211
sg8
I2
sg9
I10
sg10
g11
sg12
VMIM 120120
p9283
sa(dp9284
g7
I144
sg8
I1
sg9
I5
sg10
VP51178
p9285
sg12
VPLCD1
p9286
sa(dp9287
g7
I171
sg8
I2
sg9
I10
sg10
g11
sg12
VMIM 610573
p9288
sa(dp9289
g7
I164
sg8
I1
sg9
I5
sg10
g11
sg12
VRSPO4
p9290
sa(dp9291
g7
I246
sg8
I1
sg9
I7
sg10
g11
sg12
VSLCO2A1
p9292
sasg24
(lp9293
(dp9294
g7
I121
sg8
I2
sg9
I14
sg27
VC0027339
p9295
sg12
Vnail disorders
p9296
sa(dp9297
g7
I47
sg8
I1
sg9
I5
sg27
VC0406443
p9298
sg12
VNDNC1
p9299
sasa(dp9300
g2
VAnonychia/hyponychia congenita is a rare autosomal recessive developmental disorder characterized by the absence (anonychia) or hypoplasia (hyponuchia) of finger- and/or toenails frequently caused by mutations in the R-spondin 4 (RSPO4) gene.
p9301
sg4
(lp9302
(dp9303
g7
I217
sg8
I2
sg9
I11
sg10
g11
sg12
VR-spondin 4
p9304
sa(dp9305
g7
I230
sg8
I1
sg9
I5
sg10
g11
sg12
VRSPO4
p9306
sasg24
(lp9307
(dp9308
g7
I128
sg8
I1
sg9
I10
sg27
VC0243069
p9309
sg12
Vhypoplasia
p9310
sa(dp9311
g7
I0
sg8
I13
sg9
I112
sg27
VC0265998
p9312
sg12
VAnonychia/hyponychia congenita is a rare autosomal recessive developmental disorder characterized by the absence
p9313
sa(dp9314
g7
I114
sg8
I1
sg9
I9
sg27
VC0265998
p9315
sg12
Vanonychia
p9316
sasa(dp9317
g2
VBecause there were no other congenital abnormalities, this was considered to be anonychia congenita; probably caused by a recessive defect of the R-spondin 4-coding gene.
p9318
sg4
(lp9319
(dp9320
g7
I146
sg8
I3
sg9
I23
sg10
g11
sg12
VR-spondin 4-coding gene
p9321
sasg24
(lp9322
(dp9323
g7
I80
sg8
I2
sg9
I19
sg27
VC0265998
p9324
sg12
Vanonychia congenita
p9325
sa(dp9326
g7
I28
sg8
I2
sg9
I24
sg27
VC0000768
p9327
sg12
Vcongenital abnormalities
p9328
sasa(dp9329
g2
VTo investigate whether receipt of any antithrombin concentrate improves laboratory and clinical outcomes in children undergoing extracorporeal membrane oxygenation for respiratory failure during their hospitalization compared with those who did not receive antithrombin.
p9330
sg4
(lp9331
(dp9332
g7
I38
sg8
I1
sg9
I12
sg10
VP05546
p9333
sg12
Vantithrombin
p9334
sa(dp9335
g7
I38
sg8
I1
sg9
I12
sg10
VP05546
p9336
sg12
Vantithrombin
p9337
sasg24
(lp9338
(dp9339
g7
I168
sg8
I2
sg9
I19
sg27
VC1145670
p9340
sg12
Vrespiratory failure
p9341
sasa(dp9342
g2
VIntermittent, on-demand dosing of antithrombin concentrate in pediatric patients on extracorporeal membrane oxygenation for respiratory failure increased antithrombin levels, but not typically to the targeted level.
p9343
sg4
(lp9344
(dp9345
g7
I34
sg8
I1
sg9
I12
sg10
VP05546
p9346
sg12
Vantithrombin
p9347
sa(dp9348
g7
I34
sg8
I1
sg9
I12
sg10
VP05546
p9349
sg12
Vantithrombin
p9350
sasg24
(lp9351
(dp9352
g7
I124
sg8
I2
sg9
I19
sg27
VC1145670
p9353
sg12
Vrespiratory failure
p9354
sasa(dp9355
g2
VWe hypothesized that combining intravenous recombinant human antithrombin (rhAT), nebulized heparin, and nebulized tissue plasminogen activator (TPA) more effectively improves pulmonary gas exchange compared with a single rhAT infusion, while maintaining the anti-inflammatory properties of rhAT in ARDS.
p9356
sg4
(lp9357
(dp9358
g7
I75
sg8
I1
sg9
I4
sg10
VP05546
p9359
sg12
VrhAT
p9360
sa(dp9361
g7
I75
sg8
I1
sg9
I4
sg10
VP05546
p9362
sg12
VrhAT
p9363
sa(dp9364
g7
I43
sg8
I3
sg9
I30
sg10
VP05546
p9365
sg12
Vrecombinant human antithrombin
p9366
sa(dp9367
g7
I145
sg8
I1
sg9
I3
sg10
VP00747
p9368
sg12
VTPA
p9369
sa(dp9370
g7
I75
sg8
I1
sg9
I4
sg10
VP05546
p9371
sg12
VrhAT
p9372
sa(dp9373
g7
I115
sg8
I3
sg9
I28
sg10
VP00747
p9374
sg12
Vtissue plasminogen activator
p9375
sasg24
(lp9376
(dp9377
g7
I299
sg8
I1
sg9
I4
sg27
VC0035222
p9378
sg12
VARDS
p9379
sasa(dp9380
g2
VAfter 12 months, bonds fell from 43.9 +/- 9.5 MPa to 20.1 +/- 5.4 MPa and from 39.6 +/- 9.4 MPa to 14.2 +/- 5.0 MPa in control specimens for SB1 and XPB respectively, while bond fell only from 41.9 +/- 9.6MPa to 33.2 +/- 8.3 MPa and 38.3 +/- 8.9 MPa to 26.5 +/- 10.9 (for SB1 and XPB, respectively) when 0.2% CHX was previously used.
p9381
sg4
(lp9382
(dp9383
g7
I141
sg8
I1
sg9
I3
sg10
g11
sg12
VSB1
p9384
sa(dp9385
g7
I149
sg8
I1
sg9
I3
sg10
VP19447
p9386
sg12
VXPB
p9387
sasg24
(lp9388
(dp9389
g7
I149
sg8
I1
sg9
I3
sg27
VC0268136
p9390
sg12
VXPB
p9391
sa(dp9392
g7
I149
sg8
I1
sg9
I3
sg27
VC0268136
p9393
sg12
VXPB
p9394
sasa(dp9395
g2
VPrimary SFs from patients with rheumatoid arthritis (RA) were treated with recombinant human bone morphogenetic protein-2 or transduced with a constitutively active mutant of the ALK3 gene (ALK3CA) with or without TNF-Alfa, and then cultured in pellets.
p9396
sg4
(lp9397
(dp9398
g7
I179
sg8
I2
sg9
I9
sg10
VP36894
p9399
sg12
VALK3 gene
p9400
sa(dp9401
g7
I214
sg8
I1
sg9
I8
sg10
VP01375
p9402
sg12
VTNF-Alfa
p9403
sasg24
(lp9404
(dp9405
g7
I53
sg8
I1
sg9
I2
sg27
VC0003873
p9406
sg12
VRA
p9407
sa(dp9408
g7
I165
sg8
I1
sg9
I6
sg27
VC0596988
p9409
sg12
Vmutant
p9410
sa(dp9411
g7
I31
sg8
I2
sg9
I20
sg27
VC0003873
p9412
sg12
Vrheumatoid arthritis
p9413
sasa(dp9414
g2
VWe describe a patient with ALK-negative ALCL presenting with clinical and radiographic findings suggesting osteomyelitis 6 months after left rotator cuff repair surgery.
p9415
sg4
(lp9416
sg24
(lp9417
(dp9418
g7
I40
sg8
I1
sg9
I4
sg27
VC0206180
p9419
sg12
VALCL
p9420
sa(dp9421
g7
I107
sg8
I1
sg9
I13
sg27
VC0029443
p9422
sg12
Vosteomyelitis
p9423
sasa(dp9424
g2
VWe compared levels of GABA(B) receptor subunits GABA(B) receptor 1 (GABBR1) and GABA(B) receptor 2 (GABBR2) in cerebellum, Brodmann's area 9 (BA9), and BA40 of subjects with autism and matched controls.
p9425
sg4
(lp9426
(dp9427
g7
I80
sg8
I3
sg9
I18
sg10
g11
sg12
VGABA(B) receptor 2
p9428
sa(dp9429
g7
I100
sg8
I1
sg9
I6
sg10
g11
sg12
VGABBR2
p9430
sa(dp9431
g7
I48
sg8
I3
sg9
I18
sg10
g11
sg12
VGABA(B) receptor 1
p9432
sa(dp9433
g7
I22
sg8
I2
sg9
I16
sg10
g11
sg12
VGABA(B) receptor
p9434
sa(dp9435
g7
I68
sg8
I1
sg9
I6
sg10
g11
sg12
VGABBR1
p9436
sasg24
(lp9437
(dp9438
g7
I174
sg8
I1
sg9
I6
sg27
VC0004352
p9439
sg12
Vautism
p9440
sasa(dp9441
g2
VSclerosteosis is caused by loss-of-function mutations in the SOST gene which encodes a secreted glycoprotein, sclerostin.
p9442
sg4
(lp9443
(dp9444
g7
I61
sg8
I2
sg9
I9
sg10
g11
sg12
VSOST gene
p9445
sasg24
(lp9446
(dp9447
g7
I0
sg8
I1
sg9
I13
sg27
VC0265301
p9448
sg12
VSclerosteosis
p9449
sa(dp9450
g7
I61
sg8
I1
sg9
I4
sg27
VC0265301
p9451
sg12
VSOST
p9452
sasa(dp9453
g2
VVBD is caused by a noncoding deletion that removes a SOST-specific regulatory element in bone.
p9454
sg4
(lp9455
sg24
(lp9456
(dp9457
g7
I53
sg8
I1
sg9
I4
sg27
VC0265301
p9458
sg12
VSOST
p9459
sasa(dp9460
g2
VHere we describe how human genetics studies in sclerosteosis and VBD patients, in combination with the generation of transgenic and knockout mice, has led to a better understanding of the role of sclerostin in bone metabolism.
p9461
sg4
(lp9462
(dp9463
g7
I196
sg8
I1
sg9
I10
sg10
g11
sg12
Vsclerostin
p9464
sasg24
(lp9465
(dp9466
g7
I47
sg8
I1
sg9
I13
sg27
VC0265301
p9467
sg12
Vsclerosteosis
p9468
sasa(dp9469
g2
VIn addition, expression of SOST is delayed or suppressed; resulting in active WNT signaling and enhanced periosteal bone formation, and the combined outcome is generalized hyperostosis.
p9470
sg4
(lp9471
(dp9472
g7
I27
sg8
I1
sg9
I4
sg10
g11
sg12
VSOST
p9473
sasg24
(lp9474
(dp9475
g7
I27
sg8
I1
sg9
I4
sg27
VC0265301
p9476
sg12
VSOST
p9477
sa(dp9478
g7
I172
sg8
I1
sg9
I12
sg27
VC0020492
p9479
sg12
Vhyperostosis
p9480
sasa(dp9481
g2
VInitially, we and others reported that sclerosteosis was caused by loss-of-function mutations in SOST, encoding sclerostin.
p9482
sg4
(lp9483
(dp9484
g7
I97
sg8
I1
sg9
I4
sg10
g11
sg12
VSOST
p9485
sasg24
(lp9486
(dp9487
g7
I97
sg8
I1
sg9
I4
sg27
VC0265301
p9488
sg12
VSOST
p9489
sa(dp9490
g7
I39
sg8
I1
sg9
I13
sg27
VC0265301
p9491
sg12
Vsclerosteosis
p9492
sasa(dp9493
g2
VMore recently, we identified disease-causing mutations in LRP4, a binding partner of sclerostin, in three sclerosteosis patients.
p9494
sg4
(lp9495
(dp9496
g7
I85
sg8
I1
sg9
I10
sg10
g11
sg12
Vsclerostin
p9497
sa(dp9498
g7
I58
sg8
I1
sg9
I4
sg10
g11
sg12
VLRP4
p9499
sasg24
(lp9500
(dp9501
g7
I106
sg8
I1
sg9
I13
sg27
VC0265301
p9502
sg12
Vsclerosteosis
p9503
sasa(dp9504
g2
VThe positive correlation we found between sclerostin and age in Paget disease of bone patients indicates that in comparative studies, sclerostin serum levels must be adjusted for age.
p9505
sg4
(lp9506
sg24
(lp9507
(dp9508
g7
I64
sg8
I4
sg9
I21
sg27
VC0029401
p9509
sg12
VPaget disease of bone
p9510
sasa(dp9511
g2
VSclerosteosis and van Buchem disease are two rare bone sclerosing dysplasias caused by genetic defects in the synthesis of sclerostin.
p9512
sg4
(lp9513
sg24
(lp9514
(dp9515
g7
I0
sg8
I1
sg9
I13
sg27
VC0265301
p9516
sg12
VSclerosteosis
p9517
sa(dp9518
g7
I18
sg8
I3
sg9
I18
sg27
VC0432272
p9519
sg12
Vvan Buchem disease
p9520
sa(dp9521
g7
I66
sg8
I1
sg9
I10
sg27
VC0334044
p9522
sg12
Vdysplasias
p9523
sasa(dp9524
g2
VIn this article we review the demographic, clinical, biochemical, radiological, and histological characteristics of patients with sclerosteosis and van Buchem disease that led to a better understanding of the role of sclerostin in bone metabolism in humans and we discuss the relevance of these findings for the development of new therapeutics for the treatment of patients with osteoporosis.
p9525
sg4
(lp9526
(dp9527
g7
I217
sg8
I1
sg9
I10
sg10
g11
sg12
Vsclerostin
p9528
sasg24
(lp9529
(dp9530
g7
I148
sg8
I3
sg9
I18
sg27
VC0432272
p9531
sg12
Vvan Buchem disease
p9532
sa(dp9533
g7
I379
sg8
I1
sg9
I12
sg27
VC0029456
p9534
sg12
Vosteoporosis
p9535
sa(dp9536
g7
I130
sg8
I1
sg9
I13
sg27
VC0265301
p9537
sg12
Vsclerosteosis
p9538
sasa(dp9539
g2
VAfter discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical studies demonstrated that sclerostin plays a critical role in bone homeostasis and that its deficiency or pharmacological neutralization increases bone formation.
p9540
sg4
(lp9541
(dp9542
g7
I36
sg8
I1
sg9
I10
sg10
g11
sg12
Vsclerostin
p9543
sa(dp9544
g7
I31
sg8
I1
sg9
I4
sg10
g11
sg12
VSost
p9545
sasg24
(lp9546
(dp9547
g7
I132
sg8
I1
sg9
I13
sg27
VC0265301
p9548
sg12
Vsclerosteosis
p9549
sa(dp9550
g7
I99
sg8
I1
sg9
I9
sg27
VC0039082
p9551
sg12
Vsyndromes
p9552
sa(dp9553
g7
I31
sg8
I1
sg9
I4
sg27
VC0265301
p9554
sg12
VSost
p9555
sa(dp9556
g7
I109
sg8
I3
sg9
I18
sg27
VC0432272
p9557
sg12
VVan Buchem disease
p9558
sasa(dp9559
g2
VLoss-of-function mutations of the sclerostin gene (SOST) cause sclerosteosis and Van Buchem disease characterized by bone overgrowth.
p9560
sg4
(lp9561
(dp9562
g7
I34
sg8
I2
sg9
I15
sg10
g11
sg12
Vsclerostin gene
p9563
sa(dp9564
g7
I51
sg8
I1
sg9
I4
sg10
g11
sg12
VSOST
p9565
sasg24
(lp9566
(dp9567
g7
I34
sg8
I2
sg9
I15
sg27
VC0265301
p9568
sg12
Vsclerostin gene
p9569
sa(dp9570
g7
I63
sg8
I1
sg9
I13
sg27
VC0265301
p9571
sg12
Vsclerosteosis
p9572
sa(dp9573
g7
I51
sg8
I1
sg9
I4
sg27
VC0265301
p9574
sg12
VSOST
p9575
sa(dp9576
g7
I81
sg8
I3
sg9
I18
sg27
VC0432272
p9577
sg12
VVan Buchem disease
p9578
sasa(dp9579
g2
VMutations in the human sclerostin gene (SOST) lead to sclerosteosis with progressive skeletal overgrowth, whereas sclerostin-deficient (Sost(-/-)) mice exhibit increased bone mass and strength.
p9580
sg4
(lp9581
(dp9582
g7
I17
sg8
I3
sg9
I21
sg10
g11
sg12
Vhuman sclerostin gene
p9583
sa(dp9584
g7
I40
sg8
I1
sg9
I4
sg10
g11
sg12
VSOST
p9585
sasg24
(lp9586
(dp9587
g7
I23
sg8
I2
sg9
I15
sg27
VC0265301
p9588
sg12
Vsclerostin gene
p9589
sa(dp9590
g7
I136
sg8
I1
sg9
I4
sg27
VC0265301
p9591
sg12
VSost
p9592
sa(dp9593
g7
I40
sg8
I1
sg9
I4
sg27
VC0265301
p9594
sg12
VSOST
p9595
sa(dp9596
g7
I54
sg8
I1
sg9
I13
sg27
VC0265301
p9597
sg12
Vsclerosteosis
p9598
sasa(dp9599
g2
VTherefore, this study provides additional support to develop OGA inhibitors as a treatment for Alzheimer's disease and other neurodegenerative tauopathies.
p9600
sg4
(lp9601
(dp9602
g7
I61
sg8
I1
sg9
I3
sg10
g11
sg12
VOGA
p9603
sasg24
(lp9604
(dp9605
g7
I143
sg8
I1
sg9
I11
sg27
VC0949664
p9606
sg12
Vtauopathies
p9607
sa(dp9608
g7
I95
sg8
I2
sg9
I19
sg27
VC1521724
p9609
sg12
VAlzheimer's disease
p9610
sasa(dp9611
g2
VTo identify the association between gastrointestinal carcinomas (GIC) risk and UDP-glucuronosyltransferases (UGTs) 1A7 polymorphisms through a systematic review and network meta-analysis.
p9612
sg4
(lp9613
(dp9614
g7
I79
sg8
I1
sg9
I28
sg10
g11
sg12
VUDP-glucuronosyltransferases
p9615
sa(dp9616
g7
I109
sg8
I1
sg9
I4
sg10
g11
sg12
VUGTs
p9617
sasg24
(lp9618
(dp9619
g7
I53
sg8
I1
sg9
I10
sg27
VC0007097
p9620
sg12
Vcarcinomas
p9621
sasa(dp9622
g2
VIn this study, the expression and regulation of two androgen-inactivating enzymes, the UDP-glucuronosyltransferases UGT2B15 and UGT2B17, was assessed in breast cancer.
p9623
sg4
(lp9624
(dp9625
g7
I128
sg8
I1
sg9
I7
sg10
g11
sg12
VUGT2B17
p9626
sa(dp9627
g7
I87
sg8
I2
sg9
I36
sg10
VP54855
p9628
sg12
VUDP-glucuronosyltransferases UGT2B15
p9629
sasg24
(lp9630
(dp9631
g7
I153
sg8
I2
sg9
I13
sg27
VC0678222
p9632
sg12
Vbreast cancer
p9633
sasa(dp9634
g2
VGlobal ablation of INSL3 hormone or its receptor RXFP2 in male mice results in cryptorchidism and infertility.
p9635
sg4
(lp9636
(dp9637
g7
I49
sg8
I1
sg9
I5
sg10
g11
sg12
VRXFP2
p9638
sa(dp9639
g7
I19
sg8
I2
sg9
I13
sg10
VP51460
p9640
sg12
VINSL3 hormone
p9641
sasg24
(lp9642
(dp9643
g7
I98
sg8
I1
sg9
I11
sg27
VC0021359
p9644
sg12
Vinfertility
p9645
sa(dp9646
g7
I79
sg8
I1
sg9
I14
sg27
VC0010417
p9647
sg12
Vcryptorchidism
p9648
sasa(dp9649
g2
VWe have also produced shRNA transgenic mice with reduced RXFP2 expression Such males manifested various degree of uni- and bilateral cryptorchidism.
p9650
sg4
(lp9651
(dp9652
g7
I57
sg8
I1
sg9
I5
sg10
g11
sg12
VRXFP2
p9653
sasg24
(lp9654
(dp9655
g7
I123
sg8
I2
sg9
I24
sg27
VC0431663
p9656
sg12
Vbilateral cryptorchidism
p9657
sasa(dp9658
g2
VTo study the consequences of an aberrant testicular environment in cryptorchidism we used a mouse model with a deletion of Rxfp2 gene resulting in a high intra-abdominal testicular position.
p9659
sg4
(lp9660
(dp9661
g7
I123
sg8
I2
sg9
I10
sg10
g11
sg12
VRxfp2 gene
p9662
sasg24
(lp9663
(dp9664
g7
I67
sg8
I1
sg9
I14
sg27
VC0010417
p9665
sg12
Vcryptorchidism
p9666
sasa(dp9667
g2
VDeletion of Insl3 or Rxfp2 genes in mice caused cryptorchidism resulting from a failure of gubernaculum development.
p9668
sg4
(lp9669
(dp9670
g7
I12
sg8
I1
sg9
I5
sg10
VP51460
p9671
sg12
VInsl3
p9672
sa(dp9673
g7
I21
sg8
I2
sg9
I11
sg10
g11
sg12
VRxfp2 genes
p9674
sasg24
(lp9675
(dp9676
g7
I48
sg8
I1
sg9
I14
sg27
VC0010417
p9677
sg12
Vcryptorchidism
p9678
sasa(dp9679
g2
VUsing Cre transgene driven by retinoic acid receptor beta promoter, conditional gene targeting in gubernacular mesenchymal cells at early embryonic stages caused high intraabdominal cryptorchidism as in males with a global deletion of Rxfp2.
p9680
sg4
(lp9681
(dp9682
g7
I30
sg8
I5
sg9
I36
sg10
VP10826
p9683
sg12
Vretinoic acid receptor beta promoter
p9684
sa(dp9685
g7
I6
sg8
I2
sg9
I13
sg10
g11
sg12
VCre transgene
p9686
sa(dp9687
g7
I235
sg8
I1
sg9
I5
sg10
g11
sg12
VRxfp2
p9688
sasg24
(lp9689
(dp9690
g7
I182
sg8
I1
sg9
I14
sg27
VC0010417
p9691
sg12
Vcryptorchidism
p9692
sasa(dp9693
g2
VPrenatal exposure to diethylstilbestrol affected the expression of LGR8 mRNA in the mouse gubernaculum testis, which suggests that diethylstilbestrol may induce cryptorchidism by interfering with the INSL3-LGR8 signaling system and consequently the development of the gubernaculum testis.
p9694
sg4
(lp9695
(dp9696
g7
I67
sg8
I1
sg9
I4
sg10
VP51460
p9697
sg12
VLGR8
p9698
sa(dp9699
g7
I200
sg8
I1
sg9
I5
sg10
VP51460
p9700
sg12
VINSL3
p9701
sa(dp9702
g7
I67
sg8
I2
sg9
I9
sg10
VP51460
p9703
sg12
VLGR8 mRNA
p9704
sasg24
(lp9705
(dp9706
g7
I161
sg8
I1
sg9
I14
sg27
VC0010417
p9707
sg12
Vcryptorchidism
p9708
sasa(dp9709
g2
VProspectively collected cremaster muscle and/or hernia sac tissues from boys with congenital (79) or acquired (66) nonsyndromic cryptorchidism and hernia/hydrocele (controls, 84) were analyzed for hormone receptor (RXFP2, AR, ESR1, ESR2) and myosin heavy chain specific (MYH1, MYH2, MYH7) mRNA expression using real-time reverse transcriptase polymerase chain reaction.
p9710
sg4
(lp9711
(dp9712
g7
I226
sg8
I1
sg9
I4
sg10
VP03372
p9713
sg12
VESR1
p9714
sa(dp9715
g7
I277
sg8
I1
sg9
I4
sg10
g11
sg12
VMYH2
p9716
sa(dp9717
g7
I242
sg8
I3
sg9
I18
sg10
VP13535
p9718
sg12
Vmyosin heavy chain
p9719
sa(dp9720
g7
I193
sg8
I3
sg9
I20
sg10
VP22736
p9721
sg12
Vfor hormone receptor
p9722
sa(dp9723
g7
I271
sg8
I1
sg9
I4
sg10
VP12882
p9724
sg12
VMYH1
p9725
sa(dp9726
g7
I215
sg8
I1
sg9
I5
sg10
g11
sg12
VRXFP2
p9727
sasg24
(lp9728
(dp9729
g7
I48
sg8
I2
sg9
I10
sg27
VC0333062
p9730
sg12
Vhernia sac
p9731
sa(dp9732
g7
I128
sg8
I1
sg9
I14
sg27
VC0010417
p9733
sg12
Vcryptorchidism
p9734
sa(dp9735
g7
I48
sg8
I1
sg9
I6
sg27
VC0019270
p9736
sg12
Vhernia
p9737
sa(dp9738
g7
I154
sg8
I1
sg9
I9
sg27
VC1720771
p9739
sg12
Vhydrocele
p9740
sasa(dp9741
g2
VExon sequencing of candidate genes identified mutations in mice with cystic kidneys (Bicc1), cryptorchidism (Rxfp2), restricted germ cell deficiency (Plk4), and severe germ cell deficiency (Prdm9).
p9742
sg4
(lp9743
(dp9744
g7
I150
sg8
I1
sg9
I4
sg10
g11
sg12
VPlk4
p9745
sa(dp9746
g7
I109
sg8
I1
sg9
I5
sg10
g11
sg12
VRxfp2
p9747
sa(dp9748
g7
I190
sg8
I1
sg9
I5
sg10
g11
sg12
VPrdm9
p9749
sa(dp9750
g7
I85
sg8
I1
sg9
I5
sg10
g11
sg12
VBicc1
p9751
sasg24
(lp9752
(dp9753
g7
I93
sg8
I1
sg9
I14
sg27
VC0010417
p9754
sg12
Vcryptorchidism
p9755
sa(dp9756
g7
I69
sg8
I2
sg9
I14
sg27
VC0022679
p9757
sg12
Vcystic kidneys
p9758
sasa(dp9759
g2
VPatients with definite pneumonia at the time of admission, those with left-sided heart failure, pulmonary embolism and an identifiable cause of acute lung injury, and those whose albumin or C-reactive protein levels were not measured were excluded.
p9760
sg4
(lp9761
(dp9762
g7
I190
sg8
I2
sg9
I18
sg10
VP02741
p9763
sg12
VC-reactive protein
p9764
sa(dp9765
g7
I179
sg8
I1
sg9
I7
sg10
VP00441
p9766
sg12
Valbumin
p9767
sasg24
(lp9768
(dp9769
g7
I96
sg8
I2
sg9
I18
sg27
VC0034065
p9770
sg12
Vpulmonary embolism
p9771
sa(dp9772
g7
I23
sg8
I1
sg9
I9
sg27
VC0032285
p9773
sg12
Vpneumonia
p9774
sa(dp9775
g7
I70
sg8
I3
sg9
I24
sg27
VC0023212
p9776
sg12
Vleft-sided heart failure
p9777
sasa(dp9778
g2
VAnalyzing gene expression signatures in endometrial and stomach adenocarcinomas revealed that tumors with a JAK1 frameshift exhibited reduced expression of interferon response signatures and multiple anti-tumor immune signatures.
p9779
sg4
(lp9780
(dp9781
g7
I156
sg8
I1
sg9
I10
sg10
VP01563
p9782
sg12
Vinterferon
p9783
sa(dp9784
g7
I108
sg8
I1
sg9
I4
sg10
VP23458
p9785
sg12
VJAK1
p9786
sasg24
(lp9787
(dp9788
g7
I64
sg8
I1
sg9
I15
sg27
VC0001418
p9789
sg12
Vadenocarcinomas
p9790
sa(dp9791
g7
I113
sg8
I1
sg9
I10
sg27
VC0079380
p9792
sg12
Vframeshift
p9793
sa(dp9794
g7
I94
sg8
I1
sg9
I6
sg27
VC0027651
p9795
sg12
Vtumors
p9796
sa(dp9797
g7
I94
sg8
I1
sg9
I5
sg27
VC0027651
p9798
sg12
Vtumor
p9799
sasa(dp9800
g2
VFrom these data, we derive two primary conclusions: 1) JAK1 frameshifts are loss of function alterations that represent a potential pan-cancer adaptation to immune responses against tumors with microsatellite instability; 2) The mechanism by which JAK1 loss of function contributes to tumor immune evasion is likely associated with loss of the JAK1-mediated interferon response.
p9801
sg4
(lp9802
(dp9803
g7
I358
sg8
I1
sg9
I10
sg10
VP01563
p9804
sg12
Vinterferon
p9805
sa(dp9806
g7
I55
sg8
I1
sg9
I4
sg10
VP23458
p9807
sg12
VJAK1
p9808
sa(dp9809
g7
I55
sg8
I1
sg9
I4
sg10
VP23458
p9810
sg12
VJAK1
p9811
sa(dp9812
g7
I55
sg8
I1
sg9
I4
sg10
VP23458
p9813
sg12
VJAK1
p9814
sasg24
(lp9815
(dp9816
g7
I136
sg8
I1
sg9
I6
sg27
VC0006826
p9817
sg12
Vcancer
p9818
sa(dp9819
g7
I182
sg8
I1
sg9
I6
sg27
VC0027651
p9820
sg12
Vtumors
p9821
sa(dp9822
g7
I285
sg8
I3
sg9
I20
sg27
VC0282683
p9823
sg12
Vtumor immune evasion
p9824
sa(dp9825
g7
I194
sg8
I2
sg9
I26
sg27
VC0920269
p9826
sg12
Vmicrosatellite instability
p9827
sasa(dp9828
g2
VMAJIC (ISRCTN61925716) is a randomized phase 2 trial of ruxolitinib (JAK1/2 inhibitor) vs best available therapy (BAT) in ET and polycythemia vera patients resistant or intolerant to HC.
p9829
sg4
(lp9830
(dp9831
g7
I69
sg8
I1
sg9
I6
sg10
VP23458
p9832
sg12
VJAK1/2
p9833
sasg24
(lp9834
(dp9835
g7
I129
sg8
I2
sg9
I17
sg27
VC0032463
p9836
sg12
Vpolycythemia vera
p9837
sasa(dp9838
g2
VRuxolitinib (Rux), a JAK1/2 inhibitor, has been approved for patients with myelofibrosis and in polycythemia vera with inadequate response/intolerance to hydroxycarbamide.
p9839
sg4
(lp9840
(dp9841
g7
I21
sg8
I1
sg9
I6
sg10
VP23458
p9842
sg12
VJAK1/2
p9843
sasg24
(lp9844
(dp9845
g7
I75
sg8
I1
sg9
I13
sg27
VC0001815
p9846
sg12
Vmyelofibrosis
p9847
sa(dp9848
g7
I96
sg8
I2
sg9
I17
sg27
VC0032463
p9849
sg12
Vpolycythemia vera
p9850
sasa(dp9851
g2
VFibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder that is characterized by episodic yet cumulative heterotopic ossification (HO) in skeletal muscles, tendons, and ligaments over a patient's lifetime.
p9852
sg4
(lp9853
sg24
(lp9854
(dp9855
g7
I157
sg8
I1
sg9
I2
sg27
VC0029396
p9856
sg12
VHO
p9857
sa(dp9858
g7
I0
sg8
I3
sg9
I37
sg27
VC0016037
p9859
sg12
VFibrodysplasia ossificans progressiva
p9860
sa(dp9861
g7
I131
sg8
I2
sg9
I24
sg27
VC0029396
p9862
sg12
Vheterotopic ossification
p9863
sa(dp9864
g7
I39
sg8
I1
sg9
I3
sg27
VC0016037
p9865
sg12
VFOP
p9866
sasa(dp9867
g2
VGain-of-function mutations in the Type I Bone Morphogenic Protein (BMP) receptor ACVR1 have been identified in two diseases: Fibrodysplasia Ossificans Progressiva (FOP), a rare autosomal dominant disorder characterized by genetically driven heterotopic ossification, and in 20-25% of Diffuse Intrinsic Pontine Gliomas (DIPGs), a pediatric brain tumor with no effective therapies and dismal median survival.
p9868
sg4
(lp9869
(dp9870
g7
I34
sg8
I5
sg9
I31
sg10
VP29475
p9871
sg12
VType I Bone Morphogenic Protein
p9872
sasg24
(lp9873
(dp9874
g7
I329
sg8
I3
sg9
I21
sg27
VC0220603
p9875
sg12
Vpediatric brain tumor
p9876
sa(dp9877
g7
I310
sg8
I1
sg9
I7
sg27
VC0017638
p9878
sg12
VGliomas
p9879
sa(dp9880
g7
I241
sg8
I2
sg9
I24
sg27
VC0029396
p9881
sg12
Vheterotopic ossification
p9882
sa(dp9883
g7
I164
sg8
I1
sg9
I3
sg27
VC0016037
p9884
sg12
VFOP
p9885
sa(dp9886
g7
I125
sg8
I3
sg9
I37
sg27
VC0016037
p9887
sg12
VFibrodysplasia Ossificans Progressiva
p9888
sasa(dp9889
g2
VFibrodysplasia ossificans progressiva is an autosomal dominant disorder due to germline mutations of ACVR1/ALK2 causing progressive heterotopic endochondral ossifications.
p9890
sg4
(lp9891
(dp9892
g7
I107
sg8
I1
sg9
I4
sg10
g11
sg12
VALK2
p9893
sa(dp9894
g7
I101
sg8
I1
sg9
I5
sg10
g11
sg12
VACVR1
p9895
sasg24
(lp9896
(dp9897
g7
I0
sg8
I3
sg9
I37
sg27
VC0016037
p9898
sg12
VFibrodysplasia ossificans progressiva
p9899
sasa(dp9900
g2
VIt is an autosomal dominant disease, usually caused by a new mutation in the ACVR1 receptor gene, which is in the signaling pathway for bone morphogenic protein.
p9901
sg4
(lp9902
(dp9903
g7
I77
sg8
I3
sg9
I19
sg10
g11
sg12
VACVR1 receptor gene
p9904
sasg24
(lp9905
(dp9906
g7
I57
sg8
I2
sg9
I12
sg27
VC2985439
p9907
sg12
Vnew mutation
p9908
sasa(dp9909
g2
VFibrodysplasia ossificans progressiva (FOP), characterized by congenital malformation of bones, is an autosomal dominant disorder.
p9910
sg4
(lp9911
sg24
(lp9912
(dp9913
g7
I0
sg8
I3
sg9
I37
sg27
VC0016037
p9914
sg12
VFibrodysplasia ossificans progressiva
p9915
sa(dp9916
g7
I62
sg8
I2
sg9
I23
sg27
VC1705254
p9917
sg12
Vcongenital malformation
p9918
sa(dp9919
g7
I39
sg8
I1
sg9
I3
sg27
VC0016037
p9920
sg12
VFOP
p9921
sasa(dp9922
g2
VFibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by progressive heterotopic ossification in skeletal muscle tissue.
p9923
sg4
(lp9924
sg24
(lp9925
(dp9926
g7
I0
sg8
I3
sg9
I37
sg27
VC0016037
p9927
sg12
VFibrodysplasia ossificans progressiva
p9928
sa(dp9929
g7
I111
sg8
I2
sg9
I24
sg27
VC0029396
p9930
sg12
Vheterotopic ossification
p9931
sa(dp9932
g7
I39
sg8
I1
sg9
I3
sg27
VC0016037
p9933
sg12
VFOP
p9934
sasa(dp9935
g2
VFibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by progressive heterotopic ossification.
p9936
sg4
(lp9937
sg24
(lp9938
(dp9939
g7
I0
sg8
I3
sg9
I37
sg27
VC0016037
p9940
sg12
VFibrodysplasia ossificans progressiva
p9941
sa(dp9942
g7
I111
sg8
I2
sg9
I24
sg27
VC0029396
p9943
sg12
Vheterotopic ossification
p9944
sa(dp9945
g7
I39
sg8
I1
sg9
I3
sg27
VC0016037
p9946
sg12
VFOP
p9947
sasa(dp9948
g2
VLoss of ORAI1 function is linked with rheumatoid arthritis (RA) and hence pharmacological blockers of ORAI1 could be potential therapeutic agents for the treatment of RA.
p9949
sg4
(lp9950
(dp9951
g7
I8
sg8
I1
sg9
I5
sg10
g11
sg12
VORAI1
p9952
sa(dp9953
g7
I8
sg8
I1
sg9
I5
sg10
g11
sg12
VORAI1
p9954
sasg24
(lp9955
(dp9956
g7
I9
sg8
I1
sg9
I2
sg27
VC0003873
p9957
sg12
VRA
p9958
sa(dp9959
g7
I9
sg8
I1
sg9
I2
sg27
VC0003873
p9960
sg12
VRA
p9961
sa(dp9962
g7
I38
sg8
I2
sg9
I20
sg27
VC0003873
p9963
sg12
Vrheumatoid arthritis
p9964
sasa(dp9965
g2
VTo determine whether Ca(2+) release-activated Ca(2+) (CRAC) channels contribute to the abnormal behaviour of T cells in patients with rheumatoid arthritis (RA), we performed a cross-sectional study to characterize the expression and functional status of CRACM1 channels in RA patients.
p9966
sg4
(lp9967
sg24
(lp9968
(dp9969
g7
I87
sg8
I2
sg9
I18
sg27
VC0233514
p9970
sg12
Vabnormal behaviour
p9971
sa(dp9972
g7
I134
sg8
I2
sg9
I20
sg27
VC0003873
p9973
sg12
Vrheumatoid arthritis
p9974
sa(dp9975
g7
I55
sg8
I1
sg9
I2
sg27
VC0003873
p9976
sg12
VRA
p9977
sa(dp9978
g7
I55
sg8
I1
sg9
I2
sg27
VC0003873
p9979
sg12
VRA
p9980
sasa(dp9981
g2
VSince autoreactive T cells play an important role in the development of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and organ transplantation, Orai1 becomes an attractive therapeutic target for ameliorating autoimmune disease.
p9982
sg4
(lp9983
(dp9984
g7
I169
sg8
I1
sg9
I5
sg10
g11
sg12
VOrai1
p9985
sasg24
(lp9986
(dp9987
g7
I100
sg8
I2
sg9
I20
sg27
VC0003873
p9988
sg12
Vrheumatoid arthritis
p9989
sa(dp9990
g7
I72
sg8
I2
sg9
I19
sg27
VC0004364
p9991
sg12
Vautoimmune diseases
p9992
sa(dp9993
g7
I72
sg8
I2
sg9
I18
sg27
VC0004364
p9994
sg12
Vautoimmune disease
p9995
sa(dp9996
g7
I122
sg8
I2
sg9
I18
sg27
VC0026769
p9997
sg12
Vmultiple sclerosis
p9998
sasa(dp9999
g2
VOur results demonstrate that a few point mutations in the Lol p 5 sequence yield mutants with reduced allergenic activity that represent potential vaccine candidates for immunotherapy of grass pollen allergy.
p10000
sg4
(lp10001
(dp10002
g7
I58
sg8
I6
sg9
I30
sg10
g11
sg12
VLol p 5 sequence yield mutants
p10003
sasg24
(lp10004
(dp10005
g7
I187
sg8
I3
sg9
I20
sg27
VC0740919
p10006
sg12
Vgrass pollen allergy
p10007
sasa(dp10008
g2
VHerein we present data relative to the effect of knocking down BCKDK gene on the real time oxygen consumption rate of fibroblasts obtained from a Maple Syrup Urine Disease (MSUD) patient.
p10009
sg4
(lp10010
(dp10011
g7
I63
sg8
I2
sg9
I10
sg10
g11
sg12
VBCKDK gene
p10012
sasg24
(lp10013
(dp10014
g7
I173
sg8
I1
sg9
I4
sg27
VC0024776
p10015
sg12
VMSUD
p10016
sa(dp10017
g7
I146
sg8
I4
sg9
I25
sg27
VC0024776
p10018
sg12
VMaple Syrup Urine Disease
p10019
sasa(dp10020
g2
VData relative to the effectiveness of the knockdown together with the potentiality of the BCKDK-knockdown to increase the deficient branched-chain Alfa-ketoacid dehydrogenase activity detected in MSUD patients are also shown.
p10021
sg4
(lp10022
(dp10023
g7
I90
sg8
I1
sg9
I5
sg10
g11
sg12
VBCKDK
p10024
sa(dp10025
g7
I147
sg8
I2
sg9
I27
sg10
VP49366
p10026
sg12
VAlfa-ketoacid dehydrogenase
p10027
sasg24
(lp10028
(dp10029
g7
I196
sg8
I1
sg9
I4
sg27
VC0024776
p10030
sg12
VMSUD
p10031
sasa(dp10032
g2
VIn the study, 800 patients with coronary artery disease, cerebrovascular disease, or peripheral artery disease (PAD) or multiple cardiovascular risk factors (MRF) were recruited.
p10033
sg4
(lp10034
sg24
(lp10035
(dp10036
g7
I112
sg8
I1
sg9
I3
sg27
VC1704436
p10037
sg12
VPAD
p10038
sa(dp10039
g7
I32
sg8
I3
sg9
I23
sg27
VC1956346
p10040
sg12
Vcoronary artery disease
p10041
sa(dp10042
g7
I57
sg8
I2
sg9
I23
sg27
VC0007820
p10043
sg12
Vcerebrovascular disease
p10044
sa(dp10045
g7
I85
sg8
I3
sg9
I25
sg27
VC1704436
p10046
sg12
Vperipheral artery disease
p10047
sasa(dp10048
g2
VTo obtain Western European perspectives on the economic burden of atherothrombosis in patients with multiple risk factors only (MRF), cerebrovascular disease (CVD), coronary artery disease (CAD), and in the under-evaluated group of patients with peripheral arterial disease (PAD), we examined vascular-related hospitalisation rates and associated costs in France and Germany.
p10049
sg4
(lp10050
sg24
(lp10051
(dp10052
g7
I66
sg8
I1
sg9
I16
sg27
VC1963943
p10053
sg12
Vatherothrombosis
p10054
sa(dp10055
g7
I159
sg8
I1
sg9
I3
sg27
VC0007222
p10056
sg12
VCVD
p10057
sa(dp10058
g7
I275
sg8
I1
sg9
I3
sg27
VC1704436
p10059
sg12
VPAD
p10060
sa(dp10061
g7
I246
sg8
I3
sg9
I27
sg27
VC1704436
p10062
sg12
Vperipheral arterial disease
p10063
sa(dp10064
g7
I190
sg8
I1
sg9
I3
sg27
VC0010054
p10065
sg12
VCAD
p10066
sa(dp10067
g7
I134
sg8
I2
sg9
I23
sg27
VC0007820
p10068
sg12
Vcerebrovascular disease
p10069
sa(dp10070
g7
I165
sg8
I3
sg9
I23
sg27
VC0010054
p10071
sg12
Vcoronary artery disease
p10072
sasa(dp10073
g2
VThe stroke relationships of a Chinese character reflect its structure, which can be statistically represented by the neighborhood system and clique potentials within the MRF framework.
p10074
sg4
(lp10075
sg24
(lp10076
(dp10077
g7
I4
sg8
I1
sg9
I6
sg27
VC0038454
p10078
sg12
Vstroke
p10079
sasa(dp10080
g2
VWe penalize the structurally mismatched stroke relationships with MRFs using the prior clique potentials, and derive the likelihood clique potentials from Gaussian mixture models, which encode the large variations of stroke relationships statistically.
p10081
sg4
(lp10082
sg24
(lp10083
(dp10084
g7
I40
sg8
I1
sg9
I6
sg27
VC0038454
p10085
sg12
Vstroke
p10086
sa(dp10087
g7
I40
sg8
I1
sg9
I6
sg27
VC0038454
p10088
sg12
Vstroke
p10089
sasa(dp10090
g2
VIn the proposed HCCR system, we use the single-site likelihood clique potentials to extract many candidate strokes from character images, and use the pairsite clique potentials to determine the best structural match between the input candidate strokes and the MRF-based character models by relaxation labeling.
p10091
sg4
(lp10092
sg24
(lp10093
(dp10094
g7
I107
sg8
I1
sg9
I7
sg27
VC0038454
p10095
sg12
Vstrokes
p10096
sa(dp10097
g7
I107
sg8
I1
sg9
I7
sg27
VC0038454
p10098
sg12
Vstrokes
p10099
sasa(dp10100
g2
VTotal left ventricular stroke volume (TSV), antegrade stroke volume (ASV), and mitral regurgitation volume (MRV) and fraction (MRF) were determined and compared between the two modalities.
p10101
sg4
(lp10102
sg24
(lp10103
(dp10104
g7
I23
sg8
I1
sg9
I6
sg27
VC0038454
p10105
sg12
Vstroke
p10106
sa(dp10107
g7
I23
sg8
I1
sg9
I6
sg27
VC0038454
p10108
sg12
Vstroke
p10109
sa(dp10110
g7
I79
sg8
I2
sg9
I20
sg27
VC0026266
p10111
sg12
Vmitral regurgitation
p10112
sasa(dp10113
g2
VThe reliability of non-invasive quantification of mitral regurgitation (MR) was assessed in 76 patients with angiographically demonstrated MR by comparing the results of different echo-Doppler (ED) indices with angiographic grade and MR fraction (MRF).
p10114
sg4
(lp10115
sg24
(lp10116
(dp10117
g7
I72
sg8
I1
sg9
I2
sg27
VC0026266
p10118
sg12
VMR
p10119
sa(dp10120
g7
I50
sg8
I2
sg9
I20
sg27
VC0026266
p10121
sg12
Vmitral regurgitation
p10122
sa(dp10123
g7
I72
sg8
I1
sg9
I2
sg27
VC0026266
p10124
sg12
VMR
p10125
sa(dp10126
g7
I72
sg8
I1
sg9
I2
sg27
VC0026266
p10127
sg12
VMR
p10128
sasa(dp10129
g2
VAllergic asthma from mint is less well-recognized.
p10130
sg4
(lp10131
sg24
(lp10132
(dp10133
g7
I0
sg8
I2
sg9
I15
sg27
VC0155877
p10134
sg12
VAllergic asthma
p10135
sasa(dp10136
g2
VA case of a 54-year-old woman with dyspnea on exposure to the scent of peppermint is presented in whom mint exposure, as seemingly innocuous as the breath of others who had consumed Tic Tac candies, exacerbated her underlying asthma.
p10137
sg4
(lp10138
(dp10139
g7
I182
sg8
I2
sg9
I7
sg10
g11
sg12
VTic Tac
p10140
sasg24
(lp10141
(dp10142
g7
I35
sg8
I1
sg9
I7
sg27
VC0013404
p10143
sg12
Vdyspnea
p10144
sa(dp10145
g7
I182
sg8
I1
sg9
I3
sg27
VC0278076
p10146
sg12
VTic
p10147
sa(dp10148
g7
I226
sg8
I1
sg9
I6
sg27
VC0004096
p10149
sg12
Vasthma
p10150
sasa(dp10151
g2
VAdditionally, this cases suggests that asthma can result from inhaling the scent of mint and gives consideration to obtaining confirmatory pre- and postexposure pulmonary function data by both impulse oscillometry and spirometry.
p10152
sg4
(lp10153
sg24
(lp10154
(dp10155
g7
I39
sg8
I1
sg9
I6
sg27
VC0004096
p10156
sg12
Vasthma
p10157
sasa(dp10158
g2
VWe review the significance of elevated alpha-fetoprotein levels and discuss the clinical relevance of this unusual presentation of a possible primary Hodgkin's lymphoma.
p10159
sg4
(lp10160
(dp10161
g7
I39
sg8
I1
sg9
I17
sg10
VP02771
p10162
sg12
Valpha-fetoprotein
p10163
sasg24
(lp10164
(dp10165
g7
I150
sg8
I2
sg9
I18
sg27
VC0019829
p10166
sg12
VHodgkin's lymphoma
p10167
sasa(dp10168
g2
VHowever, we have found that exogenous 8-OHdG can paradoxically reduce ROS production, attenuate the nuclear factor-KB signaling pathway, and ameliorate the expression of proinflammatory mediators such as interleukin (IL)-1, IL-6, cyclo-oxygenase-2, and inducible nitric oxide synthase in addition to expression of nicotinamide adenine dinucleotide phosphate oxidase (NOX)-1, NOX organizer-1 and NOX activator-1 in various conditions of inflammation-based gastrointestinal (GI) diseases including gastritis, inflammatory bowel disease, pancreatitis, and even colitis-associated carcinogenesis.
p10169
sg4
(lp10170
(dp10171
g7
I230
sg8
I1
sg9
I17
sg10
VP00403
p10172
sg12
Vcyclo-oxygenase-2
p10173
sa(dp10174
g7
I395
sg8
I2
sg9
I15
sg10
VP05154
p10175
sg12
VNOX activator-1
p10176
sa(dp10177
g7
I263
sg8
I3
sg9
I21
sg10
VP29475
p10178
sg12
Vnitric oxide synthase
p10179
sa(dp10180
g7
I204
sg8
I2
sg9
I18
sg10
VP60568
p10181
sg12
Vinterleukin (IL)-1
p10182
sa(dp10183
g7
I224
sg8
I1
sg9
I4
sg10
VP05231
p10184
sg12
VIL-6
p10185
sa(dp10186
g7
I100
sg8
I2
sg9
I17
sg10
VP01160
p10187
sg12
Vnuclear factor-KB
p10188
sa(dp10189
g7
I314
sg8
I6
sg9
I59
sg10
g11
sg12
Vnicotinamide adenine dinucleotide phosphate oxidase (NOX)-1
p10190
sasg24
(lp10191
(dp10192
g7
I436
sg8
I1
sg9
I12
sg27
VC0021368
p10193
sg12
Vinflammation
p10194
sa(dp10195
g7
I535
sg8
I1
sg9
I12
sg27
VC0030305
p10196
sg12
Vpancreatitis
p10197
sa(dp10198
g7
I496
sg8
I1
sg9
I9
sg27
VC0017152
p10199
sg12
Vgastritis
p10200
sa(dp10201
g7
I577
sg8
I1
sg9
I14
sg27
VC0596263
p10202
sg12
Vcarcinogenesis
p10203
sa(dp10204
g7
I507
sg8
I3
sg9
I26
sg27
VC0021390
p10205
sg12
Vinflammatory bowel disease
p10206
sa(dp10207
g7
I558
sg8
I1
sg9
I7
sg27
VC0009319
p10208
sg12
Vcolitis
p10209
sasa(dp10210
g2
VWe studied nine patients (56 +/- 7 years) with complete AV-block and permanent dual-chamber pacemaker (DDD) under different pacing modes: ventricle pacing (VVI) 70 bpm, DDD 106 +/- 4 bpm, rate adaptive pacing (VVI-FA) 108 +/- 3 bpm.
p10211
sg4
(lp10212
sg24
(lp10213
(dp10214
g7
I103
sg8
I1
sg9
I3
sg27
VC0406811
p10215
sg12
VDDD
p10216
sa(dp10217
g7
I103
sg8
I1
sg9
I3
sg27
VC0406811
p10218
sg12
VDDD
p10219
sasa(dp10220
g2
VRecently, several reports have demonstrated that dysregulation of miR-4262 is in numerous cancers.
p10221
sg4
(lp10222
(dp10223
g7
I66
sg8
I1
sg9
I8
sg10
g11
sg12
VmiR-4262
p10224
sasg24
(lp10225
(dp10226
g7
I90
sg8
I1
sg9
I7
sg27
VC0006826
p10227
sg12
Vcancers
p10228
sasa(dp10229
g2
VOverexpression of miR-4262 was demonstrated to decrease GALNT4 mRNA and protein expression levels, and thereby suppressed cell viability, growth and cell-cycle progression in SW480 and SW620 colon cancer cells.
p10230
sg4
(lp10231
(dp10232
g7
I18
sg8
I1
sg9
I8
sg10
g11
sg12
VmiR-4262
p10233
sa(dp10234
g7
I56
sg8
I2
sg9
I11
sg10
g11
sg12
VGALNT4 mRNA
p10235
sasg24
(lp10236
(dp10237
g7
I191
sg8
I2
sg9
I12
sg27
VC0699790
p10238
sg12
Vcolon cancer
p10239
sasa(dp10240
g2
VThe expression level of miR-4262 was observed to be downregulated as the expression of GALNT4 was upregulated in colon cancer tissues and cell lines.
p10241
sg4
(lp10242
(dp10243
g7
I87
sg8
I1
sg9
I6
sg10
g11
sg12
VGALNT4
p10244
sa(dp10245
g7
I24
sg8
I1
sg9
I8
sg10
g11
sg12
VmiR-4262
p10246
sasg24
(lp10247
(dp10248
g7
I113
sg8
I2
sg9
I12
sg27
VC0699790
p10249
sg12
Vcolon cancer
p10250
sasa(dp10251
g2
VIn conclusion, the results demonstrated that miR-4262 may be involved in the development of colon cancer via targeting of GALNT4.
p10252
sg4
(lp10253
(dp10254
g7
I122
sg8
I1
sg9
I6
sg10
g11
sg12
VGALNT4
p10255
sa(dp10256
g7
I45
sg8
I1
sg9
I8
sg10
g11
sg12
VmiR-4262
p10257
sasg24
(lp10258
(dp10259
g7
I92
sg8
I2
sg9
I12
sg27
VC0699790
p10260
sg12
Vcolon cancer
p10261
sasa(dp10262
g2
VThe miR-4262/GALNT4 axis may be a novel target for diagnosing and understanding the underlying molecular mechanism of colon cancer.
p10263
sg4
(lp10264
(dp10265
g7
I13
sg8
I1
sg9
I6
sg10
g11
sg12
VGALNT4
p10266
sa(dp10267
g7
I4
sg8
I1
sg9
I8
sg10
g11
sg12
VmiR-4262
p10268
sasg24
(lp10269
(dp10270
g7
I118
sg8
I2
sg9
I12
sg27
VC0699790
p10271
sg12
Vcolon cancer
p10272
sasa(dp10273
g2
VThe aim of this study was to investigate whether miR-4262 was associated with the prognosis of acute myeloid leukemia (AML) patients.
p10274
sg4
(lp10275
sg24
(lp10276
(dp10277
g7
I119
sg8
I1
sg9
I3
sg27
VC0023467
p10278
sg12
VAML
p10279
sa(dp10280
g7
I95
sg8
I3
sg9
I22
sg27
VC0023467
p10281
sg12
Vacute myeloid leukemia
p10282
sasa(dp10283
g2
VIn this study, we investigated the role and underlying mechanism of miR-4262 in the proliferation of human cutaneous malignant melanoma (CMM) cells.
p10284
sg4
(lp10285
sg24
(lp10286
(dp10287
g7
I84
sg8
I1
sg9
I13
sg27
VC0334094
p10288
sg12
Vproliferation
p10289
sa(dp10290
g7
I107
sg8
I3
sg9
I28
sg27
VC0151779
p10291
sg12
Vcutaneous malignant melanoma
p10292
sa(dp10293
g7
I137
sg8
I1
sg9
I3
sg27
VC0151779
p10294
sg12
VCMM
p10295
sasa(dp10296
g2
VThe expression levels of miR-4262 were significantly upregulated in cancerous tissues compared with those in matched adjacent normal tissues from 110 CMM patients.
p10297
sg4
(lp10298
sg24
(lp10299
sa(dp10300
g2
VmiR-4262 was also regulated in five types of CMM cell lines, displaying an opposite expression pattern to that of Kruppel-like 6 (KLF6), a proven tumor suppressor in several cancers other than CMM.
p10301
sg4
(lp10302
(dp10303
g7
I0
sg8
I1
sg9
I8
sg10
g11
sg12
VmiR-4262
p10304
sa(dp10305
g7
I114
sg8
I2
sg9
I14
sg10
g11
sg12
VKruppel-like 6
p10306
sa(dp10307
g7
I130
sg8
I1
sg9
I4
sg10
g11
sg12
VKLF6
p10308
sasg24
(lp10309
(dp10310
g7
I174
sg8
I1
sg9
I7
sg27
VC0006826
p10311
sg12
Vcancers
p10312
sa(dp10313
g7
I146
sg8
I1
sg9
I5
sg27
VC0027651
p10314
sg12
Vtumor
p10315
sasa(dp10316
g2
VmiR-4262 is a potential tumor promoter in human cancers.
p10317
sg4
(lp10318
(dp10319
g7
I0
sg8
I1
sg9
I8
sg10
g11
sg12
VmiR-4262
p10320
sasg24
(lp10321
(dp10322
g7
I48
sg8
I1
sg9
I7
sg27
VC0006826
p10323
sg12
Vcancers
p10324
sa(dp10325
g7
I24
sg8
I1
sg9
I5
sg27
VC0027651
p10326
sg12
Vtumor
p10327
sasa(dp10328
g2
VIn this study, we first investigated the role of miR-4262 in the proliferation and invasion of human breast cancer cells.
p10329
sg4
(lp10330
sg24
(lp10331
(dp10332
g7
I65
sg8
I1
sg9
I13
sg27
VC0334094
p10333
sg12
Vproliferation
p10334
sa(dp10335
g7
I101
sg8
I2
sg9
I13
sg27
VC0678222
p10336
sg12
Vbreast cancer
p10337
sa(dp10338
g7
I83
sg8
I1
sg9
I8
sg27
VC2699153
p10339
sg12
Vinvasion
p10340
sasa(dp10341
g2
VOur results showed that, compared with the adjacent tissues and MCF-10A normal breast epithelial cells, miR-4262 was markedly increased in the breast cancer tissues and five cell lines, including MDA-MB-231, MDA-MB-468, MDA-MB-435, SKBR3, and MCF-7.
p10342
sg4
(lp10343
(dp10344
g7
I104
sg8
I1
sg9
I8
sg10
g11
sg12
VmiR-4262
p10345
sasg24
(lp10346
(dp10347
g7
I143
sg8
I2
sg9
I13
sg27
VC0678222
p10348
sg12
Vbreast cancer
p10349
sasa(dp10350
g2
VThen the miR-4262 mimic or oligo anta-miR-4262 was transfected into MDA-MB-231 and MCF-7 breast cancer cell lines.
p10351
sg4
(lp10352
sg24
(lp10353
(dp10354
g7
I89
sg8
I2
sg9
I13
sg27
VC0678222
p10355
sg12
Vbreast cancer
p10356
sasa(dp10357
g2
VIn conclusion, miR-4262 positively regulates proliferation and invasion of human breast cancer cells via suppression of KLF6 and KLF15.
p10358
sg4
(lp10359
(dp10360
g7
I15
sg8
I1
sg9
I8
sg10
g11
sg12
VmiR-4262
p10361
sa(dp10362
g7
I129
sg8
I1
sg9
I5
sg10
g11
sg12
VKLF15
p10363
sa(dp10364
g7
I120
sg8
I1
sg9
I4
sg10
g11
sg12
VKLF6
p10365
sasg24
(lp10366
(dp10367
g7
I63
sg8
I1
sg9
I8
sg27
VC2699153
p10368
sg12
Vinvasion
p10369
sa(dp10370
g7
I105
sg8
I1
sg9
I11
sg27
VC0221103
p10371
sg12
Vsuppression
p10372
sa(dp10373
g7
I81
sg8
I2
sg9
I13
sg27
VC0678222
p10374
sg12
Vbreast cancer
p10375
sa(dp10376
g7
I45
sg8
I1
sg9
I13
sg27
VC0334094
p10377
sg12
Vproliferation
p10378
sasa(dp10379
g2
VTogether, our data suggest that suppression of miR-4262 in OS cells may promote OPN-mediated cancer invasion, highlighting miR-4262 as an intriguing therapeutic target to prevent OS metastases.
p10380
sg4
(lp10381
(dp10382
g7
I80
sg8
I1
sg9
I3
sg10
VP10451
p10383
sg12
VOPN
p10384
sasg24
(lp10385
(dp10386
g7
I100
sg8
I1
sg9
I8
sg27
VC2699153
p10387
sg12
Vinvasion
p10388
sa(dp10389
g7
I32
sg8
I1
sg9
I11
sg27
VC0221103
p10390
sg12
Vsuppression
p10391
sa(dp10392
g7
I182
sg8
I1
sg9
I10
sg27
VC0027627
p10393
sg12
Vmetastases
p10394
sa(dp10395
g7
I93
sg8
I1
sg9
I6
sg27
VC0006826
p10396
sg12
Vcancer
p10397
sasa(dp10398
g2
VThose can be classified into four groups: hypercalciuric hypomagnesemias (encompassing mutations in CLDN16, CLDN19, CASR, CLCNKB), Gitelman-like hypomagnesemias (CLCNKB, SLC12A3, BSND, KCNJ10, FYXD2, HNF1B, PCBD1), mitochondrial hypomagnesemias (SARS2, MT-TI, Kearns-Sayre syndrome) and other hypomagnesemias (TRPM6, CNMM2, EGF, EGFR, KCNA1, FAM111A).
p10399
sg4
(lp10400
(dp10401
g7
I246
sg8
I1
sg9
I5
sg10
g11
sg12
VSARS2
p10402
sa(dp10403
g7
I324
sg8
I1
sg9
I3
sg10
VP01133
p10404
sg12
VEGF
p10405
sa(dp10406
g7
I108
sg8
I1
sg9
I6
sg10
g11
sg12
VCLDN19
p10407
sa(dp10408
g7
I310
sg8
I1
sg9
I5
sg10
g11
sg12
VTRPM6
p10409
sa(dp10410
g7
I122
sg8
I1
sg9
I6
sg10
VP51801
p10411
sg12
VCLCNKB
p10412
sa(dp10413
g7
I342
sg8
I1
sg9
I7
sg10
g11
sg12
VFAM111A
p10414
sa(dp10415
g7
I335
sg8
I1
sg9
I5
sg10
g11
sg12
VKCNA1
p10416
sa(dp10417
g7
I170
sg8
I1
sg9
I7
sg10
VP55017
p10418
sg12
VSLC12A3
p10419
sa(dp10420
g7
I207
sg8
I1
sg9
I5
sg10
VP61457
p10421
sg12
VPCBD1
p10422
sa(dp10423
g7
I200
sg8
I1
sg9
I5
sg10
VP35680
p10424
sg12
VHNF1B
p10425
sa(dp10426
g7
I179
sg8
I1
sg9
I4
sg10
g11
sg12
VBSND
p10427
sa(dp10428
g7
I185
sg8
I1
sg9
I6
sg10
VP78508
p10429
sg12
VKCNJ10
p10430
sa(dp10431
g7
I100
sg8
I1
sg9
I6
sg10
g11
sg12
VCLDN16
p10432
sa(dp10433
g7
I122
sg8
I1
sg9
I6
sg10
VP51801
p10434
sg12
VCLCNKB
p10435
sa(dp10436
g7
I116
sg8
I1
sg9
I4
sg10
VP41180
p10437
sg12
VCASR
p10438
sasg24
(lp10439
(dp10440
g7
I179
sg8
I1
sg9
I4
sg27
VC1865270
p10441
sg12
VBSND
p10442
sa(dp10443
g7
I260
sg8
I2
sg9
I21
sg27
VC0022541
p10444
sg12
VKearns-Sayre syndrome
p10445
sasa(dp10446
g2
VFor radiculopathy, epidural corticosteroids were associated with greater immediate-term reduction in pain (weighted mean difference on a scale of 0 to 100, -7.55 [95% CI, -11.4 to -3.74]; SOE, moderate), function (standardized mean difference after exclusion of an outlier trial, -0.33 [CI, -0.56 to -0.09]; SOE, low), and short-term surgery risk (relative risk, 0.62 [CI, 0.41 to 0.92]; SOE, low).
p10447
sg4
(lp10448
sg24
(lp10449
(dp10450
g7
I4
sg8
I1
sg9
I13
sg27
VC0700594
p10451
sg12
Vradiculopathy
p10452
sasa(dp10453
g2
VThe final multilevel growth model revealed improvements in RMDQ scores in patients with radiculopathy at the 6-week (-8.1, 95 % CI -12.6 to -2.6; P = 0.006) and 6-month (-4.1, 95 % CI -7.4 to -0.7; P = 0.020) follow-up occasions compared to patients without radiculopathy.
p10454
sg4
(lp10455
sg24
(lp10456
(dp10457
g7
I88
sg8
I1
sg9
I13
sg27
VC0700594
p10458
sg12
Vradiculopathy
p10459
sa(dp10460
g7
I88
sg8
I1
sg9
I13
sg27
VC0700594
p10461
sg12
Vradiculopathy
p10462
sasa(dp10463
g2
VAn interaction between electrodiagnostic status and time revealed faster weekly improvements in RMDQ scores in patients with radiculopathy at the 6-week (-0.72, 95 % CI -1.4 to -0.04; P = 0.040) through the 16-week (-0.30, 95 % CI, -0.57 to -0.04; P = 0.028) follow-up occasions compared to patients without radiculopathy.
p10464
sg4
(lp10465
sg24
(lp10466
(dp10467
g7
I125
sg8
I1
sg9
I13
sg27
VC0700594
p10468
sg12
Vradiculopathy
p10469
sa(dp10470
g7
I125
sg8
I1
sg9
I13
sg27
VC0700594
p10471
sg12
Vradiculopathy
p10472
sasa(dp10473
g2
VFor patients with radiculopathy, a repeated-measures analysis of variance showed a significant decrease in the H reflex amplitude (from 0.81 +/- 0.4 to 0.69 +/- 0.39 mV), an increase in radicular symptoms after reading (from 4.2 +/- 1.3 to 5.6 +/- 1.4 on the visual analog scale), an increase in the H reflex amplitude (from 0.69 +/- 0.39 to 1.01 +/- 0.49 mV), and a decrease in pain intensity (from 5.6 +/- 1.4 to 1.5 +/- 1.3) after repeated neck retractions.
p10474
sg4
(lp10475
sg24
(lp10476
(dp10477
g7
I18
sg8
I1
sg9
I13
sg27
VC0700594
p10478
sg12
Vradiculopathy
p10479
sasa(dp10480
g2
VAlthough some autoinflammatory diseases are due to gain-of-function mutations for caspase-1 activity, common diseases such as gout, type 2 diabetes, heart failure, recurrent pericarditis, rheumatoid arthritis, and smoldering myeloma also are responsive to IL-1Beta neutralization.
p10481
sg4
(lp10482
(dp10483
g7
I82
sg8
I1
sg9
I9
sg10
VP29466
p10484
sg12
Vcaspase-1
p10485
sa(dp10486
g7
I256
sg8
I1
sg9
I8
sg10
VP01584
p10487
sg12
VIL-1Beta
p10488
sasg24
(lp10489
(dp10490
g7
I126
sg8
I1
sg9
I4
sg27
VC0018099
p10491
sg12
Vgout
p10492
sa(dp10493
g7
I214
sg8
I2
sg9
I18
sg27
VC1531608
p10494
sg12
Vsmoldering myeloma
p10495
sa(dp10496
g7
I188
sg8
I2
sg9
I20
sg27
VC0003873
p10497
sg12
Vrheumatoid arthritis
p10498
sa(dp10499
g7
I174
sg8
I1
sg9
I12
sg27
VC0031046
p10500
sg12
Vpericarditis
p10501
sa(dp10502
g7
I132
sg8
I3
sg9
I15
sg27
VC0011860
p10503
sg12
Vtype 2 diabetes
p10504
sa(dp10505
g7
I149
sg8
I2
sg9
I13
sg27
VC0018802
p10506
sg12
Vheart failure
p10507
sasa(dp10508
g2
VInactivation of Ccl2 in an Lkb1-driven mouse model of endometrial cancer slowed tumor progression and increased survival.
p10509
sg4
(lp10510
(dp10511
g7
I16
sg8
I1
sg9
I4
sg10
VP13500
p10512
sg12
VCcl2
p10513
sa(dp10514
g7
I27
sg8
I1
sg9
I4
sg10
g11
sg12
VLkb1
p10515
sasg24
(lp10516
(dp10517
g7
I80
sg8
I2
sg9
I17
sg27
VC0178874
p10518
sg12
Vtumor progression
p10519
sa(dp10520
g7
I54
sg8
I2
sg9
I18
sg27
VC0476089
p10521
sg12
Vendometrial cancer
p10522
sa(dp10523
g7
I0
sg8
I1
sg9
I12
sg27
VC0544461
p10524
sg12
VInactivation
p10525
sasa(dp10526
g2
VIn human primary endometrial cancers, loss of LKB1 protein was strongly associated with increased CCL2 expression by tumor cells as well as increased macrophage density in the tumor microenvironment.
p10527
sg4
(lp10528
(dp10529
g7
I46
sg8
I2
sg9
I12
sg10
g11
sg12
VLKB1 protein
p10530
sa(dp10531
g7
I98
sg8
I1
sg9
I4
sg10
VP13500
p10532
sg12
VCCL2
p10533
sasg24
(lp10534
(dp10535
g7
I117
sg8
I1
sg9
I5
sg27
VC0027651
p10536
sg12
Vtumor
p10537
sa(dp10538
g7
I17
sg8
I2
sg9
I19
sg27
VC0476089
p10539
sg12
Vendometrial cancers
p10540
sa(dp10541
g7
I117
sg8
I1
sg9
I5
sg27
VC0027651
p10542
sg12
Vtumor
p10543
sasa(dp10544
g2
VThese data demonstrate that CCL2 is a potent effector of LKB1 loss in endometrial cancer, creating potential avenues for therapeutic opportunities.
p10545
sg4
(lp10546
(dp10547
g7
I28
sg8
I1
sg9
I4
sg10
VP13500
p10548
sg12
VCCL2
p10549
sa(dp10550
g7
I57
sg8
I1
sg9
I4
sg10
g11
sg12
VLKB1
p10551
sasg24
(lp10552
(dp10553
g7
I70
sg8
I2
sg9
I18
sg27
VC0476089
p10554
sg12
Vendometrial cancer
p10555
sasa(dp10556
g2
VOur results showed that in HEC-1-B (human endometrial cancer) cells, IL-17 stimulation induced mRNA level increases of CCL2, CCL5, CCL20, CXCL2, and IL-8.
p10557
sg4
(lp10558
(dp10559
g7
I131
sg8
I1
sg9
I5
sg10
VP78556
p10560
sg12
VCCL20
p10561
sa(dp10562
g7
I27
sg8
I1
sg9
I7
sg10
g11
sg12
VHEC-1-B
p10563
sa(dp10564
g7
I138
sg8
I1
sg9
I5
sg10
VP19875
p10565
sg12
VCXCL2
p10566
sa(dp10567
g7
I125
sg8
I1
sg9
I4
sg10
VP13501
p10568
sg12
VCCL5
p10569
sa(dp10570
g7
I119
sg8
I1
sg9
I4
sg10
VP13500
p10571
sg12
VCCL2
p10572
sasg24
(lp10573
(dp10574
g7
I42
sg8
I2
sg9
I18
sg27
VC0476089
p10575
sg12
Vendometrial cancer
p10576
sasa(dp10577
g2
VIn this study of Turkish women, the association of CCL2 A2518G and CCR2 V64I polymorphisms with endometrial cancer was investigated using 50 endometrial cancer patients and 211 controls.
p10578
sg4
(lp10579
(dp10580
g7
I67
sg8
I1
sg9
I4
sg10
VP41597
p10581
sg12
VCCR2
p10582
sa(dp10583
g7
I51
sg8
I2
sg9
I11
sg10
VP13500
p10584
sg12
VCCL2 A2518G
p10585
sasg24
(lp10586
(dp10587
g7
I96
sg8
I2
sg9
I18
sg27
VC0476089
p10588
sg12
Vendometrial cancer
p10589
sa(dp10590
g7
I96
sg8
I2
sg9
I18
sg27
VC0476089
p10591
sg12
Vendometrial cancer
p10592
sasa(dp10593
g2
VIn our study, individuals with CCL2 A2518G GG genotype showed a 6.7-fold increased risk for endometrial cancer (p&lt;0.0001) and individuals with CCL2 A2518G A allele had a 7.14-fold lower risk of endometrium cancer (p&lt;0.0001).
p10594
sg4
(lp10595
(dp10596
g7
I31
sg8
I4
sg9
I23
sg10
VP13500
p10597
sg12
VCCL2 A2518G GG genotype
p10598
sa(dp10599
g7
I146
sg8
I4
sg9
I20
sg10
VP13500
p10600
sg12
VCCL2 A2518G A allele
p10601
sasg24
(lp10602
(dp10603
g7
I92
sg8
I2
sg9
I18
sg27
VC0476089
p10604
sg12
Vendometrial cancer
p10605
sa(dp10606
g7
I197
sg8
I2
sg9
I18
sg27
VC0476089
p10607
sg12
Vendometrium cancer
p10608
sasa(dp10609
g2
VIn conclusion, we state that there appears to be an association between polymorphism of CCL2 and its receptor CCR2 and endometrial cancer.
p10610
sg4
(lp10611
(dp10612
g7
I110
sg8
I1
sg9
I4
sg10
VP41597
p10613
sg12
VCCR2
p10614
sa(dp10615
g7
I88
sg8
I1
sg9
I4
sg10
VP13500
p10616
sg12
VCCL2
p10617
sasg24
(lp10618
(dp10619
g7
I119
sg8
I2
sg9
I18
sg27
VC0476089
p10620
sg12
Vendometrial cancer
p10621
sasa(dp10622
g2
VA total of 146 cryptorchid and 140 infertile patients without a history of cryptorchidism were screened with a sequence tagged site plus/minus method and further confirmed and characterized by CDY1/DAZ gene dosage and copy analysis.
p10623
sg4
(lp10624
(dp10625
g7
I193
sg8
I1
sg9
I4
sg10
g11
sg12
VCDY1
p10626
sa(dp10627
g7
I198
sg8
I1
sg9
I3
sg10
g11
sg12
VDAZ
p10628
sasg24
(lp10629
(dp10630
g7
I35
sg8
I1
sg9
I9
sg27
VC0021359
p10631
sg12
Vinfertile
p10632
sa(dp10633
g7
I75
sg8
I1
sg9
I14
sg27
VC0010417
p10634
sg12
Vcryptorchidism
p10635
sasa(dp10636
g2
VThe aim of this study is to explore the various modes of action miR-497 has on human cervical cancer (CC) cell behavior.
p10637
sg4
(lp10638
sg24
(lp10639
(dp10640
g7
I85
sg8
I2
sg9
I15
sg27
VC0302592
p10641
sg12
Vcervical cancer
p10642
sasa(dp10643
g2
VIn this study, the expression levels of PVT1 and miR-497 in NSCLC cells were determined by qRT-PCR.
p10644
sg4
(lp10645
(dp10646
g7
I49
sg8
I1
sg9
I7
sg10
g11
sg12
VmiR-497
p10647
sasg24
(lp10648
(dp10649
g7
I60
sg8
I1
sg9
I5
sg27
VC0007131
p10650
sg12
VNSCLC
p10651
sasa(dp10652
g2
VOur findings indicated that PVT1 was significantly upregulated and miR-497 was markedly downregulated in NSCLC cell lines.
p10653
sg4
(lp10654
(dp10655
g7
I67
sg8
I1
sg9
I7
sg10
g11
sg12
VmiR-497
p10656
sasg24
(lp10657
(dp10658
g7
I105
sg8
I1
sg9
I5
sg27
VC0007131
p10659
sg12
VNSCLC
p10660
sasa(dp10661
g2
VMoreover, PVT1 overexpression reversed the inhibitory effect of miR-497 on cell viability, invasion and promotion effect on apoptosis of NSCLC cells.
p10662
sg4
(lp10663
sg24
(lp10664
(dp10665
g7
I137
sg8
I1
sg9
I5
sg27
VC0007131
p10666
sg12
VNSCLC
p10667
sa(dp10668
g7
I91
sg8
I1
sg9
I8
sg27
VC2699153
p10669
sg12
Vinvasion
p10670
sasa(dp10671
g2
VIn conclusion, knockdown of PVT1 inhibited cell viability, invasion and induced apoptosis in NSCLC by regulating miR-497 expression, elucidating the molecular mechanism of the oncogenic role of PVT1 in NSCLC and providing an lncRNA-directed target for NSCLC.
p10672
sg4
(lp10673
sg24
(lp10674
(dp10675
g7
I93
sg8
I1
sg9
I5
sg27
VC0007131
p10676
sg12
VNSCLC
p10677
sa(dp10678
g7
I59
sg8
I1
sg9
I8
sg27
VC2699153
p10679
sg12
Vinvasion
p10680
sa(dp10681
g7
I93
sg8
I1
sg9
I5
sg27
VC0007131
p10682
sg12
VNSCLC
p10683
sa(dp10684
g7
I93
sg8
I1
sg9
I5
sg27
VC0007131
p10685
sg12
VNSCLC
p10686
sasa(dp10687
g2
VMany prominent cancer-associated molecules have been identified over the recent years which include EGFR, CD44, TGFbRII, HER2, miR-497, NMP22, BTA, Fibrin/FDP etc.
p10688
sg4
(lp10689
(dp10690
g7
I127
sg8
I1
sg9
I7
sg10
g11
sg12
VmiR-497
p10691
sa(dp10692
g7
I155
sg8
I1
sg9
I3
sg10
g11
sg12
VFDP
p10693
sa(dp10694
g7
I148
sg8
I1
sg9
I6
sg10
VP22087
p10695
sg12
VFibrin
p10696
sa(dp10697
g7
I121
sg8
I1
sg9
I4
sg10
VP04626
p10698
sg12
VHER2
p10699
sasg24
(lp10700
(dp10701
g7
I15
sg8
I1
sg9
I6
sg27
VC0006826
p10702
sg12
Vcancer
p10703
sasa(dp10704
g2
VThe expression levels of miR-497 in the cancerous and the adjacent noncancerous tissues were detected using reverse transcription-quantitative polymerase chain reaction.
p10705
sg4
(lp10706
sg24
(lp10707
sa(dp10708
g2
VAn miR-497-overexpressing vector was transfected into the T24 and BIU-87 bladder cancer cell lines in order to determine the effect of miR-497 expression on cell migration and invasion using Transwell assays.
p10709
sg4
(lp10710
sg24
(lp10711
(dp10712
g7
I176
sg8
I1
sg9
I8
sg27
VC2699153
p10713
sg12
Vinvasion
p10714
sa(dp10715
g7
I73
sg8
I2
sg9
I14
sg27
VC0699885
p10716
sg12
Vbladder cancer
p10717
sasa(dp10718
g2
VThe findings of the present study revealed that miR-497 was expressed at low levels in the cancer bladder tissue compared with the adjacent noncancerous tissue, and its expression was associated with the pathological classification, TNM stage and metastasis.
p10719
sg4
(lp10720
(dp10721
g7
I48
sg8
I1
sg9
I7
sg10
g11
sg12
VmiR-497
p10722
sasg24
(lp10723
(dp10724
g7
I247
sg8
I1
sg9
I10
sg27
VC0027627
p10725
sg12
Vmetastasis
p10726
sa(dp10727
g7
I91
sg8
I1
sg9
I6
sg27
VC0006826
p10728
sg12
Vcancer
p10729
sasa(dp10730
g2
VThe present study revealed that miR-497 overexpression may be a suppressor of the metastasis of bladder cancer, and may have an important role in the diagnosis of bladder cancer.
p10731
sg4
(lp10732
sg24
(lp10733
(dp10734
g7
I82
sg8
I1
sg9
I10
sg27
VC0027627
p10735
sg12
Vmetastasis
p10736
sa(dp10737
g7
I96
sg8
I2
sg9
I14
sg27
VC0699885
p10738
sg12
Vbladder cancer
p10739
sa(dp10740
g7
I96
sg8
I2
sg9
I14
sg27
VC0699885
p10741
sg12
Vbladder cancer
p10742
sasa(dp10743
g2
VPHR patient portal users (34 percent of eligible persons) were older and more likely to be White, have private health insurance, and develop gestational diabetes than nonusers.
p10744
sg4
(lp10745
sg24
(lp10746
(dp10747
g7
I141
sg8
I2
sg9
I20
sg27
VC0085207
p10748
sg12
Vgestational diabetes
p10749
sasa(dp10750
g2
VWe searched the Internet to review patient-held medical records (PHRs) of patients with diabetes and examine current levels of integration of diabetes and depression care in Japan.
p10751
sg4
(lp10752
sg24
(lp10753
(dp10754
g7
I88
sg8
I1
sg9
I8
sg27
VC0011849
p10755
sg12
Vdiabetes
p10756
sa(dp10757
g7
I155
sg8
I1
sg9
I10
sg27
VC0011581
p10758
sg12
Vdepression
p10759
sa(dp10760
g7
I88
sg8
I1
sg9
I8
sg27
VC0011849
p10761
sg12
Vdiabetes
p10762
sasa(dp10763
g2
VEight sets of PHRs were found for people with diabetes.
p10764
sg4
(lp10765
sg24
(lp10766
(dp10767
g7
I46
sg8
I1
sg9
I8
sg27
VC0011849
p10768
sg12
Vdiabetes
p10769
sasa(dp10770
g2
VAll PHRs included clinical follow-up of diabetes and multidisciplinary clinical pathways for diabetes care.
p10771
sg4
(lp10772
sg24
(lp10773
(dp10774
g7
I40
sg8
I1
sg9
I8
sg27
VC0011849
p10775
sg12
Vdiabetes
p10776
sa(dp10777
g7
I40
sg8
I1
sg9
I8
sg27
VC0011849
p10778
sg12
Vdiabetes
p10779
sasa(dp10780
g2
VIn terms of an integrated PHR for a patient comorbid with diabetes and depression, necessary components include hopes/preferences, educational information on diabetes complications and treatment, medical history, stress and coping, resources, and monitoring diabetes and depression.
p10781
sg4
(lp10782
sg24
(lp10783
(dp10784
g7
I58
sg8
I1
sg9
I8
sg27
VC0011849
p10785
sg12
Vdiabetes
p10786
sa(dp10787
g7
I71
sg8
I1
sg9
I10
sg27
VC0011581
p10788
sg12
Vdepression
p10789
sa(dp10790
g7
I58
sg8
I1
sg9
I8
sg27
VC0011849
p10791
sg12
Vdiabetes
p10792
sa(dp10793
g7
I158
sg8
I2
sg9
I22
sg27
VC0342257
p10794
sg12
Vdiabetes complications
p10795
sa(dp10796
g7
I71
sg8
I1
sg9
I10
sg27
VC0011581
p10797
sg12
Vdepression
p10798
sasa(dp10799
g2
VA new PHR may be suitable for comorbid patients with diabetes and depression.
p10800
sg4
(lp10801
sg24
(lp10802
(dp10803
g7
I66
sg8
I1
sg9
I10
sg27
VC0011581
p10804
sg12
Vdepression
p10805
sa(dp10806
g7
I53
sg8
I1
sg9
I8
sg27
VC0011849
p10807
sg12
Vdiabetes
p10808
sasa(dp10809
g2
Vto evaluate the attitude of patients with Type II diabetes towards using a PHR to manage their condition.
p10810
sg4
(lp10811
sg24
(lp10812
(dp10813
g7
I42
sg8
I3
sg9
I16
sg27
VC0011860
p10814
sg12
VType II diabetes
p10815
sa(dp10816
g7
I95
sg8
I1
sg9
I9
sg27
VC0012634
p10817
sg12
Vcondition
p10818
sasa(dp10819
g2
VThe attitude of patients towards using PHR in management of their diabetes was positive.
p10820
sg4
(lp10821
sg24
(lp10822
(dp10823
g7
I66
sg8
I1
sg9
I8
sg27
VC0011849
p10824
sg12
Vdiabetes
p10825
sasa(dp10826
g2
VPersonal health records (PHRs) have the potential to improve patient self-management for chronic conditions such as diabetes.
p10827
sg4
(lp10828
sg24
(lp10829
(dp10830
g7
I116
sg8
I1
sg9
I8
sg27
VC0011849
p10831
sg12
Vdiabetes
p10832
sasa(dp10833
g2
VThe purpose of this qualitative study was to explore how patients with type 2 diabetes used a PHR to manage their diabetes-related health information for self-care.
p10834
sg4
(lp10835
sg24
(lp10836
(dp10837
g7
I71
sg8
I3
sg9
I15
sg27
VC0011860
p10838
sg12
Vtype 2 diabetes
p10839
sa(dp10840
g7
I78
sg8
I1
sg9
I8
sg27
VC0011849
p10841
sg12
Vdiabetes
p10842
sasa(dp10843
g2
VFifty-nine patients with type 2 diabetes were interviewed 3-6 months after receiving initial training on a free-of-charge, Web-based PHR.
p10844
sg4
(lp10845
sg24
(lp10846
(dp10847
g7
I123
sg8
I1
sg9
I3
sg27
VC0332875
p10848
sg12
VWeb
p10849
sa(dp10850
g7
I25
sg8
I3
sg9
I15
sg27
VC0011860
p10851
sg12
Vtype 2 diabetes
p10852
sasa(dp10853
g2
VThe objective of this paper is to describe the design and implementation of a Personal Health Record System (PHR-S) for supporting monitoring of blood glucose in diabetes mellitus type 2 patients.
p10854
sg4
(lp10855
sg24
(lp10856
(dp10857
g7
I162
sg8
I4
sg9
I24
sg27
VC0011860
p10858
sg12
Vdiabetes mellitus type 2
p10859
sasa(dp10860
g2
VIn this study the different applications and functionalities of the program are demonstrated such as: exhaustive assembly (rDNA region and mitochondrial genome), extracting homologous regions or genes (IGS, RPB1, RPB2 and TEF1a), as well as extracting multiple regions within a single run.
p10861
sg4
(lp10862
(dp10863
g7
I207
sg8
I1
sg9
I4
sg10
VP24928
p10864
sg12
VRPB1
p10865
sa(dp10866
g7
I213
sg8
I1
sg9
I4
sg10
VP30876
p10867
sg12
VRPB2
p10868
sa(dp10869
g7
I202
sg8
I1
sg9
I3
sg10
g11
sg12
VIGS
p10870
sasg24
(lp10871
(dp10872
g7
I202
sg8
I1
sg9
I3
sg27
VC1306856
p10873
sg12
VIGS
p10874
sasa(dp10875
g2
VSequences of the translation elongation factor 1Alfa (tef1Alfa), RNA polymerase II subunit B2 (rpb2), ATP citrate lyase subunit A (acla), and internal transcribed spacer (ITS) regions were monomorphic, while the intergenic spacer (IGS) region showed length polymorphisms at two minisatellites of 23 and 39 nucleotides (nt).
p10876
sg4
(lp10877
(dp10878
g7
I102
sg8
I5
sg9
I27
sg10
g11
sg12
VATP citrate lyase subunit A
p10879
sa(dp10880
g7
I54
sg8
I1
sg9
I8
sg10
g11
sg12
Vtef1Alfa
p10881
sa(dp10882
g7
I95
sg8
I1
sg9
I4
sg10
VP30876
p10883
sg12
Vrpb2
p10884
sa(dp10885
g7
I131
sg8
I1
sg9
I4
sg10
g11
sg12
Vacla
p10886
sa(dp10887
g7
I65
sg8
I5
sg9
I28
sg10
VP30876
p10888
sg12
VRNA polymerase II subunit B2
p10889
sa(dp10890
g7
I17
sg8
I4
sg9
I35
sg10
g11
sg12
Vtranslation elongation factor 1Alfa
p10891
sasg24
(lp10892
(dp10893
g7
I212
sg8
I2
sg9
I17
sg27
VC1306856
p10894
sg12
Vintergenic spacer
p10895
sa(dp10896
g7
I231
sg8
I1
sg9
I3
sg27
VC1306856
p10897
sg12
VIGS
p10898
sasa(dp10899
g2
VThe phylogenetic relationships of these species were determined using sequences from the ITS and IGS region of the nuclear rRNA gene complex, two nuclear genes ( Beta -tubulin (benA) and RNA polymerase II second largest subunit (rpb2)) and two mitochondrial genes (small rRNA subunit (rns) and cytochrome oxidase subunit I (cox1)) and, where available, related sequences from databases.
p10900
sg4
(lp10901
(dp10902
g7
I324
sg8
I1
sg9
I4
sg10
VP00395
p10903
sg12
Vcox1
p10904
sa(dp10905
g7
I294
sg8
I4
sg9
I28
sg10
VP00395
p10906
sg12
Vcytochrome oxidase subunit I
p10907
sa(dp10908
g7
I229
sg8
I1
sg9
I4
sg10
VP30876
p10909
sg12
Vrpb2
p10910
sa(dp10911
g7
I187
sg8
I3
sg9
I17
sg10
VP19388
p10912
sg12
VRNA polymerase II
p10913
sasg24
(lp10914
(dp10915
g7
I285
sg8
I1
sg9
I3
sg27
VC1850106
p10916
sg12
Vrns
p10917
sa(dp10918
g7
I97
sg8
I1
sg9
I3
sg27
VC1306856
p10919
sg12
VIGS
p10920
sasa(dp10921
g2
VThe combined use of the three commonly employed nuclear genes (benA, rpb2, and ITS), the IGS region, and two less often used mitochondrial gene sequences (rns and cox1) as a single unit resolved several taxonomic ambiguities.
p10922
sg4
(lp10923
(dp10924
g7
I155
sg8
I1
sg9
I3
sg10
g11
sg12
Vrns
p10925
sa(dp10926
g7
I163
sg8
I1
sg9
I4
sg10
VP00395
p10927
sg12
Vcox1
p10928
sa(dp10929
g7
I69
sg8
I1
sg9
I4
sg10
VP30876
p10930
sg12
Vrpb2
p10931
sa(dp10932
g7
I89
sg8
I2
sg9
I10
sg10
g11
sg12
VIGS region
p10933
sasg24
(lp10934
(dp10935
g7
I89
sg8
I1
sg9
I3
sg27
VC1306856
p10936
sg12
VIGS
p10937
sa(dp10938
g7
I155
sg8
I1
sg9
I3
sg27
VC1850106
p10939
sg12
Vrns
p10940
sasa(dp10941
g2
VIn order to find other markers that, in combination with the ITS rDNA region can be used for species identification in Cladonia, we studied the loci IGS rDNA, ef1Alfa, rpb2 and cox1.
p10942
sg4
(lp10943
(dp10944
g7
I149
sg8
I2
sg9
I8
sg10
g11
sg12
VIGS rDNA
p10945
sa(dp10946
g7
I168
sg8
I1
sg9
I4
sg10
VP30876
p10947
sg12
Vrpb2
p10948
sa(dp10949
g7
I177
sg8
I1
sg9
I4
sg10
VP00395
p10950
sg12
Vcox1
p10951
sasg24
(lp10952
(dp10953
g7
I149
sg8
I1
sg9
I3
sg27
VC1306856
p10954
sg12
VIGS
p10955
sasa(dp10956
g2
VThree-gene combined analyses (ITS+IGS+rpb2) were performed and the results indicated that the Chinese 'G.
p10957
sg4
(lp10958
sg24
(lp10959
sa(dp10960
g2
VSeven loci were analyzed: the translation elongation factor 1 alpha gene (EF-1Alfa); the nuclear rRNA internal transcribed spacer (ITS), large subunit (LSU), and intergenic spacer (IGS) regions; the second largest subunit of the RNA polymerase gene (RPB2); the calmodulin gene (CAM); and the mitochondrial small subunit (mtSSU) rRNA gene.
p10961
sg4
(lp10962
(dp10963
g7
I30
sg8
I6
sg9
I42
sg10
g11
sg12
Vtranslation elongation factor 1 alpha gene
p10964
sa(dp10965
g7
I250
sg8
I1
sg9
I4
sg10
VP30876
p10966
sg12
VRPB2
p10967
sa(dp10968
g7
I278
sg8
I1
sg9
I3
sg10
VP01768
p10969
sg12
VCAM
p10970
sa(dp10971
g7
I261
sg8
I2
sg9
I15
sg10
g11
sg12
Vcalmodulin gene
p10972
sasg24
(lp10973
(dp10974
g7
I162
sg8
I2
sg9
I17
sg27
VC1306856
p10975
sg12
Vintergenic spacer
p10976
sa(dp10977
g7
I261
sg8
I2
sg9
I15
sg27
VC1861821
p10978
sg12
Vcalmodulin gene
p10979
sa(dp10980
g7
I181
sg8
I1
sg9
I3
sg27
VC1306856
p10981
sg12
VIGS
p10982
sa(dp10983
g7
I278
sg8
I1
sg9
I3
sg27
VC1861821
p10984
sg12
VCAM
p10985
sasa(dp10986
g2
VTwenty-nine IGS, 27 EF-1Alfa, 26 RPB2, 24 CAM, 18 ITS, 19 LSU, and 18 mtSSU haplotypes were identified; 29 were unique, and haplotypes for 24 clinical strains were novel.
p10987
sg4
(lp10988
(dp10989
g7
I12
sg8
I5
sg9
I25
sg10
g11
sg12
VIGS, 27 EF-1Alfa, 26 RPB2
p10990
sasg24
(lp10991
(dp10992
g7
I12
sg8
I1
sg9
I3
sg27
VC1306856
p10993
sg12
VIGS
p10994
sa(dp10995
g7
I42
sg8
I1
sg9
I3
sg27
VC1861821
p10996
sg12
VCAM
p10997
sasa(dp10998
g2
VComplete absence of STAT6 was most common in pleomorphic liposarcoma and alveolar soft part sarcoma (60% and 72% cases negative, respectively).
p10999
sg4
(lp11000
(dp11001
g7
I20
sg8
I1
sg9
I5
sg10
VP42226
p11002
sg12
VSTAT6
p11003
sasg24
(lp11004
(dp11005
g7
I45
sg8
I2
sg9
I23
sg27
VC0205825
p11006
sg12
Vpleomorphic liposarcoma
p11007
sa(dp11008
g7
I73
sg8
I4
sg9
I26
sg27
VC0206657
p11009
sg12
Valveolar soft part sarcoma
p11010
sasa(dp11011
g2
VPatients with ASC due to choledocholithiasis were allocated to two groups: Those who underwent EST immediately and those who underwent EBD followed by EST 1 wk later because they were under anticoagulant therapy, had a coagulopathy (international normalized ratio &gt; 1.3, partial thromboplastin time greater than twice that of control), or had a platelet count &lt; 50000 x 10(3)/myL.
p11012
sg4
(lp11013
(dp11014
g7
I282
sg8
I1
sg9
I14
sg10
VP13726
p11015
sg12
Vthromboplastin
p11016
sa(dp11017
g7
I382
sg8
I1
sg9
I3
sg10
VP29590
p11018
sg12
VmyL
p11019
sasg24
(lp11020
(dp11021
g7
I25
sg8
I1
sg9
I19
sg27
VC0701818
p11022
sg12
Vcholedocholithiasis
p11023
sa(dp11024
g7
I219
sg8
I1
sg9
I12
sg27
VC0005779
p11025
sg12
Vcoagulopathy
p11026
sasa(dp11027
g2
VA cross of the Asd-4 mutant with wild-type resulted in fruiting bodies that appeared to be normal macroscopically but which were complete devoid of asci and ascospores.
p11028
sg4
(lp11029
(dp11030
g7
I15
sg8
I2
sg9
I12
sg10
VP51689
p11031
sg12
VAsd-4 mutant
p11032
sasg24
(lp11033
(dp11034
g7
I15
sg8
I1
sg9
I3
sg27
VC1510586
p11035
sg12
VAsd
p11036
sa(dp11037
g7
I21
sg8
I1
sg9
I6
sg27
VC0596988
p11038
sg12
Vmutant
p11039
sasa(dp11040
g2
VA mutant strain (asd-1) with a recessive crossing defect (apparently caused by the RIP process) was isolated; in this strain, early development is normal and may asci are formed, but ascospores are never delineated.
p11041
sg4
(lp11042
(dp11043
g7
I17
sg8
I1
sg9
I5
sg10
VP51689
p11044
sg12
Vasd-1
p11045
sasg24
(lp11046
(dp11047
g7
I17
sg8
I1
sg9
I3
sg27
VC1510586
p11048
sg12
Vasd
p11049
sa(dp11050
g7
I2
sg8
I1
sg9
I6
sg27
VC0596988
p11051
sg12
Vmutant
p11052
sasa(dp11053
g2
VcPGES and mPGES-2 have been found expressed in normal gastric mucosa, with no change in expression levels seen in gastritis or gastric ulcer tissue.
p11054
sg4
(lp11055
(dp11056
g7
I10
sg8
I1
sg9
I7
sg10
g11
sg12
VmPGES-2
p11057
sa(dp11058
g7
I0
sg8
I1
sg9
I5
sg10
g11
sg12
VcPGES
p11059
sasg24
(lp11060
(dp11061
g7
I114
sg8
I1
sg9
I9
sg27
VC0017152
p11062
sg12
Vgastritis
p11063
sa(dp11064
g7
I127
sg8
I2
sg9
I13
sg27
VC0038358
p11065
sg12
Vgastric ulcer
p11066
sasa(dp11067
g2
VHerein we investigated the ATR-Chk1 and ATM-Chk2 signalings in male breast cancer (MBC).
p11068
sg4
(lp11069
(dp11070
g7
I31
sg8
I1
sg9
I4
sg10
g11
sg12
VChk1
p11071
sa(dp11072
g7
I40
sg8
I1
sg9
I3
sg10
g11
sg12
VATM
p11073
sasg24
(lp11074
(dp11075
g7
I83
sg8
I1
sg9
I3
sg27
VC0242787
p11076
sg12
VMBC
p11077
sa(dp11078
g7
I63
sg8
I3
sg9
I18
sg27
VC0242787
p11079
sg12
Vmale breast cancer
p11080
sasa(dp11081
g2
VWe have previously shown that the1100delC variant of the cell-cycle-checkpoint kinase gene CHEK2, which is carried by approximately 1% of the population confers a two-fold increase in female breast cancer and a 10-fold increase in male breast cancer.
p11082
sg4
(lp11083
sg24
(lp11084
(dp11085
g7
I184
sg8
I3
sg9
I20
sg27
VC0235653
p11086
sg12
Vfemale breast cancer
p11087
sa(dp11088
g7
I186
sg8
I3
sg9
I18
sg27
VC0242787
p11089
sg12
Vmale breast cancer
p11090
sasa(dp11091
g2
VThe purpose of present study was to investigate the relation of serum interleukin-19 (IL-19) levels with diabetic nephropathy (DN).
p11092
sg4
(lp11093
(dp11094
g7
I70
sg8
I1
sg9
I14
sg10
g11
sg12
Vinterleukin-19
p11095
sa(dp11096
g7
I86
sg8
I1
sg9
I5
sg10
g11
sg12
VIL-19
p11097
sasg24
(lp11098
(dp11099
g7
I105
sg8
I2
sg9
I20
sg27
VC0011881
p11100
sg12
Vdiabetic nephropathy
p11101
sa(dp11102
g7
I127
sg8
I1
sg9
I2
sg27
VC0011881
p11103
sg12
VDN
p11104
sasa(dp11105
g2
VIL-19 is significantly positive correlated with UAE and Cystatin C. IL-19 may play an important role that contributes to the progression of diabetic nephropathy.
p11106
sg4
(lp11107
(dp11108
g7
I0
sg8
I1
sg9
I5
sg10
g11
sg12
VIL-19
p11109
sa(dp11110
g7
I0
sg8
I1
sg9
I5
sg10
g11
sg12
VIL-19
p11111
sa(dp11112
g7
I56
sg8
I2
sg9
I10
sg10
VP01034
p11113
sg12
VCystatin C
p11114
sasg24
(lp11115
(dp11116
g7
I140
sg8
I2
sg9
I20
sg27
VC0011881
p11117
sg12
Vdiabetic nephropathy
p11118
sasa(dp11119
g2
VWe also demonstrate a large increase in levels of IL-19 in urine of patients with chronic kidney disease, which significantly correlated with estimated glomerular filtration rate levels.
p11120
sg4
(lp11121
(dp11122
g7
I50
sg8
I1
sg9
I5
sg10
g11
sg12
VIL-19
p11123
sasg24
(lp11124
(dp11125
g7
I82
sg8
I3
sg9
I22
sg27
VC1561643
p11126
sg12
Vchronic kidney disease
p11127
sasa(dp11128
g2
VNon-clustered protocadherins (PCDHs) are calcium-dependent adhesion molecules which have attracted attention for their possible roles in the neuronal circuit formation during development and their implications in the neurological disorders such as autism and mental retardation.
p11129
sg4
(lp11130
sg24
(lp11131
(dp11132
g7
I217
sg8
I2
sg9
I22
sg27
VC0027765
p11133
sg12
Vneurological disorders
p11134
sa(dp11135
g7
I59
sg8
I1
sg9
I8
sg27
VC0001511
p11136
sg12
Vadhesion
p11137
sa(dp11138
g7
I248
sg8
I1
sg9
I6
sg27
VC0004352
p11139
sg12
Vautism
p11140
sa(dp11141
g7
I259
sg8
I2
sg9
I18
sg27
VC0025362
p11142
sg12
Vmental retardation
p11143
sasa(dp11144
g2
VMutation screening of 30 individuals with autism identified two PCDH11Y polymorphic amino acid changes, F885V and K980N.
p11145
sg4
(lp11146
sg24
(lp11147
(dp11148
g7
I42
sg8
I1
sg9
I6
sg27
VC0004352
p11149
sg12
Vautism
p11150
sasa(dp11151
g2
VIn the present study, we analyzed the expression levels of LETM1 in bladder cancer tissues and non-cancerous tissues as well as in four bladder cancer cell lines (T24, EJ, 5637 and J82) and a human bladder epithelial immortalized cell line SV-HUC-1.
p11152
sg4
(lp11153
(dp11154
g7
I59
sg8
I1
sg9
I5
sg10
g11
sg12
VLETM1
p11155
sasg24
(lp11156
(dp11157
g7
I68
sg8
I2
sg9
I14
sg27
VC0699885
p11158
sg12
Vbladder cancer
p11159
sa(dp11160
g7
I68
sg8
I2
sg9
I14
sg27
VC0699885
p11161
sg12
Vbladder cancer
p11162
sasa(dp11163
g2
VThe PD-L1 mRNA and protein expression levels were measured in the bladder cancer T24 cell line and the human uroepithelial SV-HUC-1 cell line, following treatment with interleukin (IL)-2, interferon (IFN)-Alfa and IFN-Gamma, by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis, respectively.
p11164
sg4
(lp11165
(dp11166
g7
I200
sg8
I1
sg9
I3
sg10
VP01562
p11167
sg12
VIFN
p11168
sa(dp11169
g7
I188
sg8
I1
sg9
I10
sg10
VP01563
p11170
sg12
Vinterferon
p11171
sa(dp11172
g7
I214
sg8
I1
sg9
I9
sg10
VP01579
p11173
sg12
VIFN-Gamma
p11174
sa(dp11175
g7
I168
sg8
I2
sg9
I18
sg10
VP60568
p11176
sg12
Vinterleukin (IL)-2
p11177
sasg24
(lp11178
(dp11179
g7
I66
sg8
I2
sg9
I14
sg27
VC0699885
p11180
sg12
Vbladder cancer
p11181
sasa(dp11182
g2
VRT-qPCR and western blotting demonstrated that cytokines IL-2, IFN-Alfa and IFN-Gamma markedly upregulated PD-L1 mRNA expression rates and protein levels in bladder cancer T24 cells (P&lt;0.05), but had no significant effect in non-tumor SV-HUC-1 cells.
p11183
sg4
(lp11184
(dp11185
g7
I63
sg8
I1
sg9
I8
sg10
VP01562
p11186
sg12
VIFN-Alfa
p11187
sa(dp11188
g7
I57
sg8
I1
sg9
I4
sg10
VP60568
p11189
sg12
VIL-2
p11190
sa(dp11191
g7
I76
sg8
I1
sg9
I9
sg10
VP01579
p11192
sg12
VIFN-Gamma
p11193
sasg24
(lp11194
(dp11195
g7
I157
sg8
I2
sg9
I14
sg27
VC0699885
p11196
sg12
Vbladder cancer
p11197
sa(dp11198
g7
I232
sg8
I1
sg9
I5
sg27
VC0027651
p11199
sg12
Vtumor
p11200
sasa(dp11201
g2
VOur data showed that miR-6838 was sharply up-regulated in the bladder tissues from bladder cancer patients and 4 human bladder cancer cell lines, compared with the healthy volunteers and SU-HUC-1 human normal bladder epithelial cells.
p11202
sg4
(lp11203
(dp11204
g7
I187
sg8
I1
sg9
I8
sg10
g11
sg12
VSU-HUC-1
p11205
sasg24
(lp11206
(dp11207
g7
I83
sg8
I2
sg9
I14
sg27
VC0699885
p11208
sg12
Vbladder cancer
p11209
sa(dp11210
g7
I83
sg8
I2
sg9
I14
sg27
VC0699885
p11211
sg12
Vbladder cancer
p11212
sasa(dp11213
g2
VTreatment with dioscin decreased viability of BC 5637 and T24 cells, but not non-cancer bladder epithelial cell, SV-HUC-1.
p11214
sg4
(lp11215
sg24
(lp11216
(dp11217
g7
I81
sg8
I1
sg9
I6
sg27
VC0006826
p11218
sg12
Vcancer
p11219
sasa(dp11220
g2
VA primary deficiency of protein C or S is proposed which would produce cerebral thrombosis with exposure of phospholipids; this thrombosis then, like antigens, would generate antibodies acting on the thrombin-thrombomodulin complex, exacerbating the thrombotic process.
p11221
sg4
(lp11222
(dp11223
g7
I24
sg8
I2
sg9
I9
sg10
VP02810
p11224
sg12
Vprotein C
p11225
sa(dp11226
g7
I200
sg8
I1
sg9
I8
sg10
VP00734
p11227
sg12
Vthrombin
p11228
sa(dp11229
g7
I209
sg8
I1
sg9
I14
sg10
VP07204
p11230
sg12
Vthrombomodulin
p11231
sasg24
(lp11232
(dp11233
g7
I71
sg8
I2
sg9
I19
sg27
VC0795687
p11234
sg12
Vcerebral thrombosis
p11235
sa(dp11236
g7
I80
sg8
I1
sg9
I10
sg27
VC0040053
p11237
sg12
Vthrombosis
p11238
sasa(dp11239
g2
VTo investigate whether defects in the SPATA17 gene are associated with azoospermia due to meiotic arrest, a mutational analysis was conducted, in which the SPATA17 coding regions of 18 Japanese patients with this condition were sequenced.
p11240
sg4
(lp11241
(dp11242
g7
I38
sg8
I2
sg9
I12
sg10
g11
sg12
VSPATA17 gene
p11243
sa(dp11244
g7
I38
sg8
I1
sg9
I7
sg10
g11
sg12
VSPATA17
p11245
sasg24
(lp11246
(dp11247
g7
I213
sg8
I1
sg9
I9
sg27
VC0012634
p11248
sg12
Vcondition
p11249
sa(dp11250
g7
I71
sg8
I1
sg9
I11
sg27
VC1321542
p11251
sg12
Vazoospermia
p11252
sasa(dp11253
g2
VThe frequencies of erythrocyte MNSs antigens and certain histocompatibility leukocyte antigen (HLA) specificities (HLA-A, HLA-B, and HLA-DR) were determined in white patients with meningitis or epiglottitis due to Haemophilus influenzae type b and in controls.
p11254
sg4
(lp11255
(dp11256
g7
I19
sg8
I3
sg9
I25
sg10
VP21333
p11257
sg12
Verythrocyte MNSs antigens
p11258
sa(dp11259
g7
I49
sg8
I4
sg9
I44
sg10
VP14209
p11260
sg12
Vcertain histocompatibility leukocyte antigen
p11261
sa(dp11262
g7
I122
sg8
I1
sg9
I5
sg10
VP30461
p11263
sg12
VHLA-B
p11264
sa(dp11265
g7
I133
sg8
I1
sg9
I6
sg10
VP30486
p11266
sg12
VHLA-DR
p11267
sa(dp11268
g7
I115
sg8
I1
sg9
I5
sg10
VP30447
p11269
sg12
VHLA-A
p11270
sa(dp11271
g7
I95
sg8
I1
sg9
I3
sg10
VP30486
p11272
sg12
VHLA
p11273
sasg24
(lp11274
(dp11275
g7
I194
sg8
I1
sg9
I12
sg27
VC0014541
p11276
sg12
Vepiglottitis
p11277
sa(dp11278
g7
I180
sg8
I1
sg9
I10
sg27
VC0025289
p11279
sg12
Vmeningitis
p11280
sasa(dp11281
g2
VAnalysis of antigen expression pattern, the presence or absence of T cell-associated antigen deletion, and the expression of CD10 and CD34 by 4-color flow cytometry can help differentiate thymoma from T-cell ALL/LBL.
p11282
sg4
(lp11283
(dp11284
g7
I125
sg8
I1
sg9
I4
sg10
VP08473
p11285
sg12
VCD10
p11286
sa(dp11287
g7
I134
sg8
I1
sg9
I4
sg10
VP28906
p11288
sg12
VCD34
p11289
sa(dp11290
g7
I67
sg8
I3
sg9
I25
sg10
VP14209
p11291
sg12
VT cell-associated antigen
p11292
sasg24
(lp11293
(dp11294
g7
I188
sg8
I1
sg9
I7
sg27
VC0040100
p11295
sg12
Vthymoma
p11296
sasa(dp11297
g2
VWe found that CYC1 was upregulated in breast tumor tissues, especially in tissues with lymph node metastasis.
p11298
sg4
(lp11299
(dp11300
g7
I14
sg8
I1
sg9
I4
sg10
VP08574
p11301
sg12
VCYC1
p11302
sasg24
(lp11303
(dp11304
g7
I38
sg8
I2
sg9
I12
sg27
VC1458155
p11305
sg12
Vbreast tumor
p11306
sa(dp11307
g7
I87
sg8
I3
sg9
I21
sg27
VC0686619
p11308
sg12
Vlymph node metastasis
p11309
sasa(dp11310
g2
VAnd higher expression of CYC1 correlates with poor prognosis in breast cancer patients using online databases and tools.
p11311
sg4
(lp11312
(dp11313
g7
I25
sg8
I1
sg9
I4
sg10
VP08574
p11314
sg12
VCYC1
p11315
sasg24
(lp11316
(dp11317
g7
I64
sg8
I2
sg9
I13
sg27
VC0678222
p11318
sg12
Vbreast cancer
p11319
sasa(dp11320
g2
VThen we confirmed that CYC1 contributed to metastasis and proliferation in two highly metastatic human breast cancer cell lines.
p11321
sg4
(lp11322
(dp11323
g7
I23
sg8
I1
sg9
I4
sg10
VP08574
p11324
sg12
VCYC1
p11325
sasg24
(lp11326
(dp11327
g7
I43
sg8
I1
sg9
I10
sg27
VC0027627
p11328
sg12
Vmetastasis
p11329
sa(dp11330
g7
I58
sg8
I1
sg9
I13
sg27
VC0334094
p11331
sg12
Vproliferation
p11332
sa(dp11333
g7
I103
sg8
I2
sg9
I13
sg27
VC0678222
p11334
sg12
Vbreast cancer
p11335
sasa(dp11336
g2
VOur results indicated that CYC1 plays crucial roles in breast cancer progression and might be a predictive factor assisting future patient diagnosis.
p11337
sg4
(lp11338
(dp11339
g7
I27
sg8
I1
sg9
I4
sg10
VP08574
p11340
sg12
VCYC1
p11341
sasg24
(lp11342
(dp11343
g7
I62
sg8
I2
sg9
I18
sg27
VC0178874
p11344
sg12
Vcancer progression
p11345
sasa(dp11346
g2
VUbiquinol-cytochrome c reductase hinge protein (UQCRH), as a connecter between cytochrome c1 with cytochrome c in complex III of respiratory chain, is top-ranked hypermethylated gene in clear cell renal cell carcinoma (ccRCC).
p11347
sg4
(lp11348
(dp11349
g7
I48
sg8
I1
sg9
I5
sg10
VP07919
p11350
sg12
VUQCRH
p11351
sa(dp11352
g7
I79
sg8
I2
sg9
I13
sg10
VP08574
p11353
sg12
Vcytochrome c1
p11354
sa(dp11355
g7
I10
sg8
I2
sg9
I12
sg10
VP99999
p11356
sg12
Vcytochrome c
p11357
sa(dp11358
g7
I0
sg8
I5
sg9
I46
sg10
VP99999
p11359
sg12
VUbiquinol-cytochrome c reductase hinge protein
p11360
sasg24
(lp11361
(dp11362
g7
I219
sg8
I1
sg9
I5
sg27
VC0279702
p11363
sg12
VccRCC
p11364
sa(dp11365
g7
I186
sg8
I5
sg9
I31
sg27
VC0279702
p11366
sg12
Vclear cell renal cell carcinoma
p11367
sasa(dp11368
g2
VThis study aimed at testing a panel of nine reference genes [beta-2-microglobulin, cytochrome c-1 (CYC1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hydroxymethylbilane synthase, hypoxanthine guanine phosphoribosyl transferase 1, ribosomal protein L13a (RPL13A), succinate dehydrogenase, TATA-box binding protein and 14-3-3 protein zeta] to identify and validate the most suitable reference genes for expression studies in human glioma of different grades (World Health Organization grades II-IV).
p11369
sg4
(lp11370
(dp11371
g7
I99
sg8
I1
sg9
I4
sg10
VP08574
p11372
sg12
VCYC1
p11373
sa(dp11374
g7
I61
sg8
I1
sg9
I20
sg10
VP61769
p11375
sg12
Vbeta-2-microglobulin
p11376
sa(dp11377
g7
I237
sg8
I3
sg9
I22
sg10
VP40429
p11378
sg12
Vribosomal protein L13a
p11379
sa(dp11380
g7
I295
sg8
I3
sg9
I24
sg10
VP20226
p11381
sg12
VTATA-box binding protein
p11382
sa(dp11383
g7
I83
sg8
I2
sg9
I14
sg10
VP99999
p11384
sg12
Vcytochrome c-1
p11385
sa(dp11386
g7
I261
sg8
I1
sg9
I6
sg10
VP40429
p11387
sg12
VRPL13A
p11388
sa(dp11389
g7
I106
sg8
I2
sg9
I40
sg10
VP04406
p11390
sg12
Vglyceraldehyde-3-phosphate dehydrogenase
p11391
sa(dp11392
g7
I186
sg8
I5
sg9
I49
sg10
VP00492
p11393
sg12
Vhypoxanthine guanine phosphoribosyl transferase 1
p11394
sa(dp11395
g7
I156
sg8
I2
sg9
I28
sg10
VP08397
p11396
sg12
Vhydroxymethylbilane synthase
p11397
sa(dp11398
g7
I148
sg8
I1
sg9
I5
sg10
VP04406
p11399
sg12
VGAPDH
p11400
sa(dp11401
g7
I270
sg8
I2
sg9
I23
sg10
VP49366
p11402
sg12
Vsuccinate dehydrogenase
p11403
sasg24
(lp11404
(dp11405
g7
I436
sg8
I1
sg9
I6
sg27
VC0017638
p11406
sg12
Vglioma
p11407
sasa(dp11408
g2
VAfter analysis of the stability values calculated using geNorm, NormFinder, and BestKeeper algorithms, GAPDH, RPL13A, and CYC1 can be indicated as reference genes applicable for accurate normalization of gene expression in glioma compared with normal brain and anaplastic astrocytoma or glioblastoma alone within this experimental setting.
p11409
sg4
(lp11410
(dp11411
g7
I110
sg8
I1
sg9
I6
sg10
VP40429
p11412
sg12
VRPL13A
p11413
sa(dp11414
g7
I122
sg8
I1
sg9
I4
sg10
VP08574
p11415
sg12
VCYC1
p11416
sa(dp11417
g7
I103
sg8
I1
sg9
I5
sg10
VP04406
p11418
sg12
VGAPDH
p11419
sasg24
(lp11420
(dp11421
g7
I287
sg8
I1
sg9
I12
sg27
VC0017636
p11422
sg12
Vglioblastoma
p11423
sa(dp11424
g7
I261
sg8
I2
sg9
I22
sg27
VC0334579
p11425
sg12
Vanaplastic astrocytoma
p11426
sa(dp11427
g7
I223
sg8
I1
sg9
I6
sg27
VC0017638
p11428
sg12
Vglioma
p11429
sasa(dp11430
g2
VKaplan-Meier plots identified correlations between individual or combined overexpression of E2F1, E2F3a, Mps1/TTK, Nek2, BubR1, or Hec1 and poor overall and relapse-free survival of breast cancer patients.
p11431
sg4
(lp11432
(dp11433
g7
I131
sg8
I1
sg9
I4
sg10
g11
sg12
VHec1
p11434
sa(dp11435
g7
I105
sg8
I1
sg9
I4
sg10
VP33981
p11436
sg12
VMps1
p11437
sa(dp11438
g7
I115
sg8
I1
sg9
I4
sg10
VP51955
p11439
sg12
VNek2
p11440
sa(dp11441
g7
I92
sg8
I1
sg9
I4
sg10
g11
sg12
VE2F1
p11442
sa(dp11443
g7
I110
sg8
I1
sg9
I3
sg10
VP49841
p11444
sg12
VTTK
p11445
sa(dp11446
g7
I98
sg8
I1
sg9
I5
sg10
g11
sg12
VE2F3a
p11447
sasg24
(lp11448
(dp11449
g7
I157
sg8
I1
sg9
I7
sg27
VC0277556
p11450
sg12
Vrelapse
p11451
sa(dp11452
g7
I182
sg8
I2
sg9
I13
sg27
VC0678222
p11453
sg12
Vbreast cancer
p11454
sasa(dp11455
g2
VBy interrogating the METABRIC database, we observed a significant correlation between p53 expression and that of c-Abl and TTK in basal-like breast cancers.
p11456
sg4
(lp11457
(dp11458
g7
I86
sg8
I1
sg9
I3
sg10
VP42771
p11459
sg12
Vp53
p11460
sa(dp11461
g7
I113
sg8
I1
sg9
I5
sg10
VP00519
p11462
sg12
Vc-Abl
p11463
sa(dp11464
g7
I123
sg8
I1
sg9
I3
sg10
VP49841
p11465
sg12
VTTK
p11466
sasg24
(lp11467
(dp11468
g7
I141
sg8
I2
sg9
I14
sg27
VC0006142
p11469
sg12
Vbreast cancers
p11470
sa(dp11471
g7
I115
sg8
I1
sg9
I3
sg27
VC0000744
p11472
sg12
VAbl
p11473
sasa(dp11474
g2
VThe protein kinase threonine tyrosine kinase (TTK; also known as Mps1) is a critical component of the spindle assembly checkpoint and a promising drug target for the treatment of aggressive cancers, such as triple negative breast cancer.
p11475
sg4
(lp11476
(dp11477
g7
I46
sg8
I1
sg9
I3
sg10
VP49841
p11478
sg12
VTTK
p11479
sa(dp11480
g7
I4
sg8
I5
sg9
I40
sg10
VP29401
p11481
sg12
Vprotein kinase threonine tyrosine kinase
p11482
sa(dp11483
g7
I65
sg8
I1
sg9
I4
sg10
VP33981
p11484
sg12
VMps1
p11485
sasg24
(lp11486
(dp11487
g7
I190
sg8
I1
sg9
I7
sg27
VC0006826
p11488
sg12
Vcancers
p11489
sa(dp11490
g7
I223
sg8
I2
sg9
I13
sg27
VC0678222
p11491
sg12
Vbreast cancer
p11492
sa(dp11493
g7
I179
sg8
I1
sg9
I10
sg27
VC0001807
p11494
sg12
Vaggressive
p11495
sasa(dp11496
g2
VHigh levels of the mitotic checkpoint kinase Mps1/TTK have correlated with high histologic grade in breast cancer, suggesting a potential new therapeutic target for aggressive breast cancers (BC).
p11497
sg4
(lp11498
(dp11499
g7
I50
sg8
I1
sg9
I3
sg10
VP49841
p11500
sg12
VTTK
p11501
sa(dp11502
g7
I45
sg8
I1
sg9
I4
sg10
VP33981
p11503
sg12
VMps1
p11504
sasg24
(lp11505
(dp11506
g7
I165
sg8
I1
sg9
I10
sg27
VC0001807
p11507
sg12
Vaggressive
p11508
sa(dp11509
g7
I176
sg8
I2
sg9
I14
sg27
VC0006142
p11510
sg12
Vbreast cancers
p11511
sa(dp11512
g7
I100
sg8
I2
sg9
I13
sg27
VC0006142
p11513
sg12
Vbreast cancer
p11514
sa(dp11515
g7
I192
sg8
I1
sg9
I2
sg27
VC0006142
p11516
sg12
VBC
p11517
sasa(dp11518
g2
VThese compounds were evaluated in anti-proliferative assays of a panel of 15 breast cancer cell lines and further examined for their ability to inhibit a variety of Mps1-dependent biological functions.
p11519
sg4
(lp11520
(dp11521
g7
I165
sg8
I1
sg9
I4
sg10
VP33981
p11522
sg12
VMps1
p11523
sasg24
(lp11524
(dp11525
g7
I77
sg8
I2
sg9
I13
sg27
VC0678222
p11526
sg12
Vbreast cancer
p11527
sa(dp11528
g7
I39
sg8
I1
sg9
I13
sg27
VC0334094
p11529
sg12
Vproliferative
p11530
sasa(dp11531
g2
VIn addition, the lead compounds 1 and 13 inhibit Mps1 kinase enzymatic activity with IC50 values from 0.356myM to 0.809myM, and inhibited Mps1-associated cellular functions such as centrosome duplication and the spindle checkpoint in triple negative breast cancer cells.
p11532
sg4
(lp11533
(dp11534
g7
I49
sg8
I1
sg9
I4
sg10
VP33981
p11535
sg12
VMps1
p11536
sa(dp11537
g7
I49
sg8
I2
sg9
I11
sg10
VP33981
p11538
sg12
VMps1 kinase
p11539
sasg24
(lp11540
(dp11541
g7
I250
sg8
I2
sg9
I13
sg27
VC0678222
p11542
sg12
Vbreast cancer
p11543
sa(dp11544
g7
I192
sg8
I1
sg9
I11
sg27
VC1705960
p11545
sg12
Vduplication
p11546
sasa(dp11547
g2
VUsing drug discovery technologies, computational modeling, medicinal chemistry, cell culture and in vivo assays, novel small molecule Mps1/TTK inhibitors have been identified as potential targeted therapies for breast cancers.
p11548
sg4
(lp11549
(dp11550
g7
I139
sg8
I1
sg9
I3
sg10
VP49841
p11551
sg12
VTTK
p11552
sa(dp11553
g7
I134
sg8
I1
sg9
I4
sg10
VP33981
p11554
sg12
VMps1
p11555
sasg24
(lp11556
(dp11557
g7
I211
sg8
I2
sg9
I14
sg27
VC0006142
p11558
sg12
Vbreast cancers
p11559
sasa(dp11560
g2
VHowever, high levels of Mps1 are found in many types of human malignancies, including glioblastoma, thyroid carcinoma, breast cancer, and other cancers.
p11561
sg4
(lp11562
(dp11563
g7
I24
sg8
I1
sg9
I4
sg10
VP33981
p11564
sg12
VMps1
p11565
sasg24
(lp11566
(dp11567
g7
I100
sg8
I2
sg9
I17
sg27
VC0549473
p11568
sg12
Vthyroid carcinoma
p11569
sa(dp11570
g7
I86
sg8
I1
sg9
I12
sg27
VC0017636
p11571
sg12
Vglioblastoma
p11572
sa(dp11573
g7
I62
sg8
I1
sg9
I12
sg27
VC0006826
p11574
sg12
Vmalignancies
p11575
sa(dp11576
g7
I144
sg8
I1
sg9
I7
sg27
VC0006826
p11577
sg12
Vcancers
p11578
sa(dp11579
g7
I119
sg8
I2
sg9
I13
sg27
VC0678222
p11580
sg12
Vbreast cancer
p11581
sasa(dp11582
g2
VHere, we employed amphiphilic polymers and silenced the expression of two cell cycle proteins, TTK and CDC20, and the anti-apoptosis protein survivin to determine the efficacy of polymer-mediated siRNA treatment in breast cancer cells as well as side effects in nonmalignant cells in vitro.
p11583
sg4
(lp11584
(dp11585
g7
I95
sg8
I1
sg9
I3
sg10
VP49841
p11586
sg12
VTTK
p11587
sa(dp11588
g7
I103
sg8
I1
sg9
I5
sg10
g11
sg12
VCDC20
p11589
sasg24
(lp11590
(dp11591
g7
I215
sg8
I2
sg9
I13
sg27
VC0678222
p11592
sg12
Vbreast cancer
p11593
sasa(dp11594
g2
VTo explore expressions of matrix metalloproteinase-1 (MMP-1), tissue inhibitor of metalloproteinases-1 (TIMP-1) and transforming growth factor-Beta1 (TGF-Beta1) in valve tissue of rheumatic heart disease (RHD), and to analyzed their roles in RHD.
p11595
sg4
(lp11596
(dp11597
g7
I62
sg8
I4
sg9
I40
sg10
VP01033
p11598
sg12
Vtissue inhibitor of metalloproteinases-1
p11599
sa(dp11600
g7
I150
sg8
I1
sg9
I9
sg10
VP01137
p11601
sg12
VTGF-Beta1
p11602
sa(dp11603
g7
I116
sg8
I3
sg9
I32
sg10
VP01137
p11604
sg12
Vtransforming growth factor-Beta1
p11605
sa(dp11606
g7
I104
sg8
I1
sg9
I6
sg10
VP01033
p11607
sg12
VTIMP-1
p11608
sa(dp11609
g7
I54
sg8
I1
sg9
I5
sg10
VP03956
p11610
sg12
VMMP-1
p11611
sa(dp11612
g7
I26
sg8
I2
sg9
I26
sg10
VP03956
p11613
sg12
Vmatrix metalloproteinase-1
p11614
sasg24
(lp11615
(dp11616
g7
I205
sg8
I1
sg9
I3
sg27
VC0035439
p11617
sg12
VRHD
p11618
sa(dp11619
g7
I180
sg8
I3
sg9
I23
sg27
VC0035439
p11620
sg12
Vrheumatic heart disease
p11621
sa(dp11622
g7
I205
sg8
I1
sg9
I3
sg27
VC0035439
p11623
sg12
VRHD
p11624
sasa(dp11625
g2
VObjectives The aim of this study was to investigate plasma ADAMTS-13 activity in patients with proliferative lupus nephritis and to evaluate the role of clinical, laboratory and pathological features, especially the vascular lesions in lupus nephritis.
p11626
sg4
(lp11627
sg24
(lp11628
(dp11629
g7
I109
sg8
I2
sg9
I15
sg27
VC0024143
p11630
sg12
Vlupus nephritis
p11631
sa(dp11632
g7
I216
sg8
I2
sg9
I16
sg27
VC1402315
p11633
sg12
Vvascular lesions
p11634
sa(dp11635
g7
I95
sg8
I1
sg9
I13
sg27
VC0334094
p11636
sg12
Vproliferative
p11637
sa(dp11638
g7
I109
sg8
I2
sg9
I15
sg27
VC0024143
p11639
sg12
Vlupus nephritis
p11640
sasa(dp11641
g2
VResults Plasma ADAMTS-13 activity in lupus nephritis patients was significantly lower than that in normal controls (84 +/- 21% vs. 90 +/- 13%, p = 0.005).
p11642
sg4
(lp11643
sg24
(lp11644
(dp11645
g7
I37
sg8
I2
sg9
I15
sg27
VC0024143
p11646
sg12
Vlupus nephritis
p11647
sasa(dp11648
g2
VConclusions Decreased ADAMTS-13 activity was found in patients with proliferative lupus nephritis, and plasma ADAMTS-13 activity was closely associated with renal injury indices, especially pathological vascular scores.
p11649
sg4
(lp11650
sg24
(lp11651
(dp11652
g7
I82
sg8
I2
sg9
I15
sg27
VC0024143
p11653
sg12
Vlupus nephritis
p11654
sa(dp11655
g7
I68
sg8
I1
sg9
I13
sg27
VC0334094
p11656
sg12
Vproliferative
p11657
sasa(dp11658
g2
VThe serum ADAMTS-13 activity was significantly lower in patients with both lupus nephritis and TTP-HUS than in patients with lupus nephritis only and in normal control (40% versus 69%, P = 0.012; 40% versus 81%, P &lt; 0.001, respectively).
p11659
sg4
(lp11660
sg24
(lp11661
(dp11662
g7
I75
sg8
I2
sg9
I15
sg27
VC0024143
p11663
sg12
Vlupus nephritis
p11664
sa(dp11665
g7
I75
sg8
I2
sg9
I15
sg27
VC0024143
p11666
sg12
Vlupus nephritis
p11667
sa(dp11668
g7
I95
sg8
I1
sg9
I3
sg27
VC1268935
p11669
sg12
VTTP
p11670
sasa(dp11671
g2
VThe prevalence of ADAMTS-13 autoantibodies was significantly higher in patients with both lupus nephritis and TTP-HUS than in patients with lupus nephritis only and in normal control (6/7, 86% versus 10/55, 18%, P &lt; 0.001; 6/7, 86% versus 0, P &lt; 0.001, respectively).
p11672
sg4
(lp11673
sg24
(lp11674
(dp11675
g7
I90
sg8
I2
sg9
I15
sg27
VC0024143
p11676
sg12
Vlupus nephritis
p11677
sa(dp11678
g7
I110
sg8
I1
sg9
I3
sg27
VC1268935
p11679
sg12
VTTP
p11680
sa(dp11681
g7
I90
sg8
I2
sg9
I15
sg27
VC0024143
p11682
sg12
Vlupus nephritis
p11683
sasa(dp11684
g2
VADAMTS-13 autoantibodies might play an important role in the pathogenesis of TTP-HUS associated with lupus nephritis.
p11685
sg4
(lp11686
(dp11687
g7
I77
sg8
I1
sg9
I7
sg10
g11
sg12
VTTP-HUS
p11688
sasg24
(lp11689
(dp11690
g7
I77
sg8
I1
sg9
I3
sg27
VC1268935
p11691
sg12
VTTP
p11692
sa(dp11693
g7
I101
sg8
I2
sg9
I15
sg27
VC0024143
p11694
sg12
Vlupus nephritis
p11695
sa(dp11696
g7
I61
sg8
I1
sg9
I12
sg27
VC0699748
p11697
sg12
Vpathogenesis
p11698
sasa(dp11699
g2
VPlasma vWF and vWF-CP activities were measured using enzyme-linked immunosorbent assay (ELISA) and residual collagen binding assay respectively in patients with lupus nephritis (n = 31), primary nephritic syndrome (n = 25), diabetic nephropathy (n = 45), chronic glomerulonephritis (n = 38) and 40 normal controls.
p11700
sg4
(lp11701
(dp11702
g7
I15
sg8
I1
sg9
I6
sg10
VP04275
p11703
sg12
VvWF-CP
p11704
sa(dp11705
g7
I7
sg8
I1
sg9
I3
sg10
VP04275
p11706
sg12
VvWF
p11707
sasg24
(lp11708
(dp11709
g7
I195
sg8
I2
sg9
I18
sg27
VC0268732
p11710
sg12
Vnephritic syndrome
p11711
sa(dp11712
g7
I161
sg8
I2
sg9
I15
sg27
VC0024143
p11713
sg12
Vlupus nephritis
p11714
sa(dp11715
g7
I224
sg8
I2
sg9
I20
sg27
VC0011881
p11716
sg12
Vdiabetic nephropathy
p11717
sa(dp11718
g7
I255
sg8
I2
sg9
I26
sg27
VC0152451
p11719
sg12
Vchronic glomerulonephritis
p11720
sasa(dp11721
g2
VRenal biopsy demonstrated that the vWF level in stage IV was higher than in stages II and III while vWF-CP activity was lower in patients with lupus nephritis.
p11722
sg4
(lp11723
(dp11724
g7
I35
sg8
I1
sg9
I3
sg10
VP04275
p11725
sg12
VvWF
p11726
sa(dp11727
g7
I100
sg8
I1
sg9
I6
sg10
VP04275
p11728
sg12
VvWF-CP
p11729
sasg24
(lp11730
(dp11731
g7
I143
sg8
I2
sg9
I15
sg27
VC0024143
p11732
sg12
Vlupus nephritis
p11733
sasa(dp11734
g2
VFurthermore the demonstration of a normal vWF-CP assay aided in the distinction between TTP and MAHA due to lupus nephritis.
p11735
sg4
(lp11736
(dp11737
g7
I42
sg8
I1
sg9
I3
sg10
VP04275
p11738
sg12
VvWF
p11739
sasg24
(lp11740
(dp11741
g7
I108
sg8
I2
sg9
I15
sg27
VC0024143
p11742
sg12
Vlupus nephritis
p11743
sa(dp11744
g7
I88
sg8
I1
sg9
I3
sg27
VC1268935
p11745
sg12
VTTP
p11746
sasa(dp11747
g2
VIn this study we have investigated the distribution and the level of expression of kinesin light chains (KLCs) (responsible for binding of cargos during anterograde transport) and of dynein intermediate chain (DIC) (a component of the dynein complex during retrograde transport) in frontal cortex and cerebellar cortex of control subjects and Alzheimer's disease patients.
p11748
sg4
(lp11749
(dp11750
g7
I83
sg8
I3
sg9
I20
sg10
g11
sg12
Vkinesin light chains
p11751
sa(dp11752
g7
I105
sg8
I1
sg9
I4
sg10
g11
sg12
VKLCs
p11753
sasg24
(lp11754
(dp11755
g7
I210
sg8
I1
sg9
I3
sg27
VC0012739
p11756
sg12
VDIC
p11757
sa(dp11758
g7
I343
sg8
I2
sg9
I19
sg27
VC1521724
p11759
sg12
VAlzheimer's disease
p11760
sa(dp11761
g7
I183
sg8
I3
sg9
I25
sg27
VC0012739
p11762
sg12
Vdynein intermediate chain
p11763
sasa(dp11764
g2
VBy immunoblotting, we found a significant decrease in the levels of expression of KLC1 and 2 and DIC in the frontal cortex, but not in the cerebellar cortex, of Alzheimer's disease patients.
p11765
sg4
(lp11766
sg24
(lp11767
(dp11768
g7
I97
sg8
I1
sg9
I3
sg27
VC0012739
p11769
sg12
VDIC
p11770
sa(dp11771
g7
I161
sg8
I2
sg9
I19
sg27
VC1521724
p11772
sg12
VAlzheimer's disease
p11773
sasa(dp11774
g2
VWe suggest that reduction of KLCs and DIC proteins in AD cortex results from both reduced expression and neuronal loss, and that these reductions and GSK-3Beta-mediated phosphorylation of KLC1 contribute to disturbances of axoplasmic flows and synaptic integrity in Alzheimer's disease.
p11775
sg4
(lp11776
(dp11777
g7
I150
sg8
I1
sg9
I9
sg10
VP49841
p11778
sg12
VGSK-3Beta
p11779
sasg24
(lp11780
(dp11781
g7
I266
sg8
I2
sg9
I19
sg27
VC1521724
p11782
sg12
VAlzheimer's disease
p11783
sa(dp11784
g7
I38
sg8
I1
sg9
I3
sg27
VC0012739
p11785
sg12
VDIC
p11786
sasa(dp11787
g2
VChildren with cystic fibrosis (CF) often have suboptimal adherence rates to nebulized medication.
p11788
sg4
(lp11789
sg24
(lp11790
(dp11791
g7
I14
sg8
I2
sg9
I15
sg27
VC0010674
p11792
sg12
Vcystic fibrosis
p11793
sa(dp11794
g7
I31
sg8
I1
sg9
I2
sg27
VC0010674
p11795
sg12
VCF
p11796
sasa(dp11797
g2
VA cocktail of three phages active against Pseudomonas aeruginosa isolates from cystic fibrosis patients was developed for a potential nebulized formulation.
p11798
sg4
(lp11799
sg24
(lp11800
(dp11801
g7
I79
sg8
I2
sg9
I15
sg27
VC0010674
p11802
sg12
Vcystic fibrosis
p11803
sasa(dp11804
g2
VTreatment regimen for families of children with cystic fibrosis (CF) is considerable, particularly when nebulised therapies for chronic Pseudomonas aeruginosa airway infection are prescribed.
p11805
sg4
(lp11806
sg24
(lp11807
(dp11808
g7
I166
sg8
I1
sg9
I9
sg27
VC0009450
p11809
sg12
Vinfection
p11810
sa(dp11811
g7
I48
sg8
I2
sg9
I15
sg27
VC0010674
p11812
sg12
Vcystic fibrosis
p11813
sa(dp11814
g7
I65
sg8
I1
sg9
I2
sg27
VC0010674
p11815
sg12
VCF
p11816
sasa(dp11817
g2
VThe time requirements for multiple daily nebulizer treatments are important impediments to the quality of life for most patients with cystic fibrosis (CF).
p11818
sg4
(lp11819
sg24
(lp11820
(dp11821
g7
I134
sg8
I2
sg9
I15
sg27
VC0010674
p11822
sg12
Vcystic fibrosis
p11823
sa(dp11824
g7
I151
sg8
I1
sg9
I2
sg27
VC0010674
p11825
sg12
VCF
p11826
sasa(dp11827
g2
VTherefore, in this study, the author describes for the first time the common feature of oral clefts in patients carrying a microduplication of 15q13.3 encompassing the CHRNA7 gene, which sheds light on the correlation between CHRNA7 and cleft palate.
p11828
sg4
(lp11829
(dp11830
g7
I168
sg8
I2
sg9
I11
sg10
VP36544
p11831
sg12
VCHRNA7 gene
p11832
sasg24
(lp11833
(dp11834
g7
I237
sg8
I2
sg9
I12
sg27
VC0008925
p11835
sg12
Vcleft palate
p11836
sasa(dp11837
g2
VIn contrast to GTG banding, array CGH determined the exact number of deleted genes and thus allowed the identification of candidate genes for cleft palate (GREM1, CX36, MEIS2), congenital heart defect (ACTC, GREM1, CX36, MEIS2), and mental retardation (ARHGAP11A, CHRNA7, CHRM5).
p11838
sg4
(lp11839
(dp11840
g7
I169
sg8
I1
sg9
I5
sg10
g11
sg12
VMEIS2
p11841
sa(dp11842
g7
I163
sg8
I1
sg9
I4
sg10
g11
sg12
VCX36
p11843
sa(dp11844
g7
I272
sg8
I1
sg9
I5
sg10
VP08912
p11845
sg12
VCHRM5
p11846
sa(dp11847
g7
I202
sg8
I1
sg9
I4
sg10
VP68032
p11848
sg12
VACTC
p11849
sa(dp11850
g7
I264
sg8
I1
sg9
I6
sg10
VP36544
p11851
sg12
VCHRNA7
p11852
sa(dp11853
g7
I169
sg8
I1
sg9
I5
sg10
g11
sg12
VMEIS2
p11854
sa(dp11855
g7
I156
sg8
I1
sg9
I5
sg10
g11
sg12
VGREM1
p11856
sa(dp11857
g7
I156
sg8
I1
sg9
I5
sg10
g11
sg12
VGREM1
p11858
sa(dp11859
g7
I163
sg8
I1
sg9
I4
sg10
g11
sg12
VCX36
p11860
sa(dp11861
g7
I253
sg8
I1
sg9
I9
sg10
g11
sg12
VARHGAP11A
p11862
sasg24
(lp11863
(dp11864
g7
I233
sg8
I2
sg9
I18
sg27
VC0025362
p11865
sg12
Vmental retardation
p11866
sa(dp11867
g7
I142
sg8
I2
sg9
I12
sg27
VC0008925
p11868
sg12
Vcleft palate
p11869
sa(dp11870
g7
I34
sg8
I1
sg9
I3
sg27
VC1855900
p11871
sg12
VCGH
p11872
sa(dp11873
g7
I177
sg8
I3
sg9
I23
sg27
VC0018798
p11874
sg12
Vcongenital heart defect
p11875
sasa(dp11876
g2
VComparative deletion mapping shows that this region can be dissected into five chromosomal segments containing at least six candidate genes (DAB1, HOOK1, NFIA, DOCK7, DNAJC6, and PDE4B) most likely responsible for syndromic intellectual disability, which was corroborated by their reduced transcript levels in RT-qPCR.
p11877
sg4
(lp11878
(dp11879
g7
I154
sg8
I1
sg9
I4
sg10
g11
sg12
VNFIA
p11880
sa(dp11881
g7
I147
sg8
I1
sg9
I5
sg10
g11
sg12
VHOOK1
p11882
sa(dp11883
g7
I167
sg8
I1
sg9
I6
sg10
g11
sg12
VDNAJC6
p11884
sa(dp11885
g7
I179
sg8
I1
sg9
I5
sg10
g11
sg12
VPDE4B
p11886
sa(dp11887
g7
I141
sg8
I1
sg9
I4
sg10
g11
sg12
VDAB1
p11888
sasg24
(lp11889
(dp11890
g7
I224
sg8
I2
sg9
I23
sg27
VC0025362
p11891
sg12
Vintellectual disability
p11892
sasa(dp11893
g2
VImportantly, one patient with an intragenic microdeletion within NFIA and an additional patient with a balanced translocation disrupting NFIA display intellectual disability coupled with macrocephaly.
p11894
sg4
(lp11895
(dp11896
g7
I65
sg8
I1
sg9
I4
sg10
g11
sg12
VNFIA
p11897
sa(dp11898
g7
I65
sg8
I1
sg9
I4
sg10
g11
sg12
VNFIA
p11899
sasg24
(lp11900
(dp11901
g7
I150
sg8
I2
sg9
I23
sg27
VC0025362
p11902
sg12
Vintellectual disability
p11903
sa(dp11904
g7
I112
sg8
I1
sg9
I13
sg27
VC0040715
p11905
sg12
Vtranslocation
p11906
sa(dp11907
g7
I187
sg8
I1
sg9
I12
sg27
VC0221355
p11908
sg12
Vmacrocephaly
p11909
sasa(dp11910
g2
VWe propose NFIA is responsible for intellectual disability coupled with macrocephaly, and microdeletions at 1p31.3p32.2 constitute a contiguous gene syndrome with several genes contributing to syndromic intellectual disability.
p11911
sg4
(lp11912
(dp11913
g7
I11
sg8
I1
sg9
I4
sg10
g11
sg12
VNFIA
p11914
sasg24
(lp11915
(dp11916
g7
I72
sg8
I1
sg9
I12
sg27
VC0221355
p11917
sg12
Vmacrocephaly
p11918
sa(dp11919
g7
I149
sg8
I1
sg9
I8
sg27
VC0039082
p11920
sg12
Vsyndrome
p11921
sa(dp11922
g7
I35
sg8
I2
sg9
I23
sg27
VC0025362
p11923
sg12
Vintellectual disability
p11924
sa(dp11925
g7
I35
sg8
I2
sg9
I23
sg27
VC0025362
p11926
sg12
Vintellectual disability
p11927
sasa(dp11928
g2
VNon-progressive cerebellar ataxia with mental retardation (CANPMR, OMIM 614756) and chromosome 1p32-p31 deletion syndrome (OMIM 613735) are two very rare inherited disorders, which are caused by mono-allelic deficiency (haplo-insufficiency) of calmodulin-binding transcription activator 1 (CAMTA1) and, respectively, nuclear factor 1 A (NFIA) genes.
p11929
sg4
(lp11930
(dp11931
g7
I244
sg8
I4
sg9
I44
sg10
g11
sg12
Vcalmodulin-binding transcription activator 1
p11932
sa(dp11933
g7
I317
sg8
I4
sg9
I18
sg10
VP01160
p11934
sg12
Vnuclear factor 1 A
p11935
sa(dp11936
g7
I290
sg8
I1
sg9
I6
sg10
g11
sg12
VCAMTA1
p11937
sa(dp11938
g7
I337
sg8
I1
sg9
I4
sg10
g11
sg12
VNFIA
p11939
sasg24
(lp11940
(dp11941
g7
I4
sg8
I3
sg9
I29
sg27
VC0393525
p11942
sg12
Vprogressive cerebellar ataxia
p11943
sa(dp11944
g7
I84
sg8
I4
sg9
I37
sg27
VC3151036
p11945
sg12
Vchromosome 1p32-p31 deletion syndrome
p11946
sa(dp11947
g7
I39
sg8
I2
sg9
I18
sg27
VC0025362
p11948
sg12
Vmental retardation
p11949
sa(dp11950
g7
I195
sg8
I1
sg9
I4
sg27
VC0021345
p11951
sg12
Vmono
p11952
sasa(dp11953
g2
VAmong these 24 genes, four transcription factors Auts2, Nfia, Nr4a2, and Sox5 were found, suggesting that TBR1 controls a transcriptional cascade relevant to autism pathogenesis.
p11954
sg4
(lp11955
(dp11956
g7
I49
sg8
I1
sg9
I5
sg10
g11
sg12
VAuts2
p11957
sa(dp11958
g7
I56
sg8
I1
sg9
I4
sg10
g11
sg12
VNfia
p11959
sa(dp11960
g7
I106
sg8
I1
sg9
I4
sg10
g11
sg12
VTBR1
p11961
sa(dp11962
g7
I62
sg8
I1
sg9
I5
sg10
VP43354
p11963
sg12
VNr4a2
p11964
sasg24
(lp11965
(dp11966
g7
I165
sg8
I1
sg9
I12
sg27
VC0699748
p11967
sg12
Vpathogenesis
p11968
sa(dp11969
g7
I158
sg8
I1
sg9
I6
sg27
VC0004352
p11970
sg12
Vautism
p11971
sasa(dp11972
g2
VSome of these maternal and maternal-child associations were in or adjacent to autism candidate genes including: PCDH9, FOXP1, GABRB3, NRXN1, RELN, MACROD2, FHIT, RORA, CNTN4, CNTNAP2, FAM135B, LAMA1, NFIA, NLGN4X, RAPGEF4, and SDK1.
p11973
sg4
(lp11974
(dp11975
g7
I200
sg8
I1
sg9
I4
sg10
g11
sg12
VNFIA
p11976
sa(dp11977
g7
I78
sg8
I3
sg9
I22
sg10
VP27635
p11978
sg12
Vautism candidate genes
p11979
sa(dp11980
g7
I162
sg8
I1
sg9
I4
sg10
VP35398
p11981
sg12
VRORA
p11982
sa(dp11983
g7
I227
sg8
I1
sg9
I4
sg10
g11
sg12
VSDK1
p11984
sa(dp11985
g7
I206
sg8
I1
sg9
I6
sg10
g11
sg12
VNLGN4X
p11986
sa(dp11987
g7
I112
sg8
I1
sg9
I5
sg10
g11
sg12
VPCDH9
p11988
sa(dp11989
g7
I156
sg8
I1
sg9
I4
sg10
VP49789
p11990
sg12
VFHIT
p11991
sa(dp11992
g7
I119
sg8
I1
sg9
I5
sg10
g11
sg12
VFOXP1
p11993
sa(dp11994
g7
I214
sg8
I1
sg9
I7
sg10
g11
sg12
VRAPGEF4
p11995
sa(dp11996
g7
I175
sg8
I1
sg9
I7
sg10
g11
sg12
VCNTNAP2
p11997
sa(dp11998
g7
I184
sg8
I1
sg9
I7
sg10
g11
sg12
VFAM135B
p11999
sa(dp12000
g7
I193
sg8
I1
sg9
I5
sg10
VP25391
p12001
sg12
VLAMA1
p12002
sa(dp12003
g7
I168
sg8
I1
sg9
I5
sg10
g11
sg12
VCNTN4
p12004
sa(dp12005
g7
I147
sg8
I1
sg9
I7
sg10
g11
sg12
VMACROD2
p12006
sa(dp12007
g7
I141
sg8
I1
sg9
I4
sg10
VP78509
p12008
sg12
VRELN
p12009
sa(dp12010
g7
I126
sg8
I1
sg9
I6
sg10
VP28472
p12011
sg12
VGABRB3
p12012
sa(dp12013
g7
I134
sg8
I1
sg9
I5
sg10
VP58400
p12014
sg12
VNRXN1
p12015
sasg24
(lp12016
(dp12017
g7
I78
sg8
I1
sg9
I6
sg27
VC0004352
p12018
sg12
Vautism
p12019
sasa(dp12020
g2
VThese results provided a mechanistic linking between TRPM2-mediated Ca2+ influx and p47 phox signaling to induce excess ROS production and TXNIP-mediated NLRP3 inflammasome activation under HG, and suggested that TRPM2 represented a potential target for alleviating NLRP3 inflammasome activation related to hyperglycemia-induced oxidative stress in Type 2 diabetes Mellitus (T2DM).
p12021
sg4
(lp12022
(dp12023
g7
I53
sg8
I1
sg9
I5
sg10
VP10909
p12024
sg12
VTRPM2
p12025
sa(dp12026
g7
I139
sg8
I1
sg9
I5
sg10
g11
sg12
VTXNIP
p12027
sa(dp12028
g7
I88
sg8
I1
sg9
I4
sg10
VP19878
p12029
sg12
Vphox
p12030
sa(dp12031
g7
I53
sg8
I1
sg9
I5
sg10
VP10909
p12032
sg12
VTRPM2
p12033
sa(dp12034
g7
I84
sg8
I1
sg9
I3
sg10
VP08567
p12035
sg12
Vp47
p12036
sasg24
(lp12037
(dp12038
g7
I349
sg8
I4
sg9
I24
sg27
VC0011860
p12039
sg12
VType 2 diabetes Mellitus
p12040
sa(dp12041
g7
I375
sg8
I1
sg9
I4
sg27
VC0011860
p12042
sg12
VT2DM
p12043
sa(dp12044
g7
I307
sg8
I1
sg9
I13
sg27
VC0020456
p12045
sg12
Vhyperglycemia
p12046
sa(dp12047
g7
I329
sg8
I2
sg9
I16
sg27
VC0242606
p12048
sg12
Voxidative stress
p12049
sasa(dp12050
g2
VSOX3 mutations have been associated with growth hormone deficiency, variable degrees of additional pituitary hormone deficiencies, and mental retardation.
p12051
sg4
(lp12052
(dp12053
g7
I41
sg8
I2
sg9
I14
sg10
VP01242
p12054
sg12
Vgrowth hormone
p12055
sa(dp12056
g7
I99
sg8
I2
sg9
I17
sg10
VP18509
p12057
sg12
Vpituitary hormone
p12058
sa(dp12059
g7
I0
sg8
I1
sg9
I4
sg10
VP41225
p12060
sg12
VSOX3
p12061
sasg24
(lp12062
(dp12063
g7
I41
sg8
I3
sg9
I25
sg27
VC0271561
p12064
sg12
Vgrowth hormone deficiency
p12065
sa(dp12066
g7
I135
sg8
I2
sg9
I18
sg27
VC0025362
p12067
sg12
Vmental retardation
p12068
sasa(dp12069
g2
VSOX3 involvement should be considered in a male with short stature due to GH deficiency associated with intellectual disability.
p12070
sg4
(lp12071
(dp12072
g7
I0
sg8
I1
sg9
I4
sg10
VP41225
p12073
sg12
VSOX3
p12074
sasg24
(lp12075
(dp12076
g7
I104
sg8
I2
sg9
I23
sg27
VC0025362
p12077
sg12
Vintellectual disability
p12078
sa(dp12079
g7
I53
sg8
I2
sg9
I13
sg27
VC0013336
p12080
sg12
Vshort stature
p12081
sasa(dp12082
g2
VA further XX male, ascertained because of intellectual disability, carried a de novo cryptic duplication at Xq27.1, involving SOX3.
p12083
sg4
(lp12084
(dp12085
g7
I126
sg8
I1
sg9
I4
sg10
VP41225
p12086
sg12
VSOX3
p12087
sasg24
(lp12088
(dp12089
g7
I42
sg8
I2
sg9
I23
sg27
VC0025362
p12090
sg12
Vintellectual disability
p12091
sa(dp12092
g7
I93
sg8
I1
sg9
I11
sg27
VC1705960
p12093
sg12
Vduplication
p12094
sa(dp12095
g7
I10
sg8
I2
sg9
I7
sg27
VC0432475
p12096
sg12
VXX male
p12097
sasa(dp12098
g2
VIn humans, over- and underdosage of SOX3 is associated with X-linked hypopituitarism with variable phenotypes ranging from isolated GH deficiency (GHD) to panhypopituitarism, with or without mental retardation and, in most cases, with reported pituitary imaging, an ectopic/undescended posterior pituitary.
p12099
sg4
(lp12100
(dp12101
g7
I36
sg8
I1
sg9
I4
sg10
VP41225
p12102
sg12
VSOX3
p12103
sasg24
(lp12104
(dp12105
g7
I191
sg8
I2
sg9
I18
sg27
VC0025362
p12106
sg12
Vmental retardation
p12107
sa(dp12108
g7
I147
sg8
I1
sg9
I3
sg27
VC0271561
p12109
sg12
VGHD
p12110
sa(dp12111
g7
I155
sg8
I1
sg9
I18
sg27
VC0242343
p12112
sg12
Vpanhypopituitarism
p12113
sa(dp12114
g7
I69
sg8
I1
sg9
I15
sg27
VC0020635
p12115
sg12
Vhypopituitarism
p12116
sa(dp12117
g7
I132
sg8
I2
sg9
I13
sg27
VC0271561
p12118
sg12
VGH deficiency
p12119
sasa(dp12120
g2
VScreening for SOX3 should be advised not only for hypopituitary patients with an ectopic posterior pituitary, but also for those with a structurally normal pituitary and additional findings, including clefts and a persistent craniopharyngeal canal, with or without mental retardation.
p12121
sg4
(lp12122
(dp12123
g7
I14
sg8
I1
sg9
I4
sg10
VP41225
p12124
sg12
VSOX3
p12125
sasg24
(lp12126
(dp12127
g7
I265
sg8
I2
sg9
I18
sg27
VC0025362
p12128
sg12
Vmental retardation
p12129
sasa(dp12130
g2
VBoth duplications encompassing SOX3 and loss-of function mutations in SOX3 have been reported in a minor portion of X-linked isolated growth hormone deficiency (GHD) or combined pituitary hormone deficiency (CPHD) patients with or without mental retardation.
p12131
sg4
(lp12132
(dp12133
g7
I169
sg8
I3
sg9
I26
sg10
VP18509
p12134
sg12
Vcombined pituitary hormone
p12135
sa(dp12136
g7
I134
sg8
I2
sg9
I14
sg10
VP01242
p12137
sg12
Vgrowth hormone
p12138
sa(dp12139
g7
I31
sg8
I1
sg9
I4
sg10
VP41225
p12140
sg12
VSOX3
p12141
sasg24
(lp12142
(dp12143
g7
I239
sg8
I2
sg9
I18
sg27
VC0025362
p12144
sg12
Vmental retardation
p12145
sa(dp12146
g7
I161
sg8
I1
sg9
I3
sg27
VC0271561
p12147
sg12
VGHD
p12148
sa(dp12149
g7
I141
sg8
I2
sg9
I18
sg27
VC0599750
p12150
sg12
Vhormone deficiency
p12151
sa(dp12152
g7
I125
sg8
I4
sg9
I34
sg27
VC0271563
p12153
sg12
Visolated growth hormone deficiency
p12154
sasa(dp12155
g2
VIn humans, duplication of SOX3 and polyalanine expansions at its C-terminus may cause intellectual disability and hypopituitarism.
p12156
sg4
(lp12157
(dp12158
g7
I26
sg8
I1
sg9
I4
sg10
VP41225
p12159
sg12
VSOX3
p12160
sasg24
(lp12161
(dp12162
g7
I11
sg8
I1
sg9
I11
sg27
VC1705960
p12163
sg12
Vduplication
p12164
sa(dp12165
g7
I114
sg8
I1
sg9
I15
sg27
VC0020635
p12166
sg12
Vhypopituitarism
p12167
sa(dp12168
g7
I86
sg8
I2
sg9
I23
sg27
VC0025362
p12169
sg12
Vintellectual disability
p12170
sasa(dp12171
g2
VThe UNH159 marker as well as RNA-binding motif protein, X-linked (rbmx), SRY-box containing gene 3 (sox3) and alpha-thalassemia/mental retardation syndrome X-linked (atrx) genes were mapped to linkage group 2.
p12172
sg4
(lp12173
(dp12174
g7
I100
sg8
I1
sg9
I4
sg10
VP41225
p12175
sg12
Vsox3
p12176
sa(dp12177
g7
I73
sg8
I4
sg9
I25
sg10
VP41225
p12178
sg12
VSRY-box containing gene 3
p12179
sasg24
(lp12180
(dp12181
g7
I110
sg8
I4
sg9
I54
sg27
VC1845055
p12182
sg12
Valpha-thalassemia/mental retardation syndrome X-linked
p12183
sa(dp12184
g7
I166
sg8
I1
sg9
I4
sg27
VC1845055
p12185
sg12
Vatrx
p12186
sasa(dp12187
g2
VBoth overdosage of SOX3, as a result of gene duplication, and loss of function resulting from expansion of the first polyalanine (PA) tract are associated with variable degrees of hypopituitarism, with or without mental retardation.
p12188
sg4
(lp12189
(dp12190
g7
I19
sg8
I1
sg9
I4
sg10
VP41225
p12191
sg12
VSOX3
p12192
sasg24
(lp12193
(dp12194
g7
I213
sg8
I2
sg9
I18
sg27
VC0025362
p12195
sg12
Vmental retardation
p12196
sa(dp12197
g7
I180
sg8
I1
sg9
I15
sg27
VC0020635
p12198
sg12
Vhypopituitarism
p12199
sa(dp12200
g7
I40
sg8
I2
sg9
I16
sg27
VC1705960
p12201
sg12
Vgene duplication
p12202
sasa(dp12203
g2
VDuplications and polyalanine expansions within the transcription factor SOX3 have recently been described in association with infundibular hypoplasia, hypopituitarism and variable mental retardation, whilst mutations in SOX2 are associated with variable hypopituitarism in association with learning difficulties, oesophageal atresia and anophthalmia.
p12204
sg4
(lp12205
(dp12206
g7
I220
sg8
I1
sg9
I4
sg10
VP48431
p12207
sg12
VSOX2
p12208
sa(dp12209
g7
I72
sg8
I1
sg9
I4
sg10
VP41225
p12210
sg12
VSOX3
p12211
sasg24
(lp12212
(dp12213
g7
I151
sg8
I1
sg9
I15
sg27
VC0020635
p12214
sg12
Vhypopituitarism
p12215
sa(dp12216
g7
I139
sg8
I1
sg9
I10
sg27
VC0243069
p12217
sg12
Vhypoplasia
p12218
sa(dp12219
g7
I337
sg8
I1
sg9
I12
sg27
VC0003119
p12220
sg12
Vanophthalmia
p12221
sa(dp12222
g7
I180
sg8
I2
sg9
I18
sg27
VC0025362
p12223
sg12
Vmental retardation
p12224
sa(dp12225
g7
I151
sg8
I1
sg9
I15
sg27
VC0020635
p12226
sg12
Vhypopituitarism
p12227
sa(dp12228
g7
I313
sg8
I2
sg9
I19
sg27
VC0014850
p12229
sg12
Voesophageal atresia
p12230
sasa(dp12231
g2
VUsing mouse P19 embryonal carcinoma cells, which divide rapidly, yet in retinoic acid adopt a neuronal phenotype, admixed with occasional (approximately 10%) fibroblast-like cells, together with a panel of peptide-specific antibodies raised to 7 of the 8 CCT subunits we show that; (1) adoption of a post mitotic phenotype is accompanied by reduced CCT protein expression, significantly more so for CCTbeta, CCTdelta, CCTepsilon, and CCTtheta than for CCTalpha (TCP-1), CCTgamma and CCTzeta; (2) CCTalpha is detected preferentially over other subunits in neurites of P19 neurons; (3) small amounts of CCTalpha and gamma are localised in nuclei (i.e.
p12232
sg4
(lp12233
(dp12234
g7
I462
sg8
I1
sg9
I5
sg10
VP00995
p12235
sg12
VTCP-1
p12236
sa(dp12237
g7
I349
sg8
I2
sg9
I11
sg10
g11
sg12
VCCT protein
p12238
sasg24
(lp12239
(dp12240
g7
I16
sg8
I2
sg9
I19
sg27
VC0206659
p12241
sg12
Vembryonal carcinoma
p12242
sa(dp12243
g7
I255
sg8
I1
sg9
I3
sg27
VC2752078
p12244
sg12
VCCT
p12245
sa(dp12246
g7
I462
sg8
I1
sg9
I3
sg27
VC1842402
p12247
sg12
VTCP
p12248
sa(dp12249
g7
I255
sg8
I1
sg9
I3
sg27
VC2752078
p12250
sg12
VCCT
p12251
sasa(dp12252
g2
VIn line with these observations, in preclinical models, SIRT2 deficiency increases survival of mice with chronic staphylococcal infection, while having no effect on the course of toxic shock syndrome toxin-1, LPS or TNF-induced shock, fulminant Escherichia coli peritonitis, sub-lethal Klebsiella pneumoniae pneumonia, and chronic candidiasis.
p12253
sg4
(lp12254
(dp12255
g7
I216
sg8
I1
sg9
I3
sg10
VP01375
p12256
sg12
VTNF
p12257
sa(dp12258
g7
I56
sg8
I1
sg9
I5
sg10
g11
sg12
VSIRT2
p12259
sasg24
(lp12260
(dp12261
g7
I179
sg8
I3
sg9
I20
sg27
VC0600327
p12262
sg12
Vtoxic shock syndrome
p12263
sa(dp12264
g7
I262
sg8
I1
sg9
I11
sg27
VC0031154
p12265
sg12
Vperitonitis
p12266
sa(dp12267
g7
I209
sg8
I1
sg9
I3
sg27
VC0175697
p12268
sg12
VLPS
p12269
sa(dp12270
g7
I286
sg8
I3
sg9
I31
sg27
VC0519030
p12271
sg12
VKlebsiella pneumoniae pneumonia
p12272
sa(dp12273
g7
I323
sg8
I2
sg9
I19
sg27
VC0857069
p12274
sg12
Vchronic candidiasis
p12275
sa(dp12276
g7
I113
sg8
I2
sg9
I24
sg27
VC0038160
p12277
sg12
Vstaphylococcal infection
p12278
sasa(dp12279
g2
VLung injury was studied by measuring: vascular permeability-related pulmonary edema; histopathologic scores, neutrophil infiltration and concentrations of inflammatory cytokines in bronchoalveolar fluid; expression of inflammatory enzymes and sirtuin (SIRT) 1 as well as nuclear factor-kappa B (NF-KB) activity in pulmonary tissues.
p12280
sg4
(lp12281
(dp12282
g7
I295
sg8
I1
sg9
I5
sg10
VP01160
p12283
sg12
VNF-KB
p12284
sa(dp12285
g7
I271
sg8
I3
sg9
I22
sg10
VP01160
p12286
sg12
Vnuclear factor-kappa B
p12287
sasg24
(lp12288
(dp12289
g7
I120
sg8
I1
sg9
I12
sg27
VC0332448
p12290
sg12
Vinfiltration
p12291
sa(dp12292
g7
I68
sg8
I2
sg9
I15
sg27
VC0034063
p12293
sg12
Vpulmonary edema
p12294
sasa(dp12295
g2
VThe aim of our study was to compare the expression of sirtuin in large and small airways in nonsmokers, asymptomatic smokers, and smokers with chronic obstructive pulmonary disease.
p12296
sg4
(lp12297
(dp12298
g7
I54
sg8
I1
sg9
I7
sg10
g11
sg12
Vsirtuin
p12299
sasg24
(lp12300
(dp12301
g7
I143
sg8
I4
sg9
I37
sg27
VC0024117
p12302
sg12
Vchronic obstructive pulmonary disease
p12303
sasa(dp12304
g2
VSmokers both with and without chronic obstructive pulmonary disease had decreased sirtuin expression in large airways.
p12305
sg4
(lp12306
(dp12307
g7
I82
sg8
I1
sg9
I7
sg10
g11
sg12
Vsirtuin
p12308
sasg24
(lp12309
(dp12310
g7
I30
sg8
I4
sg9
I37
sg27
VC0024117
p12311
sg12
Vchronic obstructive pulmonary disease
p12312
sasa(dp12313
g2
VHowever, in small airways, sirtuin expression was decreased only in patients with chronic obstructive pulmonary disease.
p12314
sg4
(lp12315
sg24
(lp12316
(dp12317
g7
I82
sg8
I4
sg9
I37
sg27
VC0024117
p12318
sg12
Vchronic obstructive pulmonary disease
p12319
sasa(dp12320
g2
VSmoking is characterized by suppressed sirtuin expression in large airways, whereas chronic obstructive pulmonary disease is characterized by more severe suppression of sirtuin expression both in large and small airways.
p12321
sg4
(lp12322
(dp12323
g7
I39
sg8
I1
sg9
I7
sg10
g11
sg12
Vsirtuin
p12324
sa(dp12325
g7
I39
sg8
I1
sg9
I7
sg10
g11
sg12
Vsirtuin
p12326
sasg24
(lp12327
(dp12328
g7
I154
sg8
I1
sg9
I11
sg27
VC0221103
p12329
sg12
Vsuppression
p12330
sa(dp12331
g7
I84
sg8
I4
sg9
I37
sg27
VC0024117
p12332
sg12
Vchronic obstructive pulmonary disease
p12333
sasa(dp12334
g2
VHuman equilibrative nucleoside transporters (hENT) 1 and 2, encoded by SLC29A1 and SLC29A2, permit the bidirectional passage of nucleoside analogues into cells and may correlate with clinical responses to chemotherapy in patients with colorectal cancer (CRC).
p12335
sg4
(lp12336
(dp12337
g7
I83
sg8
I1
sg9
I7
sg10
g11
sg12
VSLC29A2
p12338
sa(dp12339
g7
I71
sg8
I1
sg9
I7
sg10
g11
sg12
VSLC29A1
p12340
sa(dp12341
g7
I0
sg8
I4
sg9
I43
sg10
g11
sg12
VHuman equilibrative nucleoside transporters
p12342
sa(dp12343
g7
I45
sg8
I1
sg9
I4
sg10
g11
sg12
VhENT
p12344
sasg24
(lp12345
(dp12346
g7
I254
sg8
I1
sg9
I3
sg27
VC1527249
p12347
sg12
VCRC
p12348
sa(dp12349
g7
I235
sg8
I2
sg9
I17
sg27
VC1527249
p12350
sg12
Vcolorectal cancer
p12351
sasa(dp12352
g2
VThe purpose of this study was to evaluate the expression profiles of SLC29A1 and SLC29A2 in human cancer cell lines.
p12353
sg4
(lp12354
(dp12355
g7
I81
sg8
I1
sg9
I7
sg10
g11
sg12
VSLC29A2
p12356
sa(dp12357
g7
I69
sg8
I1
sg9
I7
sg10
g11
sg12
VSLC29A1
p12358
sasg24
(lp12359
(dp12360
g7
I98
sg8
I1
sg9
I6
sg27
VC0006826
p12361
sg12
Vcancer
p12362
sasa(dp12363
g2
VUsing quantitative real-time polymerase chain reaction, we comprehensively profiled the transcription levels of SLC29A1 and SLC29A2 in 16 colon cancer cell lines.
p12364
sg4
(lp12365
(dp12366
g7
I124
sg8
I1
sg9
I7
sg10
g11
sg12
VSLC29A2
p12367
sa(dp12368
g7
I112
sg8
I1
sg9
I7
sg10
g11
sg12
VSLC29A1
p12369
sasg24
(lp12370
(dp12371
g7
I138
sg8
I2
sg9
I12
sg27
VC0699790
p12372
sg12
Vcolon cancer
p12373
sasa(dp12374
g2
VWe validated the ubiquitous and heterogeneous distribution of SLC29A1 and SLC29A2 in human colon cancer cell lines and demonstrated that SLC29A1 was highly expressed in 25% of metastatic cell lines (Colo201 and Colo205) and 62.5% of primary cell lines (Caco2, Colo320, HCT116, RKO, and SW48).
p12375
sg4
(lp12376
(dp12377
g7
I62
sg8
I1
sg9
I7
sg10
g11
sg12
VSLC29A1
p12378
sa(dp12379
g7
I74
sg8
I1
sg9
I7
sg10
g11
sg12
VSLC29A2
p12380
sa(dp12381
g7
I62
sg8
I1
sg9
I7
sg10
g11
sg12
VSLC29A1
p12382
sasg24
(lp12383
(dp12384
g7
I91
sg8
I2
sg9
I12
sg27
VC0699790
p12385
sg12
Vcolon cancer
p12386
sasa(dp12387
g2
VFor the first time, we showed that both SLC29A1 and SLC29A2 were expressed at lower levels in colon cancer cell lines originating from metastatic sites than from primary sites.
p12388
sg4
(lp12389
(dp12390
g7
I40
sg8
I1
sg9
I7
sg10
g11
sg12
VSLC29A1
p12391
sa(dp12392
g7
I52
sg8
I1
sg9
I7
sg10
g11
sg12
VSLC29A2
p12393
sasg24
(lp12394
(dp12395
g7
I94
sg8
I2
sg9
I12
sg27
VC0699790
p12396
sg12
Vcolon cancer
p12397
sasa(dp12398
g2
VAs ENT inhibitors including dilazep have shown efficacy improving oHSV1 targeted oncolytic cancer therapy, a series of dilazep analogues was synthesized and biologically evaluated to examine both ENT1 and ENT2 inhibition.
p12399
sg4
(lp12400
(dp12401
g7
I196
sg8
I1
sg9
I4
sg10
g11
sg12
VENT1
p12402
sa(dp12403
g7
I205
sg8
I1
sg9
I4
sg10
g11
sg12
VENT2
p12404
sasg24
(lp12405
(dp12406
g7
I91
sg8
I1
sg9
I6
sg27
VC0006826
p12407
sg12
Vcancer
p12408
sasa(dp12409
g2
VThe most significant changes common to HLHS-RV versus control-RV and control-LV sample groups is observed for Anti mullerian hormone receptor 2 (AMHR2) (+18.79 control-RV, +3.38 control-LV), and the BMP antagonist Inhibin alpha (INHA) (+11.47 control-RV, +5.73 control-LV).
p12410
sg4
(lp12411
(dp12412
g7
I110
sg8
I5
sg9
I33
sg10
VP22736
p12413
sg12
VAnti mullerian hormone receptor 2
p12414
sa(dp12415
g7
I145
sg8
I1
sg9
I5
sg10
g11
sg12
VAMHR2
p12416
sa(dp12417
g7
I229
sg8
I1
sg9
I4
sg10
VP05111
p12418
sg12
VINHA
p12419
sa(dp12420
g7
I39
sg8
I1
sg9
I7
sg10
VP17302
p12421
sg12
VHLHS-RV
p12422
sa(dp12423
g7
I199
sg8
I4
sg9
I28
sg10
VP18075
p12424
sg12
VBMP antagonist Inhibin alpha
p12425
sasg24
(lp12426
(dp12427
g7
I39
sg8
I1
sg9
I4
sg27
VC0152101
p12428
sg12
VHLHS
p12429
sasa(dp12430
g2
VWe have described previously the Ets family member ERM/ETV5 specifically upregulated in endometrial endometrioid carcinoma (EEC) associated with myometrial infiltration.
p12431
sg4
(lp12432
(dp12433
g7
I55
sg8
I1
sg9
I4
sg10
VP41161
p12434
sg12
VETV5
p12435
sa(dp12436
g7
I51
sg8
I1
sg9
I3
sg10
VP41161
p12437
sg12
VERM
p12438
sa(dp12439
g7
I33
sg8
I3
sg9
I17
sg10
VP20908
p12440
sg12
VEts family member
p12441
sasg24
(lp12442
(dp12443
g7
I156
sg8
I1
sg9
I12
sg27
VC0332448
p12444
sg12
Vinfiltration
p12445
sa(dp12446
g7
I124
sg8
I1
sg9
I3
sg27
VC1851841
p12447
sg12
VEEC
p12448
sa(dp12449
g7
I100
sg8
I2
sg9
I22
sg27
VC0206687
p12450
sg12
Vendometrioid carcinoma
p12451
sasa(dp12452
g2
VWe have described recently the Ets family transcription factor, ERM/ETV5, specifically up-regulated in endometrioid endometrial carcinoma (EEC) and associated with myometrial infiltration.
p12453
sg4
(lp12454
(dp12455
g7
I68
sg8
I1
sg9
I4
sg10
VP41161
p12456
sg12
VETV5
p12457
sa(dp12458
g7
I64
sg8
I1
sg9
I3
sg10
VP41161
p12459
sg12
VERM
p12460
sa(dp12461
g7
I31
sg8
I4
sg9
I31
sg10
VP35398
p12462
sg12
VEts family transcription factor
p12463
sasg24
(lp12464
(dp12465
g7
I175
sg8
I1
sg9
I12
sg27
VC0332448
p12466
sg12
Vinfiltration
p12467
sa(dp12468
g7
I116
sg8
I2
sg9
I21
sg27
VC0476089
p12469
sg12
Vendometrial carcinoma
p12470
sa(dp12471
g7
I139
sg8
I1
sg9
I3
sg27
VC1851841
p12472
sg12
VEEC
p12473
sasa(dp12474
g2
VFinally, the specific localization of ERM/ETV5 and MMP-2 at the invasive front of myometrial infiltrating human endometrial carcinomas further reinforced the hypothesis of a role for ERM/ETV5 in the early steps of endometrial dissemination.
p12475
sg4
(lp12476
(dp12477
g7
I42
sg8
I1
sg9
I4
sg10
VP41161
p12478
sg12
VETV5
p12479
sa(dp12480
g7
I38
sg8
I1
sg9
I3
sg10
VP41161
p12481
sg12
VERM
p12482
sa(dp12483
g7
I38
sg8
I1
sg9
I3
sg10
VP41161
p12484
sg12
VERM
p12485
sa(dp12486
g7
I51
sg8
I1
sg9
I5
sg10
VP08253
p12487
sg12
VMMP-2
p12488
sa(dp12489
g7
I42
sg8
I1
sg9
I4
sg10
VP41161
p12490
sg12
VETV5
p12491
sasg24
(lp12492
(dp12493
g7
I93
sg8
I1
sg9
I12
sg27
VC0332448
p12494
sg12
Vinfiltrating
p12495
sa(dp12496
g7
I112
sg8
I2
sg9
I22
sg27
VC0476089
p12497
sg12
Vendometrial carcinomas
p12498
sasa(dp12499
g2
VMost importantly, the defects seen in Gfi1 deficient mice also point to roles of Gfi1 in diseases of the immune system that involve auto-immune responses and acute lymphoid leukemia and lymphoma.
p12500
sg4
(lp12501
(dp12502
g7
I38
sg8
I1
sg9
I4
sg10
g11
sg12
VGfi1
p12503
sa(dp12504
g7
I38
sg8
I1
sg9
I4
sg10
g11
sg12
VGfi1
p12505
sasg24
(lp12506
(dp12507
g7
I186
sg8
I1
sg9
I8
sg27
VC0024299
p12508
sg12
Vlymphoma
p12509
sa(dp12510
g7
I158
sg8
I3
sg9
I23
sg27
VC1961102
p12511
sg12
Vacute lymphoid leukemia
p12512
sasa(dp12513
g2
VThe results showed that the gfi-1 expression level in all leukemia patients was significantly higher than that in normal group (p &lt; 0.05); the gfi-1 mRNA expression in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) or acute lymphoid leukemia (ALL) patients was significantly higher than that in normal group (p &lt; 0.05); but the difference of gfi-1 mRNA expression between AL and CML or ALL and AML was not significant.
p12514
sg4
(lp12515
(dp12516
g7
I28
sg8
I1
sg9
I5
sg10
g11
sg12
Vgfi-1
p12517
sa(dp12518
g7
I146
sg8
I2
sg9
I10
sg10
g11
sg12
Vgfi-1 mRNA
p12519
sasg24
(lp12520
(dp12521
g7
I238
sg8
I3
sg9
I23
sg27
VC1961102
p12522
sg12
Vacute lymphoid leukemia
p12523
sa(dp12524
g7
I206
sg8
I3
sg9
I22
sg27
VC0023467
p12525
sg12
Vacute myeloid leukemia
p12526
sa(dp12527
g7
I171
sg8
I3
sg9
I24
sg27
VC0023473
p12528
sg12
Vchronic myeloid leukemia
p12529
sa(dp12530
g7
I263
sg8
I1
sg9
I3
sg27
VC1961102
p12531
sg12
VALL
p12532
sa(dp12533
g7
I230
sg8
I1
sg9
I3
sg27
VC0023467
p12534
sg12
VAML
p12535
sa(dp12536
g7
I197
sg8
I1
sg9
I3
sg27
VC0023473
p12537
sg12
VCML
p12538
sa(dp12539
g7
I197
sg8
I1
sg9
I3
sg27
VC0023473
p12540
sg12
VCML
p12541
sa(dp12542
g7
I58
sg8
I1
sg9
I8
sg27
VC0023418
p12543
sg12
Vleukemia
p12544
sa(dp12545
g7
I230
sg8
I1
sg9
I3
sg27
VC0023467
p12546
sg12
VAML
p12547
sa(dp12548
g7
I263
sg8
I1
sg9
I3
sg27
VC1961102
p12549
sg12
VALL
p12550
sasa(dp12551
g2
VThe MDM2 309GG genotype was linked to a higher risk of acute G3-4 dermatitis.
p12552
sg4
(lp12553
sg24
(lp12554
(dp12555
g7
I66
sg8
I1
sg9
I10
sg27
VC0011603
p12556
sg12
Vdermatitis
p12557
sasa(dp12558
g2
VIn an antibody microarray chip analysis, MDM2 expression was increased in atopic dermatitis patients.
p12559
sg4
(lp12560
sg24
(lp12561
(dp12562
g7
I74
sg8
I2
sg9
I17
sg27
VC0011615
p12563
sg12
Vatopic dermatitis
p12564
sasa(dp12565
g2
VAll doxorubicin (Dox)-resistant tumors expressed higher levels of cancer stem-like cell biomarkers, including CD44, Wnt and its receptor LRP5/6, relative to Dox-sensitive tumors.
p12566
sg4
(lp12567
(dp12568
g7
I137
sg8
I1
sg9
I6
sg10
g11
sg12
VLRP5/6
p12569
sasg24
(lp12570
(dp12571
g7
I66
sg8
I1
sg9
I6
sg27
VC0006826
p12572
sg12
Vcancer
p12573
sa(dp12574
g7
I32
sg8
I1
sg9
I6
sg27
VC0027651
p12575
sg12
Vtumors
p12576
sa(dp12577
g7
I32
sg8
I1
sg9
I6
sg27
VC0027651
p12578
sg12
Vtumors
p12579
sasa(dp12580
g2
VOur results showed that simultaneous binding to LRP5/6 and uPAR by the dual receptor targeted IONPs was required to inhibit breast cancer cell invasion.
p12581
sg4
(lp12582
(dp12583
g7
I48
sg8
I1
sg9
I6
sg10
g11
sg12
VLRP5/6
p12584
sasg24
(lp12585
(dp12586
g7
I138
sg8
I2
sg9
I13
sg27
VC2699153
p12587
sg12
Vcell invasion
p12588
sa(dp12589
g7
I124
sg8
I2
sg9
I13
sg27
VC0678222
p12590
sg12
Vbreast cancer
p12591
sasa(dp12592
g2
VSTAT5 LKO caused hyperglycemia, hyperinsulinemia, hyperleptinemia and elevated free fatty acid and cholesterol concentrations under HFD feeding but induced only hyperglycemia on normal diet.
p12593
sg4
(lp12594
(dp12595
g7
I0
sg8
I1
sg9
I5
sg10
VP42229
p12596
sg12
VSTAT5
p12597
sasg24
(lp12598
(dp12599
g7
I32
sg8
I1
sg9
I16
sg27
VC0020459
p12600
sg12
Vhyperinsulinemia
p12601
sa(dp12602
g7
I17
sg8
I1
sg9
I13
sg27
VC0020456
p12603
sg12
Vhyperglycemia
p12604
sa(dp12605
g7
I17
sg8
I1
sg9
I13
sg27
VC0020456
p12606
sg12
Vhyperglycemia
p12607
sasa(dp12608
g2
VPrx2 is a key cytoprotector against IO that is induced either by iron supplementation or due to chronic hemolysis as in Beta-thalassemia.
p12609
sg4
(lp12610
(dp12611
g7
I0
sg8
I1
sg9
I4
sg10
VP32119
p12612
sg12
VPrx2
p12613
sasg24
(lp12614
(dp12615
g7
I104
sg8
I1
sg9
I9
sg27
VC0019054
p12616
sg12
Vhemolysis
p12617
sa(dp12618
g7
I120
sg8
I1
sg9
I16
sg27
VC0005283
p12619
sg12
VBeta-thalassemia
p12620
sasa(dp12621
g2
VPeroxiredoxin-2 (Prx2), a typical 2-cysteine peroxiredoxin, is upregulated during Beta-thalassemic erythropoiesis, but its contribution to stress erythropoiesis, a common feature of thalassemia, is yet to be fully defined.
p12622
sg4
(lp12623
(dp12624
g7
I0
sg8
I1
sg9
I15
sg10
VP32119
p12625
sg12
VPeroxiredoxin-2
p12626
sa(dp12627
g7
I17
sg8
I1
sg9
I4
sg10
VP32119
p12628
sg12
VPrx2
p12629
sasg24
(lp12630
(dp12631
g7
I182
sg8
I1
sg9
I11
sg27
VC0039730
p12632
sg12
Vthalassemia
p12633
sasa(dp12634
g2
VIn the present study, we aimed to investigate plasma levels of peroxiredoxin 2 (Prx2) and thioredoxin 1 (Trx1), and the activity of thioredoxin reductase (TrxR), in thalassemia major (TM) patients living in the Antalya region, Turkey.
p12635
sg4
(lp12636
(dp12637
g7
I80
sg8
I1
sg9
I4
sg10
VP32119
p12638
sg12
VPrx2
p12639
sa(dp12640
g7
I90
sg8
I2
sg9
I13
sg10
VP10599
p12641
sg12
Vthioredoxin 1
p12642
sa(dp12643
g7
I132
sg8
I2
sg9
I21
sg10
VP10599
p12644
sg12
Vthioredoxin reductase
p12645
sa(dp12646
g7
I105
sg8
I1
sg9
I4
sg10
VP60606
p12647
sg12
VTrx1
p12648
sa(dp12649
g7
I63
sg8
I2
sg9
I15
sg10
VP32119
p12650
sg12
Vperoxiredoxin 2
p12651
sa(dp12652
g7
I155
sg8
I1
sg9
I4
sg10
VP30044
p12653
sg12
VTrxR
p12654
sasg24
(lp12655
(dp12656
g7
I184
sg8
I1
sg9
I2
sg27
VC0002875
p12657
sg12
VTM
p12658
sa(dp12659
g7
I165
sg8
I2
sg9
I17
sg27
VC0002875
p12660
sg12
Vthalassemia major
p12661
sasa(dp12662
g2
VProteomic analysis of microparticles released from thalassemia intermedia erythrocytes indicated that, besides hemichromes and clustered band 3, the microparticles contain a characteristic set of proteins that includes catalase, heat shock protein 70, peroxiredoxin 2 and carbonic anhydrase.
p12663
sg4
(lp12664
(dp12665
g7
I219
sg8
I1
sg9
I8
sg10
VP04040
p12666
sg12
Vcatalase
p12667
sa(dp12668
g7
I229
sg8
I4
sg9
I21
sg10
VP34932
p12669
sg12
Vheat shock protein 70
p12670
sa(dp12671
g7
I252
sg8
I2
sg9
I15
sg10
VP32119
p12672
sg12
Vperoxiredoxin 2
p12673
sa(dp12674
g7
I272
sg8
I2
sg9
I18
sg10
VP35218
p12675
sg12
Vcarbonic anhydrase
p12676
sasg24
(lp12677
(dp12678
g7
I51
sg8
I2
sg9
I22
sg27
VC0271979
p12679
sg12
Vthalassemia intermedia
p12680
sasa(dp12681
g2
VInterestingly, Prx II interacted with Hb in mouse RBCs, and their interaction, in particular, was severely impaired in RBCs of patients with thalassemia (THAL) and sickle cell anemia (SCA).
p12682
sg4
(lp12683
(dp12684
g7
I15
sg8
I2
sg9
I6
sg10
VP30041
p12685
sg12
VPrx II
p12686
sasg24
(lp12687
(dp12688
g7
I141
sg8
I1
sg9
I11
sg27
VC0039730
p12689
sg12
Vthalassemia
p12690
sa(dp12691
g7
I184
sg8
I1
sg9
I3
sg27
VC0002895
p12692
sg12
VSCA
p12693
sa(dp12694
g7
I164
sg8
I3
sg9
I18
sg27
VC0002895
p12695
sg12
Vsickle cell anemia
p12696
sa(dp12697
g7
I154
sg8
I1
sg9
I4
sg27
VC0039730
p12698
sg12
VTHAL
p12699
sa(dp12700
g7
I107
sg8
I1
sg9
I8
sg27
VC0684336
p12701
sg12
Vimpaired
p12702
sasa(dp12703
g2
VThe cover image, by Lihadh Al Gazali et al., is based on the Original Article A recessive syndrome of intellectual disability, moderate overgrowth, and renal dysplasia predisposing to Wilms tumor is caused by a mutation in FIBP gene, DOI:10.1002/ajmg.a.37741.
p12704
sg4
(lp12705
(dp12706
g7
I223
sg8
I2
sg9
I9
sg10
g11
sg12
VFIBP gene
p12707
sasg24
(lp12708
(dp12709
g7
I102
sg8
I2
sg9
I23
sg27
VC0025362
p12710
sg12
Vintellectual disability
p12711
sa(dp12712
g7
I152
sg8
I2
sg9
I15
sg27
VC0266313
p12713
sg12
Vrenal dysplasia
p12714
sa(dp12715
g7
I90
sg8
I1
sg9
I8
sg27
VC0039082
p12716
sg12
Vsyndrome
p12717
sa(dp12718
g7
I184
sg8
I2
sg9
I11
sg27
VC0027708
p12719
sg12
VWilms tumor
p12720
sasa(dp12721
g2
VDifferent observational clinical studies reported that circulating levels of ANGPTL2 increase significantly in various chronic inflammatory diseases and showed associations between ANGPTL2 levels and diagnosis and/or prognosis of cardiovascular diseases, diabetes, chronic kidney disease, and various types of cancers.
p12722
sg4
(lp12723
(dp12724
g7
I77
sg8
I1
sg9
I7
sg10
g11
sg12
VANGPTL2
p12725
sa(dp12726
g7
I77
sg8
I1
sg9
I7
sg10
g11
sg12
VANGPTL2
p12727
sasg24
(lp12728
(dp12729
g7
I255
sg8
I1
sg9
I8
sg27
VC0011849
p12730
sg12
Vdiabetes
p12731
sa(dp12732
g7
I310
sg8
I1
sg9
I7
sg27
VC0006826
p12733
sg12
Vcancers
p12734
sa(dp12735
g7
I230
sg8
I2
sg9
I23
sg27
VC0007222
p12736
sg12
Vcardiovascular diseases
p12737
sa(dp12738
g7
I265
sg8
I3
sg9
I22
sg27
VC1561643
p12739
sg12
Vchronic kidney disease
p12740
sasa(dp12741
g2
VCirculating ANGPTL2 is increased in chronic kidney disease (CKD), where the risk of CVD is amplified.
p12742
sg4
(lp12743
(dp12744
g7
I12
sg8
I1
sg9
I7
sg10
g11
sg12
VANGPTL2
p12745
sasg24
(lp12746
(dp12747
g7
I60
sg8
I1
sg9
I3
sg27
VC1561643
p12748
sg12
VCKD
p12749
sa(dp12750
g7
I36
sg8
I3
sg9
I22
sg27
VC1561643
p12751
sg12
Vchronic kidney disease
p12752
sa(dp12753
g7
I84
sg8
I1
sg9
I3
sg27
VC0007222
p12754
sg12
VCVD
p12755
sasa(dp12756
g2
VThe positive association between post-KTx ANGPTL2, aortic stiffness and mortality, suggests that ANGPTL2 may play a biological role in CKD-related CVD.
p12757
sg4
(lp12758
(dp12759
g7
I42
sg8
I1
sg9
I7
sg10
g11
sg12
VANGPTL2
p12760
sa(dp12761
g7
I42
sg8
I1
sg9
I7
sg10
g11
sg12
VANGPTL2
p12762
sasg24
(lp12763
(dp12764
g7
I147
sg8
I1
sg9
I3
sg27
VC0007222
p12765
sg12
VCVD
p12766
sa(dp12767
g7
I51
sg8
I2
sg9
I16
sg27
VC3178782
p12768
sg12
Vaortic stiffness
p12769
sasa(dp12770
g2
VHistological analysis of human kidneys indicated abundant expression of angiopoietin-like protein 2 (ANGPTL2) in renal tubule epithelial cells during progression of renal fibrosis.
p12771
sg4
(lp12772
(dp12773
g7
I72
sg8
I3
sg9
I27
sg10
g11
sg12
Vangiopoietin-like protein 2
p12774
sa(dp12775
g7
I101
sg8
I1
sg9
I7
sg10
g11
sg12
VANGPTL2
p12776
sasg24
(lp12777
(dp12778
g7
I165
sg8
I2
sg9
I14
sg27
VC0151650
p12779
sg12
Vrenal fibrosis
p12780
sasa(dp12781
g2
VFurthermore, ANGPTL2 deficiency in a mouse unilateral ureteral obstruction model significantly reduced renal fibrosis by decreasing TGF-Beta1 signal amplification in kidney.
p12782
sg4
(lp12783
(dp12784
g7
I132
sg8
I1
sg9
I9
sg10
VP01137
p12785
sg12
VTGF-Beta1
p12786
sa(dp12787
g7
I13
sg8
I1
sg9
I7
sg10
g11
sg12
VANGPTL2
p12788
sasg24
(lp12789
(dp12790
g7
I103
sg8
I2
sg9
I14
sg27
VC0151650
p12791
sg12
Vrenal fibrosis
p12792
sa(dp12793
g7
I54
sg8
I2
sg9
I20
sg27
VC0041956
p12794
sg12
Vureteral obstruction
p12795
sa(dp12796
g7
I149
sg8
I1
sg9
I13
sg27
VC1705759
p12797
sg12
Vamplification
p12798
sasa(dp12799
g2
VThus, ANGPTL2 and TGF-Beta1 positively regulate each other as renal fibrosis progresses.
p12800
sg4
(lp12801
(dp12802
g7
I6
sg8
I1
sg9
I7
sg10
g11
sg12
VANGPTL2
p12803
sa(dp12804
g7
I18
sg8
I1
sg9
I9
sg10
VP01137
p12805
sg12
VTGF-Beta1
p12806
sasg24
(lp12807
(dp12808
g7
I62
sg8
I2
sg9
I14
sg27
VC0151650
p12809
sg12
Vrenal fibrosis
p12810
sasa(dp12811
g2
Vdemonstrated that genetic depletion of Angptl2 confers amelioration of the mouse kidney fibrosis induced by a unilateral ureteral obstruction, implicating that ANGPTL2, predominantly in the renal tubular compartments, activates the transforming growth factor-Beta signaling and vice versa through miR-221.
p12812
sg4
(lp12813
(dp12814
g7
I160
sg8
I1
sg9
I7
sg10
g11
sg12
VANGPTL2
p12815
sa(dp12816
g7
I39
sg8
I1
sg9
I7
sg10
g11
sg12
VAngptl2
p12817
sa(dp12818
g7
I232
sg8
I3
sg9
I31
sg10
VP18075
p12819
sg12
Vtransforming growth factor-Beta
p12820
sasg24
(lp12821
(dp12822
g7
I81
sg8
I2
sg9
I15
sg27
VC0151650
p12823
sg12
Vkidney fibrosis
p12824
sa(dp12825
g7
I121
sg8
I2
sg9
I20
sg27
VC0041956
p12826
sg12
Vureteral obstruction
p12827
sasa(dp12828
g2
VIn the present study, we tested whether there is a correlation between increased ANGPTL2 expression and inflammation in response to Staphylococcus aureus in murine mastitis and the mechanisms involved.
p12829
sg4
(lp12830
(dp12831
g7
I81
sg8
I1
sg9
I7
sg10
g11
sg12
VANGPTL2
p12832
sasg24
(lp12833
(dp12834
g7
I104
sg8
I1
sg9
I12
sg27
VC0021368
p12835
sg12
Vinflammation
p12836
sa(dp12837
g7
I164
sg8
I1
sg9
I8
sg27
VC3251795
p12838
sg12
Vmastitis
p12839
sasa(dp12840
g2
VThe present findings indicate ANGPTL2 may mediate the inflammation in murine mastitis through the activation of IL-6 and TNF-Alfa.
p12841
sg4
(lp12842
(dp12843
g7
I112
sg8
I1
sg9
I4
sg10
VP05231
p12844
sg12
VIL-6
p12845
sa(dp12846
g7
I121
sg8
I1
sg9
I8
sg10
VP01375
p12847
sg12
VTNF-Alfa
p12848
sa(dp12849
g7
I30
sg8
I1
sg9
I7
sg10
g11
sg12
VANGPTL2
p12850
sasg24
(lp12851
(dp12852
g7
I54
sg8
I1
sg9
I12
sg27
VC0021368
p12853
sg12
Vinflammation
p12854
sa(dp12855
g7
I77
sg8
I1
sg9
I8
sg27
VC3251795
p12856
sg12
Vmastitis
p12857
sasa(dp12858
g2
VThe aim of this study was to investigate the relationship between serum Angptl2 level and chronic kidney disease (CKD).
p12859
sg4
(lp12860
(dp12861
g7
I72
sg8
I1
sg9
I7
sg10
g11
sg12
VAngptl2
p12862
sasg24
(lp12863
(dp12864
g7
I90
sg8
I3
sg9
I22
sg27
VC1561643
p12865
sg12
Vchronic kidney disease
p12866
sa(dp12867
g7
I114
sg8
I1
sg9
I3
sg27
VC1561643
p12868
sg12
VCKD
p12869
sasa(dp12870
g2
VThe age- and sex-adjusted ORs for the presence of CKD increased with higher serum Angptl2 level.
p12871
sg4
(lp12872
(dp12873
g7
I82
sg8
I1
sg9
I7
sg10
g11
sg12
VAngptl2
p12874
sasg24
(lp12875
sa(dp12876
g2
VElevated serum Angptl2 is associated with the likelihood of CKD in the general population.
p12877
sg4
(lp12878
(dp12879
g7
I9
sg8
I2
sg9
I13
sg10
g11
sg12
Vserum Angptl2
p12880
sasg24
(lp12881
sa(dp12882
g2
VWe investigated whether serum Angptl2 levels are associated with diabetic nephropathy in patients with type 2 diabetes.
p12883
sg4
(lp12884
(dp12885
g7
I30
sg8
I1
sg9
I7
sg10
g11
sg12
VAngptl2
p12886
sasg24
(lp12887
(dp12888
g7
I103
sg8
I3
sg9
I15
sg27
VC0011860
p12889
sg12
Vtype 2 diabetes
p12890
sa(dp12891
g7
I65
sg8
I2
sg9
I20
sg27
VC0011881
p12892
sg12
Vdiabetic nephropathy
p12893
sasa(dp12894
g2
VThis suggests a possible role of Angptl2 in progressive nephropathy in patients with type 2 diabetes.
p12895
sg4
(lp12896
(dp12897
g7
I33
sg8
I1
sg9
I7
sg10
g11
sg12
VAngptl2
p12898
sasg24
(lp12899
(dp12900
g7
I85
sg8
I3
sg9
I15
sg27
VC0011860
p12901
sg12
Vtype 2 diabetes
p12902
sa(dp12903
g7
I56
sg8
I1
sg9
I11
sg27
VC0022658
p12904
sg12
Vnephropathy
p12905
sasa(dp12906
g2
VImprovements to restriction fragment length polymorphism (RFLP)-based genotyping assays currently used for detection of mutations responsible for bovine ferrochelatase and myophosphorylase deficiencies, and equine hyperkalemic periodic paralysis (HYPP) are described.
p12907
sg4
(lp12908
(dp12909
g7
I146
sg8
I2
sg9
I21
sg10
VP22830
p12910
sg12
Vbovine ferrochelatase
p12911
sa(dp12912
g7
I172
sg8
I1
sg9
I16
sg10
VP11217
p12913
sg12
Vmyophosphorylase
p12914
sasg24
(lp12915
(dp12916
g7
I247
sg8
I1
sg9
I4
sg27
VC0238357
p12917
sg12
VHYPP
p12918
sa(dp12919
g7
I214
sg8
I3
sg9
I31
sg27
VC0238357
p12920
sg12
Vhyperkalemic periodic paralysis
p12921
sasa(dp12922
g2
VThus, peripheral changes of TOAG-1 and RHAMM expression can be used to predict clinical response to Alefacept treatment in psoriasis patients.
p12923
sg4
(lp12924
(dp12925
g7
I39
sg8
I1
sg9
I5
sg10
g11
sg12
VRHAMM
p12926
sasg24
(lp12927
(dp12928
g7
I123
sg8
I1
sg9
I9
sg27
VC0033860
p12929
sg12
Vpsoriasis
p12930
sasa(dp12931
g2
VIn this study, we examined the pharmacological profile of KCL-440, a new PARP inhibitor, and its neuroprotective effects in the rat acute cerebral infarction model induced by photothrombotic middle cerebral artery (MCA) occlusion.
p12932
sg4
(lp12933
(dp12934
g7
I73
sg8
I1
sg9
I4
sg10
VP09874
p12935
sg12
VPARP
p12936
sasg24
(lp12937
(dp12938
g7
I220
sg8
I1
sg9
I9
sg27
VC0028778
p12939
sg12
Vocclusion
p12940
sa(dp12941
g7
I138
sg8
I2
sg9
I19
sg27
VC0038454
p12942
sg12
Vcerebral infarction
p12943
sasa(dp12944
g2
VOur data thus suggest that the tested PARP polymorphisms do not principally contribute to cerebral infarction, although extensive searches would be required to clarify whether the PARP gene plays an important role in the pathogenesis of human stroke.
p12945
sg4
(lp12946
(dp12947
g7
I180
sg8
I2
sg9
I9
sg10
VP09874
p12948
sg12
VPARP gene
p12949
sa(dp12950
g7
I38
sg8
I1
sg9
I4
sg10
VP09874
p12951
sg12
VPARP
p12952
sasg24
(lp12953
(dp12954
g7
I221
sg8
I1
sg9
I12
sg27
VC0699748
p12955
sg12
Vpathogenesis
p12956
sa(dp12957
g7
I90
sg8
I2
sg9
I19
sg27
VC0038454
p12958
sg12
Vcerebral infarction
p12959
sa(dp12960
g7
I243
sg8
I1
sg9
I6
sg27
VC0038454
p12961
sg12
Vstroke
p12962
sasa(dp12963
g2
VThe OR of breast cancer for the percentage BPE measure (BPE%) quantified from SUB1 was 3.5 (95% Confidence Interval: 1.3, 9.8; p = 0.015) for 20% increments.
p12964
sg4
(lp12965
(dp12966
g7
I78
sg8
I1
sg9
I4
sg10
VP53999
p12967
sg12
VSUB1
p12968
sasg24
(lp12969
(dp12970
g7
I10
sg8
I2
sg9
I13
sg27
VC0678222
p12971
sg12
Vbreast cancer
p12972
sasa(dp12973
g2
VIn this study, we show elevated expression of SUB1 in aggressive prostate cancer.
p12974
sg4
(lp12975
(dp12976
g7
I46
sg8
I1
sg9
I4
sg10
VP53999
p12977
sg12
VSUB1
p12978
sasg24
(lp12979
(dp12980
g7
I54
sg8
I1
sg9
I10
sg27
VC0001807
p12981
sg12
Vaggressive
p12982
sa(dp12983
g7
I65
sg8
I2
sg9
I15
sg27
VC0600139
p12984
sg12
Vprostate cancer
p12985
sasa(dp12986
g2
VKnockdown of SUB1 in prostate cancer cells resulted in reduced cell proliferation, invasion and migration in vitro, and tumor growth and metastasis in vivo.
p12987
sg4
(lp12988
(dp12989
g7
I13
sg8
I1
sg9
I4
sg10
VP53999
p12990
sg12
VSUB1
p12991
sasg24
(lp12992
(dp12993
g7
I120
sg8
I2
sg9
I12
sg27
VC0598934
p12994
sg12
Vtumor growth
p12995
sa(dp12996
g7
I137
sg8
I1
sg9
I10
sg27
VC0027627
p12997
sg12
Vmetastasis
p12998
sa(dp12999
g7
I68
sg8
I1
sg9
I13
sg27
VC0334094
p13000
sg12
Vproliferation
p13001
sa(dp13002
g7
I21
sg8
I2
sg9
I15
sg27
VC0600139
p13003
sg12
Vprostate cancer
p13004
sa(dp13005
g7
I83
sg8
I1
sg9
I8
sg27
VC2699153
p13006
sg12
Vinvasion
p13007
sasa(dp13008
g2
VPLK1 knockdown or use of PLK1 inhibitor can mitigate oncogenic function of SUB1 in benign prostate cancer cells.
p13009
sg4
(lp13010
(dp13011
g7
I75
sg8
I1
sg9
I4
sg10
VP53999
p13012
sg12
VSUB1
p13013
sa(dp13014
g7
I0
sg8
I1
sg9
I4
sg10
VP53350
p13015
sg12
VPLK1
p13016
sa(dp13017
g7
I0
sg8
I1
sg9
I4
sg10
VP53350
p13018
sg12
VPLK1
p13019
sasg24
(lp13020
(dp13021
g7
I90
sg8
I2
sg9
I15
sg27
VC0600139
p13022
sg12
Vprostate cancer
p13023
sasa(dp13024
g2
VThus, our study suggests that miR-101 loss results in increased SUB1 expression and subsequent activation of known oncogenes driving prostate cancer progression and metastasis.
p13025
sg4
(lp13026
(dp13027
g7
I64
sg8
I1
sg9
I4
sg10
VP53999
p13028
sg12
VSUB1
p13029
sa(dp13030
g7
I30
sg8
I2
sg9
I12
sg10
g11
sg12
VmiR-101 loss
p13031
sasg24
(lp13032
(dp13033
g7
I142
sg8
I2
sg9
I18
sg27
VC0178874
p13034
sg12
Vcancer progression
p13035
sa(dp13036
g7
I165
sg8
I1
sg9
I10
sg27
VC0027627
p13037
sg12
Vmetastasis
p13038
sasa(dp13039
g2
VThis study therefore demonstrates functional role of SUB1 in prostate cancer, and identifies its regulation and potential downstream therapeutic targets of SUB1 in prostate cancer.
p13040
sg4
(lp13041
(dp13042
g7
I53
sg8
I1
sg9
I4
sg10
VP53999
p13043
sg12
VSUB1
p13044
sa(dp13045
g7
I53
sg8
I1
sg9
I4
sg10
VP53999
p13046
sg12
VSUB1
p13047
sasg24
(lp13048
(dp13049
g7
I61
sg8
I2
sg9
I15
sg27
VC0600139
p13050
sg12
Vprostate cancer
p13051
sa(dp13052
g7
I61
sg8
I2
sg9
I15
sg27
VC0600139
p13053
sg12
Vprostate cancer
p13054
sasa(dp13055
g2
VThe proposed study aims to explore whether PC4 correlates with VEGF-C/VEGF-D/VEGFR-3 axis of lymphangiogenesis in the lymph node metastasis during lung adenocarcinoma.
p13056
sg4
(lp13057
(dp13058
g7
I63
sg8
I1
sg9
I6
sg10
VP49767
p13059
sg12
VVEGF-C
p13060
sa(dp13061
g7
I77
sg8
I1
sg9
I5
sg10
VP35968
p13062
sg12
VVEGFR
p13063
sasg24
(lp13064
(dp13065
g7
I147
sg8
I2
sg9
I19
sg27
VC0152013
p13066
sg12
Vlung adenocarcinoma
p13067
sa(dp13068
g7
I118
sg8
I3
sg9
I21
sg27
VC0686619
p13069
sg12
Vlymph node metastasis
p13070
sasa(dp13071
g2
VHere, small interfering RNA technique was employed to investigate the relationship of PC4 and the VEGF-C/VEGF-D/VEGFR-3 axis in lung adenocarcinoma cell lines as well as tumor xenografts of mice model.
p13072
sg4
(lp13073
(dp13074
g7
I98
sg8
I1
sg9
I6
sg10
VP49767
p13075
sg12
VVEGF-C
p13076
sa(dp13077
g7
I86
sg8
I1
sg9
I3
sg10
VP53999
p13078
sg12
VPC4
p13079
sa(dp13080
g7
I112
sg8
I1
sg9
I7
sg10
VP35916
p13081
sg12
VVEGFR-3
p13082
sasg24
(lp13083
(dp13084
g7
I128
sg8
I2
sg9
I19
sg27
VC0152013
p13085
sg12
Vlung adenocarcinoma
p13086
sa(dp13087
g7
I170
sg8
I1
sg9
I5
sg27
VC0027651
p13088
sg12
Vtumor
p13089
sasa(dp13090
g2
VPC4 expression correlated with the levels of VEGF-C, VEGF-D and VEGFR-3 during the development of lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma in vitro and in vivo, which may be a novel marker in the development of lymphangiogenesis and lymphatic metastasis of tumors.
p13091
sg4
(lp13092
(dp13093
g7
I45
sg8
I1
sg9
I6
sg10
VP49767
p13094
sg12
VVEGF-C
p13095
sa(dp13096
g7
I53
sg8
I1
sg9
I6
sg10
g11
sg12
VVEGF-D
p13097
sa(dp13098
g7
I0
sg8
I1
sg9
I3
sg10
VP53999
p13099
sg12
VPC4
p13100
sa(dp13101
g7
I64
sg8
I1
sg9
I7
sg10
VP35916
p13102
sg12
VVEGFR-3
p13103
sasg24
(lp13104
(dp13105
g7
I144
sg8
I2
sg9
I19
sg27
VC0152013
p13106
sg12
Vlung adenocarcinoma
p13107
sa(dp13108
g7
I282
sg8
I1
sg9
I6
sg27
VC0027651
p13109
sg12
Vtumors
p13110
sa(dp13111
g7
I120
sg8
I2
sg9
I20
sg27
VC0024232
p13112
sg12
Vlymphatic metastasis
p13113
sa(dp13114
g7
I120
sg8
I2
sg9
I20
sg27
VC0024232
p13115
sg12
Vlymphatic metastasis
p13116
sasa(dp13117
g2
VTo test the hypothesis that elevated urinary levels of soluble E-cadherin (sE-cadherin) would aid in the detection of transitional cell carcinoma (TCC) of the urinary bladder.
p13118
sg4
(lp13119
(dp13120
g7
I75
sg8
I1
sg9
I11
sg10
g11
sg12
VsE-cadherin
p13121
sa(dp13122
g7
I55
sg8
I2
sg9
I18
sg10
g11
sg12
Vsoluble E-cadherin
p13123
sasg24
(lp13124
(dp13125
g7
I118
sg8
I3
sg9
I27
sg27
VC0007138
p13126
sg12
Vtransitional cell carcinoma
p13127
sa(dp13128
g7
I147
sg8
I1
sg9
I3
sg27
VC1861305
p13129
sg12
VTCC
p13130
sasa(dp13131
g2
VWe propose potential pathogenic pathways for transitional cell carcinoma of the bladder in diabetic patients based on altered integrin and cadherin distribution in urothelial cells in diabetic patients.
p13132
sg4
(lp13133
(dp13134
g7
I139
sg8
I1
sg9
I8
sg10
g11
sg12
Vcadherin
p13135
sasg24
(lp13136
(dp13137
g7
I45
sg8
I6
sg9
I42
sg27
VC0279680
p13138
sg12
Vtransitional cell carcinoma of the bladder
p13139
sasa(dp13140
g2
VTo evaluate soluble E-cadherin (sE-cadherin) as a potential tumour marker in patients with transitional cell carcinoma (TCC) of the bladder (previously shown to correlate with tumour grade, number of Ta/T1 tumours at presentation and a positive 3-month check cystoscopy) by assessing its serum concentration in relation to transurethral resection of bladder tumour (TURBT).
p13141
sg4
(lp13142
(dp13143
g7
I12
sg8
I2
sg9
I18
sg10
VP35558
p13144
sg12
Vsoluble E-cadherin
p13145
sa(dp13146
g7
I32
sg8
I1
sg9
I11
sg10
g11
sg12
VsE-cadherin
p13147
sasg24
(lp13148
(dp13149
g7
I60
sg8
I1
sg9
I6
sg27
VC0027651
p13150
sg12
Vtumour
p13151
sa(dp13152
g7
I120
sg8
I1
sg9
I3
sg27
VC1861305
p13153
sg12
VTCC
p13154
sa(dp13155
g7
I60
sg8
I1
sg9
I6
sg27
VC0027651
p13156
sg12
Vtumour
p13157
sa(dp13158
g7
I91
sg8
I3
sg9
I27
sg27
VC0007138
p13159
sg12
Vtransitional cell carcinoma
p13160
sa(dp13161
g7
I60
sg8
I1
sg9
I6
sg27
VC0027651
p13162
sg12
Vtumour
p13163
sa(dp13164
g7
I206
sg8
I1
sg9
I7
sg27
VC0027651
p13165
sg12
Vtumours
p13166
sasa(dp13167
g2
VElevated mRNA expression of liver IL-6, IL-17A, IL-17F, TGF-Beta1, Alfa-SMA, TGR5, NTCP, OATP1a1, and ileum ASBT and decreased liver IL-10, FXR, CAR, VDR, BSEP, MRP2, MRP3, MRP4 was also observed in ANIT-induced cholestasis but were attenuated or normalized by YCHT.
p13168
sg4
(lp13169
(dp13170
g7
I34
sg8
I1
sg9
I4
sg10
VP05231
p13171
sg12
VIL-6
p13172
sa(dp13173
g7
I67
sg8
I1
sg9
I8
sg10
g11
sg12
VAlfa-SMA
p13174
sa(dp13175
g7
I83
sg8
I1
sg9
I4
sg10
g11
sg12
VNTCP
p13176
sa(dp13177
g7
I140
sg8
I1
sg9
I3
sg10
VP23945
p13178
sg12
VFXR
p13179
sa(dp13180
g7
I155
sg8
I1
sg9
I4
sg10
g11
sg12
VBSEP
p13181
sa(dp13182
g7
I150
sg8
I1
sg9
I3
sg10
VP11473
p13183
sg12
VVDR
p13184
sa(dp13185
g7
I173
sg8
I1
sg9
I4
sg10
g11
sg12
VMRP4
p13186
sa(dp13187
g7
I56
sg8
I1
sg9
I9
sg10
VP01137
p13188
sg12
VTGF-Beta1
p13189
sa(dp13190
g7
I77
sg8
I1
sg9
I4
sg10
g11
sg12
VTGR5
p13191
sa(dp13192
g7
I161
sg8
I1
sg9
I4
sg10
g11
sg12
VMRP2
p13193
sasg24
(lp13194
(dp13195
g7
I145
sg8
I1
sg9
I3
sg27
VC2607929
p13196
sg12
VCAR
p13197
sa(dp13198
g7
I212
sg8
I1
sg9
I11
sg27
VC0008370
p13199
sg12
Vcholestasis
p13200
sa(dp13201
g7
I72
sg8
I1
sg9
I3
sg27
VC0026847
p13202
sg12
VSMA
p13203
sasa(dp13204
g2
VThe objective of the present study is to evaluate whether IL-6, TNF-Alfa, IL-10 are associated with nutritional status in patients with cirrhosis secondary to biliary atresia and compare to healthy controls.
p13205
sg4
(lp13206
(dp13207
g7
I58
sg8
I1
sg9
I4
sg10
VP05231
p13208
sg12
VIL-6
p13209
sa(dp13210
g7
I64
sg8
I1
sg9
I8
sg10
VP01375
p13211
sg12
VTNF-Alfa
p13212
sasg24
(lp13213
(dp13214
g7
I136
sg8
I1
sg9
I9
sg27
VC0023890
p13215
sg12
Vcirrhosis
p13216
sa(dp13217
g7
I159
sg8
I2
sg9
I15
sg27
VC0005411
p13218
sg12
Vbiliary atresia
p13219
sasa(dp13220
g2
VThe authors suggest that, in patients with cirrhosis secondary to biliary atresia, IL-6 could be used as a possible supporting biomarker of deficient nutritional status and elevated IL-10 levels could be used as a possible early-stage supporting biomarker of deteriorating nutritional status.
p13221
sg4
(lp13222
(dp13223
g7
I83
sg8
I1
sg9
I4
sg10
VP05231
p13224
sg12
VIL-6
p13225
sasg24
(lp13226
(dp13227
g7
I66
sg8
I2
sg9
I15
sg27
VC0005411
p13228
sg12
Vbiliary atresia
p13229
sa(dp13230
g7
I43
sg8
I1
sg9
I9
sg27
VC0023890
p13231
sg12
Vcirrhosis
p13232
sasa(dp13233
g2
VIn a prospective study, 47 patients with obstructive jaundice secondary to malignant lesions were evaluated before, at the fifth hour after, and on the fifth day after PTBD for neopterin, nitrate, tumor necrosis factor (TNF)-Alfa, interleukin (IL)-6, IL-10, CRP levels, and liver function.
p13234
sg4
(lp13235
(dp13236
g7
I197
sg8
I4
sg9
I32
sg10
VP01375
p13237
sg12
Vtumor necrosis factor (TNF)-Alfa
p13238
sa(dp13239
g7
I231
sg8
I2
sg9
I18
sg10
VP60568
p13240
sg12
Vinterleukin (IL)-6
p13241
sa(dp13242
g7
I258
sg8
I1
sg9
I3
sg10
VP02741
p13243
sg12
VCRP
p13244
sasg24
(lp13245
(dp13246
g7
I41
sg8
I2
sg9
I20
sg27
VC0022354
p13247
sg12
Vobstructive jaundice
p13248
sa(dp13249
g7
I197
sg8
I2
sg9
I14
sg27
VC0333516
p13250
sg12
Vtumor necrosis
p13251
sasa(dp13252
g2
VIt has been reported that the hypermethylation of APAF-1, DAPK-1 and other tumor suppressive genes (TSGs) correlates with progression of renal cell carcinoma and exerts prognostic and diagnostic relevance in renal cell carcinoma.
p13253
sg4
(lp13254
(dp13255
g7
I58
sg8
I1
sg9
I6
sg10
VP53355
p13256
sg12
VDAPK-1
p13257
sasg24
(lp13258
(dp13259
g7
I137
sg8
I3
sg9
I20
sg27
VC0007134
p13260
sg12
Vrenal cell carcinoma
p13261
sa(dp13262
g7
I137
sg8
I3
sg9
I20
sg27
VC0007134
p13263
sg12
Vrenal cell carcinoma
p13264
sa(dp13265
g7
I75
sg8
I1
sg9
I5
sg27
VC0027651
p13266
sg12
Vtumor
p13267
sasa(dp13268
g2
VThe present study confirmed that DAC demethylated the CpGs, particularly APAF-1 in renal carcinoma cells, and that the demethylation synergized the cytotoxity of CDDP in renal carcinoma cells via enhancing the CDDP-induced apoptosis.
p13269
sg4
(lp13270
(dp13271
g7
I33
sg8
I1
sg9
I3
sg10
VP57775
p13272
sg12
VDAC
p13273
sasg24
(lp13274
(dp13275
g7
I83
sg8
I2
sg9
I15
sg27
VC0007134
p13276
sg12
Vrenal carcinoma
p13277
sa(dp13278
g7
I83
sg8
I2
sg9
I15
sg27
VC0007134
p13279
sg12
Vrenal carcinoma
p13280
sasa(dp13281
g2
VThe aim of this study was to investigate the occurrence and relevance of promoter methylation of the tumor suppressor DAPK-1, APAF-1 () and SPARC in relation to different pathological stages and histological grades of tumor progression that might act as possible independent prognostic factor in the susceptibility towards renal cell carcinoma (RCC) in North Indian population.
p13282
sg4
(lp13283
(dp13284
g7
I118
sg8
I1
sg9
I6
sg10
VP53355
p13285
sg12
VDAPK-1
p13286
sa(dp13287
g7
I140
sg8
I1
sg9
I5
sg10
VP09486
p13288
sg12
VSPARC
p13289
sasg24
(lp13290
(dp13291
g7
I101
sg8
I1
sg9
I5
sg27
VC0027651
p13292
sg12
Vtumor
p13293
sa(dp13294
g7
I323
sg8
I3
sg9
I20
sg27
VC0007134
p13295
sg12
Vrenal cell carcinoma
p13296
sa(dp13297
g7
I218
sg8
I2
sg9
I17
sg27
VC0178874
p13298
sg12
Vtumor progression
p13299
sa(dp13300
g7
I345
sg8
I1
sg9
I3
sg27
VC0007134
p13301
sg12
VRCC
p13302
sasa(dp13303
g2
VTo examine the significance of the methylation level of the p53 target and tumour suppressor genes apoptotic protease activating factor-1 (APAF-1) and death-associated protein kinase-1 (DAPK-1) in 80 microdissected tumour samples from transitional cell carcinoma (TCC) of the bladder and 80 tumour samples from clear-cell renal cell carcinoma (RCC) as well as from non-tumourous bladder and kidney tissue.
p13304
sg4
(lp13305
(dp13306
g7
I186
sg8
I1
sg9
I6
sg10
VP53355
p13307
sg12
VDAPK-1
p13308
sa(dp13309
g7
I60
sg8
I10
sg9
I77
sg10
g11
sg12
Vp53 target and tumour suppressor genes apoptotic protease activating factor-1
p13310
sa(dp13311
g7
I151
sg8
I3
sg9
I33
sg10
VP53355
p13312
sg12
Vdeath-associated protein kinase-1
p13313
sasg24
(lp13314
(dp13315
g7
I75
sg8
I1
sg9
I6
sg27
VC0027651
p13316
sg12
Vtumour
p13317
sa(dp13318
g7
I75
sg8
I1
sg9
I6
sg27
VC0027651
p13319
sg12
Vtumour
p13320
sa(dp13321
g7
I344
sg8
I1
sg9
I3
sg27
VC0007134
p13322
sg12
VRCC
p13323
sa(dp13324
g7
I264
sg8
I1
sg9
I3
sg27
VC1861305
p13325
sg12
VTCC
p13326
sa(dp13327
g7
I235
sg8
I3
sg9
I27
sg27
VC0007138
p13328
sg12
Vtransitional cell carcinoma
p13329
sa(dp13330
g7
I75
sg8
I1
sg9
I6
sg27
VC0027651
p13331
sg12
Vtumour
p13332
sa(dp13333
g7
I322
sg8
I3
sg9
I20
sg27
VC0007134
p13334
sg12
Vrenal cell carcinoma
p13335
sasa(dp13336
g2
VQuantification of mRNA expression of HNF1B, six of its potential target genes (PKHD1, PKD1, PKD2, IFT88, TMEM27 and UMOD) and three genes involved in the Mg(2+) renal homeostasis (ATP1A1, FXYD2 and CLDN16) in the urinary sediment of 11 individuals with mutation of HNF1B and in 9 controls (non-invasive assessment of the renal transcriptome).
p13337
sg4
(lp13338
(dp13339
g7
I105
sg8
I1
sg9
I6
sg10
g11
sg12
VTMEM27
p13340
sa(dp13341
g7
I188
sg8
I1
sg9
I5
sg10
VP54710
p13342
sg12
VFXYD2
p13343
sa(dp13344
g7
I37
sg8
I1
sg9
I5
sg10
VP35680
p13345
sg12
VHNF1B
p13346
sa(dp13347
g7
I92
sg8
I1
sg9
I4
sg10
g11
sg12
VPKD2
p13348
sa(dp13349
g7
I180
sg8
I1
sg9
I6
sg10
VP05023
p13350
sg12
VATP1A1
p13351
sa(dp13352
g7
I37
sg8
I1
sg9
I5
sg10
VP35680
p13353
sg12
VHNF1B
p13354
sa(dp13355
g7
I98
sg8
I1
sg9
I5
sg10
g11
sg12
VIFT88
p13356
sa(dp13357
g7
I116
sg8
I1
sg9
I4
sg10
VP07911
p13358
sg12
VUMOD
p13359
sa(dp13360
g7
I79
sg8
I1
sg9
I5
sg10
VP08F94
p13361
sg12
VPKHD1
p13362
sa(dp13363
g7
I198
sg8
I1
sg9
I6
sg10
g11
sg12
VCLDN16
p13364
sa(dp13365
g7
I86
sg8
I1
sg9
I4
sg10
VP98161
p13366
sg12
VPKD1
p13367
sasg24
(lp13368
(dp13369
g7
I79
sg8
I1
sg9
I5
sg27
VC0085548
p13370
sg12
VPKHD1
p13371
sa(dp13372
g7
I92
sg8
I1
sg9
I4
sg27
VC2751306
p13373
sg12
VPKD2
p13374
sa(dp13375
g7
I86
sg8
I1
sg9
I4
sg27
VC3149841
p13376
sg12
VPKD1
p13377
sasa(dp13378
g2
VCollectrin is a downstream target of the transcription factor hepatocyte nuclear factor-1alpha (HNF-1alpha), which is mutated in maturity-onset diabetes of the young subtype 3 (MODY3).
p13379
sg4
(lp13380
(dp13381
g7
I62
sg8
I3
sg9
I32
sg10
VP20823
p13382
sg12
Vhepatocyte nuclear factor-1alpha
p13383
sa(dp13384
g7
I177
sg8
I1
sg9
I5
sg10
VP20823
p13385
sg12
VMODY3
p13386
sa(dp13387
g7
I0
sg8
I1
sg9
I10
sg10
g11
sg12
VCollectrin
p13388
sa(dp13389
g7
I96
sg8
I1
sg9
I10
sg10
VP20823
p13390
sg12
VHNF-1alpha
p13391
sa(dp13392
g7
I129
sg8
I7
sg9
I46
sg10
VP20823
p13393
sg12
Vmaturity-onset diabetes of the young subtype 3
p13394
sasg24
(lp13395
(dp13396
g7
I177
sg8
I1
sg9
I5
sg27
VC1838100
p13397
sg12
VMODY3
p13398
sa(dp13399
g7
I129
sg8
I7
sg9
I46
sg27
VC1838100
p13400
sg12
Vmaturity-onset diabetes of the young subtype 3
p13401
sasa(dp13402
g2
VSeveral forms of ichthyosis are associated with neurologic manifestations, including Sjoegren-Larsson syndrome, Refsum disease, and mental retardation-enteropathy-deafness-neuropathy-ichthyosis-keratoderma (MEDNIK) syndrome.
p13403
sg4
(lp13404
sg24
(lp13405
(dp13406
g7
I194
sg8
I1
sg9
I11
sg27
VC0022579
p13407
sg12
Vkeratoderma
p13408
sa(dp13409
g7
I85
sg8
I2
sg9
I25
sg27
VC0037231
p13410
sg12
VSjoegren-Larsson syndrome
p13411
sa(dp13412
g7
I163
sg8
I1
sg9
I8
sg27
VC0011053
p13413
sg12
Vdeafness
p13414
sa(dp13415
g7
I17
sg8
I1
sg9
I10
sg27
VC0020758
p13416
sg12
Vichthyosis
p13417
sa(dp13418
g7
I112
sg8
I2
sg9
I14
sg27
VC0034960
p13419
sg12
VRefsum disease
p13420
sa(dp13421
g7
I17
sg8
I1
sg9
I10
sg27
VC0020758
p13422
sg12
Vichthyosis
p13423
sa(dp13424
g7
I102
sg8
I1
sg9
I8
sg27
VC0039082
p13425
sg12
Vsyndrome
p13426
sa(dp13427
g7
I132
sg8
I2
sg9
I18
sg27
VC0025362
p13428
sg12
Vmental retardation
p13429
sa(dp13430
g7
I151
sg8
I1
sg9
I11
sg27
VC0021831
p13431
sg12
Venteropathy
p13432
sa(dp13433
g7
I172
sg8
I1
sg9
I10
sg27
VC0442874
p13434
sg12
Vneuropathy
p13435
sasa(dp13436
g2
VTo determine the difference in thrombomodulin expression in the myometrium and in myoma; and to understand the correlation of anticoagulation/fibrinolytic function and the mechanism of uterine artery occlusion in the treatment of leiomyoma.
p13437
sg4
(lp13438
(dp13439
g7
I31
sg8
I1
sg9
I14
sg10
VP07204
p13440
sg12
Vthrombomodulin
p13441
sasg24
(lp13442
(dp13443
g7
I230
sg8
I1
sg9
I9
sg27
VC0023267
p13444
sg12
Vleiomyoma
p13445
sa(dp13446
g7
I82
sg8
I1
sg9
I5
sg27
VC0027086
p13447
sg12
Vmyoma
p13448
sa(dp13449
g7
I193
sg8
I2
sg9
I16
sg27
VC0264995
p13450
sg12
Vartery occlusion
p13451
sasa(dp13452
g2
VThe relative transcription of thrombomodulin mRNA was 1.28 times higher in myometrial tissue than in myomal tissue (P &lt; 0.05).
p13453
sg4
(lp13454
(dp13455
g7
I30
sg8
I2
sg9
I19
sg10
VP07204
p13456
sg12
Vthrombomodulin mRNA
p13457
sasg24
(lp13458
sa(dp13459
g2
VSimilarly, leiomyoma-associated endometrium expressed less PAI-1 and thrombomodulin in vivo.
p13460
sg4
(lp13461
(dp13462
g7
I59
sg8
I1
sg9
I5
sg10
VP05121
p13463
sg12
VPAI-1
p13464
sa(dp13465
g7
I69
sg8
I1
sg9
I14
sg10
VP07204
p13466
sg12
Vthrombomodulin
p13467
sasg24
(lp13468
(dp13469
g7
I11
sg8
I1
sg9
I9
sg27
VC0023267
p13470
sg12
Vleiomyoma
p13471
sasa(dp13472
g2
VAlfa-methylacyl coenzyme A racemase (AMACR) and insulin-like growth factor-II mRNA-binding protein 3 (IMP3) are 2 markers helpful in detecting difficult cases of dysplasia in Barrett esophagus (BE).
p13473
sg4
(lp13474
(dp13475
g7
I48
sg8
I6
sg9
I52
sg10
VP01308
p13476
sg12
Vinsulin-like growth factor-II mRNA-binding protein 3
p13477
sa(dp13478
g7
I102
sg8
I1
sg9
I4
sg10
g11
sg12
VIMP3
p13479
sa(dp13480
g7
I37
sg8
I1
sg9
I5
sg10
g11
sg12
VAMACR
p13481
sa(dp13482
g7
I0
sg8
I4
sg9
I35
sg10
g11
sg12
VAlfa-methylacyl coenzyme A racemase
p13483
sasg24
(lp13484
(dp13485
g7
I194
sg8
I1
sg9
I2
sg27
VC0004763
p13486
sg12
VBE
p13487
sa(dp13488
g7
I162
sg8
I1
sg9
I9
sg27
VC0334044
p13489
sg12
Vdysplasia
p13490
sa(dp13491
g7
I175
sg8
I2
sg9
I17
sg27
VC0004763
p13492
sg12
VBarrett esophagus
p13493
sasa(dp13494
g2
VTo investigate the value of Alfa-methylacyl-CoA racemase (AMACR) immunohistochemistry for predicting neoplastic progression in Barrett's oesophagus (BO).
p13495
sg4
(lp13496
(dp13497
g7
I28
sg8
I2
sg9
I28
sg10
g11
sg12
VAlfa-methylacyl-CoA racemase
p13498
sa(dp13499
g7
I58
sg8
I1
sg9
I5
sg10
g11
sg12
VAMACR
p13500
sasg24
(lp13501
(dp13502
g7
I44
sg8
I1
sg9
I3
sg27
VC2678439
p13503
sg12
VCoA
p13504
sa(dp13505
g7
I127
sg8
I2
sg9
I20
sg27
VC0004763
p13506
sg12
VBarrett's oesophagus
p13507
sa(dp13508
g7
I101
sg8
I2
sg9
I22
sg27
VC0178874
p13509
sg12
Vneoplastic progression
p13510
sa(dp13511
g7
I149
sg8
I1
sg9
I2
sg27
VC0004763
p13512
sg12
VBO
p13513
sasa(dp13514
g2
VThe aim of this study was to evaluate AMACR expression in the metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus (BE), ulcerative colitis (UC), and Crohn's disease (CD) and to determine whether its expression can be used to detect dysplastic epithelium in these conditions.
p13515
sg4
(lp13516
sg24
(lp13517
(dp13518
g7
I160
sg8
I2
sg9
I15
sg27
VC0010346
p13519
sg12
VCrohn's disease
p13520
sa(dp13521
g7
I243
sg8
I1
sg9
I10
sg27
VC0334044
p13522
sg12
Vdysplastic
p13523
sa(dp13524
g7
I62
sg8
I1
sg9
I10
sg27
VC0025568
p13525
sg12
Vmetaplasia
p13526
sa(dp13527
g7
I73
sg8
I1
sg9
I9
sg27
VC0334044
p13528
sg12
Vdysplasia
p13529
sa(dp13530
g7
I83
sg8
I1
sg9
I9
sg27
VC0007097
p13531
sg12
Vcarcinoma
p13532
sa(dp13533
g7
I105
sg8
I2
sg9
I19
sg27
VC0004763
p13534
sg12
VBarrett's esophagus
p13535
sa(dp13536
g7
I126
sg8
I1
sg9
I2
sg27
VC0004763
p13537
sg12
VBE
p13538
sa(dp13539
g7
I177
sg8
I1
sg9
I2
sg27
VC0010346
p13540
sg12
VCD
p13541
sa(dp13542
g7
I131
sg8
I2
sg9
I18
sg27
VC0009324
p13543
sg12
Vulcerative colitis
p13544
sa(dp13545
g7
I151
sg8
I1
sg9
I2
sg27
VC0009324
p13546
sg12
VUC
p13547
sasa(dp13548
g2
VThese associations implicate genes related to apoptosis (HRK), development (WIF1), oxidative stress (MSR3B), ubiquitination (FBXW8) and neuronal migration (ASTN2), as well as enzymes targeted by new diabetes medications (DPP4), indicating new genetic influences on hippocampal size and possibly the risk of cognitive decline and dementia.
p13549
sg4
(lp13550
(dp13551
g7
I221
sg8
I1
sg9
I4
sg10
VP27487
p13552
sg12
VDPP4
p13553
sa(dp13554
g7
I125
sg8
I1
sg9
I5
sg10
g11
sg12
VFBXW8
p13555
sa(dp13556
g7
I76
sg8
I1
sg9
I4
sg10
g11
sg12
VWIF1
p13557
sasg24
(lp13558
(dp13559
g7
I199
sg8
I1
sg9
I8
sg27
VC0011849
p13560
sg12
Vdiabetes
p13561
sa(dp13562
g7
I329
sg8
I1
sg9
I8
sg27
VC0497327
p13563
sg12
Vdementia
p13564
sa(dp13565
g7
I83
sg8
I2
sg9
I16
sg27
VC0242606
p13566
sg12
Voxidative stress
p13567
sa(dp13568
g7
I307
sg8
I2
sg9
I17
sg27
VC0338656
p13569
sg12
Vcognitive decline
p13570
sasa(dp13571
g2
VHistomorphometrical analysis of experimental implants inserted in the femurs of CKD mice revealed a trend of decreased BIC ratio at 2-week healing.
p13572
sg4
(lp13573
sg24
(lp13574
sa(dp13575
g2
VA Cochrane Collaboration review (Roderick, Cochrane Data base of systemic reviews 2007, DOI 10.1002/14651858.CD0018.90.pub3) reported that there was no evidence for correction of acidosis by sodium bicarbonate in pre-end-stage renal disease (ESRD) patients, and concluded that randomized controlled trials (RCTs) are necessary to evaluate the benefits and harms of correcting metabolic acidosis in pre-ESRD patients.
p13576
sg4
(lp13577
sg24
(lp13578
(dp13579
g7
I376
sg8
I2
sg9
I18
sg27
VC0220981
p13580
sg12
Vmetabolic acidosis
p13581
sa(dp13582
g7
I179
sg8
I1
sg9
I8
sg27
VC0001122
p13583
sg12
Vacidosis
p13584
sa(dp13585
g7
I213
sg8
I3
sg9
I27
sg27
VC0022661
p13586
sg12
Vpre-end-stage renal disease
p13587
sa(dp13588
g7
I242
sg8
I1
sg9
I4
sg27
VC0022661
p13589
sg12
VESRD
p13590
sa(dp13591
g7
I242
sg8
I1
sg9
I4
sg27
VC0022661
p13592
sg12
VESRD
p13593
sasa(dp13594
g2
VWe will randomize 600 patients with chronic kidney disease (CKD) stages 3b and 4; 300 of these patients will be included in the bicarbonate study group (Bic), in which levels of bicarbonate should be kept &gt;24 mEq/L; the other 300 patients will be included in the usual-treatment group (no-Bic).
p13595
sg4
(lp13596
sg24
(lp13597
(dp13598
g7
I60
sg8
I1
sg9
I3
sg27
VC1561643
p13599
sg12
VCKD
p13600
sa(dp13601
g7
I36
sg8
I3
sg9
I22
sg27
VC1561643
p13602
sg12
Vchronic kidney disease
p13603
sasa(dp13604
g2
VAcid-Base Disorders in CKD: Moderate metabolic acidosis (Bic 16-20) mEq/L is common with glomerular filtration rates below 20 ml/min, and favors bone demineralization due to the release of calcium and phosphate from the bone, chronic hyperventilation, and muscular weakness and atrophy.
p13605
sg4
(lp13606
(dp13607
g7
I0
sg8
I1
sg9
I9
sg10
g11
sg12
VAcid-Base
p13608
sasg24
(lp13609
(dp13610
g7
I0
sg8
I2
sg9
I19
sg27
VC0740265
p13611
sg12
VAcid-Base Disorders
p13612
sa(dp13613
g7
I256
sg8
I2
sg9
I17
sg27
VC0151786
p13614
sg12
Vmuscular weakness
p13615
sa(dp13616
g7
I145
sg8
I2
sg9
I21
sg27
VC0242699
p13617
sg12
Vbone demineralization
p13618
sa(dp13619
g7
I226
sg8
I2
sg9
I24
sg27
VC0268054
p13620
sg12
Vchronic hyperventilation
p13621
sa(dp13622
g7
I37
sg8
I2
sg9
I18
sg27
VC0220981
p13623
sg12
Vmetabolic acidosis
p13624
sa(dp13625
g7
I278
sg8
I1
sg9
I7
sg27
VC0333641
p13626
sg12
Vatrophy
p13627
sasa(dp13628
g2
VIn a prospective randomized crossover trial, patients with acute renal failure received CRRT with either sodium bicarbonate (Bic) or sodium lactate (Lac) as a buffering agent over 2 consecutive 24-h periods.
p13629
sg4
(lp13630
(dp13631
g7
I140
sg8
I1
sg9
I7
sg10
VP09848
p13632
sg12
Vlactate
p13633
sa(dp13634
g7
I149
sg8
I1
sg9
I3
sg10
VP09848
p13635
sg12
VLac
p13636
sasg24
(lp13637
(dp13638
g7
I59
sg8
I3
sg9
I19
sg27
VC0022660
p13639
sg12
Vacute renal failure
p13640
sasa(dp13641
g2
VThe combination of bicarbonate and mannitol (BIC/MAN) is commonly used to prevent renal failure (RF) in patients with rhabdomyolysis despite the absence of sufficient evidence validating its use.
p13642
sg4
(lp13643
sg24
(lp13644
(dp13645
g7
I118
sg8
I1
sg9
I14
sg27
VC0035410
p13646
sg12
Vrhabdomyolysis
p13647
sa(dp13648
g7
I82
sg8
I2
sg9
I13
sg27
VC0035078
p13649
sg12
Vrenal failure
p13650
sa(dp13651
g7
I97
sg8
I1
sg9
I2
sg27
VC0035078
p13652
sg12
VRF
p13653
sasa(dp13654
g2
VTo unmask weak inputs from outside the conventional RF (CRF), cell excitability was raised by iontophoretic application of glutamate (GLU) and/or bicuculline methiodide (BIC) or by light stimulation of the CRF.
p13655
sg4
(lp13656
(dp13657
g7
I56
sg8
I1
sg9
I3
sg10
VP06850
p13658
sg12
VCRF
p13659
sa(dp13660
g7
I39
sg8
I2
sg9
I15
sg10
VP06850
p13661
sg12
Vconventional RF
p13662
sasg24
(lp13663
(dp13664
g7
I56
sg8
I1
sg9
I3
sg27
VC0022661
p13665
sg12
VCRF
p13666
sa(dp13667
g7
I67
sg8
I1
sg9
I12
sg27
VC0235169
p13668
sg12
Vexcitability
p13669
sa(dp13670
g7
I56
sg8
I1
sg9
I3
sg27
VC0022661
p13671
sg12
VCRF
p13672
sa(dp13673
g7
I39
sg8
I2
sg9
I15
sg27
VC0022661
p13674
sg12
Vconventional RF
p13675
sasa(dp13676
g2
VBicarbonate-buffered replacement fluid (RF-bic) in continuous venovenous hemofiltration (CVVH) may be superior to lactate-buffered replacement fluid (RF-lac) in acute renal failure.
p13677
sg4
(lp13678
sg24
(lp13679
(dp13680
g7
I161
sg8
I3
sg9
I19
sg27
VC0022660
p13681
sg12
Vacute renal failure
p13682
sasa(dp13683
g2
VIn an open, randomized, multicenter study, we investigated the effects of RF-bic and RF-lac on cardiovascular outcome in patients requiring CVVH following acute renal failure.
p13684
sg4
(lp13685
(dp13686
g7
I85
sg8
I1
sg9
I6
sg10
VP09848
p13687
sg12
VRF-lac
p13688
sasg24
(lp13689
(dp13690
g7
I155
sg8
I3
sg9
I19
sg27
VC0022660
p13691
sg12
Vacute renal failure
p13692
sasa(dp13693
g2
VThe data also suggest that the use of RF-bic during CVVH reduces cardiovascular events in critically ill patients with acute renal failure, particularly those with previous cardiovascular disease or heart failure.
p13694
sg4
(lp13695
sg24
(lp13696
(dp13697
g7
I119
sg8
I3
sg9
I19
sg27
VC0022660
p13698
sg12
Vacute renal failure
p13699
sa(dp13700
g7
I199
sg8
I2
sg9
I13
sg27
VC0018802
p13701
sg12
Vheart failure
p13702
sa(dp13703
g7
I173
sg8
I2
sg9
I22
sg27
VC0007222
p13704
sg12
Vcardiovascular disease
p13705
sa(dp13706
g7
I90
sg8
I2
sg9
I14
sg27
VC0010340
p13707
sg12
Vcritically ill
p13708
sasa(dp13709
g2
VThe effect of BIC on whisker-evoked responses was a preferential enhancement in the responses elicited by the whisker giving rise to the highest probability response (center receptive field whisker or CRF).
p13710
sg4
(lp13711
sg24
(lp13712
(dp13713
g7
I201
sg8
I1
sg9
I3
sg27
VC0022661
p13714
sg12
VCRF
p13715
sasa(dp13716
g2
VThe primary influence of BIC and, to a lesser degree, 2-OH-S was to prolong the response duration of VPM neurons to CRF whisker stimulation.
p13717
sg4
(lp13718
(dp13719
g7
I116
sg8
I1
sg9
I3
sg10
VP06850
p13720
sg12
VCRF
p13721
sasg24
(lp13722
(dp13723
g7
I116
sg8
I1
sg9
I3
sg27
VC0022661
p13724
sg12
VCRF
p13725
sasa(dp13726
g2
VSelective PDE5 inhibitors have shown potential in treating kidney fibrosis in patients with chronic kidney disease (CKD), via their downstream signaling, and these inhibitors also have known activity as antithrombotic and anticancer agents.
p13727
sg4
(lp13728
(dp13729
g7
I10
sg8
I1
sg9
I4
sg10
g11
sg12
VPDE5
p13730
sasg24
(lp13731
(dp13732
g7
I92
sg8
I3
sg9
I22
sg27
VC1561643
p13733
sg12
Vchronic kidney disease
p13734
sa(dp13735
g7
I116
sg8
I1
sg9
I3
sg27
VC1561643
p13736
sg12
VCKD
p13737
sa(dp13738
g7
I59
sg8
I2
sg9
I15
sg27
VC0151650
p13739
sg12
Vkidney fibrosis
p13740
sasa(dp13741
g2
VThe FGF9 subfamily, including FGF9, FGF16, and FGF20, in addition to rhFGF16, rhFGF9, and rhFGF20, were shown to stimulate the proliferation and migration of HuH7 human hepatocellular carcinoma (HCC) cells.
p13742
sg4
(lp13743
(dp13744
g7
I4
sg8
I2
sg9
I14
sg10
VP31371
p13745
sg12
VFGF9 subfamily
p13746
sa(dp13747
g7
I4
sg8
I1
sg9
I4
sg10
VP31371
p13748
sg12
VFGF9
p13749
sa(dp13750
g7
I36
sg8
I1
sg9
I5
sg10
g11
sg12
VFGF16
p13751
sa(dp13752
g7
I47
sg8
I1
sg9
I5
sg10
g11
sg12
VFGF20
p13753
sasg24
(lp13754
(dp13755
g7
I169
sg8
I2
sg9
I24
sg27
VC2239176
p13756
sg12
Vhepatocellular carcinoma
p13757
sa(dp13758
g7
I195
sg8
I1
sg9
I3
sg27
VC2239176
p13759
sg12
VHCC
p13760
sa(dp13761
g7
I127
sg8
I1
sg9
I13
sg27
VC0334094
p13762
sg12
Vproliferation
p13763
sasa(dp13764
g2
VFurthermore, the results indicate that exogenous rhFGF9- and rhFGF20-activated ERK/NF-KB signal transduction pathways play important roles in the regulation of HCC cell proliferation and migration, and this discovery helps to find the potential for new solutions of the treatment of liver cancer.
p13765
sg4
(lp13766
(dp13767
g7
I79
sg8
I1
sg9
I3
sg10
VP29323
p13768
sg12
VERK
p13769
sasg24
(lp13770
(dp13771
g7
I169
sg8
I1
sg9
I13
sg27
VC0334094
p13772
sg12
Vproliferation
p13773
sa(dp13774
g7
I160
sg8
I1
sg9
I3
sg27
VC2239176
p13775
sg12
VHCC
p13776
sa(dp13777
g7
I283
sg8
I2
sg9
I12
sg27
VC0345904
p13778
sg12
Vliver cancer
p13779
sasa(dp13780
g2
VThese include FGF3 in Michel aplasia; FGF8 in cleft lip/palate and in hypogonadotropic hypogonadism; FGF9 in carcinoma; FGF10 in the lacrimal/salivary glands aplasia, and lacrimo-auriculo-dento-digital syndrome; FGF14 in spinocerebellar ataxia; FGF20 in Parkinson disease; and FGF23 in tumoral calcinosis and hypophosphatemic rickets.
p13781
sg4
(lp13782
(dp13783
g7
I120
sg8
I1
sg9
I5
sg10
g11
sg12
VFGF10
p13784
sa(dp13785
g7
I277
sg8
I1
sg9
I5
sg10
g11
sg12
VFGF23
p13786
sa(dp13787
g7
I38
sg8
I1
sg9
I4
sg10
VP55075
p13788
sg12
VFGF8
p13789
sa(dp13790
g7
I212
sg8
I1
sg9
I5
sg10
g11
sg12
VFGF14
p13791
sa(dp13792
g7
I101
sg8
I1
sg9
I4
sg10
VP31371
p13793
sg12
VFGF9
p13794
sa(dp13795
g7
I14
sg8
I1
sg9
I4
sg10
VP11487
p13796
sg12
VFGF3
p13797
sasg24
(lp13798
(dp13799
g7
I254
sg8
I2
sg9
I17
sg27
VC0030567
p13800
sg12
VParkinson disease
p13801
sa(dp13802
g7
I29
sg8
I1
sg9
I7
sg27
VC0243065
p13803
sg12
Vaplasia
p13804
sa(dp13805
g7
I171
sg8
I2
sg9
I39
sg27
VC0265269
p13806
sg12
Vlacrimo-auriculo-dento-digital syndrome
p13807
sa(dp13808
g7
I46
sg8
I2
sg9
I16
sg27
VC0158646
p13809
sg12
Vcleft lip/palate
p13810
sa(dp13811
g7
I309
sg8
I2
sg9
I24
sg27
VC1704375
p13812
sg12
Vhypophosphatemic rickets
p13813
sa(dp13814
g7
I286
sg8
I2
sg9
I18
sg27
VC0263628
p13815
sg12
Vtumoral calcinosis
p13816
sa(dp13817
g7
I109
sg8
I1
sg9
I9
sg27
VC0007097
p13818
sg12
Vcarcinoma
p13819
sa(dp13820
g7
I29
sg8
I1
sg9
I7
sg27
VC0243065
p13821
sg12
Vaplasia
p13822
sa(dp13823
g7
I70
sg8
I2
sg9
I29
sg27
VC0022735
p13824
sg12
Vhypogonadotropic hypogonadism
p13825
sa(dp13826
g7
I221
sg8
I2
sg9
I22
sg27
VC0087012
p13827
sg12
Vspinocerebellar ataxia
p13828
sasa(dp13829
g2
VMolecular genetics and developmental studies have identified 21 genes in this region (ADRA1A, ARHGEF10, CHRNA2, CHRNA6, CHRNB3, DKK4, DPYSL2, EGR3, FGF17, FGF20, FGFR1, FZD3, LDL, NAT2, NEF3, NRG1, PCM1, PLAT, PPP3CC, SFRP1 and VMAT1/SLC18A1) that are most likely to contribute to neuropsychiatric disorders (schizophrenia, autism, bipolar disorder and depression), neurodegenerative disorders (Parkinson's and Alzheimer's disease) and cancer.
p13830
sg4
(lp13831
(dp13832
g7
I94
sg8
I1
sg9
I8
sg10
g11
sg12
VARHGEF10
p13833
sa(dp13834
g7
I186
sg8
I1
sg9
I4
sg10
VP07197
p13835
sg12
VNEF3
p13836
sa(dp13837
g7
I210
sg8
I1
sg9
I6
sg10
VP48454
p13838
sg12
VPPP3CC
p13839
sa(dp13840
g7
I142
sg8
I1
sg9
I4
sg10
g11
sg12
VEGR3
p13841
sa(dp13842
g7
I120
sg8
I1
sg9
I6
sg10
g11
sg12
VCHRNB3
p13843
sa(dp13844
g7
I86
sg8
I1
sg9
I6
sg10
VP25100
p13845
sg12
VADRA1A
p13846
sa(dp13847
g7
I234
sg8
I1
sg9
I7
sg10
VP54219
p13848
sg12
VSLC18A1
p13849
sa(dp13850
g7
I228
sg8
I1
sg9
I5
sg10
VP54219
p13851
sg12
VVMAT1
p13852
sa(dp13853
g7
I180
sg8
I1
sg9
I4
sg10
VP18440
p13854
sg12
VNAT2
p13855
sa(dp13856
g7
I128
sg8
I1
sg9
I4
sg10
g11
sg12
VDKK4
p13857
sa(dp13858
g7
I162
sg8
I1
sg9
I5
sg10
VP20930
p13859
sg12
VFGFR1
p13860
sa(dp13861
g7
I104
sg8
I1
sg9
I6
sg10
g11
sg12
VCHRNA2
p13862
sa(dp13863
g7
I134
sg8
I1
sg9
I6
sg10
g11
sg12
VDPYSL2
p13864
sa(dp13865
g7
I169
sg8
I1
sg9
I4
sg10
g11
sg12
VFZD3
p13866
sa(dp13867
g7
I148
sg8
I1
sg9
I5
sg10
g11
sg12
VFGF17
p13868
sa(dp13869
g7
I155
sg8
I1
sg9
I5
sg10
g11
sg12
VFGF20
p13870
sa(dp13871
g7
I218
sg8
I1
sg9
I5
sg10
g11
sg12
VSFRP1
p13872
sa(dp13873
g7
I198
sg8
I1
sg9
I4
sg10
g11
sg12
VPCM1
p13874
sa(dp13875
g7
I112
sg8
I1
sg9
I6
sg10
g11
sg12
VCHRNA6
p13876
sasg24
(lp13877
(dp13878
g7
I436
sg8
I1
sg9
I6
sg27
VC0006826
p13879
sg12
Vcancer
p13880
sa(dp13881
g7
I309
sg8
I1
sg9
I13
sg27
VC0036341
p13882
sg12
Vschizophrenia
p13883
sa(dp13884
g7
I332
sg8
I2
sg9
I16
sg27
VC0005586
p13885
sg12
Vbipolar disorder
p13886
sa(dp13887
g7
I324
sg8
I1
sg9
I6
sg27
VC0004352
p13888
sg12
Vautism
p13889
sa(dp13890
g7
I366
sg8
I2
sg9
I27
sg27
VC0524851
p13891
sg12
Vneurodegenerative disorders
p13892
sa(dp13893
g7
I353
sg8
I1
sg9
I10
sg27
VC0011581
p13894
sg12
Vdepression
p13895
sa(dp13896
g7
I411
sg8
I2
sg9
I19
sg27
VC1521724
p13897
sg12
VAlzheimer's disease
p13898
sasa(dp13899
g2
VEphrinB2 (erythropoietin-producing hepatoma interactor B2), a pivotal bidirectional signaling molecule ubiquitously expressed in mammals, is crucial in angiogenesis during development and disease progression.
p13900
sg4
(lp13901
(dp13902
g7
I10
sg8
I1
sg9
I14
sg10
VP01588
p13903
sg12
Verythropoietin
p13904
sa(dp13905
g7
I0
sg8
I1
sg9
I8
sg10
VP52799
p13906
sg12
VEphrinB2
p13907
sasg24
(lp13908
(dp13909
g7
I35
sg8
I1
sg9
I8
sg27
VC0023903
p13910
sg12
Vhepatoma
p13911
sa(dp13912
g7
I188
sg8
I2
sg9
I19
sg27
VC0242656
p13913
sg12
Vdisease progression
p13914
sasa(dp13915
g2
VThe aim of the present study was to detect the correlation between the expression of vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2), ephrinB2 and endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and carcinogenesis or portal vein tumor thrombus (PVTT) formation in human hepatocellular carcinoma (HCC).
p13916
sg4
(lp13917
(dp13918
g7
I128
sg8
I2
sg9
I14
sg10
g11
sg12
Vangiopoietin 2
p13919
sa(dp13920
g7
I85
sg8
I4
sg9
I34
sg10
g11
sg12
Vvascular endothelial growth factor
p13921
sa(dp13922
g7
I151
sg8
I1
sg9
I8
sg10
VP52799
p13923
sg12
VephrinB2
p13924
sa(dp13925
g7
I224
sg8
I1
sg9
I7
sg10
VP58294
p13926
sg12
VEG-VEGF
p13927
sa(dp13928
g7
I164
sg8
I6
sg9
I58
sg10
VP58294
p13929
sg12
Vendocrine gland-derived vascular endothelial growth factor
p13930
sa(dp13931
g7
I144
sg8
I1
sg9
I4
sg10
g11
sg12
VAng2
p13932
sa(dp13933
g7
I121
sg8
I1
sg9
I4
sg10
g11
sg12
VVEGF
p13934
sasg24
(lp13935
(dp13936
g7
I334
sg8
I1
sg9
I3
sg27
VC2239176
p13937
sg12
VHCC
p13938
sa(dp13939
g7
I237
sg8
I1
sg9
I14
sg27
VC0596263
p13940
sg12
Vcarcinogenesis
p13941
sa(dp13942
g7
I267
sg8
I2
sg9
I14
sg27
VC3163918
p13943
sg12
Vtumor thrombus
p13944
sa(dp13945
g7
I308
sg8
I2
sg9
I24
sg27
VC2239176
p13946
sg12
Vhepatocellular carcinoma
p13947
sasa(dp13948
g2
VWe investigated whether the human MBX gene was associated with susceptibility to microphthalmia by analyzing four Korean families demonstrating microphthalmia with congenital cataract.
p13949
sg4
(lp13950
(dp13951
g7
I28
sg8
I3
sg9
I14
sg10
g11
sg12
Vhuman MBX gene
p13952
sasg24
(lp13953
(dp13954
g7
I81
sg8
I1
sg9
I14
sg27
VC0026010
p13955
sg12
Vmicrophthalmia
p13956
sa(dp13957
g7
I81
sg8
I1
sg9
I14
sg27
VC0026010
p13958
sg12
Vmicrophthalmia
p13959
sa(dp13960
g7
I164
sg8
I2
sg9
I19
sg27
VC0009691
p13961
sg12
Vcongenital cataract
p13962
sasa(dp13963
g2
VTherefore, no indications were found for an association between the MBX gene and microphthalmia with congenital cataract in humans.
p13964
sg4
(lp13965
(dp13966
g7
I68
sg8
I2
sg9
I8
sg10
g11
sg12
VMBX gene
p13967
sasg24
(lp13968
(dp13969
g7
I81
sg8
I1
sg9
I14
sg27
VC0026010
p13970
sg12
Vmicrophthalmia
p13971
sa(dp13972
g7
I101
sg8
I2
sg9
I19
sg27
VC0009691
p13973
sg12
Vcongenital cataract
p13974
sasa(dp13975
g2
VSequence changes have been observed for both NCKX1 and NCKX2 in patients with retinal diseases, but a definitive association with retinal disease has not been shown.
p13976
sg4
(lp13977
(dp13978
g7
I55
sg8
I1
sg9
I5
sg10
g11
sg12
VNCKX2
p13979
sa(dp13980
g7
I45
sg8
I1
sg9
I5
sg10
g11
sg12
VNCKX1
p13981
sasg24
(lp13982
(dp13983
g7
I78
sg8
I2
sg9
I15
sg27
VC0035309
p13984
sg12
Vretinal disease
p13985
sa(dp13986
g7
I78
sg8
I2
sg9
I16
sg27
VC0035309
p13987
sg12
Vretinal diseases
p13988
sasa(dp13989
g2
VTo study the possible involvement of the rod (SLC24A1) and cone (SLC24A2) Na-Ca+K exchanger (NCKX) genes in retinal diseases.
p13990
sg4
(lp13991
(dp13992
g7
I74
sg8
I4
sg9
I30
sg10
g11
sg12
VNa-Ca+K exchanger (NCKX) genes
p13993
sa(dp13994
g7
I65
sg8
I1
sg9
I7
sg10
g11
sg12
VSLC24A2
p13995
sa(dp13996
g7
I41
sg8
I1
sg9
I3
sg10
VP50748
p13997
sg12
Vrod
p13998
sa(dp13999
g7
I46
sg8
I1
sg9
I7
sg10
g11
sg12
VSLC24A1
p14000
sasg24
(lp14001
(dp14002
g7
I108
sg8
I2
sg9
I16
sg27
VC0035309
p14003
sg12
Vretinal diseases
p14004
sasa(dp14005
g2
VApproximately 23% of patients with metastatic castration-resistant prostate cancer exhibit somatic or germline aberrations in genes implicated in DNA repair, such as BRCA2, BRCA1, ATM, CHEK2, and PALB2, as well as mismatch repair genes.
p14006
sg4
(lp14007
(dp14008
g7
I166
sg8
I1
sg9
I5
sg10
VP51587
p14009
sg12
VBRCA2
p14010
sa(dp14011
g7
I196
sg8
I1
sg9
I5
sg10
g11
sg12
VPALB2
p14012
sa(dp14013
g7
I180
sg8
I1
sg9
I3
sg10
g11
sg12
VATM
p14014
sa(dp14015
g7
I173
sg8
I1
sg9
I5
sg10
VP38398
p14016
sg12
VBRCA1
p14017
sasg24
(lp14018
(dp14019
g7
I67
sg8
I2
sg9
I15
sg27
VC0600139
p14020
sg12
Vprostate cancer
p14021
sasa(dp14022
g2
VMen who inherit pathogenic germline mutations in BRCA2 and BRCA1 are at increased risk of developing aggressive prostate cancer, and those with germline mutations in other DNA repair genes such as ATM, CHEK2, and MSH2/MSH6 may also have increased risks.
p14023
sg4
(lp14024
(dp14025
g7
I213
sg8
I1
sg9
I4
sg10
VP43246
p14026
sg12
VMSH2
p14027
sa(dp14028
g7
I197
sg8
I1
sg9
I3
sg10
g11
sg12
VATM
p14029
sa(dp14030
g7
I49
sg8
I1
sg9
I5
sg10
VP51587
p14031
sg12
VBRCA2
p14032
sa(dp14033
g7
I59
sg8
I1
sg9
I5
sg10
VP38398
p14034
sg12
VBRCA1
p14035
sa(dp14036
g7
I218
sg8
I1
sg9
I4
sg10
VP52701
p14037
sg12
VMSH6
p14038
sasg24
(lp14039
(dp14040
g7
I101
sg8
I1
sg9
I10
sg27
VC0001807
p14041
sg12
Vaggressive
p14042
sa(dp14043
g7
I112
sg8
I2
sg9
I15
sg27
VC0600139
p14044
sg12
Vprostate cancer
p14045
sasa(dp14046
g2
VThe CHEK2 gene del5395 is a founder mutation in the Latvian population, which, however, does not have a direct impact on genetic predisposition toward colorectal, breast, ovarian and prostate cancer.
p14047
sg4
(lp14048
sg24
(lp14049
(dp14050
g7
I183
sg8
I2
sg9
I15
sg27
VC0600139
p14051
sg12
Vprostate cancer
p14052
sa(dp14053
g7
I28
sg8
I2
sg9
I16
sg27
VC2985435
p14054
sg12
Vfounder mutation
p14055
sasa(dp14056
g2
VHuman limbal neurospheres expressed the neural lineage markers, Nestin, sex determining region box-2 and N-cadherin, and the retinal transcription factors microphthalmia-associated transcription factor, sex determining region box-2 and orthodentical homeobox-2.
p14057
sg4
(lp14058
(dp14059
g7
I250
sg8
I1
sg9
I10
sg10
VP52954
p14060
sg12
Vhomeobox-2
p14061
sa(dp14062
g7
I64
sg8
I5
sg9
I36
sg10
VP48681
p14063
sg12
VNestin, sex determining region box-2
p14064
sa(dp14065
g7
I105
sg8
I1
sg9
I10
sg10
VP19022
p14066
sg12
VN-cadherin
p14067
sa(dp14068
g7
I125
sg8
I10
sg9
I106
sg10
g11
sg12
Vretinal transcription factors microphthalmia-associated transcription factor, sex determining region box-2
p14069
sasg24
(lp14070
(dp14071
g7
I155
sg8
I1
sg9
I14
sg27
VC0026010
p14072
sg12
Vmicrophthalmia
p14073
sasa(dp14074
g2
VMutations of orthodentricle homeobox 2 (OTX2) in human and mice often cause retinal dystrophy and nyctalopia, suggesting a role of OTX2 in mature retina, in addition to its functions in the development of the eye and retina.
p14075
sg4
(lp14076
(dp14077
g7
I40
sg8
I1
sg9
I4
sg10
VP32243
p14078
sg12
VOTX2
p14079
sa(dp14080
g7
I13
sg8
I3
sg9
I25
sg10
VP32243
p14081
sg12
Vorthodentricle homeobox 2
p14082
sa(dp14083
g7
I40
sg8
I1
sg9
I4
sg10
VP32243
p14084
sg12
VOTX2
p14085
sasg24
(lp14086
(dp14087
g7
I76
sg8
I2
sg9
I17
sg27
VC0854723
p14088
sg12
Vretinal dystrophy
p14089
sa(dp14090
g7
I98
sg8
I1
sg9
I10
sg27
VC0028077
p14091
sg12
Vnyctalopia
p14092
sasa(dp14093
g2
VTHE ROLE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS: Angiotensin-converting enzyme inhibitors (ACE) affect the different mechanisms that lead to glomerulosclerosis: antihypertensive effect, with the normalisation of blood pressure having demonstrated its determining role in the production of nephrosis in various epidemiological studies; hemodynamic effect with a decrease in glomerular capillary pressure, in the filtration fraction, and inhibition of the bradykinin deterioration; antiproteinuric effect superior to that of other anti-hypertensive drugs (excepting angiotensin II-receptor antagonists).
p14094
sg4
(lp14095
(dp14096
g7
I96
sg8
I1
sg9
I3
sg10
VP12821
p14097
sg12
VACE
p14098
sa(dp14099
g7
I569
sg8
I2
sg9
I23
sg10
VP01019
p14100
sg12
Vangiotensin II-receptor
p14101
sa(dp14102
g7
I54
sg8
I3
sg9
I40
sg10
VP12821
p14103
sg12
VAngiotensin-converting enzyme inhibitors
p14104
sa(dp14105
g7
I459
sg8
I1
sg9
I10
sg10
VP01042
p14106
sg12
Vbradykinin
p14107
sasg24
(lp14108
(dp14109
g7
I294
sg8
I1
sg9
I9
sg27
VC0027720
p14110
sg12
Vnephrosis
p14111
sa(dp14112
g7
I146
sg8
I1
sg9
I18
sg27
VC0178664
p14113
sg12
Vglomerulosclerosis
p14114
sasa(dp14115
g2
VTo investigate whether the reduction in proteinuria is due to decreased generation of angiotensin II (AngII) or to decreased degradation of bradykinin, four series of experiments in established adriamycin nephrosis were performed.
p14116
sg4
(lp14117
(dp14118
g7
I140
sg8
I1
sg9
I10
sg10
VP01042
p14119
sg12
Vbradykinin
p14120
sa(dp14121
g7
I102
sg8
I1
sg9
I5
sg10
VP01019
p14122
sg12
VAngII
p14123
sa(dp14124
g7
I86
sg8
I2
sg9
I14
sg10
VP01019
p14125
sg12
Vangiotensin II
p14126
sasg24
(lp14127
(dp14128
g7
I205
sg8
I1
sg9
I9
sg27
VC0027720
p14129
sg12
Vnephrosis
p14130
sasa(dp14131
g2
VThere were few reports demonstrating behavior of kinin and kininogen in the nephrotic syndrome.
p14132
sg4
(lp14133
(dp14134
g7
I49
sg8
I3
sg9
I19
sg10
VP01042
p14135
sg12
Vkinin and kininogen
p14136
sasg24
(lp14137
(dp14138
g7
I76
sg8
I2
sg9
I18
sg27
VC0027726
p14139
sg12
Vnephrotic syndrome
p14140
sasa(dp14141
g2
VIn this paper, coagulation factors related to contact activation, such as factor XII (FXII), factor XI (FXI), prekallikrein (PK), high molecular weight kininogen (HMWKG), and kinins were measured in 15 cases of nephrotic syndrome, and clinical significance of these results were discussed.
p14142
sg4
(lp14143
(dp14144
g7
I74
sg8
I5
sg9
I28
sg10
VP00748
p14145
sg12
Vfactor XII (FXII), factor XI
p14146
sa(dp14147
g7
I86
sg8
I1
sg9
I3
sg10
g11
sg12
VFXI
p14148
sa(dp14149
g7
I110
sg8
I6
sg9
I51
sg10
VP03952
p14150
sg12
Vprekallikrein (PK), high molecular weight kininogen
p14151
sasg24
(lp14152
(dp14153
g7
I211
sg8
I2
sg9
I18
sg27
VC0027726
p14154
sg12
Vnephrotic syndrome
p14155
sasa(dp14156
g2
VIt was concluded that kinin formation in the nephrotic syndrome was not due to the activation of intrinsic coagulation system but due to release of kinin from low molecular weight kininogen.
p14157
sg4
(lp14158
sg24
(lp14159
(dp14160
g7
I45
sg8
I2
sg9
I18
sg27
VC0027726
p14161
sg12
Vnephrotic syndrome
p14162
sasa(dp14163
g2
VTo investigate the role of anti-inflammatory TSG-6 in controlling MMP-1 and MMP-3, which have been shown to be upregulated in conjunctivochalasis (CCh).
p14164
sg4
(lp14165
(dp14166
g7
I45
sg8
I1
sg9
I5
sg10
VP98066
p14167
sg12
VTSG-6
p14168
sa(dp14169
g7
I76
sg8
I1
sg9
I5
sg10
VP08254
p14170
sg12
VMMP-3
p14171
sa(dp14172
g7
I66
sg8
I1
sg9
I5
sg10
VP03956
p14173
sg12
VMMP-1
p14174
sasg24
(lp14175
(dp14176
g7
I126
sg8
I1
sg9
I19
sg27
VC0878693
p14177
sg12
Vconjunctivochalasis
p14178
sa(dp14179
g7
I147
sg8
I1
sg9
I3
sg27
VC0878693
p14180
sg12
VCCh
p14181
sasa(dp14182
g2
VDirect sequencing analyses were performed in 19 genes, including ALS/frontotemporal lobar degeneration (FTLD)-related genes (SOD2, SOD3, ALS2/alsin, SMN1, PGRN, ANG, VEGF, VCP, VAPB, DCTN1, CHMP2B, and TARDBP or TDP-43), tauopathy-related gene (GSK3beta), and parkinsonism-related genes (alpha-synuclein, LRRK2, parkin, DJ-1, PINK1, and ATP13A2).
p14183
sg4
(lp14184
(dp14185
g7
I305
sg8
I1
sg9
I5
sg10
g11
sg12
VLRRK2
p14186
sa(dp14187
g7
I260
sg8
I2
sg9
I26
sg10
VP01893
p14188
sg12
Vparkinsonism-related genes
p14189
sa(dp14190
g7
I202
sg8
I1
sg9
I6
sg10
g11
sg12
VTARDBP
p14191
sa(dp14192
g7
I183
sg8
I1
sg9
I5
sg10
g11
sg12
VDCTN1
p14193
sa(dp14194
g7
I125
sg8
I1
sg9
I4
sg10
VP04179
p14195
sg12
VSOD2
p14196
sa(dp14197
g7
I288
sg8
I1
sg9
I15
sg10
VP37840
p14198
sg12
Valpha-synuclein
p14199
sa(dp14200
g7
I190
sg8
I1
sg9
I6
sg10
g11
sg12
VCHMP2B
p14201
sa(dp14202
g7
I177
sg8
I1
sg9
I4
sg10
g11
sg12
VVAPB
p14203
sa(dp14204
g7
I149
sg8
I1
sg9
I4
sg10
g11
sg12
VSMN1
p14205
sa(dp14206
g7
I320
sg8
I1
sg9
I4
sg10
g11
sg12
VDJ-1
p14207
sa(dp14208
g7
I172
sg8
I1
sg9
I3
sg10
VP55072
p14209
sg12
VVCP
p14210
sa(dp14211
g7
I137
sg8
I1
sg9
I4
sg10
g11
sg12
VALS2
p14212
sa(dp14213
g7
I142
sg8
I1
sg9
I5
sg10
g11
sg12
Valsin
p14214
sa(dp14215
g7
I212
sg8
I1
sg9
I6
sg10
g11
sg12
VTDP-43
p14216
sa(dp14217
g7
I326
sg8
I1
sg9
I5
sg10
g11
sg12
VPINK1
p14218
sa(dp14219
g7
I337
sg8
I1
sg9
I7
sg10
g11
sg12
VATP13A2
p14220
sa(dp14221
g7
I131
sg8
I1
sg9
I4
sg10
VP08294
p14222
sg12
VSOD3
p14223
sa(dp14224
g7
I161
sg8
I1
sg9
I3
sg10
VP03950
p14225
sg12
VANG
p14226
sasg24
(lp14227
(dp14228
g7
I137
sg8
I1
sg9
I4
sg27
VC1859807
p14229
sg12
VALS2
p14230
sa(dp14231
g7
I104
sg8
I1
sg9
I4
sg27
VC0751072
p14232
sg12
VFTLD
p14233
sa(dp14234
g7
I260
sg8
I1
sg9
I12
sg27
VC0242422
p14235
sg12
Vparkinsonism
p14236
sa(dp14237
g7
I221
sg8
I1
sg9
I9
sg27
VC0949664
p14238
sg12
Vtauopathy
p14239
sa(dp14240
g7
I65
sg8
I3
sg9
I37
sg27
VC0751072
p14241
sg12
VALS/frontotemporal lobar degeneration
p14242
sasa(dp14243
g2
VThis patient broadens the phenotypic spectrum of the 22q11.2 microduplication syndrome and raises the possibility that TUBA8 and USP18 may play an important role in the pathogenesis of amyoplasia.
p14244
sg4
(lp14245
(dp14246
g7
I119
sg8
I1
sg9
I5
sg10
g11
sg12
VTUBA8
p14247
sa(dp14248
g7
I129
sg8
I1
sg9
I5
sg10
g11
sg12
VUSP18
p14249
sasg24
(lp14250
(dp14251
g7
I169
sg8
I1
sg9
I12
sg27
VC0699748
p14252
sg12
Vpathogenesis
p14253
sa(dp14254
g7
I78
sg8
I1
sg9
I8
sg27
VC0039082
p14255
sg12
Vsyndrome
p14256
sasa(dp14257
g2
VDespite the support for including patient-reported outcomes (PROs) and health-related quality of life in clinical trials, there have been deficiencies in how these have been assessed and reported in epithelial ovarian cancer (EOC) clinical trials.
p14258
sg4
(lp14259
sg24
(lp14260
(dp14261
g7
I199
sg8
I3
sg9
I25
sg27
VC0677886
p14262
sg12
Vepithelial ovarian cancer
p14263
sa(dp14264
g7
I226
sg8
I1
sg9
I3
sg27
VC0677886
p14265
sg12
VEOC
p14266
sasa(dp14267
g2
VTo redress this, the 5th Ovarian Cancer Consensus Conference, included a plenary session entitled 'How to include PROs in clinical trials'.
p14268
sg4
(lp14269
sg24
(lp14270
(dp14271
g7
I25
sg8
I2
sg9
I14
sg27
VC1140680
p14272
sg12
VOvarian Cancer
p14273
sasa(dp14274
g2
VTo test the hypothesis that ovarian cancer patients with worse PROs would drop out earlier, we examined how patients differed by time of dropout on health-related quality of life (HRQOL), anxiety, depression, optimism and insomnia.
p14275
sg4
(lp14276
sg24
(lp14277
(dp14278
g7
I28
sg8
I2
sg9
I14
sg27
VC1140680
p14279
sg12
Vovarian cancer
p14280
sa(dp14281
g7
I222
sg8
I1
sg9
I8
sg27
VC0917801
p14282
sg12
Vinsomnia
p14283
sa(dp14284
g7
I197
sg8
I1
sg9
I10
sg27
VC0011581
p14285
sg12
Vdepression
p14286
sasa(dp14287
g2
VProgression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PROs) were significantly improved by adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) in the phase III AURELIA trial.
p14288
sg4
(lp14289
sg24
(lp14290
(dp14291
g7
I190
sg8
I2
sg9
I14
sg27
VC1140680
p14292
sg12
Vovarian cancer
p14293
sasa(dp14294
g2
VDespite increased recognition of the value of including patient-reported outcomes (PROs) as important end points in phase III clinical trials, there has been a lack of pre-specified PRO hypotheses and shortcomings with the analyses and interpretation of PROs in many ovarian cancer trials.
p14295
sg4
(lp14296
sg24
(lp14297
(dp14298
g7
I267
sg8
I2
sg9
I14
sg27
VC1140680
p14299
sg12
Vovarian cancer
p14300
sasa(dp14301
g2
VPromoting the importance of hypothesis-driven PROs in ovarian cancer clinical trials will lead to improvements in the design of these trials and the interpretation of their results.
p14302
sg4
(lp14303
sg24
(lp14304
(dp14305
g7
I54
sg8
I2
sg9
I14
sg27
VC1140680
p14306
sg12
Vovarian cancer
p14307
sasa(dp14308
g2
VWe conducted the Surgery in Ovarian Cancer Quality of life Evaluation Research study (SOCQER 1), a prospective study investigating the feasibility of collection of serial PROs in patients who had extensive surgery and standard surgery for ovarian cancer.
p14309
sg4
(lp14310
sg24
(lp14311
(dp14312
g7
I28
sg8
I2
sg9
I14
sg27
VC1140680
p14313
sg12
VOvarian Cancer
p14314
sa(dp14315
g7
I239
sg8
I2
sg9
I14
sg27
VC1140680
p14316
sg12
Vovarian cancer
p14317
sasa(dp14318
g2
VThere is no consensus as to what symptoms or quality-of-life (QOL) domains should be measured as patient-reported outcomes (PROs) in ovarian cancer clinical trials.
p14319
sg4
(lp14320
sg24
(lp14321
(dp14322
g7
I133
sg8
I2
sg9
I14
sg27
VC1140680
p14323
sg12
Vovarian cancer
p14324
sasa(dp14325
g2
VThe results were included in and combined with an expert consensus-building process to identify the most salient PROs for ovarian cancer clinical trials.
p14326
sg4
(lp14327
sg24
(lp14328
(dp14329
g7
I122
sg8
I2
sg9
I14
sg27
VC1140680
p14330
sg12
Vovarian cancer
p14331
sasa(dp14332
g2
VWe identified a set of PROs specific to ovarian cancer: abdominal pain, bloating, cramping, fear of recurrence/disease progression, indigestion, sexual dysfunction, vomiting, weight gain, and weight loss.
p14333
sg4
(lp14334
(dp14335
g7
I23
sg8
I1
sg9
I4
sg10
VP07225
p14336
sg12
VPROs
p14337
sasg24
(lp14338
(dp14339
g7
I132
sg8
I1
sg9
I11
sg27
VC0013395
p14340
sg12
Vindigestion
p14341
sa(dp14342
g7
I165
sg8
I1
sg9
I8
sg27
VC0042963
p14343
sg12
Vvomiting
p14344
sa(dp14345
g7
I72
sg8
I1
sg9
I8
sg27
VC1291077
p14346
sg12
Vbloating
p14347
sa(dp14348
g7
I56
sg8
I2
sg9
I14
sg27
VC0000737
p14349
sg12
Vabdominal pain
p14350
sa(dp14351
g7
I100
sg8
I1
sg9
I10
sg27
VC1458156
p14352
sg12
Vrecurrence
p14353
sa(dp14354
g7
I111
sg8
I2
sg9
I19
sg27
VC0242656
p14355
sg12
Vdisease progression
p14356
sa(dp14357
g7
I40
sg8
I2
sg9
I14
sg27
VC1140680
p14358
sg12
Vovarian cancer
p14359
sa(dp14360
g7
I145
sg8
I2
sg9
I18
sg27
VC0036877
p14361
sg12
Vsexual dysfunction
p14362
sa(dp14363
g7
I82
sg8
I1
sg9
I8
sg27
VC1446787
p14364
sg12
Vcramping
p14365
sasa(dp14366
g2
VFindings of the review and consensus process provide good support for use of these ovarian cancer-specific PROs in ovarian cancer clinical trials.
p14367
sg4
(lp14368
sg24
(lp14369
(dp14370
g7
I83
sg8
I2
sg9
I14
sg27
VC1140680
p14371
sg12
Vovarian cancer
p14372
sa(dp14373
g7
I83
sg8
I2
sg9
I14
sg27
VC1140680
p14374
sg12
Vovarian cancer
p14375
sasa(dp14376
g2
VMutations within this gene are responsible for kinesigenic paroxysmal dyskinesias (PKD) as well as for benign familial infantile epilepsy (BFIE), a disease associating infantile convulsions and choreoathetosis (ICCA), a form of familial hemiplegic migraine (FHM type 4), paroxysmal benign torticollis of childhood, and episodic ataxia.
p14377
sg4
(lp14378
sg24
(lp14379
(dp14380
g7
I319
sg8
I2
sg9
I15
sg27
VC1720189
p14381
sg12
Vepisodic ataxia
p14382
sa(dp14383
g7
I83
sg8
I1
sg9
I3
sg27
VC1868682
p14384
sg12
VPKD
p14385
sa(dp14386
g7
I258
sg8
I1
sg9
I3
sg27
VC1832894
p14387
sg12
VFHM
p14388
sa(dp14389
g7
I59
sg8
I2
sg9
I22
sg27
VC0752210
p14390
sg12
Vparoxysmal dyskinesias
p14391
sa(dp14392
g7
I211
sg8
I1
sg9
I4
sg27
VC1865926
p14393
sg12
VICCA
p14394
sa(dp14395
g7
I289
sg8
I1
sg9
I11
sg27
VC0040485
p14396
sg12
Vtorticollis
p14397
sa(dp14398
g7
I228
sg8
I3
sg9
I28
sg27
VC0338484
p14399
sg12
Vfamilial hemiplegic migraine
p14400
sa(dp14401
g7
I129
sg8
I1
sg9
I8
sg27
VC0014544
p14402
sg12
Vepilepsy
p14403
sa(dp14404
g7
I168
sg8
I4
sg9
I41
sg27
VC1865926
p14405
sg12
Vinfantile convulsions and choreoathetosis
p14406
sasa(dp14407
g2
VFHM type 4 is attributed to mutations in the PRRT2 gene, which encodes a proline-rich transmembrane protein of as yet unknown function.
p14408
sg4
(lp14409
(dp14410
g7
I45
sg8
I2
sg9
I10
sg10
g11
sg12
VPRRT2 gene
p14411
sasg24
(lp14412
(dp14413
g7
I0
sg8
I1
sg9
I3
sg27
VC1832894
p14414
sg12
VFHM
p14415
sasa(dp14416
g2
VTwo PRRT2 mutations were in familial hemiplegic migraine or episodic ataxia, one SLC2A1 family had episodic ataxia and one PNKD family had familial hemiplegic migraine alone.
p14417
sg4
(lp14418
(dp14419
g7
I123
sg8
I2
sg9
I11
sg10
g11
sg12
VPNKD family
p14420
sa(dp14421
g7
I4
sg8
I2
sg9
I15
sg10
g11
sg12
VPRRT2 mutations
p14422
sa(dp14423
g7
I81
sg8
I1
sg9
I6
sg10
VP11166
p14424
sg12
VSLC2A1
p14425
sasg24
(lp14426
(dp14427
g7
I60
sg8
I2
sg9
I15
sg27
VC1720189
p14428
sg12
Vepisodic ataxia
p14429
sa(dp14430
g7
I28
sg8
I3
sg9
I28
sg27
VC0338484
p14431
sg12
Vfamilial hemiplegic migraine
p14432
sa(dp14433
g7
I28
sg8
I3
sg9
I28
sg27
VC0338484
p14434
sg12
Vfamilial hemiplegic migraine
p14435
sa(dp14436
g7
I60
sg8
I2
sg9
I15
sg27
VC1720189
p14437
sg12
Vepisodic ataxia
p14438
sasa(dp14439
g2
VSLC2A1 mutations were associated with variable phenotypes including paroxysmal kinesigenic dyskinesia, paroxysmal non-kinesigenic dyskinesia, episodic ataxia and myotonia and we identified a novel PNKD gene deletion in familial hemiplegic migraine.
p14440
sg4
(lp14441
(dp14442
g7
I197
sg8
I2
sg9
I9
sg10
g11
sg12
VPNKD gene
p14443
sa(dp14444
g7
I0
sg8
I1
sg9
I6
sg10
VP11166
p14445
sg12
VSLC2A1
p14446
sasg24
(lp14447
(dp14448
g7
I142
sg8
I2
sg9
I15
sg27
VC1720189
p14449
sg12
Vepisodic ataxia
p14450
sa(dp14451
g7
I68
sg8
I3
sg9
I33
sg27
VC1868682
p14452
sg12
Vparoxysmal kinesigenic dyskinesia
p14453
sa(dp14454
g7
I202
sg8
I2
sg9
I13
sg27
VC1442161
p14455
sg12
Vgene deletion
p14456
sa(dp14457
g7
I91
sg8
I1
sg9
I10
sg27
VC0013384
p14458
sg12
Vdyskinesia
p14459
sa(dp14460
g7
I219
sg8
I3
sg9
I28
sg27
VC0338484
p14461
sg12
Vfamilial hemiplegic migraine
p14462
sasa(dp14463
g2
VWe assessed the clinical features of both FHM families and performed direct sequencing of all coding exons (and adjacent sequences) of the CACNA1A, ATP1A2, PRRT2 and SCN1A genes.
p14464
sg4
(lp14465
(dp14466
g7
I148
sg8
I1
sg9
I6
sg10
VP50993
p14467
sg12
VATP1A2
p14468
sa(dp14469
g7
I166
sg8
I2
sg9
I11
sg10
VP35498
p14470
sg12
VSCN1A genes
p14471
sa(dp14472
g7
I42
sg8
I2
sg9
I12
sg10
VP19883
p14473
sg12
VFHM families
p14474
sa(dp14475
g7
I156
sg8
I1
sg9
I5
sg10
g11
sg12
VPRRT2
p14476
sasg24
(lp14477
(dp14478
g7
I42
sg8
I1
sg9
I3
sg27
VC1832894
p14479
sg12
VFHM
p14480
sasa(dp14481
g2
VIn 2012, PRRT2 has been identified as the fourth FHM gene, and encodes an axonal protein associated to the exocytosis complex.
p14482
sg4
(lp14483
(dp14484
g7
I9
sg8
I1
sg9
I5
sg10
g11
sg12
VPRRT2
p14485
sasg24
(lp14486
(dp14487
g7
I49
sg8
I1
sg9
I3
sg27
VC1832894
p14488
sg12
VFHM
p14489
sasa(dp14490
g2
VTo characterise the phenotype of a family with paroxysmal exercise induced dystonia (PED) and migraine and establish whether it is linked to the paroxysmal non-kinesigenic dyskinesia (PNKD) locus on chromosome 2q33-35, the familial hemiplegic migraine (FHM) locus on chromosome 19p, or the familial infantile convulsions and paroxysmal choreoathetosis (ICCA syndrome) locus on chromosome 16.
p14491
sg4
(lp14492
sg24
(lp14493
(dp14494
g7
I172
sg8
I1
sg9
I10
sg27
VC0013384
p14495
sg12
Vdyskinesia
p14496
sa(dp14497
g7
I253
sg8
I1
sg9
I3
sg27
VC1832894
p14498
sg12
VFHM
p14499
sa(dp14500
g7
I309
sg8
I1
sg9
I11
sg27
VC0009951
p14501
sg12
Vconvulsions
p14502
sa(dp14503
g7
I358
sg8
I1
sg9
I8
sg27
VC0039082
p14504
sg12
Vsyndrome
p14505
sa(dp14506
g7
I75
sg8
I1
sg9
I8
sg27
VC0393593
p14507
sg12
Vdystonia
p14508
sa(dp14509
g7
I223
sg8
I3
sg9
I28
sg27
VC0338484
p14510
sg12
Vfamilial hemiplegic migraine
p14511
sa(dp14512
g7
I58
sg8
I2
sg9
I16
sg27
VC0239313
p14513
sg12
Vexercise induced
p14514
sa(dp14515
g7
I94
sg8
I1
sg9
I8
sg27
VC0149931
p14516
sg12
Vmigraine
p14517
sa(dp14518
g7
I353
sg8
I1
sg9
I4
sg27
VC1865926
p14519
sg12
VICCA
p14520
sa(dp14521
g7
I325
sg8
I2
sg9
I26
sg27
VC1868682
p14522
sg12
Vparoxysmal choreoathetosis
p14523
sasa(dp14524
g2
VHaplotypes were reconstructed for all the available family members by typing several microsatellite markers spanning the PNKD, FHM, and ICCA loci.
p14525
sg4
(lp14526
(dp14527
g7
I121
sg8
I1
sg9
I4
sg10
g11
sg12
VPNKD
p14528
sasg24
(lp14529
(dp14530
g7
I127
sg8
I1
sg9
I3
sg27
VC1832894
p14531
sg12
VFHM
p14532
sa(dp14533
g7
I136
sg8
I1
sg9
I4
sg27
VC1865926
p14534
sg12
VICCA
p14535
sasa(dp14536
g2
VLinkage of the disease to the PNKD, FHM, or ICCA loci was excluded as no common haplotype was shared by all the affected members for each locus.
p14537
sg4
(lp14538
(dp14539
g7
I30
sg8
I1
sg9
I4
sg10
g11
sg12
VPNKD
p14540
sasg24
(lp14541
(dp14542
g7
I44
sg8
I1
sg9
I4
sg27
VC1865926
p14543
sg12
VICCA
p14544
sa(dp14545
g7
I36
sg8
I1
sg9
I3
sg27
VC1832894
p14546
sg12
VFHM
p14547
sasa(dp14548
g2
VThis family presented with the classic phenotype of PED and is not linked to the PNKD, FHM, or ICCA loci.
p14549
sg4
(lp14550
(dp14551
g7
I81
sg8
I1
sg9
I4
sg10
g11
sg12
VPNKD
p14552
sasg24
(lp14553
(dp14554
g7
I87
sg8
I1
sg9
I3
sg27
VC1832894
p14555
sg12
VFHM
p14556
sa(dp14557
g7
I95
sg8
I1
sg9
I4
sg27
VC1865926
p14558
sg12
VICCA
p14559
sasa(dp14560
g2
VThe (FZr-EUl/FZl-EUr) and (FZr-EUr)/(FZl-EUl) were used for the patients with unicoronal craniosynostosis.
p14561
sg4
(lp14562
sg24
(lp14563
(dp14564
g7
I78
sg8
I2
sg9
I27
sg27
VC0432124
p14565
sg12
Vunicoronal craniosynostosis
p14566
sasa(dp14567
g2
VOur findings indicated that all evaluated parameters (epididymal sperm profile, Johnsen score, Plzf, GfrAlfa-1, Scp-1, Tekt-1 expressions, and histopathological profile) were significantly decreased following testicular torsion (group 3) when compared to the control group (p &lt;= 0.05).
p14568
sg4
(lp14569
(dp14570
g7
I112
sg8
I1
sg9
I5
sg10
g11
sg12
VScp-1
p14571
sasg24
(lp14572
(dp14573
g7
I209
sg8
I2
sg9
I18
sg27
VC0037856
p14574
sg12
Vtesticular torsion
p14575
sasa(dp14576
g2
VDyschromatosis symmetrica hereditaria (DSH) is a rare type of pigmentary genodermatosis, which is autosomal dominantly inherited with high penetrance.
p14577
sg4
(lp14578
sg24
(lp14579
(dp14580
g7
I39
sg8
I1
sg9
I3
sg27
VC0406775
p14581
sg12
VDSH
p14582
sa(dp14583
g7
I73
sg8
I1
sg9
I14
sg27
VC0037277
p14584
sg12
Vgenodermatosis
p14585
sa(dp14586
g7
I0
sg8
I3
sg9
I37
sg27
VC0406775
p14587
sg12
VDyschromatosis symmetrica hereditaria
p14588
sasa(dp14589
g2
VThe onset of DSH is typically during infancy or childhood.
p14590
sg4
(lp14591
(dp14592
g7
I13
sg8
I1
sg9
I3
sg10
VP55265
p14593
sg12
VDSH
p14594
sasg24
(lp14595
(dp14596
g7
I13
sg8
I1
sg9
I3
sg27
VC0406775
p14597
sg12
VDSH
p14598
sasa(dp14599
g2
VAdditionally, there have been few significant non-cutaneous complications reported with DSH.
p14600
sg4
(lp14601
(dp14602
g7
I88
sg8
I1
sg9
I3
sg10
VP55265
p14603
sg12
VDSH
p14604
sasg24
(lp14605
(dp14606
g7
I88
sg8
I1
sg9
I3
sg27
VC0406775
p14607
sg12
VDSH
p14608
sasa(dp14609
g2
VThe present study reported two sporadic cases of patients born with DSH, confirmed by the identification of ADAR1 mutations.
p14610
sg4
(lp14611
(dp14612
g7
I68
sg8
I1
sg9
I3
sg10
VP55265
p14613
sg12
VDSH
p14614
sa(dp14615
g7
I108
sg8
I1
sg9
I5
sg10
VP55265
p14616
sg12
VADAR1
p14617
sasg24
(lp14618
(dp14619
g7
I68
sg8
I1
sg9
I3
sg27
VC0406775
p14620
sg12
VDSH
p14621
sasa(dp14622
g2
VAdditionally, comorbidity of DSH, congenital heart disease (CHD) and hemangioma disease were first reported.
p14623
sg4
(lp14624
(dp14625
g7
I29
sg8
I1
sg9
I3
sg10
VP55265
p14626
sg12
VDSH
p14627
sasg24
(lp14628
(dp14629
g7
I69
sg8
I1
sg9
I10
sg27
VC0018916
p14630
sg12
Vhemangioma
p14631
sa(dp14632
g7
I60
sg8
I1
sg9
I3
sg27
VC0152021
p14633
sg12
VCHD
p14634
sa(dp14635
g7
I34
sg8
I3
sg9
I24
sg27
VC0152021
p14636
sg12
Vcongenital heart disease
p14637
sa(dp14638
g7
I29
sg8
I1
sg9
I3
sg27
VC0406775
p14639
sg12
VDSH
p14640
sasa(dp14641
g2
VIn the patient with isolated DSH from birth, a nonsense mutation (p.Y1192X) was identified, whereas in the second patient with DSH, CHD and hemangioma from birth, a frameshift mutation (p.Glu673ValfsX652) in ADAR1 was identified.
p14642
sg4
(lp14643
(dp14644
g7
I208
sg8
I1
sg9
I5
sg10
VP55265
p14645
sg12
VADAR1
p14646
sa(dp14647
g7
I29
sg8
I1
sg9
I3
sg10
VP55265
p14648
sg12
VDSH
p14649
sasg24
(lp14650
(dp14651
g7
I47
sg8
I2
sg9
I17
sg27
VC0544885
p14652
sg12
Vnonsense mutation
p14653
sa(dp14654
g7
I140
sg8
I1
sg9
I10
sg27
VC0018916
p14655
sg12
Vhemangioma
p14656
sa(dp14657
g7
I29
sg8
I1
sg9
I3
sg27
VC0406775
p14658
sg12
VDSH
p14659
sa(dp14660
g7
I29
sg8
I1
sg9
I3
sg27
VC0406775
p14661
sg12
VDSH
p14662
sa(dp14663
g7
I165
sg8
I2
sg9
I19
sg27
VC0079380
p14664
sg12
Vframeshift mutation
p14665
sasa(dp14666
g2
VTo the best of the authors' knowledge, &gt;120 mutations in ADAR1 have been reported to cause DSH; however, no previous studies have reported mutations in ADAR1 in DSH at birth, with CHD and hemangioma.
p14667
sg4
(lp14668
(dp14669
g7
I60
sg8
I1
sg9
I5
sg10
VP55265
p14670
sg12
VADAR1
p14671
sa(dp14672
g7
I94
sg8
I1
sg9
I3
sg10
VP55265
p14673
sg12
VDSH
p14674
sa(dp14675
g7
I60
sg8
I1
sg9
I5
sg10
VP55265
p14676
sg12
VADAR1
p14677
sasg24
(lp14678
(dp14679
g7
I191
sg8
I1
sg9
I10
sg27
VC0018916
p14680
sg12
Vhemangioma
p14681
sa(dp14682
g7
I94
sg8
I1
sg9
I3
sg27
VC0406775
p14683
sg12
VDSH
p14684
sa(dp14685
g7
I94
sg8
I1
sg9
I3
sg27
VC0406775
p14686
sg12
VDSH
p14687
sasa(dp14688
g2
VThe novel variants described in the current study add to the current knowledge of ADAR1 mutations in DSH.
p14689
sg4
(lp14690
(dp14691
g7
I101
sg8
I1
sg9
I3
sg10
VP55265
p14692
sg12
VDSH
p14693
sa(dp14694
g7
I82
sg8
I1
sg9
I5
sg10
VP55265
p14695
sg12
VADAR1
p14696
sasg24
(lp14697
(dp14698
g7
I101
sg8
I1
sg9
I3
sg27
VC0406775
p14699
sg12
VDSH
p14700
sa(dp14701
g7
I50
sg8
I1
sg9
I3
sg27
VC0004269
p14702
sg12
Vadd
p14703
sasa(dp14704
g2
VPathogenic molecular variants in the ADAR gene are a known cause of rare diseases, autosomal recessive Aicardi- Goutieres syndrome type 6, severe infantile encephalopathy with intracranial calcifications and dominant dyschromatosis symmetrica hereditaria, demonstrated mainly in Asian adults.
p14705
sg4
(lp14706
(dp14707
g7
I37
sg8
I2
sg9
I9
sg10
VP55265
p14708
sg12
VADAR gene
p14709
sasg24
(lp14710
(dp14711
g7
I122
sg8
I1
sg9
I8
sg27
VC0039082
p14712
sg12
Vsyndrome
p14713
sa(dp14714
g7
I217
sg8
I3
sg9
I37
sg27
VC0406775
p14715
sg12
Vdyschromatosis symmetrica hereditaria
p14716
sa(dp14717
g7
I68
sg8
I2
sg9
I13
sg27
VC0678236
p14718
sg12
Vrare diseases
p14719
sa(dp14720
g7
I156
sg8
I1
sg9
I14
sg27
VC0085584
p14721
sg12
Vencephalopathy
p14722
sasa(dp14723
g2
VTo identify potential mutation of the ADAR1 gene in a Chinese family and a sporadic case affected with dyschromatosis symmetrica hereditaria(DSH).
p14724
sg4
(lp14725
(dp14726
g7
I38
sg8
I2
sg9
I10
sg10
VP55265
p14727
sg12
VADAR1 gene
p14728
sasg24
(lp14729
(dp14730
g7
I141
sg8
I1
sg9
I3
sg27
VC0406775
p14731
sg12
VDSH
p14732
sa(dp14733
g7
I103
sg8
I3
sg9
I37
sg27
VC0406775
p14734
sg12
Vdyschromatosis symmetrica hereditaria
p14735
sasa(dp14736
g2
VThe frame-shift mutation c.2638delG (p.Asp880ThrfsX15) and the nonsense mutation c.2867C&gt;A (p.Ser956X) in the ADAR1 gene probably underlie the DSH in our patients.
p14737
sg4
(lp14738
(dp14739
g7
I146
sg8
I1
sg9
I3
sg10
VP55265
p14740
sg12
VDSH
p14741
sa(dp14742
g7
I113
sg8
I2
sg9
I10
sg10
VP55265
p14743
sg12
VADAR1 gene
p14744
sasg24
(lp14745
(dp14746
g7
I146
sg8
I1
sg9
I3
sg27
VC0406775
p14747
sg12
VDSH
p14748
sa(dp14749
g7
I63
sg8
I2
sg9
I17
sg27
VC0544885
p14750
sg12
Vnonsense mutation
p14751
sasa(dp14752
g2
VDyschromatosis symmetrica hereditaria (DSH) is a rare autosomal dominant cutaneous disorder caused by the mutations of adenosine deaminase acting on RNA1 (ADAR1) gene.
p14753
sg4
(lp14754
(dp14755
g7
I155
sg8
I1
sg9
I5
sg10
VP55265
p14756
sg12
VADAR1
p14757
sa(dp14758
g7
I119
sg8
I5
sg9
I34
sg10
VP55265
p14759
sg12
Vadenosine deaminase acting on RNA1
p14760
sasg24
(lp14761
(dp14762
g7
I39
sg8
I1
sg9
I3
sg27
VC0406775
p14763
sg12
VDSH
p14764
sa(dp14765
g7
I73
sg8
I2
sg9
I18
sg27
VC0037274
p14766
sg12
Vcutaneous disorder
p14767
sa(dp14768
g7
I0
sg8
I3
sg9
I37
sg27
VC0406775
p14769
sg12
VDyschromatosis symmetrica hereditaria
p14770
sasa(dp14771
g2
VWe present a clinical and genetic study of seven unrelated families and two sporadic cases with DSH for mutations in the full coding sequence of ADAR1 gene.
p14772
sg4
(lp14773
(dp14774
g7
I96
sg8
I1
sg9
I3
sg10
VP55265
p14775
sg12
VDSH
p14776
sa(dp14777
g7
I145
sg8
I2
sg9
I10
sg10
VP55265
p14778
sg12
VADAR1 gene
p14779
sasg24
(lp14780
(dp14781
g7
I96
sg8
I1
sg9
I3
sg27
VC0406775
p14782
sg12
VDSH
p14783
sasa(dp14784
g2
VADAR1 gene was sequenced in seven unrelated families and two sporadic cases with DSH and 120 controls.
p14785
sg4
(lp14786
(dp14787
g7
I0
sg8
I2
sg9
I10
sg10
VP55265
p14788
sg12
VADAR1 gene
p14789
sasg24
(lp14790
(dp14791
g7
I81
sg8
I1
sg9
I3
sg27
VC0406775
p14792
sg12
VDSH
p14793
sasa(dp14794
g2
VWe describe six novel mutations of the ADAR1 gene in Chinese patients with DSH including a nonstop mutation p.Stop1227R, which was firstly reported in ADAR1 gene.
p14795
sg4
(lp14796
(dp14797
g7
I39
sg8
I2
sg9
I10
sg10
VP55265
p14798
sg12
VADAR1 gene
p14799
sa(dp14800
g7
I39
sg8
I2
sg9
I10
sg10
VP55265
p14801
sg12
VADAR1 gene
p14802
sasg24
(lp14803
(dp14804
g7
I75
sg8
I1
sg9
I3
sg27
VC0406775
p14805
sg12
VDSH
p14806
sasa(dp14807
g2
VA three-generation family exhibiting phenotypic variability with a single germline ADAR1 mutation suggests that chilblain might aggravate the clinical phenotypes of DSH.
p14808
sg4
(lp14809
(dp14810
g7
I165
sg8
I1
sg9
I3
sg10
VP55265
p14811
sg12
VDSH
p14812
sa(dp14813
g7
I83
sg8
I1
sg9
I5
sg10
VP55265
p14814
sg12
VADAR1
p14815
sasg24
(lp14816
(dp14817
g7
I165
sg8
I1
sg9
I3
sg27
VC0406775
p14818
sg12
VDSH
p14819
sa(dp14820
g7
I112
sg8
I1
sg9
I9
sg27
VC0008058
p14821
sg12
Vchilblain
p14822
sasa(dp14823
g2
VAll patients underwent upper endoscopy and subsequently liver CT. Three radiologists independently evaluated the presence of high-risk esophageal varices with transverse images alone and with three orthogonal multiplanar reformation (MPR) images, respectively.
p14824
sg4
(lp14825
sg24
(lp14826
(dp14827
g7
I135
sg8
I2
sg9
I18
sg27
VC0014867
p14828
sg12
Vesophageal varices
p14829
sasa(dp14830
g2
VTo study the correlation between changes in portosystemic collaterals, evaluated by multidetector-row computed tomography imaging using multiplanar reconstruction (MDCT-MPR), and prognosis in patients with hemorrhagic esophageal varices (EV) after endoscopic treatment.
p14831
sg4
(lp14832
(dp14833
g7
I164
sg8
I1
sg9
I8
sg10
g11
sg12
VMDCT-MPR
p14834
sa(dp14835
g7
I84
sg8
I7
sg9
I78
sg10
g11
sg12
Vmultidetector-row computed tomography imaging using multiplanar reconstruction
p14836
sasg24
(lp14837
(dp14838
g7
I238
sg8
I1
sg9
I2
sg27
VC0014867
p14839
sg12
VEV
p14840
sa(dp14841
g7
I218
sg8
I2
sg9
I18
sg27
VC0014867
p14842
sg12
Vesophageal varices
p14843
sasa(dp14844
g2
VThe purpose of our study was to assess the relationship between hemodynamic changes in portosystemic collaterals and the prognosis of patients with esophageal varices after endoscopic injection sclerotherapy using multiplanar reconstruction (MPR) MDCT images.
p14845
sg4
(lp14846
sg24
(lp14847
(dp14848
g7
I148
sg8
I2
sg9
I18
sg27
VC0014867
p14849
sg12
Vesophageal varices
p14850
sasa(dp14851
g2
VMPR MDCT images on portosystemic collaterals can accurately predict relapse of esophageal varices after endoscopic injection sclerotherapy.
p14852
sg4
(lp14853
sg24
(lp14854
(dp14855
g7
I68
sg8
I1
sg9
I7
sg27
VC0277556
p14856
sg12
Vrelapse
p14857
sa(dp14858
g7
I79
sg8
I2
sg9
I18
sg27
VC0014867
p14859
sg12
Vesophageal varices
p14860
sasa(dp14861
g2
VTTD is caused by mutations in DNA repair/transcription genes XPD, XPB or TTDA, and in TTDN1, a gene of unknown function.
p14862
sg4
(lp14863
(dp14864
g7
I66
sg8
I1
sg9
I3
sg10
VP19447
p14865
sg12
VXPB
p14866
sa(dp14867
g7
I61
sg8
I1
sg9
I3
sg10
VP18074
p14868
sg12
VXPD
p14869
sa(dp14870
g7
I73
sg8
I1
sg9
I4
sg10
g11
sg12
VTTDA
p14871
sa(dp14872
g7
I86
sg8
I1
sg9
I5
sg10
g11
sg12
VTTDN1
p14873
sasg24
(lp14874
(dp14875
g7
I66
sg8
I1
sg9
I3
sg27
VC0268136
p14876
sg12
VXPB
p14877
sa(dp14878
g7
I61
sg8
I1
sg9
I3
sg27
VC0268138
p14879
sg12
VXPD
p14880
sa(dp14881
g7
I86
sg8
I1
sg9
I5
sg27
VC1961117
p14882
sg12
VTTDN1
p14883
sasa(dp14884
g2
VTo date, four genes have been identified as responsible for TTD: XPD, XPB, p8/TTDA, and TTDN1.
p14885
sg4
(lp14886
(dp14887
g7
I65
sg8
I1
sg9
I3
sg10
VP18074
p14888
sg12
VXPD
p14889
sa(dp14890
g7
I70
sg8
I1
sg9
I3
sg10
VP19447
p14891
sg12
VXPB
p14892
sa(dp14893
g7
I88
sg8
I1
sg9
I5
sg10
g11
sg12
VTTDN1
p14894
sa(dp14895
g7
I78
sg8
I1
sg9
I4
sg10
g11
sg12
VTTDA
p14896
sasg24
(lp14897
(dp14898
g7
I65
sg8
I1
sg9
I3
sg27
VC0268138
p14899
sg12
VXPD
p14900
sa(dp14901
g7
I70
sg8
I1
sg9
I3
sg27
VC0268136
p14902
sg12
VXPB
p14903
sa(dp14904
g7
I88
sg8
I1
sg9
I5
sg27
VC1961117
p14905
sg12
VTTDN1
p14906
sasa(dp14907
g2
VWe analysed the gene expression and protein distribution of different members of the Hsp27, Hsp70, and Hsp90 families in the central nervous system of sheep naturally infected with scrapie.
p14908
sg4
(lp14909
(dp14910
g7
I92
sg8
I1
sg9
I5
sg10
VP34932
p14911
sg12
VHsp70
p14912
sa(dp14913
g7
I103
sg8
I2
sg9
I14
sg10
VP19883
p14914
sg12
VHsp90 families
p14915
sa(dp14916
g7
I85
sg8
I1
sg9
I5
sg10
g11
sg12
VHsp27
p14917
sasg24
(lp14918
(dp14919
g7
I181
sg8
I1
sg9
I7
sg27
VC0036457
p14920
sg12
Vscrapie
p14921
sa(dp14922
g7
I133
sg8
I1
sg9
I7
sg27
VC0027769
p14923
sg12
Vnervous
p14924
sasa(dp14925
g2
VWe have previously shown that scrapie-infected mouse neuroblastoma (ScN2a) cells fail to induce the expression of Hsp72 and Hsp28 after various stress conditions.
p14926
sg4
(lp14927
(dp14928
g7
I114
sg8
I1
sg9
I5
sg10
VP08107
p14929
sg12
VHsp72
p14930
sasg24
(lp14931
(dp14932
g7
I30
sg8
I1
sg9
I7
sg27
VC0036457
p14933
sg12
Vscrapie
p14934
sa(dp14935
g7
I47
sg8
I2
sg9
I19
sg27
VC1524043
p14936
sg12
Vmouse neuroblastoma
p14937
sasa(dp14938
g2
VIn scrapie-infected N2a (ScN2a) cells, Hsp72 and Hsp28 were not induced by heat shock, sodium arsenite, or an amino acid analog, in contrast to uninfected control N2a cells, while other inducible Hsps were increased by these treatments.
p14939
sg4
(lp14940
(dp14941
g7
I39
sg8
I1
sg9
I5
sg10
VP08107
p14942
sg12
VHsp72
p14943
sa(dp14944
g7
I196
sg8
I1
sg9
I4
sg10
VP08107
p14945
sg12
VHsps
p14946
sa(dp14947
g7
I25
sg8
I1
sg9
I5
sg10
g11
sg12
VScN2a
p14948
sa(dp14949
g7
I3
sg8
I2
sg9
I20
sg10
g11
sg12
Vscrapie-infected N2a
p14950
sasg24
(lp14951
(dp14952
g7
I3
sg8
I1
sg9
I7
sg27
VC0036457
p14953
sg12
Vscrapie
p14954
sasa(dp14955
g2
VWe have identified Receptor-interacting serine/threonine protein kinase 4 (RIP4) as a regulator of tumor differentiation in lung adenocarcinoma (AC).
p14956
sg4
(lp14957
(dp14958
g7
I75
sg8
I1
sg9
I4
sg10
VP57078
p14959
sg12
VRIP4
p14960
sa(dp14961
g7
I19
sg8
I5
sg9
I54
sg10
g11
sg12
VReceptor-interacting serine/threonine protein kinase 4
p14962
sasg24
(lp14963
(dp14964
g7
I99
sg8
I1
sg9
I5
sg27
VC0027651
p14965
sg12
Vtumor
p14966
sa(dp14967
g7
I124
sg8
I2
sg9
I19
sg27
VC0152013
p14968
sg12
Vlung adenocarcinoma
p14969
sasa(dp14970
g2
VAltogether, our work has identified that loss of RIP4 enhances STAT3 signaling in lung cancer cells, promoting the expression of ECM remodeling genes and cancer dedifferentiation.
p14971
sg4
(lp14972
(dp14973
g7
I129
sg8
I3
sg9
I20
sg10
g11
sg12
VECM remodeling genes
p14974
sa(dp14975
g7
I63
sg8
I1
sg9
I5
sg10
VP40763
p14976
sg12
VSTAT3
p14977
sa(dp14978
g7
I49
sg8
I1
sg9
I4
sg10
VP57078
p14979
sg12
VRIP4
p14980
sasg24
(lp14981
(dp14982
g7
I82
sg8
I2
sg9
I11
sg27
VC0684249
p14983
sg12
Vlung cancer
p14984
sa(dp14985
g7
I87
sg8
I1
sg9
I6
sg27
VC0006826
p14986
sg12
Vcancer
p14987
sa(dp14988
g7
I161
sg8
I1
sg9
I17
sg27
VC0002793
p14989
sg12
Vdedifferentiation
p14990
sasa(dp14991
g2
VIn conclusion, our data suggest that RIPK4/EZH2 markers might be used as potential predictors of prognosis in cervical cancer.
p14992
sg4
(lp14993
(dp14994
g7
I43
sg8
I1
sg9
I4
sg10
g11
sg12
VEZH2
p14995
sa(dp14996
g7
I37
sg8
I1
sg9
I5
sg10
VP57078
p14997
sg12
VRIPK4
p14998
sasg24
(lp14999
(dp15000
g7
I110
sg8
I2
sg9
I15
sg27
VC0302592
p15001
sg12
Vcervical cancer
p15002
sasa(dp15003
g2
VTo investigate the association between receptor-interacting kinase protein 4 (RIPK4) relative copy number (RCN) and prognosis of stage III( colorectal cancer (CRC) patients treated with oxaliplatin-based chemotherapy.
p15004
sg4
(lp15005
(dp15006
g7
I78
sg8
I1
sg9
I5
sg10
VP57078
p15007
sg12
VRIPK4
p15008
sa(dp15009
g7
I39
sg8
I4
sg9
I37
sg10
g11
sg12
Vreceptor-interacting kinase protein 4
p15010
sasg24
(lp15011
(dp15012
g7
I140
sg8
I2
sg9
I17
sg27
VC1527249
p15013
sg12
Vcolorectal cancer
p15014
sa(dp15015
g7
I159
sg8
I1
sg9
I3
sg27
VC1527249
p15016
sg12
VCRC
p15017
sasa(dp15018
g2
VIn colon cancer subgroup, high RIPK4 RCN was significantly associated with poor OS (median OS, 31.5 months vs. 56.6 months, P=0.015) but not with RFS (P=0.135).
p15019
sg4
(lp15020
(dp15021
g7
I31
sg8
I2
sg9
I9
sg10
VP57078
p15022
sg12
VRIPK4 RCN
p15023
sasg24
(lp15024
(dp15025
g7
I3
sg8
I2
sg9
I12
sg27
VC0699790
p15026
sg12
Vcolon cancer
p15027
sa(dp15028
g7
I146
sg8
I1
sg9
I3
sg27
VC0015624
p15029
sg12
VRFS
p15030
sasa(dp15031
g2
VIn rectal cancer subgroup, RIPK4 RCN was not associated with both OS and RFS (P=0.981, P=0.738).
p15032
sg4
(lp15033
(dp15034
g7
I27
sg8
I2
sg9
I9
sg10
VP57078
p15035
sg12
VRIPK4 RCN
p15036
sasg24
(lp15037
(dp15038
g7
I3
sg8
I2
sg9
I13
sg27
VC0007113
p15039
sg12
Vrectal cancer
p15040
sa(dp15041
g7
I73
sg8
I1
sg9
I3
sg27
VC0015624
p15042
sg12
VRFS
p15043
sasa(dp15044
g2
VRIPK4 RCN is significantly associated with OS in stage III( colon cancer patients receiving oxaliplatin-based chemotherapy and may be a novel biomarker that can predict the efficacy of oxaliplatin in colon cancer patients.
p15045
sg4
(lp15046
(dp15047
g7
I0
sg8
I2
sg9
I9
sg10
VP57078
p15048
sg12
VRIPK4 RCN
p15049
sasg24
(lp15050
(dp15051
g7
I60
sg8
I2
sg9
I12
sg27
VC0699790
p15052
sg12
Vcolon cancer
p15053
sa(dp15054
g7
I60
sg8
I2
sg9
I12
sg27
VC0699790
p15055
sg12
Vcolon cancer
p15056
sasa(dp15057
g2
VAberrant expression of receptor interacting protein kinase 4 (RIPK4), a crucial regulatory protein of Wnt/Beta-catenin signaling, has recently been reported to be involved in several cancers.
p15058
sg4
(lp15059
(dp15060
g7
I62
sg8
I1
sg9
I5
sg10
VP57078
p15061
sg12
VRIPK4
p15062
sa(dp15063
g7
I23
sg8
I5
sg9
I37
sg10
g11
sg12
Vreceptor interacting protein kinase 4
p15064
sasg24
(lp15065
(dp15066
g7
I183
sg8
I1
sg9
I7
sg27
VC0006826
p15067
sg12
Vcancers
p15068
sasa(dp15069
g2
VHere, we report the potential clinical implication and biological functions of RIPK4 in cervical squamous cell carcinoma (CSCC).
p15070
sg4
(lp15071
(dp15072
g7
I79
sg8
I1
sg9
I5
sg10
VP57078
p15073
sg12
VRIPK4
p15074
sasg24
(lp15075
(dp15076
g7
I122
sg8
I1
sg9
I4
sg27
VC0279671
p15077
sg12
VCSCC
p15078
sa(dp15079
g7
I88
sg8
I4
sg9
I32
sg27
VC0279671
p15080
sg12
Vcervical squamous cell carcinoma
p15081
sasa(dp15082
g2
VRIPK4 expression increased significantly with disease progression from 3.2% in chronic cervicitis, 19.3% in LSILs and 85.1% in HSILs to 94.4% in CSCCs (P &lt; 0.001).
p15083
sg4
(lp15084
(dp15085
g7
I0
sg8
I1
sg9
I5
sg10
VP57078
p15086
sg12
VRIPK4
p15087
sasg24
(lp15088
(dp15089
g7
I79
sg8
I2
sg9
I18
sg27
VC0269062
p15090
sg12
Vchronic cervicitis
p15091
sa(dp15092
g7
I46
sg8
I2
sg9
I19
sg27
VC0242656
p15093
sg12
Vdisease progression
p15094
sasa(dp15095
g2
VKnockdown of RIPK4 reduced cell migration and invasion via inhibition of Vimentin, MMP2 and Fibronectin expression in cervical cancer cells.
p15096
sg4
(lp15097
(dp15098
g7
I83
sg8
I1
sg9
I4
sg10
VP08253
p15099
sg12
VMMP2
p15100
sa(dp15101
g7
I13
sg8
I1
sg9
I5
sg10
VP57078
p15102
sg12
VRIPK4
p15103
sasg24
(lp15104
(dp15105
g7
I118
sg8
I2
sg9
I15
sg27
VC0302592
p15106
sg12
Vcervical cancer
p15107
sa(dp15108
g7
I46
sg8
I1
sg9
I8
sg27
VC2699153
p15109
sg12
Vinvasion
p15110
sasa(dp15111
g2
VRIPK4 might act as a potential diagnostic and independent prognostic biomarker for CSCC patients.
p15112
sg4
(lp15113
(dp15114
g7
I0
sg8
I1
sg9
I5
sg10
VP57078
p15115
sg12
VRIPK4
p15116
sasg24
(lp15117
sa(dp15118
g2
VWe previously showed that protein kinase C-associated kinase (PKK, also known as DIK/RIP4), which belongs to the receptor-interacting protein (RIP) kinase family, mediates the B cell activating factor of the TNF family (BAFF)-induced NF-KB activation in diffuse large B cell lymphoma (DLBCL) cell lines.
p15119
sg4
(lp15120
(dp15121
g7
I113
sg8
I2
sg9
I28
sg10
g11
sg12
Vreceptor-interacting protein
p15122
sa(dp15123
g7
I26
sg8
I4
sg9
I34
sg10
VP17252
p15124
sg12
Vprotein kinase C-associated kinase
p15125
sa(dp15126
g7
I176
sg8
I8
sg9
I42
sg10
g11
sg12
VB cell activating factor of the TNF family
p15127
sa(dp15128
g7
I85
sg8
I1
sg9
I3
sg10
VP52594
p15129
sg12
VRIP
p15130
sa(dp15131
g7
I81
sg8
I1
sg9
I3
sg10
VP57078
p15132
sg12
VDIK
p15133
sa(dp15134
g7
I62
sg8
I1
sg9
I3
sg10
VP57078
p15135
sg12
VPKK
p15136
sa(dp15137
g7
I85
sg8
I1
sg9
I4
sg10
VP57078
p15138
sg12
VRIP4
p15139
sa(dp15140
g7
I220
sg8
I1
sg9
I4
sg10
g11
sg12
VBAFF
p15141
sasg24
(lp15142
(dp15143
g7
I285
sg8
I1
sg9
I5
sg27
VC0079744
p15144
sg12
VDLBCL
p15145
sa(dp15146
g7
I254
sg8
I5
sg9
I29
sg27
VC0079744
p15147
sg12
Vdiffuse large B cell lymphoma
p15148
sasa(dp15149
g2
VSuppression of PKK expression by RNA interference inhibits phosphorylation of IKKAlfa and IKKBeta as well as activation of NF-KB in human cancer cell lines.
p15150
sg4
(lp15151
(dp15152
g7
I90
sg8
I1
sg9
I7
sg10
g11
sg12
VIKKBeta
p15153
sa(dp15154
g7
I15
sg8
I1
sg9
I3
sg10
VP57078
p15155
sg12
VPKK
p15156
sasg24
(lp15157
(dp15158
g7
I0
sg8
I1
sg9
I11
sg27
VC0221103
p15159
sg12
VSuppression
p15160
sa(dp15161
g7
I138
sg8
I1
sg9
I6
sg27
VC0006826
p15162
sg12
Vcancer
p15163
sasa(dp15164
g2
VWe propose that PKK may provide a critical link between IKK activation and various upstream signaling cascades, and may represent a potential target for inhibiting abnormal NF-KB activation in human cancers.
p15165
sg4
(lp15166
(dp15167
g7
I16
sg8
I1
sg9
I3
sg10
VP57078
p15168
sg12
VPKK
p15169
sa(dp15170
g7
I56
sg8
I1
sg9
I3
sg10
g11
sg12
VIKK
p15171
sasg24
(lp15172
(dp15173
g7
I199
sg8
I1
sg9
I7
sg27
VC0006826
p15174
sg12
Vcancers
p15175
sasa(dp15176
g2
VTo assess RIPK4 expression in various differentiated TSCC and to determine its basic biological function.
p15177
sg4
(lp15178
(dp15179
g7
I10
sg8
I1
sg9
I5
sg10
VP57078
p15180
sg12
VRIPK4
p15181
sasg24
(lp15182
sa(dp15183
g2
VA significantly higher level of RIPK4 was found in well-differentiated TSCC samples than in the poorly differentiated ones (p&lt;0.01).
p15184
sg4
(lp15185
(dp15186
g7
I32
sg8
I1
sg9
I5
sg10
VP57078
p15187
sg12
VRIPK4
p15188
sasg24
(lp15189
sa(dp15190
g2
VIn the present work we found a correlation between RIPK4 expression and TSCC degree of differentiation, age, and gender.
p15191
sg4
(lp15192
(dp15193
g7
I51
sg8
I1
sg9
I5
sg10
VP57078
p15194
sg12
VRIPK4
p15195
sasg24
(lp15196
sa(dp15197
g2
VThe better understanding of the molecular mechanism of RIPK4 in TSCC may provide a promising biomarker for tongue cancer prognosis and treatment.
p15198
sg4
(lp15199
(dp15200
g7
I55
sg8
I1
sg9
I5
sg10
VP57078
p15201
sg12
VRIPK4
p15202
sasg24
(lp15203
(dp15204
g7
I107
sg8
I2
sg9
I13
sg27
VC0558353
p15205
sg12
Vtongue cancer
p15206
sasa(dp15207
g2
VInterestingly, maladaptive ECM remodeling was observed in early AVM without AVD and worsened with late AVD, as evidenced by increased MMP-2 and MMP-9 expression and activity, as well as abnormalities in ADAMTS-mediated versican processing.
p15208
sg4
(lp15209
(dp15210
g7
I144
sg8
I1
sg9
I5
sg10
VP14780
p15211
sg12
VMMP-9
p15212
sa(dp15213
g7
I134
sg8
I1
sg9
I5
sg10
VP08253
p15214
sg12
VMMP-2
p15215
sasg24
(lp15216
(dp15217
g7
I64
sg8
I1
sg9
I3
sg27
VC0003857
p15218
sg12
VAVM
p15219
sasa(dp15220
g2
VIn patients with aortic stenosis or the hemolytic-uremic syndrome, abnormally high levels of shear stress across the stenotic valve or in the microcirculation inflicted with thrombosis may promote cleavage of vWF by ADAMTS13, contributing to the loss of large multimers commonly observed among these patients.
p15221
sg4
(lp15222
(dp15223
g7
I209
sg8
I1
sg9
I3
sg10
VP04275
p15224
sg12
VvWF
p15225
sa(dp15226
g7
I216
sg8
I1
sg9
I8
sg10
g11
sg12
VADAMTS13
p15227
sasg24
(lp15228
(dp15229
g7
I174
sg8
I1
sg9
I10
sg27
VC0040053
p15230
sg12
Vthrombosis
p15231
sa(dp15232
g7
I40
sg8
I2
sg9
I25
sg27
VC0019061
p15233
sg12
Vhemolytic-uremic syndrome
p15234
sa(dp15235
g7
I17
sg8
I2
sg9
I15
sg27
VC0003507
p15236
sg12
Vaortic stenosis
p15237
sasa(dp15238
g2
VThe gene and protein expression profiles and protein distribution of six potential genetic biomarkers (i.e., CAPN6, COL1A2, COL3A1, GALA1, MT2A and MTNR1B) are presented here for both the early and terminal stages of scrapie in five different brain regions.
p15239
sg4
(lp15240
(dp15241
g7
I109
sg8
I1
sg9
I5
sg10
g11
sg12
VCAPN6
p15242
sa(dp15243
g7
I139
sg8
I1
sg9
I4
sg10
VP02795
p15244
sg12
VMT2A
p15245
sa(dp15246
g7
I148
sg8
I1
sg9
I6
sg10
VP49286
p15247
sg12
VMTNR1B
p15248
sasg24
(lp15249
(dp15250
g7
I217
sg8
I1
sg9
I7
sg27
VC0036457
p15251
sg12
Vscrapie
p15252
sasa(dp15253
g2
VThe distribution of the GALA1 was identified in glial cells from the cerebellum of scrapie-infected animals, GALA1 protein expression was increased in clinical animals in the majority of regions, and the increase of MT2A was in agreement with previous reports.
p15254
sg4
(lp15255
(dp15256
g7
I216
sg8
I1
sg9
I4
sg10
VP02795
p15257
sg12
VMT2A
p15258
sasg24
(lp15259
(dp15260
g7
I83
sg8
I1
sg9
I7
sg27
VC0036457
p15261
sg12
Vscrapie
p15262
sasa(dp15263
g2
VIn conclusion, this study of gene transcription and protein expression and distribution confirm CAPN6, GALA1, MTNR1B and MT2A as potential targets for further prion disease research.
p15264
sg4
(lp15265
(dp15266
g7
I110
sg8
I1
sg9
I6
sg10
VP49286
p15267
sg12
VMTNR1B
p15268
sa(dp15269
g7
I96
sg8
I1
sg9
I5
sg10
g11
sg12
VCAPN6
p15270
sa(dp15271
g7
I121
sg8
I1
sg9
I4
sg10
VP02795
p15272
sg12
VMT2A
p15273
sasg24
(lp15274
(dp15275
g7
I159
sg8
I2
sg9
I13
sg27
VC0162534
p15276
sg12
Vprion disease
p15277
sasa(dp15278
g2
VLincRNA-p21 could lead to pulmonary fibrosis in ARDS by inhibition of the expression of Thy-1.
p15279
sg4
(lp15280
(dp15281
g7
I88
sg8
I1
sg9
I5
sg10
VP04216
p15282
sg12
VThy-1
p15283
sa(dp15284
g7
I8
sg8
I1
sg9
I3
sg10
VP42857
p15285
sg12
Vp21
p15286
sasg24
(lp15287
(dp15288
g7
I26
sg8
I2
sg9
I18
sg27
VC0034069
p15289
sg12
Vpulmonary fibrosis
p15290
sa(dp15291
g7
I48
sg8
I1
sg9
I4
sg27
VC0035222
p15292
sg12
VARDS
p15293
sasa(dp15294
g2
VLPS-induced pulmonary fibrosis was related with activation of HDAC, deacetylation of histone H3 and H4 and Thy-1 gene silencing.
p15295
sg4
(lp15296
(dp15297
g7
I107
sg8
I2
sg9
I10
sg10
VP04216
p15298
sg12
VThy-1 gene
p15299
sa(dp15300
g7
I85
sg8
I2
sg9
I10
sg10
g11
sg12
Vhistone H3
p15301
sa(dp15302
g7
I62
sg8
I1
sg9
I4
sg10
VP56524
p15303
sg12
VHDAC
p15304
sasg24
(lp15305
(dp15306
g7
I12
sg8
I2
sg9
I18
sg27
VC0034069
p15307
sg12
Vpulmonary fibrosis
p15308
sa(dp15309
g7
I0
sg8
I1
sg9
I3
sg27
VC0175697
p15310
sg12
VLPS
p15311
sasa(dp15312
g2
VHDAC inhibitor BA could inhibit LPS-induced pulmonary fibrosis and Thy-1 gene silencing through inhibiting activation of HDAC and deacetylation of histone H4.
p15313
sg4
(lp15314
(dp15315
g7
I0
sg8
I1
sg9
I4
sg10
VP56524
p15316
sg12
VHDAC
p15317
sa(dp15318
g7
I147
sg8
I2
sg9
I10
sg10
VP62805
p15319
sg12
Vhistone H4
p15320
sa(dp15321
g7
I0
sg8
I1
sg9
I4
sg10
VP56524
p15322
sg12
VHDAC
p15323
sasg24
(lp15324
(dp15325
g7
I44
sg8
I2
sg9
I18
sg27
VC0034069
p15326
sg12
Vpulmonary fibrosis
p15327
sa(dp15328
g7
I32
sg8
I1
sg9
I3
sg27
VC0175697
p15329
sg12
VLPS
p15330
sasa(dp15331
g2
VSSc patients with pulmonary fibrosis (P = 0.006) and patients with PAH (P &lt; 0.001) had increased sCD90 serum concentrations compared to patients without the respective pulmonary manifestation of SSc.
p15332
sg4
(lp15333
sg24
(lp15334
(dp15335
g7
I18
sg8
I2
sg9
I18
sg27
VC0034069
p15336
sg12
Vpulmonary fibrosis
p15337
sa(dp15338
g7
I67
sg8
I1
sg9
I3
sg27
VC0152171
p15339
sg12
VPAH
p15340
sasa(dp15341
g2
VOsteoporosis pseudoglioma syndrome (OPPGS) is a rare autosomal recessive genetic disorder characterised by congenital blindness and osteoporosis, caused by biallelic mutations in the LRP5 gene.
p15342
sg4
(lp15343
(dp15344
g7
I183
sg8
I2
sg9
I9
sg10
g11
sg12
VLRP5 gene
p15345
sasg24
(lp15346
(dp15347
g7
I73
sg8
I2
sg9
I16
sg27
VC0019247
p15348
sg12
Vgenetic disorder
p15349
sa(dp15350
g7
I107
sg8
I2
sg9
I20
sg27
VC0005754
p15351
sg12
Vcongenital blindness
p15352
sa(dp15353
g7
I26
sg8
I1
sg9
I8
sg27
VC0039082
p15354
sg12
Vsyndrome
p15355
sa(dp15356
g7
I132
sg8
I1
sg9
I12
sg27
VC0029456
p15357
sg12
Vosteoporosis
p15358
sa(dp15359
g7
I0
sg8
I2
sg9
I25
sg27
VC0432252
p15360
sg12
VOsteoporosis pseudoglioma
p15361
sasa(dp15362
g2
VMolecular genetic examination detected the LRP5 gene for FEVR.
p15363
sg4
(lp15364
(dp15365
g7
I43
sg8
I2
sg9
I9
sg10
g11
sg12
VLRP5 gene
p15366
sasg24
(lp15367
sa(dp15368
g2
VThe majority of mutations identified in FEVR are found within four genes that encode the receptor complex (FZD4, LRP5, and TSPAN12) and ligand (NDP) of a molecular pathway that controls angiogenesis, the Norrin-Beta-catenin signaling pathway.
p15369
sg4
(lp15370
(dp15371
g7
I211
sg8
I1
sg9
I12
sg10
VP35222
p15372
sg12
VBeta-catenin
p15373
sa(dp15374
g7
I107
sg8
I1
sg9
I4
sg10
g11
sg12
VFZD4
p15375
sa(dp15376
g7
I113
sg8
I1
sg9
I4
sg10
g11
sg12
VLRP5
p15377
sa(dp15378
g7
I123
sg8
I1
sg9
I7
sg10
g11
sg12
VTSPAN12
p15379
sa(dp15380
g7
I204
sg8
I1
sg9
I6
sg10
g11
sg12
VNorrin
p15381
sa(dp15382
g7
I40
sg8
I1
sg9
I4
sg10
g11
sg12
VFEVR
p15383
sasg24
(lp15384
sa(dp15385
g2
VPrimers were designed to amplify the coding exons and adjacent intronic regions of the FEVR-causing genes FZD4, LRP5, NDP and TSPAN12.
p15386
sg4
(lp15387
(dp15388
g7
I112
sg8
I1
sg9
I4
sg10
g11
sg12
VLRP5
p15389
sa(dp15390
g7
I126
sg8
I1
sg9
I7
sg10
g11
sg12
VTSPAN12
p15391
sa(dp15392
g7
I106
sg8
I1
sg9
I4
sg10
g11
sg12
VFZD4
p15393
sa(dp15394
g7
I118
sg8
I1
sg9
I3
sg10
g11
sg12
VNDP
p15395
sasg24
(lp15396
sa(dp15397
g2
VWe identified five LRP5 mutations: three novel heterozygous mutations-p.M181R, p.R399S and p.G503R and two known mutations that were never reported in FEVR patients: p.R494Q and p.G876S.
p15398
sg4
(lp15399
(dp15400
g7
I19
sg8
I2
sg9
I14
sg10
g11
sg12
VLRP5 mutations
p15401
sasg24
(lp15402
sa(dp15403
g2
VSurprisingly, we then found mutations in familial exudative vitreoretinopathy (FEVR) genes; low-density lipoprotein receptor-related protein 5 mutations (six families), tetraspanin 12 mutations (two families), and NDP mutations (two families).
p15404
sg4
(lp15405
(dp15406
g7
I214
sg8
I2
sg9
I13
sg10
g11
sg12
VNDP mutations
p15407
sa(dp15408
g7
I92
sg8
I6
sg9
I60
sg10
g11
sg12
Vlow-density lipoprotein receptor-related protein 5 mutations
p15409
sa(dp15410
g7
I169
sg8
I2
sg9
I14
sg10
g11
sg12
Vtetraspanin 12
p15411
sasg24
(lp15412
(dp15413
g7
I79
sg8
I1
sg9
I4
sg27
VC0339539
p15414
sg12
VFEVR
p15415
sa(dp15416
g7
I41
sg8
I3
sg9
I36
sg27
VC0339539
p15417
sg12
Vfamilial exudative vitreoretinopathy
p15418
sasa(dp15419
g2
VTherefore, this study aimed to determine the role of the Mdm2 SNIP 309 polymorphism in the gastric mucosal morphological patterns in patients with Helicobacter pylori associated gastritis.
p15420
sg4
(lp15421
(dp15422
g7
I57
sg8
I2
sg9
I9
sg10
g11
sg12
VMdm2 SNIP
p15423
sasg24
(lp15424
(dp15425
g7
I178
sg8
I1
sg9
I9
sg27
VC0017152
p15426
sg12
Vgastritis
p15427
sasa(dp15428
g2
VTherefore, this study aimed to determine the correlation between the patterns of Mdm2 SNIP 309 and the inflammation grading of Helicobacter pylori associated gastritis in a Thai population.
p15429
sg4
(lp15430
(dp15431
g7
I81
sg8
I3
sg9
I13
sg10
g11
sg12
VMdm2 SNIP 309
p15432
sasg24
(lp15433
(dp15434
g7
I158
sg8
I1
sg9
I9
sg27
VC0017152
p15435
sg12
Vgastritis
p15436
sa(dp15437
g7
I103
sg8
I1
sg9
I12
sg27
VC0021368
p15438
sg12
Vinflammation
p15439
sasa(dp15440
g2
VGastric mucosa from 100 patients with Helicobacter pylori associated gastritis was analyzed for MDM2 SNP309 using real-time PCR hybridization (light-cycler) probes.
p15441
sg4
(lp15442
sg24
(lp15443
(dp15444
g7
I69
sg8
I1
sg9
I9
sg27
VC0017152
p15445
sg12
Vgastritis
p15446
sasa(dp15447
g2
VWhile planning genomics, we describe that 11 well-known type 2 diabetes genetic risk variants (in TCF7L2, PPARG-P12A, KCNJ11, FTO, IGF2BP2, DUSP9, CENTD2, THADA, HHEX, CDKAL1, KCNQ1) showed similar associations compared to literature.
p15448
sg4
(lp15449
(dp15450
g7
I168
sg8
I1
sg9
I6
sg10
g11
sg12
VCDKAL1
p15451
sa(dp15452
g7
I131
sg8
I1
sg9
I7
sg10
g11
sg12
VIGF2BP2
p15453
sa(dp15454
g7
I118
sg8
I1
sg9
I6
sg10
g11
sg12
VKCNJ11
p15455
sa(dp15456
g7
I176
sg8
I1
sg9
I5
sg10
VP51787
p15457
sg12
VKCNQ1
p15458
sa(dp15459
g7
I162
sg8
I1
sg9
I4
sg10
g11
sg12
VHHEX
p15460
sa(dp15461
g7
I112
sg8
I1
sg9
I4
sg10
g11
sg12
VP12A
p15462
sa(dp15463
g7
I106
sg8
I1
sg9
I5
sg10
g11
sg12
VPPARG
p15464
sa(dp15465
g7
I126
sg8
I1
sg9
I3
sg10
g11
sg12
VFTO
p15466
sa(dp15467
g7
I140
sg8
I1
sg9
I5
sg10
g11
sg12
VDUSP9
p15468
sasg24
(lp15469
(dp15470
g7
I56
sg8
I3
sg9
I15
sg27
VC0011860
p15471
sg12
Vtype 2 diabetes
p15472
sasa(dp15473
g2
VAssociations between insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) rs11705701, insulin receptor substrate 1 rs7578326, gastric inhibitory polypeptide receptor rs10423928 and transcription factor 7-like 2 rs12255372 gene polymorphisms with prediabetes and type 2 diabetes (T2D) have not been evaluated in the Han Chinese population.
p15474
sg4
(lp15475
(dp15476
g7
I74
sg8
I1
sg9
I7
sg10
g11
sg12
VIGF2BP2
p15477
sa(dp15478
g7
I21
sg8
I7
sg9
I51
sg10
VP01308
p15479
sg12
Vinsulin-like growth factor 2 mRNA-binding protein 2
p15480
sa(dp15481
g7
I95
sg8
I17
sg9
I140
sg10
VP35568
p15482
sg12
Vinsulin receptor substrate 1 rs7578326, gastric inhibitory polypeptide receptor rs10423928 and transcription factor 7-like 2 rs12255372 gene
p15483
sasg24
(lp15484
(dp15485
g7
I271
sg8
I3
sg9
I15
sg27
VC0011860
p15486
sg12
Vtype 2 diabetes
p15487
sa(dp15488
g7
I255
sg8
I1
sg9
I11
sg27
VC0362046
p15489
sg12
Vprediabetes
p15490
sa(dp15491
g7
I288
sg8
I1
sg9
I3
sg27
VC0011860
p15492
sg12
VT2D
p15493
sasa(dp15494
g2
VA breakdown analysis by gender revealed a significant association of IGF2BP2 rs11705701 with prediabetes under the dominant genetic model in females following application of the Bonferroni correction (odds ratio = 0.26; 95% confidence interval = 0.10-0.67; P=0.005).
p15495
sg4
(lp15496
(dp15497
g7
I69
sg8
I2
sg9
I18
sg10
g11
sg12
VIGF2BP2 rs11705701
p15498
sasg24
(lp15499
(dp15500
g7
I2
sg8
I1
sg9
I9
sg27
VC1265875
p15501
sg12
Vbreakdown
p15502
sa(dp15503
g7
I93
sg8
I1
sg9
I11
sg27
VC0362046
p15504
sg12
Vprediabetes
p15505
sasa(dp15506
g2
VThe present case-control study reveals a significant association between IGF2BP2 rs11705701 and prediabetes in female patients.
p15507
sg4
(lp15508
(dp15509
g7
I73
sg8
I2
sg9
I18
sg10
g11
sg12
VIGF2BP2 rs11705701
p15510
sasg24
(lp15511
(dp15512
g7
I96
sg8
I1
sg9
I11
sg27
VC0362046
p15513
sg12
Vprediabetes
p15514
sasa(dp15515
g2
VGenome-wide association studies (GWAS) found that IGF2BP2 rs4402960 and rs1470579 polymorphisms were associated with type 2 diabetes mellitus (T2DM) risk.
p15516
sg4
(lp15517
(dp15518
g7
I50
sg8
I1
sg9
I7
sg10
g11
sg12
VIGF2BP2
p15519
sasg24
(lp15520
(dp15521
g7
I117
sg8
I4
sg9
I24
sg27
VC0011860
p15522
sg12
Vtype 2 diabetes mellitus
p15523
sa(dp15524
g7
I143
sg8
I1
sg9
I4
sg27
VC0011860
p15525
sg12
VT2DM
p15526
sasa(dp15527
g2
VDecreased expression of CHC1L is linked to pathogenesis and progression of both prostate cancer and multiple myeloma.
p15528
sg4
(lp15529
(dp15530
g7
I24
sg8
I1
sg9
I5
sg10
g11
sg12
VCHC1L
p15531
sasg24
(lp15532
(dp15533
g7
I43
sg8
I1
sg9
I12
sg27
VC0699748
p15534
sg12
Vpathogenesis
p15535
sa(dp15536
g7
I80
sg8
I2
sg9
I15
sg27
VC0600139
p15537
sg12
Vprostate cancer
p15538
sa(dp15539
g7
I100
sg8
I2
sg9
I16
sg27
VC0026764
p15540
sg12
Vmultiple myeloma
p15541
sasa(dp15542
g2
VRecent studies of the RAN (6p21), ZHX-2 (8q24.3), CHC1L (13q14.3) loci highlight the importance of these genes in multiple myeloma (MM) prognosis and therapeutic applications.
p15543
sg4
(lp15544
(dp15545
g7
I34
sg8
I5
sg9
I36
sg10
g11
sg12
VZHX-2 (8q24.3), CHC1L (13q14.3) loci
p15546
sasg24
(lp15547
(dp15548
g7
I114
sg8
I2
sg9
I16
sg27
VC0026764
p15549
sg12
Vmultiple myeloma
p15550
sasa(dp15551
g2
VLow expression levels of RAN, ZHX-2, and CHC1L were observed in myeloma patients, compared with peripheral blood lymphocytes and MOLP-8 cells.
p15552
sg4
(lp15553
(dp15554
g7
I41
sg8
I1
sg9
I5
sg10
g11
sg12
VCHC1L
p15555
sasg24
(lp15556
(dp15557
g7
I64
sg8
I1
sg9
I7
sg27
VC0026764
p15558
sg12
Vmyeloma
p15559
sasa(dp15560
g2
VRAN, ZHX2 and RCBTB2 (CHC1L) expression was evaluated by quantitative real time reverse transcription polymerase chain reaction in plasma cells from 85 monoclonal gammopathies: 58 symptomatic multiple myeloma (MM) (52 untreated, six relapsed), eight smouldering MM, five monoclonal gammopathy of undetermined significance, four plasma cell leukaemias and 10 myeloid cell lines.
p15561
sg4
(lp15562
(dp15563
g7
I22
sg8
I1
sg9
I5
sg10
g11
sg12
VCHC1L
p15564
sa(dp15565
g7
I5
sg8
I1
sg9
I4
sg10
g11
sg12
VZHX2
p15566
sa(dp15567
g7
I14
sg8
I1
sg9
I6
sg10
g11
sg12
VRCBTB2
p15568
sasg24
(lp15569
(dp15570
g7
I271
sg8
I5
sg9
I50
sg27
VC0026470
p15571
sg12
Vmonoclonal gammopathy of undetermined significance
p15572
sa(dp15573
g7
I340
sg8
I1
sg9
I10
sg27
VC0023418
p15574
sg12
Vleukaemias
p15575
sa(dp15576
g7
I192
sg8
I2
sg9
I16
sg27
VC0026764
p15577
sg12
Vmultiple myeloma
p15578
sa(dp15579
g7
I152
sg8
I2
sg9
I23
sg27
VC1136085
p15580
sg12
Vmonoclonal gammopathies
p15581
sasa(dp15582
g2
VBCCIP deficiency impaired embryonic and postnatal neural development, causing severe ataxia, cerebral and cerebellar defects, and microcephaly.
p15583
sg4
(lp15584
sg24
(lp15585
(dp15586
g7
I17
sg8
I1
sg9
I8
sg27
VC0684336
p15587
sg12
Vimpaired
p15588
sa(dp15589
g7
I130
sg8
I1
sg9
I12
sg27
VC0025958
p15590
sg12
Vmicrocephaly
p15591
sa(dp15592
g7
I85
sg8
I1
sg9
I6
sg27
VC0004134
p15593
sg12
Vataxia
p15594
sasa(dp15595
g2
VPhosphorylation also links HS1 to multiple signaling proteins, including Lck, PLCgamma1, and Vav1, and is essential for the stable recruitment of Vav1 to the IS.
p15596
sg4
(lp15597
(dp15598
g7
I93
sg8
I1
sg9
I4
sg10
VP15498
p15599
sg12
VVav1
p15600
sa(dp15601
g7
I27
sg8
I1
sg9
I3
sg10
VP27348
p15602
sg12
VHS1
p15603
sa(dp15604
g7
I78
sg8
I1
sg9
I9
sg10
VP19174
p15605
sg12
VPLCgamma1
p15606
sa(dp15607
g7
I93
sg8
I1
sg9
I4
sg10
VP15498
p15608
sg12
VVav1
p15609
sasg24
(lp15610
(dp15611
g7
I27
sg8
I1
sg9
I3
sg27
VC2674218
p15612
sg12
VHS1
p15613
sa(dp15614
g7
I131
sg8
I1
sg9
I11
sg27
VC0271510
p15615
sg12
Vrecruitment
p15616
sasa(dp15617
g2
VOn the other hand, we confirmed previously mapped Lck SH3 binding sites in ADAM15, HS1, SLP76, and NS5A, and identified putative Lck SH3 binding sites of Sam68, FasL, c-Cbl, and Cbl-b.
p15618
sg4
(lp15619
(dp15620
g7
I83
sg8
I1
sg9
I3
sg10
VP27348
p15621
sg12
VHS1
p15622
sa(dp15623
g7
I161
sg8
I1
sg9
I4
sg10
VP48023
p15624
sg12
VFasL
p15625
sa(dp15626
g7
I154
sg8
I1
sg9
I5
sg10
g11
sg12
VSam68
p15627
sa(dp15628
g7
I167
sg8
I1
sg9
I5
sg10
VP22681
p15629
sg12
Vc-Cbl
p15630
sa(dp15631
g7
I75
sg8
I1
sg9
I6
sg10
g11
sg12
VADAM15
p15632
sa(dp15633
g7
I54
sg8
I3
sg9
I17
sg10
VP63244
p15634
sg12
VSH3 binding sites
p15635
sa(dp15636
g7
I54
sg8
I3
sg9
I17
sg10
VP63244
p15637
sg12
VSH3 binding sites
p15638
sa(dp15639
g7
I88
sg8
I1
sg9
I5
sg10
g11
sg12
VSLP76
p15640
sa(dp15641
g7
I178
sg8
I1
sg9
I5
sg10
g11
sg12
VCbl-b
p15642
sasg24
(lp15643
(dp15644
g7
I83
sg8
I1
sg9
I3
sg27
VC2674218
p15645
sg12
VHS1
p15646
sasa(dp15647
g2
VThe SH2 domains of ZAP70, SHP-1 and PLC gamma 1 and the SH3 domains of lck, vav and HS1 did not bind to pp85--90.
p15648
sg4
(lp15649
(dp15650
g7
I84
sg8
I1
sg9
I3
sg10
VP27348
p15651
sg12
VHS1
p15652
sa(dp15653
g7
I76
sg8
I1
sg9
I3
sg10
VP15498
p15654
sg12
Vvav
p15655
sa(dp15656
g7
I36
sg8
I3
sg9
I11
sg10
VP98160
p15657
sg12
VPLC gamma 1
p15658
sa(dp15659
g7
I19
sg8
I1
sg9
I5
sg10
VP43403
p15660
sg12
VZAP70
p15661
sa(dp15662
g7
I26
sg8
I1
sg9
I5
sg10
VP29350
p15663
sg12
VSHP-1
p15664
sasg24
(lp15665
(dp15666
g7
I84
sg8
I1
sg9
I3
sg27
VC2674218
p15667
sg12
VHS1
p15668
sasa(dp15669
g2
VThese analyses identified several cellular proteins inside HIV-1: elongation factor 1alpha, glyceraldehyde-3-phosphate dehydrogenase, HS-1, phosphatidylethanolamine-binding protein, Pin1, Lck, Nm23-H1, and the C-terminal tail of CD43.
p15670
sg4
(lp15671
(dp15672
g7
I59
sg8
I4
sg9
I31
sg10
g11
sg12
VHIV-1: elongation factor 1alpha
p15673
sa(dp15674
g7
I140
sg8
I2
sg9
I40
sg10
VP30086
p15675
sg12
Vphosphatidylethanolamine-binding protein
p15676
sa(dp15677
g7
I182
sg8
I1
sg9
I4
sg10
g11
sg12
VPin1
p15678
sa(dp15679
g7
I193
sg8
I1
sg9
I7
sg10
VP22392
p15680
sg12
VNm23-H1
p15681
sa(dp15682
g7
I229
sg8
I1
sg9
I4
sg10
VP16150
p15683
sg12
VCD43
p15684
sa(dp15685
g7
I92
sg8
I2
sg9
I40
sg10
VP04406
p15686
sg12
Vglyceraldehyde-3-phosphate dehydrogenase
p15687
sasg24
(lp15688
(dp15689
g7
I59
sg8
I1
sg9
I3
sg27
VC0019693
p15690
sg12
VHIV
p15691
sasa(dp15692
g2
VWe find that the Src homology 3 domains of Grb2 directly associate, in vitro and in vivo, with murine hemopoietic specific protein 1 (HS1), a protein identical to Lck-binding protein 1.
p15693
sg4
(lp15694
(dp15695
g7
I43
sg8
I1
sg9
I4
sg10
VP62993
p15696
sg12
VGrb2
p15697
sa(dp15698
g7
I163
sg8
I3
sg9
I21
sg10
VP14222
p15699
sg12
VLck-binding protein 1
p15700
sa(dp15701
g7
I95
sg8
I5
sg9
I37
sg10
VP14222
p15702
sg12
Vmurine hemopoietic specific protein 1
p15703
sa(dp15704
g7
I17
sg8
I3
sg9
I14
sg10
VP12931
p15705
sg12
VSrc homology 3
p15706
sa(dp15707
g7
I134
sg8
I1
sg9
I3
sg10
VP27348
p15708
sg12
VHS1
p15709
sasg24
(lp15710
(dp15711
g7
I102
sg8
I4
sg9
I30
sg27
VC2674218
p15712
sg12
Vhemopoietic specific protein 1
p15713
sa(dp15714
g7
I134
sg8
I1
sg9
I3
sg27
VC2674218
p15715
sg12
VHS1
p15716
sasa(dp15717
g2
VBecause HS1 associates with the p56(lck) and p59(lyn) tyrosine kinases in vitro and in vivo, and becomes tyrosine phosphorylated upon various receptor stimulations, our present data suggest that HS1 mediates linkage between Lck or Lyn and Grb2 in lymphoid lineage cells.
p15718
sg4
(lp15719
(dp15720
g7
I8
sg8
I1
sg9
I3
sg10
VP27348
p15721
sg12
VHS1
p15722
sa(dp15723
g7
I49
sg8
I1
sg9
I3
sg10
VP07948
p15724
sg12
Vlyn
p15725
sa(dp15726
g7
I231
sg8
I1
sg9
I3
sg10
VP07948
p15727
sg12
VLyn
p15728
sa(dp15729
g7
I32
sg8
I1
sg9
I3
sg10
VP62191
p15730
sg12
Vp56
p15731
sa(dp15732
g7
I239
sg8
I1
sg9
I4
sg10
VP62993
p15733
sg12
VGrb2
p15734
sa(dp15735
g7
I45
sg8
I1
sg9
I3
sg10
g11
sg12
Vp59
p15736
sa(dp15737
g7
I54
sg8
I2
sg9
I16
sg10
VP29401
p15738
sg12
Vtyrosine kinases
p15739
sasg24
(lp15740
(dp15741
g7
I8
sg8
I1
sg9
I3
sg27
VC2674218
p15742
sg12
VHS1
p15743
sa(dp15744
g7
I8
sg8
I1
sg9
I3
sg27
VC2674218
p15745
sg12
VHS1
p15746
sasa(dp15747
g2
VWith this method, we previously isolated an Lck tyrosine kinase-associated protein, LckBP1, which is identical to HS1 (Kitamura et al., 1989, 1995; Takemoto et al., 1995).
p15748
sg4
(lp15749
(dp15750
g7
I84
sg8
I1
sg9
I6
sg10
VP14317
p15751
sg12
VLckBP1
p15752
sa(dp15753
g7
I48
sg8
I3
sg9
I34
sg10
VP29401
p15754
sg12
Vtyrosine kinase-associated protein
p15755
sasg24
(lp15756
(dp15757
g7
I114
sg8
I1
sg9
I3
sg27
VC2674218
p15758
sg12
VHS1
p15759
sasa(dp15760
g2
VWe have previously found that purine-rich element binding protein, PURalpha, was significantly repressed in androgen-independent prostate cancer cell lines in comparison to an androgen-dependent line.
p15761
sg4
(lp15762
(dp15763
g7
I30
sg8
I4
sg9
I35
sg10
g11
sg12
Vpurine-rich element binding protein
p15764
sa(dp15765
g7
I67
sg8
I1
sg9
I8
sg10
g11
sg12
VPURalpha
p15766
sasg24
(lp15767
(dp15768
g7
I129
sg8
I2
sg9
I15
sg27
VC0600139
p15769
sg12
Vprostate cancer
p15770
sasa(dp15771
g2
VMoreover, over-expressing PURalpha in androgen-independent prostate cancer cells attenuated their cell proliferation.
p15772
sg4
(lp15773
(dp15774
g7
I26
sg8
I1
sg9
I8
sg10
g11
sg12
VPURalpha
p15775
sasg24
(lp15776
(dp15777
g7
I103
sg8
I1
sg9
I13
sg27
VC0334094
p15778
sg12
Vproliferation
p15779
sa(dp15780
g7
I59
sg8
I2
sg9
I15
sg27
VC0600139
p15781
sg12
Vprostate cancer
p15782
sasa(dp15783
g2
VThese findings suggest that regulation of PURalpha expression in prostate cancer cells may serve as a therapeutic target for hormone refractory prostate cancer.
p15784
sg4
(lp15785
(dp15786
g7
I42
sg8
I1
sg9
I8
sg10
g11
sg12
VPURalpha
p15787
sasg24
(lp15788
(dp15789
g7
I125
sg8
I4
sg9
I34
sg27
VC1328504
p15790
sg12
Vhormone refractory prostate cancer
p15791
sa(dp15792
g7
I65
sg8
I2
sg9
I15
sg27
VC0600139
p15793
sg12
Vprostate cancer
p15794
sasa(dp15795
g2
VWe investigated the effects of the DNA damage-inducing cancer chemotherapeutic agent cisplatin on mouse embryo fibroblasts (MEFs) from PURA(-/-) knockout mice that lack Puralpha.
p15796
sg4
(lp15797
(dp15798
g7
I169
sg8
I1
sg9
I8
sg10
g11
sg12
VPuralpha
p15799
sasg24
(lp15800
(dp15801
g7
I55
sg8
I1
sg9
I6
sg27
VC0006826
p15802
sg12
Vcancer
p15803
sa(dp15804
g7
I35
sg8
I2
sg9
I10
sg27
VC0012860
p15805
sg12
VDNA damage
p15806
sasa(dp15807
g2
VMoreover, PURalpha was decreased in its expression both at the protein and mRNA levels in the androgen-independent prostate cancer cell lines, PC3 and DU145 in comparison to LNCaP cells.
p15808
sg4
(lp15809
(dp15810
g7
I10
sg8
I1
sg9
I8
sg10
g11
sg12
VPURalpha
p15811
sasg24
(lp15812
(dp15813
g7
I115
sg8
I2
sg9
I15
sg27
VC0600139
p15814
sg12
Vprostate cancer
p15815
sasa(dp15816
g2
VFrequent SIs were pneumonia (15.9%), cellulitis (9.9%), and sepsis (5.0%).
p15817
sg4
(lp15818
sg24
(lp15819
(dp15820
g7
I18
sg8
I1
sg9
I9
sg27
VC0032285
p15821
sg12
Vpneumonia
p15822
sa(dp15823
g7
I60
sg8
I1
sg9
I6
sg27
VC0243026
p15824
sg12
Vsepsis
p15825
sa(dp15826
g7
I37
sg8
I1
sg9
I10
sg27
VC0007642
p15827
sg12
Vcellulitis
p15828
sasa(dp15829
g2
VWe additionally show that pulmonary fibrosis in MyD88-KO mice was associated with the accumulation of pro-fibrotic regulatory T lymphocytes (T regs) and pro-fibrotic cytokine expression (TGF-Beta, IL-10 and PDGF-B), not with T helper (Th) 17 cell influx.
p15830
sg4
(lp15831
(dp15832
g7
I187
sg8
I1
sg9
I8
sg10
VP18075
p15833
sg12
VTGF-Beta
p15834
sa(dp15835
g7
I207
sg8
I1
sg9
I6
sg10
VP01127
p15836
sg12
VPDGF-B
p15837
sa(dp15838
g7
I48
sg8
I1
sg9
I8
sg10
g11
sg12
VMyD88-KO
p15839
sasg24
(lp15840
(dp15841
g7
I26
sg8
I2
sg9
I18
sg27
VC0034069
p15842
sg12
Vpulmonary fibrosis
p15843
sasa(dp15844
g2
VThe aim of our investigation was to analyze the pattern of interleukin-1 (IL-1) family compounds: IL-1 beta, IL-1 receptor accessory protein (Acp), IL-1 receptor antagonist (IL-1Ra) and IL-1 receptor type II (IL-1RII) in the serum and cerebrospinal fluid (CSF) from 67 multiple sclerosis (MS) patients and 31 controls.
p15845
sg4
(lp15846
(dp15847
g7
I209
sg8
I1
sg9
I7
sg10
g11
sg12
VIL-1RII
p15848
sa(dp15849
g7
I109
sg8
I4
sg9
I31
sg10
g11
sg12
VIL-1 receptor accessory protein
p15850
sa(dp15851
g7
I59
sg8
I1
sg9
I13
sg10
VP60568
p15852
sg12
Vinterleukin-1
p15853
sa(dp15854
g7
I148
sg8
I3
sg9
I24
sg10
g11
sg12
VIL-1 receptor antagonist
p15855
sa(dp15856
g7
I174
sg8
I1
sg9
I6
sg10
VP18510
p15857
sg12
VIL-1Ra
p15858
sa(dp15859
g7
I235
sg8
I3
sg9
I25
sg10
VP04141
p15860
sg12
Vcerebrospinal fluid (CSF)
p15861
sa(dp15862
g7
I142
sg8
I1
sg9
I3
sg10
VP13686
p15863
sg12
VAcp
p15864
sa(dp15865
g7
I74
sg8
I1
sg9
I4
sg10
VP01584
p15866
sg12
VIL-1
p15867
sa(dp15868
g7
I98
sg8
I2
sg9
I9
sg10
VP01584
p15869
sg12
VIL-1 beta
p15870
sa(dp15871
g7
I186
sg8
I4
sg9
I21
sg10
g11
sg12
VIL-1 receptor type II
p15872
sasg24
(lp15873
(dp15874
g7
I123
sg8
I2
sg9
I17
sg27
VC0394005
p15875
sg12
Vaccessory protein
p15876
sa(dp15877
g7
I142
sg8
I1
sg9
I3
sg27
VC0394005
p15878
sg12
VAcp
p15879
sa(dp15880
g7
I289
sg8
I1
sg9
I2
sg27
VC0026769
p15881
sg12
VMS
p15882
sa(dp15883
g7
I269
sg8
I2
sg9
I18
sg27
VC0026769
p15884
sg12
Vmultiple sclerosis
p15885
sasa(dp15886
g2
VPartial loss of IFT80 function leads Jeune asphyxiating thoracic dystrophy (JATD) or short-rib polydactyly (SRP) syndrome type III, displaying narrow thoracic cavity and multiple cartilage anomalies.
p15887
sg4
(lp15888
(dp15889
g7
I16
sg8
I1
sg9
I5
sg10
g11
sg12
VIFT80
p15890
sasg24
(lp15891
(dp15892
g7
I56
sg8
I1
sg9
I8
sg27
VC0729233
p15893
sg12
Vthoracic
p15894
sa(dp15895
g7
I95
sg8
I1
sg9
I11
sg27
VC0152427
p15896
sg12
Vpolydactyly
p15897
sa(dp15898
g7
I43
sg8
I3
sg9
I31
sg27
VC0265275
p15899
sg12
Vasphyxiating thoracic dystrophy
p15900
sa(dp15901
g7
I113
sg8
I1
sg9
I8
sg27
VC0039082
p15902
sg12
Vsyndrome
p15903
sa(dp15904
g7
I159
sg8
I1
sg9
I6
sg27
VC0011334
p15905
sg12
Vcavity
p15906
sasa(dp15907
g2
VPartial mutation of intraflagellar transport 80 (IFT80) in humans causes Jeune asphyxiating thoracic dystrophy (JATD) and short-rib polydactyly (SRP) syndrome type III.
p15908
sg4
(lp15909
(dp15910
g7
I49
sg8
I1
sg9
I5
sg10
g11
sg12
VIFT80
p15911
sa(dp15912
g7
I20
sg8
I3
sg9
I27
sg10
g11
sg12
Vintraflagellar transport 80
p15913
sasg24
(lp15914
(dp15915
g7
I150
sg8
I1
sg9
I8
sg27
VC0039082
p15916
sg12
Vsyndrome
p15917
sa(dp15918
g7
I132
sg8
I1
sg9
I11
sg27
VC0152427
p15919
sg12
Vpolydactyly
p15920
sa(dp15921
g7
I79
sg8
I3
sg9
I31
sg27
VC0265275
p15922
sg12
Vasphyxiating thoracic dystrophy
p15923
sasa(dp15924
g2
VPartial mutation of IFT80 in humans causes diseases such as Jeune asphyxiating thoracic dystrophy (JATD) and short rib polydactyly (SRP) type III with abnormal skeletal development.
p15925
sg4
(lp15926
(dp15927
g7
I20
sg8
I1
sg9
I5
sg10
g11
sg12
VIFT80
p15928
sasg24
(lp15929
(dp15930
g7
I66
sg8
I3
sg9
I31
sg27
VC0265275
p15931
sg12
Vasphyxiating thoracic dystrophy
p15932
sa(dp15933
g7
I119
sg8
I1
sg9
I11
sg27
VC0152427
p15934
sg12
Vpolydactyly
p15935
sasa(dp15936
g2
VJeune's asphyxiating thoracic dystrophy (JATD) is an autosomal recessive disorder with symptoms of retinal degeneration, kidney cysts, and chondrodysplasia and results from mutations in the ift80 gene.
p15937
sg4
(lp15938
(dp15939
g7
I190
sg8
I2
sg9
I10
sg10
g11
sg12
Vift80 gene
p15940
sasg24
(lp15941
(dp15942
g7
I99
sg8
I2
sg9
I20
sg27
VC0035304
p15943
sg12
Vretinal degeneration
p15944
sa(dp15945
g7
I121
sg8
I2
sg9
I12
sg27
VC0268800
p15946
sg12
Vkidney cysts
p15947
sa(dp15948
g7
I8
sg8
I3
sg9
I31
sg27
VC0265275
p15949
sg12
Vasphyxiating thoracic dystrophy
p15950
sa(dp15951
g7
I139
sg8
I1
sg9
I16
sg27
VC0343284
p15952
sg12
Vchondrodysplasia
p15953
sasa(dp15954
g2
VIL-33 is associated with a variety of autoimmune diseases, such as sclerosis, inflammatory bowel disease, and rheumatoid arthritis.
p15955
sg4
(lp15956
sg24
(lp15957
(dp15958
g7
I38
sg8
I2
sg9
I19
sg27
VC0004364
p15959
sg12
Vautoimmune diseases
p15960
sa(dp15961
g7
I78
sg8
I3
sg9
I26
sg27
VC0021390
p15962
sg12
Vinflammatory bowel disease
p15963
sa(dp15964
g7
I67
sg8
I1
sg9
I9
sg27
VC0036429
p15965
sg12
Vsclerosis
p15966
sa(dp15967
g7
I110
sg8
I2
sg9
I20
sg27
VC0003873
p15968
sg12
Vrheumatoid arthritis
p15969
sasa(dp15970
g2
VIL-33 was significantly higher in BD patients (101.2+/-20.1pg/ml) as compared to healthy controls (31.5+/-10.5 pg/ml) but lower than rheumatoid arthritis patients (132.5+/-19.1 pg/ml).
p15971
sg4
(lp15972
sg24
(lp15973
(dp15974
g7
I133
sg8
I2
sg9
I20
sg27
VC0003873
p15975
sg12
Vrheumatoid arthritis
p15976
sasa(dp15977
g2
VIt has been shown that the administration of interleukin-33 exacerbates collagen-induced arthritis in experimental models, and a positive correlation between cytokine concentrations in serum and synovial fluid of patients with rheumatoid arthritis and disease activity was found.
p15978
sg4
(lp15979
(dp15980
g7
I45
sg8
I1
sg9
I14
sg10
g11
sg12
Vinterleukin-33
p15981
sasg24
(lp15982
(dp15983
g7
I227
sg8
I2
sg9
I20
sg27
VC0003873
p15984
sg12
Vrheumatoid arthritis
p15985
sa(dp15986
g7
I89
sg8
I1
sg9
I9
sg27
VC0003864
p15987
sg12
Varthritis
p15988
sasa(dp15989
g2
VThis review discusses evidence for the role of interleukin-33 with a focus on rheumatoid arthritis.
p15990
sg4
(lp15991
(dp15992
g7
I47
sg8
I1
sg9
I14
sg10
g11
sg12
Vinterleukin-33
p15993
sasg24
(lp15994
(dp15995
g7
I78
sg8
I2
sg9
I20
sg27
VC0003873
p15996
sg12
Vrheumatoid arthritis
p15997
sasa(dp15998
g2
VThe antigenic protein spots reacted against sera from clonorchiasis patients and were identified as cysteine proteases, glutathione transferases, gelsolin, propionyl-CoA carboxylase (PCC), prohibitin and 14-3-3 protein (14-3-3) using LC-coupled ESI-MS/MS and an EST database for C. sinensis.
p15999
sg4
(lp16000
(dp16001
g7
I183
sg8
I1
sg9
I3
sg10
VP07320
p16002
sg12
VPCC
p16003
sa(dp16004
g7
I120
sg8
I2
sg9
I24
sg10
VP48637
p16005
sg12
Vglutathione transferases
p16006
sa(dp16007
g7
I100
sg8
I2
sg9
I18
sg10
VP49662
p16008
sg12
Vcysteine proteases
p16009
sa(dp16010
g7
I146
sg8
I3
sg9
I35
sg10
VP06396
p16011
sg12
Vgelsolin, propionyl-CoA carboxylase
p16012
sa(dp16013
g7
I189
sg8
I1
sg9
I10
sg10
VP35232
p16014
sg12
Vprohibitin
p16015
sasg24
(lp16016
(dp16017
g7
I54
sg8
I1
sg9
I13
sg27
VC0009021
p16018
sg12
Vclonorchiasis
p16019
sa(dp16020
g7
I183
sg8
I1
sg9
I3
sg27
VC1832526
p16021
sg12
VPCC
p16022
sa(dp16023
g7
I22
sg8
I1
sg9
I5
sg27
VC0015230
p16024
sg12
Vspots
p16025
sa(dp16026
g7
I156
sg8
I2
sg9
I25
sg27
VC1832526
p16027
sg12
Vpropionyl-CoA carboxylase
p16028
sasa(dp16029
g2
VTo report the effect of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia (type 2 IMT).
p16030
sg4
(lp16031
sg24
(lp16032
(dp16033
g7
I78
sg8
I1
sg9
I14
sg27
VC0039446
p16034
sg12
Vtelangiectasia
p16035
sasa(dp16036
g2
VTo identify the possible biological roles of keratinocyte growth factor (KGF), connective tissue growth factor (CTGF) and transforming growth factor-Beta (TGF-Beta) in cyclosporine-A (CsA) and phenytoin (PNT)-induced gingival overgrowth (GO) and to correlate them with each other.
p16037
sg4
(lp16038
(dp16039
g7
I45
sg8
I3
sg9
I26
sg10
VP21781
p16040
sg12
Vkeratinocyte growth factor
p16041
sa(dp16042
g7
I112
sg8
I1
sg9
I4
sg10
VP29279
p16043
sg12
VCTGF
p16044
sa(dp16045
g7
I155
sg8
I1
sg9
I8
sg10
VP18075
p16046
sg12
VTGF-Beta
p16047
sa(dp16048
g7
I73
sg8
I1
sg9
I3
sg10
VP21781
p16049
sg12
VKGF
p16050
sa(dp16051
g7
I79
sg8
I4
sg9
I31
sg10
VP29279
p16052
sg12
Vconnective tissue growth factor
p16053
sa(dp16054
g7
I122
sg8
I3
sg9
I31
sg10
VP18075
p16055
sg12
Vtransforming growth factor-Beta
p16056
sasg24
(lp16057
(dp16058
g7
I184
sg8
I1
sg9
I3
sg27
VC0751039
p16059
sg12
VCsA
p16060
sa(dp16061
g7
I168
sg8
I1
sg9
I14
sg27
VC0751039
p16062
sg12
Vcyclosporine-A
p16063
sasa(dp16064
g2
VKeratinocyte growth factor (KGF) and scatter factor (SF) are fibroblast-derived growth factors with potent mitogenic and motogenic effects on epithelial cells, and, therefore, could be involved in the pathogenesis of gingival overgrowth.
p16065
sg4
(lp16066
(dp16067
g7
I0
sg8
I3
sg9
I26
sg10
VP21781
p16068
sg12
VKeratinocyte growth factor
p16069
sa(dp16070
g7
I28
sg8
I1
sg9
I3
sg10
VP21781
p16071
sg12
VKGF
p16072
sasg24
(lp16073
(dp16074
g7
I201
sg8
I1
sg9
I12
sg27
VC0699748
p16075
sg12
Vpathogenesis
p16076
sasa(dp16077
g2
VThese results suggest that KGF and SF may have an important role in cyclosporin-induced gingival overgrowth.
p16078
sg4
(lp16079
(dp16080
g7
I27
sg8
I1
sg9
I3
sg10
VP21781
p16081
sg12
VKGF
p16082
sasg24
(lp16083
sa(dp16084
g2
VOn return to the district to calve, 54% of calves from herd 1 and 30% of calves from herd 2 were affected with congenital arthrogryposis or hydranencephaly caused by Akabane virus infection.
p16085
sg4
(lp16086
sg24
(lp16087
(dp16088
g7
I122
sg8
I1
sg9
I14
sg27
VC0003886
p16089
sg12
Varthrogryposis
p16090
sa(dp16091
g7
I140
sg8
I1
sg9
I15
sg27
VC0020225
p16092
sg12
Vhydranencephaly
p16093
sa(dp16094
g7
I174
sg8
I2
sg9
I15
sg27
VC0042769
p16095
sg12
Vvirus infection
p16096
sasa(dp16097
g2
VTwelve patients with classic radiologic and histologic features of MO, 6 with brown tumors, and 5 with cherubism diagnosed at our institution were studied for the presence of USP6 rearrangements using fluorescence in situ hybridization with probes flanking the USP6 locus on chromosome 17p13.
p16098
sg4
(lp16099
(dp16100
g7
I175
sg8
I2
sg9
I19
sg10
VP35125
p16101
sg12
VUSP6 rearrangements
p16102
sa(dp16103
g7
I261
sg8
I2
sg9
I10
sg10
VP35125
p16104
sg12
VUSP6 locus
p16105
sasg24
(lp16106
(dp16107
g7
I103
sg8
I1
sg9
I9
sg27
VC0008029
p16108
sg12
Vcherubism
p16109
sa(dp16110
g7
I78
sg8
I2
sg9
I12
sg27
VC0029405
p16111
sg12
Vbrown tumors
p16112
sasa(dp16113
g2
VNone of the patients with brown tumor or cherubism demonstrated USP6 rearrangements.
p16114
sg4
(lp16115
(dp16116
g7
I64
sg8
I2
sg9
I19
sg10
VP35125
p16117
sg12
VUSP6 rearrangements
p16118
sasg24
(lp16119
(dp16120
g7
I26
sg8
I2
sg9
I11
sg27
VC0029405
p16121
sg12
Vbrown tumor
p16122
sa(dp16123
g7
I41
sg8
I1
sg9
I9
sg27
VC0008029
p16124
sg12
Vcherubism
p16125
sasa(dp16126
g2
VIn contrast, no USP6 rearrangements were found in patients with cherubism or brown tumor, supporting the prevailing view that these lesions are distinct biologic entities.
p16127
sg4
(lp16128
(dp16129
g7
I16
sg8
I2
sg9
I19
sg10
VP35125
p16130
sg12
VUSP6 rearrangements
p16131
sasg24
(lp16132
(dp16133
g7
I64
sg8
I1
sg9
I9
sg27
VC0008029
p16134
sg12
Vcherubism
p16135
sa(dp16136
g7
I77
sg8
I2
sg9
I11
sg27
VC0029405
p16137
sg12
Vbrown tumor
p16138
sasa(dp16139
g2
VConsistent with findings in mice, marked alterations in nuclear envelope morphology, abnormal localization of RanGAP1, and nuclear accumulation of mRNA were found in cortex of Huntington's disease patients.
p16140
sg4
(lp16141
(dp16142
g7
I110
sg8
I1
sg9
I7
sg10
VP46060
p16143
sg12
VRanGAP1
p16144
sasg24
(lp16145
(dp16146
g7
I176
sg8
I2
sg9
I20
sg27
VC0020179
p16147
sg12
VHuntington's disease
p16148
sasa(dp16149
g2
VDouble immunofluorescent analyses revealed nuclear retention and apparent colocalization of RanGap1 with Nup205, Gp210 with Nup205, and partial colocalization of Nup205 with Nup107; most of the ischemic changes above were similar to those observed in patients with C9orf72-genetic amyotrophic lateral sclerosis.
p16150
sg4
(lp16151
(dp16152
g7
I105
sg8
I1
sg9
I6
sg10
g11
sg12
VNup205
p16153
sa(dp16154
g7
I92
sg8
I1
sg9
I7
sg10
VP46060
p16155
sg12
VRanGap1
p16156
sa(dp16157
g7
I174
sg8
I1
sg9
I6
sg10
VP57740
p16158
sg12
VNup107
p16159
sa(dp16160
g7
I105
sg8
I1
sg9
I6
sg10
g11
sg12
VNup205
p16161
sa(dp16162
g7
I105
sg8
I1
sg9
I6
sg10
g11
sg12
VNup205
p16163
sa(dp16164
g7
I113
sg8
I1
sg9
I5
sg10
g11
sg12
VGp210
p16165
sasg24
(lp16166
(dp16167
g7
I281
sg8
I3
sg9
I29
sg27
VC0002736
p16168
sg12
Vamyotrophic lateral sclerosis
p16169
sasa(dp16170
g2
VDetection of the expression of these proteins and genes encoding these proteins in human gastric cancer tissues by real-time PCR (RT-qPCR) and western blot revealed that the expression of Beta-ACTIN, LDH, DLD, PRPF19 and CaM genes were up-regulated and RanGAP was down-regulated in gastric cancer tissues and/or metastatic lymph nodes compared to peri-cancerous tissues.
p16171
sg4
(lp16172
(dp16173
g7
I205
sg8
I1
sg9
I3
sg10
VP98173
p16174
sg12
VDLD
p16175
sa(dp16176
g7
I200
sg8
I1
sg9
I3
sg10
g11
sg12
VLDH
p16177
sa(dp16178
g7
I188
sg8
I1
sg9
I10
sg10
VP63261
p16179
sg12
VBeta-ACTIN
p16180
sa(dp16181
g7
I221
sg8
I2
sg9
I9
sg10
VP01768
p16182
sg12
VCaM genes
p16183
sa(dp16184
g7
I210
sg8
I1
sg9
I6
sg10
g11
sg12
VPRPF19
p16185
sasg24
(lp16186
(dp16187
g7
I89
sg8
I2
sg9
I14
sg27
VC0024623
p16188
sg12
Vgastric cancer
p16189
sa(dp16190
g7
I89
sg8
I2
sg9
I14
sg27
VC0024623
p16191
sg12
Vgastric cancer
p16192
sa(dp16193
g7
I221
sg8
I1
sg9
I3
sg27
VC1861821
p16194
sg12
VCaM
p16195
sasa(dp16196
g2
VStable coronary artery disease (SCAD) patients scheduled for PCI were randomized to one of the three study arms: 1) genotyping, 2) PFT, and 3) control and evaluated by the CYP2C19 allele genotyping and PFT with P2Y12 assay.
p16197
sg4
(lp16198
(dp16199
g7
I172
sg8
I2
sg9
I14
sg10
VP33261
p16200
sg12
VCYP2C19 allele
p16201
sasg24
(lp16202
(dp16203
g7
I0
sg8
I4
sg9
I30
sg27
VC0342783
p16204
sg12
VStable coronary artery disease
p16205
sa(dp16206
g7
I107
sg8
I1
sg9
I4
sg27
VC0206655
p16207
sg12
Varms
p16208
sa(dp16209
g7
I32
sg8
I1
sg9
I4
sg27
VC0342783
p16210
sg12
VSCAD
p16211
sasa(dp16212
g2
VTo assess the association of CYP2C19 G681A, P2RY12 H1/H2, and ITGB3 T1565C polymorphisms with the extent of platelet aggregation in patients with coronary heart disease (CHD) during antiplatelet therapy.
p16213
sg4
(lp16214
(dp16215
g7
I44
sg8
I2
sg9
I12
sg10
g11
sg12
VP2RY12 H1/H2
p16216
sa(dp16217
g7
I29
sg8
I2
sg9
I13
sg10
VP33261
p16218
sg12
VCYP2C19 G681A
p16219
sa(dp16220
g7
I62
sg8
I2
sg9
I12
sg10
VP05106
p16221
sg12
VITGB3 T1565C
p16222
sasg24
(lp16223
(dp16224
g7
I170
sg8
I1
sg9
I3
sg27
VC0010054
p16225
sg12
VCHD
p16226
sa(dp16227
g7
I146
sg8
I3
sg9
I22
sg27
VC0010054
p16228
sg12
Vcoronary heart disease
p16229
sasa(dp16230
g2
VThis shortening of the HuR mRNA 3'-UTR via alternative polyadenylation (APA) was observed to be dependent on cleavage stimulation factor subunit 2 (CSTF2/CstF-64), which is up-regulated in the TAMR breast cancer cells.
p16231
sg4
(lp16232
(dp16233
g7
I148
sg8
I1
sg9
I5
sg10
VP33240
p16234
sg12
VCSTF2
p16235
sa(dp16236
g7
I23
sg8
I3
sg9
I15
sg10
g11
sg12
VHuR mRNA 3'-UTR
p16237
sa(dp16238
g7
I154
sg8
I1
sg9
I7
sg10
VP33240
p16239
sg12
VCstF-64
p16240
sa(dp16241
g7
I130
sg8
I3
sg9
I16
sg10
g11
sg12
Vfactor subunit 2
p16242
sasg24
(lp16243
(dp16244
g7
I198
sg8
I2
sg9
I13
sg27
VC0678222
p16245
sg12
Vbreast cancer
p16246
sasa(dp16247
g2
VMoreover, CSTF2, POLA1, HMOX2, and EFNB2 may be associated with the prognosis of bladder cancer patient.
p16248
sg4
(lp16249
(dp16250
g7
I24
sg8
I1
sg9
I5
sg10
VP30519
p16251
sg12
VHMOX2
p16252
sa(dp16253
g7
I17
sg8
I1
sg9
I5
sg10
VP09884
p16254
sg12
VPOLA1
p16255
sa(dp16256
g7
I35
sg8
I1
sg9
I5
sg10
VP52799
p16257
sg12
VEFNB2
p16258
sa(dp16259
g7
I10
sg8
I1
sg9
I5
sg10
VP33240
p16260
sg12
VCSTF2
p16261
sasg24
(lp16262
(dp16263
g7
I81
sg8
I2
sg9
I14
sg27
VC0699885
p16264
sg12
Vbladder cancer
p16265
sasa(dp16266
g2
VAccordingly, RNAi-induced silencing of CSTF2 decreased the proliferative rate of cancer cells.
p16267
sg4
(lp16268
(dp16269
g7
I39
sg8
I1
sg9
I5
sg10
VP33240
p16270
sg12
VCSTF2
p16271
sasg24
(lp16272
(dp16273
g7
I81
sg8
I1
sg9
I6
sg27
VC0006826
p16274
sg12
Vcancer
p16275
sa(dp16276
g7
I59
sg8
I1
sg9
I13
sg27
VC0334094
p16277
sg12
Vproliferative
p16278
sasa(dp16279
g2
VImmunohistochemical staining using tissue microarray consisting of 327 lung cancers was applied to examine the expression of CSTF2 protein and its prognostic value.
p16280
sg4
(lp16281
(dp16282
g7
I125
sg8
I2
sg9
I13
sg10
VP33240
p16283
sg12
VCSTF2 protein
p16284
sasg24
(lp16285
(dp16286
g7
I71
sg8
I2
sg9
I12
sg27
VC0242379
p16287
sg12
Vlung cancers
p16288
sasa(dp16289
g2
VA role of CSTF2 in cancer cell growth was examined by siRNA experiments.
p16290
sg4
(lp16291
(dp16292
g7
I10
sg8
I1
sg9
I5
sg10
VP33240
p16293
sg12
VCSTF2
p16294
sasg24
(lp16295
(dp16296
g7
I19
sg8
I3
sg9
I18
sg27
VC1516170
p16297
sg12
Vcancer cell growth
p16298
sasa(dp16299
g2
VImmunohistochemical analysis using tissue microarray showed an association of strong CSTF2 expression with poor prognosis of patients with non-small cell lung cancer (P = 0.0079), and multivariate analysis showed that CSTF2 positivity is an independent prognostic factor.
p16300
sg4
(lp16301
(dp16302
g7
I85
sg8
I1
sg9
I5
sg10
VP33240
p16303
sg12
VCSTF2
p16304
sa(dp16305
g7
I85
sg8
I1
sg9
I5
sg10
VP33240
p16306
sg12
VCSTF2
p16307
sasg24
(lp16308
(dp16309
g7
I139
sg8
I4
sg9
I26
sg27
VC0007131
p16310
sg12
Vnon-small cell lung cancer
p16311
sasa(dp16312
g2
VIn addition, suppression of CSTF2 expression by siRNAs suppressed lung cancer cell growth, whereas exogenous expression of CSTF2 promoted growth and invasion of mammalian cells.
p16313
sg4
(lp16314
(dp16315
g7
I28
sg8
I1
sg9
I5
sg10
VP33240
p16316
sg12
VCSTF2
p16317
sa(dp16318
g7
I28
sg8
I1
sg9
I5
sg10
VP33240
p16319
sg12
VCSTF2
p16320
sasg24
(lp16321
(dp16322
g7
I71
sg8
I3
sg9
I18
sg27
VC1516170
p16323
sg12
Vcancer cell growth
p16324
sa(dp16325
g7
I13
sg8
I1
sg9
I11
sg27
VC0221103
p16326
sg12
Vsuppression
p16327
sa(dp16328
g7
I149
sg8
I1
sg9
I8
sg27
VC2699153
p16329
sg12
Vinvasion
p16330
sasa(dp16331
g2
VImmunohistochemistry analysis of cellular immune parameters (CD4+ or CD8+ T cells, CIITA, MHC-II and CD68) was performed on NMU-induced rat mammary tumor nodules, followed by evaluation of the serum level of 34 cytokines using the cytokine antibody array.
p16332
sg4
(lp16333
(dp16334
g7
I90
sg8
I1
sg9
I6
sg10
VP13747
p16335
sg12
VMHC-II
p16336
sa(dp16337
g7
I69
sg8
I1
sg9
I4
sg10
VP01732
p16338
sg12
VCD8+
p16339
sa(dp16340
g7
I83
sg8
I1
sg9
I5
sg10
VP33076
p16341
sg12
VCIITA
p16342
sa(dp16343
g7
I61
sg8
I1
sg9
I4
sg10
VP01730
p16344
sg12
VCD4+
p16345
sa(dp16346
g7
I101
sg8
I1
sg9
I4
sg10
VP34810
p16347
sg12
VCD68
p16348
sasg24
(lp16349
(dp16350
g7
I154
sg8
I1
sg9
I7
sg27
VC0028259
p16351
sg12
Vnodules
p16352
sa(dp16353
g7
I140
sg8
I2
sg9
I13
sg27
VC1458155
p16354
sg12
Vmammary tumor
p16355
sasa(dp16356
g2
VImmunohistochemistry was performed to determine PD-L1 tumor cell expression and to enumerate CD8, CD4 and CD68 tumor-infiltrating leucocytes (TIL) in a cohort of 443 breast cancers categorized by molecular subtype.
p16357
sg4
(lp16358
(dp16359
g7
I106
sg8
I1
sg9
I4
sg10
VP34810
p16360
sg12
VCD68
p16361
sa(dp16362
g7
I142
sg8
I1
sg9
I3
sg10
VP01765
p16363
sg12
VTIL
p16364
sa(dp16365
g7
I93
sg8
I1
sg9
I3
sg10
VP01732
p16366
sg12
VCD8
p16367
sa(dp16368
g7
I98
sg8
I1
sg9
I3
sg10
VP01730
p16369
sg12
VCD4
p16370
sa(dp16371
g7
I111
sg8
I2
sg9
I29
sg10
VP01765
p16372
sg12
Vtumor-infiltrating leucocytes
p16373
sasg24
(lp16374
(dp16375
g7
I54
sg8
I1
sg9
I5
sg27
VC0027651
p16376
sg12
Vtumor
p16377
sa(dp16378
g7
I54
sg8
I1
sg9
I5
sg27
VC0027651
p16379
sg12
Vtumor
p16380
sa(dp16381
g7
I117
sg8
I1
sg9
I12
sg27
VC0332448
p16382
sg12
Vinfiltrating
p16383
sa(dp16384
g7
I166
sg8
I2
sg9
I14
sg27
VC0006142
p16385
sg12
Vbreast cancers
p16386
sasa(dp16387
g2
VThese findings demonstrate, for the first time, a novel capacity of a P-Alexa647-FA conjugate to colocalize to CD11b+CD68+ TAMs in both primary and metastatic breast tumors.
p16388
sg4
(lp16389
(dp16390
g7
I111
sg8
I2
sg9
I16
sg10
VP11215
p16391
sg12
VCD11b+CD68+ TAMs
p16392
sasg24
(lp16393
(dp16394
g7
I159
sg8
I2
sg9
I13
sg27
VC1458155
p16395
sg12
Vbreast tumors
p16396
sasa(dp16397
g2
VWe used breast tumor tissues from each patient to make tissue microarrays that were then stained for leukocyte and myeloid markers including CD4, CD8, CD20, CD25, CD68, and CD163 using immunohistochemical techniques.
p16398
sg4
(lp16399
(dp16400
g7
I151
sg8
I1
sg9
I4
sg10
VP35900
p16401
sg12
VCD20
p16402
sa(dp16403
g7
I173
sg8
I1
sg9
I5
sg10
g11
sg12
VCD163
p16404
sa(dp16405
g7
I146
sg8
I1
sg9
I3
sg10
VP01732
p16406
sg12
VCD8
p16407
sa(dp16408
g7
I157
sg8
I1
sg9
I4
sg10
VP01589
p16409
sg12
VCD25
p16410
sa(dp16411
g7
I163
sg8
I1
sg9
I4
sg10
VP34810
p16412
sg12
VCD68
p16413
sa(dp16414
g7
I141
sg8
I1
sg9
I3
sg10
VP01730
p16415
sg12
VCD4
p16416
sasg24
(lp16417
(dp16418
g7
I8
sg8
I2
sg9
I12
sg27
VC1458155
p16419
sg12
Vbreast tumor
p16420
sasa(dp16421
g2
VFurthermore, high density of CD163+ and CD68+ TAMs was observed in ovarian cancer with advanced TNM stage.
p16422
sg4
(lp16423
(dp16424
g7
I29
sg8
I1
sg9
I6
sg10
g11
sg12
VCD163+
p16425
sa(dp16426
g7
I40
sg8
I1
sg9
I5
sg10
VP34810
p16427
sg12
VCD68+
p16428
sasg24
(lp16429
(dp16430
g7
I67
sg8
I2
sg9
I14
sg27
VC1140680
p16431
sg12
Vovarian cancer
p16432
sasa(dp16433
g2
VThe number of CD68+CD163+ M2-like macrophages was significantly higher in breast cancer tissues than in benign tissues.
p16434
sg4
(lp16435
(dp16436
g7
I14
sg8
I2
sg9
I19
sg10
VP34810
p16437
sg12
VCD68+CD163+ M2-like
p16438
sasg24
(lp16439
(dp16440
g7
I74
sg8
I2
sg9
I13
sg27
VC0678222
p16441
sg12
Vbreast cancer
p16442
sasa(dp16443
S'line'
p16444
VCharacterisation of most mutations found in CLCN2 in patients with CC2L leukodystrophy show that they cause a reduction in function of the chloride channel ClC-2.
p16445
sS'genes'
p16446
(lp16447
(dp16448
S'index'
p16449
I139
sS'lengthInWords'
p16450
I3
sS'lengthInChars'
p16451
I22
sS'uniprot'
p16452
VP51800
p16453
sS'name'
p16454
Vchloride channel ClC-2
p16455
sasS'diseases'
p16456
(lp16457
(dp16458
g16449
I72
sg16450
I1
sg16451
I14
sS'cui'
p16459
VC0023520
p16460
sg16454
Vleukodystrophy
p16461
sasa(dp16462
g16444
VGlialCAM, a regulatory subunit of ClC-2 in glial cells and involved in the leukodystrophy megalencephalic leukoencephalopathy with subcortical cysts (MLC), increases the activity of a ClC-2 mutant by affecting ClC-2 gating and by stabilising the mutant at the plasma membrane.
p16463
sg16446
(lp16464
(dp16465
g16449
I0
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VGlialCAM
p16466
sa(dp16467
g16449
I184
sg16450
I2
sg16451
I12
sg16452
VP51788
p16468
sg16454
VClC-2 mutant
p16469
sa(dp16470
g16449
I34
sg16450
I1
sg16451
I5
sg16452
VP51788
p16471
sg16454
VClC-2
p16472
sasg16456
(lp16473
(dp16474
g16449
I90
sg16450
I5
sg16451
I58
sg16459
VC1858854
p16475
sg16454
Vmegalencephalic leukoencephalopathy with subcortical cysts
p16476
sa(dp16477
g16449
I190
sg16450
I1
sg16451
I6
sg16459
VC0596988
p16478
sg16454
Vmutant
p16479
sa(dp16480
g16449
I75
sg16450
I1
sg16451
I14
sg16459
VC0023520
p16481
sg16454
Vleukodystrophy
p16482
sa(dp16483
g16449
I190
sg16450
I1
sg16451
I6
sg16459
VC0596988
p16484
sg16454
Vmutant
p16485
sa(dp16486
g16449
I150
sg16450
I1
sg16451
I3
sg16459
VC1858854
p16487
sg16454
VMLC
p16488
sasa(dp16489
g16444
VWe suggest that leukodystrophy-causing CLCN2 mutations reduce the functional expression of ClC-2, which is partly counteracted by GlialCAM/MLC1-mediated increase in the gating and stability of the channel.
p16490
sg16446
(lp16491
(dp16492
g16449
I139
sg16450
I1
sg16451
I4
sg16452
VP12829
p16493
sg16454
VMLC1
p16494
sa(dp16495
g16449
I130
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VGlialCAM
p16496
sa(dp16497
g16449
I91
sg16450
I1
sg16451
I5
sg16452
VP51788
p16498
sg16454
VClC-2
p16499
sa(dp16500
g16449
I39
sg16450
I2
sg16451
I15
sg16452
VP51788
p16501
sg16454
VCLCN2 mutations
p16502
sasg16456
(lp16503
(dp16504
g16449
I139
sg16450
I1
sg16451
I4
sg16459
VC1858854
p16505
sg16454
VMLC1
p16506
sa(dp16507
g16449
I16
sg16450
I1
sg16451
I14
sg16459
VC0023520
p16508
sg16454
Vleukodystrophy
p16509
sasa(dp16510
g16444
VThe review then discusses the diseases associated with ClC-2, including degeneration of the retina, Sjoegren's syndrome, age-related cataracts, degeneration of the testes, azoospermia, lung cancer, constipation, repair of impaired intestinal mucosa barrier, leukemia, cystic fibrosis, leukoencephalopathy, epilepsy and diabetes mellitus.
p16511
sg16446
(lp16512
(dp16513
g16449
I55
sg16450
I1
sg16451
I5
sg16452
VP51788
p16514
sg16454
VClC-2
p16515
sasg16456
(lp16516
(dp16517
g16449
I268
sg16450
I2
sg16451
I15
sg16459
VC0010674
p16518
sg16454
Vcystic fibrosis
p16519
sa(dp16520
g16449
I306
sg16450
I1
sg16451
I8
sg16459
VC0014544
p16521
sg16454
Vepilepsy
p16522
sa(dp16523
g16449
I285
sg16450
I1
sg16451
I19
sg16459
VC0270612
p16524
sg16454
Vleukoencephalopathy
p16525
sa(dp16526
g16449
I133
sg16450
I1
sg16451
I9
sg16459
VC0521707
p16527
sg16454
Vcataracts
p16528
sa(dp16529
g16449
I72
sg16450
I1
sg16451
I12
sg16459
VC0011164
p16530
sg16454
Vdegeneration
p16531
sa(dp16532
g16449
I185
sg16450
I2
sg16451
I11
sg16459
VC0684249
p16533
sg16454
Vlung cancer
p16534
sa(dp16535
g16449
I258
sg16450
I1
sg16451
I8
sg16459
VC0023418
p16536
sg16454
Vleukemia
p16537
sa(dp16538
g16449
I100
sg16450
I2
sg16451
I19
sg16459
VC1527336
p16539
sg16454
VSjoegren's syndrome
p16540
sa(dp16541
g16449
I222
sg16450
I1
sg16451
I8
sg16459
VC0684336
p16542
sg16454
Vimpaired
p16543
sa(dp16544
g16449
I72
sg16450
I1
sg16451
I12
sg16459
VC0011164
p16545
sg16454
Vdegeneration
p16546
sa(dp16547
g16449
I198
sg16450
I1
sg16451
I12
sg16459
VC0009806
p16548
sg16454
Vconstipation
p16549
sa(dp16550
g16449
I172
sg16450
I1
sg16451
I11
sg16459
VC1321542
p16551
sg16454
Vazoospermia
p16552
sa(dp16553
g16449
I319
sg16450
I2
sg16451
I17
sg16459
VC0011849
p16554
sg16454
Vdiabetes mellitus
p16555
sasa(dp16556
g16444
VA subset of these genes has been implicated in other neurobehavioral disorders including depression (SLIT3), epilepsy (CLCN2, PRICKLE1), intellectual disability (AP4M1), schizophrenia (WDR60), and Tourette syndrome (OFCC1).
p16557
sg16446
(lp16558
(dp16559
g16449
I126
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VPRICKLE1
p16560
sa(dp16561
g16449
I162
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VAP4M1
p16562
sa(dp16563
g16449
I101
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSLIT3
p16564
sa(dp16565
g16449
I185
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VWDR60
p16566
sa(dp16567
g16449
I109
sg16450
I1
sg16451
I8
sg16452
VP10646
p16568
sg16454
Vepilepsy
p16569
sa(dp16570
g16449
I119
sg16450
I1
sg16451
I5
sg16452
VP51788
p16571
sg16454
VCLCN2
p16572
sasg16456
(lp16573
(dp16574
g16449
I137
sg16450
I2
sg16451
I23
sg16459
VC0025362
p16575
sg16454
Vintellectual disability
p16576
sa(dp16577
g16449
I170
sg16450
I1
sg16451
I13
sg16459
VC0036341
p16578
sg16454
Vschizophrenia
p16579
sa(dp16580
g16449
I109
sg16450
I1
sg16451
I8
sg16459
VC0014544
p16581
sg16454
Vepilepsy
p16582
sa(dp16583
g16449
I89
sg16450
I1
sg16451
I10
sg16459
VC0011581
p16584
sg16454
Vdepression
p16585
sa(dp16586
g16449
I197
sg16450
I2
sg16451
I17
sg16459
VC0040517
p16587
sg16454
VTourette syndrome
p16588
sasa(dp16589
g16444
VEpilepsy with grand mal on awakening (EGMA) is a well-defined subtype of idiopathic generalized epilepsy.
p16590
sg16446
(lp16591
sg16456
(lp16592
(dp16593
g16449
I73
sg16450
I3
sg16451
I31
sg16459
VC0270850
p16594
sg16454
Vidiopathic generalized epilepsy
p16595
sa(dp16596
g16449
I0
sg16450
I1
sg16451
I8
sg16459
VC0014544
p16597
sg16454
VEpilepsy
p16598
sa(dp16599
g16449
I14
sg16450
I2
sg16451
I9
sg16459
VC0494475
p16600
sg16454
Vgrand mal
p16601
sasa(dp16602
g16444
VAdditionally, using global gene expression analysis of partially reprogrammed cells, we identified SNAI3 as a novel invasion-related marker in human melanoma.
p16603
sg16446
(lp16604
(dp16605
g16449
I99
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSNAI3
p16606
sasg16456
(lp16607
(dp16608
g16449
I149
sg16450
I1
sg16451
I8
sg16459
VC0025202
p16609
sg16454
Vmelanoma
p16610
sa(dp16611
g16449
I116
sg16450
I1
sg16451
I8
sg16459
VC2699153
p16612
sg16454
Vinvasion
p16613
sasa(dp16614
g16444
VSNAI3 expression correlates with tumor thickness in primary melanomas and thus, may be of prognostic value.
p16615
sg16446
(lp16616
(dp16617
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSNAI3
p16618
sasg16456
(lp16619
(dp16620
g16449
I60
sg16450
I1
sg16451
I9
sg16459
VC0025202
p16621
sg16454
Vmelanomas
p16622
sa(dp16623
g16449
I33
sg16450
I1
sg16451
I5
sg16459
VC0027651
p16624
sg16454
Vtumor
p16625
sasa(dp16626
g16444
VEffective silencing of Runx2 by short interfering RNA (siRNA) demonstrated downregulation of EMT-related molecules (SNAI2, SNAI3 and TWIST1), MMP2 and vasculogenic factors (VEGFA and VEGFC) in thyroid carcinoma cells.
p16627
sg16446
(lp16628
(dp16629
g16449
I123
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSNAI3
p16630
sa(dp16631
g16449
I142
sg16450
I1
sg16451
I4
sg16452
VP08253
p16632
sg16454
VMMP2
p16633
sa(dp16634
g16449
I133
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VTWIST1
p16635
sa(dp16636
g16449
I93
sg16450
I2
sg16451
I21
sg16452
g11
sg16454
VEMT-related molecules
p16637
sa(dp16638
g16449
I23
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VRunx2
p16639
sa(dp16640
g16449
I183
sg16450
I1
sg16451
I5
sg16452
VP49767
p16641
sg16454
VVEGFC
p16642
sa(dp16643
g16449
I116
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSNAI2
p16644
sa(dp16645
g16449
I151
sg16450
I2
sg16451
I20
sg16452
VP19883
p16646
sg16454
Vvasculogenic factors
p16647
sasg16456
(lp16648
(dp16649
g16449
I193
sg16450
I2
sg16451
I17
sg16459
VC0549473
p16650
sg16454
Vthyroid carcinoma
p16651
sasa(dp16652
g16444
VThyroid-stimulating hormone levels, goiter and thyroid dysfunction were higher in children who were anti-TPO1 than in diabetic children without thyroid autoimmunity.
p16653
sg16446
(lp16654
(dp16655
g16449
I0
sg16450
I2
sg16451
I27
sg16452
VP01222
p16656
sg16454
VThyroid-stimulating hormone
p16657
sa(dp16658
g16449
I100
sg16450
I1
sg16451
I9
sg16452
g11
sg16454
Vanti-TPO1
p16659
sasg16456
(lp16660
(dp16661
g16449
I36
sg16450
I1
sg16451
I6
sg16459
VC0018021
p16662
sg16454
Vgoiter
p16663
sa(dp16664
g16449
I152
sg16450
I1
sg16451
I12
sg16459
VC0004368
p16665
sg16454
Vautoimmunity
p16666
sa(dp16667
g16449
I47
sg16450
I2
sg16451
I19
sg16459
VC0348024
p16668
sg16454
Vthyroid dysfunction
p16669
sasa(dp16670
g16444
VMultiplex ligation-dependent probe amplification (MLPA) can be used to detect rearrangements that cause Alfa-thalassemia, particularly large deletions involving the whole Alfa cluster and/or deletions in the HS-40 region.
p16671
sg16446
(lp16672
(dp16673
g16449
I208
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VHS-40 region
p16674
sasg16456
(lp16675
(dp16676
g16449
I109
sg16450
I1
sg16451
I11
sg16459
VC0039730
p16677
sg16454
Vthalassemia
p16678
sa(dp16679
g16449
I35
sg16450
I1
sg16451
I13
sg16459
VC1705759
p16680
sg16454
Vamplification
p16681
sasa(dp16682
g16444
VIn addition to the -Alfa3.7 deletion identified in the patients with Hb H disease, four different Alfa0 deletions removing 15 to 225 kb DNA segments were found: two of them remove both the Alfa genes, one affects only the regulatory element (HS-40) region, and another one extends over the entire Alfa cluster and the HS-40 region.
p16683
sg16446
(lp16684
(dp16685
g16449
I318
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VHS-40 region
p16686
sasg16456
(lp16687
(dp16688
g16449
I72
sg16450
I2
sg16451
I9
sg16459
VC0018609
p16689
sg16454
VH disease
p16690
sasa(dp16691
g16444
VThe impact of urinary VDBP and KIM-1 on MARE was independent of known CIN risk factors such as anemia, preexisting renal failure, preexisting heart failure, and diabetes.
p16692
sg16446
(lp16693
(dp16694
g16449
I40
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VMARE
p16695
sa(dp16696
g16449
I31
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VKIM-1
p16697
sa(dp16698
g16449
I22
sg16450
I1
sg16451
I4
sg16452
VP02774
p16699
sg16454
VVDBP
p16700
sasg16456
(lp16701
(dp16702
g16449
I95
sg16450
I1
sg16451
I6
sg16459
VC0002871
p16703
sg16454
Vanemia
p16704
sa(dp16705
g16449
I70
sg16450
I1
sg16451
I3
sg16459
VC0206708
p16706
sg16454
VCIN
p16707
sa(dp16708
g16449
I142
sg16450
I2
sg16451
I13
sg16459
VC0018802
p16709
sg16454
Vheart failure
p16710
sa(dp16711
g16449
I115
sg16450
I2
sg16451
I13
sg16459
VC0035078
p16712
sg16454
Vrenal failure
p16713
sa(dp16714
g16449
I161
sg16450
I1
sg16451
I8
sg16459
VC0011849
p16715
sg16454
Vdiabetes
p16716
sasa(dp16717
g16444
VThe data show that a tandem Maf recognition element (MARE) in locus control region (LCR) hypersensitive site 2 (HS2) reveals a remarkably high degree of occupancy during differentiation of mouse erythroleukemia cells.
p16718
sg16446
(lp16719
(dp16720
g16449
I53
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VMARE
p16721
sa(dp16722
g16449
I28
sg16450
I3
sg16451
I23
sg16452
g11
sg16454
VMaf recognition element
p16723
sasg16456
(lp16724
(dp16725
g16449
I195
sg16450
I1
sg16451
I15
sg16459
VC0023440
p16726
sg16454
Verythroleukemia
p16727
sasa(dp16728
g16444
VTargeting of an artificial zinc finger DNA-binding domain (ZF-DBD) to the HS2 tandem MARE caused a reduction in the association of MARE-binding proteins and transcription complexes at LCR HS2 and the adult Betamajor-globin gene promoter but did not affect expression of the Betaminor-globin gene.
p16729
sg16446
(lp16730
(dp16731
g16449
I27
sg16450
I4
sg16451
I30
sg16452
g11
sg16454
Vzinc finger DNA-binding domain
p16732
sa(dp16733
g16449
I59
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VZF-DBD
p16734
sa(dp16735
g16449
I131
sg16450
I2
sg16451
I21
sg16452
g11
sg16454
VMARE-binding proteins
p16736
sasg16456
(lp16737
sa(dp16738
g16444
VThe data demonstrate that a stable MARE-associated footprint in LCR HS2 is important for the recruitment of transcription complexes to the adult Betamajor-globin gene promoter during erythroid cell differentiation.
p16739
sg16446
(lp16740
sg16456
(lp16741
(dp16742
g16449
I93
sg16450
I1
sg16451
I11
sg16459
VC0271510
p16743
sg16454
Vrecruitment
p16744
sasa(dp16745
g16444
VNext, we demonstrate that CD172a(+)Slan DCs that produced IL-1Beta and TNF-Alfa accumulated in mLNs and colons of CD patients.
p16746
sg16446
(lp16747
(dp16748
g16449
I71
sg16450
I1
sg16451
I8
sg16452
VP01375
p16749
sg16454
VTNF-Alfa
p16750
sa(dp16751
g16449
I58
sg16450
I1
sg16451
I8
sg16452
VP01584
p16752
sg16454
VIL-1Beta
p16753
sasg16456
(lp16754
(dp16755
g16449
I95
sg16450
I1
sg16451
I4
sg16459
VC0026691
p16756
sg16454
VmLNs
p16757
sa(dp16758
g16449
I40
sg16450
I1
sg16451
I3
sg16459
VC0268238
p16759
sg16454
VDCs
p16760
sasa(dp16761
g16444
VIn conclusion, we propose that proinflammatory CD14(bright)CD172a(+)Slan DCs are a distinguishing feature between CD and UC, as these cells accumulate uniquely in mLNs and colonic mucosa of CD patients.
p16762
sg16446
(lp16763
(dp16764
g16449
I47
sg16450
I2
sg16451
I29
sg16452
VP08571
p16765
sg16454
VCD14(bright)CD172a(+)Slan DCs
p16766
sasg16456
(lp16767
(dp16768
g16449
I73
sg16450
I1
sg16451
I3
sg16459
VC0268238
p16769
sg16454
VDCs
p16770
sa(dp16771
g16449
I163
sg16450
I1
sg16451
I4
sg16459
VC0026691
p16772
sg16454
VmLNs
p16773
sasa(dp16774
g16444
VHere, we show that CD172a(+)CD11c(+) cells accumulate in the mesenteric lymph nodes (mLNs) and inflamed intestinal mucosa in patients with Crohn's disease (CD).
p16775
sg16446
(lp16776
(dp16777
g16449
I19
sg16450
I1
sg16451
I14
sg16452
VP20702
p16778
sg16454
VCD172a(+)CD11c
p16779
sasg16456
(lp16780
(dp16781
g16449
I85
sg16450
I1
sg16451
I4
sg16459
VC0026691
p16782
sg16454
VmLNs
p16783
sa(dp16784
g16449
I139
sg16450
I2
sg16451
I15
sg16459
VC0010346
p16785
sg16454
VCrohn's disease
p16786
sa(dp16787
g16449
I61
sg16450
I3
sg16451
I22
sg16459
VC0026691
p16788
sg16454
Vmesenteric lymph nodes
p16789
sa(dp16790
g16449
I19
sg16450
I1
sg16451
I2
sg16459
VC0010346
p16791
sg16454
VCD
p16792
sasa(dp16793
g16444
VAn avidity-improved CD47 fusion protein (CD47-Var1) suppresses the release of a wide array of inflammatory cytokines by CD172a(+) cells, which may include HLA-DR(-)CD172a(+) neutrophils, in inflamed colonic explant cultures and impairs the ability of HLA-DR(+)CD172a(+) cells to activate memory Th17 but not Th1 responses in mLNs.
p16794
sg16446
(lp16795
(dp16796
g16449
I41
sg16450
I1
sg16451
I9
sg16452
g11
sg16454
VCD47-Var1
p16797
sa(dp16798
g16449
I251
sg16450
I1
sg16451
I15
sg16452
VP30486
p16799
sg16454
VHLA-DR(+)CD172a
p16800
sa(dp16801
g16449
I155
sg16450
I1
sg16451
I15
sg16452
VP30486
p16802
sg16454
VHLA-DR(-)CD172a
p16803
sa(dp16804
g16449
I20
sg16450
I3
sg16451
I19
sg16452
g11
sg16454
VCD47 fusion protein
p16805
sasg16456
(lp16806
(dp16807
g16449
I325
sg16450
I1
sg16451
I4
sg16459
VC0026691
p16808
sg16454
VmLNs
p16809
sasa(dp16810
g16444
VWe first show that mucosal CD103(-) DCs selectively express SIRPalpha and that their frequency was augmented in the lamina propria and mLNs of mice that developed Th17-biased colitis in response to trinitrobenzene sulfonic acid.
p16811
sg16446
(lp16812
(dp16813
g16449
I27
sg16450
I2
sg16451
I12
sg16452
VP38570
p16814
sg16454
VCD103(-) DCs
p16815
sasg16456
(lp16816
(dp16817
g16449
I135
sg16450
I1
sg16451
I4
sg16459
VC0026691
p16818
sg16454
VmLNs
p16819
sa(dp16820
g16449
I36
sg16450
I1
sg16451
I3
sg16459
VC0268238
p16821
sg16454
VDCs
p16822
sa(dp16823
g16449
I175
sg16450
I1
sg16451
I7
sg16459
VC0009319
p16824
sg16454
Vcolitis
p16825
sasa(dp16826
g16444
VCD47 expression was required on the SIRPalpha(+)CD103(-) DCs for efficient trafficking to mLNs in vivo, whereas it was dispensable on both DCs and T cells for Th17 polarization in vitro.
p16827
sg16446
(lp16828
(dp16829
g16449
I36
sg16450
I1
sg16451
I20
sg16452
VP38570
p16830
sg16454
VSIRPalpha(+)CD103(-)
p16831
sa(dp16832
g16449
I0
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCD47
p16833
sasg16456
(lp16834
(dp16835
g16449
I57
sg16450
I1
sg16451
I3
sg16459
VC0268238
p16836
sg16454
VDCs
p16837
sa(dp16838
g16449
I57
sg16450
I1
sg16451
I3
sg16459
VC0268238
p16839
sg16454
VDCs
p16840
sa(dp16841
g16449
I90
sg16450
I1
sg16451
I4
sg16459
VC0026691
p16842
sg16454
VmLNs
p16843
sasa(dp16844
g16444
VEffects of Ca2+ and calmodulin on the adenylate cyclase activity of a prolactin and growth hormone-producing pituitary tumor cell strain (GH3) were examined.
p16845
sg16446
(lp16846
(dp16847
g16449
I38
sg16450
I2
sg16451
I17
sg16452
g11
sg16454
Vadenylate cyclase
p16848
sa(dp16849
g16449
I84
sg16450
I2
sg16451
I14
sg16452
VP01242
p16850
sg16454
Vgrowth hormone
p16851
sa(dp16852
g16449
I20
sg16450
I1
sg16451
I10
sg16452
g11
sg16454
Vcalmodulin
p16853
sa(dp16854
g16449
I70
sg16450
I1
sg16451
I9
sg16452
VP01236
p16855
sg16454
Vprolactin
p16856
sasg16456
(lp16857
(dp16858
g16449
I84
sg16450
I4
sg16451
I40
sg16459
VC0278864
p16859
sg16454
Vgrowth hormone-producing pituitary tumor
p16860
sasa(dp16861
g16444
VThe control of PTG hyperplasia is most important in the management of secondary hyperparathyroidism (SHPT), because the advanced stage of hyperplasia is considered irreversible.
p16862
sg16446
(lp16863
sg16456
(lp16864
(dp16865
g16449
I19
sg16450
I1
sg16451
I11
sg16459
VC0020507
p16866
sg16454
Vhyperplasia
p16867
sa(dp16868
g16449
I101
sg16450
I1
sg16451
I4
sg16459
VC0020503
p16869
sg16454
VSHPT
p16870
sa(dp16871
g16449
I19
sg16450
I1
sg16451
I11
sg16459
VC0020507
p16872
sg16454
Vhyperplasia
p16873
sa(dp16874
g16449
I70
sg16450
I2
sg16451
I29
sg16459
VC0020503
p16875
sg16454
Vsecondary hyperparathyroidism
p16876
sasa(dp16877
g16444
VControl of secondary hyperparathyroidism (SHPT) using active vitamin D analogues becomes difficult in advanced SHPT, because the enlarged parathyroid glands (PTGs) are resistant to medical therapy.
p16878
sg16446
(lp16879
sg16456
(lp16880
(dp16881
g16449
I11
sg16450
I2
sg16451
I29
sg16459
VC0020503
p16882
sg16454
Vsecondary hyperparathyroidism
p16883
sa(dp16884
g16449
I42
sg16450
I1
sg16451
I4
sg16459
VC0020503
p16885
sg16454
VSHPT
p16886
sa(dp16887
g16449
I42
sg16450
I1
sg16451
I4
sg16459
VC0020503
p16888
sg16454
VSHPT
p16889
sasa(dp16890
g16444
VThe long-term effect of cinacalcet hydrochloride treatment on parathyroid gland (PTG) volume has been scarcely investigated in patients with moderate to advanced secondary hyperparathyroidism (SHPT).
p16891
sg16446
(lp16892
sg16456
(lp16893
(dp16894
g16449
I193
sg16450
I1
sg16451
I4
sg16459
VC0020503
p16895
sg16454
VSHPT
p16896
sa(dp16897
g16449
I162
sg16450
I2
sg16451
I29
sg16459
VC0020503
p16898
sg16454
Vsecondary hyperparathyroidism
p16899
sasa(dp16900
g16444
VIt has been suggested that microRNA-9 (miR-9) is associated with the development of knee osteoarthritis (OA).
p16901
sg16446
(lp16902
(dp16903
g16449
I27
sg16450
I1
sg16451
I10
sg16452
g11
sg16454
VmicroRNA-9
p16904
sa(dp16905
g16449
I39
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VmiR-9
p16906
sasg16456
(lp16907
(dp16908
g16449
I84
sg16450
I2
sg16451
I19
sg16459
VC0409959
p16909
sg16454
Vknee osteoarthritis
p16910
sasa(dp16911
g16444
VX-linked hypophosphatemia (XLH), autosomal dominant HR (ADHR), and autosomal recessive HR (ARHR) are examples of hereditary forms of HR, which are mainly caused by mutations in the phosphate regulating endopeptidase homolog, X-linked (PHEX), FGF23, and, dentin matrix protein-1 (DMP1) and ecto-nucleotide pyro phosphatase/phosphodiesterase 1 (ENPP1) genes, respectively.
p16912
sg16446
(lp16913
(dp16914
g16449
I242
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VFGF23
p16915
sa(dp16916
g16449
I202
sg16450
I3
sg16451
I31
sg16452
g11
sg16454
Vendopeptidase homolog, X-linked
p16917
sa(dp16918
g16449
I33
sg16450
I3
sg16451
I21
sg16452
VP56715
p16919
sg16454
Vautosomal dominant HR
p16920
sa(dp16921
g16449
I254
sg16450
I3
sg16451
I23
sg16452
g11
sg16454
Vdentin matrix protein-1
p16922
sa(dp16923
g16449
I56
sg16450
I1
sg16451
I4
sg16452
VP30518
p16924
sg16454
VADHR
p16925
sa(dp16926
g16449
I279
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VDMP1
p16927
sa(dp16928
g16449
I343
sg16450
I1
sg16451
I5
sg16452
VP22413
p16929
sg16454
VENPP1
p16930
sa(dp16931
g16449
I235
sg16450
I1
sg16451
I4
sg16452
VP78562
p16932
sg16454
VPHEX
p16933
sa(dp16934
g16449
I289
sg16450
I4
sg16451
I52
sg16452
VP22413
p16935
sg16454
Vecto-nucleotide pyro phosphatase/phosphodiesterase 1
p16936
sasg16456
(lp16937
(dp16938
g16449
I0
sg16450
I2
sg16451
I25
sg16459
VC0733682
p16939
sg16454
VX-linked hypophosphatemia
p16940
sa(dp16941
g16449
I91
sg16450
I1
sg16451
I4
sg16459
VC0342643
p16942
sg16454
VARHR
p16943
sa(dp16944
g16449
I33
sg16450
I3
sg16451
I21
sg16459
VC0342642
p16945
sg16454
Vautosomal dominant HR
p16946
sa(dp16947
g16449
I56
sg16450
I1
sg16451
I4
sg16459
VC0342642
p16948
sg16454
VADHR
p16949
sa(dp16950
g16449
I27
sg16450
I1
sg16451
I3
sg16459
VC0733682
p16951
sg16454
VXLH
p16952
sa(dp16953
g16449
I67
sg16450
I3
sg16451
I22
sg16459
VC0342643
p16954
sg16454
Vautosomal recessive HR
p16955
sasa(dp16956
g16444
VHomozygous inactivating mutations in DMP1 (dentin matrix protein 1), the gene encoding a noncollagenous bone matrix protein expressed in osteoblasts and osteocytes, cause autosomal recessive hypophosphatemia (ARHP).
p16957
sg16446
(lp16958
sg16456
(lp16959
(dp16960
g16449
I171
sg16450
I3
sg16451
I36
sg16459
VC0342643
p16961
sg16454
Vautosomal recessive hypophosphatemia
p16962
sa(dp16963
g16449
I209
sg16450
I1
sg16451
I4
sg16459
VC0342643
p16964
sg16454
VARHP
p16965
sasa(dp16966
g16444
VAn autosomal recessive form of hypophosphatemia (ARHP) was recently shown to be caused by homozygous mutations in DMP1, the gene encoding dentin matrix protein-1 (DMP-1), a non-collagenous bone matrix protein with an important role in the development and mineralization of bone and teeth.
p16967
sg16446
(lp16968
(dp16969
g16449
I163
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VDMP-1
p16970
sa(dp16971
g16449
I173
sg16450
I4
sg16451
I35
sg16452
VP63145
p16972
sg16454
Vnon-collagenous bone matrix protein
p16973
sa(dp16974
g16449
I124
sg16450
I5
sg16451
I37
sg16452
g11
sg16454
Vgene encoding dentin matrix protein-1
p16975
sa(dp16976
g16449
I114
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VDMP1
p16977
sasg16456
(lp16978
(dp16979
g16449
I49
sg16450
I1
sg16451
I4
sg16459
VC0342643
p16980
sg16454
VARHP
p16981
sa(dp16982
g16449
I3
sg16450
I5
sg16451
I44
sg16459
VC0342643
p16983
sg16454
Vautosomal recessive form of hypophosphatemia
p16984
sasa(dp16985
g16444
VAmong various causes of low serum phosphorous are inherited disorders associated with increased urinary excretion of phosphate, including autosomal dominant hypophosphatemic rickets (ADHR), X-linked hypophosphatemia (XLH), autosomal recessive hypophosphatemia (ARHP), and hereditary hypophosphatemic rickets with hypercalciuria (HHRH).
p16986
sg16446
(lp16987
(dp16988
g16449
I183
sg16450
I1
sg16451
I4
sg16452
VP30518
p16989
sg16454
VADHR
p16990
sa(dp16991
g16449
I138
sg16450
I4
sg16451
I43
sg16452
VP30518
p16992
sg16454
Vautosomal dominant hypophosphatemic rickets
p16993
sasg16456
(lp16994
(dp16995
g16449
I261
sg16450
I1
sg16451
I4
sg16459
VC0342643
p16996
sg16454
VARHP
p16997
sa(dp16998
g16449
I138
sg16450
I4
sg16451
I43
sg16459
VC0342642
p16999
sg16454
Vautosomal dominant hypophosphatemic rickets
p17000
sa(dp17001
g16449
I283
sg16450
I4
sg16451
I44
sg16459
VC0342645
p17002
sg16454
Vhypophosphatemic rickets with hypercalciuria
p17003
sa(dp17004
g16449
I329
sg16450
I1
sg16451
I4
sg16459
VC0342645
p17005
sg16454
VHHRH
p17006
sa(dp17007
g16449
I217
sg16450
I1
sg16451
I3
sg16459
VC0733682
p17008
sg16454
VXLH
p17009
sa(dp17010
g16449
I223
sg16450
I3
sg16451
I36
sg16459
VC0342643
p17011
sg16454
Vautosomal recessive hypophosphatemia
p17012
sa(dp17013
g16449
I183
sg16450
I1
sg16451
I4
sg16459
VC0342642
p17014
sg16454
VADHR
p17015
sa(dp17016
g16449
I190
sg16450
I2
sg16451
I25
sg16459
VC0733682
p17017
sg16454
VX-linked hypophosphatemia
p17018
sasa(dp17019
g16444
VRecently, positional cloning approaches furthermore led to the identification of homozygous inactivating mutations in dentin matrix protein 1 (DMP1) as the cause of an autosomal recessive form of hypophosphatemia.
p17020
sg16446
(lp17021
(dp17022
g16449
I118
sg16450
I4
sg16451
I23
sg16452
VP14222
p17023
sg16454
Vdentin matrix protein 1
p17024
sa(dp17025
g16449
I143
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VDMP1
p17026
sasg16456
(lp17027
(dp17028
g16449
I196
sg16450
I1
sg16451
I16
sg16459
VC0085682
p17029
sg16454
Vhypophosphatemia
p17030
sasa(dp17031
g16444
VPharmacological treatment of SOD1(G37R) mice with minocycline, a compound that attenuates microgliosis and slows down disease, lessened the dysregulation of Cdk5/Cdk4 and the phosphorylation of Rb.
p17032
sg16446
(lp17033
(dp17034
g16449
I29
sg16450
I1
sg16451
I4
sg16452
VP00441
p17035
sg16454
VSOD1
p17036
sa(dp17037
g16449
I157
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCdk5
p17038
sa(dp17039
g16449
I162
sg16450
I1
sg16451
I4
sg16452
VP11802
p17040
sg16454
VCdk4
p17041
sasg16456
(lp17042
sa(dp17043
g16444
VSeventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules.
p17044
sg16446
(lp17045
(dp17046
g16449
I57
sg16450
I3
sg16451
I36
sg16452
VP35398
p17047
sg16454
VT-cell-specific transcription factor
p17048
sa(dp17049
g16449
I276
sg16450
I3
sg16451
I18
sg16452
VP11473
p17050
sg16454
Vvitamin D receptor
p17051
sa(dp17052
g16449
I109
sg16450
I3
sg16451
I39
sg16452
VP00519
p17053
sg16454
V"proto-oncogene tyrosine-protein kinase
p17054
sa(dp17055
g16449
I399
sg16450
I6
sg16451
I31
sg16452
g11
sg16454
VPR domain zinc finger protein 1
p17056
sa(dp17057
g16449
I322
sg16450
I1
sg16451
I3
sg16452
VP29323
p17058
sg16454
VERK
p17059
sa(dp17060
g16449
I362
sg16450
I4
sg16451
I35
sg16452
VP20823
p17061
sg16454
Vrunt-related transcription factor 1
p17062
sa(dp17063
g16449
I477
sg16450
I2
sg16451
I13
sg16452
VP01584
p17064
sg16454
Vinterleukin 1
p17065
sa(dp17066
g16449
I152
sg16450
I1
sg16451
I8
sg16452
VP12931
p17067
sg16454
Vsarcoma"
p17068
sa(dp17069
g16449
I163
sg16450
I4
sg16451
I30
sg16452
VP10914
p17070
sg16454
Vinterferon regulatory factor 1
p17071
sa(dp17072
g16449
I227
sg16450
I4
sg16451
I31
sg16452
VP49336
p17073
sg16454
Vcyclin-dependent kinase (CDK) 4
p17074
sa(dp17075
g16449
I296
sg16450
I2
sg16451
I19
sg16452
VP56524
p17076
sg16454
Vhistone deacetylase
p17077
sa(dp17078
g16449
I95
sg16450
I1
sg16451
I3
sg16452
VP12931
p17079
sg16454
VSrc
p17080
sa(dp17081
g16449
I217
sg16450
I2
sg16451
I8
sg16452
VP14635
p17082
sg16454
Vcyclin B
p17083
sa(dp17084
g16449
I334
sg16450
I3
sg16451
I26
sg16452
VP10415
p17085
sg16454
Vbcl-2-associated X protein
p17086
sa(dp17087
g16449
I317
sg16450
I1
sg16451
I4
sg16452
VP53779
p17088
sg16454
VMAPK
p17089
sa(dp17090
g16449
I432
sg16450
I4
sg16451
I39
sg16452
VP09619
p17091
sg16454
Vplatelet-derived growth factor receptor
p17092
sa(dp17093
g16449
I265
sg16450
I1
sg16451
I9
sg16452
VP29466
p17094
sg16454
Vcaspase-1
p17095
sa(dp17096
g16449
I195
sg16450
I2
sg16451
I20
sg16452
VP04818
p17097
sg16454
Vthymidylate synthase
p17098
sa(dp17099
g16449
I252
sg16450
I1
sg16451
I3
sg16452
VP24941
p17100
sg16454
VCDK
p17101
sasg16456
(lp17102
(dp17103
g16449
I152
sg16450
I1
sg16451
I7
sg16459
VC1261473
p17104
sg16454
Vsarcoma
p17105
sa(dp17106
g16449
I362
sg16450
I1
sg16451
I4
sg16459
VC0013336
p17107
sg16454
Vrunt
p17108
sasa(dp17109
g16444
VTherefore, targeting the caspase-1/PPARGamma/MCAD pathway might be a promising therapeutic approach to prevent tumor progression.Tumor associated macrophages (TAMs) promote cancer progression.
p17110
sg16446
(lp17111
(dp17112
g16449
I45
sg16450
I1
sg16451
I4
sg16452
VP11310
p17113
sg16454
VMCAD
p17114
sa(dp17115
g16449
I25
sg16450
I1
sg16451
I9
sg16452
VP29466
p17116
sg16454
Vcaspase-1
p17117
sasg16456
(lp17118
(dp17119
g16449
I173
sg16450
I2
sg16451
I18
sg16459
VC0178874
p17120
sg16454
Vcancer progression
p17121
sa(dp17122
g16449
I45
sg16450
I1
sg16451
I4
sg16459
VC0220710
p17123
sg16454
VMCAD
p17124
sa(dp17125
g16449
I129
sg16450
I1
sg16451
I5
sg16459
VC0027651
p17126
sg16454
VTumor
p17127
sa(dp17128
g16449
I111
sg16450
I2
sg16451
I17
sg16459
VC0178874
p17129
sg16454
Vtumor progression
p17130
sasa(dp17131
g16444
VHere, the author show that caspase-1 promotes TAMs differentiation by attenuating medium-chain acyl-CoA dehydrogenase activity and that inhibition of this axis results in suppression of tumour growth in a transgenic mouse model of breast cancer.
p17132
sg16446
(lp17133
(dp17134
g16449
I95
sg16450
I2
sg16451
I22
sg16452
VP49366
p17135
sg16454
Vacyl-CoA dehydrogenase
p17136
sa(dp17137
g16449
I27
sg16450
I1
sg16451
I9
sg16452
VP29466
p17138
sg16454
Vcaspase-1
p17139
sasg16456
(lp17140
(dp17141
g16449
I100
sg16450
I1
sg16451
I3
sg16459
VC2678439
p17142
sg16454
VCoA
p17143
sa(dp17144
g16449
I231
sg16450
I2
sg16451
I13
sg16459
VC0678222
p17145
sg16454
Vbreast cancer
p17146
sa(dp17147
g16449
I171
sg16450
I1
sg16451
I11
sg16459
VC0221103
p17148
sg16454
Vsuppression
p17149
sa(dp17150
g16449
I186
sg16450
I1
sg16451
I6
sg16459
VC0027651
p17151
sg16454
Vtumour
p17152
sasa(dp17153
g16444
VEnsuing western blotting or immunostaining results showed that Rictor/mTORC2 signaling was activated in kidney interstitial myofibroblasts from mice with unilateral ureteral obstruction.
p17154
sg16446
(lp17155
(dp17156
g16449
I63
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRictor
p17157
sasg16456
(lp17158
(dp17159
g16449
I165
sg16450
I2
sg16451
I20
sg16459
VC0041956
p17160
sg16454
Vureteral obstruction
p17161
sasa(dp17162
g16444
VCompared with control littermates, the kidneys of Rictor knockout mice developed less interstitial extracellular matrix deposition and inflammatory cell infiltration at 1 or 2 weeks after ureteral obstruction.
p17163
sg16446
(lp17164
sg16456
(lp17165
(dp17166
g16449
I188
sg16450
I2
sg16451
I20
sg16459
VC0041956
p17167
sg16454
Vureteral obstruction
p17168
sa(dp17169
g16449
I135
sg16450
I3
sg16451
I30
sg16459
VC0302158
p17170
sg16454
Vinflammatory cell infiltration
p17171
sasa(dp17172
g16444
VLess progression of Hoffa-synovitis and effusion-synovitis was observed in the TG-C group compared to placebo (9.6% vs. 21.1%, adjusted RR 0.5, 95%CI [0.2,1.2], p = 0.115).
p17173
sg16446
(lp17174
sg16456
(lp17175
(dp17176
g16449
I40
sg16450
I1
sg16451
I8
sg16459
VC0013687
p17177
sg16454
Veffusion
p17178
sa(dp17179
g16449
I26
sg16450
I1
sg16451
I9
sg16459
VC0039103
p17180
sg16454
Vsynovitis
p17181
sa(dp17182
g16449
I26
sg16450
I1
sg16451
I9
sg16459
VC0039103
p17183
sg16454
Vsynovitis
p17184
sasa(dp17185
g16444
VIntraarticular treatment with TG-C showed fewer patients in the treated group with progression in structural OA features and other MRI-defined inflammatory markers such as Hoffa-synovitis and effusion-synovitis.
p17186
sg16446
(lp17187
sg16456
(lp17188
(dp17189
g16449
I192
sg16450
I1
sg16451
I8
sg16459
VC0013687
p17190
sg16454
Veffusion
p17191
sa(dp17192
g16449
I178
sg16450
I1
sg16451
I9
sg16459
VC0039103
p17193
sg16454
Vsynovitis
p17194
sa(dp17195
g16449
I178
sg16450
I1
sg16451
I9
sg16459
VC0039103
p17196
sg16454
Vsynovitis
p17197
sasa(dp17198
g16444
VA total of 104 patients (89.4% females) fulfilling the 1990 ACR criteria for FMS and the Rome III criteria for IBS classification and 125 unrelated age- and sex-matched IBS patients without FMS underwent the following studies: haematological, coagulation and biochemistry tests, serological and genetic markers for CD (i.e., tissue transglutaminase 2 (tTG-2) and major histocompatibility complex HLA-DQ2/HLA-DQ8), multiple gastric and duodenal biopsies, FMS tender points (TPs), Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire (HAQ), 36-Item Short Form Health Survey (SF-36) and Visual Analogue Scales (VASs) for tiredness and gastrointestinal complaints.
p17199
sg16446
(lp17200
(dp17201
g16449
I325
sg16450
I3
sg16451
I25
sg16452
VP21980
p17202
sg16454
Vtissue transglutaminase 2
p17203
sa(dp17204
g16449
I400
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VDQ2
p17205
sa(dp17206
g16449
I363
sg16450
I4
sg16451
I36
sg16452
VP18464
p17207
sg16454
Vmajor histocompatibility complex HLA
p17208
sa(dp17209
g16449
I352
sg16450
I1
sg16451
I5
sg16452
VP21980
p17210
sg16454
VtTG-2
p17211
sa(dp17212
g16449
I404
sg16450
I1
sg16451
I7
sg16452
VP30486
p17213
sg16454
VHLA-DQ8
p17214
sasg16456
(lp17215
(dp17216
g16449
I111
sg16450
I1
sg16451
I3
sg16459
VC0022104
p17217
sg16454
VIBS
p17218
sa(dp17219
g16449
I77
sg16450
I1
sg16451
I3
sg16459
VC0016053
p17220
sg16454
VFMS
p17221
sa(dp17222
g16449
I638
sg16450
I1
sg16451
I9
sg16459
VC0015672
p17223
sg16454
Vtiredness
p17224
sa(dp17225
g16449
I479
sg16450
I1
sg16451
I12
sg16459
VC0016053
p17226
sg16454
VFibromyalgia
p17227
sa(dp17228
g16449
I77
sg16450
I1
sg16451
I3
sg16459
VC0016053
p17229
sg16454
VFMS
p17230
sa(dp17231
g16449
I77
sg16450
I1
sg16451
I3
sg16459
VC0016053
p17232
sg16454
VFMS
p17233
sa(dp17234
g16449
I111
sg16450
I1
sg16451
I3
sg16459
VC0022104
p17235
sg16454
VIBS
p17236
sasa(dp17237
g16444
VGFD effectiveness was assessed at baseline and after 1 year, examining the score changes in the Tender Points (TPs) test, Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire (HAQ), Short Form Health Survey (SF-36), Visual Analogue Scales (VAS) for gastrointestinal complaints, pain and tiredness, drug prescriptions and tissue-Trans-Glutaminase (tTG) serum levels.
p17238
sg16446
(lp17239
(dp17240
g16449
I367
sg16450
I1
sg16451
I3
sg16452
VP21980
p17241
sg16454
VtTG
p17242
sa(dp17243
g16449
I341
sg16450
I1
sg16451
I24
sg16452
g11
sg16454
Vtissue-Trans-Glutaminase
p17244
sasg16456
(lp17245
(dp17246
g16449
I307
sg16450
I1
sg16451
I9
sg16459
VC0015672
p17247
sg16454
Vtiredness
p17248
sa(dp17249
g16449
I0
sg16450
I1
sg16451
I3
sg16459
VC1851112
p17250
sg16454
VGFD
p17251
sa(dp17252
g16449
I122
sg16450
I1
sg16451
I12
sg16459
VC0016053
p17253
sg16454
VFibromyalgia
p17254
sasa(dp17255
g16444
VNon-organ specific AAb (ANA, anti-Ro52, anti-Ro60, anti-La, anti-RNP) but not anti-thyroid peroxidase, anti-tissue transglutaminase or myositis-specific antibodies, were more frequent in s-IBM patients, and 14/51 (27%) had another autoimmune disease (Sjoegren's syndrome, thyroiditis, psoriasis, vitiligo).
p17256
sg16446
(lp17257
(dp17258
g16449
I40
sg16450
I1
sg16451
I9
sg16452
VP10155
p17259
sg16454
Vanti-Ro60
p17260
sa(dp17261
g16449
I78
sg16450
I2
sg16451
I23
sg16452
VP40225
p17262
sg16454
Vanti-thyroid peroxidase
p17263
sa(dp17264
g16449
I60
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
Vanti-RNP
p17265
sa(dp17266
g16449
I135
sg16450
I2
sg16451
I28
sg16452
VP04280
p17267
sg16454
Vmyositis-specific antibodies
p17268
sa(dp17269
g16449
I24
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VANA
p17270
sa(dp17271
g16449
I29
sg16450
I1
sg16451
I9
sg16452
VP19474
p17272
sg16454
Vanti-Ro52
p17273
sa(dp17274
g16449
I103
sg16450
I2
sg16451
I28
sg16452
VP21980
p17275
sg16454
Vanti-tissue transglutaminase
p17276
sasg16456
(lp17277
(dp17278
g16449
I189
sg16450
I1
sg16451
I3
sg16459
VC0238190
p17279
sg16454
VIBM
p17280
sa(dp17281
g16449
I251
sg16450
I2
sg16451
I19
sg16459
VC1527336
p17282
sg16454
VSjoegren's syndrome
p17283
sa(dp17284
g16449
I231
sg16450
I2
sg16451
I18
sg16459
VC0004364
p17285
sg16454
Vautoimmune disease
p17286
sa(dp17287
g16449
I296
sg16450
I1
sg16451
I8
sg16459
VC0042900
p17288
sg16454
Vvitiligo
p17289
sa(dp17290
g16449
I135
sg16450
I1
sg16451
I8
sg16459
VC0027121
p17291
sg16454
Vmyositis
p17292
sa(dp17293
g16449
I272
sg16450
I1
sg16451
I11
sg16459
VC0040147
p17294
sg16454
Vthyroiditis
p17295
sa(dp17296
g16449
I285
sg16450
I1
sg16451
I9
sg16459
VC0033860
p17297
sg16454
Vpsoriasis
p17298
sasa(dp17299
g16444
VBy applying CD146 and CD105 antibodies on human retinas from glaucomatous eyes, CD146-positive retinal ganglion cells (RGCs) were found, some being placed in perivascular positions; ongoing processes of neurites extension were related to these neurons.
p17300
sg16446
(lp17301
(dp17302
g16449
I12
sg16450
I1
sg16451
I5
sg16452
VP43121
p17303
sg16454
VCD146
p17304
sa(dp17305
g16449
I12
sg16450
I1
sg16451
I5
sg16452
VP43121
p17306
sg16454
VCD146
p17307
sa(dp17308
g16449
I22
sg16450
I1
sg16451
I5
sg16452
VP17813
p17309
sg16454
VCD105
p17310
sasg16456
(lp17311
(dp17312
g16449
I103
sg16450
I1
sg16451
I8
sg16459
VC1258666
p17313
sg16454
Vganglion
p17314
sasa(dp17315
g16444
VThese results support the hypothesis that in glaucoma eyes the CD146-positive RGCs result from regenerative processes driven by stem cells in the retinal perivascular niches.
p17316
sg16446
(lp17317
(dp17318
g16449
I63
sg16450
I2
sg16451
I19
sg16452
VP43121
p17319
sg16454
VCD146-positive RGCs
p17320
sasg16456
(lp17321
(dp17322
g16449
I45
sg16450
I1
sg16451
I8
sg16459
VC0017601
p17323
sg16454
Vglaucoma
p17324
sasa(dp17325
g16444
VCD146/MCAM and CD166/ALCAM, previously unreported in cells from fvERMs, were also expressed.
p17326
sg16446
(lp17327
(dp17328
g16449
I15
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCD166
p17329
sa(dp17330
g16449
I21
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VALCAM
p17331
sa(dp17332
g16449
I6
sg16450
I1
sg16451
I4
sg16452
VP43121
p17333
sg16454
VMCAM
p17334
sa(dp17335
g16449
I0
sg16450
I1
sg16451
I5
sg16452
VP43121
p17336
sg16454
VCD146
p17337
sasg16456
(lp17338
sa(dp17339
g16444
VTwo new and potentially promising melanocytic markers, microphthalmia transcription factor (MiTF) and melanoma cell adhesion molecule (Mel-CAM), have been shown to be sensitive markers of epithelioid melanoma, but have not been tested in desmoplastic/spindle cell melanoma or in other rare melanocytic neuroectodermal tumors such as clear cell sarcoma.
p17340
sg16446
(lp17341
(dp17342
g16449
I55
sg16450
I3
sg16451
I35
sg16452
VP35398
p17343
sg16454
Vmicrophthalmia transcription factor
p17344
sa(dp17345
g16449
I135
sg16450
I1
sg16451
I7
sg16452
VP61006
p17346
sg16454
VMel-CAM
p17347
sa(dp17348
g16449
I92
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VMiTF
p17349
sa(dp17350
g16449
I102
sg16450
I4
sg16451
I31
sg16452
VP43121
p17351
sg16454
Vmelanoma cell adhesion molecule
p17352
sasg16456
(lp17353
(dp17354
g16449
I238
sg16450
I1
sg16451
I12
sg16459
VC1511789
p17355
sg16454
Vdesmoplastic
p17356
sa(dp17357
g16449
I55
sg16450
I1
sg16451
I14
sg16459
VC0026010
p17358
sg16454
Vmicrophthalmia
p17359
sa(dp17360
g16449
I333
sg16450
I3
sg16451
I18
sg16459
VC0206651
p17361
sg16454
Vclear cell sarcoma
p17362
sa(dp17363
g16449
I139
sg16450
I1
sg16451
I3
sg16459
VC1861821
p17364
sg16454
VCAM
p17365
sa(dp17366
g16449
I135
sg16450
I1
sg16451
I3
sg16459
VC3149631
p17367
sg16454
VMel
p17368
sa(dp17369
g16449
I188
sg16450
I2
sg16451
I20
sg16459
VC0334443
p17370
sg16454
Vepithelioid melanoma
p17371
sa(dp17372
g16449
I302
sg16450
I2
sg16451
I22
sg16459
VC0206093
p17373
sg16454
Vneuroectodermal tumors
p17374
sa(dp17375
g16449
I102
sg16450
I1
sg16451
I8
sg16459
VC0025202
p17376
sg16454
Vmelanoma
p17377
sa(dp17378
g16449
I251
sg16450
I3
sg16451
I21
sg16459
VC0334444
p17379
sg16454
Vspindle cell melanoma
p17380
sa(dp17381
g16449
I116
sg16450
I1
sg16451
I8
sg16459
VC0001511
p17382
sg16454
Vadhesion
p17383
sasa(dp17384
g16444
VWe investigated the effect of carnosine as an adjuvant therapy on urinary albumin excretion (UAE), the tubular damage marker alpha 1-microglobulin (A1M), and oxidative stress in pediatric patients with type 1 diabetes and nephropathy.
p17385
sg16446
(lp17386
(dp17387
g16449
I74
sg16450
I1
sg16451
I7
sg16452
VP00441
p17388
sg16454
Valbumin
p17389
sa(dp17390
g16449
I125
sg16450
I2
sg16451
I21
sg16452
VP25100
p17391
sg16454
Valpha 1-microglobulin
p17392
sa(dp17393
g16449
I148
sg16450
I1
sg16451
I3
sg16452
VP02760
p17394
sg16454
VA1M
p17395
sasg16456
(lp17396
(dp17397
g16449
I158
sg16450
I2
sg16451
I16
sg16459
VC0242606
p17398
sg16454
Voxidative stress
p17399
sa(dp17400
g16449
I202
sg16450
I3
sg16451
I15
sg16459
VC0011854
p17401
sg16454
Vtype 1 diabetes
p17402
sa(dp17403
g16449
I222
sg16450
I1
sg16451
I11
sg16459
VC0022658
p17404
sg16454
Vnephropathy
p17405
sasa(dp17406
g16444
VThe following parameters were measured in 377 patients with type 2 diabetes: HbA1c, serum concentrations of 1,5-AG, GA and creatinine, hemoglobin, urinary albumin/creatinine ratio, and urinary excretion of Alfa1 -microglobulin (A1M).
p17407
sg16446
(lp17408
(dp17409
g16449
I206
sg16450
I2
sg16451
I20
sg16452
VP02760
p17410
sg16454
VAlfa1 -microglobulin
p17411
sa(dp17412
g16449
I135
sg16450
I1
sg16451
I10
sg16452
g11
sg16454
Vhemoglobin
p17413
sa(dp17414
g16449
I155
sg16450
I1
sg16451
I7
sg16452
VP00441
p17415
sg16454
Valbumin
p17416
sa(dp17417
g16449
I228
sg16450
I1
sg16451
I3
sg16452
VP02760
p17418
sg16454
VA1M
p17419
sasg16456
(lp17420
(dp17421
g16449
I60
sg16450
I3
sg16451
I15
sg16459
VC0011860
p17422
sg16454
Vtype 2 diabetes
p17423
sasa(dp17424
g16444
VVonoprazan Fumarate (TAK-438F) is a new and effective drug approved in Japan in 2014 for treatment and prevention of acid-related diseases (ARDs), which exhibits many advantages compared with traditional proton-pump inhibitors (PPIs).
p17425
sg16446
(lp17426
(dp17427
g16449
I21
sg16450
I1
sg16451
I8
sg16452
VP50750
p17428
sg16454
VTAK-438F
p17429
sasg16456
(lp17430
(dp17431
g16449
I117
sg16450
I2
sg16451
I21
sg16459
VC0035222
p17432
sg16454
Vacid-related diseases
p17433
sa(dp17434
g16449
I140
sg16450
I1
sg16451
I4
sg16459
VC0035222
p17435
sg16454
VARDs
p17436
sasa(dp17437
g16444
VIn many countries, the introduction of generic proton pump inhibitors (PPIs) onto the pharmaceutical market increased the phenomenon of therapeutic substitution in acid-related disorders (ARDs).
p17438
sg16446
(lp17439
sg16456
(lp17440
(dp17441
g16449
I164
sg16450
I2
sg16451
I22
sg16459
VC0035222
p17442
sg16454
Vacid-related disorders
p17443
sa(dp17444
g16449
I188
sg16450
I1
sg16451
I4
sg16459
VC0035222
p17445
sg16454
VARDs
p17446
sasa(dp17447
g16444
VWe present confirmatory evidence for a role of dystonia genes that had not yet been unequivocally established including PRKRA, TUBB4A, ANO3, and TAF1.
p17448
sg16446
(lp17449
(dp17450
g16449
I120
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VPRKRA
p17451
sa(dp17452
g16449
I135
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VANO3
p17453
sasg16456
(lp17454
(dp17455
g16449
I47
sg16450
I1
sg16451
I8
sg16459
VC0393593
p17456
sg16454
Vdystonia
p17457
sasa(dp17458
g16444
VANO3 encodes anoctamin-3, a Ca+2-dependent phospholipid scramblase expressed in striatal-neurons, that has been implicated in autosomal dominant craniocervical dystonia (Dystonia-24, DYT24, MIM# 615034).
p17459
sg16446
(lp17460
(dp17461
g16449
I13
sg16450
I1
sg16451
I11
sg16452
g11
sg16454
Vanoctamin-3
p17462
sa(dp17463
g16449
I0
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VANO3
p17464
sa(dp17465
g16449
I28
sg16450
I3
sg16451
I38
sg16452
VP19525
p17466
sg16454
VCa+2-dependent phospholipid scramblase
p17467
sasg16456
(lp17468
(dp17469
g16449
I160
sg16450
I1
sg16451
I8
sg16459
VC0393593
p17470
sg16454
Vdystonia
p17471
sa(dp17472
g16449
I170
sg16450
I1
sg16451
I8
sg16459
VC0393593
p17473
sg16454
VDystonia
p17474
sasa(dp17475
g16444
VThree genes (GCH1, THAP1, TOR1A) were associated with isolated generalized dystonia, whereas 2 (ANO3, ADCY5) gave rise to combined dystonia-myoclonus phenotypes.
p17476
sg16446
(lp17477
(dp17478
g16449
I102
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VADCY5
p17479
sa(dp17480
g16449
I13
sg16450
I1
sg16451
I4
sg16452
VP30793
p17481
sg16454
VGCH1
p17482
sa(dp17483
g16449
I26
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTOR1A
p17484
sa(dp17485
g16449
I19
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTHAP1
p17486
sa(dp17487
g16449
I96
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VANO3
p17488
sasg16456
(lp17489
(dp17490
g16449
I75
sg16450
I1
sg16451
I8
sg16459
VC0393593
p17491
sg16454
Vdystonia
p17492
sa(dp17493
g16449
I63
sg16450
I2
sg16451
I20
sg16459
VC1848954
p17494
sg16454
Vgeneralized dystonia
p17495
sa(dp17496
g16449
I140
sg16450
I1
sg16451
I9
sg16459
VC0027066
p17497
sg16454
Vmyoclonus
p17498
sasa(dp17499
g16444
VFurthermore, it provides confirmatory evidence for a dystonia-relevant role of ANO3 and ADCY5, both of which likely associate with a broader spectrum of dystonic expressions than previously thought.
p17500
sg16446
(lp17501
(dp17502
g16449
I88
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VADCY5
p17503
sa(dp17504
g16449
I79
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VANO3
p17505
sasg16456
(lp17506
(dp17507
g16449
I53
sg16450
I1
sg16451
I8
sg16459
VC0393593
p17508
sg16454
Vdystonia
p17509
sasa(dp17510
g16444
VIn the past 4 years, the definition and classification of dystonia have been revised, and new genes have been identified in patients with isolated hereditary dystonia (DYT23, DYT24, and DYT25).
p17511
sg16446
(lp17512
sg16456
(lp17513
(dp17514
g16449
I58
sg16450
I1
sg16451
I8
sg16459
VC0393593
p17515
sg16454
Vdystonia
p17516
sa(dp17517
g16449
I147
sg16450
I2
sg16451
I19
sg16459
VC0752207
p17518
sg16454
Vhereditary dystonia
p17519
sasa(dp17520
g16444
VCompromised anoctamin function is causing a wide range of diseases, such as hearing loss (ANO2), bleeding disorder (ANO6), ataxia and dystonia (ANO3, 10), persistent borrelia and mycobacteria infection (ANO10), skeletal syndromes like gnathodiaphyseal dysplasia and limb girdle muscle dystrophy (ANO5), and cancer (ANO1, 6, 7).
p17521
sg16446
(lp17522
(dp17523
g16449
I266
sg16450
I5
sg16451
I35
sg16452
g11
sg16454
Vlimb girdle muscle dystrophy (ANO5)
p17524
sa(dp17525
g16449
I203
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VANO10
p17526
sasg16456
(lp17527
(dp17528
g16449
I166
sg16450
I1
sg16451
I8
sg16459
VC0024198
p17529
sg16454
Vborrelia
p17530
sa(dp17531
g16449
I97
sg16450
I2
sg16451
I17
sg16459
VC0005779
p17532
sg16454
Vbleeding disorder
p17533
sa(dp17534
g16449
I192
sg16450
I1
sg16451
I9
sg16459
VC0009450
p17535
sg16454
Vinfection
p17536
sa(dp17537
g16449
I134
sg16450
I1
sg16451
I8
sg16459
VC0393593
p17538
sg16454
Vdystonia
p17539
sa(dp17540
g16449
I123
sg16450
I1
sg16451
I6
sg16459
VC0004134
p17541
sg16454
Vataxia
p17542
sa(dp17543
g16449
I307
sg16450
I1
sg16451
I6
sg16459
VC0006826
p17544
sg16454
Vcancer
p17545
sa(dp17546
g16449
I220
sg16450
I1
sg16451
I9
sg16459
VC0039082
p17547
sg16454
Vsyndromes
p17548
sa(dp17549
g16449
I235
sg16450
I2
sg16451
I26
sg16459
VC1833736
p17550
sg16454
Vgnathodiaphyseal dysplasia
p17551
sa(dp17552
g16449
I76
sg16450
I2
sg16451
I12
sg16459
VC0011053
p17553
sg16454
Vhearing loss
p17554
sa(dp17555
g16449
I285
sg16450
I1
sg16451
I9
sg16459
VC0333606
p17556
sg16454
Vdystrophy
p17557
sasa(dp17558
g16444
VSome genes, such as ANO3, GNAL and CIZ1, have been discovered for isolated dystonia, but they are probably not a common cause of classic cervical dystonia.
p17559
sg16446
(lp17560
(dp17561
g16449
I20
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VANO3
p17562
sa(dp17563
g16449
I35
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCIZ1
p17564
sa(dp17565
g16449
I26
sg16450
I1
sg16451
I4
sg16452
VP38405
p17566
sg16454
VGNAL
p17567
sasg16456
(lp17568
(dp17569
g16449
I75
sg16450
I1
sg16451
I8
sg16459
VC0393593
p17570
sg16454
Vdystonia
p17571
sa(dp17572
g16449
I137
sg16450
I2
sg16451
I17
sg16459
VC0949445
p17573
sg16454
Vcervical dystonia
p17574
sasa(dp17575
g16444
VClinical and genetic heterogeneity also characterizes myoclonus-dystonia, which includes not only the classical phenotype associated with epsilon-sarcoglycan mutations but rarely also presentation of ANO3 gene mutations, TITF1 gene mutations typically underlying benign hereditary chorea, and some dopamine synthesis pathway conditions due to GCH1 and TH mutations.
p17576
sg16446
(lp17577
(dp17578
g16449
I221
sg16450
I2
sg16451
I10
sg16452
VP43699
p17579
sg16454
VTITF1 gene
p17580
sa(dp17581
g16449
I200
sg16450
I2
sg16451
I9
sg16452
g11
sg16454
VANO3 gene
p17582
sa(dp17583
g16449
I343
sg16450
I1
sg16451
I4
sg16452
VP30793
p17584
sg16454
VGCH1
p17585
sasg16456
(lp17586
(dp17587
g16449
I54
sg16450
I1
sg16451
I9
sg16459
VC0027066
p17588
sg16454
Vmyoclonus
p17589
sa(dp17590
g16449
I64
sg16450
I1
sg16451
I8
sg16459
VC0393593
p17591
sg16454
Vdystonia
p17592
sa(dp17593
g16449
I263
sg16450
I3
sg16451
I24
sg16459
VC0393584
p17594
sg16454
Vbenign hereditary chorea
p17595
sasa(dp17596
g16444
VWhen 10 cases of M5 were subdivided by the differential level into undifferentiated (M5a) and differentiated monocytic leukemia (M5b), expression of CD45RA and CD45RO was strictly restricted to cases with M5a and M5b, respectively.
p17597
sg16446
(lp17598
sg16456
(lp17599
(dp17600
g16449
I129
sg16450
I1
sg16451
I3
sg16459
VC0598894
p17601
sg16454
VM5b
p17602
sa(dp17603
g16449
I109
sg16450
I2
sg16451
I18
sg16459
VC0598894
p17604
sg16454
Vmonocytic leukemia
p17605
sa(dp17606
g16449
I129
sg16450
I1
sg16451
I3
sg16459
VC0598894
p17607
sg16454
VM5b
p17608
sasa(dp17609
g16444
VIn this review, we describe the fusion genes recently reported in bone and soft-tissue tumors such as solitary fibrous tumor, aneurysmal bone cyst, nodular fasciitis, CIC-DUX4 fusion gene-positive small round cell tumors, or BCOR-CCNB3-positive sarcoma as well as other genetic aberrations in dedifferentiated liposarcoma, malignant rhabdoid tumor, cartilaginous tumor, Langerhans cell histiocytosis chondroblastoma, or giant cell tumor of the bone.
p17610
sg16446
(lp17611
(dp17612
g16449
I171
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VDUX4
p17613
sa(dp17614
g16449
I225
sg16450
I1
sg16451
I10
sg16452
g11
sg16454
VBCOR-CCNB3
p17615
sa(dp17616
g16449
I167
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VCIC
p17617
sasg16456
(lp17618
(dp17619
g16449
I245
sg16450
I1
sg16451
I7
sg16459
VC1261473
p17620
sg16454
Vsarcoma
p17621
sa(dp17622
g16449
I87
sg16450
I1
sg16451
I6
sg16459
VC0027651
p17623
sg16454
Vtumors
p17624
sa(dp17625
g16449
I420
sg16450
I1
sg16451
I5
sg16459
VC0017547
p17626
sg16454
Vgiant
p17627
sa(dp17628
g16449
I349
sg16450
I2
sg16451
I19
sg16459
VC0476147
p17629
sg16454
Vcartilaginous tumor
p17630
sa(dp17631
g16449
I148
sg16450
I2
sg16451
I17
sg16459
VC0410005
p17632
sg16454
Vnodular fasciitis
p17633
sa(dp17634
g16449
I370
sg16450
I3
sg16451
I29
sg16459
VC0019621
p17635
sg16454
VLangerhans cell histiocytosis
p17636
sa(dp17637
g16449
I87
sg16450
I1
sg16451
I6
sg16459
VC0027651
p17638
sg16454
Vtumors
p17639
sa(dp17640
g16449
I293
sg16450
I2
sg16451
I28
sg16459
VC0205824
p17641
sg16454
Vdedifferentiated liposarcoma
p17642
sa(dp17643
g16449
I400
sg16450
I1
sg16451
I15
sg16459
VC0008441
p17644
sg16454
Vchondroblastoma
p17645
sa(dp17646
g16449
I323
sg16450
I3
sg16451
I24
sg16459
VC0206743
p17647
sg16454
Vmalignant rhabdoid tumor
p17648
sa(dp17649
g16449
I102
sg16450
I3
sg16451
I22
sg16459
VC1266119
p17650
sg16454
Vsolitary fibrous tumor
p17651
sa(dp17652
g16449
I431
sg16450
I4
sg16451
I17
sg16459
VC0005967
p17653
sg16454
Vtumor of the bone
p17654
sa(dp17655
g16449
I126
sg16450
I3
sg16451
I20
sg16459
VC0152244
p17656
sg16454
Vaneurysmal bone cyst
p17657
sasa(dp17658
g16444
VThe individual diagnostic marker positivity was 98% for GATA-binding protein 3, 95% for androgen receptor, 90% for progesterone receptor, 88% for deleted in pancreatic cancer 4, 75% for gross cystic disease fluid protein 15, 72% for cytokeratin 7, 55% for mammaglobin, and 15% for vimentin and Wilms tumor protein 1.
p17659
sg16446
(lp17660
(dp17661
g16449
I56
sg16450
I3
sg16451
I22
sg16452
VP23771
p17662
sg16454
VGATA-binding protein 3
p17663
sa(dp17664
g16449
I256
sg16450
I1
sg16451
I11
sg16452
g11
sg16454
Vmammaglobin
p17665
sa(dp17666
g16449
I115
sg16450
I2
sg16451
I21
sg16452
VP06401
p17667
sg16454
Vprogesterone receptor
p17668
sa(dp17669
g16449
I88
sg16450
I2
sg16451
I17
sg16452
VP10275
p17670
sg16454
Vandrogen receptor
p17671
sa(dp17672
g16449
I294
sg16450
I4
sg16451
I21
sg16452
VP14222
p17673
sg16454
VWilms tumor protein 1
p17674
sasg16456
(lp17675
(dp17676
g16449
I192
sg16450
I2
sg16451
I14
sg16459
VC0334054
p17677
sg16454
Vcystic disease
p17678
sa(dp17679
g16449
I157
sg16450
I2
sg16451
I17
sg16459
VC0235974
p17680
sg16454
Vpancreatic cancer
p17681
sa(dp17682
g16449
I294
sg16450
I2
sg16451
I11
sg16459
VC0027708
p17683
sg16454
VWilms tumor
p17684
sasa(dp17685
g16444
VAstrocyte loss may be caused by cytotoxic T cells as seen in Rasmussen encephalitis, auto-antibodies such as in neuromyelitis optica (aquaporin-4 antibodies), or cytokines such as TNF-Alfa in major depressive disorder.
p17686
sg16446
(lp17687
(dp17688
g16449
I180
sg16450
I1
sg16451
I8
sg16452
VP01375
p17689
sg16454
VTNF-Alfa
p17690
sa(dp17691
g16449
I134
sg16450
I2
sg16451
I22
sg16452
VP55087
p17692
sg16454
Vaquaporin-4 antibodies
p17693
sasg16456
(lp17694
(dp17695
g16449
I112
sg16450
I2
sg16451
I20
sg16459
VC0027873
p17696
sg16454
Vneuromyelitis optica
p17697
sa(dp17698
g16449
I61
sg16450
I2
sg16451
I22
sg16459
VC0393484
p17699
sg16454
VRasmussen encephalitis
p17700
sa(dp17701
g16449
I192
sg16450
I3
sg16451
I25
sg16459
VC1269683
p17702
sg16454
Vmajor depressive disorder
p17703
sasa(dp17704
g16444
VMutations in KCNJ5, ATP1A1, ATP2B3 and CACNA1D are found in aldosterone producing adenoma (APA) and familial hyperaldosteronism (FH).
p17705
sg16446
(lp17706
(dp17707
g16449
I13
sg16450
I1
sg16451
I5
sg16452
VP48544
p17708
sg16454
VKCNJ5
p17709
sa(dp17710
g16449
I39
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCACNA1D
p17711
sa(dp17712
g16449
I20
sg16450
I1
sg16451
I6
sg16452
VP05023
p17713
sg16454
VATP1A1
p17714
sa(dp17715
g16449
I28
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VATP2B3
p17716
sasg16456
(lp17717
(dp17718
g16449
I82
sg16450
I1
sg16451
I7
sg16459
VC0001430
p17719
sg16454
Vadenoma
p17720
sa(dp17721
g16449
I109
sg16450
I1
sg16451
I18
sg16459
VC0020428
p17722
sg16454
Vhyperaldosteronism
p17723
sasa(dp17724
g16444
VOur results suggest that these mutations, in addition to mutations in the KCNJ5 gene and other genes such as ATP1A1, ATP2B3 and CACNA1D, may be responsible for the tumorigenesis of APAs and CPAs with subclinical Cushing's syndrome.
p17725
sg16446
(lp17726
(dp17727
g16449
I74
sg16450
I2
sg16451
I10
sg16452
VP48544
p17728
sg16454
VKCNJ5 gene
p17729
sa(dp17730
g16449
I117
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VATP2B3
p17731
sa(dp17732
g16449
I128
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCACNA1D
p17733
sa(dp17734
g16449
I109
sg16450
I1
sg16451
I6
sg16452
VP05023
p17735
sg16454
VATP1A1
p17736
sasg16456
(lp17737
(dp17738
g16449
I164
sg16450
I1
sg16451
I13
sg16459
VC0007621
p17739
sg16454
Vtumorigenesis
p17740
sa(dp17741
g16449
I212
sg16450
I2
sg16451
I18
sg16459
VC0010481
p17742
sg16454
VCushing's syndrome
p17743
sasa(dp17744
g16444
VScreening of SOX2 was completed in 89 patients with a variety of ocular anomalies, including 28 with A/M and 61 with normal eye size and anterior segment dysgenesis (28), cataract (14), isolated coloboma (5), or other eye disorders (14).
p17745
sg16446
(lp17746
(dp17747
g16449
I13
sg16450
I1
sg16451
I4
sg16452
VP48431
p17748
sg16454
VSOX2
p17749
sasg16456
(lp17750
(dp17751
g16449
I218
sg16450
I2
sg16451
I13
sg16459
VC0015397
p17752
sg16454
Veye disorders
p17753
sa(dp17754
g16449
I195
sg16450
I1
sg16451
I8
sg16459
VC0009363
p17755
sg16454
Vcoloboma
p17756
sa(dp17757
g16449
I137
sg16450
I3
sg16451
I27
sg16459
VC0266525
p17758
sg16454
Vanterior segment dysgenesis
p17759
sa(dp17760
g16449
I171
sg16450
I1
sg16451
I8
sg16459
VC0086543
p17761
sg16454
Vcataract
p17762
sasa(dp17763
g16444
VThe overexpression of Kir3.2, a subunit of the G protein-gated inwardly rectifying K(+) channel, is implicated in some of the neurological phenotypes of Down syndrome (DS).
p17764
sg16446
(lp17765
(dp17766
g16449
I47
sg16450
I2
sg16451
I9
sg16452
g11
sg16454
VG protein
p17767
sa(dp17768
g16449
I22
sg16450
I1
sg16451
I6
sg16452
VP48051
p17769
sg16454
VKir3.2
p17770
sasg16456
(lp17771
(dp17772
g16449
I153
sg16450
I2
sg16451
I13
sg16459
VC0013080
p17773
sg16454
VDown syndrome
p17774
sa(dp17775
g16449
I168
sg16450
I1
sg16451
I2
sg16459
VC0013080
p17776
sg16454
VDS
p17777
sasa(dp17778
g16444
VKeppen-Lubinsky syndrome (KPLBS) is a rare disease mainly characterized by severe developmental delay and intellectual disability, microcephaly, large prominent eyes, a narrow nasal bridge, a tented upper lip, a high palate, an open mouth, tightly adherent skin, an aged appearance, and severe generalized lipodystrophy.
p17779
sg16446
(lp17780
sg16456
(lp17781
(dp17782
g16449
I131
sg16450
I1
sg16451
I12
sg16459
VC0025958
p17783
sg16454
Vmicrocephaly
p17784
sa(dp17785
g16449
I82
sg16450
I2
sg16451
I19
sg16459
VC0424605
p17786
sg16454
Vdevelopmental delay
p17787
sa(dp17788
g16449
I0
sg16450
I2
sg16451
I24
sg16459
VC3279800
p17789
sg16454
VKeppen-Lubinsky syndrome
p17790
sa(dp17791
g16449
I294
sg16450
I2
sg16451
I25
sg16459
VC0221032
p17792
sg16454
Vgeneralized lipodystrophy
p17793
sa(dp17794
g16449
I212
sg16450
I2
sg16451
I11
sg16459
VC1398297
p17795
sg16454
Vhigh palate
p17796
sa(dp17797
g16449
I38
sg16450
I2
sg16451
I12
sg16459
VC0678236
p17798
sg16454
Vrare disease
p17799
sa(dp17800
g16449
I106
sg16450
I2
sg16451
I23
sg16459
VC0025362
p17801
sg16454
Vintellectual disability
p17802
sa(dp17803
g16449
I26
sg16450
I1
sg16451
I5
sg16459
VC3279800
p17804
sg16454
VKPLBS
p17805
sa(dp17806
g16449
I205
sg16450
I1
sg16451
I3
sg16459
VC0264511
p17807
sg16454
Vlip
p17808
sasa(dp17809
g16444
VWe sequenced the exomes of three unrelated individuals affected by KPLBS and found de novo heterozygous mutations in KCNJ6 (GIRK2), which encodes an inwardly rectifying potassium channel and maps to the Down syndrome critical region between DIRK1A and DSCR4.
p17810
sg16446
(lp17811
(dp17812
g16449
I104
sg16450
I3
sg16451
I18
sg16452
VP48051
p17813
sg16454
Vmutations in KCNJ6
p17814
sa(dp17815
g16449
I252
sg16450
I1
sg16451
I5
sg16452
VP56555
p17816
sg16454
VDSCR4
p17817
sa(dp17818
g16449
I124
sg16450
I1
sg16451
I5
sg16452
VP48051
p17819
sg16454
VGIRK2
p17820
sasg16456
(lp17821
(dp17822
g16449
I67
sg16450
I1
sg16451
I5
sg16459
VC3279800
p17823
sg16454
VKPLBS
p17824
sa(dp17825
g16449
I203
sg16450
I4
sg16451
I29
sg16459
VC1860787
p17826
sg16454
VDown syndrome critical region
p17827
sasa(dp17828
g16444
VWe evaluated the impact of glucose-lysine Maillard reaction products (Glc-Lys MRPs) on colitis, induced in rats by an administration of 5% dextran sulfate sodium (DSS) in drinking water.
p17829
sg16446
(lp17830
(dp17831
g16449
I27
sg16450
I4
sg16451
I41
sg16452
g11
sg16454
Vglucose-lysine Maillard reaction products
p17832
sa(dp17833
g16449
I70
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VGlc-Lys MRPs
p17834
sasg16456
(lp17835
(dp17836
g16449
I139
sg16450
I3
sg16451
I22
sg16459
VC0011195
p17837
sg16454
Vdextran sulfate sodium
p17838
sa(dp17839
g16449
I163
sg16450
I1
sg16451
I3
sg16459
VC0011195
p17840
sg16454
VDSS
p17841
sa(dp17842
g16449
I87
sg16450
I1
sg16451
I7
sg16459
VC0009319
p17843
sg16454
Vcolitis
p17844
sasa(dp17845
g16444
VGlc-Lys MRPs ameliorate DSS-induced colitis, as determined by a decrease in disease index activity, colon weight/length ratio, nitric oxide levels in serum, recovery of body weight loss, colon length and serum lysozyme levels.
p17846
sg16446
(lp17847
(dp17848
g16449
I0
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VGlc-Lys MRPs
p17849
sa(dp17850
g16449
I187
sg16450
I5
sg16451
I31
sg16452
VP61626
p17851
sg16454
Vcolon length and serum lysozyme
p17852
sasg16456
(lp17853
(dp17854
g16449
I24
sg16450
I1
sg16451
I3
sg16459
VC0011195
p17855
sg16454
VDSS
p17856
sa(dp17857
g16449
I36
sg16450
I1
sg16451
I7
sg16459
VC0009319
p17858
sg16454
Vcolitis
p17859
sasa(dp17860
g16444
VThis study was aimed at determining whether repeated low-level exposure to MRPs, generated via two different heat treatments, can contribute to the modulation of experimental colitis in mice.
p17861
sg16446
(lp17862
sg16456
(lp17863
(dp17864
g16449
I175
sg16450
I1
sg16451
I7
sg16459
VC0009319
p17865
sg16454
Vcolitis
p17866
sasa(dp17867
g16444
VFurthermore, we used a sandwich immunoassay to measure serum concentrations of MRPs in 62 patients were simultaneously assessed by the Crohn's disease activity index (CDAI) and the severity activity index of Goebell (SAI).
p17868
sg16446
(lp17869
(dp17870
g16449
I135
sg16450
I4
sg16451
I30
sg16452
g11
sg16454
VCrohn's disease activity index
p17871
sa(dp17872
g16449
I167
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCDAI
p17873
sasg16456
(lp17874
(dp17875
g16449
I135
sg16450
I2
sg16451
I15
sg16459
VC0010346
p17876
sg16454
VCrohn's disease
p17877
sasa(dp17878
g16444
VIn the present study monospecific antibodies against MRPs were used to investigate immunohistochemically the distribution of these proteins in routinely processed bowel tissues from 23 patients with ulcerative colitis (UC).
p17879
sg16446
(lp17880
sg16456
(lp17881
(dp17882
g16449
I219
sg16450
I1
sg16451
I2
sg16459
VC0009324
p17883
sg16454
VUC
p17884
sa(dp17885
g16449
I199
sg16450
I2
sg16451
I18
sg16459
VC0009324
p17886
sg16454
Vulcerative colitis
p17887
sasa(dp17888
g16444
VThe dimeric hybrid-IgG/IgA inhibited the binding of digoxigenin-conjugated Stx1B to natural ligands (CD77) displayed on Burkitt's lymphoma cell line Ramos.
p17889
sg16446
(lp17890
(dp17891
g16449
I75
sg16450
I1
sg16451
I5
sg16452
VP61266
p17892
sg16454
VStx1B
p17893
sa(dp17894
g16449
I23
sg16450
I1
sg16451
I3
sg16452
VP11912
p17895
sg16454
VIgA
p17896
sasg16456
(lp17897
(dp17898
g16449
I120
sg16450
I2
sg16451
I18
sg16459
VC0006413
p17899
sg16454
VBurkitt's lymphoma
p17900
sasa(dp17901
g16444
VFurthermore, the purified Stx1 B subunit was able to bind specifically to Gb3Cer expressed on Burkitt's lymphoma cells.
p17902
sg16446
(lp17903
(dp17904
g16449
I26
sg16450
I3
sg16451
I14
sg16452
g11
sg16454
VStx1 B subunit
p17905
sasg16456
(lp17906
(dp17907
g16449
I94
sg16450
I2
sg16451
I18
sg16459
VC0006413
p17908
sg16454
VBurkitt's lymphoma
p17909
sasa(dp17910
g16444
VFurthermore, we found that Mcl-1 could be a potential therapeutic target of MECK-induced apoptosis and its stability is regulated by extracellular signal-regulated kinases 1/2 (ERK1/2) signaling MECK can be used as a safe and efficient therapeutic alternative for the treatment of salivary gland cancer.
p17911
sg16446
(lp17912
(dp17913
g16449
I177
sg16450
I1
sg16451
I6
sg16452
VP27361
p17914
sg16454
VERK1/2
p17915
sa(dp17916
g16449
I133
sg16450
I4
sg16451
I42
sg16452
g11
sg16454
Vextracellular signal-regulated kinases 1/2
p17917
sa(dp17918
g16449
I27
sg16450
I1
sg16451
I5
sg16452
VP07954
p17919
sg16454
VMcl-1
p17920
sasg16456
(lp17921
(dp17922
g16449
I281
sg16450
I3
sg16451
I21
sg16459
VC0220636
p17923
sg16454
Vsalivary gland cancer
p17924
sa(dp17925
g16449
I27
sg16450
I1
sg16451
I3
sg16459
VC1708350
p17926
sg16454
VMcl
p17927
sasa(dp17928
g16444
VAlthough NF-KB RelA (p65) is essential for the expression of many cytokines during pneumonia, its targeted mutation in the lung epithelium was inconsequential for pneumonia-driven LIF induction.
p17929
sg16446
(lp17930
(dp17931
g16449
I9
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VNF-KB RelA
p17932
sa(dp17933
g16449
I21
sg16450
I1
sg16451
I3
sg16452
VP21579
p17934
sg16454
Vp65
p17935
sasg16456
(lp17936
(dp17937
g16449
I83
sg16450
I1
sg16451
I9
sg16459
VC0032285
p17938
sg16454
Vpneumonia
p17939
sa(dp17940
g16449
I83
sg16450
I1
sg16451
I9
sg16459
VC0032285
p17941
sg16454
Vpneumonia
p17942
sasa(dp17943
g16444
VOverall, our data suggest a signaling axis whereby activation of NF-KB RelA in myeloid cells promotes epithelial LIF induction during lung infections, representing a means through which these two cell types collaborate to improve tissue resilience during pneumonia.
p17944
sg16446
(lp17945
(dp17946
g16449
I102
sg16450
I2
sg16451
I14
sg16452
VP15018
p17947
sg16454
Vepithelial LIF
p17948
sa(dp17949
g16449
I65
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VNF-KB RelA
p17950
sasg16456
(lp17951
(dp17952
g16449
I139
sg16450
I1
sg16451
I10
sg16459
VC0021311
p17953
sg16454
Vinfections
p17954
sa(dp17955
g16449
I255
sg16450
I1
sg16451
I9
sg16459
VC0032285
p17956
sg16454
Vpneumonia
p17957
sasa(dp17958
g16444
VSectm1 was induced during the early stages of pneumococcal pneumonia, and mutation of NF-KB RelA in epithelial cells did not diminish its expression.
p17959
sg16446
(lp17960
(dp17961
g16449
I86
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VNF-KB RelA
p17962
sa(dp17963
g16449
I0
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VSectm1
p17964
sasg16456
(lp17965
(dp17966
g16449
I46
sg16450
I2
sg16451
I22
sg16459
VC0155862
p17967
sg16454
Vpneumococcal pneumonia
p17968
sasa(dp17969
g16444
VTo determine the functional significance of the hepatic APR during pneumonia, we challenged APR-null mice lacking hepatocyte signal transducer and activator of transcription 3 (STAT3) and v-rel avian reticuloendotheliosis viral oncogene homolog A (RelA) with Escherichia coli in the airspaces.
p17970
sg16446
(lp17971
(dp17972
g16449
I114
sg16450
I8
sg16451
I61
sg16452
VP40763
p17973
sg16454
Vhepatocyte signal transducer and activator of transcription 3
p17974
sa(dp17975
g16449
I188
sg16450
I7
sg16451
I58
sg16452
g11
sg16454
Vv-rel avian reticuloendotheliosis viral oncogene homolog A
p17976
sa(dp17977
g16449
I248
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VRelA
p17978
sa(dp17979
g16449
I177
sg16450
I1
sg16451
I5
sg16452
VP40763
p17980
sg16454
VSTAT3
p17981
sasg16456
(lp17982
(dp17983
g16449
I67
sg16450
I1
sg16451
I9
sg16459
VC0032285
p17984
sg16454
Vpneumonia
p17985
sa(dp17986
g16449
I194
sg16450
I2
sg16451
I27
sg16459
VC0276487
p17987
sg16454
Vavian reticuloendotheliosis
p17988
sasa(dp17989
g16444
VEpithelial cells expressed multiple neutrophil-stimulating cytokines during pneumonia, all of which depended on RelA.
p17990
sg16446
(lp17991
(dp17992
g16449
I112
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VRelA
p17993
sasg16456
(lp17994
(dp17995
g16449
I76
sg16450
I1
sg16451
I9
sg16459
VC0032285
p17996
sg16454
Vpneumonia
p17997
sasa(dp17998
g16444
VEpithelial RelA mutation decreased whole lung levels of CXCL5 and GM-CSF during pneumococcal pneumonia, whereas lung levels of other neutrophil-recruiting factors were unaffected.
p17999
sg16446
(lp18000
(dp18001
g16449
I66
sg16450
I1
sg16451
I6
sg16452
VP04141
p18002
sg16454
VGM-CSF
p18003
sa(dp18004
g16449
I56
sg16450
I1
sg16451
I5
sg16452
VP42830
p18005
sg16454
VCXCL5
p18006
sa(dp18007
g16449
I11
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VRelA
p18008
sasg16456
(lp18009
(dp18010
g16449
I80
sg16450
I2
sg16451
I22
sg16459
VC0155862
p18011
sg16454
Vpneumococcal pneumonia
p18012
sasa(dp18013
g16444
VWe demonstrate that RelA-P-Ser536 is a feature of human lung and skin fibroblasts, but not lung epithelial cells, in vitro and is present in sclerotic skin and diseased lungs of patients suffering from idiopathic pulmonary fibrosis.
p18014
sg16446
(lp18015
(dp18016
g16449
I20
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRelA-P
p18017
sasg16456
(lp18018
(dp18019
g16449
I202
sg16450
I3
sg16451
I29
sg16459
VC3161101
p18020
sg16454
Vidiopathic pulmonary fibrosis
p18021
sa(dp18022
g16449
I187
sg16450
I1
sg16451
I9
sg16459
VC0683278
p18023
sg16454
Vsuffering
p18024
sa(dp18025
g16449
I141
sg16450
I1
sg16451
I9
sg16459
VC0036429
p18026
sg16454
Vsclerotic
p18027
sasa(dp18028
g16444
VBecause innate immunity gene induction depends on NF-KB RelA (also known as p65) during pneumonia, we generated a murine model of RelA mutated throughout the alveolar epithelium.
p18029
sg16446
(lp18030
(dp18031
g16449
I76
sg16450
I1
sg16451
I3
sg16452
VP21579
p18032
sg16454
Vp65
p18033
sa(dp18034
g16449
I56
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VRelA
p18035
sa(dp18036
g16449
I50
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VNF-KB RelA
p18037
sasg16456
(lp18038
(dp18039
g16449
I88
sg16450
I1
sg16451
I9
sg16459
VC0032285
p18040
sg16454
Vpneumonia
p18041
sasa(dp18042
g16444
VSorted cell populations from mouse lungs revealed that CXCL5 was induced during pneumonia in type I cells, which did not require RelA.
p18043
sg16446
(lp18044
(dp18045
g16449
I129
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VRelA
p18046
sa(dp18047
g16449
I55
sg16450
I1
sg16451
I5
sg16452
VP42830
p18048
sg16454
VCXCL5
p18049
sasg16456
(lp18050
(dp18051
g16449
I80
sg16450
I1
sg16451
I9
sg16459
VC0032285
p18052
sg16454
Vpneumonia
p18053
sasa(dp18054
g16444
VThese are also, to our knowledge, the first evidence for entirely RelA-independent pathways of innate immunity gene induction in any cell during pneumonia.
p18055
sg16446
(lp18056
(dp18057
g16449
I66
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VRelA
p18058
sasg16456
(lp18059
(dp18060
g16449
I145
sg16450
I1
sg16451
I9
sg16459
VC0032285
p18061
sg16454
Vpneumonia
p18062
sasa(dp18063
g16444
VWe review the literature of genetic PD autopsies from cases with molecularly confirmed PD or parkinsonism and summarize main findings on SNCA (n = 25), Parkin (n = 20, 17 bi-allelic and 3 heterozygotes), PINK1 (n = 5, 1 bi-allelic and 4 heterozygotes), DJ-1 (n = 1), LRRK2 (n = 55), GBA (n = 10 Gaucher disease patients with parkinsonism), DNAJC13, GCH1, ATP13A2, PLA2G6 (n = 8 patients, 2 with PD), MPAN (n = 2), FBXO7, RAB39B, and ATXN2 (SCA2), as well as on 22q deletion syndrome (n = 3).
p18064
sg16446
(lp18065
(dp18066
g16449
I421
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRAB39B
p18067
sa(dp18068
g16449
I204
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VPINK1
p18069
sa(dp18070
g16449
I440
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSCA2
p18071
sa(dp18072
g16449
I267
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VLRRK2
p18073
sa(dp18074
g16449
I349
sg16450
I1
sg16451
I4
sg16452
VP30793
p18075
sg16454
VGCH1
p18076
sa(dp18077
g16449
I414
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VFBXO7
p18078
sa(dp18079
g16449
I355
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VATP13A2
p18080
sa(dp18081
g16449
I364
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VPLA2G6
p18082
sa(dp18083
g16449
I433
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VATXN2
p18084
sasg16456
(lp18085
(dp18086
g16449
I295
sg16450
I2
sg16451
I15
sg16459
VC0017205
p18087
sg16454
VGaucher disease
p18088
sa(dp18089
g16449
I93
sg16450
I1
sg16451
I12
sg16459
VC0242422
p18090
sg16454
Vparkinsonism
p18091
sa(dp18092
g16449
I461
sg16450
I3
sg16451
I21
sg16459
VC0795880
p18093
sg16454
V22q deletion syndrome
p18094
sa(dp18095
g16449
I93
sg16450
I1
sg16451
I12
sg16459
VC0242422
p18096
sg16454
Vparkinsonism
p18097
sa(dp18098
g16449
I440
sg16450
I1
sg16451
I4
sg16459
VC0752121
p18099
sg16454
VSCA2
p18100
sasa(dp18101
g16444
VWe performed genetic testing consisting of C9orf72 hexanucleotide expansion, ATXN2 polyglutamine (polyQ) expansion, and targeted next generation sequencing using the ONDRISeq, a gene panel consisting of 80 genes known to be associated with neurodegenerative diseases such as ALS, FTD, Alzheimer's disease, Parkinson's disease, and vascular cognitive impairment.
p18102
sg16446
(lp18103
(dp18104
g16449
I77
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VATXN2
p18105
sasg16456
(lp18106
(dp18107
g16449
I340
sg16450
I2
sg16451
I20
sg16459
VC0338656
p18108
sg16454
Vcognitive impairment
p18109
sa(dp18110
g16449
I306
sg16450
I2
sg16451
I19
sg16459
VC0030567
p18111
sg16454
VParkinson's disease
p18112
sa(dp18113
g16449
I240
sg16450
I2
sg16451
I26
sg16459
VC0524851
p18114
sg16454
Vneurodegenerative diseases
p18115
sa(dp18116
g16449
I285
sg16450
I2
sg16451
I19
sg16459
VC1521724
p18117
sg16454
VAlzheimer's disease
p18118
sa(dp18119
g16449
I280
sg16450
I1
sg16451
I3
sg16459
VC0338451
p18120
sg16454
VFTD
p18121
sa(dp18122
g16449
I275
sg16450
I1
sg16451
I3
sg16459
VC0002736
p18123
sg16454
VALS
p18124
sasa(dp18125
g16444
VPathological developments leading to amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are associated with misbehavior of several key proteins, such as SOD1 (superoxide dismutase 1), TARDBP/TDP-43, FUS, C9orf72, and dipeptide repeat proteins generated as a result of the translation of the intronic hexanucleotide expansions in the C9orf72 gene, PFN1 (profilin 1), GLE1 (GLE1, RNA export mediator), PURA (purine rich element binding protein A), FLCN (folliculin), RBM45 (RNA binding motif protein 45), SS18L1/CREST, HNRNPA1 (heterogeneous nuclear ribonucleoprotein A1), HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1), ATXN2 (ataxin 2), MAPT (microtubule associated protein tau), and TIA1 (TIA1 cytotoxic granule associated RNA binding protein).
p18126
sg16446
(lp18127
(dp18128
g16449
I556
sg16450
I4
sg16451
I42
sg16452
VP09651
p18129
sg16454
Vheterogeneous nuclear ribonucleoprotein A1
p18130
sa(dp18131
g16449
I684
sg16450
I4
sg16451
I34
sg16452
g11
sg16454
Vmicrotubule associated protein tau
p18132
sa(dp18133
g16449
I396
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VGLE1
p18134
sa(dp18135
g16449
I430
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPURA
p18136
sa(dp18137
g16449
I383
sg16450
I2
sg16451
I10
sg16452
VP07737
p18138
sg16454
Vprofilin 1
p18139
sa(dp18140
g16449
I482
sg16450
I1
sg16451
I10
sg16452
g11
sg16454
Vfolliculin
p18141
sa(dp18142
g16449
I436
sg16450
I6
sg16451
I37
sg16452
g11
sg16454
Vpurine rich element binding protein A
p18143
sa(dp18144
g16449
I725
sg16450
I1
sg16451
I4
sg16452
VP31483
p18145
sg16454
VTIA1
p18146
sa(dp18147
g16449
I183
sg16450
I1
sg16451
I4
sg16452
VP00441
p18148
sg16454
VSOD1
p18149
sa(dp18150
g16449
I229
sg16450
I1
sg16451
I3
sg16452
VP35637
p18151
sg16454
VFUS
p18152
sa(dp18153
g16449
I189
sg16450
I3
sg16451
I22
sg16452
VP00441
p18154
sg16454
Vsuperoxide dismutase 1
p18155
sa(dp18156
g16449
I678
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VMAPT
p18157
sa(dp18158
g16449
I396
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VGLE1
p18159
sa(dp18160
g16449
I667
sg16450
I2
sg16451
I8
sg16452
g11
sg16454
Vataxin 2
p18161
sa(dp18162
g16449
I612
sg16450
I4
sg16451
I45
sg16452
VP22626
p18163
sg16454
Vheterogeneous nuclear ribonucleoprotein A2/B1
p18164
sa(dp18165
g16449
I234
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VC9orf72
p18166
sa(dp18167
g16449
I214
sg16450
I1
sg16451
I13
sg16452
g11
sg16454
VTARDBP/TDP-43
p18168
sa(dp18169
g16449
I731
sg16450
I7
sg16451
I53
sg16452
VP00390
p18170
sg16454
VTIA1 cytotoxic granule associated RNA binding protein
p18171
sa(dp18172
g16449
I601
sg16450
I1
sg16451
I9
sg16452
VP22626
p18173
sg16454
VHNRNPA2B1
p18174
sa(dp18175
g16449
I377
sg16450
I1
sg16451
I4
sg16452
VP07737
p18176
sg16454
VPFN1
p18177
sa(dp18178
g16449
I363
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VC9orf72 gene
p18179
sa(dp18180
g16449
I476
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VFLCN
p18181
sa(dp18182
g16449
I660
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VATXN2
p18183
sa(dp18184
g16449
I547
sg16450
I1
sg16451
I7
sg16452
VP09651
p18185
sg16454
VHNRNPA1
p18186
sasg16456
(lp18187
(dp18188
g16449
I68
sg16450
I1
sg16451
I3
sg16459
VC0002736
p18189
sg16454
VALS
p18190
sa(dp18191
g16449
I77
sg16450
I3
sg16451
I33
sg16459
VC0751072
p18192
sg16454
Vfrontotemporal lobar degeneration
p18193
sa(dp18194
g16449
I540
sg16450
I1
sg16451
I5
sg16459
VC0206138
p18195
sg16454
VCREST
p18196
sa(dp18197
g16449
I112
sg16450
I1
sg16451
I4
sg16459
VC0751072
p18198
sg16454
VFTLD
p18199
sa(dp18200
g16449
I37
sg16450
I3
sg16451
I29
sg16459
VC0002736
p18201
sg16454
Vamyotrophic lateral sclerosis
p18202
sasa(dp18203
g16444
VSpinocerebellar ataxia type 2 (SCA2) is an autosomal dominant cerebellar ataxia that occurs as a consequence of abnormal CAG expansions in the ATXN2 gene.
p18204
sg16446
(lp18205
(dp18206
g16449
I143
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VATXN2 gene
p18207
sa(dp18208
g16449
I0
sg16450
I4
sg16451
I29
sg16452
g11
sg16454
VSpinocerebellar ataxia type 2
p18209
sa(dp18210
g16449
I31
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSCA2
p18211
sasg16456
(lp18212
(dp18213
g16449
I5
sg16450
I2
sg16451
I17
sg16459
VC0007758
p18214
sg16454
Vcerebellar ataxia
p18215
sa(dp18216
g16449
I0
sg16450
I4
sg16451
I29
sg16459
VC0752121
p18217
sg16454
VSpinocerebellar ataxia type 2
p18218
sa(dp18219
g16449
I31
sg16450
I1
sg16451
I4
sg16459
VC0752121
p18220
sg16454
VSCA2
p18221
sasa(dp18222
g16444
VRecent findings linking ataxin-2 intermediate expansions to other neurodegenerative diseases such as amyotrophic lateral sclerosis have provided insights into the ataxin-2-related toxicity mechanism in neurodegenerative diseases and have raised new ethical challenges to molecular predictive diagnosis of SCA2.
p18223
sg16446
(lp18224
(dp18225
g16449
I305
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSCA2
p18226
sasg16456
(lp18227
(dp18228
g16449
I101
sg16450
I3
sg16451
I29
sg16459
VC0002736
p18229
sg16454
Vamyotrophic lateral sclerosis
p18230
sa(dp18231
g16449
I66
sg16450
I2
sg16451
I26
sg16459
VC0524851
p18232
sg16454
Vneurodegenerative diseases
p18233
sa(dp18234
g16449
I66
sg16450
I2
sg16451
I26
sg16459
VC0524851
p18235
sg16454
Vneurodegenerative diseases
p18236
sa(dp18237
g16449
I305
sg16450
I1
sg16451
I4
sg16459
VC0752121
p18238
sg16454
VSCA2
p18239
sasa(dp18240
g16444
VSpinocerebellar ataxia type 2 (SCA2) is among the most common forms of autosomal dominant ataxias, accounting for 15% of the total families.
p18241
sg16446
(lp18242
(dp18243
g16449
I0
sg16450
I4
sg16451
I29
sg16452
g11
sg16454
VSpinocerebellar ataxia type 2
p18244
sa(dp18245
g16449
I31
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSCA2
p18246
sasg16456
(lp18247
(dp18248
g16449
I90
sg16450
I1
sg16451
I7
sg16459
VC0004134
p18249
sg16454
Vataxias
p18250
sa(dp18251
g16449
I0
sg16450
I4
sg16451
I29
sg16459
VC0752121
p18252
sg16454
VSpinocerebellar ataxia type 2
p18253
sa(dp18254
g16449
I31
sg16450
I1
sg16451
I4
sg16459
VC0752121
p18255
sg16454
VSCA2
p18256
sasa(dp18257
g16444
VSpinocerebellar ataxia type 2 (SCA2) is due to a CAG expansion (CAGexp) at ATXN2.
p18258
sg16446
(lp18259
(dp18260
g16449
I75
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VATXN2
p18261
sa(dp18262
g16449
I0
sg16450
I4
sg16451
I29
sg16452
g11
sg16454
VSpinocerebellar ataxia type 2
p18263
sa(dp18264
g16449
I31
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSCA2
p18265
sasg16456
(lp18266
(dp18267
g16449
I0
sg16450
I4
sg16451
I29
sg16459
VC0752121
p18268
sg16454
VSpinocerebellar ataxia type 2
p18269
sa(dp18270
g16449
I31
sg16450
I1
sg16451
I4
sg16459
VC0752121
p18271
sg16454
VSCA2
p18272
sasa(dp18273
g16444
VExpansion of polyglutamine trinucleotide (CAG) within ATXN2 gene with 35 or more repeats, results in spinocerebellar ataxia type-2.
p18274
sg16446
(lp18275
(dp18276
g16449
I54
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VATXN2 gene
p18277
sasg16456
(lp18278
(dp18279
g16449
I101
sg16450
I2
sg16451
I22
sg16459
VC0087012
p18280
sg16454
Vspinocerebellar ataxia
p18281
sasa(dp18282
g16444
VRecent studies have identified the RNA-binding protein Ataxin-2 as a genetic determinant or risk factor for various diseases including spinocerebellar ataxia type II (SCA2) and amyotrophic lateral sclerosis (ALS), amongst others.
p18283
sg16446
(lp18284
(dp18285
g16449
I167
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSCA2
p18286
sa(dp18287
g16449
I55
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VAtaxin-2
p18288
sa(dp18289
g16449
I151
sg16450
I3
sg16451
I14
sg16452
VP27037
p18290
sg16454
Vataxia type II
p18291
sasg16456
(lp18292
(dp18293
g16449
I167
sg16450
I1
sg16451
I4
sg16459
VC0752121
p18294
sg16454
VSCA2
p18295
sa(dp18296
g16449
I177
sg16450
I3
sg16451
I29
sg16459
VC0002736
p18297
sg16454
Vamyotrophic lateral sclerosis
p18298
sa(dp18299
g16449
I208
sg16450
I1
sg16451
I3
sg16459
VC0002736
p18300
sg16454
VALS
p18301
sa(dp18302
g16449
I135
sg16450
I2
sg16451
I22
sg16459
VC0087012
p18303
sg16454
Vspinocerebellar ataxia
p18304
sasa(dp18305
g16444
VHere we show that synaptobrevin 2 sorting involves determinants within its SNARE motif that are recognized by the ANTH domains of the endocytic adaptors AP180 and clathrin assembly lymphoid myeloid leukemia (CALM).
p18306
sg16446
(lp18307
(dp18308
g16449
I18
sg16450
I2
sg16451
I15
sg16452
VP63027
p18309
sg16454
Vsynaptobrevin 2
p18310
sa(dp18311
g16449
I153
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VAP180
p18312
sasg16456
(lp18313
(dp18314
g16449
I190
sg16450
I2
sg16451
I16
sg16459
VC0023470
p18315
sg16454
Vmyeloid leukemia
p18316
sasa(dp18317
g16444
VSpecifically, fibroblast growth factor receptor 3 (FGFR3), desmoglein 2 (DSG2), E3 ubiquitin ligase c-CBL (casitas B-cell lymphoma), cancer/testis antigen NY-ESO-1 (CTAG1A/B), undifferentiated embryonic cell transcription factor 1 (UTF1) and synaptosomal-associated protein, 91 kDa homolog (SNAP91) were shown to represent specific biomarkers of human spermatogonia.
p18318
sg16446
(lp18319
(dp18320
g16449
I51
sg16450
I1
sg16451
I5
sg16452
VP22607
p18321
sg16454
VFGFR3
p18322
sa(dp18323
g16449
I100
sg16450
I1
sg16451
I5
sg16452
VP22681
p18324
sg16454
Vc-CBL
p18325
sa(dp18326
g16449
I59
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
Vdesmoglein 2
p18327
sa(dp18328
g16449
I155
sg16450
I1
sg16451
I8
sg16452
VP78358
p18329
sg16454
VNY-ESO-1
p18330
sa(dp18331
g16449
I80
sg16450
I2
sg16451
I12
sg16452
VP62979
p18332
sg16454
VE3 ubiquitin
p18333
sa(dp18334
g16449
I14
sg16450
I5
sg16451
I35
sg16452
g11
sg16454
Vfibroblast growth factor receptor 3
p18335
sa(dp18336
g16449
I176
sg16450
I6
sg16451
I54
sg16452
g11
sg16454
Vundifferentiated embryonic cell transcription factor 1
p18337
sa(dp18338
g16449
I291
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VSNAP91
p18339
sa(dp18340
g16449
I73
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VDSG2
p18341
sa(dp18342
g16449
I275
sg16450
I3
sg16451
I14
sg16452
g11
sg16454
V91 kDa homolog
p18343
sa(dp18344
g16449
I165
sg16450
I1
sg16451
I8
sg16452
VP78358
p18345
sg16454
VCTAG1A/B
p18346
sa(dp18347
g16449
I232
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VUTF1
p18348
sasg16456
(lp18349
(dp18350
g16449
I115
sg16450
I2
sg16451
I15
sg16459
VC0079731
p18351
sg16454
VB-cell lymphoma
p18352
sa(dp18353
g16449
I133
sg16450
I1
sg16451
I6
sg16459
VC0006826
p18354
sg16454
Vcancer
p18355
sasa(dp18356
g16444
VRecently, the gene encoding clathrin assembly protein of lymphoid myeloid leukemia (CALM), which is homologous to the AP180, was cloned from rat brain, and its expression differential to AP180 was reported (Kim and Lee, 1999).
p18357
sg16446
(lp18358
(dp18359
g16449
I118
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VAP180
p18360
sasg16456
(lp18361
(dp18362
g16449
I66
sg16450
I2
sg16451
I16
sg16459
VC0023470
p18363
sg16454
Vmyeloid leukemia
p18364
sasa(dp18365
g16444
VThe clathrin assembly protein lymphoid myeloid leukemia (CALM) gene, encodes a homologoue of the neuronal clathrin assembly protein AP180.
p18366
sg16446
(lp18367
sg16456
(lp18368
(dp18369
g16449
I39
sg16450
I2
sg16451
I16
sg16459
VC0023470
p18370
sg16454
Vmyeloid leukemia
p18371
sasa(dp18372
g16444
VThe clathrin assembly lymphoid myeloid leukemia (CALM) gene encodes a putative homologue of the clathrin assembly synaptic protein AP180.
p18373
sg16446
(lp18374
sg16456
(lp18375
(dp18376
g16449
I31
sg16450
I2
sg16451
I16
sg16459
VC0023470
p18377
sg16454
Vmyeloid leukemia
p18378
sasa(dp18379
g16444
VThe expression level of ERp57 was also elevated in rat insulinoma INS-1 cells by inducible knock-down of the atg7-gene.
p18380
sg16446
(lp18381
(dp18382
g16449
I51
sg16450
I3
sg16451
I20
sg16452
VP01308
p18383
sg16454
Vrat insulinoma INS-1
p18384
sa(dp18385
g16449
I109
sg16450
I1
sg16451
I9
sg16452
g11
sg16454
Vatg7-gene
p18386
sa(dp18387
g16449
I24
sg16450
I1
sg16451
I5
sg16452
VP30101
p18388
sg16454
VERp57
p18389
sasg16456
(lp18390
(dp18391
g16449
I66
sg16450
I1
sg16451
I3
sg16459
VC1533172
p18392
sg16454
VINS
p18393
sa(dp18394
g16449
I55
sg16450
I1
sg16451
I10
sg16459
VC0021670
p18395
sg16454
Vinsulinoma
p18396
sasa(dp18397
g16444
VTissue specimens of nine dental follicles and 69 ameloblastomas were immunohistochemically examined with antibodies against ATG7, LC3, and p62.
p18398
sg16446
(lp18399
(dp18400
g16449
I130
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VLC3
p18401
sa(dp18402
g16449
I139
sg16450
I1
sg16451
I3
sg16452
VP37198
p18403
sg16454
Vp62
p18404
sa(dp18405
g16449
I124
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VATG7
p18406
sasg16456
(lp18407
(dp18408
g16449
I49
sg16450
I1
sg16451
I14
sg16459
VC0002448
p18409
sg16454
Vameloblastomas
p18410
sasa(dp18411
g16444
VImmunohistochemical reactivity for ATG7, LC3, and p62 was detected in many odontogenic epithelial cells and several endothelial cells and fibroblasts in dental follicles and ameloblastomas.
p18412
sg16446
(lp18413
(dp18414
g16449
I35
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VATG7
p18415
sa(dp18416
g16449
I41
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VLC3
p18417
sa(dp18418
g16449
I50
sg16450
I1
sg16451
I3
sg16452
VP37198
p18419
sg16454
Vp62
p18420
sasg16456
(lp18421
(dp18422
g16449
I174
sg16450
I1
sg16451
I14
sg16459
VC0002448
p18423
sg16454
Vameloblastomas
p18424
sasa(dp18425
g16444
VExpression of ATG7, LC3, and p62 was found markedly in neoplastic cells near the basement membrane rather than central polyhedral cells in ameloblastomas.
p18426
sg16446
(lp18427
(dp18428
g16449
I29
sg16450
I1
sg16451
I3
sg16452
VP37198
p18429
sg16454
Vp62
p18430
sa(dp18431
g16449
I20
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VLC3
p18432
sa(dp18433
g16449
I14
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VATG7
p18434
sasg16456
(lp18435
(dp18436
g16449
I139
sg16450
I1
sg16451
I14
sg16459
VC0002448
p18437
sg16454
Vameloblastomas
p18438
sasa(dp18439
g16444
VExpression of ATG7, LC3, and p62 in dental follicles and ameloblastomas suggests that autophagy regulation might be affected by microenvironment alterations during tumorigenesis.
p18440
sg16446
(lp18441
(dp18442
g16449
I29
sg16450
I1
sg16451
I3
sg16452
VP37198
p18443
sg16454
Vp62
p18444
sa(dp18445
g16449
I20
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VLC3
p18446
sa(dp18447
g16449
I14
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VATG7
p18448
sasg16456
(lp18449
(dp18450
g16449
I164
sg16450
I1
sg16451
I13
sg16459
VC0007621
p18451
sg16454
Vtumorigenesis
p18452
sa(dp18453
g16449
I57
sg16450
I1
sg16451
I14
sg16459
VC0002448
p18454
sg16454
Vameloblastomas
p18455
sasa(dp18456
g16444
VAtg7 deficiency alters progression of Braf(V600E)-driven tumors from adenomas (Braf(V600E); atg7(-/-)) and adenocarcinomas (trp53(-/-); Braf(V600E); atg7(-/-)) to benign oncocytomas that accumulated morphologically and functionally defective mitochondria, suggesting that defects in mitochondrial metabolism may compromise continued tumor growth.
p18457
sg16446
(lp18458
(dp18459
g16449
I124
sg16450
I1
sg16451
I5
sg16452
VP42771
p18460
sg16454
Vtrp53
p18461
sa(dp18462
g16449
I0
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VAtg7
p18463
sasg16456
(lp18464
(dp18465
g16449
I170
sg16450
I1
sg16451
I11
sg16459
VC0949541
p18466
sg16454
Voncocytomas
p18467
sa(dp18468
g16449
I57
sg16450
I1
sg16451
I6
sg16459
VC0027651
p18469
sg16454
Vtumors
p18470
sa(dp18471
g16449
I107
sg16450
I1
sg16451
I15
sg16459
VC0001418
p18472
sg16454
Vadenocarcinomas
p18473
sa(dp18474
g16449
I69
sg16450
I1
sg16451
I8
sg16459
VC0001430
p18475
sg16454
Vadenomas
p18476
sa(dp18477
g16449
I333
sg16450
I2
sg16451
I12
sg16459
VC0598934
p18478
sg16454
Vtumor growth
p18479
sasa(dp18480
g16444
VAt later stages of tumorigenesis, Atg7 deficiency resulted in an accumulation of defective mitochondria, proliferative defects, reduced tumor burden, conversion of adenomas and adenocarcinomas to oncocytomas, and increased mouse life span.
p18481
sg16446
(lp18482
(dp18483
g16449
I34
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VAtg7
p18484
sasg16456
(lp18485
(dp18486
g16449
I19
sg16450
I1
sg16451
I5
sg16459
VC0027651
p18487
sg16454
Vtumor
p18488
sa(dp18489
g16449
I196
sg16450
I1
sg16451
I11
sg16459
VC0949541
p18490
sg16454
Voncocytomas
p18491
sa(dp18492
g16449
I177
sg16450
I1
sg16451
I15
sg16459
VC0001418
p18493
sg16454
Vadenocarcinomas
p18494
sa(dp18495
g16449
I19
sg16450
I1
sg16451
I13
sg16459
VC0007621
p18496
sg16454
Vtumorigenesis
p18497
sa(dp18498
g16449
I164
sg16450
I1
sg16451
I8
sg16459
VC0001430
p18499
sg16454
Vadenomas
p18500
sa(dp18501
g16449
I105
sg16450
I1
sg16451
I13
sg16459
VC0334094
p18502
sg16454
Vproliferative
p18503
sasa(dp18504
g16444
VUsing genetically engineered mouse models (GEMMs) for human non-small-cell lung cancer (NSCLC), we found that deletion of the essential autophagy gene, Atg7, in KRAS(G12D)-driven NSCLC inhibits tumor growth and converts adenomas and adenocarcinomas to benign oncocytomas characterized by the accumulation of respiration-defective mitochondria.
p18505
sg16446
(lp18506
(dp18507
g16449
I152
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VAtg7
p18508
sa(dp18509
g16449
I161
sg16450
I1
sg16451
I4
sg16452
VP01116
p18510
sg16454
VKRAS
p18511
sasg16456
(lp18512
(dp18513
g16449
I194
sg16450
I2
sg16451
I12
sg16459
VC0598934
p18514
sg16454
Vtumor growth
p18515
sa(dp18516
g16449
I88
sg16450
I1
sg16451
I5
sg16459
VC0007131
p18517
sg16454
VNSCLC
p18518
sa(dp18519
g16449
I220
sg16450
I1
sg16451
I8
sg16459
VC0001430
p18520
sg16454
Vadenomas
p18521
sa(dp18522
g16449
I259
sg16450
I1
sg16451
I11
sg16459
VC0949541
p18523
sg16454
Voncocytomas
p18524
sa(dp18525
g16449
I88
sg16450
I1
sg16451
I5
sg16459
VC0007131
p18526
sg16454
VNSCLC
p18527
sa(dp18528
g16449
I60
sg16450
I3
sg16451
I26
sg16459
VC0007131
p18529
sg16454
Vnon-small-cell lung cancer
p18530
sa(dp18531
g16449
I233
sg16450
I1
sg16451
I15
sg16459
VC0001418
p18532
sg16454
Vadenocarcinomas
p18533
sasa(dp18534
g16444
Vatg7 loss altered tumor fate from adenomas and carcinomas to oncocytomas-rare, predominantly benign tumors characterized by the accumulation of defective mitochondria.
p18535
sg16446
(lp18536
(dp18537
g16449
I0
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
Vatg7
p18538
sasg16456
(lp18539
(dp18540
g16449
I18
sg16450
I1
sg16451
I5
sg16459
VC0027651
p18541
sg16454
Vtumor
p18542
sa(dp18543
g16449
I61
sg16450
I1
sg16451
I11
sg16459
VC0949541
p18544
sg16454
Voncocytomas
p18545
sa(dp18546
g16449
I34
sg16450
I1
sg16451
I8
sg16459
VC0001430
p18547
sg16454
Vadenomas
p18548
sa(dp18549
g16449
I47
sg16450
I1
sg16451
I10
sg16459
VC0007097
p18550
sg16454
Vcarcinomas
p18551
sa(dp18552
g16449
I93
sg16450
I2
sg16451
I13
sg16459
VC0086692
p18553
sg16454
Vbenign tumors
p18554
sasa(dp18555
g16444
VSubsequent studies demonstrated that Atg5(-/-) and Atg7(-/-) livers give rise to adenomas, Atg4C(-/-) mice are susceptible to chemical carcinogenesis, and Bif1(-/-) mice are prone to spontaneous tumors, indicating that autophagy defects promote tumorigenesis.
p18556
sg16446
(lp18557
(dp18558
g16449
I91
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VAtg4C
p18559
sa(dp18560
g16449
I155
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VBif1
p18561
sa(dp18562
g16449
I37
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VAtg5
p18563
sa(dp18564
g16449
I51
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VAtg7
p18565
sasg16456
(lp18566
(dp18567
g16449
I126
sg16450
I2
sg16451
I23
sg16459
VC0596321
p18568
sg16454
Vchemical carcinogenesis
p18569
sa(dp18570
g16449
I245
sg16450
I1
sg16451
I13
sg16459
VC0007621
p18571
sg16454
Vtumorigenesis
p18572
sa(dp18573
g16449
I81
sg16450
I1
sg16451
I8
sg16459
VC0001430
p18574
sg16454
Vadenomas
p18575
sa(dp18576
g16449
I195
sg16450
I1
sg16451
I6
sg16459
VC0027651
p18577
sg16454
Vtumors
p18578
sasa(dp18579
g16444
VScavenger receptor class A, member 3 (SCARA3) was previously found to be overexpressed in ovarian/primary peritoneal carcinoma (OC/PPC) compared with breast carcinoma effusions by global gene expression analysis.
p18580
sg16446
(lp18581
(dp18582
g16449
I38
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VSCARA3
p18583
sa(dp18584
g16449
I0
sg16450
I6
sg16451
I36
sg16452
g11
sg16454
VScavenger receptor class A, member 3
p18585
sasg16456
(lp18586
(dp18587
g16449
I150
sg16450
I2
sg16451
I16
sg16459
VC0678222
p18588
sg16454
Vbreast carcinoma
p18589
sa(dp18590
g16449
I167
sg16450
I1
sg16451
I9
sg16459
VC0013687
p18591
sg16454
Veffusions
p18592
sa(dp18593
g16449
I98
sg16450
I3
sg16451
I28
sg16459
VC1514428
p18594
sg16454
Vprimary peritoneal carcinoma
p18595
sasa(dp18596
g16444
Vp15RS is a ubiquitously expressed nuclear protein that is positively regulated by p15 and, in turn, inhibits the expression of cyclin D and cyclin E. To determine whether p15RS has malignancy inhibitory functions in addition to its inhibitory effects on cell cycle entry, we ectopically expressed p15RS in metastatic melanoma A375 cells, in which p15 gene is deleted and p15RS expression is dramatically downregulated, and examined the effect on various malignant phenotypes.
p18597
sg16446
(lp18598
(dp18599
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
Vp15RS
p18600
sa(dp18601
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
Vp15RS
p18602
sa(dp18603
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
Vp15RS
p18604
sa(dp18605
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
Vp15RS
p18606
sa(dp18607
g16449
I347
sg16450
I2
sg16451
I8
sg16452
VP53999
p18608
sg16454
Vp15 gene
p18609
sa(dp18610
g16449
I0
sg16450
I1
sg16451
I3
sg16452
VP53999
p18611
sg16454
Vp15
p18612
sa(dp18613
g16449
I140
sg16450
I2
sg16451
I8
sg16452
VP24864
p18614
sg16454
Vcyclin E
p18615
sa(dp18616
g16449
I127
sg16450
I2
sg16451
I8
sg16452
VP24385
p18617
sg16454
Vcyclin D
p18618
sasg16456
(lp18619
(dp18620
g16449
I181
sg16450
I1
sg16451
I10
sg16459
VC0006826
p18621
sg16454
Vmalignancy
p18622
sa(dp18623
g16449
I306
sg16450
I2
sg16451
I19
sg16459
VC0278883
p18624
sg16454
Vmetastatic melanoma
p18625
sasa(dp18626
g16444
VWilms' tumor 1-associating protein (WTAP) has been reported to be a ubiquitously expressed nuclear protein.
p18627
sg16446
(lp18628
(dp18629
g16449
I0
sg16450
I4
sg16451
I34
sg16452
g11
sg16454
VWilms' tumor 1-associating protein
p18630
sa(dp18631
g16449
I36
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VWTAP
p18632
sasg16456
(lp18633
(dp18634
g16449
I0
sg16450
I2
sg16451
I12
sg16459
VC0027708
p18635
sg16454
VWilms' tumor
p18636
sasa(dp18637
g16444
VThe results showed that TCF7L2 polymorphism was associated with breast cancer (Homogeneous model: OR=1.17, 95%CI=1.02-1.35, I (2) =21.8%, p for heterogeneity=0.276; Heterogeneous model: OR=1.11, 95%CI=1.03-1.20, I (2) =0.0%, p for heterogeneity=0.543), prostate cancer (Homogeneous model: OR=0.89, 95%CI=0.84-0.96, I (2) =0.0%, p for heterogeneity=0.640; Heterogeneous model: OR=0.89, 95%CI=0.84-0.95, I (2) =0.0%, p for heterogeneity=0.871), and colon cancer (Heterogeneous model: OR=1.15, 95%CI=1.01-1.31, I (2) =0.0%, p for heterogeneity=0.658), but not with colorectal cancer, lung cancer, and ovarian cancer.
p18638
sg16446
(lp18639
sg16456
(lp18640
(dp18641
g16449
I598
sg16450
I2
sg16451
I14
sg16459
VC1140680
p18642
sg16454
Vovarian cancer
p18643
sa(dp18644
g16449
I253
sg16450
I2
sg16451
I15
sg16459
VC0600139
p18645
sg16454
Vprostate cancer
p18646
sa(dp18647
g16449
I64
sg16450
I2
sg16451
I13
sg16459
VC0678222
p18648
sg16454
Vbreast cancer
p18649
sa(dp18650
g16449
I447
sg16450
I2
sg16451
I12
sg16459
VC0699790
p18651
sg16454
Vcolon cancer
p18652
sa(dp18653
g16449
I562
sg16450
I2
sg16451
I17
sg16459
VC1527249
p18654
sg16454
Vcolorectal cancer
p18655
sa(dp18656
g16449
I581
sg16450
I2
sg16451
I11
sg16459
VC0684249
p18657
sg16454
Vlung cancer
p18658
sasa(dp18659
g16444
VThe present meta-analysis indicated that there were significantly associations between the TCF7L2 rs7903146 polymorphism and risk of breast, prostate and colon cancers, rather than colorectal cancer, lung cancer, and ovarian cancer.
p18660
sg16446
(lp18661
sg16456
(lp18662
(dp18663
g16449
I200
sg16450
I2
sg16451
I11
sg16459
VC0684249
p18664
sg16454
Vlung cancer
p18665
sa(dp18666
g16449
I154
sg16450
I2
sg16451
I13
sg16459
VC0007102
p18667
sg16454
Vcolon cancers
p18668
sa(dp18669
g16449
I217
sg16450
I2
sg16451
I14
sg16459
VC1140680
p18670
sg16454
Vovarian cancer
p18671
sa(dp18672
g16449
I181
sg16450
I2
sg16451
I17
sg16459
VC1527249
p18673
sg16454
Vcolorectal cancer
p18674
sasa(dp18675
g16444
VMutations in the gene encoding comparative gene identification 58 (CGI-58), also known as Alfa Beta hydrolase domain-containing 5 (ABHD5), cause neutral lipid storage disorder with ichthyosis (NLSDI).
p18676
sg16446
(lp18677
(dp18678
g16449
I90
sg16450
I5
sg16451
I39
sg16452
g11
sg16454
VAlfa Beta hydrolase domain-containing 5
p18679
sa(dp18680
g16449
I131
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VABHD5
p18681
sasg16456
(lp18682
(dp18683
g16449
I193
sg16450
I1
sg16451
I5
sg16459
VC0268238
p18684
sg16454
VNLSDI
p18685
sa(dp18686
g16449
I145
sg16450
I6
sg16451
I46
sg16459
VC0268238
p18687
sg16454
Vneutral lipid storage disorder with ichthyosis
p18688
sasa(dp18689
g16444
VIt has been elucidated that, of the ichthyosis-causative genes, ABCA12, ALOXE3, ALOX12B, CYP4F22, CERS3, ABHD5, PNPLA1 and ELOVL4 work in the formation of the corneocyte lipid envelope (CLE), a structure that is essential to sound skin barrier function.
p18690
sg16446
(lp18691
(dp18692
g16449
I72
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VALOXE3
p18693
sa(dp18694
g16449
I89
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCYP4F22
p18695
sa(dp18696
g16449
I186
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VCLE
p18697
sa(dp18698
g16449
I80
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VALOX12B
p18699
sa(dp18700
g16449
I64
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VABCA12
p18701
sa(dp18702
g16449
I105
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VABHD5
p18703
sa(dp18704
g16449
I98
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCERS3
p18705
sa(dp18706
g16449
I123
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VELOVL4
p18707
sa(dp18708
g16449
I159
sg16450
I3
sg16451
I25
sg16452
g11
sg16454
Vcorneocyte lipid envelope
p18709
sa(dp18710
g16449
I112
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VPNPLA1
p18711
sasg16456
(lp18712
(dp18713
g16449
I159
sg16450
I3
sg16451
I25
sg16459
VC2931489
p18714
sg16454
Vcorneocyte lipid envelope
p18715
sa(dp18716
g16449
I186
sg16450
I1
sg16451
I3
sg16459
VC2931489
p18717
sg16454
VCLE
p18718
sa(dp18719
g16449
I36
sg16450
I1
sg16451
I10
sg16459
VC0020758
p18720
sg16454
Vichthyosis
p18721
sasa(dp18722
g16444
VWe discuss known inborn errors of CTGM, including deficiencies of: AGPAT2 (a form of generalized lipodystrophy), LPIN1 (childhood rhabdomyolysis), LPIN2 (an inflammatory condition, Majeed syndrome, described elsewhere in this issue), DGAT1 (protein loosing enteropathy), perilipin 1 (partial lipodystrophy), CGI-58 (gene ABHD5, neutral lipid storage disease (NLSD) with ichthyosis and "Jordan's anomaly" of vacuolated polymorphonuclear leukocytes), adipose triglyceride lipase (ATGL, gene PNPLA2, NLSD with myopathy, cardiomyopathy and Jordan's anomaly), hormone-sensitive lipase (HSL, gene LIPE, hypertriglyceridemia, and insulin resistance).
p18723
sg16446
(lp18724
(dp18725
g16449
I623
sg16450
I1
sg16451
I7
sg16452
VP01308
p18726
sg16454
Vinsulin
p18727
sa(dp18728
g16449
I586
sg16450
I2
sg16451
I9
sg16452
g11
sg16454
Vgene LIPE
p18729
sa(dp18730
g16449
I478
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VATGL
p18731
sa(dp18732
g16449
I581
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VHSL
p18733
sa(dp18734
g16449
I484
sg16450
I2
sg16451
I11
sg16452
g11
sg16454
Vgene PNPLA2
p18735
sa(dp18736
g16449
I555
sg16450
I2
sg16451
I24
sg16452
g11
sg16454
Vhormone-sensitive lipase
p18737
sa(dp18738
g16449
I321
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VABHD5
p18739
sa(dp18740
g16449
I271
sg16450
I2
sg16451
I11
sg16452
g11
sg16454
Vperilipin 1
p18741
sa(dp18742
g16449
I234
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VDGAT1
p18743
sa(dp18744
g16449
I67
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VAGPAT2
p18745
sa(dp18746
g16449
I449
sg16450
I3
sg16451
I27
sg16452
VP04118
p18747
sg16454
Vadipose triglyceride lipase
p18748
sa(dp18749
g16449
I113
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VLPIN1
p18750
sasg16456
(lp18751
(dp18752
g16449
I507
sg16450
I1
sg16451
I8
sg16459
VC0026848
p18753
sg16454
Vmyopathy
p18754
sa(dp18755
g16449
I359
sg16450
I1
sg16451
I4
sg16459
VC0268238
p18756
sg16454
VNLSD
p18757
sa(dp18758
g16449
I181
sg16450
I2
sg16451
I15
sg16459
VC1864997
p18759
sg16454
VMajeed syndrome
p18760
sa(dp18761
g16449
I359
sg16450
I1
sg16451
I4
sg16459
VC0268238
p18762
sg16454
VNLSD
p18763
sa(dp18764
g16449
I370
sg16450
I1
sg16451
I10
sg16459
VC0020758
p18765
sg16454
Vichthyosis
p18766
sa(dp18767
g16449
I328
sg16450
I4
sg16451
I29
sg16459
VC0268238
p18768
sg16454
Vneutral lipid storage disease
p18769
sa(dp18770
g16449
I517
sg16450
I1
sg16451
I14
sg16459
VC0878544
p18771
sg16454
Vcardiomyopathy
p18772
sa(dp18773
g16449
I130
sg16450
I1
sg16451
I14
sg16459
VC0035410
p18774
sg16454
Vrhabdomyolysis
p18775
sa(dp18776
g16449
I85
sg16450
I2
sg16451
I25
sg16459
VC0221032
p18777
sg16454
Vgeneralized lipodystrophy
p18778
sa(dp18779
g16449
I257
sg16450
I1
sg16451
I11
sg16459
VC0021831
p18780
sg16454
Venteropathy
p18781
sa(dp18782
g16449
I170
sg16450
I1
sg16451
I9
sg16459
VC0012634
p18783
sg16454
Vcondition
p18784
sa(dp18785
g16449
I284
sg16450
I2
sg16451
I21
sg16459
VC0220989
p18786
sg16454
Vpartial lipodystrophy
p18787
sa(dp18788
g16449
I623
sg16450
I2
sg16451
I18
sg16459
VC0021655
p18789
sg16454
Vinsulin resistance
p18790
sasa(dp18791
g16444
VIn current study, we have discovered, using a comprehensive investigative regimen, a novel and tissue-specific role of claudin-3, a tight junction integral protein, in inhibiting colon cancer progression by serving as the common rheostat of Stat-3 and Wnt-signaling activation.
p18792
sg16446
(lp18793
(dp18794
g16449
I119
sg16450
I1
sg16451
I9
sg16452
g11
sg16454
Vclaudin-3
p18795
sa(dp18796
g16449
I241
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VStat-3
p18797
sasg16456
(lp18798
(dp18799
g16449
I185
sg16450
I2
sg16451
I18
sg16459
VC0178874
p18800
sg16454
Vcancer progression
p18801
sasa(dp18802
g16444
VClaudin-3-/- mice revealed dedifferentiated and leaky colonic epithelium, and developed invasive adenocarcinoma when subjected to colon cancer.
p18803
sg16446
(lp18804
sg16456
(lp18805
(dp18806
g16449
I97
sg16450
I1
sg16451
I14
sg16459
VC0001418
p18807
sg16454
Vadenocarcinoma
p18808
sa(dp18809
g16449
I130
sg16450
I2
sg16451
I12
sg16459
VC0699790
p18810
sg16454
Vcolon cancer
p18811
sasa(dp18812
g16444
VWnt-signaling hyperactivation, albeit in GSK-3Beta independent manner, differentiated colon cancer in claudin-3-/- mice versus WT-mice.
p18813
sg16446
(lp18814
(dp18815
g16449
I41
sg16450
I1
sg16451
I9
sg16452
VP49841
p18816
sg16454
VGSK-3Beta
p18817
sasg16456
(lp18818
(dp18819
g16449
I86
sg16450
I2
sg16451
I12
sg16459
VC0699790
p18820
sg16454
Vcolon cancer
p18821
sasa(dp18822
g16444
VGenetic and pharmacological studies confirmed that claudin-3 loss induces Wnt/Beta-catenin activation, which is further exacerbated by Stat-3-activation and help promote colon cancer.
p18823
sg16446
(lp18824
(dp18825
g16449
I51
sg16450
I2
sg16451
I14
sg16452
g11
sg16454
Vclaudin-3 loss
p18826
sa(dp18827
g16449
I135
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VStat-3
p18828
sa(dp18829
g16449
I78
sg16450
I1
sg16451
I12
sg16452
VP35222
p18830
sg16454
VBeta-catenin
p18831
sasg16456
(lp18832
(dp18833
g16449
I170
sg16450
I2
sg16451
I12
sg16459
VC0699790
p18834
sg16454
Vcolon cancer
p18835
sasa(dp18836
g16444
VAmong the paradoxical claudin reaction nuclear localization of marker was observed relatively rarely: claudin-3 in 2.5% cases of colon cancer; claudin-4 in 8.5% of colon polyps.
p18837
sg16446
(lp18838
sg16456
(lp18839
(dp18840
g16449
I129
sg16450
I2
sg16451
I12
sg16459
VC0699790
p18841
sg16454
Vcolon cancer
p18842
sa(dp18843
g16449
I164
sg16450
I2
sg16451
I12
sg16459
VC0009376
p18844
sg16454
Vcolon polyps
p18845
sasa(dp18846
g16444
VMislocalization claudin-3 to nucleus in colon cancer and mislocalization claudin-4 to nucleus in adenomas of the colon were detected for the first time.
p18847
sg16446
(lp18848
(dp18849
g16449
I0
sg16450
I2
sg16451
I25
sg16452
g11
sg16454
VMislocalization claudin-3
p18850
sa(dp18851
g16449
I73
sg16450
I1
sg16451
I9
sg16452
g11
sg16454
Vclaudin-4
p18852
sasg16456
(lp18853
(dp18854
g16449
I97
sg16450
I1
sg16451
I8
sg16459
VC0001430
p18855
sg16454
Vadenomas
p18856
sa(dp18857
g16449
I40
sg16450
I2
sg16451
I12
sg16459
VC0699790
p18858
sg16454
Vcolon cancer
p18859
sasa(dp18860
g16444
VOur approach aimed at evaluation of a selective and targeted cancer gene therapy of claudin-3- and/or claudin-4- expressing colon carcinoma in vitro and in vivo by using translation optimized CPE expressing vector.
p18861
sg16446
(lp18862
sg16456
(lp18863
(dp18864
g16449
I124
sg16450
I2
sg16451
I15
sg16459
VC0699790
p18865
sg16454
Vcolon carcinoma
p18866
sa(dp18867
g16449
I61
sg16450
I1
sg16451
I6
sg16459
VC0006826
p18868
sg16454
Vcancer
p18869
sasa(dp18870
g16444
VIn this study the recombinant CPE and a translation optimized CPE expressing vector (optCPE) was used for targeted gene therapy of claudin-3 and/or -4 overexpressing colon cancer cell lines.
p18871
sg16446
(lp18872
sg16456
(lp18873
(dp18874
g16449
I166
sg16450
I2
sg16451
I12
sg16459
VC0699790
p18875
sg16454
Vcolon cancer
p18876
sasa(dp18877
g16444
VAll experiments were performed in the human SW480, SW620, HCT116, CaCo-2 and HT-29 colon cancer and the isogenic Sk-Mel5 and Sk-Mel5 Cldn-3-YFP melanoma cell lines.
p18878
sg16446
(lp18879
sg16456
(lp18880
(dp18881
g16449
I83
sg16450
I2
sg16451
I12
sg16459
VC0699790
p18882
sg16454
Vcolon cancer
p18883
sa(dp18884
g16449
I144
sg16450
I1
sg16451
I8
sg16459
VC0025202
p18885
sg16454
Vmelanoma
p18886
sasa(dp18887
g16444
VClaudin-3 and -4 overexpressing colon carcinoma lines showed high sensitivity towards both recCPE application and optCPE gene transfer.
p18888
sg16446
(lp18889
(dp18890
g16449
I0
sg16450
I3
sg16451
I16
sg16452
g11
sg16454
VClaudin-3 and -4
p18891
sasg16456
(lp18892
(dp18893
g16449
I32
sg16450
I2
sg16451
I15
sg16459
VC0699790
p18894
sg16454
Vcolon carcinoma
p18895
sasa(dp18896
g16444
VThis novel approach demonstrates that optCPE gene transfer represents a promising and efficient therapeutic option for a targeted suicide gene therapy of claudin-3 and/or claudin-4 overexpressing colon carcinomas, leading to rapid and effective tumor cell killing in vitro and in vivo.
p18897
sg16446
(lp18898
(dp18899
g16449
I171
sg16450
I1
sg16451
I9
sg16452
g11
sg16454
Vclaudin-4
p18900
sasg16456
(lp18901
(dp18902
g16449
I245
sg16450
I1
sg16451
I5
sg16459
VC0027651
p18903
sg16454
Vtumor
p18904
sa(dp18905
g16449
I202
sg16450
I1
sg16451
I10
sg16459
VC0007097
p18906
sg16454
Vcarcinomas
p18907
sasa(dp18908
g16444
VTo investigate the expression of claudin-3 in colorectal carcinoma and its association with the occurrence, progression and prognosis of colorectal cancer.
p18909
sg16446
(lp18910
(dp18911
g16449
I33
sg16450
I1
sg16451
I9
sg16452
g11
sg16454
Vclaudin-3
p18912
sasg16456
(lp18913
(dp18914
g16449
I46
sg16450
I2
sg16451
I20
sg16459
VC0009402
p18915
sg16454
Vcolorectal carcinoma
p18916
sa(dp18917
g16449
I137
sg16450
I2
sg16451
I17
sg16459
VC0009402
p18918
sg16454
Vcolorectal cancer
p18919
sasa(dp18920
g16444
VClaudin-3 is over-expressed in colorectal cancer tissues, and its high expression may promote the occurrence and progression of colorectal cancer.
p18921
sg16446
(lp18922
(dp18923
g16449
I0
sg16450
I1
sg16451
I9
sg16452
g11
sg16454
VClaudin-3
p18924
sasg16456
(lp18925
(dp18926
g16449
I31
sg16450
I2
sg16451
I17
sg16459
VC1527249
p18927
sg16454
Vcolorectal cancer
p18928
sa(dp18929
g16449
I31
sg16450
I2
sg16451
I17
sg16459
VC1527249
p18930
sg16454
Vcolorectal cancer
p18931
sasa(dp18932
g16444
VHere, we report that epidermal growth factor (EGF) increases the expression of claudin-3 in human colorectal adenocarcinoma HT-29 cells.
p18933
sg16446
(lp18934
(dp18935
g16449
I79
sg16450
I1
sg16451
I9
sg16452
g11
sg16454
Vclaudin-3
p18936
sa(dp18937
g16449
I46
sg16450
I1
sg16451
I3
sg16452
VP01133
p18938
sg16454
VEGF
p18939
sa(dp18940
g16449
I21
sg16450
I3
sg16451
I23
sg16452
VP01133
p18941
sg16454
Vepidermal growth factor
p18942
sasg16456
(lp18943
(dp18944
g16449
I98
sg16450
I2
sg16451
I25
sg16459
VC1319315
p18945
sg16454
Vcolorectal adenocarcinoma
p18946
sasa(dp18947
g16444
VIn conclusion, our results show a novel role for claudin-3 overexpression in promoting the malignant potential of colorectal cancer cells, which is potentially regulated by the EGF-activated ERK1/2 and PI3K-Akt pathways.
p18948
sg16446
(lp18949
(dp18950
g16449
I49
sg16450
I1
sg16451
I9
sg16452
g11
sg16454
Vclaudin-3
p18951
sa(dp18952
g16449
I177
sg16450
I1
sg16451
I3
sg16452
VP01133
p18953
sg16454
VEGF
p18954
sa(dp18955
g16449
I202
sg16450
I1
sg16451
I4
sg16452
VP42336
p18956
sg16454
VPI3K
p18957
sa(dp18958
g16449
I207
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VAkt
p18959
sa(dp18960
g16449
I191
sg16450
I1
sg16451
I6
sg16452
VP27361
p18961
sg16454
VERK1/2
p18962
sasg16456
(lp18963
(dp18964
g16449
I114
sg16450
I2
sg16451
I17
sg16459
VC1527249
p18965
sg16454
Vcolorectal cancer
p18966
sasa(dp18967
g16444
VPatients with essential thrombocythemia (ET) and polycythemia vera (PV), complicated by microvascular ischemic or thrombotic events, have shortened platelet survival, increased beta-thromboglobulin, platelet factor 4, and thrombomodulin levels, and increased urinary thromboxane B2 excretion.
p18968
sg16446
(lp18969
(dp18970
g16449
I177
sg16450
I1
sg16451
I20
sg16452
VP02775
p18971
sg16454
Vbeta-thromboglobulin
p18972
sa(dp18973
g16449
I199
sg16450
I3
sg16451
I17
sg16452
VP02776
p18974
sg16454
Vplatelet factor 4
p18975
sa(dp18976
g16449
I222
sg16450
I1
sg16451
I14
sg16452
VP07204
p18977
sg16454
Vthrombomodulin
p18978
sasg16456
(lp18979
(dp18980
g16449
I68
sg16450
I1
sg16451
I2
sg16459
VC0032463
p18981
sg16454
VPV
p18982
sa(dp18983
g16449
I14
sg16450
I2
sg16451
I25
sg16459
VC0040028
p18984
sg16454
Vessential thrombocythemia
p18985
sa(dp18986
g16449
I41
sg16450
I1
sg16451
I2
sg16459
VC0040028
p18987
sg16454
VET
p18988
sa(dp18989
g16449
I49
sg16450
I2
sg16451
I17
sg16459
VC0032463
p18990
sg16454
Vpolycythemia vera
p18991
sasa(dp18992
g16444
VOur results suggest that CEP68 gene variants may play an important role in MNSAID-UA susceptibility and, despite the different regulatory mechanisms involved depending on the specific affected organ, in the development of hypersensitivity reactions to NSAIDs.
p18993
sg16446
(lp18994
(dp18995
g16449
I25
sg16450
I3
sg16451
I19
sg16452
g11
sg16454
VCEP68 gene variants
p18996
sasg16456
(lp18997
(dp18998
g16449
I222
sg16450
I2
sg16451
I26
sg16459
VC0020517
p18999
sg16454
Vhypersensitivity reactions
p19000
sasa(dp19001
g16444
VBaboon anti-pig antibody (Ab) was measured before CPB, before circulatory arrest, during AbA, at the end of CPB, and daily after HTx.
p19002
sg16446
(lp19003
sg16456
(lp19004
(dp19005
g16449
I62
sg16450
I2
sg16451
I18
sg16459
VC0444720
p19006
sg16454
Vcirculatory arrest
p19007
sasa(dp19008
g16444
VAt 4 dpi a severe fibrinosuppurative bronchopneumonia had developed.
p19009
sg16446
(lp19010
sg16456
(lp19011
(dp19012
g16449
I37
sg16450
I1
sg16451
I16
sg16459
VC0006285
p19013
sg16454
Vbronchopneumonia
p19014
sasa(dp19015
g16444
VHowever, the SrGAP3-deficient mice showed little to no interest in burying marbles; a behavior that is seen in some animal models related to autism, supporting the view that SrGAP3 plays a role in neurodevelopmental disorders.
p19016
sg16446
(lp19017
(dp19018
g16449
I13
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VSrGAP3
p19019
sa(dp19020
g16449
I13
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VSrGAP3
p19021
sasg16456
(lp19022
(dp19023
g16449
I141
sg16450
I1
sg16451
I6
sg16459
VC0004352
p19024
sg16454
Vautism
p19025
sasa(dp19026
g16444
VBA synthesis was directly quantified by measuring serum concentrations of 7alpha-hydroxycholest-4-en-3-one (C4), along with serum FGF19 and other parameters, in 44 patients with primary biliary cirrhosis (PBC) and 10 healthy subjects.
p19027
sg16446
(lp19028
(dp19029
g16449
I130
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VFGF19
p19030
sasg16456
(lp19031
(dp19032
g16449
I178
sg16450
I3
sg16451
I25
sg16459
VC0008312
p19033
sg16454
Vprimary biliary cirrhosis
p19034
sa(dp19035
g16449
I205
sg16450
I1
sg16451
I3
sg16459
VC0008312
p19036
sg16454
VPBC
p19037
sasa(dp19038
g16444
VWhether fibroblast growth factor 19 (FGF19) or farnesoid X receptor (FXR) dependent signaling are involved in the regulation of BA homeostasis in primary biliary cirrhosis (PBC) remains unknown.
p19039
sg16446
(lp19040
(dp19041
g16449
I8
sg16450
I4
sg16451
I27
sg16452
g11
sg16454
Vfibroblast growth factor 19
p19042
sa(dp19043
g16449
I69
sg16450
I1
sg16451
I3
sg16452
VP23945
p19044
sg16454
VFXR
p19045
sa(dp19046
g16449
I47
sg16450
I3
sg16451
I20
sg16452
g11
sg16454
Vfarnesoid X receptor
p19047
sa(dp19048
g16449
I37
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VFGF19
p19049
sasg16456
(lp19050
(dp19051
g16449
I173
sg16450
I1
sg16451
I3
sg16459
VC0008312
p19052
sg16454
VPBC
p19053
sa(dp19054
g16449
I146
sg16450
I3
sg16451
I25
sg16459
VC0008312
p19055
sg16454
Vprimary biliary cirrhosis
p19056
sasa(dp19057
g16444
VOur results provide further insight into the specific relationship between histone H4 modification and gene expression during spermatogenesis, which could help to elucidate the epigenetic disorders underlying male infertility.
p19058
sg16446
(lp19059
(dp19060
g16449
I75
sg16450
I2
sg16451
I10
sg16452
VP62805
p19061
sg16454
Vhistone H4
p19062
sasg16456
(lp19063
(dp19064
g16449
I209
sg16450
I2
sg16451
I16
sg16459
VC0021364
p19065
sg16454
Vmale infertility
p19066
sasa(dp19067
g16444
VPrevious studies have resulted in the isolation of the human HSST gene from within the Treacher Collins syndrome locus (TCOF1) critical region on 5q.
p19068
sg16446
(lp19069
(dp19070
g16449
I120
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTCOF1
p19071
sa(dp19072
g16449
I55
sg16450
I3
sg16451
I15
sg16452
VP52848
p19073
sg16454
Vhuman HSST gene
p19074
sasg16456
(lp19075
(dp19076
g16449
I87
sg16450
I3
sg16451
I25
sg16459
VC0242387
p19077
sg16454
VTreacher Collins syndrome
p19078
sasa(dp19079
g16444
VAs a result of these studies, mutations within the coding sequence and adjacent splice junctions of HSST can be excluded from a causative role in the pathogenesis of Treacher Collins syndrome.
p19080
sg16446
(lp19081
sg16456
(lp19082
(dp19083
g16449
I150
sg16450
I1
sg16451
I12
sg16459
VC0699748
p19084
sg16454
Vpathogenesis
p19085
sa(dp19086
g16449
I166
sg16450
I3
sg16451
I25
sg16459
VC0242387
p19087
sg16454
VTreacher Collins syndrome
p19088
sasa(dp19089
g16444
VIn univariate analyses, diabetes mellitus, chronic kidney disease, ischemic etiology of LBBB, dilated left atrium, reduced LVEF, dilated left ventricle, and impaired LV global strain (GLS &gt; -12.2%, global circumferential strain &gt; -11.8%, and twist &lt; 6.5) showed associations with the composite end point.
p19090
sg16446
(lp19091
sg16456
(lp19092
(dp19093
g16449
I157
sg16450
I1
sg16451
I8
sg16459
VC0684336
p19094
sg16454
Vimpaired
p19095
sa(dp19096
g16449
I24
sg16450
I2
sg16451
I17
sg16459
VC0011849
p19097
sg16454
Vdiabetes mellitus
p19098
sa(dp19099
g16449
I129
sg16450
I3
sg16451
I22
sg16459
VC0745674
p19100
sg16454
Vdilated left ventricle
p19101
sa(dp19102
g16449
I88
sg16450
I1
sg16451
I4
sg16459
VC0023211
p19103
sg16454
VLBBB
p19104
sa(dp19105
g16449
I43
sg16450
I3
sg16451
I22
sg16459
VC1561643
p19106
sg16454
Vchronic kidney disease
p19107
sasa(dp19108
g16444
VIndividuals with T1D had increased systolic torsion (P = 0.035), systolic torsion rate (P = 0.032), peak Ecl (P = 0.001), and rates of change of systolic (P = 0.007) and diastolic (P = 0.007) Ecl Individuals with T1D, with normal structure, LVEF, and strain, have increased extracellular volume and increased native T1 values with associated augmented torsion and Ecl These measures may be useful in detecting the early stages of diabetic cardiomyopathy and warrant larger prospective studies.NEW &amp; NOTEWORTHY Individuals with type 1 diabetes, with normal left ventricular structure and function (ejection fraction and strain), have signs of interstitial fibrosis, measured with MRI as increased extracellular volume fraction and increased native myocardial T1, which significantly correlated with a number of measures of augmented left ventricular twist function.
p19109
sg16446
(lp19110
sg16456
(lp19111
(dp19112
g16449
I531
sg16450
I3
sg16451
I15
sg16459
VC0011854
p19113
sg16454
Vtype 1 diabetes
p19114
sa(dp19115
g16449
I44
sg16450
I1
sg16451
I7
sg16459
VC1265748
p19116
sg16454
Vtorsion
p19117
sa(dp19118
g16449
I646
sg16450
I2
sg16451
I21
sg16459
VC0240035
p19119
sg16454
Vinterstitial fibrosis
p19120
sa(dp19121
g16449
I44
sg16450
I1
sg16451
I7
sg16459
VC1265748
p19122
sg16454
Vtorsion
p19123
sa(dp19124
g16449
I430
sg16450
I2
sg16451
I23
sg16459
VC0853897
p19125
sg16454
Vdiabetic cardiomyopathy
p19126
sa(dp19127
g16449
I44
sg16450
I1
sg16451
I7
sg16459
VC1265748
p19128
sg16454
Vtorsion
p19129
sasa(dp19130
g16444
VIn this study, we show that hyperinsulinemia in the Rag/MKR mice increases the expression of mesenchymal transcription factors, TWIST1 and ZEB1, and increases the expression of the angiogenesis marker, vascular endothelial growth factor A (VEGFA).
p19131
sg16446
(lp19132
(dp19133
g16449
I240
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VVEGFA
p19134
sa(dp19135
g16449
I52
sg16450
I1
sg16451
I3
sg16452
VP52803
p19136
sg16454
VRag
p19137
sa(dp19138
g16449
I139
sg16450
I1
sg16451
I4
sg16452
VP37275
p19139
sg16454
VZEB1
p19140
sa(dp19141
g16449
I56
sg16450
I1
sg16451
I3
sg16452
VP33032
p19142
sg16454
VMKR
p19143
sa(dp19144
g16449
I128
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VTWIST1
p19145
sa(dp19146
g16449
I202
sg16450
I5
sg16451
I36
sg16452
g11
sg16454
Vvascular endothelial growth factor A
p19147
sasg16456
(lp19148
(dp19149
g16449
I28
sg16450
I1
sg16451
I16
sg16459
VC0020459
p19150
sg16454
Vhyperinsulinemia
p19151
sasa(dp19152
g16444
VAortic PWV correlated crudely with age (p &lt; 0.001), the presence of diabetes (p &lt; 0.001), hypertension (p &lt; 0.001), eGFR (p &lt; 0.001), LVMI (p = 0.01), e/e' (p &lt; 0.001) and LV twist (p = 0.003).
p19153
sg16446
(lp19154
sg16456
(lp19155
(dp19156
g16449
I96
sg16450
I1
sg16451
I12
sg16459
VC0020538
p19157
sg16454
Vhypertension
p19158
sa(dp19159
g16449
I71
sg16450
I1
sg16451
I8
sg16459
VC0011849
p19160
sg16454
Vdiabetes
p19161
sasa(dp19162
g16444
VThere is limited information regarding the role of left ventricular (LV) twist and the effect of exercise in type 2 diabetes (T2D).
p19163
sg16446
(lp19164
sg16456
(lp19165
(dp19166
g16449
I126
sg16450
I1
sg16451
I3
sg16459
VC0011860
p19167
sg16454
VT2D
p19168
sa(dp19169
g16449
I109
sg16450
I3
sg16451
I15
sg16459
VC0011860
p19170
sg16454
Vtype 2 diabetes
p19171
sasa(dp19172
g16444
VThese results demonstrated that quercetin ameliorates the EMT of HK-2 and NRK-52E cells induced by high glucose and renal fibrosis induced by diabetes, and these effects have been associated with the inhibition of the two transcriptional factors (snail and twist) and the activation of mTORC1/p70S6K.
p19173
sg16446
(lp19174
(dp19175
g16449
I74
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VNRK-52E
p19176
sasg16456
(lp19177
(dp19178
g16449
I142
sg16450
I1
sg16451
I8
sg16459
VC0011849
p19179
sg16454
Vdiabetes
p19180
sa(dp19181
g16449
I116
sg16450
I2
sg16451
I14
sg16459
VC0151650
p19182
sg16454
Vrenal fibrosis
p19183
sasa(dp19184
g16444
VActivin Receptor-Like Kinase 5 (ALK-5) is related to some types of cancer, such as breast, lung and pancreas.
p19185
sg16446
(lp19186
(dp19187
g16449
I0
sg16450
I4
sg16451
I30
sg16452
VP36897
p19188
sg16454
VActivin Receptor-Like Kinase 5
p19189
sa(dp19190
g16449
I32
sg16450
I1
sg16451
I5
sg16452
VP36897
p19191
sg16454
VALK-5
p19192
sasg16456
(lp19193
(dp19194
g16449
I67
sg16450
I1
sg16451
I6
sg16459
VC0006826
p19195
sg16454
Vcancer
p19196
sasa(dp19197
g16444
VOverall, we discussed about the main interactions between ALK-5 and six inhibitors that may be used as starting point for designing of new molecules to the cancer treatment.
p19198
sg16446
(lp19199
(dp19200
g16449
I58
sg16450
I1
sg16451
I5
sg16452
VP36897
p19201
sg16454
VALK-5
p19202
sasg16456
(lp19203
(dp19204
g16449
I156
sg16450
I1
sg16451
I6
sg16459
VC0006826
p19205
sg16454
Vcancer
p19206
sasa(dp19207
g16444
VIn summary, the results suggest that eupatolide suppresses the migration and invasion of breast cancer cells by blocking the canonical ALK5-SMAD3 signaling pathway and the non-canonical ERK and AKT signaling pathways.
p19208
sg16446
(lp19209
(dp19210
g16449
I186
sg16450
I1
sg16451
I3
sg16452
VP29323
p19211
sg16454
VERK
p19212
sa(dp19213
g16449
I135
sg16450
I1
sg16451
I4
sg16452
VP36897
p19214
sg16454
VALK5
p19215
sa(dp19216
g16449
I194
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VAKT
p19217
sasg16456
(lp19218
(dp19219
g16449
I77
sg16450
I1
sg16451
I8
sg16459
VC2699153
p19220
sg16454
Vinvasion
p19221
sa(dp19222
g16449
I112
sg16450
I1
sg16451
I8
sg16459
VC0233660
p19223
sg16454
Vblocking
p19224
sa(dp19225
g16449
I89
sg16450
I2
sg16451
I13
sg16459
VC0678222
p19226
sg16454
Vbreast cancer
p19227
sasa(dp19228
g16444
VExpression of a mutant TBetaRI that signals but does not interact with Smad7 prevented the CerS4-mediated inhibition of migration in various cancer cells.
p19229
sg16446
(lp19230
(dp19231
g16449
I71
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSmad7
p19232
sa(dp19233
g16449
I91
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCerS4
p19234
sasg16456
(lp19235
(dp19236
g16449
I141
sg16450
I1
sg16451
I6
sg16459
VC0006826
p19237
sg16454
Vcancer
p19238
sa(dp19239
g16449
I16
sg16450
I1
sg16451
I6
sg16459
VC0596988
p19240
sg16454
Vmutant
p19241
sasa(dp19242
g16444
VTBetaRI-Smo cross-talk at the cilia in CerS4-deficient 4T1 mammary cancer cells induced liver metastasis from orthotopic allografts in both wild-type and CerS4-deficient mice, which was prevented by overexpression of Smad7 or knockdown of intraflagellar transport protein 88 (IFT88).
p19243
sg16446
(lp19244
(dp19245
g16449
I239
sg16450
I4
sg16451
I35
sg16452
g11
sg16454
Vintraflagellar transport protein 88
p19246
sa(dp19247
g16449
I39
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCerS4
p19248
sa(dp19249
g16449
I8
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VSmo
p19250
sa(dp19251
g16449
I276
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIFT88
p19252
sa(dp19253
g16449
I39
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCerS4
p19254
sa(dp19255
g16449
I217
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSmad7
p19256
sasg16456
(lp19257
(dp19258
g16449
I67
sg16450
I1
sg16451
I6
sg16459
VC0006826
p19259
sg16454
Vcancer
p19260
sa(dp19261
g16449
I88
sg16450
I2
sg16451
I16
sg16459
VC0494165
p19262
sg16454
Vliver metastasis
p19263
sasa(dp19264
g16444
VTransforming growth factor type 1 receptor (ALK5) is kinase associated with a wide variety of pathological processes, and inhibition of ALK5 is a good strategy to treat many kinds of cancer and fibrotic diseases.
p19265
sg16446
(lp19266
(dp19267
g16449
I0
sg16450
I6
sg16451
I42
sg16452
g11
sg16454
VTransforming growth factor type 1 receptor
p19268
sa(dp19269
g16449
I44
sg16450
I1
sg16451
I4
sg16452
VP36897
p19270
sg16454
VALK5
p19271
sa(dp19272
g16449
I44
sg16450
I1
sg16451
I4
sg16452
VP36897
p19273
sg16454
VALK5
p19274
sasg16456
(lp19275
(dp19276
g16449
I94
sg16450
I2
sg16451
I22
sg16459
VC0030660
p19277
sg16454
Vpathological processes
p19278
sa(dp19279
g16449
I183
sg16450
I1
sg16451
I6
sg16459
VC0006826
p19280
sg16454
Vcancer
p19281
sasa(dp19282
g16444
VThe high mortality rates observed in patients with invasive aspergillosis caused by azole-resistant A. fumigatus (ARAF) isolates pose serious challenges to the clinical microbiologist for timely identification of resistance and appropriate therapeutic interventions.
p19283
sg16446
(lp19284
sg16456
(lp19285
(dp19286
g16449
I51
sg16450
I2
sg16451
I22
sg16459
VC0238013
p19287
sg16454
Vinvasive aspergillosis
p19288
sasa(dp19289
g16444
VMKL/myocardin-like 2 (MKL2) encodes myocardin-related transcription factor B in a megakaryoblastic leukemia gene family, and C11orf95 (chromosome 11 open reading frame 95) is a hypothetical protein.
p19290
sg16446
(lp19291
(dp19292
g16449
I0
sg16450
I2
sg16451
I20
sg16452
g11
sg16454
VMKL/myocardin-like 2
p19293
sa(dp19294
g16449
I36
sg16450
I4
sg16451
I40
sg16452
g11
sg16454
Vmyocardin-related transcription factor B
p19295
sa(dp19296
g16449
I22
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VMKL2
p19297
sasg16456
(lp19298
(dp19299
g16449
I82
sg16450
I2
sg16451
I25
sg16459
VC0023462
p19300
sg16454
Vmegakaryoblastic leukemia
p19301
sasa(dp19302
g16444
VSerum levels of IL-16, IL-33 and the decoy receptor of IL-33, soluble ST2, are elevated in allergic rhinitis.
p19303
sg16446
(lp19304
(dp19305
g16449
I16
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19306
sasg16456
(lp19307
(dp19308
g16449
I91
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19309
sg16454
Vallergic rhinitis
p19310
sasa(dp19311
g16444
VRecent studies show that IL-16, soluble ST2 or anti-IL-33 reduce type 2 cytokines (such as IL-5) and eosinophilia in murine models of allergic asthma or allergic rhinitis respectively.
p19312
sg16446
(lp19313
(dp19314
g16449
I65
sg16450
I3
sg16451
I16
sg16452
VP01374
p19315
sg16454
Vtype 2 cytokines
p19316
sa(dp19317
g16449
I91
sg16450
I1
sg16451
I4
sg16452
VP05113
p19318
sg16454
VIL-5
p19319
sa(dp19320
g16449
I25
sg16450
I3
sg16451
I18
sg16452
g11
sg16454
VIL-16, soluble ST2
p19321
sasg16456
(lp19322
(dp19323
g16449
I134
sg16450
I2
sg16451
I15
sg16459
VC0155877
p19324
sg16454
Vallergic asthma
p19325
sa(dp19326
g16449
I153
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19327
sg16454
Vallergic rhinitis
p19328
sa(dp19329
g16449
I101
sg16450
I1
sg16451
I12
sg16459
VC0014457
p19330
sg16454
Veosinophilia
p19331
sasa(dp19332
g16444
VIn this study, we studied the release of IL-5, IL-16, IL-33 and soluble ST2 in allergic rhinitis patients after nasal allergen challenge and natural pollen exposure.
p19333
sg16446
(lp19334
(dp19335
g16449
I47
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19336
sa(dp19337
g16449
I41
sg16450
I1
sg16451
I4
sg16452
VP05113
p19338
sg16454
VIL-5
p19339
sasg16456
(lp19340
(dp19341
g16449
I79
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19342
sg16454
Vallergic rhinitis
p19343
sasa(dp19344
g16444
VThe observed upregulation of soluble ST2 and IL-16 after nasal allergen challenge and during peak pollination season suggests potential regulatory roles of these cytokines in the inflammatory reaction in allergic rhinitis.
p19345
sg16446
(lp19346
(dp19347
g16449
I45
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19348
sa(dp19349
g16449
I37
sg16450
I1
sg16451
I3
sg16452
VP10767
p19350
sg16454
VST2
p19351
sasg16456
(lp19352
(dp19353
g16449
I204
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19354
sg16454
Vallergic rhinitis
p19355
sa(dp19356
g16449
I179
sg16450
I2
sg16451
I21
sg16459
VC0021368
p19357
sg16454
Vinflammatory reaction
p19358
sasa(dp19359
g16444
VTo detect the expression and distribution of the lung surfactant protein D (surfactant protein D,SP-D ) and IL-16 in nasal mucosa of allergic rhinitis and nasal polyps, and then probe into their significance in the pathology of allergic rhinitis and nasal polyps.
p19360
sg16446
(lp19361
(dp19362
g16449
I97
sg16450
I1
sg16451
I4
sg16452
VP35247
p19363
sg16454
VSP-D
p19364
sa(dp19365
g16449
I54
sg16450
I3
sg16451
I20
sg16452
VP35247
p19366
sg16454
Vsurfactant protein D
p19367
sa(dp19368
g16449
I54
sg16450
I3
sg16451
I20
sg16452
VP35247
p19369
sg16454
Vsurfactant protein D
p19370
sa(dp19371
g16449
I108
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19372
sasg16456
(lp19373
(dp19374
g16449
I215
sg16450
I1
sg16451
I9
sg16459
VC0677042
p19375
sg16454
Vpathology
p19376
sa(dp19377
g16449
I155
sg16450
I2
sg16451
I12
sg16459
VC0027430
p19378
sg16454
Vnasal polyps
p19379
sa(dp19380
g16449
I133
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19381
sg16454
Vallergic rhinitis
p19382
sa(dp19383
g16449
I155
sg16450
I2
sg16451
I12
sg16459
VC0027430
p19384
sg16454
Vnasal polyps
p19385
sa(dp19386
g16449
I133
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19387
sg16454
Vallergic rhinitis
p19388
sasa(dp19389
g16444
VFifteen cases of allergic rhinitis, fifteen cases of nasal polyps and fifteen cases of inferior turbinate mucosa were studied to detect the expression of SP-D and IL-16 by immunohistochemistry method.
p19390
sg16446
(lp19391
(dp19392
g16449
I154
sg16450
I1
sg16451
I4
sg16452
VP35247
p19393
sg16454
VSP-D
p19394
sa(dp19395
g16449
I163
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19396
sasg16456
(lp19397
(dp19398
g16449
I17
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19399
sg16454
Vallergic rhinitis
p19400
sa(dp19401
g16449
I53
sg16450
I2
sg16451
I12
sg16459
VC0027430
p19402
sg16454
Vnasal polyps
p19403
sasa(dp19404
g16444
VThe expression of SP-D and IL-16 in allergic rhinitis and nasal polyps were dramatically higher in controls (P &lt; 0.01).
p19405
sg16446
(lp19406
(dp19407
g16449
I27
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19408
sa(dp19409
g16449
I18
sg16450
I1
sg16451
I4
sg16452
VP35247
p19410
sg16454
VSP-D
p19411
sasg16456
(lp19412
(dp19413
g16449
I36
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19414
sg16454
Vallergic rhinitis
p19415
sa(dp19416
g16449
I58
sg16450
I2
sg16451
I12
sg16459
VC0027430
p19417
sg16454
Vnasal polyps
p19418
sasa(dp19419
g16444
VThere was no remarkable difference in the expression of SP-D and IL-16 between allergic rhinitis and nasal polyps (P &gt; 0.05).
p19420
sg16446
(lp19421
(dp19422
g16449
I65
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19423
sa(dp19424
g16449
I56
sg16450
I1
sg16451
I4
sg16452
VP35247
p19425
sg16454
VSP-D
p19426
sasg16456
(lp19427
(dp19428
g16449
I101
sg16450
I2
sg16451
I12
sg16459
VC0027430
p19429
sg16454
Vnasal polyps
p19430
sa(dp19431
g16449
I79
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19432
sg16454
Vallergic rhinitis
p19433
sasa(dp19434
g16444
VIL-16 is an important eosinophil chemokine in the process of allergic rhinitis and nasal polyps,and it can also enhance the local role of eosinophils,thus it can involve in the process of allergic rhinitis and nasal polyps disease.
p19435
sg16446
(lp19436
(dp19437
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19438
sasg16456
(lp19439
(dp19440
g16449
I61
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19441
sg16454
Vallergic rhinitis
p19442
sa(dp19443
g16449
I61
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19444
sg16454
Vallergic rhinitis
p19445
sa(dp19446
g16449
I83
sg16450
I2
sg16451
I12
sg16459
VC0027430
p19447
sg16454
Vnasal polyps
p19448
sa(dp19449
g16449
I83
sg16450
I2
sg16451
I12
sg16459
VC0027430
p19450
sg16454
Vnasal polyps
p19451
sasa(dp19452
g16444
VThough a chemotactin for CD4(+) cells and eosinophils, IL-16 also modulates their production of factors that influence inflammatory lung diseases, e.g., asthma and allergic rhinitis.
p19453
sg16446
(lp19454
(dp19455
g16449
I55
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19456
sa(dp19457
g16449
I25
sg16450
I1
sg16451
I3
sg16452
VP01730
p19458
sg16454
VCD4
p19459
sasg16456
(lp19460
(dp19461
g16449
I153
sg16450
I1
sg16451
I6
sg16459
VC0004096
p19462
sg16454
Vasthma
p19463
sa(dp19464
g16449
I132
sg16450
I2
sg16451
I13
sg16459
VC0024115
p19465
sg16454
Vlung diseases
p19466
sa(dp19467
g16449
I164
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19468
sg16454
Vallergic rhinitis
p19469
sasa(dp19470
g16444
VInterleukin-16 (IL-16) is a cytokine that induces selective migration of CD4+ cells and participates in inflammatory diseases including allergic rhinitis.
p19471
sg16446
(lp19472
(dp19473
g16449
I16
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19474
sa(dp19475
g16449
I0
sg16450
I1
sg16451
I14
sg16452
g11
sg16454
VInterleukin-16
p19476
sa(dp19477
g16449
I73
sg16450
I1
sg16451
I4
sg16452
VP01730
p19478
sg16454
VCD4+
p19479
sasg16456
(lp19480
(dp19481
g16449
I136
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19482
sg16454
Vallergic rhinitis
p19483
sasa(dp19484
g16444
VWe evaluated the variability of IL-16 and the effects of the antiallergic drugs fexofenadine (40 mg/kg/day) and ramatroban (30 mg/kg/day) on IL-16 in an OVA-sensitized BALB/c murine experimental allergic rhinitis model.
p19485
sg16446
(lp19486
(dp19487
g16449
I32
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19488
sa(dp19489
g16449
I32
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19490
sasg16456
(lp19491
(dp19492
g16449
I195
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19493
sg16454
Vallergic rhinitis
p19494
sasa(dp19495
g16444
VThese results suggest that IL-16 was both systemically and locally upregulated in the murine allergic rhinitis model and that IL-16 changed in parallel to allergic state by treatment with the drugs.
p19496
sg16446
(lp19497
(dp19498
g16449
I27
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19499
sa(dp19500
g16449
I27
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19501
sasg16456
(lp19502
(dp19503
g16449
I155
sg16450
I2
sg16451
I14
sg16459
VC0020517
p19504
sg16454
Vallergic state
p19505
sa(dp19506
g16449
I93
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19507
sg16454
Vallergic rhinitis
p19508
sasa(dp19509
g16444
VThe results showed abnormally increased levels of IL-16 (294.4 +/- 15.24 pg/ml), serum eosinophils with absolute count (510.0 +/- 93.57, P&gt;0.05), and total serum IgE (287.9 +/- 61.22 IU/ml) using ELFA in patients of combined asthma and rhinitis, than in each of them alone.
p19510
sg16446
(lp19511
(dp19512
g16449
I159
sg16450
I2
sg16451
I9
sg16452
VP01854
p19513
sg16454
Vserum IgE
p19514
sa(dp19515
g16449
I50
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19516
sasg16456
(lp19517
(dp19518
g16449
I239
sg16450
I1
sg16451
I8
sg16459
VC0035455
p19519
sg16454
Vrhinitis
p19520
sa(dp19521
g16449
I165
sg16450
I1
sg16451
I3
sg16459
VC0270850
p19522
sg16454
VIgE
p19523
sa(dp19524
g16449
I228
sg16450
I1
sg16451
I6
sg16459
VC0004096
p19525
sg16454
Vasthma
p19526
sasa(dp19527
g16444
VWe first examined the IL-16 expression of serum and mucosal tissue in patients with allergic rhinitis.
p19528
sg16446
(lp19529
(dp19530
g16449
I22
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19531
sasg16456
(lp19532
(dp19533
g16449
I84
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19534
sg16454
Vallergic rhinitis
p19535
sasa(dp19536
g16444
VIL-16 levels were elevated in the serum of patients with allergic rhinitis compared with normal controls.
p19537
sg16446
(lp19538
(dp19539
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19540
sasg16456
(lp19541
(dp19542
g16449
I57
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19543
sg16454
Vallergic rhinitis
p19544
sasa(dp19545
g16444
VIL-16 was significantly correlated with eosinophils in the peripheral blood of allergic rhinitis patients.
p19546
sg16446
(lp19547
(dp19548
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p19549
sasg16456
(lp19550
(dp19551
g16449
I79
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19552
sg16454
Vallergic rhinitis
p19553
sasa(dp19554
g16444
VThis IL-16 cytokine may be strongly associated with the developmental mechanism of allergic rhinitis.
p19555
sg16446
(lp19556
(dp19557
g16449
I5
sg16450
I2
sg16451
I14
sg16452
g11
sg16454
VIL-16 cytokine
p19558
sasg16456
(lp19559
(dp19560
g16449
I83
sg16450
I2
sg16451
I17
sg16459
VC2607914
p19561
sg16454
Vallergic rhinitis
p19562
sasa(dp19563
g16444
VSpeech fluency was assessed in 35 patients with frontotemporal lobar degeneration (FTLD) who presented with progressive non-fluent aphasia (PNFA, n=11), semantic dementia (SemD, n=12), or a social and executive disorder without aphasia (SOC/EXEC, n=12).
p19564
sg16446
(lp19565
(dp19566
g16449
I172
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSemD
p19567
sa(dp19568
g16449
I153
sg16450
I2
sg16451
I17
sg16452
g11
sg16454
Vsemantic dementia
p19569
sasg16456
(lp19570
(dp19571
g16449
I48
sg16450
I3
sg16451
I33
sg16459
VC0751072
p19572
sg16454
Vfrontotemporal lobar degeneration
p19573
sa(dp19574
g16449
I153
sg16450
I2
sg16451
I17
sg16459
VC0338462
p19575
sg16454
Vsemantic dementia
p19576
sa(dp19577
g16449
I172
sg16450
I1
sg16451
I4
sg16459
VC0338462
p19578
sg16454
VSemD
p19579
sa(dp19580
g16449
I83
sg16450
I1
sg16451
I4
sg16459
VC0751072
p19581
sg16454
VFTLD
p19582
sa(dp19583
g16449
I131
sg16450
I1
sg16451
I7
sg16459
VC0003537
p19584
sg16454
Vaphasia
p19585
sa(dp19586
g16449
I120
sg16450
I2
sg16451
I18
sg16459
VC0349390
p19587
sg16454
Vnon-fluent aphasia
p19588
sasa(dp19589
g16444
VTwo subtypes commonly present with a language disorder: semantic dementia (SemD) and progressive nonfluent aphasia (PNFA).
p19590
sg16446
(lp19591
(dp19592
g16449
I56
sg16450
I2
sg16451
I17
sg16452
g11
sg16454
Vsemantic dementia
p19593
sa(dp19594
g16449
I75
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSemD
p19595
sasg16456
(lp19596
(dp19597
g16449
I37
sg16450
I2
sg16451
I17
sg16459
VC0023015
p19598
sg16454
Vlanguage disorder
p19599
sa(dp19600
g16449
I56
sg16450
I2
sg16451
I17
sg16459
VC0338462
p19601
sg16454
Vsemantic dementia
p19602
sa(dp19603
g16449
I85
sg16450
I3
sg16451
I29
sg16459
VC0751706
p19604
sg16454
Vprogressive nonfluent aphasia
p19605
sa(dp19606
g16449
I116
sg16450
I1
sg16451
I4
sg16459
VC0751706
p19607
sg16454
VPNFA
p19608
sa(dp19609
g16449
I75
sg16450
I1
sg16451
I4
sg16459
VC0338462
p19610
sg16454
VSemD
p19611
sasa(dp19612
g16444
VExpression of several genes associated with schizophrenia or autism including Sema3a, Trfr2 and Vldlr were found to be altered as were protein levels of Foxp2.
p19613
sg16446
(lp19614
(dp19615
g16449
I96
sg16450
I1
sg16451
I5
sg16452
VP98155
p19616
sg16454
VVldlr
p19617
sa(dp19618
g16449
I78
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VSema3a
p19619
sasg16456
(lp19620
(dp19621
g16449
I44
sg16450
I1
sg16451
I13
sg16459
VC0036341
p19622
sg16454
Vschizophrenia
p19623
sa(dp19624
g16449
I61
sg16450
I1
sg16451
I6
sg16459
VC0004352
p19625
sg16454
Vautism
p19626
sasa(dp19627
g16444
VWe classified 67 patients with PPA into three clinical variants: semantic dementia (SEMD), progressive nonfluent aphasia (PNFA), and logopenic progressive aphasia (LPA), and we compared the severity of behavioral dysfunction, as measured by the Neuropsychiatric Inventory, in these groups and patients with frontotemporal dementia (FTD) and Alzheimer disease (AD).
p19628
sg16446
(lp19629
sg16456
(lp19630
(dp19631
g16449
I65
sg16450
I2
sg16451
I17
sg16459
VC0338462
p19632
sg16454
Vsemantic dementia
p19633
sa(dp19634
g16449
I332
sg16450
I1
sg16451
I3
sg16459
VC0338451
p19635
sg16454
VFTD
p19636
sa(dp19637
g16449
I91
sg16450
I3
sg16451
I29
sg16459
VC0751706
p19638
sg16454
Vprogressive nonfluent aphasia
p19639
sa(dp19640
g16449
I341
sg16450
I2
sg16451
I17
sg16459
VC0002395
p19641
sg16454
VAlzheimer disease
p19642
sa(dp19643
g16449
I84
sg16450
I1
sg16451
I4
sg16459
VC0338462
p19644
sg16454
VSEMD
p19645
sa(dp19646
g16449
I122
sg16450
I1
sg16451
I4
sg16459
VC0751706
p19647
sg16454
VPNFA
p19648
sa(dp19649
g16449
I307
sg16450
I2
sg16451
I23
sg16459
VC0338451
p19650
sg16454
Vfrontotemporal dementia
p19651
sa(dp19652
g16449
I143
sg16450
I2
sg16451
I19
sg16459
VC0338457
p19653
sg16454
Vprogressive aphasia
p19654
sa(dp19655
g16449
I360
sg16450
I1
sg16451
I2
sg16459
VC0002395
p19656
sg16454
VAD
p19657
sa(dp19658
g16449
I31
sg16450
I1
sg16451
I3
sg16459
VC0282513
p19659
sg16454
VPPA
p19660
sasa(dp19661
g16444
VThe authors asked patients with progressive nonfluent aphasia (PNFA), patients with semantic dementia (SemD), and nonaphasic patients with a disorder of social comportment and executive functioning (SOC/EXEC) to narrate the story of a wordless children's picture book.
p19662
sg16446
(lp19663
(dp19664
g16449
I84
sg16450
I2
sg16451
I17
sg16452
g11
sg16454
Vsemantic dementia
p19665
sa(dp19666
g16449
I199
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VSOC
p19667
sa(dp19668
g16449
I103
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSemD
p19669
sasg16456
(lp19670
(dp19671
g16449
I32
sg16450
I3
sg16451
I29
sg16459
VC0751706
p19672
sg16454
Vprogressive nonfluent aphasia
p19673
sa(dp19674
g16449
I63
sg16450
I1
sg16451
I4
sg16459
VC0751706
p19675
sg16454
VPNFA
p19676
sa(dp19677
g16449
I103
sg16450
I1
sg16451
I4
sg16459
VC0338462
p19678
sg16454
VSemD
p19679
sa(dp19680
g16449
I84
sg16450
I2
sg16451
I17
sg16459
VC0338462
p19681
sg16454
Vsemantic dementia
p19682
sasa(dp19683
g16444
VEach sequence is manually annotated with primary function, subfunction and subcellular location, and extensively annotated in an automated process with data extracted from external databases, including gene information from LocusLink and Ensembl; disease information from OMIM; protein-protein interaction data from MINT and DIP; functional domain information from Pfam; protein fingerprints from PRINTS; protein family and family-specific signatures from InterPro; structure data from PDB; mutation data from PMD; BLAST homology data from NCBI NR; and proteins found to be related based on LocusLink and SWISS-PROT references and sequence and taxonomy data.
p19684
sg16446
(lp19685
sg16456
(lp19686
(dp19687
g16449
I510
sg16450
I1
sg16451
I3
sg16459
VC1832661
p19688
sg16454
VPMD
p19689
sa(dp19690
g16449
I325
sg16450
I1
sg16451
I3
sg16459
VC0238378
p19691
sg16454
VDIP
p19692
sa(dp19693
g16449
I486
sg16450
I1
sg16451
I3
sg16459
VC0029401
p19694
sg16454
VPDB
p19695
sasa(dp19696
g16444
VAn increase in the ratio of Abeta(WT)/Abeta(MUT(Arctic)), therefore, may result in the accumulation of potential neurotoxic protofibrils and acceleration of disease progression in familial Alzheimer's disease mutation carriers.
p19697
sg16446
(lp19698
(dp19699
g16449
I44
sg16450
I1
sg16451
I3
sg16452
VP22033
p19700
sg16454
VMUT
p19701
sa(dp19702
g16449
I28
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VAbeta
p19703
sa(dp19704
g16449
I28
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VAbeta
p19705
sasg16456
(lp19706
(dp19707
g16449
I157
sg16450
I2
sg16451
I19
sg16459
VC0242656
p19708
sg16454
Vdisease progression
p19709
sa(dp19710
g16449
I180
sg16450
I3
sg16451
I28
sg16459
VC0276496
p19711
sg16454
Vfamilial Alzheimer's disease
p19712
sasa(dp19713
g16444
VTo gain insight into the pathogenesis of these tumors we have analyzed the immunophenotype (ARID1A, MLH1, PMS2, MSH2, MSH6, p53, b-catenin, SMARCB1, synaptophysin, chromogranin A, and CD56) and mutational status (PTEN, KRAS, PIK3CA, TP53 and POLE) of 4 dedifferentiated endometrial carcinomas with strong and diffuse neuroendocrine expression.
p19714
sg16446
(lp19715
(dp19716
g16449
I140
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VSMARCB1
p19717
sa(dp19718
g16449
I112
sg16450
I1
sg16451
I4
sg16452
VP43246
p19719
sg16454
VMSH2
p19720
sa(dp19721
g16449
I164
sg16450
I2
sg16451
I14
sg16452
VP10645
p19722
sg16454
Vchromogranin A
p19723
sa(dp19724
g16449
I149
sg16450
I1
sg16451
I13
sg16452
VP08247
p19725
sg16454
Vsynaptophysin
p19726
sa(dp19727
g16449
I100
sg16450
I1
sg16451
I4
sg16452
VP40692
p19728
sg16454
VMLH1
p19729
sa(dp19730
g16449
I124
sg16450
I1
sg16451
I3
sg16452
VP42771
p19731
sg16454
Vp53
p19732
sa(dp19733
g16449
I225
sg16450
I1
sg16451
I6
sg16452
VP42336
p19734
sg16454
VPIK3CA
p19735
sa(dp19736
g16449
I118
sg16450
I1
sg16451
I4
sg16452
VP52701
p19737
sg16454
VMSH6
p19738
sa(dp19739
g16449
I106
sg16450
I1
sg16451
I4
sg16452
VP25054
p19740
sg16454
VPMS2
p19741
sa(dp19742
g16449
I213
sg16450
I1
sg16451
I4
sg16452
VP60484
p19743
sg16454
VPTEN
p19744
sa(dp19745
g16449
I219
sg16450
I1
sg16451
I4
sg16452
VP01116
p19746
sg16454
VKRAS
p19747
sa(dp19748
g16449
I242
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPOLE
p19749
sasg16456
(lp19750
(dp19751
g16449
I270
sg16450
I2
sg16451
I22
sg16459
VC0476089
p19752
sg16454
Vendometrial carcinomas
p19753
sa(dp19754
g16449
I47
sg16450
I1
sg16451
I6
sg16459
VC0027651
p19755
sg16454
Vtumors
p19756
sa(dp19757
g16449
I25
sg16450
I1
sg16451
I12
sg16459
VC0699748
p19758
sg16454
Vpathogenesis
p19759
sasa(dp19760
g16444
VIn gynecological cancer, ARID1A mutations have been identified in 46-57% of clear cell carcinoma and 30% of endometrioid carcinoma.
p19761
sg16446
(lp19762
sg16456
(lp19763
(dp19764
g16449
I76
sg16450
I3
sg16451
I20
sg16459
VC0206681
p19765
sg16454
Vclear cell carcinoma
p19766
sa(dp19767
g16449
I17
sg16450
I1
sg16451
I6
sg16459
VC0006826
p19768
sg16454
Vcancer
p19769
sa(dp19770
g16449
I108
sg16450
I2
sg16451
I22
sg16459
VC0206687
p19771
sg16454
Vendometrioid carcinoma
p19772
sasa(dp19773
g16444
VWe recently identified 3 mutually exclusive mechanisms of switch/sucrose nonfermentable (SWI/SNF) complex inactivation (BRG1 inactivation, INI1 inactivation or ARID1A/ARID1B co-inactivation) that are associated with histologic dedifferentiation in the majority of dedifferentiated endometrial carcinoma.
p19774
sg16446
(lp19775
(dp19776
g16449
I89
sg16450
I1
sg16451
I3
sg16452
VP28370
p19777
sg16454
VSWI
p19778
sa(dp19779
g16449
I120
sg16450
I1
sg16451
I4
sg16452
VP51532
p19780
sg16454
VBRG1
p19781
sa(dp19782
g16449
I139
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VINI1
p19783
sa(dp19784
g16449
I167
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VARID1B
p19785
sa(dp19786
g16449
I93
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VSNF
p19787
sasg16456
(lp19788
(dp19789
g16449
I106
sg16450
I1
sg16451
I12
sg16459
VC0544461
p19790
sg16454
Vinactivation
p19791
sa(dp19792
g16449
I281
sg16450
I2
sg16451
I21
sg16459
VC0476089
p19793
sg16454
Vendometrial carcinoma
p19794
sa(dp19795
g16449
I106
sg16450
I1
sg16451
I12
sg16459
VC0544461
p19796
sg16454
Vinactivation
p19797
sa(dp19798
g16449
I227
sg16450
I1
sg16451
I17
sg16459
VC0002793
p19799
sg16454
Vdedifferentiation
p19800
sa(dp19801
g16449
I106
sg16450
I1
sg16451
I12
sg16459
VC0544461
p19802
sg16454
Vinactivation
p19803
sa(dp19804
g16449
I106
sg16450
I1
sg16451
I12
sg16459
VC0544461
p19805
sg16454
Vinactivation
p19806
sasa(dp19807
g16444
VThe tumor suppressor gene, AT Rich Interactive Domain 1A (ARID1A) mutation has been reported in a variety of cancers, especially the endometrium-related gynecological cancers, including the ovarian clear cell carcinoma, ovarian endometrioid carcinoma, and uterine endometrioid carcinoma.
p19808
sg16446
(lp19809
(dp19810
g16449
I27
sg16450
I5
sg16451
I29
sg16452
g11
sg16454
VAT Rich Interactive Domain 1A
p19811
sa(dp19812
g16449
I58
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VARID1A
p19813
sasg16456
(lp19814
(dp19815
g16449
I109
sg16450
I1
sg16451
I7
sg16459
VC0006826
p19816
sg16454
Vcancers
p19817
sa(dp19818
g16449
I198
sg16450
I3
sg16451
I20
sg16459
VC0206681
p19819
sg16454
Vclear cell carcinoma
p19820
sa(dp19821
g16449
I220
sg16450
I3
sg16451
I30
sg16459
VC0346163
p19822
sg16454
Vovarian endometrioid carcinoma
p19823
sa(dp19824
g16449
I228
sg16450
I2
sg16451
I22
sg16459
VC0206687
p19825
sg16454
Vendometrioid carcinoma
p19826
sa(dp19827
g16449
I109
sg16450
I1
sg16451
I7
sg16459
VC0006826
p19828
sg16454
Vcancers
p19829
sa(dp19830
g16449
I4
sg16450
I1
sg16451
I5
sg16459
VC0027651
p19831
sg16454
Vtumor
p19832
sasa(dp19833
g16444
VThe current study aimed to evaluate serum levels of MFAP4 in patients with pulmonary fibrosis in order to test its potential as biomarker in clinical practice.
p19834
sg16446
(lp19835
(dp19836
g16449
I52
sg16450
I1
sg16451
I5
sg16452
VP55083
p19837
sg16454
VMFAP4
p19838
sasg16456
(lp19839
(dp19840
g16449
I75
sg16450
I2
sg16451
I18
sg16459
VC0034069
p19841
sg16454
Vpulmonary fibrosis
p19842
sasa(dp19843
g16444
VA further aim was to determine whether MFAP4 deficiency in mice affects the formation of pulmonary fibrosis in the bleomycin model of lung fibrosis.
p19844
sg16446
(lp19845
(dp19846
g16449
I39
sg16450
I1
sg16451
I5
sg16452
VP55083
p19847
sg16454
VMFAP4
p19848
sasg16456
(lp19849
(dp19850
g16449
I89
sg16450
I2
sg16451
I18
sg16459
VC0034069
p19851
sg16454
Vpulmonary fibrosis
p19852
sa(dp19853
g16449
I134
sg16450
I2
sg16451
I13
sg16459
VC0034069
p19854
sg16454
Vlung fibrosis
p19855
sasa(dp19856
g16444
VMFAP4 levels were increased in BAL of bleomycin treated mice with pulmonary fibrosis.
p19857
sg16446
(lp19858
(dp19859
g16449
I0
sg16450
I1
sg16451
I5
sg16452
VP55083
p19860
sg16454
VMFAP4
p19861
sasg16456
(lp19862
(dp19863
g16449
I66
sg16450
I2
sg16451
I18
sg16459
VC0034069
p19864
sg16454
Vpulmonary fibrosis
p19865
sasa(dp19866
g16444
VMFAP4 is not elevated in sera of patients with pulmonary fibrosis or bleomycin treated mice with pulmonary fibrosis.
p19867
sg16446
(lp19868
(dp19869
g16449
I0
sg16450
I1
sg16451
I5
sg16452
VP55083
p19870
sg16454
VMFAP4
p19871
sasg16456
(lp19872
(dp19873
g16449
I47
sg16450
I2
sg16451
I18
sg16459
VC0034069
p19874
sg16454
Vpulmonary fibrosis
p19875
sa(dp19876
g16449
I47
sg16450
I2
sg16451
I18
sg16459
VC0034069
p19877
sg16454
Vpulmonary fibrosis
p19878
sasa(dp19879
g16444
VThe aim of this study was to test the hypothesis that plasma MFAP4 (pMFAP4) reflects clinical outcomes in chronic obstructive pulmonary disease (COPD).
p19880
sg16446
(lp19881
(dp19882
g16449
I61
sg16450
I1
sg16451
I5
sg16452
VP55083
p19883
sg16454
VMFAP4
p19884
sasg16456
(lp19885
(dp19886
g16449
I145
sg16450
I1
sg16451
I4
sg16459
VC0024117
p19887
sg16454
VCOPD
p19888
sa(dp19889
g16449
I106
sg16450
I4
sg16451
I37
sg16459
VC0024117
p19890
sg16454
Vchronic obstructive pulmonary disease
p19891
sasa(dp19892
g16444
VMultiple linear regressions showed positive associations between pMFAP4 and the Global initiative for Obstructive Lung Disease (GOLD) grade (p = 0.01), modified Medical Research Council score (p &lt; 0.0001) and BODE index (p = 0.04).
p19893
sg16446
(lp19894
sg16456
(lp19895
(dp19896
g16449
I16
sg16450
I1
sg16451
I11
sg16459
VC0684320
p19897
sg16454
Vregressions
p19898
sa(dp19899
g16449
I102
sg16450
I3
sg16451
I24
sg16459
VC0600260
p19900
sg16454
VObstructive Lung Disease
p19901
sasa(dp19902
g16444
VFor essential thrombocythemia, reported risk factors for leukemic transformation include advanced age, extreme thrombocytosis, anemia, leukocytosis, and sequence variants/mutations involving TP53 and EZH2 (for expansion of gene symbols, see www.genenames.org); for polycythemia vera, advanced age, leukocytosis, abnormal karyotype, mutations involving SRSF2 and IDH2, and treatment with pipobroman, chlorambucil, or P32; and for PMF, increased blast percentage, thrombocytopenia, abnormal karyotype, triple-negative driver mutational status, and sequence variants/mutations involving SRSF2, RUNX1, CEBPA, and SH2B3.
p19903
sg16446
(lp19904
(dp19905
g16449
I598
sg16450
I1
sg16451
I5
sg16452
VP49715
p19906
sg16454
VCEBPA
p19907
sa(dp19908
g16449
I200
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VEZH2
p19909
sa(dp19910
g16449
I362
sg16450
I1
sg16451
I4
sg16452
VP48735
p19911
sg16454
VIDH2
p19912
sa(dp19913
g16449
I609
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSH2B3
p19914
sasg16456
(lp19915
(dp19916
g16449
I265
sg16450
I2
sg16451
I17
sg16459
VC0032463
p19917
sg16454
Vpolycythemia vera
p19918
sa(dp19919
g16449
I4
sg16450
I2
sg16451
I25
sg16459
VC0040028
p19920
sg16454
Vessential thrombocythemia
p19921
sa(dp19922
g16449
I66
sg16450
I1
sg16451
I14
sg16459
VC1510411
p19923
sg16454
Vtransformation
p19924
sa(dp19925
g16449
I135
sg16450
I1
sg16451
I12
sg16459
VC0023518
p19926
sg16454
Vleukocytosis
p19927
sa(dp19928
g16449
I127
sg16450
I1
sg16451
I6
sg16459
VC0002871
p19929
sg16454
Vanemia
p19930
sa(dp19931
g16449
I135
sg16450
I1
sg16451
I12
sg16459
VC0023518
p19932
sg16454
Vleukocytosis
p19933
sa(dp19934
g16449
I111
sg16450
I1
sg16451
I14
sg16459
VC0836924
p19935
sg16454
Vthrombocytosis
p19936
sasa(dp19937
g16444
VIn the present case, i(17q)/-17, der(12p), del(5q26), del(7q36), and del(20q11) indicate possible alterations in TP53, ETV6, IDH2, EZH2, and SRSF2 genes, which are responsible for pathomechanism, genetic instability, clonal evolution, and advancement of disease condition.
p19938
sg16446
(lp19939
(dp19940
g16449
I119
sg16450
I1
sg16451
I4
sg16452
VP41212
p19941
sg16454
VETV6
p19942
sa(dp19943
g16449
I125
sg16450
I1
sg16451
I4
sg16452
VP48735
p19944
sg16454
VIDH2
p19945
sa(dp19946
g16449
I141
sg16450
I2
sg16451
I11
sg16452
VP01893
p19947
sg16454
VSRSF2 genes
p19948
sa(dp19949
g16449
I131
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VEZH2
p19950
sasg16456
(lp19951
(dp19952
g16449
I262
sg16450
I1
sg16451
I9
sg16459
VC0012634
p19953
sg16454
Vcondition
p19954
sa(dp19955
g16449
I217
sg16450
I2
sg16451
I16
sg16459
VC1516669
p19956
sg16454
Vclonal evolution
p19957
sasa(dp19958
g16444
VAccumulating evidence indicates that enhancer of zeste homolog 2 (EZH2) promotes the metastatic ability of solid tumors, but the role of EZH2 in extramedullary infiltration (EMI) in acute myeloid leukemia (AML) has not been thoroughly explored.
p19959
sg16446
(lp19960
(dp19961
g16449
I66
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VEZH2
p19962
sa(dp19963
g16449
I37
sg16450
I5
sg16451
I27
sg16452
g11
sg16454
Venhancer of zeste homolog 2
p19964
sa(dp19965
g16449
I66
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VEZH2
p19966
sasg16456
(lp19967
(dp19968
g16449
I182
sg16450
I3
sg16451
I22
sg16459
VC0023467
p19969
sg16454
Vacute myeloid leukemia
p19970
sa(dp19971
g16449
I160
sg16450
I1
sg16451
I12
sg16459
VC0332448
p19972
sg16454
Vinfiltration
p19973
sa(dp19974
g16449
I107
sg16450
I2
sg16451
I12
sg16459
VC0280100
p19975
sg16454
Vsolid tumors
p19976
sa(dp19977
g16449
I206
sg16450
I1
sg16451
I3
sg16459
VC0023467
p19978
sg16454
VAML
p19979
sasa(dp19980
g16444
VWe found that the messenger RNA (mRNA) and protein expression levels of EZH2 in AML patients were both significantly higher than in idiopathic thrombocytopenic purpura (ITP) patients.
p19981
sg16446
(lp19982
(dp19983
g16449
I72
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VEZH2
p19984
sasg16456
(lp19985
(dp19986
g16449
I80
sg16450
I1
sg16451
I3
sg16459
VC0023467
p19987
sg16454
VAML
p19988
sa(dp19989
g16449
I169
sg16450
I1
sg16451
I3
sg16459
VC0043117
p19990
sg16454
VITP
p19991
sa(dp19992
g16449
I132
sg16450
I3
sg16451
I35
sg16459
VC0043117
p19993
sg16454
Vidiopathic thrombocytopenic purpura
p19994
sasa(dp19995
g16444
VHistopathological examination (HPE) of excised gland showed multiple Hurthle cell adenomas in both lobes of thyroid along with foci of papillary thyroid carcinoma which on immunohistochemistry were thyroglobulin positive and PSA negative.
p19996
sg16446
(lp19997
(dp19998
g16449
I225
sg16450
I1
sg16451
I3
sg16452
VP55786
p19999
sg16454
VPSA
p20000
sa(dp20001
g16449
I198
sg16450
I1
sg16451
I13
sg16452
g11
sg16454
Vthyroglobulin
p20002
sasg16456
(lp20003
(dp20004
g16449
I225
sg16450
I1
sg16451
I3
sg16459
VC1519176
p20005
sg16454
VPSA
p20006
sa(dp20007
g16449
I135
sg16450
I3
sg16451
I27
sg16459
VC0238463
p20008
sg16454
Vpapillary thyroid carcinoma
p20009
sa(dp20010
g16449
I82
sg16450
I1
sg16451
I8
sg16459
VC0001430
p20011
sg16454
Vadenomas
p20012
sasa(dp20013
g16444
VUnivariate analysis showed that male gender, thyroglobulin concentrations &gt;=300 ng/ml and tumor diameter &gt;30 mm were significantly more frequent in patients with oxyphile carcinoma compared to patients with oxyphile adenoma, while coexisting Hashimoto thyreoiditis and positive AntiTPO antibodies appeared significantly less frequent in the carcinoma group.
p20014
sg16446
(lp20015
(dp20016
g16449
I45
sg16450
I1
sg16451
I13
sg16452
g11
sg16454
Vthyroglobulin
p20017
sasg16456
(lp20018
(dp20019
g16449
I93
sg16450
I1
sg16451
I5
sg16459
VC0027651
p20020
sg16454
Vtumor
p20021
sa(dp20022
g16449
I177
sg16450
I1
sg16451
I9
sg16459
VC0007097
p20023
sg16454
Vcarcinoma
p20024
sa(dp20025
g16449
I177
sg16450
I1
sg16451
I9
sg16459
VC0007097
p20026
sg16454
Vcarcinoma
p20027
sa(dp20028
g16449
I222
sg16450
I1
sg16451
I7
sg16459
VC0001430
p20029
sg16454
Vadenoma
p20030
sasa(dp20031
g16444
VThe histologic appearance together with the immune profile was diagnostic of WCCA, with diffuse positivity for GATA3, focal weak positivity for parathyroid hormone, and negativity for PAX8, thyroglobulin, TTF1, synaptophysin, chromogranin, and S100p.
p20032
sg16446
(lp20033
(dp20034
g16449
I205
sg16450
I1
sg16451
I4
sg16452
VP43699
p20035
sg16454
VTTF1
p20036
sa(dp20037
g16449
I226
sg16450
I1
sg16451
I12
sg16452
VP08311
p20038
sg16454
Vchromogranin
p20039
sa(dp20040
g16449
I190
sg16450
I1
sg16451
I13
sg16452
g11
sg16454
Vthyroglobulin
p20041
sa(dp20042
g16449
I211
sg16450
I1
sg16451
I13
sg16452
VP08247
p20043
sg16454
Vsynaptophysin
p20044
sa(dp20045
g16449
I184
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPAX8
p20046
sa(dp20047
g16449
I144
sg16450
I2
sg16451
I19
sg16452
VP01270
p20048
sg16454
Vparathyroid hormone
p20049
sa(dp20050
g16449
I244
sg16450
I1
sg16451
I5
sg16452
VP25815
p20051
sg16454
VS100p
p20052
sa(dp20053
g16449
I111
sg16450
I1
sg16451
I5
sg16452
VP23771
p20054
sg16454
VGATA3
p20055
sasg16456
(lp20056
sa(dp20057
g16444
VAfter immunohistochemical characterization using a panel of chromogranin A, thyroglobulin, and calcitonin, 7 of the former thyroid neoplasms were diagnosed as thyroid adenomas, 1 was diagnosed as a thyroid carcinoma, and 4 were diagnosed as parathyroid adenomas.
p20058
sg16446
(lp20059
(dp20060
g16449
I95
sg16450
I1
sg16451
I10
sg16452
VP06881
p20061
sg16454
Vcalcitonin
p20062
sa(dp20063
g16449
I60
sg16450
I2
sg16451
I14
sg16452
VP10645
p20064
sg16454
Vchromogranin A
p20065
sa(dp20066
g16449
I76
sg16450
I1
sg16451
I13
sg16452
g11
sg16454
Vthyroglobulin
p20067
sasg16456
(lp20068
(dp20069
g16449
I123
sg16450
I2
sg16451
I17
sg16459
VC0040136
p20070
sg16454
Vthyroid neoplasms
p20071
sa(dp20072
g16449
I198
sg16450
I2
sg16451
I17
sg16459
VC0549473
p20073
sg16454
Vthyroid carcinoma
p20074
sa(dp20075
g16449
I241
sg16450
I2
sg16451
I20
sg16459
VC0262587
p20076
sg16454
Vparathyroid adenomas
p20077
sa(dp20078
g16449
I167
sg16450
I1
sg16451
I8
sg16459
VC0001430
p20079
sg16454
Vadenomas
p20080
sasa(dp20081
g16444
VThe findings obtained using these cell lines derived from ovarian clear cell adenocarcinoma indicate that integrin alpha3 may associated with the acquisition of malignant potential by clear cell adenocarcinoma.
p20082
sg16446
(lp20083
sg16456
(lp20084
(dp20085
g16449
I66
sg16450
I3
sg16451
I25
sg16459
VC0206681
p20086
sg16454
Vclear cell adenocarcinoma
p20087
sa(dp20088
g16449
I58
sg16450
I4
sg16451
I33
sg16459
VC1518693
p20089
sg16454
Vovarian clear cell adenocarcinoma
p20090
sasa(dp20091
g16444
VNo entanto, a existencia de uma patologia cronica pode determinar um elevado nivel de cuidados preventivos gerais, inclusivamente resultando numa melhoria global do seu nivel de saude oral, o que podera justificar os resultados obtidos.Conclusao: A presenca de diabetes mellitus tipo 1 em doentes tratados com bomba de insulina nao esta associada a um aumento da prevalencia de lesoes de carie dentaria.
p20092
sg16446
(lp20093
sg16456
(lp20094
(dp20095
g16449
I261
sg16450
I2
sg16451
I17
sg16459
VC0011849
p20096
sg16454
Vdiabetes mellitus
p20097
sasa(dp20098
g16444
VFew of the substrates of Tankyrases are Telomeric Repeat binding Factor protein (TRF1), Axis Inhibitory protein (AXIN 1&amp;amp;2), Insulin Responsive Amino Peptidase (IRAP), Nuclear Mitotic Apparatus protein (NuMa), that become aberrantly active due to the apparent overexpression of the enzyme during hyper proliferative disease conditions like cancer, fibrosis and metabolic disorders like diabetes.
p20099
sg16446
(lp20100
(dp20101
g16449
I168
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VIRAP
p20102
sa(dp20103
g16449
I25
sg16450
I1
sg16451
I10
sg16452
g11
sg16454
VTankyrases
p20104
sa(dp20105
g16449
I132
sg16450
I4
sg16451
I34
sg16452
g11
sg16454
VInsulin Responsive Amino Peptidase
p20106
sa(dp20107
g16449
I40
sg16450
I5
sg16451
I39
sg16452
VP54274
p20108
sg16454
VTelomeric Repeat binding Factor protein
p20109
sa(dp20110
g16449
I-1
sg16450
I2
sg16451
I8
sg16452
g11
sg16454
VAXIN 1&2
p20111
sa(dp20112
g16449
I81
sg16450
I1
sg16451
I4
sg16452
VP54274
p20113
sg16454
VTRF1
p20114
sasg16456
(lp20115
(dp20116
g16449
I309
sg16450
I1
sg16451
I13
sg16459
VC0334094
p20117
sg16454
Vproliferative
p20118
sa(dp20119
g16449
I368
sg16450
I2
sg16451
I19
sg16459
VC0025517
p20120
sg16454
Vmetabolic disorders
p20121
sa(dp20122
g16449
I355
sg16450
I1
sg16451
I8
sg16459
VC0016059
p20123
sg16454
Vfibrosis
p20124
sa(dp20125
g16449
I393
sg16450
I1
sg16451
I8
sg16459
VC0011849
p20126
sg16454
Vdiabetes
p20127
sa(dp20128
g16449
I347
sg16450
I1
sg16451
I6
sg16459
VC0006826
p20129
sg16454
Vcancer
p20130
sasa(dp20131
g16444
VO objetivo deste estudo foi avaliar a utilidade deste exame numa populacao de criancas e adolescentes obesos, maioritariamente de etnia caucasiana.Material e Metodos: Foram recrutados 226 doentes [indice de massa corporal z-score 3,35 A+/- 0,59, 90% caucasianos, 55% do sexo feminino, idade mediana de 12,3 (ambito: 8,9 a 17,6) anos] referenciados a consulta de obesidade pediatrica de um hospital terciario, com criterios para rastreio de diabetes mellitus tipo 2.
p20132
sg16446
(lp20133
sg16456
(lp20134
(dp20135
g16449
I440
sg16450
I2
sg16451
I17
sg16459
VC0011849
p20136
sg16454
Vdiabetes mellitus
p20137
sasa(dp20138
g16444
VFinally, we speculate on the potential benefits of the inhibition of Sin3B-containing complexes for the treatment of cancer.
p20139
sg16446
(lp20140
(dp20141
g16449
I69
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSin3B
p20142
sasg16456
(lp20143
(dp20144
g16449
I117
sg16450
I1
sg16451
I6
sg16459
VC0006826
p20145
sg16454
Vcancer
p20146
sasa(dp20147
g16444
VExpert opinion: Further identification and characterization of specific Sin3B-containing complexes provide a unique opportunity to prevent the pro-tumorigenic effects of the senescence-associated secretory phenotype, and to abrogate cancer stem cell quiescence and the associated resistance to therapy.
p20148
sg16446
(lp20149
(dp20150
g16449
I72
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSin3B
p20151
sasg16456
(lp20152
(dp20153
g16449
I233
sg16450
I1
sg16451
I6
sg16459
VC0006826
p20154
sg16454
Vcancer
p20155
sasa(dp20156
g16444
VSIN3B has been implicated in the initiation of senescence in vitro Here we show that in a mouse model of prostate cancer, SIN3B provides a barrier to malignant progression.
p20157
sg16446
(lp20158
(dp20159
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3B
p20160
sa(dp20161
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3B
p20162
sasg16456
(lp20163
(dp20164
g16449
I105
sg16450
I2
sg16451
I15
sg16459
VC0600139
p20165
sg16454
Vprostate cancer
p20166
sasa(dp20167
g16444
VSIN3B was required for PTEN-induced cellular senescence and prevented progression to invasive prostate adenocarcinoma.
p20168
sg16446
(lp20169
(dp20170
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3B
p20171
sa(dp20172
g16449
I23
sg16450
I1
sg16451
I4
sg16452
VP60484
p20173
sg16454
VPTEN
p20174
sasg16456
(lp20175
(dp20176
g16449
I94
sg16450
I2
sg16451
I23
sg16459
VC0007112
p20177
sg16454
Vprostate adenocarcinoma
p20178
sasa(dp20179
g16444
VFurthermore, SIN3B was downregulated in human prostate adenocarcinoma correlating with upregulation of its target genes.
p20180
sg16446
(lp20181
(dp20182
g16449
I13
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3B
p20183
sasg16456
(lp20184
(dp20185
g16449
I46
sg16450
I2
sg16451
I23
sg16459
VC0007112
p20186
sg16454
Vprostate adenocarcinoma
p20187
sasa(dp20188
g16444
VOur results suggest a tumor suppressor function for SIN3B that limits prostate adenocarcinoma progression, with potential implications for the use of SIN3B and its target genes as candidate diagnostic markers to distinguish indolent from aggressive disease.
p20189
sg16446
(lp20190
(dp20191
g16449
I52
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3B
p20192
sa(dp20193
g16449
I52
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3B
p20194
sasg16456
(lp20195
(dp20196
g16449
I22
sg16450
I1
sg16451
I5
sg16459
VC0027651
p20197
sg16454
Vtumor
p20198
sa(dp20199
g16449
I70
sg16450
I2
sg16451
I23
sg16459
VC0007112
p20200
sg16454
Vprostate adenocarcinoma
p20201
sa(dp20202
g16449
I238
sg16450
I1
sg16451
I10
sg16459
VC0001807
p20203
sg16454
Vaggressive
p20204
sasa(dp20205
g16444
VHowever, specific roles for SIN3A and SIN3B in breast cancer progression have not been characterized.
p20206
sg16446
(lp20207
(dp20208
g16449
I38
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3B
p20209
sa(dp20210
g16449
I28
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3A
p20211
sasg16456
(lp20212
(dp20213
g16449
I54
sg16450
I2
sg16451
I18
sg16459
VC0178874
p20214
sg16454
Vcancer progression
p20215
sasa(dp20216
g16444
VAdditionally, we analyzed microarray data sets to identify correlations of SIN3A and SIN3B expression with survival in patients with breast cancer.
p20217
sg16446
(lp20218
(dp20219
g16449
I85
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3B
p20220
sa(dp20221
g16449
I75
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3A
p20222
sasg16456
(lp20223
(dp20224
g16449
I133
sg16450
I2
sg16451
I13
sg16459
VC0678222
p20225
sg16454
Vbreast cancer
p20226
sasa(dp20227
g16444
VThese data sets indicated that high mRNA expression of SIN3A as well as low mRNA expression of SIN3B correlates with longer relapse free survival specifically in patients with triple negative breast cancer which corresponds with our in vitro and in vivo data.
p20228
sg16446
(lp20229
(dp20230
g16449
I95
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3B
p20231
sa(dp20232
g16449
I55
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3A
p20233
sasg16456
(lp20234
(dp20235
g16449
I124
sg16450
I1
sg16451
I7
sg16459
VC0277556
p20236
sg16454
Vrelapse
p20237
sa(dp20238
g16449
I192
sg16450
I2
sg16451
I13
sg16459
VC0678222
p20239
sg16454
Vbreast cancer
p20240
sasa(dp20241
g16444
VThese results demonstrate key functional differences between SIN3 paralogs in regulating the process of breast cancer metastasis and suggest metastasis suppressive roles of SIN3A and metastasis promoting roles of SIN3B.
p20242
sg16446
(lp20243
(dp20244
g16449
I173
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3A
p20245
sa(dp20246
g16449
I213
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3B
p20247
sa(dp20248
g16449
I61
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSIN3
p20249
sasg16456
(lp20250
(dp20251
g16449
I118
sg16450
I1
sg16451
I10
sg16459
VC0027627
p20252
sg16454
Vmetastasis
p20253
sa(dp20254
g16449
I104
sg16450
I2
sg16451
I13
sg16459
VC0678222
p20255
sg16454
Vbreast cancer
p20256
sa(dp20257
g16449
I118
sg16450
I1
sg16451
I10
sg16459
VC0027627
p20258
sg16454
Vmetastasis
p20259
sa(dp20260
g16449
I118
sg16450
I1
sg16451
I10
sg16459
VC0027627
p20261
sg16454
Vmetastasis
p20262
sasa(dp20263
g16444
VFinally, by immunohistochemical staining of primary breast tissue microarrays we find that EMSY/KDM5A/SIN3B complex subunits are frequently overexpressed in primary breast cancer cases in a correlative manner.
p20264
sg16446
(lp20265
(dp20266
g16449
I96
sg16450
I1
sg16451
I5
sg16452
VP29375
p20267
sg16454
VKDM5A
p20268
sa(dp20269
g16449
I102
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3B
p20270
sa(dp20271
g16449
I91
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VEMSY
p20272
sasg16456
(lp20273
(dp20274
g16449
I165
sg16450
I2
sg16451
I13
sg16459
VC0678222
p20275
sg16454
Vbreast cancer
p20276
sasa(dp20277
g16444
VHere, using a mouse model of pancreatic cancer, we have demonstrated that SIN3B is required for activated KRAS-induced senescence in vivo.
p20278
sg16446
(lp20279
(dp20280
g16449
I106
sg16450
I1
sg16451
I4
sg16452
VP01116
p20281
sg16454
VKRAS
p20282
sa(dp20283
g16449
I74
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIN3B
p20284
sasg16456
(lp20285
(dp20286
g16449
I29
sg16450
I2
sg16451
I17
sg16459
VC0235974
p20287
sg16454
Vpancreatic cancer
p20288
sasa(dp20289
g16444
VFurthermore, evaluation of human pancreatic tissue and cancer cells revealed that Sin3B was decreased in control and PDAC samples, compared with samples from patients with pancreatic inflammation.
p20290
sg16446
(lp20291
(dp20292
g16449
I82
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSin3B
p20293
sasg16456
(lp20294
(dp20295
g16449
I183
sg16450
I1
sg16451
I12
sg16459
VC0021368
p20296
sg16454
Vinflammation
p20297
sa(dp20298
g16449
I55
sg16450
I1
sg16451
I6
sg16459
VC0006826
p20299
sg16454
Vcancer
p20300
sasa(dp20301
g16444
VAmong proteins in the c-Myc/Max/Mad/Sin3 regulatory complex, Mad4 and Sin3B are routinely detected in human glioblastoma multiforme (GBM) cell lines.
p20302
sg16446
(lp20303
(dp20304
g16449
I36
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSin3
p20305
sa(dp20306
g16449
I61
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VMad4
p20307
sa(dp20308
g16449
I22
sg16450
I1
sg16451
I5
sg16452
VP12524
p20309
sg16454
Vc-Myc
p20310
sa(dp20311
g16449
I70
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSin3B
p20312
sa(dp20313
g16449
I32
sg16450
I1
sg16451
I3
sg16452
VP23109
p20314
sg16454
VMad
p20315
sasg16456
(lp20316
(dp20317
g16449
I133
sg16450
I1
sg16451
I3
sg16459
VC1621958
p20318
sg16454
VGBM
p20319
sa(dp20320
g16449
I108
sg16450
I2
sg16451
I23
sg16459
VC1621958
p20321
sg16454
Vglioblastoma multiforme
p20322
sasa(dp20323
g16444
VIn response to gamma radiation, the expression of Sin3B and Mad4 in GBM cells was upregulated in parallel over time, suggesting that Sin3B may play a role in the regulation of Mad4 stability.
p20324
sg16446
(lp20325
(dp20326
g16449
I50
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSin3B
p20327
sa(dp20328
g16449
I60
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VMad4
p20329
sa(dp20330
g16449
I60
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VMad4
p20331
sa(dp20332
g16449
I50
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSin3B
p20333
sasg16456
(lp20334
(dp20335
g16449
I68
sg16450
I1
sg16451
I3
sg16459
VC0017636
p20336
sg16454
VGBM
p20337
sasa(dp20338
g16444
VUsing the Drosophila heart as a platform for identifying novel gene interactions leading to heart disease, we found that the Rho-GTPase Cdc42 cooperates with the cardiac transcription factor Tinman/Nkx2-5.
p20339
sg16446
(lp20340
(dp20341
g16449
I198
sg16450
I1
sg16451
I6
sg16452
VP52952
p20342
sg16454
VNkx2-5
p20343
sa(dp20344
g16449
I125
sg16450
I1
sg16451
I10
sg16452
VP08100
p20345
sg16454
VRho-GTPase
p20346
sa(dp20347
g16449
I136
sg16450
I1
sg16451
I5
sg16452
VP60953
p20348
sg16454
VCdc42
p20349
sa(dp20350
g16449
I162
sg16450
I3
sg16451
I28
sg16452
VP35398
p20351
sg16454
Vcardiac transcription factor
p20352
sasg16456
(lp20353
(dp20354
g16449
I92
sg16450
I2
sg16451
I13
sg16459
VC0018799
p20355
sg16454
Vheart disease
p20356
sasa(dp20357
g16444
VWhat is more important is that the depressed-expression of Cav1.3 paralleled with enhanced-expression of Snapin was documented in atrial samples from atrial fibrillation (AF) patients.
p20358
sg16446
(lp20359
(dp20360
g16449
I105
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VSnapin
p20361
sa(dp20362
g16449
I59
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCav1.3
p20363
sasg16456
(lp20364
(dp20365
g16449
I171
sg16450
I1
sg16451
I2
sg16459
VC0004238
p20366
sg16454
VAF
p20367
sa(dp20368
g16449
I150
sg16450
I2
sg16451
I19
sg16459
VC0004238
p20369
sg16454
Vatrial fibrillation
p20370
sasa(dp20371
g16444
VFurthermore, inactivation of Cav1.3 channels promotes also atrial fibrillation and flutter in knockout mice suggesting that these channels can play a role in stabilizing atrial rhythm.
p20372
sg16446
(lp20373
(dp20374
g16449
I29
sg16450
I2
sg16451
I15
sg16452
g11
sg16454
VCav1.3 channels
p20375
sasg16456
(lp20376
(dp20377
g16449
I59
sg16450
I4
sg16451
I31
sg16459
VC0155709
p20378
sg16454
Vatrial fibrillation and flutter
p20379
sa(dp20380
g16449
I13
sg16450
I1
sg16451
I12
sg16459
VC0544461
p20381
sg16454
Vinactivation
p20382
sasa(dp20383
g16444
VThe significance of the tissue-specific expression of the channel is underpinned by our previous demonstration of atrial fibrillation in a Cav1.3 null mutant mouse model.
p20384
sg16446
(lp20385
(dp20386
g16449
I139
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCav1.3
p20387
sasg16456
(lp20388
(dp20389
g16449
I151
sg16450
I1
sg16451
I6
sg16459
VC0596988
p20390
sg16454
Vmutant
p20391
sa(dp20392
g16449
I114
sg16450
I2
sg16451
I19
sg16459
VC0004238
p20393
sg16454
Vatrial fibrillation
p20394
sasa(dp20395
g16444
VThe novel Cav1.3 (Alfa1D) L-type Ca^2+ channel plays a significant role in sinoatrial (SA) and atrioventricular (AV) nodes function and in atrial fibrillation.
p20396
sg16446
(lp20397
(dp20398
g16449
I10
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCav1.3
p20399
sasg16456
(lp20400
(dp20401
g16449
I139
sg16450
I2
sg16451
I19
sg16459
VC0004238
p20402
sg16454
Vatrial fibrillation
p20403
sasa(dp20404
g16444
VInterestingly, oncogenic CARD11 variants associated with diffuse large B cell lymphoma spontaneously induce Lin(Ub)n-Bcl10 production to extents that correlate with their abilities to activate NF-KB and with their enhanced abilities to bind HOIP and Bcl10.
p20405
sg16446
(lp20406
(dp20407
g16449
I15
sg16450
I3
sg16451
I25
sg16452
g11
sg16454
Voncogenic CARD11 variants
p20408
sa(dp20409
g16449
I117
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VBcl10
p20410
sasg16456
(lp20411
(dp20412
g16449
I57
sg16450
I5
sg16451
I29
sg16459
VC0079744
p20413
sg16454
Vdiffuse large B cell lymphoma
p20414
sasa(dp20415
g16444
VOur previous studies showed important regulatory functions of RNF31 in controlling important oncogenic pathways in breast cancer, such as ERAlfa and p53.
p20416
sg16446
(lp20417
(dp20418
g16449
I62
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VRNF31
p20419
sa(dp20420
g16449
I149
sg16450
I1
sg16451
I3
sg16452
VP42771
p20421
sg16454
Vp53
p20422
sasg16456
(lp20423
(dp20424
g16449
I115
sg16450
I2
sg16451
I13
sg16459
VC0678222
p20425
sg16454
Vbreast cancer
p20426
sasa(dp20427
g16444
VThis review highlights recent discoveries on RNF31 functions in nuclear factor modifications, breast cancer progression and possible therapeutic inhibitors targeting RNF31.
p20428
sg16446
(lp20429
(dp20430
g16449
I45
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VRNF31
p20431
sa(dp20432
g16449
I45
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VRNF31
p20433
sasg16456
(lp20434
(dp20435
g16449
I101
sg16450
I2
sg16451
I18
sg16459
VC0178874
p20436
sg16454
Vcancer progression
p20437
sasa(dp20438
g16444
VThe atypical E3 ubiquitin ligase RNF31 is highly expressed in human breast cancer, the most frequent neoplastic lethality among women.
p20439
sg16446
(lp20440
(dp20441
g16449
I13
sg16450
I2
sg16451
I12
sg16452
VP62979
p20442
sg16454
VE3 ubiquitin
p20443
sa(dp20444
g16449
I33
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VRNF31
p20445
sasg16456
(lp20446
(dp20447
g16449
I68
sg16450
I2
sg16451
I13
sg16459
VC0678222
p20448
sg16454
Vbreast cancer
p20449
sasa(dp20450
g16444
VHere, RNF31 depletion in breast cancer cells in combination with global gene expression profiling revealed p53 (TP53) signaling as a potential RNF31 target.
p20451
sg16446
(lp20452
(dp20453
g16449
I107
sg16450
I1
sg16451
I3
sg16452
VP42771
p20454
sg16454
Vp53
p20455
sa(dp20456
g16449
I6
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VRNF31
p20457
sa(dp20458
g16449
I6
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VRNF31
p20459
sasg16456
(lp20460
(dp20461
g16449
I25
sg16450
I2
sg16451
I13
sg16459
VC0678222
p20462
sg16454
Vbreast cancer
p20463
sasa(dp20464
g16444
VInterestingly, RNF31 decreased p53 stability, whereas depletion of RNF31 in breast cancer cells caused cell cycle arrest and cisplatin-induced apoptosis in a p53-dependent manner.
p20465
sg16446
(lp20466
(dp20467
g16449
I15
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VRNF31
p20468
sa(dp20469
g16449
I31
sg16450
I1
sg16451
I3
sg16452
VP42771
p20470
sg16454
Vp53
p20471
sa(dp20472
g16449
I31
sg16450
I1
sg16451
I3
sg16452
VP42771
p20473
sg16454
Vp53
p20474
sa(dp20475
g16449
I15
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VRNF31
p20476
sasg16456
(lp20477
(dp20478
g16449
I76
sg16450
I2
sg16451
I13
sg16459
VC0678222
p20479
sg16454
Vbreast cancer
p20480
sasa(dp20481
g16444
VTogether, our findings suggest RNF31 as a potential therapeutic target to restore p53 function in breast cancer.
p20482
sg16446
(lp20483
(dp20484
g16449
I82
sg16450
I1
sg16451
I3
sg16452
VP42771
p20485
sg16454
Vp53
p20486
sa(dp20487
g16449
I31
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VRNF31
p20488
sasg16456
(lp20489
(dp20490
g16449
I98
sg16450
I2
sg16451
I13
sg16459
VC0678222
p20491
sg16454
Vbreast cancer
p20492
sasa(dp20493
g16444
VBy examining the kinetics of pathway activation in TRAIL-sensitive lymphoma cells wild-type or deficient for RIP1, TRAF2, cIAP1/2 or HOIP, we report here that TRAIL induces two phases of JNK and NF-KB activation.
p20494
sg16446
(lp20495
(dp20496
g16449
I115
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTRAF2
p20497
sa(dp20498
g16449
I109
sg16450
I1
sg16451
I4
sg16452
VP47985
p20499
sg16454
VRIP1
p20500
sa(dp20501
g16449
I122
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VcIAP1/2
p20502
sa(dp20503
g16449
I187
sg16450
I1
sg16451
I3
sg16452
VP53779
p20504
sg16454
VJNK
p20505
sa(dp20506
g16449
I51
sg16450
I1
sg16451
I5
sg16452
VP50591
p20507
sg16454
VTRAIL
p20508
sasg16456
(lp20509
(dp20510
g16449
I67
sg16450
I1
sg16451
I8
sg16459
VC0024299
p20511
sg16454
Vlymphoma
p20512
sasa(dp20513
g16444
VLiterature search included the terms adrenergic, noradrenergic, reuptake, inhibitors, analgesia, NET, norepinephrine transporter, and pain using Medline, Google scholar, Web of Knowledge, www.clinicaltrials.gov, and Pharmaprojects (Informa UK Ltd. 2012).
p20514
sg16446
(lp20515
(dp20516
g16449
I102
sg16450
I2
sg16451
I26
sg16452
VP23975
p20517
sg16454
Vnorepinephrine transporter
p20518
sasg16456
(lp20519
(dp20520
g16449
I170
sg16450
I1
sg16451
I3
sg16459
VC0332875
p20521
sg16454
VWeb
p20522
sa(dp20523
g16449
I86
sg16450
I1
sg16451
I9
sg16459
VC0344307
p20524
sg16454
Vanalgesia
p20525
sasa(dp20526
g16444
VNorepinephrine transporter blockade seems to be essential for analgesia, but optimal concentrations are unknown.
p20527
sg16446
(lp20528
sg16456
(lp20529
(dp20530
g16449
I62
sg16450
I1
sg16451
I9
sg16459
VC0344307
p20531
sg16454
Vanalgesia
p20532
sasa(dp20533
g16444
VThe third type is the secondary PHA1, which is strongly associated with urinary tract infections and/or urinary tract malformations.
p20534
sg16446
(lp20535
sg16456
(lp20536
(dp20537
g16449
I118
sg16450
I1
sg16451
I13
sg16459
VC0000768
p20538
sg16454
Vmalformations
p20539
sa(dp20540
g16449
I72
sg16450
I3
sg16451
I24
sg16459
VC0042029
p20541
sg16454
Vurinary tract infections
p20542
sasa(dp20543
g16444
VTo identify mutation in SCNN1B and SCNN1G genes in an adolescent with suspicious Liddle syndrome and his family members and to explore the screening target subjects of Liddle syndrome.
p20544
sg16446
(lp20545
(dp20546
g16449
I24
sg16450
I1
sg16451
I6
sg16452
VP51168
p20547
sg16454
VSCNN1B
p20548
sa(dp20549
g16449
I35
sg16450
I2
sg16451
I12
sg16452
VP51168
p20550
sg16454
VSCNN1G genes
p20551
sasg16456
(lp20552
(dp20553
g16449
I81
sg16450
I2
sg16451
I15
sg16459
VC0221043
p20554
sg16454
VLiddle syndrome
p20555
sa(dp20556
g16449
I81
sg16450
I2
sg16451
I15
sg16459
VC0221043
p20557
sg16454
VLiddle syndrome
p20558
sasa(dp20559
g16444
VGenetic analysis of the C-terminus of SCNN1B and SCNN1G genes was conducted in an adolescent, with treatment-resistant hypertension and hypokalemia, who was suspected of having Liddle syndrome, and his family members.
p20560
sg16446
(lp20561
(dp20562
g16449
I38
sg16450
I1
sg16451
I6
sg16452
VP51168
p20563
sg16454
VSCNN1B
p20564
sa(dp20565
g16449
I49
sg16450
I2
sg16451
I12
sg16452
VP51168
p20566
sg16454
VSCNN1G genes
p20567
sasg16456
(lp20568
(dp20569
g16449
I119
sg16450
I1
sg16451
I12
sg16459
VC0020538
p20570
sg16454
Vhypertension
p20571
sa(dp20572
g16449
I177
sg16450
I2
sg16451
I15
sg16459
VC0221043
p20573
sg16454
VLiddle syndrome
p20574
sasa(dp20575
g16444
VIn adulthood, an induced nephron-specific deficiency of AlfaENaC (Scnn1a) resulted in pseudohypoaldosteronism type 1 (PHA-1) with sodium loss, hyperkalemia, and metabolic acidosis that is rescued through high-sodium/low-potassium (HNa+/LK+) diet.
p20576
sg16446
(lp20577
(dp20578
g16449
I86
sg16450
I3
sg16451
I30
sg16452
VP37088
p20579
sg16454
Vpseudohypoaldosteronism type 1
p20580
sa(dp20581
g16449
I66
sg16450
I1
sg16451
I6
sg16452
VP37088
p20582
sg16454
VScnn1a
p20583
sa(dp20584
g16449
I118
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VPHA-1
p20585
sasg16456
(lp20586
(dp20587
g16449
I86
sg16450
I3
sg16451
I30
sg16459
VC0268436
p20588
sg16454
Vpseudohypoaldosteronism type 1
p20589
sa(dp20590
g16449
I118
sg16450
I1
sg16451
I5
sg16459
VC0268436
p20591
sg16454
VPHA-1
p20592
sa(dp20593
g16449
I161
sg16450
I2
sg16451
I18
sg16459
VC0220981
p20594
sg16454
Vmetabolic acidosis
p20595
sasa(dp20596
g16444
VLiddle syndrome is an autosomal dominant genetic condition that causes hypertension and hypokalemia due to a gain-of-function mutation in the SCNN1B or SCNN1G genes which code for the epithelial sodium channel in the kidney.
p20597
sg16446
(lp20598
(dp20599
g16449
I142
sg16450
I1
sg16451
I6
sg16452
VP51168
p20600
sg16454
VSCNN1B
p20601
sa(dp20602
g16449
I152
sg16450
I2
sg16451
I12
sg16452
VP51168
p20603
sg16454
VSCNN1G genes
p20604
sasg16456
(lp20605
(dp20606
g16449
I41
sg16450
I2
sg16451
I17
sg16459
VC0019247
p20607
sg16454
Vgenetic condition
p20608
sa(dp20609
g16449
I0
sg16450
I2
sg16451
I15
sg16459
VC0221043
p20610
sg16454
VLiddle syndrome
p20611
sa(dp20612
g16449
I71
sg16450
I1
sg16451
I12
sg16459
VC0020538
p20613
sg16454
Vhypertension
p20614
sasa(dp20615
g16444
VLoss-of-function mutations of the MR are responsible for renal pseudohypoaldosteronism type 1 (PHA1), a rare disease of mineralocorticoid resistance presenting in the newborn with weight loss, failure to thrive, vomiting and dehydration, associated with hyperkalemia and metabolic acidosis, despite extremely elevated levels of plasma renin and aldosterone.
p20616
sg16446
(lp20617
(dp20618
g16449
I57
sg16450
I4
sg16451
I36
sg16452
VP37088
p20619
sg16454
Vrenal pseudohypoaldosteronism type 1
p20620
sa(dp20621
g16449
I328
sg16450
I2
sg16451
I12
sg16452
VP00797
p20622
sg16454
Vplasma renin
p20623
sa(dp20624
g16449
I95
sg16450
I1
sg16451
I4
sg16452
VP37088
p20625
sg16454
VPHA1
p20626
sasg16456
(lp20627
(dp20628
g16449
I212
sg16450
I1
sg16451
I8
sg16459
VC0042963
p20629
sg16454
Vvomiting
p20630
sa(dp20631
g16449
I104
sg16450
I2
sg16451
I12
sg16459
VC0678236
p20632
sg16454
Vrare disease
p20633
sa(dp20634
g16449
I271
sg16450
I2
sg16451
I18
sg16459
VC0220981
p20635
sg16454
Vmetabolic acidosis
p20636
sa(dp20637
g16449
I193
sg16450
I3
sg16451
I17
sg16459
VC0015544
p20638
sg16454
Vfailure to thrive
p20639
sa(dp20640
g16449
I95
sg16450
I1
sg16451
I4
sg16459
VC0268436
p20641
sg16454
VPHA1
p20642
sa(dp20643
g16449
I63
sg16450
I3
sg16451
I30
sg16459
VC0268436
p20644
sg16454
Vpseudohypoaldosteronism type 1
p20645
sa(dp20646
g16449
I225
sg16450
I1
sg16451
I11
sg16459
VC0011175
p20647
sg16454
Vdehydration
p20648
sasa(dp20649
g16444
VIn the presence of pyelonephritis, the same biochemical picture can occur with transient type 1 pseudohypoaldosteronism (PHA-1) also termed type 4 renal tubular acidosis.
p20650
sg16446
(lp20651
(dp20652
g16449
I121
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VPHA-1
p20653
sa(dp20654
g16449
I56
sg16450
I8
sg16451
I63
sg16452
g11
sg16454
Vpicture can occur with transient type 1 pseudohypoaldosteronism
p20655
sasg16456
(lp20656
(dp20657
g16449
I147
sg16450
I3
sg16451
I22
sg16459
VC0001126
p20658
sg16454
Vrenal tubular acidosis
p20659
sa(dp20660
g16449
I96
sg16450
I1
sg16451
I23
sg16459
VC0033805
p20661
sg16454
Vpseudohypoaldosteronism
p20662
sa(dp20663
g16449
I121
sg16450
I1
sg16451
I3
sg16459
VC0030779
p20664
sg16454
VPHA
p20665
sa(dp20666
g16449
I19
sg16450
I1
sg16451
I14
sg16459
VC0034186
p20667
sg16454
Vpyelonephritis
p20668
sasa(dp20669
g16444
VPseudohypoaldosteronism type 1 (PHA1) is a rare genetic disease characterized by resistance to aldosterone, and the renal form of PHA1 is associated with heterozygous inactivating mutations in NR3C2, which encodes mineralocorticoid receptor (MR).
p20670
sg16446
(lp20671
(dp20672
g16449
I32
sg16450
I1
sg16451
I4
sg16452
VP37088
p20673
sg16454
VPHA1
p20674
sa(dp20675
g16449
I32
sg16450
I1
sg16451
I4
sg16452
VP37088
p20676
sg16454
VPHA1
p20677
sa(dp20678
g16449
I193
sg16450
I1
sg16451
I5
sg16452
VP08235
p20679
sg16454
VNR3C2
p20680
sa(dp20681
g16449
I0
sg16450
I3
sg16451
I30
sg16452
VP37088
p20682
sg16454
VPseudohypoaldosteronism type 1
p20683
sasg16456
(lp20684
(dp20685
g16449
I32
sg16450
I1
sg16451
I4
sg16459
VC0268436
p20686
sg16454
VPHA1
p20687
sa(dp20688
g16449
I32
sg16450
I1
sg16451
I4
sg16459
VC0268436
p20689
sg16454
VPHA1
p20690
sa(dp20691
g16449
I0
sg16450
I3
sg16451
I30
sg16459
VC0268436
p20692
sg16454
VPseudohypoaldosteronism type 1
p20693
sa(dp20694
g16449
I48
sg16450
I2
sg16451
I15
sg16459
VC0019247
p20695
sg16454
Vgenetic disease
p20696
sasa(dp20697
g16444
VRecent work has identified cancer-associated U2AF35 missense mutations in two zinc-finger (ZnF) domains, but little is known about Q157R/P substitutions within the second ZnF.
p20698
sg16446
(lp20699
(dp20700
g16449
I45
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VU2AF35
p20701
sasg16456
(lp20702
(dp20703
g16449
I27
sg16450
I1
sg16451
I6
sg16459
VC0006826
p20704
sg16454
Vcancer
p20705
sasa(dp20706
g16444
VZinc finger (ZNF) proteins, a diverse family of proteins, have multiple biological functions in cancer.
p20707
sg16446
(lp20708
(dp20709
g16449
I0
sg16450
I4
sg16451
I26
sg16452
g11
sg16454
VZinc finger (ZNF) proteins
p20710
sasg16456
(lp20711
(dp20712
g16449
I96
sg16450
I1
sg16451
I6
sg16459
VC0006826
p20713
sg16454
Vcancer
p20714
sasa(dp20715
g16444
VHowever, the function and underlying mechanisms of ZNF185 in the tumorigenesis of lung adenocarcinoma (LAC) remain unclear.
p20716
sg16446
(lp20717
(dp20718
g16449
I51
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VZNF185
p20719
sasg16456
(lp20720
(dp20721
g16449
I103
sg16450
I1
sg16451
I3
sg16459
VC0152013
p20722
sg16454
VLAC
p20723
sa(dp20724
g16449
I82
sg16450
I2
sg16451
I19
sg16459
VC0152013
p20725
sg16454
Vlung adenocarcinoma
p20726
sa(dp20727
g16449
I65
sg16450
I1
sg16451
I13
sg16459
VC0007621
p20728
sg16454
Vtumorigenesis
p20729
sasa(dp20730
g16444
VWe found that the protein expression of ZNF185 was significantly downregulated in LAC tissues compared with the adjacent non-cancerous tissues (ANCT) (37.10% vs 58.06%, P=0.015), and was negatively correlated with the lymph node metastasis of the LAC patients (P=0.005).
p20731
sg16446
(lp20732
(dp20733
g16449
I40
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VZNF185
p20734
sasg16456
(lp20735
(dp20736
g16449
I218
sg16450
I3
sg16451
I21
sg16459
VC0686619
p20737
sg16454
Vlymph node metastasis
p20738
sasa(dp20739
g16444
VIn view of the exploitation of tetraspanins by organisms for survival, these proteins could be targeted using specific antibodies, recombinant large extracellular loop (LEL) domains, small-molecule mimetics and siRNAs as potential novel and efficacious putative targets to combat African trypanosomiasis by killing the tsetse fly vector.
p20740
sg16446
(lp20741
sg16456
(lp20742
(dp20743
g16449
I280
sg16450
I2
sg16451
I23
sg16459
VC0041228
p20744
sg16454
VAfrican trypanosomiasis
p20745
sa(dp20746
g16449
I143
sg16450
I3
sg16451
I24
sg16459
VC1846721
p20747
sg16454
Vlarge extracellular loop
p20748
sa(dp20749
g16449
I169
sg16450
I1
sg16451
I3
sg16459
VC1846721
p20750
sg16454
VLEL
p20751
sasa(dp20752
g16444
VInfection of hepatocytic cells by two major pathogens, the hepatitis C virus and the malaria parasite, also requires the tetraspanin CD81.
p20753
sg16446
(lp20754
(dp20755
g16449
I121
sg16450
I2
sg16451
I16
sg16452
g11
sg16454
Vtetraspanin CD81
p20756
sasg16456
(lp20757
(dp20758
g16449
I0
sg16450
I1
sg16451
I9
sg16459
VC0009450
p20759
sg16454
VInfection
p20760
sa(dp20761
g16449
I59
sg16450
I2
sg16451
I11
sg16459
VC0019196
p20762
sg16454
Vhepatitis C
p20763
sa(dp20764
g16449
I85
sg16450
I1
sg16451
I7
sg16459
VC0024530
p20765
sg16454
Vmalaria
p20766
sasa(dp20767
g16444
VOur results unravel a functional link between CD81 and cholesterol during infection by malaria parasites, and illustrate that tetraspanin microdomains constitute a novel type of membrane microdomains that could be used by pathogens for infection.
p20768
sg16446
(lp20769
(dp20770
g16449
I46
sg16450
I1
sg16451
I4
sg16452
VP60033
p20771
sg16454
VCD81
p20772
sa(dp20773
g16449
I126
sg16450
I2
sg16451
I24
sg16452
g11
sg16454
Vtetraspanin microdomains
p20774
sasg16456
(lp20775
(dp20776
g16449
I87
sg16450
I1
sg16451
I7
sg16459
VC0024530
p20777
sg16454
Vmalaria
p20778
sa(dp20779
g16449
I74
sg16450
I1
sg16451
I9
sg16459
VC0009450
p20780
sg16454
Vinfection
p20781
sa(dp20782
g16449
I74
sg16450
I1
sg16451
I9
sg16459
VC0009450
p20783
sg16454
Vinfection
p20784
sasa(dp20785
g16444
VThe CXCL11 gene may also play a role in BK polyomavirus-associated nephropathy.
p20786
sg16446
(lp20787
(dp20788
g16449
I4
sg16450
I2
sg16451
I11
sg16452
g11
sg16454
VCXCL11 gene
p20789
sasg16456
(lp20790
(dp20791
g16449
I43
sg16450
I2
sg16451
I35
sg16459
VC1696946
p20792
sg16454
Vpolyomavirus-associated nephropathy
p20793
sasa(dp20794
g16444
VOur aim was to compare expression levels of CXCL11 in BK polyomavirus-infected versus noninfected kidney transplant patients with nephropathy and healthy controls.
p20795
sg16446
(lp20796
(dp20797
g16449
I44
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCXCL11
p20798
sasg16456
(lp20799
(dp20800
g16449
I130
sg16450
I1
sg16451
I11
sg16459
VC0022658
p20801
sg16454
Vnephropathy
p20802
sasa(dp20803
g16444
VTaken together, the results indicated that sorafenib had protective effects against renal fibrosis; its mechanism of action was associated with inhibition of macrophage infiltration via the CXCR3/CXCL11 pathway.
p20804
sg16446
(lp20805
(dp20806
g16449
I190
sg16450
I1
sg16451
I5
sg16452
VP49682
p20807
sg16454
VCXCR3
p20808
sa(dp20809
g16449
I196
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCXCL11
p20810
sasg16456
(lp20811
(dp20812
g16449
I169
sg16450
I1
sg16451
I12
sg16459
VC0332448
p20813
sg16454
Vinfiltration
p20814
sa(dp20815
g16449
I84
sg16450
I2
sg16451
I14
sg16459
VC0151650
p20816
sg16454
Vrenal fibrosis
p20817
sasa(dp20818
g16444
VUrinary mRNA levels of CXCL10 and CXCL11 are decreased, and those of collagen I A1 chain and fibronectin are increased in diabetic nephropathy.
p20819
sg16446
(lp20820
(dp20821
g16449
I23
sg16450
I1
sg16451
I6
sg16452
VP02778
p20822
sg16454
VCXCL10
p20823
sa(dp20824
g16449
I34
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCXCL11
p20825
sasg16456
(lp20826
(dp20827
g16449
I122
sg16450
I2
sg16451
I20
sg16459
VC0011881
p20828
sg16454
Vdiabetic nephropathy
p20829
sasa(dp20830
g16444
VFor this purpose, serum concentration of interleukin 2 (IL2), interleukin 10 (IL10), interferon-gamma (IFNG), Toll-like receptor 2 (TLR2) and Toll-like receptor 9 (TLR9) were measured in blood samples obtained from F(2) piglets (n = 334) of a Duroc x Pietrain resource population (DUPI) after Mycoplasma hypopneumoniae (Mh), tetanus toxoid (TT) and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccination at 6, 9 and 15 weeks of age.
p20831
sg16446
(lp20832
(dp20833
g16449
I78
sg16450
I1
sg16451
I4
sg16452
VP22301
p20834
sg16454
VIL10
p20835
sa(dp20836
g16449
I164
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VTLR9
p20837
sa(dp20838
g16449
I56
sg16450
I1
sg16451
I3
sg16452
VP60568
p20839
sg16454
VIL2
p20840
sa(dp20841
g16449
I142
sg16450
I3
sg16451
I20
sg16452
g11
sg16454
VToll-like receptor 9
p20842
sa(dp20843
g16449
I41
sg16450
I2
sg16451
I13
sg16452
VP60568
p20844
sg16454
Vinterleukin 2
p20845
sa(dp20846
g16449
I110
sg16450
I3
sg16451
I20
sg16452
g11
sg16454
VToll-like receptor 2
p20847
sa(dp20848
g16449
I132
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VTLR2
p20849
sa(dp20850
g16449
I85
sg16450
I1
sg16451
I16
sg16452
VP01579
p20851
sg16454
Vinterferon-gamma
p20852
sa(dp20853
g16449
I103
sg16450
I1
sg16451
I4
sg16452
VP01579
p20854
sg16454
VIFNG
p20855
sa(dp20856
g16449
I62
sg16450
I2
sg16451
I14
sg16452
VP22301
p20857
sg16454
Vinterleukin 10
p20858
sasg16456
(lp20859
(dp20860
g16449
I325
sg16450
I1
sg16451
I7
sg16459
VC0039614
p20861
sg16454
Vtetanus
p20862
sa(dp20863
g16449
I349
sg16450
I5
sg16451
I45
sg16459
VC0376538
p20864
sg16454
VPorcine Reproductive and Respiratory Syndrome
p20865
sa(dp20866
g16449
I293
sg16450
I1
sg16451
I10
sg16459
VC0026936
p20867
sg16454
VMycoplasma
p20868
sasa(dp20869
g16444
VNot only TLR-2 gene polymorphisms but also immunoglobulins (IgG, IgM, IgA), IgG subsets (G1, G2, G3), and specific antibody levels (anti-tetanus and anti-hemophilus influenza) were determined to exclude humoral immunodeficiencies.
p20870
sg16446
(lp20871
(dp20872
g16449
I65
sg16450
I1
sg16451
I3
sg16452
VP29965
p20873
sg16454
VIgM
p20874
sa(dp20875
g16449
I9
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VTLR-2 gene
p20876
sa(dp20877
g16449
I70
sg16450
I1
sg16451
I3
sg16452
VP11912
p20878
sg16454
VIgA
p20879
sa(dp20880
g16449
I43
sg16450
I1
sg16451
I15
sg16452
g11
sg16454
Vimmunoglobulins
p20881
sasg16456
(lp20882
(dp20883
g16449
I165
sg16450
I1
sg16451
I9
sg16459
VC0021400
p20884
sg16454
Vinfluenza
p20885
sa(dp20886
g16449
I211
sg16450
I1
sg16451
I18
sg16459
VC0021051
p20887
sg16454
Vimmunodeficiencies
p20888
sa(dp20889
g16449
I137
sg16450
I1
sg16451
I7
sg16459
VC0039614
p20890
sg16454
Vtetanus
p20891
sasa(dp20892
g16444
VWhile glutamate is not a known OAT4 or OATP2B1 substrate, we propose that its high intracellular concentration has the potential to drive accumulation of substrates from the fetal circulation.
p20893
sg16446
(lp20894
(dp20895
g16449
I39
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VOATP2B1
p20896
sa(dp20897
g16449
I31
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VOAT4
p20898
sasg16456
(lp20899
sa(dp20900
g16444
VCycling of glutamate across the placenta involving efflux via OAT4 and OATP2B1 and subsequent reuptake will drive placental uptake of organic anions from the fetal circulation.
p20901
sg16446
(lp20902
(dp20903
g16449
I71
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VOATP2B1
p20904
sa(dp20905
g16449
I62
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VOAT4
p20906
sasg16456
(lp20907
sa(dp20908
g16444
VEfflux transport of olmesartan via OAT4 from syncytiotrophoblasts to the fetal circulation might be facilitated in the presence of an inwardly directed physiological chloride gradient and extracellular DHEAS.
p20909
sg16446
(lp20910
(dp20911
g16449
I35
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VOAT4
p20912
sasg16456
(lp20913
sa(dp20914
g16444
VThis is probably the first case report of cobalamin intracellular metabolism defect (CblC/CblD/CblF/CblJ or ABCD4) presenting as diabetic ketoacidosis.
p20915
sg16446
(lp20916
(dp20917
g16449
I85
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCblC
p20918
sa(dp20919
g16449
I108
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VABCD4
p20920
sa(dp20921
g16449
I90
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCblD
p20922
sa(dp20923
g16449
I95
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCblF
p20924
sasg16456
(lp20925
(dp20926
g16449
I129
sg16450
I2
sg16451
I21
sg16459
VC0011880
p20927
sg16454
Vdiabetic ketoacidosis
p20928
sa(dp20929
g16449
I95
sg16450
I1
sg16451
I4
sg16459
VC1848578
p20930
sg16454
VCblF
p20931
sasa(dp20932
g16444
VModerate to severe sensorineural hearing loss and progressive RP characterizes Usher syndrome type IIa (USH2A), which maps to the long arm of chromosome 1q41.
p20933
sg16446
(lp20934
(dp20935
g16449
I104
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VUSH2A
p20936
sasg16456
(lp20937
(dp20938
g16449
I104
sg16450
I1
sg16451
I5
sg16459
VC1848634
p20939
sg16454
VUSH2A
p20940
sa(dp20941
g16449
I79
sg16450
I2
sg16451
I14
sg16459
VC0271097
p20942
sg16454
VUsher syndrome
p20943
sa(dp20944
g16449
I19
sg16450
I3
sg16451
I26
sg16459
VC0018784
p20945
sg16454
Vsensorineural hearing loss
p20946
sasa(dp20947
g16444
VUsher syndrome type IIa (OMIM 276901), an autosomal recessive disorder characterized by moderate to severe sensorineural hearing loss and progressive retinitis pigmentosa, maps to the long arm of human chromosome 1q41 between markers AFM268ZD1 and AFM144XF2.
p20948
sg16446
(lp20949
sg16456
(lp20950
(dp20951
g16449
I150
sg16450
I2
sg16451
I20
sg16459
VC0035334
p20952
sg16454
Vretinitis pigmentosa
p20953
sa(dp20954
g16449
I0
sg16450
I2
sg16451
I14
sg16459
VC0271097
p20955
sg16454
VUsher syndrome
p20956
sa(dp20957
g16449
I107
sg16450
I3
sg16451
I26
sg16459
VC0018784
p20958
sg16454
Vsensorineural hearing loss
p20959
sasa(dp20960
g16444
VModerate to severe non-progressive high frequency hearing loss with RP and normal vestibular function describes Usher syndrome type IIa, which has been localized to 1q41.
p20961
sg16446
(lp20962
sg16456
(lp20963
(dp20964
g16449
I35
sg16450
I4
sg16451
I27
sg16459
VC0018780
p20965
sg16454
Vhigh frequency hearing loss
p20966
sa(dp20967
g16449
I112
sg16450
I2
sg16451
I14
sg16459
VC0271097
p20968
sg16454
VUsher syndrome
p20969
sasa(dp20970
g16444
VAs one subtype of the class IIa HDACs, HDAC9 is capable to repress/de-repress their target genes in tumor, inflammation, atherosclerosis and metabolic diseases.
p20971
sg16446
(lp20972
(dp20973
g16449
I22
sg16450
I3
sg16451
I15
sg16452
g11
sg16454
Vclass IIa HDACs
p20974
sa(dp20975
g16449
I39
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VHDAC9
p20976
sasg16456
(lp20977
(dp20978
g16449
I100
sg16450
I1
sg16451
I5
sg16459
VC0027651
p20979
sg16454
Vtumor
p20980
sa(dp20981
g16449
I107
sg16450
I1
sg16451
I12
sg16459
VC0021368
p20982
sg16454
Vinflammation
p20983
sa(dp20984
g16449
I141
sg16450
I2
sg16451
I18
sg16459
VC0025517
p20985
sg16454
Vmetabolic diseases
p20986
sa(dp20987
g16449
I121
sg16450
I1
sg16451
I15
sg16459
VC0004153
p20988
sg16454
Vatherosclerosis
p20989
sasa(dp20990
g16444
VTaken together, our data suggest that SNP rs2107595 may contribute to coronary atherosclerosis and CAD risk through a possible mechanism of regulating HDAC9 expression and gene-environment interactions.
p20991
sg16446
(lp20992
(dp20993
g16449
I151
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VHDAC9
p20994
sasg16456
(lp20995
(dp20996
g16449
I99
sg16450
I1
sg16451
I3
sg16459
VC0010054
p20997
sg16454
VCAD
p20998
sa(dp20999
g16449
I70
sg16450
I2
sg16451
I24
sg16459
VC0010054
p21000
sg16454
Vcoronary atherosclerosis
p21001
sasa(dp21002
g16444
VThese results suggest that HDAC9 may participate in ox-LDL-induced endothelial damage and inflammation during atherosclerosis development.
p21003
sg16446
(lp21004
(dp21005
g16449
I27
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VHDAC9
p21006
sasg16456
(lp21007
(dp21008
g16449
I90
sg16450
I1
sg16451
I12
sg16459
VC0021368
p21009
sg16454
Vinflammation
p21010
sa(dp21011
g16449
I110
sg16450
I1
sg16451
I15
sg16459
VC0004153
p21012
sg16454
Vatherosclerosis
p21013
sasa(dp21014
g16444
VOur results also supported robust associations with ischaemic stroke for four other loci that have been reported in previous studies, including PITX2 (first stage OR 1*39, 1*29-1*49, p=3*26 x 10-19; joint OR 1*37, 1*30-1*45, p=2*79 x 10-32) and ZFHX3 (first stage OR 1*19, 1*11-1*27, p=2*93 x 10-7; joint OR 1*17, 1*11-1*23, p=2*29 x 10-10) for cardioembolic stroke, and HDAC9 (first stage OR 1*29, 1*18-1*42, p=3*50 x 10-8; joint OR 1*24, 1*15-1*33, p=4*52 x 10-9) for large artery atherosclerosis stroke.
p21015
sg16446
(lp21016
(dp21017
g16449
I144
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VPITX2
p21018
sa(dp21019
g16449
I371
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VHDAC9
p21020
sa(dp21021
g16449
I245
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VZFHX3
p21022
sasg16456
(lp21023
(dp21024
g16449
I62
sg16450
I1
sg16451
I6
sg16459
VC0038454
p21025
sg16454
Vstroke
p21026
sa(dp21027
g16449
I52
sg16450
I2
sg16451
I16
sg16459
VC0948008
p21028
sg16454
Vischaemic stroke
p21029
sa(dp21030
g16449
I483
sg16450
I1
sg16451
I15
sg16459
VC0004153
p21031
sg16454
Vatherosclerosis
p21032
sa(dp21033
g16449
I345
sg16450
I2
sg16451
I20
sg16459
VC1531624
p21034
sg16454
Vcardioembolic stroke
p21035
sasa(dp21036
g16444
VIn this study, we investigated the candidacy and directionality of HDAC9 in atherosclerosis and analyzed associations between risk alleles at 7p21.1 and plaque characteristics.
p21037
sg16446
(lp21038
(dp21039
g16449
I67
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VHDAC9
p21040
sasg16456
(lp21041
(dp21042
g16449
I76
sg16450
I1
sg16451
I15
sg16459
VC0004153
p21043
sg16454
Vatherosclerosis
p21044
sa(dp21045
g16449
I153
sg16450
I1
sg16451
I6
sg16459
VC0011389
p21046
sg16454
Vplaque
p21047
sasa(dp21048
g16444
VTargeted inhibition of HDAC9 might be a viable strategy to prevent atherosclerosis.
p21049
sg16446
(lp21050
(dp21051
g16449
I23
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VHDAC9
p21052
sasg16456
(lp21053
(dp21054
g16449
I67
sg16450
I1
sg16451
I15
sg16459
VC0004153
p21055
sg16454
Vatherosclerosis
p21056
sasa(dp21057
g16444
VThe ability of a pulsed oxygen delivery system (Puritan-Bennett Companion Oxygen Saver (COS-5) to track respiratory rate during exercise and the oxygenation achieved during the exercise while oxygen was being delivered by this system was compared to that attained while oxygen was delivered continuously in six patients with chronic obstructive pulmonary disease (COPD) and six patients with idiopathic pulmonary fibrosis (IPF).
p21058
sg16446
(lp21059
sg16456
(lp21060
(dp21061
g16449
I325
sg16450
I4
sg16451
I37
sg16459
VC0024117
p21062
sg16454
Vchronic obstructive pulmonary disease
p21063
sa(dp21064
g16449
I392
sg16450
I3
sg16451
I29
sg16459
VC3161101
p21065
sg16454
Vidiopathic pulmonary fibrosis
p21066
sa(dp21067
g16449
I423
sg16450
I1
sg16451
I3
sg16459
VC3161101
p21068
sg16454
VIPF
p21069
sa(dp21070
g16449
I364
sg16450
I1
sg16451
I4
sg16459
VC0024117
p21071
sg16454
VCOPD
p21072
sasa(dp21073
g16444
VPeripheral blood monocyte surface marker (CD14, CD16, CD163, CSF1R, CCR2, CCR4, CCR5, CXCR3, CXCR4, CX3CR1, HLA-DR, CD62L, SIGLEC-1) expression and capacity for phagocytosis, oxidative burst and LPS-stimulated TNF production were assessed in patients with hepatitis C (HCV) (n = 39) or non-alcoholic fatty liver disease (NAFLD) (n = 34) (classified as non-advanced disease, compensated cirrhosis and decompensated cirrhosis) and healthy controls (n = 11) by flow cytometry.
p21074
sg16446
(lp21075
(dp21076
g16449
I48
sg16450
I1
sg16451
I4
sg16452
VP08637
p21077
sg16454
VCD16
p21078
sa(dp21079
g16449
I100
sg16450
I1
sg16451
I6
sg16452
VP78423
p21080
sg16454
VCX3CR1
p21081
sa(dp21082
g16449
I80
sg16450
I1
sg16451
I4
sg16452
VP32302
p21083
sg16454
VCCR5
p21084
sa(dp21085
g16449
I74
sg16450
I1
sg16451
I4
sg16452
VP51679
p21086
sg16454
VCCR4
p21087
sa(dp21088
g16449
I86
sg16450
I1
sg16451
I5
sg16452
VP49682
p21089
sg16454
VCXCR3
p21090
sa(dp21091
g16449
I54
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCD163
p21092
sa(dp21093
g16449
I210
sg16450
I1
sg16451
I3
sg16452
VP01375
p21094
sg16454
VTNF
p21095
sa(dp21096
g16449
I61
sg16450
I1
sg16451
I5
sg16452
VP09619
p21097
sg16454
VCSF1R
p21098
sa(dp21099
g16449
I108
sg16450
I1
sg16451
I6
sg16452
VP30486
p21100
sg16454
VHLA-DR
p21101
sa(dp21102
g16449
I93
sg16450
I1
sg16451
I5
sg16452
VP61073
p21103
sg16454
VCXCR4
p21104
sa(dp21105
g16449
I123
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VSIGLEC-1
p21106
sa(dp21107
g16449
I116
sg16450
I1
sg16451
I5
sg16452
VP14151
p21108
sg16454
VCD62L
p21109
sa(dp21110
g16449
I68
sg16450
I1
sg16451
I4
sg16452
VP41597
p21111
sg16454
VCCR2
p21112
sa(dp21113
g16449
I42
sg16450
I1
sg16451
I4
sg16452
VP08571
p21114
sg16454
VCD14
p21115
sasg16456
(lp21116
(dp21117
g16449
I374
sg16450
I2
sg16451
I21
sg16459
VC1608426
p21118
sg16454
Vcompensated cirrhosis
p21119
sa(dp21120
g16449
I400
sg16450
I2
sg16451
I23
sg16459
VC1619727
p21121
sg16454
Vdecompensated cirrhosis
p21122
sa(dp21123
g16449
I321
sg16450
I1
sg16451
I5
sg16459
VC0400966
p21124
sg16454
VNAFLD
p21125
sa(dp21126
g16449
I195
sg16450
I1
sg16451
I3
sg16459
VC0175697
p21127
sg16454
VLPS
p21128
sa(dp21129
g16449
I256
sg16450
I2
sg16451
I11
sg16459
VC0019196
p21130
sg16454
Vhepatitis C
p21131
sa(dp21132
g16449
I286
sg16450
I4
sg16451
I33
sg16459
VC0400966
p21133
sg16454
Vnon-alcoholic fatty liver disease
p21134
sasa(dp21135
g16444
VSoluble CD163 (sCD163), a marker of Kupffer cell activation detectable in serum, correlates with inflammation and fibrosis in chronic viral hepatitis, but its role in nonalcoholic fatty liver disease is unknown.
p21136
sg16446
(lp21137
(dp21138
g16449
I15
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VsCD163
p21139
sa(dp21140
g16449
I0
sg16450
I2
sg16451
I13
sg16452
g11
sg16454
VSoluble CD163
p21141
sasg16456
(lp21142
(dp21143
g16449
I126
sg16450
I3
sg16451
I23
sg16459
VC0276623
p21144
sg16454
Vchronic viral hepatitis
p21145
sa(dp21146
g16449
I114
sg16450
I1
sg16451
I8
sg16459
VC0016059
p21147
sg16454
Vfibrosis
p21148
sa(dp21149
g16449
I97
sg16450
I1
sg16451
I12
sg16459
VC0021368
p21150
sg16454
Vinflammation
p21151
sa(dp21152
g16449
I167
sg16450
I4
sg16451
I32
sg16459
VC0400966
p21153
sg16454
Vnonalcoholic fatty liver disease
p21154
sasa(dp21155
g16444
VWe hypothesized that sCD163 would correlate with nonalcoholic fatty liver disease activity and fibrosis.
p21156
sg16446
(lp21157
(dp21158
g16449
I21
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VsCD163
p21159
sasg16456
(lp21160
(dp21161
g16449
I49
sg16450
I4
sg16451
I32
sg16459
VC0400966
p21162
sg16454
Vnonalcoholic fatty liver disease
p21163
sa(dp21164
g16449
I95
sg16450
I1
sg16451
I8
sg16459
VC0016059
p21165
sg16454
Vfibrosis
p21166
sasa(dp21167
g16444
Vdermatoses presenting with erythematous-desquamative patches/plaques (plaque psoriasis, eczematous dermatitis, pityriasis rosea, mycosis fungoides and subacute cutaneous lupus erythematosus), papulosquamous/papulokeratotic dermatoses (lichen planus, pityriasis rosea, papulosquamous sarcoidosis, guttate psoriasis, pityriasis lichenoides chronica, classical pityriasis rubra pilaris, porokeratosis, lymphomatoid papulosis, papulosquamous chronic GVHD, parakeratosis variegata, Grover disease, Darier disease and BRAF-inhibitor-induced acantholytic dyskeratosis), facial inflammatory skin diseases (rosacea, seborrheic dermatitis, discoid lupus erythematosus, sarcoidosis, cutaneous leishmaniasis, lupus vulgaris, granuloma faciale and demodicidosis), acquired keratodermas (chronic hand eczema, palmar psoriasis, keratoderma due to mycosis fungoides, keratoderma resulting from pityriasis rubra pilaris, tinea manuum, palmar lichen planus and aquagenic palmar keratoderma), sclero-atrophic dermatoses (necrobiosis lipoidica, morphea and cutaneous lichen sclerosus), hypopigmented macular diseases (extragenital guttate lichen sclerosus, achromic pityriasis versicolor, guttate vitiligo, idiopathic guttate hypomelanosis, progressive macular hypomelanosis and postinflammatory hypopigmentations), hyperpigmented maculopapular diseases (pityriasis versicolor, lichen planus pigmentosus, Gougerot-Carteaud syndrome, Dowling-Degos disease, erythema ab igne, macular amyloidosis, lichen amyloidosus, friction melanosis, terra firma-forme dermatosis, urticaria pigmentosa and telangiectasia macularis eruptiva perstans), itchy papulonodular dermatoses (hypertrophic lichen planus, prurigo nodularis, nodular scabies and acquired perforating dermatosis), erythrodermas (due to psoriasis, atopic dermatitis, mycosis fungoides, pityriasis rubra pilaris and scabies), noninfectious balanitis (Zoon's plasma cell balanitis, psoriatic balanitis, seborrheic dermatitis and non-specific balanitis) and erythroplasia of Queyrat, inflammatory cicatricial alopecias (scalp discoid lupus erythematosus, lichen planopilaris, frontal fibrosing alopecia and folliculitis decalvans), nonscarring alopecias (alopecia areata, trichotillomania, androgenetic alopecia and telogen effluvium) and scaling disorders of the scalp (tinea capitis, scalp psoriasis, seborrheic dermatitis and pityriasis amiantacea).
p21168
sg16446
(lp21169
sg16456
(lp21170
(dp21171
g16449
I77
sg16450
I1
sg16451
I9
sg16459
VC0033860
p21172
sg16454
Vpsoriasis
p21173
sa(dp21174
g16449
I88
sg16450
I2
sg16451
I21
sg16459
VC0013595
p21175
sg16454
Veczematous dermatitis
p21176
sa(dp21177
g16449
I607
sg16450
I2
sg16451
I21
sg16459
VC0036508
p21178
sg16454
Vseborrheic dermatitis
p21179
sa(dp21180
g16449
I2316
sg16450
I2
sg16451
I15
sg16459
VC0406326
p21181
sg16454
Vscalp psoriasis
p21182
sa(dp21183
g16449
I129
sg16450
I2
sg16451
I17
sg16459
VC0026948
p21184
sg16454
Vmycosis fungoides
p21185
sa(dp21186
g16449
I358
sg16450
I3
sg16451
I24
sg16459
VC0032027
p21187
sg16454
Vpityriasis rubra pilaris
p21188
sa(dp21189
g16449
I1413
sg16450
I2
sg16451
I21
sg16459
VC0406811
p21190
sg16454
VDowling-Degos disease
p21191
sa(dp21192
g16449
I235
sg16450
I2
sg16451
I13
sg16459
VC0023646
p21193
sg16454
Vlichen planus
p21194
sa(dp21195
g16449
I1111
sg16450
I3
sg16451
I24
sg16459
VC0406644
p21196
sg16454
Vguttate lichen sclerosus
p21197
sa(dp21198
g16449
I1694
sg16450
I2
sg16451
I15
sg16459
VC0344064
p21199
sg16454
Vnodular scabies
p21200
sa(dp21201
g16449
I1177
sg16450
I1
sg16451
I8
sg16459
VC0042900
p21202
sg16454
Vvitiligo
p21203
sa(dp21204
g16449
I1723
sg16450
I2
sg16451
I22
sg16459
VC1304435
p21205
sg16454
Vperforating dermatosis
p21206
sa(dp21207
g16449
I283
sg16450
I1
sg16451
I11
sg16459
VC0036202
p21208
sg16454
Vsarcoidosis
p21209
sa(dp21210
g16449
I1025
sg16450
I1
sg16451
I7
sg16459
VC0036420
p21211
sg16454
Vmorphea
p21212
sa(dp21213
g16449
I0
sg16450
I1
sg16451
I10
sg16459
VC0037274
p21214
sg16454
Vdermatoses
p21215
sa(dp21216
g16449
I2301
sg16450
I2
sg16451
I13
sg16459
VC0040250
p21217
sg16454
Vtinea capitis
p21218
sa(dp21219
g16449
I1146
sg16450
I2
sg16451
I21
sg16459
VC0040262
p21220
sg16454
Vpityriasis versicolor
p21221
sa(dp21222
g16449
I981
sg16450
I1
sg16451
I8
sg16459
VC0333641
p21223
sg16454
Vatrophic
p21224
sa(dp21225
g16449
I2185
sg16450
I2
sg16451
I15
sg16459
VC0002171
p21226
sg16454
Valopecia areata
p21227
sa(dp21228
g16449
I1475
sg16450
I2
sg16451
I18
sg16459
VC0268397
p21229
sg16454
Vlichen amyloidosus
p21230
sa(dp21231
g16449
I630
sg16450
I3
sg16451
I27
sg16459
VC0024138
p21232
sg16454
Vdiscoid lupus erythematosus
p21233
sa(dp21234
g16449
I774
sg16450
I3
sg16451
I19
sg16459
VC1276092
p21235
sg16454
Vchronic hand eczema
p21236
sa(dp21237
g16449
I2106
sg16450
I3
sg16451
I26
sg16459
VC1274700
p21238
sg16454
Vfrontal fibrosing alopecia
p21239
sa(dp21240
g16449
I1462
sg16450
I1
sg16451
I11
sg16459
VC0002726
p21241
sg16454
Vamyloidosis
p21242
sa(dp21243
g16449
I1146
sg16450
I2
sg16451
I21
sg16459
VC0040262
p21244
sg16454
Vpityriasis versicolor
p21245
sa(dp21246
g16449
I713
sg16450
I2
sg16451
I17
sg16459
VC0239495
p21247
sg16454
Vgranuloma faciale
p21248
sa(dp21249
g16449
I1988
sg16450
I3
sg16451
I24
sg16459
VC0154089
p21250
sg16454
Verythroplasia of Queyrat
p21251
sa(dp21252
g16449
I672
sg16450
I2
sg16451
I23
sg16459
VC0023283
p21253
sg16454
Vcutaneous leishmaniasis
p21254
sa(dp21255
g16449
I0
sg16450
I1
sg16451
I10
sg16459
VC0037274
p21256
sg16454
Vdermatoses
p21257
sa(dp21258
g16449
I151
sg16450
I4
sg16451
I38
sg16459
VC0024140
p21259
sg16454
Vsubacute cutaneous lupus erythematosus
p21260
sa(dp21261
g16449
I1570
sg16450
I4
sg16451
I42
sg16459
VC0263402
p21262
sg16454
Vtelangiectasia macularis eruptiva perstans
p21263
sa(dp21264
g16449
I0
sg16450
I1
sg16451
I10
sg16459
VC0037274
p21265
sg16454
Vdermatoses
p21266
sa(dp21267
g16449
I607
sg16450
I2
sg16451
I21
sg16459
VC0036508
p21268
sg16454
Vseborrheic dermatitis
p21269
sa(dp21270
g16449
I1436
sg16450
I3
sg16451
I16
sg16459
VC0494853
p21271
sg16454
Verythema ab igne
p21272
sa(dp21273
g16449
I77
sg16450
I1
sg16451
I9
sg16459
VC0033860
p21274
sg16454
Vpsoriasis
p21275
sa(dp21276
g16449
I1702
sg16450
I1
sg16451
I7
sg16459
VC0036262
p21277
sg16454
Vscabies
p21278
sa(dp21279
g16449
I358
sg16450
I3
sg16451
I24
sg16459
VC0032027
p21280
sg16454
Vpityriasis rubra pilaris
p21281
sa(dp21282
g16449
I399
sg16450
I2
sg16451
I22
sg16459
VC0206182
p21283
sg16454
Vlymphomatoid papulosis
p21284
sa(dp21285
g16449
I0
sg16450
I1
sg16451
I10
sg16459
VC0037274
p21286
sg16454
Vdermatoses
p21287
sa(dp21288
g16449
I1206
sg16450
I1
sg16451
I13
sg16459
VC0162835
p21289
sg16454
Vhypomelanosis
p21290
sa(dp21291
g16449
I607
sg16450
I2
sg16451
I21
sg16459
VC0036508
p21292
sg16454
Vseborrheic dermatitis
p21293
sa(dp21294
g16449
I760
sg16450
I1
sg16451
I11
sg16459
VC0022579
p21295
sg16454
Vkeratoderma
p21296
sa(dp21297
g16449
I1187
sg16450
I3
sg16451
I32
sg16459
VC0263583
p21298
sg16454
Vidiopathic guttate hypomelanosis
p21299
sa(dp21300
g16449
I1647
sg16450
I3
sg16451
I26
sg16459
VC0023649
p21301
sg16454
Vhypertrophic lichen planus
p21302
sa(dp21303
g16449
I1358
sg16450
I3
sg16451
I25
sg16459
VC0406366
p21304
sg16454
Vlichen planus pigmentosus
p21305
sa(dp21306
g16449
I598
sg16450
I1
sg16451
I7
sg16459
VC0035854
p21307
sg16454
Vrosacea
p21308
sa(dp21309
g16449
I1002
sg16450
I2
sg16451
I21
sg16459
VC0027538
p21310
sg16454
Vnecrobiosis lipoidica
p21311
sa(dp21312
g16449
I1047
sg16450
I2
sg16451
I16
sg16459
VC0023652
p21313
sg16454
Vlichen sclerosus
p21314
sa(dp21315
g16449
I2202
sg16450
I1
sg16451
I16
sg16459
VC0040953
p21316
sg16454
Vtrichotillomania
p21317
sa(dp21318
g16449
I2246
sg16450
I2
sg16451
I17
sg16459
VC0263518
p21319
sg16454
Vtelogen effluvium
p21320
sa(dp21321
g16449
I111
sg16450
I2
sg16451
I16
sg16459
VC0032026
p21322
sg16454
Vpityriasis rosea
p21323
sa(dp21324
g16449
I1872
sg16450
I1
sg16451
I9
sg16459
VC0004690
p21325
sg16454
Vbalanitis
p21326
sa(dp21327
g16449
I760
sg16450
I1
sg16451
I11
sg16459
VC0022579
p21328
sg16454
Vkeratoderma
p21329
sa(dp21330
g16449
I2085
sg16450
I2
sg16451
I19
sg16459
VC0023645
p21331
sg16454
Vlichen planopilaris
p21332
sa(dp21333
g16449
I315
sg16450
I3
sg16451
I31
sg16459
VC0162851
p21334
sg16454
Vpityriasis lichenoides chronica
p21335
sa(dp21336
g16449
I452
sg16450
I2
sg16451
I23
sg16459
VC0030437
p21337
sg16454
Vparakeratosis variegata
p21338
sa(dp21339
g16449
I2137
sg16450
I2
sg16451
I22
sg16459
VC0263503
p21340
sg16454
Vfolliculitis decalvans
p21341
sa(dp21342
g16449
I1615
sg16450
I1
sg16451
I5
sg16459
VC0033774
p21343
sg16454
Vitchy
p21344
sa(dp21345
g16449
I235
sg16450
I2
sg16451
I13
sg16459
VC0023646
p21346
sg16454
Vlichen planus
p21347
sa(dp21348
g16449
I129
sg16450
I2
sg16451
I17
sg16459
VC0026948
p21349
sg16454
Vmycosis fungoides
p21350
sa(dp21351
g16449
I548
sg16450
I1
sg16451
I12
sg16459
VC0334061
p21352
sg16454
Vdyskeratosis
p21353
sa(dp21354
g16449
I358
sg16450
I3
sg16451
I24
sg16459
VC0032027
p21355
sg16454
Vpityriasis rubra pilaris
p21356
sa(dp21357
g16449
I1385
sg16450
I2
sg16451
I26
sg16459
VC0263385
p21358
sg16454
VGougerot-Carteaud syndrome
p21359
sa(dp21360
g16449
I2220
sg16450
I2
sg16451
I21
sg16459
VC0162311
p21361
sg16454
Vandrogenetic alopecia
p21362
sa(dp21363
g16449
I484
sg16450
I2
sg16451
I15
sg16459
VC0022595
p21364
sg16454
Vdisease, Darier
p21365
sa(dp21366
g16449
I1545
sg16450
I2
sg16451
I20
sg16459
VC0042111
p21367
sg16454
Vurticaria pigmentosa
p21368
sa(dp21369
g16449
I1872
sg16450
I1
sg16451
I9
sg16459
VC0004690
p21370
sg16454
Vbalanitis
p21371
sa(dp21372
g16449
I438
sg16450
I2
sg16451
I12
sg16459
VC0867389
p21373
sg16454
Vchronic GVHD
p21374
sa(dp21375
g16449
I697
sg16450
I2
sg16451
I14
sg16459
VC0024131
p21376
sg16454
Vlupus vulgaris
p21377
sa(dp21378
g16449
I384
sg16450
I1
sg16451
I13
sg16459
VC0162839
p21379
sg16454
Vporokeratosis
p21380
sa(dp21381
g16449
I904
sg16450
I2
sg16451
I12
sg16459
VC0153246
p21382
sg16454
Vtinea manuum
p21383
sa(dp21384
g16449
I70
sg16450
I2
sg16451
I16
sg16459
VC0406317
p21385
sg16454
Vplaque psoriasis
p21386
sa(dp21387
g16449
I1675
sg16450
I2
sg16451
I17
sg16459
VC0263353
p21388
sg16454
Vprurigo nodularis
p21389
sa(dp21390
g16449
I1781
sg16450
I2
sg16451
I17
sg16459
VC0011615
p21391
sg16454
Vatopic dermatitis
p21392
sa(dp21393
g16449
I1748
sg16450
I1
sg16451
I13
sg16459
VC0011606
p21394
sg16454
Verythrodermas
p21395
sa(dp21396
g16449
I583
sg16450
I2
sg16451
I13
sg16459
VC0037274
p21397
sg16454
Vskin diseases
p21398
sa(dp21399
g16449
I2359
sg16450
I2
sg16451
I21
sg16459
VC0343100
p21400
sg16454
Vpityriasis amiantacea
p21401
sa(dp21402
g16449
I283
sg16450
I1
sg16451
I11
sg16459
VC0036202
p21403
sg16454
Vsarcoidosis
p21404
sa(dp21405
g16449
I1515
sg16450
I3
sg16451
I28
sg16459
VC2721650
p21406
sg16454
Vterra firma-forme dermatosis
p21407
sa(dp21408
g16449
I111
sg16450
I2
sg16451
I16
sg16459
VC0032026
p21409
sg16454
Vpityriasis rosea
p21410
sa(dp21411
g16449
I630
sg16450
I3
sg16451
I27
sg16459
VC0024138
p21412
sg16454
Vdiscoid lupus erythematosus
p21413
sa(dp21414
g16449
I1210
sg16450
I1
sg16451
I9
sg16459
VC0221391
p21415
sg16454
Vmelanosis
p21416
sa(dp21417
g16449
I61
sg16450
I1
sg16451
I7
sg16459
VC0333463
p21418
sg16454
Vplaques
p21419
sa(dp21420
g16449
I129
sg16450
I2
sg16451
I17
sg16459
VC0026948
p21421
sg16454
Vmycosis fungoides
p21422
sa(dp21423
g16449
I1890
sg16450
I3
sg16451
I21
sg16459
VC0403761
p21424
sg16454
Vplasma cell balanitis
p21425
sa(dp21426
g16449
I296
sg16450
I2
sg16451
I17
sg16459
VC0343052
p21427
sg16454
Vguttate psoriasis
p21428
sa(dp21429
g16449
I760
sg16450
I1
sg16451
I11
sg16459
VC0022579
p21430
sg16454
Vkeratoderma
p21431
sa(dp21432
g16449
I1872
sg16450
I1
sg16451
I9
sg16459
VC0004690
p21433
sg16454
Vbalanitis
p21434
sa(dp21435
g16449
I760
sg16450
I1
sg16451
I12
sg16459
VC0022579
p21436
sg16454
Vkeratodermas
p21437
sasa(dp21438
g16444
VKaposi varicelliform eruption or eczema herpeticum is well known to be associated with several chronic dermatoses, including atopic dermatitis, foliaceus pemphigus, seborrheic dermatitis, Darier disease, and congenital ichthyosiform erythroderma.
p21439
sg16446
(lp21440
sg16456
(lp21441
(dp21442
g16449
I208
sg16450
I3
sg16451
I37
sg16459
VC0079583
p21443
sg16454
Vcongenital ichthyosiform erythroderma
p21444
sa(dp21445
g16449
I0
sg16450
I3
sg16451
I29
sg16459
VC0022504
p21446
sg16454
VKaposi varicelliform eruption
p21447
sa(dp21448
g16449
I165
sg16450
I2
sg16451
I21
sg16459
VC0036508
p21449
sg16454
Vseborrheic dermatitis
p21450
sa(dp21451
g16449
I188
sg16450
I2
sg16451
I14
sg16459
VC0022595
p21452
sg16454
VDarier disease
p21453
sa(dp21454
g16449
I154
sg16450
I1
sg16451
I9
sg16459
VC0030807
p21455
sg16454
Vpemphigus
p21456
sa(dp21457
g16449
I103
sg16450
I1
sg16451
I10
sg16459
VC0037274
p21458
sg16454
Vdermatoses
p21459
sa(dp21460
g16449
I33
sg16450
I2
sg16451
I17
sg16459
VC0936250
p21461
sg16454
Veczema herpeticum
p21462
sa(dp21463
g16449
I125
sg16450
I2
sg16451
I17
sg16459
VC0011615
p21464
sg16454
Vatopic dermatitis
p21465
sasa(dp21466
g16444
VMCI-186, a dose that prevents ischemic brain edema, had no significant effect on brain concentrations of dopamine, norepinephrine, 5-hydroxytryptamine, or their metabolites.
p21467
sg16446
(lp21468
sg16456
(lp21469
(dp21470
g16449
I39
sg16450
I2
sg16451
I11
sg16459
VC1527311
p21471
sg16454
Vbrain edema
p21472
sa(dp21473
g16449
I0
sg16450
I1
sg16451
I3
sg16459
VC1270972
p21474
sg16454
VMCI
p21475
sasa(dp21476
g16444
VPretreatments with dexamethasone, parachlorophenylalanine (an inhibitor of 5-hydroxytryptamine synthesis), mepyramine and metiamide (H1 and H2 histamine receptor antagonists) or aminophylline did not influence significantly the development of brain edema evaluated 24 h after embolization.
p21477
sg16446
(lp21478
(dp21479
g16449
I140
sg16450
I3
sg16451
I21
sg16452
g11
sg16454
VH2 histamine receptor
p21480
sasg16456
(lp21481
(dp21482
g16449
I243
sg16450
I2
sg16451
I11
sg16459
VC1527311
p21483
sg16454
Vbrain edema
p21484
sasa(dp21485
g16444
VTo study the effect of B lymphocyte-induced mature protein-1(Blimp1) expression in bone marrow mononuclear cells on the prognosis of patients with multiple myeloma.
p21486
sg16446
(lp21487
(dp21488
g16449
I61
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VBlimp1
p21489
sa(dp21490
g16449
I44
sg16450
I2
sg16451
I16
sg16452
VP17980
p21491
sg16454
Vmature protein-1
p21492
sasg16456
(lp21493
(dp21494
g16449
I147
sg16450
I2
sg16451
I16
sg16459
VC0026764
p21495
sg16454
Vmultiple myeloma
p21496
sasa(dp21497
g16444
VHere we further dissect the anti-myeloma mechanisms mediated by EZH2 inhibition and show that pharmacological inhibition of EZH2 reduces the expression of MM-associated oncogenes; IRF-4, XBP-1, PRDM1/BLIMP-1 and c-MYC.
p21498
sg16446
(lp21499
(dp21500
g16449
I64
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VEZH2
p21501
sa(dp21502
g16449
I187
sg16450
I1
sg16451
I5
sg16452
VP17861
p21503
sg16454
VXBP-1
p21504
sa(dp21505
g16449
I64
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VEZH2
p21506
sa(dp21507
g16449
I194
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VPRDM1
p21508
sa(dp21509
g16449
I212
sg16450
I1
sg16451
I5
sg16452
VP12524
p21510
sg16454
Vc-MYC
p21511
sa(dp21512
g16449
I200
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VBLIMP-1
p21513
sa(dp21514
g16449
I180
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIRF-4
p21515
sasg16456
(lp21516
(dp21517
g16449
I33
sg16450
I1
sg16451
I7
sg16459
VC0026764
p21518
sg16454
Vmyeloma
p21519
sasa(dp21520
g16444
VTo investigate the expression level of B lymphocyte-induced maturation protein-1(Blimp-1) mRNA in bone marrow mononuclear cells(BMMNC) of multiple myeloma(MM) patients and its clinical significance.
p21521
sg16446
(lp21522
(dp21523
g16449
I60
sg16450
I2
sg16451
I20
sg16452
VP17980
p21524
sg16454
Vmaturation protein-1
p21525
sasg16456
(lp21526
(dp21527
g16449
I138
sg16450
I2
sg16451
I16
sg16459
VC0026764
p21528
sg16454
Vmultiple myeloma
p21529
sasa(dp21530
g16444
VMeanwhile, plasma could promote myeloma differentiation by up-regulating Blimp-1 and XBP-1 expression.
p21531
sg16446
(lp21532
(dp21533
g16449
I85
sg16450
I1
sg16451
I5
sg16452
VP17861
p21534
sg16454
VXBP-1
p21535
sa(dp21536
g16449
I73
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VBlimp-1
p21537
sasg16456
(lp21538
(dp21539
g16449
I32
sg16450
I1
sg16451
I7
sg16459
VC0026764
p21540
sg16454
Vmyeloma
p21541
sasa(dp21542
g16444
VHowever, how Blimp-1 ensures the survival of plasma cell malignancy, multiple myeloma (MM), has remained elusive.
p21543
sg16446
(lp21544
sg16456
(lp21545
(dp21546
g16449
I57
sg16450
I1
sg16451
I10
sg16459
VC0006826
p21547
sg16454
Vmalignancy
p21548
sa(dp21549
g16449
I69
sg16450
I2
sg16451
I16
sg16459
VC0026764
p21550
sg16454
Vmultiple myeloma
p21551
sasa(dp21552
g16444
VThe finding that Blimp-1/PRDM1 enhances transcription of CS1 gene in multiple myeloma cells may help in developing novel strategies for therapeutic intervention in multiple myeloma.
p21553
sg16446
(lp21554
(dp21555
g16449
I57
sg16450
I2
sg16451
I8
sg16452
g11
sg16454
VCS1 gene
p21556
sa(dp21557
g16449
I17
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VBlimp-1
p21558
sa(dp21559
g16449
I25
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VPRDM1
p21560
sasg16456
(lp21561
(dp21562
g16449
I69
sg16450
I2
sg16451
I16
sg16459
VC0026764
p21563
sg16454
Vmultiple myeloma
p21564
sa(dp21565
g16449
I69
sg16450
I2
sg16451
I16
sg16459
VC0026764
p21566
sg16454
Vmultiple myeloma
p21567
sasa(dp21568
g16444
VLhx9 is an LIM (named for the first three proteins in which the domain was found, Lin-11, Isl1 and Mec-3) homeodomain protein involved in development and differentiation of the gonad.
p21569
sg16446
(lp21570
(dp21571
g16449
I106
sg16450
I1
sg16451
I11
sg16452
g11
sg16454
Vhomeodomain
p21572
sa(dp21573
g16449
I99
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VMec-3
p21574
sa(dp21575
g16449
I11
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VLIM
p21576
sa(dp21577
g16449
I90
sg16450
I1
sg16451
I4
sg16452
VP61371
p21578
sg16454
VIsl1
p21579
sa(dp21580
g16449
I0
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VLhx9
p21581
sasg16456
(lp21582
sa(dp21583
g16444
VWe report that CCRL2-deficient mice have a defect in neutrophil recruitment and are protected in 2 models of inflammatory arthritis.
p21584
sg16446
(lp21585
(dp21586
g16449
I15
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCCRL2
p21587
sasg16456
(lp21588
(dp21589
g16449
I64
sg16450
I1
sg16451
I11
sg16459
VC0271510
p21590
sg16454
Vrecruitment
p21591
sa(dp21592
g16449
I109
sg16450
I2
sg16451
I22
sg16459
VC0003864
p21593
sg16454
Vinflammatory arthritis
p21594
sasa(dp21595
g16444
VThe concurrence of PJS and feminizing SCTs of the testes is an increasingly recognized cause of prepubertal gynecomastia.
p21596
sg16446
(lp21597
(dp21598
g16449
I19
sg16450
I4
sg16451
I23
sg16452
g11
sg16454
VPJS and feminizing SCTs
p21599
sasg16456
(lp21600
(dp21601
g16449
I38
sg16450
I1
sg16451
I4
sg16459
VC0796149
p21602
sg16454
VSCTs
p21603
sa(dp21604
g16449
I108
sg16450
I1
sg16451
I12
sg16459
VC0018418
p21605
sg16454
Vgynecomastia
p21606
sa(dp21607
g16449
I19
sg16450
I1
sg16451
I3
sg16459
VC0031269
p21608
sg16454
VPJS
p21609
sasa(dp21610
g16444
VMost IgAD and CVID patients in our clinic population in the Southeastern United States have inherited part or all of two extended MHC haplotypes, referred to as haplotype 1 (HLA-DQB1 0201, HLA-DR3, C4B-Sf, C4A-0, G1-15, Bf-0.4, C2-a, HSP-7.5, TNF alpha-5, HLA-B8, HLA-A1) and haplotype 2 (HLA-DQB1 0201, HLA-DR-7, C4B-S, C4A-L, G11-4.5, Bf-0.6, C2-b, HSP-9, TNF alpha-9, HLA-B44, HLA-A29).
p21611
sg16446
(lp21612
(dp21613
g16449
I371
sg16450
I1
sg16451
I7
sg16452
VP30486
p21614
sg16454
VHLA-B44
p21615
sa(dp21616
g16449
I243
sg16450
I2
sg16451
I11
sg16452
VP01375
p21617
sg16454
VTNF alpha-5
p21618
sa(dp21619
g16449
I351
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VHSP-9
p21620
sa(dp21621
g16449
I358
sg16450
I2
sg16451
I11
sg16452
VP01375
p21622
sg16454
VTNF alpha-9
p21623
sa(dp21624
g16449
I174
sg16450
I2
sg16451
I13
sg16452
VP09471
p21625
sg16454
VHLA-DQB1 0201
p21626
sa(dp21627
g16449
I380
sg16450
I1
sg16451
I7
sg16452
VP30486
p21628
sg16454
VHLA-A29
p21629
sa(dp21630
g16449
I130
sg16450
I2
sg16451
I14
sg16452
VP13747
p21631
sg16454
VMHC haplotypes
p21632
sa(dp21633
g16449
I198
sg16450
I1
sg16451
I3
sg16452
VP04003
p21634
sg16454
VC4B
p21635
sa(dp21636
g16449
I189
sg16450
I1
sg16451
I7
sg16452
VP30486
p21637
sg16454
VHLA-DR3
p21638
sa(dp21639
g16449
I198
sg16450
I1
sg16451
I5
sg16452
VP04003
p21640
sg16454
VC4B-S
p21641
sa(dp21642
g16449
I234
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VHSP-7.5
p21643
sa(dp21644
g16449
I304
sg16450
I1
sg16451
I8
sg16452
VP30486
p21645
sg16454
VHLA-DR-7
p21646
sa(dp21647
g16449
I256
sg16450
I1
sg16451
I6
sg16452
VP30486
p21648
sg16454
VHLA-B8
p21649
sa(dp21650
g16449
I174
sg16450
I2
sg16451
I13
sg16452
VP09471
p21651
sg16454
VHLA-DQB1 0201
p21652
sa(dp21653
g16449
I328
sg16450
I1
sg16451
I7
sg16452
VP56715
p21654
sg16454
VG11-4.5
p21655
sasg16456
(lp21656
(dp21657
g16449
I234
sg16450
I1
sg16451
I3
sg16459
VC0034152
p21658
sg16454
VHSP
p21659
sa(dp21660
g16449
I234
sg16450
I1
sg16451
I3
sg16459
VC0034152
p21661
sg16454
VHSP
p21662
sa(dp21663
g16449
I14
sg16450
I1
sg16451
I4
sg16459
VC0009447
p21664
sg16454
VCVID
p21665
sasa(dp21666
g16444
VIn search of a genetic linkage between the two immunodeficiencies, we examined the major histocompatibility complex (MHC) class III genes encoding complement components C2, C4A, and C4B and steroid 21-hydroxylase in addition to the HLA serotypes in individuals with either common variable immunodeficiency or IgA deficiency.
p21667
sg16446
(lp21668
(dp21669
g16449
I232
sg16450
I1
sg16451
I3
sg16452
VP30486
p21670
sg16454
VHLA
p21671
sa(dp21672
g16449
I309
sg16450
I1
sg16451
I3
sg16452
VP11912
p21673
sg16454
VIgA
p21674
sa(dp21675
g16449
I182
sg16450
I1
sg16451
I3
sg16452
VP04003
p21676
sg16454
VC4B
p21677
sa(dp21678
g16449
I190
sg16450
I2
sg16451
I22
sg16452
VP08686
p21679
sg16454
Vsteroid 21-hydroxylase
p21680
sa(dp21681
g16449
I83
sg16450
I9
sg16451
I74
sg16452
g11
sg16454
Vmajor histocompatibility complex (MHC) class III genes encoding complement
p21682
sasg16456
(lp21683
(dp21684
g16449
I47
sg16450
I1
sg16451
I18
sg16459
VC0021051
p21685
sg16454
Vimmunodeficiencies
p21686
sa(dp21687
g16449
I273
sg16450
I3
sg16451
I32
sg16459
VC0009447
p21688
sg16454
Vcommon variable immunodeficiency
p21689
sa(dp21690
g16449
I309
sg16450
I2
sg16451
I14
sg16459
VC0162538
p21691
sg16454
VIgA deficiency
p21692
sasa(dp21693
g16444
VTwelve of 19 patients with common variable immunodeficiency (63%, P less than 0.001) and 9 of 16 patients with IgA deficiency (56%, P less than 0.01) had rare C2 alleles and/or C4A and 21-hydroxylase A deletions, whereas these gene features were seen in only 5 of 34 healthy individuals (15%) in the control group.
p21694
sg16446
(lp21695
(dp21696
g16449
I185
sg16450
I2
sg16451
I16
sg16452
VP08686
p21697
sg16454
V21-hydroxylase A
p21698
sa(dp21699
g16449
I111
sg16450
I1
sg16451
I3
sg16452
VP11912
p21700
sg16454
VIgA
p21701
sasg16456
(lp21702
(dp21703
g16449
I27
sg16450
I3
sg16451
I32
sg16459
VC0009447
p21704
sg16454
Vcommon variable immunodeficiency
p21705
sa(dp21706
g16449
I111
sg16450
I2
sg16451
I14
sg16459
VC0162538
p21707
sg16454
VIgA deficiency
p21708
sasa(dp21709
g16444
VTotally implantable venous access port (TIVAP)-related infections (RIs) remain a serious health problem in cancer patients receiving an intravenous (i.v.)
p21710
sg16446
(lp21711
sg16456
(lp21712
(dp21713
g16449
I107
sg16450
I1
sg16451
I6
sg16459
VC0006826
p21714
sg16454
Vcancer
p21715
sa(dp21716
g16449
I55
sg16450
I1
sg16451
I10
sg16459
VC0021311
p21717
sg16454
Vinfections
p21718
sasa(dp21719
g16444
VFurthermore, we provided a RIs-based algorithm for biomarker discovery and validation to screen for diseases such as cancer.
p21720
sg16446
(lp21721
sg16456
(lp21722
(dp21723
g16449
I117
sg16450
I1
sg16451
I6
sg16459
VC0006826
p21724
sg16454
Vcancer
p21725
sasa(dp21726
g16444
VThe first survey, sent to 94 cancer control and supportive care responsible individuals (CCL RIs) at 94 COG institutions, asked if the institution had a standardized approach to practice and focused on antiemetic agent choice.
p21727
sg16446
(lp21728
sg16456
(lp21729
(dp21730
g16449
I29
sg16450
I1
sg16451
I6
sg16459
VC0006826
p21731
sg16454
Vcancer
p21732
sa(dp21733
g16449
I89
sg16450
I1
sg16451
I3
sg16459
VC1852438
p21734
sg16454
VCCL
p21735
sasa(dp21736
g16444
VLiver sections from patients with biliary atresia were evaluated to detect antigen for the BECs marker 4 and cytokeratin-7 (CK-7), proteins (fibroblast-specific protein 1, also known S100A4; the collagen chaperone heat shock protein 47, HSP47) characteristically expressed by cells undergoing EMT, as well as myofibroblasts marker a-smooth muscle actin (a-SMA).
p21737
sg16446
(lp21738
(dp21739
g16449
I124
sg16450
I5
sg16451
I46
sg16452
VP14222
p21740
sg16454
VCK-7), proteins (fibroblast-specific protein 1
p21741
sa(dp21742
g16449
I109
sg16450
I1
sg16451
I13
sg16452
VP08729
p21743
sg16454
Vcytokeratin-7
p21744
sa(dp21745
g16449
I237
sg16450
I1
sg16451
I5
sg16452
VP50454
p21746
sg16454
VHSP47
p21747
sa(dp21748
g16449
I195
sg16450
I6
sg16451
I40
sg16452
VP34931
p21749
sg16454
Vcollagen chaperone heat shock protein 47
p21750
sa(dp21751
g16449
I183
sg16450
I1
sg16451
I6
sg16452
VP26447
p21752
sg16454
VS100A4
p21753
sa(dp21754
g16449
I354
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
Va-SMA
p21755
sa(dp21756
g16449
I331
sg16450
I3
sg16451
I21
sg16452
g11
sg16454
Va-smooth muscle actin
p21757
sasg16456
(lp21758
(dp21759
g16449
I34
sg16450
I2
sg16451
I15
sg16459
VC0005411
p21760
sg16454
Vbiliary atresia
p21761
sa(dp21762
g16449
I356
sg16450
I1
sg16451
I3
sg16459
VC0026847
p21763
sg16454
VSMA
p21764
sasa(dp21765
g16444
VHowever, BECs from biliary atresia resulted in increased expression of a-SMA, S100A4, with concurrent transition to a fibroblast-like morphology and decreased expression of AK-7.
p21766
sg16446
(lp21767
(dp21768
g16449
I173
sg16450
I1
sg16451
I4
sg16452
VP55263
p21769
sg16454
VAK-7
p21770
sa(dp21771
g16449
I78
sg16450
I1
sg16451
I6
sg16452
VP26447
p21772
sg16454
VS100A4
p21773
sa(dp21774
g16449
I73
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VSMA
p21775
sasg16456
(lp21776
(dp21777
g16449
I102
sg16450
I1
sg16451
I10
sg16459
VC0599156
p21778
sg16454
Vtransition
p21779
sa(dp21780
g16449
I19
sg16450
I2
sg16451
I15
sg16459
VC0005411
p21781
sg16454
Vbiliary atresia
p21782
sa(dp21783
g16449
I73
sg16450
I1
sg16451
I3
sg16459
VC0026847
p21784
sg16454
VSMA
p21785
sasa(dp21786
g16444
VConsequently, there has been considerable interest in the pharmaceutical industry to develop selective TPL-2 inhibitors as drugs for the treatment of TNF-dependent inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.
p21787
sg16446
(lp21788
(dp21789
g16449
I150
sg16450
I1
sg16451
I3
sg16452
VP01375
p21790
sg16454
VTNF
p21791
sa(dp21792
g16449
I103
sg16450
I1
sg16451
I5
sg16452
VP41279
p21793
sg16454
VTPL-2
p21794
sasg16456
(lp21795
(dp21796
g16449
I220
sg16450
I3
sg16451
I26
sg16459
VC0021390
p21797
sg16454
Vinflammatory bowel disease
p21798
sa(dp21799
g16449
I195
sg16450
I2
sg16451
I20
sg16459
VC0003873
p21800
sg16454
Vrheumatoid arthritis
p21801
sasa(dp21802
g16444
VThus, pharmacologic inhibition of Tpl2 should be a valid approach to therapeutic intervention in the pathogenesis of rheumatoid arthritis and other inflammatory diseases in humans.
p21803
sg16446
(lp21804
(dp21805
g16449
I34
sg16450
I1
sg16451
I4
sg16452
VP41279
p21806
sg16454
VTpl2
p21807
sasg16456
(lp21808
(dp21809
g16449
I117
sg16450
I2
sg16451
I20
sg16459
VC0003873
p21810
sg16454
Vrheumatoid arthritis
p21811
sa(dp21812
g16449
I101
sg16450
I1
sg16451
I12
sg16459
VC0699748
p21813
sg16454
Vpathogenesis
p21814
sasa(dp21815
g16444
VTaken together, our results show that inhibition of Tpl2 in primary human cell types can decrease the production of TNFalpha and other pro-inflammatory mediators during inflammatory events, and they further support the notion that Tpl2 is an appropriate therapeutic target for rheumatoid arthritis and other human inflammatory diseases.
p21816
sg16446
(lp21817
(dp21818
g16449
I116
sg16450
I1
sg16451
I8
sg16452
VP01375
p21819
sg16454
VTNFalpha
p21820
sa(dp21821
g16449
I52
sg16450
I1
sg16451
I4
sg16452
VP41279
p21822
sg16454
VTpl2
p21823
sa(dp21824
g16449
I52
sg16450
I1
sg16451
I4
sg16452
VP41279
p21825
sg16454
VTpl2
p21826
sasg16456
(lp21827
(dp21828
g16449
I277
sg16450
I2
sg16451
I20
sg16459
VC0003873
p21829
sg16454
Vrheumatoid arthritis
p21830
sasa(dp21831
g16444
VRecent studies using Tpl2 knockout mice have indicated an important role for Tpl2 in the lipopolysaccharide (LPS) induced production of tumor necrosis factor alpha (TNF-alpha) and other proinflammatory cytokines involved in diseases such as rheumatoid arthritis.
p21832
sg16446
(lp21833
(dp21834
g16449
I136
sg16450
I4
sg16451
I27
sg16452
VP01375
p21835
sg16454
Vtumor necrosis factor alpha
p21836
sa(dp21837
g16449
I21
sg16450
I1
sg16451
I4
sg16452
VP41279
p21838
sg16454
VTpl2
p21839
sa(dp21840
g16449
I21
sg16450
I1
sg16451
I4
sg16452
VP41279
p21841
sg16454
VTpl2
p21842
sa(dp21843
g16449
I165
sg16450
I1
sg16451
I9
sg16452
VP01375
p21844
sg16454
VTNF-alpha
p21845
sasg16456
(lp21846
(dp21847
g16449
I136
sg16450
I2
sg16451
I14
sg16459
VC0333516
p21848
sg16454
Vtumor necrosis
p21849
sa(dp21850
g16449
I89
sg16450
I1
sg16451
I18
sg16459
VC0175697
p21851
sg16454
Vlipopolysaccharide
p21852
sa(dp21853
g16449
I109
sg16450
I1
sg16451
I3
sg16459
VC0175697
p21854
sg16454
VLPS
p21855
sa(dp21856
g16449
I241
sg16450
I2
sg16451
I20
sg16459
VC0003873
p21857
sg16454
Vrheumatoid arthritis
p21858
sasa(dp21859
g16444
VIn all, 78.08% had stage 1 HTN while 22% had stage 2 HTN.
p21860
sg16446
(lp21861
sg16456
(lp21862
(dp21863
g16449
I27
sg16450
I1
sg16451
I3
sg16459
VC0020538
p21864
sg16454
VHTN
p21865
sa(dp21866
g16449
I27
sg16450
I1
sg16451
I3
sg16459
VC0020538
p21867
sg16454
VHTN
p21868
sasa(dp21869
g16444
VMoreover, ba-PWV showed a significant increase with increasing plasma tHcy level in subjects with both high normal BP and grade 1 HTN (p &lt; 0.05).
p21870
sg16446
(lp21871
sg16456
(lp21872
(dp21873
g16449
I130
sg16450
I1
sg16451
I3
sg16459
VC0020538
p21874
sg16454
VHTN
p21875
sasa(dp21876
g16444
VCompared with optimal BP stage, ba-PWV was significantly associated with high normal BP stage (Beta = 193, p &lt; 0.001) and grade 1 HTN (Beta = 413, p &lt; 0.001).There was a statistical interaction effect between high normal BP stage and optimal BP stage (p = 0.045).
p21877
sg16446
(lp21878
sg16456
(lp21879
(dp21880
g16449
I133
sg16450
I1
sg16451
I3
sg16459
VC0020538
p21881
sg16454
VHTN
p21882
sasa(dp21883
g16444
VThe similar result was found between subjects with optimal BP and those with grade 1 HTN (p = 0.037).
p21884
sg16446
(lp21885
sg16456
(lp21886
(dp21887
g16449
I85
sg16450
I1
sg16451
I3
sg16459
VC0020538
p21888
sg16454
VHTN
p21889
sasa(dp21890
g16444
VIn conclusion, tHcy was independently correlated with ba-PWV in subjects with high normal BP and grade 1 HTN.
p21891
sg16446
(lp21892
sg16456
(lp21893
(dp21894
g16449
I105
sg16450
I1
sg16451
I3
sg16459
VC0020538
p21895
sg16454
VHTN
p21896
sasa(dp21897
g16444
VHigh normal BP and grade 1 HTN may worsen the impact of tHcy on arterial stiffness in a Chinese rural community population.
p21898
sg16446
(lp21899
sg16456
(lp21900
(dp21901
g16449
I73
sg16450
I1
sg16451
I9
sg16459
VC0427008
p21902
sg16454
Vstiffness
p21903
sa(dp21904
g16449
I27
sg16450
I1
sg16451
I3
sg16459
VC0020538
p21905
sg16454
VHTN
p21906
sasa(dp21907
g16444
VNpeAMeToM npoAonXahweNcR ANcKyccNN RBnReTcR npoBeAeHNe EKcTpeHHblx EHAapTepEKToMNN N TpoMbNHTNMEKToMNN y namyNeHToB c NHcynbToM B xoAy, crescendo TNA, ocTpoN oKKnh3NeN BHyTpeHHeN coHHoN apTepNN.
p21908
sg16446
(lp21909
(dp21910
g16449
I0
sg16450
I17
sg16451
I149
sg16452
VP05452
p21911
sg16454
VNpeAMeToM npoAonXahweNcR ANcKyccNN RBnReTcR npoBeAeHNe EKcTpeHHblx EHAapTepEKToMNN N TpoMbNHTNMEKToMNN y namyNeHToB c NHcynbToM B xoAy, crescendo TNA
p21912
sasg16456
(lp21913
sa(dp21914
g16444
VThe upper bound of a 95% confidence interval for the difference in prevalence of Stage 1 and 2 HTN between study arms indicates that discontinuation of study medication is unlikely to be associated with an increase in Stage 1 HTN of &gt;4.8 percentage points and in Stage 2 HTN of no &gt;5.8 percentage points.
p21915
sg16446
(lp21916
sg16456
(lp21917
(dp21918
g16449
I95
sg16450
I1
sg16451
I3
sg16459
VC0020538
p21919
sg16454
VHTN
p21920
sa(dp21921
g16449
I113
sg16450
I1
sg16451
I4
sg16459
VC0206655
p21922
sg16454
Varms
p21923
sa(dp21924
g16449
I95
sg16450
I1
sg16451
I3
sg16459
VC0020538
p21925
sg16454
VHTN
p21926
sa(dp21927
g16449
I95
sg16450
I1
sg16451
I3
sg16459
VC0020538
p21928
sg16454
VHTN
p21929
sasa(dp21930
g16444
VTarget genes (e.g., cyclin-dependent kinase 6) of hsa-miR-942-5p were mainly enriched in cancer-related pathways, whereas target genes (e.g., CRK-Like Proto-Oncogene, Adaptor Protein) of hsa-miR-940 were enriched in the ErbB signaling pathway.
p21931
sg16446
(lp21932
(dp21933
g16449
I142
sg16450
I4
sg16451
I40
sg16452
VP46108
p21934
sg16454
VCRK-Like Proto-Oncogene, Adaptor Protein
p21935
sa(dp21936
g16449
I187
sg16450
I1
sg16451
I11
sg16452
g11
sg16454
Vhsa-miR-940
p21937
sa(dp21938
g16449
I50
sg16450
I1
sg16451
I14
sg16452
g11
sg16454
Vhsa-miR-942-5p
p21939
sa(dp21940
g16449
I220
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VErbB
p21941
sa(dp21942
g16449
I20
sg16450
I3
sg16451
I25
sg16452
g11
sg16454
Vcyclin-dependent kinase 6
p21943
sasg16456
(lp21944
(dp21945
g16449
I89
sg16450
I1
sg16451
I6
sg16459
VC0006826
p21946
sg16454
Vcancer
p21947
sa(dp21948
g16449
I50
sg16450
I1
sg16451
I3
sg16459
VC0393754
p21949
sg16454
Vhsa
p21950
sa(dp21951
g16449
I50
sg16450
I1
sg16451
I3
sg16459
VC0393754
p21952
sg16454
Vhsa
p21953
sasa(dp21954
g16444
VHerein, we demonstrated that hypoxia induces the high expression of microRNA-940 (miR-940) in exosomes derived from epithelial ovarian cancer (EOC).
p21955
sg16446
(lp21956
sg16456
(lp21957
(dp21958
g16449
I143
sg16450
I1
sg16451
I3
sg16459
VC0677886
p21959
sg16454
VEOC
p21960
sa(dp21961
g16449
I29
sg16450
I1
sg16451
I7
sg16459
VC0242184
p21962
sg16454
Vhypoxia
p21963
sa(dp21964
g16449
I116
sg16450
I3
sg16451
I25
sg16459
VC0677886
p21965
sg16454
Vepithelial ovarian cancer
p21966
sasa(dp21967
g16444
VResults: Expressions of hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all up regulated in high invasion capable cell lines (SNU423, SNU449) and vascular invasion patients with hepatocellular carcinoma (logFC&gt;1, P&lt;0.05).
p21968
sg16446
(lp21969
(dp21970
g16449
I24
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
Vhsa
p21971
sa(dp21972
g16449
I38
sg16450
I1
sg16451
I11
sg16452
g11
sg16454
Vhsa-mir-149
p21973
sa(dp21974
g16449
I51
sg16450
I1
sg16451
I11
sg16452
g11
sg16454
Vhsa-mir-744
p21975
sa(dp21976
g16449
I24
sg16450
I1
sg16451
I12
sg16452
g11
sg16454
Vhsa-mir-1180
p21977
sasg16456
(lp21978
(dp21979
g16449
I24
sg16450
I1
sg16451
I3
sg16459
VC0393754
p21980
sg16454
Vhsa
p21981
sa(dp21982
g16449
I24
sg16450
I1
sg16451
I3
sg16459
VC0393754
p21983
sg16454
Vhsa
p21984
sa(dp21985
g16449
I24
sg16450
I1
sg16451
I3
sg16459
VC0393754
p21986
sg16454
Vhsa
p21987
sa(dp21988
g16449
I24
sg16450
I1
sg16451
I3
sg16459
VC0393754
p21989
sg16454
Vhsa
p21990
sa(dp21991
g16449
I109
sg16450
I1
sg16451
I8
sg16459
VC2699153
p21992
sg16454
Vinvasion
p21993
sa(dp21994
g16449
I190
sg16450
I2
sg16451
I24
sg16459
VC1512411
p21995
sg16454
Vhepatocellular carcinoma
p21996
sa(dp21997
g16449
I109
sg16450
I1
sg16451
I8
sg16459
VC2699153
p21998
sg16454
Vinvasion
p21999
sasa(dp22000
g16444
VResults from the Survival analysis showed that hsa-mir-1180 (HR=1.623, 95% CI: 1.114-2.365, P=0.012), hsa-mir-149 (HR=2.400, 95% CI: 1.639-3.514) and hsa-mir-940 (HR=1.704, 95%CI: 1.188-2.443, P=0.004) were independent risk factors on the prognosis of patients with hepatocellular carcinoma (P&lt;0.05).
p22001
sg16446
(lp22002
(dp22003
g16449
I47
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
Vhsa
p22004
sa(dp22005
g16449
I47
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
Vhsa
p22006
sa(dp22007
g16449
I47
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
Vhsa
p22008
sasg16456
(lp22009
(dp22010
g16449
I47
sg16450
I1
sg16451
I3
sg16459
VC0393754
p22011
sg16454
Vhsa
p22012
sa(dp22013
g16449
I47
sg16450
I1
sg16451
I3
sg16459
VC0393754
p22014
sg16454
Vhsa
p22015
sa(dp22016
g16449
I266
sg16450
I2
sg16451
I24
sg16459
VC1512411
p22017
sg16454
Vhepatocellular carcinoma
p22018
sa(dp22019
g16449
I47
sg16450
I1
sg16451
I3
sg16459
VC0393754
p22020
sg16454
Vhsa
p22021
sasa(dp22022
g16444
VConclusion: With TCGA and GEO data mining, we found that hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all highly related to the prognosis of hepatocellular carcinoma, that enabled it to be used to further study the biomarkers related to the prognosis of hepatocellular carcinoma.
p22023
sg16446
(lp22024
(dp22025
g16449
I57
sg16450
I1
sg16451
I12
sg16452
g11
sg16454
Vhsa-mir-1180
p22026
sa(dp22027
g16449
I71
sg16450
I1
sg16451
I11
sg16452
g11
sg16454
Vhsa-mir-149
p22028
sa(dp22029
g16449
I84
sg16450
I1
sg16451
I11
sg16452
g11
sg16454
Vhsa-mir-744
p22030
sa(dp22031
g16449
I57
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
Vhsa
p22032
sasg16456
(lp22033
(dp22034
g16449
I57
sg16450
I1
sg16451
I3
sg16459
VC0393754
p22035
sg16454
Vhsa
p22036
sa(dp22037
g16449
I156
sg16450
I2
sg16451
I24
sg16459
VC1512411
p22038
sg16454
Vhepatocellular carcinoma
p22039
sa(dp22040
g16449
I156
sg16450
I2
sg16451
I24
sg16459
VC1512411
p22041
sg16454
Vhepatocellular carcinoma
p22042
sa(dp22043
g16449
I57
sg16450
I1
sg16451
I3
sg16459
VC0393754
p22044
sg16454
Vhsa
p22045
sa(dp22046
g16449
I57
sg16450
I1
sg16451
I3
sg16459
VC0393754
p22047
sg16454
Vhsa
p22048
sa(dp22049
g16449
I57
sg16450
I1
sg16451
I3
sg16459
VC0393754
p22050
sg16454
Vhsa
p22051
sasa(dp22052
g16444
V#\u76ee#\u7684#\uff1a #\u901a#\u8fc7#\u5bf9GEO (Gene Expression Omnibus) #\u4e0eTCGA (The Cancer Genome Atlas) #\u6570#\u636e#\u5e93#\u5206#\u6790, #\u6316#\u6398#\u809d#\u764c#\u8840#\u7ba1#\u4fb5#\u88ad#\u76f8#\u5173#\u7684microRNA, #\u5e76#\u5206#\u6790#\u5176#\u9884#\u540e#\u548c#\u53ef#\u80fd#\u673a#\u5236#\u3002 #\u65b9#\u6cd5#\uff1a #\u5229#\u7528GEO#\u6570#\u636e#\u5e93#\u83b7#\u5f97#\u809d#\u764c#\u8840#\u7ba1#\u4fb5#\u88admicroRNA#\u82af#\u7247#\u6570#\u636e (GSE67140) , #\u5bf95#\u79cd#\u4fb5#\u88ad#\u80fd#\u529b#\u4e0d#\u540c#\u7684#\u7ec6#\u80de#\u7cfb (SNU423#\u3001SNU449#\u3001HepG2#\u3001Hep3B#\u3001SNU398) #\u8868#\u8fbe#\u8c31#\u8fdb#\u884c#\u5dee#\u5f02#\u5206#\u6790, #\u5e76#\u572881#\u4efd#\u8840#\u7ba1#\u4fb5#\u88ad#\u9633#\u6027#\u7ec4#\u7ec7#\u6837#\u672c#\u4e0e91#\u4efd#\u8840#\u7ba1#\u4fb5#\u88ad#\u9634#\u6027#\u7ec4#\u7ec7#\u6837#\u672c#\u4e2d#\u9a8c#\u8bc1#\u5dee#\u5f02#\u5206#\u6790#\u7ed3#\u679c#\u3002#\u7ed3#\u5408TCGA#\u6570#\u636e#\u5e93#\u4e2d362#\u4f8b#\u809d#\u764c#\u75c5#\u4f8b#\u6570#\u636e#\u5206#\u6790#\u5176#\u9884#\u540e, #\u5e76#\u5bf9microRNA#\u6240#\u8c03#\u63a7#\u7684#\u57fa#\u56e0#\u8fdb#\u884cGO#\u4e0eKEGG#\u5206#\u6790#\u3002 #\u7ed3#\u679c#\uff1a hsa-mir-1180#\u3001hsa-mir-149#\u3001hsa-mir-744#\u3001hsa-mir-940#\u5728#\u4fb5#\u88ad#\u80fd#\u529b#\u5f3a#\u7684#\u809d#\u764c#\u7ec6#\u80de#\u548c#\u6709#\u8840#\u7ba1#\u4fb5#\u88ad#\u7684#\u809d#\u764c#\u7ec4#\u7ec7#\u4e2d#\u8868#\u8fbe#\u4e0a#\u8c03 (logFC&gt;1, P&lt;0.05) #\u3002#\u751f#\u5b58#\u5206#\u6790#\u663e#\u793a, hsa-mir-1180 (HR=1.623, 95%CI#\uff1a1.114~2.365, P=0.012) #\u3001hsa-mir-149 (HR=2.400, 95% CI#\uff1a1.639~3.514, P&lt;0.001) #\u3001hsa-mir-744 (HR=1.679, 95%CI#\uff1a1.161~2.427, P=0.006) #\u3001hsa-mir-940 (HR=1.704, 95%CI#\uff1a1.188~2.443, P=0.004) #\u662f#\u809d#\u764c#\u75c5#\u4f8b#\u9884#\u540e#\u72ec#\u7acb#\u5371#\u9669#\u56e0#\u7d20, #\u9ad8#\u8868#\u8fbe#\u4e0e#\u60a3#\u8005#\u751f#\u5b58#\u671f#\u7f29#\u77ed#\u663e#\u8457#\u76f8#\u5173 (P&lt;0.05) #\u3002GO#\u4e0eKEGG#\u5206#\u6790#\u5176#\u673a#\u5236#\u53ef#\u80fd#\u4e0e#\u514d#\u75ab#\u53cd#\u5e94#\u3001#\u7ec6#\u80de#\u9ecf#\u9644#\u3001#\u7d27#\u5bc6#\u8fde#\u63a5#\u7b49#\u4fe1#\u53f7#\u901a#\u8def#\u6709#\u5173#\u3002 #\u7ed3#\u8bba#\uff1a #\u901a#\u8fc7#\u5bf9TCGA#\u4e0eGEO#\u6570#\u636e#\u5e93#\u7684#\u6316#\u6398, #\u521d#\u6b65#\u53d1#\u73b0hsa-mir-1180#\u3001hsa-mir-149#\u3001hsa-mir-744#\u3001hsa-mir-940#\u5bf9#\u809d#\u764c#\u7684#\u9884#\u540e#\u6709#\u5f71#\u54cd, #\u53ef#\u4f5c#\u4e3a#\u809d#\u764c#\u9884#\u540e#\u7684#\u751f#\u7269#\u6807#\u5fd7#\u7269#\u3002.
p22053
sg16446
(lp22054
sg16456
(lp22055
(dp22056
g16449
I465
sg16450
I1
sg16451
I3
sg16459
VC0393754
p22057
sg16454
Vhsa
p22058
sa(dp22059
g16449
I478
sg16450
I1
sg16451
I4
sg16459
VC0393754
p22060
sg16454
V\u3001hsa
p22061
sa(dp22062
g16449
I478
sg16450
I1
sg16451
I4
sg16459
VC0393754
p22063
sg16454
V\u3001hsa
p22064
sa(dp22065
g16449
I478
sg16450
I1
sg16451
I4
sg16459
VC0393754
p22066
sg16454
V\u3001hsa
p22067
sa(dp22068
g16449
I478
sg16450
I1
sg16451
I4
sg16459
VC0393754
p22069
sg16454
V\u3001hsa
p22070
sa(dp22071
g16449
I465
sg16450
I1
sg16451
I3
sg16459
VC0393754
p22072
sg16454
Vhsa
p22073
sa(dp22074
g16449
I478
sg16450
I1
sg16451
I4
sg16459
VC0393754
p22075
sg16454
V\u3001hsa
p22076
sa(dp22077
g16449
I478
sg16450
I1
sg16451
I4
sg16459
VC0393754
p22078
sg16454
V\u3001hsa
p22079
sa(dp22080
g16449
I478
sg16450
I1
sg16451
I4
sg16459
VC0393754
p22081
sg16454
V\u3001hsa
p22082
sa(dp22083
g16449
I478
sg16450
I1
sg16451
I4
sg16459
VC0393754
p22084
sg16454
V\u3001hsa
p22085
sa(dp22086
g16449
I478
sg16450
I1
sg16451
I4
sg16459
VC0393754
p22087
sg16454
V\u3001hsa
p22088
sa(dp22089
g16449
I55
sg16450
I1
sg16451
I6
sg16459
VC0006826
p22090
sg16454
VCancer
p22091
sasa(dp22092
g16444
VThe high expression of miR-940 is associated with better survival in patients with ovarian serous cystadenocarcinoma.
p22093
sg16446
(lp22094
(dp22095
g16449
I23
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VmiR-940
p22096
sasg16456
(lp22097
(dp22098
g16449
I83
sg16450
I3
sg16451
I33
sg16459
VC0279663
p22099
sg16454
Vovarian serous cystadenocarcinoma
p22100
sasa(dp22101
g16444
VIn our study, real-time (RT) quantitative PCR indicated that miR-940 levels were upregulated in human cervical cancer tissue samples and cell lines.
p22102
sg16446
(lp22103
sg16456
(lp22104
(dp22105
g16449
I102
sg16450
I2
sg16451
I15
sg16459
VC0302592
p22106
sg16454
Vcervical cancer
p22107
sasa(dp22108
g16444
VEctopic miR-940 accelerated cervical cancer cell growth, proliferation and cell cycle arrest in vitro as well as tumor formation in vivo.
p22109
sg16446
(lp22110
sg16456
(lp22111
(dp22112
g16449
I37
sg16450
I3
sg16451
I18
sg16459
VC1516170
p22113
sg16454
Vcancer cell growth
p22114
sa(dp22115
g16449
I113
sg16450
I1
sg16451
I5
sg16459
VC0027651
p22116
sg16454
Vtumor
p22117
sa(dp22118
g16449
I57
sg16450
I1
sg16451
I13
sg16459
VC0334094
p22119
sg16454
Vproliferation
p22120
sasa(dp22121
g16444
Vp27 and PTEN were evidenced as direct targets for miR-940 and inhibition of p27 and PTEN recovered the suppressive function of miR-940-silenced cell towards to proliferation and tumorigenicity in cervical cancer cells.
p22122
sg16446
(lp22123
(dp22124
g16449
I0
sg16450
I1
sg16451
I3
sg16452
VP40305
p22125
sg16454
Vp27
p22126
sa(dp22127
g16449
I8
sg16450
I1
sg16451
I4
sg16452
VP60484
p22128
sg16454
VPTEN
p22129
sa(dp22130
g16449
I0
sg16450
I1
sg16451
I3
sg16452
VP40305
p22131
sg16454
Vp27
p22132
sa(dp22133
g16449
I8
sg16450
I1
sg16451
I4
sg16452
VP60484
p22134
sg16454
VPTEN
p22135
sasg16456
(lp22136
(dp22137
g16449
I196
sg16450
I2
sg16451
I15
sg16459
VC0302592
p22138
sg16454
Vcervical cancer
p22139
sa(dp22140
g16449
I160
sg16450
I1
sg16451
I13
sg16459
VC0334094
p22141
sg16454
Vproliferation
p22142
sa(dp22143
g16449
I178
sg16450
I1
sg16451
I14
sg16459
VC1519697
p22144
sg16454
Vtumorigenicity
p22145
sasa(dp22146
g16444
VIn addition, miR-940 expression was inversely associated with p27 and PTEN expression levels and actively with cyclin D1 in cervical cancer specimens.
p22147
sg16446
(lp22148
(dp22149
g16449
I111
sg16450
I2
sg16451
I9
sg16452
VP24385
p22150
sg16454
Vcyclin D1
p22151
sa(dp22152
g16449
I62
sg16450
I1
sg16451
I3
sg16452
VP40305
p22153
sg16454
Vp27
p22154
sa(dp22155
g16449
I70
sg16450
I1
sg16451
I4
sg16452
VP60484
p22156
sg16454
VPTEN
p22157
sasg16456
(lp22158
(dp22159
g16449
I124
sg16450
I2
sg16451
I15
sg16459
VC0302592
p22160
sg16454
Vcervical cancer
p22161
sasa(dp22162
g16444
VThe results from our study demonstrated that miR-940 regulated p27 and PTEN post-transcriptionally and might play a significant role in cervical cancer development and progression.
p22163
sg16446
(lp22164
(dp22165
g16449
I45
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VmiR-940
p22166
sa(dp22167
g16449
I71
sg16450
I1
sg16451
I4
sg16452
VP60484
p22168
sg16454
VPTEN
p22169
sa(dp22170
g16449
I63
sg16450
I1
sg16451
I3
sg16452
VP40305
p22171
sg16454
Vp27
p22172
sasg16456
(lp22173
(dp22174
g16449
I136
sg16450
I2
sg16451
I15
sg16459
VC0302592
p22175
sg16454
Vcervical cancer
p22176
sasa(dp22177
g16444
VThus, miR-940 might provide a potential value as therapeutic target for cervical cancer treatment in future.
p22178
sg16446
(lp22179
(dp22180
g16449
I6
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VmiR-940
p22181
sasg16456
(lp22182
(dp22183
g16449
I72
sg16450
I2
sg16451
I15
sg16459
VC0302592
p22184
sg16454
Vcervical cancer
p22185
sasa(dp22186
g16444
VWe aimed to explore the roles and regulatory mechanism of microRNA-940 (miR-940) in bladder cancer development.
p22187
sg16446
(lp22188
sg16456
(lp22189
(dp22190
g16449
I84
sg16450
I2
sg16451
I14
sg16459
VC0699885
p22191
sg16454
Vbladder cancer
p22192
sasa(dp22193
g16444
VThe expressions of miR-940 in bladder cancer tissues and cells were measured.
p22194
sg16446
(lp22195
sg16456
(lp22196
(dp22197
g16449
I30
sg16450
I2
sg16451
I14
sg16459
VC0699885
p22198
sg16454
Vbladder cancer
p22199
sasa(dp22200
g16444
VmiR-940 was up-regulated in bladder cancer tissues and cells.
p22201
sg16446
(lp22202
sg16456
(lp22203
(dp22204
g16449
I28
sg16450
I2
sg16451
I14
sg16459
VC0699885
p22205
sg16454
Vbladder cancer
p22206
sasa(dp22207
g16444
VOverexpression of miR-940 significantly increased bladder cancer cell proliferation, promoted migration and invasion, and inhibited cell apoptosis.
p22208
sg16446
(lp22209
sg16456
(lp22210
(dp22211
g16449
I108
sg16450
I1
sg16451
I8
sg16459
VC2699153
p22212
sg16454
Vinvasion
p22213
sa(dp22214
g16449
I50
sg16450
I2
sg16451
I14
sg16459
VC0699885
p22215
sg16454
Vbladder cancer
p22216
sa(dp22217
g16449
I70
sg16450
I1
sg16451
I13
sg16459
VC0334094
p22218
sg16454
Vproliferation
p22219
sasa(dp22220
g16444
VINPP4A and GSK3Beta were the direct targets of miR-940, and knockdown of INPP4A or GSK3Beta significantly increased cancer cell proliferation, migration and invasion, and inhibited cell apoptosis.
p22221
sg16446
(lp22222
(dp22223
g16449
I0
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VINPP4A
p22224
sa(dp22225
g16449
I0
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VINPP4A
p22226
sasg16456
(lp22227
(dp22228
g16449
I128
sg16450
I1
sg16451
I13
sg16459
VC0334094
p22229
sg16454
Vproliferation
p22230
sa(dp22231
g16449
I157
sg16450
I1
sg16451
I8
sg16459
VC2699153
p22232
sg16454
Vinvasion
p22233
sa(dp22234
g16449
I116
sg16450
I1
sg16451
I6
sg16459
VC0006826
p22235
sg16454
Vcancer
p22236
sasa(dp22237
g16444
VOur results indicate that overexpression of miR-940 may promote bladder cancer cell proliferation, migration and invasion, and inhibited cell apoptosis via targeting INPP4A or GSK3Beta and activating Wnt/Beta-catenin pathway.
p22238
sg16446
(lp22239
(dp22240
g16449
I44
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VmiR-940
p22241
sa(dp22242
g16449
I166
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VINPP4A
p22243
sasg16456
(lp22244
(dp22245
g16449
I113
sg16450
I1
sg16451
I8
sg16459
VC2699153
p22246
sg16454
Vinvasion
p22247
sa(dp22248
g16449
I64
sg16450
I2
sg16451
I14
sg16459
VC0699885
p22249
sg16454
Vbladder cancer
p22250
sa(dp22251
g16449
I84
sg16450
I1
sg16451
I13
sg16459
VC0334094
p22252
sg16454
Vproliferation
p22253
sasa(dp22254
g16444
VExpressions of miR-940, miR-15a, miR-16 and IL-23 in PTC tissues might be useful biomarkers and promising targets in the diagnosis of papillary thyroid carcinoma.
p22255
sg16446
(lp22256
(dp22257
g16449
I24
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VmiR-15a
p22258
sa(dp22259
g16449
I44
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-23
p22260
sa(dp22261
g16449
I15
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VmiR-940
p22262
sa(dp22263
g16449
I33
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VmiR-16
p22264
sa(dp22265
g16449
I53
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VPTC
p22266
sasg16456
(lp22267
(dp22268
g16449
I134
sg16450
I3
sg16451
I27
sg16459
VC0238463
p22269
sg16454
Vpapillary thyroid carcinoma
p22270
sa(dp22271
g16449
I53
sg16450
I1
sg16451
I3
sg16459
VC0238463
p22272
sg16454
VPTC
p22273
sasa(dp22274
g16444
VThis study investigated the pivotal role of miR-940 in the progression of ovarian cancer and to reveal the possible molecular mechanism of its action.
p22275
sg16446
(lp22276
sg16456
(lp22277
(dp22278
g16449
I74
sg16450
I2
sg16451
I14
sg16459
VC1140680
p22279
sg16454
Vovarian cancer
p22280
sasa(dp22281
g16444
VOvarian cancer OVCAR3 cells were transfected with the miR-940 vector, miR-940 inhibitor, and/or small interfering RNA (siRNA) targeting PKC-Delta (si-PKC-Delta), respectively.
p22282
sg16446
(lp22283
(dp22284
g16449
I147
sg16450
I1
sg16451
I12
sg16452
VP17252
p22285
sg16454
Vsi-PKC-Delta
p22286
sa(dp22287
g16449
I136
sg16450
I1
sg16451
I9
sg16452
VP17252
p22288
sg16454
VPKC-Delta
p22289
sasg16456
(lp22290
(dp22291
g16449
I0
sg16450
I2
sg16451
I14
sg16459
VC1140680
p22292
sg16454
VOvarian cancer
p22293
sa(dp22294
g16449
I136
sg16450
I1
sg16451
I3
sg16459
VC1868682
p22295
sg16454
VPKC
p22296
sa(dp22297
g16449
I136
sg16450
I1
sg16451
I3
sg16459
VC1868682
p22298
sg16454
VPKC
p22299
sasa(dp22300
g16444
VTaken together, the results of our study suggest that upregulation of miR-940 may function as a suppressor in the progression of ovarian cancer by inhibiting cell proliferation and inducing apoptosis by targeting PKC-Delta.
p22301
sg16446
(lp22302
(dp22303
g16449
I213
sg16450
I1
sg16451
I9
sg16452
VP17252
p22304
sg16454
VPKC-Delta
p22305
sa(dp22306
g16449
I70
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VmiR-940
p22307
sasg16456
(lp22308
(dp22309
g16449
I129
sg16450
I2
sg16451
I14
sg16459
VC1140680
p22310
sg16454
Vovarian cancer
p22311
sa(dp22312
g16449
I213
sg16450
I1
sg16451
I3
sg16459
VC1868682
p22313
sg16454
VPKC
p22314
sa(dp22315
g16449
I163
sg16450
I1
sg16451
I13
sg16459
VC0334094
p22316
sg16454
Vproliferation
p22317
sasa(dp22318
g16444
VThis study may provide a basis for the possible application of miR-940 in illustrating the molecular pathogenic mechanism of ovarian cancer.
p22319
sg16446
(lp22320
sg16456
(lp22321
(dp22322
g16449
I125
sg16450
I2
sg16451
I14
sg16459
VC1140680
p22323
sg16454
Vovarian cancer
p22324
sasa(dp22325
g16444
VTo investigate the expression of miR-940 in the hepatocellular carcinoma (HCC) and its impact on function and biological mechanism in the HCC cells.
p22326
sg16446
(lp22327
sg16456
(lp22328
(dp22329
g16449
I74
sg16450
I1
sg16451
I3
sg16459
VC2239176
p22330
sg16454
VHCC
p22331
sa(dp22332
g16449
I74
sg16450
I1
sg16451
I3
sg16459
VC2239176
p22333
sg16454
VHCC
p22334
sa(dp22335
g16449
I48
sg16450
I2
sg16451
I24
sg16459
VC2239176
p22336
sg16454
Vhepatocellular carcinoma
p22337
sasa(dp22338
g16444
VGene variants known to contribute to Autoimmune Addison's disease (AAD) susceptibility include those at the MHC, MICA, CIITA, CTLA4, PTPN22, CYP27B1, NLRP-1 and CD274 loci.
p22339
sg16446
(lp22340
(dp22341
g16449
I108
sg16450
I1
sg16451
I3
sg16452
VP13747
p22342
sg16454
VMHC
p22343
sa(dp22344
g16449
I161
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VCD274 loci
p22345
sa(dp22346
g16449
I126
sg16450
I1
sg16451
I5
sg16452
VP16410
p22347
sg16454
VCTLA4
p22348
sa(dp22349
g16449
I141
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCYP27B1
p22350
sa(dp22351
g16449
I150
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VNLRP-1
p22352
sa(dp22353
g16449
I119
sg16450
I1
sg16451
I5
sg16452
VP33076
p22354
sg16454
VCIITA
p22355
sa(dp22356
g16449
I133
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VPTPN22
p22357
sasg16456
(lp22358
(dp22359
g16449
I67
sg16450
I1
sg16451
I3
sg16459
VC0271737
p22360
sg16454
VAAD
p22361
sa(dp22362
g16449
I37
sg16450
I3
sg16451
I28
sg16459
VC0271737
p22363
sg16454
VAutoimmune Addison's disease
p22364
sa(dp22365
g16449
I113
sg16450
I1
sg16451
I4
sg16459
VC0700319
p22366
sg16454
VMICA
p22367
sasa(dp22368
g16444
VNLRP1 is genetically associated with risk of several autoimmune diseases including generalized vitiligo, Addison disease, type 1 diabetes, rheumatoid arthritis, and others.
p22369
sg16446
(lp22370
(dp22371
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VNLRP1
p22372
sasg16456
(lp22373
(dp22374
g16449
I83
sg16450
I2
sg16451
I20
sg16459
VC1304470
p22375
sg16454
Vgeneralized vitiligo
p22376
sa(dp22377
g16449
I122
sg16450
I3
sg16451
I15
sg16459
VC0011854
p22378
sg16454
Vtype 1 diabetes
p22379
sa(dp22380
g16449
I53
sg16450
I2
sg16451
I19
sg16459
VC0004364
p22381
sg16454
Vautoimmune diseases
p22382
sa(dp22383
g16449
I105
sg16450
I2
sg16451
I15
sg16459
VC0266273
p22384
sg16454
VAddison disease
p22385
sa(dp22386
g16449
I139
sg16450
I2
sg16451
I20
sg16459
VC0003873
p22387
sg16454
Vrheumatoid arthritis
p22388
sasa(dp22389
g16444
VInvestigating large patient cohorts from six different autoimmune diseases, that is autoimmune Addison's disease (n=333), type 1 diabetes (n=1086), multiple sclerosis (n=502), rheumatoid arthritis (n=945), systemic lupus erythematosus (n=156) and juvenile idiopathic arthritis (n=505), against 3273 healthy controls, we analyzed four single nucleotide polymorphisms (SNPs) in NALP1.
p22390
sg16446
(lp22391
(dp22392
g16449
I376
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VNALP1
p22393
sasg16456
(lp22394
(dp22395
g16449
I122
sg16450
I3
sg16451
I15
sg16459
VC0011854
p22396
sg16454
Vtype 1 diabetes
p22397
sa(dp22398
g16449
I148
sg16450
I2
sg16451
I18
sg16459
VC0026769
p22399
sg16454
Vmultiple sclerosis
p22400
sa(dp22401
g16449
I176
sg16450
I2
sg16451
I20
sg16459
VC0003873
p22402
sg16454
Vrheumatoid arthritis
p22403
sa(dp22404
g16449
I206
sg16450
I3
sg16451
I28
sg16459
VC0024141
p22405
sg16454
Vsystemic lupus erythematosus
p22406
sa(dp22407
g16449
I55
sg16450
I2
sg16451
I19
sg16459
VC0004364
p22408
sg16454
Vautoimmune diseases
p22409
sa(dp22410
g16449
I247
sg16450
I3
sg16451
I29
sg16459
VC0553662
p22411
sg16454
Vjuvenile idiopathic arthritis
p22412
sa(dp22413
g16449
I84
sg16450
I3
sg16451
I28
sg16459
VC0271737
p22414
sg16454
Vautoimmune Addison's disease
p22415
sasa(dp22416
g16444
VForty-four formalin-fixed, paraffin-embedded MRCL samples and 60 control cases (atypical/well-differentiated liposarcoma, pleomorphic liposarcoma, low-grade myofibrosarcoma, etc.)
p22417
sg16446
(lp22418
sg16456
(lp22419
(dp22420
g16449
I109
sg16450
I2
sg16451
I24
sg16459
VC0205825
p22421
sg16454
Vliposarcoma, pleomorphic
p22422
sa(dp22423
g16449
I109
sg16450
I1
sg16451
I11
sg16459
VC0023827
p22424
sg16454
Vliposarcoma
p22425
sa(dp22426
g16449
I157
sg16450
I1
sg16451
I15
sg16459
VC1708751
p22427
sg16454
Vmyofibrosarcoma
p22428
sasa(dp22429
g16444
VThe most frequent acupoints of acupuncture for PCOS were Sanyinjiao (SP 6), Guanyuan (CV 4), Zigong (EX-CA 1), Zhongji (CV 3) and Qihai (CV 6).
p22430
sg16446
(lp22431
(dp22432
g16449
I101
sg16450
I2
sg16451
I7
sg16452
VP00915
p22433
sg16454
VEX-CA 1
p22434
sasg16456
(lp22435
(dp22436
g16449
I47
sg16450
I1
sg16451
I4
sg16459
VC0032460
p22437
sg16454
VPCOS
p22438
sasa(dp22439
g16444
VIn the modern treatment of acupuncture for PCOS, Sanyinjiao (SP 6), Guanyuan (CV 4), Zigong (EX-CA 1), Zhongii (CV 3) and Qihai (CV 6) are most used.
p22440
sg16446
(lp22441
(dp22442
g16449
I93
sg16450
I2
sg16451
I7
sg16452
VP00915
p22443
sg16454
VEX-CA 1
p22444
sasg16456
(lp22445
(dp22446
g16449
I43
sg16450
I1
sg16451
I4
sg16459
VC0032460
p22447
sg16454
VPCOS
p22448
sasa(dp22449
g16444
VCarbonic anhydrase II (CA II) has an important role in thyroid hormone synthesis via regulating iodide (I-) transport across thyroidal cell membranes and the existence of autoantibodies against CA I and/or CA II have been shown in sera from patient with various autoimmune diseases such as Sjoegren's Syndrome, Systemic Lupus Erythmatosus, type 1 diabetes, primary biliary cirrhosis and ulcerative colitis.
p22450
sg16446
(lp22451
(dp22452
g16449
I23
sg16450
I2
sg16451
I4
sg16452
VP00915
p22453
sg16454
VCA I
p22454
sa(dp22455
g16449
I0
sg16450
I3
sg16451
I21
sg16452
VP00918
p22456
sg16454
VCarbonic anhydrase II
p22457
sa(dp22458
g16449
I23
sg16450
I2
sg16451
I5
sg16452
VP00918
p22459
sg16454
VCA II
p22460
sa(dp22461
g16449
I23
sg16450
I2
sg16451
I5
sg16452
VP00918
p22462
sg16454
VCA II
p22463
sasg16456
(lp22464
(dp22465
g16449
I340
sg16450
I3
sg16451
I15
sg16459
VC0011854
p22466
sg16454
Vtype 1 diabetes
p22467
sa(dp22468
g16449
I387
sg16450
I2
sg16451
I18
sg16459
VC0009324
p22469
sg16454
Vulcerative colitis
p22470
sa(dp22471
g16449
I320
sg16450
I1
sg16451
I5
sg16459
VC0024131
p22472
sg16454
VLupus
p22473
sa(dp22474
g16449
I290
sg16450
I2
sg16451
I19
sg16459
VC1527336
p22475
sg16454
VSjoegren's Syndrome
p22476
sa(dp22477
g16449
I262
sg16450
I2
sg16451
I19
sg16459
VC0004364
p22478
sg16454
Vautoimmune diseases
p22479
sa(dp22480
g16449
I357
sg16450
I3
sg16451
I25
sg16459
VC0008312
p22481
sg16454
Vprimary biliary cirrhosis
p22482
sasa(dp22483
g16444
VEfforts to inhibit the chemokine receptor CCR9 using the agent CCX282-B in Crohn's disease were not successful.
p22484
sg16446
(lp22485
(dp22486
g16449
I23
sg16450
I3
sg16451
I23
sg16452
VP51686
p22487
sg16454
Vchemokine receptor CCR9
p22488
sasg16456
(lp22489
(dp22490
g16449
I75
sg16450
I2
sg16451
I15
sg16459
VC0010346
p22491
sg16454
VCrohn's disease
p22492
sasa(dp22493
g16444
VOther therapeuticals that might find their way to the market the coming years include the anti-mucosal vascular addressin cell adhesion molecule (MAdCAM) PF-00547659, small molecules (including laquinimod and the CCR9 antagonist Vercirnon), as well as an orally active SMAD7 antisense oligonucleotide that showed clinical benefit in Crohn's disease patients.
p22494
sg16446
(lp22495
(dp22496
g16449
I112
sg16450
I4
sg16451
I32
sg16452
g11
sg16454
Vaddressin cell adhesion molecule
p22497
sa(dp22498
g16449
I213
sg16450
I1
sg16451
I4
sg16452
VP51686
p22499
sg16454
VCCR9
p22500
sa(dp22501
g16449
I269
sg16450
I3
sg16451
I31
sg16452
g11
sg16454
VSMAD7 antisense oligonucleotide
p22502
sasg16456
(lp22503
(dp22504
g16449
I127
sg16450
I1
sg16451
I8
sg16459
VC0001511
p22505
sg16454
Vadhesion
p22506
sa(dp22507
g16449
I333
sg16450
I2
sg16451
I15
sg16459
VC0010346
p22508
sg16454
VCrohn's disease
p22509
sasa(dp22510
g16444
VThe chemokine CCL25, and its receptor CCR9, constitute a unique chemokine/receptor pair, which regulates trafficking of T lymphocytes to the small intestine under physiological conditions and is an attractive target for small bowel Crohn's disease drug development.
p22511
sg16446
(lp22512
(dp22513
g16449
I14
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCCL25
p22514
sa(dp22515
g16449
I38
sg16450
I1
sg16451
I4
sg16452
VP51686
p22516
sg16454
VCCR9
p22517
sasg16456
(lp22518
(dp22519
g16449
I232
sg16450
I2
sg16451
I15
sg16459
VC0010346
p22520
sg16454
VCrohn's disease
p22521
sasa(dp22522
g16444
VVercirnon is a CCR9 chemokine receptor antagonist being developed for the treatment of Crohn's disease.
p22523
sg16446
(lp22524
(dp22525
g16449
I15
sg16450
I3
sg16451
I23
sg16452
VP51686
p22526
sg16454
VCCR9 chemokine receptor
p22527
sasg16456
(lp22528
(dp22529
g16449
I87
sg16450
I2
sg16451
I15
sg16459
VC0010346
p22530
sg16454
VCrohn's disease
p22531
sasa(dp22532
g16444
VIt is well established that the passive trans-placental passage of anti-Ro/SSA antibodies from mother to foetus is associated with the risk to develop an uncommon syndrome named neonatal lupus (NLE), where the congenital heart block represents the most severe clinical feature.
p22533
sg16446
(lp22534
(dp22535
g16449
I67
sg16450
I2
sg16451
I22
sg16452
VP19474
p22536
sg16454
Vanti-Ro/SSA antibodies
p22537
sasg16456
(lp22538
(dp22539
g16449
I178
sg16450
I2
sg16451
I14
sg16459
VC0409979
p22540
sg16454
Vneonatal lupus
p22541
sa(dp22542
g16449
I210
sg16450
I3
sg16451
I22
sg16459
VC0149530
p22543
sg16454
Vcongenital heart block
p22544
sa(dp22545
g16449
I163
sg16450
I1
sg16451
I8
sg16459
VC0039082
p22546
sg16454
Vsyndrome
p22547
sasa(dp22548
g16444
VThe characteristics of NLE that were studied included congenital complete heart block (CCHB), second degree heart block, and hepatic fibrosis.
p22549
sg16446
(lp22550
sg16456
(lp22551
(dp22552
g16449
I54
sg16450
I4
sg16451
I31
sg16459
VC0340496
p22553
sg16454
Vcongenital complete heart block
p22554
sa(dp22555
g16449
I94
sg16450
I4
sg16451
I25
sg16459
VC0264906
p22556
sg16454
Vsecond degree heart block
p22557
sa(dp22558
g16449
I87
sg16450
I1
sg16451
I4
sg16459
VC0340496
p22559
sg16454
VCCHB
p22560
sa(dp22561
g16449
I125
sg16450
I2
sg16451
I16
sg16459
VC0239946
p22562
sg16454
Vhepatic fibrosis
p22563
sasa(dp22564
g16444
VSera from patients known to frequently produce precipitating anti-SS-A/Ro antibody (subacute cutaneous lupus erythematosus [SCLE], 56 patients; Sjoegren's syndrome [SS], 41 patients; mothers of infants with neonatal LE [NLE], 10 individuals; infants with congenital heart block [CHB], 5 patients) were tested for reactivity to RoSP7-24 in ELISA.
p22565
sg16446
(lp22566
(dp22567
g16449
I61
sg16450
I2
sg16451
I21
sg16452
VP37268
p22568
sg16454
Vanti-SS-A/Ro antibody
p22569
sasg16456
(lp22570
(dp22571
g16449
I279
sg16450
I1
sg16451
I3
sg16459
VC0151517
p22572
sg16454
VCHB
p22573
sa(dp22574
g16449
I144
sg16450
I2
sg16451
I19
sg16459
VC1527336
p22575
sg16454
VSjoegren's syndrome
p22576
sa(dp22577
g16449
I255
sg16450
I3
sg16451
I22
sg16459
VC0149530
p22578
sg16454
Vcongenital heart block
p22579
sa(dp22580
g16449
I84
sg16450
I4
sg16451
I38
sg16459
VC0024140
p22581
sg16454
Vsubacute cutaneous lupus erythematosus
p22582
sasa(dp22583
g16444
VNLE is manifested most typically as transient subacute cutaneous lupus lesions or isolated complete congenital heart block.
p22584
sg16446
(lp22585
(dp22586
g16449
I0
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VNLE
p22587
sasg16456
(lp22588
(dp22589
g16449
I46
sg16450
I3
sg16451
I24
sg16459
VC2362320
p22590
sg16454
Vsubacute cutaneous lupus
p22591
sa(dp22592
g16449
I100
sg16450
I3
sg16451
I22
sg16459
VC0149530
p22593
sg16454
Vcongenital heart block
p22594
sasa(dp22595
g16444
VOur findings also suggested that the inhibitory effects of AC-93253 iodide on lung cancer progression may be attributable to its ability to modulate multiple proteins, including Src, PI3K, JNK, Paxillin, p130cas, MEK, ERK, and EGFR.
p22596
sg16446
(lp22597
(dp22598
g16449
I178
sg16450
I1
sg16451
I3
sg16452
VP12931
p22599
sg16454
VSrc
p22600
sa(dp22601
g16449
I204
sg16450
I1
sg16451
I7
sg16452
VP56945
p22602
sg16454
Vp130cas
p22603
sa(dp22604
g16449
I183
sg16450
I1
sg16451
I4
sg16452
VP42336
p22605
sg16454
VPI3K
p22606
sa(dp22607
g16449
I189
sg16450
I1
sg16451
I3
sg16452
VP53779
p22608
sg16454
VJNK
p22609
sa(dp22610
g16449
I218
sg16450
I1
sg16451
I3
sg16452
VP29323
p22611
sg16454
VERK
p22612
sa(dp22613
g16449
I194
sg16450
I1
sg16451
I8
sg16452
VP49023
p22614
sg16454
VPaxillin
p22615
sa(dp22616
g16449
I213
sg16450
I1
sg16451
I3
sg16452
VP45985
p22617
sg16454
VMEK
p22618
sasg16456
(lp22619
(dp22620
g16449
I83
sg16450
I2
sg16451
I18
sg16459
VC0178874
p22621
sg16454
Vcancer progression
p22622
sasa(dp22623
g16444
VPaxillin and FAK activity are reduced in lung cancer cell lines following wiskostatin and nWASP knockdown as shown by immunofluorescence and western blot.
p22624
sg16446
(lp22625
(dp22626
g16449
I13
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VFAK
p22627
sa(dp22628
g16449
I90
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VnWASP
p22629
sa(dp22630
g16449
I0
sg16450
I1
sg16451
I8
sg16452
VP49023
p22631
sg16454
VPaxillin
p22632
sasg16456
(lp22633
(dp22634
g16449
I41
sg16450
I2
sg16451
I11
sg16459
VC0684249
p22635
sg16454
Vlung cancer
p22636
sasa(dp22637
g16444
VTaken together, these results suggested that treatment with DBL may act as a potential candidate to inhibit lung cancer metastasis by inhibiting MMP-2 and -9 via affecting PI3K/AKT, MAPKs, FAK/paxillin, EMT/Snail and Slug, Nrf2/antioxidant enzymes, and NFKB signaling pathways.
p22638
sg16446
(lp22639
(dp22640
g16449
I189
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VFAK
p22641
sa(dp22642
g16449
I145
sg16450
I1
sg16451
I5
sg16452
VP08253
p22643
sg16454
VMMP-2
p22644
sa(dp22645
g16449
I217
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSlug
p22646
sa(dp22647
g16449
I177
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VAKT
p22648
sa(dp22649
g16449
I203
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VEMT
p22650
sa(dp22651
g16449
I172
sg16450
I1
sg16451
I4
sg16452
VP42336
p22652
sg16454
VPI3K
p22653
sa(dp22654
g16449
I223
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VNrf2
p22655
sa(dp22656
g16449
I253
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VNFKB
p22657
sa(dp22658
g16449
I182
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VMAPKs
p22659
sa(dp22660
g16449
I207
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSnail
p22661
sa(dp22662
g16449
I193
sg16450
I1
sg16451
I8
sg16452
VP49023
p22663
sg16454
Vpaxillin
p22664
sasg16456
(lp22665
(dp22666
g16449
I108
sg16450
I2
sg16451
I11
sg16459
VC0684249
p22667
sg16454
Vlung cancer
p22668
sa(dp22669
g16449
I120
sg16450
I1
sg16451
I10
sg16459
VC0027627
p22670
sg16454
Vmetastasis
p22671
sasa(dp22672
g16444
VEL decreased phosphorylation of FAK and its downstream targets, Src, paxillin, and decreased mRNA expression of cell motility-related genes, RhoA, Rac1, and Cdc42 in lung cancer cells.
p22673
sg16446
(lp22674
(dp22675
g16449
I147
sg16450
I1
sg16451
I4
sg16452
VP63000
p22676
sg16454
VRac1
p22677
sa(dp22678
g16449
I141
sg16450
I1
sg16451
I4
sg16452
VP61586
p22679
sg16454
VRhoA
p22680
sa(dp22681
g16449
I32
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VFAK
p22682
sa(dp22683
g16449
I64
sg16450
I1
sg16451
I3
sg16452
VP12931
p22684
sg16454
VSrc
p22685
sa(dp22686
g16449
I157
sg16450
I1
sg16451
I5
sg16452
VP60953
p22687
sg16454
VCdc42
p22688
sa(dp22689
g16449
I69
sg16450
I1
sg16451
I8
sg16452
VP49023
p22690
sg16454
Vpaxillin
p22691
sasg16456
(lp22692
(dp22693
g16449
I166
sg16450
I2
sg16451
I11
sg16459
VC0684249
p22694
sg16454
Vlung cancer
p22695
sasa(dp22696
g16444
VIt efficiently inhibits metastasis on NSCLC by reducing vascularization, and eliciting depression of the PI3K-AKT and FAK-Paxillin signaling pathways.
p22697
sg16446
(lp22698
(dp22699
g16449
I122
sg16450
I1
sg16451
I8
sg16452
VP49023
p22700
sg16454
VPaxillin
p22701
sa(dp22702
g16449
I110
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VAKT
p22703
sa(dp22704
g16449
I105
sg16450
I1
sg16451
I4
sg16452
VP42336
p22705
sg16454
VPI3K
p22706
sa(dp22707
g16449
I118
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VFAK
p22708
sasg16456
(lp22709
(dp22710
g16449
I38
sg16450
I1
sg16451
I5
sg16459
VC0007131
p22711
sg16454
VNSCLC
p22712
sa(dp22713
g16449
I24
sg16450
I1
sg16451
I10
sg16459
VC0027627
p22714
sg16454
Vmetastasis
p22715
sa(dp22716
g16449
I87
sg16450
I1
sg16451
I10
sg16459
VC0011581
p22717
sg16454
Vdepression
p22718
sa(dp22719
g16449
I56
sg16450
I1
sg16451
I15
sg16459
VC0027686
p22720
sg16454
Vvascularization
p22721
sasa(dp22722
g16444
VHere, we assessed the impact of CD101 on the course of inflammatory bowel disease (IBD).
p22723
sg16446
(lp22724
(dp22725
g16449
I32
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCD101
p22726
sasg16456
(lp22727
(dp22728
g16449
I83
sg16450
I1
sg16451
I3
sg16459
VC0021390
p22729
sg16454
VIBD
p22730
sa(dp22731
g16449
I55
sg16450
I3
sg16451
I26
sg16459
VC0021390
p22732
sg16454
Vinflammatory bowel disease
p22733
sasa(dp22734
g16444
VUsing a T-cell transfer model of chronic colitis, we found that in recipients of naive T cells from CD101(+/+) donors up to 30% of the recovered lymphocytes expressed CD101, correlating with an increased interleukin (IL)-2-mediated FoxP3 expression.
p22735
sg16446
(lp22736
(dp22737
g16449
I204
sg16450
I2
sg16451
I18
sg16452
VP60568
p22738
sg16454
Vinterleukin (IL)-2
p22739
sa(dp22740
g16449
I232
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VFoxP3
p22741
sa(dp22742
g16449
I100
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCD101
p22743
sasg16456
(lp22744
(dp22745
g16449
I33
sg16450
I2
sg16451
I15
sg16459
VC0267375
p22746
sg16454
Vchronic colitis
p22747
sasa(dp22748
g16444
VTransfer of CD101(-/-) T cells caused more severe colitis and was associated with an expansion of IL-17-producing T cells and an enhanced expression of IL-2RAlfa/Beta independently of FoxP3.
p22749
sg16446
(lp22750
(dp22751
g16449
I184
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VFoxP3
p22752
sasg16456
(lp22753
(dp22754
g16449
I50
sg16450
I1
sg16451
I7
sg16459
VC0009319
p22755
sg16454
Vcolitis
p22756
sasa(dp22757
g16444
VThe co-transfer of naive and regulatory T cells (Treg) protected most effectively from colitis, when both donor and recipient mice expressed CD101.
p22758
sg16446
(lp22759
(dp22760
g16449
I141
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCD101
p22761
sasg16456
(lp22762
(dp22763
g16449
I87
sg16450
I1
sg16451
I7
sg16459
VC0009319
p22764
sg16454
Vcolitis
p22765
sasa(dp22766
g16444
VThus, CD101 deficiency is a novel marker for progressive colitis and potential target for therapeutic intervention.
p22767
sg16446
(lp22768
(dp22769
g16449
I6
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCD101
p22770
sasg16456
(lp22771
(dp22772
g16449
I57
sg16450
I1
sg16451
I7
sg16459
VC0009319
p22773
sg16454
Vcolitis
p22774
sasa(dp22775
g16444
VSubgroups of T cells (Th : CD4(+) or Tc : CD8(+) ); naive (CD27(+) CD28(+) CD45RA(+) CCR7(+) ), central memory (CD27(+) CD28(+) CD45RA(-) CCR7(+) ), effector memory (early differentiated; CD27(+) CD28(+) CD45RA(-) CCR7(-) and late differentiated; CD27(-) CD28(-) CD45RA(-) CCR7(-) ), terminally differentiated effector cells (TEMRA; CD27(-) CD28(-) CD45RA(+) CCR7(-) ) and Treg (CD4(+) CD25(+) FOXP3(+) CD127(-) ) cells, and their expression of CD39, CD45RA, CD101 and CD129, were studied by flow cytometry in T1D and/or coeliac disease children or without any of these diseases (reference group).
p22776
sg16446
(lp22777
(dp22778
g16449
I247
sg16450
I1
sg16451
I7
sg16452
VP26842
p22779
sg16454
VCD27(-)
p22780
sa(dp22781
g16449
I445
sg16450
I1
sg16451
I4
sg16452
VP49961
p22782
sg16454
VCD39
p22783
sa(dp22784
g16449
I255
sg16450
I3
sg16451
I22
sg16452
VP33681
p22785
sg16454
VCD28(-) CD45RA(-) CCR7
p22786
sa(dp22787
g16449
I27
sg16450
I1
sg16451
I3
sg16452
VP01730
p22788
sg16454
VCD4
p22789
sa(dp22790
g16449
I341
sg16450
I3
sg16451
I22
sg16452
VP33681
p22791
sg16454
VCD28(-) CD45RA(+) CCR7
p22792
sa(dp22793
g16449
I247
sg16450
I1
sg16451
I7
sg16452
VP26842
p22794
sg16454
VCD27(-)
p22795
sa(dp22796
g16449
I112
sg16450
I4
sg16451
I30
sg16452
VP26842
p22797
sg16454
VCD27(+) CD28(+) CD45RA(-) CCR7
p22798
sa(dp22799
g16449
I42
sg16450
I1
sg16451
I3
sg16452
VP01732
p22800
sg16454
VCD8
p22801
sa(dp22802
g16449
I59
sg16450
I4
sg16451
I30
sg16452
VP26842
p22803
sg16454
VCD27(+) CD28(+) CD45RA(+) CCR7
p22804
sa(dp22805
g16449
I188
sg16450
I4
sg16451
I33
sg16452
VP26842
p22806
sg16454
VCD27(+) CD28(+) CD45RA(-) CCR7(-)
p22807
sa(dp22808
g16449
I459
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCD101
p22809
sa(dp22810
g16449
I469
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCD129
p22811
sa(dp22812
g16449
I379
sg16450
I4
sg16451
I29
sg16452
VP01730
p22813
sg16454
VCD4(+) CD25(+) FOXP3(+) CD127
p22814
sasg16456
(lp22815
(dp22816
g16449
I521
sg16450
I2
sg16451
I15
sg16459
VC0007570
p22817
sg16454
Vcoeliac disease
p22818
sasa(dp22819
g16444
VChildren with exclusively coeliac disease had a higher MFI of CD101 (P &lt; 0*01), as well as a higher percentage of CD129(+) (P &lt; 0*05), in the CD4(+) CD25(hi) lymphocyte population, compared to references.
p22820
sg16446
(lp22821
(dp22822
g16449
I62
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCD101
p22823
sa(dp22824
g16449
I148
sg16450
I2
sg16451
I11
sg16452
VP01730
p22825
sg16454
VCD4(+) CD25
p22826
sasg16456
(lp22827
(dp22828
g16449
I26
sg16450
I2
sg16451
I15
sg16459
VC0007570
p22829
sg16454
Vcoeliac disease
p22830
sasa(dp22831
g16444
VConversely, children with coeliac disease show signs of CD101(+) /CD129(+) Treg cells that may indicate suppressor activity.
p22832
sg16446
(lp22833
(dp22834
g16449
I66
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCD129
p22835
sasg16456
(lp22836
(dp22837
g16449
I26
sg16450
I2
sg16451
I15
sg16459
VC0007570
p22838
sg16454
Vcoeliac disease
p22839
sasa(dp22840
g16444
VFurther, to define the mechanism of action that explains the differential ability of C57BL/6 Treg versus dnTGF-BetaRII Treg on the ability to down-regulate autoimmune cholangitis, we noted significant differential expression of glycoprotein A repetitions predominant (GARP), CD73, CD101 and CD103 and a functionally significant increase in interleukin (IL)-10 in Treg from C57BL/6 compared to dnTGF-BetaRII mice.
p22841
sg16446
(lp22842
(dp22843
g16449
I340
sg16450
I2
sg16451
I19
sg16452
VP60568
p22844
sg16454
Vinterleukin (IL)-10
p22845
sa(dp22846
g16449
I275
sg16450
I1
sg16451
I4
sg16452
VP21589
p22847
sg16454
VCD73
p22848
sa(dp22849
g16449
I291
sg16450
I1
sg16451
I5
sg16452
VP38570
p22850
sg16454
VCD103
p22851
sa(dp22852
g16449
I281
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCD101
p22853
sa(dp22854
g16449
I228
sg16450
I4
sg16451
I38
sg16452
VP55822
p22855
sg16454
Vglycoprotein A repetitions predominant
p22856
sa(dp22857
g16449
I268
sg16450
I1
sg16451
I4
sg16452
VP55822
p22858
sg16454
VGARP
p22859
sasg16456
(lp22860
(dp22861
g16449
I167
sg16450
I1
sg16451
I11
sg16459
VC0008311
p22862
sg16454
Vcholangitis
p22863
sa(dp22864
g16449
I156
sg16450
I1
sg16451
I10
sg16459
VC0443146
p22865
sg16454
Vautoimmune
p22866
sasa(dp22867
g16444
VCD101-knockout mice generated on the B6 background also exhibit substantially more severe N. aromaticivorans-induced liver disease correlating with increased IFN-Gamma and IL-17 responses compared with wild-type mice.
p22868
sg16446
(lp22869
(dp22870
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCD101
p22871
sa(dp22872
g16449
I158
sg16450
I1
sg16451
I9
sg16452
VP01579
p22873
sg16454
VIFN-Gamma
p22874
sasg16456
(lp22875
(dp22876
g16449
I117
sg16450
I2
sg16451
I13
sg16459
VC0023895
p22877
sg16454
Vliver disease
p22878
sasa(dp22879
g16444
VGastric juice from 15 normals, 20 patients with gastric ulcer and 14 patients with erosive haemorrhagic gastroduodenitis was investigated in respect of its activity on unheated and heated fibrin plates and its content of FDP and plasminogen or plasmin with immunochemical methods.
p22880
sg16446
(lp22881
(dp22882
g16449
I188
sg16450
I1
sg16451
I6
sg16452
VP22087
p22883
sg16454
Vfibrin
p22884
sa(dp22885
g16449
I221
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VFDP
p22886
sa(dp22887
g16449
I229
sg16450
I1
sg16451
I11
sg16452
VP00747
p22888
sg16454
Vplasminogen
p22889
sa(dp22890
g16449
I229
sg16450
I1
sg16451
I7
sg16452
VP00747
p22891
sg16454
Vplasmin
p22892
sasg16456
(lp22893
(dp22894
g16449
I48
sg16450
I2
sg16451
I13
sg16459
VC0038358
p22895
sg16454
Vgastric ulcer
p22896
sa(dp22897
g16449
I104
sg16450
I1
sg16451
I16
sg16459
VC0267166
p22898
sg16454
Vgastroduodenitis
p22899
sasa(dp22900
g16444
VThe patients with erosive haemorrhagic gastroduodenitis showed no increase in fibrinolysis in the blood, but low values for plasminogen and alpha2-M, and the serum contained FDP.
p22901
sg16446
(lp22902
(dp22903
g16449
I174
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VFDP
p22904
sa(dp22905
g16449
I124
sg16450
I1
sg16451
I11
sg16452
VP00747
p22906
sg16454
Vplasminogen
p22907
sasg16456
(lp22908
(dp22909
g16449
I39
sg16450
I1
sg16451
I16
sg16459
VC0267166
p22910
sg16454
Vgastroduodenitis
p22911
sasa(dp22912
g16444
VIn the patient's lymphocytes, mRNA expression of TGFBeta2 was lower than control, and might cause DORV as it does in TGFBeta2-deficient mice.
p22913
sg16446
(lp22914
sg16456
(lp22915
(dp22916
g16449
I98
sg16450
I1
sg16451
I4
sg16459
VC0013069
p22917
sg16454
VDORV
p22918
sasa(dp22919
g16444
VActivin BA, follistatin, and activin receptor type IIA proteins were observed in normal and cleft palate tissues throughout pregnancy (gestational weeks 11 to 40).
p22920
sg16446
(lp22921
(dp22922
g16449
I0
sg16450
I1
sg16451
I7
sg16452
VP58166
p22923
sg16454
VActivin
p22924
sa(dp22925
g16449
I29
sg16450
I5
sg16451
I34
sg16452
VP27037
p22926
sg16454
Vactivin receptor type IIA proteins
p22927
sasg16456
(lp22928
(dp22929
g16449
I92
sg16450
I2
sg16451
I12
sg16459
VC0008925
p22930
sg16454
Vcleft palate
p22931
sasa(dp22932
g16444
VWe have previously shown that follistatin-deficient mice have numerous embryonic defects including shiny, taut skin, growth retardation, and cleft palate leading to death within hours of birth.
p22933
sg16446
(lp22934
(dp22935
g16449
I30
sg16450
I1
sg16451
I11
sg16452
VP19883
p22936
sg16454
Vfollistatin
p22937
sasg16456
(lp22938
(dp22939
g16449
I117
sg16450
I2
sg16451
I18
sg16459
VC0151686
p22940
sg16454
Vgrowth retardation
p22941
sa(dp22942
g16449
I141
sg16450
I2
sg16451
I12
sg16459
VC0008925
p22943
sg16454
Vcleft palate
p22944
sasa(dp22945
g16444
VTwo rheumatic disease patients had a relatively high titer of IgG(2)anti-p80-coilin antibodies.
p22946
sg16446
(lp22947
(dp22948
g16449
I62
sg16450
I2
sg16451
I32
sg16452
VP38432
p22949
sg16454
VIgG(2)anti-p80-coilin antibodies
p22950
sasg16456
(lp22951
(dp22952
g16449
I4
sg16450
I2
sg16451
I17
sg16459
VC0035435
p22953
sg16454
Vrheumatic disease
p22954
sasa(dp22955
g16444
VThe IgG(2)subclass of anti-p80-coilin antibodies may be a specific marker for systemic autoimmune disease.
p22956
sg16446
(lp22957
(dp22958
g16449
I22
sg16450
I2
sg16451
I26
sg16452
VP38432
p22959
sg16454
Vanti-p80-coilin antibodies
p22960
sasg16456
(lp22961
(dp22962
g16449
I78
sg16450
I3
sg16451
I27
sg16459
VC2895206
p22963
sg16454
Vsystemic autoimmune disease
p22964
sasa(dp22965
g16444
VThe patients with localized scleroderma who were positive for anti-p80-coilin antibody had all been classified as having linear scleroderma.
p22966
sg16446
(lp22967
(dp22968
g16449
I62
sg16450
I2
sg16451
I24
sg16452
VP38432
p22969
sg16454
Vanti-p80-coilin antibody
p22970
sasg16456
(lp22971
(dp22972
g16449
I18
sg16450
I2
sg16451
I21
sg16459
VC0036420
p22973
sg16454
Vlocalized scleroderma
p22974
sa(dp22975
g16449
I121
sg16450
I2
sg16451
I18
sg16459
VC0263409
p22976
sg16454
Vlinear scleroderma
p22977
sasa(dp22978
g16444
VOur data indicate that anti-p80-coilin antibody is uncommon in skin diseases: however, this antibody is present in patients with a milder form of linear scleroderma, although the incidence of positivity may not be high.
p22979
sg16446
(lp22980
(dp22981
g16449
I23
sg16450
I2
sg16451
I24
sg16452
VP38432
p22982
sg16454
Vanti-p80-coilin antibody
p22983
sasg16456
(lp22984
(dp22985
g16449
I63
sg16450
I2
sg16451
I13
sg16459
VC0037274
p22986
sg16454
Vskin diseases
p22987
sa(dp22988
g16449
I146
sg16450
I2
sg16451
I18
sg16459
VC0263409
p22989
sg16454
Vlinear scleroderma
p22990
sasa(dp22991
g16444
VWe also discuss several of the antigen-autoantibody systems found in systemic lupus erythematosus (Smith antigen, U1-nuclear ribonucleoprotein, SS-A/Ro, SS-B/La, proliferating cell nuclear antigen ribosomal ribonucleoprotein, double-strand DNA, histones, antiphospholipids, Ku, Ki/SL), systemic sclerosis (centromere, topo I, RNA polymerases, fibrillarin, polymyositis-Scl, Th/To), polymyositis/dermatomyositis (transferRNA synthetases, signal recognition particle, and others), and SS (SS-A/Ro, SS-B/La, nucleolar organizing region-90, p80-coilin), addressing their clinical significance, common detection methods, immunogenetic associations, and the molecular and cellular biology of the cognate antigens.
p22992
sg16446
(lp22993
(dp22994
g16449
I162
sg16450
I6
sg16451
I62
sg16452
VP12004
p22995
sg16454
Vproliferating cell nuclear antigen ribosomal ribonucleoprotein
p22996
sa(dp22997
g16449
I144
sg16450
I1
sg16451
I4
sg16452
VP37268
p22998
sg16454
VSS-A
p22999
sa(dp23000
g16449
I326
sg16450
I2
sg16451
I15
sg16452
g11
sg16454
VRNA polymerases
p23001
sa(dp23002
g16449
I343
sg16450
I1
sg16451
I11
sg16452
VP22087
p23003
sg16454
Vfibrillarin
p23004
sa(dp23005
g16449
I537
sg16450
I1
sg16451
I3
sg16452
VP20333
p23006
sg16454
Vp80
p23007
sa(dp23008
g16449
I153
sg16450
I1
sg16451
I4
sg16452
VP37268
p23009
sg16454
VSS-B
p23010
sa(dp23011
g16449
I114
sg16450
I2
sg16451
I28
sg16452
VP26599
p23012
sg16454
VU1-nuclear ribonucleoprotein
p23013
sa(dp23014
g16449
I541
sg16450
I1
sg16451
I6
sg16452
VP38432
p23015
sg16454
Vcoilin
p23016
sa(dp23017
g16449
I99
sg16450
I2
sg16451
I13
sg16452
VP14209
p23018
sg16454
VSmith antigen
p23019
sa(dp23020
g16449
I153
sg16450
I1
sg16451
I4
sg16452
VP37268
p23021
sg16454
VSS-B
p23022
sasg16456
(lp23023
(dp23024
g16449
I286
sg16450
I2
sg16451
I18
sg16459
VC0036421
p23025
sg16454
Vsystemic sclerosis
p23026
sa(dp23027
g16449
I356
sg16450
I1
sg16451
I12
sg16459
VC0085655
p23028
sg16454
Vpolymyositis
p23029
sa(dp23030
g16449
I69
sg16450
I3
sg16451
I28
sg16459
VC0024141
p23031
sg16454
Vsystemic lupus erythematosus
p23032
sa(dp23033
g16449
I356
sg16450
I1
sg16451
I12
sg16459
VC0085655
p23034
sg16454
Vpolymyositis
p23035
sa(dp23036
g16449
I395
sg16450
I1
sg16451
I15
sg16459
VC0221056
p23037
sg16454
Vdermatomyositis
p23038
sasa(dp23039
g16444
VHowever, IL-17 deficiency did not affect the development of dermatitis at all, in clear contrast to that of arthritis and aortitis.
p23040
sg16446
(lp23041
sg16456
(lp23042
(dp23043
g16449
I108
sg16450
I1
sg16451
I9
sg16459
VC0003864
p23044
sg16454
Varthritis
p23045
sa(dp23046
g16449
I122
sg16450
I1
sg16451
I8
sg16459
VC0003509
p23047
sg16454
Vaortitis
p23048
sa(dp23049
g16449
I60
sg16450
I1
sg16451
I10
sg16459
VC0011603
p23050
sg16454
Vdermatitis
p23051
sasa(dp23052
g16444
VThe development of arthritis and aortitis was significantly suppressed by the deficiency of TNFalpha or IL-17.
p23053
sg16446
(lp23054
(dp23055
g16449
I92
sg16450
I1
sg16451
I8
sg16452
VP01375
p23056
sg16454
VTNFalpha
p23057
sasg16456
(lp23058
(dp23059
g16449
I19
sg16450
I1
sg16451
I9
sg16459
VC0003864
p23060
sg16454
Varthritis
p23061
sa(dp23062
g16449
I33
sg16450
I1
sg16451
I8
sg16459
VC0003509
p23063
sg16454
Vaortitis
p23064
sasa(dp23065
g16444
VApolipoprotein E (ApoE) has been extensively studied in Alzheimer's disease (AD), but little is known of apolipoprotein A-I (ApoA-I) in cerebrospinal fluid (CSF).
p23066
sg16446
(lp23067
(dp23068
g16449
I105
sg16450
I2
sg16451
I18
sg16452
VP02647
p23069
sg16454
Vapolipoprotein A-I
p23070
sa(dp23071
g16449
I18
sg16450
I1
sg16451
I4
sg16452
VP02649
p23072
sg16454
VApoE
p23073
sa(dp23074
g16449
I0
sg16450
I2
sg16451
I16
sg16452
VP02649
p23075
sg16454
VApolipoprotein E
p23076
sa(dp23077
g16449
I125
sg16450
I1
sg16451
I6
sg16452
VP02647
p23078
sg16454
VApoA-I
p23079
sasg16456
(lp23080
(dp23081
g16449
I56
sg16450
I2
sg16451
I19
sg16459
VC1521724
p23082
sg16454
VAlzheimer's disease
p23083
sa(dp23084
g16449
I77
sg16450
I1
sg16451
I2
sg16459
VC1521724
p23085
sg16454
VAD
p23086
sasa(dp23087
g16444
VObjective To evaluate the efficacy of Ganoderma lucidum preparation on the behaviors,biochemistry,and autoimmunity parameters of mouse models of APP/PS-1 double transgenic Alzheimer's disease(AD).Methods A total of 44 4-month-old APP/PS-1 double transgenic AD mice were randomly divided into AD model group,Aricept group,Ganoderma lucidum middle-dose(LZ-M)group,and Ganoderma lucidum high-dose(LZ-H)group,with 11 mice in each group.In addition,10 4-month-old C57BL/6 mice were used as the control group.Water maze test was conducted to observe the behavior changes,and the protein expressions in brain tissues were detected by Western blot analysis.The autoimmune indicators were detected by indirect immunofluorescence method.Results In the navigation experiment,the time of finding the platform was gradually shortened since the 2nd day in the control,LZ-H,and LZ-M groups,and the time of searching the platform in the AD model group gradually increased.On the 5th day,the time of finding platform was significantly shorter in control group (t=5.607,P=0.000) and LZ-H group(t=2.750,P=0.010)than AD model group.In the space exploration experiment,the number of crossing the target platform(t=2.452,P=0.025)and the residence time in the target quadrant(t=2.530,P=0.020)in AD model group mice was significantly smaller/shorter than those in control group;in addition,the number of crossing the target platform in the AD model group was significantly smaller than that in LZ-H group(t=2.317,P=0.030)and LZ-M group(t=2.443,P=0.030),while the residence time in target quadrant decreased significantly(t=2.770,P=0.020)compared with LZ-H group;the number of crossing through the target platform quadrant(t=2.493,P=0.022)and residence time in the target quadrant(t=2.683,P=0.015)in LZ-H group were significantly higher than in Aricept group.Western blot analysis showed that the expression of ApoA1 in the brain tissues of mice in LZ-H and LZ-M groups were significantly higher than those in AD model group(P&lt;0.01,P&lt;0.05);ABeta-40 expression in LZ-H group was significantly lower than that in AD model group(P&lt;0.05);the expressions of Syt1,ApoE,and ABCA1 in brain tissues of mice in LZ-H group were significantly higher than those in model group(P&lt;0.01,P&lt;0.05).The plasma IgG level in Aricept group(t=30.945,P=0.000),LZ-M group(t=25.639,P=0.000)and LZ-H group(t=4.689,P=0.001)were significantly higher than that in the control group.Conclusion Ganoderma lucidum preparation can improve behavior disorders of AD model mice,promote the expressions of ApoA1,ApoE and Syt1,inhibit the expression of ABeta-40 protein,and improve the autoimmune function.
p23088
sg16446
(lp23089
(dp23090
g16449
I2137
sg16450
I1
sg16451
I4
sg16452
VP21579
p23091
sg16454
VSyt1
p23092
sa(dp23093
g16449
I1886
sg16450
I1
sg16451
I5
sg16452
VP02647
p23094
sg16454
VApoA1
p23095
sa(dp23096
g16449
I1065
sg16450
I2
sg16451
I10
sg16452
VP00390
p23097
sg16454
VLZ-H group
p23098
sa(dp23099
g16449
I2142
sg16450
I1
sg16451
I4
sg16452
VP02649
p23100
sg16454
VApoE
p23101
sa(dp23102
g16449
I145
sg16450
I1
sg16451
I8
sg16452
VP48651
p23103
sg16454
VAPP/PS-1
p23104
sa(dp23105
g16449
I2142
sg16450
I1
sg16451
I4
sg16452
VP02649
p23106
sg16454
VApoE
p23107
sa(dp23108
g16449
I2603
sg16450
I2
sg16451
I16
sg16452
g11
sg16454
VABeta-40 protein
p23109
sa(dp23110
g16449
I1886
sg16450
I1
sg16451
I5
sg16452
VP02647
p23111
sg16454
VApoA1
p23112
sa(dp23113
g16449
I2021
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VABeta-40
p23114
sa(dp23115
g16449
I1065
sg16450
I2
sg16451
I10
sg16452
VP00390
p23116
sg16454
VLZ-H group
p23117
sa(dp23118
g16449
I145
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VAPP
p23119
sa(dp23120
g16449
I1065
sg16450
I2
sg16451
I10
sg16452
VP00390
p23121
sg16454
VLZ-H group
p23122
sa(dp23123
g16449
I149
sg16450
I1
sg16451
I4
sg16452
VP48651
p23124
sg16454
VPS-1
p23125
sa(dp23126
g16449
I2137
sg16450
I1
sg16451
I4
sg16452
VP21579
p23127
sg16454
VSyt1
p23128
sasg16456
(lp23129
(dp23130
g16449
I102
sg16450
I1
sg16451
I12
sg16459
VC0004368
p23131
sg16454
Vautoimmunity
p23132
sa(dp23133
g16449
I172
sg16450
I2
sg16451
I19
sg16459
VC1521724
p23134
sg16454
VAlzheimer's disease
p23135
sa(dp23136
g16449
I2494
sg16450
I2
sg16451
I18
sg16459
VC0004930
p23137
sg16454
Vbehavior disorders
p23138
sa(dp23139
g16449
I653
sg16450
I1
sg16451
I10
sg16459
VC0443146
p23140
sg16454
Vautoimmune
p23141
sa(dp23142
g16449
I653
sg16450
I1
sg16451
I10
sg16459
VC0443146
p23143
sg16454
Vautoimmune
p23144
sasa(dp23145
g16444
VWe aimed to explore the correlations between eukaryotic translation initiation factor 3, subunit A (eIF3a) polymorphisms and susceptibility to and chemoradiotherapy efficacy in cervical carcinoma.
p23146
sg16446
(lp23147
(dp23148
g16449
I100
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VeIF3a
p23149
sasg16456
(lp23150
(dp23151
g16449
I177
sg16450
I2
sg16451
I18
sg16459
VC0302592
p23152
sg16454
Vcervical carcinoma
p23153
sasa(dp23154
g16444
VCompared with carriers of the CC genotype, carriers of the T genotype of the eIF3a Arg803Lys C&gt;T polymorphism had a higher risk of cervical carcinoma.
p23155
sg16446
(lp23156
(dp23157
g16449
I77
sg16450
I3
sg16451
I17
sg16452
g11
sg16454
VeIF3a Arg803Lys C
p23158
sasg16456
(lp23159
(dp23160
g16449
I134
sg16450
I2
sg16451
I18
sg16459
VC0302592
p23161
sg16454
Vcervical carcinoma
p23162
sasa(dp23163
g16444
VUnivariate analysis revealed that age, eIF3a Arg803Lys C&gt;T polymorphism, differentiation degree, FIGO stage, and LNM were prognostic factors of cervical carcinoma, and multivariate analysis showed that age &gt;= 60 years, higher FIGO stage, and LNM, as well as the CT and TT genotypes of the eIF3a Arg803Lys C&gt;T polymorphism, were risk factors related to the prognosis of cervical carcinoma.
p23164
sg16446
(lp23165
(dp23166
g16449
I39
sg16450
I3
sg16451
I17
sg16452
g11
sg16454
VeIF3a Arg803Lys C
p23167
sa(dp23168
g16449
I39
sg16450
I3
sg16451
I17
sg16452
g11
sg16454
VeIF3a Arg803Lys C
p23169
sasg16456
(lp23170
(dp23171
g16449
I147
sg16450
I2
sg16451
I18
sg16459
VC0302592
p23172
sg16454
Vcervical carcinoma
p23173
sa(dp23174
g16449
I147
sg16450
I2
sg16451
I18
sg16459
VC0302592
p23175
sg16454
Vcervical carcinoma
p23176
sasa(dp23177
g16444
VThe eIF3a Arg803Lys C&gt;T polymorphism is connected with a higher susceptibility to cervical carcinoma and may affect chemoradiotherapy efficacy in and prognosis of cervical carcinoma.
p23178
sg16446
(lp23179
(dp23180
g16449
I4
sg16450
I3
sg16451
I17
sg16452
g11
sg16454
VeIF3a Arg803Lys C
p23181
sasg16456
(lp23182
(dp23183
g16449
I85
sg16450
I2
sg16451
I18
sg16459
VC0302592
p23184
sg16454
Vcervical carcinoma
p23185
sa(dp23186
g16449
I85
sg16450
I2
sg16451
I18
sg16459
VC0302592
p23187
sg16454
Vcervical carcinoma
p23188
sasa(dp23189
g16444
VThese findings suggest that the p185 neu may be a prognostic indicator not only for breast adenocarcinomas but also for lymphoproliferative disorders, and that the transforming p185 protein may be involved in the mechanisms of aggressive expansion of lymphoid neoplasias.
p23190
sg16446
(lp23191
(dp23192
g16449
I37
sg16450
I1
sg16451
I3
sg16452
VP04626
p23193
sg16454
Vneu
p23194
sa(dp23195
g16449
I32
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
Vp185
p23196
sa(dp23197
g16449
I177
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
Vp185 protein
p23198
sasg16456
(lp23199
(dp23200
g16449
I227
sg16450
I1
sg16451
I10
sg16459
VC0001807
p23201
sg16454
Vaggressive
p23202
sa(dp23203
g16449
I91
sg16450
I1
sg16451
I15
sg16459
VC0001418
p23204
sg16454
Vadenocarcinomas
p23205
sa(dp23206
g16449
I120
sg16450
I2
sg16451
I29
sg16459
VC0024314
p23207
sg16454
Vlymphoproliferative disorders
p23208
sa(dp23209
g16449
I260
sg16450
I1
sg16451
I10
sg16459
VC0027651
p23210
sg16454
Vneoplasias
p23211
sasa(dp23212
g16444
VThe authors investigated the correlation between clinicopathologic factors and the overexpression of the p185(HER2) in Korean gastric adenocarcinoma patients, and determined whether the antiproliferative effects of anti- p185(HER2) antibody can also be observed on gastric cancer cell lines that overexpress this growth factor receptor.
p23213
sg16446
(lp23214
(dp23215
g16449
I215
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
Vanti- p185
p23216
sa(dp23217
g16449
I110
sg16450
I1
sg16451
I4
sg16452
VP04626
p23218
sg16454
VHER2
p23219
sa(dp23220
g16449
I105
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
Vp185
p23221
sa(dp23222
g16449
I313
sg16450
I3
sg16451
I22
sg16452
g11
sg16454
Vgrowth factor receptor
p23223
sa(dp23224
g16449
I110
sg16450
I1
sg16451
I4
sg16452
VP04626
p23225
sg16454
VHER2
p23226
sasg16456
(lp23227
(dp23228
g16449
I265
sg16450
I2
sg16451
I14
sg16459
VC0024623
p23229
sg16454
Vgastric cancer
p23230
sa(dp23231
g16449
I126
sg16450
I2
sg16451
I22
sg16459
VC0278701
p23232
sg16454
Vgastric adenocarcinoma
p23233
sasa(dp23234
g16444
VWe evaluated the relationship between p185(HER2) overexpression and clinicopathological features in 94 (M: F=52: 42) gastric adenocarcinoma patients (median age 59 years).
p23235
sg16446
(lp23236
(dp23237
g16449
I43
sg16450
I1
sg16451
I4
sg16452
VP04626
p23238
sg16454
VHER2
p23239
sa(dp23240
g16449
I38
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
Vp185
p23241
sasg16456
(lp23242
(dp23243
g16449
I117
sg16450
I2
sg16451
I22
sg16459
VC0278701
p23244
sg16454
Vgastric adenocarcinoma
p23245
sasa(dp23246
g16444
VTo explore the role of humanized anti-p185(HER2) monoclonal antibody trastuzumab (Herceptin ) in vitro, the growth curve of Korean gastric cancer cells that overexpress the p185(HER2) protein was studied and a cell cycle analysis was performed.
p23247
sg16446
(lp23248
(dp23249
g16449
I43
sg16450
I1
sg16451
I4
sg16452
VP04626
p23250
sg16454
VHER2
p23251
sa(dp23252
g16449
I23
sg16450
I2
sg16451
I19
sg16452
g11
sg16454
Vhumanized anti-p185
p23253
sa(dp23254
g16449
I43
sg16450
I1
sg16451
I4
sg16452
VP04626
p23255
sg16454
VHER2
p23256
sa(dp23257
g16449
I38
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
Vp185
p23258
sasg16456
(lp23259
(dp23260
g16449
I131
sg16450
I2
sg16451
I14
sg16459
VC0024623
p23261
sg16454
Vgastric cancer
p23262
sasa(dp23263
g16444
Vp185(HER2) overexpression was found to be more frequent in advanced gastric cancer than early gastric cancer (54.1% vs 24.2%, p=0.008).
p23264
sg16446
(lp23265
(dp23266
g16449
I5
sg16450
I1
sg16451
I4
sg16452
VP04626
p23267
sg16454
VHER2
p23268
sa(dp23269
g16449
I0
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
Vp185
p23270
sasg16456
(lp23271
(dp23272
g16449
I88
sg16450
I3
sg16451
I20
sg16459
VC0349530
p23273
sg16454
Vearly gastric cancer
p23274
sa(dp23275
g16449
I68
sg16450
I2
sg16451
I14
sg16459
VC0024623
p23276
sg16454
Vgastric cancer
p23277
sasa(dp23278
g16444
VAmong several Korean gastric cancer cell lines, SNU-1, SNU-5, and SNU-620 overexpress p185(HER2).
p23279
sg16446
(lp23280
(dp23281
g16449
I86
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
Vp185
p23282
sa(dp23283
g16449
I91
sg16450
I1
sg16451
I4
sg16452
VP04626
p23284
sg16454
VHER2
p23285
sasg16456
(lp23286
(dp23287
g16449
I21
sg16450
I2
sg16451
I14
sg16459
VC0024623
p23288
sg16454
Vgastric cancer
p23289
sasa(dp23290
g16444
VTrastuzumab inhibited the proliferation of p185(HER2) overexpressed Korean gastric cancer cell line by 21% with down-regulation of p185(HER2) protein expression.
p23291
sg16446
(lp23292
(dp23293
g16449
I43
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
Vp185
p23294
sa(dp23295
g16449
I48
sg16450
I1
sg16451
I4
sg16452
VP04626
p23296
sg16454
VHER2
p23297
sa(dp23298
g16449
I48
sg16450
I1
sg16451
I4
sg16452
VP04626
p23299
sg16454
VHER2
p23300
sa(dp23301
g16449
I43
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
Vp185
p23302
sasg16456
(lp23303
(dp23304
g16449
I75
sg16450
I2
sg16451
I14
sg16459
VC0024623
p23305
sg16454
Vgastric cancer
p23306
sa(dp23307
g16449
I26
sg16450
I1
sg16451
I13
sg16459
VC0334094
p23308
sg16454
Vproliferation
p23309
sasa(dp23310
g16444
VS: Taken together, our observations suggest the potential prognostic significance of p185(HER2) overexpression in Korean gastric adenocarcinoma patients and point to the need for further research on this mechanism.
p23311
sg16446
(lp23312
(dp23313
g16449
I85
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
Vp185
p23314
sa(dp23315
g16449
I90
sg16450
I1
sg16451
I4
sg16452
VP04626
p23316
sg16454
VHER2
p23317
sasg16456
(lp23318
(dp23319
g16449
I121
sg16450
I2
sg16451
I22
sg16459
VC0278701
p23320
sg16454
Vgastric adenocarcinoma
p23321
sasa(dp23322
g16444
VThis suggests the possible use of p185(HER2) as a therapeutic target in gastric cancer.
p23323
sg16446
(lp23324
(dp23325
g16449
I39
sg16450
I1
sg16451
I4
sg16452
VP04626
p23326
sg16454
VHER2
p23327
sa(dp23328
g16449
I34
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
Vp185
p23329
sasg16456
(lp23330
(dp23331
g16449
I72
sg16450
I2
sg16451
I14
sg16459
VC0024623
p23332
sg16454
Vgastric cancer
p23333
sasa(dp23334
g16444
VAdministration of trastuzumab, a fully humanized monoclonal antibody targeted to the human epidermal growth factor receptor 2 (HER2, p185), has improved outcomes for patients with HER2-positive gastric cancer (GC), but some relevant issues remain to be investigated and will emerge with new anti-GC drugs.
p23335
sg16446
(lp23336
(dp23337
g16449
I85
sg16450
I6
sg16451
I40
sg16452
VP01133
p23338
sg16454
Vhuman epidermal growth factor receptor 2
p23339
sa(dp23340
g16449
I127
sg16450
I1
sg16451
I4
sg16452
VP04626
p23341
sg16454
VHER2
p23342
sa(dp23343
g16449
I133
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
Vp185
p23344
sa(dp23345
g16449
I127
sg16450
I1
sg16451
I4
sg16452
VP04626
p23346
sg16454
VHER2
p23347
sasg16456
(lp23348
(dp23349
g16449
I194
sg16450
I2
sg16451
I14
sg16459
VC0024623
p23350
sg16454
Vgastric cancer
p23351
sa(dp23352
g16449
I210
sg16450
I1
sg16451
I2
sg16459
VC0024623
p23353
sg16454
VGC
p23354
sa(dp23355
g16449
I210
sg16450
I1
sg16451
I2
sg16459
VC0024623
p23356
sg16454
VGC
p23357
sasa(dp23358
g16444
VEukaryotic translation initiation factor 3 subunit A (eIF3a) plays critical roles in regulating the initiation of protein translation, and eIF3a is highly expressed in lung cancer.
p23359
sg16446
(lp23360
(dp23361
g16449
I54
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VeIF3a
p23362
sa(dp23363
g16449
I54
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VeIF3a
p23364
sa(dp23365
g16449
I0
sg16450
I7
sg16451
I52
sg16452
g11
sg16454
VEukaryotic translation initiation factor 3 subunit A
p23366
sasg16456
(lp23367
(dp23368
g16449
I168
sg16450
I2
sg16451
I11
sg16459
VC0684249
p23369
sg16454
Vlung cancer
p23370
sasa(dp23371
g16444
VIn this study, we investigated the association of the positively selected SNPs of eIF3a with the response to and toxicity of platinum-based chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC).
p23372
sg16446
(lp23373
(dp23374
g16449
I82
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VeIF3a
p23375
sasg16456
(lp23376
(dp23377
g16449
I206
sg16450
I1
sg16451
I5
sg16459
VC0007131
p23378
sg16454
VNSCLC
p23379
sa(dp23380
g16449
I178
sg16450
I4
sg16451
I26
sg16459
VC0007131
p23381
sg16454
Vnon-small cell lung cancer
p23382
sasa(dp23383
g16444
VThe positively selected SNPs of eIF3a are significantly correlated with platinum-based chemotherapy toxicities in Chinese NSCLC patients.
p23384
sg16446
(lp23385
(dp23386
g16449
I32
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VeIF3a
p23387
sasg16456
(lp23388
(dp23389
g16449
I122
sg16450
I1
sg16451
I5
sg16459
VC0007131
p23390
sg16454
VNSCLC
p23391
sasa(dp23392
g16444
VTo investigate the correlation between eukaryotic translation initiation factor 3, subunit A (eIF3a) and human epididymis protein 4 (HE4) expression and ovarian cancer.
p23393
sg16446
(lp23394
(dp23395
g16449
I133
sg16450
I1
sg16451
I3
sg16452
VP01031
p23396
sg16454
VHE4
p23397
sa(dp23398
g16449
I105
sg16450
I4
sg16451
I26
sg16452
VP01031
p23399
sg16454
Vhuman epididymis protein 4
p23400
sa(dp23401
g16449
I94
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VeIF3a
p23402
sasg16456
(lp23403
(dp23404
g16449
I153
sg16450
I2
sg16451
I14
sg16459
VC1140680
p23405
sg16454
Vovarian cancer
p23406
sasa(dp23407
g16444
VRT-PCR or immunohistochemistry was used to examine eIF3a and HE4 mRNA or protein expression in ovarian tissues from patients with ovarian cancer (n=181) or benign ovarian tumors, or from the healthy women.
p23408
sg16446
(lp23409
(dp23410
g16449
I51
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VeIF3a
p23411
sasg16456
(lp23412
(dp23413
g16449
I130
sg16450
I2
sg16451
I14
sg16459
VC1140680
p23414
sg16454
Vovarian cancer
p23415
sa(dp23416
g16449
I156
sg16450
I3
sg16451
I21
sg16459
VC0004997
p23417
sg16454
Vbenign ovarian tumors
p23418
sasa(dp23419
g16444
VThere were significant differences in mRNA and protein expression of eIF3a and HE4 among normal ovarian tissues, benign ovarian tumor tissues, and ovarian cancer tissues (P&lt; 0.05).
p23420
sg16446
(lp23421
(dp23422
g16449
I69
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VeIF3a
p23423
sasg16456
(lp23424
(dp23425
g16449
I147
sg16450
I2
sg16451
I14
sg16459
VC1140680
p23426
sg16454
Vovarian cancer
p23427
sa(dp23428
g16449
I113
sg16450
I3
sg16451
I20
sg16459
VC0004997
p23429
sg16454
Vbenign ovarian tumor
p23430
sasa(dp23431
g16444
VThere were significant differences in mRNA expression of eIF3a and HE4 between the normal tissues and the ovarian cancer tissues, or between the benign ovarian tumor tissues and the normal tissues (P&lt; 0.001).
p23432
sg16446
(lp23433
(dp23434
g16449
I57
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VeIF3a
p23435
sasg16456
(lp23436
(dp23437
g16449
I145
sg16450
I3
sg16451
I20
sg16459
VC0004997
p23438
sg16454
Vbenign ovarian tumor
p23439
sa(dp23440
g16449
I106
sg16450
I2
sg16451
I14
sg16459
VC1140680
p23441
sg16454
Vovarian cancer
p23442
sasa(dp23443
g16444
VThe mRNA expression of eIF3a in the normal ovarian tissues was significantly higher than that in the benign ovarian tumor tissues or that in the ovarian cancer tissues.
p23444
sg16446
(lp23445
(dp23446
g16449
I23
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VeIF3a
p23447
sasg16456
(lp23448
(dp23449
g16449
I101
sg16450
I3
sg16451
I20
sg16459
VC0004997
p23450
sg16454
Vbenign ovarian tumor
p23451
sa(dp23452
g16449
I145
sg16450
I2
sg16451
I14
sg16459
VC1140680
p23453
sg16454
Vovarian cancer
p23454
sasa(dp23455
g16444
VPositive expression rates for eIF3a or HE4 protein in normal, benign tumor, and cancer tissues were 0, 66.7%, and 81.0% or 0, 27.8%, and 56.2%, respectively.
p23456
sg16446
(lp23457
(dp23458
g16449
I30
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VeIF3a
p23459
sasg16456
(lp23460
(dp23461
g16449
I62
sg16450
I2
sg16451
I12
sg16459
VC0086692
p23462
sg16454
Vbenign tumor
p23463
sa(dp23464
g16449
I80
sg16450
I1
sg16451
I6
sg16459
VC0006826
p23465
sg16454
Vcancer
p23466
sasa(dp23467
g16444
VThere were significant differences in positive expression rates of eIF3a protein and HE4 protein between the ovarian tumor tissues and benign ovarian tumor tissues, between the ovarian cancer tissues and the normal ovarian tissues, or between the benign ovarian tumor tissues and the normal ovarian tissues (P&lt; 0.001).
p23468
sg16446
(lp23469
(dp23470
g16449
I67
sg16450
I2
sg16451
I13
sg16452
g11
sg16454
VeIF3a protein
p23471
sasg16456
(lp23472
(dp23473
g16449
I135
sg16450
I3
sg16451
I20
sg16459
VC0004997
p23474
sg16454
Vbenign ovarian tumor
p23475
sa(dp23476
g16449
I109
sg16450
I2
sg16451
I13
sg16459
VC0919267
p23477
sg16454
Vovarian tumor
p23478
sa(dp23479
g16449
I135
sg16450
I3
sg16451
I20
sg16459
VC0004997
p23480
sg16454
Vbenign ovarian tumor
p23481
sa(dp23482
g16449
I177
sg16450
I2
sg16451
I14
sg16459
VC1140680
p23483
sg16454
Vovarian cancer
p23484
sasa(dp23485
g16444
VThe expressions of eIF3a and HE4 are associated with ovarian cancer, and extracellular regulated protein kinases may play a role in the interaction between eIF3a and HE4.
p23486
sg16446
(lp23487
(dp23488
g16449
I19
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VeIF3a
p23489
sa(dp23490
g16449
I73
sg16450
I4
sg16451
I39
sg16452
VP10398
p23491
sg16454
Vextracellular regulated protein kinases
p23492
sa(dp23493
g16449
I19
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VeIF3a
p23494
sasg16456
(lp23495
(dp23496
g16449
I53
sg16450
I2
sg16451
I14
sg16459
VC1140680
p23497
sg16454
Vovarian cancer
p23498
sasa(dp23499
g16444
VWe describe an ultrasensitive electrochemical nucleic acid assay amplified by carbon nanotubes (CNTs)-based labels for the detection of human acute lymphocytic leukemia (ALL)-related p185 BCR-ABL fusion transcript.
p23500
sg16446
(lp23501
(dp23502
g16449
I192
sg16450
I1
sg16451
I3
sg16452
VP55157
p23503
sg16454
VABL
p23504
sa(dp23505
g16449
I183
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
Vp185
p23506
sa(dp23507
g16449
I188
sg16450
I1
sg16451
I3
sg16452
VP11274
p23508
sg16454
VBCR
p23509
sasg16456
(lp23510
(dp23511
g16449
I192
sg16450
I1
sg16451
I3
sg16459
VC0000744
p23512
sg16454
VABL
p23513
sa(dp23514
g16449
I142
sg16450
I3
sg16451
I26
sg16459
VC1961102
p23515
sg16454
Vacute lymphocytic leukemia
p23516
sa(dp23517
g16449
I170
sg16450
I1
sg16451
I3
sg16459
VC1961102
p23518
sg16454
VALL
p23519
sasa(dp23520
g16444
VPlasma levels of annexin V-MP, endothelial-derived MP, platelet-derived MP (CD61+ and P-Selectin+), leukocyte-derived MP, tissue factor-bearing (TF+) and CD36+MP were prospectively measured in 20 patients with III degree obesity (BMI &gt;= 40 kg/m(2)) before (T0) and 3 (T3) and 12 (T12) months after sleeve gastrectomy (SLG).
p23521
sg16446
(lp23522
(dp23523
g16449
I100
sg16450
I5
sg16451
I49
sg16452
VP13726
p23524
sg16454
Vleukocyte-derived MP, tissue factor-bearing (TF+)
p23525
sa(dp23526
g16449
I17
sg16450
I6
sg16451
I57
sg16452
VP08758
p23527
sg16454
Vannexin V-MP, endothelial-derived MP, platelet-derived MP
p23528
sa(dp23529
g16449
I76
sg16450
I1
sg16451
I5
sg16452
VP05106
p23530
sg16454
VCD61+
p23531
sasg16456
(lp23532
(dp23533
g16449
I221
sg16450
I1
sg16451
I7
sg16459
VC0028754
p23534
sg16454
Vobesity
p23535
sasa(dp23536
g16444
VKey messages Bilirubin levels are inversely related to cardiovascular disease, and overexpression of heme oxygenase-1 (the enzyme that determines bilirubin production) has prevented post-infarction ventricular remodeling in experimental animals, but the association between bilirubin levels and the progression of ventricular volumes and function in patients with acute myocardial infarction remained unexplored.
p23537
sg16446
(lp23538
(dp23539
g16449
I101
sg16450
I2
sg16451
I16
sg16452
VP09601
p23540
sg16454
Vheme oxygenase-1
p23541
sasg16456
(lp23542
(dp23543
g16449
I187
sg16450
I1
sg16451
I10
sg16459
VC0021308
p23544
sg16454
Vinfarction
p23545
sa(dp23546
g16449
I55
sg16450
I2
sg16451
I22
sg16459
VC0007222
p23547
sg16454
Vcardiovascular disease
p23548
sa(dp23549
g16449
I364
sg16450
I3
sg16451
I27
sg16459
VC0155626
p23550
sg16454
Vacute myocardial infarction
p23551
sasa(dp23552
g16444
VHO-1 is known to be protective in the setting of acute myocardial infarction.
p23553
sg16446
(lp23554
(dp23555
g16449
I0
sg16450
I1
sg16451
I4
sg16452
VP09601
p23556
sg16454
VHO-1
p23557
sasg16456
(lp23558
(dp23559
g16449
I49
sg16450
I3
sg16451
I27
sg16459
VC0155626
p23560
sg16454
Vacute myocardial infarction
p23561
sasa(dp23562
g16444
VIn vitro experiments revealed enteropeptidase as a putative substrate for Bace1 suggesting a role in acute pancreatitis.
p23563
sg16446
(lp23564
(dp23565
g16449
I74
sg16450
I1
sg16451
I5
sg16452
VP56817
p23566
sg16454
VBace1
p23567
sa(dp23568
g16449
I30
sg16450
I1
sg16451
I15
sg16452
VP98073
p23569
sg16454
Venteropeptidase
p23570
sasg16456
(lp23571
(dp23572
g16449
I101
sg16450
I2
sg16451
I18
sg16459
VC0001339
p23573
sg16454
Vacute pancreatitis
p23574
sasa(dp23575
g16444
Vacute necrotizing pancreatitis was induced in anesthetized pigs by the retrograde infusion of 1 ml/kg of 5% sodium taurocholate and 8 U/kg enterokinase in the pancreatic duct.
p23576
sg16446
(lp23577
(dp23578
g16449
I134
sg16450
I2
sg16451
I17
sg16452
VP98073
p23579
sg16454
VU/kg enterokinase
p23580
sasg16456
(lp23581
(dp23582
g16449
I0
sg16450
I3
sg16451
I30
sg16459
VC0267941
p23583
sg16454
Vacute necrotizing pancreatitis
p23584
sasa(dp23585
g16444
VConversely, duodenopancreatic reflux of proteolytically active enteropeptidase may cause acute and chronic pancreatitis.
p23586
sg16446
(lp23587
(dp23588
g16449
I63
sg16450
I1
sg16451
I15
sg16452
VP98073
p23589
sg16454
Venteropeptidase
p23590
sasg16456
(lp23591
(dp23592
g16449
I99
sg16450
I2
sg16451
I20
sg16459
VC0149521
p23593
sg16454
Vchronic pancreatitis
p23594
sa(dp23595
g16449
I30
sg16450
I1
sg16451
I6
sg16459
VC0017168
p23596
sg16454
Vreflux
p23597
sasa(dp23598
g16444
VA noninvasive model of necrohemorrhagic pancreatitis induced by simultaneous intravenous cerulein/enterokinase (EK) infusion has recently been established in rats.
p23599
sg16446
(lp23600
(dp23601
g16449
I112
sg16450
I1
sg16451
I2
sg16452
VP98073
p23602
sg16454
VEK
p23603
sa(dp23604
g16449
I89
sg16450
I1
sg16451
I21
sg16452
VP98073
p23605
sg16454
Vcerulein/enterokinase
p23606
sasg16456
(lp23607
(dp23608
g16449
I40
sg16450
I1
sg16451
I12
sg16459
VC0030305
p23609
sg16454
Vpancreatitis
p23610
sasa(dp23611
g16444
VStudy hemodynamic pattern and lipoperoxidation during methylene blue (MB) treatment on taurocholate - enterokinase induced acute pancreatitis (AP).
p23612
sg16446
(lp23613
(dp23614
g16449
I87
sg16450
I3
sg16451
I27
sg16452
VP98073
p23615
sg16454
Vtaurocholate - enterokinase
p23616
sasg16456
(lp23617
(dp23618
g16449
I123
sg16450
I2
sg16451
I18
sg16459
VC0001339
p23619
sg16454
Vacute pancreatitis
p23620
sa(dp23621
g16449
I143
sg16450
I1
sg16451
I2
sg16459
VC0001339
p23622
sg16454
VAP
p23623
sasa(dp23624
g16444
VThe HLA-B47,DR7 haplotype in congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency contains a deletion of most of the active CYP21 gene and the entire adjacent C4B gene.
p23625
sg16446
(lp23626
(dp23627
g16449
I141
sg16450
I2
sg16451
I10
sg16452
VP08686
p23628
sg16454
VCYP21 gene
p23629
sa(dp23630
g16449
I176
sg16450
I2
sg16451
I8
sg16452
VP04003
p23631
sg16454
VC4B gene
p23632
sa(dp23633
g16449
I12
sg16450
I2
sg16451
I13
sg16452
VP13761
p23634
sg16454
VDR7 haplotype
p23635
sa(dp23636
g16449
I4
sg16450
I1
sg16451
I7
sg16452
VP30486
p23637
sg16454
VHLA-B47
p23638
sa(dp23639
g16449
I73
sg16450
I1
sg16451
I14
sg16452
VP08686
p23640
sg16454
V21-hydroxylase
p23641
sasg16456
(lp23642
(dp23643
g16449
I61
sg16450
I1
sg16451
I3
sg16459
VC0520463
p23644
sg16454
VCAH
p23645
sa(dp23646
g16449
I29
sg16450
I3
sg16451
I30
sg16459
VC0001627
p23647
sg16454
Vcongenital adrenal hyperplasia
p23648
sa(dp23649
g16449
I73
sg16450
I2
sg16451
I25
sg16459
VC0852654
p23650
sg16454
V21-hydroxylase deficiency
p23651
sasa(dp23652
g16444
VThe HLA haplotype A3-Cw6-B47-C4A91-BQ0-DR7 is associated with congenital adrenal hyperplasia (CAH), since it only carries the dysfunctional steroid 21-hydroxylase A pseudogene as well as the 5' adjacent complement C4A gene.
p23653
sg16446
(lp23654
(dp23655
g16449
I4
sg16450
I3
sg16451
I38
sg16452
VP30486
p23656
sg16454
VHLA haplotype A3-Cw6-B47-C4A91-BQ0-DR7
p23657
sa(dp23658
g16449
I140
sg16450
I4
sg16451
I35
sg16452
VP08686
p23659
sg16454
Vsteroid 21-hydroxylase A pseudogene
p23660
sa(dp23661
g16449
I191
sg16450
I5
sg16451
I31
sg16452
g11
sg16454
V5' adjacent complement C4A gene
p23662
sasg16456
(lp23663
(dp23664
g16449
I62
sg16450
I3
sg16451
I30
sg16459
VC0001627
p23665
sg16454
Vcongenital adrenal hyperplasia
p23666
sa(dp23667
g16449
I94
sg16450
I1
sg16451
I3
sg16459
VC0520463
p23668
sg16454
VCAH
p23669
sasa(dp23670
g16444
VThe mutation of vesicle-associated membrane protein-associated protein B (VAPB) was proved to cause family amyotrophic lateral sclerosis (FALS).
p23671
sg16446
(lp23672
(dp23673
g16449
I16
sg16450
I5
sg16451
I56
sg16452
g11
sg16454
Vvesicle-associated membrane protein-associated protein B
p23674
sa(dp23675
g16449
I74
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VVAPB
p23676
sasg16456
(lp23677
(dp23678
g16449
I138
sg16450
I1
sg16451
I4
sg16459
VC1862939
p23679
sg16454
VFALS
p23680
sa(dp23681
g16449
I100
sg16450
I4
sg16451
I36
sg16459
VC1862939
p23682
sg16454
Vfamily amyotrophic lateral sclerosis
p23683
sa(dp23684
g16449
I16
sg16450
I1
sg16451
I7
sg16459
VC0333262
p23685
sg16454
Vvesicle
p23686
sasa(dp23687
g16444
VALS8 is a late-onset familial autosomal dominant form of Amyotrophic Lateral Sclerosis (ALS) caused by a point mutation (P56S) in the VAPB gene (VAMP associated protein isoform B).
p23688
sg16446
(lp23689
(dp23690
g16449
I0
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VALS8
p23691
sa(dp23692
g16449
I134
sg16450
I2
sg16451
I9
sg16452
g11
sg16454
VVAPB gene
p23693
sa(dp23694
g16449
I145
sg16450
I5
sg16451
I33
sg16452
g11
sg16454
VVAMP associated protein isoform B
p23695
sasg16456
(lp23696
(dp23697
g16449
I0
sg16450
I1
sg16451
I4
sg16459
VC1837728
p23698
sg16454
VALS8
p23699
sa(dp23700
g16449
I0
sg16450
I1
sg16451
I3
sg16459
VC0002736
p23701
sg16454
VALS
p23702
sa(dp23703
g16449
I57
sg16450
I3
sg16451
I29
sg16459
VC0002736
p23704
sg16454
VAmyotrophic Lateral Sclerosis
p23705
sasa(dp23706
g16444
VThis supports the loss of VAPB function in ALS8 pathogenesis and suggests that reducing intracellular PtdIns4P might be an effective therapeutic strategy in delaying progressive loss of motor neurons.
p23707
sg16446
(lp23708
(dp23709
g16449
I43
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VALS8
p23710
sa(dp23711
g16449
I26
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VVAPB
p23712
sa(dp23713
g16449
I79
sg16450
I3
sg16451
I31
sg16452
g11
sg16454
Vreducing intracellular PtdIns4P
p23714
sasg16456
(lp23715
(dp23716
g16449
I48
sg16450
I1
sg16451
I12
sg16459
VC0699748
p23717
sg16454
Vpathogenesis
p23718
sa(dp23719
g16449
I43
sg16450
I1
sg16451
I4
sg16459
VC1837728
p23720
sg16454
VALS8
p23721
sasa(dp23722
g16444
VMutations in VAP-B that have been identified in familial forms of amyotrophic lateral sclerosis (ALS or Lou-Gehrig's disease) cause aggregation of the VAP-B protein, which then impairs its binding to several proteins, including Nir2.
p23723
sg16446
(lp23724
(dp23725
g16449
I228
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VNir2
p23726
sa(dp23727
g16449
I13
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VVAP-B
p23728
sa(dp23729
g16449
I151
sg16450
I2
sg16451
I13
sg16452
g11
sg16454
VVAP-B protein
p23730
sasg16456
(lp23731
(dp23732
g16449
I97
sg16450
I1
sg16451
I3
sg16459
VC0002736
p23733
sg16454
VALS
p23734
sa(dp23735
g16449
I66
sg16450
I3
sg16451
I29
sg16459
VC0002736
p23736
sg16454
Vamyotrophic lateral sclerosis
p23737
sa(dp23738
g16449
I108
sg16450
I2
sg16451
I16
sg16459
VC0002736
p23739
sg16454
VGehrig's disease
p23740
sasa(dp23741
g16444
VA mutation in VAPB causes a familial form of Amyotrophic Lateral Sclerosis.
p23742
sg16446
(lp23743
(dp23744
g16449
I14
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VVAPB
p23745
sasg16456
(lp23746
(dp23747
g16449
I45
sg16450
I3
sg16451
I29
sg16459
VC0002736
p23748
sg16454
VAmyotrophic Lateral Sclerosis
p23749
sasa(dp23750
g16444
VWe present two cases of Peters anomaly (Peters plus syndrome and a maximum manifestation variant) with abnormally thickened cornea and corneal staphyloma.
p23751
sg16446
(lp23752
sg16456
(lp23753
(dp23754
g16449
I24
sg16450
I2
sg16451
I14
sg16459
VC0344559
p23755
sg16454
VPeters anomaly
p23756
sa(dp23757
g16449
I135
sg16450
I2
sg16451
I18
sg16459
VC0152440
p23758
sg16454
Vcorneal staphyloma
p23759
sa(dp23760
g16449
I40
sg16450
I3
sg16451
I20
sg16459
VC0796012
p23761
sg16454
VPeters plus syndrome
p23762
sasa(dp23763
g16444
VWnt3a and Wnt5a are ligands orchestrating the canonical and non-canonical pathways, respectively, with involvement in hepatocellular carcinoma (HCC).
p23764
sg16446
(lp23765
(dp23766
g16449
I10
sg16450
I1
sg16451
I5
sg16452
VP41221
p23767
sg16454
VWnt5a
p23768
sa(dp23769
g16449
I0
sg16450
I1
sg16451
I5
sg16452
VP56704
p23770
sg16454
VWnt3a
p23771
sasg16456
(lp23772
(dp23773
g16449
I144
sg16450
I1
sg16451
I3
sg16459
VC2239176
p23774
sg16454
VHCC
p23775
sa(dp23776
g16449
I118
sg16450
I2
sg16451
I24
sg16459
VC2239176
p23777
sg16454
Vhepatocellular carcinoma
p23778
sasa(dp23779
g16444
VTo investigate member 3a of Wingless-type MMTV integration site family (Wnt3a) expression in cancerous and surrounding tissues and the relationship between clinicopathologic features of hepatocellular carcinoma (HCC) and Wnt3a expression.
p23780
sg16446
(lp23781
(dp23782
g16449
I15
sg16450
I2
sg16451
I9
sg16452
VP61587
p23783
sg16454
Vmember 3a
p23784
sa(dp23785
g16449
I72
sg16450
I1
sg16451
I5
sg16452
VP56704
p23786
sg16454
VWnt3a
p23787
sa(dp23788
g16449
I28
sg16450
I5
sg16451
I42
sg16452
g11
sg16454
VWingless-type MMTV integration site family
p23789
sa(dp23790
g16449
I72
sg16450
I1
sg16451
I5
sg16452
VP56704
p23791
sg16454
VWnt3a
p23792
sasg16456
(lp23793
(dp23794
g16449
I212
sg16450
I1
sg16451
I3
sg16459
VC2239176
p23795
sg16454
VHCC
p23796
sa(dp23797
g16449
I186
sg16450
I2
sg16451
I24
sg16459
VC2239176
p23798
sg16454
Vhepatocellular carcinoma
p23799
sasa(dp23800
g16444
VWe then use a realistic GENESIS model to test two hypothesis about interneuron hypofunction and conclude that a reduction in GAD67 is the most likely candidate as the cause for hypofrontality as observed in Schizophrenia.
p23801
sg16446
(lp23802
(dp23803
g16449
I125
sg16450
I1
sg16451
I5
sg16452
VP49419
p23804
sg16454
VGAD67
p23805
sasg16456
(lp23806
(dp23807
g16449
I79
sg16450
I1
sg16451
I12
sg16459
VC0679221
p23808
sg16454
Vhypofunction
p23809
sa(dp23810
g16449
I207
sg16450
I1
sg16451
I13
sg16459
VC0036341
p23811
sg16454
VSchizophrenia
p23812
sasa(dp23813
g16444
VThe objective of this study was to determine the effect of the CYP3A5 and ATP binding cassette subfamily B member 1 (ABCB1) single-nucleotide polymorphisms on the disposition of sunitinib and SU12662, on clinical response, and on the manifestation of toxicities in Asian metastatic renal cell carcinoma patients.
p23814
sg16446
(lp23815
(dp23816
g16449
I74
sg16450
I7
sg16451
I41
sg16452
g11
sg16454
VATP binding cassette subfamily B member 1
p23817
sa(dp23818
g16449
I117
sg16450
I1
sg16451
I5
sg16452
VP08183
p23819
sg16454
VABCB1
p23820
sa(dp23821
g16449
I63
sg16450
I1
sg16451
I6
sg16452
VP20815
p23822
sg16454
VCYP3A5
p23823
sasg16456
(lp23824
(dp23825
g16449
I271
sg16450
I4
sg16451
I31
sg16459
VC0278678
p23826
sg16454
Vmetastatic renal cell carcinoma
p23827
sasa(dp23828
g16444
VPolymorphisms in VEGFR3 and CYP3A5*1 might be able to define a subset of patients with renal-cell carcinoma with decreased sunitinib response and tolerability.
p23829
sg16446
(lp23830
(dp23831
g16449
I28
sg16450
I1
sg16451
I8
sg16452
VP20815
p23832
sg16454
VCYP3A5*1
p23833
sa(dp23834
g16449
I17
sg16450
I1
sg16451
I6
sg16452
VP35916
p23835
sg16454
VVEGFR3
p23836
sasg16456
(lp23837
(dp23838
g16449
I98
sg16450
I1
sg16451
I9
sg16459
VC0007097
p23839
sg16454
Vcarcinoma
p23840
sasa(dp23841
g16444
VTo examine whether common genetic variation at the SLC10A1 locus is associated with risk of persistent HBV infection, haplotype-tagging and imputed single nucleotide polymorphisms (SNPs) were assessed in two case-control sample sets, totally including 2,550 cases (persistently HBV infected subjects, PIs) and 2,124 controls (spontaneously recovered subjects, SRs) of Southern Chinese ancestry.
p23842
sg16446
(lp23843
(dp23844
g16449
I360
sg16450
I1
sg16451
I3
sg16452
VP35270
p23845
sg16454
VSRs
p23846
sa(dp23847
g16449
I51
sg16450
I2
sg16451
I13
sg16452
g11
sg16454
VSLC10A1 locus
p23848
sasg16456
(lp23849
(dp23850
g16449
I107
sg16450
I1
sg16451
I9
sg16459
VC0009450
p23851
sg16454
Vinfection
p23852
sa(dp23853
g16449
I103
sg16450
I1
sg16451
I3
sg16459
VC0019163
p23854
sg16454
VHBV
p23855
sa(dp23856
g16449
I103
sg16450
I1
sg16451
I3
sg16459
VC0019163
p23857
sg16454
VHBV
p23858
sa(dp23859
g16449
I360
sg16450
I1
sg16451
I3
sg16459
VC0175693
p23860
sg16454
VSRs
p23861
sasa(dp23862
g16444
VThe effectiveness of topical terbinafine (TBF) to tinea pedis was evaluated an animal model in which guinea pigs were experimentally infected through their planta pedis with Trichophyton mentagrophytes, then a 1% TBF or butenafine (BTF) cream was administered topically once daily for 4 consecutive weeks.
p23863
sg16446
(lp23864
sg16456
(lp23865
(dp23866
g16449
I50
sg16450
I2
sg16451
I11
sg16459
VC0040259
p23867
sg16454
Vtinea pedis
p23868
sasa(dp23869
g16444
VHowever, mutations in RecQL4 result in three human disorders: (I) Rothmund-Thomson syndrome (RTS), (II) RAPADILINO and (III) Baller-Gerold syndrome (BGS).
p23870
sg16446
(lp23871
(dp23872
g16449
I22
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRecQL4
p23873
sasg16456
(lp23874
(dp23875
g16449
I66
sg16450
I2
sg16451
I25
sg16459
VC0032339
p23876
sg16454
VRothmund-Thomson syndrome
p23877
sa(dp23878
g16449
I149
sg16450
I1
sg16451
I3
sg16459
VC0265308
p23879
sg16454
VBGS
p23880
sa(dp23881
g16449
I93
sg16450
I1
sg16451
I3
sg16459
VC0032339
p23882
sg16454
VRTS
p23883
sa(dp23884
g16449
I125
sg16450
I2
sg16451
I22
sg16459
VC0265308
p23885
sg16454
VBaller-Gerold syndrome
p23886
sasa(dp23887
g16444
VThis is in accordance with clinical and epidemiological findings demonstrating that defects in three RecQL helicases, i.e., WRN, BLM, RECQL4, are related to human progeroid and cancer predisposition syndromes, i.e., Werner, Bloom, and Rothmund Thomson syndrome, respectively.
p23888
sg16446
(lp23889
(dp23890
g16449
I101
sg16450
I2
sg16451
I15
sg16452
VP46063
p23891
sg16454
VRecQL helicases
p23892
sa(dp23893
g16449
I129
sg16450
I1
sg16451
I3
sg16452
VP54132
p23894
sg16454
VBLM
p23895
sa(dp23896
g16449
I134
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRECQL4
p23897
sasg16456
(lp23898
(dp23899
g16449
I235
sg16450
I3
sg16451
I25
sg16459
VC0032339
p23900
sg16454
VRothmund Thomson syndrome
p23901
sa(dp23902
g16449
I199
sg16450
I1
sg16451
I9
sg16459
VC0039082
p23903
sg16454
Vsyndromes
p23904
sa(dp23905
g16449
I124
sg16450
I1
sg16451
I3
sg16459
VC0043119
p23906
sg16454
VWRN
p23907
sa(dp23908
g16449
I177
sg16450
I1
sg16451
I6
sg16459
VC0006826
p23909
sg16454
Vcancer
p23910
sa(dp23911
g16449
I129
sg16450
I1
sg16451
I3
sg16459
VC0005859
p23912
sg16454
VBLM
p23913
sasa(dp23914
g16444
VHuman RecQ homologs include RECQ1, BLM, WRN, RECQ4, and RECQ5Beta, three of which have been linked to diseases with elevated risk of cancer and growth defects (Bloom Syndrome and Rothmund-Thomson Syndrome) or premature aging (Werner Syndrome).
p23915
sg16446
(lp23916
(dp23917
g16449
I45
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VRECQ4
p23918
sa(dp23919
g16449
I40
sg16450
I1
sg16451
I3
sg16452
VP02545
p23920
sg16454
VWRN
p23921
sa(dp23922
g16449
I0
sg16450
I3
sg16451
I19
sg16452
g11
sg16454
VHuman RecQ homologs
p23923
sa(dp23924
g16449
I28
sg16450
I1
sg16451
I5
sg16452
VP46063
p23925
sg16454
VRECQ1
p23926
sa(dp23927
g16449
I35
sg16450
I1
sg16451
I3
sg16452
VP54132
p23928
sg16454
VBLM
p23929
sasg16456
(lp23930
(dp23931
g16449
I226
sg16450
I2
sg16451
I15
sg16459
VC0043119
p23932
sg16454
VWerner Syndrome
p23933
sa(dp23934
g16449
I209
sg16450
I2
sg16451
I15
sg16459
VC0231341
p23935
sg16454
Vpremature aging
p23936
sa(dp23937
g16449
I35
sg16450
I1
sg16451
I3
sg16459
VC0005859
p23938
sg16454
VBLM
p23939
sa(dp23940
g16449
I133
sg16450
I1
sg16451
I6
sg16459
VC0006826
p23941
sg16454
Vcancer
p23942
sa(dp23943
g16449
I160
sg16450
I2
sg16451
I14
sg16459
VC0005859
p23944
sg16454
VBloom Syndrome
p23945
sa(dp23946
g16449
I179
sg16450
I2
sg16451
I25
sg16459
VC0032339
p23947
sg16454
VRothmund-Thomson Syndrome
p23948
sa(dp23949
g16449
I40
sg16450
I1
sg16451
I3
sg16459
VC0043119
p23950
sg16454
VWRN
p23951
sasa(dp23952
g16444
VDepletion of PAICS largely cancelled breast cancer expansion, exemplifying a prognostic gene with breast cancer activity.
p23953
sg16446
(lp23954
sg16456
(lp23955
(dp23956
g16449
I37
sg16450
I2
sg16451
I13
sg16459
VC0678222
p23957
sg16454
Vbreast cancer
p23958
sa(dp23959
g16449
I37
sg16450
I2
sg16451
I13
sg16459
VC0678222
p23960
sg16454
Vbreast cancer
p23961
sasa(dp23962
g16444
VWe propose that pharmacological inhibition of components within this network, such as PAICS, may be used in conjunction with the Fra-1 prognostic classifier towards personalized management of poor prognosis breast cancer.
p23963
sg16446
(lp23964
(dp23965
g16449
I129
sg16450
I1
sg16451
I5
sg16452
VP15407
p23966
sg16454
VFra-1
p23967
sa(dp23968
g16449
I86
sg16450
I1
sg16451
I5
sg16452
VP22234
p23969
sg16454
VPAICS
p23970
sasg16456
(lp23971
(dp23972
g16449
I207
sg16450
I2
sg16451
I13
sg16459
VC0678222
p23973
sg16454
Vbreast cancer
p23974
sa(dp23975
g16449
I129
sg16450
I1
sg16451
I3
sg16459
VC1858361
p23976
sg16454
VFra
p23977
sasa(dp23978
g16444
VOur goal was to investigate de novo purine biosynthetic gene PAICS expression and evaluate its role in prostate cancer progression.
p23979
sg16446
(lp23980
sg16456
(lp23981
(dp23982
g16449
I112
sg16450
I2
sg16451
I18
sg16459
VC0178874
p23983
sg16454
Vcancer progression
p23984
sasa(dp23985
g16444
VNext-generation sequencing, qRTPCR and immunoblot analysis revealed an elevated expression of a de novo purine biosynthetic gene, Phosphoribosylaminoimidazole Carboxylase, Phosphoribosylaminoimidazole Succinocarboxamide Synthetase (PAICS) in a progressive manner in prostate cancer.
p23986
sg16446
(lp23987
(dp23988
g16449
I130
sg16450
I2
sg16451
I40
sg16452
VP22234
p23989
sg16454
VPhosphoribosylaminoimidazole Carboxylase
p23990
sa(dp23991
g16449
I232
sg16450
I1
sg16451
I5
sg16452
VP22234
p23992
sg16454
VPAICS
p23993
sa(dp23994
g16449
I172
sg16450
I3
sg16451
I58
sg16452
VP22234
p23995
sg16454
VPhosphoribosylaminoimidazole Succinocarboxamide Synthetase
p23996
sasg16456
(lp23997
(dp23998
g16449
I266
sg16450
I2
sg16451
I15
sg16459
VC0600139
p23999
sg16454
Vprostate cancer
p24000
sasa(dp24001
g16444
VThrough several in vitro and in vivo functional studies, we show that PAICS is necessary for proliferation and invasion in prostate cancer cells.
p24002
sg16446
(lp24003
(dp24004
g16449
I70
sg16450
I1
sg16451
I5
sg16452
VP22234
p24005
sg16454
VPAICS
p24006
sasg16456
(lp24007
(dp24008
g16449
I93
sg16450
I1
sg16451
I13
sg16459
VC0334094
p24009
sg16454
Vproliferation
p24010
sa(dp24011
g16449
I123
sg16450
I2
sg16451
I15
sg16459
VC0600139
p24012
sg16454
Vprostate cancer
p24013
sa(dp24014
g16449
I111
sg16450
I1
sg16451
I8
sg16459
VC2699153
p24015
sg16454
Vinvasion
p24016
sasa(dp24017
g16444
VWe identified JQ1, a BET bromodomain inhibitor previously implicated in regulating MYC expression and demonstrated role in prostate cancer, abrogates PAICS expression in several prostate cancer cells.
p24018
sg16446
(lp24019
(dp24020
g16449
I83
sg16450
I1
sg16451
I3
sg16452
VP12524
p24021
sg16454
VMYC
p24022
sa(dp24023
g16449
I150
sg16450
I1
sg16451
I5
sg16452
VP22234
p24024
sg16454
VPAICS
p24025
sasg16456
(lp24026
(dp24027
g16449
I123
sg16450
I2
sg16451
I15
sg16459
VC0600139
p24028
sg16454
Vprostate cancer
p24029
sa(dp24030
g16449
I123
sg16450
I2
sg16451
I15
sg16459
VC0600139
p24031
sg16454
Vprostate cancer
p24032
sasa(dp24033
g16444
VHere, we report that evaluation of PAICS in prostate cancer progression and its role in prostate cancer cell proliferation and invasion and suggest it as a valid therapeutic target.
p24034
sg16446
(lp24035
sg16456
(lp24036
(dp24037
g16449
I127
sg16450
I1
sg16451
I8
sg16459
VC2699153
p24038
sg16454
Vinvasion
p24039
sa(dp24040
g16449
I53
sg16450
I2
sg16451
I18
sg16459
VC0178874
p24041
sg16454
Vcancer progression
p24042
sa(dp24043
g16449
I109
sg16450
I1
sg16451
I13
sg16459
VC0334094
p24044
sg16454
Vproliferation
p24045
sa(dp24046
g16449
I44
sg16450
I2
sg16451
I15
sg16459
VC0600139
p24047
sg16454
Vprostate cancer
p24048
sasa(dp24049
g16444
VWe suggest JQ1, a BET-domain inhibitor, as possible therapeutic option in targeting PAICS in prostate cancer.
p24050
sg16446
(lp24051
sg16456
(lp24052
(dp24053
g16449
I93
sg16450
I2
sg16451
I15
sg16459
VC0600139
p24054
sg16454
Vprostate cancer
p24055
sasa(dp24056
g16444
VWe discovered increased expression of phosphoribosyl amidotransferase (PPAT) and phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase (PAICS) enzymes of de novo purine biosynthetic pathway in lung adenocarcinomas.
p24057
sg16446
(lp24058
(dp24059
g16449
I71
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPPAT
p24060
sa(dp24061
g16449
I183
sg16450
I1
sg16451
I5
sg16452
VP22234
p24062
sg16454
VPAICS
p24063
sa(dp24064
g16449
I38
sg16450
I2
sg16451
I31
sg16452
g11
sg16454
Vphosphoribosyl amidotransferase
p24065
sa(dp24066
g16449
I81
sg16450
I5
sg16451
I100
sg16452
VP22234
p24067
sg16454
Vphosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase
p24068
sasg16456
(lp24069
(dp24070
g16449
I245
sg16450
I1
sg16451
I15
sg16459
VC0001418
p24071
sg16454
Vadenocarcinomas
p24072
sasa(dp24073
g16444
VTranscript analyses from next-generation RNA sequencing and gene expression profiling studies suggested that PPAT and PAICS can serve as prognostic biomarkers for aggressive lung adenocarcinoma.
p24074
sg16446
(lp24075
(dp24076
g16449
I109
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPPAT
p24077
sa(dp24078
g16449
I118
sg16450
I1
sg16451
I5
sg16452
VP22234
p24079
sg16454
VPAICS
p24080
sasg16456
(lp24081
(dp24082
g16449
I174
sg16450
I2
sg16451
I19
sg16459
VC0152013
p24083
sg16454
Vlung adenocarcinoma
p24084
sa(dp24085
g16449
I163
sg16450
I1
sg16451
I10
sg16459
VC0001807
p24086
sg16454
Vaggressive
p24087
sasa(dp24088
g16444
VFurthermore we identified genomic amplification and aneuploidy of the divergently transcribed PPAT-PAICS genomic region in a subset of lung cancers.
p24089
sg16446
(lp24090
(dp24091
g16449
I99
sg16450
I1
sg16451
I5
sg16452
VP22234
p24092
sg16454
VPAICS
p24093
sa(dp24094
g16449
I94
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPPAT
p24095
sasg16456
(lp24096
(dp24097
g16449
I135
sg16450
I2
sg16451
I12
sg16459
VC0242379
p24098
sg16454
Vlung cancers
p24099
sa(dp24100
g16449
I52
sg16450
I1
sg16451
I10
sg16459
VC0002938
p24101
sg16454
Vaneuploidy
p24102
sa(dp24103
g16449
I34
sg16450
I1
sg16451
I13
sg16459
VC1705759
p24104
sg16454
Vamplification
p24105
sasa(dp24106
g16444
VIn summary, this study reveals the regulatory mechanisms by which purine biosynthetic pathway enzymes PPAT and PAICS, and pyruvate kinase activity is increased and exposes an existing metabolic vulnerability in lung cancer cells that can be explored for pharmacological intervention.
p24107
sg16446
(lp24108
(dp24109
g16449
I102
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPPAT
p24110
sa(dp24111
g16449
I122
sg16450
I2
sg16451
I15
sg16452
VP30613
p24112
sg16454
Vpyruvate kinase
p24113
sa(dp24114
g16449
I111
sg16450
I1
sg16451
I5
sg16452
VP22234
p24115
sg16454
VPAICS
p24116
sasg16456
(lp24117
(dp24118
g16449
I211
sg16450
I2
sg16451
I11
sg16459
VC0684249
p24119
sg16454
Vlung cancer
p24120
sasa(dp24121
g16444
VWe also identified mutations in four genes (MUC19, PAICS, RBMXL1, KIF23) never reported in melanoma, which might deserve further investigations.
p24122
sg16446
(lp24123
(dp24124
g16449
I58
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRBMXL1
p24125
sa(dp24126
g16449
I44
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VMUC19
p24127
sa(dp24128
g16449
I51
sg16450
I1
sg16451
I5
sg16452
VP22234
p24129
sg16454
VPAICS
p24130
sa(dp24131
g16449
I66
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VKIF23
p24132
sasg16456
(lp24133
(dp24134
g16449
I91
sg16450
I1
sg16451
I8
sg16459
VC0025202
p24135
sg16454
Vmelanoma
p24136
sasa(dp24137
g16444
VAlterations in PAICS expression in humans have been associated with various types of cancer.
p24138
sg16446
(lp24139
(dp24140
g16449
I15
sg16450
I1
sg16451
I5
sg16452
VP22234
p24141
sg16454
VPAICS
p24142
sasg16456
(lp24143
(dp24144
g16449
I85
sg16450
I1
sg16451
I6
sg16459
VC0006826
p24145
sg16454
Vcancer
p24146
sasa(dp24147
g16444
VAn IST1 clone, detected for the first time in 2000, was the most prevalent and responsible for the shigellosis epidemic in 2001 to 2003.
p24148
sg16446
(lp24149
(dp24150
g16449
I3
sg16450
I1
sg16451
I4
sg16452
VP53990
p24151
sg16454
VIST1
p24152
sasg16456
(lp24153
(dp24154
g16449
I99
sg16450
I1
sg16451
I11
sg16459
VC0013371
p24155
sg16454
Vshigellosis
p24156
sasa(dp24157
g16444
VIn this observational, cross-sectional study, circulating levels of sclerostin and other laboratory parameters of mineral and bone disease, including intact parathyroid hormone (PTH), calcium, phosphate, magnesium, 25(OH) D-vitamin, 1,25 (OH)2 D-vitamin, and bone specific alkaline phosphatase (BALP) were assessed in 100 patients with end-stage renal disease recruited from an ongoing longitudinal cohort study in Stockholm, Sweden.
p24158
sg16446
(lp24159
(dp24160
g16449
I259
sg16450
I4
sg16451
I34
sg16452
VP10696
p24161
sg16454
Vbone specific alkaline phosphatase
p24162
sa(dp24163
g16449
I178
sg16450
I1
sg16451
I3
sg16452
VP01270
p24164
sg16454
VPTH
p24165
sa(dp24166
g16449
I150
sg16450
I3
sg16451
I26
sg16452
VP01270
p24167
sg16454
Vintact parathyroid hormone
p24168
sa(dp24169
g16449
I295
sg16450
I1
sg16451
I4
sg16452
VP10696
p24170
sg16454
VBALP
p24171
sasg16456
(lp24172
(dp24173
g16449
I336
sg16450
I3
sg16451
I23
sg16459
VC0022661
p24174
sg16454
Vend-stage renal disease
p24175
sa(dp24176
g16449
I126
sg16450
I2
sg16451
I12
sg16459
VC0005940
p24177
sg16454
Vbone disease
p24178
sasa(dp24179
g16444
VFindings from research into mineral bone disorder associated with CKD (CKD-MBD) could help the medical community to better understand the vascular actions of certain molecules, such as phosphates, fibroblast growth factor 23, parathyroid hormone, sclerostin, or vitamin D and their relevance to the management of different pathologies in the general population.
p24180
sg16446
(lp24181
(dp24182
g16449
I197
sg16450
I4
sg16451
I27
sg16452
g11
sg16454
Vfibroblast growth factor 23
p24183
sa(dp24184
g16449
I226
sg16450
I2
sg16451
I19
sg16452
VP01270
p24185
sg16454
Vparathyroid hormone
p24186
sasg16456
(lp24187
(dp24188
g16449
I36
sg16450
I2
sg16451
I13
sg16459
VC0005940
p24189
sg16454
Vbone disorder
p24190
sasa(dp24191
g16444
VIn chronic kidney disease (CKD), sclerostin is a putative driver of the bone-vascular axis.
p24192
sg16446
(lp24193
(dp24194
g16449
I33
sg16450
I1
sg16451
I10
sg16452
g11
sg16454
Vsclerostin
p24195
sasg16456
(lp24196
(dp24197
g16449
I3
sg16450
I3
sg16451
I22
sg16459
VC1561643
p24198
sg16454
Vchronic kidney disease
p24199
sa(dp24200
g16449
I27
sg16450
I1
sg16451
I3
sg16459
VC1561643
p24201
sg16454
VCKD
p24202
sasa(dp24203
g16444
VClinical inference relating sclerostin levels found in the general, CKD and dialysis populations is largely influenced by the assay used to measure this biomarker.
p24204
sg16446
(lp24205
sg16456
(lp24206
sa(dp24207
g16444
V(3) Compared with the control group, the expression of CD63 in basophils increased in anaphylactic shock lung tissue.
p24208
sg16446
(lp24209
(dp24210
g16449
I55
sg16450
I1
sg16451
I4
sg16452
VP08962
p24211
sg16454
VCD63
p24212
sasg16456
(lp24213
(dp24214
g16449
I86
sg16450
I2
sg16451
I18
sg16459
VC0002792
p24215
sg16454
Vanaphylactic shock
p24216
sa(dp24217
g16449
I99
sg16450
I2
sg16451
I10
sg16459
VC0035222
p24218
sg16454
Vshock lung
p24219
sasa(dp24220
g16444
VTo elucidate a potential mechanism involving BM88/Cend1, RanBPM and Dyrk1B in cell cycle progression/exit, we transiently co-expressed these proteins in mouse neuroblastoma Neuro 2a cells.
p24221
sg16446
(lp24222
(dp24223
g16449
I68
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VDyrk1B
p24224
sa(dp24225
g16449
I50
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCend1
p24226
sa(dp24227
g16449
I45
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VBM88
p24228
sa(dp24229
g16449
I57
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRanBPM
p24230
sasg16456
(lp24231
(dp24232
g16449
I153
sg16450
I2
sg16451
I19
sg16459
VC1524043
p24233
sg16454
Vmouse neuroblastoma
p24234
sasa(dp24235
g16444
VCalcium imaging experiments revealed that P2Y-induced calcium mobilization is diminished in mouse neuroblastoma Neuro 2a cells stably transfected with BM88 (N2A-BM88 cells) as compared with N2A cells or N2A cells differentiated with retinoic acid.
p24236
sg16446
(lp24237
sg16456
(lp24238
(dp24239
g16449
I92
sg16450
I2
sg16451
I19
sg16459
VC1524043
p24240
sg16454
Vmouse neuroblastoma
p24241
sasa(dp24242
g16444
VWe report here that trichostatin-A (TSA) specifically induces the transcription of Cend1, a neuronal-lineage specific regulator of cell cycle exit and differentiation, in neuroblastoma Neuro2A cells, but not in non-neuronal cells.
p24243
sg16446
(lp24244
(dp24245
g16449
I36
sg16450
I1
sg16451
I3
sg16452
VP32119
p24246
sg16454
VTSA
p24247
sa(dp24248
g16449
I83
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCend1
p24249
sa(dp24250
g16449
I20
sg16450
I1
sg16451
I14
sg16452
VP32119
p24251
sg16454
Vtrichostatin-A
p24252
sasg16456
(lp24253
(dp24254
g16449
I171
sg16450
I1
sg16451
I13
sg16459
VC0027819
p24255
sg16454
Vneuroblastoma
p24256
sasa(dp24257
g16444
VHere we have used mouse neuroblastoma Neuro 2a cells as an in vitro model of neuronal differentiation to dissect the functional properties of BM88 by implementing gain- and loss-of-function approaches.
p24258
sg16446
(lp24259
sg16456
(lp24260
(dp24261
g16449
I18
sg16450
I2
sg16451
I19
sg16459
VC1524043
p24262
sg16454
Vmouse neuroblastoma
p24263
sasa(dp24264
g16444
VBM88 overexpression also results in increased levels of the cell cycle regulatory protein p53, and accumulation of the hypophosphorylated form of the retinoblastoma protein leading to cell cycle arrest, with concomitant decreased levels and, in many cells, cytoplasmic localization of cyclin D1.
p24265
sg16446
(lp24266
(dp24267
g16449
I0
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VBM88
p24268
sa(dp24269
g16449
I285
sg16450
I2
sg16451
I9
sg16452
VP24385
p24270
sg16454
Vcyclin D1
p24271
sa(dp24272
g16449
I150
sg16450
I2
sg16451
I22
sg16452
g11
sg16454
Vretinoblastoma protein
p24273
sa(dp24274
g16449
I82
sg16450
I2
sg16451
I11
sg16452
VP42771
p24275
sg16454
Vprotein p53
p24276
sasg16456
(lp24277
(dp24278
g16449
I150
sg16450
I1
sg16451
I14
sg16459
VC0035335
p24279
sg16454
Vretinoblastoma
p24280
sasa(dp24281
g16444
VPrevious studies have shown that the BM88 antigen, a neuron-specific molecule, promotes the differentiation of mouse neuroblastoma cells [23] (Mamalaki A., Boutou E., Hurel C., Patsavoudi E., Tzartos S. and Matsas R. (1995) The BM88 antigen, a novel neuron-specific molecule, enhances the differentiation of mouse neuroblastoma cells.
p24282
sg16446
(lp24283
(dp24284
g16449
I37
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VBM88 antigen
p24285
sa(dp24286
g16449
I37
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VBM88 antigen
p24287
sasg16456
(lp24288
(dp24289
g16449
I111
sg16450
I2
sg16451
I19
sg16459
VC1524043
p24290
sg16454
Vmouse neuroblastoma
p24291
sa(dp24292
g16449
I111
sg16450
I2
sg16451
I19
sg16459
VC1524043
p24293
sg16454
Vmouse neuroblastoma
p24294
sasa(dp24295
g16444
VMoreover, they respond differentially to growth factors [10] (Gomez J., Boutou E., Hurel C., Mamalaki A., Kentroti S. , Vernadakis A. and Matsas R. (1998) Overexpression of the neuron-specific molecule BM88 in mouse neuroblastoma cells: Altered responsiveness to growth factors.
p24296
sg16446
(lp24297
sg16456
(lp24298
(dp24299
g16449
I210
sg16450
I2
sg16451
I19
sg16459
VC1524043
p24300
sg16454
Vmouse neuroblastoma
p24301
sasa(dp24302
g16444
VPrevious studies have shown that the BM88 antigen, a novel neuron-specific molecule, promotes the differentiation of mouse neuroblastoma (Neuro 2a) cells.
p24303
sg16446
(lp24304
(dp24305
g16449
I37
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VBM88 antigen
p24306
sasg16456
(lp24307
(dp24308
g16449
I117
sg16450
I2
sg16451
I19
sg16459
VC1524043
p24309
sg16454
Vmouse neuroblastoma
p24310
sasa(dp24311
g16444
VIn conclusion, our findings show that overexpression of the neuron-specific antigen BM88 in neuroblastoma cells modifies their properties with respect to growth factor sensitivity, and, hence, the Neuro 2a and Neuro 2a-BM88 are suitable cell models to examine the role of growth factors in neuronal differentiation.
p24312
sg16446
(lp24313
(dp24314
g16449
I60
sg16450
I3
sg16451
I28
sg16452
VP14209
p24315
sg16454
Vneuron-specific antigen BM88
p24316
sa(dp24317
g16449
I210
sg16450
I2
sg16451
I13
sg16452
g11
sg16454
VNeuro 2a-BM88
p24318
sasg16456
(lp24319
(dp24320
g16449
I92
sg16450
I1
sg16451
I13
sg16459
VC0027819
p24321
sg16454
Vneuroblastoma
p24322
sasa(dp24323
g16444
VHere, we investigated the expression stabilities of ten previously recommended reference genes (ABCT, CYP, EF1A, FBOX, GPDH, RPL30, TUA4, TUB4, TUA5, and UNK2) in soybean under biotic stress from Bean pod mottle virus (BPMV), powdery mildew (PMD), soybean aphid (SBA), and two-spotted spider mite (TSSM).
p24324
sg16446
(lp24325
(dp24326
g16449
I102
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VCYP
p24327
sa(dp24328
g16449
I125
sg16450
I1
sg16451
I5
sg16452
VP62888
p24329
sg16454
VRPL30
p24330
sa(dp24331
g16449
I107
sg16450
I1
sg16451
I4
sg16452
VP68104
p24332
sg16454
VEF1A
p24333
sasg16456
(lp24334
(dp24335
g16449
I242
sg16450
I1
sg16451
I3
sg16459
VC1832661
p24336
sg16454
VPMD
p24337
sa(dp24338
g16449
I226
sg16450
I2
sg16451
I14
sg16459
VC1832661
p24339
sg16454
Vpowdery mildew
p24340
sasa(dp24341
g16444
VIn conclusion, the anti-B7-1 antibody approach may provide a novel therapy for allergic asthma.
p24342
sg16446
(lp24343
sg16456
(lp24344
(dp24345
g16449
I79
sg16450
I2
sg16451
I15
sg16459
VC0155877
p24346
sg16454
Vallergic asthma
p24347
sasa(dp24348
g16444
VTo investigate whether there is altered expression and the clinical significance of soluble co-stimulatory molecules in asthmatic patients, plasma concentrations of sCTLA-4, sCD28, sCD80 and sCD86 in 51 adult allergic asthmatic adults with or without steroid treatment, and 35 sex- and age-matched control subjects were measured by enzyme-linked immunosorbent assay (ELISA).
p24349
sg16446
(lp24350
sg16456
(lp24351
(dp24352
g16449
I120
sg16450
I1
sg16451
I9
sg16459
VC0004096
p24353
sg16454
Vasthmatic
p24354
sa(dp24355
g16449
I120
sg16450
I1
sg16451
I9
sg16459
VC0004096
p24356
sg16454
Vasthmatic
p24357
sasa(dp24358
g16444
VThe surface expression of T cell costimulatory molecules CTLA-4 and CD28 and their counter-ligands, B7 molecules (CD80, CD86), is differentially induced for T cell activation and expansion in allergic asthma.
p24359
sg16446
(lp24360
(dp24361
g16449
I68
sg16450
I1
sg16451
I4
sg16452
VP33681
p24362
sg16454
VCD28
p24363
sa(dp24364
g16449
I120
sg16450
I1
sg16451
I4
sg16452
VP42081
p24365
sg16454
VCD86
p24366
sa(dp24367
g16449
I26
sg16450
I5
sg16451
I37
sg16452
VP16410
p24368
sg16454
VT cell costimulatory molecules CTLA-4
p24369
sa(dp24370
g16449
I114
sg16450
I1
sg16451
I4
sg16452
VP33681
p24371
sg16454
VCD80
p24372
sasg16456
(lp24373
(dp24374
g16449
I192
sg16450
I2
sg16451
I15
sg16459
VC0155877
p24375
sg16454
Vallergic asthma
p24376
sasa(dp24377
g16444
VPlasma concentrations of soluble CTLA-4 (sCTLA-4), CD28, CD80 and CD86 in 51 children with chronic allergic asthma with or without inhaled corticosteroid treatment, and 22 sex- and age-matched control subjects were measured by enzyme-linked immunosorbent assay.
p24378
sg16446
(lp24379
(dp24380
g16449
I57
sg16450
I1
sg16451
I4
sg16452
VP33681
p24381
sg16454
VCD80
p24382
sa(dp24383
g16449
I66
sg16450
I1
sg16451
I4
sg16452
VP42081
p24384
sg16454
VCD86
p24385
sa(dp24386
g16449
I51
sg16450
I1
sg16451
I4
sg16452
VP33681
p24387
sg16454
VCD28
p24388
sa(dp24389
g16449
I33
sg16450
I1
sg16451
I6
sg16452
VP16410
p24390
sg16454
VCTLA-4
p24391
sasg16456
(lp24392
(dp24393
g16449
I99
sg16450
I2
sg16451
I15
sg16459
VC0155877
p24394
sg16454
Vallergic asthma
p24395
sasa(dp24396
g16444
VPlasma sCTLA-4, sCD28 and sCD80 concentrations are elevated in allergic asthma.
p24397
sg16446
(lp24398
sg16456
(lp24399
(dp24400
g16449
I63
sg16450
I2
sg16451
I15
sg16459
VC0155877
p24401
sg16454
Vallergic asthma
p24402
sasa(dp24403
g16444
VThe percentage of myoglobin denaturation (PMD) of the CA groups was also increased according to the level of CA during storage.
p24404
sg16446
(lp24405
(dp24406
g16449
I18
sg16450
I1
sg16451
I9
sg16452
VP02144
p24407
sg16454
Vmyoglobin
p24408
sasg16456
(lp24409
(dp24410
g16449
I42
sg16450
I1
sg16451
I3
sg16459
VC1832661
p24411
sg16454
VPMD
p24412
sa(dp24413
g16449
I4
sg16450
I4
sg16451
I36
sg16459
VC1832661
p24414
sg16454
Vpercentage of myoglobin denaturation
p24415
sasa(dp24416
g16444
VLow expression of (or IHC-negative) COX2, miR-200c, ERCC1 and TS, or high expression of (or IHC-positive) CDC25B and p16 are potential biomarkers for predicting the response of esophageal cancer patients treated with chemo(radio)therapy.
p24417
sg16446
(lp24418
(dp24419
g16449
I36
sg16450
I1
sg16451
I4
sg16452
VP35354
p24420
sg16454
VCOX2
p24421
sa(dp24422
g16449
I117
sg16450
I1
sg16451
I3
sg16452
VP42771
p24423
sg16454
Vp16
p24424
sa(dp24425
g16449
I42
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VmiR-200c
p24426
sa(dp24427
g16449
I106
sg16450
I1
sg16451
I6
sg16452
VP30305
p24428
sg16454
VCDC25B
p24429
sa(dp24430
g16449
I52
sg16450
I1
sg16451
I5
sg16452
VP07992
p24431
sg16454
VERCC1
p24432
sasg16456
(lp24433
(dp24434
g16449
I177
sg16450
I2
sg16451
I17
sg16459
VC0014859
p24435
sg16454
Vesophageal cancer
p24436
sasa(dp24437
g16444
VERCC1-SNP in combination with mRNA ERCC1, DPYD, and ERBB2 from pretherapeutic endoscopic biopsies can predict minor response to chemoradiation, as a basis for individualized therapy of advanced esophageal cancer.
p24438
sg16446
(lp24439
(dp24440
g16449
I6
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VSNP
p24441
sa(dp24442
g16449
I0
sg16450
I1
sg16451
I5
sg16452
VP07992
p24443
sg16454
VERCC1
p24444
sa(dp24445
g16449
I52
sg16450
I1
sg16451
I5
sg16452
VP04626
p24446
sg16454
VERBB2
p24447
sa(dp24448
g16449
I0
sg16450
I1
sg16451
I5
sg16452
VP07992
p24449
sg16454
VERCC1
p24450
sasg16456
(lp24451
(dp24452
g16449
I194
sg16450
I2
sg16451
I17
sg16459
VC0014859
p24453
sg16454
Vesophageal cancer
p24454
sasa(dp24455
g16444
VERCC1 C118T could be a predictive factor for the response to radiotherapy and chemotherapy, but not a prognostic factor for OS in esophageal cancer patients after surgery.
p24456
sg16446
(lp24457
(dp24458
g16449
I0
sg16450
I1
sg16451
I5
sg16452
VP07992
p24459
sg16454
VERCC1
p24460
sasg16456
(lp24461
(dp24462
g16449
I130
sg16450
I2
sg16451
I17
sg16459
VC0014859
p24463
sg16454
Vesophageal cancer
p24464
sasa(dp24465
g16444
VIn the present meta-analysis, we demonstrated that the ERCC1 rs3212986 polymorphism was significantly correlated with the response rate of esophageal cancer patients to neoadjuvant therapy (OR =  .49, 95% CI = 0.31-0.76, heterogeneity P = 0.480).
p24466
sg16446
(lp24467
(dp24468
g16449
I55
sg16450
I2
sg16451
I15
sg16452
VP07992
p24469
sg16454
VERCC1 rs3212986
p24470
sasg16456
(lp24471
(dp24472
g16449
I139
sg16450
I2
sg16451
I17
sg16459
VC0014859
p24473
sg16454
Vesophageal cancer
p24474
sasa(dp24475
g16444
VFurthermore, a considerable correlation was observed between ERCC1 rs11615 and the response rate of esophageal cancer patients to neoadjuvant therapy (OR = 0.228, 95% CI = 0.125-0.418, heterogeneity P = 0.291).
p24476
sg16446
(lp24477
(dp24478
g16449
I61
sg16450
I1
sg16451
I5
sg16452
VP07992
p24479
sg16454
VERCC1
p24480
sasg16456
(lp24481
(dp24482
g16449
I100
sg16450
I2
sg16451
I17
sg16459
VC0014859
p24483
sg16454
Vesophageal cancer
p24484
sasa(dp24485
g16444
VThese findings indicate that the ERCC1 rs11615 and ERCC1 rs312986 polymorphisms may be candidate pharmacogenomic factors capable of predicting the response rate of esophageal cancer patients who accept neoadjuvant therapy.
p24486
sg16446
(lp24487
(dp24488
g16449
I33
sg16450
I2
sg16451
I13
sg16452
VP07992
p24489
sg16454
VERCC1 rs11615
p24490
sa(dp24491
g16449
I33
sg16450
I1
sg16451
I5
sg16452
VP07992
p24492
sg16454
VERCC1
p24493
sasg16456
(lp24494
(dp24495
g16449
I164
sg16450
I2
sg16451
I17
sg16459
VC0014859
p24496
sg16454
Vesophageal cancer
p24497
sasa(dp24498
g16444
VIn patients with colon cancer, the expression of TSP50, MAGE-A(1-6), and SSX1,2,4 genes was associated with a poor prognosis, that of MAGE-C1 and XAGE1 was related to a favorable prognosis.
p24499
sg16446
(lp24500
(dp24501
g16449
I73
sg16450
I2
sg16451
I14
sg16452
g11
sg16454
VSSX1,2,4 genes
p24502
sa(dp24503
g16449
I49
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTSP50
p24504
sa(dp24505
g16449
I146
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VXAGE1
p24506
sa(dp24507
g16449
I56
sg16450
I1
sg16451
I4
sg16452
VP43355
p24508
sg16454
VMAGE
p24509
sasg16456
(lp24510
(dp24511
g16449
I17
sg16450
I2
sg16451
I12
sg16459
VC0699790
p24512
sg16454
Vcolon cancer
p24513
sasa(dp24514
g16444
VConsequently, the expression of CT antigens MAGE-A1, MAGE-A4, CT7/MAGE-C1, NY-ESO-1, and GAGE was analyzed in a series of pediatric melanomas.
p24515
sg16446
(lp24516
(dp24517
g16449
I32
sg16450
I3
sg16451
I19
sg16452
VP43355
p24518
sg16454
VCT antigens MAGE-A1
p24519
sa(dp24520
g16449
I44
sg16450
I1
sg16451
I4
sg16452
VP43355
p24521
sg16454
VMAGE
p24522
sa(dp24523
g16449
I62
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VCT7
p24524
sa(dp24525
g16449
I75
sg16450
I1
sg16451
I8
sg16452
VP78358
p24526
sg16454
VNY-ESO-1
p24527
sa(dp24528
g16449
I53
sg16450
I1
sg16451
I7
sg16452
VP43355
p24529
sg16454
VMAGE-A4
p24530
sasg16456
(lp24531
(dp24532
g16449
I132
sg16450
I1
sg16451
I9
sg16459
VC0025202
p24533
sg16454
Vmelanomas
p24534
sasa(dp24535
g16444
VIn this study, we show that the dying myeloma cells treated with chaetocin resulted in the induction of heat shock protein (HSP) 90, which was inhibited by antioxidant N-acetyl cysteine, and showed an increase in the expression of MAGE-A3 and MAGE-C1/CT7.
p24536
sg16446
(lp24537
(dp24538
g16449
I104
sg16450
I5
sg16451
I27
sg16452
VP34931
p24539
sg16454
Vheat shock protein (HSP) 90
p24540
sa(dp24541
g16449
I251
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VCT7
p24542
sa(dp24543
g16449
I231
sg16450
I1
sg16451
I4
sg16452
VP43355
p24544
sg16454
VMAGE
p24545
sa(dp24546
g16449
I231
sg16450
I1
sg16451
I7
sg16452
VP43355
p24547
sg16454
VMAGE-A3
p24548
sasg16456
(lp24549
(dp24550
g16449
I124
sg16450
I1
sg16451
I3
sg16459
VC0034152
p24551
sg16454
VHSP
p24552
sa(dp24553
g16449
I38
sg16450
I1
sg16451
I7
sg16459
VC0026764
p24554
sg16454
Vmyeloma
p24555
sa(dp24556
g16449
I104
sg16450
I3
sg16451
I18
sg16459
VC0034152
p24557
sg16454
Vheat shock protein
p24558
sasa(dp24559
g16444
VWe used immunohistochemistry to examine the expression of four CTAs (MAGE-A, NY-ESO-1, CT7, and GAGE7) in various types of salivary gland carcinoma (n = 95).
p24560
sg16446
(lp24561
(dp24562
g16449
I77
sg16450
I1
sg16451
I8
sg16452
VP78358
p24563
sg16454
VNY-ESO-1
p24564
sa(dp24565
g16449
I96
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VGAGE7
p24566
sa(dp24567
g16449
I87
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VCT7
p24568
sa(dp24569
g16449
I69
sg16450
I1
sg16451
I6
sg16452
VP43355
p24570
sg16454
VMAGE-A
p24571
sasg16456
(lp24572
(dp24573
g16449
I123
sg16450
I3
sg16451
I24
sg16459
VC0948750
p24574
sg16454
Vsalivary gland carcinoma
p24575
sasa(dp24576
g16444
VWhen carcinoma cases were divided into low-grade and intermediate/high-grade types, NY-ESO-1 and CT7 were expressed more frequently in intermediate/high-grade carcinomas.
p24577
sg16446
(lp24578
(dp24579
g16449
I84
sg16450
I1
sg16451
I8
sg16452
VP78358
p24580
sg16454
VNY-ESO-1
p24581
sa(dp24582
g16449
I97
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VCT7
p24583
sasg16456
(lp24584
(dp24585
g16449
I159
sg16450
I1
sg16451
I10
sg16459
VC0007097
p24586
sg16454
Vcarcinomas
p24587
sa(dp24588
g16449
I5
sg16450
I1
sg16451
I9
sg16459
VC0007097
p24589
sg16454
Vcarcinoma
p24590
sasa(dp24591
g16444
VThe expression of cancer testis antigen MAGE C1 has been linked to the malignant stem cell in this disease, and thus, we investigated the use of both flow cytometric and qRTPCR approaches to monitor its expression as an alternative monitoring methodology in this pilot study.
p24592
sg16446
(lp24593
(dp24594
g16449
I25
sg16450
I4
sg16451
I22
sg16452
VP15735
p24595
sg16454
Vtestis antigen MAGE C1
p24596
sasg16456
(lp24597
(dp24598
g16449
I18
sg16450
I2
sg16451
I13
sg16459
VC0153594
p24599
sg16454
Vcancer testis
p24600
sasa(dp24601
g16444
VThese variants were found in genes associated with cancers (ANKRD35, DNAH9, MAGEC1, TOX3) or participating in cancer-related signaling pathways (THSD1, MORN2, PTCRA).
p24602
sg16446
(lp24603
(dp24604
g16449
I152
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VMORN2
p24605
sa(dp24606
g16449
I84
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VTOX3
p24607
sa(dp24608
g16449
I69
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VDNAH9
p24609
sa(dp24610
g16449
I145
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTHSD1
p24611
sa(dp24612
g16449
I76
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VMAGEC1
p24613
sa(dp24614
g16449
I159
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VPTCRA
p24615
sa(dp24616
g16449
I60
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VANKRD35
p24617
sasg16456
(lp24618
(dp24619
g16449
I51
sg16450
I1
sg16451
I6
sg16459
VC0006826
p24620
sg16454
Vcancer
p24621
sa(dp24622
g16449
I51
sg16450
I1
sg16451
I7
sg16459
VC0006826
p24623
sg16454
Vcancers
p24624
sasa(dp24625
g16444
VOur study aims to analyze the expression pattern, mechanism, and prognostic significance of melanoma-associated antigen MAGE-C1 and MAGE-C2 in breast cancer.
p24626
sg16446
(lp24627
(dp24628
g16449
I132
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VMAGE-C2
p24629
sa(dp24630
g16449
I120
sg16450
I1
sg16451
I4
sg16452
VP43355
p24631
sg16454
VMAGE
p24632
sasg16456
(lp24633
(dp24634
g16449
I92
sg16450
I1
sg16451
I8
sg16459
VC0025202
p24635
sg16454
Vmelanoma
p24636
sa(dp24637
g16449
I143
sg16450
I2
sg16451
I13
sg16459
VC0678222
p24638
sg16454
Vbreast cancer
p24639
sasa(dp24640
g16444
VReverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry were used to investigate the expressions of MAGE-C1 and MAGE-C2 in breast benign disease specimens, tumor-free breast specimens, and breast cancer specimens; their correlation with clinicopathologic parameters and recurrence-free survival was elucidated.
p24641
sg16446
(lp24642
(dp24643
g16449
I126
sg16450
I1
sg16451
I4
sg16452
VP43355
p24644
sg16454
VMAGE
p24645
sa(dp24646
g16449
I126
sg16450
I1
sg16451
I4
sg16452
VP43355
p24647
sg16454
VMAGE
p24648
sasg16456
(lp24649
(dp24650
g16449
I215
sg16450
I2
sg16451
I13
sg16459
VC0678222
p24651
sg16454
Vbreast cancer
p24652
sa(dp24653
g16449
I182
sg16450
I1
sg16451
I5
sg16459
VC0027651
p24654
sg16454
Vtumor
p24655
sa(dp24656
g16449
I296
sg16450
I1
sg16451
I10
sg16459
VC1458156
p24657
sg16454
Vrecurrence
p24658
sasa(dp24659
g16444
VWe examined the influence of DNA methylase inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR) together with histone deacetylase inhibitor trichostatin A on the expression of MAGE-C1 and MAGE-C2 in breast cancer cell lines.
p24660
sg16446
(lp24661
(dp24662
g16449
I122
sg16450
I3
sg16451
I24
sg16452
VP32119
p24663
sg16454
Vinhibitor trichostatin A
p24664
sa(dp24665
g16449
I168
sg16450
I1
sg16451
I4
sg16452
VP43355
p24666
sg16454
VMAGE
p24667
sa(dp24668
g16449
I102
sg16450
I2
sg16451
I19
sg16452
VP56524
p24669
sg16454
Vhistone deacetylase
p24670
sa(dp24671
g16449
I180
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VMAGE-C2
p24672
sasg16456
(lp24673
(dp24674
g16449
I191
sg16450
I2
sg16451
I13
sg16459
VC0678222
p24675
sg16454
Vbreast cancer
p24676
sasa(dp24677
g16444
VProteins for MAGE-C1 and MAGE-C2 expressions were 38.3% and 58.3% in breast cancer specimens, messenger RNA for MAGE-C1 and MAGE-C2 expressions were 43.3% and 61.7%, respectively.
p24678
sg16446
(lp24679
(dp24680
g16449
I13
sg16450
I1
sg16451
I4
sg16452
VP43355
p24681
sg16454
VMAGE
p24682
sa(dp24683
g16449
I13
sg16450
I1
sg16451
I4
sg16452
VP43355
p24684
sg16454
VMAGE
p24685
sa(dp24686
g16449
I13
sg16450
I1
sg16451
I4
sg16452
VP43355
p24687
sg16454
VMAGE
p24688
sa(dp24689
g16449
I13
sg16450
I1
sg16451
I4
sg16452
VP43355
p24690
sg16454
VMAGE
p24691
sasg16456
(lp24692
(dp24693
g16449
I69
sg16450
I2
sg16451
I13
sg16459
VC0678222
p24694
sg16454
Vbreast cancer
p24695
sasa(dp24696
g16444
VMAGE-C1 and MAGE-C2 maybe potential targets for tumor immunotherapy, and their expressions are associated with advanced breast cancer and poor outcome.
p24697
sg16446
(lp24698
(dp24699
g16449
I0
sg16450
I1
sg16451
I4
sg16452
VP43355
p24700
sg16454
VMAGE
p24701
sa(dp24702
g16449
I0
sg16450
I1
sg16451
I4
sg16452
VP43355
p24703
sg16454
VMAGE
p24704
sasg16456
(lp24705
(dp24706
g16449
I120
sg16450
I2
sg16451
I13
sg16459
VC0678222
p24707
sg16454
Vbreast cancer
p24708
sa(dp24709
g16449
I48
sg16450
I1
sg16451
I5
sg16459
VC0027651
p24710
sg16454
Vtumor
p24711
sasa(dp24712
g16444
VAs CT7 and CT10 are highly expressed in cutaneous melanoma and are immunogenic in this disease, we analysed their expression throughout the different subtypes of mucosal melanoma and tumor development.
p24713
sg16446
(lp24714
(dp24715
g16449
I3
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VCT7
p24716
sa(dp24717
g16449
I11
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCT10
p24718
sasg16456
(lp24719
(dp24720
g16449
I50
sg16450
I1
sg16451
I8
sg16459
VC0025202
p24721
sg16454
Vmelanoma
p24722
sa(dp24723
g16449
I183
sg16450
I1
sg16451
I5
sg16459
VC0027651
p24724
sg16454
Vtumor
p24725
sa(dp24726
g16449
I40
sg16450
I2
sg16451
I18
sg16459
VC0025202
p24727
sg16454
Vcutaneous melanoma
p24728
sasa(dp24729
g16444
VIn the present study, we investigated expression patterns of nanog in the rat heart after acute myocardial infarction by semi-quantitative RT-PCR, immunohistochemistry and Western blot analyses.
p24730
sg16446
(lp24731
sg16456
(lp24732
(dp24733
g16449
I90
sg16450
I3
sg16451
I27
sg16459
VC0155626
p24734
sg16454
Vacute myocardial infarction
p24735
sasa(dp24736
g16444
VMRI represents the gold standard tool for differential diagnosis (with schwannoma, paraganglioma and haemangioma) and correct staging, while immunohistochemical and cytomorphologic analysis (bcl-2 and CD34 positivity in 90% of cases) is needed for definitive diagnosis.
p24737
sg16446
(lp24738
(dp24739
g16449
I191
sg16450
I1
sg16451
I5
sg16452
VP10415
p24740
sg16454
Vbcl-2
p24741
sa(dp24742
g16449
I201
sg16450
I1
sg16451
I4
sg16452
VP28906
p24743
sg16454
VCD34
p24744
sasg16456
(lp24745
(dp24746
g16449
I101
sg16450
I1
sg16451
I11
sg16459
VC0018916
p24747
sg16454
Vhaemangioma
p24748
sa(dp24749
g16449
I71
sg16450
I1
sg16451
I10
sg16459
VC0027809
p24750
sg16454
Vschwannoma
p24751
sa(dp24752
g16449
I83
sg16450
I1
sg16451
I13
sg16459
VC0030421
p24753
sg16454
Vparaganglioma
p24754
sasa(dp24755
g16444
VL'RMN rappresenta l'esame principale per escludere altre diagnosi (schwannoma, paragangliome ed emangioma) e per una corretta stadiazione mentre l'immunoistochimica e l'analisi citomorfologica (bcl-2 e CD34 positiva nel 90% dei casi) e la base per una diagnosi definitiva.
p24756
sg16446
(lp24757
(dp24758
g16449
I202
sg16450
I1
sg16451
I4
sg16452
VP28906
p24759
sg16454
VCD34
p24760
sa(dp24761
g16449
I194
sg16450
I1
sg16451
I5
sg16452
VP10415
p24762
sg16454
Vbcl-2
p24763
sasg16456
(lp24764
(dp24765
g16449
I67
sg16450
I1
sg16451
I10
sg16459
VC0027809
p24766
sg16454
Vschwannoma
p24767
sasa(dp24768
g16444
VDisease-specific iPS cells were generated from skin fibroblasts obtained from the indicated PMD patient and two other PMD patients having a 637-kb chromosomal duplication including entire PLP1 and a novel missense mutation (W212C) of PLP1, by transfections of OCT3/4, C-MYC, KLF4 and SOX2 using retro-virus vectors.
p24769
sg16446
(lp24770
(dp24771
g16449
I188
sg16450
I1
sg16451
I4
sg16452
VP60201
p24772
sg16454
VPLP1
p24773
sa(dp24774
g16449
I188
sg16450
I1
sg16451
I4
sg16452
VP60201
p24775
sg16454
VPLP1
p24776
sa(dp24777
g16449
I275
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VKLF4
p24778
sa(dp24779
g16449
I268
sg16450
I1
sg16451
I5
sg16452
VP12524
p24780
sg16454
VC-MYC
p24781
sa(dp24782
g16449
I284
sg16450
I1
sg16451
I4
sg16452
VP48431
p24783
sg16454
VSOX2
p24784
sa(dp24785
g16449
I260
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VOCT3/4
p24786
sasg16456
(lp24787
(dp24788
g16449
I147
sg16450
I2
sg16451
I23
sg16459
VC1516516
p24789
sg16454
Vchromosomal duplication
p24790
sa(dp24791
g16449
I17
sg16450
I1
sg16451
I3
sg16459
VC1837610
p24792
sg16454
ViPS
p24793
sa(dp24794
g16449
I92
sg16450
I1
sg16451
I3
sg16459
VC1832661
p24795
sg16454
VPMD
p24796
sa(dp24797
g16449
I92
sg16450
I1
sg16451
I3
sg16459
VC1832661
p24798
sg16454
VPMD
p24799
sasa(dp24800
g16444
VMice with increased KLF4 in NSCs and NSCs-derived ependymal cells developed hydrocephalus-like characteristics, including enlarged ventricles, thinned cortex, agenesis of the corpus callosum, and significantly reduced subcommissural organ.
p24801
sg16446
(lp24802
(dp24803
g16449
I20
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VKLF4
p24804
sasg16456
(lp24805
(dp24806
g16449
I76
sg16450
I1
sg16451
I13
sg16459
VC0020255
p24807
sg16454
Vhydrocephalus
p24808
sa(dp24809
g16449
I159
sg16450
I5
sg16451
I31
sg16459
VC0175754
p24810
sg16454
Vagenesis of the corpus callosum
p24811
sasa(dp24812
g16444
VThese results indicate that down-regulation of KLF4 is critical for neural development and its dysregulation may lead to hydrocephalus.
p24813
sg16446
(lp24814
(dp24815
g16449
I47
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VKLF4
p24816
sasg16456
(lp24817
(dp24818
g16449
I121
sg16450
I1
sg16451
I13
sg16459
VC0020255
p24819
sg16454
Vhydrocephalus
p24820
sasa(dp24821
g16444
VOur findings further reveal that activated Akt and STAT3 pathways induce the upregulation of HIF1Alfa and its downstream targets (LDHA and PDK1), leading to increased glycolysis in myeloma cells.
p24822
sg16446
(lp24823
(dp24824
g16449
I43
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VAkt
p24825
sa(dp24826
g16449
I139
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPDK1
p24827
sa(dp24828
g16449
I130
sg16450
I1
sg16451
I4
sg16452
VP00338
p24829
sg16454
VLDHA
p24830
sa(dp24831
g16449
I51
sg16450
I1
sg16451
I5
sg16452
VP40763
p24832
sg16454
VSTAT3
p24833
sasg16456
(lp24834
(dp24835
g16449
I181
sg16450
I1
sg16451
I7
sg16459
VC0026764
p24836
sg16454
Vmyeloma
p24837
sasa(dp24838
g16444
VWe show the unprecedented role of the metabolic phenotype in inducing drug resistance through LDHA and HIF1A in multiple myeloma, and that specific inhibition of LDHA and HIF1A can restore sensitivity to therapeutic agents such as bortezomib and can also inhibit tumor growth induced by altered metabolism.
p24839
sg16446
(lp24840
(dp24841
g16449
I94
sg16450
I1
sg16451
I4
sg16452
VP00338
p24842
sg16454
VLDHA
p24843
sa(dp24844
g16449
I103
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VHIF1A
p24845
sa(dp24846
g16449
I103
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VHIF1A
p24847
sa(dp24848
g16449
I94
sg16450
I1
sg16451
I4
sg16452
VP00338
p24849
sg16454
VLDHA
p24850
sasg16456
(lp24851
(dp24852
g16449
I263
sg16450
I2
sg16451
I12
sg16459
VC0598934
p24853
sg16454
Vtumor growth
p24854
sa(dp24855
g16449
I112
sg16450
I2
sg16451
I16
sg16459
VC0026764
p24856
sg16454
Vmultiple myeloma
p24857
sasa(dp24858
g16444
VNovel drugs that regulate metabolic pathways in multiple myeloma, specifically targeting LDHA, can be beneficial to inhibit tumor growth and overcome drug resistance.
p24859
sg16446
(lp24860
(dp24861
g16449
I89
sg16450
I1
sg16451
I4
sg16452
VP00338
p24862
sg16454
VLDHA
p24863
sasg16456
(lp24864
(dp24865
g16449
I48
sg16450
I2
sg16451
I16
sg16459
VC0026764
p24866
sg16454
Vmultiple myeloma
p24867
sa(dp24868
g16449
I124
sg16450
I2
sg16451
I12
sg16459
VC0598934
p24869
sg16454
Vtumor growth
p24870
sasa(dp24871
g16444
VA 36,000-Mr protein purified from mouse myeloma on the basis of selective binding to a single-stranded DNA (ssDNA)-cellulose column has been identified as the lactate dehydrogenase A (LDH-A) subunit.
p24872
sg16446
(lp24873
(dp24874
g16449
I184
sg16450
I1
sg16451
I5
sg16452
VP00338
p24875
sg16454
VLDH-A
p24876
sa(dp24877
g16449
I159
sg16450
I3
sg16451
I23
sg16452
VP49366
p24878
sg16454
Vlactate dehydrogenase A
p24879
sasg16456
(lp24880
(dp24881
g16449
I40
sg16450
I1
sg16451
I7
sg16459
VC0026764
p24882
sg16454
Vmyeloma
p24883
sasa(dp24884
g16444
VA homogeneous preparation of this mouse myeloma ssDNA-binding protein, termed the 'low-salt-eluting protein', was found to possess LDH activity, and rabbit antiserum prepared against this protein was shown to cross-react with purified 36,000-Mr LDH-A subunits from mouse and bovine sources.
p24885
sg16446
(lp24886
(dp24887
g16449
I131
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VLDH
p24888
sa(dp24889
g16449
I245
sg16450
I2
sg16451
I14
sg16452
VP00338
p24890
sg16454
VLDH-A subunits
p24891
sa(dp24892
g16449
I34
sg16450
I4
sg16451
I35
sg16452
g11
sg16454
Vmouse myeloma ssDNA-binding protein
p24893
sasg16456
(lp24894
(dp24895
g16449
I40
sg16450
I1
sg16451
I7
sg16459
VC0026764
p24896
sg16454
Vmyeloma
p24897
sa(dp24898
g16449
I123
sg16450
I1
sg16451
I7
sg16459
VC0850310
p24899
sg16454
Vpossess
p24900
sasa(dp24901
g16444
VThese enzymic and immunological identities with LDH-A were not observed with purified helix-destabilizing protein 1 from mouse myeloma.
p24902
sg16446
(lp24903
(dp24904
g16449
I48
sg16450
I1
sg16451
I5
sg16452
VP00338
p24905
sg16454
VLDH-A
p24906
sasg16456
(lp24907
(dp24908
g16449
I127
sg16450
I1
sg16451
I7
sg16459
VC0026764
p24909
sg16454
Vmyeloma
p24910
sasa(dp24911
g16444
VConcentrations of total lactate dehydrogenase (LDH; EC 1.1.1.27) and LDH isoenzyme patterns were studied in serum of 19 patients with multiple myeloma and in 19 healthy controls.
p24912
sg16446
(lp24913
(dp24914
g16449
I24
sg16450
I2
sg16451
I21
sg16452
VP49366
p24915
sg16454
Vlactate dehydrogenase
p24916
sa(dp24917
g16449
I47
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VLDH
p24918
sa(dp24919
g16449
I69
sg16450
I2
sg16451
I13
sg16452
g11
sg16454
VLDH isoenzyme
p24920
sasg16456
(lp24921
(dp24922
g16449
I134
sg16450
I2
sg16451
I16
sg16459
VC0026764
p24923
sg16454
Vmultiple myeloma
p24924
sasa(dp24925
g16444
VDefective DNA repair is tightly correlated with worse neurological outcomes after stroke, whereas upregulation of DNA repair enzymes, such as APE1, OGG1, and XRCC1, improves long-term functional recovery following stroke.
p24926
sg16446
(lp24927
(dp24928
g16449
I158
sg16450
I1
sg16451
I5
sg16452
VP18887
p24929
sg16454
VXRCC1
p24930
sa(dp24931
g16449
I142
sg16450
I1
sg16451
I4
sg16452
VP27695
p24932
sg16454
VAPE1
p24933
sasg16456
(lp24934
(dp24935
g16449
I184
sg16450
I2
sg16451
I19
sg16459
VC0599766
p24936
sg16454
Vfunctional recovery
p24937
sa(dp24938
g16449
I82
sg16450
I1
sg16451
I6
sg16459
VC0038454
p24939
sg16454
Vstroke
p24940
sa(dp24941
g16449
I82
sg16450
I1
sg16451
I6
sg16459
VC0038454
p24942
sg16454
Vstroke
p24943
sasa(dp24944
g16444
VOur data showed that OGG1 Ser326Cys and XRCC1 Arg399Gln gene polymorphisms had impacts on the development of stroke.
p24945
sg16446
(lp24946
(dp24947
g16449
I40
sg16450
I3
sg16451
I20
sg16452
VP18887
p24948
sg16454
VXRCC1 Arg399Gln gene
p24949
sasg16456
(lp24950
(dp24951
g16449
I109
sg16450
I1
sg16451
I6
sg16459
VC0038454
p24952
sg16454
Vstroke
p24953
sasa(dp24954
g16444
VPreviously, our laboratory showed that mice lacking the BER glycosylases 8-oxoguanine glycosylase 1 (Ogg1) or nei endonuclease VIII-like 1 (Neil1) recover more poorly from focal ischemic stroke than wild-type mice.
p24955
sg16446
(lp24956
(dp24957
g16449
I140
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VNeil1
p24958
sa(dp24959
g16449
I110
sg16450
I4
sg16451
I28
sg16452
g11
sg16454
Vnei endonuclease VIII-like 1
p24960
sasg16456
(lp24961
(dp24962
g16449
I178
sg16450
I2
sg16451
I15
sg16459
VC3272363
p24963
sg16454
Vischemic stroke
p24964
sasa(dp24965
g16444
VGenotyping of polymorphisms of the OGG1 (Ser326Cys), XRCC1 (Arg399Gln), ERCC2 (Lys751Gln), and ERCC5 (Asp1104His) genes was performed and used to evaluate LAA stroke susceptibility.
p24966
sg16446
(lp24967
(dp24968
g16449
I95
sg16450
I3
sg16451
I24
sg16452
VP28715
p24969
sg16454
VERCC5 (Asp1104His) genes
p24970
sa(dp24971
g16449
I72
sg16450
I1
sg16451
I5
sg16452
VP18074
p24972
sg16454
VERCC2
p24973
sa(dp24974
g16449
I53
sg16450
I1
sg16451
I5
sg16452
VP18887
p24975
sg16454
VXRCC1
p24976
sasg16456
(lp24977
(dp24978
g16449
I159
sg16450
I1
sg16451
I6
sg16459
VC0038454
p24979
sg16454
Vstroke
p24980
sasa(dp24981
g16444
VA joint effect on risk elevation of LAA stroke was seen in those patients with OGG1 and ERCC2 polymorphisms (OR: 2.75, 95%CI: 1.26-6.00).
p24982
sg16446
(lp24983
(dp24984
g16449
I88
sg16450
I1
sg16451
I5
sg16452
VP18074
p24985
sg16454
VERCC2
p24986
sasg16456
(lp24987
(dp24988
g16449
I40
sg16450
I1
sg16451
I6
sg16459
VC0038454
p24989
sg16454
Vstroke
p24990
sasa(dp24991
g16444
VMoreover, among smokers carrying the OGG1 Ser326Cys polymorphism, there was a tendency toward an increased risk of LAA stroke in those patients who had a greater number of high-risk genotypes of XRCC1, ERCC2, and ERCC5 polymorphisms (p(trend)=0.010).
p24992
sg16446
(lp24993
(dp24994
g16449
I202
sg16450
I1
sg16451
I5
sg16452
VP18074
p24995
sg16454
VERCC2
p24996
sa(dp24997
g16449
I213
sg16450
I1
sg16451
I5
sg16452
VP28715
p24998
sg16454
VERCC5
p24999
sa(dp25000
g16449
I195
sg16450
I1
sg16451
I5
sg16452
VP18887
p25001
sg16454
VXRCC1
p25002
sasg16456
(lp25003
(dp25004
g16449
I119
sg16450
I1
sg16451
I6
sg16459
VC0038454
p25005
sg16454
Vstroke
p25006
sasa(dp25007
g16444
VAmong 22 patients who underwent LP shunt placement for IIH, 16 (72.8%) patients had severe and fulminant opening CSF pressures with values of more than 400 mmH(2)O.
p25008
sg16446
(lp25009
sg16456
(lp25010
sa(dp25011
g16444
VThis study implicates increased I(NaL) in excessive atrial APD prolongation and arrhythmic EAD occurrence in a congenital LQTS3 mouse model.
p25012
sg16446
(lp25013
sg16456
(lp25014
(dp25015
g16449
I91
sg16450
I1
sg16451
I3
sg16459
VC1864233
p25016
sg16454
VEAD
p25017
sasa(dp25018
g16444
V(1) To report the different patterns of NAL and discuss the mechanisms encountered; (2) to determine the relationship between a given type of lymphoma and a specific type of neuropathy; and (3) to assess the prognosis of NAL.
p25019
sg16446
(lp25020
sg16456
(lp25021
(dp25022
g16449
I142
sg16450
I1
sg16451
I8
sg16459
VC0024299
p25023
sg16454
Vlymphoma
p25024
sa(dp25025
g16449
I174
sg16450
I1
sg16451
I10
sg16459
VC0442874
p25026
sg16454
Vneuropathy
p25027
sasa(dp25028
g16444
VTwo thousand four hundred ninety-three consecutive dermatitis patients in 9 dermatology clinics were patch tested with a TDM 6.6%, consisting of Disperse (D) Blue 35, D Yellow 3, D Orange 1 and 3, D Red 1 and 17, all 1.0% each, and D Blue 106 and D Blue 124, each 0.3%.
p25029
sg16446
(lp25030
(dp25031
g16449
I145
sg16450
I15
sg16451
I59
sg16452
VP16435
p25032
sg16454
VDisperse (D) Blue 35, D Yellow 3, D Orange 1 and 3, D Red 1
p25033
sasg16456
(lp25034
(dp25035
g16449
I51
sg16450
I1
sg16451
I10
sg16459
VC0011603
p25036
sg16454
Vdermatitis
p25037
sasa(dp25038
g16444
VThe name hydrolethalus refers to the main findings, namely polyhydramnios, hydrocephalus and lethality.
p25039
sg16446
(lp25040
sg16456
(lp25041
(dp25042
g16449
I75
sg16450
I1
sg16451
I13
sg16459
VC0020255
p25043
sg16454
Vhydrocephalus
p25044
sa(dp25045
g16449
I59
sg16450
I1
sg16451
I14
sg16459
VC0020224
p25046
sg16454
Vpolyhydramnios
p25047
sasa(dp25048
g16444
VVACTERL with hydrocephalus appears distinct from hydrolethalus and similar conditions but is itself heterogeneous.
p25049
sg16446
(lp25050
sg16456
(lp25051
(dp25052
g16449
I13
sg16450
I1
sg16451
I13
sg16459
VC0020255
p25053
sg16454
Vhydrocephalus
p25054
sasa(dp25055
g16444
VIn this study, we evaluated the feasibility of combining p53-DC vaccine and rAd-p53 gene therapy, using the p53-overexpressing and non-expressing prostate cancer cells in vitro.
p25056
sg16446
(lp25057
(dp25058
g16449
I57
sg16450
I1
sg16451
I6
sg16452
VP42771
p25059
sg16454
Vp53-DC
p25060
sa(dp25061
g16449
I57
sg16450
I1
sg16451
I4
sg16452
VP42771
p25062
sg16454
Vp53-
p25063
sa(dp25064
g16449
I57
sg16450
I1
sg16451
I3
sg16452
VP42771
p25065
sg16454
Vp53
p25066
sa(dp25067
g16449
I76
sg16450
I1
sg16451
I3
sg16452
VP55042
p25068
sg16454
VrAd
p25069
sasg16456
(lp25070
(dp25071
g16449
I146
sg16450
I2
sg16451
I15
sg16459
VC0600139
p25072
sg16454
Vprostate cancer
p25073
sasa(dp25074
g16444
VIn addition, rAd-p53 infection can induce overexpression of p53 and thus the cytotoxicity of CTLs differentiated by the p53-DC vaccine in p53 non-expressing prostate cancer cells.
p25075
sg16446
(lp25076
(dp25077
g16449
I17
sg16450
I1
sg16451
I3
sg16452
VP42771
p25078
sg16454
Vp53
p25079
sa(dp25080
g16449
I120
sg16450
I1
sg16451
I6
sg16452
VP42771
p25081
sg16454
Vp53-DC
p25082
sa(dp25083
g16449
I13
sg16450
I1
sg16451
I7
sg16452
VP55042
p25084
sg16454
VrAd-p53
p25085
sa(dp25086
g16449
I17
sg16450
I1
sg16451
I3
sg16452
VP42771
p25087
sg16454
Vp53
p25088
sasg16456
(lp25089
(dp25090
g16449
I77
sg16450
I1
sg16451
I12
sg16459
VC0596402
p25091
sg16454
Vcytotoxicity
p25092
sa(dp25093
g16449
I21
sg16450
I1
sg16451
I9
sg16459
VC0009450
p25094
sg16454
Vinfection
p25095
sa(dp25096
g16449
I157
sg16450
I2
sg16451
I15
sg16459
VC0600139
p25097
sg16454
Vprostate cancer
p25098
sasa(dp25099
g16444
VThis study detected the migration of MSCs to high metastasis liver carcinoma cells MHCC-97H in vitro, investigated the inhibitory effect of rAd-NK4-MSCs on the growth and metastasis of MHCC-97H cells, further explored the inhibitory mechanism of rAd-NK4-MSCs to MHCC-97H cell metastasis, and examined the inhibitory effect of rAd-NK4-MSCs on the migration of human umbilical vein endothelial cells (HUVECs) in vitro.
p25100
sg16446
(lp25101
(dp25102
g16449
I140
sg16450
I1
sg16451
I12
sg16452
VP55042
p25103
sg16454
VrAd-NK4-MSCs
p25104
sa(dp25105
g16449
I140
sg16450
I1
sg16451
I3
sg16452
VP55042
p25106
sg16454
VrAd
p25107
sa(dp25108
g16449
I140
sg16450
I1
sg16451
I12
sg16452
VP55042
p25109
sg16454
VrAd-NK4-MSCs
p25110
sa(dp25111
g16449
I144
sg16450
I1
sg16451
I3
sg16452
VP24001
p25112
sg16454
VNK4
p25113
sasg16456
(lp25114
(dp25115
g16449
I50
sg16450
I1
sg16451
I10
sg16459
VC0027627
p25116
sg16454
Vmetastasis
p25117
sa(dp25118
g16449
I50
sg16450
I1
sg16451
I10
sg16459
VC0027627
p25119
sg16454
Vmetastasis
p25120
sa(dp25121
g16449
I61
sg16450
I2
sg16451
I15
sg16459
VC2239176
p25122
sg16454
Vliver carcinoma
p25123
sa(dp25124
g16449
I50
sg16450
I1
sg16451
I10
sg16459
VC0027627
p25125
sg16454
Vmetastasis
p25126
sasa(dp25127
g16444
VThe present study was conducted to identify the anti-tumor effects of rAd/p53, which is a recombinant human serotype 5 adenovirus, in cutaneous squamous cell carcinoma (cSCC).
p25128
sg16446
(lp25129
(dp25130
g16449
I70
sg16450
I1
sg16451
I3
sg16452
VP55042
p25131
sg16454
VrAd
p25132
sa(dp25133
g16449
I74
sg16450
I1
sg16451
I3
sg16452
VP42771
p25134
sg16454
Vp53
p25135
sasg16456
(lp25136
(dp25137
g16449
I134
sg16450
I4
sg16451
I33
sg16459
VC0553723
p25138
sg16454
Vcutaneous squamous cell carcinoma
p25139
sa(dp25140
g16449
I119
sg16450
I1
sg16451
I10
sg16459
VC0001486
p25141
sg16454
Vadenovirus
p25142
sa(dp25143
g16449
I169
sg16450
I1
sg16451
I4
sg16459
VC0553723
p25144
sg16454
VcSCC
p25145
sa(dp25146
g16449
I53
sg16450
I1
sg16451
I5
sg16459
VC0027651
p25147
sg16454
Vtumor
p25148
sasa(dp25149
g16444
VFinally, the mechanistic experiments indicate that DUXAP10 could interact with Histone demethylase Lysine specific demethylase1 (LSD1) and repress tumor suppressors Large tumor suppressor 2 (LATS2) and Ras-related associated with diabetes (RRAD) transcription in NSCLC cells.
p25150
sg16446
(lp25151
(dp25152
g16449
I79
sg16450
I5
sg16451
I48
sg16452
g11
sg16454
VHistone demethylase Lysine specific demethylase1
p25153
sa(dp25154
g16449
I165
sg16450
I4
sg16451
I24
sg16452
g11
sg16454
VLarge tumor suppressor 2
p25155
sa(dp25156
g16449
I191
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VLATS2
p25157
sa(dp25158
g16449
I202
sg16450
I1
sg16451
I3
sg16452
VP01116
p25159
sg16454
VRas
p25160
sasg16456
(lp25161
(dp25162
g16449
I147
sg16450
I1
sg16451
I5
sg16459
VC0027651
p25163
sg16454
Vtumor
p25164
sa(dp25165
g16449
I230
sg16450
I1
sg16451
I8
sg16459
VC0011849
p25166
sg16454
Vdiabetes
p25167
sa(dp25168
g16449
I147
sg16450
I1
sg16451
I5
sg16459
VC0027651
p25169
sg16454
Vtumor
p25170
sa(dp25171
g16449
I263
sg16450
I1
sg16451
I5
sg16459
VC0007131
p25172
sg16454
VNSCLC
p25173
sasa(dp25174
g16444
VTo compare clinical curative effects and toxicity of recombinant human adenovirus-p53 injection (rAd-p53, Gendicine) combining chemoradiotherapy (CRT)/radiotherapy (RT) with those obtained with CRT/RT alone in nasopharyngeal carcinoma (NPC).
p25175
sg16446
(lp25176
(dp25177
g16449
I97
sg16450
I1
sg16451
I7
sg16452
VP55042
p25178
sg16454
VrAd-p53
p25179
sa(dp25180
g16449
I146
sg16450
I1
sg16451
I3
sg16452
VP27797
p25181
sg16454
VCRT
p25182
sa(dp25183
g16449
I53
sg16450
I4
sg16451
I42
sg16452
VP55042
p25184
sg16454
Vrecombinant human adenovirus-p53 injection
p25185
sa(dp25186
g16449
I127
sg16450
I1
sg16451
I17
sg16452
VP27797
p25187
sg16454
Vchemoradiotherapy
p25188
sasg16456
(lp25189
(dp25190
g16449
I71
sg16450
I1
sg16451
I10
sg16459
VC0001486
p25191
sg16454
Vadenovirus
p25192
sa(dp25193
g16449
I210
sg16450
I2
sg16451
I24
sg16459
VC2931822
p25194
sg16454
Vnasopharyngeal carcinoma
p25195
sa(dp25196
g16449
I236
sg16450
I1
sg16451
I3
sg16459
VC2931822
p25197
sg16454
VNPC
p25198
sasa(dp25199
g16444
VWe used data generated from a haploid hydatidiform mole genome (CHM1) and a diploid human genome (NA12878) to test our approach.
p25200
sg16446
(lp25201
(dp25202
g16449
I64
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCHM1
p25203
sasg16456
(lp25204
(dp25205
g16449
I38
sg16450
I2
sg16451
I17
sg16459
VC0020217
p25206
sg16454
Vhydatidiform mole
p25207
sasa(dp25208
g16444
VOur results show the recovery of an allele of the non-coding minisatellite MS1 (located on chromosome 1 at 1p33-35) at greater than 97% identity to reference (GRCh38) from the unprocessed sequence data of a haploid complete hydatidiform mole (CHM1) cell line.
p25209
sg16446
(lp25210
sg16456
(lp25211
(dp25212
g16449
I215
sg16450
I3
sg16451
I26
sg16459
VC0678213
p25213
sg16454
Vcomplete hydatidiform mole
p25214
sasa(dp25215
g16444
VWe demonstrate the utility of Alpha-CENTAURI in characterizing repeat structure for alpha satellite containing reads in the hydatidiform mole (CHM1, haploid-like) genome.
p25216
sg16446
(lp25217
(dp25218
g16449
I143
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCHM1
p25219
sasg16456
(lp25220
(dp25221
g16449
I124
sg16450
I2
sg16451
I17
sg16459
VC0020217
p25222
sg16454
Vhydatidiform mole
p25223
sasa(dp25224
g16444
VIn order to overcome the issue of allelic diversity, we used genomic DNA from an essentially haploid hydatidiform mole, CHM1.
p25225
sg16446
(lp25226
(dp25227
g16449
I120
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCHM1
p25228
sasg16456
(lp25229
(dp25230
g16449
I101
sg16450
I2
sg16451
I17
sg16459
VC0020217
p25231
sg16454
Vhydatidiform mole
p25232
sasa(dp25233
g16444
VConsistent with these findings, we observed that in an IL-33-administered asthmatic airway inflammation model, IL-13 levels were markedly increased in bronchoalveolar lavage fluid, but its levels were markedly suppressed by treatment with inhibitors of 5-LO, 12-LO or BLT2, further suggesting roles of 5-/12-LO in IL-33-induced IL-13 production.
p25234
sg16446
(lp25235
(dp25236
g16449
I268
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VBLT2
p25237
sa(dp25238
g16449
I111
sg16450
I1
sg16451
I5
sg16452
VP35225
p25239
sg16454
VIL-13
p25240
sa(dp25241
g16449
I111
sg16450
I1
sg16451
I5
sg16452
VP35225
p25242
sg16454
VIL-13
p25243
sasg16456
(lp25244
(dp25245
g16449
I91
sg16450
I1
sg16451
I12
sg16459
VC0021368
p25246
sg16454
Vinflammation
p25247
sa(dp25248
g16449
I74
sg16450
I1
sg16451
I9
sg16459
VC0004096
p25249
sg16454
Vasthmatic
p25250
sasa(dp25251
g16444
VOur results suggest that "MyD88-5-/12-LO-BLT2-NF-KB" cascade significantly contributes to the IL-33-induced synthesis of IL-13 in mast cells, thus potentially contributing to asthmatic development and exacerbation.
p25252
sg16446
(lp25253
(dp25254
g16449
I41
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VBLT2
p25255
sa(dp25256
g16449
I26
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VMyD88
p25257
sa(dp25258
g16449
I121
sg16450
I1
sg16451
I5
sg16452
VP35225
p25259
sg16454
VIL-13
p25260
sasg16456
(lp25261
(dp25262
g16449
I175
sg16450
I1
sg16451
I9
sg16459
VC0004096
p25263
sg16454
Vasthmatic
p25264
sasa(dp25265
g16444
VDNA methylation changes at a number of these genes have been linked to various forms of human disease, including cancers, such as asthma and acute myeloid leukemia (ALOX12), gastric cancer (EBF3), breast cancer (NAV1), colon cancer and acute lymphoid leukemia (KCNK15), Wilms tumor (protocadherin gene cluster; PCDHAs) and colorectal cancer (TCERG1L), suggesting a potential etiologic role for MEs in tumorigenesis and underscoring the possible developmental origins of these malignancies.
p25266
sg16446
(lp25267
(dp25268
g16449
I174
sg16450
I12
sg16451
I85
sg16452
VP12830
p25269
sg16454
Vgastric cancer (EBF3), breast cancer (NAV1), colon cancer and acute lymphoid leukemia
p25270
sa(dp25271
g16449
I270
sg16450
I10
sg16451
I80
sg16452
g11
sg16454
VWilms tumor (protocadherin gene cluster; PCDHAs) and colorectal cancer (TCERG1L)
p25272
sa(dp25273
g16449
I261
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VKCNK15
p25274
sasg16456
(lp25275
(dp25276
g16449
I197
sg16450
I2
sg16451
I13
sg16459
VC0678222
p25277
sg16454
Vbreast cancer
p25278
sa(dp25279
g16449
I401
sg16450
I1
sg16451
I13
sg16459
VC0007621
p25280
sg16454
Vtumorigenesis
p25281
sa(dp25282
g16449
I174
sg16450
I2
sg16451
I14
sg16459
VC0024623
p25283
sg16454
Vgastric cancer
p25284
sa(dp25285
g16449
I141
sg16450
I3
sg16451
I22
sg16459
VC0023467
p25286
sg16454
Vacute myeloid leukemia
p25287
sa(dp25288
g16449
I236
sg16450
I3
sg16451
I23
sg16459
VC1961102
p25289
sg16454
Vacute lymphoid leukemia
p25290
sa(dp25291
g16449
I219
sg16450
I2
sg16451
I12
sg16459
VC0699790
p25292
sg16454
Vcolon cancer
p25293
sa(dp25294
g16449
I130
sg16450
I1
sg16451
I6
sg16459
VC0004096
p25295
sg16454
Vasthma
p25296
sa(dp25297
g16449
I476
sg16450
I1
sg16451
I12
sg16459
VC0006826
p25298
sg16454
Vmalignancies
p25299
sa(dp25300
g16449
I323
sg16450
I2
sg16451
I17
sg16459
VC1527249
p25301
sg16454
Vcolorectal cancer
p25302
sa(dp25303
g16449
I394
sg16450
I1
sg16451
I3
sg16459
VC0265215
p25304
sg16454
VMEs
p25305
sa(dp25306
g16449
I113
sg16450
I1
sg16451
I7
sg16459
VC0006826
p25307
sg16454
Vcancers
p25308
sa(dp25309
g16449
I270
sg16450
I2
sg16451
I11
sg16459
VC0027708
p25310
sg16454
VWilms tumor
p25311
sasa(dp25312
g16444
VDNA methylation of ALOX12 may be an epigenetic biomarker for the risk of asthma-related phenotypes.
p25313
sg16446
(lp25314
(dp25315
g16449
I19
sg16450
I1
sg16451
I6
sg16452
VP18054
p25316
sg16454
VALOX12
p25317
sasg16456
(lp25318
(dp25319
g16449
I73
sg16450
I1
sg16451
I6
sg16459
VC0004096
p25320
sg16454
Vasthma
p25321
sasa(dp25322
g16444
VWe provide evidence that MJD in five pedigrees of Azorean descent is also linked to chromosome 14q in an 18-cM region between the markers D14S67 and AACT (multipoint lod score +7.00 near D14S81).
p25323
sg16446
(lp25324
(dp25325
g16449
I149
sg16450
I1
sg16451
I4
sg16452
VP05154
p25326
sg16454
VAACT
p25327
sasg16456
(lp25328
(dp25329
g16449
I25
sg16450
I1
sg16451
I3
sg16459
VC0024408
p25330
sg16454
VMJD
p25331
sasa(dp25332
g16444
VHere we report linkage disequilibrium of rs2288904 with rs3087969 and the association of these SLC44A2 SNPs with Meniere's disease severity.
p25333
sg16446
(lp25334
(dp25335
g16449
I95
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VSLC44A2 SNPs
p25336
sasg16456
(lp25337
(dp25338
g16449
I23
sg16450
I1
sg16451
I14
sg16459
VC0394006
p25339
sg16454
Vdisequilibrium
p25340
sa(dp25341
g16449
I113
sg16450
I2
sg16451
I17
sg16459
VC0025281
p25342
sg16454
VMeniere's disease
p25343
sasa(dp25344
g16444
VThe association of SLC44A2 SNPs with VTE suggests that thrombi affecting cochlear vessels could be a factor in Meniere's disease.
p25345
sg16446
(lp25346
(dp25347
g16449
I19
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VSLC44A2 SNPs
p25348
sasg16456
(lp25349
(dp25350
g16449
I55
sg16450
I1
sg16451
I7
sg16459
VC0087086
p25351
sg16454
Vthrombi
p25352
sa(dp25353
g16449
I111
sg16450
I2
sg16451
I17
sg16459
VC0025281
p25354
sg16454
VMeniere's disease
p25355
sasa(dp25356
g16444
VThe present study deals with CTLA-4 gene selected polymorphisms (rs11571317 C/T and rs3087243G/A) to explore their relation with breast cancer susceptibility and progression in BC patients.
p25357
sg16446
(lp25358
(dp25359
g16449
I29
sg16450
I2
sg16451
I11
sg16452
VP16410
p25360
sg16454
VCTLA-4 gene
p25361
sasg16456
(lp25362
(dp25363
g16449
I129
sg16450
I2
sg16451
I13
sg16459
VC0678222
p25364
sg16454
Vbreast cancer
p25365
sasa(dp25366
g16444
VClinical experience with checkpoint inhibitors in hepatocellular carcinoma includes early trials with the anti-CTLA-4 agent tremelimumab, and a large phase 2 trial with the anti-PD-1 agent nivolumab.
p25367
sg16446
(lp25368
(dp25369
g16449
I106
sg16450
I1
sg16451
I11
sg16452
VP16410
p25370
sg16454
Vanti-CTLA-4
p25371
sasg16456
(lp25372
(dp25373
g16449
I50
sg16450
I2
sg16451
I24
sg16459
VC1512411
p25374
sg16454
Vhepatocellular carcinoma
p25375
sasa(dp25376
g16444
VSeveral immune checkpoint inhibitors that target programmed cell death protein 1 (PD1), its ligand PDL1, and cytotoxic T lymphocyte-associated protein 4 (CTLA4) have already been approved for use in bladder cancer, representing the most important change to the urological oncologist's tool-kit in over a decade.
p25377
sg16446
(lp25378
(dp25379
g16449
I154
sg16450
I1
sg16451
I5
sg16452
VP16410
p25380
sg16454
VCTLA4
p25381
sa(dp25382
g16449
I99
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPDL1
p25383
sa(dp25384
g16449
I82
sg16450
I1
sg16451
I3
sg16452
VP37840
p25385
sg16454
VPD1
p25386
sa(dp25387
g16449
I109
sg16450
I5
sg16451
I43
sg16452
VP16410
p25388
sg16454
Vcytotoxic T lymphocyte-associated protein 4
p25389
sa(dp25390
g16449
I49
sg16450
I5
sg16451
I31
sg16452
VP37840
p25391
sg16454
Vprogrammed cell death protein 1
p25392
sasg16456
(lp25393
(dp25394
g16449
I199
sg16450
I2
sg16451
I14
sg16459
VC0699885
p25395
sg16454
Vbladder cancer
p25396
sasa(dp25397
g16444
VOur model predicts survival in anti-CTLA-4-treated patients with melanoma and anti-PD-1-treated patients with lung cancer.
p25398
sg16446
(lp25399
(dp25400
g16449
I31
sg16450
I1
sg16451
I11
sg16452
VP16410
p25401
sg16454
Vanti-CTLA-4
p25402
sa(dp25403
g16449
I78
sg16450
I1
sg16451
I9
sg16452
VP18621
p25404
sg16454
Vanti-PD-1
p25405
sasg16456
(lp25406
(dp25407
g16449
I65
sg16450
I1
sg16451
I8
sg16459
VC0025202
p25408
sg16454
Vmelanoma
p25409
sa(dp25410
g16449
I110
sg16450
I2
sg16451
I11
sg16459
VC0684249
p25411
sg16454
Vlung cancer
p25412
sasa(dp25413
g16444
VSmall animal PET/CT studies showed that 89Zr-C4 detected antigen levels on a patient derived xenograft (PDX) established from a non-small-cell lung cancer (NSCLC) patient before an 8-month response to anti-PD-1 and anti-CTLA4 therapy.
p25414
sg16446
(lp25415
(dp25416
g16449
I201
sg16450
I1
sg16451
I9
sg16452
VP18621
p25417
sg16454
Vanti-PD-1
p25418
sa(dp25419
g16449
I215
sg16450
I1
sg16451
I10
sg16452
VP16410
p25420
sg16454
Vanti-CTLA4
p25421
sasg16456
(lp25422
(dp25423
g16449
I128
sg16450
I3
sg16451
I26
sg16459
VC0007131
p25424
sg16454
Vnon-small-cell lung cancer
p25425
sa(dp25426
g16449
I156
sg16450
I1
sg16451
I5
sg16459
VC0007131
p25427
sg16454
VNSCLC
p25428
sasa(dp25429
g16444
VAutosomal disorders such as mutations of the phosphomannomutase 2 (PMM2) gene, the galactose-1-phosphate uridyltransferase (GALT) gene, the FSH receptor (FSHR) gene, chromosome 3q containing the Blepharophimosis gene and the autoimmune regulator (AIRE) gene, responsible for polyendocrinopathy-candidiasis-ectodermal dystrophy, have been identified in patients with POF.
p25430
sg16446
(lp25431
(dp25432
g16449
I124
sg16450
I1
sg16451
I4
sg16452
VP15291
p25433
sg16454
VGALT
p25434
sa(dp25435
g16449
I154
sg16450
I1
sg16451
I4
sg16452
VP23945
p25436
sg16454
VFSHR
p25437
sa(dp25438
g16449
I140
sg16450
I2
sg16451
I12
sg16452
VP23945
p25439
sg16454
VFSH receptor
p25440
sa(dp25441
g16449
I67
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPMM2
p25442
sa(dp25443
g16449
I83
sg16450
I2
sg16451
I39
sg16452
g11
sg16454
Vgalactose-1-phosphate uridyltransferase
p25444
sa(dp25445
g16449
I45
sg16450
I2
sg16451
I20
sg16452
g11
sg16454
Vphosphomannomutase 2
p25446
sasg16456
(lp25447
(dp25448
g16449
I294
sg16450
I1
sg16451
I11
sg16459
VC0006840
p25449
sg16454
Vcandidiasis
p25450
sa(dp25451
g16449
I317
sg16450
I1
sg16451
I9
sg16459
VC0333606
p25452
sg16454
Vdystrophy
p25453
sa(dp25454
g16449
I195
sg16450
I1
sg16451
I16
sg16459
VC0005744
p25455
sg16454
VBlepharophimosis
p25456
sa(dp25457
g16449
I225
sg16450
I1
sg16451
I10
sg16459
VC0443146
p25458
sg16454
Vautoimmune
p25459
sa(dp25460
g16449
I366
sg16450
I1
sg16451
I3
sg16459
VC0085215
p25461
sg16454
VPOF
p25462
sasa(dp25463
g16444
VOsteoclast-specific genes such as Trap, osteopetrosis-associated transmembrane protein 1 (Ostm1), chloride channel 7 (Clcn7), cathepsin K (Ctsk) as well as osteoclast-specific transcription factor and microphthalmia transcription factor (MITF) were up-regulated in the treated cells, whilst the messenger RNA (mRNA) levels of Dspp, Dmp1 and Opg were reduced in the induced cells.
p25464
sg16446
(lp25465
(dp25466
g16449
I332
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VDmp1
p25467
sa(dp25468
g16449
I126
sg16450
I2
sg16451
I11
sg16452
VP43235
p25469
sg16454
Vcathepsin K
p25470
sa(dp25471
g16449
I118
sg16450
I1
sg16451
I5
sg16452
VP51798
p25472
sg16454
VClcn7
p25473
sa(dp25474
g16449
I201
sg16450
I3
sg16451
I35
sg16452
VP35398
p25475
sg16454
Vmicrophthalmia transcription factor
p25476
sa(dp25477
g16449
I326
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VDspp
p25478
sa(dp25479
g16449
I139
sg16450
I1
sg16451
I4
sg16452
VP43235
p25480
sg16454
VCtsk
p25481
sa(dp25482
g16449
I238
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VMITF
p25483
sa(dp25484
g16449
I34
sg16450
I9
sg16451
I82
sg16452
g11
sg16454
VTrap, osteopetrosis-associated transmembrane protein 1 (Ostm1), chloride channel 7
p25485
sa(dp25486
g16449
I341
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VOpg
p25487
sasg16456
(lp25488
(dp25489
g16449
I40
sg16450
I1
sg16451
I13
sg16459
VC0029454
p25490
sg16454
Vosteopetrosis
p25491
sa(dp25492
g16449
I201
sg16450
I1
sg16451
I14
sg16459
VC0026010
p25493
sg16454
Vmicrophthalmia
p25494
sasa(dp25495
g16444
VCathepsin K is a protease whose expression is driven by microphthalmia transcription factor (MITF) in osteoclasts.
p25496
sg16446
(lp25497
(dp25498
g16449
I0
sg16450
I2
sg16451
I11
sg16452
VP43235
p25499
sg16454
VCathepsin K
p25500
sa(dp25501
g16449
I56
sg16450
I3
sg16451
I35
sg16452
VP35398
p25502
sg16454
Vmicrophthalmia transcription factor
p25503
sa(dp25504
g16449
I93
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VMITF
p25505
sasg16456
(lp25506
(dp25507
g16449
I56
sg16450
I1
sg16451
I14
sg16459
VC0026010
p25508
sg16454
Vmicrophthalmia
p25509
sasa(dp25510
g16444
VAmong cell species that infiltrated in perichondral granulation, LCA, CD68 (monocytes/macrophages), and CD4 cells were dominant in number; MMP-8, MMP-9, and elastase were expressed only in the perichondral granulation; whereas MMP-3 and cathepsin K and L were detected in both chondrocytes and granulations.
p25511
sg16446
(lp25512
(dp25513
g16449
I146
sg16450
I1
sg16451
I5
sg16452
VP14780
p25514
sg16454
VMMP-9
p25515
sa(dp25516
g16449
I139
sg16450
I1
sg16451
I5
sg16452
VP22894
p25517
sg16454
VMMP-8
p25518
sa(dp25519
g16449
I237
sg16450
I4
sg16451
I17
sg16452
VP43235
p25520
sg16454
Vcathepsin K and L
p25521
sa(dp25522
g16449
I104
sg16450
I1
sg16451
I3
sg16452
VP01730
p25523
sg16454
VCD4
p25524
sa(dp25525
g16449
I157
sg16450
I1
sg16451
I8
sg16452
VP30740
p25526
sg16454
Velastase
p25527
sa(dp25528
g16449
I227
sg16450
I1
sg16451
I5
sg16452
VP08254
p25529
sg16454
VMMP-3
p25530
sa(dp25531
g16449
I65
sg16450
I1
sg16451
I3
sg16452
VP09496
p25532
sg16454
VLCA
p25533
sa(dp25534
g16449
I70
sg16450
I1
sg16451
I4
sg16452
VP34810
p25535
sg16454
VCD68
p25536
sasg16456
(lp25537
(dp25538
g16449
I24
sg16450
I1
sg16451
I11
sg16459
VC0332448
p25539
sg16454
Vinfiltrated
p25540
sa(dp25541
g16449
I65
sg16450
I1
sg16451
I3
sg16459
VC0339527
p25542
sg16454
VLCA
p25543
sasa(dp25544
g16444
VOverexpression of microphthalmia transcription factor has been shown to mediate the expression of cathepsin-K in osteoclasts.
p25545
sg16446
(lp25546
(dp25547
g16449
I18
sg16450
I3
sg16451
I35
sg16452
VP35398
p25548
sg16454
Vmicrophthalmia transcription factor
p25549
sa(dp25550
g16449
I98
sg16450
I1
sg16451
I11
sg16452
VP43235
p25551
sg16454
Vcathepsin-K
p25552
sasg16456
(lp25553
(dp25554
g16449
I18
sg16450
I1
sg16451
I14
sg16459
VC0026010
p25555
sg16454
Vmicrophthalmia
p25556
sasa(dp25557
g16444
VWe studied cathepsin-K in 17 cytogenetically confirmed microphthalmia transcription factor/TFE-family translocation renal cell carcinomas.
p25558
sg16446
(lp25559
(dp25560
g16449
I55
sg16450
I3
sg16451
I35
sg16452
VP35398
p25561
sg16454
Vmicrophthalmia transcription factor
p25562
sasg16456
(lp25563
(dp25564
g16449
I116
sg16450
I3
sg16451
I21
sg16459
VC0007134
p25565
sg16454
Vrenal cell carcinomas
p25566
sa(dp25567
g16449
I55
sg16450
I1
sg16451
I14
sg16459
VC0026010
p25568
sg16454
Vmicrophthalmia
p25569
sa(dp25570
g16449
I102
sg16450
I1
sg16451
I13
sg16459
VC0040715
p25571
sg16454
Vtranslocation
p25572
sasa(dp25573
g16444
VRadiographs of the hands of 60 patients with cartilage hair hypoplasia (CHH), 69 with trichorhinophalangeal syndrome I (TRP I) and 11 with TRP II were examined, including 26 longitudinal observations.
p25574
sg16446
(lp25575
(dp25576
g16449
I139
sg16450
I2
sg16451
I6
sg16452
VP13686
p25577
sg16454
VTRP II
p25578
sasg16456
(lp25579
(dp25580
g16449
I120
sg16450
I2
sg16451
I5
sg16459
VC0432233
p25581
sg16454
VTRP I
p25582
sa(dp25583
g16449
I45
sg16450
I3
sg16451
I25
sg16459
VC0220748
p25584
sg16454
Vcartilage hair hypoplasia
p25585
sa(dp25586
g16449
I72
sg16450
I1
sg16451
I3
sg16459
VC0220748
p25587
sg16454
VCHH
p25588
sa(dp25589
g16449
I86
sg16450
I3
sg16451
I32
sg16459
VC0432233
p25590
sg16454
Vtrichorhinophalangeal syndrome I
p25591
sasa(dp25592
g16444
VWe report here the new approach of fusing putidaredoxin reductase (PdR) to the carboxy-terminus of CYP101A1 (P450cam) via a linker peptide and reconstituting camphor hydroxylase activity with free putidaredoxin (Pdx).
p25593
sg16446
(lp25594
(dp25595
g16449
I42
sg16450
I2
sg16451
I23
sg16452
g11
sg16454
Vputidaredoxin reductase
p25596
sa(dp25597
g16449
I67
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VPdR
p25598
sasg16456
(lp25599
(dp25600
g16449
I42
sg16450
I2
sg16451
I23
sg16459
VC1845050
p25601
sg16454
Vputidaredoxin reductase
p25602
sa(dp25603
g16449
I67
sg16450
I1
sg16451
I3
sg16459
VC1845050
p25604
sg16454
VPdR
p25605
sasa(dp25606
g16444
VFor other diseases, a well-established example relates to CYP1B1 where homozygosity for rare mutations occurs in primary congenital glaucoma.
p25607
sg16446
(lp25608
(dp25609
g16449
I58
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCYP1B1
p25610
sasg16456
(lp25611
(dp25612
g16449
I113
sg16450
I3
sg16451
I27
sg16459
VC1533041
p25613
sg16454
Vprimary congenital glaucoma
p25614
sasa(dp25615
g16444
VRare CYP1B1 mutations and possibly polymorphisms may also contribute to risk for more common forms of glaucoma.
p25616
sg16446
(lp25617
(dp25618
g16449
I0
sg16450
I2
sg16451
I11
sg16452
g11
sg16454
VRare CYP1B1
p25619
sasg16456
(lp25620
(dp25621
g16449
I102
sg16450
I1
sg16451
I8
sg16459
VC0017601
p25622
sg16454
Vglaucoma
p25623
sasa(dp25624
g16444
VHowever, the effects of the potential herb-drug interactions (HDIs) between LCA and therapeutic drugs on the inhibition of human cytochrome P450 (CYP) enzymes remain unclear.
p25625
sg16446
(lp25626
(dp25627
g16449
I146
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VCYP
p25628
sa(dp25629
g16449
I123
sg16450
I3
sg16451
I21
sg16452
VP20853
p25630
sg16454
Vhuman cytochrome P450
p25631
sasg16456
(lp25632
(dp25633
g16449
I76
sg16450
I1
sg16451
I3
sg16459
VC0339527
p25634
sg16454
VLCA
p25635
sasa(dp25636
g16444
VIn the present study, the inhibitory effects of LCA on seven major human CYP isoforms, including CYP1A2, 2D6, 2E1, 2C19, 2C8, 2C9 and 3A4, were investigated in human liver microsomes (HLMs).
p25637
sg16446
(lp25638
(dp25639
g16449
I61
sg16450
I4
sg16451
I24
sg16452
g11
sg16454
Vmajor human CYP isoforms
p25640
sa(dp25641
g16449
I97
sg16450
I1
sg16451
I6
sg16452
VP05177
p25642
sg16454
VCYP1A2
p25643
sasg16456
(lp25644
(dp25645
g16449
I48
sg16450
I1
sg16451
I3
sg16459
VC0339527
p25646
sg16454
VLCA
p25647
sasa(dp25648
g16444
VThe results demonstrated that LCA significantly inhibited the activities of CYP1A2, 2C19, 2C8, 2C9 and 3A4 and exhibited weak inhibitory effects on CYP2E1 and CYP2D6.
p25649
sg16446
(lp25650
(dp25651
g16449
I76
sg16450
I1
sg16451
I6
sg16452
VP05177
p25652
sg16454
VCYP1A2
p25653
sa(dp25654
g16449
I148
sg16450
I1
sg16451
I6
sg16452
VP05181
p25655
sg16454
VCYP2E1
p25656
sa(dp25657
g16449
I159
sg16450
I1
sg16451
I6
sg16452
VP10635
p25658
sg16454
VCYP2D6
p25659
sasg16456
(lp25660
(dp25661
g16449
I30
sg16450
I1
sg16451
I3
sg16459
VC0339527
p25662
sg16454
VLCA
p25663
sasa(dp25664
g16444
VDixon and Lineweaver-Burk plots revealed that the inhibition types of LCA against CYP1A2, 2C9, 2C19 and 2C8 were best fit as mixed-type inhibitions, while LCA was a competitive inhibitor towards CYP3A4.
p25665
sg16446
(lp25666
(dp25667
g16449
I195
sg16450
I1
sg16451
I6
sg16452
VP08684
p25668
sg16454
VCYP3A4
p25669
sa(dp25670
g16449
I82
sg16450
I1
sg16451
I6
sg16452
VP05177
p25671
sg16454
VCYP1A2
p25672
sasg16456
(lp25673
(dp25674
g16449
I70
sg16450
I1
sg16451
I3
sg16459
VC0339527
p25675
sg16454
VLCA
p25676
sa(dp25677
g16449
I70
sg16450
I1
sg16451
I3
sg16459
VC0339527
p25678
sg16454
VLCA
p25679
sa(dp25680
g16449
I118
sg16450
I1
sg16451
I3
sg16459
VC0036572
p25681
sg16454
Vfit
p25682
sasa(dp25683
g16444
VFurthermore, the areas under the plasma concentration-time curves (AUCs) of several drugs that are primarily metabolized by CYPs were estimated to increase by 2-398% in the presence of LCA, which suggested that LCA exhibited high HDI potentials via CYP inhibition.
p25684
sg16446
(lp25685
sg16456
(lp25686
(dp25687
g16449
I185
sg16450
I1
sg16451
I3
sg16459
VC0339527
p25688
sg16454
VLCA
p25689
sa(dp25690
g16449
I185
sg16450
I1
sg16451
I3
sg16459
VC0339527
p25691
sg16454
VLCA
p25692
sasa(dp25693
g16444
VTo evaluate safety and efficacy of intravenous pulse cyclophosphamide (CyP) in acute macular serpiginous choroiditis (SC).
p25694
sg16446
(lp25695
sg16456
(lp25696
(dp25697
g16449
I118
sg16450
I1
sg16451
I2
sg16459
VC0729842
p25698
sg16454
VSC
p25699
sa(dp25700
g16449
I93
sg16450
I2
sg16451
I23
sg16459
VC0729842
p25701
sg16454
Vserpiginous choroiditis
p25702
sasa(dp25703
g16444
VDiabetes significantly changed the kidney expression of Rage, Sod2, Tgfb1 and Ctgf, Pdp2, nephrin, and Lias.
p25704
sg16446
(lp25705
(dp25706
g16449
I68
sg16450
I1
sg16451
I5
sg16452
VP01137
p25707
sg16454
VTgfb1
p25708
sa(dp25709
g16449
I103
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VLias
p25710
sa(dp25711
g16449
I56
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VRage
p25712
sa(dp25713
g16449
I62
sg16450
I1
sg16451
I4
sg16452
VP04179
p25714
sg16454
VSod2
p25715
sa(dp25716
g16449
I84
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPdp2
p25717
sa(dp25718
g16449
I78
sg16450
I1
sg16451
I4
sg16452
VP29279
p25719
sg16454
VCtgf
p25720
sa(dp25721
g16449
I90
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
Vnephrin
p25722
sasg16456
(lp25723
(dp25724
g16449
I0
sg16450
I1
sg16451
I8
sg16459
VC0011849
p25725
sg16454
VDiabetes
p25726
sasa(dp25727
g16444
VThe main findings were 1) obesity resulted in a 46% decrease in PDP activity expressed per milligram extracted mitochondrial protein only in RG, while PDP isoform content was unchanged; 2) 8 wk of endurance training led to a significant 1.4-2.2-fold increase in PDP activity of all muscle examined from obese rats, and the concomitant increase in PDP1 protein was only seen in soleus and RG; 3) 8 wk of endurance training led to a trending 1.4-2.2-fold increase in PDP activity of all muscle examined from obese rats, and the concomitant increase in PDP1 protein was only seen in soleus and RG; and 4) PDP2 protein content was not affected by obesity or training.
p25728
sg16446
(lp25729
(dp25730
g16449
I64
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VPDP
p25731
sa(dp25732
g16449
I347
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VPDP1 protein
p25733
sa(dp25734
g16449
I347
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VPDP1 protein
p25735
sa(dp25736
g16449
I602
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPDP2
p25737
sasg16456
(lp25738
(dp25739
g16449
I303
sg16450
I1
sg16451
I5
sg16459
VC0028754
p25740
sg16454
Vobese
p25741
sa(dp25742
g16449
I303
sg16450
I1
sg16451
I5
sg16459
VC0028754
p25743
sg16454
Vobese
p25744
sa(dp25745
g16449
I26
sg16450
I1
sg16451
I7
sg16459
VC0028754
p25746
sg16454
Vobesity
p25747
sa(dp25748
g16449
I26
sg16450
I1
sg16451
I7
sg16459
VC0028754
p25749
sg16454
Vobesity
p25750
sasa(dp25751
g16444
VStarvation and streptozotocin-induced diabetes cause decreases in PDP2 mRNA abundance, PDP2 protein amount, and PDP activity in rat heart and kidney.
p25752
sg16446
(lp25753
(dp25754
g16449
I66
sg16450
I2
sg16451
I9
sg16452
g11
sg16454
VPDP2 mRNA
p25755
sa(dp25756
g16449
I87
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VPDP2 protein
p25757
sa(dp25758
g16449
I66
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VPDP
p25759
sasg16456
(lp25760
(dp25761
g16449
I38
sg16450
I1
sg16451
I8
sg16459
VC0011849
p25762
sg16454
Vdiabetes
p25763
sasa(dp25764
g16444
VThis study analyzed protein expression and DNA alterations for the KRAS, CDKN2A, SMAD4, and TP53 genes by immunohistochemistry and next-generation sequencing in formalin-fixed, paraffin-embedded tumors in 356 patients with resected pancreatic adenocarcinoma who were treated at the Dana-Farber/Brigham and Women's Cancer Center (October 26, 2002, to May 21, 2012), University of Rochester Medical Center (March 1, 2006, to November 1, 2013), or Stanford Cancer Institute (September 26, 1995, to May 22, 2013).
p25765
sg16446
(lp25766
(dp25767
g16449
I73
sg16450
I1
sg16451
I6
sg16452
VP42771
p25768
sg16454
VCDKN2A
p25769
sa(dp25770
g16449
I81
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSMAD4
p25771
sa(dp25772
g16449
I67
sg16450
I1
sg16451
I4
sg16452
VP01116
p25773
sg16454
VKRAS
p25774
sa(dp25775
g16449
I92
sg16450
I2
sg16451
I10
sg16452
VP01893
p25776
sg16454
VTP53 genes
p25777
sasg16456
(lp25778
(dp25779
g16449
I195
sg16450
I1
sg16451
I6
sg16459
VC0027651
p25780
sg16454
Vtumors
p25781
sa(dp25782
g16449
I232
sg16450
I2
sg16451
I25
sg16459
VC0281361
p25783
sg16454
Vpancreatic adenocarcinoma
p25784
sa(dp25785
g16449
I314
sg16450
I1
sg16451
I6
sg16459
VC0006826
p25786
sg16454
VCancer
p25787
sa(dp25788
g16449
I314
sg16450
I1
sg16451
I6
sg16459
VC0006826
p25789
sg16454
VCancer
p25790
sasa(dp25791
g16444
VWe established a genetic diagnosis in six families with autosomal recessive HSP (SPG11 in three families and TFG/SPG57, SACS and ALS2 in one family each).
p25792
sg16446
(lp25793
(dp25794
g16449
I109
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VTFG
p25795
sa(dp25796
g16449
I129
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VALS2
p25797
sa(dp25798
g16449
I120
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSACS
p25799
sa(dp25800
g16449
I76
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VHSP
p25801
sasg16456
(lp25802
(dp25803
g16449
I129
sg16450
I1
sg16451
I4
sg16459
VC1859807
p25804
sg16454
VALS2
p25805
sa(dp25806
g16449
I120
sg16450
I1
sg16451
I4
sg16459
VC1849140
p25807
sg16454
VSACS
p25808
sa(dp25809
g16449
I76
sg16450
I1
sg16451
I3
sg16459
VC0034152
p25810
sg16454
VHSP
p25811
sa(dp25812
g16449
I81
sg16450
I1
sg16451
I5
sg16459
VC1858479
p25813
sg16454
VSPG11
p25814
sasa(dp25815
g16444
VWe are now performing molecular testing of the HSP patients using Sanger sequencing (SPG4, SPG11, SPG31, and ARSACS), comparative genomic hybridization (CGH) array (SPG1, 2, 3A, 4, 5, 6, 7, 8, 10, 11, 13, 15, 17, 20, 21, 31, 33, 39, 42, ABCD1, alsin, and ARSACS), and resequencing microarray (SPG1, 2, 3A, 4, 5, 6, 7, 8, 10, 11, 13, 17, 20, 21, 31, 33, and ABCD1).
p25816
sg16446
(lp25817
(dp25818
g16449
I237
sg16450
I1
sg16451
I5
sg16452
VP33897
p25819
sg16454
VABCD1
p25820
sa(dp25821
g16449
I244
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
Valsin
p25822
sa(dp25823
g16449
I98
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSPG31
p25824
sa(dp25825
g16449
I85
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSPG4
p25826
sa(dp25827
g16449
I237
sg16450
I1
sg16451
I5
sg16452
VP33897
p25828
sg16454
VABCD1
p25829
sasg16456
(lp25830
(dp25831
g16449
I118
sg16450
I3
sg16451
I33
sg16459
VC1855900
p25832
sg16454
Vcomparative genomic hybridization
p25833
sa(dp25834
g16449
I98
sg16450
I1
sg16451
I5
sg16459
VC1853247
p25835
sg16454
VSPG31
p25836
sa(dp25837
g16449
I153
sg16450
I1
sg16451
I3
sg16459
VC1855900
p25838
sg16454
VCGH
p25839
sa(dp25840
g16449
I109
sg16450
I1
sg16451
I6
sg16459
VC1849140
p25841
sg16454
VARSACS
p25842
sa(dp25843
g16449
I91
sg16450
I1
sg16451
I4
sg16459
VC0795953
p25844
sg16454
VSPG1
p25845
sa(dp25846
g16449
I85
sg16450
I1
sg16451
I4
sg16459
VC1866855
p25847
sg16454
VSPG4
p25848
sa(dp25849
g16449
I91
sg16450
I1
sg16451
I4
sg16459
VC0795953
p25850
sg16454
VSPG1
p25851
sa(dp25852
g16449
I91
sg16450
I1
sg16451
I5
sg16459
VC1858479
p25853
sg16454
VSPG11
p25854
sa(dp25855
g16449
I109
sg16450
I1
sg16451
I6
sg16459
VC1849140
p25856
sg16454
VARSACS
p25857
sa(dp25858
g16449
I47
sg16450
I1
sg16451
I3
sg16459
VC0034152
p25859
sg16454
VHSP
p25860
sasa(dp25861
g16444
VMeanwhile, preliminary data showed that SPG11 and ARSACS were common in Japanese ARHSP families.
p25862
sg16446
(lp25863
sg16456
(lp25864
(dp25865
g16449
I40
sg16450
I1
sg16451
I5
sg16459
VC1858479
p25866
sg16454
VSPG11
p25867
sa(dp25868
g16449
I50
sg16450
I1
sg16451
I6
sg16459
VC1849140
p25869
sg16454
VARSACS
p25870
sasa(dp25871
g16444
VWe are now performing molecular testing for the HSP patients using direct sequencing (SPG4, SPG31, and ARSACS), comparative genomic hybridization (CGH) array (SPG1/2/3A/4/5/6/7/8/10/11/13/15/17/20/21/31/33/39/42/ABCD1/alsin/SACS), and resequencing microarray (SPG1/2/3A/4/5/6/7/8/10/11/13/17/20/21/31/33/ABCD1).
p25872
sg16446
(lp25873
(dp25874
g16449
I92
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSPG31
p25875
sa(dp25876
g16449
I212
sg16450
I1
sg16451
I5
sg16452
VP33897
p25877
sg16454
VABCD1
p25878
sa(dp25879
g16449
I212
sg16450
I1
sg16451
I5
sg16452
VP33897
p25880
sg16454
VABCD1
p25881
sa(dp25882
g16449
I86
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSPG4
p25883
sa(dp25884
g16449
I105
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VSACS
p25885
sa(dp25886
g16449
I218
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
Valsin
p25887
sasg16456
(lp25888
(dp25889
g16449
I92
sg16450
I1
sg16451
I5
sg16459
VC1853247
p25890
sg16454
VSPG31
p25891
sa(dp25892
g16449
I103
sg16450
I1
sg16451
I6
sg16459
VC1849140
p25893
sg16454
VARSACS
p25894
sa(dp25895
g16449
I112
sg16450
I3
sg16451
I33
sg16459
VC1855900
p25896
sg16454
Vcomparative genomic hybridization
p25897
sa(dp25898
g16449
I147
sg16450
I1
sg16451
I3
sg16459
VC1855900
p25899
sg16454
VCGH
p25900
sa(dp25901
g16449
I48
sg16450
I1
sg16451
I3
sg16459
VC0034152
p25902
sg16454
VHSP
p25903
sa(dp25904
g16449
I159
sg16450
I1
sg16451
I4
sg16459
VC0795953
p25905
sg16454
VSPG1
p25906
sa(dp25907
g16449
I159
sg16450
I1
sg16451
I4
sg16459
VC0795953
p25908
sg16454
VSPG1
p25909
sa(dp25910
g16449
I105
sg16450
I1
sg16451
I4
sg16459
VC1849140
p25911
sg16454
VSACS
p25912
sa(dp25913
g16449
I86
sg16450
I1
sg16451
I4
sg16459
VC1866855
p25914
sg16454
VSPG4
p25915
sasa(dp25916
g16444
VMeanwhile, preliminary data showed that SPG11 and ARSACS were common in Japanese ARHSP families.
p25917
sg16446
(lp25918
sg16456
(lp25919
(dp25920
g16449
I40
sg16450
I1
sg16451
I5
sg16459
VC1858479
p25921
sg16454
VSPG11
p25922
sa(dp25923
g16449
I50
sg16450
I1
sg16451
I6
sg16459
VC1849140
p25924
sg16454
VARSACS
p25925
sasa(dp25926
g16444
VAutosomal recessive spastic ataxia of Charlevoix-Saguenay is an early onset form of hereditary spastic paraplegia with a peculiar clinical presentation.
p25927
sg16446
(lp25928
sg16456
(lp25929
(dp25930
g16449
I0
sg16450
I6
sg16451
I57
sg16459
VC1849140
p25931
sg16454
VAutosomal recessive spastic ataxia of Charlevoix-Saguenay
p25932
sa(dp25933
g16449
I84
sg16450
I3
sg16451
I29
sg16459
VC0037773
p25934
sg16454
Vhereditary spastic paraplegia
p25935
sasa(dp25936
g16444
VOn the basis of our data, we therefore suggest that social avoidance (expressed as social phobia or avoidant personality disorder) has been underestimated in previous studies of carriers with the FMR-1 full mutation or premutation.
p25937
sg16446
(lp25938
(dp25939
g16449
I196
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VFMR-1
p25940
sasg16456
(lp25941
(dp25942
g16449
I83
sg16450
I2
sg16451
I13
sg16459
VC0031572
p25943
sg16454
Vsocial phobia
p25944
sa(dp25945
g16449
I100
sg16450
I3
sg16451
I29
sg16459
VC0004444
p25946
sg16454
Vavoidant personality disorder
p25947
sasa(dp25948
g16444
VAnalysis of GenBank-derived clones on the Y chromosome revealed the presence of two full-length copies in azoospermia factor region b (AZFb) (PRY1 and PRY2) and two shorter versions of the PRY gene containing exons 3, 4 and 5 in AZFc (PRY3 and PRY4).
p25949
sg16446
(lp25950
(dp25951
g16449
I151
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPRY2
p25952
sa(dp25953
g16449
I106
sg16450
I4
sg16451
I27
sg16452
g11
sg16454
Vazoospermia factor region b
p25954
sa(dp25955
g16449
I135
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VAZFb
p25956
sa(dp25957
g16449
I189
sg16450
I2
sg16451
I8
sg16452
g11
sg16454
VPRY gene
p25958
sa(dp25959
g16449
I142
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPRY1
p25960
sasg16456
(lp25961
(dp25962
g16449
I106
sg16450
I2
sg16451
I18
sg16459
VC1384583
p25963
sg16454
Vazoospermia factor
p25964
sasa(dp25965
g16444
VPRY1 and PRY2, two gene copies that are located in AZFb, a region often deleted in patients with severe male infertility, were shown to be expressed in the testis.
p25966
sg16446
(lp25967
(dp25968
g16449
I9
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPRY2
p25969
sa(dp25970
g16449
I0
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPRY1
p25971
sasg16456
(lp25972
(dp25973
g16449
I104
sg16450
I2
sg16451
I16
sg16459
VC0021364
p25974
sg16454
Vmale infertility
p25975
sasa(dp25976
g16444
VExpression of KIR3DL2 on NK and T cells was quantified in peripheral blood (PB) from 35 patients with SpA and 5 patients with juvenile enthesitis-related arthritis (juvenile ERA); samples were compared with samples from healthy and rheumatoid arthritis (RA) controls.
p25977
sg16446
(lp25978
(dp25979
g16449
I14
sg16450
I1
sg16451
I7
sg16452
VP43630
p25980
sg16454
VKIR3DL2
p25981
sasg16456
(lp25982
(dp25983
g16449
I175
sg16450
I1
sg16451
I2
sg16459
VC0003873
p25984
sg16454
VRA
p25985
sa(dp25986
g16449
I135
sg16450
I1
sg16451
I10
sg16459
VC1282952
p25987
sg16454
Venthesitis
p25988
sa(dp25989
g16449
I232
sg16450
I2
sg16451
I20
sg16459
VC0003873
p25990
sg16454
Vrheumatoid arthritis
p25991
sa(dp25992
g16449
I154
sg16450
I1
sg16451
I9
sg16459
VC0003864
p25993
sg16454
Varthritis
p25994
sasa(dp25995
g16444
VNKB1 inhibits cytoxic activity of T lymphocytes mediated by superantigens, which is one of the contributing factors in the pathogenesis of rheumatoid arthritis (RA).
p25996
sg16446
(lp25997
(dp25998
g16449
I0
sg16450
I1
sg16451
I4
sg16452
VP43629
p25999
sg16454
VNKB1
p26000
sasg16456
(lp26001
(dp26002
g16449
I139
sg16450
I2
sg16451
I20
sg16459
VC0003873
p26003
sg16454
Vrheumatoid arthritis
p26004
sa(dp26005
g16449
I123
sg16450
I1
sg16451
I12
sg16459
VC0699748
p26006
sg16454
Vpathogenesis
p26007
sa(dp26008
g16449
I161
sg16450
I1
sg16451
I2
sg16459
VC0003873
p26009
sg16454
VRA
p26010
sasa(dp26011
g16444
VKiller Ig-like receptors (KIRs) are expressed on CD4(+)CD28(null) T cells, a highly oligoclonal subset of T cells that is expanded in patients with rheumatoid arthritis.
p26012
sg16446
(lp26013
(dp26014
g16449
I0
sg16450
I3
sg16451
I24
sg16452
g11
sg16454
VKiller Ig-like receptors
p26015
sa(dp26016
g16449
I26
sg16450
I1
sg16451
I4
sg16452
VP55040
p26017
sg16454
VKIRs
p26018
sa(dp26019
g16449
I55
sg16450
I1
sg16451
I4
sg16452
VP33681
p26020
sg16454
VCD28
p26021
sa(dp26022
g16449
I49
sg16450
I1
sg16451
I3
sg16452
VP01730
p26023
sg16454
VCD4
p26024
sasg16456
(lp26025
(dp26026
g16449
I148
sg16450
I2
sg16451
I20
sg16459
VC0003873
p26027
sg16454
Vrheumatoid arthritis
p26028
sasa(dp26029
g16444
VFunctional involvement of NKAIN2 in miR-181d-regulated pancreatic cancer development was tested by small interfering RNA-mediated NKAIN2 knockdown in miR-181d-downregulated PANC-1 and AsPC-1 cells.
p26030
sg16446
(lp26031
(dp26032
g16449
I26
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VNKAIN2
p26033
sa(dp26034
g16449
I36
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VmiR-181d
p26035
sa(dp26036
g16449
I36
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VmiR-181d
p26037
sasg16456
(lp26038
(dp26039
g16449
I55
sg16450
I2
sg16451
I17
sg16459
VC0235974
p26040
sg16454
Vpancreatic cancer
p26041
sasa(dp26042
g16444
VNKAIN2 was directly targeted by miR-181d in pancreatic cancer.
p26043
sg16446
(lp26044
(dp26045
g16449
I32
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VmiR-181d
p26046
sa(dp26047
g16449
I0
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VNKAIN2
p26048
sasg16456
(lp26049
(dp26050
g16449
I44
sg16450
I2
sg16451
I17
sg16459
VC0235974
p26051
sg16454
Vpancreatic cancer
p26052
sasa(dp26053
g16444
VSmall interfering RNA-mediated NKAIN2 knockdown reversed the inhibition of miR-181d downregulation on pancreatic cancer development.
p26054
sg16446
(lp26055
(dp26056
g16449
I75
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VmiR-181d
p26057
sa(dp26058
g16449
I31
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VNKAIN2
p26059
sasg16456
(lp26060
(dp26061
g16449
I102
sg16450
I2
sg16451
I17
sg16459
VC0235974
p26062
sg16454
Vpancreatic cancer
p26063
sasa(dp26064
g16444
VInhibiting miR-181d may suppress pancreatic cancer development, possibly through the inverse regulation on NKAIN2.
p26065
sg16446
(lp26066
(dp26067
g16449
I107
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VNKAIN2
p26068
sa(dp26069
g16449
I11
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VmiR-181d
p26070
sasg16456
(lp26071
(dp26072
g16449
I33
sg16450
I2
sg16451
I17
sg16459
VC0235974
p26073
sg16454
Vpancreatic cancer
p26074
sasa(dp26075
g16444
VRecurrent chromosome breakpoints at 6q22.31, leading to truncation and potential loss-of-function of the NKAIN2 gene, in Chinese prostate cancer patients were previously identified.
p26076
sg16446
(lp26077
(dp26078
g16449
I105
sg16450
I2
sg16451
I11
sg16452
g11
sg16454
VNKAIN2 gene
p26079
sasg16456
(lp26080
(dp26081
g16449
I129
sg16450
I2
sg16451
I15
sg16459
VC0600139
p26082
sg16454
Vprostate cancer
p26083
sa(dp26084
g16449
I56
sg16450
I1
sg16451
I10
sg16459
VC1706395
p26085
sg16454
Vtruncation
p26086
sasa(dp26087
g16444
VIn this study we investigated genomic, methylation and expression changes of NKAIN2 in a large number of prostate cancer samples and determined its functional role in prostate cancer cells.
p26088
sg16446
(lp26089
(dp26090
g16449
I77
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VNKAIN2
p26091
sasg16456
(lp26092
(dp26093
g16449
I105
sg16450
I2
sg16451
I15
sg16459
VC0600139
p26094
sg16454
Vprostate cancer
p26095
sa(dp26096
g16449
I105
sg16450
I2
sg16451
I15
sg16459
VC0600139
p26097
sg16454
Vprostate cancer
p26098
sasa(dp26099
g16444
VFluorescence in situ hybridization analysis confirmed that NKAIN2 truncation is specific to Chinese while deletion of the gene is frequent in both Chinese and UK prostate cancers.
p26100
sg16446
(lp26101
(dp26102
g16449
I59
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VNKAIN2
p26103
sasg16456
(lp26104
(dp26105
g16449
I162
sg16450
I2
sg16451
I16
sg16459
VC0376358
p26106
sg16454
Vprostate cancers
p26107
sa(dp26108
g16449
I66
sg16450
I1
sg16451
I10
sg16459
VC1706395
p26109
sg16454
Vtruncation
p26110
sasa(dp26111
g16444
VSomatic mutations of NKAIN2 in prostate cancer samples exist but at very low frequency, suggesting that it is a putative tumor suppressor gene (TSG) with haploid insufficiency.
p26112
sg16446
(lp26113
(dp26114
g16449
I21
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VNKAIN2
p26115
sasg16456
(lp26116
(dp26117
g16449
I31
sg16450
I2
sg16451
I15
sg16459
VC0600139
p26118
sg16454
Vprostate cancer
p26119
sa(dp26120
g16449
I0
sg16450
I2
sg16451
I17
sg16459
VC0544886
p26121
sg16454
VSomatic mutations
p26122
sa(dp26123
g16449
I121
sg16450
I1
sg16451
I5
sg16459
VC0027651
p26124
sg16454
Vtumor
p26125
sasa(dp26126
g16444
VOur functional studies showed that overexpression of NKAIN2 in prostate cancer cells inhibits cellular growth by promoting cell apoptosis, and decreasing cell migration and invasion.
p26127
sg16446
(lp26128
(dp26129
g16449
I53
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VNKAIN2
p26130
sasg16456
(lp26131
(dp26132
g16449
I63
sg16450
I2
sg16451
I15
sg16459
VC0600139
p26133
sg16454
Vprostate cancer
p26134
sa(dp26135
g16449
I173
sg16450
I1
sg16451
I8
sg16459
VC2699153
p26136
sg16454
Vinvasion
p26137
sasa(dp26138
g16444
VConversely, knockdown of NKAIN2 promotes prostate cancer cell growth by inhibiting cell apoptosis, and increasing cell migration and invasion.
p26139
sg16446
(lp26140
(dp26141
g16449
I25
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VNKAIN2
p26142
sasg16456
(lp26143
(dp26144
g16449
I133
sg16450
I1
sg16451
I8
sg16459
VC2699153
p26145
sg16454
Vinvasion
p26146
sa(dp26147
g16449
I50
sg16450
I3
sg16451
I18
sg16459
VC1516170
p26148
sg16454
Vcancer cell growth
p26149
sasa(dp26150
g16444
VThese data imply that NKAIN2 is a novel TSG whose activity is commonly reduced in prostate cancer.
p26151
sg16446
(lp26152
(dp26153
g16449
I40
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VTSG
p26154
sa(dp26155
g16449
I22
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VNKAIN2
p26156
sasg16456
(lp26157
(dp26158
g16449
I82
sg16450
I2
sg16451
I15
sg16459
VC0600139
p26159
sg16454
Vprostate cancer
p26160
sasa(dp26161
g16444
VOur recent work detected recurrent chromosomal truncation at the Na(+)/K(+) transporting ATPase interacting 2 (NKAIN2) gene in prostate cancer, which was also found to be truncated in leukemia and lymphoma, suggesting that NKAIN2 is potentially one of the TSGs located in the 6q commonly deleted region in human cancers.
p26162
sg16446
(lp26163
(dp26164
g16449
I65
sg16450
I5
sg16451
I44
sg16452
g11
sg16454
VNa(+)/K(+) transporting ATPase interacting 2
p26165
sa(dp26166
g16449
I111
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VNKAIN2
p26167
sa(dp26168
g16449
I108
sg16450
I3
sg16451
I15
sg16452
g11
sg16454
V2 (NKAIN2) gene
p26169
sasg16456
(lp26170
(dp26171
g16449
I184
sg16450
I1
sg16451
I8
sg16459
VC0023418
p26172
sg16454
Vleukemia
p26173
sa(dp26174
g16449
I197
sg16450
I1
sg16451
I8
sg16459
VC0024299
p26175
sg16454
Vlymphoma
p26176
sa(dp26177
g16449
I47
sg16450
I1
sg16451
I10
sg16459
VC1706395
p26178
sg16454
Vtruncation
p26179
sa(dp26180
g16449
I312
sg16450
I1
sg16451
I7
sg16459
VC0006826
p26181
sg16454
Vcancers
p26182
sa(dp26183
g16449
I127
sg16450
I2
sg16451
I15
sg16459
VC0600139
p26184
sg16454
Vprostate cancer
p26185
sasa(dp26186
g16444
VFluorescent in situ hybridisation with BAC/PAC clones and long range polymerase chain reaction products assessed in the human genome sequence localised the chromosome 1 breakpoint to a 9.8 kb segment within a hypothetical gene, LOC388735, and the chromosome 6 breakpoint to a 12.8 kb segment in intron 4 of the T-cell lymphoma breakpoint-associated target 1 (TCBA1) gene.
p26187
sg16446
(lp26188
(dp26189
g16449
I359
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTCBA1
p26190
sa(dp26191
g16449
I311
sg16450
I5
sg16451
I46
sg16452
g11
sg16454
VT-cell lymphoma breakpoint-associated target 1
p26192
sasg16456
(lp26193
(dp26194
g16449
I311
sg16450
I2
sg16451
I15
sg16459
VC0079772
p26195
sg16454
VT-cell lymphoma
p26196
sa(dp26197
g16449
I43
sg16450
I1
sg16451
I3
sg16459
VC0033036
p26198
sg16454
VPAC
p26199
sasa(dp26200
g16444
VDisruption and/or formation of TCBA1 fusion genes in T cell lymphoma and leukaemia cell lines suggests a role for this gene in tumorigenesis.
p26201
sg16446
(lp26202
(dp26203
g16449
I31
sg16450
I3
sg16451
I18
sg16452
g11
sg16454
VTCBA1 fusion genes
p26204
sasg16456
(lp26205
(dp26206
g16449
I73
sg16450
I1
sg16451
I9
sg16459
VC0023418
p26207
sg16454
Vleukaemia
p26208
sa(dp26209
g16449
I127
sg16450
I1
sg16451
I13
sg16459
VC0007621
p26210
sg16454
Vtumorigenesis
p26211
sa(dp26212
g16449
I53
sg16450
I3
sg16451
I15
sg16459
VC0079772
p26213
sg16454
VT cell lymphoma
p26214
sasa(dp26215
g16444
VWe identified two T-cell lymphoma/leukemia cell lines with different differentiation stages that had breakpoints within the same novel gene, TCBA1 (T-cell lymphoma breakpoint associated target 1).
p26216
sg16446
(lp26217
(dp26218
g16449
I18
sg16450
I2
sg16451
I15
sg16452
g11
sg16454
VT-cell lymphoma
p26219
sa(dp26220
g16449
I148
sg16450
I6
sg16451
I46
sg16452
g11
sg16454
VT-cell lymphoma breakpoint associated target 1
p26221
sa(dp26222
g16449
I141
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTCBA1
p26223
sasg16456
(lp26224
(dp26225
g16449
I18
sg16450
I2
sg16451
I15
sg16459
VC0079772
p26226
sg16454
VT-cell lymphoma
p26227
sa(dp26228
g16449
I18
sg16450
I2
sg16451
I15
sg16459
VC0079772
p26229
sg16454
VT-cell lymphoma
p26230
sa(dp26231
g16449
I34
sg16450
I1
sg16451
I8
sg16459
VC0023418
p26232
sg16454
Vleukemia
p26233
sasa(dp26234
g16444
VIn a T-cell lymphoblastic lymphoma cell line, HT-1, the TCBA1 fused to SUSP1 (SUMO-1-specific protease), creating a SUSP1-TCBA1 chimeric gene.
p26235
sg16446
(lp26236
(dp26237
g16449
I56
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTCBA1
p26238
sa(dp26239
g16449
I56
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTCBA1
p26240
sa(dp26241
g16449
I71
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSUSP1
p26242
sa(dp26243
g16449
I71
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSUSP1
p26244
sasg16456
(lp26245
(dp26246
g16449
I12
sg16450
I2
sg16451
I22
sg16459
VC0079748
p26247
sg16454
Vlymphoblastic lymphoma
p26248
sasa(dp26249
g16444
VHowever, in an adult T-cell leukemia cell line, ATN-1, no chimeric gene was detected, although aberrant TCBA1 transcripts were produced.
p26250
sg16446
(lp26251
(dp26252
g16449
I104
sg16450
I2
sg16451
I17
sg16452
g11
sg16454
VTCBA1 transcripts
p26253
sasg16456
(lp26254
(dp26255
g16449
I15
sg16450
I3
sg16451
I21
sg16459
VC0023492
p26256
sg16454
Vadult T-cell leukemia
p26257
sa(dp26258
g16449
I48
sg16450
I1
sg16451
I3
sg16459
VC0268494
p26259
sg16454
VATN
p26260
sasa(dp26261
g16444
VThe expression levels of TUG1 were determined using Real-Time qPCR in a total of 44 patients with bladder urothelial carcinomas.
p26262
sg16446
(lp26263
sg16456
(lp26264
(dp26265
g16449
I117
sg16450
I1
sg16451
I10
sg16459
VC0007097
p26266
sg16454
Vcarcinomas
p26267
sasa(dp26268
g16444
VBladder urothelial carcinoma T24 and 5637 cells were transfected with TUG1 siRNA or negative control siRNA.
p26269
sg16446
(lp26270
sg16456
(lp26271
(dp26272
g16449
I0
sg16450
I3
sg16451
I28
sg16459
VC0279680
p26273
sg16454
VBladder urothelial carcinoma
p26274
sasa(dp26275
g16444
VTUG1 was up-regulated in bladder urothelial carcinoma compared to paired normal urothelium.
p26276
sg16446
(lp26277
sg16456
(lp26278
(dp26279
g16449
I25
sg16450
I3
sg16451
I28
sg16459
VC0279680
p26280
sg16454
Vbladder urothelial carcinoma
p26281
sasa(dp26282
g16444
VCell proliferation inhibition and apoptosis induction were observed in TUG1 siRNA-transfected bladder urothelial carcinoma T24 and 5637 cells.
p26283
sg16446
(lp26284
sg16456
(lp26285
(dp26286
g16449
I5
sg16450
I1
sg16451
I13
sg16459
VC0334094
p26287
sg16454
Vproliferation
p26288
sa(dp26289
g16449
I94
sg16450
I3
sg16451
I28
sg16459
VC0279680
p26290
sg16454
Vbladder urothelial carcinoma
p26291
sasa(dp26292
g16444
VOur data suggest that lincRNA TUG1 is emerging as a novel player in the disease state of bladder urothelial carcinoma.
p26293
sg16446
(lp26294
sg16456
(lp26295
(dp26296
g16449
I89
sg16450
I3
sg16451
I28
sg16459
VC0279680
p26297
sg16454
Vbladder urothelial carcinoma
p26298
sasa(dp26299
g16444
VTUG1 may have potential roles as a biomarker and/or a therapeutic target in bladder urothelial carcinoma.
p26300
sg16446
(lp26301
sg16456
(lp26302
(dp26303
g16449
I76
sg16450
I3
sg16451
I28
sg16459
VC0279680
p26304
sg16454
Vbladder urothelial carcinoma
p26305
sasa(dp26306
g16444
VSerial samples of serum Cystatin C and urine NGAL were collected from 139 consecutive patients with congenital heart defects aged 3 days to 30 years after admission to the intensive care unit, 2 and 6 hours after the end of cardiopulmonary bypass.
p26307
sg16446
(lp26308
(dp26309
g16449
I39
sg16450
I2
sg16451
I10
sg16452
VP80188
p26310
sg16454
Vurine NGAL
p26311
sa(dp26312
g16449
I24
sg16450
I2
sg16451
I10
sg16452
VP01034
p26313
sg16454
VCystatin C
p26314
sasg16456
(lp26315
(dp26316
g16449
I100
sg16450
I3
sg16451
I24
sg16459
VC0018798
p26317
sg16454
Vcongenital heart defects
p26318
sasa(dp26319
g16444
VHyper-IgE syndrome (HIES) is a very rare primary immune deficiency characterized by elevated serum IgE levels, recurrent bacterial infections, chronic dermatitis, and connective tissue abnormalities.
p26320
sg16446
(lp26321
(dp26322
g16449
I0
sg16450
I1
sg16451
I9
sg16452
VP01854
p26323
sg16454
VHyper-IgE
p26324
sa(dp26325
g16449
I93
sg16450
I2
sg16451
I9
sg16452
VP01854
p26326
sg16454
Vserum IgE
p26327
sasg16456
(lp26328
(dp26329
g16449
I6
sg16450
I1
sg16451
I3
sg16459
VC0270850
p26330
sg16454
VIgE
p26331
sa(dp26332
g16449
I0
sg16450
I2
sg16451
I18
sg16459
VC0022398
p26333
sg16454
VHyper-IgE syndrome
p26334
sa(dp26335
g16449
I20
sg16450
I1
sg16451
I4
sg16459
VC0022398
p26336
sg16454
VHIES
p26337
sa(dp26338
g16449
I143
sg16450
I2
sg16451
I18
sg16459
VC0262975
p26339
sg16454
Vchronic dermatitis
p26340
sa(dp26341
g16449
I49
sg16450
I2
sg16451
I17
sg16459
VC0850497
p26342
sg16454
Vimmune deficiency
p26343
sa(dp26344
g16449
I111
sg16450
I3
sg16451
I30
sg16459
VC1844383
p26345
sg16454
Vrecurrent bacterial infections
p26346
sasa(dp26347
g16444
VWe describe the clinical course of a 2-month-old infant who was evaluated for autosomal dominant Hyper IgE Syndrome based on eczema, periorbital cellulitis, skin abscesses, increased total IgE levels and blood eosinophilia.
p26348
sg16446
(lp26349
(dp26350
g16449
I103
sg16450
I1
sg16451
I3
sg16452
VP01854
p26351
sg16454
VIgE
p26352
sa(dp26353
g16449
I88
sg16450
I3
sg16451
I18
sg16452
VP01854
p26354
sg16454
Vdominant Hyper IgE
p26355
sasg16456
(lp26356
(dp26357
g16449
I97
sg16450
I3
sg16451
I18
sg16459
VC0022398
p26358
sg16454
VHyper IgE Syndrome
p26359
sa(dp26360
g16449
I125
sg16450
I1
sg16451
I6
sg16459
VC0013595
p26361
sg16454
Veczema
p26362
sa(dp26363
g16449
I210
sg16450
I1
sg16451
I12
sg16459
VC0014457
p26364
sg16454
Veosinophilia
p26365
sa(dp26366
g16449
I157
sg16450
I2
sg16451
I14
sg16459
VC0149777
p26367
sg16454
Vskin abscesses
p26368
sa(dp26369
g16449
I103
sg16450
I1
sg16451
I3
sg16459
VC0270850
p26370
sg16454
VIgE
p26371
sa(dp26372
g16449
I133
sg16450
I2
sg16451
I22
sg16459
VC0149754
p26373
sg16454
Vperiorbital cellulitis
p26374
sasa(dp26375
g16444
VIL-22 induces STAT3 phosphorylation and mediates psoriasis-related gene expression.
p26376
sg16446
(lp26377
(dp26378
g16449
I14
sg16450
I1
sg16451
I5
sg16452
VP40763
p26379
sg16454
VSTAT3
p26380
sa(dp26381
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-22
p26382
sasg16456
(lp26383
(dp26384
g16449
I49
sg16450
I1
sg16451
I9
sg16459
VC0033860
p26385
sg16454
Vpsoriasis
p26386
sasa(dp26387
g16444
VThe IL-22-STAT3-Bcl-3 pathway may be important in the pathogenesis of psoriasis.
p26388
sg16446
(lp26389
(dp26390
g16449
I4
sg16450
I1
sg16451
I17
sg16452
g11
sg16454
VIL-22-STAT3-Bcl-3
p26391
sasg16456
(lp26392
(dp26393
g16449
I54
sg16450
I1
sg16451
I12
sg16459
VC0699748
p26394
sg16454
Vpathogenesis
p26395
sa(dp26396
g16449
I70
sg16450
I1
sg16451
I9
sg16459
VC0033860
p26397
sg16454
Vpsoriasis
p26398
sasa(dp26399
g16444
VBy using quantitative real-time polymerase chain reaction, we identified significant upregulation of PMEPA1 gene expression in malignant tissues of patients with gastric adenocarcinoma.
p26400
sg16446
(lp26401
(dp26402
g16449
I101
sg16450
I2
sg16451
I11
sg16452
g11
sg16454
VPMEPA1 gene
p26403
sasg16456
(lp26404
(dp26405
g16449
I162
sg16450
I2
sg16451
I22
sg16459
VC0278701
p26406
sg16454
Vgastric adenocarcinoma
p26407
sasa(dp26408
g16444
VBy using developed antibodies, we observed pronounced expression of TMEPAI in normal gastric epithelial cells while tumor cells from gastric adenomas, and adenocarcinoma samples were mostly negative for target protein expression.
p26409
sg16446
(lp26410
sg16456
(lp26411
(dp26412
g16449
I141
sg16450
I1
sg16451
I8
sg16459
VC0001430
p26413
sg16454
Vadenomas
p26414
sa(dp26415
g16449
I116
sg16450
I1
sg16451
I5
sg16459
VC0027651
p26416
sg16454
Vtumor
p26417
sa(dp26418
g16449
I155
sg16450
I1
sg16451
I14
sg16459
VC0001418
p26419
sg16454
Vadenocarcinoma
p26420
sasa(dp26421
g16444
VAnalysis of expressed sequence tag databases showed that STAG1/PMEPA1 also was expressed in pancreatic, endometrial, and prostatic adenocarcinomas.
p26422
sg16446
(lp26423
(dp26424
g16449
I57
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSTAG1
p26425
sa(dp26426
g16449
I63
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VPMEPA1
p26427
sasg16456
(lp26428
(dp26429
g16449
I31
sg16450
I1
sg16451
I3
sg16459
VC0037293
p26430
sg16454
Vtag
p26431
sa(dp26432
g16449
I131
sg16450
I1
sg16451
I15
sg16459
VC0001418
p26433
sg16454
Vadenocarcinomas
p26434
sasa(dp26435
g16444
VIt is concluded that co-exposure to PM2.5 and FA exacerbated allergic asthma through oxidative stress and enhanced TRPV1 activation.
p26436
sg16446
(lp26437
(dp26438
g16449
I115
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTRPV1
p26439
sasg16456
(lp26440
(dp26441
g16449
I85
sg16450
I2
sg16451
I16
sg16459
VC0242606
p26442
sg16454
Voxidative stress
p26443
sa(dp26444
g16449
I61
sg16450
I2
sg16451
I15
sg16459
VC0155877
p26445
sg16454
Vallergic asthma
p26446
sasa(dp26447
g16444
VOur data suggests the involvement of TRPV1 in allergic asthma and thus we feel this target merits further investigation.
p26448
sg16446
(lp26449
(dp26450
g16449
I37
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTRPV1
p26451
sasg16456
(lp26452
(dp26453
g16449
I46
sg16450
I2
sg16451
I15
sg16459
VC0155877
p26454
sg16454
Vallergic asthma
p26455
sasa(dp26456
g16444
VTNFAlfa, a proinflammatory cytokine known to be involved in the pathogenesis of allergic asthma, has been shown to induce hyperalgesia in somatic tissue via a sensitizing effect on dorsal root ganglion neurons expressing transient receptor potential vanilloid type 1 receptor (TRPV1).
p26457
sg16446
(lp26458
(dp26459
g16449
I277
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTRPV1
p26460
sa(dp26461
g16449
I221
sg16450
I7
sg16451
I54
sg16452
g11
sg16454
Vtransient receptor potential vanilloid type 1 receptor
p26462
sasg16456
(lp26463
(dp26464
g16449
I193
sg16450
I1
sg16451
I8
sg16459
VC1258666
p26465
sg16454
Vganglion
p26466
sa(dp26467
g16449
I64
sg16450
I1
sg16451
I12
sg16459
VC0699748
p26468
sg16454
Vpathogenesis
p26469
sa(dp26470
g16449
I122
sg16450
I1
sg16451
I12
sg16459
VC0020429
p26471
sg16454
Vhyperalgesia
p26472
sa(dp26473
g16449
I80
sg16450
I2
sg16451
I15
sg16459
VC0155877
p26474
sg16454
Vallergic asthma
p26475
sasa(dp26476
g16444
VSequencing of genes known to be causative for WS [microphthalmia transcription factor (MITF), Pax3, Sox10, SNAI2 ] failed to show any candidate mutations to explain this complex cutaneous depigmentation phenotype.
p26477
sg16446
(lp26478
(dp26479
g16449
I87
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VMITF
p26480
sa(dp26481
g16449
I100
sg16450
I1
sg16451
I5
sg16452
VP56693
p26482
sg16454
VSox10
p26483
sa(dp26484
g16449
I49
sg16450
I3
sg16451
I36
sg16452
g11
sg16454
V[microphthalmia transcription factor
p26485
sa(dp26486
g16449
I107
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSNAI2
p26487
sa(dp26488
g16449
I94
sg16450
I1
sg16451
I4
sg16452
VP23760
p26489
sg16454
VPax3
p26490
sasg16456
(lp26491
(dp26492
g16449
I50
sg16450
I1
sg16451
I14
sg16459
VC0026010
p26493
sg16454
Vmicrophthalmia
p26494
sa(dp26495
g16449
I188
sg16450
I1
sg16451
I14
sg16459
VC0162835
p26496
sg16454
Vdepigmentation
p26497
sasa(dp26498
g16444
VThe mice include splotch (Sp), microphthalmia (mi), Slugh-/-, WS4, JF1, lethal-spotting (ls), and Dominant megacolon (Dom).
p26499
sg16446
(lp26500
(dp26501
g16449
I62
sg16450
I1
sg16451
I3
sg16452
VP56693
p26502
sg16454
VWS4
p26503
sasg16456
(lp26504
(dp26505
g16449
I4
sg16450
I1
sg16451
I2
sg16459
VC0026010
p26506
sg16454
Vmi
p26507
sa(dp26508
g16449
I62
sg16450
I1
sg16451
I3
sg16459
VC1848519
p26509
sg16454
VWS4
p26510
sa(dp26511
g16449
I79
sg16450
I1
sg16451
I8
sg16459
VC0025874
p26512
sg16454
Vspotting
p26513
sa(dp26514
g16449
I107
sg16450
I1
sg16451
I9
sg16459
VC0235904
p26515
sg16454
Vmegacolon
p26516
sa(dp26517
g16449
I31
sg16450
I1
sg16451
I14
sg16459
VC0026010
p26518
sg16454
Vmicrophthalmia
p26519
sasa(dp26520
g16444
VThe effect of ELL3 depletion on cell morphology, latent Epstein Barr Virus (EBV) lytic replication and differentiation markers in a Burkitt's lymphoma (BL) cell line cells are presented.
p26521
sg16446
(lp26522
(dp26523
g16449
I14
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VELL3
p26524
sasg16456
(lp26525
(dp26526
g16449
I132
sg16450
I2
sg16451
I18
sg16459
VC0006413
p26527
sg16454
VBurkitt's lymphoma
p26528
sa(dp26529
g16449
I152
sg16450
I1
sg16451
I2
sg16459
VC0006413
p26530
sg16454
VBL
p26531
sa(dp26532
g16449
I81
sg16450
I1
sg16451
I5
sg16459
VC0024348
p26533
sg16454
Vlytic
p26534
sasa(dp26535
g16444
VBurkitt's lymphoma and a sub-set of Diffuse Large B cell lymphoma cell lines abundantly express ELL3.
p26536
sg16446
(lp26537
(dp26538
g16449
I96
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VELL3
p26539
sasg16456
(lp26540
(dp26541
g16449
I0
sg16450
I2
sg16451
I18
sg16459
VC0006413
p26542
sg16454
VBurkitt's lymphoma
p26543
sa(dp26544
g16449
I36
sg16450
I5
sg16451
I29
sg16459
VC0079744
p26545
sg16454
VDiffuse Large B cell lymphoma
p26546
sasa(dp26547
g16444
VThis article provides a comprehensive review of the syndromes and disorders associated with NTDs, including Pallister-Hall syndrome, Walker-Warburg syndrome and Fukuyama congenital muscular dystrophy, MURCS association, Roberts syndrome, cerebro-costo-mandibular syndrome, laterality sequences, hydrolethalus syndrome, Knobloch syndrome, oculoauriculovertebral spectrum (hemifacial microsomia), cervico-oculo-acoustic syndrome, Fanconi anemia, Miller-Dieker lissencephaly syndrome, Fraser syndrome, frontonasal dysplasia, Adams-Oliver syndrome, CHILD syndrome, dyssegmental dysplasia, and monozygotic twinning.
p26548
sg16446
(lp26549
sg16456
(lp26550
(dp26551
g16449
I328
sg16450
I2
sg16451
I32
sg16459
VC0220681
p26552
sg16454
Vsyndrome, oculoauriculovertebral
p26553
sa(dp26554
g16449
I52
sg16450
I1
sg16451
I9
sg16459
VC0039082
p26555
sg16454
Vsyndromes
p26556
sa(dp26557
g16449
I238
sg16450
I2
sg16451
I33
sg16459
VC0265342
p26558
sg16454
Vcerebro-costo-mandibular syndrome
p26559
sa(dp26560
g16449
I511
sg16450
I1
sg16451
I9
sg16459
VC0334044
p26561
sg16454
Vdysplasia
p26562
sa(dp26563
g16449
I499
sg16450
I2
sg16451
I21
sg16459
VC1876203
p26564
sg16454
Vfrontonasal dysplasia
p26565
sa(dp26566
g16449
I201
sg16450
I2
sg16451
I17
sg16459
VC1832817
p26567
sg16454
VMURCS association
p26568
sa(dp26569
g16449
I52
sg16450
I1
sg16451
I8
sg16459
VC0039082
p26570
sg16454
Vsyndrome
p26571
sa(dp26572
g16449
I522
sg16450
I2
sg16451
I21
sg16459
VC0265268
p26573
sg16454
VAdams-Oliver syndrome
p26574
sa(dp26575
g16449
I395
sg16450
I2
sg16451
I31
sg16459
VC0265239
p26576
sg16454
Vcervico-oculo-acoustic syndrome
p26577
sa(dp26578
g16449
I108
sg16450
I2
sg16451
I23
sg16459
VC0265220
p26579
sg16454
VPallister-Hall syndrome
p26580
sa(dp26581
g16449
I371
sg16450
I2
sg16451
I21
sg16459
VC1306710
p26582
sg16454
Vhemifacial microsomia
p26583
sa(dp26584
g16449
I295
sg16450
I2
sg16451
I22
sg16459
VC2931104
p26585
sg16454
Vhydrolethalus syndrome
p26586
sa(dp26587
g16449
I123
sg16450
I2
sg16451
I24
sg16459
VC0265221
p26588
sg16454
Vsyndrome, Walker-Warburg
p26589
sa(dp26590
g16449
I161
sg16450
I4
sg16451
I38
sg16459
VC0410174
p26591
sg16454
VFukuyama congenital muscular dystrophy
p26592
sa(dp26593
g16449
I482
sg16450
I2
sg16451
I15
sg16459
VC0265233
p26594
sg16454
VFraser syndrome
p26595
sa(dp26596
g16449
I220
sg16450
I2
sg16451
I16
sg16459
VC0392475
p26597
sg16454
VRoberts syndrome
p26598
sa(dp26599
g16449
I545
sg16450
I2
sg16451
I14
sg16459
VC0265267
p26600
sg16454
VCHILD syndrome
p26601
sa(dp26602
g16449
I472
sg16450
I2
sg16451
I16
sg16459
VC0265233
p26603
sg16454
Vsyndrome, Fraser
p26604
sa(dp26605
g16449
I428
sg16450
I2
sg16451
I14
sg16459
VC3469521
p26606
sg16454
VFanconi anemia
p26607
sa(dp26608
g16449
I444
sg16450
I3
sg16451
I36
sg16459
VC0265219
p26609
sg16454
VMiller-Dieker lissencephaly syndrome
p26610
sasa(dp26611
g16444
VMoreover, the Etv5 mutation resulted in several developmental abnormalities including an increased incidence of embryonic and perinatal lethality, postnatal growth restriction, polydactyly and renal asymmetry.
p26612
sg16446
(lp26613
(dp26614
g16449
I14
sg16450
I2
sg16451
I13
sg16452
VP41161
p26615
sg16454
VEtv5 mutation
p26616
sasg16456
(lp26617
(dp26618
g16449
I177
sg16450
I1
sg16451
I11
sg16459
VC0152427
p26619
sg16454
Vpolydactyly
p26620
sasa(dp26621
g16444
VHere, we show that conditional knockout of the FGF-activated transcription factor genes Etv4 and Etv5 in mouse led to ectopic Shh expression in the anterior limb bud and a preaxial polydactyly (PPD) skeletal phenotype.
p26622
sg16446
(lp26623
(dp26624
g16449
I126
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VShh
p26625
sa(dp26626
g16449
I172
sg16450
I2
sg16451
I20
sg16452
VP32754
p26627
sg16454
Vpreaxial polydactyly
p26628
sa(dp26629
g16449
I194
sg16450
I1
sg16451
I3
sg16452
VP32754
p26630
sg16454
VPPD
p26631
sa(dp26632
g16449
I47
sg16450
I5
sg16451
I45
sg16452
VP35398
p26633
sg16454
VFGF-activated transcription factor genes Etv4
p26634
sa(dp26635
g16449
I97
sg16450
I1
sg16451
I4
sg16452
VP41161
p26636
sg16454
VEtv5
p26637
sasg16456
(lp26638
(dp26639
g16449
I172
sg16450
I2
sg16451
I20
sg16459
VC0345354
p26640
sg16454
Vpreaxial polydactyly
p26641
sa(dp26642
g16449
I194
sg16450
I1
sg16451
I3
sg16459
VC0432215
p26643
sg16454
VPPD
p26644
sasa(dp26645
g16444
VMechanistic studies showed that inducible expression of CD82 in highly metastatic melanoma cells significantly increased p21 expression upon binding of Duffy antigen receptor group (DARC), inducing tumor cell senescence and interrupting IL-8-mediated vascular endothelial (VE)-cadherin disassembly.
p26646
sg16446
(lp26647
(dp26648
g16449
I182
sg16450
I1
sg16451
I4
sg16452
VP00390
p26649
sg16454
VDARC
p26650
sa(dp26651
g16449
I152
sg16450
I4
sg16451
I28
sg16452
VP00390
p26652
sg16454
VDuffy antigen receptor group
p26653
sa(dp26654
g16449
I121
sg16450
I1
sg16451
I3
sg16452
VP42857
p26655
sg16454
Vp21
p26656
sa(dp26657
g16449
I56
sg16450
I1
sg16451
I4
sg16452
VP27701
p26658
sg16454
VCD82
p26659
sa(dp26660
g16449
I237
sg16450
I4
sg16451
I48
sg16452
g11
sg16454
VIL-8-mediated vascular endothelial (VE)-cadherin
p26661
sasg16456
(lp26662
(dp26663
g16449
I198
sg16450
I1
sg16451
I5
sg16459
VC0027651
p26664
sg16454
Vtumor
p26665
sa(dp26666
g16449
I71
sg16450
I2
sg16451
I19
sg16459
VC0278883
p26667
sg16454
Vmetastatic melanoma
p26668
sasa(dp26669
g16444
VOur oneway ANOVA analysis results showed that in all cases from benign diseases to invasive carcinoma, the concentration of CXCL8, CXCR4 and CXCL12 was significantly different; in benign subgroups (benign change, benign change with proliferation, atypia), the concentration of CCL2 and CCR5 was significantly different; in invasive carcinoma cases, DARC concentration was significantly correlated with the relapse risk of patients.
p26670
sg16446
(lp26671
(dp26672
g16449
I286
sg16450
I1
sg16451
I4
sg16452
VP32302
p26673
sg16454
VCCR5
p26674
sa(dp26675
g16449
I131
sg16450
I1
sg16451
I5
sg16452
VP61073
p26676
sg16454
VCXCR4
p26677
sa(dp26678
g16449
I277
sg16450
I1
sg16451
I4
sg16452
VP13500
p26679
sg16454
VCCL2
p26680
sa(dp26681
g16449
I141
sg16450
I1
sg16451
I6
sg16452
VP48061
p26682
sg16454
VCXCL12
p26683
sasg16456
(lp26684
(dp26685
g16449
I83
sg16450
I2
sg16451
I18
sg16459
VC1334274
p26686
sg16454
Vinvasive carcinoma
p26687
sa(dp26688
g16449
I83
sg16450
I2
sg16451
I18
sg16459
VC1334274
p26689
sg16454
Vinvasive carcinoma
p26690
sa(dp26691
g16449
I232
sg16450
I1
sg16451
I13
sg16459
VC0334094
p26692
sg16454
Vproliferation
p26693
sa(dp26694
g16449
I406
sg16450
I1
sg16451
I7
sg16459
VC0277556
p26695
sg16454
Vrelapse
p26696
sasa(dp26697
g16444
V177Lu-DOTATATE = lutetium octreotate; ACO = aconitase; Ad = adenine; AD = autosomal dominant; ATRX = ATRX chromatin remodeler; ccRCC = clear cell renal cell carcinoma; c-MYC = MYC proto oncognene; CoA = coenzyme A; COMT = catechol-O-methyl transferase; CPE = carboxypeptidase E; CS = citrate synthase; CT = computed tomography; DH = pyruvate dehydrogenase; DOTATATE = DOTA-octreotate; EGLN1/2 = egl-9 family hypoxia inducible factor 1/2; EGLN2/PHD1 = egl-9 family hypoxia inducible factor 2; elF-4E = eukaryotic initiation factor 4E; EMT = epithelial-to-mesenchymal transition; EPAS1/HIF2A = endothelial PAS domain protein 2/hypoxia-inducible factor 2Alfa; ERK = extracellular signal-regulated kinase; FH = fumarate hydroxylase; GSH = glutathione; H3F3A = histone 3.3 encoding gene; HIFs = Hypoxia-inducible factors; HIF-Alfa = hypoxia-inducible factor alpha; HNPGLs = head and neck paragangliomas; HRAS = HRas protooncogene; IDH = isocitrate dehydrogenase; IGF-1R = growth factor 1 receptor; KIF1B = kinesin family member 1B; MAX = myc-associated factor X; MDH2 = malate dehydrogenase; MN = metanephrine; MRI = magnetic resonance imaging; mTORC1 = mammalian target of rapamycin complex 1; MTY = methoxytyramine; NAd = nicotinamide adenine dinucleotide; NETs = neuroendocrine tumors; NF1 = neurofibromin 1; NMN = normetanephrine; OPLS-DA = orthogonal partial least square discriminant analysis; PFS = progression free survival; PHD = prolyl hydroxylase domain protein; PPGLs = Pheochromocytoma and Paragangliomas; PRRT = peptide receptor radionuclide therapy; Pvhl = von Hippel-Lindau protein; Raptor = regulatory associated protein of mTOR; RAS = rat sarcoma oncogene; RET = rearranged during transfection proto-oncogene; ROS = reactive oxygen species; S6K = S6 kinase; SDH = succinate dehydrogenase; SDHA, -B, -C, -D, = succinate dehydrogenase subunits A, B, C, D; SDHAF2 = succinate dehydrogenase complex assembly factor 2; SDHB, C, D = succinate dehydrogenase subunits B, C, D; SDHx = succinate dehydrogenase subunits; SSTRs = somatostatin receptors; SUCLG = succinyl-CoA synthase; TERRA = Telomeric Repeat-containing RNA; TET = ten-eleven-translocation methylcytosine dioxygenase; TMEM127 = transmembrane protein 127; VEGF = vascular endothelial growth factor; VHL = von Hippel-Lindau; Alfa-KGDH = alpha-ketoglutarate dehydrogenase.
p26698
sg16446
(lp26699
(dp26700
g16449
I1876
sg16450
I6
sg16451
I49
sg16452
VP49366
p26701
sg16454
Vsuccinate dehydrogenase complex assembly factor 2
p26702
sa(dp26703
g16449
I1927
sg16450
I1
sg16451
I4
sg16452
VP21912
p26704
sg16454
VSDHB
p26705
sa(dp26706
g16449
I1771
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VSDH
p26707
sa(dp26708
g16449
I2023
sg16450
I4
sg16451
I30
sg16452
VP61278
p26709
sg16454
VSSTRs = somatostatin receptors
p26710
sa(dp26711
g16449
I438
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VEGLN2
p26712
sa(dp26713
g16449
I2266
sg16450
I1
sg16451
I3
sg16452
VP40337
p26714
sg16454
VVHL
p26715
sa(dp26716
g16449
I1802
sg16450
I1
sg16451
I4
sg16452
VP31040
p26717
sg16454
VSDHA
p26718
sa(dp26719
g16449
I1760
sg16450
I2
sg16451
I9
sg16452
VP33981
p26720
sg16454
VS6 kinase
p26721
sa(dp26722
g16449
I578
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VEPAS1
p26723
sa(dp26724
g16449
I1434
sg16450
I4
sg16451
I33
sg16452
VP13674
p26725
sg16454
Vprolyl hydroxylase domain protein
p26726
sa(dp26727
g16449
I2303
sg16450
I2
sg16451
I33
sg16452
VP49366
p26728
sg16454
Valpha-ketoglutarate dehydrogenase
p26729
sa(dp26730
g16449
I464
sg16450
I4
sg16451
I26
sg16452
g11
sg16454
Vhypoxia inducible factor 2
p26731
sa(dp26732
g16449
I1140
sg16450
I1
sg16451
I4
sg16452
VP42345
p26733
sg16454
VmTOR
p26734
sa(dp26735
g16449
I1754
sg16450
I1
sg16451
I3
sg16452
VP62753
p26736
sg16454
VS6K
p26737
sa(dp26738
g16449
I592
sg16450
I5
sg16451
I32
sg16452
g11
sg16454
Vendothelial PAS domain protein 2
p26739
sa(dp26740
g16449
I492
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VelF
p26741
sa(dp26742
g16449
I584
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VHIF2A
p26743
sa(dp26744
g16449
I2063
sg16450
I2
sg16451
I21
sg16452
g11
sg16454
Vsuccinyl-CoA synthase
p26745
sa(dp26746
g16449
I231
sg16450
I2
sg16451
I20
sg16452
VP31947
p26747
sg16454
VO-methyl transferase
p26748
sa(dp26749
g16449
I958
sg16450
I6
sg16451
I33
sg16452
g11
sg16454
VIGF-1R = growth factor 1 receptor
p26750
sa(dp26751
g16449
I1777
sg16450
I2
sg16451
I23
sg16452
VP49366
p26752
sg16454
Vsuccinate dehydrogenase
p26753
sa(dp26754
g16449
I926
sg16450
I4
sg16451
I30
sg16452
VP48735
p26755
sg16454
VIDH = isocitrate dehydrogenase
p26756
sa(dp26757
g16449
I748
sg16450
I1
sg16451
I5
sg16452
VP84243
p26758
sg16454
VH3F3A
p26759
sa(dp26760
g16449
I900
sg16450
I1
sg16451
I3
sg16452
VP01116
p26761
sg16454
VRAS
p26762
sa(dp26763
g16449
I1058
sg16450
I4
sg16451
I27
sg16452
VP49366
p26764
sg16454
VMDH2 = malate dehydrogenase
p26765
sa(dp26766
g16449
I385
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VEGLN1/2
p26767
sa(dp26768
g16449
I253
sg16450
I4
sg16451
I24
sg16452
VP16870
p26769
sg16454
VCPE = carboxypeptidase E
p26770
sa(dp26771
g16449
I1001
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
Vkinesin
p26772
sa(dp26773
g16449
I756
sg16450
I4
sg16451
I25
sg16452
VP62805
p26774
sg16454
Vhistone 3.3 encoding gene
p26775
sa(dp26776
g16449
I625
sg16450
I3
sg16451
I30
sg16452
g11
sg16454
Vhypoxia-inducible factor 2Alfa
p26777
sa(dp26778
g16449
I1648
sg16450
I3
sg16451
I20
sg16452
VP35125
p26779
sg16454
Vrat sarcoma oncogene
p26780
sa(dp26781
g16449
I1670
sg16450
I1
sg16451
I3
sg16452
VP07949
p26782
sg16454
VRET
p26783
sa(dp26784
g16449
I657
sg16450
I1
sg16451
I3
sg16452
VP29323
p26785
sg16454
VERK
p26786
sa(dp26787
g16449
I1027
sg16450
I5
sg16451
I29
sg16452
VP61244
p26788
sg16454
VMAX = myc-associated factor X
p26789
sa(dp26790
g16449
I408
sg16450
I4
sg16451
I28
sg16452
g11
sg16454
Vhypoxia inducible factor 1/2
p26791
sa(dp26792
g16449
I2230
sg16450
I4
sg16451
I34
sg16452
g11
sg16454
Vvascular endothelial growth factor
p26793
sa(dp26794
g16449
I444
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPHD1
p26795
sasg16456
(lp26796
(dp26797
g16449
I1771
sg16450
I1
sg16451
I3
sg16459
VC0018946
p26798
sg16454
VSDH
p26799
sa(dp26800
g16449
I1261
sg16450
I2
sg16451
I21
sg16459
VC0206754
p26801
sg16454
Vneuroendocrine tumors
p26802
sa(dp26803
g16449
I1477
sg16450
I1
sg16451
I16
sg16459
VC0031511
p26804
sg16454
VPheochromocytoma
p26805
sa(dp26806
g16449
I1648
sg16450
I2
sg16451
I11
sg16459
VC1882848
p26807
sg16454
Vrat sarcoma
p26808
sa(dp26809
g16449
I408
sg16450
I1
sg16451
I7
sg16459
VC0242184
p26810
sg16454
Vhypoxia
p26811
sa(dp26812
g16449
I790
sg16450
I1
sg16451
I7
sg16459
VC0242184
p26813
sg16454
VHypoxia
p26814
sa(dp26815
g16449
I1213
sg16450
I1
sg16451
I3
sg16459
VC1850380
p26816
sg16454
VNAd
p26817
sa(dp26818
g16449
I94
sg16450
I1
sg16451
I4
sg16459
VC1845055
p26819
sg16454
VATRX
p26820
sa(dp26821
g16449
I197
sg16450
I1
sg16451
I3
sg16459
VC2678439
p26822
sg16454
VCoA
p26823
sa(dp26824
g16449
I1498
sg16450
I1
sg16451
I14
sg16459
VC0030421
p26825
sg16454
VParagangliomas
p26826
sa(dp26827
g16449
I883
sg16450
I1
sg16451
I14
sg16459
VC0030421
p26828
sg16454
Vparagangliomas
p26829
sa(dp26830
g16449
I408
sg16450
I1
sg16451
I7
sg16459
VC0242184
p26831
sg16454
Vhypoxia
p26832
sa(dp26833
g16449
I1284
sg16450
I1
sg16451
I3
sg16459
VC0027831
p26834
sg16454
VNF1
p26835
sa(dp26836
g16449
I408
sg16450
I1
sg16451
I7
sg16459
VC0242184
p26837
sg16454
Vhypoxia
p26838
sa(dp26839
g16449
I2266
sg16450
I1
sg16451
I3
sg16459
VC0019562
p26840
sg16454
VVHL
p26841
sa(dp26842
g16449
I729
sg16450
I1
sg16451
I3
sg16459
VC1260386
p26843
sg16454
VGSH
p26844
sa(dp26845
g16449
I135
sg16450
I5
sg16451
I31
sg16459
VC0279702
p26846
sg16454
Vclear cell renal cell carcinoma
p26847
sa(dp26848
g16449
I566
sg16450
I1
sg16451
I10
sg16459
VC0599156
p26849
sg16454
Vtransition
p26850
sa(dp26851
g16449
I94
sg16450
I1
sg16451
I4
sg16459
VC1845055
p26852
sg16454
VATRX
p26853
sa(dp26854
g16449
I2144
sg16450
I1
sg16451
I13
sg16459
VC0040715
p26855
sg16454
Vtranslocation
p26856
sa(dp26857
g16449
I197
sg16450
I1
sg16451
I3
sg16459
VC2678439
p26858
sg16454
VCoA
p26859
sa(dp26860
g16449
I408
sg16450
I1
sg16451
I7
sg16459
VC0242184
p26861
sg16454
Vhypoxia
p26862
sasa(dp26863
g16444
VImmunohistochemistry for phosphorylated-S6, phosphorylated-mTOR, mTOR, phosphorylated-AKT, hypoxia inducible factor-1Alfa, Raptor, phosphatase and tensin homolog (PTEN), phosphoinositide 3-kinase (PI3K), and phosphorylated 4E-binding protein-1 was performed on tissue microarray constructs of patients treated for nonmetastatic kidney cancer from 1997 to 2010.
p26864
sg16446
(lp26865
(dp26866
g16449
I86
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VAKT
p26867
sa(dp26868
g16449
I163
sg16450
I1
sg16451
I4
sg16452
VP60484
p26869
sg16454
VPTEN
p26870
sa(dp26871
g16449
I59
sg16450
I1
sg16451
I4
sg16452
VP42345
p26872
sg16454
VmTOR
p26873
sa(dp26874
g16449
I197
sg16450
I1
sg16451
I4
sg16452
VP42336
p26875
sg16454
VPI3K
p26876
sa(dp26877
g16449
I123
sg16450
I2
sg16451
I19
sg16452
g11
sg16454
VRaptor, phosphatase
p26878
sa(dp26879
g16449
I131
sg16450
I4
sg16451
I30
sg16452
VP60484
p26880
sg16454
Vphosphatase and tensin homolog
p26881
sa(dp26882
g16449
I59
sg16450
I1
sg16451
I4
sg16452
VP42345
p26883
sg16454
VmTOR
p26884
sa(dp26885
g16449
I91
sg16450
I3
sg16451
I30
sg16452
g11
sg16454
Vhypoxia inducible factor-1Alfa
p26886
sa(dp26887
g16449
I208
sg16450
I3
sg16451
I35
sg16452
g11
sg16454
Vphosphorylated 4E-binding protein-1
p26888
sa(dp26889
g16449
I170
sg16450
I2
sg16451
I25
sg16452
g11
sg16454
Vphosphoinositide 3-kinase
p26890
sasg16456
(lp26891
(dp26892
g16449
I91
sg16450
I1
sg16451
I7
sg16459
VC0242184
p26893
sg16454
Vhypoxia
p26894
sa(dp26895
g16449
I328
sg16450
I2
sg16451
I13
sg16459
VC0740457
p26896
sg16454
Vkidney cancer
p26897
sasa(dp26898
g16444
VCholangiocarcinoma is a disease entity comprising diverse epithelial tumours with features of cholangiocyte differentiation: cholangiocarcinomas are categorized according to anatomical location as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA).
p26899
sg16446
(lp26900
sg16456
(lp26901
(dp26902
g16449
I211
sg16450
I1
sg16451
I4
sg16459
VC1865926
p26903
sg16454
ViCCA
p26904
sa(dp26905
g16449
I0
sg16450
I1
sg16451
I18
sg16459
VC0206698
p26906
sg16454
VCholangiocarcinoma
p26907
sa(dp26908
g16449
I229
sg16450
I1
sg16451
I4
sg16459
VC3151140
p26909
sg16454
VpCCA
p26910
sa(dp26911
g16449
I69
sg16450
I1
sg16451
I7
sg16459
VC0027651
p26912
sg16454
Vtumours
p26913
sa(dp26914
g16449
I125
sg16450
I1
sg16451
I19
sg16459
VC0206698
p26915
sg16454
Vcholangiocarcinomas
p26916
sasa(dp26917
g16444
VCholangiocarcinoma (CCA) represents a diverse group of epithelial cancers associated with the biliary tract, and can best be stratified anatomically into intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA) subsets.
p26918
sg16446
(lp26919
sg16456
(lp26920
(dp26921
g16449
I0
sg16450
I1
sg16451
I18
sg16459
VC0206698
p26922
sg16454
VCholangiocarcinoma
p26923
sa(dp26924
g16449
I168
sg16450
I1
sg16451
I4
sg16459
VC1865926
p26925
sg16454
ViCCA
p26926
sa(dp26927
g16449
I186
sg16450
I1
sg16451
I4
sg16459
VC3151140
p26928
sg16454
VpCCA
p26929
sa(dp26930
g16449
I20
sg16450
I1
sg16451
I3
sg16459
VC0220668
p26931
sg16454
VCCA
p26932
sa(dp26933
g16449
I66
sg16450
I1
sg16451
I7
sg16459
VC0006826
p26934
sg16454
Vcancers
p26935
sasa(dp26936
g16444
VPreoperative evaluation of vasculobiliary anatomy in the umbilical fissure (U-point) is pivotal for perihilar cholangiocarcinoma (PCCA) applied to right-sided hepatectomy.
p26937
sg16446
(lp26938
sg16456
(lp26939
(dp26940
g16449
I100
sg16450
I2
sg16451
I28
sg16459
VC3151140
p26941
sg16454
Vperihilar cholangiocarcinoma
p26942
sa(dp26943
g16449
I130
sg16450
I1
sg16451
I4
sg16459
VC3151140
p26944
sg16454
VPCCA
p26945
sasa(dp26946
g16444
VThis study sought to define the role of adjuvant radiation therapy (RT) for patients with curative intent resection of perihilar cholangiocarcinoma (pCCA).
p26947
sg16446
(lp26948
sg16456
(lp26949
(dp26950
g16449
I119
sg16450
I2
sg16451
I28
sg16459
VC3151140
p26951
sg16454
Vperihilar cholangiocarcinoma
p26952
sa(dp26953
g16449
I149
sg16450
I1
sg16451
I4
sg16459
VC3151140
p26954
sg16454
VpCCA
p26955
sasa(dp26956
g16444
VOur goal was to characterize PD-L1 expression in intra-hepatic (iCCA) and perihilar (pCCA) cholangiocarcinomas, and to correlate our results with clinicopathological features, density of tumor-infiltrating lymphocytes (TILs) and PD-1 expression.A series of 58 iCCAs and 41 pCCAs was included in the study.
p26957
sg16446
(lp26958
(dp26959
g16449
I229
sg16450
I1
sg16451
I4
sg16452
VP18621
p26960
sg16454
VPD-1
p26961
sasg16456
(lp26962
(dp26963
g16449
I91
sg16450
I1
sg16451
I19
sg16459
VC0206698
p26964
sg16454
Vcholangiocarcinomas
p26965
sa(dp26966
g16449
I193
sg16450
I1
sg16451
I12
sg16459
VC0332448
p26967
sg16454
Vinfiltrating
p26968
sa(dp26969
g16449
I85
sg16450
I1
sg16451
I4
sg16459
VC3151140
p26970
sg16454
VpCCA
p26971
sa(dp26972
g16449
I64
sg16450
I1
sg16451
I4
sg16459
VC1865926
p26973
sg16454
ViCCA
p26974
sa(dp26975
g16449
I187
sg16450
I1
sg16451
I5
sg16459
VC0027651
p26976
sg16454
Vtumor
p26977
sasa(dp26978
g16444
VLiver transplantation (LT) provides a good chance of cure for selected patients with hepatocellular carcinoma (HCC) and perihilar cholangiocarcinoma (pCCA).
p26979
sg16446
(lp26980
sg16456
(lp26981
(dp26982
g16449
I150
sg16450
I1
sg16451
I4
sg16459
VC3151140
p26983
sg16454
VpCCA
p26984
sa(dp26985
g16449
I111
sg16450
I1
sg16451
I3
sg16459
VC2239176
p26986
sg16454
VHCC
p26987
sa(dp26988
g16449
I120
sg16450
I2
sg16451
I28
sg16459
VC3151140
p26989
sg16454
Vperihilar cholangiocarcinoma
p26990
sa(dp26991
g16449
I85
sg16450
I2
sg16451
I24
sg16459
VC2239176
p26992
sg16454
Vhepatocellular carcinoma
p26993
sasa(dp26994
g16444
VBTC are sub-classified as intrahepatic cholangiocarcinoma (iCCA), perhilar/hilar cholangiocarcinoma (pCCA), distal cholangiocarcinoma (dCCA), and gallbladder carcinoma.
p26995
sg16446
(lp26996
(dp26997
g16449
I0
sg16450
I1
sg16451
I3
sg16452
VP35070
p26998
sg16454
VBTC
p26999
sasg16456
(lp27000
(dp27001
g16449
I39
sg16450
I1
sg16451
I18
sg16459
VC0206698
p27002
sg16454
Vcholangiocarcinoma
p27003
sa(dp27004
g16449
I66
sg16450
I2
sg16451
I33
sg16459
VC3151140
p27005
sg16454
Vperhilar/hilar cholangiocarcinoma
p27006
sa(dp27007
g16449
I146
sg16450
I2
sg16451
I21
sg16459
VC0235782
p27008
sg16454
Vgallbladder carcinoma
p27009
sa(dp27010
g16449
I26
sg16450
I2
sg16451
I31
sg16459
VC0345905
p27011
sg16454
Vintrahepatic cholangiocarcinoma
p27012
sa(dp27013
g16449
I101
sg16450
I1
sg16451
I4
sg16459
VC3151140
p27014
sg16454
VpCCA
p27015
sa(dp27016
g16449
I59
sg16450
I1
sg16451
I4
sg16459
VC1865926
p27017
sg16454
ViCCA
p27018
sasa(dp27019
g16444
VTo evaluate prognostic factors for stent patency and survival in patients with perihilar cholangiocarcinoma (pCCA) who underwent percutaneous biliary stent placement.
p27020
sg16446
(lp27021
sg16456
(lp27022
(dp27023
g16449
I109
sg16450
I1
sg16451
I4
sg16459
VC3151140
p27024
sg16454
VpCCA
p27025
sa(dp27026
g16449
I79
sg16450
I2
sg16451
I28
sg16459
VC3151140
p27027
sg16454
Vperihilar cholangiocarcinoma
p27028
sasa(dp27029
g16444
VClinical data were collected and analyzed from 71 cases of primary nephrotic syndrome with glucocorticoid-induced ocular hypertension, glaucoma or cataract from Jun.
p27030
sg16446
(lp27031
(dp27032
g16449
I161
sg16450
I1
sg16451
I3
sg16452
VP05412
p27033
sg16454
VJun
p27034
sasg16456
(lp27035
(dp27036
g16449
I147
sg16450
I1
sg16451
I8
sg16459
VC0086543
p27037
sg16454
Vcataract
p27038
sa(dp27039
g16449
I135
sg16450
I1
sg16451
I8
sg16459
VC0017601
p27040
sg16454
Vglaucoma
p27041
sa(dp27042
g16449
I67
sg16450
I2
sg16451
I18
sg16459
VC0027726
p27043
sg16454
Vnephrotic syndrome
p27044
sa(dp27045
g16449
I114
sg16450
I2
sg16451
I19
sg16459
VC0028840
p27046
sg16454
Vocular hypertension
p27047
sasa(dp27048
g16444
Vc-Jun, c-Jun N-terminal kinase(JNK) and endothelin B (ETB) receptor have been shown to contribute to the pathogenesis of glaucoma.
p27049
sg16446
(lp27050
(dp27051
g16449
I0
sg16450
I1
sg16451
I5
sg16452
VP05412
p27052
sg16454
Vc-Jun
p27053
sa(dp27054
g16449
I31
sg16450
I1
sg16451
I3
sg16452
VP53779
p27055
sg16454
VJNK
p27056
sa(dp27057
g16449
I40
sg16450
I4
sg16451
I27
sg16452
g11
sg16454
Vendothelin B (ETB) receptor
p27058
sa(dp27059
g16449
I7
sg16450
I3
sg16451
I23
sg16452
VP53779
p27060
sg16454
Vc-Jun N-terminal kinase
p27061
sasg16456
(lp27062
(dp27063
g16449
I105
sg16450
I1
sg16451
I12
sg16459
VC0699748
p27064
sg16454
Vpathogenesis
p27065
sa(dp27066
g16449
I121
sg16450
I1
sg16451
I8
sg16459
VC0017601
p27067
sg16454
Vglaucoma
p27068
sasa(dp27069
g16444
VOcular hypertension also caused upregulations in the iron-regulating protein ceruloplasmin, the anaerobic glycolytic enzyme lactate dehydrogenase, and the transcription factors cFos and p-cJun.
p27070
sg16446
(lp27071
(dp27072
g16449
I53
sg16450
I3
sg16451
I37
sg16452
VP00450
p27073
sg16454
Viron-regulating protein ceruloplasmin
p27074
sa(dp27075
g16449
I124
sg16450
I2
sg16451
I21
sg16452
VP49366
p27076
sg16454
Vlactate dehydrogenase
p27077
sa(dp27078
g16449
I177
sg16450
I1
sg16451
I4
sg16452
VP01100
p27079
sg16454
VcFos
p27080
sasg16456
(lp27081
(dp27082
g16449
I0
sg16450
I2
sg16451
I19
sg16459
VC0028840
p27083
sg16454
VOcular hypertension
p27084
sasa(dp27085
g16444
VJUN is expressed after glaucoma-relevant injuries and Jun deficiency protects RGCs after mechanical injury to the optic nerve.
p27086
sg16446
(lp27087
(dp27088
g16449
I54
sg16450
I1
sg16451
I3
sg16452
VP05412
p27089
sg16454
VJun
p27090
sa(dp27091
g16449
I0
sg16450
I1
sg16451
I3
sg16452
VP05412
p27092
sg16454
VJUN
p27093
sasg16456
(lp27094
(dp27095
g16449
I23
sg16450
I1
sg16451
I8
sg16459
VC0017601
p27096
sg16454
Vglaucoma
p27097
sasa(dp27098
g16444
VHere, we tested the importance of JNK-JUN signaling for RGC death after ocular hypertensive axonal injury in an age-related, mouse model of ocular hypertension.
p27099
sg16446
(lp27100
(dp27101
g16449
I38
sg16450
I1
sg16451
I3
sg16452
VP05412
p27102
sg16454
VJUN
p27103
sa(dp27104
g16449
I34
sg16450
I1
sg16451
I3
sg16452
VP53779
p27105
sg16454
VJNK
p27106
sasg16456
(lp27107
(dp27108
g16449
I140
sg16450
I2
sg16451
I19
sg16459
VC0028840
p27109
sg16454
Vocular hypertension
p27110
sasa(dp27111
g16444
VJUN was expressed in a temporal and spatial pattern consistent with a role in glaucomatous injury.
p27112
sg16446
(lp27113
(dp27114
g16449
I0
sg16450
I1
sg16451
I3
sg16452
VP05412
p27115
sg16454
VJUN
p27116
sasg16456
(lp27117
sa(dp27118
g16444
VTo determine the importance of JUN in ocular hypertension-induced RGC death, a floxed allele of Jun and a retinal expressed cre recombinase (Six3-cre) were backcrossed onto the DBA/2J background.
p27119
sg16446
(lp27120
(dp27121
g16449
I124
sg16450
I2
sg16451
I15
sg16452
g11
sg16454
Vcre recombinase
p27122
sa(dp27123
g16449
I141
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VSix3-cre
p27124
sa(dp27125
g16449
I96
sg16450
I1
sg16451
I3
sg16452
VP05412
p27126
sg16454
VJun
p27127
sasg16456
(lp27128
(dp27129
g16449
I177
sg16450
I1
sg16451
I3
sg16459
VC0398550
p27130
sg16454
VDBA
p27131
sa(dp27132
g16449
I38
sg16450
I2
sg16451
I19
sg16459
VC0028840
p27133
sg16454
Vocular hypertension
p27134
sasa(dp27135
g16444
VJun deficiency protected RGC somas from ocular hypertensive injury, but did not protect RGC axons from glaucomatous neurodegeneration.
p27136
sg16446
(lp27137
(dp27138
g16449
I0
sg16450
I1
sg16451
I3
sg16452
VP05412
p27139
sg16454
VJun
p27140
sasg16456
(lp27141
(dp27142
g16449
I116
sg16450
I1
sg16451
I17
sg16459
VC0027746
p27143
sg16454
Vneurodegeneration
p27144
sasa(dp27145
g16444
VJun is a major regulator of RGC somal degeneration after glaucomatous ocular hypertensive injury.
p27146
sg16446
(lp27147
(dp27148
g16449
I0
sg16450
I1
sg16451
I3
sg16452
VP05412
p27149
sg16454
VJun
p27150
sasg16456
(lp27151
(dp27152
g16449
I38
sg16450
I1
sg16451
I12
sg16459
VC0011164
p27153
sg16454
Vdegeneration
p27154
sasa(dp27155
g16444
VThese results suggest in glaucomatous neurodegeneration, JNK-JUN signaling has a major role as a pro-death signaling pathway between axonal injury and somal degeneration.
p27156
sg16446
(lp27157
(dp27158
g16449
I61
sg16450
I1
sg16451
I3
sg16452
VP05412
p27159
sg16454
VJUN
p27160
sa(dp27161
g16449
I57
sg16450
I1
sg16451
I3
sg16452
VP53779
p27162
sg16454
VJNK
p27163
sasg16456
(lp27164
(dp27165
g16449
I43
sg16450
I1
sg16451
I12
sg16459
VC0011164
p27166
sg16454
Vdegeneration
p27167
sa(dp27168
g16449
I38
sg16450
I1
sg16451
I17
sg16459
VC0027746
p27169
sg16454
Vneurodegeneration
p27170
sasa(dp27171
g16444
VTo our knowledge the co-existence of Pompe disease and thymic neuroendocrine tumor in the same patient has not been previously reported.
p27172
sg16446
(lp27173
sg16456
(lp27174
(dp27175
g16449
I62
sg16450
I2
sg16451
I20
sg16459
VC0206754
p27176
sg16454
Vneuroendocrine tumor
p27177
sa(dp27178
g16449
I37
sg16450
I2
sg16451
I13
sg16459
VC0017921
p27179
sg16454
VPompe disease
p27180
sasa(dp27181
g16444
VSignificantly more A-C (block 2: rs230528-rs230521) haplotypes (P = 0.0003 after Bonferroni's corrections) and G-A-A (block 4: rs4648068-rs3774964-rs3774968) haplotypes (P = 0.021) were found in the patients with ovarian cancer.
p27182
sg16446
(lp27183
sg16456
(lp27184
(dp27185
g16449
I213
sg16450
I2
sg16451
I14
sg16459
VC1140680
p27186
sg16454
Vovarian cancer
p27187
sasa(dp27188
g16444
VThe thyroid conditions for which surgery was indicated were: diffuse toxic goiter in 8 patients; multinodular toxic and nontoxic goiter in 30 patients; autonomous nodule in 2 patients; 2 patients with benign nodules at fine needle aspiration biopsy (FNAB); 4 patients with nodules positive for carcinoma at FNAB, among them 2 with unilateral cervical lymph nodes enlargement; 4 patients with highly suspect nodule on FNAB.
p27189
sg16446
(lp27190
sg16456
(lp27191
(dp27192
g16449
I61
sg16450
I3
sg16451
I20
sg16459
VC0342122
p27193
sg16454
Vdiffuse toxic goiter
p27194
sa(dp27195
g16449
I163
sg16450
I1
sg16451
I6
sg16459
VC0028259
p27196
sg16454
Vnodule
p27197
sa(dp27198
g16449
I120
sg16450
I2
sg16451
I15
sg16459
VC0221777
p27199
sg16454
Vnontoxic goiter
p27200
sa(dp27201
g16449
I163
sg16450
I1
sg16451
I6
sg16459
VC0028259
p27202
sg16454
Vnodule
p27203
sa(dp27204
g16449
I208
sg16450
I1
sg16451
I7
sg16459
VC0028259
p27205
sg16454
Vnodules
p27206
sa(dp27207
g16449
I208
sg16450
I1
sg16451
I7
sg16459
VC0028259
p27208
sg16454
Vnodules
p27209
sa(dp27210
g16449
I363
sg16450
I1
sg16451
I11
sg16459
VC2711450
p27211
sg16454
Venlargement
p27212
sa(dp27213
g16449
I294
sg16450
I1
sg16451
I9
sg16459
VC0007097
p27214
sg16454
Vcarcinoma
p27215
sa(dp27216
g16449
I231
sg16450
I1
sg16451
I10
sg16459
VC0700198
p27217
sg16454
Vaspiration
p27218
sasa(dp27219
g16444
VThe aim of the present study was to comparatively investigate the effects of piroxicam, a selective COX-I inhibitor, and celecoxib, a selective COX-II inhibitor, on cognitive functions in an AlCl3-induced neurotoxicity mouse model to understand the specific role of each COX enzyme in the hippocampus and cortex.
p27220
sg16446
(lp27221
(dp27222
g16449
I100
sg16450
I1
sg16451
I5
sg16452
VP00395
p27223
sg16454
VCOX-I
p27224
sa(dp27225
g16449
I144
sg16450
I1
sg16451
I6
sg16452
VP00403
p27226
sg16454
VCOX-II
p27227
sasg16456
(lp27228
sa(dp27229
g16444
VOf these differentially expressed genes, we elected to further examine the increase in COX1 expression, because of data implicating energy utilization in METH neurotoxicity and the known role of COX1 in energy metabolism.
p27230
sg16446
(lp27231
(dp27232
g16449
I87
sg16450
I1
sg16451
I4
sg16452
VP00395
p27233
sg16454
VCOX1
p27234
sa(dp27235
g16449
I87
sg16450
I1
sg16451
I4
sg16452
VP00395
p27236
sg16454
VCOX1
p27237
sasg16456
(lp27238
sa(dp27239
g16444
VThe precise role of COX1 and other genes in METH neurotoxicity remains to be elucidated.
p27240
sg16446
(lp27241
(dp27242
g16449
I20
sg16450
I1
sg16451
I4
sg16452
VP00395
p27243
sg16454
VCOX1
p27244
sasg16456
(lp27245
sa(dp27246
g16444
VVarious genes involved in the control of cell proliferation and invasion (p16INK4A, RASSF1A, PTEN, Rap1GAP, TIMP3, DAPK, RARBeta2, E-cadherin, and CITED1) as well as genes specific of thyroid differentiation (Na+/I- symport, TSH receptor, pendrin, SL5A8, and TTF-1) present aberrant methylation in thyroid cancer.
p27247
sg16446
(lp27248
(dp27249
g16449
I93
sg16450
I1
sg16451
I4
sg16452
VP60484
p27250
sg16454
VPTEN
p27251
sa(dp27252
g16449
I115
sg16450
I1
sg16451
I4
sg16452
VP53355
p27253
sg16454
VDAPK
p27254
sa(dp27255
g16449
I225
sg16450
I2
sg16451
I12
sg16452
VP16473
p27256
sg16454
VTSH receptor
p27257
sa(dp27258
g16449
I74
sg16450
I1
sg16451
I8
sg16452
VP42771
p27259
sg16454
Vp16INK4A
p27260
sa(dp27261
g16449
I108
sg16450
I1
sg16451
I5
sg16452
VP35625
p27262
sg16454
VTIMP3
p27263
sa(dp27264
g16449
I147
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCITED1
p27265
sa(dp27266
g16449
I99
sg16450
I1
sg16451
I7
sg16452
VP47736
p27267
sg16454
VRap1GAP
p27268
sa(dp27269
g16449
I259
sg16450
I1
sg16451
I5
sg16452
VP43699
p27270
sg16454
VTTF-1
p27271
sa(dp27272
g16449
I131
sg16450
I1
sg16451
I10
sg16452
VP12830
p27273
sg16454
VE-cadherin
p27274
sa(dp27275
g16449
I239
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
Vpendrin
p27276
sasg16456
(lp27277
(dp27278
g16449
I298
sg16450
I2
sg16451
I14
sg16459
VC0007115
p27279
sg16454
Vthyroid cancer
p27280
sa(dp27281
g16449
I46
sg16450
I1
sg16451
I13
sg16459
VC0334094
p27282
sg16454
Vproliferation
p27283
sa(dp27284
g16449
I64
sg16450
I1
sg16451
I8
sg16459
VC2699153
p27285
sg16454
Vinvasion
p27286
sasa(dp27287
g16444
VImmunohistochemistry was performed using primary antibodies to cytokeratin 19, HBME1, and CITED1 that have been found to be useful in the diagnosis of thyroid carcinoma.
p27288
sg16446
(lp27289
(dp27290
g16449
I90
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCITED1
p27291
sa(dp27292
g16449
I63
sg16450
I2
sg16451
I14
sg16452
g11
sg16454
Vcytokeratin 19
p27293
sasg16456
(lp27294
(dp27295
g16449
I151
sg16450
I2
sg16451
I17
sg16459
VC0549473
p27296
sg16454
Vthyroid carcinoma
p27297
sasa(dp27298
g16444
VMarkers such as HBME-1 and CITED1 can assist in separating some difficult cases of follicular variants of papillary thyroid carcinomas from follicular adenomas.
p27299
sg16446
(lp27300
(dp27301
g16449
I27
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCITED1
p27302
sasg16456
(lp27303
(dp27304
g16449
I124
sg16450
I1
sg16451
I10
sg16459
VC0007097
p27305
sg16454
Vcarcinomas
p27306
sa(dp27307
g16449
I140
sg16450
I2
sg16451
I19
sg16459
VC0205647
p27308
sg16454
Vfollicular adenomas
p27309
sasa(dp27310
g16444
VThese analyses showed that several antibodies were useful in distinguishing follicular adenomas from follicular variant of papillary thyroid carcinomas including HBME-1, CITED1, galectin-3, cytokeratin 19, and S100A4 (p &lt; 0.0001).
p27311
sg16446
(lp27312
(dp27313
g16449
I178
sg16450
I3
sg16451
I26
sg16452
VP17931
p27314
sg16454
Vgalectin-3, cytokeratin 19
p27315
sa(dp27316
g16449
I210
sg16450
I1
sg16451
I6
sg16452
VP26447
p27317
sg16454
VS100A4
p27318
sa(dp27319
g16449
I170
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCITED1
p27320
sasg16456
(lp27321
(dp27322
g16449
I76
sg16450
I2
sg16451
I19
sg16459
VC0205647
p27323
sg16454
Vfollicular adenomas
p27324
sa(dp27325
g16449
I141
sg16450
I1
sg16451
I10
sg16459
VC0007097
p27326
sg16454
Vcarcinomas
p27327
sasa(dp27328
g16444
VA combination of markers consisting of a panel of HBME-1, galectin-3, and CK19 or a panel of HBME-1, CITED1, and galectin-3 was usually most effective in distinguishing follicular adenoma from follicular variant of papillary thyroid carcinoma.
p27329
sg16446
(lp27330
(dp27331
g16449
I58
sg16450
I1
sg16451
I10
sg16452
VP17931
p27332
sg16454
Vgalectin-3
p27333
sa(dp27334
g16449
I101
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCITED1
p27335
sa(dp27336
g16449
I58
sg16450
I1
sg16451
I10
sg16452
VP17931
p27337
sg16454
Vgalectin-3
p27338
sasg16456
(lp27339
(dp27340
g16449
I215
sg16450
I3
sg16451
I27
sg16459
VC0238463
p27341
sg16454
Vpapillary thyroid carcinoma
p27342
sa(dp27343
g16449
I169
sg16450
I2
sg16451
I18
sg16459
VC0205647
p27344
sg16454
Vfollicular adenoma
p27345
sasa(dp27346
g16444
VWe examined acetylcholinesterase, plasma neuronal proteins, secreted beta-amyloid precursor protein (APP), and amyloid-beta 40 and amyloid-beta 42 peptides in children with and without autism.
p27347
sg16446
(lp27348
(dp27349
g16449
I101
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VAPP
p27350
sa(dp27351
g16449
I12
sg16450
I1
sg16451
I20
sg16452
VP12821
p27352
sg16454
Vacetylcholinesterase
p27353
sa(dp27354
g16449
I34
sg16450
I7
sg16451
I65
sg16452
VP29475
p27355
sg16454
Vplasma neuronal proteins, secreted beta-amyloid precursor protein
p27356
sa(dp27357
g16449
I111
sg16450
I6
sg16451
I44
sg16452
g11
sg16454
Vamyloid-beta 40 and amyloid-beta 42 peptides
p27358
sasg16456
(lp27359
(dp27360
g16449
I185
sg16450
I1
sg16451
I6
sg16459
VC0004352
p27361
sg16454
Vautism
p27362
sa(dp27363
g16449
I74
sg16450
I1
sg16451
I7
sg16459
VC0011560
p27364
sg16454
Vamyloid
p27365
sa(dp27366
g16449
I74
sg16450
I1
sg16451
I7
sg16459
VC0011560
p27367
sg16454
Vamyloid
p27368
sa(dp27369
g16449
I74
sg16450
I1
sg16451
I7
sg16459
VC0011560
p27370
sg16454
Vamyloid
p27371
sasa(dp27372
g16444
VThe growth associated protein 43-positive fibres also seemed to be less in six samples of club foot.
p27373
sg16446
(lp27374
sg16456
(lp27375
(dp27376
g16449
I90
sg16450
I2
sg16451
I9
sg16459
VC0009081
p27377
sg16454
Vclub foot
p27378
sasa(dp27379
g16444
VHere we showed that miR-342-5p and miR-608 suppressed the tumorigenesis of colon cancer cells in vitro and in vivo by targeting NAA10 mRNA for degradation.
p27380
sg16446
(lp27381
(dp27382
g16449
I20
sg16450
I1
sg16451
I10
sg16452
g11
sg16454
VmiR-342-5p
p27383
sa(dp27384
g16449
I128
sg16450
I2
sg16451
I10
sg16452
VP41227
p27385
sg16454
VNAA10 mRNA
p27386
sasg16456
(lp27387
(dp27388
g16449
I75
sg16450
I2
sg16451
I12
sg16459
VC0699790
p27389
sg16454
Vcolon cancer
p27390
sa(dp27391
g16449
I58
sg16450
I1
sg16451
I13
sg16459
VC0007621
p27392
sg16454
Vtumorigenesis
p27393
sasa(dp27394
g16444
VOur results implicate miR-342-5p and miR-608 in colon cancer development and unveil the underlying mechanism of this phenomenon, which involves NAA10.
p27395
sg16446
(lp27396
(dp27397
g16449
I22
sg16450
I1
sg16451
I10
sg16452
g11
sg16454
VmiR-342-5p
p27398
sa(dp27399
g16449
I144
sg16450
I1
sg16451
I5
sg16452
VP41227
p27400
sg16454
VNAA10
p27401
sa(dp27402
g16449
I37
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VmiR-608
p27403
sasg16456
(lp27404
(dp27405
g16449
I48
sg16450
I2
sg16451
I12
sg16459
VC0699790
p27406
sg16454
Vcolon cancer
p27407
sasa(dp27408
g16444
VWe demonstrated the clinical relevance of the miRNAs and identified miR-342-5p and miR-744* as significantly down-regulated in HER2-positive breast tumors as compared to HER2-negative tumors from two cohorts of breast cancer patients (101 and 1302 cases).
p27409
sg16446
(lp27410
(dp27411
g16449
I127
sg16450
I1
sg16451
I4
sg16452
VP04626
p27412
sg16454
VHER2
p27413
sa(dp27414
g16449
I83
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VmiR-744*
p27415
sa(dp27416
g16449
I127
sg16450
I1
sg16451
I4
sg16452
VP04626
p27417
sg16454
VHER2
p27418
sa(dp27419
g16449
I68
sg16450
I1
sg16451
I10
sg16452
g11
sg16454
VmiR-342-5p
p27420
sasg16456
(lp27421
(dp27422
g16449
I211
sg16450
I2
sg16451
I13
sg16459
VC0678222
p27423
sg16454
Vbreast cancer
p27424
sa(dp27425
g16449
I141
sg16450
I2
sg16451
I13
sg16459
VC1458155
p27426
sg16454
Vbreast tumors
p27427
sa(dp27428
g16449
I148
sg16450
I1
sg16451
I6
sg16459
VC0027651
p27429
sg16454
Vtumors
p27430
sasa(dp27431
g16444
VFurthermore, higher expression of miR-342-5p was associated with better survival in both breast cancer patient cohorts.
p27432
sg16446
(lp27433
(dp27434
g16449
I34
sg16450
I1
sg16451
I10
sg16452
g11
sg16454
VmiR-342-5p
p27435
sasg16456
(lp27436
(dp27437
g16449
I89
sg16450
I2
sg16451
I13
sg16459
VC0678222
p27438
sg16454
Vbreast cancer
p27439
sasa(dp27440
g16444
VCompromised CN function is a significant cause of erectile dysfunction development following prostatectomy and serves as the primary target for potential neuroprotective or regenerative strategies utilizing NGFs such as BDNF, GDF-5, and NTN, and/or targeted novel therapeutics modulating signaling pathways.
p27441
sg16446
(lp27442
(dp27443
g16449
I226
sg16450
I1
sg16451
I5
sg16452
VP43026
p27444
sg16454
VGDF-5
p27445
sasg16456
(lp27446
(dp27447
g16449
I50
sg16450
I2
sg16451
I20
sg16459
VC0242350
p27448
sg16454
Verectile dysfunction
p27449
sasa(dp27450
g16444
VThe manifestation of LHON was associated with increased mortality and increased incidence of several disorders including stroke, demyelinating disorder, dementia, and epilepsy.
p27451
sg16446
(lp27452
sg16456
(lp27453
(dp27454
g16449
I121
sg16450
I1
sg16451
I6
sg16459
VC0038454
p27455
sg16454
Vstroke
p27456
sa(dp27457
g16449
I153
sg16450
I1
sg16451
I8
sg16459
VC0497327
p27458
sg16454
Vdementia
p27459
sa(dp27460
g16449
I21
sg16450
I1
sg16451
I4
sg16459
VC0917796
p27461
sg16454
VLHON
p27462
sa(dp27463
g16449
I129
sg16450
I2
sg16451
I22
sg16459
VC0011303
p27464
sg16454
Vdemyelinating disorder
p27465
sa(dp27466
g16449
I167
sg16450
I1
sg16451
I8
sg16459
VC0014544
p27467
sg16454
Vepilepsy
p27468
sasa(dp27469
g16444
VLeber's Hereditary Optic Neuropathy (LHON) shares features with Multiple Sclerosis (MS).
p27470
sg16446
(lp27471
sg16456
(lp27472
(dp27473
g16449
I0
sg16450
I4
sg16451
I35
sg16459
VC0917796
p27474
sg16454
VLeber's Hereditary Optic Neuropathy
p27475
sa(dp27476
g16449
I37
sg16450
I1
sg16451
I4
sg16459
VC0917796
p27477
sg16454
VLHON
p27478
sa(dp27479
g16449
I64
sg16450
I2
sg16451
I18
sg16459
VC0026769
p27480
sg16454
VMultiple Sclerosis
p27481
sa(dp27482
g16449
I84
sg16450
I1
sg16451
I2
sg16459
VC0026769
p27483
sg16454
VMS
p27484
sasa(dp27485
g16444
VLeber's hereditary optic neuropathy (LHON) is a mitochondrial DNA (mtDNA) associated neurodegenerative disorder of retinal ganglion cells.
p27486
sg16446
(lp27487
sg16456
(lp27488
(dp27489
g16449
I0
sg16450
I4
sg16451
I35
sg16459
VC0917796
p27490
sg16454
VLeber's hereditary optic neuropathy
p27491
sa(dp27492
g16449
I37
sg16450
I1
sg16451
I4
sg16459
VC0917796
p27493
sg16454
VLHON
p27494
sa(dp27495
g16449
I85
sg16450
I2
sg16451
I26
sg16459
VC0524851
p27496
sg16454
Vneurodegenerative disorder
p27497
sa(dp27498
g16449
I123
sg16450
I1
sg16451
I8
sg16459
VC1258666
p27499
sg16454
Vganglion
p27500
sasa(dp27501
g16444
VMT-ND4: mitochondrially encoded NADH dehydrogenase 4; MT-TL1: mitochondrially encoded tRNA leucine 1 (UUA/G); PCR: polymerase chain reaction; OXPHOS: mitochondrial oxidative phosphorylation; ATP: adenosine triphosphate; mtDNA: mitochondrial DNA; SNPs: single nucleotide substitutions; AD: alzheimer's disease; PD: parkinson's disease; MELAS: mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes; ROS: reactive oxygen species.
p27502
sg16446
(lp27503
(dp27504
g16449
I54
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VMT-TL1
p27505
sa(dp27506
g16449
I62
sg16450
I5
sg16451
I38
sg16452
VP30740
p27507
sg16454
Vmitochondrially encoded tRNA leucine 1
p27508
sa(dp27509
g16449
I8
sg16450
I5
sg16451
I44
sg16452
VP49366
p27510
sg16454
Vmitochondrially encoded NADH dehydrogenase 4
p27511
sa(dp27512
g16449
I0
sg16450
I1
sg16451
I6
sg16452
VP03905
p27513
sg16454
VMT-ND4
p27514
sasg16456
(lp27515
(dp27516
g16449
I314
sg16450
I2
sg16451
I19
sg16459
VC0030567
p27517
sg16454
Vparkinson's disease
p27518
sa(dp27519
g16449
I342
sg16450
I8
sg16451
I77
sg16459
VC1964017
p27520
sg16454
Vmitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes
p27521
sa(dp27522
g16449
I335
sg16450
I1
sg16451
I5
sg16459
VC0162671
p27523
sg16454
VMELAS
p27524
sa(dp27525
g16449
I289
sg16450
I2
sg16451
I19
sg16459
VC1521724
p27526
sg16454
Valzheimer's disease
p27527
sasa(dp27528
g16444
VLeber's hereditary optic neuropathy (LHON) co-occuring with multiple sclerosis-like disease (LHON-MS) is suggested to be a separate disease entity denoted Harding's disease.
p27529
sg16446
(lp27530
sg16456
(lp27531
(dp27532
g16449
I0
sg16450
I4
sg16451
I35
sg16459
VC0917796
p27533
sg16454
VLeber's hereditary optic neuropathy
p27534
sa(dp27535
g16449
I37
sg16450
I1
sg16451
I4
sg16459
VC0917796
p27536
sg16454
VLHON
p27537
sa(dp27538
g16449
I37
sg16450
I1
sg16451
I4
sg16459
VC0917796
p27539
sg16454
VLHON
p27540
sa(dp27541
g16449
I60
sg16450
I2
sg16451
I18
sg16459
VC0026769
p27542
sg16454
Vmultiple sclerosis
p27543
sasa(dp27544
g16444
VThe role of oxidative stress in the five most common inherited mitochondrial diseases, Friedreich ataxia, LHON, MELAS, MERRF, and Leigh syndrome (LS), is discussed.
p27545
sg16446
(lp27546
(dp27547
g16449
I112
sg16450
I1
sg16451
I5
sg16452
VP03886
p27548
sg16454
VMELAS
p27549
sa(dp27550
g16449
I119
sg16450
I1
sg16451
I5
sg16452
VP03915
p27551
sg16454
VMERRF
p27552
sasg16456
(lp27553
(dp27554
g16449
I63
sg16450
I2
sg16451
I22
sg16459
VC0751651
p27555
sg16454
Vmitochondrial diseases
p27556
sa(dp27557
g16449
I112
sg16450
I1
sg16451
I5
sg16459
VC0162671
p27558
sg16454
VMELAS
p27559
sa(dp27560
g16449
I130
sg16450
I2
sg16451
I14
sg16459
VC0023264
p27561
sg16454
VLeigh syndrome
p27562
sa(dp27563
g16449
I12
sg16450
I2
sg16451
I16
sg16459
VC0242606
p27564
sg16454
Voxidative stress
p27565
sa(dp27566
g16449
I146
sg16450
I1
sg16451
I2
sg16459
VC0023264
p27567
sg16454
VLS
p27568
sa(dp27569
g16449
I87
sg16450
I2
sg16451
I17
sg16459
VC0016719
p27570
sg16454
VFriedreich ataxia
p27571
sa(dp27572
g16449
I106
sg16450
I1
sg16451
I4
sg16459
VC0917796
p27573
sg16454
VLHON
p27574
sa(dp27575
g16449
I119
sg16450
I1
sg16451
I5
sg16459
VC0162672
p27576
sg16454
VMERRF
p27577
sasa(dp27578
g16444
VOf the five most common mitochondrial diseases, the strongest support for oxidative stress is for Friedreich ataxia (6.42%), followed by LHON (2.45%), MELAS (2.18%), MERRF (1.71%), and LS (1.03%).
p27579
sg16446
(lp27580
sg16456
(lp27581
(dp27582
g16449
I137
sg16450
I1
sg16451
I4
sg16459
VC0917796
p27583
sg16454
VLHON
p27584
sa(dp27585
g16449
I166
sg16450
I1
sg16451
I5
sg16459
VC0162672
p27586
sg16454
VMERRF
p27587
sa(dp27588
g16449
I24
sg16450
I2
sg16451
I22
sg16459
VC0751651
p27589
sg16454
Vmitochondrial diseases
p27590
sa(dp27591
g16449
I151
sg16450
I1
sg16451
I5
sg16459
VC0162671
p27592
sg16454
VMELAS
p27593
sa(dp27594
g16449
I98
sg16450
I2
sg16451
I17
sg16459
VC0016719
p27595
sg16454
VFriedreich ataxia
p27596
sa(dp27597
g16449
I74
sg16450
I2
sg16451
I16
sg16459
VC0242606
p27598
sg16454
Voxidative stress
p27599
sasa(dp27600
g16444
VLeber's hereditary optic neuropathy (LHON) and a multiple sclerosis (MS)-like illness appear to coexist 50 times more frequently than would be expected by chance.
p27601
sg16446
(lp27602
sg16456
(lp27603
(dp27604
g16449
I0
sg16450
I4
sg16451
I35
sg16459
VC0917796
p27605
sg16454
VLeber's hereditary optic neuropathy
p27606
sa(dp27607
g16449
I37
sg16450
I1
sg16451
I4
sg16459
VC0917796
p27608
sg16454
VLHON
p27609
sa(dp27610
g16449
I69
sg16450
I1
sg16451
I2
sg16459
VC0026769
p27611
sg16454
VMS
p27612
sa(dp27613
g16449
I49
sg16450
I2
sg16451
I18
sg16459
VC0026769
p27614
sg16454
Vmultiple sclerosis
p27615
sasa(dp27616
g16444
VMutations in the retinitis pigmentosa 1 (RP1) gene are a common cause of retinitis pigmentosa (RP).
p27617
sg16446
(lp27618
(dp27619
g16449
I17
sg16450
I3
sg16451
I22
sg16452
VP56715
p27620
sg16454
Vretinitis pigmentosa 1
p27621
sa(dp27622
g16449
I41
sg16450
I1
sg16451
I3
sg16452
VP56715
p27623
sg16454
VRP1
p27624
sasg16456
(lp27625
(dp27626
g16449
I17
sg16450
I3
sg16451
I22
sg16459
VC0220701
p27627
sg16454
Vretinitis pigmentosa 1
p27628
sa(dp27629
g16449
I41
sg16450
I1
sg16451
I2
sg16459
VC0035334
p27630
sg16454
VRP
p27631
sa(dp27632
g16449
I17
sg16450
I2
sg16451
I20
sg16459
VC0035334
p27633
sg16454
Vretinitis pigmentosa
p27634
sa(dp27635
g16449
I41
sg16450
I1
sg16451
I3
sg16459
VC0220701
p27636
sg16454
VRP1
p27637
sasa(dp27638
g16444
VFurthermore, these findings indicate that the RP1 form of inherited retinal degeneration is part of the larger class of neurodegenerative diseases caused by MAP dysfunction.
p27639
sg16446
(lp27640
(dp27641
g16449
I46
sg16450
I1
sg16451
I3
sg16452
VP56715
p27642
sg16454
VRP1
p27643
sasg16456
(lp27644
(dp27645
g16449
I46
sg16450
I1
sg16451
I3
sg16459
VC0220701
p27646
sg16454
VRP1
p27647
sa(dp27648
g16449
I120
sg16450
I2
sg16451
I26
sg16459
VC0524851
p27649
sg16454
Vneurodegenerative diseases
p27650
sa(dp27651
g16449
I68
sg16450
I2
sg16451
I20
sg16459
VC0035304
p27652
sg16454
Vretinal degeneration
p27653
sasa(dp27654
g16444
VOur objective was to determine the ethical options of Paediatric Intensive Care Unit (PICU) paediatricians as regards a child with SMA-1 and respiratory failure.
p27655
sg16446
(lp27656
(dp27657
g16449
I131
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSMA-1
p27658
sasg16456
(lp27659
(dp27660
g16449
I141
sg16450
I2
sg16451
I19
sg16459
VC1145670
p27661
sg16454
Vrespiratory failure
p27662
sa(dp27663
g16449
I131
sg16450
I1
sg16451
I3
sg16459
VC0026847
p27664
sg16454
VSMA
p27665
sasa(dp27666
g16444
VFaced with child with SMA-1 and respiratory failure, most paediatricians are in favour of initiating NIV and LET when such support is insufficient, but they would accept the family's decision, even in case of disagreement.
p27667
sg16446
(lp27668
(dp27669
g16449
I22
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSMA-1
p27670
sasg16456
(lp27671
(dp27672
g16449
I22
sg16450
I1
sg16451
I3
sg16459
VC0026847
p27673
sg16454
VSMA
p27674
sa(dp27675
g16449
I32
sg16450
I2
sg16451
I19
sg16459
VC1145670
p27676
sg16454
Vrespiratory failure
p27677
sasa(dp27678
g16444
VA scenario of acute respiratory failure in an infant with SMA-1 has been included in a training program using advanced simulation for Primary Care pediatricians (PCP).
p27679
sg16446
(lp27680
(dp27681
g16449
I58
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSMA-1
p27682
sasg16456
(lp27683
(dp27684
g16449
I58
sg16450
I1
sg16451
I3
sg16459
VC0026847
p27685
sg16454
VSMA
p27686
sa(dp27687
g16449
I134
sg16450
I3
sg16451
I26
sg16459
VC2919094
p27688
sg16454
VPrimary Care pediatricians
p27689
sa(dp27690
g16449
I162
sg16450
I1
sg16451
I3
sg16459
VC2919094
p27691
sg16454
VPCP
p27692
sa(dp27693
g16449
I14
sg16450
I3
sg16451
I25
sg16459
VC0264490
p27694
sg16454
Vacute respiratory failure
p27695
sasa(dp27696
g16444
VWhen faced with a simulated SMA-1 infant with respiratory failure, PCP have difficulties in interacting with the family, and to involve it in the decision making process.
p27697
sg16446
(lp27698
sg16456
(lp27699
(dp27700
g16449
I67
sg16450
I1
sg16451
I3
sg16459
VC2919094
p27701
sg16454
VPCP
p27702
sa(dp27703
g16449
I46
sg16450
I2
sg16451
I19
sg16459
VC1145670
p27704
sg16454
Vrespiratory failure
p27705
sa(dp27706
g16449
I28
sg16450
I1
sg16451
I3
sg16459
VC0026847
p27707
sg16454
VSMA
p27708
sasa(dp27709
g16444
VTREX1 acts in concert with the SET complex in granzyme A-mediated apoptosis, and mutations in TREX1 cause Aicardi-Goutieres syndrome and familial chilblain lupus.
p27710
sg16446
(lp27711
(dp27712
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTREX1
p27713
sa(dp27714
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTREX1
p27715
sasg16456
(lp27716
(dp27717
g16449
I146
sg16450
I2
sg16451
I15
sg16459
VC0024145
p27718
sg16454
Vchilblain lupus
p27719
sa(dp27720
g16449
I106
sg16450
I2
sg16451
I26
sg16459
VC0796126
p27721
sg16454
VAicardi-Goutieres syndrome
p27722
sasa(dp27723
g16444
VLymphoblastoid cells carrying the D18N mutation are significantly less sensitive to granzyme A-mediated cell death, suggesting a novel role for this caspase-independent form of apoptosis in the pathogenesis of familial chilblain lupus.
p27724
sg16446
(lp27725
(dp27726
g16449
I149
sg16450
I1
sg16451
I7
sg16452
VP39880
p27727
sg16454
Vcaspase
p27728
sasg16456
(lp27729
(dp27730
g16449
I194
sg16450
I1
sg16451
I12
sg16459
VC0699748
p27731
sg16454
Vpathogenesis
p27732
sa(dp27733
g16449
I219
sg16450
I2
sg16451
I15
sg16459
VC0024145
p27734
sg16454
Vchilblain lupus
p27735
sasa(dp27736
g16444
VA recent article explored protective modifiers, including plastin 3 (PLS3) and coronin 1C (CORO1C), in spinal muscular atrophy (SMA).
p27737
sg16446
(lp27738
(dp27739
g16449
I58
sg16450
I2
sg16451
I9
sg16452
VP13797
p27740
sg16454
Vplastin 3
p27741
sa(dp27742
g16449
I69
sg16450
I1
sg16451
I4
sg16452
VP13797
p27743
sg16454
VPLS3
p27744
sa(dp27745
g16449
I79
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
Vcoronin 1C
p27746
sa(dp27747
g16449
I91
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCORO1C
p27748
sasg16456
(lp27749
(dp27750
g16449
I103
sg16450
I3
sg16451
I23
sg16459
VC0026847
p27751
sg16454
Vspinal muscular atrophy
p27752
sa(dp27753
g16449
I128
sg16450
I1
sg16451
I3
sg16459
VC0026847
p27754
sg16454
VSMA
p27755
sasa(dp27756
g16444
VHowever, the expression of CYP26C1, another CYP26 family member, in primary breast carcinoma remains to be clarified.
p27757
sg16446
(lp27758
(dp27759
g16449
I44
sg16450
I3
sg16451
I19
sg16452
g11
sg16454
VCYP26 family member
p27760
sa(dp27761
g16449
I27
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCYP26C1
p27762
sasg16456
(lp27763
(dp27764
g16449
I76
sg16450
I2
sg16451
I16
sg16459
VC0678222
p27765
sg16454
Vbreast carcinoma
p27766
sasa(dp27767
g16444
VIn the present study, we examined the expression of CYP26C1 by immunohistochemistry, using three different types of microarray, and observed strong cytoplasmic staining of CYP26C1 in 73 of the 219 (33.3 %) breast carcinomas.
p27768
sg16446
(lp27769
(dp27770
g16449
I52
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCYP26C1
p27771
sa(dp27772
g16449
I52
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCYP26C1
p27773
sasg16456
(lp27774
(dp27775
g16449
I206
sg16450
I2
sg16451
I17
sg16459
VC0678222
p27776
sg16454
Vbreast carcinomas
p27777
sasa(dp27778
g16444
VIn addition, CYP26C1 positivity was independent of the expression status of the hormone receptors and immunohistochemical surrogates for the intrinsic subtypes of breast cancer.
p27779
sg16446
(lp27780
(dp27781
g16449
I13
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCYP26C1
p27782
sasg16456
(lp27783
(dp27784
g16449
I163
sg16450
I2
sg16451
I13
sg16459
VC0678222
p27785
sg16454
Vbreast cancer
p27786
sasa(dp27787
g16444
VThis report is the first to demonstrate elevated expression of CYP26C1 in primary breast carcinomas.
p27788
sg16446
(lp27789
(dp27790
g16449
I63
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCYP26C1
p27791
sasg16456
(lp27792
(dp27793
g16449
I82
sg16450
I2
sg16451
I17
sg16459
VC0678222
p27794
sg16454
Vbreast carcinomas
p27795
sasa(dp27796
g16444
VIn the present study we chose to investigate 7 genes involved in the synthesis, degradation and transportation of RA, ALDH1A1, ALDH1A2, ALDH1A3, CYP26A1, CYP26B1, CYP26C1 and Transthyretin (TTR), for their roles in the development of schizophrenia.
p27797
sg16446
(lp27798
(dp27799
g16449
I136
sg16450
I1
sg16451
I7
sg16452
VP47895
p27800
sg16454
VALDH1A3
p27801
sa(dp27802
g16449
I190
sg16450
I1
sg16451
I3
sg16452
VP02766
p27803
sg16454
VTTR
p27804
sa(dp27805
g16449
I175
sg16450
I1
sg16451
I13
sg16452
VP02766
p27806
sg16454
VTransthyretin
p27807
sa(dp27808
g16449
I163
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCYP26C1
p27809
sa(dp27810
g16449
I154
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCYP26B1
p27811
sa(dp27812
g16449
I145
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCYP26A1
p27813
sa(dp27814
g16449
I127
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VALDH1A2
p27815
sa(dp27816
g16449
I118
sg16450
I1
sg16451
I7
sg16452
VP00352
p27817
sg16454
VALDH1A1
p27818
sasg16456
(lp27819
(dp27820
g16449
I234
sg16450
I1
sg16451
I13
sg16459
VC0036341
p27821
sg16454
Vschizophrenia
p27822
sasa(dp27823
g16444
VThe index of low SIRT1 and high MMP2 respectively correlated with patients history of MI (p=0.3, p=0.01) and marginally with presence or history of atrial fibrillation (AF) (p=0.213, p=0.076).
p27824
sg16446
(lp27825
(dp27826
g16449
I17
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSIRT1
p27827
sasg16456
(lp27828
(dp27829
g16449
I148
sg16450
I2
sg16451
I19
sg16459
VC0004238
p27830
sg16454
Vatrial fibrillation
p27831
sa(dp27832
g16449
I169
sg16450
I1
sg16451
I2
sg16459
VC0004238
p27833
sg16454
VAF
p27834
sasa(dp27835
g16444
VBACKGROUND To examine changes of mRNA and protein expressions of MMP-2, Bcl-2, and BAX in atrial fibrillation (AF) patients, and investigate the correlations among these 3 biomarkers.
p27836
sg16446
(lp27837
(dp27838
g16449
I65
sg16450
I1
sg16451
I5
sg16452
VP08253
p27839
sg16454
VMMP-2
p27840
sa(dp27841
g16449
I72
sg16450
I1
sg16451
I5
sg16452
VP10415
p27842
sg16454
VBcl-2
p27843
sasg16456
(lp27844
(dp27845
g16449
I90
sg16450
I2
sg16451
I19
sg16459
VC0004238
p27846
sg16454
Vatrial fibrillation
p27847
sa(dp27848
g16449
I111
sg16450
I1
sg16451
I2
sg16459
VC0004238
p27849
sg16454
VAF
p27850
sasa(dp27851
g16444
VIn conclusion, disruption of Kcnj16 induces a severe renal phenotype that, apart from hypokalemia, is the opposite of the phenotype seen in SeSAME/EAST syndrome.
p27852
sg16446
(lp27853
(dp27854
g16449
I29
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VKcnj16
p27855
sasg16456
(lp27856
(dp27857
g16449
I147
sg16450
I2
sg16451
I13
sg16459
VC2748572
p27858
sg16454
VEAST syndrome
p27859
sasa(dp27860
g16444
VWe investigated the localization of KCNJ10 and the homologous KCNJ16 in kidney and the functional consequences of KCNJ10 mutations found in our patients with EAST syndrome.
p27861
sg16446
(lp27862
(dp27863
g16449
I62
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VKCNJ16
p27864
sa(dp27865
g16449
I36
sg16450
I1
sg16451
I6
sg16452
VP78508
p27866
sg16454
VKCNJ10
p27867
sa(dp27868
g16449
I114
sg16450
I2
sg16451
I16
sg16452
VP78508
p27869
sg16454
VKCNJ10 mutations
p27870
sasg16456
(lp27871
(dp27872
g16449
I158
sg16450
I2
sg16451
I13
sg16459
VC2748572
p27873
sg16454
VEAST syndrome
p27874
sasa(dp27875
g16444
VToxin C13S1C1 was also cytotoxic against breast adenocarcinoma MDA-MB-231 cells (LC50 = 62+/-2myg/ml) and colorectal adenocarcinoma HT-29 cells (LC50 = 110+/-4myg/ml).
p27876
sg16446
(lp27877
(dp27878
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VToxin
p27879
sasg16456
(lp27880
(dp27881
g16449
I106
sg16450
I2
sg16451
I25
sg16459
VC1319315
p27882
sg16454
Vcolorectal adenocarcinoma
p27883
sa(dp27884
g16449
I41
sg16450
I2
sg16451
I21
sg16459
VC0858252
p27885
sg16454
Vbreast adenocarcinoma
p27886
sasa(dp27887
g16444
VWe report an unusual case of invasive papillary carcinoma of the breast with high nuclear grade, brisk mitosis, necrosis, extensive apocrine differentiation, and intense lymphoplasmacytic infiltrate; additionally triple-negativity for estrogen and progesterone receptors and Her2 neu.
p27888
sg16446
(lp27889
(dp27890
g16449
I248
sg16450
I2
sg16451
I22
sg16452
VP06401
p27891
sg16454
Vprogesterone receptors
p27892
sa(dp27893
g16449
I280
sg16450
I1
sg16451
I3
sg16452
VP04626
p27894
sg16454
Vneu
p27895
sa(dp27896
g16449
I275
sg16450
I1
sg16451
I4
sg16452
VP04626
p27897
sg16454
VHer2
p27898
sasg16456
(lp27899
(dp27900
g16449
I38
sg16450
I5
sg16451
I33
sg16459
VC1335320
p27901
sg16454
Vpapillary carcinoma of the breast
p27902
sa(dp27903
g16449
I188
sg16450
I1
sg16451
I10
sg16459
VC0332448
p27904
sg16454
Vinfiltrate
p27905
sasa(dp27906
g16444
VMoreover, Sec24bY613 genetically interacts with a loss-of-function Vangl2 allele (Vangl2LP), causing a marked increase in the prevalence of spina bifida.
p27907
sg16446
(lp27908
(dp27909
g16449
I67
sg16450
I2
sg16451
I13
sg16452
g11
sg16454
VVangl2 allele
p27910
sasg16456
(lp27911
(dp27912
g16449
I140
sg16450
I2
sg16451
I12
sg16459
VC0080178
p27913
sg16454
Vspina bifida
p27914
sasa(dp27915
g16444
VThe overall goal of TASK2 of the AES/ILAE Translational Task Force is to organize and coordinate systematic reviews on selected topics regarding animal research in epilepsy.
p27916
sg16446
(lp27917
(dp27918
g16449
I20
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTASK2
p27919
sasg16456
(lp27920
(dp27921
g16449
I164
sg16450
I1
sg16451
I8
sg16459
VC0014544
p27922
sg16454
Vepilepsy
p27923
sasa(dp27924
g16444
VK2P 5.1 channels (also called TASK-2 or Kcnk5) have already been shown to be relevant in the pathophysiology of autoimmune disease because they are known to be upregulated on peripheral and central T lymphocytes of multiple sclerosis (MS) patients.
p27925
sg16446
(lp27926
(dp27927
g16449
I0
sg16450
I3
sg16451
I16
sg16452
g11
sg16454
VK2P 5.1 channels
p27928
sa(dp27929
g16449
I40
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VKcnk5
p27930
sa(dp27931
g16449
I30
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VTASK-2
p27932
sasg16456
(lp27933
(dp27934
g16449
I235
sg16450
I1
sg16451
I2
sg16459
VC0026769
p27935
sg16454
VMS
p27936
sa(dp27937
g16449
I112
sg16450
I2
sg16451
I18
sg16459
VC0004364
p27938
sg16454
Vautoimmune disease
p27939
sa(dp27940
g16449
I215
sg16450
I2
sg16451
I18
sg16459
VC0026769
p27941
sg16454
Vmultiple sclerosis
p27942
sasa(dp27943
g16444
VRecent studies have indicated the impact of K2P5.1 upregulation in T lymphocytes on the pathogenesis of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
p27944
sg16446
(lp27945
(dp27946
g16449
I44
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VK2P5.1
p27947
sasg16456
(lp27948
(dp27949
g16449
I157
sg16450
I2
sg16451
I18
sg16459
VC0026769
p27950
sg16454
Vmultiple sclerosis
p27951
sa(dp27952
g16449
I132
sg16450
I2
sg16451
I20
sg16459
VC0003873
p27953
sg16454
Vrheumatoid arthritis
p27954
sa(dp27955
g16449
I88
sg16450
I1
sg16451
I12
sg16459
VC0699748
p27956
sg16454
Vpathogenesis
p27957
sa(dp27958
g16449
I104
sg16450
I2
sg16451
I19
sg16459
VC0004364
p27959
sg16454
Vautoimmune diseases
p27960
sasa(dp27961
g16444
VSo far KCNK5 has been described to be up-regulated in T cells in multiple sclerosis patients and to be implicated in the volume regulatory mechanism regulatory volume decrease (RVD) in T cells.
p27962
sg16446
(lp27963
(dp27964
g16449
I7
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VKCNK5
p27965
sasg16456
(lp27966
(dp27967
g16449
I65
sg16450
I2
sg16451
I18
sg16459
VC0026769
p27968
sg16454
Vmultiple sclerosis
p27969
sasa(dp27970
g16444
VRecent studies highlighted the potential role of the K2P5.1 K(+) channel in the pathogenesis of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
p27971
sg16446
(lp27972
(dp27973
g16449
I53
sg16450
I2
sg16451
I8
sg16452
g11
sg16454
VK2P5.1 K
p27974
sasg16456
(lp27975
(dp27976
g16449
I96
sg16450
I2
sg16451
I19
sg16459
VC0004364
p27977
sg16454
Vautoimmune diseases
p27978
sa(dp27979
g16449
I149
sg16450
I2
sg16451
I18
sg16459
VC0026769
p27980
sg16454
Vmultiple sclerosis
p27981
sa(dp27982
g16449
I80
sg16450
I1
sg16451
I12
sg16459
VC0699748
p27983
sg16454
Vpathogenesis
p27984
sa(dp27985
g16449
I124
sg16450
I2
sg16451
I20
sg16459
VC0003873
p27986
sg16454
Vrheumatoid arthritis
p27987
sasa(dp27988
g16444
VExpression levels of K2P5.1 (TASK2; KCNK5) channels belonging to the family of two-pore domain potassium channels have previously been correlated to the activity of autoreactive T lymphocytes in patients with multiple sclerosis and rheumatoid arthritis.
p27989
sg16446
(lp27990
(dp27991
g16449
I21
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VK2P5.1
p27992
sa(dp27993
g16449
I29
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTASK2
p27994
sa(dp27995
g16449
I36
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VKCNK5
p27996
sasg16456
(lp27997
(dp27998
g16449
I209
sg16450
I2
sg16451
I18
sg16459
VC0026769
p27999
sg16454
Vmultiple sclerosis
p28000
sa(dp28001
g16449
I232
sg16450
I2
sg16451
I20
sg16459
VC0003873
p28002
sg16454
Vrheumatoid arthritis
p28003
sasa(dp28004
g16444
VThus, we evaluated the effect of serum availability on the expression of commonly used HKG (ACTB, B2M, GAPDH, GUSB, HPRT1, IPO8, MRPL19, PGK1, PPIA, RPLP0, RPS23, SDHA, TBP, UBC, and YWHAZ) in seven colon adenocarcinoma cell lines (Caco-2, DLD-1, HCT116, HT29, Lovo, SW480, and SW620).
p28005
sg16446
(lp28006
(dp28007
g16449
I110
sg16450
I1
sg16451
I4
sg16452
VP08236
p28008
sg16454
VGUSB
p28009
sa(dp28010
g16449
I98
sg16450
I1
sg16451
I3
sg16452
VP61769
p28011
sg16454
VB2M
p28012
sa(dp28013
g16449
I123
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VIPO8
p28014
sa(dp28015
g16449
I169
sg16450
I1
sg16451
I3
sg16452
VP20226
p28016
sg16454
VTBP
p28017
sa(dp28018
g16449
I240
sg16450
I1
sg16451
I5
sg16452
VP98173
p28019
sg16454
VDLD-1
p28020
sa(dp28021
g16449
I137
sg16450
I1
sg16451
I4
sg16452
VP00558
p28022
sg16454
VPGK1
p28023
sa(dp28024
g16449
I103
sg16450
I1
sg16451
I5
sg16452
VP04406
p28025
sg16454
VGAPDH
p28026
sa(dp28027
g16449
I156
sg16450
I1
sg16451
I5
sg16452
VP62266
p28028
sg16454
VRPS23
p28029
sa(dp28030
g16449
I92
sg16450
I1
sg16451
I4
sg16452
VP63261
p28031
sg16454
VACTB
p28032
sa(dp28033
g16449
I149
sg16450
I1
sg16451
I5
sg16452
VP05388
p28034
sg16454
VRPLP0
p28035
sa(dp28036
g16449
I143
sg16450
I1
sg16451
I4
sg16452
VP62937
p28037
sg16454
VPPIA
p28038
sa(dp28039
g16449
I116
sg16450
I1
sg16451
I5
sg16452
VP55884
p28040
sg16454
VHPRT1
p28041
sa(dp28042
g16449
I129
sg16450
I1
sg16451
I6
sg16452
VP49406
p28043
sg16454
VMRPL19
p28044
sa(dp28045
g16449
I163
sg16450
I1
sg16451
I4
sg16452
VP31040
p28046
sg16454
VSDHA
p28047
sa(dp28048
g16449
I174
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VUBC
p28049
sasg16456
(lp28050
(dp28051
g16449
I199
sg16450
I2
sg16451
I20
sg16459
VC0338106
p28052
sg16454
Vcolon adenocarcinoma
p28053
sasa(dp28054
g16444
VWe investigated whether the expression of PGK1 varies between metastatic and non-metastatic colon cancer.
p28055
sg16446
(lp28056
(dp28057
g16449
I42
sg16450
I1
sg16451
I4
sg16452
VP00558
p28058
sg16454
VPGK1
p28059
sasg16456
(lp28060
(dp28061
g16449
I81
sg16450
I3
sg16451
I23
sg16459
VC0278484
p28062
sg16454
Vmetastatic colon cancer
p28063
sasa(dp28064
g16444
VWe compared PGK1 expression in colon cancer patients either with or without metastasis via polymerase chain reaction (PCR) and immunohistochemistry.
p28065
sg16446
(lp28066
(dp28067
g16449
I12
sg16450
I1
sg16451
I4
sg16452
VP00558
p28068
sg16454
VPGK1
p28069
sasg16456
(lp28070
(dp28071
g16449
I31
sg16450
I2
sg16451
I12
sg16459
VC0699790
p28072
sg16454
Vcolon cancer
p28073
sa(dp28074
g16449
I76
sg16450
I1
sg16451
I10
sg16459
VC0027627
p28075
sg16454
Vmetastasis
p28076
sasa(dp28077
g16444
VPCR results showed an increased expression of PGK1 in colon cancer tissue from metastatic patients in comparison to patients with no metastasis (fold change 2.6, p&lt;0.001).
p28078
sg16446
(lp28079
(dp28080
g16449
I46
sg16450
I1
sg16451
I4
sg16452
VP00558
p28081
sg16454
VPGK1
p28082
sasg16456
(lp28083
(dp28084
g16449
I133
sg16450
I1
sg16451
I10
sg16459
VC0027627
p28085
sg16454
Vmetastasis
p28086
sa(dp28087
g16449
I54
sg16450
I2
sg16451
I12
sg16459
VC0699790
p28088
sg16454
Vcolon cancer
p28089
sasa(dp28090
g16444
VThe results indicate that increased expression of PGK1 in colon cancer tissue is associated with metastasis.
p28091
sg16446
(lp28092
(dp28093
g16449
I50
sg16450
I1
sg16451
I4
sg16452
VP00558
p28094
sg16454
VPGK1
p28095
sasg16456
(lp28096
(dp28097
g16449
I58
sg16450
I2
sg16451
I12
sg16459
VC0699790
p28098
sg16454
Vcolon cancer
p28099
sa(dp28100
g16449
I97
sg16450
I1
sg16451
I10
sg16459
VC0027627
p28101
sg16454
Vmetastasis
p28102
sasa(dp28103
g16444
VTYMS and PGK1, as well as their epitope peptides, might be appropriate target molecules for specific immunotherapy of HLA-A2(+) colon cancer patients because of the positive role of TYMS and PGK1 in chemoresistance (5-fluorouracil) and angiogenesis of tumor cells, respectively.
p28104
sg16446
(lp28105
(dp28106
g16449
I9
sg16450
I1
sg16451
I4
sg16452
VP00558
p28107
sg16454
VPGK1
p28108
sa(dp28109
g16449
I9
sg16450
I1
sg16451
I4
sg16452
VP00558
p28110
sg16454
VPGK1
p28111
sa(dp28112
g16449
I0
sg16450
I1
sg16451
I4
sg16452
VP04818
p28113
sg16454
VTYMS
p28114
sa(dp28115
g16449
I118
sg16450
I1
sg16451
I9
sg16452
VP30486
p28116
sg16454
VHLA-A2(+)
p28117
sa(dp28118
g16449
I0
sg16450
I1
sg16451
I4
sg16452
VP04818
p28119
sg16454
VTYMS
p28120
sasg16456
(lp28121
(dp28122
g16449
I128
sg16450
I2
sg16451
I12
sg16459
VC0699790
p28123
sg16454
Vcolon cancer
p28124
sa(dp28125
g16449
I252
sg16450
I1
sg16451
I5
sg16459
VC0027651
p28126
sg16454
Vtumor
p28127
sasa(dp28128
g16444
VIn one sample we sequenced 7231 contiguous base pairs that covered completely the region from the 5'end of the 16S rRNA gene to the 5'end of the 23S rRNA gene comprising the whole 16S rRNA (rrs), and the following genes: Ala tRNA (alaT), Ile tRNA (ileT), adenylosuccinate lyase (purB), adenylosuccinate synthetase (purA), methylpurine-DNA glycosylase (mag), hypoxanthine-guanine phosphoribosyltransferase (hpt), an hydrolase (HAD superfamily) and a 135 bp 5' fragment of the 23S rRNA (rrlA) genes.
p28129
sg16446
(lp28130
(dp28131
g16449
I315
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VpurA
p28132
sa(dp28133
g16449
I352
sg16450
I1
sg16451
I3
sg16452
VP20916
p28134
sg16454
Vmag
p28135
sa(dp28136
g16449
I279
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VpurB
p28137
sa(dp28138
g16449
I322
sg16450
I2
sg16451
I28
sg16452
g11
sg16454
Vmethylpurine-DNA glycosylase
p28139
sa(dp28140
g16449
I255
sg16450
I2
sg16451
I22
sg16452
VP30566
p28141
sg16454
Vadenylosuccinate lyase
p28142
sa(dp28143
g16449
I406
sg16450
I1
sg16451
I3
sg16452
VP00738
p28144
sg16454
Vhpt
p28145
sa(dp28146
g16449
I221
sg16450
I5
sg16451
I25
sg16452
VP00709
p28147
sg16454
VAla tRNA (alaT), Ile tRNA
p28148
sa(dp28149
g16449
I190
sg16450
I1
sg16451
I3
sg16452
VP49788
p28150
sg16454
Vrrs
p28151
sa(dp28152
g16449
I475
sg16450
I4
sg16451
I21
sg16452
VP01893
p28153
sg16454
V23S rRNA (rrlA) genes
p28154
sa(dp28155
g16449
I286
sg16450
I2
sg16451
I27
sg16452
VP30520
p28156
sg16454
Vadenylosuccinate synthetase
p28157
sa(dp28158
g16449
I358
sg16450
I2
sg16451
I46
sg16452
VP00492
p28159
sg16454
Vhypoxanthine-guanine phosphoribosyltransferase
p28160
sasg16456
(lp28161
(dp28162
g16449
I190
sg16450
I1
sg16451
I3
sg16459
VC1849334
p28163
sg16454
Vrrs
p28164
sasa(dp28165
g16444
VAdditionally, NOLC1 expression was decreased in human hepatocellular carcinoma (HCC) tissue, and the ectopic expression of NOLC1 repressed the proliferation of HCC cells and tumor growth in a HCC xenograft model.
p28166
sg16446
(lp28167
(dp28168
g16449
I14
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VNOLC1
p28169
sa(dp28170
g16449
I14
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VNOLC1
p28171
sasg16456
(lp28172
(dp28173
g16449
I174
sg16450
I2
sg16451
I12
sg16459
VC0598934
p28174
sg16454
Vtumor growth
p28175
sa(dp28176
g16449
I80
sg16450
I1
sg16451
I3
sg16459
VC2239176
p28177
sg16454
VHCC
p28178
sa(dp28179
g16449
I143
sg16450
I1
sg16451
I13
sg16459
VC0334094
p28180
sg16454
Vproliferation
p28181
sa(dp28182
g16449
I80
sg16450
I1
sg16451
I3
sg16459
VC2239176
p28183
sg16454
VHCC
p28184
sa(dp28185
g16449
I80
sg16450
I1
sg16451
I3
sg16459
VC2239176
p28186
sg16454
VHCC
p28187
sa(dp28188
g16449
I54
sg16450
I2
sg16451
I24
sg16459
VC2239176
p28189
sg16454
Vhepatocellular carcinoma
p28190
sasa(dp28191
g16444
VCUL3(KBTBD8) monoubiquitylates NOLC1 and its paralogue TCOF1, the mutation of which underlies the neurocristopathy Treacher Collins syndrome.
p28192
sg16446
(lp28193
(dp28194
g16449
I5
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VKBTBD8
p28195
sa(dp28196
g16449
I0
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCUL3
p28197
sa(dp28198
g16449
I55
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTCOF1
p28199
sa(dp28200
g16449
I31
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VNOLC1
p28201
sasg16456
(lp28202
(dp28203
g16449
I115
sg16450
I3
sg16451
I25
sg16459
VC0242387
p28204
sg16454
VTreacher Collins syndrome
p28205
sasa(dp28206
g16444
VTreacher Collins syndrome (TCS), a representative human ribosomopathy with craniofacial abnormalities, is attributed to mutations in the tcof1 gene that has a homologous gene called nopp140.
p28207
sg16446
(lp28208
(dp28209
g16449
I137
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
Vtcof1 gene
p28210
sa(dp28211
g16449
I182
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
Vnopp140
p28212
sasg16456
(lp28213
(dp28214
g16449
I27
sg16450
I1
sg16451
I3
sg16459
VC0242387
p28215
sg16454
VTCS
p28216
sa(dp28217
g16449
I0
sg16450
I3
sg16451
I25
sg16459
VC0242387
p28218
sg16454
VTreacher Collins syndrome
p28219
sa(dp28220
g16449
I75
sg16450
I2
sg16451
I26
sg16459
VC0376634
p28221
sg16454
Vcraniofacial abnormalities
p28222
sasa(dp28223
g16444
VPrevious studies suggest that NOLC1 is crucial for normal cell growth, and plays a role in the regulation of tumorigenesis of nasopharyngeal carcinoma (NPC) and demonstrate that both NOLC1 and tumor protein 53 work synergistically to activate the MDM2 promoter in NPC cells.
p28224
sg16446
(lp28225
(dp28226
g16449
I30
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VNOLC1
p28227
sa(dp28228
g16449
I30
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VNOLC1
p28229
sasg16456
(lp28230
(dp28231
g16449
I109
sg16450
I1
sg16451
I13
sg16459
VC0007621
p28232
sg16454
Vtumorigenesis
p28233
sa(dp28234
g16449
I126
sg16450
I2
sg16451
I24
sg16459
VC2931822
p28235
sg16454
Vnasopharyngeal carcinoma
p28236
sa(dp28237
g16449
I152
sg16450
I1
sg16451
I3
sg16459
VC2931822
p28238
sg16454
VNPC
p28239
sa(dp28240
g16449
I152
sg16450
I1
sg16451
I3
sg16459
VC2931822
p28241
sg16454
VNPC
p28242
sa(dp28243
g16449
I109
sg16450
I1
sg16451
I5
sg16459
VC0027651
p28244
sg16454
Vtumor
p28245
sasa(dp28246
g16444
VYet, the functioning of NOLC1 in liver cancer remains unknown.
p28247
sg16446
(lp28248
(dp28249
g16449
I24
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VNOLC1
p28250
sasg16456
(lp28251
(dp28252
g16449
I33
sg16450
I2
sg16451
I12
sg16459
VC0345904
p28253
sg16454
Vliver cancer
p28254
sasa(dp28255
g16444
VIn this study, we showed that NOLC1 was silenced or downregulated in liver tumor tissues when compared with that in the matched non-cancer tissues.
p28256
sg16446
(lp28257
(dp28258
g16449
I30
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VNOLC1
p28259
sasg16456
(lp28260
(dp28261
g16449
I69
sg16450
I2
sg16451
I11
sg16459
VC0023903
p28262
sg16454
Vliver tumor
p28263
sa(dp28264
g16449
I132
sg16450
I1
sg16451
I6
sg16459
VC0006826
p28265
sg16454
Vcancer
p28266
sasa(dp28267
g16444
VLow expression of NOLC1 in hepatoma cell lines and liver cancer tissues was associated with cyclin D3.
p28268
sg16446
(lp28269
(dp28270
g16449
I92
sg16450
I2
sg16451
I9
sg16452
VP30281
p28271
sg16454
Vcyclin D3
p28272
sa(dp28273
g16449
I18
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VNOLC1
p28274
sasg16456
(lp28275
(dp28276
g16449
I27
sg16450
I1
sg16451
I8
sg16459
VC0023903
p28277
sg16454
Vhepatoma
p28278
sa(dp28279
g16449
I51
sg16450
I2
sg16451
I12
sg16459
VC0345904
p28280
sg16454
Vliver cancer
p28281
sasa(dp28282
g16444
VIn conclusion, our study demonstrated that DNA methylation is a key mechanism of silenced NOLC1 expression in human hepatocellular carcinoma cells, and NOLC1 gene hypermethylation of the four CpG dinucleotides is a potential biomarker for hepatocellular carcinoma.
p28283
sg16446
(lp28284
(dp28285
g16449
I152
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VNOLC1 gene
p28286
sa(dp28287
g16449
I90
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VNOLC1
p28288
sasg16456
(lp28289
(dp28290
g16449
I116
sg16450
I2
sg16451
I24
sg16459
VC1512411
p28291
sg16454
Vhepatocellular carcinoma
p28292
sa(dp28293
g16449
I116
sg16450
I2
sg16451
I24
sg16459
VC1512411
p28294
sg16454
Vhepatocellular carcinoma
p28295
sasa(dp28296
g16444
VSevere combined immunodeficiency mice bearing NPC xenografts derived from NOLC1-short hairpin-RNA-transfected animals were found to have 82% lower levels of tumor growth than control mice as well as marked tumor cell apoptosis.
p28297
sg16446
(lp28298
(dp28299
g16449
I74
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VNOLC1
p28300
sasg16456
(lp28301
(dp28302
g16449
I157
sg16450
I2
sg16451
I12
sg16459
VC0598934
p28303
sg16454
Vtumor growth
p28304
sa(dp28305
g16449
I0
sg16450
I3
sg16451
I32
sg16459
VC0085110
p28306
sg16454
VSevere combined immunodeficiency
p28307
sa(dp28308
g16449
I157
sg16450
I1
sg16451
I5
sg16459
VC0027651
p28309
sg16454
Vtumor
p28310
sa(dp28311
g16449
I46
sg16450
I1
sg16451
I3
sg16459
VC2931822
p28312
sg16454
VNPC
p28313
sasa(dp28314
g16444
VThe aim of the study was to examine the effects of endurance exercise on circulating vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) in sickle cell trait (SCT) athletes with or without alpha-thalassemia.
p28315
sg16446
(lp28316
(dp28317
g16449
I133
sg16450
I3
sg16451
I33
sg16452
VP05362
p28318
sg16454
Vintercellular adhesion molecule-1
p28319
sa(dp28320
g16449
I85
sg16450
I4
sg16451
I33
sg16452
VP19320
p28321
sg16454
Vvascular cell adhesion molecule-1
p28322
sasg16456
(lp28323
(dp28324
g16449
I180
sg16450
I3
sg16451
I17
sg16459
VC0037054
p28325
sg16454
Vsickle cell trait
p28326
sa(dp28327
g16449
I199
sg16450
I1
sg16451
I3
sg16459
VC1848934
p28328
sg16454
VSCT
p28329
sa(dp28330
g16449
I99
sg16450
I1
sg16451
I8
sg16459
VC0001511
p28331
sg16454
Vadhesion
p28332
sa(dp28333
g16449
I99
sg16450
I1
sg16451
I8
sg16459
VC0001511
p28334
sg16454
Vadhesion
p28335
sa(dp28336
g16449
I229
sg16450
I1
sg16451
I17
sg16459
VC0002312
p28337
sg16454
Valpha-thalassemia
p28338
sasa(dp28339
g16444
VThe aim of the study was to examine the effects of exercise on soluble vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) in sickle cell trait (SCT) athletes with or without alpha-thalassemia.
p28340
sg16446
(lp28341
(dp28342
g16449
I119
sg16450
I3
sg16451
I33
sg16452
VP05362
p28343
sg16454
Vintercellular adhesion molecule-1
p28344
sa(dp28345
g16449
I71
sg16450
I4
sg16451
I33
sg16452
VP19320
p28346
sg16454
Vvascular cell adhesion molecule-1
p28347
sasg16456
(lp28348
(dp28349
g16449
I85
sg16450
I1
sg16451
I8
sg16459
VC0001511
p28350
sg16454
Vadhesion
p28351
sa(dp28352
g16449
I85
sg16450
I1
sg16451
I8
sg16459
VC0001511
p28353
sg16454
Vadhesion
p28354
sa(dp28355
g16449
I215
sg16450
I1
sg16451
I17
sg16459
VC0002312
p28356
sg16454
Valpha-thalassemia
p28357
sa(dp28358
g16449
I166
sg16450
I3
sg16451
I17
sg16459
VC0037054
p28359
sg16454
Vsickle cell trait
p28360
sa(dp28361
g16449
I185
sg16450
I1
sg16451
I3
sg16459
VC1848934
p28362
sg16454
VSCT
p28363
sasa(dp28364
g16444
VAs compared to normal, increased sICAM-1 was found in beta-thal/HbE patients with non-splenectomy; BE-NS (p = 0.002), increased ELAM-1 in beta-thal/HbE patients with splenectomy; BE-S (p = 0.01) and HbH with Hb Constant Spring; HbH/CS (p = 0.001), and increased sVCAM-1 in BE-NS; (p = &lt; 0.0001) and BE-S (p = 0.002).
p28365
sg16446
(lp28366
(dp28367
g16449
I64
sg16450
I1
sg16451
I3
sg16452
VP02100
p28368
sg16454
VHbE
p28369
sa(dp28370
g16449
I128
sg16450
I1
sg16451
I6
sg16452
VP16581
p28371
sg16454
VELAM-1
p28372
sa(dp28373
g16449
I208
sg16450
I3
sg16451
I18
sg16452
g11
sg16454
VHb Constant Spring
p28374
sasg16456
(lp28375
(dp28376
g16449
I199
sg16450
I1
sg16451
I3
sg16459
VC3161174
p28377
sg16454
VHbH
p28378
sa(dp28379
g16449
I199
sg16450
I1
sg16451
I3
sg16459
VC3161174
p28380
sg16454
VHbH
p28381
sasa(dp28382
g16444
VFurthermore, treatment with AST or DEX significantly suppressed the mRNA and protein expression levels of the transcription factor GATA-3 and retinoic acid receptor-related orphan nuclear receptor (ROR)Gammat in tissue samples isolated from the spleen and nasal mucosa of mice with allergic rhinitis.
p28383
sg16446
(lp28384
(dp28385
g16449
I173
sg16450
I3
sg16451
I23
sg16452
VP51843
p28386
sg16454
Vorphan nuclear receptor
p28387
sa(dp28388
g16449
I110
sg16450
I3
sg16451
I27
sg16452
VP23771
p28389
sg16454
Vtranscription factor GATA-3
p28390
sa(dp28391
g16449
I142
sg16450
I3
sg16451
I22
sg16452
VP10826
p28392
sg16454
Vretinoic acid receptor
p28393
sasg16456
(lp28394
(dp28395
g16449
I282
sg16450
I2
sg16451
I17
sg16459
VC2607914
p28396
sg16454
Vallergic rhinitis
p28397
sasa(dp28398
g16444
VThe present results suggested that treatment with AST may attenuate OVA-induced allergic rhinitis via regulating the expression of the transcription factors GATA-3, RORGammat, T-bet and Foxp3, which commit T helper cells to the Th1 phenotype.
p28399
sg16446
(lp28400
(dp28401
g16449
I50
sg16450
I1
sg16451
I3
sg16452
VP51689
p28402
sg16454
VAST
p28403
sa(dp28404
g16449
I135
sg16450
I3
sg16451
I28
sg16452
VP19883
p28405
sg16454
Vtranscription factors GATA-3
p28406
sa(dp28407
g16449
I176
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VT-bet
p28408
sa(dp28409
g16449
I186
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VFoxp3
p28410
sasg16456
(lp28411
(dp28412
g16449
I80
sg16450
I2
sg16451
I17
sg16459
VC2607914
p28413
sg16454
Vallergic rhinitis
p28414
sasa(dp28415
g16444
VCanagliflozin was associated with a low incidence of hypoglycemia when used with background AHAs that are not associated with hypoglycemia; the incidence was higher among patients on background AHAs associated with hypoglycemia (i.e.
p28416
sg16446
(lp28417
sg16456
(lp28418
(dp28419
g16449
I53
sg16450
I1
sg16451
I12
sg16459
VC0020615
p28420
sg16454
Vhypoglycemia
p28421
sa(dp28422
g16449
I53
sg16450
I1
sg16451
I12
sg16459
VC0020615
p28423
sg16454
Vhypoglycemia
p28424
sa(dp28425
g16449
I53
sg16450
I1
sg16451
I12
sg16459
VC0020615
p28426
sg16454
Vhypoglycemia
p28427
sasa(dp28428
g16444
VCanagliflozin was associated with a low incidence of hypoglycemia when not used in conjunction with AHAs associated with hypoglycemia (i.e., insulin or sulfonylurea).
p28429
sg16446
(lp28430
(dp28431
g16449
I141
sg16450
I1
sg16451
I7
sg16452
VP01308
p28432
sg16454
Vinsulin
p28433
sasg16456
(lp28434
(dp28435
g16449
I53
sg16450
I1
sg16451
I12
sg16459
VC0020615
p28436
sg16454
Vhypoglycemia
p28437
sa(dp28438
g16449
I53
sg16450
I1
sg16451
I12
sg16459
VC0020615
p28439
sg16454
Vhypoglycemia
p28440
sasa(dp28441
g16444
VAdding different AHAs to metformin was associated with varying effects on HbA1c, BW, SBP, hypoglycemia, UTI and GTI which should impact clinician choice when selecting adjunctive therapy.
p28442
sg16446
(lp28443
sg16456
(lp28444
(dp28445
g16449
I90
sg16450
I1
sg16451
I12
sg16459
VC0020615
p28446
sg16454
Vhypoglycemia
p28447
sa(dp28448
g16449
I104
sg16450
I1
sg16451
I3
sg16459
VC0042029
p28449
sg16454
VUTI
p28450
sasa(dp28451
g16444
VIt has been shown at least four mutations of mitochondrial genome, namely, A1555G in MT-RNR1 gene, C3256T in MT-TL1 gene, G12315A in MT-TL2 gene, and G15059A in MT-CYB gene have significantly higher prevalence and mean value in lipofibrous plaques as compared to non-atherosclerotic intima, and therefore are associated with atherosclerosis.
p28452
sg16446
(lp28453
(dp28454
g16449
I85
sg16450
I2
sg16451
I12
sg16452
VP43354
p28455
sg16454
VMT-RNR1 gene
p28456
sa(dp28457
g16449
I133
sg16450
I2
sg16451
I11
sg16452
VP50591
p28458
sg16454
VMT-TL2 gene
p28459
sa(dp28460
g16449
I109
sg16450
I2
sg16451
I11
sg16452
g11
sg16454
VMT-TL1 gene
p28461
sa(dp28462
g16449
I161
sg16450
I2
sg16451
I11
sg16452
g11
sg16454
VMT-CYB gene
p28463
sasg16456
(lp28464
(dp28465
g16449
I240
sg16450
I1
sg16451
I7
sg16459
VC0333463
p28466
sg16454
Vplaques
p28467
sa(dp28468
g16449
I325
sg16450
I1
sg16451
I15
sg16459
VC0004153
p28469
sg16454
Vatherosclerosis
p28470
sasa(dp28471
g16444
VTen mitochondrial mutations belonging to mitochondrial genes MT-RNR1 (rRNA 12S); MT-TL1 (tRNA-Leu, recognizes UUR); MT-TL2 (tRNA-Leu, recognizes CUN); MT-ND1, MT-ND2, MT-ND5, and MT-ND6 (subunits 1, 2, 5, and 6, respectively, of NADH dehydrogenase); and MT-CYB (cytochrome b) were potentially associated with atherosclerosis.
p28472
sg16446
(lp28473
(dp28474
g16449
I81
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VMT-TL1
p28475
sa(dp28476
g16449
I116
sg16450
I1
sg16451
I6
sg16452
VP50591
p28477
sg16454
VMT-TL2
p28478
sa(dp28479
g16449
I254
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VMT-CYB
p28480
sa(dp28481
g16449
I167
sg16450
I1
sg16451
I6
sg16452
VP03915
p28482
sg16454
VMT-ND5
p28483
sa(dp28484
g16449
I159
sg16450
I1
sg16451
I6
sg16452
VP03891
p28485
sg16454
VMT-ND2
p28486
sa(dp28487
g16449
I229
sg16450
I2
sg16451
I18
sg16452
VP49366
p28488
sg16454
VNADH dehydrogenase
p28489
sa(dp28490
g16449
I61
sg16450
I1
sg16451
I7
sg16452
VP43354
p28491
sg16454
VMT-RNR1
p28492
sa(dp28493
g16449
I124
sg16450
I3
sg16451
I24
sg16452
VP30740
p28494
sg16454
VtRNA-Leu, recognizes CUN
p28495
sa(dp28496
g16449
I89
sg16450
I3
sg16451
I24
sg16452
VP30740
p28497
sg16454
VtRNA-Leu, recognizes UUR
p28498
sa(dp28499
g16449
I151
sg16450
I1
sg16451
I6
sg16452
VP03886
p28500
sg16454
VMT-ND1
p28501
sasg16456
(lp28502
(dp28503
g16449
I309
sg16450
I1
sg16451
I15
sg16459
VC0004153
p28504
sg16454
Vatherosclerosis
p28505
sasa(dp28506
g16444
VThe vectors of chikungunya and dengue virus, Aedes aegypti and Aedes albopictus, the vector of lymphatic filariasis, Culex quinquefasciatus, and that of Japanese encephalitis, Culex tritaeniorhynchus, were found from 70 to 2,000 m asl in eastern Nepal.
p28507
sg16446
(lp28508
sg16456
(lp28509
(dp28510
g16449
I153
sg16450
I2
sg16451
I21
sg16459
VC0014057
p28511
sg16454
VJapanese encephalitis
p28512
sa(dp28513
g16449
I95
sg16450
I2
sg16451
I20
sg16459
VC0013884
p28514
sg16454
Vlymphatic filariasis
p28515
sa(dp28516
g16449
I15
sg16450
I1
sg16451
I11
sg16459
VC0008055
p28517
sg16454
Vchikungunya
p28518
sa(dp28519
g16449
I31
sg16450
I1
sg16451
I6
sg16459
VC0011311
p28520
sg16454
Vdengue
p28521
sasa(dp28522
g16444
VThe results of an examination of a paraffin block histopathology specimen by fluorescence in-situ hybridization (FISH) showed no mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1) (18q21.1), B-cell lymphoma 2 (BCL2) (18q21.3), or BCL6 (3q27) split signals in either the uterus or the greater omentum, however, trisomy 18 was detected in approximately 50%-70% of the tumor cells in both the uterus and the greater omentum.
p28523
sg16446
(lp28524
(dp28525
g16449
I251
sg16450
I1
sg16451
I4
sg16452
VP41182
p28526
sg16454
VBCL6
p28527
sa(dp28528
g16449
I231
sg16450
I1
sg16451
I4
sg16452
VP10415
p28529
sg16454
VBCL2
p28530
sa(dp28531
g16449
I212
sg16450
I3
sg16451
I17
sg16452
VP10415
p28532
sg16454
VB-cell lymphoma 2
p28533
sasg16456
(lp28534
(dp28535
g16449
I172
sg16450
I1
sg16451
I13
sg16459
VC0040715
p28536
sg16454
Vtranslocation
p28537
sa(dp28538
g16449
I387
sg16450
I1
sg16451
I5
sg16459
VC0027651
p28539
sg16454
Vtumor
p28540
sa(dp28541
g16449
I129
sg16450
I5
sg16451
I42
sg16459
VC0242647
p28542
sg16454
Vmucosa associated lymphoid tissue lymphoma
p28543
sa(dp28544
g16449
I212
sg16450
I2
sg16451
I15
sg16459
VC0079731
p28545
sg16454
VB-cell lymphoma
p28546
sa(dp28547
g16449
I331
sg16450
I2
sg16451
I10
sg16459
VC0152096
p28548
sg16454
Vtrisomy 18
p28549
sasa(dp28550
g16444
VThe following abnormalities were most frequently observed: rearrangements involving 14q32, 19q13, 19p13, 1p, 3q27, and 8q24; del(6q); dup(1q); and trisomy 18.
p28551
sg16446
(lp28552
sg16456
(lp28553
(dp28554
g16449
I147
sg16450
I2
sg16451
I10
sg16459
VC0152096
p28555
sg16454
Vtrisomy 18
p28556
sasa(dp28557
g16444
VPassive avoidance test showed four Group rats shuttle times were 6.8+/-0.6, 1.2+/-0.2, 5.4+/-0.5, 3.6+/-0.3, incubation period were 26.1+/-3.9, 152.2+/-12.9, 65.8+/-7.0, 91.2+/-9.1, and water maze test had the same trend, with values in epilepsy groups significantly lower than the normal group of rats, which meant cognitive dysfunction.The above results also showed Baclofen further inhibited the learning and memory ability of the rats and CGP35348 promoted the learning and memory ability.The results of the Arc/Arg3.1 and GB1, GB2 level detection showed that epilepsy groups had significantly higher expression levels of Arc/Arg3.1 and GB1, GB2 than the normal group.Comparison among epilepsy groups showed that Baclofen group expressed lower levels of Arc/Arg3.1 and expressed higher levels of GB1, GB2, however CGP35348 group expressed higher levels of Arc/Arg3.1 and expressed lower levels of GB1, GB2.
p28558
sg16446
(lp28559
(dp28560
g16449
I516
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VArg3.1
p28561
sa(dp28562
g16449
I532
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VGB2
p28563
sa(dp28564
g16449
I527
sg16450
I1
sg16451
I3
sg16452
VP62873
p28565
sg16454
VGB1
p28566
sa(dp28567
g16449
I516
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VArg3.1
p28568
sa(dp28569
g16449
I532
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VGB2
p28570
sa(dp28571
g16449
I532
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VGB2
p28572
sa(dp28573
g16449
I512
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VArc
p28574
sa(dp28575
g16449
I516
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VArg3.1
p28576
sa(dp28577
g16449
I512
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VArc
p28578
sa(dp28579
g16449
I512
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VArc
p28580
sa(dp28581
g16449
I527
sg16450
I1
sg16451
I3
sg16452
VP62873
p28582
sg16454
VGB1
p28583
sa(dp28584
g16449
I527
sg16450
I1
sg16451
I3
sg16452
VP62873
p28585
sg16454
VGB1
p28586
sa(dp28587
g16449
I532
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VGB2
p28588
sa(dp28589
g16449
I818
sg16450
I2
sg16451
I14
sg16452
VP00390
p28590
sg16454
VCGP35348 group
p28591
sa(dp28592
g16449
I512
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VArc
p28593
sa(dp28594
g16449
I516
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VArg3.1
p28595
sa(dp28596
g16449
I527
sg16450
I1
sg16451
I3
sg16452
VP62873
p28597
sg16454
VGB1
p28598
sasg16456
(lp28599
(dp28600
g16449
I237
sg16450
I1
sg16451
I8
sg16459
VC0014544
p28601
sg16454
Vepilepsy
p28602
sa(dp28603
g16449
I512
sg16450
I1
sg16451
I3
sg16459
VC0001857
p28604
sg16454
VArc
p28605
sa(dp28606
g16449
I237
sg16450
I1
sg16451
I8
sg16459
VC0014544
p28607
sg16454
Vepilepsy
p28608
sa(dp28609
g16449
I512
sg16450
I1
sg16451
I3
sg16459
VC0001857
p28610
sg16454
VArc
p28611
sa(dp28612
g16449
I512
sg16450
I1
sg16451
I3
sg16459
VC0001857
p28613
sg16454
VArc
p28614
sa(dp28615
g16449
I316
sg16450
I2
sg16451
I21
sg16459
VC0338656
p28616
sg16454
Vcognitive dysfunction
p28617
sa(dp28618
g16449
I237
sg16450
I1
sg16451
I8
sg16459
VC0014544
p28619
sg16454
Vepilepsy
p28620
sa(dp28621
g16449
I512
sg16450
I1
sg16451
I3
sg16459
VC0001857
p28622
sg16454
VArc
p28623
sasa(dp28624
g16444
VTo search for the mechanism causing clinically silent corticotroph adenoma, we immunohistochemically examined the expression of prohormone convertase 1/3 (PC1/3) in this type of adenoma and compared our results with those obtained for Cushing's disease.
p28625
sg16446
(lp28626
(dp28627
g16449
I155
sg16450
I1
sg16451
I5
sg16452
VP29120
p28628
sg16454
VPC1/3
p28629
sa(dp28630
g16449
I128
sg16450
I3
sg16451
I25
sg16452
VP29120
p28631
sg16454
Vprohormone convertase 1/3
p28632
sasg16456
(lp28633
(dp28634
g16449
I67
sg16450
I1
sg16451
I7
sg16459
VC0001430
p28635
sg16454
Vadenoma
p28636
sa(dp28637
g16449
I54
sg16450
I2
sg16451
I20
sg16459
VC1306214
p28638
sg16454
Vcorticotroph adenoma
p28639
sa(dp28640
g16449
I235
sg16450
I2
sg16451
I17
sg16459
VC0221406
p28641
sg16454
VCushing's disease
p28642
sa(dp28643
g16449
I155
sg16450
I1
sg16451
I3
sg16459
VC1706595
p28644
sg16454
VPC1
p28645
sasa(dp28646
g16444
VIn the present study, we tested the therapeutic and immunomodulatory effects of FTS and its derivative 5-fluoro-FTS (F-FTS) in the rat adjuvant-induced arthritis model (AIA).
p28647
sg16446
(lp28648
(dp28649
g16449
I117
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VF-FTS
p28650
sa(dp28651
g16449
I103
sg16450
I1
sg16451
I12
sg16452
g11
sg16454
V5-fluoro-FTS
p28652
sasg16456
(lp28653
(dp28654
g16449
I152
sg16450
I1
sg16451
I9
sg16459
VC0003864
p28655
sg16454
Varthritis
p28656
sasa(dp28657
g16444
VMR features were scored (0-3) following the Oslo hand OA score: BMLs, synovitis, cysts, flexor tenosynovitis (FTS).
p28658
sg16446
(lp28659
sg16456
(lp28660
(dp28661
g16449
I110
sg16450
I1
sg16451
I3
sg16459
VC0744058
p28662
sg16454
VFTS
p28663
sa(dp28664
g16449
I81
sg16450
I1
sg16451
I5
sg16459
VC0010709
p28665
sg16454
Vcysts
p28666
sa(dp28667
g16449
I70
sg16450
I1
sg16451
I9
sg16459
VC0039103
p28668
sg16454
Vsynovitis
p28669
sa(dp28670
g16449
I88
sg16450
I2
sg16451
I20
sg16459
VC0744058
p28671
sg16454
Vflexor tenosynovitis
p28672
sasa(dp28673
g16444
VBMLs, synovitis, cysts, FTS and ETI were demonstrated in 56%, 90%, 22%, 16% and 30% of patients, respectively.
p28674
sg16446
(lp28675
sg16456
(lp28676
(dp28677
g16449
I17
sg16450
I1
sg16451
I5
sg16459
VC0010709
p28678
sg16454
Vcysts
p28679
sa(dp28680
g16449
I6
sg16450
I1
sg16451
I9
sg16459
VC0039103
p28681
sg16454
Vsynovitis
p28682
sasa(dp28683
g16444
VBMLs (grade 2/3 vs 0: 3.5 (1.6-7.7)) and synovitis (3 vs 0: OR 3.6 (95% CI 1.9-6.6)) were severity-dependent associated with joint pain, but FTS and ETI were not.
p28684
sg16446
(lp28685
sg16456
(lp28686
(dp28687
g16449
I125
sg16450
I2
sg16451
I10
sg16459
VC0003862
p28688
sg16454
Vjoint pain
p28689
sa(dp28690
g16449
I41
sg16450
I1
sg16451
I9
sg16459
VC0039103
p28691
sg16454
Vsynovitis
p28692
sasa(dp28693
g16444
VInfectious flexor tenosynovitis (FTS) is a serious infection of the hand and wrist that can lead to necrosis and amputation without prompt diagnosis and surgical debridement.
p28694
sg16446
(lp28695
sg16456
(lp28696
(dp28697
g16449
I33
sg16450
I1
sg16451
I3
sg16459
VC0744058
p28698
sg16454
VFTS
p28699
sa(dp28700
g16449
I11
sg16450
I2
sg16451
I20
sg16459
VC0744058
p28701
sg16454
Vflexor tenosynovitis
p28702
sa(dp28703
g16449
I51
sg16450
I1
sg16451
I9
sg16459
VC0009450
p28704
sg16454
Vinfection
p28705
sa(dp28706
g16449
I0
sg16450
I1
sg16451
I10
sg16459
VC0009450
p28707
sg16454
VInfectious
p28708
sasa(dp28709
g16444
VOur objective in this work was to investigate the anti-inflammatory effects of the Ras inhibitor farnesylthiosalicylic acid (FTS) on adjuvant-induced arthritis (AIA) in rats, an experimental model for RA.
p28710
sg16446
(lp28711
(dp28712
g16449
I83
sg16450
I1
sg16451
I3
sg16452
VP01116
p28713
sg16454
VRas
p28714
sasg16456
(lp28715
(dp28716
g16449
I150
sg16450
I1
sg16451
I9
sg16459
VC0003864
p28717
sg16454
Varthritis
p28718
sasa(dp28719
g16444
VDiabetic patients are susceptible to stenosing flexor tenosynovitis (FTS) and may have a diminished response to treatment.
p28720
sg16446
(lp28721
sg16456
(lp28722
(dp28723
g16449
I47
sg16450
I2
sg16451
I20
sg16459
VC0744058
p28724
sg16454
Vflexor tenosynovitis
p28725
sa(dp28726
g16449
I69
sg16450
I1
sg16451
I3
sg16459
VC0744058
p28727
sg16454
VFTS
p28728
sasa(dp28729
g16444
VWith the rising participation of women in sports events, the prevalence of eating disorders and the female athlete triad (FTS), a syndrome of disordered eating, amenorrhea, and osteoporosis, have also increased in recent years.
p28730
sg16446
(lp28731
sg16456
(lp28732
(dp28733
g16449
I161
sg16450
I1
sg16451
I10
sg16459
VC0002453
p28734
sg16454
Vamenorrhea
p28735
sa(dp28736
g16449
I100
sg16450
I3
sg16451
I20
sg16459
VC1721053
p28737
sg16454
Vfemale athlete triad
p28738
sa(dp28739
g16449
I75
sg16450
I2
sg16451
I16
sg16459
VC0013473
p28740
sg16454
Veating disorders
p28741
sa(dp28742
g16449
I130
sg16450
I1
sg16451
I8
sg16459
VC0039082
p28743
sg16454
Vsyndrome
p28744
sa(dp28745
g16449
I177
sg16450
I1
sg16451
I12
sg16459
VC0029456
p28746
sg16454
Vosteoporosis
p28747
sasa(dp28748
g16444
VDupuytren's contracture (DC) (42 vs. 29.3%, respectively; P=0.01), limited joint mobility (LJM) (39 vs. 28.5%, respectively; P=0.01) and carpal tunnel syndrome (CTS) (5.3 vs. 1%, respectively; P=0.01) were significantly higher in T2DM patients than in the controls, but not stenosing flexor tenosynovitis (FTS, 'trigger finger').
p28749
sg16446
(lp28750
sg16456
(lp28751
(dp28752
g16449
I161
sg16450
I1
sg16451
I3
sg16459
VC0007286
p28753
sg16454
VCTS
p28754
sa(dp28755
g16449
I137
sg16450
I3
sg16451
I22
sg16459
VC0007286
p28756
sg16454
Vcarpal tunnel syndrome
p28757
sa(dp28758
g16449
I311
sg16450
I2
sg16451
I15
sg16459
VC0158328
p28759
sg16454
V'trigger finger
p28760
sa(dp28761
g16449
I25
sg16450
I1
sg16451
I2
sg16459
VC0013312
p28762
sg16454
VDC
p28763
sa(dp28764
g16449
I0
sg16450
I2
sg16451
I23
sg16459
VC0013312
p28765
sg16454
VDupuytren's contracture
p28766
sa(dp28767
g16449
I284
sg16450
I2
sg16451
I20
sg16459
VC0744058
p28768
sg16454
Vflexor tenosynovitis
p28769
sa(dp28770
g16449
I306
sg16450
I1
sg16451
I3
sg16459
VC0744058
p28771
sg16454
VFTS
p28772
sasa(dp28773
g16444
VData from several studies suggest that the gastrin family of growth factors potentiates colorectal cancer tumourigenesis.
p28774
sg16446
(lp28775
(dp28776
g16449
I43
sg16450
I2
sg16451
I14
sg16452
VP01350
p28777
sg16454
Vgastrin family
p28778
sa(dp28779
g16449
I61
sg16450
I2
sg16451
I14
sg16452
VP19883
p28780
sg16454
Vgrowth factors
p28781
sasg16456
(lp28782
(dp28783
g16449
I88
sg16450
I2
sg16451
I17
sg16459
VC1527249
p28784
sg16454
Vcolorectal cancer
p28785
sasa(dp28786
g16444
VThe aim of this study was to investigate whether progastrin expression may predict clinical outcome in colorectal cancer.
p28787
sg16446
(lp28788
sg16456
(lp28789
(dp28790
g16449
I103
sg16450
I2
sg16451
I17
sg16459
VC1527249
p28791
sg16454
Vcolorectal cancer
p28792
sasa(dp28793
g16444
VThis is the first study to show that progastrin expression may be predictive of aggressive tumour behaviour in patients with colorectal cancer and supports its clinical relevance and potential use as a biomarker.
p28794
sg16446
(lp28795
sg16456
(lp28796
(dp28797
g16449
I80
sg16450
I1
sg16451
I10
sg16459
VC0001807
p28798
sg16454
Vaggressive
p28799
sa(dp28800
g16449
I91
sg16450
I1
sg16451
I6
sg16459
VC0027651
p28801
sg16454
Vtumour
p28802
sa(dp28803
g16449
I125
sg16450
I2
sg16451
I17
sg16459
VC1527249
p28804
sg16454
Vcolorectal cancer
p28805
sasa(dp28806
g16444
VThe aim of this study was to analyze plasma concentrations of enterohormones (motilin, ghrelin, gastrin and pancreatic polypeptide) and to verify if their abnormal levels may contribute to the severity of dyspeptic symptoms in colorectal cancer patients.
p28807
sg16446
(lp28808
(dp28809
g16449
I87
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
Vghrelin
p28810
sa(dp28811
g16449
I96
sg16450
I1
sg16451
I7
sg16452
VP01350
p28812
sg16454
Vgastrin
p28813
sa(dp28814
g16449
I78
sg16450
I1
sg16451
I7
sg16452
VP12872
p28815
sg16454
Vmotilin
p28816
sasg16456
(lp28817
(dp28818
g16449
I227
sg16450
I2
sg16451
I17
sg16459
VC1527249
p28819
sg16454
Vcolorectal cancer
p28820
sasa(dp28821
g16444
VThis study examined the expression level, subcellular localization, and binding activity of CacyBP/SIP in human colon cancer cells in the presence and absence of the hormone gastrin.
p28822
sg16446
(lp28823
(dp28824
g16449
I99
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VSIP
p28825
sa(dp28826
g16449
I92
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCacyBP
p28827
sa(dp28828
g16449
I174
sg16450
I1
sg16451
I7
sg16452
VP01350
p28829
sg16454
Vgastrin
p28830
sasg16456
(lp28831
(dp28832
g16449
I112
sg16450
I2
sg16451
I12
sg16459
VC0699790
p28833
sg16454
Vcolon cancer
p28834
sasa(dp28835
g16444
VCacyBP/SIP promoted the cell proliferation of colon cancer cells under both basal and gastrin stimulated conditions as shown by knockdown studies.
p28836
sg16446
(lp28837
(dp28838
g16449
I86
sg16450
I1
sg16451
I7
sg16452
VP01350
p28839
sg16454
Vgastrin
p28840
sa(dp28841
g16449
I0
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCacyBP
p28842
sa(dp28843
g16449
I7
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VSIP
p28844
sasg16456
(lp28845
(dp28846
g16449
I46
sg16450
I2
sg16451
I12
sg16459
VC0699790
p28847
sg16454
Vcolon cancer
p28848
sa(dp28849
g16449
I29
sg16450
I1
sg16451
I13
sg16459
VC0334094
p28850
sg16454
Vproliferation
p28851
sasa(dp28852
g16444
VAs treatment with proton pump inhibitors (PPIs) increases the biosynthesis and secretion of gastrin, it has been postulated that treatment with PPIs could increase the risk of cancer, especially in Barrett's esophagus, gastric carcinoids, and colorectal cancer (CRC).
p28853
sg16446
(lp28854
(dp28855
g16449
I92
sg16450
I1
sg16451
I7
sg16452
VP01350
p28856
sg16454
Vgastrin
p28857
sasg16456
(lp28858
(dp28859
g16449
I198
sg16450
I2
sg16451
I19
sg16459
VC0004763
p28860
sg16454
VBarrett's esophagus
p28861
sa(dp28862
g16449
I243
sg16450
I2
sg16451
I17
sg16459
VC1527249
p28863
sg16454
Vcolorectal cancer
p28864
sa(dp28865
g16449
I227
sg16450
I1
sg16451
I10
sg16459
VC0007095
p28866
sg16454
Vcarcinoids
p28867
sa(dp28868
g16449
I262
sg16450
I1
sg16451
I3
sg16459
VC1527249
p28869
sg16454
VCRC
p28870
sa(dp28871
g16449
I176
sg16450
I1
sg16451
I6
sg16459
VC0006826
p28872
sg16454
Vcancer
p28873
sasa(dp28874
g16444
VPathological studies showed lymph nodes metastasis in 2 patients with pancreatic gastrinomas, and in one patient with duodenal gastrinoma.
p28875
sg16446
(lp28876
sg16456
(lp28877
(dp28878
g16449
I81
sg16450
I1
sg16451
I11
sg16459
VC0017150
p28879
sg16454
Vgastrinomas
p28880
sa(dp28881
g16449
I118
sg16450
I2
sg16451
I19
sg16459
VC1333321
p28882
sg16454
Vduodenal gastrinoma
p28883
sa(dp28884
g16449
I40
sg16450
I1
sg16451
I10
sg16459
VC0027627
p28885
sg16454
Vmetastasis
p28886
sasa(dp28887
g16444
VA progressive increase in the expression of PD-1 and B7-H1/B7-DC on T cells and APC, respectively, was observed in the pancreatic lymph nodes of female non-obese diabetic (NOD) mice as they developed diabetes.
p28888
sg16446
(lp28889
(dp28890
g16449
I53
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VB7-H1
p28891
sa(dp28892
g16449
I80
sg16450
I1
sg16451
I3
sg16452
VP25054
p28893
sg16454
VAPC
p28894
sa(dp28895
g16449
I44
sg16450
I1
sg16451
I4
sg16452
VP18621
p28896
sg16454
VPD-1
p28897
sa(dp28898
g16449
I59
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VB7-DC
p28899
sasg16456
(lp28900
(dp28901
g16449
I172
sg16450
I1
sg16451
I3
sg16459
VC0751781
p28902
sg16454
VNOD
p28903
sa(dp28904
g16449
I80
sg16450
I1
sg16451
I3
sg16459
VC0033036
p28905
sg16454
VAPC
p28906
sa(dp28907
g16449
I200
sg16450
I1
sg16451
I8
sg16459
VC0011849
p28908
sg16454
Vdiabetes
p28909
sa(dp28910
g16449
I152
sg16450
I2
sg16451
I18
sg16459
VC0751781
p28911
sg16454
Vnon-obese diabetic
p28912
sasa(dp28913
g16444
VB7-H1 and B7-DC have negative regulatory effects upon binding PD-1 on activated T cells and B7-H1 deficiency increases severity of both diabetes and EAE.
p28914
sg16446
(lp28915
(dp28916
g16449
I10
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VB7-DC
p28917
sa(dp28918
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VB7-H1
p28919
sa(dp28920
g16449
I62
sg16450
I1
sg16451
I4
sg16452
VP18621
p28921
sg16454
VPD-1
p28922
sa(dp28923
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VB7-H1
p28924
sasg16456
(lp28925
(dp28926
g16449
I136
sg16450
I1
sg16451
I8
sg16459
VC0011849
p28927
sg16454
Vdiabetes
p28928
sasa(dp28929
g16444
VThese characteristics have implicated KIR3DL2 in several pathologies: ankylosing spondylitis and cutaneous T-cell lymphomas such as Sezary syndrome, CD30+ cutaneous lymphoma, and transformed mycosis fungoides.
p28930
sg16446
(lp28931
(dp28932
g16449
I38
sg16450
I1
sg16451
I7
sg16452
VP43630
p28933
sg16454
VKIR3DL2
p28934
sasg16456
(lp28935
(dp28936
g16449
I132
sg16450
I2
sg16451
I15
sg16459
VC0036920
p28937
sg16454
VSezary syndrome
p28938
sa(dp28939
g16449
I97
sg16450
I3
sg16451
I26
sg16459
VC0079773
p28940
sg16454
Vcutaneous T-cell lymphomas
p28941
sa(dp28942
g16449
I70
sg16450
I2
sg16451
I22
sg16459
VC0038013
p28943
sg16454
Vankylosing spondylitis
p28944
sa(dp28945
g16449
I155
sg16450
I2
sg16451
I18
sg16459
VC1276146
p28946
sg16454
Vcutaneous lymphoma
p28947
sa(dp28948
g16449
I191
sg16450
I2
sg16451
I17
sg16459
VC0026948
p28949
sg16454
Vmycosis fungoides
p28950
sasa(dp28951
g16444
VKIR3DL2, an inhibitory receptor expressed by natural killer cells and a subset of normal CD8(+) T cells, is aberrantly expressed in neoplastic cells in transformed mycosis fungoides and Sezary syndrome.
p28952
sg16446
(lp28953
(dp28954
g16449
I0
sg16450
I1
sg16451
I7
sg16452
VP43630
p28955
sg16454
VKIR3DL2
p28956
sa(dp28957
g16449
I89
sg16450
I1
sg16451
I3
sg16452
VP01732
p28958
sg16454
VCD8
p28959
sasg16456
(lp28960
(dp28961
g16449
I164
sg16450
I5
sg16451
I37
sg16459
VC0862196
p28962
sg16454
Vmycosis fungoides and Sezary syndrome
p28963
sasa(dp28964
g16444
VNot only we confirmed the expression of this marker in the blood and/or skin of mycosis fungoides patients but we also show for the first time CD158k expression (often associated with CD160) on cutaneous CD4+ T cells from healthy individuals (25.3 +/- 15%).
p28965
sg16446
(lp28966
(dp28967
g16449
I184
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCD160
p28968
sa(dp28969
g16449
I143
sg16450
I1
sg16451
I6
sg16452
VP43627
p28970
sg16454
VCD158k
p28971
sasg16456
(lp28972
(dp28973
g16449
I80
sg16450
I2
sg16451
I17
sg16459
VC0026948
p28974
sg16454
Vmycosis fungoides
p28975
sasa(dp28976
g16444
VTherefore, CD4+ CD160+ T cells expressing CD158k might represent specialized cutaneous lymphocytes devoted to immune surveillance, from which could originate cutaneous T-cell lymphomas such as mycosis fungoides.
p28977
sg16446
(lp28978
(dp28979
g16449
I11
sg16450
I1
sg16451
I4
sg16452
VP01730
p28980
sg16454
VCD4+
p28981
sa(dp28982
g16449
I42
sg16450
I1
sg16451
I6
sg16452
VP43627
p28983
sg16454
VCD158k
p28984
sasg16456
(lp28985
(dp28986
g16449
I158
sg16450
I3
sg16451
I26
sg16459
VC0079773
p28987
sg16454
Vcutaneous T-cell lymphomas
p28988
sa(dp28989
g16449
I193
sg16450
I2
sg16451
I17
sg16459
VC0026948
p28990
sg16454
Vmycosis fungoides
p28991
sasa(dp28992
g16444
Vp140/KIR3DL2 has been identified in malignant cell lines isolated from the skin and blood of patients with transformed mycosis fungoides (MF) and Sezary's syndrome (SS).
p28993
sg16446
(lp28994
(dp28995
g16449
I5
sg16450
I1
sg16451
I7
sg16452
VP43630
p28996
sg16454
VKIR3DL2
p28997
sa(dp28998
g16449
I0
sg16450
I1
sg16451
I4
sg16452
VP43630
p28999
sg16454
Vp140
p29000
sasg16456
(lp29001
(dp29002
g16449
I146
sg16450
I2
sg16451
I17
sg16459
VC0036920
p29003
sg16454
VSezary's syndrome
p29004
sa(dp29005
g16449
I119
sg16450
I2
sg16451
I17
sg16459
VC0026948
p29006
sg16454
Vmycosis fungoides
p29007
sasa(dp29008
g16444
VChromosomal aberration (DS especially) are among the most frequent prenatally diagnosed birth defects, further being heart defects, neural tube defects (anencephaly, encephalocele, spina bifida), hydrocephalus, congenital skeletal system defects, abdominal wall defects (omphalocele, gastroschisis) and renal defects.
p29009
sg16446
(lp29010
sg16456
(lp29011
(dp29012
g16449
I153
sg16450
I1
sg16451
I11
sg16459
VC0002902
p29013
sg16454
Vanencephaly
p29014
sa(dp29015
g16449
I196
sg16450
I2
sg16451
I25
sg16459
VC0020256
p29016
sg16454
Vhydrocephalus, congenital
p29017
sa(dp29018
g16449
I166
sg16450
I1
sg16451
I13
sg16459
VC0014065
p29019
sg16454
Vencephalocele
p29020
sa(dp29021
g16449
I181
sg16450
I2
sg16451
I12
sg16459
VC0080178
p29022
sg16454
Vspina bifida
p29023
sa(dp29024
g16449
I0
sg16450
I2
sg16451
I22
sg16459
VC0008625
p29025
sg16454
VChromosomal aberration
p29026
sa(dp29027
g16449
I271
sg16450
I1
sg16451
I11
sg16459
VC0795690
p29028
sg16454
Vomphalocele
p29029
sa(dp29030
g16449
I284
sg16450
I1
sg16451
I13
sg16459
VC0265706
p29031
sg16454
Vgastroschisis
p29032
sa(dp29033
g16449
I117
sg16450
I2
sg16451
I13
sg16459
VC0018798
p29034
sg16454
Vheart defects
p29035
sa(dp29036
g16449
I88
sg16450
I2
sg16451
I13
sg16459
VC0000768
p29037
sg16454
Vbirth defects
p29038
sasa(dp29039
g16444
VIn some defects, prenatal diagnostics has also significantly influenced their incidence in births (anencephaly, gastroschisis and DS e.g.
p29040
sg16446
(lp29041
sg16456
(lp29042
(dp29043
g16449
I99
sg16450
I1
sg16451
I11
sg16459
VC0002902
p29044
sg16454
Vanencephaly
p29045
sa(dp29046
g16449
I112
sg16450
I1
sg16451
I13
sg16459
VC0265706
p29047
sg16454
Vgastroschisis
p29048
sasa(dp29049
g16444
VThe Fxn KO/Mck model reproduces some key features of patients with Friedreich ataxia and provides an opportunity of ameliorating their symptoms with experimental therapies.
p29050
sg16446
(lp29051
(dp29052
g16449
I4
sg16450
I2
sg16451
I6
sg16452
VP51587
p29053
sg16454
VFxn KO
p29054
sasg16456
(lp29055
(dp29056
g16449
I67
sg16450
I2
sg16451
I17
sg16459
VC0016719
p29057
sg16454
VFriedreich ataxia
p29058
sasa(dp29059
g16444
VFurther confirmation is obtained with identification of two mutations in the ARSB gene for MPS VI or mutations in the GALNS gene for MPS IVA.We report slowly progressing patients, one with MPS VI and two with MPS IVA, who presented with skeletal changes and hip findings resembling Legg-Calve-Perthes disease or spondyloepiphyseal dysplasia and normal/near normal urine GAG levels.
p29060
sg16446
(lp29061
(dp29062
g16449
I118
sg16450
I2
sg16451
I10
sg16452
VP34059
p29063
sg16454
VGALNS gene
p29064
sa(dp29065
g16449
I133
sg16450
I2
sg16451
I7
sg16452
VP05164
p29066
sg16454
VMPS IVA
p29067
sa(dp29068
g16449
I91
sg16450
I2
sg16451
I6
sg16452
VP05164
p29069
sg16454
VMPS VI
p29070
sasg16456
(lp29071
(dp29072
g16449
I133
sg16450
I2
sg16451
I7
sg16459
VC0086651
p29073
sg16454
VMPS IVA
p29074
sa(dp29075
g16449
I91
sg16450
I2
sg16451
I6
sg16459
VC0026709
p29076
sg16454
VMPS VI
p29077
sa(dp29078
g16449
I312
sg16450
I2
sg16451
I28
sg16459
VC2745959
p29079
sg16454
Vspondyloepiphyseal dysplasia
p29080
sa(dp29081
g16449
I282
sg16450
I2
sg16451
I26
sg16459
VC0023234
p29082
sg16454
VLegg-Calve-Perthes disease
p29083
sa(dp29084
g16449
I133
sg16450
I2
sg16451
I7
sg16459
VC0086651
p29085
sg16454
VMPS IVA
p29086
sa(dp29087
g16449
I91
sg16450
I2
sg16451
I6
sg16459
VC0026709
p29088
sg16454
VMPS VI
p29089
sasa(dp29090
g16444
VWe identified genes that might be truly causative, but GWAS might have failed to identify for 148 out of the GWAS-identified SNPs; for example, TUFM (P = 3.3E-48) was identified for inflammatory bowel disease (early onset); ZFP90 (P = 4.4E-34) for ulcerative colitis; and IDUA (P = 2.2E-11) for Parkinson's disease.
p29091
sg16446
(lp29092
(dp29093
g16449
I224
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VZFP90
p29094
sasg16456
(lp29095
(dp29096
g16449
I248
sg16450
I2
sg16451
I18
sg16459
VC0009324
p29097
sg16454
Vulcerative colitis
p29098
sa(dp29099
g16449
I295
sg16450
I2
sg16451
I19
sg16459
VC0030567
p29100
sg16454
VParkinson's disease
p29101
sa(dp29102
g16449
I182
sg16450
I3
sg16451
I26
sg16459
VC0021390
p29103
sg16454
Vinflammatory bowel disease
p29104
sasa(dp29105
g16444
VApart from allergic bronchopulmonary aspergillosis (ABPA) and mould-caused mycoses, only sufficient evidence for an association between moisture/mould damage and the following health effects has been established: allergic respiratory disease, asthma (manifestation, progression and exacerbation), allergic rhinitis, hypersensitivity pneumonitis (extrinsic allergic alveolitis), and increased likelihood of respiratory infections/bronchitis.
p29106
sg16446
(lp29107
sg16456
(lp29108
(dp29109
g16449
I346
sg16450
I3
sg16451
I29
sg16459
VC0002390
p29110
sg16454
Vextrinsic allergic alveolitis
p29111
sa(dp29112
g16449
I429
sg16450
I1
sg16451
I10
sg16459
VC0006277
p29113
sg16454
Vbronchitis
p29114
sa(dp29115
g16449
I11
sg16450
I3
sg16451
I39
sg16459
VC0004031
p29116
sg16454
Vallergic bronchopulmonary aspergillosis
p29117
sa(dp29118
g16449
I316
sg16450
I2
sg16451
I28
sg16459
VC0002390
p29119
sg16454
Vhypersensitivity pneumonitis
p29120
sa(dp29121
g16449
I52
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29122
sg16454
VABPA
p29123
sa(dp29124
g16449
I75
sg16450
I1
sg16451
I7
sg16459
VC0026946
p29125
sg16454
Vmycoses
p29126
sa(dp29127
g16449
I213
sg16450
I3
sg16451
I28
sg16459
VC1504369
p29128
sg16454
Vallergic respiratory disease
p29129
sa(dp29130
g16449
I243
sg16450
I1
sg16451
I6
sg16459
VC0004096
p29131
sg16454
Vasthma
p29132
sa(dp29133
g16449
I406
sg16450
I2
sg16451
I22
sg16459
VC0035243
p29134
sg16454
Vrespiratory infections
p29135
sa(dp29136
g16449
I297
sg16450
I2
sg16451
I17
sg16459
VC2607914
p29137
sg16454
Vallergic rhinitis
p29138
sasa(dp29139
g16444
VWe studied the relationship between GORD and allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), or Aspergillus bronchitis.
p29140
sg16446
(lp29141
sg16456
(lp29142
(dp29143
g16449
I61
sg16450
I2
sg16451
I23
sg16459
VC2350529
p29144
sg16454
Vpulmonary aspergillosis
p29145
sa(dp29146
g16449
I45
sg16450
I3
sg16451
I39
sg16459
VC0004031
p29147
sg16454
Vallergic bronchopulmonary aspergillosis
p29148
sa(dp29149
g16449
I135
sg16450
I2
sg16451
I22
sg16459
VC2919277
p29150
sg16454
VAspergillus bronchitis
p29151
sa(dp29152
g16449
I86
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29153
sg16454
VABPA
p29154
sasa(dp29155
g16444
VWe reviewed four patients referred with elevated Aspergillus serology markers and marked pulmonary symptoms for ABPA, CPA, and Aspergillus bronchitis, and discussed the underlying pathophysiological relationship with GORD.
p29156
sg16446
(lp29157
sg16456
(lp29158
(dp29159
g16449
I112
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29160
sg16454
VABPA
p29161
sa(dp29162
g16449
I127
sg16450
I2
sg16451
I22
sg16459
VC2919277
p29163
sg16454
VAspergillus bronchitis
p29164
sasa(dp29165
g16444
VData were collected retrospectively from medical records included age, gender, predisposing factors for ABPA, chronic pulmonary aspergillosis, or Aspergillus bronchitis; presence of nocturnal reflux, nausea, epigastric pain, Medical Research Council dyspnea scale score, pH manometry data, endoscopic results (ulcers, Barrett's esophagus), treatment of GORD [proton-pump inhibitors (PPIs), surgical operation]; history of smoking, alcohol consumption; concomitant COPD; serological markers (anti-Aspergillus IgG, anti-Aspergillus IgE), and antifungal treatment.
p29166
sg16446
(lp29167
(dp29168
g16449
I513
sg16450
I2
sg16451
I20
sg16452
VP01854
p29169
sg16454
Vanti-Aspergillus IgE
p29170
sasg16456
(lp29171
(dp29172
g16449
I310
sg16450
I1
sg16451
I6
sg16459
VC0041582
p29173
sg16454
Vulcers
p29174
sa(dp29175
g16449
I200
sg16450
I1
sg16451
I6
sg16459
VC0027497
p29176
sg16454
Vnausea
p29177
sa(dp29178
g16449
I208
sg16450
I2
sg16451
I15
sg16459
VC0232493
p29179
sg16454
Vepigastric pain
p29180
sa(dp29181
g16449
I192
sg16450
I1
sg16451
I6
sg16459
VC0017168
p29182
sg16454
Vreflux
p29183
sa(dp29184
g16449
I530
sg16450
I1
sg16451
I3
sg16459
VC0270850
p29185
sg16454
VIgE
p29186
sa(dp29187
g16449
I250
sg16450
I1
sg16451
I7
sg16459
VC0013404
p29188
sg16454
Vdyspnea
p29189
sa(dp29190
g16449
I118
sg16450
I2
sg16451
I23
sg16459
VC2350529
p29191
sg16454
Vpulmonary aspergillosis
p29192
sa(dp29193
g16449
I464
sg16450
I1
sg16451
I4
sg16459
VC0024117
p29194
sg16454
VCOPD
p29195
sa(dp29196
g16449
I146
sg16450
I2
sg16451
I22
sg16459
VC2919277
p29197
sg16454
VAspergillus bronchitis
p29198
sa(dp29199
g16449
I318
sg16450
I2
sg16451
I19
sg16459
VC0004763
p29200
sg16454
VBarrett's esophagus
p29201
sa(dp29202
g16449
I104
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29203
sg16454
VABPA
p29204
sasa(dp29205
g16444
VOne had ABPA, one CPA, and two had Aspergillus bronchitis; median age was 57 years [range 39-71]; males-to-females ratio was 1:3.
p29206
sg16446
(lp29207
sg16456
(lp29208
(dp29209
g16449
I8
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29210
sg16454
VABPA
p29211
sa(dp29212
g16449
I35
sg16450
I2
sg16451
I22
sg16459
VC2919277
p29213
sg16454
VAspergillus bronchitis
p29214
sasa(dp29215
g16444
VApart from the allergic bronchopulmonary aspergillosis (ABPA) and the mycoses caused by mold, there is only sufficient evidence for the following associations between moisture/mold damages and different health effects: Allergic respiratory diseases, asthma (manifestation, progression, exacerbation), allergic rhinitis, exogenous allergic alveolitis and respiratory tract infections/bronchitis.
p29216
sg16446
(lp29217
sg16456
(lp29218
(dp29219
g16449
I383
sg16450
I1
sg16451
I10
sg16459
VC0006277
p29220
sg16454
Vbronchitis
p29221
sa(dp29222
g16449
I228
sg16450
I2
sg16451
I20
sg16459
VC0035204
p29223
sg16454
Vrespiratory diseases
p29224
sa(dp29225
g16449
I56
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29226
sg16454
VABPA
p29227
sa(dp29228
g16449
I301
sg16450
I2
sg16451
I17
sg16459
VC2607914
p29229
sg16454
Vallergic rhinitis
p29230
sa(dp29231
g16449
I354
sg16450
I3
sg16451
I28
sg16459
VC0035243
p29232
sg16454
Vrespiratory tract infections
p29233
sa(dp29234
g16449
I15
sg16450
I3
sg16451
I39
sg16459
VC0004031
p29235
sg16454
Vallergic bronchopulmonary aspergillosis
p29236
sa(dp29237
g16449
I250
sg16450
I1
sg16451
I6
sg16459
VC0004096
p29238
sg16454
Vasthma
p29239
sa(dp29240
g16449
I70
sg16450
I1
sg16451
I7
sg16459
VC0026946
p29241
sg16454
Vmycoses
p29242
sa(dp29243
g16449
I330
sg16450
I2
sg16451
I19
sg16459
VC0002390
p29244
sg16454
Vallergic alveolitis
p29245
sasa(dp29246
g16444
Vcan lead to allergic bronchopulmonary aspergillosis (ABPA), Aspergillus sensitisation and Aspergillus bronchitis in CF.
p29247
sg16446
(lp29248
sg16456
(lp29249
(dp29250
g16449
I12
sg16450
I3
sg16451
I39
sg16459
VC0004031
p29251
sg16454
Vallergic bronchopulmonary aspergillosis
p29252
sa(dp29253
g16449
I90
sg16450
I2
sg16451
I22
sg16459
VC2919277
p29254
sg16454
VAspergillus bronchitis
p29255
sa(dp29256
g16449
I53
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29257
sg16454
VABPA
p29258
sasa(dp29259
g16444
VPublished proportions of ABPA (17.7%), Aspergillus sensitisation (14.6%) and Aspergillus bronchitis (30%) in CF were applied to those &gt;18 years and compared with notified ABPA cases.
p29260
sg16446
(lp29261
sg16456
(lp29262
(dp29263
g16449
I25
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29264
sg16454
VABPA
p29265
sa(dp29266
g16449
I25
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29267
sg16454
VABPA
p29268
sa(dp29269
g16449
I77
sg16450
I2
sg16451
I22
sg16459
VC2919277
p29270
sg16454
VAspergillus bronchitis
p29271
sasa(dp29272
g16444
VAspergillus sensitisation, associated with increased bronchiectasis and reduced FEV1, affects an anticipated 5,506 patients without ABPA or Aspergillus bronchitis.
p29273
sg16446
(lp29274
sg16456
(lp29275
(dp29276
g16449
I140
sg16450
I2
sg16451
I22
sg16459
VC2919277
p29277
sg16454
VAspergillus bronchitis
p29278
sa(dp29279
g16449
I132
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29280
sg16454
VABPA
p29281
sa(dp29282
g16449
I53
sg16450
I1
sg16451
I14
sg16459
VC0006267
p29283
sg16454
Vbronchiectasis
p29284
sasa(dp29285
g16444
VTogether ABPA and Aspergillus bronchitis are estimated to affect 17,989 adults, 47.7% of the adult CF population.
p29286
sg16446
(lp29287
sg16456
(lp29288
(dp29289
g16449
I9
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29290
sg16454
VABPA
p29291
sa(dp29292
g16449
I18
sg16450
I2
sg16451
I22
sg16459
VC2919277
p29293
sg16454
VAspergillus bronchitis
p29294
sasa(dp29295
g16444
VItraconazole is prescribed for allergic bronchopulmonary aspergillosis (ABPA) or Aspergillus bronchitis in CF subjects.
p29296
sg16446
(lp29297
sg16456
(lp29298
(dp29299
g16449
I31
sg16450
I3
sg16451
I39
sg16459
VC0004031
p29300
sg16454
Vallergic bronchopulmonary aspergillosis
p29301
sa(dp29302
g16449
I81
sg16450
I2
sg16451
I22
sg16459
VC2919277
p29303
sg16454
VAspergillus bronchitis
p29304
sa(dp29305
g16449
I72
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29306
sg16454
VABPA
p29307
sasa(dp29308
g16444
VWe selected an average of five serum samples from each of the 17 patients with ABPA (13 proven and 4 probable ABPA) and from 3 patients with Aspergillus bronchitis and rhinosinusitis.
p29309
sg16446
(lp29310
sg16456
(lp29311
(dp29312
g16449
I141
sg16450
I2
sg16451
I22
sg16459
VC2919277
p29313
sg16454
VAspergillus bronchitis
p29314
sa(dp29315
g16449
I79
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29316
sg16454
VABPA
p29317
sa(dp29318
g16449
I168
sg16450
I1
sg16451
I14
sg16459
VC0948780
p29319
sg16454
Vrhinosinusitis
p29320
sa(dp29321
g16449
I79
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29322
sg16454
VABPA
p29323
sasa(dp29324
g16444
VPatients were diagnosed with ABPA and Aspergillus bronchitis related to innate immune defects.
p29325
sg16446
(lp29326
sg16456
(lp29327
(dp29328
g16449
I29
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29329
sg16454
VABPA
p29330
sa(dp29331
g16449
I38
sg16450
I2
sg16451
I22
sg16459
VC2919277
p29332
sg16454
VAspergillus bronchitis
p29333
sasa(dp29334
g16444
VYeasts and filamentous fungi are beginning to emerge as significant microbial pathogens in patients with cystic fibrosis (CF), particularly in relation to allergic-type responses, as seen in patients with allergic bronchopulmonary aspergillosis (ABPA), Aspergillus bronchitis and in invasive fungal disease in lung transplant patients.
p29335
sg16446
(lp29336
sg16456
(lp29337
(dp29338
g16449
I246
sg16450
I1
sg16451
I4
sg16459
VC0004031
p29339
sg16454
VABPA
p29340
sa(dp29341
g16449
I122
sg16450
I1
sg16451
I2
sg16459
VC0010674
p29342
sg16454
VCF
p29343
sa(dp29344
g16449
I105
sg16450
I2
sg16451
I15
sg16459
VC0010674
p29345
sg16454
Vcystic fibrosis
p29346
sa(dp29347
g16449
I253
sg16450
I2
sg16451
I22
sg16459
VC2919277
p29348
sg16454
VAspergillus bronchitis
p29349
sa(dp29350
g16449
I292
sg16450
I2
sg16451
I14
sg16459
VC0026946
p29351
sg16454
Vfungal disease
p29352
sa(dp29353
g16449
I205
sg16450
I3
sg16451
I39
sg16459
VC0004031
p29354
sg16454
Vallergic bronchopulmonary aspergillosis
p29355
sasa(dp29356
g16444
VOn the other hand, a widespread positive reaction for CK 5/8, CK 7, CK 19, and negative reaction for CK 10, was a helpful feature in the differentiation of Paget's disease from Bowen's disease and BAK.
p29357
sg16446
(lp29358
(dp29359
g16449
I54
sg16450
I2
sg16451
I6
sg16452
VP02533
p29360
sg16454
VCK 5/8
p29361
sa(dp29362
g16449
I62
sg16450
I2
sg16451
I4
sg16452
VP08729
p29363
sg16454
VCK 7
p29364
sa(dp29365
g16449
I101
sg16450
I2
sg16451
I5
sg16452
VP13645
p29366
sg16454
VCK 10
p29367
sasg16456
(lp29368
(dp29369
g16449
I177
sg16450
I2
sg16451
I15
sg16459
VC0006079
p29370
sg16454
VBowen's disease
p29371
sa(dp29372
g16449
I156
sg16450
I2
sg16451
I15
sg16459
VC0029401
p29373
sg16454
VPaget's disease
p29374
sasa(dp29375
g16444
VTo date, the relation between serum leptin levels of dialysis patients and renal osteodystrophy, defined by histomorphometric and histodynamic parameters of bone, has not been studied.
p29376
sg16446
(lp29377
(dp29378
g16449
I36
sg16450
I1
sg16451
I6
sg16452
VP41159
p29379
sg16454
Vleptin
p29380
sasg16456
(lp29381
(dp29382
g16449
I75
sg16450
I2
sg16451
I20
sg16459
VC0035086
p29383
sg16454
Vrenal osteodystrophy
p29384
sasa(dp29385
g16444
VFor 100 years, it has been obvious that Salmonella enterica strains sharing the serotype with the formula 1,4,[5],12:b:1,2-now known as Paratyphi B-can cause diseases ranging from serious systemic infections to self-limiting gastroenteritis.
p29386
sg16446
(lp29387
sg16456
(lp29388
(dp29389
g16449
I225
sg16450
I1
sg16451
I15
sg16459
VC0017160
p29390
sg16454
Vgastroenteritis
p29391
sa(dp29392
g16449
I40
sg16450
I1
sg16451
I10
sg16459
VC0036117
p29393
sg16454
VSalmonella
p29394
sa(dp29395
g16449
I188
sg16450
I2
sg16451
I19
sg16459
VC0243026
p29396
sg16454
Vsystemic infections
p29397
sasa(dp29398
g16444
VInterestingly, in the case of breast cancer patients, this phenomenon correlated with high expression level of several molecular chaperones belonging to the HSPA, DNAJB and HSPC families.
p29399
sg16446
(lp29400
sg16456
(lp29401
(dp29402
g16449
I30
sg16450
I2
sg16451
I13
sg16459
VC0678222
p29403
sg16454
Vbreast cancer
p29404
sasa(dp29405
g16444
VUnexpectedly, conditioning before HSPC infusion was required to protect the mice from lymphoma developing when transplanting small numbers of progenitors.
p29406
sg16446
(lp29407
sg16456
(lp29408
(dp29409
g16449
I86
sg16450
I1
sg16451
I8
sg16459
VC0024299
p29410
sg16454
Vlymphoma
p29411
sasa(dp29412
g16444
VHere, we evaluated the potency of highly active NK cells derived from human CD34+ haematopoietic stem and progenitor cells (HSPC) to infiltrate and mediate killing of human ovarian cancer spheroids using an in vivo-like model system and mouse xenograft model.
p29413
sg16446
(lp29414
(dp29415
g16449
I70
sg16450
I2
sg16451
I11
sg16452
VP28906
p29416
sg16454
Vhuman CD34+
p29417
sasg16456
(lp29418
(dp29419
g16449
I173
sg16450
I2
sg16451
I14
sg16459
VC1140680
p29420
sg16454
Vovarian cancer
p29421
sa(dp29422
g16449
I133
sg16450
I1
sg16451
I10
sg16459
VC0332448
p29423
sg16454
Vinfiltrate
p29424
sasa(dp29425
g16444
VThese CD56+Perforin+ HSPC-NK cells were generated under stroma-free conditions in the presence of StemRegenin-1, IL-15, and IL-12, and exerted efficient cytolytic activity and IFNGamma production toward ovarian cancer monolayer cultures.
p29426
sg16446
(lp29427
(dp29428
g16449
I6
sg16450
I2
sg16451
I22
sg16452
VP14222
p29429
sg16454
VCD56+Perforin+ HSPC-NK
p29430
sa(dp29431
g16449
I113
sg16450
I1
sg16451
I5
sg16452
VP40933
p29432
sg16454
VIL-15
p29433
sasg16456
(lp29434
(dp29435
g16449
I203
sg16450
I2
sg16451
I14
sg16459
VC1140680
p29436
sg16454
Vovarian cancer
p29437
sasa(dp29438
g16444
VLive-imaging confocal microscopy demonstrated that these HSPC-NK cells actively migrate, infiltrate, and mediate tumor cell killing in a three-dimensional multicellular ovarian cancer spheroid.
p29439
sg16446
(lp29440
sg16456
(lp29441
(dp29442
g16449
I113
sg16450
I1
sg16451
I5
sg16459
VC0027651
p29443
sg16454
Vtumor
p29444
sa(dp29445
g16449
I89
sg16450
I1
sg16451
I10
sg16459
VC0332448
p29446
sg16454
Vinfiltrate
p29447
sa(dp29448
g16449
I169
sg16450
I2
sg16451
I14
sg16459
VC1140680
p29449
sg16454
Vovarian cancer
p29450
sasa(dp29451
g16444
VFurthermore, intraperitoneal HSPC-NK cell infusions in NOD/SCID-IL2RGammanull (NSG) mice bearing ovarian carcinoma significantly reduced tumor progression.
p29452
sg16446
(lp29453
(dp29454
g16449
I59
sg16450
I1
sg16451
I18
sg16452
VP31785
p29455
sg16454
VSCID-IL2RGammanull
p29456
sa(dp29457
g16449
I55
sg16450
I1
sg16451
I3
sg16452
VP54259
p29458
sg16454
VNOD
p29459
sasg16456
(lp29460
(dp29461
g16449
I97
sg16450
I2
sg16451
I17
sg16459
VC0029925
p29462
sg16454
Vovarian carcinoma
p29463
sa(dp29464
g16449
I55
sg16450
I1
sg16451
I3
sg16459
VC0751781
p29465
sg16454
VNOD
p29466
sa(dp29467
g16449
I59
sg16450
I1
sg16451
I4
sg16459
VC0085110
p29468
sg16454
VSCID
p29469
sa(dp29470
g16449
I137
sg16450
I2
sg16451
I17
sg16459
VC0178874
p29471
sg16454
Vtumor progression
p29472
sasa(dp29473
g16444
VThese findings demonstrate that highly functional HSPC-NK cells efficiently destruct ovarian carcinoma spheroids in vitro and kill intraperitoneal ovarian tumors in vivo, providing great promise for effective immunotherapy through intraperitoneal HSPC-NK cell adoptive transfer in ovarian carcinoma patients.
p29474
sg16446
(lp29475
sg16456
(lp29476
(dp29477
g16449
I85
sg16450
I2
sg16451
I17
sg16459
VC0029925
p29478
sg16454
Vovarian carcinoma
p29479
sa(dp29480
g16449
I147
sg16450
I2
sg16451
I14
sg16459
VC0919267
p29481
sg16454
Vovarian tumors
p29482
sa(dp29483
g16449
I85
sg16450
I2
sg16451
I17
sg16459
VC0029925
p29484
sg16454
Vovarian carcinoma
p29485
sasa(dp29486
g16444
VTreatment with vitamin C, a co-factor of Fe2+ and Alfa-KG-dependent dioxygenases, mimics TET2 restoration by enhancing 5-hydroxymethylcytosine formation in Tet2-deficient mouse HSPCs and suppresses human leukemic colony formation and leukemia progression of primary human leukemia PDXs.
p29487
sg16446
(lp29488
(dp29489
g16449
I156
sg16450
I3
sg16451
I26
sg16452
g11
sg16454
VTet2-deficient mouse HSPCs
p29490
sa(dp29491
g16449
I89
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VTET2
p29492
sasg16456
(lp29493
(dp29494
g16449
I234
sg16450
I1
sg16451
I8
sg16459
VC0023418
p29495
sg16454
Vleukemia
p29496
sa(dp29497
g16449
I234
sg16450
I1
sg16451
I8
sg16459
VC0023418
p29498
sg16454
Vleukemia
p29499
sasa(dp29500
g16444
VWe quantified extracellular IL-16 protein (ELISA) and intracellular IL-16 in NK cells, T-cells, B-cells, and monocytes (flow cytometry) in blood samples from long-term tobacco smokers with and without chronic obstructive pulmonary disease (COPD) and in never-smokers.
p29501
sg16446
(lp29502
(dp29503
g16449
I14
sg16450
I3
sg16451
I27
sg16452
g11
sg16454
Vextracellular IL-16 protein
p29504
sa(dp29505
g16449
I28
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p29506
sasg16456
(lp29507
(dp29508
g16449
I240
sg16450
I1
sg16451
I4
sg16459
VC0024117
p29509
sg16454
VCOPD
p29510
sa(dp29511
g16449
I201
sg16450
I4
sg16451
I37
sg16459
VC0024117
p29512
sg16454
Vchronic obstructive pulmonary disease
p29513
sasa(dp29514
g16444
VIn asthmatic children with positive ETC, monocyte hemotactic protein-1 (MCP-1) and IL-16 adjusted to pre-EBC forced expiratory volume in 1 s (FEV1) were significantly higher compared to children with negative ETC (p = 0.022 and p = 0.017 respectively).
p29515
sg16446
(lp29516
(dp29517
g16449
I83
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p29518
sa(dp29519
g16449
I72
sg16450
I1
sg16451
I5
sg16452
VP41597
p29520
sg16454
VMCP-1
p29521
sa(dp29522
g16449
I36
sg16450
I4
sg16451
I34
sg16452
VP17980
p29523
sg16454
VETC, monocyte hemotactic protein-1
p29524
sasg16456
(lp29525
(dp29526
g16449
I3
sg16450
I1
sg16451
I9
sg16459
VC0004096
p29527
sg16454
Vasthmatic
p29528
sasa(dp29529
g16444
VCompared with the control group, silica dust exposed group, the observation group of objects, the pneumosilicosis patients of IL-16 in induced sputum IL-16 (21.40 +/- 9.24) decreased, the content of PDGF [(5.96 +/- 0.51) ng/L], MMP-2 [(447.86 +/- 27.10) ng/L], MMP-9 [(223.91 +/- 12.28) ng/L], MCP-1 [(122.87 +/- 6.08) ng/L] increased, the differences are statistically significant (P &lt; 0.05).
p29530
sg16446
(lp29531
(dp29532
g16449
I294
sg16450
I1
sg16451
I5
sg16452
VP41597
p29533
sg16454
VMCP-1
p29534
sa(dp29535
g16449
I126
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p29536
sa(dp29537
g16449
I228
sg16450
I1
sg16451
I5
sg16452
VP08253
p29538
sg16454
VMMP-2
p29539
sa(dp29540
g16449
I261
sg16450
I1
sg16451
I5
sg16452
VP14780
p29541
sg16454
VMMP-9
p29542
sa(dp29543
g16449
I199
sg16450
I1
sg16451
I4
sg16452
VP04085
p29544
sg16454
VPDGF
p29545
sa(dp29546
g16449
I143
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
Vsputum IL-16
p29547
sasg16456
(lp29548
sa(dp29549
g16444
VAs silicosis biomarkers, TNF-alpha, TGF-beta, IL-16, PDGF, MMP-2, MMP-9 and MCP-1 have certain significance, further suggesting that early detection rate of patients with silicosis can be improved by employing the multiple indexes discriminate equation.
p29550
sg16446
(lp29551
(dp29552
g16449
I66
sg16450
I1
sg16451
I5
sg16452
VP14780
p29553
sg16454
VMMP-9
p29554
sa(dp29555
g16449
I53
sg16450
I1
sg16451
I4
sg16452
VP04085
p29556
sg16454
VPDGF
p29557
sa(dp29558
g16449
I46
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p29559
sa(dp29560
g16449
I25
sg16450
I1
sg16451
I9
sg16452
VP01375
p29561
sg16454
VTNF-alpha
p29562
sa(dp29563
g16449
I59
sg16450
I1
sg16451
I5
sg16452
VP08253
p29564
sg16454
VMMP-2
p29565
sa(dp29566
g16449
I76
sg16450
I1
sg16451
I5
sg16452
VP41597
p29567
sg16454
VMCP-1
p29568
sa(dp29569
g16449
I36
sg16450
I1
sg16451
I8
sg16452
VP18075
p29570
sg16454
VTGF-beta
p29571
sasg16456
(lp29572
(dp29573
g16449
I3
sg16450
I1
sg16451
I9
sg16459
VC0037116
p29574
sg16454
Vsilicosis
p29575
sa(dp29576
g16449
I3
sg16450
I1
sg16451
I9
sg16459
VC0037116
p29577
sg16454
Vsilicosis
p29578
sasa(dp29579
g16444
VBy contrast, compared to eosinophil-normal asthma (eosinophils&lt;=0.3%), eosinophil-high asthma (eosinophils&gt;0.3%) had higher levels of IL-5, IL-13, IL-16, and PDGF-bb, but same neutrophil percentage, IL-8, and FEV1.
p29580
sg16446
(lp29581
(dp29582
g16449
I146
sg16450
I1
sg16451
I5
sg16452
VP35225
p29583
sg16454
VIL-13
p29584
sa(dp29585
g16449
I164
sg16450
I1
sg16451
I7
sg16452
VP04085
p29586
sg16454
VPDGF-bb
p29587
sa(dp29588
g16449
I153
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VIL-16
p29589
sa(dp29590
g16449
I140
sg16450
I1
sg16451
I4
sg16452
VP05113
p29591
sg16454
VIL-5
p29592
sasg16456
(lp29593
(dp29594
g16449
I43
sg16450
I1
sg16451
I6
sg16459
VC0004096
p29595
sg16454
Vasthma
p29596
sa(dp29597
g16449
I43
sg16450
I1
sg16451
I6
sg16459
VC0004096
p29598
sg16454
Vasthma
p29599
sasa(dp29600
g16444
VHere, we demonstrate that DRG1 is elevated in lung adenocarcinomas while weakly expressed in adjacent lung tissues.
p29601
sg16446
(lp29602
(dp29603
g16449
I26
sg16450
I1
sg16451
I4
sg16452
VP55039
p29604
sg16454
VDRG1
p29605
sasg16456
(lp29606
(dp29607
g16449
I51
sg16450
I1
sg16451
I15
sg16459
VC0001418
p29608
sg16454
Vadenocarcinomas
p29609
sasa(dp29610
g16444
VTo this end, we describe the identification of developmentally regulated GTP-binding protein 1 (DRG-1) as a melanoma-associated antigen recognized by HLA-DR11-restricted CD4(+) Th1 cells.
p29611
sg16446
(lp29612
(dp29613
g16449
I96
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VDRG-1
p29614
sa(dp29615
g16449
I150
sg16450
I1
sg16451
I8
sg16452
VP30486
p29616
sg16454
VHLA-DR11
p29617
sa(dp29618
g16449
I108
sg16450
I2
sg16451
I27
sg16452
VP08962
p29619
sg16454
Vmelanoma-associated antigen
p29620
sa(dp29621
g16449
I47
sg16450
I5
sg16451
I47
sg16452
g11
sg16454
Vdevelopmentally regulated GTP-binding protein 1
p29622
sa(dp29623
g16449
I170
sg16450
I1
sg16451
I3
sg16452
VP01730
p29624
sg16454
VCD4
p29625
sasg16456
(lp29626
(dp29627
g16449
I108
sg16450
I1
sg16451
I8
sg16459
VC0025202
p29628
sg16454
Vmelanoma
p29629
sasa(dp29630
g16444
VReverse transcription-polymerase chain reaction revealed that DRG-1 was highly expressed in melanoma cell lines but not in normal tissues.
p29631
sg16446
(lp29632
(dp29633
g16449
I62
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VDRG-1
p29634
sasg16456
(lp29635
(dp29636
g16449
I92
sg16450
I1
sg16451
I8
sg16459
VC0025202
p29637
sg16454
Vmelanoma
p29638
sasa(dp29639
g16444
VDRG-1 knockdown by lentiviral-based shRNA suppressed melanoma cell proliferation and soft agar colony formation.
p29640
sg16446
(lp29641
sg16456
(lp29642
(dp29643
g16449
I67
sg16450
I1
sg16451
I13
sg16459
VC0334094
p29644
sg16454
Vproliferation
p29645
sa(dp29646
g16449
I53
sg16450
I1
sg16451
I8
sg16459
VC0025202
p29647
sg16454
Vmelanoma
p29648
sasa(dp29649
g16444
VTaken together, these data suggest that DRG-1 plays an important role in melanoma cell growth and transformation, indicating that DRG1 may represent a novel target for CD4(+) T cell-mediated immunotherapy in melanoma.
p29650
sg16446
(lp29651
(dp29652
g16449
I168
sg16450
I1
sg16451
I3
sg16452
VP01730
p29653
sg16454
VCD4
p29654
sa(dp29655
g16449
I40
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VDRG-1
p29656
sa(dp29657
g16449
I130
sg16450
I1
sg16451
I4
sg16452
VP55039
p29658
sg16454
VDRG1
p29659
sasg16456
(lp29660
(dp29661
g16449
I98
sg16450
I1
sg16451
I14
sg16459
VC1510411
p29662
sg16454
Vtransformation
p29663
sa(dp29664
g16449
I73
sg16450
I1
sg16451
I8
sg16459
VC0025202
p29665
sg16454
Vmelanoma
p29666
sa(dp29667
g16449
I73
sg16450
I1
sg16451
I8
sg16459
VC0025202
p29668
sg16454
Vmelanoma
p29669
sasa(dp29670
g16444
VFBXW7 mRNA was identified as a direct target of miR-155 in glioma.
p29671
sg16446
(lp29672
(dp29673
g16449
I0
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VFBXW7 mRNA
p29674
sasg16456
(lp29675
(dp29676
g16449
I59
sg16450
I1
sg16451
I6
sg16459
VC0017638
p29677
sg16454
Vglioma
p29678
sasa(dp29679
g16444
VFinally, we found that MALAT1 positively regulated FBXW7 expression, which was responsible for glioma progression mediated by MALAT1-miR-155 pathway.
p29680
sg16446
(lp29681
(dp29682
g16449
I51
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VFBXW7
p29683
sa(dp29684
g16449
I23
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VMALAT1
p29685
sa(dp29686
g16449
I126
sg16450
I1
sg16451
I10
sg16452
g11
sg16454
VMALAT1-miR
p29687
sasg16456
(lp29688
(dp29689
g16449
I95
sg16450
I1
sg16451
I6
sg16459
VC0017638
p29690
sg16454
Vglioma
p29691
sasa(dp29692
g16444
VBesides those, Fbxw7 activity is controlled at different levels, resulting in specific and tunable regulation of the abundance and activity of its substrates in a variety of human solid tumor types, including glioma malignancy, nasopharyngeal carcinoma, osteosarcoma, melanoma as well as colorectal, lung, breast, gastric, liver, pancreatic, renal, prostate, endometrial, and esophageal cancers.
p29693
sg16446
(lp29694
(dp29695
g16449
I15
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VFbxw7
p29696
sasg16456
(lp29697
(dp29698
g16449
I376
sg16450
I2
sg16451
I18
sg16459
VC0546837
p29699
sg16454
Vesophageal cancers
p29700
sa(dp29701
g16449
I216
sg16450
I1
sg16451
I10
sg16459
VC0006826
p29702
sg16454
Vmalignancy
p29703
sa(dp29704
g16449
I228
sg16450
I2
sg16451
I24
sg16459
VC2931822
p29705
sg16454
Vnasopharyngeal carcinoma
p29706
sa(dp29707
g16449
I209
sg16450
I1
sg16451
I6
sg16459
VC0017638
p29708
sg16454
Vglioma
p29709
sa(dp29710
g16449
I268
sg16450
I1
sg16451
I8
sg16459
VC0025202
p29711
sg16454
Vmelanoma
p29712
sa(dp29713
g16449
I254
sg16450
I1
sg16451
I12
sg16459
VC0029463
p29714
sg16454
Vosteosarcoma
p29715
sa(dp29716
g16449
I180
sg16450
I2
sg16451
I11
sg16459
VC0280100
p29717
sg16454
Vsolid tumor
p29718
sasa(dp29719
g16444
VSubsequently, miR-15/16 activities are reduced and many of their direct targets are de-repressed, including ubiquitin ligase FBXW7 that destabilizes Cyclin E. Conversely, GBM cells expressing low p21 level, or after p21 knock-down, exhibit weaker or no E2F1 response to miR-10b inhibition.
p29720
sg16446
(lp29721
(dp29722
g16449
I270
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VmiR-10b
p29723
sa(dp29724
g16449
I14
sg16450
I1
sg16451
I9
sg16452
g11
sg16454
VmiR-15/16
p29725
sa(dp29726
g16449
I108
sg16450
I3
sg16451
I22
sg16452
g11
sg16454
Vubiquitin ligase FBXW7
p29727
sa(dp29728
g16449
I196
sg16450
I1
sg16451
I3
sg16452
VP42857
p29729
sg16454
Vp21
p29730
sa(dp29731
g16449
I253
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VE2F1
p29732
sa(dp29733
g16449
I216
sg16450
I2
sg16451
I9
sg16452
VP42857
p29734
sg16454
Vp21 knock
p29735
sa(dp29736
g16449
I149
sg16450
I2
sg16451
I8
sg16452
VP24864
p29737
sg16454
VCyclin E
p29738
sasg16456
(lp29739
(dp29740
g16449
I171
sg16450
I1
sg16451
I3
sg16459
VC0017636
p29741
sg16454
VGBM
p29742
sasa(dp29743
g16444
VNotch pathway genes are overexpressed in ependymomas and gliomas along with FBXW7 downregulation.
p29744
sg16446
(lp29745
(dp29746
g16449
I0
sg16450
I3
sg16451
I19
sg16452
VP01893
p29747
sg16454
VNotch pathway genes
p29748
sa(dp29749
g16449
I76
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VFBXW7
p29750
sasg16456
(lp29751
(dp29752
g16449
I41
sg16450
I1
sg16451
I11
sg16459
VC0014474
p29753
sg16454
Vependymomas
p29754
sa(dp29755
g16449
I57
sg16450
I1
sg16451
I7
sg16459
VC0017638
p29756
sg16454
Vgliomas
p29757
sasa(dp29758
g16444
VWe propose that p53 mutations contribute to gliomagenesis by both allowing the overexpression of c-Myc through downregulation of Fbxw7 and by protecting against c-Myc-induced apoptosis.
p29759
sg16446
(lp29760
(dp29761
g16449
I16
sg16450
I2
sg16451
I13
sg16452
VP42771
p29762
sg16454
Vp53 mutations
p29763
sa(dp29764
g16449
I97
sg16450
I1
sg16451
I5
sg16452
VP12524
p29765
sg16454
Vc-Myc
p29766
sa(dp29767
g16449
I129
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VFbxw7
p29768
sa(dp29769
g16449
I97
sg16450
I1
sg16451
I5
sg16452
VP12524
p29770
sg16454
Vc-Myc
p29771
sasg16456
(lp29772
sa(dp29773
g16444
VPMD is located adjacent and medial to the nucleus prepositus hypoglossi (PH) in the dorsal medulla and is distinguished by the pattern of immunoreactivity of cells and fibers to several markers including calcium-binding proteins, a synthetic enzyme for nitric oxide (neuronal nitric oxide synthase, nNOS) and a nonphosphorylated neurofilament protein (antibody SMI-32).
p29774
sg16446
(lp29775
(dp29776
g16449
I42
sg16450
I3
sg16451
I29
sg16452
VP61457
p29777
sg16454
Vnucleus prepositus hypoglossi
p29778
sa(dp29779
g16449
I299
sg16450
I1
sg16451
I4
sg16452
VP29475
p29780
sg16454
VnNOS
p29781
sasg16456
(lp29782
(dp29783
g16449
I0
sg16450
I1
sg16451
I3
sg16459
VC1832661
p29784
sg16454
VPMD
p29785
sasa(dp29786
g16444
VCells in PMD are also immunoreactive to nNOS, and immunoreactivity to a neurofilament protein shows many labeled cells and fibers.
p29787
sg16446
(lp29788
(dp29789
g16449
I40
sg16450
I1
sg16451
I4
sg16452
VP29475
p29790
sg16454
VnNOS
p29791
sasg16456
(lp29792
(dp29793
g16449
I9
sg16450
I1
sg16451
I3
sg16459
VC1832661
p29794
sg16454
VPMD
p29795
sasa(dp29796
g16444
VRegardless of the type of surgery (PRE-OP, POS-OP1, POS-OP2), the prevalence of periodontitis proved to be high (81.45%).
p29797
sg16446
(lp29798
(dp29799
g16449
I43
sg16450
I1
sg16451
I7
sg16452
VP18075
p29800
sg16454
VPOS-OP1
p29801
sa(dp29802
g16449
I52
sg16450
I1
sg16451
I7
sg16452
VP34820
p29803
sg16454
VPOS-OP2
p29804
sasg16456
(lp29805
(dp29806
g16449
I80
sg16450
I1
sg16451
I13
sg16459
VC0031099
p29807
sg16454
Vperiodontitis
p29808
sasa(dp29809
g16444
VThere was a statistically significant difference in the prevalence of periodontitis among the PRE-OP, POS-OP1, and POS-OP2 groups (P = 0.040).
p29810
sg16446
(lp29811
(dp29812
g16449
I94
sg16450
I1
sg16451
I6
sg16452
VP58743
p29813
sg16454
VPRE-OP
p29814
sa(dp29815
g16449
I102
sg16450
I1
sg16451
I7
sg16452
VP18075
p29816
sg16454
VPOS-OP1
p29817
sasg16456
(lp29818
(dp29819
g16449
I70
sg16450
I1
sg16451
I13
sg16459
VC0031099
p29820
sg16454
Vperiodontitis
p29821
sasa(dp29822
g16444
VLong-term studies with gamma-irradiated 0.5 and 2.5mg hOP-1 per gram of xenogeneic bovine collagenous matrix induce the restitutio ad integrum of the periodontal tissues in furcation defects exposed by chronic periodontitis in P. ursinus.
p29823
sg16446
(lp29824
sg16456
(lp29825
(dp29826
g16449
I173
sg16450
I2
sg16451
I17
sg16459
VC0206306
p29827
sg16454
Vfurcation defects
p29828
sa(dp29829
g16449
I202
sg16450
I2
sg16451
I21
sg16459
VC0266929
p29830
sg16454
Vchronic periodontitis
p29831
sasa(dp29832
g16444
VBone morphogenetic protein-7 (BMP 7) induces cementogenesis in periodontitis-associated periodontal ligament (PDL) defects.
p29833
sg16446
(lp29834
(dp29835
g16449
I0
sg16450
I3
sg16451
I28
sg16452
VP18075
p29836
sg16454
VBone morphogenetic protein-7
p29837
sa(dp29838
g16449
I30
sg16450
I2
sg16451
I5
sg16452
VP18075
p29839
sg16454
VBMP 7
p29840
sasg16456
(lp29841
(dp29842
g16449
I63
sg16450
I1
sg16451
I13
sg16459
VC0031099
p29843
sg16454
Vperiodontitis
p29844
sasa(dp29845
g16444
VBoth KRT19 and ANXA8 mRNA may be useful markers for detecting lymph node metastases in OSCC patients.
p29846
sg16446
(lp29847
(dp29848
g16449
I15
sg16450
I2
sg16451
I10
sg16452
VP13928
p29849
sg16454
VANXA8 mRNA
p29850
sasg16456
(lp29851
(dp29852
g16449
I62
sg16450
I3
sg16451
I21
sg16459
VC0686619
p29853
sg16454
Vlymph node metastases
p29854
sasa(dp29855
g16444
VNone of the NF1 glioblastomas harbored isocitrate dehydrogenase 1 (IDH1) gene mutation, v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) gene mutation, and telomerase reverse transcriptase (TERT) gene promoter mutation.
p29856
sg16446
(lp29857
(dp29858
g16449
I161
sg16450
I3
sg16451
I32
sg16452
g11
sg16454
Vtelomerase reverse transcriptase
p29859
sa(dp29860
g16449
I39
sg16450
I3
sg16451
I26
sg16452
VP48735
p29861
sg16454
Visocitrate dehydrogenase 1
p29862
sa(dp29863
g16449
I136
sg16450
I1
sg16451
I4
sg16452
VP15056
p29864
sg16454
VBRAF
p29865
sa(dp29866
g16449
I67
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VIDH1
p29867
sa(dp29868
g16449
I195
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VTERT
p29869
sa(dp29870
g16449
I12
sg16450
I2
sg16451
I17
sg16452
VP21359
p29871
sg16454
VNF1 glioblastomas
p29872
sa(dp29873
g16449
I88
sg16450
I7
sg16451
I46
sg16452
VP15056
p29874
sg16454
Vv-RAF murine sarcoma viral oncogene homolog B1
p29875
sasg16456
(lp29876
(dp29877
g16449
I101
sg16450
I1
sg16451
I7
sg16459
VC1261473
p29878
sg16454
Vsarcoma
p29879
sa(dp29880
g16449
I12
sg16450
I1
sg16451
I3
sg16459
VC0027831
p29881
sg16454
VNF1
p29882
sa(dp29883
g16449
I16
sg16450
I1
sg16451
I13
sg16459
VC0017636
p29884
sg16454
Vglioblastomas
p29885
sasa(dp29886
g16444
VSomatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis.
p29887
sg16446
(lp29888
(dp29889
g16449
I55
sg16450
I1
sg16451
I4
sg16452
VP15056
p29890
sg16454
VBRAF
p29891
sa(dp29892
g16449
I0
sg16450
I8
sg16451
I53
sg16452
VP04049
p29893
sg16454
VSomatic v-Raf murine sarcoma viral oncogene homolog B
p29894
sasg16456
(lp29895
(dp29896
g16449
I21
sg16450
I1
sg16451
I7
sg16459
VC1261473
p29897
sg16454
Vsarcoma
p29898
sa(dp29899
g16449
I133
sg16450
I1
sg16451
I4
sg16459
VC0948380
p29900
sg16454
VmCRC
p29901
sa(dp29902
g16449
I103
sg16450
I3
sg16451
I28
sg16459
VC0948380
p29903
sg16454
Vmetastatic colorectal cancer
p29904
sasa(dp29905
g16444
VAll colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified.
p29906
sg16446
(lp29907
(dp29908
g16449
I42
sg16450
I1
sg16451
I4
sg16452
VP15056
p29909
sg16454
VBRAF
p29910
sasg16456
(lp29911
(dp29912
g16449
I4
sg16450
I2
sg16451
I17
sg16459
VC1527249
p29913
sg16454
Vcolorectal cancer
p29914
sasa(dp29915
g16444
VWe highlight common mechanistic themes underpinning resistance to targeted therapies that are shared by NSCLC subtypes, including those with oncogenic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1), serine/threonine-protein kinase b-raf (BRAF) and other less established oncoproteins.
p29916
sg16446
(lp29917
(dp29918
g16449
I333
sg16450
I1
sg16451
I4
sg16452
VP15056
p29919
sg16454
VBRAF
p29920
sa(dp29921
g16449
I241
sg16450
I5
sg16451
I44
sg16452
VP29401
p29922
sg16454
VROS1 proto-oncogene receptor tyrosine kinase
p29923
sa(dp29924
g16449
I200
sg16450
I1
sg16451
I4
sg16452
VP01133
p29925
sg16454
VEGFR
p29926
sa(dp29927
g16449
I241
sg16450
I1
sg16451
I4
sg16452
VP08922
p29928
sg16454
VROS1
p29929
sa(dp29930
g16449
I166
sg16450
I4
sg16451
I32
sg16452
VP01133
p29931
sg16454
Vepidermal growth factor receptor
p29932
sa(dp29933
g16449
I294
sg16450
I3
sg16451
I37
sg16452
VP15056
p29934
sg16454
Vserine/threonine-protein kinase b-raf
p29935
sa(dp29936
g16449
I235
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VALK
p29937
sa(dp29938
g16449
I207
sg16450
I3
sg16451
I26
sg16452
g11
sg16454
Vanaplastic lymphoma kinase
p29939
sasg16456
(lp29940
(dp29941
g16449
I207
sg16450
I2
sg16451
I19
sg16459
VC1321546
p29942
sg16454
Vanaplastic lymphoma
p29943
sa(dp29944
g16449
I104
sg16450
I1
sg16451
I5
sg16459
VC0007131
p29945
sg16454
VNSCLC
p29946
sasa(dp29947
g16444
VHere, we investigated the response of normal human keratinocytes to the MEK inhibitors trametinib and cobimetinib, alone and in combination with the v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors dabrafenib and vemurafenib, in terms of signal transduction and de novo gene expression.
p29948
sg16446
(lp29949
(dp29950
g16449
I196
sg16450
I1
sg16451
I4
sg16452
VP15056
p29951
sg16454
VBRAF
p29952
sa(dp29953
g16449
I149
sg16450
I7
sg16451
I45
sg16452
VP04049
p29954
sg16454
Vv-Raf murine sarcoma viral oncogene homolog B
p29955
sa(dp29956
g16449
I72
sg16450
I1
sg16451
I3
sg16452
VP45985
p29957
sg16454
VMEK
p29958
sasg16456
(lp29959
(dp29960
g16449
I162
sg16450
I1
sg16451
I7
sg16459
VC1261473
p29961
sg16454
Vsarcoma
p29962
sasa(dp29963
g16444
VThe prognostic role of the V600E mutation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC) is well established, but the therapeutic regimen targeting this disease is lacking.
p29964
sg16446
(lp29965
(dp29966
g16449
I45
sg16450
I13
sg16451
I92
sg16452
VP15056
p29967
sg16454
Vv-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC)
p29968
sasg16456
(lp29969
(dp29970
g16449
I132
sg16450
I1
sg16451
I4
sg16459
VC0948380
p29971
sg16454
VmCRC
p29972
sa(dp29973
g16449
I102
sg16450
I3
sg16451
I28
sg16459
VC0948380
p29974
sg16454
Vmetastatic colorectal cancer
p29975
sa(dp29976
g16449
I58
sg16450
I1
sg16451
I7
sg16459
VC1261473
p29977
sg16454
Vsarcoma
p29978
sasa(dp29979
g16444
VKirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and BRAF mutational status was assayed using direct sequencing.
p29980
sg16446
(lp29981
(dp29982
g16449
I104
sg16450
I1
sg16451
I4
sg16452
VP15056
p29983
sg16454
VBRAF
p29984
sa(dp29985
g16449
I51
sg16450
I5
sg16451
I40
sg16452
VP01116
p29986
sg16454
Vneuroblastoma RAS viral oncogene homolog
p29987
sa(dp29988
g16449
I0
sg16450
I6
sg16451
I42
sg16452
VP35125
p29989
sg16454
VKirsten rat sarcoma viral oncogene homolog
p29990
sa(dp29991
g16449
I93
sg16450
I1
sg16451
I4
sg16452
VP01111
p29992
sg16454
VNRAS
p29993
sa(dp29994
g16449
I44
sg16450
I1
sg16451
I4
sg16452
VP01116
p29995
sg16454
VKRAS
p29996
sasg16456
(lp29997
(dp29998
g16449
I51
sg16450
I1
sg16451
I13
sg16459
VC0027819
p29999
sg16454
Vneuroblastoma
p30000
sa(dp30001
g16449
I8
sg16450
I2
sg16451
I11
sg16459
VC1882848
p30002
sg16454
Vrat sarcoma
p30003
sasa(dp30004
g16444
VWe performed an unbiased CRISPR-Cas9 knockout screen on melanoma cells that were both resistant and addicted to inhibition of the serine/threonine-protein kinase BRAF, in order to functionally mine their genome for 'addiction genes'.
p30005
sg16446
(lp30006
(dp30007
g16449
I130
sg16450
I2
sg16451
I31
sg16452
g11
sg16454
Vserine/threonine-protein kinase
p30008
sa(dp30009
g16449
I162
sg16450
I1
sg16451
I4
sg16452
VP15056
p30010
sg16454
VBRAF
p30011
sasg16456
(lp30012
(dp30013
g16449
I56
sg16450
I1
sg16451
I8
sg16459
VC0025202
p30014
sg16454
Vmelanoma
p30015
sa(dp30016
g16449
I215
sg16450
I1
sg16451
I10
sg16459
VC0085281
p30017
sg16454
V'addiction
p30018
sasa(dp30019
g16444
VIn patients with melanoma that had progressed during treatment with a BRAF inhibitor, treatment cessation was followed by increased expression of the receptor tyrosine kinase AXL, which is associated with the phenotype switch.
p30020
sg16446
(lp30021
(dp30022
g16449
I150
sg16450
I3
sg16451
I24
sg16452
VP29401
p30023
sg16454
Vreceptor tyrosine kinase
p30024
sa(dp30025
g16449
I70
sg16450
I1
sg16451
I4
sg16452
VP15056
p30026
sg16454
VBRAF
p30027
sa(dp30028
g16449
I175
sg16450
I1
sg16451
I3
sg16452
VP30530
p30029
sg16454
VAXL
p30030
sasg16456
(lp30031
(dp30032
g16449
I17
sg16450
I1
sg16451
I8
sg16459
VC0025202
p30033
sg16454
Vmelanoma
p30034
sasa(dp30035
g16444
Vv-raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutant anaplastic xanthoastrocytomas and gangliogliomas may benefit from BRAF and mitogen-activated protein kinase inhibitors.
p30036
sg16446
(lp30037
(dp30038
g16449
I0
sg16450
I7
sg16451
I46
sg16452
VP15056
p30039
sg16454
Vv-raf murine sarcoma viral oncogene homolog B1
p30040
sa(dp30041
g16449
I48
sg16450
I1
sg16451
I4
sg16452
VP15056
p30042
sg16454
VBRAF
p30043
sa(dp30044
g16449
I48
sg16450
I1
sg16451
I4
sg16452
VP15056
p30045
sg16454
VBRAF
p30046
sa(dp30047
g16449
I136
sg16450
I3
sg16451
I32
sg16452
VP53779
p30048
sg16454
Vmitogen-activated protein kinase
p30049
sasg16456
(lp30050
(dp30051
g16449
I13
sg16450
I1
sg16451
I7
sg16459
VC1261473
p30052
sg16454
Vsarcoma
p30053
sa(dp30054
g16449
I54
sg16450
I1
sg16451
I6
sg16459
VC0596988
p30055
sg16454
Vmutant
p30056
sa(dp30057
g16449
I95
sg16450
I1
sg16451
I14
sg16459
VC0206716
p30058
sg16454
Vgangliogliomas
p30059
sasa(dp30060
g16444
VMutations in the proto-oncogene B-raf (BRAF) occur in approximately 3% of NSCLC cases.
p30061
sg16446
(lp30062
(dp30063
g16449
I39
sg16450
I1
sg16451
I4
sg16452
VP15056
p30064
sg16454
VBRAF
p30065
sa(dp30066
g16449
I17
sg16450
I2
sg16451
I20
sg16452
VP15056
p30067
sg16454
Vproto-oncogene B-raf
p30068
sasg16456
(lp30069
(dp30070
g16449
I74
sg16450
I1
sg16451
I5
sg16459
VC0007131
p30071
sg16454
VNSCLC
p30072
sasa(dp30073
g16444
VTo our knowledge, this is only the second well-documented case of gastrointestinal metastasis from BRAF-mutated lung cancer.
p30074
sg16446
(lp30075
sg16456
(lp30076
(dp30077
g16449
I83
sg16450
I1
sg16451
I10
sg16459
VC0027627
p30078
sg16454
Vmetastasis
p30079
sa(dp30080
g16449
I112
sg16450
I2
sg16451
I11
sg16459
VC0684249
p30081
sg16454
Vlung cancer
p30082
sasa(dp30083
g16444
VChanges in the epidermal growth factor receptor (EGFR) gene, Kirsten rat sarcoma viral oncogene (KRAS), v-Raf murine sarcoma viral oncogene homolog B (BRAF), gene encoding neurofibromin (NF1), anaplastic lymphoma kinase (ALK) and ROS1 are the main genes that suffer alterations in the tumors of patients with ADC.
p30084
sg16446
(lp30085
(dp30086
g16449
I187
sg16450
I1
sg16451
I3
sg16452
VP21359
p30087
sg16454
VNF1
p30088
sa(dp30089
g16449
I104
sg16450
I7
sg16451
I45
sg16452
VP04049
p30090
sg16454
Vv-Raf murine sarcoma viral oncogene homolog B
p30091
sa(dp30092
g16449
I230
sg16450
I1
sg16451
I4
sg16452
VP08922
p30093
sg16454
VROS1
p30094
sa(dp30095
g16449
I97
sg16450
I1
sg16451
I4
sg16452
VP01116
p30096
sg16454
VKRAS
p30097
sa(dp30098
g16449
I61
sg16450
I5
sg16451
I34
sg16452
VP35125
p30099
sg16454
VKirsten rat sarcoma viral oncogene
p30100
sa(dp30101
g16449
I172
sg16450
I1
sg16451
I13
sg16452
VP21359
p30102
sg16454
Vneurofibromin
p30103
sa(dp30104
g16449
I49
sg16450
I1
sg16451
I4
sg16452
VP01133
p30105
sg16454
VEGFR
p30106
sa(dp30107
g16449
I151
sg16450
I1
sg16451
I4
sg16452
VP15056
p30108
sg16454
VBRAF
p30109
sa(dp30110
g16449
I15
sg16450
I4
sg16451
I32
sg16452
VP01133
p30111
sg16454
Vepidermal growth factor receptor
p30112
sasg16456
(lp30113
(dp30114
g16449
I187
sg16450
I1
sg16451
I3
sg16459
VC0027831
p30115
sg16454
VNF1
p30116
sa(dp30117
g16449
I69
sg16450
I2
sg16451
I11
sg16459
VC1882848
p30118
sg16454
Vrat sarcoma
p30119
sa(dp30120
g16449
I73
sg16450
I1
sg16451
I7
sg16459
VC1261473
p30121
sg16454
Vsarcoma
p30122
sa(dp30123
g16449
I259
sg16450
I1
sg16451
I6
sg16459
VC0683278
p30124
sg16454
Vsuffer
p30125
sa(dp30126
g16449
I285
sg16450
I1
sg16451
I6
sg16459
VC0027651
p30127
sg16454
Vtumors
p30128
sa(dp30129
g16449
I193
sg16450
I2
sg16451
I19
sg16459
VC1321546
p30130
sg16454
Vanaplastic lymphoma
p30131
sasa(dp30132
g16444
VFor example, "Mongolism" was changed to Down's syndrome; "Australia" antigen to HBsAg; "Mexican" Swine flu to H1N1; "GRID" (Gay Related Immune Deficiency) and 4H-Disease (Haitians, Homosexuals, Haemophiliacs and Heroin Users Disease) to AIDS.
p30133
sg16446
(lp30134
sg16456
(lp30135
(dp30136
g16449
I40
sg16450
I2
sg16451
I15
sg16459
VC0013080
p30137
sg16454
VDown's syndrome
p30138
sa(dp30139
g16449
I14
sg16450
I1
sg16451
I9
sg16459
VC0013080
p30140
sg16454
VMongolism
p30141
sa(dp30142
g16449
I97
sg16450
I2
sg16451
I9
sg16459
VC2076600
p30143
sg16454
VSwine flu
p30144
sa(dp30145
g16449
I136
sg16450
I2
sg16451
I17
sg16459
VC0850497
p30146
sg16454
VImmune Deficiency
p30147
sasa(dp30148
g16444
VWHEN IT WAS CALLED 'GRID': One year ago today, I told my colleagues that I was dying of AIDS.
p30149
sg16446
(lp30150
sg16456
(lp30151
sa(dp30152
g16444
VAPL are significantly influenced by azole dose, age, cystic fibrosis, type of LTx, and comedication with proton-pump inhibitors.
p30153
sg16446
(lp30154
(dp30155
g16449
I0
sg16450
I1
sg16451
I3
sg16452
VP10276
p30156
sg16454
VAPL
p30157
sasg16456
(lp30158
(dp30159
g16449
I53
sg16450
I2
sg16451
I15
sg16459
VC0010674
p30160
sg16454
Vcystic fibrosis
p30161
sa(dp30162
g16449
I0
sg16450
I1
sg16451
I3
sg16459
VC0023487
p30163
sg16454
VAPL
p30164
sasa(dp30165
g16444
VDMSG = DutchMEN1 Study Group; D-NET = duodenal neuroendocrine tumor; DP-NET = duodenopancreatic neuroendocrine tumor; HPF = high-power field; Ki67 LI = Ki67 labeling index; MEN1 = multiple endocrine neoplasia type 1; NET = neuroendocrine tumor; OS = overall survival; P-NET = pancreatic neuroendocrine tumor; PPI = proton pump inhibitor; ULN = upper limit of normal; WHO = World Health Organization.
p30166
sg16446
(lp30167
(dp30168
g16449
I12
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VMEN1
p30169
sasg16456
(lp30170
(dp30171
g16449
I47
sg16450
I2
sg16451
I20
sg16459
VC0206754
p30172
sg16454
Vneuroendocrine tumor
p30173
sa(dp30174
g16449
I85
sg16450
I3
sg16451
I31
sg16459
VC1337011
p30175
sg16454
Vpancreatic neuroendocrine tumor
p30176
sa(dp30177
g16449
I12
sg16450
I1
sg16451
I4
sg16459
VC0025267
p30178
sg16454
VMEN1
p30179
sa(dp30180
g16449
I180
sg16450
I5
sg16451
I35
sg16459
VC0025267
p30181
sg16454
Vmultiple endocrine neoplasia type 1
p30182
sa(dp30183
g16449
I47
sg16450
I2
sg16451
I20
sg16459
VC0206754
p30184
sg16454
Vneuroendocrine tumor
p30185
sa(dp30186
g16449
I47
sg16450
I2
sg16451
I20
sg16459
VC0206754
p30187
sg16454
Vneuroendocrine tumor
p30188
sasa(dp30189
g16444
VAPL are significantly influenced by azole dose, age, cystic fibrosis, type of LTx, and co-medication with proton-pump inhibitors.
p30190
sg16446
(lp30191
(dp30192
g16449
I0
sg16450
I1
sg16451
I3
sg16452
VP10276
p30193
sg16454
VAPL
p30194
sasg16456
(lp30195
(dp30196
g16449
I53
sg16450
I2
sg16451
I15
sg16459
VC0010674
p30197
sg16454
Vcystic fibrosis
p30198
sa(dp30199
g16449
I0
sg16450
I1
sg16451
I3
sg16459
VC0023487
p30200
sg16454
VAPL
p30201
sasa(dp30202
g16444
VIn both cases, the diagnosis of multiple endocrine neoplasia type 1 was made after proton pump therapy was discontinued.
p30203
sg16446
(lp30204
sg16456
(lp30205
(dp30206
g16449
I32
sg16450
I5
sg16451
I35
sg16459
VC0025267
p30207
sg16454
Vmultiple endocrine neoplasia type 1
p30208
sasa(dp30209
g16444
VClinical assessment for features of multiple endocrine neoplasia type 1 (eg, serum calcium levels, personal and family history of hypercalcemia, pituitary or pancreatic tumors) could identify patients with higher risk for a tumoral source of hypergastrinemia where imaging studies can help support the diagnosis without the potential side effects of abrupt discontinuation of proton pump inhibitor therapy.
p30210
sg16446
(lp30211
sg16456
(lp30212
(dp30213
g16449
I36
sg16450
I5
sg16451
I35
sg16459
VC0025267
p30214
sg16454
Vmultiple endocrine neoplasia type 1
p30215
sa(dp30216
g16449
I130
sg16450
I1
sg16451
I13
sg16459
VC0020437
p30217
sg16454
Vhypercalcemia
p30218
sa(dp30219
g16449
I158
sg16450
I2
sg16451
I17
sg16459
VC0030297
p30220
sg16454
Vpancreatic tumors
p30221
sasa(dp30222
g16444
VNo correlation was detected between Ki-67 values of HGPs in CLD patients and the presence of portal hypertension, infection with Helicobacter pylori, or proton pump inhibitor use.
p30223
sg16446
(lp30224
sg16456
(lp30225
(dp30226
g16449
I93
sg16450
I2
sg16451
I19
sg16459
VC0020541
p30227
sg16454
Vportal hypertension
p30228
sa(dp30229
g16449
I52
sg16450
I1
sg16451
I4
sg16459
VC0033300
p30230
sg16454
VHGPs
p30231
sa(dp30232
g16449
I114
sg16450
I1
sg16451
I9
sg16459
VC0009450
p30233
sg16454
Vinfection
p30234
sa(dp30235
g16449
I60
sg16450
I1
sg16451
I3
sg16459
VC0746102
p30236
sg16454
VCLD
p30237
sasa(dp30238
g16444
VMutation screening and phenotypic profiling of 2 amyotrophic lateral sclerosis-(ALS) and frontotemporal dementia-(FTD) associated genes, CHCHD10 and TUBA4A, were performed in a Belgian cohort of 459 FTD, 28 FTD-ALS, and 429 ALS patients.
p30239
sg16446
(lp30240
(dp30241
g16449
I137
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCHCHD10
p30242
sa(dp30243
g16449
I149
sg16450
I1
sg16451
I6
sg16452
VP68366
p30244
sg16454
VTUBA4A
p30245
sasg16456
(lp30246
(dp30247
g16449
I207
sg16450
I1
sg16451
I7
sg16459
VC1862937
p30248
sg16454
VFTD-ALS
p30249
sa(dp30250
g16449
I114
sg16450
I1
sg16451
I3
sg16459
VC0338451
p30251
sg16454
VFTD
p30252
sa(dp30253
g16449
I49
sg16450
I3
sg16451
I29
sg16459
VC0002736
p30254
sg16454
Vamyotrophic lateral sclerosis
p30255
sa(dp30256
g16449
I80
sg16450
I1
sg16451
I3
sg16459
VC0002736
p30257
sg16454
VALS
p30258
sa(dp30259
g16449
I80
sg16450
I1
sg16451
I3
sg16459
VC0002736
p30260
sg16454
VALS
p30261
sa(dp30262
g16449
I89
sg16450
I2
sg16451
I23
sg16459
VC0338451
p30263
sg16454
Vfrontotemporal dementia
p30264
sa(dp30265
g16449
I114
sg16450
I1
sg16451
I3
sg16459
VC0338451
p30266
sg16454
VFTD
p30267
sasa(dp30268
g16444
VIn TUBA4A, we detected a novel frameshift mutation (p.Arg64Glyfs*90) leading to a truncated protein in 1 FTD patient (1/459 of 0.22%) with family history of Parkinson's disease and cognitive impairment, and a novel missense mutation (p.Thr381Met) in 2 sibs with familial ALS and memory problems (1 index patient/429, 0.23%) in whom we previously identified a pathogenic Chromosome 9 open reading frame 72 repeat expansion mutation.
p30269
sg16446
(lp30270
(dp30271
g16449
I3
sg16450
I1
sg16451
I6
sg16452
VP68366
p30272
sg16454
VTUBA4A
p30273
sasg16456
(lp30274
(dp30275
g16449
I105
sg16450
I1
sg16451
I3
sg16459
VC0338451
p30276
sg16454
VFTD
p30277
sa(dp30278
g16449
I31
sg16450
I2
sg16451
I19
sg16459
VC0079380
p30279
sg16454
Vframeshift mutation
p30280
sa(dp30281
g16449
I181
sg16450
I2
sg16451
I20
sg16459
VC0338656
p30282
sg16454
Vcognitive impairment
p30283
sa(dp30284
g16449
I279
sg16450
I2
sg16451
I15
sg16459
VC0233794
p30285
sg16454
Vmemory problems
p30286
sa(dp30287
g16449
I271
sg16450
I1
sg16451
I3
sg16459
VC0002736
p30288
sg16454
VALS
p30289
sa(dp30290
g16449
I157
sg16450
I2
sg16451
I19
sg16459
VC0030567
p30291
sg16454
VParkinson's disease
p30292
sasa(dp30293
g16444
VThe present study confirms the role of CHCHD10 and TUBA4A in the FTD-ALS spectrum, although genetic variations in these 2 genes are extremely rare in the Belgian population and often associated with symptomatology of related neurodegenerative diseases including Parkinson's disease and Alzheimer's disease.
p30294
sg16446
(lp30295
(dp30296
g16449
I51
sg16450
I1
sg16451
I6
sg16452
VP68366
p30297
sg16454
VTUBA4A
p30298
sa(dp30299
g16449
I39
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCHCHD10
p30300
sasg16456
(lp30301
(dp30302
g16449
I225
sg16450
I2
sg16451
I26
sg16459
VC0524851
p30303
sg16454
Vneurodegenerative diseases
p30304
sa(dp30305
g16449
I262
sg16450
I2
sg16451
I19
sg16459
VC0030567
p30306
sg16454
VParkinson's disease
p30307
sa(dp30308
g16449
I65
sg16450
I1
sg16451
I7
sg16459
VC1862937
p30309
sg16454
VFTD-ALS
p30310
sa(dp30311
g16449
I286
sg16450
I2
sg16451
I19
sg16459
VC1521724
p30312
sg16454
VAlzheimer's disease
p30313
sasa(dp30314
g16444
VThe tubulin alpha 4a (TUBA4A) gene has been recently associated with amyotrophic lateral sclerosis.
p30315
sg16446
(lp30316
(dp30317
g16449
I22
sg16450
I1
sg16451
I6
sg16452
VP68366
p30318
sg16454
VTUBA4A
p30319
sa(dp30320
g16449
I4
sg16450
I3
sg16451
I16
sg16452
VP68366
p30321
sg16454
Vtubulin alpha 4a
p30322
sasg16456
(lp30323
(dp30324
g16449
I69
sg16450
I3
sg16451
I29
sg16459
VC0002736
p30325
sg16454
Vamyotrophic lateral sclerosis
p30326
sasa(dp30327
g16444
VTUBA4A gene has recently been identified as a potential candidate amyotrophic lateral sclerosis(ALS)-associated gene using exome-wide rare variant burden analysis.
p30328
sg16446
(lp30329
(dp30330
g16449
I0
sg16450
I2
sg16451
I11
sg16452
VP68366
p30331
sg16454
VTUBA4A gene
p30332
sasg16456
(lp30333
(dp30334
g16449
I66
sg16450
I3
sg16451
I29
sg16459
VC0002736
p30335
sg16454
Vamyotrophic lateral sclerosis
p30336
sa(dp30337
g16449
I96
sg16450
I1
sg16451
I3
sg16459
VC0002736
p30338
sg16454
VALS
p30339
sasa(dp30340
g16444
VHere we studied the physiological function of CLAC-P/collagen XXV, a transmembrane-type collagen originally identified as a component of senile plaque amyloid of Alzheimer's disease brains, by means of generating Col25a1-deficient (KO) mice.
p30341
sg16446
(lp30342
(dp30343
g16449
I46
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCLAC-P
p30344
sa(dp30345
g16449
I213
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCol25a1
p30346
sasg16456
(lp30347
(dp30348
g16449
I151
sg16450
I1
sg16451
I7
sg16459
VC0011560
p30349
sg16454
Vamyloid
p30350
sa(dp30351
g16449
I137
sg16450
I2
sg16451
I13
sg16459
VC0333463
p30352
sg16454
Vsenile plaque
p30353
sa(dp30354
g16449
I162
sg16450
I2
sg16451
I19
sg16459
VC1521724
p30355
sg16454
VAlzheimer's disease
p30356
sasa(dp30357
g16444
VCollagen XXV alpha 1 (COL25A1) is a collagenous type II transmembrane protein purified from senile plaques of Alzheimer's disease (AD) brains.
p30358
sg16446
(lp30359
(dp30360
g16449
I0
sg16450
I4
sg16451
I20
sg16452
VP25100
p30361
sg16454
VCollagen XXV alpha 1
p30362
sa(dp30363
g16449
I36
sg16450
I5
sg16451
I41
sg16452
VP27037
p30364
sg16454
Vcollagenous type II transmembrane protein
p30365
sa(dp30366
g16449
I22
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCOL25A1
p30367
sasg16456
(lp30368
(dp30369
g16449
I131
sg16450
I1
sg16451
I2
sg16459
VC1521724
p30370
sg16454
VAD
p30371
sa(dp30372
g16449
I92
sg16450
I2
sg16451
I14
sg16459
VC0333463
p30373
sg16454
Vsenile plaques
p30374
sa(dp30375
g16449
I110
sg16450
I2
sg16451
I19
sg16459
VC1521724
p30376
sg16454
VAlzheimer's disease
p30377
sasa(dp30378
g16444
VThe COL25A1 gene, located in 4q25, encodes the CLAC protein, which has been implicated in Alzheimer's disease (AD) pathogenesis.
p30379
sg16446
(lp30380
(dp30381
g16449
I47
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VCLAC protein
p30382
sa(dp30383
g16449
I4
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VCOL25A1 gene
p30384
sasg16456
(lp30385
(dp30386
g16449
I115
sg16450
I1
sg16451
I12
sg16459
VC0699748
p30387
sg16454
Vpathogenesis
p30388
sa(dp30389
g16449
I111
sg16450
I1
sg16451
I2
sg16459
VC1521724
p30390
sg16454
VAD
p30391
sa(dp30392
g16449
I90
sg16450
I2
sg16451
I19
sg16459
VC1521724
p30393
sg16454
VAlzheimer's disease
p30394
sasa(dp30395
g16444
VThus, in addition to the biochemical data, there is now genetic evidence of association between COL25A1 and risk for Alzheimer's disease.
p30396
sg16446
(lp30397
(dp30398
g16449
I96
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCOL25A1
p30399
sasg16456
(lp30400
(dp30401
g16449
I117
sg16450
I2
sg16451
I19
sg16459
VC1521724
p30402
sg16454
VAlzheimer's disease
p30403
sasa(dp30404
g16444
VRecently, a novel plaque-associated protein, collagenous Alzheimer amyloid plaque component (CLAC), was identified in brains from patients with Alzheimer's disease.
p30405
sg16446
(lp30406
sg16456
(lp30407
(dp30408
g16449
I67
sg16450
I2
sg16451
I14
sg16459
VC0333463
p30409
sg16454
Vamyloid plaque
p30410
sa(dp30411
g16449
I18
sg16450
I1
sg16451
I6
sg16459
VC0011389
p30412
sg16454
Vplaque
p30413
sa(dp30414
g16449
I144
sg16450
I2
sg16451
I19
sg16459
VC1521724
p30415
sg16454
VAlzheimer's disease
p30416
sasa(dp30417
g16444
VThe biological function and the contribution of CLAC to the pathogenesis of Alzheimer's disease and plaque formation are unknown.
p30418
sg16446
(lp30419
sg16456
(lp30420
(dp30421
g16449
I76
sg16450
I2
sg16451
I19
sg16459
VC1521724
p30422
sg16454
VAlzheimer's disease
p30423
sa(dp30424
g16449
I100
sg16450
I1
sg16451
I6
sg16459
VC0011389
p30425
sg16454
Vplaque
p30426
sa(dp30427
g16449
I60
sg16450
I1
sg16451
I12
sg16459
VC0699748
p30428
sg16454
Vpathogenesis
p30429
sasa(dp30430
g16444
VCLAC (collagenous Alzheimer amyloid plaque component) is a proteolytic fragment derived from a novel membrane-bound collagen, CLAC-P/collagen type XXV, that deposits in senile plaques associated with amyloid beta peptides (Abeta) in the brains of patients with Alzheimer's disease.
p30431
sg16446
(lp30432
(dp30433
g16449
I200
sg16450
I3
sg16451
I21
sg16452
g11
sg16454
Vamyloid beta peptides
p30434
sa(dp30435
g16449
I126
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCLAC-P
p30436
sa(dp30437
g16449
I223
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VAbeta
p30438
sasg16456
(lp30439
(dp30440
g16449
I28
sg16450
I2
sg16451
I14
sg16459
VC0333463
p30441
sg16454
Vamyloid plaque
p30442
sa(dp30443
g16449
I169
sg16450
I2
sg16451
I14
sg16459
VC0333463
p30444
sg16454
Vsenile plaques
p30445
sa(dp30446
g16449
I28
sg16450
I1
sg16451
I7
sg16459
VC0011560
p30447
sg16454
Vamyloid
p30448
sa(dp30449
g16449
I261
sg16450
I2
sg16451
I19
sg16459
VC1521724
p30450
sg16454
VAlzheimer's disease
p30451
sasa(dp30452
g16444
VThese results suggest the anti-amyloidogenic roles of CLAC in the pathophysiology of Alzheimer's disease.
p30453
sg16446
(lp30454
(dp30455
g16449
I54
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCLAC
p30456
sasg16456
(lp30457
(dp30458
g16449
I85
sg16450
I2
sg16451
I19
sg16459
VC1521724
p30459
sg16454
VAlzheimer's disease
p30460
sasa(dp30461
g16444
VThe analysis of breast cancer and pancreatic cancer data further shows iSPCA's satisfactory performance.
p30462
sg16446
(lp30463
sg16456
(lp30464
(dp30465
g16449
I16
sg16450
I2
sg16451
I13
sg16459
VC0678222
p30466
sg16454
Vbreast cancer
p30467
sa(dp30468
g16449
I34
sg16450
I2
sg16451
I17
sg16459
VC0235974
p30469
sg16454
Vpancreatic cancer
p30470
sasa(dp30471
g16444
VTissue factor (TF) is a transmembrane receptor for coagulation factor VII/VIIa and is frequently overexpressed by cancer cells.
p30472
sg16446
(lp30473
(dp30474
g16449
I51
sg16450
I3
sg16451
I22
sg16452
VP08709
p30475
sg16454
Vcoagulation factor VII
p30476
sasg16456
(lp30477
(dp30478
g16449
I114
sg16450
I1
sg16451
I6
sg16459
VC0006826
p30479
sg16454
Vcancer
p30480
sasa(dp30481
g16444
VTo identify the location of missed significant prostate cancer (sPCa) lesions by transrectal ultrasound-guided biopsy (TRUSbx) and multiparametric magnetic resonance imaging-guided biopsy (mpMRIbx) in men undergoing repeat biopsies.
p30482
sg16446
(lp30483
sg16456
(lp30484
(dp30485
g16449
I47
sg16450
I2
sg16451
I15
sg16459
VC0600139
p30486
sg16454
Vprostate cancer
p30487
sasa(dp30488
g16444
VOf the 289 patients, prostate cancer was detected in 128 (44%) with 88 (30%) having sPCa.
p30489
sg16446
(lp30490
(dp30491
g16449
I84
sg16450
I1
sg16451
I4
sg16452
VP08709
p30492
sg16454
VsPCa
p30493
sasg16456
(lp30494
(dp30495
g16449
I21
sg16450
I2
sg16451
I15
sg16459
VC0600139
p30496
sg16454
Vprostate cancer
p30497
sasa(dp30498
g16444
VOverall, 165 separate prostate cancer lesions were detected with 100 being sPCa.
p30499
sg16446
(lp30500
sg16456
(lp30501
(dp30502
g16449
I22
sg16450
I2
sg16451
I15
sg16459
VC0600139
p30503
sg16454
Vprostate cancer
p30504
sasa(dp30505
g16444
VFactor VII (FVII) activating protease (FSAP) is a circulating serine protease that is likely to be involved in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer.
p30506
sg16446
(lp30507
(dp30508
g16449
I0
sg16450
I5
sg16451
I37
sg16452
VP08709
p30509
sg16454
VFactor VII (FVII) activating protease
p30510
sa(dp30511
g16449
I39
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VFSAP
p30512
sa(dp30513
g16449
I62
sg16450
I2
sg16451
I15
sg16452
VP57727
p30514
sg16454
Vserine protease
p30515
sasg16456
(lp30516
(dp30517
g16449
I150
sg16450
I1
sg16451
I6
sg16459
VC0038454
p30518
sg16454
Vstroke
p30519
sa(dp30520
g16449
I158
sg16450
I1
sg16451
I15
sg16459
VC0004153
p30521
sg16454
Vatherosclerosis
p30522
sa(dp30523
g16449
I175
sg16450
I2
sg16451
I14
sg16459
VC0239946
p30524
sg16454
Vliver fibrosis
p30525
sa(dp30526
g16449
I206
sg16450
I1
sg16451
I6
sg16459
VC0006826
p30527
sg16454
Vcancer
p30528
sa(dp30529
g16449
I191
sg16450
I1
sg16451
I10
sg16459
VC0040053
p30530
sg16454
Vthrombosis
p30531
sasa(dp30532
g16444
VIn the absence of factor VII in platelet-free plasma, thrombin generation in solid pancreatic cancer cell lines was significantly reduced unlike in haematological cell lines.
p30533
sg16446
(lp30534
(dp30535
g16449
I54
sg16450
I1
sg16451
I8
sg16452
VP00734
p30536
sg16454
Vthrombin
p30537
sasg16456
(lp30538
(dp30539
g16449
I83
sg16450
I2
sg16451
I17
sg16459
VC0235974
p30540
sg16454
Vpancreatic cancer
p30541
sasa(dp30542
g16444
VSPCA gene expression is significantly elevated in breast cancer subtypes that are associated with microcalcifications.
p30543
sg16446
(lp30544
(dp30545
g16449
I0
sg16450
I2
sg16451
I9
sg16452
VP08709
p30546
sg16454
VSPCA gene
p30547
sasg16456
(lp30548
(dp30549
g16449
I50
sg16450
I2
sg16451
I13
sg16459
VC0678222
p30550
sg16454
Vbreast cancer
p30551
sa(dp30552
g16449
I98
sg16450
I1
sg16451
I19
sg16459
VC0521174
p30553
sg16454
Vmicrocalcifications
p30554
sasa(dp30555
g16444
VClinically significant cancer (SPCa) was defined as Gleason score &gt;=3 + 4.
p30556
sg16446
(lp30557
sg16456
(lp30558
(dp30559
g16449
I23
sg16450
I1
sg16451
I6
sg16459
VC0006826
p30560
sg16454
Vcancer
p30561
sasa(dp30562
g16444
VHeritable disorders of connective tissue (marfan syndrome, Ehlers-Danlos syndrome, adult polycystic kidney disease, floppy mitral valve/mitral valve prolapse); congenital heart disease (bicuspid aortic valve); inflammatory/immunologic disorders (rheumatic fever, AIDS, Kawasaki disease, syphilis, seronegative spondyloarthropathies, systemic lupus erythematosus, antiphospholipid syndrome); endocardial disorders (nonbacteremic thrombotic endocarditis, infective endocarditis, endomyocardial fibroelastosis); myocardial dysfunction (ischemic heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy); diseases and disorders of other organs (chronic renal failure, carcinoid heart disease); aging (calcific aortic stenosis, mitral annular calcification); postinterventional valvular disease; drugs and physical agents are all clinical entities associated with VHD.
p30563
sg16446
(lp30564
sg16456
(lp30565
(dp30566
g16449
I136
sg16450
I3
sg16451
I21
sg16459
VC0026267
p30567
sg16454
Vmitral valve prolapse
p30568
sa(dp30569
g16449
I533
sg16450
I3
sg16451
I22
sg16459
VC0151744
p30570
sg16454
Vischemic heart disease
p30571
sa(dp30572
g16449
I116
sg16450
I3
sg16451
I19
sg16459
VC0026267
p30573
sg16454
Vfloppy mitral valve
p30574
sa(dp30575
g16449
I160
sg16450
I3
sg16451
I24
sg16459
VC0152021
p30576
sg16454
Vcongenital heart disease
p30577
sa(dp30578
g16449
I565
sg16450
I1
sg16451
I14
sg16459
VC0878544
p30579
sg16454
Vcardiomyopathy
p30580
sa(dp30581
g16449
I186
sg16450
I3
sg16451
I21
sg16459
VC0149630
p30582
sg16454
Vbicuspid aortic valve
p30583
sa(dp30584
g16449
I223
sg16450
I2
sg16451
I21
sg16459
VC0021053
p30585
sg16454
Vimmunologic disorders
p30586
sa(dp30587
g16449
I611
sg16450
I3
sg16451
I22
sg16459
VC0012634
p30588
sg16454
Vdiseases and disorders
p30589
sa(dp30590
g16449
I477
sg16450
I2
sg16451
I29
sg16459
VC0014117
p30591
sg16454
Vendomyocardial fibroelastosis
p30592
sa(dp30593
g16449
I333
sg16450
I3
sg16451
I28
sg16459
VC0024141
p30594
sg16454
Vsystemic lupus erythematosus
p30595
sa(dp30596
g16449
I674
sg16450
I3
sg16451
I23
sg16459
VC0007093
p30597
sg16454
Vcarcinoid heart disease
p30598
sa(dp30599
g16449
I565
sg16450
I2
sg16451
I28
sg16459
VC0007194
p30600
sg16454
Vcardiomyopathy, hypertrophic
p30601
sa(dp30602
g16449
I723
sg16450
I2
sg16451
I16
sg16459
VC0026269
p30603
sg16454
Vstenosis, mitral
p30604
sa(dp30605
g16449
I439
sg16450
I2
sg16451
I23
sg16459
VC1541923
p30606
sg16454
Vendocarditis, infective
p30607
sa(dp30608
g16449
I310
sg16450
I1
sg16451
I21
sg16459
VC0949691
p30609
sg16454
Vspondyloarthropathies
p30610
sa(dp30611
g16449
I246
sg16450
I2
sg16451
I15
sg16459
VC0035436
p30612
sg16454
Vrheumatic fever
p30613
sa(dp30614
g16449
I439
sg16450
I1
sg16451
I12
sg16459
VC0014118
p30615
sg16454
Vendocarditis
p30616
sa(dp30617
g16449
I49
sg16450
I2
sg16451
I23
sg16459
VC0013720
p30618
sg16454
Vsyndrome, Ehlers-Danlos
p30619
sa(dp30620
g16449
I509
sg16450
I2
sg16451
I22
sg16459
VC0340515
p30621
sg16454
Vmyocardial dysfunction
p30622
sa(dp30623
g16449
I269
sg16450
I2
sg16451
I16
sg16459
VC0026691
p30624
sg16454
VKawasaki disease
p30625
sa(dp30626
g16449
I83
sg16450
I4
sg16451
I31
sg16459
VC0085413
p30627
sg16454
Vadult polycystic kidney disease
p30628
sa(dp30629
g16449
I651
sg16450
I3
sg16451
I21
sg16459
VC0022661
p30630
sg16454
Vchronic renal failure
p30631
sa(dp30632
g16449
I49
sg16450
I1
sg16451
I8
sg16459
VC0039082
p30633
sg16454
Vsyndrome
p30634
sa(dp30635
g16449
I363
sg16450
I2
sg16451
I25
sg16459
VC0085278
p30636
sg16454
Vantiphospholipid syndrome
p30637
sa(dp30638
g16449
I287
sg16450
I1
sg16451
I8
sg16459
VC0039128
p30639
sg16454
Vsyphilis
p30640
sasa(dp30641
g16444
VDescribed here is an autopsy case of a 61-year-old man with polycystic kidney disease who had P. multocida bacteremia and acute infective endocarditis with multiple bacterial clumps involving bicuspid aortic valve.
p30642
sg16446
(lp30643
sg16456
(lp30644
(dp30645
g16449
I192
sg16450
I3
sg16451
I21
sg16459
VC0149630
p30646
sg16454
Vbicuspid aortic valve
p30647
sa(dp30648
g16449
I107
sg16450
I1
sg16451
I10
sg16459
VC0004610
p30649
sg16454
Vbacteremia
p30650
sa(dp30651
g16449
I122
sg16450
I3
sg16451
I28
sg16459
VC0155685
p30652
sg16454
Vacute infective endocarditis
p30653
sa(dp30654
g16449
I60
sg16450
I3
sg16451
I25
sg16459
VC0022680
p30655
sg16454
Vpolycystic kidney disease
p30656
sasa(dp30657
g16444
VTwenty-five people with COPD + PC (mean (standard deviation (SD)) age 73 (11) years, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II-IV), 25 people with COPD (70 (8) years, GOLD stage II-IV) and 25 controls (70 (7) years) wore the SenseWear Pro3 Armband for 7 days.
p30658
sg16446
(lp30659
sg16456
(lp30660
(dp30661
g16449
I24
sg16450
I1
sg16451
I4
sg16459
VC0024117
p30662
sg16454
VCOPD
p30663
sa(dp30664
g16449
I141
sg16450
I1
sg16451
I4
sg16459
VC0024117
p30665
sg16454
VGOLD
p30666
sa(dp30667
g16449
I141
sg16450
I1
sg16451
I4
sg16459
VC0024117
p30668
sg16454
VGOLD
p30669
sa(dp30670
g16449
I85
sg16450
I7
sg16451
I54
sg16459
VC0024117
p30671
sg16454
VGlobal Initiative for Chronic Obstructive Lung Disease
p30672
sa(dp30673
g16449
I24
sg16450
I1
sg16451
I4
sg16459
VC0024117
p30674
sg16454
VCOPD
p30675
sasa(dp30676
g16444
VPatients with severe atopic dermatitis had a decreased CD4+CD29+: CD4+CD45RA+ ratio (p &lt; 0.01).
p30677
sg16446
(lp30678
(dp30679
g16449
I66
sg16450
I1
sg16451
I11
sg16452
VP01730
p30680
sg16454
VCD4+CD45RA+
p30681
sa(dp30682
g16449
I55
sg16450
I1
sg16451
I9
sg16452
VP01730
p30683
sg16454
VCD4+CD29+
p30684
sasg16456
(lp30685
(dp30686
g16449
I21
sg16450
I2
sg16451
I17
sg16459
VC0011615
p30687
sg16454
Vatopic dermatitis
p30688
sasa(dp30689
g16444
VNo significant changes in the CD4+CD29+: CD4+CD45RA+ ratio were found in the peripheral blood of patients with clinically mild or moderate atopic dermatitis.
p30690
sg16446
(lp30691
(dp30692
g16449
I30
sg16450
I1
sg16451
I9
sg16452
VP01730
p30693
sg16454
VCD4+CD29+
p30694
sa(dp30695
g16449
I41
sg16450
I1
sg16451
I11
sg16452
VP01730
p30696
sg16454
VCD4+CD45RA+
p30697
sasg16456
(lp30698
(dp30699
g16449
I139
sg16450
I2
sg16451
I17
sg16459
VC0011615
p30700
sg16454
Vatopic dermatitis
p30701
sasa(dp30702
g16444
VTissue sections from the skin of patients with atopic dermatitis were investigated by means of hematoxylin-eosin staining, the avidin-biotin-peroxidase complex method, and double-labeling immunofluorescence using monoclonal antibodies to cell-surface antigens, including CD45R and CD29.
p30703
sg16446
(lp30704
(dp30705
g16449
I271
sg16450
I1
sg16451
I5
sg16452
VP08575
p30706
sg16454
VCD45R
p30707
sa(dp30708
g16449
I141
sg16450
I1
sg16451
I10
sg16452
VP05164
p30709
sg16454
Vperoxidase
p30710
sasg16456
(lp30711
(dp30712
g16449
I47
sg16450
I2
sg16451
I17
sg16459
VC0011615
p30713
sg16454
Vatopic dermatitis
p30714
sasa(dp30715
g16444
VThese novel data demonstrate the role of HDAC2-mediated epigenetic mechanisms in anxiety and alcoholism.
p30716
sg16446
(lp30717
(dp30718
g16449
I41
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VHDAC2
p30719
sasg16456
(lp30720
(dp30721
g16449
I93
sg16450
I1
sg16451
I10
sg16459
VC0001973
p30722
sg16454
Valcoholism
p30723
sasa(dp30724
g16444
VThe mRNA levels of cholesterol transport regulators ABCA1 and ABCG1 were markedly downregulated by UVB, parallel to the lamellar ichthyosis related glucosylceramide transporter ABCA12 and the suspected sphingosine-1-phosphate and cholesterol sulfate transporter ABCC1.
p30725
sg16446
(lp30726
(dp30727
g16449
I230
sg16450
I4
sg16451
I37
sg16452
VP50443
p30728
sg16454
Vcholesterol sulfate transporter ABCC1
p30729
sasg16456
(lp30730
(dp30731
g16449
I120
sg16450
I2
sg16451
I19
sg16459
VC0020758
p30732
sg16454
Vlamellar ichthyosis
p30733
sasa(dp30734
g16444
VTo investigate the potential tumour suppressor functions of glutathione peroxidase 7 (GPX7) and examine the interplay between epigenetic and genetic events in regulating its expression in oesophageal adenocarcinomas (OAC).
p30735
sg16446
(lp30736
(dp30737
g16449
I86
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VGPX7
p30738
sa(dp30739
g16449
I60
sg16450
I3
sg16451
I24
sg16452
g11
sg16454
Vglutathione peroxidase 7
p30740
sasg16456
(lp30741
(dp30742
g16449
I200
sg16450
I1
sg16451
I15
sg16459
VC0001418
p30743
sg16454
Vadenocarcinomas
p30744
sa(dp30745
g16449
I29
sg16450
I1
sg16451
I6
sg16459
VC0027651
p30746
sg16454
Vtumour
p30747
sasa(dp30748
g16444
VThe goal of this study was to investigate the expression and secretion levels in vitro and in vivo of kallikrein 10 in uterine serous papillary carcinoma, a highly aggressive variant of endometrial tumor.
p30749
sg16446
(lp30750
(dp30751
g16449
I102
sg16450
I2
sg16451
I13
sg16452
g11
sg16454
Vkallikrein 10
p30752
sasg16456
(lp30753
(dp30754
g16449
I134
sg16450
I2
sg16451
I19
sg16459
VC0007133
p30755
sg16454
Vpapillary carcinoma
p30756
sa(dp30757
g16449
I164
sg16450
I1
sg16451
I10
sg16459
VC0001807
p30758
sg16454
Vaggressive
p30759
sa(dp30760
g16449
I186
sg16450
I2
sg16451
I17
sg16459
VC0014170
p30761
sg16454
Vendometrial tumor
p30762
sasa(dp30763
g16444
VHuman kallikrein 10 gene expression levels were evaluated in 11 snap-frozen uterine serous papillary carcinoma biopsies and 6 normal endometrial cell biopsies by real-time polymerase chain reaction.
p30764
sg16446
(lp30765
(dp30766
g16449
I0
sg16450
I4
sg16451
I24
sg16452
g11
sg16454
VHuman kallikrein 10 gene
p30767
sasg16456
(lp30768
(dp30769
g16449
I91
sg16450
I2
sg16451
I19
sg16459
VC0007133
p30770
sg16454
Vpapillary carcinoma
p30771
sasa(dp30772
g16444
VSecretion of kallikrein 10 protein by 10 primary tumor cultures including 3 uterine serous papillary carcinomas, 2 endometrioid carcinomas, and 5 ovarian serous papillary tumors was measured using a sensitive ELISA.
p30773
sg16446
(lp30774
(dp30775
g16449
I13
sg16450
I3
sg16451
I21
sg16452
g11
sg16454
Vkallikrein 10 protein
p30776
sasg16456
(lp30777
(dp30778
g16449
I171
sg16450
I1
sg16451
I6
sg16459
VC0027651
p30779
sg16454
Vtumors
p30780
sa(dp30781
g16449
I91
sg16450
I2
sg16451
I20
sg16459
VC0007133
p30782
sg16454
Vpapillary carcinomas
p30783
sa(dp30784
g16449
I41
sg16450
I2
sg16451
I13
sg16459
VC0677930
p30785
sg16454
Vprimary tumor
p30786
sa(dp30787
g16449
I115
sg16450
I2
sg16451
I23
sg16459
VC0206687
p30788
sg16454
Vendometrioid carcinomas
p30789
sasa(dp30790
g16444
VFinally, kallikrein 10 concentration in 75 serum and plasma samples from 22 healthy women, 20 women with benign diseases, 21 women with endometrioid carcinomas, and 12 uterine serous papillary carcinoma patients was studied.
p30791
sg16446
(lp30792
(dp30793
g16449
I9
sg16450
I2
sg16451
I13
sg16452
g11
sg16454
Vkallikrein 10
p30794
sasg16456
(lp30795
(dp30796
g16449
I183
sg16450
I2
sg16451
I19
sg16459
VC0007133
p30797
sg16454
Vpapillary carcinoma
p30798
sa(dp30799
g16449
I136
sg16450
I2
sg16451
I23
sg16459
VC0206687
p30800
sg16454
Vendometrioid carcinomas
p30801
sasa(dp30802
g16444
VKallikrein 10 gene expression levels were significantly higher in uterine serous papillary carcinoma when compared with normal endometrial cell biopsies (mean copy number by real time polymerase chain reaction = 743 versus 1.4; uterine serous papillary carcinoma versus endometrioid carcinoma: P &lt; .02).
p30803
sg16446
(lp30804
(dp30805
g16449
I0
sg16450
I3
sg16451
I18
sg16452
g11
sg16454
VKallikrein 10 gene
p30806
sasg16456
(lp30807
(dp30808
g16449
I81
sg16450
I2
sg16451
I19
sg16459
VC0007133
p30809
sg16454
Vpapillary carcinoma
p30810
sa(dp30811
g16449
I81
sg16450
I2
sg16451
I19
sg16459
VC0007133
p30812
sg16454
Vpapillary carcinoma
p30813
sa(dp30814
g16449
I270
sg16450
I2
sg16451
I22
sg16459
VC0206687
p30815
sg16454
Vendometrioid carcinoma
p30816
sasa(dp30817
g16444
VIn vitro kallikrein 10 secretion was detected in all primary uterine serous papillary carcinoma cell lines tested (mean = 2.7 microg/L), and the secretion levels were not significantly different to those found in primary ovarian serous papillary tumor cultures (mean 4.2 microg/L).
p30818
sg16446
(lp30819
(dp30820
g16449
I9
sg16450
I2
sg16451
I13
sg16452
g11
sg16454
Vkallikrein 10
p30821
sasg16456
(lp30822
(dp30823
g16449
I76
sg16450
I2
sg16451
I19
sg16459
VC0007133
p30824
sg16454
Vpapillary carcinoma
p30825
sa(dp30826
g16449
I236
sg16450
I2
sg16451
I15
sg16459
VC0476073
p30827
sg16454
Vpapillary tumor
p30828
sasa(dp30829
g16444
VIn contrast, serum and plasma kallikrein 10 values in uterine serous papillary carcinoma patients (1.2 +/- 0.1) were significantly higher than those in the non-cancer group (P = .002), benign group (P = .002), and endometrioid carcinoma patients (P = .005).
p30830
sg16446
(lp30831
(dp30832
g16449
I23
sg16450
I2
sg16451
I17
sg16452
VP03952
p30833
sg16454
Vplasma kallikrein
p30834
sasg16456
(lp30835
(dp30836
g16449
I160
sg16450
I1
sg16451
I6
sg16459
VC0006826
p30837
sg16454
Vcancer
p30838
sa(dp30839
g16449
I69
sg16450
I2
sg16451
I19
sg16459
VC0007133
p30840
sg16454
Vpapillary carcinoma
p30841
sa(dp30842
g16449
I214
sg16450
I2
sg16451
I22
sg16459
VC0206687
p30843
sg16454
Vendometrioid carcinoma
p30844
sasa(dp30845
g16444
VKallikrein 10 is highly expressed in uterine serous papillary carcinoma, and it is released in the plasma and serum of uterine serous papillary carcinoma patients.
p30846
sg16446
(lp30847
(dp30848
g16449
I0
sg16450
I1
sg16451
I10
sg16452
VP06870
p30849
sg16454
VKallikrein
p30850
sasg16456
(lp30851
(dp30852
g16449
I52
sg16450
I2
sg16451
I19
sg16459
VC0007133
p30853
sg16454
Vpapillary carcinoma
p30854
sa(dp30855
g16449
I52
sg16450
I2
sg16451
I19
sg16459
VC0007133
p30856
sg16454
Vpapillary carcinoma
p30857
sasa(dp30858
g16444
VKallikrein 10 may represent a novel biomarker for uterine serous papillary carcinoma.
p30859
sg16446
(lp30860
(dp30861
g16449
I0
sg16450
I1
sg16451
I10
sg16452
VP06870
p30862
sg16454
VKallikrein
p30863
sasg16456
(lp30864
(dp30865
g16449
I65
sg16450
I2
sg16451
I19
sg16459
VC0007133
p30866
sg16454
Vpapillary carcinoma
p30867
sasa(dp30868
g16444
VThe present investigation was designed to clarify the role of the subcommissural organ (SCO) in the pathogenesis of hydrocephalus occurring in the HTx rat.
p30869
sg16446
(lp30870
sg16456
(lp30871
(dp30872
g16449
I116
sg16450
I1
sg16451
I13
sg16459
VC0020255
p30873
sg16454
Vhydrocephalus
p30874
sa(dp30875
g16449
I100
sg16450
I1
sg16451
I12
sg16459
VC0699748
p30876
sg16454
Vpathogenesis
p30877
sasa(dp30878
g16444
VAt the same time, it functions as a transcriptional regulator of particular genes and as a cytokine: HMGB-1 released from a defective cell has been reported to induce damage to the adjacent cells.With a view to examine the relationship between neuronal damage caused by hydrocephalus and HMGB-1, we analyzed the expression of HMGB-1 in the cerebellum, cerebrum, and hippocampus of 1-day-old congenitally hydrocephalic H-Tx rats.As opposed to nonhydrocephalic H-Tx rats, the hydrocephalic H-Tx rats were observed to show stronger expression of HMGB-1 in the cerebellum, cerebrum, and hippocampus.
p30879
sg16446
(lp30880
(dp30881
g16449
I101
sg16450
I1
sg16451
I6
sg16452
VP09429
p30882
sg16454
VHMGB-1
p30883
sa(dp30884
g16449
I101
sg16450
I1
sg16451
I6
sg16452
VP09429
p30885
sg16454
VHMGB-1
p30886
sa(dp30887
g16449
I101
sg16450
I1
sg16451
I6
sg16452
VP09429
p30888
sg16454
VHMGB-1
p30889
sa(dp30890
g16449
I101
sg16450
I1
sg16451
I6
sg16452
VP09429
p30891
sg16454
VHMGB-1
p30892
sasg16456
(lp30893
(dp30894
g16449
I270
sg16450
I1
sg16451
I13
sg16459
VC0020255
p30895
sg16454
Vhydrocephalus
p30896
sasa(dp30897
g16444
VAll studies utilized an animal model such as AQP4-knockout mice, H-Tx rats, and kaolin and L-Alfa-lysophosphatidylcholine (LPC) stearoyl injection models of hydrocephalus.
p30898
sg16446
(lp30899
(dp30900
g16449
I45
sg16450
I1
sg16451
I4
sg16452
VP55087
p30901
sg16454
VAQP4
p30902
sasg16456
(lp30903
(dp30904
g16449
I157
sg16450
I1
sg16451
I13
sg16459
VC0020255
p30905
sg16454
Vhydrocephalus
p30906
sasa(dp30907
g16444
VThe purpose of this study was to determine the efficacy of minocycline, an antibiotic known for its anti-inflammatory properties, to reduce gliosis in the H-Tx rat model of congenital hydrocephalus.
p30908
sg16446
(lp30909
sg16456
(lp30910
(dp30911
g16449
I173
sg16450
I2
sg16451
I24
sg16459
VC0020256
p30912
sg16454
Vcongenital hydrocephalus
p30913
sa(dp30914
g16449
I140
sg16450
I1
sg16451
I7
sg16459
VC0017639
p30915
sg16454
Vgliosis
p30916
sasa(dp30917
g16444
VIt has been well documented that up to 70% of H-Tx rats' offspring suffer from severe hydrocephalus, which can be fatal if it remains untreated.
p30918
sg16446
(lp30919
sg16456
(lp30920
(dp30921
g16449
I86
sg16450
I1
sg16451
I13
sg16459
VC0020255
p30922
sg16454
Vhydrocephalus
p30923
sa(dp30924
g16449
I67
sg16450
I1
sg16451
I6
sg16459
VC0683278
p30925
sg16454
Vsuffer
p30926
sasa(dp30927
g16444
VAside from the well-documented hydrocephalus, H-Tx rats may develop other intracranial malformations that have not yet been documented in the literature.
p30928
sg16446
(lp30929
sg16456
(lp30930
(dp30931
g16449
I31
sg16450
I1
sg16451
I13
sg16459
VC0020255
p30932
sg16454
Vhydrocephalus
p30933
sa(dp30934
g16449
I87
sg16450
I1
sg16451
I13
sg16459
VC0000768
p30935
sg16454
Vmalformations
p30936
sasa(dp30937
g16444
VWe investigated the effect of vascular endothelial growth factor (VEGF)-C on lymphangiogenesis, inflammation, and fibrosis in the mouse kidney using the unilateral ureteral obstruction (UUO) model.
p30938
sg16446
(lp30939
(dp30940
g16449
I30
sg16450
I4
sg16451
I34
sg16452
g11
sg16454
Vvascular endothelial growth factor
p30941
sa(dp30942
g16449
I66
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VVEGF
p30943
sasg16456
(lp30944
(dp30945
g16449
I164
sg16450
I2
sg16451
I20
sg16459
VC0041956
p30946
sg16454
Vureteral obstruction
p30947
sa(dp30948
g16449
I114
sg16450
I1
sg16451
I8
sg16459
VC0016059
p30949
sg16454
Vfibrosis
p30950
sa(dp30951
g16449
I96
sg16450
I1
sg16451
I12
sg16459
VC0021368
p30952
sg16454
Vinflammation
p30953
sa(dp30954
g16449
I186
sg16450
I1
sg16451
I3
sg16459
VC0041956
p30955
sg16454
VUUO
p30956
sasa(dp30957
g16444
VRenal fibrosis was consequently attenuated in the UUO+VEGF-C group.
p30958
sg16446
(lp30959
(dp30960
g16449
I50
sg16450
I1
sg16451
I10
sg16452
VP49767
p30961
sg16454
VUUO+VEGF-C
p30962
sasg16456
(lp30963
(dp30964
g16449
I0
sg16450
I2
sg16451
I14
sg16459
VC0151650
p30965
sg16454
VRenal fibrosis
p30966
sasa(dp30967
g16444
VEnhancement of the VEGF-C signaling pathway in LECs may be a therapeutic strategy for renal fibrosis.Laboratory Investigation advance online publication, 30 October 2017; doi:10.1038/labinvest.2017.77.
p30968
sg16446
(lp30969
(dp30970
g16449
I19
sg16450
I1
sg16451
I6
sg16452
VP49767
p30971
sg16454
VVEGF-C
p30972
sasg16456
(lp30973
(dp30974
g16449
I86
sg16450
I2
sg16451
I14
sg16459
VC0151650
p30975
sg16454
Vrenal fibrosis
p30976
sasa(dp30977
g16444
VHowever, the relevance of urinary and circulating VEGF-A165b levels in chronic kidney disease patients remains unclear.
p30978
sg16446
(lp30979
sg16456
(lp30980
(dp30981
g16449
I71
sg16450
I3
sg16451
I22
sg16459
VC1561643
p30982
sg16454
Vchronic kidney disease
p30983
sasa(dp30984
g16444
VTherefore, the present study aimed to investigate the urinary and circulating VEGF-A165b levels in patients with chronic kidney disease.
p30985
sg16446
(lp30986
sg16456
(lp30987
(dp30988
g16449
I113
sg16450
I3
sg16451
I22
sg16459
VC1561643
p30989
sg16454
Vchronic kidney disease
p30990
sasa(dp30991
g16444
VA low urinary VEGF-A165b level reflects renal dysfunction in the chronic kidney disease stage, while a high circulating VEGF-A165b level cannot be attributed to decreased renal clearance.
p30992
sg16446
(lp30993
sg16456
(lp30994
(dp30995
g16449
I65
sg16450
I3
sg16451
I22
sg16459
VC1561643
p30996
sg16454
Vchronic kidney disease
p30997
sasa(dp30998
g16444
VBy using a novel, advanced, multicolor fluorescence in situ hybridization approach, we enumerated copy numbers of six genes previously identified by array comparative genomic hybridization to be involved in aggressive prostate cancer [TBL1XR1, CTTNBP2, MYC (alias c-myc), PTEN, MEN1, and PDGFB] in six nonrecurrent and seven recurrent radical prostatectomy cases.
p30999
sg16446
(lp31000
(dp31001
g16449
I264
sg16450
I1
sg16451
I5
sg16452
VP12524
p31002
sg16454
Vc-myc
p31003
sa(dp31004
g16449
I253
sg16450
I1
sg16451
I3
sg16452
VP12524
p31005
sg16454
VMYC
p31006
sa(dp31007
g16449
I244
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VCTTNBP2
p31008
sa(dp31009
g16449
I235
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VTBL1XR1
p31010
sa(dp31011
g16449
I272
sg16450
I1
sg16451
I4
sg16452
VP60484
p31012
sg16454
VPTEN
p31013
sa(dp31014
g16449
I278
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VMEN1
p31015
sasg16456
(lp31016
(dp31017
g16449
I278
sg16450
I1
sg16451
I4
sg16459
VC0025267
p31018
sg16454
VMEN1
p31019
sa(dp31020
g16449
I218
sg16450
I2
sg16451
I15
sg16459
VC0600139
p31021
sg16454
Vprostate cancer
p31022
sa(dp31023
g16449
I207
sg16450
I1
sg16451
I10
sg16459
VC0001807
p31024
sg16454
Vaggressive
p31025
sasa(dp31026
g16444
VThe identification of higher NIHSS scores, higher HAMD scores, lower dopamine level, lower 5-hydroxytryptamine level, higher tumor necrosis factor-Alfa level, and lower nerve growth factor level might be useful for clinicians in recognizing and treating depression in patients after a stroke.
p31027
sg16446
(lp31028
(dp31029
g16449
I125
sg16450
I3
sg16451
I26
sg16452
VP01375
p31030
sg16454
Vtumor necrosis factor-Alfa
p31031
sa(dp31032
g16449
I169
sg16450
I3
sg16451
I19
sg16452
VP01138
p31033
sg16454
Vnerve growth factor
p31034
sasg16456
(lp31035
(dp31036
g16449
I254
sg16450
I1
sg16451
I10
sg16459
VC0011581
p31037
sg16454
Vdepression
p31038
sa(dp31039
g16449
I125
sg16450
I2
sg16451
I14
sg16459
VC0333516
p31040
sg16454
Vtumor necrosis
p31041
sa(dp31042
g16449
I285
sg16450
I1
sg16451
I6
sg16459
VC0038454
p31043
sg16454
Vstroke
p31044
sasa(dp31045
g16444
VOther effects include a reduction in the platelet levels of adenosine triphosphate (ATP), serotonin (5-hydroxytryptamine), platelet factor 3 (PF3), PF4 and Beta-thromboglobulin (BTG), decreased platelet adhesiveness in platelets from healthy volunteers and from atherosclerotic patients and an improvement in red blood cell deformability in patients with occlusive vascular disease.
p31046
sg16446
(lp31047
(dp31048
g16449
I148
sg16450
I1
sg16451
I3
sg16452
VP02776
p31049
sg16454
VPF4
p31050
sa(dp31051
g16449
I178
sg16450
I1
sg16451
I3
sg16452
VP02775
p31052
sg16454
VBTG
p31053
sa(dp31054
g16449
I123
sg16450
I3
sg16451
I17
sg16452
VP14770
p31055
sg16454
Vplatelet factor 3
p31056
sa(dp31057
g16449
I142
sg16450
I1
sg16451
I3
sg16452
VP14770
p31058
sg16454
VPF3
p31059
sa(dp31060
g16449
I156
sg16450
I1
sg16451
I20
sg16452
VP02775
p31061
sg16454
VBeta-thromboglobulin
p31062
sasg16456
(lp31063
(dp31064
g16449
I355
sg16450
I3
sg16451
I26
sg16459
VC0750145
p31065
sg16454
Vocclusive vascular disease
p31066
sasa(dp31067
g16444
VObjective: To explore the effect of trimetazidine pre-treatments on serum 5-hydroxytryptamine (5-HT) and serotonin transporter (SERT), platelet 5-HT and SERT in the Sprague Dawley rats with myocardial infarction(MI), depression, and myocardial infarction co-exist with depression (MI+ depression) and in sham operated rats.
p31068
sg16446
(lp31069
(dp31070
g16449
I128
sg16450
I1
sg16451
I4
sg16452
VP31645
p31071
sg16454
VSERT
p31072
sa(dp31073
g16449
I105
sg16450
I2
sg16451
I21
sg16452
VP31645
p31074
sg16454
Vserotonin transporter
p31075
sa(dp31076
g16449
I128
sg16450
I1
sg16451
I4
sg16452
VP31645
p31077
sg16454
VSERT
p31078
sasg16456
(lp31079
(dp31080
g16449
I217
sg16450
I1
sg16451
I10
sg16459
VC0011581
p31081
sg16454
Vdepression
p31082
sa(dp31083
g16449
I217
sg16450
I1
sg16451
I10
sg16459
VC0011581
p31084
sg16454
Vdepression
p31085
sa(dp31086
g16449
I217
sg16450
I1
sg16451
I10
sg16459
VC0011581
p31087
sg16454
Vdepression
p31088
sa(dp31089
g16449
I190
sg16450
I2
sg16451
I21
sg16459
VC0027051
p31090
sg16454
Vmyocardial infarction
p31091
sa(dp31092
g16449
I190
sg16450
I2
sg16451
I21
sg16459
VC0027051
p31093
sg16454
Vmyocardial infarction
p31094
sasa(dp31095
g16444
VThe role of histone deacetylase-3 (HDAC3) in allergic skin inflammation was reported.
p31096
sg16446
(lp31097
(dp31098
g16449
I35
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VHDAC3
p31099
sa(dp31100
g16449
I12
sg16450
I2
sg16451
I21
sg16452
VP56524
p31101
sg16454
Vhistone deacetylase-3
p31102
sasg16456
(lp31103
(dp31104
g16449
I54
sg16450
I2
sg16451
I17
sg16459
VC0011603
p31105
sg16454
Vskin inflammation
p31106
sasa(dp31107
g16444
VIn this study, we investigated SERPINA3 expression in glioma tissue samples and its significance in predicting the prognosis of glioma patients.
p31108
sg16446
(lp31109
sg16456
(lp31110
(dp31111
g16449
I54
sg16450
I1
sg16451
I6
sg16459
VC0017638
p31112
sg16454
Vglioma
p31113
sa(dp31114
g16449
I54
sg16450
I1
sg16451
I6
sg16459
VC0017638
p31115
sg16454
Vglioma
p31116
sasa(dp31117
g16444
VWe found that SERPINA3 was upregulated in glioma tissue at both mRNA and protein levels, compared with noncancerous brain tissues.
p31118
sg16446
(lp31119
sg16456
(lp31120
(dp31121
g16449
I42
sg16450
I1
sg16451
I6
sg16459
VC0017638
p31122
sg16454
Vglioma
p31123
sasa(dp31124
g16444
VWe also found that high SERPINA3 expression in glioma tissues correlated significantly with advanced World Health Organization grade.
p31125
sg16446
(lp31126
sg16456
(lp31127
(dp31128
g16449
I47
sg16450
I1
sg16451
I6
sg16459
VC0017638
p31129
sg16454
Vglioma
p31130
sasa(dp31131
g16444
VUnivariate and multivariate analyses revealed that high SERPINA3 expression was an independent prognostic factor for poor overall survival of glioma patients.
p31132
sg16446
(lp31133
sg16456
(lp31134
(dp31135
g16449
I142
sg16450
I1
sg16451
I6
sg16459
VC0017638
p31136
sg16454
Vglioma
p31137
sasa(dp31138
g16444
VTaken together, our results suggest that SERPINA3 plays an oncogenic role in glioma progression and provide an insight into the application of SERPINA3 as a novel predictor of clinical outcomes and a potential biomarker of glioma.
p31139
sg16446
(lp31140
sg16456
(lp31141
(dp31142
g16449
I77
sg16450
I1
sg16451
I6
sg16459
VC0017638
p31143
sg16454
Vglioma
p31144
sa(dp31145
g16449
I77
sg16450
I1
sg16451
I6
sg16459
VC0017638
p31146
sg16454
Vglioma
p31147
sasa(dp31148
g16444
VTo investigate the expression and prognostic value of Alfa1-ACT (Alpha1-antichymotrypsin) in patients with HCC (hepatocellular carcinoma) and identify the mechanism by which Alfa1-ACT inhibits proliferation and promotes apoptosis of HCC.
p31149
sg16446
(lp31150
(dp31151
g16449
I54
sg16450
I1
sg16451
I9
sg16452
VP63267
p31152
sg16454
VAlfa1-ACT
p31153
sa(dp31154
g16449
I54
sg16450
I1
sg16451
I9
sg16452
VP63267
p31155
sg16454
VAlfa1-ACT
p31156
sa(dp31157
g16449
I72
sg16450
I1
sg16451
I16
sg16452
VP05154
p31158
sg16454
Vantichymotrypsin
p31159
sasg16456
(lp31160
(dp31161
g16449
I112
sg16450
I2
sg16451
I24
sg16459
VC2239176
p31162
sg16454
Vhepatocellular carcinoma
p31163
sa(dp31164
g16449
I107
sg16450
I1
sg16451
I3
sg16459
VC2239176
p31165
sg16454
VHCC
p31166
sa(dp31167
g16449
I193
sg16450
I1
sg16451
I13
sg16459
VC0334094
p31168
sg16454
Vproliferation
p31169
sa(dp31170
g16449
I107
sg16450
I1
sg16451
I3
sg16459
VC2239176
p31171
sg16454
VHCC
p31172
sasa(dp31173
g16444
VDeletions were found in LEC1 (9.5% versus 14.3%), LEC2 (4.8% versus 14.3%), cagT (33.3% versus 28.6%), cagE (28.6% versus 28.6%) and the promoter region of the cagA (19.0% versus 42.9%) of gastritis and PUD strains, respectively.
p31174
sg16446
(lp31175
(dp31176
g16449
I103
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VcagE
p31177
sa(dp31178
g16449
I50
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VLEC2
p31179
sa(dp31180
g16449
I24
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VLEC1
p31181
sa(dp31182
g16449
I160
sg16450
I1
sg16451
I4
sg16452
VP05109
p31183
sg16454
VcagA
p31184
sasg16456
(lp31185
(dp31186
g16449
I203
sg16450
I1
sg16451
I3
sg16459
VC0030920
p31187
sg16454
VPUD
p31188
sa(dp31189
g16449
I189
sg16450
I1
sg16451
I9
sg16459
VC0017152
p31190
sg16454
Vgastritis
p31191
sasa(dp31192
g16444
VIn the seven women, increased FDG uptake was due to physiological endometrial uptake (n=2), leiomyoma (n=1), corpus luteum cyst (n=1), physiological ovarian uptake (n=1), urinary leak (n=1), and nonspecific colitis (n=1).
p31193
sg16446
(lp31194
sg16456
(lp31195
(dp31196
g16449
I207
sg16450
I1
sg16451
I7
sg16459
VC0009319
p31197
sg16454
Vcolitis
p31198
sa(dp31199
g16449
I92
sg16450
I1
sg16451
I9
sg16459
VC0023267
p31200
sg16454
Vleiomyoma
p31201
sa(dp31202
g16449
I109
sg16450
I3
sg16451
I18
sg16459
VC0010093
p31203
sg16454
Vcorpus luteum cyst
p31204
sasa(dp31205
g16444
VThe most significant quantitative trait locus, Hsm1 (hereditary spherocytosis modifier 1), localizes to mouse Chromosome 12 and is dominant.
p31206
sg16446
(lp31207
(dp31208
g16449
I53
sg16450
I4
sg16451
I35
sg16452
g11
sg16454
Vhereditary spherocytosis modifier 1
p31209
sa(dp31210
g16449
I47
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VHsm1
p31211
sasg16456
(lp31212
(dp31213
g16449
I53
sg16450
I2
sg16451
I24
sg16459
VC0037889
p31214
sg16454
Vhereditary spherocytosis
p31215
sasa(dp31216
g16444
VRates of noninfective synovitis and effusion ranged from 0.2% in the LARS ACL group to 27.6% in the Gore-Tex ACL group.
p31217
sg16446
(lp31218
sg16456
(lp31219
(dp31220
g16449
I22
sg16450
I1
sg16451
I9
sg16459
VC0039103
p31221
sg16454
Vsynovitis
p31222
sa(dp31223
g16449
I36
sg16450
I1
sg16451
I8
sg16459
VC0013687
p31224
sg16454
Veffusion
p31225
sasa(dp31226
g16444
VPreliminary results for newer-generation devices, specifically the LARS, show lower reported rates of failure, revision, and sterile effusion/synovitis when compared with older devices.
p31227
sg16446
(lp31228
sg16456
(lp31229
(dp31230
g16449
I142
sg16450
I1
sg16451
I9
sg16459
VC0039103
p31231
sg16454
Vsynovitis
p31232
sa(dp31233
g16449
I133
sg16450
I1
sg16451
I8
sg16459
VC0013687
p31234
sg16454
Veffusion
p31235
sa(dp31236
g16449
I125
sg16450
I1
sg16451
I7
sg16459
VC0678108
p31237
sg16454
Vsterile
p31238
sasa(dp31239
g16444
VThe Ligament Augmentation and Reconstruction System (LARS) is a third generation of synthetic ligament, designed to overcome the issues of graft failure and synovitis which led previous generations of synthetic ligaments to fall out of favour.
p31240
sg16446
(lp31241
sg16456
(lp31242
(dp31243
g16449
I139
sg16450
I2
sg16451
I13
sg16459
VC1262018
p31244
sg16454
Vgraft failure
p31245
sa(dp31246
g16449
I157
sg16450
I1
sg16451
I9
sg16459
VC0039103
p31247
sg16454
Vsynovitis
p31248
sasa(dp31249
g16444
VUsher syndrome type III (USH3), characterized by progressive deafness, variable balance disorder and blindness, is caused by destabilizing mutations in the gene encoding the clarin-1 (CLRN1) protein.
p31250
sg16446
(lp31251
(dp31252
g16449
I25
sg16450
I1
sg16451
I4
sg16452
VP58418
p31253
sg16454
VUSH3
p31254
sa(dp31255
g16449
I184
sg16450
I1
sg16451
I5
sg16452
VP58418
p31256
sg16454
VCLRN1
p31257
sa(dp31258
g16449
I174
sg16450
I1
sg16451
I8
sg16452
VP58418
p31259
sg16454
Vclarin-1
p31260
sasg16456
(lp31261
(dp31262
g16449
I25
sg16450
I1
sg16451
I4
sg16459
VC1568248
p31263
sg16454
VUSH3
p31264
sa(dp31265
g16449
I61
sg16450
I1
sg16451
I8
sg16459
VC0011053
p31266
sg16454
Vdeafness
p31267
sa(dp31268
g16449
I101
sg16450
I1
sg16451
I9
sg16459
VC0456909
p31269
sg16454
Vblindness
p31270
sa(dp31271
g16449
I0
sg16450
I2
sg16451
I14
sg16459
VC0271097
p31272
sg16454
VUsher syndrome
p31273
sa(dp31274
g16449
I80
sg16450
I2
sg16451
I16
sg16459
VC0575090
p31275
sg16454
Vbalance disorder
p31276
sasa(dp31277
g16444
VMutations in the CLRN1 gene cause Usher syndrome type 3 (USH3), a human disease characterized by progressive blindness and deafness.
p31278
sg16446
(lp31279
(dp31280
g16449
I57
sg16450
I1
sg16451
I4
sg16452
VP58418
p31281
sg16454
VUSH3
p31282
sa(dp31283
g16449
I17
sg16450
I2
sg16451
I10
sg16452
VP58418
p31284
sg16454
VCLRN1 gene
p31285
sa(dp31286
g16449
I34
sg16450
I4
sg16451
I21
sg16452
VP58418
p31287
sg16454
VUsher syndrome type 3
p31288
sasg16456
(lp31289
(dp31290
g16449
I109
sg16450
I1
sg16451
I9
sg16459
VC0456909
p31291
sg16454
Vblindness
p31292
sa(dp31293
g16449
I34
sg16450
I4
sg16451
I21
sg16459
VC1568248
p31294
sg16454
VUsher syndrome type 3
p31295
sa(dp31296
g16449
I57
sg16450
I1
sg16451
I4
sg16459
VC1568248
p31297
sg16454
VUSH3
p31298
sa(dp31299
g16449
I123
sg16450
I1
sg16451
I8
sg16459
VC0011053
p31300
sg16454
Vdeafness
p31301
sasa(dp31302
g16444
VTaken together, CD47 might be a novel target to enhance anti-PD-1 and CLTA-4 efficacy in esophageal squamous cell cancer.
p31303
sg16446
(lp31304
(dp31305
g16449
I16
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCD47
p31306
sa(dp31307
g16449
I70
sg16450
I1
sg16451
I6
sg16452
VP09496
p31308
sg16454
VCLTA-4
p31309
sa(dp31310
g16449
I56
sg16450
I1
sg16451
I9
sg16452
VP18621
p31311
sg16454
Vanti-PD-1
p31312
sasg16456
(lp31313
(dp31314
g16449
I100
sg16450
I3
sg16451
I20
sg16459
VC0007137
p31315
sg16454
Vsquamous cell cancer
p31316
sasa(dp31317
g16444
VIpilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma.
p31318
sg16446
(lp31319
(dp31320
g16449
I24
sg16450
I2
sg16451
I15
sg16452
VP09496
p31321
sg16454
VCLTA-4 antibody
p31322
sasg16456
(lp31323
(dp31324
g16449
I91
sg16450
I1
sg16451
I8
sg16459
VC0025202
p31325
sg16454
Vmelanoma
p31326
sasa(dp31327
g16444
VThe most prominent example of this shift is the management of metastatic melanoma, where BRAF and MEK inhibition and CLTA-4 blockade have established an entirely new standard of care in the last 3 years.
p31328
sg16446
(lp31329
(dp31330
g16449
I89
sg16450
I1
sg16451
I4
sg16452
VP15056
p31331
sg16454
VBRAF
p31332
sa(dp31333
g16449
I117
sg16450
I1
sg16451
I6
sg16452
VP09496
p31334
sg16454
VCLTA-4
p31335
sa(dp31336
g16449
I98
sg16450
I1
sg16451
I3
sg16452
VP45985
p31337
sg16454
VMEK
p31338
sasg16456
(lp31339
(dp31340
g16449
I62
sg16450
I2
sg16451
I19
sg16459
VC0278883
p31341
sg16454
Vmetastatic melanoma
p31342
sasa(dp31343
g16444
VThis was associated with the decreased protein expression of Notch1, Notch2, Notch3 and Hey1, and the increased expression of the tumor suppressor microRNA (miR or miRNA)-200 family members (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) that are typically downregulated in colon cancer.
p31344
sg16446
(lp31345
(dp31346
g16449
I211
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VmiR-200c
p31347
sa(dp31348
g16449
I88
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VHey1
p31349
sa(dp31350
g16449
I233
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VmiR-429
p31351
sa(dp31352
g16449
I221
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VmiR-141
p31353
sa(dp31354
g16449
I201
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VmiR-200b
p31355
sa(dp31356
g16449
I77
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VNotch3
p31357
sa(dp31358
g16449
I61
sg16450
I1
sg16451
I6
sg16452
VP46531
p31359
sg16454
VNotch1
p31360
sa(dp31361
g16449
I191
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VmiR-200a
p31362
sa(dp31363
g16449
I69
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VNotch2
p31364
sasg16456
(lp31365
(dp31366
g16449
I130
sg16450
I1
sg16451
I5
sg16459
VC0027651
p31367
sg16454
Vtumor
p31368
sa(dp31369
g16449
I278
sg16450
I2
sg16451
I12
sg16459
VC0699790
p31370
sg16454
Vcolon cancer
p31371
sasa(dp31372
g16444
VPhosphorylated IGF-IR/IR (P-IGF-IR/IR) and its downstream signaling partner phospho-S6 (P-S6) were evaluated immunohistochemically in tumor tissue microarrays representing 438 cases of invasive breast cancer.
p31373
sg16446
(lp31374
(dp31375
g16449
I15
sg16450
I1
sg16451
I6
sg16452
VP06213
p31376
sg16454
VIGF-IR
p31377
sa(dp31378
g16449
I19
sg16450
I1
sg16451
I2
sg16452
VP06213
p31379
sg16454
VIR
p31380
sa(dp31381
g16449
I26
sg16450
I1
sg16451
I8
sg16452
VP06213
p31382
sg16454
VP-IGF-IR
p31383
sa(dp31384
g16449
I19
sg16450
I1
sg16451
I2
sg16452
VP06213
p31385
sg16454
VIR
p31386
sasg16456
(lp31387
(dp31388
g16449
I185
sg16450
I3
sg16451
I22
sg16459
VC0853879
p31389
sg16454
Vinvasive breast cancer
p31390
sa(dp31391
g16449
I134
sg16450
I1
sg16451
I5
sg16459
VC0027651
p31392
sg16454
Vtumor
p31393
sasa(dp31394
g16444
VImportantly, P-IGF-IR/IR was detected in all breast cancer subtypes (luminal, 48.1%; triple negative, 41.9%; and HER2, 64.3%).
p31395
sg16446
(lp31396
(dp31397
g16449
I13
sg16450
I1
sg16451
I8
sg16452
VP06213
p31398
sg16454
VP-IGF-IR
p31399
sa(dp31400
g16449
I19
sg16450
I1
sg16451
I2
sg16452
VP06213
p31401
sg16454
VIR
p31402
sasg16456
(lp31403
(dp31404
g16449
I45
sg16450
I2
sg16451
I13
sg16459
VC0678222
p31405
sg16454
Vbreast cancer
p31406
sasa(dp31407
g16444
VThus, we can determine which patients have the activated receptor and provide evidence that P-IGF-IR/IR is a prognostic factor for breast cancer.
p31408
sg16446
(lp31409
(dp31410
g16449
I92
sg16450
I1
sg16451
I8
sg16452
VP06213
p31411
sg16454
VP-IGF-IR
p31412
sa(dp31413
g16449
I98
sg16450
I1
sg16451
I2
sg16452
VP06213
p31414
sg16454
VIR
p31415
sasg16456
(lp31416
(dp31417
g16449
I131
sg16450
I2
sg16451
I13
sg16459
VC0678222
p31418
sg16454
Vbreast cancer
p31419
sasa(dp31420
g16444
VBeyond this, P-IGF-IR/IR could be a predictive marker for response to IGF-IR and/or IR-targeted therapies, as these inhibitors may be of benefit in all breast cancer subtypes including those with acquired resistance to tamoxifen.
p31421
sg16446
(lp31422
(dp31423
g16449
I13
sg16450
I1
sg16451
I8
sg16452
VP06213
p31424
sg16454
VP-IGF-IR
p31425
sa(dp31426
g16449
I15
sg16450
I1
sg16451
I6
sg16452
VP06213
p31427
sg16454
VIGF-IR
p31428
sa(dp31429
g16449
I19
sg16450
I1
sg16451
I2
sg16452
VP06213
p31430
sg16454
VIR
p31431
sasg16456
(lp31432
(dp31433
g16449
I152
sg16450
I2
sg16451
I13
sg16459
VC0678222
p31434
sg16454
Vbreast cancer
p31435
sasa(dp31436
g16444
VThe genes plo, fimA, fimC, fimE, fimG, nanH, nanP, and cbpA were investigated in 71 T. pyogenes strains recovered from cattle, sheep, goats, dogs, equines, and a pig, recovered from mastitis (n = 35), and non-mastitis (n = 36) cases (abscesses, reproductive tract diseases, pneumonia, lymphadenitis, encephalitis).
p31437
sg16446
(lp31438
(dp31439
g16449
I39
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VnanH
p31440
sa(dp31441
g16449
I45
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VnanP
p31442
sasg16456
(lp31443
(dp31444
g16449
I182
sg16450
I1
sg16451
I8
sg16459
VC3251795
p31445
sg16454
Vmastitis
p31446
sa(dp31447
g16449
I285
sg16450
I1
sg16451
I13
sg16459
VC0024205
p31448
sg16454
Vlymphadenitis
p31449
sa(dp31450
g16449
I27
sg16450
I1
sg16451
I4
sg16459
VC0917800
p31451
sg16454
VfimE
p31452
sa(dp31453
g16449
I274
sg16450
I1
sg16451
I9
sg16459
VC0032285
p31454
sg16454
Vpneumonia
p31455
sa(dp31456
g16449
I234
sg16450
I1
sg16451
I9
sg16459
VC0000833
p31457
sg16454
Vabscesses
p31458
sa(dp31459
g16449
I182
sg16450
I1
sg16451
I8
sg16459
VC3251795
p31460
sg16454
Vmastitis
p31461
sa(dp31462
g16449
I300
sg16450
I1
sg16451
I12
sg16459
VC0014038
p31463
sg16454
Vencephalitis
p31464
sasa(dp31465
g16444
VThe aim was to assess the prevalence of anaemia among quranic schoolchildren in khalawi Wad EL Magboul village, rural Rufaa, Gezira State, central Sudan.
p31466
sg16446
(lp31467
sg16456
(lp31468
(dp31469
g16449
I40
sg16450
I1
sg16451
I7
sg16459
VC0002871
p31470
sg16454
Vanaemia
p31471
sasa(dp31472
g16444
VThrombophilia was present in 294/482 (60.9%) patients: 189/350 LC (54.0%), 31/47 (66.0%) HCC, 29/39 (74.4%) MPN, 35/38 AD (92.1%), and 10/10 (100%) WAD, and 54/150 (36.0%) in HC.
p31473
sg16446
(lp31474
sg16456
(lp31475
(dp31476
g16449
I0
sg16450
I1
sg16451
I13
sg16459
VC2827470
p31477
sg16454
VThrombophilia
p31478
sa(dp31479
g16449
I89
sg16450
I1
sg16451
I3
sg16459
VC2239176
p31480
sg16454
VHCC
p31481
sasa(dp31482
g16444
VA cross-sectional study was conducted to investigate the prevalence of anaemia, iron, zinc and copper deficiencies among pregnant women in Wad Medani hospital, central Sudan and to examine the relationship of these micronutrients with haemoglobin (Hb) levels.
p31483
sg16446
(lp31484
(dp31485
g16449
I235
sg16450
I1
sg16451
I11
sg16452
g11
sg16454
Vhaemoglobin
p31486
sa(dp31487
g16449
I248
sg16450
I1
sg16451
I2
sg16452
g11
sg16454
VHb
p31488
sasg16456
(lp31489
(dp31490
g16449
I71
sg16450
I1
sg16451
I7
sg16459
VC0002871
p31491
sg16454
Vanaemia
p31492
sasa(dp31493
g16444
VIn the orbivirinae this would result in 2 genera of cyanovirus (bluetongue, epizootic hemorrhagic disease, Eubenangee and Palyam sub-genera) and Kemerovovirus (Chenunda, Great Island, Kemerovo and Wad Medani sub-genera) and a number of ungrouped sub-genera (African horsesickness, Changuinola, Corriparta, equine encephalosis, Wallal and Warrego sub-genera and the remaining ungrouped viruses).
p31494
sg16446
(lp31495
sg16456
(lp31496
(dp31497
g16449
I86
sg16450
I2
sg16451
I19
sg16459
VC0019087
p31498
sg16454
Vhemorrhagic disease
p31499
sa(dp31500
g16449
I258
sg16450
I2
sg16451
I21
sg16459
VC0001748
p31501
sg16454
VAfrican horsesickness
p31502
sa(dp31503
g16449
I64
sg16450
I1
sg16451
I10
sg16459
VC0005866
p31504
sg16454
Vbluetongue
p31505
sasa(dp31506
g16444
VWe examined the expression of CT-1, leukemia inhibitory factor (LIF), and gp130 by competitive RT-PCR and Western blotting in Dahl salt-sensitive (DS) rats with a high-salt diet, which showed a distinct transition from left ventricular hypertrophy (LVH) to congestive heart failure (CHF).
p31507
sg16446
(lp31508
(dp31509
g16449
I36
sg16450
I3
sg16451
I26
sg16452
VP15018
p31510
sg16454
Vleukemia inhibitory factor
p31511
sa(dp31512
g16449
I64
sg16450
I1
sg16451
I3
sg16452
VP15018
p31513
sg16454
VLIF
p31514
sa(dp31515
g16449
I74
sg16450
I1
sg16451
I5
sg16452
VP40189
p31516
sg16454
Vgp130
p31517
sa(dp31518
g16449
I30
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCT-1
p31519
sasg16456
(lp31520
(dp31521
g16449
I249
sg16450
I1
sg16451
I3
sg16459
VC0149721
p31522
sg16454
VLVH
p31523
sa(dp31524
g16449
I36
sg16450
I1
sg16451
I8
sg16459
VC0023418
p31525
sg16454
Vleukemia
p31526
sa(dp31527
g16449
I257
sg16450
I3
sg16451
I24
sg16459
VC0018802
p31528
sg16454
Vcongestive heart failure
p31529
sa(dp31530
g16449
I203
sg16450
I1
sg16451
I10
sg16459
VC0599156
p31531
sg16454
Vtransition
p31532
sa(dp31533
g16449
I219
sg16450
I3
sg16451
I28
sg16459
VC0149721
p31534
sg16454
Vleft ventricular hypertrophy
p31535
sa(dp31536
g16449
I283
sg16450
I1
sg16451
I3
sg16459
VC0018802
p31537
sg16454
VCHF
p31538
sasa(dp31539
g16444
VNew factors signaling independently of the leukemia inhibitory-factor receptor pathway may sustain cardiomyocyte cell proliferation and thus be a future target for gene therapy of cardiomyopathies and cell therapy of the myocardium.
p31540
sg16446
(lp31541
(dp31542
g16449
I43
sg16450
I3
sg16451
I35
sg16452
g11
sg16454
Vleukemia inhibitory-factor receptor
p31543
sasg16456
(lp31544
(dp31545
g16449
I118
sg16450
I1
sg16451
I13
sg16459
VC0334094
p31546
sg16454
Vproliferation
p31547
sa(dp31548
g16449
I180
sg16450
I1
sg16451
I16
sg16459
VC0878544
p31549
sg16454
Vcardiomyopathies
p31550
sa(dp31551
g16449
I43
sg16450
I1
sg16451
I8
sg16459
VC0023418
p31552
sg16454
Vleukemia
p31553
sasa(dp31554
g16444
VWe propose a model in which P-Rex1 acts as a crucial node for the integration of upstream inputs from HER/ErbB receptors and CXCR4 in luminal breast cancer cells.
p31555
sg16446
(lp31556
(dp31557
g16449
I125
sg16450
I1
sg16451
I5
sg16452
VP61073
p31558
sg16454
VCXCR4
p31559
sa(dp31560
g16449
I28
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VP-Rex1
p31561
sa(dp31562
g16449
I106
sg16450
I2
sg16451
I14
sg16452
g11
sg16454
VErbB receptors
p31563
sasg16456
(lp31564
(dp31565
g16449
I142
sg16450
I2
sg16451
I13
sg16459
VC0678222
p31566
sg16454
Vbreast cancer
p31567
sasa(dp31568
g16444
VNotably, there is a significant association in the expression of P-Rex1 and MMP10 in human luminal breast cancer, and their co-expression is indicative of poor prognosis.
p31569
sg16446
(lp31570
(dp31571
g16449
I76
sg16450
I1
sg16451
I5
sg16452
VP09238
p31572
sg16454
VMMP10
p31573
sa(dp31574
g16449
I65
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VP-Rex1
p31575
sasg16456
(lp31576
(dp31577
g16449
I99
sg16450
I2
sg16451
I13
sg16459
VC0678222
p31578
sg16454
Vbreast cancer
p31579
sasa(dp31580
g16444
VTreatment of normal MCF-10A or basal-like cancer cells, MDA-MB-231 with the demethylating agent 5-aza-2'-deoxycitidine in combination with the histone deacetylase inhibitor trichostatin A restores P-REX1 levels to those observed in luminal breast cancer cell lines, suggesting that aberrant expression of P-REX1 in luminal breast cancer is a consequence of PREX1 promoter demethylation.
p31581
sg16446
(lp31582
(dp31583
g16449
I197
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VP-REX1
p31584
sa(dp31585
g16449
I197
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VP-REX1
p31586
sa(dp31587
g16449
I163
sg16450
I3
sg16451
I24
sg16452
VP32119
p31588
sg16454
Vinhibitor trichostatin A
p31589
sa(dp31590
g16449
I143
sg16450
I2
sg16451
I19
sg16452
VP56524
p31591
sg16454
Vhistone deacetylase
p31592
sasg16456
(lp31593
(dp31594
g16449
I240
sg16450
I2
sg16451
I13
sg16459
VC0678222
p31595
sg16454
Vbreast cancer
p31596
sa(dp31597
g16449
I42
sg16450
I1
sg16451
I6
sg16459
VC0006826
p31598
sg16454
Vcancer
p31599
sa(dp31600
g16449
I240
sg16450
I2
sg16451
I13
sg16459
VC0678222
p31601
sg16454
Vbreast cancer
p31602
sasa(dp31603
g16444
VWe identify 112 candidate ciliogenesis and ciliopathy genes, including 44 components of the ubiquitin-proteasome system, 12 G-protein-coupled receptors, and 3 pre-mRNA processing factors (PRPF6, PRPF8 and PRPF31) mutated in autosomal dominant retinitis pigmentosa.
p31604
sg16446
(lp31605
(dp31606
g16449
I195
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VPRPF8
p31607
sa(dp31608
g16449
I121
sg16450
I3
sg16451
I30
sg16452
g11
sg16454
V12 G-protein-coupled receptors
p31609
sa(dp31610
g16449
I205
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VPRPF31
p31611
sa(dp31612
g16449
I188
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VPRPF6
p31613
sa(dp31614
g16449
I92
sg16450
I1
sg16451
I9
sg16452
VP62979
p31615
sg16454
Vubiquitin
p31616
sasg16456
(lp31617
(dp31618
g16449
I224
sg16450
I4
sg16451
I39
sg16459
VC0339525
p31619
sg16454
Vautosomal dominant retinitis pigmentosa
p31620
sasa(dp31621
g16444
VMutations in six spliceosomal proteins, PRPF3, PRPF4, PRPF6, PRPF8, PRPF31 and SNRNP200, cause retinitis pigmentosa (RP), a disease characterized by progressive photoreceptor degeneration.
p31622
sg16446
(lp31623
(dp31624
g16449
I47
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VPRPF4
p31625
sa(dp31626
g16449
I68
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VPRPF31
p31627
sa(dp31628
g16449
I79
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VSNRNP200
p31629
sa(dp31630
g16449
I54
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VPRPF6
p31631
sa(dp31632
g16449
I61
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VPRPF8
p31633
sa(dp31634
g16449
I40
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VPRPF3
p31635
sasg16456
(lp31636
(dp31637
g16449
I41
sg16450
I1
sg16451
I2
sg16459
VC0035334
p31638
sg16454
VRP
p31639
sa(dp31640
g16449
I95
sg16450
I2
sg16451
I20
sg16459
VC0035334
p31641
sg16454
Vretinitis pigmentosa
p31642
sa(dp31643
g16449
I161
sg16450
I2
sg16451
I26
sg16459
VC1998028
p31644
sg16454
Vphotoreceptor degeneration
p31645
sasa(dp31646
g16444
VIn addition, a pAsn477Ser change in the neighboring gene PRPF6, a gene previously found to be associated with retinitis pigmentosa, segregated with the ADKD phenotype.
p31647
sg16446
(lp31648
(dp31649
g16449
I52
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
Vgene PRPF6
p31650
sasg16456
(lp31651
(dp31652
g16449
I110
sg16450
I2
sg16451
I20
sg16459
VC0035334
p31653
sg16454
Vretinitis pigmentosa
p31654
sasa(dp31655
g16444
VYeast two-hybrid analyses suggest a link between retinitis pigmentosa and an aberrant hPrp31-hPrp6 interaction that blocks U4/U6-U5 tri-snRNP formation.
p31656
sg16446
(lp31657
(dp31658
g16449
I93
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VhPrp6
p31659
sa(dp31660
g16449
I86
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VhPrp31
p31661
sasg16456
(lp31662
(dp31663
g16449
I49
sg16450
I2
sg16451
I20
sg16459
VC0035334
p31664
sg16454
Vretinitis pigmentosa
p31665
sasa(dp31666
g16444
VIn humans and in mice, mutations in the Ostm1 gene cause the most severe form of osteopetrosis, a major bone disease, and neuronal degeneration, both of which are associated with early death.
p31667
sg16446
(lp31668
(dp31669
g16449
I40
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VOstm1 gene
p31670
sasg16456
(lp31671
(dp31672
g16449
I81
sg16450
I1
sg16451
I13
sg16459
VC0029454
p31673
sg16454
Vosteopetrosis
p31674
sa(dp31675
g16449
I131
sg16450
I1
sg16451
I12
sg16459
VC0011164
p31676
sg16454
Vdegeneration
p31677
sa(dp31678
g16449
I104
sg16450
I2
sg16451
I12
sg16459
VC0005940
p31679
sg16454
Vbone disease
p31680
sasa(dp31681
g16444
VGenetic defects in OSTM1 (osteopetrosis-associated transmembrane protein 1) cause autosomal recessive osteopetrosis in humans.
p31682
sg16446
(lp31683
sg16456
(lp31684
(dp31685
g16449
I26
sg16450
I1
sg16451
I13
sg16459
VC0029454
p31686
sg16454
Vosteopetrosis
p31687
sa(dp31688
g16449
I26
sg16450
I1
sg16451
I13
sg16459
VC0029454
p31689
sg16454
Vosteopetrosis
p31690
sasa(dp31691
g16444
VThus, these findings suggest that autosomal recessive osteopetrosis patients with an OSTM1 gene mutation lacking the transmembrane domain produce a secreted form of truncated OSTM1 that inhibits osteoclastogenesis.
p31692
sg16446
(lp31693
(dp31694
g16449
I85
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VOSTM1 gene
p31695
sasg16456
(lp31696
(dp31697
g16449
I54
sg16450
I1
sg16451
I13
sg16459
VC0029454
p31698
sg16454
Vosteopetrosis
p31699
sasa(dp31700
g16444
VLoss of the lysosomal ClC-7/Ostm1 2Cl(-)/H(+) exchanger causes lysosomal storage disease and osteopetrosis in humans and additionally changes fur colour in mice.
p31701
sg16446
(lp31702
(dp31703
g16449
I12
sg16450
I2
sg16451
I15
sg16452
VP51798
p31704
sg16454
Vlysosomal ClC-7
p31705
sa(dp31706
g16449
I28
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VOstm1
p31707
sasg16456
(lp31708
(dp31709
g16449
I63
sg16450
I3
sg16451
I25
sg16459
VC0085078
p31710
sg16454
Vlysosomal storage disease
p31711
sa(dp31712
g16449
I93
sg16450
I1
sg16451
I13
sg16459
VC0029454
p31713
sg16454
Vosteopetrosis
p31714
sasa(dp31715
g16444
VLoss of Ostm1 leads to the most severe form of osteopetrosis in mice and humans.
p31716
sg16446
(lp31717
(dp31718
g16449
I8
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VOstm1
p31719
sasg16456
(lp31720
(dp31721
g16449
I47
sg16450
I1
sg16451
I13
sg16459
VC0029454
p31722
sg16454
Vosteopetrosis
p31723
sasa(dp31724
g16444
VMice lacking either ClC-7 or Ostm1 develop a lysosomal storage disease and mutations in either protein have been found to underlie osteopetrosis in mice and humans.
p31725
sg16446
(lp31726
(dp31727
g16449
I20
sg16450
I1
sg16451
I5
sg16452
VP51798
p31728
sg16454
VClC-7
p31729
sa(dp31730
g16449
I29
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VOstm1
p31731
sasg16456
(lp31732
(dp31733
g16449
I45
sg16450
I3
sg16451
I25
sg16459
VC0085078
p31734
sg16454
Vlysosomal storage disease
p31735
sa(dp31736
g16449
I131
sg16450
I1
sg16451
I13
sg16459
VC0029454
p31737
sg16454
Vosteopetrosis
p31738
sasa(dp31739
g16444
VMice or humans lacking ClC-7 or Ostm1 display osteopetrosis and lysosomal storage disease.
p31740
sg16446
(lp31741
(dp31742
g16449
I32
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VOstm1
p31743
sa(dp31744
g16449
I23
sg16450
I1
sg16451
I5
sg16452
VP51798
p31745
sg16454
VClC-7
p31746
sasg16456
(lp31747
(dp31748
g16449
I64
sg16450
I3
sg16451
I25
sg16459
VC0085078
p31749
sg16454
Vlysosomal storage disease
p31750
sa(dp31751
g16449
I46
sg16450
I1
sg16451
I13
sg16459
VC0029454
p31752
sg16454
Vosteopetrosis
p31753
sasa(dp31754
g16444
VHere we describe for the first time homozygous microdeletions of different sizes affecting the OSTM1 gene in two unrelated consanguineous families with children suffering from neuronopathic infantile malignant osteopetrosis.
p31755
sg16446
(lp31756
(dp31757
g16449
I95
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VOSTM1 gene
p31758
sasg16456
(lp31759
(dp31760
g16449
I161
sg16450
I1
sg16451
I9
sg16459
VC0683278
p31761
sg16454
Vsuffering
p31762
sa(dp31763
g16449
I190
sg16450
I3
sg16451
I33
sg16459
VC1318518
p31764
sg16454
Vinfantile malignant osteopetrosis
p31765
sasa(dp31766
g16444
VOur findings are summarized as follows: i) BPY2 (testis basic protein on Y, 2), DAZ1 (deleted in azoospermia 1), TTY4 (testis transcript Y 4) mRNAs and 23 ESTs were found; ii) Eighteen of 23 ESTs were transcripts of the DAZ gene(s), one EST was a transcript of TTY4 gene, and the remaining 4 probably corresponded to 4 different pseudogenes; iii) DAZ gene(s) were expressed not only in testis, but also in lung carcinoma cells, stomach and Ewing's sarcoma cells; iv) beta-satellite clusters were present around and within the BPY2 and TTY4 gene region; v) In this study, TTY4, BPY2 and DAZ1 genes were mapped precisely to the AC010088 region.
p31767
sg16446
(lp31768
(dp31769
g16449
I80
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VDAZ1
p31770
sa(dp31771
g16449
I49
sg16450
I3
sg16451
I20
sg16452
VP15735
p31772
sg16454
Vtestis basic protein
p31773
sa(dp31774
g16449
I43
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VBPY2
p31775
sa(dp31776
g16449
I220
sg16450
I2
sg16451
I8
sg16452
g11
sg16454
VDAZ gene
p31777
sa(dp31778
g16449
I220
sg16450
I2
sg16451
I11
sg16452
g11
sg16454
VDAZ gene(s)
p31779
sa(dp31780
g16449
I43
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VBPY2
p31781
sa(dp31782
g16449
I586
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VDAZ1 genes
p31783
sa(dp31784
g16449
I43
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VBPY2
p31785
sa(dp31786
g16449
I86
sg16450
I4
sg16451
I24
sg16452
g11
sg16454
Vdeleted in azoospermia 1
p31787
sasg16456
(lp31788
(dp31789
g16449
I406
sg16450
I2
sg16451
I14
sg16459
VC0684249
p31790
sg16454
Vlung carcinoma
p31791
sa(dp31792
g16449
I440
sg16450
I2
sg16451
I15
sg16459
VC0553580
p31793
sg16454
VEwing's sarcoma
p31794
sa(dp31795
g16449
I97
sg16450
I1
sg16451
I11
sg16459
VC1321542
p31796
sg16454
Vazoospermia
p31797
sasa(dp31798
g16444
VLowered POMC and heightened TRPV3 expressions in the HN and mNTS are involved in development of hyperphagia and obesity in OP rats.
p31799
sg16446
(lp31800
(dp31801
g16449
I8
sg16450
I1
sg16451
I4
sg16452
VP01189
p31802
sg16454
VPOMC
p31803
sa(dp31804
g16449
I28
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTRPV3
p31805
sasg16456
(lp31806
(dp31807
g16449
I112
sg16450
I1
sg16451
I7
sg16459
VC0028754
p31808
sg16454
Vobesity
p31809
sa(dp31810
g16449
I96
sg16450
I1
sg16451
I11
sg16459
VC0020505
p31811
sg16454
Vhyperphagia
p31812
sasa(dp31813
g16444
VHere, we have shown that it is applicable to 10 human colorectal carcinoma cell lines with a direct correlation between viral toxicity and CPG2 production.
p31814
sg16446
(lp31815
sg16456
(lp31816
(dp31817
g16449
I54
sg16450
I2
sg16451
I20
sg16459
VC0009402
p31818
sg16454
Vcolorectal carcinoma
p31819
sasa(dp31820
g16444
VTen patients with colorectal carcinoma expressing carcinoembryonic antigen received antibody-directed enzyme prodrug therapy with A5B7 F(ab')2 antibody to carcinoembryonic antigen conjugated to carboxypeptidase G2 (CPG2).
p31821
sg16446
(lp31822
(dp31823
g16449
I194
sg16450
I2
sg16451
I19
sg16452
VP10619
p31824
sg16454
Vcarboxypeptidase G2
p31825
sa(dp31826
g16449
I50
sg16450
I2
sg16451
I24
sg16452
VP40198
p31827
sg16454
Vcarcinoembryonic antigen
p31828
sa(dp31829
g16449
I215
sg16450
I1
sg16451
I4
sg16452
VP10619
p31830
sg16454
VCPG2
p31831
sasg16456
(lp31832
(dp31833
g16449
I18
sg16450
I2
sg16451
I20
sg16459
VC0009402
p31834
sg16454
Vcolorectal carcinoma
p31835
sasa(dp31836
g16444
VHuman tumor cell lines A2780, SK-OV-3 (ovarian adenocarcinomas), LS174T, and WiDr (colon carcinomas) were engineered to express constitutively either CPG2 or bacterial beta-galactosidase.
p31837
sg16446
(lp31838
(dp31839
g16449
I158
sg16450
I2
sg16451
I28
sg16452
VP16278
p31840
sg16454
Vbacterial beta-galactosidase
p31841
sasg16456
(lp31842
(dp31843
g16449
I6
sg16450
I1
sg16451
I5
sg16459
VC0027651
p31844
sg16454
Vtumor
p31845
sa(dp31846
g16449
I47
sg16450
I1
sg16451
I15
sg16459
VC0001418
p31847
sg16454
Vadenocarcinomas
p31848
sa(dp31849
g16449
I52
sg16450
I1
sg16451
I10
sg16459
VC0007097
p31850
sg16454
Vcarcinomas
p31851
sasa(dp31852
g16444
VThey have been used to treat mouse models of connective tissue disease such as lumican-null (Lum) and mucopolysaccharidosis (Gusb) mice.
p31853
sg16446
(lp31854
(dp31855
g16449
I93
sg16450
I1
sg16451
I3
sg16452
VP51884
p31856
sg16454
VLum
p31857
sa(dp31858
g16449
I79
sg16450
I1
sg16451
I12
sg16452
VP51884
p31859
sg16454
Vlumican-null
p31860
sasg16456
(lp31861
(dp31862
g16449
I45
sg16450
I3
sg16451
I25
sg16459
VC0009782
p31863
sg16454
Vconnective tissue disease
p31864
sa(dp31865
g16449
I102
sg16450
I1
sg16451
I21
sg16459
VC0026703
p31866
sg16454
Vmucopolysaccharidosis
p31867
sasa(dp31868
g16444
VExpression of fibromodulin was significantly higher in plaques obtained from patients with diabetes and a high fibromodulin expression was associated with a higher incidence of post-operative cerebrovascular events, whereas no such associations were seen for lumican.
p31869
sg16446
(lp31870
(dp31871
g16449
I14
sg16450
I1
sg16451
I12
sg16452
g11
sg16454
Vfibromodulin
p31872
sa(dp31873
g16449
I259
sg16450
I1
sg16451
I7
sg16452
VP51884
p31874
sg16454
Vlumican
p31875
sa(dp31876
g16449
I14
sg16450
I1
sg16451
I12
sg16452
g11
sg16454
Vfibromodulin
p31877
sasg16456
(lp31878
(dp31879
g16449
I55
sg16450
I1
sg16451
I7
sg16459
VC0333463
p31880
sg16454
Vplaques
p31881
sa(dp31882
g16449
I91
sg16450
I1
sg16451
I8
sg16459
VC0011849
p31883
sg16454
Vdiabetes
p31884
sasa(dp31885
g16444
VThis study aimed to identify which myometrial ECM components are affected by diabetes, including fibril-forming collagen types I, III and V, as well as proteoglycans, decorin, lumican, fibromodulin and biglycan.
p31886
sg16446
(lp31887
(dp31888
g16449
I185
sg16450
I1
sg16451
I12
sg16452
g11
sg16454
Vfibromodulin
p31889
sa(dp31890
g16449
I176
sg16450
I1
sg16451
I7
sg16452
VP51884
p31891
sg16454
Vlumican
p31892
sa(dp31893
g16449
I35
sg16450
I3
sg16451
I25
sg16452
g11
sg16454
Vmyometrial ECM components
p31894
sa(dp31895
g16449
I167
sg16450
I1
sg16451
I7
sg16452
VP07585
p31896
sg16454
Vdecorin
p31897
sasg16456
(lp31898
(dp31899
g16449
I77
sg16450
I1
sg16451
I8
sg16459
VC0011849
p31900
sg16454
Vdiabetes
p31901
sasa(dp31902
g16444
VUsing the polymicrobial model of murine sepsis, we investigated the role of C5a receptors in septic lymphopenia.
p31903
sg16446
(lp31904
(dp31905
g16449
I76
sg16450
I2
sg16451
I13
sg16452
VP21730
p31906
sg16454
VC5a receptors
p31907
sasg16456
(lp31908
(dp31909
g16449
I40
sg16450
I1
sg16451
I6
sg16459
VC0243026
p31910
sg16454
Vsepsis
p31911
sa(dp31912
g16449
I100
sg16450
I1
sg16451
I11
sg16459
VC0024312
p31913
sg16454
Vlymphopenia
p31914
sasa(dp31915
g16444
VIn wild-type mice, cecal ligation and puncture resulted in splenocyte apoptosis and significant lymphopenia after 3 d, which was not observed in C5aR1(-/-) or C5aR2(-/-) mice.
p31916
sg16446
(lp31917
(dp31918
g16449
I145
sg16450
I1
sg16451
I5
sg16452
VP21730
p31919
sg16454
VC5aR1
p31920
sasg16456
(lp31921
(dp31922
g16449
I96
sg16450
I1
sg16451
I11
sg16459
VC0024312
p31923
sg16454
Vlymphopenia
p31924
sasa(dp31925
g16444
VNDT 9513727 effectively inhibited C5a-induced neutropenia in gerbil and cynomolgus macaque in vivo.
p31926
sg16446
(lp31927
(dp31928
g16449
I34
sg16450
I1
sg16451
I3
sg16452
VP21730
p31929
sg16454
VC5a
p31930
sasg16456
(lp31931
sa(dp31932
g16444
VNonetheless, topical application of C5aR antagonists produced circulating levels of the drugs that antagonized the LPS-induced systemic responses of neutropenia and hypotension.
p31933
sg16446
(lp31934
(dp31935
g16449
I36
sg16450
I1
sg16451
I4
sg16452
VP21730
p31936
sg16454
VC5aR
p31937
sasg16456
(lp31938
(dp31939
g16449
I115
sg16450
I1
sg16451
I3
sg16459
VC0175697
p31940
sg16454
VLPS
p31941
sasa(dp31942
g16444
VSeveral of these antigens (CD2, CD25, CD35, CD88, CD203c) appear to be upregulated on MCs in patients with systemic mastocytosis and therefore are used as diagnostic markers.
p31943
sg16446
(lp31944
(dp31945
g16449
I27
sg16450
I1
sg16451
I3
sg16452
VP06729
p31946
sg16454
VCD2
p31947
sa(dp31948
g16449
I50
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCD203c
p31949
sa(dp31950
g16449
I32
sg16450
I1
sg16451
I4
sg16452
VP01589
p31951
sg16454
VCD25
p31952
sa(dp31953
g16449
I44
sg16450
I1
sg16451
I4
sg16452
VP21730
p31954
sg16454
VCD88
p31955
sa(dp31956
g16449
I38
sg16450
I1
sg16451
I4
sg16452
VP11274
p31957
sg16454
VCD35
p31958
sasg16456
(lp31959
(dp31960
g16449
I86
sg16450
I1
sg16451
I3
sg16459
VC0036221
p31961
sg16454
VMCs
p31962
sa(dp31963
g16449
I107
sg16450
I2
sg16451
I21
sg16459
VC0221013
p31964
sg16454
Vsystemic mastocytosis
p31965
sasa(dp31966
g16444
VThis study analysed the expression of various complement-related cell surface antigens (CD11b/CR3, CD11c/CR4, CD35/CR1, CD55/DAF, CD59/MIRL, CD88/C5aR) on bone marrow mast cells (BMMC) in patients suffering from systemic mastocytosis (SM), other haematological diseases and non-haematological disorders (control groups).
p31967
sg16446
(lp31968
(dp31969
g16449
I125
sg16450
I1
sg16451
I3
sg16452
VP08174
p31970
sg16454
VDAF
p31971
sa(dp31972
g16449
I146
sg16450
I1
sg16451
I4
sg16452
VP21730
p31973
sg16454
VC5aR
p31974
sa(dp31975
g16449
I46
sg16450
I4
sg16451
I40
sg16452
g11
sg16454
Vcomplement-related cell surface antigens
p31976
sa(dp31977
g16449
I130
sg16450
I1
sg16451
I4
sg16452
VP13987
p31978
sg16454
VCD59
p31979
sa(dp31980
g16449
I115
sg16450
I1
sg16451
I3
sg16452
VP17927
p31981
sg16454
VCR1
p31982
sa(dp31983
g16449
I105
sg16450
I1
sg16451
I3
sg16452
VP20702
p31984
sg16454
VCR4
p31985
sa(dp31986
g16449
I88
sg16450
I1
sg16451
I5
sg16452
VP11215
p31987
sg16454
VCD11b
p31988
sa(dp31989
g16449
I110
sg16450
I1
sg16451
I4
sg16452
VP11274
p31990
sg16454
VCD35
p31991
sa(dp31992
g16449
I120
sg16450
I1
sg16451
I4
sg16452
VP08174
p31993
sg16454
VCD55
p31994
sa(dp31995
g16449
I94
sg16450
I1
sg16451
I3
sg16452
VP51864
p31996
sg16454
VCR3
p31997
sa(dp31998
g16449
I135
sg16450
I1
sg16451
I4
sg16452
VP13987
p31999
sg16454
VMIRL
p32000
sa(dp32001
g16449
I99
sg16450
I1
sg16451
I5
sg16452
VP20702
p32002
sg16454
VCD11c
p32003
sa(dp32004
g16449
I141
sg16450
I1
sg16451
I4
sg16452
VP21730
p32005
sg16454
VCD88
p32006
sasg16456
(lp32007
(dp32008
g16449
I278
sg16450
I2
sg16451
I24
sg16459
VC0018939
p32009
sg16454
Vhaematological disorders
p32010
sa(dp32011
g16449
I197
sg16450
I1
sg16451
I9
sg16459
VC0683278
p32012
sg16454
Vsuffering
p32013
sa(dp32014
g16449
I235
sg16450
I1
sg16451
I2
sg16459
VC0221013
p32015
sg16454
VSM
p32016
sa(dp32017
g16449
I212
sg16450
I2
sg16451
I21
sg16459
VC0221013
p32018
sg16454
Vsystemic mastocytosis
p32019
sasa(dp32020
g16444
VA cyclic peptide, Phe-[Orn-Pro-D-Cyclohexylalanine-Trp-Arg] (F-[OPdChaWR]), was recently shown in vitro to antagonise the binding of C5a to its receptor (CD88) on human polymorphonuclear leukocytes (PMNs) and in vivo to inhibit the neutropenia associated with septic shock induced by lipopolysaccharide (LPS) in rats.
p32021
sg16446
(lp32022
(dp32023
g16449
I154
sg16450
I1
sg16451
I4
sg16452
VP21730
p32024
sg16454
VCD88
p32025
sa(dp32026
g16449
I133
sg16450
I1
sg16451
I3
sg16452
VP21730
p32027
sg16454
VC5a
p32028
sasg16456
(lp32029
(dp32030
g16449
I260
sg16450
I2
sg16451
I12
sg16459
VC0036983
p32031
sg16454
Vseptic shock
p32032
sa(dp32033
g16449
I304
sg16450
I1
sg16451
I3
sg16459
VC0175697
p32034
sg16454
VLPS
p32035
sa(dp32036
g16449
I284
sg16450
I1
sg16451
I18
sg16459
VC0175697
p32037
sg16454
Vlipopolysaccharide
p32038
sasa(dp32039
g16444
VSome in vivo activities of two complement C5a agonist analogues have been evaluated by measuring changes in blood pressure and neutropenia in the rat and comparing the results with their receptor affinities in peritoneal macrophages and polymorphonuclear leucocytes (PMNs).
p32040
sg16446
(lp32041
(dp32042
g16449
I31
sg16450
I2
sg16451
I14
sg16452
g11
sg16454
Vcomplement C5a
p32043
sasg16456
(lp32044
sa(dp32045
g16444
VThe abnormal C5aR expression on eosinophils and neutrophils became normal after spontaneous resolution of symptoms and blood eosinophilia.
p32046
sg16446
(lp32047
(dp32048
g16449
I13
sg16450
I1
sg16451
I4
sg16452
VP21730
p32049
sg16454
VC5aR
p32050
sasg16456
(lp32051
(dp32052
g16449
I125
sg16450
I1
sg16451
I12
sg16459
VC0014457
p32053
sg16454
Veosinophilia
p32054
sasa(dp32055
g16444
VThe therapeutic potential of DPPSC was tested in a wound healing mouse model and in two genetic mouse models of muscular dystrophy (Scid/mdx and Sgcb-null Rag2-null Gammac-null).
p32056
sg16446
(lp32057
(dp32058
g16449
I145
sg16450
I3
sg16451
I31
sg16452
VP55895
p32059
sg16454
VSgcb-null Rag2-null Gammac-null
p32060
sasg16456
(lp32061
(dp32062
g16449
I112
sg16450
I2
sg16451
I18
sg16459
VC0026850
p32063
sg16454
Vmuscular dystrophy
p32064
sa(dp32065
g16449
I137
sg16450
I1
sg16451
I3
sg16459
VC1839839
p32066
sg16454
Vmdx
p32067
sa(dp32068
g16449
I132
sg16450
I1
sg16451
I4
sg16459
VC0085110
p32069
sg16454
VScid
p32070
sasa(dp32071
g16444
VMutations in the RAG1/RAG2 genes are associated with a broad spectrum of clinical phenotypes, ranging from severe combined immunodeficiency to various autoimmune diseases.
p32072
sg16446
(lp32073
(dp32074
g16449
I22
sg16450
I1
sg16451
I4
sg16452
VP55895
p32075
sg16454
VRAG2
p32076
sa(dp32077
g16449
I17
sg16450
I1
sg16451
I4
sg16452
VP15918
p32078
sg16454
VRAG1
p32079
sasg16456
(lp32080
(dp32081
g16449
I107
sg16450
I3
sg16451
I32
sg16459
VC0085110
p32082
sg16454
Vsevere combined immunodeficiency
p32083
sa(dp32084
g16449
I151
sg16450
I2
sg16451
I19
sg16459
VC0004364
p32085
sg16454
Vautoimmune diseases
p32086
sasa(dp32087
g16444
VIn this review, the molecular pathology of diseases caused by RAG1/RAG2 mutations, in particular Omenn syndrome, will be discussed.
p32088
sg16446
(lp32089
(dp32090
g16449
I62
sg16450
I1
sg16451
I4
sg16452
VP15918
p32091
sg16454
VRAG1
p32092
sa(dp32093
g16449
I67
sg16450
I1
sg16451
I4
sg16452
VP55895
p32094
sg16454
VRAG2
p32095
sasg16456
(lp32096
(dp32097
g16449
I30
sg16450
I1
sg16451
I9
sg16459
VC0677042
p32098
sg16454
Vpathology
p32099
sa(dp32100
g16449
I97
sg16450
I2
sg16451
I14
sg16459
VC1801959
p32101
sg16454
VOmenn syndrome
p32102
sasa(dp32103
g16444
VSevere combined immunodeficiency (SCID) is a potentially fatal primary immunodeficiency (PID) that is caused by mutations in genes such as IL2RG, JAK3, IL7RA, RAG1, RAG2, and ADA.
p32104
sg16446
(lp32105
(dp32106
g16449
I159
sg16450
I1
sg16451
I4
sg16452
VP15918
p32107
sg16454
VRAG1
p32108
sa(dp32109
g16449
I139
sg16450
I1
sg16451
I5
sg16452
VP31785
p32110
sg16454
VIL2RG
p32111
sa(dp32112
g16449
I175
sg16450
I1
sg16451
I3
sg16452
VP00813
p32113
sg16454
VADA
p32114
sa(dp32115
g16449
I165
sg16450
I1
sg16451
I4
sg16452
VP55895
p32116
sg16454
VRAG2
p32117
sa(dp32118
g16449
I146
sg16450
I1
sg16451
I4
sg16452
VP52333
p32119
sg16454
VJAK3
p32120
sasg16456
(lp32121
(dp32122
g16449
I34
sg16450
I1
sg16451
I4
sg16459
VC0085110
p32123
sg16454
VSCID
p32124
sa(dp32125
g16449
I63
sg16450
I2
sg16451
I24
sg16459
VC0398686
p32126
sg16454
Vprimary immunodeficiency
p32127
sa(dp32128
g16449
I0
sg16450
I3
sg16451
I32
sg16459
VC0085110
p32129
sg16454
VSevere combined immunodeficiency
p32130
sa(dp32131
g16449
I89
sg16450
I1
sg16451
I3
sg16459
VC0242172
p32132
sg16454
VPID
p32133
sasa(dp32134
g16444
VSevere combined immunodeficiency can be caused by loss-of-function mutations in genes involved in the DNA recombination machinery, such as recombination-activating gene 1 (RAG1), RAG2, or DNA cross-link repair 1C (DCLRE1C).
p32135
sg16446
(lp32136
(dp32137
g16449
I139
sg16450
I3
sg16451
I31
sg16452
VP15918
p32138
sg16454
Vrecombination-activating gene 1
p32139
sa(dp32140
g16449
I179
sg16450
I1
sg16451
I4
sg16452
VP55895
p32141
sg16454
VRAG2
p32142
sa(dp32143
g16449
I172
sg16450
I1
sg16451
I4
sg16452
VP15918
p32144
sg16454
VRAG1
p32145
sasg16456
(lp32146
(dp32147
g16449
I0
sg16450
I3
sg16451
I32
sg16459
VC0085110
p32148
sg16454
VSevere combined immunodeficiency
p32149
sasa(dp32150
g16444
VSeven of the 98 cases (7%) of carcinomas showed TLE-1 expression, including 1 each of prostate adenocarcinoma (ADCA), esophageal ADCA, basal cell carcinoma, adrenocortical carcinoma, endometrial ADCA, ovarian serous carcinoma, and small cell carcinoma.
p32151
sg16446
(lp32152
sg16456
(lp32153
(dp32154
g16449
I86
sg16450
I2
sg16451
I23
sg16459
VC0007112
p32155
sg16454
Vprostate adenocarcinoma
p32156
sa(dp32157
g16449
I231
sg16450
I3
sg16451
I20
sg16459
VC0262584
p32158
sg16454
Vsmall cell carcinoma
p32159
sa(dp32160
g16449
I111
sg16450
I1
sg16451
I4
sg16459
VC0007112
p32161
sg16454
VADCA
p32162
sa(dp32163
g16449
I111
sg16450
I1
sg16451
I4
sg16459
VC0007112
p32164
sg16454
VADCA
p32165
sa(dp32166
g16449
I48
sg16450
I1
sg16451
I3
sg16459
VC0014556
p32167
sg16454
VTLE
p32168
sa(dp32169
g16449
I146
sg16450
I2
sg16451
I25
sg16459
VC0206686
p32170
sg16454
Vcarcinoma, adrenocortical
p32171
sa(dp32172
g16449
I30
sg16450
I1
sg16451
I10
sg16459
VC0007097
p32173
sg16454
Vcarcinomas
p32174
sa(dp32175
g16449
I111
sg16450
I1
sg16451
I4
sg16459
VC0007112
p32176
sg16454
VADCA
p32177
sa(dp32178
g16449
I172
sg16450
I2
sg16451
I22
sg16459
VC0476089
p32179
sg16454
Vcarcinoma, endometrial
p32180
sa(dp32181
g16449
I201
sg16450
I3
sg16451
I24
sg16459
VC1335177
p32182
sg16454
Vovarian serous carcinoma
p32183
sasa(dp32184
g16444
VHere, we evaluated the effects of 15d-PGJ2 alone and in combination with the tyrosine kinas inhibitor (TKI) dasatinib in uterine sarcoma cell lines (MES-SA, MES-SA/DX5 and SKN).
p32185
sg16446
(lp32186
(dp32187
g16449
I149
sg16450
I1
sg16451
I6
sg16452
VP31947
p32188
sg16454
VMES-SA
p32189
sa(dp32190
g16449
I77
sg16450
I3
sg16451
I24
sg16452
VP14679
p32191
sg16454
Vtyrosine kinas inhibitor
p32192
sa(dp32193
g16449
I103
sg16450
I1
sg16451
I3
sg16452
VP14679
p32194
sg16454
VTKI
p32195
sa(dp32196
g16449
I172
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VSKN
p32197
sasg16456
(lp32198
(dp32199
g16449
I149
sg16450
I1
sg16451
I3
sg16459
VC0265215
p32200
sg16454
VMES
p32201
sa(dp32202
g16449
I121
sg16450
I2
sg16451
I15
sg16459
VC0338113
p32203
sg16454
Vuterine sarcoma
p32204
sa(dp32205
g16449
I149
sg16450
I1
sg16451
I3
sg16459
VC0265215
p32206
sg16454
VMES
p32207
sasa(dp32208
g16444
VPrevious studies have shown that N(1),N(12)-bis(all-trans-retinoyl)spermine (RASP), a retinoid analog, inhibits RNase P activity and angiogenesis in the chicken embryo chorioallantoic membrane, demonstrates anti-tumor activity on prostate cancer cells, and acts as anti-inflammatory agent, being more effective and less toxic than all-trans retinoic acid.
p32209
sg16446
(lp32210
(dp32211
g16449
I112
sg16450
I2
sg16451
I7
sg16452
VP07998
p32212
sg16454
VRNase P
p32213
sasg16456
(lp32214
(dp32215
g16449
I212
sg16450
I1
sg16451
I5
sg16459
VC0027651
p32216
sg16454
Vtumor
p32217
sa(dp32218
g16449
I230
sg16450
I2
sg16451
I15
sg16459
VC0600139
p32219
sg16454
Vprostate cancer
p32220
sasa(dp32221
g16444
VThese results suggest RASP, as a promising lead compound for the treatment of several dermatological disorders and certain cancer types, has apparently minimal toxic side-effects as revealed in this two-generation reproduction study in rats.
p32222
sg16446
(lp32223
(dp32224
g16449
I22
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VRASP
p32225
sasg16456
(lp32226
(dp32227
g16449
I86
sg16450
I2
sg16451
I24
sg16459
VC0037274
p32228
sg16454
Vdermatological disorders
p32229
sa(dp32230
g16449
I123
sg16450
I1
sg16451
I6
sg16459
VC0006826
p32231
sg16454
Vcancer
p32232
sasa(dp32233
g16444
VTo determine the functional significance of Hhat expression in breast cancer, we used a panel of breast cancer cell lines that included estrogen receptor (ER) positive, HER2 amplified, triple negative, and tamoxifen resistant cells.
p32234
sg16446
(lp32235
(dp32236
g16449
I155
sg16450
I1
sg16451
I2
sg16452
VP03372
p32237
sg16454
VER
p32238
sa(dp32239
g16449
I169
sg16450
I1
sg16451
I4
sg16452
VP04626
p32240
sg16454
VHER2
p32241
sa(dp32242
g16449
I136
sg16450
I2
sg16451
I17
sg16452
VP03372
p32243
sg16454
Vestrogen receptor
p32244
sasg16456
(lp32245
(dp32246
g16449
I63
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32247
sg16454
Vbreast cancer
p32248
sa(dp32249
g16449
I63
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32250
sg16454
Vbreast cancer
p32251
sasa(dp32252
g16444
VDepletion of Hhat decreased anchorage-dependent and anchorage-independent proliferation of ER positive, but not triple negative, breast cancer cells.
p32253
sg16446
(lp32254
sg16456
(lp32255
(dp32256
g16449
I129
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32257
sg16454
Vbreast cancer
p32258
sa(dp32259
g16449
I74
sg16450
I1
sg16451
I13
sg16459
VC0334094
p32260
sg16454
Vproliferation
p32261
sasa(dp32262
g16444
VThese data suggest that Hhat plays a critical role in ER positive, HER2 amplified, and hormone resistant breast cancer proliferation and highlights the potential promise of Hhat inhibitors for therapeutic benefit in breast cancer.
p32263
sg16446
(lp32264
(dp32265
g16449
I67
sg16450
I1
sg16451
I4
sg16452
VP04626
p32266
sg16454
VHER2
p32267
sasg16456
(lp32268
(dp32269
g16449
I105
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32270
sg16454
Vbreast cancer
p32271
sa(dp32272
g16449
I119
sg16450
I1
sg16451
I13
sg16459
VC0334094
p32273
sg16454
Vproliferation
p32274
sa(dp32275
g16449
I105
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32276
sg16454
Vbreast cancer
p32277
sasa(dp32278
g16444
VHedgehog acyltransferase (HHAT) is the enzyme in the endoplasmic reticulum that palmitoylates Hedgehog proteins, is a member of a small subfamily of membrane-bound O-acyltransferase proteins that acylate secreted proteins, and is an important drug target in cancer.
p32279
sg16446
(lp32280
(dp32281
g16449
I26
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VHHAT
p32282
sa(dp32283
g16449
I164
sg16450
I2
sg16451
I26
sg16452
VP02649
p32284
sg16454
VO-acyltransferase proteins
p32285
sa(dp32286
g16449
I0
sg16450
I2
sg16451
I24
sg16452
g11
sg16454
VHedgehog acyltransferase
p32287
sasg16456
(lp32288
(dp32289
g16449
I258
sg16450
I1
sg16451
I6
sg16459
VC0006826
p32290
sg16454
Vcancer
p32291
sasa(dp32292
g16444
VThe STARD3 gene belongs to the minimal amplicon in HER2-positive breast cancers and encodes a cholesterol-binding membrane protein.
p32293
sg16446
(lp32294
(dp32295
g16449
I51
sg16450
I1
sg16451
I4
sg16452
VP04626
p32296
sg16454
VHER2
p32297
sa(dp32298
g16449
I4
sg16450
I2
sg16451
I11
sg16452
g11
sg16454
VSTARD3 gene
p32299
sa(dp32300
g16449
I94
sg16450
I3
sg16451
I36
sg16452
VP63244
p32301
sg16454
Vcholesterol-binding membrane protein
p32302
sasg16456
(lp32303
(dp32304
g16449
I65
sg16450
I2
sg16451
I14
sg16459
VC0006142
p32305
sg16454
Vbreast cancers
p32306
sasa(dp32307
g16444
VTo study how elevated StAR-related lipid transfer protein 3 (StARD3) expression affects breast cancer cells, we generated MCF-7 cells stably overexpressing StARD3-green fluorescent protein.
p32308
sg16446
(lp32309
(dp32310
g16449
I156
sg16450
I3
sg16451
I32
sg16452
g11
sg16454
VStARD3-green fluorescent protein
p32311
sa(dp32312
g16449
I22
sg16450
I5
sg16451
I37
sg16452
g11
sg16454
VStAR-related lipid transfer protein 3
p32313
sa(dp32314
g16449
I61
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VStARD3
p32315
sasg16456
(lp32316
(dp32317
g16449
I88
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32318
sg16454
Vbreast cancer
p32319
sa(dp32320
g16449
I22
sg16450
I1
sg16451
I4
sg16459
VC2678045
p32321
sg16454
VStAR
p32322
sasa(dp32323
g16444
VIn two Finnish nationwide patient cohorts, approximately 10% (212/2220) breast cancers exhibited high StARD3 protein levels, which was strongly associated with HER2 amplification; several factors related to poor disease outcome and poor breast cancer-specific survival.
p32324
sg16446
(lp32325
(dp32326
g16449
I160
sg16450
I1
sg16451
I4
sg16452
VP04626
p32327
sg16454
VHER2
p32328
sa(dp32329
g16449
I102
sg16450
I2
sg16451
I14
sg16452
g11
sg16454
VStARD3 protein
p32330
sasg16456
(lp32331
(dp32332
g16449
I165
sg16450
I1
sg16451
I13
sg16459
VC1705759
p32333
sg16454
Vamplification
p32334
sa(dp32335
g16449
I72
sg16450
I2
sg16451
I14
sg16459
VC0006142
p32336
sg16454
Vbreast cancers
p32337
sa(dp32338
g16449
I72
sg16450
I2
sg16451
I13
sg16459
VC0006142
p32339
sg16454
Vbreast cancer
p32340
sasa(dp32341
g16444
VIn addition, high StARD3 levels in breast cancers were associated with elevated 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA levels and anti-Src-Tyr416 immunoreactivity.
p32342
sg16446
(lp32343
(dp32344
g16449
I80
sg16450
I4
sg16451
I52
sg16452
VP04035
p32345
sg16454
V3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA
p32346
sa(dp32347
g16449
I144
sg16450
I1
sg16451
I8
sg16452
VP12931
p32348
sg16454
Vanti-Src
p32349
sa(dp32350
g16449
I18
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VStARD3
p32351
sasg16456
(lp32352
(dp32353
g16449
I35
sg16450
I2
sg16451
I14
sg16459
VC0006142
p32354
sg16454
Vbreast cancers
p32355
sasa(dp32356
g16444
VThese results provide evidence that StARD3 overexpression results in increased cholesterol biosynthesis and Src kinase activity in breast cancer cells and suggest that elevated StARD3 expression may contribute to breast cancer aggressiveness by increasing membrane cholesterol and enhancing oncogenic signaling.
p32357
sg16446
(lp32358
(dp32359
g16449
I36
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VStARD3
p32360
sa(dp32361
g16449
I108
sg16450
I2
sg16451
I10
sg16452
VP12931
p32362
sg16454
VSrc kinase
p32363
sa(dp32364
g16449
I36
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VStARD3
p32365
sasg16456
(lp32366
(dp32367
g16449
I227
sg16450
I1
sg16451
I14
sg16459
VC0001807
p32368
sg16454
Vaggressiveness
p32369
sa(dp32370
g16449
I131
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32371
sg16454
Vbreast cancer
p32372
sa(dp32373
g16449
I131
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32374
sg16454
Vbreast cancer
p32375
sasa(dp32376
g16444
VIn addition it will discuss the clinical and biological implications of the amplification of ten other genes at this locus (MED1, STARD3, GRB7, THRA, RARA, IGFPB4, CCR7, KRT20, KRT19 and GAST) in breast cancer.
p32377
sg16446
(lp32378
(dp32379
g16449
I124
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VMED1
p32380
sa(dp32381
g16449
I138
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VGRB7
p32382
sa(dp32383
g16449
I144
sg16450
I1
sg16451
I4
sg16452
VP10827
p32384
sg16454
VTHRA
p32385
sa(dp32386
g16449
I187
sg16450
I1
sg16451
I4
sg16452
VP01350
p32387
sg16454
VGAST
p32388
sa(dp32389
g16449
I130
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VSTARD3
p32390
sa(dp32391
g16449
I164
sg16450
I1
sg16451
I4
sg16452
VP32248
p32392
sg16454
VCCR7
p32393
sa(dp32394
g16449
I150
sg16450
I1
sg16451
I4
sg16452
VP10276
p32395
sg16454
VRARA
p32396
sa(dp32397
g16449
I170
sg16450
I1
sg16451
I5
sg16452
VP35900
p32398
sg16454
VKRT20
p32399
sasg16456
(lp32400
(dp32401
g16449
I196
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32402
sg16454
Vbreast cancer
p32403
sa(dp32404
g16449
I76
sg16450
I1
sg16451
I13
sg16459
VC1705759
p32405
sg16454
Vamplification
p32406
sasa(dp32407
g16444
VUsing a quantitative polymerase chain reaction method and DNA extracted from frozen tumor specimens, 11 genes (MED1, STARD3, HER2, GRB7, THRA, RARA, TOP2A, IGFBP4, CCR7, KRT20, KRT19 and GAS), which are localized within Chr17q12-q21 and have a putative role in breast cancer development, were quantified.
p32408
sg16446
(lp32409
(dp32410
g16449
I156
sg16450
I1
sg16451
I6
sg16452
VP22692
p32411
sg16454
VIGFBP4
p32412
sa(dp32413
g16449
I131
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VGRB7
p32414
sa(dp32415
g16449
I111
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VMED1
p32416
sa(dp32417
g16449
I117
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VSTARD3
p32418
sa(dp32419
g16449
I170
sg16450
I1
sg16451
I5
sg16452
VP35900
p32420
sg16454
VKRT20
p32421
sa(dp32422
g16449
I149
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VTOP2A
p32423
sa(dp32424
g16449
I164
sg16450
I1
sg16451
I4
sg16452
VP32248
p32425
sg16454
VCCR7
p32426
sa(dp32427
g16449
I125
sg16450
I1
sg16451
I4
sg16452
VP04626
p32428
sg16454
VHER2
p32429
sa(dp32430
g16449
I137
sg16450
I1
sg16451
I4
sg16452
VP10827
p32431
sg16454
VTHRA
p32432
sa(dp32433
g16449
I187
sg16450
I1
sg16451
I3
sg16452
VP01350
p32434
sg16454
VGAS
p32435
sa(dp32436
g16449
I143
sg16450
I1
sg16451
I4
sg16452
VP10276
p32437
sg16454
VRARA
p32438
sasg16456
(lp32439
(dp32440
g16449
I261
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32441
sg16454
Vbreast cancer
p32442
sa(dp32443
g16449
I84
sg16450
I1
sg16451
I5
sg16459
VC0027651
p32444
sg16454
Vtumor
p32445
sasa(dp32446
g16444
VThe metastatic lymph node 64 (MLN64) gene was initially identified as highly expressed in the metastatic lymph node from breast cancer.
p32447
sg16446
(lp32448
(dp32449
g16449
I30
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VMLN64
p32450
sa(dp32451
g16449
I4
sg16450
I4
sg16451
I24
sg16452
g11
sg16454
Vmetastatic lymph node 64
p32452
sasg16456
(lp32453
(dp32454
g16449
I121
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32455
sg16454
Vbreast cancer
p32456
sasa(dp32457
g16444
VHowever, the role played by MLN64 in breast cancer remains unclear.
p32458
sg16446
(lp32459
(dp32460
g16449
I28
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VMLN64
p32461
sasg16456
(lp32462
(dp32463
g16449
I37
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32464
sg16454
Vbreast cancer
p32465
sasa(dp32466
g16444
VIn the present study, the expression of MLN64 was examined in a breast cancer cohort using quantitative real-time PCR and immunohistochemical staining.
p32467
sg16446
(lp32468
(dp32469
g16449
I40
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VMLN64
p32470
sasg16456
(lp32471
(dp32472
g16449
I64
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32473
sg16454
Vbreast cancer
p32474
sasa(dp32475
g16444
VA panel of breast cancer cell sublines was subsequently developed by knockdown of MLN64 expression.
p32476
sg16446
(lp32477
(dp32478
g16449
I82
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VMLN64
p32479
sasg16456
(lp32480
(dp32481
g16449
I11
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32482
sg16454
Vbreast cancer
p32483
sasa(dp32484
g16444
VIn conclusion, MLN64 is overexpressed in breast cancer, and its level correlates with poor prognosis and patient survival.
p32485
sg16446
(lp32486
(dp32487
g16449
I15
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VMLN64
p32488
sasg16456
(lp32489
(dp32490
g16449
I41
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32491
sg16454
Vbreast cancer
p32492
sasa(dp32493
g16444
VMLN64 contributes to the development and progression of breast cancer through the regulation of cell proliferation and adhesive capacity.
p32494
sg16446
(lp32495
(dp32496
g16449
I0
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VMLN64
p32497
sasg16456
(lp32498
(dp32499
g16449
I101
sg16450
I1
sg16451
I13
sg16459
VC0334094
p32500
sg16454
Vproliferation
p32501
sa(dp32502
g16449
I56
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32503
sg16454
Vbreast cancer
p32504
sasa(dp32505
g16444
VSTARD3 and RARA also hold clinical relevance, the former having been shown to function in steroidogenesis and therefore implicated in hormone-receptor-positive breast cancer.
p32506
sg16446
(lp32507
(dp32508
g16449
I0
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VSTARD3
p32509
sa(dp32510
g16449
I11
sg16450
I1
sg16451
I4
sg16452
VP10276
p32511
sg16454
VRARA
p32512
sasg16456
(lp32513
(dp32514
g16449
I160
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32515
sg16454
Vbreast cancer
p32516
sasa(dp32517
g16444
VWe used a genetic association study design to determine if common genetic variation (frequency&gt;or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk.
p32518
sg16446
(lp32519
(dp32520
g16449
I169
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCRK7
p32521
sa(dp32522
g16449
I175
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VNEUROD2
p32523
sa(dp32524
g16449
I207
sg16450
I1
sg16451
I4
sg16452
VP11086
p32525
sg16454
VPNMT
p32526
sa(dp32527
g16449
I226
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VC17ORF37
p32528
sa(dp32529
g16449
I184
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VPPP1R1B
p32530
sa(dp32531
g16449
I236
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VGRB7
p32532
sa(dp32533
g16449
I161
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VPPARBP
p32534
sa(dp32535
g16449
I213
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCAB2
p32536
sa(dp32537
g16449
I245
sg16450
I2
sg16451
I13
sg16452
g11
sg16454
VZNFN1A3 genes
p32538
sa(dp32539
g16449
I193
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VSTARD3
p32540
sa(dp32541
g16449
I136
sg16450
I1
sg16451
I5
sg16452
VP04626
p32542
sg16454
VERBB2
p32543
sa(dp32544
g16449
I136
sg16450
I1
sg16451
I5
sg16452
VP04626
p32545
sg16454
VERBB2
p32546
sa(dp32547
g16449
I201
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VTCAP
p32548
sasg16456
(lp32549
(dp32550
g16449
I280
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32551
sg16454
Vbreast cancer
p32552
sasa(dp32553
g16444
VThe applicability of salivary Beta -hexosaminidase (Beta-HEX A%, percentage of Beta-HEX A isoenzyme to total Beta-HEX) and Beta-HEX B% (Beta-HEX B/Beta-HEX) indexes was investigated as a possible marker of periodontitis.
p32554
sg16446
(lp32555
(dp32556
g16449
I21
sg16450
I3
sg16451
I29
sg16452
VP04745
p32557
sg16454
Vsalivary Beta -hexosaminidase
p32558
sa(dp32559
g16449
I52
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VBeta-HEX
p32560
sa(dp32561
g16449
I52
sg16450
I1
sg16451
I8
sg16452
g11
sg16454
VBeta-HEX
p32562
sa(dp32563
g16449
I123
sg16450
I2
sg16451
I11
sg16452
g11
sg16454
VBeta-HEX B%
p32564
sa(dp32565
g16449
I123
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VBeta-HEX B
p32566
sa(dp32567
g16449
I52
sg16450
I2
sg16451
I10
sg16452
g11
sg16454
VBeta-HEX A
p32568
sasg16456
(lp32569
(dp32570
g16449
I206
sg16450
I1
sg16451
I13
sg16459
VC0031099
p32571
sg16454
Vperiodontitis
p32572
sasa(dp32573
g16444
VSalivary Beta-HEX A% is a promising excellent marker for the diagnosis of periodontitis.
p32574
sg16446
(lp32575
sg16456
(lp32576
(dp32577
g16449
I74
sg16450
I1
sg16451
I13
sg16459
VC0031099
p32578
sg16454
Vperiodontitis
p32579
sasa(dp32580
g16444
VTo evaluate the prognostic impact of gene expression levels (ELs) of two tumor suppressor genes, sprouty 4 (SPRY4, located on 5q) and lysine methyltransferase 2C (KMT2C, located on 7q) in correlation with clinical characteristics and genetic abnormalities assessed at initial diagnosis in acute myeloid leukemia (AML).
p32581
sg16446
(lp32582
(dp32583
g16449
I163
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VKMT2C
p32584
sa(dp32585
g16449
I134
sg16450
I3
sg16451
I27
sg16452
g11
sg16454
Vlysine methyltransferase 2C
p32586
sa(dp32587
g16449
I97
sg16450
I2
sg16451
I9
sg16452
g11
sg16454
Vsprouty 4
p32588
sa(dp32589
g16449
I108
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSPRY4
p32590
sasg16456
(lp32591
(dp32592
g16449
I73
sg16450
I1
sg16451
I5
sg16459
VC0027651
p32593
sg16454
Vtumor
p32594
sa(dp32595
g16449
I313
sg16450
I1
sg16451
I3
sg16459
VC0023467
p32596
sg16454
VAML
p32597
sa(dp32598
g16449
I289
sg16450
I3
sg16451
I22
sg16459
VC0023467
p32599
sg16454
Vacute myeloid leukemia
p32600
sasa(dp32601
g16444
VAs a well-defined antagonist in FGFR2-induced RAS/ERK activation, ectopic expression of sprouty (SPRY) family was reported in several kinds of cancers except gastric cancer.
p32602
sg16446
(lp32603
(dp32604
g16449
I50
sg16450
I1
sg16451
I3
sg16452
VP29323
p32605
sg16454
VERK
p32606
sa(dp32607
g16449
I46
sg16450
I1
sg16451
I3
sg16452
VP01116
p32608
sg16454
VRAS
p32609
sasg16456
(lp32610
(dp32611
g16449
I143
sg16450
I1
sg16451
I7
sg16459
VC0006826
p32612
sg16454
Vcancers
p32613
sa(dp32614
g16449
I158
sg16450
I2
sg16451
I14
sg16459
VC0024623
p32615
sg16454
Vgastric cancer
p32616
sasa(dp32617
g16444
VSprouty proteins are modulators of mitogeninduced signal transduction processes and therefore can influence the process of cancerogenesis.
p32618
sg16446
(lp32619
sg16456
(lp32620
sa(dp32621
g16444
VThe encoded protein of Sprouty homolog 4 (SPRY4) is associated with various human cancers.
p32622
sg16446
(lp32623
(dp32624
g16449
I23
sg16450
I3
sg16451
I17
sg16452
g11
sg16454
VSprouty homolog 4
p32625
sa(dp32626
g16449
I42
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSPRY4
p32627
sasg16456
(lp32628
(dp32629
g16449
I82
sg16450
I1
sg16451
I7
sg16459
VC0006826
p32630
sg16454
Vcancers
p32631
sasa(dp32632
g16444
VWe show that these retained super-enhancers are essential for rhabdoid tumor survival, including some that are shared by all subtypes, such as SPRY1, and other lineage-specific super-enhancers, such as SOX2 in brain-derived rhabdoid tumors.
p32633
sg16446
(lp32634
(dp32635
g16449
I202
sg16450
I1
sg16451
I4
sg16452
VP48431
p32636
sg16454
VSOX2
p32637
sa(dp32638
g16449
I143
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSPRY1
p32639
sasg16456
(lp32640
(dp32641
g16449
I224
sg16450
I2
sg16451
I15
sg16459
VC0206743
p32642
sg16454
Vrhabdoid tumors
p32643
sa(dp32644
g16449
I62
sg16450
I2
sg16451
I14
sg16459
VC0206743
p32645
sg16454
Vrhabdoid tumor
p32646
sasa(dp32647
g16444
VAs a member of the Sprouty family, Sprouty4 has been previously shown to function as a tumour suppressor in lung and breast cancer.
p32648
sg16446
(lp32649
sg16456
(lp32650
(dp32651
g16449
I117
sg16450
I2
sg16451
I13
sg16459
VC0678222
p32652
sg16454
Vbreast cancer
p32653
sa(dp32654
g16449
I87
sg16450
I1
sg16451
I6
sg16459
VC0027651
p32655
sg16454
Vtumour
p32656
sasa(dp32657
g16444
VIn this issue of Blood, Dietrich et al make the first observation of the presence of deleterious CDKN1B mutation in 16% of patients with hairy cell leukemia (HCL).
p32658
sg16446
(lp32659
(dp32660
g16449
I97
sg16450
I2
sg16451
I15
sg16452
VP46527
p32661
sg16454
VCDKN1B mutation
p32662
sasg16456
(lp32663
(dp32664
g16449
I137
sg16450
I3
sg16451
I19
sg16459
VC0023443
p32665
sg16454
Vhairy cell leukemia
p32666
sa(dp32667
g16449
I158
sg16450
I1
sg16451
I3
sg16459
VC0023443
p32668
sg16454
VHCL
p32669
sasa(dp32670
g16444
VWe previously found that global CypD knockout mice (KO) are protected from diet-induced glucose intolerance; however, the tissue-specific function of CypD and mPTP, particularly in the control of glucose homeostasis, has not been ascertained.
p32671
sg16446
(lp32672
(dp32673
g16449
I32
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCypD
p32674
sasg16456
(lp32675
(dp32676
g16449
I88
sg16450
I2
sg16451
I19
sg16459
VC0271650
p32677
sg16454
Vglucose intolerance
p32678
sasa(dp32679
g16444
VMice lacking CypD were protected from high fat diet-induced glucose intolerance due to increased glucose uptake in skeletal muscle.
p32680
sg16446
(lp32681
(dp32682
g16449
I13
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCypD
p32683
sasg16456
(lp32684
(dp32685
g16449
I60
sg16450
I2
sg16451
I19
sg16459
VC0271650
p32686
sg16454
Vglucose intolerance
p32687
sasa(dp32688
g16444
VAdult CypD(-/-) developed hyperglycemia, insulin resistance and glucose intolerance albeit resistant to DIO.
p32689
sg16446
(lp32690
(dp32691
g16449
I6
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VCypD
p32692
sa(dp32693
g16449
I41
sg16450
I1
sg16451
I7
sg16452
VP01308
p32694
sg16454
Vinsulin
p32695
sasg16456
(lp32696
(dp32697
g16449
I64
sg16450
I2
sg16451
I19
sg16459
VC0271650
p32698
sg16454
Vglucose intolerance
p32699
sa(dp32700
g16449
I26
sg16450
I1
sg16451
I13
sg16459
VC0020456
p32701
sg16454
Vhyperglycemia
p32702
sa(dp32703
g16449
I41
sg16450
I2
sg16451
I18
sg16459
VC0021655
p32704
sg16454
Vinsulin resistance
p32705
sasa(dp32706
g16444
Vvon Willebrand factor (VWF) is an independent risk factor for adverse events in patients with non-valvular atrial fibrillation (NVAF).
p32707
sg16446
(lp32708
(dp32709
g16449
I23
sg16450
I1
sg16451
I3
sg16452
VP04275
p32710
sg16454
VVWF
p32711
sa(dp32712
g16449
I0
sg16450
I3
sg16451
I21
sg16452
VP04275
p32713
sg16454
Vvon Willebrand factor
p32714
sasg16456
(lp32715
(dp32716
g16449
I107
sg16450
I2
sg16451
I19
sg16459
VC0004238
p32717
sg16454
Vatrial fibrillation
p32718
sasa(dp32719
g16444
VHigher VWF level correlated with higher CHADS2 scores and with progressing intensity of blood stasis in the left atrium and thrombus formation in all three time periods of atrial fibrillation duration.
p32720
sg16446
(lp32721
sg16456
(lp32722
(dp32723
g16449
I172
sg16450
I2
sg16451
I19
sg16459
VC0004238
p32724
sg16454
Vatrial fibrillation
p32725
sa(dp32726
g16449
I94
sg16450
I1
sg16451
I6
sg16459
VC0333138
p32727
sg16454
Vstasis
p32728
sa(dp32729
g16449
I124
sg16450
I1
sg16451
I8
sg16459
VC0302148
p32730
sg16454
Vthrombus
p32731
sasa(dp32732
g16444
VPatients with atrial fibrillation (AF) exhibit higher plasma vWF and lower ADAMTS13 levels.
p32733
sg16446
(lp32734
(dp32735
g16449
I61
sg16450
I1
sg16451
I3
sg16452
VP04275
p32736
sg16454
VvWF
p32737
sasg16456
(lp32738
(dp32739
g16449
I35
sg16450
I1
sg16451
I2
sg16459
VC0004238
p32740
sg16454
VAF
p32741
sa(dp32742
g16449
I14
sg16450
I2
sg16451
I19
sg16459
VC0004238
p32743
sg16454
Vatrial fibrillation
p32744
sasa(dp32745
g16444
VIn a multicenter case-control association study, we studied the SNPs rs11136000 (clusterin, CLU), rs541458 (phosphatidylinositol binding clatrin assembly protein, PICALM), and rs1554948 (transcription factor A, and tyrosine kinase, non-receptor, 1, TNK1) according to the three age groups 50-65 years (group 1), 66-80 years (group 2), and 80+ years (group 3) in 569 older subjects without cognitive impairment (NoCI) and 520 Alzheimer's disease (AD) patients.
p32746
sg16446
(lp32747
(dp32748
g16449
I215
sg16450
I2
sg16451
I15
sg16452
VP29401
p32749
sg16454
Vtyrosine kinase
p32750
sa(dp32751
g16449
I108
sg16450
I3
sg16451
I36
sg16452
VP63244
p32752
sg16454
Vphosphatidylinositol binding clatrin
p32753
sa(dp32754
g16449
I232
sg16450
I2
sg16451
I15
sg16452
g11
sg16454
Vnon-receptor, 1
p32755
sa(dp32756
g16449
I249
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VTNK1
p32757
sasg16456
(lp32758
(dp32759
g16449
I446
sg16450
I1
sg16451
I2
sg16459
VC1521724
p32760
sg16454
VAD
p32761
sa(dp32762
g16449
I389
sg16450
I2
sg16451
I20
sg16459
VC0338656
p32763
sg16454
Vcognitive impairment
p32764
sa(dp32765
g16449
I425
sg16450
I2
sg16451
I19
sg16459
VC1521724
p32766
sg16454
VAlzheimer's disease
p32767
sasa(dp32768
g16444
VTo study the association of apolipoprotein E (APOE), Clusterin (CLU) and phosphatidylinositol binding clathrin assembly protein (PICALM) polymorphisms in Alzheimer's disease (AD) subjects compared to cognitively normal control subjects in an Indian population.
p32769
sg16446
(lp32770
(dp32771
g16449
I64
sg16450
I1
sg16451
I3
sg16452
VP10909
p32772
sg16454
VCLU
p32773
sa(dp32774
g16449
I46
sg16450
I1
sg16451
I4
sg16452
VP02649
p32775
sg16454
VAPOE
p32776
sa(dp32777
g16449
I28
sg16450
I2
sg16451
I16
sg16452
VP02649
p32778
sg16454
Vapolipoprotein E
p32779
sa(dp32780
g16449
I73
sg16450
I3
sg16451
I37
sg16452
VP63244
p32781
sg16454
Vphosphatidylinositol binding clathrin
p32782
sa(dp32783
g16449
I53
sg16450
I1
sg16451
I9
sg16452
VP10909
p32784
sg16454
VClusterin
p32785
sasg16456
(lp32786
(dp32787
g16449
I175
sg16450
I1
sg16451
I2
sg16459
VC1521724
p32788
sg16454
VAD
p32789
sa(dp32790
g16449
I154
sg16450
I2
sg16451
I19
sg16459
VC1521724
p32791
sg16454
VAlzheimer's disease
p32792
sasa(dp32793
g16444
VGenome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB1, HLA-DRB4, INPP5D, MEF2C, MS4A4A, MS4A4E, MS4A6E, NME8, PICALM, PLD3, PTK2B, RIN3, SLC24A4, SORL1, and ZCWPW1 genes.
p32794
sg16446
(lp32795
(dp32796
g16449
I292
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VPICALM
p32797
sa(dp32798
g16449
I176
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCD2AP
p32799
sa(dp32800
g16449
I270
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VMS4A4E
p32801
sa(dp32802
g16449
I255
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VMEF2C
p32803
sa(dp32804
g16449
I227
sg16450
I1
sg16451
I3
sg16452
VP30486
p32805
sg16454
VHLA
p32806
sa(dp32807
g16449
I206
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VDSG2
p32808
sa(dp32809
g16449
I189
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCELF1
p32810
sa(dp32811
g16449
I157
sg16450
I1
sg16451
I4
sg16452
VP02649
p32812
sg16454
VAPOE
p32813
sa(dp32814
g16449
I150
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VABCA7
p32815
sa(dp32816
g16449
I313
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VRIN3
p32817
sa(dp32818
g16449
I328
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VSORL1
p32819
sa(dp32820
g16449
I319
sg16450
I1
sg16451
I7
sg16452
g11
sg16454
VSLC24A4
p32821
sa(dp32822
g16449
I247
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VINPP5D
p32823
sa(dp32824
g16449
I262
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VMS4A4A
p32825
sa(dp32826
g16449
I183
sg16450
I1
sg16451
I4
sg16452
VP20138
p32827
sg16454
VCD33
p32828
sa(dp32829
g16449
I300
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VPLD3
p32830
sa(dp32831
g16449
I219
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VFERMT2
p32832
sa(dp32833
g16449
I169
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VCASS4
p32834
sa(dp32835
g16449
I196
sg16450
I1
sg16451
I3
sg16452
VP10909
p32836
sg16454
VCLU
p32837
sa(dp32838
g16449
I306
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VPTK2B
p32839
sa(dp32840
g16449
I212
sg16450
I1
sg16451
I5
sg16452
VP21709
p32841
sg16454
VEPHA1
p32842
sa(dp32843
g16449
I278
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VMS4A6E
p32844
sa(dp32845
g16449
I227
sg16450
I1
sg16451
I3
sg16452
VP30486
p32846
sg16454
VHLA
p32847
sa(dp32848
g16449
I201
sg16450
I1
sg16451
I3
sg16452
VP17927
p32849
sg16454
VCR1
p32850
sa(dp32851
g16449
I339
sg16450
I2
sg16451
I12
sg16452
g11
sg16454
VZCWPW1 genes
p32852
sa(dp32853
g16449
I286
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VNME8
p32854
sa(dp32855
g16449
I231
sg16450
I1
sg16451
I4
sg16452
g11
sg16454
VDRB1
p32856
sasg16456
(lp32857
(dp32858
g16449
I95
sg16450
I2
sg16451
I20
sg16459
VC0002395
p32859
sg16454
VAlzheimer's diseases
p32860
sa(dp32861
g16449
I117
sg16450
I1
sg16451
I2
sg16459
VC0002395
p32862
sg16454
VAD
p32863
sasa(dp32864
g16444
VThe PICALM rs541458 T allele has been recognized as a risk factor for late-onset Alzheimer's disease, and age might modulate the effects that genetic factors have on cognitive functions and brain.
p32865
sg16446
(lp32866
(dp32867
g16449
I4
sg16450
I4
sg16451
I24
sg16452
g11
sg16454
VPICALM rs541458 T allele
p32868
sasg16456
(lp32869
(dp32870
g16449
I81
sg16450
I2
sg16451
I19
sg16459
VC1521724
p32871
sg16454
VAlzheimer's disease
p32872
sasa(dp32873
g16444
VThe association of variants in CLU, CR1, PICALM, BIN1, ABCA7, and CD33 genes with late-onset Alzheimer's disease (LOAD) was evaluated and confirmed through genome-wide association study.
p32874
sg16446
(lp32875
(dp32876
g16449
I31
sg16450
I1
sg16451
I3
sg16452
VP10909
p32877
sg16454
VCLU
p32878
sa(dp32879
g16449
I41
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VPICALM
p32880
sa(dp32881
g16449
I55
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VABCA7
p32882
sa(dp32883
g16449
I66
sg16450
I2
sg16451
I10
sg16452
VP20138
p32884
sg16454
VCD33 genes
p32885
sa(dp32886
g16449
I36
sg16450
I1
sg16451
I3
sg16452
VP17927
p32887
sg16454
VCR1
p32888
sasg16456
(lp32889
(dp32890
g16449
I93
sg16450
I2
sg16451
I19
sg16459
VC1521724
p32891
sg16454
VAlzheimer's disease
p32892
sasa(dp32893
g16444
VIn vivo, depletion of GDF-15 in Ras-driven tumor xenografts and in an orthotopic model of pancreatic cancer delayed tumor development.
p32894
sg16446
(lp32895
(dp32896
g16449
I22
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VGDF-15
p32897
sa(dp32898
g16449
I32
sg16450
I1
sg16451
I3
sg16452
VP01116
p32899
sg16454
VRas
p32900
sasg16456
(lp32901
(dp32902
g16449
I43
sg16450
I1
sg16451
I5
sg16459
VC0027651
p32903
sg16454
Vtumor
p32904
sa(dp32905
g16449
I90
sg16450
I2
sg16451
I17
sg16459
VC0235974
p32906
sg16454
Vpancreatic cancer
p32907
sa(dp32908
g16449
I43
sg16450
I1
sg16451
I5
sg16459
VC0027651
p32909
sg16454
Vtumor
p32910
sasa(dp32911
g16444
VFurther, production of GDF-15 is directly regulated by NF-KB, and the colocalization of activated NF-KB and GDF-15 in epithelial ducts of human pancreatic adenocarcinoma supports the importance of this observation.
p32912
sg16446
(lp32913
(dp32914
g16449
I23
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VGDF-15
p32915
sa(dp32916
g16449
I23
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VGDF-15
p32917
sasg16456
(lp32918
(dp32919
g16449
I144
sg16450
I2
sg16451
I25
sg16459
VC0281361
p32920
sg16454
Vpancreatic adenocarcinoma
p32921
sasa(dp32922
g16444
VThe present study investigated the association between cancer-associated weight loss and plasma GDF-15 concentration, as well as other biomarkers, in patients with metastatic lung or exocrine pancreatic cancer.
p32923
sg16446
(lp32924
(dp32925
g16449
I89
sg16450
I2
sg16451
I13
sg16452
g11
sg16454
Vplasma GDF-15
p32926
sasg16456
(lp32927
(dp32928
g16449
I183
sg16450
I3
sg16451
I26
sg16459
VC0346648
p32929
sg16454
Vexocrine pancreatic cancer
p32930
sa(dp32931
g16449
I55
sg16450
I1
sg16451
I6
sg16459
VC0006826
p32932
sg16454
Vcancer
p32933
sasa(dp32934
g16444
VIn pancreatic cancer patients, no association between GDF-15 levels and weight loss was identified.
p32935
sg16446
(lp32936
(dp32937
g16449
I54
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VGDF-15
p32938
sasg16456
(lp32939
(dp32940
g16449
I3
sg16450
I2
sg16451
I17
sg16459
VC0235974
p32941
sg16454
Vpancreatic cancer
p32942
sasa(dp32943
g16444
VThe aim of the present case-control study was to compare the diagnostic value of ULBP2, MIC-1 and carbohydrate antigen 19-9 (CA19-9) in 359 serum samples, consisting of 152 cases of PC, 20 cases of pre-pancreatic cancer, 91 cases of chronic pancreatitis (CP) and 96 normal controls (NC).
p32944
sg16446
(lp32945
(dp32946
g16449
I125
sg16450
I1
sg16451
I6
sg16452
VP14209
p32947
sg16454
VCA19-9
p32948
sa(dp32949
g16449
I88
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VMIC-1
p32950
sa(dp32951
g16449
I81
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VULBP2
p32952
sa(dp32953
g16449
I98
sg16450
I3
sg16451
I25
sg16452
VP14209
p32954
sg16454
Vcarbohydrate antigen 19-9
p32955
sasg16456
(lp32956
(dp32957
g16449
I202
sg16450
I2
sg16451
I17
sg16459
VC0235974
p32958
sg16454
Vpancreatic cancer
p32959
sa(dp32960
g16449
I255
sg16450
I1
sg16451
I2
sg16459
VC0149521
p32961
sg16454
VCP
p32962
sa(dp32963
g16449
I233
sg16450
I2
sg16451
I20
sg16459
VC0149521
p32964
sg16454
Vchronic pancreatitis
p32965
sasa(dp32966
g16444
VMacrophage inhibitory cytokine 1 (MIC-1/GDF15) has been identified as a potential novel biomarker for detection of pancreatic cancer (PCa).
p32967
sg16446
(lp32968
(dp32969
g16449
I34
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VMIC-1
p32970
sa(dp32971
g16449
I0
sg16450
I4
sg16451
I32
sg16452
g11
sg16454
VMacrophage inhibitory cytokine 1
p32972
sa(dp32973
g16449
I40
sg16450
I1
sg16451
I5
sg16452
g11
sg16454
VGDF15
p32974
sasg16456
(lp32975
(dp32976
g16449
I115
sg16450
I2
sg16451
I17
sg16459
VC0235974
p32977
sg16454
Vpancreatic cancer
p32978
sa(dp32979
g16449
I134
sg16450
I1
sg16451
I3
sg16459
VC0268398
p32980
sg16454
VPCa
p32981
sasa(dp32982
g16444
VHowever, the diagnostic value of serum MIC-1 for pancreatic ductal adenocarcinoma (PDAC), particularly for those at the early stage, and the value for treatment response monitoring have not yet been investigated.
p32983
sg16446
(lp32984
(dp32985
g16449
I33
sg16450
I2
sg16451
I11
sg16452
g11
sg16454
Vserum MIC-1
p32986
sasg16456
(lp32987
(dp32988
g16449
I83
sg16450
I1
sg16451
I4
sg16459
VC1335302
p32989
sg16454
VPDAC
p32990
sa(dp32991
g16449
I49
sg16450
I3
sg16451
I32
sg16459
VC1335302
p32992
sg16454
Vpancreatic ductal adenocarcinoma
p32993
sasa(dp32994
g16444
VCD30 ligand/TNFSF8, chordin-like 2, FGF-10/KGF-2, growth/differentiation factor 15, I-TAC/CXCL11, OSM, and SCF might represent as predictive biomarkers for gemcitabine and erlotinib response of patients with pancreatic cancer.
p32995
sg16446
(lp32996
(dp32997
g16449
I43
sg16450
I1
sg16451
I5
sg16452
VP21781
p32998
sg16454
VKGF-2
p32999
sa(dp33000
g16449
I107
sg16450
I1
sg16451
I3
sg16452
VP21583
p33001
sg16454
VSCF
p33002
sa(dp33003
g16449
I98
sg16450
I1
sg16451
I3
sg16452
VP13725
p33004
sg16454
VOSM
p33005
sa(dp33006
g16449
I20
sg16450
I2
sg16451
I14
sg16452
g11
sg16454
Vchordin-like 2
p33007
sa(dp33008
g16449
I50
sg16450
I2
sg16451
I29
sg16452
g11
sg16454
Vgrowth/differentiation factor
p33009
sa(dp33010
g16449
I0
sg16450
I2
sg16451
I11
sg16452
VP32971
p33011
sg16454
VCD30 ligand
p33012
sa(dp33013
g16449
I90
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VCXCL11
p33014
sa(dp33015
g16449
I12
sg16450
I1
sg16451
I6
sg16452
VP32971
p33016
sg16454
VTNFSF8
p33017
sasg16456
(lp33018
(dp33019
g16449
I208
sg16450
I2
sg16451
I17
sg16459
VC0235974
p33020
sg16454
Vpancreatic cancer
p33021
sasa(dp33022
g16444
VRadiologists evaluated following CT findings: maximum tumor diameter, percentage of solid component (%solid), air bronchogram, spiculation, adjacency of bullae or interstitial pneumonia (IP) around the tumor, notch, and pleural indent.
p33023
sg16446
(lp33024
sg16456
(lp33025
(dp33026
g16449
I54
sg16450
I1
sg16451
I5
sg16459
VC0027651
p33027
sg16454
Vtumor
p33028
sa(dp33029
g16449
I54
sg16450
I1
sg16451
I5
sg16459
VC0027651
p33030
sg16454
Vtumor
p33031
sa(dp33032
g16449
I163
sg16450
I2
sg16451
I22
sg16459
VC0206061
p33033
sg16454
Vinterstitial pneumonia
p33034
sa(dp33035
g16449
I153
sg16450
I1
sg16451
I6
sg16459
VC0005758
p33036
sg16454
Vbullae
p33037
sa(dp33038
g16449
I187
sg16450
I1
sg16451
I2
sg16459
VC0206061
p33039
sg16454
VIP
p33040
sasa(dp33041
g16444
VThe results strongly suggest that electronic self-auscultation at a single location (suprasternal notch) can support diagnosis of pneumonia in patients with COPD.
p33042
sg16446
(lp33043
sg16456
(lp33044
(dp33045
g16449
I130
sg16450
I1
sg16451
I9
sg16459
VC0032285
p33046
sg16454
Vpneumonia
p33047
sa(dp33048
g16449
I157
sg16450
I1
sg16451
I4
sg16459
VC0024117
p33049
sg16454
VCOPD
p33050
sasa(dp33051
g16444
VWe compared patients who underwent PAO for the treatment of Charcot-Marie-Tooth disease hip dysplasia (CMTHD group) with patients who underwent PAO for treatment of hip dysplasia secondary to DDH in terms of (1) modified Harris Hip scores; (2) radiographic correction of acetabular dysplasia; and (3) the rate of complications.
p33052
sg16446
(lp33053
(dp33054
g16449
I192
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VDDH
p33055
sasg16456
(lp33056
(dp33057
g16449
I271
sg16450
I2
sg16451
I20
sg16459
VC1306065
p33058
sg16454
Vacetabular dysplasia
p33059
sa(dp33060
g16449
I88
sg16450
I2
sg16451
I13
sg16459
VC1328407
p33061
sg16454
Vhip dysplasia
p33062
sa(dp33063
g16449
I60
sg16450
I2
sg16451
I27
sg16459
VC0007959
p33064
sg16454
VCharcot-Marie-Tooth disease
p33065
sa(dp33066
g16449
I88
sg16450
I2
sg16451
I13
sg16459
VC1328407
p33067
sg16454
Vhip dysplasia
p33068
sasa(dp33069
g16444
VTwenty-seven subjects with Charcot-Marie-Tooth disease who underwent a PAO between January 1991 and December 2010 were matched to 54 subjects with DDH on the basis of sex, age, date of surgery, and body mass index.
p33070
sg16446
(lp33071
(dp33072
g16449
I147
sg16450
I1
sg16451
I3
sg16452
g11
sg16454
VDDH
p33073
sasg16456
(lp33074
(dp33075
g16449
I27
sg16450
I2
sg16451
I27
sg16459
VC0007959
p33076
sg16454
VCharcot-Marie-Tooth disease
p33077
sasa(dp33078
g16444
VThe purpose of this study is to evaluate the use of the Dega osteotomy in the treatment of hip pathology resulting from both developmental dysplasia (DDH) and neuromuscular disease (NM).
p33079
sg16446
(lp33080
sg16456
(lp33081
(dp33082
g16449
I95
sg16450
I1
sg16451
I9
sg16459
VC0677042
p33083
sg16454
Vpathology
p33084
sa(dp33085
g16449
I182
sg16450
I1
sg16451
I2
sg16459
VC0027868
p33086
sg16454
VNM
p33087
sa(dp33088
g16449
I139
sg16450
I1
sg16451
I9
sg16459
VC0334044
p33089
sg16454
Vdysplasia
p33090
sa(dp33091
g16449
I159
sg16450
I2
sg16451
I21
sg16459
VC0027868
p33092
sg16454
Vneuromuscular disease
p33093
sasa(dp33094
g16444
VNeuromuscular dysplasia of the hip (NDH) is a sequel of neuromuscular disease, and generally presents later in childhood than DDH.
p33095
sg16446
(lp33096
sg16456
(lp33097
(dp33098
g16449
I56
sg16450
I2
sg16451
I21
sg16459
VC0027868
p33099
sg16454
Vneuromuscular disease
p33100
sa(dp33101
g16449
I14
sg16450
I1
sg16451
I9
sg16459
VC0334044
p33102
sg16454
Vdysplasia
p33103
sasa(dp33104
g16444
VTo explore this suggestion we ascertained the presence of neuromuscular disease within a cohort of DDH patients, and asked whether the neuromuscular condition is the initial etiology of the dysplasia or a coincidental finding.
p33105
sg16446
(lp33106
sg16456
(lp33107
(dp33108
g16449
I190
sg16450
I1
sg16451
I9
sg16459
VC0334044
p33109
sg16454
Vdysplasia
p33110
sa(dp33111
g16449
I149
sg16450
I1
sg16451
I9
sg16459
VC0012634
p33112
sg16454
Vcondition
p33113
sa(dp33114
g16449
I58
sg16450
I2
sg16451
I21
sg16459
VC0027868
p33115
sg16454
Vneuromuscular disease
p33116
sasa(dp33117
g16444
VWe examined 45 infants with nondevelopmental dysplasia of the hip (non-DDH), including congenital deficiency of the femur (CDF) (20 infants), neuromuscular syndrome (five infants), skeletal dysplasia (15 infants), and infection (five infants), and present the sonographic findings.
p33118
sg16446
(lp33119
sg16456
(lp33120
(dp33121
g16449
I87
sg16450
I2
sg16451
I21
sg16459
VC0333006
p33122
sg16454
Vcongenital deficiency
p33123
sa(dp33124
g16449
I218
sg16450
I1
sg16451
I9
sg16459
VC0009450
p33125
sg16454
Vinfection
p33126
sa(dp33127
g16449
I156
sg16450
I1
sg16451
I8
sg16459
VC0039082
p33128
sg16454
Vsyndrome
p33129
sa(dp33130
g16449
I181
sg16450
I2
sg16451
I18
sg16459
VC0410528
p33131
sg16454
Vskeletal dysplasia
p33132
sa(dp33133
g16449
I45
sg16450
I1
sg16451
I9
sg16459
VC0334044
p33134
sg16454
Vdysplasia
p33135
sasa(dp33136
g16444
VIn previous studies, we demonstrated that human RHBDD2 is over-expressed in the advanced stages of breast and colorectal cancers, suggesting a favorable role in cell proliferation.
p33137
sg16446
(lp33138
sg16456
(lp33139
(dp33140
g16449
I166
sg16450
I1
sg16451
I13
sg16459
VC0334094
p33141
sg16454
Vproliferation
p33142
sa(dp33143
g16449
I110
sg16450
I2
sg16451
I18
sg16459
VC1527249
p33144
sg16454
Vcolorectal cancers
p33145
sasa(dp33146
g16444
VSo far little is known about the expression of RHBDD2 in other tissues and other species, and because of similarities between cancer and embryonic cells, this study focused on the evaluation of Rhbdd2 expression in embryonic and adult rat tissues.
p33147
sg16446
(lp33148
(dp33149
g16449
I47
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRHBDD2
p33150
sa(dp33151
g16449
I194
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRhbdd2
p33152
sasg16456
(lp33153
(dp33154
g16449
I126
sg16450
I1
sg16451
I6
sg16459
VC0006826
p33155
sg16454
Vcancer
p33156
sasa(dp33157
g16444
VQuantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis showed a significant RHBDD2 mRNA overexpression in advanced breast cancer compared with normal tissue samples (p = 0.012).
p33158
sg16446
(lp33159
(dp33160
g16449
I100
sg16450
I2
sg16451
I11
sg16452
g11
sg16454
VRHBDD2 mRNA
p33161
sasg16456
(lp33162
(dp33163
g16449
I139
sg16450
I2
sg16451
I13
sg16459
VC0678222
p33164
sg16454
Vbreast cancer
p33165
sasa(dp33166
g16444
VImmunohistochemistry analysis showed a significant increase of RHBDD2 protein expression in association with breast cancer samples negative for progesterone receptor (p = 0.015).
p33167
sg16446
(lp33168
(dp33169
g16449
I63
sg16450
I2
sg16451
I14
sg16452
g11
sg16454
VRHBDD2 protein
p33170
sa(dp33171
g16449
I144
sg16450
I2
sg16451
I21
sg16452
VP06401
p33172
sg16454
Vprogesterone receptor
p33173
sasg16456
(lp33174
(dp33175
g16449
I109
sg16450
I2
sg16451
I13
sg16459
VC0678222
p33176
sg16454
Vbreast cancer
p33177
sasa(dp33178
g16444
VRhomboid domain containing 2 (RHBDD2) was previously observed overexpressed and amplified in breast cancer samples.
p33179
sg16446
(lp33180
(dp33181
g16449
I0
sg16450
I4
sg16451
I28
sg16452
g11
sg16454
VRhomboid domain containing 2
p33182
sa(dp33183
g16449
I30
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRHBDD2
p33184
sasg16456
(lp33185
(dp33186
g16449
I93
sg16450
I2
sg16451
I13
sg16459
VC0678222
p33187
sg16454
Vbreast cancer
p33188
sasa(dp33189
g16444
VIn order to identify biological pathways modulated by RHBDD2, gene expression profiles of RHBDD2 silenced breast cancer cells were analyzed using whole genome human microarray.
p33190
sg16446
(lp33191
(dp33192
g16449
I54
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRHBDD2
p33193
sa(dp33194
g16449
I54
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRHBDD2
p33195
sasg16456
(lp33196
(dp33197
g16449
I106
sg16450
I2
sg16451
I13
sg16459
VC0678222
p33198
sg16454
Vbreast cancer
p33199
sasa(dp33200
g16444
VWe used a lentivirus-based approach for stable silencing of RHBDD2 mRNA in the T47D breast cancer cell line, and we examined the transcriptional consequences on UPR genes as well as the phenotypic effects on migration and proliferation processes.
p33201
sg16446
(lp33202
(dp33203
g16449
I60
sg16450
I2
sg16451
I11
sg16452
g11
sg16454
VRHBDD2 mRNA
p33204
sasg16456
(lp33205
(dp33206
g16449
I84
sg16450
I2
sg16451
I13
sg16459
VC0678222
p33207
sg16454
Vbreast cancer
p33208
sa(dp33209
g16449
I222
sg16450
I1
sg16451
I13
sg16459
VC0334094
p33210
sg16454
Vproliferation
p33211
sasa(dp33212
g16444
VBased on these studies, we hypothesize that RHBDD2 overexpression in breast cancer could represent an adaptive phenotype to the stressful tumor microenvironment by modulating the ER stress response.
p33213
sg16446
(lp33214
(dp33215
g16449
I44
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRHBDD2
p33216
sasg16456
(lp33217
(dp33218
g16449
I69
sg16450
I2
sg16451
I13
sg16459
VC0678222
p33219
sg16454
Vbreast cancer
p33220
sa(dp33221
g16449
I138
sg16450
I1
sg16451
I5
sg16459
VC0027651
p33222
sg16454
Vtumor
p33223
sasa(dp33224
g16444
VIn previous studies, we identified rhomboid domain containing 2 (RHBDD2) gene to be markedly overexpressed in breast cancer patients that developed recurrence of the disease.
p33225
sg16446
(lp33226
(dp33227
g16449
I65
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRHBDD2
p33228
sa(dp33229
g16449
I35
sg16450
I4
sg16451
I28
sg16452
g11
sg16454
Vrhomboid domain containing 2
p33230
sasg16456
(lp33231
(dp33232
g16449
I148
sg16450
I1
sg16451
I10
sg16459
VC1458156
p33233
sg16454
Vrecurrence
p33234
sa(dp33235
g16449
I110
sg16450
I2
sg16451
I13
sg16459
VC0678222
p33236
sg16454
Vbreast cancer
p33237
sasa(dp33238
g16444
VIn this study, we evaluated for the first time RHBDD2 gene expression in colorectal cancer (CRC).
p33239
sg16446
(lp33240
(dp33241
g16449
I42
sg16450
I3
sg16451
I16
sg16452
g11
sg16454
Vtime RHBDD2 gene
p33242
sasg16456
(lp33243
(dp33244
g16449
I92
sg16450
I1
sg16451
I3
sg16459
VC1527249
p33245
sg16454
VCRC
p33246
sa(dp33247
g16449
I73
sg16450
I2
sg16451
I17
sg16459
VC1527249
p33248
sg16454
Vcolorectal cancer
p33249
sasa(dp33250
g16444
VOverall, these results showed that RHBDD2 overexpression might play a role in colorectal cancer progression.
p33251
sg16446
(lp33252
(dp33253
g16449
I35
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRHBDD2
p33254
sasg16456
(lp33255
(dp33256
g16449
I89
sg16450
I2
sg16451
I18
sg16459
VC0178874
p33257
sg16454
Vcancer progression
p33258
sasa(dp33259
g16444
VIn the course of breast cancer global gene expression studies, we identified an uncharacterized gene known as RHBDD2 (Rhomboid domain containing 2) to be markedly over-expressed in primary tumors from patients with recurrent disease.
p33260
sg16446
(lp33261
(dp33262
g16449
I118
sg16450
I4
sg16451
I28
sg16452
g11
sg16454
VRhomboid domain containing 2
p33263
sa(dp33264
g16449
I110
sg16450
I1
sg16451
I6
sg16452
g11
sg16454
VRHBDD2
p33265
sasg16456
(lp33266
(dp33267
g16449
I181
sg16450
I2
sg16451
I14
sg16459
VC0677930
p33268
sg16454
Vprimary tumors
p33269
sa(dp33270
g16449
I17
sg16450
I2
sg16451
I13
sg16459
VC0678222
p33271
sg16454
Vbreast cancer
p33272
sa(dp33273
g16449
I215
sg16450
I2
sg16451
I17
sg16459
VC0277556
p33274
sg16454
Vrecurrent disease
p33275
sasa(dp33276
S'line'
p33277
VWestern-blot, RT-PCR and cDNA sequencing analyses allowed us to identify two RHBDD2 alternatively spliced mRNA isoforms expressed in breast cancer cell lines.
p33278
sS'genes'
p33279
(lp33280
sS'diseases'
p33281
(lp33282
(dp33283
S'index'
p33284
I133
sS'lengthInWords'
p33285
I2
sS'lengthInChars'
p33286
I13
sS'cui'
p33287
VC0678222
p33288
sS'name'
p33289
Vbreast cancer
p33290
sasa(dp33291
g33277
VInterestingly, siRNA-mediated silencing of RHBDD2 expression results in a decrease of MCF7 breast cancer cells proliferation compared with the corresponding controls (p=0.001).
p33292
sg33279
(lp33293
(dp33294
g33284
I43
sg33285
I1
sg33286
I6
sS'uniprot'
p33295
g11
sg33289
VRHBDD2
p33296
sasg33281
(lp33297
(dp33298
g33284
I111
sg33285
I1
sg33286
I13
sg33287
VC0334094
p33299
sg33289
Vproliferation
p33300
sa(dp33301
g33284
I91
sg33285
I2
sg33286
I13
sg33287
VC0678222
p33302
sg33289
Vbreast cancer
p33303
sasa(dp33304
g33277
VIn conclusion, our findings suggest that RHBDD2 over-expression behaves as an indicator of poor prognosis and may play a role facilitating breast cancer progression.
p33305
sg33279
(lp33306
(dp33307
g33284
I41
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VRHBDD2
p33308
sasg33281
(lp33309
(dp33310
g33284
I146
sg33285
I2
sg33286
I18
sg33287
VC0178874
p33311
sg33289
Vcancer progression
p33312
sasa(dp33313
g33277
VThese effects could also be exerted via the upregulation of eight specific target genes, the subsequent over-activation of the PKC and PI3 K-Akt pathways, and the eventual abnormal cardiac development and VSD.
p33314
sg33279
(lp33315
(dp33316
g33284
I141
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VAkt
p33317
sa(dp33318
g33284
I127
sg33285
I1
sg33286
I3
sg33295
VP17252
p33319
sg33289
VPKC
p33320
sa(dp33321
g33284
I135
sg33285
I2
sg33286
I5
sg33295
VP19957
p33322
sg33289
VPI3 K
p33323
sasg33281
(lp33324
(dp33325
g33284
I205
sg33285
I1
sg33286
I3
sg33287
VC0018818
p33326
sg33289
VVSD
p33327
sa(dp33328
g33284
I127
sg33285
I1
sg33286
I3
sg33287
VC1868682
p33329
sg33289
VPKC
p33330
sasa(dp33331
g33277
VReduced translation of CEBPA mRNA has been associated with increased proliferation of bronchial smooth muscle (BSM) cells of asthma patients.
p33332
sg33279
(lp33333
(dp33334
g33284
I23
sg33285
I2
sg33286
I10
sg33295
VP49715
p33335
sg33289
VCEBPA mRNA
p33336
sasg33281
(lp33337
(dp33338
g33284
I125
sg33285
I1
sg33286
I6
sg33287
VC0004096
p33339
sg33289
Vasthma
p33340
sa(dp33341
g33284
I69
sg33285
I1
sg33286
I13
sg33287
VC0334094
p33342
sg33289
Vproliferation
p33343
sasa(dp33344
g33277
VHDM extract reduced the C/EBPAlfa expression in BSM cells of asthma patients, which coincided with significantly increased levels of calreticulin (CRT) protein, an inhibitor of CEBPA mRNA translation.
p33345
sg33279
(lp33346
(dp33347
g33284
I133
sg33285
I1
sg33286
I12
sg33295
VP27797
p33348
sg33289
Vcalreticulin
p33349
sa(dp33350
g33284
I177
sg33285
I2
sg33286
I10
sg33295
VP49715
p33351
sg33289
VCEBPA mRNA
p33352
sa(dp33353
g33284
I147
sg33285
I1
sg33286
I3
sg33295
VP27797
p33354
sg33289
VCRT
p33355
sasg33281
(lp33356
(dp33357
g33284
I61
sg33285
I1
sg33286
I6
sg33287
VC0004096
p33358
sg33289
Vasthma
p33359
sasa(dp33360
g33277
VIn conclusion, HDM extract reduced CEBPA mRNA translation, specifically in asthmatic BSM cells, and 1) upregulated CRT, 2) activated PAR2, and increased 3) IL-6 expression and 4) the proliferation of asthmatic BSM cells.
p33361
sg33279
(lp33362
(dp33363
g33284
I35
sg33285
I2
sg33286
I10
sg33295
VP49715
p33364
sg33289
VCEBPA mRNA
p33365
sa(dp33366
g33284
I156
sg33285
I1
sg33286
I4
sg33295
VP05231
p33367
sg33289
VIL-6
p33368
sa(dp33369
g33284
I133
sg33285
I1
sg33286
I4
sg33295
VP55085
p33370
sg33289
VPAR2
p33371
sasg33281
(lp33372
(dp33373
g33284
I183
sg33285
I1
sg33286
I13
sg33287
VC0334094
p33374
sg33289
Vproliferation
p33375
sa(dp33376
g33284
I75
sg33285
I1
sg33286
I9
sg33287
VC0004096
p33377
sg33289
Vasthmatic
p33378
sa(dp33379
g33284
I75
sg33285
I1
sg33286
I9
sg33287
VC0004096
p33380
sg33289
Vasthmatic
p33381
sasa(dp33382
g33277
VAirway smooth muscle cells from persons with asthma are deficient in C/EBP-alpha, which may explain the finding that CSs do not inhibit the proliferation of these cells in vitro.
p33383
sg33279
(lp33384
(dp33385
g33284
I69
sg33285
I1
sg33286
I11
sg33295
g11
sg33289
VC/EBP-alpha
p33386
sasg33281
(lp33387
(dp33388
g33284
I45
sg33285
I1
sg33286
I6
sg33287
VC0004096
p33389
sg33289
Vasthma
p33390
sa(dp33391
g33284
I117
sg33285
I1
sg33286
I3
sg33287
VC0265338
p33392
sg33289
VCSs
p33393
sa(dp33394
g33284
I140
sg33285
I1
sg33286
I13
sg33287
VC0334094
p33395
sg33289
Vproliferation
p33396
sasa(dp33397
g33277
VCCAAT/enhancer-binding proteins (C/EBPs) control cell proliferation; lack of C/EBPalpha correlates with increased proliferation of bronchial smooth muscle cells (BSMCs) of asthmatic patients.
p33398
sg33279
(lp33399
(dp33400
g33284
I33
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VC/EBPs
p33401
sa(dp33402
g33284
I0
sg33285
I2
sg33286
I31
sg33295
VP63244
p33403
sg33289
VCCAAT/enhancer-binding proteins
p33404
sasg33281
(lp33405
(dp33406
g33284
I54
sg33285
I1
sg33286
I13
sg33287
VC0334094
p33407
sg33289
Vproliferation
p33408
sa(dp33409
g33284
I54
sg33285
I1
sg33286
I13
sg33287
VC0334094
p33410
sg33289
Vproliferation
p33411
sa(dp33412
g33284
I172
sg33285
I1
sg33286
I9
sg33287
VC0004096
p33413
sg33289
Vasthmatic
p33414
sasa(dp33415
g33277
VExpression and function of C/EBPalpha, beta, delta, and epsilon BSMCs of control subjects (n = 9), asthmatic patients (n = 12), and patients with chronic obstructive pulmonary disease (COPD; n = 10) were determined.
p33416
sg33279
(lp33417
sg33281
(lp33418
(dp33419
g33284
I185
sg33285
I1
sg33286
I4
sg33287
VC0024117
p33420
sg33289
VCOPD
p33421
sa(dp33422
g33284
I146
sg33285
I4
sg33286
I37
sg33287
VC0024117
p33423
sg33289
Vchronic obstructive pulmonary disease
p33424
sa(dp33425
g33284
I99
sg33285
I1
sg33286
I9
sg33287
VC0004096
p33426
sg33289
Vasthmatic
p33427
sasa(dp33428
g33277
VThe asthmatic group did not appropriately express C/EBPalpha.
p33429
sg33279
(lp33430
sg33281
(lp33431
(dp33432
g33284
I4
sg33285
I1
sg33286
I9
sg33287
VC0004096
p33433
sg33289
Vasthmatic
p33434
sasa(dp33435
g33277
VProtein analysis and electrophoretic mobility shift assay confirmed the disease-specific expression pattern of C/EBPalpha in asthmatic patients and C/EBPdelta in patients with COPD.
p33436
sg33279
(lp33437
sg33281
(lp33438
(dp33439
g33284
I176
sg33285
I1
sg33286
I4
sg33287
VC0024117
p33440
sg33289
VCOPD
p33441
sa(dp33442
g33284
I125
sg33285
I1
sg33286
I9
sg33287
VC0004096
p33443
sg33289
Vasthmatic
p33444
sasa(dp33445
g33277
VThe reason for the differences which have been observed in the in vitro properties of airway smooth muscle derived from asthmatic individuals may result from an inherent "supercontractility", an increased tendency to proliferate due to the absence of an inhibitory transcription factor C/EBP-alpha, the influence of an altered extracellular matrix and/or a decrease in release of factors such as PGE(2) which would under normal circumstances inhibit both proliferation and contraction.
p33446
sg33279
(lp33447
(dp33448
g33284
I265
sg33285
I3
sg33286
I32
sg33295
g11
sg33289
Vtranscription factor C/EBP-alpha
p33449
sasg33281
(lp33450
(dp33451
g33284
I455
sg33285
I1
sg33286
I13
sg33287
VC0334094
p33452
sg33289
Vproliferation
p33453
sa(dp33454
g33284
I120
sg33285
I1
sg33286
I9
sg33287
VC0004096
p33455
sg33289
Vasthmatic
p33456
sa(dp33457
g33284
I473
sg33285
I1
sg33286
I11
sg33287
VC1140999
p33458
sg33289
Vcontraction
p33459
sasa(dp33460
g33277
VHepatocellular carcinoma etiology had no detectable influence on miR-122 expression, whereas miR-152 was increased in HCV+ tissue samples.
p33461
sg33279
(lp33462
(dp33463
g33284
I93
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VmiR-152
p33464
sa(dp33465
g33284
I65
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VmiR-122
p33466
sasg33281
(lp33467
(dp33468
g33284
I0
sg33285
I2
sg33286
I24
sg33287
VC1512411
p33469
sg33289
VHepatocellular carcinoma
p33470
sasa(dp33471
g33277
VAberrant expressions of the miR-148/152 family (miR-148a, miR-148b, and miR-152) have been documented in many tumor tissues, including hepatocellular carcinoma (HCC).
p33472
sg33279
(lp33473
(dp33474
g33284
I28
sg33285
I2
sg33286
I18
sg33295
g11
sg33289
VmiR-148/152 family
p33475
sa(dp33476
g33284
I58
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VmiR-148b
p33477
sa(dp33478
g33284
I48
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VmiR-148a
p33479
sasg33281
(lp33480
(dp33481
g33284
I135
sg33285
I2
sg33286
I24
sg33287
VC2239176
p33482
sg33289
Vhepatocellular carcinoma
p33483
sa(dp33484
g33284
I110
sg33285
I1
sg33286
I5
sg33287
VC0027651
p33485
sg33289
Vtumor
p33486
sa(dp33487
g33284
I161
sg33285
I1
sg33286
I3
sg33287
VC2239176
p33488
sg33289
VHCC
p33489
sasa(dp33490
g33277
VAnd high expression of HLA-G further suppressed NK against cancer cells, providing a new concept that miR-152 was involved in HBV-induced hepatocellular carcinoma.
p33491
sg33279
(lp33492
(dp33493
g33284
I23
sg33285
I1
sg33286
I3
sg33295
VP30486
p33494
sg33289
VHLA
p33495
sasg33281
(lp33496
(dp33497
g33284
I59
sg33285
I1
sg33286
I6
sg33287
VC0006826
p33498
sg33289
Vcancer
p33499
sa(dp33500
g33284
I138
sg33285
I2
sg33286
I24
sg33287
VC1512411
p33501
sg33289
Vhepatocellular carcinoma
p33502
sa(dp33503
g33284
I126
sg33285
I1
sg33286
I3
sg33287
VC0019163
p33504
sg33289
VHBV
p33505
sasa(dp33506
g33277
VFurther, FDA-approved arsenic trioxide (ATO) and the ND2-SmoA1 mouse model of Medulloblastoma (MB) were used to extend our analyses of combined MRI and Reverse Phase Protein Microarray (RPMA) data to assess tumor responses to ATO and to uncover the complexity of therapeutic molecular biology.
p33507
sg33279
(lp33508
(dp33509
g33284
I53
sg33285
I1
sg33286
I9
sg33295
VP03891
p33510
sg33289
VND2-SmoA1
p33511
sasg33281
(lp33512
(dp33513
g33284
I95
sg33285
I1
sg33286
I2
sg33287
VC0025149
p33514
sg33289
VMB
p33515
sa(dp33516
g33284
I78
sg33285
I1
sg33286
I15
sg33287
VC0025149
p33517
sg33289
VMedulloblastoma
p33518
sa(dp33519
g33284
I207
sg33285
I1
sg33286
I5
sg33287
VC0027651
p33520
sg33289
Vtumor
p33521
sasa(dp33522
g33277
VImportantly, while ASC deficiency did not affect normal cerebellar development, ASC knockout mice on the Smoothened (ND2:SmoA1) transgenic model of medulloblastoma exhibited a profound reduction in medulloblastoma incidence and a delayed tumor onset.
p33523
sg33279
(lp33524
(dp33525
g33284
I117
sg33285
I1
sg33286
I3
sg33295
VP03891
p33526
sg33289
VND2
p33527
sa(dp33528
g33284
I19
sg33285
I1
sg33286
I3
sg33295
VP08842
p33529
sg33289
VASC
p33530
sasg33281
(lp33531
(dp33532
g33284
I148
sg33285
I1
sg33286
I15
sg33287
VC0025149
p33533
sg33289
Vmedulloblastoma
p33534
sa(dp33535
g33284
I148
sg33285
I1
sg33286
I15
sg33287
VC0025149
p33536
sg33289
Vmedulloblastoma
p33537
sa(dp33538
g33284
I238
sg33285
I1
sg33286
I5
sg33287
VC0027651
p33539
sg33289
Vtumor
p33540
sasa(dp33541
g33277
VWe report the use of IRDye 800CW chlorotoxin (CLTX) as a targeted imaging agent for brain tumors in a spontaneous mouse model of medulloblastoma, ND2:SmoA1.
p33542
sg33279
(lp33543
(dp33544
g33284
I146
sg33285
I1
sg33286
I3
sg33295
VP03891
p33545
sg33289
VND2
p33546
sasg33281
(lp33547
(dp33548
g33284
I129
sg33285
I1
sg33286
I15
sg33287
VC0025149
p33549
sg33289
Vmedulloblastoma
p33550
sa(dp33551
g33284
I84
sg33285
I2
sg33286
I12
sg33287
VC0006118
p33552
sg33289
Vbrain tumors
p33553
sasa(dp33554
g33277
VImportantly, genetic deletion of Bax in medulloblastoma-prone ND2:SmoA1 transgenic mice greatly accelerated tumorigenesis.
p33555
sg33279
(lp33556
(dp33557
g33284
I62
sg33285
I1
sg33286
I3
sg33295
VP03891
p33558
sg33289
VND2
p33559
sasg33281
(lp33560
(dp33561
g33284
I108
sg33285
I1
sg33286
I13
sg33287
VC0007621
p33562
sg33289
Vtumorigenesis
p33563
sa(dp33564
g33284
I40
sg33285
I1
sg33286
I15
sg33287
VC0025149
p33565
sg33289
Vmedulloblastoma
p33566
sasa(dp33567
g33277
VFive common variants were associated with pancreatic cancer at nominal statistical significance (P &lt; 0.05) with the strongest finding for mt5460g in the ND2 gene [OR = 3.9; 95% confidence interval (CI), 1.5-10; P = 0.004] which encodes an A331T substitution.
p33568
sg33279
(lp33569
(dp33570
g33284
I156
sg33285
I2
sg33286
I8
sg33295
VP03891
p33571
sg33289
VND2 gene
p33572
sasg33281
(lp33573
(dp33574
g33284
I42
sg33285
I2
sg33286
I17
sg33287
VC0235974
p33575
sg33289
Vpancreatic cancer
p33576
sasa(dp33577
g33277
VOur findings indicate a critical role of HspBP1 in differential CHIP/Hsp70 activities in neuronal and glial cells and the greater neuronal vulnerability to misfolded proteins in neurodegenerative diseases.
p33578
sg33279
(lp33579
(dp33580
g33284
I41
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VHspBP1
p33581
sa(dp33582
g33284
I69
sg33285
I1
sg33286
I5
sg33295
VP34932
p33583
sg33289
VHsp70
p33584
sa(dp33585
g33284
I64
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCHIP
p33586
sasg33281
(lp33587
(dp33588
g33284
I178
sg33285
I2
sg33286
I26
sg33287
VC0524851
p33589
sg33289
Vneurodegenerative diseases
p33590
sasa(dp33591
g33277
VIn this study the adenoviral mediated over-expression of HSP70 interacting protein (HIP) alone was shown to significantly reduce inclusion formation in both an in vitro model of Spinal Bulbar Muscular Atrophy and a primary neuronal model of polyglutamine disease.
p33592
sg33279
(lp33593
(dp33594
g33284
I57
sg33285
I3
sg33286
I25
sg33295
VP50502
p33595
sg33289
VHSP70 interacting protein
p33596
sa(dp33597
g33284
I84
sg33285
I1
sg33286
I3
sg33295
VP47914
p33598
sg33289
VHIP
p33599
sasg33281
(lp33600
(dp33601
g33284
I192
sg33285
I2
sg33286
I16
sg33287
VC0026846
p33602
sg33289
VMuscular Atrophy
p33603
sasa(dp33604
g33277
VTo explore the relationship of telomerase, MYC and JAK2 in chronic myeloproliferative diseases, we investigated hTERT and MYC expression in bone marrow cells of essential thrombocythemia (ET) and polycythemia vera (PV).
p33605
sg33279
(lp33606
(dp33607
g33284
I112
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VhTERT
p33608
sa(dp33609
g33284
I51
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VJAK2
p33610
sa(dp33611
g33284
I43
sg33285
I1
sg33286
I3
sg33295
VP12524
p33612
sg33289
VMYC
p33613
sa(dp33614
g33284
I43
sg33285
I1
sg33286
I3
sg33295
VP12524
p33615
sg33289
VMYC
p33616
sasg33281
(lp33617
(dp33618
g33284
I161
sg33285
I2
sg33286
I25
sg33287
VC0040028
p33619
sg33289
Vessential thrombocythemia
p33620
sa(dp33621
g33284
I188
sg33285
I1
sg33286
I2
sg33287
VC0040028
p33622
sg33289
VET
p33623
sa(dp33624
g33284
I196
sg33285
I2
sg33286
I17
sg33287
VC0032463
p33625
sg33289
Vpolycythemia vera
p33626
sa(dp33627
g33284
I215
sg33285
I1
sg33286
I2
sg33287
VC0032463
p33628
sg33289
VPV
p33629
sasa(dp33630
g33277
VDCAF17 mutations are associated with Woodhouse-Sakati syndrome, a rare disorder characterized by alopecia, hypogonadotropic hypogonadism, sensorineural hearing loss, diabetes mellitus, and extrapyramidal movements.
p33631
sg33279
(lp33632
(dp33633
g33284
I0
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VDCAF17
p33634
sasg33281
(lp33635
(dp33636
g33284
I166
sg33285
I2
sg33286
I17
sg33287
VC0011849
p33637
sg33289
Vdiabetes mellitus
p33638
sa(dp33639
g33284
I107
sg33285
I2
sg33286
I29
sg33287
VC0022735
p33640
sg33289
Vhypogonadotropic hypogonadism
p33641
sa(dp33642
g33284
I66
sg33285
I2
sg33286
I13
sg33287
VC0678236
p33643
sg33289
Vrare disorder
p33644
sa(dp33645
g33284
I138
sg33285
I3
sg33286
I26
sg33287
VC0018784
p33646
sg33289
Vsensorineural hearing loss
p33647
sa(dp33648
g33284
I37
sg33285
I2
sg33286
I25
sg33287
VC0342286
p33649
sg33289
VWoodhouse-Sakati syndrome
p33650
sasa(dp33651
g33277
VWoodhouse-Sakati syndrome (WSS) is a rare autosomal recessive disorder characterized by alopecia, hypogonadism, diabetes mellitus, intellectual disability, sensorineural deafness, extrapyramidal signs, and low insulinlike growth factor 1 levels.
p33652
sg33279
(lp33653
(dp33654
g33284
I206
sg33285
I5
sg33286
I31
sg33295
VP05019
p33655
sg33289
Vlow insulinlike growth factor 1
p33656
sasg33281
(lp33657
(dp33658
g33284
I180
sg33285
I2
sg33286
I20
sg33287
VC0234133
p33659
sg33289
Vextrapyramidal signs
p33660
sa(dp33661
g33284
I98
sg33285
I1
sg33286
I12
sg33287
VC0020619
p33662
sg33289
Vhypogonadism
p33663
sa(dp33664
g33284
I0
sg33285
I2
sg33286
I25
sg33287
VC0342286
p33665
sg33289
VWoodhouse-Sakati syndrome
p33666
sa(dp33667
g33284
I27
sg33285
I1
sg33286
I3
sg33287
VC0406587
p33668
sg33289
VWSS
p33669
sa(dp33670
g33284
I156
sg33285
I2
sg33286
I22
sg33287
VC0018784
p33671
sg33289
Vsensorineural deafness
p33672
sa(dp33673
g33284
I131
sg33285
I2
sg33286
I23
sg33287
VC0025362
p33674
sg33289
Vintellectual disability
p33675
sa(dp33676
g33284
I112
sg33285
I2
sg33286
I17
sg33287
VC0011849
p33677
sg33289
Vdiabetes mellitus
p33678
sasa(dp33679
g33277
VWoodhouse-Sakati syndrome consists of alopecia, hypogonadism, diabetes mellitus, mild mental retardation, sensorineural deafness and ECG abnormalities.
p33680
sg33279
(lp33681
sg33281
(lp33682
(dp33683
g33284
I62
sg33285
I2
sg33286
I17
sg33287
VC0011849
p33684
sg33289
Vdiabetes mellitus
p33685
sa(dp33686
g33284
I81
sg33285
I3
sg33286
I23
sg33287
VC0026106
p33687
sg33289
Vmild mental retardation
p33688
sa(dp33689
g33284
I48
sg33285
I1
sg33286
I12
sg33287
VC0020619
p33690
sg33289
Vhypogonadism
p33691
sa(dp33692
g33284
I106
sg33285
I2
sg33286
I22
sg33287
VC0018784
p33693
sg33289
Vsensorineural deafness
p33694
sa(dp33695
g33284
I0
sg33285
I2
sg33286
I25
sg33287
VC0342286
p33696
sg33289
VWoodhouse-Sakati syndrome
p33697
sasa(dp33698
g33277
VA population of CD80+Gr-1+ myeloid cells was found to be expanded in conventional as well as in bone marrow-transplanted mice with disseminated candidiasis, but its depletion increased the IFN-gamma-mediated antifungal resistance.
p33699
sg33279
(lp33700
(dp33701
g33284
I16
sg33285
I1
sg33286
I10
sg33295
VP00390
p33702
sg33289
VCD80+Gr-1+
p33703
sa(dp33704
g33284
I189
sg33285
I1
sg33286
I9
sg33295
VP01579
p33705
sg33289
VIFN-gamma
p33706
sasg33281
(lp33707
(dp33708
g33284
I131
sg33285
I2
sg33286
I24
sg33287
VC0153252
p33709
sg33289
Vdisseminated candidiasis
p33710
sasa(dp33711
g33277
VThe patients with esophageal candidiasis had lower CD4+ cell counts (129/microliter) and CD4:CD8 ratios (0.23) than those with oropharyngeal candidiasis (CD4 179/microliter; CD4:CD8 0.35).
p33712
sg33279
(lp33713
(dp33714
g33284
I178
sg33285
I2
sg33286
I8
sg33295
VP01732
p33715
sg33289
VCD8 0.35
p33716
sa(dp33717
g33284
I51
sg33285
I1
sg33286
I3
sg33295
VP01730
p33718
sg33289
VCD4
p33719
sa(dp33720
g33284
I51
sg33285
I1
sg33286
I4
sg33295
VP01730
p33721
sg33289
VCD4+
p33722
sa(dp33723
g33284
I51
sg33285
I1
sg33286
I3
sg33295
VP01730
p33724
sg33289
VCD4
p33725
sa(dp33726
g33284
I93
sg33285
I1
sg33286
I3
sg33295
VP01732
p33727
sg33289
VCD8
p33728
sa(dp33729
g33284
I51
sg33285
I1
sg33286
I3
sg33295
VP01730
p33730
sg33289
VCD4
p33731
sasg33281
(lp33732
(dp33733
g33284
I18
sg33285
I2
sg33286
I22
sg33287
VC0239295
p33734
sg33289
Vesophageal candidiasis
p33735
sa(dp33736
g33284
I127
sg33285
I2
sg33286
I25
sg33287
VC0919659
p33737
sg33289
Voropharyngeal candidiasis
p33738
sasa(dp33739
g33277
VWe served patients with cystic fibrosis (CF, n=29), cystic fibrosis related diabetes (CFRD, n=19) and healthy controls (n=18) a standardized breakfast (23 g protein, 25 g fat and 76 g carbohydrates) after an overnight fasting.
p33740
sg33279
(lp33741
sg33281
(lp33742
(dp33743
g33284
I41
sg33285
I1
sg33286
I2
sg33287
VC0010674
p33744
sg33289
VCF
p33745
sa(dp33746
g33284
I24
sg33285
I2
sg33286
I15
sg33287
VC0010674
p33747
sg33289
Vcystic fibrosis
p33748
sa(dp33749
g33284
I52
sg33285
I4
sg33286
I32
sg33287
VC2242728
p33750
sg33289
Vcystic fibrosis related diabetes
p33751
sa(dp33752
g33284
I86
sg33285
I1
sg33286
I4
sg33287
VC2242728
p33753
sg33289
VCFRD
p33754
sasa(dp33755
g33277
VCNS anomalies included 12 Chiari malformations, 2 Dandy-Walker malformations (DWM), 1 variant of Dandy-Walker syndrome (DWS), 3 iniencephalies, 15 anencephalies, 1 alobar holoprosencephaly, 2 isolated hydrocephalies, 3 hydrocephalies with cerebellar hypoplasia, 1 occipital encephalocele, 1 lumbosacral myelomeningocele accompanied with microcephaly.
p33756
sg33279
(lp33757
sg33281
(lp33758
(dp33759
g33284
I50
sg33285
I2
sg33286
I26
sg33287
VC0010964
p33760
sg33289
VDandy-Walker malformations
p33761
sa(dp33762
g33284
I303
sg33285
I1
sg33286
I16
sg33287
VC0025312
p33763
sg33289
Vmyelomeningocele
p33764
sa(dp33765
g33284
I239
sg33285
I2
sg33286
I21
sg33287
VC0266470
p33766
sg33289
Vcerebellar hypoplasia
p33767
sa(dp33768
g33284
I26
sg33285
I2
sg33286
I20
sg33287
VC0003803
p33769
sg33289
VChiari malformations
p33770
sa(dp33771
g33284
I78
sg33285
I1
sg33286
I3
sg33287
VC0010964
p33772
sg33289
VDWM
p33773
sa(dp33774
g33284
I264
sg33285
I2
sg33286
I23
sg33287
VC0014067
p33775
sg33289
Voccipital encephalocele
p33776
sa(dp33777
g33284
I97
sg33285
I2
sg33286
I21
sg33287
VC0010964
p33778
sg33289
VDandy-Walker syndrome
p33779
sa(dp33780
g33284
I337
sg33285
I1
sg33286
I12
sg33287
VC0025958
p33781
sg33289
Vmicrocephaly
p33782
sa(dp33783
g33284
I120
sg33285
I1
sg33286
I3
sg33287
VC0010964
p33784
sg33289
VDWS
p33785
sa(dp33786
g33284
I128
sg33285
I1
sg33286
I14
sg33287
VC0152234
p33787
sg33289
Viniencephalies
p33788
sa(dp33789
g33284
I164
sg33285
I2
sg33286
I24
sg33287
VC0431363
p33790
sg33289
Valobar holoprosencephaly
p33791
sasa(dp33792
g33277
VAcrania, alobar holoprosencephaly, cephaloceles, and spina bifida can confidently be diagnosed at that stage and should actively be looked for in every fetus undergoing first-trimester ultrasound.
p33793
sg33279
(lp33794
sg33281
(lp33795
(dp33796
g33284
I9
sg33285
I2
sg33286
I24
sg33287
VC0431363
p33797
sg33289
Valobar holoprosencephaly
p33798
sa(dp33799
g33284
I53
sg33285
I2
sg33286
I12
sg33287
VC0080178
p33800
sg33289
Vspina bifida
p33801
sa(dp33802
g33284
I0
sg33285
I1
sg33286
I7
sg33287
VC0702169
p33803
sg33289
VAcrania
p33804
sa(dp33805
g33284
I35
sg33285
I1
sg33286
I12
sg33287
VC0014065
p33806
sg33289
Vcephaloceles
p33807
sasa(dp33808
g33277
VWe present a new case with 13q deletion syndrome phenotypically characterized by severe major malformations, some of them still undescribed, consisting of left diaphragmatic hernia, right pulmonary sequestration, hypoplastic left heart syndrome, pancreatic agenesis, polysplenia, and catastrophic central nervous system malformations: semilobar holoprosencephaly, occipital myelomeningocele, partial agenesis of the corpus callosum and agenesis of olfactory bulbs.
p33809
sg33279
(lp33810
sg33281
(lp33811
(dp33812
g33284
I257
sg33285
I1
sg33286
I8
sg33287
VC0332907
p33813
sg33289
Vagenesis
p33814
sa(dp33815
g33284
I213
sg33285
I4
sg33286
I31
sg33287
VC0152101
p33816
sg33289
Vhypoplastic left heart syndrome
p33817
sa(dp33818
g33284
I188
sg33285
I2
sg33286
I23
sg33287
VC0006288
p33819
sg33289
Vpulmonary sequestration
p33820
sa(dp33821
g33284
I335
sg33285
I2
sg33286
I27
sg33287
VC0751617
p33822
sg33289
Vsemilobar holoprosencephaly
p33823
sa(dp33824
g33284
I305
sg33285
I3
sg33286
I28
sg33287
VC0497552
p33825
sg33289
Vnervous system malformations
p33826
sa(dp33827
g33284
I374
sg33285
I1
sg33286
I16
sg33287
VC0025312
p33828
sg33289
Vmyelomeningocele
p33829
sa(dp33830
g33284
I392
sg33285
I6
sg33286
I39
sg33287
VC0431368
p33831
sg33289
Vpartial agenesis of the corpus callosum
p33832
sa(dp33833
g33284
I160
sg33285
I2
sg33286
I20
sg33287
VC0019284
p33834
sg33289
Vdiaphragmatic hernia
p33835
sa(dp33836
g33284
I94
sg33285
I1
sg33286
I13
sg33287
VC0000768
p33837
sg33289
Vmalformations
p33838
sa(dp33839
g33284
I267
sg33285
I1
sg33286
I11
sg33287
VC0266631
p33840
sg33289
Vpolysplenia
p33841
sa(dp33842
g33284
I27
sg33285
I3
sg33286
I21
sg33287
VC0265451
p33843
sg33289
V13q deletion syndrome
p33844
sa(dp33845
g33284
I257
sg33285
I1
sg33286
I8
sg33287
VC0332907
p33846
sg33289
Vagenesis
p33847
sasa(dp33848
g33277
VThe early scan detected all cases of acrania, alobar holoprosencephaly, exomphalos, gastroschisis, megacystis and body stalk anomaly, 77% of absent hand or foot, 50% of diaphragmatic hernia, 50% of lethal skeletal dysplasias, 60% of polydactyly, 34% of major cardiac defects, 5% of facial clefts and 14% of open spina bifida, but none of agenesis of the corpus callosum, cerebellar or vermian hypoplasia, echogenic lung lesions, bowel obstruction, most renal defects or talipes.
p33849
sg33279
(lp33850
sg33281
(lp33851
(dp33852
g33284
I393
sg33285
I1
sg33286
I10
sg33287
VC0243069
p33853
sg33289
Vhypoplasia
p33854
sa(dp33855
g33284
I214
sg33285
I1
sg33286
I10
sg33287
VC0334044
p33856
sg33289
Vdysplasias
p33857
sa(dp33858
g33284
I307
sg33285
I3
sg33286
I17
sg33287
VC0917813
p33859
sg33289
Vopen spina bifida
p33860
sa(dp33861
g33284
I338
sg33285
I5
sg33286
I31
sg33287
VC0175754
p33862
sg33289
Vagenesis of the corpus callosum
p33863
sa(dp33864
g33284
I84
sg33285
I1
sg33286
I13
sg33287
VC0265706
p33865
sg33289
Vgastroschisis
p33866
sa(dp33867
g33284
I37
sg33285
I1
sg33286
I7
sg33287
VC0702169
p33868
sg33289
Vacrania
p33869
sa(dp33870
g33284
I429
sg33285
I2
sg33286
I17
sg33287
VC0021843
p33871
sg33289
Vbowel obstruction
p33872
sa(dp33873
g33284
I470
sg33285
I1
sg33286
I7
sg33287
VC0009081
p33874
sg33289
Vtalipes
p33875
sa(dp33876
g33284
I259
sg33285
I2
sg33286
I15
sg33287
VC0741916
p33877
sg33289
Vcardiac defects
p33878
sa(dp33879
g33284
I46
sg33285
I2
sg33286
I24
sg33287
VC0431363
p33880
sg33289
Valobar holoprosencephaly
p33881
sa(dp33882
g33284
I282
sg33285
I2
sg33286
I13
sg33287
VC0685787
p33883
sg33289
Vfacial clefts
p33884
sa(dp33885
g33284
I169
sg33285
I2
sg33286
I20
sg33287
VC0019284
p33886
sg33289
Vdiaphragmatic hernia
p33887
sa(dp33888
g33284
I72
sg33285
I1
sg33286
I10
sg33287
VC1306503
p33889
sg33289
Vexomphalos
p33890
sa(dp33891
g33284
I233
sg33285
I1
sg33286
I11
sg33287
VC0152427
p33892
sg33289
Vpolydactyly
p33893
sa(dp33894
g33284
I119
sg33285
I1
sg33286
I5
sg33287
VC0935572
p33895
sg33289
Vstalk
p33896
sasa(dp33897
g33277
VThe case presented is, to our knowledge, the first published report comprising a combination of a semilobar holoprosencephaly associated with a Chiari II malformation and a myelomeningocele diagnosed prenatally and confirmed by postmortem neuropathologic evaluation.
p33898
sg33279
(lp33899
sg33281
(lp33900
(dp33901
g33284
I154
sg33285
I1
sg33286
I12
sg33287
VC0000768
p33902
sg33289
Vmalformation
p33903
sa(dp33904
g33284
I98
sg33285
I2
sg33286
I27
sg33287
VC0751617
p33905
sg33289
Vsemilobar holoprosencephaly
p33906
sa(dp33907
g33284
I173
sg33285
I1
sg33286
I16
sg33287
VC0025312
p33908
sg33289
Vmyelomeningocele
p33909
sasa(dp33910
g33277
VThese findings indicate that in the case of pre- and postnatal detection of a myelomeningocele and/or Chiari II malformation, possible additional intracranial malformation, such as a semilobar holoprosencephaly, should also be taken into account and vice versa.
p33911
sg33279
(lp33912
sg33281
(lp33913
(dp33914
g33284
I78
sg33285
I1
sg33286
I16
sg33287
VC0025312
p33915
sg33289
Vmyelomeningocele
p33916
sa(dp33917
g33284
I183
sg33285
I2
sg33286
I27
sg33287
VC0751617
p33918
sg33289
Vsemilobar holoprosencephaly
p33919
sa(dp33920
g33284
I112
sg33285
I1
sg33286
I12
sg33287
VC0000768
p33921
sg33289
Vmalformation
p33922
sa(dp33923
g33284
I112
sg33285
I1
sg33286
I12
sg33287
VC0000768
p33924
sg33289
Vmalformation
p33925
sasa(dp33926
g33277
VWe report on a female still-birth with cebocephaly, alobar holoprosencephaly, cleft palate, lumbar spina bifida, sirenomelia, a single umbilical artery, and a 46,XX karyotype, but without maternal diabetes mellitus.
p33927
sg33279
(lp33928
sg33281
(lp33929
(dp33930
g33284
I188
sg33285
I3
sg33286
I26
sg33287
VC1283034
p33931
sg33289
Vmaternal diabetes mellitus
p33932
sa(dp33933
g33284
I99
sg33285
I2
sg33286
I12
sg33287
VC0080178
p33934
sg33289
Vspina bifida
p33935
sa(dp33936
g33284
I113
sg33285
I1
sg33286
I11
sg33287
VC0037205
p33937
sg33289
Vsirenomelia
p33938
sa(dp33939
g33284
I78
sg33285
I2
sg33286
I12
sg33287
VC0008925
p33940
sg33289
Vcleft palate
p33941
sa(dp33942
g33284
I39
sg33285
I1
sg33286
I11
sg33287
VC0266679
p33943
sg33289
Vcebocephaly
p33944
sa(dp33945
g33284
I52
sg33285
I2
sg33286
I24
sg33287
VC0431363
p33946
sg33289
Valobar holoprosencephaly
p33947
sa(dp33948
g33284
I128
sg33285
I3
sg33286
I23
sg33287
VC0266795
p33949
sg33289
Vsingle umbilical artery
p33950
sasa(dp33951
g33277
VThe current study provides novel evidence that TGFBeta upregulates the expression of multiple receptor tyrosine kinases (RTKs), including IGF1R, EGFR, PDGFBetaR, and FGFR1 in human hepatocellular carcinoma (HCC) cells.
p33952
sg33279
(lp33953
(dp33954
g33284
I47
sg33285
I1
sg33286
I7
sg33295
VP01137
p33955
sg33289
VTGFBeta
p33956
sa(dp33957
g33284
I166
sg33285
I1
sg33286
I5
sg33295
VP20930
p33958
sg33289
VFGFR1
p33959
sa(dp33960
g33284
I94
sg33285
I3
sg33286
I25
sg33295
VP29401
p33961
sg33289
Vreceptor tyrosine kinases
p33962
sa(dp33963
g33284
I121
sg33285
I1
sg33286
I4
sg33295
VP35968
p33964
sg33289
VRTKs
p33965
sa(dp33966
g33284
I138
sg33285
I1
sg33286
I5
sg33295
VP08069
p33967
sg33289
VIGF1R
p33968
sasg33281
(lp33969
(dp33970
g33284
I207
sg33285
I1
sg33286
I3
sg33287
VC2239176
p33971
sg33289
VHCC
p33972
sa(dp33973
g33284
I181
sg33285
I2
sg33286
I24
sg33287
VC2239176
p33974
sg33289
Vhepatocellular carcinoma
p33975
sasa(dp33976
g33277
VWhile numerical and functional defects of invariant NKT cells have been demonstrated in rheumatoid arthritis (RA), the detailed characterization of proliferative and secretory responses following CD1d-mediated presentation is lacking; the presence of non-invariant populations has never been assessed in human autoimmunity.
p33977
sg33279
(lp33978
(dp33979
g33284
I196
sg33285
I1
sg33286
I4
sg33295
VP15813
p33980
sg33289
VCD1d
p33981
sasg33281
(lp33982
(dp33983
g33284
I310
sg33285
I1
sg33286
I12
sg33287
VC0004368
p33984
sg33289
Vautoimmunity
p33985
sa(dp33986
g33284
I110
sg33285
I1
sg33286
I2
sg33287
VC0003873
p33987
sg33289
VRA
p33988
sa(dp33989
g33284
I148
sg33285
I1
sg33286
I13
sg33287
VC0334094
p33990
sg33289
Vproliferative
p33991
sa(dp33992
g33284
I88
sg33285
I2
sg33286
I20
sg33287
VC0003873
p33993
sg33289
Vrheumatoid arthritis
p33994
sasa(dp33995
g33277
VIn adults, angiopoietin-2 (Ang-2) and its soluble receptor (sTie-2) are associated with diabetes, hypertension, and obesity and could be increased in children with OSA and obesity, particularly those with evidence of cardiometabolic alterations.
p33996
sg33279
(lp33997
(dp33998
g33284
I27
sg33285
I1
sg33286
I5
sg33295
VP03950
p33999
sg33289
VAng-2
p34000
sa(dp34001
g33284
I11
sg33285
I1
sg33286
I14
sg33295
g11
sg33289
Vangiopoietin-2
p34002
sasg33281
(lp34003
(dp34004
g33284
I98
sg33285
I1
sg33286
I12
sg33287
VC0020538
p34005
sg33289
Vhypertension
p34006
sa(dp34007
g33284
I88
sg33285
I1
sg33286
I8
sg33287
VC0011849
p34008
sg33289
Vdiabetes
p34009
sa(dp34010
g33284
I116
sg33285
I1
sg33286
I7
sg33287
VC0028754
p34011
sg33289
Vobesity
p34012
sa(dp34013
g33284
I116
sg33285
I1
sg33286
I7
sg33287
VC0028754
p34014
sg33289
Vobesity
p34015
sa(dp34016
g33284
I164
sg33285
I1
sg33286
I3
sg33287
VC0520679
p34017
sg33289
VOSA
p34018
sasa(dp34019
g33277
VChildren with obesity and OSA had significantly elevated plasma Ang-2 and sTie-2 levels compared to corresponding controls with and without obesity.
p34020
sg33279
(lp34021
(dp34022
g33284
I57
sg33285
I2
sg33286
I12
sg33295
VP03950
p34023
sg33289
Vplasma Ang-2
p34024
sasg33281
(lp34025
(dp34026
g33284
I14
sg33285
I1
sg33286
I7
sg33287
VC0028754
p34027
sg33289
Vobesity
p34028
sa(dp34029
g33284
I14
sg33285
I1
sg33286
I7
sg33287
VC0028754
p34030
sg33289
Vobesity
p34031
sa(dp34032
g33284
I26
sg33285
I1
sg33286
I3
sg33287
VC0520679
p34033
sg33289
VOSA
p34034
sasa(dp34035
g33277
VAng-2 and sTie-2 plasma levels are increased in pediatric OSA and obesity, particularly when endothelial dysfunction or insulin resistance is detectable, and appear to decrease upon OSA treatment.
p34036
sg33279
(lp34037
(dp34038
g33284
I120
sg33285
I1
sg33286
I7
sg33295
VP01308
p34039
sg33289
Vinsulin
p34040
sa(dp34041
g33284
I0
sg33285
I1
sg33286
I5
sg33295
VP03950
p34042
sg33289
VAng-2
p34043
sasg33281
(lp34044
(dp34045
g33284
I58
sg33285
I1
sg33286
I3
sg33287
VC0520679
p34046
sg33289
VOSA
p34047
sa(dp34048
g33284
I66
sg33285
I1
sg33286
I7
sg33287
VC0028754
p34049
sg33289
Vobesity
p34050
sa(dp34051
g33284
I58
sg33285
I1
sg33286
I3
sg33287
VC0520679
p34052
sg33289
VOSA
p34053
sa(dp34054
g33284
I120
sg33285
I2
sg33286
I18
sg33287
VC0021655
p34055
sg33289
Vinsulin resistance
p34056
sa(dp34057
g33284
I93
sg33285
I2
sg33286
I23
sg33287
VC0856169
p34058
sg33289
Vendothelial dysfunction
p34059
sasa(dp34060
g33277
VANG-2 overexpressing mice show increased sWAT vascularization and are resistant to HFD-induced obesity.
p34061
sg33279
(lp34062
(dp34063
g33284
I0
sg33285
I1
sg33286
I5
sg33295
VP03950
p34064
sg33289
VANG-2
p34065
sasg33281
(lp34066
(dp34067
g33284
I95
sg33285
I1
sg33286
I7
sg33287
VC0028754
p34068
sg33289
Vobesity
p34069
sa(dp34070
g33284
I46
sg33285
I1
sg33286
I15
sg33287
VC0027686
p34071
sg33289
Vvascularization
p34072
sasa(dp34073
g33277
VWe studied the effect of sleeve gastrectomy and the influence of FTO rs9930506 polymorphism on Tie-2, angiopoietin-1 and angiopoietin-2 expression in morbid obesity.
p34074
sg33279
(lp34075
(dp34076
g33284
I102
sg33285
I1
sg33286
I14
sg33295
g11
sg33289
Vangiopoietin-1
p34077
sa(dp34078
g33284
I121
sg33285
I1
sg33286
I14
sg33295
g11
sg33289
Vangiopoietin-2
p34079
sa(dp34080
g33284
I65
sg33285
I2
sg33286
I13
sg33295
g11
sg33289
VFTO rs9930506
p34081
sa(dp34082
g33284
I95
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTie-2
p34083
sasg33281
(lp34084
(dp34085
g33284
I150
sg33285
I2
sg33286
I14
sg33287
VC0028756
p34086
sg33289
Vmorbid obesity
p34087
sasa(dp34088
g33277
VThose most at risk report a family history of at least one parent with a pre-existing G-alpha protein defect, including night blindness, pseudohypoparathyroidism or adenoma of the thyroid or pituitary gland.
p34089
sg33279
(lp34090
sg33281
(lp34091
(dp34092
g33284
I165
sg33285
I4
sg33286
I22
sg33287
VC0151468
p34093
sg33289
Vadenoma of the thyroid
p34094
sa(dp34095
g33284
I137
sg33285
I1
sg33286
I24
sg33287
VC3494506
p34096
sg33289
Vpseudohypoparathyroidism
p34097
sa(dp34098
g33284
I120
sg33285
I2
sg33286
I15
sg33287
VC0028077
p34099
sg33289
Vnight blindness
p34100
sasa(dp34101
g33277
VWe have previously shown that the ethanol extract of dried Angelica gigas Nakai (AGN) root exerts anticancer activity against androgen receptor (AR)-negative human DU145 and PC-3 prostate cancer xenografts and primary carcinogenesis in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
p34102
sg33279
(lp34103
(dp34104
g33284
I126
sg33285
I2
sg33286
I17
sg33295
VP10275
p34105
sg33289
Vandrogen receptor
p34106
sa(dp34107
g33284
I145
sg33285
I1
sg33286
I2
sg33295
VP10275
p34108
sg33289
VAR
p34109
sasg33281
(lp34110
(dp34111
g33284
I251
sg33285
I1
sg33286
I14
sg33287
VC0001418
p34112
sg33289
Vadenocarcinoma
p34113
sa(dp34114
g33284
I218
sg33285
I1
sg33286
I14
sg33287
VC0596263
p34115
sg33289
Vcarcinogenesis
p34116
sa(dp34117
g33284
I179
sg33285
I2
sg33286
I15
sg33287
VC0600139
p34118
sg33289
Vprostate cancer
p34119
sasa(dp34120
g33277
VWe showed previously that nuclear localization of the androgen receptor (AR) and expression of the androgen-responsive gene FK506-binding protein 5 (FKBP5) in esophageal adenocarcinoma (EAC) tissues were associated with decreased patient survival, suggesting a role for androgens in this cancer.
p34121
sg33279
(lp34122
(dp34123
g33284
I73
sg33285
I1
sg33286
I2
sg33295
VP10275
p34124
sg33289
VAR
p34125
sa(dp34126
g33284
I99
sg33285
I5
sg33286
I48
sg33295
g11
sg33289
Vandrogen-responsive gene FK506-binding protein 5
p34127
sa(dp34128
g33284
I149
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VFKBP5
p34129
sa(dp34130
g33284
I54
sg33285
I2
sg33286
I17
sg33295
VP10275
p34131
sg33289
Vandrogen receptor
p34132
sasg33281
(lp34133
(dp34134
g33284
I159
sg33285
I2
sg33286
I25
sg33287
VC0279628
p34135
sg33289
Vesophageal adenocarcinoma
p34136
sa(dp34137
g33284
I288
sg33285
I1
sg33286
I6
sg33287
VC0006826
p34138
sg33289
Vcancer
p34139
sa(dp34140
g33284
I186
sg33285
I1
sg33286
I3
sg33287
VC1275122
p34141
sg33289
VEAC
p34142
sasa(dp34143
g33277
VOnly 5 samples were ERG-/AR- corresponding to adenocarcinoma GS of 6.
p34144
sg33279
(lp34145
(dp34146
g33284
I46
sg33285
I2
sg33286
I17
sg33295
VP15104
p34147
sg33289
Vadenocarcinoma GS
p34148
sasg33281
(lp34149
(dp34150
g33284
I46
sg33285
I1
sg33286
I14
sg33287
VC0001418
p34151
sg33289
Vadenocarcinoma
p34152
sasa(dp34153
g33277
VAR was expressed by 54% (27/50) of ECA including 60% of low grade endometrioid carcinomas, 70% high grade endometrioid carcinomas, 70% serous carcinomas, 50% carcinosarcomas, and 20% clear cell carcinomas.
p34154
sg33279
(lp34155
sg33281
(lp34156
(dp34157
g33284
I79
sg33285
I1
sg33286
I10
sg33287
VC0007097
p34158
sg33289
Vcarcinomas
p34159
sa(dp34160
g33284
I66
sg33285
I2
sg33286
I23
sg33287
VC0206687
p34161
sg33289
Vendometrioid carcinomas
p34162
sa(dp34163
g33284
I79
sg33285
I1
sg33286
I10
sg33287
VC0007097
p34164
sg33289
Vcarcinomas
p34165
sa(dp34166
g33284
I158
sg33285
I1
sg33286
I15
sg33287
VC0007140
p34167
sg33289
Vcarcinosarcomas
p34168
sa(dp34169
g33284
I66
sg33285
I2
sg33286
I23
sg33287
VC0206687
p34170
sg33289
Vendometrioid carcinomas
p34171
sasa(dp34172
g33277
VHigh AR expression was chiefly restricted to a subset of serous carcinomas (50%).
p34173
sg33279
(lp34174
sg33281
(lp34175
(dp34176
g33284
I64
sg33285
I1
sg33286
I10
sg33287
VC0007097
p34177
sg33289
Vcarcinomas
p34178
sasa(dp34179
g33277
VAR expression occurred most often in concert with ER staining, although 5 high grade cancers (1 serous carcinoma, 4 carcinosarcomas) showed AR expression in the absence of ER.
p34180
sg33279
(lp34181
sg33281
(lp34182
(dp34183
g33284
I85
sg33285
I1
sg33286
I7
sg33287
VC0006826
p34184
sg33289
Vcancers
p34185
sa(dp34186
g33284
I116
sg33285
I1
sg33286
I15
sg33287
VC0007140
p34187
sg33289
Vcarcinosarcomas
p34188
sa(dp34189
g33284
I96
sg33285
I2
sg33286
I16
sg33287
VC0206701
p34190
sg33289
Vserous carcinoma
p34191
sasa(dp34192
g33277
VIn summary, AR positivity is seen in over half of ECA in our study, including the majority of low grade endometrioid carcinomas, high grade endometrioid carcinomas, and serous carcinomas.
p34193
sg33279
(lp34194
sg33281
(lp34195
(dp34196
g33284
I104
sg33285
I2
sg33286
I23
sg33287
VC0206687
p34197
sg33289
Vendometrioid carcinomas
p34198
sa(dp34199
g33284
I117
sg33285
I1
sg33286
I10
sg33287
VC0007097
p34200
sg33289
Vcarcinomas
p34201
sa(dp34202
g33284
I104
sg33285
I2
sg33286
I23
sg33287
VC0206687
p34203
sg33289
Vendometrioid carcinomas
p34204
sasa(dp34205
g33277
VHigh level expression is seen in half of serous carcinomas and a subset of serous carcinomas and carcinosarcomas show some degree of AR staining in the absence of ER, suggesting a possible role for androgen inhibition in treatment of these cases.
p34206
sg33279
(lp34207
sg33281
(lp34208
(dp34209
g33284
I48
sg33285
I1
sg33286
I10
sg33287
VC0007097
p34210
sg33289
Vcarcinomas
p34211
sa(dp34212
g33284
I97
sg33285
I1
sg33286
I15
sg33287
VC0007140
p34213
sg33289
Vcarcinosarcomas
p34214
sa(dp34215
g33284
I48
sg33285
I1
sg33286
I10
sg33287
VC0007097
p34216
sg33289
Vcarcinomas
p34217
sasa(dp34218
g33277
VIL-6 and the MSC markers CD166 and nestin were colocalized in macroscopically normal human cartilage taken from the lateral femoral compartment of knees with medial tibiofemoral osteoarthritis.
p34219
sg33279
(lp34220
(dp34221
g33284
I35
sg33285
I1
sg33286
I6
sg33295
VP48681
p34222
sg33289
Vnestin
p34223
sa(dp34224
g33284
I25
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCD166
p34225
sa(dp34226
g33284
I13
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VMSC
p34227
sa(dp34228
g33284
I0
sg33285
I1
sg33286
I4
sg33295
VP05231
p34229
sg33289
VIL-6
p34230
sasg33281
(lp34231
(dp34232
g33284
I178
sg33285
I1
sg33286
I14
sg33287
VC0029408
p34233
sg33289
Vosteoarthritis
p34234
sasa(dp34235
g33277
VIn conclusion, our findings support a model where Sirt3 plays a protective role against oxidative stress in oocytes exposed to maternal diabetes through deacetylating SOD2K68.
p34236
sg33279
(lp34237
(dp34238
g33284
I50
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSirt3
p34239
sasg33281
(lp34240
(dp34241
g33284
I127
sg33285
I2
sg33286
I17
sg33287
VC0085207
p34242
sg33289
Vmaternal diabetes
p34243
sa(dp34244
g33284
I88
sg33285
I2
sg33286
I16
sg33287
VC0242606
p34245
sg33289
Voxidative stress
p34246
sasa(dp34247
g33277
VThe aim of our study was to investigate the effects of LPL (rs320), LIPC (rs2070895), SCARB1 (rs5888), LCAT (rs2292318), CETP (rs708272), ADIPOQ (rs1501299), RETN (rs3745367), PON1 (rs662), and MNSOD (rs4880) gene polymorphisms on lipid metabolism and diabetic dyslipidemia.
p34248
sg33279
(lp34249
(dp34250
g33284
I55
sg33285
I1
sg33286
I3
sg33295
VP06858
p34251
sg33289
VLPL
p34252
sa(dp34253
g33284
I194
sg33285
I1
sg33286
I5
sg33295
VP04179
p34254
sg33289
VMNSOD
p34255
sa(dp34256
g33284
I121
sg33285
I1
sg33286
I4
sg33295
VP11597
p34257
sg33289
VCETP
p34258
sa(dp34259
g33284
I86
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VSCARB1
p34260
sa(dp34261
g33284
I158
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VRETN
p34262
sa(dp34263
g33284
I68
sg33285
I2
sg33286
I16
sg33295
VP11150
p34264
sg33289
VLIPC (rs2070895)
p34265
sa(dp34266
g33284
I176
sg33285
I1
sg33286
I4
sg33295
VP27169
p34267
sg33289
VPON1
p34268
sasg33281
(lp34269
(dp34270
g33284
I252
sg33285
I2
sg33286
I21
sg33287
VC3160761
p34271
sg33289
Vdiabetic dyslipidemia
p34272
sasa(dp34273
g33277
VSignificant associations were observed between LPL (rs320) (p&lt;0.001), LIPC (rs2070895) (p&lt;0.001), SCARB1 (rs5888) (p&lt;0.001), LCAT (rs2292318) (p&lt;0.001), CETP (rs708272) (p&lt;0.001), ADIPOQ (rs1501299) (p=0.01), RETN (rs3745367) (p&lt;0.001), and MNSOD (rs4880) (p&lt;0.001) polymorphisms and diabetic dyslipidemia.
p34274
sg33279
(lp34275
(dp34276
g33284
I73
sg33285
I1
sg33286
I4
sg33295
VP11150
p34277
sg33289
VLIPC
p34278
sa(dp34279
g33284
I47
sg33285
I1
sg33286
I3
sg33295
VP06858
p34280
sg33289
VLPL
p34281
sa(dp34282
g33284
I104
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VSCARB1
p34283
sa(dp34284
g33284
I259
sg33285
I1
sg33286
I5
sg33295
VP04179
p34285
sg33289
VMNSOD
p34286
sa(dp34287
g33284
I165
sg33285
I1
sg33286
I4
sg33295
VP11597
p34288
sg33289
VCETP
p34289
sa(dp34290
g33284
I224
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VRETN
p34291
sasg33281
(lp34292
(dp34293
g33284
I305
sg33285
I2
sg33286
I21
sg33287
VC3160761
p34294
sg33289
Vdiabetic dyslipidemia
p34295
sasa(dp34296
g33277
VLPL (rs320), LIPC (rs2070895), SCARB1 (rs5888), LCAT (rs2292318), CETP (rs708272), ADIPOQ (rs1501299), RETN (rs3745367), and MNSOD (rs4880) polymorphisms play an important role in basic molecular metabolism in diabetic dyslipidemia.
p34297
sg33279
(lp34298
(dp34299
g33284
I31
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VSCARB1
p34300
sa(dp34301
g33284
I13
sg33285
I2
sg33286
I16
sg33295
VP11150
p34302
sg33289
VLIPC (rs2070895)
p34303
sa(dp34304
g33284
I103
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VRETN
p34305
sa(dp34306
g33284
I0
sg33285
I1
sg33286
I3
sg33295
VP06858
p34307
sg33289
VLPL
p34308
sa(dp34309
g33284
I66
sg33285
I1
sg33286
I4
sg33295
VP11597
p34310
sg33289
VCETP
p34311
sa(dp34312
g33284
I125
sg33285
I1
sg33286
I5
sg33295
VP04179
p34313
sg33289
VMNSOD
p34314
sasg33281
(lp34315
(dp34316
g33284
I210
sg33285
I2
sg33286
I21
sg33287
VC3160761
p34317
sg33289
Vdiabetic dyslipidemia
p34318
sasa(dp34319
g33277
VWe studied if YKL-40 is related to inflammation, fibrosis, and/or lung function in subjects exposed to asbestosis.
p34320
sg33279
(lp34321
sg33281
(lp34322
(dp34323
g33284
I35
sg33285
I1
sg33286
I12
sg33287
VC0021368
p34324
sg33289
Vinflammation
p34325
sa(dp34326
g33284
I103
sg33285
I1
sg33286
I10
sg33287
VC0003949
p34327
sg33289
Vasbestosis
p34328
sa(dp34329
g33284
I49
sg33285
I1
sg33286
I8
sg33287
VC0016059
p34330
sg33289
Vfibrosis
p34331
sasa(dp34332
g33277
VPlasma YKL-40 levels were significantly higher in subjects with asbestosis (n = 19) than in those with no fibrotic findings in HRCT following asbestos exposure (n = 66) or in unexposed healthy controls.
p34333
sg33279
(lp34334
(dp34335
g33284
I0
sg33285
I2
sg33286
I13
sg33295
VP36222
p34336
sg33289
VPlasma YKL-40
p34337
sasg33281
(lp34338
(dp34339
g33284
I64
sg33285
I1
sg33286
I10
sg33287
VC0003949
p34340
sg33289
Vasbestosis
p34341
sasa(dp34342
g33277
VYKL-40 is a promising marker of cardiovascular disease and liver siderosis in Beta-TM patients.
p34343
sg33279
(lp34344
(dp34345
g33284
I0
sg33285
I1
sg33286
I6
sg33295
VP36222
p34346
sg33289
VYKL-40
p34347
sasg33281
(lp34348
(dp34349
g33284
I65
sg33285
I1
sg33286
I9
sg33287
VC0037061
p34350
sg33289
Vsiderosis
p34351
sa(dp34352
g33284
I32
sg33285
I2
sg33286
I22
sg33287
VC0007222
p34353
sg33289
Vcardiovascular disease
p34354
sasa(dp34355
g33277
VThe aim of the study was to analyse the level of serum YKL-40 and plasma chitotriosidase activity of patients with beta-thalassemia to assess whether their expression correlates with liver disease and degree of liver siderosis.
p34356
sg33279
(lp34357
(dp34358
g33284
I49
sg33285
I2
sg33286
I12
sg33295
VP36222
p34359
sg33289
Vserum YKL-40
p34360
sa(dp34361
g33284
I66
sg33285
I2
sg33286
I22
sg33295
g11
sg33289
Vplasma chitotriosidase
p34362
sasg33281
(lp34363
(dp34364
g33284
I115
sg33285
I1
sg33286
I16
sg33287
VC0005283
p34365
sg33289
Vbeta-thalassemia
p34366
sa(dp34367
g33284
I217
sg33285
I1
sg33286
I9
sg33287
VC0037061
p34368
sg33289
Vsiderosis
p34369
sa(dp34370
g33284
I183
sg33285
I2
sg33286
I13
sg33287
VC0023895
p34371
sg33289
Vliver disease
p34372
sasa(dp34373
g33277
VOur results demonstrated that (1) Invasive ductal carcinoma patients with low expression of Slit2 or Robo1 exhibited worse prognosis and brain-specific metastasis, but not liver, bone or lung.
p34374
sg33279
(lp34375
(dp34376
g33284
I101
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VRobo1
p34377
sa(dp34378
g33284
I92
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSlit2
p34379
sasg33281
(lp34380
(dp34381
g33284
I152
sg33285
I1
sg33286
I10
sg33287
VC0027627
p34382
sg33289
Vmetastasis
p34383
sa(dp34384
g33284
I34
sg33285
I3
sg33286
I25
sg33287
VC1134719
p34385
sg33289
VInvasive ductal carcinoma
p34386
sasa(dp34387
g33277
VTen prognostic and diagnostic epigenetic breast cancer biomarkers (PITX2, RASSF1A, PLAU, LHX3, PITX3, LIMK1, SLITRK1, SLIT2, HS3ST2, and TFF1) were analyzed in tissue samples obtained from two patients with invasive ductal carcinoma of the breast.
p34388
sg33279
(lp34389
(dp34390
g33284
I102
sg33285
I1
sg33286
I5
sg33295
VP53667
p34391
sg33289
VLIMK1
p34392
sa(dp34393
g33284
I137
sg33285
I1
sg33286
I4
sg33295
VP04155
p34394
sg33289
VTFF1
p34395
sa(dp34396
g33284
I125
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VHS3ST2
p34397
sa(dp34398
g33284
I83
sg33285
I1
sg33286
I4
sg33295
VP00749
p34399
sg33289
VPLAU
p34400
sa(dp34401
g33284
I109
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VSLITRK1
p34402
sa(dp34403
g33284
I89
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VLHX3
p34404
sa(dp34405
g33284
I67
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VPITX2
p34406
sa(dp34407
g33284
I118
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSLIT2
p34408
sa(dp34409
g33284
I95
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VPITX3
p34410
sasg33281
(lp34411
(dp34412
g33284
I41
sg33285
I2
sg33286
I13
sg33287
VC0678222
p34413
sg33289
Vbreast cancer
p34414
sa(dp34415
g33284
I207
sg33285
I6
sg33286
I39
sg33287
VC1134719
p34416
sg33289
Vinvasive ductal carcinoma of the breast
p34417
sasa(dp34418
g33277
VThe aim of this study is to determine the correlation between methylation status of multiple cancer genes, p16(INK4A), p14(ARF), Cyclin D2 and Slit2 in invasive ductal carcinoma of the breast and paired serum DNA and clinicopathological parameters.
p34419
sg33279
(lp34420
(dp34421
g33284
I119
sg33285
I1
sg33286
I3
sg33295
VP03971
p34422
sg33289
Vp14
p34423
sa(dp34424
g33284
I129
sg33285
I2
sg33286
I9
sg33295
VP30279
p34425
sg33289
VCyclin D2
p34426
sa(dp34427
g33284
I107
sg33285
I1
sg33286
I3
sg33295
VP42771
p34428
sg33289
Vp16
p34429
sa(dp34430
g33284
I123
sg33285
I1
sg33286
I3
sg33295
VP42771
p34431
sg33289
VARF
p34432
sa(dp34433
g33284
I143
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSlit2
p34434
sa(dp34435
g33284
I111
sg33285
I1
sg33286
I5
sg33295
VP42771
p34436
sg33289
VINK4A
p34437
sasg33281
(lp34438
(dp34439
g33284
I123
sg33285
I1
sg33286
I3
sg33287
VC0264490
p34440
sg33289
VARF
p34441
sa(dp34442
g33284
I152
sg33285
I6
sg33286
I39
sg33287
VC1134719
p34443
sg33289
Vinvasive ductal carcinoma of the breast
p34444
sa(dp34445
g33284
I84
sg33285
I2
sg33286
I15
sg33287
VC0346429
p34446
sg33289
Vmultiple cancer
p34447
sasa(dp34448
g33277
VTo examine the role of IRS2 in allergic disease, we evaluated the responses of IRS2-deficient (IRS2(-/-)) mice.
p34449
sg33279
(lp34450
(dp34451
g33284
I23
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VIRS2
p34452
sa(dp34453
g33284
I23
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VIRS2
p34454
sa(dp34455
g33284
I23
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VIRS2
p34456
sasg33281
(lp34457
sa(dp34458
g33277
VAdditional work further confirmed CDK6, RICTOR, and CTSB (cathepsin B) as targets of miR-218 and examined the functional role of one of these targets, CDK6, in medulloblastoma.
p34459
sg33279
(lp34460
(dp34461
g33284
I34
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCDK6
p34462
sa(dp34463
g33284
I34
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCDK6
p34464
sa(dp34465
g33284
I40
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VRICTOR
p34466
sasg33281
(lp34467
(dp34468
g33284
I160
sg33285
I1
sg33286
I15
sg33287
VC0025149
p34469
sg33289
Vmedulloblastoma
p34470
sasa(dp34471
g33277
VOverexpression of CDK6 is present in approximately one-third of medulloblastomas and is an independent poor prognostic marker for this disease.
p34472
sg33279
(lp34473
(dp34474
g33284
I18
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCDK6
p34475
sasg33281
(lp34476
(dp34477
g33284
I64
sg33285
I1
sg33286
I16
sg33287
VC0025149
p34478
sg33289
Vmedulloblastomas
p34479
sasa(dp34480
g33277
VMicroRNA (miR)-124 inhibits expression of CDK6 and prevents proliferation of glioblastoma and medulloblastoma cells in vitro.
p34481
sg33279
(lp34482
(dp34483
g33284
I42
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCDK6
p34484
sasg33281
(lp34485
(dp34486
g33284
I94
sg33285
I1
sg33286
I15
sg33287
VC0025149
p34487
sg33289
Vmedulloblastoma
p34488
sa(dp34489
g33284
I77
sg33285
I1
sg33286
I12
sg33287
VC0017636
p34490
sg33289
Vglioblastoma
p34491
sa(dp34492
g33284
I60
sg33285
I1
sg33286
I13
sg33287
VC0334094
p34493
sg33289
Vproliferation
p34494
sasa(dp34495
g33277
VWe examined the effects of miR-124 overexpression on medulloblastoma cells both in vitro and in vivo and compared cell lines that have low and high CDK6 expression.
p34496
sg33279
(lp34497
(dp34498
g33284
I148
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCDK6
p34499
sasg33281
(lp34500
(dp34501
g33284
I53
sg33285
I1
sg33286
I15
sg33287
VC0025149
p34502
sg33289
Vmedulloblastoma
p34503
sasa(dp34504
g33277
VMiR-124 overexpression inhibits the proliferation of medulloblastoma cells, and this effect is mediated mostly through the action of miR-124 upon CDK6.
p34505
sg33279
(lp34506
(dp34507
g33284
I133
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VmiR-124
p34508
sa(dp34509
g33284
I0
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VMiR
p34510
sa(dp34511
g33284
I146
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCDK6
p34512
sasg33281
(lp34513
(dp34514
g33284
I53
sg33285
I1
sg33286
I15
sg33287
VC0025149
p34515
sg33289
Vmedulloblastoma
p34516
sa(dp34517
g33284
I36
sg33285
I1
sg33286
I13
sg33287
VC0334094
p34518
sg33289
Vproliferation
p34519
sasa(dp34520
g33277
VCDK6 is overexpressed in medulloblastoma patients and is associated with an adverse prognosis.
p34521
sg33279
(lp34522
(dp34523
g33284
I0
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCDK6
p34524
sasg33281
(lp34525
(dp34526
g33284
I25
sg33285
I1
sg33286
I15
sg33287
VC0025149
p34527
sg33289
Vmedulloblastoma
p34528
sasa(dp34529
g33277
VTo investigate the role of CDK6 in medulloblastoma, we assayed the effect of CDK6 inhibition on proliferation by depleting expression with RNA interference (RNAi) or by inhibiting kinase function with a small molecule inhibitor, PD0332991.
p34530
sg33279
(lp34531
(dp34532
g33284
I27
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCDK6
p34533
sa(dp34534
g33284
I27
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCDK6
p34535
sasg33281
(lp34536
(dp34537
g33284
I35
sg33285
I1
sg33286
I15
sg33287
VC0025149
p34538
sg33289
Vmedulloblastoma
p34539
sa(dp34540
g33284
I96
sg33285
I1
sg33286
I13
sg33287
VC0334094
p34541
sg33289
Vproliferation
p34542
sasa(dp34543
g33277
VGene expression analysis revealed that CDK6 mRNA expression is higher than normal cerebellum in fifteen out of sixteen medulloblastoma patient samples.
p34544
sg33279
(lp34545
(dp34546
g33284
I39
sg33285
I2
sg33286
I9
sg33295
g11
sg33289
VCDK6 mRNA
p34547
sasg33281
(lp34548
(dp34549
g33284
I119
sg33285
I1
sg33286
I15
sg33287
VC0025149
p34550
sg33289
Vmedulloblastoma
p34551
sasa(dp34552
g33277
VInhibition of CDK6 by RNAi significantly decreased medulloblastoma cell proliferation and colony forming potential.
p34553
sg33279
(lp34554
(dp34555
g33284
I14
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCDK6
p34556
sasg33281
(lp34557
(dp34558
g33284
I51
sg33285
I1
sg33286
I15
sg33287
VC0025149
p34559
sg33289
Vmedulloblastoma
p34560
sa(dp34561
g33284
I72
sg33285
I1
sg33286
I13
sg33287
VC0334094
p34562
sg33289
Vproliferation
p34563
sasa(dp34564
g33277
VOur findings suggest that targeting CDK6 with small molecule inhibitors may prove beneficial in the treatment of medulloblastoma, especially when combined with radiation.
p34565
sg33279
(lp34566
(dp34567
g33284
I36
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCDK6
p34568
sasg33281
(lp34569
(dp34570
g33284
I113
sg33285
I1
sg33286
I15
sg33287
VC0025149
p34571
sg33289
Vmedulloblastoma
p34572
sasa(dp34573
g33277
VIn trichoblastic fibroma (three cases), CK1/5/10/14, CK7, CK8/18, CK10/11, CK14, CK17 and CK19 were expressed in the basaloid nests, and CK6 and involucrin were detected in the inner layers of keratinous cysts.
p34574
sg33279
(lp34575
(dp34576
g33284
I75
sg33285
I1
sg33286
I4
sg33295
VP02533
p34577
sg33289
VCK14
p34578
sa(dp34579
g33284
I145
sg33285
I1
sg33286
I10
sg33295
VP07476
p34580
sg33289
Vinvolucrin
p34581
sa(dp34582
g33284
I66
sg33285
I1
sg33286
I7
sg33295
VP13645
p34583
sg33289
VCK10/11
p34584
sa(dp34585
g33284
I53
sg33285
I1
sg33286
I3
sg33295
VP08729
p34586
sg33289
VCK7
p34587
sa(dp34588
g33284
I40
sg33285
I1
sg33286
I11
sg33295
VP48729
p34589
sg33289
VCK1/5/10/14
p34590
sasg33281
(lp34591
(dp34592
g33284
I3
sg33285
I2
sg33286
I21
sg33287
VC1704236
p34593
sg33289
Vtrichoblastic fibroma
p34594
sa(dp34595
g33284
I204
sg33285
I1
sg33286
I5
sg33287
VC0010709
p34596
sg33289
Vcysts
p34597
sasa(dp34598
g33277
VSince type 1 diabetes mellitus often begins in childhood, we used juvenile (4- to 5-wk-old) rats to demonstrate that a single bout of IIH (5 U/kg sc) reduced plasma glucose by 24% and peak epinephrine by 59% 1 day later.
p34599
sg33279
(lp34600
sg33281
(lp34601
(dp34602
g33284
I6
sg33285
I4
sg33286
I24
sg33287
VC0011854
p34603
sg33289
Vtype 1 diabetes mellitus
p34604
sasa(dp34605
g33277
VPlasma membrane NADH oxidoreductase activity, studied using cytosolic NADH as substrate and assayed with DCIP as acceptor, was significantly increased in IDDM patients, suggesting a response to a deficient mitochondrial energetic activity.
p34606
sg33279
(lp34607
(dp34608
g33284
I60
sg33285
I2
sg33286
I14
sg33295
VP0C870
p34609
sg33289
Vcytosolic NADH
p34610
sa(dp34611
g33284
I0
sg33285
I4
sg33286
I35
sg33295
VP28331
p34612
sg33289
VPlasma membrane NADH oxidoreductase
p34613
sasg33281
(lp34614
(dp34615
g33284
I154
sg33285
I1
sg33286
I4
sg33287
VC0011854
p34616
sg33289
VIDDM
p34617
sasa(dp34618
g33277
VNon insulin-dependent diabetic (NIDDM) mortality is 1.4 to 3.7 times that of non-diabetics.
p34619
sg33279
(lp34620
(dp34621
g33284
I4
sg33285
I1
sg33286
I7
sg33295
VP01308
p34622
sg33289
Vinsulin
p34623
sasg33281
(lp34624
(dp34625
g33284
I32
sg33285
I1
sg33286
I5
sg33287
VC0011860
p34626
sg33289
VNIDDM
p34627
sasa(dp34628
g33277
VIn the COPD and asthma patients, the median urinary cotinine concentration was 167 ng/mL (range, 2-5,348 ng/mL) and 47 ng/mL (range, 5-2,735 ng/mL), respectively (p &lt; 0.0001), whereas the median eCO level was 8 ppm (range, 0-31 ppm) and 5 ppm (range, 2-45 ppm), respectively (p &lt; 0.05).
p34629
sg33279
(lp34630
(dp34631
g33284
I198
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34632
sasg33281
(lp34633
(dp34634
g33284
I16
sg33285
I1
sg33286
I6
sg33287
VC0004096
p34635
sg33289
Vasthma
p34636
sa(dp34637
g33284
I198
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34638
sg33289
VeCO
p34639
sa(dp34640
g33284
I7
sg33285
I1
sg33286
I4
sg33287
VC0024117
p34641
sg33289
VCOPD
p34642
sasa(dp34643
g33277
VIn 30 (29%) of the patients with asthma or COPD, the urinary cotinine concentration and the eCO level both belied the patient claims of not being current smokers.
p34644
sg33279
(lp34645
(dp34646
g33284
I92
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34647
sasg33281
(lp34648
(dp34649
g33284
I43
sg33285
I1
sg33286
I4
sg33287
VC0024117
p34650
sg33289
VCOPD
p34651
sa(dp34652
g33284
I33
sg33285
I1
sg33286
I6
sg33287
VC0004096
p34653
sg33289
Vasthma
p34654
sa(dp34655
g33284
I92
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34656
sg33289
VeCO
p34657
sasa(dp34658
g33277
VWe aimed to study eCO levels in asthmatics and detect the possible factors influencing them.
p34659
sg33279
(lp34660
sg33281
(lp34661
(dp34662
g33284
I18
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34663
sg33289
VeCO
p34664
sa(dp34665
g33284
I32
sg33285
I1
sg33286
I10
sg33287
VC0004096
p34666
sg33289
Vasthmatics
p34667
sasa(dp34668
g33277
VThe differences in eCO levels among various asthmatic phenotypes and the correlations between eCO and other measured parameters (spirometric indices, Asthma Control Test score, exhaled nitric oxide, total IgE, blood eosinophils and marker of oxidative damage of proteins) were analysed.
p34669
sg33279
(lp34670
(dp34671
g33284
I19
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34672
sa(dp34673
g33284
I19
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34674
sa(dp34675
g33284
I205
sg33285
I1
sg33286
I3
sg33295
VP01854
p34676
sg33289
VIgE
p34677
sasg33281
(lp34678
(dp34679
g33284
I19
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34680
sg33289
VeCO
p34681
sa(dp34682
g33284
I44
sg33285
I1
sg33286
I9
sg33287
VC0004096
p34683
sg33289
Vasthmatic
p34684
sa(dp34685
g33284
I19
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34686
sg33289
VeCO
p34687
sa(dp34688
g33284
I150
sg33285
I1
sg33286
I6
sg33287
VC0004096
p34689
sg33289
VAsthma
p34690
sa(dp34691
g33284
I205
sg33285
I1
sg33286
I3
sg33287
VC0270850
p34692
sg33289
VIgE
p34693
sasa(dp34694
g33277
VLevels of eCO widely differed according to the selected characteristics of asthma.
p34695
sg33279
(lp34696
sg33281
(lp34697
(dp34698
g33284
I10
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34699
sg33289
VeCO
p34700
sa(dp34701
g33284
I75
sg33285
I1
sg33286
I6
sg33287
VC0004096
p34702
sg33289
Vasthma
p34703
sasa(dp34704
g33277
VAsthmatics showed higher eCO concentrations than controls (1.44 +/- 0.12 ppm vs. 0.91 +/- 0.11 ppm, p &lt; 0.001).
p34705
sg33279
(lp34706
(dp34707
g33284
I25
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34708
sasg33281
(lp34709
(dp34710
g33284
I0
sg33285
I1
sg33286
I10
sg33287
VC0004096
p34711
sg33289
VAsthmatics
p34712
sa(dp34713
g33284
I25
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34714
sg33289
VeCO
p34715
sasa(dp34716
g33277
VAcute exacerbation of asthma was accompanied by a significant increase in eCO compared to the clinically controlled stage (2.17 +/- 0.36 ppm vs. 1.33 +/- 0.13 ppm, p &lt; 0.001).
p34717
sg33279
(lp34718
sg33281
(lp34719
(dp34720
g33284
I74
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34721
sg33289
VeCO
p34722
sa(dp34723
g33284
I22
sg33285
I1
sg33286
I6
sg33287
VC0004096
p34724
sg33289
Vasthma
p34725
sasa(dp34726
g33277
VAtopic, non-atopic asthma and asthma associated with allergic rhinitis (AR) showed elevated levels of eCO.
p34727
sg33279
(lp34728
(dp34729
g33284
I53
sg33285
I3
sg33286
I22
sg33295
g11
sg33289
Vallergic rhinitis (AR)
p34730
sa(dp34731
g33284
I102
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34732
sasg33281
(lp34733
(dp34734
g33284
I12
sg33285
I2
sg33286
I13
sg33287
VC0155877
p34735
sg33289
Vatopic asthma
p34736
sa(dp34737
g33284
I53
sg33285
I2
sg33286
I17
sg33287
VC2607914
p34738
sg33289
Vallergic rhinitis
p34739
sa(dp34740
g33284
I19
sg33285
I1
sg33286
I6
sg33287
VC0004096
p34741
sg33289
Vasthma
p34742
sa(dp34743
g33284
I102
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34744
sg33289
VeCO
p34745
sa(dp34746
g33284
I72
sg33285
I1
sg33286
I2
sg33287
VC2607914
p34747
sg33289
VAR
p34748
sa(dp34749
g33284
I0
sg33285
I1
sg33286
I6
sg33287
VC0392707
p34750
sg33289
VAtopic
p34751
sasa(dp34752
g33277
VThe levels of eCO negatively correlated with the marker of protein oxidation in asthmatics, especially in atopic form and during acute exacerbation.
p34753
sg33279
(lp34754
(dp34755
g33284
I14
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34756
sasg33281
(lp34757
(dp34758
g33284
I14
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34759
sg33289
VeCO
p34760
sa(dp34761
g33284
I80
sg33285
I1
sg33286
I10
sg33287
VC0004096
p34762
sg33289
Vasthmatics
p34763
sa(dp34764
g33284
I106
sg33285
I1
sg33286
I6
sg33287
VC0392707
p34765
sg33289
Vatopic
p34766
sasa(dp34767
g33277
VIn a population of asthmatic children, eCO levels could be considered as a marker of both allergic inflammation and oxidative stress in the airways.
p34768
sg33279
(lp34769
(dp34770
g33284
I39
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34771
sasg33281
(lp34772
(dp34773
g33284
I90
sg33285
I2
sg33286
I21
sg33287
VC0021375
p34774
sg33289
Vallergic inflammation
p34775
sa(dp34776
g33284
I116
sg33285
I2
sg33286
I16
sg33287
VC0242606
p34777
sg33289
Voxidative stress
p34778
sa(dp34779
g33284
I39
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34780
sg33289
VeCO
p34781
sa(dp34782
g33284
I19
sg33285
I1
sg33286
I9
sg33287
VC0004096
p34783
sg33289
Vasthmatic
p34784
sasa(dp34785
g33277
VConcomitant AR and asthma control were the most important factors affecting the levels of eCO in asthmatic children.
p34786
sg33279
(lp34787
(dp34788
g33284
I90
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34789
sasg33281
(lp34790
(dp34791
g33284
I97
sg33285
I1
sg33286
I9
sg33287
VC0004096
p34792
sg33289
Vasthmatic
p34793
sa(dp34794
g33284
I90
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34795
sg33289
VeCO
p34796
sa(dp34797
g33284
I19
sg33285
I1
sg33286
I6
sg33287
VC0004096
p34798
sg33289
Vasthma
p34799
sasa(dp34800
g33277
VeCO values have been evaluated as potential indicators of inflammation in asthma, stable COPD and exacerbations, cystic fibrosis, lung cancer, or during surgery or critical care.
p34801
sg33279
(lp34802
(dp34803
g33284
I0
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34804
sasg33281
(lp34805
(dp34806
g33284
I0
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34807
sg33289
VeCO
p34808
sa(dp34809
g33284
I58
sg33285
I1
sg33286
I12
sg33287
VC0021368
p34810
sg33289
Vinflammation
p34811
sa(dp34812
g33284
I113
sg33285
I2
sg33286
I15
sg33287
VC0010674
p34813
sg33289
Vcystic fibrosis
p34814
sa(dp34815
g33284
I74
sg33285
I1
sg33286
I6
sg33287
VC0004096
p34816
sg33289
Vasthma
p34817
sa(dp34818
g33284
I130
sg33285
I2
sg33286
I11
sg33287
VC0684249
p34819
sg33289
Vlung cancer
p34820
sa(dp34821
g33284
I89
sg33285
I1
sg33286
I4
sg33287
VC0024117
p34822
sg33289
VCOPD
p34823
sasa(dp34824
g33277
VTwenty-four non-smokers (10 male, 14 female, mean age 17.6 years) and 24 smokers (mean of 3.5 pack-years; 15 male, 9 female, mean age 17.8 years) were compared in terms of lung function, bronchial hyperreactivity (BHR), levels of exhaled carbon monoxide (eCO), exhaled nitric oxide (eNO), and blood counts.
p34825
sg33279
(lp34826
sg33281
(lp34827
(dp34828
g33284
I214
sg33285
I1
sg33286
I3
sg33287
VC0085129
p34829
sg33289
VBHR
p34830
sa(dp34831
g33284
I255
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34832
sg33289
VeCO
p34833
sa(dp34834
g33284
I187
sg33285
I2
sg33286
I25
sg33287
VC0085129
p34835
sg33289
Vbronchial hyperreactivity
p34836
sa(dp34837
g33284
I230
sg33285
I3
sg33286
I23
sg33287
VC2675227
p34838
sg33289
Vexhaled carbon monoxide
p34839
sasa(dp34840
g33277
VThe concentration of exhaled carbon monoxide (eCO) in young children with stable asthma and during acute asthma attack is not known.
p34841
sg33279
(lp34842
sg33281
(lp34843
(dp34844
g33284
I46
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34845
sg33289
VeCO
p34846
sa(dp34847
g33284
I21
sg33285
I3
sg33286
I23
sg33287
VC2675227
p34848
sg33289
Vexhaled carbon monoxide
p34849
sa(dp34850
g33284
I105
sg33285
I2
sg33286
I13
sg33287
VC0347950
p34851
sg33289
Vasthma attack
p34852
sa(dp34853
g33284
I81
sg33285
I1
sg33286
I6
sg33287
VC0004096
p34854
sg33289
Vasthma
p34855
sasa(dp34856
g33277
VIn preschool-age children, eCO levels of those with asthma attacks (mean +/- SE, 2.7 +/- 0.3 p.p.m., n= 43) were significantly higher than those of subjects with asymptomatic asthma (0.5 +/- 0.1 p.p.m., P &lt; 0.05), URI (0.8 +/- 0.1 p.p.m., P &lt; 0.05) and healthy children (0.4 +/- 0.1 p.p.m., P &lt; 0.05).
p34857
sg33279
(lp34858
(dp34859
g33284
I27
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34860
sasg33281
(lp34861
(dp34862
g33284
I52
sg33285
I1
sg33286
I6
sg33287
VC0004096
p34863
sg33289
Vasthma
p34864
sa(dp34865
g33284
I27
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34866
sg33289
VeCO
p34867
sa(dp34868
g33284
I52
sg33285
I2
sg33286
I14
sg33287
VC0347950
p34869
sg33289
Vasthma attacks
p34870
sasa(dp34871
g33277
VA multivariate linear regression model showed that eCO was higher in children with asthma attacks independent of age and gender.
p34872
sg33279
(lp34873
(dp34874
g33284
I51
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34875
sasg33281
(lp34876
(dp34877
g33284
I51
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34878
sg33289
VeCO
p34879
sa(dp34880
g33284
I83
sg33285
I2
sg33286
I14
sg33287
VC0347950
p34881
sg33289
Vasthma attacks
p34882
sasa(dp34883
g33277
VIn 33 asthmatic children followed before and after treatment, eCO levels during asthma attacks significantly decreased after inhalation therapy with a combination of salbutamol and sodium cromoglycate (before therapy, 2.9 +/- 0.4 p.p.m.
p34884
sg33279
(lp34885
(dp34886
g33284
I62
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34887
sasg33281
(lp34888
(dp34889
g33284
I80
sg33285
I2
sg33286
I14
sg33287
VC0347950
p34890
sg33289
Vasthma attacks
p34891
sa(dp34892
g33284
I62
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34893
sg33289
VeCO
p34894
sa(dp34895
g33284
I6
sg33285
I1
sg33286
I9
sg33287
VC0004096
p34896
sg33289
Vasthmatic
p34897
sasa(dp34898
g33277
VThe measurement of eCO using a novel collecting system is useful in the recognition of asthma in preschool children.
p34899
sg33279
(lp34900
(dp34901
g33284
I19
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34902
sasg33281
(lp34903
(dp34904
g33284
I87
sg33285
I1
sg33286
I6
sg33287
VC0004096
p34905
sg33289
Vasthma
p34906
sa(dp34907
g33284
I19
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34908
sg33289
VeCO
p34909
sasa(dp34910
g33277
VElevations in E-CO have been observed in critically ill or post-surgical patients and those with various pulmonary diseases associated with inflammation, including chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis and infections.
p34911
sg33279
(lp34912
sg33281
(lp34913
(dp34914
g33284
I238
sg33285
I1
sg33286
I10
sg33287
VC0021311
p34915
sg33289
Vinfections
p34916
sa(dp34917
g33284
I164
sg33285
I4
sg33286
I37
sg33287
VC0024117
p34918
sg33289
Vchronic obstructive pulmonary disease
p34919
sa(dp34920
g33284
I210
sg33285
I1
sg33286
I6
sg33287
VC0004096
p34921
sg33289
Vasthma
p34922
sa(dp34923
g33284
I203
sg33285
I1
sg33286
I4
sg33287
VC0024117
p34924
sg33289
VCOPD
p34925
sa(dp34926
g33284
I140
sg33285
I1
sg33286
I12
sg33287
VC0021368
p34927
sg33289
Vinflammation
p34928
sa(dp34929
g33284
I105
sg33285
I2
sg33286
I18
sg33287
VC0024115
p34930
sg33289
Vpulmonary diseases
p34931
sa(dp34932
g33284
I218
sg33285
I2
sg33286
I15
sg33287
VC0010674
p34933
sg33289
Vcystic fibrosis
p34934
sa(dp34935
g33284
I41
sg33285
I2
sg33286
I14
sg33287
VC0010340
p34936
sg33289
Vcritically ill
p34937
sasa(dp34938
g33277
VThe purpose of this meta-analysis is to determine whether eCO is elevated in asthmatics, is regulated by steroid treatment and reflects disease severity and control.
p34939
sg33279
(lp34940
(dp34941
g33284
I58
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34942
sasg33281
(lp34943
(dp34944
g33284
I58
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34945
sg33289
VeCO
p34946
sa(dp34947
g33284
I77
sg33285
I1
sg33286
I10
sg33287
VC0004096
p34948
sg33289
Vasthmatics
p34949
sasa(dp34950
g33277
VObservational studies comparing eCO in non-smoking asthmatics and healthy subjects or asthmatics before and after steroid treatment were included.
p34951
sg33279
(lp34952
sg33281
(lp34953
(dp34954
g33284
I32
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34955
sg33289
VeCO
p34956
sa(dp34957
g33284
I51
sg33285
I1
sg33286
I10
sg33287
VC0004096
p34958
sg33289
Vasthmatics
p34959
sa(dp34960
g33284
I51
sg33285
I1
sg33286
I10
sg33287
VC0004096
p34961
sg33289
Vasthmatics
p34962
sasa(dp34963
g33277
VThe eCO level was significantly higher in asthmatics as compared to healthy subjects and in intermittent asthma as compared to persistent asthma.
p34964
sg33279
(lp34965
(dp34966
g33284
I4
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34967
sasg33281
(lp34968
(dp34969
g33284
I42
sg33285
I1
sg33286
I10
sg33287
VC0004096
p34970
sg33289
Vasthmatics
p34971
sa(dp34972
g33284
I92
sg33285
I2
sg33286
I19
sg33287
VC1740754
p34973
sg33289
Vintermittent asthma
p34974
sa(dp34975
g33284
I4
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34976
sg33289
VeCO
p34977
sa(dp34978
g33284
I127
sg33285
I2
sg33286
I17
sg33287
VC3266628
p34979
sg33289
Vpersistent asthma
p34980
sasa(dp34981
g33277
VHowever, eCO could not distinguish between steroid-treated asthmatics and steroid-free patients nor separate controlled and partly-controlled asthma from uncontrolled asthma in cross-sectional studies.
p34982
sg33279
(lp34983
(dp34984
g33284
I9
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p34985
sasg33281
(lp34986
(dp34987
g33284
I59
sg33285
I1
sg33286
I6
sg33287
VC0004096
p34988
sg33289
Vasthma
p34989
sa(dp34990
g33284
I9
sg33285
I1
sg33286
I3
sg33287
VC2675227
p34991
sg33289
VeCO
p34992
sa(dp34993
g33284
I59
sg33285
I1
sg33286
I10
sg33287
VC0004096
p34994
sg33289
Vasthmatics
p34995
sa(dp34996
g33284
I59
sg33285
I1
sg33286
I6
sg33287
VC0004096
p34997
sg33289
Vasthma
p34998
sasa(dp34999
g33277
VeCO is elevated in asthmatics but levels only partially reflect disease severity and control.
p35000
sg33279
(lp35001
(dp35002
g33284
I0
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p35003
sasg33281
(lp35004
(dp35005
g33284
I19
sg33285
I1
sg33286
I10
sg33287
VC0004096
p35006
sg33289
Vasthmatics
p35007
sa(dp35008
g33284
I0
sg33285
I1
sg33286
I3
sg33287
VC2675227
p35009
sg33289
VeCO
p35010
sasa(dp35011
g33277
VeCO might be a potentially useful non-invasive biomarker of airway inflammation and oxidative stress in nonsmoking asthmatics.
p35012
sg33279
(lp35013
(dp35014
g33284
I0
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VeCO
p35015
sasg33281
(lp35016
(dp35017
g33284
I67
sg33285
I1
sg33286
I12
sg33287
VC0021368
p35018
sg33289
Vinflammation
p35019
sa(dp35020
g33284
I0
sg33285
I1
sg33286
I3
sg33287
VC2675227
p35021
sg33289
VeCO
p35022
sa(dp35023
g33284
I115
sg33285
I1
sg33286
I10
sg33287
VC0004096
p35024
sg33289
Vasthmatics
p35025
sa(dp35026
g33284
I84
sg33285
I2
sg33286
I16
sg33287
VC0242606
p35027
sg33289
Voxidative stress
p35028
sasa(dp35029
g33277
VHowever, recent studies revealed that genetic inhibition of SphK2 did not significantly impact the severity or progression of inflammatory arthritis, while pharmacologic inhibition of SphK2 led to significantly more severe arthritis.
p35030
sg33279
(lp35031
(dp35032
g33284
I60
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSphK2
p35033
sa(dp35034
g33284
I60
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSphK2
p35035
sasg33281
(lp35036
(dp35037
g33284
I139
sg33285
I1
sg33286
I9
sg33287
VC0003864
p35038
sg33289
Varthritis
p35039
sa(dp35040
g33284
I126
sg33285
I2
sg33286
I22
sg33287
VC0003864
p35041
sg33289
Vinflammatory arthritis
p35042
sasa(dp35043
g33277
VTherefore, SphK2 plays a controversial role in arthritis.
p35044
sg33279
(lp35045
(dp35046
g33284
I11
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSphK2
p35047
sasg33281
(lp35048
(dp35049
g33284
I47
sg33285
I1
sg33286
I9
sg33287
VC0003864
p35050
sg33289
Varthritis
p35051
sasa(dp35052
g33277
VA specific SphK2 inhibitor inhibited inflammatory arthritis in one model, while siRNA knockdown of SphK2 worsened arthritis in another.
p35053
sg33279
(lp35054
(dp35055
g33284
I11
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSphK2
p35056
sa(dp35057
g33284
I11
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSphK2
p35058
sasg33281
(lp35059
(dp35060
g33284
I37
sg33285
I2
sg33286
I22
sg33287
VC0003864
p35061
sg33289
Vinflammatory arthritis
p35062
sa(dp35063
g33284
I50
sg33285
I1
sg33286
I9
sg33287
VC0003864
p35064
sg33289
Varthritis
p35065
sasa(dp35066
g33277
VTo investigate the role of SphK2 in TNF-Alfa-induced arthritis, we developed SphK2 deficient hTNF-Alfa overexpressing mice and separately treated hTNF-Alfa mice with ABC294640, a SphK2-specific inhibitor.
p35067
sg33279
(lp35068
(dp35069
g33284
I27
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSphK2
p35070
sa(dp35071
g33284
I27
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSphK2
p35072
sa(dp35073
g33284
I27
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSphK2
p35074
sa(dp35075
g33284
I36
sg33285
I1
sg33286
I3
sg33295
VP01375
p35076
sg33289
VTNF
p35077
sasg33281
(lp35078
(dp35079
g33284
I53
sg33285
I1
sg33286
I9
sg33287
VC0003864
p35080
sg33289
Varthritis
p35081
sasa(dp35082
g33277
VOur data show that genetic inhibition of SphK2 did not significantly impact the severity or progression of inflammatory arthritis, while pharmacologic inhibition of SphK2 led to significantly more severe arthritis.
p35083
sg33279
(lp35084
(dp35085
g33284
I41
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSphK2
p35086
sa(dp35087
g33284
I41
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSphK2
p35088
sasg33281
(lp35089
(dp35090
g33284
I107
sg33285
I2
sg33286
I22
sg33287
VC0003864
p35091
sg33289
Vinflammatory arthritis
p35092
sa(dp35093
g33284
I120
sg33285
I1
sg33286
I9
sg33287
VC0003864
p35094
sg33289
Varthritis
p35095
sasa(dp35096
g33277
VIn this study, we examined the role of SphK1 and SphK2 in a murine collagen-induced arthritis model by down-regulating each isoenzyme via specific small interfering RNA (siRNA).
p35097
sg33279
(lp35098
(dp35099
g33284
I39
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSphK1
p35100
sa(dp35101
g33284
I49
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSphK2
p35102
sasg33281
(lp35103
(dp35104
g33284
I84
sg33285
I1
sg33286
I9
sg33287
VC0003864
p35105
sg33289
Varthritis
p35106
sasa(dp35107
g33277
VTogether, these results demonstrate the distinct immunomodulatory roles of SphK1 and SphK2 in the development of inflammatory arthritis by regulating the release of proinflammatory cytokines and T cell responses.
p35108
sg33279
(lp35109
(dp35110
g33284
I75
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSphK1
p35111
sa(dp35112
g33284
I85
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSphK2
p35113
sasg33281
(lp35114
(dp35115
g33284
I113
sg33285
I2
sg33286
I22
sg33287
VC0003864
p35116
sg33289
Vinflammatory arthritis
p35117
sasa(dp35118
g33277
VPrefrontal Brodmann Areas (BA) BA46, BA47, and BA9 in autism and age-matched controls were analyzed by blinded researchers.
p35119
sg33279
(lp35120
sg33281
(lp35121
(dp35122
g33284
I54
sg33285
I1
sg33286
I6
sg33287
VC0004352
p35123
sg33289
Vautism
p35124
sasa(dp35125
g33277
VWe show that the number of parvalbumin+ interneurons in these 3 cortical areas-BA46, BA47, and BA9-is significantly reduced in autism compared with controls.
p35126
sg33279
(lp35127
(dp35128
g33284
I27
sg33285
I1
sg33286
I12
sg33295
VP20472
p35129
sg33289
Vparvalbumin+
p35130
sasg33281
(lp35131
(dp35132
g33284
I127
sg33285
I1
sg33286
I6
sg33287
VC0004352
p35133
sg33289
Vautism
p35134
sasa(dp35135
g33277
VThese fetal structures generate regions with abnormal activity in autism, including the dorsolateral prefrontal cortex (BA46), the pars opercularis of the inferior frontal cortex and the fusiform gyrus.
p35136
sg33279
(lp35137
sg33281
(lp35138
(dp35139
g33284
I66
sg33285
I1
sg33286
I6
sg33287
VC0004352
p35140
sg33289
Vautism
p35141
sasa(dp35142
g33277
VAt the site of disease in leprosy, we found that S100A12 was more strongly expressed in skin lesions from tuberculoid leprosy (T-lep), the self-limiting form of the disease, compared to lepromatous leprosy (L-lep), the progressive form of the disease.
p35143
sg33279
(lp35144
(dp35145
g33284
I49
sg33285
I1
sg33286
I7
sg33295
VP80511
p35146
sg33289
VS100A12
p35147
sasg33281
(lp35148
(dp35149
g33284
I26
sg33285
I1
sg33286
I7
sg33287
VC0023343
p35150
sg33289
Vleprosy
p35151
sa(dp35152
g33284
I127
sg33285
I1
sg33286
I5
sg33287
VC0023351
p35153
sg33289
VT-lep
p35154
sa(dp35155
g33284
I186
sg33285
I2
sg33286
I19
sg33287
VC0023348
p35156
sg33289
Vlepromatous leprosy
p35157
sa(dp35158
g33284
I106
sg33285
I2
sg33286
I19
sg33287
VC0023351
p35159
sg33289
Vtuberculoid leprosy
p35160
sa(dp35161
g33284
I207
sg33285
I1
sg33286
I5
sg33287
VC0023348
p35162
sg33289
VL-lep
p35163
sasa(dp35164
g33277
VThe aim of this study was to predict right ventricular dysfunction (RVD) using plasma concentration of D-dimer, pro-atrial natriuretic peptide (pro-ANP), brain natriuretic peptide (BNP), endothelin-1 (ET-1) and cardiac troponin I (TNI) in patients with pulmonary embolism (PE).
p35165
sg33279
(lp35166
(dp35167
g33284
I201
sg33285
I1
sg33286
I4
sg33295
VP05305
p35168
sg33289
VET-1
p35169
sa(dp35170
g33284
I187
sg33285
I1
sg33286
I12
sg33295
VP20800
p35171
sg33289
Vendothelin-1
p35172
sa(dp35173
g33284
I231
sg33285
I1
sg33286
I3
sg33295
VP48788
p35174
sg33289
VTNI
p35175
sa(dp35176
g33284
I103
sg33285
I8
sg33286
I76
sg33295
VP16066
p35177
sg33289
VD-dimer, pro-atrial natriuretic peptide (pro-ANP), brain natriuretic peptide
p35178
sa(dp35179
g33284
I181
sg33285
I1
sg33286
I3
sg33295
VP16860
p35180
sg33289
VBNP
p35181
sa(dp35182
g33284
I211
sg33285
I3
sg33286
I18
sg33295
VP24821
p35183
sg33289
Vcardiac troponin I
p35184
sasg33281
(lp35185
(dp35186
g33284
I37
sg33285
I3
sg33286
I29
sg33287
VC0242707
p35187
sg33289
Vright ventricular dysfunction
p35188
sa(dp35189
g33284
I273
sg33285
I1
sg33286
I2
sg33287
VC0034065
p35190
sg33289
VPE
p35191
sa(dp35192
g33284
I68
sg33285
I1
sg33286
I3
sg33287
VC0242707
p35193
sg33289
VRVD
p35194
sa(dp35195
g33284
I253
sg33285
I2
sg33286
I18
sg33287
VC0034065
p35196
sg33289
Vpulmonary embolism
p35197
sasa(dp35198
g33277
VAtrial natriuretic petide (ANP), brain natriuretic peptide (BNP) and endothelin-1 (ET-1) may reflect the severity of right ventricular dysfunction (RVD) in patients with pulmonary embolism (PE).
p35199
sg33279
(lp35200
(dp35201
g33284
I27
sg33285
I1
sg33286
I3
sg33295
VP16066
p35202
sg33289
VANP
p35203
sa(dp35204
g33284
I83
sg33285
I1
sg33286
I4
sg33295
VP05305
p35205
sg33289
VET-1
p35206
sa(dp35207
g33284
I69
sg33285
I1
sg33286
I12
sg33295
VP20800
p35208
sg33289
Vendothelin-1
p35209
sa(dp35210
g33284
I0
sg33285
I3
sg33286
I25
sg33295
VP16066
p35211
sg33289
VAtrial natriuretic petide
p35212
sasg33281
(lp35213
(dp35214
g33284
I190
sg33285
I1
sg33286
I2
sg33287
VC0034065
p35215
sg33289
VPE
p35216
sa(dp35217
g33284
I148
sg33285
I1
sg33286
I3
sg33287
VC0242707
p35218
sg33289
VRVD
p35219
sa(dp35220
g33284
I117
sg33285
I3
sg33286
I29
sg33287
VC0242707
p35221
sg33289
Vright ventricular dysfunction
p35222
sa(dp35223
g33284
I170
sg33285
I2
sg33286
I18
sg33287
VC0034065
p35224
sg33289
Vpulmonary embolism
p35225
sasa(dp35226
g33277
VAcute pulmonary embolism (PE) is a life-threatening disease, and several vasoconstrictors, including endothelin-1 (ET-1), play a key role in vasoconstriction and hypoxemia during the development of PE.
p35227
sg33279
(lp35228
(dp35229
g33284
I101
sg33285
I1
sg33286
I12
sg33295
VP20800
p35230
sg33289
Vendothelin-1
p35231
sa(dp35232
g33284
I115
sg33285
I1
sg33286
I4
sg33295
VP05305
p35233
sg33289
VET-1
p35234
sasg33281
(lp35235
(dp35236
g33284
I6
sg33285
I2
sg33286
I18
sg33287
VC0034065
p35237
sg33289
Vpulmonary embolism
p35238
sa(dp35239
g33284
I26
sg33285
I1
sg33286
I2
sg33287
VC0034065
p35240
sg33289
VPE
p35241
sa(dp35242
g33284
I26
sg33285
I1
sg33286
I2
sg33287
VC0034065
p35243
sg33289
VPE
p35244
sa(dp35245
g33284
I141
sg33285
I1
sg33286
I16
sg33287
VC1456863
p35246
sg33289
Vvasoconstriction
p35247
sasa(dp35248
g33277
VImpaired repression of cone-specific genes by the corepressors atrophin-1 (dentatorubral-pallidoluysian atrophy [DRPLA] gene product) and atrophin-2 (arginine-glutamic acid dipeptide repeat [RERE] protein) appeared to be a molecular mechanism mediating the beneficial effect of the p.R311Q mutation.
p35249
sg33279
(lp35250
sg33281
(lp35251
(dp35252
g33284
I113
sg33285
I1
sg33286
I5
sg33287
VC0751781
p35253
sg33289
VDRPLA
p35254
sa(dp35255
g33284
I75
sg33285
I2
sg33286
I36
sg33287
VC0751781
p35256
sg33289
Vdentatorubral-pallidoluysian atrophy
p35257
sa(dp35258
g33284
I0
sg33285
I1
sg33286
I8
sg33287
VC0684336
p35259
sg33289
VImpaired
p35260
sasa(dp35261
g33277
VRE repeats encoded (RERE) was identified recently as a protein with high homology to the atrophin-1 protein, which appears to be causal in the hereditary neurodegenerative disorder termed dentatorubral-pallidoluysian atrophy (DRPLA) caused by an abnormal glutamine expansion.
p35262
sg33279
(lp35263
(dp35264
g33284
I89
sg33285
I2
sg33286
I18
sg33295
VP54259
p35265
sg33289
Vatrophin-1 protein
p35266
sasg33281
(lp35267
(dp35268
g33284
I188
sg33285
I2
sg33286
I36
sg33287
VC0751781
p35269
sg33289
Vdentatorubral-pallidoluysian atrophy
p35270
sa(dp35271
g33284
I226
sg33285
I1
sg33286
I5
sg33287
VC0751781
p35272
sg33289
VDRPLA
p35273
sa(dp35274
g33284
I143
sg33285
I3
sg33286
I37
sg33287
VC3273225
p35275
sg33289
Vhereditary neurodegenerative disorder
p35276
sasa(dp35277
g33277
VThe gene isolated, designated RERE, has an open reading frame of 1566 amino acids, of which the C-terminal portion has 67% homology to DRPLA, whereas the N-terminal portion is distinctive.
p35278
sg33279
(lp35279
(dp35280
g33284
I135
sg33285
I1
sg33286
I5
sg33295
VP54259
p35281
sg33289
VDRPLA
p35282
sa(dp35283
g33284
I30
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VRERE
p35284
sasg33281
(lp35285
(dp35286
g33284
I135
sg33285
I1
sg33286
I5
sg33287
VC0751781
p35287
sg33289
VDRPLA
p35288
sasa(dp35289
g33277
VImmunoprecipitation and in vitro binding assays demonstrate that the DRPLA and RERE proteins bind each other, for which one of the RE repeats has a primary role, and extended polyglutamine enhances the binding.
p35290
sg33279
(lp35291
(dp35292
g33284
I79
sg33285
I2
sg33286
I13
sg33295
g11
sg33289
VRERE proteins
p35293
sa(dp35294
g33284
I69
sg33285
I1
sg33286
I5
sg33295
VP54259
p35295
sg33289
VDRPLA
p35296
sasg33281
(lp35297
(dp35298
g33284
I69
sg33285
I1
sg33286
I5
sg33287
VC0751781
p35299
sg33289
VDRPLA
p35300
sasa(dp35301
g33277
VMoreover, when RERE is overexpressed, the distribution of endogenous DRPLA protein alters from the diffused to the speckled pattern in the nucleus so as to co-localize with RERE.
p35302
sg33279
(lp35303
(dp35304
g33284
I15
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VRERE
p35305
sa(dp35306
g33284
I58
sg33285
I3
sg33286
I24
sg33295
VP54259
p35307
sg33289
Vendogenous DRPLA protein
p35308
sasg33281
(lp35309
(dp35310
g33284
I69
sg33285
I1
sg33286
I5
sg33287
VC0751781
p35311
sg33289
VDRPLA
p35312
sasa(dp35313
g33277
VMore RERE protein is recruited into nuclear aggregates of the DRPLA protein with extended polyglutamine than into those of pure polyglutamine.
p35314
sg33279
(lp35315
(dp35316
g33284
I62
sg33285
I2
sg33286
I13
sg33295
VP54259
p35317
sg33289
VDRPLA protein
p35318
sasg33281
(lp35319
(dp35320
g33284
I62
sg33285
I1
sg33286
I5
sg33287
VC0751781
p35321
sg33289
VDRPLA
p35322
sasa(dp35323
g33277
VThe DNB1/ARPh gene, which was found to be ubiquitously expressed in human adult and fetal tissues, is highly related to the DRPLA gene, in which expansion of a CAG triplet appears to be causal in the dentatorubral and pallidolysian atrophy disease phenotype.
p35324
sg33279
(lp35325
(dp35326
g33284
I124
sg33285
I2
sg33286
I10
sg33295
VP54259
p35327
sg33289
VDRPLA gene
p35328
sa(dp35329
g33284
I4
sg33285
I1
sg33286
I4
sg33295
VP55145
p35330
sg33289
VDNB1
p35331
sasg33281
(lp35332
(dp35333
g33284
I124
sg33285
I1
sg33286
I5
sg33287
VC0751781
p35334
sg33289
VDRPLA
p35335
sa(dp35336
g33284
I232
sg33285
I1
sg33286
I7
sg33287
VC0333641
p35337
sg33289
Vatrophy
p35338
sasa(dp35339
g33277
VTherefore, we evaluated the roles of CSNK2A1, SIRT6, and phosphorylated SIRT6 and their relationships in breast carcinoma.
p35340
sg33279
(lp35341
(dp35342
g33284
I37
sg33285
I1
sg33286
I7
sg33295
VP19784
p35343
sg33289
VCSNK2A1
p35344
sasg33281
(lp35345
(dp35346
g33284
I105
sg33285
I2
sg33286
I16
sg33287
VC0678222
p35347
sg33289
Vbreast carcinoma
p35348
sasa(dp35349
g33277
VThis study demonstrates that CSNK2A1 and SIRT6 are indicators of poor prognosis for breast carcinomas and that CSNK2A1-mediated phosphorylation of SIRT6 might be involved in the progression of breast carcinoma.
p35350
sg33279
(lp35351
(dp35352
g33284
I29
sg33285
I1
sg33286
I7
sg33295
VP19784
p35353
sg33289
VCSNK2A1
p35354
sa(dp35355
g33284
I29
sg33285
I1
sg33286
I7
sg33295
VP19784
p35356
sg33289
VCSNK2A1
p35357
sasg33281
(lp35358
(dp35359
g33284
I84
sg33285
I2
sg33286
I16
sg33287
VC0678222
p35360
sg33289
Vbreast carcinoma
p35361
sa(dp35362
g33284
I84
sg33285
I2
sg33286
I17
sg33287
VC0678222
p35363
sg33289
Vbreast carcinomas
p35364
sasa(dp35365
g33277
VRNA expression levels of CDC2L1, CDC2L2, CCNL1, CCNL2, CSNK2A1, CSNK2A2, and CSNK2B genes in breast cancer subtypes were analyzed.
p35366
sg33279
(lp35367
(dp35368
g33284
I77
sg33285
I2
sg33286
I12
sg33295
VP67870
p35369
sg33289
VCSNK2B genes
p35370
sa(dp35371
g33284
I64
sg33285
I1
sg33286
I7
sg33295
VP19784
p35372
sg33289
VCSNK2A2
p35373
sa(dp35374
g33284
I41
sg33285
I1
sg33286
I5
sg33295
VP49736
p35375
sg33289
VCCNL1
p35376
sa(dp35377
g33284
I55
sg33285
I1
sg33286
I7
sg33295
VP19784
p35378
sg33289
VCSNK2A1
p35379
sasg33281
(lp35380
(dp35381
g33284
I93
sg33285
I2
sg33286
I13
sg33287
VC0678222
p35382
sg33289
Vbreast cancer
p35383
sasa(dp35384
g33277
VRecent evidence suggests the role of Wnt signaling in human breast cancer involves elevated levels of nuclear and/or cytoplasmic beta-catenin using immunohistochemistry, overexpression or downregulation of specific Wnt proteins, overexpression of CKII and sFRP4, downregulation of WIF-1 and sFRP1, as well as amplification of DVL-1.
p35385
sg33279
(lp35386
(dp35387
g33284
I117
sg33285
I2
sg33286
I24
sg33295
g11
sg33289
Vcytoplasmic beta-catenin
p35388
sa(dp35389
g33284
I247
sg33285
I1
sg33286
I4
sg33295
VP68400
p35390
sg33289
VCKII
p35391
sa(dp35392
g33284
I326
sg33285
I1
sg33286
I5
sg33295
VP54792
p35393
sg33289
VDVL-1
p35394
sa(dp35395
g33284
I291
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VsFRP1
p35396
sa(dp35397
g33284
I256
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VsFRP4
p35398
sasg33281
(lp35399
(dp35400
g33284
I60
sg33285
I2
sg33286
I13
sg33287
VC0678222
p35401
sg33289
Vbreast cancer
p35402
sa(dp35403
g33284
I309
sg33285
I1
sg33286
I13
sg33287
VC1705759
p35404
sg33289
Vamplification
p35405
sasa(dp35406
g33277
VBy combining the mutational data in the Catalogue of Somatic Mutations in Cancer (COSMIC) and the spatial information in the Protein Data Bank (PDB), SpacePAC is able to identify novel mutation clusters in many proteins such as FGFR3 and CHRM2.
p35407
sg33279
(lp35408
(dp35409
g33284
I228
sg33285
I1
sg33286
I5
sg33295
VP22607
p35410
sg33289
VFGFR3
p35411
sa(dp35412
g33284
I238
sg33285
I1
sg33286
I5
sg33295
VP08172
p35413
sg33289
VCHRM2
p35414
sasg33281
(lp35415
(dp35416
g33284
I53
sg33285
I2
sg33286
I17
sg33287
VC0544886
p35417
sg33289
VSomatic Mutations
p35418
sa(dp35419
g33284
I125
sg33285
I3
sg33286
I17
sg33287
VC0029401
p35420
sg33289
VProtein Data Bank
p35421
sa(dp35422
g33284
I179
sg33285
I2
sg33286
I14
sg33287
VC2985438
p35423
sg33289
Vnovel mutation
p35424
sa(dp35425
g33284
I74
sg33285
I1
sg33286
I6
sg33287
VC0006826
p35426
sg33289
VCancer
p35427
sa(dp35428
g33284
I144
sg33285
I1
sg33286
I3
sg33287
VC0029401
p35429
sg33289
VPDB
p35430
sasa(dp35431
g33277
VColorectal cancer (HCT 116, LoVo, C 170 HM 2, CaCO-2), fibroblast (46-BR.IGI, CCD-18 Co) and fibrosarcoma (HT1080) cell lines were irradiated at 4 gray (4 Gy) and matrix metalloproteinase gene and protein expression examined over a 96 h period by real time polymerase chain reaction and gelatin zymography.
p35432
sg33279
(lp35433
(dp35434
g33284
I78
sg33285
I2
sg33286
I9
sg33295
VP21817
p35435
sg33289
VCCD-18 Co
p35436
sa(dp35437
g33284
I163
sg33285
I3
sg33286
I29
sg33295
g11
sg33289
Vmatrix metalloproteinase gene
p35438
sa(dp35439
g33284
I73
sg33285
I1
sg33286
I3
sg33295
VP12018
p35440
sg33289
VIGI
p35441
sasg33281
(lp35442
(dp35443
g33284
I0
sg33285
I2
sg33286
I17
sg33287
VC1527249
p35444
sg33289
VColorectal cancer
p35445
sa(dp35446
g33284
I93
sg33285
I1
sg33286
I12
sg33287
VC0016057
p35447
sg33289
Vfibrosarcoma
p35448
sa(dp35449
g33284
I78
sg33285
I1
sg33286
I3
sg33287
VC0008928
p35450
sg33289
VCCD
p35451
sasa(dp35452
g33277
VIn addition, because HBL is a major enterotoxin, we also designed HBL gene-specific polymerase chain reaction (PCR) primers, i.e., Hm1 and Hm2, that generated the same results as those of the hemolysis and BCET-RPLA assays.
p35453
sg33279
(lp35454
(dp35455
g33284
I66
sg33285
I2
sg33286
I8
sg33295
VP09382
p35456
sg33289
VHBL gene
p35457
sa(dp35458
g33284
I131
sg33285
I1
sg33286
I3
sg33295
VP11229
p35459
sg33289
VHm1
p35460
sa(dp35461
g33284
I21
sg33285
I1
sg33286
I3
sg33295
VP09382
p35462
sg33289
VHBL
p35463
sa(dp35464
g33284
I139
sg33285
I1
sg33286
I3
sg33295
VP08172
p35465
sg33289
VHm2
p35466
sasg33281
(lp35467
(dp35468
g33284
I192
sg33285
I1
sg33286
I9
sg33287
VC0019054
p35469
sg33289
Vhemolysis
p35470
sasa(dp35471
g33277
VPrimers B16S1/B16S2 and Hm1/Hm2 could be combined into a multiplex PCR system for the simultaneous detection of B. cereus group cells and the possible presence of their HBL enterotoxins.
p35472
sg33279
(lp35473
(dp35474
g33284
I24
sg33285
I1
sg33286
I3
sg33295
VP11229
p35475
sg33289
VHm1
p35476
sa(dp35477
g33284
I169
sg33285
I2
sg33286
I16
sg33295
VP09382
p35478
sg33289
VHBL enterotoxins
p35479
sa(dp35480
g33284
I28
sg33285
I1
sg33286
I3
sg33295
VP08172
p35481
sg33289
VHm2
p35482
sasg33281
(lp35483
sa(dp35484
g33277
VPositive cancer invasion in the cut end was classified as hm2 or dm2 in 8 patients and em2 in 13.
p35485
sg33279
(lp35486
(dp35487
g33284
I58
sg33285
I1
sg33286
I3
sg33295
VP08172
p35488
sg33289
Vhm2
p35489
sasg33281
(lp35490
(dp35491
g33284
I16
sg33285
I1
sg33286
I8
sg33287
VC2699153
p35492
sg33289
Vinvasion
p35493
sa(dp35494
g33284
I65
sg33285
I1
sg33286
I3
sg33287
VC2931689
p35495
sg33289
Vdm2
p35496
sa(dp35497
g33284
I9
sg33285
I1
sg33286
I6
sg33287
VC0006826
p35498
sg33289
Vcancer
p35499
sasa(dp35500
g33277
VBiopsy samples from five acquired immune deficiency syndrome (AIDS)-Kaposi's sarcomas and one non-AIDS-associated Kaposi's sarcoma were assayed by in situ RNA hybridization onto paraformaldehyde-fixed, paraffin-embedded skin sections for the presence of two fibroblast growth factor gene transcripts, FGFB and FGF5.
p35501
sg33279
(lp35502
(dp35503
g33284
I258
sg33285
I5
sg33286
I41
sg33295
g11
sg33289
Vfibroblast growth factor gene transcripts
p35504
sa(dp35505
g33284
I310
sg33285
I1
sg33286
I4
sg33295
VP12034
p35506
sg33289
VFGF5
p35507
sasg33281
(lp35508
(dp35509
g33284
I25
sg33285
I4
sg33286
I35
sg33287
VC0001175
p35510
sg33289
Vacquired immune deficiency syndrome
p35511
sa(dp35512
g33284
I62
sg33285
I1
sg33286
I4
sg33287
VC0001175
p35513
sg33289
VAIDS
p35514
sa(dp35515
g33284
I77
sg33285
I1
sg33286
I8
sg33287
VC1261473
p35516
sg33289
Vsarcomas
p35517
sa(dp35518
g33284
I68
sg33285
I2
sg33286
I16
sg33287
VC0036220
p35519
sg33289
VKaposi's sarcoma
p35520
sa(dp35521
g33284
I62
sg33285
I1
sg33286
I4
sg33287
VC0001175
p35522
sg33289
VAIDS
p35523
sasa(dp35524
g33277
VFGF5 gene expression was detected in the characteristic Kaposi's sarcoma spindle-shaped cells in the five samples from human immunodeficiency-positive (HIV+) patients.
p35525
sg33279
(lp35526
(dp35527
g33284
I0
sg33285
I2
sg33286
I9
sg33295
VP12034
p35528
sg33289
VFGF5 gene
p35529
sasg33281
(lp35530
(dp35531
g33284
I125
sg33285
I1
sg33286
I16
sg33287
VC0021051
p35532
sg33289
Vimmunodeficiency
p35533
sa(dp35534
g33284
I56
sg33285
I2
sg33286
I16
sg33287
VC0036220
p35535
sg33289
VKaposi's sarcoma
p35536
sasa(dp35537
g33277
VFurthermore, they demonstrate a contrasting expression pattern of FGF5 and FGFB genes, both involved in the growth factor pathogenic cascade leading to Kaposi's sarcoma.
p35538
sg33279
(lp35539
(dp35540
g33284
I75
sg33285
I2
sg33286
I10
sg33295
VP01893
p35541
sg33289
VFGFB genes
p35542
sa(dp35543
g33284
I66
sg33285
I1
sg33286
I4
sg33295
VP12034
p35544
sg33289
VFGF5
p35545
sasg33281
(lp35546
(dp35547
g33284
I152
sg33285
I2
sg33286
I16
sg33287
VC0036220
p35548
sg33289
VKaposi's sarcoma
p35549
sasa(dp35550
g33277
VObjective To explore the efficacy of ganoderma lucidum preparation(Ling Zhi) in treating APP/PS-1 transgenic mouse models of Alzheimer's disease(AD).Methods APP/PS-1 transgenic mice of 4 months were randomly divided into model group,ganoderma lucidum treatment groups,including high [2250 mg/(kg*d)] and middle [750 mg/(kg*d)] dose groups,i.e.LZ-H and LZ-M groups,and the positive control group(treated with donepezil hydrochloride [2 mg/(kg*d)]).In addition,C57BL/6J wild mice were selected as normal group.The animals were administered for 4 months.Histopathological examinations including hematoxylin-eosin(HE) staining,immunohistochemistry,special staining,and electron microscopy were applied,and then the pathological morphology and structures in different groups were compared.
p35551
sg33279
(lp35552
(dp35553
g33284
I89
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VAPP
p35554
sa(dp35555
g33284
I93
sg33285
I1
sg33286
I4
sg33295
VP48651
p35556
sg33289
VPS-1
p35557
sasg33281
(lp35558
(dp35559
g33284
I125
sg33285
I2
sg33286
I19
sg33287
VC1521724
p35560
sg33289
VAlzheimer's disease
p35561
sasa(dp35562
g33277
VFor the hydrogel prepared using the comonomer mixture with 5.0 wt % SBMA, the amount of adsorbed Lyz is 0.91 myg/cm2, which corresponds to only 56.8% of the amount adsorbed on EASY DAY(R) SCLs.
p35563
sg33279
(lp35564
sg33281
(lp35565
(dp35566
g33284
I68
sg33285
I1
sg33286
I4
sg33287
VC1839259
p35567
sg33289
VSBMA
p35568
sa(dp35569
g33284
I113
sg33285
I1
sg33286
I3
sg33287
VC0555206
p35570
sg33289
Vcm2
p35571
sasa(dp35572
g33277
VObjective To evaluate the efficacy of Ganoderma lucidum preparation on the behaviors,biochemistry,and autoimmunity parameters of mouse models of APP/PS-1 double transgenic Alzheimer's disease(AD).Methods A total of 44 4-month-old APP/PS-1 double transgenic AD mice were randomly divided into AD model group,Aricept group,Ganoderma lucidum middle-dose(LZ-M)group,and Ganoderma lucidum high-dose(LZ-H)group,with 11 mice in each group.In addition,10 4-month-old C57BL/6 mice were used as the control group.Water maze test was conducted to observe the behavior changes,and the protein expressions in brain tissues were detected by Western blot analysis.The autoimmune indicators were detected by indirect immunofluorescence method.Results In the navigation experiment,the time of finding the platform was gradually shortened since the 2nd day in the control,LZ-H,and LZ-M groups,and the time of searching the platform in the AD model group gradually increased.On the 5th day,the time of finding platform was significantly shorter in control group (t=5.607,P=0.000) and LZ-H group(t=2.750,P=0.010)than AD model group.In the space exploration experiment,the number of crossing the target platform(t=2.452,P=0.025)and the residence time in the target quadrant(t=2.530,P=0.020)in AD model group mice was significantly smaller/shorter than those in control group;in addition,the number of crossing the target platform in the AD model group was significantly smaller than that in LZ-H group(t=2.317,P=0.030)and LZ-M group(t=2.443,P=0.030),while the residence time in target quadrant decreased significantly(t=2.770,P=0.020)compared with LZ-H group;the number of crossing through the target platform quadrant(t=2.493,P=0.022)and residence time in the target quadrant(t=2.683,P=0.015)in LZ-H group were significantly higher than in Aricept group.Western blot analysis showed that the expression of ApoA1 in the brain tissues of mice in LZ-H and LZ-M groups were significantly higher than those in AD model group(P&lt;0.01,P&lt;0.05);ABeta-40 expression in LZ-H group was significantly lower than that in AD model group(P&lt;0.05);the expressions of Syt1,ApoE,and ABCA1 in brain tissues of mice in LZ-H group were significantly higher than those in model group(P&lt;0.01,P&lt;0.05).The plasma IgG level in Aricept group(t=30.945,P=0.000),LZ-M group(t=25.639,P=0.000)and LZ-H group(t=4.689,P=0.001)were significantly higher than that in the control group.Conclusion Ganoderma lucidum preparation can improve behavior disorders of AD model mice,promote the expressions of ApoA1,ApoE and Syt1,inhibit the expression of ABeta-40 protein,and improve the autoimmune function.
p35573
sg33279
(lp35574
(dp35575
g33284
I2137
sg33285
I1
sg33286
I4
sg33295
VP21579
p35576
sg33289
VSyt1
p35577
sa(dp35578
g33284
I1886
sg33285
I1
sg33286
I5
sg33295
VP02647
p35579
sg33289
VApoA1
p35580
sa(dp35581
g33284
I1065
sg33285
I2
sg33286
I10
sg33295
VP00390
p35582
sg33289
VLZ-H group
p35583
sa(dp35584
g33284
I2142
sg33285
I1
sg33286
I4
sg33295
VP02649
p35585
sg33289
VApoE
p35586
sa(dp35587
g33284
I145
sg33285
I1
sg33286
I8
sg33295
VP48651
p35588
sg33289
VAPP/PS-1
p35589
sa(dp35590
g33284
I2142
sg33285
I1
sg33286
I4
sg33295
VP02649
p35591
sg33289
VApoE
p35592
sa(dp35593
g33284
I2603
sg33285
I2
sg33286
I16
sg33295
g11
sg33289
VABeta-40 protein
p35594
sa(dp35595
g33284
I1886
sg33285
I1
sg33286
I5
sg33295
VP02647
p35596
sg33289
VApoA1
p35597
sa(dp35598
g33284
I2021
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VABeta-40
p35599
sa(dp35600
g33284
I1065
sg33285
I2
sg33286
I10
sg33295
VP00390
p35601
sg33289
VLZ-H group
p35602
sa(dp35603
g33284
I145
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VAPP
p35604
sa(dp35605
g33284
I1065
sg33285
I2
sg33286
I10
sg33295
VP00390
p35606
sg33289
VLZ-H group
p35607
sa(dp35608
g33284
I149
sg33285
I1
sg33286
I4
sg33295
VP48651
p35609
sg33289
VPS-1
p35610
sa(dp35611
g33284
I2137
sg33285
I1
sg33286
I4
sg33295
VP21579
p35612
sg33289
VSyt1
p35613
sasg33281
(lp35614
(dp35615
g33284
I102
sg33285
I1
sg33286
I12
sg33287
VC0004368
p35616
sg33289
Vautoimmunity
p35617
sa(dp35618
g33284
I172
sg33285
I2
sg33286
I19
sg33287
VC1521724
p35619
sg33289
VAlzheimer's disease
p35620
sa(dp35621
g33284
I2494
sg33285
I2
sg33286
I18
sg33287
VC0004930
p35622
sg33289
Vbehavior disorders
p35623
sa(dp35624
g33284
I653
sg33285
I1
sg33286
I10
sg33287
VC0443146
p35625
sg33289
Vautoimmune
p35626
sa(dp35627
g33284
I653
sg33285
I1
sg33286
I10
sg33287
VC0443146
p35628
sg33289
Vautoimmune
p35629
sasa(dp35630
g33277
VSomatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis.
p35631
sg33279
(lp35632
(dp35633
g33284
I55
sg33285
I1
sg33286
I4
sg33295
VP15056
p35634
sg33289
VBRAF
p35635
sa(dp35636
g33284
I0
sg33285
I8
sg33286
I53
sg33295
VP04049
p35637
sg33289
VSomatic v-Raf murine sarcoma viral oncogene homolog B
p35638
sasg33281
(lp35639
(dp35640
g33284
I21
sg33285
I1
sg33286
I7
sg33287
VC1261473
p35641
sg33289
Vsarcoma
p35642
sa(dp35643
g33284
I133
sg33285
I1
sg33286
I4
sg33287
VC0948380
p35644
sg33289
VmCRC
p35645
sa(dp35646
g33284
I103
sg33285
I3
sg33286
I28
sg33287
VC0948380
p35647
sg33289
Vmetastatic colorectal cancer
p35648
sasa(dp35649
g33277
VAll colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified.
p35650
sg33279
(lp35651
(dp35652
g33284
I42
sg33285
I1
sg33286
I4
sg33295
VP15056
p35653
sg33289
VBRAF
p35654
sasg33281
(lp35655
(dp35656
g33284
I4
sg33285
I2
sg33286
I17
sg33287
VC1527249
p35657
sg33289
Vcolorectal cancer
p35658
sasa(dp35659
g33277
VThe prognostic role of the V600E mutation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC) is well established, but the therapeutic regimen targeting this disease is lacking.
p35660
sg33279
(lp35661
(dp35662
g33284
I45
sg33285
I13
sg33286
I92
sg33295
VP15056
p35663
sg33289
Vv-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC)
p35664
sasg33281
(lp35665
(dp35666
g33284
I132
sg33285
I1
sg33286
I4
sg33287
VC0948380
p35667
sg33289
VmCRC
p35668
sa(dp35669
g33284
I102
sg33285
I3
sg33286
I28
sg33287
VC0948380
p35670
sg33289
Vmetastatic colorectal cancer
p35671
sa(dp35672
g33284
I58
sg33285
I1
sg33286
I7
sg33287
VC1261473
p35673
sg33289
Vsarcoma
p35674
sasa(dp35675
g33277
VThe aim of our study was to evaluate the incidence of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving first line oxaliplatin based chemotherapy with or without bevacizumab and to evaluate their prognostic and predictive significance.
p35676
sg33279
(lp35677
(dp35678
g33284
I66
sg33285
I1
sg33286
I4
sg33295
VP15056
p35679
sg33289
VBRAF
p35680
sa(dp35681
g33284
I60
sg33285
I1
sg33286
I4
sg33295
VP01111
p35682
sg33289
VNRAS
p35683
sa(dp35684
g33284
I75
sg33285
I1
sg33286
I6
sg33295
VP42336
p35685
sg33289
VPIK3CA
p35686
sa(dp35687
g33284
I54
sg33285
I1
sg33286
I4
sg33295
VP01116
p35688
sg33289
VKRAS
p35689
sasg33281
(lp35690
(dp35691
g33284
I95
sg33285
I3
sg33286
I28
sg33287
VC0948380
p35692
sg33289
Vmetastatic colorectal cancer
p35693
sasa(dp35694
g33277
VActivating BRAF (V-raf murine sarcoma viral oncogene homolog B) mutations occur in approximately 5% to 10% of patients with metastatic colorectal cancer, mostly V600E mutation, and it is associated with distinct clinical and pathological features.
p35695
sg33279
(lp35696
(dp35697
g33284
I11
sg33285
I1
sg33286
I4
sg33295
VP15056
p35698
sg33289
VBRAF
p35699
sa(dp35700
g33284
I17
sg33285
I7
sg33286
I45
sg33295
VP04049
p35701
sg33289
VV-raf murine sarcoma viral oncogene homolog B
p35702
sasg33281
(lp35703
(dp35704
g33284
I30
sg33285
I1
sg33286
I7
sg33287
VC1261473
p35705
sg33289
Vsarcoma
p35706
sa(dp35707
g33284
I124
sg33285
I3
sg33286
I28
sg33287
VC0948380
p35708
sg33289
Vmetastatic colorectal cancer
p35709
sasa(dp35710
g33277
VThis review aims to provide data about new strategies to target to BRAF gene mutation in metastatic colorectal cancer.
p35711
sg33279
(lp35712
(dp35713
g33284
I67
sg33285
I2
sg33286
I9
sg33295
VP15056
p35714
sg33289
VBRAF gene
p35715
sasg33281
(lp35716
(dp35717
g33284
I89
sg33285
I3
sg33286
I28
sg33287
VC0948380
p35718
sg33289
Vmetastatic colorectal cancer
p35719
sa(dp35720
g33284
I67
sg33285
I3
sg33286
I18
sg33287
VC1511021
p35721
sg33289
VBRAF gene mutation
p35722
sasa(dp35723
g33277
VThe variables of age, incidence of autoimmune hepatitis, model of end-stage liver disease (MELD) score, values for total bilirubin and prothrombin time-international ratio (PT-INR), and Japan Hepatic Encephalopathy Prediction Model (JHEPM) probability at registration were significantly higher in ALF patients than in ALI patients.
p35724
sg33279
(lp35725
(dp35726
g33284
I135
sg33285
I1
sg33286
I11
sg33295
VP00734
p35727
sg33289
Vprothrombin
p35728
sasg33281
(lp35729
(dp35730
g33284
I35
sg33285
I2
sg33286
I20
sg33287
VC0241910
p35731
sg33289
Vautoimmune hepatitis
p35732
sa(dp35733
g33284
I76
sg33285
I2
sg33286
I13
sg33287
VC0023895
p35734
sg33289
Vliver disease
p35735
sa(dp35736
g33284
I192
sg33285
I2
sg33286
I22
sg33287
VC0019151
p35737
sg33289
VHepatic Encephalopathy
p35738
sasa(dp35739
g33277
VOn the other hand, the multivariate Cox proportional hazard model showed that positivity for serum anti-PD-1 antibody, probable diagnosis based on the revised scoring system proposed by the International Autoimmune Hepatitis Group, and prothrombin activity of less than 60% were associated with the later normalization of serum transaminase levels.
p35740
sg33279
(lp35741
(dp35742
g33284
I93
sg33285
I3
sg33286
I24
sg33295
VP18621
p35743
sg33289
Vserum anti-PD-1 antibody
p35744
sa(dp35745
g33284
I322
sg33285
I2
sg33286
I18
sg33295
g11
sg33289
Vserum transaminase
p35746
sa(dp35747
g33284
I236
sg33285
I1
sg33286
I11
sg33295
VP00734
p35748
sg33289
Vprothrombin
p35749
sasg33281
(lp35750
(dp35751
g33284
I204
sg33285
I2
sg33286
I20
sg33287
VC0241910
p35752
sg33289
VAutoimmune Hepatitis
p35753
sasa(dp35754
g33277
VMyeloma cell maturity was classified via immunophenotyping: myeloma cells showing mature plasma cell 1 (MPC-1)-positive and CD49e-positive cells were considered mature type; MPC-1-positive and CD49e-negative cells were considered intermediate type; and MPC-1-negative cells were considered immature type.
p35755
sg33279
(lp35756
(dp35757
g33284
I124
sg33285
I1
sg33286
I5
sg33295
VP08648
p35758
sg33289
VCD49e
p35759
sa(dp35760
g33284
I124
sg33285
I1
sg33286
I5
sg33295
VP08648
p35761
sg33289
VCD49e
p35762
sasg33281
(lp35763
(dp35764
g33284
I60
sg33285
I1
sg33286
I7
sg33287
VC0026764
p35765
sg33289
Vmyeloma
p35766
sa(dp35767
g33284
I0
sg33285
I1
sg33286
I7
sg33287
VC0026764
p35768
sg33289
VMyeloma
p35769
sasa(dp35770
g33277
VThe findings of this study demonstrate the clinical importance of myeloma cell classification according to immunophenotyping using MPC-1 and CD49e antibodies to determine patient prognosis in this era of novel therapeutic agents.
p35771
sg33279
(lp35772
(dp35773
g33284
I131
sg33285
I1
sg33286
I5
sg33295
VP28062
p35774
sg33289
VMPC-1
p35775
sa(dp35776
g33284
I141
sg33285
I2
sg33286
I16
sg33295
VP08648
p35777
sg33289
VCD49e antibodies
p35778
sasg33281
(lp35779
(dp35780
g33284
I66
sg33285
I1
sg33286
I7
sg33287
VC0026764
p35781
sg33289
Vmyeloma
p35782
sasa(dp35783
g33277
VOn the basis of biopsies of the masses in the pharynx and finger, he was diagnosed with extramedullary plasmablastic plasmacytoma, with somewhat immature CD45(+), MPC-1(-), and CD49e(-).
p35784
sg33279
(lp35785
(dp35786
g33284
I177
sg33285
I1
sg33286
I5
sg33295
VP08648
p35787
sg33289
VCD49e
p35788
sa(dp35789
g33284
I154
sg33285
I1
sg33286
I7
sg33295
VP08575
p35790
sg33289
VCD45(+)
p35791
sa(dp35792
g33284
I163
sg33285
I1
sg33286
I5
sg33295
VP28062
p35793
sg33289
VMPC-1
p35794
sasg33281
(lp35795
(dp35796
g33284
I117
sg33285
I1
sg33286
I12
sg33287
VC0032131
p35797
sg33289
Vplasmacytoma
p35798
sasa(dp35799
g33277
VChanges to CD45 negativity and MPC-1 partial positivity were seen, while CD49e negativity persisted, suggesting that the plasmablastic plasmacytoma had reverted to a more immature state.
p35800
sg33279
(lp35801
(dp35802
g33284
I31
sg33285
I1
sg33286
I5
sg33295
VP28062
p35803
sg33289
VMPC-1
p35804
sa(dp35805
g33284
I73
sg33285
I1
sg33286
I5
sg33295
VP08648
p35806
sg33289
VCD49e
p35807
sa(dp35808
g33284
I11
sg33285
I2
sg33286
I15
sg33295
VP08575
p35809
sg33289
VCD45 negativity
p35810
sasg33281
(lp35811
(dp35812
g33284
I135
sg33285
I1
sg33286
I12
sg33287
VC0032131
p35813
sg33289
Vplasmacytoma
p35814
sasa(dp35815
g33277
VHe had the following poor prognostic factors: 1) multiple extramedullary plasmacytomas, 2) massive myelomatous effusion, 3) increasing immature myeloma cells with plasmablastic morphology, and 4) predominance of MPC1-CD49e-CD45+ phenotype immature myeloma cells.
p35816
sg33279
(lp35817
(dp35818
g33284
I212
sg33285
I1
sg33286
I4
sg33295
VP28062
p35819
sg33289
VMPC1
p35820
sa(dp35821
g33284
I223
sg33285
I1
sg33286
I5
sg33295
VP08575
p35822
sg33289
VCD45+
p35823
sa(dp35824
g33284
I217
sg33285
I1
sg33286
I5
sg33295
VP08648
p35825
sg33289
VCD49e
p35826
sasg33281
(lp35827
(dp35828
g33284
I99
sg33285
I1
sg33286
I7
sg33287
VC0026764
p35829
sg33289
Vmyeloma
p35830
sa(dp35831
g33284
I111
sg33285
I1
sg33286
I8
sg33287
VC0013687
p35832
sg33289
Veffusion
p35833
sa(dp35834
g33284
I99
sg33285
I1
sg33286
I7
sg33287
VC0026764
p35835
sg33289
Vmyeloma
p35836
sa(dp35837
g33284
I73
sg33285
I1
sg33286
I13
sg33287
VC0032131
p35838
sg33289
Vplasmacytomas
p35839
sasa(dp35840
g33277
VCD32 was significantly expressed on primary myeloma cells, but immature, MPC-1- myeloma cells expressed CD32 more weakly than mature, MPC-1+ cells.
p35841
sg33279
(lp35842
(dp35843
g33284
I0
sg33285
I1
sg33286
I4
sg33295
VP12318
p35844
sg33289
VCD32
p35845
sa(dp35846
g33284
I73
sg33285
I1
sg33286
I5
sg33295
VP28062
p35847
sg33289
VMPC-1
p35848
sa(dp35849
g33284
I0
sg33285
I1
sg33286
I4
sg33295
VP12318
p35850
sg33289
VCD32
p35851
sasg33281
(lp35852
(dp35853
g33284
I44
sg33285
I1
sg33286
I7
sg33287
VC0026764
p35854
sg33289
Vmyeloma
p35855
sa(dp35856
g33284
I44
sg33285
I1
sg33286
I7
sg33287
VC0026764
p35857
sg33289
Vmyeloma
p35858
sasa(dp35859
g33277
VTreatment with anti-CD32 antibody decreased the viability of normal plasma cells (CD38++ CD19+) more than that of myeloma cells (CD38++ CD19-); CD32-mediated growth suppression was greater in mature MPC-1+ cells than in immature MPC-1- cells.
p35860
sg33279
(lp35861
(dp35862
g33284
I15
sg33285
I2
sg33286
I18
sg33295
VP12318
p35863
sg33289
Vanti-CD32 antibody
p35864
sa(dp35865
g33284
I82
sg33285
I2
sg33286
I12
sg33295
VP28907
p35866
sg33289
VCD38++ CD19+
p35867
sa(dp35868
g33284
I20
sg33285
I1
sg33286
I4
sg33295
VP12318
p35869
sg33289
VCD32
p35870
sasg33281
(lp35871
(dp35872
g33284
I158
sg33285
I2
sg33286
I18
sg33287
VC0151686
p35873
sg33289
Vgrowth suppression
p35874
sa(dp35875
g33284
I114
sg33285
I1
sg33286
I7
sg33287
VC0026764
p35876
sg33289
Vmyeloma
p35877
sasa(dp35878
g33277
VTo date, at least 5 subpopulations of plasma cells have been identified in the bone marrow of multiple myeloma (MM) patients with regard to the expression of MPC-1, CD49e (VLA-5), and CD45: MPC-1(-)CD49e(-)CD45(+) proliferative immature cells, MPC-1(-)CD49e(-)CD45(-) immature myeloma cells, MPC-1(+)CD49e(-)CD45(-) and MPC-1(+)CD49e(-)CD45(+) intermediate myeloma cells, and MPC-1(+)CD49e(+)CD45(+) mature myeloma cells.
p35879
sg33279
(lp35880
(dp35881
g33284
I376
sg33285
I1
sg33286
I23
sg33295
VP28062
p35882
sg33289
VMPC-1(+)CD49e(+)CD45(+)
p35883
sa(dp35884
g33284
I184
sg33285
I2
sg33286
I26
sg33295
VP08575
p35885
sg33289
VCD45: MPC-1(-)CD49e(-)CD45
p35886
sa(dp35887
g33284
I158
sg33285
I1
sg33286
I5
sg33295
VP28062
p35888
sg33289
VMPC-1
p35889
sa(dp35890
g33284
I260
sg33285
I1
sg33286
I7
sg33295
VP08575
p35891
sg33289
VCD45(-)
p35892
sa(dp35893
g33284
I190
sg33285
I1
sg33286
I16
sg33295
VP28062
p35894
sg33289
VMPC-1(-)CD49e(-)
p35895
sa(dp35896
g33284
I292
sg33285
I1
sg33286
I23
sg33295
VP28062
p35897
sg33289
VMPC-1(+)CD49e(-)CD45(-)
p35898
sa(dp35899
g33284
I172
sg33285
I1
sg33286
I5
sg33295
VP08648
p35900
sg33289
VVLA-5
p35901
sa(dp35902
g33284
I165
sg33285
I1
sg33286
I5
sg33295
VP08648
p35903
sg33289
VCD49e
p35904
sa(dp35905
g33284
I320
sg33285
I1
sg33286
I23
sg33295
VP28062
p35906
sg33289
VMPC-1(+)CD49e(-)CD45(+)
p35907
sasg33281
(lp35908
(dp35909
g33284
I103
sg33285
I1
sg33286
I7
sg33287
VC0026764
p35910
sg33289
Vmyeloma
p35911
sa(dp35912
g33284
I94
sg33285
I2
sg33286
I16
sg33287
VC0026764
p35913
sg33289
Vmultiple myeloma
p35914
sa(dp35915
g33284
I214
sg33285
I1
sg33286
I13
sg33287
VC0334094
p35916
sg33289
Vproliferative
p35917
sa(dp35918
g33284
I112
sg33285
I1
sg33286
I2
sg33287
VC0026764
p35919
sg33289
VMM
p35920
sa(dp35921
g33284
I103
sg33285
I1
sg33286
I7
sg33287
VC0026764
p35922
sg33289
Vmyeloma
p35923
sa(dp35924
g33284
I103
sg33285
I1
sg33286
I7
sg33287
VC0026764
p35925
sg33289
Vmyeloma
p35926
sasa(dp35927
g33277
VIn 31 cases of progressive MM disease, MPC-1(-) immature and MPC-1(-)CD45(+) proliferative immature myeloma cells were significantly increased up to &gt;25% and &gt;10%, respectively, of the plasma cell fractions (CD38(++) cells), whereas there were no increases in MPC-1(-) or MPC-1(-)CD45(+) proliferative immature myeloma cells in 15 cases of stable disease.
p35928
sg33279
(lp35929
(dp35930
g33284
I61
sg33285
I1
sg33286
I15
sg33295
VP28062
p35931
sg33289
VMPC-1(-)CD45(+)
p35932
sa(dp35933
g33284
I214
sg33285
I1
sg33286
I4
sg33295
VP28907
p35934
sg33289
VCD38
p35935
sa(dp35936
g33284
I61
sg33285
I1
sg33286
I15
sg33295
VP28062
p35937
sg33289
VMPC-1(-)CD45(+)
p35938
sa(dp35939
g33284
I39
sg33285
I1
sg33286
I8
sg33295
VP28062
p35940
sg33289
VMPC-1(-)
p35941
sasg33281
(lp35942
(dp35943
g33284
I77
sg33285
I1
sg33286
I13
sg33287
VC0334094
p35944
sg33289
Vproliferative
p35945
sa(dp35946
g33284
I77
sg33285
I1
sg33286
I13
sg33287
VC0334094
p35947
sg33289
Vproliferative
p35948
sa(dp35949
g33284
I100
sg33285
I1
sg33286
I7
sg33287
VC0026764
p35950
sg33289
Vmyeloma
p35951
sa(dp35952
g33284
I100
sg33285
I1
sg33286
I7
sg33287
VC0026764
p35953
sg33289
Vmyeloma
p35954
sasa(dp35955
g33277
VInterestingly, the proportions of MPC-1(-) and MPC-1(-)CD45(+) immature monoclonal plasma cells also increased in the 7 progressive cases of MGUS.
p35956
sg33279
(lp35957
(dp35958
g33284
I47
sg33285
I1
sg33286
I15
sg33295
VP28062
p35959
sg33289
VMPC-1(-)CD45(+)
p35960
sa(dp35961
g33284
I34
sg33285
I1
sg33286
I5
sg33295
VP28062
p35962
sg33289
VMPC-1
p35963
sasg33281
(lp35964
(dp35965
g33284
I141
sg33285
I1
sg33286
I4
sg33287
VC0026470
p35966
sg33289
VMGUS
p35967
sasa(dp35968
g33277
VResults with flow cytometry using a combination of MPC1, CD49e, and CD45 supported the morphologic findings for the myeloma cells.
p35969
sg33279
(lp35970
(dp35971
g33284
I51
sg33285
I1
sg33286
I4
sg33295
VP28062
p35972
sg33289
VMPC1
p35973
sa(dp35974
g33284
I57
sg33285
I1
sg33286
I5
sg33295
VP08648
p35975
sg33289
VCD49e
p35976
sa(dp35977
g33284
I68
sg33285
I1
sg33286
I4
sg33295
VP08575
p35978
sg33289
VCD45
p35979
sasg33281
(lp35980
(dp35981
g33284
I116
sg33285
I1
sg33286
I7
sg33287
VC0026764
p35982
sg33289
Vmyeloma
p35983
sasa(dp35984
g33277
VInterestingly, the region encompassing the SNF1LK locus has been implicated in congenital heart defects often observed in patients with Down syndrome.
p35985
sg33279
(lp35986
(dp35987
g33284
I43
sg33285
I2
sg33286
I12
sg33295
VP57059
p35988
sg33289
VSNF1LK locus
p35989
sasg33281
(lp35990
(dp35991
g33284
I136
sg33285
I2
sg33286
I13
sg33287
VC0013080
p35992
sg33289
VDown syndrome
p35993
sa(dp35994
g33284
I79
sg33285
I3
sg33286
I24
sg33287
VC0018798
p35995
sg33289
Vcongenital heart defects
p35996
sasa(dp35997
g33277
VOn the other hand, a significant increase was demonstrated in CD14-positive cells at 3 weeks after immunization in only arthritis-developed monkeys regardless of sex.
p35998
sg33279
(lp35999
(dp36000
g33284
I62
sg33285
I1
sg33286
I4
sg33295
VP08571
p36001
sg33289
VCD14
p36002
sasg33281
(lp36003
(dp36004
g33284
I120
sg33285
I1
sg33286
I9
sg33287
VC0003864
p36005
sg33289
Varthritis
p36006
sasa(dp36007
g33277
VWe previously reported the accumulation of abnormal myeloid cell populations reacting with CD14 (MY4) monoclonal antibody in the iliac and epiphyseal bone marrow of patients with severe rheumatoid arthritis (RA).
p36008
sg33279
(lp36009
(dp36010
g33284
I91
sg33285
I1
sg33286
I4
sg33295
VP08571
p36011
sg33289
VCD14
p36012
sasg33281
(lp36013
(dp36014
g33284
I208
sg33285
I1
sg33286
I2
sg33287
VC0003873
p36015
sg33289
VRA
p36016
sa(dp36017
g33284
I186
sg33285
I2
sg33286
I20
sg33287
VC0003873
p36018
sg33289
Vrheumatoid arthritis
p36019
sasa(dp36020
g33277
VPrior to treatment, monocyte-macrophage activation in rheumatoid arthritis was signified by an increased expression of HLA-class II antigens and the CD14 antigen, and by an increased production of neopterin and interleukin-1.
p36021
sg33279
(lp36022
(dp36023
g33284
I149
sg33285
I2
sg33286
I12
sg33295
VP08571
p36024
sg33289
VCD14 antigen
p36025
sa(dp36026
g33284
I211
sg33285
I1
sg33286
I13
sg33295
VP60568
p36027
sg33289
Vinterleukin-1
p36028
sa(dp36029
g33284
I119
sg33285
I3
sg33286
I21
sg33295
VP30486
p36030
sg33289
VHLA-class II antigens
p36031
sasg33281
(lp36032
(dp36033
g33284
I54
sg33285
I2
sg33286
I20
sg33287
VC0003873
p36034
sg33289
Vrheumatoid arthritis
p36035
sasa(dp36036
g33277
VMonocytes, defined by staining with the Mo-2 and Leu-M3 monoclonal antibodies which both detect the CD14 antigen, were studied in peripheral blood of control subjects and patients with rheumatoid arthritis as well as in rheumatoid synovial fluid of the latter for expression of activation/differentiation markers.
p36037
sg33279
(lp36038
(dp36039
g33284
I49
sg33285
I3
sg33286
I28
sg33295
VP30740
p36040
sg33289
VLeu-M3 monoclonal antibodies
p36041
sa(dp36042
g33284
I100
sg33285
I2
sg33286
I12
sg33295
VP08571
p36043
sg33289
VCD14 antigen
p36044
sasg33281
(lp36045
(dp36046
g33284
I185
sg33285
I2
sg33286
I20
sg33287
VC0003873
p36047
sg33289
Vrheumatoid arthritis
p36048
sasa(dp36049
g33277
VWe review recent findings implicating variants of FCRL3 (gene for FC receptor-like-3 protein), SCGB3A2 (gene for secretory uteroglobin-related protein 1- UGRP1) as well as other unverified possible candidate genes for GD selected through their documented association with type 1 diabetes mellitus: Tenr-IL2-IL21, CAPSL (encoding calcyphosine-like protein), IFIH1(gene for interferon-induced helicase C domain 1), AFF3, CD226 and PTPN2.
p36050
sg33279
(lp36051
(dp36052
g33284
I413
sg33285
I1
sg33286
I4
sg33295
VP51826
p36053
sg33289
VAFF3
p36054
sa(dp36055
g33284
I307
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VIL21
p36056
sa(dp36057
g33284
I113
sg33285
I5
sg33286
I46
sg33295
VP11684
p36058
sg33289
Vsecretory uteroglobin-related protein 1- UGRP1
p36059
sa(dp36060
g33284
I50
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VFCRL3
p36061
sa(dp36062
g33284
I329
sg33285
I2
sg33286
I25
sg33295
g11
sg33289
Vcalcyphosine-like protein
p36063
sa(dp36064
g33284
I429
sg33285
I1
sg33286
I5
sg33295
VP17706
p36065
sg33289
VPTPN2
p36066
sa(dp36067
g33284
I66
sg33285
I3
sg33286
I26
sg33295
g11
sg33289
VFC receptor-like-3 protein
p36068
sa(dp36069
g33284
I372
sg33285
I5
sg33286
I38
sg33295
VP01563
p36070
sg33289
Vinterferon-induced helicase C domain 1
p36071
sa(dp36072
g33284
I357
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VIFIH1
p36073
sa(dp36074
g33284
I95
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VSCGB3A2
p36075
sa(dp36076
g33284
I303
sg33285
I1
sg33286
I3
sg33295
VP60568
p36077
sg33289
VIL2
p36078
sa(dp36079
g33284
I419
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCD226
p36080
sa(dp36081
g33284
I313
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCAPSL
p36082
sasg33281
(lp36083
(dp36084
g33284
I272
sg33285
I4
sg33286
I24
sg33287
VC0011854
p36085
sg33289
Vtype 1 diabetes mellitus
p36086
sasa(dp36087
g33277
VAutoantibody-positive diabetic subjects (n = 1,384) and population-based control subjects (n = 2,235) were genotyped at 20 childhood-onset type 1 diabetes loci and FCRL3, GAD2, TCF7L2, and FTO.
p36088
sg33279
(lp36089
(dp36090
g33284
I171
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VGAD2
p36091
sasg33281
(lp36092
(dp36093
g33284
I139
sg33285
I3
sg33286
I15
sg33287
VC0011854
p36094
sg33289
Vtype 1 diabetes
p36095
sasa(dp36096
g33277
VWe analyzed the same four 5' FCRL3 single nucleotide polymorphism markers, together with three additional exonic single nucleotide polymorphisms in the FCRL3 gene, in cohorts of white Caucasians with Graves' disease (n = 625), type 1 diabetes (n = 279), autoimmune Addison's disease (AAD; n = 200), and RA (n = 769).
p36097
sg33279
(lp36098
sg33281
(lp36099
(dp36100
g33284
I227
sg33285
I3
sg33286
I15
sg33287
VC0011854
p36101
sg33289
Vtype 1 diabetes
p36102
sa(dp36103
g33284
I254
sg33285
I3
sg33286
I28
sg33287
VC0271737
p36104
sg33289
Vautoimmune Addison's disease
p36105
sa(dp36106
g33284
I200
sg33285
I2
sg33286
I15
sg33287
VC0018213
p36107
sg33289
VGraves' disease
p36108
sa(dp36109
g33284
I284
sg33285
I1
sg33286
I3
sg33287
VC0271737
p36110
sg33289
VAAD
p36111
sasa(dp36112
g33277
VIn vivo, in a model of experimental autoimmune encephalomyelitis, we show that an agonist of DR3 suppressed disease, correlating with expansion of CD4+Foxp3+ Tregs, and this protective effect was lost in Galectin-9-/- mice.
p36113
sg33279
(lp36114
(dp36115
g33284
I147
sg33285
I1
sg33286
I10
sg33295
VP01730
p36116
sg33289
VCD4+Foxp3+
p36117
sa(dp36118
g33284
I204
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VGalectin-9
p36119
sasg33281
(lp36120
(dp36121
g33284
I36
sg33285
I1
sg33286
I10
sg33287
VC0443146
p36122
sg33289
Vautoimmune
p36123
sa(dp36124
g33284
I47
sg33285
I1
sg33286
I17
sg33287
VC0014070
p36125
sg33289
Vencephalomyelitis
p36126
sasa(dp36127
g33277
VGalectin-9 concentrations in CSF were higher in SPMS patients than healthy controls and RRMS patients in both cohorts.
p36128
sg33279
(lp36129
(dp36130
g33284
I0
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VGalectin-9
p36131
sasg33281
(lp36132
sa(dp36133
g33277
VOur objective is to identify phenotypically the position of CD43(+) B cells among peripheral B-lineage cell compartments in healthy donors, with reference to B-cell subsets from patients with systemic lupus erythematosus (SLE).
p36134
sg33279
(lp36135
(dp36136
g33284
I60
sg33285
I1
sg33286
I4
sg33295
VP16150
p36137
sg33289
VCD43
p36138
sasg33281
(lp36139
(dp36140
g33284
I192
sg33285
I3
sg33286
I28
sg33287
VC0024141
p36141
sg33289
Vsystemic lupus erythematosus
p36142
sa(dp36143
g33284
I222
sg33285
I1
sg33286
I3
sg33287
VC0024141
p36144
sg33289
VSLE
p36145
sasa(dp36146
g33277
VPrevious studies indicate that CD43 plays a role in regulating the adhesion of lymphocytes, cell mutation and activation, however, little is known about its effect on systemic lupus erythematosus (SLE).
p36147
sg33279
(lp36148
(dp36149
g33284
I31
sg33285
I1
sg33286
I4
sg33295
VP16150
p36150
sg33289
VCD43
p36151
sasg33281
(lp36152
(dp36153
g33284
I197
sg33285
I1
sg33286
I3
sg33287
VC0024141
p36154
sg33289
VSLE
p36155
sa(dp36156
g33284
I67
sg33285
I1
sg33286
I8
sg33287
VC0001511
p36157
sg33289
Vadhesion
p36158
sa(dp36159
g33284
I167
sg33285
I3
sg33286
I28
sg33287
VC0024141
p36160
sg33289
Vsystemic lupus erythematosus
p36161
sasa(dp36162
g33277
VTwo new cases of primary Ficolin-3 deficiency are reported here: a 50-year old male, suffering from membranous nephropathy and an 11-month old male infant who was operated on to repair congenital heart disease.
p36163
sg33279
(lp36164
(dp36165
g33284
I25
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VFicolin-3
p36166
sasg33281
(lp36167
(dp36168
g33284
I185
sg33285
I3
sg33286
I24
sg33287
VC0152021
p36169
sg33289
Vcongenital heart disease
p36170
sa(dp36171
g33284
I85
sg33285
I1
sg33286
I9
sg33287
VC0683278
p36172
sg33289
Vsuffering
p36173
sa(dp36174
g33284
I100
sg33285
I2
sg33286
I22
sg33287
VC0017665
p36175
sg33289
Vmembranous nephropathy
p36176
sasa(dp36177
g33277
VIn order to investigate its potential pathogenicity for turkeys a UK isolate of Mim from a partridge with sinusitis was first passaged through turkey poults and then assessed for pathogenicity in turkey embryo tracheal organ cultures (TOCs) and in one-day-old turkey poults with or without turkey rhinotracheitis virus (TRTV).
p36178
sg33279
(lp36179
(dp36180
g33284
I80
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VMim
p36181
sasg33281
(lp36182
(dp36183
g33284
I290
sg33285
I2
sg33286
I22
sg33287
VC0275744
p36184
sg33289
Vturkey rhinotracheitis
p36185
sa(dp36186
g33284
I106
sg33285
I1
sg33286
I9
sg33287
VC0037199
p36187
sg33289
Vsinusitis
p36188
sasa(dp36189
g33277
VBoth up- and down-regulation of the Toll-like receptors (TLRs) and antimicrobial peptides (AMPs) of the sinonasal mucosa have already been associated with the pathogenesis of chronic rhinosinusitis with (CRSwNP) or without (CRSsNP) nasal polyps.
p36190
sg33279
(lp36191
(dp36192
g33284
I36
sg33285
I2
sg33286
I19
sg33295
g11
sg33289
VToll-like receptors
p36193
sa(dp36194
g33284
I57
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTLRs
p36195
sasg33281
(lp36196
(dp36197
g33284
I159
sg33285
I1
sg33286
I12
sg33287
VC0699748
p36198
sg33289
Vpathogenesis
p36199
sa(dp36200
g33284
I175
sg33285
I2
sg33286
I22
sg33287
VC0149516
p36201
sg33289
Vchronic rhinosinusitis
p36202
sa(dp36203
g33284
I232
sg33285
I2
sg33286
I12
sg33287
VC0027430
p36204
sg33289
Vnasal polyps
p36205
sasa(dp36206
g33277
VIt is suggested that elevated plasma nociceptin level found in Wilson disease patients is due to inhibition of nociceptin-inactivating Zn-metallopeptidases (aminopeptidase N (APN) and endopeptidase 24.15) by the toxic copper deposits in liver and/or brain.
p36207
sg33279
(lp36208
(dp36209
g33284
I175
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VAPN
p36210
sa(dp36211
g33284
I111
sg33285
I2
sg33286
I44
sg33295
g11
sg33289
Vnociceptin-inactivating Zn-metallopeptidases
p36212
sa(dp36213
g33284
I184
sg33285
I2
sg33286
I19
sg33295
VP52888
p36214
sg33289
Vendopeptidase 24.15
p36215
sa(dp36216
g33284
I157
sg33285
I2
sg33286
I16
sg33295
VP15144
p36217
sg33289
Vaminopeptidase N
p36218
sa(dp36219
g33284
I30
sg33285
I2
sg33286
I17
sg33295
g11
sg33289
Vplasma nociceptin
p36220
sasg33281
(lp36221
(dp36222
g33284
I63
sg33285
I2
sg33286
I14
sg33287
VC0019202
p36223
sg33289
VWilson disease
p36224
sasa(dp36225
g33277
VIt is evident from the study that body iron (serum iron, TIBC &amp; transferrin saturation) level significantly increases among acute myocardial infarction patients in Bangladesh.
p36226
sg33279
(lp36227
(dp36228
g33284
I68
sg33285
I1
sg33286
I11
sg33295
VP02787
p36229
sg33289
Vtransferrin
p36230
sasg33281
(lp36231
(dp36232
g33284
I128
sg33285
I3
sg33286
I27
sg33287
VC0155626
p36233
sg33289
Vacute myocardial infarction
p36234
sasa(dp36235
g33277
VWe investigated the relation of NTBI, serum iron, transferrin saturation, and serum ferritin with risk of CHD and acute myocardial infarction (AMI).
p36236
sg33279
(lp36237
(dp36238
g33284
I78
sg33285
I2
sg33286
I14
sg33295
VP02794
p36239
sg33289
Vserum ferritin
p36240
sa(dp36241
g33284
I50
sg33285
I1
sg33286
I11
sg33295
VP02787
p36242
sg33289
Vtransferrin
p36243
sasg33281
(lp36244
(dp36245
g33284
I114
sg33285
I3
sg33286
I27
sg33287
VC0155626
p36246
sg33289
Vacute myocardial infarction
p36247
sa(dp36248
g33284
I143
sg33285
I1
sg33286
I3
sg33287
VC0155626
p36249
sg33289
VAMI
p36250
sasa(dp36251
g33277
VIn this study, the effects of chiral pesticide metalaxyl on CYP1A1, CYP1A2, CYP2B1, CYP2B2, CYP2E1 and CYP3A were investigated in human hepatoma HepG2, rat hepatic H4IIE, chicken hepatic LMH and grass carp hepatic L8824 cells.
p36252
sg33279
(lp36253
(dp36254
g33284
I171
sg33285
I3
sg33286
I19
sg33295
g11
sg33289
Vchicken hepatic LMH
p36255
sa(dp36256
g33284
I68
sg33285
I1
sg33286
I6
sg33295
VP05177
p36257
sg33289
VCYP1A2
p36258
sa(dp36259
g33284
I92
sg33285
I1
sg33286
I6
sg33295
VP05181
p36260
sg33289
VCYP2E1
p36261
sa(dp36262
g33284
I60
sg33285
I1
sg33286
I6
sg33295
VP04798
p36263
sg33289
VCYP1A1
p36264
sa(dp36265
g33284
I103
sg33285
I1
sg33286
I5
sg33295
VP08684
p36266
sg33289
VCYP3A
p36267
sasg33281
(lp36268
(dp36269
g33284
I201
sg33285
I1
sg33286
I4
sg33287
VC0263385
p36270
sg33289
Vcarp
p36271
sa(dp36272
g33284
I136
sg33285
I1
sg33286
I8
sg33287
VC0023903
p36273
sg33289
Vhepatoma
p36274
sasa(dp36275
g33277
VER+ cancers exhibited lower ADORA1, ADORA2B, and RYR1 and elevated PDE4A, CYP2A6, and CYP2E expressions.
p36276
sg33279
(lp36277
(dp36278
g33284
I28
sg33285
I1
sg33286
I6
sg33295
VP30542
p36279
sg33289
VADORA1
p36280
sa(dp36281
g33284
I36
sg33285
I1
sg33286
I7
sg33295
VP29275
p36282
sg33289
VADORA2B
p36283
sa(dp36284
g33284
I86
sg33285
I1
sg33286
I5
sg33295
VP05181
p36285
sg33289
VCYP2E
p36286
sa(dp36287
g33284
I49
sg33285
I1
sg33286
I4
sg33295
VP21817
p36288
sg33289
VRYR1
p36289
sasg33281
(lp36290
(dp36291
g33284
I4
sg33285
I1
sg33286
I7
sg33287
VC0006826
p36292
sg33289
Vcancers
p36293
sasa(dp36294
g33277
VThe mechanisms were investigated by detecting levels of NADPH Oxidase 4 (NOX4),p22phox, cytochrome P4502E1 (CYP2E1),Bax,B-cell lymphoma 2 (Bcl-2),cleaved-caspase 3 and 9 and phosphorylated extracellular regulated protein kinases(ERK),phosphorylated c-Jun N-terminal kinase (JNK), and phosphorylated p38 mitogen-activated protein kinase (MAPK) using real-time polymerase chain reaction (PCR) and Western blotting.
p36295
sg33279
(lp36296
(dp36297
g33284
I337
sg33285
I1
sg33286
I4
sg33295
VP53779
p36298
sg33289
VMAPK
p36299
sa(dp36300
g33284
I249
sg33285
I3
sg33286
I23
sg33295
VP53779
p36301
sg33289
Vc-Jun N-terminal kinase
p36302
sa(dp36303
g33284
I79
sg33285
I1
sg33286
I7
sg33295
VP13498
p36304
sg33289
Vp22phox
p36305
sa(dp36306
g33284
I299
sg33285
I4
sg33286
I36
sg33295
g11
sg33289
Vp38 mitogen-activated protein kinase
p36307
sa(dp36308
g33284
I108
sg33285
I1
sg33286
I6
sg33295
VP05181
p36309
sg33289
VCYP2E1
p36310
sa(dp36311
g33284
I274
sg33285
I1
sg33286
I3
sg33295
VP53779
p36312
sg33289
VJNK
p36313
sa(dp36314
g33284
I88
sg33285
I2
sg33286
I18
sg33295
VP05181
p36315
sg33289
Vcytochrome P4502E1
p36316
sa(dp36317
g33284
I154
sg33285
I1
sg33286
I7
sg33295
VP39880
p36318
sg33289
Vcaspase
p36319
sa(dp36320
g33284
I115
sg33285
I3
sg33286
I22
sg33295
VP10415
p36321
sg33289
V,Bax,B-cell lymphoma 2
p36322
sa(dp36323
g33284
I56
sg33285
I3
sg33286
I15
sg33295
g11
sg33289
VNADPH Oxidase 4
p36324
sa(dp36325
g33284
I189
sg33285
I4
sg33286
I39
sg33295
VP10398
p36326
sg33289
Vextracellular regulated protein kinases
p36327
sa(dp36328
g33284
I73
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNOX4
p36329
sa(dp36330
g33284
I229
sg33285
I1
sg33286
I3
sg33295
VP29323
p36331
sg33289
VERK
p36332
sa(dp36333
g33284
I139
sg33285
I1
sg33286
I5
sg33295
VP10415
p36334
sg33289
VBcl-2
p36335
sasg33281
(lp36336
(dp36337
g33284
I120
sg33285
I2
sg33286
I15
sg33287
VC0079731
p36338
sg33289
VB-cell lymphoma
p36339
sasa(dp36340
g33277
VTwenty-two variants from 21 genes (APEX1 rs1130409 and rs1760944, ATM rs664677, AXIN2 rs2240308, CHRNA3 rs6495309, CHRNA5 rs16969968, CLPTM1L rs402710, CXCR2 rs1126579, CYP1A1 rs4646903, CYP2E1 rs6413432, ERCC1 rs11615, ERCC2 rs13181, FGFR4 rs351855, HYKK rs931794, MIR146A rs2910164, MIR196A2 rs11614913, OGG1 rs1052133, PON1 rs662, REV3L rs462779, SOD2 rs4880, TERT rs2736098, and TP53 rs1042522) showed significant associations with lung cancer susceptibility with strong cumulative epidemiological evidence.
p36341
sg33279
(lp36342
(dp36343
g33284
I322
sg33285
I2
sg33286
I10
sg33295
VP27169
p36344
sg33289
VPON1 rs662
p36345
sa(dp36346
g33284
I35
sg33285
I2
sg33286
I15
sg33295
VP27695
p36347
sg33289
VAPEX1 rs1130409
p36348
sa(dp36349
g33284
I205
sg33285
I2
sg33286
I13
sg33295
VP07992
p36350
sg33289
VERCC1 rs11615
p36351
sa(dp36352
g33284
I334
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VREV3L rs462779
p36353
sa(dp36354
g33284
I436
sg33285
I3
sg33286
I26
sg33295
g11
sg33289
Vlung cancer susceptibility
p36355
sa(dp36356
g33284
I363
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VTERT rs2736098
p36357
sa(dp36358
g33284
I80
sg33285
I2
sg33286
I15
sg33295
g11
sg33289
VAXIN2 rs2240308
p36359
sa(dp36360
g33284
I350
sg33285
I2
sg33286
I11
sg33295
VP04179
p36361
sg33289
VSOD2 rs4880
p36362
sa(dp36363
g33284
I169
sg33285
I2
sg33286
I16
sg33295
VP04798
p36364
sg33289
VCYP1A1 rs4646903
p36365
sa(dp36366
g33284
I235
sg33285
I2
sg33286
I14
sg33295
VP22455
p36367
sg33289
VFGFR4 rs351855
p36368
sa(dp36369
g33284
I97
sg33285
I2
sg33286
I16
sg33295
VP32297
p36370
sg33289
VCHRNA3 rs6495309
p36371
sa(dp36372
g33284
I66
sg33285
I2
sg33286
I12
sg33295
g11
sg33289
VATM rs664677
p36373
sa(dp36374
g33284
I187
sg33285
I2
sg33286
I16
sg33295
VP05181
p36375
sg33289
VCYP2E1 rs6413432
p36376
sa(dp36377
g33284
I115
sg33285
I2
sg33286
I17
sg33295
VP30532
p36378
sg33289
VCHRNA5 rs16969968
p36379
sa(dp36380
g33284
I134
sg33285
I2
sg33286
I16
sg33295
g11
sg33289
VCLPTM1L rs402710
p36381
sa(dp36382
g33284
I220
sg33285
I2
sg33286
I13
sg33295
VP18074
p36383
sg33289
VERCC2 rs13181
p36384
sa(dp36385
g33284
I152
sg33285
I2
sg33286
I15
sg33295
VP25025
p36386
sg33289
VCXCR2 rs1126579
p36387
sasg33281
(lp36388
(dp36389
g33284
I436
sg33285
I2
sg33286
I11
sg33287
VC0684249
p36390
sg33289
Vlung cancer
p36391
sasa(dp36392
g33277
VThis study aimed to determine the serum levels of angiopoietin-like 4 (ANGPTL4) in patients with renal cell carcinoma (RCC) and explore its potential as a biomarker.
p36393
sg33279
(lp36394
(dp36395
g33284
I50
sg33285
I2
sg33286
I19
sg33295
g11
sg33289
Vangiopoietin-like 4
p36396
sa(dp36397
g33284
I71
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VANGPTL4
p36398
sasg33281
(lp36399
(dp36400
g33284
I119
sg33285
I1
sg33286
I3
sg33287
VC0007134
p36401
sg33289
VRCC
p36402
sa(dp36403
g33284
I97
sg33285
I3
sg33286
I20
sg33287
VC0007134
p36404
sg33289
Vrenal cell carcinoma
p36405
sasa(dp36406
g33277
VWe have previously shown that angiopoietin-like 4 (angptl4) mRNA, a hypoxia-inducible gene, is highly expressed in clear cell renal-cell carcinoma (ccRCC), the most common subtype of RCC for which no specific marker is available.
p36407
sg33279
(lp36408
(dp36409
g33284
I51
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
Vangptl4
p36410
sa(dp36411
g33284
I30
sg33285
I2
sg33286
I19
sg33295
g11
sg33289
Vangiopoietin-like 4
p36412
sasg33281
(lp36413
(dp36414
g33284
I68
sg33285
I1
sg33286
I7
sg33287
VC0242184
p36415
sg33289
Vhypoxia
p36416
sa(dp36417
g33284
I137
sg33285
I1
sg33286
I9
sg33287
VC0007097
p36418
sg33289
Vcarcinoma
p36419
sa(dp36420
g33284
I150
sg33285
I1
sg33286
I3
sg33287
VC0007134
p36421
sg33289
VRCC
p36422
sasa(dp36423
g33277
VWe observed particularly high levels of ANGPTL4 mRNA in tumor cells of conventional renal cell carcinoma.
p36424
sg33279
(lp36425
(dp36426
g33284
I40
sg33285
I2
sg33286
I12
sg33295
g11
sg33289
VANGPTL4 mRNA
p36427
sasg33281
(lp36428
(dp36429
g33284
I56
sg33285
I1
sg33286
I5
sg33287
VC0027651
p36430
sg33289
Vtumor
p36431
sa(dp36432
g33284
I71
sg33285
I4
sg33286
I33
sg33287
VC0279702
p36433
sg33289
Vconventional renal cell carcinoma
p36434
sasa(dp36435
g33277
VResults The smoking subgroup (n=15) of NSIP patients had a significantly lower % diffusing capacity for carbon monoxide/ alveolar ventilation (DLCO/VA) and tended to have higher SP-D values than the nonsmoking subgroup (n=16).
p36436
sg33279
(lp36437
sg33281
(lp36438
sa(dp36439
g33277
VAs compared with major IIPs such as idiopathic pulmonary fibrosis and fibrotic nonspecific interstitial pneumonia, IPPFE significantly showed higher frequency of cases with a unique pattern of serum biomarkers, which is characterized by an elevated level of SP-D with a normal range of KL-6.
p36440
sg33279
(lp36441
(dp36442
g33284
I258
sg33285
I1
sg33286
I4
sg33295
VP35247
p36443
sg33289
VSP-D
p36444
sasg33281
(lp36445
(dp36446
g33284
I36
sg33285
I3
sg33286
I29
sg33287
VC3161101
p36447
sg33289
Vidiopathic pulmonary fibrosis
p36448
sa(dp36449
g33284
I79
sg33285
I3
sg33286
I34
sg33287
VC1290344
p36450
sg33289
Vnonspecific interstitial pneumonia
p36451
sasa(dp36452
g33277
VHowever, associations of serum KL-6 and SP-D with radiologic findings in nonspecific interstitial pneumonia (NSIP) remain unclear.
p36453
sg33279
(lp36454
(dp36455
g33284
I25
sg33285
I2
sg33286
I10
sg33295
g11
sg33289
Vserum KL-6
p36456
sa(dp36457
g33284
I40
sg33285
I1
sg33286
I4
sg33295
VP35247
p36458
sg33289
VSP-D
p36459
sasg33281
(lp36460
(dp36461
g33284
I109
sg33285
I1
sg33286
I4
sg33287
VC1290344
p36462
sg33289
VNSIP
p36463
sa(dp36464
g33284
I73
sg33285
I3
sg33286
I34
sg33287
VC1290344
p36465
sg33289
Vnonspecific interstitial pneumonia
p36466
sasa(dp36467
g33277
VTo determine whether serum levels of KL-6 and SP-D reflect fibrotic and/or inflammatory processes in NSIP, we investigated the correlation between high-resolution computed tomography (HRCT) findings and serum KL-6 and SP-D levels.
p36468
sg33279
(lp36469
(dp36470
g33284
I46
sg33285
I1
sg33286
I4
sg33295
VP35247
p36471
sg33289
VSP-D
p36472
sa(dp36473
g33284
I46
sg33285
I1
sg33286
I4
sg33295
VP35247
p36474
sg33289
VSP-D
p36475
sasg33281
(lp36476
sa(dp36477
g33277
VSerum levels of KL-6 and SP-D were measured in 21 patients with biopsy-confirmed NSIP.
p36478
sg33279
(lp36479
(dp36480
g33284
I25
sg33285
I1
sg33286
I4
sg33295
VP35247
p36481
sg33289
VSP-D
p36482
sasg33281
(lp36483
sa(dp36484
g33277
VSerum levels of SP-D in NSIP showed a positive correlation with the area of ground-glass attenuation without traction bronchiectasis and the inflammatory CT pattern, but the levels were inversely correlated with the area of ground-glass attenuation with traction bronchiectasis and the fibrotic CT pattern.
p36485
sg33279
(lp36486
(dp36487
g33284
I16
sg33285
I1
sg33286
I4
sg33295
VP35247
p36488
sg33289
VSP-D
p36489
sasg33281
(lp36490
(dp36491
g33284
I109
sg33285
I2
sg33286
I23
sg33287
VC0264361
p36492
sg33289
Vtraction bronchiectasis
p36493
sa(dp36494
g33284
I109
sg33285
I2
sg33286
I23
sg33287
VC0264361
p36495
sg33289
Vtraction bronchiectasis
p36496
sasa(dp36497
g33277
VThe results indicate that serum levels of KL-6 in NSIP reflect the overall extent of interstitial lesions, which include both inflammatory and fibrotic lesions, while the levels of SP-D mainly reflect the extent of inflammatory lesions.
p36498
sg33279
(lp36499
(dp36500
g33284
I181
sg33285
I1
sg33286
I4
sg33295
VP35247
p36501
sg33289
VSP-D
p36502
sasg33281
(lp36503
sa(dp36504
g33277
VRecently, we identified high expression of 2 RHOGAPs, ARHGAP11A and RACGAP1, in the basal-like breast cancer subtype.
p36505
sg33279
(lp36506
(dp36507
g33284
I68
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VRACGAP1
p36508
sa(dp36509
g33284
I54
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VARHGAP11A
p36510
sasg33281
(lp36511
(dp36512
g33284
I95
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36513
sg33289
Vbreast cancer
p36514
sasa(dp36515
g33277
VWe have established that, via the suppression of RhoA, ArhGAP11A and RacGAP1 are both critical drivers of BLBC growth, and propose that RhoGAPs can act as oncogenes in cancer.
p36516
sg33279
(lp36517
(dp36518
g33284
I69
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VRacGAP1
p36519
sa(dp36520
g33284
I49
sg33285
I1
sg33286
I4
sg33295
VP61586
p36521
sg33289
VRhoA
p36522
sa(dp36523
g33284
I55
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VArhGAP11A
p36524
sasg33281
(lp36525
(dp36526
g33284
I168
sg33285
I1
sg33286
I6
sg33287
VC0006826
p36527
sg33289
Vcancer
p36528
sa(dp36529
g33284
I34
sg33285
I1
sg33286
I11
sg33287
VC0221103
p36530
sg33289
Vsuppression
p36531
sasa(dp36532
g33277
VWe found significant methylation differences at a number of experimentally implicated breast cancer-related genes, including attenuated 5' untranslated region (UTR)/first exon methylation at the proinvasive ARHGAP11A gene in variant mimic-transfected cells.
p36533
sg33279
(lp36534
(dp36535
g33284
I207
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VARHGAP11A gene
p36536
sasg33281
(lp36537
(dp36538
g33284
I86
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36539
sg33289
Vbreast cancer
p36540
sasa(dp36541
g33277
VFollow-up functional analyses revealed both concurrent increased ARHGAP11A mRNA expression and enhanced invasiveness in variant versus WT piR-021285 mimic-transfected breast cancer cell lines.
p36542
sg33279
(lp36543
(dp36544
g33284
I65
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VARHGAP11A mRNA
p36545
sasg33281
(lp36546
(dp36547
g33284
I167
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36548
sg33289
Vbreast cancer
p36549
sasa(dp36550
g33277
VExpression of ARHGAP11A in cancer cells suppressed RhoA-dependent mechanisms, such as stress fiber formation and focal adhesion, which made the cells more prone to migrate.
p36551
sg33279
(lp36552
(dp36553
g33284
I14
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VARHGAP11A
p36554
sa(dp36555
g33284
I51
sg33285
I1
sg33286
I4
sg33295
VP61586
p36556
sg33289
VRhoA
p36557
sasg33281
(lp36558
(dp36559
g33284
I119
sg33285
I1
sg33286
I8
sg33287
VC0001511
p36560
sg33289
Vadhesion
p36561
sa(dp36562
g33284
I27
sg33285
I1
sg33286
I6
sg33287
VC0006826
p36563
sg33289
Vcancer
p36564
sasa(dp36565
g33277
VRNAi-based inhibition of Arhgap11a reduced the invasion and in vivo expansion of cancers.
p36566
sg33279
(lp36567
(dp36568
g33284
I25
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VArhgap11a
p36569
sasg33281
(lp36570
(dp36571
g33284
I81
sg33285
I1
sg33286
I7
sg33287
VC0006826
p36572
sg33289
Vcancers
p36573
sa(dp36574
g33284
I47
sg33285
I1
sg33286
I8
sg33287
VC2699153
p36575
sg33289
Vinvasion
p36576
sasa(dp36577
g33277
VAdditionally, analysis of human specimens showed the significant up-regulation of Arhgap11a in colon cancers, which was correlated with clinical invasion status.
p36578
sg33279
(lp36579
(dp36580
g33284
I82
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VArhgap11a
p36581
sasg33281
(lp36582
(dp36583
g33284
I95
sg33285
I2
sg33286
I13
sg33287
VC0007102
p36584
sg33289
Vcolon cancers
p36585
sa(dp36586
g33284
I145
sg33285
I1
sg33286
I8
sg33287
VC2699153
p36587
sg33289
Vinvasion
p36588
sasa(dp36589
g33277
VThe present study suggests that ARHGAP11A, a cell cycle-dependent RhoGAP, is a critical regulator of cancer cell mobility and is thus a promising therapeutic target in invasive cancers.
p36590
sg33279
(lp36591
(dp36592
g33284
I66
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VRhoGAP
p36593
sa(dp36594
g33284
I32
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VARHGAP11A
p36595
sasg33281
(lp36596
(dp36597
g33284
I177
sg33285
I1
sg33286
I7
sg33287
VC0006826
p36598
sg33289
Vcancers
p36599
sa(dp36600
g33284
I101
sg33285
I1
sg33286
I6
sg33287
VC0006826
p36601
sg33289
Vcancer
p36602
sasa(dp36603
g33277
VIdentified genome-wide significant loci: 1) corroborated genes implicated in other studies (MTNR1B, ZNF259/APOA5, XPA/FOXE1 (TTF-2), DARC, CCR3, ABO); 2) localized novel genes in plausible biological pathways (PCSK2, ARHGAP11A, CHRNA3); and 3) revealed novel genes with unknown function in obesity pathogenesis (MATK, COL4A1).
p36604
sg33279
(lp36605
(dp36606
g33284
I312
sg33285
I1
sg33286
I4
sg33295
VP42679
p36607
sg33289
VMATK
p36608
sa(dp36609
g33284
I114
sg33285
I1
sg33286
I3
sg33295
VP23025
p36610
sg33289
VXPA
p36611
sa(dp36612
g33284
I139
sg33285
I1
sg33286
I4
sg33295
VP51677
p36613
sg33289
VCCR3
p36614
sa(dp36615
g33284
I118
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VFOXE1
p36616
sa(dp36617
g33284
I125
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTTF-2
p36618
sa(dp36619
g33284
I318
sg33285
I1
sg33286
I6
sg33295
VP02462
p36620
sg33289
VCOL4A1
p36621
sa(dp36622
g33284
I210
sg33285
I1
sg33286
I5
sg33295
VP16519
p36623
sg33289
VPCSK2
p36624
sa(dp36625
g33284
I217
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VARHGAP11A
p36626
sa(dp36627
g33284
I100
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VZNF259
p36628
sa(dp36629
g33284
I92
sg33285
I1
sg33286
I6
sg33295
VP49286
p36630
sg33289
VMTNR1B
p36631
sa(dp36632
g33284
I228
sg33285
I1
sg33286
I6
sg33295
VP32297
p36633
sg33289
VCHRNA3
p36634
sa(dp36635
g33284
I107
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VAPOA5
p36636
sasg33281
(lp36637
(dp36638
g33284
I290
sg33285
I1
sg33286
I7
sg33287
VC0028754
p36639
sg33289
Vobesity
p36640
sa(dp36641
g33284
I298
sg33285
I1
sg33286
I12
sg33287
VC0699748
p36642
sg33289
Vpathogenesis
p36643
sasa(dp36644
g33277
VIn contrast to GTG banding, array CGH determined the exact number of deleted genes and thus allowed the identification of candidate genes for cleft palate (GREM1, CX36, MEIS2), congenital heart defect (ACTC, GREM1, CX36, MEIS2), and mental retardation (ARHGAP11A, CHRNA7, CHRM5).
p36645
sg33279
(lp36646
(dp36647
g33284
I169
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VMEIS2
p36648
sa(dp36649
g33284
I163
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCX36
p36650
sa(dp36651
g33284
I272
sg33285
I1
sg33286
I5
sg33295
VP08912
p36652
sg33289
VCHRM5
p36653
sa(dp36654
g33284
I202
sg33285
I1
sg33286
I4
sg33295
VP68032
p36655
sg33289
VACTC
p36656
sa(dp36657
g33284
I264
sg33285
I1
sg33286
I6
sg33295
VP36544
p36658
sg33289
VCHRNA7
p36659
sa(dp36660
g33284
I169
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VMEIS2
p36661
sa(dp36662
g33284
I156
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VGREM1
p36663
sa(dp36664
g33284
I156
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VGREM1
p36665
sa(dp36666
g33284
I163
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCX36
p36667
sa(dp36668
g33284
I253
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VARHGAP11A
p36669
sasg33281
(lp36670
(dp36671
g33284
I233
sg33285
I2
sg33286
I18
sg33287
VC0025362
p36672
sg33289
Vmental retardation
p36673
sa(dp36674
g33284
I142
sg33285
I2
sg33286
I12
sg33287
VC0008925
p36675
sg33289
Vcleft palate
p36676
sa(dp36677
g33284
I34
sg33285
I1
sg33286
I3
sg33287
VC1855900
p36678
sg33289
VCGH
p36679
sa(dp36680
g33284
I177
sg33285
I3
sg33286
I23
sg33287
VC0018798
p36681
sg33289
Vcongenital heart defect
p36682
sasa(dp36683
g33277
VThe expression levels of four genes identified by microarray screening (PLCB2, HVCN1, CTSS, and DEF8) and one purine/thiopurine related gene (NME6) correlated significantly with the clinical activity of Crohn's disease.
p36684
sg33279
(lp36685
(dp36686
g33284
I86
sg33285
I1
sg33286
I4
sg33295
VP25774
p36687
sg33289
VCTSS
p36688
sa(dp36689
g33284
I110
sg33285
I3
sg33286
I30
sg33295
g11
sg33289
Vpurine/thiopurine related gene
p36690
sa(dp36691
g33284
I79
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VHVCN1
p36692
sa(dp36693
g33284
I96
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VDEF8
p36694
sa(dp36695
g33284
I142
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNME6
p36696
sa(dp36697
g33284
I72
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VPLCB2
p36698
sasg33281
(lp36699
(dp36700
g33284
I203
sg33285
I2
sg33286
I15
sg33287
VC0010346
p36701
sg33289
VCrohn's disease
p36702
sasa(dp36703
g33277
VZNF366, involved in estrogen metabolism and progression of breast cancer, is a new biologically plausible candidate for endometriosis.
p36704
sg33279
(lp36705
(dp36706
g33284
I0
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VZNF366
p36707
sasg33281
(lp36708
(dp36709
g33284
I59
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36710
sg33289
Vbreast cancer
p36711
sa(dp36712
g33284
I120
sg33285
I1
sg33286
I13
sg33287
VC0014175
p36713
sg33289
Vendometriosis
p36714
sasa(dp36715
g33277
VRecently, we have identified DC-SCRIPT (ZNF366) as a co-suppressor of ERAlfa and as a strong and independent prognostic marker in ESR1 (ERAlfa gene)-positive breast cancer patients.
p36716
sg33279
(lp36717
(dp36718
g33284
I29
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VDC-SCRIPT
p36719
sa(dp36720
g33284
I40
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VZNF366
p36721
sa(dp36722
g33284
I130
sg33285
I1
sg33286
I4
sg33295
VP03372
p36723
sg33289
VESR1
p36724
sasg33281
(lp36725
(dp36726
g33284
I158
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36727
sg33289
Vbreast cancer
p36728
sasa(dp36729
g33277
VIn this study, we further investigated the molecular mechanism on how DC-SCRIPT inhibits breast cancer cell growth.
p36730
sg33279
(lp36731
sg33281
(lp36732
(dp36733
g33284
I96
sg33285
I3
sg33286
I18
sg33287
VC1516170
p36734
sg33289
Vcancer cell growth
p36735
sasa(dp36736
g33277
VDC-SCRIPT mRNA levels from 190 primary ESR1-positive breast tumors were related to global gene expression, followed by gene ontology and pathway analysis.
p36737
sg33279
(lp36738
(dp36739
g33284
I0
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VDC-SCRIPT mRNA
p36740
sasg33281
(lp36741
(dp36742
g33284
I53
sg33285
I2
sg33286
I13
sg33287
VC1458155
p36743
sg33289
Vbreast tumors
p36744
sasa(dp36745
g33277
VThe effect of DC-SCRIPT on breast cancer cell growth and cell cycle arrest was investigated using novel DC-SCRIPT-inducible MCF7 breast cancer cell lines.
p36746
sg33279
(lp36747
sg33281
(lp36748
(dp36749
g33284
I27
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36750
sg33289
Vbreast cancer
p36751
sa(dp36752
g33284
I34
sg33285
I3
sg33286
I18
sg33287
VC1516170
p36753
sg33289
Vcancer cell growth
p36754
sasa(dp36755
g33277
VIn the primary ESR1-positive breast tumors, DC-SCRIPT expression negatively correlated with several cell cycle gene ontologies and pathways.
p36756
sg33279
(lp36757
(dp36758
g33284
I15
sg33285
I1
sg33286
I4
sg33295
VP03372
p36759
sg33289
VESR1
p36760
sasg33281
(lp36761
(dp36762
g33284
I29
sg33285
I2
sg33286
I13
sg33287
VC1458155
p36763
sg33289
Vbreast tumors
p36764
sasa(dp36765
g33277
VDC-SCRIPT expression strongly reduced breast cancer cell growth in vitro, breast tumor growth in vivo, and induced cell cycle arrest.
p36766
sg33279
(lp36767
(dp36768
g33284
I0
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VDC-SCRIPT
p36769
sasg33281
(lp36770
(dp36771
g33284
I45
sg33285
I3
sg33286
I18
sg33287
VC1516170
p36772
sg33289
Vcancer cell growth
p36773
sa(dp36774
g33284
I81
sg33285
I2
sg33286
I12
sg33287
VC0598934
p36775
sg33289
Vtumor growth
p36776
sasa(dp36777
g33277
VMoreover, in 1,132 primary ESR1-positive breast tumors, DC-SCRIPT expression also correlated with CDKN2B expression.
p36778
sg33279
(lp36779
(dp36780
g33284
I98
sg33285
I1
sg33286
I6
sg33295
VP42772
p36781
sg33289
VCDKN2B
p36782
sa(dp36783
g33284
I27
sg33285
I1
sg33286
I4
sg33295
VP03372
p36784
sg33289
VESR1
p36785
sasg33281
(lp36786
(dp36787
g33284
I41
sg33285
I2
sg33286
I13
sg33287
VC1458155
p36788
sg33289
Vbreast tumors
p36789
sasa(dp36790
g33277
VCollectively, these data show that DC-SCRIPT acts as a novel regulator of CDKN2B and induces cell cycle arrest in ESR1-positive breast cancer cells.
p36791
sg33279
(lp36792
(dp36793
g33284
I74
sg33285
I1
sg33286
I6
sg33295
VP42772
p36794
sg33289
VCDKN2B
p36795
sa(dp36796
g33284
I114
sg33285
I1
sg33286
I4
sg33295
VP03372
p36797
sg33289
VESR1
p36798
sasg33281
(lp36799
(dp36800
g33284
I128
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36801
sg33289
Vbreast cancer
p36802
sasa(dp36803
g33277
VWe recently found that DC-SCRIPT is a prognostic marker in breast cancer and a unique NR coregulator differentially regulating different classes of NRs.
p36804
sg33279
(lp36805
sg33281
(lp36806
(dp36807
g33284
I59
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36808
sg33289
Vbreast cancer
p36809
sasa(dp36810
g33277
VIn this study we aimed to validate the prognostic value of DC-SCRIPT mRNA expression in a large independent breast cancer cohort.
p36811
sg33279
(lp36812
(dp36813
g33284
I59
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VDC-SCRIPT mRNA
p36814
sasg33281
(lp36815
(dp36816
g33284
I108
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36817
sg33289
Vbreast cancer
p36818
sasa(dp36819
g33277
VDC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and associated with outcome (disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS)) using univariate and multivariable Cox regression analysis.
p36820
sg33279
(lp36821
(dp36822
g33284
I0
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VDC-SCRIPT mRNA
p36823
sasg33281
(lp36824
(dp36825
g33284
I152
sg33285
I1
sg33286
I10
sg33287
VC0027627
p36826
sg33289
Vmetastasis
p36827
sa(dp36828
g33284
I79
sg33285
I2
sg33286
I14
sg33287
VC0006142
p36829
sg33289
Vbreast cancers
p36830
sa(dp36831
g33284
I178
sg33285
I1
sg33286
I3
sg33287
VC0024796
p36832
sg33289
VMFS
p36833
sasa(dp36834
g33277
VThis study provides a higher level of evidence that DC-SCRIPT is indeed an independent, pure prognostic, factor for primary breast cancer and shows that DC-SCRIPT mRNA expression is most informative for either ESR1-positive and/or ESR2-low pT1 tumors.
p36835
sg33279
(lp36836
(dp36837
g33284
I153
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VDC-SCRIPT mRNA
p36838
sa(dp36839
g33284
I52
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VDC-SCRIPT
p36840
sasg33281
(lp36841
(dp36842
g33284
I244
sg33285
I1
sg33286
I6
sg33287
VC0027651
p36843
sg33289
Vtumors
p36844
sa(dp36845
g33284
I124
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36846
sg33289
Vbreast cancer
p36847
sasa(dp36848
g33277
VWe investigated the role of dendritic cell-specific transcript (DC-SCRIPT) as coregulator of these nuclear receptors and as a prognostic factor in breast cancer.
p36849
sg33279
(lp36850
sg33281
(lp36851
(dp36852
g33284
I147
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36853
sg33289
Vbreast cancer
p36854
sasa(dp36855
g33277
VDC-SCRIPT expression in normal and tumor tissue from breast cancer patients was analyzed by polymerase chain reaction and immunohistochemistry.
p36856
sg33279
(lp36857
sg33281
(lp36858
(dp36859
g33284
I35
sg33285
I1
sg33286
I5
sg33287
VC0027651
p36860
sg33289
Vtumor
p36861
sa(dp36862
g33284
I53
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36863
sg33289
Vbreast cancer
p36864
sasa(dp36865
g33277
VThe prognostic value of tumor DC-SCRIPT mRNA expression was assessed in three independent cohorts of breast cancer patients: a discovery group (n = 47) and a validation group (n = 97) (neither of which had received systemic adjuvant therapy) and in a tamoxifen-treated validation group (n = 68) by using a DC-SCRIPT to porphobilinogen deaminase transcript ratio cutoff of 0.15 determined in the discovery group.
p36866
sg33279
(lp36867
(dp36868
g33284
I319
sg33285
I3
sg33286
I36
sg33295
VP08397
p36869
sg33289
Vporphobilinogen deaminase transcript
p36870
sa(dp36871
g33284
I30
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VDC-SCRIPT
p36872
sasg33281
(lp36873
(dp36874
g33284
I101
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36875
sg33289
Vbreast cancer
p36876
sa(dp36877
g33284
I24
sg33285
I1
sg33286
I5
sg33287
VC0027651
p36878
sg33289
Vtumor
p36879
sasa(dp36880
g33277
VDC-SCRIPT is a key regulator of nuclear receptor activity that has prognostic value in breast cancer.
p36881
sg33279
(lp36882
sg33281
(lp36883
(dp36884
g33284
I87
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36885
sg33289
Vbreast cancer
p36886
sasa(dp36887
g33277
VBoth SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.
p36888
sg33279
(lp36889
(dp36890
g33284
I140
sg33285
I1
sg33286
I5
sg33295
VP03952
p36891
sg33289
VKLKB1
p36892
sa(dp36893
g33284
I176
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VKLK4
p36894
sa(dp36895
g33284
I189
sg33285
I1
sg33286
I4
sg33295
VP19878
p36896
sg33289
VNCF2
p36897
sa(dp36898
g33284
I195
sg33285
I1
sg33286
I4
sg33295
VP22362
p36899
sg33289
VCCL1
p36900
sa(dp36901
g33284
I201
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VC1QR1
p36902
sa(dp36903
g33284
I182
sg33285
I1
sg33286
I5
sg33295
VP42226
p36904
sg33289
VSTAT6
p36905
sa(dp36906
g33284
I169
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VIRAK3
p36907
sa(dp36908
g33284
I123
sg33285
I1
sg33286
I7
sg33295
VP78357
p36909
sg33289
VCNTNAP1
p36910
sa(dp36911
g33284
I132
sg33285
I1
sg33286
I6
sg33295
VP35222
p36912
sg33289
VCTNNB1
p36913
sa(dp36914
g33284
I147
sg33285
I1
sg33286
I5
sg33295
VP05107
p36915
sg33289
VITGB2
p36916
sa(dp36917
g33284
I109
sg33285
I1
sg33286
I6
sg33295
VP12319
p36918
sg33289
VFCER1A
p36919
sa(dp36920
g33284
I117
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNCF4
p36921
sa(dp36922
g33284
I208
sg33285
I1
sg33286
I3
sg33295
VP13727
p36923
sg33289
VMBP
p36924
sa(dp36925
g33284
I101
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VOR10J3
p36926
sa(dp36927
g33284
I216
sg33285
I1
sg33286
I4
sg33295
VP29475
p36928
sg33289
VNOS1
p36929
sa(dp36930
g33284
I154
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VALOX12B
p36931
sa(dp36932
g33284
I163
sg33285
I1
sg33286
I4
sg33295
VP20151
p36933
sg33289
VKLK2
p36934
sasg33281
(lp36935
(dp36936
g33284
I68
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36937
sg33289
Vbreast cancer
p36938
sasa(dp36939
g33277
VWhen the data were divided by menopausal status, the optimal models to predict breast cancer, which included NAF hK2 or PSA and age, were 100% sensitive and 41% specific in pre- vs. 93% sensitive and 12% specific in postmenopausal women.
p36940
sg33279
(lp36941
(dp36942
g33284
I120
sg33285
I1
sg33286
I3
sg33295
VP55786
p36943
sg33289
VPSA
p36944
sa(dp36945
g33284
I109
sg33285
I2
sg33286
I7
sg33295
VP20151
p36946
sg33289
VNAF hK2
p36947
sasg33281
(lp36948
(dp36949
g33284
I120
sg33285
I1
sg33286
I3
sg33287
VC1519176
p36950
sg33289
VPSA
p36951
sa(dp36952
g33284
I79
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36953
sg33289
Vbreast cancer
p36954
sasa(dp36955
g33277
VSeveral lines of evidence suggest that members of the kallikrein family are involved in various malignancies such as prostate (PSA, KLK2, KLK15), ovarian (KLK4, KLK5, KLK6, KLK8, KLK10), and breast cancer (KLK10, KLK13, KLK14).
p36956
sg33279
(lp36957
(dp36958
g33284
I173
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VKLK8
p36959
sa(dp36960
g33284
I155
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VKLK4
p36961
sa(dp36962
g33284
I179
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VKLK10
p36963
sa(dp36964
g33284
I213
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VKLK13
p36965
sa(dp36966
g33284
I132
sg33285
I1
sg33286
I4
sg33295
VP20151
p36967
sg33289
VKLK2
p36968
sa(dp36969
g33284
I54
sg33285
I2
sg33286
I17
sg33295
VP06870
p36970
sg33289
Vkallikrein family
p36971
sa(dp36972
g33284
I167
sg33285
I1
sg33286
I4
sg33295
VP06870
p36973
sg33289
VKLK6
p36974
sa(dp36975
g33284
I138
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VKLK15
p36976
sa(dp36977
g33284
I220
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VKLK14
p36978
sa(dp36979
g33284
I179
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VKLK10
p36980
sa(dp36981
g33284
I161
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VKLK5
p36982
sa(dp36983
g33284
I117
sg33285
I1
sg33286
I8
sg33295
VP55786
p36984
sg33289
Vprostate
p36985
sa(dp36986
g33284
I127
sg33285
I1
sg33286
I3
sg33295
VP55786
p36987
sg33289
VPSA
p36988
sasg33281
(lp36989
(dp36990
g33284
I127
sg33285
I1
sg33286
I3
sg33287
VC1519176
p36991
sg33289
VPSA
p36992
sa(dp36993
g33284
I191
sg33285
I2
sg33286
I13
sg33287
VC0678222
p36994
sg33289
Vbreast cancer
p36995
sa(dp36996
g33284
I96
sg33285
I1
sg33286
I12
sg33287
VC0006826
p36997
sg33289
Vmalignancies
p36998
sa(dp36999
g33284
I117
sg33285
I1
sg33286
I8
sg33287
VC1519176
p37000
sg33289
Vprostate
p37001
sasa(dp37002
g33277
VWe examined previously the steroid hormone regulation of 2 known androgen-regulated kallikreins, KLK3 (encoding PSA) and KLK2 (encoding human kallikrein 2 or hK2) in BT-474, T-47D, ZR75-1, MCF-7, MFM-223 and BT-20 human breast cancer cells and found that they were differentially regulated, with the cells showing variable responses to androgen.
p37003
sg33279
(lp37004
(dp37005
g33284
I121
sg33285
I1
sg33286
I4
sg33295
VP20151
p37006
sg33289
VKLK2
p37007
sa(dp37008
g33284
I142
sg33285
I4
sg33286
I19
sg33295
VP20151
p37009
sg33289
Vkallikrein 2 or hK2
p37010
sa(dp37011
g33284
I65
sg33285
I2
sg33286
I30
sg33295
VP10398
p37012
sg33289
Vandrogen-regulated kallikreins
p37013
sa(dp37014
g33284
I136
sg33285
I3
sg33286
I18
sg33295
VP20151
p37015
sg33289
Vhuman kallikrein 2
p37016
sasg33281
(lp37017
(dp37018
g33284
I220
sg33285
I2
sg33286
I13
sg33287
VC0678222
p37019
sg33289
Vbreast cancer
p37020
sa(dp37021
g33284
I112
sg33285
I1
sg33286
I3
sg33287
VC1519176
p37022
sg33289
VPSA
p37023
sasa(dp37024
g33277
VEvery breast cancer cell line exhibited a distinct expression pattern of the nuclear receptor co-regulators examined raising the possibility that the relative levels of these co-activators/-repressors might differentially modulate androgen receptor transcriptional activity within the promoter/enhancer region of KLK2 and KLK3 of these cells.
p37025
sg33279
(lp37026
(dp37027
g33284
I231
sg33285
I2
sg33286
I17
sg33295
VP10275
p37028
sg33289
Vandrogen receptor
p37029
sa(dp37030
g33284
I322
sg33285
I1
sg33286
I4
sg33295
VP03952
p37031
sg33289
VKLK3
p37032
sa(dp37033
g33284
I313
sg33285
I1
sg33286
I4
sg33295
VP20151
p37034
sg33289
VKLK2
p37035
sasg33281
(lp37036
(dp37037
g33284
I6
sg33285
I2
sg33286
I13
sg33287
VC0678222
p37038
sg33289
Vbreast cancer
p37039
sasa(dp37040
g33277
VLike KLK2 and KLK3, the KLK5 gene is regulated by steroid hormones in the BT-474 breast cancer cell line.
p37041
sg33279
(lp37042
(dp37043
g33284
I5
sg33285
I1
sg33286
I4
sg33295
VP20151
p37044
sg33289
VKLK2
p37045
sa(dp37046
g33284
I14
sg33285
I1
sg33286
I4
sg33295
VP03952
p37047
sg33289
VKLK3
p37048
sa(dp37049
g33284
I24
sg33285
I2
sg33286
I9
sg33295
g11
sg33289
VKLK5 gene
p37050
sasg33281
(lp37051
(dp37052
g33284
I81
sg33285
I2
sg33286
I13
sg33287
VC0678222
p37053
sg33289
Vbreast cancer
p37054
sasa(dp37055
g33277
VKLK2 and KLK3 have important applications in prostate cancer diagnostics and, more recently, in breast cancer diagnostics.
p37056
sg33279
(lp37057
(dp37058
g33284
I9
sg33285
I1
sg33286
I4
sg33295
VP03952
p37059
sg33289
VKLK3
p37060
sa(dp37061
g33284
I0
sg33285
I1
sg33286
I4
sg33295
VP20151
p37062
sg33289
VKLK2
p37063
sasg33281
(lp37064
(dp37065
g33284
I96
sg33285
I2
sg33286
I13
sg33287
VC0678222
p37066
sg33289
Vbreast cancer
p37067
sa(dp37068
g33284
I45
sg33285
I2
sg33286
I15
sg33287
VC0600139
p37069
sg33289
Vprostate cancer
p37070
sasa(dp37071
g33277
VOligonucleotide 5'-SH-(A)(12)-AGACAAGAGAGG-3' (Oligo 1) modified AuNPs and oligonucleotide 5'-CAACAGAGAACG-(A)(12)-HS-3' (Oligo 2) modified AuNPs could hybridize with oligonulceotide 5'-CGTTCTCTGTTGCCTCTCTTGTCT-3' (Oligo 3), which resulted in the aggregation of Oligo-AuNPs probes, and triggered the increase of their average diameter.
p37072
sg33279
(lp37073
sg33281
(lp37074
sa(dp37075
g33277
VTo observe the effect of Bushen Huoxue Recipe (BHR) on inhibiting vascular calcification (VC) in chronic renal failure (CRF) rats by regulating BMP-2/Runx2/Osterix signal pathway, and to explore its possible mechanism.
p37076
sg33279
(lp37077
(dp37078
g33284
I144
sg33285
I1
sg33286
I5
sg33295
VP12643
p37079
sg33289
VBMP-2
p37080
sa(dp37081
g33284
I150
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VRunx2
p37082
sa(dp37083
g33284
I156
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VOsterix
p37084
sasg33281
(lp37085
(dp37086
g33284
I90
sg33285
I1
sg33286
I2
sg33287
VC0342649
p37087
sg33289
VVC
p37088
sa(dp37089
g33284
I66
sg33285
I2
sg33286
I22
sg33287
VC0342649
p37090
sg33289
Vvascular calcification
p37091
sa(dp37092
g33284
I97
sg33285
I3
sg33286
I21
sg33287
VC0022661
p37093
sg33289
Vchronic renal failure
p37094
sa(dp37095
g33284
I120
sg33285
I1
sg33286
I3
sg33287
VC0022661
p37096
sg33289
VCRF
p37097
sasa(dp37098
g33277
VHere, we report that inhibition of Src significantly reduced survival of H37Rv as well as multidrug-resistant (MDR) and extremely drug-resistant (XDR) strains of M. tuberculosis in THP-1 macrophages.
p37099
sg33279
(lp37100
(dp37101
g33284
I35
sg33285
I1
sg33286
I3
sg33295
VP12931
p37102
sg33289
VSrc
p37103
sasg33281
(lp37104
(dp37105
g33284
I165
sg33285
I1
sg33286
I12
sg33287
VC0041296
p37106
sg33289
Vtuberculosis
p37107
sasa(dp37108
g33277
VSrc inhibition was also effective in controlling M. tuberculosis infection in guinea pigs.
p37109
sg33279
(lp37110
(dp37111
g33284
I0
sg33285
I1
sg33286
I3
sg33295
VP12931
p37112
sg33289
VSrc
p37113
sasg33281
(lp37114
(dp37115
g33284
I52
sg33285
I2
sg33286
I22
sg33287
VC0041296
p37116
sg33289
Vtuberculosis infection
p37117
sasa(dp37118
g33277
VIn guinea pigs, reduced M. tuberculosis burden due to Src inhibition also led to a marked decline in the disease pathology.
p37119
sg33279
(lp37120
(dp37121
g33284
I54
sg33285
I1
sg33286
I3
sg33295
VP12931
p37122
sg33289
VSrc
p37123
sasg33281
(lp37124
(dp37125
g33284
I27
sg33285
I1
sg33286
I12
sg33287
VC0041296
p37126
sg33289
Vtuberculosis
p37127
sa(dp37128
g33284
I113
sg33285
I1
sg33286
I9
sg33287
VC0677042
p37129
sg33289
Vpathology
p37130
sasa(dp37131
g33277
VWe propose that Src inhibitors could be developed into effective host-directed anti-TB drugs, which could be indiscriminately used against both drug-sensitive and drug-resistant strains of M. tuberculosis.
p37132
sg33279
(lp37133
(dp37134
g33284
I16
sg33285
I1
sg33286
I3
sg33295
VP12931
p37135
sg33289
VSrc
p37136
sasg33281
(lp37137
(dp37138
g33284
I192
sg33285
I1
sg33286
I12
sg33287
VC0041296
p37139
sg33289
Vtuberculosis
p37140
sasa(dp37141
g33277
VWe explored tyrosine kinase Src as a host factor exploited by virulent M. tuberculosis for intracellular survival.
p37142
sg33279
(lp37143
(dp37144
g33284
I12
sg33285
I3
sg33286
I19
sg33295
VP29401
p37145
sg33289
Vtyrosine kinase Src
p37146
sasg33281
(lp37147
(dp37148
g33284
I74
sg33285
I1
sg33286
I12
sg33287
VC0041296
p37149
sg33289
Vtuberculosis
p37150
sasa(dp37151
g33277
VWe show that Src inhibition can effectively control tuberculosis in infected guinea pigs.
p37152
sg33279
(lp37153
(dp37154
g33284
I13
sg33285
I1
sg33286
I3
sg33295
VP12931
p37155
sg33289
VSrc
p37156
sasg33281
(lp37157
(dp37158
g33284
I52
sg33285
I1
sg33286
I12
sg33287
VC0041296
p37159
sg33289
Vtuberculosis
p37160
sasa(dp37161
g33277
VIn the current study we aimed to find out the impact of cytokine-inducible Src homology 2 domain protein (CISH) gene polymorphisms on the risk of pulmonary tuberculosis (PTB) in a sample of Iranian population.
p37162
sg33279
(lp37163
(dp37164
g33284
I56
sg33285
I6
sg33286
I48
sg33295
g11
sg33289
Vcytokine-inducible Src homology 2 domain protein
p37165
sa(dp37166
g33284
I106
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCISH
p37167
sasg33281
(lp37168
(dp37169
g33284
I170
sg33285
I1
sg33286
I3
sg33287
VC0041327
p37170
sg33289
VPTB
p37171
sa(dp37172
g33284
I146
sg33285
I2
sg33286
I22
sg33287
VC0041327
p37173
sg33289
Vpulmonary tuberculosis
p37174
sasa(dp37175
g33277
VA recent multi-center case-control study identified several single nucleotide polymorphisms (SNPs) within the cytokine-inducible SRC homology 2 domain (CISH) gene that are associated with susceptibility to tuberculosis (TB) in both African and Asian populations.
p37176
sg33279
(lp37177
(dp37178
g33284
I152
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCISH
p37179
sa(dp37180
g33284
I110
sg33285
I5
sg33286
I40
sg33295
g11
sg33289
Vcytokine-inducible SRC homology 2 domain
p37181
sasg33281
(lp37182
(dp37183
g33284
I220
sg33285
I1
sg33286
I2
sg33287
VC0041296
p37184
sg33289
VTB
p37185
sa(dp37186
g33284
I206
sg33285
I1
sg33286
I12
sg33287
VC0041296
p37187
sg33289
Vtuberculosis
p37188
sasa(dp37189
g33277
VAmong them, the human Cytokine-inducible Src homology 2(SH2) domain protein (CISH) gene has been very recently reported to be involved in T cell activation and differentiation in response to Mycobacterium tuberculosis infection.
p37190
sg33279
(lp37191
(dp37192
g33284
I41
sg33285
I3
sg33286
I14
sg33295
VP12931
p37193
sg33289
VSrc homology 2
p37194
sasg33281
(lp37195
(dp37196
g33284
I205
sg33285
I2
sg33286
I22
sg33287
VC0041296
p37197
sg33289
Vtuberculosis infection
p37198
sasa(dp37199
g33277
VFor the first time, we report different genetic anomalies between adult and paediatric BLs, suggesting age-related heterogeneity in Burkitt lymphomagenesis.
p37200
sg33279
(lp37201
sg33281
(lp37202
(dp37203
g33284
I87
sg33285
I1
sg33286
I3
sg33287
VC0005859
p37204
sg33289
VBLs
p37205
sa(dp37206
g33284
I140
sg33285
I1
sg33286
I15
sg33287
VC0598766
p37207
sg33289
Vlymphomagenesis
p37208
sasa(dp37209
g33277
VAlthough there are conflicting data regarding prognostic implications of isolated MYC aberrancy in these non-BLs, the co-occurrence of MYC rearrangements and either the antiapoptotic gene B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) or the transcriptional repressor BCL6 leads to an entity termed double-hit B-cell lymphoma (DHL) (or triple-hit if all 3 abnormalities are observed) with a particularly poor prognosis and no established treatment paradigms.
p37210
sg33279
(lp37211
(dp37212
g33284
I275
sg33285
I1
sg33286
I4
sg33295
VP41182
p37213
sg33289
VBCL6
p37214
sa(dp37215
g33284
I236
sg33285
I1
sg33286
I4
sg33295
VP10415
p37216
sg33289
VBCL2
p37217
sa(dp37218
g33284
I82
sg33285
I1
sg33286
I3
sg33295
VP12524
p37219
sg33289
VMYC
p37220
sa(dp37221
g33284
I188
sg33285
I5
sg33286
I46
sg33295
VP10415
p37222
sg33289
VB-cell chronic lymphocytic leukemia/lymphoma 2
p37223
sasg33281
(lp37224
(dp37225
g33284
I317
sg33285
I2
sg33286
I15
sg33287
VC0079731
p37226
sg33289
VB-cell lymphoma
p37227
sa(dp37228
g33284
I188
sg33285
I4
sg33286
I35
sg33287
VC1868683
p37229
sg33289
VB-cell chronic lymphocytic leukemia
p37230
sa(dp37231
g33284
I109
sg33285
I1
sg33286
I3
sg33287
VC0005859
p37232
sg33289
VBLs
p37233
sa(dp37234
g33284
I224
sg33285
I1
sg33286
I8
sg33287
VC0024299
p37235
sg33289
Vlymphoma
p37236
sasa(dp37237
g33277
VThe clinicopathologic findings in Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) may show significant overlap, and MYC abnormalities, found in all BLs, also occur in a subset of DLBCL.
p37238
sg33279
(lp37239
(dp37240
g33284
I132
sg33285
I1
sg33286
I3
sg33295
VP12524
p37241
sg33289
VMYC
p37242
sasg33281
(lp37243
(dp37244
g33284
I34
sg33285
I2
sg33286
I16
sg33287
VC0006413
p37245
sg33289
VBurkitt lymphoma
p37246
sa(dp37247
g33284
I91
sg33285
I1
sg33286
I5
sg33287
VC0079744
p37248
sg33289
VDLBCL
p37249
sa(dp37250
g33284
I91
sg33285
I1
sg33286
I5
sg33287
VC0079744
p37251
sg33289
VDLBCL
p37252
sa(dp37253
g33284
I60
sg33285
I4
sg33286
I29
sg33287
VC0079744
p37254
sg33289
Vdiffuse large B-cell lymphoma
p37255
sa(dp37256
g33284
I52
sg33285
I1
sg33286
I2
sg33287
VC0006413
p37257
sg33289
VBL
p37258
sa(dp37259
g33284
I164
sg33285
I1
sg33286
I3
sg33287
VC0005859
p37260
sg33289
VBLs
p37261
sasa(dp37262
g33277
VDouble negative cases were absent in the group of BLs but could be found in approximately one third of the remaining cases of mature aggressive B-cell lymphomas.
p37263
sg33279
(lp37264
sg33281
(lp37265
(dp37266
g33284
I133
sg33285
I1
sg33286
I10
sg33287
VC0001807
p37267
sg33289
Vaggressive
p37268
sa(dp37269
g33284
I50
sg33285
I1
sg33286
I3
sg33287
VC0005859
p37270
sg33289
VBLs
p37271
sa(dp37272
g33284
I144
sg33285
I2
sg33286
I16
sg33287
VC0079731
p37273
sg33289
VB-cell lymphomas
p37274
sasa(dp37275
g33277
VIn particular, we determined the expression and production of several angiogenic factors including tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), Leptin, connective tissue growth factor (CTGF), meningioma-associated complimentary DNA (Mac25), basic fibroblast growth factor (bFGF), and Midkine.
p37276
sg33279
(lp37277
(dp37278
g33284
I70
sg33285
I8
sg33286
I76
sg33295
VP19883
p37279
sg33289
Vangiogenic factors including tissue inhibitor of matrix metalloproteinases-1
p37280
sa(dp37281
g33284
I254
sg33285
I4
sg33286
I30
sg33295
VP53370
p37282
sg33289
Vbasic fibroblast growth factor
p37283
sa(dp37284
g33284
I148
sg33285
I1
sg33286
I6
sg33295
VP01033
p37285
sg33289
VTIMP-1
p37286
sa(dp37287
g33284
I286
sg33285
I1
sg33286
I4
sg33295
VP53370
p37288
sg33289
VbFGF
p37289
sa(dp37290
g33284
I198
sg33285
I1
sg33286
I4
sg33295
VP29279
p37291
sg33289
VCTGF
p37292
sa(dp37293
g33284
I165
sg33285
I4
sg33286
I31
sg33295
VP29279
p37294
sg33289
Vconnective tissue growth factor
p37295
sa(dp37296
g33284
I157
sg33285
I1
sg33286
I6
sg33295
VP41159
p37297
sg33289
VLeptin
p37298
sasg33281
(lp37299
(dp37300
g33284
I205
sg33285
I1
sg33286
I10
sg33287
VC0025286
p37301
sg33289
Vmeningioma
p37302
sasa(dp37303
g33277
VAltered expression levels of several genes identified in this study have been previously noted in meningiomas (eg, growth hormone receptor, IGFBP-7, endothelin receptor A, IGF2).
p37304
sg33279
(lp37305
(dp37306
g33284
I149
sg33285
I3
sg33286
I21
sg33295
g11
sg33289
Vendothelin receptor A
p37307
sa(dp37308
g33284
I172
sg33285
I1
sg33286
I4
sg33295
VP01344
p37309
sg33289
VIGF2
p37310
sa(dp37311
g33284
I115
sg33285
I3
sg33286
I23
sg33295
VP10912
p37312
sg33289
Vgrowth hormone receptor
p37313
sasg33281
(lp37314
(dp37315
g33284
I98
sg33285
I1
sg33286
I11
sg33287
VC0025286
p37316
sg33289
Vmeningiomas
p37317
sasa(dp37318
g33277
Vmac25, a retinoic acid-inducible gene that is expressed at high levels in senescent epithelial cells, was initially cloned as a gene that is differentially expressed in meningioma.
p37319
sg33279
(lp37320
(dp37321
g33284
I0
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
Vmac25
p37322
sasg33281
(lp37323
(dp37324
g33284
I169
sg33285
I1
sg33286
I10
sg33287
VC0025286
p37325
sg33289
Vmeningioma
p37326
sasa(dp37327
g33277
Vmac25 had previously been cloned as a discrete gene, preferentially expressed in normal, leptomeningial cells compared with meningioma tumors.
p37328
sg33279
(lp37329
(dp37330
g33284
I0
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
Vmac25
p37331
sasg33281
(lp37332
(dp37333
g33284
I135
sg33285
I1
sg33286
I6
sg33287
VC0027651
p37334
sg33289
Vtumors
p37335
sa(dp37336
g33284
I124
sg33285
I1
sg33286
I10
sg33287
VC0025286
p37337
sg33289
Vmeningioma
p37338
sasa(dp37339
g33277
VOutcome assessments included the Sheehan Panic Disorder Scale (SPS), Panic Disorder Severity Scale (PDSS), Bandelow Panic and Agoraphobia Scale (PAS), Hamilton Rating Scale for Anxiety (HAM-A), 21-point Clinician Global Improvement Scale (CGI-21), 21-point Patient Global Improvement (PGI-21) and the Sheehan Disability Scale (SDS).
p37340
sg33279
(lp37341
sg33281
(lp37342
(dp37343
g33284
I327
sg33285
I1
sg33286
I3
sg33287
VC0272170
p37344
sg33289
VSDS
p37345
sa(dp37346
g33284
I186
sg33285
I1
sg33286
I3
sg33287
VC0030481
p37347
sg33289
VHAM
p37348
sa(dp37349
g33284
I33
sg33285
I4
sg33286
I28
sg33287
VC0085292
p37350
sg33289
VSheehan Panic Disorder Scale
p37351
sa(dp37352
g33284
I126
sg33285
I1
sg33286
I11
sg33287
VC0001818
p37353
sg33289
VAgoraphobia
p37354
sa(dp37355
g33284
I63
sg33285
I1
sg33286
I3
sg33287
VC0085292
p37356
sg33289
VSPS
p37357
sa(dp37358
g33284
I301
sg33285
I3
sg33286
I24
sg33287
VC0272170
p37359
sg33289
VSheehan Disability Scale
p37360
sa(dp37361
g33284
I41
sg33285
I2
sg33286
I14
sg33287
VC1868649
p37362
sg33289
VPanic Disorder
p37363
sasa(dp37364
g33277
VTaken together, the results of the present study concluded that human FAT2 may function as a key molecule that governs not only PCP, but also NF2-Hpo signaling in arachnoid cells; thus, a mutation in this gene may result in spinal meningioma.
p37365
sg33279
(lp37366
(dp37367
g33284
I146
sg33285
I1
sg33286
I3
sg33295
VP55789
p37368
sg33289
VHpo
p37369
sa(dp37370
g33284
I70
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VFAT2
p37371
sa(dp37372
g33284
I128
sg33285
I1
sg33286
I3
sg33295
VP42785
p37373
sg33289
VPCP
p37374
sasg33281
(lp37375
(dp37376
g33284
I142
sg33285
I1
sg33286
I3
sg33287
VC0027832
p37377
sg33289
VNF2
p37378
sa(dp37379
g33284
I128
sg33285
I1
sg33286
I3
sg33287
VC2919094
p37380
sg33289
VPCP
p37381
sa(dp37382
g33284
I224
sg33285
I2
sg33286
I17
sg33287
VC0347515
p37383
sg33289
Vspinal meningioma
p37384
sasa(dp37385
g33277
VEight human STS cell lines were used: fibrosarcoma (HT1080), liposarcoma (SW872, T778, MLS-402), synovial sarcoma (SW982, SYO1, 1273), and malignant fibrous histiocytoma (U2197).
p37386
sg33279
(lp37387
sg33281
(lp37388
(dp37389
g33284
I139
sg33285
I3
sg33286
I30
sg33287
VC0334463
p37390
sg33289
Vmalignant fibrous histiocytoma
p37391
sa(dp37392
g33284
I87
sg33285
I1
sg33286
I3
sg33287
VC0796070
p37393
sg33289
VMLS
p37394
sa(dp37395
g33284
I12
sg33285
I1
sg33286
I3
sg33287
VC0079588
p37396
sg33289
VSTS
p37397
sa(dp37398
g33284
I38
sg33285
I1
sg33286
I12
sg33287
VC0016057
p37399
sg33289
Vfibrosarcoma
p37400
sa(dp37401
g33284
I61
sg33285
I1
sg33286
I11
sg33287
VC0023827
p37402
sg33289
Vliposarcoma
p37403
sa(dp37404
g33284
I97
sg33285
I2
sg33286
I16
sg33287
VC0039101
p37405
sg33289
Vsynovial sarcoma
p37406
sasa(dp37407
g33277
VVAE diminished the CI in most of the synovial sarcoma (SW982, SYO1) and liposarcoma (SW872, T778) cell lines as well as HT1080.
p37408
sg33279
(lp37409
sg33281
(lp37410
(dp37411
g33284
I72
sg33285
I1
sg33286
I11
sg33287
VC0023827
p37412
sg33289
Vliposarcoma
p37413
sa(dp37414
g33284
I37
sg33285
I2
sg33286
I16
sg33287
VC0039101
p37415
sg33289
Vsynovial sarcoma
p37416
sasa(dp37417
g33277
VA total of eight different human STS cell lines were used in the study: Fibrosarcoma (HT1080), liposarcoma (SW872, T778 and MLS-402), synovial sarcoma (SW982, SYO1 and 1273) and pleomorphic sarcoma (U2197).
p37418
sg33279
(lp37419
sg33281
(lp37420
(dp37421
g33284
I33
sg33285
I1
sg33286
I3
sg33287
VC0079588
p37422
sg33289
VSTS
p37423
sa(dp37424
g33284
I77
sg33285
I1
sg33286
I7
sg33287
VC1261473
p37425
sg33289
Vsarcoma
p37426
sa(dp37427
g33284
I72
sg33285
I1
sg33286
I12
sg33287
VC0016057
p37428
sg33289
VFibrosarcoma
p37429
sa(dp37430
g33284
I124
sg33285
I1
sg33286
I3
sg33287
VC0796070
p37431
sg33289
VMLS
p37432
sa(dp37433
g33284
I95
sg33285
I1
sg33286
I11
sg33287
VC0023827
p37434
sg33289
Vliposarcoma
p37435
sa(dp37436
g33284
I134
sg33285
I2
sg33286
I16
sg33287
VC0039101
p37437
sg33289
Vsynovial sarcoma
p37438
sasa(dp37439
g33277
VIn SYO-1 synovial sarcoma xenografts, administration of small molecule Tcf/Beta-catenin complex inhibitors significantly reduced tumor growth, associated with diminished AXIN2 protein levels.
p37440
sg33279
(lp37441
(dp37442
g33284
I170
sg33285
I2
sg33286
I13
sg33295
g11
sg33289
VAXIN2 protein
p37443
sasg33281
(lp37444
(dp37445
g33284
I9
sg33285
I2
sg33286
I16
sg33287
VC0039101
p37446
sg33289
Vsynovial sarcoma
p37447
sa(dp37448
g33284
I129
sg33285
I2
sg33286
I12
sg33287
VC0598934
p37449
sg33289
Vtumor growth
p37450
sasa(dp37451
g33277
VThese plasmids were transfected in synovial sarcoma SYO-1 cells and we observed the expression of these proteins using a fluorescence microscope.
p37452
sg33279
(lp37453
sg33281
(lp37454
(dp37455
g33284
I35
sg33285
I2
sg33286
I16
sg33287
VC0039101
p37456
sg33289
Vsynovial sarcoma
p37457
sasa(dp37458
g33277
VFurthermore, cell proliferation and colony formation of synovial sarcoma SYO-1 and YaFuSS cells were suppressed by exogenous tSSX expression.
p37459
sg33279
(lp37460
sg33281
(lp37461
(dp37462
g33284
I18
sg33285
I1
sg33286
I13
sg33287
VC0334094
p37463
sg33289
Vproliferation
p37464
sa(dp37465
g33284
I56
sg33285
I2
sg33286
I16
sg33287
VC0039101
p37466
sg33289
Vsynovial sarcoma
p37467
sasa(dp37468
g33277
VPsoriasis area and severity index (PASI), serum P-selectin and interleukin (IL)-6 were monitored throughout the treatment.
p37469
sg33279
(lp37470
(dp37471
g33284
I42
sg33285
I2
sg33286
I16
sg33295
VP16109
p37472
sg33289
Vserum P-selectin
p37473
sa(dp37474
g33284
I63
sg33285
I2
sg33286
I18
sg33295
VP60568
p37475
sg33289
Vinterleukin (IL)-6
p37476
sasg33281
(lp37477
(dp37478
g33284
I0
sg33285
I1
sg33286
I9
sg33287
VC0033860
p37479
sg33289
VPsoriasis
p37480
sasa(dp37481
g33277
VWe aimed to study the association of the endothelial activation biomarkers monocyte chemoattractant protein 1 (MCP-1), soluble (s) E-selectin and P-selectin with disease activity and severity in psoriasis patients treated with anti-TNF-Alfa therapy.
p37482
sg33279
(lp37483
(dp37484
g33284
I41
sg33285
I7
sg33286
I68
sg33295
VP14222
p37485
sg33289
Vendothelial activation biomarkers monocyte chemoattractant protein 1
p37486
sa(dp37487
g33284
I227
sg33285
I1
sg33286
I13
sg33295
VP01375
p37488
sg33289
Vanti-TNF-Alfa
p37489
sa(dp37490
g33284
I146
sg33285
I1
sg33286
I10
sg33295
VP16109
p37491
sg33289
VP-selectin
p37492
sasg33281
(lp37493
(dp37494
g33284
I195
sg33285
I1
sg33286
I9
sg33287
VC0033860
p37495
sg33289
Vpsoriasis
p37496
sasa(dp37497
g33277
VPlasma soluble P-selectin concentrations, PDMP and platelet aggregation were significantly elevated in patients with psoriasis, as compared to controls.
p37498
sg33279
(lp37499
(dp37500
g33284
I0
sg33285
I3
sg33286
I25
sg33295
VP16109
p37501
sg33289
VPlasma soluble P-selectin
p37502
sasg33281
(lp37503
(dp37504
g33284
I117
sg33285
I1
sg33286
I9
sg33287
VC0033860
p37505
sg33289
Vpsoriasis
p37506
sasa(dp37507
g33277
VMost efficient among them is the newly identified SOXN (neuroblastoma-derived sulfhydryl oxidase), which comprises 12 exons and maps to 9q34.3.
p37508
sg33279
(lp37509
sg33281
(lp37510
(dp37511
g33284
I56
sg33285
I1
sg33286
I13
sg33287
VC0027819
p37512
sg33289
Vneuroblastoma
p37513
sasa(dp37514
g33277
VThese results identify SOXN as a major player in regulating the sensitization of neuroblastoma cells for IFN-gamma-induced apoptosis.
p37515
sg33279
(lp37516
(dp37517
g33284
I105
sg33285
I1
sg33286
I9
sg33295
VP01579
p37518
sg33289
VIFN-gamma
p37519
sa(dp37520
g33284
I23
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VSOXN
p37521
sasg33281
(lp37522
(dp37523
g33284
I81
sg33285
I1
sg33286
I13
sg33287
VC0027819
p37524
sg33289
Vneuroblastoma
p37525
sasa(dp37526
g33277
VThe cartilage proteins melanoma inhibitory activity (MIA) and human cartilage gp-39 (HC gp-39) are candidate autoantigens in rheumatoid arthritis (RA).
p37527
sg33279
(lp37528
sg33281
(lp37529
(dp37530
g33284
I125
sg33285
I2
sg33286
I20
sg33287
VC0003873
p37531
sg33289
Vrheumatoid arthritis
p37532
sa(dp37533
g33284
I23
sg33285
I1
sg33286
I8
sg33287
VC0025202
p37534
sg33289
Vmelanoma
p37535
sa(dp37536
g33284
I147
sg33285
I1
sg33286
I2
sg33287
VC0003873
p37537
sg33289
VRA
p37538
sasa(dp37539
g33277
VThe presented results confirm expression of CDRAP by normal and osteoarthritic articular chondrocytes, but indicate that increased expression levels by chondrocytes are not the cause of the increased levels of CDRAP in the synovial fluid of patients with osteoarthritis.
p37540
sg33279
(lp37541
(dp37542
g33284
I44
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCDRAP
p37543
sa(dp37544
g33284
I44
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCDRAP
p37545
sasg33281
(lp37546
(dp37547
g33284
I255
sg33285
I1
sg33286
I14
sg33287
VC0029408
p37548
sg33289
Vosteoarthritis
p37549
sasa(dp37550
g33277
VWe have measured the concentration of cartilage-derived retinoic-acid-sensitive protein (CD-RAP) in synovial fluid (SF) from the knees of 49 patients with osteoarthritis (OA) and 79 with rheumatoid arthritis (RA) in order to investigate the correlation between the type of joint disease and level of CD-RAP.
p37551
sg33279
(lp37552
sg33281
(lp37553
(dp37554
g33284
I92
sg33285
I1
sg33286
I2
sg33287
VC0003873
p37555
sg33289
VRA
p37556
sa(dp37557
g33284
I171
sg33285
I1
sg33286
I2
sg33287
VC0029408
p37558
sg33289
VOA
p37559
sa(dp37560
g33284
I155
sg33285
I1
sg33286
I14
sg33287
VC0029408
p37561
sg33289
Vosteoarthritis
p37562
sa(dp37563
g33284
I187
sg33285
I2
sg33286
I20
sg33287
VC0003873
p37564
sg33289
Vrheumatoid arthritis
p37565
sa(dp37566
g33284
I273
sg33285
I2
sg33286
I13
sg33287
VC0022408
p37567
sg33289
Vjoint disease
p37568
sasa(dp37569
g33277
VIn this study, we demonstrated that osteopontin (OPN) was dramatically reduced by loss of TSC1/TSC2 complex in Tsc2-null mouse embryonic fibroblasts (MEFs), rat uterine leiomyoma-derived Tsc2-deficient cells, genetically modified mouse TSC models, and clinical samples.
p37570
sg33279
(lp37571
(dp37572
g33284
I111
sg33285
I1
sg33286
I4
sg33295
VP49815
p37573
sg33289
VTsc2
p37574
sa(dp37575
g33284
I49
sg33285
I1
sg33286
I3
sg33295
VP10451
p37576
sg33289
VOPN
p37577
sa(dp37578
g33284
I90
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTSC1
p37579
sa(dp37580
g33284
I36
sg33285
I1
sg33286
I11
sg33295
VP10451
p37581
sg33289
Vosteopontin
p37582
sa(dp37583
g33284
I111
sg33285
I1
sg33286
I4
sg33295
VP49815
p37584
sg33289
VTsc2
p37585
sa(dp37586
g33284
I95
sg33285
I1
sg33286
I4
sg33295
VP49815
p37587
sg33289
VTSC2
p37588
sasg33281
(lp37589
(dp37590
g33284
I111
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37591
sg33289
VTsc2
p37592
sa(dp37593
g33284
I161
sg33285
I2
sg33286
I17
sg33287
VC0042133
p37594
sg33289
Vuterine leiomyoma
p37595
sa(dp37596
g33284
I90
sg33285
I1
sg33286
I4
sg33287
VC1854465
p37597
sg33289
VTSC1
p37598
sa(dp37599
g33284
I90
sg33285
I1
sg33286
I3
sg33287
VC0041341
p37600
sg33289
VTSC
p37601
sa(dp37602
g33284
I111
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37603
sg33289
VTsc2
p37604
sa(dp37605
g33284
I95
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37606
sg33289
VTSC2
p37607
sasa(dp37608
g33277
VTSC2-deficient Eker rat uterine leiomyoma ELT3 cells were stably transfected with empty vector or plasmid for the expression of TSC2.
p37609
sg33279
(lp37610
(dp37611
g33284
I0
sg33285
I1
sg33286
I4
sg33295
VP49815
p37612
sg33289
VTSC2
p37613
sa(dp37614
g33284
I0
sg33285
I1
sg33286
I4
sg33295
VP49815
p37615
sg33289
VTSC2
p37616
sasg33281
(lp37617
(dp37618
g33284
I0
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37619
sg33289
VTSC2
p37620
sa(dp37621
g33284
I24
sg33285
I2
sg33286
I17
sg33287
VC0042133
p37622
sg33289
Vuterine leiomyoma
p37623
sa(dp37624
g33284
I0
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37625
sg33289
VTSC2
p37626
sasa(dp37627
g33277
VBy analyzing Tsc2-null mouse embryonic fibroblasts (MEFs) and rat uterine leiomyoma-derived Tsc2-null ELT3 cells, we detected evidence for the involvement of cyclooxygenase 2 (COX2) as a downstream target of mTORC1 in the development of TSC tumors.
p37628
sg33279
(lp37629
(dp37630
g33284
I13
sg33285
I1
sg33286
I4
sg33295
VP49815
p37631
sg33289
VTsc2
p37632
sa(dp37633
g33284
I13
sg33285
I1
sg33286
I4
sg33295
VP49815
p37634
sg33289
VTsc2
p37635
sa(dp37636
g33284
I176
sg33285
I1
sg33286
I4
sg33295
VP35354
p37637
sg33289
VCOX2
p37638
sa(dp37639
g33284
I158
sg33285
I2
sg33286
I16
sg33295
VP35354
p37640
sg33289
Vcyclooxygenase 2
p37641
sasg33281
(lp37642
(dp37643
g33284
I66
sg33285
I2
sg33286
I17
sg33287
VC0042133
p37644
sg33289
Vuterine leiomyoma
p37645
sa(dp37646
g33284
I237
sg33285
I1
sg33286
I3
sg33287
VC0041341
p37647
sg33289
VTSC
p37648
sa(dp37649
g33284
I13
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37650
sg33289
VTsc2
p37651
sa(dp37652
g33284
I13
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37653
sg33289
VTsc2
p37654
sa(dp37655
g33284
I241
sg33285
I1
sg33286
I6
sg33287
VC0027651
p37656
sg33289
Vtumors
p37657
sasa(dp37658
g33277
VTSC2-positive and TSC2-negative mouse embryonic fibroblasts (MEF), 323-TSC2-positive and 323-TSC2-null MEF and Eker rat uterine leiomyoma (ELT3) cells were treated with doxycycline or rapamycin alone, or in combination.
p37659
sg33279
(lp37660
(dp37661
g33284
I0
sg33285
I1
sg33286
I4
sg33295
VP49815
p37662
sg33289
VTSC2
p37663
sa(dp37664
g33284
I0
sg33285
I1
sg33286
I4
sg33295
VP49815
p37665
sg33289
VTSC2
p37666
sa(dp37667
g33284
I0
sg33285
I1
sg33286
I4
sg33295
VP49815
p37668
sg33289
VTSC2
p37669
sa(dp37670
g33284
I0
sg33285
I1
sg33286
I4
sg33295
VP49815
p37671
sg33289
VTSC2
p37672
sasg33281
(lp37673
(dp37674
g33284
I0
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37675
sg33289
VTSC2
p37676
sa(dp37677
g33284
I0
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37678
sg33289
VTSC2
p37679
sa(dp37680
g33284
I0
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37681
sg33289
VTSC2
p37682
sa(dp37683
g33284
I120
sg33285
I2
sg33286
I17
sg33287
VC0042133
p37684
sg33289
Vuterine leiomyoma
p37685
sa(dp37686
g33284
I0
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37687
sg33289
VTSC2
p37688
sasa(dp37689
g33277
VImportantly, rapamycin treatment did not affect the expression of AdPLA2 and the production of PGE2 by TSC2-deficient mouse embryonic fibroblast (Tsc2-/-MEFs), rat uterine leiomyoma-derived ELT3 cells, and LAM patient-associated renal angiomyolipoma-derived "mesenchymal" cells.
p37690
sg33279
(lp37691
(dp37692
g33284
I146
sg33285
I1
sg33286
I11
sg33295
VP49815
p37693
sg33289
VTsc2-/-MEFs
p37694
sa(dp37695
g33284
I103
sg33285
I4
sg33286
I41
sg33295
VP49815
p37696
sg33289
VTSC2-deficient mouse embryonic fibroblast
p37697
sasg33281
(lp37698
(dp37699
g33284
I229
sg33285
I2
sg33286
I20
sg33287
VC0241961
p37700
sg33289
Vrenal angiomyolipoma
p37701
sa(dp37702
g33284
I206
sg33285
I1
sg33286
I3
sg33287
VC0751674
p37703
sg33289
VLAM
p37704
sa(dp37705
g33284
I164
sg33285
I2
sg33286
I17
sg33287
VC0042133
p37706
sg33289
Vuterine leiomyoma
p37707
sa(dp37708
g33284
I103
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37709
sg33289
VTSC2
p37710
sa(dp37711
g33284
I146
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37712
sg33289
VTsc2
p37713
sasa(dp37714
g33277
VLoss of the Tuberous Sclerosis 2 (TSC2) tumor suppressor has been proposed as a mechanism important for the etiology of uterine leiomyomata based on the Eker rat model.
p37715
sg33279
(lp37716
(dp37717
g33284
I34
sg33285
I1
sg33286
I4
sg33295
VP49815
p37718
sg33289
VTSC2
p37719
sa(dp37720
g33284
I12
sg33285
I3
sg33286
I20
sg33295
VP49815
p37721
sg33289
VTuberous Sclerosis 2
p37722
sasg33281
(lp37723
(dp37724
g33284
I120
sg33285
I2
sg33286
I19
sg33287
VC0042133
p37725
sg33289
Vuterine leiomyomata
p37726
sa(dp37727
g33284
I34
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37728
sg33289
VTSC2
p37729
sa(dp37730
g33284
I12
sg33285
I3
sg33286
I20
sg33287
VC1860707
p37731
sg33289
VTuberous Sclerosis 2
p37732
sa(dp37733
g33284
I40
sg33285
I1
sg33286
I5
sg33287
VC0027651
p37734
sg33289
Vtumor
p37735
sasa(dp37736
g33277
VHowever, conflicting evidence showing increased TSC2 expression has been reported in human uterine leiomyomata, suggesting that TSC2 might not be involved in the pathogenesis of this disorder.
p37737
sg33279
(lp37738
(dp37739
g33284
I48
sg33285
I1
sg33286
I4
sg33295
VP49815
p37740
sg33289
VTSC2
p37741
sa(dp37742
g33284
I48
sg33285
I1
sg33286
I4
sg33295
VP49815
p37743
sg33289
VTSC2
p37744
sasg33281
(lp37745
(dp37746
g33284
I162
sg33285
I1
sg33286
I12
sg33287
VC0699748
p37747
sg33289
Vpathogenesis
p37748
sa(dp37749
g33284
I91
sg33285
I2
sg33286
I19
sg33287
VC0042133
p37750
sg33289
Vuterine leiomyomata
p37751
sa(dp37752
g33284
I48
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37753
sg33289
VTSC2
p37754
sa(dp37755
g33284
I48
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37756
sg33289
VTSC2
p37757
sasa(dp37758
g33277
VIn cell culture models of TSC2-deficient LAM patient-derived and rat uterine leiomyoma-derived cells, we found that progesterone treatment or progesterone plus estradiol resulted in increased phosphorylation of Protein Kinase B (Akt) and Extracellular signal-regulated kinases1/2 (ERK1/2), induced the proliferation, and enhanced the migration and invasiveness.
p37759
sg33279
(lp37760
(dp37761
g33284
I211
sg33285
I3
sg33286
I16
sg33295
VP31749
p37762
sg33289
VProtein Kinase B
p37763
sa(dp37764
g33284
I26
sg33285
I1
sg33286
I4
sg33295
VP49815
p37765
sg33289
VTSC2
p37766
sa(dp37767
g33284
I238
sg33285
I3
sg33286
I41
sg33295
VP35555
p37768
sg33289
VExtracellular signal-regulated kinases1/2
p37769
sa(dp37770
g33284
I229
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VAkt
p37771
sa(dp37772
g33284
I281
sg33285
I1
sg33286
I6
sg33295
VP27361
p37773
sg33289
VERK1/2
p37774
sasg33281
(lp37775
(dp37776
g33284
I41
sg33285
I1
sg33286
I3
sg33287
VC0751674
p37777
sg33289
VLAM
p37778
sa(dp37779
g33284
I302
sg33285
I1
sg33286
I13
sg33287
VC0334094
p37780
sg33289
Vproliferation
p37781
sa(dp37782
g33284
I26
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37783
sg33289
VTSC2
p37784
sa(dp37785
g33284
I69
sg33285
I2
sg33286
I17
sg33287
VC0042133
p37786
sg33289
Vuterine leiomyoma
p37787
sasa(dp37788
g33277
VWe report here that expression of AlfaB-crystallin was upregulated in Tsc1-/- or Tsc2-/- mouse embryonic fibroblasts, Eker rat uterine leiomyoma-derived Tsc2-deficient ELT3 cells, mutant Tsc2-associated mouse kidney tumors, and human lung lymphangioleiomyomatosis nodules.
p37789
sg33279
(lp37790
(dp37791
g33284
I81
sg33285
I1
sg33286
I4
sg33295
VP49815
p37792
sg33289
VTsc2
p37793
sa(dp37794
g33284
I34
sg33285
I1
sg33286
I16
sg33295
VP22914
p37795
sg33289
VAlfaB-crystallin
p37796
sa(dp37797
g33284
I81
sg33285
I1
sg33286
I4
sg33295
VP49815
p37798
sg33289
VTsc2
p37799
sa(dp37800
g33284
I81
sg33285
I1
sg33286
I4
sg33295
VP49815
p37801
sg33289
VTsc2
p37802
sa(dp37803
g33284
I70
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTsc1
p37804
sasg33281
(lp37805
(dp37806
g33284
I81
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37807
sg33289
VTsc2
p37808
sa(dp37809
g33284
I70
sg33285
I1
sg33286
I4
sg33287
VC1854465
p37810
sg33289
VTsc1
p37811
sa(dp37812
g33284
I209
sg33285
I2
sg33286
I13
sg33287
VC0022665
p37813
sg33289
Vkidney tumors
p37814
sa(dp37815
g33284
I81
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37816
sg33289
VTsc2
p37817
sa(dp37818
g33284
I264
sg33285
I1
sg33286
I7
sg33287
VC0028259
p37819
sg33289
Vnodules
p37820
sa(dp37821
g33284
I127
sg33285
I2
sg33286
I17
sg33287
VC0042133
p37822
sg33289
Vuterine leiomyoma
p37823
sa(dp37824
g33284
I81
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37825
sg33289
VTsc2
p37826
sa(dp37827
g33284
I180
sg33285
I1
sg33286
I6
sg33287
VC0596988
p37828
sg33289
Vmutant
p37829
sa(dp37830
g33284
I234
sg33285
I2
sg33286
I29
sg33287
VC0349649
p37831
sg33289
Vlung lymphangioleiomyomatosis
p37832
sasa(dp37833
g33277
VFemale Eker rats harboring an insertional deletion in one copy of the tuberous sclerosis complex 2 (Tsc2) gene develop uterine leiomyoma, but the underlying mechanism of human uterine leiomyoma is not completely understood.
p37834
sg33279
(lp37835
(dp37836
g33284
I100
sg33285
I1
sg33286
I4
sg33295
VP49815
p37837
sg33289
VTsc2
p37838
sa(dp37839
g33284
I70
sg33285
I4
sg33286
I28
sg33295
VP49815
p37840
sg33289
Vtuberous sclerosis complex 2
p37841
sasg33281
(lp37842
(dp37843
g33284
I119
sg33285
I2
sg33286
I17
sg33287
VC0042133
p37844
sg33289
Vuterine leiomyoma
p37845
sa(dp37846
g33284
I100
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37847
sg33289
VTsc2
p37848
sa(dp37849
g33284
I70
sg33285
I4
sg33286
I28
sg33287
VC1860707
p37850
sg33289
Vtuberous sclerosis complex 2
p37851
sa(dp37852
g33284
I119
sg33285
I2
sg33286
I17
sg33287
VC0042133
p37853
sg33289
Vuterine leiomyoma
p37854
sasa(dp37855
g33277
VTo examine whether down-regulation of tuberin, a TSC2 gene product, is present in human uterine leiomyoma, we analyzed leiomyoma and matched myometrium tissues from 22 Chinese patients with Western blotting and real-time polymerase chain reaction analyses, and found that the expression of tuberin was significantly increased in leiomyoma tissues compared with matched myometrium tissues with inhibition of both the mammalian target of rapacmycin pathway and mitogen-activated protein kinase pathways.
p37856
sg33279
(lp37857
(dp37858
g33284
I38
sg33285
I1
sg33286
I7
sg33295
VP49815
p37859
sg33289
Vtuberin
p37860
sa(dp37861
g33284
I49
sg33285
I3
sg33286
I17
sg33295
VP49815
p37862
sg33289
VTSC2 gene product
p37863
sa(dp37864
g33284
I38
sg33285
I1
sg33286
I7
sg33295
VP49815
p37865
sg33289
Vtuberin
p37866
sa(dp37867
g33284
I459
sg33285
I3
sg33286
I32
sg33295
VP53779
p37868
sg33289
Vmitogen-activated protein kinase
p37869
sasg33281
(lp37870
(dp37871
g33284
I96
sg33285
I1
sg33286
I9
sg33287
VC0042133
p37872
sg33289
Vleiomyoma
p37873
sa(dp37874
g33284
I88
sg33285
I2
sg33286
I17
sg33287
VC0042133
p37875
sg33289
Vuterine leiomyoma
p37876
sa(dp37877
g33284
I96
sg33285
I1
sg33286
I9
sg33287
VC0042133
p37878
sg33289
Vleiomyoma
p37879
sa(dp37880
g33284
I49
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37881
sg33289
VTSC2
p37882
sasa(dp37883
g33277
VCells derived from an Eker rat uterine leiomyoma (ELT3 cells) are Tsc2-null and these have been used in a rodent cell models for LAM.
p37884
sg33279
(lp37885
(dp37886
g33284
I66
sg33285
I1
sg33286
I9
sg33295
VP49815
p37887
sg33289
VTsc2-null
p37888
sasg33281
(lp37889
(dp37890
g33284
I129
sg33285
I1
sg33286
I3
sg33287
VC0751674
p37891
sg33289
VLAM
p37892
sa(dp37893
g33284
I31
sg33285
I2
sg33286
I17
sg33287
VC0042133
p37894
sg33289
Vuterine leiomyoma
p37895
sa(dp37896
g33284
I66
sg33285
I1
sg33286
I4
sg33287
VC1860707
p37897
sg33289
VTsc2
p37898
sasa(dp37899
g33277
VIn patients with rheumatoid arthritis, furin is reported to be highly expressed in the synovial pannus compared with healthy persons.
p37900
sg33279
(lp37901
(dp37902
g33284
I39
sg33285
I1
sg33286
I5
sg33295
VP09958
p37903
sg33289
Vfurin
p37904
sasg33281
(lp37905
(dp37906
g33284
I96
sg33285
I1
sg33286
I6
sg33287
VC0155094
p37907
sg33289
Vpannus
p37908
sa(dp37909
g33284
I17
sg33285
I2
sg33286
I20
sg33287
VC0003873
p37910
sg33289
Vrheumatoid arthritis
p37911
sasa(dp37912
g33277
VInhibition of furin enhances invasive phenotype of synoviocytes from patients with rheumatoid arthritis, implying a protective role of furin.
p37913
sg33279
(lp37914
(dp37915
g33284
I14
sg33285
I1
sg33286
I5
sg33295
VP09958
p37916
sg33289
Vfurin
p37917
sa(dp37918
g33284
I14
sg33285
I1
sg33286
I5
sg33295
VP09958
p37919
sg33289
Vfurin
p37920
sasg33281
(lp37921
(dp37922
g33284
I83
sg33285
I2
sg33286
I20
sg33287
VC0003873
p37923
sg33289
Vrheumatoid arthritis
p37924
sasa(dp37925
g33277
VAgents targeting upregulation of furin may have therapeutic potential for rheumatoid arthritis.
p37926
sg33279
(lp37927
(dp37928
g33284
I33
sg33285
I1
sg33286
I5
sg33295
VP09958
p37929
sg33289
Vfurin
p37930
sasg33281
(lp37931
(dp37932
g33284
I74
sg33285
I2
sg33286
I20
sg33287
VC0003873
p37933
sg33289
Vrheumatoid arthritis
p37934
sasa(dp37935
g33277
VThe effect of furin and its inhibitor Alfa1-PDX was tested in mice with collagen-induced arthritis (CIA).
p37936
sg33279
(lp37937
(dp37938
g33284
I14
sg33285
I1
sg33286
I5
sg33295
VP09958
p37939
sg33289
Vfurin
p37940
sasg33281
(lp37941
(dp37942
g33284
I89
sg33285
I1
sg33286
I9
sg33287
VC0003864
p37943
sg33289
Varthritis
p37944
sasa(dp37945
g33277
VSystemic administration of furin prevented increases in the arthritis score, joint destruction, and bone loss, in contrast to systemic administration of the furin inhibitor Alfa1-PDX, which enhanced these parameters.
p37946
sg33279
(lp37947
(dp37948
g33284
I27
sg33285
I1
sg33286
I5
sg33295
VP09958
p37949
sg33289
Vfurin
p37950
sa(dp37951
g33284
I27
sg33285
I1
sg33286
I5
sg33295
VP09958
p37952
sg33289
Vfurin
p37953
sasg33281
(lp37954
(dp37955
g33284
I60
sg33285
I1
sg33286
I9
sg33287
VC0003864
p37956
sg33289
Varthritis
p37957
sa(dp37958
g33284
I100
sg33285
I2
sg33286
I9
sg33287
VC0029453
p37959
sg33289
Vbone loss
p37960
sasa(dp37961
g33277
VThey also suggest that Adamts5 induction in joint components other than cartilage, and its post-translational activation by PACE4 and/or furin may be important in the pathophysiology of arthritis.
p37962
sg33279
(lp37963
(dp37964
g33284
I23
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VAdamts5
p37965
sa(dp37966
g33284
I137
sg33285
I1
sg33286
I5
sg33295
VP09958
p37967
sg33289
Vfurin
p37968
sasg33281
(lp37969
(dp37970
g33284
I186
sg33285
I1
sg33286
I9
sg33287
VC0003864
p37971
sg33289
Varthritis
p37972
sasa(dp37973
g33277
VWhen comparing the chorioamniotic membranes from women in spontaneous preterm labor with acute histologic chorioamnionitis to those without this placental lesion, we found that (1) the mRNA of NLR family pyrin domain-containing protein ( NLRP) 1, NLRP3, NLR family CARD domain-containing protein 4 ( NLRC4), and NOD2 were higher; (2) the NLRP3 protein was increased; (3) the mRNA and active form (p10) of CASP-1 were greater; (4) the mRNA and active form of CASP-4 were increased; (5) the mRNA and mature form of IL-1Beta were higher; (6) the mature form of IL-18 was elevated; and (7) ASC/CASP-1 complex formation was increased.
p37974
sg33279
(lp37975
(dp37976
g33284
I193
sg33285
I8
sg33286
I52
sg33295
g11
sg33289
VNLR family pyrin domain-containing protein ( NLRP) 1
p37977
sa(dp37978
g33284
I513
sg33285
I1
sg33286
I8
sg33295
VP01584
p37979
sg33289
VIL-1Beta
p37980
sa(dp37981
g33284
I300
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VNLRC4
p37982
sa(dp37983
g33284
I254
sg33285
I6
sg33286
I43
sg33295
g11
sg33289
VNLR family CARD domain-containing protein 4
p37984
sa(dp37985
g33284
I458
sg33285
I1
sg33286
I6
sg33295
VP39880
p37986
sg33289
VCASP-4
p37987
sa(dp37988
g33284
I405
sg33285
I1
sg33286
I6
sg33295
VP39880
p37989
sg33289
VCASP-1
p37990
sa(dp37991
g33284
I312
sg33285
I1
sg33286
I4
sg33295
VP22301
p37992
sg33289
VNOD2
p37993
sa(dp37994
g33284
I397
sg33285
I1
sg33286
I3
sg33295
VP60903
p37995
sg33289
Vp10
p37996
sasg33281
(lp37997
(dp37998
g33284
I106
sg33285
I1
sg33286
I16
sg33287
VC0008495
p37999
sg33289
Vchorioamnionitis
p38000
sa(dp38001
g33284
I70
sg33285
I2
sg33286
I13
sg33287
VC0022876
p38002
sg33289
Vpreterm labor
p38003
sasa(dp38004
g33277
VWhen comparing the chorioamniotic membranes from women in spontaneous labor at term with acute histologic chorioamnionitis to those without this placental lesion, we found that (1) the messenger RNA (mRNA) abundance of NLR family pyrin domain containing 3 ( NLRP3), NLR family CARD domain containing 4 ( NLRC4), absent in melanoma 2 ( AIM2), and nucleotide binding oligomerization domain 2 ( NOD2) was higher; (2) the NLRP3 and NLRC4 protein quantities were increased; (3) the mRNA and protein expressions of CASP-1 and its active forms were greater; (4) CASP-4 was increased at the mRNA level only; (5) the mRNA and protein expressions of IL-1Beta and its mature form were higher; and (6) a modest increase in the total protein concentration and abundance of the mature form of IL-18 was observed.
p38005
sg33279
(lp38006
(dp38007
g33284
I335
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VAIM2
p38008
sa(dp38009
g33284
I266
sg33285
I6
sg33286
I35
sg33295
g11
sg33289
VNLR family CARD domain containing 4
p38010
sa(dp38011
g33284
I640
sg33285
I1
sg33286
I8
sg33295
VP01584
p38012
sg33289
VIL-1Beta
p38013
sa(dp38014
g33284
I304
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VNLRC4
p38015
sa(dp38016
g33284
I509
sg33285
I1
sg33286
I6
sg33295
VP39880
p38017
sg33289
VCASP-1
p38018
sa(dp38019
g33284
I219
sg33285
I6
sg33286
I36
sg33295
g11
sg33289
VNLR family pyrin domain containing 3
p38020
sa(dp38021
g33284
I346
sg33285
I5
sg33286
I43
sg33295
VP63244
p38022
sg33289
Vnucleotide binding oligomerization domain 2
p38023
sa(dp38024
g33284
I428
sg33285
I2
sg33286
I13
sg33295
g11
sg33289
VNLRC4 protein
p38025
sa(dp38026
g33284
I392
sg33285
I1
sg33286
I4
sg33295
VP22301
p38027
sg33289
VNOD2
p38028
sasg33281
(lp38029
(dp38030
g33284
I106
sg33285
I1
sg33286
I16
sg33287
VC0008495
p38031
sg33289
Vchorioamnionitis
p38032
sa(dp38033
g33284
I322
sg33285
I1
sg33286
I8
sg33287
VC0025202
p38034
sg33289
Vmelanoma
p38035
sasa(dp38036
g33277
VMutations in NLRP7 (NOD-like-receptor family, pyrin domain containing 7) are responsible for a type of recurrent pregnancy loss known as recurrent hydatidiform mole (HYDM1).
p38037
sg33279
(lp38038
(dp38039
g33284
I20
sg33285
I2
sg33286
I24
sg33295
VP54259
p38040
sg33289
VNOD-like-receptor family
p38041
sa(dp38042
g33284
I13
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VNLRP7
p38043
sa(dp38044
g33284
I46
sg33285
I4
sg33286
I25
sg33295
g11
sg33289
Vpyrin domain containing 7
p38045
sasg33281
(lp38046
(dp38047
g33284
I20
sg33285
I1
sg33286
I3
sg33287
VC0751781
p38048
sg33289
VNOD
p38049
sa(dp38050
g33284
I103
sg33285
I3
sg33286
I24
sg33287
VC2921106
p38051
sg33289
Vrecurrent pregnancy loss
p38052
sa(dp38053
g33284
I147
sg33285
I2
sg33286
I17
sg33287
VC0020217
p38054
sg33289
Vhydatidiform mole
p38055
sa(dp38056
g33284
I166
sg33285
I1
sg33286
I5
sg33287
VC3463897
p38057
sg33289
VHYDM1
p38058
sasa(dp38059
g33277
VNRG1 fusion-positive lung cancers have emerged as potentially actionable events in lung cancer but clinical support is currently limited and no evidence of efficacy of this approach in cancers beyond lung has been shown.
p38060
sg33279
(lp38061
sg33281
(lp38062
(dp38063
g33284
I26
sg33285
I1
sg33286
I7
sg33287
VC0006826
p38064
sg33289
Vcancers
p38065
sa(dp38066
g33284
I21
sg33285
I2
sg33286
I12
sg33287
VC0242379
p38067
sg33289
Vlung cancers
p38068
sa(dp38069
g33284
I21
sg33285
I2
sg33286
I11
sg33287
VC0242379
p38070
sg33289
Vlung cancer
p38071
sasa(dp38072
g33277
VIn patient 1 an SDC4-NRG1 gene fusion was detected, similar gene fusions having been described in lung cancers previously.
p38073
sg33279
(lp38074
(dp38075
g33284
I60
sg33285
I2
sg33286
I12
sg33295
VP35637
p38076
sg33289
Vgene fusions
p38077
sa(dp38078
g33284
I16
sg33285
I1
sg33286
I4
sg33295
VP31431
p38079
sg33289
VSDC4
p38080
sasg33281
(lp38081
(dp38082
g33284
I26
sg33285
I2
sg33286
I11
sg33287
VC1705736
p38083
sg33289
Vgene fusion
p38084
sa(dp38085
g33284
I98
sg33285
I2
sg33286
I12
sg33287
VC0242379
p38086
sg33289
Vlung cancers
p38087
sasa(dp38088
g33277
VUnexpected molecular lesions of the NRG1 gene followed by an aberrant ErbB signaling were recently described as a new molecular features of non-small cell lung cancer, but it has been also sporadically reported in other tumors.
p38089
sg33279
(lp38090
(dp38091
g33284
I70
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VErbB
p38092
sasg33281
(lp38093
(dp38094
g33284
I220
sg33285
I1
sg33286
I6
sg33287
VC0027651
p38095
sg33289
Vtumors
p38096
sa(dp38097
g33284
I140
sg33285
I4
sg33286
I26
sg33287
VC0007131
p38098
sg33289
Vnon-small cell lung cancer
p38099
sasa(dp38100
g33277
VWe highlight the current knowledge about the ErbB network and NRG1 deregulation in lung cancer and their merger into the ErbB/PI3K-AKT axis modulation and current therapeutic strategies.
p38101
sg33279
(lp38102
(dp38103
g33284
I45
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VErbB
p38104
sa(dp38105
g33284
I131
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VAKT
p38106
sa(dp38107
g33284
I126
sg33285
I1
sg33286
I4
sg33295
VP42336
p38108
sg33289
VPI3K
p38109
sa(dp38110
g33284
I45
sg33285
I2
sg33286
I12
sg33295
g11
sg33289
VErbB network
p38111
sasg33281
(lp38112
(dp38113
g33284
I83
sg33285
I2
sg33286
I11
sg33287
VC0684249
p38114
sg33289
Vlung cancer
p38115
sasa(dp38116
g33277
VMore advances in knowledge of crosstalk between NRG1, ErbB3 and PI3K-AKT pathways may increase and strongly support the therapeutic choice for lung cancer patients.
p38117
sg33279
(lp38118
(dp38119
g33284
I64
sg33285
I1
sg33286
I4
sg33295
VP42336
p38120
sg33289
VPI3K
p38121
sa(dp38122
g33284
I54
sg33285
I1
sg33286
I5
sg33295
VP21860
p38123
sg33289
VErbB3
p38124
sa(dp38125
g33284
I69
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VAKT
p38126
sasg33281
(lp38127
(dp38128
g33284
I143
sg33285
I2
sg33286
I11
sg33287
VC0684249
p38129
sg33289
Vlung cancer
p38130
sasa(dp38131
g33277
VAll coding exons of SCN1B, GABRG2, and CACNB4 genes were screened for mutations in 38 SCN1A-mutation-positive SMEI probands.
p38132
sg33279
(lp38133
(dp38134
g33284
I86
sg33285
I1
sg33286
I5
sg33295
VP35498
p38135
sg33289
VSCN1A
p38136
sa(dp38137
g33284
I20
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSCN1B
p38138
sa(dp38139
g33284
I39
sg33285
I2
sg33286
I12
sg33295
g11
sg33289
VCACNB4 genes
p38140
sa(dp38141
g33284
I27
sg33285
I1
sg33286
I6
sg33295
VP18507
p38142
sg33289
VGABRG2
p38143
sasg33281
(lp38144
(dp38145
g33284
I110
sg33285
I1
sg33286
I4
sg33287
VC0751122
p38146
sg33289
VSMEI
p38147
sasa(dp38148
g33277
VFollowing the univariate analysis, high expressions of nuclear Beta-arrestin1 and p300 were classed as poor prognostic factors for both OS (P = .016) and DFS (P = .025).The expression of Beta-arrestin1 in the nucleus is associated with increased malignant tendency of lung adenocarcinoma, and the predictive value of Beta-arrestin1 may be optimized by combining information about the expression of p300 acetyltransferase.
p38149
sg33279
(lp38150
(dp38151
g33284
I82
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
Vp300
p38152
sa(dp38153
g33284
I398
sg33285
I2
sg33286
I22
sg33295
g11
sg33289
Vp300 acetyltransferase
p38154
sasg33281
(lp38155
(dp38156
g33284
I268
sg33285
I2
sg33286
I19
sg33287
VC0152013
p38157
sg33289
Vlung adenocarcinoma
p38158
sasa(dp38159
g33277
VFurthermore, we demonstrated that the activation of COX-2 expression by hnRNPA2/B1 was mediated through the cooperation with p300, a transcriptional co-activator, in NSCLC cells.
p38160
sg33279
(lp38161
(dp38162
g33284
I72
sg33285
I1
sg33286
I7
sg33295
VP22626
p38163
sg33289
VhnRNPA2
p38164
sa(dp38165
g33284
I52
sg33285
I1
sg33286
I5
sg33295
VP35354
p38166
sg33289
VCOX-2
p38167
sa(dp38168
g33284
I125
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
Vp300
p38169
sasg33281
(lp38170
(dp38171
g33284
I166
sg33285
I1
sg33286
I5
sg33287
VC0007131
p38172
sg33289
VNSCLC
p38173
sasa(dp38174
g33277
VPPARGC1A and PPARGC1B) are key agents in the development and pathophysiology of type 2 diabetes mellitus (T2DM).
p38175
sg33279
(lp38176
(dp38177
g33284
I0
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VPPARGC1A
p38178
sasg33281
(lp38179
(dp38180
g33284
I106
sg33285
I1
sg33286
I4
sg33287
VC0011860
p38181
sg33289
VT2DM
p38182
sa(dp38183
g33284
I80
sg33285
I4
sg33286
I24
sg33287
VC0011860
p38184
sg33289
Vtype 2 diabetes mellitus
p38185
sasa(dp38186
g33277
VFurthermore, eight of the 17 CpG sites reside in genes (FSTL1, SORCS2, NRF1, DLC1, PPARGC1B, CHN2, NXPH1) that have prior known associations with obesity, diabetes, and the insulin pathway.
p38187
sg33279
(lp38188
(dp38189
g33284
I63
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VSORCS2
p38190
sa(dp38191
g33284
I93
sg33285
I1
sg33286
I4
sg33295
VP52757
p38192
sg33289
VCHN2
p38193
sa(dp38194
g33284
I71
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNRF1
p38195
sa(dp38196
g33284
I56
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VFSTL1
p38197
sa(dp38198
g33284
I77
sg33285
I1
sg33286
I4
sg33295
VP63167
p38199
sg33289
VDLC1
p38200
sa(dp38201
g33284
I173
sg33285
I1
sg33286
I7
sg33295
VP01308
p38202
sg33289
Vinsulin
p38203
sa(dp38204
g33284
I99
sg33285
I1
sg33286
I5
sg33295
VP58417
p38205
sg33289
VNXPH1
p38206
sasg33281
(lp38207
(dp38208
g33284
I155
sg33285
I1
sg33286
I8
sg33287
VC0011849
p38209
sg33289
Vdiabetes
p38210
sa(dp38211
g33284
I146
sg33285
I1
sg33286
I7
sg33287
VC0028754
p38212
sg33289
Vobesity
p38213
sasa(dp38214
g33277
VNo significant associations were found, although the top significant CpGs in boys were located in the LRPAP1, HAGH, PPARGC1B, KCNQ1 and KCNQ1DN genes, previously associated to birth weight, Type 2 diabetes, obesity or steroid hormone signaling.
p38215
sg33279
(lp38216
(dp38217
g33284
I136
sg33285
I2
sg33286
I13
sg33295
g11
sg33289
VKCNQ1DN genes
p38218
sa(dp38219
g33284
I126
sg33285
I1
sg33286
I5
sg33295
VP51787
p38220
sg33289
VKCNQ1
p38221
sa(dp38222
g33284
I102
sg33285
I1
sg33286
I6
sg33295
VP30533
p38223
sg33289
VLRPAP1
p38224
sa(dp38225
g33284
I110
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VHAGH
p38226
sasg33281
(lp38227
(dp38228
g33284
I190
sg33285
I3
sg33286
I15
sg33287
VC0011860
p38229
sg33289
VType 2 diabetes
p38230
sa(dp38231
g33284
I207
sg33285
I1
sg33286
I7
sg33287
VC0028754
p38232
sg33289
Vobesity
p38233
sasa(dp38234
g33277
VWe used a two-stage study design to evaluate whether variations in the peroxisome proliferator-activated receptors (PPAR) and the PPAR gamma co-activator 1 (PGC1) gene families (PPARA, PPARG, PPARD, PPARGC1A, and PPARGC1B) are associated with type 2 diabetes (T2D) risk.
p38235
sg33279
(lp38236
(dp38237
g33284
I163
sg33285
I2
sg33286
I13
sg33295
VP19883
p38238
sg33289
Vgene families
p38239
sa(dp38240
g33284
I157
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VPGC1
p38241
sa(dp38242
g33284
I199
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VPPARGC1A
p38243
sa(dp38244
g33284
I116
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VPPAR
p38245
sa(dp38246
g33284
I71
sg33285
I3
sg33286
I43
sg33295
g11
sg33289
Vperoxisome proliferator-activated receptors
p38247
sa(dp38248
g33284
I130
sg33285
I4
sg33286
I25
sg33295
g11
sg33289
VPPAR gamma co-activator 1
p38249
sa(dp38250
g33284
I185
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VPPARG
p38251
sa(dp38252
g33284
I192
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VPPARD
p38253
sa(dp38254
g33284
I178
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VPPARA
p38255
sasg33281
(lp38256
(dp38257
g33284
I260
sg33285
I1
sg33286
I3
sg33287
VC0011860
p38258
sg33289
VT2D
p38259
sa(dp38260
g33284
I243
sg33285
I3
sg33286
I15
sg33287
VC0011860
p38261
sg33289
Vtype 2 diabetes
p38262
sasa(dp38263
g33277
VA recently identified muscular dystrophy gene TOR1AIP1 was detected as a hub gene in dysferlinopathy.
p38264
sg33279
(lp38265
(dp38266
g33284
I73
sg33285
I2
sg33286
I8
sg33295
g11
sg33289
Vhub gene
p38267
sa(dp38268
g33284
I22
sg33285
I4
sg33286
I32
sg33295
VP43034
p38269
sg33289
Vmuscular dystrophy gene TOR1AIP1
p38270
sasg33281
(lp38271
(dp38272
g33284
I22
sg33285
I2
sg33286
I18
sg33287
VC0026850
p38273
sg33289
Vmuscular dystrophy
p38274
sa(dp38275
g33284
I85
sg33285
I1
sg33286
I15
sg33287
VC2931687
p38276
sg33289
Vdysferlinopathy
p38277
sasa(dp38278
g33277
VTorsinA-interacting protein 1 (TOR1AIP1) gene is a novel gene that has recently been described to cause limb-girdle muscular dystrophy (LGMD) with mild dilated cardiomyopathy.
p38279
sg33279
(lp38280
(dp38281
g33284
I0
sg33285
I3
sg33286
I29
sg33295
VP14222
p38282
sg33289
VTorsinA-interacting protein 1
p38283
sasg33281
(lp38284
(dp38285
g33284
I152
sg33285
I2
sg33286
I22
sg33287
VC0007193
p38286
sg33289
Vdilated cardiomyopathy
p38287
sa(dp38288
g33284
I104
sg33285
I3
sg33286
I30
sg33287
VC0686353
p38289
sg33289
Vlimb-girdle muscular dystrophy
p38290
sa(dp38291
g33284
I136
sg33285
I1
sg33286
I4
sg33287
VC0686353
p38292
sg33289
VLGMD
p38293
sasa(dp38294
g33277
VWe report a family with mutations in TOR1AIP1 where the striking clinical feature is severe cardiac failure requiring cardiac transplant in two siblings, in addition to musculoskeletal weakness and muscular dystrophy.
p38295
sg33279
(lp38296
sg33281
(lp38297
(dp38298
g33284
I92
sg33285
I2
sg33286
I15
sg33287
VC0018801
p38299
sg33289
Vcardiac failure
p38300
sa(dp38301
g33284
I198
sg33285
I2
sg33286
I18
sg33287
VC0026850
p38302
sg33289
Vmuscular dystrophy
p38303
sa(dp38304
g33284
I185
sg33285
I1
sg33286
I8
sg33287
VC1883552
p38305
sg33289
Vweakness
p38306
sasa(dp38307
g33277
VThese scientific contributions strengthen the role of LAP1 in DYT1 dystonia and muscular dystrophy.
p38308
sg33279
(lp38309
(dp38310
g33284
I62
sg33285
I2
sg33286
I13
sg33295
g11
sg33289
VDYT1 dystonia
p38311
sa(dp38312
g33284
I54
sg33285
I1
sg33286
I4
sg33295
VP15144
p38313
sg33289
VLAP1
p38314
sasg33281
(lp38315
(dp38316
g33284
I62
sg33285
I1
sg33286
I4
sg33287
VC1851945
p38317
sg33289
VDYT1
p38318
sa(dp38319
g33284
I67
sg33285
I1
sg33286
I8
sg33287
VC0393593
p38320
sg33289
Vdystonia
p38321
sa(dp38322
g33284
I80
sg33285
I2
sg33286
I18
sg33287
VC0026850
p38323
sg33289
Vmuscular dystrophy
p38324
sasa(dp38325
g33277
VMoreover, LAP1 also interacts with torsinA and emerin, proteins involved in DYT1 dystonia and X-linked Emery-Dreifuss muscular dystrophy disorder, respectively.
p38326
sg33279
(lp38327
(dp38328
g33284
I76
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VDYT1
p38329
sa(dp38330
g33284
I47
sg33285
I1
sg33286
I6
sg33295
VP50402
p38331
sg33289
Vemerin
p38332
sa(dp38333
g33284
I35
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VtorsinA
p38334
sa(dp38335
g33284
I10
sg33285
I1
sg33286
I4
sg33295
VP15144
p38336
sg33289
VLAP1
p38337
sasg33281
(lp38338
(dp38339
g33284
I76
sg33285
I1
sg33286
I4
sg33287
VC1851945
p38340
sg33289
VDYT1
p38341
sa(dp38342
g33284
I94
sg33285
I4
sg33286
I42
sg33287
VC0751337
p38343
sg33289
VX-linked Emery-Dreifuss muscular dystrophy
p38344
sa(dp38345
g33284
I81
sg33285
I1
sg33286
I8
sg33287
VC0393593
p38346
sg33289
Vdystonia
p38347
sasa(dp38348
g33277
VDeletions encompassing TAK1-binding protein 2 (TAB2) associated with isolated and syndromic congenital heart defects.
p38349
sg33279
(lp38350
(dp38351
g33284
I23
sg33285
I3
sg33286
I22
sg33295
g11
sg33289
VTAK1-binding protein 2
p38352
sa(dp38353
g33284
I47
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTAB2
p38354
sasg33281
(lp38355
(dp38356
g33284
I92
sg33285
I3
sg33286
I24
sg33287
VC0018798
p38357
sg33289
Vcongenital heart defects
p38358
sasa(dp38359
g33277
VHaploinsufficiency of TAB2 was recently implicated as a cause for a variety of congenital heart defects.
p38360
sg33279
(lp38361
(dp38362
g33284
I22
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTAB2
p38363
sasg33281
(lp38364
(dp38365
g33284
I79
sg33285
I3
sg33286
I24
sg33287
VC0018798
p38366
sg33289
Vcongenital heart defects
p38367
sasa(dp38368
g33277
VThis is the smallest reported deletion involving TAB2 that segregates with congenital heart defects.
p38369
sg33279
(lp38370
(dp38371
g33284
I49
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTAB2
p38372
sasg33281
(lp38373
(dp38374
g33284
I75
sg33285
I3
sg33286
I24
sg33287
VC0018798
p38375
sg33289
Vcongenital heart defects
p38376
sasa(dp38377
g33277
VFindings from this family support a key role of TAB2 haploinsufficiency in congenital heart defects and expand the phenotypic spectrum of TAB2-microdeletion syndrome.
p38378
sg33279
(lp38379
(dp38380
g33284
I48
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTAB2
p38381
sa(dp38382
g33284
I48
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTAB2
p38383
sasg33281
(lp38384
(dp38385
g33284
I157
sg33285
I1
sg33286
I8
sg33287
VC0039082
p38386
sg33289
Vsyndrome
p38387
sa(dp38388
g33284
I75
sg33285
I3
sg33286
I24
sg33287
VC0018798
p38389
sg33289
Vcongenital heart defects
p38390
sasa(dp38391
g33277
VIn addition, the present deletion is the smallest so far recorded in the 6q25 region encompassing eight known genes [vs. 41 of Bisgaard et al., and 23 of Caselli et al.,], including the TAB2 (likely responsible for the girl's congenital heart defect), LATS1 gene, and the UST gene (a regulator of the homeostasis of proteoglycans, which could have played a role in the abnormal dermal and cartilage elasticity).
p38392
sg33279
(lp38393
(dp38394
g33284
I272
sg33285
I2
sg33286
I8
sg33295
g11
sg33289
VUST gene
p38395
sa(dp38396
g33284
I252
sg33285
I2
sg33286
I10
sg33295
g11
sg33289
VLATS1 gene
p38397
sa(dp38398
g33284
I186
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTAB2
p38399
sasg33281
(lp38400
(dp38401
g33284
I226
sg33285
I3
sg33286
I23
sg33287
VC0018798
p38402
sg33289
Vcongenital heart defect
p38403
sasa(dp38404
g33277
VThe isozymes hPAD2 and hPAD4 have been implicated in the development and progression of several autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.
p38405
sg33279
(lp38406
sg33281
(lp38407
(dp38408
g33284
I96
sg33285
I2
sg33286
I19
sg33287
VC0004364
p38409
sg33289
Vautoimmune diseases
p38410
sa(dp38411
g33284
I127
sg33285
I2
sg33286
I20
sg33287
VC0003873
p38412
sg33289
Vrheumatoid arthritis
p38413
sa(dp38414
g33284
I152
sg33285
I2
sg33286
I18
sg33287
VC0026769
p38415
sg33289
Vmultiple sclerosis
p38416
sasa(dp38417
g33277
VProtein arginine deiminase 2 (PAD2) plays a key role in the onset and progression of multiple sclerosis, rheumatoid arthritis, and breast cancer.
p38418
sg33279
(lp38419
(dp38420
g33284
I0
sg33285
I4
sg33286
I28
sg33295
g11
sg33289
VProtein arginine deiminase 2
p38421
sa(dp38422
g33284
I30
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VPAD2
p38423
sasg33281
(lp38424
(dp38425
g33284
I105
sg33285
I2
sg33286
I20
sg33287
VC0003873
p38426
sg33289
Vrheumatoid arthritis
p38427
sa(dp38428
g33284
I131
sg33285
I2
sg33286
I13
sg33287
VC0678222
p38429
sg33289
Vbreast cancer
p38430
sa(dp38431
g33284
I85
sg33285
I2
sg33286
I18
sg33287
VC0026769
p38432
sg33289
Vmultiple sclerosis
p38433
sasa(dp38434
g33277
VThe enzyme peptidylarginine deiminase 2 (PAD2) has been associated with inflammatory diseases, such as rheumatoid arthritis and neurodegenerative diseases including multiple sclerosis.
p38435
sg33279
(lp38436
(dp38437
g33284
I11
sg33285
I3
sg33286
I28
sg33295
g11
sg33289
Vpeptidylarginine deiminase 2
p38438
sa(dp38439
g33284
I41
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VPAD2
p38440
sasg33281
(lp38441
(dp38442
g33284
I103
sg33285
I2
sg33286
I20
sg33287
VC0003873
p38443
sg33289
Vrheumatoid arthritis
p38444
sa(dp38445
g33284
I128
sg33285
I2
sg33286
I26
sg33287
VC0524851
p38446
sg33289
Vneurodegenerative diseases
p38447
sa(dp38448
g33284
I165
sg33285
I2
sg33286
I18
sg33287
VC0026769
p38449
sg33289
Vmultiple sclerosis
p38450
sasa(dp38451
g33277
VPeptidylarginine deiminase 2 (PAD2) and peptidylarginine deiminase 4 (PAD4) are two members of PAD family which are over-expressed in the multiple sclerosis (MS) brain.
p38452
sg33279
(lp38453
(dp38454
g33284
I95
sg33285
I2
sg33286
I10
sg33295
g11
sg33289
VPAD family
p38455
sa(dp38456
g33284
I70
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VPAD4
p38457
sa(dp38458
g33284
I40
sg33285
I3
sg33286
I28
sg33295
g11
sg33289
Vpeptidylarginine deiminase 4
p38459
sa(dp38460
g33284
I0
sg33285
I3
sg33286
I28
sg33295
g11
sg33289
VPeptidylarginine deiminase 2
p38461
sa(dp38462
g33284
I30
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VPAD2
p38463
sasg33281
(lp38464
(dp38465
g33284
I138
sg33285
I2
sg33286
I18
sg33287
VC0026769
p38466
sg33289
Vmultiple sclerosis
p38467
sa(dp38468
g33284
I158
sg33285
I1
sg33286
I2
sg33287
VC0026769
p38469
sg33289
VMS
p38470
sa(dp38471
g33284
I30
sg33285
I1
sg33286
I3
sg33287
VC1704436
p38472
sg33289
VPAD
p38473
sasa(dp38474
g33277
VRecent studies have revealed that abnormal activation of PADI2, the gene for which is expressed throughout the nervous system, is likely to be related to the pathogenesis of neuropsychiatric diseases with neurodegenerative processes, such as Alzheimer's disease and multiple sclerosis.
p38475
sg33279
(lp38476
(dp38477
g33284
I57
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VPADI2
p38478
sasg33281
(lp38479
(dp38480
g33284
I158
sg33285
I1
sg33286
I12
sg33287
VC0699748
p38481
sg33289
Vpathogenesis
p38482
sa(dp38483
g33284
I266
sg33285
I2
sg33286
I18
sg33287
VC0026769
p38484
sg33289
Vmultiple sclerosis
p38485
sa(dp38486
g33284
I111
sg33285
I1
sg33286
I7
sg33287
VC0027769
p38487
sg33289
Vnervous
p38488
sa(dp38489
g33284
I242
sg33285
I2
sg33286
I19
sg33287
VC1521724
p38490
sg33289
VAlzheimer's disease
p38491
sasa(dp38492
g33277
VVEGF-Flt-1 signaling induces osteoclastogenesis in OSCC through two possible ways: 1) VEGF produced from OSCC cells can directly stimulate the Flt-1 pathway in preosteoclasts to induce migration to future bone resorbing area and differentiation into osteoclasts, and 2) VEGF-Flt-1 signaling upregulates RANKL expression in OSCC cells, which indirectly leads to osteoclast differentiation.
p38493
sg33279
(lp38494
(dp38495
g33284
I0
sg33285
I1
sg33286
I10
sg33295
VP17948
p38496
sg33289
VVEGF-Flt-1
p38497
sa(dp38498
g33284
I5
sg33285
I1
sg33286
I5
sg33295
VP17948
p38499
sg33289
VFlt-1
p38500
sa(dp38501
g33284
I303
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VRANKL
p38502
sa(dp38503
g33284
I5
sg33285
I1
sg33286
I5
sg33295
VP17948
p38504
sg33289
VFlt-1
p38505
sasg33281
(lp38506
sa(dp38507
g33277
VThus, the transcriptional targets normally activated by RANKL that promote a proliferative response in luminal progenitors can contribute to the susceptibility of mammary epithelial cells to BRCA1-mutated breast cancers as a consequence of DDR-induced NF-kappaB.
p38508
sg33279
(lp38509
(dp38510
g33284
I191
sg33285
I1
sg33286
I5
sg33295
VP38398
p38511
sg33289
VBRCA1
p38512
sa(dp38513
g33284
I252
sg33285
I1
sg33286
I9
sg33295
VP19838
p38514
sg33289
VNF-kappaB
p38515
sa(dp38516
g33284
I56
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VRANKL
p38517
sasg33281
(lp38518
(dp38519
g33284
I77
sg33285
I1
sg33286
I13
sg33287
VC0334094
p38520
sg33289
Vproliferative
p38521
sa(dp38522
g33284
I205
sg33285
I2
sg33286
I14
sg33287
VC0006142
p38523
sg33289
Vbreast cancers
p38524
sasa(dp38525
g33277
VOur finding provides mechanistic support for a breast cancer chemoprevention trial with a RANKL inhibitor among high-risk premenopausal women with dense breasts.
p38526
sg33279
(lp38527
(dp38528
g33284
I90
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VRANKL
p38529
sasg33281
(lp38530
(dp38531
g33284
I47
sg33285
I2
sg33286
I13
sg33287
VC0678222
p38532
sg33289
Vbreast cancer
p38533
sasa(dp38534
g33277
VThe present study examined the effects of brucine on the OPG/RANKL/RANK signaling pathway for exploring the mechanism of brucine suppression of bone metastasis in breast cancer.
p38535
sg33279
(lp38536
(dp38537
g33284
I61
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VRANKL
p38538
sa(dp38539
g33284
I57
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VOPG
p38540
sasg33281
(lp38541
(dp38542
g33284
I129
sg33285
I1
sg33286
I11
sg33287
VC0221103
p38543
sg33289
Vsuppression
p38544
sa(dp38545
g33284
I163
sg33285
I2
sg33286
I13
sg33287
VC0678222
p38546
sg33289
Vbreast cancer
p38547
sa(dp38548
g33284
I144
sg33285
I2
sg33286
I15
sg33287
VC0153690
p38549
sg33289
Vbone metastasis
p38550
sasa(dp38551
g33277
VIn the present study, we evaluated the clinical usefulness of OPG and sRANKL assessment in bronchoalveolar lavage fluid (BALF) of patients with advanced non-small cell lung cancer (NSCLC).
p38552
sg33279
(lp38553
(dp38554
g33284
I62
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VOPG
p38555
sasg33281
(lp38556
(dp38557
g33284
I181
sg33285
I1
sg33286
I5
sg33287
VC0007131
p38558
sg33289
VNSCLC
p38559
sa(dp38560
g33284
I153
sg33285
I4
sg33286
I26
sg33287
VC0007131
p38561
sg33289
Vnon-small cell lung cancer
p38562
sasa(dp38563
g33277
VWe measured the concentration of OPG and sRANKL in BALF of 44 NSCLC patients and 15 healthy volunteers taken as control subjects.
p38564
sg33279
(lp38565
(dp38566
g33284
I33
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VOPG
p38567
sasg33281
(lp38568
(dp38569
g33284
I62
sg33285
I1
sg33286
I5
sg33287
VC0007131
p38570
sg33289
VNSCLC
p38571
sasa(dp38572
g33277
VThere were no significant differences in sRANKL content between the NSCLC and control groups [1.22 (0.74-23.00) vs. 1.12 (0.79-4.39) pmol/l; p = 0.67].
p38573
sg33279
(lp38574
sg33281
(lp38575
(dp38576
g33284
I68
sg33285
I1
sg33286
I5
sg33287
VC0007131
p38577
sg33289
VNSCLC
p38578
sasa(dp38579
g33277
VHowever, we found that the greater the level of sRANKL in NSCLC patients, the shorter the overall survival.
p38580
sg33279
(lp38581
sg33281
(lp38582
(dp38583
g33284
I58
sg33285
I1
sg33286
I5
sg33287
VC0007131
p38584
sg33289
VNSCLC
p38585
sasa(dp38586
g33277
VWe found a correlation between the content of sRANKL and the percentage of lymphocytes in BALF of NSCLC patients (r = 0.52; p = 0.041).
p38587
sg33279
(lp38588
sg33281
(lp38589
(dp38590
g33284
I98
sg33285
I1
sg33286
I5
sg33287
VC0007131
p38591
sg33289
VNSCLC
p38592
sasa(dp38593
g33277
VA high level of sRANKL in BALF of NSCLC patients may predict worse survival.
p38594
sg33279
(lp38595
sg33281
(lp38596
(dp38597
g33284
I34
sg33285
I1
sg33286
I5
sg33287
VC0007131
p38598
sg33289
VNSCLC
p38599
sasa(dp38600
g33277
VThe goal of our study was to assess the prognostic impact of the necroptosis relative protein RIPK1 genetic polymorphism in ischemia-reperfusion injury and survival after hepatectomy in hepatocellular carcinoma (HCC) patients.
p38601
sg33279
(lp38602
(dp38603
g33284
I94
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VRIPK1
p38604
sasg33281
(lp38605
(dp38606
g33284
I212
sg33285
I1
sg33286
I3
sg33287
VC2239176
p38607
sg33289
VHCC
p38608
sa(dp38609
g33284
I186
sg33285
I2
sg33286
I24
sg33287
VC2239176
p38610
sg33289
Vhepatocellular carcinoma
p38611
sa(dp38612
g33284
I124
sg33285
I1
sg33286
I8
sg33287
VC0022116
p38613
sg33289
Vischemia
p38614
sa(dp38615
g33284
I65
sg33285
I1
sg33286
I11
sg33287
VC2610958
p38616
sg33289
Vnecroptosis
p38617
sasa(dp38618
g33277
VHere, we discuss our recent data on RIPK1 in liver injury and hepatocellular carcinoma development and put these into relation to previous experimental findings to underpin that it exerts opposing kinase-dependent and kinase independent functions in liver cells.
p38619
sg33279
(lp38620
(dp38621
g33284
I36
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VRIPK1
p38622
sasg33281
(lp38623
(dp38624
g33284
I62
sg33285
I2
sg33286
I24
sg33287
VC1512411
p38625
sg33289
Vhepatocellular carcinoma
p38626
sasa(dp38627
g33277
VMoreover, loss of both Ripk1 and Traf2 in LPC not only resulted in caspase-8 hyperactivation but also impaired NF-KB activation, promoting the spontaneous development of hepatocellular carcinoma.
p38628
sg33279
(lp38629
(dp38630
g33284
I23
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VRipk1
p38631
sa(dp38632
g33284
I33
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTraf2
p38633
sa(dp38634
g33284
I67
sg33285
I1
sg33286
I9
sg33295
VP39880
p38635
sg33289
Vcaspase-8
p38636
sasg33281
(lp38637
(dp38638
g33284
I170
sg33285
I2
sg33286
I24
sg33287
VC1512411
p38639
sg33289
Vhepatocellular carcinoma
p38640
sa(dp38641
g33284
I102
sg33285
I1
sg33286
I8
sg33287
VC0684336
p38642
sg33289
Vimpaired
p38643
sasa(dp38644
g33277
VThe single-stranded DNA cytidine deaminases APOBEC3B, APOBEC3H haplotype I, and APOBEC3A can contribute to cancer through deamination of cytosine to form promutagenic uracil in genomic DNA.
p38645
sg33279
(lp38646
(dp38647
g33284
I54
sg33285
I3
sg33286
I20
sg33295
g11
sg33289
VAPOBEC3H haplotype I
p38648
sa(dp38649
g33284
I44
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VAPOBEC3B
p38650
sa(dp38651
g33284
I80
sg33285
I1
sg33286
I8
sg33295
VP31941
p38652
sg33289
VAPOBEC3A
p38653
sa(dp38654
g33284
I4
sg33285
I4
sg33286
I39
sg33295
VP32320
p38655
sg33289
Vsingle-stranded DNA cytidine deaminases
p38656
sasg33281
(lp38657
(dp38658
g33284
I107
sg33285
I1
sg33286
I6
sg33287
VC0006826
p38659
sg33289
Vcancer
p38660
sasa(dp38661
g33277
VTo study this, we developed a method to purify full length APOBEC3B and characterized it in comparison to APOBEC3A and APOBEC3H on substrates relevant to cancer mutagenesis.
p38662
sg33279
(lp38663
(dp38664
g33284
I106
sg33285
I1
sg33286
I8
sg33295
VP31941
p38665
sg33289
VAPOBEC3A
p38666
sa(dp38667
g33284
I119
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VAPOBEC3H
p38668
sasg33281
(lp38669
(dp38670
g33284
I154
sg33285
I1
sg33286
I6
sg33287
VC0006826
p38671
sg33289
Vcancer
p38672
sasa(dp38673
g33277
VA3H-I also associates with clonal TCA/T-biased mutations in lung adenocarcinoma suggesting this enzyme makes broader contributions to cancer mutagenesis.
p38674
sg33279
(lp38675
sg33281
(lp38676
(dp38677
g33284
I134
sg33285
I1
sg33286
I6
sg33287
VC0006826
p38678
sg33289
Vcancer
p38679
sa(dp38680
g33284
I60
sg33285
I2
sg33286
I19
sg33287
VC0152013
p38681
sg33289
Vlung adenocarcinoma
p38682
sasa(dp38683
g33277
VThese studies combine to suggest that A3B and A3H-I, together, explain the bulk of 'APOBEC signature' mutations in cancer.
p38684
sg33279
(lp38685
(dp38686
g33284
I38
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VA3B
p38687
sasg33281
(lp38688
(dp38689
g33284
I115
sg33285
I1
sg33286
I6
sg33287
VC0006826
p38690
sg33289
Vcancer
p38691
sasa(dp38692
g33277
VTCGA data analyses revealed that expression of APOBEC3D and APOBEC3H also correlates with CD3D across multiple cancer types.
p38693
sg33279
(lp38694
(dp38695
g33284
I90
sg33285
I1
sg33286
I4
sg33295
VP04234
p38696
sg33289
VCD3D
p38697
sa(dp38698
g33284
I60
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VAPOBEC3H
p38699
sa(dp38700
g33284
I47
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VAPOBEC3D
p38701
sasg33281
(lp38702
(dp38703
g33284
I102
sg33285
I2
sg33286
I15
sg33287
VC0346429
p38704
sg33289
Vmultiple cancer
p38705
sasa(dp38706
g33277
VWe found that the T allele of rs139293 in exon 2 of APOBEC3H was significantly associated with decreased risk of lung cancer (odds ratio = 0.76, 95% confidence interval: 0.63-0.91).
p38707
sg33279
(lp38708
(dp38709
g33284
I52
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VAPOBEC3H
p38710
sasg33281
(lp38711
(dp38712
g33284
I113
sg33285
I2
sg33286
I11
sg33287
VC0684249
p38713
sg33289
Vlung cancer
p38714
sasa(dp38715
g33277
VThese results indicate that genetic variants in APOBEC3H may contribute to lung cancer susceptibility in Chinese population.
p38716
sg33279
(lp38717
(dp38718
g33284
I48
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VAPOBEC3H
p38719
sasg33281
(lp38720
(dp38721
g33284
I75
sg33285
I2
sg33286
I11
sg33287
VC0684249
p38722
sg33289
Vlung cancer
p38723
sasa(dp38724
g33277
VA 56-year-old male with cirrhosis presented with acute bleeding from cardiofundal gastroesophageal varices (GOV) and was treated with endoscopic cyanoacrylate glue.
p38725
sg33279
(lp38726
sg33281
(lp38727
(dp38728
g33284
I24
sg33285
I1
sg33286
I9
sg33287
VC0023890
p38729
sg33289
Vcirrhosis
p38730
sa(dp38731
g33284
I82
sg33285
I2
sg33286
I24
sg33287
VC2609266
p38732
sg33289
Vgastroesophageal varices
p38733
sa(dp38734
g33284
I108
sg33285
I1
sg33286
I3
sg33287
VC2609266
p38735
sg33289
VGOV
p38736
sa(dp38737
g33284
I49
sg33285
I2
sg33286
I14
sg33287
VC0333276
p38738
sg33289
Vacute bleeding
p38739
sasa(dp38740
g33277
VAt that time, he underwent retreatment with balloon-occluded retrograde obliteration (BRTO), with no recurrence at a follow-up of 14 months.Available treatments for bleeding GOV include methods to (a) directly obstruct the varices (endoscopic variceal ligation , sclerotherapy and cyanoacrylate glue, BRTO) or to (b) decrease portal pressure (surgical portacaval shunts; transportal intrahepatic portosystemic shunt).
p38741
sg33279
(lp38742
sg33281
(lp38743
(dp38744
g33284
I101
sg33285
I1
sg33286
I10
sg33287
VC1458156
p38745
sg33289
Vrecurrence
p38746
sa(dp38747
g33284
I165
sg33285
I1
sg33286
I8
sg33287
VC0019080
p38748
sg33289
Vbleeding
p38749
sa(dp38750
g33284
I52
sg33285
I1
sg33286
I8
sg33287
VC0028778
p38751
sg33289
Voccluded
p38752
sa(dp38753
g33284
I223
sg33285
I1
sg33286
I7
sg33287
VC0042345
p38754
sg33289
Vvarices
p38755
sasa(dp38756
g33277
VGastroesophageal varices (GOV) is a common complication in patients with portal hypertension.
p38757
sg33279
(lp38758
sg33281
(lp38759
(dp38760
g33284
I73
sg33285
I2
sg33286
I19
sg33287
VC0020541
p38761
sg33289
Vportal hypertension
p38762
sa(dp38763
g33284
I0
sg33285
I2
sg33286
I24
sg33287
VC2609266
p38764
sg33289
VGastroesophageal varices
p38765
sa(dp38766
g33284
I26
sg33285
I1
sg33286
I3
sg33287
VC2609266
p38767
sg33289
VGOV
p38768
sa(dp38769
g33284
I43
sg33285
I1
sg33286
I12
sg33287
VC0009566
p38770
sg33289
Vcomplication
p38771
sasa(dp38772
g33277
VGastric varices were categorized as GOV-1 (3%), GOV-2 (61%), and isolated gastric varices type 1 (36%) per Sarin classification.
p38773
sg33279
(lp38774
sg33281
(lp38775
(dp38776
g33284
I74
sg33285
I2
sg33286
I15
sg33287
VC0017145
p38777
sg33289
Vgastric varices
p38778
sa(dp38779
g33284
I0
sg33285
I2
sg33286
I15
sg33287
VC0017145
p38780
sg33289
VGastric varices
p38781
sasa(dp38782
g33277
VOf the 9 children with associated gastroeosophageal varices (GOV), the severity of lesions was reduced in 8 of them.
p38783
sg33279
(lp38784
sg33281
(lp38785
(dp38786
g33284
I52
sg33285
I1
sg33286
I7
sg33287
VC0042345
p38787
sg33289
Vvarices
p38788
sasa(dp38789
g33277
VHere, we address the contribution of the EP3 receptor in dictating early outcomes after transient cerebral ischemia.
p38790
sg33279
(lp38791
(dp38792
g33284
I41
sg33285
I2
sg33286
I12
sg33295
VP43115
p38793
sg33289
VEP3 receptor
p38794
sasg33281
(lp38795
(dp38796
g33284
I88
sg33285
I3
sg33286
I27
sg33287
VC0917805
p38797
sg33289
Vtransient cerebral ischemia
p38798
sasa(dp38799
g33277
VFollowing S1, separate scalp recordings in 4 patients in the epilepsy group displayed EP 3 times in the 'over 300 ms' time window.
p38800
sg33279
(lp38801
sg33281
(lp38802
(dp38803
g33284
I61
sg33285
I1
sg33286
I8
sg33287
VC0014544
p38804
sg33289
Vepilepsy
p38805
sasa(dp38806
g33277
VConversely, patients with endometriosis had significantly shortened activated partial thromboplastin time (APTT) when compared to controls (1.08 +/- 0.06 and 1.12 +/- 0.19, respectively; P &lt; .01).
p38807
sg33279
(lp38808
(dp38809
g33284
I86
sg33285
I1
sg33286
I14
sg33295
VP13726
p38810
sg33289
Vthromboplastin
p38811
sasg33281
(lp38812
(dp38813
g33284
I26
sg33285
I1
sg33286
I13
sg33287
VC0014175
p38814
sg33289
Vendometriosis
p38815
sasa(dp38816
g33277
VActivated partial thromboplastin time is shorter in women with endometriosis but still in the normal range.
p38817
sg33279
(lp38818
(dp38819
g33284
I18
sg33285
I1
sg33286
I14
sg33295
VP13726
p38820
sg33289
Vthromboplastin
p38821
sasg33281
(lp38822
(dp38823
g33284
I63
sg33285
I1
sg33286
I13
sg33287
VC0014175
p38824
sg33289
Vendometriosis
p38825
sasa(dp38826
g33277
VAre the levels of total circulating cell-derived microparticles (cMPs) and circulating tissue factor-containing microparticles (cMP-TF) increased in patients with endometriosis?
p38827
sg33279
(lp38828
(dp38829
g33284
I128
sg33285
I1
sg33286
I6
sg33295
VP21941
p38830
sg33289
VcMP-TF
p38831
sasg33281
(lp38832
(dp38833
g33284
I163
sg33285
I1
sg33286
I13
sg33287
VC0014175
p38834
sg33289
Vendometriosis
p38835
sasa(dp38836
g33277
VIncreased expression of tissue factor (a transmembrane receptor for Factor VII/VIIa) in eutopic and ectopic endometrium from patients with endometriosis has been described.
p38837
sg33279
(lp38838
(dp38839
g33284
I68
sg33285
I2
sg33286
I15
sg33295
VP08709
p38840
sg33289
VFactor VII/VIIa
p38841
sasg33281
(lp38842
(dp38843
g33284
I139
sg33285
I1
sg33286
I13
sg33287
VC0014175
p38844
sg33289
Vendometriosis
p38845
sasa(dp38846
g33277
VTissue factor (TF) expression was elevated in endometriosis and TF concentrations were significantly elevated both in the supernatant of cultured primary endometriotic stromal cells and in peritoneal fluid from women with endometriosis.
p38847
sg33279
(lp38848
sg33281
(lp38849
(dp38850
g33284
I46
sg33285
I1
sg33286
I13
sg33287
VC0014175
p38851
sg33289
Vendometriosis
p38852
sa(dp38853
g33284
I46
sg33285
I1
sg33286
I13
sg33287
VC0014175
p38854
sg33289
Vendometriosis
p38855
sasa(dp38856
g33277
VHere, we first determined the value of ALCAM as a marker of recurrence in endometrioid endometrial cancer by conducting a retrospective multicentre study of 174 primary tumours.
p38857
sg33279
(lp38858
(dp38859
g33284
I39
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VALCAM
p38860
sasg33281
(lp38861
(dp38862
g33284
I169
sg33285
I1
sg33286
I7
sg33287
VC0027651
p38863
sg33289
Vtumours
p38864
sa(dp38865
g33284
I60
sg33285
I1
sg33286
I10
sg33287
VC1458156
p38866
sg33289
Vrecurrence
p38867
sa(dp38868
g33284
I87
sg33285
I2
sg33286
I18
sg33287
VC0476089
p38869
sg33289
Vendometrial cancer
p38870
sasa(dp38871
g33277
VThen we demonstrated in vitro a role for ALCAM in cell migration and invasion by using a loss-of-function model in two endometrial cancer cell lines.
p38872
sg33279
(lp38873
(dp38874
g33284
I41
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VALCAM
p38875
sasg33281
(lp38876
(dp38877
g33284
I69
sg33285
I1
sg33286
I8
sg33287
VC2699153
p38878
sg33289
Vinvasion
p38879
sa(dp38880
g33284
I119
sg33285
I2
sg33286
I18
sg33287
VC0476089
p38881
sg33289
Vendometrial cancer
p38882
sasa(dp38883
g33277
VIn conclusion, our results highlight the potential of ALCAM as a recurrent biomarker in early-stage endometrioid endometrial cancer and point to ALCAM as an important molecule in endometrial cancer dissemination by regulating cell migration, invasion, and metastasis.
p38884
sg33279
(lp38885
(dp38886
g33284
I54
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VALCAM
p38887
sasg33281
(lp38888
(dp38889
g33284
I113
sg33285
I2
sg33286
I18
sg33287
VC0476089
p38890
sg33289
Vendometrial cancer
p38891
sa(dp38892
g33284
I242
sg33285
I1
sg33286
I8
sg33287
VC2699153
p38893
sg33289
Vinvasion
p38894
sa(dp38895
g33284
I256
sg33285
I1
sg33286
I10
sg33287
VC0027627
p38896
sg33289
Vmetastasis
p38897
sa(dp38898
g33284
I113
sg33285
I2
sg33286
I18
sg33287
VC0476089
p38899
sg33289
Vendometrial cancer
p38900
sasa(dp38901
g33277
VOverexpressing miR-378 in ovarian cancer cells altered expression of genes associated with angiogenesis (ALCAM, EHD1, ELK3, TLN1), apoptosis (RPN2, HIPK3), and cell cycle regulation (SWAP-70, LSM14A, RDX).
p38902
sg33279
(lp38903
(dp38904
g33284
I148
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VHIPK3
p38905
sa(dp38906
g33284
I15
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VmiR-378
p38907
sa(dp38908
g33284
I105
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VALCAM
p38909
sa(dp38910
g33284
I192
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VLSM14A
p38911
sa(dp38912
g33284
I142
sg33285
I1
sg33286
I4
sg33295
VP04844
p38913
sg33289
VRPN2
p38914
sa(dp38915
g33284
I200
sg33285
I1
sg33286
I3
sg33295
VP35241
p38916
sg33289
VRDX
p38917
sa(dp38918
g33284
I183
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VSWAP-70
p38919
sa(dp38920
g33284
I118
sg33285
I1
sg33286
I4
sg33295
VP41970
p38921
sg33289
VELK3
p38922
sa(dp38923
g33284
I124
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTLN1
p38924
sa(dp38925
g33284
I112
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VEHD1
p38926
sasg33281
(lp38927
(dp38928
g33284
I26
sg33285
I2
sg33286
I14
sg33287
VC1140680
p38929
sg33289
Vovarian cancer
p38930
sasa(dp38931
g33277
VActivated leukocyte cell adhesion molecule (ALCAM) is expressed at the surface of epithelial ovarian cancer (EOC) cells and is released in a soluble form (sALCAM) by ADAM-17-mediated shedding.
p38932
sg33279
(lp38933
(dp38934
g33284
I44
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VALCAM
p38935
sa(dp38936
g33284
I166
sg33285
I1
sg33286
I7
sg33295
VP78536
p38937
sg33289
VADAM-17
p38938
sa(dp38939
g33284
I0
sg33285
I5
sg33286
I42
sg33295
g11
sg33289
VActivated leukocyte cell adhesion molecule
p38940
sasg33281
(lp38941
(dp38942
g33284
I109
sg33285
I1
sg33286
I3
sg33287
VC0677886
p38943
sg33289
VEOC
p38944
sa(dp38945
g33284
I25
sg33285
I1
sg33286
I8
sg33287
VC0001511
p38946
sg33289
Vadhesion
p38947
sa(dp38948
g33284
I82
sg33285
I3
sg33286
I25
sg33287
VC0677886
p38949
sg33289
Vepithelial ovarian cancer
p38950
sasa(dp38951
g33277
VHere, we show that serum sALCAM levels were significantly higher in epithelial ovarian cancer (EOC) (p &lt; 0.005) than in controls.
p38952
sg33279
(lp38953
(dp38954
g33284
I19
sg33285
I2
sg33286
I12
sg33295
g11
sg33289
Vserum sALCAM
p38955
sasg33281
(lp38956
(dp38957
g33284
I95
sg33285
I1
sg33286
I3
sg33287
VC0677886
p38958
sg33289
VEOC
p38959
sa(dp38960
g33284
I68
sg33285
I3
sg33286
I25
sg33287
VC0677886
p38961
sg33289
Vepithelial ovarian cancer
p38962
sasa(dp38963
g33277
VTo date there are no data on the role of ALCAM in cervical cancer available.
p38964
sg33279
(lp38965
(dp38966
g33284
I41
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VALCAM
p38967
sasg33281
(lp38968
(dp38969
g33284
I50
sg33285
I2
sg33286
I15
sg33287
VC0302592
p38970
sg33289
Vcervical cancer
p38971
sasa(dp38972
g33277
VIn this study, ALCAM expression was analysed by immunohistochemistry (IHC) in tissue samples of 233 patients with cervical cancer, among them 178 with complete follow-up information.
p38973
sg33279
(lp38974
sg33281
(lp38975
(dp38976
g33284
I114
sg33285
I2
sg33286
I15
sg33287
VC0302592
p38977
sg33289
Vcervical cancer
p38978
sasa(dp38979
g33277
VALCAM overexpression was detected (immunoreactive score (IRS) 2-12) in 58.4% of the cervical cancer samples.
p38980
sg33279
(lp38981
(dp38982
g33284
I0
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VALCAM
p38983
sasg33281
(lp38984
(dp38985
g33284
I84
sg33285
I2
sg33286
I15
sg33287
VC0302592
p38986
sg33289
Vcervical cancer
p38987
sasa(dp38988
g33277
VESs and USTSs were further separated by CD166 staining, wherein increased expression was associated with ES (P &lt; 0.0001).
p38989
sg33279
(lp38990
(dp38991
g33284
I40
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCD166
p38992
sasg33281
(lp38993
sa(dp38994
g33277
VUSP22 is one of the important targets for inhibiting tumor growth, but clear illustration regarding its effects of telomerase, tumor cell immortality and retinoblastoma cell aging or apoptosis via suppressing TERT/P53 signal pathway remains to be elusive.
p38995
sg33279
(lp38996
(dp38997
g33284
I209
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTERT
p38998
sa(dp38999
g33284
I0
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP22
p39000
sa(dp39001
g33284
I214
sg33285
I1
sg33286
I3
sg33295
VP42771
p39002
sg33289
VP53
p39003
sasg33281
(lp39004
(dp39005
g33284
I53
sg33285
I1
sg33286
I5
sg33287
VC0027651
p39006
sg33289
Vtumor
p39007
sa(dp39008
g33284
I154
sg33285
I1
sg33286
I14
sg33287
VC0035335
p39009
sg33289
Vretinoblastoma
p39010
sa(dp39011
g33284
I53
sg33285
I2
sg33286
I12
sg33287
VC0598934
p39012
sg33289
Vtumor growth
p39013
sasa(dp39014
g33277
VUSP22 played an important role in retinoblastoma cell proliferation/aging and apoptosis.
p39015
sg33279
(lp39016
(dp39017
g33284
I0
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP22
p39018
sasg33281
(lp39019
(dp39020
g33284
I34
sg33285
I1
sg33286
I14
sg33287
VC0035335
p39021
sg33289
Vretinoblastoma
p39022
sa(dp39023
g33284
I54
sg33285
I1
sg33286
I13
sg33287
VC0334094
p39024
sg33289
Vproliferation
p39025
sasa(dp39026
g33277
VThe reduction of USP22 expression facilitated human retinoblastoma cell aging or apoptosis via suppressing TERT/P53 signal pathway.
p39027
sg33279
(lp39028
(dp39029
g33284
I17
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP22
p39030
sa(dp39031
g33284
I112
sg33285
I1
sg33286
I3
sg33295
VP42771
p39032
sg33289
VP53
p39033
sa(dp39034
g33284
I107
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTERT
p39035
sasg33281
(lp39036
(dp39037
g33284
I52
sg33285
I1
sg33286
I14
sg33287
VC0035335
p39038
sg33289
Vretinoblastoma
p39039
sasa(dp39040
g33277
VUSP22, thus, may work as a target for treating retinoblastoma.
p39041
sg33279
(lp39042
(dp39043
g33284
I0
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP22
p39044
sasg33281
(lp39045
(dp39046
g33284
I47
sg33285
I1
sg33286
I14
sg33287
VC0035335
p39047
sg33289
Vretinoblastoma
p39048
sasa(dp39049
g33277
VThe present study aimed to investigate the correlation of ubiquitin-specific peptidase 22 (USP22) with acquired resistance to cisplatin in lung adenocarcinoma.
p39050
sg33279
(lp39051
(dp39052
g33284
I58
sg33285
I3
sg33286
I31
sg33295
VP62979
p39053
sg33289
Vubiquitin-specific peptidase 22
p39054
sa(dp39055
g33284
I91
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP22
p39056
sasg33281
(lp39057
(dp39058
g33284
I139
sg33285
I2
sg33286
I19
sg33287
VC0152013
p39059
sg33289
Vlung adenocarcinoma
p39060
sasa(dp39061
g33277
VUSP22 is a potential target in cisplatin-resistant lung adenocarcinoma and should be considered in future therapeutic practice.
p39062
sg33279
(lp39063
(dp39064
g33284
I0
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP22
p39065
sasg33281
(lp39066
(dp39067
g33284
I51
sg33285
I2
sg33286
I19
sg33287
VC0152013
p39068
sg33289
Vlung adenocarcinoma
p39069
sasa(dp39070
g33277
VUbiquitin specific peptidase 22 (USP22), a putative cancer stem cell marker, is overexpressed in liver metastases of colorectal cancer (CRC).
p39071
sg33279
(lp39072
(dp39073
g33284
I0
sg33285
I4
sg33286
I31
sg33295
g11
sg33289
VUbiquitin specific peptidase 22
p39074
sa(dp39075
g33284
I33
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP22
p39076
sasg33281
(lp39077
(dp39078
g33284
I52
sg33285
I1
sg33286
I6
sg33287
VC0006826
p39079
sg33289
Vcancer
p39080
sa(dp39081
g33284
I97
sg33285
I2
sg33286
I16
sg33287
VC0494165
p39082
sg33289
Vliver metastases
p39083
sa(dp39084
g33284
I136
sg33285
I1
sg33286
I3
sg33287
VC1527249
p39085
sg33289
VCRC
p39086
sa(dp39087
g33284
I117
sg33285
I2
sg33286
I17
sg33287
VC1527249
p39088
sg33289
Vcolorectal cancer
p39089
sasa(dp39090
g33277
VIn this study, we explored the functional role of USP22 in modulating c-Myc stability and its physiological relevance in breast cancer progression.
p39091
sg33279
(lp39092
(dp39093
g33284
I70
sg33285
I1
sg33286
I5
sg33295
VP12524
p39094
sg33289
Vc-Myc
p39095
sa(dp39096
g33284
I50
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP22
p39097
sasg33281
(lp39098
(dp39099
g33284
I128
sg33285
I2
sg33286
I18
sg33287
VC0178874
p39100
sg33289
Vcancer progression
p39101
sasa(dp39102
g33277
VWe found that USP22 promotes deubiquitination of c-Myc in several breast cancer cell lines, resulting in increased levels of c-Myc.
p39103
sg33279
(lp39104
(dp39105
g33284
I49
sg33285
I1
sg33286
I5
sg33295
VP12524
p39106
sg33289
Vc-Myc
p39107
sa(dp39108
g33284
I14
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP22
p39109
sa(dp39110
g33284
I49
sg33285
I1
sg33286
I5
sg33295
VP12524
p39111
sg33289
Vc-Myc
p39112
sasg33281
(lp39113
(dp39114
g33284
I66
sg33285
I2
sg33286
I13
sg33287
VC0678222
p39115
sg33289
Vbreast cancer
p39116
sasa(dp39117
g33277
VFurthermore, overexpression of USP22 stimulates breast cancer cell growth and colony formation, and increases c-Myc tumorigenic activity.
p39118
sg33279
(lp39119
(dp39120
g33284
I110
sg33285
I1
sg33286
I5
sg33295
VP12524
p39121
sg33289
Vc-Myc
p39122
sa(dp39123
g33284
I31
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP22
p39124
sasg33281
(lp39125
(dp39126
g33284
I55
sg33285
I3
sg33286
I18
sg33287
VC1516170
p39127
sg33289
Vcancer cell growth
p39128
sasa(dp39129
g33277
VIn conclusion, the present study reveals that USP22 in breast cancer cell lines increases c-Myc stability through c-Myc deubiquitination, which is closely correlated with breast cancer progression.
p39130
sg33279
(lp39131
(dp39132
g33284
I90
sg33285
I1
sg33286
I5
sg33295
VP12524
p39133
sg33289
Vc-Myc
p39134
sa(dp39135
g33284
I90
sg33285
I1
sg33286
I5
sg33295
VP12524
p39136
sg33289
Vc-Myc
p39137
sa(dp39138
g33284
I46
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP22
p39139
sasg33281
(lp39140
(dp39141
g33284
I178
sg33285
I2
sg33286
I18
sg33287
VC0178874
p39142
sg33289
Vcancer progression
p39143
sa(dp39144
g33284
I55
sg33285
I2
sg33286
I13
sg33287
VC0678222
p39145
sg33289
Vbreast cancer
p39146
sasa(dp39147
g33277
VIn this study, we investigated the effects of the deubiquitinating enzyme USP22 on the expression of the drug-resistance genes BMI1 and EZH2 in hepatocellular carcinoma (HCC) and on prognosis.
p39148
sg33279
(lp39149
(dp39150
g33284
I136
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VEZH2
p39151
sa(dp39152
g33284
I74
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP22
p39153
sa(dp39154
g33284
I127
sg33285
I1
sg33286
I4
sg33295
VP35226
p39155
sg33289
VBMI1
p39156
sasg33281
(lp39157
(dp39158
g33284
I170
sg33285
I1
sg33286
I3
sg33287
VC2239176
p39159
sg33289
VHCC
p39160
sa(dp39161
g33284
I144
sg33285
I2
sg33286
I24
sg33287
VC2239176
p39162
sg33289
Vhepatocellular carcinoma
p39163
sasa(dp39164
g33277
VUbiquitin-specific protease 22 (USP22) aberrance has been implicated in several malignancies; however, whether USP22 plays a role in anaplastic thyroid carcinoma (ATC) remains unclear.
p39165
sg33279
(lp39166
(dp39167
g33284
I0
sg33285
I3
sg33286
I30
sg33295
g11
sg33289
VUbiquitin-specific protease 22
p39168
sa(dp39169
g33284
I32
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP22
p39170
sa(dp39171
g33284
I32
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP22
p39172
sasg33281
(lp39173
(dp39174
g33284
I80
sg33285
I1
sg33286
I12
sg33287
VC0006826
p39175
sg33289
Vmalignancies
p39176
sa(dp39177
g33284
I163
sg33285
I1
sg33286
I3
sg33287
VC0238461
p39178
sg33289
VATC
p39179
sa(dp39180
g33284
I133
sg33285
I3
sg33286
I28
sg33287
VC0238461
p39181
sg33289
Vanaplastic thyroid carcinoma
p39182
sasa(dp39183
g33277
VCurcumin might have therapeutic potential in breast cancer through regulating breast cancer-related genes, including SERPINE1, PGAP3, MAP3K1, MAPK1, GSTO2, VIM, SPARC, and FGF2.
p39184
sg33279
(lp39185
(dp39186
g33284
I161
sg33285
I1
sg33286
I5
sg33295
VP09486
p39187
sg33289
VSPARC
p39188
sa(dp39189
g33284
I142
sg33285
I1
sg33286
I5
sg33295
VP28482
p39190
sg33289
VMAPK1
p39191
sa(dp39192
g33284
I134
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VMAP3K1
p39193
sa(dp39194
g33284
I78
sg33285
I3
sg33286
I27
sg33295
VP01893
p39195
sg33289
Vbreast cancer-related genes
p39196
sa(dp39197
g33284
I117
sg33285
I1
sg33286
I8
sg33295
VP05121
p39198
sg33289
VSERPINE1
p39199
sa(dp39200
g33284
I149
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VGSTO2
p39201
sa(dp39202
g33284
I127
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VPGAP3
p39203
sa(dp39204
g33284
I172
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VFGF2
p39205
sasg33281
(lp39206
(dp39207
g33284
I45
sg33285
I2
sg33286
I13
sg33287
VC0678222
p39208
sg33289
Vbreast cancer
p39209
sa(dp39210
g33284
I45
sg33285
I2
sg33286
I13
sg33287
VC0678222
p39211
sg33289
Vbreast cancer
p39212
sasa(dp39213
g33277
VOur data showed that the level of CENPE, BAG2, SOD2, GDI2, CORO1C, CFL1, DSTN, CALD1, PHGDH, PDHA1, AKR1B1, TST and TBCA proteins were significantly up-regulated in the fibroblasts co-cultured with ovarian cancer cells, whereas HSPB1, P4HB and VIM were significantly down-regulated.
p39214
sg33279
(lp39215
(dp39216
g33284
I93
sg33285
I1
sg33286
I5
sg33295
VP08559
p39217
sg33289
VPDHA1
p39218
sa(dp39219
g33284
I100
sg33285
I1
sg33286
I6
sg33295
VP15121
p39220
sg33289
VAKR1B1
p39221
sa(dp39222
g33284
I79
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCALD1
p39223
sa(dp39224
g33284
I67
sg33285
I1
sg33286
I4
sg33295
VP23528
p39225
sg33289
VCFL1
p39226
sa(dp39227
g33284
I59
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VCORO1C
p39228
sa(dp39229
g33284
I116
sg33285
I2
sg33286
I13
sg33295
g11
sg33289
VTBCA proteins
p39230
sa(dp39231
g33284
I73
sg33285
I1
sg33286
I4
sg33295
VP60981
p39232
sg33289
VDSTN
p39233
sa(dp39234
g33284
I47
sg33285
I1
sg33286
I4
sg33295
VP04179
p39235
sg33289
VSOD2
p39236
sa(dp39237
g33284
I53
sg33285
I1
sg33286
I4
sg33295
VP50395
p39238
sg33289
VGDI2
p39239
sa(dp39240
g33284
I235
sg33285
I1
sg33286
I4
sg33295
VP07237
p39241
sg33289
VP4HB
p39242
sa(dp39243
g33284
I108
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VTST
p39244
sa(dp39245
g33284
I41
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VBAG2
p39246
sa(dp39247
g33284
I86
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VPHGDH
p39248
sa(dp39249
g33284
I34
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCENPE
p39250
sasg33281
(lp39251
(dp39252
g33284
I198
sg33285
I2
sg33286
I14
sg33287
VC1140680
p39253
sg33289
Vovarian cancer
p39254
sasa(dp39255
g33277
VPreviously, using systems biology approach and cancer signaling networks, we identified top-5 highly expressed and connected proteins (HSP90AB1, CSNK2B, TK1, YWHAB and VIM) in the invasive MDA-MB-231 breast cancer cell line.
p39256
sg33279
(lp39257
(dp39258
g33284
I158
sg33285
I1
sg33286
I5
sg33295
VP31946
p39259
sg33289
VYWHAB
p39260
sa(dp39261
g33284
I135
sg33285
I1
sg33286
I8
sg33295
VP08238
p39262
sg33289
VHSP90AB1
p39263
sa(dp39264
g33284
I153
sg33285
I1
sg33286
I3
sg33295
VP04183
p39265
sg33289
VTK1
p39266
sa(dp39267
g33284
I145
sg33285
I1
sg33286
I6
sg33295
VP67870
p39268
sg33289
VCSNK2B
p39269
sasg33281
(lp39270
(dp39271
g33284
I200
sg33285
I2
sg33286
I13
sg33287
VC0678222
p39272
sg33289
Vbreast cancer
p39273
sa(dp39274
g33284
I47
sg33285
I1
sg33286
I6
sg33287
VC0006826
p39275
sg33289
Vcancer
p39276
sasa(dp39277
g33277
VMiR-208b was also upregulated in DCM patients, but not in heart failure patients due to ischemic heart disease or myocarditis.
p39278
sg33279
(lp39279
(dp39280
g33284
I0
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VMiR-208b
p39281
sasg33281
(lp39282
(dp39283
g33284
I58
sg33285
I2
sg33286
I13
sg33287
VC0018802
p39284
sg33289
Vheart failure
p39285
sa(dp39286
g33284
I114
sg33285
I1
sg33286
I11
sg33287
VC0027059
p39287
sg33289
Vmyocarditis
p39288
sa(dp39289
g33284
I88
sg33285
I3
sg33286
I22
sg33287
VC0151744
p39290
sg33289
Vischemic heart disease
p39291
sasa(dp39292
g33277
VElevated cAMP levels increased cell size and altered expression levels of cardiac genes and micro-RNAs associated with hypertrophic cardiomyopathy (HCM), including Myh6, Myh7, Myh7b, Tnni3, Anp, Bnp, Gata4, Mef2c, Mef2d, Nfatc1, miR208a, and miR208b.
p39293
sg33279
(lp39294
(dp39295
g33284
I221
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VNfatc1
p39296
sa(dp39297
g33284
I214
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VMef2d
p39298
sa(dp39299
g33284
I176
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VMyh7b
p39300
sa(dp39301
g33284
I183
sg33285
I1
sg33286
I5
sg33295
VP19429
p39302
sg33289
VTnni3
p39303
sa(dp39304
g33284
I200
sg33285
I1
sg33286
I5
sg33295
VP43694
p39305
sg33289
VGata4
p39306
sa(dp39307
g33284
I190
sg33285
I1
sg33286
I3
sg33295
VP16066
p39308
sg33289
VAnp
p39309
sa(dp39310
g33284
I164
sg33285
I1
sg33286
I4
sg33295
VP13533
p39311
sg33289
VMyh6
p39312
sa(dp39313
g33284
I195
sg33285
I1
sg33286
I3
sg33295
VP16860
p39314
sg33289
VBnp
p39315
sa(dp39316
g33284
I207
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VMef2c
p39317
sasg33281
(lp39318
(dp39319
g33284
I119
sg33285
I2
sg33286
I27
sg33287
VC0007194
p39320
sg33289
Vhypertrophic cardiomyopathy
p39321
sa(dp39322
g33284
I148
sg33285
I1
sg33286
I3
sg33287
VC0007194
p39323
sg33289
VHCM
p39324
sasa(dp39325
g33277
VThe aim of this study was to determine whether miR-208, miR-208b, and miR-499 are expressed with MHC mRNA in human dilated cardiomyopathy (DCM), and whether these levels are related to left ventricular (LV) function and to clinical outcomes.
p39326
sg33279
(lp39327
(dp39328
g33284
I56
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VmiR-208b
p39329
sa(dp39330
g33284
I47
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VmiR-208
p39331
sa(dp39332
g33284
I70
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VmiR-499
p39333
sa(dp39334
g33284
I97
sg33285
I2
sg33286
I8
sg33295
VP13747
p39335
sg33289
VMHC mRNA
p39336
sasg33281
(lp39337
(dp39338
g33284
I139
sg33285
I1
sg33286
I3
sg33287
VC0007193
p39339
sg33289
VDCM
p39340
sa(dp39341
g33284
I115
sg33285
I2
sg33286
I22
sg33287
VC0007193
p39342
sg33289
Vdilated cardiomyopathy
p39343
sasa(dp39344
g33277
VThe goal of this study was to examine the long-term effects of maternal postpartum corticosterone (CORT, a model of postpartum depression) and concurrent FLX on hippocampal neurogenesis in male and female offspring.
p39345
sg33279
(lp39346
sg33281
(lp39347
(dp39348
g33284
I116
sg33285
I2
sg33286
I21
sg33287
VC0221074
p39349
sg33289
Vpostpartum depression
p39350
sasa(dp39351
g33277
VUsing high-resolution magnetic resonance imaging (MRI), the present pilot study examined the relationship between morning serum cortisol, DHEA(S), and HCV in nineteen normal controls and eighteen unmedicated subjects with Major Depressive Disorder (MDD).
p39352
sg33279
(lp39353
sg33281
(lp39354
(dp39355
g33284
I222
sg33285
I3
sg33286
I25
sg33287
VC1269683
p39356
sg33289
VMajor Depressive Disorder
p39357
sa(dp39358
g33284
I249
sg33285
I1
sg33286
I3
sg33287
VC1269683
p39359
sg33289
VMDD
p39360
sasa(dp39361
g33277
VTo assess the association of neural development-related genes LIS1and TSNAX with bipolar disorder in a Chinese Han population.
p39362
sg33279
(lp39363
(dp39364
g33284
I56
sg33285
I3
sg33286
I19
sg33295
g11
sg33289
Vgenes LIS1and TSNAX
p39365
sasg33281
(lp39366
(dp39367
g33284
I81
sg33285
I2
sg33286
I16
sg33287
VC0005586
p39368
sg33289
Vbipolar disorder
p39369
sasa(dp39370
g33277
VOur results indicated that LIS1 and TSNAX genes are not associated with susceptibility to bipolar I disorder in Chinese Han population.
p39371
sg33279
(lp39372
(dp39373
g33284
I27
sg33285
I1
sg33286
I4
sg33295
VP43034
p39374
sg33289
VLIS1
p39375
sa(dp39376
g33284
I36
sg33285
I2
sg33286
I11
sg33295
g11
sg33289
VTSNAX genes
p39377
sasg33281
(lp39378
(dp39379
g33284
I27
sg33285
I1
sg33286
I4
sg33287
VC1843916
p39380
sg33289
VLIS1
p39381
sa(dp39382
g33284
I90
sg33285
I3
sg33286
I18
sg33287
VC0853193
p39383
sg33289
Vbipolar I disorder
p39384
sasa(dp39385
g33277
VThe translin-associated factor X gene (TSNAX)/disrupted-in-schizophrenia-1 gene (DISC1) has been associated with psychiatric disorders, including schizophrenia, MDD and bipolar disorder.
p39386
sg33279
(lp39387
(dp39388
g33284
I4
sg33285
I4
sg33286
I33
sg33295
g11
sg33289
Vtranslin-associated factor X gene
p39389
sa(dp39390
g33284
I81
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VDISC1
p39391
sa(dp39392
g33284
I39
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTSNAX
p39393
sa(dp39394
g33284
I45
sg33285
I2
sg33286
I34
sg33295
g11
sg33289
V/disrupted-in-schizophrenia-1 gene
p39395
sasg33281
(lp39396
(dp39397
g33284
I59
sg33285
I1
sg33286
I13
sg33287
VC0036341
p39398
sg33289
Vschizophrenia
p39399
sa(dp39400
g33284
I59
sg33285
I1
sg33286
I13
sg33287
VC0036341
p39401
sg33289
Vschizophrenia
p39402
sa(dp39403
g33284
I161
sg33285
I1
sg33286
I3
sg33287
VC1269683
p39404
sg33289
VMDD
p39405
sa(dp39406
g33284
I113
sg33285
I2
sg33286
I21
sg33287
VC0004936
p39407
sg33289
Vpsychiatric disorders
p39408
sa(dp39409
g33284
I169
sg33285
I2
sg33286
I16
sg33287
VC0005586
p39410
sg33289
Vbipolar disorder
p39411
sasa(dp39412
g33277
VSeveral investigations have reported that the translin-associated factor X gene (TSNAX)/disrupted-in-schizophrenia-1 gene (DISC1) was associated with major psychiatric disorders including schizophrenia, bipolar disorder (BP), and major depressive disorder (MDD).
p39413
sg33279
(lp39414
(dp39415
g33284
I123
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VDISC1
p39416
sa(dp39417
g33284
I87
sg33285
I2
sg33286
I34
sg33295
g11
sg33289
V/disrupted-in-schizophrenia-1 gene
p39418
sa(dp39419
g33284
I46
sg33285
I4
sg33286
I33
sg33295
g11
sg33289
Vtranslin-associated factor X gene
p39420
sa(dp39421
g33284
I81
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTSNAX
p39422
sasg33281
(lp39423
(dp39424
g33284
I230
sg33285
I3
sg33286
I25
sg33287
VC1269683
p39425
sg33289
Vmajor depressive disorder
p39426
sa(dp39427
g33284
I101
sg33285
I1
sg33286
I13
sg33287
VC0036341
p39428
sg33289
Vschizophrenia
p39429
sa(dp39430
g33284
I257
sg33285
I1
sg33286
I3
sg33287
VC1269683
p39431
sg33289
VMDD
p39432
sa(dp39433
g33284
I156
sg33285
I2
sg33286
I21
sg33287
VC0004936
p39434
sg33289
Vpsychiatric disorders
p39435
sa(dp39436
g33284
I221
sg33285
I1
sg33286
I2
sg33287
VC0005586
p39437
sg33289
VBP
p39438
sa(dp39439
g33284
I203
sg33285
I2
sg33286
I16
sg33287
VC0005586
p39440
sg33289
Vbipolar disorder
p39441
sa(dp39442
g33284
I101
sg33285
I1
sg33286
I13
sg33287
VC0036341
p39443
sg33289
Vschizophrenia
p39444
sasa(dp39445
g33277
VThe Translin-associated factor X/Disrupted in Schizophrenia 1 (TRAX/DISC) region was first implicated as a susceptibility locus for schizophrenia by analysis of a large Scottish family in which a t(1;11) translocation cosegregates with schizophrenia, bipolar disorder and recurrent major depression.
p39446
sg33279
(lp39447
(dp39448
g33284
I4
sg33285
I3
sg33286
I28
sg33295
g11
sg33289
VTranslin-associated factor X
p39449
sa(dp39450
g33284
I46
sg33285
I2
sg33286
I15
sg33295
VP35462
p39451
sg33289
VSchizophrenia 1
p39452
sa(dp39453
g33284
I63
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTRAX
p39454
sasg33281
(lp39455
(dp39456
g33284
I272
sg33285
I3
sg33286
I26
sg33287
VC0154409
p39457
sg33289
Vrecurrent major depression
p39458
sa(dp39459
g33284
I132
sg33285
I1
sg33286
I13
sg33287
VC0036341
p39460
sg33289
Vschizophrenia
p39461
sa(dp39462
g33284
I132
sg33285
I1
sg33286
I13
sg33287
VC0036341
p39463
sg33289
Vschizophrenia
p39464
sa(dp39465
g33284
I204
sg33285
I1
sg33286
I13
sg33287
VC0040715
p39466
sg33289
Vtranslocation
p39467
sa(dp39468
g33284
I251
sg33285
I2
sg33286
I16
sg33287
VC0005586
p39469
sg33289
Vbipolar disorder
p39470
sa(dp39471
g33284
I46
sg33285
I2
sg33286
I15
sg33287
VC0220702
p39472
sg33289
VSchizophrenia 1
p39473
sasa(dp39474
g33277
VTwo further regions, one in TRAX and the second in DISC1, showed weaker evidence for sex-specific associations of individual haplotypes with bipolar disorder in men and women respectively, P&lt;0.01.
p39475
sg33279
(lp39476
(dp39477
g33284
I51
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VDISC1
p39478
sasg33281
(lp39479
(dp39480
g33284
I141
sg33285
I2
sg33286
I16
sg33287
VC0005586
p39481
sg33289
Vbipolar disorder
p39482
sasa(dp39483
g33277
VCompared with non-CKD controls, mice with CKD had downregulated expression of GSTA4 at the mRNA and protein levels, with concomitant increase in 4-HNE in arteries and veins.
p39484
sg33279
(lp39485
(dp39486
g33284
I78
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VGSTA4
p39487
sasg33281
(lp39488
sa(dp39489
g33277
VThe data showed age-related upregulation of downstream signaling molecules such as mitogen activated protein kinases (MAPKs), activator protein-1 (AP-1), NF-KB, and COX-2 in a cell culture cell system.Taken together, the results of this study show that the formation of adducts between 4-HNE and Src activates inflammatory signaling pathways in the aged kidney, contributing to age-related nephropathy.
p39490
sg33279
(lp39491
(dp39492
g33284
I165
sg33285
I1
sg33286
I5
sg33295
VP35354
p39493
sg33289
VCOX-2
p39494
sa(dp39495
g33284
I296
sg33285
I1
sg33286
I3
sg33295
VP12931
p39496
sg33289
VSrc
p39497
sa(dp39498
g33284
I147
sg33285
I1
sg33286
I4
sg33295
VP01100
p39499
sg33289
VAP-1
p39500
sa(dp39501
g33284
I288
sg33285
I1
sg33286
I3
sg33295
VP08246
p39502
sg33289
VHNE
p39503
sa(dp39504
g33284
I83
sg33285
I7
sg33286
I62
sg33295
VP17980
p39505
sg33289
Vmitogen activated protein kinases (MAPKs), activator protein-1
p39506
sasg33281
(lp39507
(dp39508
g33284
I390
sg33285
I1
sg33286
I11
sg33287
VC0022658
p39509
sg33289
Vnephropathy
p39510
sasa(dp39511
g33277
VElevated plasma 4-HNE has been associated with renal failure, septic shock and cardiopulmonary bypass surgery.
p39512
sg33279
(lp39513
(dp39514
g33284
I9
sg33285
I2
sg33286
I12
sg33295
VP08246
p39515
sg33289
Vplasma 4-HNE
p39516
sasg33281
(lp39517
(dp39518
g33284
I62
sg33285
I2
sg33286
I12
sg33287
VC0036983
p39519
sg33289
Vseptic shock
p39520
sa(dp39521
g33284
I47
sg33285
I2
sg33286
I13
sg33287
VC0035078
p39522
sg33289
Vrenal failure
p39523
sasa(dp39524
g33277
VAdditionally, the effect of PlGF (inhibition) on IOP was investigated, since aqueous PlGF is known to be upregulated in glaucoma patients.
p39525
sg33279
(lp39526
(dp39527
g33284
I28
sg33285
I1
sg33286
I4
sg33295
VP49763
p39528
sg33289
VPlGF
p39529
sa(dp39530
g33284
I28
sg33285
I1
sg33286
I4
sg33295
VP49763
p39531
sg33289
VPlGF
p39532
sasg33281
(lp39533
(dp39534
g33284
I120
sg33285
I1
sg33286
I8
sg33287
VC0017601
p39535
sg33289
Vglaucoma
p39536
sasa(dp39537
g33277
VInhibition of PlGF also might open alternative perspectives as IOP-lowering strategy for glaucoma patients with increased aqueous PlGF levels.
p39538
sg33279
(lp39539
(dp39540
g33284
I14
sg33285
I1
sg33286
I4
sg33295
VP49763
p39541
sg33289
VPlGF
p39542
sa(dp39543
g33284
I14
sg33285
I1
sg33286
I4
sg33295
VP49763
p39544
sg33289
VPlGF
p39545
sasg33281
(lp39546
(dp39547
g33284
I89
sg33285
I1
sg33286
I8
sg33287
VC0017601
p39548
sg33289
Vglaucoma
p39549
sasa(dp39550
g33277
VTo evaluate changes in the concentrations of placental growth factor (PlGF) and vascular endothelial growth factor-A (VEGF-A) in aqueous humor of patients with neovascular glaucoma (NVG) before and after an intravitreal injection of ranibizumab (IVR) and to determine the underlying correlation between the levels.
p39551
sg33279
(lp39552
(dp39553
g33284
I80
sg33285
I4
sg33286
I36
sg33295
g11
sg33289
Vvascular endothelial growth factor-A
p39554
sa(dp39555
g33284
I118
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VVEGF-A
p39556
sa(dp39557
g33284
I70
sg33285
I1
sg33286
I4
sg33295
VP49763
p39558
sg33289
VPlGF
p39559
sa(dp39560
g33284
I45
sg33285
I3
sg33286
I23
sg33295
VP49763
p39561
sg33289
Vplacental growth factor
p39562
sasg33281
(lp39563
(dp39564
g33284
I160
sg33285
I2
sg33286
I20
sg33287
VC0017609
p39565
sg33289
Vneovascular glaucoma
p39566
sa(dp39567
g33284
I129
sg33285
I2
sg33286
I13
sg33287
VC0595936
p39568
sg33289
Vaqueous humor
p39569
sa(dp39570
g33284
I182
sg33285
I1
sg33286
I3
sg33287
VC0017609
p39571
sg33289
VNVG
p39572
sasa(dp39573
g33277
VELISA experiments showed that PlGF levels were significantly increased in aqueous humour of glaucoma patients and after VEGF treatment, which may indicate an important contribution of this growth factor to wound healing after trabeculectomy.
p39574
sg33279
(lp39575
(dp39576
g33284
I30
sg33285
I1
sg33286
I4
sg33295
VP49763
p39577
sg33289
VPlGF
p39578
sasg33281
(lp39579
(dp39580
g33284
I92
sg33285
I1
sg33286
I8
sg33287
VC0017601
p39581
sg33289
Vglaucoma
p39582
sasa(dp39583
g33277
VUsing a mouse model of glaucoma filtration surgery, we were able to show that intracameral injection of a previously characterized anti-PlGF antibody (ThromboGenics NV) significantly improved surgical outcome by increasing bleb survival and bleb area.
p39584
sg33279
(lp39585
(dp39586
g33284
I131
sg33285
I2
sg33286
I18
sg33295
VP49763
p39587
sg33289
Vanti-PlGF antibody
p39588
sasg33281
(lp39589
(dp39590
g33284
I223
sg33285
I1
sg33286
I4
sg33287
VC0005758
p39591
sg33289
Vbleb
p39592
sa(dp39593
g33284
I223
sg33285
I1
sg33286
I4
sg33287
VC0005758
p39594
sg33289
Vbleb
p39595
sa(dp39596
g33284
I23
sg33285
I1
sg33286
I8
sg33287
VC0017601
p39597
sg33289
Vglaucoma
p39598
sasa(dp39599
g33277
VThe 17-phenyl PGF(2Alfa) analogue bimatoprost (10a) is the most efficacious ocular hypotensive agent currently available for the treatment of glaucoma or ocular hypertension.
p39600
sg33279
(lp39601
sg33281
(lp39602
(dp39603
g33284
I154
sg33285
I2
sg33286
I19
sg33287
VC0028840
p39604
sg33289
Vocular hypertension
p39605
sa(dp39606
g33284
I142
sg33285
I1
sg33286
I8
sg33287
VC0017601
p39607
sg33289
Vglaucoma
p39608
sa(dp39609
g33284
I83
sg33285
I1
sg33286
I11
sg33287
VC0857353
p39610
sg33289
Vhypotensive
p39611
sasa(dp39612
g33277
VLatanoprost, a synthetic derivative of the natural prostaglandin F(2a) (PGF(2a)), is a powerful antiglaucoma agent with ocular hypotensive and neuroprotective effects.
p39613
sg33279
(lp39614
sg33281
(lp39615
(dp39616
g33284
I127
sg33285
I1
sg33286
I11
sg33287
VC0857353
p39617
sg33289
Vhypotensive
p39618
sasa(dp39619
g33277
VEndotoxaemia enhanced early VT occurs in a TLR-4 and ICAM-1 dependent fashion, and is potentiated by neutropenia.
p39620
sg33279
(lp39621
(dp39622
g33284
I43
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTLR-4
p39623
sa(dp39624
g33284
I53
sg33285
I1
sg33286
I6
sg33295
VP05362
p39625
sg33289
VICAM-1
p39626
sasg33281
(lp39627
sa(dp39628
g33277
VThe aim of this study was to investigate the mannose-binding lectin 2 (MBL-2), interleukin (IL)-4, Toll-like receptor 4 (TLR-4), angiotensin converting enzyme (ACE), chemokine receptor 5 (CCR-5), and IL-1 receptor antagonist (RA) gene polymorphisms (GPs) in acute leukemias (ALs) and to evaluate their roles in febrile neutropenia (FN) resulting from chemotherapy.
p39629
sg33279
(lp39630
(dp39631
g33284
I45
sg33285
I3
sg33286
I24
sg33295
VP11226
p39632
sg33289
Vmannose-binding lectin 2
p39633
sa(dp39634
g33284
I71
sg33285
I1
sg33286
I5
sg33295
VP11226
p39635
sg33289
VMBL-2
p39636
sa(dp39637
g33284
I200
sg33285
I2
sg33286
I13
sg33295
g11
sg33289
VIL-1 receptor
p39638
sa(dp39639
g33284
I79
sg33285
I2
sg33286
I18
sg33295
VP60568
p39640
sg33289
Vinterleukin (IL)-4
p39641
sa(dp39642
g33284
I129
sg33285
I3
sg33286
I29
sg33295
VP12821
p39643
sg33289
Vangiotensin converting enzyme
p39644
sa(dp39645
g33284
I188
sg33285
I1
sg33286
I5
sg33295
VP61073
p39646
sg33289
VCCR-5
p39647
sa(dp39648
g33284
I121
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTLR-4
p39649
sa(dp39650
g33284
I166
sg33285
I3
sg33286
I20
sg33295
VP61073
p39651
sg33289
Vchemokine receptor 5
p39652
sa(dp39653
g33284
I99
sg33285
I3
sg33286
I20
sg33295
g11
sg33289
VToll-like receptor 4
p39654
sa(dp39655
g33284
I160
sg33285
I1
sg33286
I3
sg33295
VP12821
p39656
sg33289
VACE
p39657
sasg33281
(lp39658
(dp39659
g33284
I332
sg33285
I1
sg33286
I2
sg33287
VC0746883
p39660
sg33289
VFN
p39661
sa(dp39662
g33284
I250
sg33285
I1
sg33286
I3
sg33287
VC0272302
p39663
sg33289
VGPs
p39664
sa(dp39665
g33284
I230
sg33285
I2
sg33286
I18
sg33287
VC0272302
p39666
sg33289
Vgene polymorphisms
p39667
sa(dp39668
g33284
I258
sg33285
I2
sg33286
I15
sg33287
VC0085669
p39669
sg33289
Vacute leukemias
p39670
sa(dp39671
g33284
I275
sg33285
I1
sg33286
I3
sg33287
VC0002736
p39672
sg33289
VALs
p39673
sa(dp39674
g33284
I311
sg33285
I2
sg33286
I19
sg33287
VC0746883
p39675
sg33289
Vfebrile neutropenia
p39676
sasa(dp39677
g33277
VIn a multivariate analysis, adjusted for occurrence of graft-versus-host-disease, Cytomegalovirus serostatus and duration of neutropenia, paired presence of the TLR4 1063A&gt;G and IFNG 874T&gt;A single nucleotide polymorphisms showed a trend towards increased susceptibility to invasive aspergillosis (p = 0.04).
p39678
sg33279
(lp39679
(dp39680
g33284
I181
sg33285
I2
sg33286
I9
sg33295
VP01579
p39681
sg33289
VIFNG 874T
p39682
sasg33281
(lp39683
(dp39684
g33284
I55
sg33285
I1
sg33286
I25
sg33287
VC0018133
p39685
sg33289
Vgraft-versus-host-disease
p39686
sa(dp39687
g33284
I279
sg33285
I2
sg33286
I22
sg33287
VC0238013
p39688
sg33289
Vinvasive aspergillosis
p39689
sasa(dp39690
g33277
VFour SNPs in the TLR4 gene (rs10759931, rs11536889, rs1927911 and rs6478317) were associated with an increased risk of developing chemotherapy-induced neutropenia, each sustaining correction for multiple testing.
p39691
sg33279
(lp39692
sg33281
(lp39693
(dp39694
g33284
I130
sg33285
I2
sg33286
I32
sg33287
VC1827687
p39695
sg33289
Vchemotherapy-induced neutropenia
p39696
sasa(dp39697
g33277
VThe rs1064395 single nucleotide polymorphism, within the gene encoding neurocan (NCAN), is reported to be associated with schizophrenia in European populations and may influence brain structure in patients with schizophrenia.
p39698
sg33279
(lp39699
(dp39700
g33284
I81
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNCAN
p39701
sa(dp39702
g33284
I57
sg33285
I3
sg33286
I22
sg33295
g11
sg33289
Vgene encoding neurocan
p39703
sasg33281
(lp39704
(dp39705
g33284
I122
sg33285
I1
sg33286
I13
sg33287
VC0036341
p39706
sg33289
Vschizophrenia
p39707
sa(dp39708
g33284
I122
sg33285
I1
sg33286
I13
sg33287
VC0036341
p39709
sg33289
Vschizophrenia
p39710
sasa(dp39711
g33277
VIn this study, we aimed to explore whether NCAN rs1064395 confers some risk for schizophrenia and cognitive dysfunction in Han Chinese.
p39712
sg33279
(lp39713
(dp39714
g33284
I43
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VNCAN rs1064395
p39715
sasg33281
(lp39716
(dp39717
g33284
I80
sg33285
I1
sg33286
I13
sg33287
VC0036341
p39718
sg33289
Vschizophrenia
p39719
sa(dp39720
g33284
I98
sg33285
I2
sg33286
I21
sg33287
VC0338656
p39721
sg33289
Vcognitive dysfunction
p39722
sasa(dp39723
g33277
VThe A allele of the single nucleotide polymorphism (SNP) rs1064395 in the NCAN gene has recently been identified as a susceptibility factor for bipolar disorder and schizophrenia.
p39724
sg33279
(lp39725
(dp39726
g33284
I74
sg33285
I2
sg33286
I9
sg33295
g11
sg33289
VNCAN gene
p39727
sasg33281
(lp39728
(dp39729
g33284
I144
sg33285
I2
sg33286
I16
sg33287
VC0005586
p39730
sg33289
Vbipolar disorder
p39731
sa(dp39732
g33284
I165
sg33285
I1
sg33286
I13
sg33287
VC0036341
p39733
sg33289
Vschizophrenia
p39734
sasa(dp39735
g33277
VRecently, it was shown that some CSPGs members like aggrecan, versican, and neurocan were strongly involved in brain disorders like bipolar disorder (BD), schizophrenia, and ADHD.
p39736
sg33279
(lp39737
(dp39738
g33284
I52
sg33285
I1
sg33286
I8
sg33295
VP16112
p39739
sg33289
Vaggrecan
p39740
sa(dp39741
g33284
I174
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VADHD
p39742
sasg33281
(lp39743
(dp39744
g33284
I174
sg33285
I1
sg33286
I4
sg33287
VC1263846
p39745
sg33289
VADHD
p39746
sa(dp39747
g33284
I111
sg33285
I2
sg33286
I15
sg33287
VC0006111
p39748
sg33289
Vbrain disorders
p39749
sa(dp39750
g33284
I132
sg33285
I2
sg33286
I16
sg33287
VC0005586
p39751
sg33289
Vbipolar disorder
p39752
sa(dp39753
g33284
I150
sg33285
I1
sg33286
I2
sg33287
VC0005586
p39754
sg33289
VBD
p39755
sa(dp39756
g33284
I155
sg33285
I1
sg33286
I13
sg33287
VC0036341
p39757
sg33289
Vschizophrenia
p39758
sasa(dp39759
g33277
VRecent studies have provided strong evidence that variation in the gene neurocan (NCAN, rs1064395) is a common risk factor for bipolar disorder (BD) and schizophrenia.
p39760
sg33279
(lp39761
(dp39762
g33284
I82
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNCAN
p39763
sa(dp39764
g33284
I72
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
Vneurocan
p39765
sasg33281
(lp39766
(dp39767
g33284
I145
sg33285
I1
sg33286
I2
sg33287
VC0005586
p39768
sg33289
VBD
p39769
sa(dp39770
g33284
I153
sg33285
I1
sg33286
I13
sg33287
VC0036341
p39771
sg33289
Vschizophrenia
p39772
sa(dp39773
g33284
I127
sg33285
I2
sg33286
I16
sg33287
VC0005586
p39774
sg33289
Vbipolar disorder
p39775
sasa(dp39776
g33277
VIn this work, authors investigated the association between previously confirmed bipolar disorder genetic risk factor- neurocan with schizophrenia in a population sample of Bosnia and Herzegovina.
p39777
sg33279
(lp39778
sg33281
(lp39779
(dp39780
g33284
I132
sg33285
I1
sg33286
I13
sg33287
VC0036341
p39781
sg33289
Vschizophrenia
p39782
sa(dp39783
g33284
I80
sg33285
I2
sg33286
I16
sg33287
VC0005586
p39784
sg33289
Vbipolar disorder
p39785
sasa(dp39786
g33277
VA case-control analysis of common genetic polymorphism within neurocan gene and schizophrenia status in a consecutively sampled patient cohort have been done using Fisher-exact test with odds-ratio calculation.
p39787
sg33279
(lp39788
sg33281
(lp39789
(dp39790
g33284
I80
sg33285
I1
sg33286
I13
sg33287
VC0036341
p39791
sg33289
Vschizophrenia
p39792
sasa(dp39793
g33277
VOur data suggest that genetic variation in NCAN is a common risk factor for BD and schizophrenia.
p39794
sg33279
(lp39795
(dp39796
g33284
I43
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNCAN
p39797
sasg33281
(lp39798
(dp39799
g33284
I83
sg33285
I1
sg33286
I13
sg33287
VC0036341
p39800
sg33289
Vschizophrenia
p39801
sasa(dp39802
g33277
VIn contrast, studies have associated primary biliary cirrhosis and primary sclerosing cholangitis with genes encoding major histocompatibility complex proteins and identified loci associated with microbial sensing and immune regulatory pathways outside this region, such as genes encoding IL12, STAT4, IRF5, IL2 and its receptor (IL2R), CD28, and CD80.
p39803
sg33279
(lp39804
(dp39805
g33284
I308
sg33285
I4
sg33286
I20
sg33295
VP01589
p39806
sg33289
VIL2 and its receptor
p39807
sa(dp39808
g33284
I330
sg33285
I1
sg33286
I4
sg33295
VP01589
p39809
sg33289
VIL2R
p39810
sa(dp39811
g33284
I302
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VIRF5
p39812
sa(dp39813
g33284
I118
sg33285
I4
sg33286
I41
sg33295
VP18464
p39814
sg33289
Vmajor histocompatibility complex proteins
p39815
sa(dp39816
g33284
I347
sg33285
I1
sg33286
I4
sg33295
VP33681
p39817
sg33289
VCD80
p39818
sa(dp39819
g33284
I295
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSTAT4
p39820
sa(dp39821
g33284
I337
sg33285
I1
sg33286
I4
sg33295
VP33681
p39822
sg33289
VCD28
p39823
sasg33281
(lp39824
(dp39825
g33284
I37
sg33285
I3
sg33286
I25
sg33287
VC0008312
p39826
sg33289
Vprimary biliary cirrhosis
p39827
sa(dp39828
g33284
I67
sg33285
I3
sg33286
I30
sg33287
VC0566602
p39829
sg33289
Vprimary sclerosing cholangitis
p39830
sasa(dp39831
g33277
VIn this condition, 8CR inhibited edema and myonecrosis induced by the sPLA2 activity of Crotalus durissus terrificus in a dose-dependent manner by decreasing interleukin-1Beta (IL-1Beta), tumor necrosis factor Alfa (TNF-Alfa), prostaglandin E2 (PGE2), and lipid peroxidation.
p39832
sg33279
(lp39833
(dp39834
g33284
I216
sg33285
I1
sg33286
I8
sg33295
VP01375
p39835
sg33289
VTNF-Alfa
p39836
sa(dp39837
g33284
I177
sg33285
I1
sg33286
I8
sg33295
VP01584
p39838
sg33289
VIL-1Beta
p39839
sa(dp39840
g33284
I158
sg33285
I1
sg33286
I17
sg33295
VP01584
p39841
sg33289
Vinterleukin-1Beta
p39842
sa(dp39843
g33284
I188
sg33285
I4
sg33286
I26
sg33295
VP01375
p39844
sg33289
Vtumor necrosis factor Alfa
p39845
sa(dp39846
g33284
I70
sg33285
I1
sg33286
I5
sg33295
VP14555
p39847
sg33289
VsPLA2
p39848
sasg33281
(lp39849
(dp39850
g33284
I8
sg33285
I1
sg33286
I9
sg33287
VC0012634
p39851
sg33289
Vcondition
p39852
sa(dp39853
g33284
I43
sg33285
I1
sg33286
I11
sg33287
VC0235957
p39854
sg33289
Vmyonecrosis
p39855
sa(dp39856
g33284
I33
sg33285
I1
sg33286
I5
sg33287
VC0013604
p39857
sg33289
Vedema
p39858
sa(dp39859
g33284
I188
sg33285
I2
sg33286
I14
sg33287
VC0333516
p39860
sg33289
Vtumor necrosis
p39861
sasa(dp39862
g33277
VIn addition, it was shown that Crotalus durissus terrificus sPLA2 increases cell oxidative stress during edema and myonecrosis, and the antioxidant properties of the polyphenolic compound may be significant in mitigating the pharmacological effect induced by sPLA2 and other snake venom toxins.
p39863
sg33279
(lp39864
(dp39865
g33284
I60
sg33285
I1
sg33286
I5
sg33295
VP14555
p39866
sg33289
VsPLA2
p39867
sasg33281
(lp39868
(dp39869
g33284
I115
sg33285
I1
sg33286
I11
sg33287
VC0235957
p39870
sg33289
Vmyonecrosis
p39871
sa(dp39872
g33284
I105
sg33285
I1
sg33286
I5
sg33287
VC0013604
p39873
sg33289
Vedema
p39874
sa(dp39875
g33284
I81
sg33285
I2
sg33286
I16
sg33287
VC0242606
p39876
sg33289
Voxidative stress
p39877
sasa(dp39878
g33277
VTherefore, it's necessary to express CssPLA2 in water-soluble form and determine whether the enzymatic activity of CssPLA2 or cell signalling pathways is involved in liver fibrosis caused by clonorchiasis.
p39879
sg33279
(lp39880
sg33281
(lp39881
(dp39882
g33284
I191
sg33285
I1
sg33286
I13
sg33287
VC0009021
p39883
sg33289
Vclonorchiasis
p39884
sa(dp39885
g33284
I166
sg33285
I2
sg33286
I14
sg33287
VC0239946
p39886
sg33289
Vliver fibrosis
p39887
sasa(dp39888
g33277
VWe sought to investigate if mast cell activation and increases in secretory sPLA2s are associated with an increase in PAF and occurrence of dengue haemorrhagic fever (DHF).
p39889
sg33279
(lp39890
(dp39891
g33284
I66
sg33285
I2
sg33286
I16
sg33295
g11
sg33289
Vsecretory sPLA2s
p39892
sasg33281
(lp39893
(dp39894
g33284
I167
sg33285
I1
sg33286
I3
sg33287
VC0019100
p39895
sg33289
VDHF
p39896
sa(dp39897
g33284
I140
sg33285
I3
sg33286
I25
sg33287
VC0019100
p39898
sg33289
Vdengue haemorrhagic fever
p39899
sa(dp39900
g33284
I118
sg33285
I1
sg33286
I3
sg33287
VC0235480
p39901
sg33289
VPAF
p39902
sasa(dp39903
g33277
VThe changes in the levels of mast cell tryptase, PAF and the activity of sPLA2 were determined throughout the course of illness in 13 adult patients with DHF, and 30 patients with dengue fever (DF).
p39904
sg33279
(lp39905
(dp39906
g33284
I49
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VPAF
p39907
sa(dp39908
g33284
I73
sg33285
I1
sg33286
I5
sg33295
VP14555
p39909
sg33289
VsPLA2
p39910
sa(dp39911
g33284
I29
sg33285
I3
sg33286
I18
sg33295
VP15157
p39912
sg33289
Vmast cell tryptase
p39913
sasg33281
(lp39914
(dp39915
g33284
I49
sg33285
I1
sg33286
I3
sg33287
VC0235480
p39916
sg33289
VPAF
p39917
sa(dp39918
g33284
I180
sg33285
I2
sg33286
I12
sg33287
VC0011311
p39919
sg33289
Vdengue fever
p39920
sa(dp39921
g33284
I110
sg33285
I3
sg33286
I17
sg33287
VC0242656
p39922
sg33289
Vcourse of illness
p39923
sa(dp39924
g33284
I194
sg33285
I1
sg33286
I2
sg33287
VC0011311
p39925
sg33289
VDF
p39926
sasa(dp39927
g33277
VThe difference in serum levels of PLA2G2A was analyzed among chronic hepatitis B (CHB), LC, and HCC patients.
p39928
sg33279
(lp39929
(dp39930
g33284
I34
sg33285
I1
sg33286
I7
sg33295
VP14555
p39931
sg33289
VPLA2G2A
p39932
sasg33281
(lp39933
(dp39934
g33284
I82
sg33285
I1
sg33286
I3
sg33287
VC0151517
p39935
sg33289
VCHB
p39936
sa(dp39937
g33284
I61
sg33285
I3
sg33286
I19
sg33287
VC0524909
p39938
sg33289
Vchronic hepatitis B
p39939
sa(dp39940
g33284
I96
sg33285
I1
sg33286
I3
sg33287
VC2239176
p39941
sg33289
VHCC
p39942
sasa(dp39943
g33277
VWe have previously shown that secreted phospholipases A2 (sPLA2s) from animal venoms inhibit the in vitro development of Plasmodium falciparum, the agent of malaria.
p39944
sg33279
(lp39945
(dp39946
g33284
I58
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VsPLA2s
p39947
sa(dp39948
g33284
I39
sg33285
I2
sg33286
I17
sg33295
VP04054
p39949
sg33289
Vphospholipases A2
p39950
sasg33281
(lp39951
(dp39952
g33284
I157
sg33285
I1
sg33286
I7
sg33287
VC0024530
p39953
sg33289
Vmalaria
p39954
sasa(dp39955
g33277
VIn addition, the inflammatory-type human group IIA (hGIIA) sPLA2 circulates at high levels in the serum of malaria patients.
p39956
sg33279
(lp39957
(dp39958
g33284
I59
sg33285
I1
sg33286
I5
sg33295
VP14555
p39959
sg33289
VsPLA2
p39960
sasg33281
(lp39961
(dp39962
g33284
I107
sg33285
I1
sg33286
I7
sg33287
VC0024530
p39963
sg33289
Vmalaria
p39964
sasa(dp39965
g33277
VTogether, our findings indicate that 4 human sPLA2s are active against P. falciparum in vitro and pave the way to future investigations on their in vivo contribution in malaria pathophysiology.
p39966
sg33279
(lp39967
sg33281
(lp39968
(dp39969
g33284
I169
sg33285
I1
sg33286
I7
sg33287
VC0024530
p39970
sg33289
Vmalaria
p39971
sasa(dp39972
g33277
VTwo subtypes of phospholipases A2 (PLA2s) with the ability to induce myonecrosis, 'Asp49' and 'Lys49' myotoxins, often coexist in viperid snake venoms.
p39973
sg33279
(lp39974
(dp39975
g33284
I16
sg33285
I2
sg33286
I17
sg33295
VP04054
p39976
sg33289
Vphospholipases A2
p39977
sa(dp39978
g33284
I35
sg33285
I1
sg33286
I5
sg33295
VP04054
p39979
sg33289
VPLA2s
p39980
sasg33281
(lp39981
(dp39982
g33284
I69
sg33285
I1
sg33286
I11
sg33287
VC0235957
p39983
sg33289
Vmyonecrosis
p39984
sasa(dp39985
g33277
VIn order to assess the contribution of the IL-18 to susceptibility to Chronic Chagas Disease, we investigated the association between a single nucleotide polymorphism (SNP) located in the IL-18 gene with the risk of developing Chagas cardiomyopathy.
p39986
sg33279
(lp39987
sg33281
(lp39988
(dp39989
g33284
I227
sg33285
I2
sg33286
I21
sg33287
VC0007930
p39990
sg33289
VChagas cardiomyopathy
p39991
sa(dp39992
g33284
I78
sg33285
I2
sg33286
I14
sg33287
VC0041234
p39993
sg33289
VChagas Disease
p39994
sasa(dp39995
g33277
VWe analyzed the rs2043055 marker in the IL18 gene in a cohort of Chagas disease cardiomyopathy patients (n=849) and asymptomatic subjects (n=202).
p39996
sg33279
(lp39997
(dp39998
g33284
I40
sg33285
I2
sg33286
I9
sg33295
g11
sg33289
VIL18 gene
p39999
sasg33281
(lp40000
(dp40001
g33284
I80
sg33285
I1
sg33286
I14
sg33287
VC0878544
p40002
sg33289
Vcardiomyopathy
p40003
sa(dp40004
g33284
I65
sg33285
I2
sg33286
I14
sg33287
VC0041234
p40005
sg33289
VChagas disease
p40006
sasa(dp40007
g33277
VTo describe a peculiar flecked-retina phenotype in a young female affected by early-onset retinal dystrophy due to a heterozygous mutation in the cone-rod transcription factor CRX gene.
p40008
sg33279
(lp40009
(dp40010
g33284
I176
sg33285
I2
sg33286
I8
sg33295
g11
sg33289
VCRX gene
p40011
sasg33281
(lp40012
(dp40013
g33284
I90
sg33285
I2
sg33286
I17
sg33287
VC0854723
p40014
sg33289
Vretinal dystrophy
p40015
sasa(dp40016
g33277
VWe identified a novel early-onset retinal dystrophy-related heterozygous CRX mutation associated with early and severe rod and cone dysfunction and regressive flecked-retina appearance on ophthalmoscopy.
p40017
sg33279
(lp40018
(dp40019
g33284
I73
sg33285
I2
sg33286
I12
sg33295
g11
sg33289
VCRX mutation
p40020
sasg33281
(lp40021
(dp40022
g33284
I34
sg33285
I2
sg33286
I17
sg33287
VC0854723
p40023
sg33289
Vretinal dystrophy
p40024
sasa(dp40025
g33277
VWe found that retinal disease-related genes were efficiently detected in CRX-transduced cells, most of which are crucial to photoreceptor functions.
p40026
sg33279
(lp40027
sg33281
(lp40028
(dp40029
g33284
I14
sg33285
I2
sg33286
I15
sg33287
VC0035309
p40030
sg33289
Vretinal disease
p40031
sasa(dp40032
g33277
VMoreover, by modification of the culture conditions including additional transduction of RAX1 and NEUROD1, we found a greater variety of retinal disease-related genes than that observed in CRX-transduced PBMCs.
p40033
sg33279
(lp40034
(dp40035
g33284
I98
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VNEUROD1
p40036
sasg33281
(lp40037
(dp40038
g33284
I137
sg33285
I2
sg33286
I15
sg33287
VC0035309
p40039
sg33289
Vretinal disease
p40040
sasa(dp40041
g33277
VThese data suggest that CRX acts as a master control gene for reprogramming PBMCs into photoreceptor-like cells and that our induced photoreceptor-like cells might contribute to individualized drug screening and disease modeling of inherited retinal degeneration.
p40042
sg33279
(lp40043
(dp40044
g33284
I24
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VCRX
p40045
sasg33281
(lp40046
(dp40047
g33284
I242
sg33285
I2
sg33286
I20
sg33287
VC0035304
p40048
sg33289
Vretinal degeneration
p40049
sasa(dp40050
g33277
VFinally, anisomycin was the highest correlation with DEGs.MiR-124a might be involved in the pathogenesis of hypertension via targeting Ebf3 and Rgs7 bp, which possibly represent a novel and effective strategy for treatment of hypertension.
p40051
sg33279
(lp40052
(dp40053
g33284
I135
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VEbf3
p40054
sa(dp40055
g33284
I53
sg33285
I1
sg33286
I13
sg33295
g11
sg33289
VDEGs.MiR-124a
p40056
sa(dp40057
g33284
I144
sg33285
I1
sg33286
I4
sg33295
VP49802
p40058
sg33289
VRgs7
p40059
sasg33281
(lp40060
(dp40061
g33284
I92
sg33285
I1
sg33286
I12
sg33287
VC0699748
p40062
sg33289
Vpathogenesis
p40063
sa(dp40064
g33284
I108
sg33285
I1
sg33286
I12
sg33287
VC0020538
p40065
sg33289
Vhypertension
p40066
sa(dp40067
g33284
I108
sg33285
I1
sg33286
I12
sg33287
VC0020538
p40068
sg33289
Vhypertension
p40069
sasa(dp40070
g33277
VThe serum miR-124 expression levels in 114 osteosarcoma patients, 40 periostitis patients and 50 normal controls were detected using real-time quantitative polymerase chain reaction (RT-qPCR).
p40071
sg33279
(lp40072
(dp40073
g33284
I10
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VmiR-124
p40074
sasg33281
(lp40075
(dp40076
g33284
I43
sg33285
I1
sg33286
I12
sg33287
VC0029463
p40077
sg33289
Vosteosarcoma
p40078
sa(dp40079
g33284
I69
sg33285
I1
sg33286
I11
sg33287
VC0031111
p40080
sg33289
Vperiostitis
p40081
sasa(dp40082
g33277
VThe level of serum miR-124 was remarkably decreased in osteosarcoma patients when compared to periostitis patients and healthy controls (both p&lt; 0.05).
p40083
sg33279
(lp40084
(dp40085
g33284
I13
sg33285
I2
sg33286
I13
sg33295
g11
sg33289
Vserum miR-124
p40086
sasg33281
(lp40087
(dp40088
g33284
I94
sg33285
I1
sg33286
I11
sg33287
VC0031111
p40089
sg33289
Vperiostitis
p40090
sa(dp40091
g33284
I55
sg33285
I1
sg33286
I12
sg33287
VC0029463
p40092
sg33289
Vosteosarcoma
p40093
sasa(dp40094
g33277
VMoreover, the Kaplan-Meier method with log-rank test showed that osteosarcoma patients with lower serum miR-124 levels had unfavorable 5 year overall survival and disease free survival rates.
p40095
sg33279
(lp40096
sg33281
(lp40097
(dp40098
g33284
I65
sg33285
I1
sg33286
I12
sg33287
VC0029463
p40099
sg33289
Vosteosarcoma
p40100
sasa(dp40101
g33277
VIt was also demonstrated that miR-124-3p expression was positively associated with mTOR signaling and this relationship was dependent on the tuberous sclerosis proteins 1/2 complex.
p40102
sg33279
(lp40103
(dp40104
g33284
I30
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VmiR-124-3p
p40105
sa(dp40106
g33284
I83
sg33285
I1
sg33286
I4
sg33295
VP42345
p40107
sg33289
VmTOR
p40108
sasg33281
(lp40109
(dp40110
g33284
I141
sg33285
I2
sg33286
I18
sg33287
VC0041341
p40111
sg33289
Vtuberous sclerosis
p40112
sasa(dp40113
g33277
VAmong these microRNAs, miR-142-3p/5p and miR-146a expression was found to be significantly increased in MPA-treated lupus CD4(+)T cells compared to untreated controls.
p40114
sg33279
(lp40115
(dp40116
g33284
I23
sg33285
I1
sg33286
I13
sg33295
g11
sg33289
VmiR-142-3p/5p
p40117
sa(dp40118
g33284
I41
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VmiR-146a
p40119
sasg33281
(lp40120
(dp40121
g33284
I116
sg33285
I1
sg33286
I5
sg33287
VC0024131
p40122
sg33289
Vlupus
p40123
sasa(dp40124
g33277
VTo examine the role of microRNA-142-3p/5p (miR-142-3p/5p) in the development of autoimmunity in patients with systemic lupus erythematosus (SLE).
p40125
sg33279
(lp40126
(dp40127
g33284
I43
sg33285
I1
sg33286
I13
sg33295
g11
sg33289
VmiR-142-3p/5p
p40128
sa(dp40129
g33284
I23
sg33285
I1
sg33286
I18
sg33295
g11
sg33289
VmicroRNA-142-3p/5p
p40130
sasg33281
(lp40131
(dp40132
g33284
I110
sg33285
I3
sg33286
I28
sg33287
VC0024141
p40133
sg33289
Vsystemic lupus erythematosus
p40134
sa(dp40135
g33284
I140
sg33285
I1
sg33286
I3
sg33287
VC0024141
p40136
sg33289
VSLE
p40137
sa(dp40138
g33284
I80
sg33285
I1
sg33286
I12
sg33287
VC0004368
p40139
sg33289
Vautoimmunity
p40140
sasa(dp40141
g33277
VTo establish the cytologic and immunocytochemical features of lymphangioleiomyomatosis (LAM) cell clusters (LCCs) and to clarify its diagnostic significance for LAM.
p40142
sg33279
(lp40143
sg33281
(lp40144
(dp40145
g33284
I108
sg33285
I1
sg33286
I4
sg33287
VC1854664
p40146
sg33289
VLCCs
p40147
sa(dp40148
g33284
I62
sg33285
I1
sg33286
I24
sg33287
VC0751674
p40149
sg33289
Vlymphangioleiomyomatosis
p40150
sa(dp40151
g33284
I88
sg33285
I1
sg33286
I3
sg33287
VC0751674
p40152
sg33289
VLAM
p40153
sa(dp40154
g33284
I88
sg33285
I1
sg33286
I3
sg33287
VC0751674
p40155
sg33289
VLAM
p40156
sasa(dp40157
g33277
VThis study aimed to evaluate fibrosis and elastin destruction in childhood interstitial lung disease (chILD) patients.
p40158
sg33279
(lp40159
(dp40160
g33284
I42
sg33285
I1
sg33286
I7
sg33295
VP49918
p40161
sg33289
Velastin
p40162
sasg33281
(lp40163
(dp40164
g33284
I75
sg33285
I3
sg33286
I25
sg33287
VC0206062
p40165
sg33289
Vinterstitial lung disease
p40166
sa(dp40167
g33284
I29
sg33285
I1
sg33286
I8
sg33287
VC0016059
p40168
sg33289
Vfibrosis
p40169
sasa(dp40170
g33277
VInhibitors of the cGMP-degrading phosphodiesterase (PDE) 5 have achieved blockbuster status in the treatment of penile erectile dysfunction (PED).
p40171
sg33279
(lp40172
(dp40173
g33284
I52
sg33285
I1
sg33286
I3
sg33295
VP49419
p40174
sg33289
VPDE
p40175
sa(dp40176
g33284
I18
sg33285
I2
sg33286
I32
sg33295
VP22413
p40177
sg33289
VcGMP-degrading phosphodiesterase
p40178
sasg33281
(lp40179
(dp40180
g33284
I52
sg33285
I1
sg33286
I3
sg33287
VC1849508
p40181
sg33289
VPDE
p40182
sa(dp40183
g33284
I33
sg33285
I1
sg33286
I17
sg33287
VC1849508
p40184
sg33289
Vphosphodiesterase
p40185
sa(dp40186
g33284
I119
sg33285
I2
sg33286
I20
sg33287
VC0242350
p40187
sg33289
Verectile dysfunction
p40188
sasa(dp40189
g33277
VTo compare the effectiveness of the phosphodiesterase type 5 inhibitor (PDE-5i) tadalafil alone and in combination with a biologically active dietary supplement (BADS) NeyroDoz, containing the precursors of serotonin in patients with erectile dysfunction (ED) associated with secondary premature ejaculation (SPE).
p40190
sg33279
(lp40191
(dp40192
g33284
I36
sg33285
I4
sg33286
I34
sg33295
VP22413
p40193
sg33289
Vphosphodiesterase type 5 inhibitor
p40194
sa(dp40195
g33284
I72
sg33285
I1
sg33286
I6
sg33295
VP49419
p40196
sg33289
VPDE-5i
p40197
sasg33281
(lp40198
(dp40199
g33284
I72
sg33285
I1
sg33286
I3
sg33287
VC1849508
p40200
sg33289
VPDE
p40201
sa(dp40202
g33284
I286
sg33285
I2
sg33286
I21
sg33287
VC0033038
p40203
sg33289
Vpremature ejaculation
p40204
sa(dp40205
g33284
I256
sg33285
I1
sg33286
I2
sg33287
VC0242350
p40206
sg33289
VED
p40207
sa(dp40208
g33284
I234
sg33285
I2
sg33286
I20
sg33287
VC0242350
p40209
sg33289
Verectile dysfunction
p40210
sasa(dp40211
g33277
VOf these enzymes, PDE5 has attracted a special attention over the years after its recognition as being the target enzyme in treating erectile dysfunction.
p40212
sg33279
(lp40213
(dp40214
g33284
I18
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VPDE5
p40215
sasg33281
(lp40216
(dp40217
g33284
I133
sg33285
I2
sg33286
I20
sg33287
VC0242350
p40218
sg33289
Verectile dysfunction
p40219
sasa(dp40220
g33277
VPhosphodiesterase (PDE) 5 inhibitor induced muscle relaxation in corporal smooth muscle cells and was used to treat erectile dysfunction by inhibiting cGMP degradation.
p40221
sg33279
(lp40222
(dp40223
g33284
I0
sg33285
I3
sg33286
I25
sg33295
VP22413
p40224
sg33289
VPhosphodiesterase (PDE) 5
p40225
sasg33281
(lp40226
(dp40227
g33284
I0
sg33285
I1
sg33286
I17
sg33287
VC1849508
p40228
sg33289
VPhosphodiesterase
p40229
sa(dp40230
g33284
I19
sg33285
I1
sg33286
I3
sg33287
VC1849508
p40231
sg33289
VPDE
p40232
sa(dp40233
g33284
I44
sg33285
I2
sg33286
I17
sg33287
VC0700323
p40234
sg33289
Vmuscle relaxation
p40235
sa(dp40236
g33284
I116
sg33285
I2
sg33286
I20
sg33287
VC0242350
p40237
sg33289
Verectile dysfunction
p40238
sasa(dp40239
g33277
VCyclic guanosine monophosphate (cGMP)-specific phosphodiesterase (PDE) inhibitors are hypothesized to improve cognition in schizophrenia and Alzheimer disease by increasing cGMP levels in certain brain regions.
p40240
sg33279
(lp40241
(dp40242
g33284
I66
sg33285
I1
sg33286
I3
sg33295
VP49419
p40243
sg33289
VPDE
p40244
sa(dp40245
g33284
I0
sg33285
I5
sg33286
I64
sg33295
VP22413
p40246
sg33289
VCyclic guanosine monophosphate (cGMP)-specific phosphodiesterase
p40247
sasg33281
(lp40248
(dp40249
g33284
I47
sg33285
I1
sg33286
I17
sg33287
VC1849508
p40250
sg33289
Vphosphodiesterase
p40251
sa(dp40252
g33284
I141
sg33285
I2
sg33286
I17
sg33287
VC0002395
p40253
sg33289
VAlzheimer disease
p40254
sa(dp40255
g33284
I123
sg33285
I1
sg33286
I13
sg33287
VC0036341
p40256
sg33289
Vschizophrenia
p40257
sa(dp40258
g33284
I66
sg33285
I1
sg33286
I3
sg33287
VC1849508
p40259
sg33289
VPDE
p40260
sasa(dp40261
g33277
VTo find out whether increased spinal nociception represents a premotor feature, experimental pain sensitivity was assessed in idiopathic REM-sleep behavior disorder (IRBD) patients with or without signs of a neurodegenerative disorder compared to early Parkinson's disease (ePD) patients and healthy controls (HC).
p40262
sg33279
(lp40263
sg33281
(lp40264
(dp40265
g33284
I247
sg33285
I3
sg33286
I25
sg33287
VC1849508
p40266
sg33289
Vearly Parkinson's disease
p40267
sa(dp40268
g33284
I208
sg33285
I2
sg33286
I26
sg33287
VC0524851
p40269
sg33289
Vneurodegenerative disorder
p40270
sa(dp40271
g33284
I147
sg33285
I2
sg33286
I17
sg33287
VC0004930
p40272
sg33289
Vbehavior disorder
p40273
sa(dp40274
g33284
I274
sg33285
I1
sg33286
I3
sg33287
VC1849508
p40275
sg33289
VePD
p40276
sasa(dp40277
g33277
VPhosphodiesterase (PDE) inhibitors are currently under evaluation as agents that may facilitate the improvement of cognitive impairment associated with Alzheimer's disease.
p40278
sg33279
(lp40279
(dp40280
g33284
I0
sg33285
I2
sg33286
I23
sg33295
VP22413
p40281
sg33289
VPhosphodiesterase (PDE)
p40282
sasg33281
(lp40283
(dp40284
g33284
I0
sg33285
I1
sg33286
I17
sg33287
VC1849508
p40285
sg33289
VPhosphodiesterase
p40286
sa(dp40287
g33284
I152
sg33285
I2
sg33286
I19
sg33287
VC1521724
p40288
sg33289
VAlzheimer's disease
p40289
sa(dp40290
g33284
I19
sg33285
I1
sg33286
I3
sg33287
VC1849508
p40291
sg33289
VPDE
p40292
sa(dp40293
g33284
I115
sg33285
I2
sg33286
I20
sg33287
VC0338656
p40294
sg33289
Vcognitive impairment
p40295
sasa(dp40296
g33277
VNotably, much experimental and clinical evidence show that PXR senses xenobiotics and triggers the detoxification response to prevent diseases such as diabetes, obesity, intestinal inflammatory diseases and liver fibrosis.
p40297
sg33279
(lp40298
sg33281
(lp40299
(dp40300
g33284
I161
sg33285
I1
sg33286
I7
sg33287
VC0028754
p40301
sg33289
Vobesity
p40302
sa(dp40303
g33284
I151
sg33285
I1
sg33286
I8
sg33287
VC0011849
p40304
sg33289
Vdiabetes
p40305
sa(dp40306
g33284
I99
sg33285
I2
sg33286
I23
sg33287
VC1622680
p40307
sg33289
Vdetoxification response
p40308
sa(dp40309
g33284
I207
sg33285
I2
sg33286
I14
sg33287
VC0239946
p40310
sg33289
Vliver fibrosis
p40311
sasa(dp40312
g33277
VRescued Tg(INV-Cst6)Cst6ichq/ichq mice survive the neonatal phase, but display severe eye pathology and alopecia after 4 mo.
p40313
sg33279
(lp40314
(dp40315
g33284
I11
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VINV-Cst6
p40316
sasg33281
(lp40317
(dp40318
g33284
I90
sg33285
I1
sg33286
I9
sg33287
VC0677042
p40319
sg33289
Vpathology
p40320
sasa(dp40321
g33277
VIntriguingly, both Cst6(-/-)Ctsl(-/-) and Cst6(-/-)Ctsl(+/-) mice were viable, but the absence of cystatin M/E caused scarring alopecia in adult animals.
p40322
sg33279
(lp40323
(dp40324
g33284
I19
sg33285
I1
sg33286
I4
sg33295
VP04080
p40325
sg33289
VCst6
p40326
sa(dp40327
g33284
I19
sg33285
I1
sg33286
I4
sg33295
VP04080
p40328
sg33289
VCst6
p40329
sa(dp40330
g33284
I98
sg33285
I2
sg33286
I12
sg33295
g11
sg33289
Vcystatin M/E
p40331
sasg33281
(lp40332
(dp40333
g33284
I118
sg33285
I2
sg33286
I17
sg33287
VC2936846
p40334
sg33289
Vscarring alopecia
p40335
sasa(dp40336
g33277
VTranscription factor 4 (TCF-4) was recently identified as a candidate gene for the cause of type 2 diabetes, although the mechanisms have not been fully elucidated.
p40337
sg33279
(lp40338
(dp40339
g33284
I0
sg33285
I3
sg33286
I22
sg33295
VP15884
p40340
sg33289
VTranscription factor 4
p40341
sa(dp40342
g33284
I24
sg33285
I1
sg33286
I5
sg33295
VP15884
p40343
sg33289
VTCF-4
p40344
sasg33281
(lp40345
(dp40346
g33284
I92
sg33285
I3
sg33286
I15
sg33287
VC0011860
p40347
sg33289
Vtype 2 diabetes
p40348
sasa(dp40349
g33277
VCollectively, these observations demonstrate a disease-promoting role of E2-2 dependent pDCs in the pancreas during autoimmune diabetes in the NOD mouse.
p40350
sg33279
(lp40351
(dp40352
g33284
I73
sg33285
I1
sg33286
I4
sg33295
VP15884
p40353
sg33289
VE2-2
p40354
sasg33281
(lp40355
(dp40356
g33284
I143
sg33285
I1
sg33286
I3
sg33287
VC0751781
p40357
sg33289
VNOD
p40358
sa(dp40359
g33284
I116
sg33285
I2
sg33286
I19
sg33287
VC0205734
p40360
sg33289
Vautoimmune diabetes
p40361
sasa(dp40362
g33277
VFecal incontinence and constipation still remain the major complications after procedures for anorectal malformations (ARMs).
p40363
sg33279
(lp40364
sg33281
(lp40365
(dp40366
g33284
I23
sg33285
I1
sg33286
I12
sg33287
VC0009806
p40367
sg33289
Vconstipation
p40368
sa(dp40369
g33284
I94
sg33285
I2
sg33286
I23
sg33287
VC2974527
p40370
sg33289
Vanorectal malformations
p40371
sa(dp40372
g33284
I119
sg33285
I1
sg33286
I4
sg33287
VC0206655
p40373
sg33289
VARMs
p40374
sa(dp40375
g33284
I0
sg33285
I2
sg33286
I18
sg33287
VC0015732
p40376
sg33289
VFecal incontinence
p40377
sasa(dp40378
g33277
VNumerous patients with anorectal malformations (ARMs) continue to experience fecal incontinence and constipation following surgical procedures.
p40379
sg33279
(lp40380
sg33281
(lp40381
(dp40382
g33284
I100
sg33285
I1
sg33286
I12
sg33287
VC0009806
p40383
sg33289
Vconstipation
p40384
sa(dp40385
g33284
I48
sg33285
I1
sg33286
I4
sg33287
VC0206655
p40386
sg33289
VARMs
p40387
sa(dp40388
g33284
I77
sg33285
I2
sg33286
I18
sg33287
VC0015732
p40389
sg33289
Vfecal incontinence
p40390
sa(dp40391
g33284
I23
sg33285
I2
sg33286
I23
sg33287
VC2974527
p40392
sg33289
Vanorectal malformations
p40393
sasa(dp40394
g33277
VOver the last two decades, advances in laparoscopic surgery and minimally invasive techniques have transformed the operative management of neonatal colorectal surgery for conditions such as anorectal malformations (ARMs) and Hirschsprung's disease.
p40395
sg33279
(lp40396
sg33281
(lp40397
(dp40398
g33284
I215
sg33285
I1
sg33286
I4
sg33287
VC0206655
p40399
sg33289
VARMs
p40400
sa(dp40401
g33284
I190
sg33285
I2
sg33286
I23
sg33287
VC2974527
p40402
sg33289
Vanorectal malformations
p40403
sa(dp40404
g33284
I225
sg33285
I2
sg33286
I22
sg33287
VC0019569
p40405
sg33289
VHirschsprung's disease
p40406
sasa(dp40407
g33277
VThis review describes these advances and outlines the main minimally invasive techniques currently used for management of ARMs and Hirschsprung's disease.
p40408
sg33279
(lp40409
sg33281
(lp40410
(dp40411
g33284
I122
sg33285
I1
sg33286
I4
sg33287
VC0206655
p40412
sg33289
VARMs
p40413
sa(dp40414
g33284
I131
sg33285
I2
sg33286
I22
sg33287
VC0019569
p40415
sg33289
VHirschsprung's disease
p40416
sasa(dp40417
g33277
VFurther analysis of the PRKAG3 signaling pathway may provide insights into muscle physiology as well as the pathogenesis of noninsulin-dependent diabetes mellitus in humans, a metabolic disorder associated with impaired glycogen synthesis.
p40418
sg33279
(lp40419
(dp40420
g33284
I24
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VPRKAG3
p40421
sasg33281
(lp40422
(dp40423
g33284
I211
sg33285
I1
sg33286
I8
sg33287
VC0684336
p40424
sg33289
Vimpaired
p40425
sa(dp40426
g33284
I124
sg33285
I3
sg33286
I38
sg33287
VC0011860
p40427
sg33289
Vnoninsulin-dependent diabetes mellitus
p40428
sa(dp40429
g33284
I176
sg33285
I2
sg33286
I18
sg33287
VC0025517
p40430
sg33289
Vmetabolic disorder
p40431
sa(dp40432
g33284
I108
sg33285
I1
sg33286
I12
sg33287
VC0699748
p40433
sg33289
Vpathogenesis
p40434
sasa(dp40435
g33277
VIn primates, a PGBD3 element inserted into the Cockayne syndrome group B (CSB) gene over 43 Mya serves as an alternative 3' terminal exon, enabling the CSB gene to generate both full length CSB and a conserved CSB-PGBD3 fusion protein that joins an N-terminal CSB domain to the C-terminal transposase domain.
p40436
sg33279
(lp40437
(dp40438
g33284
I152
sg33285
I2
sg33286
I8
sg33295
VP35548
p40439
sg33289
VCSB gene
p40440
sa(dp40441
g33284
I278
sg33285
I3
sg33286
I29
sg33295
g11
sg33289
VC-terminal transposase domain
p40442
sa(dp40443
g33284
I74
sg33285
I1
sg33286
I3
sg33295
VP35548
p40444
sg33289
VCSB
p40445
sa(dp40446
g33284
I15
sg33285
I2
sg33286
I13
sg33295
g11
sg33289
VPGBD3 element
p40447
sa(dp40448
g33284
I15
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VPGBD3
p40449
sa(dp40450
g33284
I47
sg33285
I4
sg33286
I25
sg33295
VP35548
p40451
sg33289
VCockayne syndrome group B
p40452
sa(dp40453
g33284
I74
sg33285
I1
sg33286
I3
sg33295
VP35548
p40454
sg33289
VCSB
p40455
sasg33281
(lp40456
(dp40457
g33284
I74
sg33285
I1
sg33286
I3
sg33287
VC1858160
p40458
sg33289
VCSB
p40459
sa(dp40460
g33284
I74
sg33285
I1
sg33286
I3
sg33287
VC1858160
p40461
sg33289
VCSB
p40462
sa(dp40463
g33284
I74
sg33285
I1
sg33286
I3
sg33287
VC1858160
p40464
sg33289
VCSB
p40465
sa(dp40466
g33284
I47
sg33285
I4
sg33286
I25
sg33287
VC1858160
p40467
sg33289
VCockayne syndrome group B
p40468
sa(dp40469
g33284
I74
sg33285
I1
sg33286
I3
sg33287
VC1858160
p40470
sg33289
VCSB
p40471
sa(dp40472
g33284
I74
sg33285
I1
sg33286
I3
sg33287
VC1858160
p40473
sg33289
VCSB
p40474
sasa(dp40475
g33277
VThe CSB-PGBD3 fusion protein arose more than 43 million years ago when a 2.5-kb piggyBac 3 (PGBD3) transposon inserted into intron 5 of the Cockayne syndrome Group B (CSB) gene in the common ancestor of all higher primates.
p40476
sg33279
(lp40477
(dp40478
g33284
I4
sg33285
I1
sg33286
I3
sg33295
VP35548
p40479
sg33289
VCSB
p40480
sa(dp40481
g33284
I8
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VPGBD3
p40482
sa(dp40483
g33284
I8
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VPGBD3
p40484
sa(dp40485
g33284
I4
sg33285
I1
sg33286
I3
sg33295
VP35548
p40486
sg33289
VCSB
p40487
sa(dp40488
g33284
I140
sg33285
I4
sg33286
I25
sg33295
VP35548
p40489
sg33289
VCockayne syndrome Group B
p40490
sasg33281
(lp40491
(dp40492
g33284
I4
sg33285
I1
sg33286
I3
sg33287
VC1858160
p40493
sg33289
VCSB
p40494
sa(dp40495
g33284
I140
sg33285
I4
sg33286
I25
sg33287
VC1858160
p40496
sg33289
VCockayne syndrome Group B
p40497
sa(dp40498
g33284
I4
sg33285
I1
sg33286
I3
sg33287
VC1858160
p40499
sg33289
VCSB
p40500
sasa(dp40501
g33277
VOur data suggest that the CSB-PGBD3 fusion protein is important in both health and disease, and could play a role in Cockayne syndrome.
p40502
sg33279
(lp40503
(dp40504
g33284
I30
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VPGBD3
p40505
sa(dp40506
g33284
I26
sg33285
I1
sg33286
I3
sg33295
VP35548
p40507
sg33289
VCSB
p40508
sasg33281
(lp40509
(dp40510
g33284
I117
sg33285
I2
sg33286
I17
sg33287
VC0009207
p40511
sg33289
VCockayne syndrome
p40512
sa(dp40513
g33284
I26
sg33285
I1
sg33286
I3
sg33287
VC1858160
p40514
sg33289
VCSB
p40515
sasa(dp40516
g33277
VIn this study, we searched for cerebral MBs in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a unique type of small-vessel disease caused by mutations in the Notch3 gene.
p40517
sg33279
(lp40518
(dp40519
g33284
I214
sg33285
I2
sg33286
I11
sg33295
g11
sg33289
VNotch3 gene
p40520
sasg33281
(lp40521
(dp40522
g33284
I47
sg33285
I9
sg33286
I90
sg33287
VC0751587
p40523
sg33289
Vcerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
p40524
sa(dp40525
g33284
I139
sg33285
I1
sg33286
I7
sg33287
VC0751587
p40526
sg33289
VCADASIL
p40527
sa(dp40528
g33284
I40
sg33285
I1
sg33286
I3
sg33287
VC0221060
p40529
sg33289
VMBs
p40530
sasa(dp40531
g33277
VOur purposes were (1) to determine the frequency, extent, and pattern of MBs in CADASIL; (2) to analyze the relationship between MBs and T2-hyperintense lesions; and (3) to evaluate the histopathology of brain tissue affected by MBs.
p40532
sg33279
(lp40533
(dp40534
g33284
I73
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VMBs
p40535
sasg33281
(lp40536
(dp40537
g33284
I73
sg33285
I1
sg33286
I3
sg33287
VC0221060
p40538
sg33289
VMBs
p40539
sa(dp40540
g33284
I73
sg33285
I1
sg33286
I3
sg33287
VC0221060
p40541
sg33289
VMBs
p40542
sa(dp40543
g33284
I73
sg33285
I1
sg33286
I3
sg33287
VC0221060
p40544
sg33289
VMBs
p40545
sa(dp40546
g33284
I80
sg33285
I1
sg33286
I7
sg33287
VC0751587
p40547
sg33289
VCADASIL
p40548
sasa(dp40549
g33277
VFocal areas of signal loss on gradient-echo images suggesting past MBs were found in 11 CADASIL individuals (69%) and no control subjects (P&lt;0.001).
p40550
sg33279
(lp40551
(dp40552
g33284
I67
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VMBs
p40553
sasg33281
(lp40554
(dp40555
g33284
I67
sg33285
I1
sg33286
I3
sg33287
VC0221060
p40556
sg33289
VMBs
p40557
sa(dp40558
g33284
I88
sg33285
I1
sg33286
I7
sg33287
VC0751587
p40559
sg33289
VCADASIL
p40560
sasa(dp40561
g33277
VThe average number of MBs was 5.9+/-7.3 (range, 0 to 22) in individual CADASIL patients.
p40562
sg33279
(lp40563
sg33281
(lp40564
(dp40565
g33284
I22
sg33285
I1
sg33286
I3
sg33287
VC0221060
p40566
sg33289
VMBs
p40567
sa(dp40568
g33284
I71
sg33285
I1
sg33286
I7
sg33287
VC0751587
p40569
sg33289
VCADASIL
p40570
sasa(dp40571
g33277
VThis study shows a high frequency and multiplicity of MBs in individuals with CADASIL.
p40572
sg33279
(lp40573
sg33281
(lp40574
(dp40575
g33284
I78
sg33285
I1
sg33286
I7
sg33287
VC0751587
p40576
sg33289
VCADASIL
p40577
sa(dp40578
g33284
I54
sg33285
I1
sg33286
I3
sg33287
VC0221060
p40579
sg33289
VMBs
p40580
sasa(dp40581
g33277
VAt stimulation, the tubulovesicles fuse with the apical canaliculi and the HK-ATPase is incorporated into the apical membrane where it actively pumps H ions in exchange for K. Acute infection with Helicobacter pylori results in hypochlorhydria, whereas chronic infection can cause either hypo- or hyperchlorhydria, depending on the distribution of the infection and the degree of corpus gastritis.
p40582
sg33279
(lp40583
(dp40584
g33284
I75
sg33285
I1
sg33286
I9
sg33295
VP38606
p40585
sg33289
VHK-ATPase
p40586
sasg33281
(lp40587
(dp40588
g33284
I176
sg33285
I2
sg33286
I15
sg33287
VC0275518
p40589
sg33289
VAcute infection
p40590
sa(dp40591
g33284
I297
sg33285
I1
sg33286
I16
sg33287
VC0151713
p40592
sg33289
Vhyperchlorhydria
p40593
sa(dp40594
g33284
I253
sg33285
I2
sg33286
I17
sg33287
VC0151317
p40595
sg33289
Vchronic infection
p40596
sa(dp40597
g33284
I182
sg33285
I1
sg33286
I9
sg33287
VC0009450
p40598
sg33289
Vinfection
p40599
sa(dp40600
g33284
I387
sg33285
I1
sg33286
I9
sg33287
VC0017152
p40601
sg33289
Vgastritis
p40602
sa(dp40603
g33284
I228
sg33285
I1
sg33286
I15
sg33287
VC0079581
p40604
sg33289
Vhypochlorhydria
p40605
sasa(dp40606
g33277
VThe results directly confirm that the gastric H+/K(+)-ATPase is the causative autoantigen in the genesis of autoimmune gastritis.
p40607
sg33279
(lp40608
(dp40609
g33284
I38
sg33285
I2
sg33286
I22
sg33295
VP38606
p40610
sg33289
Vgastric H+/K(+)-ATPase
p40611
sasg33281
(lp40612
(dp40613
g33284
I108
sg33285
I2
sg33286
I20
sg33287
VC0017154
p40614
sg33289
Vautoimmune gastritis
p40615
sasa(dp40616
g33277
VWe conclude that the beta subunit of the gastric H/K ATPase is a major T cell target in autoimmune gastritis and that thymic expression of a single autoantigen can abrogate an autoimmune response to multiple autoantigens.
p40617
sg33279
(lp40618
(dp40619
g33284
I41
sg33285
I3
sg33286
I18
sg33295
VP38606
p40620
sg33289
Vgastric H/K ATPase
p40621
sasg33281
(lp40622
(dp40623
g33284
I176
sg33285
I2
sg33286
I19
sg33287
VC0004366
p40624
sg33289
Vautoimmune response
p40625
sa(dp40626
g33284
I88
sg33285
I2
sg33286
I20
sg33287
VC0017154
p40627
sg33289
Vautoimmune gastritis
p40628
sasa(dp40629
g33277
V8 cases of pneumophathia osteoplastica (ppo) of branching type observed at patients having no vascular deformities and one case of a focal ppo at a patient with mitral stenosis are reported.
p40630
sg33279
(lp40631
(dp40632
g33284
I40
sg33285
I1
sg33286
I3
sg33295
VP50336
p40633
sg33289
Vppo
p40634
sasg33281
(lp40635
(dp40636
g33284
I161
sg33285
I2
sg33286
I15
sg33287
VC0026269
p40637
sg33289
Vmitral stenosis
p40638
sa(dp40639
g33284
I103
sg33285
I1
sg33286
I11
sg33287
VC0000768
p40640
sg33289
Vdeformities
p40641
sasa(dp40642
g33277
VCDKN3 is often overexpressed in human cancer, and this overexpression correlates with reduced survival in several types of cancer.
p40643
sg33279
(lp40644
sg33281
(lp40645
(dp40646
g33284
I38
sg33285
I1
sg33286
I6
sg33287
VC0006826
p40647
sg33289
Vcancer
p40648
sa(dp40649
g33284
I38
sg33285
I1
sg33286
I6
sg33287
VC0006826
p40650
sg33289
Vcancer
p40651
sasa(dp40652
g33277
VThe mechanism of CDKN3 overexpression and the role of CDKN3 transcript variants in human cancer are not entirely clear.
p40653
sg33279
(lp40654
(dp40655
g33284
I54
sg33285
I3
sg33286
I25
sg33295
VP26640
p40656
sg33289
VCDKN3 transcript variants
p40657
sasg33281
(lp40658
(dp40659
g33284
I89
sg33285
I1
sg33286
I6
sg33287
VC0006826
p40660
sg33289
Vcancer
p40661
sasa(dp40662
g33277
VBesides the full-length CDKN3 encoding transcript and a major transcript that skips exon 2 express in normal and cancer cells, minor aberrant transcript variants have been reported.
p40663
sg33279
(lp40664
sg33281
(lp40665
(dp40666
g33284
I113
sg33285
I1
sg33286
I6
sg33287
VC0006826
p40667
sg33289
Vcancer
p40668
sasa(dp40669
g33277
VAberrant CDKN3 transcripts were postulated to encode dominant-negative inhibitors of CDKN3 as an explanation for overexpression of the perceived tumor suppressor gene in human cancer.
p40670
sg33279
(lp40671
sg33281
(lp40672
(dp40673
g33284
I145
sg33285
I1
sg33286
I5
sg33287
VC0027651
p40674
sg33289
Vtumor
p40675
sa(dp40676
g33284
I176
sg33285
I1
sg33286
I6
sg33287
VC0006826
p40677
sg33289
Vcancer
p40678
sasa(dp40679
g33277
VHowever, while CDKN3 is often overexpressed in human cancer, aberrant CDKN3 transcripts occur infrequently and at lower levels.
p40680
sg33279
(lp40681
sg33281
(lp40682
(dp40683
g33284
I53
sg33285
I1
sg33286
I6
sg33287
VC0006826
p40684
sg33289
Vcancer
p40685
sasa(dp40686
g33277
VCDKN3 mutations and copy number alternation are rare in human cancer, implying that neither loss of CDKN3 activity nor constitutive gain of CDKN3 expression offer an advantage to tumorigenesis.
p40687
sg33279
(lp40688
sg33281
(lp40689
(dp40690
g33284
I179
sg33285
I1
sg33286
I13
sg33287
VC0007621
p40691
sg33289
Vtumorigenesis
p40692
sa(dp40693
g33284
I62
sg33285
I1
sg33286
I6
sg33287
VC0006826
p40694
sg33289
Vcancer
p40695
sa(dp40696
g33284
I32
sg33285
I1
sg33286
I11
sg33287
VC0919661
p40697
sg33289
Valternation
p40698
sasa(dp40699
g33277
VGiven that rapidly growing tumors have more mitotic cells, the high level of mitotic CDKN3 expression is the most plausible mechanism of frequent CDKN3 overexpression in human cancer.
p40700
sg33279
(lp40701
sg33281
(lp40702
(dp40703
g33284
I27
sg33285
I1
sg33286
I6
sg33287
VC0027651
p40704
sg33289
Vtumors
p40705
sa(dp40706
g33284
I176
sg33285
I1
sg33286
I6
sg33287
VC0006826
p40707
sg33289
Vcancer
p40708
sasa(dp40709
g33277
VThis finding clarifies the mechanism of CDKN3 overexpression in human cancer and questions the view of CDKN3 as a tumor suppressor.
p40710
sg33279
(lp40711
sg33281
(lp40712
(dp40713
g33284
I70
sg33285
I1
sg33286
I6
sg33287
VC0006826
p40714
sg33289
Vcancer
p40715
sa(dp40716
g33284
I114
sg33285
I1
sg33286
I5
sg33287
VC0027651
p40717
sg33289
Vtumor
p40718
sasa(dp40719
g33277
VAbnormal expression of CDKN3 has been found in numerous types of cancer.
p40720
sg33279
(lp40721
sg33281
(lp40722
(dp40723
g33284
I65
sg33285
I1
sg33286
I6
sg33287
VC0006826
p40724
sg33289
Vcancer
p40725
sasa(dp40726
g33277
VSince it is unclear whether CDKN3 participates in the development of human gastric cancer, this study assessed the association between CDKN3 expression and cell biological function and demonstrated the clinical significance and prognosis of CDKN3 in human gastric cancer.
p40727
sg33279
(lp40728
sg33281
(lp40729
(dp40730
g33284
I75
sg33285
I2
sg33286
I14
sg33287
VC0024623
p40731
sg33289
Vgastric cancer
p40732
sa(dp40733
g33284
I75
sg33285
I2
sg33286
I14
sg33287
VC0024623
p40734
sg33289
Vgastric cancer
p40735
sasa(dp40736
g33277
VIn this study, we found that CDKN3 showed a high expression in 35 paired human gastric cancer tissues and was correlated with poor patient survival, AJCC clinical staging, and recurrence.
p40737
sg33279
(lp40738
sg33281
(lp40739
(dp40740
g33284
I79
sg33285
I2
sg33286
I14
sg33287
VC0024623
p40741
sg33289
Vgastric cancer
p40742
sa(dp40743
g33284
I176
sg33285
I1
sg33286
I10
sg33287
VC1458156
p40744
sg33289
Vrecurrence
p40745
sasa(dp40746
g33277
VSilencing of CDKN3 in human gastric cancer cells can significantly reduce proliferation, migration, invasion, and adhesion abilities.
p40747
sg33279
(lp40748
sg33281
(lp40749
(dp40750
g33284
I100
sg33285
I1
sg33286
I8
sg33287
VC2699153
p40751
sg33289
Vinvasion
p40752
sa(dp40753
g33284
I28
sg33285
I2
sg33286
I14
sg33287
VC0024623
p40754
sg33289
Vgastric cancer
p40755
sa(dp40756
g33284
I74
sg33285
I1
sg33286
I13
sg33287
VC0334094
p40757
sg33289
Vproliferation
p40758
sa(dp40759
g33284
I114
sg33285
I1
sg33286
I8
sg33287
VC0001511
p40760
sg33289
Vadhesion
p40761
sasa(dp40762
g33277
VAlso, silencing of CDKN3 in human gastric cancer cells can induce G0-G1 cell cycle arrest and apoptosis.
p40763
sg33279
(lp40764
sg33281
(lp40765
(dp40766
g33284
I34
sg33285
I2
sg33286
I14
sg33287
VC0024623
p40767
sg33289
Vgastric cancer
p40768
sasa(dp40769
g33277
VDetection of cell cycle marker expression showed that CDKN3 knockdown promotes cell cycle arrest by decreasing the expression of CDK2, CDC25A, CCNB1, and CCNB2 in human gastric cancer cells.
p40770
sg33279
(lp40771
(dp40772
g33284
I129
sg33285
I1
sg33286
I4
sg33295
VP24941
p40773
sg33289
VCDK2
p40774
sa(dp40775
g33284
I154
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCCNB2
p40776
sa(dp40777
g33284
I143
sg33285
I1
sg33286
I5
sg33295
VP14635
p40778
sg33289
VCCNB1
p40779
sa(dp40780
g33284
I135
sg33285
I1
sg33286
I6
sg33295
VP30304
p40781
sg33289
VCDC25A
p40782
sasg33281
(lp40783
(dp40784
g33284
I169
sg33285
I2
sg33286
I14
sg33287
VC0024623
p40785
sg33289
Vgastric cancer
p40786
sasa(dp40787
g33277
VThe results of this study will help elucidate the oncogene function of CDKN3 in human gastric cancer.
p40788
sg33279
(lp40789
sg33281
(lp40790
(dp40791
g33284
I86
sg33285
I2
sg33286
I14
sg33287
VC0024623
p40792
sg33289
Vgastric cancer
p40793
sasa(dp40794
g33277
VHowever, whether CDKN3 is a potential therapeutic target for breast cancer remains to be elucidated.
p40795
sg33279
(lp40796
sg33281
(lp40797
(dp40798
g33284
I61
sg33285
I2
sg33286
I13
sg33287
VC0678222
p40799
sg33289
Vbreast cancer
p40800
sasa(dp40801
g33277
VThe present in vitro study aimed to investigate the potential roles of CDKN3 in breast cancer.
p40802
sg33279
(lp40803
sg33281
(lp40804
(dp40805
g33284
I80
sg33285
I2
sg33286
I13
sg33287
VC0678222
p40806
sg33289
Vbreast cancer
p40807
sasa(dp40808
g33277
VBreast cancer cell lines were used to detect CDKN3 expression, and CDKN3 expression was silenced to investigate its role in cell apoptosis, cell cycle arrest and migration.
p40809
sg33279
(lp40810
sg33281
(lp40811
(dp40812
g33284
I0
sg33285
I2
sg33286
I13
sg33287
VC0678222
p40813
sg33289
VBreast cancer
p40814
sasa(dp40815
g33277
VThese results suggest that CDKN3 acts as an oncogene during breast cancer progression.
p40816
sg33279
(lp40817
sg33281
(lp40818
(dp40819
g33284
I67
sg33285
I2
sg33286
I18
sg33287
VC0178874
p40820
sg33289
Vcancer progression
p40821
sasa(dp40822
g33277
VCDKN3 may therefore be considered a potential target for the treatment of breast cancer.
p40823
sg33279
(lp40824
sg33281
(lp40825
(dp40826
g33284
I74
sg33285
I2
sg33286
I13
sg33287
VC0678222
p40827
sg33289
Vbreast cancer
p40828
sasa(dp40829
g33277
VParadoxically, CDKN3 is often overexpressed in human cancer.
p40830
sg33279
(lp40831
sg33281
(lp40832
(dp40833
g33284
I53
sg33285
I1
sg33286
I6
sg33287
VC0006826
p40834
sg33289
Vcancer
p40835
sasa(dp40836
g33277
VWe analysed CDKN3 expression and its association with patient survival in three cohorts of lung adenocarcinoma.
p40837
sg33279
(lp40838
sg33281
(lp40839
(dp40840
g33284
I91
sg33285
I2
sg33286
I19
sg33287
VC0152013
p40841
sg33289
Vlung adenocarcinoma
p40842
sasa(dp40843
g33277
VWe also examined CDKN3 mutations in the Cancer Genome Atlas (TCGA) and the Moffitt Cancer Center's Total Cancer Care (TCC) projects.
p40844
sg33279
(lp40845
sg33281
(lp40846
(dp40847
g33284
I40
sg33285
I1
sg33286
I6
sg33287
VC0006826
p40848
sg33289
VCancer
p40849
sa(dp40850
g33284
I118
sg33285
I1
sg33286
I3
sg33287
VC1861305
p40851
sg33289
VTCC
p40852
sa(dp40853
g33284
I40
sg33285
I1
sg33286
I6
sg33287
VC0006826
p40854
sg33289
VCancer
p40855
sa(dp40856
g33284
I99
sg33285
I3
sg33286
I17
sg33287
VC1861305
p40857
sg33289
VTotal Cancer Care
p40858
sasa(dp40859
g33277
VCDKN3 transcripts were further analysed in a panel of cell lines and lung adenocarcinoma tissues.
p40860
sg33279
(lp40861
sg33281
(lp40862
(dp40863
g33284
I69
sg33285
I2
sg33286
I19
sg33287
VC0152013
p40864
sg33289
Vlung adenocarcinoma
p40865
sasa(dp40866
g33277
VCDKN3 is overexpressed in non small cell lung cancer.
p40867
sg33279
(lp40868
sg33281
(lp40869
(dp40870
g33284
I26
sg33285
I5
sg33286
I26
sg33287
VC0007131
p40871
sg33289
Vnon small cell lung cancer
p40872
sasa(dp40873
g33277
VHigh CDKN3 expression is associated with poor overall survival in lung adenocarcinoma.
p40874
sg33279
(lp40875
sg33281
(lp40876
(dp40877
g33284
I66
sg33285
I2
sg33286
I19
sg33287
VC0152013
p40878
sg33289
Vlung adenocarcinoma
p40879
sasa(dp40880
g33277
VCDKN3 overexpression is prognostic of poor overall survival in lung adenocarcinoma.
p40881
sg33279
(lp40882
sg33281
(lp40883
(dp40884
g33284
I63
sg33285
I2
sg33286
I19
sg33287
VC0152013
p40885
sg33289
Vlung adenocarcinoma
p40886
sasa(dp40887
g33277
VCDKN3 overexpression in lung adenocarcinoma is not attributed to alternative splicing or mutation but is likely due to increased mitotic activity, arguing against CDKN3 as a tumour suppressor.
p40888
sg33279
(lp40889
sg33281
(lp40890
(dp40891
g33284
I174
sg33285
I1
sg33286
I6
sg33287
VC0027651
p40892
sg33289
Vtumour
p40893
sa(dp40894
g33284
I24
sg33285
I2
sg33286
I19
sg33287
VC0152013
p40895
sg33289
Vlung adenocarcinoma
p40896
sasa(dp40897
g33277
VThe cyclin-dependent kinase inhibitor 3 (CDKN3) gene, involved in mitosis, is upregulated in cervical cancer (CC).
p40898
sg33279
(lp40899
(dp40900
g33284
I4
sg33285
I4
sg33286
I35
sg33295
VP38936
p40901
sg33289
Vcyclin-dependent kinase inhibitor 3
p40902
sa(dp40903
g33284
I41
sg33285
I1
sg33286
I5
sg33295
VP38936
p40904
sg33289
VCDKN3
p40905
sasg33281
(lp40906
(dp40907
g33284
I93
sg33285
I2
sg33286
I15
sg33287
VC0302592
p40908
sg33289
Vcervical cancer
p40909
sasa(dp40910
g33277
VThe aim of this study is to investigate the possible mechanisms of silence of CDKN3 exerting the suppressive role on epithelial ovarian cancer (EOC).
p40911
sg33279
(lp40912
sg33281
(lp40913
(dp40914
g33284
I144
sg33285
I1
sg33286
I3
sg33287
VC0677886
p40915
sg33289
VEOC
p40916
sa(dp40917
g33284
I67
sg33285
I1
sg33286
I7
sg33287
VC0858952
p40918
sg33289
Vsilence
p40919
sa(dp40920
g33284
I117
sg33285
I3
sg33286
I25
sg33287
VC0677886
p40921
sg33289
Vepithelial ovarian cancer
p40922
sasa(dp40923
g33277
VFunctional studies showed that silence of CDKN3 inhibited cancer cell proliferation by promoting cell cycle progression in G1 phase, decreased cell invasion and promoted EOC cells apoptosis.
p40924
sg33279
(lp40925
sg33281
(lp40926
(dp40927
g33284
I31
sg33285
I1
sg33286
I7
sg33287
VC0858952
p40928
sg33289
Vsilence
p40929
sa(dp40930
g33284
I58
sg33285
I1
sg33286
I6
sg33287
VC0006826
p40931
sg33289
Vcancer
p40932
sa(dp40933
g33284
I143
sg33285
I2
sg33286
I13
sg33287
VC2699153
p40934
sg33289
Vcell invasion
p40935
sa(dp40936
g33284
I70
sg33285
I1
sg33286
I13
sg33287
VC0334094
p40937
sg33289
Vproliferation
p40938
sasa(dp40939
g33277
VThese findings indicated that CDKN3 might serve as a useful potential target for treatment of ovarian cancer.
p40940
sg33279
(lp40941
sg33281
(lp40942
(dp40943
g33284
I94
sg33285
I2
sg33286
I14
sg33287
VC1140680
p40944
sg33289
Vovarian cancer
p40945
sasa(dp40946
g33277
VWe first discovered the pro-tumor effect of a controversial cell cycle regulator, cylin-dependent kinase inhibitor 3 (CDKN3), which is highly expressed in colorectal cancer, and the possible related signaling pathways, by bioinformatics tools.
p40947
sg33279
(lp40948
(dp40949
g33284
I82
sg33285
I4
sg33286
I34
sg33295
VP19525
p40950
sg33289
Vcylin-dependent kinase inhibitor 3
p40951
sa(dp40952
g33284
I118
sg33285
I1
sg33286
I5
sg33295
VP19525
p40953
sg33289
VCDKN3
p40954
sasg33281
(lp40955
(dp40956
g33284
I28
sg33285
I1
sg33286
I5
sg33287
VC0027651
p40957
sg33289
Vtumor
p40958
sa(dp40959
g33284
I155
sg33285
I2
sg33286
I17
sg33287
VC1527249
p40960
sg33289
Vcolorectal cancer
p40961
sasa(dp40962
g33277
VWe found that CDKN3 had remarkable effects in suppressing colorectal cancer cell proliferation and migration, inducing cell cycle arrest and apoptosis in a colorectal cancer cell line, SW480 cells.
p40963
sg33279
(lp40964
sg33281
(lp40965
(dp40966
g33284
I58
sg33285
I2
sg33286
I17
sg33287
VC1527249
p40967
sg33289
Vcolorectal cancer
p40968
sa(dp40969
g33284
I58
sg33285
I2
sg33286
I17
sg33287
VC1527249
p40970
sg33289
Vcolorectal cancer
p40971
sa(dp40972
g33284
I81
sg33285
I1
sg33286
I13
sg33287
VC0334094
p40973
sg33289
Vproliferation
p40974
sasa(dp40975
g33277
VOur study, for the first time, provided consistent evidence showing overexpression of cell cycle regulator CDKN3, in colorectal cancer.
p40976
sg33279
(lp40977
sg33281
(lp40978
(dp40979
g33284
I117
sg33285
I2
sg33286
I17
sg33287
VC1527249
p40980
sg33289
Vcolorectal cancer
p40981
sasa(dp40982
g33277
VThe in vitro studies in SW480 cells revealed a unique role of CDKN3 in regulating cellular behavior of colorectal cancer cells, and implied the possibility of targeting CDKN3 as a novel treatment for colorectal cancer.
p40983
sg33279
(lp40984
sg33281
(lp40985
(dp40986
g33284
I103
sg33285
I2
sg33286
I17
sg33287
VC1527249
p40987
sg33289
Vcolorectal cancer
p40988
sa(dp40989
g33284
I103
sg33285
I2
sg33286
I17
sg33287
VC1527249
p40990
sg33289
Vcolorectal cancer
p40991
sasa(dp40992
g33277
VHowever, the role of CDKN3 in Bcr-Abl-mediated chronic myelogenous leukemia (CML) remains unknown.
p40993
sg33279
(lp40994
(dp40995
g33284
I30
sg33285
I1
sg33286
I3
sg33295
VP11274
p40996
sg33289
VBcr
p40997
sa(dp40998
g33284
I34
sg33285
I1
sg33286
I3
sg33295
VP55157
p40999
sg33289
VAbl
p41000
sasg33281
(lp41001
(dp41002
g33284
I47
sg33285
I3
sg33286
I28
sg33287
VC0023473
p41003
sg33289
Vchronic myelogenous leukemia
p41004
sa(dp41005
g33284
I77
sg33285
I1
sg33286
I3
sg33287
VC0023473
p41006
sg33289
VCML
p41007
sa(dp41008
g33284
I34
sg33285
I1
sg33286
I3
sg33287
VC0000744
p41009
sg33289
VAbl
p41010
sasa(dp41011
g33277
VIn contrast, depletion of CDKN3 expression conferred resistance to imatinib-induced apoptosis in the leukemic cells and accelerated the growth of xenograph leukemia in mice.
p41012
sg33279
(lp41013
sg33281
(lp41014
(dp41015
g33284
I156
sg33285
I1
sg33286
I8
sg33287
VC0023418
p41016
sg33289
Vleukemia
p41017
sasa(dp41018
g33277
VOur results highlight the importance of CDKN3 in Bcr-Abl-mediated leukemogenesis, and provide new insights into diagnostics and therapeutics of the leukemia.
p41019
sg33279
(lp41020
(dp41021
g33284
I49
sg33285
I1
sg33286
I3
sg33295
VP11274
p41022
sg33289
VBcr
p41023
sa(dp41024
g33284
I53
sg33285
I1
sg33286
I3
sg33295
VP55157
p41025
sg33289
VAbl
p41026
sasg33281
(lp41027
(dp41028
g33284
I148
sg33285
I1
sg33286
I8
sg33287
VC0023418
p41029
sg33289
Vleukemia
p41030
sa(dp41031
g33284
I66
sg33285
I1
sg33286
I14
sg33287
VC0598766
p41032
sg33289
Vleukemogenesis
p41033
sa(dp41034
g33284
I53
sg33285
I1
sg33286
I3
sg33287
VC0000744
p41035
sg33289
VAbl
p41036
sasa(dp41037
g33277
VUsing in situ hybridization, the expression of key clock genes, including period circadian protein homolog (Per) 1 and 2, cryptochrome 1 (Cry1), circadian locomoter output cycles protein kaput (Clock), brain and muscle ARNT-like protein 1 (Bmal1) and casein kinase 1Epsilon (CK1Epsilon) were retrospectively examined in 51 cases of colorectal carcinoma and 10 cases of adenoma.
p41038
sg33279
(lp41039
(dp41040
g33284
I219
sg33285
I3
sg33286
I19
sg33295
VP14222
p41041
sg33289
VARNT-like protein 1
p41042
sa(dp41043
g33284
I275
sg33285
I1
sg33286
I10
sg33295
VP48729
p41044
sg33289
VCK1Epsilon
p41045
sa(dp41046
g33284
I138
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCry1
p41047
sa(dp41048
g33284
I122
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
Vcryptochrome 1
p41049
sa(dp41050
g33284
I81
sg33285
I7
sg33286
I39
sg33295
g11
sg33289
Vcircadian protein homolog (Per) 1 and 2
p41051
sa(dp41052
g33284
I251
sg33285
I3
sg33286
I22
sg33295
VP48729
p41053
sg33289
Vcasein kinase 1Epsilon
p41054
sasg33281
(lp41055
(dp41056
g33284
I369
sg33285
I1
sg33286
I7
sg33287
VC0001430
p41057
sg33289
Vadenoma
p41058
sa(dp41059
g33284
I332
sg33285
I2
sg33286
I20
sg33287
VC0009402
p41060
sg33289
Vcolorectal carcinoma
p41061
sasa(dp41062
g33277
VThe present study demonstrated that the protein expression levels of human circadian locomoter output cycles protein kaput (hCLOCK) is significantly increased, while miR-124 is attenuated in high-grade human CRC tissues and in the more invasive colorectal cancer cell lines SW620 and LOVO.
p41063
sg33279
(lp41064
(dp41065
g33284
I166
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VmiR-124
p41066
sa(dp41067
g33284
I124
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VhCLOCK
p41068
sa(dp41069
g33284
I69
sg33285
I7
sg33286
I53
sg33295
g11
sg33289
Vhuman circadian locomoter output cycles protein kaput
p41070
sasg33281
(lp41071
(dp41072
g33284
I208
sg33285
I1
sg33286
I3
sg33287
VC1527249
p41073
sg33289
VCRC
p41074
sa(dp41075
g33284
I245
sg33285
I2
sg33286
I17
sg33287
VC1527249
p41076
sg33289
Vcolorectal cancer
p41077
sasa(dp41078
g33277
VThe CLOCK gene may be designated as a novel candidate for targeted gene therapy in drug-resistant ovarian cancer.
p41079
sg33279
(lp41080
(dp41081
g33284
I4
sg33285
I2
sg33286
I10
sg33295
g11
sg33289
VCLOCK gene
p41082
sasg33281
(lp41083
(dp41084
g33284
I98
sg33285
I2
sg33286
I14
sg33287
VC1140680
p41085
sg33289
Vovarian cancer
p41086
sasa(dp41087
g33277
VStudy distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.
p41088
sg33279
(lp41089
(dp41090
g33284
I495
sg33285
I2
sg33286
I15
sg33295
g11
sg33289
VCLOCK rs3749474
p41091
sa(dp41092
g33284
I376
sg33285
I2
sg33286
I16
sg33295
g11
sg33289
VNPAS2 rs10165970
p41093
sa(dp41094
g33284
I671
sg33285
I1
sg33286
I4
sg33295
VP56645
p41095
sg33289
VPER3
p41096
sa(dp41097
g33284
I624
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VRORB rs7867494
p41098
sasg33281
(lp41099
(dp41100
g33284
I219
sg33285
I4
sg33286
I26
sg33287
VC0007131
p41101
sg33289
Vnon-small cell lung cancer
p41102
sa(dp41103
g33284
I144
sg33285
I1
sg33286
I6
sg33287
VC0017638
p41104
sg33289
Vglioma
p41105
sa(dp41106
g33284
I22
sg33285
I1
sg33286
I5
sg33287
VC0027651
p41107
sg33289
Vtumor
p41108
sa(dp41109
g33284
I44
sg33285
I2
sg33286
I13
sg33287
VC0678222
p41110
sg33289
Vbreast cancer
p41111
sa(dp41112
g33284
I44
sg33285
I2
sg33286
I13
sg33287
VC0678222
p41113
sg33289
Vbreast cancer
p41114
sa(dp41115
g33284
I44
sg33285
I2
sg33286
I13
sg33287
VC0678222
p41116
sg33289
Vbreast cancer
p41117
sa(dp41118
g33284
I51
sg33285
I1
sg33286
I6
sg33287
VC0006826
p41119
sg33289
Vcancer
p41120
sa(dp41121
g33284
I89
sg33285
I2
sg33286
I17
sg33287
VC0235974
p41122
sg33289
Vpancreatic cancer
p41123
sa(dp41124
g33284
I256
sg33285
I2
sg33286
I14
sg33287
VC1140680
p41125
sg33289
Vovarian cancer
p41126
sa(dp41127
g33284
I44
sg33285
I2
sg33286
I13
sg33287
VC0678222
p41128
sg33289
Vbreast cancer
p41129
sa(dp41130
g33284
I44
sg33285
I2
sg33286
I13
sg33287
VC0678222
p41131
sg33289
Vbreast cancer
p41132
sa(dp41133
g33284
I158
sg33285
I3
sg33286
I28
sg33287
VC0023434
p41134
sg33289
Vchronic lymphocytic leukemia
p41135
sa(dp41136
g33284
I114
sg33285
I2
sg33286
I22
sg33287
VC0024305
p41137
sg33289
Vnon-Hodgkin's lymphoma
p41138
sa(dp41139
g33284
I66
sg33285
I2
sg33286
I15
sg33287
VC0600139
p41140
sg33289
Vprostate cancer
p41141
sa(dp41142
g33284
I194
sg33285
I2
sg33286
I17
sg33287
VC1527249
p41143
sg33289
Vcolorectal cancer
p41144
sasa(dp41145
g33277
VWe summarize fifteen epidemiological studies, including five studies on shift work that have indicated BMAL1, BMAL2, CLOCK, NPAS2, CRY1, CRY2, PER1, PER3 and TIMELESS as a candidate breast cancer risk variants.
p41146
sg33279
(lp41147
(dp41148
g33284
I149
sg33285
I1
sg33286
I4
sg33295
VP56645
p41149
sg33289
VPER3
p41150
sa(dp41151
g33284
I131
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCRY1
p41152
sa(dp41153
g33284
I124
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VNPAS2
p41154
sa(dp41155
g33284
I158
sg33285
I1
sg33286
I8
sg33295
VP60174
p41156
sg33289
VTIMELESS
p41157
sa(dp41158
g33284
I143
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VPER1
p41159
sa(dp41160
g33284
I117
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCLOCK
p41161
sa(dp41162
g33284
I137
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCRY2
p41163
sasg33281
(lp41164
(dp41165
g33284
I182
sg33285
I2
sg33286
I13
sg33287
VC0678222
p41166
sg33289
Vbreast cancer
p41167
sasa(dp41168
g33277
VThis study sought to determine TANK (rs1921310, rs3820998) gene polymorphism in patients suffering from chronic periodontitis and peri-implantitis among an Iranian population.
p41169
sg33279
(lp41170
(dp41171
g33284
I31
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTANK
p41172
sasg33281
(lp41173
(dp41174
g33284
I89
sg33285
I1
sg33286
I9
sg33287
VC0683278
p41175
sg33289
Vsuffering
p41176
sa(dp41177
g33284
I104
sg33285
I2
sg33286
I21
sg33287
VC0266929
p41178
sg33289
Vchronic periodontitis
p41179
sa(dp41180
g33284
I130
sg33285
I1
sg33286
I16
sg33287
VC2936258
p41181
sg33289
Vperi-implantitis
p41182
sasa(dp41183
g33277
VThe tumor necrosis factor receptor-associated factor family member-associated nuclear factor-KB (NF-KB) activator (TANK) takes part in the tumor necrosis factor-Alfa (TNF-Alfa)-mediated NF-KB signaling pathway and the interferon (IFN)-induction pathways that have relevance to HBV-related liver disease.
p41184
sg33279
(lp41185
(dp41186
g33284
I4
sg33285
I9
sg33286
I91
sg33295
VP01375
p41187
sg33289
Vtumor necrosis factor receptor-associated factor family member-associated nuclear factor-KB
p41188
sa(dp41189
g33284
I218
sg33285
I1
sg33286
I10
sg33295
VP01563
p41190
sg33289
Vinterferon
p41191
sa(dp41192
g33284
I115
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTANK
p41193
sa(dp41194
g33284
I139
sg33285
I3
sg33286
I26
sg33295
VP01375
p41195
sg33289
Vtumor necrosis factor-Alfa
p41196
sa(dp41197
g33284
I167
sg33285
I1
sg33286
I8
sg33295
VP01375
p41198
sg33289
VTNF-Alfa
p41199
sa(dp41200
g33284
I230
sg33285
I1
sg33286
I3
sg33295
VP01562
p41201
sg33289
VIFN
p41202
sasg33281
(lp41203
(dp41204
g33284
I4
sg33285
I2
sg33286
I14
sg33287
VC0333516
p41205
sg33289
Vtumor necrosis
p41206
sa(dp41207
g33284
I289
sg33285
I2
sg33286
I13
sg33287
VC0023895
p41208
sg33289
Vliver disease
p41209
sa(dp41210
g33284
I4
sg33285
I2
sg33286
I14
sg33287
VC0333516
p41211
sg33289
Vtumor necrosis
p41212
sa(dp41213
g33284
I277
sg33285
I1
sg33286
I3
sg33287
VC0019163
p41214
sg33289
VHBV
p41215
sasa(dp41216
g33277
VThese results indicate that treatment with TUDCA may be helpful to counteract obesity-induced hyperinsulinemia through increasing insulin clearance, likely through enhanced liver IDE expression in a mechanism dependent on S1PR2-Insulin pathway activation.
p41217
sg33279
(lp41218
(dp41219
g33284
I228
sg33285
I1
sg33286
I7
sg33295
VP01308
p41220
sg33289
VInsulin
p41221
sa(dp41222
g33284
I99
sg33285
I1
sg33286
I7
sg33295
VP01308
p41223
sg33289
Vinsulin
p41224
sa(dp41225
g33284
I179
sg33285
I1
sg33286
I3
sg33295
VP14735
p41226
sg33289
VIDE
p41227
sa(dp41228
g33284
I222
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VS1PR2
p41229
sasg33281
(lp41230
(dp41231
g33284
I78
sg33285
I1
sg33286
I7
sg33287
VC0028754
p41232
sg33289
Vobesity
p41233
sa(dp41234
g33284
I119
sg33285
I2
sg33286
I18
sg33287
VC0020459
p41235
sg33289
Vincreasing insulin
p41236
sa(dp41237
g33284
I94
sg33285
I1
sg33286
I16
sg33287
VC0020459
p41238
sg33289
Vhyperinsulinemia
p41239
sasa(dp41240
g33277
VInsulin-degrading enzyme (IDE) is a ubiquitous zinc peptidase of the inverzincin family, which has been initially discovered as the enzyme responsible for insulin catabolism; therefore, its involvement in the onset of diabetes has been largely investigated.
p41241
sg33279
(lp41242
(dp41243
g33284
I0
sg33285
I2
sg33286
I24
sg33295
VP14735
p41244
sg33289
VInsulin-degrading enzyme
p41245
sa(dp41246
g33284
I47
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
Vzinc peptidase
p41247
sa(dp41248
g33284
I26
sg33285
I1
sg33286
I3
sg33295
VP14735
p41249
sg33289
VIDE
p41250
sa(dp41251
g33284
I155
sg33285
I1
sg33286
I7
sg33295
VP01308
p41252
sg33289
Vinsulin
p41253
sasg33281
(lp41254
(dp41255
g33284
I218
sg33285
I1
sg33286
I8
sg33287
VC0011849
p41256
sg33289
Vdiabetes
p41257
sasa(dp41258
g33277
VImpairment of the insulin-degrading enzyme (IDE) is associated with obesity and type 2 diabetes mellitus (T2DM).
p41259
sg33279
(lp41260
(dp41261
g33284
I18
sg33285
I2
sg33286
I24
sg33295
VP14735
p41262
sg33289
Vinsulin-degrading enzyme
p41263
sa(dp41264
g33284
I44
sg33285
I1
sg33286
I3
sg33295
VP14735
p41265
sg33289
VIDE
p41266
sasg33281
(lp41267
(dp41268
g33284
I106
sg33285
I1
sg33286
I4
sg33287
VC0011860
p41269
sg33289
VT2DM
p41270
sa(dp41271
g33284
I80
sg33285
I4
sg33286
I24
sg33287
VC0011860
p41272
sg33289
Vtype 2 diabetes mellitus
p41273
sa(dp41274
g33284
I0
sg33285
I1
sg33286
I10
sg33287
VC0684336
p41275
sg33289
VImpairment
p41276
sa(dp41277
g33284
I68
sg33285
I1
sg33286
I7
sg33287
VC0028754
p41278
sg33289
Vobesity
p41279
sasa(dp41280
g33277
VSeveral mechanisms have been reported underlying the association of the two disorders, diabetes and dementia, one among which is the insulin-degrading enzyme (IDE) which is known to degrade insulin as well beta-amyloid peptides.
p41281
sg33279
(lp41282
(dp41283
g33284
I159
sg33285
I1
sg33286
I3
sg33295
VP14735
p41284
sg33289
VIDE
p41285
sa(dp41286
g33284
I133
sg33285
I2
sg33286
I24
sg33295
VP14735
p41287
sg33289
Vinsulin-degrading enzyme
p41288
sa(dp41289
g33284
I133
sg33285
I1
sg33286
I7
sg33295
VP01308
p41290
sg33289
Vinsulin
p41291
sasg33281
(lp41292
(dp41293
g33284
I100
sg33285
I1
sg33286
I8
sg33287
VC0497327
p41294
sg33289
Vdementia
p41295
sa(dp41296
g33284
I211
sg33285
I1
sg33286
I7
sg33287
VC0011560
p41297
sg33289
Vamyloid
p41298
sa(dp41299
g33284
I87
sg33285
I1
sg33286
I8
sg33287
VC0011849
p41300
sg33289
Vdiabetes
p41301
sasa(dp41302
g33277
VWe concluded that vitamin D3 ameliorated insulin resistance and hyperinsulinemia in diabetic rat model received HFW through reduction of IDE and activation of insulin receptor phosphorylation.
p41303
sg33279
(lp41304
(dp41305
g33284
I41
sg33285
I1
sg33286
I7
sg33295
VP01308
p41306
sg33289
Vinsulin
p41307
sa(dp41308
g33284
I159
sg33285
I2
sg33286
I16
sg33295
VP01308
p41309
sg33289
Vinsulin receptor
p41310
sasg33281
(lp41311
(dp41312
g33284
I64
sg33285
I1
sg33286
I16
sg33287
VC0020459
p41313
sg33289
Vhyperinsulinemia
p41314
sa(dp41315
g33284
I41
sg33285
I2
sg33286
I18
sg33287
VC0021655
p41316
sg33289
Vinsulin resistance
p41317
sasa(dp41318
g33277
VIndependently, the same approach identified a second homozygous truncating GZF1 variant in another multiplex consanguineous family affected by severe myopia, retinal detachment, and milder skeletal involvement.
p41319
sg33279
(lp41320
(dp41321
g33284
I64
sg33285
I3
sg33286
I23
sg33295
g11
sg33289
Vtruncating GZF1 variant
p41322
sasg33281
(lp41323
(dp41324
g33284
I158
sg33285
I2
sg33286
I18
sg33287
VC0035305
p41325
sg33289
Vretinal detachment
p41326
sa(dp41327
g33284
I143
sg33285
I2
sg33286
I13
sg33287
VC0271183
p41328
sg33289
Vsevere myopia
p41329
sasa(dp41330
g33277
VSubgroup analyses found that the IL4RA I50V polymorphism was significantly associated with asthma risk in Asians (OR = 1.72, 95% CI 1.31-2.25, P&lt;0.0001), pediatric asthma risk (OR = 1.50, 95% CI 1.13-1.99, P = 0.005), and atopic asthma risk (OR = 1.88, 95% CI 1.27-2.79, P = 0.002).
p41331
sg33279
(lp41332
sg33281
(lp41333
(dp41334
g33284
I225
sg33285
I2
sg33286
I13
sg33287
VC0155877
p41335
sg33289
Vatopic asthma
p41336
sa(dp41337
g33284
I91
sg33285
I1
sg33286
I6
sg33287
VC0004096
p41338
sg33289
Vasthma
p41339
sa(dp41340
g33284
I91
sg33285
I1
sg33286
I6
sg33287
VC0004096
p41341
sg33289
Vasthma
p41342
sasa(dp41343
g33277
VTo verify the association of transforming growth factor-beta1(TGF-beta1) (C-509T and T869C), CD14 (C-159T), IL-4 (C-590T), IL-4R (ILe50Val) and ADAM33 (S_2) gene polymorphisms with asthma severity in a sample of patients with mild, moderate and severe persistent atopic asthma.
p41344
sg33279
(lp41345
(dp41346
g33284
I108
sg33285
I1
sg33286
I4
sg33295
VP05112
p41347
sg33289
VIL-4
p41348
sa(dp41349
g33284
I29
sg33285
I3
sg33286
I32
sg33295
VP01137
p41350
sg33289
Vtransforming growth factor-beta1
p41351
sa(dp41352
g33284
I144
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VADAM33
p41353
sa(dp41354
g33284
I62
sg33285
I1
sg33286
I9
sg33295
VP01137
p41355
sg33289
VTGF-beta1
p41356
sa(dp41357
g33284
I93
sg33285
I1
sg33286
I4
sg33295
VP08571
p41358
sg33289
VCD14
p41359
sasg33281
(lp41360
(dp41361
g33284
I263
sg33285
I2
sg33286
I13
sg33287
VC0155877
p41362
sg33289
Vatopic asthma
p41363
sa(dp41364
g33284
I181
sg33285
I1
sg33286
I6
sg33287
VC0004096
p41365
sg33289
Vasthma
p41366
sasa(dp41367
g33277
VTo investigate the correlation between Chlamydia pneumonia (Cpn) infection and chronic obstructive pulmonary disease (COPD).
p41368
sg33279
(lp41369
sg33281
(lp41370
(dp41371
g33284
I79
sg33285
I4
sg33286
I37
sg33287
VC0024117
p41372
sg33289
Vchronic obstructive pulmonary disease
p41373
sa(dp41374
g33284
I118
sg33285
I1
sg33286
I4
sg33287
VC0024117
p41375
sg33289
VCOPD
p41376
sa(dp41377
g33284
I49
sg33285
I1
sg33286
I9
sg33287
VC0032285
p41378
sg33289
Vpneumonia
p41379
sa(dp41380
g33284
I65
sg33285
I1
sg33286
I9
sg33287
VC0009450
p41381
sg33289
Vinfection
p41382
sasa(dp41383
g33277
VChlamydia pneumoniae (Cpn) infection may play a role in the pathogenesis of chronic obstructive pulmonary disease (COPD).
p41384
sg33279
(lp41385
(dp41386
g33284
I0
sg33285
I2
sg33286
I20
sg33295
VP15169
p41387
sg33289
VChlamydia pneumoniae
p41388
sa(dp41389
g33284
I22
sg33285
I1
sg33286
I3
sg33295
VP15169
p41390
sg33289
VCpn
p41391
sasg33281
(lp41392
(dp41393
g33284
I27
sg33285
I1
sg33286
I9
sg33287
VC0009450
p41394
sg33289
Vinfection
p41395
sa(dp41396
g33284
I115
sg33285
I1
sg33286
I4
sg33287
VC0024117
p41397
sg33289
VCOPD
p41398
sa(dp41399
g33284
I76
sg33285
I4
sg33286
I37
sg33287
VC0024117
p41400
sg33289
Vchronic obstructive pulmonary disease
p41401
sa(dp41402
g33284
I60
sg33285
I1
sg33286
I12
sg33287
VC0699748
p41403
sg33289
Vpathogenesis
p41404
sasa(dp41405
g33277
VTo determine the possible association between Chlamydiae pneumoniae (Cpn) infection and chronic obstructive pulmonary disease (COPD).
p41406
sg33279
(lp41407
(dp41408
g33284
I46
sg33285
I2
sg33286
I21
sg33295
VP15169
p41409
sg33289
VChlamydiae pneumoniae
p41410
sa(dp41411
g33284
I69
sg33285
I1
sg33286
I3
sg33295
VP15169
p41412
sg33289
VCpn
p41413
sasg33281
(lp41414
(dp41415
g33284
I127
sg33285
I1
sg33286
I4
sg33287
VC0024117
p41416
sg33289
VCOPD
p41417
sa(dp41418
g33284
I88
sg33285
I4
sg33286
I37
sg33287
VC0024117
p41419
sg33289
Vchronic obstructive pulmonary disease
p41420
sa(dp41421
g33284
I74
sg33285
I1
sg33286
I9
sg33287
VC0009450
p41422
sg33289
Vinfection
p41423
sasa(dp41424
g33277
VThe objective of the study was to investigate the possible association of Chlamydia pneumoniae (Cpn) in acute exacerbations of chronic obstructive pulmonary disease (COPD) patients.
p41425
sg33279
(lp41426
(dp41427
g33284
I96
sg33285
I1
sg33286
I3
sg33295
VP15169
p41428
sg33289
VCpn
p41429
sa(dp41430
g33284
I74
sg33285
I2
sg33286
I20
sg33295
VP15169
p41431
sg33289
VChlamydia pneumoniae
p41432
sasg33281
(lp41433
(dp41434
g33284
I127
sg33285
I4
sg33286
I37
sg33287
VC0024117
p41435
sg33289
Vchronic obstructive pulmonary disease
p41436
sa(dp41437
g33284
I166
sg33285
I1
sg33286
I4
sg33287
VC0024117
p41438
sg33289
VCOPD
p41439
sasa(dp41440
g33277
VReading this article will familiarize the reader with (1) the unique chlamydial intracellular life cycle and the propensity for human chlamydial infections to become persistent and to result in immunopathologic (inflammatory) damage in target organs and (2) current evidence linking Chlamydia pneumoniae (Cpn) infection to obstructive lung diseases (asthma and chronic obstructive pulmonary disease, COPD).
p41441
sg33279
(lp41442
(dp41443
g33284
I305
sg33285
I1
sg33286
I3
sg33295
VP15169
p41444
sg33289
VCpn
p41445
sa(dp41446
g33284
I283
sg33285
I2
sg33286
I20
sg33295
VP15169
p41447
sg33289
VChlamydia pneumoniae
p41448
sasg33281
(lp41449
(dp41450
g33284
I400
sg33285
I1
sg33286
I4
sg33287
VC0024117
p41451
sg33289
VCOPD
p41452
sa(dp41453
g33284
I145
sg33285
I1
sg33286
I9
sg33287
VC0009450
p41454
sg33289
Vinfection
p41455
sa(dp41456
g33284
I323
sg33285
I3
sg33286
I25
sg33287
VC0600260
p41457
sg33289
Vobstructive lung diseases
p41458
sa(dp41459
g33284
I134
sg33285
I2
sg33286
I21
sg33287
VC0008149
p41460
sg33289
Vchlamydial infections
p41461
sa(dp41462
g33284
I361
sg33285
I4
sg33286
I37
sg33287
VC0024117
p41463
sg33289
Vchronic obstructive pulmonary disease
p41464
sa(dp41465
g33284
I350
sg33285
I1
sg33286
I6
sg33287
VC0004096
p41466
sg33289
Vasthma
p41467
sasa(dp41468
g33277
VAlthough the full clinical significance of these Cpn-obstructive lung disease associations remains to be established, reports of asthma improvement after treatment of Cpn infection deserve further investigation.
p41469
sg33279
(lp41470
sg33281
(lp41471
(dp41472
g33284
I53
sg33285
I3
sg33286
I24
sg33287
VC0600260
p41473
sg33289
Vobstructive lung disease
p41474
sa(dp41475
g33284
I129
sg33285
I1
sg33286
I6
sg33287
VC0004096
p41476
sg33289
Vasthma
p41477
sa(dp41478
g33284
I171
sg33285
I1
sg33286
I9
sg33287
VC0009450
p41479
sg33289
Vinfection
p41480
sasa(dp41481
g33277
VTaken together, we conclude that EGFR TKIs enhance the sensitivity of NSCLC cells to vATPase inhibitors by decreasing Hif-1Alfa/Bnip3 expression.
p41482
sg33279
(lp41483
(dp41484
g33284
I128
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VBnip3
p41485
sasg33281
(lp41486
(dp41487
g33284
I70
sg33285
I1
sg33286
I5
sg33287
VC0007131
p41488
sg33289
VNSCLC
p41489
sasa(dp41490
g33277
VWe found a significant upregulation of BNIP3 in human lung cancer datasets, and we identified a direct association between BNIP3 expression and survival rate of lung cancer patients.
p41491
sg33279
(lp41492
(dp41493
g33284
I39
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VBNIP3
p41494
sa(dp41495
g33284
I39
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VBNIP3
p41496
sasg33281
(lp41497
(dp41498
g33284
I54
sg33285
I2
sg33286
I11
sg33287
VC0684249
p41499
sg33289
Vlung cancer
p41500
sa(dp41501
g33284
I54
sg33285
I2
sg33286
I11
sg33287
VC0684249
p41502
sg33289
Vlung cancer
p41503
sasa(dp41504
g33277
VIn this study we used 115 NSCLC tissues to examine the immunohistochemical expression of four distinct molecules - the major regulator of autophagy Beclin 1, the anti-apoptotic and anti-autophagic protein Bcl-2, the pro-apoptotic and pro-autophagic protein BNIP3, and a marker of hypoxia and glucolysis, the glucose transporter Glut 1.
p41505
sg33279
(lp41506
(dp41507
g33284
I138
sg33285
I3
sg33286
I18
sg33295
g11
sg33289
Vautophagy Beclin 1
p41508
sa(dp41509
g33284
I181
sg33285
I3
sg33286
I29
sg33295
VP10415
p41510
sg33289
Vanti-autophagic protein Bcl-2
p41511
sa(dp41512
g33284
I234
sg33285
I3
sg33286
I28
sg33295
g11
sg33289
Vpro-autophagic protein BNIP3
p41513
sasg33281
(lp41514
(dp41515
g33284
I280
sg33285
I1
sg33286
I7
sg33287
VC0242184
p41516
sg33289
Vhypoxia
p41517
sa(dp41518
g33284
I26
sg33285
I1
sg33286
I5
sg33287
VC0007131
p41519
sg33289
VNSCLC
p41520
sasa(dp41521
g33277
VIn conclusion, the accelerated autophagic status in NSCLC is unrelated to Beclin 1 and BNIP3 expression, but does show significant association with Bcl-2 reactivity.
p41522
sg33279
(lp41523
(dp41524
g33284
I74
sg33285
I2
sg33286
I8
sg33295
g11
sg33289
VBeclin 1
p41525
sa(dp41526
g33284
I87
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VBNIP3
p41527
sa(dp41528
g33284
I148
sg33285
I1
sg33286
I5
sg33295
VP10415
p41529
sg33289
VBcl-2
p41530
sasg33281
(lp41531
(dp41532
g33284
I52
sg33285
I1
sg33286
I5
sg33287
VC0007131
p41533
sg33289
VNSCLC
p41534
sasa(dp41535
g33277
VThis study was designed to determine the pattern and correlation between expression of the HIF-1Alfa transcriptional targets TGM2 and BNIP3 in laryngeal cancer, and investigate the association of BNIP3 and TGM2 with clinical outcome in laryngeal squamous cell carcinoma (SCC) patients receiving postoperative radiotherapy.
p41536
sg33279
(lp41537
(dp41538
g33284
I134
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VBNIP3
p41539
sa(dp41540
g33284
I125
sg33285
I1
sg33286
I4
sg33295
VP21980
p41541
sg33289
VTGM2
p41542
sa(dp41543
g33284
I125
sg33285
I1
sg33286
I4
sg33295
VP21980
p41544
sg33289
VTGM2
p41545
sa(dp41546
g33284
I134
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VBNIP3
p41547
sasg33281
(lp41548
(dp41549
g33284
I236
sg33285
I4
sg33286
I33
sg33287
VC0280324
p41550
sg33289
Vlaryngeal squamous cell carcinoma
p41551
sa(dp41552
g33284
I143
sg33285
I2
sg33286
I16
sg33287
VC0595989
p41553
sg33289
Vlaryngeal cancer
p41554
sasa(dp41555
g33277
VConsidering tumors with telomere shortening, expression for BNIP3, DAPK1, NDRG1, EGFR, and CDKN2A was significantly higher in NSCLC than in CRC, whereas TP53 was overexpressed in CRC with respect to NSCLC.
p41556
sg33279
(lp41557
(dp41558
g33284
I140
sg33285
I3
sg33286
I17
sg33295
VP31749
p41559
sg33289
VCRC, whereas TP53
p41560
sa(dp41561
g33284
I91
sg33285
I1
sg33286
I6
sg33295
VP42771
p41562
sg33289
VCDKN2A
p41563
sa(dp41564
g33284
I67
sg33285
I1
sg33286
I5
sg33295
VP53355
p41565
sg33289
VDAPK1
p41566
sa(dp41567
g33284
I140
sg33285
I1
sg33286
I3
sg33295
VP31749
p41568
sg33289
VCRC
p41569
sa(dp41570
g33284
I74
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VNDRG1
p41571
sa(dp41572
g33284
I60
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VBNIP3
p41573
sasg33281
(lp41574
(dp41575
g33284
I24
sg33285
I2
sg33286
I19
sg33287
VC1515263
p41576
sg33289
Vtelomere shortening
p41577
sa(dp41578
g33284
I140
sg33285
I1
sg33286
I3
sg33287
VC1527249
p41579
sg33289
VCRC
p41580
sa(dp41581
g33284
I12
sg33285
I1
sg33286
I6
sg33287
VC0027651
p41582
sg33289
Vtumors
p41583
sa(dp41584
g33284
I126
sg33285
I1
sg33286
I5
sg33287
VC0007131
p41585
sg33289
VNSCLC
p41586
sa(dp41587
g33284
I140
sg33285
I1
sg33286
I3
sg33287
VC1527249
p41588
sg33289
VCRC
p41589
sa(dp41590
g33284
I126
sg33285
I1
sg33286
I5
sg33287
VC0007131
p41591
sg33289
VNSCLC
p41592
sasa(dp41593
g33277
VKIAA0513 was previously identified as upregulated in the dorsolateral prefrontal cortex of subjects with schizophrenia by microarray analysis.
p41594
sg33279
(lp41595
sg33281
(lp41596
(dp41597
g33284
I105
sg33285
I1
sg33286
I13
sg33287
VC0036341
p41598
sg33289
Vschizophrenia
p41599
sasa(dp41600
g33277
VHigher fasting glucose levels may amplify obesity-risk in FTO carriers and lead to an exaggerated weight gain over time.
p41601
sg33279
(lp41602
sg33281
(lp41603
(dp41604
g33284
I42
sg33285
I1
sg33286
I7
sg33287
VC0028754
p41605
sg33289
Vobesity
p41606
sasa(dp41607
g33277
VType 2 diabetes-associated genes TCF7L2 and FTO; and a miRNA, miR21 were further investigated in another B12-supplementation cohort.
p41608
sg33279
(lp41609
(dp41610
g33284
I44
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VFTO
p41611
sasg33281
(lp41612
(dp41613
g33284
I0
sg33285
I3
sg33286
I15
sg33287
VC0011860
p41614
sg33289
VType 2 diabetes
p41615
sasa(dp41616
g33277
VRecent studies show that FTO single nucleotide polymorphisms (SNPs) are associated with obesity and type 2 diabetes mellitus (T2DM).
p41617
sg33279
(lp41618
sg33281
(lp41619
(dp41620
g33284
I88
sg33285
I1
sg33286
I7
sg33287
VC0028754
p41621
sg33289
Vobesity
p41622
sa(dp41623
g33284
I126
sg33285
I1
sg33286
I4
sg33287
VC0011860
p41624
sg33289
VT2DM
p41625
sa(dp41626
g33284
I100
sg33285
I4
sg33286
I24
sg33287
VC0011860
p41627
sg33289
Vtype 2 diabetes mellitus
p41628
sasa(dp41629
g33277
VThe FTO gene is associated with type-2 diabetes (T2D) and increased fat mass.
p41630
sg33279
(lp41631
(dp41632
g33284
I4
sg33285
I2
sg33286
I8
sg33295
g11
sg33289
VFTO gene
p41633
sasg33281
(lp41634
(dp41635
g33284
I32
sg33285
I2
sg33286
I15
sg33287
VC0011860
p41636
sg33289
Vtype-2 diabetes
p41637
sa(dp41638
g33284
I49
sg33285
I1
sg33286
I3
sg33287
VC0011860
p41639
sg33289
VT2D
p41640
sasa(dp41641
g33277
VA significant association was found between the perilipin rs1052700 polymorphism and T2D, and between the FTO rs3751812 polymorphism and obesity (P = 0.03 and 0.003, respectively); however, no significant relationship was found between rs3751812 and T2D.
p41642
sg33279
(lp41643
(dp41644
g33284
I48
sg33285
I2
sg33286
I19
sg33295
g11
sg33289
Vperilipin rs1052700
p41645
sasg33281
(lp41646
(dp41647
g33284
I85
sg33285
I1
sg33286
I3
sg33287
VC0011860
p41648
sg33289
VT2D
p41649
sa(dp41650
g33284
I85
sg33285
I1
sg33286
I3
sg33287
VC0011860
p41651
sg33289
VT2D
p41652
sa(dp41653
g33284
I137
sg33285
I1
sg33286
I7
sg33287
VC0028754
p41654
sg33289
Vobesity
p41655
sasa(dp41656
g33277
VThe FTO rs3751812 polymorphism is a major genetic determinant of obesity, but not T2D.
p41657
sg33279
(lp41658
sg33281
(lp41659
(dp41660
g33284
I65
sg33285
I1
sg33286
I7
sg33287
VC0028754
p41661
sg33289
Vobesity
p41662
sa(dp41663
g33284
I82
sg33285
I1
sg33286
I3
sg33287
VC0011860
p41664
sg33289
VT2D
p41665
sasa(dp41666
g33277
VRecent studies have implicated the FTO gene in child and adult obesity.
p41667
sg33279
(lp41668
(dp41669
g33284
I35
sg33285
I2
sg33286
I8
sg33295
g11
sg33289
VFTO gene
p41670
sasg33281
(lp41671
(dp41672
g33284
I63
sg33285
I1
sg33286
I7
sg33287
VC0028754
p41673
sg33289
Vobesity
p41674
sasa(dp41675
g33277
VVariants (rs1558902, rs1121980, rs9939609, and rs9941349) in the fat mass and obesity-associated (FTO) gene exhibited strong but ethnicity-independent association with obesity.
p41676
sg33279
(lp41677
sg33281
(lp41678
(dp41679
g33284
I78
sg33285
I1
sg33286
I7
sg33287
VC0028754
p41680
sg33289
Vobesity
p41681
sa(dp41682
g33284
I78
sg33285
I1
sg33286
I7
sg33287
VC0028754
p41683
sg33289
Vobesity
p41684
sasa(dp41685
g33277
VThere is increasing interest of which dietary patterns can modify the association of fat mass and obesity associated (FTO) variants with obesity.
p41686
sg33279
(lp41687
sg33281
(lp41688
(dp41689
g33284
I98
sg33285
I1
sg33286
I7
sg33287
VC0028754
p41690
sg33289
Vobesity
p41691
sa(dp41692
g33284
I98
sg33285
I1
sg33286
I7
sg33287
VC0028754
p41693
sg33289
Vobesity
p41694
sasa(dp41695
g33277
VThis study was aimed at investigating the interaction of the Mediterranean dietary pattern (Med Diet) with FTO polymorphisms in relation to obesity phenotypes.
p41696
sg33279
(lp41697
sg33281
(lp41698
(dp41699
g33284
I140
sg33285
I1
sg33286
I7
sg33287
VC0028754
p41700
sg33289
Vobesity
p41701
sasa(dp41702
g33277
VObesity is a heritable disorder, and some of the many obesity susceptible genes are fat mass and obesity (FTO), leptin, and Melanocortin-4 receptor (MC4R).
p41703
sg33279
(lp41704
(dp41705
g33284
I124
sg33285
I2
sg33286
I23
sg33295
VP32245
p41706
sg33289
VMelanocortin-4 receptor
p41707
sa(dp41708
g33284
I149
sg33285
I1
sg33286
I4
sg33295
VP32245
p41709
sg33289
VMC4R
p41710
sa(dp41711
g33284
I112
sg33285
I1
sg33286
I6
sg33295
VP41159
p41712
sg33289
Vleptin
p41713
sasg33281
(lp41714
(dp41715
g33284
I0
sg33285
I1
sg33286
I7
sg33287
VC0028754
p41716
sg33289
VObesity
p41717
sa(dp41718
g33284
I54
sg33285
I1
sg33286
I7
sg33287
VC0028754
p41719
sg33289
Vobesity
p41720
sa(dp41721
g33284
I54
sg33285
I1
sg33286
I7
sg33287
VC0028754
p41722
sg33289
Vobesity
p41723
sasa(dp41724
g33277
VWe showed that: (1) there was a significant association between the biased usage of IGHV4-34 (binds to the carbohydrate I/i antigens) and inactivating mutation of TNFAIP3 [encoding a global negative regulator of the canonical nuclear factor-KB (NF-KB) pathway] in ocular adnexal MALT lymphoma; (2) IGHV1-69 was significantly overrepresented (54%) in MALT lymphoma of the salivary gland, but was not associated with mutation in any of the 17 genes investigated; and (3) MALT lymphoma lacked mutations that are frequently seen in other B-cell lymphomas characterized by constitutive NF-KB activities, including mutations in CD79B, CARD11, MYD88, TNFRSF11A, and TRAF3.
p41725
sg33279
(lp41726
(dp41727
g33284
I637
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VMYD88
p41728
sa(dp41729
g33284
I644
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VTNFRSF11A
p41730
sa(dp41731
g33284
I226
sg33285
I2
sg33286
I17
sg33295
VP01160
p41732
sg33289
Vnuclear factor-KB
p41733
sa(dp41734
g33284
I629
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VCARD11
p41735
sa(dp41736
g33284
I245
sg33285
I1
sg33286
I5
sg33295
VP01160
p41737
sg33289
VNF-KB
p41738
sa(dp41739
g33284
I659
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRAF3
p41740
sa(dp41741
g33284
I245
sg33285
I1
sg33286
I5
sg33295
VP01160
p41742
sg33289
VNF-KB
p41743
sa(dp41744
g33284
I107
sg33285
I3
sg33286
I25
sg33295
g11
sg33289
Vcarbohydrate I/i antigens
p41745
sa(dp41746
g33284
I163
sg33285
I1
sg33286
I7
sg33295
VP21580
p41747
sg33289
VTNFAIP3
p41748
sa(dp41749
g33284
I622
sg33285
I1
sg33286
I5
sg33295
VP40259
p41750
sg33289
VCD79B
p41751
sasg33281
(lp41752
(dp41753
g33284
I279
sg33285
I2
sg33286
I13
sg33287
VC0242647
p41754
sg33289
VMALT lymphoma
p41755
sa(dp41756
g33284
I534
sg33285
I2
sg33286
I16
sg33287
VC0079731
p41757
sg33289
VB-cell lymphomas
p41758
sa(dp41759
g33284
I264
sg33285
I4
sg33286
I28
sg33287
VC1335103
p41760
sg33289
Vocular adnexal MALT lymphoma
p41761
sa(dp41762
g33284
I279
sg33285
I2
sg33286
I13
sg33287
VC0242647
p41763
sg33289
VMALT lymphoma
p41764
sasa(dp41765
g33277
VTherefore, we aim to assess the correlation of endothelin-1 concentrations with the development and severity of knee osteoarthritis (OA).
p41766
sg33279
(lp41767
(dp41768
g33284
I47
sg33285
I1
sg33286
I12
sg33295
VP20800
p41769
sg33289
Vendothelin-1
p41770
sasg33281
(lp41771
(dp41772
g33284
I112
sg33285
I2
sg33286
I19
sg33287
VC0409959
p41773
sg33289
Vknee osteoarthritis
p41774
sasa(dp41775
g33277
VTogether, the results here demonstrate that the febrile response in zymosan-induced arthritis in rats depends on the centrally acting pyrogenic cytokines TNF-Alfa, IL-1Beta, and IL-6, but does not depend on either CRF or ET-1.
p41776
sg33279
(lp41777
(dp41778
g33284
I221
sg33285
I1
sg33286
I4
sg33295
VP05305
p41779
sg33289
VET-1
p41780
sa(dp41781
g33284
I178
sg33285
I1
sg33286
I4
sg33295
VP05231
p41782
sg33289
VIL-6
p41783
sa(dp41784
g33284
I164
sg33285
I1
sg33286
I8
sg33295
VP01584
p41785
sg33289
VIL-1Beta
p41786
sa(dp41787
g33284
I214
sg33285
I1
sg33286
I3
sg33295
VP06850
p41788
sg33289
VCRF
p41789
sa(dp41790
g33284
I144
sg33285
I2
sg33286
I18
sg33295
VP01375
p41791
sg33289
Vcytokines TNF-Alfa
p41792
sasg33281
(lp41793
(dp41794
g33284
I84
sg33285
I1
sg33286
I9
sg33287
VC0003864
p41795
sg33289
Varthritis
p41796
sa(dp41797
g33284
I214
sg33285
I1
sg33286
I3
sg33287
VC0022661
p41798
sg33289
VCRF
p41799
sasa(dp41800
g33277
VAntibodies to AQP4 and AQP1 are detected in neuromyelitis optica and are believed to play a pathogenic role.
p41801
sg33279
(lp41802
(dp41803
g33284
I14
sg33285
I1
sg33286
I4
sg33295
VP55087
p41804
sg33289
VAQP4
p41805
sa(dp41806
g33284
I23
sg33285
I1
sg33286
I4
sg33295
VP29972
p41807
sg33289
VAQP1
p41808
sasg33281
(lp41809
(dp41810
g33284
I44
sg33285
I2
sg33286
I20
sg33287
VC0027873
p41811
sg33289
Vneuromyelitis optica
p41812
sasa(dp41813
g33277
VAmong thirteen different mammalian AQPs, AQP1 and AQP4 have been mainly studied in the CNS and evidence has been presented that they play important roles in the pathogenesis of CNS injury, edema and multiple diseases such as multiple sclerosis, neuromyelitis optica spectrum disorders, amyotrophic lateral sclerosis, glioblastoma multiforme, Alzheimer's disease and Parkinson's disease.
p41814
sg33279
(lp41815
(dp41816
g33284
I50
sg33285
I1
sg33286
I4
sg33295
VP55087
p41817
sg33289
VAQP4
p41818
sa(dp41819
g33284
I41
sg33285
I1
sg33286
I4
sg33295
VP29972
p41820
sg33289
VAQP1
p41821
sasg33281
(lp41822
(dp41823
g33284
I161
sg33285
I1
sg33286
I12
sg33287
VC0699748
p41824
sg33289
Vpathogenesis
p41825
sa(dp41826
g33284
I366
sg33285
I2
sg33286
I19
sg33287
VC0030567
p41827
sg33289
VParkinson's disease
p41828
sa(dp41829
g33284
I317
sg33285
I2
sg33286
I23
sg33287
VC1621958
p41830
sg33289
Vglioblastoma multiforme
p41831
sa(dp41832
g33284
I286
sg33285
I3
sg33286
I29
sg33287
VC0002736
p41833
sg33289
Vamyotrophic lateral sclerosis
p41834
sa(dp41835
g33284
I245
sg33285
I2
sg33286
I20
sg33287
VC0027873
p41836
sg33289
Vneuromyelitis optica
p41837
sa(dp41838
g33284
I342
sg33285
I2
sg33286
I19
sg33287
VC1521724
p41839
sg33289
VAlzheimer's disease
p41840
sa(dp41841
g33284
I225
sg33285
I2
sg33286
I18
sg33287
VC0026769
p41842
sg33289
Vmultiple sclerosis
p41843
sa(dp41844
g33284
I189
sg33285
I1
sg33286
I5
sg33287
VC0013604
p41845
sg33289
Vedema
p41846
sasa(dp41847
g33277
VICOSL knockout (ICOSL-KO) mice and wild-type C57BL/6J mice were used as experimental Schistosomiasis model infected with Schistosoma japonicum.
p41848
sg33279
(lp41849
sg33281
(lp41850
(dp41851
g33284
I85
sg33285
I1
sg33286
I15
sg33287
VC0036323
p41852
sg33289
VSchistosomiasis
p41853
sasa(dp41854
g33277
VThe ICOS-ICOSL signaling has a regulatory effect on CD154-CD40 signaling pathway, and may play an important role in the hepatic egg granuloma formation of Schistosomiasis.
p41855
sg33279
(lp41856
(dp41857
g33284
I52
sg33285
I1
sg33286
I5
sg33295
VP29965
p41858
sg33289
VCD154
p41859
sa(dp41860
g33284
I58
sg33285
I1
sg33286
I4
sg33295
VP25942
p41861
sg33289
VCD40
p41862
sa(dp41863
g33284
I4
sg33285
I1
sg33286
I10
sg33295
VP16410
p41864
sg33289
VICOS-ICOSL
p41865
sasg33281
(lp41866
(dp41867
g33284
I132
sg33285
I1
sg33286
I9
sg33287
VC0018188
p41868
sg33289
Vgranuloma
p41869
sa(dp41870
g33284
I155
sg33285
I1
sg33286
I15
sg33287
VC0036323
p41871
sg33289
VSchistosomiasis
p41872
sasa(dp41873
g33277
VUsing models of schistosomiasis in ICOSL KO and the C57BL/6 WT mice, we studied the role of the ICOSL/ICOS interaction in the mediation of the Th17 response in host granulomatous inflammation, particularly in liver fibrosis during S. japonicum infection, and investigated the immune responses and pathology of ICOSL KO mice in these models.
p41874
sg33279
(lp41875
(dp41876
g33284
I35
sg33285
I2
sg33286
I8
sg33295
g11
sg33289
VICOSL KO
p41877
sa(dp41878
g33284
I35
sg33285
I1
sg33286
I4
sg33295
VP16410
p41879
sg33289
VICOS
p41880
sa(dp41881
g33284
I35
sg33285
I2
sg33286
I8
sg33295
g11
sg33289
VICOSL KO
p41882
sa(dp41883
g33284
I35
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VICOSL
p41884
sasg33281
(lp41885
(dp41886
g33284
I16
sg33285
I1
sg33286
I15
sg33287
VC0036323
p41887
sg33289
Vschistosomiasis
p41888
sa(dp41889
g33284
I209
sg33285
I2
sg33286
I14
sg33287
VC0239946
p41890
sg33289
Vliver fibrosis
p41891
sa(dp41892
g33284
I244
sg33285
I1
sg33286
I9
sg33287
VC0009450
p41893
sg33289
Vinfection
p41894
sa(dp41895
g33284
I165
sg33285
I2
sg33286
I26
sg33287
VC0553697
p41896
sg33289
Vgranulomatous inflammation
p41897
sa(dp41898
g33284
I297
sg33285
I1
sg33286
I9
sg33287
VC0677042
p41899
sg33289
Vpathology
p41900
sasa(dp41901
g33277
VImportantly, there was a clearly positive correlation between the presence of IL-17-producing cells and ICOS expression in ICOSL KO mice, and additional results indicated that Th17 was involved in the pathological tissue remodeling in liver fibrosis induced by schistosomiasis.
p41902
sg33279
(lp41903
(dp41904
g33284
I123
sg33285
I2
sg33286
I8
sg33295
g11
sg33289
VICOSL KO
p41905
sasg33281
(lp41906
(dp41907
g33284
I235
sg33285
I2
sg33286
I14
sg33287
VC0239946
p41908
sg33289
Vliver fibrosis
p41909
sa(dp41910
g33284
I261
sg33285
I1
sg33286
I15
sg33287
VC0036323
p41911
sg33289
Vschistosomiasis
p41912
sasa(dp41913
g33277
VLncRNA ZEB1 Antisense 1 (ZEB1-AS1) has been suggested to be an oncogenic role in human hepatocellular carcinoma, osteosarcoma, glioma and esophageal carcinoma progression.
p41914
sg33279
(lp41915
(dp41916
g33284
I7
sg33285
I1
sg33286
I4
sg33295
VP37275
p41917
sg33289
VZEB1
p41918
sa(dp41919
g33284
I30
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VAS1
p41920
sa(dp41921
g33284
I0
sg33285
I4
sg33286
I23
sg33295
VP37275
p41922
sg33289
VLncRNA ZEB1 Antisense 1
p41923
sasg33281
(lp41924
(dp41925
g33284
I87
sg33285
I2
sg33286
I24
sg33287
VC1512411
p41926
sg33289
Vhepatocellular carcinoma
p41927
sa(dp41928
g33284
I138
sg33285
I2
sg33286
I20
sg33287
VC0152018
p41929
sg33289
Vesophageal carcinoma
p41930
sa(dp41931
g33284
I30
sg33285
I1
sg33286
I3
sg33287
VC1846534
p41932
sg33289
VAS1
p41933
sa(dp41934
g33284
I113
sg33285
I1
sg33286
I12
sg33287
VC0029463
p41935
sg33289
Vosteosarcoma
p41936
sa(dp41937
g33284
I127
sg33285
I1
sg33286
I6
sg33287
VC0017638
p41938
sg33289
Vglioma
p41939
sasa(dp41940
g33277
VZEB1-AS1 acts as an oncogene in hepatocellular carcinoma, accelerating tumor growth and promoting metastasis.
p41941
sg33279
(lp41942
(dp41943
g33284
I0
sg33285
I1
sg33286
I4
sg33295
VP37275
p41944
sg33289
VZEB1
p41945
sa(dp41946
g33284
I5
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VAS1
p41947
sasg33281
(lp41948
(dp41949
g33284
I32
sg33285
I2
sg33286
I24
sg33287
VC1512411
p41950
sg33289
Vhepatocellular carcinoma
p41951
sa(dp41952
g33284
I98
sg33285
I1
sg33286
I10
sg33287
VC0027627
p41953
sg33289
Vmetastasis
p41954
sa(dp41955
g33284
I5
sg33285
I1
sg33286
I3
sg33287
VC1846534
p41956
sg33289
VAS1
p41957
sa(dp41958
g33284
I71
sg33285
I2
sg33286
I12
sg33287
VC0598934
p41959
sg33289
Vtumor growth
p41960
sasa(dp41961
g33277
VLncRNA ZEB1-AS1 has been identified as a tumor oncogene in hepatocellular carcinoma.
p41962
sg33279
(lp41963
(dp41964
g33284
I12
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VAS1
p41965
sa(dp41966
g33284
I7
sg33285
I1
sg33286
I4
sg33295
VP37275
p41967
sg33289
VZEB1
p41968
sasg33281
(lp41969
(dp41970
g33284
I12
sg33285
I1
sg33286
I3
sg33287
VC1846534
p41971
sg33289
VAS1
p41972
sa(dp41973
g33284
I59
sg33285
I2
sg33286
I24
sg33287
VC1512411
p41974
sg33289
Vhepatocellular carcinoma
p41975
sa(dp41976
g33284
I41
sg33285
I1
sg33286
I5
sg33287
VC0027651
p41977
sg33289
Vtumor
p41978
sasa(dp41979
g33277
VWe analyzed the outcome of allo-SCT in a population of FLT3-positive AML patients according to molecular MRD at the pretransplantation workup, assessed by the quantitative expression evaluation of the panleukemic marker Wilms' tumor (WT1) gene.
p41980
sg33279
(lp41981
(dp41982
g33284
I55
sg33285
I1
sg33286
I4
sg33295
VP36888
p41983
sg33289
VFLT3
p41984
sasg33281
(lp41985
(dp41986
g33284
I220
sg33285
I2
sg33286
I12
sg33287
VC0027708
p41987
sg33289
VWilms' tumor
p41988
sa(dp41989
g33284
I32
sg33285
I1
sg33286
I3
sg33287
VC1848934
p41990
sg33289
VSCT
p41991
sa(dp41992
g33284
I105
sg33285
I1
sg33286
I3
sg33287
VC1840451
p41993
sg33289
VMRD
p41994
sa(dp41995
g33284
I234
sg33285
I1
sg33286
I3
sg33287
VC0027708
p41996
sg33289
VWT1
p41997
sa(dp41998
g33284
I69
sg33285
I1
sg33286
I3
sg33287
VC0023467
p41999
sg33289
VAML
p42000
sasa(dp42001
g33277
VTo determine the chemokine receptor expression profile in gastric mucosa-associated lymphoid tissue (MALT) lymphoma, we performed an expression analysis of 19 chemokine receptors at mRNA levels by using real-time RT-PCR, as well as of five chemokine receptors--CCR8, CCR9, CXCR4, CXCR6 and CXCR7--by immunohistochemistry on human tissue samples of Helicobacter pylori-associated gastritis, gastric MALT lymphoma and gastric extranodal diffuse large B-cell lymphoma originating from MALT lymphoma (transformed MALT lymphoma).
p42002
sg33279
(lp42003
(dp42004
g33284
I261
sg33285
I1
sg33286
I4
sg33295
VP51685
p42005
sg33289
VCCR8
p42006
sa(dp42007
g33284
I267
sg33285
I1
sg33286
I4
sg33295
VP51686
p42008
sg33289
VCCR9
p42009
sa(dp42010
g33284
I273
sg33285
I1
sg33286
I5
sg33295
VP61073
p42011
sg33289
VCXCR4
p42012
sa(dp42013
g33284
I290
sg33285
I1
sg33286
I5
sg33295
VP25106
p42014
sg33289
VCXCR7
p42015
sa(dp42016
g33284
I280
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCXCR6
p42017
sasg33281
(lp42018
(dp42019
g33284
I398
sg33285
I2
sg33286
I13
sg33287
VC0242647
p42020
sg33289
VMALT lymphoma
p42021
sa(dp42022
g33284
I107
sg33285
I1
sg33286
I8
sg33287
VC0024299
p42023
sg33289
Vlymphoma
p42024
sa(dp42025
g33284
I435
sg33285
I4
sg33286
I29
sg33287
VC0079744
p42026
sg33289
Vdiffuse large B-cell lymphoma
p42027
sa(dp42028
g33284
I398
sg33285
I2
sg33286
I13
sg33287
VC0242647
p42029
sg33289
VMALT lymphoma
p42030
sa(dp42031
g33284
I390
sg33285
I3
sg33286
I21
sg33287
VC1333782
p42032
sg33289
Vgastric MALT lymphoma
p42033
sa(dp42034
g33284
I348
sg33285
I3
sg33286
I40
sg33287
VC0343378
p42035
sg33289
VHelicobacter pylori-associated gastritis
p42036
sasa(dp42037
g33277
VThe transformation of gastric MALT lymphomas to gastric extranodal diffuse large B-cell lymphoma was accompanied by upregulation of CCR1, CCR5, CCR7, CCR8, CCR9, CXCR3, CXCR6, CXCR7 and XCR1.
p42038
sg33279
(lp42039
(dp42040
g33284
I162
sg33285
I1
sg33286
I5
sg33295
VP49682
p42041
sg33289
VCXCR3
p42042
sa(dp42043
g33284
I169
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCXCR6
p42044
sa(dp42045
g33284
I138
sg33285
I1
sg33286
I4
sg33295
VP32302
p42046
sg33289
VCCR5
p42047
sa(dp42048
g33284
I132
sg33285
I1
sg33286
I4
sg33295
VP32246
p42049
sg33289
VCCR1
p42050
sa(dp42051
g33284
I176
sg33285
I1
sg33286
I5
sg33295
VP25106
p42052
sg33289
VCXCR7
p42053
sa(dp42054
g33284
I156
sg33285
I1
sg33286
I4
sg33295
VP51686
p42055
sg33289
VCCR9
p42056
sa(dp42057
g33284
I150
sg33285
I1
sg33286
I4
sg33295
VP51685
p42058
sg33289
VCCR8
p42059
sa(dp42060
g33284
I186
sg33285
I1
sg33286
I4
sg33295
VP46094
p42061
sg33289
VXCR1
p42062
sa(dp42063
g33284
I144
sg33285
I1
sg33286
I4
sg33295
VP32248
p42064
sg33289
VCCR7
p42065
sasg33281
(lp42066
(dp42067
g33284
I67
sg33285
I4
sg33286
I29
sg33287
VC0079744
p42068
sg33289
Vdiffuse large B-cell lymphoma
p42069
sa(dp42070
g33284
I4
sg33285
I1
sg33286
I14
sg33287
VC1510411
p42071
sg33289
Vtransformation
p42072
sa(dp42073
g33284
I30
sg33285
I2
sg33286
I14
sg33287
VC0242647
p42074
sg33289
VMALT lymphomas
p42075
sasa(dp42076
g33277
VFeline leukemia virus (FeLV) p27 or gp70 antigen was detected in 21 lymphomas (54%).
p42077
sg33279
(lp42078
(dp42079
g33284
I29
sg33285
I1
sg33286
I3
sg33295
VP40305
p42080
sg33289
Vp27
p42081
sa(dp42082
g33284
I36
sg33285
I2
sg33286
I12
sg33295
g11
sg33289
Vgp70 antigen
p42083
sasg33281
(lp42084
(dp42085
g33284
I68
sg33285
I1
sg33286
I9
sg33287
VC0024299
p42086
sg33289
Vlymphomas
p42087
sa(dp42088
g33284
I0
sg33285
I2
sg33286
I15
sg33287
VC0085164
p42089
sg33289
VFeline leukemia
p42090
sasa(dp42091
g33277
VVaccines to large B cell lymphoma were made by the covalent attachment of an epitope from the gp70 glycoprotein (SSWDFITV) to the N-termini of the conformationally biased, response-selective C5a agonists EP54 (YSFKPMPLaR) and EP67 (YSFKDMP(MeL)aR).
p42092
sg33279
(lp42093
(dp42094
g33284
I94
sg33285
I2
sg33286
I17
sg33295
g11
sg33289
Vgp70 glycoprotein
p42095
sa(dp42096
g33284
I191
sg33285
I1
sg33286
I3
sg33295
VP21730
p42097
sg33289
VC5a
p42098
sa(dp42099
g33284
I240
sg33285
I1
sg33286
I3
sg33295
VP61006
p42100
sg33289
VMeL
p42101
sasg33281
(lp42102
(dp42103
g33284
I18
sg33285
I3
sg33286
I15
sg33287
VC0079731
p42104
sg33289
VB cell lymphoma
p42105
sa(dp42106
g33284
I240
sg33285
I1
sg33286
I3
sg33287
VC3149631
p42107
sg33289
VMeL
p42108
sasa(dp42109
g33277
VSyngeneic Balb/c mice were immunized with these EP54/EP67-containing vaccines and challenged with a lethal dose of the highly liver metastatic and gp70-expressing lymphoma cell line RAW117-H10 to evaluate the ability of these vaccines to induce protective immune outcomes.
p42110
sg33279
(lp42111
(dp42112
g33284
I147
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
Vgp70
p42113
sasg33281
(lp42114
(dp42115
g33284
I163
sg33285
I1
sg33286
I8
sg33287
VC0024299
p42116
sg33289
Vlymphoma
p42117
sasa(dp42118
g33277
VCD8(+) T lymphocytes activated in response to Vaccines 2 and 3 express cytotoxic specificity for gp70-expressing RAW117-H10 lymphoma cells, but not antigen-irrelevant MDA-MB231A human breast cancer cells.
p42119
sg33279
(lp42120
(dp42121
g33284
I0
sg33285
I1
sg33286
I3
sg33295
VP01732
p42122
sg33289
VCD8
p42123
sa(dp42124
g33284
I97
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
Vgp70
p42125
sasg33281
(lp42126
(dp42127
g33284
I124
sg33285
I1
sg33286
I8
sg33287
VC0024299
p42128
sg33289
Vlymphoma
p42129
sa(dp42130
g33284
I184
sg33285
I2
sg33286
I13
sg33287
VC0678222
p42131
sg33289
Vbreast cancer
p42132
sasa(dp42133
g33277
VOur strategy relies on the fact that feline leukemia virus subgroup B (FeLV-B) and amphotropic murine leukemia virus (A-MLV) have closely related gp70 surface envelope glycoproteins and use related Na(+)-dependent phosphate symporters, Pit1 and Pit2, respectively, as their receptors.
p42134
sg33279
(lp42135
(dp42136
g33284
I245
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VPit2
p42137
sa(dp42138
g33284
I236
sg33285
I1
sg33286
I4
sg33295
VP28069
p42139
sg33289
VPit1
p42140
sa(dp42141
g33284
I146
sg33285
I4
sg33286
I35
sg33295
g11
sg33289
Vgp70 surface envelope glycoproteins
p42142
sa(dp42143
g33284
I198
sg33285
I3
sg33286
I36
sg33295
VP19525
p42144
sg33289
VNa(+)-dependent phosphate symporters
p42145
sasg33281
(lp42146
(dp42147
g33284
I37
sg33285
I2
sg33286
I15
sg33287
VC0085164
p42148
sg33289
Vfeline leukemia
p42149
sa(dp42150
g33284
I44
sg33285
I1
sg33286
I8
sg33287
VC0023418
p42151
sg33289
Vleukemia
p42152
sasa(dp42153
g33277
VNumerous studies have investigated the utility of serum intestinal fatty-acid binding protein (I-FABP) in differentiating acute intestinal ischemia from acute abdomen.
p42154
sg33279
(lp42155
(dp42156
g33284
I56
sg33285
I4
sg33286
I37
sg33295
VP12104
p42157
sg33289
Vintestinal fatty-acid binding protein
p42158
sa(dp42159
g33284
I95
sg33285
I1
sg33286
I6
sg33295
VP12104
p42160
sg33289
VI-FABP
p42161
sasg33281
(lp42162
(dp42163
g33284
I122
sg33285
I3
sg33286
I25
sg33287
VC0001363
p42164
sg33289
Vacute intestinal ischemia
p42165
sa(dp42166
g33284
I153
sg33285
I2
sg33286
I13
sg33287
VC0000727
p42167
sg33289
Vacute abdomen
p42168
sasa(dp42169
g33277
VThe aim of this meta-analysis is to determine the overall accuracy of serum I-FABP in the diagnosis of acute intestinal ischemia.
p42170
sg33279
(lp42171
(dp42172
g33284
I70
sg33285
I2
sg33286
I12
sg33295
VP12104
p42173
sg33289
Vserum I-FABP
p42174
sasg33281
(lp42175
(dp42176
g33284
I103
sg33285
I3
sg33286
I25
sg33287
VC0001363
p42177
sg33289
Vacute intestinal ischemia
p42178
sasa(dp42179
g33277
VThe meta-analysis carried out in this report suggests that the I-FABP may be a useful diagnostic tool to confirm acute intestinal ischemia in acute abdomen, but better-designed trials are still required to confirm our findings.
p42180
sg33279
(lp42181
(dp42182
g33284
I63
sg33285
I1
sg33286
I6
sg33295
VP12104
p42183
sg33289
VI-FABP
p42184
sasg33281
(lp42185
(dp42186
g33284
I142
sg33285
I2
sg33286
I13
sg33287
VC0000727
p42187
sg33289
Vacute abdomen
p42188
sa(dp42189
g33284
I113
sg33285
I3
sg33286
I25
sg33287
VC0001363
p42190
sg33289
Vacute intestinal ischemia
p42191
sasa(dp42192
g33277
VThe aim of the present study was to evaluate whether I-FABP can predict active disease or remission in Crohn's disease (CD) and ulcerative colitis (UC) in a real-life IBD cohort.
p42193
sg33279
(lp42194
sg33281
(lp42195
(dp42196
g33284
I120
sg33285
I1
sg33286
I2
sg33287
VC0010346
p42197
sg33289
VCD
p42198
sa(dp42199
g33284
I167
sg33285
I1
sg33286
I3
sg33287
VC0021390
p42200
sg33289
VIBD
p42201
sa(dp42202
g33284
I90
sg33285
I1
sg33286
I9
sg33287
VC0687702
p42203
sg33289
Vremission
p42204
sa(dp42205
g33284
I148
sg33285
I1
sg33286
I2
sg33287
VC0009324
p42206
sg33289
VUC
p42207
sa(dp42208
g33284
I103
sg33285
I2
sg33286
I15
sg33287
VC0010346
p42209
sg33289
VCrohn's disease
p42210
sa(dp42211
g33284
I128
sg33285
I2
sg33286
I18
sg33287
VC0009324
p42212
sg33289
Vulcerative colitis
p42213
sasa(dp42214
g33277
VIn our study, we found the expression of EWSAT1 was upregulated in ovarian cancer cell lines and samples.
p42215
sg33279
(lp42216
sg33281
(lp42217
(dp42218
g33284
I67
sg33285
I2
sg33286
I14
sg33287
VC1140680
p42219
sg33289
Vovarian cancer
p42220
sasa(dp42221
g33277
VEcoptic expression of EWSAT1 suppressed miR-330-5p expression in ovarian cancer cell.
p42222
sg33279
(lp42223
(dp42224
g33284
I40
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VmiR-330-5p
p42225
sasg33281
(lp42226
(dp42227
g33284
I65
sg33285
I2
sg33286
I14
sg33287
VC1140680
p42228
sg33289
Vovarian cancer
p42229
sasa(dp42230
g33277
VMoreover, the expression of miR-330-5p was negatively related with the expression of EWSAT1 in ovarian cancer samples.
p42231
sg33279
(lp42232
(dp42233
g33284
I28
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VmiR-330-5p
p42234
sasg33281
(lp42235
(dp42236
g33284
I95
sg33285
I2
sg33286
I14
sg33287
VC1140680
p42237
sg33289
Vovarian cancer
p42238
sasa(dp42239
g33277
VEcoptic expression of miR-330-5p suppressed Pdia3 expression and overexpression of EWSAT1 promoted Pdia3 expression in ovarian cancer cell.
p42240
sg33279
(lp42241
(dp42242
g33284
I22
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VmiR-330-5p
p42243
sa(dp42244
g33284
I44
sg33285
I1
sg33286
I5
sg33295
VP30101
p42245
sg33289
VPdia3
p42246
sa(dp42247
g33284
I44
sg33285
I1
sg33286
I5
sg33295
VP30101
p42248
sg33289
VPdia3
p42249
sasg33281
(lp42250
(dp42251
g33284
I119
sg33285
I2
sg33286
I14
sg33287
VC1140680
p42252
sg33289
Vovarian cancer
p42253
sasa(dp42254
g33277
VOverexpression of EWSAT1 increased ovarian cancer cell proliferation, colony formation and invasion through targeting miR-330-5p.
p42255
sg33279
(lp42256
(dp42257
g33284
I118
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VmiR-330-5p
p42258
sasg33281
(lp42259
(dp42260
g33284
I55
sg33285
I1
sg33286
I13
sg33287
VC0334094
p42261
sg33289
Vproliferation
p42262
sa(dp42263
g33284
I91
sg33285
I1
sg33286
I8
sg33287
VC2699153
p42264
sg33289
Vinvasion
p42265
sa(dp42266
g33284
I35
sg33285
I2
sg33286
I14
sg33287
VC1140680
p42267
sg33289
Vovarian cancer
p42268
sasa(dp42269
g33277
VThese data suggested that EWSAT1 might act as an oncogene in the development of ovarian cancer partly through inhibiting miR-330-5p expression.
p42270
sg33279
(lp42271
(dp42272
g33284
I121
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VmiR-330-5p
p42273
sasg33281
(lp42274
(dp42275
g33284
I80
sg33285
I2
sg33286
I14
sg33287
VC1140680
p42276
sg33289
Vovarian cancer
p42277
sasa(dp42278
g33277
VRecently, lncRNA Ewing sarcoma-associated transcript 1 (EWSAT1) was functionally identified in Ewing sarcoma, a highly aggressive primary pediatric bone tumor.
p42279
sg33279
(lp42280
(dp42281
g33284
I10
sg33285
I5
sg33286
I44
sg33295
VP11308
p42282
sg33289
VlncRNA Ewing sarcoma-associated transcript 1
p42283
sasg33281
(lp42284
(dp42285
g33284
I148
sg33285
I2
sg33286
I10
sg33287
VC0005967
p42286
sg33289
Vbone tumor
p42287
sa(dp42288
g33284
I17
sg33285
I2
sg33286
I13
sg33287
VC0553580
p42289
sg33289
VEwing sarcoma
p42290
sa(dp42291
g33284
I119
sg33285
I1
sg33286
I10
sg33287
VC0001807
p42292
sg33289
Vaggressive
p42293
sa(dp42294
g33284
I17
sg33285
I2
sg33286
I13
sg33287
VC0553580
p42295
sg33289
VEwing sarcoma
p42296
sasa(dp42297
g33277
VLong non-coding RNA (lncRNA) Ewing sarcoma associated transcript 1 (EWSAT1) has been identified as an oncogene, and its dysregulation is closed corrected with tumor progression in Ewing sarcoma.
p42298
sg33279
(lp42299
sg33281
(lp42300
(dp42301
g33284
I29
sg33285
I2
sg33286
I13
sg33287
VC0553580
p42302
sg33289
VEwing sarcoma
p42303
sa(dp42304
g33284
I159
sg33285
I2
sg33286
I17
sg33287
VC0178874
p42305
sg33289
Vtumor progression
p42306
sa(dp42307
g33284
I29
sg33285
I2
sg33286
I13
sg33287
VC0553580
p42308
sg33289
VEwing sarcoma
p42309
sasa(dp42310
g33277
VRecently, high-through put analysis reveals that EWSAT1 is also highly expressed in human nasopharyngeal carcinoma (NPC).
p42311
sg33279
(lp42312
sg33281
(lp42313
(dp42314
g33284
I90
sg33285
I2
sg33286
I24
sg33287
VC2931822
p42315
sg33289
Vnasopharyngeal carcinoma
p42316
sa(dp42317
g33284
I116
sg33285
I1
sg33286
I3
sg33287
VC2931822
p42318
sg33289
VNPC
p42319
sasa(dp42320
g33277
VWe determined that long noncoding RNA-277 (Ewing sarcoma-associated transcript 1 [EWSAT1]) is upregulated by EWS-FLI1 in pMPCs.
p42321
sg33279
(lp42322
(dp42323
g33284
I82
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VEWS
p42324
sa(dp42325
g33284
I113
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VFLI1
p42326
sasg33281
(lp42327
(dp42328
g33284
I43
sg33285
I2
sg33286
I13
sg33287
VC0553580
p42329
sg33289
VEwing sarcoma
p42330
sasa(dp42331
g33277
VInhibition of EWSAT1 expression diminished the ability of Ewing sarcoma cell lines to proliferate and form colonies in soft agar, whereas EWSAT1 inhibition had no effect on other cell types tested.
p42332
sg33279
(lp42333
sg33281
(lp42334
(dp42335
g33284
I58
sg33285
I2
sg33286
I13
sg33287
VC0553580
p42336
sg33289
VEwing sarcoma
p42337
sasa(dp42338
g33277
VAnalysis of RNAseq data from primary human Ewing sarcoma further supported a role for EWSAT1 in mediating gene repression.
p42339
sg33279
(lp42340
sg33281
(lp42341
(dp42342
g33284
I43
sg33285
I2
sg33286
I13
sg33287
VC0553580
p42343
sg33289
VEwing sarcoma
p42344
sasa(dp42345
g33277
VTogether, our data reveal that EWSAT1 is a downstream target of EWS-FLI1 that facilitates the development of Ewing sarcoma via the repression of target genes.
p42346
sg33279
(lp42347
(dp42348
g33284
I31
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VEWS
p42349
sa(dp42350
g33284
I68
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VFLI1
p42351
sasg33281
(lp42352
(dp42353
g33284
I109
sg33285
I2
sg33286
I13
sg33287
VC0553580
p42354
sg33289
VEwing sarcoma
p42355
sasa(dp42356
g33277
VResults: The data show that the expression of MZF-1/Elk-1 is correlated with that of PKCAlfa in hepatocellular carcinoma (HCC), but not in bladder and lung cancers.
p42357
sg33279
(lp42358
(dp42359
g33284
I52
sg33285
I1
sg33286
I5
sg33295
VP54762
p42360
sg33289
VElk-1
p42361
sa(dp42362
g33284
I46
sg33285
I1
sg33286
I5
sg33295
VP28698
p42363
sg33289
VMZF-1
p42364
sasg33281
(lp42365
(dp42366
g33284
I122
sg33285
I1
sg33286
I3
sg33287
VC2239176
p42367
sg33289
VHCC
p42368
sa(dp42369
g33284
I151
sg33285
I2
sg33286
I12
sg33287
VC0242379
p42370
sg33289
Vlung cancers
p42371
sa(dp42372
g33284
I96
sg33285
I2
sg33286
I24
sg33287
VC2239176
p42373
sg33289
Vhepatocellular carcinoma
p42374
sasa(dp42375
g33277
VHere, using PEI-Mn0.5Zn0.5Fe2O4 nanoparticles (PEI-MZF-NPs) as magnetic media for MFH (magnetic fluid hyperthermia) and gene transfer vector for gene-therapy, a combined therapy, pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH, for hepatoma is developed.
p42376
sg33279
(lp42377
(dp42378
g33284
I179
sg33285
I1
sg33286
I16
sg33295
VP29401
p42379
sg33289
VpHRE-Egr1-HSV-TK
p42380
sa(dp42381
g33284
I12
sg33285
I2
sg33286
I33
sg33295
g11
sg33289
VPEI-Mn0.5Zn0.5Fe2O4 nanoparticles
p42382
sa(dp42383
g33284
I47
sg33285
I1
sg33286
I11
sg33295
VP28698
p42384
sg33289
VPEI-MZF-NPs
p42385
sasg33281
(lp42386
(dp42387
g33284
I228
sg33285
I1
sg33286
I8
sg33287
VC0023903
p42388
sg33289
Vhepatoma
p42389
sa(dp42390
g33284
I55
sg33285
I1
sg33286
I3
sg33287
VC0027341
p42391
sg33289
VNPs
p42392
sasa(dp42393
g33277
VTo explore a new combination of thermal treatment and gene therapy for hepatoma, a heat-inducible herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) gene therapy system was developed in which thermal energy generated by Mn0.5Zn0.5Fe2O4 nanoparticles (MZF-NPs) under an alternating magnetic field was used to activate gene expression.
p42394
sg33279
(lp42395
(dp42396
g33284
I232
sg33285
I2
sg33286
I29
sg33295
g11
sg33289
VMn0.5Zn0.5Fe2O4 nanoparticles
p42397
sa(dp42398
g33284
I156
sg33285
I1
sg33286
I3
sg33295
VP23434
p42399
sg33289
VGCV
p42400
sa(dp42401
g33284
I153
sg33285
I1
sg33286
I2
sg33295
VP29401
p42402
sg33289
VTK
p42403
sa(dp42404
g33284
I263
sg33285
I1
sg33286
I7
sg33295
VP28698
p42405
sg33289
VMZF-NPs
p42406
sasg33281
(lp42407
(dp42408
g33284
I71
sg33285
I1
sg33286
I8
sg33287
VC0023903
p42409
sg33289
Vhepatoma
p42410
sa(dp42411
g33284
I98
sg33285
I2
sg33286
I14
sg33287
VC0019348
p42412
sg33289
Vherpes simplex
p42413
sa(dp42414
g33284
I267
sg33285
I1
sg33286
I3
sg33287
VC0027341
p42415
sg33289
VNPs
p42416
sasa(dp42417
g33277
VMagnet-induced heating was then applied to cells to assess the antihepatoma effects of the polyethylenimine (PEI)-MZF-NPs/pHsp 70-HSV-TK/GCV complex, in vitro and in vivo.
p42418
sg33279
(lp42419
(dp42420
g33284
I137
sg33285
I1
sg33286
I3
sg33295
VP23434
p42421
sg33289
VGCV
p42422
sa(dp42423
g33284
I118
sg33285
I1
sg33286
I3
sg33295
VP0C0P6
p42424
sg33289
VNPs
p42425
sa(dp42426
g33284
I114
sg33285
I1
sg33286
I3
sg33295
VP28698
p42427
sg33289
VMZF
p42428
sa(dp42429
g33284
I134
sg33285
I1
sg33286
I2
sg33295
VP29401
p42430
sg33289
VTK
p42431
sasg33281
(lp42432
(dp42433
g33284
I118
sg33285
I1
sg33286
I3
sg33287
VC0027341
p42434
sg33289
VNPs
p42435
sasa(dp42436
g33277
VIn this study, the molecular mechanism of protein kinase C alpha (PKCAlfa) gene regulation in hepatocellular carcinoma (HCC) involving Ets-like protein-1 (Elk-1) and myeloid zinc finger-1 (MZF-1) was investigated.
p42437
sg33279
(lp42438
(dp42439
g33284
I166
sg33285
I3
sg33286
I21
sg33295
VP28698
p42440
sg33289
Vmyeloid zinc finger-1
p42441
sa(dp42442
g33284
I155
sg33285
I1
sg33286
I5
sg33295
VP54762
p42443
sg33289
VElk-1
p42444
sa(dp42445
g33284
I135
sg33285
I2
sg33286
I18
sg33295
VP17980
p42446
sg33289
VEts-like protein-1
p42447
sa(dp42448
g33284
I42
sg33285
I4
sg33286
I22
sg33295
VP17252
p42449
sg33289
Vprotein kinase C alpha
p42450
sa(dp42451
g33284
I189
sg33285
I1
sg33286
I5
sg33295
VP28698
p42452
sg33289
VMZF-1
p42453
sasg33281
(lp42454
(dp42455
g33284
I120
sg33285
I1
sg33286
I3
sg33287
VC2239176
p42456
sg33289
VHCC
p42457
sa(dp42458
g33284
I94
sg33285
I2
sg33286
I24
sg33287
VC2239176
p42459
sg33289
Vhepatocellular carcinoma
p42460
sasa(dp42461
g33277
VBesides, PEI-MZF-NPs were used as magnetic media for thermotherapy to treat hepatoma by magnet-induced heating, combined with radiation-gene therapy.
p42462
sg33279
(lp42463
(dp42464
g33284
I9
sg33285
I1
sg33286
I11
sg33295
VP28698
p42465
sg33289
VPEI-MZF-NPs
p42466
sasg33281
(lp42467
(dp42468
g33284
I17
sg33285
I1
sg33286
I3
sg33287
VC0027341
p42469
sg33289
VNPs
p42470
sa(dp42471
g33284
I76
sg33285
I1
sg33286
I8
sg33287
VC0023903
p42472
sg33289
Vhepatoma
p42473
sasa(dp42474
g33277
VIn a recent study on hepatocellular carcinoma (HCC), we have shown that the transcription factors Myeloid Zinc Finger-1 (MZF-1) and Ets-like-protein 1 (Elk-1) are significantly related to protein kinase C alpha (PKCAlfa) expression.
p42475
sg33279
(lp42476
(dp42477
g33284
I121
sg33285
I1
sg33286
I5
sg33295
VP28698
p42478
sg33289
VMZF-1
p42479
sa(dp42480
g33284
I132
sg33285
I2
sg33286
I18
sg33295
VP14222
p42481
sg33289
VEts-like-protein 1
p42482
sa(dp42483
g33284
I188
sg33285
I4
sg33286
I22
sg33295
VP17252
p42484
sg33289
Vprotein kinase C alpha
p42485
sa(dp42486
g33284
I98
sg33285
I3
sg33286
I21
sg33295
VP28698
p42487
sg33289
VMyeloid Zinc Finger-1
p42488
sa(dp42489
g33284
I152
sg33285
I1
sg33286
I5
sg33295
VP54762
p42490
sg33289
VElk-1
p42491
sasg33281
(lp42492
(dp42493
g33284
I21
sg33285
I2
sg33286
I24
sg33287
VC2239176
p42494
sg33289
Vhepatocellular carcinoma
p42495
sa(dp42496
g33284
I47
sg33285
I1
sg33286
I3
sg33287
VC2239176
p42497
sg33289
VHCC
p42498
sasa(dp42499
g33277
VRecently, our research into hepatocellular carcinoma (HCC) has shown that the transcription factors Myeloid Zinc Finger-1 (MZF-1) and Ets-like-protein 1 are related to protein kinase C alpha (PKCAlfa) expression.
p42500
sg33279
(lp42501
(dp42502
g33284
I100
sg33285
I3
sg33286
I21
sg33295
VP28698
p42503
sg33289
VMyeloid Zinc Finger-1
p42504
sa(dp42505
g33284
I123
sg33285
I1
sg33286
I5
sg33295
VP28698
p42506
sg33289
VMZF-1
p42507
sa(dp42508
g33284
I168
sg33285
I4
sg33286
I22
sg33295
VP17252
p42509
sg33289
Vprotein kinase C alpha
p42510
sa(dp42511
g33284
I134
sg33285
I2
sg33286
I18
sg33295
VP14222
p42512
sg33289
VEts-like-protein 1
p42513
sasg33281
(lp42514
(dp42515
g33284
I54
sg33285
I1
sg33286
I3
sg33287
VC2239176
p42516
sg33289
VHCC
p42517
sa(dp42518
g33284
I28
sg33285
I2
sg33286
I24
sg33287
VC2239176
p42519
sg33289
Vhepatocellular carcinoma
p42520
sasa(dp42521
g33277
VUsing immunocytochemistry, we investigated the distribution of chromogranin A, chromogranin B, secretoneurin, and, for comparison, dynorphin in hippocampal specimens removed at routine surgery from patients with drug-resistant mesial temporal lobe epilepsy and in autopsy tissues from nonneurologically deceased subjects.
p42522
sg33279
(lp42523
(dp42524
g33284
I79
sg33285
I2
sg33286
I14
sg33295
VP08311
p42525
sg33289
Vchromogranin B
p42526
sa(dp42527
g33284
I131
sg33285
I1
sg33286
I9
sg33295
VP01213
p42528
sg33289
Vdynorphin
p42529
sa(dp42530
g33284
I95
sg33285
I1
sg33286
I13
sg33295
VP13521
p42531
sg33289
Vsecretoneurin
p42532
sa(dp42533
g33284
I63
sg33285
I2
sg33286
I14
sg33295
VP10645
p42534
sg33289
Vchromogranin A
p42535
sasg33281
(lp42536
(dp42537
g33284
I234
sg33285
I3
sg33286
I22
sg33287
VC0014556
p42538
sg33289
Vtemporal lobe epilepsy
p42539
sasa(dp42540
g33277
VThe most intriguing change seen in human temporal lobe epilepsy specimens and in the kainic acid model of the rat was the prominent staining of the inner molecular layer, indicating storage of chromogranins A and B and secretoneurin in terminals of reorganized mossy fibers, from which they may be released upon nerve stimulation.
p42541
sg33279
(lp42542
(dp42543
g33284
I193
sg33285
I6
sg33286
I39
sg33295
VP08311
p42544
sg33289
Vchromogranins A and B and secretoneurin
p42545
sasg33281
(lp42546
(dp42547
g33284
I41
sg33285
I3
sg33286
I22
sg33287
VC0014556
p42548
sg33289
Vtemporal lobe epilepsy
p42549
sasa(dp42550
g33277
VTransition of control prediabetic ZDF rats to diabetes was associated with reduced plasma insulin levels, reduced islet insulin content and GSIS, reduced stearoyl-CoA desaturase 2 (SCD 2) expression, and increased islet TAG, diacylglyceride (DAG) and ceramides species containing saturated FA.
p42551
sg33279
(lp42552
(dp42553
g33284
I114
sg33285
I2
sg33286
I13
sg33295
VP01308
p42554
sg33289
Vislet insulin
p42555
sa(dp42556
g33284
I154
sg33285
I3
sg33286
I25
sg33295
g11
sg33289
Vstearoyl-CoA desaturase 2
p42557
sa(dp42558
g33284
I83
sg33285
I2
sg33286
I14
sg33295
VP01308
p42559
sg33289
Vplasma insulin
p42560
sa(dp42561
g33284
I181
sg33285
I2
sg33286
I5
sg33295
g11
sg33289
VSCD 2
p42562
sasg33281
(lp42563
(dp42564
g33284
I46
sg33285
I1
sg33286
I8
sg33287
VC0011849
p42565
sg33289
Vdiabetes
p42566
sa(dp42567
g33284
I0
sg33285
I1
sg33286
I10
sg33287
VC0599156
p42568
sg33289
VTransition
p42569
sa(dp42570
g33284
I163
sg33285
I1
sg33286
I3
sg33287
VC2678439
p42571
sg33289
VCoA
p42572
sa(dp42573
g33284
I220
sg33285
I1
sg33286
I3
sg33287
VC0037293
p42574
sg33289
VTAG
p42575
sa(dp42576
g33284
I181
sg33285
I1
sg33286
I3
sg33287
VC0002895
p42577
sg33289
VSCD
p42578
sasa(dp42579
g33277
VIn this research, we have found that lycorine significantly induces the apoptotic and autophagic capacities of hepatocellular carcinoma (HCC) cells in vitro and in vivo Treatment with specific autophagy inhibitor (3-methyladenine/Bafilomycin A1) or knockdown of LC-3B/Atg5 by siRNA drastically enhances the apoptotic cell death effect by facilitating the switch from autophagy to apoptosis.
p42580
sg33279
(lp42581
(dp42582
g33284
I268
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VAtg5
p42583
sasg33281
(lp42584
(dp42585
g33284
I137
sg33285
I1
sg33286
I3
sg33287
VC2239176
p42586
sg33289
VHCC
p42587
sa(dp42588
g33284
I111
sg33285
I2
sg33286
I24
sg33287
VC2239176
p42589
sg33289
Vhepatocellular carcinoma
p42590
sasa(dp42591
g33277
VThe differential expression of 10 miRNAs were validated by RT-qPCR (let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC; the expression of miR-1275 was variable in tumours, with high levels associated to regional lymph node invasion; additionally, miR-223 exhibited an association with advanced tumour stage/size).
p42592
sg33279
(lp42593
(dp42594
g33284
I136
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VmiR-142-3p
p42595
sa(dp42596
g33284
I157
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VmiR-203
p42597
sa(dp42598
g33284
I127
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VmiR-29b
p42599
sa(dp42600
g33284
I148
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VmiR-144
p42601
sa(dp42602
g33284
I95
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VmiR-16
p42603
sasg33281
(lp42604
(dp42605
g33284
I247
sg33285
I1
sg33286
I6
sg33287
VC0027651
p42606
sg33289
Vtumour
p42607
sa(dp42608
g33284
I247
sg33285
I1
sg33286
I7
sg33287
VC0027651
p42609
sg33289
Vtumours
p42610
sa(dp42611
g33284
I307
sg33285
I1
sg33286
I8
sg33287
VC2699153
p42612
sg33289
Vinvasion
p42613
sasa(dp42614
g33277
VTo the best of our knowledge, this is the first report to show the association of miR-1275 with nodal invasion and the upregulation of miR-144 in OSCC.
p42615
sg33279
(lp42616
(dp42617
g33284
I82
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VmiR-1275
p42618
sasg33281
(lp42619
(dp42620
g33284
I102
sg33285
I1
sg33286
I8
sg33287
VC2699153
p42621
sg33289
Vinvasion
p42622
sasa(dp42623
g33277
VIn the subgroup of non-vomiting drinkers with Wernicke's encephalopathy (WE), the slope of the linear regression of AETK on ETK was 1.21, so that apoTK decreased as ETK decreased.
p42624
sg33279
(lp42625
(dp42626
g33284
I117
sg33285
I1
sg33286
I3
sg33295
VP51813
p42627
sg33289
VETK
p42628
sa(dp42629
g33284
I117
sg33285
I1
sg33286
I3
sg33295
VP51813
p42630
sg33289
VETK
p42631
sasg33281
(lp42632
(dp42633
g33284
I46
sg33285
I2
sg33286
I25
sg33287
VC0043121
p42634
sg33289
VWernicke's encephalopathy
p42635
sa(dp42636
g33284
I23
sg33285
I1
sg33286
I8
sg33287
VC0042963
p42637
sg33289
Vvomiting
p42638
sa(dp42639
g33284
I73
sg33285
I1
sg33286
I2
sg33287
VC0043121
p42640
sg33289
VWE
p42641
sasa(dp42642
g33277
VIn pancreatic ductal adenocarcinoma, the CCL2-CCR2 chemokine axis is used to recruit tumour-associated macrophages for construction of an immunosuppressive tumour microenvironment.
p42643
sg33279
(lp42644
(dp42645
g33284
I41
sg33285
I1
sg33286
I4
sg33295
VP13500
p42646
sg33289
VCCL2
p42647
sa(dp42648
g33284
I46
sg33285
I1
sg33286
I4
sg33295
VP41597
p42649
sg33289
VCCR2
p42650
sasg33281
(lp42651
(dp42652
g33284
I3
sg33285
I3
sg33286
I32
sg33287
VC1335302
p42653
sg33289
Vpancreatic ductal adenocarcinoma
p42654
sa(dp42655
g33284
I85
sg33285
I1
sg33286
I6
sg33287
VC0027651
p42656
sg33289
Vtumour
p42657
sa(dp42658
g33284
I85
sg33285
I1
sg33286
I6
sg33287
VC0027651
p42659
sg33289
Vtumour
p42660
sasa(dp42661
g33277
VThis pathway has prognostic implications in pancreatic cancer, and blockade of CCR2 restores anti-tumour immunity in preclinical models.
p42662
sg33279
(lp42663
(dp42664
g33284
I79
sg33285
I1
sg33286
I4
sg33295
VP41597
p42665
sg33289
VCCR2
p42666
sasg33281
(lp42667
(dp42668
g33284
I44
sg33285
I2
sg33286
I17
sg33287
VC0235974
p42669
sg33289
Vpancreatic cancer
p42670
sa(dp42671
g33284
I98
sg33285
I1
sg33286
I6
sg33287
VC0027651
p42672
sg33289
Vtumour
p42673
sasa(dp42674
g33277
VTo determine the role of the CCL2/CCR2 axis and inflammatory monocytes (CCR2(+)/CD14(+)) as immunotherapeutic targets in the treatment of pancreatic cancer.
p42675
sg33279
(lp42676
(dp42677
g33284
I29
sg33285
I1
sg33286
I4
sg33295
VP13500
p42678
sg33289
VCCL2
p42679
sa(dp42680
g33284
I34
sg33285
I1
sg33286
I4
sg33295
VP41597
p42681
sg33289
VCCR2
p42682
sa(dp42683
g33284
I34
sg33285
I1
sg33286
I4
sg33295
VP41597
p42684
sg33289
VCCR2
p42685
sa(dp42686
g33284
I80
sg33285
I1
sg33286
I4
sg33295
VP08571
p42687
sg33289
VCD14
p42688
sasg33281
(lp42689
(dp42690
g33284
I138
sg33285
I2
sg33286
I17
sg33287
VC0235974
p42691
sg33289
Vpancreatic cancer
p42692
sasa(dp42693
g33277
VA novel CCR2 inhibitor (PF-04136309) was tested in an orthotopic model of murine pancreatic cancer.
p42694
sg33279
(lp42695
(dp42696
g33284
I8
sg33285
I1
sg33286
I4
sg33295
VP41597
p42697
sg33289
VCCR2
p42698
sasg33281
(lp42699
(dp42700
g33284
I81
sg33285
I2
sg33286
I17
sg33287
VC0235974
p42701
sg33289
Vpancreatic cancer
p42702
sasa(dp42703
g33277
VHuman pancreatic cancer produces CCL2, and immunosuppressive CCR2(+) macrophages infiltrate these tumors.
p42704
sg33279
(lp42705
(dp42706
g33284
I33
sg33285
I1
sg33286
I4
sg33295
VP13500
p42707
sg33289
VCCL2
p42708
sasg33281
(lp42709
(dp42710
g33284
I6
sg33285
I2
sg33286
I17
sg33287
VC0235974
p42711
sg33289
Vpancreatic cancer
p42712
sa(dp42713
g33284
I98
sg33285
I1
sg33286
I6
sg33287
VC0027651
p42714
sg33289
Vtumors
p42715
sa(dp42716
g33284
I81
sg33285
I1
sg33286
I10
sg33287
VC0332448
p42717
sg33289
Vinfiltrate
p42718
sasa(dp42719
g33277
VInflammatory monocyte recruitment is critical to pancreatic cancer progression, and targeting CCR2 may be an effective immunotherapeutic strategy in this disease.
p42720
sg33279
(lp42721
(dp42722
g33284
I94
sg33285
I1
sg33286
I4
sg33295
VP41597
p42723
sg33289
VCCR2
p42724
sasg33281
(lp42725
(dp42726
g33284
I22
sg33285
I1
sg33286
I11
sg33287
VC0271510
p42727
sg33289
Vrecruitment
p42728
sa(dp42729
g33284
I60
sg33285
I2
sg33286
I18
sg33287
VC0178874
p42730
sg33289
Vcancer progression
p42731
sasa(dp42732
g33277
VWeaver syndrome (WS) is a rare congenital overgrowth disorder caused by heterozygous mutations in EZH2 (enhancer of zeste homolog 2) or EED (embryonic ectoderm development).
p42733
sg33279
(lp42734
sg33281
(lp42735
(dp42736
g33284
I17
sg33285
I1
sg33286
I2
sg33287
VC0265210
p42737
sg33289
VWS
p42738
sa(dp42739
g33284
I0
sg33285
I2
sg33286
I15
sg33287
VC0265210
p42740
sg33289
VWeaver syndrome
p42741
sa(dp42742
g33284
I31
sg33285
I2
sg33286
I21
sg33287
VC0332887
p42743
sg33289
Vcongenital overgrowth
p42744
sasa(dp42745
g33277
VWe evaluated the associations of six nonsynonymous SNPs in the MMP3, MMP8, and MMP9 genes with skin cancer risk in a nested case-control study of Caucasians within the Nurses' Health Study among 218 melanoma cases, 285 squamous cell carcinoma (SCC) cases, 300 basal cell carcinoma (BCC) cases, and 870 normal controls.
p42746
sg33279
(lp42747
(dp42748
g33284
I79
sg33285
I2
sg33286
I10
sg33295
VP14780
p42749
sg33289
VMMP9 genes
p42750
sa(dp42751
g33284
I63
sg33285
I1
sg33286
I4
sg33295
VP08254
p42752
sg33289
VMMP3
p42753
sa(dp42754
g33284
I69
sg33285
I1
sg33286
I4
sg33295
VP22894
p42755
sg33289
VMMP8
p42756
sasg33281
(lp42757
(dp42758
g33284
I199
sg33285
I1
sg33286
I8
sg33287
VC0025202
p42759
sg33289
Vmelanoma
p42760
sa(dp42761
g33284
I244
sg33285
I1
sg33286
I3
sg33287
VC0007137
p42762
sg33289
VSCC
p42763
sa(dp42764
g33284
I95
sg33285
I2
sg33286
I11
sg33287
VC0007114
p42765
sg33289
Vskin cancer
p42766
sa(dp42767
g33284
I219
sg33285
I3
sg33286
I23
sg33287
VC0007137
p42768
sg33289
Vsquamous cell carcinoma
p42769
sa(dp42770
g33284
I282
sg33285
I1
sg33286
I3
sg33287
VC0007117
p42771
sg33289
VBCC
p42772
sa(dp42773
g33284
I260
sg33285
I3
sg33286
I20
sg33287
VC0007117
p42774
sg33289
Vbasal cell carcinoma
p42775
sasa(dp42776
g33277
VNinety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
p42777
sg33279
(lp42778
(dp42779
g33284
I199
sg33285
I1
sg33286
I5
sg33295
VP08254
p42780
sg33289
VMMP-3
p42781
sa(dp42782
g33284
I189
sg33285
I1
sg33286
I5
sg33295
VP03956
p42783
sg33289
VMMP-1
p42784
sa(dp42785
g33284
I170
sg33285
I1
sg33286
I3
sg33295
VP42771
p42786
sg33289
Vp53
p42787
sa(dp42788
g33284
I163
sg33285
I1
sg33286
I5
sg33295
VP46013
p42789
sg33289
VKi-67
p42790
sasg33281
(lp42791
(dp42792
g33284
I21
sg33285
I3
sg33286
I23
sg33287
VC0007137
p42793
sg33289
Vsquamous cell carcinoma
p42794
sa(dp42795
g33284
I62
sg33285
I3
sg33286
I20
sg33287
VC0007117
p42796
sg33289
Vbasal cell carcinoma
p42797
sasa(dp42798
g33277
VA novel zinc oxide-binding peptide (ZBP), FPYPGGDA, with high affinity to ZNP (K a  = 2.26 x 106 M-1) was isolated from a random peptide library and fused with a bacterial antigen, ScaA of Orientia tsutsugamushi, the causative agent of scrub typhus.
p42799
sg33279
(lp42800
(dp42801
g33284
I36
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VZBP
p42802
sa(dp42803
g33284
I8
sg33285
I3
sg33286
I26
sg33295
VP10070
p42804
sg33289
Vzinc oxide-binding peptide
p42805
sa(dp42806
g33284
I162
sg33285
I2
sg33286
I17
sg33295
g11
sg33289
Vbacterial antigen
p42807
sasg33281
(lp42808
(dp42809
g33284
I198
sg33285
I1
sg33286
I13
sg33287
VC0036472
p42810
sg33289
Vtsutsugamushi
p42811
sa(dp42812
g33284
I236
sg33285
I2
sg33286
I12
sg33287
VC0036472
p42813
sg33289
Vscrub typhus
p42814
sasa(dp42815
g33277
VThe results show that the main latex allergen, a glycine-rich protein molecule, can cause cutaneous, inhalant and systemic hypersensitivity reactions.
p42816
sg33279
(lp42817
(dp42818
g33284
I49
sg33285
I3
sg33286
I29
sg33295
g11
sg33289
Vglycine-rich protein molecule
p42819
sasg33281
(lp42820
(dp42821
g33284
I123
sg33285
I2
sg33286
I26
sg33287
VC0020517
p42822
sg33289
Vhypersensitivity reactions
p42823
sasa(dp42824
g33277
VOne hundred and one consecutive patients of Han nationality with rheumatic heart disease undergoing valve surgery were enrolled and randomly assigned to an experimental group (n=50, based on CYP2C9 and VKORC1 genotypes, pharmacogenetic-based "predicted warfarin dose" for 3 days and then was adjusted to INR until stable warfarin maintenance dose) or a control group (n=51, 2.5mg/d for 3 days and then was adjusted to INR until stable warfarin maintenance dose).
p42825
sg33279
(lp42826
(dp42827
g33284
I191
sg33285
I1
sg33286
I6
sg33295
VP11712
p42828
sg33289
VCYP2C9
p42829
sa(dp42830
g33284
I202
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VVKORC1
p42831
sasg33281
(lp42832
(dp42833
g33284
I65
sg33285
I3
sg33286
I23
sg33287
VC0035439
p42834
sg33289
Vrheumatic heart disease
p42835
sasa(dp42836
g33277
VRNF216) have recently been identified in patients suffering from Gordon Holmes syndrome (GHS), characterized by cognitive decline, dementia, and movement disorders.
p42837
sg33279
(lp42838
(dp42839
g33284
I0
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VRNF216
p42840
sasg33281
(lp42841
(dp42842
g33284
I131
sg33285
I1
sg33286
I8
sg33287
VC0497327
p42843
sg33289
Vdementia
p42844
sa(dp42845
g33284
I89
sg33285
I1
sg33286
I3
sg33287
VC1859305
p42846
sg33289
VGHS
p42847
sa(dp42848
g33284
I50
sg33285
I1
sg33286
I9
sg33287
VC0683278
p42849
sg33289
Vsuffering
p42850
sa(dp42851
g33284
I145
sg33285
I2
sg33286
I18
sg33287
VC0026650
p42852
sg33289
Vmovement disorders
p42853
sa(dp42854
g33284
I65
sg33285
I3
sg33286
I22
sg33287
VC1859305
p42855
sg33289
VGordon Holmes syndrome
p42856
sa(dp42857
g33284
I112
sg33285
I2
sg33286
I17
sg33287
VC0338656
p42858
sg33289
Vcognitive decline
p42859
sasa(dp42860
g33277
VOur current findings of Arc misregulation by TRIAD3A variants suggest that loss-of-function mutations in TRIAD3A may contribute to dementia observed in patients with GHS driven by dysfunctional UPS components, leading to cognitive impairments through the synaptic protein Arc.
p42861
sg33279
(lp42862
(dp42863
g33284
I24
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VArc
p42864
sa(dp42865
g33284
I255
sg33285
I3
sg33286
I20
sg33295
g11
sg33289
Vsynaptic protein Arc
p42866
sa(dp42867
g33284
I45
sg33285
I2
sg33286
I16
sg33295
g11
sg33289
VTRIAD3A variants
p42868
sa(dp42869
g33284
I45
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VTRIAD3A
p42870
sasg33281
(lp42871
(dp42872
g33284
I24
sg33285
I1
sg33286
I3
sg33287
VC0001857
p42873
sg33289
VArc
p42874
sa(dp42875
g33284
I221
sg33285
I2
sg33286
I21
sg33287
VC0338656
p42876
sg33289
Vcognitive impairments
p42877
sa(dp42878
g33284
I24
sg33285
I1
sg33286
I3
sg33287
VC0001857
p42879
sg33289
VArc
p42880
sa(dp42881
g33284
I131
sg33285
I1
sg33286
I8
sg33287
VC0497327
p42882
sg33289
Vdementia
p42883
sasa(dp42884
g33277
VGordon Holmes syndrome (GHS) is a distinct phenotype of autosomal recessive cerebellar ataxia, characterized by ataxia, dementia, reproductive defects and hypogonadism; it has been recently found to be associated with RNF216 mutation.
p42885
sg33279
(lp42886
(dp42887
g33284
I218
sg33285
I2
sg33286
I15
sg33295
g11
sg33289
VRNF216 mutation
p42888
sasg33281
(lp42889
(dp42890
g33284
I87
sg33285
I1
sg33286
I6
sg33287
VC0004134
p42891
sg33289
Vataxia
p42892
sa(dp42893
g33284
I120
sg33285
I1
sg33286
I8
sg33287
VC0497327
p42894
sg33289
Vdementia
p42895
sa(dp42896
g33284
I155
sg33285
I1
sg33286
I12
sg33287
VC0020619
p42897
sg33289
Vhypogonadism
p42898
sa(dp42899
g33284
I0
sg33285
I3
sg33286
I22
sg33287
VC1859305
p42900
sg33289
VGordon Holmes syndrome
p42901
sa(dp42902
g33284
I76
sg33285
I2
sg33286
I17
sg33287
VC0007758
p42903
sg33289
Vcerebellar ataxia
p42904
sa(dp42905
g33284
I24
sg33285
I1
sg33286
I3
sg33287
VC1859305
p42906
sg33289
VGHS
p42907
sasa(dp42908
g33277
VThe syndrome of hypogonadotropic hypogonadism, ataxia, and dementia can be caused by inactivating mutations in RNF216 or by the combination of mutations in RNF216 and OTUD4.
p42909
sg33279
(lp42910
(dp42911
g33284
I111
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VRNF216
p42912
sa(dp42913
g33284
I167
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VOTUD4
p42914
sa(dp42915
g33284
I111
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VRNF216
p42916
sasg33281
(lp42917
(dp42918
g33284
I16
sg33285
I2
sg33286
I29
sg33287
VC0022735
p42919
sg33289
Vhypogonadotropic hypogonadism
p42920
sa(dp42921
g33284
I59
sg33285
I1
sg33286
I8
sg33287
VC0497327
p42922
sg33289
Vdementia
p42923
sa(dp42924
g33284
I47
sg33285
I1
sg33286
I6
sg33287
VC0004134
p42925
sg33289
Vataxia
p42926
sa(dp42927
g33284
I4
sg33285
I1
sg33286
I8
sg33287
VC0039082
p42928
sg33289
Vsyndrome
p42929
sasa(dp42930
g33277
Vto investigate the molecular mechanisms and morphological substrate of reduced uterine leiomyoma in patients receiving the selective progesterone receptor modulator (SPRM) ulipristal acetate for 3 months, by estimating the immunohistochemical expression of the markers steroid receptor coactivator 1 (SRC-1), nuclear receptor corepressor 1 (NCoR-1), ER, PgR, Ki-67, p16, TGF-Beta, and VEGF in tumor tissue.
p42931
sg33279
(lp42932
(dp42933
g33284
I371
sg33285
I1
sg33286
I8
sg33295
VP18075
p42934
sg33289
VTGF-Beta
p42935
sa(dp42936
g33284
I354
sg33285
I1
sg33286
I3
sg33295
VP06401
p42937
sg33289
VPgR
p42938
sa(dp42939
g33284
I301
sg33285
I1
sg33286
I5
sg33295
VP12931
p42940
sg33289
VSRC-1
p42941
sa(dp42942
g33284
I341
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VNCoR-1
p42943
sa(dp42944
g33284
I366
sg33285
I1
sg33286
I3
sg33295
VP42771
p42945
sg33289
Vp16
p42946
sa(dp42947
g33284
I309
sg33285
I4
sg33286
I30
sg33295
g11
sg33289
Vnuclear receptor corepressor 1
p42948
sa(dp42949
g33284
I359
sg33285
I1
sg33286
I5
sg33295
VP46013
p42950
sg33289
VKi-67
p42951
sa(dp42952
g33284
I269
sg33285
I4
sg33286
I30
sg33295
g11
sg33289
Vsteroid receptor coactivator 1
p42953
sa(dp42954
g33284
I133
sg33285
I2
sg33286
I21
sg33295
VP06401
p42955
sg33289
Vprogesterone receptor
p42956
sasg33281
(lp42957
(dp42958
g33284
I79
sg33285
I2
sg33286
I17
sg33287
VC0042133
p42959
sg33289
Vuterine leiomyoma
p42960
sa(dp42961
g33284
I393
sg33285
I1
sg33286
I5
sg33287
VC0027651
p42962
sg33289
Vtumor
p42963
sasa(dp42964
g33277
VThe morphological substrate of partial leiomyoma reduction was leiomyocyte apoptosis and dystrophy, tumor stroma sclerosis and hyalinosis with diminished Ki-67 expression and elevated p16 in the smooth muscle cells, trophic nodular tissue disorders exhibited by vascular wall sclerosis and lower VEGF and TGF-Beta expression, and leiomyocyte hormonal reception dysregulation that made itself evident through the reduced expression of SRC-1 with the unchanged expression of PR and ER and the maintained level of NCoR-1.
p42965
sg33279
(lp42966
(dp42967
g33284
I305
sg33285
I1
sg33286
I8
sg33295
VP18075
p42968
sg33289
VTGF-Beta
p42969
sa(dp42970
g33284
I511
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VNCoR-1
p42971
sa(dp42972
g33284
I184
sg33285
I1
sg33286
I3
sg33295
VP42771
p42973
sg33289
Vp16
p42974
sa(dp42975
g33284
I434
sg33285
I1
sg33286
I5
sg33295
VP12931
p42976
sg33289
VSRC-1
p42977
sasg33281
(lp42978
(dp42979
g33284
I113
sg33285
I1
sg33286
I9
sg33287
VC0036429
p42980
sg33289
Vsclerosis
p42981
sa(dp42982
g33284
I89
sg33285
I1
sg33286
I9
sg33287
VC0333606
p42983
sg33289
Vdystrophy
p42984
sa(dp42985
g33284
I100
sg33285
I1
sg33286
I5
sg33287
VC0027651
p42986
sg33289
Vtumor
p42987
sa(dp42988
g33284
I39
sg33285
I1
sg33286
I9
sg33287
VC0023267
p42989
sg33289
Vleiomyoma
p42990
sa(dp42991
g33284
I127
sg33285
I1
sg33286
I10
sg33287
VC0333438
p42992
sg33289
Vhyalinosis
p42993
sa(dp42994
g33284
I113
sg33285
I1
sg33286
I9
sg33287
VC0036429
p42995
sg33289
Vsclerosis
p42996
sasa(dp42997
g33277
VUenb - N3y4NTb MoneKynRpHble MexaHN3Mbl N MopoonorN4ecKNN cybcTpaT peAyKmyNN neNoMNoMbl MaTKN y namyNeHToK, nony4aBwNx ceneKTNBHblN MoAynRTop nporecTepoHoBblx pemyenTopoB ynNnpNcTana amyeTaT B Te4eHNe 3 Mec, Ha ocHoBaHNN omyeHKN NMMyHorNcToxNMN4ecKoN EKcnpeccNN SRC-1, NCoR-1, ER, PGR, Ki-67, p16, TGF-Beta, VEGF B TKaHN onyxonN.
p42998
sg33279
(lp42999
(dp43000
g33284
I208
sg33285
I6
sg33286
I59
sg33295
VP12931
p43001
sg33289
VHa ocHoBaHNN omyeHKN NMMyHorNcToxNMN4ecKoN EKcnpeccNN SRC-1
p43002
sa(dp43003
g33284
I269
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VNCoR-1
p43004
sa(dp43005
g33284
I293
sg33285
I1
sg33286
I3
sg33295
VP42771
p43006
sg33289
Vp16
p43007
sa(dp43008
g33284
I281
sg33285
I1
sg33286
I3
sg33295
VP06401
p43009
sg33289
VPGR
p43010
sa(dp43011
g33284
I0
sg33285
I24
sg33286
I206
sg33295
g11
sg33289
VUenb - N3y4NTb MoneKynRpHble MexaHN3Mbl N MopoonorN4ecKNN cybcTpaT peAyKmyNN neNoMNoMbl MaTKN y namyNeHToK, nony4aBwNx ceneKTNBHblN MoAynRTop nporecTepoHoBblx pemyenTopoB ynNnpNcTana amyeTaT B Te4eHNe 3 Mec
p43012
sa(dp43013
g33284
I308
sg33285
I4
sg33286
I20
sg33295
VP49765
p43014
sg33289
VVEGF B TKaHN onyxonN
p43015
sa(dp43016
g33284
I286
sg33285
I1
sg33286
I5
sg33295
VP46013
p43017
sg33289
VKi-67
p43018
sa(dp43019
g33284
I298
sg33285
I1
sg33286
I8
sg33295
VP18075
p43020
sg33289
VTGF-Beta
p43021
sasg33281
(lp43022
sa(dp43023
g33277
VWe find that AML1-ETO and corepressor NCoR co-occupy the miR-29a/b-1 locus and downregulate its expression in leukemia cells.
p43024
sg33279
(lp43025
(dp43026
g33284
I57
sg33285
I2
sg33286
I17
sg33295
g11
sg33289
VmiR-29a/b-1 locus
p43027
sa(dp43028
g33284
I38
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNCoR
p43029
sasg33281
(lp43030
(dp43031
g33284
I110
sg33285
I1
sg33286
I8
sg33287
VC0023418
p43032
sg33289
Vleukemia
p43033
sasa(dp43034
g33277
VAuthors present the history of a patient with extra-adrenal pheochromocytoma who represents in Hungary the first genetically confirmed case of hereditary paraganglioma/pheochromocytoma syndrome due to disease-causing mutation of the SDHD gene.
p43035
sg33279
(lp43036
(dp43037
g33284
I233
sg33285
I2
sg33286
I9
sg33295
g11
sg33289
VSDHD gene
p43038
sasg33281
(lp43039
(dp43040
g33284
I46
sg33285
I2
sg33286
I30
sg33287
VC1257877
p43041
sg33289
Vextra-adrenal pheochromocytoma
p43042
sa(dp43043
g33284
I168
sg33285
I2
sg33286
I25
sg33287
VC0031511
p43044
sg33289
Vpheochromocytoma syndrome
p43045
sa(dp43046
g33284
I143
sg33285
I2
sg33286
I24
sg33287
VC1333993
p43047
sg33289
Vhereditary paraganglioma
p43048
sa(dp43049
g33284
I201
sg33285
I2
sg33286
I24
sg33287
VC2985434
p43050
sg33289
Vdisease-causing mutation
p43051
sasa(dp43052
g33277
VWhile SDHD has been more frequently associated with the pathogenesis of head and neck paragangliomas, SDHB mutations were mainly associated with malignant and/or extra-adrenal pheochromocytoma/paraganglioma.
p43053
sg33279
(lp43054
(dp43055
g33284
I102
sg33285
I2
sg33286
I14
sg33295
VP21912
p43056
sg33289
VSDHB mutations
p43057
sa(dp43058
g33284
I6
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VSDHD
p43059
sasg33281
(lp43060
(dp43061
g33284
I56
sg33285
I1
sg33286
I12
sg33287
VC0699748
p43062
sg33289
Vpathogenesis
p43063
sa(dp43064
g33284
I162
sg33285
I2
sg33286
I30
sg33287
VC1257877
p43065
sg33289
Vextra-adrenal pheochromocytoma
p43066
sa(dp43067
g33284
I86
sg33285
I1
sg33286
I13
sg33287
VC0030421
p43068
sg33289
Vparaganglioma
p43069
sa(dp43070
g33284
I86
sg33285
I1
sg33286
I14
sg33287
VC0030421
p43071
sg33289
Vparagangliomas
p43072
sasa(dp43073
g33277
VSDHB mutation carriers were more likely than SDHD mutation carriers to develop extraadrenal pheochromocytomas and malignant disease, whereas SDHD mutation carriers had a greater propensity to develop head and neck paragangliomas and multiple tumors.
p43074
sg33279
(lp43075
(dp43076
g33284
I45
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VSDHD
p43077
sa(dp43078
g33284
I45
sg33285
I2
sg33286
I13
sg33295
g11
sg33289
VSDHD mutation
p43079
sa(dp43080
g33284
I0
sg33285
I1
sg33286
I4
sg33295
VP21912
p43081
sg33289
VSDHB
p43082
sasg33281
(lp43083
(dp43084
g33284
I92
sg33285
I1
sg33286
I17
sg33287
VC0031511
p43085
sg33289
Vpheochromocytomas
p43086
sa(dp43087
g33284
I233
sg33285
I2
sg33286
I15
sg33287
VC0260037
p43088
sg33289
Vmultiple tumors
p43089
sa(dp43090
g33284
I114
sg33285
I2
sg33286
I17
sg33287
VC0442867
p43091
sg33289
Vmalignant disease
p43092
sa(dp43093
g33284
I214
sg33285
I1
sg33286
I14
sg33287
VC0030421
p43094
sg33289
Vparagangliomas
p43095
sasa(dp43096
g33277
VIn contrast, SDHD mutation carriers, in addition to head and neck paragangliomas, should be observed for multifocal tumors, infrequent malignancy, and the possibility of extraadrenal pheochromocytoma.
p43097
sg33279
(lp43098
(dp43099
g33284
I13
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VSDHD
p43100
sasg33281
(lp43101
(dp43102
g33284
I170
sg33285
I2
sg33286
I29
sg33287
VC1257877
p43103
sg33289
Vextraadrenal pheochromocytoma
p43104
sa(dp43105
g33284
I116
sg33285
I1
sg33286
I6
sg33287
VC0027651
p43106
sg33289
Vtumors
p43107
sa(dp43108
g33284
I135
sg33285
I1
sg33286
I10
sg33287
VC0006826
p43109
sg33289
Vmalignancy
p43110
sa(dp43111
g33284
I66
sg33285
I1
sg33286
I14
sg33287
VC0030421
p43112
sg33289
Vparagangliomas
p43113
sasa(dp43114
g33277
VHowever, in the presence of extra-adrenal pheochromocytoma, it may be more useful to screen for VHL, SDHD and SDHB mutations.
p43115
sg33279
(lp43116
(dp43117
g33284
I110
sg33285
I1
sg33286
I4
sg33295
VP21912
p43118
sg33289
VSDHB
p43119
sa(dp43120
g33284
I96
sg33285
I1
sg33286
I3
sg33295
VP40337
p43121
sg33289
VVHL
p43122
sa(dp43123
g33284
I101
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VSDHD
p43124
sasg33281
(lp43125
(dp43126
g33284
I28
sg33285
I2
sg33286
I30
sg33287
VC1257877
p43127
sg33289
Vextra-adrenal pheochromocytoma
p43128
sa(dp43129
g33284
I96
sg33285
I1
sg33286
I3
sg33287
VC0019562
p43130
sg33289
VVHL
p43131
sasa(dp43132
g33277
VHere we show, using two different techniques, FISH and quantitative PCR that SHFM3 is caused by a minimal 325 kb duplication containing only two genes (BTRC and POLL).
p43133
sg33279
(lp43134
(dp43135
g33284
I161
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VPOLL
p43136
sa(dp43137
g33284
I152
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VBTRC
p43138
sa(dp43139
g33284
I77
sg33285
I1
sg33286
I5
sg33295
VP57775
p43140
sg33289
VSHFM3
p43141
sasg33281
(lp43142
(dp43143
g33284
I77
sg33285
I1
sg33286
I5
sg33287
VC1838652
p43144
sg33289
VSHFM3
p43145
sa(dp43146
g33284
I113
sg33285
I1
sg33286
I11
sg33287
VC1705960
p43147
sg33289
Vduplication
p43148
sasa(dp43149
g33277
VThe smaller duplication in the second patient contained the LBX1, BTRC, POLL, and DPCD genes and a disrupted extra copy of the dactylin gene, and was nearly identical to the smallest known duplicated region of SHFM3.
p43150
sg33279
(lp43151
(dp43152
g33284
I82
sg33285
I2
sg33286
I10
sg33295
g11
sg33289
VDPCD genes
p43153
sa(dp43154
g33284
I127
sg33285
I2
sg33286
I13
sg33295
VP57775
p43155
sg33289
Vdactylin gene
p43156
sa(dp43157
g33284
I72
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VPOLL
p43158
sa(dp43159
g33284
I210
sg33285
I1
sg33286
I5
sg33295
VP57775
p43160
sg33289
VSHFM3
p43161
sa(dp43162
g33284
I60
sg33285
I1
sg33286
I4
sg33295
VP52954
p43163
sg33289
VLBX1
p43164
sa(dp43165
g33284
I66
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VBTRC
p43166
sasg33281
(lp43167
(dp43168
g33284
I210
sg33285
I1
sg33286
I5
sg33287
VC1838652
p43169
sg33289
VSHFM3
p43170
sa(dp43171
g33284
I12
sg33285
I1
sg33286
I11
sg33287
VC1705960
p43172
sg33289
Vduplication
p43173
sasa(dp43174
g33277
VIn the diagnostic work-up of alcoholic cardiomyopathy, the confirmation of alcohol abuse by carbohydrate deficient transferrin (CDT) and increased liver enzymes, and the involvement of the heart by markers of heart failure (e.g., NT-proBNP) and of necrosis (e.g., troponins or CKMb) is mandatory.
p43175
sg33279
(lp43176
(dp43177
g33284
I92
sg33285
I3
sg33286
I34
sg33295
g11
sg33289
Vcarbohydrate deficient transferrin
p43178
sa(dp43179
g33284
I128
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VCDT
p43180
sasg33281
(lp43181
(dp43182
g33284
I209
sg33285
I2
sg33286
I13
sg33287
VC0018802
p43183
sg33289
Vheart failure
p43184
sa(dp43185
g33284
I92
sg33285
I3
sg33286
I34
sg33287
VC1846385
p43186
sg33289
Vcarbohydrate deficient transferrin
p43187
sa(dp43188
g33284
I75
sg33285
I2
sg33286
I13
sg33287
VC0085762
p43189
sg33289
Valcohol abuse
p43190
sa(dp43191
g33284
I128
sg33285
I1
sg33286
I3
sg33287
VC1846385
p43192
sg33289
VCDT
p43193
sa(dp43194
g33284
I29
sg33285
I2
sg33286
I24
sg33287
VC0007192
p43195
sg33289
Valcoholic cardiomyopathy
p43196
sasa(dp43197
g33277
VEach 10 myg/m(3) increment in daily mean concentration at lag 2 day was associated with a 0.61% (95% CI: 0.19%, 1.03%) increase in overall respiratory mortality and a 0.67% (95% CI: 0.14%, 1.21%) increase in pneumonia mortality.
p43198
sg33279
(lp43199
sg33281
(lp43200
(dp43201
g33284
I208
sg33285
I1
sg33286
I9
sg33287
VC0032285
p43202
sg33289
Vpneumonia
p43203
sasa(dp43204
g33277
VThe values of the relative risks for hospitalization for pneumonia and asthma were significant for lag 0 (RR=1.051, 95%CI; 1.016 to 1.088); lag 2 (RR=1.066, 95%CI: 1.023 to 1.113); lag 3 (RR=1.053, 95%CI: 1.015 to 1.092); lag 4 (RR=1.043, 95%CI: 1.004 to 1.088) and lag 5 (RR=1.061, 95%CI: 1.018 to 1.106).
p43205
sg33279
(lp43206
(dp43207
g33284
I140
sg33285
I2
sg33286
I5
sg33295
VP16949
p43208
sg33289
Vlag 2
p43209
sa(dp43210
g33284
I266
sg33285
I2
sg33286
I5
sg33295
VP16949
p43211
sg33289
Vlag 5
p43212
sa(dp43213
g33284
I181
sg33285
I2
sg33286
I5
sg33295
VP16949
p43214
sg33289
Vlag 3
p43215
sa(dp43216
g33284
I99
sg33285
I2
sg33286
I5
sg33295
VP16949
p43217
sg33289
Vlag 0
p43218
sa(dp43219
g33284
I222
sg33285
I2
sg33286
I5
sg33295
VP16949
p43220
sg33289
Vlag 4
p43221
sasg33281
(lp43222
(dp43223
g33284
I57
sg33285
I1
sg33286
I9
sg33287
VC0032285
p43224
sg33289
Vpneumonia
p43225
sa(dp43226
g33284
I71
sg33285
I1
sg33286
I6
sg33287
VC0004096
p43227
sg33289
Vasthma
p43228
sasa(dp43229
g33277
VA 10 microg/m increase in bushfire PM10 was associated with a 1.24% (95% confidence interval = 0.22% to 2.27%) increase in all respiratory disease admissions (at lag 0), a 3.80% (1.40% to 6.26%) increase in chronic obstructive pulmonary disease admissions (at lag 2), and a 5.02% (1.77% to 8.37%) increase in adult asthma admissions (at lag 0).
p43230
sg33279
(lp43231
(dp43232
g33284
I260
sg33285
I2
sg33286
I5
sg33295
VP16949
p43233
sg33289
Vlag 2
p43234
sasg33281
(lp43235
(dp43236
g33284
I315
sg33285
I1
sg33286
I6
sg33287
VC0004096
p43237
sg33289
Vasthma
p43238
sa(dp43239
g33284
I127
sg33285
I2
sg33286
I19
sg33287
VC0035242
p43240
sg33289
Vrespiratory disease
p43241
sa(dp43242
g33284
I207
sg33285
I4
sg33286
I37
sg33287
VC0024117
p43243
sg33289
Vchronic obstructive pulmonary disease
p43244
sasa(dp43245
g33277
VWe confirmed that inhibition of TREM-1 attenuates the severity of colitis at clinically, endoscopically and histologically levels.
p43246
sg33279
(lp43247
(dp43248
g33284
I32
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VTREM-1
p43249
sasg33281
(lp43250
(dp43251
g33284
I66
sg33285
I1
sg33286
I7
sg33287
VC0009319
p43252
sg33289
Vcolitis
p43253
sasa(dp43254
g33277
VIndeed, TREM-1 receptor and its signaling pathways contribute to the pathology of several non-infectious acute and chronic inflammatory diseases, including atherosclerosis, ischemia reperfusion-induced tissue injury, colitis, fibrosis and cancer.
p43255
sg33279
(lp43256
(dp43257
g33284
I8
sg33285
I2
sg33286
I15
sg33295
g11
sg33289
VTREM-1 receptor
p43258
sasg33281
(lp43259
(dp43260
g33284
I217
sg33285
I1
sg33286
I7
sg33287
VC0009319
p43261
sg33289
Vcolitis
p43262
sa(dp43263
g33284
I173
sg33285
I1
sg33286
I8
sg33287
VC0022116
p43264
sg33289
Vischemia
p43265
sa(dp43266
g33284
I156
sg33285
I1
sg33286
I15
sg33287
VC0004153
p43267
sg33289
Vatherosclerosis
p43268
sa(dp43269
g33284
I239
sg33285
I1
sg33286
I6
sg33287
VC0006826
p43270
sg33289
Vcancer
p43271
sa(dp43272
g33284
I226
sg33285
I1
sg33286
I8
sg33287
VC0016059
p43273
sg33289
Vfibrosis
p43274
sa(dp43275
g33284
I69
sg33285
I1
sg33286
I9
sg33287
VC0677042
p43276
sg33289
Vpathology
p43277
sa(dp43278
g33284
I94
sg33285
I1
sg33286
I10
sg33287
VC0009450
p43279
sg33289
Vinfectious
p43280
sasa(dp43281
g33277
VIn CD4(+) T cell- and dextran sodium sulfate-induced models of colitis, Trem1(-/-) mice displayed significantly attenuated disease that was associated with reduced inflammatory infiltrates and diminished expression of pro-inflammatory cytokines.
p43282
sg33279
(lp43283
(dp43284
g33284
I3
sg33285
I1
sg33286
I3
sg33295
VP01730
p43285
sg33289
VCD4
p43286
sa(dp43287
g33284
I72
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTrem1
p43288
sasg33281
(lp43289
(dp43290
g33284
I63
sg33285
I1
sg33286
I7
sg33287
VC0009319
p43291
sg33289
Vcolitis
p43292
sa(dp43293
g33284
I177
sg33285
I1
sg33286
I11
sg33287
VC0332448
p43294
sg33289
Vinfiltrates
p43295
sasa(dp43296
g33277
VIn vivo, the treatment with the TREM-1 antagonist LP17 or control peptide was initiated at the beginning of or after induction of experimental colitis or colitis-associated tumorigenesis.
p43297
sg33279
(lp43298
(dp43299
g33284
I32
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VTREM-1
p43300
sasg33281
(lp43301
(dp43302
g33284
I143
sg33285
I1
sg33286
I7
sg33287
VC0009319
p43303
sg33289
Vcolitis
p43304
sa(dp43305
g33284
I143
sg33285
I1
sg33286
I7
sg33287
VC0009319
p43306
sg33289
Vcolitis
p43307
sa(dp43308
g33284
I173
sg33285
I1
sg33286
I13
sg33287
VC0007621
p43309
sg33289
Vtumorigenesis
p43310
sasa(dp43311
g33277
VIn ulcerative colitis, sTREM-1 level was correlated more strongly with the endoscopic activity (r=0.498) than the C-reactive protein level (r=0.386) or erythrocyte sedimentation rate (r=0.272), although not superior to the partial Mayo score (r=0.611).
p43312
sg33279
(lp43313
(dp43314
g33284
I114
sg33285
I2
sg33286
I18
sg33295
VP02741
p43315
sg33289
VC-reactive protein
p43316
sasg33281
(lp43317
(dp43318
g33284
I3
sg33285
I2
sg33286
I18
sg33287
VC0009324
p43319
sg33289
Vulcerative colitis
p43320
sasa(dp43321
g33277
VIn ulcerative colitis, sTREM-1 level was correlated most closely with the endoscopic disease activity among serum biomarkers, but was not superior to the clinical activity index.
p43322
sg33279
(lp43323
sg33281
(lp43324
(dp43325
g33284
I3
sg33285
I2
sg33286
I18
sg33287
VC0009324
p43326
sg33289
Vulcerative colitis
p43327
sasa(dp43328
g33277
VOur results suggest that sTREM-1 level may represent a complementary marker for the assessment of endoscopic activity in ulcerative colitis, but not in Crohn's disease.
p43329
sg33279
(lp43330
sg33281
(lp43331
(dp43332
g33284
I152
sg33285
I2
sg33286
I15
sg33287
VC0010346
p43333
sg33289
VCrohn's disease
p43334
sa(dp43335
g33284
I121
sg33285
I2
sg33286
I18
sg33287
VC0009324
p43336
sg33289
Vulcerative colitis
p43337
sasa(dp43338
g33277
VIntestinal biopsies and concurrently collected sera from patients with Crohn's disease (CD) and Ulcerative colitis (UC) enrolled in the Swiss IBD cohort study were analyzed for intestinal TREM-1 mRNA and serum sTREM-1 expression.
p43339
sg33279
(lp43340
(dp43341
g33284
I204
sg33285
I2
sg33286
I13
sg33295
g11
sg33289
Vserum sTREM-1
p43342
sa(dp43343
g33284
I188
sg33285
I2
sg33286
I11
sg33295
g11
sg33289
VTREM-1 mRNA
p43344
sasg33281
(lp43345
(dp43346
g33284
I96
sg33285
I2
sg33286
I18
sg33287
VC0009324
p43347
sg33289
VUlcerative colitis
p43348
sa(dp43349
g33284
I71
sg33285
I2
sg33286
I15
sg33287
VC0010346
p43350
sg33289
VCrohn's disease
p43351
sa(dp43352
g33284
I142
sg33285
I1
sg33286
I3
sg33287
VC0021390
p43353
sg33289
VIBD
p43354
sa(dp43355
g33284
I116
sg33285
I1
sg33286
I2
sg33287
VC0009324
p43356
sg33289
VUC
p43357
sa(dp43358
g33284
I88
sg33285
I1
sg33286
I2
sg33287
VC0010346
p43359
sg33289
VCD
p43360
sasa(dp43361
g33277
VSerum sTREM-1 and TREM-1 mRNA expression levels were further determined in sera and colonic tissues collected at various time-points post disease induction in an experimental mouse model of colitis and correlated with disease activity.
p43362
sg33279
(lp43363
(dp43364
g33284
I18
sg33285
I2
sg33286
I11
sg33295
g11
sg33289
VTREM-1 mRNA
p43365
sasg33281
(lp43366
(dp43367
g33284
I190
sg33285
I1
sg33286
I7
sg33287
VC0009319
p43368
sg33289
Vcolitis
p43369
sasa(dp43370
g33277
VThree TREM-1 single nucleotide polymorphisms (SNPs, rs2234237, rs3789205, and rs9471535) were genotyped by Taqman technology on 202 Crohn's disease (CD), 265 ulcerative colitis (UC), 138 with intestinal Behcet's disease (BD), and 234 healthy controls and the relationships between these SNPs and IBD development and phenotypes were evaluated.
p43371
sg33279
(lp43372
sg33281
(lp43373
(dp43374
g33284
I203
sg33285
I2
sg33286
I16
sg33287
VC0004943
p43375
sg33289
VBehcet's disease
p43376
sa(dp43377
g33284
I149
sg33285
I1
sg33286
I2
sg33287
VC0010346
p43378
sg33289
VCD
p43379
sa(dp43380
g33284
I221
sg33285
I1
sg33286
I2
sg33287
VC0004943
p43381
sg33289
VBD
p43382
sa(dp43383
g33284
I132
sg33285
I2
sg33286
I15
sg33287
VC0010346
p43384
sg33289
VCrohn's disease
p43385
sa(dp43386
g33284
I158
sg33285
I2
sg33286
I18
sg33287
VC0009324
p43387
sg33289
Vulcerative colitis
p43388
sa(dp43389
g33284
I178
sg33285
I1
sg33286
I2
sg33287
VC0009324
p43390
sg33289
VUC
p43391
sa(dp43392
g33284
I296
sg33285
I1
sg33286
I3
sg33287
VC0021390
p43393
sg33289
VIBD
p43394
sasa(dp43395
g33277
VHowever, TREM-1 SNPs were not significantly associated with the development of Crohn's disease or ulcerative colitis.
p43396
sg33279
(lp43397
(dp43398
g33284
I9
sg33285
I2
sg33286
I11
sg33295
g11
sg33289
VTREM-1 SNPs
p43399
sasg33281
(lp43400
(dp43401
g33284
I79
sg33285
I2
sg33286
I15
sg33287
VC0010346
p43402
sg33289
VCrohn's disease
p43403
sa(dp43404
g33284
I98
sg33285
I2
sg33286
I18
sg33287
VC0009324
p43405
sg33289
Vulcerative colitis
p43406
sasa(dp43407
g33277
VStable expression of miR-124 in diffuse large B cell lymphoma (DLBCL) cell lines diminished PDE4B expression.
p43408
sg33279
(lp43409
(dp43410
g33284
I92
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VPDE4B
p43411
sa(dp43412
g33284
I21
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VmiR-124
p43413
sasg33281
(lp43414
(dp43415
g33284
I63
sg33285
I1
sg33286
I5
sg33287
VC0079744
p43416
sg33289
VDLBCL
p43417
sa(dp43418
g33284
I32
sg33285
I5
sg33286
I29
sg33287
VC0079744
p43419
sg33289
Vdiffuse large B cell lymphoma
p43420
sasa(dp43421
g33277
VStarting from the GSEA, we found that overexpression of the PDE4B in diffuse large B-cell lymphoma (DLBCL) impinge on the same genes/pathways that are abnormally active in GC-resistant tumors.
p43422
sg33279
(lp43423
(dp43424
g33284
I60
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VPDE4B
p43425
sasg33281
(lp43426
(dp43427
g33284
I69
sg33285
I4
sg33286
I29
sg33287
VC0079744
p43428
sg33289
Vdiffuse large B-cell lymphoma
p43429
sa(dp43430
g33284
I185
sg33285
I1
sg33286
I6
sg33287
VC0027651
p43431
sg33289
Vtumors
p43432
sa(dp43433
g33284
I100
sg33285
I1
sg33286
I5
sg33287
VC0079744
p43434
sg33289
VDLBCL
p43435
sasa(dp43436
g33277
VOn the basis of biopsies of the masses in the pharynx and finger, he was diagnosed with extramedullary plasmablastic plasmacytoma, with somewhat immature CD45(+), MPC-1(-), and CD49e(-).
p43437
sg33279
(lp43438
(dp43439
g33284
I177
sg33285
I1
sg33286
I5
sg33295
VP08648
p43440
sg33289
VCD49e
p43441
sa(dp43442
g33284
I154
sg33285
I1
sg33286
I7
sg33295
VP08575
p43443
sg33289
VCD45(+)
p43444
sa(dp43445
g33284
I163
sg33285
I1
sg33286
I5
sg33295
VP28062
p43446
sg33289
VMPC-1
p43447
sasg33281
(lp43448
(dp43449
g33284
I117
sg33285
I1
sg33286
I12
sg33287
VC0032131
p43450
sg33289
Vplasmacytoma
p43451
sasa(dp43452
g33277
VChanges to CD45 negativity and MPC-1 partial positivity were seen, while CD49e negativity persisted, suggesting that the plasmablastic plasmacytoma had reverted to a more immature state.
p43453
sg33279
(lp43454
(dp43455
g33284
I31
sg33285
I1
sg33286
I5
sg33295
VP28062
p43456
sg33289
VMPC-1
p43457
sa(dp43458
g33284
I73
sg33285
I1
sg33286
I5
sg33295
VP08648
p43459
sg33289
VCD49e
p43460
sa(dp43461
g33284
I11
sg33285
I2
sg33286
I15
sg33295
VP08575
p43462
sg33289
VCD45 negativity
p43463
sasg33281
(lp43464
(dp43465
g33284
I135
sg33285
I1
sg33286
I12
sg33287
VC0032131
p43466
sg33289
Vplasmacytoma
p43467
sasa(dp43468
g33277
VHe had the following poor prognostic factors: 1) multiple extramedullary plasmacytomas, 2) massive myelomatous effusion, 3) increasing immature myeloma cells with plasmablastic morphology, and 4) predominance of MPC1-CD49e-CD45+ phenotype immature myeloma cells.
p43469
sg33279
(lp43470
(dp43471
g33284
I212
sg33285
I1
sg33286
I4
sg33295
VP28062
p43472
sg33289
VMPC1
p43473
sa(dp43474
g33284
I223
sg33285
I1
sg33286
I5
sg33295
VP08575
p43475
sg33289
VCD45+
p43476
sa(dp43477
g33284
I217
sg33285
I1
sg33286
I5
sg33295
VP08648
p43478
sg33289
VCD49e
p43479
sasg33281
(lp43480
(dp43481
g33284
I99
sg33285
I1
sg33286
I7
sg33287
VC0026764
p43482
sg33289
Vmyeloma
p43483
sa(dp43484
g33284
I111
sg33285
I1
sg33286
I8
sg33287
VC0013687
p43485
sg33289
Veffusion
p43486
sa(dp43487
g33284
I99
sg33285
I1
sg33286
I7
sg33287
VC0026764
p43488
sg33289
Vmyeloma
p43489
sa(dp43490
g33284
I73
sg33285
I1
sg33286
I13
sg33287
VC0032131
p43491
sg33289
Vplasmacytomas
p43492
sasa(dp43493
g33277
VInterestingly, the proportions of MPC-1(-) and MPC-1(-)CD45(+) immature monoclonal plasma cells also increased in the 7 progressive cases of MGUS.
p43494
sg33279
(lp43495
(dp43496
g33284
I47
sg33285
I1
sg33286
I15
sg33295
VP28062
p43497
sg33289
VMPC-1(-)CD45(+)
p43498
sa(dp43499
g33284
I34
sg33285
I1
sg33286
I5
sg33295
VP28062
p43500
sg33289
VMPC-1
p43501
sasg33281
(lp43502
(dp43503
g33284
I141
sg33285
I1
sg33286
I4
sg33287
VC0026470
p43504
sg33289
VMGUS
p43505
sasa(dp43506
g33277
VThe main hereditary LMNSs in adulthood are Kennedy's disease, late-onset spinal muscular atrophy and distal hereditary motor neuropathies.
p43507
sg33279
(lp43508
sg33281
(lp43509
(dp43510
g33284
I125
sg33285
I1
sg33286
I12
sg33287
VC0442874
p43511
sg33289
Vneuropathies
p43512
sa(dp43513
g33284
I73
sg33285
I3
sg33286
I23
sg33287
VC0026847
p43514
sg33289
Vspinal muscular atrophy
p43515
sa(dp43516
g33284
I43
sg33285
I2
sg33286
I17
sg33287
VC1839259
p43517
sg33289
VKennedy's disease
p43518
sasa(dp43519
g33277
VIn contrast, spinal muscular atrophy (SMA) involves the specific degeneration of LMNs, with symmetrical muscle weakness and atrophy.
p43520
sg33279
(lp43521
sg33281
(lp43522
(dp43523
g33284
I38
sg33285
I1
sg33286
I3
sg33287
VC0026847
p43524
sg33289
VSMA
p43525
sa(dp43526
g33284
I65
sg33285
I1
sg33286
I12
sg33287
VC0011164
p43527
sg33289
Vdegeneration
p43528
sa(dp43529
g33284
I13
sg33285
I3
sg33286
I23
sg33287
VC0026847
p43530
sg33289
Vspinal muscular atrophy
p43531
sa(dp43532
g33284
I104
sg33285
I2
sg33286
I15
sg33287
VC0030552
p43533
sg33289
Vmuscle weakness
p43534
sa(dp43535
g33284
I29
sg33285
I1
sg33286
I7
sg33287
VC0333641
p43536
sg33289
Vatrophy
p43537
sasa(dp43538
g33277
VTargeting lower motor neurons (LMNs) for gene delivery could be useful for disorders such as spinal muscular atrophy and amyotrophic lateral sclerosis.
p43539
sg33279
(lp43540
sg33281
(lp43541
(dp43542
g33284
I93
sg33285
I3
sg33286
I23
sg33287
VC0026847
p43543
sg33289
Vspinal muscular atrophy
p43544
sa(dp43545
g33284
I121
sg33285
I3
sg33286
I29
sg33287
VC0002736
p43546
sg33289
Vamyotrophic lateral sclerosis
p43547
sasa(dp43548
g33277
VOur previous study showed that reduction of KCa3.1 channel expression by lyso-globotriaosylceramide (lyso-Gb3) inhibits differentiation into myofibroblasts and collagen synthesis, which might lead to development of ascending thoracic aortic aneurysm secondary to Fabry disease.
p43549
sg33279
(lp43550
sg33281
(lp43551
(dp43552
g33284
I225
sg33285
I3
sg33286
I24
sg33287
VC0162872
p43553
sg33289
Vthoracic aortic aneurysm
p43554
sa(dp43555
g33284
I263
sg33285
I2
sg33286
I13
sg33287
VC0002986
p43556
sg33289
VFabry disease
p43557
sasa(dp43558
g33277
VMoreover, lyso-Gb3 suppressed expression of class II phosphatidylinositol 3-kinase C2Beta (PI3KC2Beta) by PKA activation, which reduces the production of phosphatidylinositol 3-phosphate [PI(3)P], and the reduced membrane surface expression of KCa3.1 channel was recovered by increasing the intracellular levels of PI(3)P. Consequently, our findings that lyso-Gb3 inhibited both KCa3.1 channel synthesis and surface expression by increasing intracellular cAMP, and controlled surface expression through changes in PI3KC2Beta-mediated PI(3)P production, suggest that modulation of PKA and PI3KC2Beta activity to control of KCa3.1 channel expression can be an alternative important target to attenuate ascending thoracic aortic aneurysms in Fabry disease.
p43559
sg33279
(lp43560
(dp43561
g33284
I244
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VKCa3.1
p43562
sa(dp43563
g33284
I44
sg33285
I5
sg33286
I45
sg33295
g11
sg33289
Vclass II phosphatidylinositol 3-kinase C2Beta
p43564
sa(dp43565
g33284
I244
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VKCa3.1
p43566
sa(dp43567
g33284
I244
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VKCa3.1
p43568
sa(dp43569
g33284
I106
sg33285
I1
sg33286
I3
sg33295
VP17612
p43570
sg33289
VPKA
p43571
sa(dp43572
g33284
I154
sg33285
I3
sg33286
I41
sg33295
VP48426
p43573
sg33289
Vphosphatidylinositol 3-phosphate [PI(3)P]
p43574
sa(dp43575
g33284
I106
sg33285
I1
sg33286
I3
sg33295
VP17612
p43576
sg33289
VPKA
p43577
sasg33281
(lp43578
(dp43579
g33284
I739
sg33285
I2
sg33286
I13
sg33287
VC0002986
p43580
sg33289
VFabry disease
p43581
sa(dp43582
g33284
I710
sg33285
I3
sg33286
I25
sg33287
VC0162872
p43583
sg33289
Vthoracic aortic aneurysms
p43584
sasa(dp43585
g33277
VThese findings suggest that the KCa3.1 channel can serve as a new target to attenuate and prevent development of ascending thoracic aortic aneurysm in Fabry disease.
p43586
sg33279
(lp43587
(dp43588
g33284
I32
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VKCa3.1 channel
p43589
sasg33281
(lp43590
(dp43591
g33284
I151
sg33285
I2
sg33286
I13
sg33287
VC0002986
p43592
sg33289
VFabry disease
p43593
sa(dp43594
g33284
I123
sg33285
I3
sg33286
I24
sg33287
VC0162872
p43595
sg33289
Vthoracic aortic aneurysm
p43596
sasa(dp43597
g33277
VWe sequenced BCAs in patients with autism or related NDDs, revealing disruption of 33 loci in four general categories: (1) genes previously associated with abnormal neurodevelopment (e.g., AUTS2, FOXP1, and CDKL5), (2) single-gene contributors to microdeletion syndromes (MBD5, SATB2, EHMT1, and SNURF-SNRPN), (3) novel risk loci (e.g., CHD8, KIRREL3, and ZNF507), and (4) genes associated with later-onset psychiatric disorders (e.g., TCF4, ZNF804A, PDE10A, GRIN2B, and ANK3).
p43598
sg33279
(lp43599
(dp43600
g33284
I436
sg33285
I1
sg33286
I4
sg33295
VP15884
p43601
sg33289
VTCF4
p43602
sa(dp43603
g33284
I459
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VGRIN2B
p43604
sa(dp43605
g33284
I189
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VAUTS2
p43606
sa(dp43607
g33284
I296
sg33285
I1
sg33286
I11
sg33295
VP63162
p43608
sg33289
VSNURF-SNRPN
p43609
sa(dp43610
g33284
I196
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VFOXP1
p43611
sa(dp43612
g33284
I471
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VANK3
p43613
sa(dp43614
g33284
I278
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSATB2
p43615
sa(dp43616
g33284
I356
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VZNF507
p43617
sa(dp43618
g33284
I207
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCDKL5
p43619
sa(dp43620
g33284
I285
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VEHMT1
p43621
sa(dp43622
g33284
I272
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VMBD5
p43623
sa(dp43624
g33284
I343
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VKIRREL3
p43625
sa(dp43626
g33284
I442
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VZNF804A
p43627
sa(dp43628
g33284
I451
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VPDE10A
p43629
sasg33281
(lp43630
(dp43631
g33284
I35
sg33285
I1
sg33286
I6
sg33287
VC0004352
p43632
sg33289
Vautism
p43633
sa(dp43634
g33284
I407
sg33285
I2
sg33286
I21
sg33287
VC0004936
p43635
sg33289
Vpsychiatric disorders
p43636
sa(dp43637
g33284
I261
sg33285
I1
sg33286
I9
sg33287
VC0039082
p43638
sg33289
Vsyndromes
p43639
sasa(dp43640
g33277
VTheir protein products listed below immediately suggest cell signalling pathways/processes worthy of further investigation in elucidating the mechanism of CpG 5mer activity: caspase 2, the transcription factors Atf4, Hic, HoxB3 and Rqcd1, the splicing factors Rbmx, Sfrs5 and Sfrs7, the DNA replication factors Mcm5 and Brd4, phosphoinositide-3-kinase, annexin A1, mucosa-associated lymphoid tissue lymphoma translocation 1 and three enzymes involved in protein ubiquitylation, Siah1, Gsa7 and Nin283.
p43641
sg33279
(lp43642
(dp43643
g33284
I266
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSfrs5
p43644
sa(dp43645
g33284
I211
sg33285
I1
sg33286
I4
sg33295
VP18848
p43646
sg33289
VAtf4
p43647
sa(dp43648
g33284
I276
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSfrs7
p43649
sa(dp43650
g33284
I232
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VRqcd1
p43651
sa(dp43652
g33284
I485
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VGsa7
p43653
sa(dp43654
g33284
I217
sg33285
I1
sg33286
I3
sg33295
VP18136
p43655
sg33289
VHic
p43656
sa(dp43657
g33284
I311
sg33285
I1
sg33286
I4
sg33295
VP33992
p43658
sg33289
VMcm5
p43659
sa(dp43660
g33284
I222
sg33285
I1
sg33286
I5
sg33295
VP14651
p43661
sg33289
VHoxB3
p43662
sa(dp43663
g33284
I320
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VBrd4
p43664
sa(dp43665
g33284
I494
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VNin283
p43666
sa(dp43667
g33284
I353
sg33285
I2
sg33286
I10
sg33295
VP04083
p43668
sg33289
Vannexin A1
p43669
sa(dp43670
g33284
I260
sg33285
I1
sg33286
I4
sg33295
VP38159
p43671
sg33289
VRbmx
p43672
sa(dp43673
g33284
I478
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSiah1
p43674
sa(dp43675
g33284
I174
sg33285
I2
sg33286
I9
sg33295
VP42575
p43676
sg33289
Vcaspase 2
p43677
sa(dp43678
g33284
I326
sg33285
I1
sg33286
I25
sg33295
VP33981
p43679
sg33289
Vphosphoinositide-3-kinase
p43680
sasg33281
(lp43681
(dp43682
g33284
I365
sg33285
I4
sg33286
I42
sg33287
VC0242647
p43683
sg33289
Vmucosa-associated lymphoid tissue lymphoma
p43684
sa(dp43685
g33284
I408
sg33285
I1
sg33286
I13
sg33287
VC0040715
p43686
sg33289
Vtranslocation
p43687
sasa(dp43688
g33277
VMultiple cylindromas can have a syndromic association as seen in Brooke-Spiegler syndrome and familial cylindromatosis.
p43689
sg33279
(lp43690
sg33281
(lp43691
(dp43692
g33284
I9
sg33285
I1
sg33286
I11
sg33287
VC0010606
p43693
sg33289
Vcylindromas
p43694
sa(dp43695
g33284
I94
sg33285
I2
sg33286
I24
sg33287
VC1851526
p43696
sg33289
Vfamilial cylindromatosis
p43697
sa(dp43698
g33284
I65
sg33285
I2
sg33286
I24
sg33287
VC1857941
p43699
sg33289
VBrooke-Spiegler syndrome
p43700
sasa(dp43701
g33277
VA predisposition to multiple cylindromas is seen in patients with Brooke-Spiegler syndrome, who carry germline mutations in the tumour suppressor gene CYLD.
p43702
sg33279
(lp43703
(dp43704
g33284
I146
sg33285
I2
sg33286
I9
sg33295
g11
sg33289
Vgene CYLD
p43705
sasg33281
(lp43706
(dp43707
g33284
I29
sg33285
I1
sg33286
I11
sg33287
VC0010606
p43708
sg33289
Vcylindromas
p43709
sa(dp43710
g33284
I66
sg33285
I2
sg33286
I24
sg33287
VC1857941
p43711
sg33289
VBrooke-Spiegler syndrome
p43712
sa(dp43713
g33284
I128
sg33285
I1
sg33286
I6
sg33287
VC0027651
p43714
sg33289
Vtumour
p43715
sasa(dp43716
g33277
VPrevious studies of inherited cylindromas have highlighted the frequent presence of bi-allelic truncating CYLD mutations as a recurrent driver mutation.
p43717
sg33279
(lp43718
(dp43719
g33284
I106
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VCYLD mutations
p43720
sasg33281
(lp43721
(dp43722
g33284
I30
sg33285
I1
sg33286
I11
sg33287
VC0010606
p43723
sg33289
Vcylindromas
p43724
sasa(dp43725
g33277
VHere, we investigated inherited cylindromas from several families with germline CYLD mutations for the presence of MYB activation.
p43726
sg33279
(lp43727
(dp43728
g33284
I115
sg33285
I1
sg33286
I3
sg33295
VP10243
p43729
sg33289
VMYB
p43730
sa(dp43731
g33284
I80
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCYLD
p43732
sasg33281
(lp43733
(dp43734
g33284
I32
sg33285
I1
sg33286
I11
sg33287
VC0010606
p43735
sg33289
Vcylindromas
p43736
sasa(dp43737
g33277
VCylindroma is a rare skin tumour that is inherited in several skin-tumour syndromes caused by germline mutations in the tumour suppressor gene, CYLD.
p43738
sg33279
(lp43739
(dp43740
g33284
I144
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCYLD
p43741
sasg33281
(lp43742
(dp43743
g33284
I0
sg33285
I1
sg33286
I10
sg33287
VC0010606
p43744
sg33289
VCylindroma
p43745
sa(dp43746
g33284
I26
sg33285
I1
sg33286
I6
sg33287
VC0027651
p43747
sg33289
Vtumour
p43748
sa(dp43749
g33284
I26
sg33285
I1
sg33286
I6
sg33287
VC0027651
p43750
sg33289
Vtumour
p43751
sa(dp43752
g33284
I74
sg33285
I1
sg33286
I9
sg33287
VC0039082
p43753
sg33289
Vsyndromes
p43754
sa(dp43755
g33284
I21
sg33285
I2
sg33286
I11
sg33287
VC0037286
p43756
sg33289
Vskin tumour
p43757
sasa(dp43758
g33277
VThe aims of this study were to perform a whole-exome sequencing analysis of a breast cylindroma and to investigate the role of molecular analyses in the differentiation between breast cylindroma, a benign tumour that displays MYB expression, and CYLD gene mutations, and its main differential diagnosis, the breast solid-basaloid adenoid cystic carcinoma, a malignant tumour that is characterized by the presence of the MYB-NFIB fusion gene and MYB overexpression.
p43759
sg33279
(lp43760
(dp43761
g33284
I424
sg33285
I3
sg33286
I16
sg33295
g11
sg33289
VNFIB fusion gene
p43762
sa(dp43763
g33284
I226
sg33285
I1
sg33286
I3
sg33295
VP10243
p43764
sg33289
VMYB
p43765
sa(dp43766
g33284
I226
sg33285
I1
sg33286
I3
sg33295
VP10243
p43767
sg33289
VMYB
p43768
sa(dp43769
g33284
I246
sg33285
I2
sg33286
I9
sg33295
g11
sg33289
VCYLD gene
p43770
sa(dp43771
g33284
I226
sg33285
I1
sg33286
I3
sg33295
VP10243
p43772
sg33289
VMYB
p43773
sasg33281
(lp43774
(dp43775
g33284
I330
sg33285
I3
sg33286
I24
sg33287
VC0010606
p43776
sg33289
Vadenoid cystic carcinoma
p43777
sa(dp43778
g33284
I358
sg33285
I2
sg33286
I16
sg33287
VC0006826
p43779
sg33289
Vmalignant tumour
p43780
sa(dp43781
g33284
I85
sg33285
I1
sg33286
I10
sg33287
VC0010606
p43782
sg33289
Vcylindroma
p43783
sa(dp43784
g33284
I198
sg33285
I2
sg33286
I13
sg33287
VC0086692
p43785
sg33289
Vbenign tumour
p43786
sa(dp43787
g33284
I85
sg33285
I1
sg33286
I10
sg33287
VC0010606
p43788
sg33289
Vcylindroma
p43789
sasa(dp43790
g33277
VThe clinical presentation of multiple, rare, skin appendage tumours called cylindromas has been attributed to germline mutations in the tumour suppressor gene CYLD (OMIM 605018).
p43791
sg33279
(lp43792
(dp43793
g33284
I159
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCYLD
p43794
sasg33281
(lp43795
(dp43796
g33284
I75
sg33285
I1
sg33286
I11
sg33287
VC0010606
p43797
sg33289
Vcylindromas
p43798
sa(dp43799
g33284
I60
sg33285
I1
sg33286
I6
sg33287
VC0027651
p43800
sg33289
Vtumour
p43801
sa(dp43802
g33284
I60
sg33285
I1
sg33286
I7
sg33287
VC0027651
p43803
sg33289
Vtumours
p43804
sasa(dp43805
g33277
VBrooke-Spiegler Syndrome (BSS), familial cylindromatosis (FC) and multiple familial trichoepitheliomas (MFT) (OMIM #605041, #132700, #601606 respectively) differ due to the types of other skin appendage tumour seen together with cylindroma, such as spiradenoma and trichoepithelioma.
p43806
sg33279
(lp43807
sg33281
(lp43808
(dp43809
g33284
I84
sg33285
I1
sg33286
I17
sg33287
VC0349658
p43810
sg33289
Vtrichoepithelioma
p43811
sa(dp43812
g33284
I84
sg33285
I1
sg33286
I18
sg33287
VC0349658
p43813
sg33289
Vtrichoepitheliomas
p43814
sa(dp43815
g33284
I41
sg33285
I1
sg33286
I10
sg33287
VC0010606
p43816
sg33289
Vcylindroma
p43817
sa(dp43818
g33284
I188
sg33285
I3
sg33286
I21
sg33287
VC0345988
p43819
sg33289
Vskin appendage tumour
p43820
sa(dp43821
g33284
I32
sg33285
I2
sg33286
I24
sg33287
VC1851526
p43822
sg33289
Vfamilial cylindromatosis
p43823
sa(dp43824
g33284
I58
sg33285
I1
sg33286
I2
sg33287
VC1851526
p43825
sg33289
VFC
p43826
sa(dp43827
g33284
I249
sg33285
I1
sg33286
I11
sg33287
VC0334347
p43828
sg33289
Vspiradenoma
p43829
sa(dp43830
g33284
I0
sg33285
I2
sg33286
I24
sg33287
VC1857941
p43831
sg33289
VBrooke-Spiegler Syndrome
p43832
sa(dp43833
g33284
I26
sg33285
I1
sg33286
I3
sg33287
VC1857941
p43834
sg33289
VBSS
p43835
sasa(dp43836
g33277
VUnique tumors included a cutaneous cylindroma invasive of skull convexity occurring in familial cylindromatosis and a ganglioneuroma of the middle ear with massive bilateral skull base extension.
p43837
sg33279
(lp43838
sg33281
(lp43839
(dp43840
g33284
I118
sg33285
I1
sg33286
I14
sg33287
VC0017075
p43841
sg33289
Vganglioneuroma
p43842
sa(dp43843
g33284
I87
sg33285
I2
sg33286
I24
sg33287
VC1851526
p43844
sg33289
Vfamilial cylindromatosis
p43845
sa(dp43846
g33284
I35
sg33285
I1
sg33286
I10
sg33287
VC0010606
p43847
sg33289
Vcylindroma
p43848
sa(dp43849
g33284
I7
sg33285
I1
sg33286
I6
sg33287
VC0027651
p43850
sg33289
Vtumors
p43851
sasa(dp43852
g33277
VThis review will examine and extrapolate from the recent literature to build support for the use of AXT in mitigating neuropathy in normal aging and neurodegenerative disease.
p43853
sg33279
(lp43854
(dp43855
g33284
I100
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VAXT
p43856
sasg33281
(lp43857
(dp43858
g33284
I149
sg33285
I2
sg33286
I25
sg33287
VC0524851
p43859
sg33289
Vneurodegenerative disease
p43860
sa(dp43861
g33284
I118
sg33285
I1
sg33286
I10
sg33287
VC0442874
p43862
sg33289
Vneuropathy
p43863
sasa(dp43864
g33277
VWe investigated frequencies of single nucleotide polymorphisms (SNPs) in the candidate genes protein tyrosine phosphatase, non-receptor type 22 (PTPN22), B-cell scaffold protein with ankyrin repeats (BANK1), B lymphocyte kinase (Blk), and Fc gamma receptor class IIB (FCGR2B), which have been found to be associated with other autoimmune diseases, CD1A and CD1E, important for antigen presentation of glycolipids, and transient axonal glycoprotein 1 (TAG-1), which is associated with responsiveness to intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy.
p43865
sg33279
(lp43866
(dp43867
g33284
I348
sg33285
I1
sg33286
I4
sg33295
VP15813
p43868
sg33289
VCD1A
p43869
sa(dp43870
g33284
I200
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VBANK1
p43871
sa(dp43872
g33284
I514
sg33285
I1
sg33286
I14
sg33295
g11
sg33289
Vimmunoglobulin
p43873
sa(dp43874
g33284
I208
sg33285
I3
sg33286
I19
sg33295
VP51451
p43875
sg33289
VB lymphocyte kinase
p43876
sa(dp43877
g33284
I87
sg33285
I4
sg33286
I34
sg33295
VP60484
p43878
sg33289
Vgenes protein tyrosine phosphatase
p43879
sa(dp43880
g33284
I418
sg33285
I4
sg33286
I31
sg33295
g11
sg33289
Vtransient axonal glycoprotein 1
p43881
sa(dp43882
g33284
I268
sg33285
I1
sg33286
I6
sg33295
VP31995
p43883
sg33289
VFCGR2B
p43884
sa(dp43885
g33284
I239
sg33285
I5
sg33286
I27
sg33295
VP12314
p43886
sg33289
VFc gamma receptor class IIB
p43887
sa(dp43888
g33284
I145
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VPTPN22
p43889
sa(dp43890
g33284
I183
sg33285
I1
sg33286
I7
sg33295
VP16157
p43891
sg33289
Vankyrin
p43892
sa(dp43893
g33284
I451
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTAG-1
p43894
sa(dp43895
g33284
I229
sg33285
I1
sg33286
I3
sg33295
VP51451
p43896
sg33289
VBlk
p43897
sa(dp43898
g33284
I123
sg33285
I3
sg33286
I20
sg33295
g11
sg33289
Vnon-receptor type 22
p43899
sasg33281
(lp43900
(dp43901
g33284
I546
sg33285
I4
sg33286
I49
sg33287
VC0393819
p43902
sg33289
Vchronic inflammatory demyelinating polyneuropathy
p43903
sa(dp43904
g33284
I451
sg33285
I1
sg33286
I3
sg33287
VC0037293
p43905
sg33289
VTAG
p43906
sa(dp43907
g33284
I327
sg33285
I2
sg33286
I19
sg33287
VC0004364
p43908
sg33289
Vautoimmune diseases
p43909
sasa(dp43910
g33277
VTo investigate the clinical features of A-pattern exotropia and to evaluate the efficacy of surgical treatment for the correction of A-pattern exotropia (A-XT).
p43911
sg33279
(lp43912
sg33281
(lp43913
(dp43914
g33284
I50
sg33285
I1
sg33286
I9
sg33287
VC0015310
p43915
sg33289
Vexotropia
p43916
sa(dp43917
g33284
I50
sg33285
I1
sg33286
I9
sg33287
VC0015310
p43918
sg33289
Vexotropia
p43919
sasa(dp43920
g33277
VWe identified 10 patients from three CA and from two GMS families with WDR73 mutations including the original family described with CA, mental retardation, optic atrophy, and skin abnormalities (CAMOS).
p43921
sg33279
(lp43922
(dp43923
g33284
I71
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VWDR73
p43924
sasg33281
(lp43925
(dp43926
g33284
I136
sg33285
I2
sg33286
I18
sg33287
VC0025362
p43927
sg33289
Vmental retardation
p43928
sa(dp43929
g33284
I156
sg33285
I2
sg33286
I13
sg33287
VC0029124
p43930
sg33289
Voptic atrophy
p43931
sa(dp43932
g33284
I175
sg33285
I2
sg33286
I18
sg33287
VC0037268
p43933
sg33289
Vskin abnormalities
p43934
sa(dp43935
g33284
I195
sg33285
I1
sg33286
I5
sg33287
VC1847114
p43936
sg33289
VCAMOS
p43937
sasa(dp43938
g33277
VCAMOS (Cerebellar Ataxia with Mental retardation, Optic atrophy and Skin abnormalities) is a rare autosomal recessive syndrome characterized by a nonprogressive congenital cerebellar ataxia associated with mental retardation, optic atrophy, and skin abnormalities.
p43939
sg33279
(lp43940
sg33281
(lp43941
(dp43942
g33284
I161
sg33285
I3
sg33286
I28
sg33287
VC0852975
p43943
sg33289
Vcongenital cerebellar ataxia
p43944
sa(dp43945
g33284
I206
sg33285
I2
sg33286
I18
sg33287
VC0025362
p43946
sg33289
Vmental retardation
p43947
sa(dp43948
g33284
I118
sg33285
I1
sg33286
I8
sg33287
VC0039082
p43949
sg33289
Vsyndrome
p43950
sa(dp43951
g33284
I0
sg33285
I1
sg33286
I5
sg33287
VC1847114
p43952
sg33289
VCAMOS
p43953
sa(dp43954
g33284
I30
sg33285
I2
sg33286
I18
sg33287
VC0025362
p43955
sg33289
VMental retardation
p43956
sa(dp43957
g33284
I226
sg33285
I2
sg33286
I13
sg33287
VC0029124
p43958
sg33289
Voptic atrophy
p43959
sa(dp43960
g33284
I7
sg33285
I2
sg33286
I17
sg33287
VC0007758
p43961
sg33289
VCerebellar Ataxia
p43962
sa(dp43963
g33284
I68
sg33285
I2
sg33286
I18
sg33287
VC0037268
p43964
sg33289
VSkin abnormalities
p43965
sa(dp43966
g33284
I50
sg33285
I2
sg33286
I13
sg33287
VC0029124
p43967
sg33289
VOptic atrophy
p43968
sa(dp43969
g33284
I245
sg33285
I2
sg33286
I18
sg33287
VC0037268
p43970
sg33289
Vskin abnormalities
p43971
sasa(dp43972
g33277
VEyes with laser-treated threshold ROP had significant myopia at both ages (mean spherical equivalent [MSE] in right eye at both refractions -0.72, -1.21 diopters [D]), astigmatism (MSE -1.62, -1.80 D), and anisometropia (MSE 0.82, 1.02 D; ANOVA p &lt; 0.05), and increased refractive errors across ages (paired t test p &lt; 0.05).
p43973
sg33279
(lp43974
sg33281
(lp43975
(dp43976
g33284
I54
sg33285
I1
sg33286
I6
sg33287
VC0027092
p43977
sg33289
Vmyopia
p43978
sa(dp43979
g33284
I206
sg33285
I1
sg33286
I13
sg33287
VC0003081
p43980
sg33289
Vanisometropia
p43981
sa(dp43982
g33284
I168
sg33285
I1
sg33286
I11
sg33287
VC0004106
p43983
sg33289
Vastigmatism
p43984
sa(dp43985
g33284
I273
sg33285
I2
sg33286
I17
sg33287
VC0034951
p43986
sg33289
Vrefractive errors
p43987
sa(dp43988
g33284
I34
sg33285
I1
sg33286
I3
sg33287
VC0035344
p43989
sg33289
VROP
p43990
sasa(dp43991
g33277
VMonocular deprivation does affect the binding parameters (KD and Bmax) of GluRs, which may be a molecular mechanism of the development of amblyopia.
p43992
sg33279
(lp43993
sg33281
(lp43994
sa(dp43995
g33277
VExpressions of GluRs and CaBPs (i.e., parvalbumin and calbindin D-28k) were observed to be increased in the retinal ganglion cell layer (GCL) and inner nuclear layer (INL) at 3 days and 1 week after the onset of glaucoma.
p43996
sg33279
(lp43997
(dp43998
g33284
I38
sg33285
I1
sg33286
I11
sg33295
VP20472
p43999
sg33289
Vparvalbumin
p44000
sa(dp44001
g33284
I54
sg33285
I2
sg33286
I15
sg33295
VP05937
p44002
sg33289
Vcalbindin D-28k
p44003
sasg33281
(lp44004
(dp44005
g33284
I116
sg33285
I3
sg33286
I19
sg33287
VC0023521
p44006
sg33289
Vganglion cell layer
p44007
sa(dp44008
g33284
I212
sg33285
I1
sg33286
I8
sg33287
VC0017601
p44009
sg33289
Vglaucoma
p44010
sa(dp44011
g33284
I137
sg33285
I1
sg33286
I3
sg33287
VC0023521
p44012
sg33289
VGCL
p44013
sasa(dp44014
g33277
VThe finding that both NMDA and non-NMDA GluRs were involved in glutamate-induced excitotoxicity suggests that isolated pig RGCs provide a good model for glaucoma.
p44015
sg33279
(lp44016
sg33281
(lp44017
(dp44018
g33284
I153
sg33285
I1
sg33286
I8
sg33287
VC0017601
p44019
sg33289
Vglaucoma
p44020
sasa(dp44021
g33277
VUSP45 associates with ERCC1, a subunit of the DNA repair endonuclease XPF-ERCC1, via a short acidic motif outside of the USP45 catalytic domain.
p44022
sg33279
(lp44023
(dp44024
g33284
I22
sg33285
I1
sg33286
I5
sg33295
VP07992
p44025
sg33289
VERCC1
p44026
sa(dp44027
g33284
I46
sg33285
I4
sg33286
I27
sg33295
g11
sg33289
VDNA repair endonuclease XPF
p44028
sa(dp44029
g33284
I22
sg33285
I1
sg33286
I5
sg33295
VP07992
p44030
sg33289
VERCC1
p44031
sa(dp44032
g33284
I0
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP45
p44033
sa(dp44034
g33284
I121
sg33285
I3
sg33286
I22
sg33295
g11
sg33289
VUSP45 catalytic domain
p44035
sasg33281
(lp44036
(dp44037
g33284
I70
sg33285
I1
sg33286
I3
sg33287
VC0268140
p44038
sg33289
VXPF
p44039
sasa(dp44040
g33277
VFinally, USP45 localises to sites of DNA damage in a manner dependent on its deubiquitylase activity, but independent of its ability to bind ERCC1-XPF.
p44041
sg33279
(lp44042
(dp44043
g33284
I147
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VXPF
p44044
sa(dp44045
g33284
I141
sg33285
I1
sg33286
I5
sg33295
VP07992
p44046
sg33289
VERCC1
p44047
sa(dp44048
g33284
I9
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP45
p44049
sasg33281
(lp44050
(dp44051
g33284
I37
sg33285
I2
sg33286
I10
sg33287
VC0012860
p44052
sg33289
VDNA damage
p44053
sa(dp44054
g33284
I147
sg33285
I1
sg33286
I3
sg33287
VC0268140
p44055
sg33289
VXPF
p44056
sasa(dp44057
g33277
VTogether, these results establish USP45 as a new regulator of XPF-ERCC1 crucial for efficient DNA repair.
p44058
sg33279
(lp44059
(dp44060
g33284
I34
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VUSP45
p44061
sa(dp44062
g33284
I62
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VXPF-ERCC1
p44063
sasg33281
(lp44064
(dp44065
g33284
I62
sg33285
I1
sg33286
I3
sg33287
VC0268140
p44066
sg33289
VXPF
p44067
sasa(dp44068
g33277
VWe used a polycistronic lentiviral vector (hSTEMCCA-loxP) encoding OCT4, SOX2, KLF4, and cMYC genes and containing loxP sites, excisible by Cre recombinase, to reprogram patient-specific fetal cells derived from prenatal diagnosis for several genetic disorders, such as myotonic dystrophy type 1 (DM1), Beta-thalassemia (Beta-Thal), lymphedema-distichiasis syndrome (LDS), spinal muscular atrophy (SMA), cystic fibrosis (CF), as well as from wild-type (WT) fetal cells.
p44069
sg33279
(lp44070
(dp44071
g33284
I297
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VDM1
p44072
sa(dp44073
g33284
I140
sg33285
I2
sg33286
I15
sg33295
g11
sg33289
VCre recombinase
p44074
sa(dp44075
g33284
I79
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VKLF4
p44076
sa(dp44077
g33284
I270
sg33285
I4
sg33286
I25
sg33295
g11
sg33289
Vmyotonic dystrophy type 1
p44078
sa(dp44079
g33284
I89
sg33285
I2
sg33286
I10
sg33295
VP01893
p44080
sg33289
VcMYC genes
p44081
sa(dp44082
g33284
I73
sg33285
I1
sg33286
I4
sg33295
VP48431
p44083
sg33289
VSOX2
p44084
sasg33281
(lp44085
(dp44086
g33284
I333
sg33285
I2
sg33286
I32
sg33287
VC0265345
p44087
sg33289
Vlymphedema-distichiasis syndrome
p44088
sa(dp44089
g33284
I421
sg33285
I1
sg33286
I2
sg33287
VC0010674
p44090
sg33289
VCF
p44091
sa(dp44092
g33284
I270
sg33285
I2
sg33286
I18
sg33287
VC0027126
p44093
sg33289
Vmyotonic dystrophy
p44094
sa(dp44095
g33284
I404
sg33285
I2
sg33286
I15
sg33287
VC0010674
p44096
sg33289
Vcystic fibrosis
p44097
sa(dp44098
g33284
I243
sg33285
I2
sg33286
I17
sg33287
VC0019247
p44099
sg33289
Vgenetic disorders
p44100
sa(dp44101
g33284
I297
sg33285
I1
sg33286
I3
sg33287
VC2931688
p44102
sg33289
VDM1
p44103
sa(dp44104
g33284
I303
sg33285
I1
sg33286
I16
sg33287
VC0005283
p44105
sg33289
VBeta-thalassemia
p44106
sa(dp44107
g33284
I398
sg33285
I1
sg33286
I3
sg33287
VC0026847
p44108
sg33289
VSMA
p44109
sa(dp44110
g33284
I373
sg33285
I3
sg33286
I23
sg33287
VC0026847
p44111
sg33289
Vspinal muscular atrophy
p44112
sa(dp44113
g33284
I367
sg33285
I1
sg33286
I3
sg33287
VC0265345
p44114
sg33289
VLDS
p44115
sa(dp44116
g33284
I321
sg33285
I1
sg33286
I9
sg33287
VC0005283
p44117
sg33289
VBeta-Thal
p44118
sasa(dp44119
g33277
VTwelve CpG loci (11 genes) showed greater than 10% comparative difference in DNA methylation, including hyper-methylated loci of FAM181A, MRI1, PIWIL1, CHFR, DEFA1, MRPL28, AURKA, and hypo-methylated loci of NALP1L5, MAP8KIP3, ACAT2, and PM20D1 in maternal asthma.
p44120
sg33279
(lp44121
(dp44122
g33284
I173
sg33285
I1
sg33286
I5
sg33295
VP17038
p44123
sg33289
VAURKA
p44124
sa(dp44125
g33284
I138
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VMRI1
p44126
sa(dp44127
g33284
I129
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VFAM181A
p44128
sa(dp44129
g33284
I144
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VPIWIL1
p44130
sa(dp44131
g33284
I165
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VMRPL28
p44132
sa(dp44133
g33284
I152
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCHFR
p44134
sa(dp44135
g33284
I238
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VPM20D1
p44136
sa(dp44137
g33284
I158
sg33285
I1
sg33286
I5
sg33295
VP59665
p44138
sg33289
VDEFA1
p44139
sa(dp44140
g33284
I227
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VACAT2
p44141
sasg33281
(lp44142
(dp44143
g33284
I257
sg33285
I1
sg33286
I6
sg33287
VC0004096
p44144
sg33289
Vasthma
p44145
sasa(dp44146
g33277
VSystemic expression of DEFA1,1B,3,4,CTSG and ELA2 was significantly higher in the neutrophilic asthma (NA) phenotype.
p44147
sg33279
(lp44148
(dp44149
g33284
I45
sg33285
I1
sg33286
I4
sg33295
VP08246
p44150
sg33289
VELA2
p44151
sa(dp44152
g33284
I23
sg33285
I1
sg33286
I5
sg33295
VP59665
p44153
sg33289
VDEFA1
p44154
sa(dp44155
g33284
I36
sg33285
I1
sg33286
I4
sg33295
VP08311
p44156
sg33289
VCTSG
p44157
sasg33281
(lp44158
(dp44159
g33284
I103
sg33285
I1
sg33286
I2
sg33287
VC2363774
p44160
sg33289
VNA
p44161
sa(dp44162
g33284
I82
sg33285
I2
sg33286
I19
sg33287
VC2363774
p44163
sg33289
Vneutrophilic asthma
p44164
sasa(dp44165
g33277
VThe objective of this study was to determine the combined influence of alpha thalassemia, fetal hemoglobin, and the UGT1A1 polymorphism on serum bilirubin levels and cholelithiasis in patients with sickle cell disease.
p44166
sg33279
(lp44167
(dp44168
g33284
I90
sg33285
I2
sg33286
I16
sg33295
VP14207
p44169
sg33289
Vfetal hemoglobin
p44170
sa(dp44171
g33284
I116
sg33285
I1
sg33286
I6
sg33295
VP35504
p44172
sg33289
VUGT1A1
p44173
sasg33281
(lp44174
(dp44175
g33284
I198
sg33285
I3
sg33286
I19
sg33287
VC0002895
p44176
sg33289
Vsickle cell disease
p44177
sa(dp44178
g33284
I166
sg33285
I1
sg33286
I14
sg33287
VC0008350
p44179
sg33289
Vcholelithiasis
p44180
sa(dp44181
g33284
I71
sg33285
I2
sg33286
I17
sg33287
VC0002312
p44182
sg33289
Valpha thalassemia
p44183
sasa(dp44184
g33277
VThe present study investigated the role of several genetic factors (UGT1A1 promoter (TA)n repeat polymorphism, alpha-globin status), hematological parameters, clinical severity, and hydroxyurea (HU) therapy on the occurrence of cholelithiasis in SCD.
p44185
sg33279
(lp44186
(dp44187
g33284
I111
sg33285
I1
sg33286
I12
sg33295
VP69905
p44188
sg33289
Valpha-globin
p44189
sasg33281
(lp44190
(dp44191
g33284
I246
sg33285
I1
sg33286
I3
sg33287
VC0002895
p44192
sg33289
VSCD
p44193
sa(dp44194
g33284
I228
sg33285
I1
sg33286
I14
sg33287
VC0008350
p44195
sg33289
Vcholelithiasis
p44196
sasa(dp44197
g33277
VWe confirmed that alpha-thalassemia and low basal reticulocyte (RET) count were independent protective factors for cholelithiasis while 7/7, 8/8 and 7/8 UGT1A1 (TA)n genotypes were independent predisposing factors for this complication.
p44198
sg33279
(lp44199
sg33281
(lp44200
(dp44201
g33284
I18
sg33285
I1
sg33286
I17
sg33287
VC0002312
p44202
sg33289
Valpha-thalassemia
p44203
sa(dp44204
g33284
I115
sg33285
I1
sg33286
I14
sg33287
VC0008350
p44205
sg33289
Vcholelithiasis
p44206
sa(dp44207
g33284
I223
sg33285
I1
sg33286
I12
sg33287
VC0009566
p44208
sg33289
Vcomplication
p44209
sasa(dp44210
g33277
VWe explored the potential relationship between steady state serum bilirubin levels and the incidence of cholelithiasis in the context of UGT1A1 gene A(TA)nTAA promoter polymorphism in Omani sickle cell anemia (SCA) patients, homozygotes for African (Benin and Bantu) and Arab-Indian Beta(S) haplotypes, but sharing the same microgeographical environment and comparable life style factors.
p44211
sg33279
(lp44212
(dp44213
g33284
I137
sg33285
I3
sg33286
I13
sg33295
VP35504
p44214
sg33289
VUGT1A1 gene A
p44215
sasg33281
(lp44216
(dp44217
g33284
I210
sg33285
I1
sg33286
I3
sg33287
VC0002895
p44218
sg33289
VSCA
p44219
sa(dp44220
g33284
I190
sg33285
I3
sg33286
I18
sg33287
VC0002895
p44221
sg33289
Vsickle cell anemia
p44222
sa(dp44223
g33284
I104
sg33285
I1
sg33286
I14
sg33287
VC0008350
p44224
sg33289
Vcholelithiasis
p44225
sasa(dp44226
g33277
VThus, not cholelithiasis but total serum bilirubin was influenced by UGT1A1 polymorphism in this SCA cohort.
p44227
sg33279
(lp44228
(dp44229
g33284
I69
sg33285
I1
sg33286
I6
sg33295
VP35504
p44230
sg33289
VUGT1A1
p44231
sasg33281
(lp44232
(dp44233
g33284
I10
sg33285
I1
sg33286
I14
sg33287
VC0008350
p44234
sg33289
Vcholelithiasis
p44235
sasa(dp44236
g33277
VAltogether our data provide the implication of UGT1A1 and SLCO1A2 in sickle cell anemia-related cholelithiasis.
p44237
sg33279
(lp44238
(dp44239
g33284
I58
sg33285
I1
sg33286
I7
sg33295
VP46721
p44240
sg33289
VSLCO1A2
p44241
sa(dp44242
g33284
I47
sg33285
I1
sg33286
I6
sg33295
VP35504
p44243
sg33289
VUGT1A1
p44244
sasg33281
(lp44245
(dp44246
g33284
I69
sg33285
I3
sg33286
I18
sg33287
VC0002895
p44247
sg33289
Vsickle cell anemia
p44248
sa(dp44249
g33284
I96
sg33285
I1
sg33286
I14
sg33287
VC0008350
p44250
sg33289
Vcholelithiasis
p44251
sasa(dp44252
g33277
VPresent study was aimed to explore the effect of (TA)n UGT1A1 gene promoter polymorphism on bilirubin metabolism, bilirubinaemia, predisposition to cholelithiasis and subsequent cholecystectomy, in Sickle-Cell Anemia (SCA) and beta-Thalasemia major (bTH) in Kuwaiti subjects compared to other population.
p44253
sg33279
(lp44254
(dp44255
g33284
I55
sg33285
I3
sg33286
I20
sg33295
VP35504
p44256
sg33289
VUGT1A1 gene promoter
p44257
sasg33281
(lp44258
(dp44259
g33284
I198
sg33285
I2
sg33286
I18
sg33287
VC0002895
p44260
sg33289
VSickle-Cell Anemia
p44261
sa(dp44262
g33284
I114
sg33285
I1
sg33286
I14
sg33287
VC0020433
p44263
sg33289
Vbilirubinaemia
p44264
sa(dp44265
g33284
I148
sg33285
I1
sg33286
I14
sg33287
VC0008350
p44266
sg33289
Vcholelithiasis
p44267
sa(dp44268
g33284
I218
sg33285
I1
sg33286
I3
sg33287
VC0002895
p44269
sg33289
VSCA
p44270
sasa(dp44271
g33277
VOur results confirm UGT1A1 (TA)7 allele as one of the factors accounting for the hyperbilirubinemia and cholelithiasis observed in SCA and bTH.
p44272
sg33279
(lp44273
(dp44274
g33284
I20
sg33285
I1
sg33286
I6
sg33295
VP35504
p44275
sg33289
VUGT1A1
p44276
sasg33281
(lp44277
(dp44278
g33284
I81
sg33285
I1
sg33286
I18
sg33287
VC0020433
p44279
sg33289
Vhyperbilirubinemia
p44280
sa(dp44281
g33284
I104
sg33285
I1
sg33286
I14
sg33287
VC0008350
p44282
sg33289
Vcholelithiasis
p44283
sasa(dp44284
g33277
VWe analyzed the polymorphism A(TA)nTAA at the UGT1A1 promoter and the relationships between the various A(TA)nTAA genotypes and alleles and bilirubin levels and occurrence of cholelithiasis.
p44285
sg33279
(lp44286
(dp44287
g33284
I46
sg33285
I2
sg33286
I15
sg33295
VP35504
p44288
sg33289
VUGT1A1 promoter
p44289
sasg33281
(lp44290
(dp44291
g33284
I175
sg33285
I1
sg33286
I14
sg33287
VC0008350
p44292
sg33289
Vcholelithiasis
p44293
sasa(dp44294
g33277
VWe analyzed the polymorphism A(TA)&lt;formula&gt;_{n}&lt;/formula&gt; TAA at the UGT1A1 promoter and the relationships between the various A(TA)&lt;formula&gt;_{n}&lt;/formula&gt; TAA genotypes and alleles and bilirubin levels and occurrence of cholelithiasis.
p44295
sg33279
(lp44296
(dp44297
g33284
I81
sg33285
I2
sg33286
I15
sg33295
VP35504
p44298
sg33289
VUGT1A1 promoter
p44299
sasg33281
(lp44300
(dp44301
g33284
I245
sg33285
I1
sg33286
I14
sg33287
VC0008350
p44302
sg33289
Vcholelithiasis
p44303
sa(dp44304
g33284
I70
sg33285
I1
sg33286
I3
sg33287
VC0162872
p44305
sg33289
VTAA
p44306
sa(dp44307
g33284
I70
sg33285
I1
sg33286
I3
sg33287
VC0162872
p44308
sg33289
VTAA
p44309
sasa(dp44310
g33277
VThe ADP-ribosyltransferase 3 gene (ART3) has been reported to be associated with non-obstructive azoospermia (NOA) in the Japanese population.
p44311
sg33279
(lp44312
(dp44313
g33284
I35
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VART3
p44314
sa(dp44315
g33284
I4
sg33285
I3
sg33286
I29
sg33295
g11
sg33289
VADP-ribosyltransferase 3 gene
p44316
sasg33281
(lp44317
(dp44318
g33284
I97
sg33285
I1
sg33286
I11
sg33287
VC1321542
p44319
sg33289
Vazoospermia
p44320
sasa(dp44321
g33277
VA recent Japanese study provided evidence that the rs6836703: G&gt;A single-nucleotide polymorphism (SNP) from the ADP-ribosyltransferase 3 (ART3) gene is significantly associated with non-obstructive azoospermia.
p44322
sg33279
(lp44323
(dp44324
g33284
I115
sg33285
I2
sg33286
I24
sg33295
g11
sg33289
VADP-ribosyltransferase 3
p44325
sa(dp44326
g33284
I141
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VART3
p44327
sasg33281
(lp44328
(dp44329
g33284
I201
sg33285
I1
sg33286
I11
sg33287
VC1321542
p44330
sg33289
Vazoospermia
p44331
sasa(dp44332
g33277
VThe analysis of genes involved in hereditary spherocytosis, by next-generation sequencing in two patients with clinical diagnosis of the disease, showed the presence of the c.1795+1G&gt;A mutation in the SPTB gene.
p44333
sg33279
(lp44334
(dp44335
g33284
I204
sg33285
I2
sg33286
I9
sg33295
g11
sg33289
VSPTB gene
p44336
sasg33281
(lp44337
(dp44338
g33284
I34
sg33285
I2
sg33286
I24
sg33287
VC0037889
p44339
sg33289
Vhereditary spherocytosis
p44340
sasa(dp44341
g33277
VHereditary spherocytosis stems from mutations in one of the genes encoding ankyrin-1 (ANKI), alpha spectrin (SPTA1) and beta spectrin (SPTB), the anion exchanger 1 (SLC4A 1), and protein 4.2 (EPB42).
p44342
sg33279
(lp44343
(dp44344
g33284
I120
sg33285
I2
sg33286
I13
sg33295
VP11277
p44345
sg33289
Vbeta spectrin
p44346
sa(dp44347
g33284
I93
sg33285
I2
sg33286
I14
sg33295
VP02549
p44348
sg33289
Valpha spectrin
p44349
sa(dp44350
g33284
I192
sg33285
I1
sg33286
I5
sg33295
VP16452
p44351
sg33289
VEPB42
p44352
sa(dp44353
g33284
I86
sg33285
I1
sg33286
I4
sg33295
VP16157
p44354
sg33289
VANKI
p44355
sa(dp44356
g33284
I135
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VSPTB
p44357
sa(dp44358
g33284
I109
sg33285
I1
sg33286
I5
sg33295
VP02549
p44359
sg33289
VSPTA1
p44360
sa(dp44361
g33284
I75
sg33285
I1
sg33286
I9
sg33295
VP16157
p44362
sg33289
Vankyrin-1
p44363
sa(dp44364
g33284
I179
sg33285
I2
sg33286
I11
sg33295
VP01031
p44365
sg33289
Vprotein 4.2
p44366
sa(dp44367
g33284
I146
sg33285
I3
sg33286
I17
sg33295
VP02730
p44368
sg33289
Vanion exchanger 1
p44369
sasg33281
(lp44370
(dp44371
g33284
I0
sg33285
I2
sg33286
I24
sg33287
VC0037889
p44372
sg33289
VHereditary spherocytosis
p44373
sasa(dp44374
g33277
VWe also investigated methylation profiles in peripheral blood mononuclear cells from patients with red cell membrane diseases, such as complete protein 4.2 deficiency due to ELB42 mutations, hereditary spherocytosis with EPB3 mutations, and hereditary elliptocytosis with SPTB mutations.
p44375
sg33279
(lp44376
(dp44377
g33284
I221
sg33285
I2
sg33286
I14
sg33295
VP02730
p44378
sg33289
VEPB3 mutations
p44379
sa(dp44380
g33284
I272
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VSPTB
p44381
sa(dp44382
g33284
I144
sg33285
I2
sg33286
I11
sg33295
VP01031
p44383
sg33289
Vprotein 4.2
p44384
sasg33281
(lp44385
(dp44386
g33284
I241
sg33285
I2
sg33286
I25
sg33287
VC0013902
p44387
sg33289
Vhereditary elliptocytosis
p44388
sa(dp44389
g33284
I191
sg33285
I2
sg33286
I24
sg33287
VC0037889
p44390
sg33289
Vhereditary spherocytosis
p44391
sasa(dp44392
g33277
VThe mutations of most cases of hereditary spherocytosis (HS) are located in the following genes: ANK1, SPTB, SLC4A1, EPB42 and SPTA1, which encode ankyrin, spectrin beta-chain, the anion exchanger 1 (band 3), protein 4.2 and spectrin alpha-chain, respectively.
p44393
sg33279
(lp44394
(dp44395
g33284
I97
sg33285
I1
sg33286
I4
sg33295
VP16157
p44396
sg33289
VANK1
p44397
sa(dp44398
g33284
I156
sg33285
I2
sg33286
I19
sg33295
g11
sg33289
Vspectrin beta-chain
p44399
sa(dp44400
g33284
I109
sg33285
I1
sg33286
I6
sg33295
VP02730
p44401
sg33289
VSLC4A1
p44402
sa(dp44403
g33284
I209
sg33285
I2
sg33286
I11
sg33295
VP01031
p44404
sg33289
Vprotein 4.2
p44405
sa(dp44406
g33284
I117
sg33285
I1
sg33286
I5
sg33295
VP16452
p44407
sg33289
VEPB42
p44408
sa(dp44409
g33284
I225
sg33285
I2
sg33286
I20
sg33295
VP55899
p44410
sg33289
Vspectrin alpha-chain
p44411
sa(dp44412
g33284
I127
sg33285
I1
sg33286
I5
sg33295
VP02549
p44413
sg33289
VSPTA1
p44414
sa(dp44415
g33284
I147
sg33285
I1
sg33286
I7
sg33295
VP16157
p44416
sg33289
Vankyrin
p44417
sa(dp44418
g33284
I103
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VSPTB
p44419
sasg33281
(lp44420
(dp44421
g33284
I31
sg33285
I2
sg33286
I24
sg33287
VC0037889
p44422
sg33289
Vhereditary spherocytosis
p44423
sa(dp44424
g33284
I57
sg33285
I1
sg33286
I2
sg33287
VC0037889
p44425
sg33289
VHS
p44426
sasa(dp44427
g33277
VMutations in bone morphogenetic protein 1 (BMP1) in humans or deletion of BMP1 and related protease tolloid like 1 (TLL1) in mice lead to osteogenesis imperfecta (OI).
p44428
sg33279
(lp44429
(dp44430
g33284
I43
sg33285
I1
sg33286
I4
sg33295
VP14222
p44431
sg33289
VBMP1
p44432
sa(dp44433
g33284
I100
sg33285
I3
sg33286
I14
sg33295
g11
sg33289
Vtolloid like 1
p44434
sa(dp44435
g33284
I116
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTLL1
p44436
sa(dp44437
g33284
I74
sg33285
I4
sg33286
I25
sg33295
VP63123
p44438
sg33289
VBMP1 and related protease
p44439
sa(dp44440
g33284
I13
sg33285
I4
sg33286
I28
sg33295
VP14222
p44441
sg33289
Vbone morphogenetic protein 1
p44442
sasg33281
(lp44443
(dp44444
g33284
I163
sg33285
I1
sg33286
I2
sg33287
VC0029434
p44445
sg33289
VOI
p44446
sa(dp44447
g33284
I138
sg33285
I2
sg33286
I23
sg33287
VC0029434
p44448
sg33289
Vosteogenesis imperfecta
p44449
sasa(dp44450
g33277
VMutations in the proteinase bone morphogenetic protein-1 (BMP1) were recently identified in patients with osteogenesis imperfecta, which can be associated with type 1 dentinogenesis imperfecta.
p44451
sg33279
(lp44452
(dp44453
g33284
I17
sg33285
I4
sg33286
I39
sg33295
VP63123
p44454
sg33289
Vproteinase bone morphogenetic protein-1
p44455
sasg33281
(lp44456
(dp44457
g33284
I167
sg33285
I2
sg33286
I25
sg33287
VC0011436
p44458
sg33289
Vdentinogenesis imperfecta
p44459
sa(dp44460
g33284
I106
sg33285
I2
sg33286
I23
sg33287
VC0029434
p44461
sg33289
Vosteogenesis imperfecta
p44462
sasa(dp44463
g33277
VWe previously showed these mice to have a skeletal phenotype that includes elements of osteogenesis imperfecta (OI), osteomalacia, and deficient osteocyte maturation, observations validated by the finding of BMP1 mutations in a subset of human patients with OI-like phenotypes.
p44464
sg33279
(lp44465
sg33281
(lp44466
(dp44467
g33284
I112
sg33285
I1
sg33286
I2
sg33287
VC0029434
p44468
sg33289
VOI
p44469
sa(dp44470
g33284
I87
sg33285
I2
sg33286
I23
sg33287
VC0029434
p44471
sg33289
Vosteogenesis imperfecta
p44472
sa(dp44473
g33284
I112
sg33285
I1
sg33286
I2
sg33287
VC0029434
p44474
sg33289
VOI
p44475
sa(dp44476
g33284
I117
sg33285
I1
sg33286
I12
sg33287
VC0029442
p44477
sg33289
Vosteomalacia
p44478
sasa(dp44479
g33277
VAutosomal recessive osteogenesis imperfecta (OI) accounts for 10% of all OI cases, and, currently, mutations in 10 genes (CRTAP, LEPRE1, PPIB, SERPINH1, FKBP10, SERPINF1, SP7, BMP1, TMEM38B, and WNT1) are known to be responsible for this form of the disease.
p44480
sg33279
(lp44481
(dp44482
g33284
I171
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VSP7
p44483
sa(dp44484
g33284
I182
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VTMEM38B
p44485
sa(dp44486
g33284
I122
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCRTAP
p44487
sa(dp44488
g33284
I137
sg33285
I1
sg33286
I4
sg33295
VP23284
p44489
sg33289
VPPIB
p44490
sa(dp44491
g33284
I143
sg33285
I1
sg33286
I8
sg33295
VP50454
p44492
sg33289
VSERPINH1
p44493
sa(dp44494
g33284
I153
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VFKBP10
p44495
sa(dp44496
g33284
I161
sg33285
I1
sg33286
I8
sg33295
VP36955
p44497
sg33289
VSERPINF1
p44498
sa(dp44499
g33284
I195
sg33285
I1
sg33286
I4
sg33295
VP04628
p44500
sg33289
VWNT1
p44501
sasg33281
(lp44502
(dp44503
g33284
I20
sg33285
I2
sg33286
I23
sg33287
VC0029434
p44504
sg33289
Vosteogenesis imperfecta
p44505
sa(dp44506
g33284
I45
sg33285
I1
sg33286
I2
sg33287
VC0029434
p44507
sg33289
VOI
p44508
sa(dp44509
g33284
I45
sg33285
I1
sg33286
I2
sg33287
VC0029434
p44510
sg33289
VOI
p44511
sasa(dp44512
g33277
VIsolated 3-methylcrotonyl-CoA carboxylase deficiency (3MCCD) is an autosomal recessive disorder of leucine metabolism biochemically characterized by accumulation of 3-methylcrotonylglycine (3MCG), 3-methylcrotonic acid (3MCA) and 3-hydroxyisovaleric acid.
p44513
sg33279
(lp44514
(dp44515
g33284
I0
sg33285
I3
sg33286
I41
sg33295
g11
sg33289
VIsolated 3-methylcrotonyl-CoA carboxylase
p44516
sasg33281
(lp44517
(dp44518
g33284
I54
sg33285
I1
sg33286
I5
sg33287
VC0268600
p44519
sg33289
V3MCCD
p44520
sa(dp44521
g33284
I9
sg33285
I3
sg33286
I43
sg33287
VC0268600
p44522
sg33289
V3-methylcrotonyl-CoA carboxylase deficiency
p44523
sasa(dp44524
g33277
VIsolated 3-methylcrotonyl-CoA carboxylase (MCC) deficiency is an autosomal recessive disorder of leucine metabolism caused by mutations in MCCC1 or MCCC2 encoding the Alfa and Beta subunit of MCC, respectively.
p44525
sg33279
(lp44526
(dp44527
g33284
I0
sg33285
I3
sg33286
I41
sg33295
g11
sg33289
VIsolated 3-methylcrotonyl-CoA carboxylase
p44528
sa(dp44529
g33284
I43
sg33285
I1
sg33286
I3
sg33295
VP23508
p44530
sg33289
VMCC
p44531
sa(dp44532
g33284
I139
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VMCCC1
p44533
sa(dp44534
g33284
I148
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VMCCC2
p44535
sa(dp44536
g33284
I43
sg33285
I1
sg33286
I3
sg33295
VP23508
p44537
sg33289
VMCC
p44538
sasg33281
(lp44539
(dp44540
g33284
I43
sg33285
I1
sg33286
I3
sg33287
VC0007129
p44541
sg33289
VMCC
p44542
sa(dp44543
g33284
I43
sg33285
I1
sg33286
I3
sg33287
VC0007129
p44544
sg33289
VMCC
p44545
sa(dp44546
g33284
I9
sg33285
I2
sg33286
I32
sg33287
VC0007129
p44547
sg33289
V3-methylcrotonyl-CoA carboxylase
p44548
sasa(dp44549
g33277
VWe performed mutational analysis in the four main HPE causing genes (SHH, SIX3, TGIF, and ZIC2) and GLI3, a gene associated with polydactyly as well as fluorescent in situ hybridization (FISH) to search for microdeletions in these genes and two candidate HPE genes (DISP1 and FOXA2).
p44550
sg33279
(lp44551
(dp44552
g33284
I90
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VZIC2
p44553
sa(dp44554
g33284
I69
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VSHH
p44555
sa(dp44556
g33284
I276
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VFOXA2
p44557
sa(dp44558
g33284
I255
sg33285
I2
sg33286
I9
sg33295
VP01893
p44559
sg33289
VHPE genes
p44560
sa(dp44561
g33284
I100
sg33285
I1
sg33286
I4
sg33295
VP10071
p44562
sg33289
VGLI3
p44563
sa(dp44564
g33284
I266
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VDISP1
p44565
sa(dp44566
g33284
I74
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VSIX3
p44567
sa(dp44568
g33284
I80
sg33285
I1
sg33286
I4
sg33295
VP22301
p44569
sg33289
VTGIF
p44570
sasg33281
(lp44571
(dp44572
g33284
I129
sg33285
I1
sg33286
I11
sg33287
VC0152427
p44573
sg33289
Vpolydactyly
p44574
sasa(dp44575
g33277
VAlthough the CCK-1 receptor has been shown to be highly expressed in resected human pancreatic cancer samples, its role is less clear.
p44576
sg33279
(lp44577
(dp44578
g33284
I13
sg33285
I2
sg33286
I14
sg33295
VP06307
p44579
sg33289
VCCK-1 receptor
p44580
sasg33281
(lp44581
(dp44582
g33284
I84
sg33285
I2
sg33286
I17
sg33287
VC0235974
p44583
sg33289
Vpancreatic cancer
p44584
sasa(dp44585
g33277
VThe aim of this in vitro study was to investigate the CCK-1 receptor expression and the function of the CCK-CCK-1 receptor pathway in the human pancreatic adenocarcinoma cell line, Mia PaCa-2.
p44586
sg33279
(lp44587
(dp44588
g33284
I54
sg33285
I2
sg33286
I14
sg33295
VP06307
p44589
sg33289
VCCK-1 receptor
p44590
sa(dp44591
g33284
I104
sg33285
I2
sg33286
I18
sg33295
VP06307
p44592
sg33289
VCCK-CCK-1 receptor
p44593
sa(dp44594
g33284
I181
sg33285
I2
sg33286
I10
sg33295
g11
sg33289
VMia PaCa-2
p44595
sasg33281
(lp44596
(dp44597
g33284
I185
sg33285
I1
sg33286
I4
sg33287
VC1836780
p44598
sg33289
VPaCa
p44599
sa(dp44600
g33284
I144
sg33285
I2
sg33286
I25
sg33287
VC0281361
p44601
sg33289
Vpancreatic adenocarcinoma
p44602
sasa(dp44603
g33277
VHowever, the main source of CCK receptors in the pancreatic tumor samples consisted of CCK2-expressing islets and/or CCK1-expressing nerves rather than neoplastic tissue.
p44604
sg33279
(lp44605
(dp44606
g33284
I28
sg33285
I2
sg33286
I13
sg33295
VP06307
p44607
sg33289
VCCK receptors
p44608
sa(dp44609
g33284
I117
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCCK1
p44610
sasg33281
(lp44611
(dp44612
g33284
I49
sg33285
I2
sg33286
I16
sg33287
VC0030297
p44613
sg33289
Vpancreatic tumor
p44614
sasa(dp44615
g33277
VThese data indicate that the presence of CCK receptors in human ductal pancreatic tumor samples is mainly due to CCK2 expression in residual pancreatic islets and CCK1 in pancreatic nerves.
p44616
sg33279
(lp44617
(dp44618
g33284
I41
sg33285
I2
sg33286
I13
sg33295
VP06307
p44619
sg33289
VCCK receptors
p44620
sa(dp44621
g33284
I163
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCCK1
p44622
sasg33281
(lp44623
(dp44624
g33284
I71
sg33285
I2
sg33286
I16
sg33287
VC0030297
p44625
sg33289
Vpancreatic tumor
p44626
sasa(dp44627
g33277
VThe aim of this study was to evaluate the association of the polymorphisms in TCN2 (rs1801198) gene and in MTRR (rs1801394) gene with nonsyndromic cleft lip and/or palate (NSCL/P) in a Brazilian population.
p44628
sg33279
(lp44629
(dp44630
g33284
I78
sg33285
I3
sg33286
I21
sg33295
VP20062
p44631
sg33289
VTCN2 (rs1801198) gene
p44632
sasg33281
(lp44633
(dp44634
g33284
I147
sg33285
I2
sg33286
I9
sg33287
VC0008924
p44635
sg33289
Vcleft lip
p44636
sasa(dp44637
g33277
VWhile the roles of the GluN2A and GluN2B subunit in ischemic stroke have been well developed, the role of the GluN2C subunit in ischemia is not well understood.
p44638
sg33279
(lp44639
sg33281
(lp44640
(dp44641
g33284
I128
sg33285
I1
sg33286
I8
sg33287
VC0022116
p44642
sg33289
Vischemia
p44643
sa(dp44644
g33284
I52
sg33285
I2
sg33286
I15
sg33287
VC3272363
p44645
sg33289
Vischemic stroke
p44646
sasa(dp44647
g33277
VIn the Western blotting assay, clonidine treatment led to significant up-regulation of the expression level of NR2B and Phospho-NR2B in the hippocampus of the rats when compared with the cerebral ischemia group.
p44648
sg33279
(lp44649
(dp44650
g33284
I120
sg33285
I1
sg33286
I12
sg33295
g11
sg33289
VPhospho-NR2B
p44651
sa(dp44652
g33284
I111
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNR2B
p44653
sasg33281
(lp44654
(dp44655
g33284
I187
sg33285
I2
sg33286
I17
sg33287
VC0917798
p44656
sg33289
Vcerebral ischemia
p44657
sasa(dp44658
g33277
VIn conclusion, clonidine could improve the learning and memory ability of rats with cerebral ischemia, and NR2B, ERK1/2, CREB, NF-KB were involved in this effect.
p44659
sg33279
(lp44660
(dp44661
g33284
I121
sg33285
I1
sg33286
I4
sg33295
VP16220
p44662
sg33289
VCREB
p44663
sa(dp44664
g33284
I113
sg33285
I1
sg33286
I6
sg33295
VP27361
p44665
sg33289
VERK1/2
p44666
sa(dp44667
g33284
I107
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNR2B
p44668
sasg33281
(lp44669
(dp44670
g33284
I84
sg33285
I2
sg33286
I17
sg33287
VC0917798
p44671
sg33289
Vcerebral ischemia
p44672
sasa(dp44673
g33277
VDWEYS-IgG cross-reactive with DNA and the N-methyl-D-aspartate receptor subunits GluN2A/GluN2B has been associated with neuropsychiatric systemic lupus erythematosus (NPSLE).
p44674
sg33279
(lp44675
(dp44676
g33284
I42
sg33285
I4
sg33286
I52
sg33295
g11
sg33289
VN-methyl-D-aspartate receptor subunits GluN2A/GluN2B
p44677
sasg33281
(lp44678
(dp44679
g33284
I167
sg33285
I1
sg33286
I5
sg33287
VC0752335
p44680
sg33289
VNPSLE
p44681
sa(dp44682
g33284
I120
sg33285
I4
sg33286
I45
sg33287
VC0752335
p44683
sg33289
Vneuropsychiatric systemic lupus erythematosus
p44684
sasa(dp44685
g33277
VTherefore, NMDAR antagonists, especially NR2B-selective ones, combined with IGF-1 may serve as an alternative therapeutic agent for oxidative stress related neurodegenerative disease.
p44686
sg33279
(lp44687
(dp44688
g33284
I41
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNR2B
p44689
sa(dp44690
g33284
I76
sg33285
I1
sg33286
I5
sg33295
VP01343
p44691
sg33289
VIGF-1
p44692
sasg33281
(lp44693
(dp44694
g33284
I157
sg33285
I2
sg33286
I25
sg33287
VC0524851
p44695
sg33289
Vneurodegenerative disease
p44696
sa(dp44697
g33284
I132
sg33285
I2
sg33286
I16
sg33287
VC0242606
p44698
sg33289
Voxidative stress
p44699
sasa(dp44700
g33277
VTaken together, our results demonstrated that LBP is neuroprotective against ischemic injury by its dual roles in activation of NR2A and inhibition of NR2B signaling pathways, which suggests that LBP may be a superior therapeutic candidate for targeting glutamate excitotoxicity for the treatment of ischemic stroke.
p44701
sg33279
(lp44702
(dp44703
g33284
I151
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNR2B
p44704
sa(dp44705
g33284
I128
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNR2A
p44706
sa(dp44707
g33284
I46
sg33285
I1
sg33286
I3
sg33295
VP18428
p44708
sg33289
VLBP
p44709
sa(dp44710
g33284
I46
sg33285
I1
sg33286
I3
sg33295
VP18428
p44711
sg33289
VLBP
p44712
sasg33281
(lp44713
(dp44714
g33284
I300
sg33285
I2
sg33286
I15
sg33287
VC3272363
p44715
sg33289
Vischemic stroke
p44716
sa(dp44717
g33284
I46
sg33285
I1
sg33286
I3
sg33287
VC0024031
p44718
sg33289
VLBP
p44719
sa(dp44720
g33284
I46
sg33285
I1
sg33286
I3
sg33287
VC0024031
p44721
sg33289
VLBP
p44722
sasa(dp44723
g33277
VThe obesity-induced changes in adipose tissue macrophage numbers are mainly due to increases in the triple-positive CD11b+ F4/80+ CD11c+ adipose tissue macrophage subpopulation.
p44724
sg33279
(lp44725
(dp44726
g33284
I116
sg33285
I3
sg33286
I20
sg33295
VP11215
p44727
sg33289
VCD11b+ F4/80+ CD11c+
p44728
sasg33281
(lp44729
(dp44730
g33284
I4
sg33285
I1
sg33286
I7
sg33287
VC0028754
p44731
sg33289
Vobesity
p44732
sasa(dp44733
g33277
VContrary to our hypothesis that obesity-mediated white AT inflammation is Nlrp3-dependent, we found that Western diet-induced expression of AT inflammatory markers (i.e., Cd68, Cd11c, Emr1, Itgam, Lgals, Il18, Mcp1, Tnf, Ccr2, Ccl5 mRNAs, and Mac-2 protein) were not accompanied by increased caspase-1 cleavage, a hallmark feature of NLRP3 inflammasome activation.
p44734
sg33279
(lp44735
(dp44736
g33284
I227
sg33285
I2
sg33286
I10
sg33295
VP13501
p44737
sg33289
VCcl5 mRNAs
p44738
sa(dp44739
g33284
I292
sg33285
I1
sg33286
I9
sg33295
VP29466
p44740
sg33289
Vcaspase-1
p44741
sa(dp44742
g33284
I221
sg33285
I1
sg33286
I4
sg33295
VP41597
p44743
sg33289
VCcr2
p44744
sa(dp44745
g33284
I210
sg33285
I1
sg33286
I4
sg33295
VP13500
p44746
sg33289
VMcp1
p44747
sa(dp44748
g33284
I190
sg33285
I1
sg33286
I5
sg33295
VP11215
p44749
sg33289
VItgam
p44750
sa(dp44751
g33284
I243
sg33285
I2
sg33286
I13
sg33295
VP17931
p44752
sg33289
VMac-2 protein
p44753
sa(dp44754
g33284
I216
sg33285
I1
sg33286
I3
sg33295
VP01375
p44755
sg33289
VTnf
p44756
sa(dp44757
g33284
I184
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VEmr1
p44758
sa(dp44759
g33284
I171
sg33285
I1
sg33286
I4
sg33295
VP34810
p44760
sg33289
VCd68
p44761
sa(dp44762
g33284
I177
sg33285
I1
sg33286
I5
sg33295
VP20702
p44763
sg33289
VCd11c
p44764
sa(dp44765
g33284
I204
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VIl18
p44766
sasg33281
(lp44767
(dp44768
g33284
I32
sg33285
I1
sg33286
I7
sg33287
VC0028754
p44769
sg33289
Vobesity
p44770
sa(dp44771
g33284
I58
sg33285
I1
sg33286
I12
sg33287
VC0021368
p44772
sg33289
Vinflammation
p44773
sasa(dp44774
g33277
VIn current practice, an antibody cocktail comprising p63, CK903, and AMACR (PIN-4 cocktail) is frequently utilized to evaluate foci suspicious for prostatic adenocarcinoma.
p44775
sg33279
(lp44776
(dp44777
g33284
I53
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
Vp63
p44778
sasg33281
(lp44779
(dp44780
g33284
I76
sg33285
I1
sg33286
I3
sg33287
VC0282612
p44781
sg33289
VPIN
p44782
sa(dp44783
g33284
I147
sg33285
I2
sg33286
I24
sg33287
VC0007112
p44784
sg33289
Vprostatic adenocarcinoma
p44785
sasa(dp44786
g33277
VOnly 2 NA cases displayed an overall PIN-4 staining pattern compatible with prostate cancer.
p44787
sg33279
(lp44788
sg33281
(lp44789
(dp44790
g33284
I76
sg33285
I2
sg33286
I15
sg33287
VC0600139
p44791
sg33289
Vprostate cancer
p44792
sa(dp44793
g33284
I37
sg33285
I1
sg33286
I3
sg33287
VC0282612
p44794
sg33289
VPIN
p44795
sasa(dp44796
g33277
VAlthough heterogenous staining patterns were seen within individual cases, use of the PIN-4 cocktail effectively discriminates NA from prostate cancer because of the high frequency of coexpression of AMACR and CK903 within NA.
p44797
sg33279
(lp44798
(dp44799
g33284
I86
sg33285
I1
sg33286
I5
sg33295
VP63167
p44800
sg33289
VPIN-4
p44801
sasg33281
(lp44802
(dp44803
g33284
I86
sg33285
I1
sg33286
I3
sg33287
VC0282612
p44804
sg33289
VPIN
p44805
sa(dp44806
g33284
I135
sg33285
I2
sg33286
I15
sg33287
VC0600139
p44807
sg33289
Vprostate cancer
p44808
sasa(dp44809
g33277
VKidney and prostate cancer tumor and benign biopsies were stained with hemotoxylin and eosin and prostate biopsies were subjected to PIN-4 immunohistochemistry.
p44810
sg33279
(lp44811
(dp44812
g33284
I133
sg33285
I1
sg33286
I5
sg33295
VP63167
p44813
sg33289
VPIN-4
p44814
sasg33281
(lp44815
(dp44816
g33284
I11
sg33285
I2
sg33286
I15
sg33287
VC0600139
p44817
sg33289
Vprostate cancer
p44818
sa(dp44819
g33284
I133
sg33285
I1
sg33286
I3
sg33287
VC0282612
p44820
sg33289
VPIN
p44821
sa(dp44822
g33284
I27
sg33285
I1
sg33286
I5
sg33287
VC0027651
p44823
sg33289
Vtumor
p44824
sasa(dp44825
g33277
VA subset of biopsy sections was analyzed by IHC, and cancerous and non-cancerous regions could be readily visualized by PIN4 staining.
p44826
sg33279
(lp44827
(dp44828
g33284
I120
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VPIN4
p44829
sasg33281
(lp44830
sa(dp44831
g33277
VElevated serum levels of Ang-2 and high values for the Ang-2/Ang-1 ratio may potentially be used as predictors of worst-case prognoses for P. vivax malaria, especially in patients with thrombocytopenia.
p44832
sg33279
(lp44833
(dp44834
g33284
I25
sg33285
I1
sg33286
I5
sg33295
VP03950
p44835
sg33289
VAng-2
p44836
sa(dp44837
g33284
I25
sg33285
I1
sg33286
I5
sg33295
VP03950
p44838
sg33289
VAng-2
p44839
sa(dp44840
g33284
I61
sg33285
I1
sg33286
I5
sg33295
VP03950
p44841
sg33289
VAng-1
p44842
sasg33281
(lp44843
(dp44844
g33284
I142
sg33285
I2
sg33286
I13
sg33287
VC0024537
p44845
sg33289
Vvivax malaria
p44846
sasa(dp44847
g33277
VDengue-associated thrombocytopenia and endothelial activation are associated with an imbalance in angiopoietin-2: angiopoietin-1 plasma levels.
p44848
sg33279
(lp44849
(dp44850
g33284
I114
sg33285
I1
sg33286
I14
sg33295
g11
sg33289
Vangiopoietin-1
p44851
sa(dp44852
g33284
I98
sg33285
I1
sg33286
I14
sg33295
g11
sg33289
Vangiopoietin-2
p44853
sasg33281
(lp44854
(dp44855
g33284
I85
sg33285
I1
sg33286
I9
sg33287
VC1397014
p44856
sg33289
Vimbalance
p44857
sa(dp44858
g33284
I0
sg33285
I1
sg33286
I6
sg33287
VC0011311
p44859
sg33289
VDengue
p44860
sasa(dp44861
g33277
VIt has been previously reported that mutations in retinal G protein coupled receptor (RGR) are associated with retinitis pigmentosa.
p44862
sg33279
(lp44863
(dp44864
g33284
I86
sg33285
I1
sg33286
I3
sg33295
VP47804
p44865
sg33289
VRGR
p44866
sa(dp44867
g33284
I50
sg33285
I5
sg33286
I34
sg33295
VP47804
p44868
sg33289
Vretinal G protein coupled receptor
p44869
sasg33281
(lp44870
(dp44871
g33284
I111
sg33285
I2
sg33286
I20
sg33287
VC0035334
p44872
sg33289
Vretinitis pigmentosa
p44873
sasa(dp44874
g33277
VThe present study aims to systemically analyze the potential role of variants of RGR in retinal diseases.
p44875
sg33279
(lp44876
(dp44877
g33284
I81
sg33285
I1
sg33286
I3
sg33295
VP47804
p44878
sg33289
VRGR
p44879
sasg33281
(lp44880
(dp44881
g33284
I88
sg33285
I2
sg33286
I16
sg33287
VC0035309
p44882
sg33289
Vretinal diseases
p44883
sasa(dp44884
g33277
VThese data suggest that the recessive retinal disorder previously reported to be due to homozygous mutation in RGR is, at least in part, due to variants in CDHR1 and that the true consequences of RGR knock-out on human retinal structure and function are yet to be determined.
p44885
sg33279
(lp44886
(dp44887
g33284
I111
sg33285
I1
sg33286
I3
sg33295
VP47804
p44888
sg33289
VRGR
p44889
sa(dp44890
g33284
I196
sg33285
I2
sg33286
I13
sg33295
VP47804
p44891
sg33289
VRGR knock-out
p44892
sa(dp44893
g33284
I156
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCDHR1
p44894
sasg33281
(lp44895
(dp44896
g33284
I38
sg33285
I2
sg33286
I16
sg33287
VC0035309
p44897
sg33289
Vretinal disorder
p44898
sasa(dp44899
g33277
VRare mutations in the human RGR gene lead to autosomal recessive retinitis pigmentosa or dominantly inherited peripapillary choroidal atrophy.
p44900
sg33279
(lp44901
(dp44902
g33284
I22
sg33285
I3
sg33286
I14
sg33295
VP47804
p44903
sg33289
Vhuman RGR gene
p44904
sasg33281
(lp44905
(dp44906
g33284
I134
sg33285
I1
sg33286
I7
sg33287
VC0333641
p44907
sg33289
Vatrophy
p44908
sa(dp44909
g33284
I45
sg33285
I4
sg33286
I40
sg33287
VC0339526
p44910
sg33289
Vautosomal recessive retinitis pigmentosa
p44911
sasa(dp44912
g33277
VIn Western blot assays, the RGR-d protein was detected in retinas of a large proportion ( approximately 53%) of individual donors, including patients with age-related macular degeneration (AMD).
p44913
sg33279
(lp44914
(dp44915
g33284
I28
sg33285
I2
sg33286
I13
sg33295
VP47804
p44916
sg33289
VRGR-d protein
p44917
sasg33281
(lp44918
(dp44919
g33284
I155
sg33285
I3
sg33286
I32
sg33287
VC0242383
p44920
sg33289
Vage-related macular degeneration
p44921
sa(dp44922
g33284
I189
sg33285
I1
sg33286
I3
sg33287
VC0242383
p44923
sg33289
VAMD
p44924
sasa(dp44925
g33277
VMutations in the human gene encoding RGR are associated with retinitis pigmentosa.
p44926
sg33279
(lp44927
(dp44928
g33284
I17
sg33285
I4
sg33286
I23
sg33295
VP47804
p44929
sg33289
Vhuman gene encoding RGR
p44930
sasg33281
(lp44931
(dp44932
g33284
I61
sg33285
I2
sg33286
I20
sg33287
VC0035334
p44933
sg33289
Vretinitis pigmentosa
p44934
sasa(dp44935
g33277
VIn recognition of the clinical significance of AML MRD, the European LeukemiaNet (ELN) recently recommended the establishment of CR-MRDNegative as a separate category of treatment response.
p44936
sg33279
(lp44937
sg33281
(lp44938
(dp44939
g33284
I51
sg33285
I1
sg33286
I3
sg33287
VC1840451
p44940
sg33289
VMRD
p44941
sa(dp44942
g33284
I47
sg33285
I1
sg33286
I3
sg33287
VC0023467
p44943
sg33289
VAML
p44944
sasa(dp44945
g33277
VThe distribution according to the European LeukemiaNet (ELN) risk categorization from 2010 was 20% favorable, 31% intermediate-1, 28% intermediate-2, and 21% adverse.
p44946
sg33279
(lp44947
sg33281
(lp44948
sa(dp44949
g33277
VPatients were stratified using the ELN European Leukemia Net classification.
p44950
sg33279
(lp44951
sg33281
(lp44952
(dp44953
g33284
I48
sg33285
I1
sg33286
I8
sg33287
VC0023418
p44954
sg33289
VLeukemia
p44955
sasa(dp44956
g33277
VoH(E)mT-DCN treatment also attenuated the expression of major ECM components, such as collagen I/III, elastin and fibronectin and induced tumor cell apoptosis, leading to extensive viral dispersion within orthotopic pancreatic tumors and pancreatic cancer patient-derived tumor spheroids.
p44957
sg33279
(lp44958
(dp44959
g33284
I102
sg33285
I1
sg33286
I7
sg33295
VP49918
p44960
sg33289
Velastin
p44961
sasg33281
(lp44962
(dp44963
g33284
I138
sg33285
I1
sg33286
I5
sg33287
VC0027651
p44964
sg33289
Vtumor
p44965
sa(dp44966
g33284
I138
sg33285
I1
sg33286
I5
sg33287
VC0027651
p44967
sg33289
Vtumor
p44968
sa(dp44969
g33284
I238
sg33285
I2
sg33286
I17
sg33287
VC0235974
p44970
sg33289
Vpancreatic cancer
p44971
sa(dp44972
g33284
I216
sg33285
I2
sg33286
I17
sg33287
VC0030297
p44973
sg33289
Vpancreatic tumors
p44974
sasa(dp44975
g33277
VIn this study, we firstly examined neuroprotective effects of pre- or post-treatment with 15 and 30 mg/kg ATX against ischemic damage in the gerbil hippocampal cornus ammonis 1 (CA1) region subjected to 5 min of transient cerebral ischemia using cresyl violet staining, neuronal nuclei immunohistochemistry and Fluoro-J B histofluorescence staining.
p44976
sg33279
(lp44977
sg33281
(lp44978
(dp44979
g33284
I212
sg33285
I3
sg33286
I27
sg33287
VC0917805
p44980
sg33289
Vtransient cerebral ischemia
p44981
sasa(dp44982
g33277
VDysregulation of cysteinyl cathepsins and their inhibitors, cystatins (stefins), were implied in progression of tumorgenesis; nevertheless, their role in sinonasal inverted papilloma (IP) is still unrecognized.
p44983
sg33279
(lp44984
(dp44985
g33284
I17
sg33285
I2
sg33286
I20
sg33295
VP25774
p44986
sg33289
Vcysteinyl cathepsins
p44987
sasg33281
(lp44988
(dp44989
g33284
I184
sg33285
I1
sg33286
I2
sg33287
VC1881254
p44990
sg33289
VIP
p44991
sa(dp44992
g33284
I164
sg33285
I2
sg33286
I18
sg33287
VC1881254
p44993
sg33289
Vinverted papilloma
p44994
sasa(dp44995
g33277
VDespite fundamental limitations applying to these models, such as the distinct immune system and the different metabolism regulating liver homeostasis in rodents when compared to humans, multiple approaches, such as surgery (bile duct ligation), chemical-induced (3,5-diethoxycarbonyl-1,4-dihydrocollidine, DDC, Alfa-naphthylisothiocyanate, ANIT), viral infections (Rhesus rotavirustype A, RRV-A), and genetic manipulation (Mdr2, Cftr, Pkd1, Pkd2, Prkcsh, Sec63, Pkhd1) have been developed.
p44996
sg33279
(lp44997
(dp44998
g33284
I424
sg33285
I1
sg33286
I4
sg33295
VP21439
p44999
sg33289
VMdr2
p45000
sa(dp45001
g33284
I442
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VPkd2
p45002
sa(dp45003
g33284
I463
sg33285
I1
sg33286
I5
sg33295
VP08F94
p45004
sg33289
VPkhd1
p45005
sa(dp45006
g33284
I436
sg33285
I1
sg33286
I4
sg33295
VP98161
p45007
sg33289
VPkd1
p45008
sa(dp45009
g33284
I456
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSec63
p45010
sa(dp45011
g33284
I430
sg33285
I1
sg33286
I4
sg33295
VP13569
p45012
sg33289
VCftr
p45013
sa(dp45014
g33284
I448
sg33285
I1
sg33286
I6
sg33295
VP14314
p45015
sg33289
VPrkcsh
p45016
sasg33281
(lp45017
(dp45018
g33284
I442
sg33285
I1
sg33286
I4
sg33287
VC2751306
p45019
sg33289
VPkd2
p45020
sa(dp45021
g33284
I463
sg33285
I1
sg33286
I5
sg33287
VC0085548
p45022
sg33289
VPkhd1
p45023
sa(dp45024
g33284
I348
sg33285
I2
sg33286
I16
sg33287
VC0042769
p45025
sg33289
Vviral infections
p45026
sa(dp45027
g33284
I436
sg33285
I1
sg33286
I4
sg33287
VC3149841
p45028
sg33289
VPkd1
p45029
sasa(dp45030
g33277
VProgressive familial intrahepatic cholestasis type 3 (PFIC3) is an autosomal recessive disorder of cholestasis of hepatocellular origin, typically seen in infancy or childhood caused by a defect in the ABCB4 located on chromosome 7.
p45031
sg33279
(lp45032
(dp45033
g33284
I54
sg33285
I1
sg33286
I5
sg33295
VP21439
p45034
sg33289
VPFIC3
p45035
sa(dp45036
g33284
I0
sg33285
I6
sg33286
I52
sg33295
VP21439
p45037
sg33289
VProgressive familial intrahepatic cholestasis type 3
p45038
sa(dp45039
g33284
I202
sg33285
I1
sg33286
I5
sg33295
VP21439
p45040
sg33289
VABCB4
p45041
sasg33281
(lp45042
(dp45043
g33284
I54
sg33285
I1
sg33286
I5
sg33287
VC1865643
p45044
sg33289
VPFIC3
p45045
sa(dp45046
g33284
I34
sg33285
I1
sg33286
I11
sg33287
VC0008370
p45047
sg33289
Vcholestasis
p45048
sa(dp45049
g33284
I0
sg33285
I6
sg33286
I52
sg33287
VC1865643
p45050
sg33289
VProgressive familial intrahepatic cholestasis type 3
p45051
sasa(dp45052
g33277
VFor example, mutations in ABCA1 cause Tangier disease associated with defective efflux of cholesterol and phosphatidylcholine from the plasma membrane to the lipid acceptor protein apoA1 (apolipoprotein AI), mutations in ABCA3 cause neonatal surfactant deficiency associated with a loss in secretion of the lipid pulmonary surfactants from lungs of newborns, mutations in ABCA4 cause Stargardt macular degeneration, a retinal degenerative disease linked to the reduced clearance of retinoid compounds from photoreceptor cells, mutations in ABCA12 cause harlequin and lamellar ichthyosis, skin diseases associated with defective lipid trafficking in keratinocytes, and mutations in ABCB4 and ABCG5/ABCG8 are responsible for progressive intrafamilial hepatic disease and sitosterolaemia associated with defective phospholipid and sterol transport respectively.
p45053
sg33279
(lp45054
(dp45055
g33284
I188
sg33285
I2
sg33286
I17
sg33295
VP02656
p45056
sg33289
Vapolipoprotein AI
p45057
sa(dp45058
g33284
I181
sg33285
I1
sg33286
I5
sg33295
VP02647
p45059
sg33289
VapoA1
p45060
sa(dp45061
g33284
I372
sg33285
I1
sg33286
I5
sg33295
VP78363
p45062
sg33289
VABCA4
p45063
sa(dp45064
g33284
I221
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VABCA3
p45065
sa(dp45066
g33284
I540
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VABCA12
p45067
sa(dp45068
g33284
I681
sg33285
I1
sg33286
I5
sg33295
VP21439
p45069
sg33289
VABCB4
p45070
sa(dp45071
g33284
I697
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VABCG8
p45072
sa(dp45073
g33284
I691
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VABCG5
p45074
sasg33281
(lp45075
(dp45076
g33284
I38
sg33285
I2
sg33286
I15
sg33287
VC0039292
p45077
sg33289
VTangier disease
p45078
sa(dp45079
g33284
I588
sg33285
I2
sg33286
I13
sg33287
VC0037274
p45080
sg33289
Vskin diseases
p45081
sa(dp45082
g33284
I426
sg33285
I2
sg33286
I20
sg33287
VC1285162
p45083
sg33289
Vdegenerative disease
p45084
sa(dp45085
g33284
I394
sg33285
I2
sg33286
I20
sg33287
VC0242383
p45086
sg33289
Vmacular degeneration
p45087
sa(dp45088
g33284
I749
sg33285
I2
sg33286
I15
sg33287
VC0023895
p45089
sg33289
Vhepatic disease
p45090
sa(dp45091
g33284
I567
sg33285
I2
sg33286
I19
sg33287
VC0020758
p45092
sg33289
Vlamellar ichthyosis
p45093
sa(dp45094
g33284
I769
sg33285
I1
sg33286
I15
sg33287
VC0342907
p45095
sg33289
Vsitosterolaemia
p45096
sasa(dp45097
g33277
VWe further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.
p45098
sg33279
(lp45099
(dp45100
g33284
I122
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VKLHDC9
p45101
sa(dp45102
g33284
I93
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VIGF2BP2
p45103
sa(dp45104
g33284
I111
sg33285
I1
sg33286
I5
sg33295
VP18564
p45105
sg33289
VITGB6
p45106
sa(dp45107
g33284
I102
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VNECTIN4
p45108
sasg33281
(lp45109
(dp45110
g33284
I35
sg33285
I2
sg33286
I13
sg33287
VC0678222
p45111
sg33289
Vbreast cancer
p45112
sasa(dp45113
g33277
VRT-qPCR and Spearman's correlation analysis were then performed to measure IGF2BP2 mRNA expression in clinical glioma tissues and its correlation with miR-188 expression.
p45114
sg33279
(lp45115
(dp45116
g33284
I75
sg33285
I2
sg33286
I12
sg33295
g11
sg33289
VIGF2BP2 mRNA
p45117
sasg33281
(lp45118
(dp45119
g33284
I111
sg33285
I1
sg33286
I6
sg33287
VC0017638
p45120
sg33289
Vglioma
p45121
sasa(dp45122
g33277
VFinally, the biological roles of IGF2BP2 in glioma cells were assessed.
p45123
sg33279
(lp45124
(dp45125
g33284
I33
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VIGF2BP2
p45126
sasg33281
(lp45127
(dp45128
g33284
I44
sg33285
I1
sg33286
I6
sg33287
VC0017638
p45129
sg33289
Vglioma
p45130
sasa(dp45131
g33277
VThe present study identified IGF2BP2 as a direct target of miR-188 in glioma, and IGF2BP2 under-expression served tumour-suppressive roles in glioma growth and metastasis.
p45132
sg33279
(lp45133
(dp45134
g33284
I29
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VIGF2BP2
p45135
sa(dp45136
g33284
I29
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VIGF2BP2
p45137
sa(dp45138
g33284
I59
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VmiR-188
p45139
sasg33281
(lp45140
(dp45141
g33284
I114
sg33285
I1
sg33286
I6
sg33287
VC0027651
p45142
sg33289
Vtumour
p45143
sa(dp45144
g33284
I70
sg33285
I1
sg33286
I6
sg33287
VC0017638
p45145
sg33289
Vglioma
p45146
sa(dp45147
g33284
I70
sg33285
I1
sg33286
I6
sg33287
VC0017638
p45148
sg33289
Vglioma
p45149
sa(dp45150
g33284
I160
sg33285
I1
sg33286
I10
sg33287
VC0027627
p45151
sg33289
Vmetastasis
p45152
sasa(dp45153
g33277
VThus, miR-188 had a similar role in glioma by inhibiting the action of its downstream target, IGF2BP2.
p45154
sg33279
(lp45155
(dp45156
g33284
I6
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VmiR-188
p45157
sa(dp45158
g33284
I94
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VIGF2BP2
p45159
sasg33281
(lp45160
(dp45161
g33284
I36
sg33285
I1
sg33286
I6
sg33287
VC0017638
p45162
sg33289
Vglioma
p45163
sasa(dp45164
g33277
VBackground: Serum autoantibodies against tumor-associated antigens (TAAs) are detectable in early-stage gastric cancer patients; however, the time point during cancerogenesis when they appear in circulation is still obscure.Methods: In this study, we developed a recombinant antigen microarray and analyzed the prevalence of autoantibodies against 102 TAAs in 829 gastric cancer patients and 929 healthy controls from Caucasian and Asian populations, as well as 100 patients with chronic atrophic gastritis and 775 individuals staged according to different grades of intestinal metaplasia.Results: Six antigens, including CTAG1B/CTAG2, DDX53, IGF2BP2, TP53, and MAGEA3, were predominantly reacting with sera from gastric cancer patients when compared with healthy controls, and the seroreactivity was associated with intestinal-type gastric cancer, but not with patients' Helicobacter pylori status, grade, age, gender, or stage of gastric cancer.
p45165
sg33279
(lp45166
(dp45167
g33284
I643
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VIGF2BP2
p45168
sa(dp45169
g33284
I636
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VDDX53
p45170
sa(dp45171
g33284
I41
sg33285
I2
sg33286
I25
sg33295
VP51572
p45172
sg33289
Vtumor-associated antigens
p45173
sa(dp45174
g33284
I68
sg33285
I1
sg33286
I4
sg33295
VP51572
p45175
sg33289
VTAAs
p45176
sa(dp45177
g33284
I629
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCTAG2
p45178
sa(dp45179
g33284
I68
sg33285
I1
sg33286
I4
sg33295
VP51572
p45180
sg33289
VTAAs
p45181
sa(dp45182
g33284
I622
sg33285
I1
sg33286
I6
sg33295
VP78358
p45183
sg33289
VCTAG1B
p45184
sasg33281
(lp45185
(dp45186
g33284
I104
sg33285
I2
sg33286
I14
sg33287
VC0024623
p45187
sg33289
Vgastric cancer
p45188
sa(dp45189
g33284
I104
sg33285
I2
sg33286
I14
sg33287
VC0024623
p45190
sg33289
Vgastric cancer
p45191
sa(dp45192
g33284
I567
sg33285
I2
sg33286
I21
sg33287
VC0334037
p45193
sg33289
Vintestinal metaplasia
p45194
sa(dp45195
g33284
I41
sg33285
I1
sg33286
I5
sg33287
VC0027651
p45196
sg33289
Vtumor
p45197
sa(dp45198
g33284
I104
sg33285
I2
sg33286
I14
sg33287
VC0024623
p45199
sg33289
Vgastric cancer
p45200
sa(dp45201
g33284
I104
sg33285
I2
sg33286
I14
sg33287
VC0024623
p45202
sg33289
Vgastric cancer
p45203
sa(dp45204
g33284
I104
sg33285
I2
sg33286
I14
sg33287
VC0024623
p45205
sg33289
Vgastric cancer
p45206
sa(dp45207
g33284
I480
sg33285
I3
sg33286
I26
sg33287
VC0017154
p45208
sg33289
Vchronic atrophic gastritis
p45209
sasa(dp45210
g33277
VThe gene encoding the Insulin-like Growth Factor 2 mRNA binding protein 2/IMP2 is amplified and overexpressed in many human cancers, accompanied by a poorer prognosis.
p45211
sg33279
(lp45212
(dp45213
g33284
I74
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VIMP2
p45214
sa(dp45215
g33284
I22
sg33285
I8
sg33286
I51
sg33295
VP01308
p45216
sg33289
VInsulin-like Growth Factor 2 mRNA binding protein 2
p45217
sasg33281
(lp45218
(dp45219
g33284
I124
sg33285
I1
sg33286
I7
sg33287
VC0006826
p45220
sg33289
Vcancers
p45221
sasa(dp45222
g33277
VHerein we show in a diverse array of human cancer cells that IMP2 overexpression stimulates and IMP2 elimination diminishes proliferation by 50-80%.
p45223
sg33279
(lp45224
(dp45225
g33284
I61
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VIMP2
p45226
sa(dp45227
g33284
I61
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VIMP2
p45228
sasg33281
(lp45229
(dp45230
g33284
I43
sg33285
I1
sg33286
I6
sg33287
VC0006826
p45231
sg33289
Vcancer
p45232
sa(dp45233
g33284
I124
sg33285
I1
sg33286
I13
sg33287
VC0334094
p45234
sg33289
Vproliferation
p45235
sasa(dp45236
g33277
VIMP2 stabilization of HMGA1 mRNA plus IMP2 stimulated IGF2 production synergistically drive cancer cell proliferation and account for IMP2's tumor promoting action.
p45237
sg33279
(lp45238
(dp45239
g33284
I0
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VIMP2
p45240
sa(dp45241
g33284
I0
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VIMP2
p45242
sa(dp45243
g33284
I54
sg33285
I1
sg33286
I4
sg33295
VP01344
p45244
sg33289
VIGF2
p45245
sa(dp45246
g33284
I22
sg33285
I2
sg33286
I10
sg33295
VP17096
p45247
sg33289
VHMGA1 mRNA
p45248
sa(dp45249
g33284
I0
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VIMP2
p45250
sasg33281
(lp45251
(dp45252
g33284
I141
sg33285
I1
sg33286
I5
sg33287
VC0027651
p45253
sg33289
Vtumor
p45254
sa(dp45255
g33284
I92
sg33285
I1
sg33286
I6
sg33287
VC0006826
p45256
sg33289
Vcancer
p45257
sa(dp45258
g33284
I104
sg33285
I1
sg33286
I13
sg33287
VC0334094
p45259
sg33289
Vproliferation
p45260
sasa(dp45261
g33277
VIn conclusion, miR-1193 suppressed proliferation and invasion of human breast cancer cells via translational suppression of IGF2BP2.
p45262
sg33279
(lp45263
(dp45264
g33284
I124
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VIGF2BP2
p45265
sasg33281
(lp45266
(dp45267
g33284
I53
sg33285
I1
sg33286
I8
sg33287
VC2699153
p45268
sg33289
Vinvasion
p45269
sa(dp45270
g33284
I109
sg33285
I1
sg33286
I11
sg33287
VC0221103
p45271
sg33289
Vsuppression
p45272
sa(dp45273
g33284
I35
sg33285
I1
sg33286
I13
sg33287
VC0334094
p45274
sg33289
Vproliferation
p45275
sa(dp45276
g33284
I71
sg33285
I2
sg33286
I13
sg33287
VC0678222
p45277
sg33289
Vbreast cancer
p45278
sasa(dp45279
g33277
VNew genes HTRP5, CAPN6, STPK, 14-3-3PKR, and CALM1 and previously known genes including BTK, DDP, GLA, PLP, COL4A5, COL4A6, PAK3, and DCX are localized; candidate loci for other disorders for which genes have not yet been identified, including DFN-2, POF, megalocornea, and syndromic and nonsyndromic mental retardation, are also mapped in the region.
p45280
sg33279
(lp45281
(dp45282
g33284
I134
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VDCX
p45283
sa(dp45284
g33284
I98
sg33285
I1
sg33286
I3
sg33295
VP06280
p45285
sg33289
VGLA
p45286
sa(dp45287
g33284
I251
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VPOF
p45288
sa(dp45289
g33284
I0
sg33285
I3
sg33286
I15
sg33295
VP01701
p45290
sg33289
VNew genes HTRP5
p45291
sa(dp45292
g33284
I17
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCAPN6
p45293
sa(dp45294
g33284
I103
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VPLP
p45295
sa(dp45296
g33284
I24
sg33285
I1
sg33286
I4
sg33295
VP53350
p45297
sg33289
VSTPK
p45298
sa(dp45299
g33284
I88
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VBTK
p45300
sa(dp45301
g33284
I108
sg33285
I1
sg33286
I6
sg33295
VP29400
p45302
sg33289
VCOL4A5
p45303
sa(dp45304
g33284
I93
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VDDP
p45305
sasg33281
(lp45306
(dp45307
g33284
I251
sg33285
I1
sg33286
I3
sg33287
VC0085215
p45308
sg33289
VPOF
p45309
sa(dp45310
g33284
I93
sg33285
I1
sg33286
I3
sg33287
VC0796074
p45311
sg33289
VDDP
p45312
sa(dp45313
g33284
I301
sg33285
I2
sg33286
I18
sg33287
VC0025362
p45314
sg33289
Vmental retardation
p45315
sa(dp45316
g33284
I256
sg33285
I1
sg33286
I12
sg33287
VC0344530
p45317
sg33289
Vmegalocornea
p45318
sasa(dp45319
g33277
VTo study the expression status of Ras-association domain family 7 (RASSF7) and Ras-association domain family 8 (RASSF8) in nodular thyroid goiter (NTG), medullary thyroid carcinoma (MTC), and papillary thyroid carcinoma (PTC) and establish whether a correlation exists between the presence of RASSF7 and RASSF8 proteins and clinicopathological parameters of the disease.
p45320
sg33279
(lp45321
(dp45322
g33284
I67
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VRASSF7
p45323
sa(dp45324
g33284
I67
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VRASSF7
p45325
sa(dp45326
g33284
I304
sg33285
I2
sg33286
I15
sg33295
g11
sg33289
VRASSF8 proteins
p45327
sa(dp45328
g33284
I79
sg33285
I4
sg33286
I31
sg33295
VP01116
p45329
sg33289
VRas-association domain family 8
p45330
sa(dp45331
g33284
I112
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VRASSF8
p45332
sa(dp45333
g33284
I34
sg33285
I4
sg33286
I31
sg33295
VP01116
p45334
sg33289
VRas-association domain family 7
p45335
sasg33281
(lp45336
(dp45337
g33284
I131
sg33285
I2
sg33286
I14
sg33287
VC0018021
p45338
sg33289
Vthyroid goiter
p45339
sa(dp45340
g33284
I192
sg33285
I3
sg33286
I27
sg33287
VC0238463
p45341
sg33289
Vpapillary thyroid carcinoma
p45342
sa(dp45343
g33284
I221
sg33285
I1
sg33286
I3
sg33287
VC0238463
p45344
sg33289
VPTC
p45345
sa(dp45346
g33284
I182
sg33285
I1
sg33286
I3
sg33287
VC1833921
p45347
sg33289
VMTC
p45348
sa(dp45349
g33284
I153
sg33285
I3
sg33286
I27
sg33287
VC0238462
p45350
sg33289
Vmedullary thyroid carcinoma
p45351
sasa(dp45352
g33277
VMoreover, HO-1 diminished ischemia-induced expression of MyoD involved in satellite cell differentiation in HO-1 KO mice.
p45353
sg33279
(lp45354
(dp45355
g33284
I57
sg33285
I1
sg33286
I4
sg33295
VP15172
p45356
sg33289
VMyoD
p45357
sasg33281
(lp45358
(dp45359
g33284
I26
sg33285
I1
sg33286
I8
sg33287
VC0022116
p45360
sg33289
Vischemia
p45361
sasa(dp45362
g33277
VCoprecipitation of CD36, CD9, and alpha6beta1 was also observed on platelets from a patient with Glanzmann thrombasthenia, indicating that alphaII(b)beta3 is not required for the other proteins to associate.
p45363
sg33279
(lp45364
(dp45365
g33284
I25
sg33285
I1
sg33286
I3
sg33295
VP21926
p45366
sg33289
VCD9
p45367
sasg33281
(lp45368
(dp45369
g33284
I97
sg33285
I2
sg33286
I24
sg33287
VC0040015
p45370
sg33289
VGlanzmann thrombasthenia
p45371
sasa(dp45372
g33277
VTo rule out a cross-reactivity of the two polyclonal antibodies with GPIIb/IIIa, we studied PECAM1 and CD9 expression on the platelets from a patient with type I Glanzmann's thrombasthenia whose platelets are devoid of GPIIb/IIIa.
p45373
sg33279
(lp45374
(dp45375
g33284
I69
sg33285
I1
sg33286
I10
sg33295
VP08514
p45376
sg33289
VGPIIb/IIIa
p45377
sa(dp45378
g33284
I69
sg33285
I1
sg33286
I10
sg33295
VP08514
p45379
sg33289
VGPIIb/IIIa
p45380
sa(dp45381
g33284
I103
sg33285
I1
sg33286
I3
sg33295
VP21926
p45382
sg33289
VCD9
p45383
sasg33281
(lp45384
(dp45385
g33284
I162
sg33285
I2
sg33286
I26
sg33287
VC0040015
p45386
sg33289
VGlanzmann's thrombasthenia
p45387
sasa(dp45388
g33277
VIn contrast to TASK-1, which was not differentially expressed in lung cancer vs. normal lung tissue, we found the Na+-coupled nutrient transporters, SLC5A3, SLC5A6, and SLC38A1, transporters for myo-inositol, biotin and glutamine, respectively, to be significantly overexpressed in lung adenocarcinomas.
p45389
sg33279
(lp45390
(dp45391
g33284
I15
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VTASK-1
p45392
sa(dp45393
g33284
I114
sg33285
I3
sg33286
I33
sg33295
g11
sg33289
VNa+-coupled nutrient transporters
p45394
sa(dp45395
g33284
I157
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VSLC5A6
p45396
sa(dp45397
g33284
I169
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VSLC38A1
p45398
sa(dp45399
g33284
I149
sg33285
I1
sg33286
I6
sg33295
VP53794
p45400
sg33289
VSLC5A3
p45401
sasg33281
(lp45402
(dp45403
g33284
I65
sg33285
I2
sg33286
I11
sg33287
VC0684249
p45404
sg33289
Vlung cancer
p45405
sa(dp45406
g33284
I287
sg33285
I1
sg33286
I15
sg33287
VC0001418
p45407
sg33289
Vadenocarcinomas
p45408
sasa(dp45409
g33277
VqPCR analysis showed elevated expression of efflux transporters (P-glycoprotein, multidrug resistant protein 2, breast cancer resistant protein) and influx transporters (folate receptor-Alfa, cationic and neutral amino acid transporter, sodium dependent multivitamin transporter) in a time dependent manner.
p45410
sg33279
(lp45411
(dp45412
g33284
I237
sg33285
I4
sg33286
I41
sg33295
VP19525
p45413
sg33289
Vsodium dependent multivitamin transporter
p45414
sa(dp45415
g33284
I44
sg33285
I2
sg33286
I19
sg33295
g11
sg33289
Vefflux transporters
p45416
sa(dp45417
g33284
I213
sg33285
I3
sg33286
I22
sg33295
g11
sg33289
Vamino acid transporter
p45418
sa(dp45419
g33284
I65
sg33285
I1
sg33286
I14
sg33295
VP08183
p45420
sg33289
VP-glycoprotein
p45421
sasg33281
(lp45422
(dp45423
g33284
I112
sg33285
I2
sg33286
I13
sg33287
VC0678222
p45424
sg33289
Vbreast cancer
p45425
sasa(dp45426
g33277
VImmunoblot analysis further confirmed elevated expression of breast cancer resistant protein and sodium dependent multivitamin transporter.
p45427
sg33279
(lp45428
(dp45429
g33284
I97
sg33285
I4
sg33286
I41
sg33295
VP19525
p45430
sg33289
Vsodium dependent multivitamin transporter
p45431
sasg33281
(lp45432
(dp45433
g33284
I61
sg33285
I2
sg33286
I13
sg33287
VC0678222
p45434
sg33289
Vbreast cancer
p45435
sasa(dp45436
g33277
VAll these studies demonstrated for the first time the functional and molecular expression of sodium dependent multivitamin transporter (SMVT), a specific carrier-mediated system for biotin uptake, in human derived breast cancer (T47D) cells.
p45437
sg33279
(lp45438
(dp45439
g33284
I93
sg33285
I4
sg33286
I41
sg33295
VP19525
p45440
sg33289
Vsodium dependent multivitamin transporter
p45441
sa(dp45442
g33284
I136
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VSMVT
p45443
sasg33281
(lp45444
(dp45445
g33284
I214
sg33285
I2
sg33286
I13
sg33287
VC0678222
p45446
sg33289
Vbreast cancer
p45447
sasa(dp45448
g33277
VThe overall objective of this study was to investigate the differential expression of folate receptor-alpha (FR-Alfa), sodium-dependent multivitamin transporter (SMVT), and amino acid transporter [B ((0, +))] in retinoblastoma (Y-79) and retinal pigment epithelial (ARPE-19) cells.
p45449
sg33279
(lp45450
(dp45451
g33284
I86
sg33285
I2
sg33286
I21
sg33295
VP15328
p45452
sg33289
Vfolate receptor-alpha
p45453
sa(dp45454
g33284
I162
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VSMVT
p45455
sa(dp45456
g33284
I119
sg33285
I3
sg33286
I41
sg33295
g11
sg33289
Vsodium-dependent multivitamin transporter
p45457
sasg33281
(lp45458
(dp45459
g33284
I212
sg33285
I1
sg33286
I14
sg33287
VC0035335
p45460
sg33289
Vretinoblastoma
p45461
sasa(dp45462
g33277
VThis work demonstrated for the first time the higher expression and affinity of FR-Alfa, SMVT, and B ((0, +)) mRNA levels in retinoblastoma (Y-79) cells compared with retinal pigment epithelial (ARPE-19) cells.
p45463
sg33279
(lp45464
(dp45465
g33284
I89
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VSMVT
p45466
sasg33281
(lp45467
(dp45468
g33284
I125
sg33285
I1
sg33286
I14
sg33287
VC0035335
p45469
sg33289
Vretinoblastoma
p45470
sasa(dp45471
g33277
VTo synthesize a novel camptothecin-poly(ethylene glycol) conjugate (CPT-PEG) which includes biotin as a moiety to enhance nonspecific and/or targeted uptake via the sodium-dependent multivitamin transporter (SMVT) and to evaluate its anticancer activity and apoptosis induction.
p45472
sg33279
(lp45473
(dp45474
g33284
I165
sg33285
I3
sg33286
I41
sg33295
g11
sg33289
Vsodium-dependent multivitamin transporter
p45475
sa(dp45476
g33284
I208
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VSMVT
p45477
sasg33281
(lp45478
sa(dp45479
g33277
VThis suggests that the targeting approach utilizing transporters such as SMVT may substantially improve the delivery of CPT and its anticancer activity by enhancing cellular permeability and possibly retention of CPT.
p45480
sg33279
(lp45481
sg33281
(lp45482
sa(dp45483
g33277
VWe have cloned the human Na+-dependent multivitamin transporter (SMVT), which transports the water-soluble vitamins pantothenate, biotin, and lipoate, from a placental choriocarcinoma cell line (JAR).
p45484
sg33279
(lp45485
(dp45486
g33284
I19
sg33285
I4
sg33286
I44
sg33295
g11
sg33289
Vhuman Na+-dependent multivitamin transporter
p45487
sa(dp45488
g33284
I65
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VSMVT
p45489
sasg33281
(lp45490
(dp45491
g33284
I158
sg33285
I2
sg33286
I25
sg33287
VC0855173
p45492
sg33289
Vplacental choriocarcinoma
p45493
sasa(dp45494
g33277
VWhile the association between IL-16 plasma levels and tumor progression has been reported for many types of cancer, the mechanism for IL-16 involvement has been partially elucidated for three of the cancer types, cutaneous T cell lymphoma (CTCL), multiple myeloma (MM), and breast cancer.
p45495
sg33279
(lp45496
(dp45497
g33284
I30
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VIL-16
p45498
sa(dp45499
g33284
I30
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VIL-16
p45500
sasg33281
(lp45501
(dp45502
g33284
I213
sg33285
I4
sg33286
I25
sg33287
VC0079773
p45503
sg33289
Vcutaneous T cell lymphoma
p45504
sa(dp45505
g33284
I108
sg33285
I1
sg33286
I6
sg33287
VC0006826
p45506
sg33289
Vcancer
p45507
sa(dp45508
g33284
I108
sg33285
I1
sg33286
I6
sg33287
VC0006826
p45509
sg33289
Vcancer
p45510
sa(dp45511
g33284
I54
sg33285
I2
sg33286
I17
sg33287
VC0178874
p45512
sg33289
Vtumor progression
p45513
sa(dp45514
g33284
I240
sg33285
I1
sg33286
I4
sg33287
VC0079773
p45515
sg33289
VCTCL
p45516
sa(dp45517
g33284
I274
sg33285
I2
sg33286
I13
sg33287
VC0678222
p45518
sg33289
Vbreast cancer
p45519
sa(dp45520
g33284
I247
sg33285
I2
sg33286
I16
sg33287
VC0026764
p45521
sg33289
Vmultiple myeloma
p45522
sasa(dp45523
g33277
VNuclear translocation of pro-interleukin-16 was not observed in late stages of Sezary syndrome, indicating this loss is not reversible.
p45524
sg33279
(lp45525
(dp45526
g33284
I25
sg33285
I1
sg33286
I18
sg33295
g11
sg33289
Vpro-interleukin-16
p45527
sasg33281
(lp45528
(dp45529
g33284
I8
sg33285
I1
sg33286
I13
sg33287
VC0040715
p45530
sg33289
Vtranslocation
p45531
sa(dp45532
g33284
I79
sg33285
I2
sg33286
I15
sg33287
VC0036920
p45533
sg33289
VSezary syndrome
p45534
sasa(dp45535
g33277
VWe propose that it is feasible to use plasma levels of IL-16 as a potential diagnostic marker of Sezary syndrome and to use loss of intracellular IL-16 as a prognostic indicator of disease severity and stage.
p45536
sg33279
(lp45537
(dp45538
g33284
I55
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VIL-16
p45539
sa(dp45540
g33284
I55
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VIL-16
p45541
sasg33281
(lp45542
(dp45543
g33284
I97
sg33285
I2
sg33286
I15
sg33287
VC0036920
p45544
sg33289
VSezary syndrome
p45545
sasa(dp45546
g33277
VBy reverse transcription-polymerase chain reaction, interleukin-16 mRNA was detected in 18 of 18 mycosis fungoides lesions investigated.
p45547
sg33279
(lp45548
(dp45549
g33284
I52
sg33285
I2
sg33286
I19
sg33295
g11
sg33289
Vinterleukin-16 mRNA
p45550
sasg33281
(lp45551
(dp45552
g33284
I97
sg33285
I2
sg33286
I17
sg33287
VC0026948
p45553
sg33289
Vmycosis fungoides
p45554
sasa(dp45555
g33277
VGiven the biologic properties of interleukin-16 and the parallel activation of the interleukin-2/CD25 pathway, interleukin-16 might be involved in the recruitment and stimulation of CD4+ lymphocytes in mycosis fungoides lesions and therefore contribute to the perpetuation of the associated cutaneous inflammation.
p45556
sg33279
(lp45557
(dp45558
g33284
I182
sg33285
I1
sg33286
I4
sg33295
VP01730
p45559
sg33289
VCD4+
p45560
sa(dp45561
g33284
I83
sg33285
I1
sg33286
I13
sg33295
VP60568
p45562
sg33289
Vinterleukin-2
p45563
sa(dp45564
g33284
I33
sg33285
I1
sg33286
I14
sg33295
g11
sg33289
Vinterleukin-16
p45565
sa(dp45566
g33284
I33
sg33285
I1
sg33286
I14
sg33295
g11
sg33289
Vinterleukin-16
p45567
sa(dp45568
g33284
I97
sg33285
I1
sg33286
I4
sg33295
VP01589
p45569
sg33289
VCD25
p45570
sasg33281
(lp45571
(dp45572
g33284
I202
sg33285
I2
sg33286
I17
sg33287
VC0026948
p45573
sg33289
Vmycosis fungoides
p45574
sa(dp45575
g33284
I151
sg33285
I1
sg33286
I11
sg33287
VC0271510
p45576
sg33289
Vrecruitment
p45577
sa(dp45578
g33284
I301
sg33285
I1
sg33286
I12
sg33287
VC0021368
p45579
sg33289
Vinflammation
p45580
sasa(dp45581
g33277
VThree additional patients with possible parathyroid adenomas at 11C-choline PET/CT were ultimately found to have thyroid lesions on the basis of tissue diagnosis; however, none of these patients had abnormal calcium or parathyroid hormone levels.
p45582
sg33279
(lp45583
(dp45584
g33284
I219
sg33285
I2
sg33286
I19
sg33295
VP01270
p45585
sg33289
Vparathyroid hormone
p45586
sasg33281
(lp45587
(dp45588
g33284
I40
sg33285
I2
sg33286
I20
sg33287
VC0262587
p45589
sg33289
Vparathyroid adenomas
p45590
sasa(dp45591
g33277
VPatients with primary hyperparathyroidism generally have a single parathyroid adenoma that causes excessive excretion of parathyroid hormone.
p45592
sg33279
(lp45593
(dp45594
g33284
I121
sg33285
I2
sg33286
I19
sg33295
VP01270
p45595
sg33289
Vparathyroid hormone
p45596
sasg33281
(lp45597
(dp45598
g33284
I66
sg33285
I2
sg33286
I19
sg33287
VC0262587
p45599
sg33289
Vparathyroid adenoma
p45600
sa(dp45601
g33284
I14
sg33285
I2
sg33286
I27
sg33287
VC0221002
p45602
sg33289
Vprimary hyperparathyroidism
p45603
sasa(dp45604
g33277
VAlthough double adenomas are not yet widely acknowledged, presurgical imaging and nuclear scans can help to localize multiple lesions, and intraoperative parathyroid hormone assays can confirm the diagnosis and cure.
p45605
sg33279
(lp45606
(dp45607
g33284
I154
sg33285
I2
sg33286
I19
sg33295
VP01270
p45608
sg33289
Vparathyroid hormone
p45609
sasg33281
(lp45610
(dp45611
g33284
I16
sg33285
I1
sg33286
I8
sg33287
VC0001430
p45612
sg33289
Vadenomas
p45613
sasa(dp45614
g33277
VFinally, MMGP analysis revealed a positive correlation between the transcript levels of B7-H4 and proliferation-related genes including MKI67, CCNA1, and Myc in several patients with multiple myeloma.
p45615
sg33279
(lp45616
(dp45617
g33284
I154
sg33285
I1
sg33286
I3
sg33295
VP12524
p45618
sg33289
VMyc
p45619
sa(dp45620
g33284
I143
sg33285
I1
sg33286
I5
sg33295
VP78396
p45621
sg33289
VCCNA1
p45622
sa(dp45623
g33284
I88
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VB7-H4
p45624
sa(dp45625
g33284
I136
sg33285
I1
sg33286
I5
sg33295
VP46013
p45626
sg33289
VMKI67
p45627
sa(dp45628
g33284
I98
sg33285
I2
sg33286
I27
sg33295
VP01893
p45629
sg33289
Vproliferation-related genes
p45630
sasg33281
(lp45631
(dp45632
g33284
I98
sg33285
I1
sg33286
I13
sg33287
VC0334094
p45633
sg33289
Vproliferation
p45634
sa(dp45635
g33284
I183
sg33285
I2
sg33286
I16
sg33287
VC0026764
p45636
sg33289
Vmultiple myeloma
p45637
sasa(dp45638
g33277
VThe purpose of this study was to evaluate the expression of cyclin A1 mRNA in patients with myelodysplastic syndrome (MDS) and its clinical significance.
p45639
sg33279
(lp45640
(dp45641
g33284
I60
sg33285
I3
sg33286
I14
sg33295
VP78396
p45642
sg33289
Vcyclin A1 mRNA
p45643
sasg33281
(lp45644
(dp45645
g33284
I92
sg33285
I2
sg33286
I24
sg33287
VC3463824
p45646
sg33289
Vmyelodysplastic syndrome
p45647
sa(dp45648
g33284
I118
sg33285
I1
sg33286
I3
sg33287
VC0265219
p45649
sg33289
VMDS
p45650
sasa(dp45651
g33277
VCyclin A1 mRNA was detectable in 11 of 11 patients with acute myeloid leukemia, three of three patients with acute biphenotypic leukemia, eight of eight patients with myelodysplastic syndrome, 59 of 69 patients with chronic myelogenous leukemia (CML) at diagnosis, 13 of 15 patients with CML in blastic transformation, 10 of 18 patients with chronic lymphocytic leukemia, two of nine patients with essential thrombocythemia, and only two of 10 patients with acute lymphoblastic leukemia (ALL) with both cyclin A1 RT-PCR positive ALL leukemias being undifferentiated relapses.
p45652
sg33279
(lp45653
(dp45654
g33284
I0
sg33285
I3
sg33286
I14
sg33295
VP78396
p45655
sg33289
VCyclin A1 mRNA
p45656
sa(dp45657
g33284
I503
sg33285
I3
sg33286
I12
sg33295
VP78396
p45658
sg33289
Vcyclin A1 RT
p45659
sasg33281
(lp45660
(dp45661
g33284
I488
sg33285
I1
sg33286
I3
sg33287
VC1961102
p45662
sg33289
VALL
p45663
sa(dp45664
g33284
I246
sg33285
I1
sg33286
I3
sg33287
VC0023473
p45665
sg33289
VCML
p45666
sa(dp45667
g33284
I109
sg33285
I3
sg33286
I27
sg33287
VC0023464
p45668
sg33289
Vacute biphenotypic leukemia
p45669
sa(dp45670
g33284
I246
sg33285
I1
sg33286
I3
sg33287
VC0023473
p45671
sg33289
VCML
p45672
sa(dp45673
g33284
I342
sg33285
I3
sg33286
I28
sg33287
VC0023434
p45674
sg33289
Vchronic lymphocytic leukemia
p45675
sa(dp45676
g33284
I56
sg33285
I3
sg33286
I22
sg33287
VC0023467
p45677
sg33289
Vacute myeloid leukemia
p45678
sa(dp45679
g33284
I167
sg33285
I2
sg33286
I24
sg33287
VC0033027
p45680
sg33289
Vmyelodysplastic syndrome
p45681
sa(dp45682
g33284
I398
sg33285
I2
sg33286
I25
sg33287
VC0040028
p45683
sg33289
Vessential thrombocythemia
p45684
sa(dp45685
g33284
I303
sg33285
I1
sg33286
I14
sg33287
VC1510411
p45686
sg33289
Vtransformation
p45687
sa(dp45688
g33284
I216
sg33285
I3
sg33286
I28
sg33287
VC0023473
p45689
sg33289
Vchronic myelogenous leukemia
p45690
sa(dp45691
g33284
I458
sg33285
I3
sg33286
I28
sg33287
VC1961102
p45692
sg33289
Vacute lymphoblastic leukemia
p45693
sa(dp45694
g33284
I488
sg33285
I1
sg33286
I3
sg33287
VC1961102
p45695
sg33289
VALL
p45696
sa(dp45697
g33284
I533
sg33285
I1
sg33286
I9
sg33287
VC0023418
p45698
sg33289
Vleukemias
p45699
sasa(dp45700
g33277
VMice with ANP showed increased apoptosis of pancreatic acinar cells, pancreatic myeloperoxidase activity, serum lactate dehydrogenase activity, amylase, tumor necrosis factor-Alfa (TNF-Alfa), interleukin-6 (IL-6) levels as well as decreased serum IL-10 level, pancreatic expression of heat shock factor 1 (HSF1), sirtuin 1 (SIRT1) and p53, but the ratio of acetylated HSF1 and p53 was markedly increased.
p45701
sg33279
(lp45702
(dp45703
g33284
I80
sg33285
I1
sg33286
I15
sg33295
VP05164
p45704
sg33289
Vmyeloperoxidase
p45705
sa(dp45706
g33284
I324
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSIRT1
p45707
sa(dp45708
g33284
I335
sg33285
I1
sg33286
I3
sg33295
VP42771
p45709
sg33289
Vp53
p45710
sa(dp45711
g33284
I144
sg33285
I1
sg33286
I7
sg33295
VP04746
p45712
sg33289
Vamylase
p45713
sa(dp45714
g33284
I313
sg33285
I2
sg33286
I9
sg33295
g11
sg33289
Vsirtuin 1
p45715
sa(dp45716
g33284
I306
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VHSF1
p45717
sa(dp45718
g33284
I153
sg33285
I3
sg33286
I26
sg33295
VP01375
p45719
sg33289
Vtumor necrosis factor-Alfa
p45720
sa(dp45721
g33284
I285
sg33285
I4
sg33286
I19
sg33295
g11
sg33289
Vheat shock factor 1
p45722
sa(dp45723
g33284
I192
sg33285
I1
sg33286
I13
sg33295
VP05231
p45724
sg33289
Vinterleukin-6
p45725
sa(dp45726
g33284
I335
sg33285
I1
sg33286
I3
sg33295
VP42771
p45727
sg33289
Vp53
p45728
sa(dp45729
g33284
I306
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VHSF1
p45730
sa(dp45731
g33284
I106
sg33285
I3
sg33286
I27
sg33295
VP49366
p45732
sg33289
Vserum lactate dehydrogenase
p45733
sa(dp45734
g33284
I241
sg33285
I2
sg33286
I11
sg33295
g11
sg33289
Vserum IL-10
p45735
sa(dp45736
g33284
I10
sg33285
I1
sg33286
I3
sg33295
VP16066
p45737
sg33289
VANP
p45738
sa(dp45739
g33284
I181
sg33285
I1
sg33286
I8
sg33295
VP01375
p45740
sg33289
VTNF-Alfa
p45741
sa(dp45742
g33284
I207
sg33285
I1
sg33286
I4
sg33295
VP05231
p45743
sg33289
VIL-6
p45744
sasg33281
(lp45745
(dp45746
g33284
I153
sg33285
I2
sg33286
I14
sg33287
VC0333516
p45747
sg33289
Vtumor necrosis
p45748
sasa(dp45749
g33277
VThese data suggest that resveratrol protects against L-arginine-induced ANP, which may be related to the enhancement of SIRT1-mediated deacetylation of p53 and HSF1.
p45750
sg33279
(lp45751
(dp45752
g33284
I72
sg33285
I1
sg33286
I3
sg33295
VP16066
p45753
sg33289
VANP
p45754
sa(dp45755
g33284
I160
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VHSF1
p45756
sa(dp45757
g33284
I120
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSIRT1
p45758
sa(dp45759
g33284
I152
sg33285
I1
sg33286
I3
sg33295
VP42771
p45760
sg33289
Vp53
p45761
sasg33281
(lp45762
sa(dp45763
g33277
VThe aim of this study was to explore the role of the p38 mitogen-activated protein kinase (p38MAPK)/p53 signaling pathway in injury to the intestinal mucosal barrier during severe acute pancreatitis (SAP).
p45764
sg33279
(lp45765
(dp45766
g33284
I91
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
Vp38MAPK
p45767
sa(dp45768
g33284
I53
sg33285
I4
sg33286
I36
sg33295
g11
sg33289
Vp38 mitogen-activated protein kinase
p45769
sa(dp45770
g33284
I100
sg33285
I1
sg33286
I3
sg33295
VP42771
p45771
sg33289
Vp53
p45772
sasg33281
(lp45773
(dp45774
g33284
I180
sg33285
I2
sg33286
I18
sg33287
VC0001339
p45775
sg33289
Vacute pancreatitis
p45776
sasa(dp45777
g33277
VFurthermore, compared with homozygous missense mutations, compound heterozygous mutations appeared to have a more severe effect on phenotype, causing more severe growth retardation in ORC4 and more frequently pulmonary emphysema in CDT1.
p45778
sg33279
(lp45779
(dp45780
g33284
I232
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCDT1
p45781
sasg33281
(lp45782
(dp45783
g33284
I162
sg33285
I2
sg33286
I18
sg33287
VC0151686
p45784
sg33289
Vgrowth retardation
p45785
sa(dp45786
g33284
I209
sg33285
I2
sg33286
I19
sg33287
VC0034067
p45787
sg33289
Vpulmonary emphysema
p45788
sasa(dp45789
g33277
VWe recently identified an RBP HNRNPL as a novel prostate cancer dependency via regulation of RNA splicing, suggesting the potential to target RBP or RBP-RNA interaction to treat cancer.
p45790
sg33279
(lp45791
(dp45792
g33284
I26
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VRBP
p45793
sa(dp45794
g33284
I26
sg33285
I2
sg33286
I10
sg33295
g11
sg33289
VRBP HNRNPL
p45795
sa(dp45796
g33284
I149
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VRBP-RNA
p45797
sasg33281
(lp45798
(dp45799
g33284
I57
sg33285
I1
sg33286
I6
sg33287
VC0006826
p45800
sg33289
Vcancer
p45801
sa(dp45802
g33284
I48
sg33285
I2
sg33286
I15
sg33287
VC0600139
p45803
sg33289
Vprostate cancer
p45804
sasa(dp45805
g33277
VHNRNPL directly regulates the alternative splicing of a set of RNAs, including those encoding the androgen receptor, the key lineage-specific prostate cancer oncogene.
p45806
sg33279
(lp45807
(dp45808
g33284
I0
sg33285
I1
sg33286
I6
sg33295
VP14866
p45809
sg33289
VHNRNPL
p45810
sa(dp45811
g33284
I98
sg33285
I2
sg33286
I17
sg33295
VP10275
p45812
sg33289
Vandrogen receptor
p45813
sasg33281
(lp45814
(dp45815
g33284
I142
sg33285
I2
sg33286
I15
sg33287
VC0600139
p45816
sg33289
Vprostate cancer
p45817
sasa(dp45818
g33277
VCollectively, our data reveal HNRNPL and its RNA clients as players in prostate cancer growth and potential therapeutic targets.
p45819
sg33279
(lp45820
sg33281
(lp45821
(dp45822
g33284
I71
sg33285
I2
sg33286
I15
sg33287
VC0600139
p45823
sg33289
Vprostate cancer
p45824
sasa(dp45825
g33277
VHeterogeneous nuclear ribonucleoprotein L (hnRNP-L) is a promoter of various kinds of cancers, but its actions in bladder cancer (BC) are unclear.
p45826
sg33279
(lp45827
(dp45828
g33284
I0
sg33285
I4
sg33286
I41
sg33295
VP14866
p45829
sg33289
VHeterogeneous nuclear ribonucleoprotein L
p45830
sa(dp45831
g33284
I43
sg33285
I1
sg33286
I7
sg33295
VP14866
p45832
sg33289
VhnRNP-L
p45833
sasg33281
(lp45834
(dp45835
g33284
I86
sg33285
I1
sg33286
I7
sg33287
VC0006826
p45836
sg33289
Vcancers
p45837
sa(dp45838
g33284
I114
sg33285
I2
sg33286
I14
sg33287
VC0699885
p45839
sg33289
Vbladder cancer
p45840
sa(dp45841
g33284
I130
sg33285
I1
sg33286
I2
sg33287
VC0699885
p45842
sg33289
VBC
p45843
sasa(dp45844
g33277
VIn this study, we examined the role of HnRNP-L in prostate cancer (Pca).
p45845
sg33279
(lp45846
(dp45847
g33284
I39
sg33285
I4
sg33286
I26
sg33295
VP14866
p45848
sg33289
VHnRNP-L in prostate cancer
p45849
sa(dp45850
g33284
I67
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VPca
p45851
sasg33281
(lp45852
(dp45853
g33284
I50
sg33285
I2
sg33286
I15
sg33287
VC0600139
p45854
sg33289
Vprostate cancer
p45855
sa(dp45856
g33284
I67
sg33285
I1
sg33286
I3
sg33287
VC0268398
p45857
sg33289
VPca
p45858
sasa(dp45859
g33277
VThese results suggest a rationale for dose reduction of doxorubicin and docetaxel in prostate cancer therapy, since the doses needed to achieve 50% cell death may be decreased by approximately 4- to 15-fold or 3- to 8-fold, respectively, after a pre-treatment with ciprofloxacin.
p45860
sg33279
(lp45861
sg33281
(lp45862
(dp45863
g33284
I85
sg33285
I2
sg33286
I15
sg33287
VC0600139
p45864
sg33289
Vprostate cancer
p45865
sasa(dp45866
g33277
VThis study investigated the presence of CA I and II autoantibodies in patients with iron deficiency anemia (IDA).
p45867
sg33279
(lp45868
(dp45869
g33284
I40
sg33285
I5
sg33286
I26
sg33295
VP00915
p45870
sg33289
VCA I and II autoantibodies
p45871
sasg33281
(lp45872
(dp45873
g33284
I108
sg33285
I1
sg33286
I3
sg33287
VC0162316
p45874
sg33289
VIDA
p45875
sa(dp45876
g33284
I84
sg33285
I3
sg33286
I22
sg33287
VC0162316
p45877
sg33289
Viron deficiency anemia
p45878
sasa(dp45879
g33277
VCompared with controls, CAIII concentration was lower in iron deficiency anemia (P&lt;0.01), but higher in beta-thalassemia anemia (P&lt;0.001).
p45880
sg33279
(lp45881
(dp45882
g33284
I24
sg33285
I1
sg33286
I5
sg33295
VP07451
p45883
sg33289
VCAIII
p45884
sasg33281
(lp45885
(dp45886
g33284
I73
sg33285
I1
sg33286
I6
sg33287
VC0002871
p45887
sg33289
Vanemia
p45888
sa(dp45889
g33284
I107
sg33285
I1
sg33286
I16
sg33287
VC0005283
p45890
sg33289
Vbeta-thalassemia
p45891
sa(dp45892
g33284
I57
sg33285
I3
sg33286
I22
sg33287
VC0162316
p45893
sg33289
Viron deficiency anemia
p45894
sasa(dp45895
g33277
VThe levels of erythrocyte carbonic anhydrase isozymes (CA-B and CA-C) were determined by a quantitative immunochemical technique in order to elucidate their clinical significances in patients with iron deficiency anemia.
p45896
sg33279
(lp45897
(dp45898
g33284
I14
sg33285
I4
sg33286
I39
sg33295
VP35218
p45899
sg33289
Verythrocyte carbonic anhydrase isozymes
p45900
sasg33281
(lp45901
(dp45902
g33284
I197
sg33285
I3
sg33286
I22
sg33287
VC0162316
p45903
sg33289
Viron deficiency anemia
p45904
sasa(dp45905
g33277
V1 The levels of erythrocyte CA-B per gram hemoglobin, CA-B per ml erythrocyte and CA-C per gram hemoglobin all increased but CA-C per ml erythrocyte did not increased in iron deficiency anemia.
p45906
sg33279
(lp45907
(dp45908
g33284
I42
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
Vhemoglobin
p45909
sa(dp45910
g33284
I37
sg33285
I2
sg33286
I15
sg33295
g11
sg33289
Vgram hemoglobin
p45911
sasg33281
(lp45912
(dp45913
g33284
I170
sg33285
I3
sg33286
I22
sg33287
VC0162316
p45914
sg33289
Viron deficiency anemia
p45915
sasa(dp45916
g33277
VThe content of CA-B synthesized in lysates was much higher than that of CA-C. 6 In iron deficiency anemia, the increase of erythrocyte CA is speculated to be compensatory mechanism, which brought about the transportation of CO2 and right shifts of O2 dissociation curve.
p45917
sg33279
(lp45918
sg33281
(lp45919
(dp45920
g33284
I83
sg33285
I3
sg33286
I22
sg33287
VC0162316
p45921
sg33289
Viron deficiency anemia
p45922
sa(dp45923
g33284
I251
sg33285
I1
sg33286
I12
sg33287
VC0086168
p45924
sg33289
Vdissociation
p45925
sasa(dp45926
g33277
VInhibition of inducible T-cell kinase (ITK), a nonreceptor tyrosine kinase, may represent a novel treatment for allergic asthma.
p45927
sg33279
(lp45928
(dp45929
g33284
I39
sg33285
I1
sg33286
I3
sg33295
VP19823
p45930
sg33289
VITK
p45931
sa(dp45932
g33284
I14
sg33285
I3
sg33286
I23
sg33295
VP19823
p45933
sg33289
Vinducible T-cell kinase
p45934
sasg33281
(lp45935
(dp45936
g33284
I112
sg33285
I2
sg33286
I15
sg33287
VC0155877
p45937
sg33289
Vallergic asthma
p45938
sasa(dp45939
g33277
VHere we show that Itk, a mediator of T cell receptor signalling required for Th2 immune responses and the development of asthma, is a positive regulator of Th9 differentiation.
p45940
sg33279
(lp45941
(dp45942
g33284
I37
sg33285
I3
sg33286
I15
sg33295
g11
sg33289
VT cell receptor
p45943
sa(dp45944
g33284
I18
sg33285
I1
sg33286
I3
sg33295
VP19823
p45945
sg33289
VItk
p45946
sasg33281
(lp45947
(dp45948
g33284
I121
sg33285
I1
sg33286
I6
sg33287
VC0004096
p45949
sg33289
Vasthma
p45950
sasa(dp45951
g33277
VCompared to wild-type mice, ITK knockout mice are resistant to asthma and exhibit reduced lung inflammation and decreased amounts of TH2-type cytokines in the bronchoalveolar lavage fluid.
p45952
sg33279
(lp45953
sg33281
(lp45954
(dp45955
g33284
I90
sg33285
I2
sg33286
I17
sg33287
VC0032285
p45956
sg33289
Vlung inflammation
p45957
sa(dp45958
g33284
I63
sg33285
I1
sg33286
I6
sg33287
VC0004096
p45959
sg33289
Vasthma
p45960
sasa(dp45961
g33277
VUnexpectedly, inhibition of the kinase activity of ITK during or after antigen rechallenge in an ovalbumin-induced mouse model of asthma failed to reduce airway hyperresponsiveness and inflammation.
p45962
sg33279
(lp45963
(dp45964
g33284
I51
sg33285
I1
sg33286
I3
sg33295
VP19823
p45965
sg33289
VITK
p45966
sasg33281
(lp45967
(dp45968
g33284
I130
sg33285
I1
sg33286
I6
sg33287
VC0004096
p45969
sg33289
Vasthma
p45970
sa(dp45971
g33284
I185
sg33285
I1
sg33286
I12
sg33287
VC0021368
p45972
sg33289
Vinflammation
p45973
sasa(dp45974
g33277
VThus, our studies predict that inhibition of the kinase activity of ITK may not be therapeutic in patients with asthma.
p45975
sg33279
(lp45976
(dp45977
g33284
I68
sg33285
I1
sg33286
I3
sg33295
VP19823
p45978
sg33289
VITK
p45979
sasg33281
(lp45980
(dp45981
g33284
I112
sg33285
I1
sg33286
I6
sg33287
VC0004096
p45982
sg33289
Vasthma
p45983
sasa(dp45984
g33277
VFeNO levels were significantly elevated in the asthma compared to the control group (26 +/- 18 versus 11 +/- 4 ppb; p &lt; 0.05), and trended higher than levels in the tetraplegia group (15 +/- 6; p = 0.08).
p45985
sg33279
(lp45986
sg33281
(lp45987
(dp45988
g33284
I47
sg33285
I1
sg33286
I6
sg33287
VC0004096
p45989
sg33289
Vasthma
p45990
sa(dp45991
g33284
I111
sg33285
I1
sg33286
I3
sg33287
VC1266144
p45992
sg33289
Vppb
p45993
sa(dp45994
g33284
I168
sg33285
I1
sg33286
I11
sg33287
VC0034372
p45995
sg33289
Vtetraplegia
p45996
sasa(dp45997
g33277
VThe medicinal chemistry community has directed considerable efforts toward the discovery of selective inhibitors of interleukin-2 inducible T-cell kinase (ITK), given its role in T-cell signaling downstream of the T-cell receptor (TCR) and the implications of this target for inflammatory disorders such as asthma.
p45998
sg33279
(lp45999
(dp46000
g33284
I130
sg33285
I3
sg33286
I23
sg33295
VP19823
p46001
sg33289
Vinducible T-cell kinase
p46002
sa(dp46003
g33284
I214
sg33285
I2
sg33286
I15
sg33295
g11
sg33289
VT-cell receptor
p46004
sa(dp46005
g33284
I116
sg33285
I1
sg33286
I13
sg33295
VP60568
p46006
sg33289
Vinterleukin-2
p46007
sa(dp46008
g33284
I231
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VTCR
p46009
sa(dp46010
g33284
I155
sg33285
I1
sg33286
I3
sg33295
VP19823
p46011
sg33289
VITK
p46012
sasg33281
(lp46013
(dp46014
g33284
I307
sg33285
I1
sg33286
I6
sg33287
VC0004096
p46015
sg33289
Vasthma
p46016
sasa(dp46017
g33277
VThe caspase-3 apoptotic index was a strong risk factor for subsequent gestational trophoblastic neoplasia development.
p46018
sg33279
(lp46019
(dp46020
g33284
I4
sg33285
I1
sg33286
I9
sg33295
VP42574
p46021
sg33289
Vcaspase-3
p46022
sasg33281
(lp46023
(dp46024
g33284
I70
sg33285
I3
sg33286
I35
sg33287
VC1135868
p46025
sg33289
Vgestational trophoblastic neoplasia
p46026
sasa(dp46027
g33277
VThe two genes were CXCL6 (chemokine (C-X-C motif) ligand 6) and BBS5 (Bardet-Biedl syndrome 5).
p46028
sg33279
(lp46029
(dp46030
g33284
I19
sg33285
I1
sg33286
I5
sg33295
VP80162
p46031
sg33289
VCXCL6
p46032
sa(dp46033
g33284
I64
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VBBS5
p46034
sa(dp46035
g33284
I70
sg33285
I3
sg33286
I23
sg33295
g11
sg33289
VBardet-Biedl syndrome 5
p46036
sa(dp46037
g33284
I36
sg33285
I4
sg33286
I22
sg33295
VP80162
p46038
sg33289
V(C-X-C motif) ligand 6
p46039
sasg33281
(lp46040
(dp46041
g33284
I70
sg33285
I2
sg33286
I21
sg33287
VC0752166
p46042
sg33289
VBardet-Biedl syndrome
p46043
sasa(dp46044
g33277
VCompared with patients with a false-positive penicillin allergy result (confirmed by negative penicillin skin testing result), patients reporting a true penicillin allergy confirmed by positive penicillin skin test results tended to be more frequently men (61.5% versus 44.5%; Delta 17.0%; 95% CI -13.5% to 42%), black (69.2% versus 44.5%; Delta 24.7%; 95% CI -6.9% to 46.8%), and have no family history of drug allergy (7.7% versus 17.5%; Delta9.8%; 95% CI -20.9% to 20.4%), but self-reported other drug allergies more frequently (61.5% versus 38.7%; Delta 22.9%; 95% CI -7.7% to 47.5%).
p46045
sg33279
(lp46046
sg33281
(lp46047
(dp46048
g33284
I407
sg33285
I2
sg33286
I12
sg33287
VC0013182
p46049
sg33289
Vdrug allergy
p46050
sa(dp46051
g33284
I45
sg33285
I2
sg33286
I18
sg33287
VC0030824
p46052
sg33289
Vpenicillin allergy
p46053
sa(dp46054
g33284
I45
sg33285
I2
sg33286
I18
sg33287
VC0030824
p46055
sg33289
Vpenicillin allergy
p46056
sa(dp46057
g33284
I500
sg33285
I2
sg33286
I14
sg33287
VC0013182
p46058
sg33289
Vdrug allergies
p46059
sasa(dp46060
g33277
VWe identified 12 biomarkers consistently associated with either clinical groups "upstream" towards culture-positive TB on the TB disease spectrum (CD14, FCGR1A, FPR1, MMP9, RAB24, SEC14L1, and TIMP2) or "downstream" towards a decreased likelihood of TB disease (BLR1, CD3E, CD8A, IL7R, and TGFBR2), suggesting a correlation with MTB-related pathology and high relevance to a future POC test for pediatric TB.
p46061
sg33279
(lp46062
(dp46063
g33284
I147
sg33285
I1
sg33286
I4
sg33295
VP08571
p46064
sg33289
VCD14
p46065
sa(dp46066
g33284
I173
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VRAB24
p46067
sa(dp46068
g33284
I153
sg33285
I1
sg33286
I6
sg33295
VP12314
p46069
sg33289
VFCGR1A
p46070
sa(dp46071
g33284
I268
sg33285
I1
sg33286
I4
sg33295
VP07766
p46072
sg33289
VCD3E
p46073
sa(dp46074
g33284
I274
sg33285
I1
sg33286
I4
sg33295
VP01732
p46075
sg33289
VCD8A
p46076
sa(dp46077
g33284
I262
sg33285
I1
sg33286
I4
sg33295
VP32302
p46078
sg33289
VBLR1
p46079
sa(dp46080
g33284
I180
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VSEC14L1
p46081
sa(dp46082
g33284
I167
sg33285
I1
sg33286
I4
sg33295
VP14780
p46083
sg33289
VMMP9
p46084
sa(dp46085
g33284
I193
sg33285
I1
sg33286
I5
sg33295
VP16035
p46086
sg33289
VTIMP2
p46087
sa(dp46088
g33284
I161
sg33285
I1
sg33286
I4
sg33295
VP21462
p46089
sg33289
VFPR1
p46090
sa(dp46091
g33284
I290
sg33285
I1
sg33286
I6
sg33295
VP37173
p46092
sg33289
VTGFBR2
p46093
sasg33281
(lp46094
(dp46095
g33284
I341
sg33285
I1
sg33286
I9
sg33287
VC0677042
p46096
sg33289
Vpathology
p46097
sasa(dp46098
g33277
VHowever, aberrant expression of class III Beta-tubulin has been observed in passaged RPE cells and RPE cells with dedifferentiated morphology in pathologic epiretinal membranes from idiopathic macular pucker, proliferative vitreoretinopathy (PVR) and proliferative diabetic retinopathy (PDR).
p46099
sg33279
(lp46100
(dp46101
g33284
I42
sg33285
I1
sg33286
I12
sg33295
VP68371
p46102
sg33289
VBeta-tubulin
p46103
sasg33281
(lp46104
(dp46105
g33284
I251
sg33285
I3
sg33286
I34
sg33287
VC0154830
p46106
sg33289
Vproliferative diabetic retinopathy
p46107
sa(dp46108
g33284
I209
sg33285
I2
sg33286
I31
sg33287
VC1860404
p46109
sg33289
Vproliferative vitreoretinopathy
p46110
sa(dp46111
g33284
I242
sg33285
I1
sg33286
I3
sg33287
VC1860404
p46112
sg33289
VPVR
p46113
sa(dp46114
g33284
I287
sg33285
I1
sg33286
I3
sg33287
VC0154830
p46115
sg33289
VPDR
p46116
sa(dp46117
g33284
I156
sg33285
I2
sg33286
I20
sg33287
VC0339543
p46118
sg33289
Vepiretinal membranes
p46119
sa(dp46120
g33284
I193
sg33285
I2
sg33286
I14
sg33287
VC0154853
p46121
sg33289
Vmacular pucker
p46122
sasa(dp46123
g33277
VDisorders in the ability ofleukocytes to produce IFN-alpha and IFN-gamma were detected in patients with bronchial asthma and allergic rhinitis.
p46124
sg33279
(lp46125
(dp46126
g33284
I63
sg33285
I1
sg33286
I9
sg33295
VP01579
p46127
sg33289
VIFN-gamma
p46128
sa(dp46129
g33284
I49
sg33285
I1
sg33286
I9
sg33295
VP01562
p46130
sg33289
VIFN-alpha
p46131
sasg33281
(lp46132
(dp46133
g33284
I125
sg33285
I2
sg33286
I17
sg33287
VC2607914
p46134
sg33289
Vallergic rhinitis
p46135
sa(dp46136
g33284
I104
sg33285
I2
sg33286
I16
sg33287
VC0004096
p46137
sg33289
Vbronchial asthma
p46138
sasa(dp46139
g33277
VFactors underlying the 'exacerbation-prone' phenotype are incompletely understood but include extrinsic factors: cigarette smoking, medication non-compliance, psychosocial factors, and co-morbidities such as gastroesophageal reflux disease, rhinosinusitis, obesity, and intolerance to non-steroidal anti-inflammatory medications; as well as intrinsic factors such as deficient epithelial cell production of the anti-viral type I interferons (IFN-alpha and IFN-beta).
p46140
sg33279
(lp46141
(dp46142
g33284
I411
sg33285
I4
sg33286
I29
sg33295
VP29475
p46143
sg33289
Vanti-viral type I interferons
p46144
sa(dp46145
g33284
I442
sg33285
I1
sg33286
I9
sg33295
VP01562
p46146
sg33289
VIFN-alpha
p46147
sa(dp46148
g33284
I456
sg33285
I1
sg33286
I8
sg33295
VP01574
p46149
sg33289
VIFN-beta
p46150
sasg33281
(lp46151
(dp46152
g33284
I257
sg33285
I1
sg33286
I7
sg33287
VC0028754
p46153
sg33289
Vobesity
p46154
sa(dp46155
g33284
I208
sg33285
I3
sg33286
I31
sg33287
VC0017168
p46156
sg33289
Vgastroesophageal reflux disease
p46157
sa(dp46158
g33284
I241
sg33285
I1
sg33286
I14
sg33287
VC0948780
p46159
sg33289
Vrhinosinusitis
p46160
sasa(dp46161
g33277
VThese data indicate that therapeutic strategies using SAHPs targeting CD36, but not necessarily mimicking all apolipoprotein A-I functions, may be considered a possible new treatment approach for inflammation-induced ALI and pulmonary edema.
p46162
sg33279
(lp46163
(dp46164
g33284
I110
sg33285
I2
sg33286
I18
sg33295
VP02647
p46165
sg33289
Vapolipoprotein A-I
p46166
sasg33281
(lp46167
(dp46168
g33284
I196
sg33285
I1
sg33286
I12
sg33287
VC0021368
p46169
sg33289
Vinflammation
p46170
sa(dp46171
g33284
I225
sg33285
I2
sg33286
I15
sg33287
VC0034063
p46172
sg33289
Vpulmonary edema
p46173
sasa(dp46174
g33277
VThe enhanced expression of IL-17 that is observed in patients with Crohn's disease could act on intestinal fibroblasts to induce expression of transcription factor NFKBIZ and proinflammatory chemokine CXCL1.
p46175
sg33279
(lp46176
(dp46177
g33284
I143
sg33285
I7
sg33286
I63
sg33295
VP35398
p46178
sg33289
Vtranscription factor NFKBIZ and proinflammatory chemokine CXCL1
p46179
sasg33281
(lp46180
(dp46181
g33284
I67
sg33285
I2
sg33286
I15
sg33287
VC0010346
p46182
sg33289
VCrohn's disease
p46183
sasa(dp46184
g33277
VIn the majority of cases, autosomal dominant nonsyndromic hearing loss is postlingual and progressive, with the exception of hearing impairment in families in which the impairment is linked to DFNA3, DFNA8/12, and DFNA24, the novel locus described in this report.
p46185
sg33279
(lp46186
(dp46187
g33284
I193
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VDFNA3
p46188
sa(dp46189
g33284
I200
sg33285
I1
sg33286
I8
sg33295
g11
sg33289
VDFNA8/12
p46190
sasg33281
(lp46191
(dp46192
g33284
I214
sg33285
I1
sg33286
I6
sg33287
VC1853451
p46193
sg33289
VDFNA24
p46194
sa(dp46195
g33284
I133
sg33285
I1
sg33286
I10
sg33287
VC0684336
p46196
sg33289
Vimpairment
p46197
sa(dp46198
g33284
I58
sg33285
I2
sg33286
I12
sg33287
VC0011053
p46199
sg33289
Vhearing loss
p46200
sa(dp46201
g33284
I200
sg33285
I1
sg33286
I5
sg33287
VC1832187
p46202
sg33289
VDFNA8
p46203
sa(dp46204
g33284
I133
sg33285
I1
sg33286
I10
sg33287
VC0684336
p46205
sg33289
Vimpairment
p46206
sasa(dp46207
g33277
VThe morphological similarity and resemblance of keratin 1, 10, and 14 profiles, and p63 and Beta-catenin expression between mixed epidermal and inner root sheath hybrid cysts and keratoacanthomas suggests that hybrid cysts progressed to keratoacanthomas, and the cells from infundibular cells to inner root sheath cells of the pilar segment seem to be the origin of rat keratoacanthomas.
p46208
sg33279
(lp46209
(dp46210
g33284
I48
sg33285
I2
sg33286
I9
sg33295
VP04264
p46211
sg33289
Vkeratin 1
p46212
sa(dp46213
g33284
I84
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
Vp63
p46214
sa(dp46215
g33284
I92
sg33285
I1
sg33286
I12
sg33295
VP35222
p46216
sg33289
VBeta-catenin
p46217
sasg33281
(lp46218
(dp46219
g33284
I179
sg33285
I1
sg33286
I16
sg33287
VC0022572
p46220
sg33289
Vkeratoacanthomas
p46221
sa(dp46222
g33284
I179
sg33285
I1
sg33286
I16
sg33287
VC0022572
p46223
sg33289
Vkeratoacanthomas
p46224
sa(dp46225
g33284
I169
sg33285
I1
sg33286
I5
sg33287
VC0010709
p46226
sg33289
Vcysts
p46227
sa(dp46228
g33284
I179
sg33285
I1
sg33286
I16
sg33287
VC0022572
p46229
sg33289
Vkeratoacanthomas
p46230
sa(dp46231
g33284
I169
sg33285
I1
sg33286
I5
sg33287
VC0010709
p46232
sg33289
Vcysts
p46233
sasa(dp46234
g33277
VUCDs include a spectrum of enzyme deficiencies, namely n-acetylglutamate synthase deficiency (NAGS), carbamoyl phosphate synthetase I deficiency (CPS1), ornithine transcarbamylase deficiency (OTC), argininosuccinate lyase deficiency (ASL), citrullinemia type I (ASS1), and argininemia (ARG).
p46235
sg33279
(lp46236
(dp46237
g33284
I55
sg33285
I2
sg33286
I26
sg33295
g11
sg33289
Vn-acetylglutamate synthase
p46238
sa(dp46239
g33284
I153
sg33285
I2
sg33286
I26
sg33295
VP00480
p46240
sg33289
Vornithine transcarbamylase
p46241
sa(dp46242
g33284
I146
sg33285
I1
sg33286
I4
sg33295
VP31327
p46243
sg33289
VCPS1
p46244
sa(dp46245
g33284
I101
sg33285
I4
sg33286
I32
sg33295
VP31327
p46246
sg33289
Vcarbamoyl phosphate synthetase I
p46247
sa(dp46248
g33284
I262
sg33285
I1
sg33286
I4
sg33295
VP00966
p46249
sg33289
VASS1
p46250
sa(dp46251
g33284
I240
sg33285
I3
sg33286
I20
sg33295
VP00966
p46252
sg33289
Vcitrullinemia type I
p46253
sa(dp46254
g33284
I198
sg33285
I2
sg33286
I23
sg33295
VP04424
p46255
sg33289
Vargininosuccinate lyase
p46256
sasg33281
(lp46257
(dp46258
g33284
I153
sg33285
I3
sg33286
I37
sg33287
VC0268542
p46259
sg33289
Vornithine transcarbamylase deficiency
p46260
sa(dp46261
g33284
I286
sg33285
I1
sg33286
I3
sg33287
VC0268548
p46262
sg33289
VARG
p46263
sa(dp46264
g33284
I101
sg33285
I5
sg33286
I43
sg33287
VC0751753
p46265
sg33289
Vcarbamoyl phosphate synthetase I deficiency
p46266
sa(dp46267
g33284
I240
sg33285
I1
sg33286
I13
sg33287
VC0175683
p46268
sg33289
Vcitrullinemia
p46269
sa(dp46270
g33284
I55
sg33285
I3
sg33286
I37
sg33287
VC0268543
p46271
sg33289
Vn-acetylglutamate synthase deficiency
p46272
sa(dp46273
g33284
I234
sg33285
I1
sg33286
I3
sg33287
VC0268547
p46274
sg33289
VASL
p46275
sa(dp46276
g33284
I273
sg33285
I1
sg33286
I11
sg33287
VC0268548
p46277
sg33289
Vargininemia
p46278
sa(dp46279
g33284
I94
sg33285
I1
sg33286
I4
sg33287
VC0268543
p46280
sg33289
VNAGS
p46281
sa(dp46282
g33284
I198
sg33285
I3
sg33286
I34
sg33287
VC0268547
p46283
sg33289
Vargininosuccinate lyase deficiency
p46284
sa(dp46285
g33284
I192
sg33285
I1
sg33286
I3
sg33287
VC0268542
p46286
sg33289
VOTC
p46287
sasa(dp46288
g33277
VRecovery was also associated with maternal obesity, and there was some ethnic variation - in the adjusted analysis indigenous (Orang Asal) Malaysians had lower odds of recovery.
p46289
sg33279
(lp46290
sg33281
(lp46291
(dp46292
g33284
I43
sg33285
I1
sg33286
I7
sg33287
VC0028754
p46293
sg33289
Vobesity
p46294
sasa(dp46295
g33277
VArgininosuccinic acid lyase (ASL) deficiency, caused by mutations in the ASL gene (OMIM: 608310) is a urea cycle disorder that has pleiotropic presentations.
p46296
sg33279
(lp46297
(dp46298
g33284
I73
sg33285
I2
sg33286
I8
sg33295
VP30566
p46299
sg33289
VASL gene
p46300
sa(dp46301
g33284
I29
sg33285
I1
sg33286
I3
sg33295
VP30566
p46302
sg33289
VASL
p46303
sa(dp46304
g33284
I0
sg33285
I3
sg33286
I27
sg33295
g11
sg33289
VArgininosuccinic acid lyase
p46305
sasg33281
(lp46306
(dp46307
g33284
I102
sg33285
I3
sg33286
I19
sg33287
VC0154246
p46308
sg33289
Vurea cycle disorder
p46309
sasa(dp46310
g33277
VThese include N-acetylglutamate synthase deficiency (NAGSD); Carbamyl phosphate synthetase 1 deficiency (CPS1D); Ornithine transcarbamylase deficiency (OTCD); Argininosuccinate synthetase deficiency (ASSD) (Citrullinemia); Argininosuccinate lyase deficiency (ASLD) (Argininosuccinic aciduria); Arginase deficiency (ARGD, Argininemia); Hyperornithinemia, hyperammonemia, homocitrullinuria (HHH) syndrome (or mitochondrial ornithine transporter 1 deficiency [ORNT1D]); and Citrullinemia type II (mitochondrial aspartate/glutamate carrier deficiency [CITRIN]).
p46311
sg33279
(lp46312
(dp46313
g33284
I407
sg33285
I4
sg33286
I37
sg33295
g11
sg33289
Vmitochondrial ornithine transporter 1
p46314
sa(dp46315
g33284
I61
sg33285
I4
sg33286
I31
sg33295
g11
sg33289
VCarbamyl phosphate synthetase 1
p46316
sa(dp46317
g33284
I223
sg33285
I2
sg33286
I23
sg33295
VP04424
p46318
sg33289
VArgininosuccinate lyase
p46319
sa(dp46320
g33284
I294
sg33285
I1
sg33286
I8
sg33295
VP05089
p46321
sg33289
VArginase
p46322
sa(dp46323
g33284
I113
sg33285
I2
sg33286
I26
sg33295
VP00480
p46324
sg33289
VOrnithine transcarbamylase
p46325
sa(dp46326
g33284
I159
sg33285
I2
sg33286
I28
sg33295
VP00966
p46327
sg33289
VArgininosuccinate synthetase
p46328
sa(dp46329
g33284
I14
sg33285
I2
sg33286
I26
sg33295
g11
sg33289
VN-acetylglutamate synthase
p46330
sa(dp46331
g33284
I494
sg33285
I5
sg33286
I61
sg33295
g11
sg33289
Vmitochondrial aspartate/glutamate carrier deficiency [CITRIN]
p46332
sasg33281
(lp46333
(dp46334
g33284
I389
sg33285
I1
sg33286
I3
sg33287
VC0268540
p46335
sg33289
VHHH
p46336
sa(dp46337
g33284
I335
sg33285
I1
sg33286
I17
sg33287
VC0599035
p46338
sg33289
VHyperornithinemia
p46339
sa(dp46340
g33284
I394
sg33285
I1
sg33286
I8
sg33287
VC0039082
p46341
sg33289
Vsyndrome
p46342
sa(dp46343
g33284
I159
sg33285
I3
sg33286
I39
sg33287
VC0175683
p46344
sg33289
VArgininosuccinate synthetase deficiency
p46345
sa(dp46346
g33284
I14
sg33285
I3
sg33286
I37
sg33287
VC0268543
p46347
sg33289
VN-acetylglutamate synthase deficiency
p46348
sa(dp46349
g33284
I315
sg33285
I1
sg33286
I4
sg33287
VC0268548
p46350
sg33289
VARGD
p46351
sa(dp46352
g33284
I223
sg33285
I3
sg33286
I34
sg33287
VC0268547
p46353
sg33289
VArgininosuccinate lyase deficiency
p46354
sa(dp46355
g33284
I207
sg33285
I1
sg33286
I13
sg33287
VC0175683
p46356
sg33289
VCitrullinemia
p46357
sa(dp46358
g33284
I152
sg33285
I1
sg33286
I4
sg33287
VC0268542
p46359
sg33289
VOTCD
p46360
sa(dp46361
g33284
I53
sg33285
I1
sg33286
I5
sg33287
VC0268543
p46362
sg33289
VNAGSD
p46363
sa(dp46364
g33284
I200
sg33285
I1
sg33286
I4
sg33287
VC0175683
p46365
sg33289
VASSD
p46366
sa(dp46367
g33284
I259
sg33285
I1
sg33286
I4
sg33287
VC0268547
p46368
sg33289
VASLD
p46369
sa(dp46370
g33284
I207
sg33285
I1
sg33286
I13
sg33287
VC0175683
p46371
sg33289
VCitrullinemia
p46372
sa(dp46373
g33284
I321
sg33285
I1
sg33286
I11
sg33287
VC0268548
p46374
sg33289
VArgininemia
p46375
sa(dp46376
g33284
I266
sg33285
I2
sg33286
I25
sg33287
VC0268547
p46377
sg33289
VArgininosuccinic aciduria
p46378
sa(dp46379
g33284
I354
sg33285
I1
sg33286
I14
sg33287
VC0220994
p46380
sg33289
Vhyperammonemia
p46381
sa(dp46382
g33284
I113
sg33285
I3
sg33286
I37
sg33287
VC0268542
p46383
sg33289
VOrnithine transcarbamylase deficiency
p46384
sa(dp46385
g33284
I294
sg33285
I2
sg33286
I19
sg33287
VC0268548
p46386
sg33289
VArginase deficiency
p46387
sasa(dp46388
g33277
VCardiomyopathy [methylmalonic (MMA) and propionic aciduria (PA)], prolonged QTc interval (PA), optic nerve atrophy [MMA, isovaleric aciduria (IVA)], pancytopenia (PA), and macrocephaly [glutaric aciduria type 1 (GA1)] were exclusively found in OAD patients, whereas hepatic involvement was more frequent in UCD patients, in particular in argininosuccinate lyase (ASL) deficiency.
p46389
sg33279
(lp46390
(dp46391
g33284
I363
sg33285
I1
sg33286
I3
sg33295
VP30566
p46392
sg33289
VASL
p46393
sa(dp46394
g33284
I338
sg33285
I2
sg33286
I23
sg33295
VP04424
p46395
sg33289
Vargininosuccinate lyase
p46396
sasg33281
(lp46397
(dp46398
g33284
I186
sg33285
I4
sg33286
I24
sg33287
VC0268595
p46399
sg33289
Vglutaric aciduria type 1
p46400
sa(dp46401
g33284
I60
sg33285
I1
sg33286
I2
sg33287
VC2717876
p46402
sg33289
VPA
p46403
sa(dp46404
g33284
I149
sg33285
I1
sg33286
I12
sg33287
VC0030312
p46405
sg33289
Vpancytopenia
p46406
sa(dp46407
g33284
I121
sg33285
I2
sg33286
I19
sg33287
VC0268575
p46408
sg33289
Visovaleric aciduria
p46409
sa(dp46410
g33284
I31
sg33285
I1
sg33286
I3
sg33287
VC0276096
p46411
sg33289
VMMA
p46412
sa(dp46413
g33284
I60
sg33285
I1
sg33286
I2
sg33287
VC2717876
p46414
sg33289
VPA
p46415
sa(dp46416
g33284
I0
sg33285
I1
sg33286
I14
sg33287
VC0878544
p46417
sg33289
VCardiomyopathy
p46418
sa(dp46419
g33284
I95
sg33285
I3
sg33286
I19
sg33287
VC0029124
p46420
sg33289
Voptic nerve atrophy
p46421
sa(dp46422
g33284
I40
sg33285
I2
sg33286
I18
sg33287
VC2717876
p46423
sg33289
Vpropionic aciduria
p46424
sa(dp46425
g33284
I60
sg33285
I1
sg33286
I2
sg33287
VC2717876
p46426
sg33289
VPA
p46427
sa(dp46428
g33284
I172
sg33285
I1
sg33286
I12
sg33287
VC0221355
p46429
sg33289
Vmacrocephaly
p46430
sa(dp46431
g33284
I15
sg33285
I1
sg33286
I14
sg33287
VC0276096
p46432
sg33289
V[methylmalonic
p46433
sa(dp46434
g33284
I31
sg33285
I1
sg33286
I3
sg33287
VC0276096
p46435
sg33289
VMMA
p46436
sa(dp46437
g33284
I66
sg33285
I3
sg33286
I22
sg33287
VC1560305
p46438
sg33289
Vprolonged QTc interval
p46439
sa(dp46440
g33284
I142
sg33285
I1
sg33286
I3
sg33287
VC0268575
p46441
sg33289
VIVA
p46442
sasa(dp46443
g33277
VFifteen patients (8 argininosuccinate lyase deficiency, 3 argininosuccinic acid synthetase deficiency, 3 ornithine transcarbamylase deficiency, 1 arginase deficiency) ages 2 months through 5 years enrolled in and completed the study.
p46444
sg33279
(lp46445
(dp46446
g33284
I58
sg33285
I3
sg33286
I32
sg33295
g11
sg33289
Vargininosuccinic acid synthetase
p46447
sa(dp46448
g33284
I20
sg33285
I2
sg33286
I23
sg33295
VP04424
p46449
sg33289
Vargininosuccinate lyase
p46450
sa(dp46451
g33284
I103
sg33285
I6
sg33286
I51
sg33295
VP00480
p46452
sg33289
V3 ornithine transcarbamylase deficiency, 1 arginase
p46453
sasg33281
(lp46454
(dp46455
g33284
I105
sg33285
I3
sg33286
I37
sg33287
VC0268542
p46456
sg33289
Vornithine transcarbamylase deficiency
p46457
sa(dp46458
g33284
I146
sg33285
I2
sg33286
I19
sg33287
VC0268548
p46459
sg33289
Varginase deficiency
p46460
sa(dp46461
g33284
I58
sg33285
I4
sg33286
I43
sg33287
VC0175683
p46462
sg33289
Vargininosuccinic acid synthetase deficiency
p46463
sa(dp46464
g33284
I20
sg33285
I3
sg33286
I34
sg33287
VC0268547
p46465
sg33289
Vargininosuccinate lyase deficiency
p46466
sasa(dp46467
g33277
VThe 20 genes with at least a 3-fold change, annotated with known phenotypic associations in the current gene databank (phenotype association, fold change) were aspartoacylase (Canavan disease, 9.96), growth hormone receptor (Laron dwarfism, idiopathic short stature, 8.25), lipoprotein lipase (familial chylomicronemia syndrome, lipoprotein lipase deficiency, 8.00), vitamin D (1,25- dihydroxyvitamin D3) receptor (involutional osteoporosis, vitamin D resistant rickets, 7.94), intercellular adhesion molecule 1 human rhinovirus receptor (cerebral malaria susceptibility, 7.16), peroxisomal membrane protein 3 35-kDa (Refsum disease, infantile form, Zellweger syndrome-3, 6.00), Bardet-Biedl syndrome 2 (Bardet-Biedl syndrome, 5.87), ribosomal protein S19 (Diamond Blackfan anemia, 5.85), apolipoprotein C-III (hypertriglyceridemia, 5.44), argininosuccinate lyase (argininosuccinicaciduria, 5.22), myosin VA (Griscelli syndrome-type pigmentary dilution with mental retardation, 4.92), lysozyme (renal amyloidosis, 4.17), SAM domain, SH3 domain and nuclear localisation signals 1 (Cherubism, 4.12 ), von Hippel-Lindau syndrome (hemangioblastoma, cerebellar, somatic, von Hippel-Lindau syndrome, 3.94), early-onset breast cancer 1 (BRCA1, papillary serous carcinoma of the peritoneum, 3.73), UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (inclusion body myopathy, autosomal recessive, sialuria, 3.53), apolipoprotein A-I (amyloidosis, 3 or more types, hypoalphalipoproteinemia, 3.29), midline 1 Opitz/BBB syndrome (Opitz G syndrome, type I, 3.28), ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide (familial hemiplegic migraine, 3.05).
p46468
sg33279
(lp46469
(dp46470
g33284
I789
sg33285
I2
sg33286
I20
sg33295
VP02656
p46471
sg33289
Vapolipoprotein C-III
p46472
sa(dp46473
g33284
I274
sg33285
I2
sg33286
I18
sg33295
VP06858
p46474
sg33289
Vlipoprotein lipase
p46475
sa(dp46476
g33284
I898
sg33285
I2
sg33286
I9
sg33295
g11
sg33289
Vmyosin VA
p46477
sa(dp46478
g33284
I274
sg33285
I2
sg33286
I18
sg33295
VP06858
p46479
sg33289
Vlipoprotein lipase
p46480
sa(dp46481
g33284
I1201
sg33285
I4
sg33286
I27
sg33295
VP38398
p46482
sg33289
Vearly-onset breast cancer 1
p46483
sa(dp46484
g33284
I865
sg33285
I2
sg33286
I30
sg33295
VP04424
p46485
sg33289
Vargininosuccinicaciduria, 5.22
p46486
sa(dp46487
g33284
I985
sg33285
I1
sg33286
I8
sg33295
VP61626
p46488
sg33289
Vlysozyme
p46489
sa(dp46490
g33284
I1417
sg33285
I2
sg33286
I18
sg33295
VP02647
p46491
sg33289
Vapolipoprotein A-I
p46492
sa(dp46493
g33284
I840
sg33285
I2
sg33286
I23
sg33295
VP04424
p46494
sg33289
Vargininosuccinate lyase
p46495
sa(dp46496
g33284
I200
sg33285
I3
sg33286
I23
sg33295
VP10912
p46497
sg33289
Vgrowth hormone receptor
p46498
sa(dp46499
g33284
I478
sg33285
I7
sg33286
I59
sg33295
VP05362
p46500
sg33289
Vintercellular adhesion molecule 1 human rhinovirus receptor
p46501
sa(dp46502
g33284
I734
sg33285
I3
sg33286
I21
sg33295
VP39019
p46503
sg33289
Vribosomal protein S19
p46504
sa(dp46505
g33284
I1021
sg33285
I2
sg33286
I10
sg33295
g11
sg33289
VSAM domain
p46506
sa(dp46507
g33284
I1230
sg33285
I1
sg33286
I5
sg33295
VP38398
p46508
sg33289
VBRCA1
p46509
sa(dp46510
g33284
I1563
sg33285
I1
sg33286
I6
sg33295
VP38606
p46511
sg33289
VATPase
p46512
sa(dp46513
g33284
I160
sg33285
I1
sg33286
I14
sg33295
VP45381
p46514
sg33289
Vaspartoacylase
p46515
sasg33281
(lp46516
(dp46517
g33284
I492
sg33285
I1
sg33286
I8
sg33287
VC0001511
p46518
sg33289
Vadhesion
p46519
sa(dp46520
g33284
I225
sg33285
I2
sg33286
I14
sg33287
VC0271568
p46521
sg33289
VLaron dwarfism
p46522
sa(dp46523
g33284
I1237
sg33285
I3
sg33286
I26
sg33287
VC0334359
p46524
sg33289
Vpapillary serous carcinoma
p46525
sa(dp46526
g33284
I995
sg33285
I2
sg33286
I17
sg33287
VC0268382
p46527
sg33289
Vrenal amyloidosis
p46528
sa(dp46529
g33284
I865
sg33285
I1
sg33286
I24
sg33287
VC0268547
p46530
sg33289
Vargininosuccinicaciduria
p46531
sa(dp46532
g33284
I303
sg33285
I2
sg33286
I24
sg33287
VC1274228
p46533
sg33289
Vchylomicronemia syndrome
p46534
sa(dp46535
g33284
I757
sg33285
I3
sg33286
I23
sg33287
VC1260899
p46536
sg33289
VDiamond Blackfan anemia
p46537
sa(dp46538
g33284
I176
sg33285
I2
sg33286
I15
sg33287
VC0206307
p46539
sg33289
VCanavan disease
p46540
sa(dp46541
g33284
I442
sg33285
I4
sg33286
I27
sg33287
VC2363065
p46542
sg33289
Vvitamin D resistant rickets
p46543
sa(dp46544
g33284
I958
sg33285
I2
sg33286
I18
sg33287
VC0025362
p46545
sg33289
Vmental retardation
p46546
sa(dp46547
g33284
I329
sg33285
I3
sg33286
I29
sg33287
VC0023817
p46548
sg33289
Vlipoprotein lipase deficiency
p46549
sa(dp46550
g33284
I539
sg33285
I2
sg33286
I16
sg33287
VC0024534
p46551
sg33289
Vcerebral malaria
p46552
sa(dp46553
g33284
I679
sg33285
I3
sg33286
I23
sg33287
VC2936863
p46554
sg33289
VBardet-Biedl syndrome 2
p46555
sa(dp46556
g33284
I1099
sg33285
I3
sg33286
I26
sg33287
VC0019562
p46557
sg33289
Vvon Hippel-Lindau syndrome
p46558
sa(dp46559
g33284
I1080
sg33285
I1
sg33286
I9
sg33287
VC0008029
p46560
sg33289
VCherubism
p46561
sa(dp46562
g33284
I1400
sg33285
I1
sg33286
I8
sg33287
VC0342853
p46563
sg33289
Vsialuria
p46564
sa(dp46565
g33284
I241
sg33285
I3
sg33286
I24
sg33287
VC1740819
p46566
sg33289
Vidiopathic short stature
p46567
sa(dp46568
g33284
I1099
sg33285
I3
sg33286
I26
sg33287
VC0019562
p46569
sg33289
Vvon Hippel-Lindau syndrome
p46570
sa(dp46571
g33284
I1213
sg33285
I2
sg33286
I13
sg33287
VC0678222
p46572
sg33289
Vbreast cancer
p46573
sa(dp46574
g33284
I319
sg33285
I1
sg33286
I8
sg33287
VC0039082
p46575
sg33289
Vsyndrome
p46576
sa(dp46577
g33284
I618
sg33285
I4
sg33286
I30
sg33287
VC0282527
p46578
sg33289
VRefsum disease, infantile form
p46579
sa(dp46580
g33284
I1127
sg33285
I1
sg33286
I16
sg33287
VC0206734
p46581
sg33289
Vhemangioblastoma
p46582
sa(dp46583
g33284
I1536
sg33285
I2
sg33286
I10
sg33287
VC2936904
p46584
sg33289
VG syndrome
p46585
sa(dp46586
g33284
I650
sg33285
I2
sg33286
I18
sg33287
VC0043459
p46587
sg33289
VZellweger syndrome
p46588
sa(dp46589
g33284
I1021
sg33285
I1
sg33286
I3
sg33287
VC1563296
p46590
sg33289
VSAM
p46591
sa(dp46592
g33284
I415
sg33285
I2
sg33286
I25
sg33287
VC0029459
p46593
sg33289
Vinvolutional osteoporosis
p46594
sa(dp46595
g33284
I1354
sg33285
I5
sg33286
I44
sg33287
VC1833373
p46596
sg33289
Vinclusion body myopathy, autosomal recessive
p46597
sa(dp46598
g33284
I679
sg33285
I2
sg33286
I21
sg33287
VC0752166
p46599
sg33289
VBardet-Biedl syndrome
p46600
sa(dp46601
g33284
I1617
sg33285
I3
sg33286
I28
sg33287
VC0338484
p46602
sg33289
Vfamilial hemiplegic migraine
p46603
sa(dp46604
g33284
I1001
sg33285
I1
sg33286
I11
sg33287
VC0002726
p46605
sg33289
Vamyloidosis
p46606
sa(dp46607
g33284
I1516
sg33285
I2
sg33286
I12
sg33287
VC2936904
p46608
sg33289
VBBB syndrome
p46609
sasa(dp46610
g33277
VThirteen families were investigated, of which two were affected by N-acetylglutamate synthase deficiency, four by carbamoylphosphate synthetase 1 deficiency, one by ornithine transcarbamylase deficiency, three by argininosuccinate synthetase deficiency, two by argininosuccinate lyase deficiency, and one by arginase deficiency.
p46611
sg33279
(lp46612
(dp46613
g33284
I67
sg33285
I2
sg33286
I26
sg33295
g11
sg33289
VN-acetylglutamate synthase
p46614
sa(dp46615
g33284
I261
sg33285
I2
sg33286
I23
sg33295
VP04424
p46616
sg33289
Vargininosuccinate lyase
p46617
sa(dp46618
g33284
I213
sg33285
I2
sg33286
I28
sg33295
VP00966
p46619
sg33289
Vargininosuccinate synthetase
p46620
sa(dp46621
g33284
I308
sg33285
I1
sg33286
I8
sg33295
VP05089
p46622
sg33289
Varginase
p46623
sa(dp46624
g33284
I114
sg33285
I3
sg33286
I31
sg33295
VP31327
p46625
sg33289
Vcarbamoylphosphate synthetase 1
p46626
sa(dp46627
g33284
I165
sg33285
I2
sg33286
I26
sg33295
VP00480
p46628
sg33289
Vornithine transcarbamylase
p46629
sasg33281
(lp46630
(dp46631
g33284
I213
sg33285
I3
sg33286
I39
sg33287
VC0175683
p46632
sg33289
Vargininosuccinate synthetase deficiency
p46633
sa(dp46634
g33284
I308
sg33285
I2
sg33286
I19
sg33287
VC0268548
p46635
sg33289
Varginase deficiency
p46636
sa(dp46637
g33284
I165
sg33285
I3
sg33286
I37
sg33287
VC0268542
p46638
sg33289
Vornithine transcarbamylase deficiency
p46639
sa(dp46640
g33284
I67
sg33285
I3
sg33286
I37
sg33287
VC0268543
p46641
sg33289
VN-acetylglutamate synthase deficiency
p46642
sa(dp46643
g33284
I261
sg33285
I3
sg33286
I34
sg33287
VC0268547
p46644
sg33289
Vargininosuccinate lyase deficiency
p46645
sasa(dp46646
g33277
VIn this study, we examined the relationship between the lactic acid concentration and expression of LDHA and GLUT1, which are related to the Warburg effect, in human head and neck squamous cell carcinoma (HNSCC).
p46647
sg33279
(lp46648
(dp46649
g33284
I100
sg33285
I1
sg33286
I4
sg33295
VP00338
p46650
sg33289
VLDHA
p46651
sa(dp46652
g33284
I109
sg33285
I1
sg33286
I5
sg33295
VP11166
p46653
sg33289
VGLUT1
p46654
sasg33281
(lp46655
(dp46656
g33284
I141
sg33285
I2
sg33286
I14
sg33287
VC1520120
p46657
sg33289
VWarburg effect
p46658
sa(dp46659
g33284
I205
sg33285
I1
sg33286
I5
sg33287
VC1168401
p46660
sg33289
VHNSCC
p46661
sa(dp46662
g33284
I166
sg33285
I6
sg33286
I37
sg33287
VC1168401
p46663
sg33289
Vhead and neck squamous cell carcinoma
p46664
sasa(dp46665
g33277
VWe found that cetuximab downregulated lactate dehydrogenase A (LDH-A) and inhibited glycolysis in cetuximab-sensitive head and neck squamous cell carcinoma (HNSCC) cells in an HIF-1Alfa downregulation-dependent manner.
p46666
sg33279
(lp46667
(dp46668
g33284
I38
sg33285
I3
sg33286
I23
sg33295
VP49366
p46669
sg33289
Vlactate dehydrogenase A
p46670
sa(dp46671
g33284
I63
sg33285
I1
sg33286
I5
sg33295
VP00338
p46672
sg33289
VLDH-A
p46673
sasg33281
(lp46674
(dp46675
g33284
I157
sg33285
I1
sg33286
I5
sg33287
VC1168401
p46676
sg33289
VHNSCC
p46677
sa(dp46678
g33284
I118
sg33285
I6
sg33286
I37
sg33287
VC1168401
p46679
sg33289
Vhead and neck squamous cell carcinoma
p46680
sasa(dp46681
g33277
VAn Australian cohort of 252 unrelated familial hypertrophic cardiomyopathy patients were screened for mutations in the Ca(2+) regulatory genes, sorcin (SRI), calstabin (FKBP1B), calsequestrin (CASQ2), phospholamban (PLN), sarcolipin (SLN), calreticulin (CALR3) and calmodulin (CALM).
p46682
sg33279
(lp46683
(dp46684
g33284
I277
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCALM
p46685
sa(dp46686
g33284
I169
sg33285
I1
sg33286
I6
sg33295
VP68106
p46687
sg33289
VFKBP1B
p46688
sa(dp46689
g33284
I265
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
Vcalmodulin
p46690
sa(dp46691
g33284
I240
sg33285
I2
sg33286
I20
sg33295
VP27797
p46692
sg33289
Vcalreticulin (CALR3)
p46693
sa(dp46694
g33284
I178
sg33285
I1
sg33286
I13
sg33295
VP31415
p46695
sg33289
Vcalsequestrin
p46696
sa(dp46697
g33284
I222
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
Vsarcolipin
p46698
sa(dp46699
g33284
I193
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCASQ2
p46700
sa(dp46701
g33284
I234
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VSLN
p46702
sa(dp46703
g33284
I144
sg33285
I2
sg33286
I12
sg33295
VP30626
p46704
sg33289
Vsorcin (SRI)
p46705
sa(dp46706
g33284
I119
sg33285
I3
sg33286
I23
sg33295
VP01893
p46707
sg33289
VCa(2+) regulatory genes
p46708
sasg33281
(lp46709
(dp46710
g33284
I38
sg33285
I3
sg33286
I36
sg33287
VC0949658
p46711
sg33289
Vfamilial hypertrophic cardiomyopathy
p46712
sasa(dp46713
g33277
VThe validated proteins contain the clinically used hepatocellular carcinoma (HCC) biomarker alpha-fetoprotein (AFP) and the reported biomarker candidates Heat shock protein HSP 90-beta (HSP90), fatty acid-binding protein, epidermal (FABP5) and alcohol dehydrogenase 4 (ADH4), which demonstrated the robustness of the strategy.
p46714
sg33279
(lp46715
(dp46716
g33284
I269
sg33285
I1
sg33286
I4
sg33295
VP40394
p46717
sg33289
VADH4
p46718
sa(dp46719
g33284
I111
sg33285
I1
sg33286
I3
sg33295
VP02771
p46720
sg33289
VAFP
p46721
sa(dp46722
g33284
I194
sg33285
I3
sg33286
I26
sg33295
VP00505
p46723
sg33289
Vfatty acid-binding protein
p46724
sa(dp46725
g33284
I173
sg33285
I2
sg33286
I11
sg33295
g11
sg33289
VHSP 90-beta
p46726
sa(dp46727
g33284
I222
sg33285
I6
sg33286
I45
sg33295
VP08319
p46728
sg33289
Vepidermal (FABP5) and alcohol dehydrogenase 4
p46729
sa(dp46730
g33284
I92
sg33285
I1
sg33286
I17
sg33295
VP02771
p46731
sg33289
Valpha-fetoprotein
p46732
sa(dp46733
g33284
I186
sg33285
I1
sg33286
I5
sg33295
VP07900
p46734
sg33289
VHSP90
p46735
sasg33281
(lp46736
(dp46737
g33284
I77
sg33285
I1
sg33286
I3
sg33287
VC2239176
p46738
sg33289
VHCC
p46739
sa(dp46740
g33284
I51
sg33285
I2
sg33286
I24
sg33287
VC2239176
p46741
sg33289
Vhepatocellular carcinoma
p46742
sa(dp46743
g33284
I173
sg33285
I1
sg33286
I3
sg33287
VC0034152
p46744
sg33289
VHSP
p46745
sasa(dp46746
g33277
VIn vivo, Hsp90Beta promoted VEGFRs and CD31 expression in human hepatocellular carcinoma tumor xenografts and was associated with increased tumor microvessel density.
p46747
sg33279
(lp46748
(dp46749
g33284
I28
sg33285
I1
sg33286
I6
sg33295
VP35968
p46750
sg33289
VVEGFRs
p46751
sa(dp46752
g33284
I39
sg33285
I1
sg33286
I4
sg33295
VP69905
p46753
sg33289
VCD31
p46754
sa(dp46755
g33284
I9
sg33285
I1
sg33286
I9
sg33295
VP08238
p46756
sg33289
VHsp90Beta
p46757
sasg33281
(lp46758
(dp46759
g33284
I89
sg33285
I1
sg33286
I5
sg33287
VC0027651
p46760
sg33289
Vtumor
p46761
sa(dp46762
g33284
I64
sg33285
I2
sg33286
I24
sg33287
VC1512411
p46763
sg33289
Vhepatocellular carcinoma
p46764
sa(dp46765
g33284
I89
sg33285
I1
sg33286
I5
sg33287
VC0027651
p46766
sg33289
Vtumor
p46767
sasa(dp46768
g33277
VIn this study we report an apparent synergy between TGF-Beta1 and Hsp90Beta in stimulating migratory behaviour of colon cancer cells when signalling occurs via AlfavBeta6 integrin as opposed to the canonical TGF-Beta1 pathway.
p46769
sg33279
(lp46770
(dp46771
g33284
I52
sg33285
I1
sg33286
I9
sg33295
VP01137
p46772
sg33289
VTGF-Beta1
p46773
sa(dp46774
g33284
I52
sg33285
I3
sg33286
I23
sg33295
VP01137
p46775
sg33289
VTGF-Beta1 and Hsp90Beta
p46776
sasg33281
(lp46777
(dp46778
g33284
I114
sg33285
I2
sg33286
I12
sg33287
VC0699790
p46779
sg33289
Vcolon cancer
p46780
sasa(dp46781
g33277
VOur findings indicate that the C allele of the novel colorectal cancer-associated variant rs2282151 is associated with increased expression levels of HSP90AB1, which is expressed higher in colorectal tumor tissues than in normal tissues.
p46782
sg33279
(lp46783
(dp46784
g33284
I150
sg33285
I1
sg33286
I8
sg33295
VP08238
p46785
sg33289
VHSP90AB1
p46786
sa(dp46787
g33284
I53
sg33285
I4
sg33286
I46
sg33295
VP31749
p46788
sg33289
Vcolorectal cancer-associated variant rs2282151
p46789
sasg33281
(lp46790
(dp46791
g33284
I53
sg33285
I2
sg33286
I17
sg33287
VC1527249
p46792
sg33289
Vcolorectal cancer
p46793
sa(dp46794
g33284
I189
sg33285
I2
sg33286
I16
sg33287
VC0009404
p46795
sg33289
Vcolorectal tumor
p46796
sasa(dp46797
g33277
VBortezomib induced internalization and degradation of c-KIT by binding c-KIT to Cbl, an E3 ubiquitin-protein ligase, and the subsequent release of Apaf-1, which was originally bound to the c-KIT-Hsp90Beta-Apaf-1 complex, induced primary apoptosis in GIST-T1 cells.
p46798
sg33279
(lp46799
(dp46800
g33284
I54
sg33285
I1
sg33286
I5
sg33295
VP10721
p46801
sg33289
Vc-KIT
p46802
sa(dp46803
g33284
I189
sg33285
I1
sg33286
I15
sg33295
VP10721
p46804
sg33289
Vc-KIT-Hsp90Beta
p46805
sa(dp46806
g33284
I91
sg33285
I2
sg33286
I24
sg33295
VP49427
p46807
sg33289
Vubiquitin-protein ligase
p46808
sa(dp46809
g33284
I80
sg33285
I1
sg33286
I3
sg33295
VP22681
p46810
sg33289
VCbl
p46811
sa(dp46812
g33284
I54
sg33285
I1
sg33286
I5
sg33295
VP10721
p46813
sg33289
Vc-KIT
p46814
sasg33281
(lp46815
(dp46816
g33284
I250
sg33285
I1
sg33286
I4
sg33287
VC1847319
p46817
sg33289
VGIST
p46818
sasa(dp46819
g33277
VBoth Annexin A1 and HSP90Beta were GlcNAcylated, and their protein expressions were elevated in colon cancer, compared to normal tissues.
p46820
sg33279
(lp46821
(dp46822
g33284
I5
sg33285
I2
sg33286
I10
sg33295
VP04083
p46823
sg33289
VAnnexin A1
p46824
sa(dp46825
g33284
I20
sg33285
I1
sg33286
I9
sg33295
VP08238
p46826
sg33289
VHSP90Beta
p46827
sasg33281
(lp46828
(dp46829
g33284
I96
sg33285
I2
sg33286
I12
sg33287
VC0699790
p46830
sg33289
Vcolon cancer
p46831
sasa(dp46832
g33277
VMoreover, specific changes of GlcNAc abundances in Annexin A1 and HSP90Beta suggested that tumor-specific glycan patterns could serve as candidate biomarkers of colon cancer for distinguishing cancer patients from healthy individuals.
p46833
sg33279
(lp46834
(dp46835
g33284
I66
sg33285
I1
sg33286
I9
sg33295
VP08238
p46836
sg33289
VHSP90Beta
p46837
sa(dp46838
g33284
I51
sg33285
I2
sg33286
I10
sg33295
VP04083
p46839
sg33289
VAnnexin A1
p46840
sasg33281
(lp46841
(dp46842
g33284
I91
sg33285
I1
sg33286
I5
sg33287
VC0027651
p46843
sg33289
Vtumor
p46844
sa(dp46845
g33284
I167
sg33285
I1
sg33286
I6
sg33287
VC0006826
p46846
sg33289
Vcancer
p46847
sa(dp46848
g33284
I161
sg33285
I2
sg33286
I12
sg33287
VC0699790
p46849
sg33289
Vcolon cancer
p46850
sasa(dp46851
g33277
VIn addition, the knockdown of PEPCK, which is the rate-limiting enzyme for gluconeogenesis, led to a reduction in glucose production in rat hepatoma H4IIEC3 cells.
p46852
sg33279
(lp46853
(dp46854
g33284
I30
sg33285
I1
sg33286
I5
sg33295
VP35558
p46855
sg33289
VPEPCK
p46856
sasg33281
(lp46857
(dp46858
g33284
I140
sg33285
I1
sg33286
I8
sg33287
VC0023903
p46859
sg33289
Vhepatoma
p46860
sasa(dp46861
g33277
VWe recently reported expression of the chemokine receptors CXC chemokine receptor 3 (CXCR3) and CC chemokine receptor 4 (CCR4) in adult T-cell leukemia/lymphoma and showed a preferential expression of CCR4 and its association with an unfavorable outcome.
p46862
sg33279
(lp46863
(dp46864
g33284
I39
sg33285
I6
sg33286
I44
sg33295
VP55773
p46865
sg33289
Vchemokine receptors CXC chemokine receptor 3
p46866
sa(dp46867
g33284
I96
sg33285
I4
sg33286
I23
sg33295
g11
sg33289
VCC chemokine receptor 4
p46868
sa(dp46869
g33284
I121
sg33285
I1
sg33286
I4
sg33295
VP51679
p46870
sg33289
VCCR4
p46871
sa(dp46872
g33284
I85
sg33285
I1
sg33286
I5
sg33295
VP49682
p46873
sg33289
VCXCR3
p46874
sa(dp46875
g33284
I121
sg33285
I1
sg33286
I4
sg33295
VP51679
p46876
sg33289
VCCR4
p46877
sasg33281
(lp46878
(dp46879
g33284
I130
sg33285
I3
sg33286
I30
sg33287
VC0023493
p46880
sg33289
Vadult T-cell leukemia/lymphoma
p46881
sasa(dp46882
g33277
VWe present a review of the current knowledge on cellular metabolism in non-cancerous and cancerous thyroid tissues, focusing on the monocarboxylate transporters MCT1 and MCT4, and on a transporter of the outer mitochondrial membrane TOMM20.
p46883
sg33279
(lp46884
(dp46885
g33284
I132
sg33285
I3
sg33286
I33
sg33295
VP23946
p46886
sg33289
Vmonocarboxylate transporters MCT1
p46887
sa(dp46888
g33284
I204
sg33285
I4
sg33286
I35
sg33295
g11
sg33289
Vouter mitochondrial membrane TOMM20
p46889
sa(dp46890
g33284
I170
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VMCT4
p46891
sasg33281
(lp46892
sa(dp46893
g33277
VPapillary thyroid cancer and FA thyrocytes had high staining for TOMM20 compared to NCT and nodular goiter (NG) (P &lt; 0.01).
p46894
sg33279
(lp46895
(dp46896
g33284
I65
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VTOMM20
p46897
sasg33281
(lp46898
(dp46899
g33284
I0
sg33285
I3
sg33286
I24
sg33287
VC0238463
p46900
sg33289
VPapillary thyroid cancer
p46901
sa(dp46902
g33284
I108
sg33285
I1
sg33286
I2
sg33287
VC1318500
p46903
sg33289
VNG
p46904
sa(dp46905
g33284
I92
sg33285
I2
sg33286
I14
sg33287
VC1318500
p46906
sg33289
Vnodular goiter
p46907
sasa(dp46908
g33277
VStaining patterns of MCT1 and TOMM20 in 35 human thyroid samples (15 ATC, 12 papillary thyroid cancer [PTC], and eight non-cancerous thyroid) and nine ATC mouse orthotopic xenografts were assessed by visual and Aperio digital scoring.
p46909
sg33279
(lp46910
(dp46911
g33284
I21
sg33285
I3
sg33286
I15
sg33295
VP23946
p46912
sg33289
VMCT1 and TOMM20
p46913
sasg33281
(lp46914
(dp46915
g33284
I77
sg33285
I3
sg33286
I24
sg33287
VC0238463
p46916
sg33289
Vpapillary thyroid cancer
p46917
sa(dp46918
g33284
I103
sg33285
I1
sg33286
I3
sg33287
VC0238463
p46919
sg33289
VPTC
p46920
sasa(dp46921
g33277
VTOMM20 is also highly expressed in both ATC and PTC compared to non-cancerous thyroid tissue (P&lt;.01 for both).
p46922
sg33279
(lp46923
(dp46924
g33284
I0
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VTOMM20
p46925
sasg33281
(lp46926
(dp46927
g33284
I48
sg33285
I1
sg33286
I3
sg33287
VC0238463
p46928
sg33289
VPTC
p46929
sasa(dp46930
g33277
VHigh MCT1 and TOMM20 expression is also found in ATC mouse xenograft tumors compared to non-cancerous thyroid tissue (P&lt;.001).
p46931
sg33279
(lp46932
(dp46933
g33284
I5
sg33285
I1
sg33286
I4
sg33295
VP23946
p46934
sg33289
VMCT1
p46935
sa(dp46936
g33284
I14
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VTOMM20
p46937
sasg33281
(lp46938
(dp46939
g33284
I69
sg33285
I1
sg33286
I6
sg33287
VC0027651
p46940
sg33289
Vtumors
p46941
sasa(dp46942
g33277
VATC has metabolic features that distinguish it from PTC and non-cancerous thyroid tissue, including high expression of MCT1 and TOMM20.
p46943
sg33279
(lp46944
(dp46945
g33284
I128
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VTOMM20
p46946
sa(dp46947
g33284
I119
sg33285
I1
sg33286
I4
sg33295
VP23946
p46948
sg33289
VMCT1
p46949
sasg33281
(lp46950
(dp46951
g33284
I52
sg33285
I1
sg33286
I3
sg33287
VC0238463
p46952
sg33289
VPTC
p46953
sasa(dp46954
g33277
VPTC has low expression of MCT1 and non-cancerous thyroid tissue has low expression of both MCT1 and TOMM20.
p46955
sg33279
(lp46956
(dp46957
g33284
I100
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VTOMM20
p46958
sa(dp46959
g33284
I26
sg33285
I1
sg33286
I4
sg33295
VP23946
p46960
sg33289
VMCT1
p46961
sa(dp46962
g33284
I26
sg33285
I1
sg33286
I4
sg33295
VP23946
p46963
sg33289
VMCT1
p46964
sa(dp46965
g33284
I0
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VPTC
p46966
sasg33281
(lp46967
(dp46968
g33284
I0
sg33285
I1
sg33286
I3
sg33287
VC0238463
p46969
sg33289
VPTC
p46970
sasa(dp46971
g33277
VAM can induce a metastatic phenotype in prostate cancer cells through its action on TRPV2 calcium channels and is also capable of influencing localised levels of RANKL in the bone to favour tumourigenesis.
p46972
sg33279
(lp46973
(dp46974
g33284
I84
sg33285
I3
sg33286
I22
sg33295
g11
sg33289
VTRPV2 calcium channels
p46975
sa(dp46976
g33284
I162
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VRANKL
p46977
sasg33281
(lp46978
(dp46979
g33284
I40
sg33285
I2
sg33286
I15
sg33287
VC0600139
p46980
sg33289
Vprostate cancer
p46981
sasa(dp46982
g33277
VTo determine the profiles of soluble cytokine receptors and cytokines, including mostly their ligands, in the vitreous humor of patients with B-cell vitreoretinal lymphoma (VRL) and uveitis.
p46983
sg33279
(lp46984
sg33281
(lp46985
(dp46986
g33284
I163
sg33285
I1
sg33286
I8
sg33287
VC0024299
p46987
sg33289
Vlymphoma
p46988
sa(dp46989
g33284
I182
sg33285
I1
sg33286
I7
sg33287
VC0042164
p46990
sg33289
Vuveitis
p46991
sasa(dp46992
g33277
VIn analyses in patients with VRL, elevation of sVEGFR1 and sVEGFR2 levels was more prominent in patients with systemic metastatic retinal lymphoma (SMRL) than in those with primary VRL/primary central nervous system lymphoma (PVRL/PCNSL).
p46993
sg33279
(lp46994
sg33281
(lp46995
(dp46996
g33284
I231
sg33285
I1
sg33286
I5
sg33287
VC0280803
p46997
sg33289
VPCNSL
p46998
sa(dp46999
g33284
I185
sg33285
I5
sg33286
I39
sg33287
VC0280803
p47000
sg33289
Vprimary central nervous system lymphoma
p47001
sa(dp47002
g33284
I130
sg33285
I2
sg33286
I16
sg33287
VC0339556
p47003
sg33289
Vretinal lymphoma
p47004
sasa(dp47005
g33277
VFor example in prostate cancer cells, the TRPV2 activation following lysophospholipid or adrenomedullin stimulation enhances the invasiveness of cancer cells; furthermore, the increased malignancy of castration-resistant prostate cancer cells was associated with enhanced TRPV2 expression, mainly in metastatic prostate cancer cells.
p47006
sg33279
(lp47007
(dp47008
g33284
I42
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPV2
p47009
sa(dp47010
g33284
I42
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPV2
p47011
sa(dp47012
g33284
I89
sg33285
I1
sg33286
I14
sg33295
VP35318
p47013
sg33289
Vadrenomedullin
p47014
sasg33281
(lp47015
(dp47016
g33284
I300
sg33285
I3
sg33286
I26
sg33287
VC0936223
p47017
sg33289
Vmetastatic prostate cancer
p47018
sa(dp47019
g33284
I186
sg33285
I1
sg33286
I10
sg33287
VC0006826
p47020
sg33289
Vmalignancy
p47021
sa(dp47022
g33284
I15
sg33285
I2
sg33286
I15
sg33287
VC0600139
p47023
sg33289
Vprostate cancer
p47024
sa(dp47025
g33284
I15
sg33285
I2
sg33286
I15
sg33287
VC0600139
p47026
sg33289
Vprostate cancer
p47027
sa(dp47028
g33284
I24
sg33285
I1
sg33286
I6
sg33287
VC0006826
p47029
sg33289
Vcancer
p47030
sasa(dp47031
g33277
VIn this regard, bladder cancer tumors show loss or reduction of a short TRPV2 variant during cancer progression, with increased malignancy and invasiveness.
p47032
sg33279
(lp47033
(dp47034
g33284
I72
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPV2
p47035
sasg33281
(lp47036
(dp47037
g33284
I31
sg33285
I1
sg33286
I6
sg33287
VC0027651
p47038
sg33289
Vtumors
p47039
sa(dp47040
g33284
I128
sg33285
I1
sg33286
I10
sg33287
VC0006826
p47041
sg33289
Vmalignancy
p47042
sa(dp47043
g33284
I93
sg33285
I2
sg33286
I18
sg33287
VC0178874
p47044
sg33289
Vcancer progression
p47045
sa(dp47046
g33284
I16
sg33285
I2
sg33286
I14
sg33287
VC0699885
p47047
sg33289
Vbladder cancer
p47048
sasa(dp47049
g33277
VTRPV2 and TRPM7 expression levels and TRPV2 activator-induced intracellular Ca(2+) increases were significantly higher, whereas TRPV4 expression and TRPV4 activator-induced intracellular Ca(2+) increases were significantly lower in mouse bladder cancer (MBT-2) cells compared to normal mouse urothelial cells.
p47050
sg33279
(lp47051
(dp47052
g33284
I0
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPV2
p47053
sa(dp47054
g33284
I0
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPV2
p47055
sa(dp47056
g33284
I10
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPM7
p47057
sasg33281
(lp47058
(dp47059
g33284
I238
sg33285
I2
sg33286
I14
sg33287
VC0699885
p47060
sg33289
Vbladder cancer
p47061
sasa(dp47062
g33277
VIncreases in the expression of TRPV2 mRNA, immunoreactivity, and TRPV2 activator-induced intracellular Ca(2+) were also observed in T24 human bladder cancer cells.
p47063
sg33279
(lp47064
(dp47065
g33284
I31
sg33285
I2
sg33286
I10
sg33295
g11
sg33289
VTRPV2 mRNA
p47066
sa(dp47067
g33284
I31
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPV2
p47068
sasg33281
(lp47069
(dp47070
g33284
I142
sg33285
I2
sg33286
I14
sg33287
VC0699885
p47071
sg33289
Vbladder cancer
p47072
sasa(dp47073
g33277
VThese results suggested that TRPV2 and TRPM7 were functionally expressed in bladder cancer cells and served as negative regulators of bladder cancer cell proliferation, most likely to prevent excess mechanical stresses.
p47074
sg33279
(lp47075
(dp47076
g33284
I39
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPM7
p47077
sa(dp47078
g33284
I29
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPV2
p47079
sasg33281
(lp47080
(dp47081
g33284
I76
sg33285
I2
sg33286
I14
sg33287
VC0699885
p47082
sg33289
Vbladder cancer
p47083
sa(dp47084
g33284
I76
sg33285
I2
sg33286
I14
sg33287
VC0699885
p47085
sg33289
Vbladder cancer
p47086
sa(dp47087
g33284
I154
sg33285
I1
sg33286
I13
sg33287
VC0334094
p47088
sg33289
Vproliferation
p47089
sasa(dp47090
g33277
VOn the other hand, in prostate cancer cells, Ca2+-dependent activation of TRPV2 induced by lysophospholipids increases the invasion of tumor cells.
p47091
sg33279
(lp47092
(dp47093
g33284
I74
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPV2
p47094
sasg33281
(lp47095
(dp47096
g33284
I123
sg33285
I1
sg33286
I8
sg33287
VC2699153
p47097
sg33289
Vinvasion
p47098
sa(dp47099
g33284
I22
sg33285
I2
sg33286
I15
sg33287
VC0600139
p47100
sg33289
Vprostate cancer
p47101
sa(dp47102
g33284
I135
sg33285
I1
sg33286
I5
sg33287
VC0027651
p47103
sg33289
Vtumor
p47104
sasa(dp47105
g33277
VIn addition, the progression of prostate cancer to the castration-resistant phenotype is characterized by de novo TRPV2 expression, with higher TRPV2 transcript levels in patients with metastatic cancer.
p47106
sg33279
(lp47107
(dp47108
g33284
I114
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPV2
p47109
sa(dp47110
g33284
I144
sg33285
I2
sg33286
I16
sg33295
g11
sg33289
VTRPV2 transcript
p47111
sasg33281
(lp47112
(dp47113
g33284
I17
sg33285
I4
sg33286
I30
sg33287
VC1739135
p47114
sg33289
Vprogression of prostate cancer
p47115
sa(dp47116
g33284
I185
sg33285
I2
sg33286
I17
sg33287
VC0027627
p47117
sg33289
Vmetastatic cancer
p47118
sasa(dp47119
g33277
VThe aim of the present study was to investigate the effects of TRPV2 on the proliferation, migration and invasion of 5637 bladder cancer cells in vitro.
p47120
sg33279
(lp47121
(dp47122
g33284
I63
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPV2
p47123
sasg33281
(lp47124
(dp47125
g33284
I76
sg33285
I1
sg33286
I13
sg33287
VC0334094
p47126
sg33289
Vproliferation
p47127
sa(dp47128
g33284
I105
sg33285
I1
sg33286
I8
sg33287
VC2699153
p47129
sg33289
Vinvasion
p47130
sa(dp47131
g33284
I122
sg33285
I2
sg33286
I14
sg33287
VC0699885
p47132
sg33289
Vbladder cancer
p47133
sasa(dp47134
g33277
VRat TRPV2 cDNA was transfected into 5637 bladder cancer cells and changes in the behavior of the cells were detected.
p47135
sg33279
(lp47136
(dp47137
g33284
I0
sg33285
I3
sg33286
I14
sg33295
g11
sg33289
VRat TRPV2 cDNA
p47138
sasg33281
(lp47139
(dp47140
g33284
I41
sg33285
I2
sg33286
I14
sg33287
VC0699885
p47141
sg33289
Vbladder cancer
p47142
sasa(dp47143
g33277
VIt was observed that TRPV2 enhanced bladder cancer cell migration and invasion; however, it did not affect cell proliferation in vitro.
p47144
sg33279
(lp47145
(dp47146
g33284
I21
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPV2
p47147
sasg33281
(lp47148
(dp47149
g33284
I112
sg33285
I1
sg33286
I13
sg33287
VC0334094
p47150
sg33289
Vproliferation
p47151
sa(dp47152
g33284
I36
sg33285
I2
sg33286
I14
sg33287
VC0699885
p47153
sg33289
Vbladder cancer
p47154
sa(dp47155
g33284
I70
sg33285
I1
sg33286
I8
sg33287
VC2699153
p47156
sg33289
Vinvasion
p47157
sasa(dp47158
g33277
VThe results of this study suggest that TRPV2 channels are a potential therapeutic target for bladder carcinoma.
p47159
sg33279
(lp47160
(dp47161
g33284
I39
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VTRPV2 channels
p47162
sasg33281
(lp47163
(dp47164
g33284
I93
sg33285
I2
sg33286
I17
sg33287
VC0699885
p47165
sg33289
Vbladder carcinoma
p47166
sasa(dp47167
g33277
VThe Transient Receptor Potential channel TRPV2 is known to promote in prostate cancer cell migration and invasive phenotype and is correlated with the stage and grade of bladder cancer.
p47168
sg33279
(lp47169
(dp47170
g33284
I41
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPV2
p47171
sasg33281
(lp47172
(dp47173
g33284
I170
sg33285
I2
sg33286
I14
sg33287
VC0699885
p47174
sg33289
Vbladder cancer
p47175
sa(dp47176
g33284
I70
sg33285
I2
sg33286
I15
sg33287
VC0600139
p47177
sg33289
Vprostate cancer
p47178
sasa(dp47179
g33277
VInitial studies showed that expression profile of some TRP channels, notably TRP melastatin 8 (TRPM8), TRP vanilloid 6 (TRPV6),TRP canonical (TRPC6) and TRPV2, is changing during the development and the progression of prostate cancer towards the hormone-refractory stages.
p47180
sg33279
(lp47181
(dp47182
g33284
I95
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPM8
p47183
sa(dp47184
g33284
I142
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPC6
p47185
sa(dp47186
g33284
I55
sg33285
I1
sg33286
I3
sg33295
VP13686
p47187
sg33289
VTRP
p47188
sa(dp47189
g33284
I120
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPV6
p47190
sa(dp47191
g33284
I103
sg33285
I3
sg33286
I15
sg33295
VP13686
p47192
sg33289
VTRP vanilloid 6
p47193
sa(dp47194
g33284
I153
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VTRPV2
p47195
sa(dp47196
g33284
I55
sg33285
I2
sg33286
I12
sg33295
VP13686
p47197
sg33289
VTRP channels
p47198
sa(dp47199
g33284
I77
sg33285
I3
sg33286
I16
sg33295
VP13686
p47200
sg33289
VTRP melastatin 8
p47201
sasg33281
(lp47202
(dp47203
g33284
I203
sg33285
I4
sg33286
I30
sg33287
VC1739135
p47204
sg33289
Vprogression of prostate cancer
p47205
sasa(dp47206
g33277
VThe expression of TRPV2 mRNA in bladder cancer cell lines (T24, a poorly differentiated UC cell line and RT4, a well-differentiated UC cell line) was analyzed using reverse transcriptase-polymerase chain reaction.
p47207
sg33279
(lp47208
(dp47209
g33284
I18
sg33285
I2
sg33286
I10
sg33295
g11
sg33289
VTRPV2 mRNA
p47210
sa(dp47211
g33284
I165
sg33285
I2
sg33286
I21
sg33295
VP63136
p47212
sg33289
Vreverse transcriptase
p47213
sasg33281
(lp47214
(dp47215
g33284
I32
sg33285
I2
sg33286
I14
sg33287
VC0699885
p47216
sg33289
Vbladder cancer
p47217
sasa(dp47218
g33277
VFurthermore, the effects of resveratrol and Shh on human colorectal cancer HCT116 cells were in a dose- and time-dependent manner.
p47219
sg33279
(lp47220
(dp47221
g33284
I44
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VShh
p47222
sasg33281
(lp47223
(dp47224
g33284
I57
sg33285
I2
sg33286
I17
sg33287
VC1527249
p47225
sg33289
Vcolorectal cancer
p47226
sasa(dp47227
g33277
VFurthermore, knockdown of PFTK1 suppressed the expression of Shh as well as Smo, Ptc, and Gli-1 in colon cancer cells.
p47228
sg33279
(lp47229
(dp47230
g33284
I76
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VSmo
p47231
sa(dp47232
g33284
I61
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VShh
p47233
sa(dp47234
g33284
I81
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VPtc
p47235
sa(dp47236
g33284
I90
sg33285
I1
sg33286
I5
sg33295
VP08151
p47237
sg33289
VGli-1
p47238
sasg33281
(lp47239
(dp47240
g33284
I99
sg33285
I2
sg33286
I12
sg33287
VC0699790
p47241
sg33289
Vcolon cancer
p47242
sa(dp47243
g33284
I81
sg33285
I1
sg33286
I3
sg33287
VC0238463
p47244
sg33289
VPtc
p47245
sasa(dp47246
g33277
VTaken together, these results suggest that knockdown of PFTK1 inhibited the proliferation and invasion of colon cancer cells as well as the EMT progress by suppressing the Sonic hedgehog signaling pathway.
p47247
sg33279
(lp47248
(dp47249
g33284
I140
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VEMT
p47250
sa(dp47251
g33284
I172
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VSonic hedgehog
p47252
sasg33281
(lp47253
(dp47254
g33284
I106
sg33285
I2
sg33286
I12
sg33287
VC0699790
p47255
sg33289
Vcolon cancer
p47256
sa(dp47257
g33284
I76
sg33285
I1
sg33286
I13
sg33287
VC0334094
p47258
sg33289
Vproliferation
p47259
sa(dp47260
g33284
I94
sg33285
I1
sg33286
I8
sg33287
VC2699153
p47261
sg33289
Vinvasion
p47262
sasa(dp47263
g33277
VThis case illustrates the potential severity of the renal anomalies in the BOR syndrome and the inadequacy of oligohydramnios and maternal serum alpha-fetoprotein as screening methods for renal agenesis.
p47264
sg33279
(lp47265
sg33281
(lp47266
(dp47267
g33284
I75
sg33285
I2
sg33286
I12
sg33287
VC0265234
p47268
sg33289
VBOR syndrome
p47269
sa(dp47270
g33284
I52
sg33285
I2
sg33286
I15
sg33287
VC0266292
p47271
sg33289
Vrenal anomalies
p47272
sa(dp47273
g33284
I188
sg33285
I2
sg33286
I14
sg33287
VC0542519
p47274
sg33289
Vrenal agenesis
p47275
sa(dp47276
g33284
I110
sg33285
I1
sg33286
I15
sg33287
VC0079924
p47277
sg33289
Voligohydramnios
p47278
sasa(dp47279
g33277
VSevere sepsis and antibiotic use were both associated with moderate thrombocytopenia, and proton pump inhibitor use was statistically significant in both univariate and multivariate analysis.
p47280
sg33279
(lp47281
sg33281
(lp47282
(dp47283
g33284
I0
sg33285
I2
sg33286
I13
sg33287
VC1719672
p47284
sg33289
VSevere sepsis
p47285
sasa(dp47286
g33277
VThrombocytopenia is associated with poor prognosis, and the association between moderate thrombocytopenia and proton pump inhibitor use is relatively novel and should be validated in prospective studies.
p47287
sg33279
(lp47288
sg33281
(lp47289
sa(dp47290
g33277
VWe identified 12 biomarkers consistently associated with either clinical groups "upstream" towards culture-positive TB on the TB disease spectrum (CD14, FCGR1A, FPR1, MMP9, RAB24, SEC14L1, and TIMP2) or "downstream" towards a decreased likelihood of TB disease (BLR1, CD3E, CD8A, IL7R, and TGFBR2), suggesting a correlation with MTB-related pathology and high relevance to a future POC test for pediatric TB.
p47291
sg33279
(lp47292
(dp47293
g33284
I147
sg33285
I1
sg33286
I4
sg33295
VP08571
p47294
sg33289
VCD14
p47295
sa(dp47296
g33284
I173
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VRAB24
p47297
sa(dp47298
g33284
I153
sg33285
I1
sg33286
I6
sg33295
VP12314
p47299
sg33289
VFCGR1A
p47300
sa(dp47301
g33284
I268
sg33285
I1
sg33286
I4
sg33295
VP07766
p47302
sg33289
VCD3E
p47303
sa(dp47304
g33284
I274
sg33285
I1
sg33286
I4
sg33295
VP01732
p47305
sg33289
VCD8A
p47306
sa(dp47307
g33284
I262
sg33285
I1
sg33286
I4
sg33295
VP32302
p47308
sg33289
VBLR1
p47309
sa(dp47310
g33284
I180
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VSEC14L1
p47311
sa(dp47312
g33284
I167
sg33285
I1
sg33286
I4
sg33295
VP14780
p47313
sg33289
VMMP9
p47314
sa(dp47315
g33284
I193
sg33285
I1
sg33286
I5
sg33295
VP16035
p47316
sg33289
VTIMP2
p47317
sa(dp47318
g33284
I161
sg33285
I1
sg33286
I4
sg33295
VP21462
p47319
sg33289
VFPR1
p47320
sa(dp47321
g33284
I290
sg33285
I1
sg33286
I6
sg33295
VP37173
p47322
sg33289
VTGFBR2
p47323
sasg33281
(lp47324
(dp47325
g33284
I341
sg33285
I1
sg33286
I9
sg33287
VC0677042
p47326
sg33289
Vpathology
p47327
sasa(dp47328
g33277
VWestern blot assay further confirmed that anti-ICAM-T0901317 liposomes inhibited retinoblastoma (Rb) phosphorylation and MCM6 expression.
p47329
sg33279
(lp47330
(dp47331
g33284
I81
sg33285
I2
sg33286
I19
sg33295
g11
sg33289
Vretinoblastoma (Rb)
p47332
sa(dp47333
g33284
I121
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VMCM6
p47334
sasg33281
(lp47335
(dp47336
g33284
I97
sg33285
I1
sg33286
I2
sg33287
VC0035335
p47337
sg33289
VRb
p47338
sa(dp47339
g33284
I81
sg33285
I1
sg33286
I14
sg33287
VC0035335
p47340
sg33289
Vretinoblastoma
p47341
sasa(dp47342
g33277
VInhibition of MCM6 and MCM7 expression by nTZDpa and rosiglitazone paralleled their effect to inhibit phosphorylation of the retinoblastoma protein and cell proliferation.
p47343
sg33279
(lp47344
(dp47345
g33284
I125
sg33285
I2
sg33286
I22
sg33295
g11
sg33289
Vretinoblastoma protein
p47346
sa(dp47347
g33284
I23
sg33285
I1
sg33286
I4
sg33295
VP33993
p47348
sg33289
VMCM7
p47349
sa(dp47350
g33284
I14
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VMCM6
p47351
sasg33281
(lp47352
(dp47353
g33284
I125
sg33285
I1
sg33286
I14
sg33287
VC0035335
p47354
sg33289
Vretinoblastoma
p47355
sa(dp47356
g33284
I157
sg33285
I1
sg33286
I13
sg33287
VC0334094
p47357
sg33289
Vproliferation
p47358
sasa(dp47359
g33277
VSnord3A expression was also elevated in scrapie infected mice, but not in PrP(0/0) mice, indicating that while the expression levels of this transcript may reflect diverse prion etiologies, they are not related to the loss of PrP(C)'s function.
p47360
sg33279
(lp47361
(dp47362
g33284
I74
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VPrP
p47363
sasg33281
(lp47364
(dp47365
g33284
I40
sg33285
I1
sg33286
I7
sg33287
VC0036457
p47366
sg33289
Vscrapie
p47367
sasa(dp47368
g33277
VWe hypothesize that in addition to its function as a disease marker, Snord3A may play an important role in the mechanism of prion disease manifestation and progression.
p47369
sg33279
(lp47370
sg33281
(lp47371
(dp47372
g33284
I124
sg33285
I2
sg33286
I13
sg33287
VC0162534
p47373
sg33289
Vprion disease
p47374
sasa(dp47375
g33277
VHer son has type 1 diabetes, arthritis, reduced IgG levels and IgA deficiency, but has not inherited the TNFRSF13B/TACI mutation.
p47376
sg33279
(lp47377
(dp47378
g33284
I63
sg33285
I1
sg33286
I3
sg33295
VP11912
p47379
sg33289
VIgA
p47380
sa(dp47381
g33284
I105
sg33285
I1
sg33286
I9
sg33295
g11
sg33289
VTNFRSF13B
p47382
sa(dp47383
g33284
I115
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTACI
p47384
sasg33281
(lp47385
(dp47386
g33284
I29
sg33285
I1
sg33286
I9
sg33287
VC0003864
p47387
sg33289
Varthritis
p47388
sa(dp47389
g33284
I12
sg33285
I3
sg33286
I15
sg33287
VC0011854
p47390
sg33289
Vtype 1 diabetes
p47391
sa(dp47392
g33284
I63
sg33285
I2
sg33286
I14
sg33287
VC0162538
p47393
sg33289
VIgA deficiency
p47394
sasa(dp47395
g33277
VOur results support the hypothesis that increased TACI expression on NOD B cells contributes to the pathogenesis of type 1 diabetes in the NOD mouse.
p47396
sg33279
(lp47397
(dp47398
g33284
I69
sg33285
I2
sg33286
I5
sg33295
VP54259
p47399
sg33289
VNOD B
p47400
sa(dp47401
g33284
I50
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTACI
p47402
sasg33281
(lp47403
(dp47404
g33284
I116
sg33285
I3
sg33286
I15
sg33287
VC0011854
p47405
sg33289
Vtype 1 diabetes
p47406
sa(dp47407
g33284
I69
sg33285
I1
sg33286
I3
sg33287
VC0751781
p47408
sg33289
VNOD
p47409
sa(dp47410
g33284
I69
sg33285
I1
sg33286
I3
sg33287
VC0751781
p47411
sg33289
VNOD
p47412
sa(dp47413
g33284
I100
sg33285
I1
sg33286
I12
sg33287
VC0699748
p47414
sg33289
Vpathogenesis
p47415
sasa(dp47416
g33277
VA family member with a wild type TACI variant had CVID-related phenotype including IgA deficiency and type 1 diabetes.
p47417
sg33279
(lp47418
(dp47419
g33284
I50
sg33285
I2
sg33286
I22
sg33295
g11
sg33289
VCVID-related phenotype
p47420
sa(dp47421
g33284
I23
sg33285
I4
sg33286
I22
sg33295
g11
sg33289
Vwild type TACI variant
p47422
sa(dp47423
g33284
I83
sg33285
I1
sg33286
I3
sg33295
VP11912
p47424
sg33289
VIgA
p47425
sasg33281
(lp47426
(dp47427
g33284
I102
sg33285
I3
sg33286
I15
sg33287
VC0011854
p47428
sg33289
Vtype 1 diabetes
p47429
sa(dp47430
g33284
I50
sg33285
I1
sg33286
I4
sg33287
VC0009447
p47431
sg33289
VCVID
p47432
sa(dp47433
g33284
I83
sg33285
I2
sg33286
I14
sg33287
VC0162538
p47434
sg33289
VIgA deficiency
p47435
sasa(dp47436
g33277
VWe mapped the loci contributing to the increased proportion of TACI(high) expressing splenic B cells and found that the control of TACI expression was strongly linked to chromosome 1, in a region which includes the insulin-dependent diabetes (Idd) 5 loci.
p47437
sg33279
(lp47438
(dp47439
g33284
I63
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VTACI
p47440
sa(dp47441
g33284
I215
sg33285
I1
sg33286
I7
sg33295
VP01308
p47442
sg33289
Vinsulin
p47443
sasg33281
(lp47444
(dp47445
g33284
I215
sg33285
I2
sg33286
I26
sg33287
VC0011854
p47446
sg33289
Vinsulin-dependent diabetes
p47447
sa(dp47448
g33284
I243
sg33285
I1
sg33286
I3
sg33287
VC0011854
p47449
sg33289
VIdd
p47450
sasa(dp47451
g33277
VOur findings corroborate the notion that B cell deviations contribute to type 1 diabetes development, and suggest a temporal regulation of TACI(high) expression, possibly influenced by the ongoing autoimmune process.
p47452
sg33279
(lp47453
sg33281
(lp47454
(dp47455
g33284
I73
sg33285
I3
sg33286
I15
sg33287
VC0011854
p47456
sg33289
Vtype 1 diabetes
p47457
sa(dp47458
g33284
I197
sg33285
I2
sg33286
I18
sg33287
VC0443146
p47459
sg33289
Vautoimmune process
p47460
sasa(dp47461
g33277
VOctamer-binding transcription factor 4 (OCT4) was closely related to pancreatic cancer progression, but its regulation in pancreatic cancer by microRNA (miRNA) is not fully clear.
p47462
sg33279
(lp47463
(dp47464
g33284
I0
sg33285
I4
sg33286
I38
sg33295
VP15884
p47465
sg33289
VOctamer-binding transcription factor 4
p47466
sa(dp47467
g33284
I40
sg33285
I1
sg33286
I4
sg33295
VP15884
p47468
sg33289
VOCT4
p47469
sasg33281
(lp47470
(dp47471
g33284
I69
sg33285
I2
sg33286
I17
sg33287
VC0235974
p47472
sg33289
Vpancreatic cancer
p47473
sa(dp47474
g33284
I80
sg33285
I2
sg33286
I18
sg33287
VC0178874
p47475
sg33289
Vcancer progression
p47476
sasa(dp47477
g33277
VThis study was designed to investigate the expression of the T-box transcription factor 4 (TBX4), a tumor biomarker that was previously identified by proteomics, in pancreatic ductal adenocarcinoma (PDAC) and evaluate its clinical utility as a potential prognostic biomarkers for PDAC.
p47478
sg33279
(lp47479
(dp47480
g33284
I91
sg33285
I1
sg33286
I4
sg33295
VP57082
p47481
sg33289
VTBX4
p47482
sa(dp47483
g33284
I61
sg33285
I4
sg33286
I28
sg33295
VP15884
p47484
sg33289
VT-box transcription factor 4
p47485
sasg33281
(lp47486
(dp47487
g33284
I100
sg33285
I1
sg33286
I5
sg33287
VC0027651
p47488
sg33289
Vtumor
p47489
sa(dp47490
g33284
I199
sg33285
I1
sg33286
I4
sg33287
VC1335302
p47491
sg33289
VPDAC
p47492
sa(dp47493
g33284
I199
sg33285
I1
sg33286
I4
sg33287
VC1335302
p47494
sg33289
VPDAC
p47495
sa(dp47496
g33284
I165
sg33285
I3
sg33286
I32
sg33287
VC1335302
p47497
sg33289
Vpancreatic ductal adenocarcinoma
p47498
sasa(dp47499
g33277
VWhereas the pathological functions of LTB4/BLT1 axis in allergy, autoimmunity and cardiovascular disorders are well established; its role in cancer is only beginning to emerge.
p47500
sg33279
(lp47501
(dp47502
g33284
I43
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VBLT1
p47503
sasg33281
(lp47504
(dp47505
g33284
I141
sg33285
I1
sg33286
I6
sg33287
VC0006826
p47506
sg33289
Vcancer
p47507
sa(dp47508
g33284
I56
sg33285
I1
sg33286
I7
sg33287
VC0020517
p47509
sg33289
Vallergy
p47510
sa(dp47511
g33284
I65
sg33285
I1
sg33286
I12
sg33287
VC0004368
p47512
sg33289
Vautoimmunity
p47513
sa(dp47514
g33284
I82
sg33285
I2
sg33286
I24
sg33287
VC0007222
p47515
sg33289
Vcardiovascular disorders
p47516
sasa(dp47517
g33277
VBioluminescence tomography (BLT) is a powerful non-invasive molecular imaging tool for in vivo studies of glioma in mice.
p47518
sg33279
(lp47519
sg33281
(lp47520
(dp47521
g33284
I106
sg33285
I1
sg33286
I6
sg33287
VC0017638
p47522
sg33289
Vglioma
p47523
sasa(dp47524
g33277
VTo the best of our knowledge, this is the first study that achieved such accurate BLT morphological reconstruction of orthotopic glioma without using any segmented tumor structure from any other structural imaging modalities as the prior for reconstruction guidance.
p47525
sg33279
(lp47526
sg33281
(lp47527
(dp47528
g33284
I129
sg33285
I1
sg33286
I6
sg33287
VC0017638
p47529
sg33289
Vglioma
p47530
sa(dp47531
g33284
I164
sg33285
I1
sg33286
I5
sg33287
VC0027651
p47532
sg33289
Vtumor
p47533
sasa(dp47534
g33277
VThis enabled BLT more suitable and practical for in vivo imaging of orthotopic glioma mouse models.
p47535
sg33279
(lp47536
sg33281
(lp47537
(dp47538
g33284
I79
sg33285
I1
sg33286
I6
sg33287
VC0017638
p47539
sg33289
Vglioma
p47540
sasa(dp47541
g33277
VThe major objective of this study is to address this gap in our understanding of how IDO1 expression contributes to the biology of GBM, and whether its level of expression is a determinant of GBM patient outcome.Experimental Design: Patient-resected GBM, The Cancer Genome Atlas, human T-cell:GBM cocultures, as well as nu/nu, NOD-scid, and humanized (NSG-SGM3-BLT) mice-engrafted human GBM form the basis of our investigation.Results:In situ hybridization for IDO1 revealed transcript expression throughout patient-resected GBM, whereas immunohistochemical IDO1 positivity was highly variable.
p47542
sg33279
(lp47543
(dp47544
g33284
I85
sg33285
I1
sg33286
I4
sg33295
VP14902
p47545
sg33289
VIDO1
p47546
sa(dp47547
g33284
I85
sg33285
I1
sg33286
I4
sg33295
VP14902
p47548
sg33289
VIDO1
p47549
sasg33281
(lp47550
(dp47551
g33284
I331
sg33285
I1
sg33286
I4
sg33287
VC0085110
p47552
sg33289
Vscid
p47553
sa(dp47554
g33284
I131
sg33285
I1
sg33286
I3
sg33287
VC0017636
p47555
sg33289
VGBM
p47556
sa(dp47557
g33284
I259
sg33285
I1
sg33286
I6
sg33287
VC0006826
p47558
sg33289
VCancer
p47559
sa(dp47560
g33284
I327
sg33285
I1
sg33286
I3
sg33287
VC0751781
p47561
sg33289
VNOD
p47562
sa(dp47563
g33284
I131
sg33285
I1
sg33286
I3
sg33287
VC0017636
p47564
sg33289
VGBM
p47565
sa(dp47566
g33284
I131
sg33285
I1
sg33286
I3
sg33287
VC0017636
p47567
sg33289
VGBM
p47568
sa(dp47569
g33284
I131
sg33285
I1
sg33286
I3
sg33287
VC0017636
p47570
sg33289
VGBM
p47571
sa(dp47572
g33284
I131
sg33285
I1
sg33286
I3
sg33287
VC0017636
p47573
sg33289
VGBM
p47574
sa(dp47575
g33284
I131
sg33285
I1
sg33286
I3
sg33287
VC0017636
p47576
sg33289
VGBM
p47577
sasa(dp47578
g33277
VTogether with CT, BLT can provide precision radiation guidance and robust tumor volume assessment in small animal cancer research.
p47579
sg33279
(lp47580
sg33281
(lp47581
(dp47582
g33284
I114
sg33285
I1
sg33286
I6
sg33287
VC0006826
p47583
sg33289
Vcancer
p47584
sa(dp47585
g33284
I74
sg33285
I1
sg33286
I5
sg33287
VC0027651
p47586
sg33289
Vtumor
p47587
sasa(dp47588
g33277
VVariation of detected bioluminescence signals emitted from molecular cancer cells was depicted on BLT images.
p47589
sg33279
(lp47590
sg33281
(lp47591
(dp47592
g33284
I69
sg33285
I1
sg33286
I6
sg33287
VC0006826
p47593
sg33289
Vcancer
p47594
sasa(dp47595
g33277
VMultispectral BLT images elaborated on early detection of cancer cells, characteristics of tumor growth, and metastasis for more accurate determination of internal bioluminescent sources.
p47596
sg33279
(lp47597
sg33281
(lp47598
(dp47599
g33284
I58
sg33285
I1
sg33286
I6
sg33287
VC0006826
p47600
sg33289
Vcancer
p47601
sa(dp47602
g33284
I91
sg33285
I2
sg33286
I12
sg33287
VC0598934
p47603
sg33289
Vtumor growth
p47604
sa(dp47605
g33284
I109
sg33285
I1
sg33286
I10
sg33287
VC0027627
p47606
sg33289
Vmetastasis
p47607
sasa(dp47608
g33277
VRegistration of BLT with CT images guided molecular cancer cells on anatomical coordinates.
p47609
sg33279
(lp47610
sg33281
(lp47611
(dp47612
g33284
I52
sg33285
I1
sg33286
I6
sg33287
VC0006826
p47613
sg33289
Vcancer
p47614
sasa(dp47615
g33277
VThe BLT imaging was a useful tool to localize cancer cells and to quantify radiation response.
p47616
sg33279
(lp47617
sg33281
(lp47618
(dp47619
g33284
I46
sg33285
I1
sg33286
I6
sg33287
VC0006826
p47620
sg33289
Vcancer
p47621
sasa(dp47622
g33277
VApplication of BLT led to more accurate definition of tumor volumes including molecular probe-based microscopic cancer cells.
p47623
sg33279
(lp47624
sg33281
(lp47625
(dp47626
g33284
I54
sg33285
I1
sg33286
I5
sg33287
VC0027651
p47627
sg33289
Vtumor
p47628
sa(dp47629
g33284
I112
sg33285
I1
sg33286
I6
sg33287
VC0006826
p47630
sg33289
Vcancer
p47631
sasa(dp47632
g33277
VThus, in this report, we not only provide a novel strategy to expand super-charged NK cells, but also demonstrate that rapid and sustained expansion of residual T cells within the purified NK cells during expansion with DCs or OCs could be a potential mechanism by which the numbers and function of NK cells decline in cancer patients and in BLT-humanized mice.
p47633
sg33279
(lp47634
sg33281
(lp47635
(dp47636
g33284
I220
sg33285
I1
sg33286
I3
sg33287
VC0268238
p47637
sg33289
VDCs
p47638
sa(dp47639
g33284
I319
sg33285
I1
sg33286
I6
sg33287
VC0006826
p47640
sg33289
Vcancer
p47641
sasa(dp47642
g33277
VVerrucous carcinoma (VC) is a variant of well-differentiated squamous cell carcinoma and in the anal region is regarded as synonymous with giant condyloma (Buschke-Loewenstein tumour) (BLT).
p47643
sg33279
(lp47644
sg33281
(lp47645
(dp47646
g33284
I176
sg33285
I1
sg33286
I6
sg33287
VC0027651
p47647
sg33289
Vtumour
p47648
sa(dp47649
g33284
I145
sg33285
I1
sg33286
I9
sg33287
VC0009663
p47650
sg33289
Vcondyloma
p47651
sa(dp47652
g33284
I0
sg33285
I2
sg33286
I19
sg33287
VC0206706
p47653
sg33289
VVerrucous carcinoma
p47654
sa(dp47655
g33284
I139
sg33285
I1
sg33286
I5
sg33287
VC0017547
p47656
sg33289
Vgiant
p47657
sa(dp47658
g33284
I21
sg33285
I1
sg33286
I2
sg33287
VC0206706
p47659
sg33289
VVC
p47660
sa(dp47661
g33284
I61
sg33285
I3
sg33286
I23
sg33287
VC0007137
p47662
sg33289
Vsquamous cell carcinoma
p47663
sasa(dp47664
g33277
VTo test this idea, we infected migrating neural crest cells of chicken embryos with  replication-competent avian sarcoma virus expressing either FgfR2(C278F), a receptor mutation found in Crouzon syndrome or the ligand Fgf8.
p47665
sg33279
(lp47666
(dp47667
g33284
I219
sg33285
I1
sg33286
I4
sg33295
VP55075
p47668
sg33289
VFgf8
p47669
sasg33281
(lp47670
(dp47671
g33284
I48
sg33285
I1
sg33286
I5
sg33287
VC0206138
p47672
sg33289
Vcrest
p47673
sa(dp47674
g33284
I188
sg33285
I2
sg33286
I16
sg33287
VC0010273
p47675
sg33289
VCrouzon syndrome
p47676
sa(dp47677
g33284
I107
sg33285
I2
sg33286
I13
sg33287
VC0004426
p47678
sg33289
Vavian sarcoma
p47679
sasa(dp47680
g33277
VThese defects are similar in presentation to several human craniofacial disorders (e.g., craniosynostosis, hemifacial microsomia), and may be related to increased levels of bone metabolism observed in ace(ti282a)/fgf8 heterozygotes.
p47681
sg33279
(lp47682
(dp47683
g33284
I213
sg33285
I1
sg33286
I4
sg33295
VP55075
p47684
sg33289
Vfgf8
p47685
sasg33281
(lp47686
(dp47687
g33284
I89
sg33285
I1
sg33286
I16
sg33287
VC0010278
p47688
sg33289
Vcraniosynostosis
p47689
sa(dp47690
g33284
I107
sg33285
I2
sg33286
I21
sg33287
VC1306710
p47691
sg33289
Vhemifacial microsomia
p47692
sasa(dp47693
g33277
VSince FGF8 maps to the same chromosomal region as FGFR2, has indeed been shown to be a ligand for FGFR2, and has an expression pattern consistent with limb and craniofacial anomalies, we have screened two kindreds with Pfeiffer syndrome that were previously linked to markers from 10q24-25 and a large number of individuals with craniosynostosis and limb anomalies for mutations in the coding sequence of FGF8.
p47694
sg33279
(lp47695
(dp47696
g33284
I6
sg33285
I1
sg33286
I4
sg33295
VP55075
p47697
sg33289
VFGF8
p47698
sa(dp47699
g33284
I6
sg33285
I1
sg33286
I4
sg33295
VP55075
p47700
sg33289
VFGF8
p47701
sasg33281
(lp47702
(dp47703
g33284
I329
sg33285
I1
sg33286
I16
sg33287
VC0010278
p47704
sg33289
Vcraniosynostosis
p47705
sa(dp47706
g33284
I219
sg33285
I2
sg33286
I17
sg33287
VC0265303
p47707
sg33289
VPfeiffer syndrome
p47708
sasa(dp47709
g33277
VThe results demonstrated that rhTrx-1 significantly improved neurological functions and reduced cerebral infarction and apoptotic cell death at 24h after MCAO.
p47710
sg33279
(lp47711
sg33281
(lp47712
(dp47713
g33284
I96
sg33285
I2
sg33286
I19
sg33287
VC0038454
p47714
sg33289
Vcerebral infarction
p47715
sasa(dp47716
g33277
VTreatment with Trx1 siRNA significantly increased mortality, behavioral deficits, and cerebral infarction volume and exacerbated neuronal cell apoptotic death after MCAO injury.
p47717
sg33279
(lp47718
(dp47719
g33284
I15
sg33285
I2
sg33286
I10
sg33295
VP60606
p47720
sg33289
VTrx1 siRNA
p47721
sasg33281
(lp47722
(dp47723
g33284
I86
sg33285
I2
sg33286
I19
sg33287
VC0038454
p47724
sg33289
Vcerebral infarction
p47725
sasa(dp47726
g33277
VThe results showed that intravenously administered rhTrx-1 (10 mg/kg) significantly improved neurological functions and reduced cerebral infarction and apoptotic cell death following cerebral ischemia.
p47727
sg33279
(lp47728
sg33281
(lp47729
(dp47730
g33284
I128
sg33285
I2
sg33286
I19
sg33287
VC0038454
p47731
sg33289
Vcerebral infarction
p47732
sa(dp47733
g33284
I183
sg33285
I2
sg33286
I17
sg33287
VC0917798
p47734
sg33289
Vcerebral ischemia
p47735
sasa(dp47736
g33277
VFurthermore, the suppression on ONOO- formation by either rhTrx-1 or an ONOO- scavenger uric acid reduced cerebral infarct size in mice subjected to cerebral ischemia.
p47737
sg33279
(lp47738
sg33281
(lp47739
(dp47740
g33284
I149
sg33285
I2
sg33286
I17
sg33287
VC0007785
p47741
sg33289
Vcerebral ischemia
p47742
sa(dp47743
g33284
I17
sg33285
I1
sg33286
I11
sg33287
VC0221103
p47744
sg33289
Vsuppression
p47745
sa(dp47746
g33284
I106
sg33285
I2
sg33286
I16
sg33287
VC0007785
p47747
sg33289
Vcerebral infarct
p47748
sasa(dp47749
g33277
VProenkephalin (pro-ENK), a stable and reliable surrogate marker for unstable enkephalins, was found to be associated with acute kidney injury and chronic renal failure in previous studies.
p47750
sg33279
(lp47751
(dp47752
g33284
I0
sg33285
I1
sg33286
I13
sg33295
VP01210
p47753
sg33289
VProenkephalin
p47754
sa(dp47755
g33284
I15
sg33285
I1
sg33286
I7
sg33295
VP01210
p47756
sg33289
Vpro-ENK
p47757
sasg33281
(lp47758
(dp47759
g33284
I146
sg33285
I3
sg33286
I21
sg33287
VC0022661
p47760
sg33289
Vchronic renal failure
p47761
sasa(dp47762
g33277
VPENK and NGAL concentrations were measured and GFR was estimated by using the isotope dilution mass spectrometry traceable-Modification of Diet in Renal Disease (MDRD) Study and three Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations: CKD-EPI(Cr), CDK-EPI(CysC), and CKD-EPI(Cr-CysC).
p47763
sg33279
(lp47764
(dp47765
g33284
I268
sg33285
I1
sg33286
I7
sg33295
VP10646
p47766
sg33289
VCDK-EPI
p47767
sa(dp47768
g33284
I0
sg33285
I1
sg33286
I4
sg33295
VP01210
p47769
sg33289
VPENK
p47770
sa(dp47771
g33284
I184
sg33285
I5
sg33286
I49
sg33295
VP10646
p47772
sg33289
VChronic Kidney Disease Epidemiology Collaboration
p47773
sa(dp47774
g33284
I9
sg33285
I1
sg33286
I4
sg33295
VP80188
p47775
sg33289
VNGAL
p47776
sa(dp47777
g33284
I295
sg33285
I1
sg33286
I7
sg33295
VP22676
p47778
sg33289
VCr-CysC
p47779
sa(dp47780
g33284
I235
sg33285
I1
sg33286
I7
sg33295
VP10646
p47781
sg33289
VCKD-EPI
p47782
sasg33281
(lp47783
(dp47784
g33284
I184
sg33285
I3
sg33286
I22
sg33287
VC1561643
p47785
sg33289
VChronic Kidney Disease
p47786
sa(dp47787
g33284
I239
sg33285
I1
sg33286
I3
sg33287
VC0267963
p47788
sg33289
VEPI
p47789
sa(dp47790
g33284
I147
sg33285
I2
sg33286
I13
sg33287
VC0022658
p47791
sg33289
VRenal Disease
p47792
sa(dp47793
g33284
I239
sg33285
I1
sg33286
I3
sg33287
VC0267963
p47794
sg33289
VEPI
p47795
sa(dp47796
g33284
I239
sg33285
I1
sg33286
I3
sg33287
VC0267963
p47797
sg33289
VEPI
p47798
sa(dp47799
g33284
I239
sg33285
I1
sg33286
I3
sg33287
VC0267963
p47800
sg33289
VEPI
p47801
sasa(dp47802
g33277
VProenkephalin cleavage products stored within cells, which included the 5.3-kDa peptide, could be released upon stimulation of cells with BaCl2 (2-fold above basal levels), 8-bromo-cAMP or CRF (7- and 8-fold above basal levels, respectively), and a mixture of BaCl2 and 8-bromo-cAMP (20-fold above basal levels).
p47803
sg33279
(lp47804
(dp47805
g33284
I0
sg33285
I1
sg33286
I13
sg33295
VP01210
p47806
sg33289
VProenkephalin
p47807
sasg33281
(lp47808
(dp47809
g33284
I189
sg33285
I1
sg33286
I3
sg33287
VC0022661
p47810
sg33289
VCRF
p47811
sasa(dp47812
g33277
VPart 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a summary and outlook.
p47813
sg33279
(lp47814
(dp47815
g33284
I59
sg33285
I12
sg33286
I126
sg33295
g11
sg33289
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p47816
sa(dp47817
g33284
I527
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VAP3B2
p47818
sa(dp47819
g33284
I247
sg33285
I7
sg33286
I61
sg33295
VP05129
p47820
sg33289
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p47821
sa(dp47822
g33284
I18
sg33285
I4
sg33286
I38
sg33295
VP42261
p47823
sg33289
Vanti-metabotropic glutamate receptor 1
p47824
sa(dp47825
g33284
I356
sg33285
I4
sg33286
I49
sg33295
g11
sg33289
Vanti-voltage-gated calcium channel-associated ACA
p47826
sa(dp47827
g33284
I476
sg33285
I4
sg33286
I40
sg33295
VP01133
p47828
sg33289
Vepidermal growth factor-related receptor
p47829
sasg33281
(lp47830
(dp47831
g33284
I227
sg33285
I1
sg33286
I3
sg33287
VC0007758
p47832
sg33289
VACA
p47833
sa(dp47834
g33284
I227
sg33285
I1
sg33286
I3
sg33287
VC0007758
p47835
sg33289
VACA
p47836
sa(dp47837
g33284
I227
sg33285
I1
sg33286
I3
sg33287
VC0007758
p47838
sg33289
VACA
p47839
sa(dp47840
g33284
I197
sg33285
I3
sg33286
I28
sg33287
VC0007758
p47841
sg33289
Vautoimmune cerebellar ataxia
p47842
sa(dp47843
g33284
I543
sg33285
I2
sg33286
I23
sg33287
VC0262404
p47844
sg33289
Vcerebellar degeneration
p47845
sasa(dp47846
g33277
VPart 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects, and provides a summary and outlook.
p47847
sg33279
(lp47848
(dp47849
g33284
I59
sg33285
I12
sg33286
I126
sg33295
g11
sg33289
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p47850
sa(dp47851
g33284
I527
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VAP3B2
p47852
sa(dp47853
g33284
I247
sg33285
I7
sg33286
I61
sg33295
VP05129
p47854
sg33289
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p47855
sa(dp47856
g33284
I18
sg33285
I4
sg33286
I38
sg33295
VP42261
p47857
sg33289
Vanti-metabotropic glutamate receptor 1
p47858
sa(dp47859
g33284
I356
sg33285
I4
sg33286
I49
sg33295
g11
sg33289
Vanti-voltage-gated calcium channel-associated ACA
p47860
sa(dp47861
g33284
I476
sg33285
I4
sg33286
I40
sg33295
VP01133
p47862
sg33289
Vepidermal growth factor-related receptor
p47863
sasg33281
(lp47864
(dp47865
g33284
I227
sg33285
I1
sg33286
I3
sg33287
VC0007758
p47866
sg33289
VACA
p47867
sa(dp47868
g33284
I227
sg33285
I1
sg33286
I3
sg33287
VC0007758
p47869
sg33289
VACA
p47870
sa(dp47871
g33284
I227
sg33285
I1
sg33286
I3
sg33287
VC0007758
p47872
sg33289
VACA
p47873
sa(dp47874
g33284
I197
sg33285
I3
sg33286
I28
sg33287
VC0007758
p47875
sg33289
Vautoimmune cerebellar ataxia
p47876
sa(dp47877
g33284
I543
sg33285
I2
sg33286
I23
sg33287
VC0262404
p47878
sg33289
Vcerebellar degeneration
p47879
sasa(dp47880
g33277
VPart 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a summary and outlook.
p47881
sg33279
(lp47882
(dp47883
g33284
I59
sg33285
I12
sg33286
I126
sg33295
g11
sg33289
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p47884
sa(dp47885
g33284
I527
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VAP3B2
p47886
sa(dp47887
g33284
I247
sg33285
I7
sg33286
I61
sg33295
VP05129
p47888
sg33289
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p47889
sa(dp47890
g33284
I18
sg33285
I4
sg33286
I38
sg33295
VP42261
p47891
sg33289
Vanti-metabotropic glutamate receptor 1
p47892
sa(dp47893
g33284
I356
sg33285
I4
sg33286
I49
sg33295
g11
sg33289
Vanti-voltage-gated calcium channel-associated ACA
p47894
sa(dp47895
g33284
I476
sg33285
I4
sg33286
I40
sg33295
VP01133
p47896
sg33289
Vepidermal growth factor-related receptor
p47897
sasg33281
(lp47898
(dp47899
g33284
I227
sg33285
I1
sg33286
I3
sg33287
VC0007758
p47900
sg33289
VACA
p47901
sa(dp47902
g33284
I227
sg33285
I1
sg33286
I3
sg33287
VC0007758
p47903
sg33289
VACA
p47904
sa(dp47905
g33284
I227
sg33285
I1
sg33286
I3
sg33287
VC0007758
p47906
sg33289
VACA
p47907
sa(dp47908
g33284
I197
sg33285
I3
sg33286
I28
sg33287
VC0007758
p47909
sg33289
Vautoimmune cerebellar ataxia
p47910
sa(dp47911
g33284
I543
sg33285
I2
sg33286
I23
sg33287
VC0262404
p47912
sg33289
Vcerebellar degeneration
p47913
sasa(dp47914
g33277
VLastly, a recent study identified delta/notch-like epidermal growth factor-related receptor (DNER) as the target antigen of Tr antibodies, a marker of cerebellar ataxia and Hodgkin's lymphoma.
p47915
sg33279
(lp47916
(dp47917
g33284
I51
sg33285
I4
sg33286
I40
sg33295
VP01133
p47918
sg33289
Vepidermal growth factor-related receptor
p47919
sasg33281
(lp47920
(dp47921
g33284
I173
sg33285
I2
sg33286
I18
sg33287
VC0019829
p47922
sg33289
VHodgkin's lymphoma
p47923
sa(dp47924
g33284
I151
sg33285
I2
sg33286
I17
sg33287
VC0007758
p47925
sg33289
Vcerebellar ataxia
p47926
sasa(dp47927
g33277
VReal-time quantitative PCR confirmed significantly increased expression of HAS2, CHSY1, and C4ST1 in the combined groups of CLE lesions (n = 8) compared to healthy controls (n = 4).
p47928
sg33279
(lp47929
(dp47930
g33284
I75
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VHAS2
p47931
sa(dp47932
g33284
I81
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCHSY1
p47933
sa(dp47934
g33284
I92
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VC4ST1
p47935
sasg33281
(lp47936
(dp47937
g33284
I124
sg33285
I1
sg33286
I3
sg33287
VC2931489
p47938
sg33289
VCLE
p47939
sasa(dp47940
g33277
VThus, the increase in HA in CLE presumably results from upregulation of HAS2, whereas CHSY1 and C4ST1 appear to contribute to increased CS.
p47941
sg33279
(lp47942
(dp47943
g33284
I96
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VC4ST1
p47944
sa(dp47945
g33284
I86
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCHSY1
p47946
sa(dp47947
g33284
I72
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VHAS2
p47948
sasg33281
(lp47949
(dp47950
g33284
I28
sg33285
I1
sg33286
I3
sg33287
VC2931489
p47951
sg33289
VCLE
p47952
sasa(dp47953
g33277
VThrough Part 4 of Maintenance of Certification for Family Physicians (MC-FP), American Board of Family Medicine (ABFM) diplomates participate in quality improvement (QI) modules for diabetes.
p47954
sg33279
(lp47955
sg33281
(lp47956
(dp47957
g33284
I182
sg33285
I1
sg33286
I8
sg33287
VC0011849
p47958
sg33289
Vdiabetes
p47959
sasa(dp47960
g33277
VFamily physicians participating in MC-FP implemented improvement projects and showed quality improvements in caring for patients with diabetes.
p47961
sg33279
(lp47962
sg33281
(lp47963
(dp47964
g33284
I134
sg33285
I1
sg33286
I8
sg33287
VC0011849
p47965
sg33289
Vdiabetes
p47966
sasa(dp47967
g33277
VInsulin-dependent diabetes mellitus (IDDM) and Graves' disease (GD) are autoimmune endocrinopathies and associated with distinct HLA-DR and -DQ alleles as well as several tumor necrosis factor alpha (TNF-alpha) and beta (TNF-beta) alleles.
p47968
sg33279
(lp47969
(dp47970
g33284
I129
sg33285
I1
sg33286
I6
sg33295
VP30486
p47971
sg33289
VHLA-DR
p47972
sa(dp47973
g33284
I171
sg33285
I4
sg33286
I27
sg33295
VP01375
p47974
sg33289
Vtumor necrosis factor alpha
p47975
sa(dp47976
g33284
I200
sg33285
I1
sg33286
I9
sg33295
VP01375
p47977
sg33289
VTNF-alpha
p47978
sa(dp47979
g33284
I221
sg33285
I1
sg33286
I8
sg33295
VP01375
p47980
sg33289
VTNF-beta
p47981
sa(dp47982
g33284
I0
sg33285
I1
sg33286
I7
sg33295
VP01308
p47983
sg33289
VInsulin
p47984
sasg33281
(lp47985
(dp47986
g33284
I64
sg33285
I1
sg33286
I2
sg33287
VC0018213
p47987
sg33289
VGD
p47988
sa(dp47989
g33284
I72
sg33285
I1
sg33286
I10
sg33287
VC0443146
p47990
sg33289
Vautoimmune
p47991
sa(dp47992
g33284
I171
sg33285
I2
sg33286
I14
sg33287
VC0333516
p47993
sg33289
Vtumor necrosis
p47994
sa(dp47995
g33284
I0
sg33285
I3
sg33286
I35
sg33287
VC0011854
p47996
sg33289
VInsulin-dependent diabetes mellitus
p47997
sa(dp47998
g33284
I47
sg33285
I2
sg33286
I15
sg33287
VC0018213
p47999
sg33289
VGraves' disease
p48000
sa(dp48001
g33284
I83
sg33285
I1
sg33286
I16
sg33287
VC0014130
p48002
sg33289
Vendocrinopathies
p48003
sa(dp48004
g33284
I37
sg33285
I1
sg33286
I4
sg33287
VC0011854
p48005
sg33289
VIDDM
p48006
sasa(dp48007
g33277
VStudies in Caucasians have suggested that the TNFB gene might be a susceptibility gene for Graves' disease.
p48008
sg33279
(lp48009
(dp48010
g33284
I46
sg33285
I2
sg33286
I9
sg33295
VP10515
p48011
sg33289
VTNFB gene
p48012
sasg33281
(lp48013
(dp48014
g33284
I91
sg33285
I2
sg33286
I15
sg33287
VC0018213
p48015
sg33289
VGraves' disease
p48016
sasa(dp48017
g33277
VTo investigate further the role of TNFB in predisposition to Graves' disease, we determined whether the TNFB disease associations in the Chinese were similar to those in Caucasians.
p48018
sg33279
(lp48019
(dp48020
g33284
I35
sg33285
I1
sg33286
I4
sg33295
VP10515
p48021
sg33289
VTNFB
p48022
sasg33281
(lp48023
(dp48024
g33284
I61
sg33285
I2
sg33286
I15
sg33287
VC0018213
p48025
sg33289
VGraves' disease
p48026
sasa(dp48027
g33277
VWe conclude that the TNFB associations with Graves' disease in the Hong Kong Chinese differ between the genders and from those described in Caucasians.
p48028
sg33279
(lp48029
sg33281
(lp48030
(dp48031
g33284
I44
sg33285
I2
sg33286
I15
sg33287
VC0018213
p48032
sg33289
VGraves' disease
p48033
sasa(dp48034
g33277
VThe TNFB gene is not a susceptibility gene for Graves' disease.
p48035
sg33279
(lp48036
(dp48037
g33284
I4
sg33285
I2
sg33286
I9
sg33295
VP10515
p48038
sg33289
VTNFB gene
p48039
sasg33281
(lp48040
(dp48041
g33284
I47
sg33285
I2
sg33286
I15
sg33287
VC0018213
p48042
sg33289
VGraves' disease
p48043
sasa(dp48044
g33277
VWe show here a significant association of TNF beta polymorphisms with Graves' disease.
p48045
sg33279
(lp48046
(dp48047
g33284
I42
sg33285
I2
sg33286
I8
sg33295
VP01375
p48048
sg33289
VTNF beta
p48049
sasg33281
(lp48050
(dp48051
g33284
I70
sg33285
I2
sg33286
I15
sg33287
VC0018213
p48052
sg33289
VGraves' disease
p48053
sasa(dp48054
g33277
VAlthough TNF beta polymorphisms are linked to A1B8DR3, these results suggest that they represent an additional susceptibility marker in Graves' disease.
p48055
sg33279
(lp48056
(dp48057
g33284
I9
sg33285
I2
sg33286
I8
sg33295
VP01375
p48058
sg33289
VTNF beta
p48059
sasg33281
(lp48060
(dp48061
g33284
I136
sg33285
I2
sg33286
I15
sg33287
VC0018213
p48062
sg33289
VGraves' disease
p48063
sasa(dp48064
g33277
VHere, we summarize our findings of targeted SOX9 destruction by SCFFBW7 (Skp1/Cul1/F-box) in medulloblastoma and its potential for therapeutic intervention.
p48065
sg33279
(lp48066
(dp48067
g33284
I78
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCul1
p48068
sa(dp48069
g33284
I44
sg33285
I2
sg33286
I16
sg33295
VP48436
p48070
sg33289
VSOX9 destruction
p48071
sa(dp48072
g33284
I73
sg33285
I1
sg33286
I4
sg33295
VP63208
p48073
sg33289
VSkp1
p48074
sasg33281
(lp48075
(dp48076
g33284
I93
sg33285
I1
sg33286
I15
sg33287
VC0025149
p48077
sg33289
Vmedulloblastoma
p48078
sasa(dp48079
g33277
VA point mutation in mouse Vps33a (Buff mouse) causes albinism and bleeding (Hermansky-Pudlak syndrome) because of abnormalities in the trafficking of melanosomes and platelets.
p48080
sg33279
(lp48081
(dp48082
g33284
I26
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VVps33a
p48083
sasg33281
(lp48084
(dp48085
g33284
I53
sg33285
I1
sg33286
I8
sg33287
VC0001916
p48086
sg33289
Valbinism
p48087
sa(dp48088
g33284
I66
sg33285
I1
sg33286
I8
sg33287
VC0019080
p48089
sg33289
Vbleeding
p48090
sa(dp48091
g33284
I76
sg33285
I2
sg33286
I25
sg33287
VC0079504
p48092
sg33289
VHermansky-Pudlak syndrome
p48093
sasa(dp48094
g33277
VA mutation in the Vps33a gene causes Hermansky-Pudlak Syndrome (HPS)-like-symptoms in the buff (bf) mouse mutant.
p48095
sg33279
(lp48096
(dp48097
g33284
I18
sg33285
I2
sg33286
I11
sg33295
g11
sg33289
VVps33a gene
p48098
sasg33281
(lp48099
(dp48100
g33284
I64
sg33285
I1
sg33286
I3
sg33287
VC0242994
p48101
sg33289
VHPS
p48102
sa(dp48103
g33284
I37
sg33285
I2
sg33286
I25
sg33287
VC0079504
p48104
sg33289
VHermansky-Pudlak Syndrome
p48105
sa(dp48106
g33284
I106
sg33285
I1
sg33286
I6
sg33287
VC0596988
p48107
sg33289
Vmutant
p48108
sasa(dp48109
g33277
VEpicardial LGEs were identified in 10/13 and pericarditis in 6/13 RAH.
p48110
sg33279
(lp48111
sg33281
(lp48112
(dp48113
g33284
I45
sg33285
I1
sg33286
I12
sg33287
VC0031046
p48114
sg33289
Vpericarditis
p48115
sasa(dp48116
g33277
VAn RA relapse was observed after 7-40 days in 10/13 RAH with myopericarditis.
p48117
sg33279
(lp48118
sg33281
(lp48119
(dp48120
g33284
I6
sg33285
I1
sg33286
I7
sg33287
VC0277556
p48121
sg33289
Vrelapse
p48122
sa(dp48123
g33284
I61
sg33285
I1
sg33286
I15
sg33287
VC0854532
p48124
sg33289
Vmyopericarditis
p48125
sasa(dp48126
g33277
VWe found that LGI3 and its receptors, ADAM22 and ADAM23, were significantly downregulated in glioma tissues.
p48127
sg33279
(lp48128
(dp48129
g33284
I49
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VADAM23
p48130
sa(dp48131
g33284
I14
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VLGI3
p48132
sa(dp48133
g33284
I38
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VADAM22
p48134
sasg33281
(lp48135
(dp48136
g33284
I93
sg33285
I1
sg33286
I6
sg33287
VC0017638
p48137
sg33289
Vglioma
p48138
sasa(dp48139
g33277
VAnalysis of expression microarray data of glioma cohorts demonstrated that low expression levels of LGI3, ADAM22 and ADAM23 were significantly associated with poor prognosis of glioma.
p48140
sg33279
(lp48141
(dp48142
g33284
I106
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VADAM22
p48143
sa(dp48144
g33284
I100
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VLGI3
p48145
sa(dp48146
g33284
I117
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VADAM23
p48147
sasg33281
(lp48148
(dp48149
g33284
I42
sg33285
I1
sg33286
I6
sg33287
VC0017638
p48150
sg33289
Vglioma
p48151
sa(dp48152
g33284
I42
sg33285
I1
sg33286
I6
sg33287
VC0017638
p48153
sg33289
Vglioma
p48154
sasa(dp48155
g33277
VRather, we observed that, in ADAM23-heterotypic environments, ADAM23-negative cells promote tumor growth and metastasis by enhancing the proliferation and invasion of adjacent A23-positive cells through the production of LGI4 (Leucine-rich Glioma Inactivated 4) and nitric oxide (NO).
p48156
sg33279
(lp48157
(dp48158
g33284
I227
sg33285
I4
sg33286
I33
sg33295
VP30740
p48159
sg33289
VLeucine-rich Glioma Inactivated 4
p48160
sa(dp48161
g33284
I221
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VLGI4
p48162
sasg33281
(lp48163
(dp48164
g33284
I92
sg33285
I2
sg33286
I12
sg33287
VC0598934
p48165
sg33289
Vtumor growth
p48166
sa(dp48167
g33284
I137
sg33285
I1
sg33286
I13
sg33287
VC0334094
p48168
sg33289
Vproliferation
p48169
sa(dp48170
g33284
I155
sg33285
I1
sg33286
I8
sg33287
VC2699153
p48171
sg33289
Vinvasion
p48172
sa(dp48173
g33284
I240
sg33285
I1
sg33286
I6
sg33287
VC0017638
p48174
sg33289
VGlioma
p48175
sa(dp48176
g33284
I109
sg33285
I1
sg33286
I10
sg33287
VC0027627
p48177
sg33289
Vmetastasis
p48178
sasa(dp48179
g33277
VThe aim of the present study was to evaluate ADAM28 and Insulin Like Growth Factor Binding Protein-3 (IGFBP-3)) gene expression in colorectal carcinoma tissues with regard to the overweight or obese status of the patients using an oligonucleotide microarray technique.
p48180
sg33279
(lp48181
(dp48182
g33284
I102
sg33285
I1
sg33286
I7
sg33295
VP17936
p48183
sg33289
VIGFBP-3
p48184
sa(dp48185
g33284
I45
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VADAM28
p48186
sa(dp48187
g33284
I56
sg33285
I6
sg33286
I44
sg33295
VP01308
p48188
sg33289
VInsulin Like Growth Factor Binding Protein-3
p48189
sasg33281
(lp48190
(dp48191
g33284
I193
sg33285
I1
sg33286
I5
sg33287
VC0028754
p48192
sg33289
Vobese
p48193
sa(dp48194
g33284
I131
sg33285
I2
sg33286
I20
sg33287
VC0009402
p48195
sg33289
Vcolorectal carcinoma
p48196
sa(dp48197
g33284
I179
sg33285
I1
sg33286
I10
sg33287
VC0497406
p48198
sg33289
Voverweight
p48199
sasa(dp48200
g33277
VThe expression of cancer stem cell marker cluster of differentiation 271 (CD271) was determined in traditional two-dimensional (2D) and 3D cultures of C918 uveal melanoma cells by fluorescent immunocytochemistry.
p48201
sg33279
(lp48202
sg33281
(lp48203
(dp48204
g33284
I156
sg33285
I2
sg33286
I14
sg33287
VC0220633
p48205
sg33289
Vuveal melanoma
p48206
sa(dp48207
g33284
I18
sg33285
I1
sg33286
I6
sg33287
VC0006826
p48208
sg33289
Vcancer
p48209
sasa(dp48210
g33277
VThe missense mutation (c.370G &gt; A) in the TGFBI gene and insert mutation (c.1456-1457ins GAT) in the KRT12 gene were identified in a 23-year-old male patient with concurrent KC and GCD.
p48211
sg33279
(lp48212
(dp48213
g33284
I77
sg33285
I2
sg33286
I18
sg33295
g11
sg33289
Vc.1456-1457ins GAT
p48214
sa(dp48215
g33284
I104
sg33285
I2
sg33286
I10
sg33295
g11
sg33289
VKRT12 gene
p48216
sasg33281
(lp48217
sa(dp48218
g33277
VThis study investigated the TGFBI gene mutation types in outpatients clinically diagnosed with granular corneal dystrophy (GCD) prior to phototherapeutic keratectomy (PTK), also calculated the mutation rate of subjects with normal corneas, but positive family history.
p48219
sg33279
(lp48220
(dp48221
g33284
I167
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VPTK
p48222
sa(dp48223
g33284
I137
sg33285
I2
sg33286
I28
sg33295
g11
sg33289
Vphototherapeutic keratectomy
p48224
sasg33281
(lp48225
(dp48226
g33284
I95
sg33285
I3
sg33286
I26
sg33287
VC0018179
p48227
sg33289
Vgranular corneal dystrophy
p48228
sa(dp48229
g33284
I123
sg33285
I1
sg33286
I3
sg33287
VC0018179
p48230
sg33289
VGCD
p48231
sasa(dp48232
g33277
VTo describe 2 unrelated families with multiple members demonstrating a less commonly recognized vortex pattern of corneal deposits confirmed to be granular corneal dystrophy type 1 (GCD1) after identification of the p.(Arg555Trp) mutation in the transforming growth factor Beta-induced gene (TGFBI).
p48233
sg33279
(lp48234
(dp48235
g33284
I246
sg33285
I4
sg33286
I31
sg33295
VP18075
p48236
sg33289
Vtransforming growth factor Beta
p48237
sasg33281
(lp48238
(dp48239
g33284
I182
sg33285
I1
sg33286
I4
sg33287
VC1641846
p48240
sg33289
VGCD1
p48241
sa(dp48242
g33284
I114
sg33285
I2
sg33286
I16
sg33287
VC0162281
p48243
sg33289
Vcorneal deposits
p48244
sa(dp48245
g33284
I147
sg33285
I5
sg33286
I33
sg33287
VC1641846
p48246
sg33289
Vgranular corneal dystrophy type 1
p48247
sasa(dp48248
g33277
VScreening of TGFBI in both families revealed a heterozygous missense mutation [p.(Arg555Trp)] in exon 12, confirming the diagnosis of GCD1.
p48249
sg33279
(lp48250
sg33281
(lp48251
(dp48252
g33284
I134
sg33285
I1
sg33286
I4
sg33287
VC1641846
p48253
sg33289
VGCD1
p48254
sasa(dp48255
g33277
VAlthough this pattern of dystrophic deposits is not recognized by clinicians as a typical phenotype of GCD1, it is consistent with the production of the majority of the TGFBI protein by the corneal epithelium.
p48256
sg33279
(lp48257
sg33281
(lp48258
(dp48259
g33284
I103
sg33285
I1
sg33286
I4
sg33287
VC1641846
p48260
sg33289
VGCD1
p48261
sasa(dp48262
g33277
VIn this study, patients with macular corneal dystrophy (MCD; n = 18), granular corneal dystrophy type 1 (GCD1; n = 12), and lattice corneal dystrophy type 1 (LCD1; n = 4), as well as 50 healthy controls, were subjected to clinical and genetic examinations.
p48263
sg33279
(lp48264
sg33281
(lp48265
(dp48266
g33284
I158
sg33285
I1
sg33286
I4
sg33287
VC1690006
p48267
sg33289
VLCD1
p48268
sa(dp48269
g33284
I70
sg33285
I5
sg33286
I33
sg33287
VC1641846
p48270
sg33289
Vgranular corneal dystrophy type 1
p48271
sa(dp48272
g33284
I105
sg33285
I1
sg33286
I4
sg33287
VC1641846
p48273
sg33289
VGCD1
p48274
sa(dp48275
g33284
I29
sg33285
I3
sg33286
I25
sg33287
VC0024439
p48276
sg33289
Vmacular corneal dystrophy
p48277
sa(dp48278
g33284
I56
sg33285
I1
sg33286
I3
sg33287
VC1636149
p48279
sg33289
VMCD
p48280
sa(dp48281
g33284
I124
sg33285
I5
sg33286
I32
sg33287
VC2931650
p48282
sg33289
Vlattice corneal dystrophy type 1
p48283
sasa(dp48284
g33277
VVariations were analyzed with DNA sequencing in the coding region of CHST6 in patients with MCD and exons 4 and 12 in TGFBI in patients with LCD1 and GCD1.
p48285
sg33279
(lp48286
(dp48287
g33284
I69
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCHST6
p48288
sasg33281
(lp48289
(dp48290
g33284
I141
sg33285
I1
sg33286
I4
sg33287
VC1690006
p48291
sg33289
VLCD1
p48292
sa(dp48293
g33284
I92
sg33285
I1
sg33286
I3
sg33287
VC1636149
p48294
sg33289
VMCD
p48295
sa(dp48296
g33284
I150
sg33285
I1
sg33286
I4
sg33287
VC1641846
p48297
sg33289
VGCD1
p48298
sasa(dp48299
g33277
VThe previously reported R555W mutation in TGFBI was detected in 12 patients with GCD1, and the R124C mutation in TGFBI was detected in four patients with LCD1.
p48300
sg33279
(lp48301
sg33281
(lp48302
(dp48303
g33284
I81
sg33285
I1
sg33286
I4
sg33287
VC1641846
p48304
sg33289
VGCD1
p48305
sa(dp48306
g33284
I154
sg33285
I1
sg33286
I4
sg33287
VC1690006
p48307
sg33289
VLCD1
p48308
sasa(dp48309
g33277
VWe detected previously reported, well-known hot spot mutations in TGFBI in the patients with GCD1 and LCD1.
p48310
sg33279
(lp48311
sg33281
(lp48312
(dp48313
g33284
I93
sg33285
I1
sg33286
I4
sg33287
VC1641846
p48314
sg33289
VGCD1
p48315
sa(dp48316
g33284
I44
sg33285
I2
sg33286
I8
sg33287
VC0263214
p48317
sg33289
Vhot spot
p48318
sa(dp48319
g33284
I102
sg33285
I1
sg33286
I4
sg33287
VC1690006
p48320
sg33289
VLCD1
p48321
sasa(dp48322
g33277
VTGFBeta1-induced expression of transforming growth factor Beta-induced protein (TGFBIp) and extracellular matrix (ECM) genes plays a major role in the development of granular corneal dystrophy type 2 (GCD2: also called Avellino corneal dystrophy).
p48323
sg33279
(lp48324
(dp48325
g33284
I0
sg33285
I1
sg33286
I8
sg33295
VP01137
p48326
sg33289
VTGFBeta1
p48327
sa(dp48328
g33284
I31
sg33285
I4
sg33286
I31
sg33295
VP18075
p48329
sg33289
Vtransforming growth factor Beta
p48330
sa(dp48331
g33284
I92
sg33285
I4
sg33286
I32
sg33295
g11
sg33289
Vextracellular matrix (ECM) genes
p48332
sasg33281
(lp48333
(dp48334
g33284
I219
sg33285
I3
sg33286
I26
sg33287
VC1275685
p48335
sg33289
VAvellino corneal dystrophy
p48336
sa(dp48337
g33284
I166
sg33285
I5
sg33286
I33
sg33287
VC1275685
p48338
sg33289
Vgranular corneal dystrophy type 2
p48339
sasa(dp48340
g33277
VWe examined the role of chromatin markers such as histone H3 lysine methylation (H3Kme) in TGFBeta1-induced TGFBIp and ECM gene expression in normal and GCD2-derived human corneal fibroblasts.
p48341
sg33279
(lp48342
(dp48343
g33284
I91
sg33285
I1
sg33286
I8
sg33295
VP01137
p48344
sg33289
VTGFBeta1
p48345
sa(dp48346
g33284
I119
sg33285
I2
sg33286
I8
sg33295
g11
sg33289
VECM gene
p48347
sa(dp48348
g33284
I50
sg33285
I2
sg33286
I10
sg33295
g11
sg33289
Vhistone H3
p48349
sasg33281
(lp48350
sa(dp48351
g33277
VTranscription and extracellular-secretion levels of TGFBIp were high in normal cells compared with those in GCD2-derived cells and were related to H3K4me3 levels but not to DNA methylation over the TGFBI locus.
p48352
sg33279
(lp48353
sg33281
(lp48354
sa(dp48355
g33277
VThis study expands on our previous research investigating dystrophic stromal aggregates, with the aim of better elucidating the pathomechanism of two conditions arising from the most common TGFBI mutations: granular corneal dystrophy type 1 (GCD1; R555W) and lattice corneal dystrophy type 1 (LCD1; R124C).
p48356
sg33279
(lp48357
sg33281
(lp48358
(dp48359
g33284
I259
sg33285
I5
sg33286
I32
sg33287
VC2931650
p48360
sg33289
Vlattice corneal dystrophy type 1
p48361
sa(dp48362
g33284
I207
sg33285
I5
sg33286
I33
sg33287
VC1641846
p48363
sg33289
Vgranular corneal dystrophy type 1
p48364
sa(dp48365
g33284
I293
sg33285
I1
sg33286
I4
sg33287
VC1690006
p48366
sg33289
VLCD1
p48367
sa(dp48368
g33284
I242
sg33285
I1
sg33286
I4
sg33287
VC1641846
p48369
sg33289
VGCD1
p48370
sasa(dp48371
g33277
VPatient corneas with GCD1 and LCD1 were stained with hematoxylin and eosin and Congo red to visualize stromal nonamyloid and amyloid deposits, respectively.
p48372
sg33279
(lp48373
sg33281
(lp48374
(dp48375
g33284
I30
sg33285
I1
sg33286
I4
sg33287
VC1690006
p48376
sg33289
VLCD1
p48377
sa(dp48378
g33284
I21
sg33285
I1
sg33286
I4
sg33287
VC1641846
p48379
sg33289
VGCD1
p48380
sa(dp48381
g33284
I125
sg33285
I2
sg33286
I16
sg33287
VC2936349
p48382
sg33289
Vamyloid deposits
p48383
sasa(dp48384
g33277
VAn increase in the number of residues experiencing cleavage was observed in both GCD1 aggregates and LCD1 deposits.
p48385
sg33279
(lp48386
sg33281
(lp48387
(dp48388
g33284
I81
sg33285
I1
sg33286
I4
sg33287
VC1641846
p48389
sg33289
VGCD1
p48390
sa(dp48391
g33284
I101
sg33285
I1
sg33286
I4
sg33287
VC1690006
p48392
sg33289
VLCD1
p48393
sasa(dp48394
g33277
VThe study reveals previously unknown differences between the protein composition of GCD1 and LCD1 aggregates, and confirms the presence of the HtrA1 protease in LCD1-amyloid aggregates.
p48395
sg33279
(lp48396
(dp48397
g33284
I143
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VHtrA1 protease
p48398
sasg33281
(lp48399
(dp48400
g33284
I93
sg33285
I1
sg33286
I4
sg33287
VC1690006
p48401
sg33289
VLCD1
p48402
sa(dp48403
g33284
I93
sg33285
I1
sg33286
I4
sg33287
VC1690006
p48404
sg33289
VLCD1
p48405
sa(dp48406
g33284
I166
sg33285
I1
sg33286
I7
sg33287
VC0011560
p48407
sg33289
Vamyloid
p48408
sa(dp48409
g33284
I84
sg33285
I1
sg33286
I4
sg33287
VC1641846
p48410
sg33289
VGCD1
p48411
sasa(dp48412
g33277
VGCD is a Category 1, Stromal, TGFBI-associated corneal dystrophy.
p48413
sg33279
(lp48414
sg33281
(lp48415
(dp48416
g33284
I47
sg33285
I2
sg33286
I17
sg33287
VC0010036
p48417
sg33289
Vcorneal dystrophy
p48418
sasa(dp48419
g33277
VWe show here that the Arg555Trp mutant of the fourth fasciclin 1 (FAS1-4) domain of the protein (TGFBIp/keratoepithelin/Betaig-h3), associated with granular corneal dystrophy type 1, is significantly less susceptible to proteolysis by thermolysin and trypsin than the WT domain.
p48420
sg33279
(lp48421
(dp48422
g33284
I66
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VFAS1-4
p48423
sa(dp48424
g33284
I251
sg33285
I1
sg33286
I7
sg33295
VP35030
p48425
sg33289
Vtrypsin
p48426
sa(dp48427
g33284
I22
sg33285
I2
sg33286
I16
sg33295
g11
sg33289
VArg555Trp mutant
p48428
sasg33281
(lp48429
(dp48430
g33284
I32
sg33285
I1
sg33286
I6
sg33287
VC0596988
p48431
sg33289
Vmutant
p48432
sa(dp48433
g33284
I148
sg33285
I3
sg33286
I26
sg33287
VC0018179
p48434
sg33289
Vgranular corneal dystrophy
p48435
sasa(dp48436
g33277
VMiR-139-5p has been reported to be overexpressed in many types of cancers, but its role in bladder cancer has not been elucidated yet.
p48437
sg33279
(lp48438
(dp48439
g33284
I0
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VMiR-139-5p
p48440
sasg33281
(lp48441
(dp48442
g33284
I91
sg33285
I2
sg33286
I14
sg33287
VC0699885
p48443
sg33289
Vbladder cancer
p48444
sa(dp48445
g33284
I66
sg33285
I1
sg33286
I7
sg33287
VC0006826
p48446
sg33289
Vcancers
p48447
sasa(dp48448
g33277
VHere, we report that miR-139-5p functions as a tumor suppressor in bladder cancer and inhibits the cancer stem cell self-renewal by targeting Bmi1 directly.
p48449
sg33279
(lp48450
(dp48451
g33284
I21
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VmiR-139-5p
p48452
sa(dp48453
g33284
I142
sg33285
I1
sg33286
I4
sg33295
VP35226
p48454
sg33289
VBmi1
p48455
sasg33281
(lp48456
(dp48457
g33284
I47
sg33285
I1
sg33286
I5
sg33287
VC0027651
p48458
sg33289
Vtumor
p48459
sa(dp48460
g33284
I67
sg33285
I2
sg33286
I14
sg33287
VC0699885
p48461
sg33289
Vbladder cancer
p48462
sa(dp48463
g33284
I75
sg33285
I1
sg33286
I6
sg33287
VC0006826
p48464
sg33289
Vcancer
p48465
sasa(dp48466
g33277
VWe found that miR-139-5p expression was significantly downregulated in the bladder cancer specimens compared with that in adjacent normal tissues.
p48467
sg33279
(lp48468
(dp48469
g33284
I14
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VmiR-139-5p
p48470
sasg33281
(lp48471
(dp48472
g33284
I75
sg33285
I2
sg33286
I14
sg33287
VC0699885
p48473
sg33289
Vbladder cancer
p48474
sasa(dp48475
g33277
VIn vitro, restoration of miR-139-5p expression significantly inhibited the proliferation of bladder cancer cells.
p48476
sg33279
(lp48477
(dp48478
g33284
I25
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VmiR-139-5p
p48479
sasg33281
(lp48480
(dp48481
g33284
I75
sg33285
I1
sg33286
I13
sg33287
VC0334094
p48482
sg33289
Vproliferation
p48483
sa(dp48484
g33284
I92
sg33285
I2
sg33286
I14
sg33287
VC0699885
p48485
sg33289
Vbladder cancer
p48486
sasa(dp48487
g33277
VStem cell-related proteins such as c-MYC, NANOG, OCT4, and KLF4 and signaling pathways such as Wnt signaling were suppressed by restoration of miR-139-5p in bladder cancer cells.
p48488
sg33279
(lp48489
(dp48490
g33284
I143
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VmiR-139-5p
p48491
sa(dp48492
g33284
I42
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VNANOG
p48493
sa(dp48494
g33284
I35
sg33285
I1
sg33286
I5
sg33295
VP12524
p48495
sg33289
Vc-MYC
p48496
sa(dp48497
g33284
I59
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VKLF4
p48498
sa(dp48499
g33284
I0
sg33285
I3
sg33286
I26
sg33295
VP02649
p48500
sg33289
VStem cell-related proteins
p48501
sasg33281
(lp48502
(dp48503
g33284
I157
sg33285
I2
sg33286
I14
sg33287
VC0699885
p48504
sg33289
Vbladder cancer
p48505
sasa(dp48506
g33277
VIn addition, miR-139-5p expression also blocked self-renewal of bladder cancer stem cells by inhibiting Bmi1.
p48507
sg33279
(lp48508
(dp48509
g33284
I104
sg33285
I1
sg33286
I4
sg33295
VP35226
p48510
sg33289
VBmi1
p48511
sa(dp48512
g33284
I13
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VmiR-139-5p
p48513
sasg33281
(lp48514
(dp48515
g33284
I64
sg33285
I2
sg33286
I14
sg33287
VC0699885
p48516
sg33289
Vbladder cancer
p48517
sasa(dp48518
g33277
VIn summary, our study supports that miR-139-5p acts as a tumor suppressor in bladder cancer development and suppresses cancer stem cell property of bladder cancer.
p48519
sg33279
(lp48520
(dp48521
g33284
I36
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VmiR-139-5p
p48522
sasg33281
(lp48523
(dp48524
g33284
I77
sg33285
I2
sg33286
I14
sg33287
VC0699885
p48525
sg33289
Vbladder cancer
p48526
sa(dp48527
g33284
I57
sg33285
I1
sg33286
I5
sg33287
VC0027651
p48528
sg33289
Vtumor
p48529
sa(dp48530
g33284
I77
sg33285
I2
sg33286
I14
sg33287
VC0699885
p48531
sg33289
Vbladder cancer
p48532
sa(dp48533
g33284
I85
sg33285
I1
sg33286
I6
sg33287
VC0006826
p48534
sg33289
Vcancer
p48535
sasa(dp48536
g33277
VOur study also suggests that miR-139-5p has the potential to be used as a therapeutic molecule for bladder cancer treatment.
p48537
sg33279
(lp48538
(dp48539
g33284
I29
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
VmiR-139-5p
p48540
sasg33281
(lp48541
(dp48542
g33284
I99
sg33285
I2
sg33286
I14
sg33287
VC0699885
p48543
sg33289
Vbladder cancer
p48544
sasa(dp48545
g33277
VWe present a case with CblC disease and pulmonary arterial hypertension (PAH) as the main symptom.
p48546
sg33279
(lp48547
(dp48548
g33284
I23
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCblC
p48549
sasg33281
(lp48550
(dp48551
g33284
I40
sg33285
I3
sg33286
I31
sg33287
VC0152171
p48552
sg33289
Vpulmonary arterial hypertension
p48553
sa(dp48554
g33284
I73
sg33285
I1
sg33286
I3
sg33287
VC0152171
p48555
sg33289
VPAH
p48556
sa(dp48557
g33284
I90
sg33285
I1
sg33286
I7
sg33287
VC1457887
p48558
sg33289
Vsymptom
p48559
sasa(dp48560
g33277
VCblC disease should be considered in the differential diagnosis of pulmonary hypertension.
p48561
sg33279
(lp48562
(dp48563
g33284
I0
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCblC
p48564
sasg33281
(lp48565
(dp48566
g33284
I67
sg33285
I2
sg33286
I22
sg33287
VC0020542
p48567
sg33289
Vpulmonary hypertension
p48568
sasa(dp48569
g33277
VGenetic association of rs678849 along with neuroimaging and biomarker phenotypes, parallel with the known involvements of the OPRD1 in drug abuse, provided additional support for targeting these receptors as potential therapeutic targets in both neurodegenerative diseases and neuropsychiactric disorders such as Alzheimer's disease.
p48570
sg33279
(lp48571
(dp48572
g33284
I126
sg33285
I1
sg33286
I5
sg33295
VP41143
p48573
sg33289
VOPRD1
p48574
sasg33281
(lp48575
(dp48576
g33284
I313
sg33285
I2
sg33286
I19
sg33287
VC1521724
p48577
sg33289
VAlzheimer's disease
p48578
sa(dp48579
g33284
I246
sg33285
I2
sg33286
I26
sg33287
VC0524851
p48580
sg33289
Vneurodegenerative diseases
p48581
sa(dp48582
g33284
I135
sg33285
I2
sg33286
I10
sg33287
VC0013146
p48583
sg33289
Vdrug abuse
p48584
sasa(dp48585
g33277
VRecently, a robust up-regulation of human natural killer-1 sulfotransferase (HNK-1ST) was found in several subsets of melanoma cells during RA-mediated differentiation.
p48586
sg33279
(lp48587
(dp48588
g33284
I36
sg33285
I4
sg33286
I39
sg33295
g11
sg33289
Vhuman natural killer-1 sulfotransferase
p48589
sa(dp48590
g33284
I77
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VHNK-1ST
p48591
sasg33281
(lp48592
(dp48593
g33284
I118
sg33285
I1
sg33286
I8
sg33287
VC0025202
p48594
sg33289
Vmelanoma
p48595
sasa(dp48596
g33277
VHere, we show that HNK-1ST changed the glycosylation state and reduced the ligand binding activity of Alfa-dystroglycan (Alfa-DG) in RA-treated S91 melanoma cells, which contributed to an attenuation of cell migration.
p48597
sg33279
(lp48598
(dp48599
g33284
I121
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VAlfa-DG
p48600
sa(dp48601
g33284
I102
sg33285
I1
sg33286
I17
sg33295
g11
sg33289
VAlfa-dystroglycan
p48602
sa(dp48603
g33284
I19
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VHNK-1ST
p48604
sasg33281
(lp48605
(dp48606
g33284
I148
sg33285
I1
sg33286
I8
sg33287
VC0025202
p48607
sg33289
Vmelanoma
p48608
sasa(dp48609
g33277
VTen genes of importance for HNK-1 biosynthesis (B3GAT1, B3GAT2, and CHST10) or for the formation of perineuronal nets (TNR, BCAN, NCAN, HAPLN1, HAPLN2, HAPLN3, and HAPLN4) were investigated for potential involvement in schizophrenia (SCZ) susceptibility, by genotyping 104 tagSNPs in the Scandinavian Collaboration on Psychiatric Etiology sample (849 cases; 1602 control subjects).
p48610
sg33279
(lp48611
(dp48612
g33284
I144
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VHAPLN2
p48613
sa(dp48614
g33284
I28
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VHNK-1
p48615
sa(dp48616
g33284
I119
sg33285
I1
sg33286
I3
sg33295
g11
sg33289
VTNR
p48617
sa(dp48618
g33284
I83
sg33285
I5
sg33286
I34
sg33295
g11
sg33289
Vthe formation of perineuronal nets
p48619
sa(dp48620
g33284
I130
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNCAN
p48621
sa(dp48622
g33284
I136
sg33285
I1
sg33286
I6
sg33295
VP10915
p48623
sg33289
VHAPLN1
p48624
sa(dp48625
g33284
I124
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VBCAN
p48626
sa(dp48627
g33284
I152
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VHAPLN3
p48628
sa(dp48629
g33284
I48
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VB3GAT1
p48630
sa(dp48631
g33284
I68
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VCHST10
p48632
sa(dp48633
g33284
I56
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VB3GAT2
p48634
sa(dp48635
g33284
I164
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VHAPLN4
p48636
sasg33281
(lp48637
(dp48638
g33284
I234
sg33285
I1
sg33286
I3
sg33287
VC0036341
p48639
sg33289
VSCZ
p48640
sa(dp48641
g33284
I219
sg33285
I1
sg33286
I13
sg33287
VC0036341
p48642
sg33289
Vschizophrenia
p48643
sasa(dp48644
g33277
VWe show that CHST10 is also regulated by RARgamma in a significant subset of human melanoma cells, and three-dimensional cell culture migration assays suggest that CHST10 functions as a suppressor of invasiveness, but not proliferation, in these cells.
p48645
sg33279
(lp48646
(dp48647
g33284
I41
sg33285
I1
sg33286
I8
sg33295
VP13631
p48648
sg33289
VRARgamma
p48649
sa(dp48650
g33284
I13
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VCHST10
p48651
sa(dp48652
g33284
I13
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VCHST10
p48653
sasg33281
(lp48654
(dp48655
g33284
I83
sg33285
I1
sg33286
I8
sg33287
VC0025202
p48656
sg33289
Vmelanoma
p48657
sa(dp48658
g33284
I222
sg33285
I1
sg33286
I13
sg33287
VC0334094
p48659
sg33289
Vproliferation
p48660
sasa(dp48661
g33277
VInduction of CHST10 by RARgamma-activating retinoids may present a novel therapeutic strategy to inhibit invasiveness in a subset of melanoma patients.
p48662
sg33279
(lp48663
(dp48664
g33284
I23
sg33285
I1
sg33286
I8
sg33295
VP13631
p48665
sg33289
VRARgamma
p48666
sa(dp48667
g33284
I13
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VCHST10
p48668
sasg33281
(lp48669
(dp48670
g33284
I133
sg33285
I1
sg33286
I8
sg33287
VC0025202
p48671
sg33289
Vmelanoma
p48672
sasa(dp48673
g33277
VNo disease-associated mutations were detected in the candidate genes SEMA4C, CNGA3 or HNK1ST from within the region.
p48674
sg33279
(lp48675
(dp48676
g33284
I77
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VCNGA3
p48677
sa(dp48678
g33284
I86
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VHNK1ST
p48679
sa(dp48680
g33284
I69
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VSEMA4C
p48681
sasg33281
(lp48682
sa(dp48683
g33277
VMost XLMTM patients develop severe muscle weakness leading to respiratory failure and death, typically within 2 years of age.
p48684
sg33279
(lp48685
sg33281
(lp48686
(dp48687
g33284
I35
sg33285
I2
sg33286
I15
sg33287
VC0030552
p48688
sg33289
Vmuscle weakness
p48689
sa(dp48690
g33284
I62
sg33285
I2
sg33286
I19
sg33287
VC1145670
p48691
sg33289
Vrespiratory failure
p48692
sa(dp48693
g33284
I5
sg33285
I1
sg33286
I5
sg33287
VC0410203
p48694
sg33289
VXLMTM
p48695
sasa(dp48696
g33277
VMutations in the MTM1 gene cause X-linked myotubular myopathy (XLMTM), characterized by neonatal hypotonia and respiratory failure, and are responsible for a premature mortality in affected males.
p48697
sg33279
(lp48698
(dp48699
g33284
I17
sg33285
I2
sg33286
I9
sg33295
g11
sg33289
VMTM1 gene
p48700
sasg33281
(lp48701
(dp48702
g33284
I17
sg33285
I1
sg33286
I4
sg33287
VC0410203
p48703
sg33289
VMTM1
p48704
sa(dp48705
g33284
I33
sg33285
I3
sg33286
I28
sg33287
VC0410203
p48706
sg33289
VX-linked myotubular myopathy
p48707
sa(dp48708
g33284
I88
sg33285
I2
sg33286
I18
sg33287
VC0270971
p48709
sg33289
Vneonatal hypotonia
p48710
sa(dp48711
g33284
I63
sg33285
I1
sg33286
I5
sg33287
VC0410203
p48712
sg33289
VXLMTM
p48713
sa(dp48714
g33284
I111
sg33285
I2
sg33286
I19
sg33287
VC1145670
p48715
sg33289
Vrespiratory failure
p48716
sasa(dp48717
g33277
VX-linked myotubular myopathy (XLMTM) is a congenital neuromuscular disorder defined by severe hypotonia, respiratory failure and histopathologic changes in muscle biopsy.
p48718
sg33279
(lp48719
sg33281
(lp48720
(dp48721
g33284
I0
sg33285
I3
sg33286
I28
sg33287
VC0410203
p48722
sg33289
VX-linked myotubular myopathy
p48723
sa(dp48724
g33284
I105
sg33285
I2
sg33286
I19
sg33287
VC1145670
p48725
sg33289
Vrespiratory failure
p48726
sa(dp48727
g33284
I30
sg33285
I1
sg33286
I5
sg33287
VC0410203
p48728
sg33289
VXLMTM
p48729
sa(dp48730
g33284
I94
sg33285
I1
sg33286
I9
sg33287
VC0026827
p48731
sg33289
Vhypotonia
p48732
sa(dp48733
g33284
I42
sg33285
I3
sg33286
I33
sg33287
VC0596371
p48734
sg33289
Vcongenital neuromuscular disorder
p48735
sasa(dp48736
g33277
VCentronuclear (myotubular) myopathy (CNM) is congenital and produces various degrees of muscular weakness and associated complications such as respiratory failure.
p48737
sg33279
(lp48738
sg33281
(lp48739
(dp48740
g33284
I27
sg33285
I1
sg33286
I8
sg33287
VC0026848
p48741
sg33289
Vmyopathy
p48742
sa(dp48743
g33284
I143
sg33285
I2
sg33286
I19
sg33287
VC1145670
p48744
sg33289
Vrespiratory failure
p48745
sa(dp48746
g33284
I88
sg33285
I2
sg33286
I17
sg33287
VC0151786
p48747
sg33289
Vmuscular weakness
p48748
sasa(dp48749
g33277
VPatients with XLMTM often have severe perinatal weakness that requires mechanical ventilation to prevent death from respiratory failure.
p48750
sg33279
(lp48751
sg33281
(lp48752
(dp48753
g33284
I48
sg33285
I1
sg33286
I8
sg33287
VC1883552
p48754
sg33289
Vweakness
p48755
sa(dp48756
g33284
I116
sg33285
I2
sg33286
I19
sg33287
VC1145670
p48757
sg33289
Vrespiratory failure
p48758
sa(dp48759
g33284
I14
sg33285
I1
sg33286
I5
sg33287
VC0410203
p48760
sg33289
VXLMTM
p48761
sasa(dp48762
g33277
VThis review addresses hearing loss as it occurs and has been reported in Muenke syndrome as well as six additional FGFR related craniosynostosis syndromes (Apert syndrome, Pfeiffer syndrome, Crouzon syndrome, Beare-Stevenson syndrome, Crouzon syndrome with acanthosis nigricans, and Jackson-Weiss syndrome.
p48763
sg33279
(lp48764
sg33281
(lp48765
(dp48766
g33284
I235
sg33285
I5
sg33286
I42
sg33287
VC2677099
p48767
sg33289
VCrouzon syndrome with acanthosis nigricans
p48768
sa(dp48769
g33284
I22
sg33285
I2
sg33286
I12
sg33287
VC0011053
p48770
sg33289
Vhearing loss
p48771
sa(dp48772
g33284
I162
sg33285
I2
sg33286
I18
sg33287
VC0220658
p48773
sg33289
Vsyndrome, Pfeiffer
p48774
sa(dp48775
g33284
I128
sg33285
I2
sg33286
I26
sg33287
VC0010278
p48776
sg33289
Vcraniosynostosis syndromes
p48777
sa(dp48778
g33284
I181
sg33285
I2
sg33286
I17
sg33287
VC2931196
p48779
sg33289
Vsyndrome, Crouzon
p48780
sa(dp48781
g33284
I283
sg33285
I2
sg33286
I22
sg33287
VC0795998
p48782
sg33289
VJackson-Weiss syndrome
p48783
sa(dp48784
g33284
I209
sg33285
I2
sg33286
I24
sg33287
VC1852406
p48785
sg33289
VBeare-Stevenson syndrome
p48786
sa(dp48787
g33284
I73
sg33285
I2
sg33286
I15
sg33287
VC1864436
p48788
sg33289
VMuenke syndrome
p48789
sa(dp48790
g33284
I80
sg33285
I1
sg33286
I8
sg33287
VC0039082
p48791
sg33289
Vsyndrome
p48792
sa(dp48793
g33284
I181
sg33285
I2
sg33286
I17
sg33287
VC2931196
p48794
sg33289
Vsyndrome, Crouzon
p48795
sasa(dp48796
g33277
VOur literature review revealed the following incidences of hearing loss in FGFR craniosynostoses: 61% in Muenke syndrome, 80% in Apert Syndrome, 92% in Pfeiffer syndrome, 74% in Crouzon syndrome, 68% in Jackson Weiss syndrome, 4% in Beare Stevenson syndrome and 14% in Crouzon syndrome with Acanthosis Nigricans.
p48797
sg33279
(lp48798
sg33281
(lp48799
(dp48800
g33284
I112
sg33285
I1
sg33286
I8
sg33287
VC0039082
p48801
sg33289
Vsyndrome
p48802
sa(dp48803
g33284
I59
sg33285
I2
sg33286
I12
sg33287
VC0011053
p48804
sg33289
Vhearing loss
p48805
sa(dp48806
g33284
I80
sg33285
I1
sg33286
I16
sg33287
VC0010278
p48807
sg33289
Vcraniosynostoses
p48808
sa(dp48809
g33284
I203
sg33285
I3
sg33286
I22
sg33287
VC0795998
p48810
sg33289
VJackson Weiss syndrome
p48811
sa(dp48812
g33284
I269
sg33285
I5
sg33286
I42
sg33287
VC2677099
p48813
sg33289
VCrouzon syndrome with Acanthosis Nigricans
p48814
sa(dp48815
g33284
I105
sg33285
I2
sg33286
I15
sg33287
VC1864436
p48816
sg33289
VMuenke syndrome
p48817
sa(dp48818
g33284
I178
sg33285
I2
sg33286
I16
sg33287
VC0010273
p48819
sg33289
VCrouzon syndrome
p48820
sa(dp48821
g33284
I152
sg33285
I2
sg33286
I17
sg33287
VC0265303
p48822
sg33289
VPfeiffer syndrome
p48823
sa(dp48824
g33284
I129
sg33285
I2
sg33286
I14
sg33287
VC0001193
p48825
sg33289
VApert Syndrome
p48826
sasa(dp48827
g33277
VThis study reveals the pleiotropic effects of the FGFR2 Y394C mutation evidenced by cutis gyrata, acanthosis nigricans, and craniosynostosis and provides a useful model for investigating the molecular mechanisms of skin and skull development.
p48828
sg33279
(lp48829
sg33281
(lp48830
(dp48831
g33284
I98
sg33285
I2
sg33286
I20
sg33287
VC0000889
p48832
sg33289
Vacanthosis nigricans
p48833
sa(dp48834
g33284
I124
sg33285
I1
sg33286
I16
sg33287
VC0010278
p48835
sg33289
Vcraniosynostosis
p48836
sasa(dp48837
g33277
VSome cases of congenital skeletal disorders with an FGFR2 mutation show skin phenotypes, including acne, cutis gyrata, and acanthosis nigricans.
p48838
sg33279
(lp48839
sg33281
(lp48840
(dp48841
g33284
I99
sg33285
I1
sg33286
I4
sg33287
VC0001144
p48842
sg33289
Vacne
p48843
sa(dp48844
g33284
I123
sg33285
I2
sg33286
I20
sg33287
VC0000889
p48845
sg33289
Vacanthosis nigricans
p48846
sasa(dp48847
g33277
VPeripheral nerve and spinal cord injuries, along with other painful syndromes such as fibromyalgia, diabetic neuropathy, chemotherapeutic neuropathy, trigeminal neuralgia, complex regional pain syndrome, and/or irritable bowel syndrome, cause several neuroplasticity changes in the nervous system along its entire axis affecting the different neuronal nuclei.
p48848
sg33279
(lp48849
sg33281
(lp48850
(dp48851
g33284
I282
sg33285
I1
sg33286
I7
sg33287
VC0027769
p48852
sg33289
Vnervous
p48853
sa(dp48854
g33284
I100
sg33285
I2
sg33286
I19
sg33287
VC0011882
p48855
sg33289
Vdiabetic neuropathy
p48856
sa(dp48857
g33284
I60
sg33285
I1
sg33286
I7
sg33287
VC0030193
p48858
sg33289
Vpainful
p48859
sa(dp48860
g33284
I86
sg33285
I1
sg33286
I12
sg33287
VC0016053
p48861
sg33289
Vfibromyalgia
p48862
sa(dp48863
g33284
I172
sg33285
I4
sg33286
I30
sg33287
VC0458219
p48864
sg33289
Vcomplex regional pain syndrome
p48865
sa(dp48866
g33284
I161
sg33285
I1
sg33286
I9
sg33287
VC0027796
p48867
sg33289
Vneuralgia
p48868
sa(dp48869
g33284
I211
sg33285
I3
sg33286
I24
sg33287
VC0022104
p48870
sg33289
Virritable bowel syndrome
p48871
sa(dp48872
g33284
I138
sg33285
I2
sg33286
I22
sg33287
VC0152177
p48873
sg33289
Vneuropathy, trigeminal
p48874
sa(dp48875
g33284
I68
sg33285
I1
sg33286
I9
sg33287
VC0039082
p48876
sg33289
Vsyndromes
p48877
sa(dp48878
g33284
I28
sg33285
I1
sg33286
I4
sg33287
VC0035334
p48879
sg33289
Vcord
p48880
sasa(dp48881
g33277
VSortilin-related receptor with LDLR class A repeats (SORLA, SORL1, or LR11) is a genetic risk factor associated with Alzheimer's disease (AD).
p48882
sg33279
(lp48883
(dp48884
g33284
I0
sg33285
I7
sg33286
I51
sg33295
g11
sg33289
VSortilin-related receptor with LDLR class A repeats
p48885
sa(dp48886
g33284
I60
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSORL1
p48887
sa(dp48888
g33284
I53
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSORLA
p48889
sasg33281
(lp48890
(dp48891
g33284
I138
sg33285
I1
sg33286
I2
sg33287
VC1521724
p48892
sg33289
VAD
p48893
sa(dp48894
g33284
I117
sg33285
I2
sg33286
I19
sg33287
VC1521724
p48895
sg33289
VAlzheimer's disease
p48896
sasa(dp48897
g33277
VA meta-analysis was performed to identify empirical data assessing the effects of a single nucleotide polymorphisms of sortilin-related receptor on Alzheimer's disease based on 14 studies involving 37941 cases and 49727 control studies.
p48898
sg33279
(lp48899
(dp48900
g33284
I119
sg33285
I2
sg33286
I25
sg33295
g11
sg33289
Vsortilin-related receptor
p48901
sasg33281
(lp48902
(dp48903
g33284
I148
sg33285
I2
sg33286
I19
sg33287
VC1521724
p48904
sg33289
VAlzheimer's disease
p48905
sasa(dp48906
g33277
VGiven these data, we provide crucial evidence to manifest that a significant relationship exists between SORL1 polymorphisms and the susceptibility of Alzheimer's disease.
p48907
sg33279
(lp48908
(dp48909
g33284
I105
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VSORL1
p48910
sasg33281
(lp48911
(dp48912
g33284
I151
sg33285
I2
sg33286
I19
sg33287
VC1521724
p48913
sg33289
VAlzheimer's disease
p48914
sasa(dp48915
g33277
VFurthermore, a third SORL1 variant, c.5195G &gt; C, recently identified in a Swedish case control cohort included in the European Early-Onset Dementia (EU EOD) consortium study, was detected in two affected siblings in a third family with familial EOAD.
p48916
sg33279
(lp48917
(dp48918
g33284
I21
sg33285
I2
sg33286
I13
sg33295
g11
sg33289
VSORL1 variant
p48919
sasg33281
(lp48920
(dp48921
g33284
I142
sg33285
I1
sg33286
I8
sg33287
VC0497327
p48922
sg33289
VDementia
p48923
sasa(dp48924
g33277
VThrombospondin-1 (TSP1) is a ligand for CD47 and TSP1-/- mice are protected from pulmonary hypertension (PH).
p48925
sg33279
(lp48926
(dp48927
g33284
I18
sg33285
I1
sg33286
I4
sg33295
VP07996
p48928
sg33289
VTSP1
p48929
sa(dp48930
g33284
I18
sg33285
I1
sg33286
I4
sg33295
VP07996
p48931
sg33289
VTSP1
p48932
sa(dp48933
g33284
I0
sg33285
I1
sg33286
I16
sg33295
VP07996
p48934
sg33289
VThrombospondin-1
p48935
sa(dp48936
g33284
I40
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCD47
p48937
sasg33281
(lp48938
(dp48939
g33284
I105
sg33285
I1
sg33286
I2
sg33287
VC0020542
p48940
sg33289
VPH
p48941
sa(dp48942
g33284
I81
sg33285
I2
sg33286
I22
sg33287
VC0020542
p48943
sg33289
Vpulmonary hypertension
p48944
sasa(dp48945
g33277
VWe further discuss therapeutic strategies for enhancing or inhibiting CD47 signaling and applications of such agents in preclinical models of ischemia and ischemia/reperfusion injuries, organ transplantation, pulmonary hypertension, radioprotection, and cancer.
p48946
sg33279
(lp48947
(dp48948
g33284
I70
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VCD47
p48949
sasg33281
(lp48950
(dp48951
g33284
I142
sg33285
I1
sg33286
I8
sg33287
VC0022116
p48952
sg33289
Vischemia
p48953
sa(dp48954
g33284
I254
sg33285
I1
sg33286
I6
sg33287
VC0006826
p48955
sg33289
Vcancer
p48956
sa(dp48957
g33284
I209
sg33285
I2
sg33286
I22
sg33287
VC0020542
p48958
sg33289
Vpulmonary hypertension
p48959
sa(dp48960
g33284
I142
sg33285
I1
sg33286
I8
sg33287
VC0022116
p48961
sg33289
Vischemia
p48962
sasa(dp48963
g33277
VIn present study, anticancer activity of ethanol extract of Chinese propolis (EECP) at 25, 50, 100, and 200  my g/mL was explored by testing the cytotoxicity in MCF-7 (human breast cancer ER(+)) and MDA-MB-231 (human breast cancer ER(-)) cells.
p48964
sg33279
(lp48965
sg33281
(lp48966
(dp48967
g33284
I145
sg33285
I1
sg33286
I12
sg33287
VC0596402
p48968
sg33289
Vcytotoxicity
p48969
sa(dp48970
g33284
I174
sg33285
I2
sg33286
I13
sg33287
VC0678222
p48971
sg33289
Vbreast cancer
p48972
sa(dp48973
g33284
I174
sg33285
I2
sg33286
I13
sg33287
VC0678222
p48974
sg33289
Vbreast cancer
p48975
sasa(dp48976
g33277
VWe exposed human pancreatic cancer cell line MiaPaCa-2 (CRL-1420) to 34  my g/mL of LE for 24, 48, and 72 hours.
p48977
sg33279
(lp48978
sg33281
(lp48979
(dp48980
g33284
I17
sg33285
I2
sg33286
I17
sg33287
VC0235974
p48981
sg33289
Vpancreatic cancer
p48982
sasa(dp48983
g33277
VIn addition, variations in JAG1 have been found to be associated with multiple types of cancer including breast cancer and adrenocortical carcinoma.
p48984
sg33279
(lp48985
(dp48986
g33284
I27
sg33285
I1
sg33286
I4
sg33295
VP78504
p48987
sg33289
VJAG1
p48988
sasg33281
(lp48989
(dp48990
g33284
I105
sg33285
I2
sg33286
I13
sg33287
VC0678222
p48991
sg33289
Vbreast cancer
p48992
sa(dp48993
g33284
I88
sg33285
I1
sg33286
I6
sg33287
VC0006826
p48994
sg33289
Vcancer
p48995
sa(dp48996
g33284
I123
sg33285
I2
sg33286
I24
sg33287
VC0206686
p48997
sg33289
Vadrenocortical carcinoma
p48998
sasa(dp48999
g33277
VThe role of the extract in pancreatic cancer treatment was associated with down-regulation of Notch-4 and Jagged-1 in Notch signaling pathway.
p49000
sg33279
(lp49001
sg33281
(lp49002
(dp49003
g33284
I27
sg33285
I2
sg33286
I17
sg33287
VC0235974
p49004
sg33289
Vpancreatic cancer
p49005
sasa(dp49006
g33277
VThe patient was a 64-year-old man with situs inversus totalis who had previously undergone sigmoidectomy with regional lymphadenectomy for sigmoid colon cancer at age 62.
p49007
sg33279
(lp49008
sg33281
(lp49009
(dp49010
g33284
I39
sg33285
I2
sg33286
I14
sg33287
VC0037221
p49011
sg33289
Vsitus inversus
p49012
sa(dp49013
g33284
I139
sg33285
I3
sg33286
I20
sg33287
VC0751498
p49014
sg33289
Vsigmoid colon cancer
p49015
sasa(dp49016
g33277
VFor the treatment of hepatic metastases from sigmoid colon cancer in a patient with situs inversus totalis, "left" hepatic lobectomy, partial hepatectomy, and radiofrequency ablation therapy were performed.
p49017
sg33279
(lp49018
sg33281
(lp49019
(dp49020
g33284
I21
sg33285
I2
sg33286
I18
sg33287
VC0494165
p49021
sg33289
Vhepatic metastases
p49022
sa(dp49023
g33284
I45
sg33285
I3
sg33286
I20
sg33287
VC0751498
p49024
sg33289
Vsigmoid colon cancer
p49025
sa(dp49026
g33284
I84
sg33285
I2
sg33286
I14
sg33287
VC0037221
p49027
sg33289
Vsitus inversus
p49028
sasa(dp49029
g33277
VOn day 25, pulmonary eosinophilia, airway hyperresponsiveness, mucus hypersecretion, inflammatory cytokines such as IL-4, -5 and -13 in BAL fluid, gene expression of inflammatory mediators such as 5-LOX, E-selectin, VCAM-1, CCL5, TNF-Alfa, AMCase, Ym2, YKL-40, Muc5ac, CCL2 and iNOS in animal lung tissues, and serum IgE were determined.
p49030
sg33279
(lp49031
(dp49032
g33284
I278
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
ViNOS
p49033
sa(dp49034
g33284
I269
sg33285
I1
sg33286
I4
sg33295
VP13500
p49035
sg33289
VCCL2
p49036
sa(dp49037
g33284
I224
sg33285
I1
sg33286
I4
sg33295
VP13501
p49038
sg33289
VCCL5
p49039
sa(dp49040
g33284
I311
sg33285
I2
sg33286
I9
sg33295
VP01854
p49041
sg33289
Vserum IgE
p49042
sa(dp49043
g33284
I204
sg33285
I1
sg33286
I10
sg33295
VP16581
p49044
sg33289
VE-selectin
p49045
sa(dp49046
g33284
I230
sg33285
I1
sg33286
I8
sg33295
VP01375
p49047
sg33289
VTNF-Alfa
p49048
sa(dp49049
g33284
I197
sg33285
I1
sg33286
I5
sg33295
VP09917
p49050
sg33289
V5-LOX
p49051
sa(dp49052
g33284
I116
sg33285
I1
sg33286
I4
sg33295
VP05112
p49053
sg33289
VIL-4
p49054
sa(dp49055
g33284
I216
sg33285
I1
sg33286
I6
sg33295
VP19320
p49056
sg33289
VVCAM-1
p49057
sa(dp49058
g33284
I253
sg33285
I1
sg33286
I6
sg33295
VP36222
p49059
sg33289
VYKL-40
p49060
sasg33281
(lp49061
(dp49062
g33284
I317
sg33285
I1
sg33286
I3
sg33287
VC0270850
p49063
sg33289
VIgE
p49064
sa(dp49065
g33284
I11
sg33285
I2
sg33286
I22
sg33287
VC0034068
p49066
sg33289
Vpulmonary eosinophilia
p49067
sasa(dp49068
g33277
VOur results show that tropical pulmonary eosinophilia mice exhibited increased levels of IL-4, IL-5, CCL5, and CCL11 in the bronchoalveolar lavage fluid and lung parenchyma along with elevated titers of IgE and IgG subtypes in the serum.
p49069
sg33279
(lp49070
(dp49071
g33284
I95
sg33285
I1
sg33286
I4
sg33295
VP05113
p49072
sg33289
VIL-5
p49073
sa(dp49074
g33284
I203
sg33285
I1
sg33286
I3
sg33295
VP01854
p49075
sg33289
VIgE
p49076
sa(dp49077
g33284
I111
sg33285
I1
sg33286
I5
sg33295
VP51671
p49078
sg33289
VCCL11
p49079
sa(dp49080
g33284
I89
sg33285
I1
sg33286
I4
sg33295
VP05112
p49081
sg33289
VIL-4
p49082
sa(dp49083
g33284
I101
sg33285
I1
sg33286
I4
sg33295
VP13501
p49084
sg33289
VCCL5
p49085
sasg33281
(lp49086
(dp49087
g33284
I203
sg33285
I1
sg33286
I3
sg33287
VC0270850
p49088
sg33289
VIgE
p49089
sa(dp49090
g33284
I22
sg33285
I3
sg33286
I31
sg33287
VC0014458
p49091
sg33289
Vtropical pulmonary eosinophilia
p49092
sasa(dp49093
g33277
VA(2B) R deficiency resulted in a dramatic reduction on Th2-type airways responses with decreased pulmonary eosinophilia without augmenting neutrophilia, and decreased lung IL-4, IL-5, and IL-13 production.
p49094
sg33279
(lp49095
(dp49096
g33284
I188
sg33285
I1
sg33286
I5
sg33295
VP35225
p49097
sg33289
VIL-13
p49098
sa(dp49099
g33284
I167
sg33285
I2
sg33286
I9
sg33295
VP05112
p49100
sg33289
Vlung IL-4
p49101
sa(dp49102
g33284
I178
sg33285
I1
sg33286
I4
sg33295
VP05113
p49103
sg33289
VIL-5
p49104
sasg33281
(lp49105
(dp49106
g33284
I97
sg33285
I2
sg33286
I22
sg33287
VC0034068
p49107
sg33289
Vpulmonary eosinophilia
p49108
sasa(dp49109
g33277
VBoth isoforms caused pulmonary infiltration of lymphocytes and neutrophils, whereas mm IL-33 also caused pulmonary eosinophilia and goblet cell hyperplasia and increased expression of IL-4, IL-5, IL-13, IL-17, MCP-1, and KC.
p49110
sg33279
(lp49111
(dp49112
g33284
I190
sg33285
I1
sg33286
I4
sg33295
VP05113
p49113
sg33289
VIL-5
p49114
sa(dp49115
g33284
I184
sg33285
I1
sg33286
I4
sg33295
VP05112
p49116
sg33289
VIL-4
p49117
sa(dp49118
g33284
I210
sg33285
I1
sg33286
I5
sg33295
VP41597
p49119
sg33289
VMCP-1
p49120
sa(dp49121
g33284
I196
sg33285
I1
sg33286
I5
sg33295
VP35225
p49122
sg33289
VIL-13
p49123
sasg33281
(lp49124
(dp49125
g33284
I21
sg33285
I2
sg33286
I22
sg33287
VC0235896
p49126
sg33289
Vpulmonary infiltration
p49127
sa(dp49128
g33284
I144
sg33285
I1
sg33286
I11
sg33287
VC0020507
p49129
sg33289
Vhyperplasia
p49130
sa(dp49131
g33284
I105
sg33285
I2
sg33286
I22
sg33287
VC0034068
p49132
sg33289
Vpulmonary eosinophilia
p49133
sasa(dp49134
g33277
VGermline deficiency of the cell surface receptor chain ST2 abrogated the mm IL-33-induced Th2-associated effects (pulmonary eosinophilia, goblet cell hyperplasia, and increased IL-4 and IL-5), yet the lymphocytic infiltration induced by full-length mouse IL-33 or mm IL-33 was not fully abrogated by the absence of ST2.
p49135
sg33279
(lp49136
(dp49137
g33284
I177
sg33285
I1
sg33286
I4
sg33295
VP05112
p49138
sg33289
VIL-4
p49139
sa(dp49140
g33284
I237
sg33285
I3
sg33286
I23
sg33295
g11
sg33289
Vfull-length mouse IL-33
p49141
sa(dp49142
g33284
I186
sg33285
I1
sg33286
I4
sg33295
VP05113
p49143
sg33289
VIL-5
p49144
sasg33281
(lp49145
(dp49146
g33284
I114
sg33285
I2
sg33286
I22
sg33287
VC0034068
p49147
sg33289
Vpulmonary eosinophilia
p49148
sa(dp49149
g33284
I201
sg33285
I2
sg33286
I24
sg33287
VC1262091
p49150
sg33289
Vlymphocytic infiltration
p49151
sa(dp49152
g33284
I150
sg33285
I1
sg33286
I11
sg33287
VC0020507
p49153
sg33289
Vhyperplasia
p49154
sasa(dp49155
g33277
VOVA-challenged STAT6-/- mice had neither AHR nor pulmonary eosinophilia, but had increased expression of mRNA for TNF-Alfa, IFN-Gamma and IL-4.
p49156
sg33279
(lp49157
(dp49158
g33284
I138
sg33285
I1
sg33286
I4
sg33295
VP05112
p49159
sg33289
VIL-4
p49160
sa(dp49161
g33284
I114
sg33285
I1
sg33286
I3
sg33295
VP01375
p49162
sg33289
VTNF
p49163
sa(dp49164
g33284
I124
sg33285
I1
sg33286
I9
sg33295
VP01579
p49165
sg33289
VIFN-Gamma
p49166
sa(dp49167
g33284
I41
sg33285
I1
sg33286
I3
sg33295
VP35869
p49168
sg33289
VAHR
p49169
sa(dp49170
g33284
I15
sg33285
I1
sg33286
I5
sg33295
VP42226
p49171
sg33289
VSTAT6
p49172
sasg33281
(lp49173
(dp49174
g33284
I49
sg33285
I2
sg33286
I22
sg33287
VC0034068
p49175
sg33289
Vpulmonary eosinophilia
p49176
sasa(dp49177
g33277
VGLP-1R agonists are used to treat diabetes and obesity, and a GLP-2R agonist is approved to treat short bowel syndrome.
p49178
sg33279
(lp49179
(dp49180
g33284
I0
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VGLP-1R
p49181
sa(dp49182
g33284
I62
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VGLP-2R
p49183
sasg33281
(lp49184
(dp49185
g33284
I47
sg33285
I1
sg33286
I7
sg33287
VC0028754
p49186
sg33289
Vobesity
p49187
sa(dp49188
g33284
I98
sg33285
I3
sg33286
I20
sg33287
VC0036992
p49189
sg33289
Vshort bowel syndrome
p49190
sa(dp49191
g33284
I34
sg33285
I1
sg33286
I8
sg33287
VC0011849
p49192
sg33289
Vdiabetes
p49193
sasa(dp49194
g33277
VRNA-seq analysis and quantitative real-time polymerase chain reaction (qRT-PCR) were performed to evaluate the presence of GLP-1R and GLP-2R in EAT and subcutaneous fat (SAT) obtained from 8 subjects with coronary artery disease and type 2 diabetes mellitus undergoing elective cardiac surgery.
p49195
sg33279
(lp49196
(dp49197
g33284
I134
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VGLP-2R
p49198
sa(dp49199
g33284
I123
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VGLP-1R
p49200
sasg33281
(lp49201
(dp49202
g33284
I205
sg33285
I3
sg33286
I23
sg33287
VC1956346
p49203
sg33289
Vcoronary artery disease
p49204
sa(dp49205
g33284
I233
sg33285
I4
sg33286
I24
sg33287
VC0011860
p49206
sg33289
Vtype 2 diabetes mellitus
p49207
sasa(dp49208
g33277
VGastric tissue samples of non-obese patients (NOB, n=10) and obese patients without diabetes (OB, n=31) and with diabetes (OWD, n=12) were used to evaluate GLP2R expression and distribution.
p49209
sg33279
(lp49210
(dp49211
g33284
I156
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VGLP2R
p49212
sasg33281
(lp49213
(dp49214
g33284
I30
sg33285
I1
sg33286
I5
sg33287
VC0028754
p49215
sg33289
Vobese
p49216
sa(dp49217
g33284
I84
sg33285
I1
sg33286
I8
sg33287
VC0011849
p49218
sg33289
Vdiabetes
p49219
sa(dp49220
g33284
I30
sg33285
I1
sg33286
I5
sg33287
VC0028754
p49221
sg33289
Vobese
p49222
sa(dp49223
g33284
I84
sg33285
I1
sg33286
I8
sg33287
VC0011849
p49224
sg33289
Vdiabetes
p49225
sasa(dp49226
g33277
VThis is the first evidence of increased GLP2R expression in chief cells of patients with severe obesity regardless of diabetes status.
p49227
sg33279
(lp49228
(dp49229
g33284
I40
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VGLP2R
p49230
sasg33281
(lp49231
(dp49232
g33284
I118
sg33285
I1
sg33286
I8
sg33287
VC0011849
p49233
sg33289
Vdiabetes
p49234
sa(dp49235
g33284
I89
sg33285
I2
sg33286
I14
sg33287
VC0028756
p49236
sg33289
Vsevere obesity
p49237
sasa(dp49238
g33277
VWe examined the importance of GLP-2 receptor (GLP-2R) signaling for glucose homeostasis in multiple models of metabolic stress, diabetes, and obesity.
p49239
sg33279
(lp49240
(dp49241
g33284
I30
sg33285
I2
sg33286
I14
sg33295
g11
sg33289
VGLP-2 receptor
p49242
sa(dp49243
g33284
I46
sg33285
I1
sg33286
I6
sg33295
g11
sg33289
VGLP-2R
p49244
sasg33281
(lp49245
(dp49246
g33284
I128
sg33285
I1
sg33286
I8
sg33287
VC0011849
p49247
sg33289
Vdiabetes
p49248
sa(dp49249
g33284
I142
sg33285
I1
sg33286
I7
sg33287
VC0028754
p49250
sg33289
Vobesity
p49251
sasa(dp49252
g33277
VMoreover, glucose homeostasis was comparable in Glp2r(-/-) and Glp2r(+/+) mice fed a high-fat diet for 5 months or after induction of streptozotocin-induced diabetes.
p49253
sg33279
(lp49254
(dp49255
g33284
I48
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VGlp2r
p49256
sa(dp49257
g33284
I48
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VGlp2r
p49258
sasg33281
(lp49259
(dp49260
g33284
I157
sg33285
I1
sg33286
I8
sg33287
VC0011849
p49261
sg33289
Vdiabetes
p49262
sasa(dp49263
g33277
VIn a model of tubulointerstitial fibrosis induced by unilateral ureteral obstruction in mice, increased collagen I protein content and an almost complete disappearance of erythropoietin mRNA expression were observed in the ureteral ligated kidney with respect to the contralateral control.
p49264
sg33279
(lp49265
(dp49266
g33284
I171
sg33285
I2
sg33286
I19
sg33295
VP01588
p49267
sg33289
Verythropoietin mRNA
p49268
sa(dp49269
g33284
I104
sg33285
I3
sg33286
I18
sg33295
VP42768
p49270
sg33289
Vcollagen I protein
p49271
sasg33281
(lp49272
(dp49273
g33284
I33
sg33285
I1
sg33286
I8
sg33287
VC0016059
p49274
sg33289
Vfibrosis
p49275
sa(dp49276
g33284
I64
sg33285
I2
sg33286
I20
sg33287
VC0041956
p49277
sg33289
Vureteral obstruction
p49278
sasa(dp49279
g33277
VIn the present study, employing a mouse model of renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction (UUO), we demonstrated that EPO markedly reduced the disruption of the tubular basement membrane (TBM) through attenuating the activation of tissue plasminogen activator (tPA) and matrix metalloproteinase 9 (MMP9), the major matrix proteolytic network in the obstructed kidney.
p49280
sg33279
(lp49281
(dp49282
g33284
I297
sg33285
I1
sg33286
I3
sg33295
VP00747
p49283
sg33289
VtPA
p49284
sa(dp49285
g33284
I306
sg33285
I3
sg33286
I26
sg33295
VP14780
p49286
sg33289
Vmatrix metalloproteinase 9
p49287
sa(dp49288
g33284
I154
sg33285
I1
sg33286
I3
sg33295
VP01588
p49289
sg33289
VEPO
p49290
sa(dp49291
g33284
I267
sg33285
I3
sg33286
I28
sg33295
VP00747
p49292
sg33289
Vtissue plasminogen activator
p49293
sa(dp49294
g33284
I334
sg33285
I1
sg33286
I4
sg33295
VP14780
p49295
sg33289
VMMP9
p49296
sasg33281
(lp49297
(dp49298
g33284
I127
sg33285
I1
sg33286
I3
sg33287
VC0041956
p49299
sg33289
VUUO
p49300
sa(dp49301
g33284
I74
sg33285
I1
sg33286
I8
sg33287
VC0016059
p49302
sg33289
Vfibrosis
p49303
sa(dp49304
g33284
I105
sg33285
I2
sg33286
I20
sg33287
VC0041956
p49305
sg33289
Vureteral obstruction
p49306
sasa(dp49307
g33277
VThe MVs derived from untreated MSCs (MSC-MVs) or from MSCs incubated in different concentrations of EPO (1, 10, 100, and 500 IU/ml EPO-MVs) were used to treat renal injury of unilateral ureteral obstruction (UUO) in vivo, and transforming growth factor-Beta1 (TGF-Beta1)-induced fibrosis in a human renal proximal tubular epithelial (HK2) cell line in vitro.
p49308
sg33279
(lp49309
(dp49310
g33284
I100
sg33285
I1
sg33286
I3
sg33295
VP01588
p49311
sg33289
VEPO
p49312
sa(dp49313
g33284
I226
sg33285
I3
sg33286
I32
sg33295
VP01137
p49314
sg33289
Vtransforming growth factor-Beta1
p49315
sa(dp49316
g33284
I260
sg33285
I1
sg33286
I9
sg33295
VP01137
p49317
sg33289
VTGF-Beta1
p49318
sasg33281
(lp49319
(dp49320
g33284
I208
sg33285
I1
sg33286
I3
sg33287
VC0041956
p49321
sg33289
VUUO
p49322
sa(dp49323
g33284
I186
sg33285
I2
sg33286
I20
sg33287
VC0041956
p49324
sg33289
Vureteral obstruction
p49325
sa(dp49326
g33284
I279
sg33285
I1
sg33286
I8
sg33287
VC0016059
p49327
sg33289
Vfibrosis
p49328
sasa(dp49329
g33277
VTwenty-four male C57BL6 mice were randomly divided into four groups, each comprising six mice: (i) control group (Sh); (ii) unilateral ureteral obstruction (UUO) plus vehicle group (U+V); (#\u2172) UUO plus 300 U/kg body weight recombinant human (rh)EPO (U+E1) and (#\u2173) UUO plus 1,000 U/kg body weight rhEPO (U+E2).
p49330
sg33279
(lp49331
(dp49332
g33284
I245
sg33285
I1
sg33286
I3
sg33295
VP01588
p49333
sg33289
VEPO
p49334
sasg33281
(lp49335
(dp49336
g33284
I157
sg33285
I1
sg33286
I3
sg33287
VC0041956
p49337
sg33289
VUUO
p49338
sa(dp49339
g33284
I157
sg33285
I1
sg33286
I3
sg33287
VC0041956
p49340
sg33289
VUUO
p49341
sa(dp49342
g33284
I135
sg33285
I2
sg33286
I20
sg33287
VC0041956
p49343
sg33289
Vureteral obstruction
p49344
sa(dp49345
g33284
I157
sg33285
I1
sg33286
I3
sg33287
VC0041956
p49346
sg33289
VUUO
p49347
sasa(dp49348
g33277
VThe aim of this study is to show and compare the actions of Simvastatin (Simv) and Erythropoietin (Epo) in renal expression of nuclear factor kappa B (NFKB), transforming growth factor-Beta (TGF-Beta), basic fibroblast growth factor (bFGF), platelet-derived growth factor B (PDGF-B), fibronectin and development of interstitial fibrosis in rats with unilateral ureteral obstruction (UUO).
p49349
sg33279
(lp49350
(dp49351
g33284
I151
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNFKB
p49352
sa(dp49353
g33284
I99
sg33285
I1
sg33286
I3
sg33295
VP01588
p49354
sg33289
VEpo
p49355
sa(dp49356
g33284
I158
sg33285
I3
sg33286
I31
sg33295
VP18075
p49357
sg33289
Vtransforming growth factor-Beta
p49358
sa(dp49359
g33284
I191
sg33285
I1
sg33286
I8
sg33295
VP18075
p49360
sg33289
VTGF-Beta
p49361
sa(dp49362
g33284
I275
sg33285
I1
sg33286
I6
sg33295
VP01127
p49363
sg33289
VPDGF-B
p49364
sa(dp49365
g33284
I83
sg33285
I1
sg33286
I14
sg33295
VP01588
p49366
sg33289
VErythropoietin
p49367
sa(dp49368
g33284
I234
sg33285
I1
sg33286
I4
sg33295
VP53370
p49369
sg33289
VbFGF
p49370
sa(dp49371
g33284
I127
sg33285
I4
sg33286
I22
sg33295
VP01160
p49372
sg33289
Vnuclear factor kappa B
p49373
sa(dp49374
g33284
I241
sg33285
I4
sg33286
I32
sg33295
VP01127
p49375
sg33289
Vplatelet-derived growth factor B
p49376
sa(dp49377
g33284
I202
sg33285
I4
sg33286
I30
sg33295
VP53370
p49378
sg33289
Vbasic fibroblast growth factor
p49379
sasg33281
(lp49380
(dp49381
g33284
I383
sg33285
I1
sg33286
I3
sg33287
VC0041956
p49382
sg33289
VUUO
p49383
sa(dp49384
g33284
I315
sg33285
I2
sg33286
I21
sg33287
VC0240035
p49385
sg33289
Vinterstitial fibrosis
p49386
sa(dp49387
g33284
I361
sg33285
I2
sg33286
I20
sg33287
VC0041956
p49388
sg33289
Vureteral obstruction
p49389
sasa(dp49390
g33277
VIn a novel mouse model, unilateral ureteral obstruction-induced inflammatory milieu activated NFKB and Smad signaling pathways in REPs, rapidly repressed the Epo-producing potential of REPs, and led to myofibroblast transformation of these cells.
p49391
sg33279
(lp49392
(dp49393
g33284
I94
sg33285
I1
sg33286
I4
sg33295
g11
sg33289
VNFKB
p49394
sa(dp49395
g33284
I158
sg33285
I1
sg33286
I3
sg33295
VP01588
p49396
sg33289
VEpo
p49397
sasg33281
(lp49398
(dp49399
g33284
I35
sg33285
I2
sg33286
I20
sg33287
VC0041956
p49400
sg33289
Vureteral obstruction
p49401
sa(dp49402
g33284
I216
sg33285
I1
sg33286
I14
sg33287
VC1510411
p49403
sg33289
Vtransformation
p49404
sasa(dp49405
g33277
VReversing the unilateral ureteral obstruction-induced inflammatory microenvironment restored the Epo-producing potential and the physiologic phenotype of REPs.
p49406
sg33279
(lp49407
(dp49408
g33284
I97
sg33285
I1
sg33286
I3
sg33295
VP01588
p49409
sg33289
VEpo
p49410
sasg33281
(lp49411
(dp49412
g33284
I25
sg33285
I2
sg33286
I20
sg33287
VC0041956
p49413
sg33289
Vureteral obstruction
p49414
sasa(dp49415
g33277
VSecondary polycythemia with increased production of erythropoietin (EPO) is known to occur in kidney diseases such as hydronephrosis and cystic disease, but the mechanism remains unclear.
p49416
sg33279
(lp49417
(dp49418
g33284
I52
sg33285
I1
sg33286
I14
sg33295
VP01588
p49419
sg33289
Verythropoietin
p49420
sa(dp49421
g33284
I68
sg33285
I1
sg33286
I3
sg33295
VP01588
p49422
sg33289
VEPO
p49423
sasg33281
(lp49424
(dp49425
g33284
I118
sg33285
I1
sg33286
I14
sg33287
VC0020295
p49426
sg33289
Vhydronephrosis
p49427
sa(dp49428
g33284
I0
sg33285
I2
sg33286
I22
sg33287
VC1318533
p49429
sg33289
VSecondary polycythemia
p49430
sa(dp49431
g33284
I137
sg33285
I2
sg33286
I14
sg33287
VC0334054
p49432
sg33289
Vcystic disease
p49433
sa(dp49434
g33284
I94
sg33285
I2
sg33286
I15
sg33287
VC0022658
p49435
sg33289
Vkidney diseases
p49436
sasa(dp49437
g33277
VDecompartmentalized hemoglobin, arginase 1, asymmetric dimethylarginine, and adenine nucleotides are all products of hemolysis that promote vasomotor dysfunction, proliferative vasculopathy, and a multitude of clinical complications of pulmonary and systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic kidney disease, and large-artery ischemic stroke.
p49438
sg33279
(lp49439
(dp49440
g33284
I20
sg33285
I1
sg33286
I10
sg33295
g11
sg33289
Vhemoglobin
p49441
sa(dp49442
g33284
I32
sg33285
I2
sg33286
I10
sg33295
VP05089
p49443
sg33289
Varginase 1
p49444
sasg33281
(lp49445
(dp49446
g33284
I307
sg33285
I2
sg33286
I10
sg33287
VC0023223
p49447
sg33289
Vleg ulcers
p49448
sa(dp49449
g33284
I329
sg33285
I3
sg33286
I22
sg33287
VC1561643
p49450
sg33289
Vchronic kidney disease
p49451
sa(dp49452
g33284
I163
sg33285
I1
sg33286
I13
sg33287
VC0334094
p49453
sg33289
Vproliferative
p49454
sa(dp49455
g33284
I283
sg33285
I2
sg33286
I22
sg33287
VC0020542
p49456
sg33289
Vpulmonary hypertension
p49457
sa(dp49458
g33284
I370
sg33285
I2
sg33286
I15
sg33287
VC3272363
p49459
sg33289
Vischemic stroke
p49460
sa(dp49461
g33284
I117
sg33285
I1
sg33286
I9
sg33287
VC0019054
p49462
sg33289
Vhemolysis
p49463
sa(dp49464
g33284
I319
sg33285
I1
sg33286
I8
sg33287
VC0033117
p49465
sg33289
Vpriapism
p49466
sasa(dp49467
g33277
VWe report a patient with bilateral incyclotorsion, asymmetric facial palsy, monocular depression deficiency, and unilateral Type 3 Duane syndrome, along with contralateral anotia and a midline cleft palate.
p49468
sg33279
(lp49469
sg33281
(lp49470
(dp49471
g33284
I172
sg33285
I1
sg33286
I6
sg33287
VC0702139
p49472
sg33289
Vanotia
p49473
sa(dp49474
g33284
I86
sg33285
I1
sg33286
I10
sg33287
VC0011581
p49475
sg33289
Vdepression
p49476
sa(dp49477
g33284
I193
sg33285
I2
sg33286
I12
sg33287
VC0008925
p49478
sg33289
Vcleft palate
p49479
sa(dp49480
g33284
I131
sg33285
I2
sg33286
I14
sg33287
VC0013261
p49481
sg33289
VDuane syndrome
p49482
sa(dp49483
g33284
I62
sg33285
I2
sg33286
I12
sg33287
VC0015469
p49484
sg33289
Vfacial palsy
p49485
sasa(dp49486
g33277
VThe authors report a child with features of Cardiofacial syndrome with anotia and facial paralysis.
p49487
sg33279
(lp49488
sg33281
(lp49489
(dp49490
g33284
I82
sg33285
I2
sg33286
I16
sg33287
VC0015469
p49491
sg33289
Vfacial paralysis
p49492
sa(dp49493
g33284
I44
sg33285
I2
sg33286
I21
sg33287
VC0431406
p49494
sg33289
VCardiofacial syndrome
p49495
sa(dp49496
g33284
I71
sg33285
I1
sg33286
I6
sg33287
VC0702139
p49497
sg33289
Vanotia
p49498
sasa(dp49499
g33277
VThirty-three cases had microtia or anotia, and all instances of facial palsy were associated with auricular malformation.
p49500
sg33279
(lp49501
sg33281
(lp49502
(dp49503
g33284
I64
sg33285
I2
sg33286
I12
sg33287
VC0015469
p49504
sg33289
Vfacial palsy
p49505
sa(dp49506
g33284
I23
sg33285
I1
sg33286
I8
sg33287
VC0152423
p49507
sg33289
Vmicrotia
p49508
sa(dp49509
g33284
I108
sg33285
I1
sg33286
I12
sg33287
VC0000768
p49510
sg33289
Vmalformation
p49511
sa(dp49512
g33284
I35
sg33285
I1
sg33286
I6
sg33287
VC0702139
p49513
sg33289
Vanotia
p49514
sasa(dp49515
g33277
VA girl was born with anotia, facial palsy and cardiac malformations.
p49516
sg33279
(lp49517
sg33281
(lp49518
(dp49519
g33284
I21
sg33285
I1
sg33286
I6
sg33287
VC0702139
p49520
sg33289
Vanotia
p49521
sa(dp49522
g33284
I29
sg33285
I2
sg33286
I12
sg33287
VC0015469
p49523
sg33289
Vfacial palsy
p49524
sa(dp49525
g33284
I54
sg33285
I1
sg33286
I13
sg33287
VC0000768
p49526
sg33289
Vmalformations
p49527
sasa(dp49528
g33277
VFreshly isolated LSECs, Kupffer cells (KCs), and stabilin-1- and stabilin-2-transfected human embryonic kidney cells were incubated with fluorescently labeled or radiolabeled oxLDLs [oxidized for 3 h (oxLDL(3)), 6 h, or 24 h (oxLDL(24))] to measure endocytosis.
p49529
sg33279
(lp49530
(dp49531
g33284
I49
sg33285
I3
sg33286
I26
sg33295
g11
sg33289
Vstabilin-1- and stabilin-2
p49532
sasg33281
(lp49533
(dp49534
g33284
I39
sg33285
I1
sg33286
I3
sg33287
VC0022575
p49535
sg33289
VKCs
p49536
sa(dp49537
g33284
I24
sg33285
I2
sg33286
I13
sg33287
VC0022575
p49538
sg33289
VKupffer cells
p49539
sasa(dp49540
g33277
VFurthermore, pleiotrophin (PTN), an endogenous ligand of Ptprz, also induced gastritis specifically in Ptprz+/+ mice when administered orally.
p49541
sg33279
(lp49542
(dp49543
g33284
I27
sg33285
I1
sg33286
I3
sg33295
VP21246
p49544
sg33289
VPTN
p49545
sa(dp49546
g33284
I13
sg33285
I1
sg33286
I12
sg33295
VP21246
p49547
sg33289
Vpleiotrophin
p49548
sasg33281
(lp49549
(dp49550
g33284
I77
sg33285
I1
sg33286
I9
sg33287
VC0017152
p49551
sg33289
Vgastritis
p49552
sasa(dp49553
g33277
VWe aimed to determine whether serum levels of Krebs von den Lungen-6 (KL-6) and surfactant protein-D (SP-D) correlate with SSc/MCTD-associated ILD activity.
p49554
sg33279
(lp49555
(dp49556
g33284
I102
sg33285
I1
sg33286
I4
sg33295
VP35247
p49557
sg33289
VSP-D
p49558
sa(dp49559
g33284
I80
sg33285
I2
sg33286
I20
sg33295
VP35453
p49560
sg33289
Vsurfactant protein-D
p49561
sasg33281
(lp49562
(dp49563
g33284
I127
sg33285
I1
sg33286
I4
sg33287
VC0026272
p49564
sg33289
VMCTD
p49565
sasa(dp49566
g33277
VSerum KL-6 correlated positively with diffusing capacity of the lung for carbon monoxide (DLCO) (% predicted) and disease extent on HRCT, and the changes in serum levels of KL-6 were significantly related to the changes in forced vital capacity (FVC) in SSc/MCTD-associated ILD.
p49567
sg33279
(lp49568
(dp49569
g33284
I0
sg33285
I2
sg33286
I10
sg33295
g11
sg33289
VSerum KL-6
p49570
sasg33281
(lp49571
(dp49572
g33284
I258
sg33285
I1
sg33286
I4
sg33287
VC0026272
p49573
sg33289
VMCTD
p49574
sasa(dp49575
g33277
VOur study suggests that serum KL-6 can be a useful monitoring tool of SSc/MCTD-associated ILD activity.
p49576
sg33279
(lp49577
(dp49578
g33284
I24
sg33285
I2
sg33286
I10
sg33295
g11
sg33289
Vserum KL-6
p49579
sasg33281
(lp49580
(dp49581
g33284
I74
sg33285
I1
sg33286
I4
sg33287
VC0026272
p49582
sg33289
VMCTD
p49583
sasa(dp49584
g33277
VThe KL-6 levels did not differ significantly according to the connective tissue diseases in the diagnostic groups (systemic lupus erythematosus, Sjoegren's syndrome, rheumatoid arthritis, mixed connective tissue disease, scleroderma, polymyositis/ dermatomyositis).
p49585
sg33279
(lp49586
sg33281
(lp49587
(dp49588
g33284
I221
sg33285
I1
sg33286
I11
sg33287
VC0011644
p49589
sg33289
Vscleroderma
p49590
sa(dp49591
g33284
I234
sg33285
I1
sg33286
I12
sg33287
VC0085655
p49592
sg33289
Vpolymyositis
p49593
sa(dp49594
g33284
I166
sg33285
I2
sg33286
I20
sg33287
VC0003873
p49595
sg33289
Vrheumatoid arthritis
p49596
sa(dp49597
g33284
I145
sg33285
I2
sg33286
I19
sg33287
VC1527336
p49598
sg33289
VSjoegren's syndrome
p49599
sa(dp49600
g33284
I115
sg33285
I3
sg33286
I28
sg33287
VC0024141
p49601
sg33289
Vsystemic lupus erythematosus
p49602
sa(dp49603
g33284
I62
sg33285
I3
sg33286
I26
sg33287
VC0009782
p49604
sg33289
Vconnective tissue diseases
p49605
sa(dp49606
g33284
I188
sg33285
I4
sg33286
I31
sg33287
VC0026272
p49607
sg33289
Vmixed connective tissue disease
p49608
sa(dp49609
g33284
I248
sg33285
I1
sg33286
I15
sg33287
VC0221056
p49610
sg33289
Vdermatomyositis
p49611
sasa(dp49612
g33277
VTo quantify and compare human mucin 1 (MUC1) protein and mRNA expression in tears and conjunctival epithelial cells collected from Sjogren's syndrome (SS), non-Sjogren's keratoconjunctivitus sicca (KCS) and non-dry eyed (NDE) control subjects.
p49613
sg33279
(lp49614
(dp49615
g33284
I24
sg33285
I3
sg33286
I13
sg33295
g11
sg33289
Vhuman mucin 1
p49616
sasg33281
(lp49617
(dp49618
g33284
I131
sg33285
I2
sg33286
I18
sg33287
VC1527336
p49619
sg33289
VSjogren's syndrome
p49620
sa(dp49621
g33284
I131
sg33285
I1
sg33286
I9
sg33287
VC1527336
p49622
sg33289
VSjogren's
p49623
sa(dp49624
g33284
I198
sg33285
I1
sg33286
I3
sg33287
VC0022575
p49625
sg33289
VKCS
p49626
sa(dp49627
g33284
I170
sg33285
I2
sg33286
I26
sg33287
VC0022575
p49628
sg33289
Vkeratoconjunctivitus sicca
p49629
sa(dp49630
g33284
I151
sg33285
I1
sg33286
I2
sg33287
VC1527336
p49631
sg33289
VSS
p49632
sasa(dp49633
g33277
VWe studied 21 patients referred for idiopathic short stature, 5 with clinically suspected hypochondroplasia and 4 with achondroplasia.
p49634
sg33279
(lp49635
sg33281
(lp49636
(dp49637
g33284
I90
sg33285
I1
sg33286
I17
sg33287
VC0410529
p49638
sg33289
Vhypochondroplasia
p49639
sa(dp49640
g33284
I119
sg33285
I1
sg33286
I14
sg33287
VC0001080
p49641
sg33289
Vachondroplasia
p49642
sa(dp49643
g33284
I36
sg33285
I3
sg33286
I24
sg33287
VC1740819
p49644
sg33289
Vidiopathic short stature
p49645
sasa(dp49646
g33277
VA series of 140 patients with short stature operated on for limb lengthening (80 had achondroplasia, 20 had hypochondroplasia, 20 had Turner syndrome, 10 had idiopathic short stature due to an undemonstrated cause, 5 regarded their stature as too short, and 5 had a psychopathic personality due to dysmorphophobia that had developed because of their short stature) was reviewed.
p49647
sg33279
(lp49648
sg33281
(lp49649
(dp49650
g33284
I30
sg33285
I2
sg33286
I13
sg33287
VC0013336
p49651
sg33289
Vshort stature
p49652
sa(dp49653
g33284
I108
sg33285
I1
sg33286
I17
sg33287
VC0410529
p49654
sg33289
Vhypochondroplasia
p49655
sa(dp49656
g33284
I30
sg33285
I2
sg33286
I13
sg33287
VC0013336
p49657
sg33289
Vshort stature
p49658
sa(dp49659
g33284
I298
sg33285
I1
sg33286
I15
sg33287
VC0005887
p49660
sg33289
Vdysmorphophobia
p49661
sa(dp49662
g33284
I85
sg33285
I1
sg33286
I14
sg33287
VC0001080
p49663
sg33289
Vachondroplasia
p49664
sa(dp49665
g33284
I266
sg33285
I2
sg33286
I24
sg33287
VC0003431
p49666
sg33289
Vpsychopathic personality
p49667
sa(dp49668
g33284
I134
sg33285
I2
sg33286
I15
sg33287
VC0041408
p49669
sg33289
VTurner syndrome
p49670
sa(dp49671
g33284
I158
sg33285
I3
sg33286
I24
sg33287
VC1740819
p49672
sg33289
Vidiopathic short stature
p49673
sasa(dp49674
g33277
VIn the present study, we investigated whether the impairment of IRS-1-mediated insulin signaling contributes to neurite outgrowth and neuronal loss, both in mice fed a high-fat diet and in mouse neuroblastoma (Neuro2A) cells.
p49675
sg33279
(lp49676
(dp49677
g33284
I64
sg33285
I1
sg33286
I5
sg33295
VP35568
p49678
sg33289
VIRS-1
p49679
sa(dp49680
g33284
I79
sg33285
I1
sg33286
I7
sg33295
VP01308
p49681
sg33289
Vinsulin
p49682
sasg33281
(lp49683
(dp49684
g33284
I50
sg33285
I1
sg33286
I10
sg33287
VC0684336
p49685
sg33289
Vimpairment
p49686
sa(dp49687
g33284
I189
sg33285
I2
sg33286
I19
sg33287
VC1524043
p49688
sg33289
Vmouse neuroblastoma
p49689
sasa(dp49690
g33277
VTo investigate the changes caused by the inhibition of IRS-1-mediated insulin signaling in neuroblastoma cells, we performed Western blot analysis, reverse transcription-PCR, and immunochemical analysis.
p49691
sg33279
(lp49692
(dp49693
g33284
I55
sg33285
I1
sg33286
I5
sg33295
VP35568
p49694
sg33289
VIRS-1
p49695
sa(dp49696
g33284
I70
sg33285
I1
sg33286
I7
sg33295
VP01308
p49697
sg33289
Vinsulin
p49698
sasg33281
(lp49699
(dp49700
g33284
I91
sg33285
I1
sg33286
I13
sg33287
VC0027819
p49701
sg33289
Vneuroblastoma
p49702
sasa(dp49703
g33277
VmiR-145 might act as a tumor suppressor in uveal melanoma, and downregulation of the target IRS-1 might be a potential mechanism.
p49704
sg33279
(lp49705
(dp49706
g33284
I0
sg33285
I1
sg33286
I7
sg33295
g11
sg33289
VmiR-145
p49707
sa(dp49708
g33284
I85
sg33285
I2
sg33286
I12
sg33295
VP35568
p49709
sg33289
Vtarget IRS-1
p49710
sasg33281
(lp49711
(dp49712
g33284
I23
sg33285
I1
sg33286
I5
sg33287
VC0027651
p49713
sg33289
Vtumor
p49714
sa(dp49715
g33284
I43
sg33285
I2
sg33286
I14
sg33287
VC0220633
p49716
sg33289
Vuveal melanoma
p49717
sasa(dp49718
g33277
VAlmost a decade ago, we reported the presence of nuclear IRS-1 in medulloblastoma clinical samples, which express viral oncoprotein, large T-antigen of human polyomavirus JC (JCV T-antigen).
p49719
sg33279
(lp49720
(dp49721
g33284
I133
sg33285
I2
sg33286
I15
sg33295
VP14209
p49722
sg33289
Vlarge T-antigen
p49723
sa(dp49724
g33284
I175
sg33285
I2
sg33286
I13
sg33295
VP14209
p49725
sg33289
VJCV T-antigen
p49726
sasg33281
(lp49727
(dp49728
g33284
I66
sg33285
I1
sg33286
I15
sg33287
VC0025149
p49729
sg33289
Vmedulloblastoma
p49730
sasa(dp49731
g33277
VMore recently, nuclear IRS-1 was detected in breast cancer cells in association with estrogen receptor alpha (ERAlfa), and in JC virus negative medulloblastoma cells expressing estrogen receptor beta (ERBeta), further implicating nuclear IRS-1 in cellular transformation.
p49732
sg33279
(lp49733
(dp49734
g33284
I85
sg33285
I3
sg33286
I23
sg33295
VP03372
p49735
sg33289
Vestrogen receptor alpha
p49736
sa(dp49737
g33284
I177
sg33285
I3
sg33286
I22
sg33295
VP03372
p49738
sg33289
Vestrogen receptor beta
p49739
sa(dp49740
g33284
I15
sg33285
I2
sg33286
I13
sg33295
VP35568
p49741
sg33289
Vnuclear IRS-1
p49742
sa(dp49743
g33284
I201
sg33285
I1
sg33286
I6
sg33295
VP03372
p49744
sg33289
VERBeta
p49745
sasg33281
(lp49746
(dp49747
g33284
I247
sg33285
I2
sg33286
I23
sg33287
VC1510411
p49748
sg33289
Vcellular transformation
p49749
sa(dp49750
g33284
I45
sg33285
I2
sg33286
I13
sg33287
VC0678222
p49751
sg33289
Vbreast cancer
p49752
sa(dp49753
g33284
I144
sg33285
I1
sg33286
I15
sg33287
VC0025149
p49754
sg33289
Vmedulloblastoma
p49755
sasa(dp49756
g33277
VWe have previously reported that ERBeta, which is highly expressed in medulloblastomas, translocates insulin receptor substrate 1 (IRS-1) to the nucleus, and that nuclear IRS-1 binds to Rad51 and attenuates homologous recombination directed DNA repair (HRR).
p49757
sg33279
(lp49758
(dp49759
g33284
I186
sg33285
I1
sg33286
I5
sg33295
g11
sg33289
VRad51
p49760
sa(dp49761
g33284
I101
sg33285
I4
sg33286
I28
sg33295
VP35568
p49762
sg33289
Vinsulin receptor substrate 1
p49763
sa(dp49764
g33284
I163
sg33285
I2
sg33286
I13
sg33295
VP35568
p49765
sg33289
Vnuclear IRS-1
p49766
sa(dp49767
g33284
I131
sg33285
I1
sg33286
I5
sg33295
VP35568
p49768
sg33289
VIRS-1
p49769
sasg33281
(lp49770
(dp49771
g33284
I70
sg33285
I1
sg33286
I16
sg33287
VC0025149
p49772
sg33289
Vmedulloblastomas
p49773
sasa(dp49774
S'line'
p49775
VJacobsen syndrome (JBS) is a contiguous gene deletion syndrome involving terminal chromosome 11q.
p49776
sS'genes'
p49777
(lp49778
sS'diseases'
p49779
(lp49780
(dp49781
S'index'
p49782
I0
sS'lengthInWords'
p49783
I2
sS'lengthInChars'
p49784
I17
sS'cui'
p49785
VC0795841
p49786
sS'name'
p49787
VJacobsen syndrome
p49788
sa(dp49789
g49782
I40
sg49783
I2
sg49784
I13
sg49785
VC1442161
p49790
sg49787
Vgene deletion
p49791
sa(dp49792
g49782
I9
sg49783
I1
sg49784
I8
sg49785
VC0039082
p49793
sg49787
Vsyndrome
p49794
sa(dp49795
g49782
I19
sg49783
I1
sg49784
I3
sg49785
VC0795841
p49796
sg49787
VJBS
p49797
sasa(dp49798
g49775
VWe investigated a boy with features of JBS using classic cytogenetic methods, FISH and high-resolution array CGH.
p49799
sg49777
(lp49800
sg49779
(lp49801
(dp49802
g49782
I109
sg49783
I1
sg49784
I3
sg49785
VC1855900
p49803
sg49787
VCGH
p49804
sa(dp49805
g49782
I39
sg49783
I1
sg49784
I3
sg49785
VC0795841
p49806
sg49787
VJBS
p49807
sasa(dp49808
g49775
VThe patient had a hemizygous deletion in the FLI1 gene region without apparent thrombocytopenia, and he developed diabetes mellitus type I, which has not previously been described in the spectrum of disorders associated with JBS.
p49809
sg49777
(lp49810
(dp49811
g49782
I45
sg49783
I2
sg49784
I9
sS'uniprot'
p49812
g11
sg49787
VFLI1 gene
p49813
sasg49779
(lp49814
(dp49815
g49782
I225
sg49783
I1
sg49784
I3
sg49785
VC0795841
p49816
sg49787
VJBS
p49817
sa(dp49818
g49782
I114
sg49783
I4
sg49784
I24
sg49785
VC0011854
p49819
sg49787
Vdiabetes mellitus type I
p49820
sasa(dp49821
g49775
VThe relationship of some of the genes within the context of the phenotype caused by a partial deletion of 11q has provided insights concerning the developmental anomalies presented in this patient with atypical features of JBS.
p49822
sg49777
(lp49823
sg49779
(lp49824
(dp49825
g49782
I223
sg49783
I1
sg49784
I3
sg49785
VC0795841
p49826
sg49787
VJBS
p49827
sasa(dp49828
g49775
VAll local patients were clustered "high-risk" for future CV events based on the Framingham score (mean 21.8%, 95% CI 20.0-23.6), JBS-2 (16.3%, 14.7-17.9) and ASSIGN (25.2%, 22.7-27.7).
p49829
sg49777
(lp49830
(dp49831
g49782
I129
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VJBS-2
p49832
sasg49779
(lp49833
(dp49834
g49782
I129
sg49783
I1
sg49784
I3
sg49785
VC0795841
p49835
sg49787
VJBS
p49836
sasa(dp49837
g49775
VLoss-of-function mutations in the UBR1 gene cause Johanson-Blizzard syndrome, which involves pancreatic exocrine insufficiency.
p49838
sg49777
(lp49839
(dp49840
g49782
I34
sg49783
I2
sg49784
I9
sg49812
g11
sg49787
VUBR1 gene
p49841
sasg49779
(lp49842
(dp49843
g49782
I50
sg49783
I2
sg49784
I26
sg49785
VC0175692
p49844
sg49787
VJohanson-Blizzard syndrome
p49845
sasa(dp49846
g49775
VNo previous studies have examined an association of UBR1 variants with pancreatitis, in part due to the large size of the gene.
p49847
sg49777
(lp49848
(dp49849
g49782
I52
sg49783
I2
sg49784
I13
sg49812
g11
sg49787
VUBR1 variants
p49850
sasg49779
(lp49851
(dp49852
g49782
I71
sg49783
I1
sg49784
I12
sg49785
VC0030305
p49853
sg49787
Vpancreatitis
p49854
sasa(dp49855
g49775
VThis study aimed to clarify whether UBR1 variants are associated with chronic pancreatitis (CP) by the application of targeted next generation sequencing.
p49856
sg49777
(lp49857
(dp49858
g49782
I36
sg49783
I2
sg49784
I13
sg49812
g11
sg49787
VUBR1 variants
p49859
sasg49779
(lp49860
(dp49861
g49782
I70
sg49783
I2
sg49784
I20
sg49785
VC0149521
p49862
sg49787
Vchronic pancreatitis
p49863
sa(dp49864
g49782
I92
sg49783
I1
sg49784
I2
sg49785
VC0149521
p49865
sg49787
VCP
p49866
sasa(dp49867
g49775
VJacobsen syndrome (JBS) is a contiguous gene deletion syndrome involving 11q terminal deletion.
p49868
sg49777
(lp49869
sg49779
(lp49870
(dp49871
g49782
I0
sg49783
I2
sg49784
I17
sg49785
VC0795841
p49872
sg49787
VJacobsen syndrome
p49873
sa(dp49874
g49782
I40
sg49783
I2
sg49784
I13
sg49785
VC1442161
p49875
sg49787
Vgene deletion
p49876
sa(dp49877
g49782
I9
sg49783
I1
sg49784
I8
sg49785
VC0039082
p49878
sg49787
Vsyndrome
p49879
sa(dp49880
g49782
I19
sg49783
I1
sg49784
I3
sg49785
VC0795841
p49881
sg49787
VJBS
p49882
sasa(dp49883
g49775
VInterstitial deletions at distal 11q are rare and their contributions to the clinical phenotype of JBS are unknown.
p49884
sg49777
(lp49885
sg49779
(lp49886
(dp49887
g49782
I99
sg49783
I1
sg49784
I3
sg49785
VC0795841
p49888
sg49787
VJBS
p49889
sasa(dp49890
g49775
VOur finds support the notion that more than one critical region at 11q23.3-qter are responsible for the variable clinical presentation of JBS, thus JBS is a true contiguous gene deletion syndrome where multiple loci contributed to the clinical characteristics of JBS.
p49891
sg49777
(lp49892
(dp49893
g49782
I138
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VJBS
p49894
sasg49779
(lp49895
(dp49896
g49782
I138
sg49783
I1
sg49784
I3
sg49785
VC0795841
p49897
sg49787
VJBS
p49898
sa(dp49899
g49782
I138
sg49783
I1
sg49784
I3
sg49785
VC0795841
p49900
sg49787
VJBS
p49901
sa(dp49902
g49782
I138
sg49783
I1
sg49784
I3
sg49785
VC0795841
p49903
sg49787
VJBS
p49904
sa(dp49905
g49782
I187
sg49783
I1
sg49784
I8
sg49785
VC0039082
p49906
sg49787
Vsyndrome
p49907
sa(dp49908
g49782
I173
sg49783
I2
sg49784
I13
sg49785
VC1442161
p49909
sg49787
Vgene deletion
p49910
sasa(dp49911
g49775
VJacobsen syndrome (JBS) is an uncommon contiguous gene syndrome.
p49912
sg49777
(lp49913
sg49779
(lp49914
(dp49915
g49782
I0
sg49783
I2
sg49784
I17
sg49785
VC0795841
p49916
sg49787
VJacobsen syndrome
p49917
sa(dp49918
g49782
I9
sg49783
I1
sg49784
I8
sg49785
VC0039082
p49919
sg49787
Vsyndrome
p49920
sa(dp49921
g49782
I19
sg49783
I1
sg49784
I3
sg49785
VC0795841
p49922
sg49787
VJBS
p49923
sasa(dp49924
g49775
VThe typical clinical features in JBS include intellectual disability, growth retardation, craniofacial dysmorphism as well as craniosynostosis, congenital heart disease, and platelet abnormalities.
p49925
sg49777
(lp49926
sg49779
(lp49927
(dp49928
g49782
I126
sg49783
I1
sg49784
I16
sg49785
VC0010278
p49929
sg49787
Vcraniosynostosis
p49930
sa(dp49931
g49782
I144
sg49783
I3
sg49784
I24
sg49785
VC0152021
p49932
sg49787
Vcongenital heart disease
p49933
sa(dp49934
g49782
I45
sg49783
I2
sg49784
I23
sg49785
VC0025362
p49935
sg49787
Vintellectual disability
p49936
sa(dp49937
g49782
I33
sg49783
I1
sg49784
I3
sg49785
VC0795841
p49938
sg49787
VJBS
p49939
sa(dp49940
g49782
I70
sg49783
I2
sg49784
I18
sg49785
VC0151686
p49941
sg49787
Vgrowth retardation
p49942
sa(dp49943
g49782
I103
sg49783
I1
sg49784
I11
sg49785
VC1737329
p49944
sg49787
Vdysmorphism
p49945
sasa(dp49946
g49775
VWe report a novel deletion in JBS that increases the knowledge of the variability in the mutation sites in this region and expands the spectrum of molecular and clinical defects in this syndrome.
p49947
sg49777
(lp49948
sg49779
(lp49949
(dp49950
g49782
I186
sg49783
I1
sg49784
I8
sg49785
VC0039082
p49951
sg49787
Vsyndrome
p49952
sa(dp49953
g49782
I30
sg49783
I1
sg49784
I3
sg49785
VC0795841
p49954
sg49787
VJBS
p49955
sasa(dp49956
g49775
VJohanson-Blizzard syndrome (JBS) is considered as an infrequent, but clinically easily recognizable autosomal recessive entity by the pathognomonic combination of congenital exocrine pancreatic insufficiency and hypoplastic alae nasi, in addition to other distinctive findings such as scalp defects, hypothyroidism, and rectourogenital malformations.
p49957
sg49777
(lp49958
sg49779
(lp49959
(dp49960
g49782
I336
sg49783
I1
sg49784
I13
sg49785
VC0000768
p49961
sg49787
Vmalformations
p49962
sa(dp49963
g49782
I0
sg49783
I2
sg49784
I26
sg49785
VC0175692
p49964
sg49787
VJohanson-Blizzard syndrome
p49965
sa(dp49966
g49782
I300
sg49783
I1
sg49784
I14
sg49785
VC0020676
p49967
sg49787
Vhypothyroidism
p49968
sa(dp49969
g49782
I28
sg49783
I1
sg49784
I3
sg49785
VC0175692
p49970
sg49787
VJBS
p49971
sa(dp49972
g49782
I174
sg49783
I3
sg49784
I33
sg49785
VC0267963
p49973
sg49787
Vexocrine pancreatic insufficiency
p49974
sasa(dp49975
g49775
VThere are few reports of patients with JBS in association with facial clefting, referring all to types 2 to 6 of Tessier's classification that can be characterized properly as oblique facial clefts (OFCs).
p49976
sg49777
(lp49977
sg49779
(lp49978
(dp49979
g49782
I199
sg49783
I1
sg49784
I4
sg49785
VC1838348
p49980
sg49787
VOFCs
p49981
sa(dp49982
g49782
I176
sg49783
I3
sg49784
I21
sg49785
VC1838348
p49983
sg49787
Voblique facial clefts
p49984
sa(dp49985
g49782
I39
sg49783
I1
sg49784
I3
sg49785
VC0795841
p49986
sg49787
VJBS
p49987
sasa(dp49988
g49775
VWe describe the clinical aspects in four patients with JBS and extensive OFCs.
p49989
sg49777
(lp49990
sg49779
(lp49991
(dp49992
g49782
I55
sg49783
I1
sg49784
I3
sg49785
VC0795841
p49993
sg49787
VJBS
p49994
sasa(dp49995
g49775
VIn all of them, the diagnosis of JBS was confirmed by the demonstration of homozygous or compound-heterozygous mutations in the UBR1 gene.
p49996
sg49777
(lp49997
(dp49998
g49782
I128
sg49783
I2
sg49784
I9
sg49812
g11
sg49787
VUBR1 gene
p49999
sasg49779
(lp50000
(dp50001
g49782
I33
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50002
sg49787
VJBS
p50003
sasa(dp50004
g49775
VAdditionally, we review three previously reported cases of JBS with OFCs.
p50005
sg49777
(lp50006
sg49779
(lp50007
(dp50008
g49782
I59
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50009
sg49787
VJBS
p50010
sasa(dp50011
g49775
VTaking into account a number of approximately 100 individuals affected by JBS that have been published in the literature we estimate that the frequency of OFCs in JBS is between 5% and 10%.
p50012
sg49777
(lp50013
sg49779
(lp50014
(dp50015
g49782
I74
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50016
sg49787
VJBS
p50017
sa(dp50018
g49782
I74
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50019
sg49787
VJBS
p50020
sasa(dp50021
g49775
VThis report emphasizes that extensive OFCs may be the severe end of the spectrum of facial malformations occurring in JBS.
p50022
sg49777
(lp50023
sg49779
(lp50024
(dp50025
g49782
I84
sg49783
I2
sg49784
I20
sg49785
VC0266617
p50026
sg49787
Vfacial malformations
p50027
sa(dp50028
g49782
I118
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50029
sg49787
VJBS
p50030
sasa(dp50031
g49775
VJacobsen syndrome (JBS) is a rare congenital disorder caused by a terminal deletion of the long arm of chromosome 11.
p50032
sg49777
(lp50033
sg49779
(lp50034
(dp50035
g49782
I0
sg49783
I2
sg49784
I17
sg49785
VC0795841
p50036
sg49787
VJacobsen syndrome
p50037
sa(dp50038
g49782
I34
sg49783
I2
sg49784
I19
sg49785
VC0242354
p50039
sg49787
Vcongenital disorder
p50040
sa(dp50041
g49782
I19
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50042
sg49787
VJBS
p50043
sasa(dp50044
g49775
VPX-RICS is located in the chromosomal region commonly deleted in JBS patients with autistic-like behaviour.
p50045
sg49777
(lp50046
(dp50047
g49782
I0
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VPX-RICS
p50048
sasg49779
(lp50049
(dp50050
g49782
I65
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50051
sg49787
VJBS
p50052
sa(dp50053
g49782
I83
sg49783
I1
sg49784
I8
sg49785
VC0004352
p50054
sg49787
Vautistic
p50055
sasa(dp50056
g49775
VOur findings demonstrate a critical role of PX-RICS in cognition and suggest a causal link between PX-RICS deletion and ASD-like behaviour in JBS patients.
p50057
sg49777
(lp50058
(dp50059
g49782
I44
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VPX-RICS
p50060
sasg49779
(lp50061
(dp50062
g49782
I142
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50063
sg49787
VJBS
p50064
sa(dp50065
g49782
I120
sg49783
I1
sg49784
I3
sg49785
VC1510586
p50066
sg49787
VASD
p50067
sasa(dp50068
g49775
VJohanson-Blizzard Syndrome (JBS) (MIM #243800) is a rare autosomal recessive genetic disorder characterized by exocrine pancreatic insufficiency, abnormal facial appearance and varying degrees of mental retardation.
p50069
sg49777
(lp50070
sg49779
(lp50071
(dp50072
g49782
I0
sg49783
I2
sg49784
I26
sg49785
VC0175692
p50073
sg49787
VJohanson-Blizzard Syndrome
p50074
sa(dp50075
g49782
I77
sg49783
I2
sg49784
I16
sg49785
VC0019247
p50076
sg49787
Vgenetic disorder
p50077
sa(dp50078
g49782
I28
sg49783
I1
sg49784
I3
sg49785
VC0175692
p50079
sg49787
VJBS
p50080
sa(dp50081
g49782
I196
sg49783
I2
sg49784
I18
sg49785
VC0025362
p50082
sg49787
Vmental retardation
p50083
sa(dp50084
g49782
I111
sg49783
I3
sg49784
I33
sg49785
VC0267963
p50085
sg49787
Vexocrine pancreatic insufficiency
p50086
sasa(dp50087
g49775
VHere, we report a 3 year-old mentally normal JBS girl.
p50088
sg49777
(lp50089
sg49779
(lp50090
(dp50091
g49782
I45
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50092
sg49787
VJBS
p50093
sasa(dp50094
g49775
VWith these findings, JBS diagnosis was established clinically.
p50095
sg49777
(lp50096
sg49779
(lp50097
(dp50098
g49782
I21
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50099
sg49787
VJBS
p50100
sasa(dp50101
g49775
VJoubert syndrome (JBS) is a rare neurodevelopmental disorder belonging to the group of ciliary diseases.
p50102
sg49777
(lp50103
sg49779
(lp50104
(dp50105
g49782
I18
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50106
sg49787
VJBS
p50107
sa(dp50108
g49782
I0
sg49783
I2
sg49784
I16
sg49785
VC0431399
p50109
sg49787
VJoubert syndrome
p50110
sa(dp50111
g49782
I33
sg49783
I2
sg49784
I27
sg49785
VC1535926
p50112
sg49787
Vneurodevelopmental disorder
p50113
sasa(dp50114
g49775
VJBS is genetically heterogeneous, with &gt;20 causative genes identified to date.
p50115
sg49777
(lp50116
sg49779
(lp50117
(dp50118
g49782
I0
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50119
sg49787
VJBS
p50120
sasa(dp50121
g49775
VA molecular diagnosis of JBS is essential for prediction of disease progression and genetic counseling.
p50122
sg49777
(lp50123
sg49779
(lp50124
(dp50125
g49782
I25
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50126
sg49787
VJBS
p50127
sa(dp50128
g49782
I60
sg49783
I2
sg49784
I19
sg49785
VC0242656
p50129
sg49787
Vdisease progression
p50130
sasa(dp50131
g49775
VWe developed a targeted next-generation sequencing (NGS) approach for parallel sequencing of 22 known JBS genes plus 599 additional ciliary genes.
p50132
sg49777
(lp50133
sg49779
(lp50134
(dp50135
g49782
I102
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50136
sg49787
VJBS
p50137
sasa(dp50138
g49775
VThis method was used to genotype a cohort of 51 well-phenotyped Northern European JBS cases (in some of the cases, Sanger sequencing of individual JBS genes had been performed previously).
p50139
sg49777
(lp50140
sg49779
(lp50141
(dp50142
g49782
I82
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50143
sg49787
VJBS
p50144
sa(dp50145
g49782
I82
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50146
sg49787
VJBS
p50147
sasa(dp50148
g49775
VAltogether, 21 of the 51 cases (41%) harbored biallelic pathogenic mutations in known JBS genes, including 14 mutations not previously described.
p50149
sg49777
(lp50150
sg49779
(lp50151
(dp50152
g49782
I86
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50153
sg49787
VJBS
p50154
sasa(dp50155
g49775
VOur study represents a population-based cohort of JBS patients not enriched for consanguinity, providing insight into the relative importance of the different JBS genes in a Northern European population.
p50156
sg49777
(lp50157
(dp50158
g49782
I159
sg49783
I2
sg49784
I9
sg49812
g11
sg49787
VJBS genes
p50159
sasg49779
(lp50160
(dp50161
g49782
I50
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50162
sg49787
VJBS
p50163
sa(dp50164
g49782
I50
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50165
sg49787
VJBS
p50166
sasa(dp50167
g49775
VFurthermore, we report a case with heterozygous mutations in CC2D2A and B9D1, a gene associated with the more severe Meckel-Gruber syndrome that was recently published as a potential new JBS gene, and discuss the significance of this finding.
p50168
sg49777
(lp50169
(dp50170
g49782
I187
sg49783
I2
sg49784
I8
sg49812
g11
sg49787
VJBS gene
p50171
sa(dp50172
g49782
I72
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VB9D1
p50173
sa(dp50174
g49782
I61
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VCC2D2A
p50175
sasg49779
(lp50176
(dp50177
g49782
I187
sg49783
I1
sg49784
I3
sg49785
VC0795841
p50178
sg49787
VJBS
p50179
sa(dp50180
g49782
I117
sg49783
I2
sg49784
I22
sg49785
VC0265215
p50181
sg49787
VMeckel-Gruber syndrome
p50182
sasa(dp50183
g49775
VZIC2 and OVOL1 may function in nasopharyngeal carcinoma through targeting significantly up-regulated genes (such as PTGS2, FN1, CXCL9 and CXCL10) in the Transcription factor-differentially expressed gene regulatory network (e.g., ZIC2-&gt;PTGS2 and OVOL1-&gt;CXCL10).
p50184
sg49777
(lp50185
(dp50186
g49782
I116
sg49783
I1
sg49784
I5
sg49812
VP35354
p50187
sg49787
VPTGS2
p50188
sa(dp50189
g49782
I128
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCXCL9
p50190
sa(dp50191
g49782
I116
sg49783
I1
sg49784
I5
sg49812
VP35354
p50192
sg49787
VPTGS2
p50193
sa(dp50194
g49782
I0
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VZIC2
p50195
sa(dp50196
g49782
I9
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VOVOL1
p50197
sa(dp50198
g49782
I0
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VZIC2
p50199
sa(dp50200
g49782
I-1
sg49783
I1
sg49784
I13
sg49812
g11
sg49787
VOVOL1->CXCL10
p50201
sa(dp50202
g49782
I138
sg49783
I1
sg49784
I6
sg49812
VP02778
p50203
sg49787
VCXCL10
p50204
sasg49779
(lp50205
(dp50206
g49782
I31
sg49783
I2
sg49784
I24
sg49785
VC2931822
p50207
sg49787
Vnasopharyngeal carcinoma
p50208
sasa(dp50209
g49775
VPTGS2, FN1, CXCL9, CXCL10, ZIC2 and OVOL1 might play roles in nasopharyngeal carcinoma.
p50210
sg49777
(lp50211
(dp50212
g49782
I12
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCXCL9
p50213
sa(dp50214
g49782
I36
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VOVOL1
p50215
sa(dp50216
g49782
I27
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VZIC2
p50217
sa(dp50218
g49782
I19
sg49783
I1
sg49784
I6
sg49812
VP02778
p50219
sg49787
VCXCL10
p50220
sa(dp50221
g49782
I0
sg49783
I1
sg49784
I5
sg49812
VP35354
p50222
sg49787
VPTGS2
p50223
sasg49779
(lp50224
(dp50225
g49782
I48
sg49783
I2
sg49784
I10
sg49785
VC0699820
p50226
sg49787
Vplay roles
p50227
sa(dp50228
g49782
I62
sg49783
I2
sg49784
I24
sg49785
VC2931822
p50229
sg49787
Vnasopharyngeal carcinoma
p50230
sasa(dp50231
g49775
VLiterature data indicate that hyperprolactinemia (HPRL) is one of the important factors in the pathogenesis and course of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis and Sjogren's syndrome.
p50232
sg49777
(lp50233
(dp50234
g49782
I50
sg49783
I1
sg49784
I4
sg49812
VP01236
p50235
sg49787
VHPRL
p50236
sa(dp50237
g49782
I30
sg49783
I1
sg49784
I18
sg49812
VP01236
p50238
sg49787
Vhyperprolactinemia
p50239
sasg49779
(lp50240
(dp50241
g49782
I225
sg49783
I2
sg49784
I18
sg49785
VC1527336
p50242
sg49787
VSjogren's syndrome
p50243
sa(dp50244
g49782
I180
sg49783
I2
sg49784
I20
sg49785
VC0003873
p50245
sg49787
Vrheumatoid arthritis
p50246
sa(dp50247
g49782
I202
sg49783
I2
sg49784
I18
sg49785
VC0036421
p50248
sg49787
Vsystemic sclerosis
p50249
sa(dp50250
g49782
I30
sg49783
I1
sg49784
I18
sg49785
VC0020514
p50251
sg49787
Vhyperprolactinemia
p50252
sa(dp50253
g49782
I122
sg49783
I2
sg49784
I19
sg49785
VC0004364
p50254
sg49787
Vautoimmune diseases
p50255
sa(dp50256
g49782
I50
sg49783
I1
sg49784
I4
sg49785
VC0020514
p50257
sg49787
VHPRL
p50258
sa(dp50259
g49782
I95
sg49783
I1
sg49784
I12
sg49785
VC0699748
p50260
sg49787
Vpathogenesis
p50261
sa(dp50262
g49782
I150
sg49783
I3
sg49784
I28
sg49785
VC0024141
p50263
sg49787
Vsystemic lupus erythematosus
p50264
sasa(dp50265
g49775
VFurthermore in the last 2 decades multi-organ and organ specific autoimmune diseases like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome (SS), Hashimoto's thyroiditis (HT), multiple sclerosis (MS), psoriasis, hepatitis C patients, Behcet's disease, peripartum cardiomyopathy (PPCM) and active celiac disease were discussed to be associated with HPRL.
p50266
sg49777
(lp50267
(dp50268
g49782
I380
sg49783
I1
sg49784
I4
sg49812
VP01236
p50269
sg49787
VHPRL
p50270
sasg49779
(lp50271
(dp50272
g49782
I148
sg49783
I1
sg49784
I2
sg49785
VC0003873
p50273
sg49787
VRA
p50274
sa(dp50275
g49782
I120
sg49783
I1
sg49784
I3
sg49785
VC0024141
p50276
sg49787
VSLE
p50277
sa(dp50278
g49782
I173
sg49783
I1
sg49784
I2
sg49785
VC1527336
p50279
sg49787
VSS
p50280
sa(dp50281
g49782
I244
sg49783
I2
sg49784
I11
sg49785
VC0019196
p50282
sg49787
Vhepatitis C
p50283
sa(dp50284
g49782
I90
sg49783
I3
sg49784
I28
sg49785
VC0024141
p50285
sg49787
Vsystemic lupus erythematosus
p50286
sa(dp50287
g49782
I233
sg49783
I1
sg49784
I9
sg49785
VC0033860
p50288
sg49787
Vpsoriasis
p50289
sa(dp50290
g49782
I208
sg49783
I2
sg49784
I18
sg49785
VC0026769
p50291
sg49787
Vmultiple sclerosis
p50292
sa(dp50293
g49782
I153
sg49783
I2
sg49784
I18
sg49785
VC1527336
p50294
sg49787
VSjogren's syndrome
p50295
sa(dp50296
g49782
I284
sg49783
I2
sg49784
I25
sg49785
VC0877208
p50297
sg49787
Vperipartum cardiomyopathy
p50298
sa(dp50299
g49782
I203
sg49783
I1
sg49784
I2
sg49785
VC0920350
p50300
sg49787
VHT
p50301
sa(dp50302
g49782
I65
sg49783
I2
sg49784
I19
sg49785
VC0004364
p50303
sg49787
Vautoimmune diseases
p50304
sa(dp50305
g49782
I266
sg49783
I2
sg49784
I16
sg49785
VC0004943
p50306
sg49787
VBehcet's disease
p50307
sa(dp50308
g49782
I228
sg49783
I1
sg49784
I2
sg49785
VC0026769
p50309
sg49787
VMS
p50310
sa(dp50311
g49782
I126
sg49783
I2
sg49784
I20
sg49785
VC0003873
p50312
sg49787
Vrheumatoid arthritis
p50313
sa(dp50314
g49782
I328
sg49783
I2
sg49784
I14
sg49785
VC0007570
p50315
sg49787
Vceliac disease
p50316
sa(dp50317
g49782
I311
sg49783
I1
sg49784
I4
sg49785
VC0877208
p50318
sg49787
VPPCM
p50319
sa(dp50320
g49782
I178
sg49783
I2
sg49784
I23
sg49785
VC0920350
p50321
sg49787
VHashimoto's thyroiditis
p50322
sasa(dp50323
g49775
VHyperprolactinemia (HPRL) is observed in multi-organ and organ specific autoimmune diseases like systemic lupus erythematosus (SLE) rheumatoid arthritis (RA), Sjogren's syndrome (SS), Hashimoto's thyroiditis (HT) and multiple sclerosis (MS).
p50324
sg49777
(lp50325
(dp50326
g49782
I20
sg49783
I1
sg49784
I4
sg49812
VP01236
p50327
sg49787
VHPRL
p50328
sa(dp50329
g49782
I0
sg49783
I1
sg49784
I18
sg49812
VP01236
p50330
sg49787
VHyperprolactinemia
p50331
sasg49779
(lp50332
(dp50333
g49782
I97
sg49783
I3
sg49784
I28
sg49785
VC0024141
p50334
sg49787
Vsystemic lupus erythematosus
p50335
sa(dp50336
g49782
I154
sg49783
I1
sg49784
I2
sg49785
VC0003873
p50337
sg49787
VRA
p50338
sa(dp50339
g49782
I127
sg49783
I1
sg49784
I3
sg49785
VC0024141
p50340
sg49787
VSLE
p50341
sa(dp50342
g49782
I159
sg49783
I2
sg49784
I18
sg49785
VC1527336
p50343
sg49787
VSjogren's syndrome
p50344
sa(dp50345
g49782
I179
sg49783
I1
sg49784
I2
sg49785
VC1527336
p50346
sg49787
VSS
p50347
sa(dp50348
g49782
I217
sg49783
I2
sg49784
I18
sg49785
VC0026769
p50349
sg49787
Vmultiple sclerosis
p50350
sa(dp50351
g49782
I132
sg49783
I2
sg49784
I20
sg49785
VC0003873
p50352
sg49787
Vrheumatoid arthritis
p50353
sa(dp50354
g49782
I20
sg49783
I1
sg49784
I4
sg49785
VC0020514
p50355
sg49787
VHPRL
p50356
sa(dp50357
g49782
I72
sg49783
I2
sg49784
I19
sg49785
VC0004364
p50358
sg49787
Vautoimmune diseases
p50359
sa(dp50360
g49782
I237
sg49783
I1
sg49784
I2
sg49785
VC0026769
p50361
sg49787
VMS
p50362
sa(dp50363
g49782
I0
sg49783
I1
sg49784
I18
sg49785
VC0020514
p50364
sg49787
VHyperprolactinemia
p50365
sa(dp50366
g49782
I184
sg49783
I2
sg49784
I23
sg49785
VC0920350
p50367
sg49787
VHashimoto's thyroiditis
p50368
sa(dp50369
g49782
I209
sg49783
I1
sg49784
I2
sg49785
VC0920350
p50370
sg49787
VHT
p50371
sasa(dp50372
g49775
VWe describe the role of PRL in the pathogenesis of rheumatic diseases, particularly connective tissue diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), primary Sjoegren's syndrome, systemic sclerosis, polymyalgia rheumatica, and seronegative arthritis.
p50373
sg49777
(lp50374
(dp50375
g49782
I24
sg49783
I1
sg49784
I3
sg49812
VP01236
p50376
sg49787
VPRL
p50377
sasg49779
(lp50378
(dp50379
g49782
I214
sg49783
I2
sg49784
I18
sg49785
VC0036421
p50380
sg49787
Vsystemic sclerosis
p50381
sa(dp50382
g49782
I158
sg49783
I2
sg49784
I20
sg49785
VC0003873
p50383
sg49787
Vrheumatoid arthritis
p50384
sa(dp50385
g49782
I35
sg49783
I1
sg49784
I12
sg49785
VC0699748
p50386
sg49787
Vpathogenesis
p50387
sa(dp50388
g49782
I193
sg49783
I2
sg49784
I19
sg49785
VC1527336
p50389
sg49787
VSjoegren's syndrome
p50390
sa(dp50391
g49782
I122
sg49783
I3
sg49784
I28
sg49785
VC0024141
p50392
sg49787
Vsystemic lupus erythematosus
p50393
sa(dp50394
g49782
I152
sg49783
I1
sg49784
I3
sg49785
VC0024141
p50395
sg49787
VSLE
p50396
sa(dp50397
g49782
I262
sg49783
I2
sg49784
I22
sg49785
VC0409679
p50398
sg49787
Vseronegative arthritis
p50399
sa(dp50400
g49782
I180
sg49783
I1
sg49784
I2
sg49785
VC0003873
p50401
sg49787
VRA
p50402
sa(dp50403
g49782
I84
sg49783
I3
sg49784
I26
sg49785
VC0009782
p50404
sg49787
Vconnective tissue diseases
p50405
sa(dp50406
g49782
I234
sg49783
I2
sg49784
I22
sg49785
VC0032533
p50407
sg49787
Vpolymyalgia rheumatica
p50408
sa(dp50409
g49782
I51
sg49783
I2
sg49784
I18
sg49785
VC0035435
p50410
sg49787
Vrheumatic diseases
p50411
sasa(dp50412
g49775
VMoreover, we show that the reduction of eosinophilia and the recruitment of inflammatory monocytes to the lungs required early triggering of TLR9, IFN-Gamma and CCR2 by immunotherapy components.
p50413
sg49777
(lp50414
(dp50415
g49782
I147
sg49783
I1
sg49784
I9
sg49812
VP01579
p50416
sg49787
VIFN-Gamma
p50417
sa(dp50418
g49782
I161
sg49783
I1
sg49784
I4
sg49812
VP41597
p50419
sg49787
VCCR2
p50420
sa(dp50421
g49782
I141
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR9
p50422
sasg49779
(lp50423
(dp50424
g49782
I61
sg49783
I1
sg49784
I11
sg49785
VC0271510
p50425
sg49787
Vrecruitment
p50426
sa(dp50427
g49782
I40
sg49783
I1
sg49784
I12
sg49785
VC0014457
p50428
sg49787
Veosinophilia
p50429
sasa(dp50430
g49775
VSubjects treated with TLR9 agonists were at a higher risk of anemia (risk ratio [RR] 1.04, 95% confidence interval [CI]: 1.02-1.06), neutropenia (RR 1.16, 95% CI: 1.11-1.21), leukopenia (RR 1.16, 95% CI: 1.11-1.22), lymphopenia (RR 1.17, 95% CI: 1.10-1.25), thrombocytopenia (RR 1.20, 95% CI: 1.14-1.27), flu-like symptoms (RR 10.59, 95% CI: 3.66-30.66), diarrhea (RR 1.40, 95% CI: 1.18-1.67) and headache (RR 1.61, 95% CI: 1.26-2.06).
p50431
sg49777
(lp50432
(dp50433
g49782
I305
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
Vflu
p50434
sa(dp50435
g49782
I22
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR9
p50436
sasg49779
(lp50437
(dp50438
g49782
I61
sg49783
I1
sg49784
I6
sg49785
VC0002871
p50439
sg49787
Vanemia
p50440
sa(dp50441
g49782
I305
sg49783
I2
sg49784
I17
sg49785
VC0392171
p50442
sg49787
Vflu-like symptoms
p50443
sa(dp50444
g49782
I355
sg49783
I1
sg49784
I8
sg49785
VC0011991
p50445
sg49787
Vdiarrhea
p50446
sa(dp50447
g49782
I397
sg49783
I1
sg49784
I8
sg49785
VC0018681
p50448
sg49787
Vheadache
p50449
sa(dp50450
g49782
I216
sg49783
I1
sg49784
I11
sg49785
VC0024312
p50451
sg49787
Vlymphopenia
p50452
sa(dp50453
g49782
I175
sg49783
I1
sg49784
I10
sg49785
VC0023530
p50454
sg49787
Vleukopenia
p50455
sasa(dp50456
g49775
VBoth the TLR7 and TLR9 agonists dose dependently reduced airway eosinophilia, while the TLR3 agonist only reduced airway eosinophilia at a dose of 1.0 mg/kg.
p50457
sg49777
(lp50458
(dp50459
g49782
I18
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR9
p50460
sa(dp50461
g49782
I9
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR7
p50462
sa(dp50463
g49782
I88
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR3
p50464
sasg49779
(lp50465
(dp50466
g49782
I64
sg49783
I1
sg49784
I12
sg49785
VC0014457
p50467
sg49787
Veosinophilia
p50468
sa(dp50469
g49782
I64
sg49783
I1
sg49784
I12
sg49785
VC0014457
p50470
sg49787
Veosinophilia
p50471
sasa(dp50472
g49775
V&lt;p&gt;Lichen planopilaris (LPP) is a variant of lichen planus that affects the scalp causing scarring hair loss.
p50473
sg49777
(lp50474
sg49779
(lp50475
(dp50476
g49782
I51
sg49783
I2
sg49784
I13
sg49785
VC0023646
p50477
sg49787
Vlichen planus
p50478
sa(dp50479
g49782
I96
sg49783
I1
sg49784
I8
sg49785
VC0008767
p50480
sg49787
Vscarring
p50481
sa(dp50482
g49782
I9
sg49783
I2
sg49784
I19
sg49785
VC0023645
p50483
sg49787
VLichen planopilaris
p50484
sasa(dp50485
g49775
VThis family of diseases contains 2 subgroups, largely based on clinical features: keratosis pilaris atrophicans (KPA; including keratosis pilaris atrophicans faciei/ulerythema ophryogenes, atrophoderma vermiculata, and keratosis follicularis spinulosa decalvans); and the lichen planopilaris (LPP) subgroup (including LPP, frontal fibrosing alopecia, Graham-Little-Piccardi-Lassueur Syndrome and fibrosing alopecia in a pattern distribution).
p50486
sg49777
(lp50487
sg49779
(lp50488
(dp50489
g49782
I113
sg49783
I1
sg49784
I3
sg49785
VC0263428
p50490
sg49787
VKPA
p50491
sa(dp50492
g49782
I82
sg49783
I3
sg49784
I29
sg49785
VC0263428
p50493
sg49787
Vkeratosis pilaris atrophicans
p50494
sa(dp50495
g49782
I323
sg49783
I3
sg49784
I26
sg49785
VC1274700
p50496
sg49787
Vfrontal fibrosing alopecia
p50497
sa(dp50498
g49782
I189
sg49783
I1
sg49784
I12
sg49785
VC0151514
p50499
sg49787
Vatrophoderma
p50500
sa(dp50501
g49782
I383
sg49783
I1
sg49784
I8
sg49785
VC0039082
p50502
sg49787
VSyndrome
p50503
sa(dp50504
g49782
I293
sg49783
I1
sg49784
I3
sg49785
VC0023645
p50505
sg49787
VLPP
p50506
sa(dp50507
g49782
I219
sg49783
I4
sg49784
I42
sg49785
VC0343057
p50508
sg49787
Vkeratosis follicularis spinulosa decalvans
p50509
sa(dp50510
g49782
I165
sg49783
I2
sg49784
I22
sg49785
VC0263428
p50511
sg49787
Vulerythema ophryogenes
p50512
sa(dp50513
g49782
I82
sg49783
I3
sg49784
I29
sg49785
VC0263428
p50514
sg49787
Vkeratosis pilaris atrophicans
p50515
sa(dp50516
g49782
I293
sg49783
I1
sg49784
I3
sg49785
VC0023645
p50517
sg49787
VLPP
p50518
sa(dp50519
g49782
I272
sg49783
I2
sg49784
I19
sg49785
VC0023645
p50520
sg49787
Vlichen planopilaris
p50521
sasa(dp50522
g49775
VAn interface dermatitis with lichenoid inflammation is characteristic of the LPP group of disorders, but the literature provides scant information about the histopathology of the KPA group.
p50523
sg49777
(lp50524
sg49779
(lp50525
(dp50526
g49782
I39
sg49783
I1
sg49784
I12
sg49785
VC0021368
p50527
sg49787
Vinflammation
p50528
sa(dp50529
g49782
I3
sg49783
I2
sg49784
I20
sg49785
VC0262981
p50530
sg49787
Vinterface dermatitis
p50531
sasa(dp50532
g49775
VRecently, there have been25 cases reported in the literature of lichen planuspigmentosus (LPPi) that preceded the developmentof frontal fibrosing alopecia (FFA), which is a variantof lichen planopilaris (LPP).
p50533
sg49777
(lp50534
sg49779
(lp50535
(dp50536
g49782
I64
sg49783
I1
sg49784
I6
sg49785
VC0023643
p50537
sg49787
Vlichen
p50538
sa(dp50539
g49782
I90
sg49783
I1
sg49784
I3
sg49785
VC0023645
p50540
sg49787
VLPP
p50541
sa(dp50542
g49782
I128
sg49783
I3
sg49784
I26
sg49785
VC1274700
p50543
sg49787
Vfrontal fibrosing alopecia
p50544
sa(dp50545
g49782
I183
sg49783
I2
sg49784
I19
sg49785
VC0023645
p50546
sg49787
Vlichen planopilaris
p50547
sa(dp50548
g49782
I156
sg49783
I1
sg49784
I3
sg49785
VC1274700
p50549
sg49787
VFFA
p50550
sasa(dp50551
g49775
VLower levels of acylCer and LPP accompany skin diseases, such as atopic dermatitis, lamellar ichthyosis, and psoriasis.
p50552
sg49777
(lp50553
sg49779
(lp50554
(dp50555
g49782
I109
sg49783
I1
sg49784
I9
sg49785
VC0033860
p50556
sg49787
Vpsoriasis
p50557
sa(dp50558
g49782
I84
sg49783
I2
sg49784
I19
sg49785
VC0020758
p50559
sg49787
Vlamellar ichthyosis
p50560
sa(dp50561
g49782
I42
sg49783
I2
sg49784
I13
sg49785
VC0037274
p50562
sg49787
Vskin diseases
p50563
sa(dp50564
g49782
I65
sg49783
I2
sg49784
I17
sg49785
VC0011615
p50565
sg49787
Vatopic dermatitis
p50566
sasa(dp50567
g49775
VA number of associations such as hepatitis C virus infection, frontal fibrosing alopecia, acrokeratosis of Bazex and nephrotic syndrome have been reported with LPP.
p50568
sg49777
(lp50569
sg49779
(lp50570
(dp50571
g49782
I62
sg49783
I3
sg49784
I26
sg49785
VC1274700
p50572
sg49787
Vfrontal fibrosing alopecia
p50573
sa(dp50574
g49782
I117
sg49783
I2
sg49784
I18
sg49785
VC0027726
p50575
sg49787
Vnephrotic syndrome
p50576
sa(dp50577
g49782
I90
sg49783
I1
sg49784
I13
sg49785
VC0001202
p50578
sg49787
Vacrokeratosis
p50579
sa(dp50580
g49782
I33
sg49783
I2
sg49784
I11
sg49785
VC0019196
p50581
sg49787
Vhepatitis C
p50582
sa(dp50583
g49782
I45
sg49783
I2
sg49784
I15
sg49785
VC0042769
p50584
sg49787
Vvirus infection
p50585
sasa(dp50586
g49775
VLichen planopilaris (LPP) is a follicular variant of lichen planus.
p50587
sg49777
(lp50588
sg49779
(lp50589
(dp50590
g49782
I21
sg49783
I1
sg49784
I3
sg49785
VC0023645
p50591
sg49787
VLPP
p50592
sa(dp50593
g49782
I0
sg49783
I2
sg49784
I19
sg49785
VC0023645
p50594
sg49787
VLichen planopilaris
p50595
sa(dp50596
g49782
I53
sg49783
I2
sg49784
I13
sg49785
VC0023646
p50597
sg49787
Vlichen planus
p50598
sasa(dp50599
g49775
VHowever, genes like HSP90, PAK2, CD247 and others included in the first 1% of the prioritized list need to be further explored in preeclampsia pathogenesis through experimental approaches.
p50600
sg49777
(lp50601
(dp50602
g49782
I20
sg49783
I1
sg49784
I5
sg49812
VP07900
p50603
sg49787
VHSP90
p50604
sa(dp50605
g49782
I33
sg49783
I1
sg49784
I5
sg49812
VP20963
p50606
sg49787
VCD247
p50607
sa(dp50608
g49782
I27
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VPAK2
p50609
sasg49779
(lp50610
(dp50611
g49782
I143
sg49783
I1
sg49784
I12
sg49785
VC0699748
p50612
sg49787
Vpathogenesis
p50613
sa(dp50614
g49782
I130
sg49783
I1
sg49784
I12
sg49785
VC0032914
p50615
sg49787
Vpreeclampsia
p50616
sasa(dp50617
g49775
VWe report a case of acute pancreatitis with diabetic ketoacidosis associated with increased serum myoglobin concentration, acute renal failure, and disseminated intravascular coagulation.
p50618
sg49777
(lp50619
(dp50620
g49782
I92
sg49783
I2
sg49784
I15
sg49812
VP02144
p50621
sg49787
Vserum myoglobin
p50622
sasg49779
(lp50623
(dp50624
g49782
I148
sg49783
I3
sg49784
I38
sg49785
VC0012739
p50625
sg49787
Vdisseminated intravascular coagulation
p50626
sa(dp50627
g49782
I44
sg49783
I2
sg49784
I21
sg49785
VC0011880
p50628
sg49787
Vdiabetic ketoacidosis
p50629
sa(dp50630
g49782
I20
sg49783
I2
sg49784
I18
sg49785
VC0001339
p50631
sg49787
Vacute pancreatitis
p50632
sa(dp50633
g49782
I123
sg49783
I3
sg49784
I19
sg49785
VC0022660
p50634
sg49787
Vacute renal failure
p50635
sasa(dp50636
g49775
VWe examined the relationship among acute pancreatitis, diabetic ketoacidosis, and hypermyoglobinemia in the literature.
p50637
sg49777
(lp50638
sg49779
(lp50639
(dp50640
g49782
I35
sg49783
I2
sg49784
I18
sg49785
VC0001339
p50641
sg49787
Vacute pancreatitis
p50642
sa(dp50643
g49782
I55
sg49783
I2
sg49784
I21
sg49785
VC0011880
p50644
sg49787
Vdiabetic ketoacidosis
p50645
sasa(dp50646
g49775
VThe frequency of nontraumatic rhabdomyolysis in diabetic ketoacidosis was investigated by serial measurements of the serum levels of myoglobin and the serum activity of creatine kinase isoenzyme MM in 12 consecutively admitted ketoacidotic patients.
p50647
sg49777
(lp50648
(dp50649
g49782
I133
sg49783
I1
sg49784
I9
sg49812
VP02144
p50650
sg49787
Vmyoglobin
p50651
sa(dp50652
g49782
I169
sg49783
I2
sg49784
I15
sg49812
VP12532
p50653
sg49787
Vcreatine kinase
p50654
sasg49779
(lp50655
(dp50656
g49782
I30
sg49783
I1
sg49784
I14
sg49785
VC0035410
p50657
sg49787
Vrhabdomyolysis
p50658
sa(dp50659
g49782
I48
sg49783
I2
sg49784
I21
sg49785
VC0011880
p50660
sg49787
Vdiabetic ketoacidosis
p50661
sasa(dp50662
g49775
VIn conclusion, our findings suggest that nontraumatic rhabdomyolysis with hypermyoglobinaemia and elevated serum activity of creatine kinase isoenzyme MM may be a hitherto unrecognized common feature of diabetic ketoacidosis.
p50663
sg49777
(lp50664
(dp50665
g49782
I125
sg49783
I4
sg49784
I28
sg49812
VP12532
p50666
sg49787
Vcreatine kinase isoenzyme MM
p50667
sasg49779
(lp50668
(dp50669
g49782
I54
sg49783
I1
sg49784
I14
sg49785
VC0035410
p50670
sg49787
Vrhabdomyolysis
p50671
sa(dp50672
g49782
I203
sg49783
I2
sg49784
I21
sg49785
VC0011880
p50673
sg49787
Vdiabetic ketoacidosis
p50674
sasa(dp50675
g49775
VBioinformatics and luciferase reporter assays demonstrated that miR-495 targets the 3'-untranslated region of high-mobility group nucleosome-binding domain 5 (HMGN5), a potential oncogene in various types of cancers.
p50676
sg49777
(lp50677
(dp50678
g49782
I110
sg49783
I5
sg49784
I47
sg49812
VP00390
p50679
sg49787
Vhigh-mobility group nucleosome-binding domain 5
p50680
sa(dp50681
g49782
I159
sg49783
I1
sg49784
I5
sg49812
VP82970
p50682
sg49787
VHMGN5
p50683
sasg49779
(lp50684
(dp50685
g49782
I208
sg49783
I1
sg49784
I7
sg49785
VC0006826
p50686
sg49787
Vcancers
p50687
sasa(dp50688
g49775
VHigh-mobility group nucleosome-binding domain 5 (HMGN5), a well-known oncogene in gliomas, was identified as a functional target of miR-409-3p using bioinformatics, dual-luciferase reporter assay, real-time quantitative polymerase chain reaction, and Western blot analysis.
p50689
sg49777
(lp50690
(dp50691
g49782
I132
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-409-3p
p50692
sa(dp50693
g49782
I49
sg49783
I1
sg49784
I5
sg49812
VP82970
p50694
sg49787
VHMGN5
p50695
sa(dp50696
g49782
I0
sg49783
I5
sg49784
I47
sg49812
VP00390
p50697
sg49787
VHigh-mobility group nucleosome-binding domain 5
p50698
sasg49779
(lp50699
(dp50700
g49782
I82
sg49783
I1
sg49784
I7
sg49785
VC0017638
p50701
sg49787
Vgliomas
p50702
sasa(dp50703
g49775
VRestoration of HMGN5 expression significantly reversed the inhibitory effects of miR-409-3p overexpression on glioma cell invasion and proliferation.
p50704
sg49777
(lp50705
(dp50706
g49782
I81
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-409-3p
p50707
sa(dp50708
g49782
I15
sg49783
I1
sg49784
I5
sg49812
VP82970
p50709
sg49787
VHMGN5
p50710
sasg49779
(lp50711
(dp50712
g49782
I135
sg49783
I1
sg49784
I13
sg49785
VC0334094
p50713
sg49787
Vproliferation
p50714
sa(dp50715
g49782
I110
sg49783
I1
sg49784
I6
sg49785
VC0017638
p50716
sg49787
Vglioma
p50717
sa(dp50718
g49782
I117
sg49783
I2
sg49784
I13
sg49785
VC2699153
p50719
sg49787
Vcell invasion
p50720
sasa(dp50721
g49775
VTaken together, our results suggest that miR-409-3p inhibits glioma cell invasion and proliferation by targeting HMGN5, representing a potential therapeutic target for glioma.
p50722
sg49777
(lp50723
(dp50724
g49782
I41
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-409-3p
p50725
sa(dp50726
g49782
I113
sg49783
I1
sg49784
I5
sg49812
VP82970
p50727
sg49787
VHMGN5
p50728
sasg49779
(lp50729
(dp50730
g49782
I86
sg49783
I1
sg49784
I13
sg49785
VC0334094
p50731
sg49787
Vproliferation
p50732
sa(dp50733
g49782
I61
sg49783
I1
sg49784
I6
sg49785
VC0017638
p50734
sg49787
Vglioma
p50735
sa(dp50736
g49782
I68
sg49783
I2
sg49784
I13
sg49785
VC2699153
p50737
sg49787
Vcell invasion
p50738
sa(dp50739
g49782
I61
sg49783
I1
sg49784
I6
sg49785
VC0017638
p50740
sg49787
Vglioma
p50741
sasa(dp50742
g49775
VIt was first discovered in mouse, and recent studies found that the expressions of HMGN5 in many human cancers were also highly regulated, such as prostate, bladder, breast, and lung and clear cell renal cell carcinoma.
p50743
sg49777
(lp50744
(dp50745
g49782
I83
sg49783
I1
sg49784
I5
sg49812
VP82970
p50746
sg49787
VHMGN5
p50747
sasg49779
(lp50748
(dp50749
g49782
I103
sg49783
I1
sg49784
I7
sg49785
VC0006826
p50750
sg49787
Vcancers
p50751
sa(dp50752
g49782
I187
sg49783
I5
sg49784
I31
sg49785
VC0279702
p50753
sg49787
Vclear cell renal cell carcinoma
p50754
sasa(dp50755
g49775
VImportantly, deficiency of HMGN5 has been shown to be linked to cancer cell growth, cell cycle regulation, migration, invasion, and clinical outcomes, and it represents a promising therapeutic target for many malignant tumors.
p50756
sg49777
(lp50757
(dp50758
g49782
I27
sg49783
I1
sg49784
I5
sg49812
VP82970
p50759
sg49787
VHMGN5
p50760
sasg49779
(lp50761
(dp50762
g49782
I64
sg49783
I3
sg49784
I18
sg49785
VC1516170
p50763
sg49787
Vcancer cell growth
p50764
sa(dp50765
g49782
I209
sg49783
I2
sg49784
I16
sg49785
VC0006826
p50766
sg49787
Vmalignant tumors
p50767
sa(dp50768
g49782
I118
sg49783
I1
sg49784
I8
sg49785
VC2699153
p50769
sg49787
Vinvasion
p50770
sasa(dp50771
g49775
VIn the present review, we provide an overview of the current knowledge concerning the role of HMGN5 in cancer development and progression.
p50772
sg49777
(lp50773
(dp50774
g49782
I94
sg49783
I1
sg49784
I5
sg49812
VP82970
p50775
sg49787
VHMGN5
p50776
sasg49779
(lp50777
(dp50778
g49782
I103
sg49783
I1
sg49784
I6
sg49785
VC0006826
p50779
sg49787
Vcancer
p50780
sasa(dp50781
g49775
VNucleosome-binding protein 1 (NSBP1) has been suggested as an oncogene in various types of human cancers.
p50782
sg49777
(lp50783
(dp50784
g49782
I0
sg49783
I3
sg49784
I28
sg49812
VP14222
p50785
sg49787
VNucleosome-binding protein 1
p50786
sa(dp50787
g49782
I30
sg49783
I1
sg49784
I5
sg49812
VP82970
p50788
sg49787
VNSBP1
p50789
sasg49779
(lp50790
(dp50791
g49782
I97
sg49783
I1
sg49784
I7
sg49785
VC0006826
p50792
sg49787
Vcancers
p50793
sasa(dp50794
g49775
VWe found that NSBP1 was highly expressed in non-small cell lung cancer (NSCLC) cells, and knockdown of NSBP1 by NSBP1 small interfering RNA (siRNA) significantly suppressed NSCLC cell proliferation and invasion.
p50795
sg49777
(lp50796
(dp50797
g49782
I112
sg49783
I4
sg49784
I27
sg49812
VP82970
p50798
sg49787
VNSBP1 small interfering RNA
p50799
sa(dp50800
g49782
I14
sg49783
I1
sg49784
I5
sg49812
VP82970
p50801
sg49787
VNSBP1
p50802
sa(dp50803
g49782
I14
sg49783
I1
sg49784
I5
sg49812
VP82970
p50804
sg49787
VNSBP1
p50805
sasg49779
(lp50806
(dp50807
g49782
I72
sg49783
I1
sg49784
I5
sg49785
VC0007131
p50808
sg49787
VNSCLC
p50809
sa(dp50810
g49782
I44
sg49783
I4
sg49784
I26
sg49785
VC0007131
p50811
sg49787
Vnon-small cell lung cancer
p50812
sa(dp50813
g49782
I184
sg49783
I1
sg49784
I13
sg49785
VC0334094
p50814
sg49787
Vproliferation
p50815
sa(dp50816
g49782
I72
sg49783
I1
sg49784
I5
sg49785
VC0007131
p50817
sg49787
VNSCLC
p50818
sa(dp50819
g49782
I202
sg49783
I1
sg49784
I8
sg49785
VC2699153
p50820
sg49787
Vinvasion
p50821
sasa(dp50822
g49775
VOverexpression of miR-326 significantly inhibited NSCLC cell proliferation and invasion, which mimicked the effect of NSBP1 siRNA.
p50823
sg49777
(lp50824
(dp50825
g49782
I118
sg49783
I2
sg49784
I11
sg49812
VP82970
p50826
sg49787
VNSBP1 siRNA
p50827
sa(dp50828
g49782
I18
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-326
p50829
sasg49779
(lp50830
(dp50831
g49782
I50
sg49783
I1
sg49784
I5
sg49785
VC0007131
p50832
sg49787
VNSCLC
p50833
sa(dp50834
g49782
I79
sg49783
I1
sg49784
I8
sg49785
VC2699153
p50835
sg49787
Vinvasion
p50836
sa(dp50837
g49782
I61
sg49783
I1
sg49784
I13
sg49785
VC0334094
p50838
sg49787
Vproliferation
p50839
sasa(dp50840
g49775
VFurthermore, suppression of NSBP1 by NSBP1 siRNA or miR-326 overexpression remarkably repressed the expression of cyclin B1 and matrix metalloproteinase 9 (MMP9), which are associated with cancer cell proliferation and invasion.
p50841
sg49777
(lp50842
(dp50843
g49782
I114
sg49783
I2
sg49784
I9
sg49812
VP14635
p50844
sg49787
Vcyclin B1
p50845
sa(dp50846
g49782
I37
sg49783
I2
sg49784
I11
sg49812
VP82970
p50847
sg49787
VNSBP1 siRNA
p50848
sa(dp50849
g49782
I28
sg49783
I1
sg49784
I5
sg49812
VP82970
p50850
sg49787
VNSBP1
p50851
sa(dp50852
g49782
I156
sg49783
I1
sg49784
I4
sg49812
VP14780
p50853
sg49787
VMMP9
p50854
sa(dp50855
g49782
I52
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-326
p50856
sa(dp50857
g49782
I128
sg49783
I3
sg49784
I26
sg49812
VP14780
p50858
sg49787
Vmatrix metalloproteinase 9
p50859
sasg49779
(lp50860
(dp50861
g49782
I201
sg49783
I1
sg49784
I13
sg49785
VC0334094
p50862
sg49787
Vproliferation
p50863
sa(dp50864
g49782
I219
sg49783
I1
sg49784
I8
sg49785
VC2699153
p50865
sg49787
Vinvasion
p50866
sa(dp50867
g49782
I13
sg49783
I1
sg49784
I11
sg49785
VC0221103
p50868
sg49787
Vsuppression
p50869
sa(dp50870
g49782
I189
sg49783
I1
sg49784
I6
sg49785
VC0006826
p50871
sg49787
Vcancer
p50872
sasa(dp50873
g49775
VIn addition, an inverse correlation between miR-326 and NSBP1 expression levels was found in NSCLC clinical specimens.
p50874
sg49777
(lp50875
(dp50876
g49782
I56
sg49783
I1
sg49784
I5
sg49812
VP82970
p50877
sg49787
VNSBP1
p50878
sasg49779
(lp50879
(dp50880
g49782
I93
sg49783
I1
sg49784
I5
sg49785
VC0007131
p50881
sg49787
VNSCLC
p50882
sasa(dp50883
g49775
VOur study demonstrated a direct target relationship between NSBP1 and miR-326 through which miR-326 inhibited cell proliferation and invasion of NSCLC cells.
p50884
sg49777
(lp50885
(dp50886
g49782
I60
sg49783
I1
sg49784
I5
sg49812
VP82970
p50887
sg49787
VNSBP1
p50888
sa(dp50889
g49782
I70
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-326
p50890
sasg49779
(lp50891
(dp50892
g49782
I133
sg49783
I1
sg49784
I8
sg49785
VC2699153
p50893
sg49787
Vinvasion
p50894
sa(dp50895
g49782
I115
sg49783
I1
sg49784
I13
sg49785
VC0334094
p50896
sg49787
Vproliferation
p50897
sa(dp50898
g49782
I145
sg49783
I1
sg49784
I5
sg49785
VC0007131
p50899
sg49787
VNSCLC
p50900
sasa(dp50901
g49775
VThus, miR-326-NSBP1 is a promising candidate target for developing novel anticancer therapeutics for NSCLC.
p50902
sg49777
(lp50903
(dp50904
g49782
I6
sg49783
I1
sg49784
I13
sg49812
g11
sg49787
VmiR-326-NSBP1
p50905
sasg49779
(lp50906
(dp50907
g49782
I101
sg49783
I1
sg49784
I5
sg49785
VC0007131
p50908
sg49787
VNSCLC
p50909
sasa(dp50910
g49775
VCorrelation analysis also showed that HMGN5 expression levels were significantly inversely correlated with the miR-340 expression in prostate cancer tissues.
p50911
sg49777
(lp50912
(dp50913
g49782
I38
sg49783
I1
sg49784
I5
sg49812
VP82970
p50914
sg49787
VHMGN5
p50915
sa(dp50916
g49782
I111
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-340
p50917
sasg49779
(lp50918
(dp50919
g49782
I133
sg49783
I2
sg49784
I15
sg49785
VC0600139
p50920
sg49787
Vprostate cancer
p50921
sasa(dp50922
g49775
VIn addition, overexpression of HMGN5 significantly reversed the inhibitory effect of miR-340 on prostate cancer cell proliferation and invasion.
p50923
sg49777
(lp50924
(dp50925
g49782
I31
sg49783
I1
sg49784
I5
sg49812
VP82970
p50926
sg49787
VHMGN5
p50927
sa(dp50928
g49782
I85
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-340
p50929
sasg49779
(lp50930
(dp50931
g49782
I135
sg49783
I1
sg49784
I8
sg49785
VC2699153
p50932
sg49787
Vinvasion
p50933
sa(dp50934
g49782
I117
sg49783
I1
sg49784
I13
sg49785
VC0334094
p50935
sg49787
Vproliferation
p50936
sa(dp50937
g49782
I96
sg49783
I2
sg49784
I15
sg49785
VC0600139
p50938
sg49787
Vprostate cancer
p50939
sasa(dp50940
g49775
VMoreover, the decreased miR-340 expression may contribute to the development and progression of prostate cancer through a mechanism that involves HMGN5.
p50941
sg49777
(lp50942
(dp50943
g49782
I146
sg49783
I1
sg49784
I5
sg49812
VP82970
p50944
sg49787
VHMGN5
p50945
sasg49779
(lp50946
(dp50947
g49782
I81
sg49783
I4
sg49784
I30
sg49785
VC1739135
p50948
sg49787
Vprogression of prostate cancer
p50949
sasa(dp50950
g49775
VThus, miR340 and its target gene HMGN5 can serve as potentially useful therapeutic candidates for prostate cancer treatment.
p50951
sg49777
(lp50952
(dp50953
g49782
I33
sg49783
I1
sg49784
I5
sg49812
VP82970
p50954
sg49787
VHMGN5
p50955
sasg49779
(lp50956
(dp50957
g49782
I98
sg49783
I2
sg49784
I15
sg49785
VC0600139
p50958
sg49787
Vprostate cancer
p50959
sasa(dp50960
g49775
VThe high-mobility group nucleosome-binding protein-5 (HMGN5) is frequently overexpressed in various malignant cancers.
p50961
sg49777
(lp50962
(dp50963
g49782
I54
sg49783
I1
sg49784
I5
sg49812
VP82970
p50964
sg49787
VHMGN5
p50965
sa(dp50966
g49782
I4
sg49783
I4
sg49784
I48
sg49812
VP00390
p50967
sg49787
Vhigh-mobility group nucleosome-binding protein-5
p50968
sasg49779
(lp50969
(dp50970
g49782
I110
sg49783
I1
sg49784
I7
sg49785
VC0006826
p50971
sg49787
Vcancers
p50972
sasa(dp50973
g49775
VHowever, the potential correlation between HMGN5 and prognosis in patients with meningiomas remains unknown.
p50974
sg49777
(lp50975
(dp50976
g49782
I43
sg49783
I1
sg49784
I5
sg49812
VP82970
p50977
sg49787
VHMGN5
p50978
sasg49779
(lp50979
(dp50980
g49782
I80
sg49783
I1
sg49784
I11
sg49785
VC0025286
p50981
sg49787
Vmeningiomas
p50982
sasa(dp50983
g49775
VIn the present study, we explored the expression of HMGN5 in meningiomas with immunohistochemistry and correlated the results to the patient outcome.
p50984
sg49777
(lp50985
(dp50986
g49782
I52
sg49783
I1
sg49784
I5
sg49812
VP82970
p50987
sg49787
VHMGN5
p50988
sasg49779
(lp50989
(dp50990
g49782
I61
sg49783
I1
sg49784
I11
sg49785
VC0025286
p50991
sg49787
Vmeningiomas
p50992
sasa(dp50993
g49775
VWe demonstrate that there is a positive association between HMGN5 expression and meningioma histological grade.
p50994
sg49777
(lp50995
(dp50996
g49782
I60
sg49783
I1
sg49784
I5
sg49812
VP82970
p50997
sg49787
VHMGN5
p50998
sasg49779
(lp50999
(dp51000
g49782
I81
sg49783
I1
sg49784
I10
sg49785
VC0025286
p51001
sg49787
Vmeningioma
p51002
sasa(dp51003
g49775
VStatistical analysis reveals that lower HMGN5 expression predict lower meningioma recurrence.
p51004
sg49777
(lp51005
(dp51006
g49782
I40
sg49783
I1
sg49784
I5
sg49812
VP82970
p51007
sg49787
VHMGN5
p51008
sasg49779
(lp51009
(dp51010
g49782
I82
sg49783
I1
sg49784
I10
sg49785
VC1458156
p51011
sg49787
Vrecurrence
p51012
sa(dp51013
g49782
I71
sg49783
I1
sg49784
I10
sg49785
VC0025286
p51014
sg49787
Vmeningioma
p51015
sasa(dp51016
g49775
VOur results further revealed that HMGN5 inhibition decreased P-glycoprotein (MDR-1) expression without affecting multidrug resistance associated proteins 1 (MRP-1) expression to increase chemosensitivity to temozolomide (TMZ) of meningioma cells.
p51017
sg49777
(lp51018
(dp51019
g49782
I113
sg49783
I5
sg49784
I42
sg49812
g11
sg49787
Vmultidrug resistance associated proteins 1
p51020
sa(dp51021
g49782
I61
sg49783
I1
sg49784
I14
sg49812
VP08183
p51022
sg49787
VP-glycoprotein
p51023
sa(dp51024
g49782
I34
sg49783
I1
sg49784
I5
sg49812
VP82970
p51025
sg49787
VHMGN5
p51026
sa(dp51027
g49782
I77
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VMDR-1
p51028
sa(dp51029
g49782
I157
sg49783
I1
sg49784
I5
sg49812
VP08183
p51030
sg49787
VMRP-1
p51031
sasg49779
(lp51032
(dp51033
g49782
I229
sg49783
I1
sg49784
I10
sg49785
VC0025286
p51034
sg49787
Vmeningioma
p51035
sasa(dp51036
g49775
VCollectively, this study indicates that HMGN5 is a novel target for developing effective therapeutic strategies for malignant meningiomas.
p51037
sg49777
(lp51038
(dp51039
g49782
I40
sg49783
I1
sg49784
I5
sg49812
VP82970
p51040
sg49787
VHMGN5
p51041
sasg49779
(lp51042
(dp51043
g49782
I116
sg49783
I2
sg49784
I21
sg49785
VC0259785
p51044
sg49787
Vmalignant meningiomas
p51045
sasa(dp51046
g49775
VLuciferase reporter assay showed that miR-186 targets NSBP1 3'-untranslated region (UTR) directly and suppresses NSBP1 (HMGN5) expression in human bladder cancer cells.
p51047
sg49777
(lp51048
(dp51049
g49782
I54
sg49783
I2
sg49784
I7
sg49812
VP82970
p51050
sg49787
VNSBP1 3
p51051
sa(dp51052
g49782
I54
sg49783
I1
sg49784
I5
sg49812
VP82970
p51053
sg49787
VNSBP1
p51054
sa(dp51055
g49782
I38
sg49783
I2
sg49784
I15
sg49812
g11
sg49787
VmiR-186 targets
p51056
sa(dp51057
g49782
I120
sg49783
I1
sg49784
I5
sg49812
VP82970
p51058
sg49787
VHMGN5
p51059
sasg49779
(lp51060
(dp51061
g49782
I147
sg49783
I2
sg49784
I14
sg49785
VC0699885
p51062
sg49787
Vbladder cancer
p51063
sasa(dp51064
g49775
VOur data first time identified miR-186 as the upstream regulator of NSBP1 and also suggest miR-186-suppressed NSBP1 as a novel therapeutic approach for bladder cancer.
p51065
sg49777
(lp51066
(dp51067
g49782
I91
sg49783
I2
sg49784
I24
sg49812
g11
sg49787
VmiR-186-suppressed NSBP1
p51068
sa(dp51069
g49782
I68
sg49783
I1
sg49784
I5
sg49812
VP82970
p51070
sg49787
VNSBP1
p51071
sa(dp51072
g49782
I31
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-186
p51073
sasg49779
(lp51074
(dp51075
g49782
I152
sg49783
I2
sg49784
I14
sg49785
VC0699885
p51076
sg49787
Vbladder cancer
p51077
sasa(dp51078
g49775
VIn this study, we show that TK1 is upregulated and localizes on the plasma membrane of Burkitt's lymphoma, acute promyelocytic leukemia, T cell leukemia, and acute lymphoblastic leukemia (ALL).
p51079
sg49777
(lp51080
(dp51081
g49782
I28
sg49783
I1
sg49784
I3
sg49812
VP04183
p51082
sg49787
VTK1
p51083
sasg49779
(lp51084
(dp51085
g49782
I107
sg49783
I3
sg49784
I28
sg49785
VC0023487
p51086
sg49787
Vacute promyelocytic leukemia
p51087
sa(dp51088
g49782
I87
sg49783
I2
sg49784
I18
sg49785
VC0006413
p51089
sg49787
VBurkitt's lymphoma
p51090
sa(dp51091
g49782
I188
sg49783
I1
sg49784
I3
sg49785
VC1961102
p51092
sg49787
VALL
p51093
sa(dp51094
g49782
I158
sg49783
I3
sg49784
I28
sg49785
VC1961102
p51095
sg49787
Vacute lymphoblastic leukemia
p51096
sa(dp51097
g49782
I137
sg49783
I3
sg49784
I15
sg49785
VC0023492
p51098
sg49787
VT cell leukemia
p51099
sasa(dp51100
g49775
VTK1 has been reported as a reliable prognostic factor in solid tumors and chronic lymphocytic leukemia, but has not yet been tested in large populations of patients with non-Hodgkin lymphoma.
p51101
sg49777
(lp51102
(dp51103
g49782
I0
sg49783
I1
sg49784
I3
sg49812
VP04183
p51104
sg49787
VTK1
p51105
sasg49779
(lp51106
(dp51107
g49782
I57
sg49783
I2
sg49784
I12
sg49785
VC0280100
p51108
sg49787
Vsolid tumors
p51109
sa(dp51110
g49782
I170
sg49783
I2
sg49784
I20
sg49785
VC0024305
p51111
sg49787
Vnon-Hodgkin lymphoma
p51112
sa(dp51113
g49782
I74
sg49783
I3
sg49784
I28
sg49785
VC0023434
p51114
sg49787
Vchronic lymphocytic leukemia
p51115
sasa(dp51116
g49775
VIn this study, the prognostic significance of TK1 levels was assessed in 170 prospectively enrolled patients with previously untreated follicular lymphoma (FL).
p51117
sg49777
(lp51118
(dp51119
g49782
I46
sg49783
I1
sg49784
I3
sg49812
VP04183
p51120
sg49787
VTK1
p51121
sasg49779
(lp51122
(dp51123
g49782
I135
sg49783
I2
sg49784
I19
sg49785
VC0024301
p51124
sg49787
Vfollicular lymphoma
p51125
sa(dp51126
g49782
I156
sg49783
I1
sg49784
I2
sg49785
VC0024301
p51127
sg49787
VFL
p51128
sasa(dp51129
g49775
VThe TK1 level at the time of treatment initiation was shown to correlate with the clinical stage, Follicular Lymphoma International Prognostic Index (FLIPI) score, Beta(2)-microglobulin level, lactate dehydrogenase level and B symptoms.
p51130
sg49777
(lp51131
(dp51132
g49782
I164
sg49783
I1
sg49784
I21
sg49812
VP61769
p51133
sg49787
VBeta(2)-microglobulin
p51134
sa(dp51135
g49782
I4
sg49783
I1
sg49784
I3
sg49812
VP04183
p51136
sg49787
VTK1
p51137
sa(dp51138
g49782
I193
sg49783
I2
sg49784
I21
sg49812
VP49366
p51139
sg49787
Vlactate dehydrogenase
p51140
sasg49779
(lp51141
(dp51142
g49782
I98
sg49783
I2
sg49784
I19
sg49785
VC0024301
p51143
sg49787
VFollicular Lymphoma
p51144
sasa(dp51145
g49775
VWe show that high serum TK1 levels predict poorer overall survival and correlate with unmutated immunoglobulin variable region genes, CD38 and ZAP-70 expression, and subsequent risk of developing large B-cell lymphoma (Richter syndrome).
p51146
sg49777
(lp51147
(dp51148
g49782
I134
sg49783
I1
sg49784
I4
sg49812
VP28907
p51149
sg49787
VCD38
p51150
sa(dp51151
g49782
I96
sg49783
I4
sg49784
I36
sg49812
g11
sg49787
Vimmunoglobulin variable region genes
p51152
sa(dp51153
g49782
I24
sg49783
I1
sg49784
I3
sg49812
VP04183
p51154
sg49787
VTK1
p51155
sa(dp51156
g49782
I143
sg49783
I1
sg49784
I6
sg49812
VP43403
p51157
sg49787
VZAP-70
p51158
sasg49779
(lp51159
(dp51160
g49782
I219
sg49783
I2
sg49784
I16
sg49785
VC0349631
p51161
sg49787
VRichter syndrome
p51162
sa(dp51163
g49782
I202
sg49783
I2
sg49784
I15
sg49785
VC0079731
p51164
sg49787
VB-cell lymphoma
p51165
sasa(dp51166
g49775
VIn the present study, we revealed that the Hippo transducer, the transcriptional coactivator with PDZ-binding motif (TAZ), acts as a downstream mediator of PODXL in colon cancer.
p51167
sg49777
(lp51168
(dp51169
g49782
I156
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51170
sa(dp51171
g49782
I65
sg49783
I5
sg49784
I50
sg49812
g11
sg49787
Vtranscriptional coactivator with PDZ-binding motif
p51172
sa(dp51173
g49782
I117
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VTAZ
p51174
sasg49779
(lp51175
(dp51176
g49782
I165
sg49783
I2
sg49784
I12
sg49785
VC0699790
p51177
sg49787
Vcolon cancer
p51178
sasa(dp51179
g49775
VMoreover, PODXL plays a critical role in cancer stemness, invasiveness, and sensitivity to chemotherapies in colon cancer HCT15 cells.
p51180
sg49777
(lp51181
(dp51182
g49782
I10
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51183
sasg49779
(lp51184
(dp51185
g49782
I41
sg49783
I1
sg49784
I6
sg49785
VC0006826
p51186
sg49787
Vcancer
p51187
sa(dp51188
g49782
I109
sg49783
I2
sg49784
I12
sg49785
VC0699790
p51189
sg49787
Vcolon cancer
p51190
sasa(dp51191
g49775
VNotably, expression of PODXL showed a positive correlation with stem-like and epithelial-mesenchymal transition (EMT) core signatures, and was associated with poor survival outcomes in patients with colon cancer.
p51192
sg49777
(lp51193
(dp51194
g49782
I23
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51195
sasg49779
(lp51196
(dp51197
g49782
I199
sg49783
I2
sg49784
I12
sg49785
VC0699790
p51198
sg49787
Vcolon cancer
p51199
sa(dp51200
g49782
I101
sg49783
I1
sg49784
I10
sg49785
VC0599156
p51201
sg49787
Vtransition
p51202
sasa(dp51203
g49775
VThese findings provide novel insights into the molecular mechanism of PODXL-mediated tumorigenesis in colon cancer.
p51204
sg49777
(lp51205
(dp51206
g49782
I70
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51207
sasg49779
(lp51208
(dp51209
g49782
I102
sg49783
I2
sg49784
I12
sg49785
VC0699790
p51210
sg49787
Vcolon cancer
p51211
sa(dp51212
g49782
I85
sg49783
I1
sg49784
I13
sg49785
VC0007621
p51213
sg49787
Vtumorigenesis
p51214
sasa(dp51215
g49775
VPodocalyxin (PODXL), which belongs to the CD34 family and regulates cell morphology, has been linked to EMT in lung cancer, and PODXL overexpression is associated with poor prognosis in several different classes of cancers.
p51216
sg49777
(lp51217
(dp51218
g49782
I104
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VEMT
p51219
sa(dp51220
g49782
I13
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51221
sa(dp51222
g49782
I42
sg49783
I2
sg49784
I11
sg49812
VP28906
p51223
sg49787
VCD34 family
p51224
sa(dp51225
g49782
I13
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51226
sa(dp51227
g49782
I0
sg49783
I1
sg49784
I11
sg49812
g11
sg49787
VPodocalyxin
p51228
sasg49779
(lp51229
(dp51230
g49782
I215
sg49783
I1
sg49784
I7
sg49785
VC0006826
p51231
sg49787
Vcancers
p51232
sa(dp51233
g49782
I111
sg49783
I2
sg49784
I11
sg49785
VC0684249
p51234
sg49787
Vlung cancer
p51235
sasa(dp51236
g49775
VThe aim of this study was to clarify the role of PODXL overexpression in EMT in lung cancer, and to determine the prognostic value of PODXL overexpression in tumors from lung cancer patients.
p51237
sg49777
(lp51238
(dp51239
g49782
I49
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51240
sa(dp51241
g49782
I73
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VEMT
p51242
sa(dp51243
g49782
I49
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51244
sasg49779
(lp51245
(dp51246
g49782
I158
sg49783
I1
sg49784
I6
sg49785
VC0027651
p51247
sg49787
Vtumors
p51248
sa(dp51249
g49782
I80
sg49783
I2
sg49784
I11
sg49785
VC0684249
p51250
sg49787
Vlung cancer
p51251
sa(dp51252
g49782
I80
sg49783
I2
sg49784
I11
sg49785
VC0684249
p51253
sg49787
Vlung cancer
p51254
sasa(dp51255
g49775
VThe morphology, EMT marker expression, and migration and invasion abilities of engineered A549 PODXL-knockdown (KD) or PODXL-overexpression (OE) lung adenocarcinoma cells were examined.
p51256
sg49777
(lp51257
sg49779
(lp51258
(dp51259
g49782
I145
sg49783
I2
sg49784
I19
sg49785
VC0152013
p51260
sg49787
Vlung adenocarcinoma
p51261
sa(dp51262
g49782
I57
sg49783
I1
sg49784
I8
sg49785
VC2699153
p51263
sg49787
Vinvasion
p51264
sasa(dp51265
g49775
VPODXL expression levels were assessed by immunohistochemistry in 114 human clinical lung adenocarcinoma specimens and correlated with clinical outcomes.
p51266
sg49777
(lp51267
(dp51268
g49782
I0
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51269
sasg49779
(lp51270
(dp51271
g49782
I84
sg49783
I2
sg49784
I19
sg49785
VC0152013
p51272
sg49787
Vlung adenocarcinoma
p51273
sasa(dp51274
g49775
VA highly selective inhibitor of phosphatidylinositol 3-kinase-Akt signaling attenuated EMT of PODXL-OE cells, while a transforming growth factor inhibitor did not, suggesting that PODXL induces EMT of lung adenocarcinoma cells via the phosphatidylinositol 3-kinase pathway.
p51275
sg49777
(lp51276
(dp51277
g49782
I87
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VEMT
p51278
sa(dp51279
g49782
I118
sg49783
I3
sg49784
I26
sg49812
g11
sg49787
Vtransforming growth factor
p51280
sa(dp51281
g49782
I94
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51282
sa(dp51283
g49782
I32
sg49783
I2
sg49784
I29
sg49812
VP42336
p51284
sg49787
Vphosphatidylinositol 3-kinase
p51285
sa(dp51286
g49782
I32
sg49783
I2
sg49784
I29
sg49812
VP42336
p51287
sg49787
Vphosphatidylinositol 3-kinase
p51288
sa(dp51289
g49782
I94
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VPODXL-OE
p51290
sa(dp51291
g49782
I62
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VAkt
p51292
sasg49779
(lp51293
(dp51294
g49782
I201
sg49783
I2
sg49784
I19
sg49785
VC0152013
p51295
sg49787
Vlung adenocarcinoma
p51296
sasa(dp51297
g49775
VIn lung adenocarcinoma clinical specimens, PODXL expression was detected in minimally invasive and invasive adenocarcinoma, but not in non-invasive adenocarcinoma.
p51298
sg49777
(lp51299
(dp51300
g49782
I43
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51301
sasg49779
(lp51302
(dp51303
g49782
I3
sg49783
I2
sg49784
I19
sg49785
VC0152013
p51304
sg49787
Vlung adenocarcinoma
p51305
sa(dp51306
g49782
I8
sg49783
I1
sg49784
I14
sg49785
VC0001418
p51307
sg49787
Vadenocarcinoma
p51308
sa(dp51309
g49782
I8
sg49783
I1
sg49784
I14
sg49785
VC0001418
p51310
sg49787
Vadenocarcinoma
p51311
sasa(dp51312
g49775
VPODXL overexpression induces EMT in lung adenocarcinoma and contributes to tumor progression.
p51313
sg49777
(lp51314
(dp51315
g49782
I29
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VEMT
p51316
sa(dp51317
g49782
I0
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51318
sasg49779
(lp51319
(dp51320
g49782
I75
sg49783
I2
sg49784
I17
sg49785
VC0178874
p51321
sg49787
Vtumor progression
p51322
sa(dp51323
g49782
I36
sg49783
I2
sg49784
I19
sg49785
VC0152013
p51324
sg49787
Vlung adenocarcinoma
p51325
sasa(dp51326
g49775
VThe aim of this study was to investigate the impact of PODXL expression on survival in esophageal and gastric adenocarcinoma.
p51327
sg49777
(lp51328
(dp51329
g49782
I55
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51330
sasg49779
(lp51331
(dp51332
g49782
I102
sg49783
I2
sg49784
I22
sg49785
VC0278701
p51333
sg49787
Vgastric adenocarcinoma
p51334
sasa(dp51335
g49775
VIn gastric adenocarcinoma, patients with PODXL negative tumors had a superior TTR and a trend towards an improved OS.
p51336
sg49777
(lp51337
sg49779
(lp51338
(dp51339
g49782
I56
sg49783
I1
sg49784
I6
sg49785
VC0027651
p51340
sg49787
Vtumors
p51341
sa(dp51342
g49782
I3
sg49783
I2
sg49784
I22
sg49785
VC0278701
p51343
sg49787
Vgastric adenocarcinoma
p51344
sasa(dp51345
g49775
VIn esophageal and gastric adenocarcinoma combined, the prognostic significance of PODXL expression on TTR was confirmed in unadjusted Cox regression analysis (HR = 5.36, 95 % CI 1.68-17.06, p = 0.005) and remained significant in the adjusted model (HR = 3.39, 95 % CI 1.01-11.35, p = 0.048).
p51346
sg49777
(lp51347
(dp51348
g49782
I82
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51349
sa(dp51350
g49782
I102
sg49783
I1
sg49784
I3
sg49812
VP02766
p51351
sg49787
VTTR
p51352
sasg49779
(lp51353
(dp51354
g49782
I18
sg49783
I2
sg49784
I22
sg49785
VC0278701
p51355
sg49787
Vgastric adenocarcinoma
p51356
sasa(dp51357
g49775
VIn esophageal and gastric adenocarcinoma, PODXL expression is an independent prognostic biomarker for reduced time to recurrence and poor overall survival.
p51358
sg49777
(lp51359
(dp51360
g49782
I42
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51361
sasg49779
(lp51362
(dp51363
g49782
I118
sg49783
I1
sg49784
I10
sg49785
VC1458156
p51364
sg49787
Vrecurrence
p51365
sa(dp51366
g49782
I18
sg49783
I2
sg49784
I22
sg49785
VC0278701
p51367
sg49787
Vgastric adenocarcinoma
p51368
sasa(dp51369
g49775
VHere, we report that high PODXL expression was an independent predictor of worse overall survival of pancreatic cancer patients, and that PODXL promoted pancreatic cancer cell motility and invasion by physically binding to the cytoskeletal protein gelsolin.
p51370
sg49777
(lp51371
(dp51372
g49782
I26
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51373
sa(dp51374
g49782
I26
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51375
sasg49779
(lp51376
(dp51377
g49782
I101
sg49783
I2
sg49784
I17
sg49785
VC0235974
p51378
sg49787
Vpancreatic cancer
p51379
sa(dp51380
g49782
I101
sg49783
I2
sg49784
I17
sg49785
VC0235974
p51381
sg49787
Vpancreatic cancer
p51382
sa(dp51383
g49782
I189
sg49783
I1
sg49784
I8
sg49785
VC2699153
p51384
sg49787
Vinvasion
p51385
sasa(dp51386
g49775
VFurthermore, transfection of a PODXL-rescue construct into pancreatic cancer cells in which both PODXL and gelsolin were suppressed failed to increase the formation of the protrusions.
p51387
sg49777
(lp51388
(dp51389
g49782
I31
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51390
sa(dp51391
g49782
I107
sg49783
I1
sg49784
I8
sg49812
VP06396
p51392
sg49787
Vgelsolin
p51393
sa(dp51394
g49782
I31
sg49783
I2
sg49784
I22
sg49812
g11
sg49787
VPODXL-rescue construct
p51395
sasg49779
(lp51396
(dp51397
g49782
I172
sg49783
I1
sg49784
I11
sg49785
VC0333056
p51398
sg49787
Vprotrusions
p51399
sa(dp51400
g49782
I59
sg49783
I2
sg49784
I17
sg49785
VC0235974
p51401
sg49787
Vpancreatic cancer
p51402
sasa(dp51403
g49775
VPodocalyxin-like 1 (PODXL) is an anti-adhesive transmembrane protein that has been demonstrated to be an independent factor of poor prognosis in colorectal cancer (CRC).
p51404
sg49777
(lp51405
(dp51406
g49782
I20
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51407
sa(dp51408
g49782
I0
sg49783
I2
sg49784
I18
sg49812
g11
sg49787
VPodocalyxin-like 1
p51409
sasg49779
(lp51410
(dp51411
g49782
I164
sg49783
I1
sg49784
I3
sg49785
VC1527249
p51412
sg49787
VCRC
p51413
sa(dp51414
g49782
I145
sg49783
I2
sg49784
I17
sg49785
VC1527249
p51415
sg49787
Vcolorectal cancer
p51416
sasa(dp51417
g49775
VIn addition, we identified a possible target of miR-5100, podocalyxin-like 1 (PODXL), and demonstrated miR-5100 directly binds to the 3' untranslated region of PODXL and post-transcriptionally regulates its expression in pancreatic cancer cells.
p51418
sg49777
(lp51419
(dp51420
g49782
I78
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51421
sa(dp51422
g49782
I78
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51423
sa(dp51424
g49782
I58
sg49783
I2
sg49784
I18
sg49812
g11
sg49787
Vpodocalyxin-like 1
p51425
sa(dp51426
g49782
I48
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VmiR-5100
p51427
sasg49779
(lp51428
(dp51429
g49782
I221
sg49783
I2
sg49784
I17
sg49785
VC0235974
p51430
sg49787
Vpancreatic cancer
p51431
sasa(dp51432
g49775
VWe also clarified the close relationship between expression of PODXL in human pancreatic cancer specimens and liver metastasis (P=0.0003), and determined that post-operative survival was longer in the low-PODXL expression group than in the high-PODXL expression group (P&lt;0.05).
p51433
sg49777
(lp51434
(dp51435
g49782
I63
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51436
sa(dp51437
g49782
I63
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51438
sasg49779
(lp51439
(dp51440
g49782
I110
sg49783
I2
sg49784
I16
sg49785
VC0494165
p51441
sg49787
Vliver metastasis
p51442
sa(dp51443
g49782
I78
sg49783
I2
sg49784
I17
sg49785
VC0235974
p51444
sg49787
Vpancreatic cancer
p51445
sasa(dp51446
g49775
VThese results indicate that miR-5100 and PODXL have considerable therapeutic potential for anti-metastatic therapy and could be potential indicators for cancer metastases in patients with pancreatic cancer.
p51447
sg49777
(lp51448
(dp51449
g49782
I28
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VmiR-5100
p51450
sa(dp51451
g49782
I41
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPODXL
p51452
sasg49779
(lp51453
(dp51454
g49782
I188
sg49783
I2
sg49784
I17
sg49785
VC0235974
p51455
sg49787
Vpancreatic cancer
p51456
sa(dp51457
g49782
I160
sg49783
I1
sg49784
I10
sg49785
VC0027627
p51458
sg49787
Vmetastases
p51459
sa(dp51460
g49782
I153
sg49783
I1
sg49784
I6
sg49785
VC0006826
p51461
sg49787
Vcancer
p51462
sasa(dp51463
g49775
VPreviously we demonstrated that miR-199b was significantly downregulated in acute myeloid leukemia (AML) and targets podocalyxin and discoidin domain receptor 1.
p51464
sg49777
(lp51465
(dp51466
g49782
I117
sg49783
I1
sg49784
I11
sg49812
g11
sg49787
Vpodocalyxin
p51467
sa(dp51468
g49782
I133
sg49783
I4
sg49784
I27
sg49812
g11
sg49787
Vdiscoidin domain receptor 1
p51469
sa(dp51470
g49782
I32
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VmiR-199b
p51471
sasg49779
(lp51472
(dp51473
g49782
I76
sg49783
I3
sg49784
I22
sg49785
VC0023467
p51474
sg49787
Vacute myeloid leukemia
p51475
sa(dp51476
g49782
I100
sg49783
I1
sg49784
I3
sg49785
VC0023467
p51477
sg49787
VAML
p51478
sasa(dp51479
g49775
VTherefore, we set out to determine if podocalyxin plays a functional role in breast tumor progression.
p51480
sg49777
(lp51481
sg49779
(lp51482
(dp51483
g49782
I84
sg49783
I2
sg49784
I17
sg49785
VC0178874
p51484
sg49787
Vtumor progression
p51485
sasa(dp51486
g49775
VForced overexpression of podocalyxin caused cohesive clusters of epithelial MCF-7 breast tumor cells to bud off from the primary tumor and collectively invade the stroma of the mouse mammary gland in vivo.
p51487
sg49777
(lp51488
sg49779
(lp51489
(dp51490
g49782
I121
sg49783
I2
sg49784
I13
sg49785
VC0677930
p51491
sg49787
Vprimary tumor
p51492
sa(dp51493
g49782
I82
sg49783
I2
sg49784
I12
sg49785
VC1458155
p51494
sg49787
Vbreast tumor
p51495
sasa(dp51496
g49775
VThe DEGs MAPT, DSTN, SPTBN1, ARHGEF2 and SKA1 are suggested to be candidate biomarkers for childhood obesity.
p51497
sg49777
(lp51498
(dp51499
g49782
I4
sg49783
I2
sg49784
I9
sg49812
g11
sg49787
VDEGs MAPT
p51500
sa(dp51501
g49782
I15
sg49783
I1
sg49784
I4
sg49812
VP60981
p51502
sg49787
VDSTN
p51503
sa(dp51504
g49782
I29
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VARHGEF2
p51505
sa(dp51506
g49782
I21
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VSPTBN1
p51507
sa(dp51508
g49782
I41
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSKA1
p51509
sasg49779
(lp51510
(dp51511
g49782
I91
sg49783
I2
sg49784
I17
sg49785
VC2362324
p51512
sg49787
Vchildhood obesity
p51513
sasa(dp51514
g49775
VAll received support and advice by community Diabetes Specialist Nurses (DSNs) and Dieticians covering Central and Eastern Cheshire, UK.
p51515
sg49777
(lp51516
sg49779
(lp51517
(dp51518
g49782
I45
sg49783
I1
sg49784
I8
sg49785
VC0011849
p51519
sg49787
VDiabetes
p51520
sasa(dp51521
g49775
VIn 2009, the PCT confirmed 3 years funding for a Paediatric Diabetes specialist nurse (PDSN) for schools.
p51522
sg49777
(lp51523
sg49779
(lp51524
(dp51525
g49782
I60
sg49783
I1
sg49784
I8
sg49785
VC0011849
p51526
sg49787
VDiabetes
p51527
sa(dp51528
g49782
I13
sg49783
I1
sg49784
I3
sg49785
VC0162566
p51529
sg49787
VPCT
p51530
sasa(dp51531
g49775
VThe aim of this study was to explore the interaction between diabetes specialist nurses (DSNs) and patients with type 2 diabetes (T2D) during group sessions about self-management.
p51532
sg49777
(lp51533
sg49779
(lp51534
(dp51535
g49782
I130
sg49783
I1
sg49784
I3
sg49785
VC0011860
p51536
sg49787
VT2D
p51537
sa(dp51538
g49782
I113
sg49783
I3
sg49784
I15
sg49785
VC0011860
p51539
sg49787
Vtype 2 diabetes
p51540
sa(dp51541
g49782
I61
sg49783
I1
sg49784
I8
sg49785
VC0011849
p51542
sg49787
Vdiabetes
p51543
sasa(dp51544
g49775
VIn 8 Italian municipalities, 2,512 men and women without both diabetes and CI-DSN at baseline are examined.
p51545
sg49777
(lp51546
sg49779
(lp51547
(dp51548
g49782
I78
sg49783
I1
sg49784
I3
sg49785
VC0011195
p51549
sg49787
VDSN
p51550
sa(dp51551
g49782
I62
sg49783
I1
sg49784
I8
sg49785
VC0011849
p51552
sg49787
Vdiabetes
p51553
sasa(dp51554
g49775
VThe majority (72%) of PHCCs had diabetes-responsible general practitioners (GPs) and almost all (97%) had diabetes specialist nurses (DSNs) with some degree of postgraduate education in diabetes.
p51555
sg49777
(lp51556
sg49779
(lp51557
(dp51558
g49782
I32
sg49783
I1
sg49784
I8
sg49785
VC0011849
p51559
sg49787
Vdiabetes
p51560
sa(dp51561
g49782
I32
sg49783
I1
sg49784
I8
sg49785
VC0011849
p51562
sg49787
Vdiabetes
p51563
sa(dp51564
g49782
I53
sg49783
I2
sg49784
I21
sg49785
VC0272302
p51565
sg49787
Vgeneral practitioners
p51566
sa(dp51567
g49782
I32
sg49783
I1
sg49784
I8
sg49785
VC0011849
p51568
sg49787
Vdiabetes
p51569
sa(dp51570
g49782
I76
sg49783
I1
sg49784
I3
sg49785
VC0272302
p51571
sg49787
VGPs
p51572
sasa(dp51573
g49775
VThe PHCCs reported that they used regional/local diabetes guidelines (93%), were engaged in call-recall diabetic reviews by GP(s) (66%) and DSN(s) (89%), checked that patients had participated in the reviews by GP(s) (69%) and DSN(s) (78%), arranged group education programmes (23%) and reported data to a National Diabetes Register (82%).
p51574
sg49777
(lp51575
sg49779
(lp51576
(dp51577
g49782
I315
sg49783
I1
sg49784
I8
sg49785
VC0011849
p51578
sg49787
VDiabetes
p51579
sa(dp51580
g49782
I140
sg49783
I1
sg49784
I3
sg49785
VC0011195
p51581
sg49787
VDSN
p51582
sa(dp51583
g49782
I140
sg49783
I1
sg49784
I3
sg49785
VC0011195
p51584
sg49787
VDSN
p51585
sa(dp51586
g49782
I49
sg49783
I1
sg49784
I8
sg49785
VC0011849
p51587
sg49787
Vdiabetes
p51588
sasa(dp51589
g49775
VThe presence of diabetes-responsible GP(s) and DSN(s) who use guidelines may contribute to good and equal quality of care.
p51590
sg49777
(lp51591
sg49779
(lp51592
(dp51593
g49782
I47
sg49783
I1
sg49784
I3
sg49785
VC0011195
p51594
sg49787
VDSN
p51595
sa(dp51596
g49782
I16
sg49783
I1
sg49784
I8
sg49785
VC0011849
p51597
sg49787
Vdiabetes
p51598
sasa(dp51599
g49775
VTo review the working practices of UK diabetes specialist nurses (DSNs), specific clinical roles, and to examine changes since 2000.
p51600
sg49777
(lp51601
sg49779
(lp51602
(dp51603
g49782
I38
sg49783
I1
sg49784
I8
sg49785
VC0011849
p51604
sg49787
Vdiabetes
p51605
sasa(dp51606
g49775
VPostal questionnaires were sent to lead DSNs from all identifiable UK diabetes centres (n = 361).
p51607
sg49777
(lp51608
sg49779
(lp51609
(dp51610
g49782
I70
sg49783
I1
sg49784
I8
sg49785
VC0011849
p51611
sg49787
Vdiabetes
p51612
sasa(dp51613
g49775
VQuantitative and qualitative data were collected on the specific clinical roles, employment, and continual professional development of hospital and community DSNs, Nurse Consultants and Diabetes Healthcare Assistants.
p51614
sg49777
(lp51615
sg49779
(lp51616
(dp51617
g49782
I186
sg49783
I1
sg49784
I8
sg49785
VC0011849
p51618
sg49787
VDiabetes
p51619
sasa(dp51620
g49775
V22% of DSNs have a formal role in diabetes research compared with 48% in 2000.
p51621
sg49777
(lp51622
sg49779
(lp51623
(dp51624
g49782
I34
sg49783
I1
sg49784
I8
sg49785
VC0011849
p51625
sg49787
Vdiabetes
p51626
sasa(dp51627
g49775
VPatients were recruited from 40 general practices and randomised (40:40:20 ratio) to receive routine care alone or, in addition, motivational telephone support from a peer supporter or a diabetes specialist nurse (9 peers and 12 DSNs) for a period of up to 6 months.
p51628
sg49777
(lp51629
sg49779
(lp51630
(dp51631
g49782
I187
sg49783
I1
sg49784
I8
sg49785
VC0011849
p51632
sg49787
Vdiabetes
p51633
sasa(dp51634
g49775
VWe exposed the human NSCLC cell lines Calu-1, CL3, H1299, CH27, H23, and H1355 to B[a]P and assessed cell cycle progression using flow cytometry.
p51635
sg49777
(lp51636
sg49779
(lp51637
(dp51638
g49782
I21
sg49783
I1
sg49784
I5
sg49785
VC0007131
p51639
sg49787
VNSCLC
p51640
sasa(dp51641
g49775
VMoreover, DOX-loaded micelles could slowly and efficiency decrease cell viability of non-small-cell lung carcinoma CL3 cells.
p51642
sg49777
(lp51643
sg49779
(lp51644
(dp51645
g49782
I85
sg49783
I3
sg49784
I29
sg49785
VC0007131
p51646
sg49787
Vnon-small-cell lung carcinoma
p51647
sasa(dp51648
g49775
VComet assay was used to evaluate the DNA damage induced by a relatively low dose of COF (100 g/ml) in human lung adenocarcinoma CL-3 cells.
p51649
sg49777
(lp51650
sg49779
(lp51651
(dp51652
g49782
I108
sg49783
I2
sg49784
I19
sg49785
VC0152013
p51653
sg49787
Vlung adenocarcinoma
p51654
sa(dp51655
g49782
I37
sg49783
I2
sg49784
I10
sg49785
VC0012860
p51656
sg49787
VDNA damage
p51657
sasa(dp51658
g49775
VPb(II) increased the phosphorylated ERK1/2 and phosphorylated AKT but not the phosphorylated ERK5, phosphorylated p38 and JNK activity in human non-small cell lung adenocarcinoma CL3 cells.
p51659
sg49777
(lp51660
(dp51661
g49782
I36
sg49783
I1
sg49784
I6
sg49812
VP27361
p51662
sg49787
VERK1/2
p51663
sa(dp51664
g49782
I93
sg49783
I1
sg49784
I4
sg49812
VP53778
p51665
sg49787
VERK5
p51666
sa(dp51667
g49782
I114
sg49783
I1
sg49784
I3
sg49812
VP46108
p51668
sg49787
Vp38
p51669
sa(dp51670
g49782
I122
sg49783
I1
sg49784
I3
sg49812
VP53779
p51671
sg49787
VJNK
p51672
sa(dp51673
g49782
I62
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VAKT
p51674
sasg49779
(lp51675
(dp51676
g49782
I159
sg49783
I2
sg49784
I19
sg49785
VC0152013
p51677
sg49787
Vlung adenocarcinoma
p51678
sasa(dp51679
g49775
VThe results from reverse-transcription polymerase chain reaction showed that the hOGG1 mRNA expression was induced by hydrogen peroxide (H2O2) and COF in human lung adenocarcinoma CL-3 cells.
p51680
sg49777
(lp51681
sg49779
(lp51682
(dp51683
g49782
I160
sg49783
I2
sg49784
I19
sg49785
VC0152013
p51684
sg49787
Vlung adenocarcinoma
p51685
sasa(dp51686
g49775
VTo reveal the relationship between the high mortality rate of lung cancer in Chinese women and exposure to cooking oil fumes (COF), DNA adduct formation, induced by COF collected from frying fish under domestic conditions, was assessed in human lung adenocarcinoma CL-3 cell lines using the (32)P-postlabeling assay.
p51687
sg49777
(lp51688
sg49779
(lp51689
(dp51690
g49782
I245
sg49783
I2
sg49784
I19
sg49785
VC0152013
p51691
sg49787
Vlung adenocarcinoma
p51692
sa(dp51693
g49782
I62
sg49783
I2
sg49784
I11
sg49785
VC0684249
p51694
sg49787
Vlung cancer
p51695
sa(dp51696
g49782
I132
sg49783
I3
sg49784
I20
sg49785
VC1511660
p51697
sg49787
VDNA adduct formation
p51698
sasa(dp51699
g49775
VIn this study we have explored the involvement of oxidative stress in Cr(VI)-induced JNK, p38 and ERK signaling pathways and their effects on Cr(VI) cytotoxicity in human non-small cell lung carcinoma CL3 cells.
p51700
sg49777
(lp51701
(dp51702
g49782
I90
sg49783
I1
sg49784
I3
sg49812
VP46108
p51703
sg49787
Vp38
p51704
sa(dp51705
g49782
I98
sg49783
I1
sg49784
I3
sg49812
VP29323
p51706
sg49787
VERK
p51707
sa(dp51708
g49782
I85
sg49783
I1
sg49784
I3
sg49812
VP53779
p51709
sg49787
VJNK
p51710
sasg49779
(lp51711
(dp51712
g49782
I171
sg49783
I4
sg49784
I29
sg49785
VC0007131
p51713
sg49787
Vnon-small cell lung carcinoma
p51714
sa(dp51715
g49782
I149
sg49783
I1
sg49784
I12
sg49785
VC0596402
p51716
sg49787
Vcytotoxicity
p51717
sa(dp51718
g49782
I50
sg49783
I2
sg49784
I16
sg49785
VC0242606
p51719
sg49787
Voxidative stress
p51720
sasa(dp51721
g49775
VThe expression pattern of mucin genes was studied in 7 lung adenocarcinoma cell lines (CL1, CL2, CL3, NCL2, PC9, PC13, PC14) and 12 lung adenocarcinoma tissues.
p51722
sg49777
(lp51723
(dp51724
g49782
I102
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNCL2
p51725
sa(dp51726
g49782
I92
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VCL2
p51727
sa(dp51728
g49782
I108
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VPC9
p51729
sa(dp51730
g49782
I26
sg49783
I2
sg49784
I11
sg49812
g11
sg49787
Vmucin genes
p51731
sa(dp51732
g49782
I87
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VCL1
p51733
sasg49779
(lp51734
(dp51735
g49782
I55
sg49783
I2
sg49784
I19
sg49785
VC0152013
p51736
sg49787
Vlung adenocarcinoma
p51737
sa(dp51738
g49782
I55
sg49783
I2
sg49784
I19
sg49785
VC0152013
p51739
sg49787
Vlung adenocarcinoma
p51740
sasa(dp51741
g49775
VOsteogenesis imperfecta model, oim(-/-) , mice have a defect in the collagen, which leads to brittle bone; PHOSPHO1 mutants, Phospho1(-/-) , have ductile bone resulting from altered mineralization.
p51742
sg49777
(lp51743
(dp51744
g49782
I107
sg49783
I2
sg49784
I16
sg49812
g11
sg49787
VPHOSPHO1 mutants
p51745
sasg49779
(lp51746
(dp51747
g49782
I0
sg49783
I2
sg49784
I23
sg49785
VC0029434
p51748
sg49787
VOsteogenesis imperfecta
p51749
sasa(dp51750
g49775
VBecause two mammalian isoforms of iPLA2 (iPLA2beta and iPLA2gamma) have been cloned and characterized, the aim of this study was to identify the specific isoform(s) in macrophages that regulates the expression of iNOS in response to virus infection.
p51751
sg49777
(lp51752
(dp51753
g49782
I34
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
ViPLA2
p51754
sa(dp51755
g49782
I55
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
ViPLA2gamma
p51756
sa(dp51757
g49782
I41
sg49783
I1
sg49784
I9
sg49812
g11
sg49787
ViPLA2beta
p51758
sasg49779
(lp51759
(dp51760
g49782
I233
sg49783
I2
sg49784
I15
sg49785
VC0042769
p51761
sg49787
Vvirus infection
p51762
sasa(dp51763
g49775
VcAMP response element-binding protein (CREB) is one downstream target of iPLA2 that is required for the transcriptional activation of iNOS in response to virus infection, and consistent with the effects of BEL enantiomers on iNOS expression, (S)-BEL more effectively inhibits EMCV-induced CREB phosphorylation than (R)-BEL in macrophages.
p51764
sg49777
(lp51765
(dp51766
g49782
I73
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
ViPLA2
p51767
sa(dp51768
g49782
I0
sg49783
I4
sg49784
I37
sg49812
g11
sg49787
VcAMP response element-binding protein
p51769
sa(dp51770
g49782
I39
sg49783
I1
sg49784
I4
sg49812
VP16220
p51771
sg49787
VCREB
p51772
sa(dp51773
g49782
I39
sg49783
I1
sg49784
I4
sg49812
VP16220
p51774
sg49787
VCREB
p51775
sa(dp51776
g49782
I134
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
ViNOS
p51777
sasg49779
(lp51778
(dp51779
g49782
I154
sg49783
I2
sg49784
I15
sg49785
VC0042769
p51780
sg49787
Vvirus infection
p51781
sasa(dp51782
g49775
VUsing macrophages isolated from iPLA2beta-null mice, virus infection fails to stimulate iNOS mRNA accumulation and protein expression, thus providing genetic evidence that iPLA2beta is required for EMCV-induced iNOS expression.
p51783
sg49777
(lp51784
(dp51785
g49782
I88
sg49783
I2
sg49784
I9
sg49812
g11
sg49787
ViNOS mRNA
p51786
sa(dp51787
g49782
I88
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
ViNOS
p51788
sa(dp51789
g49782
I32
sg49783
I1
sg49784
I9
sg49812
g11
sg49787
ViPLA2beta
p51790
sa(dp51791
g49782
I32
sg49783
I1
sg49784
I9
sg49812
g11
sg49787
ViPLA2beta
p51792
sasg49779
(lp51793
(dp51794
g49782
I53
sg49783
I2
sg49784
I15
sg49785
VC0042769
p51795
sg49787
Vvirus infection
p51796
sasa(dp51797
g49775
VSpecific attention will be placed on the ability of virus infection to activate multiple signaling cascades (such as PKR, MAPK, iPLA2, NF-kappaB) and how these pathways are integrated in the regulation of individual target gene expression.
p51798
sg49777
(lp51799
(dp51800
g49782
I135
sg49783
I1
sg49784
I9
sg49812
VP19838
p51801
sg49787
VNF-kappaB
p51802
sa(dp51803
g49782
I117
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VPKR
p51804
sa(dp51805
g49782
I122
sg49783
I1
sg49784
I4
sg49812
VP53779
p51806
sg49787
VMAPK
p51807
sa(dp51808
g49782
I128
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
ViPLA2
p51809
sasg49779
(lp51810
(dp51811
g49782
I52
sg49783
I2
sg49784
I15
sg49785
VC0042769
p51812
sg49787
Vvirus infection
p51813
sasa(dp51814
g49775
VIn comparison with PRCC1, PRCC2 cases showed upregulated expression of Alfa5-integrin (ITGA5) whereas the expression of Alfa6- (ITGA6) and Beta8-integrins (ITGB8) was downregulated.
p51815
sg49777
(lp51816
(dp51817
g49782
I87
sg49783
I1
sg49784
I5
sg49812
VP08648
p51818
sg49787
VITGA5
p51819
sa(dp51820
g49782
I156
sg49783
I1
sg49784
I5
sg49812
VP26012
p51821
sg49787
VITGB8
p51822
sasg49779
(lp51823
sa(dp51824
g49775
VHFD-fed mice lacking Cnot7 and Tob express elevated levels of Ucp1 mRNA in iWAT and are resistant to diet-induced obesity.
p51825
sg49777
(lp51826
(dp51827
g49782
I31
sg49783
I1
sg49784
I3
sg49812
VP50616
p51828
sg49787
VTob
p51829
sa(dp51830
g49782
I21
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCnot7
p51831
sa(dp51832
g49782
I62
sg49783
I2
sg49784
I9
sg49812
VP25874
p51833
sg49787
VUcp1 mRNA
p51834
sasg49779
(lp51835
(dp51836
g49782
I114
sg49783
I1
sg49784
I7
sg49785
VC0028754
p51837
sg49787
Vobesity
p51838
sasa(dp51839
g49775
VThus, the Cnot7-Tob-BRF1 axis inhibits Ucp1 expression and contributes to obesity.
p51840
sg49777
(lp51841
(dp51842
g49782
I39
sg49783
I1
sg49784
I4
sg49812
VP25874
p51843
sg49787
VUcp1
p51844
sa(dp51845
g49782
I20
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VBRF1
p51846
sa(dp51847
g49782
I16
sg49783
I1
sg49784
I3
sg49812
VP50616
p51848
sg49787
VTob
p51849
sa(dp51850
g49782
I10
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCnot7
p51851
sasg49779
(lp51852
(dp51853
g49782
I74
sg49783
I1
sg49784
I7
sg49785
VC0028754
p51854
sg49787
Vobesity
p51855
sasa(dp51856
g49775
VSince abnormal and unbalanced JAK/STAT activation is associated with immune disorders and cancer, hCAF1 could play a major role in innate immunity and oncogenesis, contributing to tumour escape.
p51857
sg49777
(lp51858
(dp51859
g49782
I34
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSTAT
p51860
sa(dp51861
g49782
I98
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VhCAF1
p51862
sasg49779
(lp51863
(dp51864
g49782
I180
sg49783
I1
sg49784
I6
sg49785
VC0027651
p51865
sg49787
Vtumour
p51866
sa(dp51867
g49782
I69
sg49783
I2
sg49784
I16
sg49785
VC0021053
p51868
sg49787
Vimmune disorders
p51869
sa(dp51870
g49782
I151
sg49783
I1
sg49784
I11
sg49785
VC0007621
p51871
sg49787
Voncogenesis
p51872
sa(dp51873
g49782
I90
sg49783
I1
sg49784
I6
sg49785
VC0006826
p51874
sg49787
Vcancer
p51875
sasa(dp51876
g49775
VOur previous study (Nakamura et al., 2004) showed that deletion of the Cnot7 gene in mice caused almost no abnormal phenotypes except for male infertility, due to oligo-astheno-teratozoospermia.
p51877
sg49777
(lp51878
(dp51879
g49782
I71
sg49783
I2
sg49784
I10
sg49812
g11
sg49787
VCnot7 gene
p51880
sasg49779
(lp51881
(dp51882
g49782
I138
sg49783
I2
sg49784
I16
sg49785
VC0021364
p51883
sg49787
Vmale infertility
p51884
sasa(dp51885
g49775
VMutations in the gene encoding the neural cell adhesion molecule L1CAM cause several neurological disorders collectively referred to as L1 syndrome.
p51886
sg49777
(lp51887
(dp51888
g49782
I35
sg49783
I5
sg49784
I35
sg49812
g11
sg49787
Vneural cell adhesion molecule L1CAM
p51889
sasg49779
(lp51890
(dp51891
g49782
I85
sg49783
I2
sg49784
I22
sg49785
VC0027765
p51892
sg49787
Vneurological disorders
p51893
sa(dp51894
g49782
I139
sg49783
I1
sg49784
I8
sg49785
VC0039082
p51895
sg49787
Vsyndrome
p51896
sa(dp51897
g49782
I47
sg49783
I1
sg49784
I8
sg49785
VC0001511
p51898
sg49787
Vadhesion
p51899
sasa(dp51900
g49775
VA 59-year-old woman receiving methotrexate and tacrolimus for rheumatoid arthritis (RA) was referred to our hospital following bilateral ground-glass opacity observed in her chest X-ray and elevated serum KL-6.
p51901
sg49777
(lp51902
(dp51903
g49782
I199
sg49783
I2
sg49784
I10
sg49812
g11
sg49787
Vserum KL-6
p51904
sasg49779
(lp51905
(dp51906
g49782
I84
sg49783
I1
sg49784
I2
sg49785
VC0003873
p51907
sg49787
VRA
p51908
sa(dp51909
g49782
I150
sg49783
I1
sg49784
I7
sg49785
VC1265876
p51910
sg49787
Vopacity
p51911
sa(dp51912
g49782
I62
sg49783
I2
sg49784
I20
sg49785
VC0003873
p51913
sg49787
Vrheumatoid arthritis
p51914
sasa(dp51915
g49775
VDuring treatment of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) with prednisolone, chest image findings improved in association with decreased KL-6 levels.
p51916
sg49777
(lp51917
sg49779
(lp51918
(dp51919
g49782
I57
sg49783
I3
sg49784
I25
sg49785
VC0206062
p51920
sg49787
Vinterstitial lung disease
p51921
sa(dp51922
g49782
I20
sg49783
I2
sg49784
I20
sg49785
VC0003873
p51923
sg49787
Vrheumatoid arthritis
p51924
sa(dp51925
g49782
I42
sg49783
I1
sg49784
I2
sg49785
VC0003873
p51926
sg49787
VRA
p51927
sa(dp51928
g49782
I84
sg49783
I1
sg49784
I3
sg49785
VC0206062
p51929
sg49787
VILD
p51930
sasa(dp51931
g49775
VThe results showed that treatment with the MUC1-MBP/BCG anti-tumor vaccine did not cause any organ toxicity, except for arthritis or local nodules induced by BCG in several rats.
p51932
sg49777
(lp51933
(dp51934
g49782
I48
sg49783
I1
sg49784
I3
sg49812
VP13727
p51935
sg49787
VMBP
p51936
sasg49779
(lp51937
(dp51938
g49782
I120
sg49783
I1
sg49784
I9
sg49785
VC0003864
p51939
sg49787
Varthritis
p51940
sa(dp51941
g49782
I139
sg49783
I1
sg49784
I7
sg49785
VC0028259
p51942
sg49787
Vnodules
p51943
sa(dp51944
g49782
I61
sg49783
I1
sg49784
I5
sg49785
VC0027651
p51945
sg49787
Vtumor
p51946
sasa(dp51947
g49775
VTo investigate leptin, adiponectin, soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) levels and their relationship with each other and metabolic parameters in women with polycystic ovary syndrome (PCOS).
p51948
sg49777
(lp51949
(dp51950
g49782
I23
sg49783
I1
sg49784
I11
sg49812
g11
sg49787
Vadiponectin
p51951
sa(dp51952
g49782
I97
sg49783
I4
sg49784
I33
sg49812
VP19320
p51953
sg49787
Vvascular cell adhesion molecule-1
p51954
sa(dp51955
g49782
I79
sg49783
I1
sg49784
I7
sg49812
VP05362
p51956
sg49787
VsICAM-1
p51957
sa(dp51958
g49782
I36
sg49783
I4
sg49784
I41
sg49812
VP05362
p51959
sg49787
Vsoluble intercellular adhesion molecule-1
p51960
sa(dp51961
g49782
I15
sg49783
I1
sg49784
I6
sg49812
VP41159
p51962
sg49787
Vleptin
p51963
sasg49779
(lp51964
(dp51965
g49782
I253
sg49783
I1
sg49784
I4
sg49785
VC0032460
p51966
sg49787
VPCOS
p51967
sa(dp51968
g49782
I58
sg49783
I1
sg49784
I8
sg49785
VC0001511
p51969
sg49787
Vadhesion
p51970
sa(dp51971
g49782
I58
sg49783
I1
sg49784
I8
sg49785
VC0001511
p51972
sg49787
Vadhesion
p51973
sa(dp51974
g49782
I226
sg49783
I3
sg49784
I25
sg49785
VC0032460
p51975
sg49787
Vpolycystic ovary syndrome
p51976
sasa(dp51977
g49775
VNon-insulin resistant PCOS had significantly higher adiponectin and sVCAM-1 levels.
p51978
sg49777
(lp51979
(dp51980
g49782
I4
sg49783
I1
sg49784
I7
sg49812
VP01308
p51981
sg49787
Vinsulin
p51982
sa(dp51983
g49782
I52
sg49783
I1
sg49784
I11
sg49812
g11
sg49787
Vadiponectin
p51984
sasg49779
(lp51985
(dp51986
g49782
I22
sg49783
I1
sg49784
I4
sg49785
VC0032460
p51987
sg49787
VPCOS
p51988
sasa(dp51989
g49775
VIncreases in IL-6 and TNF-Alfa and adhesion molecules (E-selectin, ICAM-1 and VCAM-1) were also observed, particularly in the PCOS IR group, providing evidence that inflammation and oxidative stress are related in PCOS patients.
p51990
sg49777
(lp51991
(dp51992
g49782
I22
sg49783
I4
sg49784
I31
sg49812
VP01375
p51993
sg49787
VTNF-Alfa and adhesion molecules
p51994
sa(dp51995
g49782
I78
sg49783
I1
sg49784
I6
sg49812
VP19320
p51996
sg49787
VVCAM-1
p51997
sa(dp51998
g49782
I67
sg49783
I1
sg49784
I6
sg49812
VP05362
p51999
sg49787
VICAM-1
p52000
sa(dp52001
g49782
I13
sg49783
I1
sg49784
I4
sg49812
VP05231
p52002
sg49787
VIL-6
p52003
sa(dp52004
g49782
I55
sg49783
I1
sg49784
I10
sg49812
VP16581
p52005
sg49787
VE-selectin
p52006
sasg49779
(lp52007
(dp52008
g49782
I182
sg49783
I2
sg49784
I16
sg49785
VC0242606
p52009
sg49787
Voxidative stress
p52010
sa(dp52011
g49782
I126
sg49783
I1
sg49784
I4
sg49785
VC0032460
p52012
sg49787
VPCOS
p52013
sa(dp52014
g49782
I165
sg49783
I1
sg49784
I12
sg49785
VC0021368
p52015
sg49787
Vinflammation
p52016
sa(dp52017
g49782
I35
sg49783
I1
sg49784
I8
sg49785
VC0001511
p52018
sg49787
Vadhesion
p52019
sa(dp52020
g49782
I126
sg49783
I1
sg49784
I4
sg49785
VC0032460
p52021
sg49787
VPCOS
p52022
sasa(dp52023
g49775
VInflammation in PCOS induces leukocyte-endothelium interactions and a simultaneous increase in IL-6, TNF-Alfa, E-selectin, ICAM-1 and VCAM-1.
p52024
sg49777
(lp52025
(dp52026
g49782
I123
sg49783
I1
sg49784
I6
sg49812
VP05362
p52027
sg49787
VICAM-1
p52028
sa(dp52029
g49782
I95
sg49783
I1
sg49784
I4
sg49812
VP05231
p52030
sg49787
VIL-6
p52031
sa(dp52032
g49782
I101
sg49783
I1
sg49784
I8
sg49812
VP01375
p52033
sg49787
VTNF-Alfa
p52034
sa(dp52035
g49782
I111
sg49783
I1
sg49784
I10
sg49812
VP16581
p52036
sg49787
VE-selectin
p52037
sa(dp52038
g49782
I134
sg49783
I1
sg49784
I6
sg49812
VP19320
p52039
sg49787
VVCAM-1
p52040
sasg49779
(lp52041
(dp52042
g49782
I0
sg49783
I1
sg49784
I12
sg49785
VC0021368
p52043
sg49787
VInflammation
p52044
sa(dp52045
g49782
I16
sg49783
I1
sg49784
I4
sg49785
VC0032460
p52046
sg49787
VPCOS
p52047
sasa(dp52048
g49775
VIn conclusion, we disclosed a novel mechanism that JQ1 inhibits cell proliferation, induces cell senescence and apoptosis of chondrosarcoma cells through the regulation of the YAP/p21/c-Myc/Bcl-xL signaling axis.
p52049
sg49777
(lp52050
(dp52051
g49782
I190
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl-xL
p52052
sa(dp52053
g49782
I176
sg49783
I1
sg49784
I3
sg49812
VP46937
p52054
sg49787
VYAP
p52055
sa(dp52056
g49782
I180
sg49783
I1
sg49784
I3
sg49812
VP42857
p52057
sg49787
Vp21
p52058
sa(dp52059
g49782
I184
sg49783
I1
sg49784
I5
sg49812
VP12524
p52060
sg49787
Vc-Myc
p52061
sasg49779
(lp52062
(dp52063
g49782
I125
sg49783
I1
sg49784
I14
sg49785
VC0008479
p52064
sg49787
Vchondrosarcoma
p52065
sa(dp52066
g49782
I69
sg49783
I1
sg49784
I13
sg49785
VC0334094
p52067
sg49787
Vproliferation
p52068
sasa(dp52069
g49775
VBH-3 mimetics ABT-737 and ABT-263 are synthetic small-molecule inhibitors of anti-apoptotic proteins B-cell lymphoma-2 (Bcl2) and Bcl-xL, which play a critical role in survival of chondrosarcoma cells.
p52070
sg49777
(lp52071
(dp52072
g49782
I120
sg49783
I1
sg49784
I4
sg49812
VP10415
p52073
sg49787
VBcl2
p52074
sa(dp52075
g49782
I77
sg49783
I4
sg49784
I41
sg49812
g11
sg49787
Vanti-apoptotic proteins B-cell lymphoma-2
p52076
sa(dp52077
g49782
I130
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl-xL
p52078
sasg49779
(lp52079
(dp52080
g49782
I180
sg49783
I1
sg49784
I14
sg49785
VC0008479
p52081
sg49787
Vchondrosarcoma
p52082
sa(dp52083
g49782
I101
sg49783
I2
sg49784
I15
sg49785
VC0079731
p52084
sg49787
VB-cell lymphoma
p52085
sasa(dp52086
g49775
VHere we show that the IHh signal pathway was activated in chondrosarcoma, and knocking down the expression of Gli1 attenuated the disturbed IHh signal pathway, which not only suppressed cell proliferation and promoted G2/M cell cycle arrest but also enhanced cell apoptosis by downregulating Bcl-2 and Bcl-xl expression.
p52087
sg49777
(lp52088
(dp52089
g49782
I292
sg49783
I1
sg49784
I5
sg49812
VP10415
p52090
sg49787
VBcl-2
p52091
sa(dp52092
g49782
I22
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VIHh
p52093
sa(dp52094
g49782
I110
sg49783
I1
sg49784
I4
sg49812
VP08151
p52095
sg49787
VGli1
p52096
sa(dp52097
g49782
I302
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl-xl
p52098
sasg49779
(lp52099
(dp52100
g49782
I191
sg49783
I1
sg49784
I13
sg49785
VC0334094
p52101
sg49787
Vproliferation
p52102
sa(dp52103
g49782
I22
sg49783
I1
sg49784
I3
sg49785
VC0342384
p52104
sg49787
VIHh
p52105
sa(dp52106
g49782
I58
sg49783
I1
sg49784
I14
sg49785
VC0008479
p52107
sg49787
Vchondrosarcoma
p52108
sa(dp52109
g49782
I22
sg49783
I1
sg49784
I3
sg49785
VC0342384
p52110
sg49787
VIHh
p52111
sasa(dp52112
g49775
VAs in conventional chondrosarcoma, antiapoptotic proteins (Bcl-2, and/or Bcl-xl) were highly expressed in all subtypes.
p52113
sg49777
(lp52114
(dp52115
g49782
I73
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl-xl
p52116
sa(dp52117
g49782
I59
sg49783
I1
sg49784
I5
sg49812
VP10415
p52118
sg49787
VBcl-2
p52119
sasg49779
(lp52120
(dp52121
g49782
I6
sg49783
I2
sg49784
I27
sg49785
VC1335473
p52122
sg49787
Vconventional chondrosarcoma
p52123
sasa(dp52124
g49775
VBPB induced upregulation of Bax, Bad and Bak, downregulation of Bcl-2, Bid and Bcl-XL and dysfunction of mitochondria in chondrosarcoma.
p52125
sg49777
(lp52126
(dp52127
g49782
I64
sg49783
I1
sg49784
I5
sg49812
VP10415
p52128
sg49787
VBcl-2
p52129
sa(dp52130
g49782
I71
sg49783
I1
sg49784
I3
sg49812
VP55957
p52131
sg49787
VBid
p52132
sa(dp52133
g49782
I79
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl-XL
p52134
sa(dp52135
g49782
I41
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VBak
p52136
sa(dp52137
g49782
I33
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VBad
p52138
sasg49779
(lp52139
(dp52140
g49782
I121
sg49783
I1
sg49784
I14
sg49785
VC0008479
p52141
sg49787
Vchondrosarcoma
p52142
sasa(dp52143
g49775
VEGCG induced upregulation of Bax and Bak, downregulation of Bcl-2 and Bcl-XL, and dysfunction of mitochondria in chondrosarcoma.
p52144
sg49777
(lp52145
(dp52146
g49782
I70
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl-XL
p52147
sa(dp52148
g49782
I37
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VBak
p52149
sa(dp52150
g49782
I60
sg49783
I1
sg49784
I5
sg49812
VP10415
p52151
sg49787
VBcl-2
p52152
sasg49779
(lp52153
(dp52154
g49782
I113
sg49783
I1
sg49784
I14
sg49785
VC0008479
p52155
sg49787
Vchondrosarcoma
p52156
sasa(dp52157
g49775
VFPTB induced up-regulation of Bax and Bak, down-regulation of Bcl-2 and Bcl-XL and dysfunction of mitochondria in chondrosarcoma.
p52158
sg49777
(lp52159
(dp52160
g49782
I72
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl-XL
p52161
sa(dp52162
g49782
I62
sg49783
I1
sg49784
I5
sg49812
VP10415
p52163
sg49787
VBcl-2
p52164
sa(dp52165
g49782
I38
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VBak
p52166
sa(dp52167
g49782
I0
sg49783
I1
sg49784
I4
sg49812
VP49356
p52168
sg49787
VFPTB
p52169
sasg49779
(lp52170
(dp52171
g49782
I114
sg49783
I1
sg49784
I14
sg49785
VC0008479
p52172
sg49787
Vchondrosarcoma
p52173
sasa(dp52174
g49775
VThis study aims to investigate the expression patterns of HIF-1Alfa in chondrosarcoma, and its association with clinicopathologic features, Bcl-xL expression, apoptosis index (AI), and overall survival of patients with chondrosarcoma.
p52175
sg49777
(lp52176
(dp52177
g49782
I140
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl-xL
p52178
sasg49779
(lp52179
(dp52180
g49782
I71
sg49783
I1
sg49784
I14
sg49785
VC0008479
p52181
sg49787
Vchondrosarcoma
p52182
sa(dp52183
g49782
I71
sg49783
I1
sg49784
I14
sg49785
VC0008479
p52184
sg49787
Vchondrosarcoma
p52185
sasa(dp52186
g49775
VIn eight patients with chondrosarcoma, increased expression of HIF-1Alfa and Bcl-xL was detected in chondrosarcoma tissues compared with the paired adjacent normal tissues.
p52187
sg49777
(lp52188
(dp52189
g49782
I77
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl-xL
p52190
sasg49779
(lp52191
(dp52192
g49782
I23
sg49783
I1
sg49784
I14
sg49785
VC0008479
p52193
sg49787
Vchondrosarcoma
p52194
sa(dp52195
g49782
I23
sg49783
I1
sg49784
I14
sg49785
VC0008479
p52196
sg49787
Vchondrosarcoma
p52197
sasa(dp52198
g49775
VThese findings suggest that increased HIF-1Alfa levels mediated up-regulation of Bcl-xL play a prominent role in evasion of apoptosis and tumor progression, and can be predictive for the prognosis in human chondrosarcoma.
p52199
sg49777
(lp52200
(dp52201
g49782
I81
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl-xL
p52202
sasg49779
(lp52203
(dp52204
g49782
I138
sg49783
I2
sg49784
I17
sg49785
VC0178874
p52205
sg49787
Vtumor progression
p52206
sa(dp52207
g49782
I206
sg49783
I1
sg49784
I14
sg49785
VC0008479
p52208
sg49787
Vchondrosarcoma
p52209
sasa(dp52210
g49775
VThree-dimensional speckle tracking echocardiography (3D-STE) was used to evaluate the improvement of continuous subcutaneous insulin infusion on the left ventricular (LV) systolic function of patients with type 2 diabetes mellitu (T2DM).
p52211
sg49777
(lp52212
(dp52213
g49782
I125
sg49783
I1
sg49784
I7
sg49812
VP01308
p52214
sg49787
Vinsulin
p52215
sasg49779
(lp52216
(dp52217
g49782
I206
sg49783
I3
sg49784
I15
sg49785
VC0011860
p52218
sg49787
Vtype 2 diabetes
p52219
sasa(dp52220
g49775
VTo elucidate association of renal dysfunction (RD) with unfavorable outcomes of in-hospital and long-term (1 year) treatment stages of patients with ST-elevation (STE) myocardial infarction (MI) and concomitant diabetes mellitus (DM).
p52221
sg49777
(lp52222
sg49779
(lp52223
(dp52224
g49782
I230
sg49783
I1
sg49784
I2
sg49785
VC0011849
p52225
sg49787
VDM
p52226
sa(dp52227
g49782
I211
sg49783
I2
sg49784
I17
sg49785
VC0011849
p52228
sg49787
Vdiabetes mellitus
p52229
sa(dp52230
g49782
I168
sg49783
I2
sg49784
I21
sg49785
VC0027051
p52231
sg49787
Vmyocardial infarction
p52232
sa(dp52233
g49782
I191
sg49783
I1
sg49784
I2
sg49785
VC0027051
p52234
sg49787
VMI
p52235
sasa(dp52236
g49775
VMultivariate regression analysis showed that GPLS and diabetes mellitus were independent predictors for complex NSTE-ACS.
p52237
sg49777
(lp52238
(dp52239
g49782
I112
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VNSTE-ACS
p52240
sasg49779
(lp52241
(dp52242
g49782
I54
sg49783
I2
sg49784
I17
sg49785
VC0011849
p52243
sg49787
Vdiabetes mellitus
p52244
sasa(dp52245
g49775
VNo differences were observed between the two groups in baseline characteristics; except AS-STEMI group had more patients with diabetes and EA-STEMI group had more patients with family history of coronary artery disease.
p52246
sg49777
(lp52247
sg49779
(lp52248
(dp52249
g49782
I195
sg49783
I3
sg49784
I23
sg49785
VC1956346
p52250
sg49787
Vcoronary artery disease
p52251
sa(dp52252
g49782
I91
sg49783
I1
sg49784
I5
sg49785
VC1536220
p52253
sg49787
VSTEMI
p52254
sa(dp52255
g49782
I126
sg49783
I1
sg49784
I8
sg49785
VC0011849
p52256
sg49787
Vdiabetes
p52257
sa(dp52258
g49782
I91
sg49783
I1
sg49784
I5
sg49785
VC1536220
p52259
sg49787
VSTEMI
p52260
sasa(dp52261
g49775
VTo elucidate association of renal dysfunction (RD) with unfavorable outcomes of in-hospital and long-term (1 year) treatment stages of patients with ST-elevation (STE) myocardial infarction (M) and concomitant diabetes mellitus (DM).
p52262
sg49777
(lp52263
sg49779
(lp52264
(dp52265
g49782
I229
sg49783
I1
sg49784
I2
sg49785
VC0011849
p52266
sg49787
VDM
p52267
sa(dp52268
g49782
I210
sg49783
I2
sg49784
I17
sg49785
VC0011849
p52269
sg49787
Vdiabetes mellitus
p52270
sa(dp52271
g49782
I168
sg49783
I2
sg49784
I21
sg49785
VC0027051
p52272
sg49787
Vmyocardial infarction
p52273
sasa(dp52274
g49775
VIncidence of complicated diabetes (P &lt; 0.05), pre-PCI Killip &gt;= II (55.9% (19/34) vs. 26.8% (15/56), P &lt; 0.05) and multivessel disease (70.6% (24/34) vs. 35.7% (20/56), P &lt; 0.05) were significantly higher in group D than in group C. TIMI 3 and the opening time of IRA was similar between group A and group B and between group C and group D. The incidence of in-hospital MACE was significantly higher in group B than in group A (14.4% (13/90) vs. 3.0% (4/135), P &lt; 0.05) which was similar between group C and group D. Early (1 hour) but not late (24 hours) ST resolution post PCI is related to a favorable clinical outcome in STEMI patients.
p52275
sg49777
(lp52276
sg49779
(lp52277
(dp52278
g49782
I640
sg49783
I1
sg49784
I5
sg49785
VC1536220
p52279
sg49787
VSTEMI
p52280
sa(dp52281
g49782
I312
sg49783
I2
sg49784
I7
sg49785
VC0348801
p52282
sg49787
Vgroup B
p52283
sa(dp52284
g49782
I25
sg49783
I1
sg49784
I8
sg49785
VC0011849
p52285
sg49787
Vdiabetes
p52286
sa(dp52287
g49782
I312
sg49783
I2
sg49784
I7
sg49785
VC0348801
p52288
sg49787
Vgroup B
p52289
sasa(dp52290
g49775
VImmunohistochemistry (IHC) and Western blotting were performed to evaluate SOX4 expression between OLP and OLP-OSCC tissues and among oral cancer cell lines and normal human oral keratinocytes (NHOKs).
p52291
sg49777
(lp52292
(dp52293
g49782
I75
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSOX4
p52294
sasg49779
(lp52295
(dp52296
g49782
I134
sg49783
I2
sg49784
I11
sg49785
VC0153381
p52297
sg49787
Voral cancer
p52298
sasa(dp52299
g49775
VLC-MS/MS analysis showed that 88 proteins including SOX4 were only identified in OLP-OSCC FFPE tissues when compared to OLP FFPE tissues.
p52300
sg49777
(lp52301
(dp52302
g49782
I52
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSOX4
p52303
sasg49779
(lp52304
sa(dp52305
g49775
VIHC confirmed that SOX4 expression was significantly higher in OLP-OSCC than OLP and Western blot analysis indicated that SOX4 was over-expressed in UM1/UM2 cells when compared to NHOKs.
p52306
sg49777
(lp52307
(dp52308
g49782
I19
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSOX4
p52309
sa(dp52310
g49782
I19
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSOX4
p52311
sasg49779
(lp52312
sa(dp52313
g49775
VOur study indicated that SOX4 is significantly upregulated in OLP-OSCC versus OLP tissues.
p52314
sg49777
(lp52315
(dp52316
g49782
I25
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSOX4
p52317
sasg49779
(lp52318
sa(dp52319
g49775
VThese findings suggest that SOX4 might be actively involved in the progression of OLP to OSCC.
p52320
sg49777
(lp52321
(dp52322
g49782
I28
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSOX4
p52323
sasg49779
(lp52324
sa(dp52325
g49775
VThis study evaluated whether SOX4 affects oncogenic behavior and chemoradiotherapy response in head and neck squamous cell carcinoma (HNSCC) cells, and documented the relationship between its expression and prognosis in oral squamous cell carcinoma (OSCC).
p52326
sg49777
(lp52327
(dp52328
g49782
I29
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSOX4
p52329
sasg49779
(lp52330
(dp52331
g49782
I95
sg49783
I6
sg49784
I37
sg49785
VC1168401
p52332
sg49787
Vhead and neck squamous cell carcinoma
p52333
sa(dp52334
g49782
I109
sg49783
I3
sg49784
I23
sg49785
VC0007137
p52335
sg49787
Vsquamous cell carcinoma
p52336
sa(dp52337
g49782
I134
sg49783
I1
sg49784
I5
sg49785
VC1168401
p52338
sg49787
VHNSCC
p52339
sasa(dp52340
g49775
VSOX4 expression in OSCC tissues was investigated by immunohistochemistry.
p52341
sg49777
(lp52342
(dp52343
g49782
I0
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSOX4
p52344
sasg49779
(lp52345
sa(dp52346
g49775
VImmunostaining showed SOX4 protein was significantly increased in OSCC tissues compared with adjacent normal mucosa.
p52347
sg49777
(lp52348
(dp52349
g49782
I22
sg49783
I2
sg49784
I12
sg49812
g11
sg49787
VSOX4 protein
p52350
sasg49779
(lp52351
sa(dp52352
g49775
VSOX4 expression was observed in 51.8 % of 85 OSCC tissues, and was significantly correlated with treatment failure (P = 0.032) and shorter overall survival (P = 0.036) in patients with OSCC.
p52353
sg49777
(lp52354
(dp52355
g49782
I0
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSOX4
p52356
sasg49779
(lp52357
sa(dp52358
g49775
VThis study was the first to investigate correlations between SOX4 expression levels and the clinicopathologic factors of oral squamous cell carcinoma (OSCC).
p52359
sg49777
(lp52360
(dp52361
g49782
I61
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSOX4
p52362
sasg49779
(lp52363
(dp52364
g49782
I126
sg49783
I3
sg49784
I23
sg49785
VC0007137
p52365
sg49787
Vsquamous cell carcinoma
p52366
sasa(dp52367
g49775
VWe analyzed SOX4 expression levels in 50 patients with OSCC using immunohistochemistry.
p52368
sg49777
(lp52369
(dp52370
g49782
I12
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSOX4
p52371
sasg49779
(lp52372
sa(dp52373
g49775
VThe expression level of SOX4 in primary foci of poorly differentiated OSCC was higher than that of well differentiated OSCC, which indicated that SOX4 expression is associated with the differentiation of OSCC.
p52374
sg49777
(lp52375
(dp52376
g49782
I24
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSOX4
p52377
sa(dp52378
g49782
I24
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSOX4
p52379
sasg49779
(lp52380
sa(dp52381
g49775
VThese results indicate that undifferentiated OSCC cells expressing SOX4 are more likely to metastasize and neoadjuvant therapy including chemoradiation therapy may have some effect in metastatic prevention.
p52382
sg49777
(lp52383
(dp52384
g49782
I67
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSOX4
p52385
sasg49779
(lp52386
(dp52387
g49782
I91
sg49783
I1
sg49784
I11
sg49785
VC0027627
p52388
sg49787
Vmetastasize
p52389
sasa(dp52390
g49775
VCryptorchidism was significantly associated with development of MGCSCTs, SCTs, and SEMs, but not ICTs (p&lt;0.01).
p52391
sg49777
(lp52392
sg49779
(lp52393
(dp52394
g49782
I0
sg49783
I1
sg49784
I14
sg49785
VC0010417
p52395
sg49787
VCryptorchidism
p52396
sa(dp52397
g49782
I67
sg49783
I1
sg49784
I4
sg49785
VC0796149
p52398
sg49787
VSCTs
p52399
sasa(dp52400
g49775
VSince nerve functions are affected by inflammatory response during the course of leprosy, changes in the production of NGF and its receptor (NGF R) may be directly associated with disability and sensory loss.
p52401
sg49777
(lp52402
(dp52403
g49782
I119
sg49783
I1
sg49784
I3
sg49812
VP01138
p52404
sg49787
VNGF
p52405
sa(dp52406
g49782
I119
sg49783
I1
sg49784
I3
sg49812
VP01138
p52407
sg49787
VNGF
p52408
sasg49779
(lp52409
(dp52410
g49782
I38
sg49783
I2
sg49784
I21
sg49785
VC1155266
p52411
sg49787
Vinflammatory response
p52412
sa(dp52413
g49782
I195
sg49783
I2
sg49784
I12
sg49785
VC0278134
p52414
sg49787
Vsensory loss
p52415
sa(dp52416
g49782
I81
sg49783
I1
sg49784
I7
sg49785
VC0023343
p52417
sg49787
Vleprosy
p52418
sasa(dp52419
g49775
VSkin biopsies were collected and submitted to immunohistochemistry using specific antibodies to IL-17, NGF and NGF R. Quantitative analysis of NGF, NGFR and IL-17 immunostaining showed a significant difference between the clinical forms, with higher expression of NGF and NGFR in lepromatous leprosy and IL-17 in tuberculoid leprosy.
p52420
sg49777
(lp52421
(dp52422
g49782
I111
sg49783
I2
sg49784
I5
sg49812
VP01138
p52423
sg49787
VNGF R
p52424
sa(dp52425
g49782
I103
sg49783
I1
sg49784
I3
sg49812
VP01138
p52426
sg49787
VNGF
p52427
sa(dp52428
g49782
I103
sg49783
I1
sg49784
I3
sg49812
VP01138
p52429
sg49787
VNGF
p52430
sa(dp52431
g49782
I103
sg49783
I1
sg49784
I3
sg49812
VP01138
p52432
sg49787
VNGF
p52433
sa(dp52434
g49782
I148
sg49783
I1
sg49784
I4
sg49812
VP08138
p52435
sg49787
VNGFR
p52436
sa(dp52437
g49782
I148
sg49783
I1
sg49784
I4
sg49812
VP08138
p52438
sg49787
VNGFR
p52439
sasg49779
(lp52440
(dp52441
g49782
I280
sg49783
I2
sg49784
I19
sg49785
VC0023348
p52442
sg49787
Vlepromatous leprosy
p52443
sa(dp52444
g49782
I313
sg49783
I2
sg49784
I19
sg49785
VC0023351
p52445
sg49787
Vtuberculoid leprosy
p52446
sasa(dp52447
g49775
VThe recovered CD271(+) BM-MSCs from post-therapy mice, when injected into healthy mice, caused active tuberculosis infection in the animal's lung.
p52448
sg49777
(lp52449
sg49779
(lp52450
(dp52451
g49782
I102
sg49783
I2
sg49784
I22
sg49785
VC0041296
p52452
sg49787
Vtuberculosis infection
p52453
sasa(dp52454
g49775
VNext, in human subjects, previously treated for pulmonary tuberculosis, the MTB-containing CD271(+) BM-MSCs exhibited high expression of hypoxia-inducible factor 1Alfa and low expression of CD146, a hypoxia down-regulated cell surface marker of human BM-MSCs.
p52455
sg49777
(lp52456
(dp52457
g49782
I137
sg49783
I3
sg49784
I30
sg49812
g11
sg49787
Vhypoxia-inducible factor 1Alfa
p52458
sa(dp52459
g49782
I190
sg49783
I1
sg49784
I5
sg49812
VP43121
p52460
sg49787
VCD146
p52461
sasg49779
(lp52462
(dp52463
g49782
I48
sg49783
I2
sg49784
I22
sg49785
VC0041327
p52464
sg49787
Vpulmonary tuberculosis
p52465
sa(dp52466
g49782
I137
sg49783
I1
sg49784
I7
sg49785
VC0242184
p52467
sg49787
Vhypoxia
p52468
sa(dp52469
g49782
I137
sg49783
I1
sg49784
I7
sg49785
VC0242184
p52470
sg49787
Vhypoxia
p52471
sasa(dp52472
g49775
VThe bone marrow niche of Mycobacterium tuberculosis within CD271(+) BM-MSCs stem cells is the proposed explanation for the localized cortical resorption that is observed in bone stress markers.
p52473
sg49777
(lp52474
sg49779
(lp52475
(dp52476
g49782
I39
sg49783
I1
sg49784
I12
sg49785
VC0041296
p52477
sg49787
Vtuberculosis
p52478
sasa(dp52479
g49775
VTherefore, the objective of this study was to correlate the immunoexpression patterns of NGF and NGF-R in the different clinical forms of leprosy, and to associate the findings with the in situ expression of TGF-Beta and clinical classification of the disease.
p52480
sg49777
(lp52481
(dp52482
g49782
I89
sg49783
I1
sg49784
I3
sg49812
VP01138
p52483
sg49787
VNGF
p52484
sa(dp52485
g49782
I97
sg49783
I1
sg49784
I5
sg49812
VP01138
p52486
sg49787
VNGF-R
p52487
sa(dp52488
g49782
I208
sg49783
I1
sg49784
I8
sg49812
VP18075
p52489
sg49787
VTGF-Beta
p52490
sasg49779
(lp52491
(dp52492
g49782
I138
sg49783
I1
sg49784
I7
sg49785
VC0023343
p52493
sg49787
Vleprosy
p52494
sasa(dp52495
g49775
VThere was a significant positive correlation between NGF and NGF-R in the different clinical forms of leprosy.
p52496
sg49777
(lp52497
(dp52498
g49782
I53
sg49783
I1
sg49784
I3
sg49812
VP01138
p52499
sg49787
VNGF
p52500
sa(dp52501
g49782
I61
sg49783
I1
sg49784
I5
sg49812
VP01138
p52502
sg49787
VNGF-R
p52503
sasg49779
(lp52504
(dp52505
g49782
I102
sg49783
I1
sg49784
I7
sg49785
VC0023343
p52506
sg49787
Vleprosy
p52507
sasa(dp52508
g49775
VMoreover, most viable M. tuberculosis was recovered from the bone marrow CD271(+)CD45(-)-enriched cell fraction, and only few viable bacteria could be isolated from the CD271(-)CD45(+) cell fraction.
p52509
sg49777
(lp52510
(dp52511
g49782
I81
sg49783
I1
sg49784
I4
sg49812
VP08575
p52512
sg49787
VCD45
p52513
sa(dp52514
g49782
I169
sg49783
I1
sg49784
I12
sg49812
VP08138
p52515
sg49787
VCD271(-)CD45
p52516
sasg49779
(lp52517
(dp52518
g49782
I25
sg49783
I1
sg49784
I12
sg49785
VC0041296
p52519
sg49787
Vtuberculosis
p52520
sasa(dp52521
g49775
VWe recently developed a systems biological approach to vaccine safety evaluation where identification of specific biomarkers in a rat pre-clinical study evaluated the safety of vaccines for pandemic H5N1 influenza including Irf7, Lgals9, Lgalsbp3, Cxcl11, Timp1, Tap2, Psmb9, Psme1, Tapbp, C2, Csf1, Mx2, Zbp1, Ifrd1, Trafd1, Cxcl9, Beta2m, Npc1, Ngfr and Ifi47.
p52522
sg49777
(lp52523
(dp52524
g49782
I318
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VTrafd1
p52525
sa(dp52526
g49782
I326
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCxcl9
p52527
sa(dp52528
g49782
I311
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VIfrd1
p52529
sa(dp52530
g49782
I300
sg49783
I1
sg49784
I3
sg49812
VP20592
p52531
sg49787
VMx2
p52532
sa(dp52533
g49782
I256
sg49783
I1
sg49784
I5
sg49812
VP01033
p52534
sg49787
VTimp1
p52535
sa(dp52536
g49782
I248
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VCxcl11
p52537
sa(dp52538
g49782
I347
sg49783
I1
sg49784
I4
sg49812
VP08138
p52539
sg49787
VNgfr
p52540
sa(dp52541
g49782
I224
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VIrf7
p52542
sa(dp52543
g49782
I341
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNpc1
p52544
sa(dp52545
g49782
I230
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VLgals9
p52546
sa(dp52547
g49782
I333
sg49783
I1
sg49784
I6
sg49812
VP61769
p52548
sg49787
VBeta2m
p52549
sa(dp52550
g49782
I269
sg49783
I1
sg49784
I5
sg49812
VP28065
p52551
sg49787
VPsmb9
p52552
sa(dp52553
g49782
I294
sg49783
I1
sg49784
I4
sg49812
VP09919
p52554
sg49787
VCsf1
p52555
sa(dp52556
g49782
I263
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTap2
p52557
sa(dp52558
g49782
I276
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPsme1
p52559
sa(dp52560
g49782
I305
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VZbp1
p52561
sasg49779
(lp52562
(dp52563
g49782
I341
sg49783
I1
sg49784
I4
sg49785
VC3179455
p52564
sg49787
VNpc1
p52565
sa(dp52566
g49782
I199
sg49783
I2
sg49784
I14
sg49785
VC2748361
p52567
sg49787
VH5N1 influenza
p52568
sasa(dp52569
g49775
VMdmX overexpression contributes to the development of cancer by inhibiting tumor suppressor p53.
p52570
sg49777
(lp52571
(dp52572
g49782
I75
sg49783
I3
sg49784
I20
sg49812
VP42771
p52573
sg49787
Vtumor suppressor p53
p52574
sa(dp52575
g49782
I0
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VMdmX
p52576
sasg49779
(lp52577
(dp52578
g49782
I54
sg49783
I1
sg49784
I6
sg49785
VC0006826
p52579
sg49787
Vcancer
p52580
sa(dp52581
g49782
I75
sg49783
I1
sg49784
I5
sg49785
VC0027651
p52582
sg49787
Vtumor
p52583
sasa(dp52584
g49775
VA switch in the alternative splicing of MdmX transcript, leading to the inclusion of exon 6, has been identified as the primary mechanism responsible for increased MdmX protein levels in human cancers, including melanoma.
p52585
sg49777
(lp52586
(dp52587
g49782
I164
sg49783
I2
sg49784
I12
sg49812
g11
sg49787
VMdmX protein
p52588
sa(dp52589
g49782
I40
sg49783
I2
sg49784
I15
sg49812
g11
sg49787
VMdmX transcript
p52590
sasg49779
(lp52591
(dp52592
g49782
I193
sg49783
I1
sg49784
I7
sg49785
VC0006826
p52593
sg49787
Vcancers
p52594
sa(dp52595
g49782
I212
sg49783
I1
sg49784
I8
sg49785
VC0025202
p52596
sg49787
Vmelanoma
p52597
sasa(dp52598
g49775
VRecent studies showed that interfering with cellular splicing machinery can result in MdmX downregulation in cancer cells.
p52599
sg49777
(lp52600
(dp52601
g49782
I86
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VMdmX
p52602
sasg49779
(lp52603
(dp52604
g49782
I109
sg49783
I1
sg49784
I6
sg49785
VC0006826
p52605
sg49787
Vcancer
p52606
sasa(dp52607
g49775
VWe, therefore, hypothesized that enoxacin could, by modulating miRNAs targeting splicing machinery, activate p53 in melanoma cells overexpressing MdmX.
p52608
sg49777
(lp52609
(dp52610
g49782
I146
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VMdmX
p52611
sa(dp52612
g49782
I109
sg49783
I1
sg49784
I3
sg49812
VP42771
p52613
sg49787
Vp53
p52614
sasg49779
(lp52615
(dp52616
g49782
I116
sg49783
I1
sg49784
I8
sg49785
VC0025202
p52617
sg49787
Vmelanoma
p52618
sasa(dp52619
g49775
VNot only in melanoma, but also in MCF7 breast carcinoma and A2780 ovarian carcinoma cells overexpressing MdmX.
p52620
sg49777
(lp52621
(dp52622
g49782
I105
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VMdmX
p52623
sasg49779
(lp52624
(dp52625
g49782
I39
sg49783
I2
sg49784
I16
sg49785
VC0678222
p52626
sg49787
Vbreast carcinoma
p52627
sa(dp52628
g49782
I12
sg49783
I1
sg49784
I8
sg49785
VC0025202
p52629
sg49787
Vmelanoma
p52630
sa(dp52631
g49782
I66
sg49783
I2
sg49784
I17
sg49785
VC0029925
p52632
sg49787
Vovarian carcinoma
p52633
sasa(dp52634
g49775
VTogether, our results suggest that some clinically approved fluoroquinolones could potentially be repurposed as activators of p53 tumor suppressor in cancers overexpressing MdmX oncoprotein and that p53 activation might contribute to the previously reported activity of enoxacin towards human cancer cells.
p52635
sg49777
(lp52636
(dp52637
g49782
I126
sg49783
I3
sg49784
I20
sg49812
VP42771
p52638
sg49787
Vp53 tumor suppressor
p52639
sa(dp52640
g49782
I126
sg49783
I1
sg49784
I3
sg49812
VP42771
p52641
sg49787
Vp53
p52642
sa(dp52643
g49782
I173
sg49783
I2
sg49784
I16
sg49812
g11
sg49787
VMdmX oncoprotein
p52644
sasg49779
(lp52645
(dp52646
g49782
I130
sg49783
I1
sg49784
I5
sg49785
VC0027651
p52647
sg49787
Vtumor
p52648
sa(dp52649
g49782
I150
sg49783
I1
sg49784
I6
sg49785
VC0006826
p52650
sg49787
Vcancer
p52651
sa(dp52652
g49782
I150
sg49783
I1
sg49784
I7
sg49785
VC0006826
p52653
sg49787
Vcancers
p52654
sasa(dp52655
g49775
VThese will be discussed as will recent findings of MDMX inhibitors: these are of special importance as it has been shown that cancers that become resistant to MDM2 inhibitors often amplify MDM4.
p52656
sg49777
(lp52657
(dp52658
g49782
I51
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VMDMX
p52659
sa(dp52660
g49782
I189
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VMDM4
p52661
sasg49779
(lp52662
(dp52663
g49782
I126
sg49783
I1
sg49784
I7
sg49785
VC0006826
p52664
sg49787
Vcancers
p52665
sasa(dp52666
g49775
VWe speculate that E3 ubiquitin ligases MDM2 and MDM4 can be attractive therapeutic target for p53 and Notch signaling pathways in malignant melanoma by using small molecule inhibitors.
p52667
sg49777
(lp52668
(dp52669
g49782
I94
sg49783
I1
sg49784
I3
sg49812
VP42771
p52670
sg49787
Vp53
p52671
sa(dp52672
g49782
I18
sg49783
I2
sg49784
I12
sg49812
VP62979
p52673
sg49787
VE3 ubiquitin
p52674
sa(dp52675
g49782
I48
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VMDM4
p52676
sasg49779
(lp52677
(dp52678
g49782
I130
sg49783
I2
sg49784
I18
sg49785
VC0025202
p52679
sg49787
Vmalignant melanoma
p52680
sasa(dp52681
g49775
VOur recent studies conducted in South America have shown that mycotoxin contamination of red chili peppers (RCPs) may be associated with an increased risk of gallbladder cancer (GBC).
p52682
sg49777
(lp52683
sg49779
(lp52684
(dp52685
g49782
I178
sg49783
I1
sg49784
I3
sg49785
VC0153452
p52686
sg49787
VGBC
p52687
sa(dp52688
g49782
I158
sg49783
I2
sg49784
I18
sg49785
VC0153452
p52689
sg49787
Vgallbladder cancer
p52690
sasa(dp52691
g49775
VThree proteins were uniquely altered in vaginal carcinoma (DDX48, erbB3-binding protein and biliverdin reductase) and five in cervical carcinoma (peroxiredoxin 2, annexin A2, sarcomeric tropomyosin kappa, human ribonuclease inhibitor and prolyl-4-hydrolase beta).
p52692
sg49777
(lp52693
(dp52694
g49782
I92
sg49783
I2
sg49784
I20
sg49812
VP53004
p52695
sg49787
Vbiliverdin reductase
p52696
sa(dp52697
g49782
I59
sg49783
I1
sg49784
I5
sg49812
VP38919
p52698
sg49787
VDDX48
p52699
sa(dp52700
g49782
I66
sg49783
I2
sg49784
I21
sg49812
VP21860
p52701
sg49787
VerbB3-binding protein
p52702
sa(dp52703
g49782
I163
sg49783
I5
sg49784
I40
sg49812
VP07355
p52704
sg49787
Vannexin A2, sarcomeric tropomyosin kappa
p52705
sa(dp52706
g49782
I146
sg49783
I2
sg49784
I15
sg49812
VP32119
p52707
sg49787
Vperoxiredoxin 2
p52708
sa(dp52709
g49782
I205
sg49783
I3
sg49784
I28
sg49812
VP13489
p52710
sg49787
Vhuman ribonuclease inhibitor
p52711
sasg49779
(lp52712
(dp52713
g49782
I126
sg49783
I2
sg49784
I18
sg49785
VC0302592
p52714
sg49787
Vcervical carcinoma
p52715
sa(dp52716
g49782
I40
sg49783
I2
sg49784
I17
sg49785
VC0262659
p52717
sg49787
Vvaginal carcinoma
p52718
sasa(dp52719
g49775
VMitochondrial (mt) DNA-associated NARP (neurogenic muscle weakness, ataxia, and retinitis pigmentosa) syndrome is due to mutation in the MT-ATP6 gene.
p52720
sg49777
(lp52721
(dp52722
g49782
I34
sg49783
I1
sg49784
I4
sg49812
VP47972
p52723
sg49787
VNARP
p52724
sa(dp52725
g49782
I137
sg49783
I2
sg49784
I12
sg49812
VP36543
p52726
sg49787
VMT-ATP6 gene
p52727
sasg49779
(lp52728
(dp52729
g49782
I80
sg49783
I2
sg49784
I20
sg49785
VC0035334
p52730
sg49787
Vretinitis pigmentosa
p52731
sa(dp52732
g49782
I51
sg49783
I2
sg49784
I15
sg49785
VC0030552
p52733
sg49787
Vmuscle weakness
p52734
sa(dp52735
g49782
I68
sg49783
I1
sg49784
I6
sg49785
VC0004134
p52736
sg49787
Vataxia
p52737
sa(dp52738
g49782
I102
sg49783
I1
sg49784
I8
sg49785
VC0039082
p52739
sg49787
Vsyndrome
p52740
sasa(dp52741
g49775
VPathogenic mutations in MT-ATP6 are associated with the Leigh syndrome, the syndrome of neuropathy, ataxia, and retinitis pigmentosa (NARP), as well as with non-classical phenotypes, while MT-ATP8 is less frequently mutated in patients with mitochondrial disease.
p52742
sg49777
(lp52743
(dp52744
g49782
I189
sg49783
I1
sg49784
I7
sg49812
VP03928
p52745
sg49787
VMT-ATP8
p52746
sa(dp52747
g49782
I24
sg49783
I1
sg49784
I7
sg49812
VP36543
p52748
sg49787
VMT-ATP6
p52749
sasg49779
(lp52750
(dp52751
g49782
I241
sg49783
I2
sg49784
I21
sg49785
VC0751651
p52752
sg49787
Vmitochondrial disease
p52753
sa(dp52754
g49782
I88
sg49783
I5
sg49784
I44
sg49785
VC1328349
p52755
sg49787
Vneuropathy, ataxia, and retinitis pigmentosa
p52756
sa(dp52757
g49782
I56
sg49783
I2
sg49784
I14
sg49785
VC0023264
p52758
sg49787
VLeigh syndrome
p52759
sa(dp52760
g49782
I62
sg49783
I1
sg49784
I8
sg49785
VC0039082
p52761
sg49787
Vsyndrome
p52762
sasa(dp52763
g49775
VAnalysis of these populations demonstrated an altered metabolic signature in cells harbouring decreased levels of mutant m.8993T&gt;G mtDNA, associated with neuropathy, ataxia, and retinitis pigmentosa (NARP).
p52764
sg49777
(lp52765
sg49779
(lp52766
(dp52767
g49782
I157
sg49783
I5
sg49784
I44
sg49785
VC1328349
p52768
sg49787
Vneuropathy, ataxia, and retinitis pigmentosa
p52769
sa(dp52770
g49782
I114
sg49783
I1
sg49784
I6
sg49785
VC0596988
p52771
sg49787
Vmutant
p52772
sasa(dp52773
g49775
VNeurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP) is caused by m.8993T&gt;G/C mutations in the mitochondrial adenosine triphosphate synthase subunit 6 gene (MT-ATP6).
p52774
sg49777
(lp52775
(dp52776
g49782
I113
sg49783
I7
sg49784
I60
sg49812
VP56381
p52777
sg49787
Vmitochondrial adenosine triphosphate synthase subunit 6 gene
p52778
sa(dp52779
g49782
I175
sg49783
I1
sg49784
I7
sg49812
VP36543
p52780
sg49787
VMT-ATP6
p52781
sasg49779
(lp52782
(dp52783
g49782
I28
sg49783
I1
sg49784
I6
sg49785
VC0004134
p52784
sg49787
Vataxia
p52785
sa(dp52786
g49782
I40
sg49783
I2
sg49784
I20
sg49785
VC0035334
p52787
sg49787
Vretinitis pigmentosa
p52788
sa(dp52789
g49782
I11
sg49783
I2
sg49784
I15
sg49785
VC0030552
p52790
sg49787
Vmuscle weakness
p52791
sasa(dp52792
g49775
VIn addition, we successfully reduced human mutated mtDNA levels responsible for Leber's hereditary optic neuropathy (LHOND), and neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP), in mammalian oocytes using mitochondria-targeted TALEN (mito-TALENs).
p52793
sg49777
(lp52794
sg49779
(lp52795
(dp52796
g49782
I140
sg49783
I2
sg49784
I15
sg49785
VC0030552
p52797
sg49787
Vmuscle weakness
p52798
sa(dp52799
g49782
I80
sg49783
I4
sg49784
I35
sg49785
VC0917796
p52800
sg49787
VLeber's hereditary optic neuropathy
p52801
sa(dp52802
g49782
I169
sg49783
I2
sg49784
I20
sg49785
VC0035334
p52803
sg49787
Vretinitis pigmentosa
p52804
sa(dp52805
g49782
I157
sg49783
I1
sg49784
I6
sg49785
VC0004134
p52806
sg49787
Vataxia
p52807
sasa(dp52808
g49775
VBased on our previous findings that ROS level was higher in human osteosarcoma cybrids--Neuropathy, Ataxia and Retinitis Pigmentosa (NARP) and was reduced by selenite treatment, this study was designed to elucidate the effects of selenite administration on oxidative and nitrosative damage to lipids, proteins and DNA.
p52809
sg49777
(lp52810
sg49779
(lp52811
(dp52812
g49782
I100
sg49783
I1
sg49784
I6
sg49785
VC0004134
p52813
sg49787
VAtaxia
p52814
sa(dp52815
g49782
I66
sg49783
I1
sg49784
I12
sg49785
VC0029463
p52816
sg49787
Vosteosarcoma
p52817
sa(dp52818
g49782
I88
sg49783
I1
sg49784
I10
sg49785
VC0442874
p52819
sg49787
VNeuropathy
p52820
sa(dp52821
g49782
I111
sg49783
I2
sg49784
I20
sg49785
VC0035334
p52822
sg49787
VRetinitis Pigmentosa
p52823
sasa(dp52824
g49775
VWe report a patient having classical clinical feature of neurologic muscle weakness, ataxia, and retinitis pigmentosa (NARP) and a novel mutation, m.8729 G&gt;A in mitochondria DNA.
p52825
sg49777
(lp52826
sg49779
(lp52827
(dp52828
g49782
I97
sg49783
I2
sg49784
I20
sg49785
VC0035334
p52829
sg49787
Vretinitis pigmentosa
p52830
sa(dp52831
g49782
I68
sg49783
I2
sg49784
I15
sg49785
VC0030552
p52832
sg49787
Vmuscle weakness
p52833
sa(dp52834
g49782
I131
sg49783
I2
sg49784
I14
sg49785
VC2985438
p52835
sg49787
Vnovel mutation
p52836
sa(dp52837
g49782
I85
sg49783
I1
sg49784
I6
sg49785
VC0004134
p52838
sg49787
Vataxia
p52839
sasa(dp52840
g49775
VHis mother, who had previously been diagnosed with cerebral palsy, was concurrently diagnosed with neuropathy, ataxia, and retinitis pigmentosa (NARP) due to heteroplasmy of the same mutation.
p52841
sg49777
(lp52842
sg49779
(lp52843
(dp52844
g49782
I99
sg49783
I5
sg49784
I44
sg49785
VC1328349
p52845
sg49787
Vneuropathy, ataxia, and retinitis pigmentosa
p52846
sa(dp52847
g49782
I51
sg49783
I2
sg49784
I14
sg49785
VC0007789
p52848
sg49787
Vcerebral palsy
p52849
sasa(dp52850
g49775
VIn this issue, Gammage and colleagues successfully apply this improved technology on patients' cells with two types of genetic alterations responsible for neuropathy ataxia and retinitis pigmentosa (NARP) syndrome and Kearns Sayre syndrome and progressive external ophthalmoplegia (PEO).
p52851
sg49777
(lp52852
sg49779
(lp52853
(dp52854
g49782
I166
sg49783
I1
sg49784
I6
sg49785
VC0004134
p52855
sg49787
Vataxia
p52856
sa(dp52857
g49782
I155
sg49783
I1
sg49784
I10
sg49785
VC0442874
p52858
sg49787
Vneuropathy
p52859
sa(dp52860
g49782
I244
sg49783
I3
sg49784
I36
sg49785
VC0162674
p52861
sg49787
Vprogressive external ophthalmoplegia
p52862
sa(dp52863
g49782
I218
sg49783
I3
sg49784
I21
sg49785
VC0022541
p52864
sg49787
VKearns Sayre syndrome
p52865
sa(dp52866
g49782
I205
sg49783
I1
sg49784
I8
sg49785
VC0039082
p52867
sg49787
Vsyndrome
p52868
sa(dp52869
g49782
I177
sg49783
I2
sg49784
I20
sg49785
VC0035334
p52870
sg49787
Vretinitis pigmentosa
p52871
sa(dp52872
g49782
I282
sg49783
I1
sg49784
I3
sg49785
VC0162674
p52873
sg49787
VPEO
p52874
sasa(dp52875
g49775
VThere are several diseases that have a mitochondrial origin such as chronic progressive external ophthalmoplegia (CPEO) and the Kearns- Sayre syndrome (KSS), myoclonic epilepsy with ragged-red fibers (MERRF), mitochondrial encephalomyopathy, lactic acidosis and strokelike episodes (MELAS), Leber's hereditary optic neuropathy (LHON), the syndrome of neurogenic muscle weakness, ataxia and retinitis pigmentosa (NARP), and Leigh's syndrome.
p52876
sg49777
(lp52877
sg49779
(lp52878
(dp52879
g49782
I158
sg49783
I5
sg49784
I41
sg49785
VC0162672
p52880
sg49787
Vmyoclonic epilepsy with ragged-red fibers
p52881
sa(dp52882
g49782
I201
sg49783
I1
sg49784
I5
sg49785
VC0162672
p52883
sg49787
VMERRF
p52884
sa(dp52885
g49782
I128
sg49783
I3
sg49784
I22
sg49785
VC0022541
p52886
sg49787
VKearns- Sayre syndrome
p52887
sa(dp52888
g49782
I291
sg49783
I4
sg49784
I35
sg49785
VC0917796
p52889
sg49787
VLeber's hereditary optic neuropathy
p52890
sa(dp52891
g49782
I114
sg49783
I1
sg49784
I4
sg49785
VC0162674
p52892
sg49787
VCPEO
p52893
sa(dp52894
g49782
I142
sg49783
I1
sg49784
I8
sg49785
VC0039082
p52895
sg49787
Vsyndrome
p52896
sa(dp52897
g49782
I142
sg49783
I1
sg49784
I8
sg49785
VC0039082
p52898
sg49787
Vsyndrome
p52899
sa(dp52900
g49782
I242
sg49783
I2
sg49784
I15
sg49785
VC0001125
p52901
sg49787
Vlactic acidosis
p52902
sa(dp52903
g49782
I209
sg49783
I2
sg49784
I31
sg49785
VC0162666
p52904
sg49787
Vmitochondrial encephalomyopathy
p52905
sa(dp52906
g49782
I152
sg49783
I1
sg49784
I3
sg49785
VC0022541
p52907
sg49787
VKSS
p52908
sa(dp52909
g49782
I283
sg49783
I1
sg49784
I5
sg49785
VC0162671
p52910
sg49787
VMELAS
p52911
sa(dp52912
g49782
I328
sg49783
I1
sg49784
I4
sg49785
VC0917796
p52913
sg49787
VLHON
p52914
sa(dp52915
g49782
I351
sg49783
I7
sg49784
I59
sg49785
VC0342772
p52916
sg49787
Vneurogenic muscle weakness, ataxia and retinitis pigmentosa
p52917
sa(dp52918
g49782
I68
sg49783
I4
sg49784
I44
sg49785
VC0162674
p52919
sg49787
Vchronic progressive external ophthalmoplegia
p52920
sasa(dp52921
g49775
VNeuroblastoma cells treated with free myb-as or nontargeted CCL-myb-as showed the same level of c-myb protein expression as control cells.
p52922
sg49777
(lp52923
(dp52924
g49782
I96
sg49783
I2
sg49784
I13
sg49812
VP10243
p52925
sg49787
Vc-myb protein
p52926
sa(dp52927
g49782
I38
sg49783
I1
sg49784
I3
sg49812
VP10243
p52928
sg49787
Vmyb
p52929
sa(dp52930
g49782
I38
sg49783
I1
sg49784
I3
sg49812
VP10243
p52931
sg49787
Vmyb
p52932
sa(dp52933
g49782
I60
sg49783
I1
sg49784
I3
sg49812
VP43320
p52934
sg49787
VCCL
p52935
sasg49779
(lp52936
(dp52937
g49782
I0
sg49783
I1
sg49784
I13
sg49785
VC0027819
p52938
sg49787
VNeuroblastoma
p52939
sa(dp52940
g49782
I60
sg49783
I1
sg49784
I3
sg49785
VC1852438
p52941
sg49787
VCCL
p52942
sasa(dp52943
g49775
VImmune cell activation, involving the time-dependent activation of macrophages and NK cells, contributes to the antitumor activity of targeted liposome-CpG-myb-as against neuroblastoma and could improve the effectiveness of antitumor targeted liposomes.
p52944
sg49777
(lp52945
sg49779
(lp52946
(dp52947
g49782
I171
sg49783
I1
sg49784
I13
sg49785
VC0027819
p52948
sg49787
Vneuroblastoma
p52949
sasa(dp52950
g49775
VWhile YY1 is known to exert both positive and negative regulatory influences on nuclear-encoded mitochondrial proteins, as well as on neurodegeneration-related genes, in all cell lines we studied (including neuroblastoma) the effect of YY1 on GDAP1 expression is activatory.
p52951
sg49777
(lp52952
(dp52953
g49782
I6
sg49783
I1
sg49784
I3
sg49812
VP25490
p52954
sg49787
VYY1
p52955
sa(dp52956
g49782
I6
sg49783
I1
sg49784
I3
sg49812
VP25490
p52957
sg49787
VYY1
p52958
sa(dp52959
g49782
I243
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VGDAP1
p52960
sa(dp52961
g49782
I80
sg49783
I3
sg49784
I38
sg49812
VP02649
p52962
sg49787
Vnuclear-encoded mitochondrial proteins
p52963
sasg49779
(lp52964
(dp52965
g49782
I207
sg49783
I1
sg49784
I13
sg49785
VC0027819
p52966
sg49787
Vneuroblastoma
p52967
sa(dp52968
g49782
I134
sg49783
I1
sg49784
I17
sg49785
VC0027746
p52969
sg49787
Vneurodegeneration
p52970
sasa(dp52971
g49775
VUsing the DBH-expressing human neuroblastoma SK-N-BE(2)C and DBH-negative HeLa cell lines as model systems, we report here that this CRE/YY1/AP1 area interacts with multiple nuclear proteins, including CRE-binding protein (CREB) and transcription factor YY1 in a cell-specific manner.
p52972
sg49777
(lp52973
(dp52974
g49782
I202
sg49783
I2
sg49784
I19
sg49812
g11
sg49787
VCRE-binding protein
p52975
sa(dp52976
g49782
I233
sg49783
I3
sg49784
I24
sg49812
VP25490
p52977
sg49787
Vtranscription factor YY1
p52978
sa(dp52979
g49782
I10
sg49783
I1
sg49784
I3
sg49812
VP09172
p52980
sg49787
VDBH
p52981
sa(dp52982
g49782
I223
sg49783
I1
sg49784
I4
sg49812
VP16220
p52983
sg49787
VCREB
p52984
sa(dp52985
g49782
I137
sg49783
I1
sg49784
I3
sg49812
VP25490
p52986
sg49787
VYY1
p52987
sa(dp52988
g49782
I141
sg49783
I1
sg49784
I3
sg49812
VP27695
p52989
sg49787
VAP1
p52990
sasg49779
(lp52991
(dp52992
g49782
I31
sg49783
I1
sg49784
I13
sg49785
VC0027819
p52993
sg49787
Vneuroblastoma
p52994
sasa(dp52995
g49775
VHowever, little is known about the expression of CD44v6 in Gastric Carcinoma (GC).
p52996
sg49777
(lp52997
sg49779
(lp52998
(dp52999
g49782
I59
sg49783
I2
sg49784
I17
sg49785
VC0699791
p53000
sg49787
VGastric Carcinoma
p53001
sa(dp53002
g49782
I78
sg49783
I1
sg49784
I2
sg49785
VC0699791
p53003
sg49787
VGC
p53004
sasa(dp53005
g49775
VMultiple carcinomas including breast, ovarian, colon, lung and stomach cancer, overexpress the hyaluronic acid (HA) receptor, CD44.
p53006
sg49777
(lp53007
sg49779
(lp53008
(dp53009
g49782
I63
sg49783
I2
sg49784
I14
sg49785
VC0024623
p53010
sg49787
Vstomach cancer
p53011
sa(dp53012
g49782
I9
sg49783
I1
sg49784
I10
sg49785
VC0007097
p53013
sg49787
Vcarcinomas
p53014
sasa(dp53015
g49775
VHere, we show that the transcription of a long non-coding RNA (lncRNA), Gastric Adenocarcinoma Associated, Positive CD44 Regulator, Long Intergenic Non-Coding RNA (GAPLINC), is directly activated by HIF-1Alfa in gastric cancer (GC).
p53016
sg49777
(lp53017
sg49779
(lp53018
(dp53019
g49782
I228
sg49783
I1
sg49784
I2
sg49785
VC0024623
p53020
sg49787
VGC
p53021
sa(dp53022
g49782
I72
sg49783
I2
sg49784
I22
sg49785
VC0278701
p53023
sg49787
VGastric Adenocarcinoma
p53024
sa(dp53025
g49782
I212
sg49783
I2
sg49784
I14
sg49785
VC0024623
p53026
sg49787
Vgastric cancer
p53027
sasa(dp53028
g49775
VThe expressions of 10 putative cell surface markers of CSCs, as well as aldehyde dehydrogenase (ALDH) activity, were studied, and the tumorigenic properties of cells were evaluated by in vitro tumorsphere assays and in vivo xenografts by limiting dilution assays.Results: We found that a subpopulation of gastric carcinoma cells expressing EPCAM, CD133, CD166, CD44, and a high ALDH activity presented the properties to generate new heterogeneous tumorspheres in vitro and tumors in vivo CD44 and CD166 were coexpressed, representing 6.1% to 37.5% of the cells; ALDH activity was detected in 1.6% to 15.4% of the cells; and the ALDH+ cells represented a core within the CD44+/CD166+ subpopulation that contained the highest frequency of tumorigenic CSCs in vivo The ALDH+ cells possessed drug efflux properties and were more resistant to standard chemotherapy than the ALDH- cells, a process that was partially reversed by verapamil treatment.Conclusions: CD44 and ALDH are the most specific biomarkers to detect and isolate tumorigenic and chemoresistant gastric CSCs in noncardia gastric carcinomas independently of the histologic classification of the tumor.
p53029
sg49777
(lp53030
(dp53031
g49782
I96
sg49783
I1
sg49784
I4
sg49812
VP00352
p53032
sg49787
VALDH
p53033
sa(dp53034
g49782
I676
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VCD166+
p53035
sa(dp53036
g49782
I354
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCD166
p53037
sa(dp53038
g49782
I340
sg49783
I1
sg49784
I5
sg49812
VP16422
p53039
sg49787
VEPCAM
p53040
sa(dp53041
g49782
I96
sg49783
I1
sg49784
I4
sg49812
VP49366
p53042
sg49787
VALDH
p53043
sa(dp53044
g49782
I96
sg49783
I1
sg49784
I4
sg49812
VP00352
p53045
sg49787
VALDH
p53046
sa(dp53047
g49782
I96
sg49783
I1
sg49784
I4
sg49812
VP00352
p53048
sg49787
VALDH
p53049
sa(dp53050
g49782
I354
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCD166
p53051
sa(dp53052
g49782
I96
sg49783
I1
sg49784
I4
sg49812
VP00352
p53053
sg49787
VALDH
p53054
sa(dp53055
g49782
I347
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCD133
p53056
sa(dp53057
g49782
I72
sg49783
I2
sg49784
I22
sg49812
VP49366
p53058
sg49787
Valdehyde dehydrogenase
p53059
sasg49779
(lp53060
(dp53061
g49782
I193
sg49783
I1
sg49784
I6
sg49785
VC0027651
p53062
sg49787
Vtumors
p53063
sa(dp53064
g49782
I778
sg49783
I1
sg49784
I9
sg49785
VC0850310
p53065
sg49787
Vpossessed
p53066
sa(dp53067
g49782
I305
sg49783
I2
sg49784
I17
sg49785
VC0699791
p53068
sg49787
Vgastric carcinoma
p53069
sa(dp53070
g49782
I134
sg49783
I1
sg49784
I5
sg49785
VC0027651
p53071
sg49787
Vtumor
p53072
sa(dp53073
g49782
I1090
sg49783
I1
sg49784
I10
sg49785
VC0007097
p53074
sg49787
Vcarcinomas
p53075
sasa(dp53076
g49775
VClinically, low CD10 expression was consistent with a specific set of ovarian cancer patient samples.
p53077
sg49777
(lp53078
(dp53079
g49782
I16
sg49783
I1
sg49784
I4
sg49812
VP08473
p53080
sg49787
VCD10
p53081
sasg49779
(lp53082
(dp53083
g49782
I70
sg49783
I2
sg49784
I14
sg49785
VC1140680
p53084
sg49787
Vovarian cancer
p53085
sasa(dp53086
g49775
VFurthermore, our data indicate that primary stage targeting of CD10-/ALDH- CSCs in specific ovarian cancer patients in future may facilitate targeting of recurrent disease, before it ever develops.
p53087
sg49777
(lp53088
(dp53089
g49782
I63
sg49783
I2
sg49784
I16
sg49812
VP08473
p53090
sg49787
VCD10-/ALDH- CSCs
p53091
sasg49779
(lp53092
(dp53093
g49782
I92
sg49783
I2
sg49784
I14
sg49785
VC1140680
p53094
sg49787
Vovarian cancer
p53095
sa(dp53096
g49782
I154
sg49783
I2
sg49784
I17
sg49785
VC0277556
p53097
sg49787
Vrecurrent disease
p53098
sasa(dp53099
g49775
VAll cases were negative for CD10 and WT-1 ruling out endometrial stromal tumor and were negative for HMB-45 and melan-A ruling out perivascular epithelioid cell tumor (both endometrial stromal tumor and perivascular epithelioid cell tumor have prominent vessels but have different histomorphology).
p53100
sg49777
(lp53101
(dp53102
g49782
I112
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
Vmelan-A
p53103
sa(dp53104
g49782
I28
sg49783
I1
sg49784
I4
sg49812
VP08473
p53105
sg49787
VCD10
p53106
sa(dp53107
g49782
I101
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VHMB-45
p53108
sasg49779
(lp53109
(dp53110
g49782
I53
sg49783
I3
sg49784
I25
sg49785
VC0334695
p53111
sg49787
Vendometrial stromal tumor
p53112
sa(dp53113
g49782
I73
sg49783
I1
sg49784
I5
sg49785
VC0027651
p53114
sg49787
Vtumor
p53115
sa(dp53116
g49782
I73
sg49783
I1
sg49784
I5
sg49785
VC0027651
p53117
sg49787
Vtumor
p53118
sa(dp53119
g49782
I53
sg49783
I3
sg49784
I25
sg49785
VC0334695
p53120
sg49787
Vendometrial stromal tumor
p53121
sasa(dp53122
g49775
VImmunohistochemistry indicated a phenotypic transition from a uterine leiomyosarcoma to a vaginal epithelioid lesion; marker expression changed from the uterine tumor actin+/desmin+/caldesmon+/CD10- phenotype, through the tumor emboli, to an actin-/desmin-/caldesmon-/CD10+ phenotype in the vaginal lesion.
p53123
sg49777
(lp53124
(dp53125
g49782
I182
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
Vcaldesmon+
p53126
sa(dp53127
g49782
I257
sg49783
I2
sg49784
I26
sg49812
g11
sg49787
Vcaldesmon-/CD10+ phenotype
p53128
sa(dp53129
g49782
I174
sg49783
I1
sg49784
I7
sg49812
VP98155
p53130
sg49787
Vdesmin+
p53131
sa(dp53132
g49782
I242
sg49783
I1
sg49784
I13
sg49812
VP98155
p53133
sg49787
Vactin-/desmin
p53134
sa(dp53135
g49782
I193
sg49783
I1
sg49784
I4
sg49812
VP08473
p53136
sg49787
VCD10
p53137
sasg49779
(lp53138
(dp53139
g49782
I161
sg49783
I1
sg49784
I5
sg49785
VC0027651
p53140
sg49787
Vtumor
p53141
sa(dp53142
g49782
I44
sg49783
I1
sg49784
I10
sg49785
VC0599156
p53143
sg49787
Vtransition
p53144
sa(dp53145
g49782
I291
sg49783
I2
sg49784
I14
sg49785
VC0566943
p53146
sg49787
Vvaginal lesion
p53147
sa(dp53148
g49782
I62
sg49783
I2
sg49784
I22
sg49785
VC0280631
p53149
sg49787
Vuterine leiomyosarcoma
p53150
sa(dp53151
g49782
I153
sg49783
I2
sg49784
I13
sg49785
VC0042138
p53152
sg49787
Vuterine tumor
p53153
sasa(dp53154
g49775
VImmunohistochemistry for IFITM1 and CD10 was performed in 20 cases of smooth muscle neoplasms (10 cases leiomyoma, 10 cases leiomyosarcoma), 14 cases of endometrial stromal sarcoma (ESS) (12 cases of low grade and 2 cases of high grade) and 12 cases of carcinosarcoma.
p53155
sg49777
(lp53156
(dp53157
g49782
I25
sg49783
I1
sg49784
I6
sg49812
VP13164
p53158
sg49787
VIFITM1
p53159
sa(dp53160
g49782
I36
sg49783
I1
sg49784
I4
sg49812
VP08473
p53161
sg49787
VCD10
p53162
sasg49779
(lp53163
(dp53164
g49782
I124
sg49783
I1
sg49784
I14
sg49785
VC0023269
p53165
sg49787
Vleiomyosarcoma
p53166
sa(dp53167
g49782
I182
sg49783
I1
sg49784
I3
sg49785
VC0206630
p53168
sg49787
VESS
p53169
sa(dp53170
g49782
I253
sg49783
I1
sg49784
I14
sg49785
VC0007140
p53171
sg49787
Vcarcinosarcoma
p53172
sa(dp53173
g49782
I77
sg49783
I2
sg49784
I16
sg49785
VC0282606
p53174
sg49787
Vmuscle neoplasms
p53175
sa(dp53176
g49782
I104
sg49783
I1
sg49784
I9
sg49785
VC0023267
p53177
sg49787
Vleiomyoma
p53178
sa(dp53179
g49782
I153
sg49783
I3
sg49784
I27
sg49785
VC0206630
p53180
sg49787
Vendometrial stromal sarcoma
p53181
sasa(dp53182
g49775
VWhile both IFITM1 (83%) and CD10 (91%) had high sensitivity in differentiating low-grade ESSs from smooth muscle neoplasms, IFITM1 (70%) had higher specificity compared with CD10 (45%).
p53183
sg49777
(lp53184
(dp53185
g49782
I28
sg49783
I1
sg49784
I4
sg49812
VP08473
p53186
sg49787
VCD10
p53187
sa(dp53188
g49782
I28
sg49783
I1
sg49784
I4
sg49812
VP08473
p53189
sg49787
VCD10
p53190
sa(dp53191
g49782
I11
sg49783
I1
sg49784
I6
sg49812
VP13164
p53192
sg49787
VIFITM1
p53193
sa(dp53194
g49782
I11
sg49783
I1
sg49784
I6
sg49812
VP13164
p53195
sg49787
VIFITM1
p53196
sasg49779
(lp53197
(dp53198
g49782
I106
sg49783
I2
sg49784
I16
sg49785
VC0282606
p53199
sg49787
Vmuscle neoplasms
p53200
sasa(dp53201
g49775
VIn this study IFITM1 appears to be a more specific marker of endometrial stromal differentiation compared with CD10 in differentiating low-grade ESSs from smooth muscle neoplasms.
p53202
sg49777
(lp53203
(dp53204
g49782
I111
sg49783
I1
sg49784
I4
sg49812
VP08473
p53205
sg49787
VCD10
p53206
sasg49779
(lp53207
(dp53208
g49782
I162
sg49783
I2
sg49784
I16
sg49785
VC0282606
p53209
sg49787
Vmuscle neoplasms
p53210
sasa(dp53211
g49775
VTo further evaluate the nature of the HLA association with alopecia areata (AA), we investigated the HLA-DRB1 locus in 161 AA patients and 165 matched controls from Belgium and Germany.
p53212
sg49777
(lp53213
(dp53214
g49782
I38
sg49783
I1
sg49784
I3
sg49812
VP30486
p53215
sg49787
VHLA
p53216
sa(dp53217
g49782
I101
sg49783
I2
sg49784
I14
sg49812
VP20039
p53218
sg49787
VHLA-DRB1 locus
p53219
sasg49779
(lp53220
(dp53221
g49782
I76
sg49783
I1
sg49784
I2
sg49785
VC0002171
p53222
sg49787
VAA
p53223
sa(dp53224
g49782
I76
sg49783
I1
sg49784
I2
sg49785
VC0002171
p53225
sg49787
VAA
p53226
sa(dp53227
g49782
I59
sg49783
I2
sg49784
I15
sg49785
VC0002171
p53228
sg49787
Valopecia areata
p53229
sasa(dp53230
g49775
VIn the present study, we found that miR-19a expression was significantly upregulated in metastatic clear cell renal carcinoma than that in adjacent and primary carcinoma tissues using qPCR and in situ hybridization experiments.
p53231
sg49777
(lp53232
(dp53233
g49782
I36
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-19a
p53234
sasg49779
(lp53235
(dp53236
g49782
I152
sg49783
I2
sg49784
I17
sg49785
VC1335475
p53237
sg49787
Vprimary carcinoma
p53238
sa(dp53239
g49782
I99
sg49783
I4
sg49784
I26
sg49785
VC0279702
p53240
sg49787
Vclear cell renal carcinoma
p53241
sasa(dp53242
g49775
VThus, we provide evidence demonstrating that downregulation of miR-19a may be therapeutically beneficial for metastatic renal carcinoma.
p53243
sg49777
(lp53244
(dp53245
g49782
I63
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-19a
p53246
sasg49779
(lp53247
(dp53248
g49782
I109
sg49783
I3
sg49784
I26
sg49785
VC0919989
p53249
sg49787
Vmetastatic renal carcinoma
p53250
sasa(dp53251
g49775
VTaqman probe stem-loop real-time PCR was used to accurately measure the levels of miR-19a in bladder cancer cell lines, 100 pairs of bladder cancer tissues and the adjacent non-neoplastic tissues and also the plasma collected from bladder cancer patients and normal controls.
p53252
sg49777
(lp53253
(dp53254
g49782
I82
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-19a
p53255
sasg49779
(lp53256
(dp53257
g49782
I93
sg49783
I2
sg49784
I14
sg49785
VC0699885
p53258
sg49787
Vbladder cancer
p53259
sa(dp53260
g49782
I93
sg49783
I2
sg49784
I14
sg49785
VC0699885
p53261
sg49787
Vbladder cancer
p53262
sa(dp53263
g49782
I93
sg49783
I2
sg49784
I14
sg49785
VC0699885
p53264
sg49787
Vbladder cancer
p53265
sasa(dp53266
g49775
VmiR-19a mimics and inhibitors were transfected into bladder cancer cells to investigate its role on regulating cell proliferation which was measured by CCK-8 and colony formation assay.
p53267
sg49777
(lp53268
(dp53269
g49782
I0
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-19a
p53270
sasg49779
(lp53271
(dp53272
g49782
I52
sg49783
I2
sg49784
I14
sg49785
VC0699885
p53273
sg49787
Vbladder cancer
p53274
sa(dp53275
g49782
I116
sg49783
I1
sg49784
I13
sg49785
VC0334094
p53276
sg49787
Vproliferation
p53277
sasa(dp53278
g49775
VmiR-19a was significantly up-regulated in bladder cancer tissues and high-level of miR-19a was correlative with more aggressive phenotypes of bladder cancer.
p53279
sg49777
(lp53280
(dp53281
g49782
I0
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-19a
p53282
sa(dp53283
g49782
I0
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-19a
p53284
sasg49779
(lp53285
(dp53286
g49782
I42
sg49783
I2
sg49784
I14
sg49785
VC0699885
p53287
sg49787
Vbladder cancer
p53288
sa(dp53289
g49782
I117
sg49783
I1
sg49784
I10
sg49785
VC0001807
p53290
sg49787
Vaggressive
p53291
sa(dp53292
g49782
I42
sg49783
I2
sg49784
I14
sg49785
VC0699885
p53293
sg49787
Vbladder cancer
p53294
sasa(dp53295
g49775
VMeanwhile, gain or loss of function of miR-19a demonstrated that miR-19a can promote cell growth of bladder cancer cells and the further mechanism studies indicated that its oncogenic role was dependent on targeting PTEN.
p53296
sg49777
(lp53297
(dp53298
g49782
I39
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-19a
p53299
sa(dp53300
g49782
I216
sg49783
I1
sg49784
I4
sg49812
VP60484
p53301
sg49787
VPTEN
p53302
sa(dp53303
g49782
I39
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-19a
p53304
sasg49779
(lp53305
(dp53306
g49782
I100
sg49783
I2
sg49784
I14
sg49785
VC0699885
p53307
sg49787
Vbladder cancer
p53308
sasa(dp53309
g49775
VFurthermore, investigation of miR-19a expression in the plasma of bladder cancer patients showed that miR-19a was also increased in plasma of bladder cancer patients which strongly supported miR-19a could be developed as potential diagnostic marker of bladder cancer.
p53310
sg49777
(lp53311
(dp53312
g49782
I30
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-19a
p53313
sa(dp53314
g49782
I30
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-19a
p53315
sa(dp53316
g49782
I30
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-19a
p53317
sasg49779
(lp53318
(dp53319
g49782
I66
sg49783
I2
sg49784
I14
sg49785
VC0699885
p53320
sg49787
Vbladder cancer
p53321
sa(dp53322
g49782
I66
sg49783
I2
sg49784
I14
sg49785
VC0699885
p53323
sg49787
Vbladder cancer
p53324
sa(dp53325
g49782
I66
sg49783
I2
sg49784
I14
sg49785
VC0699885
p53326
sg49787
Vbladder cancer
p53327
sasa(dp53328
g49775
VOur data indicated that miR-19a might act as an oncogenic microRNA in bladder cancer and was significantly up-regulated in bladder cancer carcinogenesis.
p53329
sg49777
(lp53330
(dp53331
g49782
I24
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-19a
p53332
sasg49779
(lp53333
(dp53334
g49782
I70
sg49783
I2
sg49784
I14
sg49785
VC0699885
p53335
sg49787
Vbladder cancer
p53336
sa(dp53337
g49782
I138
sg49783
I1
sg49784
I14
sg49785
VC0596263
p53338
sg49787
Vcarcinogenesis
p53339
sa(dp53340
g49782
I70
sg49783
I2
sg49784
I14
sg49785
VC0699885
p53341
sg49787
Vbladder cancer
p53342
sasa(dp53343
g49775
VThe oncogenic role of miR19a in bladder cancer was dependent on targeting PTEN.
p53344
sg49777
(lp53345
(dp53346
g49782
I74
sg49783
I1
sg49784
I4
sg49812
VP60484
p53347
sg49787
VPTEN
p53348
sasg49779
(lp53349
(dp53350
g49782
I32
sg49783
I2
sg49784
I14
sg49785
VC0699885
p53351
sg49787
Vbladder cancer
p53352
sasa(dp53353
g49775
VThe synergy effect between miRNA-19a and arsenic trioxide that advocates targeting the mir-19a may represent a potential approach to enhance the efficacy and safety of ATO to treat bladder cancer by a decrease in dose.
p53354
sg49777
(lp53355
(dp53356
g49782
I87
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
Vmir-19a
p53357
sasg49779
(lp53358
(dp53359
g49782
I181
sg49783
I2
sg49784
I14
sg49785
VC0699885
p53360
sg49787
Vbladder cancer
p53361
sasa(dp53362
g49775
VThere was significant decreases in serum albumin and haptoglobin and increases in alpha-1 globulin, ceruloplasmin and alpha-1 globulin, there were no significant differences between schistosomiasis patients and the controls in terms of changes in any laboratory test as a result of the treatment, thus suggesting that patients with active schistosomiasis do not incur a higher risk of hepatic dysfunction while using oral contraception.
p53363
sg49777
(lp53364
(dp53365
g49782
I100
sg49783
I1
sg49784
I13
sg49812
VP00450
p53366
sg49787
Vceruloplasmin
p53367
sa(dp53368
g49782
I82
sg49783
I2
sg49784
I16
sg49812
VP25100
p53369
sg49787
Valpha-1 globulin
p53370
sa(dp53371
g49782
I82
sg49783
I2
sg49784
I16
sg49812
VP25100
p53372
sg49787
Valpha-1 globulin
p53373
sa(dp53374
g49782
I35
sg49783
I2
sg49784
I13
sg49812
g11
sg49787
Vserum albumin
p53375
sa(dp53376
g49782
I53
sg49783
I1
sg49784
I11
sg49812
VP00738
p53377
sg49787
Vhaptoglobin
p53378
sasg49779
(lp53379
(dp53380
g49782
I182
sg49783
I1
sg49784
I15
sg49785
VC0036323
p53381
sg49787
Vschistosomiasis
p53382
sa(dp53383
g49782
I182
sg49783
I1
sg49784
I15
sg49785
VC0036323
p53384
sg49787
Vschistosomiasis
p53385
sa(dp53386
g49782
I385
sg49783
I2
sg49784
I19
sg49785
VC0086565
p53387
sg49787
Vhepatic dysfunction
p53388
sasa(dp53389
g49775
VAqueous flare values and the vitreous levels of VEGF, IL-6, MCP-1, sICAM-1, and sVEGFR-2 were compared between previously untreated patients with BRVO and patients with macular hole (MH).
p53390
sg49777
(lp53391
(dp53392
g49782
I60
sg49783
I1
sg49784
I5
sg49812
VP41597
p53393
sg49787
VMCP-1
p53394
sa(dp53395
g49782
I54
sg49783
I1
sg49784
I4
sg49812
VP05231
p53396
sg49787
VIL-6
p53397
sasg49779
(lp53398
(dp53399
g49782
I169
sg49783
I2
sg49784
I12
sg49785
VC0024441
p53400
sg49787
Vmacular hole
p53401
sa(dp53402
g49782
I183
sg49783
I1
sg49784
I2
sg49785
VC0024441
p53403
sg49787
VMH
p53404
sa(dp53405
g49782
I8
sg49783
I1
sg49784
I5
sg49785
VC1517205
p53406
sg49787
Vflare
p53407
sasa(dp53408
g49775
VWe investigated the relations between the aqueous flare value and vitreous levels of vascular endothelial growth factor (VEGF), soluble intercellular adhesion molecule-1 (sICAM-1), and interleukin-6 (IL-6) in patients with CRVO and macular edema or patients with idiopathic macular hole (MH).
p53409
sg49777
(lp53410
(dp53411
g49782
I200
sg49783
I1
sg49784
I4
sg49812
VP05231
p53412
sg49787
VIL-6
p53413
sa(dp53414
g49782
I185
sg49783
I1
sg49784
I13
sg49812
VP05231
p53415
sg49787
Vinterleukin-6
p53416
sa(dp53417
g49782
I85
sg49783
I4
sg49784
I34
sg49812
g11
sg49787
Vvascular endothelial growth factor
p53418
sa(dp53419
g49782
I136
sg49783
I3
sg49784
I33
sg49812
VP05362
p53420
sg49787
Vintercellular adhesion molecule-1
p53421
sa(dp53422
g49782
I121
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VVEGF
p53423
sasg49779
(lp53424
(dp53425
g49782
I274
sg49783
I2
sg49784
I12
sg49785
VC0024441
p53426
sg49787
Vmacular hole
p53427
sa(dp53428
g49782
I232
sg49783
I2
sg49784
I13
sg49785
VC0271051
p53429
sg49787
Vmacular edema
p53430
sa(dp53431
g49782
I150
sg49783
I1
sg49784
I8
sg49785
VC0001511
p53432
sg49787
Vadhesion
p53433
sa(dp53434
g49782
I288
sg49783
I1
sg49784
I2
sg49785
VC0024441
p53435
sg49787
VMH
p53436
sa(dp53437
g49782
I50
sg49783
I1
sg49784
I5
sg49785
VC1517205
p53438
sg49787
Vflare
p53439
sasa(dp53440
g49775
VVitreous fluid levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor 2 (sVEGFR-2), soluble intercellular adhesion molecule 1 (sICAM-1), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), and pentraxin 3 (PTX3) were significantly higher in CRVO patients than in macular hole patients.
p53441
sg49777
(lp53442
(dp53443
g49782
I61
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VVEGF
p53444
sa(dp53445
g49782
I223
sg49783
I2
sg49784
I11
sg49812
VP26022
p53446
sg49787
Vpentraxin 3
p53447
sa(dp53448
g49782
I112
sg49783
I4
sg49784
I33
sg49812
VP05362
p53449
sg49787
Vintercellular adhesion molecule 1
p53450
sa(dp53451
g49782
I76
sg49783
I3
sg49784
I15
sg49812
g11
sg49787
VVEGF receptor 2
p53452
sa(dp53453
g49782
I236
sg49783
I1
sg49784
I4
sg49812
VP26022
p53454
sg49787
VPTX3
p53455
sa(dp53456
g49782
I211
sg49783
I1
sg49784
I5
sg49812
VP41597
p53457
sg49787
VMCP-1
p53458
sa(dp53459
g49782
I172
sg49783
I1
sg49784
I4
sg49812
VP05231
p53460
sg49787
VIL-6
p53461
sa(dp53462
g49782
I25
sg49783
I4
sg49784
I34
sg49812
g11
sg49787
Vvascular endothelial growth factor
p53463
sa(dp53464
g49782
I157
sg49783
I2
sg49784
I13
sg49812
VP05231
p53465
sg49787
Vinterleukin 6
p53466
sa(dp53467
g49782
I179
sg49783
I4
sg49784
I30
sg49812
VP14222
p53468
sg49787
Vmonocyte chemotactic protein 1
p53469
sasg49779
(lp53470
(dp53471
g49782
I126
sg49783
I1
sg49784
I8
sg49785
VC0001511
p53472
sg49787
Vadhesion
p53473
sa(dp53474
g49782
I293
sg49783
I2
sg49784
I12
sg49785
VC0024441
p53475
sg49787
Vmacular hole
p53476
sasa(dp53477
g49775
VIn 39 patients with BRVO and macular edema and 21 individuals with idiopathic macular hole (MH) serving as controls, vitreous fluid samples were obtained during vitreoretinal surgery, and the levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor 2 (sVEGFR-2), soluble intercellular adhesion molecule 1 (sICAM-1), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), pentraxin 3 (PTX3), and pigment epithelium-derived factor (PEDF) were measured by enzyme-linked immunosorbent assay.
p53478
sg49777
(lp53479
(dp53480
g49782
I202
sg49783
I4
sg49784
I34
sg49812
g11
sg49787
Vvascular endothelial growth factor
p53481
sa(dp53482
g49782
I238
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VVEGF
p53483
sa(dp53484
g49782
I349
sg49783
I1
sg49784
I4
sg49812
VP05231
p53485
sg49787
VIL-6
p53486
sa(dp53487
g49782
I334
sg49783
I2
sg49784
I13
sg49812
VP05231
p53488
sg49787
Vinterleukin 6
p53489
sa(dp53490
g49782
I388
sg49783
I1
sg49784
I5
sg49812
VP41597
p53491
sg49787
VMCP-1
p53492
sa(dp53493
g49782
I409
sg49783
I1
sg49784
I4
sg49812
VP26022
p53494
sg49787
VPTX3
p53495
sa(dp53496
g49782
I396
sg49783
I2
sg49784
I11
sg49812
VP26022
p53497
sg49787
Vpentraxin 3
p53498
sa(dp53499
g49782
I289
sg49783
I4
sg49784
I33
sg49812
VP05362
p53500
sg49787
Vintercellular adhesion molecule 1
p53501
sa(dp53502
g49782
I356
sg49783
I4
sg49784
I30
sg49812
VP14222
p53503
sg49787
Vmonocyte chemotactic protein 1
p53504
sa(dp53505
g49782
I253
sg49783
I3
sg49784
I15
sg49812
g11
sg49787
VVEGF receptor 2
p53506
sasg49779
(lp53507
(dp53508
g49782
I92
sg49783
I1
sg49784
I2
sg49785
VC0024441
p53509
sg49787
VMH
p53510
sa(dp53511
g49782
I78
sg49783
I2
sg49784
I12
sg49785
VC0024441
p53512
sg49787
Vmacular hole
p53513
sa(dp53514
g49782
I29
sg49783
I2
sg49784
I13
sg49785
VC0271051
p53515
sg49787
Vmacular edema
p53516
sa(dp53517
g49782
I303
sg49783
I1
sg49784
I8
sg49785
VC0001511
p53518
sg49787
Vadhesion
p53519
sasa(dp53520
g49775
VTo investigate relationships among vitreous fluid levels of soluble vascular endothelial growth factor receptor-2 (sVEGFR-2), vascular endothelial growth factor (VEGF), and soluble intercellular adhesion molecule 1 (sICAM-1) in patients with branch retinal vein occlusion (BRVO) and macular edema or patients with idiopathic macular hole.
p53521
sg49777
(lp53522
(dp53523
g49782
I116
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VVEGF
p53524
sa(dp53525
g49782
I68
sg49783
I5
sg49784
I45
sg49812
VP35968
p53526
sg49787
Vvascular endothelial growth factor receptor-2
p53527
sa(dp53528
g49782
I181
sg49783
I4
sg49784
I33
sg49812
VP05362
p53529
sg49787
Vintercellular adhesion molecule 1
p53530
sa(dp53531
g49782
I68
sg49783
I4
sg49784
I34
sg49812
g11
sg49787
Vvascular endothelial growth factor
p53532
sasg49779
(lp53533
(dp53534
g49782
I283
sg49783
I2
sg49784
I13
sg49785
VC0271051
p53535
sg49787
Vmacular edema
p53536
sa(dp53537
g49782
I325
sg49783
I2
sg49784
I12
sg49785
VC0024441
p53538
sg49787
Vmacular hole
p53539
sa(dp53540
g49782
I242
sg49783
I4
sg49784
I29
sg49785
VC0339505
p53541
sg49787
Vbranch retinal vein occlusion
p53542
sa(dp53543
g49782
I195
sg49783
I1
sg49784
I8
sg49785
VC0001511
p53544
sg49787
Vadhesion
p53545
sa(dp53546
g49782
I273
sg49783
I1
sg49784
I4
sg49785
VC0339505
p53547
sg49787
VBRVO
p53548
sasa(dp53549
g49775
VBRVO patients had a significantly higher vitreous fluid level of sVEGFR-2 (median, 1670 pg/mL; interquartile range [IQL], 1205 to 2225 pg/mL) than macular hole patients (median, 1265 pg/mL; IQR, 731 to 1800 pg/mL; P = .017), as was the case for VEGF (median, 237 pg/mL; IQR, 42.2 to 1305 pg/mL; vs median, 15.6 pg/mL; IQR, 15.6 to 15.6 pg/mL; P &lt; .001) and sICAM-1 (median, 10.1 ng/mL; IQR, 6.3 to 22.5 ng/mL; vs median, 4.1 ng/mL; IQR, 3.3 to 6.0 ng/mL; P &lt; .001).
p53550
sg49777
(lp53551
sg49779
(lp53552
(dp53553
g49782
I147
sg49783
I2
sg49784
I12
sg49785
VC0024441
p53554
sg49787
Vmacular hole
p53555
sasa(dp53556
g49775
VVitreous levels of sICAM-1 were significantly increased in vitreous specimens from both PVR (median +/- SD; 12.0 +/- 76.3 ng/ml; P &lt; 0.01) and PDR (8.4 +/- 24.0 ng/ml; P &lt; 0.01) when compared to vitreous from eyes with macular holes (0.
p53557
sg49777
(lp53558
sg49779
(lp53559
(dp53560
g49782
I88
sg49783
I1
sg49784
I3
sg49785
VC1860404
p53561
sg49787
VPVR
p53562
sa(dp53563
g49782
I146
sg49783
I1
sg49784
I3
sg49785
VC1845050
p53564
sg49787
VPDR
p53565
sa(dp53566
g49782
I225
sg49783
I2
sg49784
I13
sg49785
VC0024441
p53567
sg49787
Vmacular holes
p53568
sasa(dp53569
g49775
VLevels of sICAM-1 in this group were compared with those in vitreous from 31 eyes with RRD without clinical risk factors for PVR, 32 eyes with established PVR and 10 eyes with macular holes.
p53570
sg49777
(lp53571
(dp53572
g49782
I125
sg49783
I1
sg49784
I3
sg49812
VP15151
p53573
sg49787
VPVR
p53574
sasg49779
(lp53575
(dp53576
g49782
I125
sg49783
I1
sg49784
I3
sg49785
VC1860404
p53577
sg49787
VPVR
p53578
sa(dp53579
g49782
I125
sg49783
I1
sg49784
I3
sg49785
VC1860404
p53580
sg49787
VPVR
p53581
sa(dp53582
g49782
I176
sg49783
I2
sg49784
I13
sg49785
VC0024441
p53583
sg49787
Vmacular holes
p53584
sasa(dp53585
g49775
VVitreous sICAM-1 levels in eyes with RRD at high risk of developing PVR were significantly lower than in eyes with established PVR (p=0.037), but higher than in eyes with macular holes (p &lt;0.0001).
p53586
sg49777
(lp53587
(dp53588
g49782
I68
sg49783
I1
sg49784
I3
sg49812
VP15151
p53589
sg49787
VPVR
p53590
sasg49779
(lp53591
(dp53592
g49782
I68
sg49783
I1
sg49784
I3
sg49785
VC1860404
p53593
sg49787
VPVR
p53594
sa(dp53595
g49782
I171
sg49783
I2
sg49784
I13
sg49785
VC0024441
p53596
sg49787
Vmacular holes
p53597
sa(dp53598
g49782
I68
sg49783
I1
sg49784
I3
sg49785
VC1860404
p53599
sg49787
VPVR
p53600
sasa(dp53601
g49775
VRare pathogenic alleles with high penetrance and associated haplotypes at 10 loci (CFTR, FAH, HBB, HEXA, LDLR, LPL, PAH, PABP2, PDDR, and SACS) are expressed in probands with cystic fibrosis, tyrosinemia, beta-thalassemia, Tay-Sachs, familial hypercholesterolemia, hyperchylomicronemia, PKU, oculopharyngeal muscular dystrophy, pseudo vitamin D deficiency rickets, and spastic ataxia of Charlevoix-Saguenay, respectively) reveal the interpopulation and intrapopulation genetic diversity of Quebec.
p53602
sg49777
(lp53603
(dp53604
g49782
I89
sg49783
I1
sg49784
I3
sg49812
VP16930
p53605
sg49787
VFAH
p53606
sa(dp53607
g49782
I94
sg49783
I1
sg49784
I3
sg49812
VP02042
p53608
sg49787
VHBB
p53609
sa(dp53610
g49782
I83
sg49783
I1
sg49784
I4
sg49812
VP13569
p53611
sg49787
VCFTR
p53612
sa(dp53613
g49782
I128
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VPDDR
p53614
sa(dp53615
g49782
I116
sg49783
I1
sg49784
I3
sg49812
VP00439
p53616
sg49787
VPAH
p53617
sa(dp53618
g49782
I99
sg49783
I1
sg49784
I4
sg49812
VP06865
p53619
sg49787
VHEXA
p53620
sa(dp53621
g49782
I105
sg49783
I1
sg49784
I4
sg49812
VP01130
p53622
sg49787
VLDLR
p53623
sa(dp53624
g49782
I121
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPABP2
p53625
sa(dp53626
g49782
I111
sg49783
I1
sg49784
I3
sg49812
VP06858
p53627
sg49787
VLPL
p53628
sasg49779
(lp53629
(dp53630
g49782
I175
sg49783
I2
sg49784
I15
sg49785
VC0010674
p53631
sg49787
Vcystic fibrosis
p53632
sa(dp53633
g49782
I192
sg49783
I1
sg49784
I11
sg49785
VC0268483
p53634
sg49787
Vtyrosinemia
p53635
sa(dp53636
g49782
I292
sg49783
I3
sg49784
I34
sg49785
VC0270952
p53637
sg49787
Voculopharyngeal muscular dystrophy
p53638
sa(dp53639
g49782
I116
sg49783
I1
sg49784
I3
sg49785
VC0152171
p53640
sg49787
VPAH
p53641
sa(dp53642
g49782
I138
sg49783
I1
sg49784
I4
sg49785
VC1849140
p53643
sg49787
VSACS
p53644
sa(dp53645
g49782
I356
sg49783
I1
sg49784
I7
sg49785
VC0035579
p53646
sg49787
Vrickets
p53647
sa(dp53648
g49782
I369
sg49783
I4
sg49784
I37
sg49785
VC1849140
p53649
sg49787
Vspastic ataxia of Charlevoix-Saguenay
p53650
sa(dp53651
g49782
I205
sg49783
I1
sg49784
I16
sg49785
VC0005283
p53652
sg49787
Vbeta-thalassemia
p53653
sa(dp53654
g49782
I265
sg49783
I1
sg49784
I20
sg49785
VC0023817
p53655
sg49787
Vhyperchylomicronemia
p53656
sa(dp53657
g49782
I234
sg49783
I2
sg49784
I29
sg49785
VC0020445
p53658
sg49787
Vfamilial hypercholesterolemia
p53659
sa(dp53660
g49782
I335
sg49783
I3
sg49784
I20
sg49785
VC0042870
p53661
sg49787
Vvitamin D deficiency
p53662
sa(dp53663
g49782
I287
sg49783
I1
sg49784
I3
sg49785
VC0031485
p53664
sg49787
VPKU
p53665
sasa(dp53666
g49775
VBiochemical, neuropathological, and genetic evidence suggests an important role for TCERG1 in Huntington's disease (HD) pathogenesis.
p53667
sg49777
(lp53668
(dp53669
g49782
I84
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VTCERG1
p53670
sasg49779
(lp53671
(dp53672
g49782
I94
sg49783
I2
sg49784
I20
sg49785
VC0020179
p53673
sg49787
VHuntington's disease
p53674
sa(dp53675
g49782
I120
sg49783
I1
sg49784
I12
sg49785
VC0699748
p53676
sg49787
Vpathogenesis
p53677
sa(dp53678
g49782
I116
sg49783
I1
sg49784
I2
sg49785
VC0020179
p53679
sg49787
VHD
p53680
sasa(dp53681
g49775
VFurther investigations on the underlying mechanisms showed that the depletion of dG9a repressed starvation-induced autophagy by controlling the expression level of Atg8a, a critical gene for the progression of autophagy, in a different manner to that in cancer cells.
p53682
sg49777
(lp53683
sg49779
(lp53684
(dp53685
g49782
I254
sg49783
I1
sg49784
I6
sg49785
VC0006826
p53686
sg49787
Vcancer
p53687
sasa(dp53688
g49775
VBioinformatic analysis of human tumours revealed that several core autophagy genes, including GABARAP, correlate with oncogenic KRAS mutations and poor prognosis in human pancreatic cancer, supporting a potential tumour-suppressive effect of the pathway in Ras-driven human cancers.
p53689
sg49777
(lp53690
(dp53691
g49782
I128
sg49783
I1
sg49784
I4
sg49812
VP01116
p53692
sg49787
VKRAS
p53693
sa(dp53694
g49782
I94
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VGABARAP
p53695
sa(dp53696
g49782
I257
sg49783
I1
sg49784
I3
sg49812
VP01116
p53697
sg49787
VRas
p53698
sasg49779
(lp53699
(dp53700
g49782
I32
sg49783
I1
sg49784
I7
sg49785
VC0027651
p53701
sg49787
Vtumours
p53702
sa(dp53703
g49782
I32
sg49783
I1
sg49784
I6
sg49785
VC0027651
p53704
sg49787
Vtumour
p53705
sa(dp53706
g49782
I171
sg49783
I2
sg49784
I17
sg49785
VC0235974
p53707
sg49787
Vpancreatic cancer
p53708
sa(dp53709
g49782
I274
sg49783
I1
sg49784
I7
sg49785
VC0006826
p53710
sg49787
Vcancers
p53711
sasa(dp53712
g49775
VUsing a yeast two-hybrid screening approach, based on a thyroid cancer patients library, we showed that CDH6 directly interacts with GABARAP, BNIP3 and BNIP3L, and that through these interactions CDH6 restrains autophagy and promotes re-organization of mitochondrial network through a DRP1-mediated mechanism.
p53713
sg49777
(lp53714
(dp53715
g49782
I152
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBNIP3L
p53716
sa(dp53717
g49782
I104
sg49783
I1
sg49784
I4
sg49812
VP55285
p53718
sg49787
VCDH6
p53719
sa(dp53720
g49782
I285
sg49783
I1
sg49784
I4
sg49812
VP46939
p53721
sg49787
VDRP1
p53722
sa(dp53723
g49782
I104
sg49783
I1
sg49784
I4
sg49812
VP55285
p53724
sg49787
VCDH6
p53725
sa(dp53726
g49782
I133
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VGABARAP
p53727
sa(dp53728
g49782
I142
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VBNIP3
p53729
sasg49779
(lp53730
(dp53731
g49782
I56
sg49783
I2
sg49784
I14
sg49785
VC0007115
p53732
sg49787
Vthyroid cancer
p53733
sasa(dp53734
g49775
VWe previously reported that GABARAPL1 expression was frequently downregulated in cancer cells while a high GABARAPL1 expression is a good prognosis marker for patients with lymph node-positive breast cancer.
p53735
sg49777
(lp53736
(dp53737
g49782
I28
sg49783
I1
sg49784
I9
sg49812
g11
sg49787
VGABARAPL1
p53738
sa(dp53739
g49782
I28
sg49783
I1
sg49784
I9
sg49812
g11
sg49787
VGABARAPL1
p53740
sasg49779
(lp53741
(dp53742
g49782
I179
sg49783
I3
sg49784
I27
sg49785
VC3160887
p53743
sg49787
Vnode-positive breast cancer
p53744
sa(dp53745
g49782
I81
sg49783
I1
sg49784
I6
sg49785
VC0006826
p53746
sg49787
Vcancer
p53747
sasa(dp53748
g49775
VIn this study, we asked using qRT-PCR, western blotting and epigenetic quantification whether the expression of the GABARAP family was regulated in breast cancer by epigenetic modifications.
p53749
sg49777
(lp53750
(dp53751
g49782
I116
sg49783
I2
sg49784
I14
sg49812
g11
sg49787
VGABARAP family
p53752
sasg49779
(lp53753
(dp53754
g49782
I148
sg49783
I2
sg49784
I13
sg49785
VC0678222
p53755
sg49787
Vbreast cancer
p53756
sasa(dp53757
g49775
VOur data demonstrated that a specific decrease of GABARAPL1 expression in breast cancers was associated with both DNA methylation and histone deacetylation and that CREB-1 recruitment on GABARAPL1 promoter was required for GABARAPL1 expression.
p53758
sg49777
(lp53759
(dp53760
g49782
I50
sg49783
I1
sg49784
I9
sg49812
g11
sg49787
VGABARAPL1
p53761
sa(dp53762
g49782
I165
sg49783
I1
sg49784
I6
sg49812
VP16220
p53763
sg49787
VCREB-1
p53764
sa(dp53765
g49782
I134
sg49783
I1
sg49784
I7
sg49812
VP62805
p53766
sg49787
Vhistone
p53767
sa(dp53768
g49782
I187
sg49783
I2
sg49784
I18
sg49812
g11
sg49787
VGABARAPL1 promoter
p53769
sa(dp53770
g49782
I50
sg49783
I1
sg49784
I9
sg49812
g11
sg49787
VGABARAPL1
p53771
sasg49779
(lp53772
(dp53773
g49782
I172
sg49783
I1
sg49784
I11
sg49785
VC0271510
p53774
sg49787
Vrecruitment
p53775
sa(dp53776
g49782
I74
sg49783
I2
sg49784
I14
sg49785
VC0006142
p53777
sg49787
Vbreast cancers
p53778
sasa(dp53779
g49775
VHere we demonstrate that runx1 deletion in mice induces the persistence of MYH10 in platelets, and a similar persistence was observed in platelets of patients with constitutional (familial platelet disorder/acute myeloid leukemia) or acquired (chronic myelomonocytic leukemia) RUNX1 mutations.
p53780
sg49777
(lp53781
(dp53782
g49782
I25
sg49783
I2
sg49784
I14
sg49812
VP01719
p53783
sg49787
Vrunx1 deletion
p53784
sa(dp53785
g49782
I75
sg49783
I1
sg49784
I5
sg49812
VP35580
p53786
sg49787
VMYH10
p53787
sasg49779
(lp53788
(dp53789
g49782
I244
sg49783
I3
sg49784
I31
sg49785
VC0023480
p53790
sg49787
Vchronic myelomonocytic leukemia
p53791
sa(dp53792
g49782
I189
sg49783
I2
sg49784
I17
sg49785
VC0005818
p53793
sg49787
Vplatelet disorder
p53794
sa(dp53795
g49782
I207
sg49783
I3
sg49784
I22
sg49785
VC0023467
p53796
sg49787
Vacute myeloid leukemia
p53797
sasa(dp53798
g49775
VMYH10 was also detected in platelets of patients with the Paris-Trousseau syndrome, a thrombocytopenia related to the deletion of the transcription factor FLI1 that forms a complex with RUNX1 to regulate megakaryopoiesis, whereas MYH10 persistence was not observed in other inherited forms of thrombocytopenia.
p53799
sg49777
(lp53800
(dp53801
g49782
I155
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VFLI1
p53802
sa(dp53803
g49782
I0
sg49783
I1
sg49784
I5
sg49812
VP35580
p53804
sg49787
VMYH10
p53805
sa(dp53806
g49782
I0
sg49783
I1
sg49784
I5
sg49812
VP35580
p53807
sg49787
VMYH10
p53808
sasg49779
(lp53809
(dp53810
g49782
I58
sg49783
I2
sg49784
I24
sg49785
VC0795841
p53811
sg49787
VParis-Trousseau syndrome
p53812
sasa(dp53813
g49775
VWe propose MYH10 detection as a new and simple tool to identify inherited platelet disorders and myeloid neoplasms with abnormalities in RUNX1 and its associated proteins.
p53814
sg49777
(lp53815
(dp53816
g49782
I11
sg49783
I1
sg49784
I5
sg49812
VP35580
p53817
sg49787
VMYH10
p53818
sasg49779
(lp53819
(dp53820
g49782
I74
sg49783
I2
sg49784
I18
sg49785
VC0005818
p53821
sg49787
Vplatelet disorders
p53822
sa(dp53823
g49782
I105
sg49783
I1
sg49784
I9
sg49785
VC0027651
p53824
sg49787
Vneoplasms
p53825
sasa(dp53826
g49775
VThe existence of gynecomastia, age, detection of heterogeneous nodules on ultrasound, and preoperative alpha-fetoprotein and beta HCG are relevant data in relation to histological type of tumor.
p53827
sg49777
(lp53828
(dp53829
g49782
I103
sg49783
I4
sg49784
I30
sg49812
VP02771
p53830
sg49787
Valpha-fetoprotein and beta HCG
p53831
sasg49779
(lp53832
(dp53833
g49782
I130
sg49783
I1
sg49784
I3
sg49785
VC1855900
p53834
sg49787
VHCG
p53835
sa(dp53836
g49782
I63
sg49783
I1
sg49784
I7
sg49785
VC0028259
p53837
sg49787
Vnodules
p53838
sa(dp53839
g49782
I17
sg49783
I1
sg49784
I12
sg49785
VC0018418
p53840
sg49787
Vgynecomastia
p53841
sa(dp53842
g49782
I188
sg49783
I1
sg49784
I5
sg49785
VC0027651
p53843
sg49787
Vtumor
p53844
sasa(dp53845
g49775
VList of Abbreviations: AO: Acridine orange, AIDS: Acquired immunodeficiency syndrome, ACT: Artemisinin-based combination therapy, CM:Cerebral malaria, BCP:Benzothiocarboxypurine, DDT:Dichloro-diphenyl-trichloroethane, DNA:DeoxyriboNucleic Acid, ELAM-1: Endothelial leukocyte adhesion molecule, G6PD: Glucose-6-Phosphate Dehydrogenase, HIV: Human immuno deficiency virus, HRP 2: Histidine Rich Protein 2, ICAM -1: Inter cellular adhesion molecule1, ICER: Incremental cost effectiveness ratio, IL-1: Interleukin -1, IFN-g: Interferon-gamma, IgG: Immunoglobulin G, MP: Malaria parasite, NADP: Oxidised Nicotinamide Adenine Dinucleotide Phosphate, NADPH: Reduced Nicotinamide Adenine Dinucleotide Phosphate, PCV: Packed Cell Volume (haematocrit), P. falciparum: Plasmodium falciparum, PLDH: Plasmodium lactate dehydrogenase, PCR: Polymerase Chain Reaction, PPV: Positive predictive value, QBC: Quantitative Buffy Coat examination, TNF: Tumour necrosis factor, NPV: Negative predictive value, RDT: Rapid diagnostic test, SP: Sulphadoxine -Pyrimethamine, SMA: Severe malarial anaemia, UM: Uncomplicated malaria, USA:United States of America, VCAM-1: Vascular cell adhesion molecule, WBC: White Blood Cell, WHO: World Health Organization.
p53846
sg49777
(lp53847
(dp53848
g49782
I1144
sg49783
I4
sg49784
I31
sg49812
g11
sg49787
VVascular cell adhesion molecule
p53849
sa(dp53850
g49782
I521
sg49783
I1
sg49784
I16
sg49812
VP01579
p53851
sg49787
VInterferon-gamma
p53852
sa(dp53853
g49782
I413
sg49783
I4
sg49784
I33
sg49812
VP01185
p53854
sg49787
VInter cellular adhesion molecule1
p53855
sa(dp53856
g49782
I927
sg49783
I1
sg49784
I3
sg49812
VP01375
p53857
sg49787
VTNF
p53858
sa(dp53859
g49782
I514
sg49783
I1
sg49784
I5
sg49812
VP01579
p53860
sg49787
VIFN-g
p53861
sa(dp53862
g49782
I300
sg49783
I2
sg49784
I33
sg49812
VP49366
p53863
sg49787
VGlucose-6-Phosphate Dehydrogenase
p53864
sa(dp53865
g49782
I294
sg49783
I1
sg49784
I4
sg49812
VP11441
p53866
sg49787
VG6PD
p53867
sa(dp53868
g49782
I498
sg49783
I2
sg49784
I14
sg49812
VP60568
p53869
sg49787
VInterleukin -1
p53870
sa(dp53871
g49782
I245
sg49783
I1
sg49784
I6
sg49812
VP16581
p53872
sg49787
VELAM-1
p53873
sa(dp53874
g49782
I539
sg49783
I3
sg49784
I21
sg49812
g11
sg49787
VIgG: Immunoglobulin G
p53875
sa(dp53876
g49782
I492
sg49783
I1
sg49784
I4
sg49812
VP01584
p53877
sg49787
VIL-1
p53878
sa(dp53879
g49782
I1136
sg49783
I1
sg49784
I6
sg49812
VP19320
p53880
sg49787
VVCAM-1
p53881
sa(dp53882
g49782
I932
sg49783
I3
sg49784
I22
sg49812
VP01375
p53883
sg49787
VTumour necrosis factor
p53884
sa(dp53885
g49782
I340
sg49783
I10
sg49784
I62
sg49812
g11
sg49787
VHuman immuno deficiency virus, HRP 2: Histidine Rich Protein 2
p53886
sa(dp53887
g49782
I253
sg49783
I4
sg49784
I39
sg49812
g11
sg49787
VEndothelial leukocyte adhesion molecule
p53888
sa(dp53889
g49782
I787
sg49783
I3
sg49784
I32
sg49812
VP49366
p53890
sg49787
VPlasmodium lactate dehydrogenase
p53891
sasg49779
(lp53892
(dp53893
g49782
I133
sg49783
I2
sg49784
I16
sg49785
VC0024534
p53894
sg49787
VCerebral malaria
p53895
sa(dp53896
g49782
I275
sg49783
I1
sg49784
I8
sg49785
VC0001511
p53897
sg49787
Vadhesion
p53898
sa(dp53899
g49782
I988
sg49783
I1
sg49784
I3
sg49785
VC0206743
p53900
sg49787
VRDT
p53901
sa(dp53902
g49782
I275
sg49783
I1
sg49784
I8
sg49785
VC0001511
p53903
sg49787
Vadhesion
p53904
sa(dp53905
g49782
I1049
sg49783
I1
sg49784
I3
sg49785
VC0026847
p53906
sg49787
VSMA
p53907
sa(dp53908
g49782
I275
sg49783
I1
sg49784
I8
sg49785
VC0001511
p53909
sg49787
Vadhesion
p53910
sa(dp53911
g49782
I50
sg49783
I3
sg49784
I34
sg49785
VC0001175
p53912
sg49787
VAcquired immunodeficiency syndrome
p53913
sa(dp53914
g49782
I142
sg49783
I1
sg49784
I7
sg49785
VC0024530
p53915
sg49787
Vmalaria
p53916
sa(dp53917
g49782
I335
sg49783
I1
sg49784
I3
sg49785
VC0019693
p53918
sg49787
VHIV
p53919
sa(dp53920
g49782
I566
sg49783
I1
sg49784
I7
sg49785
VC0024530
p53921
sg49787
VMalaria
p53922
sa(dp53923
g49782
I1070
sg49783
I1
sg49784
I7
sg49785
VC0002871
p53924
sg49787
Vanaemia
p53925
sa(dp53926
g49782
I932
sg49783
I2
sg49784
I15
sg49785
VC0333516
p53927
sg49787
VTumour necrosis
p53928
sasa(dp53929
g49775
VHS intake increased natriuresis, diuresis, and urinary DA while it decreased cortical NOS I expression (P &lt; 0.05 vs. NS), Nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d) activity in MD (P &lt; 0.001 vs. NS) and cortical nitrates+nitrites (NOx) production (NS 2.04 +/- 0.22 vs. HS 1.28 +/- 0.10 nmol mg protein-1, P &lt; 0.01).
p53930
sg49777
(lp53931
(dp53932
g49782
I125
sg49783
I5
sg49784
I54
sg49812
VP28331
p53933
sg49787
VNicotinamide adenine dinucleotide phosphate diaphorase
p53934
sa(dp53935
g49782
I181
sg49783
I1
sg49784
I7
sg49812
VP30043
p53936
sg49787
VNADPH-d
p53937
sasg49779
(lp53938
sa(dp53939
g49775
VDecreased G6PD activity and, as a result, decreased NADPH level have been associated with diabetic kidney disease, altered nitric oxide production, aldosterone-mediated endothelial dysfunction, and dialysis-associated anemia.
p53940
sg49777
(lp53941
(dp53942
g49782
I10
sg49783
I1
sg49784
I4
sg49812
VP11441
p53943
sg49787
VG6PD
p53944
sasg49779
(lp53945
(dp53946
g49782
I169
sg49783
I2
sg49784
I23
sg49785
VC0856169
p53947
sg49787
Vendothelial dysfunction
p53948
sa(dp53949
g49782
I90
sg49783
I3
sg49784
I23
sg49785
VC0011881
p53950
sg49787
Vdiabetic kidney disease
p53951
sa(dp53952
g49782
I218
sg49783
I1
sg49784
I6
sg49785
VC0002871
p53953
sg49787
Vanemia
p53954
sasa(dp53955
g49775
VGlucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic disorder of red blood cells in human subjects, causing hemolytic anemia linked to impaired nicotinamide adenine dinucleotide phosphate (NADPH) production and imbalanced redox homeostasis in erythrocytes.
p53956
sg49777
(lp53957
(dp53958
g49782
I0
sg49783
I2
sg49784
I33
sg49812
VP49366
p53959
sg49787
VGlucose-6-phosphate dehydrogenase
p53960
sa(dp53961
g49782
I35
sg49783
I1
sg49784
I4
sg49812
VP11441
p53962
sg49787
VG6PD
p53963
sasg49779
(lp53964
(dp53965
g49782
I163
sg49783
I1
sg49784
I8
sg49785
VC0684336
p53966
sg49787
Vimpaired
p53967
sa(dp53968
g49782
I136
sg49783
I2
sg49784
I16
sg49785
VC0002878
p53969
sg49787
Vhemolytic anemia
p53970
sasa(dp53971
g49775
VInterestingly, D2 recovery was accompanied by improvements in photosynthetic parameters (Asat and Fv/Fm) and the NADPH/NADP(+) ratio.
p53972
sg49777
(lp53973
sg49779
(lp53974
(dp53975
g49782
I89
sg49783
I1
sg49784
I4
sg49785
VC1845028
p53976
sg49787
VAsat
p53977
sasa(dp53978
g49775
VHFD significantly enhanced the Asm activity, ceramide production, colocalization of Nlrp3 (Nod-like receptor protein 3) with ASC (apoptosis-associated speck-like protein) or Caspase-1, NADPH-dependent superoxide (O2(*-)) production in glomeruli of Asm(+/+) mice than in control diet-fed mice.
p53979
sg49777
(lp53980
(dp53981
g49782
I31
sg49783
I1
sg49784
I3
sg49812
VP17405
p53982
sg49787
VAsm
p53983
sa(dp53984
g49782
I91
sg49783
I4
sg49784
I27
sg49812
VP54259
p53985
sg49787
VNod-like receptor protein 3
p53986
sa(dp53987
g49782
I185
sg49783
I2
sg49784
I26
sg49812
VP30043
p53988
sg49787
VNADPH-dependent superoxide
p53989
sa(dp53990
g49782
I174
sg49783
I1
sg49784
I9
sg49812
VP29466
p53991
sg49787
VCaspase-1
p53992
sa(dp53993
g49782
I84
sg49783
I1
sg49784
I5
sg49812
VP54259
p53994
sg49787
VNlrp3
p53995
sasg49779
(lp53996
(dp53997
g49782
I91
sg49783
I1
sg49784
I3
sg49785
VC0751781
p53998
sg49787
VNod
p53999
sasa(dp54000
g49775
VWe have studied the effects of growth factors and cytokines on the tumorigenicity and invasion capacity of tumor cells by using regressor and progressor tumor cell lines (ER-1 and ERpP, respectively) derived from an SHR rat mammary adenocarcinoma.
p54001
sg49777
(lp54002
sg49779
(lp54003
(dp54004
g49782
I224
sg49783
I2
sg49784
I22
sg49785
VC0858252
p54005
sg49787
Vmammary adenocarcinoma
p54006
sa(dp54007
g49782
I86
sg49783
I1
sg49784
I8
sg49785
VC2699153
p54008
sg49787
Vinvasion
p54009
sa(dp54010
g49782
I67
sg49783
I1
sg49784
I14
sg49785
VC1519697
p54011
sg49787
Vtumorigenicity
p54012
sa(dp54013
g49782
I67
sg49783
I1
sg49784
I5
sg49785
VC0027651
p54014
sg49787
Vtumor
p54015
sa(dp54016
g49782
I67
sg49783
I1
sg49784
I5
sg49785
VC0027651
p54017
sg49787
Vtumor
p54018
sasa(dp54019
g49775
VWe have studied the effect of growth factors and cytokine on tumorigenesis and invasive capacity of tumor cells by examining a regressor tumor cell line (ER-1) derived from SHR rat mammary adenocarcinoma.
p54020
sg49777
(lp54021
sg49779
(lp54022
(dp54023
g49782
I61
sg49783
I1
sg49784
I5
sg49785
VC0027651
p54024
sg49787
Vtumor
p54025
sa(dp54026
g49782
I181
sg49783
I2
sg49784
I22
sg49785
VC0858252
p54027
sg49787
Vmammary adenocarcinoma
p54028
sa(dp54029
g49782
I61
sg49783
I1
sg49784
I13
sg49785
VC0007621
p54030
sg49787
Vtumorigenesis
p54031
sa(dp54032
g49782
I61
sg49783
I1
sg49784
I5
sg49785
VC0027651
p54033
sg49787
Vtumor
p54034
sasa(dp54035
g49775
VLevel of several proteins including haptoglobin, transthyretin, osteopontin, vitronectin, complement factor H and different classes of immunoglobulins are found to be considerably increased in CSF of higher grades of gliomas.
p54036
sg49777
(lp54037
(dp54038
g49782
I36
sg49783
I1
sg49784
I11
sg49812
VP00738
p54039
sg49787
Vhaptoglobin
p54040
sa(dp54041
g49782
I49
sg49783
I1
sg49784
I13
sg49812
VP02766
p54042
sg49787
Vtransthyretin
p54043
sa(dp54044
g49782
I64
sg49783
I1
sg49784
I11
sg49812
VP10451
p54045
sg49787
Vosteopontin
p54046
sa(dp54047
g49782
I77
sg49783
I1
sg49784
I11
sg49812
VP04004
p54048
sg49787
Vvitronectin
p54049
sa(dp54050
g49782
I135
sg49783
I1
sg49784
I15
sg49812
g11
sg49787
Vimmunoglobulins
p54051
sa(dp54052
g49782
I90
sg49783
I3
sg49784
I19
sg49812
g11
sg49787
Vcomplement factor H
p54053
sasg49779
(lp54054
(dp54055
g49782
I217
sg49783
I1
sg49784
I7
sg49785
VC0017638
p54056
sg49787
Vgliomas
p54057
sasa(dp54058
g49775
VVitronectin is an extracellular matrix protein, the synthesis of which by glioma cells correlates with tumor grade.
p54059
sg49777
(lp54060
(dp54061
g49782
I18
sg49783
I3
sg49784
I28
sg49812
VP55082
p54062
sg49787
Vextracellular matrix protein
p54063
sa(dp54064
g49782
I0
sg49783
I1
sg49784
I11
sg49812
VP04004
p54065
sg49787
VVitronectin
p54066
sasg49779
(lp54067
(dp54068
g49782
I103
sg49783
I1
sg49784
I5
sg49785
VC0027651
p54069
sg49787
Vtumor
p54070
sa(dp54071
g49782
I74
sg49783
I1
sg49784
I6
sg49785
VC0017638
p54072
sg49787
Vglioma
p54073
sasa(dp54074
g49775
VThe current study was designed to investigate the relationship between serum vitronectin levels and clinicopathological characteristics, diagnosis and prognosis in glioma patients.
p54075
sg49777
(lp54076
(dp54077
g49782
I71
sg49783
I2
sg49784
I17
sg49812
VP04004
p54078
sg49787
Vserum vitronectin
p54079
sasg49779
(lp54080
(dp54081
g49782
I164
sg49783
I1
sg49784
I6
sg49785
VC0017638
p54082
sg49787
Vglioma
p54083
sasa(dp54084
g49775
VSerum vitronectin levels were significantly elevated in glioma patients as compared with other groups.
p54085
sg49777
(lp54086
(dp54087
g49782
I0
sg49783
I2
sg49784
I17
sg49812
VP04004
p54088
sg49787
VSerum vitronectin
p54089
sasg49779
(lp54090
(dp54091
g49782
I56
sg49783
I1
sg49784
I6
sg49785
VC0017638
p54092
sg49787
Vglioma
p54093
sasa(dp54094
g49775
VSerum vitronectin levels could significantly distinguish glioma patients from other groups and discriminate high-grade glioma from low-grade glioma.
p54095
sg49777
(lp54096
(dp54097
g49782
I0
sg49783
I2
sg49784
I17
sg49812
VP04004
p54098
sg49787
VSerum vitronectin
p54099
sasg49779
(lp54100
(dp54101
g49782
I57
sg49783
I1
sg49784
I6
sg49785
VC0017638
p54102
sg49787
Vglioma
p54103
sa(dp54104
g49782
I57
sg49783
I1
sg49784
I6
sg49785
VC0017638
p54105
sg49787
Vglioma
p54106
sa(dp54107
g49782
I131
sg49783
I2
sg49784
I16
sg49785
VC1997217
p54108
sg49787
Vlow-grade glioma
p54109
sasa(dp54110
g49775
VSerum vitronectin may be a promising diagnostic and prognostic biomarker that can be detected in the peripheral blood of patients with glioma.
p54111
sg49777
(lp54112
(dp54113
g49782
I6
sg49783
I1
sg49784
I11
sg49812
VP04004
p54114
sg49787
Vvitronectin
p54115
sasg49779
(lp54116
(dp54117
g49782
I135
sg49783
I1
sg49784
I6
sg49785
VC0017638
p54118
sg49787
Vglioma
p54119
sasa(dp54120
g49775
VBioinformatics analysis emphasized key roles of integrin Beta3, hypoxia and vitronectin and their strong correlations with EGFRvIII expression in malignant glioma patient samples in vivo.
p54121
sg49777
(lp54122
(dp54123
g49782
I64
sg49783
I3
sg49784
I23
sg49812
VP04004
p54124
sg49787
Vhypoxia and vitronectin
p54125
sasg49779
(lp54126
(dp54127
g49782
I64
sg49783
I1
sg49784
I7
sg49785
VC0242184
p54128
sg49787
Vhypoxia
p54129
sa(dp54130
g49782
I146
sg49783
I2
sg49784
I16
sg49785
VC0555198
p54131
sg49787
Vmalignant glioma
p54132
sasa(dp54133
g49775
VIn conclusion, we demonstrate that EGFRvIII/integrin Beta3 complexes promote GBM progression and metastasis in the environment of hypoxia and vitronectin-enrichment, and cilengitide may serve as a promising therapeutics for EGFRvIII-positive GBMs.
p54134
sg49777
(lp54135
sg49779
(lp54136
(dp54137
g49782
I77
sg49783
I1
sg49784
I3
sg49785
VC0017636
p54138
sg49787
VGBM
p54139
sa(dp54140
g49782
I130
sg49783
I1
sg49784
I7
sg49785
VC0242184
p54141
sg49787
Vhypoxia
p54142
sa(dp54143
g49782
I97
sg49783
I1
sg49784
I10
sg49785
VC0027627
p54144
sg49787
Vmetastasis
p54145
sasa(dp54146
g49775
VGlioma cells derived from the brain of the (12) V-Ha-Ras transgenic mice were used to study the effect of PI-3 kinase inhibitor SF1126 on activation of AKT and ERK signaling, proliferation, vitronectin mediated migration and changes in the distribution of cortical actin on vitronectin in the glioma cells in vitro.
p54147
sg49777
(lp54148
(dp54149
g49782
I106
sg49783
I2
sg49784
I11
sg49812
g11
sg49787
VPI-3 kinase
p54150
sa(dp54151
g49782
I190
sg49783
I1
sg49784
I11
sg49812
VP04004
p54152
sg49787
Vvitronectin
p54153
sa(dp54154
g49782
I190
sg49783
I1
sg49784
I11
sg49812
VP04004
p54155
sg49787
Vvitronectin
p54156
sa(dp54157
g49782
I152
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VAKT
p54158
sa(dp54159
g49782
I160
sg49783
I1
sg49784
I3
sg49812
VP29323
p54160
sg49787
VERK
p54161
sa(dp54162
g49782
I53
sg49783
I1
sg49784
I3
sg49812
VP01116
p54163
sg49787
VRas
p54164
sasg49779
(lp54165
(dp54166
g49782
I293
sg49783
I1
sg49784
I6
sg49785
VC0017638
p54167
sg49787
Vglioma
p54168
sa(dp54169
g49782
I175
sg49783
I1
sg49784
I13
sg49785
VC0334094
p54170
sg49787
Vproliferation
p54171
sa(dp54172
g49782
I0
sg49783
I1
sg49784
I6
sg49785
VC0017638
p54173
sg49787
VGlioma
p54174
sasa(dp54175
g49775
VMost notably, treatment of SF1126 blocked integrin-dependent migration in transwell and scratch assays and caused a significant change in the organization and distribution of cortical actin on vitronectin in the glioma cells.
p54176
sg49777
(lp54177
(dp54178
g49782
I193
sg49783
I1
sg49784
I11
sg49812
VP04004
p54179
sg49787
Vvitronectin
p54180
sasg49779
(lp54181
(dp54182
g49782
I212
sg49783
I1
sg49784
I6
sg49785
VC0017638
p54183
sg49787
Vglioma
p54184
sasa(dp54185
g49775
VThe hit compound 5.3d inhibited invasion and migration of both GBM stem cells (Gli7 and Gli4) and GBM cancer cell lines (C6, SNB75) on fibronectin, vitronectin, and laminin.
p54186
sg49777
(lp54187
(dp54188
g49782
I148
sg49783
I1
sg49784
I11
sg49812
VP04004
p54189
sg49787
Vvitronectin
p54190
sa(dp54191
g49782
I165
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
Vlaminin
p54192
sa(dp54193
g49782
I88
sg49783
I1
sg49784
I4
sg49812
VP10075
p54194
sg49787
VGli4
p54195
sasg49779
(lp54196
(dp54197
g49782
I63
sg49783
I1
sg49784
I3
sg49785
VC0017636
p54198
sg49787
VGBM
p54199
sa(dp54200
g49782
I32
sg49783
I1
sg49784
I8
sg49785
VC2699153
p54201
sg49787
Vinvasion
p54202
sa(dp54203
g49782
I102
sg49783
I1
sg49784
I6
sg49785
VC0006826
p54204
sg49787
Vcancer
p54205
sa(dp54206
g49782
I63
sg49783
I1
sg49784
I3
sg49785
VC0017636
p54207
sg49787
VGBM
p54208
sasa(dp54209
g49775
VIn this study, efficient downregulation of cathepsin B and uPAR by siRNA treatments significantly reduced glioma cell adhesion to laminin as compared to vitronectin, fibronectin, or collagen I in U251 and 4910 glioma cell lines.
p54210
sg49777
(lp54211
(dp54212
g49782
I130
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
Vlaminin
p54213
sa(dp54214
g49782
I43
sg49783
I2
sg49784
I11
sg49812
VP07858
p54215
sg49787
Vcathepsin B
p54216
sa(dp54217
g49782
I153
sg49783
I1
sg49784
I11
sg49812
VP04004
p54218
sg49787
Vvitronectin
p54219
sasg49779
(lp54220
(dp54221
g49782
I106
sg49783
I1
sg49784
I6
sg49785
VC0017638
p54222
sg49787
Vglioma
p54223
sa(dp54224
g49782
I106
sg49783
I1
sg49784
I6
sg49785
VC0017638
p54225
sg49787
Vglioma
p54226
sa(dp54227
g49782
I118
sg49783
I1
sg49784
I8
sg49785
VC0001511
p54228
sg49787
Vadhesion
p54229
sasa(dp54230
g49775
VNecl-5, a cell surface receptor for vitronectin, is expressed in GBM but not normal brain.
p54231
sg49777
(lp54232
(dp54233
g49782
I36
sg49783
I1
sg49784
I11
sg49812
VP04004
p54234
sg49787
Vvitronectin
p54235
sa(dp54236
g49782
I0
sg49783
I1
sg49784
I6
sg49812
VP15151
p54237
sg49787
VNecl-5
p54238
sasg49779
(lp54239
(dp54240
g49782
I65
sg49783
I1
sg49784
I3
sg49785
VC0017636
p54241
sg49787
VGBM
p54242
sasa(dp54243
g49775
VThese included sudden appearance of tender, erythematous nodular eruptions mimicking ENL, severe constitutional symptoms like high grade fever, malaise, vomiting, epistaxis, joint pain and tenosynovitis simulating Type 2 Lepra Reaction.
p54244
sg49777
(lp54245
sg49779
(lp54246
(dp54247
g49782
I65
sg49783
I1
sg49784
I9
sg49785
VC0302295
p54248
sg49787
Veruptions
p54249
sa(dp54250
g49782
I174
sg49783
I2
sg49784
I10
sg49785
VC0003862
p54251
sg49787
Vjoint pain
p54252
sa(dp54253
g49782
I144
sg49783
I1
sg49784
I7
sg49785
VC0231218
p54254
sg49787
Vmalaise
p54255
sa(dp54256
g49782
I189
sg49783
I1
sg49784
I13
sg49785
VC0039520
p54257
sg49787
Vtenosynovitis
p54258
sa(dp54259
g49782
I214
sg49783
I4
sg49784
I21
sg49785
VC0343466
p54260
sg49787
VType 2 Lepra Reaction
p54261
sa(dp54262
g49782
I153
sg49783
I1
sg49784
I8
sg49785
VC0042963
p54263
sg49787
Vvomiting
p54264
sa(dp54265
g49782
I163
sg49783
I1
sg49784
I9
sg49785
VC0014591
p54266
sg49787
Vepistaxis
p54267
sasa(dp54268
g49775
VOGR1 and TRPC4 are prominently expressed in healthy cerebellar tissue throughout postnatal development and in primary cerebellar medulloblastoma tissues.
p54269
sg49777
(lp54270
(dp54271
g49782
I9
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTRPC4
p54272
sa(dp54273
g49782
I0
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VOGR1
p54274
sasg49779
(lp54275
(dp54276
g49782
I118
sg49783
I2
sg49784
I26
sg49785
VC1862179
p54277
sg49787
Vcerebellar medulloblastoma
p54278
sasa(dp54279
g49775
VOur results suggest that OGR1 enhances expression of TRPC4-containing channels that contribute to enhanced invasion and metastasis of granule precursor-derived human medulloblastoma.
p54280
sg49777
(lp54281
(dp54282
g49782
I25
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VOGR1
p54283
sa(dp54284
g49782
I53
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTRPC4
p54285
sasg49779
(lp54286
(dp54287
g49782
I166
sg49783
I1
sg49784
I15
sg49785
VC0025149
p54288
sg49787
Vmedulloblastoma
p54289
sa(dp54290
g49782
I120
sg49783
I1
sg49784
I10
sg49785
VC0027627
p54291
sg49787
Vmetastasis
p54292
sa(dp54293
g49782
I107
sg49783
I1
sg49784
I8
sg49785
VC2699153
p54294
sg49787
Vinvasion
p54295
sasa(dp54296
g49775
VHere, we report that OGR1 and G2A are expressed in human medulloblastoma tissue and its corresponding neuronal cell line.
p54297
sg49777
(lp54298
(dp54299
g49782
I30
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VG2A
p54300
sa(dp54301
g49782
I21
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VOGR1
p54302
sasg49779
(lp54303
(dp54304
g49782
I57
sg49783
I1
sg49784
I15
sg49785
VC0025149
p54305
sg49787
Vmedulloblastoma
p54306
sasa(dp54307
g49775
VTwo daughters of an affected mother demonstrated symptoms of stage III ADNIV, with posterior uveitis, cystoid macular edema, intraocular fibrosis, retinal neovascularization, retinal degeneration, and cataract.
p54308
sg49777
(lp54309
sg49779
(lp54310
(dp54311
g49782
I175
sg49783
I2
sg49784
I20
sg49785
VC0035304
p54312
sg49787
Vretinal degeneration
p54313
sa(dp54314
g49782
I137
sg49783
I1
sg49784
I8
sg49785
VC0016059
p54315
sg49787
Vfibrosis
p54316
sa(dp54317
g49782
I201
sg49783
I1
sg49784
I8
sg49785
VC0086543
p54318
sg49787
Vcataract
p54319
sa(dp54320
g49782
I102
sg49783
I3
sg49784
I21
sg49785
VC0024440
p54321
sg49787
Vcystoid macular edema
p54322
sa(dp54323
g49782
I83
sg49783
I2
sg49784
I17
sg49785
VC0042167
p54324
sg49787
Vposterior uveitis
p54325
sa(dp54326
g49782
I155
sg49783
I2
sg49784
I27
sg49785
VC0035320
p54327
sg49787
Vneovascularization, retinal
p54328
sasa(dp54329
g49775
VVisual acuity and features of ADNIV, including inflammatory cells, neovascularization, fibrosis, and cystoid macular edema, were reviewed.
p54330
sg49777
(lp54331
sg49779
(lp54332
(dp54333
g49782
I67
sg49783
I1
sg49784
I18
sg49785
VC0027686
p54334
sg49787
Vneovascularization
p54335
sa(dp54336
g49782
I101
sg49783
I3
sg49784
I21
sg49785
VC0024440
p54337
sg49787
Vcystoid macular edema
p54338
sa(dp54339
g49782
I87
sg49783
I1
sg49784
I8
sg49785
VC0016059
p54340
sg49787
Vfibrosis
p54341
sasa(dp54342
g49775
VAutosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is an inherited eye disease characterized by retinal and iris neovascularization, abnormal retinal pigmentation, anterior chamber and vitreous inflammation, cystoid macular edema, vitreous hemorrhage, and traction retinal detachment.
p54343
sg49777
(lp54344
sg49779
(lp54345
(dp54346
g49782
I127
sg49783
I2
sg49784
I23
sg49785
VC0154916
p54347
sg49787
Viris neovascularization
p54348
sa(dp54349
g49782
I227
sg49783
I3
sg49784
I21
sg49785
VC0024440
p54350
sg49787
Vcystoid macular edema
p54351
sa(dp54352
g49782
I250
sg49783
I2
sg49784
I19
sg49785
VC0042909
p54353
sg49787
Vvitreous hemorrhage
p54354
sa(dp54355
g49782
I275
sg49783
I3
sg49784
I27
sg49785
VC0154828
p54356
sg49787
Vtraction retinal detachment
p54357
sa(dp54358
g49782
I86
sg49783
I2
sg49784
I11
sg49785
VC0015397
p54359
sg49787
Veye disease
p54360
sa(dp54361
g49782
I213
sg49783
I1
sg49784
I12
sg49785
VC0021368
p54362
sg49787
Vinflammation
p54363
sasa(dp54364
g49775
VCommon metabolic problems in northeastern Thailand include renal stone disease, distal renal tubular acidosis, hypokalemic periodic paralysis, sudden unexplained nocturnal death and malnutrition-related diabetes mellitus.
p54365
sg49777
(lp54366
sg49779
(lp54367
(dp54368
g49782
I111
sg49783
I3
sg49784
I30
sg49785
VC0238358
p54369
sg49787
Vhypokalemic periodic paralysis
p54370
sa(dp54371
g49782
I203
sg49783
I2
sg49784
I17
sg49785
VC0011849
p54372
sg49787
Vdiabetes mellitus
p54373
sa(dp54374
g49782
I80
sg49783
I4
sg49784
I29
sg49785
VC1704380
p54375
sg49787
Vdistal renal tubular acidosis
p54376
sa(dp54377
g49782
I59
sg49783
I2
sg49784
I11
sg49785
VC0022650
p54378
sg49787
Vrenal stone
p54379
sa(dp54380
g49782
I182
sg49783
I1
sg49784
I12
sg49785
VC0162429
p54381
sg49787
Vmalnutrition
p54382
sasa(dp54383
g49775
VHigh prevalence of CD in presence of anemia and short stature in seropositive FDR in index study indicates need of targeted screening of this subgroup for the presence of CD.CD is unlikely in the absence of HLADQ2/DQ8.
p54384
sg49777
(lp54385
sg49779
(lp54386
(dp54387
g49782
I48
sg49783
I2
sg49784
I13
sg49785
VC0013336
p54388
sg49787
Vshort stature
p54389
sa(dp54390
g49782
I37
sg49783
I1
sg49784
I6
sg49785
VC0002871
p54391
sg49787
Vanemia
p54392
sasa(dp54393
g49775
VThe concurrence of the intracranial multiple primary tumors (MPTs) consisting of acoustic neuroma (AN) and pituitary adenoma is very rare.
p54394
sg49777
(lp54395
sg49779
(lp54396
(dp54397
g49782
I99
sg49783
I1
sg49784
I2
sg49785
VC0027859
p54398
sg49787
VAN
p54399
sa(dp54400
g49782
I81
sg49783
I2
sg49784
I16
sg49785
VC0027859
p54401
sg49787
Vacoustic neuroma
p54402
sa(dp54403
g49782
I45
sg49783
I2
sg49784
I14
sg49785
VC0677930
p54404
sg49787
Vprimary tumors
p54405
sa(dp54406
g49782
I107
sg49783
I2
sg49784
I17
sg49785
VC0032000
p54407
sg49787
Vpituitary adenoma
p54408
sasa(dp54409
g49775
VThirty five cases of MPTs were subdivided into three subtypes, i.e., 1) main duct type, 2) branch duct type and 3) peripheral type (mucinous cystadenoma/cystadenocarcinoma).
p54410
sg49777
(lp54411
(dp54412
g49782
I21
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VMPTs
p54413
sasg49779
(lp54414
(dp54415
g49782
I153
sg49783
I1
sg49784
I18
sg49785
VC0010631
p54416
sg49787
Vcystadenocarcinoma
p54417
sa(dp54418
g49782
I132
sg49783
I2
sg49784
I20
sg49785
VC0010635
p54419
sg49787
Vmucinous cystadenoma
p54420
sasa(dp54421
g49775
VTogether, these data suggest that IL11 could trigger an ER stress response in the placenta, which may contribute to obstetric complications such as preeclampsia.
p54422
sg49777
(lp54423
(dp54424
g49782
I34
sg49783
I1
sg49784
I4
sg49812
VP20809
p54425
sg49787
VIL11
p54426
sasg49779
(lp54427
(dp54428
g49782
I148
sg49783
I1
sg49784
I12
sg49785
VC0032914
p54429
sg49787
Vpreeclampsia
p54430
sasa(dp54431
g49775
VThe relationship between IL-11 and CLS has rarely been reported, especially in patients with colorectal cancer.
p54432
sg49777
(lp54433
(dp54434
g49782
I25
sg49783
I1
sg49784
I5
sg49812
VP20809
p54435
sg49787
VIL-11
p54436
sa(dp54437
g49782
I35
sg49783
I1
sg49784
I3
sg49812
VP51812
p54438
sg49787
VCLS
p54439
sasg49779
(lp54440
(dp54441
g49782
I35
sg49783
I1
sg49784
I3
sg49785
VC0265252
p54442
sg49787
VCLS
p54443
sa(dp54444
g49782
I93
sg49783
I2
sg49784
I17
sg49785
VC1527249
p54445
sg49787
Vcolorectal cancer
p54446
sasa(dp54447
g49775
VAlthough rare, CLS could be a severe side effect after the administration of IL-11.
p54448
sg49777
(lp54449
(dp54450
g49782
I77
sg49783
I1
sg49784
I5
sg49812
VP20809
p54451
sg49787
VIL-11
p54452
sasg49779
(lp54453
(dp54454
g49782
I15
sg49783
I1
sg49784
I3
sg49785
VC0265252
p54455
sg49787
VCLS
p54456
sa(dp54457
g49782
I37
sg49783
I2
sg49784
I11
sg49785
VC0879626
p54458
sg49787
Vside effect
p54459
sasa(dp54460
g49775
VWe describe four cases of the patients with ST-elevation myocardial infarction (STEMI) that were treated with interleukin-11 (IL-11), a cardioprotective cytokine.
p54461
sg49777
(lp54462
(dp54463
g49782
I110
sg49783
I1
sg49784
I14
sg49812
VP20809
p54464
sg49787
Vinterleukin-11
p54465
sa(dp54466
g49782
I126
sg49783
I1
sg49784
I5
sg49812
VP20809
p54467
sg49787
VIL-11
p54468
sasg49779
(lp54469
(dp54470
g49782
I80
sg49783
I1
sg49784
I5
sg49785
VC1536220
p54471
sg49787
VSTEMI
p54472
sa(dp54473
g49782
I44
sg49783
I3
sg49784
I34
sg49785
VC1536220
p54474
sg49787
VST-elevation myocardial infarction
p54475
sasa(dp54476
g49775
VThe protective role of IL-11, an IL-6 family cytokine, has been implicated in ischemia/reperfusion injury (IRI) in the heart and kidney, but its role has not been elucidated in liver IRI.
p54477
sg49777
(lp54478
(dp54479
g49782
I33
sg49783
I3
sg49784
I20
sg49812
VP05231
p54480
sg49787
VIL-6 family cytokine
p54481
sa(dp54482
g49782
I23
sg49783
I1
sg49784
I5
sg49812
VP20809
p54483
sg49787
VIL-11
p54484
sasg49779
(lp54485
(dp54486
g49782
I78
sg49783
I1
sg49784
I8
sg49785
VC0022116
p54487
sg49787
Vischemia
p54488
sasa(dp54489
g49775
VNext, IL-11 was injected intraperitoneally (ip) 1 hour before ischemia.
p54490
sg49777
(lp54491
(dp54492
g49782
I6
sg49783
I1
sg49784
I5
sg49812
VP20809
p54493
sg49787
VIL-11
p54494
sasg49779
(lp54495
(dp54496
g49782
I62
sg49783
I1
sg49784
I8
sg49785
VC0022116
p54497
sg49787
Vischemia
p54498
sasa(dp54499
g49775
VPertussis toxin gene (ptxA-Pr), insertion sequence genes (IS481 and IS1001), adenylate cyclase genes and structural porin and flagellin genes were chosen as targets for PCR, in different studies.
p54500
sg49777
(lp54501
(dp54502
g49782
I77
sg49783
I2
sg49784
I17
sg49812
g11
sg49787
Vadenylate cyclase
p54503
sa(dp54504
g49782
I0
sg49783
I3
sg49784
I20
sg49812
g11
sg49787
VPertussis toxin gene
p54505
sasg49779
(lp54506
(dp54507
g49782
I0
sg49783
I1
sg49784
I9
sg49785
VC0043167
p54508
sg49787
VPertussis
p54509
sasa(dp54510
g49775
VPCR assays targeting insertion sequence IS481 (IS), pertussis toxin ptxA promoter region (PT), and outer membrane porin (PO), or recA (RA) were evaluated in respiratory specimens collected from 4,442 patients with suspected pertussis.
p54511
sg49777
(lp54512
(dp54513
g49782
I52
sg49783
I10
sg49784
I67
sg49812
VP0CE72
p54514
sg49787
Vpertussis toxin ptxA promoter region (PT), and outer membrane porin
p54515
sa(dp54516
g49782
I135
sg49783
I1
sg49784
I2
sg49812
g11
sg49787
VRA
p54517
sa(dp54518
g49782
I129
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VrecA
p54519
sasg49779
(lp54520
(dp54521
g49782
I52
sg49783
I1
sg49784
I9
sg49785
VC0043167
p54522
sg49787
Vpertussis
p54523
sa(dp54524
g49782
I52
sg49783
I1
sg49784
I9
sg49785
VC0043167
p54525
sg49787
Vpertussis
p54526
sasa(dp54527
g49775
VIn this study, we evaluated the role of miR-135b in colorectal cancer (CRC) and its regulatory role for metastasis suppressor-1 (MTSS1) and its mechanisms.
p54528
sg49777
(lp54529
(dp54530
g49782
I40
sg49783
I5
sg49784
I35
sg49812
g11
sg49787
VmiR-135b in colorectal cancer (CRC)
p54531
sa(dp54532
g49782
I129
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VMTSS1
p54533
sa(dp54534
g49782
I104
sg49783
I2
sg49784
I23
sg49812
g11
sg49787
Vmetastasis suppressor-1
p54535
sasg49779
(lp54536
(dp54537
g49782
I52
sg49783
I2
sg49784
I17
sg49785
VC1527249
p54538
sg49787
Vcolorectal cancer
p54539
sa(dp54540
g49782
I71
sg49783
I1
sg49784
I3
sg49785
VC1527249
p54541
sg49787
VCRC
p54542
sa(dp54543
g49782
I104
sg49783
I1
sg49784
I10
sg49785
VC0027627
p54544
sg49787
Vmetastasis
p54545
sasa(dp54546
g49775
VThe levels of miR-135b and MTSS1 gene expression in 35 CRC and corresponding cancer-adjacent tissues, 27 colorectal adenoma, and 16 normal tissue samples were quantified using qRT-PCR and western blot analysis.
p54547
sg49777
(lp54548
(dp54549
g49782
I14
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VmiR-135b
p54550
sa(dp54551
g49782
I27
sg49783
I6
sg49784
I31
sg49812
g11
sg49787
VMTSS1 gene expression in 35 CRC
p54552
sasg49779
(lp54553
(dp54554
g49782
I55
sg49783
I1
sg49784
I3
sg49785
VC1527249
p54555
sg49787
VCRC
p54556
sa(dp54557
g49782
I105
sg49783
I2
sg49784
I18
sg49785
VC1302401
p54558
sg49787
Vcolorectal adenoma
p54559
sa(dp54560
g49782
I77
sg49783
I1
sg49784
I6
sg49785
VC0006826
p54561
sg49787
Vcancer
p54562
sasa(dp54563
g49775
VJahid and colleagues have shown that miR-23a promotes the transition from indolent to invasive colorectal cancer through inhibition of the MTSS1 tumor suppressor.
p54564
sg49777
(lp54565
(dp54566
g49782
I139
sg49783
I3
sg49784
I22
sg49812
g11
sg49787
VMTSS1 tumor suppressor
p54567
sa(dp54568
g49782
I37
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-23a
p54569
sasg49779
(lp54570
(dp54571
g49782
I145
sg49783
I1
sg49784
I5
sg49785
VC0027651
p54572
sg49787
Vtumor
p54573
sa(dp54574
g49782
I95
sg49783
I2
sg49784
I17
sg49785
VC1527249
p54575
sg49787
Vcolorectal cancer
p54576
sa(dp54577
g49782
I58
sg49783
I1
sg49784
I10
sg49785
VC0599156
p54578
sg49787
Vtransition
p54579
sasa(dp54580
g49775
VTo investigate the expression of miR-23a and metastasis suppressor 1 (MTSS1) and their clinical significance in colon carcinoma.
p54581
sg49777
(lp54582
(dp54583
g49782
I33
sg49783
I5
sg49784
I35
sg49812
g11
sg49787
VmiR-23a and metastasis suppressor 1
p54584
sa(dp54585
g49782
I70
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VMTSS1
p54586
sasg49779
(lp54587
(dp54588
g49782
I45
sg49783
I1
sg49784
I10
sg49785
VC0027627
p54589
sg49787
Vmetastasis
p54590
sa(dp54591
g49782
I112
sg49783
I2
sg49784
I15
sg49785
VC0699790
p54592
sg49787
Vcolon carcinoma
p54593
sasa(dp54594
g49775
VThe expression rates of miR-23a and MTSS1 were 87.0% (80/92) and 17.4% (16/92) in colon carcinoma cases, respectively (P &lt; 0.01).
p54595
sg49777
(lp54596
(dp54597
g49782
I24
sg49783
I3
sg49784
I17
sg49812
g11
sg49787
VmiR-23a and MTSS1
p54598
sasg49779
(lp54599
(dp54600
g49782
I82
sg49783
I2
sg49784
I15
sg49785
VC0699790
p54601
sg49787
Vcolon carcinoma
p54602
sasa(dp54603
g49775
VBoth the low expression of MTSS1 and high expression of miR-23a may serve as important biological markers for the malignant phenotypes of colon cancer, such as invasion and metastasis.
p54604
sg49777
(lp54605
(dp54606
g49782
I56
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-23a
p54607
sa(dp54608
g49782
I27
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VMTSS1
p54609
sasg49779
(lp54610
(dp54611
g49782
I160
sg49783
I1
sg49784
I8
sg49785
VC2699153
p54612
sg49787
Vinvasion
p54613
sa(dp54614
g49782
I138
sg49783
I2
sg49784
I12
sg49785
VC0699790
p54615
sg49787
Vcolon cancer
p54616
sa(dp54617
g49782
I173
sg49783
I1
sg49784
I10
sg49785
VC0027627
p54618
sg49787
Vmetastasis
p54619
sasa(dp54620
g49775
VThe aims of this study were to investigate metastasis suppressor 1 (MTSS1) expression in benign and malignant colorectal tissues and to explore its significance in the prognosis of colorectal cancer (CRC) patients.
p54621
sg49777
(lp54622
sg49779
(lp54623
(dp54624
g49782
I200
sg49783
I1
sg49784
I3
sg49785
VC1527249
p54625
sg49787
VCRC
p54626
sa(dp54627
g49782
I43
sg49783
I1
sg49784
I10
sg49785
VC0027627
p54628
sg49787
Vmetastasis
p54629
sa(dp54630
g49782
I181
sg49783
I2
sg49784
I17
sg49785
VC1527249
p54631
sg49787
Vcolorectal cancer
p54632
sasa(dp54633
g49775
VMTSS1 expression was detected by immunohistochemistry in CRC, colorectal adenomatous polyp (precancerous lesion) and normal colorectal tissues.
p54634
sg49777
(lp54635
(dp54636
g49782
I0
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VMTSS1
p54637
sasg49779
(lp54638
(dp54639
g49782
I57
sg49783
I1
sg49784
I3
sg49785
VC1527249
p54640
sg49787
VCRC
p54641
sa(dp54642
g49782
I62
sg49783
I3
sg49784
I28
sg49785
VC3272805
p54643
sg49787
Vcolorectal adenomatous polyp
p54644
sasa(dp54645
g49775
VThese genes (CACNA1C, COL2A1, CPNE8, C3F, C12ORF4, DDX11, GDF11, HOXC8, KCNA1, MDS028, TMEM106C, NR4A1, PHB2, PRICKLE1, Q6ZUQ4, SCN8A, TUBA8 and USP18) are located on porcine chromosome 5 (SSC5) and represent positional and functional candidates for arthrogryposis multiplex congenita (AMC), which maps to SSC5.
p54646
sg49777
(lp54647
(dp54648
g49782
I128
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSCN8A
p54649
sa(dp54650
g49782
I58
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VGDF11
p54651
sa(dp54652
g49782
I87
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VTMEM106C
p54653
sa(dp54654
g49782
I51
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VDDX11
p54655
sa(dp54656
g49782
I110
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VPRICKLE1
p54657
sa(dp54658
g49782
I37
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VC3F
p54659
sa(dp54660
g49782
I104
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VPHB2
p54661
sa(dp54662
g49782
I97
sg49783
I1
sg49784
I5
sg49812
VP22736
p54663
sg49787
VNR4A1
p54664
sa(dp54665
g49782
I65
sg49783
I1
sg49784
I5
sg49812
VP31273
p54666
sg49787
VHOXC8
p54667
sa(dp54668
g49782
I42
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VC12ORF4
p54669
sa(dp54670
g49782
I30
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCPNE8
p54671
sa(dp54672
g49782
I79
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VMDS028
p54673
sa(dp54674
g49782
I72
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VKCNA1
p54675
sa(dp54676
g49782
I135
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTUBA8
p54677
sa(dp54678
g49782
I145
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VUSP18
p54679
sasg49779
(lp54680
(dp54681
g49782
I250
sg49783
I3
sg49784
I34
sg49785
VC2931264
p54682
sg49787
Varthrogryposis multiplex congenita
p54683
sa(dp54684
g49782
I286
sg49783
I1
sg49784
I3
sg49785
VC2931264
p54685
sg49787
VAMC
p54686
sasa(dp54687
g49775
VIn this study, we tested whether this tolerance is intact in systemic lupus erythematosus-prone (New Zealand Black x SWR)F1 mice (SNF1).
p54688
sg49777
(lp54689
sg49779
(lp54690
(dp54691
g49782
I38
sg49783
I1
sg49784
I9
sg49785
VC0020963
p54692
sg49787
Vtolerance
p54693
sa(dp54694
g49782
I61
sg49783
I3
sg49784
I28
sg49785
VC0024141
p54695
sg49787
Vsystemic lupus erythematosus
p54696
sasa(dp54697
g49775
VThe F1 cross between SWR and NZB mice, SNF1, develops severe immune complex glomerulonephritis, in a similar manner to humans with systemic lupus erythematosus (SLE).
p54698
sg49777
(lp54699
sg49779
(lp54700
(dp54701
g49782
I131
sg49783
I3
sg49784
I28
sg49785
VC0024141
p54702
sg49787
Vsystemic lupus erythematosus
p54703
sa(dp54704
g49782
I61
sg49783
I3
sg49784
I33
sg49785
VC0744421
p54705
sg49787
Vimmune complex glomerulonephritis
p54706
sa(dp54707
g49782
I161
sg49783
I1
sg49784
I3
sg49785
VC0024141
p54708
sg49787
VSLE
p54709
sasa(dp54710
g49775
VExposure to bone morphogenetic protein (BMP)-4 was found to enhance a TrkAhigh/CD15-/CD184- neuroblastoma cellular subset, accompanied by a reduction in doublecortin-positive neuroblasts and of NMYC protein expression in SH-SY5Y cells.
p54711
sg49777
(lp54712
(dp54713
g49782
I79
sg49783
I1
sg49784
I4
sg49812
VP22083
p54714
sg49787
VCD15
p54715
sa(dp54716
g49782
I194
sg49783
I2
sg49784
I12
sg49812
VP04198
p54717
sg49787
VNMYC protein
p54718
sa(dp54719
g49782
I17
sg49783
I3
sg49784
I29
sg49812
VP18075
p54720
sg49787
Vmorphogenetic protein (BMP)-4
p54721
sa(dp54722
g49782
I85
sg49783
I1
sg49784
I5
sg49812
VP61073
p54723
sg49787
VCD184
p54724
sasg49779
(lp54725
(dp54726
g49782
I92
sg49783
I1
sg49784
I13
sg49785
VC0027819
p54727
sg49787
Vneuroblastoma
p54728
sasa(dp54729
g49775
VIn cell-based assays, it is demonstrated that PST3.1a alters the Beta1,6-GlcNAc N-glycans of GBM-initiating cells (GIC) by inhibiting MGAT5 enzymatic activity, resulting in the inhibition of TGFBetaR and FAK signaling associated with doublecortin (DCX) upregulation and increase oligodendrocyte lineage transcription factor 2 (OLIG2) expression.
p54730
sg49777
(lp54731
(dp54732
g49782
I279
sg49783
I5
sg49784
I46
sg49812
g11
sg49787
Voligodendrocyte lineage transcription factor 2
p54733
sa(dp54734
g49782
I234
sg49783
I1
sg49784
I12
sg49812
g11
sg49787
Vdoublecortin
p54735
sa(dp54736
g49782
I327
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VOLIG2
p54737
sa(dp54738
g49782
I204
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VFAK
p54739
sa(dp54740
g49782
I248
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VDCX
p54741
sa(dp54742
g49782
I134
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VMGAT5
p54743
sasg49779
(lp54744
(dp54745
g49782
I93
sg49783
I1
sg49784
I3
sg49785
VC0017636
p54746
sg49787
VGBM
p54747
sasa(dp54748
g49775
VTo assess the expression of Toll-like receptor 3 (TLR-3) and TLR-7 in muscle tissue from patients with polymyositis (PM) and dermatomyositis (DM) and to investigate the function and regulation of TLR-3 in cultured muscle cells.
p54749
sg49777
(lp54750
(dp54751
g49782
I28
sg49783
I3
sg49784
I20
sg49812
g11
sg49787
VToll-like receptor 3
p54752
sa(dp54753
g49782
I50
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTLR-3
p54754
sa(dp54755
g49782
I61
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTLR-7
p54756
sa(dp54757
g49782
I50
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTLR-3
p54758
sasg49779
(lp54759
(dp54760
g49782
I117
sg49783
I1
sg49784
I2
sg49785
VC0085655
p54761
sg49787
VPM
p54762
sa(dp54763
g49782
I142
sg49783
I1
sg49784
I2
sg49785
VC0221056
p54764
sg49787
VDM
p54765
sa(dp54766
g49782
I125
sg49783
I1
sg49784
I15
sg49785
VC0221056
p54767
sg49787
Vdermatomyositis
p54768
sa(dp54769
g49782
I103
sg49783
I1
sg49784
I12
sg49785
VC0085655
p54770
sg49787
Vpolymyositis
p54771
sasa(dp54772
g49775
VWe analyzed the coding sequences and exon-intron boundaries of GLIALCAM, encoding an IgG-like cell adhesion protein, in 81 individuals with Autism Spectrum Disorders, either with or without comorbid epilepsy, paroxysmal EEG and/or macrocephaly, and the PTEN gene in the subsample with macrocephaly.
p54773
sg49777
(lp54774
(dp54775
g49782
I253
sg49783
I2
sg49784
I9
sg49812
VP60484
p54776
sg49787
VPTEN gene
p54777
sa(dp54778
g49782
I63
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VGLIALCAM
p54779
sa(dp54780
g49782
I85
sg49783
I4
sg49784
I30
sg49812
VP01185
p54781
sg49787
VIgG-like cell adhesion protein
p54782
sasg49779
(lp54783
(dp54784
g49782
I231
sg49783
I1
sg49784
I12
sg49785
VC0221355
p54785
sg49787
Vmacrocephaly
p54786
sa(dp54787
g49782
I199
sg49783
I1
sg49784
I8
sg49785
VC0014544
p54788
sg49787
Vepilepsy
p54789
sa(dp54790
g49782
I231
sg49783
I1
sg49784
I12
sg49785
VC0221355
p54791
sg49787
Vmacrocephaly
p54792
sa(dp54793
g49782
I99
sg49783
I1
sg49784
I8
sg49785
VC0001511
p54794
sg49787
Vadhesion
p54795
sa(dp54796
g49782
I140
sg49783
I3
sg49784
I25
sg49785
VC1510586
p54797
sg49787
VAutism Spectrum Disorders
p54798
sasa(dp54799
g49775
VWhilst we detected in GLIALCAM several single nucleotide variants without clear pathogenic effects, we found a novel PTEN heterozygous frameshift mutation in one case with "extreme" macrocephaly, autism, intellectual disability and seizures.
p54800
sg49777
(lp54801
(dp54802
g49782
I117
sg49783
I1
sg49784
I4
sg49812
VP60484
p54803
sg49787
VPTEN
p54804
sasg49779
(lp54805
(dp54806
g49782
I232
sg49783
I1
sg49784
I8
sg49785
VC0036572
p54807
sg49787
Vseizures
p54808
sa(dp54809
g49782
I182
sg49783
I1
sg49784
I12
sg49785
VC0221355
p54810
sg49787
Vmacrocephaly
p54811
sa(dp54812
g49782
I135
sg49783
I2
sg49784
I19
sg49785
VC0079380
p54813
sg49787
Vframeshift mutation
p54814
sa(dp54815
g49782
I196
sg49783
I1
sg49784
I6
sg49785
VC0004352
p54816
sg49787
Vautism
p54817
sa(dp54818
g49782
I204
sg49783
I2
sg49784
I23
sg49785
VC0025362
p54819
sg49787
Vintellectual disability
p54820
sasa(dp54821
g49775
VIn other families with dominant HEPACAM mutations, patients had macrocephaly and mental retardation with or without autism.
p54822
sg49777
(lp54823
sg49779
(lp54824
(dp54825
g49782
I64
sg49783
I1
sg49784
I12
sg49785
VC0221355
p54826
sg49787
Vmacrocephaly
p54827
sa(dp54828
g49782
I81
sg49783
I2
sg49784
I18
sg49785
VC0025362
p54829
sg49787
Vmental retardation
p54830
sa(dp54831
g49782
I116
sg49783
I1
sg49784
I6
sg49785
VC0004352
p54832
sg49787
Vautism
p54833
sasa(dp54834
g49775
VDominant HEPACAM mutations can cause either macrocephaly and mental retardation with or without autism or benign familial macrocephaly.
p54835
sg49777
(lp54836
sg49779
(lp54837
(dp54838
g49782
I106
sg49783
I3
sg49784
I28
sg49785
VC0220690
p54839
sg49787
Vbenign familial macrocephaly
p54840
sa(dp54841
g49782
I96
sg49783
I1
sg49784
I6
sg49785
VC0004352
p54842
sg49787
Vautism
p54843
sa(dp54844
g49782
I61
sg49783
I2
sg49784
I18
sg49785
VC0025362
p54845
sg49787
Vmental retardation
p54846
sa(dp54847
g49782
I44
sg49783
I1
sg49784
I12
sg49785
VC0221355
p54848
sg49787
Vmacrocephaly
p54849
sasa(dp54850
g49775
VB AaHHoe NccneAoBaHNe BownN 59 AeTeN c ANcoyHKmyNeN wyHTNpyhweN cNcTeMbl B Bo3pacTe oT 1 roAa Ao 14 neT, npoxoANBwNx ne4eHNe B OeAepanbHoM myeHTpe HeNpoxNpyprNN (HoBocNbNpcK) c 2014 no 2016 r. KpNTepNN BKnh4eHNR B NccneAoBaHNe: 1) Bo3pacT Ha MoMeHT obcneAoBaHNR cTapwe 1 roAa; 2) NMnnaHTamyNR wyHTNpyhweN cNcTeMbl B nepBble 12 Mec XN3HN.
p54851
sg49777
(lp54852
sg49779
(lp54853
sa(dp54854
g49775
VThus, myocyte autonomous inhibition of PKCalpha protects the adult heart from decompensation and dilated cardiomyopathy after infarction injury in association with a primary enhancement in contractility.
p54855
sg49777
(lp54856
(dp54857
g49782
I39
sg49783
I1
sg49784
I8
sg49812
VP17252
p54858
sg49787
VPKCalpha
p54859
sasg49779
(lp54860
(dp54861
g49782
I97
sg49783
I2
sg49784
I22
sg49785
VC0007193
p54862
sg49787
Vdilated cardiomyopathy
p54863
sa(dp54864
g49782
I126
sg49783
I1
sg49784
I10
sg49785
VC0021308
p54865
sg49787
Vinfarction
p54866
sasa(dp54867
g49775
VHypercontractility caused by Prkca deletion protects against heart failure induced by pressure overload, and against dilated cardiomyopathy induced by deleting the gene encoding muscle LIM protein (Csrp3).
p54868
sg49777
(lp54869
(dp54870
g49782
I198
sg49783
I1
sg49784
I5
sg49812
VP50461
p54871
sg49787
VCsrp3
p54872
sa(dp54873
g49782
I164
sg49783
I5
sg49784
I32
sg49812
VP50461
p54874
sg49787
Vgene encoding muscle LIM protein
p54875
sasg49779
(lp54876
(dp54877
g49782
I61
sg49783
I2
sg49784
I13
sg49785
VC0018802
p54878
sg49787
Vheart failure
p54879
sa(dp54880
g49782
I117
sg49783
I2
sg49784
I22
sg49785
VC0007193
p54881
sg49787
Vdilated cardiomyopathy
p54882
sasa(dp54883
g49775
VDeletion of Prkca also rescues cardiomyopathy associated with overexpression of PP-1.
p54884
sg49777
(lp54885
(dp54886
g49782
I80
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VPP-1
p54887
sasg49779
(lp54888
(dp54889
g49782
I31
sg49783
I1
sg49784
I14
sg49785
VC0878544
p54890
sg49787
Vcardiomyopathy
p54891
sasa(dp54892
g49775
VPD-L1 staining was detected in 80% of anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma and follicular dendritic cell sarcoma, 75% of nodular lymphocyte predominant Hodgkin lymphoma, 53% of primary mediastinal large B-cell lymphoma, 39% of extranodal NK/T cell lymphoma, 26% of peripheral T-cell lymphoma, 10% of diffuse large B-cell lymphoma and very rare examples of mantle, marginal zone and small lymphocytic lymphomas.
p54893
sg49777
(lp54894
sg49779
(lp54895
(dp54896
g49782
I109
sg49783
I4
sg49784
I33
sg49785
VC1260325
p54897
sg49787
Vfollicular dendritic cell sarcoma
p54898
sa(dp54899
g49782
I330
sg49783
I4
sg49784
I29
sg49785
VC0079744
p54900
sg49787
Vdiffuse large B-cell lymphoma
p54901
sa(dp54902
g49782
I271
sg49783
I3
sg49784
I15
sg49785
VC0079772
p54903
sg49787
VT cell lymphoma
p54904
sa(dp54905
g49782
I295
sg49783
I3
sg49784
I26
sg49785
VC0079774
p54906
sg49787
Vperipheral T-cell lymphoma
p54907
sa(dp54908
g49782
I207
sg49783
I5
sg49784
I41
sg49785
VC0855152
p54909
sg49787
Vprimary mediastinal large B-cell lymphoma
p54910
sa(dp54911
g49782
I412
sg49783
I3
sg49784
I27
sg49785
VC0023434
p54912
sg49787
Vsmall lymphocytic lymphomas
p54913
sa(dp54914
g49782
I151
sg49783
I5
sg49784
I47
sg49785
VC1334968
p54915
sg49787
Vnodular lymphocyte predominant Hodgkin lymphoma
p54916
sa(dp54917
g49782
I70
sg49783
I3
sg49784
I34
sg49785
VC0020981
p54918
sg49787
Vangioimmunoblastic T-cell lymphoma
p54919
sa(dp54920
g49782
I38
sg49783
I4
sg49784
I30
sg49785
VC0206180
p54921
sg49787
Vanaplastic large cell lymphoma
p54922
sasa(dp54923
g49775
VPD-L1 also showed stronger expression in ALK+ ALCL compared with ALK- ALCL, suggesting an additional role of C/EBPBeta in ALK+ ALCL in generating an immunosuppressive environment.
p54924
sg49777
(lp54925
(dp54926
g49782
I41
sg49783
I2
sg49784
I9
sg49812
g11
sg49787
VALK+ ALCL
p54927
sa(dp54928
g49782
I65
sg49783
I2
sg49784
I9
sg49812
g11
sg49787
VALK- ALCL
p54929
sasg49779
(lp54930
(dp54931
g49782
I46
sg49783
I1
sg49784
I4
sg49785
VC0206180
p54932
sg49787
VALCL
p54933
sa(dp54934
g49782
I46
sg49783
I1
sg49784
I4
sg49785
VC0206180
p54935
sg49787
VALCL
p54936
sa(dp54937
g49782
I46
sg49783
I1
sg49784
I4
sg49785
VC0206180
p54938
sg49787
VALCL
p54939
sasa(dp54940
g49775
VIn conclusion, surface antigen expression profiling demonstrates that C/EBPBeta plays a critical role in the activation state of ALK+ ALCL cells and reveals CD147 and PD-L1 as important downstream targets.
p54941
sg49777
(lp54942
(dp54943
g49782
I157
sg49783
I1
sg49784
I5
sg49812
VP35613
p54944
sg49787
VCD147
p54945
sasg49779
(lp54946
(dp54947
g49782
I134
sg49783
I1
sg49784
I4
sg49785
VC0206180
p54948
sg49787
VALCL
p54949
sasa(dp54950
g49775
VAlso, the neoplastic cells of classical Hodgkin lymphoma, anaplastic large cell lymphoma, schwannoma, thymoma, and squamous cell carcinoma of various sites frequently expressed PD-L1.
p54951
sg49777
(lp54952
sg49779
(lp54953
(dp54954
g49782
I58
sg49783
I4
sg49784
I30
sg49785
VC0206180
p54955
sg49787
Vanaplastic large cell lymphoma
p54956
sa(dp54957
g49782
I102
sg49783
I1
sg49784
I7
sg49785
VC0040100
p54958
sg49787
Vthymoma
p54959
sa(dp54960
g49782
I30
sg49783
I3
sg49784
I26
sg49785
VC1333064
p54961
sg49787
Vclassical Hodgkin lymphoma
p54962
sa(dp54963
g49782
I115
sg49783
I3
sg49784
I23
sg49785
VC0007137
p54964
sg49787
Vsquamous cell carcinoma
p54965
sa(dp54966
g49782
I90
sg49783
I1
sg49784
I10
sg49785
VC0027809
p54967
sg49787
Vschwannoma
p54968
sasa(dp54969
g49775
VThese unique features, which are strictly dependent on NPM-ALK activity and expression, include perpetual cell growth, proliferation, and survival; activation of the key signal transduction pathways STAT3 and mTORC1; and expression of CD30 (the hallmark of anaplastic large-cell lymphoma) and of immunosuppressive cytokine IL-10 and cell-surface protein PD-L1/CD274.
p54970
sg49777
(lp54971
(dp54972
g49782
I59
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VALK
p54973
sa(dp54974
g49782
I360
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCD274
p54975
sa(dp54976
g49782
I55
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VNPM
p54977
sa(dp54978
g49782
I235
sg49783
I1
sg49784
I4
sg49812
VP28908
p54979
sg49787
VCD30
p54980
sa(dp54981
g49782
I199
sg49783
I1
sg49784
I5
sg49812
VP40763
p54982
sg49787
VSTAT3
p54983
sasg49779
(lp54984
(dp54985
g49782
I119
sg49783
I1
sg49784
I13
sg49785
VC0334094
p54986
sg49787
Vproliferation
p54987
sa(dp54988
g49782
I257
sg49783
I3
sg49784
I30
sg49785
VC0206180
p54989
sg49787
Vanaplastic large-cell lymphoma
p54990
sasa(dp54991
g49775
VPD-L1 was expressed uniformly by anaplastic large cell lymphoma (ALCL) cell lines, but rarely in B-cell NHL, confined to a subset of diffuse large B-cell lymphomas (DLBCL) with activated B-cell features (3 of 28 cell lines and 24% of primary DLBCL).
p54992
sg49777
(lp54993
sg49779
(lp54994
(dp54995
g49782
I147
sg49783
I2
sg49784
I16
sg49785
VC0079731
p54996
sg49787
VB-cell lymphomas
p54997
sa(dp54998
g49782
I104
sg49783
I1
sg49784
I3
sg49785
VC0024305
p54999
sg49787
VNHL
p55000
sa(dp55001
g49782
I65
sg49783
I1
sg49784
I4
sg49785
VC0206180
p55002
sg49787
VALCL
p55003
sa(dp55004
g49782
I33
sg49783
I4
sg49784
I30
sg49785
VC0206180
p55005
sg49787
Vanaplastic large cell lymphoma
p55006
sasa(dp55007
g49775
VAnti-PD-L1 blocking antibody boosted proliferation and IFN-Gamma secretion by allogeneic T cells responding to ALCL and DLBCL cells.
p55008
sg49777
(lp55009
(dp55010
g49782
I55
sg49783
I1
sg49784
I9
sg49812
VP01579
p55011
sg49787
VIFN-Gamma
p55012
sasg49779
(lp55013
(dp55014
g49782
I111
sg49783
I1
sg49784
I4
sg49785
VC0206180
p55015
sg49787
VALCL
p55016
sa(dp55017
g49782
I11
sg49783
I1
sg49784
I8
sg49785
VC0233660
p55018
sg49787
Vblocking
p55019
sa(dp55020
g49782
I37
sg49783
I1
sg49784
I13
sg49785
VC0334094
p55021
sg49787
Vproliferation
p55022
sasa(dp55023
g49775
VIn autologous cultures of primary ALCL and DLBCL, PD-L1 blockade enhanced secretion of inflammatory cytokines IFN-Gamma, granulocyte macrophage colony-stimulating factor, interleukin (IL)-1, IL-6, IL-8, IL-13, TNF-Alfa, and macrophage inflammatory protein-1Alfa.
p55024
sg49777
(lp55025
(dp55026
g49782
I100
sg49783
I2
sg49784
I19
sg49812
VP01579
p55027
sg49787
Vcytokines IFN-Gamma
p55028
sa(dp55029
g49782
I203
sg49783
I1
sg49784
I5
sg49812
VP35225
p55030
sg49787
VIL-13
p55031
sa(dp55032
g49782
I210
sg49783
I1
sg49784
I8
sg49812
VP01375
p55033
sg49787
VTNF-Alfa
p55034
sa(dp55035
g49782
I121
sg49783
I4
sg49784
I48
sg49812
VP04141
p55036
sg49787
Vgranulocyte macrophage colony-stimulating factor
p55037
sa(dp55038
g49782
I171
sg49783
I2
sg49784
I18
sg49812
VP60568
p55039
sg49787
Vinterleukin (IL)-1
p55040
sa(dp55041
g49782
I191
sg49783
I1
sg49784
I4
sg49812
VP05231
p55042
sg49787
VIL-6
p55043
sasg49779
(lp55044
(dp55045
g49782
I34
sg49783
I1
sg49784
I4
sg49785
VC0206180
p55046
sg49787
VALCL
p55047
sasa(dp55048
g49775
VWe examined B7-H1 expression in anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma (HL) and found that it was constitutively expressed in both clinical samples and cell lines.
p55049
sg49777
(lp55050
(dp55051
g49782
I12
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VB7-H1
p55052
sasg49779
(lp55053
(dp55054
g49782
I92
sg49783
I1
sg49784
I2
sg49785
VC0019829
p55055
sg49787
VHL
p55056
sa(dp55057
g49782
I74
sg49783
I2
sg49784
I16
sg49785
VC0019829
p55058
sg49787
VHodgkin lymphoma
p55059
sa(dp55060
g49782
I32
sg49783
I4
sg49784
I30
sg49785
VC0206180
p55061
sg49787
Vanaplastic large cell lymphoma
p55062
sa(dp55063
g49782
I64
sg49783
I1
sg49784
I4
sg49785
VC0206180
p55064
sg49787
VALCL
p55065
sasa(dp55066
g49775
VIn anaplastic lymphoma kinase-positive (ALK(+)) ALCL cells, B7-H1 expression was suppressed by the blocking of extracellular signal-regulated kinase (ERK) signaling and upregulated by the augmentation of ERK activity by phorbol 13-myristate 12-acetate stimulation, suggesting that B7-H1 expression is regulated by ERK signaling pathway in ALCL.
p55067
sg49777
(lp55068
(dp55069
g49782
I150
sg49783
I1
sg49784
I3
sg49812
VP29323
p55070
sg49787
VERK
p55071
sa(dp55072
g49782
I60
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VB7-H1
p55073
sa(dp55074
g49782
I111
sg49783
I3
sg49784
I37
sg49812
VP53779
p55075
sg49787
Vextracellular signal-regulated kinase
p55076
sa(dp55077
g49782
I150
sg49783
I1
sg49784
I3
sg49812
VP29323
p55078
sg49787
VERK
p55079
sa(dp55080
g49782
I150
sg49783
I1
sg49784
I3
sg49812
VP29323
p55081
sg49787
VERK
p55082
sa(dp55083
g49782
I60
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VB7-H1
p55084
sasg49779
(lp55085
(dp55086
g49782
I48
sg49783
I1
sg49784
I4
sg49785
VC0206180
p55087
sg49787
VALCL
p55088
sa(dp55089
g49782
I99
sg49783
I1
sg49784
I8
sg49785
VC0233660
p55090
sg49787
Vblocking
p55091
sa(dp55092
g49782
I48
sg49783
I1
sg49784
I4
sg49785
VC0206180
p55093
sg49787
VALCL
p55094
sa(dp55095
g49782
I3
sg49783
I2
sg49784
I19
sg49785
VC1321546
p55096
sg49787
Vanaplastic lymphoma
p55097
sasa(dp55098
g49775
VERK is one of the downstream mediators of nucleophosmin (NPM)/ALK signaling in ALK(+)ALCL, and pharmacological inhibition of ALK was shown to dephosphorylate ERK and down-regulate B7-H1.
p55099
sg49777
(lp55100
(dp55101
g49782
I62
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VALK
p55102
sa(dp55103
g49782
I62
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VALK
p55104
sa(dp55105
g49782
I0
sg49783
I1
sg49784
I3
sg49812
VP29323
p55106
sg49787
VERK
p55107
sa(dp55108
g49782
I180
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VB7-H1
p55109
sa(dp55110
g49782
I0
sg49783
I1
sg49784
I3
sg49812
VP29323
p55111
sg49787
VERK
p55112
sasg49779
(lp55113
(dp55114
g49782
I85
sg49783
I1
sg49784
I4
sg49785
VC0206180
p55115
sg49787
VALCL
p55116
sasa(dp55117
g49775
VThe involvement of NPM/ALK in B7-H1 expression was also demonstrated by introducing the construct into human non-ALCL lymphoid cell lines, which resulted in B7-H1 expression.
p55118
sg49777
(lp55119
(dp55120
g49782
I30
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VB7-H1
p55121
sa(dp55122
g49782
I30
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VB7-H1
p55123
sa(dp55124
g49782
I19
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VNPM
p55125
sa(dp55126
g49782
I23
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VALK
p55127
sasg49779
(lp55128
(dp55129
g49782
I113
sg49783
I1
sg49784
I4
sg49785
VC0206180
p55130
sg49787
VALCL
p55131
sasa(dp55132
g49775
VThese results suggest that B7-H1 expression is controlled by common ERK signaling pathways in ALCL and HL cells.
p55133
sg49777
(lp55134
(dp55135
g49782
I68
sg49783
I1
sg49784
I3
sg49812
VP29323
p55136
sg49787
VERK
p55137
sa(dp55138
g49782
I27
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VB7-H1
p55139
sasg49779
(lp55140
(dp55141
g49782
I94
sg49783
I1
sg49784
I4
sg49785
VC0206180
p55142
sg49787
VALCL
p55143
sasa(dp55144
g49775
VThe applicability of clinical genetics in nephrology is due to the fact that many kidney diseases are characterized by genetic mutations (e.g., von-Hippel Lindau syndrome, MYH9 related disorders, Fabry's syndrome, Liddle's and Bartter's Syndrome, and others).
p55145
sg49777
(lp55146
(dp55147
g49782
I172
sg49783
I1
sg49784
I4
sg49812
VP35579
p55148
sg49787
VMYH9
p55149
sasg49779
(lp55150
(dp55151
g49782
I204
sg49783
I2
sg49784
I16
sg49785
VC0221043
p55152
sg49787
Vsyndrome, Liddle
p55153
sa(dp55154
g49782
I227
sg49783
I2
sg49784
I18
sg49785
VC0004775
p55155
sg49787
VBartter's Syndrome
p55156
sa(dp55157
g49782
I82
sg49783
I2
sg49784
I15
sg49785
VC0022658
p55158
sg49787
Vkidney diseases
p55159
sa(dp55160
g49782
I148
sg49783
I3
sg49784
I22
sg49785
VC0019562
p55161
sg49787
VHippel Lindau syndrome
p55162
sasa(dp55163
g49775
VIn this study, we tested the hypothesis that a common single nucleotide polymorphism rs16996677 in the MYH9 gene may contribute to the etiology of DN in type 2 diabetes (T2D) in a Taiwanese population with T2D.
p55164
sg49777
(lp55165
(dp55166
g49782
I103
sg49783
I2
sg49784
I9
sg49812
VP35579
p55167
sg49787
VMYH9 gene
p55168
sasg49779
(lp55169
(dp55170
g49782
I170
sg49783
I1
sg49784
I3
sg49785
VC0011860
p55171
sg49787
VT2D
p55172
sa(dp55173
g49782
I170
sg49783
I1
sg49784
I3
sg49785
VC0011860
p55174
sg49787
VT2D
p55175
sa(dp55176
g49782
I153
sg49783
I3
sg49784
I15
sg49785
VC0011860
p55177
sg49787
Vtype 2 diabetes
p55178
sasa(dp55179
g49775
VIt has been demonstrated that Wnt signaling through the secretion of Wnt inhibitors, such as DKK1, sFRP-2, and sFRP-3, plays a key role in the decreased osteoblast activity associated with multiple myeloma (MM) bone disease.
p55180
sg49777
(lp55181
(dp55182
g49782
I111
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VsFRP-3
p55183
sa(dp55184
g49782
I99
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VsFRP-2
p55185
sa(dp55186
g49782
I93
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VDKK1
p55187
sasg49779
(lp55188
(dp55189
g49782
I211
sg49783
I2
sg49784
I12
sg49785
VC0005940
p55190
sg49787
Vbone disease
p55191
sa(dp55192
g49782
I189
sg49783
I2
sg49784
I16
sg49785
VC0026764
p55193
sg49787
Vmultiple myeloma
p55194
sasa(dp55195
g49775
VThe authors studied the methylation status of CDKN2A, CDKN2B, XAF1, CDH13, JUNB and a panel of soluble Wnt inhibitors including WIF1, DKK3, APC, SFRP1, SFRP2, SFRP4 and SFRP5 by methylation-specific PCR in 31 bone marrow and 21 peripheral blood samples of patients with essential thrombocythaemia.
p55196
sg49777
(lp55197
(dp55198
g49782
I54
sg49783
I1
sg49784
I6
sg49812
VP42772
p55199
sg49787
VCDKN2B
p55200
sa(dp55201
g49782
I62
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VXAF1
p55202
sa(dp55203
g49782
I128
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VWIF1
p55204
sa(dp55205
g49782
I134
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VDKK3
p55206
sa(dp55207
g49782
I159
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSFRP4
p55208
sa(dp55209
g49782
I169
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSFRP5
p55210
sa(dp55211
g49782
I145
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSFRP1
p55212
sa(dp55213
g49782
I140
sg49783
I1
sg49784
I3
sg49812
VP25054
p55214
sg49787
VAPC
p55215
sa(dp55216
g49782
I68
sg49783
I1
sg49784
I5
sg49812
VP55290
p55217
sg49787
VCDH13
p55218
sa(dp55219
g49782
I46
sg49783
I1
sg49784
I6
sg49812
VP42771
p55220
sg49787
VCDKN2A
p55221
sa(dp55222
g49782
I152
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSFRP2
p55223
sa(dp55224
g49782
I75
sg49783
I1
sg49784
I4
sg49812
VP17275
p55225
sg49787
VJUNB
p55226
sasg49779
(lp55227
(dp55228
g49782
I270
sg49783
I2
sg49784
I26
sg49785
VC0040028
p55229
sg49787
Vessential thrombocythaemia
p55230
sa(dp55231
g49782
I140
sg49783
I1
sg49784
I3
sg49785
VC0033036
p55232
sg49787
VAPC
p55233
sasa(dp55234
g49775
VWe studied the activity of Wnt signaling and the methylation status of WIF1, DKK3, APC, SFRP1, SFRP2, SFRP4 and SFRP5 by methylation-specific PCR in myeloma cell lines and primary myeloma samples.
p55235
sg49777
(lp55236
(dp55237
g49782
I71
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VWIF1
p55238
sa(dp55239
g49782
I88
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSFRP1
p55240
sa(dp55241
g49782
I102
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSFRP4
p55242
sa(dp55243
g49782
I77
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VDKK3
p55244
sa(dp55245
g49782
I112
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSFRP5
p55246
sa(dp55247
g49782
I95
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSFRP2
p55248
sa(dp55249
g49782
I83
sg49783
I1
sg49784
I3
sg49812
VP25054
p55250
sg49787
VAPC
p55251
sasg49779
(lp55252
(dp55253
g49782
I149
sg49783
I1
sg49784
I7
sg49785
VC0026764
p55254
sg49787
Vmyeloma
p55255
sa(dp55256
g49782
I149
sg49783
I1
sg49784
I7
sg49785
VC0026764
p55257
sg49787
Vmyeloma
p55258
sa(dp55259
g49782
I83
sg49783
I1
sg49784
I3
sg49785
VC0033036
p55260
sg49787
VAPC
p55261
sasa(dp55262
g49775
VOn the other hand, myeloma cells suppress osteoblast function by the secretion of osteoblast inhibiting factors, e.g., the Wnt inhibitors DKK-1 and sFRP-2.
p55263
sg49777
(lp55264
(dp55265
g49782
I138
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VDKK-1
p55266
sa(dp55267
g49782
I148
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VsFRP-2
p55268
sasg49779
(lp55269
(dp55270
g49782
I19
sg49783
I1
sg49784
I7
sg49785
VC0026764
p55271
sg49787
Vmyeloma
p55272
sasa(dp55273
g49775
VHedgehog signaling is frequently activated in esophageal cancer, gastric cancer and pancreatic cancer due to transcriptional upregulation of Hedgehog ligands and epigenetic silencing of HHIP1/HHIP gene, encoding the Hedgehog inhibitor.
p55274
sg49777
(lp55275
(dp55276
g49782
I192
sg49783
I2
sg49784
I9
sg49812
g11
sg49787
VHHIP gene
p55277
sasg49779
(lp55278
(dp55279
g49782
I65
sg49783
I2
sg49784
I14
sg49785
VC0024623
p55280
sg49787
Vgastric cancer
p55281
sa(dp55282
g49782
I84
sg49783
I2
sg49784
I17
sg49785
VC0235974
p55283
sg49787
Vpancreatic cancer
p55284
sa(dp55285
g49782
I46
sg49783
I2
sg49784
I17
sg49785
VC0014859
p55286
sg49787
Vesophageal cancer
p55287
sasa(dp55288
g49775
VSel-1-like (SEL1L) is a putative tumor suppressor gene that is significantly downregulated in human pancreatic ductal adenocarcinoma (PDA).
p55289
sg49777
(lp55290
(dp55291
g49782
I0
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VSel-1-like
p55292
sa(dp55293
g49782
I12
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSEL1L
p55294
sasg49779
(lp55295
(dp55296
g49782
I134
sg49783
I1
sg49784
I3
sg49785
VC0013274
p55297
sg49787
VPDA
p55298
sa(dp55299
g49782
I33
sg49783
I1
sg49784
I5
sg49785
VC0027651
p55300
sg49787
Vtumor
p55301
sa(dp55302
g49782
I100
sg49783
I3
sg49784
I32
sg49785
VC1335302
p55303
sg49787
Vpancreatic ductal adenocarcinoma
p55304
sasa(dp55305
g49775
VSEL1L is a putative tumor suppressor gene that is frequently down-regulated in pancreatic ductal adenocarcinoma (PDA).
p55306
sg49777
(lp55307
(dp55308
g49782
I0
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSEL1L
p55309
sasg49779
(lp55310
(dp55311
g49782
I20
sg49783
I1
sg49784
I5
sg49785
VC0027651
p55312
sg49787
Vtumor
p55313
sa(dp55314
g49782
I79
sg49783
I3
sg49784
I32
sg49785
VC1335302
p55315
sg49787
Vpancreatic ductal adenocarcinoma
p55316
sa(dp55317
g49782
I113
sg49783
I1
sg49784
I3
sg49785
VC0013274
p55318
sg49787
VPDA
p55319
sasa(dp55320
g49775
VUsing a functional genomic approach, we identified a seven-gene panel (TNC, TFPI, TGFBI, SEL-1L, L1CAM, WWTR1, and CDC42BPA) that was differentially expressed across three different expression platforms, including pancreatic tumor/normal samples.
p55321
sg49777
(lp55322
(dp55323
g49782
I76
sg49783
I1
sg49784
I4
sg49812
VP10646
p55324
sg49787
VTFPI
p55325
sa(dp55326
g49782
I97
sg49783
I1
sg49784
I5
sg49812
VP32004
p55327
sg49787
VL1CAM
p55328
sa(dp55329
g49782
I71
sg49783
I1
sg49784
I3
sg49812
VP63316
p55330
sg49787
VTNC
p55331
sa(dp55332
g49782
I89
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VSEL-1L
p55333
sa(dp55334
g49782
I104
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VWWTR1
p55335
sasg49779
(lp55336
(dp55337
g49782
I214
sg49783
I2
sg49784
I16
sg49785
VC0030297
p55338
sg49787
Vpancreatic tumor
p55339
sasa(dp55340
g49775
VPreviously, it was reported that SEL1L is able to decrease the aggressive behavior of human pancreatic tumor cells both in vitro and in vivo.
p55341
sg49777
(lp55342
(dp55343
g49782
I33
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSEL1L
p55344
sasg49779
(lp55345
(dp55346
g49782
I63
sg49783
I2
sg49784
I19
sg49785
VC0001807
p55347
sg49787
Vaggressive behavior
p55348
sa(dp55349
g49782
I92
sg49783
I2
sg49784
I16
sg49785
VC0030297
p55350
sg49787
Vpancreatic tumor
p55351
sasa(dp55352
g49775
VTo gain insights into the involvement of SEL1L in tumor invasion, we performed gene expression analysis on the pancreatic cancer cell line Suit-2 subjected to two complementary strategies: upregulation and downregulation of SEL1L expression by stable transfection of the entire cDNA under an inducible promoter and by RNA-mediated interference.
p55353
sg49777
(lp55354
(dp55355
g49782
I41
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSEL1L
p55356
sa(dp55357
g49782
I41
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSEL1L
p55358
sasg49779
(lp55359
(dp55360
g49782
I50
sg49783
I1
sg49784
I5
sg49785
VC0027651
p55361
sg49787
Vtumor
p55362
sa(dp55363
g49782
I56
sg49783
I1
sg49784
I8
sg49785
VC2699153
p55364
sg49787
Vinvasion
p55365
sa(dp55366
g49782
I111
sg49783
I2
sg49784
I17
sg49785
VC0235974
p55367
sg49787
Vpancreatic cancer
p55368
sasa(dp55369
g49775
VThe gene SEL1L is involved both in human breast and pancreatic cancer progression.
p55370
sg49777
(lp55371
(dp55372
g49782
I4
sg49783
I2
sg49784
I10
sg49812
g11
sg49787
Vgene SEL1L
p55373
sasg49779
(lp55374
(dp55375
g49782
I63
sg49783
I2
sg49784
I18
sg49785
VC0178874
p55376
sg49787
Vcancer progression
p55377
sasa(dp55378
g49775
VRecent data suggest that SEL1L may play an important role in pancreatic carcinoma, similar to breast cancer, where the expression of SEL1L has been associated with a reduction in both proliferative activity in vitro and clinical tumor aggressiveness.
p55379
sg49777
(lp55380
(dp55381
g49782
I25
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSEL1L
p55382
sa(dp55383
g49782
I25
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSEL1L
p55384
sasg49779
(lp55385
(dp55386
g49782
I94
sg49783
I2
sg49784
I13
sg49785
VC0678222
p55387
sg49787
Vbreast cancer
p55388
sa(dp55389
g49782
I229
sg49783
I1
sg49784
I5
sg49785
VC0027651
p55390
sg49787
Vtumor
p55391
sa(dp55392
g49782
I61
sg49783
I2
sg49784
I20
sg49785
VC0235974
p55393
sg49787
Vpancreatic carcinoma
p55394
sa(dp55395
g49782
I235
sg49783
I1
sg49784
I14
sg49785
VC0001807
p55396
sg49787
Vaggressiveness
p55397
sa(dp55398
g49782
I184
sg49783
I1
sg49784
I13
sg49785
VC0334094
p55399
sg49787
Vproliferative
p55400
sasa(dp55401
g49775
VTo investigate this possibility, we examined the expression of Sel1L in a series of primary pancreatic carcinomas by immunohistochemistry and characterized the effects of Sel1L overexpression both in vitro and in vivo.
p55402
sg49777
(lp55403
(dp55404
g49782
I63
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSel1L
p55405
sa(dp55406
g49782
I63
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSel1L
p55407
sasg49779
(lp55408
(dp55409
g49782
I103
sg49783
I1
sg49784
I10
sg49785
VC0007097
p55410
sg49787
Vcarcinomas
p55411
sasa(dp55412
g49775
VIn 74 pancreatic cancers analysed, 36% lacked Sel1L expression, although there was no significant correlation between the expression of Sel1L and any clinicopathologic parameter, including survival.
p55413
sg49777
(lp55414
(dp55415
g49782
I46
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSel1L
p55416
sa(dp55417
g49782
I46
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSel1L
p55418
sasg49779
(lp55419
(dp55420
g49782
I6
sg49783
I2
sg49784
I18
sg49785
VC0346647
p55421
sg49787
Vpancreatic cancers
p55422
sasa(dp55423
g49775
VOverexpression of SEL1L in stably transfected pancreatic cancer cells caused both a decrease in clonogenicity and anchorage-independent growth as well as a significant increase in the levels of activin A and SMAD4.
p55424
sg49777
(lp55425
(dp55426
g49782
I208
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSMAD4
p55427
sa(dp55428
g49782
I194
sg49783
I2
sg49784
I9
sg49812
VP08476
p55429
sg49787
Vactivin A
p55430
sa(dp55431
g49782
I18
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSEL1L
p55432
sasg49779
(lp55433
(dp55434
g49782
I46
sg49783
I2
sg49784
I17
sg49785
VC0235974
p55435
sg49787
Vpancreatic cancer
p55436
sasa(dp55437
g49775
VThus, it can be hypothesized that Sel1L plays an important function in the growth and aggressiveness of pancreatic carcinoma.
p55438
sg49777
(lp55439
(dp55440
g49782
I34
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSel1L
p55441
sasg49779
(lp55442
(dp55443
g49782
I86
sg49783
I1
sg49784
I14
sg49785
VC0001807
p55444
sg49787
Vaggressiveness
p55445
sa(dp55446
g49782
I104
sg49783
I2
sg49784
I20
sg49785
VC0235974
p55447
sg49787
Vpancreatic carcinoma
p55448
sasa(dp55449
g49775
VLevels of angiogenic markers bFGF, angiogenin and VEGF in EBC significantly discriminated between 17 individuals with newly detected NSCLC versus stable and exacerbated chronic obstructive pulmonary disease (COPD) patients as well as healthy volunteers.
p55450
sg49777
(lp55451
(dp55452
g49782
I29
sg49783
I1
sg49784
I4
sg49812
VP53370
p55453
sg49787
VbFGF
p55454
sa(dp55455
g49782
I35
sg49783
I3
sg49784
I19
sg49812
VP03950
p55456
sg49787
Vangiogenin and VEGF
p55457
sasg49779
(lp55458
(dp55459
g49782
I169
sg49783
I4
sg49784
I37
sg49785
VC0024117
p55460
sg49787
Vchronic obstructive pulmonary disease
p55461
sa(dp55462
g49782
I208
sg49783
I1
sg49784
I4
sg49785
VC0024117
p55463
sg49787
VCOPD
p55464
sa(dp55465
g49782
I133
sg49783
I1
sg49784
I5
sg49785
VC0007131
p55466
sg49787
VNSCLC
p55467
sasa(dp55468
g49775
VHereditary amyloidosis of the Finnish type (HAF, or familial amyloid polyneuropathy type IV) is an autosomal dominant disease that has been described most commonly in the Finnish population but has also been found in some other countries.
p55469
sg49777
(lp55470
sg49779
(lp55471
(dp55472
g49782
I0
sg49783
I2
sg49784
I22
sg49785
VC0206246
p55473
sg49787
VHereditary amyloidosis
p55474
sa(dp55475
g49782
I52
sg49783
I3
sg49784
I31
sg49785
VC0206245
p55476
sg49787
Vfamilial amyloid polyneuropathy
p55477
sasa(dp55478
g49775
VPlasma fibrinogen, FII, FV, FVII, FVIII, FIX, FX, FXI and FXII activity levels and C4BP concentrations were determined in 73 patients with non-metastatic colorectal cancer (48 colon and 25 rectum) and in 67 matched control subjects.
p55479
sg49777
(lp55480
(dp55481
g49782
I34
sg49783
I1
sg49784
I5
sg49812
VP00451
p55482
sg49787
VFVIII
p55483
sa(dp55484
g49782
I7
sg49783
I1
sg49784
I10
sg49812
VP22087
p55485
sg49787
Vfibrinogen
p55486
sa(dp55487
g49782
I58
sg49783
I1
sg49784
I4
sg49812
VP00748
p55488
sg49787
VFXII
p55489
sa(dp55490
g49782
I50
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VFXI
p55491
sa(dp55492
g49782
I41
sg49783
I1
sg49784
I3
sg49812
VP00740
p55493
sg49787
VFIX
p55494
sa(dp55495
g49782
I83
sg49783
I1
sg49784
I4
sg49812
VP04003
p55496
sg49787
VC4BP
p55497
sasg49779
(lp55498
(dp55499
g49782
I143
sg49783
I3
sg49784
I28
sg49785
VC0948380
p55500
sg49787
Vmetastatic colorectal cancer
p55501
sasa(dp55502
g49775
VMean plasma concentrations of fibrinogen (functional and antigen), FVIII, FIX, FV and C4BP were significantly higher in colorectal cancer patients than in control subjects, while FVII and FXII levels were significantly decreased.
p55503
sg49777
(lp55504
(dp55505
g49782
I86
sg49783
I1
sg49784
I4
sg49812
VP04003
p55506
sg49787
VC4BP
p55507
sa(dp55508
g49782
I74
sg49783
I1
sg49784
I3
sg49812
VP00740
p55509
sg49787
VFIX
p55510
sa(dp55511
g49782
I67
sg49783
I1
sg49784
I5
sg49812
VP00451
p55512
sg49787
VFVIII
p55513
sa(dp55514
g49782
I188
sg49783
I1
sg49784
I4
sg49812
VP00748
p55515
sg49787
VFXII
p55516
sa(dp55517
g49782
I30
sg49783
I1
sg49784
I10
sg49812
VP22087
p55518
sg49787
Vfibrinogen
p55519
sasg49779
(lp55520
(dp55521
g49782
I120
sg49783
I2
sg49784
I17
sg49785
VC1527249
p55522
sg49787
Vcolorectal cancer
p55523
sasa(dp55524
g49775
VIn colorectal cancer patients high plasma fibrinogen, FVIII and FIX levels might represent further risk factors for venous thrombotic complications in the immediate post-surgery period, while decreased FVII and FXII concentrations may be an index of intravascular coagulation activation, still in a subclinical phase.
p55525
sg49777
(lp55526
(dp55527
g49782
I42
sg49783
I4
sg49784
I25
sg49812
VP00451
p55528
sg49787
Vfibrinogen, FVIII and FIX
p55529
sa(dp55530
g49782
I211
sg49783
I1
sg49784
I4
sg49812
VP00748
p55531
sg49787
VFXII
p55532
sasg49779
(lp55533
(dp55534
g49782
I3
sg49783
I2
sg49784
I17
sg49785
VC1527249
p55535
sg49787
Vcolorectal cancer
p55536
sasa(dp55537
g49775
VComplications of PPROM include prematurity, chorioamnionitis, neonatal sepsis, limb position defects, respiratory distress syndrome, pulmonary hypoplasia chronic lung disease, periventricular leukomalacia and intraventricular haemorrhage.A number of different sealing techniques have been employed which aim to restore a physical barrier against infection and encourage the re-accumulation of amniotic fluid.
p55538
sg49777
(lp55539
sg49779
(lp55540
(dp55541
g49782
I62
sg49783
I2
sg49784
I15
sg49785
VC0456103
p55542
sg49787
Vneonatal sepsis
p55543
sa(dp55544
g49782
I102
sg49783
I3
sg49784
I29
sg49785
VC0035220
p55545
sg49787
Vrespiratory distress syndrome
p55546
sa(dp55547
g49782
I133
sg49783
I2
sg49784
I20
sg49785
VC0265783
p55548
sg49787
Vpulmonary hypoplasia
p55549
sa(dp55550
g49782
I209
sg49783
I2
sg49784
I28
sg49785
VC0240059
p55551
sg49787
Vintraventricular haemorrhage
p55552
sa(dp55553
g49782
I44
sg49783
I1
sg49784
I16
sg49785
VC0008495
p55554
sg49787
Vchorioamnionitis
p55555
sa(dp55556
g49782
I17
sg49783
I1
sg49784
I5
sg49785
VC0729264
p55557
sg49787
VPPROM
p55558
sa(dp55559
g49782
I154
sg49783
I3
sg49784
I20
sg49785
VC0746102
p55560
sg49787
Vchronic lung disease
p55561
sa(dp55562
g49782
I346
sg49783
I1
sg49784
I9
sg49785
VC0009450
p55563
sg49787
Vinfection
p55564
sa(dp55565
g49782
I176
sg49783
I2
sg49784
I28
sg49785
VC0023529
p55566
sg49787
Vperiventricular leukomalacia
p55567
sasa(dp55568
g49775
VNL infants were unexposed to PPROM or maternal hypertension, had highest requirement for surfactant, did not develop IVH and periventricular leukomalacia (PVL) and none of them were Caucasian.
p55569
sg49777
(lp55570
sg49779
(lp55571
(dp55572
g49782
I29
sg49783
I1
sg49784
I5
sg49785
VC0729264
p55573
sg49787
VPPROM
p55574
sa(dp55575
g49782
I125
sg49783
I2
sg49784
I28
sg49785
VC0023529
p55576
sg49787
Vperiventricular leukomalacia
p55577
sa(dp55578
g49782
I155
sg49783
I1
sg49784
I3
sg49785
VC0023529
p55579
sg49787
VPVL
p55580
sa(dp55581
g49782
I38
sg49783
I2
sg49784
I21
sg49785
VC0565599
p55582
sg49787
Vmaternal hypertension
p55583
sasa(dp55584
g49775
VMolecular analysis indicated that the livers of BDNF mutants fed HFD contained elevated levels of peroxisome proliferator-activated receptor alpha (Pparalpha or Ppara as listed in the MGI Database) and fibroblast growth factor 21 (Fgf21) transcripts compared with WTs.
p55585
sg49777
(lp55586
(dp55587
g49782
I48
sg49783
I2
sg49784
I12
sg49812
g11
sg49787
VBDNF mutants
p55588
sa(dp55589
g49782
I98
sg49783
I4
sg49784
I48
sg49812
g11
sg49787
Vperoxisome proliferator-activated receptor alpha
p55590
sa(dp55591
g49782
I148
sg49783
I1
sg49784
I9
sg49812
g11
sg49787
VPparalpha
p55592
sasg49779
(lp55593
(dp55594
g49782
I264
sg49783
I1
sg49784
I3
sg49785
VC1839736
p55595
sg49787
VWTs
p55596
sasa(dp55597
g49775
VWe measured the cerebrospinal fluid (CSF) and plasma concentrations of interleukin (IL)-1Alfa, IL-1Beta, IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-Alfa, TNF-Beta, interferon (IFN)-Gamma, the IL-1 receptor antagonist, and soluble IL-4 receptor (sIL-4r) by ELISA in 12 patients each with acute, monosymptomatic, idiopathic optic neuritis (ON), ON as part of MS, other attack forms of MS, and in neurological control subjects.
p55598
sg49777
(lp55599
(dp55600
g49782
I105
sg49783
I1
sg49784
I4
sg49812
VP60568
p55601
sg49787
VIL-2
p55602
sa(dp55603
g49782
I95
sg49783
I1
sg49784
I8
sg49812
VP01584
p55604
sg49787
VIL-1Beta
p55605
sa(dp55606
g49782
I117
sg49783
I1
sg49784
I4
sg49812
VP05231
p55607
sg49787
VIL-6
p55608
sa(dp55609
g49782
I164
sg49783
I1
sg49784
I8
sg49812
VP01375
p55610
sg49787
VTNF-Beta
p55611
sa(dp55612
g49782
I153
sg49783
I1
sg49784
I3
sg49812
VP01375
p55613
sg49787
VTNF
p55614
sa(dp55615
g49782
I111
sg49783
I1
sg49784
I4
sg49812
VP05112
p55616
sg49787
VIL-4
p55617
sa(dp55618
g49782
I174
sg49783
I1
sg49784
I10
sg49812
VP01563
p55619
sg49787
Vinterferon
p55620
sa(dp55621
g49782
I255
sg49783
I1
sg49784
I6
sg49812
VP40967
p55622
sg49787
VsIL-4r
p55623
sa(dp55624
g49782
I232
sg49783
I3
sg49784
I21
sg49812
VP40967
p55625
sg49787
Vsoluble IL-4 receptor
p55626
sa(dp55627
g49782
I71
sg49783
I2
sg49784
I22
sg49812
VP60568
p55628
sg49787
Vinterleukin (IL)-1Alfa
p55629
sa(dp55630
g49782
I130
sg49783
I3
sg49784
I21
sg49812
VP01375
p55631
sg49787
Vtumor necrosis factor
p55632
sa(dp55633
g49782
I186
sg49783
I1
sg49784
I3
sg49812
VP01562
p55634
sg49787
VIFN
p55635
sa(dp55636
g49782
I202
sg49783
I2
sg49784
I13
sg49812
g11
sg49787
VIL-1 receptor
p55637
sasg49779
(lp55638
(dp55639
g49782
I348
sg49783
I1
sg49784
I2
sg49785
VC0029134
p55640
sg49787
VON
p55641
sa(dp55642
g49782
I255
sg49783
I1
sg49784
I3
sg49785
VC0333873
p55643
sg49787
VsIL
p55644
sa(dp55645
g49782
I348
sg49783
I1
sg49784
I2
sg49785
VC0029134
p55646
sg49787
VON
p55647
sa(dp55648
g49782
I332
sg49783
I2
sg49784
I14
sg49785
VC0029134
p55649
sg49787
Voptic neuritis
p55650
sa(dp55651
g49782
I130
sg49783
I2
sg49784
I14
sg49785
VC0333516
p55652
sg49787
Vtumor necrosis
p55653
sasa(dp55654
g49775
VWe have reported previously that ocular infection of different strains of mice with recombinant herpes simplex virus 1 (HSV-1) constitutively expressing interleukin-2 (IL-2) provokes central nervous system (CNS) demyelination and optic neuropathy, as determined by changes in visual evoked cortical potentials and pathological changes in the optic nerve and CNS, whereas recombinant viruses expressing IL-4, gamma interferon, IL-12p35, IL-12p40, or IL-12p70 do not induce this neuropathy.
p55655
sg49777
(lp55656
(dp55657
g49782
I168
sg49783
I1
sg49784
I4
sg49812
VP60568
p55658
sg49787
VIL-2
p55659
sa(dp55660
g49782
I153
sg49783
I1
sg49784
I13
sg49812
VP60568
p55661
sg49787
Vinterleukin-2
p55662
sa(dp55663
g49782
I408
sg49783
I2
sg49784
I16
sg49812
VP01579
p55664
sg49787
Vgamma interferon
p55665
sa(dp55666
g49782
I402
sg49783
I1
sg49784
I4
sg49812
VP05112
p55667
sg49787
VIL-4
p55668
sasg49779
(lp55669
(dp55670
g49782
I33
sg49783
I2
sg49784
I16
sg49785
VC0015403
p55671
sg49787
Vocular infection
p55672
sa(dp55673
g49782
I230
sg49783
I2
sg49784
I16
sg49785
VC0029132
p55674
sg49787
Voptic neuropathy
p55675
sa(dp55676
g49782
I236
sg49783
I1
sg49784
I10
sg49785
VC0442874
p55677
sg49787
Vneuropathy
p55678
sa(dp55679
g49782
I96
sg49783
I2
sg49784
I14
sg49785
VC0019348
p55680
sg49787
Vherpes simplex
p55681
sa(dp55682
g49782
I191
sg49783
I1
sg49784
I7
sg49785
VC0027769
p55683
sg49787
Vnervous
p55684
sa(dp55685
g49782
I212
sg49783
I1
sg49784
I13
sg49785
VC0011304
p55686
sg49787
Vdemyelination
p55687
sasa(dp55688
g49775
VThe objective of this study was to detect interleukin-17 (IL-17), interferon-gamma (IFN-gamma), interleukin-4 (IL-4) and forkhead/winged helix transcription factor p3 (Foxp3) protein and gene expression of the optic nerve and to further explore the role of T helper cell subsets such as Th1, Th2, Th17 and Treg in the pathogenesis of optic neuritis in experimental autoimmune encephalomyelitis (EAE).
p55689
sg49777
(lp55690
(dp55691
g49782
I42
sg49783
I1
sg49784
I14
sg49812
VP60568
p55692
sg49787
Vinterleukin-17
p55693
sa(dp55694
g49782
I121
sg49783
I5
sg49784
I45
sg49812
g11
sg49787
Vforkhead/winged helix transcription factor p3
p55695
sa(dp55696
g49782
I58
sg49783
I1
sg49784
I5
sg49812
VP60568
p55697
sg49787
VIL-17
p55698
sa(dp55699
g49782
I168
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VFoxp3
p55700
sa(dp55701
g49782
I84
sg49783
I1
sg49784
I9
sg49812
VP01579
p55702
sg49787
VIFN-gamma
p55703
sa(dp55704
g49782
I96
sg49783
I1
sg49784
I13
sg49812
VP05112
p55705
sg49787
Vinterleukin-4
p55706
sa(dp55707
g49782
I66
sg49783
I1
sg49784
I16
sg49812
VP01579
p55708
sg49787
Vinterferon-gamma
p55709
sa(dp55710
g49782
I111
sg49783
I1
sg49784
I4
sg49812
VP05112
p55711
sg49787
VIL-4
p55712
sasg49779
(lp55713
(dp55714
g49782
I334
sg49783
I2
sg49784
I14
sg49785
VC0029134
p55715
sg49787
Voptic neuritis
p55716
sa(dp55717
g49782
I395
sg49783
I1
sg49784
I3
sg49785
VC0014070
p55718
sg49787
VEAE
p55719
sa(dp55720
g49782
I318
sg49783
I1
sg49784
I12
sg49785
VC0699748
p55721
sg49787
Vpathogenesis
p55722
sa(dp55723
g49782
I365
sg49783
I1
sg49784
I10
sg49785
VC0443146
p55724
sg49787
Vautoimmune
p55725
sa(dp55726
g49782
I376
sg49783
I1
sg49784
I17
sg49785
VC0014070
p55727
sg49787
Vencephalomyelitis
p55728
sasa(dp55729
g49775
VIn MS and optic neuritis, IL-4 mRNA expressing cells predominated, followed by TGF-beta- and IFN-gamma-positive cells.
p55730
sg49777
(lp55731
(dp55732
g49782
I26
sg49783
I2
sg49784
I9
sg49812
VP05112
p55733
sg49787
VIL-4 mRNA
p55734
sa(dp55735
g49782
I93
sg49783
I1
sg49784
I9
sg49812
VP01579
p55736
sg49787
VIFN-gamma
p55737
sa(dp55738
g49782
I79
sg49783
I1
sg49784
I8
sg49812
VP18075
p55739
sg49787
VTGF-beta
p55740
sasg49779
(lp55741
(dp55742
g49782
I10
sg49783
I2
sg49784
I14
sg49785
VC0029134
p55743
sg49787
Voptic neuritis
p55744
sasa(dp55745
g49775
VGKN1, GKN2, and the trefoil factors TFF1 and TFF3 were examined in tissue microarrays from 155 distal gastric adenocarcinomas.
p55746
sg49777
(lp55747
(dp55748
g49782
I36
sg49783
I1
sg49784
I4
sg49812
VP04155
p55749
sg49787
VTFF1
p55750
sa(dp55751
g49782
I6
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VGKN2
p55752
sa(dp55753
g49782
I20
sg49783
I2
sg49784
I15
sg49812
VP19883
p55754
sg49787
Vtrefoil factors
p55755
sa(dp55756
g49782
I45
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTFF3
p55757
sa(dp55758
g49782
I0
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VGKN1
p55759
sasg49779
(lp55760
(dp55761
g49782
I110
sg49783
I1
sg49784
I15
sg49785
VC0001418
p55762
sg49787
Vadenocarcinomas
p55763
sasa(dp55764
g49775
VLoss of GKN1 and GKN2 expression occurs frequently in gastric adenocarcinomas, especially in the diffuse subtype.
p55765
sg49777
(lp55766
(dp55767
g49782
I17
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VGKN2
p55768
sa(dp55769
g49782
I8
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VGKN1
p55770
sasg49779
(lp55771
(dp55772
g49782
I62
sg49783
I1
sg49784
I15
sg49785
VC0001418
p55773
sg49787
Vadenocarcinomas
p55774
sasa(dp55775
g49775
VSince RIs significantly correlate with renal function, they have been proposed to be independent risk factors for CKD progression, besides proteinuria, low GFR and arterial hypertension.
p55776
sg49777
(lp55777
sg49779
(lp55778
(dp55779
g49782
I164
sg49783
I2
sg49784
I21
sg49785
VC0020538
p55780
sg49787
Varterial hypertension
p55781
sasa(dp55782
g49775
VHigh uterine artery Doppler resistance indexes (RIs) are predictive of placental complications of pregnancy, such as preeclampsia, fetal growth restriction, and stillbirth.
p55783
sg49777
(lp55784
sg49779
(lp55785
(dp55786
g49782
I117
sg49783
I1
sg49784
I12
sg49785
VC0032914
p55787
sg49787
Vpreeclampsia
p55788
sa(dp55789
g49782
I131
sg49783
I3
sg49784
I24
sg49785
VC0015934
p55790
sg49787
Vfetal growth restriction
p55791
sa(dp55792
g49782
I161
sg49783
I1
sg49784
I10
sg49785
VC0595939
p55793
sg49787
Vstillbirth
p55794
sa(dp55795
g49782
I81
sg49783
I3
sg49784
I26
sg49785
VC0032962
p55796
sg49787
Vcomplications of pregnancy
p55797
sasa(dp55798
g49775
VPatients with hypertension or diabetes mellitus showed higher RIs (p &lt; 0.05) than those without the ailments.
p55799
sg49777
(lp55800
sg49779
(lp55801
(dp55802
g49782
I30
sg49783
I2
sg49784
I17
sg49785
VC0011849
p55803
sg49787
Vdiabetes mellitus
p55804
sa(dp55805
g49782
I14
sg49783
I1
sg49784
I12
sg49785
VC0020538
p55806
sg49787
Vhypertension
p55807
sasa(dp55808
g49775
VMyelodysplastic syndrome (MDS) and myeloproliferative disorders are rare in children; they are divided into low-grade MDS (refractory cytopenia of childhood [RCC]), advanced MDS (refractory anemia with excess blasts in transformation), and juvenile myelomonocytic leukemia (JMML), each with different characteristics and management strategies.
p55809
sg49777
(lp55810
sg49779
(lp55811
(dp55812
g49782
I274
sg49783
I1
sg49784
I4
sg49785
VC0349639
p55813
sg49787
VJMML
p55814
sa(dp55815
g49782
I35
sg49783
I2
sg49784
I28
sg49785
VC0027022
p55816
sg49787
Vmyeloproliferative disorders
p55817
sa(dp55818
g49782
I123
sg49783
I4
sg49784
I33
sg49785
VC2826323
p55819
sg49787
Vrefractory cytopenia of childhood
p55820
sa(dp55821
g49782
I26
sg49783
I1
sg49784
I3
sg49785
VC0265219
p55822
sg49787
VMDS
p55823
sa(dp55824
g49782
I240
sg49783
I3
sg49784
I32
sg49785
VC0349639
p55825
sg49787
Vjuvenile myelomonocytic leukemia
p55826
sa(dp55827
g49782
I158
sg49783
I1
sg49784
I3
sg49785
VC0007134
p55828
sg49787
VRCC
p55829
sa(dp55830
g49782
I179
sg49783
I7
sg49784
I54
sg49785
VC0280028
p55831
sg49787
Vrefractory anemia with excess blasts in transformation
p55832
sa(dp55833
g49782
I0
sg49783
I2
sg49784
I24
sg49785
VC3463824
p55834
sg49787
VMyelodysplastic syndrome
p55835
sa(dp55836
g49782
I26
sg49783
I1
sg49784
I3
sg49785
VC0265219
p55837
sg49787
VMDS
p55838
sa(dp55839
g49782
I26
sg49783
I1
sg49784
I3
sg49785
VC0265219
p55840
sg49787
VMDS
p55841
sasa(dp55842
g49775
VThus, genetic ablation or pharmacologic inhibition of Shp2 suppresses the leukemogenic effect of Pten loss, yet simultaneously induces severe anemia in mice with Pten deficiency in blood cells.
p55843
sg49777
(lp55844
(dp55845
g49782
I97
sg49783
I1
sg49784
I4
sg49812
VP60484
p55846
sg49787
VPten
p55847
sa(dp55848
g49782
I97
sg49783
I2
sg49784
I9
sg49812
VP60484
p55849
sg49787
VPten loss
p55850
sa(dp55851
g49782
I54
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VShp2
p55852
sasg49779
(lp55853
(dp55854
g49782
I97
sg49783
I2
sg49784
I9
sg49785
VC3272693
p55855
sg49787
VPten loss
p55856
sa(dp55857
g49782
I135
sg49783
I2
sg49784
I13
sg49785
VC0238644
p55858
sg49787
Vsevere anemia
p55859
sasa(dp55860
g49775
VSurprisingly, the Shp2 and Pten double-knockout mice suffered lethal anemia, a phenotype that reveals previously unappreciated cooperative roles of Pten and Shp2 in erythropoiesis.
p55861
sg49777
(lp55862
(dp55863
g49782
I27
sg49783
I1
sg49784
I4
sg49812
VP60484
p55864
sg49787
VPten
p55865
sa(dp55866
g49782
I18
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VShp2
p55867
sa(dp55868
g49782
I148
sg49783
I3
sg49784
I13
sg49812
VP60484
p55869
sg49787
VPten and Shp2
p55870
sasg49779
(lp55871
(dp55872
g49782
I53
sg49783
I1
sg49784
I8
sg49785
VC0683278
p55873
sg49787
Vsuffered
p55874
sa(dp55875
g49782
I69
sg49783
I1
sg49784
I6
sg49785
VC0002871
p55876
sg49787
Vanemia
p55877
sasa(dp55878
g49775
VConsistently, treatment of Pten-deficient mice with a specific Shp2 inhibitor suppressed myeloproliferative neoplasm while causing anemia.
p55879
sg49777
(lp55880
(dp55881
g49782
I63
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VShp2
p55882
sasg49779
(lp55883
(dp55884
g49782
I89
sg49783
I2
sg49784
I27
sg49785
VC1292778
p55885
sg49787
Vmyeloproliferative neoplasm
p55886
sa(dp55887
g49782
I131
sg49783
I1
sg49784
I6
sg49785
VC0002871
p55888
sg49787
Vanemia
p55889
sasa(dp55890
g49775
VInfants with non-metabolic disorders (n = 34); 10 (three neuroblastoma [NBL], three brain tumor, two acute meylogenous leukemia [AML], one rhabdomyosarcoma, and one retinoblastoma) received auto HSCT, and 24 (eight hemophagocytic lymphohistiocytosis [HLH], four juvenile meylomonocytic leukemia [JMML], four Wiscott-Aldrych Syndrome [WAS], three acute lymphoblastic leukemia [ALL], two AML, one severe aplastic anemia [SAA], one chronic granulomatous disease [CGD], and one amegakaryocytic thrombocytopenia) received allo HSCT.
p55891
sg49777
(lp55892
sg49779
(lp55893
(dp55894
g49782
I395
sg49783
I3
sg49784
I22
sg49785
VC1883018
p55895
sg49787
Vsevere aplastic anemia
p55896
sa(dp55897
g49782
I474
sg49783
I2
sg49784
I32
sg49785
VC0398639
p55898
sg49787
Vamegakaryocytic thrombocytopenia
p55899
sa(dp55900
g49782
I215
sg49783
I2
sg49784
I34
sg49785
VC0024291
p55901
sg49787
Vhemophagocytic lymphohistiocytosis
p55902
sa(dp55903
g49782
I324
sg49783
I1
sg49784
I8
sg49785
VC0039082
p55904
sg49787
VSyndrome
p55905
sa(dp55906
g49782
I460
sg49783
I1
sg49784
I3
sg49785
VC0018203
p55907
sg49787
VCGD
p55908
sa(dp55909
g49782
I129
sg49783
I1
sg49784
I3
sg49785
VC0023467
p55910
sg49787
VAML
p55911
sa(dp55912
g49782
I346
sg49783
I3
sg49784
I28
sg49785
VC1961102
p55913
sg49787
Vacute lymphoblastic leukemia
p55914
sa(dp55915
g49782
I139
sg49783
I1
sg49784
I16
sg49785
VC0035412
p55916
sg49787
Vrhabdomyosarcoma
p55917
sa(dp55918
g49782
I17
sg49783
I2
sg49784
I19
sg49785
VC0025517
p55919
sg49787
Vmetabolic disorders
p55920
sa(dp55921
g49782
I119
sg49783
I1
sg49784
I8
sg49785
VC0023418
p55922
sg49787
Vleukemia
p55923
sa(dp55924
g49782
I84
sg49783
I2
sg49784
I11
sg49785
VC0006118
p55925
sg49787
Vbrain tumor
p55926
sa(dp55927
g49782
I119
sg49783
I1
sg49784
I8
sg49785
VC0023418
p55928
sg49787
Vleukemia
p55929
sa(dp55930
g49782
I165
sg49783
I1
sg49784
I14
sg49785
VC0035335
p55931
sg49787
Vretinoblastoma
p55932
sa(dp55933
g49782
I429
sg49783
I3
sg49784
I29
sg49785
VC0018203
p55934
sg49787
Vchronic granulomatous disease
p55935
sa(dp55936
g49782
I129
sg49783
I1
sg49784
I3
sg49785
VC0023467
p55937
sg49787
VAML
p55938
sa(dp55939
g49782
I296
sg49783
I1
sg49784
I4
sg49785
VC0349639
p55940
sg49787
VJMML
p55941
sa(dp55942
g49782
I57
sg49783
I1
sg49784
I13
sg49785
VC0027819
p55943
sg49787
Vneuroblastoma
p55944
sa(dp55945
g49782
I251
sg49783
I1
sg49784
I3
sg49785
VC0024291
p55946
sg49787
VHLH
p55947
sasa(dp55948
g49775
VThe human choroideremia-like (CHML) gene and a locus for Usher syndrome type 2 (USH2) were recently mapped to the 1q31-qter region employing physical mapping and genetic linkage studies, respectively.
p55949
sg49777
(lp55950
(dp55951
g49782
I57
sg49783
I4
sg49784
I21
sg49812
g11
sg49787
VUsher syndrome type 2
p55952
sa(dp55953
g49782
I80
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VUSH2
p55954
sa(dp55955
g49782
I30
sg49783
I1
sg49784
I4
sg49812
VP26374
p55956
sg49787
VCHML
p55957
sa(dp55958
g49782
I10
sg49783
I1
sg49784
I18
sg49812
VP26374
p55959
sg49787
Vchoroideremia-like
p55960
sasg49779
(lp55961
(dp55962
g49782
I57
sg49783
I4
sg49784
I21
sg49785
VC0339534
p55963
sg49787
VUsher syndrome type 2
p55964
sa(dp55965
g49782
I80
sg49783
I1
sg49784
I4
sg49785
VC0339534
p55966
sg49787
VUSH2
p55967
sa(dp55968
g49782
I10
sg49783
I1
sg49784
I13
sg49785
VC0008525
p55969
sg49787
Vchoroideremia
p55970
sasa(dp55971
g49775
VTo investigate a possible role of the CHML gene in the pathogenesis of USH2, we investigated 10 Dutch and 9 Danish USH2 patients for point mutations in the open reading frame of the CHML gene.
p55972
sg49777
(lp55973
(dp55974
g49782
I71
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VUSH2
p55975
sa(dp55976
g49782
I38
sg49783
I2
sg49784
I9
sg49812
VP26374
p55977
sg49787
VCHML gene
p55978
sa(dp55979
g49782
I38
sg49783
I2
sg49784
I9
sg49812
VP26374
p55980
sg49787
VCHML gene
p55981
sasg49779
(lp55982
(dp55983
g49782
I55
sg49783
I1
sg49784
I12
sg49785
VC0699748
p55984
sg49787
Vpathogenesis
p55985
sasa(dp55986
g49775
VThese results suggest that CHML is not involved in the pathogenesis of USH2.
p55987
sg49777
(lp55988
(dp55989
g49782
I27
sg49783
I1
sg49784
I4
sg49812
VP26374
p55990
sg49787
VCHML
p55991
sa(dp55992
g49782
I71
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VUSH2
p55993
sasg49779
(lp55994
(dp55995
g49782
I55
sg49783
I1
sg49784
I12
sg49785
VC0699748
p55996
sg49787
Vpathogenesis
p55997
sasa(dp55998
g49775
VWe hypothesized that the Hrad17 may be expressed in thymoma, especially in invasive thymoma.
p55999
sg49777
(lp56000
(dp56001
g49782
I25
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VHrad17
p56002
sasg49779
(lp56003
(dp56004
g49782
I75
sg49783
I2
sg49784
I16
sg49785
VC0278846
p56005
sg49787
Vinvasive thymoma
p56006
sa(dp56007
g49782
I52
sg49783
I1
sg49784
I7
sg49785
VC0040100
p56008
sg49787
Vthymoma
p56009
sasa(dp56010
g49775
VWe attempted to determine the influence of Hrad17 expression on clinicopathological features for patients with thymoma who had undergone surgery.
p56011
sg49777
(lp56012
(dp56013
g49782
I43
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VHrad17
p56014
sasg49779
(lp56015
(dp56016
g49782
I111
sg49783
I1
sg49784
I7
sg49785
VC0040100
p56017
sg49787
Vthymoma
p56018
sasa(dp56019
g49775
VExpression of Hrad17 messenger ribonucleic acid (RNA) was evaluated by reverse transcription-polymerase chain reaction using a LightCycler in 38 thymomas and 10 adjacent histologically normal thymus samples from patients for whom follow-up data was available.
p56020
sg49777
(lp56021
(dp56022
g49782
I14
sg49783
I2
sg49784
I16
sg49812
g11
sg49787
VHrad17 messenger
p56023
sasg49779
(lp56024
(dp56025
g49782
I145
sg49783
I1
sg49784
I8
sg49785
VC0040100
p56026
sg49787
Vthymomas
p56027
sasa(dp56028
g49775
VNo relationship was seen between Hrad17 gene expression and age, gender, or pathological thymoma subtypes.
p56029
sg49777
(lp56030
(dp56031
g49782
I33
sg49783
I2
sg49784
I11
sg49812
g11
sg49787
VHrad17 gene
p56032
sasg49779
(lp56033
(dp56034
g49782
I89
sg49783
I1
sg49784
I7
sg49785
VC0040100
p56035
sg49787
Vthymoma
p56036
sasa(dp56037
g49775
VHrad17 mRNA expression in invasive thymomas (stage II-IV, 10.067 +/- 5.293) was significantly higher than that in stage I thymomas (5.193 +/- 4.485, p = 0.0168).
p56038
sg49777
(lp56039
(dp56040
g49782
I0
sg49783
I2
sg49784
I11
sg49812
g11
sg49787
VHrad17 mRNA
p56041
sasg49779
(lp56042
(dp56043
g49782
I35
sg49783
I1
sg49784
I8
sg49785
VC0040100
p56044
sg49787
Vthymomas
p56045
sa(dp56046
g49782
I35
sg49783
I1
sg49784
I8
sg49785
VC0040100
p56047
sg49787
Vthymomas
p56048
sasa(dp56049
g49775
VImmunohistochemistry showed that Hrad17 protein was highly expressed in invasive thymoma tumor tissue but not within the normal thymus tissue.
p56050
sg49777
(lp56051
(dp56052
g49782
I33
sg49783
I2
sg49784
I14
sg49812
g11
sg49787
VHrad17 protein
p56053
sasg49779
(lp56054
(dp56055
g49782
I72
sg49783
I2
sg49784
I16
sg49785
VC0278846
p56056
sg49787
Vinvasive thymoma
p56057
sa(dp56058
g49782
I89
sg49783
I1
sg49784
I5
sg49785
VC0027651
p56059
sg49787
Vtumor
p56060
sasa(dp56061
g49775
VHrad17 was highly expressed in invasive thymoma.
p56062
sg49777
(lp56063
(dp56064
g49782
I0
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VHrad17
p56065
sasg49779
(lp56066
(dp56067
g49782
I31
sg49783
I2
sg49784
I16
sg49785
VC0278846
p56068
sg49787
Vinvasive thymoma
p56069
sasa(dp56070
g49775
VIn induced apical periodontitis, osteoblastic expression of SIRT6 was significantly suppressed (P = 0.001) which was associated with significantly elevated levels of LDHA (P = 0.003) and 8-OHdG (P = 0.004) and significantly enhanced recruitment of macrophages (P = 0.004).
p56071
sg49777
(lp56072
(dp56073
g49782
I166
sg49783
I1
sg49784
I4
sg49812
VP00338
p56074
sg49787
VLDHA
p56075
sasg49779
(lp56076
(dp56077
g49782
I233
sg49783
I1
sg49784
I11
sg49785
VC0271510
p56078
sg49787
Vrecruitment
p56079
sa(dp56080
g49782
I11
sg49783
I2
sg49784
I20
sg49785
VC0031030
p56081
sg49787
Vapical periodontitis
p56082
sasa(dp56083
g49775
VThe main objective of this work was to evaluate a new therapeutic strategy against a colitis-related colorectal cancer in vivo and in vitro by targeting mTOR-signaling and lactate dehydrogenase A.
p56084
sg49777
(lp56085
(dp56086
g49782
I85
sg49783
I3
sg49784
I33
sg49812
VP31749
p56087
sg49787
Vcolitis-related colorectal cancer
p56088
sa(dp56089
g49782
I153
sg49783
I1
sg49784
I4
sg49812
VP42345
p56090
sg49787
VmTOR
p56091
sa(dp56092
g49782
I172
sg49783
I3
sg49784
I23
sg49812
VP49366
p56093
sg49787
Vlactate dehydrogenase A
p56094
sasg49779
(lp56095
(dp56096
g49782
I85
sg49783
I1
sg49784
I7
sg49785
VC0009319
p56097
sg49787
Vcolitis
p56098
sa(dp56099
g49782
I101
sg49783
I2
sg49784
I17
sg49785
VC1527249
p56100
sg49787
Vcolorectal cancer
p56101
sasa(dp56102
g49775
VThere were striking laboratory abnormalities in the groups diagnosed with toxic hepatitis (mean peak values: AST 775 +/- 464 U/L, ALT 400 +/- 447 U/L, ALP 767 +/- 408 U/L, LDH 1,469 +/- 779 U/L).
p56103
sg49777
(lp56104
(dp56105
g49782
I172
sg49783
I2
sg49784
I5
sg49812
g11
sg49787
VLDH 1
p56106
sasg49779
(lp56107
(dp56108
g49782
I80
sg49783
I1
sg49784
I9
sg49785
VC0019159
p56109
sg49787
Vhepatitis
p56110
sasa(dp56111
g49775
VTo determine Lactate Dehydrogenase Activity (LDHA) in whole saliva in individuals with periodontal disease and the effect of ultrasonic scaling on this enzyme activity.
p56112
sg49777
(lp56113
(dp56114
g49782
I45
sg49783
I1
sg49784
I4
sg49812
VP00338
p56115
sg49787
VLDHA
p56116
sa(dp56117
g49782
I13
sg49783
I3
sg49784
I30
sg49812
VP00338
p56118
sg49787
VLactate Dehydrogenase Activity
p56119
sasg49779
(lp56120
(dp56121
g49782
I87
sg49783
I2
sg49784
I19
sg49785
VC0031090
p56122
sg49787
Vperiodontal disease
p56123
sasa(dp56124
g49775
VLDH-1 activity was detected to be significantly higher in the sterile cirrhotic ascites when compared with spontaneous bacterial peritonitis, malignant ascites, tuberculous ascites and congestive heart failure-related ascites.
p56125
sg49777
(lp56126
(dp56127
g49782
I0
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VLDH-1
p56128
sasg49779
(lp56129
(dp56130
g49782
I107
sg49783
I3
sg49784
I33
sg49785
VC0275551
p56131
sg49787
Vspontaneous bacterial peritonitis
p56132
sa(dp56133
g49782
I62
sg49783
I1
sg49784
I7
sg49785
VC0678108
p56134
sg49787
Vsterile
p56135
sa(dp56136
g49782
I185
sg49783
I3
sg49784
I24
sg49785
VC0018802
p56137
sg49787
Vcongestive heart failure
p56138
sa(dp56139
g49782
I142
sg49783
I2
sg49784
I17
sg49785
VC0220656
p56140
sg49787
Vmalignant ascites
p56141
sa(dp56142
g49782
I161
sg49783
I2
sg49784
I19
sg49785
VC0275919
p56143
sg49787
Vtuberculous ascites
p56144
sasa(dp56145
g49775
VHirudin variants (HV1 and HV2) were produced in infected insect cells as secreted proteins by joining their coding sequences to the leader peptide sequence of the vescicular stomatitis virus G protein.
p56146
sg49777
(lp56147
(dp56148
g49782
I18
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VHV1
p56149
sa(dp56150
g49782
I0
sg49783
I2
sg49784
I16
sg49812
VP26640
p56151
sg49787
VHirudin variants
p56152
sasg49779
(lp56153
(dp56154
g49782
I174
sg49783
I1
sg49784
I10
sg49785
VC0038362
p56155
sg49787
Vstomatitis
p56156
sasa(dp56157
g49775
VMacrophage migration inhibitory factor (MIF) is a proinflammatory cytokine involved in systemic, autoimmune, and inflammatory diseases, such as obesity, rheumatoid arthritis, and systemic lupus erythematosus.
p56158
sg49777
(lp56159
sg49779
(lp56160
(dp56161
g49782
I144
sg49783
I1
sg49784
I7
sg49785
VC0028754
p56162
sg49787
Vobesity
p56163
sa(dp56164
g49782
I97
sg49783
I1
sg49784
I10
sg49785
VC0443146
p56165
sg49787
Vautoimmune
p56166
sa(dp56167
g49782
I179
sg49783
I3
sg49784
I28
sg49785
VC0024141
p56168
sg49787
Vsystemic lupus erythematosus
p56169
sa(dp56170
g49782
I153
sg49783
I2
sg49784
I20
sg49785
VC0003873
p56171
sg49787
Vrheumatoid arthritis
p56172
sasa(dp56173
g49775
VTo systematically review evidence regarding the relationship between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis (RA), and the association between MIF gene polymorphisms and RA susceptibility.
p56174
sg49777
(lp56175
(dp56176
g49782
I192
sg49783
I2
sg49784
I8
sg49812
VP05109
p56177
sg49787
VMIF gene
p56178
sasg49779
(lp56179
(dp56180
g49782
I159
sg49783
I1
sg49784
I2
sg49785
VC0003873
p56181
sg49787
VRA
p56182
sa(dp56183
g49782
I159
sg49783
I1
sg49784
I2
sg49785
VC0003873
p56184
sg49787
VRA
p56185
sa(dp56186
g49782
I137
sg49783
I2
sg49784
I20
sg49785
VC0003873
p56187
sg49787
Vrheumatoid arthritis
p56188
sasa(dp56189
g49775
VTo investigate the role of macrophage migration inhibitory factor (MIF) in the pathogenesis of ankylosing spondylitis (AS).
p56190
sg49777
(lp56191
sg49779
(lp56192
(dp56193
g49782
I95
sg49783
I2
sg49784
I22
sg49785
VC0038013
p56194
sg49787
Vankylosing spondylitis
p56195
sa(dp56196
g49782
I79
sg49783
I1
sg49784
I12
sg49785
VC0699748
p56197
sg49787
Vpathogenesis
p56198
sa(dp56199
g49782
I119
sg49783
I1
sg49784
I2
sg49785
VC0038013
p56200
sg49787
VAS
p56201
sasa(dp56202
g49775
VRheumatoid SAAT secreted more adiponectin and macrophage migration inhibitory factor (MIF) than respective osteoarthritis tissue.
p56203
sg49777
(lp56204
(dp56205
g49782
I86
sg49783
I1
sg49784
I3
sg49812
VP05109
p56206
sg49787
VMIF
p56207
sa(dp56208
g49782
I30
sg49783
I6
sg49784
I54
sg49812
g11
sg49787
Vadiponectin and macrophage migration inhibitory factor
p56209
sasg49779
(lp56210
(dp56211
g49782
I107
sg49783
I1
sg49784
I14
sg49785
VC0029408
p56212
sg49787
Vosteoarthritis
p56213
sasa(dp56214
g49775
VMacrophage migration inhibitory factor (MIF) has emerged as a promising drug target in diseases including sepsis, rheumatoid arthritis, and cancer.
p56215
sg49777
(lp56216
sg49779
(lp56217
(dp56218
g49782
I114
sg49783
I2
sg49784
I20
sg49785
VC0003873
p56219
sg49787
Vrheumatoid arthritis
p56220
sa(dp56221
g49782
I140
sg49783
I1
sg49784
I6
sg49785
VC0006826
p56222
sg49787
Vcancer
p56223
sa(dp56224
g49782
I106
sg49783
I1
sg49784
I6
sg49785
VC0243026
p56225
sg49787
Vsepsis
p56226
sasa(dp56227
g49775
VMacrophage migration inhibitory factor (MIF) and vascular endothelial growth factor (VEGF), as crucial parameters of angiogenesis and inflammation, were evaluated to identify the role of cyclic citrullinated peptide antibodies (anti-CCP) during angiogenesis in rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
p56228
sg49777
(lp56229
(dp56230
g49782
I49
sg49783
I4
sg49784
I34
sg49812
g11
sg49787
Vvascular endothelial growth factor
p56231
sa(dp56232
g49782
I228
sg49783
I1
sg49784
I8
sg49812
VP07320
p56233
sg49787
Vanti-CCP
p56234
sa(dp56235
g49782
I85
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VVEGF
p56236
sasg49779
(lp56237
(dp56238
g49782
I261
sg49783
I2
sg49784
I20
sg49785
VC0003873
p56239
sg49787
Vrheumatoid arthritis
p56240
sa(dp56241
g49782
I134
sg49783
I1
sg49784
I12
sg49785
VC0021368
p56242
sg49787
Vinflammation
p56243
sa(dp56244
g49782
I283
sg49783
I1
sg49784
I2
sg49785
VC0003873
p56245
sg49787
VRA
p56246
sa(dp56247
g49782
I312
sg49783
I1
sg49784
I3
sg49785
VC1519176
p56248
sg49787
VPsA
p56249
sa(dp56250
g49782
I291
sg49783
I2
sg49784
I19
sg49785
VC0003872
p56251
sg49787
Vpsoriatic arthritis
p56252
sa(dp56253
g49782
I233
sg49783
I1
sg49784
I3
sg49785
VC1832526
p56254
sg49787
VCCP
p56255
sasa(dp56256
g49775
VThe aim of this study was to search for any difference between the serum levels of OPG, FGF-23, and vitamin D in patients with hypogonadism and the healthy controls.
p56257
sg49777
(lp56258
(dp56259
g49782
I83
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VOPG
p56260
sa(dp56261
g49782
I88
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VFGF-23
p56262
sasg49779
(lp56263
(dp56264
g49782
I127
sg49783
I1
sg49784
I12
sg49785
VC0020619
p56265
sg49787
Vhypogonadism
p56266
sasa(dp56267
g49775
VThese include FGF3 in Michel aplasia; FGF8 in cleft lip/palate and in hypogonadotropic hypogonadism; FGF9 in carcinoma; FGF10 in the lacrimal/salivary glands aplasia, and lacrimo-auriculo-dento-digital syndrome; FGF14 in spinocerebellar ataxia; FGF20 in Parkinson disease; and FGF23 in tumoral calcinosis and hypophosphatemic rickets.
p56268
sg49777
(lp56269
(dp56270
g49782
I120
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VFGF10
p56271
sa(dp56272
g49782
I277
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VFGF23
p56273
sa(dp56274
g49782
I38
sg49783
I1
sg49784
I4
sg49812
VP55075
p56275
sg49787
VFGF8
p56276
sa(dp56277
g49782
I212
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VFGF14
p56278
sa(dp56279
g49782
I101
sg49783
I1
sg49784
I4
sg49812
VP31371
p56280
sg49787
VFGF9
p56281
sa(dp56282
g49782
I14
sg49783
I1
sg49784
I4
sg49812
VP11487
p56283
sg49787
VFGF3
p56284
sasg49779
(lp56285
(dp56286
g49782
I254
sg49783
I2
sg49784
I17
sg49785
VC0030567
p56287
sg49787
VParkinson disease
p56288
sa(dp56289
g49782
I29
sg49783
I1
sg49784
I7
sg49785
VC0243065
p56290
sg49787
Vaplasia
p56291
sa(dp56292
g49782
I171
sg49783
I2
sg49784
I39
sg49785
VC0265269
p56293
sg49787
Vlacrimo-auriculo-dento-digital syndrome
p56294
sa(dp56295
g49782
I46
sg49783
I2
sg49784
I16
sg49785
VC0158646
p56296
sg49787
Vcleft lip/palate
p56297
sa(dp56298
g49782
I309
sg49783
I2
sg49784
I24
sg49785
VC1704375
p56299
sg49787
Vhypophosphatemic rickets
p56300
sa(dp56301
g49782
I286
sg49783
I2
sg49784
I18
sg49785
VC0263628
p56302
sg49787
Vtumoral calcinosis
p56303
sa(dp56304
g49782
I109
sg49783
I1
sg49784
I9
sg49785
VC0007097
p56305
sg49787
Vcarcinoma
p56306
sa(dp56307
g49782
I29
sg49783
I1
sg49784
I7
sg49785
VC0243065
p56308
sg49787
Vaplasia
p56309
sa(dp56310
g49782
I70
sg49783
I2
sg49784
I29
sg49785
VC0022735
p56311
sg49787
Vhypogonadotropic hypogonadism
p56312
sa(dp56313
g49782
I221
sg49783
I2
sg49784
I22
sg49785
VC0087012
p56314
sg49787
Vspinocerebellar ataxia
p56315
sasa(dp56316
g49775
VRecent studies using genetically modified mice, such as FGF23-/- and Klotho-/- mice that exhibit altered mineral homeostasis due to a high vitamin D activity showed features of premature aging that include retarded growth, osteoporosis, atherosclerosis, ectopic calcification, immunological deficiency, skin and general organ atrophy, hypogonadism and short lifespan.
p56317
sg49777
(lp56318
(dp56319
g49782
I56
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VFGF23
p56320
sasg49779
(lp56321
(dp56322
g49782
I326
sg49783
I1
sg49784
I7
sg49785
VC0333641
p56323
sg49787
Vatrophy
p56324
sa(dp56325
g49782
I335
sg49783
I1
sg49784
I12
sg49785
VC0020619
p56326
sg49787
Vhypogonadism
p56327
sa(dp56328
g49782
I206
sg49783
I2
sg49784
I15
sg49785
VC0151686
p56329
sg49787
Vretarded growth
p56330
sa(dp56331
g49782
I223
sg49783
I1
sg49784
I12
sg49785
VC0029456
p56332
sg49787
Vosteoporosis
p56333
sa(dp56334
g49782
I237
sg49783
I1
sg49784
I15
sg49785
VC0004153
p56335
sg49787
Vatherosclerosis
p56336
sa(dp56337
g49782
I177
sg49783
I2
sg49784
I15
sg49785
VC0231341
p56338
sg49787
Vpremature aging
p56339
sasa(dp56340
g49775
VMoreover, Fgf23(-/-)/klotho(-/-) mice show soft tissue and vascular calcification, severe muscle wasting, hypogonadism, pulmonary emphysema, distention of intestinal wall, and skin atrophy, all of which are also seen in Fgf23(-/-) and klotho(-/-) mice.
p56341
sg49777
(lp56342
sg49779
(lp56343
(dp56344
g49782
I176
sg49783
I2
sg49784
I12
sg49785
VC0151514
p56345
sg49787
Vskin atrophy
p56346
sa(dp56347
g49782
I141
sg49783
I1
sg49784
I10
sg49785
VC0012359
p56348
sg49787
Vdistention
p56349
sa(dp56350
g49782
I120
sg49783
I2
sg49784
I19
sg49785
VC0034067
p56351
sg49787
Vpulmonary emphysema
p56352
sa(dp56353
g49782
I59
sg49783
I2
sg49784
I22
sg49785
VC0342649
p56354
sg49787
Vvascular calcification
p56355
sa(dp56356
g49782
I90
sg49783
I2
sg49784
I14
sg49785
VC0026846
p56357
sg49787
Vmuscle wasting
p56358
sa(dp56359
g49782
I106
sg49783
I1
sg49784
I12
sg49785
VC0020619
p56360
sg49787
Vhypogonadism
p56361
sasa(dp56362
g49775
VRecent studies using genetically altered mouse models, such as in Fgf-23(-/-) and klotho mutant mice, that exhibit altered mineral ion metabolism due to high vitamin D activities showed features of premature aging that include atherosclerosis, emphysema, osteopenia/osteoporosis, hypogonadism, soft tissue calcifications and generalized atrophy of organs; the pathologic effects of vitamin D in these mouse models are obvious, as diminution or genetic ablation of the vitamin D pathway ameliorated most of the above-mentioned phenotypes, by reversing mineral ion metabolism, and the resultant effect being prolonged survival of the mutant mice.
p56363
sg49777
(lp56364
sg49779
(lp56365
(dp56366
g49782
I89
sg49783
I1
sg49784
I6
sg49785
VC0596988
p56367
sg49787
Vmutant
p56368
sa(dp56369
g49782
I244
sg49783
I1
sg49784
I9
sg49785
VC0013990
p56370
sg49787
Vemphysema
p56371
sa(dp56372
g49782
I280
sg49783
I1
sg49784
I12
sg49785
VC0020619
p56373
sg49787
Vhypogonadism
p56374
sa(dp56375
g49782
I89
sg49783
I1
sg49784
I6
sg49785
VC0596988
p56376
sg49787
Vmutant
p56377
sa(dp56378
g49782
I255
sg49783
I1
sg49784
I23
sg49785
VC0262586
p56379
sg49787
Vosteopenia/osteoporosis
p56380
sa(dp56381
g49782
I337
sg49783
I1
sg49784
I7
sg49785
VC0333641
p56382
sg49787
Vatrophy
p56383
sa(dp56384
g49782
I227
sg49783
I1
sg49784
I15
sg49785
VC0004153
p56385
sg49787
Vatherosclerosis
p56386
sa(dp56387
g49782
I198
sg49783
I2
sg49784
I15
sg49785
VC0231341
p56388
sg49787
Vpremature aging
p56389
sasa(dp56390
g49775
VClinical, cytogenetic and molecular features of acute myeloid leukemia with a MLL-SEPT5 fusion gene are reviewed.
p56391
sg49777
(lp56392
(dp56393
g49782
I82
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSEPT5
p56394
sa(dp56395
g49782
I78
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VMLL
p56396
sasg49779
(lp56397
(dp56398
g49782
I48
sg49783
I3
sg49784
I22
sg49785
VC0023467
p56399
sg49787
Vacute myeloid leukemia
p56400
sasa(dp56401
g49775
VThe MLL-LCX fusion protein lacked a CXXC domain of LCX, but retained an alpha-helical coiled-coil region at the COOH terminus, similar to MLL-SEPTING, MLL-CDCREL1, MLL-AF1p/Eps15, and MLL-AF6, which suggests that these fusion proteins are involved in the pathogenesis of 11q23-associated leukemia through similar mechanisms.
p56402
sg49777
(lp56403
(dp56404
g49782
I4
sg49783
I3
sg49784
I22
sg49812
g11
sg49787
VMLL-LCX fusion protein
p56405
sa(dp56406
g49782
I173
sg49783
I1
sg49784
I5
sg49812
VP42566
p56407
sg49787
VEps15
p56408
sa(dp56409
g49782
I155
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VCDCREL1
p56410
sa(dp56411
g49782
I4
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VMLL
p56412
sa(dp56413
g49782
I4
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VMLL
p56414
sa(dp56415
g49782
I188
sg49783
I1
sg49784
I3
sg49812
VP55196
p56416
sg49787
VAF6
p56417
sa(dp56418
g49782
I138
sg49783
I1
sg49784
I11
sg49812
g11
sg49787
VMLL-SEPTING
p56419
sa(dp56420
g49782
I168
sg49783
I1
sg49784
I4
sg49812
VP42566
p56421
sg49787
VAF1p
p56422
sa(dp56423
g49782
I4
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VMLL
p56424
sasg49779
(lp56425
(dp56426
g49782
I255
sg49783
I1
sg49784
I12
sg49785
VC0699748
p56427
sg49787
Vpathogenesis
p56428
sa(dp56429
g49782
I288
sg49783
I1
sg49784
I8
sg49785
VC0023418
p56430
sg49787
Vleukemia
p56431
sasa(dp56432
g49775
VWe also investigated TG101348 activity against feeder cells and observed that STAT5 phosphorylation, granulocyte macrophage colony-stimulating factor, and interleukin 6 levels decreased, indicating reduced cytokine production in HS-5 cells treated with TG101348.
p56433
sg49777
(lp56434
(dp56435
g49782
I155
sg49783
I2
sg49784
I13
sg49812
VP05231
p56436
sg49787
Vinterleukin 6
p56437
sa(dp56438
g49782
I101
sg49783
I4
sg49784
I48
sg49812
VP04141
p56439
sg49787
Vgranulocyte macrophage colony-stimulating factor
p56440
sa(dp56441
g49782
I78
sg49783
I1
sg49784
I5
sg49812
VP42229
p56442
sg49787
VSTAT5
p56443
sasg49779
(lp56444
sa(dp56445
g49775
VIn the present study, we examined the impact of cytoplasmic/mitochondrial localization of p33ING1b in oral squamous cell carcinoma (OSCC) patient samples and explored the therapeutic potential of adenovirally-overexpressed p33ING1b in OSCC cell lines in combination with ionizing radiation (IR) treatment.
p56446
sg49777
(lp56447
sg49779
(lp56448
(dp56449
g49782
I102
sg49783
I4
sg49784
I28
sg49785
VC0007137
p56450
sg49787
Voral squamous cell carcinoma
p56451
sa(dp56452
g49782
I132
sg49783
I1
sg49784
I4
sg49785
VC0007137
p56453
sg49787
VOSCC
p56454
sa(dp56455
g49782
I132
sg49783
I1
sg49784
I4
sg49785
VC0007137
p56456
sg49787
VOSCC
p56457
sasa(dp56458
g49775
VIn contrast with previous reports, we found that p33ING1b protein and mRNA levels are higher in OSCC compared to normal epithelial cells.
p56459
sg49777
(lp56460
sg49779
(lp56461
sa(dp56462
g49775
VIn OSCC patient samples, higher levels of intra-tumoral cytoplasmic p33ING1b correlated with increased apoptotic markers and significantly better patient survival.
p56463
sg49777
(lp56464
sg49779
(lp56465
sa(dp56466
g49775
VIR treatment induced p33ING1b translocation to the mitochondria and adenoviral-p33ING1b synergized with IR to kill OSCC cells.
p56467
sg49777
(lp56468
sg49779
(lp56469
(dp56470
g49782
I30
sg49783
I1
sg49784
I13
sg49785
VC0040715
p56471
sg49787
Vtranslocation
p56472
sasa(dp56473
g49775
VOur results identify a novel functional relationship between cytoplasmic p33ING1b and patient survival and highlight the potential for the use of p33ING1b as a therapeutic agent in combination with adjuvant radiotherapy in OSCC.
p56474
sg49777
(lp56475
sg49779
(lp56476
sa(dp56477
g49775
VSince loss of heterozygosity at 13q34 has been reported in squamous cell carcinoma of head and neck, we screened for mutations in ING1 by polymerase chain reaction-single strand conformation polymorphism in 71 oral squamous cell carcinomas (OSCC) from India, 15 of which were known to harbor p53 mutations.
p56478
sg49777
(lp56479
(dp56480
g49782
I292
sg49783
I2
sg49784
I13
sg49812
VP42771
p56481
sg49787
Vp53 mutations
p56482
sasg49779
(lp56483
(dp56484
g49782
I215
sg49783
I3
sg49784
I24
sg49785
VC0007137
p56485
sg49787
Vsquamous cell carcinomas
p56486
sa(dp56487
g49782
I59
sg49783
I7
sg49784
I40
sg49785
VC1168401
p56488
sg49787
Vsquamous cell carcinoma of head and neck
p56489
sasa(dp56490
g49775
VThese results suggest that ING1 is not a target for mutational inactivation in OSCC of Indians.
p56491
sg49777
(lp56492
sg49779
(lp56493
(dp56494
g49782
I63
sg49783
I1
sg49784
I12
sg49785
VC0544461
p56495
sg49787
Vinactivation
p56496
sasa(dp56497
g49775
VThe incidence of human T cell lymphotropic virus type 1 (HLTV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is not well defined in the literature.
p56498
sg49777
(lp56499
(dp56500
g49782
I117
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VHAM
p56501
sa(dp56502
g49782
I121
sg49783
I1
sg49784
I3
sg49812
VP07996
p56503
sg49787
VTSP
p56504
sasg49779
(lp56505
(dp56506
g49782
I76
sg49783
I1
sg49784
I10
sg49785
VC0037928
p56507
sg49787
Vmyelopathy
p56508
sa(dp56509
g49782
I87
sg49783
I3
sg49784
I28
sg49785
VC0030481
p56510
sg49787
Vtropical spastic paraparesis
p56511
sa(dp56512
g49782
I117
sg49783
I1
sg49784
I3
sg49785
VC0030481
p56513
sg49787
VHAM
p56514
sasa(dp56515
g49775
VFollowing adult T cell leukemia/lymphoma and HLTV-1-associated myelopathy/tropical spastic paraparesis, HTLV-1 uveitis (HU) has been established as a distinct clinical entity caused by HTLV-1 based on seroepidemiological, clinical, and virological studies.
p56516
sg49777
(lp56517
sg49779
(lp56518
(dp56519
g49782
I10
sg49783
I4
sg49784
I21
sg49785
VC0023492
p56520
sg49787
Vadult T cell leukemia
p56521
sa(dp56522
g49782
I74
sg49783
I3
sg49784
I28
sg49785
VC0030481
p56523
sg49787
Vtropical spastic paraparesis
p56524
sa(dp56525
g49782
I32
sg49783
I1
sg49784
I8
sg49785
VC0024299
p56526
sg49787
Vlymphoma
p56527
sa(dp56528
g49782
I63
sg49783
I1
sg49784
I10
sg49785
VC0037928
p56529
sg49787
Vmyelopathy
p56530
sa(dp56531
g49782
I111
sg49783
I1
sg49784
I7
sg49785
VC0042164
p56532
sg49787
Vuveitis
p56533
sasa(dp56534
g49775
VThis is a study of the early identification of a new case of tropical spastic paraparesis/HLTV-1-associated myelopathy in a Spanish patient not previously reported on.
p56535
sg49777
(lp56536
sg49779
(lp56537
(dp56538
g49782
I108
sg49783
I1
sg49784
I10
sg49785
VC0037928
p56539
sg49787
Vmyelopathy
p56540
sa(dp56541
g49782
I61
sg49783
I3
sg49784
I28
sg49785
VC0030481
p56542
sg49787
Vtropical spastic paraparesis
p56543
sasa(dp56544
g49775
VMyxoid liposarcoma (MLS) is a soft tissue sarcoma characterized by a recurrent t(12;16) translocation.
p56545
sg49777
(lp56546
sg49779
(lp56547
(dp56548
g49782
I88
sg49783
I1
sg49784
I13
sg49785
VC0040715
p56549
sg49787
Vtranslocation
p56550
sa(dp56551
g49782
I0
sg49783
I2
sg49784
I18
sg49785
VC0206634
p56552
sg49787
VMyxoid liposarcoma
p56553
sa(dp56554
g49782
I20
sg49783
I1
sg49784
I3
sg49785
VC0796070
p56555
sg49787
VMLS
p56556
sa(dp56557
g49782
I30
sg49783
I3
sg49784
I19
sg49785
VC1261473
p56558
sg49787
Vsoft tissue sarcoma
p56559
sasa(dp56560
g49775
VAlthough myxoid liposarcomas (MLS) are the most common type of soft-tissue sarcomas in adults, their primary location in the superficial tissues is rare.
p56561
sg49777
(lp56562
sg49779
(lp56563
(dp56564
g49782
I20
sg49783
I1
sg49784
I8
sg49785
VC1261473
p56565
sg49787
Vsarcomas
p56566
sa(dp56567
g49782
I30
sg49783
I1
sg49784
I3
sg49785
VC0796070
p56568
sg49787
VMLS
p56569
sa(dp56570
g49782
I9
sg49783
I2
sg49784
I19
sg49785
VC0206634
p56571
sg49787
Vmyxoid liposarcomas
p56572
sasa(dp56573
g49775
VPRG4 is one of the downstream molecules of the myxoid liposarcoma (MLS)-specific fusion oncoproteins TLS-CHOP and EWS-CHOP.
p56574
sg49777
(lp56575
(dp56576
g49782
I101
sg49783
I1
sg49784
I3
sg49812
VP35637
p56577
sg49787
VTLS
p56578
sa(dp56579
g49782
I114
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VEWS
p56580
sa(dp56581
g49782
I105
sg49783
I1
sg49784
I4
sg49812
VP35638
p56582
sg49787
VCHOP
p56583
sa(dp56584
g49782
I0
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VPRG4
p56585
sa(dp56586
g49782
I105
sg49783
I1
sg49784
I4
sg49812
VP35638
p56587
sg49787
VCHOP
p56588
sasg49779
(lp56589
(dp56590
g49782
I67
sg49783
I1
sg49784
I3
sg49785
VC0796070
p56591
sg49787
VMLS
p56592
sa(dp56593
g49782
I47
sg49783
I2
sg49784
I18
sg49785
VC0206634
p56594
sg49787
Vmyxoid liposarcoma
p56595
sasa(dp56596
g49775
VThe SUV max values of the low-grade thymomas, high-grade thymomas, TCs and MLs were 3.14 +/- 0.73, 4.34 +/- 1.49, 8.59 +/- 3.05, and 10.08 +/- 2.53, respectively, with significant differences between the low- and high-grade thymomas, and between TCs and MLs.
p56597
sg49777
(lp56598
sg49779
(lp56599
(dp56600
g49782
I75
sg49783
I1
sg49784
I3
sg49785
VC0796070
p56601
sg49787
VMLs
p56602
sa(dp56603
g49782
I36
sg49783
I1
sg49784
I8
sg49785
VC0040100
p56604
sg49787
Vthymomas
p56605
sa(dp56606
g49782
I75
sg49783
I1
sg49784
I3
sg49785
VC0796070
p56607
sg49787
VMLs
p56608
sa(dp56609
g49782
I67
sg49783
I1
sg49784
I3
sg49785
VC0242387
p56610
sg49787
VTCs
p56611
sa(dp56612
g49782
I36
sg49783
I1
sg49784
I8
sg49785
VC0040100
p56613
sg49787
Vthymomas
p56614
sa(dp56615
g49782
I36
sg49783
I1
sg49784
I8
sg49785
VC0040100
p56616
sg49787
Vthymomas
p56617
sa(dp56618
g49782
I67
sg49783
I1
sg49784
I3
sg49785
VC0242387
p56619
sg49787
VTCs
p56620
sasa(dp56621
g49775
VOf 24 patients with actionable mutations, five were given genotype-matched drugs corresponding to actionable mutations: everolimus to PIK3CA mutation in parotid carcinosarcoma (partial response) and tracheal squamous cell carcinoma (stable disease; 21% reduction), sorafenib to PDGFRA mutation in auditory canal adenocarcinoma (partial response), sorafenib to BRAF mutation in microcytic adnexal carcinoma (progressive disease), and afatinib to ERBB2 mutation in esophageal adenocarcinoma (progressive disease).
p56622
sg49777
(lp56623
(dp56624
g49782
I134
sg49783
I1
sg49784
I6
sg49812
VP42336
p56625
sg49787
VPIK3CA
p56626
sa(dp56627
g49782
I360
sg49783
I1
sg49784
I4
sg49812
VP15056
p56628
sg49787
VBRAF
p56629
sa(dp56630
g49782
I445
sg49783
I1
sg49784
I5
sg49812
VP04626
p56631
sg49787
VERBB2
p56632
sa(dp56633
g49782
I278
sg49783
I1
sg49784
I6
sg49812
VP16234
p56634
sg49787
VPDGFRA
p56635
sasg49779
(lp56636
(dp56637
g49782
I463
sg49783
I2
sg49784
I25
sg49785
VC0279628
p56638
sg49787
Vesophageal adenocarcinoma
p56639
sa(dp56640
g49782
I199
sg49783
I4
sg49784
I32
sg49785
VC0345946
p56641
sg49787
Vtracheal squamous cell carcinoma
p56642
sa(dp56643
g49782
I407
sg49783
I2
sg49784
I19
sg49785
VC0677932
p56644
sg49787
Vprogressive disease
p56645
sa(dp56646
g49782
I388
sg49783
I2
sg49784
I17
sg49785
VC0206697
p56647
sg49787
Vadnexal carcinoma
p56648
sa(dp56649
g49782
I407
sg49783
I2
sg49784
I19
sg49785
VC0677932
p56650
sg49787
Vprogressive disease
p56651
sa(dp56652
g49782
I312
sg49783
I1
sg49784
I14
sg49785
VC0001418
p56653
sg49787
Vadenocarcinoma
p56654
sa(dp56655
g49782
I161
sg49783
I1
sg49784
I14
sg49785
VC0007140
p56656
sg49787
Vcarcinosarcoma
p56657
sasa(dp56658
g49775
VThe objective of this study was to determine the efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma.
p56659
sg49777
(lp56660
(dp56661
g49782
I91
sg49783
I1
sg49784
I4
sg49812
VP04626
p56662
sg49787
VHER2
p56663
sasg49779
(lp56664
(dp56665
g49782
I106
sg49783
I1
sg49784
I14
sg49785
VC0007140
p56666
sg49787
Vcarcinosarcoma
p56667
sasa(dp56668
g49775
VThe efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma was determined in vitro using seven primary carcinosarcoma cell lines with differential expression of HER2/neu.
p56669
sg49777
(lp56670
(dp56671
g49782
I183
sg49783
I1
sg49784
I3
sg49812
VP04626
p56672
sg49787
Vneu
p56673
sa(dp56674
g49782
I46
sg49783
I1
sg49784
I4
sg49812
VP04626
p56675
sg49787
VHER2
p56676
sa(dp56677
g49782
I46
sg49783
I1
sg49784
I4
sg49812
VP04626
p56678
sg49787
VHER2
p56679
sasg49779
(lp56680
(dp56681
g49782
I61
sg49783
I1
sg49784
I14
sg49785
VC0007140
p56682
sg49787
Vcarcinosarcoma
p56683
sa(dp56684
g49782
I61
sg49783
I1
sg49784
I14
sg49785
VC0007140
p56685
sg49787
Vcarcinosarcoma
p56686
sasa(dp56687
g49775
VThe efficacy of neratinib was determined in treating mice harboring HER2 amplified carcinosarcoma xenografts.
p56688
sg49777
(lp56689
sg49779
(lp56690
(dp56691
g49782
I83
sg49783
I1
sg49784
I14
sg49785
VC0007140
p56692
sg49787
Vcarcinosarcoma
p56693
sasa(dp56694
g49775
VTwo of seven (28.5%) carcinosarcoma cell lines were HER2/neu amplified.
p56695
sg49777
(lp56696
(dp56697
g49782
I52
sg49783
I1
sg49784
I4
sg49812
VP04626
p56698
sg49787
VHER2
p56699
sa(dp56700
g49782
I57
sg49783
I1
sg49784
I3
sg49812
VP04626
p56701
sg49787
Vneu
p56702
sasg49779
(lp56703
(dp56704
g49782
I21
sg49783
I1
sg49784
I14
sg49785
VC0007140
p56705
sg49787
Vcarcinosarcoma
p56706
sasa(dp56707
g49775
VHER2/neu amplified cell lines SARARK6 and SARARK9 were significantly more sensitive to neratinib than the five non-HER2/neu amplified carcinosarcoma cell lines (mean+/-SEM IC50:0.014myM+/-0.004vs.0.164myM+/-0.019 p=0.0003).
p56708
sg49777
(lp56709
(dp56710
g49782
I5
sg49783
I1
sg49784
I3
sg49812
VP04626
p56711
sg49787
Vneu
p56712
sa(dp56713
g49782
I5
sg49783
I1
sg49784
I3
sg49812
VP04626
p56714
sg49787
Vneu
p56715
sa(dp56716
g49782
I0
sg49783
I1
sg49784
I4
sg49812
VP04626
p56717
sg49787
VHER2
p56718
sa(dp56719
g49782
I0
sg49783
I1
sg49784
I4
sg49812
VP04626
p56720
sg49787
VHER2
p56721
sasg49779
(lp56722
(dp56723
g49782
I134
sg49783
I1
sg49784
I14
sg49785
VC0007140
p56724
sg49787
Vcarcinosarcoma
p56725
sa(dp56726
g49782
I168
sg49783
I1
sg49784
I3
sg49785
VC0432222
p56727
sg49787
VSEM
p56728
sasa(dp56729
g49775
VNeratinib inhibited tumor growth (p=0.012) and prolonged survival in mice harboring HER2 amplified carcinosarcoma xenografts (p=0.0039).
p56730
sg49777
(lp56731
sg49779
(lp56732
(dp56733
g49782
I20
sg49783
I2
sg49784
I12
sg49785
VC0598934
p56734
sg49787
Vtumor growth
p56735
sa(dp56736
g49782
I99
sg49783
I1
sg49784
I14
sg49785
VC0007140
p56737
sg49787
Vcarcinosarcoma
p56738
sasa(dp56739
g49775
VNeratinib inhibits HER2 amplified carcinosarcoma proliferation, signaling, cell cycle progression and tumor growth in vitro.
p56740
sg49777
(lp56741
(dp56742
g49782
I19
sg49783
I1
sg49784
I4
sg49812
VP04626
p56743
sg49787
VHER2
p56744
sasg49779
(lp56745
(dp56746
g49782
I49
sg49783
I1
sg49784
I13
sg49785
VC0334094
p56747
sg49787
Vproliferation
p56748
sa(dp56749
g49782
I34
sg49783
I1
sg49784
I14
sg49785
VC0007140
p56750
sg49787
Vcarcinosarcoma
p56751
sa(dp56752
g49782
I102
sg49783
I2
sg49784
I12
sg49785
VC0598934
p56753
sg49787
Vtumor growth
p56754
sasa(dp56755
g49775
VNumerous correlative scientific investigations have demonstrated that the HER2 (ERBB2) gene is amplified in 17%-33% of carcinosarcoma, uterine serous carcinoma, and a subset of high-grade endometrioid endometrial tumors.
p56756
sg49777
(lp56757
(dp56758
g49782
I74
sg49783
I1
sg49784
I4
sg49812
VP04626
p56759
sg49787
VHER2
p56760
sa(dp56761
g49782
I80
sg49783
I1
sg49784
I5
sg49812
VP04626
p56762
sg49787
VERBB2
p56763
sasg49779
(lp56764
(dp56765
g49782
I143
sg49783
I2
sg49784
I16
sg49785
VC0206701
p56766
sg49787
Vserous carcinoma
p56767
sa(dp56768
g49782
I213
sg49783
I1
sg49784
I6
sg49785
VC0027651
p56769
sg49787
Vtumors
p56770
sa(dp56771
g49782
I119
sg49783
I1
sg49784
I14
sg49785
VC0007140
p56772
sg49787
Vcarcinosarcoma
p56773
sasa(dp56774
g49775
VThe analysis of human datasets and GBM tumors revealed higher expression of p65 in GBM-associated CD68+ macrophages compared to neighboring stroma.
p56775
sg49777
(lp56776
(dp56777
g49782
I76
sg49783
I1
sg49784
I3
sg49812
VP21579
p56778
sg49787
Vp65
p56779
sa(dp56780
g49782
I83
sg49783
I2
sg49784
I20
sg49812
g11
sg49787
VGBM-associated CD68+
p56781
sasg49779
(lp56782
(dp56783
g49782
I39
sg49783
I1
sg49784
I6
sg49785
VC0027651
p56784
sg49787
Vtumors
p56785
sa(dp56786
g49782
I35
sg49783
I1
sg49784
I3
sg49785
VC0017636
p56787
sg49787
VGBM
p56788
sa(dp56789
g49782
I35
sg49783
I1
sg49784
I3
sg49785
VC0017636
p56790
sg49787
VGBM
p56791
sasa(dp56792
g49775
VOf paramount importance in the recognition of oligodendroglial and astrocytic tumor cells were the double immunostainings for ATRX/GFAP, ATRX/IDH1R132H, ATRX/Iba-1 and ATRX/CD68.
p56793
sg49777
(lp56794
(dp56795
g49782
I173
sg49783
I1
sg49784
I4
sg49812
VP34810
p56796
sg49787
VCD68
p56797
sasg49779
(lp56798
(dp56799
g49782
I126
sg49783
I1
sg49784
I4
sg49785
VC1845055
p56800
sg49787
VATRX
p56801
sa(dp56802
g49782
I126
sg49783
I1
sg49784
I4
sg49785
VC1845055
p56803
sg49787
VATRX
p56804
sa(dp56805
g49782
I126
sg49783
I1
sg49784
I4
sg49785
VC1845055
p56806
sg49787
VATRX
p56807
sa(dp56808
g49782
I67
sg49783
I2
sg49784
I16
sg49785
VC0004114
p56809
sg49787
Vastrocytic tumor
p56810
sa(dp56811
g49782
I126
sg49783
I1
sg49784
I4
sg49785
VC1845055
p56812
sg49787
VATRX
p56813
sasa(dp56814
g49775
VTherefore, Dan-gua Fang might be an ideal drug for comprehensive intervention for glucose and lipid metabolism disorders in type 2 diabetes mellitus.
p56815
sg49777
(lp56816
(dp56817
g49782
I11
sg49783
I2
sg49784
I12
sg49812
VP41271
p56818
sg49787
VDan-gua Fang
p56819
sasg49779
(lp56820
(dp56821
g49782
I124
sg49783
I4
sg49784
I24
sg49785
VC0011860
p56822
sg49787
Vtype 2 diabetes mellitus
p56823
sa(dp56824
g49782
I94
sg49783
I3
sg49784
I26
sg49785
VC0154251
p56825
sg49787
Vlipid metabolism disorders
p56826
sasa(dp56827
g49775
VAn electrochemical study of the oxidation of 8-hydroxyguanine (8-OH-Gua) at gold nanoparticles attached to single walled carbon nanotube modified edge plane pyrolytic graphite electrode (AuNP-SWCNT/EPPGE) has been carried out to develop a method for the self diagnosis of diabetes.
p56828
sg49777
(lp56829
sg49779
(lp56830
(dp56831
g49782
I272
sg49783
I1
sg49784
I8
sg49785
VC0011849
p56832
sg49787
Vdiabetes
p56833
sasa(dp56834
g49775
VConsequently, Metformin - the biguanide drug of choice orally administered for diabetes type II - is anticipated to see a spike in production.
p56835
sg49777
(lp56836
sg49779
(lp56837
(dp56838
g49782
I79
sg49783
I3
sg49784
I16
sg49785
VC0011860
p56839
sg49787
Vdiabetes type II
p56840
sasa(dp56841
g49775
VTo study the toxicity features of high glucose on the endothelial cell cycle and the influence of Dan Gua-Fang, a Chinese herbal compound prescription, on the reproductive cycle of vascular endothelial cells cultivated under a high glucose condition; to reveal the partial mechanisms of Dan Gua-Fang in the prevention and treatment of endothelial injury caused by hyperglycemia in diabetes mellitus (DM); and offer a reference for dealing with the vascular complications of DM patients with long-term high blood glucose.
p56842
sg49777
(lp56843
(dp56844
g49782
I98
sg49783
I2
sg49784
I7
sg49812
VP41271
p56845
sg49787
VDan Gua
p56846
sasg49779
(lp56847
(dp56848
g49782
I240
sg49783
I1
sg49784
I9
sg49785
VC0012634
p56849
sg49787
Vcondition
p56850
sa(dp56851
g49782
I381
sg49783
I2
sg49784
I17
sg49785
VC0011849
p56852
sg49787
Vdiabetes mellitus
p56853
sa(dp56854
g49782
I400
sg49783
I1
sg49784
I2
sg49785
VC0011849
p56855
sg49787
VDM
p56856
sa(dp56857
g49782
I400
sg49783
I1
sg49784
I2
sg49785
VC0011849
p56858
sg49787
VDM
p56859
sa(dp56860
g49782
I364
sg49783
I1
sg49784
I13
sg49785
VC0020456
p56861
sg49787
Vhyperglycemia
p56862
sasa(dp56863
g49775
VTo study the effect of anticolchicine cytotoxicity of Dan Gua-Fang, a Chinesea Chinese), a Chinese herbal compound prescription on endothelial cells of vein (ECV304) cultivated in mediums of different glucose concentrations as well as the proliferation of those cells in the same conditions, in order to reveal the value of Dan Gua-Fang in preventing and treating endothelial damage caused by hyperglycemia in diabetes mellitus.
p56864
sg49777
(lp56865
(dp56866
g49782
I54
sg49783
I2
sg49784
I12
sg49812
VP41271
p56867
sg49787
VDan Gua-Fang
p56868
sasg49779
(lp56869
(dp56870
g49782
I239
sg49783
I1
sg49784
I13
sg49785
VC0334094
p56871
sg49787
Vproliferation
p56872
sa(dp56873
g49782
I410
sg49783
I2
sg49784
I17
sg49785
VC0011849
p56874
sg49787
Vdiabetes mellitus
p56875
sa(dp56876
g49782
I38
sg49783
I1
sg49784
I12
sg49785
VC0596402
p56877
sg49787
Vcytotoxicity
p56878
sa(dp56879
g49782
I393
sg49783
I1
sg49784
I13
sg49785
VC0020456
p56880
sg49787
Vhyperglycemia
p56881
sasa(dp56882
g49775
V(1) Dan Gua-Fang at all concentrations reduced the floating cell population of ECV304 cultivated in hyperglycemia mediums.
p56883
sg49777
(lp56884
sg49779
(lp56885
(dp56886
g49782
I100
sg49783
I1
sg49784
I13
sg49785
VC0020456
p56887
sg49787
Vhyperglycemia
p56888
sasa(dp56889
g49775
V(2) Dan Gua-Fang at all concentrations and hyperglycemia both had a function of promoting "pseudopod-like" structure formation in cultivated ECV304, but the function was not superimposed in mediums containing both hyperglycemia and Dan Gua-Fang.
p56890
sg49777
(lp56891
sg49779
(lp56892
(dp56893
g49782
I43
sg49783
I1
sg49784
I13
sg49785
VC0020456
p56894
sg49787
Vhyperglycemia
p56895
sa(dp56896
g49782
I43
sg49783
I1
sg49784
I13
sg49785
VC0020456
p56897
sg49787
Vhyperglycemia
p56898
sasa(dp56899
g49775
V(3) Colchicine reduced and even vanished the "pseudopod-like" structure of the endotheliocyte apparently cultivated in mediums of hyperglycemia or with Dan Gua-Fang.
p56900
sg49777
(lp56901
sg49779
(lp56902
(dp56903
g49782
I130
sg49783
I1
sg49784
I13
sg49785
VC0020456
p56904
sg49787
Vhyperglycemia
p56905
sasa(dp56906
g49775
VThe "pseudopod-like" structure of the endotheliocyte emerged quickly in Dan Gua-Fang groups after colchicine was removed, but it was not the case in hyperglycemia only without Dan Gua-Fang groups.
p56907
sg49777
(lp56908
sg49779
(lp56909
(dp56910
g49782
I149
sg49783
I1
sg49784
I13
sg49785
VC0020456
p56911
sg49787
Vhyperglycemia
p56912
sasa(dp56913
g49775
VThe spinodal point concentration of statistical significance of hyperglycemia cytotoxicity is 22.2 mmol/l; 1/300 Dan Gua can reverse the endothelia cytotoxicity in different concentrations of hyperglycemia.
p56914
sg49777
(lp56915
sg49779
(lp56916
(dp56917
g49782
I78
sg49783
I1
sg49784
I12
sg49785
VC0596402
p56918
sg49787
Vcytotoxicity
p56919
sa(dp56920
g49782
I64
sg49783
I1
sg49784
I13
sg49785
VC0020456
p56921
sg49787
Vhyperglycemia
p56922
sa(dp56923
g49782
I78
sg49783
I1
sg49784
I12
sg49785
VC0596402
p56924
sg49787
Vcytotoxicity
p56925
sa(dp56926
g49782
I64
sg49783
I1
sg49784
I13
sg49785
VC0020456
p56927
sg49787
Vhyperglycemia
p56928
sasa(dp56929
g49775
VPatients with resected stage III colon cancer who were 18 years of age or older, with an Eastern Cooperative Oncology Group performance status of 0 or 1, from four randomised controlled trials (NSABP C-08, XELOXA, X-ACT, and AVANT; 8734 patients in total) were pooled and analysed.
p56930
sg49777
(lp56931
sg49779
(lp56932
(dp56933
g49782
I23
sg49783
I4
sg49784
I22
sg49785
VC3146254
p56934
sg49787
Vstage III colon cancer
p56935
sasa(dp56936
g49775
VBased on the results of the X-ACT study, capecitabine has become one of the standard postoperative adjuvant chemotherapies for colon cancer.
p56937
sg49777
(lp56938
sg49779
(lp56939
(dp56940
g49782
I127
sg49783
I2
sg49784
I12
sg49785
VC0699790
p56941
sg49787
Vcolon cancer
p56942
sasa(dp56943
g49775
VIn the adjuvant setting, the Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial demonstrated that capecitabine as a single agent led to improvement in relapse-free survival (hazard ratio: 0.86, 95% confidence interval: 0.74-0.99, P = 0.04) and was associated with significantly fewer adverse events than 5-FU plus leucovorin (LV, folinic acid).
p56944
sg49777
(lp56945
sg49779
(lp56946
(dp56947
g49782
I48
sg49783
I2
sg49784
I12
sg49785
VC0699790
p56948
sg49787
VColon Cancer
p56949
sa(dp56950
g49782
I154
sg49783
I1
sg49784
I7
sg49785
VC0277556
p56951
sg49787
Vrelapse
p56952
sasa(dp56953
g49775
VOn the basis of the X-ACT trial, capecitabine was approved by the United States Food and Drug Administration, the National Institute for Clinical Excellence, and the Scottish Medicines Consortium as monotherapy for the adjuvant treatment of stage III colon cancer.
p56954
sg49777
(lp56955
sg49779
(lp56956
(dp56957
g49782
I241
sg49783
I4
sg49784
I22
sg49785
VC3146254
p56958
sg49787
Vstage III colon cancer
p56959
sasa(dp56960
g49775
VThe Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) study confirmed that capecitabine (Xeloda) is at least as effective and is less toxic than a bolus 5-FU and leucovorin regimen for patients with stage III colon cancer.
p56961
sg49777
(lp56962
sg49779
(lp56963
(dp56964
g49782
I23
sg49783
I2
sg49784
I12
sg49785
VC0699790
p56965
sg49787
VColon Cancer
p56966
sa(dp56967
g49782
I197
sg49783
I4
sg49784
I22
sg49785
VC3146254
p56968
sg49787
Vstage III colon cancer
p56969
sasa(dp56970
g49775
VIn the recent X-ACT (Xeloda in Adjuvant Colon cancer Therapy) trial, oral capecitabine (Xeloda) demonstrated superior efficacy and an improved safety profile compared with infused fluorouracil + leucovorin (folinic acid) [FU+LV] in patients with Dukes' C colorectal cancer.
p56971
sg49777
(lp56972
sg49779
(lp56973
(dp56974
g49782
I255
sg49783
I2
sg49784
I17
sg49785
VC1527249
p56975
sg49787
Vcolorectal cancer
p56976
sa(dp56977
g49782
I40
sg49783
I2
sg49784
I12
sg49785
VC0699790
p56978
sg49787
VColon cancer
p56979
sasa(dp56980
g49775
VThe X-ACT trial (Xeloda in Adjuvant Colon Cancer Therapy) compared traditional bolus 5-FU/LV (as per the Mayo Clinic regimen) with capecitabine, in the adjuvant treatment of 1987 stage III colon cancer patients.
p56981
sg49777
(lp56982
sg49779
(lp56983
(dp56984
g49782
I179
sg49783
I4
sg49784
I22
sg49785
VC3146254
p56985
sg49787
Vstage III colon cancer
p56986
sa(dp56987
g49782
I36
sg49783
I2
sg49784
I12
sg49785
VC0699790
p56988
sg49787
VColon Cancer
p56989
sasa(dp56990
g49775
VOn the basis of the X-ACT trial, capecitabine was approved by the US FDA, the National Institute for Clinical Excellence and the Scottish Medicines Consortium as monotherapy for the adjuvant treatment of stage III colon cancer.
p56991
sg49777
(lp56992
sg49779
(lp56993
(dp56994
g49782
I204
sg49783
I4
sg49784
I22
sg49785
VC3146254
p56995
sg49787
Vstage III colon cancer
p56996
sasa(dp56997
g49775
VIn order to specifically target GD2 overexpressed on the surface of neuroblastoma stNB-V1 cells, anti-GD2 was conjugated to chitosan modified GNRs (CGNRs).
p56998
sg49777
(lp56999
sg49779
(lp57000
(dp57001
g49782
I68
sg49783
I1
sg49784
I13
sg49785
VC0027819
p57002
sg49787
Vneuroblastoma
p57003
sasa(dp57004
g49775
VOur results illustrated that anti-GD2-conjugated CGNRs were extensively endocytosed by GD2+ stNB-V1 neuroblastoma cells via antibody-mediated endocytosis.
p57005
sg49777
(lp57006
sg49779
(lp57007
(dp57008
g49782
I100
sg49783
I1
sg49784
I13
sg49785
VC0027819
p57009
sg49787
Vneuroblastoma
p57010
sasa(dp57011
g49775
VIn order to specifically target disialoganglioside (GD2) overexpressed on the surface of neuroblastoma stNB-V1 cells, GD2 monoclonal antibody (anti-GD2) was conjugated to acidified CNTs.
p57012
sg49777
(lp57013
sg49779
(lp57014
(dp57015
g49782
I89
sg49783
I1
sg49784
I13
sg49785
VC0027819
p57016
sg49787
Vneuroblastoma
p57017
sasa(dp57018
g49775
VIn addition to the well-known increase in glial fibrillary acidic protein and other proteins in reactive astrocytes, astrocytopathy is evidenced by deposition of abnormal proteins such as Beta-amyloid, hyper-phosphorylated tau, abnormal Alfa-synuclein, mutated huntingtin, phosphorylated TDP-43 and mutated SOD1, and PrPres , in Alzheimer's disease, tauopathies, Lewy body diseases, Huntington's disease, amyotrophic lateral sclerosis and Creutzfeldt-Jakob disease, respectively.
p57019
sg49777
(lp57020
(dp57021
g49782
I299
sg49783
I2
sg49784
I12
sg49812
VP00441
p57022
sg49787
Vmutated SOD1
p57023
sa(dp57024
g49782
I273
sg49783
I2
sg49784
I21
sg49812
g11
sg49787
Vphosphorylated TDP-43
p57025
sa(dp57026
g49782
I237
sg49783
I1
sg49784
I14
sg49812
VP37840
p57027
sg49787
VAlfa-synuclein
p57028
sa(dp57029
g49782
I253
sg49783
I2
sg49784
I18
sg49812
VP42858
p57030
sg49787
Vmutated huntingtin
p57031
sa(dp57032
g49782
I42
sg49783
I4
sg49784
I31
sg49812
VP05230
p57033
sg49787
Vglial fibrillary acidic protein
p57034
sasg49779
(lp57035
(dp57036
g49782
I193
sg49783
I1
sg49784
I7
sg49785
VC0011560
p57037
sg49787
Vamyloid
p57038
sa(dp57039
g49782
I329
sg49783
I2
sg49784
I19
sg49785
VC1521724
p57040
sg49787
VAlzheimer's disease
p57041
sa(dp57042
g49782
I405
sg49783
I3
sg49784
I29
sg49785
VC0002736
p57043
sg49787
Vamyotrophic lateral sclerosis
p57044
sa(dp57045
g49782
I350
sg49783
I1
sg49784
I11
sg49785
VC0949664
p57046
sg49787
Vtauopathies
p57047
sa(dp57048
g49782
I383
sg49783
I2
sg49784
I20
sg49785
VC0020179
p57049
sg49787
VHuntington's disease
p57050
sa(dp57051
g49782
I439
sg49783
I2
sg49784
I25
sg49785
VC0022336
p57052
sg49787
VCreutzfeldt-Jakob disease
p57053
sasa(dp57054
g49775
VInterestingly, BAG3-mediated selective macroautophagy is also involved in the clearance of aggregated proteins associated with age-related neurodegenerative disorders, like Alzheimer's disease (tau-protein), Huntington's disease (mutated huntingtin/polyQ proteins), and amyotrophic lateral sclerosis (mutated SOD1).
p57055
sg49777
(lp57056
(dp57057
g49782
I249
sg49783
I2
sg49784
I14
sg49812
VP02649
p57058
sg49787
VpolyQ proteins
p57059
sa(dp57060
g49782
I15
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VBAG3
p57061
sa(dp57062
g49782
I238
sg49783
I1
sg49784
I10
sg49812
VP42858
p57063
sg49787
Vhuntingtin
p57064
sa(dp57065
g49782
I309
sg49783
I1
sg49784
I4
sg49812
VP00441
p57066
sg49787
VSOD1
p57067
sasg49779
(lp57068
(dp57069
g49782
I173
sg49783
I2
sg49784
I19
sg49785
VC1521724
p57070
sg49787
VAlzheimer's disease
p57071
sa(dp57072
g49782
I270
sg49783
I3
sg49784
I29
sg49785
VC0002736
p57073
sg49787
Vamyotrophic lateral sclerosis
p57074
sa(dp57075
g49782
I208
sg49783
I2
sg49784
I20
sg49785
VC0020179
p57076
sg49787
VHuntington's disease
p57077
sa(dp57078
g49782
I139
sg49783
I2
sg49784
I27
sg49785
VC0524851
p57079
sg49787
Vneurodegenerative disorders
p57080
sasa(dp57081
g49775
VThis report is the first successful generation of neural cells using iPSCs from sleep bruxism patients with 5-HT2A polymorphism, which has the potential to elucidate the etiology and underlying mechanism of SB.
p57082
sg49777
(lp57083
(dp57084
g49782
I110
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VHT2A
p57085
sasg49779
(lp57086
(dp57087
g49782
I80
sg49783
I2
sg49784
I13
sg49785
VC0751771
p57088
sg49787
Vsleep bruxism
p57089
sasa(dp57090
g49775
VAt present, variants of the 5-hydroxytryptamine receptor 2A (5-HTR2A) and interleukin-6 (IL-6) genes may be susceptible markers to develop for obstructive sleep apnea-hypopnea syndrome (OSAHS).
p57091
sg49777
(lp57092
(dp57093
g49782
I89
sg49783
I1
sg49784
I4
sg49812
VP05231
p57094
sg49787
VIL-6
p57095
sa(dp57096
g49782
I74
sg49783
I1
sg49784
I13
sg49812
VP05231
p57097
sg49787
Vinterleukin-6
p57098
sasg49779
(lp57099
(dp57100
g49782
I186
sg49783
I1
sg49784
I5
sg49785
VC0520679
p57101
sg49787
VOSAHS
p57102
sa(dp57103
g49782
I143
sg49783
I4
sg49784
I41
sg49785
VC0520679
p57104
sg49787
Vobstructive sleep apnea-hypopnea syndrome
p57105
sasa(dp57106
g49775
VThe results of our study showed that tumor necrosis factor-Alfa (TNF-Alfa) -308 G/A (OR = 3.70, 95 % CI = 1.39-9.83), gene-linked polymorphic region (LPR) (OR = 0.57, 95 % CI = 0.41-0.79), and variable number tandem repeat (VNTR) of the 5-hydroxytryptamine transporter gene (5-HTT) (OR = 3.44, 95 % CI = 1.49-7.95) polymorphisms were associated with OSAS risk in the Chinese population, while there was no significant association between 5-hydroxytryptamine 2A receptor (5-HTR2A) 102C/T, 5-HTR2A A1438G, angiotensin-converting enzyme (ACE) insertion (I)/deletion (D), or leptin receptor (LEPR)-Gln 223Arg polymorphism and risk of OSAS in the Chinese population.
p57107
sg49777
(lp57108
(dp57109
g49782
I237
sg49783
I3
sg49784
I36
sg49812
VP31645
p57110
sg49787
V5-hydroxytryptamine transporter gene
p57111
sa(dp57112
g49782
I488
sg49783
I2
sg49784
I14
sg49812
VP28223
p57113
sg49787
V5-HTR2A A1438G
p57114
sa(dp57115
g49782
I588
sg49783
I1
sg49784
I4
sg49812
VP48357
p57116
sg49787
VLEPR
p57117
sa(dp57118
g49782
I535
sg49783
I1
sg49784
I3
sg49812
VP12821
p57119
sg49787
VACE
p57120
sa(dp57121
g49782
I37
sg49783
I3
sg49784
I26
sg49812
VP01375
p57122
sg49787
Vtumor necrosis factor-Alfa
p57123
sa(dp57124
g49782
I504
sg49783
I2
sg49784
I29
sg49812
VP12821
p57125
sg49787
Vangiotensin-converting enzyme
p57126
sa(dp57127
g49782
I65
sg49783
I1
sg49784
I8
sg49812
VP01375
p57128
sg49787
VTNF-Alfa
p57129
sa(dp57130
g49782
I571
sg49783
I2
sg49784
I15
sg49812
VP48357
p57131
sg49787
Vleptin receptor
p57132
sa(dp57133
g49782
I438
sg49783
I3
sg49784
I31
sg49812
VP34969
p57134
sg49787
V5-hydroxytryptamine 2A receptor
p57135
sa(dp57136
g49782
I275
sg49783
I1
sg49784
I5
sg49812
VP31645
p57137
sg49787
V5-HTT
p57138
sa(dp57139
g49782
I471
sg49783
I1
sg49784
I7
sg49812
VP28223
p57140
sg49787
V5-HTR2A
p57141
sasg49779
(lp57142
(dp57143
g49782
I350
sg49783
I1
sg49784
I4
sg49785
VC0520679
p57144
sg49787
VOSAS
p57145
sa(dp57146
g49782
I37
sg49783
I2
sg49784
I14
sg49785
VC0333516
p57147
sg49787
Vtumor necrosis
p57148
sa(dp57149
g49782
I193
sg49783
I4
sg49784
I29
sg49785
VC1710347
p57150
sg49787
Vvariable number tandem repeat
p57151
sa(dp57152
g49782
I224
sg49783
I1
sg49784
I4
sg49785
VC1710347
p57153
sg49787
VVNTR
p57154
sa(dp57155
g49782
I350
sg49783
I1
sg49784
I4
sg49785
VC0520679
p57156
sg49787
VOSAS
p57157
sasa(dp57158
g49775
VOur study demonstrated that TNF-Alfa 308 G/A, 5-HTT LPR, and 5-HTT-VNTR polymorphisms were associated with OSAS risk, whereas little association was observed between 5-HTR2A 102C/T, 5-HTR2A A1438G, ACE I/D, or LEPR-Gln 223Arg polymorphism and risk of OSAS in the Chinese population.
p57159
sg49777
(lp57160
(dp57161
g49782
I198
sg49783
I2
sg49784
I7
sg49812
VP12821
p57162
sg49787
VACE I/D
p57163
sa(dp57164
g49782
I28
sg49783
I1
sg49784
I3
sg49812
VP01375
p57165
sg49787
VTNF
p57166
sa(dp57167
g49782
I182
sg49783
I2
sg49784
I14
sg49812
VP28223
p57168
sg49787
V5-HTR2A A1438G
p57169
sa(dp57170
g49782
I166
sg49783
I2
sg49784
I12
sg49812
VP28223
p57171
sg49787
V5-HTR2A 102C
p57172
sasg49779
(lp57173
(dp57174
g49782
I107
sg49783
I1
sg49784
I4
sg49785
VC0520679
p57175
sg49787
VOSAS
p57176
sa(dp57177
g49782
I107
sg49783
I1
sg49784
I4
sg49785
VC0520679
p57178
sg49787
VOSAS
p57179
sasa(dp57180
g49775
VWe performed a meta-analysis to better evaluate the associations between 5-HT2A, 5-HTT, and LEPR polymorphisms, and OSAS.
p57181
sg49777
(lp57182
(dp57183
g49782
I75
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VHT2A
p57184
sa(dp57185
g49782
I81
sg49783
I1
sg49784
I5
sg49812
VP31645
p57186
sg49787
V5-HTT
p57187
sasg49779
(lp57188
(dp57189
g49782
I116
sg49783
I1
sg49784
I4
sg49785
VC0520679
p57190
sg49787
VOSAS
p57191
sasa(dp57192
g49775
V5-HT2A, 5-HTT, and LEPR polymorphisms and OSAS were identified in PubMed and EMBASE.
p57193
sg49777
(lp57194
(dp57195
g49782
I2
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VHT2A
p57196
sa(dp57197
g49782
I8
sg49783
I1
sg49784
I5
sg49812
VP31645
p57198
sg49787
V5-HTT
p57199
sasg49779
(lp57200
(dp57201
g49782
I42
sg49783
I1
sg49784
I4
sg49785
VC0520679
p57202
sg49787
VOSAS
p57203
sasa(dp57204
g49775
VThe -1438 "A" allele of 5-HT2A was identified as a candidate genetic risk factor for OSAS (OR: 2.33, 95%CI 1.49-3.66).
p57205
sg49777
(lp57206
(dp57207
g49782
I26
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VHT2A
p57208
sasg49779
(lp57209
(dp57210
g49782
I85
sg49783
I1
sg49784
I4
sg49785
VC0520679
p57211
sg49787
VOSAS
p57212
sasa(dp57213
g49775
VThere was no significant association between 5-HT2A 102C/T and OSAS risk, using any model.
p57214
sg49777
(lp57215
(dp57216
g49782
I45
sg49783
I2
sg49784
I11
sg49812
VP28223
p57217
sg49787
V5-HT2A 102C
p57218
sasg49779
(lp57219
(dp57220
g49782
I63
sg49783
I1
sg49784
I4
sg49785
VC0520679
p57221
sg49787
VOSAS
p57222
sasa(dp57223
g49775
VEight studies were finally included in the meta-analysis of the association between 5-HTR2A gene variants (including 102T/C and 1438G/A), 5-HTT gene polymorphisms (including 5-HTT gene-linked promoter region (5-HTTLRP), and serotonin transporter intron 2 variable number tandem repeat (STin2VNTR) and OSAS risk.
p57224
sg49777
(lp57225
(dp57226
g49782
I224
sg49783
I2
sg49784
I21
sg49812
VP31645
p57227
sg49787
Vserotonin transporter
p57228
sa(dp57229
g49782
I138
sg49783
I2
sg49784
I10
sg49812
VP31645
p57230
sg49787
V5-HTT gene
p57231
sa(dp57232
g49782
I84
sg49783
I2
sg49784
I12
sg49812
VP28223
p57233
sg49787
V5-HTR2A gene
p57234
sasg49779
(lp57235
(dp57236
g49782
I301
sg49783
I1
sg49784
I4
sg49785
VC0520679
p57237
sg49787
VOSAS
p57238
sa(dp57239
g49782
I255
sg49783
I4
sg49784
I29
sg49785
VC1710347
p57240
sg49787
Vvariable number tandem repeat
p57241
sasa(dp57242
g49775
VThe G allele of 5-HTR2A 1438G/A, long 5-HTTLPR, and 10-tandem-repeats STin2VNTR were shown to increase OSAS susceptibility, with ORs of 2.33 (A vs. G, 95% CI 1.48-3.66), 1.24 (L vs. S, 95% CI: 1.04-1.49), and 2.87 (10 vs. 12, 95% CI: 1.38-5.97), respectively.
p57243
sg49777
(lp57244
(dp57245
g49782
I4
sg49783
I10
sg49784
I75
sg49812
VP28223
p57246
sg49787
VG allele of 5-HTR2A 1438G/A, long 5-HTTLPR, and 10-tandem-repeats STin2VNTR
p57247
sa(dp57248
g49782
I103
sg49783
I2
sg49784
I19
sg49812
VP27986
p57249
sg49787
VOSAS susceptibility
p57250
sasg49779
(lp57251
(dp57252
g49782
I103
sg49783
I1
sg49784
I4
sg49785
VC0520679
p57253
sg49787
VOSAS
p57254
sasa(dp57255
g49775
VOf the 5-HTR2A 1438G/A gene polymorphism, the AA genotype increased the OSAS risk, with an OR of 4.21 (95% CI: 2.83-6.25) in a recessive model in male OSAS patients, but no significant association was found in females.
p57256
sg49777
(lp57257
(dp57258
g49782
I7
sg49783
I2
sg49784
I13
sg49812
VP28223
p57259
sg49787
V5-HTR2A 1438G
p57260
sasg49779
(lp57261
(dp57262
g49782
I72
sg49783
I1
sg49784
I4
sg49785
VC0520679
p57263
sg49787
VOSAS
p57264
sa(dp57265
g49782
I72
sg49783
I1
sg49784
I4
sg49785
VC0520679
p57266
sg49787
VOSAS
p57267
sasa(dp57268
g49775
VOur meta-analysis demonstrated that polymorphisms in the 5-HTR2A 1438G/A and 5-HTT genes contributed to susceptibility to OSAS.
p57269
sg49777
(lp57270
(dp57271
g49782
I77
sg49783
I2
sg49784
I11
sg49812
VP31645
p57272
sg49787
V5-HTT genes
p57273
sa(dp57274
g49782
I57
sg49783
I2
sg49784
I13
sg49812
VP28223
p57275
sg49787
V5-HTR2A 1438G
p57276
sasg49779
(lp57277
(dp57278
g49782
I122
sg49783
I1
sg49784
I4
sg49785
VC0520679
p57279
sg49787
VOSAS
p57280
sasa(dp57281
g49775
VThe serotonin 2A (5-HT2A) receptor has been implicated in obstructive sleep apnea (OSA).
p57282
sg49777
(lp57283
(dp57284
g49782
I4
sg49783
I2
sg49784
I12
sg49812
g11
sg49787
Vserotonin 2A
p57285
sasg49779
(lp57286
(dp57287
g49782
I83
sg49783
I1
sg49784
I3
sg49785
VC0520679
p57288
sg49787
VOSA
p57289
sa(dp57290
g49782
I58
sg49783
I3
sg49784
I23
sg49785
VC0520679
p57291
sg49787
Vobstructive sleep apnea
p57292
sasa(dp57293
g49775
VOur findings suggest that upregulated functional TRPC5 gene may be one cause of EPO-induced hypertension in patients with chronic kidney disease.
p57294
sg49777
(lp57295
(dp57296
g49782
I49
sg49783
I2
sg49784
I10
sg49812
g11
sg49787
VTRPC5 gene
p57297
sa(dp57298
g49782
I80
sg49783
I1
sg49784
I3
sg49812
VP01588
p57299
sg49787
VEPO
p57300
sasg49779
(lp57301
(dp57302
g49782
I92
sg49783
I1
sg49784
I12
sg49785
VC0020538
p57303
sg49787
Vhypertension
p57304
sa(dp57305
g49782
I122
sg49783
I3
sg49784
I22
sg49785
VC1561643
p57306
sg49787
Vchronic kidney disease
p57307
sasa(dp57308
g49775
VTTR (transthyretin) gene could be a possible candidate for lumbosacral stenosis in Labrador retrievers based on previous human studies that have reported an association between human lumbar spinal stenosis and transthyretin protein amyloidosis.
p57309
sg49777
(lp57310
(dp57311
g49782
I0
sg49783
I1
sg49784
I3
sg49812
VP02766
p57312
sg49787
VTTR
p57313
sa(dp57314
g49782
I5
sg49783
I1
sg49784
I13
sg49812
VP02766
p57315
sg49787
Vtransthyretin
p57316
sa(dp57317
g49782
I5
sg49783
I1
sg49784
I13
sg49812
VP02766
p57318
sg49787
Vtransthyretin
p57319
sasg49779
(lp57320
(dp57321
g49782
I59
sg49783
I2
sg49784
I20
sg49785
VC1299881
p57322
sg49787
Vlumbosacral stenosis
p57323
sa(dp57324
g49782
I183
sg49783
I3
sg49784
I22
sg49785
VC0158288
p57325
sg49787
Vlumbar spinal stenosis
p57326
sa(dp57327
g49782
I232
sg49783
I1
sg49784
I11
sg49785
VC0002726
p57328
sg49787
Vamyloidosis
p57329
sasa(dp57330
g49775
VWild-type ATTR amyloidosis mainly involves the heart, although the reported occurrence of bilateral carpal tunnel syndrome, spinal stenosis and biceps tendon rupture in these patients speaks to more generalized protein deposition.
p57331
sg49777
(lp57332
(dp57333
g49782
I0
sg49783
I2
sg49784
I14
sg49812
VP02766
p57334
sg49787
VWild-type ATTR
p57335
sasg49779
(lp57336
(dp57337
g49782
I100
sg49783
I3
sg49784
I22
sg49785
VC0007286
p57338
sg49787
Vcarpal tunnel syndrome
p57339
sa(dp57340
g49782
I124
sg49783
I2
sg49784
I15
sg49785
VC0037944
p57341
sg49787
Vspinal stenosis
p57342
sa(dp57343
g49782
I211
sg49783
I2
sg49784
I18
sg49785
VC0333584
p57344
sg49787
Vprotein deposition
p57345
sa(dp57346
g49782
I15
sg49783
I1
sg49784
I11
sg49785
VC0002726
p57347
sg49787
Vamyloidosis
p57348
sasa(dp57349
g49775
VIn all groups, but the HBD group, the livers were pretreated with FK506 and prostaglandin I2 analogue, and were preserved in University of Wisconsin solution after cardiac arrest.
p57350
sg49777
(lp57351
sg49779
(lp57352
(dp57353
g49782
I23
sg49783
I1
sg49784
I3
sg49785
VC1840321
p57354
sg49787
VHBD
p57355
sa(dp57356
g49782
I164
sg49783
I2
sg49784
I14
sg49785
VC0018790
p57357
sg49787
Vcardiac arrest
p57358
sasa(dp57359
g49775
VWe used a new vasodilator, TTC-909 (a prostaglandin I2 analog incorporated in lipid microspheres), which produced marked reduction in the pulmonary arterial pressure and resistance in an infant with primary pulmonary hypertension.
p57360
sg49777
(lp57361
sg49779
(lp57362
(dp57363
g49782
I199
sg49783
I3
sg49784
I30
sg49785
VC0152171
p57364
sg49787
Vprimary pulmonary hypertension
p57365
sasa(dp57366
g49775
VA prostaglandin I2 (PGI2) was administered before cardiac arrest by St. Thomas solution.
p57367
sg49777
(lp57368
sg49779
(lp57369
(dp57370
g49782
I50
sg49783
I2
sg49784
I14
sg49785
VC0018790
p57371
sg49787
Vcardiac arrest
p57372
sasa(dp57373
g49775
VRecently, with the introduction of prostacyclin (Prostaglandin I2, epoprostenon) as a potent vasodilator, several reports have shown a positive effect in primary pulmonary hypertension.
p57374
sg49777
(lp57375
sg49779
(lp57376
(dp57377
g49782
I154
sg49783
I3
sg49784
I30
sg49785
VC0152171
p57378
sg49787
Vprimary pulmonary hypertension
p57379
sasa(dp57380
g49775
VFurthermore, the involvement of functional GREM1 in the epithelial-mesenchymal transition (EMT) process of glioma was investigated by detecting the expression levels of glioma-associated oncogene homologue 3 (GLI3) and EMT-related molecules.
p57381
sg49777
(lp57382
(dp57383
g49782
I219
sg49783
I2
sg49784
I21
sg49812
g11
sg49787
VEMT-related molecules
p57384
sa(dp57385
g49782
I43
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VGREM1
p57386
sa(dp57387
g49782
I169
sg49783
I4
sg49784
I38
sg49812
VP08151
p57388
sg49787
Vglioma-associated oncogene homologue 3
p57389
sa(dp57390
g49782
I209
sg49783
I1
sg49784
I4
sg49812
VP10071
p57391
sg49787
VGLI3
p57392
sasg49779
(lp57393
(dp57394
g49782
I91
sg49783
I1
sg49784
I3
sg49785
VC0599156
p57395
sg49787
VEMT
p57396
sa(dp57397
g49782
I91
sg49783
I1
sg49784
I3
sg49785
VC0599156
p57398
sg49787
VEMT
p57399
sa(dp57400
g49782
I107
sg49783
I1
sg49784
I6
sg49785
VC0017638
p57401
sg49787
Vglioma
p57402
sa(dp57403
g49782
I56
sg49783
I2
sg49784
I33
sg49785
VC0599156
p57404
sg49787
Vepithelial-mesenchymal transition
p57405
sa(dp57406
g49782
I107
sg49783
I1
sg49784
I6
sg49785
VC0017638
p57407
sg49787
Vglioma
p57408
sasa(dp57409
g49775
VSuppression of GLI1/GLI2 functions by a C-terminus truncated GLI3 repressor mutant (GLI3R), or by GANT61, a pharmacological inhibitor of GLI1/GLI2, reduced hTERT protein expression in human colon cancer, prostate cancer and Glioblastoma multiforme (GBM) cell lines.
p57410
sg49777
(lp57411
(dp57412
g49782
I20
sg49783
I1
sg49784
I4
sg49812
VP10070
p57413
sg49787
VGLI2
p57414
sa(dp57415
g49782
I156
sg49783
I2
sg49784
I13
sg49812
g11
sg49787
VhTERT protein
p57416
sa(dp57417
g49782
I84
sg49783
I1
sg49784
I5
sg49812
VP10071
p57418
sg49787
VGLI3R
p57419
sa(dp57420
g49782
I15
sg49783
I1
sg49784
I4
sg49812
VP08151
p57421
sg49787
VGLI1
p57422
sa(dp57423
g49782
I20
sg49783
I1
sg49784
I4
sg49812
VP10070
p57424
sg49787
VGLI2
p57425
sa(dp57426
g49782
I15
sg49783
I1
sg49784
I4
sg49812
VP08151
p57427
sg49787
VGLI1
p57428
sa(dp57429
g49782
I61
sg49783
I3
sg49784
I21
sg49812
VP10071
p57430
sg49787
VGLI3 repressor mutant
p57431
sasg49779
(lp57432
(dp57433
g49782
I196
sg49783
I2
sg49784
I16
sg49785
VC0376358
p57434
sg49787
Vcancer, prostate
p57435
sa(dp57436
g49782
I196
sg49783
I1
sg49784
I6
sg49785
VC0006826
p57437
sg49787
Vcancer
p57438
sa(dp57439
g49782
I224
sg49783
I2
sg49784
I23
sg49785
VC1621958
p57440
sg49787
VGlioblastoma multiforme
p57441
sa(dp57442
g49782
I249
sg49783
I1
sg49784
I3
sg49785
VC1621958
p57443
sg49787
VGBM
p57444
sa(dp57445
g49782
I76
sg49783
I1
sg49784
I6
sg49785
VC0596988
p57446
sg49787
Vmutant
p57447
sa(dp57448
g49782
I0
sg49783
I1
sg49784
I11
sg49785
VC0221103
p57449
sg49787
VSuppression
p57450
sasa(dp57451
g49775
VInhibitor of DNA binding protein-1 (ID1) has been shown to maintain the self-renewal capacity of neural stem cells and might be involved in the therapeutic resistance of GBM.
p57452
sg49777
(lp57453
(dp57454
g49782
I36
sg49783
I1
sg49784
I3
sg49812
VP29372
p57455
sg49787
VID1
p57456
sa(dp57457
g49782
I0
sg49783
I5
sg49784
I34
sg49812
VP29372
p57458
sg49787
VInhibitor of DNA binding protein-1
p57459
sasg49779
(lp57460
(dp57461
g49782
I170
sg49783
I1
sg49784
I3
sg49785
VC0017636
p57462
sg49787
VGBM
p57463
sasa(dp57464
g49775
VIn glioblastoma neurosphere cultures that contain cancer stem cells (GBM-CSCs), the bHLH family member inhibitors of DNA binding protein 2 and 4 (Id2 and Id4) were found to be upregulated during the differentiation of GBM-CSCs in response to histone deacetylase inhibitors.
p57465
sg49777
(lp57466
(dp57467
g49782
I84
sg49783
I2
sg49784
I11
sg49812
g11
sg49787
VbHLH family
p57468
sa(dp57469
g49782
I154
sg49783
I1
sg49784
I3
sg49812
VP47928
p57470
sg49787
VId4
p57471
sa(dp57472
g49782
I242
sg49783
I2
sg49784
I19
sg49812
VP56524
p57473
sg49787
Vhistone deacetylase
p57474
sa(dp57475
g49782
I117
sg49783
I6
sg49784
I27
sg49812
VP51523
p57476
sg49787
VDNA binding protein 2 and 4
p57477
sa(dp57478
g49782
I146
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VId2
p57479
sasg49779
(lp57480
(dp57481
g49782
I69
sg49783
I1
sg49784
I3
sg49785
VC0017636
p57482
sg49787
VGBM
p57483
sa(dp57484
g49782
I50
sg49783
I1
sg49784
I6
sg49785
VC0006826
p57485
sg49787
Vcancer
p57486
sa(dp57487
g49782
I3
sg49783
I1
sg49784
I12
sg49785
VC0017636
p57488
sg49787
Vglioblastoma
p57489
sa(dp57490
g49782
I69
sg49783
I1
sg49784
I3
sg49785
VC0017636
p57491
sg49787
VGBM
p57492
sasa(dp57493
g49775
VThe improvement in mitral regurgitation was greater for the mitral repair group (-2.1 +/- 0.3 vs -1.1 +/- 0.8, P &lt; .0001), and mitral regurgitation remained significantly lower on follow-up at 6 months or more (0.6 +/- 0.4 0.9 +/- 0.2, P = .002).
p57494
sg49777
(lp57495
sg49779
(lp57496
(dp57497
g49782
I19
sg49783
I2
sg49784
I20
sg49785
VC0026266
p57498
sg49787
Vmitral regurgitation
p57499
sa(dp57500
g49782
I19
sg49783
I2
sg49784
I20
sg49785
VC0026266
p57501
sg49787
Vmitral regurgitation
p57502
sasa(dp57503
g49775
VThis study was undertaken to examine changes in 1-cysPrx expression in human cataract samples, human lens epithelial (HLE B3) cell line, and rat organ-cultured lenses in response to oxidative insult induced by H2O2 or transforming growth factor-beta1 (TGF-beta1).
p57504
sg49777
(lp57505
(dp57506
g49782
I252
sg49783
I1
sg49784
I9
sg49812
VP01137
p57507
sg49787
VTGF-beta1
p57508
sa(dp57509
g49782
I218
sg49783
I3
sg49784
I32
sg49812
VP01137
p57510
sg49787
Vtransforming growth factor-beta1
p57511
sasg49779
(lp57512
(dp57513
g49782
I77
sg49783
I1
sg49784
I8
sg49785
VC0086543
p57514
sg49787
Vcataract
p57515
sasa(dp57516
g49775
VIn a functional analysis, transient cotransfections in nonerythroid NIH/3T3 cells of SP1, SP3, BKLF, or EKLF and HS2 epsilony promoter-luciferase constructs, with or without coactivators (p300, CREB-binding protein [CBP], or p300/CBP-associated factor [PCAF]) and SCFAs, were performed.
p57517
sg49777
(lp57518
(dp57519
g49782
I230
sg49783
I3
sg49784
I28
sg49812
g11
sg49787
VCBP-associated factor [PCAF]
p57520
sa(dp57521
g49782
I85
sg49783
I1
sg49784
I3
sg49812
VP08047
p57522
sg49787
VSP1
p57523
sa(dp57524
g49782
I113
sg49783
I4
sg49784
I43
sg49812
VP11277
p57525
sg49787
VHS2 epsilony promoter-luciferase constructs
p57526
sa(dp57527
g49782
I95
sg49783
I1
sg49784
I4
sg49812
VP57682
p57528
sg49787
VBKLF
p57529
sa(dp57530
g49782
I194
sg49783
I3
sg49784
I26
sg49812
g11
sg49787
VCREB-binding protein [CBP]
p57531
sa(dp57532
g49782
I90
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VSP3
p57533
sa(dp57534
g49782
I188
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
Vp300
p57535
sa(dp57536
g49782
I188
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
Vp300
p57537
sa(dp57538
g49782
I104
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VEKLF
p57539
sasg49779
(lp57540
sa(dp57541
g49775
VUsing our newly created Ngb overexpressing transgenic (Ngb-Tg) mice, we measured brain infarction on day 1 and day 14 after transient focal cerebral ischemia and performed neurobehavioral assessments in sensorimotor deficits on days 1, 3, 7, and 14.
p57542
sg49777
(lp57543
(dp57544
g49782
I24
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VNgb
p57545
sa(dp57546
g49782
I24
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VNgb
p57547
sasg49779
(lp57548
(dp57549
g49782
I140
sg49783
I2
sg49784
I17
sg49785
VC0917798
p57550
sg49787
Vcerebral ischemia
p57551
sa(dp57552
g49782
I81
sg49783
I2
sg49784
I16
sg49785
VC0751955
p57553
sg49787
Vbrain infarction
p57554
sasa(dp57555
g49775
VCompared with wild-type controls, brain infarction volumes 1 day and 14 days after transient focal cerebral ischemia were significantly reduced in Ngb-Tg mice.
p57556
sg49777
(lp57557
(dp57558
g49782
I147
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VNgb
p57559
sasg49779
(lp57560
(dp57561
g49782
I34
sg49783
I2
sg49784
I16
sg49785
VC0751955
p57562
sg49787
Vbrain infarction
p57563
sa(dp57564
g49782
I99
sg49783
I2
sg49784
I17
sg49785
VC0917798
p57565
sg49787
Vcerebral ischemia
p57566
sasa(dp57567
g49775
VEvidence includes the observations that neuronal hypoxia and cerebral ischemia induce Ngb expression, that enhancing Ngb expression reduces--and knocking down Ngb expression increases--hypoxic neuronal injury in vitro and ischemic cerebral injury in vivo, and that Ngb-overexpressing transgenic mice are resistant to cerebral infarction.
p57568
sg49777
(lp57569
(dp57570
g49782
I86
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VNgb
p57571
sa(dp57572
g49782
I86
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VNgb
p57573
sa(dp57574
g49782
I86
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VNgb
p57575
sa(dp57576
g49782
I86
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VNgb
p57577
sasg49779
(lp57578
(dp57579
g49782
I61
sg49783
I2
sg49784
I17
sg49785
VC0917798
p57580
sg49787
Vcerebral ischemia
p57581
sa(dp57582
g49782
I317
sg49783
I2
sg49784
I19
sg49785
VC0038454
p57583
sg49787
Vcerebral infarction
p57584
sa(dp57585
g49782
I185
sg49783
I1
sg49784
I7
sg49785
VC0242184
p57586
sg49787
Vhypoxic
p57587
sa(dp57588
g49782
I49
sg49783
I1
sg49784
I7
sg49785
VC0242184
p57589
sg49787
Vhypoxia
p57590
sasa(dp57591
g49775
VSono stati presentati i casi di un effetto paradosso di aggressivita sotto la possibile influenza di acepromazina e un protocollo modificato per il trattamento di un avvelenamento da permetrina nei gatti.
p57592
sg49777
(lp57593
sg49779
(lp57594
(dp57595
g49782
I88
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57596
sg49787
Vinfluenza
p57597
sasa(dp57598
g49775
VADRP and perilipin localized to the phagosomal membrane, which contains M. leprae in skin biopsy specimens of lepromatous leprosy.
p57599
sg49777
(lp57600
(dp57601
g49782
I9
sg49783
I1
sg49784
I9
sg49812
g11
sg49787
Vperilipin
p57602
sa(dp57603
g49782
I0
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VADRP
p57604
sasg49779
(lp57605
(dp57606
g49782
I110
sg49783
I2
sg49784
I19
sg49785
VC0023348
p57607
sg49787
Vlepromatous leprosy
p57608
sasa(dp57609
g49775
VIn this work, two novel exonic BCKDK mutations, c.520C&gt;G/p.R174G and c.1166T&gt;C/p.L389P, were identified at the homozygous state in two unrelated children with persistently reduced body fluid levels of branched-chain amino acids (BCAAs), developmental delay, microcephaly, and neurobehavioral abnormalities.
p57610
sg49777
(lp57611
(dp57612
g49782
I31
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VBCKDK
p57613
sasg49779
(lp57614
(dp57615
g49782
I264
sg49783
I1
sg49784
I12
sg49785
VC0025958
p57616
sg49787
Vmicrocephaly
p57617
sa(dp57618
g49782
I243
sg49783
I2
sg49784
I19
sg49785
VC0424605
p57619
sg49787
Vdevelopmental delay
p57620
sasa(dp57621
g49775
VAR-12-stimulated the co-localization of Influenza, EBV and HIV virus proteins with LC3 in autophagosomes and reduced viral protein association with the chaperones HSP90, HSP70, and GRP78.
p57622
sg49777
(lp57623
(dp57624
g49782
I83
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VLC3
p57625
sa(dp57626
g49782
I170
sg49783
I1
sg49784
I5
sg49812
VP34932
p57627
sg49787
VHSP70
p57628
sa(dp57629
g49782
I181
sg49783
I1
sg49784
I5
sg49812
VP11021
p57630
sg49787
VGRP78
p57631
sa(dp57632
g49782
I163
sg49783
I1
sg49784
I5
sg49812
VP07900
p57633
sg49787
VHSP90
p57634
sasg49779
(lp57635
(dp57636
g49782
I40
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57637
sg49787
VInfluenza
p57638
sa(dp57639
g49782
I59
sg49783
I1
sg49784
I3
sg49785
VC0019693
p57640
sg49787
VHIV
p57641
sasa(dp57642
g49775
VHence, in agreement with heat shock protein 70 (HSP70) acting as Th1 cytokine-like adjuvant, an Escherichia coli-expressed r4M2e.HSP70c fusion protein comprising C-terminus of Mycobacterium tuberculosis HSP70 genetically fused to four tandem repeats of influenza A virus M2e was constructed.
p57643
sg49777
(lp57644
(dp57645
g49782
I48
sg49783
I1
sg49784
I5
sg49812
VP34932
p57646
sg49787
VHSP70
p57647
sa(dp57648
g49782
I25
sg49783
I4
sg49784
I21
sg49812
VP34932
p57649
sg49787
Vheat shock protein 70
p57650
sa(dp57651
g49782
I48
sg49783
I1
sg49784
I5
sg49812
VP34932
p57652
sg49787
VHSP70
p57653
sa(dp57654
g49782
I253
sg49783
I4
sg49784
I21
sg49812
g11
sg49787
Vinfluenza A virus M2e
p57655
sa(dp57656
g49782
I129
sg49783
I3
sg49784
I21
sg49812
VP35637
p57657
sg49787
VHSP70c fusion protein
p57658
sasg49779
(lp57659
(dp57660
g49782
I190
sg49783
I1
sg49784
I12
sg49785
VC0041296
p57661
sg49787
Vtuberculosis
p57662
sa(dp57663
g49782
I253
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57664
sg49787
Vinfluenza
p57665
sasa(dp57666
g49775
VFurthermore, a virus challenge experiment revealed that mice vaccinated with r4M2e.HSP70c limited the severity of influenza A disease by 100% survival rate, less sever body weight loss and delaying the onset of morbidity in mice for 2days rather than other control groups.
p57667
sg49777
(lp57668
sg49779
(lp57669
(dp57670
g49782
I114
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57671
sg49787
Vinfluenza
p57672
sasa(dp57673
g49775
VTo prepare an effective vaccine against influenza A viruses, a chimerical DNA plasmid encoding Influenza virus M2 protein and Leishmania major HSP70 was constructed.
p57674
sg49777
(lp57675
(dp57676
g49782
I126
sg49783
I3
sg49784
I22
sg49812
VP34932
p57677
sg49787
VLeishmania major HSP70
p57678
sasg49779
(lp57679
(dp57680
g49782
I40
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57681
sg49787
Vinfluenza
p57682
sa(dp57683
g49782
I95
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57684
sg49787
VInfluenza
p57685
sasa(dp57686
g49775
VOur previous study have shown that a prime-boost administration of recombinant 4xM2e.HSP70c (r4M2e/H70c) fusion protein compared to conventional HA-based influenza vaccines provided full protection against lethal dose of influenza A viruses in mice.
p57687
sg49777
(lp57688
sg49779
(lp57689
(dp57690
g49782
I154
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57691
sg49787
Vinfluenza
p57692
sa(dp57693
g49782
I154
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57694
sg49787
Vinfluenza
p57695
sasa(dp57696
g49775
VThe data reported herein show that protection against H9N2 viral challenge was significantly increased in chickens by injection of r4M2e/H70c compared with injection of conventional HA-based influenza vaccine adjuvanted with MF59 or recombinant 4xM2e (r4M2e) without HSP70c.
p57697
sg49777
(lp57698
sg49779
(lp57699
(dp57700
g49782
I191
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57701
sg49787
Vinfluenza
p57702
sasa(dp57703
g49775
VThis protective immunity might be attributed to enhanced cell-mediated immunity, which is interpreted as increased lymphocytes proliferation, increased levels of Th1-type (IFN-Gamma) and Th2-type (IL-4) cytokines production and increased CD4(+) to CD8(+) ratios, resulting from the injection of four tandem repeats of the ectodomain of the conserved influenza matrix protein M2 (4xM2e) genetically fused to C-terminus of Mycobacterium tuberculosis HSP70 (mHSP70c).
p57704
sg49777
(lp57705
(dp57706
g49782
I448
sg49783
I1
sg49784
I5
sg49812
VP34932
p57707
sg49787
VHSP70
p57708
sa(dp57709
g49782
I248
sg49783
I1
sg49784
I3
sg49812
VP01732
p57710
sg49787
VCD8
p57711
sa(dp57712
g49782
I238
sg49783
I1
sg49784
I3
sg49812
VP01730
p57713
sg49787
VCD4
p57714
sa(dp57715
g49782
I172
sg49783
I1
sg49784
I9
sg49812
VP01579
p57716
sg49787
VIFN-Gamma
p57717
sasg49779
(lp57718
(dp57719
g49782
I435
sg49783
I1
sg49784
I12
sg49785
VC0041296
p57720
sg49787
Vtuberculosis
p57721
sa(dp57722
g49782
I350
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57723
sg49787
Vinfluenza
p57724
sa(dp57725
g49782
I127
sg49783
I1
sg49784
I13
sg49785
VC0334094
p57726
sg49787
Vproliferation
p57727
sasa(dp57728
g49775
VHeat shock protein 70 (Hsp70) was identified as a cellular interaction partner of the influenza virus ribonucleoprotein (RNP) complex.
p57729
sg49777
(lp57730
(dp57731
g49782
I0
sg49783
I4
sg49784
I21
sg49812
VP34932
p57732
sg49787
VHeat shock protein 70
p57733
sa(dp57734
g49782
I23
sg49783
I1
sg49784
I5
sg49812
VP34932
p57735
sg49787
VHsp70
p57736
sasg49779
(lp57737
(dp57738
g49782
I86
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57739
sg49787
Vinfluenza
p57740
sasa(dp57741
g49775
VHere we demonstrated that Hsp70 was involved in the regulation of influenza A viral transcription and replication.
p57742
sg49777
(lp57743
(dp57744
g49782
I26
sg49783
I1
sg49784
I5
sg49812
VP34932
p57745
sg49787
VHsp70
p57746
sasg49779
(lp57747
(dp57748
g49782
I66
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57749
sg49787
Vinfluenza
p57750
sasa(dp57751
g49775
VFurthermore, delivered Hsp70 could inhibit the replication of influenza A virus in mice.
p57752
sg49777
(lp57753
(dp57754
g49782
I23
sg49783
I1
sg49784
I5
sg49812
VP34932
p57755
sg49787
VHsp70
p57756
sasg49779
(lp57757
(dp57758
g49782
I62
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57759
sg49787
Vinfluenza
p57760
sasa(dp57761
g49775
VIn this study, antigenic peptides from tetanus toxin and influenza hemagglutinin complexed to human stress-inducible Hsp70 were found to enhance the proliferation and cytokine production of human antigen-specific CD4(+) T cells.
p57762
sg49777
(lp57763
(dp57764
g49782
I117
sg49783
I1
sg49784
I5
sg49812
VP34932
p57765
sg49787
VHsp70
p57766
sa(dp57767
g49782
I190
sg49783
I3
sg49784
I26
sg49812
VP14209
p57768
sg49787
Vhuman antigen-specific CD4
p57769
sasg49779
(lp57770
(dp57771
g49782
I57
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57772
sg49787
Vinfluenza
p57773
sa(dp57774
g49782
I39
sg49783
I1
sg49784
I7
sg49785
VC0039614
p57775
sg49787
Vtetanus
p57776
sa(dp57777
g49782
I149
sg49783
I1
sg49784
I13
sg49785
VC0334094
p57778
sg49787
Vproliferation
p57779
sasa(dp57780
g49775
VHerein, to construct a recombinant M2e-based vaccine candidate with the appropriate structural conformation and immunogenicity the corresponding nucleotide sequence from an H9N2 influenza strain was fused to the N-terminus of the truncated Mycobacterium tuberculosis HSP70(359-610), as a potent adjuvant, and following its cloning into the pPICZ alpha A plasmid the fusion gene was expressed in Pichia pastoris KM71H yeast.
p57781
sg49777
(lp57782
(dp57783
g49782
I267
sg49783
I1
sg49784
I14
sg49812
VP34932
p57784
sg49787
VHSP70(359-610)
p57785
sasg49779
(lp57786
(dp57787
g49782
I178
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57788
sg49787
Vinfluenza
p57789
sa(dp57790
g49782
I254
sg49783
I1
sg49784
I12
sg49785
VC0041296
p57791
sg49787
Vtuberculosis
p57792
sasa(dp57793
g49775
VAccording to previous reports, this study was designed to produce a novel influenza A virus recombinant fusion protein consisted of M2e, a potent immunogenic protein from influenza A virus, fused to C-terminal domain of mycobacterium tuberculosis HSP70, HSP70(359-610), as a carrier and adjuvant.
p57794
sg49777
(lp57795
(dp57796
g49782
I247
sg49783
I1
sg49784
I5
sg49812
VP34932
p57797
sg49787
VHSP70
p57798
sa(dp57799
g49782
I254
sg49783
I1
sg49784
I14
sg49812
VP34932
p57800
sg49787
VHSP70(359-610)
p57801
sasg49779
(lp57802
(dp57803
g49782
I234
sg49783
I1
sg49784
I12
sg49785
VC0041296
p57804
sg49787
Vtuberculosis
p57805
sa(dp57806
g49782
I74
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57807
sg49787
Vinfluenza
p57808
sa(dp57809
g49782
I74
sg49783
I1
sg49784
I9
sg49785
VC0021400
p57810
sg49787
Vinfluenza
p57811
sasa(dp57812
g49775
VDe novo mutations in ATAD3A (ATPase family AAA-domain containing protein 3A) were recently found to cause a neurological syndrome with developmental delay, hypotonia, spasticity, optic atrophy, axonal neuropathy, and hypertrophic cardiomyopathy.
p57813
sg49777
(lp57814
(dp57815
g49782
I21
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VATAD3A
p57816
sa(dp57817
g49782
I29
sg49783
I6
sg49784
I46
sg49812
VP38606
p57818
sg49787
VATPase family AAA-domain containing protein 3A
p57819
sasg49779
(lp57820
(dp57821
g49782
I194
sg49783
I2
sg49784
I17
sg49785
VC0270921
p57822
sg49787
Vaxonal neuropathy
p57823
sa(dp57824
g49782
I156
sg49783
I1
sg49784
I9
sg49785
VC0026827
p57825
sg49787
Vhypotonia
p57826
sa(dp57827
g49782
I121
sg49783
I1
sg49784
I8
sg49785
VC0039082
p57828
sg49787
Vsyndrome
p57829
sa(dp57830
g49782
I179
sg49783
I2
sg49784
I13
sg49785
VC0029124
p57831
sg49787
Voptic atrophy
p57832
sa(dp57833
g49782
I167
sg49783
I1
sg49784
I10
sg49785
VC0026838
p57834
sg49787
Vspasticity
p57835
sa(dp57836
g49782
I43
sg49783
I1
sg49784
I3
sg49785
VC0162871
p57837
sg49787
VAAA
p57838
sa(dp57839
g49782
I217
sg49783
I2
sg49784
I27
sg49785
VC0007194
p57840
sg49787
Vhypertrophic cardiomyopathy
p57841
sa(dp57842
g49782
I135
sg49783
I2
sg49784
I19
sg49785
VC0424605
p57843
sg49787
Vdevelopmental delay
p57844
sasa(dp57845
g49775
VWe identified a recurrent de novo ATAD3A c.1582C&gt;T (p.Arg528Trp) variant by whole-exome sequencing (WES) in five unrelated individuals with a core phenotype of global developmental delay, hypotonia, optic atrophy, axonal neuropathy, and hypertrophic cardiomyopathy.
p57846
sg49777
(lp57847
(dp57848
g49782
I34
sg49783
I2
sg49784
I14
sg49812
g11
sg49787
VATAD3A c.1582C
p57849
sasg49779
(lp57850
(dp57851
g49782
I217
sg49783
I2
sg49784
I17
sg49785
VC0270921
p57852
sg49787
Vaxonal neuropathy
p57853
sa(dp57854
g49782
I240
sg49783
I2
sg49784
I27
sg49785
VC0007194
p57855
sg49787
Vhypertrophic cardiomyopathy
p57856
sa(dp57857
g49782
I202
sg49783
I2
sg49784
I13
sg49785
VC0029124
p57858
sg49787
Voptic atrophy
p57859
sa(dp57860
g49782
I163
sg49783
I3
sg49784
I26
sg49785
VC0557874
p57861
sg49787
Vglobal developmental delay
p57862
sa(dp57863
g49782
I191
sg49783
I1
sg49784
I9
sg49785
VC0026827
p57864
sg49787
Vhypotonia
p57865
sasa(dp57866
g49775
VImmunoblot and mass spectrometry analyses revealed that the 800-kDa complex contained the OMM translocator protein (18-kDa) and VDAC along with IMM CYP11A1, ATPase family AAA domain-containing protein 3A (ATAD3A), and optic atrophy type 1 proteins, but not ANT.
p57867
sg49777
(lp57868
(dp57869
g49782
I144
sg49783
I2
sg49784
I11
sg49812
VP05108
p57870
sg49787
VIMM CYP11A1
p57871
sa(dp57872
g49782
I157
sg49783
I6
sg49784
I46
sg49812
g11
sg49787
VATPase family AAA domain-containing protein 3A
p57873
sa(dp57874
g49782
I257
sg49783
I1
sg49784
I3
sg49812
VP12235
p57875
sg49787
VANT
p57876
sa(dp57877
g49782
I90
sg49783
I3
sg49784
I24
sg49812
VP30536
p57878
sg49787
VOMM translocator protein
p57879
sa(dp57880
g49782
I205
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VATAD3A
p57881
sasg49779
(lp57882
(dp57883
g49782
I218
sg49783
I4
sg49784
I20
sg49785
VC0338508
p57884
sg49787
Voptic atrophy type 1
p57885
sa(dp57886
g49782
I171
sg49783
I1
sg49784
I3
sg49785
VC0162871
p57887
sg49787
VAAA
p57888
sasa(dp57889
g49775
VKnockdown of ATAD3A, but not ANT or optic atrophy type 1, in Leydig cells resulted in a significant decrease in hormone-induced, but not 22R-hydroxycholesterol-supported, steroid production.
p57890
sg49777
(lp57891
(dp57892
g49782
I29
sg49783
I1
sg49784
I3
sg49812
VP12235
p57893
sg49787
VANT
p57894
sa(dp57895
g49782
I13
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VATAD3A
p57896
sasg49779
(lp57897
(dp57898
g49782
I36
sg49783
I4
sg49784
I20
sg49785
VC0338508
p57899
sg49787
Voptic atrophy type 1
p57900
sasa(dp57901
g49775
VSo, we attempted to evaluate the association between dopamine D2 (DRD2) receptor, serotonergic (5HT2A) receptor and CYP2D6 gene polymorphisms and response to treatment with risperidone in persons with schizophrenia from North India.
p57902
sg49777
(lp57903
(dp57904
g49782
I53
sg49783
I4
sg49784
I27
sg49812
VP14416
p57905
sg49787
Vdopamine D2 (DRD2) receptor
p57906
sa(dp57907
g49782
I116
sg49783
I2
sg49784
I11
sg49812
VP10635
p57908
sg49787
VCYP2D6 gene
p57909
sa(dp57910
g49782
I82
sg49783
I3
sg49784
I29
sg49812
VP28223
p57911
sg49787
Vserotonergic (5HT2A) receptor
p57912
sasg49779
(lp57913
(dp57914
g49782
I201
sg49783
I1
sg49784
I13
sg49785
VC0036341
p57915
sg49787
Vschizophrenia
p57916
sasa(dp57917
g49775
VWe identified 60 miRNAs that were significantly increased in recurrent serous ovarian carcinoma compared with primary tumor tissue, including miR-630, miR-370, and miR-575.
p57918
sg49777
(lp57919
(dp57920
g49782
I142
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-630
p57921
sa(dp57922
g49782
I151
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-370
p57923
sasg49779
(lp57924
(dp57925
g49782
I110
sg49783
I2
sg49784
I13
sg49785
VC0677930
p57926
sg49787
Vprimary tumor
p57927
sa(dp57928
g49782
I78
sg49783
I2
sg49784
I17
sg49785
VC0029925
p57929
sg49787
Vovarian carcinoma
p57930
sasa(dp57931
g49775
VThree other miRNAs, miR-19b, miR-433, and miR-370 were associated with lymph node metastasis, decreased curvature, and poorly differentiated carcinoma.
p57932
sg49777
(lp57933
(dp57934
g49782
I29
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-433
p57935
sa(dp57936
g49782
I42
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-370
p57937
sa(dp57938
g49782
I20
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-19b
p57939
sasg49779
(lp57940
(dp57941
g49782
I71
sg49783
I3
sg49784
I21
sg49785
VC0686619
p57942
sg49787
Vlymph node metastasis
p57943
sa(dp57944
g49782
I119
sg49783
I3
sg49784
I31
sg49785
VC0741899
p57945
sg49787
Vpoorly differentiated carcinoma
p57946
sasa(dp57947
g49775
VA preliminary screening study suggested that down-regulation of miR-370 occurs in oral squamous cell carcinoma (OSCC) tissue.
p57948
sg49777
(lp57949
(dp57950
g49782
I64
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-370
p57951
sasg49779
(lp57952
(dp57953
g49782
I87
sg49783
I3
sg49784
I23
sg49785
VC0007137
p57954
sg49787
Vsquamous cell carcinoma
p57955
sasa(dp57956
g49775
VSquamous cell carcinoma tissues with perineural invasion had lowered miR-370 expression compared with contrasting OSCC.
p57957
sg49777
(lp57958
(dp57959
g49782
I69
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-370
p57960
sasg49779
(lp57961
(dp57962
g49782
I48
sg49783
I1
sg49784
I8
sg49785
VC2699153
p57963
sg49787
Vinvasion
p57964
sa(dp57965
g49782
I0
sg49783
I3
sg49784
I23
sg49785
VC0007137
p57966
sg49787
VSquamous cell carcinoma
p57967
sasa(dp57968
g49775
VExpression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues.
p57969
sg49777
(lp57970
(dp57971
g49782
I36
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-30d
p57972
sa(dp57973
g49782
I57
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-370
p57974
sa(dp57975
g49782
I27
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-30c
p57976
sa(dp57977
g49782
I45
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-30e-3p
p57978
sasg49779
(lp57979
(dp57980
g49782
I102
sg49783
I1
sg49784
I9
sg49785
VC0007097
p57981
sg49787
Vcarcinoma
p57982
sa(dp57983
g49782
I102
sg49783
I1
sg49784
I10
sg49785
VC0007097
p57984
sg49787
Vcarcinomas
p57985
sasa(dp57986
g49775
VPruritus was assessed by the number of scratching bouts, whilst skin inflammation was evaluated by the extravascular accumulation of intravenously injected 125I-albumin (plasma extravasation) and myeloperoxidase (MPO) activity (neutrophil recruitment).
p57987
sg49777
(lp57988
(dp57989
g49782
I196
sg49783
I1
sg49784
I15
sg49812
VP05164
p57990
sg49787
Vmyeloperoxidase
p57991
sa(dp57992
g49782
I161
sg49783
I1
sg49784
I7
sg49812
VP00441
p57993
sg49787
Valbumin
p57994
sa(dp57995
g49782
I213
sg49783
I1
sg49784
I3
sg49812
VP05164
p57996
sg49787
VMPO
p57997
sasg49779
(lp57998
(dp57999
g49782
I239
sg49783
I1
sg49784
I11
sg49785
VC0271510
p58000
sg49787
Vrecruitment
p58001
sa(dp58002
g49782
I64
sg49783
I2
sg49784
I17
sg49785
VC0011603
p58003
sg49787
Vskin inflammation
p58004
sa(dp58005
g49782
I0
sg49783
I1
sg49784
I8
sg49785
VC0033774
p58006
sg49787
VPruritus
p58007
sa(dp58008
g49782
I177
sg49783
I1
sg49784
I13
sg49785
VC0015376
p58009
sg49787
Vextravasation
p58010
sasa(dp58011
g49775
VThe neuropeptide PACAP and VPAC1 were previously found to negatively regulate megakaryopoiesis, and inhibition of their physiological pathway was found to have a thrombopoietic effect in conditions where megakaryopoiesis and thrombopoiesis were impaired, such as chemotherapy-induced thrombocytopenia and congenital thrombocytopenia.
p58012
sg49777
(lp58013
(dp58014
g49782
I27
sg49783
I1
sg49784
I5
sg49812
VP32241
p58015
sg49787
VVPAC1
p58016
sa(dp58017
g49782
I17
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPACAP
p58018
sasg49779
(lp58019
(dp58020
g49782
I305
sg49783
I2
sg49784
I27
sg49785
VC0272278
p58021
sg49787
Vcongenital thrombocytopenia
p58022
sa(dp58023
g49782
I245
sg49783
I1
sg49784
I8
sg49785
VC0684336
p58024
sg49787
Vimpaired
p58025
sasa(dp58026
g49775
VThe present study explored the thrombopoietic effect of VPAC1 inhibition in a murine model of syngeneic bone marrow transplantation (BMT) and in passive immune thrombocytopenia.
p58027
sg49777
(lp58028
(dp58029
g49782
I56
sg49783
I1
sg49784
I5
sg49812
VP32241
p58030
sg49787
VVPAC1
p58031
sasg49779
(lp58032
(dp58033
g49782
I153
sg49783
I2
sg49784
I23
sg49785
VC0272286
p58034
sg49787
Vimmune thrombocytopenia
p58035
sasa(dp58036
g49775
VRheumatoid arthritis (RA) is an autoimmune disease which may lead to severe disabilities due to structural joint damage and extraarticular manifestations The dendritic cell marker CD83 belongs to the immunoglobulin superfamily and has previously been associated with autoimmune diseases.
p58037
sg49777
(lp58038
(dp58039
g49782
I180
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VCD83
p58040
sa(dp58041
g49782
I200
sg49783
I2
sg49784
I26
sg49812
g11
sg49787
Vimmunoglobulin superfamily
p58042
sasg49779
(lp58043
(dp58044
g49782
I32
sg49783
I2
sg49784
I18
sg49785
VC0004364
p58045
sg49787
Vautoimmune disease
p58046
sa(dp58047
g49782
I267
sg49783
I2
sg49784
I19
sg49785
VC0004364
p58048
sg49787
Vautoimmune diseases
p58049
sa(dp58050
g49782
I22
sg49783
I1
sg49784
I2
sg49785
VC0003873
p58051
sg49787
VRA
p58052
sa(dp58053
g49782
I0
sg49783
I2
sg49784
I20
sg49785
VC0003873
p58054
sg49787
VRheumatoid arthritis
p58055
sasa(dp58056
g49775
VPatients with PLCH displayed a normal expression of the maturity marker CD83 on BALF myeloid DCs.
p58057
sg49777
(lp58058
(dp58059
g49782
I72
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VCD83
p58060
sasg49779
(lp58061
(dp58062
g49782
I93
sg49783
I1
sg49784
I3
sg49785
VC0268238
p58063
sg49787
VDCs
p58064
sasa(dp58065
g49775
VTo the differentiation-related markers, the BRAF/MAP2K1-mut LCH expressed CD14 but rarely expressed CD83 or CD86 (P &lt; .001).
p58066
sg49777
(lp58067
(dp58068
g49782
I56
sg49783
I1
sg49784
I3
sg49812
VP22033
p58069
sg49787
Vmut
p58070
sa(dp58071
g49782
I100
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VCD83
p58072
sa(dp58073
g49782
I49
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VMAP2K1
p58074
sa(dp58075
g49782
I74
sg49783
I1
sg49784
I4
sg49812
VP08571
p58076
sg49787
VCD14
p58077
sa(dp58078
g49782
I108
sg49783
I1
sg49784
I4
sg49812
VP42081
p58079
sg49787
VCD86
p58080
sa(dp58081
g49782
I44
sg49783
I1
sg49784
I4
sg49812
VP15056
p58082
sg49787
VBRAF
p58083
sasg49779
(lp58084
(dp58085
g49782
I60
sg49783
I1
sg49784
I3
sg49785
VC0019621
p58086
sg49787
VLCH
p58087
sasa(dp58088
g49775
VOn the contrary, BRAF/MAP2K1-wt LCH cells rarely expressed CD14 but expressed CD86, and some also expressed CD83 (P &lt; .001).
p58089
sg49777
(lp58090
(dp58091
g49782
I108
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VCD83
p58092
sa(dp58093
g49782
I59
sg49783
I1
sg49784
I4
sg49812
VP08571
p58094
sg49787
VCD14
p58095
sa(dp58096
g49782
I17
sg49783
I1
sg49784
I4
sg49812
VP15056
p58097
sg49787
VBRAF
p58098
sa(dp58099
g49782
I22
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VMAP2K1
p58100
sa(dp58101
g49782
I78
sg49783
I1
sg49784
I4
sg49812
VP42081
p58102
sg49787
VCD86
p58103
sasg49779
(lp58104
(dp58105
g49782
I32
sg49783
I1
sg49784
I3
sg49785
VC0019621
p58106
sg49787
VLCH
p58107
sasa(dp58108
g49775
VThe protein phosphatase 1-like gene (PPM1l) was identified as causal gene for obesity and metabolic abnormalities in mice.
p58109
sg49777
(lp58110
(dp58111
g49782
I4
sg49783
I4
sg49784
I31
sg49812
g11
sg49787
Vprotein phosphatase 1-like gene
p58112
sa(dp58113
g49782
I37
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPPM1l
p58114
sasg49779
(lp58115
(dp58116
g49782
I78
sg49783
I1
sg49784
I7
sg49785
VC0028754
p58117
sg49787
Vobesity
p58118
sasa(dp58119
g49775
VThree genes in this network, lipoprotein lipase (Lpl), lactamase beta (Lactb) and protein phosphatase 1-like (Ppm1l), are validated as previously unknown obesity genes, strengthening the association between this network and metabolic disease traits.
p58120
sg49777
(lp58121
(dp58122
g49782
I110
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPpm1l
p58123
sa(dp58124
g49782
I71
sg49783
I1
sg49784
I5
sg49812
VP83111
p58125
sg49787
VLactb
p58126
sa(dp58127
g49782
I49
sg49783
I1
sg49784
I3
sg49812
VP06858
p58128
sg49787
VLpl
p58129
sa(dp58130
g49782
I55
sg49783
I2
sg49784
I14
sg49812
VP83111
p58131
sg49787
Vlactamase beta
p58132
sa(dp58133
g49782
I29
sg49783
I2
sg49784
I18
sg49812
VP06858
p58134
sg49787
Vlipoprotein lipase
p58135
sa(dp58136
g49782
I82
sg49783
I3
sg49784
I26
sg49812
g11
sg49787
Vprotein phosphatase 1-like
p58137
sasg49779
(lp58138
(dp58139
g49782
I154
sg49783
I1
sg49784
I7
sg49785
VC0028754
p58140
sg49787
Vobesity
p58141
sa(dp58142
g49782
I224
sg49783
I2
sg49784
I17
sg49785
VC0025517
p58143
sg49787
Vmetabolic disease
p58144
sasa(dp58145
g49775
VBased on previous research, we hypothesized that RES regulates FoxO1 transcriptional activity through the phosphatidylinositol-3-kinase (PI3K)/AKT signaling pathway to achieve an antioxidative effect on osteoporosis and then we confirmed this hypothesis in the present study.
p58146
sg49777
(lp58147
(dp58148
g49782
I137
sg49783
I1
sg49784
I4
sg49812
VP42336
p58149
sg49787
VPI3K
p58150
sa(dp58151
g49782
I106
sg49783
I1
sg49784
I29
sg49812
VP33981
p58152
sg49787
Vphosphatidylinositol-3-kinase
p58153
sa(dp58154
g49782
I143
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VAKT
p58155
sasg49779
(lp58156
(dp58157
g49782
I203
sg49783
I1
sg49784
I12
sg49785
VC0029456
p58158
sg49787
Vosteoporosis
p58159
sasa(dp58160
g49775
VFoxO1 is a major action target of RES to confer anti-osteoporosis function, and whose effect stems from its power to improve redox balance.
p58161
sg49777
(lp58162
(dp58163
g49782
I0
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VFoxO1
p58164
sasg49779
(lp58165
(dp58166
g49782
I53
sg49783
I1
sg49784
I12
sg49785
VC0029456
p58167
sg49787
Vosteoporosis
p58168
sasa(dp58169
g49775
VBut whether FoxO1 is involved in the oxidative damage during osteoporosis is largely unknown.
p58170
sg49777
(lp58171
(dp58172
g49782
I12
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VFoxO1
p58173
sasg49779
(lp58174
(dp58175
g49782
I61
sg49783
I1
sg49784
I12
sg49785
VC0029456
p58176
sg49787
Vosteoporosis
p58177
sasa(dp58178
g49775
VIn conclusion, our study revealed that the decline of FoxO1 is an important etiology factor of osteoporosis and unclosed a novel mechanism of FoxO1 regulation by TNF-Alfa.
p58179
sg49777
(lp58180
(dp58181
g49782
I162
sg49783
I1
sg49784
I8
sg49812
VP01375
p58182
sg49787
VTNF-Alfa
p58183
sa(dp58184
g49782
I54
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VFoxO1
p58185
sa(dp58186
g49782
I54
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VFoxO1
p58187
sasg49779
(lp58188
(dp58189
g49782
I95
sg49783
I1
sg49784
I12
sg49785
VC0029456
p58190
sg49787
Vosteoporosis
p58191
sasa(dp58192
g49775
VIn addition, several new PheWAS findings were identified including a cluster of association near the NDFIP1 gene for mental retardation (best SNP rs10057309, p = 4.33 x 10(-7), OR = 1.70, 95%CI = 1.38 - 2.09); association near PLCL1 gene for developmental delays and speech disorder [best SNP rs1595825, p = 1.13 x 10(-8), OR = 0.65(0.57 - 0.76)]; a cluster of associations in the IL5-IL13 region with Eosinophilic Esophagitis (EoE) [best at rs12653750, p = 3.03 x 10(-9), OR = 1.73 95%CI = (1.44 - 2.07)], previously implicated in asthma, allergy, and eosinophilia; and association of variants in GCKR and JAZF1 with allergic rhinitis in our pediatric cohorts [best SNP rs780093, p = 2.18 x 10(-5), OR = 1.39, 95%CI = (1.19 - 1.61)], previously demonstrated in metabolic disease and diabetes in adults.
p58193
sg49777
(lp58194
(dp58195
g49782
I101
sg49783
I2
sg49784
I11
sg49812
g11
sg49787
VNDFIP1 gene
p58196
sa(dp58197
g49782
I227
sg49783
I2
sg49784
I10
sg49812
g11
sg49787
VPLCL1 gene
p58198
sa(dp58199
g49782
I598
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VGCKR
p58200
sa(dp58201
g49782
I607
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VJAZF1
p58202
sa(dp58203
g49782
I381
sg49783
I2
sg49784
I15
sg49812
VP05113
p58204
sg49787
VIL5-IL13 region
p58205
sasg49779
(lp58206
(dp58207
g49782
I428
sg49783
I1
sg49784
I3
sg49785
VC0341106
p58208
sg49787
VEoE
p58209
sa(dp58210
g49782
I762
sg49783
I2
sg49784
I17
sg49785
VC0025517
p58211
sg49787
Vmetabolic disease
p58212
sa(dp58213
g49782
I784
sg49783
I1
sg49784
I8
sg49785
VC0011849
p58214
sg49787
Vdiabetes
p58215
sa(dp58216
g49782
I553
sg49783
I1
sg49784
I12
sg49785
VC0014457
p58217
sg49787
Veosinophilia
p58218
sa(dp58219
g49782
I267
sg49783
I2
sg49784
I15
sg49785
VC0037822
p58220
sg49787
Vspeech disorder
p58221
sa(dp58222
g49782
I540
sg49783
I1
sg49784
I7
sg49785
VC0020517
p58223
sg49787
Vallergy
p58224
sa(dp58225
g49782
I117
sg49783
I2
sg49784
I18
sg49785
VC0025362
p58226
sg49787
Vmental retardation
p58227
sa(dp58228
g49782
I618
sg49783
I2
sg49784
I17
sg49785
VC2607914
p58229
sg49787
Vallergic rhinitis
p58230
sa(dp58231
g49782
I402
sg49783
I2
sg49784
I24
sg49785
VC0341106
p58232
sg49787
VEosinophilic Esophagitis
p58233
sa(dp58234
g49782
I532
sg49783
I1
sg49784
I6
sg49785
VC0004096
p58235
sg49787
Vasthma
p58236
sasa(dp58237
g49775
V177Lu-DOTATATE = lutetium octreotate; ACO = aconitase; Ad = adenine; AD = autosomal dominant; ATRX = ATRX chromatin remodeler; ccRCC = clear cell renal cell carcinoma; c-MYC = MYC proto oncognene; CoA = coenzyme A; COMT = catechol-O-methyl transferase; CPE = carboxypeptidase E; CS = citrate synthase; CT = computed tomography; DH = pyruvate dehydrogenase; DOTATATE = DOTA-octreotate; EGLN1/2 = egl-9 family hypoxia inducible factor 1/2; EGLN2/PHD1 = egl-9 family hypoxia inducible factor 2; elF-4E = eukaryotic initiation factor 4E; EMT = epithelial-to-mesenchymal transition; EPAS1/HIF2A = endothelial PAS domain protein 2/hypoxia-inducible factor 2Alfa; ERK = extracellular signal-regulated kinase; FH = fumarate hydroxylase; GSH = glutathione; H3F3A = histone 3.3 encoding gene; HIFs = Hypoxia-inducible factors; HIF-Alfa = hypoxia-inducible factor alpha; HNPGLs = head and neck paragangliomas; HRAS = HRas protooncogene; IDH = isocitrate dehydrogenase; IGF-1R = growth factor 1 receptor; KIF1B = kinesin family member 1B; MAX = myc-associated factor X; MDH2 = malate dehydrogenase; MN = metanephrine; MRI = magnetic resonance imaging; mTORC1 = mammalian target of rapamycin complex 1; MTY = methoxytyramine; NAd = nicotinamide adenine dinucleotide; NETs = neuroendocrine tumors; NF1 = neurofibromin 1; NMN = normetanephrine; OPLS-DA = orthogonal partial least square discriminant analysis; PFS = progression free survival; PHD = prolyl hydroxylase domain protein; PPGLs = Pheochromocytoma and Paragangliomas; PRRT = peptide receptor radionuclide therapy; Pvhl = von Hippel-Lindau protein; Raptor = regulatory associated protein of mTOR; RAS = rat sarcoma oncogene; RET = rearranged during transfection proto-oncogene; ROS = reactive oxygen species; S6K = S6 kinase; SDH = succinate dehydrogenase; SDHA, -B, -C, -D, = succinate dehydrogenase subunits A, B, C, D; SDHAF2 = succinate dehydrogenase complex assembly factor 2; SDHB, C, D = succinate dehydrogenase subunits B, C, D; SDHx = succinate dehydrogenase subunits; SSTRs = somatostatin receptors; SUCLG = succinyl-CoA synthase; TERRA = Telomeric Repeat-containing RNA; TET = ten-eleven-translocation methylcytosine dioxygenase; TMEM127 = transmembrane protein 127; VEGF = vascular endothelial growth factor; VHL = von Hippel-Lindau; Alfa-KGDH = alpha-ketoglutarate dehydrogenase.
p58238
sg49777
(lp58239
(dp58240
g49782
I1876
sg49783
I6
sg49784
I49
sg49812
VP49366
p58241
sg49787
Vsuccinate dehydrogenase complex assembly factor 2
p58242
sa(dp58243
g49782
I1927
sg49783
I1
sg49784
I4
sg49812
VP21912
p58244
sg49787
VSDHB
p58245
sa(dp58246
g49782
I1771
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VSDH
p58247
sa(dp58248
g49782
I2023
sg49783
I4
sg49784
I30
sg49812
VP61278
p58249
sg49787
VSSTRs = somatostatin receptors
p58250
sa(dp58251
g49782
I438
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VEGLN2
p58252
sa(dp58253
g49782
I2266
sg49783
I1
sg49784
I3
sg49812
VP40337
p58254
sg49787
VVHL
p58255
sa(dp58256
g49782
I1802
sg49783
I1
sg49784
I4
sg49812
VP31040
p58257
sg49787
VSDHA
p58258
sa(dp58259
g49782
I1760
sg49783
I2
sg49784
I9
sg49812
VP33981
p58260
sg49787
VS6 kinase
p58261
sa(dp58262
g49782
I578
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VEPAS1
p58263
sa(dp58264
g49782
I1434
sg49783
I4
sg49784
I33
sg49812
VP13674
p58265
sg49787
Vprolyl hydroxylase domain protein
p58266
sa(dp58267
g49782
I2303
sg49783
I2
sg49784
I33
sg49812
VP49366
p58268
sg49787
Valpha-ketoglutarate dehydrogenase
p58269
sa(dp58270
g49782
I464
sg49783
I4
sg49784
I26
sg49812
g11
sg49787
Vhypoxia inducible factor 2
p58271
sa(dp58272
g49782
I1140
sg49783
I1
sg49784
I4
sg49812
VP42345
p58273
sg49787
VmTOR
p58274
sa(dp58275
g49782
I1754
sg49783
I1
sg49784
I3
sg49812
VP62753
p58276
sg49787
VS6K
p58277
sa(dp58278
g49782
I592
sg49783
I5
sg49784
I32
sg49812
g11
sg49787
Vendothelial PAS domain protein 2
p58279
sa(dp58280
g49782
I492
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VelF
p58281
sa(dp58282
g49782
I584
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VHIF2A
p58283
sa(dp58284
g49782
I2063
sg49783
I2
sg49784
I21
sg49812
g11
sg49787
Vsuccinyl-CoA synthase
p58285
sa(dp58286
g49782
I231
sg49783
I2
sg49784
I20
sg49812
VP31947
p58287
sg49787
VO-methyl transferase
p58288
sa(dp58289
g49782
I958
sg49783
I6
sg49784
I33
sg49812
g11
sg49787
VIGF-1R = growth factor 1 receptor
p58290
sa(dp58291
g49782
I1777
sg49783
I2
sg49784
I23
sg49812
VP49366
p58292
sg49787
Vsuccinate dehydrogenase
p58293
sa(dp58294
g49782
I926
sg49783
I4
sg49784
I30
sg49812
VP48735
p58295
sg49787
VIDH = isocitrate dehydrogenase
p58296
sa(dp58297
g49782
I748
sg49783
I1
sg49784
I5
sg49812
VP84243
p58298
sg49787
VH3F3A
p58299
sa(dp58300
g49782
I900
sg49783
I1
sg49784
I3
sg49812
VP01116
p58301
sg49787
VRAS
p58302
sa(dp58303
g49782
I1058
sg49783
I4
sg49784
I27
sg49812
VP49366
p58304
sg49787
VMDH2 = malate dehydrogenase
p58305
sa(dp58306
g49782
I385
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VEGLN1/2
p58307
sa(dp58308
g49782
I253
sg49783
I4
sg49784
I24
sg49812
VP16870
p58309
sg49787
VCPE = carboxypeptidase E
p58310
sa(dp58311
g49782
I1001
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
Vkinesin
p58312
sa(dp58313
g49782
I756
sg49783
I4
sg49784
I25
sg49812
VP62805
p58314
sg49787
Vhistone 3.3 encoding gene
p58315
sa(dp58316
g49782
I625
sg49783
I3
sg49784
I30
sg49812
g11
sg49787
Vhypoxia-inducible factor 2Alfa
p58317
sa(dp58318
g49782
I1648
sg49783
I3
sg49784
I20
sg49812
VP35125
p58319
sg49787
Vrat sarcoma oncogene
p58320
sa(dp58321
g49782
I1670
sg49783
I1
sg49784
I3
sg49812
VP07949
p58322
sg49787
VRET
p58323
sa(dp58324
g49782
I657
sg49783
I1
sg49784
I3
sg49812
VP29323
p58325
sg49787
VERK
p58326
sa(dp58327
g49782
I1027
sg49783
I5
sg49784
I29
sg49812
VP61244
p58328
sg49787
VMAX = myc-associated factor X
p58329
sa(dp58330
g49782
I408
sg49783
I4
sg49784
I28
sg49812
g11
sg49787
Vhypoxia inducible factor 1/2
p58331
sa(dp58332
g49782
I2230
sg49783
I4
sg49784
I34
sg49812
g11
sg49787
Vvascular endothelial growth factor
p58333
sa(dp58334
g49782
I444
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VPHD1
p58335
sasg49779
(lp58336
(dp58337
g49782
I1771
sg49783
I1
sg49784
I3
sg49785
VC0018946
p58338
sg49787
VSDH
p58339
sa(dp58340
g49782
I1261
sg49783
I2
sg49784
I21
sg49785
VC0206754
p58341
sg49787
Vneuroendocrine tumors
p58342
sa(dp58343
g49782
I1477
sg49783
I1
sg49784
I16
sg49785
VC0031511
p58344
sg49787
VPheochromocytoma
p58345
sa(dp58346
g49782
I1648
sg49783
I2
sg49784
I11
sg49785
VC1882848
p58347
sg49787
Vrat sarcoma
p58348
sa(dp58349
g49782
I408
sg49783
I1
sg49784
I7
sg49785
VC0242184
p58350
sg49787
Vhypoxia
p58351
sa(dp58352
g49782
I790
sg49783
I1
sg49784
I7
sg49785
VC0242184
p58353
sg49787
VHypoxia
p58354
sa(dp58355
g49782
I1213
sg49783
I1
sg49784
I3
sg49785
VC1850380
p58356
sg49787
VNAd
p58357
sa(dp58358
g49782
I94
sg49783
I1
sg49784
I4
sg49785
VC1845055
p58359
sg49787
VATRX
p58360
sa(dp58361
g49782
I197
sg49783
I1
sg49784
I3
sg49785
VC2678439
p58362
sg49787
VCoA
p58363
sa(dp58364
g49782
I1498
sg49783
I1
sg49784
I14
sg49785
VC0030421
p58365
sg49787
VParagangliomas
p58366
sa(dp58367
g49782
I883
sg49783
I1
sg49784
I14
sg49785
VC0030421
p58368
sg49787
Vparagangliomas
p58369
sa(dp58370
g49782
I408
sg49783
I1
sg49784
I7
sg49785
VC0242184
p58371
sg49787
Vhypoxia
p58372
sa(dp58373
g49782
I1284
sg49783
I1
sg49784
I3
sg49785
VC0027831
p58374
sg49787
VNF1
p58375
sa(dp58376
g49782
I408
sg49783
I1
sg49784
I7
sg49785
VC0242184
p58377
sg49787
Vhypoxia
p58378
sa(dp58379
g49782
I2266
sg49783
I1
sg49784
I3
sg49785
VC0019562
p58380
sg49787
VVHL
p58381
sa(dp58382
g49782
I729
sg49783
I1
sg49784
I3
sg49785
VC1260386
p58383
sg49787
VGSH
p58384
sa(dp58385
g49782
I135
sg49783
I5
sg49784
I31
sg49785
VC0279702
p58386
sg49787
Vclear cell renal cell carcinoma
p58387
sa(dp58388
g49782
I566
sg49783
I1
sg49784
I10
sg49785
VC0599156
p58389
sg49787
Vtransition
p58390
sa(dp58391
g49782
I94
sg49783
I1
sg49784
I4
sg49785
VC1845055
p58392
sg49787
VATRX
p58393
sa(dp58394
g49782
I2144
sg49783
I1
sg49784
I13
sg49785
VC0040715
p58395
sg49787
Vtranslocation
p58396
sa(dp58397
g49782
I197
sg49783
I1
sg49784
I3
sg49785
VC2678439
p58398
sg49787
VCoA
p58399
sa(dp58400
g49782
I408
sg49783
I1
sg49784
I7
sg49785
VC0242184
p58401
sg49787
Vhypoxia
p58402
sasa(dp58403
g49775
VWe report a case of MAX-associated renal cell carcinoma and confirm the role of TMEM127 mutations with renal cell carcinoma predisposition.
p58404
sg49777
(lp58405
sg49779
(lp58406
(dp58407
g49782
I35
sg49783
I3
sg49784
I20
sg49785
VC0007134
p58408
sg49787
Vrenal cell carcinoma
p58409
sa(dp58410
g49782
I35
sg49783
I3
sg49784
I20
sg49785
VC0007134
p58411
sg49787
Vrenal cell carcinoma
p58412
sasa(dp58413
g49775
VAlterations of von Hippel-Lindau (VHL), succinate dehydrogenase (SDHX), and TMEM127 have been associated with the development of pheochromocytomas (PCs) and paragangliomas (PGLs) and are also associated with the development of renal neoplasms.
p58414
sg49777
(lp58415
(dp58416
g49782
I40
sg49783
I2
sg49784
I23
sg49812
VP49366
p58417
sg49787
Vsuccinate dehydrogenase
p58418
sa(dp58419
g49782
I34
sg49783
I1
sg49784
I3
sg49812
VP40337
p58420
sg49787
VVHL
p58421
sa(dp58422
g49782
I76
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VTMEM127
p58423
sa(dp58424
g49782
I15
sg49783
I2
sg49784
I17
sg49812
VP40337
p58425
sg49787
Vvon Hippel-Lindau
p58426
sasg49779
(lp58427
(dp58428
g49782
I129
sg49783
I1
sg49784
I17
sg49785
VC0031511
p58429
sg49787
Vpheochromocytomas
p58430
sa(dp58431
g49782
I15
sg49783
I2
sg49784
I17
sg49785
VC0019562
p58432
sg49787
Vvon Hippel-Lindau
p58433
sa(dp58434
g49782
I148
sg49783
I1
sg49784
I3
sg49785
VC1864389
p58435
sg49787
VPCs
p58436
sa(dp58437
g49782
I157
sg49783
I1
sg49784
I14
sg49785
VC0030421
p58438
sg49787
Vparagangliomas
p58439
sa(dp58440
g49782
I34
sg49783
I1
sg49784
I3
sg49785
VC0019562
p58441
sg49787
VVHL
p58442
sa(dp58443
g49782
I227
sg49783
I2
sg49784
I15
sg49785
VC0022665
p58444
sg49787
Vrenal neoplasms
p58445
sa(dp58446
g49782
I173
sg49783
I1
sg49784
I4
sg49785
VC0030421
p58447
sg49787
VPGLs
p58448
sasa(dp58449
g49775
VImmunohistochemistry for SDHB and mutation analysis for TMEM127 was performed, in addition to analysis of The Cancer Genome Atlas datasets for SDHX and TMEM127 mutated renal cell carcinomas (RCCs).
p58450
sg49777
(lp58451
(dp58452
g49782
I25
sg49783
I1
sg49784
I4
sg49812
VP21912
p58453
sg49787
VSDHB
p58454
sa(dp58455
g49782
I56
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VTMEM127
p58456
sasg49779
(lp58457
(dp58458
g49782
I110
sg49783
I1
sg49784
I6
sg49785
VC0006826
p58459
sg49787
VCancer
p58460
sa(dp58461
g49782
I168
sg49783
I3
sg49784
I21
sg49785
VC0007134
p58462
sg49787
Vrenal cell carcinomas
p58463
sa(dp58464
g49782
I191
sg49783
I1
sg49784
I4
sg49785
VC0007134
p58465
sg49787
VRCCs
p58466
sasa(dp58467
g49775
VThe expanding etiology for hereditary pheochromocytomas and paragangliomas has recently included SDHA, TMEM127, MAX, and SDHAF2 as susceptibility genes.
p58468
sg49777
(lp58469
(dp58470
g49782
I103
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VTMEM127
p58471
sa(dp58472
g49782
I121
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VSDHAF2
p58473
sa(dp58474
g49782
I97
sg49783
I1
sg49784
I4
sg49812
VP31040
p58475
sg49787
VSDHA
p58476
sasg49779
(lp58477
(dp58478
g49782
I38
sg49783
I1
sg49784
I17
sg49785
VC0031511
p58479
sg49787
Vpheochromocytomas
p58480
sa(dp58481
g49782
I60
sg49783
I1
sg49784
I14
sg49785
VC0030421
p58482
sg49787
Vparagangliomas
p58483
sasa(dp58484
g49775
VThis study analyzed the prospective, longitudinally followed up European-American-Asian Pheochromocytoma-Paraganglioma Registry for prevalence of SDHA, TMEM127, MAX, and SDHAF2 germline mutation carriers from 1993 to 2016.
p58485
sg49777
(lp58486
(dp58487
g49782
I146
sg49783
I1
sg49784
I4
sg49812
VP31040
p58488
sg49787
VSDHA
p58489
sa(dp58490
g49782
I170
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VSDHAF2
p58491
sa(dp58492
g49782
I152
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VTMEM127
p58493
sasg49779
(lp58494
(dp58495
g49782
I177
sg49783
I2
sg49784
I17
sg49785
VC1705427
p58496
sg49787
Vgermline mutation
p58497
sa(dp58498
g49782
I105
sg49783
I1
sg49784
I13
sg49785
VC0030421
p58499
sg49787
VParaganglioma
p58500
sa(dp58501
g49782
I88
sg49783
I1
sg49784
I16
sg49785
VC0031511
p58502
sg49787
VPheochromocytoma
p58503
sasa(dp58504
g49775
VOf 972 unrelated registrants without mutations in the classic pheochromocytoma- and paraganglioma-associated genes (632 female [65.0%] and 340 male [35.0%]; age range, 8-80; mean [SD] age, 41.0 [13.3] years), 58 (6.0%) carried germline mutations of interest, including 29 SDHA, 20 TMEM127, 8 MAX, and 1 SDHAF2.
p58505
sg49777
(lp58506
sg49779
(lp58507
(dp58508
g49782
I62
sg49783
I1
sg49784
I16
sg49785
VC0031511
p58509
sg49787
Vpheochromocytoma
p58510
sa(dp58511
g49782
I84
sg49783
I1
sg49784
I13
sg49785
VC0030421
p58512
sg49787
Vparaganglioma
p58513
sasa(dp58514
g49775
VNewly uncovered are 7 of 63 (11%) malignant pheochromocytomas and paragangliomas in SDHA and TMEM127 disease.
p58515
sg49777
(lp58516
sg49779
(lp58517
(dp58518
g49782
I44
sg49783
I1
sg49784
I17
sg49785
VC0031511
p58519
sg49787
Vpheochromocytomas
p58520
sa(dp58521
g49782
I66
sg49783
I1
sg49784
I14
sg49785
VC0030421
p58522
sg49787
Vparagangliomas
p58523
sasa(dp58524
g49775
VThe SDHA, TMEM127, MAX, and SDHAF2 genes may contribute to hereditary pheochromocytoma and paraganglioma.
p58525
sg49777
(lp58526
(dp58527
g49782
I4
sg49783
I1
sg49784
I4
sg49812
VP31040
p58528
sg49787
VSDHA
p58529
sa(dp58530
g49782
I28
sg49783
I2
sg49784
I12
sg49812
g11
sg49787
VSDHAF2 genes
p58531
sa(dp58532
g49782
I10
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VTMEM127
p58533
sasg49779
(lp58534
(dp58535
g49782
I91
sg49783
I1
sg49784
I13
sg49785
VC0030421
p58536
sg49787
Vparaganglioma
p58537
sa(dp58538
g49782
I70
sg49783
I1
sg49784
I16
sg49785
VC0031511
p58539
sg49787
Vpheochromocytoma
p58540
sasa(dp58541
g49775
V3-MT = 3-methoxytyramine; EPAS1 = endothelial pas domain protein 1; FH = fumarate hydratase; HIF2A = hypoxia inducible factor type 2A; MEN2 = multiple endocrine neoplasia type 2; NF1 = neurofibromatosis type 1; PNMT = phenylethanolamine N-methyltransferase; PPGL = pheochromocytoma and paraganglioma; RET = rearranged during transfection; SDH = succinate dehydrogenase; SDHAF2 = succinate dehydrogenase complex assembly factor 2; TCA = tricarboxylic acid; TH = tyrosine hydroxylase; TMEM127 = transmembrane protein 127; VHL = von Hippel-Lindau.
p58542
sg49777
(lp58543
(dp58544
g49782
I370
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VSDHAF2
p58545
sa(dp58546
g49782
I93
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VHIF2A
p58547
sa(dp58548
g49782
I101
sg49783
I5
sg49784
I32
sg49812
g11
sg49787
Vhypoxia inducible factor type 2A
p58549
sa(dp58550
g49782
I483
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VTMEM127
p58551
sa(dp58552
g49782
I456
sg49783
I4
sg49784
I25
sg49812
VP07101
p58553
sg49787
VTH = tyrosine hydroxylase
p58554
sa(dp58555
g49782
I339
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VSDH
p58556
sa(dp58557
g49782
I345
sg49783
I2
sg49784
I23
sg49812
VP49366
p58558
sg49787
Vsuccinate dehydrogenase
p58559
sa(dp58560
g49782
I345
sg49783
I2
sg49784
I23
sg49812
VP49366
p58561
sg49787
Vsuccinate dehydrogenase
p58562
sasg49779
(lp58563
(dp58564
g49782
I265
sg49783
I1
sg49784
I16
sg49785
VC0031511
p58565
sg49787
Vpheochromocytoma
p58566
sa(dp58567
g49782
I286
sg49783
I1
sg49784
I13
sg49785
VC0030421
p58568
sg49787
Vparaganglioma
p58569
sa(dp58570
g49782
I179
sg49783
I1
sg49784
I3
sg49785
VC0027831
p58571
sg49787
VNF1
p58572
sa(dp58573
g49782
I520
sg49783
I1
sg49784
I3
sg49785
VC0019562
p58574
sg49787
VVHL
p58575
sa(dp58576
g49782
I142
sg49783
I5
sg49784
I35
sg49785
VC0025268
p58577
sg49787
Vmultiple endocrine neoplasia type 2
p58578
sa(dp58579
g49782
I101
sg49783
I1
sg49784
I7
sg49785
VC0242184
p58580
sg49787
Vhypoxia
p58581
sa(dp58582
g49782
I339
sg49783
I1
sg49784
I3
sg49785
VC0018946
p58583
sg49787
VSDH
p58584
sa(dp58585
g49782
I185
sg49783
I3
sg49784
I24
sg49785
VC0027831
p58586
sg49787
Vneurofibromatosis type 1
p58587
sasa(dp58588
g49775
VThis study assessed the effects of leukemia-related protein 16 (LRP16) on the regulation of pancreatic functions in mouse insulinoma (MIN6) cells.
p58589
sg49777
(lp58590
(dp58591
g49782
I35
sg49783
I3
sg49784
I27
sg49812
g11
sg49787
Vleukemia-related protein 16
p58592
sa(dp58593
g49782
I64
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VLRP16
p58594
sasg49779
(lp58595
(dp58596
g49782
I35
sg49783
I1
sg49784
I8
sg49785
VC0023418
p58597
sg49787
Vleukemia
p58598
sa(dp58599
g49782
I116
sg49783
I2
sg49784
I16
sg49785
VC1522248
p58600
sg49787
Vmouse insulinoma
p58601
sasa(dp58602
g49775
VOur recent studies have shown that a selective ABHD6 inhibitor WWL70 has anti-inflammatory and neuroprotective effects in animal models of traumatic brain injury and multiple sclerosis.
p58603
sg49777
(lp58604
(dp58605
g49782
I47
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VABHD6
p58606
sasg49779
(lp58607
(dp58608
g49782
I166
sg49783
I2
sg49784
I18
sg49785
VC0026769
p58609
sg49787
Vmultiple sclerosis
p58610
sasa(dp58611
g49775
VIn this study, we investigated the role of targeting ABHD6 in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).
p58612
sg49777
(lp58613
(dp58614
g49782
I53
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VABHD6
p58615
sasg49779
(lp58616
(dp58617
g49782
I105
sg49783
I1
sg49784
I3
sg49785
VC0014070
p58618
sg49787
VEAE
p58619
sa(dp58620
g49782
I86
sg49783
I1
sg49784
I17
sg49785
VC0014070
p58621
sg49787
Vencephalomyelitis
p58622
sa(dp58623
g49782
I150
sg49783
I1
sg49784
I2
sg49785
VC0026769
p58624
sg49787
VMS
p58625
sa(dp58626
g49782
I130
sg49783
I2
sg49784
I18
sg49785
VC0026769
p58627
sg49787
Vmultiple sclerosis
p58628
sa(dp58629
g49782
I75
sg49783
I1
sg49784
I10
sg49785
VC0443146
p58630
sg49787
Vautoimmune
p58631
sasa(dp58632
g49775
VExpression of clusterin correlates with tumor progression and therapeutic response in several human malignancies, including breast cancer.
p58633
sg49777
(lp58634
sg49779
(lp58635
(dp58636
g49782
I100
sg49783
I1
sg49784
I12
sg49785
VC0006826
p58637
sg49787
Vmalignancies
p58638
sa(dp58639
g49782
I40
sg49783
I2
sg49784
I17
sg49785
VC0178874
p58640
sg49787
Vtumor progression
p58641
sa(dp58642
g49782
I124
sg49783
I2
sg49784
I13
sg49785
VC0678222
p58643
sg49787
Vbreast cancer
p58644
sasa(dp58645
g49775
VThe objective of this explorative study was to determine whether clusterin expression in breast cancer correlated with clinical pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy (NAC).
p58646
sg49777
(lp58647
sg49779
(lp58648
(dp58649
g49782
I89
sg49783
I2
sg49784
I13
sg49785
VC0678222
p58650
sg49787
Vbreast cancer
p58651
sasa(dp58652
g49775
VWe determined the clusterin expression pattern in 72 triple negative breast cancers (TNBC) treated with NAC before surgery.
p58653
sg49777
(lp58654
(dp58655
g49782
I18
sg49783
I1
sg49784
I9
sg49812
VP10909
p58656
sg49787
Vclusterin
p58657
sasg49779
(lp58658
(dp58659
g49782
I69
sg49783
I2
sg49784
I14
sg49785
VC0006142
p58660
sg49787
Vbreast cancers
p58661
sasa(dp58662
g49775
VClusterin was present at higher levels in both fractions of patients with early and intermediate stages of breast cancer.
p58663
sg49777
(lp58664
(dp58665
g49782
I0
sg49783
I1
sg49784
I9
sg49812
VP10909
p58666
sg49787
VClusterin
p58667
sasg49779
(lp58668
(dp58669
g49782
I107
sg49783
I2
sg49784
I13
sg49785
VC0678222
p58670
sg49787
Vbreast cancer
p58671
sasa(dp58672
g49775
VDiscovery and development of a novel anticancer PEG-SMR-Clu peptide to prevent breast cancer metastasis.
p58673
sg49777
(lp58674
(dp58675
g49782
I48
sg49783
I2
sg49784
I19
sg49812
VP09466
p58676
sg49787
VPEG-SMR-Clu peptide
p58677
sasg49779
(lp58678
(dp58679
g49782
I93
sg49783
I1
sg49784
I10
sg49785
VC0027627
p58680
sg49787
Vmetastasis
p58681
sa(dp58682
g49782
I79
sg49783
I2
sg49784
I13
sg49785
VC0678222
p58683
sg49787
Vbreast cancer
p58684
sasa(dp58685
g49775
VPEG-SMRwt-Clu and PEG-SMRwt peptides inhibited the growth of both of MCF-7 (estrogen responsive, ER+) and MDA-MD-231 (estrogen non-responsive, ER-) human breast cancer cells in a dose and time-dependent manner, without inducing cytotoxic effects.
p58686
sg49777
(lp58687
(dp58688
g49782
I18
sg49783
I2
sg49784
I18
sg49812
VP09466
p58689
sg49787
VPEG-SMRwt peptides
p58690
sa(dp58691
g49782
I0
sg49783
I1
sg49784
I3
sg49812
VP09466
p58692
sg49787
VPEG
p58693
sa(dp58694
g49782
I10
sg49783
I1
sg49784
I3
sg49812
VP10909
p58695
sg49787
VClu
p58696
sasg49779
(lp58697
(dp58698
g49782
I154
sg49783
I2
sg49784
I13
sg49785
VC0678222
p58699
sg49787
Vbreast cancer
p58700
sasa(dp58701
g49775
VPEG-SMRwt-CLU peptides inhibited the growth of human breast cancer cells and blocked tumor exosome release in vitro.
p58702
sg49777
(lp58703
(dp58704
g49782
I0
sg49783
I2
sg49784
I22
sg49812
VP09466
p58705
sg49787
VPEG-SMRwt-CLU peptides
p58706
sasg49779
(lp58707
(dp58708
g49782
I53
sg49783
I2
sg49784
I13
sg49785
VC0678222
p58709
sg49787
Vbreast cancer
p58710
sa(dp58711
g49782
I85
sg49783
I1
sg49784
I5
sg49785
VC0027651
p58712
sg49787
Vtumor
p58713
sasa(dp58714
g49775
VClinically, breast cancer patients possess sCLU expression only in mature CD68(+) macrophages but not in immature CD33(+) immunosuppressive myeloid cells infiltrating the tumors.
p58715
sg49777
(lp58716
(dp58717
g49782
I74
sg49783
I1
sg49784
I4
sg49812
VP34810
p58718
sg49787
VCD68
p58719
sasg49779
(lp58720
(dp58721
g49782
I35
sg49783
I1
sg49784
I7
sg49785
VC0850310
p58722
sg49787
Vpossess
p58723
sa(dp58724
g49782
I154
sg49783
I1
sg49784
I12
sg49785
VC0332448
p58725
sg49787
Vinfiltrating
p58726
sa(dp58727
g49782
I12
sg49783
I2
sg49784
I13
sg49785
VC0678222
p58728
sg49787
Vbreast cancer
p58729
sa(dp58730
g49782
I171
sg49783
I1
sg49784
I6
sg49785
VC0027651
p58731
sg49787
Vtumors
p58732
sasa(dp58733
g49775
VImmunoblotting and MRM-based validation in a separate cohort testified a panel of 21 proteins such as zinc-alpha2-glycoprotein, A2GL, retinol-binding protein 4, annexin A1, SAP3, SRC8, gelsolin, kininogen 1, CO9, clusterin, ceruloplasmin, and Alfa1-antitrypsin could be a panel of candidate markers that could discriminate HE breast cancer from healthy controls.
p58734
sg49777
(lp58735
(dp58736
g49782
I224
sg49783
I1
sg49784
I13
sg49812
VP00450
p58737
sg49787
Vceruloplasmin
p58738
sa(dp58739
g49782
I208
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VCO9
p58740
sa(dp58741
g49782
I173
sg49783
I1
sg49784
I4
sg49812
VP17900
p58742
sg49787
VSAP3
p58743
sa(dp58744
g49782
I134
sg49783
I3
sg49784
I25
sg49812
VP02753
p58745
sg49787
Vretinol-binding protein 4
p58746
sa(dp58747
g49782
I213
sg49783
I1
sg49784
I9
sg49812
VP10909
p58748
sg49787
Vclusterin
p58749
sa(dp58750
g49782
I243
sg49783
I1
sg49784
I17
sg49812
g11
sg49787
VAlfa1-antitrypsin
p58751
sa(dp58752
g49782
I185
sg49783
I1
sg49784
I8
sg49812
VP06396
p58753
sg49787
Vgelsolin
p58754
sa(dp58755
g49782
I195
sg49783
I2
sg49784
I11
sg49812
VP01042
p58756
sg49787
Vkininogen 1
p58757
sa(dp58758
g49782
I102
sg49783
I1
sg49784
I24
sg49812
VP36222
p58759
sg49787
Vzinc-alpha2-glycoprotein
p58760
sa(dp58761
g49782
I161
sg49783
I2
sg49784
I10
sg49812
VP04083
p58762
sg49787
Vannexin A1
p58763
sasg49779
(lp58764
(dp58765
g49782
I326
sg49783
I2
sg49784
I13
sg49785
VC0678222
p58766
sg49787
Vbreast cancer
p58767
sasa(dp58768
g49775
VExportin 4 (XPO4) is a novel identified candidate tumour-suppressor gene involved in the pathogenesis of hepatocellular carcinoma (HCC).
p58769
sg49777
(lp58770
(dp58771
g49782
I12
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VXPO4
p58772
sa(dp58773
g49782
I0
sg49783
I2
sg49784
I10
sg49812
g11
sg49787
VExportin 4
p58774
sasg49779
(lp58775
(dp58776
g49782
I105
sg49783
I2
sg49784
I24
sg49785
VC2239176
p58777
sg49787
Vhepatocellular carcinoma
p58778
sa(dp58779
g49782
I131
sg49783
I1
sg49784
I3
sg49785
VC2239176
p58780
sg49787
VHCC
p58781
sa(dp58782
g49782
I89
sg49783
I1
sg49784
I12
sg49785
VC0699748
p58783
sg49787
Vpathogenesis
p58784
sa(dp58785
g49782
I50
sg49783
I1
sg49784
I6
sg49785
VC0027651
p58786
sg49787
Vtumour
p58787
sasa(dp58788
g49775
VTo evaluate potential biomarkers in HCC, we employed multiple methods in this study, including qPCR, immunostaining methods and tissue microarrays (TMAs), as well as histological and pathological analysis, to assess TGFBeta, XPO4, elF5A2 and ANGPTL4 in cancerous and paracancerous liver tissues from 280 patients suffering from liver cancer.
p58789
sg49777
(lp58790
(dp58791
g49782
I225
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VXPO4
p58792
sa(dp58793
g49782
I216
sg49783
I1
sg49784
I7
sg49812
VP01137
p58794
sg49787
VTGFBeta
p58795
sa(dp58796
g49782
I242
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VANGPTL4
p58797
sasg49779
(lp58798
(dp58799
g49782
I313
sg49783
I1
sg49784
I9
sg49785
VC0683278
p58800
sg49787
Vsuffering
p58801
sa(dp58802
g49782
I328
sg49783
I2
sg49784
I12
sg49785
VC0345904
p58803
sg49787
Vliver cancer
p58804
sa(dp58805
g49782
I36
sg49783
I1
sg49784
I3
sg49785
VC2239176
p58806
sg49787
VHCC
p58807
sasa(dp58808
g49775
VXPO4 in cancerous liver tissue and TGFBeta1 in paracancerous liver tissue were positively correlated with tumor differentiation.
p58809
sg49777
(lp58810
(dp58811
g49782
I0
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VXPO4
p58812
sasg49779
(lp58813
(dp58814
g49782
I106
sg49783
I1
sg49784
I5
sg49785
VC0027651
p58815
sg49787
Vtumor
p58816
sasa(dp58817
g49775
VAdditionally, higher levels of XPO4 in cancerous liver tissue suggested that the patient would have a better prognosis and survival rate.
p58818
sg49777
(lp58819
(dp58820
g49782
I31
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VXPO4
p58821
sasg49779
(lp58822
sa(dp58823
g49775
VHowever, higher production of XPO4 in paracancerous liver tissue suggested a worse prognosis.
p58824
sg49777
(lp58825
(dp58826
g49782
I30
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VXPO4
p58827
sasg49779
(lp58828
sa(dp58829
g49775
VAll the results above provide new insights into better understanding biological indicators, such as XPO4, TGFBeta1, ANGPTL4 and elF5A2, in the prediction and evaluation of liver cancer, as well as signaling pathways in the control of liver cancer.
p58830
sg49777
(lp58831
(dp58832
g49782
I106
sg49783
I1
sg49784
I8
sg49812
VP01137
p58833
sg49787
VTGFBeta1
p58834
sa(dp58835
g49782
I116
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VANGPTL4
p58836
sa(dp58837
g49782
I100
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VXPO4
p58838
sasg49779
(lp58839
(dp58840
g49782
I172
sg49783
I2
sg49784
I12
sg49785
VC0345904
p58841
sg49787
Vliver cancer
p58842
sa(dp58843
g49782
I172
sg49783
I2
sg49784
I12
sg49785
VC0345904
p58844
sg49787
Vliver cancer
p58845
sasa(dp58846
g49775
VXPO4 and TGFBeta1 may serve as useful markers to evaluate the size and prognosis of liver cancer.
p58847
sg49777
(lp58848
(dp58849
g49782
I9
sg49783
I1
sg49784
I8
sg49812
VP01137
p58850
sg49787
VTGFBeta1
p58851
sa(dp58852
g49782
I0
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VXPO4
p58853
sasg49779
(lp58854
(dp58855
g49782
I84
sg49783
I2
sg49784
I12
sg49785
VC0345904
p58856
sg49787
Vliver cancer
p58857
sasa(dp58858
g49775
VExportin 4 (XPO4) is a recently-discovered candidate tumor-suppressor gene identified in a liver cancer mouse model.
p58859
sg49777
(lp58860
(dp58861
g49782
I12
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VXPO4
p58862
sa(dp58863
g49782
I0
sg49783
I2
sg49784
I10
sg49812
g11
sg49787
VExportin 4
p58864
sasg49779
(lp58865
(dp58866
g49782
I91
sg49783
I2
sg49784
I12
sg49785
VC0345904
p58867
sg49787
Vliver cancer
p58868
sa(dp58869
g49782
I53
sg49783
I1
sg49784
I5
sg49785
VC0027651
p58870
sg49787
Vtumor
p58871
sasa(dp58872
g49775
VTo investigate the role of XPO4 in hepatocellular carcinoma (HCC) pathogenesis, we determined XPO4 expression and its correlation to prognosis in human primary HCC.
p58873
sg49777
(lp58874
(dp58875
g49782
I27
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VXPO4
p58876
sa(dp58877
g49782
I27
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VXPO4
p58878
sasg49779
(lp58879
(dp58880
g49782
I66
sg49783
I1
sg49784
I12
sg49785
VC0699748
p58881
sg49787
Vpathogenesis
p58882
sa(dp58883
g49782
I61
sg49783
I1
sg49784
I3
sg49785
VC2239176
p58884
sg49787
VHCC
p58885
sa(dp58886
g49782
I61
sg49783
I1
sg49784
I3
sg49785
VC2239176
p58887
sg49787
VHCC
p58888
sa(dp58889
g49782
I35
sg49783
I2
sg49784
I24
sg49785
VC2239176
p58890
sg49787
Vhepatocellular carcinoma
p58891
sasa(dp58892
g49775
VOne gene, XPO4, encodes a nuclear export protein whose substrate, EIF5A2, is amplified in human tumors, is required for proliferation of XPO4-deficient tumor cells, and promotes hepatocellular carcinoma in mice.
p58893
sg49777
(lp58894
(dp58895
g49782
I10
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VXPO4
p58896
sa(dp58897
g49782
I10
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VXPO4
p58898
sa(dp58899
g49782
I66
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VEIF5A2
p58900
sasg49779
(lp58901
(dp58902
g49782
I120
sg49783
I1
sg49784
I13
sg49785
VC0334094
p58903
sg49787
Vproliferation
p58904
sa(dp58905
g49782
I96
sg49783
I1
sg49784
I5
sg49785
VC0027651
p58906
sg49787
Vtumor
p58907
sa(dp58908
g49782
I96
sg49783
I1
sg49784
I6
sg49785
VC0027651
p58909
sg49787
Vtumors
p58910
sa(dp58911
g49782
I178
sg49783
I2
sg49784
I24
sg49785
VC1512411
p58912
sg49787
Vhepatocellular carcinoma
p58913
sasa(dp58914
g49775
VIn a population of 159 patients on renal replacement therapy (RDT) we performed a 1-yr prospective observational study, with common parameters to indicate cardiovascular pathologies (PAS, LVMI), calcium-phosphorous metabolism (Ca, PO 4 , Ca x PO 4 ), dialytic adequacy (Kt/V, URR%), nutritional status (nPCR, Alb, K), and anemia (hemoglobin (Hb)).
p58915
sg49777
(lp58916
(dp58917
g49782
I330
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
Vhemoglobin
p58918
sa(dp58919
g49782
I276
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VURR
p58920
sa(dp58921
g49782
I309
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VAlb
p58922
sasg49779
(lp58923
(dp58924
g49782
I322
sg49783
I1
sg49784
I6
sg49785
VC0002871
p58925
sg49787
Vanemia
p58926
sa(dp58927
g49782
I62
sg49783
I1
sg49784
I3
sg49785
VC0206743
p58928
sg49787
VRDT
p58929
sasa(dp58930
g49775
VBased on serial mortality rates for the general population of England and Wales, significantly increased mortality was shown for cancers of the pharynx (observed (Obs) 4, expected (Exp) 0.7, standardised mortality ratio (SMR) 559, p&lt;0.05), non-malignant diseases of the respiratory system (Obs 61, Exp 43.0, SMR 142, p&lt;0.05), and non-malignant diseases of the genitourinary system (Obs 10, Exp 4.1, SMR 243, p&lt;0.05).
p58931
sg49777
(lp58932
sg49779
(lp58933
(dp58934
g49782
I350
sg49783
I5
sg49784
I36
sg49785
VC0080276
p58935
sg49787
Vdiseases of the genitourinary system
p58936
sa(dp58937
g49782
I129
sg49783
I1
sg49784
I7
sg49785
VC0006826
p58938
sg49787
Vcancers
p58939
sa(dp58940
g49782
I257
sg49783
I5
sg49784
I34
sg49785
VC0035204
p58941
sg49787
Vdiseases of the respiratory system
p58942
sasa(dp58943
g49775
VNon-significantly increased SMRs were shown for lung cancer (Obs 45, Exp 40.7, SMR 111) and cancer of the prostate (Obs 9, Exp 7.5, SMR 116).
p58944
sg49777
(lp58945
(dp58946
g49782
I79
sg49783
I2
sg49784
I7
sg49812
g11
sg49787
VSMR 111
p58947
sa(dp58948
g49782
I116
sg49783
I2
sg49784
I5
sg49812
VP41159
p58949
sg49787
VObs 9
p58950
sa(dp58951
g49782
I123
sg49783
I2
sg49784
I5
sg49812
g11
sg49787
VExp 7
p58952
sasg49779
(lp58953
(dp58954
g49782
I92
sg49783
I4
sg49784
I22
sg49785
VC0600139
p58955
sg49787
Vcancer of the prostate
p58956
sa(dp58957
g49782
I48
sg49783
I2
sg49784
I11
sg49785
VC0684249
p58958
sg49787
Vlung cancer
p58959
sasa(dp58960
g49775
VIn this largest-ever GWAS meta-analysis for nicotine dependence and the largest-ever cross-ancestry GWAS meta-analysis for any smoking phenotype, we reconfirmed the well-known CHRNA5-CHRNA3-CHRNB4 genes and further yielded a novel association in the DNA methyltransferase gene DNMT3B.
p58961
sg49777
(lp58962
(dp58963
g49782
I250
sg49783
I4
sg49784
I33
sg49812
g11
sg49787
VDNA methyltransferase gene DNMT3B
p58964
sa(dp58965
g49782
I176
sg49783
I2
sg49784
I26
sg49812
VP30532
p58966
sg49787
VCHRNA5-CHRNA3-CHRNB4 genes
p58967
sasg49779
(lp58968
(dp58969
g49782
I44
sg49783
I2
sg49784
I19
sg49785
VC0028043
p58970
sg49787
Vnicotine dependence
p58971
sasa(dp58972
g49775
VThe relationship of HTR4 (rs3995090), HTR2A (rs6313), GRIK5 (rs8099939), GRIN2B (rs2268132), and CHRNB4 (rs1948) gene polymorphisms and COPD, as well as the contribution of these polymorphisms to the variations in quantitative characteristics that describe respiratory function, smoking behavior, and nicotine dependence was assessed in an ethnically homogeneous Tatar population.
p58973
sg49777
(lp58974
(dp58975
g49782
I38
sg49783
I1
sg49784
I5
sg49812
VP28223
p58976
sg49787
VHTR2A
p58977
sa(dp58978
g49782
I97
sg49783
I1
sg49784
I6
sg49812
VP30926
p58979
sg49787
VCHRNB4
p58980
sa(dp58981
g49782
I73
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VGRIN2B
p58982
sa(dp58983
g49782
I54
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VGRIK5
p58984
sasg49779
(lp58985
(dp58986
g49782
I136
sg49783
I1
sg49784
I4
sg49785
VC0024117
p58987
sg49787
VCOPD
p58988
sa(dp58989
g49782
I301
sg49783
I2
sg49784
I19
sg49785
VC0028043
p58990
sg49787
Vnicotine dependence
p58991
sasa(dp58992
g49775
VGenome-wide association studies (GWASs) have identified associations between the CHRNA5-CHRNA3-CHRNB4 gene cluster and smoking heaviness and nicotine dependence.
p58993
sg49777
(lp58994
(dp58995
g49782
I81
sg49783
I1
sg49784
I6
sg49812
VP30532
p58996
sg49787
VCHRNA5
p58997
sa(dp58998
g49782
I95
sg49783
I1
sg49784
I6
sg49812
VP30926
p58999
sg49787
VCHRNB4
p59000
sa(dp59001
g49782
I88
sg49783
I1
sg49784
I6
sg49812
VP32297
p59002
sg49787
VCHRNA3
p59003
sasg49779
(lp59004
(dp59005
g49782
I141
sg49783
I2
sg49784
I19
sg49785
VC0028043
p59006
sg49787
Vnicotine dependence
p59007
sasa(dp59008
g49775
VPolymorphisms in the CHRNA5-CHRNA3-CHRNB4 gene cluster (Chr15q25) have been robustly associated with nicotine dependence, including genome-wide studies, as well as with cognitive and neuropsychological measures.
p59009
sg49777
(lp59010
(dp59011
g49782
I21
sg49783
I3
sg49784
I33
sg49812
VP30532
p59012
sg49787
VCHRNA5-CHRNA3-CHRNB4 gene cluster
p59013
sasg49779
(lp59014
(dp59015
g49782
I101
sg49783
I2
sg49784
I19
sg49785
VC0028043
p59016
sg49787
Vnicotine dependence
p59017
sasa(dp59018
g49775
VHere, we evaluated the effect of polymorphisms in CHRNA5-CHRNA3-CHRNB4 gene cluster and their interaction with tobacco smoking status on cognition in patients with Attention Deficit/Hyperactivity Disorder (ADHD).
p59019
sg49777
(lp59020
(dp59021
g49782
I50
sg49783
I3
sg49784
I33
sg49812
VP30532
p59022
sg49787
VCHRNA5-CHRNA3-CHRNB4 gene cluster
p59023
sasg49779
(lp59024
(dp59025
g49782
I164
sg49783
I3
sg49784
I40
sg49785
VC1263846
p59026
sg49787
VAttention Deficit/Hyperactivity Disorder
p59027
sa(dp59028
g49782
I206
sg49783
I1
sg49784
I4
sg49785
VC1263846
p59029
sg49787
VADHD
p59030
sasa(dp59031
g49775
VEight SNPs from the CHRNA5-CHRNA3-CHRNB4 gene cluster were evaluated on a clinical sample of 403 adults with ADHD.
p59032
sg49777
(lp59033
(dp59034
g49782
I34
sg49783
I1
sg49784
I6
sg49812
VP30926
p59035
sg49787
VCHRNB4
p59036
sa(dp59037
g49782
I20
sg49783
I1
sg49784
I6
sg49812
VP30532
p59038
sg49787
VCHRNA5
p59039
sa(dp59040
g49782
I27
sg49783
I1
sg49784
I6
sg49812
VP32297
p59041
sg49787
VCHRNA3
p59042
sasg49779
(lp59043
(dp59044
g49782
I109
sg49783
I1
sg49784
I4
sg49785
VC1263846
p59045
sg49787
VADHD
p59046
sasa(dp59047
g49775
VThe associations between CHRNA5-CHRNA3-CHRNB4 variants and cigarettes per day (CPD), the Fagerstroem Test for Nicotine Dependence (FTND), and craving were analyzed in data from 662 lifetime smokers from an Israeli adult Jewish household sample.
p59048
sg49777
(lp59049
(dp59050
g49782
I25
sg49783
I2
sg49784
I29
sg49812
VP30532
p59051
sg49787
VCHRNA5-CHRNA3-CHRNB4 variants
p59052
sasg49779
(lp59053
(dp59054
g49782
I110
sg49783
I2
sg49784
I19
sg49785
VC0028043
p59055
sg49787
VNicotine Dependence
p59056
sasa(dp59057
g49775
VWe found a significant increase in levels of adhesion molecules (VCAM-1) and selectins (E-selectin) in parallel with increased severity of diabetic retinopathy, with a significant difference of inflammatory markers between stages of retinopathy.
p59058
sg49777
(lp59059
(dp59060
g49782
I88
sg49783
I1
sg49784
I10
sg49812
VP16581
p59061
sg49787
VE-selectin
p59062
sa(dp59063
g49782
I65
sg49783
I1
sg49784
I6
sg49812
VP19320
p59064
sg49787
VVCAM-1
p59065
sasg49779
(lp59066
(dp59067
g49782
I148
sg49783
I1
sg49784
I11
sg49785
VC0035309
p59068
sg49787
Vretinopathy
p59069
sa(dp59070
g49782
I139
sg49783
I2
sg49784
I20
sg49785
VC0011884
p59071
sg49787
Vdiabetic retinopathy
p59072
sa(dp59073
g49782
I45
sg49783
I1
sg49784
I8
sg49785
VC0001511
p59074
sg49787
Vadhesion
p59075
sasa(dp59076
g49775
VOur aim was to investigate the role of soluble E-selectin in the formation of diabetic retinopathy.
p59077
sg49777
(lp59078
(dp59079
g49782
I47
sg49783
I1
sg49784
I10
sg49812
VP16581
p59080
sg49787
VE-selectin
p59081
sasg49779
(lp59082
(dp59083
g49782
I78
sg49783
I2
sg49784
I20
sg49785
VC0011884
p59084
sg49787
Vdiabetic retinopathy
p59085
sasa(dp59086
g49775
VAn elevated E-selectin level can play a role in the development of diabetic retinopathy, but it does not seem to alter disease severity.
p59087
sg49777
(lp59088
(dp59089
g49782
I12
sg49783
I1
sg49784
I10
sg49812
VP16581
p59090
sg49787
VE-selectin
p59091
sasg49779
(lp59092
(dp59093
g49782
I67
sg49783
I2
sg49784
I20
sg49785
VC0011884
p59094
sg49787
Vdiabetic retinopathy
p59095
sasa(dp59096
g49775
VHowever, glycemic control and the reduction of cardiovascular risk factors may also alter the level of E-selectin that might play a role in the prevention of diabetic retinopathy.
p59097
sg49777
(lp59098
(dp59099
g49782
I103
sg49783
I1
sg49784
I10
sg49812
VP16581
p59100
sg49787
VE-selectin
p59101
sasg49779
(lp59102
(dp59103
g49782
I158
sg49783
I2
sg49784
I20
sg49785
VC0011884
p59104
sg49787
Vdiabetic retinopathy
p59105
sasa(dp59106
g49775
VTo evaluate efficacy of the treatment, the progression of the disease (number of laser treatments, number of bevacizumab treatments, and incidence of retinal detachment) was evaluated by serial ophthalmologic examinations, and plasma soluble E-selectin levels were measured weekly.
p59107
sg49777
(lp59108
(dp59109
g49782
I227
sg49783
I3
sg49784
I25
sg49812
VP16581
p59110
sg49787
Vplasma soluble E-selectin
p59111
sasg49779
(lp59112
(dp59113
g49782
I150
sg49783
I2
sg49784
I18
sg49785
VC0035305
p59114
sg49787
Vretinal detachment
p59115
sasa(dp59116
g49775
VAfter adjusting for age, glycemic control, and other potential confounders, baseline plasma levels of E-selectin were associated significantly with progression of DR, E-selectin and tumor necrosis factor-Alfa (TNF-Alfa) levels with incidence of proliferative DR (PDR), and soluble intercellular adhesion molecule-1 (sICAM-1) and TNF-Alfa levels with incidence of macular edema (ME).
p59117
sg49777
(lp59118
(dp59119
g49782
I210
sg49783
I1
sg49784
I8
sg49812
VP01375
p59120
sg49787
VTNF-Alfa
p59121
sa(dp59122
g49782
I210
sg49783
I1
sg49784
I8
sg49812
VP01375
p59123
sg49787
VTNF-Alfa
p59124
sa(dp59125
g49782
I102
sg49783
I1
sg49784
I10
sg49812
VP16581
p59126
sg49787
VE-selectin
p59127
sa(dp59128
g49782
I102
sg49783
I1
sg49784
I10
sg49812
VP16581
p59129
sg49787
VE-selectin
p59130
sa(dp59131
g49782
I281
sg49783
I3
sg49784
I33
sg49812
VP05362
p59132
sg49787
Vintercellular adhesion molecule-1
p59133
sa(dp59134
g49782
I182
sg49783
I3
sg49784
I26
sg49812
VP01375
p59135
sg49787
Vtumor necrosis factor-Alfa
p59136
sasg49779
(lp59137
(dp59138
g49782
I263
sg49783
I1
sg49784
I3
sg49785
VC1845050
p59139
sg49787
VPDR
p59140
sa(dp59141
g49782
I363
sg49783
I2
sg49784
I13
sg49785
VC0271051
p59142
sg49787
Vmacular edema
p59143
sa(dp59144
g49782
I182
sg49783
I2
sg49784
I14
sg49785
VC0333516
p59145
sg49787
Vtumor necrosis
p59146
sa(dp59147
g49782
I295
sg49783
I1
sg49784
I8
sg49785
VC0001511
p59148
sg49787
Vadhesion
p59149
sa(dp59150
g49782
I378
sg49783
I1
sg49784
I2
sg49785
VC0271051
p59151
sg49787
VME
p59152
sa(dp59153
g49782
I245
sg49783
I2
sg49784
I16
sg49785
VC1845050
p59154
sg49787
Vproliferative DR
p59155
sasa(dp59156
g49775
VThe 6-HT was administrated by perfusion and ejection in "brain slices" of hippocampus, inducing epileptic activity after its administration; the toxin was not able to block the epileptogenic crisis observed in the chronic model of the epilepsy, suggesting that 6-HT did not block the overactive GluRs responsible for this epileptic activity.
p59157
sg49777
(lp59158
sg49779
(lp59159
(dp59160
g49782
I96
sg49783
I1
sg49784
I9
sg49785
VC0014544
p59161
sg49787
Vepileptic
p59162
sa(dp59163
g49782
I96
sg49783
I1
sg49784
I9
sg49785
VC0014544
p59164
sg49787
Vepileptic
p59165
sa(dp59166
g49782
I235
sg49783
I1
sg49784
I8
sg49785
VC0014544
p59167
sg49787
Vepilepsy
p59168
sasa(dp59169
g49775
VIn patients with systemic sclerosis (SSc), the relationship between innate immune activation, represented by increased expression of interferon (IFN)-regulated genes, and vascular injury/activation, manifest by increased endothelin-1 (ET-1), endothelin converting enzyme-1 (ECE1) and intercellular adhesion molecule-1, is uncertain.
p59170
sg49777
(lp59171
(dp59172
g49782
I274
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VECE1
p59173
sa(dp59174
g49782
I145
sg49783
I1
sg49784
I3
sg49812
VP01562
p59175
sg49787
VIFN
p59176
sa(dp59177
g49782
I235
sg49783
I1
sg49784
I4
sg49812
VP05305
p59178
sg49787
VET-1
p59179
sa(dp59180
g49782
I221
sg49783
I1
sg49784
I12
sg49812
VP20800
p59181
sg49787
Vendothelin-1
p59182
sa(dp59183
g49782
I242
sg49783
I3
sg49784
I30
sg49812
g11
sg49787
Vendothelin converting enzyme-1
p59184
sa(dp59185
g49782
I284
sg49783
I3
sg49784
I33
sg49812
VP05362
p59186
sg49787
Vintercellular adhesion molecule-1
p59187
sa(dp59188
g49782
I133
sg49783
I1
sg49784
I10
sg49812
VP01563
p59189
sg49787
Vinterferon
p59190
sasg49779
(lp59191
(dp59192
g49782
I298
sg49783
I1
sg49784
I8
sg49785
VC0001511
p59193
sg49787
Vadhesion
p59194
sa(dp59195
g49782
I17
sg49783
I2
sg49784
I18
sg49785
VC0036421
p59196
sg49787
Vsystemic sclerosis
p59197
sa(dp59198
g49782
I37
sg49783
I1
sg49784
I3
sg49785
VC0036421
p59199
sg49787
VSSc
p59200
sasa(dp59201
g49775
VRecent findings indicate that the level of SR-BI expression correlate with aggressiveness and poor survival in breast and prostate cancer.
p59202
sg49777
(lp59203
(dp59204
g49782
I43
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSR-BI
p59205
sasg49779
(lp59206
(dp59207
g49782
I75
sg49783
I1
sg49784
I14
sg49785
VC0001807
p59208
sg49787
Vaggressiveness
p59209
sa(dp59210
g49782
I122
sg49783
I2
sg49784
I15
sg49785
VC0600139
p59211
sg49787
Vprostate cancer
p59212
sasa(dp59213
g49775
VFurthermore, we performed immunohistochemistry analysis on human primary prostate cancer tissue sections derived from patients to investigate the correlation of SR-BI with clinicopathological parameters and the mTOR target pS6.
p59214
sg49777
(lp59215
(dp59216
g49782
I211
sg49783
I1
sg49784
I4
sg49812
VP42345
p59217
sg49787
VmTOR
p59218
sa(dp59219
g49782
I161
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSR-BI
p59220
sasg49779
(lp59221
(dp59222
g49782
I73
sg49783
I2
sg49784
I15
sg49785
VC0600139
p59223
sg49787
Vprostate cancer
p59224
sasa(dp59225
g49775
VIn contrast to LDLR, we identified SR-BI mRNA and protein expression to be induced in high Gleason grade primary prostate cancers.
p59226
sg49777
(lp59227
(dp59228
g49782
I15
sg49783
I1
sg49784
I4
sg49812
VP01130
p59229
sg49787
VLDLR
p59230
sa(dp59231
g49782
I35
sg49783
I2
sg49784
I10
sg49812
g11
sg49787
VSR-BI mRNA
p59232
sasg49779
(lp59233
(dp59234
g49782
I113
sg49783
I2
sg49784
I16
sg49785
VC0376358
p59235
sg49787
Vprostate cancers
p59236
sasa(dp59237
g49775
VWe identified SR-BI to indicate human prostate cancer formation, suggesting that increased levels of SR-BI may be involved in the generation of a castration-resistant phenotype.
p59238
sg49777
(lp59239
(dp59240
g49782
I14
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSR-BI
p59241
sa(dp59242
g49782
I14
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSR-BI
p59243
sasg49779
(lp59244
(dp59245
g49782
I38
sg49783
I2
sg49784
I15
sg49785
VC0600139
p59246
sg49787
Vprostate cancer
p59247
sasa(dp59248
g49775
VSilencing of SR-BI may impact the ability of prostate cancer cells, particularly those of castration-resistant state, to maintain the intracellular supply of androgens by removing a supply of cholesterol.
p59249
sg49777
(lp59250
(dp59251
g49782
I13
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSR-BI
p59252
sasg49779
(lp59253
(dp59254
g49782
I45
sg49783
I2
sg49784
I15
sg49785
VC0600139
p59255
sg49787
Vprostate cancer
p59256
sasa(dp59257
g49775
VThe down-regulation of SR-BI significantly impacts PSA production of prostate cancer cells, as well as the viability of C4-2 cells in the presence and absence of HDL.
p59258
sg49777
(lp59259
(dp59260
g49782
I51
sg49783
I1
sg49784
I3
sg49812
VP55786
p59261
sg49787
VPSA
p59262
sa(dp59263
g49782
I23
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSR-BI
p59264
sa(dp59265
g49782
I162
sg49783
I1
sg49784
I3
sg49812
VP28845
p59266
sg49787
VHDL
p59267
sasg49779
(lp59268
(dp59269
g49782
I69
sg49783
I2
sg49784
I15
sg49785
VC0600139
p59270
sg49787
Vprostate cancer
p59271
sa(dp59272
g49782
I51
sg49783
I1
sg49784
I3
sg49785
VC1519176
p59273
sg49787
VPSA
p59274
sasa(dp59275
g49775
VThis may indicate a deficiency in cholesterol availability to the androgen synthesis pathway or may implicate a role for SR-BI in prostate cancer signal transduction pathways.
p59276
sg49777
(lp59277
(dp59278
g49782
I121
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSR-BI
p59279
sasg49779
(lp59280
(dp59281
g49782
I130
sg49783
I2
sg49784
I15
sg49785
VC0600139
p59282
sg49787
Vprostate cancer
p59283
sasa(dp59284
g49775
Vplay roles in preterm labor and preterm premature rupture of membranes (pPROM); 3) integrated aspects of maternal and fetal host responses (inflammation, altered immune adaptations, endocrine and paracrine mechanisms) play increasingly understood roles in premature activation of parturition; and 4) identification and systemic treatment of common genitourinary infections, most importantly bacterial vaginosis (BV), reduce the risks of preterm delivery and PROM.
p59285
sg49777
(lp59286
(dp59287
g49782
I72
sg49783
I1
sg49784
I5
sg49812
VP50454
p59288
sg49787
VpPROM
p59289
sasg49779
(lp59290
(dp59291
g49782
I391
sg49783
I2
sg49784
I19
sg49785
VC0085166
p59292
sg49787
Vbacterial vaginosis
p59293
sa(dp59294
g49782
I437
sg49783
I2
sg49784
I16
sg49785
VC0151526
p59295
sg49787
Vpreterm delivery
p59296
sa(dp59297
g49782
I14
sg49783
I2
sg49784
I13
sg49785
VC0022876
p59298
sg49787
Vpreterm labor
p59299
sa(dp59300
g49782
I362
sg49783
I1
sg49784
I10
sg49785
VC0021311
p59301
sg49787
Vinfections
p59302
sa(dp59303
g49782
I0
sg49783
I2
sg49784
I10
sg49785
VC0699820
p59304
sg49787
Vplay roles
p59305
sa(dp59306
g49782
I72
sg49783
I1
sg49784
I5
sg49785
VC0729264
p59307
sg49787
VpPROM
p59308
sa(dp59309
g49782
I140
sg49783
I1
sg49784
I12
sg49785
VC0021368
p59310
sg49787
Vinflammation
p59311
sa(dp59312
g49782
I32
sg49783
I5
sg49784
I38
sg49785
VC0729264
p59313
sg49787
Vpreterm premature rupture of membranes
p59314
sasa(dp59315
g49775
VUnivariate analysis showed the following to be significant predictors of PPROM at &lt; 35 weeks: a past history of PTD between 25 and 30 weeks (P &lt; 0.008), cerclage in the current pregnancy (P &lt; 0.0001), bacterial vaginosis (P &lt; 0.011), CL &lt; 25 mm (P &lt; 0.0001) and CF &gt; 25% (P &lt; 0.0001).
p59316
sg49777
(lp59317
sg49779
(lp59318
(dp59319
g49782
I73
sg49783
I1
sg49784
I5
sg49785
VC0729264
p59320
sg49787
VPPROM
p59321
sa(dp59322
g49782
I210
sg49783
I2
sg49784
I19
sg49785
VC0085166
p59323
sg49787
Vbacterial vaginosis
p59324
sa(dp59325
g49782
I115
sg49783
I1
sg49784
I3
sg49785
VC0266006
p59326
sg49787
VPTD
p59327
sasa(dp59328
g49775
VIn this study, localization of gelatinase activities in six cases of glioblastoma, two cases of anaplastic astrocytoma, and six cases of low-grade astrocytomas was investigated by film in situ zymography (FIZ).
p59329
sg49777
(lp59330
sg49779
(lp59331
(dp59332
g49782
I147
sg49783
I1
sg49784
I12
sg49785
VC0004114
p59333
sg49787
Vastrocytomas
p59334
sa(dp59335
g49782
I96
sg49783
I2
sg49784
I22
sg49785
VC0334579
p59336
sg49787
Vanaplastic astrocytoma
p59337
sa(dp59338
g49782
I69
sg49783
I1
sg49784
I12
sg49785
VC0017636
p59339
sg49787
Vglioblastoma
p59340
sasa(dp59341
g49775
VIn situ hybridization of the null cell line HLN-STL-C established from an adult T-cell leukemia patient showed that 100% of the cells contained both EBERs and LMP1 mRNA and about 0.1% of the cells contained gp350/220 mRNA, indicating that a few of the null cells which carried the EBV genome spontaneously entered the late EBV replication cycle.
p59342
sg49777
(lp59343
(dp59344
g49782
I159
sg49783
I2
sg49784
I9
sg49812
g11
sg49787
VLMP1 mRNA
p59345
sasg49779
(lp59346
(dp59347
g49782
I74
sg49783
I3
sg49784
I21
sg49785
VC0023492
p59348
sg49787
Vadult T-cell leukemia
p59349
sasa(dp59350
g49775
VIQ and CELF-3 performance were highly interrelated regardless of whether subjects had autism or were controls.
p59351
sg49777
(lp59352
sg49779
(lp59353
(dp59354
g49782
I86
sg49783
I1
sg49784
I6
sg49785
VC0004352
p59355
sg49787
Vautism
p59356
sasa(dp59357
g49775
VBoth IQ and CELF-3 ability were positively correlated with STG in controls, but a different pattern was observed in subjects with autism.
p59358
sg49777
(lp59359
sg49779
(lp59360
(dp59361
g49782
I130
sg49783
I1
sg49784
I6
sg49785
VC0004352
p59362
sg49787
Vautism
p59363
sasa(dp59364
g49775
VIn controls, left STG gray matter was significantly (r = .42, p &lt; or = .05) related to receptive language on the CELF-3; in contrast, a zero order correlation was found with autism.
p59365
sg49777
(lp59366
(dp59367
g49782
I116
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VCELF-3
p59368
sasg49779
(lp59369
(dp59370
g49782
I177
sg49783
I1
sg49784
I6
sg49785
VC0004352
p59371
sg49787
Vautism
p59372
sasa(dp59373
g49775
VHere, we showed that DUSP10 knockout (KO) mice had increased intestinal epithelial cell (IEC) proliferation and migration and developed less severe colitis than wild-type (WT) mice in response to dextran sodium sulphate (DSS) treatment, which is associated with increased ERK1/2 activation and Kruppel-like factor 5 (KLF5) expression in IEC.
p59374
sg49777
(lp59375
(dp59376
g49782
I272
sg49783
I1
sg49784
I6
sg49812
VP27361
p59377
sg49787
VERK1/2
p59378
sa(dp59379
g49782
I294
sg49783
I3
sg49784
I21
sg49812
g11
sg49787
VKruppel-like factor 5
p59380
sa(dp59381
g49782
I317
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VKLF5
p59382
sa(dp59383
g49782
I21
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VDUSP10
p59384
sasg49779
(lp59385
(dp59386
g49782
I221
sg49783
I1
sg49784
I3
sg49785
VC0011195
p59387
sg49787
VDSS
p59388
sa(dp59389
g49782
I148
sg49783
I1
sg49784
I7
sg49785
VC0009319
p59390
sg49787
Vcolitis
p59391
sa(dp59392
g49782
I196
sg49783
I3
sg49784
I23
sg49785
VC0011195
p59393
sg49787
Vdextran sodium sulphate
p59394
sa(dp59395
g49782
I94
sg49783
I1
sg49784
I13
sg49785
VC0334094
p59396
sg49787
Vproliferation
p59397
sasa(dp59398
g49775
VModels of painful small-fiber sensory neuropathy were developed and several laboratories have progressed in the conception of TRPV1 agonists and antagonists.
p59399
sg49777
(lp59400
(dp59401
g49782
I126
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTRPV1
p59402
sasg49779
(lp59403
(dp59404
g49782
I30
sg49783
I2
sg49784
I18
sg49785
VC0151313
p59405
sg49787
Vsensory neuropathy
p59406
sa(dp59407
g49782
I10
sg49783
I1
sg49784
I7
sg49785
VC0030193
p59408
sg49787
Vpainful
p59409
sasa(dp59410
g49775
VTRPV1 is involved in oxidant stress-induced pain and in neuronal injury, contributing to diabetic sensory neuropathy.
p59411
sg49777
(lp59412
(dp59413
g49782
I0
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTRPV1
p59414
sasg49779
(lp59415
(dp59416
g49782
I98
sg49783
I2
sg49784
I18
sg49785
VC0151313
p59417
sg49787
Vsensory neuropathy
p59418
sasa(dp59419
g49775
VDespite the impediments posed by phenotypic and genetic heterogeneity among women with PCOS, investigation into one locus, the DENND1A gene, is providing insight into the ovarian steroidogenesis.
p59420
sg49777
(lp59421
(dp59422
g49782
I127
sg49783
I2
sg49784
I12
sg49812
g11
sg49787
VDENND1A gene
p59423
sasg49779
(lp59424
(dp59425
g49782
I87
sg49783
I1
sg49784
I4
sg49785
VC0032460
p59426
sg49787
VPCOS
p59427
sasa(dp59428
g49775
VWe conducted a meta-analysis to evaluate the rs10818854, rs2479106, and rs10986105 polymorphism in DENND1A gene with PCOS susceptibility.
p59429
sg49777
(lp59430
(dp59431
g49782
I99
sg49783
I2
sg49784
I12
sg49812
g11
sg49787
VDENND1A gene
p59432
sasg49779
(lp59433
(dp59434
g49782
I117
sg49783
I1
sg49784
I4
sg49785
VC0032460
p59435
sg49787
VPCOS
p59436
sasa(dp59437
g49775
VIn conclusion, the DENND1A gene variant is likely to have influence on PCOS risk.
p59438
sg49777
(lp59439
(dp59440
g49782
I19
sg49783
I2
sg49784
I12
sg49812
g11
sg49787
VDENND1A gene
p59441
sasg49779
(lp59442
(dp59443
g49782
I71
sg49783
I1
sg49784
I4
sg49785
VC0032460
p59444
sg49787
VPCOS
p59445
sasa(dp59446
g49775
VPCOS has a strong genetic component, and genome-wide association studies have identified several candidate genes, notably DENND1A, which encodes connecdenn 1, involved in trafficking of endosomes.
p59447
sg49777
(lp59448
(dp59449
g49782
I145
sg49783
I2
sg49784
I12
sg49812
g11
sg49787
Vconnecdenn 1
p59450
sa(dp59451
g49782
I122
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VDENND1A
p59452
sasg49779
(lp59453
(dp59454
g49782
I0
sg49783
I1
sg49784
I4
sg49785
VC0032460
p59455
sg49787
VPCOS
p59456
sasa(dp59457
g49775
VFurthermore, overexpression of DENND1A variant 2 in normal theca cells resulted in a PCOS phenotype with increased androgen production.
p59458
sg49777
(lp59459
(dp59460
g49782
I31
sg49783
I3
sg49784
I17
sg49812
g11
sg49787
VDENND1A variant 2
p59461
sasg49779
(lp59462
(dp59463
g49782
I85
sg49783
I1
sg49784
I4
sg49785
VC0032460
p59464
sg49787
VPCOS
p59465
sasa(dp59466
g49775
VIn addition, GWAS have suggested that DENND1A, epidermal growth factor signaling, and DNA repair pathways play a role in PCOS pathogenesis.
p59467
sg49777
(lp59468
(dp59469
g49782
I47
sg49783
I3
sg49784
I23
sg49812
VP01133
p59470
sg49787
Vepidermal growth factor
p59471
sa(dp59472
g49782
I38
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VDENND1A
p59473
sasg49779
(lp59474
(dp59475
g49782
I126
sg49783
I1
sg49784
I12
sg49785
VC0699748
p59476
sg49787
Vpathogenesis
p59477
sa(dp59478
g49782
I121
sg49783
I1
sg49784
I4
sg49785
VC0032460
p59479
sg49787
VPCOS
p59480
sasa(dp59481
g49775
VThe rs2479106 and rs10818854 polymorphisms in the DENND1A gene have been reported to be extensively associated with risk of polycystic ovary syndrome (PCOS).
p59482
sg49777
(lp59483
(dp59484
g49782
I50
sg49783
I2
sg49784
I12
sg49812
g11
sg49787
VDENND1A gene
p59485
sasg49779
(lp59486
(dp59487
g49782
I151
sg49783
I1
sg49784
I4
sg49785
VC0032460
p59488
sg49787
VPCOS
p59489
sa(dp59490
g49782
I124
sg49783
I3
sg49784
I25
sg49785
VC0032460
p59491
sg49787
Vpolycystic ovary syndrome
p59492
sasa(dp59493
g49775
VOverall, significant increase of PCOS risk was found between DENND1A-rs10818854 and PCOS susceptibility.
p59494
sg49777
(lp59495
(dp59496
g49782
I61
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VDENND1A
p59497
sasg49779
(lp59498
(dp59499
g49782
I33
sg49783
I1
sg49784
I4
sg49785
VC0032460
p59500
sg49787
VPCOS
p59501
sa(dp59502
g49782
I33
sg49783
I1
sg49784
I4
sg49785
VC0032460
p59503
sg49787
VPCOS
p59504
sasa(dp59505
g49775
VThis meta-analysis suggested that rs2479106 and rs10818854 polymorphisms in the DENND1A gene were associated with increased risk of PCOS.
p59506
sg49777
(lp59507
(dp59508
g49782
I80
sg49783
I2
sg49784
I12
sg49812
g11
sg49787
VDENND1A gene
p59509
sasg49779
(lp59510
(dp59511
g49782
I132
sg49783
I1
sg49784
I4
sg49785
VC0032460
p59512
sg49787
VPCOS
p59513
sasa(dp59514
g49775
VVariant 2 of the DENND1A gene was found overexpressed in PCOS theca cells and confirmed to enhance androgen production.
p59515
sg49777
(lp59516
(dp59517
g49782
I17
sg49783
I2
sg49784
I12
sg49812
g11
sg49787
VDENND1A gene
p59518
sasg49779
(lp59519
(dp59520
g49782
I57
sg49783
I1
sg49784
I4
sg49785
VC0032460
p59521
sg49787
VPCOS
p59522
sasa(dp59523
g49775
VOur previous research had identified three susceptibility loci (rs2479106, DENND1A; rs13405728, LHCGR; rs13429458, THADA) for PCOS in Han Chinese women.
p59524
sg49777
(lp59525
(dp59526
g49782
I75
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VDENND1A
p59527
sa(dp59528
g49782
I96
sg49783
I1
sg49784
I5
sg49812
VP22888
p59529
sg49787
VLHCGR
p59530
sasg49779
(lp59531
(dp59532
g49782
I126
sg49783
I1
sg49784
I4
sg49785
VC0032460
p59533
sg49787
VPCOS
p59534
sasa(dp59535
g49775
VThree of the eleven variants associated with PCOS in the Han Chinese genome-wide association studies were also associated with PCOS in at least one European population when corrected for multiple testing (DENND1A, THADA and YAP1).
p59536
sg49777
(lp59537
(dp59538
g49782
I224
sg49783
I1
sg49784
I4
sg49812
VP46937
p59539
sg49787
VYAP1
p59540
sa(dp59541
g49782
I205
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VDENND1A
p59542
sasg49779
(lp59543
(dp59544
g49782
I45
sg49783
I1
sg49784
I4
sg49785
VC0032460
p59545
sg49787
VPCOS
p59546
sa(dp59547
g49782
I45
sg49783
I1
sg49784
I4
sg49785
VC0032460
p59548
sg49787
VPCOS
p59549
sasa(dp59550
g49775
VMicroRNA-106a-5p (MiR-106a-5p), a small non-coding RNA, has been reported to be downregulated in astrocytoma, osteosarcoma and colorectal cancer.
p59551
sg49777
(lp59552
(dp59553
g49782
I0
sg49783
I1
sg49784
I16
sg49812
g11
sg49787
VMicroRNA-106a-5p
p59554
sa(dp59555
g49782
I18
sg49783
I1
sg49784
I11
sg49812
g11
sg49787
VMiR-106a-5p
p59556
sasg49779
(lp59557
(dp59558
g49782
I127
sg49783
I2
sg49784
I17
sg49785
VC1527249
p59559
sg49787
Vcolorectal cancer
p59560
sa(dp59561
g49782
I97
sg49783
I1
sg49784
I11
sg49785
VC0004114
p59562
sg49787
Vastrocytoma
p59563
sa(dp59564
g49782
I110
sg49783
I1
sg49784
I12
sg49785
VC0029463
p59565
sg49787
Vosteosarcoma
p59566
sasa(dp59567
g49775
VThe study aimed to evaluate the effects of miR-106a on prostate cancer cells and the underlying molecular mechanism.
p59568
sg49777
(lp59569
(dp59570
g49782
I43
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VmiR-106a
p59571
sasg49779
(lp59572
(dp59573
g49782
I55
sg49783
I2
sg49784
I15
sg49785
VC0600139
p59574
sg49787
Vprostate cancer
p59575
sasa(dp59576
g49775
VMiR-106a as an oncogene could promote proliferation and metastasis of prostate cancer cells by directly targeting PTEN in vivo and in vitro.
p59577
sg49777
(lp59578
(dp59579
g49782
I114
sg49783
I1
sg49784
I4
sg49812
VP60484
p59580
sg49787
VPTEN
p59581
sa(dp59582
g49782
I0
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VMiR-106a
p59583
sasg49779
(lp59584
(dp59585
g49782
I38
sg49783
I1
sg49784
I13
sg49785
VC0334094
p59586
sg49787
Vproliferation
p59587
sa(dp59588
g49782
I56
sg49783
I1
sg49784
I10
sg49785
VC0027627
p59589
sg49787
Vmetastasis
p59590
sa(dp59591
g49782
I70
sg49783
I2
sg49784
I15
sg49785
VC0600139
p59592
sg49787
Vprostate cancer
p59593
sasa(dp59594
g49775
VCXCL1 secreted by hAdSCs downregulated miR-106a expression in triple negative breast cancer, and resulted in ABCG2 upregulation and doxorubicin resistance.
p59595
sg49777
(lp59596
(dp59597
g49782
I39
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VmiR-106a
p59598
sa(dp59599
g49782
I0
sg49783
I1
sg49784
I5
sg49812
VP09341
p59600
sg49787
VCXCL1
p59601
sasg49779
(lp59602
(dp59603
g49782
I78
sg49783
I2
sg49784
I13
sg49785
VC0678222
p59604
sg49787
Vbreast cancer
p59605
sasa(dp59606
g49775
VOur findings suggest that CXCL1 secreted by hAdSCs elicits doxorubicin resistance through miR-106a-mediated ABCG2 upregulation in triple negative breast cancer.
p59607
sg49777
(lp59608
(dp59609
g49782
I90
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VmiR-106a
p59610
sa(dp59611
g49782
I26
sg49783
I1
sg49784
I5
sg49812
VP09341
p59612
sg49787
VCXCL1
p59613
sasg49779
(lp59614
(dp59615
g49782
I146
sg49783
I2
sg49784
I13
sg49785
VC0678222
p59616
sg49787
Vbreast cancer
p59617
sasa(dp59618
g49775
VPrevious studies have revealed that miR-106a is abnormally expressed in various cancers.
p59619
sg49777
(lp59620
(dp59621
g49782
I36
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VmiR-106a
p59622
sasg49779
(lp59623
(dp59624
g49782
I80
sg49783
I1
sg49784
I7
sg49785
VC0006826
p59625
sg49787
Vcancers
p59626
sasa(dp59627
g49775
VCopy number gains in SOX2 in the region of 3q26-28 occur in 94% of SQCCs, and appear to act both early and late in disease progression by stabilizing the initial squamous injury response in stem cells and promoting growth of invasive carcinoma.
p59628
sg49777
(lp59629
(dp59630
g49782
I21
sg49783
I1
sg49784
I4
sg49812
VP48431
p59631
sg49787
VSOX2
p59632
sasg49779
(lp59633
(dp59634
g49782
I225
sg49783
I2
sg49784
I18
sg49785
VC1334274
p59635
sg49787
Vinvasive carcinoma
p59636
sa(dp59637
g49782
I115
sg49783
I2
sg49784
I19
sg49785
VC0242656
p59638
sg49787
Vdisease progression
p59639
sasa(dp59640
g49775
VA key feature of high-grade serous ovarian carcinoma (HGSOC) is frequent amplification of the 3q26 locus harboring PRKC-l (PRKCI).
p59641
sg49777
(lp59642
(dp59643
g49782
I115
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VPRKC-l
p59644
sa(dp59645
g49782
I123
sg49783
I1
sg49784
I5
sg49812
VP41743
p59646
sg49787
VPRKCI
p59647
sasg49779
(lp59648
(dp59649
g49782
I73
sg49783
I1
sg49784
I13
sg49785
VC1705759
p59650
sg49787
Vamplification
p59651
sa(dp59652
g49782
I35
sg49783
I2
sg49784
I17
sg49785
VC0029925
p59653
sg49787
Vovarian carcinoma
p59654
sasa(dp59655
g49775
VFour loci, 5p15.33 (TERT), 6p21.3 (BTNL2), 3q28 (TP63) and 17q24.2 (BPTF), previously shown to be strongly associated with overall lung adenocarcinoma risk in East Asians, were re-discovered as loci associated with a higher susceptibility to EGFR mutation-positive lung adenocarcinoma.
p59656
sg49777
(lp59657
sg49779
(lp59658
(dp59659
g49782
I131
sg49783
I2
sg49784
I19
sg49785
VC0152013
p59660
sg49787
Vlung adenocarcinoma
p59661
sa(dp59662
g49782
I131
sg49783
I2
sg49784
I19
sg49785
VC0152013
p59663
sg49787
Vlung adenocarcinoma
p59664
sasa(dp59665
g49775
VChromosome 3q26-28 is a critical region of genomic amplification in non-small cell lung cancer (NSCLC), particularly lung squamous cell carcinomas (SCCs).
p59666
sg49777
(lp59667
sg49779
(lp59668
(dp59669
g49782
I96
sg49783
I1
sg49784
I5
sg49785
VC0007131
p59670
sg49787
VNSCLC
p59671
sa(dp59672
g49782
I68
sg49783
I4
sg49784
I26
sg49785
VC0007131
p59673
sg49787
Vnon-small cell lung cancer
p59674
sa(dp59675
g49782
I51
sg49783
I1
sg49784
I13
sg49785
VC1705759
p59676
sg49787
Vamplification
p59677
sa(dp59678
g49782
I148
sg49783
I1
sg49784
I4
sg49785
VC0007137
p59679
sg49787
VSCCs
p59680
sa(dp59681
g49782
I122
sg49783
I3
sg49784
I24
sg49785
VC0007137
p59682
sg49787
Vsquamous cell carcinomas
p59683
sasa(dp59684
g49775
VThe PIK3CA gene at chromosome 3q26.32 was found to be amplified in up to 45% of patients with squamous cell carcinoma of the lung.
p59685
sg49777
(lp59686
(dp59687
g49782
I4
sg49783
I2
sg49784
I11
sg49812
VP42336
p59688
sg49787
VPIK3CA gene
p59689
sasg49779
(lp59690
(dp59691
g49782
I94
sg49783
I6
sg49784
I35
sg49785
VC0149782
p59692
sg49787
Vsquamous cell carcinoma of the lung
p59693
sasa(dp59694
g49775
VAspirin/NSAID interacted with MAP3K7 (colon cancer) and with MAPK14, NFAT5, and TRAF2 (rectal cancer); smoking cigarettes interacted with NFAM1 and NFAT2 (colon cancer) and MAPK8, NFAT5, and TNFRSF1A (rectal cancer); BMI interacted with NFAM1 and NFAT5 (colon cancer) and with MAPK8 and TNFRSF1A (rectal cancer).
p59695
sg49777
(lp59696
(dp59697
g49782
I148
sg49783
I3
sg49784
I20
sg49812
g11
sg49787
VNFAT2 (colon cancer)
p59698
sa(dp59699
g49782
I191
sg49783
I1
sg49784
I8
sg49812
VP19438
p59700
sg49787
VTNFRSF1A
p59701
sa(dp59702
g49782
I69
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VNFAT5
p59703
sa(dp59704
g49782
I138
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VNFAM1
p59705
sa(dp59706
g49782
I69
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VNFAT5
p59707
sa(dp59708
g49782
I30
sg49783
I3
sg49784
I21
sg49812
g11
sg49787
VMAP3K7 (colon cancer)
p59709
sa(dp59710
g49782
I80
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTRAF2
p59711
sa(dp59712
g49782
I173
sg49783
I1
sg49784
I5
sg49812
VP45983
p59713
sg49787
VMAPK8
p59714
sa(dp59715
g49782
I138
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VNFAM1
p59716
sa(dp59717
g49782
I247
sg49783
I3
sg49784
I20
sg49812
g11
sg49787
VNFAT5 (colon cancer)
p59718
sa(dp59719
g49782
I173
sg49783
I1
sg49784
I5
sg49812
VP45983
p59720
sg49787
VMAPK8
p59721
sa(dp59722
g49782
I61
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VMAPK14
p59723
sa(dp59724
g49782
I191
sg49783
I1
sg49784
I8
sg49812
VP19438
p59725
sg49787
VTNFRSF1A
p59726
sasg49779
(lp59727
(dp59728
g49782
I87
sg49783
I2
sg49784
I13
sg49785
VC0007113
p59729
sg49787
Vrectal cancer
p59730
sa(dp59731
g49782
I87
sg49783
I2
sg49784
I13
sg49785
VC0007113
p59732
sg49787
Vrectal cancer
p59733
sa(dp59734
g49782
I38
sg49783
I2
sg49784
I12
sg49785
VC0699790
p59735
sg49787
Vcolon cancer
p59736
sa(dp59737
g49782
I38
sg49783
I2
sg49784
I12
sg49785
VC0699790
p59738
sg49787
Vcolon cancer
p59739
sa(dp59740
g49782
I87
sg49783
I2
sg49784
I13
sg49785
VC0007113
p59741
sg49787
Vrectal cancer
p59742
sa(dp59743
g49782
I38
sg49783
I2
sg49784
I12
sg49785
VC0699790
p59744
sg49787
Vcolon cancer
p59745
sasa(dp59746
g49775
VPreviously, we have cloned the cDNAs for the meningioma expressed antigen 6 (MGEA6) and its splice variant MGEA11.
p59747
sg49777
(lp59748
sg49779
(lp59749
(dp59750
g49782
I45
sg49783
I1
sg49784
I10
sg49785
VC0025286
p59751
sg49787
Vmeningioma
p59752
sasa(dp59753
g49775
VHere, we show that antibodies against recombinantly expressed MGEA6/11 are found in 41.7% (10/24) of the sera from meningioma patients and in 2/8 sera of glioblastoma patients, whereas no response was seen in 12 sera from healthy persons.
p59754
sg49777
(lp59755
(dp59756
g49782
I62
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VMGEA6/11
p59757
sasg49779
(lp59758
(dp59759
g49782
I154
sg49783
I1
sg49784
I12
sg49785
VC0017636
p59760
sg49787
Vglioblastoma
p59761
sa(dp59762
g49782
I115
sg49783
I1
sg49784
I10
sg49785
VC0025286
p59763
sg49787
Vmeningioma
p59764
sasa(dp59765
g49775
VThe immune response to MGEA6/11 is frequent in both meningioma and glioma patients and may likely be attributed to overexpression of the MGEA6/11 protein in the tumor cells.
p59766
sg49777
(lp59767
(dp59768
g49782
I137
sg49783
I2
sg49784
I16
sg49812
g11
sg49787
VMGEA6/11 protein
p59769
sa(dp59770
g49782
I23
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VMGEA6/11
p59771
sasg49779
(lp59772
(dp59773
g49782
I161
sg49783
I1
sg49784
I5
sg49785
VC0027651
p59774
sg49787
Vtumor
p59775
sa(dp59776
g49782
I67
sg49783
I1
sg49784
I6
sg49785
VC0017638
p59777
sg49787
Vglioma
p59778
sa(dp59779
g49782
I52
sg49783
I1
sg49784
I10
sg49785
VC0025286
p59780
sg49787
Vmeningioma
p59781
sasa(dp59782
g49775
VThe meningioma expressed antigen-6 (MGEA6) was originally identified as an immunogenic antigen in meningioma patients.
p59783
sg49777
(lp59784
(dp59785
g49782
I4
sg49783
I3
sg49784
I30
sg49812
g11
sg49787
Vmeningioma expressed antigen-6
p59786
sa(dp59787
g49782
I36
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VMGEA6
p59788
sasg49779
(lp59789
(dp59790
g49782
I4
sg49783
I1
sg49784
I10
sg49785
VC0025286
p59791
sg49787
Vmeningioma
p59792
sa(dp59793
g49782
I4
sg49783
I1
sg49784
I10
sg49785
VC0025286
p59794
sg49787
Vmeningioma
p59795
sasa(dp59796
g49775
VThe clones were sequenced, and sequence comparison revealed that the seven clones represent five different genes, providing evidence that meningiomas express a spectrum of immunoreactive antigens, which were termed meningioma expressed antigens (MGEAs).
p59797
sg49777
(lp59798
sg49779
(lp59799
(dp59800
g49782
I138
sg49783
I1
sg49784
I10
sg49785
VC0025286
p59801
sg49787
Vmeningioma
p59802
sa(dp59803
g49782
I138
sg49783
I1
sg49784
I11
sg49785
VC0025286
p59804
sg49787
Vmeningiomas
p59805
sasa(dp59806
g49775
VThese data suggest that the newly identified MGEA genes may be useful for diagnosis and possibly therapy of meningioma.
p59807
sg49777
(lp59808
(dp59809
g49782
I45
sg49783
I2
sg49784
I10
sg49812
g11
sg49787
VMGEA genes
p59810
sasg49779
(lp59811
(dp59812
g49782
I108
sg49783
I1
sg49784
I10
sg49785
VC0025286
p59813
sg49787
Vmeningioma
p59814
sasa(dp59815
g49775
VThe longest open reading frame was found to be 2412 bp encoding an immunoreactive antigen termed meningioma expressed antigen 6 (MEA6).
p59816
sg49777
(lp59817
sg49779
(lp59818
(dp59819
g49782
I97
sg49783
I1
sg49784
I10
sg49785
VC0025286
p59820
sg49787
Vmeningioma
p59821
sasa(dp59822
g49775
VUsing the keywords [St John's Wort OR Hypericum perforatum OR hypericin OR hyperforin OR johanniskraut OR] AND [depression OR antidepressant OR SSRI], a preliminary search (without language restriction) on the PubMed, Ovid, Clinical Trials Register of the Cochrane Collaboration Depression, Anxiety and Neurosis Group, Cochrane Field for Complementary Medicine, China National Knowledge Infrastructure and WanFang database yielded 5428 papers between 1-Jan-1960 and 1-May-2016.
p59823
sg49777
(lp59824
sg49779
(lp59825
(dp59826
g49782
I303
sg49783
I1
sg49784
I8
sg49785
VC0027932
p59827
sg49787
VNeurosis
p59828
sa(dp59829
g49782
I112
sg49783
I1
sg49784
I10
sg49785
VC0011581
p59830
sg49787
Vdepression
p59831
sa(dp59832
g49782
I279
sg49783
I1
sg49784
I10
sg49785
VC0011581
p59833
sg49787
VDepression
p59834
sasa(dp59835
g49775
VThere is evidence to suggest that caregivers of patients with head and neck cancer (HNC) are susceptible to post-traumatic stress disorder (PTSD) symptoms.
p59836
sg49777
(lp59837
sg49779
(lp59838
(dp59839
g49782
I108
sg49783
I3
sg49784
I30
sg49785
VC0038436
p59840
sg49787
Vpost-traumatic stress disorder
p59841
sa(dp59842
g49782
I140
sg49783
I1
sg49784
I4
sg49785
VC0038436
p59843
sg49787
VPTSD
p59844
sa(dp59845
g49782
I62
sg49783
I4
sg49784
I20
sg49785
VC0278996
p59846
sg49787
Vhead and neck cancer
p59847
sa(dp59848
g49782
I84
sg49783
I1
sg49784
I3
sg49785
VC0278996
p59849
sg49787
VHNC
p59850
sasa(dp59851
g49775
VEvidence suggests that patients with head and neck cancer (HNC) are susceptible to post-traumatic stress disorder (PTSD).
p59852
sg49777
(lp59853
sg49779
(lp59854
(dp59855
g49782
I83
sg49783
I3
sg49784
I30
sg49785
VC0038436
p59856
sg49787
Vpost-traumatic stress disorder
p59857
sa(dp59858
g49782
I115
sg49783
I1
sg49784
I4
sg49785
VC0038436
p59859
sg49787
VPTSD
p59860
sa(dp59861
g49782
I59
sg49783
I1
sg49784
I3
sg49785
VC0278996
p59862
sg49787
VHNC
p59863
sa(dp59864
g49782
I37
sg49783
I4
sg49784
I20
sg49785
VC0278996
p59865
sg49787
Vhead and neck cancer
p59866
sasa(dp59867
g49775
VAmong distressed HNC survivors, higher PTG was associated with lower tumor stage, absence of an anxiety disorder, absence of an alcohol use disorder, and better social functioning.
p59868
sg49777
(lp59869
sg49779
(lp59870
(dp59871
g49782
I69
sg49783
I1
sg49784
I5
sg49785
VC0027651
p59872
sg49787
Vtumor
p59873
sa(dp59874
g49782
I96
sg49783
I2
sg49784
I16
sg49785
VC0003469
p59875
sg49787
Vanxiety disorder
p59876
sa(dp59877
g49782
I6
sg49783
I1
sg49784
I10
sg49785
VC0700361
p59878
sg49787
Vdistressed
p59879
sa(dp59880
g49782
I128
sg49783
I3
sg49784
I20
sg49785
VC0001956
p59881
sg49787
Valcohol use disorder
p59882
sasa(dp59883
g49775
VAlthough lysyl oxidase-like 1 (LOXL1) is known as the principal genetic risk factor for pseudoexfoliation (PEX) syndrome, a major cause of glaucoma and cardiovascular complications, no functional variants have been identified to date.
p59884
sg49777
(lp59885
(dp59886
g49782
I31
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VLOXL1
p59887
sa(dp59888
g49782
I9
sg49783
I3
sg49784
I20
sg49812
g11
sg49787
Vlysyl oxidase-like 1
p59889
sasg49779
(lp59890
(dp59891
g49782
I112
sg49783
I1
sg49784
I8
sg49785
VC0039082
p59892
sg49787
Vsyndrome
p59893
sa(dp59894
g49782
I139
sg49783
I1
sg49784
I8
sg49785
VC0017601
p59895
sg49787
Vglaucoma
p59896
sasa(dp59897
g49775
VRecent studies have shed new light on the genetic factors underlying pseudoexfoliation syndrome, growing our understanding of the role of the lysyl oxidase-like 1 (LOXL1) gene and its various polymorphisms as well as identifying new genetic associations.
p59898
sg49777
(lp59899
(dp59900
g49782
I142
sg49783
I3
sg49784
I20
sg49812
g11
sg49787
Vlysyl oxidase-like 1
p59901
sa(dp59902
g49782
I164
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VLOXL1
p59903
sasg49779
(lp59904
(dp59905
g49782
I69
sg49783
I2
sg49784
I26
sg49785
VC0206368
p59906
sg49787
Vpseudoexfoliation syndrome
p59907
sasa(dp59908
g49775
VWe found that TAPP2, syntrophin, and utrophin are coexpressed in normal human B cells and B-chronic lymphocytic leukemia (B-CLL) cells.
p59909
sg49777
(lp59910
(dp59911
g49782
I37
sg49783
I1
sg49784
I8
sg49812
VP46939
p59912
sg49787
Vutrophin
p59913
sa(dp59914
g49782
I14
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTAPP2
p59915
sasg49779
(lp59916
(dp59917
g49782
I124
sg49783
I1
sg49784
I3
sg49785
VC0023434
p59918
sg49787
VCLL
p59919
sa(dp59920
g49782
I92
sg49783
I3
sg49784
I28
sg49785
VC0023434
p59921
sg49787
Vchronic lymphocytic leukemia
p59922
sasa(dp59923
g49775
VCREB1 expression, which was activated by E2F, was coupled with RFC3 expression during the G1/S progression in the KG-1 acute myeloid leukemia (AML) cell line.
p59924
sg49777
(lp59925
(dp59926
g49782
I0
sg49783
I1
sg49784
I5
sg49812
VP16220
p59927
sg49787
VCREB1
p59928
sa(dp59929
g49782
I63
sg49783
I1
sg49784
I4
sg49812
VP40938
p59930
sg49787
VRFC3
p59931
sasg49779
(lp59932
(dp59933
g49782
I143
sg49783
I1
sg49784
I3
sg49785
VC0023467
p59934
sg49787
VAML
p59935
sa(dp59936
g49782
I119
sg49783
I3
sg49784
I22
sg49785
VC0023467
p59937
sg49787
Vacute myeloid leukemia
p59938
sasa(dp59939
g49775
VThe National Reference Center for equine infectious anemia (EIA) validated a commercial ELISA (Eradikit(R) EIAV Indirect ELISA, In3diagnostic(R), Turin, Italy) employing a chimeric recombinant gag and env peptide for the detection of EIA virus antibodies, following the guidelines of the World Organization for Animal Health.
p59940
sg49777
(lp59941
(dp59942
g49782
I172
sg49783
I3
sg49784
I24
sg49812
VP87889
p59943
sg49787
Vchimeric recombinant gag
p59944
sa(dp59945
g49782
I201
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
Venv
p59946
sasg49779
(lp59947
(dp59948
g49782
I60
sg49783
I1
sg49784
I3
sg49785
VC0014661
p59949
sg49787
VEIA
p59950
sa(dp59951
g49782
I60
sg49783
I1
sg49784
I3
sg49785
VC0014661
p59952
sg49787
VEIA
p59953
sa(dp59954
g49782
I34
sg49783
I3
sg49784
I24
sg49785
VC0014661
p59955
sg49787
Vequine infectious anemia
p59956
sasa(dp59957
g49775
VThe development of anaemia in feline leukaemia virus (FeLV)-infected cats is associated with the emergence of a novel viral subgroup, FeLV-C. FeLV-C arises from the subgroup that is transmitted, FeLV-A, through alterations in the amino acid sequence of the receptor binding domain (RBD) of the envelope glycoprotein that result in a shift in the receptor usage and the cell tropism of the virus.
p59958
sg49777
(lp59959
(dp59960
g49782
I294
sg49783
I2
sg49784
I21
sg49812
g11
sg49787
Venvelope glycoprotein
p59961
sasg49779
(lp59962
(dp59963
g49782
I37
sg49783
I1
sg49784
I9
sg49785
VC0023418
p59964
sg49787
Vleukaemia
p59965
sa(dp59966
g49782
I19
sg49783
I1
sg49784
I7
sg49785
VC0002871
p59967
sg49787
Vanaemia
p59968
sa(dp59969
g49782
I182
sg49783
I1
sg49784
I11
sg49785
VC0242781
p59970
sg49787
Vtransmitted
p59971
sasa(dp59972
g49775
VThese results suggest that the interaction between sf-Stk and the envelope proteins of the polycythemia- and anemia-inducing variants of SFFV is architecturally different.
p59973
sg49777
(lp59974
(dp59975
g49782
I66
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
Venvelope
p59976
sa(dp59977
g49782
I51
sg49783
I1
sg49784
I6
sg49812
VP52823
p59978
sg49787
Vsf-Stk
p59979
sasg49779
(lp59980
(dp59981
g49782
I109
sg49783
I1
sg49784
I6
sg49785
VC0002871
p59982
sg49787
Vanemia
p59983
sa(dp59984
g49782
I91
sg49783
I1
sg49784
I12
sg49785
VC0032461
p59985
sg49787
Vpolycythemia
p59986
sasa(dp59987
g49775
VWe conclude that the common clinical features of patients with an isolated mutation of ZRSR2 are a macrocytic anemia without leukopenia, thrombocytopenia or an increase in marrow blast percentage.
p59988
sg49777
(lp59989
(dp59990
g49782
I87
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VZRSR2
p59991
sasg49779
(lp59992
(dp59993
g49782
I99
sg49783
I2
sg49784
I17
sg49785
VC0002886
p59994
sg49787
Vmacrocytic anemia
p59995
sa(dp59996
g49782
I125
sg49783
I1
sg49784
I10
sg49785
VC0023530
p59997
sg49787
Vleukopenia
p59998
sasa(dp59999
g49775
VRecent studies have shown that recombinant human thrombomodulin (rhTM) improves exacerbation and clinical outcome of idiopathic pulmonary fibrosis, but the mechanism remains unknown.
p60000
sg49777
(lp60001
(dp60002
g49782
I31
sg49783
I3
sg49784
I32
sg49812
VP07204
p60003
sg49787
Vrecombinant human thrombomodulin
p60004
sa(dp60005
g49782
I65
sg49783
I1
sg49784
I4
sg49812
VP07204
p60006
sg49787
VrhTM
p60007
sasg49779
(lp60008
(dp60009
g49782
I117
sg49783
I3
sg49784
I29
sg49785
VC3161101
p60010
sg49787
Vidiopathic pulmonary fibrosis
p60011
sasa(dp60012
g49775
VThis furthers our understanding of the regulatory mechanism of cardiac sarcomere assembly in both physiologic and pathologic contexts, and uncovers a potential novel pathway to cardiomyopathy through modulating the Stk38/Rbm24 protein activity.
p60013
sg49777
(lp60014
(dp60015
g49782
I215
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VStk38
p60016
sa(dp60017
g49782
I221
sg49783
I2
sg49784
I13
sg49812
g11
sg49787
VRbm24 protein
p60018
sasg49779
(lp60019
(dp60020
g49782
I177
sg49783
I1
sg49784
I14
sg49785
VC0878544
p60021
sg49787
Vcardiomyopathy
p60022
sasa(dp60023
g49775
VThis study uncovers a potential novel pathway to cardiomyopathy through down-regulation of the RBP Rbm24.
p60024
sg49777
(lp60025
(dp60026
g49782
I95
sg49783
I2
sg49784
I9
sg49812
g11
sg49787
VRBP Rbm24
p60027
sasg49779
(lp60028
(dp60029
g49782
I49
sg49783
I1
sg49784
I14
sg49785
VC0878544
p60030
sg49787
Vcardiomyopathy
p60031
sasa(dp60032
g49775
VNsp3 proteins of Semliki Forest (SFV), Sindbis (SINV), and Chikungunya viruses all showed avid and SH3-dependent binding to amphiphysins.
p60033
sg49777
(lp60034
(dp60035
g49782
I0
sg49783
I2
sg49784
I13
sg49812
g11
sg49787
VNsp3 proteins
p60036
sasg49779
(lp60037
(dp60038
g49782
I59
sg49783
I1
sg49784
I11
sg49785
VC0008055
p60039
sg49787
VChikungunya
p60040
sasa(dp60041
g49775
VColitis severity was assessed by body weight, colonoscopy, colon length, histological score, cytokine mRNA expression, and myeloperoxidase (MPO) activity.
p60042
sg49777
(lp60043
(dp60044
g49782
I123
sg49783
I1
sg49784
I15
sg49812
VP05164
p60045
sg49787
Vmyeloperoxidase
p60046
sa(dp60047
g49782
I140
sg49783
I1
sg49784
I3
sg49812
VP05164
p60048
sg49787
VMPO
p60049
sasg49779
(lp60050
(dp60051
g49782
I0
sg49783
I1
sg49784
I7
sg49785
VC0009319
p60052
sg49787
VColitis
p60053
sasa(dp60054
g49775
VPigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) is associated with recessive mutations in SLC29A3, encoding the equilibrative nucleoside transporter hENT3 expressed in mitochondria, causing PHID and H syndromes, familial Rosai-Dorfman disease, and histiocytosis-lymphadenopathy-plus syndrome.
p60055
sg49777
(lp60056
(dp60057
g49782
I45
sg49783
I1
sg49784
I7
sg49812
VP01308
p60058
sg49787
Vinsulin
p60059
sa(dp60060
g49782
I166
sg49783
I3
sg49784
I28
sg49812
g11
sg49787
Vnucleoside transporter hENT3
p60061
sasg49779
(lp60062
(dp60063
g49782
I82
sg49783
I1
sg49784
I4
sg49785
VC1864445
p60064
sg49787
VPHID
p60065
sa(dp60066
g49782
I241
sg49783
I1
sg49784
I8
sg49785
VC0039082
p60067
sg49787
Vsyndrome
p60068
sa(dp60069
g49782
I11
sg49783
I1
sg49784
I14
sg49785
VC0020555
p60070
sg49787
Vhypertrichosis
p60071
sa(dp60072
g49782
I288
sg49783
I1
sg49784
I13
sg49785
VC0019618
p60073
sg49787
Vhistiocytosis
p60074
sa(dp60075
g49782
I34
sg49783
I1
sg49784
I10
sg49785
VC0443146
p60076
sg49787
Vautoimmune
p60077
sa(dp60078
g49782
I241
sg49783
I1
sg49784
I9
sg49785
VC0039082
p60079
sg49787
Vsyndromes
p60080
sa(dp60081
g49782
I82
sg49783
I1
sg49784
I4
sg49785
VC1864445
p60082
sg49787
VPHID
p60083
sa(dp60084
g49782
I261
sg49783
I2
sg49784
I21
sg49785
VC0019625
p60085
sg49787
VRosai-Dorfman disease
p60086
sa(dp60087
g49782
I45
sg49783
I3
sg49784
I35
sg49785
VC0011854
p60088
sg49787
Vinsulin-dependent diabetes mellitus
p60089
sasa(dp60090
g49775
VThe patients share many of the characteristics previously reported with H syndrome, including hyperpigmentation, hypertrichosis, short stature, insulin-dependent diabetes, arthritis and systemic inflammation, as well as some novel features, including selective IgG subclass deficiency and autoimmune hepatitis.
p60091
sg49777
(lp60092
(dp60093
g49782
I144
sg49783
I1
sg49784
I7
sg49812
VP01308
p60094
sg49787
Vinsulin
p60095
sasg49779
(lp60096
(dp60097
g49782
I172
sg49783
I1
sg49784
I9
sg49785
VC0003864
p60098
sg49787
Varthritis
p60099
sa(dp60100
g49782
I251
sg49783
I4
sg49784
I33
sg49785
VC0162539
p60101
sg49787
Vselective IgG subclass deficiency
p60102
sa(dp60103
g49782
I129
sg49783
I2
sg49784
I13
sg49785
VC0013336
p60104
sg49787
Vshort stature
p60105
sa(dp60106
g49782
I195
sg49783
I1
sg49784
I12
sg49785
VC0021368
p60107
sg49787
Vinflammation
p60108
sa(dp60109
g49782
I94
sg49783
I1
sg49784
I17
sg49785
VC0162834
p60110
sg49787
Vhyperpigmentation
p60111
sa(dp60112
g49782
I72
sg49783
I2
sg49784
I10
sg49785
VC1864445
p60113
sg49787
VH syndrome
p60114
sa(dp60115
g49782
I289
sg49783
I2
sg49784
I20
sg49785
VC0241910
p60116
sg49787
Vautoimmune hepatitis
p60117
sa(dp60118
g49782
I144
sg49783
I2
sg49784
I26
sg49785
VC0011854
p60119
sg49787
Vinsulin-dependent diabetes
p60120
sa(dp60121
g49782
I113
sg49783
I1
sg49784
I14
sg49785
VC0020555
p60122
sg49787
Vhypertrichosis
p60123
sasa(dp60124
g49775
VLoss of function recessive mutations in the SLC29A3 gene that encodes human equilibrative nucleoside transporter 3 (ENT3) have been identified in patients with pigmented hypertrichotic dermatosis with insulin-dependent diabetes (PHID).
p60125
sg49777
(lp60126
(dp60127
g49782
I70
sg49783
I5
sg49784
I44
sg49812
g11
sg49787
Vhuman equilibrative nucleoside transporter 3
p60128
sa(dp60129
g49782
I201
sg49783
I1
sg49784
I7
sg49812
VP01308
p60130
sg49787
Vinsulin
p60131
sasg49779
(lp60132
(dp60133
g49782
I160
sg49783
I6
sg49784
I67
sg49785
VC1864445
p60134
sg49787
Vpigmented hypertrichotic dermatosis with insulin-dependent diabetes
p60135
sa(dp60136
g49782
I229
sg49783
I1
sg49784
I4
sg49785
VC1864445
p60137
sg49787
VPHID
p60138
sasa(dp60139
g49775
VThus, apoptotic loss of islet Beta-cells may contribute to the occurrence of autoantibody-negative insulin-dependent diabetes in individuals with non-functional ENT3 mutations.
p60140
sg49777
(lp60141
(dp60142
g49782
I99
sg49783
I1
sg49784
I7
sg49812
VP01308
p60143
sg49787
Vinsulin
p60144
sasg49779
(lp60145
(dp60146
g49782
I99
sg49783
I2
sg49784
I26
sg49785
VC0011854
p60147
sg49787
Vinsulin-dependent diabetes
p60148
sasa(dp60149
g49775
VH syndrome and pigmented hypertrichosis with insulin-dependent diabetes mellitus (PHID) had been described as two autosomal recessive disorders.
p60150
sg49777
(lp60151
(dp60152
g49782
I45
sg49783
I1
sg49784
I7
sg49812
VP01308
p60153
sg49787
Vinsulin
p60154
sasg49779
(lp60155
(dp60156
g49782
I82
sg49783
I1
sg49784
I4
sg49785
VC1864445
p60157
sg49787
VPHID
p60158
sa(dp60159
g49782
I0
sg49783
I2
sg49784
I10
sg49785
VC1864445
p60160
sg49787
VH syndrome
p60161
sa(dp60162
g49782
I15
sg49783
I6
sg49784
I65
sg49785
VC1864445
p60163
sg49787
Vpigmented hypertrichosis with insulin-dependent diabetes mellitus
p60164
sasa(dp60165
g49775
VThe term H syndrome was coined to denote the major clinical findings which include hyperpigmentation, hypertrichosis, hearing loss, hepatosplenomegaly, hypogonadism, hyperglycemia/diabetes mellitus and hallux valgus/flexion contractures.
p60166
sg49777
(lp60167
sg49779
(lp60168
(dp60169
g49782
I202
sg49783
I2
sg49784
I13
sg49785
VC0018536
p60170
sg49787
Vhallux valgus
p60171
sa(dp60172
g49782
I152
sg49783
I1
sg49784
I12
sg49785
VC0020619
p60173
sg49787
Vhypogonadism
p60174
sa(dp60175
g49782
I180
sg49783
I2
sg49784
I17
sg49785
VC0011849
p60176
sg49787
Vdiabetes mellitus
p60177
sa(dp60178
g49782
I118
sg49783
I2
sg49784
I12
sg49785
VC0011053
p60179
sg49787
Vhearing loss
p60180
sa(dp60181
g49782
I9
sg49783
I2
sg49784
I10
sg49785
VC1864445
p60182
sg49787
VH syndrome
p60183
sa(dp60184
g49782
I132
sg49783
I1
sg49784
I18
sg49785
VC0019214
p60185
sg49787
Vhepatosplenomegaly
p60186
sa(dp60187
g49782
I166
sg49783
I1
sg49784
I13
sg49785
VC0020456
p60188
sg49787
Vhyperglycemia
p60189
sa(dp60190
g49782
I51
sg49783
I2
sg49784
I17
sg49785
VC0037088
p60191
sg49787
Vclinical findings
p60192
sa(dp60193
g49782
I83
sg49783
I1
sg49784
I17
sg49785
VC0162834
p60194
sg49787
Vhyperpigmentation
p60195
sa(dp60196
g49782
I216
sg49783
I2
sg49784
I20
sg49785
VC0333068
p60197
sg49787
Vflexion contractures
p60198
sa(dp60199
g49782
I102
sg49783
I1
sg49784
I14
sg49785
VC0020555
p60200
sg49787
Vhypertrichosis
p60201
sasa(dp60202
g49775
VMutations in SLC29A3 lead to pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) and H syndromes, familial Rosai-Dorfman disease, and histiocytosis-lymphadenopathy plus syndrome.
p60203
sg49777
(lp60204
(dp60205
g49782
I74
sg49783
I1
sg49784
I7
sg49812
VP01308
p60206
sg49787
Vinsulin
p60207
sasg49779
(lp60208
(dp60209
g49782
I63
sg49783
I1
sg49784
I10
sg49785
VC0443146
p60210
sg49787
Vautoimmune
p60211
sa(dp60212
g49782
I74
sg49783
I3
sg49784
I35
sg49785
VC0011854
p60213
sg49787
Vinsulin-dependent diabetes mellitus
p60214
sa(dp60215
g49782
I170
sg49783
I3
sg49784
I43
sg49785
VC1864445
p60216
sg49787
Vhistiocytosis-lymphadenopathy plus syndrome
p60217
sa(dp60218
g49782
I123
sg49783
I1
sg49784
I9
sg49785
VC0039082
p60219
sg49787
Vsyndromes
p60220
sa(dp60221
g49782
I111
sg49783
I1
sg49784
I4
sg49785
VC1864445
p60222
sg49787
VPHID
p60223
sa(dp60224
g49782
I40
sg49783
I1
sg49784
I14
sg49785
VC0020555
p60225
sg49787
Vhypertrichosis
p60226
sa(dp60227
g49782
I143
sg49783
I2
sg49784
I21
sg49785
VC0019625
p60228
sg49787
VRosai-Dorfman disease
p60229
sasa(dp60230
g49775
VThis report describes an insulin-dependent diabetes patient with a syndromic presentation in whom a homozygous SLC29A3 mutation was identified.
p60231
sg49777
(lp60232
(dp60233
g49782
I25
sg49783
I1
sg49784
I7
sg49812
VP01308
p60234
sg49787
Vinsulin
p60235
sasg49779
(lp60236
(dp60237
g49782
I25
sg49783
I2
sg49784
I26
sg49785
VC0011854
p60238
sg49787
Vinsulin-dependent diabetes
p60239
sasa(dp60240
g49775
VThese clinical features overlapped with pigmented hypertrichosis with insulin-dependent diabetes (PHID), H syndrome, Faisalabad histiocytosis and sinus histiocytosis with massive lymphadenopathy (SHML), all of which are also caused by SLC29A3 mutations.
p60241
sg49777
(lp60242
(dp60243
g49782
I70
sg49783
I1
sg49784
I7
sg49812
VP01308
p60244
sg49787
Vinsulin
p60245
sasg49779
(lp60246
(dp60247
g49782
I146
sg49783
I5
sg49784
I48
sg49785
VC0019625
p60248
sg49787
Vsinus histiocytosis with massive lymphadenopathy
p60249
sa(dp60250
g49782
I105
sg49783
I2
sg49784
I10
sg49785
VC1864445
p60251
sg49787
VH syndrome
p60252
sa(dp60253
g49782
I40
sg49783
I5
sg49784
I56
sg49785
VC1864445
p60254
sg49787
Vpigmented hypertrichosis with insulin-dependent diabetes
p60255
sa(dp60256
g49782
I117
sg49783
I2
sg49784
I24
sg49785
VC1864445
p60257
sg49787
VFaisalabad histiocytosis
p60258
sa(dp60259
g49782
I196
sg49783
I1
sg49784
I4
sg49785
VC1864445
p60260
sg49787
VSHML
p60261
sa(dp60262
g49782
I98
sg49783
I1
sg49784
I4
sg49785
VC1864445
p60263
sg49787
VPHID
p60264
sasa(dp60265
g49775
VGermline mutations in the SLC29A3 gene result in a range of recessive, clinically related syndromes: H syndrome, pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome, Faisalabad histiocytosis, and sinus histiocytosis with massive lymphadenopathy.
p60266
sg49777
(lp60267
(dp60268
g49782
I143
sg49783
I1
sg49784
I7
sg49812
VP01308
p60269
sg49787
Vinsulin
p60270
sasg49779
(lp60271
(dp60272
g49782
I101
sg49783
I2
sg49784
I10
sg49785
VC1864445
p60273
sg49787
VH syndrome
p60274
sa(dp60275
g49782
I219
sg49783
I5
sg49784
I48
sg49785
VC0019625
p60276
sg49787
Vsinus histiocytosis with massive lymphadenopathy
p60277
sa(dp60278
g49782
I189
sg49783
I2
sg49784
I24
sg49785
VC1864445
p60279
sg49787
VFaisalabad histiocytosis
p60280
sa(dp60281
g49782
I90
sg49783
I1
sg49784
I8
sg49785
VC0039082
p60282
sg49787
Vsyndrome
p60283
sa(dp60284
g49782
I113
sg49783
I6
sg49784
I65
sg49785
VC1864445
p60285
sg49787
Vpigmented hypertrichosis with insulin-dependent diabetes mellitus
p60286
sa(dp60287
g49782
I90
sg49783
I1
sg49784
I9
sg49785
VC0039082
p60288
sg49787
Vsyndromes
p60289
sasa(dp60290
g49775
VCharacteristic ADC map features were identified for protrusion, extrusion and sequester types of lumbar disk herniations, spondylolisthesis, reactive Modic endplate changes, Pfirrmann grades of IVD degeneration, and compromised spinal nerves.
p60291
sg49777
(lp60292
sg49779
(lp60293
(dp60294
g49782
I122
sg49783
I1
sg49784
I17
sg49785
VC0038017
p60295
sg49787
Vspondylolisthesis
p60296
sa(dp60297
g49782
I52
sg49783
I1
sg49784
I10
sg49785
VC0333056
p60298
sg49787
Vprotrusion
p60299
sa(dp60300
g49782
I198
sg49783
I1
sg49784
I12
sg49785
VC0011164
p60301
sg49787
Vdegeneration
p60302
sa(dp60303
g49782
I109
sg49783
I1
sg49784
I11
sg49785
VC0019270
p60304
sg49787
Vherniations
p60305
sasa(dp60306
g49775
VWe measured T2 relaxation time of the intervertebral discs (IVD) and facet joints (FJ) in patients with degenerative spondylolisthesis (DS) and no spondylolisthesis (NS) and investigated the characteristics of these parts in DS.
p60307
sg49777
(lp60308
sg49779
(lp60309
(dp60310
g49782
I136
sg49783
I1
sg49784
I2
sg49785
VC0264184
p60311
sg49787
VDS
p60312
sa(dp60313
g49782
I117
sg49783
I1
sg49784
I17
sg49785
VC0038017
p60314
sg49787
Vspondylolisthesis
p60315
sa(dp60316
g49782
I104
sg49783
I2
sg49784
I30
sg49785
VC0264184
p60317
sg49787
Vdegenerative spondylolisthesis
p60318
sa(dp60319
g49782
I136
sg49783
I1
sg49784
I2
sg49785
VC0264184
p60320
sg49787
VDS
p60321
sasa(dp60322
g49775
VEarly stages of scoliosis and spondylolisthesis entail changes in the intervertebral disc (IVD) structure and biochemistry.
p60323
sg49777
(lp60324
sg49779
(lp60325
(dp60326
g49782
I30
sg49783
I1
sg49784
I17
sg49785
VC0038017
p60327
sg49787
Vspondylolisthesis
p60328
sa(dp60329
g49782
I16
sg49783
I1
sg49784
I9
sg49785
VC0700208
p60330
sg49787
Vscoliosis
p60331
sasa(dp60332
g49775
VTherefore, this study aims to develop the AMRSID (analysis of MR signal intensity distribution) method to analyze the 3D distribution of the MR signal intensity within the IVD and to evaluate their sensitivity to scoliosis and spondylolisthesis and their severities.
p60333
sg49777
(lp60334
sg49779
(lp60335
(dp60336
g49782
I227
sg49783
I1
sg49784
I17
sg49785
VC0038017
p60337
sg49787
Vspondylolisthesis
p60338
sa(dp60339
g49782
I213
sg49783
I1
sg49784
I9
sg49785
VC0700208
p60340
sg49787
Vscoliosis
p60341
sasa(dp60342
g49775
VIVDs were collected from patients with lumbar fracture, vertebral tumor, disc herniation or spondylolisthesis.
p60343
sg49777
(lp60344
sg49779
(lp60345
(dp60346
g49782
I92
sg49783
I1
sg49784
I17
sg49785
VC0038017
p60347
sg49787
Vspondylolisthesis
p60348
sa(dp60349
g49782
I66
sg49783
I1
sg49784
I5
sg49785
VC0027651
p60350
sg49787
Vtumor
p60351
sa(dp60352
g49782
I78
sg49783
I1
sg49784
I10
sg49785
VC0019270
p60353
sg49787
Vherniation
p60354
sasa(dp60355
g49775
V"Pedra hume caa" is the common name of five species of Myrcia genus used as traditional medicine for the treatment of diabetes mellitus.
p60356
sg49777
(lp60357
sg49779
(lp60358
(dp60359
g49782
I12
sg49783
I1
sg49784
I3
sg49785
VC1842937
p60360
sg49787
Vcaa
p60361
sa(dp60362
g49782
I118
sg49783
I2
sg49784
I17
sg49785
VC0011849
p60363
sg49787
Vdiabetes mellitus
p60364
sasa(dp60365
g49775
VSome of the species are used in folk medicine, such as a group known as "pedra-hume-caa" or "pedra-ume-caa" or "insulina vegetal" (insulin plant) that it is used for the treatment of diabetes.
p60366
sg49777
(lp60367
(dp60368
g49782
I112
sg49783
I1
sg49784
I7
sg49812
VP01308
p60369
sg49787
Vinsulin
p60370
sasg49779
(lp60371
(dp60372
g49782
I84
sg49783
I1
sg49784
I3
sg49785
VC1842937
p60373
sg49787
Vcaa
p60374
sa(dp60375
g49782
I84
sg49783
I1
sg49784
I3
sg49785
VC1842937
p60376
sg49787
Vcaa
p60377
sa(dp60378
g49782
I183
sg49783
I1
sg49784
I8
sg49785
VC0011849
p60379
sg49787
Vdiabetes
p60380
sasa(dp60381
g49775
VSome of the species are used in folk medicine, such as a group known as "pedra-hume-caa" or "pedra-ume-caa" or "insulina vegetal" (insulin plant) that it is used for the treatment of diabetes.
p60382
sg49777
(lp60383
(dp60384
g49782
I112
sg49783
I1
sg49784
I7
sg49812
VP01308
p60385
sg49787
Vinsulin
p60386
sasg49779
(lp60387
(dp60388
g49782
I84
sg49783
I1
sg49784
I3
sg49785
VC1842937
p60389
sg49787
Vcaa
p60390
sa(dp60391
g49782
I84
sg49783
I1
sg49784
I3
sg49785
VC1842937
p60392
sg49787
Vcaa
p60393
sa(dp60394
g49782
I183
sg49783
I1
sg49784
I8
sg49785
VC0011849
p60395
sg49787
Vdiabetes
p60396
sasa(dp60397
g49775
VSome of the species are used in folk medicine, such as a group known as "pedra-hume-caa" or "pedra-ume-caa" or "insulina vegetal" (insulin plant) that it is used for the treatment of diabetes.
p60398
sg49777
(lp60399
(dp60400
g49782
I112
sg49783
I1
sg49784
I7
sg49812
VP01308
p60401
sg49787
Vinsulin
p60402
sasg49779
(lp60403
(dp60404
g49782
I84
sg49783
I1
sg49784
I3
sg49785
VC1842937
p60405
sg49787
Vcaa
p60406
sa(dp60407
g49782
I84
sg49783
I1
sg49784
I3
sg49785
VC1842937
p60408
sg49787
Vcaa
p60409
sa(dp60410
g49782
I183
sg49783
I1
sg49784
I8
sg49785
VC0011849
p60411
sg49787
Vdiabetes
p60412
sasa(dp60413
g49775
VAdult Tshz1(+/-) mice display glucose intolerance due to defects in glucose-stimulated insulin secretion associated with reduced Pdx1 and Clec16a expression in Tshz1(+/-) islets.
p60414
sg49777
(lp60415
(dp60416
g49782
I138
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VClec16a
p60417
sa(dp60418
g49782
I129
sg49783
I1
sg49784
I4
sg49812
VP52945
p60419
sg49787
VPdx1
p60420
sa(dp60421
g49782
I6
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTshz1
p60422
sa(dp60423
g49782
I87
sg49783
I1
sg49784
I7
sg49812
VP01308
p60424
sg49787
Vinsulin
p60425
sasg49779
(lp60426
(dp60427
g49782
I30
sg49783
I2
sg49784
I19
sg49785
VC0271650
p60428
sg49787
Vglucose intolerance
p60429
sasa(dp60430
g49775
VLastly, we demonstrate that TSHZ1 levels are reduced in human islets of donors with type 2 diabetes.
p60431
sg49777
(lp60432
(dp60433
g49782
I28
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTSHZ1
p60434
sasg49779
(lp60435
(dp60436
g49782
I84
sg49783
I3
sg49784
I15
sg49785
VC0011860
p60437
sg49787
Vtype 2 diabetes
p60438
sasa(dp60439
g49775
VThus, we position Tshz1 in the transcriptional network of maturing Beta-cells and suggest that its dysregulation could contribute to the islet phenotype of human type 2 diabetes.
p60440
sg49777
(lp60441
(dp60442
g49782
I18
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTshz1
p60443
sasg49779
(lp60444
(dp60445
g49782
I162
sg49783
I3
sg49784
I15
sg49785
VC0011860
p60446
sg49787
Vtype 2 diabetes
p60447
sasa(dp60448
g49775
VMaterial e Metodos: Revisao bibliografica, atraves da Medline e PubMed, utilizando como palavras-chave: 'borderline personality disorder', 'cognitive-behavioral therapy', 'efficacy'.
p60449
sg49777
(lp60450
sg49779
(lp60451
(dp60452
g49782
I104
sg49783
I3
sg49784
I32
sg49785
VC0006012
p60453
sg49787
V'borderline personality disorder
p60454
sasa(dp60455
g49775
V#\u76ee#\u7684#\uff1a #\u7814#\u7a76#\u963b#\u585e#\u6027#\u7761#\u7720#\u547c#\u5438#\u6682#\u505c#\u4f4e#\u901a#\u6c14#\u7efc#\u5408#\u5f81(obstructive sleep apnea hypopnea syndrome, OSAHS)#\u5408#\u5e76#\u96be#\u6cbb#\u6027#\u9ad8#\u8840#\u538b(resistant hypertension, RH)#\u60a3#\u8005#\u4e2d, OSAHS#\u7684#\u6cbb#\u7597#\u5bf9#\u8840#\u538b#\u63a7#\u5236#\u7684#\u610f#\u4e49#\u3002 #\u65b9#\u6cd5#\uff1a 80#\u4f8bOSAHS#\u5408#\u5e76RH#\u60a3#\u8005[#\u81f3#\u5c113#\u79cd#\u6297#\u9ad8#\u8840#\u538b#\u836f(#\u5305#\u62ec#\u5229#\u5c3f#\u5242)#\u6cbb#\u7597, #\u4ecd#\u4e0d#\u80fd#\u5c06#\u6536#\u7f29#\u538b#\u548c#\u8212#\u5f20#\u538b#\u63a7#\u5236#\u5728#\u76ee#\u6807#\u6c34#\u5e73(140/90 mmHg, 1 mmHg=0.133 kPa)]#\u884c#\u624b#\u672f#\u6216#\u6301#\u7eed#\u6b63#\u538b#\u901a#\u6c14#\u6cbb#\u7597, #\u6cbb#\u7597#\u524d#\u53ca#\u6cbb#\u75976#\u4e2a#\u6708#\u540e#\u884c#\u591a#\u9053#\u7761#\u7720#\u76d1#\u6d4b#\u548c#\u52a8#\u6001#\u8840#\u538b#\u76d1#\u6d4b, #\u8bb0#\u5f55#\u547c#\u5438#\u6682#\u505c#\u4f4e#\u901a#\u6c14#\u6307#\u6570(apnea hypopnea index, AHI)#\u3001#\u6700#\u4f4e#\u8840#\u6c27#\u9971#\u548c#\u5ea6(SaO(2))#\u3001#\u8840#\u538b#\u3001#\u591c#\u95f4#\u8840#\u538b#\u4e0b#\u964d#\u7387, #\u6bd4#\u8f83#\u6cbb#\u7597#\u524d#\u540e#\u964d#\u538b#\u836f#\u7269#\u79cd#\u7c7b#\u7684#\u53d8#\u5316#\u3002 #\u7ed3#\u679c#\uff1a #\u6cbb#\u7597#\u540e, AHI#\u7531(32.9+/-10.8)#\u6b21/h(x+/-s, #\u4e0b#\u540c)#\u964d#\u81f3(9.4+/-6.5)#\u6b21/h, #\u6700#\u4f4eSaO(2)#\u7531(0.682+/-0.062)#\u589e#\u81f3(0.884+/-0.056), #\u5dee#\u5f02#\u5747#\u6709#\u7edf#\u8ba1#\u5b66#\u610f#\u4e49(t#\u503c#\u5206#\u522b#\u4e3a18.863#\u300126.614, P#\u503c#\u5747&lt;0.001)#\u3002#\u5168#\u5929#\u6536#\u7f29#\u538b#\u7531(150.5+/-9.8) mmHg#\u964d#\u81f3(140.7+/-6.8) mmHg, #\u8212#\u5f20#\u538b#\u7531(97.8+/-7.3) mmHg#\u964d#\u81f3(88.6+/-6.3) mmHg#\uff1b#\u65e5#\u95f4#\u6536#\u7f29#\u538b#\u7531(154.3+/-8.9) mmHg#\u964d#\u81f3(144.8+/-5.8) mmHg, #\u8212#\u5f20#\u538b#\u7531(100.6+/-7.4) mmHg#\u964d#\u81f3(91.3+/-5.5) mmHg#\uff1b#\u591c#\u95f4#\u6536#\u7f29#\u538b#\u7531(145.5+/-8.8) mmHg#\u964d#\u81f3(135.8+/-5.7) mmHg, #\u8212#\u5f20#\u538b#\u7531(93.8+/-6.4) mmHg#\u964d#\u81f3(84.6+/-5.9) mmHg, #\u5dee#\u5f02#\u5747#\u6709#\u7edf#\u8ba1#\u5b66#\u610f#\u4e49(t#\u503c#\u5206#\u522b#\u4e3a7.832#\u30016.903#\u30017.005#\u30016.848#\u30018.025#\u30017.554, P#\u503c#\u5747&lt;0.001)#\u3002#\u591c#\u95f4#\u6536#\u7f29#\u538b#\u4e0b#\u964d#\u503c#\u4e3a(11.5+/-2.2)mmHg#\u3001#\u8212#\u5f20#\u538b#\u4e0b#\u964d#\u503c#\u4e3a(10.2+/-3.1)mmHg, #\u65e5#\u95f4#\u6536#\u7f29#\u538b#\u4e0b#\u964d#\u503c#\u4e3a(9.0+/-2.8)mmHg#\u3001#\u8212#\u5f20#\u538b#\u4e0b#\u964d#\u503c#\u4e3a(7.9+/-3.5)mmHg, #\u591c#\u95f4#\u6536#\u7f29#\u538b#\u53ca#\u8212#\u5f20#\u538b#\u4e0b#\u964d#\u8f83#\u65e5#\u95f4#\u66f4#\u660e#\u663e, #\u5dee#\u5f02#\u5747#\u6709#\u7edf#\u8ba1#\u5b66#\u610f#\u4e49(t#\u503c#\u5206#\u522b#\u4e3a9.732#\u30016.936, P#\u503c#\u5747&lt;0.001)#\u3002#\u591c#\u95f4#\u8840#\u538b#\u4e0b#\u964d#\u7387&lt;10%#\u7684#\u60a3#\u8005#\u6bd4#\u4f8b#\u7531#\u6cbb#\u7597#\u524d#\u768475.0%#\u964d#\u4e3a#\u6cbb#\u7597#\u540e#\u768437.5%, #\u5dee#\u5f02#\u6709#\u7edf#\u8ba1#\u5b66#\u610f#\u4e49(X(2)=22.857, P&lt;0.01), #\u63d0#\u793a#\u8840#\u538b#\u663c#\u591c#\u8282#\u5f8b#\u53d8#\u5316#\u60c5#\u51b5#\u597d#\u8f6c#\u300245#\u4f8b#\u60a3#\u8005#\u670d#\u7528#\u7684#\u964d#\u538b#\u836f#\u7269#\u79cd#\u7c7b#\u51cf#\u5c11, #\u7531#\u6cbb#\u7597#\u524d#\u7684(3.2+/-0.4)#\u79cd#\u51cf#\u4e3a#\u6cbb#\u7597#\u540e#\u7684(2.6+/-0.5)#\u79cd, #\u5dee#\u5f02#\u6709#\u7edf#\u8ba1#\u5b66#\u610f#\u4e49(t=9.276, P&lt;0.01)#\u3002 #\u7ed3#\u8bba#\uff1a OSAHS#\u5408#\u5e76RH#\u60a3#\u8005#\u4e2d, #\u6cbb#\u7597OSAHS#\u80fd#\u6709#\u6548#\u6539#\u5584#\u8840#\u538b#\u63a7#\u5236#\u6c34#\u5e73, #\u6539#\u5584#\u8840#\u538b#\u663c#\u591c#\u8282#\u5f8b, #\u51cf#\u5c11#\u964d#\u538b#\u836f#\u7269#\u7684#\u4f7f#\u7528#\u3002.
p60456
sg49777
(lp60457
sg49779
(lp60458
(dp60459
g49782
I85
sg49783
I1
sg49784
I5
sg49785
VC0520679
p60460
sg49787
VOSAHS
p60461
sa(dp60462
g49782
I118
sg49783
I1
sg49784
I12
sg49785
VC0020538
p60463
sg49787
Vhypertension
p60464
sa(dp60465
g49782
I85
sg49783
I1
sg49784
I5
sg49785
VC0520679
p60466
sg49787
VOSAHS
p60467
sa(dp60468
g49782
I42
sg49783
I3
sg49784
I23
sg49785
VC0520679
p60469
sg49787
Vobstructive sleep apnea
p60470
sa(dp60471
g49782
I66
sg49783
I2
sg49784
I17
sg49785
VC2748060
p60472
sg49787
Vhypopnea syndrome
p60473
sa(dp60474
g49782
I60
sg49783
I1
sg49784
I5
sg49785
VC0003578
p60475
sg49787
Vapnea
p60476
sa(dp60477
g49782
I85
sg49783
I1
sg49784
I5
sg49785
VC0520679
p60478
sg49787
VOSAHS
p60479
sasa(dp60480
g49775
VIn case of coronary atherosclerosis the organism reaction to expressed CMC is manifested basically by intensified synthesis of cathodic complement-C3-similar autoprecipitin, but in case of endocarditis--by consumption of one with formation of anodic autoprecipitin and by intensified synthesis of autoprecipitating immunoglobulin G. These membranotropic autoimmune reactions are identical with the organism reactions to alien (heterologous) agents and differentially participate in development both of basic disease and perioperational complications after cardiac operations using trans- and implants, hence, they should be taken into account during membrane-stabilising and immunocorrecting therapy of recipients.
p60481
sg49777
(lp60482
(dp60483
g49782
I315
sg49783
I2
sg49784
I16
sg49812
g11
sg49787
Vimmunoglobulin G
p60484
sa(dp60485
g49782
I127
sg49783
I2
sg49784
I22
sg49812
g11
sg49787
Vcathodic complement-C3
p60486
sasg49779
(lp60487
(dp60488
g49782
I354
sg49783
I2
sg49784
I20
sg49785
VC0443146
p60489
sg49787
Vautoimmune reactions
p60490
sa(dp60491
g49782
I11
sg49783
I2
sg49784
I24
sg49785
VC2733225
p60492
sg49787
Vcoronary atherosclerosis
p60493
sa(dp60494
g49782
I189
sg49783
I1
sg49784
I12
sg49785
VC0014118
p60495
sg49787
Vendocarditis
p60496
sasa(dp60497
g49775
VIn cultured rat hepatoma (H4IIE) cells, TNF-Alfa significantly increased hemopexin mRNA accumulation.
p60498
sg49777
(lp60499
(dp60500
g49782
I73
sg49783
I2
sg49784
I14
sg49812
VP02790
p60501
sg49787
Vhemopexin mRNA
p60502
sa(dp60503
g49782
I40
sg49783
I1
sg49784
I8
sg49812
VP01375
p60504
sg49787
VTNF-Alfa
p60505
sasg49779
(lp60506
(dp60507
g49782
I16
sg49783
I1
sg49784
I8
sg49785
VC0023903
p60508
sg49787
Vhepatoma
p60509
sasa(dp60510
g49775
VThis analytical method was applied to an in vitro diagnostic multivariate index assay where a panel of hepatocellular carcinoma (HCC) biomarkers comprising alpha-fetoprotein, hemopexin, and alpha-2-macroglobulin (A2M) was examined in terms of the serum level and their fuco-fractions.
p60511
sg49777
(lp60512
(dp60513
g49782
I175
sg49783
I1
sg49784
I9
sg49812
VP02790
p60514
sg49787
Vhemopexin
p60515
sa(dp60516
g49782
I156
sg49783
I1
sg49784
I17
sg49812
VP02771
p60517
sg49787
Valpha-fetoprotein
p60518
sa(dp60519
g49782
I190
sg49783
I1
sg49784
I21
sg49812
VP01023
p60520
sg49787
Valpha-2-macroglobulin
p60521
sa(dp60522
g49782
I213
sg49783
I1
sg49784
I3
sg49812
VP01023
p60523
sg49787
VA2M
p60524
sasg49779
(lp60525
(dp60526
g49782
I129
sg49783
I1
sg49784
I3
sg49785
VC2239176
p60527
sg49787
VHCC
p60528
sa(dp60529
g49782
I103
sg49783
I2
sg49784
I24
sg49785
VC2239176
p60530
sg49787
Vhepatocellular carcinoma
p60531
sasa(dp60532
g49775
VThe aim of this study was to identify new target genes for microRNA polymorphisms (miR-146aC&gt;G and miR-196a2T&gt;C) in primary ovarian insufficiency (POI).
p60533
sg49777
(lp60534
(dp60535
g49782
I-1
sg49783
I1
sg49784
I12
sg49812
g11
sg49787
VmiR-196a2T>C
p60536
sa(dp60537
g49782
I83
sg49783
I1
sg49784
I9
sg49812
g11
sg49787
VmiR-146aC
p60538
sasg49779
(lp60539
(dp60540
g49782
I153
sg49783
I1
sg49784
I3
sg49785
VC0041408
p60541
sg49787
VPOI
p60542
sa(dp60543
g49782
I122
sg49783
I3
sg49784
I29
sg49785
VC0041408
p60544
sg49787
Vprimary ovarian insufficiency
p60545
sasa(dp60546
g49775
VIn addition, several specific miRNAs (miR-23a, miR-27a, miR-22-3p, miR-146a, miR-196a, miR-290-295, miR-423, and miR-608) related to POI are also examined in order to highlight the issues that deserve further investigation.
p60547
sg49777
(lp60548
(dp60549
g49782
I67
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VmiR-146a
p60550
sa(dp60551
g49782
I47
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-27a
p60552
sa(dp60553
g49782
I56
sg49783
I1
sg49784
I9
sg49812
g11
sg49787
VmiR-22-3p
p60554
sa(dp60555
g49782
I113
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-608
p60556
sa(dp60557
g49782
I77
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VmiR-196a
p60558
sa(dp60559
g49782
I38
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-23a
p60560
sasg49779
(lp60561
sa(dp60562
g49775
V(2) Expand sample size to 14 cases for endometriosis group and 16 cases for control group.Reverse transcription (RT)-PCR technique was utilized to detect the expression of miR- 142- 5p, miR- 146a- 5p and miR- 543 in endometrial tissues, and verify miRNA microarray results.
p60563
sg49777
(lp60564
(dp60565
g49782
I186
sg49783
I3
sg49784
I13
sg49812
g11
sg49787
VmiR- 146a- 5p
p60566
sa(dp60567
g49782
I172
sg49783
I3
sg49784
I12
sg49812
g11
sg49787
VmiR- 142- 5p
p60568
sa(dp60569
g49782
I204
sg49783
I2
sg49784
I8
sg49812
g11
sg49787
VmiR- 543
p60570
sasg49779
(lp60571
(dp60572
g49782
I39
sg49783
I1
sg49784
I13
sg49785
VC0014175
p60573
sg49787
Vendometriosis
p60574
sasa(dp60575
g49775
V(1) miRNA and mRNA microarray screening results showed that, among the endometrial tissues of patients with endometriosis infertility and with implantation window phase, 6 differentially expressed miRNA were indentified, among which miR-142-5p, miR-146a-5p, miR-1281, miR-940, miR-4634 showed significantly enhanced expression and miR- 543 showed significantly inhibited expression.
p60576
sg49777
(lp60577
(dp60578
g49782
I233
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-142-5p
p60579
sa(dp60580
g49782
I268
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VmiR-940
p60581
sa(dp60582
g49782
I277
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VmiR-4634
p60583
sa(dp60584
g49782
I245
sg49783
I1
sg49784
I11
sg49812
g11
sg49787
VmiR-146a-5p
p60585
sa(dp60586
g49782
I258
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VmiR-1281
p60587
sa(dp60588
g49782
I331
sg49783
I2
sg49784
I8
sg49812
g11
sg49787
VmiR- 543
p60589
sasg49779
(lp60590
(dp60591
g49782
I122
sg49783
I1
sg49784
I11
sg49785
VC0021359
p60592
sg49787
Vinfertility
p60593
sa(dp60594
g49782
I108
sg49783
I1
sg49784
I13
sg49785
VC0014175
p60595
sg49787
Vendometriosis
p60596
sasa(dp60597
g49775
V(2) RT- PCR test showed that the average levels of expression of miR-142-5p and miR-146a-5p in implantation window phase endometrium in endometriosis group were 8.3+/-10.6 and 1.9+/-0.8 respectively; the average levels of that in control group were 1.1+/-0.6 and 0.9+/-0.4, respectively.
p60598
sg49777
(lp60599
(dp60600
g49782
I80
sg49783
I1
sg49784
I11
sg49812
g11
sg49787
VmiR-146a-5p
p60601
sa(dp60602
g49782
I65
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-142-5p
p60603
sasg49779
(lp60604
(dp60605
g49782
I136
sg49783
I1
sg49784
I13
sg49785
VC0014175
p60606
sg49787
Vendometriosis
p60607
sasa(dp60608
g49775
VThere are multiple differential expressions of miRNA in the implantation window phase endometrium tissues of endometriosis infertility patients, among which miR-142-5p and miR-146a-5p show significantly enhanced expression and may affect embryo implantation by acting on a variety of endometrial receptivity marker molecules.
p60609
sg49777
(lp60610
(dp60611
g49782
I172
sg49783
I1
sg49784
I11
sg49812
g11
sg49787
VmiR-146a-5p
p60612
sa(dp60613
g49782
I157
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-142-5p
p60614
sasg49779
(lp60615
(dp60616
g49782
I123
sg49783
I1
sg49784
I11
sg49785
VC0021359
p60617
sg49787
Vinfertility
p60618
sa(dp60619
g49782
I109
sg49783
I1
sg49784
I13
sg49785
VC0014175
p60620
sg49787
Vendometriosis
p60621
sasa(dp60622
g49775
VWe also analyze the ezrin-meditated regulation of critical pathways associated with asthma, such as the RhoA, Rho-associated protein kinase (ROCK), and protein kinase A (cAMP/PKA) pathways.
p60623
sg49777
(lp60624
(dp60625
g49782
I141
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VROCK
p60626
sa(dp60627
g49782
I170
sg49783
I1
sg49784
I8
sg49812
VP49913
p60628
sg49787
VcAMP/PKA
p60629
sa(dp60630
g49782
I110
sg49783
I3
sg49784
I29
sg49812
VP08100
p60631
sg49787
VRho-associated protein kinase
p60632
sa(dp60633
g49782
I152
sg49783
I3
sg49784
I16
sg49812
VP17612
p60634
sg49787
Vprotein kinase A
p60635
sa(dp60636
g49782
I104
sg49783
I1
sg49784
I4
sg49812
VP61586
p60637
sg49787
VRhoA
p60638
sasg49779
(lp60639
(dp60640
g49782
I84
sg49783
I1
sg49784
I6
sg49785
VC0004096
p60641
sg49787
Vasthma
p60642
sasa(dp60643
g49775
VPneumothorax is a well-recognized complication of central venous line insertion (CVL).
p60644
sg49777
(lp60645
sg49779
(lp60646
(dp60647
g49782
I34
sg49783
I1
sg49784
I12
sg49785
VC0009566
p60648
sg49787
Vcomplication
p60649
sa(dp60650
g49782
I0
sg49783
I1
sg49784
I12
sg49785
VC0032326
p60651
sg49787
VPneumothorax
p60652
sasa(dp60653
g49775
VWe identify and replicate an association between the constituents of the apical plasma membrane and CF lung disease (p = 0.0099 and p = 0.0180, respectively) and highlight a role for the SLC9A3-SLC9A3R1/2-EZR complex in contributing to CF lung disease.
p60654
sg49777
(lp60655
(dp60656
g49782
I187
sg49783
I2
sg49784
I29
sg49812
VP48764
p60657
sg49787
VSLC9A3-SLC9A3R1/2-EZR complex
p60658
sasg49779
(lp60659
(dp60660
g49782
I103
sg49783
I2
sg49784
I12
sg49785
VC0024115
p60661
sg49787
Vlung disease
p60662
sa(dp60663
g49782
I103
sg49783
I2
sg49784
I12
sg49785
VC0024115
p60664
sg49787
Vlung disease
p60665
sasa(dp60666
g49775
VThe BrGR-expressing yeast strain induced the activation of metabolic enzymes (Hxt, G6PDH, GAPDH and Ald), antioxidant systems (Gpx, Trx2, Trx3, Trr1, Tsa1 and porin) and molecular chaperones (Hsp104, Hsp90, Hsp70, Hsp42, Hsp26, Grp, Sti1 and Zpr1), which led to lower oxidative protein damage after a reduction in the level of cellular ROS in the BrGR-expressing yeast strain exposed to H(2)O(2) than in the wild-type yeast strain.
p60667
sg49777
(lp60668
(dp60669
g49782
I100
sg49783
I1
sg49784
I3
sg49812
VP33897
p60670
sg49787
VAld
p60671
sa(dp60672
g49782
I127
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VGpx
p60673
sa(dp60674
g49782
I228
sg49783
I1
sg49784
I3
sg49812
VP07492
p60675
sg49787
VGrp
p60676
sa(dp60677
g49782
I90
sg49783
I1
sg49784
I5
sg49812
VP04406
p60678
sg49787
VGAPDH
p60679
sa(dp60680
g49782
I159
sg49783
I1
sg49784
I5
sg49812
VP21796
p60681
sg49787
Vporin
p60682
sa(dp60683
g49782
I132
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTrx2
p60684
sa(dp60685
g49782
I150
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTsa1
p60686
sa(dp60687
g49782
I207
sg49783
I1
sg49784
I5
sg49812
VP34932
p60688
sg49787
VHsp70
p60689
sa(dp60690
g49782
I242
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VZpr1
p60691
sa(dp60692
g49782
I83
sg49783
I1
sg49784
I5
sg49812
VP11413
p60693
sg49787
VG6PDH
p60694
sa(dp60695
g49782
I200
sg49783
I1
sg49784
I5
sg49812
VP07900
p60696
sg49787
VHsp90
p60697
sa(dp60698
g49782
I78
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VHxt
p60699
sa(dp60700
g49782
I233
sg49783
I1
sg49784
I4
sg49812
VP31948
p60701
sg49787
VSti1
p60702
sasg49779
(lp60703
(dp60704
g49782
I100
sg49783
I1
sg49784
I3
sg49785
VC0162309
p60705
sg49787
VAld
p60706
sasa(dp60707
g49775
VIn this review, we focus on the use of these agents in children to treat inflammatory skin diseases other than psoriasis, including atopic dermatitis, hidradenitis suppurativa, pemphigus vulgaris, bullous pemphigoid, and toxic epidermal necrolysis, with an emphasis on the use of etanercept, infliximab, rituximab, omalizumab, and ustekinumab.
p60708
sg49777
(lp60709
sg49779
(lp60710
(dp60711
g49782
I177
sg49783
I2
sg49784
I18
sg49785
VC0030809
p60712
sg49787
Vpemphigus vulgaris
p60713
sa(dp60714
g49782
I111
sg49783
I1
sg49784
I9
sg49785
VC0033860
p60715
sg49787
Vpsoriasis
p60716
sa(dp60717
g49782
I151
sg49783
I2
sg49784
I24
sg49785
VC0162836
p60718
sg49787
Vhidradenitis suppurativa
p60719
sa(dp60720
g49782
I221
sg49783
I3
sg49784
I26
sg49785
VC0014518
p60721
sg49787
Vtoxic epidermal necrolysis
p60722
sa(dp60723
g49782
I197
sg49783
I2
sg49784
I18
sg49785
VC0030805
p60724
sg49787
Vbullous pemphigoid
p60725
sa(dp60726
g49782
I132
sg49783
I2
sg49784
I17
sg49785
VC0011615
p60727
sg49787
Vatopic dermatitis
p60728
sa(dp60729
g49782
I86
sg49783
I2
sg49784
I13
sg49785
VC0037274
p60730
sg49787
Vskin diseases
p60731
sasa(dp60732
g49775
VThe addition of distamycin A enhanced the double-strand DNA cleavage at the 5'-CCT-3'/3'-GGA-5' and 5'-CCA-3'/3'-GGT-5' sequences, with a two-nucleotide 3'-stagger of the cleaved residues.
p60733
sg49777
(lp60734
sg49779
(lp60735
(dp60736
g49782
I79
sg49783
I1
sg49784
I3
sg49785
VC2752078
p60737
sg49787
VCCT
p60738
sa(dp60739
g49782
I103
sg49783
I1
sg49784
I3
sg49785
VC0220668
p60740
sg49787
VCCA
p60741
sasa(dp60742
g49775
VBesides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).
p60743
sg49777
(lp60744
(dp60745
g49782
I133
sg49783
I1
sg49784
I6
sg49812
VP02545
p60746
sg49787
VCMT2B1
p60747
sa(dp60748
g49782
I112
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VCMT2A2
p60749
sa(dp60750
g49782
I140
sg49783
I1
sg49784
I4
sg49812
VP02545
p60751
sg49787
VLMNA
p60752
sa(dp60753
g49782
I127
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VMFN2
p60754
sa(dp60755
g49782
I214
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VLRSAM1
p60756
sa(dp60757
g49782
I195
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCMT2K
p60758
sa(dp60759
g49782
I235
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCMT2S
p60760
sa(dp60761
g49782
I294
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VGAN
p60762
sa(dp60763
g49782
I449
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSPG15
p60764
sa(dp60765
g49782
I439
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSPG7
p60766
sa(dp60767
g49782
I294
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VGAN
p60768
sa(dp60769
g49782
I483
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VFA2H
p60770
sa(dp60771
g49782
I455
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VZFYVE26
p60772
sa(dp60773
g49782
I241
sg49783
I1
sg49784
I7
sg49812
VP38935
p60774
sg49787
VIGHMBP2
p60775
sa(dp60776
g49782
I256
sg49783
I1
sg49784
I4
sg49812
VP25686
p60777
sg49787
VHSJ1
p60778
sa(dp60779
g49782
I444
sg49783
I1
sg49784
I3
sg49812
VP00747
p60780
sg49787
VPGN
p60781
sa(dp60782
g49782
I228
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTRIM2
p60783
sa(dp60784
g49782
I153
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VMED25
p60785
sa(dp60786
g49782
I495
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VGBA2
p60787
sa(dp60788
g49782
I167
sg49783
I1
sg49784
I4
sg49812
VP07196
p60789
sg49787
VNEFL
p60790
sa(dp60791
g49782
I285
sg49783
I1
sg49784
I4
sg49812
VP49773
p60792
sg49787
VHINT
p60793
sa(dp60794
g49782
I507
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VC12orf65
p60795
sa(dp60796
g49782
I470
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VACP33
p60797
sa(dp60798
g49782
I520
sg49783
I1
sg49784
I12
sg49812
g11
sg49787
VSPG56/CYP2U1
p60799
sa(dp60800
g49782
I201
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VGDAP1
p60801
sa(dp60802
g49782
I119
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VHMSN2A2
p60803
sa(dp60804
g49782
I464
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSPG21
p60805
sa(dp60806
g49782
I269
sg49783
I1
sg49784
I6
sg49812
VP12074
p60807
sg49787
VCOX6A1
p60808
sasg49779
(lp60809
(dp60810
g49782
I208
sg49783
I1
sg49784
I5
sg49785
VC3280797
p60811
sg49787
VCMT2P
p60812
sa(dp60813
g49782
I146
sg49783
I1
sg49784
I6
sg49785
VC1854150
p60814
sg49787
VCMT2B2
p60815
sa(dp60816
g49782
I294
sg49783
I1
sg49784
I3
sg49785
VC1850386
p60817
sg49787
VGAN
p60818
sa(dp60819
g49782
I449
sg49783
I1
sg49784
I5
sg49785
VC1849128
p60820
sg49787
VSPG15
p60821
sa(dp60822
g49782
I439
sg49783
I1
sg49784
I4
sg49785
VC1846564
p60823
sg49787
VSPG7
p60824
sa(dp60825
g49782
I133
sg49783
I1
sg49784
I6
sg49785
VC1854154
p60826
sg49787
VCMT2B1
p60827
sa(dp60828
g49782
I294
sg49783
I1
sg49784
I3
sg49785
VC1850386
p60829
sg49787
VGAN
p60830
sa(dp60831
g49782
I83
sg49783
I2
sg49784
I27
sg49785
VC0007959
p60832
sg49787
VCharcot-Marie-Tooth disease
p60833
sa(dp60834
g49782
I112
sg49783
I1
sg49784
I6
sg49785
VC1836485
p60835
sg49787
VCMT2A2
p60836
sa(dp60837
g49782
I119
sg49783
I1
sg49784
I7
sg49785
VC1836485
p60838
sg49787
VHMSN2A2
p60839
sa(dp60840
g49782
I409
sg49783
I3
sg49784
I28
sg49785
VC1263857
p60841
sg49787
Vaxonal peripheral neuropathy
p60842
sa(dp60843
g49782
I181
sg49783
I1
sg49784
I6
sg49785
VC2608087
p60844
sg49787
VdHMN2B
p60845
sa(dp60846
g49782
I610
sg49783
I5
sg49784
I31
sg49785
VC0175754
p60847
sg49787
Vagenesis of the corpus callosum
p60848
sa(dp60849
g49782
I464
sg49783
I1
sg49784
I5
sg49785
VC1855346
p60850
sg49787
VSPG21
p60851
sa(dp60852
g49782
I329
sg49783
I5
sg49784
I49
sg49785
VC0751603
p60853
sg49787
Vautosomal recessive hereditary spastic paraplegia
p60854
sa(dp60855
g49782
I416
sg49783
I2
sg49784
I21
sg49785
VC0031117
p60856
sg49787
Vperipheral neuropathy
p60857
sa(dp60858
g49782
I195
sg49783
I1
sg49784
I5
sg49785
VC1842983
p60859
sg49787
VCMT2K
p60860
sasa(dp60861
g49775
VPlasmacytomas often present as a collection of findings known as POEMS-syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-Protein spike, and Skin changes).
p60862
sg49777
(lp60863
sg49779
(lp60864
(dp60865
g49782
I71
sg49783
I1
sg49784
I8
sg49785
VC0039082
p60866
sg49787
Vsyndrome
p60867
sa(dp60868
g49782
I111
sg49783
I1
sg49784
I14
sg49785
VC0014130
p60869
sg49787
VEndocrinopathy
p60870
sa(dp60871
g49782
I0
sg49783
I1
sg49784
I13
sg49785
VC0032131
p60872
sg49787
VPlasmacytomas
p60873
sa(dp60874
g49782
I81
sg49783
I1
sg49784
I14
sg49785
VC0152025
p60875
sg49787
VPolyneuropathy
p60876
sasa(dp60877
g49775
VPOEMS (acronym for polyneuropathy, organomegaly, endocrinopathy, M protein myeloma and skin changes), is a rare disease which occurs in the setting of plasma cell dyscrasias.
p60878
sg49777
(lp60879
(dp60880
g49782
I65
sg49783
I2
sg49784
I9
sg49812
VP54296
p60881
sg49787
VM protein
p60882
sasg49779
(lp60883
(dp60884
g49782
I107
sg49783
I2
sg49784
I12
sg49785
VC0678236
p60885
sg49787
Vrare disease
p60886
sa(dp60887
g49782
I49
sg49783
I1
sg49784
I14
sg49785
VC0014130
p60888
sg49787
Vendocrinopathy
p60889
sa(dp60890
g49782
I19
sg49783
I1
sg49784
I14
sg49785
VC0152025
p60891
sg49787
Vpolyneuropathy
p60892
sa(dp60893
g49782
I151
sg49783
I3
sg49784
I22
sg49785
VC1136084
p60894
sg49787
Vplasma cell dyscrasias
p60895
sa(dp60896
g49782
I75
sg49783
I1
sg49784
I7
sg49785
VC0026764
p60897
sg49787
Vmyeloma
p60898
sasa(dp60899
g49775
VPrevious case reports and studies have shown that anti-myelin-associated glycoprotein (MAG) antibody can be detected in patients with polyneuropathy without any detectable M-protein.
p60900
sg49777
(lp60901
(dp60902
g49782
I50
sg49783
I4
sg49784
I50
sg49812
VP20916
p60903
sg49787
Vanti-myelin-associated glycoprotein (MAG) antibody
p60904
sasg49779
(lp60905
(dp60906
g49782
I134
sg49783
I1
sg49784
I14
sg49785
VC0152025
p60907
sg49787
Vpolyneuropathy
p60908
sasa(dp60909
g49775
VPolyneuropathy, Organomegaly, Endocrinopathy, M protein and Skin changes (POEMS) syndrome is rare plasma cell dyscrasia with multisystem involvement.
p60910
sg49777
(lp60911
sg49779
(lp60912
(dp60913
g49782
I81
sg49783
I1
sg49784
I8
sg49785
VC0039082
p60914
sg49787
Vsyndrome
p60915
sa(dp60916
g49782
I98
sg49783
I3
sg49784
I21
sg49785
VC1136084
p60917
sg49787
Vplasma cell dyscrasia
p60918
sa(dp60919
g49782
I30
sg49783
I1
sg49784
I14
sg49785
VC0014130
p60920
sg49787
VEndocrinopathy
p60921
sa(dp60922
g49782
I0
sg49783
I1
sg49784
I14
sg49785
VC0152025
p60923
sg49787
VPolyneuropathy
p60924
sasa(dp60925
g49775
VThe name comes from the five characteristic features: Polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes.
p60926
sg49777
(lp60927
sg49779
(lp60928
(dp60929
g49782
I84
sg49783
I1
sg49784
I14
sg49785
VC0014130
p60930
sg49787
Vendocrinopathy
p60931
sa(dp60932
g49782
I54
sg49783
I1
sg49784
I14
sg49785
VC0152025
p60933
sg49787
VPolyneuropathy
p60934
sasa(dp60935
g49775
VPolyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome and monoclonal gammopathy of undetermined significance (MGUS) are paraproteinemic disorders that can cause demyelinating polyneuropathy.
p60936
sg49777
(lp60937
sg49779
(lp60938
(dp60939
g49782
I82
sg49783
I1
sg49784
I8
sg49785
VC0039082
p60940
sg49787
Vsyndrome
p60941
sa(dp60942
g49782
I95
sg49783
I5
sg49784
I50
sg49785
VC0026470
p60943
sg49787
Vmonoclonal gammopathy of undetermined significance
p60944
sa(dp60945
g49782
I147
sg49783
I1
sg49784
I4
sg49785
VC0026470
p60946
sg49787
VMGUS
p60947
sa(dp60948
g49782
I198
sg49783
I2
sg49784
I28
sg49785
VC0270922
p60949
sg49787
Vdemyelinating polyneuropathy
p60950
sa(dp60951
g49782
I30
sg49783
I1
sg49784
I14
sg49785
VC0014130
p60952
sg49787
Vendocrinopathy
p60953
sa(dp60954
g49782
I0
sg49783
I1
sg49784
I14
sg49785
VC0152025
p60955
sg49787
VPolyneuropathy
p60956
sasa(dp60957
g49775
VPolyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome, a form of osteosclerotic myeloma, is a multisystem disease related to a monoclonal plasma cell proliferative disorder.
p60958
sg49777
(lp60959
sg49779
(lp60960
(dp60961
g49782
I82
sg49783
I1
sg49784
I8
sg49785
VC0039082
p60962
sg49787
Vsyndrome
p60963
sa(dp60964
g49782
I102
sg49783
I2
sg49784
I22
sg49785
VC1510415
p60965
sg49787
Vosteosclerotic myeloma
p60966
sa(dp60967
g49782
I187
sg49783
I1
sg49784
I13
sg49785
VC0334094
p60968
sg49787
Vproliferative
p60969
sa(dp60970
g49782
I30
sg49783
I1
sg49784
I14
sg49785
VC0014130
p60971
sg49787
Vendocrinopathy
p60972
sa(dp60973
g49782
I0
sg49783
I1
sg49784
I14
sg49785
VC0152025
p60974
sg49787
VPolyneuropathy
p60975
sasa(dp60976
g49775
VShe had been treated with cyclophosphamide, melphalan, lenalidomide and corticosteroids for POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy or edema, M protein, skin changes).
p60977
sg49777
(lp60978
sg49779
(lp60979
(dp60980
g49782
I138
sg49783
I1
sg49784
I14
sg49785
VC0014130
p60981
sg49787
Vendocrinopathy
p60982
sa(dp60983
g49782
I156
sg49783
I1
sg49784
I5
sg49785
VC0013604
p60984
sg49787
Vedema
p60985
sa(dp60986
g49782
I108
sg49783
I1
sg49784
I14
sg49785
VC0152025
p60987
sg49787
Vpolyneuropathy
p60988
sa(dp60989
g49782
I92
sg49783
I2
sg49784
I14
sg49785
VC0085404
p60990
sg49787
VPOEMS syndrome
p60991
sasa(dp60992
g49775
VPolyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome is a rare cause of demyelinating neuropathy, with multi-organ involvement characterised by plasma cell dyscrasia and VEGF overproduction.
p60993
sg49777
(lp60994
sg49779
(lp60995
(dp60996
g49782
I110
sg49783
I2
sg49784
I24
sg49785
VC0270922
p60997
sg49787
Vdemyelinating neuropathy
p60998
sa(dp60999
g49782
I82
sg49783
I1
sg49784
I8
sg49785
VC0039082
p61000
sg49787
Vsyndrome
p61001
sa(dp61002
g49782
I30
sg49783
I1
sg49784
I14
sg49785
VC0014130
p61003
sg49787
Vendocrinopathy
p61004
sa(dp61005
g49782
I182
sg49783
I3
sg49784
I21
sg49785
VC1136084
p61006
sg49787
Vplasma cell dyscrasia
p61007
sa(dp61008
g49782
I0
sg49783
I1
sg49784
I14
sg49785
VC0152025
p61009
sg49787
VPolyneuropathy
p61010
sasa(dp61011
g49775
VAs a consequence, leukemia induction and leukemia maintenance were severely impaired in Inca1-/- bone marrow cells.
p61012
sg49777
(lp61013
sg49779
(lp61014
(dp61015
g49782
I18
sg49783
I1
sg49784
I8
sg49785
VC0023418
p61016
sg49787
Vleukemia
p61017
sa(dp61018
g49782
I18
sg49783
I1
sg49784
I8
sg49785
VC0023418
p61019
sg49787
Vleukemia
p61020
sa(dp61021
g49782
I76
sg49783
I1
sg49784
I8
sg49785
VC0684336
p61022
sg49787
Vimpaired
p61023
sasa(dp61024
g49775
VThe re-initiation of leukemia was also significantly inhibited in absence of Inca1-/- in MLL-AF9- and c-myc/BCL2-positive leukemia mouse models.
p61025
sg49777
(lp61026
(dp61027
g49782
I102
sg49783
I1
sg49784
I5
sg49812
VP12524
p61028
sg49787
Vc-myc
p61029
sa(dp61030
g49782
I93
sg49783
I1
sg49784
I3
sg49812
VP42568
p61031
sg49787
VAF9
p61032
sa(dp61033
g49782
I108
sg49783
I1
sg49784
I4
sg49812
VP10415
p61034
sg49787
VBCL2
p61035
sa(dp61036
g49782
I77
sg49783
I3
sg49784
I15
sg49812
g11
sg49787
VInca1-/- in MLL
p61037
sasg49779
(lp61038
(dp61039
g49782
I21
sg49783
I1
sg49784
I8
sg49785
VC0023418
p61040
sg49787
Vleukemia
p61041
sa(dp61042
g49782
I21
sg49783
I1
sg49784
I8
sg49785
VC0023418
p61043
sg49787
Vleukemia
p61044
sasa(dp61045
g49775
VThese findings indicate distinct functional properties of Inca1 in normal hematopoietic cells compared to leukemia initiating cells.
p61046
sg49777
(lp61047
(dp61048
g49782
I58
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VInca1
p61049
sasg49779
(lp61050
(dp61051
g49782
I106
sg49783
I1
sg49784
I8
sg49785
VC0023418
p61052
sg49787
Vleukemia
p61053
sasa(dp61054
g49775
VThis preliminary study indicated the tumor suppressing roles of miR-372 in cell cycle progression of TW01 cells, possibly via the down-regulation of CDK2 and CCNA1 as well as the up-regulation of CDKN1A and INCA1.Key Words: apoptosis, microRNA, nasopharyngeal carcinoma, miR-372, CDK2, CCNA1.
p61055
sg49777
(lp61056
(dp61057
g49782
I158
sg49783
I1
sg49784
I5
sg49812
VP78396
p61058
sg49787
VCCNA1
p61059
sa(dp61060
g49782
I196
sg49783
I1
sg49784
I6
sg49812
VP38936
p61061
sg49787
VCDKN1A
p61062
sa(dp61063
g49782
I149
sg49783
I1
sg49784
I4
sg49812
VP24941
p61064
sg49787
VCDK2
p61065
sa(dp61066
g49782
I149
sg49783
I1
sg49784
I4
sg49812
VP24941
p61067
sg49787
VCDK2
p61068
sa(dp61069
g49782
I158
sg49783
I1
sg49784
I5
sg49812
VP78396
p61070
sg49787
VCCNA1
p61071
sa(dp61072
g49782
I207
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VINCA1
p61073
sasg49779
(lp61074
(dp61075
g49782
I245
sg49783
I2
sg49784
I24
sg49785
VC2931822
p61076
sg49787
Vnasopharyngeal carcinoma
p61077
sa(dp61078
g49782
I37
sg49783
I1
sg49784
I5
sg49785
VC0027651
p61079
sg49787
Vtumor
p61080
sasa(dp61081
g49775
VFurthermore, blasts from acute lymphoid leukemia and acute myeloid leukemia patients expressed significantly reduced INCA1 levels highlighting its relevance for growth control in vivo.
p61082
sg49777
(lp61083
(dp61084
g49782
I117
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VINCA1
p61085
sasg49779
(lp61086
(dp61087
g49782
I25
sg49783
I3
sg49784
I23
sg49785
VC1961102
p61088
sg49787
Vacute lymphoid leukemia
p61089
sa(dp61090
g49782
I53
sg49783
I3
sg49784
I22
sg49785
VC0023467
p61091
sg49787
Vacute myeloid leukemia
p61092
sasa(dp61093
g49775
VOur objectives were (i) to assess the current prevalence of childhood overweight (including obesity) (OWOB) in France and its relationship with comprehensive socioeconomic status (SES) indicators and (ii) to examine trends in OWOB prevalence and changes in energy intake (EI) and sedentary behavior (SED) based on the previous INCA 1 (Individuelle Nationale des Consommations Alimentaires) data (1998-1999).
p61094
sg49777
(lp61095
(dp61096
g49782
I327
sg49783
I2
sg49784
I6
sg49812
g11
sg49787
VINCA 1
p61097
sasg49779
(lp61098
(dp61099
g49782
I92
sg49783
I1
sg49784
I7
sg49785
VC0028754
p61100
sg49787
Vobesity
p61101
sa(dp61102
g49782
I70
sg49783
I1
sg49784
I10
sg49785
VC0497406
p61103
sg49787
Voverweight
p61104
sa(dp61105
g49782
I358
sg49783
I1
sg49784
I3
sg49785
VC0394006
p61106
sg49787
Vdes
p61107
sasa(dp61108
g49775
VBoth estradiol and global ischemia markedly increased ERalpha, but not ERbeta, protein in CA1.
p61109
sg49777
(lp61110
(dp61111
g49782
I54
sg49783
I1
sg49784
I7
sg49812
VP03372
p61112
sg49787
VERalpha
p61113
sasg49779
(lp61114
(dp61115
g49782
I26
sg49783
I1
sg49784
I8
sg49785
VC0022116
p61116
sg49787
Vischemia
p61117
sasa(dp61118
g49775
VIt has been reported that BMPR2 is associated with chondrosarcoma.
p61119
sg49777
(lp61120
(dp61121
g49782
I26
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VBMPR2
p61122
sasg49779
(lp61123
(dp61124
g49782
I51
sg49783
I1
sg49784
I14
sg49785
VC0008479
p61125
sg49787
Vchondrosarcoma
p61126
sasa(dp61127
g49775
VMoreover, the detection of BMPR2 is more frequent in dedifferentiated chondrosarcomas (DDCS) than in conventional chondrosarcomas (CCS).
p61128
sg49777
(lp61129
(dp61130
g49782
I27
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VBMPR2
p61131
sasg49779
(lp61132
(dp61133
g49782
I131
sg49783
I1
sg49784
I3
sg49785
VC0008479
p61134
sg49787
VCCS
p61135
sa(dp61136
g49782
I70
sg49783
I1
sg49784
I15
sg49785
VC0008479
p61137
sg49787
Vchondrosarcomas
p61138
sa(dp61139
g49782
I70
sg49783
I1
sg49784
I15
sg49785
VC0008479
p61140
sg49787
Vchondrosarcomas
p61141
sasa(dp61142
g49775
VBMPR2, phospho-SMAD1/5 (pSMAD1/5), and runt-related transcription factor 2 (RUNX2) expressions were found to be associated with the pathological grades of chondrosarcoma and could be a promising target of treatment outcome.
p61143
sg49777
(lp61144
(dp61145
g49782
I76
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VRUNX2
p61146
sa(dp61147
g49782
I0
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VBMPR2
p61148
sa(dp61149
g49782
I7
sg49783
I1
sg49784
I15
sg49812
VP41250
p61150
sg49787
Vphospho-SMAD1/5
p61151
sa(dp61152
g49782
I24
sg49783
I1
sg49784
I8
sg49812
VP41250
p61153
sg49787
VpSMAD1/5
p61154
sasg49779
(lp61155
(dp61156
g49782
I39
sg49783
I1
sg49784
I4
sg49785
VC0013336
p61157
sg49787
Vrunt
p61158
sa(dp61159
g49782
I155
sg49783
I1
sg49784
I14
sg49785
VC0008479
p61160
sg49787
Vchondrosarcoma
p61161
sasa(dp61162
g49775
VIt has been demonstrated that more prevalent expression of bone morphogenetic protein receptor 2 (BMPR2) has been detected in dedifferentiated chondrosarcomas than conventional chondrosarcomas.
p61163
sg49777
(lp61164
(dp61165
g49782
I98
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VBMPR2
p61166
sa(dp61167
g49782
I59
sg49783
I5
sg49784
I37
sg49812
g11
sg49787
Vbone morphogenetic protein receptor 2
p61168
sasg49779
(lp61169
(dp61170
g49782
I143
sg49783
I1
sg49784
I15
sg49785
VC0008479
p61171
sg49787
Vchondrosarcomas
p61172
sa(dp61173
g49782
I143
sg49783
I1
sg49784
I15
sg49785
VC0008479
p61174
sg49787
Vchondrosarcomas
p61175
sasa(dp61176
g49775
VHere, we find that BMPR2 inhibition induces apoptosis and autophagy of chondrosarcoma.
p61177
sg49777
(lp61178
(dp61179
g49782
I19
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VBMPR2
p61180
sasg49779
(lp61181
(dp61182
g49782
I71
sg49783
I1
sg49784
I14
sg49785
VC0008479
p61183
sg49787
Vchondrosarcoma
p61184
sasa(dp61185
g49775
VWe found that BMPR2 expression was correlated with the clinicopathological features of chondrosarcomas, and could predict the treatment outcome.
p61186
sg49777
(lp61187
(dp61188
g49782
I14
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VBMPR2
p61189
sasg49779
(lp61190
(dp61191
g49782
I87
sg49783
I1
sg49784
I15
sg49785
VC0008479
p61192
sg49787
Vchondrosarcomas
p61193
sasa(dp61194
g49775
VKnockdown of BMPR2 by small interfering RNA results in growth inhibition in chondrosarcoma cells.
p61195
sg49777
(lp61196
(dp61197
g49782
I13
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VBMPR2
p61198
sasg49779
(lp61199
(dp61200
g49782
I76
sg49783
I1
sg49784
I14
sg49785
VC0008479
p61201
sg49787
Vchondrosarcoma
p61202
sasa(dp61203
g49775
VSilencing BMPR2 promoted G2/M cell cycle arrest, induced chondrosarcoma cell apoptosis through caspase-3-dependent pathway via repression of X-linked inhibitor of apoptosis protein (XIAP) and induced autophagy of chondrosarcoma cells via XIAP-Mdm2-p53 pathway.
p61204
sg49777
(lp61205
(dp61206
g49782
I248
sg49783
I1
sg49784
I3
sg49812
VP42771
p61207
sg49787
Vp53
p61208
sa(dp61209
g49782
I95
sg49783
I1
sg49784
I9
sg49812
VP42574
p61210
sg49787
Vcaspase-3
p61211
sa(dp61212
g49782
I182
sg49783
I1
sg49784
I4
sg49812
VP98170
p61213
sg49787
VXIAP
p61214
sa(dp61215
g49782
I10
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VBMPR2
p61216
sa(dp61217
g49782
I182
sg49783
I1
sg49784
I4
sg49812
VP98170
p61218
sg49787
VXIAP
p61219
sa(dp61220
g49782
I141
sg49783
I5
sg49784
I39
sg49812
VP98170
p61221
sg49787
VX-linked inhibitor of apoptosis protein
p61222
sasg49779
(lp61223
(dp61224
g49782
I57
sg49783
I1
sg49784
I14
sg49785
VC0008479
p61225
sg49787
Vchondrosarcoma
p61226
sa(dp61227
g49782
I57
sg49783
I1
sg49784
I14
sg49785
VC0008479
p61228
sg49787
Vchondrosarcoma
p61229
sasa(dp61230
g49775
VInhibition of autophagy induced by BMPR2 small interfering RNA (siBMPR2) sensitized chondrosarcoma cells to siBMPR2-induced apoptotic cell death, suggesting that autophagy has a protective role for chondrosarcoma cells in context of siBMPR2-induced apoptotic cell death.
p61231
sg49777
(lp61232
(dp61233
g49782
I35
sg49783
I4
sg49784
I27
sg49812
g11
sg49787
VBMPR2 small interfering RNA
p61234
sasg49779
(lp61235
(dp61236
g49782
I84
sg49783
I1
sg49784
I14
sg49785
VC0008479
p61237
sg49787
Vchondrosarcoma
p61238
sa(dp61239
g49782
I84
sg49783
I1
sg49784
I14
sg49785
VC0008479
p61240
sg49787
Vchondrosarcoma
p61241
sasa(dp61242
g49775
VTaken together, our results suggest that BMPR2 has a significant role in the tumorigenesis of chondrosarcoma, and could be an important prognostic marker for chondrosarcoma.
p61243
sg49777
(lp61244
(dp61245
g49782
I41
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VBMPR2
p61246
sasg49779
(lp61247
(dp61248
g49782
I94
sg49783
I1
sg49784
I14
sg49785
VC0008479
p61249
sg49787
Vchondrosarcoma
p61250
sa(dp61251
g49782
I77
sg49783
I1
sg49784
I13
sg49785
VC0007621
p61252
sg49787
Vtumorigenesis
p61253
sa(dp61254
g49782
I94
sg49783
I1
sg49784
I14
sg49785
VC0008479
p61255
sg49787
Vchondrosarcoma
p61256
sasa(dp61257
g49775
VBMPR2 inhibition could eventually provide a promising therapy for chondrosarcoma treatment.
p61258
sg49777
(lp61259
(dp61260
g49782
I0
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VBMPR2
p61261
sasg49779
(lp61262
(dp61263
g49782
I66
sg49783
I1
sg49784
I14
sg49785
VC0008479
p61264
sg49787
Vchondrosarcoma
p61265
sasa(dp61266
g49775
VThe role of Beta-defensin-1 in asthma and chronic obstructive pulmonary disease (COPD) remains unclear.
p61267
sg49777
(lp61268
(dp61269
g49782
I12
sg49783
I1
sg49784
I15
sg49812
VP60022
p61270
sg49787
VBeta-defensin-1
p61271
sasg49779
(lp61272
(dp61273
g49782
I81
sg49783
I1
sg49784
I4
sg49785
VC0024117
p61274
sg49787
VCOPD
p61275
sa(dp61276
g49782
I42
sg49783
I4
sg49784
I37
sg49785
VC0024117
p61277
sg49787
Vchronic obstructive pulmonary disease
p61278
sa(dp61279
g49782
I31
sg49783
I1
sg49784
I6
sg49785
VC0004096
p61280
sg49787
Vasthma
p61281
sasa(dp61282
g49775
VIn Japanese and Chinese populations, two different beta-defensin-1 polymorphisms have been associated with chronic obstructive pulmonary disease phenotypes.
p61283
sg49777
(lp61284
(dp61285
g49782
I51
sg49783
I1
sg49784
I15
sg49812
VP60022
p61286
sg49787
Vbeta-defensin-1
p61287
sasg49779
(lp61288
(dp61289
g49782
I107
sg49783
I4
sg49784
I37
sg49785
VC0024117
p61290
sg49787
Vchronic obstructive pulmonary disease
p61291
sasa(dp61292
g49775
VThe autosomal recessive ataxias are separated into Friedreich ataxia, ataxia due to vitamin E deficiency, ataxia due to Abeta-lipoproteinemia, Refsum disease, late-onset Tay-Sachs disease, cerebrotendineous xanthomatosis, spinocerebellar ataxia with axonal neuropathy, ataxia telangiectasia, ataxia telangiectasia-like disorder, ataxia with oculomotor apraxia 1 and 2, spastic ataxia of Charlevoix-Saguenay, Cayman ataxia, Marinesco-Sjoegren syndrome, and autosomal recessive mitochondrial ataxias (AR-CPEO, SANDO, SCAE, AHS, IOSCA, MEMSA, LBSL CoQ-deficiency, PDC-deficiency).
p61293
sg49777
(lp61294
(dp61295
g49782
I120
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VAbeta
p61296
sa(dp61297
g49782
I526
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VIOSCA
p61298
sa(dp61299
g49782
I508
sg49783
I1
sg49784
I5
sg49812
VP54098
p61300
sg49787
VSANDO
p61301
sa(dp61302
g49782
I561
sg49783
I1
sg49784
I3
sg49812
VP20941
p61303
sg49787
VPDC
p61304
sa(dp61305
g49782
I521
sg49783
I1
sg49784
I3
sg49812
VP02765
p61306
sg49787
VAHS
p61307
sa(dp61308
g49782
I540
sg49783
I2
sg49784
I8
sg49812
g11
sg49787
VLBSL CoQ
p61309
sa(dp61310
g49782
I515
sg49783
I1
sg49784
I4
sg49812
VP54098
p61311
sg49787
VSCAE
p61312
sasg49779
(lp61313
(dp61314
g49782
I269
sg49783
I2
sg49784
I21
sg49785
VC0004135
p61315
sg49787
Vataxia telangiectasia
p61316
sa(dp61317
g49782
I508
sg49783
I1
sg49784
I5
sg49785
VC1843851
p61318
sg49787
VSANDO
p61319
sa(dp61320
g49782
I369
sg49783
I4
sg49784
I37
sg49785
VC1849140
p61321
sg49787
Vspastic ataxia of Charlevoix-Saguenay
p61322
sa(dp61323
g49782
I24
sg49783
I1
sg49784
I7
sg49785
VC0004134
p61324
sg49787
Vataxias
p61325
sa(dp61326
g49782
I515
sg49783
I1
sg49784
I4
sg49785
VC1843852
p61327
sg49787
VSCAE
p61328
sa(dp61329
g49782
I51
sg49783
I2
sg49784
I17
sg49785
VC0016719
p61330
sg49787
VFriedreich ataxia
p61331
sa(dp61332
g49782
I222
sg49783
I2
sg49784
I22
sg49785
VC0087012
p61333
sg49787
Vspinocerebellar ataxia
p61334
sa(dp61335
g49782
I207
sg49783
I1
sg49784
I13
sg49785
VC0043325
p61336
sg49787
Vxanthomatosis
p61337
sa(dp61338
g49782
I143
sg49783
I2
sg49784
I14
sg49785
VC0034960
p61339
sg49787
VRefsum disease
p61340
sa(dp61341
g49782
I526
sg49783
I1
sg49784
I5
sg49785
VC1849096
p61342
sg49787
VIOSCA
p61343
sa(dp61344
g49782
I250
sg49783
I2
sg49784
I17
sg49785
VC0270921
p61345
sg49787
Vaxonal neuropathy
p61346
sa(dp61347
g49782
I24
sg49783
I1
sg49784
I6
sg49785
VC0004134
p61348
sg49787
Vataxia
p61349
sa(dp61350
g49782
I341
sg49783
I2
sg49784
I18
sg49785
VC0271270
p61351
sg49787
Voculomotor apraxia
p61352
sa(dp61353
g49782
I84
sg49783
I3
sg49784
I20
sg49785
VC0042875
p61354
sg49787
Vvitamin E deficiency
p61355
sa(dp61356
g49782
I502
sg49783
I1
sg49784
I4
sg49785
VC0162674
p61357
sg49787
VCPEO
p61358
sa(dp61359
g49782
I170
sg49783
I2
sg49784
I17
sg49785
VC0039373
p61360
sg49787
VTay-Sachs disease
p61361
sa(dp61362
g49782
I442
sg49783
I1
sg49784
I8
sg49785
VC0039082
p61363
sg49787
Vsyndrome
p61364
sa(dp61365
g49782
I24
sg49783
I1
sg49784
I6
sg49785
VC0004134
p61366
sg49787
Vataxia
p61367
sa(dp61368
g49782
I24
sg49783
I1
sg49784
I6
sg49785
VC0004134
p61369
sg49787
Vataxia
p61370
sa(dp61371
g49782
I269
sg49783
I2
sg49784
I21
sg49785
VC0004135
p61372
sg49787
Vataxia telangiectasia
p61373
sa(dp61374
g49782
I24
sg49783
I1
sg49784
I6
sg49785
VC0004134
p61375
sg49787
Vataxia
p61376
sa(dp61377
g49782
I540
sg49783
I1
sg49784
I4
sg49785
VC1970180
p61378
sg49787
VLBSL
p61379
sa(dp61380
g49782
I24
sg49783
I1
sg49784
I7
sg49785
VC0004134
p61381
sg49787
Vataxias
p61382
sa(dp61383
g49782
I561
sg49783
I1
sg49784
I3
sg49785
VC1869117
p61384
sg49787
VPDC
p61385
sasa(dp61386
g49775
VOnly patients presenting PEO as part of their clinical phenotype had POLG mutations, in seven of them together with myopathic signs and in one with a sensori-motor peripheral neuropathy.
p61387
sg49777
(lp61388
(dp61389
g49782
I69
sg49783
I1
sg49784
I4
sg49812
VP54098
p61390
sg49787
VPOLG
p61391
sasg49779
(lp61392
(dp61393
g49782
I158
sg49783
I3
sg49784
I27
sg49785
VC0235025
p61394
sg49787
Vmotor peripheral neuropathy
p61395
sasa(dp61396
g49775
VMoreover, it is suggested that blockades of 5-HT3 and 5-HT4 receptors are not relevant to the control of motion sickness; and furthermore, it suggested that blocking 5-HT4 receptors in addition to 5-HT3 receptors does not have an additional effect on the control of cisplatin-induced emesis, but that 5-HT4 receptors are at least partly involved in the mechanism of emesis induced by copper sulfate.
p61397
sg49777
(lp61398
(dp61399
g49782
I197
sg49783
I2
sg49784
I15
sg49812
g11
sg49787
V5-HT3 receptors
p61400
sa(dp61401
g49782
I44
sg49783
I4
sg49784
I25
sg49812
g11
sg49787
V5-HT3 and 5-HT4 receptors
p61402
sa(dp61403
g49782
I54
sg49783
I2
sg49784
I15
sg49812
g11
sg49787
V5-HT4 receptors
p61404
sa(dp61405
g49782
I54
sg49783
I2
sg49784
I15
sg49812
g11
sg49787
V5-HT4 receptors
p61406
sasg49779
(lp61407
(dp61408
g49782
I105
sg49783
I2
sg49784
I15
sg49785
VC0026603
p61409
sg49787
Vmotion sickness
p61410
sa(dp61411
g49782
I284
sg49783
I1
sg49784
I6
sg49785
VC0042963
p61412
sg49787
Vemesis
p61413
sa(dp61414
g49782
I157
sg49783
I1
sg49784
I8
sg49785
VC0233660
p61415
sg49787
Vblocking
p61416
sa(dp61417
g49782
I284
sg49783
I1
sg49784
I6
sg49785
VC0042963
p61418
sg49787
Vemesis
p61419
sasa(dp61420
g49775
VTherefore, we used Biolog GN2 microplates to analyze the ability of 103 clinical, predominantly diarrheal, isolates of Aeromonas to use various carbon sources, and we verified whether, among the substrates metabolized by these strains, there were some endogenous to the human intestine.
p61421
sg49777
(lp61422
sg49779
(lp61423
sa(dp61424
g49775
VRP30 was one of these strains that was randomly selected and analysed by using a morphological, physiological and biochemical plate, Biolog GN2 Microplate System and API 20E system.
p61425
sg49777
(lp61426
(dp61427
g49782
I0
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VRP30
p61428
sasg49779
(lp61429
(dp61430
g49782
I0
sg49783
I1
sg49784
I4
sg49785
VC1842816
p61431
sg49787
VRP30
p61432
sasa(dp61433
g49775
VHistological and clinical diagnoses of the 14 patients were as follows: IgA nephropathy 3, non-IgA GN 2, and asymptomatic significant microscopic hematuria [more than 100 red blood cells per high-power field (x400)] with or without proteinuria 9.
p61434
sg49777
(lp61435
(dp61436
g49782
I91
sg49783
I3
sg49784
I12
sg49812
g11
sg49787
Vnon-IgA GN 2
p61437
sa(dp61438
g49782
I72
sg49783
I3
sg49784
I17
sg49812
VP11912
p61439
sg49787
VIgA nephropathy 3
p61440
sasg49779
(lp61441
(dp61442
g49782
I134
sg49783
I2
sg49784
I21
sg49785
VC0239937
p61443
sg49787
Vmicroscopic hematuria
p61444
sa(dp61445
g49782
I72
sg49783
I2
sg49784
I15
sg49785
VC0017661
p61446
sg49787
VIgA nephropathy
p61447
sasa(dp61448
g49775
VThe incidence of membranous form of glomerulonephritis was high (34 out of 44 kidney biopsy cases, 77%), the rest of patients showing mesangiocapillary GN-8 (18%) and mesangial proliferative GN-2 (5%).
p61449
sg49777
(lp61450
sg49779
(lp61451
(dp61452
g49782
I36
sg49783
I1
sg49784
I18
sg49785
VC0017658
p61453
sg49787
Vglomerulonephritis
p61454
sa(dp61455
g49782
I177
sg49783
I1
sg49784
I13
sg49785
VC0334094
p61456
sg49787
Vproliferative
p61457
sasa(dp61458
g49775
VIn organ cultures, nephrosis-producing IBV strains (GN-2 and M-41) were slightly more ciliostatic and respiratory strains (Beaudette and Kita-1/Tokushima) less ciliostatic at 40.5 degrees C than at 37 degrees C. Mortality of chicken embryos infected with the GN-2, M-41 and Kita-1/Tokushima strains was greater at 40.5 degrees C than at 37 degrees C, while the reverse was true of the Beaudette strain which caused no embryo mortality at 40.5 degrees C. The Beaudette strain of IBV was the only one which could not be recovered from the kidneys of young chickens four days after infection.
p61459
sg49777
(lp61460
(dp61461
g49782
I52
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VGN-2
p61462
sasg49779
(lp61463
(dp61464
g49782
I19
sg49783
I1
sg49784
I9
sg49785
VC0027720
p61465
sg49787
Vnephrosis
p61466
sa(dp61467
g49782
I579
sg49783
I1
sg49784
I9
sg49785
VC0009450
p61468
sg49787
Vinfection
p61469
sasa(dp61470
g49775
VIn addition, in Alzheimer's disease we found simple gangliosides (GN2, GM3) to be elevated in the frontal and parietal cortex, which might correlate accelerated lysosomal degradation of gangliosides and/or astrogliosis occurring during neuronal death.
p61471
sg49777
(lp61472
sg49779
(lp61473
(dp61474
g49782
I16
sg49783
I2
sg49784
I19
sg49785
VC1521724
p61475
sg49787
VAlzheimer's disease
p61476
sa(dp61477
g49782
I206
sg49783
I1
sg49784
I12
sg49785
VC0017639
p61478
sg49787
Vastrogliosis
p61479
sasa(dp61480
g49775
VThe aim of this study was to investigate the immunoreactivity to tryptase and to cathepsin-G of MC from human cutaneous mastocytosis and to compare their number in normal skin and cutaneous mastocytosis.
p61481
sg49777
(lp61482
(dp61483
g49782
I81
sg49783
I1
sg49784
I11
sg49812
VP25774
p61484
sg49787
Vcathepsin-G
p61485
sasg49779
(lp61486
(dp61487
g49782
I110
sg49783
I2
sg49784
I22
sg49785
VC1136033
p61488
sg49787
Vcutaneous mastocytosis
p61489
sa(dp61490
g49782
I110
sg49783
I2
sg49784
I22
sg49785
VC1136033
p61491
sg49787
Vcutaneous mastocytosis
p61492
sasa(dp61493
g49775
VMorphometric evaluation of MC number demostrated that the number of both tryptase- and cathepsin-G-positive MC was significantly higher in cutaneous mastocytosis as compared to normal skin and that in both conditions the number of tryptase-positive MC was significantly higher as compared to the number of cathepsin-G-positive MC.
p61494
sg49777
(lp61495
(dp61496
g49782
I87
sg49783
I1
sg49784
I11
sg49812
VP25774
p61497
sg49787
Vcathepsin-G
p61498
sa(dp61499
g49782
I87
sg49783
I1
sg49784
I11
sg49812
VP25774
p61500
sg49787
Vcathepsin-G
p61501
sasg49779
(lp61502
(dp61503
g49782
I139
sg49783
I2
sg49784
I22
sg49785
VC1136033
p61504
sg49787
Vcutaneous mastocytosis
p61505
sasa(dp61506
g49775
VIn conclusion, in this study, for the first time we have demonstrated the presence of MC with immunoreactivity to cathepsin-G in human cutaneous mastocytosis, as well as the co-localization of tryptase and cathepsin-G in MC secretory granules.
p61507
sg49777
(lp61508
(dp61509
g49782
I114
sg49783
I1
sg49784
I11
sg49812
VP25774
p61510
sg49787
Vcathepsin-G
p61511
sa(dp61512
g49782
I114
sg49783
I1
sg49784
I11
sg49812
VP25774
p61513
sg49787
Vcathepsin-G
p61514
sasg49779
(lp61515
(dp61516
g49782
I135
sg49783
I2
sg49784
I22
sg49785
VC1136033
p61517
sg49787
Vcutaneous mastocytosis
p61518
sasa(dp61519
g49775
VThe aim of our retrospective study was to evaluate the association of miR-126-3p, miR-126-5p and miR-664-3p tumour expression levels with outcomes of patients with metastatic colorectal cancer treated with bevacizumab.
p61520
sg49777
(lp61521
(dp61522
g49782
I97
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-664-3p
p61523
sa(dp61524
g49782
I82
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-126-5p
p61525
sa(dp61526
g49782
I70
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-126-3p
p61527
sasg49779
(lp61528
(dp61529
g49782
I164
sg49783
I3
sg49784
I28
sg49785
VC0948380
p61530
sg49787
Vmetastatic colorectal cancer
p61531
sa(dp61532
g49782
I108
sg49783
I1
sg49784
I6
sg49785
VC0027651
p61533
sg49787
Vtumour
p61534
sasa(dp61535
g49775
VIn the present study, we investigated the role of miR-126-5p and Bcl2l2 in cervical cancer cells.
p61536
sg49777
(lp61537
(dp61538
g49782
I65
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl2l2
p61539
sa(dp61540
g49782
I50
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-126-5p
p61541
sasg49779
(lp61542
(dp61543
g49782
I75
sg49783
I2
sg49784
I15
sg49785
VC0302592
p61544
sg49787
Vcervical cancer
p61545
sasa(dp61546
g49775
VFirst, miR-126-5p expression was aberrantly downregulated in human cervical cancer tumor tissues in comparison with normal tissues, as evaluated by RT-PCR.
p61547
sg49777
(lp61548
(dp61549
g49782
I7
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-126-5p
p61550
sasg49779
(lp61551
(dp61552
g49782
I83
sg49783
I1
sg49784
I5
sg49785
VC0027651
p61553
sg49787
Vtumor
p61554
sa(dp61555
g49782
I67
sg49783
I2
sg49784
I15
sg49785
VC0302592
p61556
sg49787
Vcervical cancer
p61557
sasa(dp61558
g49775
VConsistently, the levels of miR-126-5p were also significantly reduced in cervical cancer cell lines when compared to normal cervical epithelial cells.
p61559
sg49777
(lp61560
(dp61561
g49782
I28
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-126-5p
p61562
sasg49779
(lp61563
(dp61564
g49782
I74
sg49783
I2
sg49784
I15
sg49785
VC0302592
p61565
sg49787
Vcervical cancer
p61566
sasa(dp61567
g49775
VFlow cytometric analysis showed that the rate of apoptosis of cervical cancer cells was significantly increased by miR-126-5p overexpression but inhibited by miR-126-5p inhibitor.
p61568
sg49777
(lp61569
(dp61570
g49782
I115
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-126-5p
p61571
sa(dp61572
g49782
I115
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-126-5p
p61573
sasg49779
(lp61574
(dp61575
g49782
I62
sg49783
I2
sg49784
I15
sg49785
VC0302592
p61576
sg49787
Vcervical cancer
p61577
sasa(dp61578
g49775
VA similar change pattern was observed in the expression of apoptosis-regulated protein caspase 3 in cervical cancer cells transfected with miR-126-5p mimic or inhibitor.
p61579
sg49777
(lp61580
(dp61581
g49782
I139
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-126-5p
p61582
sa(dp61583
g49782
I79
sg49783
I3
sg49784
I17
sg49812
VP42574
p61584
sg49787
Vprotein caspase 3
p61585
sasg49779
(lp61586
(dp61587
g49782
I100
sg49783
I2
sg49784
I15
sg49785
VC0302592
p61588
sg49787
Vcervical cancer
p61589
sasa(dp61590
g49775
VBy bioinformatic prediction with online databases and verification using luciferase reporter assay, we then identified that Bcl2l2 is a direct target of miR-126-5p in cervical cancer cells.
p61591
sg49777
(lp61592
(dp61593
g49782
I124
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl2l2
p61594
sa(dp61595
g49782
I153
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-126-5p
p61596
sasg49779
(lp61597
(dp61598
g49782
I167
sg49783
I2
sg49784
I15
sg49785
VC0302592
p61599
sg49787
Vcervical cancer
p61600
sasa(dp61601
g49775
VThe expression of Bcl2l2 was strongly downregulated by the miR-126-5p mimic but upregulated by the miR-126-5p inhibitor in cervical cancer cells, and Bcl2l2 expression was significantly increased in human cervical cancer tumor tissues, which was negatively correlated with miR-126-5p levels.
p61602
sg49777
(lp61603
(dp61604
g49782
I18
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl2l2
p61605
sa(dp61606
g49782
I59
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-126-5p
p61607
sa(dp61608
g49782
I59
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-126-5p
p61609
sa(dp61610
g49782
I18
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl2l2
p61611
sasg49779
(lp61612
(dp61613
g49782
I123
sg49783
I2
sg49784
I15
sg49785
VC0302592
p61614
sg49787
Vcervical cancer
p61615
sa(dp61616
g49782
I123
sg49783
I2
sg49784
I15
sg49785
VC0302592
p61617
sg49787
Vcervical cancer
p61618
sa(dp61619
g49782
I221
sg49783
I1
sg49784
I5
sg49785
VC0027651
p61620
sg49787
Vtumor
p61621
sasa(dp61622
g49775
VFurthermore, we confirmed that the rate of apoptosis was significantly increased by Bcl2l2 silencing in cervical cancer cells, which was not affected by the miR-126-5p inhibitor.
p61623
sg49777
(lp61624
(dp61625
g49782
I84
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl2l2
p61626
sa(dp61627
g49782
I157
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-126-5p
p61628
sasg49779
(lp61629
(dp61630
g49782
I104
sg49783
I2
sg49784
I15
sg49785
VC0302592
p61631
sg49787
Vcervical cancer
p61632
sasa(dp61633
g49775
VIn summary, miR-126-5p plays an inhibitory role in human cervical cancer progression, regulating the apoptosis of cancer cells via directly targeting Bcl2l2.
p61634
sg49777
(lp61635
(dp61636
g49782
I12
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VmiR-126-5p
p61637
sa(dp61638
g49782
I150
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBcl2l2
p61639
sasg49779
(lp61640
(dp61641
g49782
I66
sg49783
I1
sg49784
I6
sg49785
VC0006826
p61642
sg49787
Vcancer
p61643
sa(dp61644
g49782
I66
sg49783
I2
sg49784
I18
sg49785
VC0178874
p61645
sg49787
Vcancer progression
p61646
sasa(dp61647
g49775
VPatients with miR-126*low myelodysplastic syndrome had significantly lower response rates (P = 0.04) and higher relapse rates (P = 0.03), as well as shorter progression-free (PFS; P = 0.004) and overall survival (OS; P = 0.004).
p61648
sg49777
(lp61649
sg49779
(lp61650
(dp61651
g49782
I26
sg49783
I2
sg49784
I24
sg49785
VC0033027
p61652
sg49787
Vmyelodysplastic syndrome
p61653
sa(dp61654
g49782
I112
sg49783
I1
sg49784
I7
sg49785
VC0277556
p61655
sg49787
Vrelapse
p61656
sasa(dp61657
g49775
VIn the present study, the relationship between miR-126-5p/3p expression levels and overall survival in 109 patients with acute myeloid leukemia (AML) who received intensive therapy were evaluated.
p61658
sg49777
(lp61659
(dp61660
g49782
I47
sg49783
I1
sg49784
I13
sg49812
g11
sg49787
VmiR-126-5p/3p
p61661
sasg49779
(lp61662
(dp61663
g49782
I121
sg49783
I3
sg49784
I22
sg49785
VC0023467
p61664
sg49787
Vacute myeloid leukemia
p61665
sa(dp61666
g49782
I145
sg49783
I1
sg49784
I3
sg49785
VC0023467
p61667
sg49787
VAML
p61668
sasa(dp61669
g49775
VThe presence of XBP-1s, the active form of XBP-1, after administration of anti-Ig to Akata Burkitt's lymphoma cells is consistent with a role for this factor in reactivation of the EBV lytic cycle, although signalling through MEF2D was quantitatively much more significant in activation of Zp.
p61670
sg49777
(lp61671
(dp61672
g49782
I16
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VXBP-1s
p61673
sa(dp61674
g49782
I226
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VMEF2D
p61675
sa(dp61676
g49782
I16
sg49783
I1
sg49784
I5
sg49812
VP17861
p61677
sg49787
VXBP-1
p61678
sasg49779
(lp61679
(dp61680
g49782
I185
sg49783
I1
sg49784
I5
sg49785
VC0024348
p61681
sg49787
Vlytic
p61682
sa(dp61683
g49782
I91
sg49783
I2
sg49784
I18
sg49785
VC0006413
p61684
sg49787
VBurkitt's lymphoma
p61685
sasa(dp61686
g49775
VAs expected, markers of neuronal differentiation such as anti-apoptotic protein B-cell lymphoma 2 (BCL2), myocyte enhancer factor-2D (MEF2D) and zipper protein kinase (MAP3K12; aka ZPK/MUK/DLK) were each up-regulated in response to differentiation.
p61687
sg49777
(lp61688
(dp61689
g49782
I189
sg49783
I1
sg49784
I3
sg49812
VP80370
p61690
sg49787
VDLK
p61691
sa(dp61692
g49782
I99
sg49783
I1
sg49784
I4
sg49812
VP10415
p61693
sg49787
VBCL2
p61694
sa(dp61695
g49782
I134
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VMEF2D
p61696
sa(dp61697
g49782
I168
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VMAP3K12
p61698
sa(dp61699
g49782
I185
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VMUK
p61700
sa(dp61701
g49782
I145
sg49783
I3
sg49784
I21
sg49812
g11
sg49787
Vzipper protein kinase
p61702
sa(dp61703
g49782
I106
sg49783
I3
sg49784
I26
sg49812
g11
sg49787
Vmyocyte enhancer factor-2D
p61704
sa(dp61705
g49782
I177
sg49783
I2
sg49784
I7
sg49812
g11
sg49787
Vaka ZPK
p61706
sa(dp61707
g49782
I57
sg49783
I5
sg49784
I40
sg49812
g11
sg49787
Vanti-apoptotic protein B-cell lymphoma 2
p61708
sasg49779
(lp61709
(dp61710
g49782
I80
sg49783
I2
sg49784
I15
sg49785
VC0079731
p61711
sg49787
VB-cell lymphoma
p61712
sasa(dp61713
g49775
VThe decrease in T-Shc and T1 were less obvious in mucinous adenocarcinoma and not observed in serous or endometrioid adenocarcinoma.
p61714
sg49777
(lp61715
sg49779
(lp61716
(dp61717
g49782
I104
sg49783
I2
sg49784
I27
sg49785
VC1569637
p61718
sg49787
Vendometrioid adenocarcinoma
p61719
sa(dp61720
g49782
I50
sg49783
I2
sg49784
I23
sg49785
VC0007130
p61721
sg49787
Vmucinous adenocarcinoma
p61722
sasa(dp61723
g49775
VOverexpression of the signalling adaptor protein ShcD in melanoma was found to be a prerequisite for melanoma migration and invasion.
p61724
sg49777
(lp61725
(dp61726
g49782
I49
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VShcD
p61727
sasg49779
(lp61728
(dp61729
g49782
I124
sg49783
I1
sg49784
I8
sg49785
VC2699153
p61730
sg49787
Vinvasion
p61731
sa(dp61732
g49782
I57
sg49783
I1
sg49784
I8
sg49785
VC0025202
p61733
sg49787
Vmelanoma
p61734
sa(dp61735
g49782
I57
sg49783
I1
sg49784
I8
sg49785
VC0025202
p61736
sg49787
Vmelanoma
p61737
sasa(dp61738
g49775
VWe have further demonstrated that ShcD accumulates in the nucleus upon hydrogen peroxide treatment in FLAG-ShcD expressing HEK293 cells, as well as 518.A2 melanoma cells.
p61739
sg49777
(lp61740
(dp61741
g49782
I34
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VShcD
p61742
sa(dp61743
g49782
I34
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VShcD
p61744
sasg49779
(lp61745
(dp61746
g49782
I155
sg49783
I1
sg49784
I8
sg49785
VC0025202
p61747
sg49787
Vmelanoma
p61748
sasa(dp61749
g49775
VWe suggest that ShcD nuclear translocation might provide melanoma cells with a mechanism that enables them to resist DNA damage due to oxidative stress.
p61750
sg49777
(lp61751
(dp61752
g49782
I16
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VShcD
p61753
sasg49779
(lp61754
(dp61755
g49782
I135
sg49783
I2
sg49784
I16
sg49785
VC0242606
p61756
sg49787
Voxidative stress
p61757
sa(dp61758
g49782
I57
sg49783
I1
sg49784
I8
sg49785
VC0025202
p61759
sg49787
Vmelanoma
p61760
sa(dp61761
g49782
I117
sg49783
I2
sg49784
I10
sg49785
VC0012860
p61762
sg49787
VDNA damage
p61763
sa(dp61764
g49782
I29
sg49783
I1
sg49784
I13
sg49785
VC0040715
p61765
sg49787
Vtranslocation
p61766
sasa(dp61767
g49775
VRai like protein (RaLP) is a newly identified Src homology 2 domain containing (Shc) family member selectively expressed during the transition to metastatic melanoma and thus is a potential melanoma-specific drugable target.
p61768
sg49777
(lp61769
(dp61770
g49782
I46
sg49783
I8
sg49784
I52
sg49812
VP12931
p61771
sg49787
VSrc homology 2 domain containing (Shc) family member
p61772
sa(dp61773
g49782
I18
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VRaLP
p61774
sa(dp61775
g49782
I0
sg49783
I3
sg49784
I16
sg49812
VP13489
p61776
sg49787
VRai like protein
p61777
sasg49779
(lp61778
(dp61779
g49782
I132
sg49783
I1
sg49784
I10
sg49785
VC0599156
p61780
sg49787
Vtransition
p61781
sa(dp61782
g49782
I157
sg49783
I1
sg49784
I8
sg49785
VC0025202
p61783
sg49787
Vmelanoma
p61784
sa(dp61785
g49782
I146
sg49783
I2
sg49784
I19
sg49785
VC0278883
p61786
sg49787
Vmetastatic melanoma
p61787
sasa(dp61788
g49775
VMutations in ABHD5 gene are associated with the onset of Chanarin-Dorfman syndrome (CDS), a rare autosomal recessive lipid storage disorder, characterized by non-bullous congenital ichthyosiform erythroderma (NCIE), hepatomegaly and liver steatosis.
p61789
sg49777
(lp61790
(dp61791
g49782
I13
sg49783
I2
sg49784
I10
sg49812
g11
sg49787
VABHD5 gene
p61792
sasg49779
(lp61793
(dp61794
g49782
I216
sg49783
I1
sg49784
I12
sg49785
VC0019209
p61795
sg49787
Vhepatomegaly
p61796
sa(dp61797
g49782
I209
sg49783
I1
sg49784
I4
sg49785
VC1855792
p61798
sg49787
VNCIE
p61799
sa(dp61800
g49782
I57
sg49783
I2
sg49784
I25
sg49785
VC0268238
p61801
sg49787
VChanarin-Dorfman syndrome
p61802
sa(dp61803
g49782
I158
sg49783
I4
sg49784
I49
sg49785
VC1855792
p61804
sg49787
Vnon-bullous congenital ichthyosiform erythroderma
p61805
sa(dp61806
g49782
I233
sg49783
I2
sg49784
I15
sg49785
VC0015695
p61807
sg49787
Vliver steatosis
p61808
sa(dp61809
g49782
I84
sg49783
I1
sg49784
I3
sg49785
VC0268238
p61810
sg49787
VCDS
p61811
sasa(dp61812
g49775
VIt is an autosomal recessive disease caused by mutations in the ABHD5 gene.
p61813
sg49777
(lp61814
(dp61815
g49782
I64
sg49783
I2
sg49784
I10
sg49812
g11
sg49787
VABHD5 gene
p61816
sasg49779
(lp61817
sa(dp61818
g49775
VMutations of comparative gene identification 58 (CGI-58) in humans cause Chanarin-Dorfman syndrome, a rare autosomal recessive disease in which excess triacylglycerol (TAG) accumulates in multiple tissues.
p61819
sg49777
(lp61820
sg49779
(lp61821
(dp61822
g49782
I151
sg49783
I1
sg49784
I15
sg49785
VC0037293
p61823
sg49787
Vtriacylglycerol
p61824
sa(dp61825
g49782
I168
sg49783
I1
sg49784
I3
sg49785
VC0037293
p61826
sg49787
VTAG
p61827
sa(dp61828
g49782
I73
sg49783
I2
sg49784
I25
sg49785
VC0268238
p61829
sg49787
VChanarin-Dorfman syndrome
p61830
sasa(dp61831
g49775
VThe case histories of two children (aged two months) affected by myocarditis showing an atypical band of serum creatine kinase (EC 2.7.3.2; CK) in the CK isoenzyme electrophoretic pattern are reported.
p61832
sg49777
(lp61833
(dp61834
g49782
I105
sg49783
I3
sg49784
I21
sg49812
VP12532
p61835
sg49787
Vserum creatine kinase
p61836
sasg49779
(lp61837
(dp61838
g49782
I65
sg49783
I1
sg49784
I11
sg49785
VC0027059
p61839
sg49787
Vmyocarditis
p61840
sasa(dp61841
g49775
VThe objective of this study was to evaluate the nephroprotective potential of resveratrol and piperine at same dose on cationic bovine serum albumin (cBSA) induced immune complex glomerulonephritis (ICGN) in BALB/c mice.
p61842
sg49777
(lp61843
(dp61844
g49782
I128
sg49783
I3
sg49784
I20
sg49812
VP49639
p61845
sg49787
Vbovine serum albumin
p61846
sasg49779
(lp61847
(dp61848
g49782
I199
sg49783
I1
sg49784
I4
sg49785
VC0744421
p61849
sg49787
VICGN
p61850
sa(dp61851
g49782
I164
sg49783
I3
sg49784
I33
sg49785
VC0744421
p61852
sg49787
Vimmune complex glomerulonephritis
p61853
sasa(dp61854
g49775
VThe object of the present study was to investigate the effects of VA, alone and in combination with methylprednisolone (MP), on cationic bovine serum albumin (cBSA induced immune-complex glomerulonephritis in female BALB/c mice.
p61855
sg49777
(lp61856
(dp61857
g49782
I128
sg49783
I4
sg49784
I29
sg49812
VP49639
p61858
sg49787
Vcationic bovine serum albumin
p61859
sasg49779
(lp61860
(dp61861
g49782
I172
sg49783
I2
sg49784
I33
sg49785
VC0744421
p61862
sg49787
Vimmune-complex glomerulonephritis
p61863
sasa(dp61864
g49775
VBovine serum albumin (BSA) glomerulonephritis is a type of immune complex glomerulonephritis that is characterized by a large number of leukocytes infiltrating the kidney.
p61865
sg49777
(lp61866
(dp61867
g49782
I22
sg49783
I1
sg49784
I3
sg49812
VP49639
p61868
sg49787
VBSA
p61869
sa(dp61870
g49782
I0
sg49783
I3
sg49784
I20
sg49812
VP49639
p61871
sg49787
VBovine serum albumin
p61872
sasg49779
(lp61873
(dp61874
g49782
I27
sg49783
I1
sg49784
I18
sg49785
VC0017658
p61875
sg49787
Vglomerulonephritis
p61876
sa(dp61877
g49782
I147
sg49783
I1
sg49784
I12
sg49785
VC0332448
p61878
sg49787
Vinfiltrating
p61879
sa(dp61880
g49782
I59
sg49783
I3
sg49784
I33
sg49785
VC0744421
p61881
sg49787
Vimmune complex glomerulonephritis
p61882
sasa(dp61883
g49775
VThe aim of this study is to show the results of the retrospective analysis (2010-2012) on hospital discharge records (HDRs) related to diseases potentially due to S. pneumoniae, using a selection of ICD9-CM codes.
p61884
sg49777
(lp61885
sg49779
(lp61886
(dp61887
g49782
I90
sg49783
I3
sg49784
I26
sg49785
VC1840333
p61888
sg49787
Vhospital discharge records
p61889
sa(dp61890
g49782
I118
sg49783
I1
sg49784
I4
sg49785
VC1840333
p61891
sg49787
VHDRs
p61892
sasa(dp61893
g49775
VThe aim of this study is to show the results of the retrospective analysis (2010-2012) on hospital discharge records (HDRs) related to diseases potentially due to S. pneumoniae, using a selection of ICD9-CM codes.
p61894
sg49777
(lp61895
sg49779
(lp61896
(dp61897
g49782
I90
sg49783
I3
sg49784
I26
sg49785
VC1840333
p61898
sg49787
Vhospital discharge records
p61899
sa(dp61900
g49782
I118
sg49783
I1
sg49784
I4
sg49785
VC1840333
p61901
sg49787
VHDRs
p61902
sasa(dp61903
g49775
VGATA binding protein 3 (GATA3) and suppressors of cytokine signalling3 mRNA were differentially regulated in HDM and influenza-stimulated cultures+/-IFN-Beta.
p61904
sg49777
(lp61905
(dp61906
g49782
I149
sg49783
I1
sg49784
I8
sg49812
VP01574
p61907
sg49787
VIFN-Beta
p61908
sa(dp61909
g49782
I0
sg49783
I4
sg49784
I22
sg49812
VP23771
p61910
sg49787
VGATA binding protein 3
p61911
sa(dp61912
g49782
I24
sg49783
I1
sg49784
I5
sg49812
VP23771
p61913
sg49787
VGATA3
p61914
sasg49779
(lp61915
(dp61916
g49782
I117
sg49783
I1
sg49784
I9
sg49785
VC0021400
p61917
sg49787
Vinfluenza
p61918
sasa(dp61919
g49775
VIn this article we review the current available evidence describing the effects of allopurinol in hypertension, kidney disease, and coronary heart disease, highlighting unresolved issues surrounding allopurinol use for uric acid lowering in individuals without gout.
p61920
sg49777
(lp61921
sg49779
(lp61922
(dp61923
g49782
I98
sg49783
I1
sg49784
I12
sg49785
VC0020538
p61924
sg49787
Vhypertension
p61925
sa(dp61926
g49782
I261
sg49783
I1
sg49784
I4
sg49785
VC0018099
p61927
sg49787
Vgout
p61928
sa(dp61929
g49782
I112
sg49783
I2
sg49784
I14
sg49785
VC0022658
p61930
sg49787
Vkidney disease
p61931
sa(dp61932
g49782
I132
sg49783
I3
sg49784
I22
sg49785
VC0010054
p61933
sg49787
Vcoronary heart disease
p61934
sasa(dp61935
g49775
VMany epidemiological studies have evaluated associations of platelet glycoprotein receptor alpha2beta1 integrin (ITGA2) and glycoprotein IIIa (ITGB3) gene polymorphisms with diabetic retinopathy (DR), but the published data are inconclusive.
p61936
sg49777
(lp61937
(dp61938
g49782
I124
sg49783
I2
sg49784
I17
sg49812
VP05106
p61939
sg49787
Vglycoprotein IIIa
p61940
sa(dp61941
g49782
I60
sg49783
I5
sg49784
I51
sg49812
VP14770
p61942
sg49787
Vplatelet glycoprotein receptor alpha2beta1 integrin
p61943
sa(dp61944
g49782
I143
sg49783
I1
sg49784
I5
sg49812
VP05106
p61945
sg49787
VITGB3
p61946
sa(dp61947
g49782
I113
sg49783
I1
sg49784
I5
sg49812
VP17301
p61948
sg49787
VITGA2
p61949
sasg49779
(lp61950
(dp61951
g49782
I174
sg49783
I2
sg49784
I20
sg49785
VC0011884
p61952
sg49787
Vdiabetic retinopathy
p61953
sa(dp61954
g49782
I196
sg49783
I1
sg49784
I2
sg49785
VC0011884
p61955
sg49787
VDR
p61956
sasa(dp61957
g49775
VGenetic polymorphisms of the alpha2beta1 integrin and glycoprotein IIIa (GPIIIa) have been associated with myocardial infarction, stroke, and diabetic retinopathy.
p61958
sg49777
(lp61959
(dp61960
g49782
I29
sg49783
I5
sg49784
I42
sg49812
VP05106
p61961
sg49787
Valpha2beta1 integrin and glycoprotein IIIa
p61962
sa(dp61963
g49782
I73
sg49783
I1
sg49784
I6
sg49812
VP05106
p61964
sg49787
VGPIIIa
p61965
sasg49779
(lp61966
(dp61967
g49782
I130
sg49783
I1
sg49784
I6
sg49785
VC0038454
p61968
sg49787
Vstroke
p61969
sa(dp61970
g49782
I142
sg49783
I2
sg49784
I20
sg49785
VC0011884
p61971
sg49787
Vdiabetic retinopathy
p61972
sa(dp61973
g49782
I107
sg49783
I2
sg49784
I21
sg49785
VC0027051
p61974
sg49787
Vmyocardial infarction
p61975
sasa(dp61976
g49775
VImmunostaining procedures were used to seek for the expression of the following 30 membrane antigens related to the immune system, using dendriform cells obtained in conjunctival specimens from 80 normal subjects and 105 with chronic conjunctivitis: class II antigens HLADR and DQ, CD1a (T6) and CD5, which usually mark Langerhans cells, macrophage markers CD14, CD36 and CD63, various lymphocyte antigens (CD2, CD4 and CD8), receptor to interleukin 2 (CD25), adhesion molecules and integrins (CD11a, CD11b, CD11c, CD18, CD29, CD41, CD61), the selectin CD62, ICAM-1 (CD54), ICAM-3 (CD50) and ELAM-1, CD45RO, related to activation of immune cells, and its ligand CD22, receptors to immunoglobulins (CD23 and CD32) and complement (CD21), transferrin receptor CD71, tryptase and vimentin, were thus investigated.
p61977
sg49777
(lp61978
(dp61979
g49782
I592
sg49783
I1
sg49784
I6
sg49812
VP16581
p61980
sg49787
VELAM-1
p61981
sa(dp61982
g49782
I296
sg49783
I1
sg49784
I3
sg49812
VP06127
p61983
sg49787
VCD5
p61984
sa(dp61985
g49782
I420
sg49783
I1
sg49784
I3
sg49812
VP01732
p61986
sg49787
VCD8
p61987
sa(dp61988
g49782
I527
sg49783
I1
sg49784
I4
sg49812
VP08514
p61989
sg49787
VCD41
p61990
sa(dp61991
g49782
I508
sg49783
I1
sg49784
I5
sg49812
VP20702
p61992
sg49787
VCD11c
p61993
sa(dp61994
g49782
I372
sg49783
I1
sg49784
I4
sg49812
VP08962
p61995
sg49787
VCD63
p61996
sa(dp61997
g49782
I494
sg49783
I1
sg49784
I5
sg49812
VP20701
p61998
sg49787
VCD11a
p61999
sa(dp62000
g49782
I438
sg49783
I2
sg49784
I13
sg49812
VP60568
p62001
sg49787
Vinterleukin 2
p62002
sa(dp62003
g49782
I501
sg49783
I1
sg49784
I5
sg49812
VP11215
p62004
sg49787
VCD11b
p62005
sa(dp62006
g49782
I707
sg49783
I1
sg49784
I4
sg49812
VP12318
p62007
sg49787
VCD32
p62008
sa(dp62009
g49782
I453
sg49783
I1
sg49784
I4
sg49812
VP01589
p62010
sg49787
VCD25
p62011
sa(dp62012
g49782
I412
sg49783
I1
sg49784
I3
sg49812
VP01730
p62013
sg49787
VCD4
p62014
sa(dp62015
g49782
I574
sg49783
I1
sg49784
I6
sg49812
VP32942
p62016
sg49787
VICAM-3
p62017
sa(dp62018
g49782
I698
sg49783
I1
sg49784
I4
sg49812
VP06734
p62019
sg49787
VCD23
p62020
sa(dp62021
g49782
I736
sg49783
I3
sg49784
I25
sg49812
VP02787
p62022
sg49787
Vtransferrin receptor CD71
p62023
sa(dp62024
g49782
I567
sg49783
I1
sg49784
I4
sg49812
VP05362
p62025
sg49787
VCD54
p62026
sa(dp62027
g49782
I515
sg49783
I1
sg49784
I4
sg49812
VP05107
p62028
sg49787
VCD18
p62029
sa(dp62030
g49782
I533
sg49783
I1
sg49784
I4
sg49812
VP05106
p62031
sg49787
VCD61
p62032
sa(dp62033
g49782
I559
sg49783
I1
sg49784
I6
sg49812
VP05362
p62034
sg49787
VICAM-1
p62035
sa(dp62036
g49782
I407
sg49783
I1
sg49784
I3
sg49812
VP06729
p62037
sg49787
VCD2
p62038
sa(dp62039
g49782
I282
sg49783
I1
sg49784
I4
sg49812
VP15813
p62040
sg49787
VCD1a
p62041
sa(dp62042
g49782
I681
sg49783
I1
sg49784
I15
sg49812
g11
sg49787
Vimmunoglobulins
p62043
sa(dp62044
g49782
I386
sg49783
I2
sg49784
I19
sg49812
VP30486
p62045
sg49787
Vlymphocyte antigens
p62046
sa(dp62047
g49782
I582
sg49783
I1
sg49784
I4
sg49812
VP32942
p62048
sg49787
VCD50
p62049
sa(dp62050
g49782
I729
sg49783
I1
sg49784
I4
sg49812
VP20023
p62051
sg49787
VCD21
p62052
sa(dp62053
g49782
I250
sg49783
I2
sg49784
I8
sg49812
g11
sg49787
Vclass II
p62054
sa(dp62055
g49782
I553
sg49783
I1
sg49784
I4
sg49812
VP16109
p62056
sg49787
VCD62
p62057
sa(dp62058
g49782
I357
sg49783
I1
sg49784
I4
sg49812
VP08571
p62059
sg49787
VCD14
p62060
sasg49779
(lp62061
(dp62062
g49782
I226
sg49783
I2
sg49784
I22
sg49785
VC0155145
p62063
sg49787
Vchronic conjunctivitis
p62064
sa(dp62065
g49782
I460
sg49783
I1
sg49784
I8
sg49785
VC0001511
p62066
sg49787
Vadhesion
p62067
sasa(dp62068
g49775
VIn order to elucidate the involvement of adhesion mechanisms in the process of megakaryocyte-dependent fibroblast growth, we applied BSA-coupled polymers of glucose, galactose, fucose, mannose, and several lectins (AAA, LCA, LTA, UEA-I) to cocultures of CD61 -positive (CD61+)/MACS-enriched megakaryocytes and human bone marrow fibroblasts.
p62069
sg49777
(lp62070
(dp62071
g49782
I254
sg49783
I2
sg49784
I14
sg49812
VP05106
p62072
sg49787
VCD61 -positive
p62073
sa(dp62074
g49782
I270
sg49783
I1
sg49784
I5
sg49812
VP05106
p62075
sg49787
VCD61+
p62076
sa(dp62077
g49782
I215
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VAAA
p62078
sa(dp62079
g49782
I133
sg49783
I1
sg49784
I3
sg49812
VP49639
p62080
sg49787
VBSA
p62081
sa(dp62082
g49782
I220
sg49783
I1
sg49784
I3
sg49812
VP09496
p62083
sg49787
VLCA
p62084
sa(dp62085
g49782
I225
sg49783
I1
sg49784
I3
sg49812
VP10515
p62086
sg49787
VLTA
p62087
sasg49779
(lp62088
(dp62089
g49782
I41
sg49783
I1
sg49784
I8
sg49785
VC0001511
p62090
sg49787
Vadhesion
p62091
sa(dp62092
g49782
I220
sg49783
I1
sg49784
I3
sg49785
VC0339527
p62093
sg49787
VLCA
p62094
sa(dp62095
g49782
I215
sg49783
I1
sg49784
I3
sg49785
VC0162871
p62096
sg49787
VAAA
p62097
sasa(dp62098
g49775
VComplications included pyogenic granuloma (10 patients, 24.4%), exposure keratopathy (7 patients, 17.1%) lagophthalmos (5 patients, 12.2%), ectropion (6 patients, 14.6%), lateral canthal dystopia (2 cases, 4.9%), eyelid notch (2 cases, 4.9%) and trichiasis (4 cases, 9.8%).
p62099
sg49777
(lp62100
sg49779
(lp62101
(dp62102
g49782
I23
sg49783
I2
sg49784
I18
sg49785
VC0085653
p62103
sg49787
Vpyogenic granuloma
p62104
sa(dp62105
g49782
I246
sg49783
I1
sg49784
I10
sg49785
VC0221259
p62106
sg49787
Vtrichiasis
p62107
sa(dp62108
g49782
I105
sg49783
I1
sg49784
I13
sg49785
VC0152226
p62109
sg49787
Vlagophthalmos
p62110
sa(dp62111
g49782
I64
sg49783
I2
sg49784
I20
sg49785
VC0339295
p62112
sg49787
Vexposure keratopathy
p62113
sa(dp62114
g49782
I140
sg49783
I1
sg49784
I9
sg49785
VC0013592
p62115
sg49787
Vectropion
p62116
sasa(dp62117
g49775
VComplications included eyelid margin notch (3 cases), persistent canthal dystopia (3 cases), trichiasis (2 cases), pyogenic granuloma (2 cases), eyelid margin nodule (1 case), lower eyelid elevation of 1 mm (1 case), and mild resolving medial lagophthalmos (1 case).
p62118
sg49777
(lp62119
sg49779
(lp62120
(dp62121
g49782
I159
sg49783
I1
sg49784
I6
sg49785
VC0028259
p62122
sg49787
Vnodule
p62123
sa(dp62124
g49782
I93
sg49783
I1
sg49784
I10
sg49785
VC0221259
p62125
sg49787
Vtrichiasis
p62126
sa(dp62127
g49782
I115
sg49783
I2
sg49784
I18
sg49785
VC0085653
p62128
sg49787
Vpyogenic granuloma
p62129
sa(dp62130
g49782
I243
sg49783
I1
sg49784
I13
sg49785
VC0152226
p62131
sg49787
Vlagophthalmos
p62132
sasa(dp62133
g49775
VAfter operation slight entropion occurred in 8 cases, slight ectropion in 3 cases, lagophthalmos for 2 -- 3 mm in 7 cases, notch of the palpebral margin in 5 cases and thinness of the donor tarsal plates in 4 cases, but the functional and aesthetic results were normal.
p62134
sg49777
(lp62135
sg49779
(lp62136
(dp62137
g49782
I23
sg49783
I1
sg49784
I9
sg49785
VC0014390
p62138
sg49787
Ventropion
p62139
sa(dp62140
g49782
I83
sg49783
I1
sg49784
I13
sg49785
VC0152226
p62141
sg49787
Vlagophthalmos
p62142
sa(dp62143
g49782
I61
sg49783
I1
sg49784
I9
sg49785
VC0013592
p62144
sg49787
Vectropion
p62145
sasa(dp62146
g49775
VWe screened the exons of RAY1/ST7 and ST7OT1-3 for sequence variants in 90 unrelated autism probands and identified several rare variants, including a Ile361Val substitution.
p62147
sg49777
(lp62148
(dp62149
g49782
I30
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VST7
p62150
sa(dp62151
g49782
I25
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VRAY1
p62152
sasg49779
(lp62153
(dp62154
g49782
I85
sg49783
I1
sg49784
I6
sg49785
VC0004352
p62155
sg49787
Vautism
p62156
sasa(dp62157
g49775
VSeveral signaling systems downstream of G-CSFR have been identified that are defective or hyperactivated in myeloid cells of patients with congenital neutropenia: severely reduced expression of myeloid-specific transcription factors LEF-1 and C/EBPAlfa, severely reduced expression and functions of HCLS1 protein, severely reduced expression of neutrophil elastase protein, dramatic compensatory up-regulation of the NAMPT/NAD(+)/SIRT pathway leading to continuous activation of emergency granulopoiesis via the transcription factor C/EBPBeta, and hyperactivation of STAT5 protein by tyrosine phosphorylation.
p62158
sg49777
(lp62159
(dp62160
g49782
I40
sg49783
I1
sg49784
I6
sg49812
VP07333
p62161
sg49787
VG-CSFR
p62162
sa(dp62163
g49782
I345
sg49783
I2
sg49784
I19
sg49812
VP08246
p62164
sg49787
Vneutrophil elastase
p62165
sa(dp62166
g49782
I299
sg49783
I2
sg49784
I13
sg49812
VP14317
p62167
sg49787
VHCLS1 protein
p62168
sa(dp62169
g49782
I512
sg49783
I3
sg49784
I30
sg49812
VP35398
p62170
sg49787
Vtranscription factor C/EBPBeta
p62171
sa(dp62172
g49782
I194
sg49783
I4
sg49784
I44
sg49812
g11
sg49787
Vmyeloid-specific transcription factors LEF-1
p62173
sa(dp62174
g49782
I567
sg49783
I2
sg49784
I13
sg49812
VP42229
p62175
sg49787
VSTAT5 protein
p62176
sasg49779
(lp62177
(dp62178
g49782
I139
sg49783
I2
sg49784
I22
sg49785
VC0340970
p62179
sg49787
Vcongenital neutropenia
p62180
sa(dp62181
g49782
I479
sg49783
I1
sg49784
I9
sg49785
VC2745965
p62182
sg49787
Vemergency
p62183
sa(dp62184
g49782
I423
sg49783
I1
sg49784
I3
sg49785
VC1850380
p62185
sg49787
VNAD
p62186
sasa(dp62187
g49775
VWe observed spontaneous osteoclastogenesis with a significant increase in OC formation and bone resorbing activity in late-stage CKD and HD patients when compared with early-stage CKD patients and healthy donors, likely due to an increased expression of RANKL and LIGHT (homologous to Lymphotoxins exhibiting Inducible expression and competing with herpes simplex virus Glycoprotein D for herpes virus entry mediator [HVEM], a receptor expressed by T lymphocytes) in PBMCs.
p62188
sg49777
(lp62189
(dp62190
g49782
I264
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VLIGHT
p62191
sa(dp62192
g49782
I254
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VRANKL
p62193
sasg49779
(lp62194
(dp62195
g49782
I349
sg49783
I2
sg49784
I14
sg49785
VC0019348
p62196
sg49787
Vherpes simplex
p62197
sa(dp62198
g49782
I349
sg49783
I1
sg49784
I6
sg49785
VC0019340
p62199
sg49787
Vherpes
p62200
sasa(dp62201
g49775
VHealthy individuals of African ancestry have neutropenia that has been linked with the variant rs2814778(G) of the gene encoding atypical chemokine receptor 1 (ACKR1).
p62202
sg49777
(lp62203
(dp62204
g49782
I115
sg49783
I6
sg49784
I43
sg49812
VP61073
p62205
sg49787
Vgene encoding atypical chemokine receptor 1
p62206
sasg49779
(lp62207
sa(dp62208
g49775
VHere we describe an unexpected fundamental role for ACKR1 in hematopoiesis and provide the mechanism that links its absence with neutropenia.
p62209
sg49777
(lp62210
sg49779
(lp62211
sa(dp62212
g49775
VThe absence of erythroid ACKR1 altered mouse hematopoiesis including stem and progenitor cells, which ultimately gave rise to phenotypically distinct neutrophils that readily left the circulation, causing neutropenia.
p62213
sg49777
(lp62214
(dp62215
g49782
I15
sg49783
I2
sg49784
I15
sg49812
VP22557
p62216
sg49787
Verythroid ACKR1
p62217
sasg49779
(lp62218
sa(dp62219
g49775
VIn vivo studies in Adult Dark Agouti (DA) rats with unilateral surgically-induced ocular hypertension (OHT) treated with either CoQ10/TPGS micelles or TPGS vehicle twice daily for three weeks were performed, following which retinal cell health was assessed in vivo using DARC (Detection of Apoptotic Retinal Cells) and post-mortem with Brn3a histological assessment on whole retinal mounts.
p62220
sg49777
(lp62221
(dp62222
g49782
I271
sg49783
I1
sg49784
I4
sg49812
VP55283
p62223
sg49787
VDARC
p62224
sa(dp62225
g49782
I277
sg49783
I5
sg49784
I36
sg49812
VP55283
p62226
sg49787
VDetection of Apoptotic Retinal Cells
p62227
sa(dp62228
g49782
I336
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VBrn3a
p62229
sasg49779
(lp62230
(dp62231
g49782
I103
sg49783
I1
sg49784
I3
sg49785
VC0028840
p62232
sg49787
VOHT
p62233
sa(dp62234
g49782
I82
sg49783
I2
sg49784
I19
sg49785
VC0028840
p62235
sg49787
Vocular hypertension
p62236
sasa(dp62237
g49775
VAfter correction for multiple testing, DARC polymorphism rs3027012 in 5'-UTR was associated with higher risk of low absolute phagocyte count (APC&lt;500 and &lt;1000 cells per microliter, P=0.001 and P&lt;0.0005, respectively) and hospitalization due to febrile neutropenia (P=0.002).
p62238
sg49777
(lp62239
sg49779
(lp62240
(dp62241
g49782
I254
sg49783
I2
sg49784
I19
sg49785
VC0746883
p62242
sg49787
Vfebrile neutropenia
p62243
sa(dp62244
g49782
I142
sg49783
I1
sg49784
I3
sg49785
VC0033036
p62245
sg49787
VAPC
p62246
sasa(dp62247
g49775
VWe examined the effects of PR and EZ on NPC1L1, ABCG5, and ABCG8 expression in human hepatoma HepG2 cells and the murine small intestine.
p62248
sg49777
(lp62249
(dp62250
g49782
I40
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VNPC1L1
p62251
sa(dp62252
g49782
I48
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VABCG5
p62253
sa(dp62254
g49782
I59
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VABCG8
p62255
sasg49779
(lp62256
(dp62257
g49782
I85
sg49783
I1
sg49784
I8
sg49785
VC0023903
p62258
sg49787
Vhepatoma
p62259
sasa(dp62260
g49775
VIn addition, knockdown of epigenetic regulator UHRF1 (ubiquitin-like, containing PHD and RING finger domains 1) in RIP3-null cancer cells reduces the methylation level of the Rip3 promoter.
p62261
sg49777
(lp62262
(dp62263
g49782
I115
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VRIP3
p62264
sa(dp62265
g49782
I175
sg49783
I2
sg49784
I13
sg49812
g11
sg49787
VRip3 promoter
p62266
sa(dp62267
g49782
I81
sg49783
I1
sg49784
I3
sg49812
VP20941
p62268
sg49787
VPHD
p62269
sa(dp62270
g49782
I54
sg49783
I1
sg49784
I9
sg49812
VP62979
p62271
sg49787
Vubiquitin
p62272
sa(dp62273
g49782
I47
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VUHRF1
p62274
sasg49779
(lp62275
(dp62276
g49782
I125
sg49783
I1
sg49784
I6
sg49785
VC0006826
p62277
sg49787
Vcancer
p62278
sasa(dp62279
g49775
VA previous study revealed that ubiquitin-like with PHD and RING finger domains 1 (UHRF1) promoted cell proliferation and was a potential biomarker in medulloblastoma (MB).
p62280
sg49777
(lp62281
(dp62282
g49782
I82
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VUHRF1
p62283
sa(dp62284
g49782
I31
sg49783
I8
sg49784
I49
sg49812
g11
sg49787
Vubiquitin-like with PHD and RING finger domains 1
p62285
sasg49779
(lp62286
(dp62287
g49782
I150
sg49783
I1
sg49784
I15
sg49785
VC0025149
p62288
sg49787
Vmedulloblastoma
p62289
sa(dp62290
g49782
I103
sg49783
I1
sg49784
I13
sg49785
VC0334094
p62291
sg49787
Vproliferation
p62292
sa(dp62293
g49782
I167
sg49783
I1
sg49784
I2
sg49785
VC0025149
p62294
sg49787
VMB
p62295
sasa(dp62296
g49775
VThree lncRNAs, sex determining region Y-box 2 overlapping transcript (SOX2-OT), NCBP2 antisense RNA 2 (NCBP2-AS2) and ubiquitin like with PHD and ring finger domains 1 (UHRF1), were predicted to be associated with lung cancer; RT-qPCR confirmed that SOX2-OT and NCBP2-AS2 were associated with lung cancer.
p62297
sg49777
(lp62298
(dp62299
g49782
I118
sg49783
I9
sg49784
I49
sg49812
g11
sg49787
Vubiquitin like with PHD and ring finger domains 1
p62300
sa(dp62301
g49782
I169
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VUHRF1
p62302
sa(dp62303
g49782
I103
sg49783
I1
sg49784
I9
sg49812
VP52298
p62304
sg49787
VNCBP2-AS2
p62305
sa(dp62306
g49782
I70
sg49783
I1
sg49784
I7
sg49812
VP48431
p62307
sg49787
VSOX2-OT
p62308
sa(dp62309
g49782
I103
sg49783
I1
sg49784
I9
sg49812
VP52298
p62310
sg49787
VNCBP2-AS2
p62311
sa(dp62312
g49782
I80
sg49783
I4
sg49784
I21
sg49812
VP52298
p62313
sg49787
VNCBP2 antisense RNA 2
p62314
sa(dp62315
g49782
I15
sg49783
I7
sg49784
I53
sg49812
VP48431
p62316
sg49787
Vsex determining region Y-box 2 overlapping transcript
p62317
sa(dp62318
g49782
I70
sg49783
I1
sg49784
I7
sg49812
VP48431
p62319
sg49787
VSOX2-OT
p62320
sasg49779
(lp62321
(dp62322
g49782
I214
sg49783
I2
sg49784
I11
sg49785
VC0684249
p62323
sg49787
Vlung cancer
p62324
sa(dp62325
g49782
I214
sg49783
I2
sg49784
I11
sg49785
VC0684249
p62326
sg49787
Vlung cancer
p62327
sasa(dp62328
g49775
VUHRF1 (ubiquitin-like, with PHD and RING finger domains 1) plays a crucial role in DNA methylation, chromatin remodeling and gene expression and is aberrantly upregulated in various types of human cancers.
p62329
sg49777
(lp62330
(dp62331
g49782
I28
sg49783
I1
sg49784
I3
sg49812
VP20941
p62332
sg49787
VPHD
p62333
sa(dp62334
g49782
I7
sg49783
I1
sg49784
I14
sg49812
VP62979
p62335
sg49787
Vubiquitin-like
p62336
sa(dp62337
g49782
I0
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VUHRF1
p62338
sasg49779
(lp62339
(dp62340
g49782
I197
sg49783
I1
sg49784
I7
sg49785
VC0006826
p62341
sg49787
Vcancers
p62342
sasa(dp62343
g49775
VUHRF1 (ubiquitin-like with PHD and RING finger domains 1) is a critical regulator for DNA methylation, and its frequent overexpression in human cancers has been associated with tumor-promoting effects.
p62344
sg49777
(lp62345
(dp62346
g49782
I0
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VUHRF1
p62347
sa(dp62348
g49782
I7
sg49783
I8
sg49784
I49
sg49812
VP20941
p62349
sg49787
Vubiquitin-like with PHD and RING finger domains 1
p62350
sasg49779
(lp62351
(dp62352
g49782
I177
sg49783
I1
sg49784
I5
sg49785
VC0027651
p62353
sg49787
Vtumor
p62354
sa(dp62355
g49782
I144
sg49783
I1
sg49784
I7
sg49785
VC0006826
p62356
sg49787
Vcancers
p62357
sasa(dp62358
g49775
VThe lower level of PHRF1 mRNA was observed in human lung cancer tissues than that in paracancerous tissues.
p62359
sg49777
(lp62360
(dp62361
g49782
I19
sg49783
I2
sg49784
I10
sg49812
g11
sg49787
VPHRF1 mRNA
p62362
sasg49779
(lp62363
(dp62364
g49782
I52
sg49783
I2
sg49784
I11
sg49785
VC0684249
p62365
sg49787
Vlung cancer
p62366
sasa(dp62367
g49775
VIn conclusion, our findings suggest that overexpression of PHRF1 attenuated the proliferation and tumorigenicity of non-small cell lung cancer cell line of H1299.
p62368
sg49777
(lp62369
(dp62370
g49782
I59
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPHRF1
p62371
sasg49779
(lp62372
(dp62373
g49782
I98
sg49783
I1
sg49784
I14
sg49785
VC1519697
p62374
sg49787
Vtumorigenicity
p62375
sa(dp62376
g49782
I80
sg49783
I1
sg49784
I13
sg49785
VC0334094
p62377
sg49787
Vproliferation
p62378
sa(dp62379
g49782
I116
sg49783
I4
sg49784
I26
sg49785
VC0007131
p62380
sg49787
Vnon-small cell lung cancer
p62381
sasa(dp62382
g49775
VRecessive mutations in ORC1, ORC4, ORC6, CDT1 or CDC6 of the preRC in human cause Meier-Gorlin syndrome (MGS) that is characterized by impaired post-natal growth, short stature and microcephaly.
p62383
sg49777
(lp62384
(dp62385
g49782
I35
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VORC6
p62386
sa(dp62387
g49782
I49
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VCDC6
p62388
sa(dp62389
g49782
I23
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VORC1
p62390
sa(dp62391
g49782
I41
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VCDT1
p62392
sa(dp62393
g49782
I29
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VORC4
p62394
sasg49779
(lp62395
(dp62396
g49782
I181
sg49783
I1
sg49784
I12
sg49785
VC0025958
p62397
sg49787
Vmicrocephaly
p62398
sa(dp62399
g49782
I135
sg49783
I1
sg49784
I8
sg49785
VC0684336
p62400
sg49787
Vimpaired
p62401
sa(dp62402
g49782
I82
sg49783
I2
sg49784
I21
sg49785
VC1868684
p62403
sg49787
VMeier-Gorlin syndrome
p62404
sa(dp62405
g49782
I105
sg49783
I1
sg49784
I3
sg49785
VC1969653
p62406
sg49787
VMGS
p62407
sa(dp62408
g49782
I163
sg49783
I2
sg49784
I13
sg49785
VC0013336
p62409
sg49787
Vshort stature
p62410
sasa(dp62411
g49775
VMutations in ORC1, ORC4, ORC6, CDT1, and CDC6, which encode proteins required for DNA replication origin licensing, cause Meier-Gorlin syndrome (MGS), a disorder conferring microcephaly, primordial dwarfism, underdeveloped ears, and skeletal abnormalities.
p62412
sg49777
(lp62413
(dp62414
g49782
I41
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VCDC6
p62415
sa(dp62416
g49782
I31
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VCDT1
p62417
sa(dp62418
g49782
I25
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VORC6
p62419
sa(dp62420
g49782
I13
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VORC1
p62421
sa(dp62422
g49782
I19
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VORC4
p62423
sasg49779
(lp62424
(dp62425
g49782
I145
sg49783
I1
sg49784
I3
sg49785
VC1969653
p62426
sg49787
VMGS
p62427
sa(dp62428
g49782
I187
sg49783
I2
sg49784
I19
sg49785
VC0013336
p62429
sg49787
Vprimordial dwarfism
p62430
sa(dp62431
g49782
I173
sg49783
I1
sg49784
I12
sg49785
VC0025958
p62432
sg49787
Vmicrocephaly
p62433
sa(dp62434
g49782
I122
sg49783
I2
sg49784
I21
sg49785
VC1868684
p62435
sg49787
VMeier-Gorlin syndrome
p62436
sasa(dp62437
g49775
VSignificantly higher concentrations of HMGB1 were found in nasal secretions from patients with chronic rhinosinusitis with nasal polyp or allergic rhinitis compared with the control subjects.
p62438
sg49777
(lp62439
(dp62440
g49782
I39
sg49783
I1
sg49784
I5
sg49812
VP09429
p62441
sg49787
VHMGB1
p62442
sasg49779
(lp62443
(dp62444
g49782
I123
sg49783
I2
sg49784
I11
sg49785
VC0027430
p62445
sg49787
Vnasal polyp
p62446
sa(dp62447
g49782
I95
sg49783
I2
sg49784
I22
sg49785
VC0149516
p62448
sg49787
Vchronic rhinosinusitis
p62449
sa(dp62450
g49782
I138
sg49783
I2
sg49784
I17
sg49785
VC2607914
p62451
sg49787
Vallergic rhinitis
p62452
sasa(dp62453
g49775
VPrevious studies have shown that HMGB1 is elevated in the nasal lavage fluids (NLF) of children suffering from allergic rhinitis (AR) and is associated with the severity of this disease.
p62454
sg49777
(lp62455
(dp62456
g49782
I33
sg49783
I1
sg49784
I5
sg49812
VP09429
p62457
sg49787
VHMGB1
p62458
sasg49779
(lp62459
(dp62460
g49782
I96
sg49783
I1
sg49784
I9
sg49785
VC0683278
p62461
sg49787
Vsuffering
p62462
sa(dp62463
g49782
I130
sg49783
I1
sg49784
I2
sg49785
VC2607914
p62464
sg49787
VAR
p62465
sa(dp62466
g49782
I111
sg49783
I2
sg49784
I17
sg49785
VC2607914
p62467
sg49787
Vallergic rhinitis
p62468
sasa(dp62469
g49775
VThe major cystinosis mutation is a 57 kb deletion on human chromosome 17p13 that removes the majority of CTNS and the entire adjacent gene, CARKL/SHPK.
p62470
sg49777
(lp62471
(dp62472
g49782
I140
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCARKL
p62473
sa(dp62474
g49782
I146
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VSHPK
p62475
sasg49779
(lp62476
(dp62477
g49782
I105
sg49783
I1
sg49784
I4
sg49785
VC0015624
p62478
sg49787
VCTNS
p62479
sa(dp62480
g49782
I10
sg49783
I1
sg49784
I10
sg49785
VC0010690
p62481
sg49787
Vcystinosis
p62482
sasa(dp62483
g49775
VThe most common mutation in the nephropathic cystinosis (CTNS) gene is a homozygous 57-kb deletion that also includes an adjacent gene carbohydrate kinase-like (CARKL).
p62484
sg49777
(lp62485
(dp62486
g49782
I161
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCARKL
p62487
sa(dp62488
g49782
I135
sg49783
I2
sg49784
I24
sg49812
g11
sg49787
Vcarbohydrate kinase-like
p62489
sasg49779
(lp62490
(dp62491
g49782
I57
sg49783
I1
sg49784
I4
sg49785
VC0015624
p62492
sg49787
VCTNS
p62493
sa(dp62494
g49782
I32
sg49783
I2
sg49784
I23
sg49785
VC0015624
p62495
sg49787
Vnephropathic cystinosis
p62496
sasa(dp62497
g49775
VAnalysis of the resulting data revealed a number of interesting features about this genomic region, including the long-range organization of CTNS, insight about the breakpoints and intervening DNA associated with the common cystinosis-causing deletion, and structural information about five genes neighboring CTNS (human ortholog of rat vanilloid receptor subtype 1 gene, CARKL, TIP-1, P2X5, and HUMINAE).
p62498
sg49777
(lp62499
(dp62500
g49782
I141
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VCTNS
p62501
sa(dp62502
g49782
I372
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCARKL
p62503
sa(dp62504
g49782
I379
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTIP-1
p62505
sa(dp62506
g49782
I386
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VP2X5
p62507
sa(dp62508
g49782
I333
sg49783
I6
sg49784
I37
sg49812
g11
sg49787
Vrat vanilloid receptor subtype 1 gene
p62509
sasg49779
(lp62510
(dp62511
g49782
I141
sg49783
I1
sg49784
I4
sg49785
VC0015624
p62512
sg49787
VCTNS
p62513
sa(dp62514
g49782
I224
sg49783
I1
sg49784
I10
sg49785
VC0010690
p62515
sg49787
Vcystinosis
p62516
sa(dp62517
g49782
I141
sg49783
I1
sg49784
I4
sg49785
VC0015624
p62518
sg49787
VCTNS
p62519
sasa(dp62520
g49775
VIn particular, sequence analysis detected the presence of a novel gene (CARKL) residing within the most common cystinosis-causing deletion.
p62521
sg49777
(lp62522
(dp62523
g49782
I72
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCARKL
p62524
sasg49779
(lp62525
(dp62526
g49782
I111
sg49783
I1
sg49784
I10
sg49785
VC0010690
p62527
sg49787
Vcystinosis
p62528
sasa(dp62529
g49775
VInterestingly, both CTNS and CARKL are absent in nearly half of all cystinosis patients (i.e., those homozygous for the common deletion).
p62530
sg49777
(lp62531
(dp62532
g49782
I20
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VCTNS
p62533
sa(dp62534
g49782
I29
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCARKL
p62535
sasg49779
(lp62536
(dp62537
g49782
I68
sg49783
I1
sg49784
I10
sg49785
VC0010690
p62538
sg49787
Vcystinosis
p62539
sa(dp62540
g49782
I20
sg49783
I1
sg49784
I4
sg49785
VC0015624
p62541
sg49787
VCTNS
p62542
sasa(dp62543
g49775
VThere is limited evidence regarding interactions between pulmonary (dys)function, posture, and mobility of the upper body quadrant in patients with chronic obstructive pulmonary disease (COPD).
p62544
sg49777
(lp62545
sg49779
(lp62546
(dp62547
g49782
I187
sg49783
I1
sg49784
I4
sg49785
VC0024117
p62548
sg49787
VCOPD
p62549
sa(dp62550
g49782
I68
sg49783
I1
sg49784
I3
sg49785
VC0013364
p62551
sg49787
Vdys
p62552
sa(dp62553
g49782
I148
sg49783
I4
sg49784
I37
sg49785
VC0024117
p62554
sg49787
Vchronic obstructive pulmonary disease
p62555
sasa(dp62556
g49775
VBackground There is limited evidence regarding interactions between pulmonary (dys)function, posture, and mobility of the upper body quadrant in patients with chronic obstructive pulmonary disease (COPD).
p62557
sg49777
(lp62558
sg49779
(lp62559
(dp62560
g49782
I79
sg49783
I1
sg49784
I3
sg49785
VC0013364
p62561
sg49787
Vdys
p62562
sa(dp62563
g49782
I198
sg49783
I1
sg49784
I4
sg49785
VC0024117
p62564
sg49787
VCOPD
p62565
sa(dp62566
g49782
I159
sg49783
I4
sg49784
I37
sg49785
VC0024117
p62567
sg49787
Vchronic obstructive pulmonary disease
p62568
sasa(dp62569
g49775
VRecent progress in our understanding of the developmental regulation of this tissue, the differentiation pathways, recognition of pathogens and antimicrobial responses is now exploited to help understand how epithelial cell function and dysfunction contributes to the pathogenesis of a variety of inflammatory lung diseases.
p62570
sg49777
(lp62571
sg49779
(lp62572
(dp62573
g49782
I310
sg49783
I2
sg49784
I13
sg49785
VC0024115
p62574
sg49787
Vlung diseases
p62575
sa(dp62576
g49782
I268
sg49783
I1
sg49784
I12
sg49785
VC0699748
p62577
sg49787
Vpathogenesis
p62578
sasa(dp62579
g49775
VHerein, advances in our knowledge of the biology of airway epithelium, as well as its role and (dys)function in asthma, chronic obstructive pulmonary fibrosis and cystic fibrosis will be discussed.
p62580
sg49777
(lp62581
sg49779
(lp62582
(dp62583
g49782
I163
sg49783
I2
sg49784
I15
sg49785
VC0010674
p62584
sg49787
Vcystic fibrosis
p62585
sa(dp62586
g49782
I96
sg49783
I1
sg49784
I3
sg49785
VC0013364
p62587
sg49787
Vdys
p62588
sa(dp62589
g49782
I112
sg49783
I1
sg49784
I6
sg49785
VC0004096
p62590
sg49787
Vasthma
p62591
sa(dp62592
g49782
I140
sg49783
I2
sg49784
I18
sg49785
VC0034069
p62593
sg49787
Vpulmonary fibrosis
p62594
sasa(dp62595
g49775
VManaging neurogenic dysphagia with effective protection of the airway passages and prompt treatment of aspiration pneumonias is necessary to prevent respiratory failure.
p62596
sg49777
(lp62597
sg49779
(lp62598
(dp62599
g49782
I103
sg49783
I2
sg49784
I21
sg49785
VC0032290
p62600
sg49787
Vaspiration pneumonias
p62601
sa(dp62602
g49782
I9
sg49783
I2
sg49784
I20
sg49785
VC1955520
p62603
sg49787
Vneurogenic dysphagia
p62604
sa(dp62605
g49782
I149
sg49783
I2
sg49784
I19
sg49785
VC1145670
p62606
sg49787
Vrespiratory failure
p62607
sasa(dp62608
g49775
VMultivariate analysis identified four independent risk factors for mortality in patients with severe sepsis and septic shock: three or more organ dysfunctions (OR, 3.212; 95% CI, 1.585-6.506; p&lt;0.001), acute respiratory failure (OR, 2.649 95% CI, 1.327-5.287; p=0.006), positive blood culture (OR, 2.708; 95% CI, 1.289-5.689; p=0.009) and chronic heart failure (OR, 2.112; 95% CI, 1.036-4.308; p=0.040).
p62609
sg49777
(lp62610
sg49779
(lp62611
(dp62612
g49782
I112
sg49783
I2
sg49784
I12
sg49785
VC0036983
p62613
sg49787
Vseptic shock
p62614
sa(dp62615
g49782
I205
sg49783
I3
sg49784
I25
sg49785
VC0264490
p62616
sg49787
Vacute respiratory failure
p62617
sa(dp62618
g49782
I342
sg49783
I3
sg49784
I21
sg49785
VC0264716
p62619
sg49787
Vchronic heart failure
p62620
sa(dp62621
g49782
I94
sg49783
I2
sg49784
I13
sg49785
VC1719672
p62622
sg49787
Vsevere sepsis
p62623
sasa(dp62624
g49775
VOur results highlight the importance of three or more organ dys-functions, acute respiratory failure, positive blood culture and chronic heart failure as independent risk factors for mortality in the first 24 hours after admission in patients with severe sepsis and septic shock.
p62625
sg49777
(lp62626
sg49779
(lp62627
(dp62628
g49782
I248
sg49783
I2
sg49784
I13
sg49785
VC1719672
p62629
sg49787
Vsevere sepsis
p62630
sa(dp62631
g49782
I266
sg49783
I2
sg49784
I12
sg49785
VC0036983
p62632
sg49787
Vseptic shock
p62633
sa(dp62634
g49782
I75
sg49783
I3
sg49784
I25
sg49785
VC0264490
p62635
sg49787
Vacute respiratory failure
p62636
sa(dp62637
g49782
I129
sg49783
I3
sg49784
I21
sg49785
VC0264716
p62638
sg49787
Vchronic heart failure
p62639
sa(dp62640
g49782
I60
sg49783
I1
sg49784
I3
sg49785
VC0013364
p62641
sg49787
Vdys
p62642
sasa(dp62643
g49775
VThis review briefly touches on CF genetics as it applies to lung disease and will focus on the current hypotheses of CFTR (dys)function and its impact on pulmonary fluid homeostasis.
p62644
sg49777
(lp62645
(dp62646
g49782
I117
sg49783
I1
sg49784
I4
sg49812
VP13569
p62647
sg49787
VCFTR
p62648
sa(dp62649
g49782
I123
sg49783
I1
sg49784
I3
sg49812
VP11532
p62650
sg49787
Vdys
p62651
sasg49779
(lp62652
(dp62653
g49782
I123
sg49783
I1
sg49784
I3
sg49785
VC0013364
p62654
sg49787
Vdys
p62655
sa(dp62656
g49782
I60
sg49783
I2
sg49784
I12
sg49785
VC0024115
p62657
sg49787
Vlung disease
p62658
sasa(dp62659
g49775
VTo investigate the expression of the CDH13 gene and BCR/ABL fusion gene in chronic myeloid leukemia(CML) patients at different stages and explore their relationship.
p62660
sg49777
(lp62661
(dp62662
g49782
I52
sg49783
I1
sg49784
I3
sg49812
VP11274
p62663
sg49787
VBCR
p62664
sa(dp62665
g49782
I37
sg49783
I2
sg49784
I10
sg49812
VP55290
p62666
sg49787
VCDH13 gene
p62667
sa(dp62668
g49782
I56
sg49783
I1
sg49784
I3
sg49812
VP55157
p62669
sg49787
VABL
p62670
sasg49779
(lp62671
(dp62672
g49782
I100
sg49783
I1
sg49784
I3
sg49785
VC0023473
p62673
sg49787
VCML
p62674
sa(dp62675
g49782
I56
sg49783
I1
sg49784
I3
sg49785
VC0000744
p62676
sg49787
VABL
p62677
sa(dp62678
g49782
I75
sg49783
I3
sg49784
I24
sg49785
VC0023473
p62679
sg49787
Vchronic myeloid leukemia
p62680
sasa(dp62681
g49775
VWe performed genomewide screening for methylated CpG islands and identified 8 genes frequently methylated in leukemia cell lines and in patients with acute myeloid leukemia (AML): NOR1, CDH13, p15, NPM2, OLIG2, PGR, HIN1, and SLC26A4.
p62682
sg49777
(lp62683
(dp62684
g49782
I198
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNPM2
p62685
sa(dp62686
g49782
I204
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VOLIG2
p62687
sa(dp62688
g49782
I180
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNOR1
p62689
sa(dp62690
g49782
I186
sg49783
I1
sg49784
I5
sg49812
VP55290
p62691
sg49787
VCDH13
p62692
sa(dp62693
g49782
I226
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VSLC26A4
p62694
sa(dp62695
g49782
I216
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VHIN1
p62696
sa(dp62697
g49782
I211
sg49783
I1
sg49784
I3
sg49812
VP06401
p62698
sg49787
VPGR
p62699
sa(dp62700
g49782
I193
sg49783
I1
sg49784
I3
sg49812
VP53999
p62701
sg49787
Vp15
p62702
sasg49779
(lp62703
(dp62704
g49782
I150
sg49783
I3
sg49784
I22
sg49785
VC0023467
p62705
sg49787
Vacute myeloid leukemia
p62706
sa(dp62707
g49782
I174
sg49783
I1
sg49784
I3
sg49785
VC0023467
p62708
sg49787
VAML
p62709
sa(dp62710
g49782
I109
sg49783
I1
sg49784
I8
sg49785
VC0023418
p62711
sg49787
Vleukemia
p62712
sasa(dp62713
g49775
VAlthough defective progenitor-stromal adhesion is a well-recognized feature of chronic myeloid leukemia (CML), the role of CDH13 abnormalities has not been evaluated in this disease.
p62714
sg49777
(lp62715
(dp62716
g49782
I123
sg49783
I1
sg49784
I5
sg49812
VP55290
p62717
sg49787
VCDH13
p62718
sasg49779
(lp62719
(dp62720
g49782
I38
sg49783
I1
sg49784
I8
sg49785
VC0001511
p62721
sg49787
Vadhesion
p62722
sa(dp62723
g49782
I105
sg49783
I1
sg49784
I3
sg49785
VC0023473
p62724
sg49787
VCML
p62725
sa(dp62726
g49782
I79
sg49783
I3
sg49784
I24
sg49785
VC0023473
p62727
sg49787
Vchronic myeloid leukemia
p62728
sasa(dp62729
g49775
VRecent work from our laboratory suggested pIgR may be upregulated in pancreatic ductal adenocarcinoma (PDAC).
p62730
sg49777
(lp62731
(dp62732
g49782
I42
sg49783
I1
sg49784
I4
sg49812
VP01833
p62733
sg49787
VpIgR
p62734
sasg49779
(lp62735
(dp62736
g49782
I103
sg49783
I1
sg49784
I4
sg49785
VC1335302
p62737
sg49787
VPDAC
p62738
sa(dp62739
g49782
I69
sg49783
I3
sg49784
I32
sg49785
VC1335302
p62740
sg49787
Vpancreatic ductal adenocarcinoma
p62741
sasa(dp62742
g49775
VIn this work we investigated the expression of the SERCA3-type calcium pump in choroid plexus epithelial cells grown in vitro, and in normal and hyperplastic choroid plexus tissue, in choroid plexus papillomas displaying various degrees of atypia, and in choroid plexus carcinoma by immunohistochemistry in situ.
p62743
sg49777
(lp62744
sg49779
(lp62745
(dp62746
g49782
I255
sg49783
I3
sg49784
I24
sg49785
VC0431109
p62747
sg49787
Vchoroid plexus carcinoma
p62748
sa(dp62749
g49782
I145
sg49783
I1
sg49784
I12
sg49785
VC0020507
p62750
sg49787
Vhyperplastic
p62751
sa(dp62752
g49782
I184
sg49783
I3
sg49784
I25
sg49785
VC0205770
p62753
sg49787
Vchoroid plexus papillomas
p62754
sasa(dp62755
g49775
VWhereas normal choroid plexus epithelial cells express SERCA3 abundantly, SERCA3 expression is strongly decreased in papillomas, and is absent in choroid plexus carcinoma, while expression in hyperplastic epithelium is high, similarly to normal epithelium.
p62756
sg49777
(lp62757
sg49779
(lp62758
(dp62759
g49782
I117
sg49783
I1
sg49784
I10
sg49785
VC0030354
p62760
sg49787
Vpapillomas
p62761
sa(dp62762
g49782
I192
sg49783
I1
sg49784
I12
sg49785
VC0020507
p62763
sg49787
Vhyperplastic
p62764
sa(dp62765
g49782
I146
sg49783
I3
sg49784
I24
sg49785
VC0431109
p62766
sg49787
Vchoroid plexus carcinoma
p62767
sasa(dp62768
g49775
VDue to the inverse interaction of Rac1 and Ras homolog family member A (RhoA) signaling in the transition between mesenchymal and amoeboid morphology, simultaneous treatment of NSC23766 and Y27632 (selective Rho associated coiled-coil containing protein kinase 1 inhibitor), abolished U87 GBM cell migration through inhibiting MAT and amoeboid-mesenchymal transition.
p62769
sg49777
(lp62770
(dp62771
g49782
I285
sg49783
I2
sg49784
I7
sg49812
g11
sg49787
VU87 GBM
p62772
sa(dp62773
g49782
I327
sg49783
I1
sg49784
I3
sg49812
VP24752
p62774
sg49787
VMAT
p62775
sa(dp62776
g49782
I43
sg49783
I5
sg49784
I27
sg49812
VP01116
p62777
sg49787
VRas homolog family member A
p62778
sa(dp62779
g49782
I34
sg49783
I1
sg49784
I4
sg49812
VP63000
p62780
sg49787
VRac1
p62781
sa(dp62782
g49782
I72
sg49783
I1
sg49784
I4
sg49812
VP61586
p62783
sg49787
VRhoA
p62784
sa(dp62785
g49782
I223
sg49783
I5
sg49784
I39
sg49812
VP38432
p62786
sg49787
Vcoiled-coil containing protein kinase 1
p62787
sa(dp62788
g49782
I72
sg49783
I1
sg49784
I3
sg49812
VP08100
p62789
sg49787
VRho
p62790
sasg49779
(lp62791
(dp62792
g49782
I289
sg49783
I1
sg49784
I3
sg49785
VC0017636
p62793
sg49787
VGBM
p62794
sa(dp62795
g49782
I95
sg49783
I1
sg49784
I10
sg49785
VC0599156
p62796
sg49787
Vtransition
p62797
sa(dp62798
g49782
I95
sg49783
I1
sg49784
I10
sg49785
VC0599156
p62799
sg49787
Vtransition
p62800
sasa(dp62801
g49775
VThe combined inhibition of Rac1 and RhoA signaling would be a promising strategy to suppress GBM invasion.
p62802
sg49777
(lp62803
(dp62804
g49782
I36
sg49783
I1
sg49784
I4
sg49812
VP61586
p62805
sg49787
VRhoA
p62806
sa(dp62807
g49782
I27
sg49783
I1
sg49784
I4
sg49812
VP63000
p62808
sg49787
VRac1
p62809
sasg49779
(lp62810
(dp62811
g49782
I97
sg49783
I1
sg49784
I8
sg49785
VC2699153
p62812
sg49787
Vinvasion
p62813
sa(dp62814
g49782
I93
sg49783
I1
sg49784
I3
sg49785
VC0017636
p62815
sg49787
VGBM
p62816
sasa(dp62817
g49775
VSpecifically, combination therapy inhibited TLR7 expression in the kidneys of mice with lupus nephritis; combination of tacrolimus and mycophenolate mofetil led to better stabilization of the podocyte actin cytoskeleton through the reciprocal regulation of RhoA and Rac1 activities.
p62818
sg49777
(lp62819
(dp62820
g49782
I44
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR7
p62821
sa(dp62822
g49782
I257
sg49783
I1
sg49784
I4
sg49812
VP61586
p62823
sg49787
VRhoA
p62824
sa(dp62825
g49782
I266
sg49783
I1
sg49784
I4
sg49812
VP63000
p62826
sg49787
VRac1
p62827
sasg49779
(lp62828
(dp62829
g49782
I88
sg49783
I2
sg49784
I15
sg49785
VC0024143
p62830
sg49787
Vlupus nephritis
p62831
sasa(dp62832
g49775
VWe hypothesized that mutations in AP2S1 and GNA11 are causative in Danish patients with suspected FHH and that these mutations are not found in patients with primary hyperparathyroidism (PHPT), which is the main differential diagnostic disorder.
p62833
sg49777
(lp62834
(dp62835
g49782
I44
sg49783
I1
sg49784
I5
sg49812
VP29992
p62836
sg49787
VGNA11
p62837
sa(dp62838
g49782
I34
sg49783
I1
sg49784
I5
sg49812
VP53680
p62839
sg49787
VAP2S1
p62840
sasg49779
(lp62841
(dp62842
g49782
I187
sg49783
I1
sg49784
I4
sg49785
VC0221002
p62843
sg49787
VPHPT
p62844
sa(dp62845
g49782
I158
sg49783
I2
sg49784
I27
sg49785
VC0221002
p62846
sg49787
Vprimary hyperparathyroidism
p62847
sasa(dp62848
g49775
VFamilial hypocalciuric hypercalcemia (FHH) is a genetically heterogeneous condition resembling primary hyperparathyroidism (PHPT) but not curable by surgery; FHH types 1, 2, and 3 are due to loss-of-function mutations of the CASR, GNA11, or AP2S1 genes, respectively.
p62849
sg49777
(lp62850
(dp62851
g49782
I225
sg49783
I1
sg49784
I4
sg49812
VP41180
p62852
sg49787
VCASR
p62853
sa(dp62854
g49782
I231
sg49783
I1
sg49784
I5
sg49812
VP29992
p62855
sg49787
VGNA11
p62856
sa(dp62857
g49782
I241
sg49783
I2
sg49784
I11
sg49812
VP53680
p62858
sg49787
VAP2S1 genes
p62859
sasg49779
(lp62860
(dp62861
g49782
I124
sg49783
I1
sg49784
I4
sg49785
VC0221002
p62862
sg49787
VPHPT
p62863
sa(dp62864
g49782
I74
sg49783
I1
sg49784
I9
sg49785
VC0012634
p62865
sg49787
Vcondition
p62866
sa(dp62867
g49782
I38
sg49783
I1
sg49784
I3
sg49785
VC0342637
p62868
sg49787
VFHH
p62869
sa(dp62870
g49782
I38
sg49783
I1
sg49784
I3
sg49785
VC0342637
p62871
sg49787
VFHH
p62872
sa(dp62873
g49782
I95
sg49783
I2
sg49784
I27
sg49785
VC0221002
p62874
sg49787
Vprimary hyperparathyroidism
p62875
sa(dp62876
g49782
I0
sg49783
I3
sg49784
I36
sg49785
VC0342637
p62877
sg49787
VFamilial hypocalciuric hypercalcemia
p62878
sasa(dp62879
g49775
VThe aim of this study was to analyse prevalence and pathogenicity of CaSR, GNA11 and AP2S1 mutations in patients with an FHH phenotype and to compare them with a sample of patients with primary hyperparathyroidism (PHPT) in order to identify the most useful laboratory parameter for a differential diagnosis.
p62880
sg49777
(lp62881
(dp62882
g49782
I85
sg49783
I1
sg49784
I5
sg49812
VP53680
p62883
sg49787
VAP2S1
p62884
sa(dp62885
g49782
I69
sg49783
I1
sg49784
I4
sg49812
VP41180
p62886
sg49787
VCaSR
p62887
sa(dp62888
g49782
I75
sg49783
I1
sg49784
I5
sg49812
VP29992
p62889
sg49787
VGNA11
p62890
sa(dp62891
g49782
I121
sg49783
I1
sg49784
I3
sg49812
VP41180
p62892
sg49787
VFHH
p62893
sasg49779
(lp62894
(dp62895
g49782
I215
sg49783
I1
sg49784
I4
sg49785
VC0221002
p62896
sg49787
VPHPT
p62897
sa(dp62898
g49782
I186
sg49783
I2
sg49784
I27
sg49785
VC0221002
p62899
sg49787
Vprimary hyperparathyroidism
p62900
sasa(dp62901
g49775
VTripartite motif-containing protein 37 (TRIM37), a new member of the RING-B-box-coiled-coil (RBCC) subfamily of zinc finger proteins, was found to be involved in the development and progression of several cancers.
p62902
sg49777
(lp62903
(dp62904
g49782
I112
sg49783
I3
sg49784
I20
sg49812
g11
sg49787
Vzinc finger proteins
p62905
sa(dp62906
g49782
I40
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VTRIM37
p62907
sa(dp62908
g49782
I69
sg49783
I1
sg49784
I22
sg49812
VP38432
p62909
sg49787
VRING-B-box-coiled-coil
p62910
sa(dp62911
g49782
I93
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VRBCC
p62912
sa(dp62913
g49782
I0
sg49783
I4
sg49784
I38
sg49812
g11
sg49787
VTripartite motif-containing protein 37
p62914
sasg49779
(lp62915
(dp62916
g49782
I205
sg49783
I1
sg49784
I7
sg49785
VC0006826
p62917
sg49787
Vcancers
p62918
sasa(dp62919
g49775
VIn the present work, we clearly demonstrate that HMGB1 secreted by cancer cells is N-glycosylated at Asn37, which facilitates monocytic (M)-MDSC differentiation from bone marrow via the p38/NFKB/Erk1/2 pathway and also contributes to conversion of monocytes into MDSC-like cells; HMGB1 blockade by a monoclonal antibody against the HMGB1 B box obviously reduced the accumulation of M-MDSC in tumor-bearing mice, delaying tumor growth and development; additionally, MDSC expansion and HMGB1 up-regulation were also found in breast cancer patients.
p62920
sg49777
(lp62921
(dp62922
g49782
I195
sg49783
I1
sg49784
I6
sg49812
VP27361
p62923
sg49787
VErk1/2
p62924
sa(dp62925
g49782
I49
sg49783
I1
sg49784
I5
sg49812
VP09429
p62926
sg49787
VHMGB1
p62927
sa(dp62928
g49782
I190
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNFKB
p62929
sa(dp62930
g49782
I49
sg49783
I1
sg49784
I5
sg49812
VP09429
p62931
sg49787
VHMGB1
p62932
sa(dp62933
g49782
I186
sg49783
I1
sg49784
I3
sg49812
VP46108
p62934
sg49787
Vp38
p62935
sa(dp62936
g49782
I49
sg49783
I1
sg49784
I5
sg49812
VP09429
p62937
sg49787
VHMGB1
p62938
sa(dp62939
g49782
I332
sg49783
I2
sg49784
I7
sg49812
VP09429
p62940
sg49787
VHMGB1 B
p62941
sasg49779
(lp62942
(dp62943
g49782
I67
sg49783
I1
sg49784
I6
sg49785
VC0006826
p62944
sg49787
Vcancer
p62945
sa(dp62946
g49782
I523
sg49783
I2
sg49784
I13
sg49785
VC0678222
p62947
sg49787
Vbreast cancer
p62948
sa(dp62949
g49782
I421
sg49783
I2
sg49784
I12
sg49785
VC0598934
p62950
sg49787
Vtumor growth
p62951
sa(dp62952
g49782
I392
sg49783
I1
sg49784
I5
sg49785
VC0027651
p62953
sg49787
Vtumor
p62954
sasa(dp62955
g49775
VWe examined a possible association between the COMT Val158Met polymorphism and conversion disorder in a study of 48 patients with conversion disorder and 48 control patients.
p62956
sg49777
(lp62957
(dp62958
g49782
I47
sg49783
I2
sg49784
I14
sg49812
VP21964
p62959
sg49787
VCOMT Val158Met
p62960
sasg49779
(lp62961
(dp62962
g49782
I79
sg49783
I2
sg49784
I19
sg49785
VC0009946
p62963
sg49787
Vconversion disorder
p62964
sa(dp62965
g49782
I79
sg49783
I2
sg49784
I19
sg49785
VC0009946
p62966
sg49787
Vconversion disorder
p62967
sasa(dp62968
g49775
VWe conclude that the COMT Val158Met genotype is quite common in Turkey and that it is not a risk factor for conversion disorder in the Turkish population.
p62969
sg49777
(lp62970
(dp62971
g49782
I21
sg49783
I3
sg49784
I23
sg49812
VP21964
p62972
sg49787
VCOMT Val158Met genotype
p62973
sasg49779
(lp62974
(dp62975
g49782
I108
sg49783
I2
sg49784
I19
sg49785
VC0009946
p62976
sg49787
Vconversion disorder
p62977
sasa(dp62978
g49775
VFactor VII (FVII) activating protease (FSAP) is a circulating serine protease that is likely to be involved in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer.
p62979
sg49777
(lp62980
(dp62981
g49782
I0
sg49783
I5
sg49784
I37
sg49812
VP08709
p62982
sg49787
VFactor VII (FVII) activating protease
p62983
sa(dp62984
g49782
I39
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VFSAP
p62985
sa(dp62986
g49782
I62
sg49783
I2
sg49784
I15
sg49812
VP57727
p62987
sg49787
Vserine protease
p62988
sasg49779
(lp62989
(dp62990
g49782
I150
sg49783
I1
sg49784
I6
sg49785
VC0038454
p62991
sg49787
Vstroke
p62992
sa(dp62993
g49782
I158
sg49783
I1
sg49784
I15
sg49785
VC0004153
p62994
sg49787
Vatherosclerosis
p62995
sa(dp62996
g49782
I175
sg49783
I2
sg49784
I14
sg49785
VC0239946
p62997
sg49787
Vliver fibrosis
p62998
sa(dp62999
g49782
I206
sg49783
I1
sg49784
I6
sg49785
VC0006826
p63000
sg49787
Vcancer
p63001
sa(dp63002
g49782
I191
sg49783
I1
sg49784
I10
sg49785
VC0040053
p63003
sg49787
Vthrombosis
p63004
sasa(dp63005
g49775
VWith purpose to study content of alpha-defensins (1-3) and synthesis and liberation of other proteins and peptides by neutrophils the concentrations of alpha-defensins, lipoprotein (alpha), C-reactive protein, precursor of cerebral natriuretic peptide, coagulation factor VII and von Willebrand factor were determined in supernatants of leukocytal cultures in patients with exertional angina pectoris and atherosclerosis of lower extremities.
p63006
sg49777
(lp63007
(dp63008
g49782
I280
sg49783
I3
sg49784
I21
sg49812
VP04275
p63009
sg49787
Vvon Willebrand factor
p63010
sa(dp63011
g49782
I190
sg49783
I2
sg49784
I18
sg49812
VP02741
p63012
sg49787
VC-reactive protein
p63013
sa(dp63014
g49782
I223
sg49783
I3
sg49784
I28
sg49812
VP16860
p63015
sg49787
Vcerebral natriuretic peptide
p63016
sa(dp63017
g49782
I33
sg49783
I1
sg49784
I15
sg49812
VP59665
p63018
sg49787
Valpha-defensins
p63019
sa(dp63020
g49782
I253
sg49783
I3
sg49784
I22
sg49812
VP08709
p63021
sg49787
Vcoagulation factor VII
p63022
sa(dp63023
g49782
I169
sg49783
I2
sg49784
I19
sg49812
VP02652
p63024
sg49787
Vlipoprotein (alpha)
p63025
sasg49779
(lp63026
(dp63027
g49782
I374
sg49783
I2
sg49784
I17
sg49785
VC0577698
p63028
sg49787
Vexertional angina
p63029
sa(dp63030
g49782
I405
sg49783
I1
sg49784
I15
sg49785
VC0004153
p63031
sg49787
Vatherosclerosis
p63032
sasa(dp63033
g49775
VThe frequency of HLA-DR4 was increased in patients with optic neuritis alone compared to controls and to patients with multiple sclerosis, but further studies are required to confirm this finding.
p63034
sg49777
(lp63035
(dp63036
g49782
I17
sg49783
I1
sg49784
I7
sg49812
VP30486
p63037
sg49787
VHLA-DR4
p63038
sasg49779
(lp63039
(dp63040
g49782
I56
sg49783
I2
sg49784
I14
sg49785
VC0029134
p63041
sg49787
Voptic neuritis
p63042
sa(dp63043
g49782
I119
sg49783
I2
sg49784
I18
sg49785
VC0026769
p63044
sg49787
Vmultiple sclerosis
p63045
sasa(dp63046
g49775
VThe MS profiling by PGC-LC also revealed several glycan structural isomers that corresponded to LacdiNAc-type (GalNAcBeta1-4GlcNAc) motifs that were unique to the serous ovarian cancers and that correlated with elevated gene expression of B4GALNT3 and B4GALNT4 in patients with serous cancer.
p63047
sg49777
(lp63048
(dp63049
g49782
I252
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VB4GALNT4
p63050
sa(dp63051
g49782
I239
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VB4GALNT3
p63052
sasg49779
(lp63053
(dp63054
g49782
I178
sg49783
I1
sg49784
I6
sg49785
VC0006826
p63055
sg49787
Vcancer
p63056
sa(dp63057
g49782
I170
sg49783
I2
sg49784
I15
sg49785
VC1140680
p63058
sg49787
Vovarian cancers
p63059
sasa(dp63060
g49775
VWe previously showed that B4GALNT3 overexpression enhances colon cancer cell malignant phenotypes in vitro and in vivo.
p63061
sg49777
(lp63062
(dp63063
g49782
I26
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VB4GALNT3
p63064
sasg49779
(lp63065
(dp63066
g49782
I59
sg49783
I2
sg49784
I12
sg49785
VC0699790
p63067
sg49787
Vcolon cancer
p63068
sasa(dp63069
g49775
VHowever, the role of B4GALNT3 in cancer stemness remains unclear.
p63070
sg49777
(lp63071
(dp63072
g49782
I21
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VB4GALNT3
p63073
sasg49779
(lp63074
(dp63075
g49782
I33
sg49783
I1
sg49784
I6
sg49785
VC0006826
p63076
sg49787
Vcancer
p63077
sasa(dp63078
g49775
VWe found that B4GALNT3 expression was positively correlated with advanced stages and poor survival in colorectal cancer patients.
p63079
sg49777
(lp63080
(dp63081
g49782
I14
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VB4GALNT3
p63082
sasg49779
(lp63083
(dp63084
g49782
I102
sg49783
I2
sg49784
I17
sg49785
VC1527249
p63085
sg49787
Vcolorectal cancer
p63086
sasa(dp63087
g49775
VKnockdown of B4GALNT3 using small interfering (si) RNAs in colon cancer cell lines (HCT116, SW480, HCT15, and HT29 cells) decreased sphere formation and the expression of stem cell markers, OCT4 and NANOG.
p63088
sg49777
(lp63089
(dp63090
g49782
I199
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VNANOG
p63091
sasg49779
(lp63092
(dp63093
g49782
I59
sg49783
I2
sg49784
I12
sg49785
VC0699790
p63094
sg49787
Vcolon cancer
p63095
sasa(dp63096
g49775
VTaken together, these data suggest B4GALNT3 regulates cancer stemness and the invasive properties of colon cancer cells through modifying EGFR glycosylation and signaling.
p63097
sg49777
(lp63098
(dp63099
g49782
I35
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VB4GALNT3
p63100
sasg49779
(lp63101
(dp63102
g49782
I54
sg49783
I1
sg49784
I6
sg49785
VC0006826
p63103
sg49787
Vcancer
p63104
sa(dp63105
g49782
I101
sg49783
I2
sg49784
I12
sg49785
VC0699790
p63106
sg49787
Vcolon cancer
p63107
sasa(dp63108
g49775
VIn this study, we investigated the expression and role of B4GALNT3 in human neuroblastoma (NB).
p63109
sg49777
(lp63110
(dp63111
g49782
I58
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VB4GALNT3
p63112
sasg49779
(lp63113
(dp63114
g49782
I91
sg49783
I1
sg49784
I2
sg49785
VC0027819
p63115
sg49787
VNB
p63116
sa(dp63117
g49782
I76
sg49783
I1
sg49784
I13
sg49785
VC0027819
p63118
sg49787
Vneuroblastoma
p63119
sasa(dp63120
g49775
VDetection rates were as follows: IL-7: NVG higher than POAG; IL-10: POAG lower than cataract or NVG; and GM-CSF: cataract higher than POAG or NVG.
p63121
sg49777
(lp63122
(dp63123
g49782
I105
sg49783
I1
sg49784
I6
sg49812
VP04141
p63124
sg49787
VGM-CSF
p63125
sa(dp63126
g49782
I33
sg49783
I1
sg49784
I4
sg49812
VP13232
p63127
sg49787
VIL-7
p63128
sasg49779
(lp63129
(dp63130
g49782
I55
sg49783
I1
sg49784
I4
sg49785
VC0339573
p63131
sg49787
VPOAG
p63132
sa(dp63133
g49782
I84
sg49783
I1
sg49784
I8
sg49785
VC0086543
p63134
sg49787
Vcataract
p63135
sa(dp63136
g49782
I55
sg49783
I1
sg49784
I4
sg49785
VC0339573
p63137
sg49787
VPOAG
p63138
sa(dp63139
g49782
I84
sg49783
I1
sg49784
I8
sg49785
VC0086543
p63140
sg49787
Vcataract
p63141
sa(dp63142
g49782
I55
sg49783
I1
sg49784
I4
sg49785
VC0339573
p63143
sg49787
VPOAG
p63144
sasa(dp63145
g49775
VSixty-four vitreous samples (40 RVO, 24 controls with idiopathic floaters) were analyzed in this retrospective case series using LC/MS for LPAs 16:0, 18:0, 18:1, 20:4, and ELISA kits or Luminex technology for ATX, angiopoetin-1 (ANG-1), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), pigment epithelium-derived factor (PEDF), and vascular endothelial growth factor (VEGF).
p63146
sg49777
(lp63147
(dp63148
g49782
I274
sg49783
I1
sg49784
I4
sg49812
VP13232
p63149
sg49787
VIL-7
p63150
sa(dp63151
g49782
I393
sg49783
I4
sg49784
I34
sg49812
g11
sg49787
Vvascular endothelial growth factor
p63152
sa(dp63153
g49782
I237
sg49783
I1
sg49784
I13
sg49812
VP05231
p63154
sg49787
Vinterleukin-6
p63155
sa(dp63156
g49782
I259
sg49783
I1
sg49784
I13
sg49812
VP13232
p63157
sg49787
Vinterleukin-7
p63158
sa(dp63159
g49782
I339
sg49783
I1
sg49784
I5
sg49812
VP41597
p63160
sg49787
VMCP-1
p63161
sa(dp63162
g49782
I209
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VATX
p63163
sa(dp63164
g49782
I229
sg49783
I1
sg49784
I5
sg49812
VP03950
p63165
sg49787
VANG-1
p63166
sa(dp63167
g49782
I214
sg49783
I1
sg49784
I13
sg49812
VP03950
p63168
sg49787
Vangiopoetin-1
p63169
sa(dp63170
g49782
I252
sg49783
I1
sg49784
I4
sg49812
VP05231
p63171
sg49787
VIL-6
p63172
sa(dp63173
g49782
I429
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VVEGF
p63174
sa(dp63175
g49782
I281
sg49783
I1
sg49784
I13
sg49812
VP60568
p63176
sg49787
Vinterleukin-8
p63177
sa(dp63178
g49782
I303
sg49783
I3
sg49784
I34
sg49812
VP41597
p63179
sg49787
Vmonocyte chemoattractant protein-1
p63180
sa(dp63181
g49782
I296
sg49783
I1
sg49784
I4
sg49812
VP60568
p63182
sg49787
VIL-8
p63183
sasg49779
(lp63184
sa(dp63185
g49775
VPoly I:C induces IL-7 production, early inflammatory responses, and characteristic pathologies of SS-like dacryoadenitis in non-autoimmune-prone C57BL/6 mice.
p63186
sg49777
(lp63187
(dp63188
g49782
I17
sg49783
I1
sg49784
I4
sg49812
VP13232
p63189
sg49787
VIL-7
p63190
sasg49779
(lp63191
(dp63192
g49782
I40
sg49783
I2
sg49784
I22
sg49785
VC1155266
p63193
sg49787
Vinflammatory responses
p63194
sa(dp63195
g49782
I106
sg49783
I1
sg49784
I14
sg49785
VC0155223
p63196
sg49787
Vdacryoadenitis
p63197
sa(dp63198
g49782
I128
sg49783
I1
sg49784
I10
sg49785
VC0443146
p63199
sg49787
Vautoimmune
p63200
sasa(dp63201
g49775
VDiagnosis of AIDS-NHL was preceded by a significantly elevated frequency of activated/germinal center-like CD19CD10CD71CD86AID B cells (P = 0.0072), elevated serum prevalence of the TLR2 ligand, and significantly elevated B-cell TLR2 expression (P = 0.0015), positively correlating with the frequency of activated/germinal center-like B cells (rho = 0.7273, P = 0.0144).
p63202
sg49777
(lp63203
(dp63204
g49782
I222
sg49783
I2
sg49784
I11
sg49812
g11
sg49787
VB-cell TLR2
p63205
sa(dp63206
g49782
I182
sg49783
I2
sg49784
I11
sg49812
g11
sg49787
VTLR2 ligand
p63207
sasg49779
(lp63208
(dp63209
g49782
I18
sg49783
I1
sg49784
I3
sg49785
VC0024305
p63210
sg49787
VNHL
p63211
sasa(dp63212
g49775
VTLR2-stimulated purified B cells exhibited the activated B-cell phenotype observed in HIV+ subjects before AIDS-NHL diagnosis.
p63213
sg49777
(lp63214
(dp63215
g49782
I0
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR2
p63216
sasg49779
(lp63217
(dp63218
g49782
I112
sg49783
I1
sg49784
I3
sg49785
VC0024305
p63219
sg49787
VNHL
p63220
sasa(dp63221
g49775
VThese results indicate that an elevated fraction of B cells display an activated/germinal center phenotype in those HIV+ subjects who go on to develop AIDS-NHL and suggest that TLR2-mediated activation may play a role in HIV infection-associated B-cell activation, potentially contributing to the genesis of AIDS-NHL.
p63222
sg49777
(lp63223
(dp63224
g49782
I177
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR2
p63225
sasg49779
(lp63226
(dp63227
g49782
I156
sg49783
I1
sg49784
I3
sg49785
VC0024305
p63228
sg49787
VNHL
p63229
sa(dp63230
g49782
I221
sg49783
I2
sg49784
I13
sg49785
VC0019693
p63231
sg49787
VHIV infection
p63232
sa(dp63233
g49782
I156
sg49783
I1
sg49784
I3
sg49785
VC0024305
p63234
sg49787
VNHL
p63235
sasa(dp63236
g49775
VThe regulatory role of AVP on the hypothalamic-pituitary-adrenal (HPA) axis suggests potential uses for AVP receptor modulators in various CNS indications, including depression, anxiety and post-traumatic stress disorder.
p63237
sg49777
(lp63238
(dp63239
g49782
I104
sg49783
I2
sg49784
I12
sg49812
VP01185
p63240
sg49787
VAVP receptor
p63241
sa(dp63242
g49782
I23
sg49783
I1
sg49784
I3
sg49812
VP01185
p63243
sg49787
VAVP
p63244
sasg49779
(lp63245
(dp63246
g49782
I190
sg49783
I3
sg49784
I30
sg49785
VC0038436
p63247
sg49787
Vpost-traumatic stress disorder
p63248
sa(dp63249
g49782
I166
sg49783
I1
sg49784
I10
sg49785
VC0011581
p63250
sg49787
Vdepression
p63251
sasa(dp63252
g49775
VWhen POLN was ectopically overexpressed in human cells, it specifically coimmunoprecipitated with the homologous recombination factors BRCA1 and FANCJ, but not with previously suggested interaction partners (HELQ and members of the Fanconi anemia core complex).
p63253
sg49777
(lp63254
(dp63255
g49782
I208
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VHELQ
p63256
sa(dp63257
g49782
I232
sg49783
I4
sg49784
I27
sg49812
VP51587
p63258
sg49787
VFanconi anemia core complex
p63259
sa(dp63260
g49782
I145
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VFANCJ
p63261
sa(dp63262
g49782
I102
sg49783
I4
sg49784
I38
sg49812
VP19883
p63263
sg49787
Vhomologous recombination factors BRCA1
p63264
sasg49779
(lp63265
(dp63266
g49782
I232
sg49783
I2
sg49784
I14
sg49785
VC3469521
p63267
sg49787
VFanconi anemia
p63268
sa(dp63269
g49782
I145
sg49783
I1
sg49784
I5
sg49785
VC1836860
p63270
sg49787
VFANCJ
p63271
sasa(dp63272
g49775
VMoreover, we obtained evidence for physical and functional interaction of POLN with factors belonging to the Fanconi anemia pathway, a master regulator of cross-link repair.
p63273
sg49777
(lp63274
(dp63275
g49782
I74
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VPOLN
p63276
sasg49779
(lp63277
(dp63278
g49782
I109
sg49783
I2
sg49784
I14
sg49785
VC3469521
p63279
sg49787
VFanconi anemia
p63280
sasa(dp63281
g49775
VThe results indicate that the Pol n I component MV is an allergen for human beings as well as for mice, and useful as a diagnostic tool for chironomid allergy.
p63282
sg49777
(lp63283
(dp63284
g49782
I30
sg49783
I5
sg49784
I20
sg49812
VP10266
p63285
sg49787
VPol n I component MV
p63286
sasg49779
(lp63287
(dp63288
g49782
I151
sg49783
I1
sg49784
I7
sg49785
VC0020517
p63289
sg49787
Vallergy
p63290
sasa(dp63291
g49775
VPrevalence of service receipt was highest among women in the highest family income category (&gt;400% of federal poverty level [FPL]) and among women with insurance coverage for each of the following: contraceptive services among women at risk for unintended pregnancy; medical services beyond advice to help achieve pregnancy; vaccinations (hepatitis B and human papillomavirus [HPV], ever; tetanus, past 10 years; influenza, past year); discussions with a health care professional about improving health before pregnancy and taking vitamins with folic acid; blood pressure and diabetes screening; discussions with a health care professional in the past year about diet, among those with obesity; discussions with a health care professional in the past year about smoking, among current smokers; Pap tests within the past 3 years; and mammograms within the past 2 years.
p63292
sg49777
(lp63293
sg49779
(lp63294
(dp63295
g49782
I689
sg49783
I1
sg49784
I7
sg49785
VC0028754
p63296
sg49787
Vobesity
p63297
sa(dp63298
g49782
I416
sg49783
I1
sg49784
I9
sg49785
VC0021400
p63299
sg49787
Vinfluenza
p63300
sa(dp63301
g49782
I797
sg49783
I1
sg49784
I3
sg49785
VC1863340
p63302
sg49787
VPap
p63303
sa(dp63304
g49782
I342
sg49783
I2
sg49784
I11
sg49785
VC0019163
p63305
sg49787
Vhepatitis B
p63306
sa(dp63307
g49782
I579
sg49783
I1
sg49784
I8
sg49785
VC0011849
p63308
sg49787
Vdiabetes
p63309
sa(dp63310
g49782
I392
sg49783
I1
sg49784
I7
sg49785
VC0039614
p63311
sg49787
Vtetanus
p63312
sasa(dp63313
g49775
VHerein we describe a new phenotype associated with a mutation in exon 11 of the LMNA gene: hypertrophic cardiomyopathy, atrioventricular block, severe dyslipidemia and diabetes.
p63314
sg49777
(lp63315
(dp63316
g49782
I80
sg49783
I2
sg49784
I9
sg49812
VP02545
p63317
sg49787
VLMNA gene
p63318
sasg49779
(lp63319
(dp63320
g49782
I168
sg49783
I1
sg49784
I8
sg49785
VC0011849
p63321
sg49787
Vdiabetes
p63322
sa(dp63323
g49782
I91
sg49783
I2
sg49784
I27
sg49785
VC0007194
p63324
sg49787
Vhypertrophic cardiomyopathy
p63325
sa(dp63326
g49782
I120
sg49783
I2
sg49784
I22
sg49785
VC0004245
p63327
sg49787
Vatrioventricular block
p63328
sa(dp63329
g49782
I151
sg49783
I1
sg49784
I12
sg49785
VC0242339
p63330
sg49787
Vdyslipidemia
p63331
sasa(dp63332
g49775
VIndependent analysis of LMNA variants via the type 2 diabetes (T2D) Knowledge Portal showed that variant p.G602S associated significantly with type 2 diabetes (p = 0.02; odds ratio = 4.58), and was more frequent in African Americans (allele frequency 0.297%).
p63333
sg49777
(lp63334
(dp63335
g49782
I24
sg49783
I2
sg49784
I13
sg49812
VP02545
p63336
sg49787
VLMNA variants
p63337
sasg49779
(lp63338
(dp63339
g49782
I63
sg49783
I1
sg49784
I3
sg49785
VC0011860
p63340
sg49787
VT2D
p63341
sa(dp63342
g49782
I46
sg49783
I3
sg49784
I15
sg49785
VC0011860
p63343
sg49787
Vtype 2 diabetes
p63344
sa(dp63345
g49782
I46
sg49783
I3
sg49784
I15
sg49785
VC0011860
p63346
sg49787
Vtype 2 diabetes
p63347
sasa(dp63348
g49775
VLipodystrophy is a rare disorder characterized by the complete or partial loss of subcutaneous adipose tissue, insulin resistance, diabetes mellitus and hyperlipidemia.Proteinuric renal disease is a prevalent feature of generalized lipodystrophy but rare in familial partial lipodystrophy.Patients carrying the c.1045C &gt; T missense LMNA mutation (p.R349W) may present with familial partial lipodystrophy, proteinuric nephropathy, cardiomyopathy and atypical myopathy.
p63349
sg49777
(lp63350
(dp63351
g49782
I111
sg49783
I1
sg49784
I7
sg49812
VP01308
p63352
sg49787
Vinsulin
p63353
sasg49779
(lp63354
(dp63355
g49782
I220
sg49783
I2
sg49784
I25
sg49785
VC0221032
p63356
sg49787
Vgeneralized lipodystrophy
p63357
sa(dp63358
g49782
I131
sg49783
I2
sg49784
I17
sg49785
VC0011849
p63359
sg49787
Vdiabetes mellitus
p63360
sa(dp63361
g49782
I258
sg49783
I3
sg49784
I30
sg49785
VC0271694
p63362
sg49787
Vfamilial partial lipodystrophy
p63363
sa(dp63364
g49782
I439
sg49783
I1
sg49784
I8
sg49785
VC0026848
p63365
sg49787
Vmyopathy
p63366
sa(dp63367
g49782
I420
sg49783
I1
sg49784
I11
sg49785
VC0022658
p63368
sg49787
Vnephropathy
p63369
sa(dp63370
g49782
I433
sg49783
I1
sg49784
I14
sg49785
VC0878544
p63371
sg49787
Vcardiomyopathy
p63372
sa(dp63373
g49782
I153
sg49783
I1
sg49784
I14
sg49785
VC0020473
p63374
sg49787
Vhyperlipidemia
p63375
sa(dp63376
g49782
I180
sg49783
I2
sg49784
I13
sg49785
VC0022658
p63377
sg49787
Vrenal disease
p63378
sa(dp63379
g49782
I111
sg49783
I2
sg49784
I18
sg49785
VC0021655
p63380
sg49787
Vinsulin resistance
p63381
sa(dp63382
g49782
I19
sg49783
I2
sg49784
I13
sg49785
VC0678236
p63383
sg49787
Vrare disorder
p63384
sa(dp63385
g49782
I258
sg49783
I3
sg49784
I30
sg49785
VC0271694
p63386
sg49787
Vfamilial partial lipodystrophy
p63387
sa(dp63388
g49782
I0
sg49783
I1
sg49784
I13
sg49785
VC0023787
p63389
sg49787
VLipodystrophy
p63390
sasa(dp63391
g49775
VBAT 5'-deiodinase activity was unaffected by propylthiouracil (PTU) and was elevated in hypothyroid rats, whereas EPI 5'-deiodinase was totally inhibited by PTU and was depressed in hypothyroidism.
p63392
sg49777
(lp63393
(dp63394
g49782
I114
sg49783
I2
sg49784
I17
sg49812
VP10646
p63395
sg49787
VEPI 5'-deiodinase
p63396
sa(dp63397
g49782
I0
sg49783
I2
sg49784
I17
sg49812
g11
sg49787
VBAT 5'-deiodinase
p63398
sasg49779
(lp63399
(dp63400
g49782
I88
sg49783
I1
sg49784
I11
sg49785
VC0020676
p63401
sg49787
Vhypothyroid
p63402
sa(dp63403
g49782
I114
sg49783
I1
sg49784
I3
sg49785
VC0267963
p63404
sg49787
VEPI
p63405
sa(dp63406
g49782
I182
sg49783
I1
sg49784
I14
sg49785
VC0020676
p63407
sg49787
Vhypothyroidism
p63408
sasa(dp63409
g49775
VHere, we report a novel mutation in ERCC8 gene in a 16-year-old boy who suffers from poor weight gain, short stature, microcephaly, intellectual disability, and photosensitivity.
p63410
sg49777
(lp63411
(dp63412
g49782
I36
sg49783
I2
sg49784
I10
sg49812
VP01243
p63413
sg49787
VERCC8 gene
p63414
sasg49779
(lp63415
(dp63416
g49782
I85
sg49783
I3
sg49784
I16
sg49785
VC0231246
p63417
sg49787
Vpoor weight gain
p63418
sa(dp63419
g49782
I161
sg49783
I1
sg49784
I16
sg49785
VC0393720
p63420
sg49787
Vphotosensitivity
p63421
sa(dp63422
g49782
I72
sg49783
I1
sg49784
I7
sg49785
VC0683278
p63423
sg49787
Vsuffers
p63424
sa(dp63425
g49782
I118
sg49783
I1
sg49784
I12
sg49785
VC0025958
p63426
sg49787
Vmicrocephaly
p63427
sa(dp63428
g49782
I132
sg49783
I2
sg49784
I23
sg49785
VC0025362
p63429
sg49787
Vintellectual disability
p63430
sa(dp63431
g49782
I18
sg49783
I2
sg49784
I14
sg49785
VC2985438
p63432
sg49787
Vnovel mutation
p63433
sa(dp63434
g49782
I103
sg49783
I2
sg49784
I13
sg49785
VC0013336
p63435
sg49787
Vshort stature
p63436
sasa(dp63437
g49775
VCockayne syndrome is caused by biallelic ERCC8 (CSA) or ERCC6 (CSB) mutations and is characterized by growth restriction, microcephaly, developmental delay, and premature pathological aging.
p63438
sg49777
(lp63439
(dp63440
g49782
I41
sg49783
I2
sg49784
I11
sg49812
VP01243
p63441
sg49787
VERCC8 (CSA)
p63442
sa(dp63443
g49782
I56
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VERCC6
p63444
sa(dp63445
g49782
I63
sg49783
I1
sg49784
I3
sg49812
VP35548
p63446
sg49787
VCSB
p63447
sasg49779
(lp63448
(dp63449
g49782
I122
sg49783
I1
sg49784
I12
sg49785
VC0025958
p63450
sg49787
Vmicrocephaly
p63451
sa(dp63452
g49782
I0
sg49783
I2
sg49784
I17
sg49785
VC0009207
p63453
sg49787
VCockayne syndrome
p63454
sa(dp63455
g49782
I48
sg49783
I1
sg49784
I3
sg49785
VC0751039
p63456
sg49787
VCSA
p63457
sa(dp63458
g49782
I63
sg49783
I1
sg49784
I3
sg49785
VC1858160
p63459
sg49787
VCSB
p63460
sa(dp63461
g49782
I21
sg49783
I4
sg49784
I25
sg49785
VC0751039
p63462
sg49787
Vcaused by biallelic ERCC8
p63463
sa(dp63464
g49782
I136
sg49783
I2
sg49784
I19
sg49785
VC0424605
p63465
sg49787
Vdevelopmental delay
p63466
sasa(dp63467
g49775
VThis study included 54 beta-thalassemia major patients divided into 2 groups; group A consisted of 28 patients who have thrombocytosis secondary to a previous splenectomy and group B comprised of 26 patients who did not have a splenectomy with normal platelet count, as well as a control group of 30 healthy individuals.
p63468
sg49777
(lp63469
sg49779
(lp63470
(dp63471
g49782
I28
sg49783
I2
sg49784
I17
sg49785
VC0002875
p63472
sg49787
Vthalassemia major
p63473
sa(dp63474
g49782
I120
sg49783
I1
sg49784
I14
sg49785
VC0836924
p63475
sg49787
Vthrombocytosis
p63476
sa(dp63477
g49782
I175
sg49783
I2
sg49784
I7
sg49785
VC0348801
p63478
sg49787
Vgroup B
p63479
sasa(dp63480
g49775
VA microarray analysis of the B-1 lymphocytes revealed that IL-10 deficiency is associated with down-regulation of the genes that code for claudin-10, a protein that is involved in cell-to-cell contact and that has been linked to lung adenocarcinoma.
p63481
sg49777
(lp63482
(dp63483
g49782
I138
sg49783
I1
sg49784
I10
sg49812
VP78369
p63484
sg49787
Vclaudin-10
p63485
sasg49779
(lp63486
(dp63487
g49782
I229
sg49783
I2
sg49784
I19
sg49785
VC0152013
p63488
sg49787
Vlung adenocarcinoma
p63489
sasa(dp63490
g49775
VThus, our findings suggest that the axis IL-10/claudin-10 is a promising target for the development of therapeutic agents against aggressive melanoma.
p63491
sg49777
(lp63492
(dp63493
g49782
I47
sg49783
I1
sg49784
I10
sg49812
VP78369
p63494
sg49787
Vclaudin-10
p63495
sasg49779
(lp63496
(dp63497
g49782
I141
sg49783
I1
sg49784
I8
sg49785
VC0025202
p63498
sg49787
Vmelanoma
p63499
sa(dp63500
g49782
I130
sg49783
I1
sg49784
I10
sg49785
VC0001807
p63501
sg49787
Vaggressive
p63502
sasa(dp63503
g49775
VTo explore the expression distinction of the cell adhesion proteins claudin-10,-14,-17 and E-cadherin in the adjacent non-neoplastic tissues and gastric cancer tissues, 50 gastric cancer tissues and 50 samples of adjacent non-neoplastic tissues adjacent to the tumors were examined for expression of claudin-10,-14,-17 and E-cadherin by streptavidin-perosidase immunohistochemical staining method.
p63504
sg49777
(lp63505
(dp63506
g49782
I68
sg49783
I1
sg49784
I18
sg49812
VP78369
p63507
sg49787
Vclaudin-10,-14,-17
p63508
sa(dp63509
g49782
I337
sg49783
I1
sg49784
I23
sg49812
g11
sg49787
Vstreptavidin-perosidase
p63510
sa(dp63511
g49782
I68
sg49783
I1
sg49784
I18
sg49812
VP78369
p63512
sg49787
Vclaudin-10,-14,-17
p63513
sa(dp63514
g49782
I91
sg49783
I1
sg49784
I10
sg49812
VP12830
p63515
sg49787
VE-cadherin
p63516
sa(dp63517
g49782
I91
sg49783
I1
sg49784
I10
sg49812
VP12830
p63518
sg49787
VE-cadherin
p63519
sasg49779
(lp63520
(dp63521
g49782
I145
sg49783
I2
sg49784
I14
sg49785
VC0024623
p63522
sg49787
Vgastric cancer
p63523
sa(dp63524
g49782
I261
sg49783
I1
sg49784
I6
sg49785
VC0027651
p63525
sg49787
Vtumors
p63526
sa(dp63527
g49782
I50
sg49783
I1
sg49784
I8
sg49785
VC0001511
p63528
sg49787
Vadhesion
p63529
sa(dp63530
g49782
I145
sg49783
I2
sg49784
I14
sg49785
VC0024623
p63531
sg49787
Vgastric cancer
p63532
sasa(dp63533
g49775
VThe positive expression rates of claudin-10 in gastric cancer tissues and adjacent non-neoplastic tissues were 24% and 72% respectively (P &lt; 0.01).
p63534
sg49777
(lp63535
(dp63536
g49782
I33
sg49783
I1
sg49784
I10
sg49812
VP78369
p63537
sg49787
Vclaudin-10
p63538
sasg49779
(lp63539
(dp63540
g49782
I47
sg49783
I2
sg49784
I14
sg49785
VC0024623
p63541
sg49787
Vgastric cancer
p63542
sasa(dp63543
g49775
VIn contrast, the positive expression rates of claudin-14 in gastric cancer tissues and adjacent non-neoplastic tissues were 58% and 24% respectively (P = 0.015 &lt; 0.05) Thus in our study, the expression of E-cadherin, claudin-10, and claudin-17 was down-regulated in gastric cancer tissue while the expression of claudin-14 was up-regulated.
p63544
sg49777
(lp63545
(dp63546
g49782
I46
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
Vclaudin-14
p63547
sa(dp63548
g49782
I208
sg49783
I1
sg49784
I10
sg49812
VP12830
p63549
sg49787
VE-cadherin
p63550
sa(dp63551
g49782
I236
sg49783
I1
sg49784
I10
sg49812
VP56750
p63552
sg49787
Vclaudin-17
p63553
sa(dp63554
g49782
I220
sg49783
I1
sg49784
I10
sg49812
VP78369
p63555
sg49787
Vclaudin-10
p63556
sasg49779
(lp63557
(dp63558
g49782
I60
sg49783
I2
sg49784
I14
sg49785
VC0024623
p63559
sg49787
Vgastric cancer
p63560
sa(dp63561
g49782
I60
sg49783
I2
sg49784
I14
sg49785
VC0024623
p63562
sg49787
Vgastric cancer
p63563
sasa(dp63564
g49775
VOur study reveals that the expression of E-cadherin, claudin-10, and claudin-17 were down-regulated in gastric cancer tissue while the expression of claudin-14 was up-regulated and correlation between claudins and E-cadherin expression with lymphatic metastasis were observed.
p63565
sg49777
(lp63566
(dp63567
g49782
I69
sg49783
I1
sg49784
I10
sg49812
VP56750
p63568
sg49787
Vclaudin-17
p63569
sa(dp63570
g49782
I41
sg49783
I1
sg49784
I10
sg49812
VP12830
p63571
sg49787
VE-cadherin
p63572
sa(dp63573
g49782
I41
sg49783
I1
sg49784
I10
sg49812
VP12830
p63574
sg49787
VE-cadherin
p63575
sa(dp63576
g49782
I53
sg49783
I1
sg49784
I10
sg49812
VP78369
p63577
sg49787
Vclaudin-10
p63578
sasg49779
(lp63579
(dp63580
g49782
I103
sg49783
I2
sg49784
I14
sg49785
VC0024623
p63581
sg49787
Vgastric cancer
p63582
sa(dp63583
g49782
I241
sg49783
I2
sg49784
I20
sg49785
VC0024232
p63584
sg49787
Vlymphatic metastasis
p63585
sasa(dp63586
g49775
VFour genes (MMP-2, c-fos, claudin 1 (CLDN1) and claudin 10(CLDN10)) were correlated with the results of microarray and real time RT-PCR analyses for the gene-expression data in samples from 41 patients with lung adenocarcinoma.
p63587
sg49777
(lp63588
(dp63589
g49782
I12
sg49783
I1
sg49784
I5
sg49812
VP08253
p63590
sg49787
VMMP-2
p63591
sa(dp63592
g49782
I48
sg49783
I2
sg49784
I10
sg49812
VP78369
p63593
sg49787
Vclaudin 10
p63594
sa(dp63595
g49782
I19
sg49783
I1
sg49784
I5
sg49812
VP01100
p63596
sg49787
Vc-fos
p63597
sa(dp63598
g49782
I26
sg49783
I2
sg49784
I9
sg49812
g11
sg49787
Vclaudin 1
p63599
sa(dp63600
g49782
I37
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCLDN1
p63601
sa(dp63602
g49782
I59
sg49783
I1
sg49784
I6
sg49812
VP78369
p63603
sg49787
VCLDN10
p63604
sasg49779
(lp63605
(dp63606
g49782
I207
sg49783
I2
sg49784
I19
sg49785
VC0152013
p63607
sg49787
Vlung adenocarcinoma
p63608
sasa(dp63609
g49775
VImmunohistochemical staining for these genes in samples from 81 cases of lung adenocarcinoma demonstrated the expressions of CLDN1 and CLDN10 were correlated with overall survival of patients with lung adenocarcinoma.
p63610
sg49777
(lp63611
(dp63612
g49782
I135
sg49783
I1
sg49784
I6
sg49812
VP78369
p63613
sg49787
VCLDN10
p63614
sa(dp63615
g49782
I125
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCLDN1
p63616
sasg49779
(lp63617
(dp63618
g49782
I73
sg49783
I2
sg49784
I19
sg49785
VC0152013
p63619
sg49787
Vlung adenocarcinoma
p63620
sa(dp63621
g49782
I73
sg49783
I2
sg49784
I19
sg49785
VC0152013
p63622
sg49787
Vlung adenocarcinoma
p63623
sasa(dp63624
g49775
VOverexpression of CLDN1 and CLDN10 indicates a favorable prognosis for overall survival in some patients with lung adenocarcinoma.
p63625
sg49777
(lp63626
(dp63627
g49782
I18
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCLDN1
p63628
sa(dp63629
g49782
I28
sg49783
I1
sg49784
I6
sg49812
VP78369
p63630
sg49787
VCLDN10
p63631
sasg49779
(lp63632
(dp63633
g49782
I110
sg49783
I2
sg49784
I19
sg49785
VC0152013
p63634
sg49787
Vlung adenocarcinoma
p63635
sasa(dp63636
g49775
VFurthermore, circadian regulation of Gnaz was disturbed in the db/db mouse, a model of diabetic retinopathy.
p63637
sg49777
(lp63638
sg49779
(lp63639
(dp63640
g49782
I87
sg49783
I2
sg49784
I20
sg49785
VC0011884
p63641
sg49787
Vdiabetic retinopathy
p63642
sasa(dp63643
g49775
VThe highest rates of somatic, non-synonymous mutations were found in GNG10 and GNAZ, neither of which has been previously reported to be mutated in melanoma.
p63644
sg49777
(lp63645
(dp63646
g49782
I69
sg49783
I1
sg49784
I5
sg49812
VP50151
p63647
sg49787
VGNG10
p63648
sa(dp63649
g49782
I79
sg49783
I1
sg49784
I4
sg49812
VP19086
p63650
sg49787
VGNAZ
p63651
sasg49779
(lp63652
(dp63653
g49782
I148
sg49783
I1
sg49784
I8
sg49785
VC0025202
p63654
sg49787
Vmelanoma
p63655
sasa(dp63656
g49775
VVarious other protein products of genes associated with bipolar disorder either bind to or are affected by phosphatidyl-inositol phosphate products of this pathway (ADBRK2, HIP1R, KCNQ2, RGS4, WFS1), are associated with its constituent elements (BCR, DUSP6, FAT, GNAZ) or are downstream targets of this signalling cascade (DPYSL2, DRD3, GAD1, G6PD, GCH1, KCNQ2, NOS3, SLC6A3, SLC6A4, SST, TH, TIMELESS).
p63657
sg49777
(lp63658
(dp63659
g49782
I343
sg49783
I1
sg49784
I4
sg49812
VP11441
p63660
sg49787
VG6PD
p63661
sa(dp63662
g49782
I193
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VWFS1
p63663
sa(dp63664
g49782
I384
sg49783
I1
sg49784
I3
sg49812
VP61278
p63665
sg49787
VSST
p63666
sa(dp63667
g49782
I251
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VDUSP6
p63668
sa(dp63669
g49782
I263
sg49783
I1
sg49784
I4
sg49812
VP19086
p63670
sg49787
VGNAZ
p63671
sa(dp63672
g49782
I337
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VGAD1
p63673
sa(dp63674
g49782
I258
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VFAT
p63675
sa(dp63676
g49782
I323
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VDPYSL2
p63677
sa(dp63678
g49782
I349
sg49783
I1
sg49784
I4
sg49812
VP30793
p63679
sg49787
VGCH1
p63680
sa(dp63681
g49782
I393
sg49783
I1
sg49784
I8
sg49812
VP60174
p63682
sg49787
VTIMELESS
p63683
sa(dp63684
g49782
I362
sg49783
I1
sg49784
I4
sg49812
VP60323
p63685
sg49787
VNOS3
p63686
sa(dp63687
g49782
I376
sg49783
I1
sg49784
I6
sg49812
VP31645
p63688
sg49787
VSLC6A4
p63689
sa(dp63690
g49782
I368
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VSLC6A3
p63691
sa(dp63692
g49782
I246
sg49783
I1
sg49784
I3
sg49812
VP11274
p63693
sg49787
VBCR
p63694
sa(dp63695
g49782
I180
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VKCNQ2
p63696
sa(dp63697
g49782
I331
sg49783
I1
sg49784
I4
sg49812
VP35462
p63698
sg49787
VDRD3
p63699
sa(dp63700
g49782
I173
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VHIP1R
p63701
sa(dp63702
g49782
I187
sg49783
I1
sg49784
I4
sg49812
VP49798
p63703
sg49787
VRGS4
p63704
sa(dp63705
g49782
I180
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VKCNQ2
p63706
sasg49779
(lp63707
(dp63708
g49782
I56
sg49783
I2
sg49784
I16
sg49785
VC0005586
p63709
sg49787
Vbipolar disorder
p63710
sa(dp63711
g49782
I193
sg49783
I1
sg49784
I4
sg49785
VC0043207
p63712
sg49787
VWFS1
p63713
sasa(dp63714
g49775
VIn a recent study we found that the risk for unilateral retinoblastoma in offspring is 4 fold higher in women that are homozygotes for the 19 bp deletion in the DHFR gene and took folic acid supplement during pregnancy.
p63715
sg49777
(lp63716
(dp63717
g49782
I161
sg49783
I2
sg49784
I9
sg49812
VP00374
p63718
sg49787
VDHFR gene
p63719
sasg49779
(lp63720
(dp63721
g49782
I45
sg49783
I2
sg49784
I25
sg49785
VC0854915
p63722
sg49787
Vunilateral retinoblastoma
p63723
sasa(dp63724
g49775
VRetinoblastoma protein (pRb) was highly phosphorylated but p107 was upregulated, and the expression of E2f target genes was dysregulated as shown by upregulation of Cdc6 but downregulation of cyclin E, dihydrofolate reductase (dhfr), Cdc25a and B-Myb in chondrocytes of K6(H)/D1(H) mice.
p63725
sg49777
(lp63726
(dp63727
g49782
I103
sg49783
I3
sg49784
I16
sg49812
VP01893
p63728
sg49787
VE2f target genes
p63729
sa(dp63730
g49782
I192
sg49783
I2
sg49784
I8
sg49812
VP24864
p63731
sg49787
Vcyclin E
p63732
sa(dp63733
g49782
I234
sg49783
I1
sg49784
I6
sg49812
VP30304
p63734
sg49787
VCdc25a
p63735
sa(dp63736
g49782
I227
sg49783
I1
sg49784
I4
sg49812
VP00374
p63737
sg49787
Vdhfr
p63738
sa(dp63739
g49782
I0
sg49783
I2
sg49784
I22
sg49812
g11
sg49787
VRetinoblastoma protein
p63740
sa(dp63741
g49782
I245
sg49783
I1
sg49784
I5
sg49812
VP10244
p63742
sg49787
VB-Myb
p63743
sa(dp63744
g49782
I24
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VpRb
p63745
sa(dp63746
g49782
I165
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VCdc6
p63747
sa(dp63748
g49782
I59
sg49783
I1
sg49784
I4
sg49812
VP28749
p63749
sg49787
Vp107
p63750
sa(dp63751
g49782
I202
sg49783
I2
sg49784
I23
sg49812
VP00374
p63752
sg49787
Vdihydrofolate reductase
p63753
sasg49779
(lp63754
(dp63755
g49782
I0
sg49783
I1
sg49784
I14
sg49785
VC0035335
p63756
sg49787
VRetinoblastoma
p63757
sasa(dp63758
g49775
VThe authors used a case-control study design to examine the association between retinoblastoma risk and maternal variations in the folate-metabolizing genes methylenetetrahydrofolate reductase (MTHFR) (a cytosine-to-thymine substitution at nucleotide 677 [MTHFR677C-&gt;T]; reference single nucleotide polymorphism rs1801133) and dihydrofolate reductase (DHFR) (a 19-base-pair deletion of intron 1a [DHFR19bpdel]; rs70991108).
p63759
sg49777
(lp63760
(dp63761
g49782
I330
sg49783
I2
sg49784
I23
sg49812
VP00374
p63762
sg49787
Vdihydrofolate reductase
p63763
sa(dp63764
g49782
I355
sg49783
I1
sg49784
I4
sg49812
VP00374
p63765
sg49787
VDHFR
p63766
sa(dp63767
g49782
I194
sg49783
I1
sg49784
I5
sg49812
VP42898
p63768
sg49787
VMTHFR
p63769
sa(dp63770
g49782
I131
sg49783
I4
sg49784
I61
sg49812
VP42898
p63771
sg49787
Vfolate-metabolizing genes methylenetetrahydrofolate reductase
p63772
sasg49779
(lp63773
(dp63774
g49782
I80
sg49783
I1
sg49784
I14
sg49785
VC0035335
p63775
sg49787
Vretinoblastoma
p63776
sasa(dp63777
g49775
VThe risk of having a child with unilateral retinoblastoma was associated with maternal homozygosity for DHFR19bpdel (odds ratio, 3.78; 95% confidence interval, 1.89-7.55; P = .0002), even after controlling for the child's DHFR19bpdel genotype (odds ratio, 2.81; 95% confidence interval, 1.32-5.99; P = .0073).
p63778
sg49777
(lp63779
sg49779
(lp63780
(dp63781
g49782
I32
sg49783
I2
sg49784
I25
sg49785
VC0854915
p63782
sg49787
Vunilateral retinoblastoma
p63783
sasa(dp63784
g49775
VMaternal homozygosity for a polymorphism in the DHFR gene necessary for converting synthetic folic acid into biologic folate was associated with an increased risk for retinoblastoma.
p63785
sg49777
(lp63786
(dp63787
g49782
I48
sg49783
I2
sg49784
I9
sg49812
VP00374
p63788
sg49787
VDHFR gene
p63789
sasg49779
(lp63790
(dp63791
g49782
I167
sg49783
I1
sg49784
I14
sg49785
VC0035335
p63792
sg49787
Vretinoblastoma
p63793
sasa(dp63794
g49775
VTo explore the role of Major Vault Protein (MVP) in oral cavity squamous cell carcinoma patients.
p63795
sg49777
(lp63796
(dp63797
g49782
I23
sg49783
I3
sg49784
I19
sg49812
g11
sg49787
VMajor Vault Protein
p63798
sa(dp63799
g49782
I44
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VMVP
p63800
sasg49779
(lp63801
(dp63802
g49782
I23
sg49783
I3
sg49784
I19
sg49785
VC0026267
p63803
sg49787
VMajor Vault Protein
p63804
sa(dp63805
g49782
I44
sg49783
I1
sg49784
I3
sg49785
VC0026267
p63806
sg49787
VMVP
p63807
sa(dp63808
g49782
I52
sg49783
I5
sg49784
I35
sg49785
VC0585362
p63809
sg49787
Voral cavity squamous cell carcinoma
p63810
sasa(dp63811
g49775
VMolecular analysis of the GYS2 gene was not feasible, but this particular gene was included in the panel of hypoglycemia of whole exome sequencing (WES) which was at our disposal.
p63812
sg49777
(lp63813
(dp63814
g49782
I26
sg49783
I2
sg49784
I9
sg49812
VP54840
p63815
sg49787
VGYS2 gene
p63816
sasg49779
(lp63817
(dp63818
g49782
I108
sg49783
I1
sg49784
I12
sg49785
VC0020615
p63819
sg49787
Vhypoglycemia
p63820
sasa(dp63821
g49775
VTo understand the frequency of GSD0 in patients presenting with ketotic hypoglycaemia and to report a novel mutation in the GYS2 gene.
p63822
sg49777
(lp63823
(dp63824
g49782
I124
sg49783
I2
sg49784
I9
sg49812
VP54840
p63825
sg49787
VGYS2 gene
p63826
sasg49779
(lp63827
(dp63828
g49782
I64
sg49783
I2
sg49784
I21
sg49785
VC0271713
p63829
sg49787
Vketotic hypoglycaemia
p63830
sa(dp63831
g49782
I102
sg49783
I2
sg49784
I14
sg49785
VC2985438
p63832
sg49787
Vnovel mutation
p63833
sasa(dp63834
g49775
VThe GYS2 gene was sequenced in 50 patients diagnosed with ketotic hypoglycaemia.
p63835
sg49777
(lp63836
(dp63837
g49782
I4
sg49783
I2
sg49784
I9
sg49812
VP54840
p63838
sg49787
VGYS2 gene
p63839
sasg49779
(lp63840
(dp63841
g49782
I58
sg49783
I2
sg49784
I21
sg49785
VC0271713
p63842
sg49787
Vketotic hypoglycaemia
p63843
sasa(dp63844
g49775
VSequencing of the GYS2 gene is more likely to be positive in patients with fasting ketotic hypoglycaemia and concomitant postprandial hyperglycaemia with hyperlactataemia.
p63845
sg49777
(lp63846
(dp63847
g49782
I18
sg49783
I2
sg49784
I9
sg49812
VP54840
p63848
sg49787
VGYS2 gene
p63849
sasg49779
(lp63850
(dp63851
g49782
I83
sg49783
I2
sg49784
I21
sg49785
VC0271713
p63852
sg49787
Vketotic hypoglycaemia
p63853
sa(dp63854
g49782
I134
sg49783
I1
sg49784
I14
sg49785
VC0020456
p63855
sg49787
Vhyperglycaemia
p63856
sasa(dp63857
g49775
VBiochemical evaluation as well as direct sequencing of exons and exon-intron boundary regions of the GYS2 gene were performed in a patient presenting fasting hypoglycemia and postprandial hyperglycemia and her parents.
p63858
sg49777
(lp63859
(dp63860
g49782
I101
sg49783
I2
sg49784
I9
sg49812
VP54840
p63861
sg49787
VGYS2 gene
p63862
sasg49779
(lp63863
(dp63864
g49782
I188
sg49783
I1
sg49784
I13
sg49785
VC0020456
p63865
sg49787
Vhyperglycemia
p63866
sa(dp63867
g49782
I150
sg49783
I2
sg49784
I20
sg49785
VC0271708
p63868
sg49787
Vfasting hypoglycemia
p63869
sasa(dp63870
g49775
VA 7 year-old boy presenting with growth retardation, fasting hypoglycemia and ketoacidosis was diagnosed as having both idiopathic growth hormone (GH) deficiency and hepatic glycogen synthase (GS) deficiency caused by a homozygous mutation in exon 5 of the liver glycogen synthase gene (GYS-2).
p63871
sg49777
(lp63872
(dp63873
g49782
I120
sg49783
I3
sg49784
I25
sg49812
VP01242
p63874
sg49787
Vidiopathic growth hormone
p63875
sa(dp63876
g49782
I287
sg49783
I1
sg49784
I5
sg49812
VP13807
p63877
sg49787
VGYS-2
p63878
sa(dp63879
g49782
I263
sg49783
I3
sg49784
I22
sg49812
VP13807
p63880
sg49787
Vglycogen synthase gene
p63881
sa(dp63882
g49782
I193
sg49783
I1
sg49784
I2
sg49812
VP15104
p63883
sg49787
VGS
p63884
sa(dp63885
g49782
I166
sg49783
I3
sg49784
I25
sg49812
g11
sg49787
Vhepatic glycogen synthase
p63886
sasg49779
(lp63887
(dp63888
g49782
I53
sg49783
I2
sg49784
I20
sg49785
VC0271708
p63889
sg49787
Vfasting hypoglycemia
p63890
sa(dp63891
g49782
I78
sg49783
I1
sg49784
I12
sg49785
VC0220982
p63892
sg49787
Vketoacidosis
p63893
sa(dp63894
g49782
I33
sg49783
I2
sg49784
I18
sg49785
VC0151686
p63895
sg49787
Vgrowth retardation
p63896
sasa(dp63897
g49775
VGPB dosed at 6 mL BID lowered fasting ammonia levels in cirrhotic patients with HE as compared with baseline, was better tolerated than 9 mL BID, and is appropriate for further evaluation in patients with cirrhosis and episodic HE.
p63898
sg49777
(lp63899
sg49779
(lp63900
(dp63901
g49782
I205
sg49783
I1
sg49784
I9
sg49785
VC0023890
p63902
sg49787
Vcirrhosis
p63903
sasa(dp63904
g49775
VGPB reduced HE events as well as ammonia in patients with cirrhosis and HE and its safety profile was similar to placebo.
p63905
sg49777
(lp63906
sg49779
(lp63907
(dp63908
g49782
I58
sg49783
I1
sg49784
I9
sg49785
VC0023890
p63909
sg49787
Vcirrhosis
p63910
sasa(dp63911
g49775
VIn vitro and clinical studies have been performed to assess GPB digestion, safety, and pharmacology in healthy adults and individuals with cirrhosis.
p63912
sg49777
(lp63913
sg49779
(lp63914
(dp63915
g49782
I139
sg49783
I1
sg49784
I9
sg49785
VC0023890
p63916
sg49787
Vcirrhosis
p63917
sasa(dp63918
g49775
VGPB exhibits delayed release characteristics, presumably reflecting gradual PBA release by pancreatic lipases, and is well tolerated in adults with cirrhosis, suggesting that further clinical testing for HE is warranted.
p63919
sg49777
(lp63920
(dp63921
g49782
I0
sg49783
I1
sg49784
I3
sg49812
VP06028
p63922
sg49787
VGPB
p63923
sa(dp63924
g49782
I102
sg49783
I1
sg49784
I7
sg49812
VP04118
p63925
sg49787
Vlipases
p63926
sasg49779
(lp63927
(dp63928
g49782
I148
sg49783
I1
sg49784
I9
sg49785
VC0023890
p63929
sg49787
Vcirrhosis
p63930
sasa(dp63931
g49775
VHowever, the role of S1PR1 in the progression of human acute myeloid leukemia (AML) remains to be fully elucidated.
p63932
sg49777
(lp63933
(dp63934
g49782
I21
sg49783
I1
sg49784
I5
sg49812
VP21453
p63935
sg49787
VS1PR1
p63936
sasg49779
(lp63937
(dp63938
g49782
I79
sg49783
I1
sg49784
I3
sg49785
VC0023467
p63939
sg49787
VAML
p63940
sa(dp63941
g49782
I55
sg49783
I3
sg49784
I22
sg49785
VC0023467
p63942
sg49787
Vacute myeloid leukemia
p63943
sasa(dp63944
g49775
VUsing overexpression and RNA interference knockdown assays, it was shown that the expression of S1PR1 in several human myeloid leukemia cell lines contributed to the suppression of cell apoptosis and promotion of cell proliferation.
p63945
sg49777
(lp63946
(dp63947
g49782
I96
sg49783
I1
sg49784
I5
sg49812
VP21453
p63948
sg49787
VS1PR1
p63949
sasg49779
(lp63950
(dp63951
g49782
I218
sg49783
I1
sg49784
I13
sg49785
VC0334094
p63952
sg49787
Vproliferation
p63953
sa(dp63954
g49782
I166
sg49783
I1
sg49784
I11
sg49785
VC0221103
p63955
sg49787
Vsuppression
p63956
sa(dp63957
g49782
I119
sg49783
I2
sg49784
I16
sg49785
VC0023470
p63958
sg49787
Vmyeloid leukemia
p63959
sasa(dp63960
g49775
VCirculating chronic lymphocytic leukemia (CLL) cells display an abnormal increase in the surface levels of the homing receptors CCR7 and CXCR4 concomitant with low S1P receptor 1 (S1P1) expression.
p63961
sg49777
(lp63962
(dp63963
g49782
I128
sg49783
I1
sg49784
I4
sg49812
VP32248
p63964
sg49787
VCCR7
p63965
sa(dp63966
g49782
I164
sg49783
I3
sg49784
I14
sg49812
g11
sg49787
VS1P receptor 1
p63967
sa(dp63968
g49782
I137
sg49783
I1
sg49784
I5
sg49812
VP61073
p63969
sg49787
VCXCR4
p63970
sa(dp63971
g49782
I180
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VS1P1
p63972
sasg49779
(lp63973
(dp63974
g49782
I12
sg49783
I3
sg49784
I28
sg49785
VC0023434
p63975
sg49787
Vchronic lymphocytic leukemia
p63976
sa(dp63977
g49782
I42
sg49783
I1
sg49784
I3
sg49785
VC0023434
p63978
sg49787
VCLL
p63979
sasa(dp63980
g49775
VPrevious work in our laboratory identified keratin 17 (K17) as a specific and sensitive biomarker for high-grade squamous intraepithelial lesions and cervical squamous cell carcinoma (SCC).
p63981
sg49777
(lp63982
(dp63983
g49782
I55
sg49783
I1
sg49784
I3
sg49812
VP02533
p63984
sg49787
VK17
p63985
sa(dp63986
g49782
I43
sg49783
I2
sg49784
I10
sg49812
VP02533
p63987
sg49787
Vkeratin 17
p63988
sasg49779
(lp63989
(dp63990
g49782
I150
sg49783
I4
sg49784
I32
sg49785
VC0279671
p63991
sg49787
Vcervical squamous cell carcinoma
p63992
sasa(dp63993
g49775
VIn this study, we show that high expression of keratin-17 (K17) predicts poor outcome in patients with cervical cancer, at early or late stages of disease, surpassing in accuracy either tumor staging or loss of p27(KIP1) as a negative prognostic marker in this setting.
p63994
sg49777
(lp63995
(dp63996
g49782
I47
sg49783
I1
sg49784
I10
sg49812
VP02533
p63997
sg49787
Vkeratin-17
p63998
sa(dp63999
g49782
I211
sg49783
I1
sg49784
I3
sg49812
VP40305
p64000
sg49787
Vp27
p64001
sa(dp64002
g49782
I59
sg49783
I1
sg49784
I3
sg49812
VP02533
p64003
sg49787
VK17
p64004
sa(dp64005
g49782
I215
sg49783
I1
sg49784
I4
sg49812
VP46527
p64006
sg49787
VKIP1
p64007
sasg49779
(lp64008
(dp64009
g49782
I103
sg49783
I2
sg49784
I15
sg49785
VC0302592
p64010
sg49787
Vcervical cancer
p64011
sa(dp64012
g49782
I186
sg49783
I1
sg49784
I5
sg49785
VC0027651
p64013
sg49787
Vtumor
p64014
sasa(dp64015
g49775
VIn summary, both KRT4 and KRT17 expressions are related to the histopathology of the cervical squamous mucosa; KRT17 is highly overexpressed in immature squamous metaplasia, in HSIL, and in squamous cell carcinoma and the level of KRT17 in squamous cell carcinoma may help to identify patients who are at greatest risk for cervical cancer mortality.
p64016
sg49777
(lp64017
(dp64018
g49782
I17
sg49783
I1
sg49784
I4
sg49812
VP19013
p64019
sg49787
VKRT4
p64020
sasg49779
(lp64021
(dp64022
g49782
I323
sg49783
I2
sg49784
I15
sg49785
VC0302592
p64023
sg49787
Vcervical cancer
p64024
sa(dp64025
g49782
I153
sg49783
I2
sg49784
I19
sg49785
VC0025570
p64026
sg49787
Vsquamous metaplasia
p64027
sa(dp64028
g49782
I177
sg49783
I1
sg49784
I4
sg49785
VC0333875
p64029
sg49787
VHSIL
p64030
sa(dp64031
g49782
I190
sg49783
I3
sg49784
I23
sg49785
VC0007137
p64032
sg49787
Vsquamous cell carcinoma
p64033
sa(dp64034
g49782
I190
sg49783
I3
sg49784
I23
sg49785
VC0007137
p64035
sg49787
Vsquamous cell carcinoma
p64036
sasa(dp64037
g49775
VP2X4 receptors in microglia are up-regulated in epilepsy and in neuropathic pain; that is to say, their total and/or PM expression levels increase.
p64038
sg49777
(lp64039
(dp64040
g49782
I0
sg49783
I2
sg49784
I14
sg49812
g11
sg49787
VP2X4 receptors
p64041
sasg49779
(lp64042
(dp64043
g49782
I48
sg49783
I1
sg49784
I8
sg49785
VC0014544
p64044
sg49787
Vepilepsy
p64045
sa(dp64046
g49782
I64
sg49783
I2
sg49784
I16
sg49785
VC0027796
p64047
sg49787
Vneuropathic pain
p64048
sasa(dp64049
g49775
VExpression of several members of the family including P2X2, P2X4, and P2X7 receptors has been reported to be altered in the hippocampus following status epilepticus.
p64050
sg49777
(lp64051
(dp64052
g49782
I70
sg49783
I2
sg49784
I14
sg49812
g11
sg49787
VP2X7 receptors
p64053
sasg49779
(lp64054
(dp64055
g49782
I146
sg49783
I2
sg49784
I18
sg49785
VC0038220
p64056
sg49787
Vstatus epilepticus
p64057
sasa(dp64058
g49775
VRecent work also found altered neuronal injury and inflammation after status epilepticus in mice lacking the P2X4 receptor.
p64059
sg49777
(lp64060
(dp64061
g49782
I109
sg49783
I2
sg49784
I13
sg49812
g11
sg49787
VP2X4 receptor
p64062
sasg49779
(lp64063
(dp64064
g49782
I70
sg49783
I2
sg49784
I18
sg49785
VC0038220
p64065
sg49787
Vstatus epilepticus
p64066
sa(dp64067
g49782
I51
sg49783
I1
sg49784
I12
sg49785
VC0021368
p64068
sg49787
Vinflammation
p64069
sasa(dp64070
g49775
VIn this study, we investigated the potential involvement of P2X4R in microglial functions in a model of kainate (KA)-induced status epilepticus (SE).
p64071
sg49777
(lp64072
(dp64073
g49782
I60
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VP2X4R
p64074
sasg49779
(lp64075
(dp64076
g49782
I125
sg49783
I2
sg49784
I18
sg49785
VC0038220
p64077
sg49787
Vstatus epilepticus
p64078
sa(dp64079
g49782
I145
sg49783
I1
sg49784
I2
sg49785
VC0038220
p64080
sg49787
VSE
p64081
sasa(dp64082
g49775
VHere we show that, in the seizure-sensitive (SS) gerbil hippocampus, a recognized genetic epilepsy model, the expressions of both P2X2 and P2X4 receptors are markedly decreased as compared with that in the seizure-resistant (SR) gerbil.
p64083
sg49777
(lp64084
(dp64085
g49782
I139
sg49783
I2
sg49784
I14
sg49812
g11
sg49787
VP2X4 receptors
p64086
sasg49779
(lp64087
(dp64088
g49782
I26
sg49783
I1
sg49784
I7
sg49785
VC0036572
p64089
sg49787
Vseizure
p64090
sa(dp64091
g49782
I26
sg49783
I1
sg49784
I7
sg49785
VC0036572
p64092
sg49787
Vseizure
p64093
sa(dp64094
g49782
I90
sg49783
I1
sg49784
I8
sg49785
VC0014544
p64095
sg49787
Vepilepsy
p64096
sasa(dp64097
g49775
VIn addition to pathogen recognition, DCIR has been shown to be pivotal in preventing autoimmune disease by controlling dendritic cell proliferation.
p64098
sg49777
(lp64099
(dp64100
g49782
I37
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VDCIR
p64101
sasg49779
(lp64102
(dp64103
g49782
I134
sg49783
I1
sg49784
I13
sg49785
VC0334094
p64104
sg49787
Vproliferation
p64105
sa(dp64106
g49782
I85
sg49783
I2
sg49784
I18
sg49785
VC0004364
p64107
sg49787
Vautoimmune disease
p64108
sasa(dp64109
g49775
VThis study was aimed to further investigate whether DCIR polymorphisms are novel susceptibility factors for other autoimmune diseases, i.e.
p64110
sg49777
(lp64111
sg49779
(lp64112
(dp64113
g49782
I114
sg49783
I2
sg49784
I19
sg49785
VC0004364
p64114
sg49787
Vautoimmune diseases
p64115
sasa(dp64116
g49775
VTubulointerstitial nephritis and uveitis syndrome, HLA-B27-associated uveitis, inflammatory bowel disease, and Kawasaki disease each made up fewer than 5% of diagnoses.
p64117
sg49777
(lp64118
(dp64119
g49782
I51
sg49783
I1
sg49784
I7
sg49812
VP30486
p64120
sg49787
VHLA-B27
p64121
sasg49779
(lp64122
(dp64123
g49782
I0
sg49783
I5
sg49784
I49
sg49785
VC1639520
p64124
sg49787
VTubulointerstitial nephritis and uveitis syndrome
p64125
sa(dp64126
g49782
I79
sg49783
I3
sg49784
I26
sg49785
VC0021390
p64127
sg49787
Vinflammatory bowel disease
p64128
sa(dp64129
g49782
I33
sg49783
I1
sg49784
I7
sg49785
VC0042164
p64130
sg49787
Vuveitis
p64131
sa(dp64132
g49782
I111
sg49783
I2
sg49784
I16
sg49785
VC0026691
p64133
sg49787
VKawasaki disease
p64134
sasa(dp64135
g49775
VStromal tissue was isolated from epithelial cells with laser capture microdissection (LCMD) and analyzed by cDNA array for the expression of TGFalpha, TGF-beta1, HGF, PDGF-alpha, IGFII, bFGF, aFGF, VEGFC, and VEGF.
p64136
sg49777
(lp64137
(dp64138
g49782
I151
sg49783
I1
sg49784
I9
sg49812
VP01137
p64139
sg49787
VTGF-beta1
p64140
sa(dp64141
g49782
I192
sg49783
I1
sg49784
I4
sg49812
VP05230
p64142
sg49787
VaFGF
p64143
sa(dp64144
g49782
I198
sg49783
I1
sg49784
I5
sg49812
VP49767
p64145
sg49787
VVEGFC
p64146
sa(dp64147
g49782
I141
sg49783
I1
sg49784
I8
sg49812
VP01135
p64148
sg49787
VTGFalpha
p64149
sa(dp64150
g49782
I167
sg49783
I1
sg49784
I10
sg49812
VP04085
p64151
sg49787
VPDGF-alpha
p64152
sa(dp64153
g49782
I162
sg49783
I1
sg49784
I3
sg49812
VP05231
p64154
sg49787
VHGF
p64155
sa(dp64156
g49782
I186
sg49783
I1
sg49784
I4
sg49812
VP53370
p64157
sg49787
VbFGF
p64158
sa(dp64159
g49782
I179
sg49783
I1
sg49784
I5
sg49812
VP01344
p64160
sg49787
VIGFII
p64161
sasg49779
(lp64162
(dp64163
g49782
I162
sg49783
I1
sg49784
I3
sg49785
VC0399440
p64164
sg49787
VHGF
p64165
sasa(dp64166
g49775
VHere, we demonstrate that Inositol Polyphosphate-5-Phosphatase F (INPP5F), one of the polyphosphoinositide phosphatases, is differentially expressed in GSCs from glioma patients, and is identified as an inhibitor of STAT3 signaling via interaction with STAT3 and inhibition of its phosphorylation.
p64167
sg49777
(lp64168
(dp64169
g49782
I66
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VINPP5F
p64170
sa(dp64171
g49782
I216
sg49783
I1
sg49784
I5
sg49812
VP40763
p64172
sg49787
VSTAT3
p64173
sa(dp64174
g49782
I216
sg49783
I1
sg49784
I5
sg49812
VP40763
p64175
sg49787
VSTAT3
p64176
sa(dp64177
g49782
I26
sg49783
I3
sg49784
I38
sg49812
g11
sg49787
VInositol Polyphosphate-5-Phosphatase F
p64178
sasg49779
(lp64179
(dp64180
g49782
I162
sg49783
I1
sg49784
I6
sg49785
VC0017638
p64181
sg49787
Vglioma
p64182
sasa(dp64183
g49775
VIn addition, loss of INPP5F gene in gliomas is significantly correlated with lower overall patient survivals.
p64184
sg49777
(lp64185
(dp64186
g49782
I21
sg49783
I2
sg49784
I11
sg49812
g11
sg49787
VINPP5F gene
p64187
sasg49779
(lp64188
(dp64189
g49782
I36
sg49783
I1
sg49784
I7
sg49785
VC0017638
p64190
sg49787
Vgliomas
p64191
sasa(dp64192
g49775
VThese findings suggest that INPP5F is a potential tumor suppressor in gliomas via inhibition of STAT3 pathway, and that deregulation of INPP5F may lead to contribution to gliomagenesis.
p64193
sg49777
(lp64194
(dp64195
g49782
I28
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VINPP5F
p64196
sa(dp64197
g49782
I96
sg49783
I1
sg49784
I5
sg49812
VP40763
p64198
sg49787
VSTAT3
p64199
sa(dp64200
g49782
I28
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VINPP5F
p64201
sasg49779
(lp64202
(dp64203
g49782
I70
sg49783
I1
sg49784
I7
sg49785
VC0017638
p64204
sg49787
Vgliomas
p64205
sa(dp64206
g49782
I50
sg49783
I1
sg49784
I5
sg49785
VC0027651
p64207
sg49787
Vtumor
p64208
sasa(dp64209
g49775
VThe patient and his identical twin show a retinal dystrophy that, based on clinical appearance, visual fields, amd electrophysiology, is most likely autosomal recessive retinitis pigmentosa.
p64210
sg49777
(lp64211
sg49779
(lp64212
(dp64213
g49782
I42
sg49783
I2
sg49784
I17
sg49785
VC0854723
p64214
sg49787
Vretinal dystrophy
p64215
sa(dp64216
g49782
I149
sg49783
I4
sg49784
I40
sg49785
VC0339526
p64217
sg49787
Vautosomal recessive retinitis pigmentosa
p64218
sa(dp64219
g49782
I111
sg49783
I1
sg49784
I3
sg49785
VC0242383
p64220
sg49787
Vamd
p64221
sasa(dp64222
g49775
VAlthough Gln supplementation had no effect on the loss of the tight junction protein occludin, the increased portal endotoxin and fasting glucose concentrations found in WSD-fed mice, markers of liver damage (e.g., nonalcoholic fatty liver disease activity score and number of neutrophils in the liver) were significantly lower in the WSD+Gln group than in the WSD group (~47% and ~60% less, respectively; P &lt; 0.05).
p64223
sg49777
(lp64224
(dp64225
g49782
I109
sg49783
I2
sg49784
I16
sg49812
g11
sg49787
Vportal endotoxin
p64226
sasg49779
(lp64227
(dp64228
g49782
I215
sg49783
I4
sg49784
I32
sg49785
VC0400966
p64229
sg49787
Vnonalcoholic fatty liver disease
p64230
sa(dp64231
g49782
I195
sg49783
I2
sg49784
I12
sg49785
VC0151763
p64232
sg49787
Vliver damage
p64233
sasa(dp64234
g49775
VThe purpose of this Evidence-Based Practice (EBP) paper is to answer PICOT questions by a review the effectiveness of chronotherapeutics interventions on depressive symptoms with depression and the depressive episode in the course of bipolar disorder.
p64235
sg49777
(lp64236
sg49779
(lp64237
(dp64238
g49782
I179
sg49783
I1
sg49784
I10
sg49785
VC0011581
p64239
sg49787
Vdepression
p64240
sa(dp64241
g49782
I234
sg49783
I2
sg49784
I16
sg49785
VC0005586
p64242
sg49787
Vbipolar disorder
p64243
sa(dp64244
g49782
I154
sg49783
I2
sg49784
I19
sg49785
VC0086132
p64245
sg49787
Vdepressive symptoms
p64246
sa(dp64247
g49782
I198
sg49783
I2
sg49784
I18
sg49785
VC0349217
p64248
sg49787
Vdepressive episode
p64249
sasa(dp64250
g49775
VWe evaluated whether post-bronchiolitis asthma was associated with polymorphisms in the TLR3 rs3775291, TLR4 rs4986790, TLR7 rs179008, TLR8 rs2407992, TLR9 rs187084, and TLR10 rs4129009 genes.
p64251
sg49777
(lp64252
(dp64253
g49782
I151
sg49783
I2
sg49784
I13
sg49812
g11
sg49787
VTLR9 rs187084
p64254
sa(dp64255
g49782
I170
sg49783
I3
sg49784
I21
sg49812
g11
sg49787
VTLR10 rs4129009 genes
p64256
sa(dp64257
g49782
I135
sg49783
I2
sg49784
I14
sg49812
g11
sg49787
VTLR8 rs2407992
p64258
sa(dp64259
g49782
I88
sg49783
I2
sg49784
I14
sg49812
g11
sg49787
VTLR3 rs3775291
p64260
sa(dp64261
g49782
I120
sg49783
I2
sg49784
I13
sg49812
g11
sg49787
VTLR7 rs179008
p64262
sasg49779
(lp64263
(dp64264
g49782
I40
sg49783
I1
sg49784
I6
sg49785
VC0004096
p64265
sg49787
Vasthma
p64266
sa(dp64267
g49782
I26
sg49783
I1
sg49784
I13
sg49785
VC0006271
p64268
sg49787
Vbronchiolitis
p64269
sasa(dp64270
g49775
VThere were no significant associations between TLR3, TLR4, TLR8, or TLR9 polymorphisms and post-bronchiolitis asthma.
p64271
sg49777
(lp64272
(dp64273
g49782
I68
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR9
p64274
sa(dp64275
g49782
I59
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR8
p64276
sa(dp64277
g49782
I47
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR3
p64278
sasg49779
(lp64279
(dp64280
g49782
I110
sg49783
I1
sg49784
I6
sg49785
VC0004096
p64281
sg49787
Vasthma
p64282
sa(dp64283
g49782
I96
sg49783
I1
sg49784
I13
sg49785
VC0006271
p64284
sg49787
Vbronchiolitis
p64285
sasa(dp64286
g49775
VSignificant associations with SAFS compared with atopic asthma included Toll-like receptor 3 (TLR3) (p = .009), TLR9 (p = .025), C-type lectin domain family seven member A (dectin-1) (p = .043), interleukin-10 (IL-10) (p = .0010), mannose-binding lectin (MBL2) (p = .007), CC-chemokine ligand 2 (CCL2) (2 SNPs, p = .025 and .041), CCL17 (p = .002), plasminogen (p = .049) and adenosine A2a receptor (p = .024).
p64287
sg49777
(lp64288
(dp64289
g49782
I211
sg49783
I1
sg49784
I5
sg49812
VP22301
p64290
sg49787
VIL-10
p64291
sa(dp64292
g49782
I94
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR3
p64293
sa(dp64294
g49782
I129
sg49783
I7
sg49784
I42
sg49812
g11
sg49787
VC-type lectin domain family seven member A
p64295
sa(dp64296
g49782
I195
sg49783
I1
sg49784
I14
sg49812
VP22301
p64297
sg49787
Vinterleukin-10
p64298
sa(dp64299
g49782
I376
sg49783
I3
sg49784
I22
sg49812
VP29274
p64300
sg49787
Vadenosine A2a receptor
p64301
sa(dp64302
g49782
I349
sg49783
I1
sg49784
I11
sg49812
VP00747
p64303
sg49787
Vplasminogen
p64304
sa(dp64305
g49782
I112
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR9
p64306
sa(dp64307
g49782
I72
sg49783
I3
sg49784
I20
sg49812
g11
sg49787
VToll-like receptor 3
p64308
sa(dp64309
g49782
I255
sg49783
I1
sg49784
I4
sg49812
VP11226
p64310
sg49787
VMBL2
p64311
sa(dp64312
g49782
I331
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCCL17
p64313
sa(dp64314
g49782
I296
sg49783
I1
sg49784
I4
sg49812
VP13500
p64315
sg49787
VCCL2
p64316
sa(dp64317
g49782
I231
sg49783
I2
sg49784
I22
sg49812
VP11226
p64318
sg49787
Vmannose-binding lectin
p64319
sa(dp64320
g49782
I273
sg49783
I3
sg49784
I21
sg49812
VP51671
p64321
sg49787
VCC-chemokine ligand 2
p64322
sasg49779
(lp64323
(dp64324
g49782
I49
sg49783
I2
sg49784
I13
sg49785
VC0155877
p64325
sg49787
Vatopic asthma
p64326
sasa(dp64327
g49775
VAsthmatics had significantly lower circulating HPC expressing TLR-2 and TLR-9 with a similar trend for TLR-4.
p64328
sg49777
(lp64329
(dp64330
g49782
I47
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VHPC
p64331
sa(dp64332
g49782
I62
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTLR-2
p64333
sa(dp64334
g49782
I72
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VTLR-9
p64335
sasg49779
(lp64336
(dp64337
g49782
I47
sg49783
I1
sg49784
I3
sg49785
VC0238339
p64338
sg49787
VHPC
p64339
sa(dp64340
g49782
I0
sg49783
I1
sg49784
I10
sg49785
VC0004096
p64341
sg49787
VAsthmatics
p64342
sasa(dp64343
g49775
VThe endosomal TLRs have been shown to be associated with the induction of asthmatic inflammation (TLR3), and with disease exacerbations (TLR7, TLR8 and TLR9).
p64344
sg49777
(lp64345
(dp64346
g49782
I137
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR7
p64347
sa(dp64348
g49782
I152
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR9
p64349
sa(dp64350
g49782
I143
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR8
p64351
sa(dp64352
g49782
I98
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VTLR3
p64353
sasg49779
(lp64354
(dp64355
g49782
I84
sg49783
I1
sg49784
I12
sg49785
VC0021368
p64356
sg49787
Vinflammation
p64357
sa(dp64358
g49782
I74
sg49783
I1
sg49784
I9
sg49785
VC0004096
p64359
sg49787
Vasthmatic
p64360
sasa(dp64361
g49775
VA defect in the P-protein component of the glycine cleavage system has been the most frequent abnormality found in patients with glycine encephalopathy (NKH).
p64362
sg49777
(lp64363
sg49779
(lp64364
(dp64365
g49782
I153
sg49783
I1
sg49784
I3
sg49785
VC0751748
p64366
sg49787
VNKH
p64367
sa(dp64368
g49782
I129
sg49783
I2
sg49784
I22
sg49785
VC0751748
p64369
sg49787
Vglycine encephalopathy
p64370
sasa(dp64371
g49775
VSoluble tumor necrosis factor receptor 1 (sTNF-R1), interleukin-1 receptor antagonist (IL-1Ra), von Willebrand factor (VWF), and osteoprotegerin (OPG) were measured in schizophrenia (n = 69) and affective (n = 55) spectrum patients at baseline and at one-year follow-up, and compared to healthy controls (HC) (n = 92) with analysis of covariance.
p64372
sg49777
(lp64373
(dp64374
g49782
I96
sg49783
I3
sg49784
I21
sg49812
VP04275
p64375
sg49787
Vvon Willebrand factor
p64376
sa(dp64377
g49782
I129
sg49783
I1
sg49784
I15
sg49812
g11
sg49787
Vosteoprotegerin
p64378
sa(dp64379
g49782
I52
sg49783
I3
sg49784
I33
sg49812
VP18510
p64380
sg49787
Vinterleukin-1 receptor antagonist
p64381
sa(dp64382
g49782
I0
sg49783
I6
sg49784
I40
sg49812
g11
sg49787
VSoluble tumor necrosis factor receptor 1
p64383
sa(dp64384
g49782
I146
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VOPG
p64385
sa(dp64386
g49782
I87
sg49783
I1
sg49784
I6
sg49812
VP18510
p64387
sg49787
VIL-1Ra
p64388
sa(dp64389
g49782
I119
sg49783
I1
sg49784
I3
sg49812
VP04275
p64390
sg49787
VVWF
p64391
sa(dp64392
g49782
I42
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VsTNF-R1
p64393
sasg49779
(lp64394
(dp64395
g49782
I168
sg49783
I1
sg49784
I13
sg49785
VC0036341
p64396
sg49787
Vschizophrenia
p64397
sa(dp64398
g49782
I8
sg49783
I2
sg49784
I14
sg49785
VC0333516
p64399
sg49787
Vtumor necrosis
p64400
sasa(dp64401
g49775
VSerum sTNFR1 was significantly higher in patients with acute-stage schizophrenia compared to matched controls while no significant group differences were observed for the other markers.
p64402
sg49777
(lp64403
sg49779
(lp64404
(dp64405
g49782
I67
sg49783
I1
sg49784
I13
sg49785
VC0036341
p64406
sg49787
Vschizophrenia
p64407
sasa(dp64408
g49775
VPlasma levels of soluble tumor necrosis factor receptor 1 (sTNF-R1), interleukin 1 receptor antagonist (IL-1Ra), osteoprotegerin (OPG), and von Willebrand factor (vWf) were measured in patients (n=992) with schizophrenia spectrum (SCZ, n=584), schizoaffective disorder (SA, n=93), affective spectrum disorders (AFF, n=315), and healthy controls (HC, n=638).
p64409
sg49777
(lp64410
(dp64411
g49782
I163
sg49783
I1
sg49784
I3
sg49812
VP04275
p64412
sg49787
VvWf
p64413
sa(dp64414
g49782
I17
sg49783
I6
sg49784
I40
sg49812
g11
sg49787
Vsoluble tumor necrosis factor receptor 1
p64415
sa(dp64416
g49782
I104
sg49783
I1
sg49784
I6
sg49812
VP18510
p64417
sg49787
VIL-1Ra
p64418
sa(dp64419
g49782
I130
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VOPG
p64420
sa(dp64421
g49782
I59
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VsTNF-R1
p64422
sa(dp64423
g49782
I69
sg49783
I4
sg49784
I33
sg49812
VP18510
p64424
sg49787
Vinterleukin 1 receptor antagonist
p64425
sa(dp64426
g49782
I140
sg49783
I3
sg49784
I21
sg49812
VP04275
p64427
sg49787
Vvon Willebrand factor
p64428
sa(dp64429
g49782
I113
sg49783
I1
sg49784
I15
sg49812
g11
sg49787
Vosteoprotegerin
p64430
sasg49779
(lp64431
(dp64432
g49782
I244
sg49783
I2
sg49784
I24
sg49785
VC0036337
p64433
sg49787
Vschizoaffective disorder
p64434
sa(dp64435
g49782
I25
sg49783
I2
sg49784
I14
sg49785
VC0333516
p64436
sg49787
Vtumor necrosis
p64437
sa(dp64438
g49782
I270
sg49783
I1
sg49784
I2
sg49785
VC0036337
p64439
sg49787
VSA
p64440
sa(dp64441
g49782
I207
sg49783
I1
sg49784
I13
sg49785
VC0036341
p64442
sg49787
Vschizophrenia
p64443
sasa(dp64444
g49775
VMIS includes 10 components: dry weight changes, dietary intake, functional capacity, comorbidity, muscle wasting and loss of subcutaneous fat as well as body mass index (BMI), serum albumin level and total iron binding capacity (TIBC).
p64445
sg49777
(lp64446
(dp64447
g49782
I176
sg49783
I2
sg49784
I13
sg49812
g11
sg49787
Vserum albumin
p64448
sasg49779
(lp64449
(dp64450
g49782
I98
sg49783
I2
sg49784
I14
sg49785
VC0026846
p64451
sg49787
Vmuscle wasting
p64452
sasa(dp64453
g49775
VThis study suggests that consecutive PNC contributed to the improvement of the protein intake, serum levels of albumin, cholesterol and to the delay of muscle wasting, which could also have a positive impact on the nutritional status, particularly in malnourished patients receiving HD treatment.
p64454
sg49777
(lp64455
(dp64456
g49782
I111
sg49783
I1
sg49784
I7
sg49812
VP00441
p64457
sg49787
Valbumin
p64458
sasg49779
(lp64459
(dp64460
g49782
I152
sg49783
I2
sg49784
I14
sg49785
VC0026846
p64461
sg49787
Vmuscle wasting
p64462
sa(dp64463
g49782
I251
sg49783
I1
sg49784
I12
sg49785
VC0162429
p64464
sg49787
Vmalnourished
p64465
sasa(dp64466
g49775
VGCs = glucocorticoids; HDG = high-dose glucocorticoids; A1C = Hemoglobin A1C; GA = Glycated Albumin; FBG = fasting blood glucose; IG = interstitial glucose; BG = blood glucose; GIH = Glucocorticoids-induced hyperglycemia; HOMA-IR = Homeostasis Model Assessment-Insulin Resistance; CGMS = continuous glucose monitoring system; AUC = the area under the curve; MODD = absolute means of daily differences; LAGE = the largest amplitude of glycemic excursions; BMI = body mass index; DM = diabetes mellitus; SLE = systemic lupus erythematosus; IQR = interquartile range; HR = hazard ratio; PUMCH = Peking Union Medical College Hospital.
p64467
sg49777
(lp64468
(dp64469
g49782
I261
sg49783
I1
sg49784
I7
sg49812
VP01308
p64470
sg49787
VInsulin
p64471
sa(dp64472
g49782
I62
sg49783
I1
sg49784
I10
sg49812
g11
sg49787
VHemoglobin
p64473
sasg49779
(lp64474
(dp64475
g49782
I502
sg49783
I1
sg49784
I3
sg49785
VC0024141
p64476
sg49787
VSLE
p64477
sa(dp64478
g49782
I508
sg49783
I3
sg49784
I28
sg49785
VC0024141
p64479
sg49787
Vsystemic lupus erythematosus
p64480
sa(dp64481
g49782
I483
sg49783
I2
sg49784
I17
sg49785
VC0011849
p64482
sg49787
Vdiabetes mellitus
p64483
sa(dp64484
g49782
I261
sg49783
I2
sg49784
I18
sg49785
VC0021655
p64485
sg49787
VInsulin Resistance
p64486
sa(dp64487
g49782
I207
sg49783
I1
sg49784
I13
sg49785
VC0020456
p64488
sg49787
Vhyperglycemia
p64489
sasa(dp64490
g49775
VObjective To evaluate the presence and localization of folate receptor expressing macrophages in the rat groove model of osteoarthritis and determine the suitability of a new folate conjugate with albumin-binding entity (cm09) for in vivo SPECT (single-photon emission computed tomography) analysis.
p64491
sg49777
(lp64492
(dp64493
g49782
I55
sg49783
I2
sg49784
I15
sg49812
VP15328
p64494
sg49787
Vfolate receptor
p64495
sa(dp64496
g49782
I197
sg49783
I1
sg49784
I7
sg49812
VP00441
p64497
sg49787
Valbumin
p64498
sasg49779
(lp64499
(dp64500
g49782
I121
sg49783
I1
sg49784
I14
sg49785
VC0029408
p64501
sg49787
Vosteoarthritis
p64502
sasa(dp64503
g49775
VResults In vivo SPECT/CT imaging of the new folate conjugate (cm09) was as useful as a folate conjugate without albumin-binding entity in the groove model of osteoarthritis with less renal accumulation.
p64504
sg49777
(lp64505
(dp64506
g49782
I112
sg49783
I1
sg49784
I7
sg49812
VP00441
p64507
sg49787
Valbumin
p64508
sasg49779
(lp64509
(dp64510
g49782
I158
sg49783
I1
sg49784
I14
sg49785
VC0029408
p64511
sg49787
Vosteoarthritis
p64512
sasa(dp64513
g49775
VHowever, the effects of agonistic anti-4-1BB Abs have not been examined in an experimental mouse model of psoriasis.
p64514
sg49777
(lp64515
sg49779
(lp64516
(dp64517
g49782
I106
sg49783
I1
sg49784
I9
sg49785
VC0033860
p64518
sg49787
Vpsoriasis
p64519
sasa(dp64520
g49775
VTherefore, we investigated the protective effects of agonistic anti-4-1BB Abs, using imiquimod (IMQ)-induced psoriasis-like dermatitis in mice, a condition histologically and clinically similar to human psoriasis.
p64521
sg49777
(lp64522
sg49779
(lp64523
(dp64524
g49782
I109
sg49783
I1
sg49784
I9
sg49785
VC0033860
p64525
sg49787
Vpsoriasis
p64526
sa(dp64527
g49782
I109
sg49783
I1
sg49784
I9
sg49785
VC0033860
p64528
sg49787
Vpsoriasis
p64529
sa(dp64530
g49782
I146
sg49783
I1
sg49784
I9
sg49785
VC0012634
p64531
sg49787
Vcondition
p64532
sa(dp64533
g49782
I124
sg49783
I1
sg49784
I10
sg49785
VC0011603
p64534
sg49787
Vdermatitis
p64535
sasa(dp64536
g49775
VWe found that administration of agonistic anti-4-1BB Abs (10mg/kg) significantly alleviated the severity of IMQ-induced psoriasis-like skin inflammation in mice, with reduced histologic symptoms, including inflammatory infiltration, parakeratosis, and hyperkeratosis.
p64537
sg49777
(lp64538
sg49779
(lp64539
(dp64540
g49782
I252
sg49783
I1
sg49784
I14
sg49785
VC0870082
p64541
sg49787
Vhyperkeratosis
p64542
sa(dp64543
g49782
I233
sg49783
I1
sg49784
I13
sg49785
VC0030436
p64544
sg49787
Vparakeratosis
p64545
sa(dp64546
g49782
I206
sg49783
I2
sg49784
I25
sg49785
VC0302158
p64547
sg49787
Vinflammatory infiltration
p64548
sa(dp64549
g49782
I135
sg49783
I2
sg49784
I17
sg49785
VC0011603
p64550
sg49787
Vskin inflammation
p64551
sa(dp64552
g49782
I120
sg49783
I1
sg49784
I9
sg49785
VC0033860
p64553
sg49787
Vpsoriasis
p64554
sasa(dp64555
g49775
VTaken together, our data provide evidence that agonistic anti-4-1BB Abs possesses immunosuppressive properties in IMQ-induced psoriasis-like skin inflammation, providing insight into the immunomodulatory effect of agonistic anti-4-1BB Abs for psoriasis immunotherapy.
p64556
sg49777
(lp64557
sg49779
(lp64558
(dp64559
g49782
I126
sg49783
I1
sg49784
I9
sg49785
VC0033860
p64560
sg49787
Vpsoriasis
p64561
sa(dp64562
g49782
I72
sg49783
I1
sg49784
I9
sg49785
VC0850310
p64563
sg49787
Vpossesses
p64564
sa(dp64565
g49782
I141
sg49783
I2
sg49784
I17
sg49785
VC0011603
p64566
sg49787
Vskin inflammation
p64567
sa(dp64568
g49782
I126
sg49783
I1
sg49784
I9
sg49785
VC0033860
p64569
sg49787
Vpsoriasis
p64570
sasa(dp64571
g49775
VAmong identified psoriasis risk variants, three were more strongly associated with PsC than PsA (rs12189871 near HLA-C, p = 5.0 x 10(-19); rs4908742 near TNFRSF9, p = 0.00020; rs10888503 near LCE3A, p = 0.0014), and two were more strongly associated with PsA than PsC (rs12044149 near IL23R, p = 0.00018; rs9321623 near TNFAIP3, p = 0.00022).
p64572
sg49777
(lp64573
(dp64574
g49782
I192
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VLCE3A
p64575
sa(dp64576
g49782
I154
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VTNFRSF9
p64577
sa(dp64578
g49782
I320
sg49783
I1
sg49784
I7
sg49812
VP21580
p64579
sg49787
VTNFAIP3
p64580
sa(dp64581
g49782
I113
sg49783
I1
sg49784
I3
sg49812
VP30486
p64582
sg49787
VHLA
p64583
sasg49779
(lp64584
(dp64585
g49782
I83
sg49783
I1
sg49784
I3
sg49785
VC0566602
p64586
sg49787
VPsC
p64587
sa(dp64588
g49782
I92
sg49783
I1
sg49784
I3
sg49785
VC1519176
p64589
sg49787
VPsA
p64590
sa(dp64591
g49782
I83
sg49783
I1
sg49784
I3
sg49785
VC0566602
p64592
sg49787
VPsC
p64593
sa(dp64594
g49782
I92
sg49783
I1
sg49784
I3
sg49785
VC1519176
p64595
sg49787
VPsA
p64596
sa(dp64597
g49782
I17
sg49783
I1
sg49784
I9
sg49785
VC0033860
p64598
sg49787
Vpsoriasis
p64599
sasa(dp64600
g49775
VInteratrial electromechanical delay (IA-EMD) and intra-left atrial electromechanical delay (ILA-EMD) were significantly longer in the psoriasis group compared with controls.
p64601
sg49777
(lp64602
(dp64603
g49782
I49
sg49783
I4
sg49784
I41
sg49812
g11
sg49787
Vintra-left atrial electromechanical delay
p64604
sa(dp64605
g49782
I92
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VILA-EMD
p64606
sasg49779
(lp64607
(dp64608
g49782
I40
sg49783
I1
sg49784
I3
sg49785
VC0340861
p64609
sg49787
VEMD
p64610
sa(dp64611
g49782
I134
sg49783
I1
sg49784
I9
sg49785
VC0033860
p64612
sg49787
Vpsoriasis
p64613
sa(dp64614
g49782
I40
sg49783
I1
sg49784
I3
sg49785
VC0340861
p64615
sg49787
VEMD
p64616
sasa(dp64617
g49775
VTo investigate the expression of the peripheral blood retinoid-related orphan receptor gamma t (RORgamma t) and 4-1BB/4-1BBL mRNA in oral lichen planus (OLP) patients.
p64618
sg49777
(lp64619
(dp64620
g49782
I71
sg49783
I9
sg49784
I58
sg49812
VP25106
p64621
sg49787
Vorphan receptor gamma t (RORgamma t) and 4-1BB/4-1BBL mRNA
p64622
sasg49779
(lp64623
(dp64624
g49782
I153
sg49783
I1
sg49784
I3
sg49785
VC0206139
p64625
sg49787
VOLP
p64626
sa(dp64627
g49782
I133
sg49783
I3
sg49784
I18
sg49785
VC0206139
p64628
sg49787
Voral lichen planus
p64629
sasa(dp64630
g49775
VBlood and tissue eosinophils from patients with IgE-mediated allergic responses (atopic dermatitis, extrinsic asthma) express CD137.
p64631
sg49777
(lp64632
(dp64633
g49782
I126
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCD137
p64634
sa(dp64635
g49782
I48
sg49783
I1
sg49784
I3
sg49812
VP01854
p64636
sg49787
VIgE
p64637
sasg49779
(lp64638
(dp64639
g49782
I81
sg49783
I2
sg49784
I17
sg49785
VC0011615
p64640
sg49787
Vatopic dermatitis
p64641
sa(dp64642
g49782
I100
sg49783
I2
sg49784
I16
sg49785
VC0155877
p64643
sg49787
Vextrinsic asthma
p64644
sa(dp64645
g49782
I48
sg49783
I1
sg49784
I3
sg49785
VC0270850
p64646
sg49787
VIgE
p64647
sasa(dp64648
g49775
VProteomic analysis revealed 14 statistically significant differentially expressed proteins, with nine showing increased expression (PDIA3, VIM/HEXA, SELENBP1, ENO1, CAPZA1, ERP29, TPI1, PARK7, and FABP3) and five showing decreased expression (EIF2S, PSMA3, RPSA, TUBB, and TUBA1B) in uveal melanomas that subsequently metastasized compared with those that did not.
p64649
sg49777
(lp64650
(dp64651
g49782
I165
sg49783
I1
sg49784
I6
sg49812
VP52907
p64652
sg49787
VCAPZA1
p64653
sa(dp64654
g49782
I149
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VSELENBP1
p64655
sa(dp64656
g49782
I132
sg49783
I1
sg49784
I5
sg49812
VP30101
p64657
sg49787
VPDIA3
p64658
sa(dp64659
g49782
I143
sg49783
I1
sg49784
I4
sg49812
VP06865
p64660
sg49787
VHEXA
p64661
sa(dp64662
g49782
I273
sg49783
I1
sg49784
I6
sg49812
VP68363
p64663
sg49787
VTUBA1B
p64664
sa(dp64665
g49782
I197
sg49783
I1
sg49784
I5
sg49812
VP05413
p64666
sg49787
VFABP3
p64667
sa(dp64668
g49782
I173
sg49783
I1
sg49784
I5
sg49812
VP30040
p64669
sg49787
VERP29
p64670
sa(dp64671
g49782
I250
sg49783
I1
sg49784
I5
sg49812
VP25788
p64672
sg49787
VPSMA3
p64673
sa(dp64674
g49782
I263
sg49783
I1
sg49784
I4
sg49812
VP04350
p64675
sg49787
VTUBB
p64676
sa(dp64677
g49782
I180
sg49783
I1
sg49784
I4
sg49812
VP60174
p64678
sg49787
VTPI1
p64679
sa(dp64680
g49782
I186
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VPARK7
p64681
sasg49779
(lp64682
(dp64683
g49782
I318
sg49783
I1
sg49784
I12
sg49785
VC0027627
p64684
sg49787
Vmetastasized
p64685
sa(dp64686
g49782
I290
sg49783
I1
sg49784
I9
sg49785
VC0025202
p64687
sg49787
Vmelanomas
p64688
sa(dp64689
g49782
I186
sg49783
I1
sg49784
I5
sg49785
VC1853445
p64690
sg49787
VPARK7
p64691
sasa(dp64692
g49775
VAmong these, 14 genes (FTL, K-ALPHA1, LDHA, RPL4, ENO1, ANXA2, RPL9, RPL10, RPL13A, GNB2L1, AMBP, GC, A1BG, and SERPINC1), in addition to previously well-known liver cancer related genes, were confirmed to be differentially expressed in seven liver cancer cell lines and 17 HCC tissues by semi-quantitative RT-PCR.
p64693
sg49777
(lp64694
(dp64695
g49782
I69
sg49783
I1
sg49784
I5
sg49812
VP61313
p64696
sg49787
VRPL10
p64697
sa(dp64698
g49782
I56
sg49783
I1
sg49784
I5
sg49812
VP07355
p64699
sg49787
VANXA2
p64700
sa(dp64701
g49782
I28
sg49783
I1
sg49784
I8
sg49812
VP25100
p64702
sg49787
VK-ALPHA1
p64703
sa(dp64704
g49782
I92
sg49783
I1
sg49784
I4
sg49812
VP02760
p64705
sg49787
VAMBP
p64706
sa(dp64707
g49782
I76
sg49783
I1
sg49784
I6
sg49812
VP40429
p64708
sg49787
VRPL13A
p64709
sa(dp64710
g49782
I102
sg49783
I1
sg49784
I4
sg49812
VP04217
p64711
sg49787
VA1BG
p64712
sa(dp64713
g49782
I63
sg49783
I1
sg49784
I4
sg49812
VP32969
p64714
sg49787
VRPL9
p64715
sa(dp64716
g49782
I44
sg49783
I1
sg49784
I4
sg49812
VP36578
p64717
sg49787
VRPL4
p64718
sa(dp64719
g49782
I23
sg49783
I1
sg49784
I3
sg49812
VP02792
p64720
sg49787
VFTL
p64721
sa(dp64722
g49782
I84
sg49783
I1
sg49784
I6
sg49812
VP63244
p64723
sg49787
VGNB2L1
p64724
sa(dp64725
g49782
I38
sg49783
I1
sg49784
I4
sg49812
VP00338
p64726
sg49787
VLDHA
p64727
sasg49779
(lp64728
(dp64729
g49782
I160
sg49783
I2
sg49784
I12
sg49785
VC0345904
p64730
sg49787
Vliver cancer
p64731
sa(dp64732
g49782
I274
sg49783
I1
sg49784
I3
sg49785
VC2239176
p64733
sg49787
VHCC
p64734
sa(dp64735
g49782
I160
sg49783
I2
sg49784
I12
sg49785
VC0345904
p64736
sg49787
Vliver cancer
p64737
sasa(dp64738
g49775
VExpression profiles of the 9 genes ACTB, ALAS1, G6PD, GAPD, HMBS, HPRT1, K-ALPHA-1, SDHA and TBP were established in matched malignant and nonmalignant tissue specimens from 14 patients with bladder cancer.
p64739
sg49777
(lp64740
(dp64741
g49782
I73
sg49783
I1
sg49784
I9
sg49812
VP68363
p64742
sg49787
VK-ALPHA-1
p64743
sa(dp64744
g49782
I41
sg49783
I1
sg49784
I5
sg49812
VP13196
p64745
sg49787
VALAS1
p64746
sa(dp64747
g49782
I66
sg49783
I1
sg49784
I5
sg49812
VP55884
p64748
sg49787
VHPRT1
p64749
sa(dp64750
g49782
I93
sg49783
I1
sg49784
I3
sg49812
VP20226
p64751
sg49787
VTBP
p64752
sa(dp64753
g49782
I48
sg49783
I1
sg49784
I4
sg49812
VP11441
p64754
sg49787
VG6PD
p64755
sa(dp64756
g49782
I54
sg49783
I1
sg49784
I4
sg49812
VP04406
p64757
sg49787
VGAPD
p64758
sa(dp64759
g49782
I35
sg49783
I1
sg49784
I4
sg49812
VP63261
p64760
sg49787
VACTB
p64761
sa(dp64762
g49782
I84
sg49783
I1
sg49784
I4
sg49812
VP31040
p64763
sg49787
VSDHA
p64764
sa(dp64765
g49782
I60
sg49783
I1
sg49784
I4
sg49812
VP08397
p64766
sg49787
VHMBS
p64767
sasg49779
(lp64768
(dp64769
g49782
I191
sg49783
I2
sg49784
I14
sg49785
VC0699885
p64770
sg49787
Vbladder cancer
p64771
sasa(dp64772
g49775
VThe use of HPRT1 alone as a reference gene shown in our study was sufficient, but the normalization factors generated from two (HRPT1, ALAS1) or all three genes (HRPT1, ALAS1, K-ALPHA-1) should be considered for an improved reliability of normalization in gene profiling studies of prostate cancer.
p64773
sg49777
(lp64774
(dp64775
g49782
I128
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VHRPT1
p64776
sa(dp64777
g49782
I176
sg49783
I1
sg49784
I9
sg49812
VP68363
p64778
sg49787
VK-ALPHA-1
p64779
sa(dp64780
g49782
I128
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VHRPT1
p64781
sa(dp64782
g49782
I11
sg49783
I1
sg49784
I5
sg49812
VP55884
p64783
sg49787
VHPRT1
p64784
sa(dp64785
g49782
I135
sg49783
I1
sg49784
I5
sg49812
VP13196
p64786
sg49787
VALAS1
p64787
sa(dp64788
g49782
I135
sg49783
I1
sg49784
I5
sg49812
VP13196
p64789
sg49787
VALAS1
p64790
sasg49779
(lp64791
(dp64792
g49782
I128
sg49783
I1
sg49784
I5
sg49785
VC1840402
p64793
sg49787
VHRPT1
p64794
sa(dp64795
g49782
I282
sg49783
I2
sg49784
I15
sg49785
VC0600139
p64796
sg49787
Vprostate cancer
p64797
sa(dp64798
g49782
I128
sg49783
I1
sg49784
I5
sg49785
VC1840402
p64799
sg49787
VHRPT1
p64800
sasa(dp64801
g49775
VWe show that glucose clearance rates are affected in both children with marasmus as well as kwashiorkor, which correlate with plasma albumin concentrations.
p64802
sg49777
(lp64803
(dp64804
g49782
I126
sg49783
I2
sg49784
I14
sg49812
VP00441
p64805
sg49787
Vplasma albumin
p64806
sasg49779
(lp64807
(dp64808
g49782
I92
sg49783
I1
sg49784
I11
sg49785
VC0022806
p64809
sg49787
Vkwashiorkor
p64810
sa(dp64811
g49782
I72
sg49783
I1
sg49784
I8
sg49785
VC0086588
p64812
sg49787
Vmarasmus
p64813
sasa(dp64814
g49775
VAlthough marasmus is characterized by clinical wasting, kwashiorkor is associated with peripheral edema, oxidative stress, hypoalbuminemia, and hypoglycemia.
p64815
sg49777
(lp64816
sg49779
(lp64817
(dp64818
g49782
I47
sg49783
I1
sg49784
I7
sg49785
VC0235394
p64819
sg49787
Vwasting
p64820
sa(dp64821
g49782
I56
sg49783
I1
sg49784
I11
sg49785
VC0022806
p64822
sg49787
Vkwashiorkor
p64823
sa(dp64824
g49782
I105
sg49783
I2
sg49784
I16
sg49785
VC0242606
p64825
sg49787
Voxidative stress
p64826
sa(dp64827
g49782
I98
sg49783
I1
sg49784
I5
sg49785
VC0013604
p64828
sg49787
Vedema
p64829
sa(dp64830
g49782
I9
sg49783
I1
sg49784
I8
sg49785
VC0086588
p64831
sg49787
Vmarasmus
p64832
sa(dp64833
g49782
I144
sg49783
I1
sg49784
I12
sg49785
VC0020615
p64834
sg49787
Vhypoglycemia
p64835
sasa(dp64836
g49775
VTotal proteins, albumin and transferrin were all significantly lower in children with edema than in those with marasmus.
p64837
sg49777
(lp64838
(dp64839
g49782
I28
sg49783
I1
sg49784
I11
sg49812
VP02787
p64840
sg49787
Vtransferrin
p64841
sa(dp64842
g49782
I16
sg49783
I1
sg49784
I7
sg49812
VP00441
p64843
sg49787
Valbumin
p64844
sasg49779
(lp64845
(dp64846
g49782
I86
sg49783
I1
sg49784
I5
sg49785
VC0013604
p64847
sg49787
Vedema
p64848
sa(dp64849
g49782
I111
sg49783
I1
sg49784
I8
sg49785
VC0086588
p64850
sg49787
Vmarasmus
p64851
sasa(dp64852
g49775
VIn this condition, 8CR inhibited edema and myonecrosis induced by the sPLA2 activity of Crotalus durissus terrificus in a dose-dependent manner by decreasing interleukin-1Beta (IL-1Beta), tumor necrosis factor Alfa (TNF-Alfa), prostaglandin E2 (PGE2), and lipid peroxidation.
p64853
sg49777
(lp64854
(dp64855
g49782
I216
sg49783
I1
sg49784
I8
sg49812
VP01375
p64856
sg49787
VTNF-Alfa
p64857
sa(dp64858
g49782
I177
sg49783
I1
sg49784
I8
sg49812
VP01584
p64859
sg49787
VIL-1Beta
p64860
sa(dp64861
g49782
I158
sg49783
I1
sg49784
I17
sg49812
VP01584
p64862
sg49787
Vinterleukin-1Beta
p64863
sa(dp64864
g49782
I188
sg49783
I4
sg49784
I26
sg49812
VP01375
p64865
sg49787
Vtumor necrosis factor Alfa
p64866
sa(dp64867
g49782
I70
sg49783
I1
sg49784
I5
sg49812
VP14555
p64868
sg49787
VsPLA2
p64869
sasg49779
(lp64870
(dp64871
g49782
I8
sg49783
I1
sg49784
I9
sg49785
VC0012634
p64872
sg49787
Vcondition
p64873
sa(dp64874
g49782
I43
sg49783
I1
sg49784
I11
sg49785
VC0235957
p64875
sg49787
Vmyonecrosis
p64876
sa(dp64877
g49782
I33
sg49783
I1
sg49784
I5
sg49785
VC0013604
p64878
sg49787
Vedema
p64879
sa(dp64880
g49782
I188
sg49783
I2
sg49784
I14
sg49785
VC0333516
p64881
sg49787
Vtumor necrosis
p64882
sasa(dp64883
g49775
VIn addition, it was shown that Crotalus durissus terrificus sPLA2 increases cell oxidative stress during edema and myonecrosis, and the antioxidant properties of the polyphenolic compound may be significant in mitigating the pharmacological effect induced by sPLA2 and other snake venom toxins.
p64884
sg49777
(lp64885
(dp64886
g49782
I60
sg49783
I1
sg49784
I5
sg49812
VP14555
p64887
sg49787
VsPLA2
p64888
sasg49779
(lp64889
(dp64890
g49782
I115
sg49783
I1
sg49784
I11
sg49785
VC0235957
p64891
sg49787
Vmyonecrosis
p64892
sa(dp64893
g49782
I105
sg49783
I1
sg49784
I5
sg49785
VC0013604
p64894
sg49787
Vedema
p64895
sa(dp64896
g49782
I81
sg49783
I2
sg49784
I16
sg49785
VC0242606
p64897
sg49787
Voxidative stress
p64898
sasa(dp64899
g49775
VMoreover, 5CQA significantly decreased the enzymatic activity and the oedema and myonecrosis induced by native sPLA2.
p64900
sg49777
(lp64901
sg49779
(lp64902
(dp64903
g49782
I70
sg49783
I1
sg49784
I6
sg49785
VC0013604
p64904
sg49787
Voedema
p64905
sa(dp64906
g49782
I81
sg49783
I1
sg49784
I11
sg49785
VC0235957
p64907
sg49787
Vmyonecrosis
p64908
sasa(dp64909
g49775
VThis flavonoid was able to decrease enzymatic activity and some pharmacological effects, such as myonecrosis, platelet aggregation, and neurotoxic activity caused by sPLA2, however, the inflammatory effect was not affected by naringin.
p64910
sg49777
(lp64911
sg49779
(lp64912
(dp64913
g49782
I97
sg49783
I1
sg49784
I11
sg49785
VC0235957
p64914
sg49787
Vmyonecrosis
p64915
sasa(dp64916
g49775
VUnder the conditions tested, we observed that both Boc-5 and Boc-10 strongly decreased edema, myonecrosis, and neurotoxicity induced by native sPLA2.
p64917
sg49777
(lp64918
(dp64919
g49782
I51
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VBoc-5
p64920
sa(dp64921
g49782
I61
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VBoc-10
p64922
sasg49779
(lp64923
(dp64924
g49782
I94
sg49783
I1
sg49784
I11
sg49785
VC0235957
p64925
sg49787
Vmyonecrosis
p64926
sa(dp64927
g49782
I87
sg49783
I1
sg49784
I5
sg49785
VC0013604
p64928
sg49787
Vedema
p64929
sasa(dp64930
g49775
VIncubation with pertussis toxin prior to the addition of either sPLA2 or LPA only showed abrogation of the response to LPA, thus suggesting the involvement of pertussis-sensitive Gi-proteins in the case of LPA.
p64931
sg49777
(lp64932
(dp64933
g49782
I64
sg49783
I1
sg49784
I5
sg49812
VP14555
p64934
sg49787
VsPLA2
p64935
sa(dp64936
g49782
I16
sg49783
I2
sg49784
I15
sg49812
g11
sg49787
Vpertussis toxin
p64937
sa(dp64938
g49782
I179
sg49783
I1
sg49784
I11
sg49812
VP63096
p64939
sg49787
VGi-proteins
p64940
sasg49779
(lp64941
(dp64942
g49782
I16
sg49783
I1
sg49784
I9
sg49785
VC0043167
p64943
sg49787
Vpertussis
p64944
sa(dp64945
g49782
I16
sg49783
I1
sg49784
I9
sg49785
VC0043167
p64946
sg49787
Vpertussis
p64947
sasa(dp64948
g49775
VIn contrast, all of the four classical CMNs tested were negative, as were cases of Wilms' tumor and clear cell sarcoma of the kidney.
p64949
sg49777
(lp64950
sg49779
(lp64951
(dp64952
g49782
I100
sg49783
I6
sg49784
I32
sg49785
VC0334488
p64953
sg49787
Vclear cell sarcoma of the kidney
p64954
sa(dp64955
g49782
I83
sg49783
I2
sg49784
I12
sg49785
VC0027708
p64956
sg49787
VWilms' tumor
p64957
sasa(dp64958
g49775
VThe aspirates were from 16 cases of classical Wilms' tumor (WT), one anaplastic WT, 2 clear cell sarcomas of the kidney (CCSK), 2 malignant rhabdoid tumors of the kidney (MRTK) and 6 congenital mesoblastic nephromas (CMNs).
p64959
sg49777
(lp64960
sg49779
(lp64961
(dp64962
g49782
I60
sg49783
I1
sg49784
I2
sg49785
VC0027708
p64963
sg49787
VWT
p64964
sa(dp64965
g49782
I46
sg49783
I2
sg49784
I12
sg49785
VC0027708
p64966
sg49787
VWilms' tumor
p64967
sa(dp64968
g49782
I183
sg49783
I3
sg49784
I32
sg49785
VC1332965
p64969
sg49787
Vcongenital mesoblastic nephromas
p64970
sa(dp64971
g49782
I60
sg49783
I1
sg49784
I2
sg49785
VC0027708
p64972
sg49787
VWT
p64973
sa(dp64974
g49782
I86
sg49783
I3
sg49784
I19
sg49785
VC0206651
p64975
sg49787
Vclear cell sarcomas
p64976
sa(dp64977
g49782
I140
sg49783
I2
sg49784
I15
sg49785
VC0206743
p64978
sg49787
Vrhabdoid tumors
p64979
sa(dp64980
g49782
I217
sg49783
I1
sg49784
I4
sg49785
VC1332965
p64981
sg49787
VCMNs
p64982
sasa(dp64983
g49775
VArchival tissue from 38 patients with superficial smooth muscle cell and so-called fibrohistiocytic tumors (8 benign fibrous histiocytomas (BFHs), 6 dermatofibrosarcoma protuberans (DFPT), 9 malignant fibrous histiocytomas (MFHs), 9 leiomyomas (LMs) and 6 leiomyosarcomas (LMSs)) were immunostained with antibodies against SMA, HCD, CALP, PLAP and HPL.
p64984
sg49777
(lp64985
(dp64986
g49782
I323
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VSMA
p64987
sa(dp64988
g49782
I339
sg49783
I1
sg49784
I4
sg49812
VP51003
p64989
sg49787
VPLAP
p64990
sa(dp64991
g49782
I348
sg49783
I1
sg49784
I3
sg49812
VP09382
p64992
sg49787
VHPL
p64993
sa(dp64994
g49782
I328
sg49783
I1
sg49784
I3
sg49812
VP0C7U2
p64995
sg49787
VHCD
p64996
sa(dp64997
g49782
I333
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VCALP
p64998
sasg49779
(lp64999
(dp65000
g49782
I110
sg49783
I3
sg49784
I28
sg49785
VC0206644
p65001
sg49787
Vbenign fibrous histiocytomas
p65002
sa(dp65003
g49782
I233
sg49783
I1
sg49784
I10
sg49785
VC0023267
p65004
sg49787
Vleiomyomas
p65005
sa(dp65006
g49782
I100
sg49783
I1
sg49784
I6
sg49785
VC0027651
p65007
sg49787
Vtumors
p65008
sa(dp65009
g49782
I191
sg49783
I3
sg49784
I31
sg49785
VC0334463
p65010
sg49787
Vmalignant fibrous histiocytomas
p65011
sa(dp65012
g49782
I256
sg49783
I1
sg49784
I15
sg49785
VC0023269
p65013
sg49787
Vleiomyosarcomas
p65014
sa(dp65015
g49782
I323
sg49783
I1
sg49784
I3
sg49785
VC0026847
p65016
sg49787
VSMA
p65017
sa(dp65018
g49782
I328
sg49783
I1
sg49784
I3
sg49785
VC0235833
p65019
sg49787
VHCD
p65020
sa(dp65021
g49782
I245
sg49783
I1
sg49784
I3
sg49785
VC1851710
p65022
sg49787
VLMs
p65023
sa(dp65024
g49782
I149
sg49783
I2
sg49784
I31
sg49785
VC0392784
p65025
sg49787
Vdermatofibrosarcoma protuberans
p65026
sa(dp65027
g49782
I273
sg49783
I1
sg49784
I4
sg49785
VC0023269
p65028
sg49787
VLMSs
p65029
sa(dp65030
g49782
I224
sg49783
I1
sg49784
I4
sg49785
VC0334463
p65031
sg49787
VMFHs
p65032
sasa(dp65033
g49775
VIn cell culture, d12.CALP at low multiplicity of infection (0.001 plaque-forming unit/cell) selectively killed calponin-positive human synovial sarcoma, leiomyosarcoma, and osteosarcoma cells.
p65034
sg49777
(lp65035
(dp65036
g49782
I111
sg49783
I1
sg49784
I8
sg49812
VP51911
p65037
sg49787
Vcalponin
p65038
sasg49779
(lp65039
(dp65040
g49782
I49
sg49783
I1
sg49784
I9
sg49785
VC0009450
p65041
sg49787
Vinfection
p65042
sa(dp65043
g49782
I66
sg49783
I1
sg49784
I6
sg49785
VC0011389
p65044
sg49787
Vplaque
p65045
sa(dp65046
g49782
I173
sg49783
I1
sg49784
I12
sg49785
VC0029463
p65047
sg49787
Vosteosarcoma
p65048
sa(dp65049
g49782
I135
sg49783
I2
sg49784
I16
sg49785
VC0039101
p65050
sg49787
Vsynovial sarcoma
p65051
sa(dp65052
g49782
I153
sg49783
I1
sg49784
I14
sg49785
VC0023269
p65053
sg49787
Vleiomyosarcoma
p65054
sasa(dp65055
g49775
VTo investigate the possible role of beta-defensins in gingival health and periodontal disease, we examined the effect of several stimuli on the expression of interleukin-8 (IL-8), human beta-defensin-1, -2, -3, and -4 (hBD) in primary human diseased gingival epithelial (HGE) cell cultures from periodontitis patients by quantitative TaqMan reverse transcription polymerase chain reaction (RT-PCR).
p65056
sg49777
(lp65057
(dp65058
g49782
I219
sg49783
I1
sg49784
I3
sg49812
VP02042
p65059
sg49787
VhBD
p65060
sa(dp65061
g49782
I36
sg49783
I1
sg49784
I14
sg49812
g11
sg49787
Vbeta-defensins
p65062
sa(dp65063
g49782
I173
sg49783
I1
sg49784
I4
sg49812
VP60568
p65064
sg49787
VIL-8
p65065
sa(dp65066
g49782
I158
sg49783
I1
sg49784
I13
sg49812
VP60568
p65067
sg49787
Vinterleukin-8
p65068
sasg49779
(lp65069
(dp65070
g49782
I219
sg49783
I1
sg49784
I3
sg49785
VC1840321
p65071
sg49787
VhBD
p65072
sa(dp65073
g49782
I295
sg49783
I1
sg49784
I13
sg49785
VC0031099
p65074
sg49787
Vperiodontitis
p65075
sa(dp65076
g49782
I74
sg49783
I2
sg49784
I19
sg49785
VC0031090
p65077
sg49787
Vperiodontal disease
p65078
sasa(dp65079
g49775
VHuman gingival epithelial cells (HGE) express two antimicrobial peptides of the beta-defensin family, human beta-defensin 1 (hBD-1) and hBD-2, as well as cytokines and chemokines that contribute to innate immunity.
p65080
sg49777
(lp65081
(dp65082
g49782
I125
sg49783
I1
sg49784
I5
sg49812
VP60022
p65083
sg49787
VhBD-1
p65084
sa(dp65085
g49782
I136
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VhBD-2
p65086
sa(dp65087
g49782
I102
sg49783
I3
sg49784
I21
sg49812
VP60022
p65088
sg49787
Vhuman beta-defensin 1
p65089
sa(dp65090
g49782
I80
sg49783
I2
sg49784
I20
sg49812
VP59861
p65091
sg49787
Vbeta-defensin family
p65092
sasg49779
(lp65093
(dp65094
g49782
I125
sg49783
I1
sg49784
I3
sg49785
VC1840321
p65095
sg49787
VhBD
p65096
sa(dp65097
g49782
I125
sg49783
I1
sg49784
I3
sg49785
VC1840321
p65098
sg49787
VhBD
p65099
sasa(dp65100
g49775
VSSKcnj16-/- rats exhibited hypokalemia and reduced blood pressure, and when fed a high-salt diet (4% NaCl), experienced 100% mortality within a few days triggered by salt wasting and severe hypokalemia.
p65101
sg49777
(lp65102
sg49779
(lp65103
(dp65104
g49782
I171
sg49783
I1
sg49784
I7
sg49785
VC0235394
p65105
sg49787
Vwasting
p65106
sasa(dp65107
g49775
VHence, patients with HNF1Beta mutations may have reduced Kir5.1 activity in the kidney, resulting in hypokalemia and hypomagnesemia.
p65108
sg49777
(lp65109
(dp65110
g49782
I57
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VKir5.1
p65111
sa(dp65112
g49782
I21
sg49783
I2
sg49784
I18
sg49812
VP35680
p65113
sg49787
VHNF1Beta mutations
p65114
sasg49779
(lp65115
sa(dp65116
g49775
VThe Kir5.1(-/-) mice displayed hypokalemic, hyperchloremic metabolic acidosis with hypercalciuria.
p65117
sg49777
(lp65118
(dp65119
g49782
I4
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VKir5.1
p65120
sasg49779
(lp65121
(dp65122
g49782
I83
sg49783
I1
sg49784
I14
sg49785
VC0020438
p65123
sg49787
Vhypercalciuria
p65124
sa(dp65125
g49782
I59
sg49783
I2
sg49784
I18
sg49785
VC0220981
p65126
sg49787
Vmetabolic acidosis
p65127
sasa(dp65128
g49775
VIn conclusion, disruption of Kcnj16 induces a severe renal phenotype that, apart from hypokalemia, is the opposite of the phenotype seen in SeSAME/EAST syndrome.
p65129
sg49777
(lp65130
(dp65131
g49782
I29
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VKcnj16
p65132
sasg49779
(lp65133
(dp65134
g49782
I147
sg49783
I2
sg49784
I13
sg49785
VC2748572
p65135
sg49787
VEAST syndrome
p65136
sasa(dp65137
g49775
VWe found that Kir5.1(-/-) mice presented with persistent metabolic acidosis and a clear respiratory phenotype.
p65138
sg49777
(lp65139
(dp65140
g49782
I14
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VKir5.1
p65141
sasg49779
(lp65142
(dp65143
g49782
I57
sg49783
I2
sg49784
I18
sg49785
VC0220981
p65144
sg49787
Vmetabolic acidosis
p65145
sasa(dp65146
g49775
VDespite metabolic acidosis, ventilation at rest and in hyperoxic hypercapnia were similar in wild-type and Kir5.1(-/-) mice.
p65147
sg49777
(lp65148
sg49779
(lp65149
(dp65150
g49782
I8
sg49783
I2
sg49784
I18
sg49785
VC0220981
p65151
sg49787
Vmetabolic acidosis
p65152
sa(dp65153
g49782
I65
sg49783
I1
sg49784
I11
sg49785
VC0020440
p65154
sg49787
Vhypercapnia
p65155
sasa(dp65156
g49775
VWe suggest that this compensatory modulation of the peripheral chemosensory inputs develops in Kir5.1(-/-) mice in order to counteract the effect of continuing metabolic acidosis on the activity of the peripheral chemoreceptors.
p65157
sg49777
(lp65158
(dp65159
g49782
I95
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VKir5.1
p65160
sasg49779
(lp65161
(dp65162
g49782
I160
sg49783
I2
sg49784
I18
sg49785
VC0220981
p65163
sg49787
Vmetabolic acidosis
p65164
sasa(dp65165
g49775
VIn this study, CYP2E1*5B, CYP2E1*6, CYP2E1*7B, GSTO1 (A140D), and TP53 (Arg72Pro) polymorphisms and response to platinum-based chemotherapy and survival in 137 advanced stage NSCLC patients were investigated.
p65166
sg49777
(lp65167
(dp65168
g49782
I36
sg49783
I1
sg49784
I9
sg49812
VP05181
p65169
sg49787
VCYP2E1*7B
p65170
sa(dp65171
g49782
I15
sg49783
I1
sg49784
I9
sg49812
VP05181
p65172
sg49787
VCYP2E1*5B
p65173
sa(dp65174
g49782
I47
sg49783
I4
sg49784
I23
sg49812
VP78417
p65175
sg49787
VGSTO1 (A140D), and TP53
p65176
sa(dp65177
g49782
I26
sg49783
I1
sg49784
I8
sg49812
VP05181
p65178
sg49787
VCYP2E1*6
p65179
sasg49779
(lp65180
(dp65181
g49782
I175
sg49783
I1
sg49784
I5
sg49785
VC0007131
p65182
sg49787
VNSCLC
p65183
sasa(dp65184
g49775
VGSTO1-1 expression pattern has not been studied in transitional cell carcinoma (TCC), as yet.
p65185
sg49777
(lp65186
(dp65187
g49782
I0
sg49783
I1
sg49784
I7
sg49812
VP78417
p65188
sg49787
VGSTO1-1
p65189
sasg49779
(lp65190
(dp65191
g49782
I80
sg49783
I1
sg49784
I3
sg49785
VC1861305
p65192
sg49787
VTCC
p65193
sa(dp65194
g49782
I51
sg49783
I3
sg49784
I27
sg49785
VC0007138
p65195
sg49787
Vtransitional cell carcinoma
p65196
sasa(dp65197
g49775
VIncreased GSTO1-1 expression might contribute to TCC development and/or progression supporting the notion that GSTO1-1 may be a promising novel cancer target.
p65198
sg49777
(lp65199
(dp65200
g49782
I10
sg49783
I1
sg49784
I7
sg49812
VP78417
p65201
sg49787
VGSTO1-1
p65202
sa(dp65203
g49782
I10
sg49783
I1
sg49784
I7
sg49812
VP78417
p65204
sg49787
VGSTO1-1
p65205
sasg49779
(lp65206
(dp65207
g49782
I49
sg49783
I1
sg49784
I3
sg49785
VC1861305
p65208
sg49787
VTCC
p65209
sa(dp65210
g49782
I144
sg49783
I1
sg49784
I6
sg49785
VC0006826
p65211
sg49787
Vcancer
p65212
sasa(dp65213
g49775
VGlutathione S-transferase omega 1 (GSTO1) is an atypical GST isoform that is overexpressed in several cancers and has been implicated in drug resistance.
p65214
sg49777
(lp65215
(dp65216
g49782
I0
sg49783
I4
sg49784
I33
sg49812
VP78417
p65217
sg49787
VGlutathione S-transferase omega 1
p65218
sa(dp65219
g49782
I35
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VGST
p65220
sa(dp65221
g49782
I35
sg49783
I1
sg49784
I5
sg49812
VP78417
p65222
sg49787
VGSTO1
p65223
sasg49779
(lp65224
(dp65225
g49782
I102
sg49783
I1
sg49784
I7
sg49785
VC0006826
p65226
sg49787
Vcancers
p65227
sasa(dp65228
g49775
VHere we show that silencing of GSTO1 with siRNA significantly impairs cancer cell viability, validating GSTO1 as a potential new target in oncology.
p65229
sg49777
(lp65230
(dp65231
g49782
I31
sg49783
I1
sg49784
I5
sg49812
VP78417
p65232
sg49787
VGSTO1
p65233
sa(dp65234
g49782
I31
sg49783
I1
sg49784
I5
sg49812
VP78417
p65235
sg49787
VGSTO1
p65236
sasg49779
(lp65237
(dp65238
g49782
I70
sg49783
I1
sg49784
I6
sg49785
VC0006826
p65239
sg49787
Vcancer
p65240
sasa(dp65241
g49775
VThese potent GSTO1 inhibitors suppress cancer cell growth, enhance the cytotoxic effects of cisplatin and inhibit tumour growth in colon cancer models as single agent.
p65242
sg49777
(lp65243
(dp65244
g49782
I13
sg49783
I1
sg49784
I5
sg49812
VP78417
p65245
sg49787
VGSTO1
p65246
sasg49779
(lp65247
(dp65248
g49782
I114
sg49783
I1
sg49784
I6
sg49785
VC0027651
p65249
sg49787
Vtumour
p65250
sa(dp65251
g49782
I131
sg49783
I2
sg49784
I12
sg49785
VC0699790
p65252
sg49787
Vcolon cancer
p65253
sa(dp65254
g49782
I39
sg49783
I3
sg49784
I18
sg49785
VC1516170
p65255
sg49787
Vcancer cell growth
p65256
sasa(dp65257
g49775
VOur findings demonstrate the therapeutic utility of GSTO1 inhibitors as anticancer agents and identify the novel cellular pathways under GSTO1 regulation in colorectal cancer.
p65258
sg49777
(lp65259
(dp65260
g49782
I52
sg49783
I1
sg49784
I5
sg49812
VP78417
p65261
sg49787
VGSTO1
p65262
sasg49779
(lp65263
(dp65264
g49782
I157
sg49783
I2
sg49784
I17
sg49785
VC1527249
p65265
sg49787
Vcolorectal cancer
p65266
sasa(dp65267
g49775
VTo explore the relationship between angiogenin-1/2 (Ang-1/2) and clinical parameters of idiopathic pulmonary fibrosis (IPF), and to assess the value of Ang-1/2 in predicting the prognosis of patients with IPF.
p65268
sg49777
(lp65269
(dp65270
g49782
I36
sg49783
I1
sg49784
I14
sg49812
VP03950
p65271
sg49787
Vangiogenin-1/2
p65272
sa(dp65273
g49782
I52
sg49783
I1
sg49784
I7
sg49812
VP03950
p65274
sg49787
VAng-1/2
p65275
sa(dp65276
g49782
I52
sg49783
I1
sg49784
I7
sg49812
VP03950
p65277
sg49787
VAng-1/2
p65278
sasg49779
(lp65279
(dp65280
g49782
I119
sg49783
I1
sg49784
I3
sg49785
VC3161101
p65281
sg49787
VIPF
p65282
sa(dp65283
g49782
I88
sg49783
I3
sg49784
I29
sg49785
VC3161101
p65284
sg49787
Vidiopathic pulmonary fibrosis
p65285
sa(dp65286
g49782
I119
sg49783
I1
sg49784
I3
sg49785
VC3161101
p65287
sg49787
VIPF
p65288
sasa(dp65289
g49775
VPreterm infants exposed to oxygen and mechanical ventilation are at risk for bronchopulmonary dysplasia (BPD), a multifactorial chronic lung disorder characterized by arrested alveolar development and nonsprouting, dysmorphic microvascular angiogenesis.
p65290
sg49777
(lp65291
sg49779
(lp65292
(dp65293
g49782
I77
sg49783
I2
sg49784
I26
sg49785
VC0006287
p65294
sg49787
Vbronchopulmonary dysplasia
p65295
sa(dp65296
g49782
I128
sg49783
I3
sg49784
I21
sg49785
VC0746102
p65297
sg49787
Vchronic lung disorder
p65298
sa(dp65299
g49782
I167
sg49783
I1
sg49784
I8
sg49785
VC0018790
p65300
sg49787
Varrested
p65301
sa(dp65302
g49782
I105
sg49783
I1
sg49784
I3
sg49785
VC0006012
p65303
sg49787
VBPD
p65304
sasa(dp65305
g49775
VMany genes previously known to be affected by BPA and involved in obesity, hypertension, or heart disease were altered following these treatments, and AP-1, EGR1, and EGFR were key hubs affected by BPA and/or overfeeding.
p65306
sg49777
(lp65307
(dp65308
g49782
I157
sg49783
I1
sg49784
I4
sg49812
VP18146
p65309
sg49787
VEGR1
p65310
sa(dp65311
g49782
I151
sg49783
I1
sg49784
I4
sg49812
VP01100
p65312
sg49787
VAP-1
p65313
sasg49779
(lp65314
(dp65315
g49782
I66
sg49783
I1
sg49784
I7
sg49785
VC0028754
p65316
sg49787
Vobesity
p65317
sa(dp65318
g49782
I75
sg49783
I1
sg49784
I12
sg49785
VC0020538
p65319
sg49787
Vhypertension
p65320
sa(dp65321
g49782
I92
sg49783
I2
sg49784
I13
sg49785
VC0018799
p65322
sg49787
Vheart disease
p65323
sasa(dp65324
g49775
VUsing immunohistochemistry, we studied Egr-1 expression specifically in a wide morphologic spectrum of pulmonary arteries in the lung tissue of 72 patients with different forms and stages of PAH, specifically idiopathic PAH (n = 18), advanced-stage congenital heart disease-associated PAH (PAH-CHD) (n = 21), early-stage PAH-CHD (n = 19) and non-neointimal hypoxic pulmonary hypertension (PH) (n = 4), and controls (n = 10).
p65325
sg49777
(lp65326
(dp65327
g49782
I290
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
VPAH-CHD
p65328
sa(dp65329
g49782
I191
sg49783
I1
sg49784
I3
sg49812
VP00439
p65330
sg49787
VPAH
p65331
sa(dp65332
g49782
I39
sg49783
I1
sg49784
I5
sg49812
VP18146
p65333
sg49787
VEgr-1
p65334
sa(dp65335
g49782
I191
sg49783
I1
sg49784
I3
sg49812
VP00439
p65336
sg49787
VPAH
p65337
sasg49779
(lp65338
(dp65339
g49782
I389
sg49783
I1
sg49784
I2
sg49785
VC0020542
p65340
sg49787
VPH
p65341
sa(dp65342
g49782
I365
sg49783
I2
sg49784
I22
sg49785
VC0020542
p65343
sg49787
Vpulmonary hypertension
p65344
sa(dp65345
g49782
I191
sg49783
I1
sg49784
I3
sg49785
VC0152171
p65346
sg49787
VPAH
p65347
sa(dp65348
g49782
I191
sg49783
I1
sg49784
I3
sg49785
VC0152171
p65349
sg49787
VPAH
p65350
sa(dp65351
g49782
I191
sg49783
I1
sg49784
I3
sg49785
VC0152171
p65352
sg49787
VPAH
p65353
sa(dp65354
g49782
I191
sg49783
I1
sg49784
I3
sg49785
VC0152171
p65355
sg49787
VPAH
p65356
sa(dp65357
g49782
I357
sg49783
I1
sg49784
I7
sg49785
VC0242184
p65358
sg49787
Vhypoxic
p65359
sa(dp65360
g49782
I249
sg49783
I3
sg49784
I24
sg49785
VC0152021
p65361
sg49787
Vcongenital heart disease
p65362
sa(dp65363
g49782
I191
sg49783
I1
sg49784
I3
sg49785
VC0152171
p65364
sg49787
VPAH
p65365
sasa(dp65366
g49775
VParkin substrates include two septins; SEPT4/CDCrel-2 which coaggregates with Alfa-synuclein as Lewy bodies in Parkinson's disease, and its closest homolog SEPT5/CDCrel-1/PNUTL1 whose overload with viral vector can rapidly eliminate dopamine neurons in rats.
p65367
sg49777
(lp65368
(dp65369
g49782
I156
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSEPT5
p65370
sa(dp65371
g49782
I30
sg49783
I1
sg49784
I7
sg49812
g11
sg49787
Vseptins
p65372
sa(dp65373
g49782
I171
sg49783
I1
sg49784
I6
sg49812
g11
sg49787
VPNUTL1
p65374
sa(dp65375
g49782
I78
sg49783
I1
sg49784
I14
sg49812
VP37840
p65376
sg49787
VAlfa-synuclein
p65377
sa(dp65378
g49782
I39
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VSEPT4
p65379
sa(dp65380
g49782
I162
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VCDCrel-1
p65381
sa(dp65382
g49782
I45
sg49783
I1
sg49784
I8
sg49812
g11
sg49787
VCDCrel-2
p65383
sasg49779
(lp65384
(dp65385
g49782
I111
sg49783
I2
sg49784
I19
sg49785
VC0030567
p65386
sg49787
VParkinson's disease
p65387
sasa(dp65388
g49775
VAfter validation by Western blot and quantitative real-time PCR, the expressions of three proteins related to neurodegenerative disease, septin 5, Alfa-internexin, and Alfa-synuclein, were identified to be altered by MCLR exposure.
p65389
sg49777
(lp65390
(dp65391
g49782
I168
sg49783
I1
sg49784
I14
sg49812
VP37840
p65392
sg49787
VAlfa-synuclein
p65393
sa(dp65394
g49782
I137
sg49783
I2
sg49784
I8
sg49812
g11
sg49787
Vseptin 5
p65395
sasg49779
(lp65396
(dp65397
g49782
I110
sg49783
I2
sg49784
I25
sg49785
VC0524851
p65398
sg49787
Vneurodegenerative disease
p65399
sasa(dp65400
g49775
VInterestingly, Septin 5, one of the genes isolated from HPAI H5N1-infected brain tissues has been reported to participate in the pathogenic process of Parkinson's disease.
p65401
sg49777
(lp65402
(dp65403
g49782
I15
sg49783
I2
sg49784
I8
sg49812
g11
sg49787
VSeptin 5
p65404
sasg49779
(lp65405
(dp65406
g49782
I61
sg49783
I1
sg49784
I4
sg49785
VC0016627
p65407
sg49787
VH5N1
p65408
sa(dp65409
g49782
I151
sg49783
I2
sg49784
I19
sg49785
VC0030567
p65410
sg49787
VParkinson's disease
p65411
sasa(dp65412
g49775
VA previous study successfully developed and validated a self-report BPD measure, the Minnesota Borderline Personality Disorder Scale (MBPD).
p65413
sg49777
(lp65414
sg49779
(lp65415
(dp65416
g49782
I68
sg49783
I1
sg49784
I3
sg49785
VC0006012
p65417
sg49787
VBPD
p65418
sa(dp65419
g49782
I95
sg49783
I3
sg49784
I31
sg49785
VC0006012
p65420
sg49787
VBorderline Personality Disorder
p65421
sasa(dp65422
g49775
VA previous study successfully developed and validated a BPD measure embedded within a normal trait measure, the Minnesota Borderline Personality Disorder Scale (MBPD).
p65423
sg49777
(lp65424
sg49779
(lp65425
(dp65426
g49782
I122
sg49783
I3
sg49784
I31
sg49785
VC0006012
p65427
sg49787
VBorderline Personality Disorder
p65428
sa(dp65429
g49782
I56
sg49783
I1
sg49784
I3
sg49785
VC0006012
p65430
sg49787
VBPD
p65431
sasa(dp65432
g49775
VThis study was to investigate HSP70 expression in the peripheral lung tissues of chronic obstructive pulmonary disease (COPD) patients and in human bronchial epithelial cells (16-HBE) exposed to cigarette smoke extract (CSE).
p65433
sg49777
(lp65434
(dp65435
g49782
I30
sg49783
I1
sg49784
I5
sg49812
VP34932
p65436
sg49787
VHSP70
p65437
sasg49779
(lp65438
(dp65439
g49782
I220
sg49783
I1
sg49784
I3
sg49785
VC1832855
p65440
sg49787
VCSE
p65441
sa(dp65442
g49782
I81
sg49783
I4
sg49784
I37
sg49785
VC0024117
p65443
sg49787
Vchronic obstructive pulmonary disease
p65444
sa(dp65445
g49782
I195
sg49783
I3
sg49784
I23
sg49785
VC1832855
p65446
sg49787
Vcigarette smoke extract
p65447
sa(dp65448
g49782
I120
sg49783
I1
sg49784
I4
sg49785
VC0024117
p65449
sg49787
VCOPD
p65450
sasa(dp65451
g49775
VSequencing analysis of the endogenous E2F4 gene in a series of colorectal cancer cell lines showed that the microsatellite-unstable cell line SW48 exhibited a serine deletion in this gene.
p65452
sg49777
(lp65453
(dp65454
g49782
I38
sg49783
I2
sg49784
I9
sg49812
g11
sg49787
VE2F4 gene
p65455
sasg49779
(lp65456
(dp65457
g49782
I63
sg49783
I2
sg49784
I17
sg49785
VC1527249
p65458
sg49787
Vcolorectal cancer
p65459
sasa(dp65460
g49775
VIn conclusion, our data demonstrate that cancer-associated E2F4 mutations enhance the capacity of colorectal cancer cells to grow without anchorage, thereby contributing to tumor progression.
p65461
sg49777
(lp65462
(dp65463
g49782
I59
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VE2F4
p65464
sasg49779
(lp65465
(dp65466
g49782
I41
sg49783
I1
sg49784
I6
sg49785
VC0006826
p65467
sg49787
Vcancer
p65468
sa(dp65469
g49782
I173
sg49783
I2
sg49784
I17
sg49785
VC0178874
p65470
sg49787
Vtumor progression
p65471
sa(dp65472
g49782
I98
sg49783
I2
sg49784
I17
sg49785
VC1527249
p65473
sg49787
Vcolorectal cancer
p65474
sasa(dp65475
g49775
VThe inverse immunohistochemical relationship between E2F1 and E2F4 indicates a possible mechanistic interlink in colorectal cancer.
p65476
sg49777
(lp65477
(dp65478
g49782
I62
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VE2F4
p65479
sa(dp65480
g49782
I53
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VE2F1
p65481
sasg49779
(lp65482
(dp65483
g49782
I113
sg49783
I2
sg49784
I17
sg49785
VC1527249
p65484
sg49787
Vcolorectal cancer
p65485
sasa(dp65486
g49775
VIn an attempt to identify the role of E2F-4 as a potential mediator of cell proliferation, differentiation, tumorigenesis, and apoptosis in colorectal mucosa comparing with that of E2F-1, the authors examine 20 patients with human colon cancer and their corresponding histologically healthy mucosa by using immunohistochemical methods, computerized quantitative image analysis, and immunoblot analysis.
p65487
sg49777
(lp65488
(dp65489
g49782
I38
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VE2F-4
p65490
sa(dp65491
g49782
I181
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VE2F-1
p65492
sasg49779
(lp65493
(dp65494
g49782
I108
sg49783
I1
sg49784
I13
sg49785
VC0007621
p65495
sg49787
Vtumorigenesis
p65496
sa(dp65497
g49782
I76
sg49783
I1
sg49784
I13
sg49785
VC0334094
p65498
sg49787
Vproliferation
p65499
sa(dp65500
g49782
I231
sg49783
I2
sg49784
I12
sg49785
VC0699790
p65501
sg49787
Vcolon cancer
p65502
sasa(dp65503
g49775
VEighteen colorectal cancer (CRC) patients from 13 kindreds meeting the Amsterdam criteria for HNPCC were analyzed and compared to sporadic CRC patients with MSI-H. We detected mutations of E2F-4 at the same repeat sequence in HNPCC.
p65504
sg49777
(lp65505
(dp65506
g49782
I189
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VE2F-4
p65507
sasg49779
(lp65508
(dp65509
g49782
I28
sg49783
I1
sg49784
I3
sg49785
VC1527249
p65510
sg49787
VCRC
p65511
sa(dp65512
g49782
I157
sg49783
I1
sg49784
I3
sg49785
VC0920269
p65513
sg49787
VMSI
p65514
sa(dp65515
g49782
I9
sg49783
I2
sg49784
I17
sg49785
VC1527249
p65516
sg49787
Vcolorectal cancer
p65517
sa(dp65518
g49782
I28
sg49783
I1
sg49784
I3
sg49785
VC1527249
p65519
sg49787
VCRC
p65520
sa(dp65521
g49782
I94
sg49783
I1
sg49784
I5
sg49785
VC1333990
p65522
sg49787
VHNPCC
p65523
sa(dp65524
g49782
I94
sg49783
I1
sg49784
I5
sg49785
VC1333990
p65525
sg49787
VHNPCC
p65526
sasa(dp65527
g49775
VAlthough the implication of vascular endothelial growth factor, angiopoietin-2, and C-X-C motif chemokine 10 has been suggested, the pathogenesis of systemic capillary leak syndrome remains unclear.
p65528
sg49777
(lp65529
(dp65530
g49782
I64
sg49783
I1
sg49784
I14
sg49812
g11
sg49787
Vangiopoietin-2
p65531
sa(dp65532
g49782
I28
sg49783
I4
sg49784
I34
sg49812
g11
sg49787
Vvascular endothelial growth factor
p65533
sasg49779
(lp65534
(dp65535
g49782
I149
sg49783
I4
sg49784
I32
sg49785
VC0343084
p65536
sg49787
Vsystemic capillary leak syndrome
p65537
sa(dp65538
g49782
I133
sg49783
I1
sg49784
I12
sg49785
VC0699748
p65539
sg49787
Vpathogenesis
p65540
sasa(dp65541
g49775
VMicrovascular dysfunction under septic shock is related to: increased capillary permeability that manifests as a breakdown of the microvascular endothelial barrier (factors which may contribute to capillary leak syndrome include endogenous proinflammatory cytokines, angiopoietin 2, vascular endothelial growth factor); arteriolar hyporesponsiveness to vasoconstrictors and vasodilators, the loss of adrenergic sensitivity and tone of smooth muscle cells lining the arterioles; loss of the anti-adhesive function of endothelial surfaces; decreased density of perfused capillaries (due to several contributing factors: decreased deformability of erythrocytes and neutrophils; activation of the clotting cascade with fibrin deposition and the formation of microthrombi; dysfunction of vascular autoregulatory mechanisms by nitric oxide; enhanced functional arteriovenous shunting of the microcirculation).
p65542
sg49777
(lp65543
(dp65544
g49782
I283
sg49783
I4
sg49784
I34
sg49812
g11
sg49787
Vvascular endothelial growth factor
p65545
sa(dp65546
g49782
I267
sg49783
I2
sg49784
I14
sg49812
g11
sg49787
Vangiopoietin 2
p65547
sa(dp65548
g49782
I715
sg49783
I1
sg49784
I6
sg49812
VP22087
p65549
sg49787
Vfibrin
p65550
sasg49779
(lp65551
(dp65552
g49782
I113
sg49783
I1
sg49784
I9
sg49785
VC1265875
p65553
sg49787
Vbreakdown
p65554
sa(dp65555
g49782
I715
sg49783
I2
sg49784
I17
sg49785
VC0333565
p65556
sg49787
Vfibrin deposition
p65557
sa(dp65558
g49782
I197
sg49783
I3
sg49784
I23
sg49785
VC0343084
p65559
sg49787
Vcapillary leak syndrome
p65560
sa(dp65561
g49782
I32
sg49783
I2
sg49784
I12
sg49785
VC0036983
p65562
sg49787
Vseptic shock
p65563
sasa(dp65564
g49775
VFurther investigations of AL-1 as a promising new agent for treatment and/or prevention of diabetes are warranted.
p65565
sg49777
(lp65566
sg49779
(lp65567
(dp65568
g49782
I91
sg49783
I1
sg49784
I8
sg49785
VC0011849
p65569
sg49787
Vdiabetes
p65570
sasa(dp65571
g49775
VIn established cardiac ATTR amyloidosis, T1 elevation was not as high as in AL amyloidosis (AL 1,130 +/- 68 ms; p = 0.01).
p65572
sg49777
(lp65573
sg49779
(lp65574
(dp65575
g49782
I28
sg49783
I1
sg49784
I11
sg49785
VC0002726
p65576
sg49787
Vamyloidosis
p65577
sa(dp65578
g49782
I76
sg49783
I2
sg49784
I14
sg49785
VC0268381
p65579
sg49787
VAL amyloidosis
p65580
sasa(dp65581
g49775
VWe previously reported that EphA5 receptor-ephrinA5 interactions within the ventromedial hypothalamus (VMH) influence counterregulatory hormone responses during acute hypoglycemia in nondiabetic rats.
p65582
sg49777
(lp65583
(dp65584
g49782
I28
sg49783
I2
sg49784
I14
sg49812
VP54756
p65585
sg49787
VEphA5 receptor
p65586
sasg49779
(lp65587
(dp65588
g49782
I161
sg49783
I2
sg49784
I18
sg49785
VC0745150
p65589
sg49787
Vacute hypoglycemia
p65590
sasa(dp65591
g49775
VIn this study, we examined whether recurrent hypoglycemia alters the capacity of the ephrinA5 ligand to activate VMH EphA5 receptors, and if so, whether these changes could contribute to pathogenesis of defective glucose counterregulation in response to a standard hypoglycemic stimulus.
p65592
sg49777
(lp65593
(dp65594
g49782
I85
sg49783
I2
sg49784
I15
sg49812
g11
sg49787
VephrinA5 ligand
p65595
sa(dp65596
g49782
I113
sg49783
I3
sg49784
I19
sg49812
VP54756
p65597
sg49787
VVMH EphA5 receptors
p65598
sasg49779
(lp65599
(dp65600
g49782
I187
sg49783
I1
sg49784
I12
sg49785
VC0699748
p65601
sg49787
Vpathogenesis
p65602
sa(dp65603
g49782
I45
sg49783
I1
sg49784
I12
sg49785
VC0020615
p65604
sg49787
Vhypoglycemia
p65605
sasa(dp65606
g49775
VThe expression of ephrinA5, but not EphA5 receptors within the VMH, was reduced by antecedent recurrent hypoglycemia.
p65607
sg49777
(lp65608
(dp65609
g49782
I36
sg49783
I2
sg49784
I15
sg49812
VP54756
p65610
sg49787
VEphA5 receptors
p65611
sasg49779
(lp65612
(dp65613
g49782
I104
sg49783
I1
sg49784
I12
sg49785
VC0020615
p65614
sg49787
Vhypoglycemia
p65615
sasa(dp65616
g49775
VActivation of VMH EphA5 receptors via targeted microinjection of ephrinA5-Fc before a hyperinsulinemic hypoglycemic clamp study caused a reduction in the glucose infusion rate in nondiabetic rats exposed to recurrent hypoglycemia.
p65617
sg49777
(lp65618
(dp65619
g49782
I14
sg49783
I3
sg49784
I19
sg49812
VP54756
p65620
sg49787
VVMH EphA5 receptors
p65621
sasg49779
(lp65622
(dp65623
g49782
I217
sg49783
I1
sg49784
I12
sg49785
VC0020615
p65624
sg49787
Vhypoglycemia
p65625
sasa(dp65626
g49775
VThese data suggest that changes in ephrinA5/EphA5 interactions and synaptic plasticity within the VMH, a key glucose-sensing region in the brain, may contribute to the impairment in glucagon secretion and counterregulatory responses caused by recurrent hypoglycemia.
p65627
sg49777
(lp65628
(dp65629
g49782
I44
sg49783
I1
sg49784
I5
sg49812
VP54756
p65630
sg49787
VEphA5
p65631
sa(dp65632
g49782
I182
sg49783
I1
sg49784
I8
sg49812
VP01275
p65633
sg49787
Vglucagon
p65634
sasg49779
(lp65635
(dp65636
g49782
I253
sg49783
I1
sg49784
I12
sg49785
VC0020615
p65637
sg49787
Vhypoglycemia
p65638
sa(dp65639
g49782
I168
sg49783
I1
sg49784
I10
sg49785
VC0684336
p65640
sg49787
Vimpairment
p65641
sasa(dp65642
g49775
VActivation of Beta-cell EphA5 receptors by its ligand ephrinA5 from adjacent Beta-cells has been reported to decrease insulin secretion during hypoglycemia.
p65643
sg49777
(lp65644
(dp65645
g49782
I14
sg49783
I3
sg49784
I25
sg49812
VP54756
p65646
sg49787
VBeta-cell EphA5 receptors
p65647
sa(dp65648
g49782
I118
sg49783
I1
sg49784
I7
sg49812
VP01308
p65649
sg49787
Vinsulin
p65650
sasg49779
(lp65651
(dp65652
g49782
I143
sg49783
I1
sg49784
I12
sg49785
VC0020615
p65653
sg49787
Vhypoglycemia
p65654
sasa(dp65655
g49775
VGiven the similarities between islet and ventromedial hypothalamus (VMH) glucose sensing, we tested the hypothesis that the EphA5/ephrinA5 system might function within the VMH during hypoglycemia to stimulate counterregulatory hormone release as well.
p65656
sg49777
(lp65657
(dp65658
g49782
I124
sg49783
I1
sg49784
I5
sg49812
VP54756
p65659
sg49787
VEphA5
p65660
sasg49779
(lp65661
(dp65662
g49782
I183
sg49783
I1
sg49784
I12
sg49785
VC0020615
p65663
sg49787
Vhypoglycemia
p65664
sasa(dp65665
g49775
VLocal stimulation of VMH EphA5 receptors by ephrinA5-Fc or ephrinA5 overexpression increased, whereas knockdown of VMH ephrinA5 reduced counterregulatory responses during hypoglycemia.
p65666
sg49777
(lp65667
(dp65668
g49782
I21
sg49783
I3
sg49784
I19
sg49812
VP54756
p65669
sg49787
VVMH EphA5 receptors
p65670
sasg49779
(lp65671
(dp65672
g49782
I171
sg49783
I1
sg49784
I12
sg49785
VC0020615
p65673
sg49787
Vhypoglycemia
p65674
sasa(dp65675
g49775
VOverexpression of VMH ephrinA5 transiently increased local glutamate concentrations, whereas ephrinA5 knockdown produced profound suppression of VMH interstitial fluid glutamine concentrations in the basal state and during hypoglycemia.
p65676
sg49777
(lp65677
(dp65678
g49782
I93
sg49783
I2
sg49784
I18
sg49812
g11
sg49787
VephrinA5 knockdown
p65679
sasg49779
(lp65680
(dp65681
g49782
I223
sg49783
I1
sg49784
I12
sg49785
VC0020615
p65682
sg49787
Vhypoglycemia
p65683
sa(dp65684
g49782
I130
sg49783
I1
sg49784
I11
sg49785
VC0221103
p65685
sg49787
Vsuppression
p65686
sasa(dp65687
g49775
VChanges in ephrinA5/EphA5 interactions within the VMH, a key brain glucose-sensing region, act in concert with islets to restore glucose homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in glutamate/glutamine cycling.
p65688
sg49777
(lp65689
(dp65690
g49782
I20
sg49783
I1
sg49784
I5
sg49812
VP54756
p65691
sg49787
VEphA5
p65692
sasg49779
(lp65693
(dp65694
g49782
I156
sg49783
I2
sg49784
I18
sg49785
VC0745150
p65695
sg49787
Vacute hypoglycemia
p65696
sasa(dp65697
g49775
VFractionation of dichloromethane (DCM) molecules with different chlorine isotopes by aerobic methylobacteria Methylobacterium dichloromethanicum DM4 and Albibacter nethylovorans DM10; cell-free extract of strain DM4; and transconjugant Methylobacterium evtorquens Al1/pME 8220, expressing the dcmA gene for DCM dehalogenase but unable to grow on DCM, was studied.
p65698
sg49777
(lp65699
(dp65700
g49782
I268
sg49783
I1
sg49784
I3
sg49812
VP04080
p65701
sg49787
VpME
p65702
sa(dp65703
g49782
I293
sg49783
I2
sg49784
I9
sg49812
g11
sg49787
VdcmA gene
p65704
sasg49779
(lp65705
(dp65706
g49782
I268
sg49783
I1
sg49784
I3
sg49785
VC0751785
p65707
sg49787
VpME
p65708
sa(dp65709
g49782
I293
sg49783
I1
sg49784
I4
sg49785
VC1857776
p65710
sg49787
VdcmA
p65711
sasa(dp65712
g49775
VWe also describe the first RCC with a DVL2-TFE3 gene fusion, in addition to an extrarenal pigmented PEComa with a NONO-TFE3 gene fusion.
p65713
sg49777
(lp65714
(dp65715
g49782
I43
sg49783
I1
sg49784
I4
sg49812
VP19532
p65716
sg49787
VTFE3
p65717
sa(dp65718
g49782
I114
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNONO
p65719
sa(dp65720
g49782
I38
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VDVL2
p65721
sa(dp65722
g49782
I43
sg49783
I1
sg49784
I4
sg49812
VP19532
p65723
sg49787
VTFE3
p65724
sasg49779
(lp65725
(dp65726
g49782
I48
sg49783
I2
sg49784
I11
sg49785
VC1705736
p65727
sg49787
Vgene fusion
p65728
sa(dp65729
g49782
I100
sg49783
I1
sg49784
I6
sg49785
VC1300127
p65730
sg49787
VPEComa
p65731
sa(dp65732
g49782
I48
sg49783
I2
sg49784
I11
sg49785
VC1705736
p65733
sg49787
Vgene fusion
p65734
sa(dp65735
g49782
I27
sg49783
I1
sg49784
I3
sg49785
VC0007134
p65736
sg49787
VRCC
p65737
sasa(dp65738
g49775
VFurthermore, among neoplasms with the SFPQ-TFE3, NONO-TFE3, DVL2-TFE3, and ASPL-TFE3 gene fusions, the RCCs are almost always PAX8 positive, cathepsin K negative by immunohistochemistry, whereas the mesenchymal counterparts (Xp11 translocation PEComas, melanotic Xp11 translocation renal cancers, and alveolar soft part sarcoma) are PAX8 negative, cathepsin K positive.
p65739
sg49777
(lp65740
(dp65741
g49782
I225
sg49783
I3
sg49784
I26
sg49812
g11
sg49787
VXp11 translocation PEComas
p65742
sa(dp65743
g49782
I49
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNONO
p65744
sa(dp65745
g49782
I38
sg49783
I1
sg49784
I4
sg49812
VP23246
p65746
sg49787
VSFPQ
p65747
sa(dp65748
g49782
I43
sg49783
I1
sg49784
I4
sg49812
VP19532
p65749
sg49787
VTFE3
p65750
sa(dp65751
g49782
I126
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VPAX8
p65752
sa(dp65753
g49782
I43
sg49783
I1
sg49784
I4
sg49812
VP19532
p65754
sg49787
VTFE3
p65755
sa(dp65756
g49782
I141
sg49783
I2
sg49784
I11
sg49812
VP43235
p65757
sg49787
Vcathepsin K
p65758
sa(dp65759
g49782
I75
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VASPL
p65760
sa(dp65761
g49782
I253
sg49783
I5
sg49784
I42
sg49812
g11
sg49787
Vmelanotic Xp11 translocation renal cancers
p65762
sa(dp65763
g49782
I43
sg49783
I1
sg49784
I4
sg49812
VP19532
p65764
sg49787
VTFE3
p65765
sa(dp65766
g49782
I126
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VPAX8
p65767
sa(dp65768
g49782
I60
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VDVL2
p65769
sa(dp65770
g49782
I141
sg49783
I2
sg49784
I11
sg49812
VP43235
p65771
sg49787
Vcathepsin K
p65772
sa(dp65773
g49782
I43
sg49783
I1
sg49784
I4
sg49812
VP19532
p65774
sg49787
VTFE3
p65775
sasg49779
(lp65776
(dp65777
g49782
I244
sg49783
I1
sg49784
I7
sg49785
VC1300127
p65778
sg49787
VPEComas
p65779
sa(dp65780
g49782
I19
sg49783
I1
sg49784
I9
sg49785
VC0027651
p65781
sg49787
Vneoplasms
p65782
sa(dp65783
g49782
I230
sg49783
I1
sg49784
I13
sg49785
VC0040715
p65784
sg49787
Vtranslocation
p65785
sa(dp65786
g49782
I230
sg49783
I1
sg49784
I13
sg49785
VC0040715
p65787
sg49787
Vtranslocation
p65788
sa(dp65789
g49782
I282
sg49783
I2
sg49784
I13
sg49785
VC0740457
p65790
sg49787
Vrenal cancers
p65791
sa(dp65792
g49782
I301
sg49783
I4
sg49784
I26
sg49785
VC0206657
p65793
sg49787
Valveolar soft part sarcoma
p65794
sa(dp65795
g49782
I103
sg49783
I1
sg49784
I4
sg49785
VC0007134
p65796
sg49787
VRCCs
p65797
sasa(dp65798
g49775
VThe compound was further tested in vitro for acetylation of histone H4 and other non-histone proteins, and in vivo in a colon carcinoma model, showing significant proapoptotic and antitumor activities.
p65799
sg49777
(lp65800
(dp65801
g49782
I81
sg49783
I2
sg49784
I20
sg49812
VP62805
p65802
sg49787
Vnon-histone proteins
p65803
sa(dp65804
g49782
I60
sg49783
I2
sg49784
I10
sg49812
VP62805
p65805
sg49787
Vhistone H4
p65806
sasg49779
(lp65807
(dp65808
g49782
I120
sg49783
I2
sg49784
I15
sg49785
VC0699790
p65809
sg49787
Vcolon carcinoma
p65810
sasa(dp65811
g49775
VAs a proof-of-principle, we have identified cytochrome C and Histone H4 as two of the predominant protein species in the 3D colon carcinoma cultures.
p65812
sg49777
(lp65813
(dp65814
g49782
I44
sg49783
I2
sg49784
I12
sg49812
VP99999
p65815
sg49787
Vcytochrome C
p65816
sa(dp65817
g49782
I61
sg49783
I2
sg49784
I10
sg49812
VP62805
p65818
sg49787
VHistone H4
p65819
sasg49779
(lp65820
(dp65821
g49782
I124
sg49783
I2
sg49784
I15
sg49785
VC0699790
p65822
sg49787
Vcolon carcinoma
p65823
sasa(dp65824
g49775
VDouble 2-mm core tissue microarrays were made from 261 paraffin-embedded gastric adenocarcinoma samples and examined by immunohistochemistry for histone H3 lysine 9 (H3K9) acetylation and trimethylation, histone H4 lysine 16 acetylation, and histone H4 lysine 20 trimethylation.
p65825
sg49777
(lp65826
(dp65827
g49782
I145
sg49783
I4
sg49784
I19
sg49812
g11
sg49787
Vhistone H3 lysine 9
p65828
sa(dp65829
g49782
I204
sg49783
I2
sg49784
I10
sg49812
VP62805
p65830
sg49787
Vhistone H4
p65831
sa(dp65832
g49782
I204
sg49783
I4
sg49784
I20
sg49812
VP62805
p65833
sg49787
Vhistone H4 lysine 16
p65834
sasg49779
(lp65835
(dp65836
g49782
I73
sg49783
I2
sg49784
I22
sg49785
VC0278701
p65837
sg49787
Vgastric adenocarcinoma
p65838
sasa(dp65839
g49775
VThis study aimed to investigate the expression of NOR1 in hepatocellular carcinoma (HCC) tissue and its relationship with prognosis.
p65840
sg49777
(lp65841
(dp65842
g49782
I50
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNOR1
p65843
sasg49779
(lp65844
(dp65845
g49782
I84
sg49783
I1
sg49784
I3
sg49785
VC2239176
p65846
sg49787
VHCC
p65847
sa(dp65848
g49782
I58
sg49783
I2
sg49784
I24
sg49785
VC2239176
p65849
sg49787
Vhepatocellular carcinoma
p65850
sasa(dp65851
g49775
VOxidored-nitro domain-containing protein 1 (NOR1) expression levels are greater in hepatitis, cirrhosis and hepatocellular carcinoma samples compared with from normal liver samples.
p65852
sg49777
(lp65853
(dp65854
g49782
I44
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNOR1
p65855
sa(dp65856
g49782
I0
sg49783
I4
sg49784
I42
sg49812
g11
sg49787
VOxidored-nitro domain-containing protein 1
p65857
sasg49779
(lp65858
(dp65859
g49782
I94
sg49783
I1
sg49784
I9
sg49785
VC0023890
p65860
sg49787
Vcirrhosis
p65861
sa(dp65862
g49782
I108
sg49783
I2
sg49784
I24
sg49785
VC1512411
p65863
sg49787
Vhepatocellular carcinoma
p65864
sa(dp65865
g49782
I83
sg49783
I1
sg49784
I9
sg49785
VC0019159
p65866
sg49787
Vhepatitis
p65867
sasa(dp65868
g49775
VIn conclusion, these results indicate that NOR1 may be involved in the progression of HCC and thus may be a potential target for the treatment of liver cancer.
p65869
sg49777
(lp65870
(dp65871
g49782
I43
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNOR1
p65872
sasg49779
(lp65873
(dp65874
g49782
I86
sg49783
I1
sg49784
I3
sg49785
VC2239176
p65875
sg49787
VHCC
p65876
sa(dp65877
g49782
I146
sg49783
I2
sg49784
I12
sg49785
VC0345904
p65878
sg49787
Vliver cancer
p65879
sasa(dp65880
g49775
VTo date, several studies have revealed that gene mutations of the transporters are likely to be associated with some diseases; however, there are no data concerning the genetic polymorphism of the hOSCP1 gene in Japanese patients with non-viral liver carcinoma (LC).
p65881
sg49777
(lp65882
(dp65883
g49782
I197
sg49783
I2
sg49784
I11
sg49812
g11
sg49787
VhOSCP1 gene
p65884
sasg49779
(lp65885
(dp65886
g49782
I245
sg49783
I2
sg49784
I15
sg49785
VC2239176
p65887
sg49787
Vliver carcinoma
p65888
sa(dp65889
g49782
I262
sg49783
I1
sg49784
I2
sg49785
VC2239176
p65890
sg49787
VLC
p65891
sasa(dp65892
g49775
VThe nitroreductase oxidored-nitro domain containing protein 1 (NOR1) gene may be involved in the chemical carcinogenesis of hepatic cancer and nasopharyngeal carcinoma (NPC).
p65893
sg49777
(lp65894
(dp65895
g49782
I63
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNOR1
p65896
sa(dp65897
g49782
I4
sg49783
I6
sg49784
I57
sg49812
VP14222
p65898
sg49787
Vnitroreductase oxidored-nitro domain containing protein 1
p65899
sasg49779
(lp65900
(dp65901
g49782
I124
sg49783
I2
sg49784
I14
sg49785
VC0345904
p65902
sg49787
Vhepatic cancer
p65903
sa(dp65904
g49782
I97
sg49783
I2
sg49784
I23
sg49785
VC0596321
p65905
sg49787
Vchemical carcinogenesis
p65906
sa(dp65907
g49782
I169
sg49783
I1
sg49784
I3
sg49785
VC2931822
p65908
sg49787
VNPC
p65909
sa(dp65910
g49782
I143
sg49783
I2
sg49784
I24
sg49785
VC2931822
p65911
sg49787
Vnasopharyngeal carcinoma
p65912
sasa(dp65913
g49775
VUsing cDNA microarrays and quantitative real-time PCR, we previously discovered that NOR1 increases the expression of growth factor receptor-bound protein 2 (Grb2) mRNA by 4.8-fold in the human hepatocellular carcinoma cell line HepG2.
p65914
sg49777
(lp65915
(dp65916
g49782
I158
sg49783
I1
sg49784
I4
sg49812
VP62993
p65917
sg49787
VGrb2
p65918
sa(dp65919
g49782
I85
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNOR1
p65920
sa(dp65921
g49782
I118
sg49783
I5
sg49784
I38
sg49812
VP62993
p65922
sg49787
Vgrowth factor receptor-bound protein 2
p65923
sasg49779
(lp65924
(dp65925
g49782
I194
sg49783
I2
sg49784
I24
sg49785
VC1512411
p65926
sg49787
Vhepatocellular carcinoma
p65927
sasa(dp65928
g49775
VIn addition, expression of human NOR1 protein in different normal and cancerous human tissues was analyzed via search of the human RNA and protein databases; the data showed that although most malignant cells weakly stained or were negative for NOR1 expression, the liver cancer cells displayed moderate to strong expression of NOR1.
p65929
sg49777
(lp65930
(dp65931
g49782
I33
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNOR1
p65932
sa(dp65933
g49782
I27
sg49783
I3
sg49784
I18
sg49812
g11
sg49787
Vhuman NOR1 protein
p65934
sa(dp65935
g49782
I33
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNOR1
p65936
sasg49779
(lp65937
(dp65938
g49782
I266
sg49783
I2
sg49784
I12
sg49785
VC0345904
p65939
sg49787
Vliver cancer
p65940
sasa(dp65941
g49775
VThese data suggested that NOR1 might serve as a cancer/testis/brain antigen in cells, and that altered NOR1 expression in liver cancer may help us to elucidate the functions of NOR1 protein in liver carcinogenesis.
p65942
sg49777
(lp65943
(dp65944
g49782
I26
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNOR1
p65945
sa(dp65946
g49782
I26
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VNOR1
p65947
sa(dp65948
g49782
I177
sg49783
I2
sg49784
I12
sg49812
g11
sg49787
VNOR1 protein
p65949
sasg49779
(lp65950
(dp65951
g49782
I48
sg49783
I1
sg49784
I6
sg49785
VC0006826
p65952
sg49787
Vcancer
p65953
sa(dp65954
g49782
I122
sg49783
I2
sg49784
I12
sg49785
VC0345904
p65955
sg49787
Vliver cancer
p65956
sa(dp65957
g49782
I193
sg49783
I2
sg49784
I20
sg49785
VC1512409
p65958
sg49787
Vliver carcinogenesis
p65959
sasa(dp65960
g49775
VSignificant allelic associations with SLE were detected in European Americans (EA) and African Americans (AA), which could be attributed to an intronic CFH SNP (rs6677604, in intron 11, P(meta) = 6.6x10(-8), OR = 1.18) and an intergenic SNP between CFHR1 and CFHR4 (rs16840639, P(meta) = 2.9x10(-7), OR = 1.17) rather than to previously identified disease-associated CFH exonic SNPs, including I62V, Y402H, A474A, and D936E.
p65961
sg49777
(lp65962
(dp65963
g49782
I152
sg49783
I2
sg49784
I7
sg49812
g11
sg49787
VCFH SNP
p65964
sa(dp65965
g49782
I249
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCFHR1
p65966
sa(dp65967
g49782
I259
sg49783
I1
sg49784
I5
sg49812
g11
sg49787
VCFHR4
p65968
sasg49779
(lp65969
(dp65970
g49782
I38
sg49783
I1
sg49784
I3
sg49785
VC0014060
p65971
sg49787
VSLE
p65972
sasa(dp65973
g49775
VGastroschisis and omphalocele are the most common fetal abdominal wall defects (AWDs).
p65974
sg49777
(lp65975
sg49779
(lp65976
(dp65977
g49782
I0
sg49783
I1
sg49784
I13
sg49785
VC0265706
p65978
sg49787
VGastroschisis
p65979
sa(dp65980
g49782
I18
sg49783
I1
sg49784
I11
sg49785
VC0795690
p65981
sg49787
Vomphalocele
p65982
sasa(dp65983
g49775
VAWDs were identified through gastroschisis and omphalocele checkboxes from publicly available US Natality data (2006 to 2010).
p65984
sg49777
(lp65985
sg49779
(lp65986
(dp65987
g49782
I47
sg49783
I1
sg49784
I11
sg49785
VC0795690
p65988
sg49787
Vomphalocele
p65989
sa(dp65990
g49782
I29
sg49783
I1
sg49784
I13
sg49785
VC0265706
p65991
sg49787
Vgastroschisis
p65992
sasa(dp65993
g49775
VThe angiogenic proteins vascular endothelial growth factor (VEGF) and prokineticin1 (PROK1) proteins are considered important in colorectal cancer, the relationship between their simultaneous expression and prognosis was investigated in the present study.
p65994
sg49777
(lp65995
(dp65996
g49782
I60
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VVEGF
p65997
sa(dp65998
g49782
I24
sg49783
I4
sg49784
I34
sg49812
g11
sg49787
Vvascular endothelial growth factor
p65999
sa(dp66000
g49782
I70
sg49783
I3
sg49784
I30
sg49812
VP58294
p66001
sg49787
Vprokineticin1 (PROK1) proteins
p66002
sasg49779
(lp66003
(dp66004
g49782
I129
sg49783
I2
sg49784
I17
sg49785
VC1527249
p66005
sg49787
Vcolorectal cancer
p66006
sasa(dp66007
g49775
VVEGF and PROK1 expression in 620 primary human colorectal cancer lesions was confirmed via immunohistochemical staining with anti-VEGF and anti-PROK1 antibodies, and the correlation between the expression of these 2 proteins and recurrence/prognosis were investigated.
p66008
sg49777
(lp66009
(dp66010
g49782
I139
sg49783
I2
sg49784
I21
sg49812
VP58294
p66011
sg49787
Vanti-PROK1 antibodies
p66012
sa(dp66013
g49782
I9
sg49783
I1
sg49784
I5
sg49812
VP58294
p66014
sg49787
VPROK1
p66015
sasg49779
(lp66016
(dp66017
g49782
I229
sg49783
I1
sg49784
I10
sg49785
VC1458156
p66018
sg49787
Vrecurrence
p66019
sa(dp66020
g49782
I47
sg49783
I2
sg49784
I17
sg49785
VC1527249
p66021
sg49787
Vcolorectal cancer
p66022
sasa(dp66023
g49775
VThe prognosis was poorer in colorectal cancers that expressed both PROK1 and VEGF relative to the cases that expressed only 1 protein, and the expression of both proteins was found to be an independent prognostic factor.
p66024
sg49777
(lp66025
(dp66026
g49782
I67
sg49783
I1
sg49784
I5
sg49812
VP58294
p66027
sg49787
VPROK1
p66028
sasg49779
(lp66029
(dp66030
g49782
I28
sg49783
I2
sg49784
I18
sg49785
VC1527249
p66031
sg49787
Vcolorectal cancers
p66032
sasa(dp66033
g49775
VTwo angiogenic growth factors, in particular, Vascular endothelial growth factor (VEGF) and Prokineticin1(PROK1), are considered to have an important role in hematogenous metastasis of colorectal cancer.
p66034
sg49777
(lp66035
(dp66036
g49782
I4
sg49783
I3
sg49784
I25
sg49812
VP19883
p66037
sg49787
Vangiogenic growth factors
p66038
sa(dp66039
g49782
I82
sg49783
I1
sg49784
I4
sg49812
g11
sg49787
VVEGF
p66040
sa(dp66041
g49782
I46
sg49783
I4
sg49784
I34
sg49812
g11
sg49787
VVascular endothelial growth factor
p66042
sa(dp66043
g49782
I106
sg49783
I1
sg49784
I5
sg49812
VP58294
p66044
sg49787
VPROK1
p66045
sasg49779
(lp66046
(dp66047
g49782
I185
sg49783
I2
sg49784
I17
sg49785
VC1527249
p66048
sg49787
Vcolorectal cancer
p66049
sa(dp66050
g49782
I171
sg49783
I1
sg49784
I10
sg49785
VC0027627
p66051
sg49787
Vmetastasis
p66052
sasa(dp66053
g49775
VAccordingly, we report our findings on the importance of the anti-tumor efffect by inhibiting these two factors in human colorectal cancer.When the culture fluid of Colorectal cancer cell lines(DLD-1, HCT116, and LoVo) with high levels of VEGF/PROK1 expression was injected subcutaneously into mice, the culture fluid increased subcutaneous angiogenesis.
p66054
sg49777
(lp66055
(dp66056
g49782
I194
sg49783
I1
sg49784
I5
sg49812
VP98173
p66057
sg49787
VDLD-1
p66058
sa(dp66059
g49782
I244
sg49783
I1
sg49784
I5
sg49812
VP58294
p66060
sg49787
VPROK1
p66061
sasg49779
(lp66062
(dp66063
g49782
I66
sg49783
I1
sg49784
I5
sg49785
VC0027651
p66064
sg49787
Vtumor
p66065
sa(dp66066
g49782
I165
sg49783
I2
sg49784
I17
sg49785
VC1527249
p66067
sg49787
VColorectal cancer
p66068
sa(dp66069
g49782
I121
sg49783
I2
sg49784
I17
sg49785
VC1527249
p66070
sg49787
Vcolorectal cancer
p66071
sasa(dp66072
g49775
VAlso, tumor masses were produced in mice by subcutaneously embedding colorectal cancer cells with high levels VEGF/PROK1 expression.
p66073
sg49777
(lp66074
(dp66075
g49782
I115
sg49783
I1
sg49784
I5
sg49812
VP58294
p66076
sg49787
VPROK1
p66077
sasg49779
(lp66078
(dp66079
g49782
I6
sg49783
I1
sg49784
I5
sg49785
VC0027651
p66080
sg49787
Vtumor
p66081
sa(dp66082
g49782
I69
sg49783
I2
sg49784
I17
sg49785
VC1527249
p66083
sg49787
Vcolorectal cancer
p66084
sasa(dp66085
g49775
VWhen both anti-PROK1 and anti-VEGF antibodies were simultaneously applied, tumor formation and peritumoral angiogenesis were strongly suppressed, compared with when either anti-PROK1 antibody or anti-VEGF antibody was applied alone.Simultaneous targeting of both angiogenic growth factors (VEGF/PROK1) may prove more useful in colorectal cancer.
p66086
sg49777
(lp66087
(dp66088
g49782
I15
sg49783
I1
sg49784
I5
sg49812
VP58294
p66089
sg49787
VPROK1
p66090
sa(dp66091
g49782
I172
sg49783
I2
sg49784
I19
sg49812
VP58294
p66092
sg49787
Vanti-PROK1 antibody
p66093
sa(dp66094
g49782
I10
sg49783
I1
sg49784
I10
sg49812
VP58294
p66095
sg49787
Vanti-PROK1
p66096
sa(dp66097
g49782
I263
sg49783
I3
sg49784
I25
sg49812
VP19883
p66098
sg49787
Vangiogenic growth factors
p66099
sasg49779
(lp66100
(dp66101
g49782
I327
sg49783
I2
sg49784
I17
sg49785
VC1527249
p66102
sg49787
Vcolorectal cancer
p66103
sa(dp66104
g49782
I75
sg49783
I1
sg49784
I5
sg49785
VC0027651
p66105
sg49787
Vtumor
p66106
sasa(dp66107
g49775
VThe current study established the anti-PROK1 monoclonal antibody (mAb) and examined the relationship between the expression of PROK1 protein and human colorectal cancer.
p66108
sg49777
(lp66109
(dp66110
g49782
I34
sg49783
I3
sg49784
I30
sg49812
VP58294
p66111
sg49787
Vanti-PROK1 monoclonal antibody
p66112
sa(dp66113
g49782
I127
sg49783
I2
sg49784
I13
sg49812
VP58294
p66114
sg49787
VPROK1 protein
p66115
sasg49779
(lp66116
(dp66117
g49782
I151
sg49783
I2
sg49784
I17
sg49785
VC1527249
p66118
sg49787
Vcolorectal cancer
p66119
sasa(dp66120
g49775
VThe expression of PROK1 protein was assessed in 620 resected sporadic colorectal cancer tissue samples by immunohistochemical staining with in-house-developed human PROK1 mAb to investigate the relationship of PROK1 expression to clinicopathologic factors, recurrence, and survival rate and to evaluate its prognostic significance.
p66121
sg49777
(lp66122
(dp66123
g49782
I18
sg49783
I2
sg49784
I13
sg49812
VP58294
p66124
sg49787
VPROK1 protein
p66125
sa(dp66126
g49782
I18
sg49783
I1
sg49784
I5
sg49812
VP58294
p66127
sg49787
VPROK1
p66128
sa(dp66129
g49782
I159
sg49783
I3
sg49784
I15
sg49812
VP58294
p66130
sg49787
Vhuman PROK1 mAb
p66131
sasg49779
(lp66132
(dp66133
g49782
I70
sg49783
I2
sg49784
I17
sg49785
VC1527249
p66134
sg49787
Vcolorectal cancer
p66135
sa(dp66136
g49782
I257
sg49783
I1
sg49784
I10
sg49785
VC1458156
p66137
sg49787
Vrecurrence
p66138
sasa(dp66139
g49775
VThe expression of PROK1 protein was detected in 36 % (223/620) of human primary colorectal cancer lesions but no in the healthy mucosa adjacent to the colorectal cancer lesions.
p66140
sg49777
(lp66141
(dp66142
g49782
I18
sg49783
I2
sg49784
I13
sg49812
VP58294
p66143
sg49787
VPROK1 protein
p66144
sasg49779
(lp66145
(dp66146
g49782
I80
sg49783
I2
sg49784
I17
sg49785
VC1527249
p66147
sg49787
Vcolorectal cancer
p66148
sa(dp66149
g49782
I80
sg49783
I2
sg49784
I17
sg49785
VC1527249
p66150
sg49787
Vcolorectal cancer
p66151
sasa(dp66152
g49775
VThe expression of PROK1 protein was identified for the first time as a new prognostic factor in colorectal cancer.
p66153
sg49777
(lp66154
(dp66155
g49782
I18
sg49783
I2
sg49784
I13
sg49812
VP58294
p66156
sg49787
VPROK1 protein
p66157
sasg49779
(lp66158
(dp66159
g49782
I96
sg49783
I2
sg49784
I17
sg49785
VC1527249
p66160
sg49787
Vcolorectal cancer
p66161
sasa(dp66162
g49775
VHere we investigated how the anti-PROK1 monoclonal antibody (mAb; established by our department) would affect the high-PROK1-expressing colorectal cancer (CRC) cells in vitro and vivo.
p66163
sg49777
(lp66164
(dp66165
g49782
I29
sg49783
I3
sg49784
I30
sg49812
VP58294
p66166
sg49787
Vanti-PROK1 monoclonal antibody
p66167
sa(dp66168
g49782
I34
sg49783
I1
sg49784
I5
sg49812
VP58294
p66169
sg49787
VPROK1
p66170
sasg49779
(lp66171
(dp66172
g49782
I155
sg49783
I1
sg49784
I3
sg49785
VC1527249
p66173
sg49787
VCRC
p66174
sa(dp66175
g49782
I136
sg49783
I2
sg49784
I17
sg49785
VC1527249
p66176
sg49787
Vcolorectal cancer
p66177
sasa(dp66178
g49775
VPROK1 expression was not observed in healthy gastrointestinal mucosa, but was observed in the primary lesions in 23 out of 98 (31.6%) patients with colorectal cancer, 19 out of 55 (34.5%) patients with gastric cancer, and 5 of 10 (50%) patients with cancer of the small intestine.
p66179
sg49777
(lp66180
(dp66181
g49782
I0
sg49783
I1
sg49784
I5
sg49812
VP58294
p66182
sg49787
VPROK1
p66183
sasg49779
(lp66184
(dp66185
g49782
I148
sg49783
I2
sg49784
I17
sg49785
VC1527249
p66186
sg49787
Vcolorectal cancer
p66187
sa(dp66188
g49782
I202
sg49783
I2
sg49784
I14
sg49785
VC0024623
p66189
sg49787
Vgastric cancer
p66190
sa(dp66191
g49782
I159
sg49783
I1
sg49784
I6
sg49785
VC0006826
p66192
sg49787
Vcancer
p66193
sasa(dp66194
g49775
VEndocrine gland-derived vascular endothelial growth factor (EG-VEGF) has             recently been identified as one of the vascular endothelial growth factors, and             it is considered that the overexpression of EG-VEGF in colon cancer is related             to hepatic metastasis.
p66195
sg49777
(lp66196
(dp66197
g49782
I60
sg49783
I1
sg49784
I7
sg49812
VP58294
p66198
sg49787
VEG-VEGF
p66199
sa(dp66200
g49782
I124
sg49783
I4
sg49784
I35
sg49812
VP19883
p66201
sg49787
Vvascular endothelial growth factors
p66202
sa(dp66203
g49782
I0
sg49783
I6
sg49784
I58
sg49812
VP58294
p66204
sg49787
VEndocrine gland-derived vascular endothelial growth factor
p66205
sa(dp66206
g49782
I60
sg49783
I1
sg49784
I7
sg49812
VP58294
p66207
sg49787
VEG-VEGF
p66208
sasg49779
(lp66209
(dp66210
g49782
I271
sg49783
I2
sg49784
I18
sg49785
VC0494165
p66211
sg49787
Vhepatic metastasis
p66212
sa(dp66213
g49782
I232
sg49783
I2
sg49784
I12
sg49785
VC0699790
p66214
sg49787
Vcolon cancer
p66215
sasa(dp66216
g49775
VIn this study, we report our recent novel findings of the             involvement of EG-VEGF in cell invasion of colon cancer cells.
p66217
sg49777
(lp66218
(dp66219
g49782
I85
sg49783
I1
sg49784
I7
sg49812
VP58294
p66220
sg49787
VEG-VEGF
p66221
sasg49779
(lp66222
(dp66223
g49782
I113
sg49783
I2
sg49784
I12
sg49785
VC0699790
p66224
sg49787
Vcolon cancer
p66225
sa(dp66226
g49782
I96
sg49783
I2
sg49784
I13
sg49785
VC2699153
p66227
sg49787
Vcell invasion
p66228
sasa(dp66229
g49775
VFinally, the EG-VEGF receptor on the colon cancer cell membrane             was blocked by anti-PK-R1 and -PK-R2 antibodies to study whether cell invasion             ability would be altered.
p66230
sg49777
(lp66231
(dp66232
g49782
I13
sg49783
I2
sg49784
I16
sg49812
VP58294
p66233
sg49787
VEG-VEGF receptor
p66234
sa(dp66235
g49782
I91
sg49783
I4
sg49784
I32
sg49812
g11
sg49787
Vanti-PK-R1 and -PK-R2 antibodies
p66236
sasg49779
(lp66237
(dp66238
g49782
I141
sg49783
I2
sg49784
I13
sg49785
VC2699153
p66239
sg49787
Vcell invasion
p66240
sa(dp66241
g49782
I37
sg49783
I2
sg49784
I12
sg49785
VC0699790
p66242
sg49787
Vcolon cancer
p66243
sasa(dp66244
g49775
VIn colon cancer cell lines where the expression of PK-R1             and 2 was confirmed, stimulation with EG-VEGF increased cell invasion a maximum             of ~3-5 times.
p66245
sg49777
(lp66246
(dp66247
g49782
I107
sg49783
I1
sg49784
I7
sg49812
VP58294
p66248
sg49787
VEG-VEGF
p66249
sasg49779
(lp66250
(dp66251
g49782
I3
sg49783
I2
sg49784
I12
sg49785
VC0699790
p66252
sg49787
Vcolon cancer
p66253
sa(dp66254
g49782
I125
sg49783
I2
sg49784
I13
sg49785
VC2699153
p66255
sg49787
Vcell invasion
p66256
sasa(dp66257
g49775
VThe study showed that the EG-VEGF             protein may act on MMP-2, -7 and -9 via PK-R2 to strengthen cell invasion ability             in colon cancer cell lines.
p66258
sg49777
(lp66259
(dp66260
g49782
I26
sg49783
I1
sg49784
I7
sg49812
VP58294
p66261
sg49787
VEG-VEGF
p66262
sa(dp66263
g49782
I65
sg49783
I2
sg49784
I9
sg49812
VP08253
p66264
sg49787
VMMP-2, -7
p66265
sasg49779
(lp66266
(dp66267
g49782
I143
sg49783
I2
sg49784
I12
sg49785
VC0699790
p66268
sg49787
Vcolon cancer
p66269
sa(dp66270
g49782
I106
sg49783
I2
sg49784
I13
sg49785
VC2699153
p66271
sg49787
Vcell invasion
p66272
sasa(dp66273
g49775
VTo study the implication of prokineticin 1 (PK1/EG-VEGF) and prokineticin 2 (PK2/Bv8) in hepatocellular carcinoma angiogenesis.
p66274
sg49777
(lp66275
(dp66276
g49782
I28
sg49783
I2
sg49784
I14
sg49812
VP58294
p66277
sg49787
Vprokineticin 1
p66278
sa(dp66279
g49782
I77
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VPK2
p66280
sa(dp66281
g49782
I81
sg49783
I1
sg49784
I3
sg49812
g11
sg49787
VBv8
p66282
sa(dp66283
g49782
I61
sg49783
I2
sg49784
I14
sg49812
g11
sg49787
Vprokineticin 2
p66284
sa(dp66285
g49782
I44
sg49783
I1
sg49784
I3
sg49812
VP58294
p66286
sg49787
VPK1
p66287
sa(dp66288
g49782
I48
sg49783
I1
sg49784
I7
sg49812
VP58294
p66289
sg49787
VEG-VEGF
p66290
sasg49779
(lp66291
(dp66292
g49782
I89
sg49783
I2
sg49784
I24
sg49785
VC1512411
p66293
sg49787
Vhepatocellular carcinoma
p66294
sasa(dp66295
S'line'
p66296
VIn this study, we investigated the expression of EG-VEGF in colorectal cancer, the relationship between its expression and clinicopathological factors, and the in vitro activity of EG-VEGF transfectants.
p66297
sS'genes'
p66298
(lp66299
(dp66300
S'index'
p66301
I49
sS'lengthInWords'
p66302
I1
sS'lengthInChars'
p66303
I7
sS'uniprot'
p66304
VP58294
p66305
sS'name'
p66306
VEG-VEGF
p66307
sa(dp66308
g66301
I49
sg66302
I1
sg66303
I7
sg66304
VP58294
p66309
sg66306
VEG-VEGF
p66310
sasS'diseases'
p66311
(lp66312
(dp66313
g66301
I60
sg66302
I2
sg66303
I17
sS'cui'
p66314
VC1527249
p66315
sg66306
Vcolorectal cancer
p66316
sasa(dp66317
g66296
VWe determined expression levels of EG-VEGF in 113 advanced colorectal cancers resected in our hospital by quantitative PCR, and compared the expression levels and clinicopathological findings by multivariate analyses.
p66318
sg66298
(lp66319
(dp66320
g66301
I35
sg66302
I1
sg66303
I7
sg66304
VP58294
p66321
sg66306
VEG-VEGF
p66322
sasg66311
(lp66323
(dp66324
g66301
I59
sg66302
I2
sg66303
I18
sg66314
VC1527249
p66325
sg66306
Vcolorectal cancers
p66326
sasa(dp66327
g66296
VWe speculate that, in colorectal cancers, the EG-VEGF gene functions as an important factor in angiogenesis in primary and metastatic lesions, and consider that it is useful as a novel prognostic factor.
p66328
sg66298
(lp66329
(dp66330
g66301
I46
sg66302
I2
sg66303
I12
sg66304
VP58294
p66331
sg66306
VEG-VEGF gene
p66332
sasg66311
(lp66333
(dp66334
g66301
I22
sg66302
I2
sg66303
I18
sg66314
VC1527249
p66335
sg66306
Vcolorectal cancers
p66336
sasa(dp66337
g66296
VThe aim of the present study was to detect the correlation between the expression of vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2), ephrinB2 and endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and carcinogenesis or portal vein tumor thrombus (PVTT) formation in human hepatocellular carcinoma (HCC).
p66338
sg66298
(lp66339
(dp66340
g66301
I128
sg66302
I2
sg66303
I14
sg66304
g11
sg66306
Vangiopoietin 2
p66341
sa(dp66342
g66301
I85
sg66302
I4
sg66303
I34
sg66304
g11
sg66306
Vvascular endothelial growth factor
p66343
sa(dp66344
g66301
I151
sg66302
I1
sg66303
I8
sg66304
VP52799
p66345
sg66306
VephrinB2
p66346
sa(dp66347
g66301
I224
sg66302
I1
sg66303
I7
sg66304
VP58294
p66348
sg66306
VEG-VEGF
p66349
sa(dp66350
g66301
I164
sg66302
I6
sg66303
I58
sg66304
VP58294
p66351
sg66306
Vendocrine gland-derived vascular endothelial growth factor
p66352
sa(dp66353
g66301
I144
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VAng2
p66354
sa(dp66355
g66301
I121
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VVEGF
p66356
sasg66311
(lp66357
(dp66358
g66301
I334
sg66302
I1
sg66303
I3
sg66314
VC2239176
p66359
sg66306
VHCC
p66360
sa(dp66361
g66301
I237
sg66302
I1
sg66303
I14
sg66314
VC0596263
p66362
sg66306
Vcarcinogenesis
p66363
sa(dp66364
g66301
I267
sg66302
I2
sg66303
I14
sg66314
VC3163918
p66365
sg66306
Vtumor thrombus
p66366
sa(dp66367
g66301
I308
sg66302
I2
sg66303
I24
sg66314
VC2239176
p66368
sg66306
Vhepatocellular carcinoma
p66369
sasa(dp66370
g66296
VA recent genome-wide association study (GWA) reported a significant association between single nucleotide polymorphisms (SNPs) at the PCDH11X gene and late-onset Alzheimer's disease (LOAD).
p66371
sg66298
(lp66372
sg66311
(lp66373
(dp66374
g66301
I162
sg66302
I2
sg66303
I19
sg66314
VC1521724
p66375
sg66306
VAlzheimer's disease
p66376
sasa(dp66377
g66296
VProtocadherin 11X (Pcdh11X) has been suspected to be associated with Alzheimer's disease through participating in the metabolism of PP1Alfa and Beta-catenin or by altering the synaptic functions.
p66378
sg66298
(lp66379
(dp66380
g66301
I144
sg66302
I1
sg66303
I12
sg66304
VP35222
p66381
sg66306
VBeta-catenin
p66382
sa(dp66383
g66301
I0
sg66302
I2
sg66303
I17
sg66304
g11
sg66306
VProtocadherin 11X
p66384
sa(dp66385
g66301
I19
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VPcdh11X
p66386
sasg66311
(lp66387
(dp66388
g66301
I69
sg66302
I2
sg66303
I19
sg66314
VC1521724
p66389
sg66306
VAlzheimer's disease
p66390
sasa(dp66391
g66296
VA recent genome-wide association study reported that a common single nucleotide polymorphism (SNP, rs5984894) in the gene encoding Pcdh11X was associated with susceptibility to late-onset Alzheimer's disease (LOAD) in Caucasians.
p66392
sg66298
(lp66393
sg66311
(lp66394
(dp66395
g66301
I188
sg66302
I2
sg66303
I19
sg66314
VC1521724
p66396
sg66306
VAlzheimer's disease
p66397
sasa(dp66398
g66296
VA recent genome-wide study on late-onset Alzheimer's disease identified a SNP (rs5984894) on Xq21.3 in the PCDH11X gene strongly associated with LOAD individuals of European descent from the United States.
p66399
sg66298
(lp66400
sg66311
(lp66401
(dp66402
g66301
I41
sg66302
I2
sg66303
I19
sg66314
VC1521724
p66403
sg66306
VAlzheimer's disease
p66404
sasa(dp66405
g66296
VBy analyzing late-onset Alzheimer's disease (LOAD) in a genome-wide association study (313,504 SNPs, three series, 844 cases and 1,255 controls) and evaluating the 25 SNPs with the most significant allelic association in four additional series (1,547 cases and 1,209 controls), we identified a SNP (rs5984894) on Xq21.3 in PCDH11X that is strongly associated with LOAD in individuals of European descent from the United States.
p66406
sg66298
(lp66407
sg66311
(lp66408
(dp66409
g66301
I45
sg66302
I1
sg66303
I4
sg66314
VC1521724
p66410
sg66306
VLOAD
p66411
sa(dp66412
g66301
I13
sg66302
I3
sg66303
I30
sg66314
VC1521724
p66413
sg66306
Vlate-onset Alzheimer's disease
p66414
sa(dp66415
g66301
I45
sg66302
I1
sg66303
I4
sg66314
VC1521724
p66416
sg66306
VLOAD
p66417
sasa(dp66418
g66296
VIn this study, we investigated the effect of Bim-1 siRNA on cell proliferation, cell cycle, cell apoptosis and migration of human esophageal carcinoma EC9706 cells, and explored its potential mechanisms.
p66419
sg66298
(lp66420
sg66311
(lp66421
(dp66422
g66301
I65
sg66302
I1
sg66303
I13
sg66314
VC0334094
p66423
sg66306
Vproliferation
p66424
sa(dp66425
g66301
I130
sg66302
I2
sg66303
I20
sg66314
VC0152018
p66426
sg66306
Vesophageal carcinoma
p66427
sasa(dp66428
g66296
VIn the present study, 4-mm samples of BIM (n=31) and CIM (n=9) were selected from esophagectomy specimens that had been resected for esophageal cancer.
p66429
sg66298
(lp66430
(dp66431
g66301
I53
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VCIM
p66432
sasg66311
(lp66433
(dp66434
g66301
I133
sg66302
I2
sg66303
I17
sg66314
VC0014859
p66435
sg66306
Vesophageal cancer
p66436
sasa(dp66437
g66296
VMechanistically, HCMV upregulated two specific cellular antiapoptotic proteins, myeloid leukemia sequence 1 (Mcl-1) and heat shock protein 27 (HSP27), to block the two proteolytic cleavages necessary for the formation of fully active caspase 3 and the subsequent initiation of apoptosis.
p66438
sg66298
(lp66439
(dp66440
g66301
I120
sg66302
I4
sg66303
I21
sg66304
VP34931
p66441
sg66306
Vheat shock protein 27
p66442
sa(dp66443
g66301
I109
sg66302
I1
sg66303
I5
sg66304
VP07954
p66444
sg66306
VMcl-1
p66445
sa(dp66446
g66301
I234
sg66302
I2
sg66303
I9
sg66304
VP42574
p66447
sg66306
Vcaspase 3
p66448
sa(dp66449
g66301
I143
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VHSP27
p66450
sasg66311
(lp66451
(dp66452
g66301
I109
sg66302
I1
sg66303
I3
sg66314
VC1708350
p66453
sg66306
VMcl
p66454
sa(dp66455
g66301
I80
sg66302
I2
sg66303
I16
sg66314
VC0023470
p66456
sg66306
Vmyeloid leukemia
p66457
sasa(dp66458
g66296
VHeat shock protein 27 (HSP27) has been reported to promote the development of leukemia by protecting tumor cells from apoptosis through various mechanisms.
p66459
sg66298
(lp66460
(dp66461
g66301
I0
sg66302
I4
sg66303
I21
sg66304
VP34931
p66462
sg66306
VHeat shock protein 27
p66463
sa(dp66464
g66301
I23
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VHSP27
p66465
sasg66311
(lp66466
(dp66467
g66301
I101
sg66302
I1
sg66303
I5
sg66314
VC0027651
p66468
sg66306
Vtumor
p66469
sa(dp66470
g66301
I78
sg66302
I1
sg66303
I8
sg66314
VC0023418
p66471
sg66306
Vleukemia
p66472
sasa(dp66473
g66296
VThe present study investigated the effects of small hairpin (sh)RNA-mediated HSP27 knockdown on the anti-cancer effects of quercetin in U937 human leukemia cells.
p66474
sg66298
(lp66475
(dp66476
g66301
I77
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VHSP27
p66477
sasg66311
(lp66478
(dp66479
g66301
I105
sg66302
I1
sg66303
I6
sg66314
VC0006826
p66480
sg66306
Vcancer
p66481
sa(dp66482
g66301
I147
sg66302
I1
sg66303
I8
sg66314
VC0023418
p66483
sg66306
Vleukemia
p66484
sasa(dp66485
g66296
VTherefore, these findings collectively suggested that suppression of HSP27 expression amplified the anti-cancer effects of quercetin in U937 human leukemia cells, and that quercetin in combination with shHSP27 represents a promising therapeutic strategy for human leukemia.
p66486
sg66298
(lp66487
(dp66488
g66301
I69
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VHSP27
p66489
sasg66311
(lp66490
(dp66491
g66301
I105
sg66302
I1
sg66303
I6
sg66314
VC0006826
p66492
sg66306
Vcancer
p66493
sa(dp66494
g66301
I147
sg66302
I1
sg66303
I8
sg66314
VC0023418
p66495
sg66306
Vleukemia
p66496
sa(dp66497
g66301
I54
sg66302
I1
sg66303
I11
sg66314
VC0221103
p66498
sg66306
Vsuppression
p66499
sa(dp66500
g66301
I147
sg66302
I1
sg66303
I8
sg66314
VC0023418
p66501
sg66306
Vleukemia
p66502
sasa(dp66503
g66296
VAmong these proteins, enolase, aldolase, HSP70 and sorcin were up-regulated in doxorubicin-resistant myelogenous leukemia cell line, whereas HSP27 was down-regulated.
p66504
sg66298
(lp66505
(dp66506
g66301
I22
sg66302
I1
sg66303
I7
sg66304
VP13929
p66507
sg66306
Venolase
p66508
sa(dp66509
g66301
I31
sg66302
I1
sg66303
I8
sg66304
VP05062
p66510
sg66306
Valdolase
p66511
sa(dp66512
g66301
I41
sg66302
I1
sg66303
I5
sg66304
VP34932
p66513
sg66306
VHSP70
p66514
sa(dp66515
g66301
I141
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VHSP27
p66516
sa(dp66517
g66301
I51
sg66302
I1
sg66303
I6
sg66304
VP30626
p66518
sg66306
Vsorcin
p66519
sasg66311
(lp66520
(dp66521
g66301
I101
sg66302
I2
sg66303
I20
sg66314
VC0023470
p66522
sg66306
Vmyelogenous leukemia
p66523
sasa(dp66524
g66296
VHowever, the role of Hsp27 in the pathogenesis of pediatric acute             leukemia (AL) remains unknown.
p66525
sg66298
(lp66526
(dp66527
g66301
I21
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VHsp27
p66528
sasg66311
(lp66529
(dp66530
g66301
I78
sg66302
I1
sg66303
I8
sg66314
VC0023418
p66531
sg66306
Vleukemia
p66532
sa(dp66533
g66301
I34
sg66302
I1
sg66303
I12
sg66314
VC0699748
p66534
sg66306
Vpathogenesis
p66535
sasa(dp66536
g66296
VIn this study, we evaluated the expression levels             of Hsp27 in bone marrow samples from 94 children with newly diagnosed acute lymphoblastic             leukemia (ALL), acute myeloid leukemia (AML) and 5 leukemia cell lines.
p66537
sg66298
(lp66538
(dp66539
g66301
I65
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VHsp27
p66540
sasg66311
(lp66541
(dp66542
g66301
I164
sg66302
I1
sg66303
I8
sg66314
VC0023418
p66543
sg66306
Vleukemia
p66544
sa(dp66545
g66301
I164
sg66302
I1
sg66303
I8
sg66314
VC0023418
p66546
sg66306
Vleukemia
p66547
sa(dp66548
g66301
I180
sg66302
I3
sg66303
I22
sg66314
VC0023467
p66549
sg66306
Vacute myeloid leukemia
p66550
sa(dp66551
g66301
I204
sg66302
I1
sg66303
I3
sg66314
VC0023467
p66552
sg66306
VAML
p66553
sasa(dp66554
g66296
VAdditionally,             we transfected a target-specific siRNA duplex against Hsp27 into leukemia cells,             and examined the chemosensitivity and cell apoptosis in the response to antitumor             drugs.
p66555
sg66298
(lp66556
(dp66557
g66301
I80
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VHsp27
p66558
sasg66311
(lp66559
(dp66560
g66301
I91
sg66302
I1
sg66303
I8
sg66314
VC0023418
p66561
sg66306
Vleukemia
p66562
sasa(dp66563
g66296
VHsp27 was abundantly expressed in newly diagnosed AML-M4/M5 bone marrow             mononuclear cells (BMMCs) and THP-1, OCI/AML-3 leukemia cell lines.
p66564
sg66298
(lp66565
(dp66566
g66301
I50
sg66302
I1
sg66303
I3
sg66304
VP41212
p66567
sg66306
VAML
p66568
sa(dp66569
g66301
I0
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VHsp27
p66570
sasg66311
(lp66571
(dp66572
g66301
I131
sg66302
I1
sg66303
I8
sg66314
VC0023418
p66573
sg66306
Vleukemia
p66574
sa(dp66575
g66301
I50
sg66302
I1
sg66303
I3
sg66314
VC0023467
p66576
sg66306
VAML
p66577
sa(dp66578
g66301
I50
sg66302
I1
sg66303
I3
sg66314
VC0023467
p66579
sg66306
VAML
p66580
sasa(dp66581
g66296
VKnockdown of Hsp27 expression increased the chemosensitivity of             leukemia cells and the anticancer drug-induced apoptosis.
p66582
sg66298
(lp66583
(dp66584
g66301
I13
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VHsp27
p66585
sasg66311
(lp66586
(dp66587
g66301
I76
sg66302
I1
sg66303
I8
sg66314
VC0023418
p66588
sg66306
Vleukemia
p66589
sasa(dp66590
g66296
VTherefore, Hsp27 may be exploited as a new target for enhancing the             efficacy of chemotherapeutic drugs against leukemia.
p66591
sg66298
(lp66592
(dp66593
g66301
I11
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VHsp27
p66594
sasg66311
(lp66595
(dp66596
g66301
I123
sg66302
I1
sg66303
I8
sg66314
VC0023418
p66597
sg66306
Vleukemia
p66598
sasa(dp66599
g66296
VIt was: xS-D-D-K-K-A-K-A-A-T-S-S-V-L-T-K-F-T-Q-N-Q-I-Q-E-M-K-E-A-F-T-M-I-D-Q-N-R -D-G-L- I-D-V-S-D-L-K-E-M-Y-S-N-L-G-T-A-P-Q-D-S-V-L-Q-A-M-V-K-E-A-P-Q-M-N-F-T-G- F-L-S-L- F-S-E-K-M-S-G-T-D-P-E-E-T-L-R-N-A-F-Q-M-F-D-S-D-N-T-G-Y-I-P-E-E-Y-M-K-D- L- L-E-N-M-G-D-N-F-S-K-D-E-V-R-Q-T-W-K-E-A-P-I-A-G-G-K-V-D-Y-N-A-F-V-S-K-I- K- G-K-E-Q-D-D-A.
p66600
sg66298
(lp66601
(dp66602
g66301
I8
sg66302
I7
sg66303
I246
sg66304
g11
sg66306
VxS-D-D-K-K-A-K-A-A-T-S-S-V-L-T-K-F-T-Q-N-Q-I-Q-E-M-K-E-A-F-T-M-I-D-Q-N-R -D-G-L- I-D-V-S-D-L-K-E-M-Y-S-N-L-G-T-A-P-Q-D-S-V-L-Q-A-M-V-K-E-A-P-Q-M-N-F-T-G- F-L-S-L- F-S-E-K-M-S-G-T-D-P-E-E-T-L-R-N-A-F-Q-M-F-D-S-D-N-T-G-Y-I-P-E-E-Y-M-K-D- L- L-E-N-M
p66603
sasg66311
(lp66604
sa(dp66605
g66296
VIntegrin alpha 8 (ITGA8) encodes the alpha 8 subunit of the integrin alpha8beta1 protein and has recently been suggested as a new candidate gene for Parkinson's disease, an age related neurodegenerative disease with unknown etiology.
p66606
sg66298
(lp66607
(dp66608
g66301
I18
sg66302
I1
sg66303
I5
sg66304
VP53708
p66609
sg66306
VITGA8
p66610
sa(dp66611
g66301
I0
sg66302
I3
sg66303
I16
sg66304
VP53708
p66612
sg66306
VIntegrin alpha 8
p66613
sasg66311
(lp66614
(dp66615
g66301
I149
sg66302
I2
sg66303
I19
sg66314
VC0030567
p66616
sg66306
VParkinson's disease
p66617
sa(dp66618
g66301
I185
sg66302
I2
sg66303
I25
sg66314
VC0524851
p66619
sg66306
Vneurodegenerative disease
p66620
sasa(dp66621
g66296
VScreen a Swedish case control material for rs7077361, a genetic variant in ITGA8, in order to investigate its possible implication in Parkinson's disease in Sweden.
p66622
sg66298
(lp66623
(dp66624
g66301
I75
sg66302
I1
sg66303
I5
sg66304
VP53708
p66625
sg66306
VITGA8
p66626
sasg66311
(lp66627
(dp66628
g66301
I134
sg66302
I2
sg66303
I19
sg66314
VC0030567
p66629
sg66306
VParkinson's disease
p66630
sasa(dp66631
g66296
VOur results do not support the hypothesis of ITGA8 as a candidate gene for Parkinson's disease in Sweden.
p66632
sg66298
(lp66633
(dp66634
g66301
I45
sg66302
I1
sg66303
I5
sg66304
VP53708
p66635
sg66306
VITGA8
p66636
sasg66311
(lp66637
(dp66638
g66301
I75
sg66302
I2
sg66303
I19
sg66314
VC0030567
p66639
sg66306
VParkinson's disease
p66640
sasa(dp66641
g66296
VCYFIP1 maps to the interval between proximal breakpoint 1 (BP1) and breakpoint 2 (BP2) of chromosomal 15q11-q13 deletions that are implicated in the Angelman (AS) and Prader-Willi syndrome (PWS).
p66642
sg66298
(lp66643
(dp66644
g66301
I82
sg66302
I1
sg66303
I3
sg66304
VP18065
p66645
sg66306
VBP2
p66646
sa(dp66647
g66301
I45
sg66302
I6
sg66303
I35
sg66304
g11
sg66306
Vbreakpoint 1 (BP1) and breakpoint 2
p66648
sa(dp66649
g66301
I0
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCYFIP1
p66650
sasg66311
(lp66651
(dp66652
g66301
I167
sg66302
I2
sg66303
I21
sg66314
VC0032897
p66653
sg66306
VPrader-Willi syndrome
p66654
sa(dp66655
g66301
I190
sg66302
I1
sg66303
I3
sg66314
VC0032897
p66656
sg66306
VPWS
p66657
sasa(dp66658
g66296
VWe found copy number variants in PDE10A (phosphodiesterase 10A), CYFIP1 [cytoplasmic FMR1 (Fragile X mental retardation 1)-interacting protein 1], K(+) channel genes KCNE1 and KCNE2, the Down's syndrome critical region 1 gene RCAN1 (regulator of calcineurin 1), cell-recognition protein CHL1 (cell adhesion molecule with homology with L1CAM), the transcription factor SP4 (specificity protein 4) and histone deacetylase HDAC9, among others (see http://www.genes2cognition.org/SCZ-CNV).
p66659
sg66298
(lp66660
(dp66661
g66301
I335
sg66302
I1
sg66303
I5
sg66304
VP32004
p66662
sg66306
VL1CAM
p66663
sa(dp66664
g66301
I33
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VPDE10A
p66665
sa(dp66666
g66301
I166
sg66302
I1
sg66303
I5
sg66304
VP15382
p66667
sg66306
VKCNE1
p66668
sa(dp66669
g66301
I176
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VKCNE2
p66670
sa(dp66671
g66301
I41
sg66302
I2
sg66303
I21
sg66304
g11
sg66306
Vphosphodiesterase 10A
p66672
sa(dp66673
g66301
I400
sg66302
I3
sg66303
I25
sg66304
g11
sg66306
Vhistone deacetylase HDAC9
p66674
sa(dp66675
g66301
I287
sg66302
I4
sg66303
I28
sg66304
g11
sg66306
VCHL1 (cell adhesion molecule
p66676
sasg66311
(lp66677
(dp66678
g66301
I298
sg66302
I1
sg66303
I8
sg66314
VC0001511
p66679
sg66306
Vadhesion
p66680
sa(dp66681
g66301
I187
sg66302
I2
sg66303
I15
sg66314
VC0013080
p66682
sg66306
VDown's syndrome
p66683
sa(dp66684
g66301
I101
sg66302
I2
sg66303
I18
sg66314
VC0025362
p66685
sg66306
Vmental retardation
p66686
sasa(dp66687
g66296
VWe describe nine cases with a microdeletion at 15q11.2 between BP1-BP2, thus having a haploinsufficiency for TUBGCP5, NIPA1, NIPA2, and CYFIP1 without Prader-Willi/Angelman syndrome.
p66688
sg66298
(lp66689
(dp66690
g66301
I63
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VBP1-BP2
p66691
sa(dp66692
g66301
I118
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VNIPA1
p66693
sa(dp66694
g66301
I109
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VTUBGCP5
p66695
sa(dp66696
g66301
I136
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCYFIP1
p66697
sa(dp66698
g66301
I125
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VNIPA2
p66699
sasg66311
(lp66700
(dp66701
g66301
I164
sg66302
I2
sg66303
I17
sg66314
VC0162635
p66702
sg66306
VAngelman syndrome
p66703
sasa(dp66704
g66296
VAltered expression of CYFIP1 is seen in other developmental disabilities, including 15q disorders, and haploinsufficiency of CYFIP1 in Type I PWS cases may be associated with age-related phenotypic effects.
p66705
sg66298
(lp66706
(dp66707
g66301
I22
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCYFIP1
p66708
sa(dp66709
g66301
I22
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCYFIP1
p66710
sasg66311
(lp66711
(dp66712
g66301
I142
sg66302
I1
sg66303
I3
sg66314
VC0032897
p66713
sg66306
VPWS
p66714
sa(dp66715
g66301
I46
sg66302
I2
sg66303
I26
sg66314
VC0008073
p66716
sg66306
Vdevelopmental disabilities
p66717
sasa(dp66718
g66296
VExpression analysis of cultured human cells and brain tissues from PWS patients indicates that CYFIP1 and NIPA2 are biallelically expressed.
p66719
sg66298
(lp66720
(dp66721
g66301
I95
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCYFIP1
p66722
sa(dp66723
g66301
I106
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VNIPA2
p66724
sasg66311
(lp66725
(dp66726
g66301
I67
sg66302
I1
sg66303
I3
sg66314
VC0032897
p66727
sg66306
VPWS
p66728
sasa(dp66729
g66296
VFour genes (NIPA1, NIPA2, CYFIP1, and GCP5) have been identified in the chromosomal region between breakpoints 1 and 2 and are implicated in compulsive behavior and lower intellectual ability observed in individuals with Prader-Willi syndrome with TI versus TII deletions.
p66730
sg66298
(lp66731
(dp66732
g66301
I38
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGCP5
p66733
sa(dp66734
g66301
I19
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VNIPA2
p66735
sa(dp66736
g66301
I26
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCYFIP1
p66737
sa(dp66738
g66301
I12
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VNIPA1
p66739
sasg66311
(lp66740
(dp66741
g66301
I141
sg66302
I2
sg66303
I19
sg66314
VC0600104
p66742
sg66306
Vcompulsive behavior
p66743
sa(dp66744
g66301
I221
sg66302
I2
sg66303
I21
sg66314
VC0032897
p66745
sg66306
VPrader-Willi syndrome
p66746
sasa(dp66747
g66296
VMessenger RNA from NIPA1, NIPA2, CYFIP1, and GCP5 was reduced but detectable in the subjects with Prader-Willi syndrome with the TI deletion, supporting biallelic expression.
p66748
sg66298
(lp66749
(dp66750
g66301
I26
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VNIPA2
p66751
sa(dp66752
g66301
I45
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGCP5
p66753
sa(dp66754
g66301
I33
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCYFIP1
p66755
sa(dp66756
g66301
I19
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VNIPA1
p66757
sasg66311
(lp66758
(dp66759
g66301
I98
sg66302
I2
sg66303
I21
sg66314
VC0032897
p66760
sg66306
VPrader-Willi syndrome
p66761
sasa(dp66762
g66296
VTherefore, we recruited 50 untreated house dust mite-sensitive allergic rhinitis patients and 29 non-atopic healthy individuals and performed comprehensive simultaneous flow cytometric analysis of mutual correlations between levels of CD14, CD16, CD163, CD206, CD124 (IL-4R), CD210 (IL-10R) and CD25, CD124, CD127 (IL-7R), CD210, ICOS expression on monocytes and CD4+ T cells, respectively.
p66763
sg66298
(lp66764
(dp66765
g66301
I254
sg66302
I1
sg66303
I5
sg66304
VP22897
p66766
sg66306
VCD206
p66767
sa(dp66768
g66301
I363
sg66302
I1
sg66303
I4
sg66304
VP01730
p66769
sg66306
VCD4+
p66770
sa(dp66771
g66301
I295
sg66302
I1
sg66303
I4
sg66304
VP01589
p66772
sg66306
VCD25
p66773
sa(dp66774
g66301
I283
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VIL-10R
p66775
sa(dp66776
g66301
I247
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD163
p66777
sa(dp66778
g66301
I235
sg66302
I1
sg66303
I4
sg66304
VP08571
p66779
sg66306
VCD14
p66780
sa(dp66781
g66301
I241
sg66302
I1
sg66303
I4
sg66304
VP08637
p66782
sg66306
VCD16
p66783
sasg66311
(lp66784
(dp66785
g66301
I63
sg66302
I2
sg66303
I17
sg66314
VC2607914
p66786
sg66306
Vallergic rhinitis
p66787
sa(dp66788
g66301
I101
sg66302
I1
sg66303
I6
sg66314
VC0392707
p66789
sg66306
Vatopic
p66790
sasa(dp66791
g66296
VWe did not observe any statistically significant differences between healthy and diabetic children in mRNA expression for FoxP3, IL-7R (CD127), IL-8RA, IL-10RA, IL-12A, IL-2RA (CD25), IL-21, STAT1, STAT3, SOCS2, SOCS3, TGF-beta1-R1, TGF-beta-R2 and TBX-21 genes.
p66792
sg66298
(lp66793
(dp66794
g66301
I191
sg66302
I1
sg66303
I5
sg66304
VP42224
p66795
sg66306
VSTAT1
p66796
sa(dp66797
g66301
I198
sg66302
I1
sg66303
I5
sg66304
VP40763
p66798
sg66306
VSTAT3
p66799
sa(dp66800
g66301
I184
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VIL-21
p66801
sa(dp66802
g66301
I122
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFoxP3
p66803
sa(dp66804
g66301
I177
sg66302
I1
sg66303
I4
sg66304
VP01589
p66805
sg66306
VCD25
p66806
sa(dp66807
g66301
I205
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSOCS2
p66808
sa(dp66809
g66301
I161
sg66302
I1
sg66303
I6
sg66304
VP29459
p66810
sg66306
VIL-12A
p66811
sa(dp66812
g66301
I233
sg66302
I1
sg66303
I11
sg66304
VP18075
p66813
sg66306
VTGF-beta-R2
p66814
sa(dp66815
g66301
I212
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSOCS3
p66816
sa(dp66817
g66301
I219
sg66302
I1
sg66303
I12
sg66304
VP01137
p66818
sg66306
VTGF-beta1-R1
p66819
sasg66311
(lp66820
sa(dp66821
g66296
VExpression of the Growth Hormone (GH)-stimulated gene Socs2 (Suppressor of Cytokine Signaling 2) is mediated by the transcription activator STAT5 (Signal Transducer and Activator of Transcription 5) and the transcription repressor BCL6 (B-Cell Lymphoma 6).
p66822
sg66298
(lp66823
(dp66824
g66301
I18
sg66302
I2
sg66303
I14
sg66304
VP01242
p66825
sg66306
VGrowth Hormone
p66826
sa(dp66827
g66301
I140
sg66302
I1
sg66303
I5
sg66304
VP42229
p66828
sg66306
VSTAT5
p66829
sa(dp66830
g66301
I34
sg66302
I1
sg66303
I2
sg66304
VP01242
p66831
sg66306
VGH
p66832
sa(dp66833
g66301
I54
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSocs2
p66834
sa(dp66835
g66301
I61
sg66302
I5
sg66303
I34
sg66304
g11
sg66306
VSuppressor of Cytokine Signaling 2
p66836
sa(dp66837
g66301
I231
sg66302
I1
sg66303
I4
sg66304
VP41182
p66838
sg66306
VBCL6
p66839
sa(dp66840
g66301
I147
sg66302
I7
sg66303
I50
sg66304
VP42229
p66841
sg66306
VSignal Transducer and Activator of Transcription 5
p66842
sa(dp66843
g66301
I237
sg66302
I3
sg66303
I17
sg66304
VP41182
p66844
sg66306
VB-Cell Lymphoma 6
p66845
sasg66311
(lp66846
(dp66847
g66301
I237
sg66302
I2
sg66303
I15
sg66314
VC0079731
p66848
sg66306
VB-Cell Lymphoma
p66849
sasa(dp66850
g66296
VGene expression analysis revealed increased expression of MAPK1, AKT1, PRKCE, IL4R and DROSHA and decreased expression of CDKN1A/p21, SOCS2, CHEK1, RAD51, KLF4, BLIMP1 and IRF4 in follicular lymphoma.
p66851
sg66298
(lp66852
(dp66853
g66301
I141
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCHEK1
p66854
sa(dp66855
g66301
I129
sg66302
I1
sg66303
I3
sg66304
VP42857
p66856
sg66306
Vp21
p66857
sa(dp66858
g66301
I161
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VBLIMP1
p66859
sa(dp66860
g66301
I155
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKLF4
p66861
sa(dp66862
g66301
I172
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VIRF4
p66863
sa(dp66864
g66301
I87
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VDROSHA
p66865
sa(dp66866
g66301
I122
sg66302
I1
sg66303
I6
sg66304
VP38936
p66867
sg66306
VCDKN1A
p66868
sa(dp66869
g66301
I148
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VRAD51
p66870
sa(dp66871
g66301
I134
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSOCS2
p66872
sa(dp66873
g66301
I65
sg66302
I1
sg66303
I4
sg66304
VP31749
p66874
sg66306
VAKT1
p66875
sa(dp66876
g66301
I58
sg66302
I1
sg66303
I5
sg66304
VP28482
p66877
sg66306
VMAPK1
p66878
sa(dp66879
g66301
I71
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VPRKCE
p66880
sasg66311
(lp66881
(dp66882
g66301
I180
sg66302
I2
sg66303
I19
sg66314
VC0024301
p66883
sg66306
Vfollicular lymphoma
p66884
sasa(dp66885
g66296
VmiR-20a/b and miR-194 target CDKN1A and SOCS2 in follicular lymphoma, potentially contributing to tumor cell proliferation and survival.
p66886
sg66298
(lp66887
(dp66888
g66301
I40
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSOCS2
p66889
sa(dp66890
g66301
I0
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
VmiR-20a/b
p66891
sa(dp66892
g66301
I29
sg66302
I1
sg66303
I6
sg66304
VP38936
p66893
sg66306
VCDKN1A
p66894
sa(dp66895
g66301
I14
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-194
p66896
sasg66311
(lp66897
(dp66898
g66301
I98
sg66302
I1
sg66303
I5
sg66314
VC0027651
p66899
sg66306
Vtumor
p66900
sa(dp66901
g66301
I49
sg66302
I2
sg66303
I19
sg66314
VC0024301
p66902
sg66306
Vfollicular lymphoma
p66903
sa(dp66904
g66301
I109
sg66302
I1
sg66303
I13
sg66314
VC0334094
p66905
sg66306
Vproliferation
p66906
sasa(dp66907
g66296
VNuclear factors such as pregnane X receptor (PXR) and constitutive androstane receptor (CAR), as well as transporters and conjugation enzymes involved in the detoxification of lithocholic acid (LCA), also showed higher expression in SPF mice.
p66908
sg66298
(lp66909
(dp66910
g66301
I24
sg66302
I3
sg66303
I19
sg66304
g11
sg66306
Vpregnane X receptor
p66911
sa(dp66912
g66301
I45
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPXR
p66913
sasg66311
(lp66914
(dp66915
g66301
I54
sg66302
I3
sg66303
I32
sg66314
VC2607929
p66916
sg66306
Vconstitutive androstane receptor
p66917
sa(dp66918
g66301
I88
sg66302
I1
sg66303
I3
sg66314
VC2607929
p66919
sg66306
VCAR
p66920
sa(dp66921
g66301
I176
sg66302
I2
sg66303
I16
sg66314
VC0339527
p66922
sg66306
Vlithocholic acid
p66923
sa(dp66924
g66301
I194
sg66302
I1
sg66303
I3
sg66314
VC0339527
p66925
sg66306
VLCA
p66926
sasa(dp66927
g66296
VIn this study, using transgenic mice bearing conditional expression of the activated constitutive androstane receptor (CAR), we demonstrate that activation of CAR is both necessary and sufficient to confer resistance to the hepatotoxicity of lithocholic acid (LCA).
p66928
sg66298
(lp66929
sg66311
(lp66930
(dp66931
g66301
I119
sg66302
I1
sg66303
I3
sg66314
VC2607929
p66932
sg66306
VCAR
p66933
sa(dp66934
g66301
I260
sg66302
I1
sg66303
I3
sg66314
VC0339527
p66935
sg66306
VLCA
p66936
sa(dp66937
g66301
I119
sg66302
I1
sg66303
I3
sg66314
VC2607929
p66938
sg66306
VCAR
p66939
sa(dp66940
g66301
I85
sg66302
I3
sg66303
I32
sg66314
VC2607929
p66941
sg66306
Vconstitutive androstane receptor
p66942
sa(dp66943
g66301
I242
sg66302
I2
sg66303
I16
sg66314
VC0339527
p66944
sg66306
Vlithocholic acid
p66945
sasa(dp66946
g66296
VThese results support the conclusion that dental caries is highly affected by the activity of CA VI in saliva as well as by the salivary flow rate.
p66947
sg66298
(lp66948
(dp66949
g66301
I94
sg66302
I2
sg66303
I5
sg66304
VP23280
p66950
sg66306
VCA VI
p66951
sasg66311
(lp66952
(dp66953
g66301
I42
sg66302
I2
sg66303
I13
sg66314
VC0333519
p66954
sg66306
Vdental caries
p66955
sasa(dp66956
g66296
VEleven articles found a consistent association between salivary protein polymorphisms and risk of dental caries, for proteins related to antimicrobial activity (beta defensin 1 and lysozyme-like protein), pH control (carbonic anhydrase VI), and bacterial colonization/adhesion (lactotransferrin, mucin, and proline-rich protein Db).
p66957
sg66298
(lp66958
(dp66959
g66301
I217
sg66302
I3
sg66303
I21
sg66304
VP23280
p66960
sg66306
Vcarbonic anhydrase VI
p66961
sa(dp66962
g66301
I161
sg66302
I6
sg66303
I41
sg66304
VP60022
p66963
sg66306
Vbeta defensin 1 and lysozyme-like protein
p66964
sa(dp66965
g66301
I296
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
Vmucin
p66966
sasg66311
(lp66967
(dp66968
g66301
I268
sg66302
I1
sg66303
I8
sg66314
VC0001511
p66969
sg66306
Vadhesion
p66970
sa(dp66971
g66301
I98
sg66302
I2
sg66303
I13
sg66314
VC0333519
p66972
sg66306
Vdental caries
p66973
sasa(dp66974
g66296
VThe rs17032907 genetic variant and the haplotype (ACA) of CA VI may be associated with dental caries susceptibility.
p66975
sg66298
(lp66976
(dp66977
g66301
I58
sg66302
I2
sg66303
I5
sg66304
VP23280
p66978
sg66306
VCA VI
p66979
sasg66311
(lp66980
(dp66981
g66301
I87
sg66302
I2
sg66303
I13
sg66314
VC0333519
p66982
sg66306
Vdental caries
p66983
sasa(dp66984
g66296
VThe oral pathogenic bacterium involved in human dental caries formation Streptococcus mutans, encodes for two carbonic anhydrase (CA, EC 4.2.1.1) one belonging to the Alfa- and the other one to the Beta-class.
p66985
sg66298
(lp66986
(dp66987
g66301
I110
sg66302
I2
sg66303
I18
sg66304
VP35218
p66988
sg66306
Vcarbonic anhydrase
p66989
sa(dp66990
g66301
I130
sg66302
I1
sg66303
I2
sg66304
VP35218
p66991
sg66306
VCA
p66992
sasg66311
(lp66993
(dp66994
g66301
I48
sg66302
I2
sg66303
I13
sg66314
VC0333519
p66995
sg66306
Vdental caries
p66996
sasa(dp66997
g66296
VStreptococcus mutans, the oral pathogenic bacterium provoking dental caries formation, encodes for a Beta-class carbonic anhydrase (CA, EC 4.2.1.1), SmuCA.
p66998
sg66298
(lp66999
(dp67000
g66301
I101
sg66302
I3
sg66303
I29
sg66304
VP35218
p67001
sg66306
VBeta-class carbonic anhydrase
p67002
sasg66311
(lp67003
(dp67004
g66301
I62
sg66302
I2
sg66303
I13
sg66314
VC0333519
p67005
sg66306
Vdental caries
p67006
sasa(dp67007
g66296
VWe used mice lacking the CNTNAP2 gene, which has been implicated in autism, and achieved a temporally precise reduction in E:I balance in the medial prefrontal cortex (mPFC) either by optogenetically increasing the excitability of inhibitory parvalbumin (PV) neurons or decreasing the excitability of excitatory pyramidal neurons.
p67008
sg66298
(lp67009
(dp67010
g66301
I255
sg66302
I1
sg66303
I2
sg66304
VP20472
p67011
sg66306
VPV
p67012
sa(dp67013
g66301
I242
sg66302
I1
sg66303
I11
sg66304
VP20472
p67014
sg66306
Vparvalbumin
p67015
sa(dp67016
g66301
I25
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VCNTNAP2 gene
p67017
sasg66311
(lp67018
(dp67019
g66301
I215
sg66302
I1
sg66303
I12
sg66314
VC0235169
p67020
sg66306
Vexcitability
p67021
sa(dp67022
g66301
I68
sg66302
I1
sg66303
I6
sg66314
VC0004352
p67023
sg66306
Vautism
p67024
sa(dp67025
g66301
I215
sg66302
I1
sg66303
I12
sg66314
VC0235169
p67026
sg66306
Vexcitability
p67027
sasa(dp67028
g66296
VPost-mortem analyses have demonstrated a selective reduction in the expression of parvalbumin (PV) in GABAergic interneurons in the frontal rather than the sensory cortex of patients with neuropsychiatric disorders such as schizophrenia, autism spectrum disorders, and bipolar disorders.
p67029
sg66298
(lp67030
(dp67031
g66301
I82
sg66302
I1
sg66303
I11
sg66304
VP20472
p67032
sg66306
Vparvalbumin
p67033
sa(dp67034
g66301
I95
sg66302
I1
sg66303
I2
sg66304
VP20472
p67035
sg66306
VPV
p67036
sasg66311
(lp67037
(dp67038
g66301
I223
sg66302
I1
sg66303
I13
sg66314
VC0036341
p67039
sg66306
Vschizophrenia
p67040
sa(dp67041
g66301
I269
sg66302
I2
sg66303
I17
sg66314
VC0005586
p67042
sg66306
Vbipolar disorders
p67043
sa(dp67044
g66301
I238
sg66302
I3
sg66303
I25
sg66314
VC1510586
p67045
sg66306
Vautism spectrum disorders
p67046
sasa(dp67047
g66296
VRecent neuropathology studies in human brains indicate that several areas of the prefrontal cortex have decreased numbers of parvalbumin interneurons or decreased parvalbumin expression in Autism Spectrum disorders (ASD) [Hashemi, Ariza, Rogers, Noctor, &amp; Martinez-Cerdeno, 2017; Zikopoulos &amp; Barbas, ].
p67048
sg66298
(lp67049
(dp67050
g66301
I125
sg66302
I1
sg66303
I11
sg66304
VP20472
p67051
sg66306
Vparvalbumin
p67052
sa(dp67053
g66301
I125
sg66302
I1
sg66303
I11
sg66304
VP20472
p67054
sg66306
Vparvalbumin
p67055
sasg66311
(lp67056
(dp67057
g66301
I189
sg66302
I3
sg66303
I25
sg66314
VC1510586
p67058
sg66306
VAutism Spectrum disorders
p67059
sa(dp67060
g66301
I216
sg66302
I1
sg66303
I3
sg66314
VC1510586
p67061
sg66306
VASD
p67062
sa(dp67063
g66301
I7
sg66302
I1
sg66303
I14
sg66314
VC1540677
p67064
sg66306
Vneuropathology
p67065
sasa(dp67066
g66296
VIn view of the documented association between parvalbumin-expressing neurons and autism, the objective of the present study was to determine if parvalbumin gene expression is also altered in Purkinje neurons of the cerebellum.
p67067
sg66298
(lp67068
(dp67069
g66301
I46
sg66302
I1
sg66303
I11
sg66304
VP20472
p67070
sg66306
Vparvalbumin
p67071
sa(dp67072
g66301
I144
sg66302
I2
sg66303
I16
sg66304
VP20472
p67073
sg66306
Vparvalbumin gene
p67074
sasg66311
(lp67075
(dp67076
g66301
I81
sg66302
I1
sg66303
I6
sg66314
VC0004352
p67077
sg66306
Vautism
p67078
sasa(dp67079
g66296
VOur hypothesis is that parvalbumin, a molecule that controls and coordinate many cellular brain functions, contributes to the excitatory/inhibitory imbalance in Autism.
p67080
sg66298
(lp67081
(dp67082
g66301
I23
sg66302
I1
sg66303
I11
sg66304
VP20472
p67083
sg66306
Vparvalbumin
p67084
sasg66311
(lp67085
(dp67086
g66301
I148
sg66302
I1
sg66303
I9
sg66314
VC1397014
p67087
sg66306
Vimbalance
p67088
sa(dp67089
g66301
I161
sg66302
I1
sg66303
I6
sg66314
VC0004352
p67090
sg66306
VAutism
p67091
sasa(dp67092
g66296
VWe report that parvalbumin expression is depressed in Purkinje cells of the cerebellum in autism.
p67093
sg66298
(lp67094
(dp67095
g66301
I15
sg66302
I1
sg66303
I11
sg66304
VP20472
p67096
sg66306
Vparvalbumin
p67097
sasg66311
(lp67098
(dp67099
g66301
I90
sg66302
I1
sg66303
I6
sg66314
VC0004352
p67100
sg66306
Vautism
p67101
sasa(dp67102
g66296
VFor children less than 32 weeks, FVL homozygosity may be associated with an increase in the risk of developing quadriplegia (OR 9.12, 95% CI 0.86-53.71).
p67103
sg66298
(lp67104
sg66311
(lp67105
(dp67106
g66301
I111
sg66302
I1
sg66303
I12
sg66314
VC0034372
p67107
sg66306
Vquadriplegia
p67108
sasa(dp67109
g66296
VIn the myocardium activation of NFATc3 down-regulates the expression of voltage-gated K(+) (Kv) channels after myocardial infarction (MI).
p67110
sg66298
(lp67111
(dp67112
g66301
I32
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VNFATc3
p67113
sasg66311
(lp67114
(dp67115
g66301
I134
sg66302
I1
sg66303
I2
sg66314
VC0027051
p67116
sg66306
VMI
p67117
sa(dp67118
g66301
I111
sg66302
I2
sg66303
I21
sg66314
VC0027051
p67119
sg66306
Vmyocardial infarction
p67120
sasa(dp67121
g66296
VKnockdown of NFAT4 suppresses mitochondrial fission and protects cardiomyocyte from apoptosis and myocardial infarction.
p67122
sg66298
(lp67123
(dp67124
g66301
I13
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VNFAT4
p67125
sasg66311
(lp67126
(dp67127
g66301
I98
sg66302
I2
sg66303
I21
sg66314
VC0027051
p67128
sg66306
Vmyocardial infarction
p67129
sasa(dp67130
g66296
VThe expression pattern of WNT3A is consistent with BRG1 in colon cancer tissues and WNT3A expression was inhibited in BRG1 knockdown cells.
p67131
sg66298
(lp67132
(dp67133
g66301
I51
sg66302
I1
sg66303
I4
sg66304
VP51532
p67134
sg66306
VBRG1
p67135
sa(dp67136
g66301
I26
sg66302
I1
sg66303
I5
sg66304
VP56704
p67137
sg66306
VWNT3A
p67138
sa(dp67139
g66301
I51
sg66302
I5
sg66303
I28
sg66304
VP51532
p67140
sg66306
VBRG1 in colon cancer tissues
p67141
sa(dp67142
g66301
I26
sg66302
I1
sg66303
I5
sg66304
VP56704
p67143
sg66306
VWNT3A
p67144
sasg66311
(lp67145
(dp67146
g66301
I59
sg66302
I2
sg66303
I12
sg66314
VC0699790
p67147
sg66306
Vcolon cancer
p67148
sasa(dp67149
g66296
VIn this study, we demonstrate that BRG1 may contribute to colon cancer progression through upregulating WNT3A expression.
p67150
sg66298
(lp67151
(dp67152
g66301
I104
sg66302
I1
sg66303
I5
sg66304
VP56704
p67153
sg66306
VWNT3A
p67154
sa(dp67155
g66301
I35
sg66302
I1
sg66303
I4
sg66304
VP51532
p67156
sg66306
VBRG1
p67157
sasg66311
(lp67158
(dp67159
g66301
I64
sg66302
I2
sg66303
I18
sg66314
VC0178874
p67160
sg66306
Vcancer progression
p67161
sasa(dp67162
g66296
VVM-positive colon cancer samples showed increased Wnt3a expression (p &lt; 0.001) and Beta-catenin nuclear expression (p &lt; 0.001) compared with the VM-negative samples.
p67163
sg66298
(lp67164
(dp67165
g66301
I50
sg66302
I1
sg66303
I5
sg66304
VP56704
p67166
sg66306
VWnt3a
p67167
sa(dp67168
g66301
I86
sg66302
I1
sg66303
I12
sg66304
VP35222
p67169
sg66306
VBeta-catenin
p67170
sasg66311
(lp67171
(dp67172
g66301
I12
sg66302
I2
sg66303
I12
sg66314
VC0699790
p67173
sg66306
Vcolon cancer
p67174
sasa(dp67175
g66296
VIn vitro, over-regulated Wnt3a expression in HT29 colon cancer cells promoted the capacity to form tube-like structures in the three-dimensional (3-D) culture together with increased expression of endothelial phenotype-associated proteins such as VEGFR2 and VE-cadherin.
p67176
sg66298
(lp67177
(dp67178
g66301
I258
sg66302
I1
sg66303
I11
sg66304
VP33151
p67179
sg66306
VVE-cadherin
p67180
sa(dp67181
g66301
I247
sg66302
I1
sg66303
I6
sg66304
VP35968
p67182
sg66306
VVEGFR2
p67183
sa(dp67184
g66301
I25
sg66302
I1
sg66303
I5
sg66304
VP56704
p67185
sg66306
VWnt3a
p67186
sasg66311
(lp67187
(dp67188
g66301
I50
sg66302
I2
sg66303
I12
sg66314
VC0699790
p67189
sg66306
Vcolon cancer
p67190
sasa(dp67191
g66296
VHowever, the roles of Wnt3a, the representative canonical Wnt ligand, in EMT and colon cancer progression have not yet been fully explored.
p67192
sg66298
(lp67193
(dp67194
g66301
I58
sg66302
I2
sg66303
I10
sg66304
g11
sg66306
VWnt ligand
p67195
sa(dp67196
g66301
I22
sg66302
I1
sg66303
I5
sg66304
VP56704
p67197
sg66306
VWnt3a
p67198
sa(dp67199
g66301
I73
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VEMT
p67200
sasg66311
(lp67201
(dp67202
g66301
I87
sg66302
I2
sg66303
I18
sg66314
VC0178874
p67203
sg66306
Vcancer progression
p67204
sasa(dp67205
g66296
VThe expression levels of Wnt3a and EMT-associated proteins (E-cadherin, vimentin, and Beta-catenin) were assessed by immunohistochemistry in human colon cancer tissues to evaluate the clinicopathological significance of Wnt3a, as well as the correlation between Wnt3a and EMT.
p67206
sg66298
(lp67207
(dp67208
g66301
I25
sg66302
I1
sg66303
I5
sg66304
VP56704
p67209
sg66306
VWnt3a
p67210
sa(dp67211
g66301
I35
sg66302
I2
sg66303
I23
sg66304
g11
sg66306
VEMT-associated proteins
p67212
sa(dp67213
g66301
I60
sg66302
I1
sg66303
I10
sg66304
VP12830
p67214
sg66306
VE-cadherin
p67215
sa(dp67216
g66301
I86
sg66302
I1
sg66303
I12
sg66304
VP35222
p67217
sg66306
VBeta-catenin
p67218
sa(dp67219
g66301
I35
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VEMT
p67220
sa(dp67221
g66301
I25
sg66302
I1
sg66303
I5
sg66304
VP56704
p67222
sg66306
VWnt3a
p67223
sa(dp67224
g66301
I25
sg66302
I1
sg66303
I5
sg66304
VP56704
p67225
sg66306
VWnt3a
p67226
sasg66311
(lp67227
(dp67228
g66301
I147
sg66302
I2
sg66303
I12
sg66314
VC0699790
p67229
sg66306
Vcolon cancer
p67230
sasa(dp67231
g66296
VWe then upregulated Wnt3a expression in HCT116 colon cancer cells, established a nude mouse xenograft model, detected the expression of EMT and Wnt/Beta-catenin signaling-associated proteins, and observed invasion and clone-initiating abilities.
p67232
sg66298
(lp67233
(dp67234
g66301
I20
sg66302
I1
sg66303
I5
sg66304
VP56704
p67235
sg66306
VWnt3a
p67236
sa(dp67237
g66301
I136
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VEMT
p67238
sa(dp67239
g66301
I148
sg66302
I1
sg66303
I12
sg66304
VP35222
p67240
sg66306
VBeta-catenin
p67241
sasg66311
(lp67242
(dp67243
g66301
I47
sg66302
I2
sg66303
I12
sg66314
VC0699790
p67244
sg66306
Vcolon cancer
p67245
sa(dp67246
g66301
I205
sg66302
I1
sg66303
I8
sg66314
VC2699153
p67247
sg66306
Vinvasion
p67248
sasa(dp67249
g66296
VIn 203 human colon cancer tissue samples, Wnt3a protein overexpression was related to colon cancer histological differentiation (P = 0.004), clinical stage (P = 0.008), presence of metastasis and recurrence (P = 0.036), and survival time (P = 0.007) of colon cancer patients.
p67250
sg66298
(lp67251
(dp67252
g66301
I42
sg66302
I1
sg66303
I5
sg66304
VP56704
p67253
sg66306
VWnt3a
p67254
sasg66311
(lp67255
(dp67256
g66301
I181
sg66302
I1
sg66303
I10
sg66314
VC0027627
p67257
sg66306
Vmetastasis
p67258
sa(dp67259
g66301
I13
sg66302
I2
sg66303
I12
sg66314
VC0699790
p67260
sg66306
Vcolon cancer
p67261
sa(dp67262
g66301
I13
sg66302
I2
sg66303
I12
sg66314
VC0699790
p67263
sg66306
Vcolon cancer
p67264
sa(dp67265
g66301
I13
sg66302
I2
sg66303
I12
sg66314
VC0699790
p67266
sg66306
Vcolon cancer
p67267
sa(dp67268
g66301
I196
sg66302
I1
sg66303
I10
sg66314
VC1458156
p67269
sg66306
Vrecurrence
p67270
sasa(dp67271
g66296
VWnt3a expression was associated with EMT and promoted colon cancer progression.
p67272
sg66298
(lp67273
(dp67274
g66301
I37
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VEMT
p67275
sa(dp67276
g66301
I0
sg66302
I1
sg66303
I5
sg66304
VP56704
p67277
sg66306
VWnt3a
p67278
sasg66311
(lp67279
(dp67280
g66301
I60
sg66302
I2
sg66303
I18
sg66314
VC0178874
p67281
sg66306
Vcancer progression
p67282
sasa(dp67283
g66296
VDisruption of 11-cis-RDHs causes a slowly developing cone dystrophy caused by inefficient cone pigment regeneration.
p67284
sg66298
(lp67285
(dp67286
g66301
I14
sg66302
I1
sg66303
I11
sg66304
g11
sg66306
V11-cis-RDHs
p67287
sasg66311
(lp67288
(dp67289
g66301
I53
sg66302
I2
sg66303
I14
sg66314
VC0730290
p67290
sg66306
Vcone dystrophy
p67291
sa(dp67292
g66301
I17
sg66302
I1
sg66303
I3
sg66314
VC0007099
p67293
sg66306
Vcis
p67294
sasa(dp67295
g66296
VTo evaluate the GH-releasing hormone (GH-RH)-induced response of GH in patients affected by hypothalamic amenorrhea.
p67296
sg66298
(lp67297
(dp67298
g66301
I38
sg66302
I1
sg66303
I5
sg66304
VP01286
p67299
sg66306
VGH-RH
p67300
sa(dp67301
g66301
I16
sg66302
I2
sg66303
I20
sg66304
VP01286
p67302
sg66306
VGH-releasing hormone
p67303
sasg66311
(lp67304
(dp67305
g66301
I92
sg66302
I2
sg66303
I23
sg66314
VC0341862
p67306
sg66306
Vhypothalamic amenorrhea
p67307
sasa(dp67308
g66296
VThe amenorrheic condition associated with reduced BMI changes the GH-RH--induced GH response in hypothalamic amenorrhea, supporting a GH and a IGF-I disregulation in weight-loss--related amenorrhea.
p67309
sg66298
(lp67310
(dp67311
g66301
I143
sg66302
I1
sg66303
I5
sg66304
VP01343
p67312
sg66306
VIGF-I
p67313
sasg66311
(lp67314
(dp67315
g66301
I109
sg66302
I1
sg66303
I10
sg66314
VC0002453
p67316
sg66306
Vamenorrhea
p67317
sa(dp67318
g66301
I96
sg66302
I2
sg66303
I23
sg66314
VC0341862
p67319
sg66306
Vhypothalamic amenorrhea
p67320
sa(dp67321
g66301
I16
sg66302
I1
sg66303
I9
sg66314
VC0012634
p67322
sg66306
Vcondition
p67323
sasa(dp67324
g66296
VWe report the case of a 17-year-old girl presenting short stature (height 149 cm, below the 3rd percentile), obesity (weight 83.5 kg, body mass index 37 kg/m2) and secondary amenorrhea, in whom endocrinological evaluation disclosed an absolute lack of GH responsiveness to both suprapituitary challenges and repetitive growth hormone releasing hormone administration together with failure of plasma gonadotropins and PRL, low under basal conditions, to rise in response to GnRH and insulin-hypoglycemia, respectively.
p67325
sg66298
(lp67326
(dp67327
g66301
I319
sg66302
I2
sg66303
I14
sg66304
VP01242
p67328
sg66306
Vgrowth hormone
p67329
sa(dp67330
g66301
I482
sg66302
I1
sg66303
I7
sg66304
VP01308
p67331
sg66306
Vinsulin
p67332
sa(dp67333
g66301
I417
sg66302
I1
sg66303
I3
sg66304
VP01236
p67334
sg66306
VPRL
p67335
sa(dp67336
g66301
I473
sg66302
I1
sg66303
I4
sg66304
VP01148
p67337
sg66306
VGnRH
p67338
sasg66311
(lp67339
(dp67340
g66301
I164
sg66302
I2
sg66303
I20
sg66314
VC0232940
p67341
sg66306
Vsecondary amenorrhea
p67342
sa(dp67343
g66301
I109
sg66302
I1
sg66303
I7
sg66314
VC0028754
p67344
sg66306
Vobesity
p67345
sa(dp67346
g66301
I490
sg66302
I1
sg66303
I12
sg66314
VC0020615
p67347
sg66306
Vhypoglycemia
p67348
sa(dp67349
g66301
I52
sg66302
I2
sg66303
I13
sg66314
VC0013336
p67350
sg66306
Vshort stature
p67351
sasa(dp67352
g66296
VCommon genes include Jagged 1 (Jag1), Tetraspanin 2 (Tspan2), neuroblastoma, suppression of tumourigenicity 1 (Nbl1) and N-myc downstream regulated gene 2 (Ndrg2).
p67353
sg66298
(lp67354
(dp67355
g66301
I21
sg66302
I2
sg66303
I8
sg66304
VP78504
p67356
sg66306
VJagged 1
p67357
sa(dp67358
g66301
I121
sg66302
I1
sg66303
I5
sg66304
VP04198
p67359
sg66306
VN-myc
p67360
sa(dp67361
g66301
I38
sg66302
I2
sg66303
I13
sg66304
g11
sg66306
VTetraspanin 2
p67362
sa(dp67363
g66301
I31
sg66302
I1
sg66303
I4
sg66304
VP78504
p67364
sg66306
VJag1
p67365
sa(dp67366
g66301
I53
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VTspan2
p67367
sasg66311
(lp67368
(dp67369
g66301
I62
sg66302
I1
sg66303
I13
sg66314
VC0027819
p67370
sg66306
Vneuroblastoma
p67371
sa(dp67372
g66301
I77
sg66302
I1
sg66303
I11
sg66314
VC0221103
p67373
sg66306
Vsuppression
p67374
sasa(dp67375
g66296
VWhile vincristine was effective against 1 out 4 neuroblastoma xenografts, TS-N-2, with 58.1% maximum inhibition rate, etoposide was assessed ineffective as a single agent in all of the 3 xenografts used.
p67376
sg66298
(lp67377
sg66311
(lp67378
(dp67379
g66301
I48
sg66302
I1
sg66303
I13
sg66314
VC0027819
p67380
sg66306
Vneuroblastoma
p67381
sasa(dp67382
g66296
VThe purpose of this study was to evaluate the correlation of somatostatin receptor-2 (SSTR2) expression with 68Ga-DOTA-TATE uptake and 177Lu-DOTA-TATE therapy in neuroblastoma (NB) xenograft models.
p67383
sg66298
(lp67384
(dp67385
g66301
I86
sg66302
I1
sg66303
I5
sg66304
VP30874
p67386
sg66306
VSSTR2
p67387
sa(dp67388
g66301
I61
sg66302
I2
sg66303
I23
sg66304
VP61278
p67389
sg66306
Vsomatostatin receptor-2
p67390
sasg66311
(lp67391
(dp67392
g66301
I177
sg66302
I1
sg66303
I2
sg66314
VC0027819
p67393
sg66306
VNB
p67394
sa(dp67395
g66301
I162
sg66302
I1
sg66303
I13
sg66314
VC0027819
p67396
sg66306
Vneuroblastoma
p67397
sasa(dp67398
g66296
VNeuroblastoma may be treated with molecular radiotherapy, 131I meta-Iodobenzylguanidine and 177Lu Lutetium DOTATATE, directed at distinct molecular targets: Noradrenaline Transporter Molecule (NAT) and Somatostatin Receptor (SSTR2), respectively.
p67399
sg66298
(lp67400
(dp67401
g66301
I225
sg66302
I1
sg66303
I5
sg66304
VP30874
p67402
sg66306
VSSTR2
p67403
sa(dp67404
g66301
I202
sg66302
I2
sg66303
I21
sg66304
VP61278
p67405
sg66306
VSomatostatin Receptor
p67406
sasg66311
(lp67407
(dp67408
g66301
I0
sg66302
I1
sg66303
I13
sg66314
VC0027819
p67409
sg66306
VNeuroblastoma
p67410
sasa(dp67411
g66296
VTissue bank samples of formalin fixed paraffin embedded neuroblastoma tissue from patients for whom clinical outcome data were available were sectioned and stained with haematoxylin and eosin, and monoclonal antibodies directed against NAT and SSTR2.
p67412
sg66298
(lp67413
(dp67414
g66301
I244
sg66302
I1
sg66303
I5
sg66304
VP30874
p67415
sg66306
VSSTR2
p67416
sa(dp67417
g66301
I236
sg66302
I1
sg66303
I3
sg66304
VP18440
p67418
sg66306
VNAT
p67419
sasg66311
(lp67420
(dp67421
g66301
I56
sg66302
I1
sg66303
I13
sg66314
VC0027819
p67422
sg66306
Vneuroblastoma
p67423
sasa(dp67424
g66296
V68Ga-DOTATATE PET/CT enables detection of meningioma tissue based on somatostatin receptor 2 expression.
p67425
sg66298
(lp67426
(dp67427
g66301
I69
sg66302
I3
sg66303
I23
sg66304
VP61278
p67428
sg66306
Vsomatostatin receptor 2
p67429
sasg66311
(lp67430
(dp67431
g66301
I42
sg66302
I1
sg66303
I10
sg66314
VC0025286
p67432
sg66306
Vmeningioma
p67433
sasa(dp67434
g66296
VImmunohistochemistry for the meningioma markers EMA and SSTR2A raised the possibility of intraosseous meningioma, as all 3 lesions were convincingly positive for epithelial membrane antigen (EMA) and 1 lesion was convincingly positive for the somatostatin receptor subtype 2A (SSTR2A); weak, questionable positivity for SSTR2 was present in the remaining 2 cases.
p67435
sg66298
(lp67436
(dp67437
g66301
I56
sg66302
I1
sg66303
I6
sg66304
VP61278
p67438
sg66306
VSSTR2A
p67439
sa(dp67440
g66301
I162
sg66302
I3
sg66303
I27
sg66304
VP12830
p67441
sg66306
Vepithelial membrane antigen
p67442
sa(dp67443
g66301
I48
sg66302
I1
sg66303
I3
sg66304
VP13804
p67444
sg66306
VEMA
p67445
sa(dp67446
g66301
I56
sg66302
I1
sg66303
I5
sg66304
VP30874
p67447
sg66306
VSSTR2
p67448
sa(dp67449
g66301
I56
sg66302
I1
sg66303
I6
sg66304
VP61278
p67450
sg66306
VSSTR2A
p67451
sa(dp67452
g66301
I243
sg66302
I4
sg66303
I32
sg66304
VP61278
p67453
sg66306
Vsomatostatin receptor subtype 2A
p67454
sa(dp67455
g66301
I48
sg66302
I1
sg66303
I3
sg66304
VP12830
p67456
sg66306
VEMA
p67457
sasg66311
(lp67458
(dp67459
g66301
I29
sg66302
I1
sg66303
I10
sg66314
VC0025286
p67460
sg66306
Vmeningioma
p67461
sa(dp67462
g66301
I48
sg66302
I1
sg66303
I3
sg66314
VC0268596
p67463
sg66306
VEMA
p67464
sa(dp67465
g66301
I29
sg66302
I1
sg66303
I10
sg66314
VC0025286
p67466
sg66306
Vmeningioma
p67467
sa(dp67468
g66301
I48
sg66302
I1
sg66303
I3
sg66314
VC0268596
p67469
sg66306
VEMA
p67470
sa(dp67471
g66301
I162
sg66302
I3
sg66303
I27
sg66314
VC0268596
p67472
sg66306
Vepithelial membrane antigen
p67473
sasa(dp67474
g66296
VSomatostatine receptors subtype 2 (SSTR2) are regarded as a potential target in neuroblastoma (NB) for imaging and promising therapeutic approaches.
p67475
sg66298
(lp67476
(dp67477
g66301
I0
sg66302
I4
sg66303
I33
sg66304
g11
sg66306
VSomatostatine receptors subtype 2
p67478
sa(dp67479
g66301
I35
sg66302
I1
sg66303
I5
sg66304
VP30874
p67480
sg66306
VSSTR2
p67481
sasg66311
(lp67482
(dp67483
g66301
I80
sg66302
I1
sg66303
I13
sg66314
VC0027819
p67484
sg66306
Vneuroblastoma
p67485
sa(dp67486
g66301
I95
sg66302
I1
sg66303
I2
sg66314
VC0027819
p67487
sg66306
VNB
p67488
sasa(dp67489
g66296
VGaTATE PET was positive in a high proportion of patients with refractory neuroblastoma, correlating with SSTR 2 on IHC, with additional disease identified compared with MIBG imaging.
p67490
sg66298
(lp67491
(dp67492
g66301
I105
sg66302
I2
sg66303
I6
sg66304
VP31391
p67493
sg66306
VSSTR 2
p67494
sasg66311
(lp67495
(dp67496
g66301
I73
sg66302
I1
sg66303
I13
sg66314
VC0027819
p67497
sg66306
Vneuroblastoma
p67498
sasa(dp67499
g66296
VPET using the SSTR2 analog (68)Ga-DOTATATE has recently been introduced for imaging of meningiomas.
p67500
sg66298
(lp67501
(dp67502
g66301
I14
sg66302
I1
sg66303
I5
sg66304
VP30874
p67503
sg66306
VSSTR2
p67504
sasg66311
(lp67505
(dp67506
g66301
I87
sg66302
I1
sg66303
I11
sg66314
VC0025286
p67507
sg66306
Vmeningiomas
p67508
sasa(dp67509
g66296
V(68)Ga-DOTATATE uptake correlates with SSTR2 expression and offers high diagnostic accuracy to delineate meningioma from tumor-free tissue even in recurrent tumors after previous therapy.
p67510
sg66298
(lp67511
(dp67512
g66301
I39
sg66302
I1
sg66303
I5
sg66304
VP30874
p67513
sg66306
VSSTR2
p67514
sasg66311
(lp67515
(dp67516
g66301
I105
sg66302
I1
sg66303
I10
sg66314
VC0025286
p67517
sg66306
Vmeningioma
p67518
sa(dp67519
g66301
I121
sg66302
I1
sg66303
I5
sg66314
VC0027651
p67520
sg66306
Vtumor
p67521
sa(dp67522
g66301
I157
sg66302
I1
sg66303
I6
sg66314
VC0027651
p67523
sg66306
Vtumors
p67524
sasa(dp67525
g66296
VWe aimed to compare the frequency of perineurial marker expression in these two entities, and to determine whether somatostatin receptor 2 (SSTR2) and progesterone receptor (PR), both expressed frequently in meningiomas, are also expressed in perineuriomas.
p67526
sg66298
(lp67527
(dp67528
g66301
I115
sg66302
I3
sg66303
I23
sg66304
VP61278
p67529
sg66306
Vsomatostatin receptor 2
p67530
sa(dp67531
g66301
I151
sg66302
I2
sg66303
I21
sg66304
VP06401
p67532
sg66306
Vprogesterone receptor
p67533
sa(dp67534
g66301
I174
sg66302
I1
sg66303
I2
sg66304
VP06401
p67535
sg66306
VPR
p67536
sa(dp67537
g66301
I140
sg66302
I1
sg66303
I5
sg66304
VP30874
p67538
sg66306
VSSTR2
p67539
sasg66311
(lp67540
(dp67541
g66301
I208
sg66302
I1
sg66303
I11
sg66314
VC0025286
p67542
sg66306
Vmeningiomas
p67543
sa(dp67544
g66301
I243
sg66302
I1
sg66303
I13
sg66314
VC0751691
p67545
sg66306
Vperineuriomas
p67546
sasa(dp67547
g66296
VAll tumours were stained using five antibodies against antigens that are known to be expressed in perineuriomas or meningiomas: epithelial membrane antigen (EMA), claudin-1, GLUT-1 (glucose transporter-1), SSTR2, and PR.
p67548
sg66298
(lp67549
(dp67550
g66301
I174
sg66302
I1
sg66303
I6
sg66304
VP11166
p67551
sg66306
VGLUT-1
p67552
sa(dp67553
g66301
I128
sg66302
I3
sg66303
I27
sg66304
VP12830
p67554
sg66306
Vepithelial membrane antigen
p67555
sa(dp67556
g66301
I182
sg66302
I2
sg66303
I21
sg66304
VP11166
p67557
sg66306
Vglucose transporter-1
p67558
sa(dp67559
g66301
I206
sg66302
I1
sg66303
I5
sg66304
VP30874
p67560
sg66306
VSSTR2
p67561
sa(dp67562
g66301
I157
sg66302
I1
sg66303
I3
sg66304
VP13804
p67563
sg66306
VEMA
p67564
sa(dp67565
g66301
I163
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
Vclaudin-1
p67566
sasg66311
(lp67567
(dp67568
g66301
I98
sg66302
I1
sg66303
I13
sg66314
VC0751691
p67569
sg66306
Vperineuriomas
p67570
sa(dp67571
g66301
I115
sg66302
I1
sg66303
I11
sg66314
VC0025286
p67572
sg66306
Vmeningiomas
p67573
sa(dp67574
g66301
I128
sg66302
I3
sg66303
I27
sg66314
VC0268596
p67575
sg66306
Vepithelial membrane antigen
p67576
sa(dp67577
g66301
I4
sg66302
I1
sg66303
I7
sg66314
VC0027651
p67578
sg66306
Vtumours
p67579
sa(dp67580
g66301
I157
sg66302
I1
sg66303
I3
sg66314
VC0268596
p67581
sg66306
VEMA
p67582
sasa(dp67583
g66296
VOf the meningiomas, EMA was expressed in 59 of 61, claudin-1 in five of 63, GLUT-1 in 19 of 62, SSTR2 in 59 of 68, and PR in 44 of 62.
p67584
sg66298
(lp67585
(dp67586
g66301
I51
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
Vclaudin-1
p67587
sasg66311
(lp67588
(dp67589
g66301
I7
sg66302
I1
sg66303
I11
sg66314
VC0025286
p67590
sg66306
Vmeningiomas
p67591
sa(dp67592
g66301
I20
sg66302
I1
sg66303
I3
sg66314
VC0268596
p67593
sg66306
VEMA
p67594
sasa(dp67595
g66296
VThe SSTR2-positive/PR-positive phenotype was detected in 42 of 60 meningiomas, but in none of 20 perineuriomas.
p67596
sg66298
(lp67597
(dp67598
g66301
I4
sg66302
I1
sg66303
I5
sg66304
VP30874
p67599
sg66306
VSSTR2
p67600
sasg66311
(lp67601
(dp67602
g66301
I66
sg66302
I1
sg66303
I11
sg66314
VC0025286
p67603
sg66306
Vmeningiomas
p67604
sa(dp67605
g66301
I97
sg66302
I1
sg66303
I13
sg66314
VC0751691
p67606
sg66306
Vperineuriomas
p67607
sasa(dp67608
g66296
VSSTR2 and PR are highly sensitive and, in this context, specific meningioma markers.
p67609
sg66298
(lp67610
(dp67611
g66301
I0
sg66302
I1
sg66303
I5
sg66304
VP30874
p67612
sg66306
VSSTR2
p67613
sasg66311
(lp67614
(dp67615
g66301
I65
sg66302
I1
sg66303
I10
sg66314
VC0025286
p67616
sg66306
Vmeningioma
p67617
sasa(dp67618
g66296
VWe utilized inhibitors of cPLA2 alpha, COX-1/2 and 5-LO to determine the potential roles of these enzymes in development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).
p67619
sg66298
(lp67620
(dp67621
g66301
I39
sg66302
I1
sg66303
I7
sg66304
VP00395
p67622
sg66306
VCOX-1/2
p67623
sa(dp67624
g66301
I26
sg66302
I2
sg66303
I11
sg66304
VP47712
p67625
sg66306
VcPLA2 alpha
p67626
sasg66311
(lp67627
(dp67628
g66301
I167
sg66302
I1
sg66303
I3
sg66314
VC0014070
p67629
sg66306
VEAE
p67630
sa(dp67631
g66301
I212
sg66302
I1
sg66303
I2
sg66314
VC0026769
p67632
sg66306
VMS
p67633
sa(dp67634
g66301
I148
sg66302
I1
sg66303
I17
sg66314
VC0014070
p67635
sg66306
Vencephalomyelitis
p67636
sa(dp67637
g66301
I192
sg66302
I2
sg66303
I18
sg66314
VC0026769
p67638
sg66306
Vmultiple sclerosis
p67639
sa(dp67640
g66301
I137
sg66302
I1
sg66303
I10
sg66314
VC0443146
p67641
sg66306
Vautoimmune
p67642
sasa(dp67643
g66296
VThis study aimed to better understand the role of miR-200a-3p and its correlation with HBx in HBV-induced hepatocellular carcinoma (HCC).
p67644
sg66298
(lp67645
(dp67646
g66301
I87
sg66302
I1
sg66303
I3
sg66304
VP24821
p67647
sg66306
VHBx
p67648
sa(dp67649
g66301
I50
sg66302
I1
sg66303
I11
sg66304
g11
sg66306
VmiR-200a-3p
p67650
sasg66311
(lp67651
(dp67652
g66301
I106
sg66302
I2
sg66303
I24
sg66314
VC2239176
p67653
sg66306
Vhepatocellular carcinoma
p67654
sa(dp67655
g66301
I94
sg66302
I1
sg66303
I3
sg66314
VC0019163
p67656
sg66306
VHBV
p67657
sa(dp67658
g66301
I132
sg66302
I1
sg66303
I3
sg66314
VC2239176
p67659
sg66306
VHCC
p67660
sasa(dp67661
g66296
VFurther study suggested that lncRNA-PE downregulated miR-200a/b by repressing the primary transcript expression, enhanced ZEB1 expression, and promoted epithelial-mesenchymal transition of hepatocellular carcinoma cells.
p67662
sg66298
(lp67663
(dp67664
g66301
I53
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-200a/b
p67665
sa(dp67666
g66301
I29
sg66302
I1
sg66303
I9
sg66304
VP48147
p67667
sg66306
VlncRNA-PE
p67668
sa(dp67669
g66301
I122
sg66302
I1
sg66303
I4
sg66304
VP37275
p67670
sg66306
VZEB1
p67671
sasg66311
(lp67672
(dp67673
g66301
I175
sg66302
I1
sg66303
I10
sg66314
VC0599156
p67674
sg66306
Vtransition
p67675
sa(dp67676
g66301
I189
sg66302
I2
sg66303
I24
sg66314
VC1512411
p67677
sg66306
Vhepatocellular carcinoma
p67678
sasa(dp67679
g66296
VAll these data imply that lncRNA-PE might play an important role in hepatocellular carcinoma development via the miR-200a/b-ZEB1 pathway.
p67680
sg66298
(lp67681
(dp67682
g66301
I26
sg66302
I1
sg66303
I9
sg66304
VP48147
p67683
sg66306
VlncRNA-PE
p67684
sa(dp67685
g66301
I124
sg66302
I1
sg66303
I4
sg66304
VP37275
p67686
sg66306
VZEB1
p67687
sa(dp67688
g66301
I113
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VmiR-200a
p67689
sasg66311
(lp67690
(dp67691
g66301
I68
sg66302
I2
sg66303
I24
sg66314
VC1512411
p67692
sg66306
Vhepatocellular carcinoma
p67693
sasa(dp67694
g66296
VHerein, we found that hepatocellular carcinoma cells shed more microvesicles than normal hepatocytes and miR-200a were shown to inhibit the release of microvesicles in hepatocellular carcinoma cells.
p67695
sg66298
(lp67696
(dp67697
g66301
I105
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VmiR-200a
p67698
sasg66311
(lp67699
(dp67700
g66301
I22
sg66302
I2
sg66303
I24
sg66314
VC1512411
p67701
sg66306
Vhepatocellular carcinoma
p67702
sa(dp67703
g66301
I22
sg66302
I2
sg66303
I24
sg66314
VC1512411
p67704
sg66306
Vhepatocellular carcinoma
p67705
sasa(dp67706
g66296
VCollectively, our findings indicate that miR-200a regulated the microvesicle biogenesis involved in the hepatocellular carcinoma progression.
p67707
sg66298
(lp67708
(dp67709
g66301
I41
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VmiR-200a
p67710
sasg66311
(lp67711
(dp67712
g66301
I104
sg66302
I2
sg66303
I24
sg66314
VC1512411
p67713
sg66306
Vhepatocellular carcinoma
p67714
sasa(dp67715
g66296
VConclusions: These findings indicate that miR-200a regulates the proliferation, migration and invasion of HCC cells by targeting Foxa2, suggesting that miR-200a may function as a potential therapeutic molecular for the diagnosis and treatment of the liver cancer.
p67716
sg66298
(lp67717
(dp67718
g66301
I129
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFoxa2
p67719
sa(dp67720
g66301
I42
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VmiR-200a
p67721
sa(dp67722
g66301
I42
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VmiR-200a
p67723
sasg66311
(lp67724
(dp67725
g66301
I65
sg66302
I1
sg66303
I13
sg66314
VC0334094
p67726
sg66306
Vproliferation
p67727
sa(dp67728
g66301
I94
sg66302
I1
sg66303
I8
sg66314
VC2699153
p67729
sg66306
Vinvasion
p67730
sa(dp67731
g66301
I250
sg66302
I2
sg66303
I12
sg66314
VC0345904
p67732
sg66306
Vliver cancer
p67733
sa(dp67734
g66301
I106
sg66302
I1
sg66303
I3
sg66314
VC2239176
p67735
sg66306
VHCC
p67736
sasa(dp67737
g66296
VLong noncoding RNAs (lncRNAs)-activated by transforming growth factor beta (lncRNA-ATB) is known to be involved in the invasion of hepatocellular carcinoma by regulating target genes of miR-200a.
p67738
sg66298
(lp67739
(dp67740
g66301
I186
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VmiR-200a
p67741
sa(dp67742
g66301
I76
sg66302
I1
sg66303
I10
sg66304
VP00325
p67743
sg66306
VlncRNA-ATB
p67744
sa(dp67745
g66301
I43
sg66302
I4
sg66303
I31
sg66304
VP18075
p67746
sg66306
Vtransforming growth factor beta
p67747
sasg66311
(lp67748
(dp67749
g66301
I119
sg66302
I1
sg66303
I8
sg66314
VC2699153
p67750
sg66306
Vinvasion
p67751
sa(dp67752
g66301
I131
sg66302
I2
sg66303
I24
sg66314
VC1512411
p67753
sg66306
Vhepatocellular carcinoma
p67754
sasa(dp67755
g66296
VIn this study, we determined that miR-200a was downregulated in hepatocellular carcinoma (HCC) tissues and cell lines, consistent with the results of our previous study.
p67756
sg66298
(lp67757
(dp67758
g66301
I34
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VmiR-200a
p67759
sasg66311
(lp67760
(dp67761
g66301
I90
sg66302
I1
sg66303
I3
sg66314
VC2239176
p67762
sg66306
VHCC
p67763
sa(dp67764
g66301
I64
sg66302
I2
sg66303
I24
sg66314
VC2239176
p67765
sg66306
Vhepatocellular carcinoma
p67766
sasa(dp67767
g66296
VOur data indicate that nine distinct genes associated with multiple sclerosis risk, Bach2, Il2ra, Irf8, Mertk, Odf3b, Plek, Rgs1, Slc30a7 and Thada, can be confirmed to be differentially regulated in pathogenic CD4(+) T cells.
p67768
sg66298
(lp67769
(dp67770
g66301
I111
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VOdf3b
p67771
sa(dp67772
g66301
I98
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VIrf8
p67773
sa(dp67774
g66301
I91
sg66302
I1
sg66303
I5
sg66304
VP01589
p67775
sg66306
VIl2ra
p67776
sa(dp67777
g66301
I104
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VMertk
p67778
sa(dp67779
g66301
I211
sg66302
I1
sg66303
I3
sg66304
VP01730
p67780
sg66306
VCD4
p67781
sa(dp67782
g66301
I84
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VBach2
p67783
sa(dp67784
g66301
I130
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSlc30a7
p67785
sa(dp67786
g66301
I124
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VRgs1
p67787
sa(dp67788
g66301
I118
sg66302
I1
sg66303
I4
sg66304
VP08567
p67789
sg66306
VPlek
p67790
sasg66311
(lp67791
(dp67792
g66301
I59
sg66302
I2
sg66303
I18
sg66314
VC0026769
p67793
sg66306
Vmultiple sclerosis
p67794
sasa(dp67795
g66296
VGenetic polymorphisms within a single locus encoding the transcription factor BACH2 are associated with numerous autoimmune and allergic diseases including asthma, Crohn's disease, coeliac disease, vitiligo, multiple sclerosis and type 1 diabetes.
p67796
sg66298
(lp67797
(dp67798
g66301
I57
sg66302
I3
sg66303
I26
sg66304
VP35398
p67799
sg66306
Vtranscription factor BACH2
p67800
sasg66311
(lp67801
(dp67802
g66301
I208
sg66302
I2
sg66303
I18
sg66314
VC0026769
p67803
sg66306
Vmultiple sclerosis
p67804
sa(dp67805
g66301
I164
sg66302
I2
sg66303
I15
sg66314
VC0010346
p67806
sg66306
VCrohn's disease
p67807
sa(dp67808
g66301
I113
sg66302
I1
sg66303
I10
sg66314
VC0443146
p67809
sg66306
Vautoimmune
p67810
sa(dp67811
g66301
I181
sg66302
I2
sg66303
I15
sg66314
VC0007570
p67812
sg66306
Vcoeliac disease
p67813
sa(dp67814
g66301
I231
sg66302
I3
sg66303
I15
sg66314
VC0011854
p67815
sg66306
Vtype 1 diabetes
p67816
sa(dp67817
g66301
I198
sg66302
I1
sg66303
I8
sg66314
VC0042900
p67818
sg66306
Vvitiligo
p67819
sa(dp67820
g66301
I156
sg66302
I1
sg66303
I6
sg66314
VC0004096
p67821
sg66306
Vasthma
p67822
sasa(dp67823
g66296
VHowever, array-based copy number analysis and qPCR were used to detect a hemizygous deletion in the PACD linkage interval containing 4 genes encoding small leucine-rich proteoglycans (SLRPs): KERA, LUM, DCN, and EPYC.
p67824
sg66298
(lp67825
(dp67826
g66301
I192
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKERA
p67827
sa(dp67828
g66301
I212
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VEPYC
p67829
sa(dp67830
g66301
I198
sg66302
I1
sg66303
I3
sg66304
VP51884
p67831
sg66306
VLUM
p67832
sa(dp67833
g66301
I203
sg66302
I1
sg66303
I3
sg66304
VP07585
p67834
sg66306
VDCN
p67835
sa(dp67836
g66301
I184
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSLRPs
p67837
sa(dp67838
g66301
I150
sg66302
I3
sg66303
I32
sg66304
VP30740
p67839
sg66306
Vsmall leucine-rich proteoglycans
p67840
sasg66311
(lp67841
(dp67842
g66301
I100
sg66302
I1
sg66303
I4
sg66314
VC2748502
p67843
sg66306
VPACD
p67844
sasa(dp67845
g66296
VThe authors performed clinical evaluation of a previously unreported pedigree with PACD, light and electron microscopic examination of an excised corneal button, genomewide linkage analysis, fine mapping linkage and haplotype analysis, and screening of four candidate genes (KERA, LUM, DCN, and EPYC).
p67846
sg66298
(lp67847
(dp67848
g66301
I295
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VEPYC
p67849
sa(dp67850
g66301
I286
sg66302
I1
sg66303
I3
sg66304
VP07585
p67851
sg66306
VDCN
p67852
sa(dp67853
g66301
I275
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKERA
p67854
sa(dp67855
g66301
I281
sg66302
I1
sg66303
I3
sg66304
VP51884
p67856
sg66306
VLUM
p67857
sasg66311
(lp67858
(dp67859
g66301
I83
sg66302
I1
sg66303
I4
sg66314
VC2748502
p67860
sg66306
VPACD
p67861
sasa(dp67862
g66296
VEmerging evidence indicates that elevated CD164 expression is associated with aggressive metastasis, advanced stages, and shorter overall survival in lung cancer.
p67863
sg66298
(lp67864
(dp67865
g66301
I42
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD164
p67866
sasg66311
(lp67867
(dp67868
g66301
I150
sg66302
I2
sg66303
I11
sg66314
VC0684249
p67869
sg66306
Vlung cancer
p67870
sa(dp67871
g66301
I89
sg66302
I1
sg66303
I10
sg66314
VC0027627
p67872
sg66306
Vmetastasis
p67873
sa(dp67874
g66301
I78
sg66302
I1
sg66303
I10
sg66314
VC0001807
p67875
sg66306
Vaggressive
p67876
sasa(dp67877
g66296
VHowever, no data are available regarding the clinical significance of CD164 expression in lung cancer.
p67878
sg66298
(lp67879
(dp67880
g66301
I70
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD164
p67881
sasg66311
(lp67882
(dp67883
g66301
I90
sg66302
I2
sg66303
I11
sg66314
VC0684249
p67884
sg66306
Vlung cancer
p67885
sasa(dp67886
g66296
VUsing tissue microarrays, we determine that CD164 expression is correlated with clinicopathological characteristics in human lung cancer.
p67887
sg66298
(lp67888
(dp67889
g66301
I44
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD164
p67890
sasg66311
(lp67891
(dp67892
g66301
I125
sg66302
I2
sg66303
I11
sg66314
VC0684249
p67893
sg66306
Vlung cancer
p67894
sasa(dp67895
g66296
VTherefore, identification of CD164 as a cancer stem cell therapeutic marker may develop an effective therapy in patients with chemoresistant lung cancer.
p67896
sg66298
(lp67897
(dp67898
g66301
I29
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD164
p67899
sasg66311
(lp67900
(dp67901
g66301
I40
sg66302
I1
sg66303
I6
sg66314
VC0006826
p67902
sg66306
Vcancer
p67903
sa(dp67904
g66301
I141
sg66302
I2
sg66303
I11
sg66314
VC0684249
p67905
sg66306
Vlung cancer
p67906
sasa(dp67907
g66296
VCluster of differentiation 164 (CD164), a sialomucin, has been demonstrated to be involved in the regulation of proliferation, apoptosis, adhesion and differentiation in multiple cancers.
p67908
sg66298
(lp67909
(dp67910
g66301
I42
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
Vsialomucin
p67911
sa(dp67912
g66301
I0
sg66302
I4
sg66303
I30
sg66304
g11
sg66306
VCluster of differentiation 164
p67913
sa(dp67914
g66301
I32
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD164
p67915
sasg66311
(lp67916
(dp67917
g66301
I138
sg66302
I1
sg66303
I8
sg66314
VC0001511
p67918
sg66306
Vadhesion
p67919
sa(dp67920
g66301
I112
sg66302
I1
sg66303
I13
sg66314
VC0334094
p67921
sg66306
Vproliferation
p67922
sa(dp67923
g66301
I179
sg66302
I1
sg66303
I7
sg66314
VC0006826
p67924
sg66306
Vcancers
p67925
sasa(dp67926
g66296
VHowever, the involvement of CD164 in human glioma proliferation and apoptosis remains unknown.
p67927
sg66298
(lp67928
(dp67929
g66301
I28
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD164
p67930
sasg66311
(lp67931
(dp67932
g66301
I43
sg66302
I1
sg66303
I6
sg66314
VC0017638
p67933
sg66306
Vglioma
p67934
sa(dp67935
g66301
I50
sg66302
I1
sg66303
I13
sg66314
VC0334094
p67936
sg66306
Vproliferation
p67937
sasa(dp67938
g66296
VThe aim of the present study was to investigate the expression and oncogenic function of CD164 in normal human astrocytes (NHA) and glioma cells in vitro and in vivo.
p67939
sg66298
(lp67940
(dp67941
g66301
I89
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD164
p67942
sasg66311
(lp67943
(dp67944
g66301
I132
sg66302
I1
sg66303
I6
sg66314
VC0017638
p67945
sg66306
Vglioma
p67946
sasa(dp67947
g66296
VThe results of the present study demonstrated that CD164 mRNA and protein levels were significantly increased in human glioma cell lines and tissue samples.
p67948
sg66298
(lp67949
(dp67950
g66301
I51
sg66302
I2
sg66303
I10
sg66304
g11
sg66306
VCD164 mRNA
p67951
sasg66311
(lp67952
(dp67953
g66301
I119
sg66302
I1
sg66303
I6
sg66314
VC0017638
p67954
sg66306
Vglioma
p67955
sasa(dp67956
g66296
VKnockdown of CD164 inhibited cell proliferation and promoted apoptosis of the U87 human glioma cell line in vitro and in vivo.
p67957
sg66298
(lp67958
(dp67959
g66301
I13
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD164
p67960
sasg66311
(lp67961
(dp67962
g66301
I88
sg66302
I1
sg66303
I6
sg66314
VC0017638
p67963
sg66306
Vglioma
p67964
sa(dp67965
g66301
I34
sg66302
I1
sg66303
I13
sg66314
VC0334094
p67966
sg66306
Vproliferation
p67967
sasa(dp67968
g66296
VThe results suggest that CD164 expression may have affected the proliferation and apoptosis of human glioma cells via the PTEN/phosphoinositide 3-kinase/AKT pathway, and may therefore present a potential target for the diagnosis and treatment of glioma.
p67969
sg66298
(lp67970
(dp67971
g66301
I127
sg66302
I2
sg66303
I25
sg66304
g11
sg66306
Vphosphoinositide 3-kinase
p67972
sa(dp67973
g66301
I122
sg66302
I1
sg66303
I4
sg66304
VP60484
p67974
sg66306
VPTEN
p67975
sa(dp67976
g66301
I153
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VAKT
p67977
sa(dp67978
g66301
I25
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD164
p67979
sasg66311
(lp67980
(dp67981
g66301
I64
sg66302
I1
sg66303
I13
sg66314
VC0334094
p67982
sg66306
Vproliferation
p67983
sa(dp67984
g66301
I101
sg66302
I1
sg66303
I6
sg66314
VC0017638
p67985
sg66306
Vglioma
p67986
sa(dp67987
g66301
I101
sg66302
I1
sg66303
I6
sg66314
VC0017638
p67988
sg66306
Vglioma
p67989
sasa(dp67990
g66296
VWe recently demonstrated the high expression of CD164 on CD4+ T cells from Sezary syndrome patients with a wide range of circulating tumor burdens.
p67991
sg66298
(lp67992
(dp67993
g66301
I48
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD164
p67994
sa(dp67995
g66301
I57
sg66302
I1
sg66303
I4
sg66304
VP01730
p67996
sg66306
VCD4+
p67997
sasg66311
(lp67998
(dp67999
g66301
I133
sg66302
I1
sg66303
I5
sg66314
VC0027651
p68000
sg66306
Vtumor
p68001
sa(dp68002
g66301
I75
sg66302
I2
sg66303
I15
sg66314
VC0036920
p68003
sg66306
VSezary syndrome
p68004
sasa(dp68005
g66296
VOur results suggest that miR-124 function as a tumor suppressor miRNA and suppress tumor proliferation and aggression by directly targeting oncogenic CD164 signaling pathway in NSCLC.
p68006
sg66298
(lp68007
(dp68008
g66301
I150
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD164
p68009
sasg66311
(lp68010
(dp68011
g66301
I47
sg66302
I1
sg66303
I5
sg66314
VC0027651
p68012
sg66306
Vtumor
p68013
sa(dp68014
g66301
I47
sg66302
I1
sg66303
I5
sg66314
VC0027651
p68015
sg66306
Vtumor
p68016
sa(dp68017
g66301
I177
sg66302
I1
sg66303
I5
sg66314
VC0007131
p68018
sg66306
VNSCLC
p68019
sa(dp68020
g66301
I107
sg66302
I1
sg66303
I10
sg66314
VC0001807
p68021
sg66306
Vaggression
p68022
sa(dp68023
g66301
I89
sg66302
I1
sg66303
I13
sg66314
VC0334094
p68024
sg66306
Vproliferation
p68025
sasa(dp68026
g66296
VIn a cohort of patients with Sezary syndrome, CD164 expression on total CD4+ lymphocytes was significantly upregulated compared with healthy controls.
p68027
sg66298
(lp68028
(dp68029
g66301
I72
sg66302
I1
sg66303
I4
sg66304
VP01730
p68030
sg66306
VCD4+
p68031
sa(dp68032
g66301
I46
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD164
p68033
sasg66311
(lp68034
(dp68035
g66301
I29
sg66302
I2
sg66303
I15
sg66314
VC0036920
p68036
sg66306
VSezary syndrome
p68037
sasa(dp68038
g66296
VIncreased expression of CD164 may be a promising diagnostic parameter and a potential target for a CD164-linked therapeutic approach in Sezary syndrome.
p68039
sg66298
(lp68040
(dp68041
g66301
I24
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD164
p68042
sa(dp68043
g66301
I24
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD164
p68044
sasg66311
(lp68045
(dp68046
g66301
I136
sg66302
I2
sg66303
I15
sg66314
VC0036920
p68047
sg66306
VSezary syndrome
p68048
sasa(dp68049
g66296
VThese results indicate that miR-219 suppresses the proliferation, migration and invasion of medulloblastoma cells by targeting CD164.
p68050
sg66298
(lp68051
(dp68052
g66301
I127
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD164
p68053
sasg66311
(lp68054
(dp68055
g66301
I80
sg66302
I1
sg66303
I8
sg66314
VC2699153
p68056
sg66306
Vinvasion
p68057
sa(dp68058
g66301
I51
sg66302
I1
sg66303
I13
sg66314
VC0334094
p68059
sg66306
Vproliferation
p68060
sa(dp68061
g66301
I92
sg66302
I1
sg66303
I15
sg66314
VC0025149
p68062
sg66306
Vmedulloblastoma
p68063
sasa(dp68064
g66296
VDespite the known engagement of the AFAP1-AS in several human diseases, its biological function in Hirschsprung disease (HSCR) remains elusive.
p68065
sg66298
(lp68066
(dp68067
g66301
I36
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VAFAP1-AS
p68068
sa(dp68069
g66301
I121
sg66302
I1
sg66303
I4
sg66304
VP14138
p68070
sg66306
VHSCR
p68071
sa(dp68072
g66301
I99
sg66302
I2
sg66303
I20
sg66304
VP14138
p68073
sg66306
VHirschsprung disease
p68074
sasg66311
(lp68075
(dp68076
g66301
I121
sg66302
I1
sg66303
I4
sg66314
VC2931876
p68077
sg66306
VHSCR
p68078
sa(dp68079
g66301
I99
sg66302
I2
sg66303
I20
sg66314
VC0019569
p68080
sg66306
VHirschsprung disease
p68081
sasa(dp68082
g66296
VThis prospective observational study included 47 patients (mean age 29 years, range 3-50) with different resistant generalized epilepsy syndromes: idiopathic generalized syndromes (IGE) 15 patients, (juvenile myoclonic epilepsy four, absence epilepsy four, myoclonic absence two, unclassified IGE five), progressive myoclonic epilepsy type 1 (PME1) four, severe myoclonic epilepsy of infancy (SMEI) three, borderline SMEI three, Lennox-Gastaut syndrome/secondary generalized epileptic encephalopties 23 patients.
p68083
sg66298
(lp68084
(dp68085
g66301
I304
sg66302
I5
sg66303
I37
sg66304
g11
sg66306
Vprogressive myoclonic epilepsy type 1
p68086
sa(dp68087
g66301
I343
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VPME1
p68088
sasg66311
(lp68089
(dp68090
g66301
I115
sg66302
I2
sg66303
I20
sg66314
VC0014548
p68091
sg66306
Vgeneralized epilepsy
p68092
sa(dp68093
g66301
I147
sg66302
I3
sg66303
I32
sg66314
VC0270850
p68094
sg66306
Vidiopathic generalized syndromes
p68095
sa(dp68096
g66301
I393
sg66302
I1
sg66303
I4
sg66314
VC0751122
p68097
sg66306
VSMEI
p68098
sa(dp68099
g66301
I304
sg66302
I3
sg66303
I30
sg66314
VC0751778
p68100
sg66306
Vprogressive myoclonic epilepsy
p68101
sa(dp68102
g66301
I234
sg66302
I2
sg66303
I16
sg66314
VC0014553
p68103
sg66306
Vabsence epilepsy
p68104
sa(dp68105
g66301
I393
sg66302
I1
sg66303
I4
sg66314
VC0751122
p68106
sg66306
VSMEI
p68107
sa(dp68108
g66301
I355
sg66302
I5
sg66303
I36
sg66314
VC0751122
p68109
sg66306
Vsevere myoclonic epilepsy of infancy
p68110
sa(dp68111
g66301
I181
sg66302
I1
sg66303
I3
sg66314
VC0270850
p68112
sg66306
VIGE
p68113
sa(dp68114
g66301
I475
sg66302
I1
sg66303
I9
sg66314
VC0014544
p68115
sg66306
Vepileptic
p68116
sa(dp68117
g66301
I200
sg66302
I3
sg66303
I27
sg66314
VC0270853
p68118
sg66306
Vjuvenile myoclonic epilepsy
p68119
sa(dp68120
g66301
I429
sg66302
I2
sg66303
I23
sg66314
VC0238111
p68121
sg66306
VLennox-Gastaut syndrome
p68122
sa(dp68123
g66301
I181
sg66302
I1
sg66303
I3
sg66314
VC0270850
p68124
sg66306
VIGE
p68125
sa(dp68126
g66301
I136
sg66302
I1
sg66303
I9
sg66314
VC0039082
p68127
sg66306
Vsyndromes
p68128
sasa(dp68129
g66296
VThe International League Against Epilepsy (ILAE) classification recognizes 2 forms of myoclonic epilepsy with a good prognosis: benign myoclonic epilepsy of infancy (BMEI) and juvenile myoclonic epilepsy (JME); recent studies confirm the efficacy of levetiracetam (LEV) in treating idiopathic generalized epilepsies (IGE) in patients with myoclonic seizures.
p68130
sg66298
(lp68131
sg66311
(lp68132
(dp68133
g66301
I86
sg66302
I2
sg66303
I18
sg66314
VC0014550
p68134
sg66306
Vmyoclonic epilepsy
p68135
sa(dp68136
g66301
I339
sg66302
I2
sg66303
I18
sg66314
VC0014550
p68137
sg66306
Vmyoclonic seizures
p68138
sa(dp68139
g66301
I317
sg66302
I1
sg66303
I3
sg66314
VC0270850
p68140
sg66306
VIGE
p68141
sa(dp68142
g66301
I86
sg66302
I2
sg66303
I18
sg66314
VC0014550
p68143
sg66306
Vmyoclonic epilepsy
p68144
sa(dp68145
g66301
I205
sg66302
I1
sg66303
I3
sg66314
VC0270853
p68146
sg66306
VJME
p68147
sa(dp68148
g66301
I33
sg66302
I1
sg66303
I8
sg66314
VC0014544
p68149
sg66306
VEpilepsy
p68150
sa(dp68151
g66301
I176
sg66302
I3
sg66303
I27
sg66314
VC0270853
p68152
sg66306
Vjuvenile myoclonic epilepsy
p68153
sa(dp68154
g66301
I282
sg66302
I3
sg66303
I33
sg66314
VC0270850
p68155
sg66306
Vidiopathic generalized epilepsies
p68156
sasa(dp68157
g66296
VWe evaluated 35 patients (21 female, mean age 24.7 years) with different types of generalised epilepsies (juvenile myoclonic epilepsy (JME), severe myoclonic epilepsy of infancy (SMEI), Lennox-Gastaut syndrome (LGS), myoclonic-astatic epilepsy (MAE), myoclonic absences (MA), benign myoclonic epilepsy in infancy (BMEI) and 4 patients had unspecified epileptic syndromes).
p68158
sg66298
(lp68159
sg66311
(lp68160
(dp68161
g66301
I211
sg66302
I1
sg66303
I3
sg66314
VC0023003
p68162
sg66306
VLGS
p68163
sa(dp68164
g66301
I125
sg66302
I1
sg66303
I8
sg66314
VC0014544
p68165
sg66306
Vepilepsy
p68166
sa(dp68167
g66301
I314
sg66302
I1
sg66303
I4
sg66314
VC0751120
p68168
sg66306
VBMEI
p68169
sa(dp68170
g66301
I135
sg66302
I1
sg66303
I3
sg66314
VC0270853
p68171
sg66306
VJME
p68172
sa(dp68173
g66301
I276
sg66302
I5
sg66303
I36
sg66314
VC0751120
p68174
sg66306
Vbenign myoclonic epilepsy in infancy
p68175
sa(dp68176
g66301
I179
sg66302
I1
sg66303
I4
sg66314
VC0751122
p68177
sg66306
VSMEI
p68178
sa(dp68179
g66301
I361
sg66302
I1
sg66303
I9
sg66314
VC0039082
p68180
sg66306
Vsyndromes
p68181
sa(dp68182
g66301
I141
sg66302
I5
sg66303
I36
sg66314
VC0751122
p68183
sg66306
Vsevere myoclonic epilepsy of infancy
p68184
sa(dp68185
g66301
I186
sg66302
I2
sg66303
I23
sg66314
VC0238111
p68186
sg66306
VLennox-Gastaut syndrome
p68187
sa(dp68188
g66301
I106
sg66302
I3
sg66303
I27
sg66314
VC0270853
p68189
sg66306
Vjuvenile myoclonic epilepsy
p68190
sa(dp68191
g66301
I351
sg66302
I1
sg66303
I9
sg66314
VC0014544
p68192
sg66306
Vepileptic
p68193
sa(dp68194
g66301
I94
sg66302
I1
sg66303
I10
sg66314
VC0014544
p68195
sg66306
Vepilepsies
p68196
sasa(dp68197
g66296
VThe electroclinical features suggested juvenile myoclonic epilepsy in 14 patients, progressive myoclonus epilepsy in three, progressive familial cerebellar ataxia with myoclonus in two, and severe myoclonic epilepsy of infancy in one.
p68198
sg66298
(lp68199
sg66311
(lp68200
(dp68201
g66301
I83
sg66302
I3
sg66303
I30
sg66314
VC0751778
p68202
sg66306
Vprogressive myoclonus epilepsy
p68203
sa(dp68204
g66301
I190
sg66302
I5
sg66303
I36
sg66314
VC0751122
p68205
sg66306
Vsevere myoclonic epilepsy of infancy
p68206
sa(dp68207
g66301
I136
sg66302
I3
sg66303
I26
sg66314
VC0270749
p68208
sg66306
Vfamilial cerebellar ataxia
p68209
sa(dp68210
g66301
I39
sg66302
I3
sg66303
I27
sg66314
VC0270853
p68211
sg66306
Vjuvenile myoclonic epilepsy
p68212
sa(dp68213
g66301
I95
sg66302
I1
sg66303
I9
sg66314
VC0027066
p68214
sg66306
Vmyoclonus
p68215
sasa(dp68216
g66296
VIn the idiopathic generalized epilepsies we consider the benign myoclonic epilepsy of infancy and its reflex variant, juvenile myoclonic epilepsy and palpebral myoclonias with absences.
p68217
sg66298
(lp68218
sg66311
(lp68219
(dp68220
g66301
I118
sg66302
I3
sg66303
I27
sg66314
VC0270853
p68221
sg66306
Vjuvenile myoclonic epilepsy
p68222
sa(dp68223
g66301
I18
sg66302
I2
sg66303
I22
sg66314
VC0014548
p68224
sg66306
Vgeneralized epilepsies
p68225
sa(dp68226
g66301
I64
sg66302
I2
sg66303
I18
sg66314
VC0014550
p68227
sg66306
Vmyoclonic epilepsy
p68228
sasa(dp68229
g66296
VGroup 5 comprises the true myoclonic epilepsies, differentiating syndromes recognized as idiopathic--such as "Benign myoclonic epilepsy of infancy" and "Juvenile myoclonic epilepsy"--from those which are cryptogenic and carry a more cautious prognosis--as "Cryptogenic myoclonic and myoclonoastatic epilepsies" and "Severe myoclonic epilepsy of infancy".
p68230
sg66298
(lp68231
sg66311
(lp68232
(dp68233
g66301
I117
sg66302
I2
sg66303
I18
sg66314
VC0014550
p68234
sg66306
Vmyoclonic epilepsy
p68235
sa(dp68236
g66301
I27
sg66302
I2
sg66303
I20
sg66314
VC0014550
p68237
sg66306
Vmyoclonic epilepsies
p68238
sa(dp68239
g66301
I37
sg66302
I1
sg66303
I10
sg66314
VC0014544
p68240
sg66306
Vepilepsies
p68241
sa(dp68242
g66301
I153
sg66302
I3
sg66303
I27
sg66314
VC0270853
p68243
sg66306
VJuvenile myoclonic epilepsy
p68244
sa(dp68245
g66301
I316
sg66302
I5
sg66303
I36
sg66314
VC0751122
p68246
sg66306
VSevere myoclonic epilepsy of infancy
p68247
sa(dp68248
g66301
I65
sg66302
I1
sg66303
I9
sg66314
VC0039082
p68249
sg66306
Vsyndromes
p68250
sasa(dp68251
g66296
VInteraction studies also showed that CEP78 binds to FAM161A, another ciliary protein associated with retinal degeneration.
p68252
sg66298
(lp68253
(dp68254
g66301
I52
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VFAM161A
p68255
sa(dp68256
g66301
I37
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCEP78
p68257
sasg66311
(lp68258
(dp68259
g66301
I101
sg66302
I2
sg66303
I20
sg66314
VC0035304
p68260
sg66306
Vretinal degeneration
p68261
sasa(dp68262
g66296
VAltogether, our data strongly suggest that mutations in CEP78 cause a previously undescribed clinical entity of a ciliary nature characterized by blindness and deafness but clearly distinct from Usher syndrome, a condition for which visual impairment is due to retinitis pigmentosa.
p68263
sg66298
(lp68264
(dp68265
g66301
I56
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCEP78
p68266
sasg66311
(lp68267
(dp68268
g66301
I261
sg66302
I2
sg66303
I20
sg66314
VC0035334
p68269
sg66306
Vretinitis pigmentosa
p68270
sa(dp68271
g66301
I195
sg66302
I2
sg66303
I14
sg66314
VC0271097
p68272
sg66306
VUsher syndrome
p68273
sa(dp68274
g66301
I160
sg66302
I1
sg66303
I8
sg66314
VC0011053
p68275
sg66306
Vdeafness
p68276
sa(dp68277
g66301
I233
sg66302
I2
sg66303
I17
sg66314
VC3489703
p68278
sg66306
Vvisual impairment
p68279
sa(dp68280
g66301
I213
sg66302
I1
sg66303
I9
sg66314
VC0012634
p68281
sg66306
Vcondition
p68282
sa(dp68283
g66301
I146
sg66302
I1
sg66303
I9
sg66314
VC0456909
p68284
sg66306
Vblindness
p68285
sasa(dp68286
g66296
VMethods Eligible survivors had curable breast or colorectal cancer or melanoma, had completed treatment (not including endocrine therapy) 2 months to 5 years previously, were age &gt; 18 years, and had scores above the clinical cutoff on the FCR Inventory (FCRI) severity subscale at screening.
p68287
sg66298
(lp68288
sg66311
(lp68289
(dp68290
g66301
I49
sg66302
I2
sg66303
I17
sg66314
VC1527249
p68291
sg66306
Vcolorectal cancer
p68292
sa(dp68293
g66301
I70
sg66302
I1
sg66303
I8
sg66314
VC0025202
p68294
sg66306
Vmelanoma
p68295
sasa(dp68296
g66296
VConquerFear participants had clinically and statistically greater improvements than control participants from T0 to T1 on FCRI total ( P &lt; .001) and severity subscale scores ( P = .001), which were maintained at T2 ( P = .017 and P = .023, respectively) and, for FCRI total only, at T3 ( P = .018), and from T0 to T1 on three FCRI subscales (coping, psychological distress, and triggers) as well as in general anxiety, cancer-specific distress (total), and mental quality of life and metacognitions (total).
p68297
sg66298
(lp68298
(dp68299
g66301
I122
sg66302
I1
sg66303
I4
sg66304
VP12314
p68300
sg66306
VFCRI
p68301
sa(dp68302
g66301
I122
sg66302
I1
sg66303
I4
sg66304
VP12314
p68303
sg66306
VFCRI
p68304
sasg66311
(lp68305
(dp68306
g66301
I353
sg66302
I2
sg66303
I22
sg66314
VC0815107
p68307
sg66306
Vpsychological distress
p68308
sa(dp68309
g66301
I422
sg66302
I1
sg66303
I6
sg66314
VC0006826
p68310
sg66306
Vcancer
p68311
sasa(dp68312
g66296
VDifferences in FCRI psychological distress and cancer-specific distress (total) remained significantly different at T3.
p68313
sg66298
(lp68314
sg66311
(lp68315
(dp68316
g66301
I20
sg66302
I2
sg66303
I22
sg66314
VC0815107
p68317
sg66306
Vpsychological distress
p68318
sa(dp68319
g66301
I47
sg66302
I1
sg66303
I6
sg66314
VC0006826
p68320
sg66306
Vcancer
p68321
sasa(dp68322
g66296
VGanoderic acid interacts and modulates the signaling network in IR, IGFR-1, IGFR-2, VEGFR-1, VEFGR-2, and EGFR in cancer signaling pathways.
p68323
sg66298
(lp68324
(dp68325
g66301
I68
sg66302
I1
sg66303
I6
sg66304
VP08069
p68326
sg66306
VIGFR-1
p68327
sa(dp68328
g66301
I84
sg66302
I1
sg66303
I7
sg66304
VP17948
p68329
sg66306
VVEGFR-1
p68330
sa(dp68331
g66301
I76
sg66302
I1
sg66303
I6
sg66304
VP08069
p68332
sg66306
VIGFR-2
p68333
sasg66311
(lp68334
(dp68335
g66301
I114
sg66302
I1
sg66303
I6
sg66314
VC0006826
p68336
sg66306
Vcancer
p68337
sasa(dp68338
g66296
VSixty-four patients with hematological tumors were selected and divided into the group complicated with bacterial infection (infection group, 33 cases) and the non-infection group (31 cases), the flow cytometry was be used to detect the related peripheral blood markers CD64 and CD14, the nCD64 IND and CD14 IND were calculated, and the peripheral blood WBC count, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were determined at the same time.
p68339
sg66298
(lp68340
(dp68341
g66301
I406
sg66302
I2
sg66303
I18
sg66304
VP02741
p68342
sg66306
VC-reactive protein
p68343
sa(dp68344
g66301
I279
sg66302
I1
sg66303
I4
sg66304
VP08571
p68345
sg66306
VCD14
p68346
sa(dp68347
g66301
I426
sg66302
I1
sg66303
I3
sg66304
VP02741
p68348
sg66306
VCRP
p68349
sa(dp68350
g66301
I270
sg66302
I1
sg66303
I4
sg66304
VP12314
p68351
sg66306
VCD64
p68352
sa(dp68353
g66301
I303
sg66302
I2
sg66303
I8
sg66304
VP08571
p68354
sg66306
VCD14 IND
p68355
sasg66311
(lp68356
(dp68357
g66301
I25
sg66302
I2
sg66303
I20
sg66314
VC0376545
p68358
sg66306
Vhematological tumors
p68359
sa(dp68360
g66301
I104
sg66302
I2
sg66303
I19
sg66314
VC0004623
p68361
sg66306
Vbacterial infection
p68362
sa(dp68363
g66301
I114
sg66302
I1
sg66303
I9
sg66314
VC0009450
p68364
sg66306
Vinfection
p68365
sa(dp68366
g66301
I114
sg66302
I1
sg66303
I9
sg66314
VC0009450
p68367
sg66306
Vinfection
p68368
sasa(dp68369
g66296
VThe study objectives are to translate the FCRI in Dutch, and to explore the factor structure and the psychometric qualities of the Dutch translation of the Fear of Cancer Recurrence Inventory (FCRI-NL).
p68370
sg66298
(lp68371
sg66311
(lp68372
(dp68373
g66301
I164
sg66302
I2
sg66303
I17
sg66314
VC0920420
p68374
sg66306
VCancer Recurrence
p68375
sa(dp68376
g66301
I156
sg66302
I3
sg66303
I14
sg66314
VC0233705
p68377
sg66306
VFear of Cancer
p68378
sasa(dp68379
g66296
VThe Severity subscale (FCRI-SF-NL) may be a valuable screening tool for fear of cancer recurrence severity in clinical care.
p68380
sg66298
(lp68381
sg66311
(lp68382
(dp68383
g66301
I80
sg66302
I2
sg66303
I17
sg66314
VC0920420
p68384
sg66306
Vcancer recurrence
p68385
sa(dp68386
g66301
I72
sg66302
I3
sg66303
I14
sg66314
VC0233705
p68387
sg66306
Vfear of cancer
p68388
sasa(dp68389
g66296
VFCI features, with single-tube 8-color combination using CD45, CD34, HAL-DR, CD11b, CD13, CD33, and CD117 and CD64, were compared for the 30 consecutive APL and 30 non-APL acute myeloid leukemia (AML) cases which morphologically mimicked an APL.
p68390
sg66298
(lp68391
(dp68392
g66301
I100
sg66302
I1
sg66303
I5
sg66304
VP10721
p68393
sg66306
VCD117
p68394
sa(dp68395
g66301
I57
sg66302
I1
sg66303
I4
sg66304
VP08575
p68396
sg66306
VCD45
p68397
sa(dp68398
g66301
I90
sg66302
I1
sg66303
I4
sg66304
VP20138
p68399
sg66306
VCD33
p68400
sa(dp68401
g66301
I84
sg66302
I1
sg66303
I4
sg66304
VP15144
p68402
sg66306
VCD13
p68403
sa(dp68404
g66301
I77
sg66302
I1
sg66303
I5
sg66304
VP11215
p68405
sg66306
VCD11b
p68406
sa(dp68407
g66301
I69
sg66302
I1
sg66303
I6
sg66304
VP42357
p68408
sg66306
VHAL-DR
p68409
sa(dp68410
g66301
I110
sg66302
I1
sg66303
I4
sg66304
VP12314
p68411
sg66306
VCD64
p68412
sa(dp68413
g66301
I63
sg66302
I1
sg66303
I4
sg66304
VP28906
p68414
sg66306
VCD34
p68415
sasg66311
(lp68416
(dp68417
g66301
I196
sg66302
I1
sg66303
I3
sg66314
VC0023467
p68418
sg66306
VAML
p68419
sa(dp68420
g66301
I153
sg66302
I1
sg66303
I3
sg66314
VC0023487
p68421
sg66306
VAPL
p68422
sa(dp68423
g66301
I172
sg66302
I3
sg66303
I22
sg66314
VC0023467
p68424
sg66306
Vacute myeloid leukemia
p68425
sa(dp68426
g66301
I153
sg66302
I1
sg66303
I3
sg66314
VC0023487
p68427
sg66306
VAPL
p68428
sa(dp68429
g66301
I153
sg66302
I1
sg66303
I3
sg66314
VC0023487
p68430
sg66306
VAPL
p68431
sasa(dp68432
g66296
VThis study aimed to confirm the cultural equivalence, reliability, and validity of the Korean version of Fear of Cancer Recurrence Inventory (K-FCRI).
p68433
sg66298
(lp68434
sg66311
(lp68435
(dp68436
g66301
I113
sg66302
I2
sg66303
I17
sg66314
VC0920420
p68437
sg66306
VCancer Recurrence
p68438
sa(dp68439
g66301
I105
sg66302
I3
sg66303
I14
sg66314
VC0233705
p68440
sg66306
VFear of Cancer
p68441
sasa(dp68442
g66296
VThe psychometric property of the K-FCRI was then validated in 444 survivors from cancers at various sites.
p68443
sg66298
(lp68444
(dp68445
g66301
I33
sg66302
I1
sg66303
I6
sg66304
VP12314
p68446
sg66306
VK-FCRI
p68447
sasg66311
(lp68448
(dp68449
g66301
I81
sg66302
I1
sg66303
I7
sg66314
VC0006826
p68450
sg66306
Vcancers
p68451
sasa(dp68452
g66296
VThe K-FCRI had significant correlations with the Korean version of Fear of Progression Questionnaire, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0, Hospital Anxiety and Depression Scale, and Fatigue Severity Score, supporting the good construct validity and psychometric properties of K-FCRI.
p68453
sg66298
(lp68454
sg66311
(lp68455
(dp68456
g66301
I154
sg66302
I1
sg66303
I6
sg66314
VC0006826
p68457
sg66306
VCancer
p68458
sa(dp68459
g66301
I247
sg66302
I1
sg66303
I7
sg66314
VC0015672
p68460
sg66306
VFatigue
p68461
sa(dp68462
g66301
I225
sg66302
I1
sg66303
I10
sg66314
VC0011581
p68463
sg66306
VDepression
p68464
sasa(dp68465
g66296
VThe K-FCRI was confirmed as a valid and reliable psychometric test for measuring FCR of Korean survivors from cancers at various sites.
p68466
sg66298
(lp68467
(dp68468
g66301
I4
sg66302
I1
sg66303
I6
sg66304
VP12314
p68469
sg66306
VK-FCRI
p68470
sasg66311
(lp68471
(dp68472
g66301
I110
sg66302
I1
sg66303
I7
sg66314
VC0006826
p68473
sg66306
Vcancers
p68474
sasa(dp68475
g66296
VRecently, CLPB deficiency has been shown to cause a genetic syndrome with cataracts, neutropenia, and 3-methylglutaconic aciduria.
p68476
sg66298
(lp68477
(dp68478
g66301
I10
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VCLPB
p68479
sasg66311
(lp68480
(dp68481
g66301
I102
sg66302
I2
sg66303
I27
sg66314
VC0342727
p68482
sg66306
V3-methylglutaconic aciduria
p68483
sa(dp68484
g66301
I52
sg66302
I2
sg66303
I16
sg66314
VC0567439
p68485
sg66306
Vgenetic syndrome
p68486
sa(dp68487
g66301
I74
sg66302
I1
sg66303
I9
sg66314
VC0521707
p68488
sg66306
Vcataracts
p68489
sasa(dp68490
g66296
VCLPB deficiency should be considered in neonates with absence of voluntary movements, respiratory insufficiency and swallowing problems, especially if associated with 3-methylglutaconic aciduria, neutropenia and cataracts.
p68491
sg66298
(lp68492
sg66311
(lp68493
(dp68494
g66301
I167
sg66302
I2
sg66303
I27
sg66314
VC0342727
p68495
sg66306
V3-methylglutaconic aciduria
p68496
sa(dp68497
g66301
I86
sg66302
I2
sg66303
I25
sg66314
VC0035229
p68498
sg66306
Vrespiratory insufficiency
p68499
sa(dp68500
g66301
I212
sg66302
I1
sg66303
I9
sg66314
VC0521707
p68501
sg66306
Vcataracts
p68502
sa(dp68503
g66301
I116
sg66302
I2
sg66303
I19
sg66314
VC0392678
p68504
sg66306
Vswallowing problems
p68505
sasa(dp68506
g66296
VMutations in CLPB, SERAC1, TAZ genes were identified in neonates with 3-methylglutaconic aciduria (3-MGA) as a discriminative feature.
p68507
sg66298
(lp68508
(dp68509
g66301
I27
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VTAZ genes
p68510
sa(dp68511
g66301
I19
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSERAC1
p68512
sasg66311
(lp68513
(dp68514
g66301
I99
sg66302
I1
sg66303
I5
sg66314
VC0342727
p68515
sg66306
V3-MGA
p68516
sa(dp68517
g66301
I70
sg66302
I2
sg66303
I27
sg66314
VC0342727
p68518
sg66306
V3-methylglutaconic aciduria
p68519
sasa(dp68520
g66296
VAltogether, our study suggests that disruption of CLPB causes a novel form of neonatal encephalopathy associated with 3-methylglutaconic aciduria.
p68521
sg66298
(lp68522
(dp68523
g66301
I50
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VCLPB
p68524
sasg66311
(lp68525
(dp68526
g66301
I78
sg66302
I2
sg66303
I23
sg66314
VC0235820
p68527
sg66306
Vneonatal encephalopathy
p68528
sa(dp68529
g66301
I118
sg66302
I2
sg66303
I27
sg66314
VC0342727
p68530
sg66306
V3-methylglutaconic aciduria
p68531
sasa(dp68532
g66296
VTaken together, mutations in CLPB define a syndrome with intellectual disability, congenital neutropenia, progressive brain atrophy, movement disorder, cataracts, and 3-methylglutaconic aciduria.
p68533
sg66298
(lp68534
sg66311
(lp68535
(dp68536
g66301
I152
sg66302
I1
sg66303
I9
sg66314
VC0521707
p68537
sg66306
Vcataracts
p68538
sa(dp68539
g66301
I57
sg66302
I2
sg66303
I23
sg66314
VC0025362
p68540
sg66306
Vintellectual disability
p68541
sa(dp68542
g66301
I167
sg66302
I2
sg66303
I27
sg66314
VC0342727
p68543
sg66306
V3-methylglutaconic aciduria
p68544
sa(dp68545
g66301
I82
sg66302
I2
sg66303
I22
sg66314
VC0340970
p68546
sg66306
Vcongenital neutropenia
p68547
sa(dp68548
g66301
I133
sg66302
I2
sg66303
I17
sg66314
VC0026650
p68549
sg66306
Vmovement disorder
p68550
sa(dp68551
g66301
I43
sg66302
I1
sg66303
I8
sg66314
VC0039082
p68552
sg66306
Vsyndrome
p68553
sa(dp68554
g66301
I118
sg66302
I2
sg66303
I13
sg66314
VC0235946
p68555
sg66306
Vbrain atrophy
p68556
sasa(dp68557
g66296
VWe conclude that accumulation of protein aggregates underlies the development of cataracts and nephrocalcinosis in CLPB deficiency, which is a novel genetic cause of 3-methylglutaconic aciduria.
p68558
sg66298
(lp68559
sg66311
(lp68560
(dp68561
g66301
I95
sg66302
I1
sg66303
I16
sg66314
VC0027709
p68562
sg66306
Vnephrocalcinosis
p68563
sa(dp68564
g66301
I81
sg66302
I1
sg66303
I9
sg66314
VC0521707
p68565
sg66306
Vcataracts
p68566
sa(dp68567
g66301
I166
sg66302
I2
sg66303
I27
sg66314
VC0342727
p68568
sg66306
V3-methylglutaconic aciduria
p68569
sasa(dp68570
g66296
VWe now propose that perturbation of the mitochondrial membranes by abnormal protein aggregates leads to 3-methylglutaconic aciduria in CLPB deficiency.
p68571
sg66298
(lp68572
sg66311
(lp68573
(dp68574
g66301
I104
sg66302
I2
sg66303
I27
sg66314
VC0342727
p68575
sg66306
V3-methylglutaconic aciduria
p68576
sasa(dp68577
g66296
VHere, we present mechanistic details about the Hsp100 chaperone inhibition by GdmCl using the Hsp104 homolog ClpB from Thermus thermophilus.
p68578
sg66298
(lp68579
(dp68580
g66301
I94
sg66302
I3
sg66303
I19
sg66304
g11
sg66306
VHsp104 homolog ClpB
p68581
sasg66311
(lp68582
sa(dp68583
g66296
VWe present a crystal structure of ClpB NBD1 in complex with GdmCl and ADP, showing that the Gdm(+) ion binds specifically to the active site of NBD1.
p68584
sg66298
(lp68585
(dp68586
g66301
I34
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VClpB NBD1
p68587
sasg66311
(lp68588
(dp68589
g66301
I60
sg66302
I1
sg66303
I3
sg66314
VC0085207
p68590
sg66306
VGdm
p68591
sasa(dp68592
g66296
VOne patient with nesidioblastosis had no response to secretin, indicating that the pathophysiology of this entity is distinct from that of other forms of islet hyperplasia.
p68593
sg66298
(lp68594
(dp68595
g66301
I53
sg66302
I1
sg66303
I8
sg66304
VP09683
p68596
sg66306
Vsecretin
p68597
sasg66311
(lp68598
(dp68599
g66301
I160
sg66302
I1
sg66303
I11
sg66314
VC0020507
p68600
sg66306
Vhyperplasia
p68601
sa(dp68602
g66301
I17
sg66302
I1
sg66303
I16
sg66314
VC0027773
p68603
sg66306
Vnesidioblastosis
p68604
sasa(dp68605
g66296
VIn addition, the ability to respond to secretin appears to be lost in patients with single insulinomas and nesidioblastosis, but not in those with multiple B-cell adenomas and hyperplasia.
p68606
sg66298
(lp68607
(dp68608
g66301
I39
sg66302
I1
sg66303
I8
sg66304
VP09683
p68609
sg66306
Vsecretin
p68610
sasg66311
(lp68611
(dp68612
g66301
I176
sg66302
I1
sg66303
I11
sg66314
VC0020507
p68613
sg66306
Vhyperplasia
p68614
sa(dp68615
g66301
I91
sg66302
I1
sg66303
I11
sg66314
VC0021670
p68616
sg66306
Vinsulinomas
p68617
sa(dp68618
g66301
I107
sg66302
I1
sg66303
I16
sg66314
VC0027773
p68619
sg66306
Vnesidioblastosis
p68620
sa(dp68621
g66301
I163
sg66302
I1
sg66303
I8
sg66314
VC0001430
p68622
sg66306
Vadenomas
p68623
sasa(dp68624
g66296
VIn addition, HLXB9 is recurrently rearranged in young children with acute myeloid leukemia characterized by a chromosomal translocation t(7;12)-HLXB9/TEL and concomitant high expression of the unrearranged, wild-type HLXB9 allele.
p68625
sg66298
(lp68626
(dp68627
g66301
I13
sg66302
I1
sg66303
I5
sg66304
VP50219
p68628
sg66306
VHLXB9
p68629
sa(dp68630
g66301
I207
sg66302
I3
sg66303
I22
sg66304
VP50219
p68631
sg66306
Vwild-type HLXB9 allele
p68632
sa(dp68633
g66301
I150
sg66302
I1
sg66303
I3
sg66304
VP41212
p68634
sg66306
VTEL
p68635
sa(dp68636
g66301
I13
sg66302
I1
sg66303
I5
sg66304
VP50219
p68637
sg66306
VHLXB9
p68638
sasg66311
(lp68639
(dp68640
g66301
I110
sg66302
I2
sg66303
I25
sg66314
VC0040715
p68641
sg66306
Vchromosomal translocation
p68642
sa(dp68643
g66301
I68
sg66302
I3
sg66303
I22
sg66314
VC0023467
p68644
sg66306
Vacute myeloid leukemia
p68645
sasa(dp68646
g66296
VHerein, we report the clinical course of an 8-month-old patient with acute myeloid leukemia, M2 subtype and with a HLXB9/TEL rearrangement.
p68647
sg66298
(lp68648
(dp68649
g66301
I121
sg66302
I1
sg66303
I3
sg66304
VP41212
p68650
sg66306
VTEL
p68651
sa(dp68652
g66301
I115
sg66302
I1
sg66303
I5
sg66304
VP50219
p68653
sg66306
VHLXB9
p68654
sasg66311
(lp68655
(dp68656
g66301
I69
sg66302
I3
sg66303
I22
sg66314
VC0023467
p68657
sg66306
Vacute myeloid leukemia
p68658
sasa(dp68659
g66296
VUsing RT-PCR, we screened members of the EHG family of homeobox genes, comprising EN1 (at 2q14), GBX2 (at 2q36), and EN2, GBX1, and HLXB9 (at 7q36), for dysregulation in acute myeloid leukemia (AML) cell lines indicated by chromosomal breakpoints at these sites.
p68660
sg66298
(lp68661
(dp68662
g66301
I55
sg66302
I2
sg66303
I14
sg66304
VP52954
p68663
sg66306
Vhomeobox genes
p68664
sa(dp68665
g66301
I97
sg66302
I1
sg66303
I4
sg66304
VP52951
p68666
sg66306
VGBX2
p68667
sa(dp68668
g66301
I122
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGBX1
p68669
sa(dp68670
g66301
I132
sg66302
I1
sg66303
I5
sg66304
VP50219
p68671
sg66306
VHLXB9
p68672
sa(dp68673
g66301
I117
sg66302
I1
sg66303
I3
sg66304
VP41208
p68674
sg66306
VEN2
p68675
sasg66311
(lp68676
(dp68677
g66301
I194
sg66302
I1
sg66303
I3
sg66314
VC0023467
p68678
sg66306
VAML
p68679
sa(dp68680
g66301
I170
sg66302
I3
sg66303
I22
sg66314
VC0023467
p68681
sg66306
Vacute myeloid leukemia
p68682
sasa(dp68683
g66296
VPreviously, we showed that KLF5 is a mediator of RAS/MAPK and WNT signaling pathways under homeostatic conditions and that it promotes their tumorigenic functions during the development and progression of intestinal adenomas.
p68684
sg66298
(lp68685
(dp68686
g66301
I27
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKLF5
p68687
sa(dp68688
g66301
I53
sg66302
I1
sg66303
I4
sg66304
VP53779
p68689
sg66306
VMAPK
p68690
sa(dp68691
g66301
I49
sg66302
I1
sg66303
I3
sg66304
VP01116
p68692
sg66306
VRAS
p68693
sasg66311
(lp68694
(dp68695
g66301
I216
sg66302
I1
sg66303
I8
sg66314
VC0001430
p68696
sg66306
Vadenomas
p68697
sasa(dp68698
g66296
VMoreover, production of lethal adenomas and carcinomas by specific expression of an oncogenic mutant of Beta-catenin in Lgr5(+) stem cells was suppressed completely by Klf5 deletion in the same cells.
p68699
sg66298
(lp68700
(dp68701
g66301
I168
sg66302
I2
sg66303
I13
sg66304
g11
sg66306
VKlf5 deletion
p68702
sa(dp68703
g66301
I120
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VLgr5
p68704
sa(dp68705
g66301
I104
sg66302
I1
sg66303
I12
sg66304
VP35222
p68706
sg66306
VBeta-catenin
p68707
sasg66311
(lp68708
(dp68709
g66301
I31
sg66302
I1
sg66303
I8
sg66314
VC0001430
p68710
sg66306
Vadenomas
p68711
sa(dp68712
g66301
I44
sg66302
I1
sg66303
I10
sg66314
VC0007097
p68713
sg66306
Vcarcinomas
p68714
sa(dp68715
g66301
I94
sg66302
I1
sg66303
I6
sg66314
VC0596988
p68716
sg66306
Vmutant
p68717
sasa(dp68718
g66296
VElevated levels of two particular Fbxw7 substrates, Klf5 and Tgif1, were found in normal intestine and adenomas of R482Q/+, R482Q/R482Q and Fbxw7(-/-) mice, but not Fbxw7(+/-) animals.
p68719
sg66298
(lp68720
(dp68721
g66301
I52
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKlf5
p68722
sa(dp68723
g66301
I61
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTgif1
p68724
sa(dp68725
g66301
I34
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFbxw7
p68726
sa(dp68727
g66301
I34
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFbxw7
p68728
sa(dp68729
g66301
I34
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFbxw7
p68730
sasg66311
(lp68731
(dp68732
g66301
I103
sg66302
I1
sg66303
I8
sg66314
VC0001430
p68733
sg66306
Vadenomas
p68734
sasa(dp68735
g66296
VHere we investigated the in vivo effect of Klf5 heterozygosity on the propensity of ApcMin/KRASV12 double transgenic mice to develop intestinal tumors.
p68736
sg66298
(lp68737
(dp68738
g66301
I43
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKlf5
p68739
sasg66311
(lp68740
(dp68741
g66301
I133
sg66302
I2
sg66303
I17
sg66314
VC0021841
p68742
sg66306
Vintestinal tumors
p68743
sasa(dp68744
g66296
VTo determine whether KLF5 contributes to intestinal adenoma formation, we examined tumor burdens in Apc(Min/+) mice and Apc(Min/+)/Klf5(+/-) mice.
p68745
sg66298
(lp68746
(dp68747
g66301
I100
sg66302
I1
sg66303
I3
sg66304
VP25054
p68748
sg66306
VApc
p68749
sa(dp68750
g66301
I100
sg66302
I1
sg66303
I3
sg66304
VP25054
p68751
sg66306
VApc
p68752
sa(dp68753
g66301
I21
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKLF5
p68754
sa(dp68755
g66301
I131
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKlf5
p68756
sasg66311
(lp68757
(dp68758
g66301
I41
sg66302
I2
sg66303
I18
sg66314
VC1142339
p68759
sg66306
Vintestinal adenoma
p68760
sa(dp68761
g66301
I83
sg66302
I1
sg66303
I5
sg66314
VC0027651
p68762
sg66306
Vtumor
p68763
sa(dp68764
g66301
I100
sg66302
I1
sg66303
I3
sg66314
VC0033036
p68765
sg66306
VApc
p68766
sa(dp68767
g66301
I100
sg66302
I1
sg66303
I3
sg66314
VC0033036
p68768
sg66306
VApc
p68769
sasa(dp68770
g66296
VCompared with Apc(Min/+) mice, Apc(Min/+)/Klf5(+/-) mice had a 96% reduction in the number of intestinal adenomas.
p68771
sg66298
(lp68772
(dp68773
g66301
I14
sg66302
I1
sg66303
I3
sg66304
VP25054
p68774
sg66306
VApc
p68775
sa(dp68776
g66301
I42
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKlf5
p68777
sa(dp68778
g66301
I14
sg66302
I1
sg66303
I3
sg66304
VP25054
p68779
sg66306
VApc
p68780
sasg66311
(lp68781
(dp68782
g66301
I14
sg66302
I1
sg66303
I3
sg66314
VC0033036
p68783
sg66306
VApc
p68784
sa(dp68785
g66301
I105
sg66302
I1
sg66303
I8
sg66314
VC0001430
p68786
sg66306
Vadenomas
p68787
sa(dp68788
g66301
I14
sg66302
I1
sg66303
I3
sg66314
VC0033036
p68789
sg66306
VApc
p68790
sasa(dp68791
g66296
VThus, KLF5 is necessary for the tumor-initiating activity of beta-catenin during intestinal adenoma formation in Apc(Min/+) mice, and reduced expression of KLF5 offsets the tumor-initiating activity of the Apc(Min) mutation by reducing the nuclear localization and activity of beta-catenin.
p68792
sg66298
(lp68793
(dp68794
g66301
I6
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKLF5
p68795
sa(dp68796
g66301
I61
sg66302
I1
sg66303
I12
sg66304
VP35222
p68797
sg66306
Vbeta-catenin
p68798
sa(dp68799
g66301
I113
sg66302
I1
sg66303
I3
sg66304
VP25054
p68800
sg66306
VApc
p68801
sa(dp68802
g66301
I6
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKLF5
p68803
sa(dp68804
g66301
I61
sg66302
I1
sg66303
I12
sg66304
VP35222
p68805
sg66306
Vbeta-catenin
p68806
sa(dp68807
g66301
I113
sg66302
I1
sg66303
I3
sg66304
VP25054
p68808
sg66306
VApc
p68809
sasg66311
(lp68810
(dp68811
g66301
I113
sg66302
I1
sg66303
I3
sg66314
VC0033036
p68812
sg66306
VApc
p68813
sa(dp68814
g66301
I81
sg66302
I2
sg66303
I18
sg66314
VC1142339
p68815
sg66306
Vintestinal adenoma
p68816
sa(dp68817
g66301
I32
sg66302
I1
sg66303
I5
sg66314
VC0027651
p68818
sg66306
Vtumor
p68819
sa(dp68820
g66301
I113
sg66302
I1
sg66303
I3
sg66314
VC0033036
p68821
sg66306
VApc
p68822
sa(dp68823
g66301
I32
sg66302
I1
sg66303
I5
sg66314
VC0027651
p68824
sg66306
Vtumor
p68825
sasa(dp68826
g66296
VKLF5 expression was examined in intestinal tumors derived from transgenic mice expressing KRAS(V12G) under villin promoter and in human colorectal cancers with mutated KRAS.
p68827
sg66298
(lp68828
(dp68829
g66301
I90
sg66302
I1
sg66303
I4
sg66304
VP01116
p68830
sg66306
VKRAS
p68831
sa(dp68832
g66301
I107
sg66302
I2
sg66303
I15
sg66304
VP09327
p68833
sg66306
Vvillin promoter
p68834
sa(dp68835
g66301
I0
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKLF5
p68836
sa(dp68837
g66301
I90
sg66302
I1
sg66303
I4
sg66304
VP01116
p68838
sg66306
VKRAS
p68839
sasg66311
(lp68840
(dp68841
g66301
I32
sg66302
I2
sg66303
I17
sg66314
VC0021841
p68842
sg66306
Vintestinal tumors
p68843
sa(dp68844
g66301
I136
sg66302
I2
sg66303
I18
sg66314
VC1527249
p68845
sg66306
Vcolorectal cancers
p68846
sasa(dp68847
g66296
VIn vivo, both intestinal tumors derived from mice transgenic for villin-KRAS(V12G) and human primary colorectal cancers with mutated KRAS contained high levels of KLF5 and increased staining of the proliferative marker Ki67.
p68848
sg66298
(lp68849
(dp68850
g66301
I65
sg66302
I1
sg66303
I6
sg66304
VP09327
p68851
sg66306
Vvillin
p68852
sa(dp68853
g66301
I72
sg66302
I1
sg66303
I4
sg66304
VP01116
p68854
sg66306
VKRAS
p68855
sa(dp68856
g66301
I72
sg66302
I1
sg66303
I4
sg66304
VP01116
p68857
sg66306
VKRAS
p68858
sa(dp68859
g66301
I163
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKLF5
p68860
sasg66311
(lp68861
(dp68862
g66301
I198
sg66302
I1
sg66303
I13
sg66314
VC0334094
p68863
sg66306
Vproliferative
p68864
sa(dp68865
g66301
I14
sg66302
I2
sg66303
I17
sg66314
VC0021841
p68866
sg66306
Vintestinal tumors
p68867
sa(dp68868
g66301
I101
sg66302
I2
sg66303
I18
sg66314
VC1527249
p68869
sg66306
Vcolorectal cancers
p68870
sasa(dp68871
g66296
VElevated levels of KLF5 protein are strongly correlated with activating KRAS mutations in intestinal tumors in vitro and in vivo.
p68872
sg66298
(lp68873
(dp68874
g66301
I19
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VKLF5 protein
p68875
sa(dp68876
g66301
I72
sg66302
I1
sg66303
I4
sg66304
VP01116
p68877
sg66306
VKRAS
p68878
sasg66311
(lp68879
(dp68880
g66301
I90
sg66302
I2
sg66303
I17
sg66314
VC0021841
p68881
sg66306
Vintestinal tumors
p68882
sasa(dp68883
g66296
VRas-transformation also markedly down-regulated KLF5; further analysis indicated that reduced expression of KLF5 mRNA and destabilization of KLF5 protein occur in intestinal tumors.
p68884
sg66298
(lp68885
(dp68886
g66301
I141
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VKLF5 protein
p68887
sa(dp68888
g66301
I108
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VKLF5 mRNA
p68889
sa(dp68890
g66301
I48
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKLF5
p68891
sa(dp68892
g66301
I0
sg66302
I1
sg66303
I3
sg66304
VP01116
p68893
sg66306
VRas
p68894
sasg66311
(lp68895
(dp68896
g66301
I163
sg66302
I2
sg66303
I17
sg66314
VC0021841
p68897
sg66306
Vintestinal tumors
p68898
sa(dp68899
g66301
I4
sg66302
I1
sg66303
I14
sg66314
VC1510411
p68900
sg66306
Vtransformation
p68901
sasa(dp68902
g66296
VReduced levels of KLF5 mRNA were also detected in APC(min) mouse and human familial adenomatous polyposis adenomas compared with normal crypt epithelium, indicating that down-regulation of KLF5 is an early event in intestinal tumorigenesis in vivo.
p68903
sg66298
(lp68904
(dp68905
g66301
I18
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKLF5
p68906
sa(dp68907
g66301
I18
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VKLF5 mRNA
p68908
sasg66311
(lp68909
(dp68910
g66301
I75
sg66302
I3
sg66303
I30
sg66314
VC0032580
p68911
sg66306
Vfamilial adenomatous polyposis
p68912
sa(dp68913
g66301
I106
sg66302
I1
sg66303
I8
sg66314
VC0001430
p68914
sg66306
Vadenomas
p68915
sa(dp68916
g66301
I226
sg66302
I1
sg66303
I13
sg66314
VC0007621
p68917
sg66306
Vtumorigenesis
p68918
sa(dp68919
g66301
I50
sg66302
I1
sg66303
I3
sg66314
VC0033036
p68920
sg66306
VAPC
p68921
sasa(dp68922
g66296
VCollectively, these data indicate that intestinal tumor progression is associated with a change in the growth-related functions of KLF5 and that intestinal tumors down-regulate KLF5 expression by multiple mechanisms.
p68923
sg66298
(lp68924
(dp68925
g66301
I131
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKLF5
p68926
sa(dp68927
g66301
I131
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VKLF5
p68928
sasg66311
(lp68929
(dp68930
g66301
I145
sg66302
I2
sg66303
I17
sg66314
VC0021841
p68931
sg66306
Vintestinal tumors
p68932
sa(dp68933
g66301
I50
sg66302
I2
sg66303
I17
sg66314
VC0178874
p68934
sg66306
Vtumor progression
p68935
sasa(dp68936
g66296
VVariable major lipoprotein (Vmp) is a major tumor necrosis factor (TNF)-inducing component of Borrelia recurrentis, the agent of louse-borne relapsing fever.
p68937
sg66298
(lp68938
(dp68939
g66301
I44
sg66302
I3
sg66303
I21
sg66304
VP01375
p68940
sg66306
Vtumor necrosis factor
p68941
sa(dp68942
g66301
I67
sg66302
I1
sg66303
I3
sg66304
VP01375
p68943
sg66306
VTNF
p68944
sasg66311
(lp68945
(dp68946
g66301
I94
sg66302
I1
sg66303
I8
sg66314
VC0024198
p68947
sg66306
VBorrelia
p68948
sa(dp68949
g66301
I129
sg66302
I3
sg66303
I27
sg66314
VC0152061
p68950
sg66306
Vlouse-borne relapsing fever
p68951
sa(dp68952
g66301
I44
sg66302
I2
sg66303
I14
sg66314
VC0333516
p68953
sg66306
Vtumor necrosis
p68954
sasa(dp68955
g66296
VLouse-borne relapsing fever, caused by Borrelia recurrentis, provides one of the best documented examples of the causative role of tumor necrosis factor (TNF) in the pathology of severe infection in humans.
p68956
sg66298
(lp68957
(dp68958
g66301
I154
sg66302
I1
sg66303
I3
sg66304
VP01375
p68959
sg66306
VTNF
p68960
sa(dp68961
g66301
I131
sg66302
I3
sg66303
I21
sg66304
VP01375
p68962
sg66306
Vtumor necrosis factor
p68963
sasg66311
(lp68964
(dp68965
g66301
I186
sg66302
I1
sg66303
I9
sg66314
VC0009450
p68966
sg66306
Vinfection
p68967
sa(dp68968
g66301
I166
sg66302
I1
sg66303
I9
sg66314
VC0677042
p68969
sg66306
Vpathology
p68970
sa(dp68971
g66301
I0
sg66302
I3
sg66303
I27
sg66314
VC0152061
p68972
sg66306
VLouse-borne relapsing fever
p68973
sa(dp68974
g66301
I131
sg66302
I2
sg66303
I14
sg66314
VC0333516
p68975
sg66306
Vtumor necrosis
p68976
sa(dp68977
g66301
I39
sg66302
I1
sg66303
I8
sg66314
VC0024198
p68978
sg66306
VBorrelia
p68979
sasa(dp68980
g66296
VSevere Jarisch Herxheimer reaction (J-HR) precipitated by antibiotic treatment of louse-borne relapsing fever (LBRF) is associated with a transient, marked rise in circulating tumour necrosis factor alpha (TNF alpha), interleukin 6 (IL-6) and interleukin 8 (IL-8).
p68981
sg66298
(lp68982
(dp68983
g66301
I206
sg66302
I2
sg66303
I9
sg66304
VP01375
p68984
sg66306
VTNF alpha
p68985
sa(dp68986
g66301
I258
sg66302
I1
sg66303
I4
sg66304
VP60568
p68987
sg66306
VIL-8
p68988
sa(dp68989
g66301
I218
sg66302
I2
sg66303
I13
sg66304
VP05231
p68990
sg66306
Vinterleukin 6
p68991
sa(dp68992
g66301
I233
sg66302
I1
sg66303
I4
sg66304
VP05231
p68993
sg66306
VIL-6
p68994
sa(dp68995
g66301
I176
sg66302
I4
sg66303
I28
sg66304
VP01375
p68996
sg66306
Vtumour necrosis factor alpha
p68997
sa(dp68998
g66301
I243
sg66302
I2
sg66303
I13
sg66304
VP60568
p68999
sg66306
Vinterleukin 8
p69000
sasg66311
(lp69001
(dp69002
g66301
I111
sg66302
I1
sg66303
I4
sg66314
VC0152061
p69003
sg66306
VLBRF
p69004
sa(dp69005
g66301
I82
sg66302
I3
sg66303
I27
sg66314
VC0152061
p69006
sg66306
Vlouse-borne relapsing fever
p69007
sa(dp69008
g66301
I176
sg66302
I2
sg66303
I15
sg66314
VC0333516
p69009
sg66306
Vtumour necrosis
p69010
sasa(dp69011
g66296
VIn patients with louse-borne relapsing fever (Borrelia recurrentis infection), antimicrobial treatment is often followed by sudden fever, rigors, and persistent hypotension (Jarisch-Herxheimer reactions) that are associated with increases in plasma concentrations of tumor necrosis factor alpha (TNF-alpha), interleukin-6, and interleukin-8.
p69012
sg66298
(lp69013
(dp69014
g66301
I296
sg66302
I1
sg66303
I9
sg66304
VP01375
p69015
sg66306
VTNF-alpha
p69016
sa(dp69017
g66301
I327
sg66302
I1
sg66303
I13
sg66304
VP60568
p69018
sg66306
Vinterleukin-8
p69019
sa(dp69020
g66301
I308
sg66302
I1
sg66303
I13
sg66304
VP05231
p69021
sg66306
Vinterleukin-6
p69022
sa(dp69023
g66301
I267
sg66302
I4
sg66303
I27
sg66304
VP01375
p69024
sg66306
Vtumor necrosis factor alpha
p69025
sasg66311
(lp69026
(dp69027
g66301
I267
sg66302
I2
sg66303
I14
sg66314
VC0333516
p69028
sg66306
Vtumor necrosis
p69029
sa(dp69030
g66301
I17
sg66302
I3
sg66303
I27
sg66314
VC0152061
p69031
sg66306
Vlouse-borne relapsing fever
p69032
sa(dp69033
g66301
I46
sg66302
I3
sg66303
I30
sg66314
VC0857817
p69034
sg66306
VBorrelia recurrentis infection
p69035
sa(dp69036
g66301
I138
sg66302
I1
sg66303
I6
sg66314
VC0424790
p69037
sg66306
Vrigors
p69038
sasa(dp69039
g66296
VPretreatment with sheep anti-TNF-alpha Fab suppresses Jarisch-Herxheimer reactions that occur after penicillin treatment for louse-borne relapsing fever, reduces the associated increases in plasma concentrations of interleukin-6 and interleukin-8, and may be useful in other forms of sepsis.
p69040
sg66298
(lp69041
(dp69042
g66301
I233
sg66302
I1
sg66303
I13
sg66304
VP60568
p69043
sg66306
Vinterleukin-8
p69044
sa(dp69045
g66301
I215
sg66302
I1
sg66303
I13
sg66304
VP05231
p69046
sg66306
Vinterleukin-6
p69047
sa(dp69048
g66301
I24
sg66302
I2
sg66303
I18
sg66304
VP01375
p69049
sg66306
Vanti-TNF-alpha Fab
p69050
sasg66311
(lp69051
(dp69052
g66301
I125
sg66302
I3
sg66303
I27
sg66314
VC0152061
p69053
sg66306
Vlouse-borne relapsing fever
p69054
sa(dp69055
g66301
I284
sg66302
I1
sg66303
I6
sg66314
VC0243026
p69056
sg66306
Vsepsis
p69057
sasa(dp69058
g66296
VA frail 84-year old lady with situs inversus totalis and symptomatic aortic stenosis underwent a successful transcatheter aortic valve implantation (TAVI) after extensive diagnostic work-up.
p69059
sg66298
(lp69060
sg66311
(lp69061
(dp69062
g66301
I57
sg66302
I3
sg66303
I27
sg66314
VC0741183
p69063
sg66306
Vsymptomatic aortic stenosis
p69064
sa(dp69065
g66301
I30
sg66302
I2
sg66303
I14
sg66314
VC0037221
p69066
sg66306
Vsitus inversus
p69067
sasa(dp69068
g66296
VHere, we report the first known case of Marfan's syndrome, combined with situs inversus totalis with dextrocardia and discrete subaortic stenosis and aortic insufficiency in a 22-year-old woman.
p69069
sg66298
(lp69070
sg66311
(lp69071
(dp69072
g66301
I101
sg66302
I1
sg66303
I12
sg66314
VC0011813
p69073
sg66306
Vdextrocardia
p69074
sa(dp69075
g66301
I118
sg66302
I3
sg66303
I27
sg66314
VC0012628
p69076
sg66306
Vdiscrete subaortic stenosis
p69077
sa(dp69078
g66301
I73
sg66302
I2
sg66303
I14
sg66314
VC0037221
p69079
sg66306
Vsitus inversus
p69080
sa(dp69081
g66301
I40
sg66302
I2
sg66303
I17
sg66314
VC0024796
p69082
sg66306
VMarfan's syndrome
p69083
sa(dp69084
g66301
I150
sg66302
I2
sg66303
I20
sg66314
VC0003504
p69085
sg66306
Vaortic insufficiency
p69086
sasa(dp69087
g66296
VLow-frequency artifacts that plague traditional TIE methods can be suppressed without an excessive number of captured images.
p69088
sg66298
(lp69089
sg66311
(lp69090
(dp69091
g66301
I29
sg66302
I1
sg66303
I6
sg66314
VC0032064
p69092
sg66306
Vplague
p69093
sasa(dp69094
g66296
VThe FGF9 subfamily, including FGF9, FGF16, and FGF20, in addition to rhFGF16, rhFGF9, and rhFGF20, were shown to stimulate the proliferation and migration of HuH7 human hepatocellular carcinoma (HCC) cells.
p69095
sg66298
(lp69096
(dp69097
g66301
I4
sg66302
I2
sg66303
I14
sg66304
VP31371
p69098
sg66306
VFGF9 subfamily
p69099
sa(dp69100
g66301
I4
sg66302
I1
sg66303
I4
sg66304
VP31371
p69101
sg66306
VFGF9
p69102
sa(dp69103
g66301
I36
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFGF16
p69104
sa(dp69105
g66301
I47
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFGF20
p69106
sasg66311
(lp69107
(dp69108
g66301
I169
sg66302
I2
sg66303
I24
sg66314
VC2239176
p69109
sg66306
Vhepatocellular carcinoma
p69110
sa(dp69111
g66301
I195
sg66302
I1
sg66303
I3
sg66314
VC2239176
p69112
sg66306
VHCC
p69113
sa(dp69114
g66301
I127
sg66302
I1
sg66303
I13
sg66314
VC0334094
p69115
sg66306
Vproliferation
p69116
sasa(dp69117
g66296
VFGF16 promoted proliferation and invasion behavior of SKOV-3 ovarian cancer cells, whose function may be similar in lung cancer.
p69118
sg66298
(lp69119
(dp69120
g66301
I0
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFGF16
p69121
sasg66311
(lp69122
(dp69123
g66301
I61
sg66302
I2
sg66303
I14
sg66314
VC1140680
p69124
sg66306
Vovarian cancer
p69125
sa(dp69126
g66301
I33
sg66302
I1
sg66303
I8
sg66314
VC2699153
p69127
sg66306
Vinvasion
p69128
sa(dp69129
g66301
I116
sg66302
I2
sg66303
I11
sg66314
VC0684249
p69130
sg66306
Vlung cancer
p69131
sa(dp69132
g66301
I15
sg66302
I1
sg66303
I13
sg66314
VC0334094
p69133
sg66306
Vproliferation
p69134
sasa(dp69135
g66296
VThis finding indicated possible involvement of FGF16 in ovarian cancer progression.
p69136
sg66298
(lp69137
(dp69138
g66301
I47
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFGF16
p69139
sasg66311
(lp69140
(dp69141
g66301
I64
sg66302
I2
sg66303
I18
sg66314
VC0178874
p69142
sg66306
Vcancer progression
p69143
sasa(dp69144
g66296
VWe observed that FGF16 stimulates the proliferation of human ovarian adenocarcinoma cells, SKOV-3 and OAW-42.
p69145
sg66298
(lp69146
(dp69147
g66301
I17
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFGF16
p69148
sasg66311
(lp69149
(dp69150
g66301
I61
sg66302
I2
sg66303
I22
sg66314
VC0948216
p69151
sg66306
Vovarian adenocarcinoma
p69152
sa(dp69153
g66301
I38
sg66302
I1
sg66303
I13
sg66314
VC0334094
p69154
sg66306
Vproliferation
p69155
sasa(dp69156
g66296
VTaken together, our findings indicate that FGF16 in conjunction with Wnt pathway contributes to the cancer phenotype of ovarian cells and suggests that modulation of its expression in ovarian cells might be a promising therapeutic strategy for the treatment of invasive ovarian cancers.
p69157
sg66298
(lp69158
(dp69159
g66301
I43
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFGF16
p69160
sasg66311
(lp69161
(dp69162
g66301
I270
sg66302
I2
sg66303
I15
sg66314
VC1140680
p69163
sg66306
Vovarian cancers
p69164
sa(dp69165
g66301
I100
sg66302
I1
sg66303
I6
sg66314
VC0006826
p69166
sg66306
Vcancer
p69167
sasa(dp69168
g66296
VLoss-of-function mutations in the UBR1 gene cause Johanson-Blizzard syndrome, which involves pancreatic exocrine insufficiency.
p69169
sg66298
(lp69170
(dp69171
g66301
I34
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VUBR1 gene
p69172
sasg66311
(lp69173
(dp69174
g66301
I50
sg66302
I2
sg66303
I26
sg66314
VC0175692
p69175
sg66306
VJohanson-Blizzard syndrome
p69176
sasa(dp69177
g66296
VJohanson-Blizzard syndrome (JBS) is considered as an infrequent, but clinically easily recognizable autosomal recessive entity by the pathognomonic combination of congenital exocrine pancreatic insufficiency and hypoplastic alae nasi, in addition to other distinctive findings such as scalp defects, hypothyroidism, and rectourogenital malformations.
p69178
sg66298
(lp69179
sg66311
(lp69180
(dp69181
g66301
I336
sg66302
I1
sg66303
I13
sg66314
VC0000768
p69182
sg66306
Vmalformations
p69183
sa(dp69184
g66301
I0
sg66302
I2
sg66303
I26
sg66314
VC0175692
p69185
sg66306
VJohanson-Blizzard syndrome
p69186
sa(dp69187
g66301
I300
sg66302
I1
sg66303
I14
sg66314
VC0020676
p69188
sg66306
Vhypothyroidism
p69189
sa(dp69190
g66301
I28
sg66302
I1
sg66303
I3
sg66314
VC0175692
p69191
sg66306
VJBS
p69192
sa(dp69193
g66301
I174
sg66302
I3
sg66303
I33
sg66314
VC0267963
p69194
sg66306
Vexocrine pancreatic insufficiency
p69195
sasa(dp69196
g66296
VThere are few reports of patients with JBS in association with facial clefting, referring all to types 2 to 6 of Tessier's classification that can be characterized properly as oblique facial clefts (OFCs).
p69197
sg66298
(lp69198
sg66311
(lp69199
(dp69200
g66301
I199
sg66302
I1
sg66303
I4
sg66314
VC1838348
p69201
sg66306
VOFCs
p69202
sa(dp69203
g66301
I176
sg66302
I3
sg66303
I21
sg66314
VC1838348
p69204
sg66306
Voblique facial clefts
p69205
sa(dp69206
g66301
I39
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69207
sg66306
VJBS
p69208
sasa(dp69209
g66296
VWe describe the clinical aspects in four patients with JBS and extensive OFCs.
p69210
sg66298
(lp69211
sg66311
(lp69212
(dp69213
g66301
I55
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69214
sg66306
VJBS
p69215
sasa(dp69216
g66296
VIn all of them, the diagnosis of JBS was confirmed by the demonstration of homozygous or compound-heterozygous mutations in the UBR1 gene.
p69217
sg66298
(lp69218
(dp69219
g66301
I128
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VUBR1 gene
p69220
sasg66311
(lp69221
(dp69222
g66301
I33
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69223
sg66306
VJBS
p69224
sasa(dp69225
g66296
VAdditionally, we review three previously reported cases of JBS with OFCs.
p69226
sg66298
(lp69227
sg66311
(lp69228
(dp69229
g66301
I59
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69230
sg66306
VJBS
p69231
sasa(dp69232
g66296
VTaking into account a number of approximately 100 individuals affected by JBS that have been published in the literature we estimate that the frequency of OFCs in JBS is between 5% and 10%.
p69233
sg66298
(lp69234
sg66311
(lp69235
(dp69236
g66301
I74
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69237
sg66306
VJBS
p69238
sa(dp69239
g66301
I74
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69240
sg66306
VJBS
p69241
sasa(dp69242
g66296
VThis report emphasizes that extensive OFCs may be the severe end of the spectrum of facial malformations occurring in JBS.
p69243
sg66298
(lp69244
sg66311
(lp69245
(dp69246
g66301
I84
sg66302
I2
sg66303
I20
sg66314
VC0266617
p69247
sg66306
Vfacial malformations
p69248
sa(dp69249
g66301
I118
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69250
sg66306
VJBS
p69251
sasa(dp69252
g66296
VJohanson-Blizzard Syndrome (JBS) (MIM #243800) is a rare autosomal recessive genetic disorder characterized by exocrine pancreatic insufficiency, abnormal facial appearance and varying degrees of mental retardation.
p69253
sg66298
(lp69254
sg66311
(lp69255
(dp69256
g66301
I0
sg66302
I2
sg66303
I26
sg66314
VC0175692
p69257
sg66306
VJohanson-Blizzard Syndrome
p69258
sa(dp69259
g66301
I77
sg66302
I2
sg66303
I16
sg66314
VC0019247
p69260
sg66306
Vgenetic disorder
p69261
sa(dp69262
g66301
I28
sg66302
I1
sg66303
I3
sg66314
VC0175692
p69263
sg66306
VJBS
p69264
sa(dp69265
g66301
I196
sg66302
I2
sg66303
I18
sg66314
VC0025362
p69266
sg66306
Vmental retardation
p69267
sa(dp69268
g66301
I111
sg66302
I3
sg66303
I33
sg66314
VC0267963
p69269
sg66306
Vexocrine pancreatic insufficiency
p69270
sasa(dp69271
g66296
VHere, we report a 3 year-old mentally normal JBS girl.
p69272
sg66298
(lp69273
sg66311
(lp69274
(dp69275
g66301
I45
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69276
sg66306
VJBS
p69277
sasa(dp69278
g66296
VWith these findings, JBS diagnosis was established clinically.
p69279
sg66298
(lp69280
sg66311
(lp69281
(dp69282
g66301
I21
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69283
sg66306
VJBS
p69284
sasa(dp69285
g66296
VJohanson-Blizzard syndrome (JBS) is a rare autosomal recessive syndrome characterized by dysmorphic nasal alae, ectodermal abnormalities, exocrine pancreatic insufficiency and early growth failure.
p69286
sg66298
(lp69287
sg66311
(lp69288
(dp69289
g66301
I138
sg66302
I3
sg66303
I33
sg66314
VC0267963
p69290
sg66306
Vexocrine pancreatic insufficiency
p69291
sa(dp69292
g66301
I0
sg66302
I2
sg66303
I26
sg66314
VC0175692
p69293
sg66306
VJohanson-Blizzard syndrome
p69294
sa(dp69295
g66301
I28
sg66302
I1
sg66303
I3
sg66314
VC0175692
p69296
sg66306
VJBS
p69297
sa(dp69298
g66301
I182
sg66302
I2
sg66303
I14
sg66314
VC0878787
p69299
sg66306
Vgrowth failure
p69300
sa(dp69301
g66301
I18
sg66302
I1
sg66303
I8
sg66314
VC0039082
p69302
sg66306
Vsyndrome
p69303
sasa(dp69304
g66296
VNonsense, frame shift and splice-site mutations of the ubiquitin ligase gene (UBR1) lead to early loss of acinar cells in individuals with JBS.
p69305
sg66298
(lp69306
(dp69307
g66301
I55
sg66302
I3
sg66303
I21
sg66304
g11
sg66306
Vubiquitin ligase gene
p69308
sa(dp69309
g66301
I78
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VUBR1
p69310
sasg66311
(lp69311
(dp69312
g66301
I139
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69313
sg66306
VJBS
p69314
sasa(dp69315
g66296
VThis case illustrates that the phenotypic variability of pancreatic involvement in JBS may be subtle and may not manifest until the second decade of life.
p69316
sg66298
(lp69317
(dp69318
g66301
I83
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VJBS
p69319
sasg66311
(lp69320
(dp69321
g66301
I83
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69322
sg66306
VJBS
p69323
sasa(dp69324
g66296
VJohanson-Blizzard syndrome (JBS) is a rare autosomal recessive disorder resulting from loss-of-function mutations in the UBR1 gene.
p69325
sg66298
(lp69326
(dp69327
g66301
I121
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VUBR1 gene
p69328
sasg66311
(lp69329
(dp69330
g66301
I0
sg66302
I2
sg66303
I26
sg66314
VC0175692
p69331
sg66306
VJohanson-Blizzard syndrome
p69332
sa(dp69333
g66301
I28
sg66302
I1
sg66303
I3
sg66314
VC0175692
p69334
sg66306
VJBS
p69335
sasa(dp69336
g66296
VJBS can be easily recognized by its unique clinical presentation (including exocrine pancreatic insufficiency, hypoplasia/aplasia of the alae nasi, congenital scalp defects, sensorineural hearing loss, growth retardation, psychomotor retardation, and anal and genitourinary anomalies).
p69337
sg66298
(lp69338
sg66311
(lp69339
(dp69340
g66301
I174
sg66302
I3
sg66303
I26
sg66314
VC0018784
p69341
sg66306
Vsensorineural hearing loss
p69342
sa(dp69343
g66301
I76
sg66302
I3
sg66303
I33
sg66314
VC0267963
p69344
sg66306
Vexocrine pancreatic insufficiency
p69345
sa(dp69346
g66301
I202
sg66302
I2
sg66303
I18
sg66314
VC0151686
p69347
sg66306
Vgrowth retardation
p69348
sa(dp69349
g66301
I122
sg66302
I1
sg66303
I7
sg66314
VC0243065
p69350
sg66306
Vaplasia
p69351
sa(dp69352
g66301
I0
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69353
sg66306
VJBS
p69354
sa(dp69355
g66301
I111
sg66302
I1
sg66303
I10
sg66314
VC0243069
p69356
sg66306
Vhypoplasia
p69357
sasa(dp69358
g66296
VThe objective of this study is to report on the first familial case of gender-discordant twins presenting JBS and a novel mutation in the UBR1 gene.
p69359
sg66298
(lp69360
(dp69361
g66301
I138
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VUBR1 gene
p69362
sasg66311
(lp69363
(dp69364
g66301
I116
sg66302
I2
sg66303
I14
sg66314
VC2985438
p69365
sg66306
Vnovel mutation
p69366
sa(dp69367
g66301
I106
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69368
sg66306
VJBS
p69369
sasa(dp69370
g66296
VWe also review literature describing molecularly confirmed cases of JBS.
p69371
sg66298
(lp69372
sg66311
(lp69373
(dp69374
g66301
I68
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69375
sg66306
VJBS
p69376
sasa(dp69377
g66296
VBoth patients presented typical clinical features of JBS.
p69378
sg66298
(lp69379
sg66311
(lp69380
(dp69381
g66301
I53
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69382
sg66306
VJBS
p69383
sasa(dp69384
g66296
VSevere presentation of JBS usually involves deleterious (nonsense, frameshift, or splice-site) mutations in the UBR1 gene that are thought to completely abolish the expression of a functional protein product, as in this familial case; however, milder presentation of JBS has occasionally been observed with missense mutations in at least 1 of the 2 copies of UBR1, in which there may be residual activity of the product of this gene.
p69385
sg66298
(lp69386
(dp69387
g66301
I112
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VUBR1 gene
p69388
sa(dp69389
g66301
I112
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VUBR1
p69390
sasg66311
(lp69391
(dp69392
g66301
I23
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69393
sg66306
VJBS
p69394
sa(dp69395
g66301
I23
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69396
sg66306
VJBS
p69397
sa(dp69398
g66301
I67
sg66302
I1
sg66303
I10
sg66314
VC0079380
p69399
sg66306
Vframeshift
p69400
sasa(dp69401
g66296
VJohanson-Blizzard syndrome (JBS) is a rare, autosomal recessive disorder characterized by exocrine pancreatic insufficiency, typical facial features, dental anomalies, hypothyroidism, sensorineural hearing loss, scalp defects, urogenital and anorectal anomalies, short stature, and cognitive impairment of variable degree.
p69402
sg66298
(lp69403
sg66311
(lp69404
(dp69405
g66301
I168
sg66302
I1
sg66303
I14
sg66314
VC0020676
p69406
sg66306
Vhypothyroidism
p69407
sa(dp69408
g66301
I28
sg66302
I1
sg66303
I3
sg66314
VC0175692
p69409
sg66306
VJBS
p69410
sa(dp69411
g66301
I0
sg66302
I2
sg66303
I26
sg66314
VC0175692
p69412
sg66306
VJohanson-Blizzard syndrome
p69413
sa(dp69414
g66301
I242
sg66302
I2
sg66303
I19
sg66314
VC2974527
p69415
sg66306
Vanorectal anomalies
p69416
sa(dp69417
g66301
I282
sg66302
I2
sg66303
I20
sg66314
VC0338656
p69418
sg66306
Vcognitive impairment
p69419
sa(dp69420
g66301
I90
sg66302
I3
sg66303
I33
sg66314
VC0267963
p69421
sg66306
Vexocrine pancreatic insufficiency
p69422
sa(dp69423
g66301
I263
sg66302
I2
sg66303
I13
sg66314
VC0013336
p69424
sg66306
Vshort stature
p69425
sa(dp69426
g66301
I184
sg66302
I3
sg66303
I26
sg66314
VC0018784
p69427
sg66306
Vsensorineural hearing loss
p69428
sasa(dp69429
g66296
VMutation types include nonsense, frameshift, splice site, missense, and small in-frame deletions consistent with the hypothesis that loss of UBR1 protein function is the molecular basis of JBS.
p69430
sg66298
(lp69431
(dp69432
g66301
I141
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VUBR1 protein
p69433
sasg66311
(lp69434
(dp69435
g66301
I33
sg66302
I1
sg66303
I10
sg66314
VC0079380
p69436
sg66306
Vframeshift
p69437
sa(dp69438
g66301
I189
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69439
sg66306
VJBS
p69440
sasa(dp69441
g66296
VThe review of clinical data of a large number of molecularly confirmed JBS cases allows us to define minimal clinical criteria for the diagnosis of JBS.
p69442
sg66298
(lp69443
sg66311
(lp69444
(dp69445
g66301
I71
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69446
sg66306
VJBS
p69447
sa(dp69448
g66301
I71
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69449
sg66306
VJBS
p69450
sasa(dp69451
g66296
VJohanson-Blizzard syndrome (JBS) is a rare autosomal recessive disease characterized by exocrine pancreatic insufficiency, hypoplastic or aplastic nasal alae, cutis aplasia on the scalp, and other features including developmental delay, failure to thrive, hearing loss, mental retardation, hypothyroidism, dental abnormalities, and anomalies in cardiac and genitourinary systems.
p69452
sg66298
(lp69453
sg66311
(lp69454
(dp69455
g66301
I159
sg66302
I2
sg66303
I13
sg66314
VC0282160
p69456
sg66306
Vcutis aplasia
p69457
sa(dp69458
g66301
I256
sg66302
I2
sg66303
I12
sg66314
VC0011053
p69459
sg66306
Vhearing loss
p69460
sa(dp69461
g66301
I88
sg66302
I3
sg66303
I33
sg66314
VC0267963
p69462
sg66306
Vexocrine pancreatic insufficiency
p69463
sa(dp69464
g66301
I28
sg66302
I1
sg66303
I3
sg66314
VC0175692
p69465
sg66306
VJBS
p69466
sa(dp69467
g66301
I0
sg66302
I2
sg66303
I26
sg66314
VC0175692
p69468
sg66306
VJohanson-Blizzard syndrome
p69469
sa(dp69470
g66301
I216
sg66302
I2
sg66303
I19
sg66314
VC0424605
p69471
sg66306
Vdevelopmental delay
p69472
sa(dp69473
g66301
I237
sg66302
I3
sg66303
I17
sg66314
VC0015544
p69474
sg66306
Vfailure to thrive
p69475
sa(dp69476
g66301
I270
sg66302
I2
sg66303
I18
sg66314
VC0025362
p69477
sg66306
Vmental retardation
p69478
sa(dp69479
g66301
I290
sg66302
I1
sg66303
I14
sg66314
VC0020676
p69480
sg66306
Vhypothyroidism
p69481
sasa(dp69482
g66296
VWe describe the case of a male infant with typical symptoms of JBS.
p69483
sg66298
(lp69484
sg66311
(lp69485
(dp69486
g66301
I63
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69487
sg66306
VJBS
p69488
sasa(dp69489
g66296
VJohanson-Blizzard syndrome (JBS; OMIM 243800) is an autosomal recessive disorder that includes congenital exocrine pancreatic insufficiency, facial dysmorphism with the characteristic nasal wing hypoplasia, multiple malformations, and frequent mental retardation.
p69490
sg66298
(lp69491
sg66311
(lp69492
(dp69493
g66301
I216
sg66302
I1
sg66303
I13
sg66314
VC0000768
p69494
sg66306
Vmalformations
p69495
sa(dp69496
g66301
I195
sg66302
I1
sg66303
I10
sg66314
VC0243069
p69497
sg66306
Vhypoplasia
p69498
sa(dp69499
g66301
I28
sg66302
I1
sg66303
I3
sg66314
VC0175692
p69500
sg66306
VJBS
p69501
sa(dp69502
g66301
I106
sg66302
I3
sg66303
I33
sg66314
VC0267963
p69503
sg66306
Vexocrine pancreatic insufficiency
p69504
sa(dp69505
g66301
I244
sg66302
I2
sg66303
I18
sg66314
VC0025362
p69506
sg66306
Vmental retardation
p69507
sa(dp69508
g66301
I0
sg66302
I2
sg66303
I26
sg66314
VC0175692
p69509
sg66306
VJohanson-Blizzard syndrome
p69510
sa(dp69511
g66301
I141
sg66302
I2
sg66303
I18
sg66314
VC0266617
p69512
sg66306
Vfacial dysmorphism
p69513
sasa(dp69514
g66296
VOur previous work has shown that JBS is caused by mutations in human UBR1, which encodes one of the E3 ubiquitin ligases of the N-end rule pathway.
p69515
sg66298
(lp69516
(dp69517
g66301
I63
sg66302
I2
sg66303
I10
sg66304
g11
sg66306
Vhuman UBR1
p69518
sa(dp69519
g66301
I33
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VJBS
p69520
sa(dp69521
g66301
I100
sg66302
I3
sg66303
I20
sg66304
VP62979
p69522
sg66306
VE3 ubiquitin ligases
p69523
sasg66311
(lp69524
(dp69525
g66301
I33
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69526
sg66306
VJBS
p69527
sasa(dp69528
g66296
VMost JBS-causing alterations of UBR1 are nonsense, frameshift or splice-site mutations that abolish UBR1 activity.
p69529
sg66298
(lp69530
(dp69531
g66301
I32
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VUBR1
p69532
sa(dp69533
g66301
I32
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VUBR1
p69534
sasg66311
(lp69535
(dp69536
g66301
I51
sg66302
I1
sg66303
I10
sg66314
VC0079380
p69537
sg66306
Vframeshift
p69538
sa(dp69539
g66301
I5
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69540
sg66306
VJBS
p69541
sasa(dp69542
g66296
VWe report here missense mutations of human UBR1 in patients with milder variants of JBS.
p69543
sg66298
(lp69544
(dp69545
g66301
I37
sg66302
I2
sg66303
I10
sg66304
g11
sg66306
Vhuman UBR1
p69546
sasg66311
(lp69547
(dp69548
g66301
I84
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69549
sg66306
VJBS
p69550
sasa(dp69551
g66296
VTaking advantage of this conservation, we constructed alleles of the yeast Saccharomyces cerevisiae UBR1 that were counterparts of missense JBS-UBR1 alleles.
p69552
sg66298
(lp69553
(dp69554
g66301
I140
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VJBS
p69555
sa(dp69556
g66301
I69
sg66302
I4
sg66303
I35
sg66304
g11
sg66306
Vyeast Saccharomyces cerevisiae UBR1
p69557
sa(dp69558
g66301
I100
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VUBR1
p69559
sasg66311
(lp69560
(dp69561
g66301
I140
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69562
sg66306
VJBS
p69563
sasa(dp69564
g66296
VAmong these yeast Ubr1 mutants, one of them (H160R) was inactive in yeast-based activity assays, the other one (Q1224E) had a detectable but weak activity, and the third one (V146L) exhibited a decreased but significant activity, in agreement with manifestations of JBS in the corresponding JBS patients.
p69565
sg66298
(lp69566
(dp69567
g66301
I18
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VUbr1 mutants
p69568
sasg66311
(lp69569
(dp69570
g66301
I266
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69571
sg66306
VJBS
p69572
sa(dp69573
g66301
I266
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69574
sg66306
VJBS
p69575
sasa(dp69576
g66296
VThese results, made possible by modeling defects of a human ubiquitin ligase in its yeast counterpart, verified and confirmed the relevance of specific missense UBR1 alleles to JBS, and suggested that a residual activity of a missense allele is causally associated with milder variants of JBS.
p69577
sg66298
(lp69578
(dp69579
g66301
I54
sg66302
I3
sg66303
I22
sg66304
g11
sg66306
Vhuman ubiquitin ligase
p69580
sa(dp69581
g66301
I161
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VUBR1 alleles
p69582
sasg66311
(lp69583
(dp69584
g66301
I177
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69585
sg66306
VJBS
p69586
sa(dp69587
g66301
I177
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69588
sg66306
VJBS
p69589
sasa(dp69590
g66296
VWe report on a triplet pregnancy of consanguineous parents with one fetus being affected by recurrent Johanson-Blizzard syndrome (JBS).
p69591
sg66298
(lp69592
sg66311
(lp69593
(dp69594
g66301
I130
sg66302
I1
sg66303
I3
sg66314
VC0175692
p69595
sg66306
VJBS
p69596
sa(dp69597
g66301
I15
sg66302
I2
sg66303
I17
sg66314
VC0152151
p69598
sg66306
Vtriplet pregnancy
p69599
sa(dp69600
g66301
I102
sg66302
I2
sg66303
I26
sg66314
VC0175692
p69601
sg66306
VJohanson-Blizzard syndrome
p69602
sasa(dp69603
g66296
VIn addition to the lack of exocrine acini as the characteristic feature of JBS, the pancreas revealed a resorptive inflammatory reaction with infiltration by eosinophilic granulocytes that focally dispersed onto islets of Langerhans, thus favoring a progressive destructive rather than primary dysplastic process and possibly explaining the occurrence of diabetes mellitus in later life.
p69604
sg66298
(lp69605
sg66311
(lp69606
(dp69607
g66301
I142
sg66302
I1
sg66303
I12
sg66314
VC0332448
p69608
sg66306
Vinfiltration
p69609
sa(dp69610
g66301
I355
sg66302
I2
sg66303
I17
sg66314
VC0011849
p69611
sg66306
Vdiabetes mellitus
p69612
sa(dp69613
g66301
I115
sg66302
I2
sg66303
I21
sg66314
VC0021368
p69614
sg66306
Vinflammatory reaction
p69615
sa(dp69616
g66301
I294
sg66302
I1
sg66303
I10
sg66314
VC0334044
p69617
sg66306
Vdysplastic
p69618
sa(dp69619
g66301
I75
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69620
sg66306
VJBS
p69621
sasa(dp69622
g66296
VJBS maps to chromosome 15q15-q21.1 and is associated with mutations in the UBR1 gene.
p69623
sg66298
(lp69624
(dp69625
g66301
I0
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VJBS
p69626
sa(dp69627
g66301
I75
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VUBR1 gene
p69628
sasg66311
(lp69629
(dp69630
g66301
I0
sg66302
I1
sg66303
I3
sg66314
VC0795841
p69631
sg66306
VJBS
p69632
sasa(dp69633
g66296
VJohanson-Blizzard syndrome is a rare autosomal recessive multisystem disorder, it is characterized by the association of congenital exocrine pancreatic insufficiency and hypoplasia or aplasia of the nasal wings, and can be diagnosed by clinical characteristics and UBR1 gene analysis.
p69634
sg66298
(lp69635
(dp69636
g66301
I265
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VUBR1 gene
p69637
sasg66311
(lp69638
(dp69639
g66301
I0
sg66302
I2
sg66303
I26
sg66314
VC0175692
p69640
sg66306
VJohanson-Blizzard syndrome
p69641
sa(dp69642
g66301
I57
sg66302
I2
sg66303
I20
sg66314
VC0559758
p69643
sg66306
Vmultisystem disorder
p69644
sa(dp69645
g66301
I184
sg66302
I1
sg66303
I7
sg66314
VC0243065
p69646
sg66306
Vaplasia
p69647
sa(dp69648
g66301
I170
sg66302
I1
sg66303
I10
sg66314
VC0243069
p69649
sg66306
Vhypoplasia
p69650
sa(dp69651
g66301
I132
sg66302
I3
sg66303
I33
sg66314
VC0267963
p69652
sg66306
Vexocrine pancreatic insufficiency
p69653
sasa(dp69654
g66296
V* Sixteen distinct haplotypes were detected from 258 individuals in the C. conica complex inferred from the cpDNA sequences of intergenic spacer (IGS) between atpB and rbcL, IGS between trnT and trnL, trnL intron, and IGS between trnL and trnF.
p69655
sg66298
(lp69656
(dp69657
g66301
I146
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VIGS
p69658
sa(dp69659
g66301
I186
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VtrnT
p69660
sa(dp69661
g66301
I201
sg66302
I2
sg66303
I11
sg66304
VP49184
p69662
sg66306
VtrnL intron
p69663
sa(dp69664
g66301
I146
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VIGS
p69665
sa(dp69666
g66301
I195
sg66302
I1
sg66303
I4
sg66304
VP49184
p69667
sg66306
VtrnL
p69668
sa(dp69669
g66301
I159
sg66302
I1
sg66303
I4
sg66304
VP05026
p69670
sg66306
VatpB
p69671
sa(dp69672
g66301
I195
sg66302
I1
sg66303
I4
sg66304
VP49184
p69673
sg66306
VtrnL
p69674
sasg66311
(lp69675
(dp69676
g66301
I146
sg66302
I1
sg66303
I3
sg66314
VC1306856
p69677
sg66306
VIGS
p69678
sa(dp69679
g66301
I146
sg66302
I1
sg66303
I3
sg66314
VC1306856
p69680
sg66306
VIGS
p69681
sa(dp69682
g66301
I146
sg66302
I1
sg66303
I3
sg66314
VC1306856
p69683
sg66306
VIGS
p69684
sasa(dp69685
g66296
VMaximum parsimony and Bayesian inference analyses of DNA sequence data of the plastid (the trnT-L igs, the trnL intron, two parts of the trnK intron, and the psbA-trnH igs) and nuclear genome (ITS1, 5.8S, and ITS2) showed these markers to be suitable to assess the species composition of sect.
p69686
sg66298
(lp69687
(dp69688
g66301
I158
sg66302
I2
sg66303
I13
sg66304
VP40306
p69689
sg66306
VpsbA-trnH igs
p69690
sa(dp69691
g66301
I107
sg66302
I2
sg66303
I11
sg66304
VP49184
p69692
sg66306
VtrnL intron
p69693
sa(dp69694
g66301
I91
sg66302
I2
sg66303
I10
sg66304
g11
sg66306
VtrnT-L igs
p69695
sa(dp69696
g66301
I137
sg66302
I2
sg66303
I11
sg66304
g11
sg66306
VtrnK intron
p69697
sasg66311
(lp69698
(dp69699
g66301
I98
sg66302
I1
sg66303
I3
sg66314
VC1306856
p69700
sg66306
Vigs
p69701
sa(dp69702
g66301
I98
sg66302
I1
sg66303
I3
sg66314
VC1306856
p69703
sg66306
Vigs
p69704
sasa(dp69705
g66296
VHowever, the primers for amplification of chloroplast trnD-trnT intron and rRNA IGS failed to amplify the respective region in Elymus species.
p69706
sg66298
(lp69707
(dp69708
g66301
I42
sg66302
I3
sg66303
I28
sg66304
VP27708
p69709
sg66306
Vchloroplast trnD-trnT intron
p69710
sasg66311
(lp69711
(dp69712
g66301
I25
sg66302
I1
sg66303
I13
sg66314
VC1705759
p69713
sg66306
Vamplification
p69714
sa(dp69715
g66301
I80
sg66302
I1
sg66303
I3
sg66314
VC1306856
p69716
sg66306
VIGS
p69717
sasa(dp69718
g66296
VNew primer pairs were designed and successfully amplified the cpDNA trnD-trnT intron and rRNA IGS region in Elymus species.
p69719
sg66298
(lp69720
(dp69721
g66301
I73
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VtrnT
p69722
sasg66311
(lp69723
(dp69724
g66301
I94
sg66302
I1
sg66303
I3
sg66314
VC1306856
p69725
sg66306
VIGS
p69726
sasa(dp69727
g66296
VIn the present study, we investigated the effect of taspine derivative 12k on human colorectal cancer targeted at EphrinB2 and its PDZ.
p69728
sg66298
(lp69729
(dp69730
g66301
I114
sg66302
I1
sg66303
I8
sg66304
VP52799
p69731
sg66306
VEphrinB2
p69732
sasg66311
(lp69733
(dp69734
g66301
I84
sg66302
I2
sg66303
I17
sg66314
VC1527249
p69735
sg66306
Vcolorectal cancer
p69736
sasa(dp69737
g66296
VIn this study, we investigated the mechanism of chemoresistance and epithelial-to-mesenchymal transition (EMT) in colorectal cancer involving the gain-of-function (GOF) mutant p53/ephrin-B2 signaling axis.
p69738
sg66298
(lp69739
(dp69740
g66301
I176
sg66302
I1
sg66303
I3
sg66304
VP42771
p69741
sg66306
Vp53
p69742
sasg66311
(lp69743
(dp69744
g66301
I169
sg66302
I1
sg66303
I6
sg66314
VC0596988
p69745
sg66306
Vmutant
p69746
sa(dp69747
g66301
I94
sg66302
I1
sg66303
I10
sg66314
VC0599156
p69748
sg66306
Vtransition
p69749
sa(dp69750
g66301
I114
sg66302
I2
sg66303
I17
sg66314
VC1527249
p69751
sg66306
Vcolorectal cancer
p69752
sasa(dp69753
g66296
VTwenty proteins from different signaling pathways (epidermal growth factor receptor [EGFR], phosphorylated extracellular signal regulated kinase [pERK], receptor for hyalouronic acid mediated motility [RHAMM], Raf-1 kinase inhibitor protein [RKIP], Beta-catenin, E-cadherin, phosphorylated AK transforming [pAKT], p16, p21, Ki-67, B-cell Lymphoma-2 [BCL2], vascular endothelial growth factor, apoptosis protease activating factor 1 [APAF-1], mucin1 [MUC1], ephrin B2 receptor [EphB2], matrix metalloproteinase 7 [MMP7], phosphorylated mothers against decapentaplegic 2 [pSMAD2], caudal type homeobox transcription factor 2 [CDX2], Laminin5Gamma2, and mammalian sterile 20-like kinase 1 [MST1]) involved in colorectal cancer progression were studied immunohistochemically on 220 well-characterized patients using a multiple-punch tissue microarray including 437 and 430 samples from the tumor center and the invasive front, respectively.
p69754
sg66298
(lp69755
(dp69756
g66301
I223
sg66302
I3
sg66303
I24
sg66304
VP30086
p69757
sg66306
Vinhibitor protein [RKIP]
p69758
sa(dp69759
g66301
I210
sg66302
I2
sg66303
I12
sg66304
VP04049
p69760
sg66306
VRaf-1 kinase
p69761
sa(dp69762
g66301
I51
sg66302
I4
sg66303
I32
sg66304
VP01133
p69763
sg66306
Vepidermal growth factor receptor
p69764
sa(dp69765
g66301
I201
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
V[RHAMM]
p69766
sa(dp69767
g66301
I249
sg66302
I1
sg66303
I12
sg66304
VP35222
p69768
sg66306
VBeta-catenin
p69769
sa(dp69770
g66301
I263
sg66302
I1
sg66303
I10
sg66304
VP12830
p69771
sg66306
VE-cadherin
p69772
sa(dp69773
g66301
I579
sg66302
I7
sg66303
I50
sg66304
g11
sg66306
Vcaudal type homeobox transcription factor 2 [CDX2]
p69774
sa(dp69775
g66301
I357
sg66302
I4
sg66303
I34
sg66304
g11
sg66306
Vvascular endothelial growth factor
p69776
sa(dp69777
g66301
I314
sg66302
I1
sg66303
I3
sg66304
VP42771
p69778
sg66306
Vp16
p69779
sa(dp69780
g66301
I393
sg66302
I5
sg66303
I38
sg66304
VP63123
p69781
sg66306
Vapoptosis protease activating factor 1
p69782
sa(dp69783
g66301
I324
sg66302
I1
sg66303
I5
sg66304
VP46013
p69784
sg66306
VKi-67
p69785
sa(dp69786
g66301
I319
sg66302
I1
sg66303
I3
sg66304
VP42857
p69787
sg66306
Vp21
p69788
sa(dp69789
g66301
I669
sg66302
I3
sg66303
I16
sg66304
VP27361
p69790
sg66306
V20-like kinase 1
p69791
sa(dp69792
g66301
I275
sg66302
I2
sg66303
I17
sg66304
VP55263
p69793
sg66306
Vphosphorylated AK
p69794
sa(dp69795
g66301
I457
sg66302
I8
sg66303
I61
sg66304
VP52799
p69796
sg66306
Vephrin B2 receptor [EphB2], matrix metalloproteinase 7 [MMP7]
p69797
sa(dp69798
g66301
I331
sg66302
I3
sg66303
I24
sg66304
VP10415
p69799
sg66306
VB-cell Lymphoma-2 [BCL2]
p69800
sa(dp69801
g66301
I687
sg66302
I1
sg66303
I4
sg66304
VP26927
p69802
sg66306
VMST1
p69803
sa(dp69804
g66301
I107
sg66302
I11
sg66303
I93
sg66304
VP53778
p69805
sg66306
Vextracellular signal regulated kinase [pERK], receptor for hyalouronic acid mediated motility
p69806
sasg66311
(lp69807
(dp69808
g66301
I717
sg66302
I2
sg66303
I18
sg66314
VC0178874
p69809
sg66306
Vcancer progression
p69810
sa(dp69811
g66301
I886
sg66302
I1
sg66303
I5
sg66314
VC0027651
p69812
sg66306
Vtumor
p69813
sa(dp69814
g66301
I661
sg66302
I1
sg66303
I7
sg66314
VC0678108
p69815
sg66306
Vsterile
p69816
sa(dp69817
g66301
I331
sg66302
I2
sg66303
I15
sg66314
VC0079731
p69818
sg66306
VB-cell Lymphoma
p69819
sasa(dp69820
g66296
VAbundant expression of IFN-Gamma-inducible protein 10 (IP-10) was observed on macrophages and in T cells in perimysial infiltrates of dermatomyositis (DM), and strong chemokine (C-X-C motif) receptor (CXCR)3 expression was observed on the majority of T cells in DM.
p69821
sg66298
(lp69822
(dp69823
g66301
I23
sg66302
I1
sg66303
I9
sg66304
VP01579
p69824
sg66306
VIFN-Gamma
p69825
sasg66311
(lp69826
(dp69827
g66301
I151
sg66302
I1
sg66303
I2
sg66314
VC0221056
p69828
sg66306
VDM
p69829
sa(dp69830
g66301
I119
sg66302
I1
sg66303
I11
sg66314
VC0332448
p69831
sg66306
Vinfiltrates
p69832
sa(dp69833
g66301
I134
sg66302
I1
sg66303
I15
sg66314
VC0221056
p69834
sg66306
Vdermatomyositis
p69835
sa(dp69836
g66301
I151
sg66302
I1
sg66303
I2
sg66314
VC0221056
p69837
sg66306
VDM
p69838
sasa(dp69839
g66296
VAbundant expression of IP-10 was observed on macrophages and T cells surrounding and invading non-necrotic muscle fibers in polymyositis and sporadic inclusion body myositis and in T cells in perimysial infiltrates of dermatomyositis.
p69840
sg66298
(lp69841
sg66311
(lp69842
(dp69843
g66301
I141
sg66302
I4
sg66303
I32
sg66314
VC0751713
p69844
sg66306
Vsporadic inclusion body myositis
p69845
sa(dp69846
g66301
I218
sg66302
I1
sg66303
I15
sg66314
VC0221056
p69847
sg66306
Vdermatomyositis
p69848
sa(dp69849
g66301
I203
sg66302
I1
sg66303
I11
sg66314
VC0332448
p69850
sg66306
Vinfiltrates
p69851
sa(dp69852
g66301
I124
sg66302
I1
sg66303
I12
sg66314
VC0085655
p69853
sg66306
Vpolymyositis
p69854
sasa(dp69855
g66296
VDORs were colocalized in tissue slices and synaptosomes from the canine right atrium and SA node along with cholinergic and adrenergic markers, vesicular acetylcholine transporter (VAChT), and tyrosine hydroxylase (TH).
p69856
sg66298
(lp69857
(dp69858
g66301
I144
sg66302
I3
sg66303
I35
sg66304
g11
sg66306
Vvesicular acetylcholine transporter
p69859
sa(dp69860
g66301
I181
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VVAChT
p69861
sa(dp69862
g66301
I193
sg66302
I2
sg66303
I20
sg66304
VP07101
p69863
sg66306
Vtyrosine hydroxylase
p69864
sa(dp69865
g66301
I215
sg66302
I1
sg66303
I2
sg66304
VP07101
p69866
sg66306
VTH
p69867
sasg66311
(lp69868
sa(dp69869
g66296
VFurthermore, the lack of interdigital programmed cell death and associated syndactyly was related to down-regulated gene expression of Bmp2, Bmp7, Msx1, and Msx2, which are known to promote apoptosis in the interdigital mesenchyme.
p69870
sg66298
(lp69871
(dp69872
g66301
I135
sg66302
I1
sg66303
I4
sg66304
VP12643
p69873
sg66306
VBmp2
p69874
sa(dp69875
g66301
I147
sg66302
I1
sg66303
I4
sg66304
VP28360
p69876
sg66306
VMsx1
p69877
sa(dp69878
g66301
I141
sg66302
I1
sg66303
I4
sg66304
VP18075
p69879
sg66306
VBmp7
p69880
sa(dp69881
g66301
I157
sg66302
I1
sg66303
I4
sg66304
VP35548
p69882
sg66306
VMsx2
p69883
sasg66311
(lp69884
(dp69885
g66301
I75
sg66302
I1
sg66303
I10
sg66314
VC0039075
p69886
sg66306
Vsyndactyly
p69887
sasa(dp69888
g66296
VIn this context, ERdj3 suppression may eliminate the toxic gain of function associated with polymerization of ZAAT, thus providing a potential new therapeutic approach to the treatment of AATD-related liver disease.
p69889
sg66298
(lp69890
(dp69891
g66301
I17
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VERdj3
p69892
sasg66311
(lp69893
(dp69894
g66301
I201
sg66302
I2
sg66303
I13
sg66314
VC0023895
p69895
sg66306
Vliver disease
p69896
sa(dp69897
g66301
I23
sg66302
I1
sg66303
I11
sg66314
VC0221103
p69898
sg66306
Vsuppression
p69899
sa(dp69900
g66301
I188
sg66302
I1
sg66303
I4
sg66314
VC0221757
p69901
sg66306
VAATD
p69902
sasa(dp69903
g66296
VThe CPK, aldolase, GOT, GPT, and LDH concentrations in the serum and lumbar CSF of 80 patients with neuromuscular diseases and 20 controls were measured.
p69904
sg66298
(lp69905
(dp69906
g66301
I33
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VLDH
p69907
sa(dp69908
g66301
I9
sg66302
I1
sg66303
I8
sg66304
VP05062
p69909
sg66306
Valdolase
p69910
sa(dp69911
g66301
I69
sg66302
I2
sg66303
I10
sg66304
VP04141
p69912
sg66306
Vlumbar CSF
p69913
sa(dp69914
g66301
I4
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VCPK
p69915
sa(dp69916
g66301
I24
sg66302
I1
sg66303
I3
sg66304
VP24298
p69917
sg66306
VGPT
p69918
sasg66311
(lp69919
(dp69920
g66301
I100
sg66302
I2
sg66303
I22
sg66314
VC0027868
p69921
sg66306
Vneuromuscular diseases
p69922
sasa(dp69923
g66296
VIn 60 cases of various neuromuscular diseases, serum CA-III, CPK and aldolase were measured.
p69924
sg66298
(lp69925
(dp69926
g66301
I53
sg66302
I1
sg66303
I6
sg66304
VP07451
p69927
sg66306
VCA-III
p69928
sa(dp69929
g66301
I69
sg66302
I1
sg66303
I8
sg66304
VP05062
p69930
sg66306
Valdolase
p69931
sa(dp69932
g66301
I61
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VCPK
p69933
sasg66311
(lp69934
(dp69935
g66301
I23
sg66302
I2
sg66303
I22
sg66314
VC0027868
p69936
sg66306
Vneuromuscular diseases
p69937
sasa(dp69938
g66296
VTogether, our results show that P. gingivalis activates the ERK1/2-Ets1, p38/HSP27, and PAR2/NF-kB pathways to induce proMMP9 expression, after which the proenzyme is activated by gingipains to promote cellular invasion of OSCC cell lines.
p69939
sg66298
(lp69940
(dp69941
g66301
I88
sg66302
I1
sg66303
I4
sg66304
VP55085
p69942
sg66306
VPAR2
p69943
sa(dp69944
g66301
I60
sg66302
I1
sg66303
I6
sg66304
VP27361
p69945
sg66306
VERK1/2
p69946
sa(dp69947
g66301
I77
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VHSP27
p69948
sa(dp69949
g66301
I73
sg66302
I1
sg66303
I3
sg66304
VP46108
p69950
sg66306
Vp38
p69951
sa(dp69952
g66301
I67
sg66302
I1
sg66303
I4
sg66304
VP14921
p69953
sg66306
VEts1
p69954
sasg66311
(lp69955
(dp69956
g66301
I211
sg66302
I1
sg66303
I8
sg66314
VC2699153
p69957
sg66306
Vinvasion
p69958
sasa(dp69959
g66296
VTissue sections ranging from normal mucosa to moderately-differentiated oral squamous cell carcinoma were studied using monoclonal antibodies against N-ras and ets-1 proteins.
p69960
sg66298
(lp69961
(dp69962
g66301
I152
sg66302
I1
sg66303
I3
sg66304
VP01116
p69963
sg66306
Vras
p69964
sa(dp69965
g66301
I160
sg66302
I2
sg66303
I14
sg66304
VP14921
p69966
sg66306
Vets-1 proteins
p69967
sasg66311
(lp69968
(dp69969
g66301
I77
sg66302
I3
sg66303
I23
sg66314
VC0007137
p69970
sg66306
Vsquamous cell carcinoma
p69971
sasa(dp69972
g66296
VIn a randomized controlled trial of patients with dyslipidemia assigned to either extended release niacin (ERN) alone, ERN combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (ERN-L) or placebo, niacin lowered serum phosphorus; however, it is not known if it lowers FGF23 concentrations.
p69973
sg66298
(lp69974
(dp69975
g66301
I300
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFGF23
p69976
sasg66311
(lp69977
(dp69978
g66301
I50
sg66302
I1
sg66303
I12
sg66314
VC0242339
p69979
sg66306
Vdyslipidemia
p69980
sasa(dp69981
g66296
VThe use of nicotinic acid to treat dyslipidemia is limited by induction of a "flushing" response, mediated in part by the interaction of prostaglandin D(2) (PGD(2)) with its G-protein coupled receptor, DP1 (Ptgdr).
p69982
sg66298
(lp69983
(dp69984
g66301
I174
sg66302
I3
sg66303
I26
sg66304
VP32247
p69985
sg66306
VG-protein coupled receptor
p69986
sa(dp69987
g66301
I202
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VDP1
p69988
sa(dp69989
g66301
I207
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VPtgdr
p69990
sasg66311
(lp69991
(dp69992
g66301
I78
sg66302
I1
sg66303
I8
sg66314
VC0016382
p69993
sg66306
Vflushing
p69994
sa(dp69995
g66301
I35
sg66302
I1
sg66303
I12
sg66314
VC0242339
p69996
sg66306
Vdyslipidemia
p69997
sasa(dp69998
g66296
VWe performed a post hoc data analysis of serum phosphorus concentrations that had been determined serially (at baseline and weeks 4, 8, 12, 18, and 24) among 1547 patients who had dyslipidemia and were randomly assigned in a 3:2:1 ratio to treatment with extended release niacin (ERN; 1 g/d for 4 weeks and dose advanced to 2 g/d for 20 weeks) combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (L; n = 761), ERN alone (n = 518), or placebo (n = 268).
p69999
sg66298
(lp70000
sg66311
(lp70001
(dp70002
g66301
I180
sg66302
I1
sg66303
I12
sg66314
VC0242339
p70003
sg66306
Vdyslipidemia
p70004
sasa(dp70005
g66296
VApart from primary aldosteronism, mineralocorticoid excess can be caused by congenital adrenal hyperplasia (CAH) due to mutations of the 11beta-hydroxylase and 17alpha-hydroxylase genes, by inactivating mutations of the glucocorticoid receptor gene (Chrousos syndrome), endogenous hypercortisolism (Cushing's syndrome), by mutations of the 11beta-hydroxysteroid dehydrogenase type 2 gene (apparent mineralocorticoid excess/AME) or licorice/carbenoxolone intake, mutations of the epithelial sodium channel genes (Liddle syndrome), mutations of the mineralocorticoid receptor gene (Geller syndrome), and by mutations in the WNK1, WNK4, KLHL3, CUL3 genes (pseudohypoaldosteronism type 2 or Gordon syndrome).
p70006
sg66298
(lp70007
(dp70008
g66301
I340
sg66302
I5
sg66303
I47
sg66304
VP49366
p70009
sg66306
V11beta-hydroxysteroid dehydrogenase type 2 gene
p70010
sa(dp70011
g66301
I220
sg66302
I3
sg66303
I28
sg66304
VP04150
p70012
sg66306
Vglucocorticoid receptor gene
p70013
sa(dp70014
g66301
I641
sg66302
I2
sg66303
I10
sg66304
g11
sg66306
VCUL3 genes
p70015
sa(dp70016
g66301
I622
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VWNK1
p70017
sa(dp70018
g66301
I160
sg66302
I2
sg66303
I25
sg66304
VP01893
p70019
sg66306
V17alpha-hydroxylase genes
p70020
sa(dp70021
g66301
I547
sg66302
I3
sg66303
I31
sg66304
VP08235
p70022
sg66306
Vmineralocorticoid receptor gene
p70023
sa(dp70024
g66301
I634
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VKLHL3
p70025
sa(dp70026
g66301
I628
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VWNK4
p70027
sa(dp70028
g66301
I479
sg66302
I4
sg66303
I31
sg66304
VP12830
p70029
sg66306
Vepithelial sodium channel genes
p70030
sasg66311
(lp70031
(dp70032
g66301
I11
sg66302
I2
sg66303
I21
sg66314
VC1384514
p70033
sg66306
Vprimary aldosteronism
p70034
sa(dp70035
g66301
I259
sg66302
I1
sg66303
I8
sg66314
VC0039082
p70036
sg66306
Vsyndrome
p70037
sa(dp70038
g66301
I281
sg66302
I1
sg66303
I16
sg66314
VC0010481
p70039
sg66306
Vhypercortisolism
p70040
sa(dp70041
g66301
I259
sg66302
I1
sg66303
I8
sg66314
VC0039082
p70042
sg66306
Vsyndrome
p70043
sa(dp70044
g66301
I76
sg66302
I3
sg66303
I30
sg66314
VC0001627
p70045
sg66306
Vcongenital adrenal hyperplasia
p70046
sa(dp70047
g66301
I687
sg66302
I2
sg66303
I15
sg66314
VC0220666
p70048
sg66306
VGordon syndrome
p70049
sa(dp70050
g66301
I299
sg66302
I2
sg66303
I18
sg66314
VC0010481
p70051
sg66306
VCushing's syndrome
p70052
sa(dp70053
g66301
I108
sg66302
I1
sg66303
I3
sg66314
VC0520463
p70054
sg66306
VCAH
p70055
sa(dp70056
g66301
I389
sg66302
I3
sg66303
I33
sg66314
VC2936861
p70057
sg66306
Vapparent mineralocorticoid excess
p70058
sa(dp70059
g66301
I512
sg66302
I2
sg66303
I15
sg66314
VC0221043
p70060
sg66306
VLiddle syndrome
p70061
sa(dp70062
g66301
I653
sg66302
I3
sg66303
I30
sg66314
VC1449844
p70063
sg66306
Vpseudohypoaldosteronism type 2
p70064
sasa(dp70065
g66296
VWe provide an overview and diagnostic approach to apparent mineralocorticoid excess, glucocorticoid remediable aldosteronism, familial hyperaldosteronism type 2, Liddle's syndrome, Gordon's syndrome, activating mutations of the mineralocorticoid receptor, generalized glucocorticoid resistance and hypertensive forms of congenital adrenal hyperplasia.
p70066
sg66298
(lp70067
sg66311
(lp70068
(dp70069
g66301
I181
sg66302
I2
sg66303
I17
sg66314
VC0220666
p70070
sg66306
VGordon's syndrome
p70071
sa(dp70072
g66301
I162
sg66302
I2
sg66303
I17
sg66314
VC0221043
p70073
sg66306
VLiddle's syndrome
p70074
sa(dp70075
g66301
I320
sg66302
I3
sg66303
I30
sg66314
VC0001627
p70076
sg66306
Vcongenital adrenal hyperplasia
p70077
sa(dp70078
g66301
I135
sg66302
I1
sg66303
I18
sg66314
VC0020428
p70079
sg66306
Vhyperaldosteronism
p70080
sa(dp70081
g66301
I268
sg66302
I2
sg66303
I25
sg66314
VC1841971
p70082
sg66306
Vglucocorticoid resistance
p70083
sa(dp70084
g66301
I50
sg66302
I3
sg66303
I33
sg66314
VC2936861
p70085
sg66306
Vapparent mineralocorticoid excess
p70086
sa(dp70087
g66301
I111
sg66302
I1
sg66303
I13
sg66314
VC0020428
p70088
sg66306
Valdosteronism
p70089
sasa(dp70090
g66296
VAs chronic pancreatitis (CP) is characterized by tissue infiltration of inflammatory cells, fibrosis, pancreatic neuritis and severe pain, the roles of fractalkine and CX3CR1 were investigated in CP (n=61) and normal pancreas (NP, n=21) by QRT-PCR, western blot and immunohistochemistry analyses.
p70091
sg66298
(lp70092
sg66311
(lp70093
(dp70094
g66301
I49
sg66302
I2
sg66303
I19
sg66314
VC0332448
p70095
sg66306
Vtissue infiltration
p70096
sa(dp70097
g66301
I92
sg66302
I1
sg66303
I8
sg66314
VC0016059
p70098
sg66306
Vfibrosis
p70099
sa(dp70100
g66301
I126
sg66302
I2
sg66303
I11
sg66314
VC0278140
p70101
sg66306
Vsevere pain
p70102
sa(dp70103
g66301
I113
sg66302
I1
sg66303
I8
sg66314
VC0027813
p70104
sg66306
Vneuritis
p70105
sa(dp70106
g66301
I3
sg66302
I2
sg66303
I20
sg66314
VC0149521
p70107
sg66306
Vchronic pancreatitis
p70108
sa(dp70109
g66301
I25
sg66302
I1
sg66303
I2
sg66314
VC0149521
p70110
sg66306
VCP
p70111
sa(dp70112
g66301
I25
sg66302
I1
sg66303
I2
sg66314
VC0149521
p70113
sg66306
VCP
p70114
sasa(dp70115
g66296
VNeuro-immunoreactivity for fractalkine and CX3CR1 was strongest in patients suffering from severe pain and pancreatic neuritis.
p70116
sg66298
(lp70117
(dp70118
g66301
I43
sg66302
I1
sg66303
I6
sg66304
VP78423
p70119
sg66306
VCX3CR1
p70120
sasg66311
(lp70121
(dp70122
g66301
I76
sg66302
I1
sg66303
I9
sg66314
VC0683278
p70123
sg66306
Vsuffering
p70124
sa(dp70125
g66301
I91
sg66302
I2
sg66303
I11
sg66314
VC0278140
p70126
sg66306
Vsevere pain
p70127
sa(dp70128
g66301
I118
sg66302
I1
sg66303
I8
sg66314
VC0027813
p70129
sg66306
Vneuritis
p70130
sasa(dp70131
g66296
VOur data suggest that CRISPR/Cas9-mediated NRL disruption in rods may be a promising treatment option for patients with retinitis pigmentosa.
p70132
sg66298
(lp70133
sg66311
(lp70134
(dp70135
g66301
I120
sg66302
I2
sg66303
I20
sg66314
VC0035334
p70136
sg66306
Vretinitis pigmentosa
p70137
sasa(dp70138
g66296
VThe index patients were homozygotes for both a dominant mutation of the PABPN1 gene, (GCN)13, and a recessive mutation of the NRL gene, p.R31X, on chromosome 14q11.1, leading to early-onset OPMD accompanied by night blindness and reduced visual acuity.
p70139
sg66298
(lp70140
(dp70141
g66301
I126
sg66302
I2
sg66303
I8
sg66304
VP54845
p70142
sg66306
VNRL gene
p70143
sa(dp70144
g66301
I72
sg66302
I2
sg66303
I11
sg66304
g11
sg66306
VPABPN1 gene
p70145
sasg66311
(lp70146
(dp70147
g66301
I210
sg66302
I2
sg66303
I15
sg66314
VC0028077
p70148
sg66306
Vnight blindness
p70149
sa(dp70150
g66301
I190
sg66302
I1
sg66303
I4
sg66314
VC0270952
p70151
sg66306
VOPMD
p70152
sasa(dp70153
g66296
VHomozygosity for the recessive NRL mutation described here appears to be associated with a distinct retinal phenotype, demonstrating ERG characteristics similar to those of ESCS patients.
p70154
sg66298
(lp70155
(dp70156
g66301
I31
sg66302
I2
sg66303
I12
sg66304
VP54845
p70157
sg66306
VNRL mutation
p70158
sasg66311
(lp70159
(dp70160
g66301
I173
sg66302
I1
sg66303
I4
sg66314
VC1849394
p70161
sg66306
VESCS
p70162
sasa(dp70163
g66296
VThis report expands the spectrum of NRL recessive mutations, as well as the genetic spectrum of ESCS, and indicates a new syndrome of OPMD with an ESCS-like phenotype.
p70164
sg66298
(lp70165
(dp70166
g66301
I96
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VESCS
p70167
sa(dp70168
g66301
I36
sg66302
I1
sg66303
I3
sg66304
VP54845
p70169
sg66306
VNRL
p70170
sa(dp70171
g66301
I147
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
VESCS-like
p70172
sasg66311
(lp70173
(dp70174
g66301
I96
sg66302
I1
sg66303
I4
sg66314
VC1849394
p70175
sg66306
VESCS
p70176
sa(dp70177
g66301
I122
sg66302
I1
sg66303
I8
sg66314
VC0039082
p70178
sg66306
Vsyndrome
p70179
sa(dp70180
g66301
I96
sg66302
I1
sg66303
I4
sg66314
VC1849394
p70181
sg66306
VESCS
p70182
sa(dp70183
g66301
I134
sg66302
I1
sg66303
I4
sg66314
VC0270952
p70184
sg66306
VOPMD
p70185
sasa(dp70186
g66296
VBlue light exposure of the R91W;Nrl(-/-) mouse could therefore be used to study molecular events preceding edema formation in a cone-rich environment, and thus potentially help to develop treatment strategies for edema-based complications in macular degenerations.
p70187
sg66298
(lp70188
(dp70189
g66301
I32
sg66302
I1
sg66303
I8
sg66304
VP54845
p70190
sg66306
VNrl(-/-)
p70191
sasg66311
(lp70192
(dp70193
g66301
I107
sg66302
I1
sg66303
I5
sg66314
VC0013604
p70194
sg66306
Vedema
p70195
sa(dp70196
g66301
I242
sg66302
I2
sg66303
I21
sg66314
VC0242383
p70197
sg66306
Vmacular degenerations
p70198
sa(dp70199
g66301
I107
sg66302
I1
sg66303
I5
sg66314
VC0013604
p70200
sg66306
Vedema
p70201
sasa(dp70202
g66296
VCXCL6 and CXCL2 enhanced angiogenesis by HUVECs when cultured with fibroblast cells and colon cancer cells (P &lt; 0.01).
p70203
sg66298
(lp70204
(dp70205
g66301
I0
sg66302
I1
sg66303
I5
sg66304
VP80162
p70206
sg66306
VCXCL6
p70207
sa(dp70208
g66301
I10
sg66302
I1
sg66303
I5
sg66304
VP19875
p70209
sg66306
VCXCL2
p70210
sasg66311
(lp70211
(dp70212
g66301
I88
sg66302
I2
sg66303
I12
sg66314
VC0699790
p70213
sg66306
Vcolon cancer
p70214
sasa(dp70215
g66296
VAfter quality and quantity measurements, gene expression analysis of a colorectal cancer-specific marker set with 11 genes (CA7, COL12A1, CXCL1, CXCL2, CHI3L1, GREM1, IL1B, IL1RN, IL8, MMP3, SLC5A7) was performed with array real-time PCR using Transcriptor First Strand cDNA Synthesis Kit (Roche) and RealTime ready assays on LightCycler480 System (Roche).
p70216
sg66298
(lp70217
(dp70218
g66301
I167
sg66302
I1
sg66303
I4
sg66304
VP01584
p70219
sg66306
VIL1B
p70220
sa(dp70221
g66301
I173
sg66302
I1
sg66303
I5
sg66304
VP18510
p70222
sg66306
VIL1RN
p70223
sa(dp70224
g66301
I152
sg66302
I1
sg66303
I6
sg66304
VP36222
p70225
sg66306
VCHI3L1
p70226
sa(dp70227
g66301
I160
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VGREM1
p70228
sa(dp70229
g66301
I124
sg66302
I1
sg66303
I3
sg66304
VP43166
p70230
sg66306
VCA7
p70231
sa(dp70232
g66301
I138
sg66302
I1
sg66303
I5
sg66304
VP09341
p70233
sg66306
VCXCL1
p70234
sa(dp70235
g66301
I185
sg66302
I1
sg66303
I4
sg66304
VP08254
p70236
sg66306
VMMP3
p70237
sa(dp70238
g66301
I145
sg66302
I1
sg66303
I5
sg66304
VP19875
p70239
sg66306
VCXCL2
p70240
sa(dp70241
g66301
I129
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VCOL12A1
p70242
sa(dp70243
g66301
I191
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSLC5A7
p70244
sasg66311
(lp70245
(dp70246
g66301
I71
sg66302
I2
sg66303
I17
sg66314
VC1527249
p70247
sg66306
Vcolorectal cancer
p70248
sasa(dp70249
g66296
VThese observations indicate a crucial role for TANs in the initiation and progression of CAC and suggest that the CXCL2-CXCR2 axis might be useful in reducing the risk of UC-associated colon cancer.
p70250
sg66298
(lp70251
(dp70252
g66301
I120
sg66302
I1
sg66303
I5
sg66304
VP25025
p70253
sg66306
VCXCR2
p70254
sa(dp70255
g66301
I114
sg66302
I1
sg66303
I5
sg66304
VP19875
p70256
sg66306
VCXCL2
p70257
sasg66311
(lp70258
(dp70259
g66301
I185
sg66302
I2
sg66303
I12
sg66314
VC0699790
p70260
sg66306
Vcolon cancer
p70261
sasa(dp70262
g66296
VGene expression analysis of a colorectal cancer-specific marker set (with 7 genes: COL12A1, CXCL1, CXCL2, GREM1, IL1B, IL8, SLC7A5) was performed with array real-time PCR using Transcriptor First Strand cDNA Synthesis Kit (Roche) and RealTime ready assays on LightCycler(R) 480 System (Roche).
p70263
sg66298
(lp70264
(dp70265
g66301
I99
sg66302
I1
sg66303
I5
sg66304
VP19875
p70266
sg66306
VCXCL2
p70267
sa(dp70268
g66301
I83
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VCOL12A1
p70269
sa(dp70270
g66301
I124
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSLC7A5
p70271
sa(dp70272
g66301
I113
sg66302
I1
sg66303
I4
sg66304
VP01584
p70273
sg66306
VIL1B
p70274
sa(dp70275
g66301
I92
sg66302
I1
sg66303
I5
sg66304
VP09341
p70276
sg66306
VCXCL1
p70277
sa(dp70278
g66301
I106
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VGREM1
p70279
sasg66311
(lp70280
(dp70281
g66301
I30
sg66302
I2
sg66303
I17
sg66314
VC1527249
p70282
sg66306
Vcolorectal cancer
p70283
sasa(dp70284
g66296
VIt is approved for use in all indications for which reference etanercept is approved, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis.
p70285
sg66298
(lp70286
sg66311
(lp70287
(dp70288
g66301
I211
sg66302
I2
sg66303
I23
sg66314
VC3203547
p70289
sg66306
Vaxial spondyloarthritis
p70290
sa(dp70291
g66301
I236
sg66302
I2
sg66303
I16
sg66314
VC0406317
p70292
sg66306
Vplaque psoriasis
p70293
sa(dp70294
g66301
I107
sg66302
I1
sg66303
I9
sg66314
VC0003864
p70295
sg66306
Varthritis
p70296
sa(dp70297
g66301
I236
sg66302
I2
sg66303
I16
sg66314
VC0406317
p70298
sg66306
Vplaque psoriasis
p70299
sa(dp70300
g66301
I107
sg66302
I3
sg66303
I30
sg66314
VC0553662
p70301
sg66306
Varthritis, juvenile idiopathic
p70302
sa(dp70303
g66301
I138
sg66302
I2
sg66303
I20
sg66314
VC0003872
p70304
sg66306
Varthritis, psoriatic
p70305
sa(dp70306
g66301
I170
sg66302
I2
sg66303
I22
sg66314
VC0038013
p70307
sg66306
Vankylosing spondylitis
p70308
sasa(dp70309
g66296
VWe describe the case of a boy with a TUBA1A mutation presenting with microphthalmia and congenital cataracts in addition to microcephaly and severe brain malformation.
p70310
sg66298
(lp70311
(dp70312
g66301
I37
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VTUBA1A
p70313
sasg66311
(lp70314
(dp70315
g66301
I69
sg66302
I1
sg66303
I14
sg66314
VC0026010
p70316
sg66306
Vmicrophthalmia
p70317
sa(dp70318
g66301
I148
sg66302
I2
sg66303
I18
sg66314
VC0266449
p70319
sg66306
Vbrain malformation
p70320
sa(dp70321
g66301
I88
sg66302
I2
sg66303
I20
sg66314
VC0009691
p70322
sg66306
Vcongenital cataracts
p70323
sa(dp70324
g66301
I124
sg66302
I1
sg66303
I12
sg66314
VC0025958
p70325
sg66306
Vmicrocephaly
p70326
sasa(dp70327
g66296
VWe previously showed that Decorin--a leucine-rich proteoglycan inhibiting the progression of glomerulonephritis and glomerular sclerosis--can be degraded by the ubiquitin-proteasome pathway and deubiquitinated and stabilized by ubiquitin-specific processing protease 2-69(Usp2-69).
p70328
sg66298
(lp70329
(dp70330
g66301
I26
sg66302
I1
sg66303
I7
sg66304
VP07585
p70331
sg66306
VDecorin
p70332
sa(dp70333
g66301
I161
sg66302
I1
sg66303
I9
sg66304
VP62979
p70334
sg66306
Vubiquitin
p70335
sa(dp70336
g66301
I228
sg66302
I4
sg66303
I43
sg66304
g11
sg66306
Vubiquitin-specific processing protease 2-69
p70337
sa(dp70338
g66301
I272
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VUsp2-69
p70339
sasg66311
(lp70340
(dp70341
g66301
I116
sg66302
I2
sg66303
I20
sg66314
VC0178664
p70342
sg66306
Vglomerular sclerosis
p70343
sa(dp70344
g66301
I93
sg66302
I1
sg66303
I18
sg66314
VC0017658
p70345
sg66306
Vglomerulonephritis
p70346
sasa(dp70347
g66296
VHere, we explored the effect of Usp2-69 on MC proliferation and ECM deposition by transfecting Usp2-69 plasmid into rat anti-Thy1.1 nephritis model and into cultured MCs, as well as detected Usp2-69 and Decorin in rat anti-Thy1.1 nephritis model by western blot.
p70348
sg66298
(lp70349
(dp70350
g66301
I32
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VUsp2-69
p70351
sa(dp70352
g66301
I32
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VUsp2-69
p70353
sa(dp70354
g66301
I116
sg66302
I2
sg66303
I13
sg66304
VP04216
p70355
sg66306
Vrat anti-Thy1
p70356
sa(dp70357
g66301
I203
sg66302
I1
sg66303
I7
sg66304
VP07585
p70358
sg66306
VDecorin
p70359
sa(dp70360
g66301
I32
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VUsp2-69
p70361
sasg66311
(lp70362
(dp70363
g66301
I166
sg66302
I1
sg66303
I3
sg66314
VC0036221
p70364
sg66306
VMCs
p70365
sa(dp70366
g66301
I132
sg66302
I1
sg66303
I9
sg66314
VC0027697
p70367
sg66306
Vnephritis
p70368
sa(dp70369
g66301
I46
sg66302
I1
sg66303
I13
sg66314
VC0334094
p70370
sg66306
Vproliferation
p70371
sa(dp70372
g66301
I132
sg66302
I1
sg66303
I9
sg66314
VC0027697
p70373
sg66306
Vnephritis
p70374
sasa(dp70375
g66296
VOverexpressing Usp2-69 at the early stage, but not advanced stage, of anti-Thy1.1 nephritis alleviated cell proliferation and ECM deposition, which was shown by decreased Ki-67, Collagen IV and Fibronectin detected by immunohistochemistry.
p70376
sg66298
(lp70377
(dp70378
g66301
I15
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VUsp2-69
p70379
sa(dp70380
g66301
I171
sg66302
I1
sg66303
I5
sg66304
VP46013
p70381
sg66306
VKi-67
p70382
sa(dp70383
g66301
I70
sg66302
I1
sg66303
I11
sg66304
VP04216
p70384
sg66306
Vanti-Thy1.1
p70385
sasg66311
(lp70386
(dp70387
g66301
I82
sg66302
I1
sg66303
I9
sg66314
VC0027697
p70388
sg66306
Vnephritis
p70389
sa(dp70390
g66301
I108
sg66302
I1
sg66303
I13
sg66314
VC0334094
p70391
sg66306
Vproliferation
p70392
sasa(dp70393
g66296
VIn conclusion, our findings suggest that Usp2-69 overexpression alleviates the progression of rat anti-Thy1.1 nephritis and, therefore, that exogenous plasmid injection via the renal artery enhanced by electrotransfer technology could be a promising avenue for glomerular disease research.
p70394
sg66298
(lp70395
(dp70396
g66301
I94
sg66302
I2
sg66303
I15
sg66304
VP04216
p70397
sg66306
Vrat anti-Thy1.1
p70398
sa(dp70399
g66301
I41
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VUsp2-69
p70400
sasg66311
(lp70401
(dp70402
g66301
I261
sg66302
I2
sg66303
I18
sg66314
VC0268731
p70403
sg66306
Vglomerular disease
p70404
sa(dp70405
g66301
I110
sg66302
I1
sg66303
I9
sg66314
VC0027697
p70406
sg66306
Vnephritis
p70407
sasa(dp70408
g66296
VThe proportion of USP2-69 positive area in the glomeruli was 3.90% in normal kidney, 4.96% in minimal change disease, and 4.39% in membranous glomerulonephritides, while it was 14.84% in IgA nephropathy (IgAN) (mesangial proliferative type), 16.18% in lupus nephritis (LN; diffuse proliferative type) and 15.54% in acute proliferative glomerulonephritides (APGN); the difference of the percentages between IgAN, LN (IV subtype) and APGN and normal kidney were statistically significant (P &lt; 0.05).
p70409
sg66298
(lp70410
(dp70411
g66301
I187
sg66302
I2
sg66303
I15
sg66304
VP11912
p70412
sg66306
VIgA nephropathy
p70413
sa(dp70414
g66301
I204
sg66302
I1
sg66303
I4
sg66304
VP11912
p70415
sg66306
VIgAN
p70416
sa(dp70417
g66301
I18
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VUSP2-69
p70418
sa(dp70419
g66301
I204
sg66302
I1
sg66303
I4
sg66304
VP11912
p70420
sg66306
VIgAN
p70421
sasg66311
(lp70422
(dp70423
g66301
I187
sg66302
I2
sg66303
I15
sg66314
VC0017661
p70424
sg66306
VIgA nephropathy
p70425
sa(dp70426
g66301
I269
sg66302
I1
sg66303
I2
sg66314
VC0024143
p70427
sg66306
VLN
p70428
sa(dp70429
g66301
I357
sg66302
I1
sg66303
I4
sg66314
VC0017658
p70430
sg66306
VAPGN
p70431
sa(dp70432
g66301
I221
sg66302
I1
sg66303
I13
sg66314
VC0334094
p70433
sg66306
Vproliferative
p70434
sa(dp70435
g66301
I269
sg66302
I1
sg66303
I2
sg66314
VC0024143
p70436
sg66306
VLN
p70437
sa(dp70438
g66301
I131
sg66302
I2
sg66303
I31
sg66314
VC0017665
p70439
sg66306
Vmembranous glomerulonephritides
p70440
sa(dp70441
g66301
I252
sg66302
I2
sg66303
I15
sg66314
VC0024143
p70442
sg66306
Vlupus nephritis
p70443
sa(dp70444
g66301
I204
sg66302
I1
sg66303
I4
sg66314
VC0017661
p70445
sg66306
VIgAN
p70446
sa(dp70447
g66301
I315
sg66302
I3
sg66303
I40
sg66314
VC0017658
p70448
sg66306
Vacute proliferative glomerulonephritides
p70449
sa(dp70450
g66301
I357
sg66302
I1
sg66303
I4
sg66314
VC0017658
p70451
sg66306
VAPGN
p70452
sa(dp70453
g66301
I221
sg66302
I1
sg66303
I13
sg66314
VC0334094
p70454
sg66306
Vproliferative
p70455
sa(dp70456
g66301
I204
sg66302
I1
sg66303
I4
sg66314
VC0017661
p70457
sg66306
VIgAN
p70458
sa(dp70459
g66301
I94
sg66302
I3
sg66303
I22
sg66314
VC1704320
p70460
sg66306
Vminimal change disease
p70461
sasa(dp70462
g66296
VWe analysed surviving human SN DA neurons from patients with Parkinson's disease and from controls, and detected elevated messenger RNA levels of D2-autoreceptors and GIRK2 in Parkinson's disease.
p70463
sg66298
(lp70464
(dp70465
g66301
I167
sg66302
I1
sg66303
I5
sg66304
VP48051
p70466
sg66306
VGIRK2
p70467
sasg66311
(lp70468
(dp70469
g66301
I61
sg66302
I2
sg66303
I19
sg66314
VC0030567
p70470
sg66306
VParkinson's disease
p70471
sa(dp70472
g66301
I61
sg66302
I2
sg66303
I19
sg66314
VC0030567
p70473
sg66306
VParkinson's disease
p70474
sasa(dp70475
g66296
VThus, our findings provide a novel homeostatic functional link in SN DA neurons between Cav1.3- L-type-Ca(2+) channels and D2-autoreceptor activity, controlled by NCS-1, and indicate that this adaptive signalling network (Cav1.3/NCS-1/D2/GIRK2) is also active in human SN DA neurons, and contributes to Parkinson's disease pathology.
p70476
sg66298
(lp70477
(dp70478
g66301
I88
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VCav1.3- L
p70479
sa(dp70480
g66301
I222
sg66302
I1
sg66303
I12
sg66304
VP62166
p70481
sg66306
VCav1.3/NCS-1
p70482
sa(dp70483
g66301
I238
sg66302
I1
sg66303
I5
sg66304
VP48051
p70484
sg66306
VGIRK2
p70485
sasg66311
(lp70486
(dp70487
g66301
I323
sg66302
I1
sg66303
I9
sg66314
VC0677042
p70488
sg66306
Vpathology
p70489
sa(dp70490
g66301
I303
sg66302
I2
sg66303
I19
sg66314
VC0030567
p70491
sg66306
VParkinson's disease
p70492
sasa(dp70493
g66296
VIn conclusion, sera from AIH-1 patients reacted with the amino acids in the sequence 33-37 (PQDGS) of the N-terminal of UGT1A6.
p70494
sg66298
(lp70495
(dp70496
g66301
I120
sg66302
I1
sg66303
I6
sg66304
VP35504
p70497
sg66306
VUGT1A6
p70498
sasg66311
(lp70499
sa(dp70500
g66296
VSeveral proapoptotic genes (AKT1 and AKT2) were down-regulated and antiapoptotic genes (APAF1 and BCL2L1) were up-regulated in multiple myeloma, both symptomatic and asymptomatic, compared to monoclonal gammopathy of undetermined significance.
p70501
sg66298
(lp70502
(dp70503
g66301
I98
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VBCL2L1
p70504
sa(dp70505
g66301
I37
sg66302
I1
sg66303
I4
sg66304
VP31751
p70506
sg66306
VAKT2
p70507
sa(dp70508
g66301
I28
sg66302
I1
sg66303
I4
sg66304
VP31749
p70509
sg66306
VAKT1
p70510
sasg66311
(lp70511
(dp70512
g66301
I192
sg66302
I5
sg66303
I50
sg66314
VC0026470
p70513
sg66306
Vmonoclonal gammopathy of undetermined significance
p70514
sa(dp70515
g66301
I127
sg66302
I2
sg66303
I16
sg66314
VC0026764
p70516
sg66306
Vmultiple myeloma
p70517
sasa(dp70518
g66296
VTo study the role of gene promoter hypermethylation of the putative tumour suppressor genes involved in the death-associated protein (DAP) kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma (MM).
p70519
sg66298
(lp70520
(dp70521
g66301
I155
sg66302
I1
sg66303
I3
sg66304
VP42771
p70522
sg66306
Vp53
p70523
sa(dp70524
g66301
I134
sg66302
I1
sg66303
I3
sg66304
VP51397
p70525
sg66306
VDAP
p70526
sa(dp70527
g66301
I108
sg66302
I2
sg66303
I24
sg66304
VP51397
p70528
sg66306
Vdeath-associated protein
p70529
sa(dp70530
g66301
I146
sg66302
I1
sg66303
I3
sg66304
VP03971
p70531
sg66306
Vp14
p70532
sasg66311
(lp70533
(dp70534
g66301
I187
sg66302
I2
sg66303
I16
sg66314
VC0026764
p70535
sg66306
Vmultiple myeloma
p70536
sa(dp70537
g66301
I68
sg66302
I1
sg66303
I6
sg66314
VC0027651
p70538
sg66306
Vtumour
p70539
sasa(dp70540
g66296
VThe other was a spermatocytic seminoma with focal primitive neuroectodermal differentiation: formation of Homer-Wright rosettes and perivascular pseudorosettes, with immunoreactivity for S-100 protein, neuron-specific enolase, synaptophysin, neurofilament-68 kDa, microtubule-associated protein 2, and vimentin.
p70541
sg66298
(lp70542
(dp70543
g66301
I264
sg66302
I3
sg66303
I32
sg66304
VP11137
p70544
sg66306
Vmicrotubule-associated protein 2
p70545
sa(dp70546
g66301
I187
sg66302
I2
sg66303
I13
sg66304
VP04271
p70547
sg66306
VS-100 protein
p70548
sa(dp70549
g66301
I202
sg66302
I2
sg66303
I23
sg66304
VP09104
p70550
sg66306
Vneuron-specific enolase
p70551
sa(dp70552
g66301
I227
sg66302
I1
sg66303
I13
sg66304
VP08247
p70553
sg66306
Vsynaptophysin
p70554
sasg66311
(lp70555
(dp70556
g66301
I16
sg66302
I2
sg66303
I22
sg66314
VC0334517
p70557
sg66306
Vspermatocytic seminoma
p70558
sasa(dp70559
g66296
VIn addition to Rett syndrome and breast/ovarian cancer observed in other studies, we report evidence for the first time, to our knowledge, that overexpression of ubiquinol-cytochrome c reductase core protein I might affect mitochondrial morphology and/or physiology and lead to development of obesity and related conditions.
p70560
sg66298
(lp70561
(dp70562
g66301
I162
sg66302
I6
sg66303
I47
sg66304
VP99999
p70563
sg66306
Vubiquinol-cytochrome c reductase core protein I
p70564
sasg66311
(lp70565
(dp70566
g66301
I293
sg66302
I1
sg66303
I7
sg66314
VC0028754
p70567
sg66306
Vobesity
p70568
sa(dp70569
g66301
I15
sg66302
I2
sg66303
I13
sg66314
VC0035372
p70570
sg66306
VRett syndrome
p70571
sa(dp70572
g66301
I40
sg66302
I2
sg66303
I14
sg66314
VC1140680
p70573
sg66306
Vovarian cancer
p70574
sasa(dp70575
g66296
VFrom the therapeutic standpoint, colitis-associated cancers are associated with a lower prevalence of KRAS mutations than the sporadic variant.
p70576
sg66298
(lp70577
(dp70578
g66301
I102
sg66302
I1
sg66303
I4
sg66304
VP01116
p70579
sg66306
VKRAS
p70580
sasg66311
(lp70581
(dp70582
g66301
I33
sg66302
I1
sg66303
I7
sg66314
VC0009319
p70583
sg66306
Vcolitis
p70584
sa(dp70585
g66301
I52
sg66302
I1
sg66303
I7
sg66314
VC0006826
p70586
sg66306
Vcancers
p70587
sasa(dp70588
g66296
VIn a murine acute systemic candidiasis model, C albicans strongly stimulated hepcidin, accompanied by a major reduction in transferrin saturation.
p70589
sg66298
(lp70590
(dp70591
g66301
I123
sg66302
I1
sg66303
I11
sg66304
VP02787
p70592
sg66306
Vtransferrin
p70593
sasg66311
(lp70594
(dp70595
g66301
I18
sg66302
I2
sg66303
I20
sg66314
VC0153252
p70596
sg66306
Vsystemic candidiasis
p70597
sasa(dp70598
g66296
VOn the other hand, iron overload (iron saturated transferrin) is a serious risk factor for candidiasis in newborn and in leukemic patients.
p70599
sg66298
(lp70600
(dp70601
g66301
I49
sg66302
I1
sg66303
I11
sg66304
VP02787
p70602
sg66306
Vtransferrin
p70603
sasg66311
(lp70604
(dp70605
g66301
I19
sg66302
I2
sg66303
I13
sg66314
VC0282193
p70606
sg66306
Viron overload
p70607
sa(dp70608
g66301
I91
sg66302
I1
sg66303
I11
sg66314
VC0006840
p70609
sg66306
Vcandidiasis
p70610
sasa(dp70611
g66296
VIt has been suggested that blockade of the Na+/H+ exchanger (NHE1) can prevent atrial fibrillation (AF)-induced electrical remodeling and the development of AF.
p70612
sg66298
(lp70613
(dp70614
g66301
I61
sg66302
I1
sg66303
I4
sg66304
VP19634
p70615
sg66306
VNHE1
p70616
sasg66311
(lp70617
(dp70618
g66301
I79
sg66302
I2
sg66303
I19
sg66314
VC0004238
p70619
sg66306
Vatrial fibrillation
p70620
sa(dp70621
g66301
I100
sg66302
I1
sg66303
I2
sg66314
VC0232197
p70622
sg66306
VAF
p70623
sa(dp70624
g66301
I100
sg66302
I1
sg66303
I2
sg66314
VC0232197
p70625
sg66306
VAF
p70626
sasa(dp70627
g66296
VThe case of a 13-year-old boy is presented and the diagnostic process discussed especially the differentiation between trance states and epilepsy.
p70628
sg66298
(lp70629
sg66311
(lp70630
(dp70631
g66301
I137
sg66302
I1
sg66303
I8
sg66314
VC0014544
p70632
sg66306
Vepilepsy
p70633
sa(dp70634
g66301
I119
sg66302
I1
sg66303
I6
sg66314
VC0855240
p70635
sg66306
Vtrance
p70636
sasa(dp70637
g66296
VThe phenotype is usually T-B+NK+ SCID with lymphopenia where the clinical findings may be mild (CD3Gamma) or severe (CD3Delta, Epsilon, Zeta) owing to the underlying molecular defect.
p70638
sg66298
(lp70639
(dp70640
g66301
I25
sg66302
I2
sg66303
I12
sg66304
VP31785
p70641
sg66306
VT-B+NK+ SCID
p70642
sasg66311
(lp70643
(dp70644
g66301
I43
sg66302
I1
sg66303
I11
sg66314
VC0024312
p70645
sg66306
Vlymphopenia
p70646
sa(dp70647
g66301
I65
sg66302
I2
sg66303
I17
sg66314
VC0037088
p70648
sg66306
Vclinical findings
p70649
sa(dp70650
g66301
I33
sg66302
I1
sg66303
I4
sg66314
VC0085110
p70651
sg66306
VSCID
p70652
sasa(dp70653
g66296
VIn contrast, all reported human complete CD3delta (or CD3epsilon) deficiencies are in infants with life-threatening SCID and very severe alphabeta and gammadelta T lymphocytopenia.
p70654
sg66298
(lp70655
sg66311
(lp70656
(dp70657
g66301
I116
sg66302
I1
sg66303
I4
sg66314
VC0085110
p70658
sg66306
VSCID
p70659
sa(dp70660
g66301
I164
sg66302
I1
sg66303
I15
sg66314
VC0024312
p70661
sg66306
Vlymphocytopenia
p70662
sasa(dp70663
g66296
VAlthough clozapine, olanzapine, and other atypical antipsychotic drugs (APDs) have fewer extrapyramidal side effects, they have serious metabolic side effects such as substantial weight gain, intra-abdominal obesity, and type 2 diabetes mellitus.
p70664
sg66298
(lp70665
sg66311
(lp70666
(dp70667
g66301
I221
sg66302
I4
sg66303
I24
sg66314
VC0011860
p70668
sg66306
Vtype 2 diabetes mellitus
p70669
sa(dp70670
g66301
I198
sg66302
I2
sg66303
I17
sg66314
VC0311277
p70671
sg66306
Vabdominal obesity
p70672
sasa(dp70673
g66296
VGiven that most patients with mental disorders face chronic, even life-long, treatment with APDs, the risks of weight gain/obesity and other metabolic symptoms are major considerations for APD maintenance treatment.
p70674
sg66298
(lp70675
sg66311
(lp70676
(dp70677
g66301
I141
sg66302
I2
sg66303
I18
sg66314
VC0476237
p70678
sg66306
Vmetabolic symptoms
p70679
sa(dp70680
g66301
I47
sg66302
I1
sg66303
I4
sg66314
VC3160739
p70681
sg66306
Vface
p70682
sa(dp70683
g66301
I30
sg66302
I2
sg66303
I16
sg66314
VC0004936
p70684
sg66306
Vmental disorders
p70685
sa(dp70686
g66301
I123
sg66302
I1
sg66303
I7
sg66314
VC0028754
p70687
sg66306
Vobesity
p70688
sasa(dp70689
g66296
VAlthough offering many benefits for several psychiatric disorders, antipsychotic drugs (APDs) as a class have a major liability in their tendency to promote adiposity, obesity, and metabolic dysregulation in an already metabolically vulnerable population.
p70690
sg66298
(lp70691
sg66311
(lp70692
(dp70693
g66301
I168
sg66302
I1
sg66303
I7
sg66314
VC0028754
p70694
sg66306
Vobesity
p70695
sa(dp70696
g66301
I44
sg66302
I2
sg66303
I21
sg66314
VC0004936
p70697
sg66306
Vpsychiatric disorders
p70698
sa(dp70699
g66301
I157
sg66302
I1
sg66303
I9
sg66314
VC0028754
p70700
sg66306
Vadiposity
p70701
sasa(dp70702
g66296
VTo describe the association between obesity and the use of antipsychotic drugs (APDs) in adult outpatients followed-up on in five Primary Care settings.
p70703
sg66298
(lp70704
sg66311
(lp70705
(dp70706
g66301
I36
sg66302
I1
sg66303
I7
sg66314
VC0028754
p70707
sg66306
Vobesity
p70708
sasa(dp70709
g66296
VObesity was associated with the use of APDs [OR = 1.5 (CI: 1.3-1.8)], hypertension [OR = 2.4 (CI: 2.2-2.5)], diabetes [OR = 1.4 (CI: 1.3-1.5)] and dyslipidemia [OR = 1.3 (CI: 1.2-1.4)], p &lt; 0.0001 in all cases.
p70710
sg66298
(lp70711
sg66311
(lp70712
(dp70713
g66301
I0
sg66302
I1
sg66303
I7
sg66314
VC0028754
p70714
sg66306
VObesity
p70715
sa(dp70716
g66301
I147
sg66302
I1
sg66303
I12
sg66314
VC0242339
p70717
sg66306
Vdyslipidemia
p70718
sa(dp70719
g66301
I70
sg66302
I1
sg66303
I12
sg66314
VC0020538
p70720
sg66306
Vhypertension
p70721
sa(dp70722
g66301
I109
sg66302
I1
sg66303
I8
sg66314
VC0011849
p70723
sg66306
Vdiabetes
p70724
sasa(dp70725
g66296
VObesity was associated with the use of APDs, regardless of the type of drug, and with the presence of hypertension, diabetes and dyslipidemia.
p70726
sg66298
(lp70727
sg66311
(lp70728
(dp70729
g66301
I0
sg66302
I1
sg66303
I7
sg66314
VC0028754
p70730
sg66306
VObesity
p70731
sa(dp70732
g66301
I116
sg66302
I1
sg66303
I8
sg66314
VC0011849
p70733
sg66306
Vdiabetes
p70734
sa(dp70735
g66301
I129
sg66302
I1
sg66303
I12
sg66314
VC0242339
p70736
sg66306
Vdyslipidemia
p70737
sa(dp70738
g66301
I102
sg66302
I1
sg66303
I12
sg66314
VC0020538
p70739
sg66306
Vhypertension
p70740
sasa(dp70741
g66296
VHigher DARs were associated with lower rates of moderate or severe paravalvular aortic regurgitation: DAR &lt;=10%, 17.6%; DAR 10% to 15%, 9.9%; DAR 15% to 20%, 6.3%; and DAR &gt;20%, 4.9%; P&lt;0.001.
p70742
sg66298
(lp70743
(dp70744
g66301
I7
sg66302
I1
sg66303
I4
sg66304
VP14868
p70745
sg66306
VDARs
p70746
sasg66311
(lp70747
(dp70748
g66301
I7
sg66302
I1
sg66303
I3
sg66314
VC0022595
p70749
sg66306
VDAR
p70750
sa(dp70751
g66301
I7
sg66302
I1
sg66303
I3
sg66314
VC0022595
p70752
sg66306
VDAR
p70753
sa(dp70754
g66301
I80
sg66302
I2
sg66303
I20
sg66314
VC0003504
p70755
sg66306
Vaortic regurgitation
p70756
sa(dp70757
g66301
I7
sg66302
I1
sg66303
I3
sg66314
VC0022595
p70758
sg66306
VDAR
p70759
sa(dp70760
g66301
I7
sg66302
I1
sg66303
I3
sg66314
VC0022595
p70761
sg66306
VDAR
p70762
sasa(dp70763
g66296
VIn 1990, Hopkins and Ruiz-Riben stated that the target date o f the end o f 1995 for the eradication of dracunculiasis is unrealistic only if it is judged to be unimportant.
p70764
sg66298
(lp70765
sg66311
(lp70766
(dp70767
g66301
I104
sg66302
I1
sg66303
I14
sg66314
VC0013100
p70768
sg66306
Vdracunculiasis
p70769
sasa(dp70770
g66296
VDLL1 influence drug resistance of small cell lung cancer through activating transcription of downstream genes HES1 and HEY1.
p70771
sg66298
(lp70772
(dp70773
g66301
I119
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VHEY1
p70774
sa(dp70775
g66301
I110
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VHES1
p70776
sa(dp70777
g66301
I0
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VDLL1
p70778
sasg66311
(lp70779
(dp70780
g66301
I34
sg66302
I4
sg66303
I22
sg66314
VC0149925
p70781
sg66306
Vsmall cell lung cancer
p70782
sasa(dp70783
g66296
VIn this study, we showed that a high percentage of lung cancer lines expressed Jagged1, Notch receptors, and their transcriptional target genes (HES1, Hey1), suggesting that the Notch pathway plays an important role in lung cancer biology.
p70784
sg66298
(lp70785
(dp70786
g66301
I145
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VHES1
p70787
sa(dp70788
g66301
I79
sg66302
I1
sg66303
I7
sg66304
VP78504
p70789
sg66306
VJagged1
p70790
sa(dp70791
g66301
I151
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VHey1
p70792
sa(dp70793
g66301
I88
sg66302
I2
sg66303
I15
sg66304
g11
sg66306
VNotch receptors
p70794
sasg66311
(lp70795
(dp70796
g66301
I51
sg66302
I2
sg66303
I11
sg66314
VC0684249
p70797
sg66306
Vlung cancer
p70798
sa(dp70799
g66301
I51
sg66302
I2
sg66303
I11
sg66314
VC0684249
p70800
sg66306
Vlung cancer
p70801
sasa(dp70802
g66296
VALPs easily insert in the outer leaflet of the plasma membrane and cross the membrane via an ATP-dependent CDC50a-containing 'flippase' complex (in carcinoma cells), or are internalized by lipid raft-dependent endocytosis (in lymphoma/leukemic cells).
p70803
sg66298
(lp70804
(dp70805
g66301
I107
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCDC50a
p70806
sa(dp70807
g66301
I125
sg66302
I1
sg66303
I9
sg66304
VP98196
p70808
sg66306
V'flippase
p70809
sa(dp70810
g66301
I0
sg66302
I1
sg66303
I4
sg66304
VP03973
p70811
sg66306
VALPs
p70812
sasg66311
(lp70813
(dp70814
g66301
I148
sg66302
I1
sg66303
I9
sg66314
VC0007097
p70815
sg66306
Vcarcinoma
p70816
sa(dp70817
g66301
I226
sg66302
I1
sg66303
I8
sg66314
VC0024299
p70818
sg66306
Vlymphoma
p70819
sa(dp70820
g66301
I0
sg66302
I1
sg66303
I4
sg66314
VC1328840
p70821
sg66306
VALPs
p70822
sasa(dp70823
g66296
VLevels of 27 transcripts were investigated as potential novel markers for prostate cancer, including genes encoding plasma membrane proteins (ADAM2, ELOVL5, MARCKSL1, RAMP1, TMEM30A, and TMEM66); secreted proteins (SPON2, TMEM30A, TMEM66, and truncated TMEFF2 (called POP4)); intracellular proteins (CAMK2N1, DHCR24, GLO1, NGFRAP1, PGK1, PSMA7, SBDS, and YWHAQ); and noncoding transcripts (POP1 (100 kb) from mRNA AK000023), POP2 (4 kb from mRNA AL832227), POP3 (50 kb from EST CFI40309), POP5 (intron of NCAM2, accession DO668384), POP6 (intron of FHIT), POP7 (intron of TNFAIP8), POP8 (intron of EFNA5), POP9 (intron of DSTN), POP10 (intron of ADAM2, accession DO668396), POP11 (87kb from EST BG194644), and POP12 (intron of EST BQ226050)).
p70824
sg66298
(lp70825
(dp70826
g66301
I489
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VPOP5
p70827
sa(dp70828
g66301
I149
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VELOVL5
p70829
sa(dp70830
g66301
I332
sg66302
I1
sg66303
I4
sg66304
VP00558
p70831
sg66306
VPGK1
p70832
sa(dp70833
g66301
I174
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VTMEM30A
p70834
sa(dp70835
g66301
I582
sg66302
I4
sg66303
I22
sg66304
VP52803
p70836
sg66306
VPOP8 (intron of EFNA5)
p70837
sa(dp70838
g66301
I157
sg66302
I1
sg66303
I8
sg66304
VP49006
p70839
sg66306
VMARCKSL1
p70840
sa(dp70841
g66301
I142
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VADAM2
p70842
sa(dp70843
g66301
I309
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VDHCR24
p70844
sa(dp70845
g66301
I300
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VCAMK2N1
p70846
sa(dp70847
g66301
I317
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGLO1
p70848
sa(dp70849
g66301
I142
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VADAM2
p70850
sa(dp70851
g66301
I187
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VTMEM66
p70852
sa(dp70853
g66301
I323
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VNGFRAP1
p70854
sa(dp70855
g66301
I556
sg66302
I4
sg66303
I24
sg66304
g11
sg66306
VPOP7 (intron of TNFAIP8)
p70856
sa(dp70857
g66301
I533
sg66302
I4
sg66303
I21
sg66304
VP49789
p70858
sg66306
VPOP6 (intron of FHIT)
p70859
sa(dp70860
g66301
I505
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VNCAM2
p70861
sa(dp70862
g66301
I167
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VRAMP1
p70863
sa(dp70864
g66301
I268
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VPOP4
p70865
sa(dp70866
g66301
I457
sg66302
I6
sg66303
I29
sg66304
VP49888
p70867
sg66306
VPOP3 (50 kb from EST CFI40309
p70868
sa(dp70869
g66301
I174
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VTMEM30A
p70870
sa(dp70871
g66301
I187
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VTMEM66
p70872
sa(dp70873
g66301
I116
sg66302
I3
sg66303
I24
sg66304
VP35968
p70874
sg66306
Vplasma membrane proteins
p70875
sa(dp70876
g66301
I338
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VPSMA7
p70877
sa(dp70878
g66301
I215
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSPON2
p70879
sa(dp70880
g66301
I390
sg66302
I6
sg66303
I32
sg66304
g11
sg66306
VPOP1 (100 kb) from mRNA AK000023
p70881
sasg66311
(lp70882
(dp70883
g66301
I74
sg66302
I2
sg66303
I15
sg66314
VC0600139
p70884
sg66306
Vprostate cancer
p70885
sasa(dp70886
g66296
VLevels of CAMK2N1, GLO1, SDBS, and TMEM30A transcripts tended to be increased in primary prostate cancer from patients who later had biochemical failure.
p70887
sg66298
(lp70888
(dp70889
g66301
I10
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VCAMK2N1
p70890
sa(dp70891
g66301
I35
sg66302
I2
sg66303
I19
sg66304
g11
sg66306
VTMEM30A transcripts
p70892
sa(dp70893
g66301
I19
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGLO1
p70894
sasg66311
(lp70895
(dp70896
g66301
I89
sg66302
I2
sg66303
I15
sg66314
VC0600139
p70897
sg66306
Vprostate cancer
p70898
sasa(dp70899
g66296
VHuman CDC50A mRNA was expressed in embryonic stem (ES) cells, placenta, brain and chondrosarcoma, while CDC50B mRNA was expressed in pancreatic islet, kidney, prostate as well as in lung carcinoid, parathyroid tumor, bladder tumor, meningioma and pancreatic cancer.
p70900
sg66298
(lp70901
(dp70902
g66301
I0
sg66302
I3
sg66303
I17
sg66304
g11
sg66306
VHuman CDC50A mRNA
p70903
sa(dp70904
g66301
I104
sg66302
I2
sg66303
I11
sg66304
g11
sg66306
VCDC50B mRNA
p70905
sasg66311
(lp70906
(dp70907
g66301
I198
sg66302
I2
sg66303
I17
sg66314
VC0030521
p70908
sg66306
Vparathyroid tumor
p70909
sa(dp70910
g66301
I247
sg66302
I2
sg66303
I17
sg66314
VC0235974
p70911
sg66306
Vpancreatic cancer
p70912
sa(dp70913
g66301
I232
sg66302
I1
sg66303
I10
sg66314
VC0025286
p70914
sg66306
Vmeningioma
p70915
sa(dp70916
g66301
I217
sg66302
I2
sg66303
I13
sg66314
VC0005695
p70917
sg66306
Vbladder tumor
p70918
sa(dp70919
g66301
I82
sg66302
I1
sg66303
I14
sg66314
VC0008479
p70920
sg66306
Vchondrosarcoma
p70921
sa(dp70922
g66301
I187
sg66302
I1
sg66303
I9
sg66314
VC0007095
p70923
sg66306
Vcarcinoid
p70924
sasa(dp70925
g66296
VFinally, ephrin-B2/Fc promoted angiogenesis in vivo in corneal neovascularization and Matrigel plug assays in adult mice, whereas LY294002 reduced angiogenesis in Matrigel that was induced by ephrin-B2/Fc.
p70926
sg66298
(lp70927
(dp70928
g66301
I9
sg66302
I1
sg66303
I9
sg66304
VP52799
p70929
sg66306
Vephrin-B2
p70930
sasg66311
(lp70931
(dp70932
g66301
I55
sg66302
I2
sg66303
I26
sg66314
VC0085109
p70933
sg66306
Vcorneal neovascularization
p70934
sasa(dp70935
g66296
VMutations of SYNGAP1 have been frequently linked to brain disorders including intellectual disability, autisms, and seizure.
p70936
sg66298
(lp70937
(dp70938
g66301
I13
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSYNGAP1
p70939
sasg66311
(lp70940
(dp70941
g66301
I116
sg66302
I1
sg66303
I7
sg66314
VC0036572
p70942
sg66306
Vseizure
p70943
sa(dp70944
g66301
I103
sg66302
I1
sg66303
I7
sg66314
VC0004352
p70945
sg66306
Vautisms
p70946
sa(dp70947
g66301
I52
sg66302
I2
sg66303
I15
sg66314
VC0006111
p70948
sg66306
Vbrain disorders
p70949
sa(dp70950
g66301
I78
sg66302
I2
sg66303
I23
sg66314
VC0025362
p70951
sg66306
Vintellectual disability
p70952
sasa(dp70953
g66296
VFurthermore, the LTP-regulated phosphoproteins, which included the scaffold proteins Shank3, Syngap1, Dlgap1, and Dlg4, represented the "PSD risk" for schizophrenia and autism spectrum disorder, such that without these proteins in the analysis, the association with the PSD and these two psychiatric diseases was not present.
p70954
sg66298
(lp70955
(dp70956
g66301
I102
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VDlgap1
p70957
sa(dp70958
g66301
I114
sg66302
I1
sg66303
I4
sg66304
VP78352
p70959
sg66306
VDlg4
p70960
sa(dp70961
g66301
I137
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPSD
p70962
sa(dp70963
g66301
I85
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VShank3
p70964
sa(dp70965
g66301
I93
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSyngap1
p70966
sasg66311
(lp70967
(dp70968
g66301
I151
sg66302
I1
sg66303
I13
sg66314
VC0036341
p70969
sg66306
Vschizophrenia
p70970
sa(dp70971
g66301
I169
sg66302
I3
sg66303
I24
sg66314
VC1510586
p70972
sg66306
Vautism spectrum disorder
p70973
sasa(dp70974
g66296
VDevelopmental delay was the first manifestation of SYNGAP1-related encephalopathy; intellectual disability became progressively obvious and was associated with autistic behaviours in eight patients.
p70975
sg66298
(lp70976
(dp70977
g66301
I51
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSYNGAP1
p70978
sasg66311
(lp70979
(dp70980
g66301
I0
sg66302
I2
sg66303
I19
sg66314
VC0424605
p70981
sg66306
VDevelopmental delay
p70982
sa(dp70983
g66301
I83
sg66302
I2
sg66303
I23
sg66314
VC0025362
p70984
sg66306
Vintellectual disability
p70985
sa(dp70986
g66301
I160
sg66302
I1
sg66303
I8
sg66314
VC0004352
p70987
sg66306
Vautistic
p70988
sa(dp70989
g66301
I67
sg66302
I1
sg66303
I14
sg66314
VC0085584
p70990
sg66306
Vencephalopathy
p70991
sasa(dp70992
g66296
VThe only two genes upregulated across all transcriptome-wide PE analyses to date (microarray, RNA-Seq and PAS-Seq) are NRIP1 (RIP140), a transcriptional co-regulator linked to metabolic syndromes associated with obesity, and Flt1.
p70993
sg66298
(lp70994
(dp70995
g66301
I126
sg66302
I1
sg66303
I6
sg66304
VP48552
p70996
sg66306
VRIP140
p70997
sa(dp70998
g66301
I106
sg66302
I1
sg66303
I7
sg66304
VP05165
p70999
sg66306
VPAS-Seq
p71000
sa(dp71001
g66301
I119
sg66302
I1
sg66303
I5
sg66304
VP48552
p71002
sg66306
VNRIP1
p71003
sa(dp71004
g66301
I225
sg66302
I1
sg66303
I4
sg66304
VP17948
p71005
sg66306
VFlt1
p71006
sasg66311
(lp71007
(dp71008
g66301
I212
sg66302
I1
sg66303
I7
sg66314
VC0028754
p71009
sg66306
Vobesity
p71010
sa(dp71011
g66301
I176
sg66302
I2
sg66303
I19
sg66314
VC0524620
p71012
sg66306
Vmetabolic syndromes
p71013
sasa(dp71014
g66296
VFurthermore, endothelial Flt1 gene deletion enhanced the effect of VEGFB, activating the thermogenic program in subcutaneous adipose tissue, which increased the basal metabolic rate, thus preventing diet-induced obesity and related metabolic complications.
p71015
sg66298
(lp71016
(dp71017
g66301
I25
sg66302
I1
sg66303
I4
sg66304
VP17948
p71018
sg66306
VFlt1
p71019
sa(dp71020
g66301
I67
sg66302
I1
sg66303
I5
sg66304
VP49765
p71021
sg66306
VVEGFB
p71022
sasg66311
(lp71023
(dp71024
g66301
I212
sg66302
I1
sg66303
I7
sg66314
VC0028754
p71025
sg66306
Vobesity
p71026
sa(dp71027
g66301
I30
sg66302
I2
sg66303
I13
sg66314
VC1442161
p71028
sg66306
Vgene deletion
p71029
sasa(dp71030
g66296
V(2016) demonstrate that VEGF-B, by displacing VEGF-A from VEGFR1 and activating VEGFR2, increases adipose tissue vascularity, improves insulin sensitivity, diminishes obesity, and alleviates metabolic syndrome.
p71031
sg66298
(lp71032
(dp71033
g66301
I135
sg66302
I1
sg66303
I7
sg66304
VP01308
p71034
sg66306
Vinsulin
p71035
sa(dp71036
g66301
I58
sg66302
I1
sg66303
I6
sg66304
VP17948
p71037
sg66306
VVEGFR1
p71038
sa(dp71039
g66301
I24
sg66302
I1
sg66303
I6
sg66304
VP49765
p71040
sg66306
VVEGF-B
p71041
sa(dp71042
g66301
I69
sg66302
I2
sg66303
I17
sg66304
VP35968
p71043
sg66306
Vactivating VEGFR2
p71044
sasg66311
(lp71045
(dp71046
g66301
I135
sg66302
I2
sg66303
I19
sg66314
VC0920563
p71047
sg66306
Vinsulin sensitivity
p71048
sa(dp71049
g66301
I191
sg66302
I2
sg66303
I18
sg66314
VC0524620
p71050
sg66306
Vmetabolic syndrome
p71051
sa(dp71052
g66301
I167
sg66302
I1
sg66303
I7
sg66314
VC0028754
p71053
sg66306
Vobesity
p71054
sasa(dp71055
g66296
VHere, we hypothesized that increased activity of PlGF/VEGFR-1 signaling mediates obesity-induced tumor progression by augmenting tumor angiogenesis and TAM recruitment/activity.
p71056
sg66298
(lp71057
(dp71058
g66301
I49
sg66302
I1
sg66303
I4
sg66304
VP49763
p71059
sg66306
VPlGF
p71060
sa(dp71061
g66301
I54
sg66302
I1
sg66303
I7
sg66304
VP17948
p71062
sg66306
VVEGFR-1
p71063
sasg66311
(lp71064
(dp71065
g66301
I81
sg66302
I1
sg66303
I7
sg66314
VC0028754
p71066
sg66306
Vobesity
p71067
sa(dp71068
g66301
I156
sg66302
I1
sg66303
I11
sg66314
VC0271510
p71069
sg66306
Vrecruitment
p71070
sa(dp71071
g66301
I97
sg66302
I2
sg66303
I17
sg66314
VC0178874
p71072
sg66306
Vtumor progression
p71073
sa(dp71074
g66301
I129
sg66302
I2
sg66303
I18
sg66314
VC1519670
p71075
sg66306
Vtumor angiogenesis
p71076
sa(dp71077
g66301
I152
sg66302
I1
sg66303
I3
sg66314
VC1834582
p71078
sg66306
VTAM
p71079
sasa(dp71080
g66296
VAblation of VEGFR-1 signaling prevented obesity-induced tumor progression and shifted the tumor immune environment toward an antitumor phenotype.
p71081
sg66298
(lp71082
(dp71083
g66301
I12
sg66302
I1
sg66303
I7
sg66304
VP17948
p71084
sg66306
VVEGFR-1
p71085
sasg66311
(lp71086
(dp71087
g66301
I56
sg66302
I1
sg66303
I5
sg66314
VC0027651
p71088
sg66306
Vtumor
p71089
sa(dp71090
g66301
I56
sg66302
I2
sg66303
I17
sg66314
VC0178874
p71091
sg66306
Vtumor progression
p71092
sa(dp71093
g66301
I40
sg66302
I1
sg66303
I7
sg66314
VC0028754
p71094
sg66306
Vobesity
p71095
sasa(dp71096
g66296
VTargeting PlGF/VEGFR-1 signaling reprograms the tumor immune microenvironment and inhibits obesity-induced acceleration of tumor progression.
p71097
sg66298
(lp71098
(dp71099
g66301
I15
sg66302
I1
sg66303
I7
sg66304
VP17948
p71100
sg66306
VVEGFR-1
p71101
sa(dp71102
g66301
I10
sg66302
I1
sg66303
I4
sg66304
VP49763
p71103
sg66306
VPlGF
p71104
sasg66311
(lp71105
(dp71106
g66301
I123
sg66302
I2
sg66303
I17
sg66314
VC0178874
p71107
sg66306
Vtumor progression
p71108
sa(dp71109
g66301
I91
sg66302
I1
sg66303
I7
sg66314
VC0028754
p71110
sg66306
Vobesity
p71111
sa(dp71112
g66301
I48
sg66302
I1
sg66303
I5
sg66314
VC0027651
p71113
sg66306
Vtumor
p71114
sasa(dp71115
g66296
VIn a group of unmedicated patients with major depressive disorder matched for age with normal control group, we found a significant increase in 5-HT (100 microM)-induced accumulation of IP-1 (150 +/- 7% of basal for depressed patients, 132 +/- 3% for controls).
p71116
sg66298
(lp71117
sg66311
(lp71118
(dp71119
g66301
I40
sg66302
I3
sg66303
I25
sg66314
VC1269683
p71120
sg66306
Vmajor depressive disorder
p71121
sasa(dp71122
g66296
VIt is hoped that the same will happen in other MPN with specific genetic alterations: polycythemia vera (JAK2 V617F and other JAK2 mutations), essential thrombocythemia (JAK2V617F and MPL515 mutations), primary myelofibrosis (JAK2 V617F and MPL515 mutations), systemic mastocytosis (KITD816V and other KIT mutations) and stem cell leukaemia/lymphoma (ZNF198-FGFR1 and other FGFR1 fusion genes).
p71123
sg66298
(lp71124
(dp71125
g66301
I126
sg66302
I2
sg66303
I14
sg66304
g11
sg66306
VJAK2 mutations
p71126
sa(dp71127
g66301
I302
sg66302
I2
sg66303
I13
sg66304
VP10721
p71128
sg66306
VKIT mutations
p71129
sa(dp71130
g66301
I374
sg66302
I3
sg66303
I18
sg66304
VP35637
p71131
sg66306
VFGFR1 fusion genes
p71132
sa(dp71133
g66301
I105
sg66302
I2
sg66303
I10
sg66304
g11
sg66306
VJAK2 V617F
p71134
sa(dp71135
g66301
I105
sg66302
I2
sg66303
I10
sg66304
g11
sg66306
VJAK2 V617F
p71136
sa(dp71137
g66301
I358
sg66302
I1
sg66303
I5
sg66304
VP20930
p71138
sg66306
VFGFR1
p71139
sasg66311
(lp71140
(dp71141
g66301
I321
sg66302
I3
sg66303
I19
sg66314
VC1378511
p71142
sg66306
Vstem cell leukaemia
p71143
sa(dp71144
g66301
I203
sg66302
I2
sg66303
I21
sg66314
VC0001815
p71145
sg66306
Vprimary myelofibrosis
p71146
sa(dp71147
g66301
I143
sg66302
I2
sg66303
I25
sg66314
VC0040028
p71148
sg66306
Vessential thrombocythemia
p71149
sa(dp71150
g66301
I260
sg66302
I2
sg66303
I21
sg66314
VC0221013
p71151
sg66306
Vsystemic mastocytosis
p71152
sa(dp71153
g66301
I86
sg66302
I2
sg66303
I17
sg66314
VC0032463
p71154
sg66306
Vpolycythemia vera
p71155
sa(dp71156
g66301
I341
sg66302
I1
sg66303
I8
sg66314
VC0024299
p71157
sg66306
Vlymphoma
p71158
sasa(dp71159
g66296
VWe show that stimulation of B-cells with the TLR9 ligands CpG-oligodeoxynucleotides (CpG-ODN) prevents spontaneous and irradiation-induced death of normal peripheral blood B-cells, and of B-cells from patients diagnosed with Common variable immunodeficiency (CVID).
p71160
sg66298
(lp71161
(dp71162
g66301
I45
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTLR9
p71163
sasg66311
(lp71164
(dp71165
g66301
I259
sg66302
I1
sg66303
I4
sg66314
VC0009447
p71166
sg66306
VCVID
p71167
sa(dp71168
g66301
I225
sg66302
I3
sg66303
I32
sg66314
VC0009447
p71169
sg66306
VCommon variable immunodeficiency
p71170
sasa(dp71171
g66296
VDecreased IFN-Alfa secretion induced by TLR7/TLR8 activation was observed in CVID, which was recovered with TLR9 signaling.
p71172
sg66298
(lp71173
(dp71174
g66301
I45
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTLR8
p71175
sa(dp71176
g66301
I108
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTLR9
p71177
sa(dp71178
g66301
I40
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTLR7
p71179
sa(dp71180
g66301
I10
sg66302
I1
sg66303
I8
sg66304
VP01562
p71181
sg66306
VIFN-Alfa
p71182
sasg66311
(lp71183
(dp71184
g66301
I77
sg66302
I1
sg66303
I4
sg66314
VC0009447
p71185
sg66306
VCVID
p71186
sasa(dp71187
g66296
VOur findings revealed that TLR9 activation has an adjuvant effect on the altered type I response in CVID.
p71188
sg66298
(lp71189
(dp71190
g66301
I27
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTLR9
p71191
sasg66311
(lp71192
(dp71193
g66301
I100
sg66302
I1
sg66303
I4
sg66314
VC0009447
p71194
sg66306
VCVID
p71195
sasa(dp71196
g66296
VWe activated purified CVID B-cells with surrogate T-dependent (anti-CD40), T-independent (TLR-9 ligand) stimuli or through B-cell receptor engagement (anti-IgM) with or without IL-21.
p71197
sg66298
(lp71198
(dp71199
g66301
I123
sg66302
I3
sg66303
I26
sg66304
g11
sg66306
VB-cell receptor engagement
p71200
sa(dp71201
g66301
I151
sg66302
I1
sg66303
I8
sg66304
VP29965
p71202
sg66306
Vanti-IgM
p71203
sasg66311
(lp71204
(dp71205
g66301
I22
sg66302
I1
sg66303
I4
sg66314
VC0009447
p71206
sg66306
VCVID
p71207
sasa(dp71208
g66296
VMoreover, studies at the single cell level showed that DCs from CVID patients and healthy controls produced similar amounts of interferon-Alfa or interleukin-12 and expressed similar levels of activation markers in response to human cytomegalovirus and ligands for TLR-7 and TLR-9.
p71209
sg66298
(lp71210
(dp71211
g66301
I127
sg66302
I1
sg66303
I15
sg66304
VP01563
p71212
sg66306
Vinterferon-Alfa
p71213
sa(dp71214
g66301
I146
sg66302
I1
sg66303
I14
sg66304
VP60568
p71215
sg66306
Vinterleukin-12
p71216
sa(dp71217
g66301
I265
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTLR-7
p71218
sa(dp71219
g66301
I275
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTLR-9
p71220
sasg66311
(lp71221
(dp71222
g66301
I64
sg66302
I1
sg66303
I4
sg66314
VC0009447
p71223
sg66306
VCVID
p71224
sa(dp71225
g66301
I55
sg66302
I1
sg66303
I3
sg66314
VC0268238
p71226
sg66306
VDCs
p71227
sasa(dp71228
g66296
VIn conclusion, it seems unlikely that CVID is secondary to insufficient production of naturally occurring DCs or a defect in their signalling through TLR-7 or TLR-9.
p71229
sg66298
(lp71230
(dp71231
g66301
I150
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTLR-7
p71232
sa(dp71233
g66301
I159
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTLR-9
p71234
sasg66311
(lp71235
(dp71236
g66301
I38
sg66302
I1
sg66303
I4
sg66314
VC0009447
p71237
sg66306
VCVID
p71238
sa(dp71239
g66301
I106
sg66302
I1
sg66303
I3
sg66314
VC0268238
p71240
sg66306
VDCs
p71241
sasa(dp71242
g66296
VGiven the established link between vitamin A deficiency and increased susceptibility to infections, we investigated the ability of the vitamin A metabolite all-trans retinoic acid (RA) to restore the defective immune responses in CVID-derived B cells activated through the TLRs TLR9 and RP105.
p71243
sg66298
(lp71244
(dp71245
g66301
I273
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VTLRs TLR9
p71246
sa(dp71247
g66301
I287
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VRP105
p71248
sasg66311
(lp71249
(dp71250
g66301
I88
sg66302
I1
sg66303
I10
sg66314
VC0021311
p71251
sg66306
Vinfections
p71252
sa(dp71253
g66301
I35
sg66302
I3
sg66303
I20
sg66314
VC0042842
p71254
sg66306
Vvitamin A deficiency
p71255
sa(dp71256
g66301
I230
sg66302
I1
sg66303
I4
sg66314
VC0009447
p71257
sg66306
VCVID
p71258
sasa(dp71259
g66296
VThis can be explained by impaired RA-mediated isotype switching in TLR9/RP105-stimulated CVID-derived B cells owing to reduced induction of activation-induced deaminase.
p71260
sg66298
(lp71261
(dp71262
g66301
I72
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VRP105
p71263
sa(dp71264
g66301
I67
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTLR9
p71265
sasg66311
(lp71266
(dp71267
g66301
I89
sg66302
I1
sg66303
I4
sg66314
VC0009447
p71268
sg66306
VCVID
p71269
sa(dp71270
g66301
I25
sg66302
I1
sg66303
I8
sg66314
VC0684336
p71271
sg66306
Vimpaired
p71272
sasa(dp71273
g66296
VThe ability of RA to improve critical immune parameters in CVID-derived B cells stimulated through TLR9 and RP105 support the possibility of combining RA with TLR stimulation for the treatment of CVID.
p71274
sg66298
(lp71275
(dp71276
g66301
I99
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTLR9
p71277
sa(dp71278
g66301
I108
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VRP105
p71279
sasg66311
(lp71280
(dp71281
g66301
I59
sg66302
I1
sg66303
I4
sg66314
VC0009447
p71282
sg66306
VCVID
p71283
sa(dp71284
g66301
I59
sg66302
I1
sg66303
I4
sg66314
VC0009447
p71285
sg66306
VCVID
p71286
sasa(dp71287
g66296
VThe CD21(low) V(H)1-69(+) B cells of MC patients, like those of CVID and HIV patients, are anergic to BCR and TLR9 stimulation and display deregulation of several anergy-related genes; proliferative anergy is also observed in CD21(high) MZ-like V(H)1-69(+) B cells, that over-express the antiproliferative transcriptional repressor Stra13.
p71288
sg66298
(lp71289
(dp71290
g66301
I4
sg66302
I2
sg66303
I18
sg66304
VP20023
p71291
sg66306
VCD21(low) V(H)1-69
p71292
sa(dp71293
g66301
I226
sg66302
I3
sg66303
I27
sg66304
VP20023
p71294
sg66306
VCD21(high) MZ-like V(H)1-69
p71295
sa(dp71296
g66301
I332
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VStra13
p71297
sa(dp71298
g66301
I102
sg66302
I1
sg66303
I3
sg66304
VP11274
p71299
sg66306
VBCR
p71300
sa(dp71301
g66301
I110
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTLR9
p71302
sasg66311
(lp71303
(dp71304
g66301
I185
sg66302
I1
sg66303
I13
sg66314
VC0334094
p71305
sg66306
Vproliferative
p71306
sa(dp71307
g66301
I64
sg66302
I1
sg66303
I4
sg66314
VC0009447
p71308
sg66306
VCVID
p71309
sa(dp71310
g66301
I73
sg66302
I1
sg66303
I3
sg66314
VC0019693
p71311
sg66306
VHIV
p71312
sasa(dp71313
g66296
VThe secretion of glucagon by islet Alfa cells is normally suppressed by high blood glucose, but this suppressibility is impaired in patients with diabetes or cystic fibrosis (CF), a disease caused by mutations in the gene encoding CF transmembrane conductance regulator (CFTR), a cyclic adenosine monophosphate-activated Cl- channel.
p71314
sg66298
(lp71315
(dp71316
g66301
I17
sg66302
I1
sg66303
I8
sg66304
VP01275
p71317
sg66306
Vglucagon
p71318
sa(dp71319
g66301
I231
sg66302
I4
sg66303
I38
sg66304
g11
sg66306
VCF transmembrane conductance regulator
p71320
sa(dp71321
g66301
I271
sg66302
I1
sg66303
I4
sg66304
VP13569
p71322
sg66306
VCFTR
p71323
sasg66311
(lp71324
(dp71325
g66301
I175
sg66302
I1
sg66303
I2
sg66314
VC0016059
p71326
sg66306
VCF
p71327
sa(dp71328
g66301
I158
sg66302
I2
sg66303
I15
sg66314
VC0010674
p71329
sg66306
Vcystic fibrosis
p71330
sa(dp71331
g66301
I146
sg66302
I1
sg66303
I8
sg66314
VC0011849
p71332
sg66306
Vdiabetes
p71333
sa(dp71334
g66301
I120
sg66302
I1
sg66303
I8
sg66314
VC0684336
p71335
sg66306
Vimpaired
p71336
sa(dp71337
g66301
I175
sg66302
I1
sg66303
I2
sg66314
VC0016059
p71338
sg66306
VCF
p71339
sasa(dp71340
g66296
VThe results reveal that by potentiating KATP channels, CFTR acts as a glucose-sensing negative regulator of glucagon secretion in Alfa cells, a defect of which may contribute to glucose intolerance in CF and other types of diabetes.
p71341
sg66298
(lp71342
(dp71343
g66301
I55
sg66302
I1
sg66303
I4
sg66304
VP13569
p71344
sg66306
VCFTR
p71345
sa(dp71346
g66301
I108
sg66302
I1
sg66303
I8
sg66304
VP01275
p71347
sg66306
Vglucagon
p71348
sasg66311
(lp71349
(dp71350
g66301
I178
sg66302
I2
sg66303
I19
sg66314
VC0271650
p71351
sg66306
Vglucose intolerance
p71352
sa(dp71353
g66301
I223
sg66302
I1
sg66303
I8
sg66314
VC0011849
p71354
sg66306
Vdiabetes
p71355
sasa(dp71356
g66296
VAlthough Beta-cell dysfunction in cystic fibrosis (CF) leads to diabetes, the mechanism by which the cystic fibrosis transmembrane conductance regulator (CFTR) channel influences islet insulin secretion remains debated.
p71357
sg66298
(lp71358
(dp71359
g66301
I101
sg66302
I5
sg66303
I51
sg66304
VP13569
p71360
sg66306
Vcystic fibrosis transmembrane conductance regulator
p71361
sa(dp71362
g66301
I9
sg66302
I6
sg66303
I45
sg66304
VP13569
p71363
sg66306
VBeta-cell dysfunction in cystic fibrosis (CF)
p71364
sa(dp71365
g66301
I185
sg66302
I1
sg66303
I7
sg66304
VP01308
p71366
sg66306
Vinsulin
p71367
sa(dp71368
g66301
I154
sg66302
I1
sg66303
I4
sg66304
VP13569
p71369
sg66306
VCFTR
p71370
sasg66311
(lp71371
(dp71372
g66301
I64
sg66302
I1
sg66303
I8
sg66314
VC0011849
p71373
sg66306
Vdiabetes
p71374
sa(dp71375
g66301
I34
sg66302
I2
sg66303
I15
sg66314
VC0010674
p71376
sg66306
Vcystic fibrosis
p71377
sa(dp71378
g66301
I34
sg66302
I2
sg66303
I15
sg66314
VC0010674
p71379
sg66306
Vcystic fibrosis
p71380
sa(dp71381
g66301
I51
sg66302
I1
sg66303
I2
sg66314
VC0010674
p71382
sg66306
VCF
p71383
sasa(dp71384
g66296
VBaseline estimated cost in 2008 for a hypothetical underweight, homozygous F508del-CFTR 6-year-old female without chronic Pseudomonas aeruginosa/Staphylococcus aureus, CF-related diabetes (CFRD) or methicillin-resistant S. aureus (MRSA), and with a poor percent predicted forced expiratory volume in 1 s (ppFEV1) was Euro10,113, and was Euro21,082 in a 25-year-old with the same hypothetical profile.
p71385
sg66298
(lp71386
(dp71387
g66301
I75
sg66302
I2
sg66303
I14
sg66304
VP13569
p71388
sg66306
VF508del-CFTR 6
p71389
sasg66311
(lp71390
(dp71391
g66301
I179
sg66302
I1
sg66303
I8
sg66314
VC0011849
p71392
sg66306
Vdiabetes
p71393
sa(dp71394
g66301
I231
sg66302
I1
sg66303
I4
sg66314
VC0343401
p71395
sg66306
VMRSA
p71396
sasa(dp71397
g66296
VThe goal of this work was to evaluate renal function and the expression of megalin, cubilin, CFTR (cystic fibrosis transmembrane conductance regulator), and ClC-5 in the proximal tubule and renal cortex of rats with type 1 diabetes.
p71398
sg66298
(lp71399
(dp71400
g66301
I157
sg66302
I1
sg66303
I5
sg66304
VP51795
p71401
sg66306
VClC-5
p71402
sa(dp71403
g66301
I84
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
Vcubilin
p71404
sa(dp71405
g66301
I75
sg66302
I1
sg66303
I7
sg66304
VP54317
p71406
sg66306
Vmegalin
p71407
sasg66311
(lp71408
(dp71409
g66301
I216
sg66302
I3
sg66303
I15
sg66314
VC0011854
p71410
sg66306
Vtype 1 diabetes
p71411
sa(dp71412
g66301
I99
sg66302
I2
sg66303
I15
sg66314
VC0010674
p71413
sg66306
Vcystic fibrosis
p71414
sasa(dp71415
g66296
VMean values in lichen ruber planus were Zn 784 micrograms/l, RBP 5.26 mg/dl and Vit A 656 ng/ml; in leukoplakia Zn 696 micrograms/l, RBP 5.30 mg/dl and Vit A 652 ng/ml; and in OSCC Zn 659 micrograms/l, RBP 5.00 mg/dl and Vit A 617 ng/ml.
p71416
sg66298
(lp71417
sg66311
(lp71418
(dp71419
g66301
I100
sg66302
I1
sg66303
I11
sg66314
VC0023531
p71420
sg66306
Vleukoplakia
p71421
sa(dp71422
g66301
I15
sg66302
I3
sg66303
I19
sg66314
VC0023646
p71423
sg66306
Vlichen ruber planus
p71424
sasa(dp71425
g66296
VThese observations indicate that HYA and PIIINP mainly reflect expansive synovitis proliferation while galectin-3 is more closely linked to autoimmunity, smoking and joint destructive processes.
p71426
sg66298
(lp71427
(dp71428
g66301
I103
sg66302
I1
sg66303
I10
sg66304
VP17931
p71429
sg66306
Vgalectin-3
p71430
sasg66311
(lp71431
(dp71432
g66301
I73
sg66302
I1
sg66303
I9
sg66314
VC0039103
p71433
sg66306
Vsynovitis
p71434
sa(dp71435
g66301
I83
sg66302
I1
sg66303
I13
sg66314
VC0334094
p71436
sg66306
Vproliferation
p71437
sa(dp71438
g66301
I140
sg66302
I1
sg66303
I12
sg66314
VC0004368
p71439
sg66306
Vautoimmunity
p71440
sasa(dp71441
g66296
VIn the entire UA cohort, galectin-3 correlated with the MRI bone marrow edema score, while PIIANP correlated with the MRI erosion score, and HYA with the synovitis and erosion scores.
p71442
sg66298
(lp71443
(dp71444
g66301
I25
sg66302
I1
sg66303
I10
sg66304
VP17931
p71445
sg66306
Vgalectin-3
p71446
sasg66311
(lp71447
(dp71448
g66301
I122
sg66302
I1
sg66303
I7
sg66314
VC1959609
p71449
sg66306
Verosion
p71450
sa(dp71451
g66301
I154
sg66302
I1
sg66303
I9
sg66314
VC0039103
p71452
sg66306
Vsynovitis
p71453
sa(dp71454
g66301
I60
sg66302
I3
sg66303
I17
sg66314
VC0948162
p71455
sg66306
Vbone marrow edema
p71456
sa(dp71457
g66301
I122
sg66302
I1
sg66303
I7
sg66314
VC1959609
p71458
sg66306
Verosion
p71459
sasa(dp71460
g66296
VPrevious studies have reported overexpression of Galectin-3 in RA synovitis and increased levels in synovial fluid and serum in long-standing RA compared with osteoarthritis and healthy controls.
p71461
sg66298
(lp71462
(dp71463
g66301
I49
sg66302
I1
sg66303
I10
sg66304
VP17931
p71464
sg66306
VGalectin-3
p71465
sasg66311
(lp71466
(dp71467
g66301
I159
sg66302
I1
sg66303
I14
sg66314
VC0029408
p71468
sg66306
Vosteoarthritis
p71469
sa(dp71470
g66301
I66
sg66302
I1
sg66303
I9
sg66314
VC0039103
p71471
sg66306
Vsynovitis
p71472
sasa(dp71473
g66296
VWe defined by immunohistology the infiltrating cells and examined the in situ expression of plausible protagonists in synovitis of FMF: myeloperoxidase, lysozyme, galectin 1, galectin 3, p65 (RelA)/nuclear factor KB, inducible nitric-oxide synthase, cyclooxygenase 2, and cleaved caspase 3.
p71474
sg66298
(lp71475
(dp71476
g66301
I192
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VRelA
p71477
sa(dp71478
g66301
I187
sg66302
I1
sg66303
I3
sg66304
VP21579
p71479
sg66306
Vp65
p71480
sa(dp71481
g66301
I131
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VFMF
p71482
sa(dp71483
g66301
I153
sg66302
I1
sg66303
I8
sg66304
VP61626
p71484
sg66306
Vlysozyme
p71485
sa(dp71486
g66301
I280
sg66302
I2
sg66303
I9
sg66304
VP42574
p71487
sg66306
Vcaspase 3
p71488
sa(dp71489
g66301
I163
sg66302
I2
sg66303
I10
sg66304
VP09382
p71490
sg66306
Vgalectin 1
p71491
sa(dp71492
g66301
I198
sg66302
I3
sg66303
I17
sg66304
VP01160
p71493
sg66306
Vnuclear factor KB
p71494
sa(dp71495
g66301
I175
sg66302
I2
sg66303
I10
sg66304
VP17931
p71496
sg66306
Vgalectin 3
p71497
sa(dp71498
g66301
I250
sg66302
I2
sg66303
I16
sg66304
VP35354
p71499
sg66306
Vcyclooxygenase 2
p71500
sa(dp71501
g66301
I227
sg66302
I2
sg66303
I21
sg66304
VP29475
p71502
sg66306
Vnitric-oxide synthase
p71503
sa(dp71504
g66301
I136
sg66302
I1
sg66303
I15
sg66304
VP05164
p71505
sg66306
Vmyeloperoxidase
p71506
sasg66311
(lp71507
(dp71508
g66301
I131
sg66302
I1
sg66303
I3
sg66314
VC0031069
p71509
sg66306
VFMF
p71510
sa(dp71511
g66301
I34
sg66302
I1
sg66303
I12
sg66314
VC0332448
p71512
sg66306
Vinfiltrating
p71513
sa(dp71514
g66301
I118
sg66302
I1
sg66303
I9
sg66314
VC0039103
p71515
sg66306
Vsynovitis
p71516
sasa(dp71517
g66296
VOnly one of these, pFLJ2, was mobilized by the IncP plasmids RP4, pRK231 and R702, but not by plasmids pSa, R40a, R387, pN3 or R16.
p71518
sg66298
(lp71519
sg66311
(lp71520
(dp71521
g66301
I103
sg66302
I1
sg66303
I3
sg66314
VC1519176
p71522
sg66306
VpSa
p71523
sa(dp71524
g66301
I61
sg66302
I1
sg66303
I3
sg66314
VC3151001
p71525
sg66306
VRP4
p71526
sasa(dp71527
g66296
VChanges in the frequencies of genotypes and mutant alleles of ACE, AGTR1, AGT, and ITGB3 genes were analyzed in patients with arterial hypertension coupled with metabolic syndrome (N=15) and compared with population data and corresponding parameters in patients with isolated hypertension (N=15).
p71528
sg66298
(lp71529
(dp71530
g66301
I67
sg66302
I1
sg66303
I5
sg66304
VP30556
p71531
sg66306
VAGTR1
p71532
sa(dp71533
g66301
I62
sg66302
I1
sg66303
I3
sg66304
VP12821
p71534
sg66306
VACE
p71535
sa(dp71536
g66301
I83
sg66302
I2
sg66303
I11
sg66304
VP05106
p71537
sg66306
VITGB3 genes
p71538
sa(dp71539
g66301
I67
sg66302
I1
sg66303
I3
sg66304
VP21549
p71540
sg66306
VAGT
p71541
sasg66311
(lp71542
(dp71543
g66301
I126
sg66302
I2
sg66303
I21
sg66314
VC0020538
p71544
sg66306
Varterial hypertension
p71545
sa(dp71546
g66301
I135
sg66302
I1
sg66303
I12
sg66314
VC0020538
p71547
sg66306
Vhypertension
p71548
sa(dp71549
g66301
I44
sg66302
I1
sg66303
I6
sg66314
VC0596988
p71550
sg66306
Vmutant
p71551
sa(dp71552
g66301
I161
sg66302
I2
sg66303
I18
sg66314
VC0524620
p71553
sg66306
Vmetabolic syndrome
p71554
sasa(dp71555
g66296
VWe examined associations between 15 single nucleotide polymorphisms (SNPs) across ITGB3 and five CVD-related traits in the Hutterites: plasma levels of high density lipoprotein-cholesterol (HDL-c), triglycerides (TG), low density lipoprotein-cholesterol (LDL-c), and lipoprotein(a) [Lp(a)] and blood pressure or hypertension.
p71556
sg66298
(lp71557
(dp71558
g66301
I218
sg66302
I3
sg66303
I35
sg66304
VP02652
p71559
sg66306
Vlow density lipoprotein-cholesterol
p71560
sa(dp71561
g66301
I255
sg66302
I1
sg66303
I5
sg66304
VP02652
p71562
sg66306
VLDL-c
p71563
sa(dp71564
g66301
I152
sg66302
I3
sg66303
I36
sg66304
VP28845
p71565
sg66306
Vhigh density lipoprotein-cholesterol
p71566
sa(dp71567
g66301
I267
sg66302
I1
sg66303
I14
sg66304
VP02652
p71568
sg66306
Vlipoprotein(a)
p71569
sa(dp71570
g66301
I190
sg66302
I1
sg66303
I5
sg66304
VP28845
p71571
sg66306
VHDL-c
p71572
sasg66311
(lp71573
(dp71574
g66301
I97
sg66302
I1
sg66303
I3
sg66314
VC0007222
p71575
sg66306
VCVD
p71576
sa(dp71577
g66301
I312
sg66302
I1
sg66303
I12
sg66314
VC0020538
p71578
sg66306
Vhypertension
p71579
sasa(dp71580
g66296
VThe present study was performed to investigate the expressions of transforming growth factor Beta1 (TGF-Beta1) and matrix metalloproteinase-9 (MMP-9) in an experimental model of tympanosclerosis and their possible roles in the formation of this disorder.
p71581
sg66298
(lp71582
(dp71583
g66301
I66
sg66302
I4
sg66303
I32
sg66304
VP01137
p71584
sg66306
Vtransforming growth factor Beta1
p71585
sa(dp71586
g66301
I100
sg66302
I1
sg66303
I9
sg66304
VP01137
p71587
sg66306
VTGF-Beta1
p71588
sa(dp71589
g66301
I115
sg66302
I2
sg66303
I26
sg66304
VP14780
p71590
sg66306
Vmatrix metalloproteinase-9
p71591
sa(dp71592
g66301
I143
sg66302
I1
sg66303
I5
sg66304
VP14780
p71593
sg66306
VMMP-9
p71594
sasg66311
(lp71595
(dp71596
g66301
I178
sg66302
I1
sg66303
I16
sg66314
VC0395887
p71597
sg66306
Vtympanosclerosis
p71598
sasa(dp71599
g66296
VRT-PCR analysis showed that the overall transcriptional activity of the main HS biosynthesis-involved genes (EXT1, EXT2, NDST1, NDST2, GLCE, HS2ST1, HS3ST1, HS3ST2, HS6ST1, HS6ST2, SULF1, SULF2, HPSE) was decreased by 1.5-2-fold in Grade II-III glioma (p &lt; 0.01) and by 3-fold in Grade IV glioma (glioblastoma multiforme, GBM) (p &lt; 0.05), as compared with the para-tumourous tissue.
p71600
sg66298
(lp71601
(dp71602
g66301
I157
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VHS3ST2
p71603
sa(dp71604
g66301
I115
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VEXT2
p71605
sa(dp71606
g66301
I195
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VHPSE
p71607
sa(dp71608
g66301
I181
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSULF1
p71609
sa(dp71610
g66301
I128
sg66302
I1
sg66303
I5
sg66304
VP52849
p71611
sg66306
VNDST2
p71612
sa(dp71613
g66301
I141
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VHS2ST1
p71614
sa(dp71615
g66301
I121
sg66302
I1
sg66303
I5
sg66304
VP52848
p71616
sg66306
VNDST1
p71617
sa(dp71618
g66301
I135
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGLCE
p71619
sa(dp71620
g66301
I109
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VEXT1
p71621
sa(dp71622
g66301
I149
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VHS3ST1
p71623
sa(dp71624
g66301
I165
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VHS6ST1
p71625
sa(dp71626
g66301
I188
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSULF2
p71627
sasg66311
(lp71628
(dp71629
g66301
I115
sg66302
I1
sg66303
I4
sg66314
VC1851413
p71630
sg66306
VEXT2
p71631
sa(dp71632
g66301
I245
sg66302
I1
sg66303
I6
sg66314
VC0017638
p71633
sg66306
Vglioma
p71634
sa(dp71635
g66301
I245
sg66302
I1
sg66303
I6
sg66314
VC0017638
p71636
sg66306
Vglioma
p71637
sa(dp71638
g66301
I300
sg66302
I2
sg66303
I23
sg66314
VC1621958
p71639
sg66306
Vglioblastoma multiforme
p71640
sa(dp71641
g66301
I109
sg66302
I1
sg66303
I4
sg66314
VC0015306
p71642
sg66306
VEXT1
p71643
sa(dp71644
g66301
I325
sg66302
I1
sg66303
I3
sg66314
VC1621958
p71645
sg66306
VGBM
p71646
sasa(dp71647
g66296
VThis study aimed to analyze the expression and function of HS6ST3 in breast cancer.
p71648
sg66298
(lp71649
(dp71650
g66301
I59
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VHS6ST3
p71651
sasg66311
(lp71652
(dp71653
g66301
I69
sg66302
I2
sg66303
I13
sg66314
VC0678222
p71654
sg66306
Vbreast cancer
p71655
sasa(dp71656
g66296
VHS6ST3 was found up-regulated in T47D, MCF7 and MDA-MB231 breast cancer cell lines.
p71657
sg66298
(lp71658
(dp71659
g66301
I0
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VHS6ST3
p71660
sasg66311
(lp71661
(dp71662
g66301
I58
sg66302
I2
sg66303
I13
sg66314
VC0678222
p71663
sg66306
Vbreast cancer
p71664
sasa(dp71665
g66296
VSilencing HS6ST3 diminished tumor cell growth, migration and invasion, but enhanced cell adhesion and apoptosis in breast cancer.
p71666
sg66298
(lp71667
sg66311
(lp71668
(dp71669
g66301
I28
sg66302
I1
sg66303
I5
sg66314
VC0027651
p71670
sg66306
Vtumor
p71671
sa(dp71672
g66301
I115
sg66302
I2
sg66303
I13
sg66314
VC0678222
p71673
sg66306
Vbreast cancer
p71674
sa(dp71675
g66301
I61
sg66302
I1
sg66303
I8
sg66314
VC2699153
p71676
sg66306
Vinvasion
p71677
sa(dp71678
g66301
I89
sg66302
I1
sg66303
I8
sg66314
VC0001511
p71679
sg66306
Vadhesion
p71680
sasa(dp71681
g66296
VGene microarray analysis revealed that silencing HS6ST3 significantly changed the expression of IGF1R and XAF1 in breast cancer cells.
p71682
sg66298
(lp71683
(dp71684
g66301
I96
sg66302
I1
sg66303
I5
sg66304
VP08069
p71685
sg66306
VIGF1R
p71686
sa(dp71687
g66301
I49
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VHS6ST3
p71688
sa(dp71689
g66301
I106
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VXAF1
p71690
sasg66311
(lp71691
(dp71692
g66301
I114
sg66302
I2
sg66303
I13
sg66314
VC0678222
p71693
sg66306
Vbreast cancer
p71694
sasa(dp71695
g66296
VFurther functional studies showed that the cellular processes were mediated by IGF1R and XAF1 after silencing HS6ST3 in breast cancer cells.
p71696
sg66298
(lp71697
(dp71698
g66301
I89
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VXAF1
p71699
sa(dp71700
g66301
I79
sg66302
I1
sg66303
I5
sg66304
VP08069
p71701
sg66306
VIGF1R
p71702
sa(dp71703
g66301
I110
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VHS6ST3
p71704
sasg66311
(lp71705
(dp71706
g66301
I120
sg66302
I2
sg66303
I13
sg66314
VC0678222
p71707
sg66306
Vbreast cancer
p71708
sasa(dp71709
g66296
VTogether these results indicate that HS6ST3 might be involved in the tumorigenesis of breast cancer and it could be a promising target in breast cancer therapy.
p71710
sg66298
(lp71711
(dp71712
g66301
I37
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VHS6ST3
p71713
sasg66311
(lp71714
(dp71715
g66301
I86
sg66302
I2
sg66303
I13
sg66314
VC0678222
p71716
sg66306
Vbreast cancer
p71717
sa(dp71718
g66301
I69
sg66302
I1
sg66303
I13
sg66314
VC0007621
p71719
sg66306
Vtumorigenesis
p71720
sa(dp71721
g66301
I86
sg66302
I2
sg66303
I13
sg66314
VC0678222
p71722
sg66306
Vbreast cancer
p71723
sasa(dp71724
g66296
VWe aimed to examine the relationship between the preoperative GSA index [uptake ratio of the liver to the liver plus heart at 15 min (LHL15) to uptake ratio of the heart at 15 min to that at 3 min (HH15) ratio] calculated from 99mTc-labeled diethylene triamine pentaacetate-galactosyl human serum albumin (99mTc-GSA) scintigraphy and background liver fibrosis and to investigate whether the GSA index can be a useful predictor in hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) patients treated with surgical resection (SR).
p71725
sg66298
(lp71726
(dp71727
g66301
I285
sg66302
I3
sg66303
I19
sg66304
g11
sg66306
Vhuman serum albumin
p71728
sasg66311
(lp71729
(dp71730
g66301
I462
sg66302
I2
sg66303
I24
sg66314
VC2239176
p71731
sg66306
Vhepatocellular carcinoma
p71732
sa(dp71733
g66301
I345
sg66302
I2
sg66303
I14
sg66314
VC0239946
p71734
sg66306
Vliver fibrosis
p71735
sa(dp71736
g66301
I430
sg66302
I2
sg66303
I11
sg66314
VC0019196
p71737
sg66306
Vhepatitis C
p71738
sa(dp71739
g66301
I488
sg66302
I1
sg66303
I3
sg66314
VC2239176
p71740
sg66306
VHCC
p71741
sasa(dp71742
g66296
VHere we demonstrate that HS 6-O-sulfotransferases 1 and 2 (HS6ST-1 and HS6ST-2), which perform sulfation at 6-O position in glucosamine in HS, impact ovarian cancer angiogenesis through the HS-dependent HB-EGF/EGFR axis that subsequently modulates the expression of multiple angiogenic cytokines.
p71743
sg66298
(lp71744
(dp71745
g66301
I190
sg66302
I2
sg66303
I19
sg66304
VP19525
p71746
sg66306
VHS-dependent HB-EGF
p71747
sa(dp71748
g66301
I59
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VHS6ST-1
p71749
sa(dp71750
g66301
I25
sg66302
I5
sg66303
I32
sg66304
g11
sg66306
VHS 6-O-sulfotransferases 1 and 2
p71751
sa(dp71752
g66301
I71
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VHS6ST-2
p71753
sasg66311
(lp71754
(dp71755
g66301
I158
sg66302
I2
sg66303
I19
sg66314
VC1536999
p71756
sg66306
Vcancer angiogenesis
p71757
sasa(dp71758
g66296
VDown-regulation of HS6ST-1 or HS6ST-2 in human ovarian cancer cell lines results in 30-50% reduction in glucosamine 6-O-sulfate levels in HS, impairing HB-EGF-dependent EGFR signaling and diminishing FGF2, IL-6, and IL-8 mRNA and protein levels in cancer cells.
p71759
sg66298
(lp71760
(dp71761
g66301
I19
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VHS6ST-1
p71762
sa(dp71763
g66301
I30
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VHS6ST-2
p71764
sa(dp71765
g66301
I152
sg66302
I2
sg66303
I21
sg66304
g11
sg66306
VHB-EGF-dependent EGFR
p71766
sa(dp71767
g66301
I206
sg66302
I1
sg66303
I4
sg66304
VP05231
p71768
sg66306
VIL-6
p71769
sa(dp71770
g66301
I200
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VFGF2
p71771
sasg66311
(lp71772
(dp71773
g66301
I55
sg66302
I1
sg66303
I6
sg66314
VC0006826
p71774
sg66306
Vcancer
p71775
sa(dp71776
g66301
I47
sg66302
I2
sg66303
I14
sg66314
VC1140680
p71777
sg66306
Vovarian cancer
p71778
sasa(dp71779
g66296
VOur results show that in addition to the critical role that 6-O-sulfate moieties play in angiogenic cytokine activation, HS 6-O-sulfation level, determined by the expression of HS6ST isoforms in ovarian cancer cells, is a major regulator of angiogenic program in ovarian cancer cells impacting HB-EGF signaling and subsequent expression of angiogenic cytokines by cancer cells.
p71780
sg66298
(lp71781
(dp71782
g66301
I340
sg66302
I2
sg66303
I20
sg66304
VP01374
p71783
sg66306
Vangiogenic cytokines
p71784
sa(dp71785
g66301
I297
sg66302
I1
sg66303
I3
sg66304
VP01133
p71786
sg66306
VEGF
p71787
sa(dp71788
g66301
I177
sg66302
I2
sg66303
I14
sg66304
g11
sg66306
VHS6ST isoforms
p71789
sasg66311
(lp71790
(dp71791
g66301
I195
sg66302
I2
sg66303
I14
sg66314
VC1140680
p71792
sg66306
Vovarian cancer
p71793
sa(dp71794
g66301
I203
sg66302
I1
sg66303
I6
sg66314
VC0006826
p71795
sg66306
Vcancer
p71796
sa(dp71797
g66301
I195
sg66302
I2
sg66303
I14
sg66314
VC1140680
p71798
sg66306
Vovarian cancer
p71799
sasa(dp71800
g66296
VWe have investigated whether the expression of HS6STs and SULFs changes during chondrosarcoma progression and have determined 6O-sulphation levels in two chondrosarcoma cell lines.
p71801
sg66298
(lp71802
(dp71803
g66301
I47
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VHS6STs
p71804
sasg66311
(lp71805
(dp71806
g66301
I79
sg66302
I1
sg66303
I14
sg66314
VC0008479
p71807
sg66306
Vchondrosarcoma
p71808
sa(dp71809
g66301
I79
sg66302
I1
sg66303
I14
sg66314
VC0008479
p71810
sg66306
Vchondrosarcoma
p71811
sasa(dp71812
g66296
VImmunohistochemistry on tissue microarrays of chondrosarcomas showed that HS6ST3 and SULF1 were highly expressed in most chondrosarcomas, whereas SULF2 expression was absent in most cases.
p71813
sg66298
(lp71814
(dp71815
g66301
I85
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSULF1
p71816
sa(dp71817
g66301
I74
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VHS6ST3
p71818
sa(dp71819
g66301
I146
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSULF2
p71820
sasg66311
(lp71821
(dp71822
g66301
I46
sg66302
I1
sg66303
I15
sg66314
VC0008479
p71823
sg66306
Vchondrosarcomas
p71824
sa(dp71825
g66301
I46
sg66302
I1
sg66303
I15
sg66314
VC0008479
p71826
sg66306
Vchondrosarcomas
p71827
sasa(dp71828
g66296
VHS6ST1 and HS6ST2 expression are significantly increased during chondrosarcoma progression, which suggest that 6O-sulphation is increased during progression.
p71829
sg66298
(lp71830
(dp71831
g66301
I0
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VHS6ST1
p71832
sasg66311
(lp71833
(dp71834
g66301
I64
sg66302
I1
sg66303
I14
sg66314
VC0008479
p71835
sg66306
Vchondrosarcoma
p71836
sasa(dp71837
g66296
VIn conclusion, our results show increased HS6ST1 and HS6ST2 expression during chondrosarcoma progression and increased HS 6O-sulphation in vitro.
p71838
sg66298
(lp71839
(dp71840
g66301
I42
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VHS6ST1
p71841
sasg66311
(lp71842
(dp71843
g66301
I78
sg66302
I1
sg66303
I14
sg66314
VC0008479
p71844
sg66306
Vchondrosarcoma
p71845
sasa(dp71846
g66296
VAs 6O-sulphation plays an important role in signal transduction, altered HS6ST expression might be associated with changes in signal transduction pathways in chondrosarcoma progression.
p71847
sg66298
(lp71848
(dp71849
g66301
I73
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VHS6ST
p71850
sasg66311
(lp71851
(dp71852
g66301
I158
sg66302
I1
sg66303
I14
sg66314
VC0008479
p71853
sg66306
Vchondrosarcoma
p71854
sasa(dp71855
g66296
VThus, neutrophils and NK cells act as important disease-promoting immune cells in experimental osteoarthritis and their functional interaction is promoted by the CXCL10/CXCR3 axis.
p71856
sg66298
(lp71857
(dp71858
g66301
I162
sg66302
I1
sg66303
I6
sg66304
VP02778
p71859
sg66306
VCXCL10
p71860
sa(dp71861
g66301
I169
sg66302
I1
sg66303
I5
sg66304
VP49682
p71862
sg66306
VCXCR3
p71863
sasg66311
(lp71864
(dp71865
g66301
I95
sg66302
I1
sg66303
I14
sg66314
VC0029408
p71866
sg66306
Vosteoarthritis
p71867
sasa(dp71868
g66296
VOvarian cancer cell line OC316 was reverse transfected with a miR-223 mimic and relative expression levels of miR-223 and SMARCD1 were quantified by RT-PCR; protein expression of SMARCD1 was evaluated by Western Blot.
p71869
sg66298
(lp71870
(dp71871
g66301
I122
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSMARCD1
p71872
sa(dp71873
g66301
I122
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSMARCD1
p71874
sa(dp71875
g66301
I62
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-223
p71876
sasg66311
(lp71877
(dp71878
g66301
I0
sg66302
I2
sg66303
I14
sg66314
VC1140680
p71879
sg66306
VOvarian cancer
p71880
sasa(dp71881
g66296
VmiR-223 expression was upregulated in high grade ovarian serous carcinoma samples (median RQ=4.8881, P=.0045), whilst SMARCD1 was down-regulated (median RQ=0.5107, P=.0492).
p71882
sg66298
(lp71883
(dp71884
g66301
I118
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSMARCD1
p71885
sasg66311
(lp71886
(dp71887
g66301
I49
sg66302
I3
sg66303
I24
sg66314
VC1335177
p71888
sg66306
Vovarian serous carcinoma
p71889
sasa(dp71890
g66296
VIt was indicated that SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily D, member 1, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily D, member 1, dihydropyrimidinase-like 2, RMND5A and ANGPTL1 were potential prognostic markers in breast cancer, and the cell cycle may be involved in the regulation of breast cancer.
p71891
sg66298
(lp71892
(dp71893
g66301
I186
sg66302
I7
sg66303
I60
sg66304
g11
sg66306
Vchromatin, subfamily D, member 1, dihydropyrimidinase-like 2
p71894
sa(dp71895
g66301
I259
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VANGPTL1
p71896
sa(dp71897
g66301
I248
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VRMND5A
p71898
sa(dp71899
g66301
I22
sg66302
I1
sg66303
I3
sg66304
VP28370
p71900
sg66306
VSWI
p71901
sa(dp71902
g66301
I26
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VSNF
p71903
sa(dp71904
g66301
I26
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VSNF
p71905
sa(dp71906
g66301
I87
sg66302
I5
sg66303
I32
sg66304
g11
sg66306
Vchromatin, subfamily D, member 1
p71907
sa(dp71908
g66301
I22
sg66302
I1
sg66303
I3
sg66304
VP28370
p71909
sg66306
VSWI
p71910
sasg66311
(lp71911
(dp71912
g66301
I304
sg66302
I2
sg66303
I13
sg66314
VC0678222
p71913
sg66306
Vbreast cancer
p71914
sa(dp71915
g66301
I304
sg66302
I2
sg66303
I13
sg66314
VC0678222
p71916
sg66306
Vbreast cancer
p71917
sasa(dp71918
g66296
VMiR-490-3p plays a tumour suppressor role in epithelial ovarian cancer by targeting CDK1 regulation and influencing SMARCD1 and cyclin D1 (CCND1) expressions.
p71919
sg66298
(lp71920
(dp71921
g66301
I84
sg66302
I1
sg66303
I4
sg66304
VP06493
p71922
sg66306
VCDK1
p71923
sa(dp71924
g66301
I139
sg66302
I1
sg66303
I5
sg66304
VP24385
p71925
sg66306
VCCND1
p71926
sa(dp71927
g66301
I116
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSMARCD1
p71928
sa(dp71929
g66301
I0
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VMiR-490-3p
p71930
sa(dp71931
g66301
I128
sg66302
I2
sg66303
I9
sg66304
VP24385
p71932
sg66306
Vcyclin D1
p71933
sasg66311
(lp71934
(dp71935
g66301
I19
sg66302
I1
sg66303
I6
sg66314
VC0027651
p71936
sg66306
Vtumour
p71937
sa(dp71938
g66301
I45
sg66302
I3
sg66303
I25
sg66314
VC0677886
p71939
sg66306
Vepithelial ovarian cancer
p71940
sasa(dp71941
g66296
VHepatocyte-specific inactivation of Baf60a reduced bile acid production and cholesterol absorption, and attenuated diet-induced hypercholesterolemia and atherosclerosis in mice.
p71942
sg66298
(lp71943
(dp71944
g66301
I36
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VBaf60a
p71945
sasg66311
(lp71946
(dp71947
g66301
I128
sg66302
I1
sg66303
I20
sg66314
VC0020443
p71948
sg66306
Vhypercholesterolemia
p71949
sa(dp71950
g66301
I153
sg66302
I1
sg66303
I15
sg66314
VC0004153
p71951
sg66306
Vatherosclerosis
p71952
sa(dp71953
g66301
I20
sg66302
I1
sg66303
I12
sg66314
VC0544461
p71954
sg66306
Vinactivation
p71955
sasa(dp71956
g66296
VmiR-7 expression reduced SMARCD1 protein expression in lung cancer cell lines.
p71957
sg66298
(lp71958
(dp71959
g66301
I25
sg66302
I2
sg66303
I15
sg66304
g11
sg66306
VSMARCD1 protein
p71960
sa(dp71961
g66301
I0
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VmiR-7
p71962
sasg66311
(lp71963
(dp71964
g66301
I55
sg66302
I2
sg66303
I11
sg66314
VC0684249
p71965
sg66306
Vlung cancer
p71966
sasa(dp71967
g66296
VWe found that although SMARCD1 sensitized lung cancer cells to chemotherapy drug-induced apoptosis, miR-7 enhanced the drug resistance potential of lung cancer cells against chemotherapy drugs.
p71968
sg66298
(lp71969
(dp71970
g66301
I100
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VmiR-7
p71971
sa(dp71972
g66301
I23
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSMARCD1
p71973
sasg66311
(lp71974
(dp71975
g66301
I42
sg66302
I2
sg66303
I11
sg66314
VC0684249
p71976
sg66306
Vlung cancer
p71977
sa(dp71978
g66301
I42
sg66302
I2
sg66303
I11
sg66314
VC0684249
p71979
sg66306
Vlung cancer
p71980
sasa(dp71981
g66296
VSMARCD1 was down-regulated in patients with non-small cell lung cancer and lung adenocarcinoma cell lines, and SMARCD1 and miR-7 expression levels were negatively correlated in clinical samples.
p71982
sg66298
(lp71983
(dp71984
g66301
I0
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSMARCD1
p71985
sa(dp71986
g66301
I0
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSMARCD1
p71987
sa(dp71988
g66301
I123
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VmiR-7
p71989
sasg66311
(lp71990
(dp71991
g66301
I75
sg66302
I2
sg66303
I19
sg66314
VC0152013
p71992
sg66306
Vlung adenocarcinoma
p71993
sa(dp71994
g66301
I44
sg66302
I4
sg66303
I26
sg66314
VC0007131
p71995
sg66306
Vnon-small cell lung cancer
p71996
sasa(dp71997
g66296
VOur investigation into the involvement of the EGFR-regulated microRNA pathway in the SWI/SNF chromatin remodeling complex suggests that EGFR-mediated miR-7 suppresses the coupling of the chromatin remodeling factor SMARCD1 with p53, resulting in increased chemo-resistance of lung cancer cells.
p71998
sg66298
(lp71999
(dp72000
g66301
I187
sg66302
I3
sg66303
I27
sg66304
g11
sg66306
Vchromatin remodeling factor
p72001
sa(dp72002
g66301
I85
sg66302
I1
sg66303
I3
sg66304
VP28370
p72003
sg66306
VSWI
p72004
sa(dp72005
g66301
I89
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VSNF
p72006
sa(dp72007
g66301
I150
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VmiR-7
p72008
sa(dp72009
g66301
I215
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSMARCD1
p72010
sa(dp72011
g66301
I228
sg66302
I1
sg66303
I3
sg66304
VP42771
p72012
sg66306
Vp53
p72013
sasg66311
(lp72014
(dp72015
g66301
I276
sg66302
I2
sg66303
I11
sg66314
VC0684249
p72016
sg66306
Vlung cancer
p72017
sasa(dp72018
g66296
VmiR-490-3p exerted growth- and metastasis-suppressive effects on gastric cancer cells through directly targeting SMARCD1, a SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling complex subunit.
p72019
sg66298
(lp72020
(dp72021
g66301
I159
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VSNF
p72022
sa(dp72023
g66301
I124
sg66302
I1
sg66303
I3
sg66304
VP28370
p72024
sg66306
VSWI
p72025
sa(dp72026
g66301
I0
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-490-3p
p72027
sa(dp72028
g66301
I113
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSMARCD1
p72029
sasg66311
(lp72030
(dp72031
g66301
I65
sg66302
I2
sg66303
I14
sg66314
VC0024623
p72032
sg66306
Vgastric cancer
p72033
sa(dp72034
g66301
I31
sg66302
I1
sg66303
I10
sg66314
VC0027627
p72035
sg66306
Vmetastasis
p72036
sasa(dp72037
g66296
VKnockdown of SMARCD1 significantly attenuated the protumorigenic effects of miR-490-3p inhibitor, whereas enforced expression of SMARCD1 promoted in vitro and in vivo oncogenic phenotypes of gastric cancer cells.
p72038
sg66298
(lp72039
(dp72040
g66301
I13
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSMARCD1
p72041
sa(dp72042
g66301
I13
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSMARCD1
p72043
sa(dp72044
g66301
I76
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-490-3p
p72045
sasg66311
(lp72046
(dp72047
g66301
I191
sg66302
I2
sg66303
I14
sg66314
VC0024623
p72048
sg66306
Vgastric cancer
p72049
sasa(dp72050
g66296
VSMARCD1 was markedly upregulated in gastric cancer in which its high expression was associated with shortened patients' survival independent of TNM staging.
p72051
sg66298
(lp72052
(dp72053
g66301
I144
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VTNM
p72054
sa(dp72055
g66301
I0
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSMARCD1
p72056
sasg66311
(lp72057
(dp72058
g66301
I36
sg66302
I2
sg66303
I14
sg66314
VC0024623
p72059
sg66306
Vgastric cancer
p72060
sasa(dp72061
g66296
ViTD, nTD, and ECLNI were all significant independent adverse factors for RFS in rectal cancer, and were all associated with pT, pN, and LN ratio.
p72062
sg66298
(lp72063
(dp72064
g66301
I5
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VnTD
p72065
sasg66311
(lp72066
(dp72067
g66301
I73
sg66302
I1
sg66303
I3
sg66314
VC0015624
p72068
sg66306
VRFS
p72069
sa(dp72070
g66301
I80
sg66302
I2
sg66303
I13
sg66314
VC0007113
p72071
sg66306
Vrectal cancer
p72072
sasa(dp72073
g66296
VSilencing CCM3 by siRNA stimulated endothelial proliferation, migration and sprouting accompanied by significant downregulation of the core components of Notch signalling including DLL4, Notch4, HEY2 and HES1 and by activation of VEGF and Erk pathways.
p72074
sg66298
(lp72075
(dp72076
g66301
I204
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VHES1
p72077
sa(dp72078
g66301
I195
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VHEY2
p72079
sa(dp72080
g66301
I181
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VDLL4
p72081
sa(dp72082
g66301
I10
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VCCM3
p72083
sa(dp72084
g66301
I239
sg66302
I1
sg66303
I3
sg66304
VP29323
p72085
sg66306
VErk
p72086
sa(dp72087
g66301
I187
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VNotch4
p72088
sasg66311
(lp72089
(dp72090
g66301
I10
sg66302
I1
sg66303
I4
sg66314
VC1864040
p72091
sg66306
VCCM3
p72092
sa(dp72093
g66301
I47
sg66302
I1
sg66303
I13
sg66314
VC0334094
p72094
sg66306
Vproliferation
p72095
sasa(dp72096
g66296
VThe aim was to assess the efficacy of glucomannan (GNN) as a sole treatment for functional constipation.
p72097
sg66298
(lp72098
sg66311
(lp72099
(dp72100
g66301
I80
sg66302
I2
sg66303
I23
sg66314
VC0401146
p72101
sg66306
Vfunctional constipation
p72102
sasa(dp72103
g66296
VChildren aged 3-16 years with functional constipation according to Rome III criteria were randomly assigned to receive GNN (2.52 g/d) or placebo for 4 weeks.
p72104
sg66298
(lp72105
sg66311
(lp72106
(dp72107
g66301
I30
sg66302
I2
sg66303
I23
sg66314
VC0401146
p72108
sg66306
Vfunctional constipation
p72109
sasa(dp72110
g66296
VInterestingly, using Affymetrix gene expression data of a cohort of 285 patients with acute myeloid leukemia (AML), we found that GNN/TU12B1-TY expression was specifically increased in two AML clusters.
p72111
sg66298
(lp72112
(dp72113
g66301
I130
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VGNN
p72114
sasg66311
(lp72115
(dp72116
g66301
I110
sg66302
I1
sg66303
I3
sg66314
VC0023467
p72117
sg66306
VAML
p72118
sa(dp72119
g66301
I110
sg66302
I1
sg66303
I3
sg66314
VC0023467
p72120
sg66306
VAML
p72121
sa(dp72122
g66301
I86
sg66302
I3
sg66303
I22
sg66314
VC0023467
p72123
sg66306
Vacute myeloid leukemia
p72124
sasa(dp72125
g66296
VThe present results indicate that reduced function of TU12B1-TY may contribute to the development and/or progression of human pancreatic cancer.
p72126
sg66298
(lp72127
(dp72128
g66301
I54
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
VTU12B1-TY
p72129
sasg66311
(lp72130
(dp72131
g66301
I126
sg66302
I2
sg66303
I17
sg66314
VC0235974
p72132
sg66306
Vpancreatic cancer
p72133
sasa(dp72134
g66296
VTo characterize morphologic alterations in the retina of the visual mutant zebrafish gantenbein (gnn) and to examine whether these alterations correlate with those present in human hereditary eye diseases.
p72135
sg66298
(lp72136
(dp72137
g66301
I61
sg66302
I4
sg66303
I34
sg66304
g11
sg66306
Vvisual mutant zebrafish gantenbein
p72138
sa(dp72139
g66301
I97
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
Vgnn
p72140
sasg66311
(lp72141
(dp72142
g66301
I181
sg66302
I3
sg66303
I23
sg66314
VC0015398
p72143
sg66306
Vhereditary eye diseases
p72144
sa(dp72145
g66301
I68
sg66302
I1
sg66303
I6
sg66314
VC0596988
p72146
sg66306
Vmutant
p72147
sasa(dp72148
g66296
VThus, the early developmental morphology of gnn exhibits similarities to cone dystrophies most commonly seen in age-related macular degeneration (AMD) among humans, whereas the later stages of degeneration in gnn resemble RPE alterations in retinitis pigmentosa (RP) in humans.
p72149
sg66298
(lp72150
(dp72151
g66301
I44
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
Vgnn
p72152
sasg66311
(lp72153
(dp72154
g66301
I78
sg66302
I1
sg66303
I11
sg66314
VC0333606
p72155
sg66306
Vdystrophies
p72156
sa(dp72157
g66301
I132
sg66302
I1
sg66303
I12
sg66314
VC0011164
p72158
sg66306
Vdegeneration
p72159
sa(dp72160
g66301
I222
sg66302
I1
sg66303
I2
sg66314
VC0035334
p72161
sg66306
VRP
p72162
sa(dp72163
g66301
I112
sg66302
I3
sg66303
I32
sg66314
VC0242383
p72164
sg66306
Vage-related macular degeneration
p72165
sa(dp72166
g66301
I241
sg66302
I2
sg66303
I20
sg66314
VC0035334
p72167
sg66306
Vretinitis pigmentosa
p72168
sa(dp72169
g66301
I146
sg66302
I1
sg66303
I3
sg66314
VC0242383
p72170
sg66306
VAMD
p72171
sasa(dp72172
g66296
VThe gnn zebrafish mutant may therefore be a useful model for examining the possible interplay and connection between cone dystrophy and RPE degeneration.
p72173
sg66298
(lp72174
(dp72175
g66301
I4
sg66302
I3
sg66303
I20
sg66304
g11
sg66306
Vgnn zebrafish mutant
p72176
sasg66311
(lp72177
(dp72178
g66301
I117
sg66302
I2
sg66303
I14
sg66314
VC0730290
p72179
sg66306
Vcone dystrophy
p72180
sa(dp72181
g66301
I18
sg66302
I1
sg66303
I6
sg66314
VC0596988
p72182
sg66306
Vmutant
p72183
sa(dp72184
g66301
I140
sg66302
I1
sg66303
I12
sg66314
VC0011164
p72185
sg66306
Vdegeneration
p72186
sasa(dp72187
g66296
VOur goal was to assess the patterns of familial aggregation of three melanoma risk factors: great number of naevi (GNN), light phototype (LP) and high degree of sun exposure (HDSE).
p72188
sg66298
(lp72189
(dp72190
g66301
I69
sg66302
I3
sg66303
I21
sg66304
VP19883
p72191
sg66306
Vmelanoma risk factors
p72192
sasg66311
(lp72193
(dp72194
g66301
I69
sg66302
I1
sg66303
I8
sg66314
VC0025202
p72195
sg66306
Vmelanoma
p72196
sasa(dp72197
g66296
VTwenty-five patients were divided into the following groups: (1) chronic glomerulonephritis with normal renal function (GNN) (2) chronic glomerulonephritis with moderate renal insufficiency (GNI) (3) severe chronic renal failure undergoing maintenance dialysis (CRF) (4) acute renal failure during oliguric phase (ARF) (5) normal control without renal suffering (NC).
p72198
sg66298
(lp72199
sg66311
(lp72200
(dp72201
g66301
I65
sg66302
I2
sg66303
I26
sg66314
VC0152451
p72202
sg66306
Vchronic glomerulonephritis
p72203
sa(dp72204
g66301
I170
sg66302
I2
sg66303
I19
sg66314
VC0035078
p72205
sg66306
Vrenal insufficiency
p72206
sa(dp72207
g66301
I271
sg66302
I6
sg66303
I41
sg66314
VC0022660
p72208
sg66306
Vacute renal failure during oliguric phase
p72209
sa(dp72210
g66301
I262
sg66302
I1
sg66303
I3
sg66314
VC0022661
p72211
sg66306
VCRF
p72212
sa(dp72213
g66301
I314
sg66302
I1
sg66303
I3
sg66314
VC0022660
p72214
sg66306
VARF
p72215
sa(dp72216
g66301
I352
sg66302
I1
sg66303
I9
sg66314
VC0683278
p72217
sg66306
Vsuffering
p72218
sa(dp72219
g66301
I207
sg66302
I6
sg66303
I53
sg66314
VC0022661
p72220
sg66306
Vchronic renal failure undergoing maintenance dialysis
p72221
sa(dp72222
g66301
I65
sg66302
I2
sg66303
I26
sg66314
VC0152451
p72223
sg66306
Vchronic glomerulonephritis
p72224
sasa(dp72225
g66296
VThe levels of PTH/PTHrP receptor mRNA (corrected by beta-actin mRNA) in the kidney of GNN, GNI, CRF and ARF patients was markedly decreased by up to 35.7%, 68.5%, 77.9% and 92.2%, respectively.
p72226
sg66298
(lp72227
(dp72228
g66301
I86
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VGNN
p72229
sa(dp72230
g66301
I96
sg66302
I1
sg66303
I3
sg66304
VP06850
p72231
sg66306
VCRF
p72232
sa(dp72233
g66301
I14
sg66302
I1
sg66303
I3
sg66304
VP01270
p72234
sg66306
VPTH
p72235
sa(dp72236
g66301
I18
sg66302
I3
sg66303
I19
sg66304
VP12272
p72237
sg66306
VPTHrP receptor mRNA
p72238
sa(dp72239
g66301
I52
sg66302
I2
sg66303
I15
sg66304
VP63261
p72240
sg66306
Vbeta-actin mRNA
p72241
sa(dp72242
g66301
I104
sg66302
I1
sg66303
I3
sg66304
VP42771
p72243
sg66306
VARF
p72244
sasg66311
(lp72245
(dp72246
g66301
I104
sg66302
I1
sg66303
I3
sg66314
VC0264490
p72247
sg66306
VARF
p72248
sa(dp72249
g66301
I96
sg66302
I1
sg66303
I3
sg66314
VC0022661
p72250
sg66306
VCRF
p72251
sasa(dp72252
g66296
VHere, we tested whether rhMG53 protein can improve membrane repair in a dysferlin-deficient mouse model of LGMD2B (B6.129-Dysftm1Kcam/J).
p72253
sg66298
(lp72254
sg66311
(lp72255
(dp72256
g66301
I107
sg66302
I1
sg66303
I6
sg66314
VC1850889
p72257
sg66306
VLGMD2B
p72258
sasa(dp72259
g66296
VThree interacting partners of dysferlin are also implicated in membrane resealing: caveolin-3 (in limb girdle muscular dystrophy type 1C), annexin A1, and the newly identified protein mitsugumin 53 (MG53).
p72260
sg66298
(lp72261
(dp72262
g66301
I139
sg66302
I2
sg66303
I10
sg66304
VP04083
p72263
sg66306
Vannexin A1
p72264
sa(dp72265
g66301
I83
sg66302
I1
sg66303
I10
sg66304
VP56539
p72266
sg66306
Vcaveolin-3
p72267
sasg66311
(lp72268
(dp72269
g66301
I98
sg66302
I4
sg66303
I30
sg66314
VC0686353
p72270
sg66306
Vlimb girdle muscular dystrophy
p72271
sasa(dp72272
g66296
VLatency and amplitude of the visual P300 and N270 were examined in patients with transient ischemic attack (TIA) and in age-matched healthy control subjects to investigate the feasibility of N270 as a clinical examination method to evaluate the cognitive status of patients with TIA.
p72273
sg66298
(lp72274
sg66311
(lp72275
(dp72276
g66301
I81
sg66302
I3
sg66303
I25
sg66314
VC0007787
p72277
sg66306
Vtransient ischemic attack
p72278
sa(dp72279
g66301
I108
sg66302
I1
sg66303
I3
sg66314
VC0007787
p72280
sg66306
VTIA
p72281
sa(dp72282
g66301
I108
sg66302
I1
sg66303
I3
sg66314
VC0007787
p72283
sg66306
VTIA
p72284
sasa(dp72285
g66296
VWe applied multichannel recording of P300 in 28 patients (68.3 +/- 8.1 years; 15 asymptomatic, 13 with a history of transient ischemic attack (TIA)) and compared them with an age- and sex-matched control group.
p72286
sg66298
(lp72287
sg66311
(lp72288
(dp72289
g66301
I116
sg66302
I3
sg66303
I25
sg66314
VC0007787
p72290
sg66306
Vtransient ischemic attack
p72291
sa(dp72292
g66301
I143
sg66302
I1
sg66303
I3
sg66314
VC0007787
p72293
sg66306
VTIA
p72294
sasa(dp72295
g66296
VPrevious studies have implicated the roles of NT and NTR1 in the etiology or expression of schizophrenia.
p72296
sg66298
(lp72297
(dp72298
g66301
I53
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VNTR1
p72299
sasg66311
(lp72300
(dp72301
g66301
I91
sg66302
I1
sg66303
I13
sg66314
VC0036341
p72302
sg66306
Vschizophrenia
p72303
sasa(dp72304
g66296
VThis case-control study examined the associations between schizophrenia and three NTR1 gene polymorphisms (rs6090453C/G, rs6011914C/G, and rs2427422A/G) previously linked to working memory performance in a Han Chinese population.
p72305
sg66298
(lp72306
(dp72307
g66301
I82
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VNTR1 gene
p72308
sasg66311
(lp72309
(dp72310
g66301
I58
sg66302
I1
sg66303
I13
sg66314
VC0036341
p72311
sg66306
Vschizophrenia
p72312
sasa(dp72313
g66296
VThis suggested that nonpeptide agonist mimetics acting at the NTR1 might be helpful in the treatment of Parkinson's disease and schizophrenia.
p72314
sg66298
(lp72315
(dp72316
g66301
I62
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VNTR1
p72317
sasg66311
(lp72318
(dp72319
g66301
I104
sg66302
I2
sg66303
I19
sg66314
VC0030567
p72320
sg66306
VParkinson's disease
p72321
sa(dp72322
g66301
I128
sg66302
I1
sg66303
I13
sg66314
VC0036341
p72323
sg66306
Vschizophrenia
p72324
sasa(dp72325
g66296
VThe patients carrying either one or both of GCT and AGG alleles of SP-A2 and patients with A allele at position 1011 of MBL had markedly higher eosinophilia, total IgE antibodies and lower FEV1 (the clinical markers of ABPA).
p72326
sg66298
(lp72327
(dp72328
g66301
I164
sg66302
I1
sg66303
I3
sg66304
VP01854
p72329
sg66306
VIgE
p72330
sasg66311
(lp72331
(dp72332
g66301
I219
sg66302
I1
sg66303
I4
sg66314
VC0004031
p72333
sg66306
VABPA
p72334
sa(dp72335
g66301
I144
sg66302
I1
sg66303
I12
sg66314
VC0014457
p72336
sg66306
Veosinophilia
p72337
sa(dp72338
g66301
I164
sg66302
I1
sg66303
I3
sg66314
VC0270850
p72339
sg66306
VIgE
p72340
sasa(dp72341
g66296
VThe patients carrying either one or both of GCT and AGG alleles of SP-A2 and patients with A allele at position 1011 of MBL had markedly higher eosinophilia, total IgE antibodies and lower FEV1 (the clinical markers of ABPA).
p72342
sg66298
(lp72343
(dp72344
g66301
I164
sg66302
I1
sg66303
I3
sg66304
VP01854
p72345
sg66306
VIgE
p72346
sasg66311
(lp72347
(dp72348
g66301
I219
sg66302
I1
sg66303
I4
sg66314
VC0004031
p72349
sg66306
VABPA
p72350
sa(dp72351
g66301
I144
sg66302
I1
sg66303
I12
sg66314
VC0014457
p72352
sg66306
Veosinophilia
p72353
sa(dp72354
g66301
I164
sg66302
I1
sg66303
I3
sg66314
VC0270850
p72355
sg66306
VIgE
p72356
sasa(dp72357
g66296
Vsph1- and spa2-deleted cells possess defects in mating projection morphology and pseudohyphal growth.
p72358
sg66298
(lp72359
(dp72360
g66301
I0
sg66302
I1
sg66303
I4
sg66304
VP16157
p72361
sg66306
Vsph1
p72362
sa(dp72363
g66301
I10
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
Vspa2
p72364
sasg66311
(lp72365
(dp72366
g66301
I29
sg66302
I1
sg66303
I7
sg66314
VC0850310
p72367
sg66306
Vpossess
p72368
sa(dp72369
g66301
I0
sg66302
I1
sg66303
I4
sg66314
VC2674218
p72370
sg66306
Vsph1
p72371
sasa(dp72372
g66296
Vsph1(Delta) spa2(Delta) double mutants also exhibit a strong haploid invasive growth defect and an exacerbated mating projection defect relative to either sph1(Delta) or spa2(Delta) single mutants.
p72373
sg66298
(lp72374
(dp72375
g66301
I170
sg66302
I3
sg66303
I26
sg66304
g11
sg66306
Vspa2(Delta) single mutants
p72376
sa(dp72377
g66301
I0
sg66302
I1
sg66303
I11
sg66304
VP16157
p72378
sg66306
Vsph1(Delta)
p72379
sa(dp72380
g66301
I0
sg66302
I4
sg66303
I38
sg66304
VP16157
p72381
sg66306
Vsph1(Delta) spa2(Delta) double mutants
p72382
sasg66311
(lp72383
(dp72384
g66301
I0
sg66302
I1
sg66303
I4
sg66314
VC2674218
p72385
sg66306
Vsph1
p72386
sa(dp72387
g66301
I0
sg66302
I1
sg66303
I4
sg66314
VC2674218
p72388
sg66306
Vsph1
p72389
sa(dp72390
g66301
I69
sg66302
I2
sg66303
I15
sg66314
VC1156244
p72391
sg66306
Vinvasive growth
p72392
sasa(dp72393
g66296
VSPH1, which is similar to SPA2, is required for bipolar budding and plays a role in shmoo formation.
p72394
sg66298
(lp72395
(dp72396
g66301
I0
sg66302
I1
sg66303
I4
sg66304
VP16157
p72397
sg66306
VSPH1
p72398
sa(dp72399
g66301
I26
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VSPA2
p72400
sasg66311
(lp72401
(dp72402
g66301
I0
sg66302
I1
sg66303
I4
sg66314
VC2674218
p72403
sg66306
VSPH1
p72404
sasa(dp72405
g66296
VOutcomes were best in patients with ovarian cancer (MS 15.9 months) and colorectal cancer (MS 14.3 months) and worst in patients with lung (MS 2.4 months) and pancreas (MS 1.9 months) cancers.
p72406
sg66298
(lp72407
sg66311
(lp72408
(dp72409
g66301
I184
sg66302
I1
sg66303
I7
sg66314
VC0006826
p72410
sg66306
Vcancers
p72411
sa(dp72412
g66301
I72
sg66302
I2
sg66303
I17
sg66314
VC1527249
p72413
sg66306
Vcolorectal cancer
p72414
sa(dp72415
g66301
I36
sg66302
I2
sg66303
I14
sg66314
VC1140680
p72416
sg66306
Vovarian cancer
p72417
sasa(dp72418
g66296
VThis study was undertaken to evaluate the effect of ADAM8 on the proliferation and apoptosis of hepatocytes and hepatoma carcinoma cells during hepatocellular carcinoma (HCC) progression.
p72419
sg66298
(lp72420
(dp72421
g66301
I52
sg66302
I1
sg66303
I5
sg66304
VP78325
p72422
sg66306
VADAM8
p72423
sasg66311
(lp72424
(dp72425
g66301
I170
sg66302
I1
sg66303
I3
sg66314
VC2239176
p72426
sg66306
VHCC
p72427
sa(dp72428
g66301
I65
sg66302
I1
sg66303
I13
sg66314
VC0334094
p72429
sg66306
Vproliferation
p72430
sa(dp72431
g66301
I121
sg66302
I1
sg66303
I9
sg66314
VC0007097
p72432
sg66306
Vcarcinoma
p72433
sa(dp72434
g66301
I144
sg66302
I2
sg66303
I24
sg66314
VC2239176
p72435
sg66306
Vhepatocellular carcinoma
p72436
sa(dp72437
g66301
I112
sg66302
I1
sg66303
I8
sg66314
VC2239176
p72438
sg66306
Vhepatoma
p72439
sasa(dp72440
g66296
VIn conclusion, our study suggested that ADAM8 could promote the proliferation of normal hepatocytes and render hepatoma carcinoma cells more resistant to apoptosis to play important roles during the progression of HCC.
p72441
sg66298
(lp72442
(dp72443
g66301
I40
sg66302
I1
sg66303
I5
sg66304
VP78325
p72444
sg66306
VADAM8
p72445
sasg66311
(lp72446
(dp72447
g66301
I64
sg66302
I1
sg66303
I13
sg66314
VC0334094
p72448
sg66306
Vproliferation
p72449
sa(dp72450
g66301
I111
sg66302
I1
sg66303
I8
sg66314
VC2239176
p72451
sg66306
Vhepatoma
p72452
sa(dp72453
g66301
I120
sg66302
I1
sg66303
I9
sg66314
VC0007097
p72454
sg66306
Vcarcinoma
p72455
sa(dp72456
g66301
I214
sg66302
I1
sg66303
I3
sg66314
VC2239176
p72457
sg66306
VHCC
p72458
sasa(dp72459
g66296
VThus, our data integrate ADAM8 in pancreatic cancer signalling and validate ADAM8 as a target for PDAC therapy.
p72460
sg66298
(lp72461
(dp72462
g66301
I25
sg66302
I1
sg66303
I5
sg66304
VP78325
p72463
sg66306
VADAM8
p72464
sa(dp72465
g66301
I25
sg66302
I1
sg66303
I5
sg66304
VP78325
p72466
sg66306
VADAM8
p72467
sasg66311
(lp72468
(dp72469
g66301
I34
sg66302
I2
sg66303
I17
sg66314
VC0235974
p72470
sg66306
Vpancreatic cancer
p72471
sasa(dp72472
g66296
VThis study focuses on investigating the concrete role of a disintegrin and metalloproteinase 8 (ADAM8) in the progression of hepatocellular carcinoma (HCC).
p72473
sg66298
(lp72474
(dp72475
g66301
I59
sg66302
I5
sg66303
I43
sg66304
VP78325
p72476
sg66306
Vdisintegrin and metalloproteinase 8 (ADAM8)
p72477
sasg66311
(lp72478
(dp72479
g66301
I125
sg66302
I2
sg66303
I24
sg66314
VC2239176
p72480
sg66306
Vhepatocellular carcinoma
p72481
sa(dp72482
g66301
I151
sg66302
I1
sg66303
I3
sg66314
VC2239176
p72483
sg66306
VHCC
p72484
sasa(dp72485
g66296
VHowever, no studies have examined ADAM8 association in colorectal cancer (CRC).
p72486
sg66298
(lp72487
(dp72488
g66301
I34
sg66302
I6
sg66303
I44
sg66304
VP78325
p72489
sg66306
VADAM8 association in colorectal cancer (CRC)
p72490
sasg66311
(lp72491
(dp72492
g66301
I74
sg66302
I1
sg66303
I3
sg66314
VC1527249
p72493
sg66306
VCRC
p72494
sa(dp72495
g66301
I55
sg66302
I2
sg66303
I17
sg66314
VC1527249
p72496
sg66306
Vcolorectal cancer
p72497
sasa(dp72498
g66296
VSubgroup analysis showed that 5-year OS of colon cancer, T3-T4 stage and N0 stage was worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p &lt; 0.05).
p72499
sg66298
(lp72500
(dp72501
g66301
I110
sg66302
I1
sg66303
I5
sg66304
VP78325
p72502
sg66306
VADAM8
p72503
sasg66311
(lp72504
(dp72505
g66301
I125
sg66302
I1
sg66303
I6
sg66314
VC0027651
p72506
sg66306
Vtumors
p72507
sa(dp72508
g66301
I43
sg66302
I2
sg66303
I12
sg66314
VC0699790
p72509
sg66306
Vcolon cancer
p72510
sa(dp72511
g66301
I125
sg66302
I1
sg66303
I6
sg66314
VC0027651
p72512
sg66306
Vtumors
p72513
sasa(dp72514
g66296
VThe 5-year DFS in colon cancer, T3-T4 stage, N0 stage, TNM stage II, adenocarcinoma, moderate differentiation and male patient subgroups was also worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p &lt; 0.05).
p72515
sg66298
(lp72516
(dp72517
g66301
I170
sg66302
I1
sg66303
I5
sg66304
VP78325
p72518
sg66306
VADAM8
p72519
sa(dp72520
g66301
I55
sg66302
I3
sg66303
I12
sg66304
g11
sg66306
VTNM stage II
p72521
sasg66311
(lp72522
(dp72523
g66301
I69
sg66302
I1
sg66303
I14
sg66314
VC0001418
p72524
sg66306
Vadenocarcinoma
p72525
sa(dp72526
g66301
I18
sg66302
I2
sg66303
I12
sg66314
VC0699790
p72527
sg66306
Vcolon cancer
p72528
sa(dp72529
g66301
I185
sg66302
I1
sg66303
I6
sg66314
VC0027651
p72530
sg66306
Vtumors
p72531
sa(dp72532
g66301
I185
sg66302
I1
sg66303
I6
sg66314
VC0027651
p72533
sg66306
Vtumors
p72534
sasa(dp72535
g66296
VThe aim of this study was to examine the role of the inflammatory cells in the invasion of pancreatic cancer cells, focusing on the involvement of a disintegrin and metalloproteinase 8 (ADAM8) and matrix metalloproteinase 9 (MMP9) proteins.
p72536
sg66298
(lp72537
(dp72538
g66301
I197
sg66302
I5
sg66303
I42
sg66304
VP14780
p72539
sg66306
Vmatrix metalloproteinase 9 (MMP9) proteins
p72540
sa(dp72541
g66301
I149
sg66302
I5
sg66303
I43
sg66304
VP78325
p72542
sg66306
Vdisintegrin and metalloproteinase 8 (ADAM8)
p72543
sasg66311
(lp72544
(dp72545
g66301
I91
sg66302
I2
sg66303
I17
sg66314
VC0235974
p72546
sg66306
Vpancreatic cancer
p72547
sa(dp72548
g66301
I79
sg66302
I1
sg66303
I8
sg66314
VC2699153
p72549
sg66306
Vinvasion
p72550
sasa(dp72551
g66296
VADAM8 expression is associated with worse survival of pancreatic cancer patients.
p72552
sg66298
(lp72553
(dp72554
g66301
I0
sg66302
I1
sg66303
I5
sg66304
VP78325
p72555
sg66306
VADAM8
p72556
sasg66311
(lp72557
(dp72558
g66301
I54
sg66302
I2
sg66303
I17
sg66314
VC0235974
p72559
sg66306
Vpancreatic cancer
p72560
sasa(dp72561
g66296
VAnti-inflammatory macrophages increase pancreatic cancer cell migration rate in basement membrane matrix by inducing ADAM8 and MMP9 expression in cancer cells, thereby possibly enhancing the invasiveness of cancer.
p72562
sg66298
(lp72563
(dp72564
g66301
I127
sg66302
I1
sg66303
I4
sg66304
VP14780
p72565
sg66306
VMMP9
p72566
sa(dp72567
g66301
I117
sg66302
I1
sg66303
I5
sg66304
VP78325
p72568
sg66306
VADAM8
p72569
sasg66311
(lp72570
(dp72571
g66301
I39
sg66302
I2
sg66303
I17
sg66314
VC0235974
p72572
sg66306
Vpancreatic cancer
p72573
sa(dp72574
g66301
I50
sg66302
I1
sg66303
I6
sg66314
VC0006826
p72575
sg66306
Vcancer
p72576
sa(dp72577
g66301
I50
sg66302
I1
sg66303
I6
sg66314
VC0006826
p72578
sg66306
Vcancer
p72579
sasa(dp72580
g66296
VIn this study,we investigated the ADAM8 expression in hepatocellular carcinoma (HCC) and its correlation with clinicopathologic features,including the survival of patients with HCC.
p72581
sg66298
(lp72582
(dp72583
g66301
I34
sg66302
I1
sg66303
I5
sg66304
VP78325
p72584
sg66306
VADAM8
p72585
sasg66311
(lp72586
(dp72587
g66301
I54
sg66302
I2
sg66303
I24
sg66314
VC2239176
p72588
sg66306
Vhepatocellular carcinoma
p72589
sa(dp72590
g66301
I80
sg66302
I1
sg66303
I3
sg66314
VC2239176
p72591
sg66306
VHCC
p72592
sa(dp72593
g66301
I80
sg66302
I1
sg66303
I3
sg66314
VC2239176
p72594
sg66306
VHCC
p72595
sasa(dp72596
g66296
VOther studies have demonstrated overexpression of some ADAM family proteins in a variety of human tumors, but no report is available on the actual expression of ADAM8 and the correlation between clinicopathologic features and prognosis of hepatocellular carcinoma (HCC) patients.
p72597
sg66298
(lp72598
(dp72599
g66301
I55
sg66302
I3
sg66303
I20
sg66304
VP02649
p72600
sg66306
VADAM family proteins
p72601
sa(dp72602
g66301
I161
sg66302
I1
sg66303
I5
sg66304
VP78325
p72603
sg66306
VADAM8
p72604
sasg66311
(lp72605
(dp72606
g66301
I98
sg66302
I1
sg66303
I6
sg66314
VC0027651
p72607
sg66306
Vtumors
p72608
sa(dp72609
g66301
I265
sg66302
I1
sg66303
I3
sg66314
VC2239176
p72610
sg66306
VHCC
p72611
sa(dp72612
g66301
I239
sg66302
I2
sg66303
I24
sg66314
VC2239176
p72613
sg66306
Vhepatocellular carcinoma
p72614
sasa(dp72615
g66296
VTo evaluate the association between ADAM8 tissue expression and patient prognosis in hepatocellular carcinoma (HCC).
p72616
sg66298
(lp72617
(dp72618
g66301
I36
sg66302
I1
sg66303
I5
sg66304
VP78325
p72619
sg66306
VADAM8
p72620
sasg66311
(lp72621
(dp72622
g66301
I111
sg66302
I1
sg66303
I3
sg66314
VC2239176
p72623
sg66306
VHCC
p72624
sa(dp72625
g66301
I85
sg66302
I2
sg66303
I24
sg66314
VC2239176
p72626
sg66306
Vhepatocellular carcinoma
p72627
sasa(dp72628
g66296
VSome of the previously reported gout associated loci (except ALDH16A1), including ABCG2, SLC2A9, GCKR, ALDH2 and CNIH2, were replicated.
p72629
sg66298
(lp72630
(dp72631
g66301
I113
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCNIH2
p72632
sa(dp72633
g66301
I89
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSLC2A9
p72634
sa(dp72635
g66301
I103
sg66302
I1
sg66303
I5
sg66304
VP05091
p72636
sg66306
VALDH2
p72637
sa(dp72638
g66301
I61
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VALDH16A1
p72639
sa(dp72640
g66301
I97
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGCKR
p72641
sasg66311
(lp72642
(dp72643
g66301
I32
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72644
sg66306
Vgout
p72645
sasa(dp72646
g66296
VThe aim of this study was to examine the role of SLC2A9 and ABCG2 variants in tophaceous disease in people with gout.
p72647
sg66298
(lp72648
(dp72649
g66301
I49
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSLC2A9
p72650
sa(dp72651
g66301
I60
sg66302
I2
sg66303
I14
sg66304
VP26640
p72652
sg66306
VABCG2 variants
p72653
sasg66311
(lp72654
(dp72655
g66301
I112
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72656
sg66306
Vgout
p72657
sasa(dp72658
g66296
VThe main objective of this study is to elucidate the clinical significance of the SLC2A9/GLUT9 rs11722228 polymorphism among male gout patients.
p72659
sg66298
(lp72660
(dp72661
g66301
I89
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VGLUT9
p72662
sa(dp72663
g66301
I82
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSLC2A9
p72664
sasg66311
(lp72665
(dp72666
g66301
I130
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72667
sg66306
Vgout
p72668
sasa(dp72669
g66296
VThe genotypic frequencies of SLC2A9/GLUT9 rs1172228 did not differ significantly between the gout cases and the healthy controls.
p72670
sg66298
(lp72671
(dp72672
g66301
I29
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSLC2A9
p72673
sa(dp72674
g66301
I36
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VGLUT9
p72675
sasg66311
(lp72676
(dp72677
g66301
I93
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72678
sg66306
Vgout
p72679
sasa(dp72680
g66296
VThe genotypic distribution of SLC2A9/GLUT9 rs1172228 in male gout patients did not differ significantly from that of healthy male controls.
p72681
sg66298
(lp72682
(dp72683
g66301
I37
sg66302
I2
sg66303
I15
sg66304
g11
sg66306
VGLUT9 rs1172228
p72684
sa(dp72685
g66301
I30
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSLC2A9
p72686
sasg66311
(lp72687
(dp72688
g66301
I61
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72689
sg66306
Vgout
p72690
sasa(dp72691
g66296
VThe relationship between the SLC2A9 (solute carrier family 2, member 9) gene polymorphisms and gout was still inconsistent among the individual genetic association studies.
p72692
sg66298
(lp72693
(dp72694
g66301
I37
sg66302
I4
sg66303
I23
sg66304
g11
sg66306
Vsolute carrier family 2
p72695
sa(dp72696
g66301
I29
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSLC2A9
p72697
sasg66311
(lp72698
(dp72699
g66301
I95
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72700
sg66306
Vgout
p72701
sasa(dp72702
g66296
VTherefore, this present research was aimed to systematically evaluate the association between SLC2A9 gene polymorphisms and gout susceptibility.
p72703
sg66298
(lp72704
(dp72705
g66301
I94
sg66302
I2
sg66303
I11
sg66304
g11
sg66306
VSLC2A9 gene
p72706
sasg66311
(lp72707
(dp72708
g66301
I124
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72709
sg66306
Vgout
p72710
sasa(dp72711
g66296
VThis study demonstrated that the genetic susceptibility for gout is associated with the SLC2A9 gene polymorphisms.
p72712
sg66298
(lp72713
(dp72714
g66301
I88
sg66302
I2
sg66303
I11
sg66304
g11
sg66306
VSLC2A9 gene
p72715
sasg66311
(lp72716
(dp72717
g66301
I60
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72718
sg66306
Vgout
p72719
sasa(dp72720
g66296
VEight variants of ABCG2, SLC2A9, SLC22A12, SLC22A11 and SLC17A3 were genotyped in male individuals in a case-control study with 157 gout (33% tophi), 106 asymptomatic hyperuricaemia and 295 control subjects from Taiwan.
p72721
sg66298
(lp72722
(dp72723
g66301
I33
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VSLC22A12
p72724
sa(dp72725
g66301
I43
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VSLC22A11
p72726
sa(dp72727
g66301
I25
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSLC2A9
p72728
sa(dp72729
g66301
I56
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VSLC17A3
p72730
sasg66311
(lp72731
(dp72732
g66301
I142
sg66302
I1
sg66303
I5
sg66314
VC0221248
p72733
sg66306
Vtophi
p72734
sa(dp72735
g66301
I132
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72736
sg66306
Vgout
p72737
sa(dp72738
g66301
I167
sg66302
I1
sg66303
I14
sg66314
VC0740394
p72739
sg66306
Vhyperuricaemia
p72740
sasa(dp72741
g66296
VABCG2 Q141K (T), SLC2A9 rs1014290 (A) and SLC22A12 rs475688 (C) under an additive model and alcohol use independently predicted the risk of gout (respective odds ratio for each factor=2.48, 2.03, 1.95 and 2.48).
p72742
sg66298
(lp72743
(dp72744
g66301
I17
sg66302
I2
sg66303
I16
sg66304
g11
sg66306
VSLC2A9 rs1014290
p72745
sa(dp72746
g66301
I42
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VSLC22A12
p72747
sasg66311
(lp72748
(dp72749
g66301
I140
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72750
sg66306
Vgout
p72751
sasa(dp72752
g66296
VThe aim of this study was to determine whether polymorphisms in solute carrier family 2 and facilitated glucose transporter member 9 (SLC2A9) are associated with susceptibility to gout.
p72753
sg66298
(lp72754
(dp72755
g66301
I134
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSLC2A9
p72756
sa(dp72757
g66301
I64
sg66302
I10
sg66303
I68
sg66304
g11
sg66306
Vsolute carrier family 2 and facilitated glucose transporter member 9
p72758
sasg66311
(lp72759
(dp72760
g66301
I180
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72761
sg66306
Vgout
p72762
sasa(dp72763
g66296
VA meta-analysis was conducted on associations between the rs12510549, rs16890979, and rs1014290 polymorphisms of SLC2A9 and gout susceptibility using fixed and random effects models.
p72764
sg66298
(lp72765
(dp72766
g66301
I113
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSLC2A9
p72767
sasg66311
(lp72768
(dp72769
g66301
I124
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72770
sg66306
Vgout
p72771
sasa(dp72772
g66296
VThis meta-analysis shows that the rs12510549, rs16890979, and rs1014290 polymorphisms of SLC2A9 protect against the development of gout in Caucasians and/or Asians.
p72773
sg66298
(lp72774
sg66311
(lp72775
(dp72776
g66301
I131
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72777
sg66306
Vgout
p72778
sasa(dp72779
g66296
VWe investigated the association of polymorphisms in the ABCG2 and SLC2A9 genes with gout in Korean patients and healthy individuals.
p72780
sg66298
(lp72781
(dp72782
g66301
I66
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VSLC2A9 genes
p72783
sasg66311
(lp72784
(dp72785
g66301
I84
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72786
sg66306
Vgout
p72787
sasa(dp72788
g66296
VWe demonstrated a significant association between rs2231142 in the ABCG2 gene and gout and identified novel SNPs, c.881A&gt;G and c.1002+78G&gt;A, in the SLC2A9 gene that may be associated with gout in a Korean population.
p72789
sg66298
(lp72790
(dp72791
g66301
I154
sg66302
I2
sg66303
I11
sg66304
g11
sg66306
VSLC2A9 gene
p72792
sasg66311
(lp72793
(dp72794
g66301
I82
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72795
sg66306
Vgout
p72796
sa(dp72797
g66301
I82
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72798
sg66306
Vgout
p72799
sasa(dp72800
g66296
VSLC2A9 and ZNF518B may play a role in gout progression in different populations, but no studies have focused on the Tibetan Chinese population.
p72801
sg66298
(lp72802
(dp72803
g66301
I11
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VZNF518B
p72804
sa(dp72805
g66301
I0
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSLC2A9
p72806
sasg66311
(lp72807
(dp72808
g66301
I38
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72809
sg66306
Vgout
p72810
sasa(dp72811
g66296
VWe detected 6 single nucleotide polymorphisms in SLC2A9 and ZNF518B in 319 Chinese Tibetan gout patients.
p72812
sg66298
(lp72813
(dp72814
g66301
I49
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSLC2A9
p72815
sa(dp72816
g66301
I60
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VZNF518B
p72817
sasg66311
(lp72818
(dp72819
g66301
I91
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72820
sg66306
Vgout
p72821
sasa(dp72822
g66296
VPolymorphisms in SLC2A9 and ZNF518B affected multiple risk factors related to gout development.
p72823
sg66298
(lp72824
(dp72825
g66301
I17
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSLC2A9
p72826
sa(dp72827
g66301
I28
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VZNF518B
p72828
sasg66311
(lp72829
(dp72830
g66301
I78
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72831
sg66306
Vgout
p72832
sasa(dp72833
g66296
VThis study is the first to investigate and identify positive correlations between SLC2A9 and ZNF518B gene polymorphisms and metabolic indices in Tibetan gout patients.
p72834
sg66298
(lp72835
(dp72836
g66301
I93
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VZNF518B gene
p72837
sa(dp72838
g66301
I82
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSLC2A9
p72839
sasg66311
(lp72840
(dp72841
g66301
I153
sg66302
I1
sg66303
I4
sg66314
VC0018099
p72842
sg66306
Vgout
p72843
sasa(dp72844
g66296
VIn conclusion, two patients who developed hypercalcemia associated with bone metastasis after surgery for HCC were treated with alendronate and they experienced alleviation of the pain due to bone metastasis, improvement of their quality of life and a marked decrease in AFP levels with tumor regression.
p72845
sg66298
(lp72846
sg66311
(lp72847
(dp72848
g66301
I42
sg66302
I1
sg66303
I13
sg66314
VC0020437
p72849
sg66306
Vhypercalcemia
p72850
sa(dp72851
g66301
I72
sg66302
I2
sg66303
I15
sg66314
VC0153690
p72852
sg66306
Vbone metastasis
p72853
sa(dp72854
g66301
I287
sg66302
I1
sg66303
I5
sg66314
VC0027651
p72855
sg66306
Vtumor
p72856
sa(dp72857
g66301
I106
sg66302
I1
sg66303
I3
sg66314
VC2239176
p72858
sg66306
VHCC
p72859
sa(dp72860
g66301
I72
sg66302
I2
sg66303
I15
sg66314
VC0153690
p72861
sg66306
Vbone metastasis
p72862
sasa(dp72863
g66296
VColoboma-like optic discs might be an additional feature observed in patients with SPTAN1 mutations.
p72864
sg66298
(lp72865
sg66311
(lp72866
(dp72867
g66301
I0
sg66302
I1
sg66303
I8
sg66314
VC0009363
p72868
sg66306
VColoboma
p72869
sasa(dp72870
g66296
VA newly described autoantibody to alpha-fodrin found in other neurodegenerative diseases such as Alzheimer's, further implicate a role for autoimmunity and the neurodegenerative processes in glaucoma.
p72871
sg66298
(lp72872
sg66311
(lp72873
(dp72874
g66301
I62
sg66302
I2
sg66303
I26
sg66314
VC0524851
p72875
sg66306
Vneurodegenerative diseases
p72876
sa(dp72877
g66301
I191
sg66302
I1
sg66303
I8
sg66314
VC0017601
p72878
sg66306
Vglaucoma
p72879
sa(dp72880
g66301
I139
sg66302
I1
sg66303
I12
sg66314
VC0004368
p72881
sg66306
Vautoimmunity
p72882
sasa(dp72883
g66296
VIn a similar experiment, ocular hypertension was induced in four eyes pre-treated with an intravitreal injection of AAV-BIRC4 to assess alpha-fodrin cleavage.
p72884
sg66298
(lp72885
sg66311
(lp72886
(dp72887
g66301
I25
sg66302
I2
sg66303
I19
sg66314
VC0028840
p72888
sg66306
Vocular hypertension
p72889
sasa(dp72890
g66296
VComparison of the Zrs z-scores between the healthy children and the health groups found significant differences in children with asthma, current wheeze and respiratory symptoms, but not in children born preterm or with early-life wheeze.
p72891
sg66298
(lp72892
sg66311
(lp72893
(dp72894
g66301
I156
sg66302
I2
sg66303
I20
sg66314
VC0037090
p72895
sg66306
Vrespiratory symptoms
p72896
sa(dp72897
g66301
I145
sg66302
I1
sg66303
I6
sg66314
VC0043144
p72898
sg66306
Vwheeze
p72899
sa(dp72900
g66301
I145
sg66302
I1
sg66303
I6
sg66314
VC0043144
p72901
sg66306
Vwheeze
p72902
sa(dp72903
g66301
I129
sg66302
I1
sg66303
I6
sg66314
VC0004096
p72904
sg66306
Vasthma
p72905
sasa(dp72906
g66296
VThe aim of this retrospective study was to assess responses to a bronchodilator by forced oscillation technique (FOT) and to relate the results of respiratory impedance (Zrs) to spirometric parameters in patients with chronic obstructive pulmonary disease (COPD).
p72907
sg66298
(lp72908
sg66311
(lp72909
(dp72910
g66301
I218
sg66302
I4
sg66303
I37
sg66314
VC0024117
p72911
sg66306
Vchronic obstructive pulmonary disease
p72912
sa(dp72913
g66301
I257
sg66302
I1
sg66303
I4
sg66314
VC0024117
p72914
sg66306
VCOPD
p72915
sasa(dp72916
g66296
VThe diagnostic efficiency of Zrs, R5 and X35 when diagnosis asthma, expressed by ROC curve parameters, was as follows: AUC (0.721, 0.710, 0.695), sensitivity (62%, 72%, 53%) and specificity (72%, 61%, 76%), respectively.
p72917
sg66298
(lp72918
sg66311
(lp72919
(dp72920
g66301
I60
sg66302
I1
sg66303
I6
sg66314
VC0004096
p72921
sg66306
Vasthma
p72922
sasa(dp72923
g66296
VAnd R5, X35 and Zrs may provide useful IOS parameters for asthma.
p72924
sg66298
(lp72925
(dp72926
g66301
I16
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VZrs
p72927
sasg66311
(lp72928
(dp72929
g66301
I58
sg66302
I1
sg66303
I6
sg66314
VC0004096
p72930
sg66306
Vasthma
p72931
sasa(dp72932
g66296
VBirth weight less than 3,000 g was associated with larger exercise-induced changes in Zrs and Rrs at 5 Hz, and in reactance (Xrs) at 5 Hz, than those with birth weight more than 3,000 g. Preliminary evidence was found that obesity may be associated with airway obstruction, but not with bronchial hyper-reactivity.
p72933
sg66298
(lp72934
sg66311
(lp72935
(dp72936
g66301
I223
sg66302
I1
sg66303
I7
sg66314
VC0028754
p72937
sg66306
Vobesity
p72938
sa(dp72939
g66301
I94
sg66302
I1
sg66303
I3
sg66314
VC1849334
p72940
sg66306
VRrs
p72941
sa(dp72942
g66301
I254
sg66302
I2
sg66303
I18
sg66314
VC0001883
p72943
sg66306
Vairway obstruction
p72944
sasa(dp72945
g66296
VTo investigate the nature of mutations in exons 4 and 5 of the uromodulin (UM) gene, including in the area encoding the domain of 8 cysteines (D8C), in patients with multiple myeloma (MM) with the secretion of monoclonal light chains (LC) in cast nephropathy (CN) and without kidney injury.
p72946
sg66298
(lp72947
(dp72948
g66301
I63
sg66302
I3
sg66303
I20
sg66304
VP07911
p72949
sg66306
Vuromodulin (UM) gene
p72950
sasg66311
(lp72951
(dp72952
g66301
I247
sg66302
I1
sg66303
I11
sg66314
VC0022658
p72953
sg66306
Vnephropathy
p72954
sa(dp72955
g66301
I166
sg66302
I2
sg66303
I16
sg66314
VC0026764
p72956
sg66306
Vmultiple myeloma
p72957
sasa(dp72958
g66296
VThe aim of the study was to investigate the association of the uromodulin (UMOD) genotype with patient health status and with renal cell carcinoma (RCC) aggressiveness.
p72959
sg66298
(lp72960
(dp72961
g66301
I75
sg66302
I1
sg66303
I4
sg66304
VP07911
p72962
sg66306
VUMOD
p72963
sa(dp72964
g66301
I63
sg66302
I1
sg66303
I10
sg66304
VP07911
p72965
sg66306
Vuromodulin
p72966
sasg66311
(lp72967
(dp72968
g66301
I148
sg66302
I1
sg66303
I3
sg66314
VC0007134
p72969
sg66306
VRCC
p72970
sa(dp72971
g66301
I126
sg66302
I3
sg66303
I20
sg66314
VC0007134
p72972
sg66306
Vrenal cell carcinoma
p72973
sa(dp72974
g66301
I153
sg66302
I1
sg66303
I14
sg66314
VC0001807
p72975
sg66306
Vaggressiveness
p72976
sasa(dp72977
g66296
VIn patients diagnosed with renal cell carcinoma and treated with surgery, uromodulin homozygous genotype is associated with more aggressive renal cell carcinoma clinical and pathological characteristics.
p72978
sg66298
(lp72979
(dp72980
g66301
I74
sg66302
I1
sg66303
I10
sg66304
VP07911
p72981
sg66306
Vuromodulin
p72982
sasg66311
(lp72983
(dp72984
g66301
I129
sg66302
I1
sg66303
I10
sg66314
VC0001807
p72985
sg66306
Vaggressive
p72986
sa(dp72987
g66301
I27
sg66302
I3
sg66303
I20
sg66314
VC0007134
p72988
sg66306
Vrenal cell carcinoma
p72989
sa(dp72990
g66301
I27
sg66302
I3
sg66303
I20
sg66314
VC0007134
p72991
sg66306
Vrenal cell carcinoma
p72992
sasa(dp72993
g66296
VCYP11B2 was sequenced if the aldosterone level was high (primary aldosteronism phenotype); SCNN1B, NEDD4L, GRK4, UMOD, and NPPA genes were sequenced if the aldosterone level was low (Liddle phenotype).
p72994
sg66298
(lp72995
(dp72996
g66301
I91
sg66302
I1
sg66303
I6
sg66304
VP51168
p72997
sg66306
VSCNN1B
p72998
sa(dp72999
g66301
I0
sg66302
I1
sg66303
I7
sg66304
VP19099
p73000
sg66306
VCYP11B2
p73001
sa(dp73002
g66301
I123
sg66302
I2
sg66303
I10
sg66304
VP01160
p73003
sg66306
VNPPA genes
p73004
sa(dp73005
g66301
I113
sg66302
I1
sg66303
I4
sg66304
VP07911
p73006
sg66306
VUMOD
p73007
sasg66311
(lp73008
(dp73009
g66301
I57
sg66302
I2
sg66303
I21
sg66314
VC1384514
p73010
sg66306
Vprimary aldosteronism
p73011
sasa(dp73012
g66296
VMT1F, MT1G, MT1X, and MT2A gene expression was significantly downregulated in colon cancer tissue (p&lt;0.05).
p73013
sg66298
(lp73014
(dp73015
g66301
I12
sg66302
I1
sg66303
I4
sg66304
VP80297
p73016
sg66306
VMT1X
p73017
sa(dp73018
g66301
I6
sg66302
I1
sg66303
I4
sg66304
VP04733
p73019
sg66306
VMT1G
p73020
sa(dp73021
g66301
I0
sg66302
I1
sg66303
I4
sg66304
VP04733
p73022
sg66306
VMT1F
p73023
sa(dp73024
g66301
I22
sg66302
I2
sg66303
I9
sg66304
VP02795
p73025
sg66306
VMT2A gene
p73026
sasg66311
(lp73027
(dp73028
g66301
I78
sg66302
I2
sg66303
I12
sg66314
VC0699790
p73029
sg66306
Vcolon cancer
p73030
sasa(dp73031
g66296
VHere, we describe the discovery of a new MSI marker for colorectal cancer located in the 3'-untranslated region (3'UTR, T20 mononucleotide repeat) of the metallothionein 1X gene (MT1XT20).
p73032
sg66298
(lp73033
(dp73034
g66301
I154
sg66302
I3
sg66303
I23
sg66304
VP80297
p73035
sg66306
Vmetallothionein 1X gene
p73036
sasg66311
(lp73037
(dp73038
g66301
I41
sg66302
I1
sg66303
I3
sg66314
VC0920269
p73039
sg66306
VMSI
p73040
sa(dp73041
g66301
I56
sg66302
I2
sg66303
I17
sg66314
VC1527249
p73042
sg66306
Vcolorectal cancer
p73043
sasa(dp73044
g66296
VIndeed, MT1XT20 instability was detected in 36 out of 37 cases (97.3%) of MSI-high colorectal cancers, whereas no MT1XT20 alterations were observed in 254 MSS or in 46 MSI-low cases.
p73045
sg66298
(lp73046
sg66311
(lp73047
(dp73048
g66301
I74
sg66302
I1
sg66303
I3
sg66314
VC0920269
p73049
sg66306
VMSI
p73050
sa(dp73051
g66301
I155
sg66302
I1
sg66303
I3
sg66314
VC0024814
p73052
sg66306
VMSS
p73053
sa(dp73054
g66301
I74
sg66302
I1
sg66303
I3
sg66314
VC0920269
p73055
sg66306
VMSI
p73056
sa(dp73057
g66301
I83
sg66302
I2
sg66303
I18
sg66314
VC1527249
p73058
sg66306
Vcolorectal cancers
p73059
sasa(dp73060
g66296
VHNF-1Beta regulates tissue-specific gene expression in endometriosis, as well as the expression of several genes, including CD44v9, which binds several molecules, including hyaluronan, epidermal growth factor receptor (EGFR), leukemia-associated Rho-guanine nucleotide exchange factor (LARG), IQ motif containing GTPase activating protein 1 (IQGAP1), macrophage migration inhibitory factor (MIF), major histocompatibility complex, class II invariant chain (CD74), cystine transporter subunit (xCT), Fas and extracellular matrix (ECM) proteins.
p73061
sg66298
(lp73062
(dp73063
g66301
I342
sg66302
I1
sg66303
I6
sg66304
VP46940
p73064
sg66306
VIQGAP1
p73065
sa(dp73066
g66301
I286
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VLARG
p73067
sa(dp73068
g66301
I0
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
VHNF-1Beta
p73069
sa(dp73070
g66301
I507
sg66302
I4
sg66303
I35
sg66304
g11
sg66306
Vextracellular matrix (ECM) proteins
p73071
sa(dp73072
g66301
I293
sg66302
I7
sg66303
I47
sg66304
VP46940
p73073
sg66306
VIQ motif containing GTPase activating protein 1
p73074
sa(dp73075
g66301
I226
sg66302
I5
sg66303
I58
sg66304
g11
sg66306
Vleukemia-associated Rho-guanine nucleotide exchange factor
p73076
sa(dp73077
g66301
I219
sg66302
I1
sg66303
I4
sg66304
VP01133
p73078
sg66306
VEGFR
p73079
sa(dp73080
g66301
I499
sg66302
I1
sg66303
I3
sg66304
VP48023
p73081
sg66306
VFas
p73082
sa(dp73083
g66301
I457
sg66302
I1
sg66303
I4
sg66304
VP04233
p73084
sg66306
VCD74
p73085
sa(dp73086
g66301
I397
sg66302
I7
sg66303
I58
sg66304
VP18464
p73087
sg66306
Vmajor histocompatibility complex, class II invariant chain
p73088
sa(dp73089
g66301
I464
sg66302
I3
sg66303
I27
sg66304
g11
sg66306
Vcystine transporter subunit
p73090
sa(dp73091
g66301
I185
sg66302
I4
sg66303
I32
sg66304
VP01133
p73092
sg66306
Vepidermal growth factor receptor
p73093
sa(dp73094
g66301
I493
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VxCT
p73095
sasg66311
(lp73096
(dp73097
g66301
I226
sg66302
I1
sg66303
I8
sg66314
VC0023418
p73098
sg66306
Vleukemia
p73099
sa(dp73100
g66301
I55
sg66302
I1
sg66303
I13
sg66314
VC0014175
p73101
sg66306
Vendometriosis
p73102
sa(dp73103
g66301
I499
sg66302
I1
sg66303
I3
sg66314
VC0015923
p73104
sg66306
VFas
p73105
sasa(dp73106
g66296
VWe sought to determine whether oxidative stress or a relative deficit of l-arginine plays a role in reducing cutaneous vasodilation in response to local heating in chronic kidney disease (CKD).
p73107
sg66298
(lp73108
sg66311
(lp73109
(dp73110
g66301
I62
sg66302
I1
sg66303
I7
sg66314
VC0162429
p73111
sg66306
Vdeficit
p73112
sa(dp73113
g66301
I164
sg66302
I3
sg66303
I22
sg66314
VC1561643
p73114
sg66306
Vchronic kidney disease
p73115
sa(dp73116
g66301
I188
sg66302
I1
sg66303
I3
sg66314
VC1561643
p73117
sg66306
VCKD
p73118
sa(dp73119
g66301
I119
sg66302
I1
sg66303
I12
sg66314
VC0595862
p73120
sg66306
Vvasodilation
p73121
sa(dp73122
g66301
I31
sg66302
I2
sg66303
I16
sg66314
VC0242606
p73123
sg66306
Voxidative stress
p73124
sasa(dp73125
g66296
VEight patients with stage 3-4 CKD and eight age- and sex-matched healthy control (HC) subjects were instrumented with four microdialysis (MD) fibers for the local delivery of 1) Ringers solution (R), 2) 20 mM ascorbic acid (AA), 3) 10 mM l-arginine (l-Arg), and 4) 10 mM N(G)-nitro-l-arginine methyl ester (l-NAME).
p73126
sg66298
(lp73127
sg66311
(lp73128
sa(dp73129
g66296
VThe plateau %CVC(max) in the CKD group was significantly greater at the AA and l-Arg sites compared with R (AA: 89 +/- 2; l-Arg: 90 +/- 1; R: 76 +/- 4; P &lt; 0.05) and did not differ from HC.
p73130
sg66298
(lp73131
sg66311
(lp73132
sa(dp73133
g66296
VInitial peak %CVC(max) was also significantly attenuated at the R and l-Arg sites in CKD (P &lt; 0.05) but did not differ at the AA site.
p73134
sg66298
(lp73135
sg66311
(lp73136
sa(dp73137
g66296
VThese results suggest that cutaneous microvascular function is impaired in stage 3-4 CKD and that oxidative stress and a deficit of l-arginine play a role in this impairment.
p73138
sg66298
(lp73139
sg66311
(lp73140
(dp73141
g66301
I163
sg66302
I1
sg66303
I10
sg66314
VC0684336
p73142
sg66306
Vimpairment
p73143
sa(dp73144
g66301
I63
sg66302
I1
sg66303
I8
sg66314
VC0684336
p73145
sg66306
Vimpaired
p73146
sa(dp73147
g66301
I121
sg66302
I1
sg66303
I7
sg66314
VC0162429
p73148
sg66306
Vdeficit
p73149
sa(dp73150
g66301
I98
sg66302
I2
sg66303
I16
sg66314
VC0242606
p73151
sg66306
Voxidative stress
p73152
sasa(dp73153
g66296
VIf true, plasma L-arg should be severely reduced in chronic renal failure (CRF); however, plasma L-arg is frequently unchanged in CRF.
p73154
sg66298
(lp73155
(dp73156
g66301
I75
sg66302
I1
sg66303
I3
sg66304
VP06850
p73157
sg66306
VCRF
p73158
sa(dp73159
g66301
I52
sg66302
I3
sg66303
I21
sg66304
VP06850
p73160
sg66306
Vchronic renal failure
p73161
sasg66311
(lp73162
(dp73163
g66301
I75
sg66302
I1
sg66303
I3
sg66314
VC0022661
p73164
sg66306
VCRF
p73165
sa(dp73166
g66301
I52
sg66302
I3
sg66303
I21
sg66314
VC0022661
p73167
sg66306
Vchronic renal failure
p73168
sa(dp73169
g66301
I75
sg66302
I1
sg66303
I3
sg66314
VC0022661
p73170
sg66306
VCRF
p73171
sasa(dp73172
g66296
Vl-arg, by its cytoprotective effect, maintained the thiol status, thereby preserving the activities of the membrane bound ATPases and preventing proteinuria and subsequent weight loss in EG-treated rats.
p73173
sg66298
(lp73174
(dp73175
g66301
I122
sg66302
I1
sg66303
I7
sg66304
VP05026
p73176
sg66306
VATPases
p73177
sasg66311
(lp73178
sa(dp73179
g66296
VAs expected, a physiological analgesia is produced by administration of inhibitors, especially kelatorphan and analogues, demonstrating unambiguously the implication of enkephalinase and aminopeptidase M in enkephalin metabolism.
p73180
sg66298
(lp73181
(dp73182
g66301
I187
sg66302
I2
sg66303
I16
sg66304
VP15144
p73183
sg66306
Vaminopeptidase M
p73184
sa(dp73185
g66301
I169
sg66302
I1
sg66303
I13
sg66304
VP08473
p73186
sg66306
Venkephalinase
p73187
sasg66311
(lp73188
(dp73189
g66301
I29
sg66302
I1
sg66303
I9
sg66314
VC0344307
p73190
sg66306
Vanalgesia
p73191
sasa(dp73192
g66296
VAssociated with antigliadin and anti-HSP antibodies, children with autism and patients with autoimmune disease developed anti-dipeptidylpeptidase I (DPP I), anti-dipeptidylpeptidase IV (DPP IV [or CD26]) and anti-aminopeptidase N (CD13) autoantibodies.
p73193
sg66298
(lp73194
(dp73195
g66301
I32
sg66302
I2
sg66303
I19
sg66304
g11
sg66306
Vanti-HSP antibodies
p73196
sa(dp73197
g66301
I149
sg66302
I2
sg66303
I5
sg66304
g11
sg66306
VDPP I
p73198
sa(dp73199
g66301
I121
sg66302
I2
sg66303
I26
sg66304
g11
sg66306
Vanti-dipeptidylpeptidase I
p73200
sa(dp73201
g66301
I208
sg66302
I2
sg66303
I21
sg66304
VP15144
p73202
sg66306
Vanti-aminopeptidase N
p73203
sa(dp73204
g66301
I231
sg66302
I1
sg66303
I4
sg66304
VP15144
p73205
sg66306
VCD13
p73206
sa(dp73207
g66301
I186
sg66302
I2
sg66303
I6
sg66304
VP27487
p73208
sg66306
VDPP IV
p73209
sa(dp73210
g66301
I157
sg66302
I2
sg66303
I27
sg66304
VP27487
p73211
sg66306
Vanti-dipeptidylpeptidase IV
p73212
sasg66311
(lp73213
(dp73214
g66301
I92
sg66302
I2
sg66303
I18
sg66314
VC0004364
p73215
sg66306
Vautoimmune disease
p73216
sa(dp73217
g66301
I37
sg66302
I1
sg66303
I3
sg66314
VC0034152
p73218
sg66306
VHSP
p73219
sa(dp73220
g66301
I67
sg66302
I1
sg66303
I6
sg66314
VC0004352
p73221
sg66306
Vautism
p73222
sasa(dp73223
g66296
VWe therefore investigated plasma ApN in anorexia nervosa (AN).
p73224
sg66298
(lp73225
sg66311
(lp73226
(dp73227
g66301
I58
sg66302
I1
sg66303
I2
sg66314
VC0003125
p73228
sg66306
VAN
p73229
sa(dp73230
g66301
I40
sg66302
I2
sg66303
I16
sg66314
VC0003125
p73231
sg66306
Vanorexia nervosa
p73232
sasa(dp73233
g66296
VThe observed ocular comorbidities included nystagmus (36.7%, 18/49), vitreous opacity (28.6%, 14/49), foveal hypoplasia (20.4%, 10/49), ametropia (12.2%, 6/49), exotropia (12.2%, 6/49), congenital glaucoma (12.2%, 6/49), esotropia (4.1%, 2/49), congenital ptosis (4.1%, 2/49), lens ectopia (4.1%, 2/49), scleral staphyloma (2.0%, 1/49) and pigmentary degeneration of retina (2.0%, 1/49).
p73234
sg66298
(lp73235
sg66311
(lp73236
(dp73237
g66301
I351
sg66302
I3
sg66303
I22
sg66314
VC0035304
p73238
sg66306
Vdegeneration of retina
p73239
sa(dp73240
g66301
I186
sg66302
I2
sg66303
I19
sg66314
VC0020302
p73241
sg66306
Vcongenital glaucoma
p73242
sa(dp73243
g66301
I340
sg66302
I2
sg66303
I23
sg66314
VC0333446
p73244
sg66306
Vpigmentary degeneration
p73245
sa(dp73246
g66301
I245
sg66302
I2
sg66303
I17
sg66314
VC0266573
p73247
sg66306
Vcongenital ptosis
p73248
sa(dp73249
g66301
I161
sg66302
I1
sg66303
I9
sg66314
VC0015310
p73250
sg66306
Vexotropia
p73251
sa(dp73252
g66301
I109
sg66302
I1
sg66303
I10
sg66314
VC0243069
p73253
sg66306
Vhypoplasia
p73254
sa(dp73255
g66301
I221
sg66302
I1
sg66303
I9
sg66314
VC0014877
p73256
sg66306
Vesotropia
p73257
sa(dp73258
g66301
I136
sg66302
I1
sg66303
I9
sg66314
VC1527310
p73259
sg66306
Vametropia
p73260
sa(dp73261
g66301
I43
sg66302
I1
sg66303
I9
sg66314
VC0028738
p73262
sg66306
Vnystagmus
p73263
sa(dp73264
g66301
I78
sg66302
I1
sg66303
I7
sg66314
VC1265876
p73265
sg66306
Vopacity
p73266
sa(dp73267
g66301
I304
sg66302
I2
sg66303
I18
sg66314
VC0155359
p73268
sg66306
Vscleral staphyloma
p73269
sa(dp73270
g66301
I282
sg66302
I1
sg66303
I7
sg66314
VC1562630
p73271
sg66306
Vectopia
p73272
sasa(dp73273
g66296
VThe common eye disorders for which genetic testing is commonly requested are briefly discussed - anophthalmia, microphthalmia, coloboma, anterior segment dysgenesis, corneal dystrophies, cataracts, optic atrophy, congenital glaucoma, congenital amaurosis, retinitis pigmentosa, color blindness, juvenile retinoshisis, retinoblastoma etc.
p73274
sg66298
(lp73275
(dp73276
g66301
I318
sg66302
I2
sg66303
I18
sg66304
g11
sg66306
Vretinoblastoma etc
p73277
sasg66311
(lp73278
(dp73279
g66301
I97
sg66302
I1
sg66303
I12
sg66314
VC0003119
p73280
sg66306
Vanophthalmia
p73281
sa(dp73282
g66301
I318
sg66302
I1
sg66303
I14
sg66314
VC0035335
p73283
sg66306
Vretinoblastoma
p73284
sa(dp73285
g66301
I256
sg66302
I2
sg66303
I20
sg66314
VC0035334
p73286
sg66306
Vretinitis pigmentosa
p73287
sa(dp73288
g66301
I137
sg66302
I3
sg66303
I27
sg66314
VC0266525
p73289
sg66306
Vanterior segment dysgenesis
p73290
sa(dp73291
g66301
I245
sg66302
I1
sg66303
I9
sg66314
VC0376288
p73292
sg66306
Vamaurosis
p73293
sa(dp73294
g66301
I166
sg66302
I2
sg66303
I19
sg66314
VC0010036
p73295
sg66306
Vcorneal dystrophies
p73296
sa(dp73297
g66301
I187
sg66302
I1
sg66303
I9
sg66314
VC0521707
p73298
sg66306
Vcataracts
p73299
sa(dp73300
g66301
I198
sg66302
I2
sg66303
I13
sg66314
VC0029124
p73301
sg66306
Voptic atrophy
p73302
sa(dp73303
g66301
I224
sg66302
I2
sg66303
I20
sg66314
VC0020302
p73304
sg66306
Vglaucoma, congenital
p73305
sa(dp73306
g66301
I111
sg66302
I1
sg66303
I14
sg66314
VC0026010
p73307
sg66306
Vmicrophthalmia
p73308
sa(dp73309
g66301
I278
sg66302
I2
sg66303
I15
sg66314
VC0242225
p73310
sg66306
Vcolor blindness
p73311
sa(dp73312
g66301
I127
sg66302
I1
sg66303
I8
sg66314
VC0009363
p73313
sg66306
Vcoloboma
p73314
sa(dp73315
g66301
I11
sg66302
I2
sg66303
I13
sg66314
VC0015397
p73316
sg66306
Veye disorders
p73317
sasa(dp73318
g66296
VThe anatomical causes of blindness include optic nerve disorders in 75 (24.8%) cases, retinal disorders in 55 (18.2%), corneal disorders in 47 (15.6%), lens-related disorders in 39 (12.9%), congenital anomalies in 11 (3.6%), and congenital glaucoma in 20 (6.6%) cases.
p73319
sg66298
(lp73320
sg66311
(lp73321
(dp73322
g66301
I86
sg66302
I2
sg66303
I17
sg66314
VC0035309
p73323
sg66306
Vretinal disorders
p73324
sa(dp73325
g66301
I190
sg66302
I2
sg66303
I20
sg66314
VC0000768
p73326
sg66306
Vcongenital anomalies
p73327
sa(dp73328
g66301
I119
sg66302
I2
sg66303
I17
sg66314
VC0010034
p73329
sg66306
Vcorneal disorders
p73330
sa(dp73331
g66301
I229
sg66302
I2
sg66303
I19
sg66314
VC0020302
p73332
sg66306
Vcongenital glaucoma
p73333
sa(dp73334
g66301
I25
sg66302
I1
sg66303
I9
sg66314
VC0456909
p73335
sg66306
Vblindness
p73336
sa(dp73337
g66301
I43
sg66302
I3
sg66303
I21
sg66314
VC0029132
p73338
sg66306
Voptic nerve disorders
p73339
sasa(dp73340
g66296
VAmong conditions causing blindness, optic atrophy seen in 73 (24.17%) cases was the most common, followed by retinal dystrophy in 44 (14.56%), corneal scarring in 35 (11.59%), cataract in 22 (7.28%), and congenital glaucoma in 20 (6.6%) cases.
p73341
sg66298
(lp73342
sg66311
(lp73343
(dp73344
g66301
I36
sg66302
I2
sg66303
I13
sg66314
VC0029124
p73345
sg66306
Voptic atrophy
p73346
sa(dp73347
g66301
I151
sg66302
I1
sg66303
I8
sg66314
VC0008767
p73348
sg66306
Vscarring
p73349
sa(dp73350
g66301
I204
sg66302
I2
sg66303
I19
sg66314
VC0020302
p73351
sg66306
Vcongenital glaucoma
p73352
sa(dp73353
g66301
I176
sg66302
I1
sg66303
I8
sg66314
VC0086543
p73354
sg66306
Vcataract
p73355
sa(dp73356
g66301
I109
sg66302
I2
sg66303
I17
sg66314
VC0854723
p73357
sg66306
Vretinal dystrophy
p73358
sa(dp73359
g66301
I25
sg66302
I1
sg66303
I9
sg66314
VC0456909
p73360
sg66306
Vblindness
p73361
sasa(dp73362
g66296
VOther abnormalities included vitreous hemorrhage (n=1), congenital glaucoma (n=2), uveal coloboma (n=2), retinopathy mimicking retinopathy of prematurity (n=2), and cystic fovea (n=3).
p73363
sg66298
(lp73364
sg66311
(lp73365
(dp73366
g66301
I29
sg66302
I2
sg66303
I19
sg66314
VC0042909
p73367
sg66306
Vvitreous hemorrhage
p73368
sa(dp73369
g66301
I89
sg66302
I1
sg66303
I8
sg66314
VC0009363
p73370
sg66306
Vcoloboma
p73371
sa(dp73372
g66301
I105
sg66302
I1
sg66303
I11
sg66314
VC0035309
p73373
sg66306
Vretinopathy
p73374
sa(dp73375
g66301
I56
sg66302
I2
sg66303
I19
sg66314
VC0020302
p73376
sg66306
Vcongenital glaucoma
p73377
sa(dp73378
g66301
I127
sg66302
I3
sg66303
I26
sg66314
VC0035344
p73379
sg66306
Vretinopathy of prematurity
p73380
sasa(dp73381
g66296
VPrimary congenital glaucoma (PCG) is isolated, non-syndromic glaucoma that occurs in the first three years of life and is a major cause of childhood blindness.
p73382
sg66298
(lp73383
sg66311
(lp73384
(dp73385
g66301
I19
sg66302
I1
sg66303
I8
sg66314
VC0017601
p73386
sg66306
Vglaucoma
p73387
sa(dp73388
g66301
I149
sg66302
I1
sg66303
I9
sg66314
VC0456909
p73389
sg66306
Vblindness
p73390
sa(dp73391
g66301
I0
sg66302
I3
sg66303
I27
sg66314
VC1533041
p73392
sg66306
VPrimary congenital glaucoma
p73393
sa(dp73394
g66301
I29
sg66302
I1
sg66303
I3
sg66314
VC1533041
p73395
sg66306
VPCG
p73396
sasa(dp73397
g66296
VThe purpose of the present study is to investigate the association between the polymorphisms in AXIN1 with susceptibility to clear cell renal cell carcinoma (ccRCC).
p73398
sg66298
(lp73399
(dp73400
g66301
I96
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VAXIN1
p73401
sasg66311
(lp73402
(dp73403
g66301
I158
sg66302
I1
sg66303
I5
sg66314
VC0279702
p73404
sg66306
VccRCC
p73405
sa(dp73406
g66301
I125
sg66302
I5
sg66303
I31
sg66314
VC0279702
p73407
sg66306
Vclear cell renal cell carcinoma
p73408
sasa(dp73409
g66296
VIn both cultured melanoma cell lines and in vivo in melanoma cell-derived tumor xenografts, 1-benzyl-I3C disrupted canonical Wnt/Beta-catenin signaling that resulted in the down regulation of Beta-catenin protein levels with a concomitant increase in levels of the Beta-catenin destruction complex components GSK3Beta and Axin.
p73410
sg66298
(lp73411
(dp73412
g66301
I192
sg66302
I2
sg66303
I20
sg66304
VP35222
p73413
sg66306
VBeta-catenin protein
p73414
sa(dp73415
g66301
I129
sg66302
I1
sg66303
I12
sg66304
VP35222
p73416
sg66306
VBeta-catenin
p73417
sa(dp73418
g66301
I322
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VAxin
p73419
sasg66311
(lp73420
(dp73421
g66301
I74
sg66302
I1
sg66303
I5
sg66314
VC0027651
p73422
sg66306
Vtumor
p73423
sa(dp73424
g66301
I17
sg66302
I1
sg66303
I8
sg66314
VC0025202
p73425
sg66306
Vmelanoma
p73426
sa(dp73427
g66301
I17
sg66302
I1
sg66303
I8
sg66314
VC0025202
p73428
sg66306
Vmelanoma
p73429
sasa(dp73430
g66296
VHere, we showed that SKL2001, which has been identified as an activator for Wnt signaling by disrupting the Axin/Beta-Catenin complex, negatively regulates growth of colon cancer spheroids cultured in the 3D condition that simulates tumor microenvironment in vivo.
p73431
sg66298
(lp73432
(dp73433
g66301
I108
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VAxin
p73434
sasg66311
(lp73435
(dp73436
g66301
I233
sg66302
I1
sg66303
I5
sg66314
VC0027651
p73437
sg66306
Vtumor
p73438
sa(dp73439
g66301
I166
sg66302
I2
sg66303
I12
sg66314
VC0699790
p73440
sg66306
Vcolon cancer
p73441
sa(dp73442
g66301
I208
sg66302
I1
sg66303
I9
sg66314
VC0012634
p73443
sg66306
Vcondition
p73444
sasa(dp73445
g66296
VDefective lysosomal function defines many neurodegenerative diseases, such as neuronal ceroid lipofuscinoses (NCL) and Niemann-Pick type C (NPC), and is implicated in Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD-TDP) with progranulin (PGRN) deficiency.
p73446
sg66298
(lp73447
(dp73448
g66301
I140
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VNPC
p73449
sa(dp73450
g66301
I119
sg66302
I3
sg66303
I19
sg66304
g11
sg66306
VNiemann-Pick type C
p73451
sasg66311
(lp73452
(dp73453
g66301
I231
sg66302
I1
sg66303
I4
sg66314
VC0751072
p73454
sg66306
VFTLD
p73455
sa(dp73456
g66301
I167
sg66302
I2
sg66303
I19
sg66314
VC1521724
p73457
sg66306
VAlzheimer's disease
p73458
sa(dp73459
g66301
I110
sg66302
I1
sg66303
I3
sg66314
VC0027877
p73460
sg66306
VNCL
p73461
sa(dp73462
g66301
I140
sg66302
I1
sg66303
I3
sg66314
VC2931822
p73463
sg66306
VNPC
p73464
sa(dp73465
g66301
I188
sg66302
I1
sg66303
I2
sg66314
VC1521724
p73466
sg66306
VAD
p73467
sa(dp73468
g66301
I196
sg66302
I3
sg66303
I33
sg66314
VC0751072
p73469
sg66306
Vfrontotemporal lobar degeneration
p73470
sa(dp73471
g66301
I119
sg66302
I3
sg66303
I19
sg66314
VC2931822
p73472
sg66306
VNiemann-Pick type C
p73473
sa(dp73474
g66301
I78
sg66302
I3
sg66303
I30
sg66314
VC0027877
p73475
sg66306
Vneuronal ceroid lipofuscinoses
p73476
sa(dp73477
g66301
I42
sg66302
I2
sg66303
I26
sg66314
VC0524851
p73478
sg66306
Vneurodegenerative diseases
p73479
sasa(dp73480
g66296
VMoreover, recent findings indicate that Grn mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer's disease.
p73481
sg66298
(lp73482
sg66311
(lp73483
(dp73484
g66301
I117
sg66302
I1
sg66303
I9
sg66314
VC0677042
p73485
sg66306
Vpathology
p73486
sa(dp73487
g66301
I80
sg66302
I2
sg66303
I27
sg66314
VC0524851
p73488
sg66306
Vneurodegenerative disorders
p73489
sa(dp73490
g66301
I138
sg66302
I2
sg66303
I19
sg66314
VC1521724
p73491
sg66306
VAlzheimer's disease
p73492
sasa(dp73493
g66296
VTogether, these critical roles in the CNS suggest that PGRN has the potential to be an important therapeutic target for the treatment of various neurodegenerative disorders, particularly Alzheimer's disease (AD).
p73494
sg66298
(lp73495
sg66311
(lp73496
(dp73497
g66301
I187
sg66302
I2
sg66303
I19
sg66314
VC1521724
p73498
sg66306
VAlzheimer's disease
p73499
sa(dp73500
g66301
I145
sg66302
I2
sg66303
I27
sg66314
VC0524851
p73501
sg66306
Vneurodegenerative disorders
p73502
sa(dp73503
g66301
I208
sg66302
I1
sg66303
I2
sg66314
VC1521724
p73504
sg66306
VAD
p73505
sasa(dp73506
g66296
VPathological examination revealed Alzheimer's disease in three cases (all LPA), pathological PSP in two cases (one clinical PSP and one PNFA) and corticobasal degeneration in one case (PNFA).
p73507
sg66298
(lp73508
sg66311
(lp73509
(dp73510
g66301
I93
sg66302
I1
sg66303
I3
sg66314
VC0038868
p73511
sg66306
VPSP
p73512
sa(dp73513
g66301
I34
sg66302
I2
sg66303
I19
sg66314
VC1521724
p73514
sg66306
VAlzheimer's disease
p73515
sa(dp73516
g66301
I146
sg66302
I2
sg66303
I25
sg66314
VC0393570
p73517
sg66306
Vcorticobasal degeneration
p73518
sa(dp73519
g66301
I93
sg66302
I1
sg66303
I3
sg66314
VC0038868
p73520
sg66306
VPSP
p73521
sasa(dp73522
g66296
VGranulin mutations were initially found in tau-negative patients, though recent findings indicate that these mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer's disease and corticobasal degeneration.
p73523
sg66298
(lp73524
sg66311
(lp73525
(dp73526
g66301
I182
sg66302
I1
sg66303
I9
sg66314
VC0677042
p73527
sg66306
Vpathology
p73528
sa(dp73529
g66301
I227
sg66302
I2
sg66303
I25
sg66314
VC0393570
p73530
sg66306
Vcorticobasal degeneration
p73531
sa(dp73532
g66301
I145
sg66302
I2
sg66303
I27
sg66314
VC0524851
p73533
sg66306
Vneurodegenerative disorders
p73534
sa(dp73535
g66301
I203
sg66302
I2
sg66303
I19
sg66314
VC1521724
p73536
sg66306
VAlzheimer's disease
p73537
sasa(dp73538
g66296
VInter-individual variation in CCAAT/enhancer binding protein gamma (CEBPG) transcript expression in normal human bronchial epithelial cells (NBEC) is associated with predisposition to lung cancer.
p73539
sg66298
(lp73540
(dp73541
g66301
I30
sg66302
I4
sg66303
I36
sg66304
g11
sg66306
VCCAAT/enhancer binding protein gamma
p73542
sa(dp73543
g66301
I68
sg66302
I1
sg66303
I5
sg66304
VP53567
p73544
sg66306
VCEBPG
p73545
sasg66311
(lp73546
(dp73547
g66301
I184
sg66302
I2
sg66303
I11
sg66314
VC0684249
p73548
sg66306
Vlung cancer
p73549
sasa(dp73550
g66296
VThese data support the hypothesis that genetic variation in linkage disequilibrium with rs2772 influences regulation of CEBPG transcript expression through a trans-effect downstream of RNA polymerase II transcription and confirm that cis-acting genetic variation contributes to inter-individual variation in CEBPG transcript expression in NBEC, which is associated with variation in lung cancer risk.
p73551
sg66298
(lp73552
(dp73553
g66301
I120
sg66302
I2
sg66303
I16
sg66304
VP53567
p73554
sg66306
VCEBPG transcript
p73555
sa(dp73556
g66301
I120
sg66302
I2
sg66303
I16
sg66304
VP53567
p73557
sg66306
VCEBPG transcript
p73558
sa(dp73559
g66301
I185
sg66302
I3
sg66303
I17
sg66304
VP19388
p73560
sg66306
VRNA polymerase II
p73561
sasg66311
(lp73562
(dp73563
g66301
I383
sg66302
I2
sg66303
I11
sg66314
VC0684249
p73564
sg66306
Vlung cancer
p73565
sa(dp73566
g66301
I234
sg66302
I1
sg66303
I3
sg66314
VC0007099
p73567
sg66306
Vcis
p73568
sa(dp73569
g66301
I68
sg66302
I1
sg66303
I14
sg66314
VC0394006
p73570
sg66306
Vdisequilibrium
p73571
sasa(dp73572
g66296
VIn an effort to develop a biomarker for lung cancer risk, we evaluated the transcript expressions of 14 antioxidant, DNA repair, and transcription factor genes in normal bronchial epithelial cells (HUGO names CAT, CEBPG, E2F1, ERCC4, ERCC5, GPX1, GPX3, GSTM3, GSTP1, GSTT1, GSTZ1, MGST1, SOD1, and XRCC1).
p73573
sg66298
(lp73574
(dp73575
g66301
I227
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VERCC4
p73576
sa(dp73577
g66301
I209
sg66302
I1
sg66303
I3
sg66304
VP04040
p73578
sg66306
VCAT
p73579
sa(dp73580
g66301
I234
sg66302
I1
sg66303
I5
sg66304
VP28715
p73581
sg66306
VERCC5
p73582
sa(dp73583
g66301
I274
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VGSTZ1
p73584
sa(dp73585
g66301
I214
sg66302
I1
sg66303
I5
sg66304
VP53567
p73586
sg66306
VCEBPG
p73587
sa(dp73588
g66301
I221
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VE2F1
p73589
sa(dp73590
g66301
I267
sg66302
I1
sg66303
I5
sg66304
VP30711
p73591
sg66306
VGSTT1
p73592
sa(dp73593
g66301
I260
sg66302
I1
sg66303
I5
sg66304
VP09211
p73594
sg66306
VGSTP1
p73595
sa(dp73596
g66301
I288
sg66302
I1
sg66303
I4
sg66304
VP00441
p73597
sg66306
VSOD1
p73598
sa(dp73599
g66301
I298
sg66302
I1
sg66303
I5
sg66304
VP18887
p73600
sg66306
VXRCC1
p73601
sa(dp73602
g66301
I253
sg66302
I1
sg66303
I5
sg66304
VP21266
p73603
sg66306
VGSTM3
p73604
sa(dp73605
g66301
I281
sg66302
I1
sg66303
I5
sg66304
VP10620
p73606
sg66306
VMGST1
p73607
sa(dp73608
g66301
I247
sg66302
I1
sg66303
I4
sg66304
VP22352
p73609
sg66306
VGPX3
p73610
sa(dp73611
g66301
I241
sg66302
I1
sg66303
I4
sg66304
VP07203
p73612
sg66306
VGPX1
p73613
sasg66311
(lp73614
(dp73615
g66301
I40
sg66302
I2
sg66303
I11
sg66314
VC0684249
p73616
sg66306
Vlung cancer
p73617
sasa(dp73618
g66296
VWe sought to review English language research articles examining the presence, clinical significance, and/or pathophysiology of MM in Parkinson's disease (PD), corticobasal syndrome (CBS), essential tremor (ET), focal hand dystonia, Creutzfeldt-Jakob's disease (CJD), and Huntington's disease.
p73619
sg66298
(lp73620
sg66311
(lp73621
(dp73622
g66301
I155
sg66302
I1
sg66303
I2
sg66314
VC0030567
p73623
sg66306
VPD
p73624
sa(dp73625
g66301
I262
sg66302
I1
sg66303
I3
sg66314
VC0022336
p73626
sg66306
VCJD
p73627
sa(dp73628
g66301
I207
sg66302
I1
sg66303
I2
sg66314
VC0270736
p73629
sg66306
VET
p73630
sa(dp73631
g66301
I189
sg66302
I2
sg66303
I16
sg66314
VC0270736
p73632
sg66306
Vessential tremor
p73633
sa(dp73634
g66301
I272
sg66302
I2
sg66303
I20
sg66314
VC0020179
p73635
sg66306
VHuntington's disease
p73636
sa(dp73637
g66301
I173
sg66302
I1
sg66303
I8
sg66314
VC0039082
p73638
sg66306
Vsyndrome
p73639
sa(dp73640
g66301
I212
sg66302
I3
sg66303
I19
sg66314
VC3267192
p73641
sg66306
Vfocal hand dystonia
p73642
sa(dp73643
g66301
I134
sg66302
I2
sg66303
I19
sg66314
VC0030567
p73644
sg66306
VParkinson's disease
p73645
sa(dp73646
g66301
I233
sg66302
I2
sg66303
I27
sg66314
VC0022336
p73647
sg66306
VCreutzfeldt-Jakob's disease
p73648
sasa(dp73649
g66296
VWe report a patient that presented with the corticobasal syndrome (CBS), including progressive dementia, asymmetric parkinsonism associated with constructional and ideomotor apraxia, action myoclonus and focal hand dystonia.
p73650
sg66298
(lp73651
sg66311
(lp73652
(dp73653
g66301
I83
sg66302
I2
sg66303
I20
sg66314
VC0743039
p73654
sg66306
Vprogressive dementia
p73655
sa(dp73656
g66301
I204
sg66302
I3
sg66303
I19
sg66314
VC3267192
p73657
sg66306
Vfocal hand dystonia
p73658
sa(dp73659
g66301
I116
sg66302
I1
sg66303
I12
sg66314
VC0242422
p73660
sg66306
Vparkinsonism
p73661
sa(dp73662
g66301
I183
sg66302
I2
sg66303
I16
sg66314
VC0751354
p73663
sg66306
Vaction myoclonus
p73664
sa(dp73665
g66301
I164
sg66302
I2
sg66303
I17
sg66314
VC0234523
p73666
sg66306
Videomotor apraxia
p73667
sa(dp73668
g66301
I57
sg66302
I1
sg66303
I8
sg66314
VC0039082
p73669
sg66306
Vsyndrome
p73670
sasa(dp73671
g66296
VFifteen rearrangements detected in Sezary syndrome patients and SeAx resulted in an expression of new fusion transcripts, nine of them were in frame (EHD1-CAPN12, TMEM66-BAIAP2, MBD4-PTPRC, PTPRC-CPN2, MYB-MBNL1, TFG-GPR128, MAP4K3-FIGLA, DCP1A-CCL27, MBNL1-KIAA2018) and five resulted in ectopic expression of fragments of genes not expressed in normal T-cells (BAIAP2, CPN2, GPR128, CAPN12, FIGLA).
p73672
sg66298
(lp73673
(dp73674
g66301
I150
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VEHD1
p73675
sa(dp73676
g66301
I163
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VTMEM66
p73677
sa(dp73678
g66301
I190
sg66302
I1
sg66303
I10
sg66304
VP08575
p73679
sg66306
VPTPRC-CPN2
p73680
sa(dp73681
g66301
I232
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFIGLA
p73682
sa(dp73683
g66301
I217
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VGPR128
p73684
sa(dp73685
g66301
I155
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCAPN12
p73686
sa(dp73687
g66301
I252
sg66302
I1
sg66303
I14
sg66304
g11
sg66306
VMBNL1-KIAA2018
p73688
sa(dp73689
g66301
I217
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VGPR128
p73690
sa(dp73691
g66301
I178
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VMBD4
p73692
sa(dp73693
g66301
I232
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFIGLA
p73694
sa(dp73695
g66301
I155
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCAPN12
p73696
sa(dp73697
g66301
I225
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VMAP4K3
p73698
sa(dp73699
g66301
I206
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VMBNL1
p73700
sa(dp73701
g66301
I170
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VBAIAP2
p73702
sa(dp73703
g66301
I213
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VTFG
p73704
sa(dp73705
g66301
I170
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VBAIAP2
p73706
sa(dp73707
g66301
I196
sg66302
I1
sg66303
I4
sg66304
VP15538
p73708
sg66306
VCPN2
p73709
sa(dp73710
g66301
I202
sg66302
I1
sg66303
I3
sg66304
VP10243
p73711
sg66306
VMYB
p73712
sa(dp73713
g66301
I239
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VDCP1A
p73714
sa(dp73715
g66301
I245
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCCL27
p73716
sa(dp73717
g66301
I183
sg66302
I1
sg66303
I5
sg66304
VP08575
p73718
sg66306
VPTPRC
p73719
sasg66311
(lp73720
(dp73721
g66301
I35
sg66302
I2
sg66303
I15
sg66314
VC0036920
p73722
sg66306
VSezary syndrome
p73723
sasa(dp73724
g66296
VIn addition, we found eleven potential cancer-related genes with mutations (EZH1, SPOP, NF1, TCF12, IGF2BP3, KMT2C, CNOT1, BRIP1, KDM5C, STAG2 and MAP4K3) that have not been reported in thyroid follicular tumors.
p73725
sg66298
(lp73726
(dp73727
g66301
I123
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VBRIP1
p73728
sa(dp73729
g66301
I82
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VSPOP
p73730
sa(dp73731
g66301
I137
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSTAG2
p73732
sa(dp73733
g66301
I109
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VKMT2C
p73734
sa(dp73735
g66301
I130
sg66302
I1
sg66303
I5
sg66304
VP41229
p73736
sg66306
VKDM5C
p73737
sa(dp73738
g66301
I88
sg66302
I1
sg66303
I3
sg66304
VP21359
p73739
sg66306
VNF1
p73740
sa(dp73741
g66301
I93
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTCF12
p73742
sa(dp73743
g66301
I76
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VEZH1
p73744
sa(dp73745
g66301
I147
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VMAP4K3
p73746
sa(dp73747
g66301
I100
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VIGF2BP3
p73748
sasg66311
(lp73749
(dp73750
g66301
I194
sg66302
I2
sg66303
I17
sg66314
VC0474808
p73751
sg66306
Vfollicular tumors
p73752
sa(dp73753
g66301
I39
sg66302
I1
sg66303
I6
sg66314
VC0006826
p73754
sg66306
Vcancer
p73755
sa(dp73756
g66301
I88
sg66302
I1
sg66303
I3
sg66314
VC0027831
p73757
sg66306
VNF1
p73758
sasa(dp73759
g66296
VSince GLK (also named MAP4K3) induces activation of NF-KB, which contributes to tumor progression, we investigated the role of GLK in NSCLC.
p73760
sg66298
(lp73761
(dp73762
g66301
I6
sg66302
I1
sg66303
I3
sg66304
VP35557
p73763
sg66306
VGLK
p73764
sa(dp73765
g66301
I22
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VMAP4K3
p73766
sa(dp73767
g66301
I6
sg66302
I1
sg66303
I3
sg66304
VP35557
p73768
sg66306
VGLK
p73769
sasg66311
(lp73770
(dp73771
g66301
I80
sg66302
I2
sg66303
I17
sg66314
VC0178874
p73772
sg66306
Vtumor progression
p73773
sa(dp73774
g66301
I134
sg66302
I1
sg66303
I5
sg66314
VC0007131
p73775
sg66306
VNSCLC
p73776
sasa(dp73777
g66296
VGLK protein levels of 190 samples from pulmonary tissue arrays and 58 pulmonary resection samples from stage I to stage III NSCLC patients were studied using immunohistochemistry or immunoblotting.
p73778
sg66298
(lp73779
(dp73780
g66301
I0
sg66302
I1
sg66303
I3
sg66304
VP35557
p73781
sg66306
VGLK
p73782
sasg66311
(lp73783
(dp73784
g66301
I114
sg66302
I3
sg66303
I15
sg66314
VC0278506
p73785
sg66306
Vstage III NSCLC
p73786
sasa(dp73787
g66296
VHigh levels of GLK proteins were detected in pulmonary tissues from NSCLC patients.
p73788
sg66298
(lp73789
(dp73790
g66301
I15
sg66302
I2
sg66303
I12
sg66304
VP35557
p73791
sg66306
VGLK proteins
p73792
sasg66311
(lp73793
(dp73794
g66301
I68
sg66302
I1
sg66303
I5
sg66314
VC0007131
p73795
sg66306
VNSCLC
p73796
sasa(dp73797
g66296
VElevated GLK protein levels were correlated with increased recurrence risks and poor recurrence-free survival rates in NSCLC patients after adjusting for pathologic stage, smoking status, alcohol status, and EGFR levels.
p73798
sg66298
(lp73799
(dp73800
g66301
I9
sg66302
I2
sg66303
I11
sg66304
VP35557
p73801
sg66306
VGLK protein
p73802
sasg66311
(lp73803
(dp73804
g66301
I59
sg66302
I1
sg66303
I10
sg66314
VC1458156
p73805
sg66306
Vrecurrence
p73806
sa(dp73807
g66301
I59
sg66302
I1
sg66303
I10
sg66314
VC1458156
p73808
sg66306
Vrecurrence
p73809
sa(dp73810
g66301
I119
sg66302
I1
sg66303
I5
sg66314
VC0007131
p73811
sg66306
VNSCLC
p73812
sasa(dp73813
g66296
VThus, GLK is a novel prognostic biomarker for NSCLC recurrence.
p73814
sg66298
(lp73815
(dp73816
g66301
I6
sg66302
I1
sg66303
I3
sg66304
VP35557
p73817
sg66306
VGLK
p73818
sasg66311
(lp73819
(dp73820
g66301
I46
sg66302
I1
sg66303
I5
sg66314
VC0007131
p73821
sg66306
VNSCLC
p73822
sa(dp73823
g66301
I52
sg66302
I1
sg66303
I10
sg66314
VC1458156
p73824
sg66306
Vrecurrence
p73825
sasa(dp73826
g66296
VRNA fusion-based CISs were identified corresponding to both DNA-based CISs (Cdkn2a, Mycl1, Nf2, Pten, Sema6d, and Rere) and additional regions strongly associated with cancer that were not observed by LM-PCR (Myc, Akt1, Pth, Csf1r, Fgfr2, Wisp1, Map3k5, and Map4k3).
p73827
sg66298
(lp73828
(dp73829
g66301
I84
sg66302
I1
sg66303
I3
sg66304
VP12524
p73830
sg66306
VMyc
p73831
sa(dp73832
g66301
I258
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VMap4k3
p73833
sa(dp73834
g66301
I84
sg66302
I1
sg66303
I5
sg66304
VP12524
p73835
sg66306
VMycl1
p73836
sa(dp73837
g66301
I96
sg66302
I1
sg66303
I4
sg66304
VP60484
p73838
sg66306
VPten
p73839
sa(dp73840
g66301
I225
sg66302
I1
sg66303
I5
sg66304
VP09619
p73841
sg66306
VCsf1r
p73842
sa(dp73843
g66301
I220
sg66302
I1
sg66303
I3
sg66304
VP01270
p73844
sg66306
VPth
p73845
sa(dp73846
g66301
I76
sg66302
I1
sg66303
I6
sg66304
VP42771
p73847
sg66306
VCdkn2a
p73848
sa(dp73849
g66301
I239
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VWisp1
p73850
sa(dp73851
g66301
I17
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VCISs
p73852
sa(dp73853
g66301
I214
sg66302
I1
sg66303
I4
sg66304
VP31749
p73854
sg66306
VAkt1
p73855
sa(dp73856
g66301
I246
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VMap3k5
p73857
sasg66311
(lp73858
(dp73859
g66301
I168
sg66302
I1
sg66303
I6
sg66314
VC0006826
p73860
sg66306
Vcancer
p73861
sa(dp73862
g66301
I91
sg66302
I1
sg66303
I3
sg66314
VC0027832
p73863
sg66306
VNf2
p73864
sasa(dp73865
g66296
VComputationally, PTPRF, PRKAR2B, MAP4K3, and RICTOR were calculated as highly drug-targetable genes for breast cancer.
p73866
sg66298
(lp73867
(dp73868
g66301
I24
sg66302
I1
sg66303
I7
sg66304
VP31323
p73869
sg66306
VPRKAR2B
p73870
sa(dp73871
g66301
I33
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VMAP4K3
p73872
sa(dp73873
g66301
I17
sg66302
I1
sg66303
I5
sg66304
VP10586
p73874
sg66306
VPTPRF
p73875
sa(dp73876
g66301
I45
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VRICTOR
p73877
sasg66311
(lp73878
(dp73879
g66301
I104
sg66302
I2
sg66303
I13
sg66314
VC0678222
p73880
sg66306
Vbreast cancer
p73881
sasa(dp73882
g66296
VIn the GeparTrio FFPE training cohort, a significant linear correlation between TMSB15A expression and pCR was apparent in triple-negative breast cancer (TNBC) (n=61, P=0.040).
p73883
sg66298
(lp73884
(dp73885
g66301
I80
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VTMSB15A
p73886
sasg66311
(lp73887
(dp73888
g66301
I139
sg66302
I2
sg66303
I13
sg66314
VC0678222
p73889
sg66306
Vbreast cancer
p73890
sasa(dp73891
g66296
VIn normal human prostate and prostate cancer tissues, TMSB15A was the predominant isoform expressed.
p73892
sg66298
(lp73893
sg66311
(lp73894
(dp73895
g66301
I29
sg66302
I2
sg66303
I15
sg66314
VC0600139
p73896
sg66306
Vprostate cancer
p73897
sasa(dp73898
g66296
VIn contrast, normal colon and colon cancer tissue expressed predominantly TMSB15B.
p73899
sg66298
(lp73900
(dp73901
g66301
I74
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VTMSB15B
p73902
sasg66311
(lp73903
(dp73904
g66301
I30
sg66302
I2
sg66303
I12
sg66314
VC0699790
p73905
sg66306
Vcolon cancer
p73906
sasa(dp73907
g66296
VTreatment of MCF-7 breast cancer cells with transforming growth factor beta 1 repressed TMSB15A expression but had no effect on TMSB15B.
p73908
sg66298
(lp73909
(dp73910
g66301
I88
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VTMSB15A
p73911
sa(dp73912
g66301
I128
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VTMSB15B
p73913
sa(dp73914
g66301
I44
sg66302
I5
sg66303
I33
sg66304
VP01137
p73915
sg66306
Vtransforming growth factor beta 1
p73916
sasg66311
(lp73917
(dp73918
g66301
I19
sg66302
I2
sg66303
I13
sg66314
VC0678222
p73919
sg66306
Vbreast cancer
p73920
sasa(dp73921
g66296
VsiRNA specific to the TMSB15B isoform suppressed cell migration of prostate cancer cells to epidermal growth factor, suggesting a functional role for this second isoform.
p73922
sg66298
(lp73923
(dp73924
g66301
I92
sg66302
I3
sg66303
I23
sg66304
VP01133
p73925
sg66306
Vepidermal growth factor
p73926
sasg66311
(lp73927
(dp73928
g66301
I67
sg66302
I2
sg66303
I15
sg66314
VC0600139
p73929
sg66306
Vprostate cancer
p73930
sasa(dp73931
g66296
VWe showed earlier that human beta-thymosin 15 (Tb15) is up-regulated in prostate cancer, confirming studies from others that propagated Tb15 as a prostate cancer biomarker.
p73932
sg66298
(lp73933
(dp73934
g66301
I18
sg66302
I4
sg66303
I27
sg66304
g11
sg66306
Vthat human beta-thymosin 15
p73935
sa(dp73936
g66301
I47
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTb15
p73937
sa(dp73938
g66301
I47
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTb15
p73939
sasg66311
(lp73940
(dp73941
g66301
I72
sg66302
I2
sg66303
I15
sg66314
VC0600139
p73942
sg66306
Vprostate cancer
p73943
sa(dp73944
g66301
I72
sg66302
I2
sg66303
I15
sg66314
VC0600139
p73945
sg66306
Vprostate cancer
p73946
sasa(dp73947
g66296
VTb15r is present also in mouse prostate cancer cell lines.
p73948
sg66298
(lp73949
sg66311
(lp73950
(dp73951
g66301
I31
sg66302
I2
sg66303
I15
sg66314
VC0600139
p73952
sg66306
Vprostate cancer
p73953
sasa(dp73954
g66296
VIn those patients with isolated adenopathy the following diagnoses were reached; sarcoidosis 23, TB 15, lymphoma 4, carcinoma 4, no diagnosis 1.
p73955
sg66298
(lp73956
sg66311
(lp73957
(dp73958
g66301
I81
sg66302
I1
sg66303
I11
sg66314
VC0036202
p73959
sg66306
Vsarcoidosis
p73960
sa(dp73961
g66301
I116
sg66302
I1
sg66303
I9
sg66314
VC0007097
p73962
sg66306
Vcarcinoma
p73963
sa(dp73964
g66301
I104
sg66302
I1
sg66303
I8
sg66314
VC0024299
p73965
sg66306
Vlymphoma
p73966
sasa(dp73967
g66296
VHowever, in this report we provide evidence that TbNB, initially identified in human neuroblastoma, is the only Tb isoform upregulated in human prostate cancer and that the Tb15 sequence is not present herein.
p73968
sg66298
(lp73969
(dp73970
g66301
I49
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTbNB
p73971
sa(dp73972
g66301
I173
sg66302
I2
sg66303
I13
sg66304
g11
sg66306
VTb15 sequence
p73973
sasg66311
(lp73974
(dp73975
g66301
I144
sg66302
I2
sg66303
I15
sg66314
VC0600139
p73976
sg66306
Vprostate cancer
p73977
sa(dp73978
g66301
I85
sg66302
I1
sg66303
I13
sg66314
VC0027819
p73979
sg66306
Vneuroblastoma
p73980
sasa(dp73981
g66296
VHuman NB thymosin beta is a beta-thymosin originally found in neuroblastoma.
p73982
sg66298
(lp73983
(dp73984
g66301
I0
sg66302
I4
sg66303
I22
sg66304
VP20962
p73985
sg66306
VHuman NB thymosin beta
p73986
sa(dp73987
g66301
I28
sg66302
I1
sg66303
I13
sg66304
VP20962
p73988
sg66306
Vbeta-thymosin
p73989
sasg66311
(lp73990
(dp73991
g66301
I62
sg66302
I1
sg66303
I13
sg66314
VC0027819
p73992
sg66306
Vneuroblastoma
p73993
sasa(dp73994
g66296
VOur studies provide the first evidence that Upk1b is directly associated with the development of congenital anomalies of the urinary tract (CAKUT), spontaneous age-dependent hydronephrosis, and dysplastic urothelia.
p73995
sg66298
(lp73996
(dp73997
g66301
I44
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VUpk1b
p73998
sasg66311
(lp73999
(dp74000
g66301
I97
sg66302
I2
sg66303
I20
sg66314
VC0000768
p74001
sg66306
Vcongenital anomalies
p74002
sa(dp74003
g66301
I140
sg66302
I1
sg66303
I5
sg66314
VC1968949
p74004
sg66306
VCAKUT
p74005
sa(dp74006
g66301
I194
sg66302
I1
sg66303
I10
sg66314
VC0334044
p74007
sg66306
Vdysplastic
p74008
sa(dp74009
g66301
I174
sg66302
I1
sg66303
I14
sg66314
VC0020295
p74010
sg66306
Vhydronephrosis
p74011
sasa(dp74012
g66296
VUpk1b(RFP/RFP) mice developed age-dependent progressive hydronephrosis.
p74013
sg66298
(lp74014
(dp74015
g66301
I0
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VUpk1b
p74016
sa(dp74017
g66301
I6
sg66302
I1
sg66303
I3
sg66304
VP25090
p74018
sg66306
VRFP
p74019
sa(dp74020
g66301
I6
sg66302
I1
sg66303
I3
sg66304
VP25090
p74021
sg66306
VRFP
p74022
sasg66311
(lp74023
(dp74024
g66301
I56
sg66302
I1
sg66303
I14
sg66314
VC0020295
p74025
sg66306
Vhydronephrosis
p74026
sasa(dp74027
g66296
VThe aim of the present study was to investigate the role of serotonin (5-hydroxytryptamine) in the rostral ventromedial medulla (RVM) and spinal cord in pain sensory abnormalities in a 6-hydroxydopamine-treated rat model of Parkinson's disease.
p74028
sg66298
(lp74029
sg66311
(lp74030
(dp74031
g66301
I145
sg66302
I1
sg66303
I4
sg66314
VC0035334
p74032
sg66306
Vcord
p74033
sa(dp74034
g66301
I224
sg66302
I2
sg66303
I19
sg66314
VC0030567
p74035
sg66306
VParkinson's disease
p74036
sasa(dp74037
g66296
VConclusions These results suggest that the decreased 5-hydroxytryptamine contents in the rostral ventromedial medulla and spinal dorsal horn may be involved in hyperalgesia in the 6-hydroxydopamine-induced rat model of Parkinson's disease.
p74038
sg66298
(lp74039
sg66311
(lp74040
(dp74041
g66301
I219
sg66302
I2
sg66303
I19
sg66314
VC0030567
p74042
sg66306
VParkinson's disease
p74043
sa(dp74044
g66301
I160
sg66302
I1
sg66303
I12
sg66314
VC0020429
p74045
sg66306
Vhyperalgesia
p74046
sasa(dp74047
g66296
VThe role of serotonin7 (5-HT7) receptors in the regulation of depression is poorly understood, particularly in Parkinson's disease-associated depression.
p74048
sg66298
(lp74049
(dp74050
g66301
I12
sg66302
I3
sg66303
I28
sg66304
VP34969
p74051
sg66306
Vserotonin7 (5-HT7) receptors
p74052
sasg66311
(lp74053
(dp74054
g66301
I62
sg66302
I1
sg66303
I10
sg66314
VC0011581
p74055
sg66306
Vdepression
p74056
sa(dp74057
g66301
I111
sg66302
I2
sg66303
I19
sg66314
VC0030567
p74058
sg66306
VParkinson's disease
p74059
sa(dp74060
g66301
I62
sg66302
I1
sg66303
I10
sg66314
VC0011581
p74061
sg66306
Vdepression
p74062
sasa(dp74063
g66296
VThe expression of 13 fibrosis-related microRNAs (miRNAs) (miR-20a, miR-21, miR-27a, miR-27b, miR-29a, miR-29c, miR-92a, miR-122, miR-146a, miR-155, miR-221, miR-222, and miR-224) was analyzed in 194 serums and 177 liver biopsies of patients with either CHB or CHC to develop models to diagnose advanced fibrosis and cirrhosis (Metavir F3-F4).
p74064
sg66298
(lp74065
(dp74066
g66301
I75
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-27a
p74067
sa(dp74068
g66301
I148
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-221
p74069
sa(dp74070
g66301
I67
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VmiR-21
p74071
sa(dp74072
g66301
I58
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-20a
p74073
sa(dp74074
g66301
I139
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-155
p74075
sa(dp74076
g66301
I102
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-29c
p74077
sa(dp74078
g66301
I93
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-29a
p74079
sa(dp74080
g66301
I111
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-92a
p74081
sa(dp74082
g66301
I157
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-222
p74083
sa(dp74084
g66301
I129
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VmiR-146a
p74085
sa(dp74086
g66301
I84
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-27b
p74087
sa(dp74088
g66301
I120
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-122
p74089
sasg66311
(lp74090
(dp74091
g66301
I21
sg66302
I1
sg66303
I8
sg66314
VC0016059
p74092
sg66306
Vfibrosis
p74093
sa(dp74094
g66301
I253
sg66302
I1
sg66303
I3
sg66314
VC0151517
p74095
sg66306
VCHB
p74096
sa(dp74097
g66301
I21
sg66302
I1
sg66303
I8
sg66314
VC0016059
p74098
sg66306
Vfibrosis
p74099
sa(dp74100
g66301
I316
sg66302
I1
sg66303
I9
sg66314
VC0023890
p74101
sg66306
Vcirrhosis
p74102
sasa(dp74103
g66296
VFor this reason, the expression levels of 24 miRNA (let-7c, miR-92a-3p, 423-5p, 150-5p, 223-3p, 125b-5p, 342-3p, miR-206, 122-5p, 375, 223-5p, 10a-5p, 23b-5p, 99a-5p, 23a-5p, 10a-3p, 122-3p, 125b-1-3p, 23b-3p, 125b-2-3p, 23a-3p, 92a-1-5p, 92a-2-5p, 99a-3p) were analyzed in plasma of patients with chronic hepatitis B, HBV-positive cirrhosis and HBV-positive HCC and compared with control group samples.
p74104
sg66298
(lp74105
(dp74106
g66301
I60
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-92a-3p
p74107
sasg66311
(lp74108
(dp74109
g66301
I359
sg66302
I1
sg66303
I3
sg66314
VC2239176
p74110
sg66306
VHCC
p74111
sa(dp74112
g66301
I319
sg66302
I1
sg66303
I3
sg66314
VC0019163
p74113
sg66306
VHBV
p74114
sa(dp74115
g66301
I319
sg66302
I1
sg66303
I3
sg66314
VC0019163
p74116
sg66306
VHBV
p74117
sa(dp74118
g66301
I298
sg66302
I3
sg66303
I19
sg66314
VC0524909
p74119
sg66306
Vchronic hepatitis B
p74120
sa(dp74121
g66301
I332
sg66302
I1
sg66303
I9
sg66314
VC0023890
p74122
sg66306
Vcirrhosis
p74123
sasa(dp74124
g66296
VConsistently, Bhlhb2 expression was significantly higher in PFC of ADHD model SHR than control.
p74125
sg66298
(lp74126
(dp74127
g66301
I67
sg66302
I3
sg66303
I14
sg66304
g11
sg66306
VADHD model SHR
p74128
sa(dp74129
g66301
I14
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VBhlhb2
p74130
sa(dp74131
g66301
I60
sg66302
I1
sg66303
I3
sg66304
VP27918
p74132
sg66306
VPFC
p74133
sasg66311
(lp74134
(dp74135
g66301
I67
sg66302
I1
sg66303
I4
sg66314
VC1263846
p74136
sg66306
VADHD
p74137
sasa(dp74138
g66296
VWe examined ANG expression in WTs, human fetal kidney (FK) and childhood kidney (NK) samples and studied its relationship with microvascular density (MVD) and with three other hypoxia-induced angiogenic factors: lactate dehydrogenase A (LDHA), vascular endothelial growth factor (VEGFA) and BHLHE40 (basic helix-loop-helix transcription factor E40).
p74139
sg66298
(lp74140
(dp74141
g66301
I244
sg66302
I4
sg66303
I34
sg66304
g11
sg66306
Vvascular endothelial growth factor
p74142
sa(dp74143
g66301
I291
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VBHLHE40
p74144
sa(dp74145
g66301
I280
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VVEGFA
p74146
sa(dp74147
g66301
I212
sg66302
I3
sg66303
I23
sg66304
VP49366
p74148
sg66306
Vlactate dehydrogenase A
p74149
sa(dp74150
g66301
I237
sg66302
I1
sg66303
I4
sg66304
VP00338
p74151
sg66306
VLDHA
p74152
sa(dp74153
g66301
I300
sg66302
I5
sg66303
I47
sg66304
g11
sg66306
Vbasic helix-loop-helix transcription factor E40
p74154
sasg66311
(lp74155
(dp74156
g66301
I176
sg66302
I1
sg66303
I7
sg66314
VC0242184
p74157
sg66306
Vhypoxia
p74158
sa(dp74159
g66301
I30
sg66302
I1
sg66303
I3
sg66314
VC1839736
p74160
sg66306
VWTs
p74161
sasa(dp74162
g66296
VANG, CD31, VEGFA and BHLHE40 mRNA levels were significantly lower in 15 WTs compared with matched-paired NKs.
p74163
sg66298
(lp74164
(dp74165
g66301
I0
sg66302
I1
sg66303
I3
sg66304
VP03950
p74166
sg66306
VANG
p74167
sa(dp74168
g66301
I5
sg66302
I1
sg66303
I4
sg66304
VP69905
p74169
sg66306
VCD31
p74170
sa(dp74171
g66301
I21
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VBHLHE40 mRNA
p74172
sasg66311
(lp74173
(dp74174
g66301
I72
sg66302
I1
sg66303
I3
sg66314
VC1839736
p74175
sg66306
VWTs
p74176
sasa(dp74177
g66296
VMutations in the SLC5A5 gene encoding NIS that result in a non-functional protein lead to congenital hypothyroidism due to I- transport defect (ITD).
p74178
sg66298
(lp74179
(dp74180
g66301
I17
sg66302
I4
sg66303
I24
sg66304
g11
sg66306
VSLC5A5 gene encoding NIS
p74181
sasg66311
(lp74182
(dp74183
g66301
I90
sg66302
I2
sg66303
I25
sg66314
VC0342200
p74184
sg66306
Vcongenital hypothyroidism
p74185
sasa(dp74186
g66296
VThyroid concentrates radioactive iodine by sodium-iodide symporter; this is used for treating hyperthyroidism and thyroid cancer.
p74187
sg66298
(lp74188
sg66311
(lp74189
(dp74190
g66301
I94
sg66302
I1
sg66303
I15
sg66314
VC0020550
p74191
sg66306
Vhyperthyroidism
p74192
sa(dp74193
g66301
I114
sg66302
I2
sg66303
I14
sg66314
VC0007115
p74194
sg66306
Vthyroid cancer
p74195
sasa(dp74196
g66296
VIn this study, we investigated the relationship between iodine content and sodium iodide symporter (NIS) expression by using the clinical specimens from patients with nodular goiter and explored the pathogenesis triggered by iodine deficiency in nodular goiter.
p74197
sg66298
(lp74198
(dp74199
g66301
I100
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VNIS
p74200
sa(dp74201
g66301
I75
sg66302
I3
sg66303
I23
sg66304
g11
sg66306
Vsodium iodide symporter
p74202
sasg66311
(lp74203
(dp74204
g66301
I167
sg66302
I2
sg66303
I14
sg66314
VC1318500
p74205
sg66306
Vnodular goiter
p74206
sa(dp74207
g66301
I167
sg66302
I2
sg66303
I14
sg66314
VC1318500
p74208
sg66306
Vnodular goiter
p74209
sa(dp74210
g66301
I225
sg66302
I2
sg66303
I17
sg66314
VC0342199
p74211
sg66306
Viodine deficiency
p74212
sa(dp74213
g66301
I199
sg66302
I1
sg66303
I12
sg66314
VC0699748
p74214
sg66306
Vpathogenesis
p74215
sasa(dp74216
g66296
VThe same technique was used for the assays of the hepatic levels of FGF-21, silent information regulator (SIRT1), malondialdehyde (MDA),IL-10, tumor necrosis factor-Alfa (TNF-Alfa) as well as the apoptotic markers; caspase-3 and B-cell lymphoma (Bcl-2).
p74217
sg66298
(lp74218
(dp74219
g66301
I68
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VFGF-21
p74220
sa(dp74221
g66301
I171
sg66302
I1
sg66303
I8
sg66304
VP01375
p74222
sg66306
VTNF-Alfa
p74223
sa(dp74224
g66301
I215
sg66302
I1
sg66303
I9
sg66304
VP42574
p74225
sg66306
Vcaspase-3
p74226
sa(dp74227
g66301
I106
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSIRT1
p74228
sa(dp74229
g66301
I143
sg66302
I3
sg66303
I26
sg66304
VP01375
p74230
sg66306
Vtumor necrosis factor-Alfa
p74231
sasg66311
(lp74232
(dp74233
g66301
I229
sg66302
I2
sg66303
I15
sg66314
VC0079731
p74234
sg66306
VB-cell lymphoma
p74235
sa(dp74236
g66301
I143
sg66302
I2
sg66303
I14
sg66314
VC0333516
p74237
sg66306
Vtumor necrosis
p74238
sasa(dp74239
g66296
VWe report here the case of a 25-year-old woman with a bulbar onset ALS that progressed in less than 12 months to invasive ventilation due to respiratory failure; Genetic screening identified a new mutation in the FUS gene that lies within the last codon.
p74240
sg66298
(lp74241
(dp74242
g66301
I213
sg66302
I2
sg66303
I8
sg66304
VP35637
p74243
sg66306
VFUS gene
p74244
sasg66311
(lp74245
(dp74246
g66301
I141
sg66302
I2
sg66303
I19
sg66314
VC1145670
p74247
sg66306
Vrespiratory failure
p74248
sa(dp74249
g66301
I193
sg66302
I2
sg66303
I12
sg66314
VC2985439
p74250
sg66306
Vnew mutation
p74251
sa(dp74252
g66301
I67
sg66302
I1
sg66303
I3
sg66314
VC0002736
p74253
sg66306
VALS
p74254
sasa(dp74255
g66296
VThe expression and biological function of Grb2-associated binding 2 (Gab2) in renal cell carcinoma (RCC) cells was tested here.
p74256
sg66298
(lp74257
(dp74258
g66301
I69
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGab2
p74259
sa(dp74260
g66301
I42
sg66302
I3
sg66303
I25
sg66304
VP62993
p74261
sg66306
VGrb2-associated binding 2
p74262
sasg66311
(lp74263
(dp74264
g66301
I78
sg66302
I3
sg66303
I20
sg66314
VC0007134
p74265
sg66306
Vrenal cell carcinoma
p74266
sa(dp74267
g66301
I100
sg66302
I1
sg66303
I3
sg66314
VC0007134
p74268
sg66306
VRCC
p74269
sasa(dp74270
g66296
VHowever, the significance of Grb2 and Sos proteins, which is related to EGF-triggered Ras activation, has not been elucidated in human bladder cancer.
p74271
sg66298
(lp74272
(dp74273
g66301
I72
sg66302
I1
sg66303
I3
sg66304
VP01133
p74274
sg66306
VEGF
p74275
sa(dp74276
g66301
I29
sg66302
I1
sg66303
I4
sg66304
VP62993
p74277
sg66306
VGrb2
p74278
sa(dp74279
g66301
I86
sg66302
I1
sg66303
I3
sg66304
VP01116
p74280
sg66306
VRas
p74281
sa(dp74282
g66301
I38
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VSos proteins
p74283
sasg66311
(lp74284
(dp74285
g66301
I135
sg66302
I2
sg66303
I14
sg66314
VC0699885
p74286
sg66306
Vbladder cancer
p74287
sasa(dp74288
g66296
VOn the other hand, expression of Grb2 and Sos proteins was substantially increased in all human bladder cancer cell lines examined in comparison with cultured normal urothelial cells, whether codon 12 of H-ras was mutated or not.
p74289
sg66298
(lp74290
(dp74291
g66301
I42
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VSos proteins
p74292
sa(dp74293
g66301
I204
sg66302
I1
sg66303
I5
sg66304
VP01112
p74294
sg66306
VH-ras
p74295
sa(dp74296
g66301
I33
sg66302
I1
sg66303
I4
sg66304
VP62993
p74297
sg66306
VGrb2
p74298
sasg66311
(lp74299
(dp74300
g66301
I96
sg66302
I2
sg66303
I14
sg66314
VC0699885
p74301
sg66306
Vbladder cancer
p74302
sasa(dp74303
g66296
VThese results suggest that the amplification of both Grb2 and SOS proteins plays an important role in the carcinogenesis of human bladder cancer.
p74304
sg66298
(lp74305
(dp74306
g66301
I62
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VSOS proteins
p74307
sa(dp74308
g66301
I53
sg66302
I1
sg66303
I4
sg66304
VP62993
p74309
sg66306
VGrb2
p74310
sasg66311
(lp74311
(dp74312
g66301
I31
sg66302
I1
sg66303
I13
sg66314
VC1705759
p74313
sg66306
Vamplification
p74314
sa(dp74315
g66301
I130
sg66302
I2
sg66303
I14
sg66314
VC0699885
p74316
sg66306
Vbladder cancer
p74317
sa(dp74318
g66301
I106
sg66302
I1
sg66303
I14
sg66314
VC0596263
p74319
sg66306
Vcarcinogenesis
p74320
sasa(dp74321
g66296
VIn the 32 patients studied, bladder cancer was diagnosed as pTaG1-2 in 8 cases, pT1G2 in 6, pT1G3 in 7, pT2G2-3 in 7, pT3G2-3 in 3 and pT4 in 1 patient.
p74322
sg66298
(lp74323
sg66311
(lp74324
(dp74325
g66301
I28
sg66302
I2
sg66303
I14
sg66314
VC0699885
p74326
sg66306
Vbladder cancer
p74327
sasa(dp74328
g66296
VIn this study, we investigated whether silencing Wnt2B expression could inhibit the invasiveness of ovarian cancer cells and reduce drug resistance.
p74329
sg66298
(lp74330
(dp74331
g66301
I49
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VWnt2B
p74332
sasg66311
(lp74333
(dp74334
g66301
I100
sg66302
I2
sg66303
I14
sg66314
VC1140680
p74335
sg66306
Vovarian cancer
p74336
sasa(dp74337
g66296
VThese data suggest that Wnt2B indeed plays an important role in ovarian cancer metastasis and drug resistance.
p74338
sg66298
(lp74339
(dp74340
g66301
I24
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VWnt2B
p74341
sasg66311
(lp74342
(dp74343
g66301
I64
sg66302
I2
sg66303
I14
sg66314
VC1140680
p74344
sg66306
Vovarian cancer
p74345
sa(dp74346
g66301
I79
sg66302
I1
sg66303
I10
sg66314
VC0027627
p74347
sg66306
Vmetastasis
p74348
sasa(dp74349
g66296
VWNT2B is expressed in several types of human cancer, such as basal cell carcinoma, gastric cancer, breast cancer, head/neck squamous cell carcinoma, cervical cancer and leukemia.
p74350
sg66298
(lp74351
(dp74352
g66301
I0
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VWNT2B
p74353
sasg66311
(lp74354
(dp74355
g66301
I45
sg66302
I1
sg66303
I6
sg66314
VC0006826
p74356
sg66306
Vcancer
p74357
sa(dp74358
g66301
I149
sg66302
I2
sg66303
I15
sg66314
VC0302592
p74359
sg66306
Vcervical cancer
p74360
sa(dp74361
g66301
I91
sg66302
I2
sg66303
I14
sg66314
VC0006142
p74362
sg66306
Vcancer, breast
p74363
sa(dp74364
g66301
I124
sg66302
I3
sg66303
I23
sg66314
VC0007137
p74365
sg66306
Vsquamous cell carcinoma
p74366
sa(dp74367
g66301
I45
sg66302
I1
sg66303
I6
sg66314
VC0006826
p74368
sg66306
Vcancer
p74369
sa(dp74370
g66301
I61
sg66302
I3
sg66303
I20
sg66314
VC0007117
p74371
sg66306
Vbasal cell carcinoma
p74372
sa(dp74373
g66301
I169
sg66302
I1
sg66303
I8
sg66314
VC0023418
p74374
sg66306
Vleukemia
p74375
sasa(dp74376
g66296
VAmong various cancer cell lines, the Wnt-13 mRNA was detected in HeLa (cervical cancer), MKN28 and MKN74 (gastric cancer).
p74377
sg66298
(lp74378
(dp74379
g66301
I37
sg66302
I2
sg66303
I11
sg66304
g11
sg66306
VWnt-13 mRNA
p74380
sasg66311
(lp74381
(dp74382
g66301
I14
sg66302
I1
sg66303
I6
sg66314
VC0006826
p74383
sg66306
Vcancer
p74384
sa(dp74385
g66301
I71
sg66302
I2
sg66303
I15
sg66314
VC0302592
p74386
sg66306
Vcervical cancer
p74387
sa(dp74388
g66301
I106
sg66302
I2
sg66303
I14
sg66314
VC0024623
p74389
sg66306
Vgastric cancer
p74390
sasa(dp74391
g66296
VThe receptor protein tyrosine phosphatase PTPRG has been genetically associated with psychiatric disorders and is a ligand for members of the contactin family, which are themselves linked to autism spectrum disorders.
p74392
sg66298
(lp74393
(dp74394
g66301
I142
sg66302
I2
sg66303
I16
sg66304
g11
sg66306
Vcontactin family
p74395
sa(dp74396
g66301
I4
sg66302
I5
sg66303
I43
sg66304
g11
sg66306
Vreceptor protein tyrosine phosphatase PTPRG
p74397
sasg66311
(lp74398
(dp74399
g66301
I191
sg66302
I3
sg66303
I25
sg66314
VC1510586
p74400
sg66306
Vautism spectrum disorders
p74401
sa(dp74402
g66301
I85
sg66302
I2
sg66303
I21
sg66314
VC0004936
p74403
sg66306
Vpsychiatric disorders
p74404
sasa(dp74405
g66296
VBased on our finding of a phosphatase-null de novo mutation in PTPRG associated with a case of sporadic schizophrenia, we used PTPRG knockout (KO) mice to model the effect of a loss-of-function mutation.
p74406
sg66298
(lp74407
(dp74408
g66301
I63
sg66302
I1
sg66303
I5
sg66304
VP23470
p74409
sg66306
VPTPRG
p74410
sasg66311
(lp74411
(dp74412
g66301
I43
sg66302
I3
sg66303
I16
sg66314
VC2985439
p74413
sg66306
Vde novo mutation
p74414
sa(dp74415
g66301
I104
sg66302
I1
sg66303
I13
sg66314
VC0036341
p74416
sg66306
Vschizophrenia
p74417
sasa(dp74418
g66296
VThe most notable behavioral consequences of PTPRG gene inactivation were reduced immobilization in the forced swim test, suggestive of some negative symptoms of schizophrenia.
p74419
sg66298
(lp74420
(dp74421
g66301
I44
sg66302
I2
sg66303
I10
sg66304
VP23470
p74422
sg66306
VPTPRG gene
p74423
sasg66311
(lp74424
(dp74425
g66301
I161
sg66302
I1
sg66303
I13
sg66314
VC0036341
p74426
sg66306
Vschizophrenia
p74427
sa(dp74428
g66301
I55
sg66302
I1
sg66303
I12
sg66314
VC0544461
p74429
sg66306
Vinactivation
p74430
sasa(dp74431
g66296
VThe subgroups significantly differed in important features, including specific working memory deficits for PTPRG (n=5); severe negative symptoms, global cognitive deficits and poor educational attainment, suggesting a developmental disorder, for SLC39A13 (n=4); slow processing speed, childhood attention deficit disorder and milder symptoms for TGM5 (n=4); and global cognitive deficits with good educational attainment suggesting neurodegeneration for ARMS/KIDINS220 (n=5).
p74432
sg66298
(lp74433
(dp74434
g66301
I246
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VSLC39A13
p74435
sa(dp74436
g66301
I346
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTGM5
p74437
sa(dp74438
g66301
I107
sg66302
I1
sg66303
I5
sg66304
VP23470
p74439
sg66306
VPTPRG
p74440
sa(dp74441
g66301
I459
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
VKIDINS220
p74442
sasg66311
(lp74443
(dp74444
g66301
I432
sg66302
I1
sg66303
I17
sg66314
VC0027746
p74445
sg66306
Vneurodegeneration
p74446
sa(dp74447
g66301
I153
sg66302
I2
sg66303
I18
sg66314
VC0679466
p74448
sg66306
Vcognitive deficits
p74449
sa(dp74450
g66301
I87
sg66302
I2
sg66303
I15
sg66314
VC0233794
p74451
sg66306
Vmemory deficits
p74452
sa(dp74453
g66301
I295
sg66302
I3
sg66303
I26
sg66314
VC0339002
p74454
sg66306
Vattention deficit disorder
p74455
sa(dp74456
g66301
I153
sg66302
I2
sg66303
I18
sg66314
VC0679466
p74457
sg66306
Vcognitive deficits
p74458
sa(dp74459
g66301
I218
sg66302
I2
sg66303
I22
sg66314
VC0008073
p74460
sg66306
Vdevelopmental disorder
p74461
sa(dp74462
g66301
I454
sg66302
I1
sg66303
I4
sg66314
VC0206655
p74463
sg66306
VARMS
p74464
sasa(dp74465
g66296
VFirst, whole exome sequencing was conducted to identify disruptive de novo mutations in 14 complete parent-offspring trios with sporadic schizophrenia from Jerusalem, which identified 5 sporadic cases with de novo gene mutations in 5 different genes (PTPRG, TGM5, SLC39A13, BTK, CDKN3).
p74466
sg66298
(lp74467
(dp74468
g66301
I258
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTGM5
p74469
sa(dp74470
g66301
I264
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VSLC39A13
p74471
sa(dp74472
g66301
I251
sg66302
I1
sg66303
I5
sg66304
VP23470
p74473
sg66306
VPTPRG
p74474
sa(dp74475
g66301
I274
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VBTK
p74476
sasg66311
(lp74477
(dp74478
g66301
I137
sg66302
I1
sg66303
I13
sg66314
VC0036341
p74479
sg66306
Vschizophrenia
p74480
sasa(dp74481
g66296
VNext, targeted exome capture of these genes was conducted in 48 well-characterized, unrelated, ethnically diverse schizophrenia cases, recruited and characterized by the same research team in New York (NY sample), which demonstrated extremely rare and potentially damaging variants in three of the five genes (MAF&lt;0.01) in 12/48 cases (25%); including PTPRG (5 cases), SCL39A13 (4 cases) and TGM5 (4 cases), a higher number than usually identified by whole exome sequencing.
p74482
sg66298
(lp74483
sg66311
(lp74484
(dp74485
g66301
I114
sg66302
I1
sg66303
I13
sg66314
VC0036341
p74486
sg66306
Vschizophrenia
p74487
sasa(dp74488
g66296
VActivated astrocytes were found to be strongly positive for RPTPGamma also in a mice model of Alzheimer's disease.
p74489
sg66298
(lp74490
(dp74491
g66301
I60
sg66302
I1
sg66303
I9
sg66304
VP23470
p74492
sg66306
VRPTPGamma
p74493
sasg66311
(lp74494
(dp74495
g66301
I94
sg66302
I2
sg66303
I19
sg66314
VC1521724
p74496
sg66306
VAlzheimer's disease
p74497
sasa(dp74498
g66296
VAqueous humor (AH) samples from 14 patients with presumed tuberculous uveitis (PTU), and 30 control patients were assayed for the proinflammatory cytokines interleukin IL-4, IL-12, IL-15, IL-17, interferon (IFN)-Gamma, and tumor necrosis factor (TNF)-Alfa, the immunosuppressive cytokine IL-10, and the chemokines GRO-Alfa/CXCL1, IL-8/CXCL8, MIG/CXCL9, IP-10/CXCL10 and SDF-1/CXCL12 with the use of a multiplex assay.
p74499
sg66298
(lp74500
(dp74501
g66301
I342
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VMIG
p74502
sa(dp74503
g66301
I353
sg66302
I1
sg66303
I5
sg66304
VP02778
p74504
sg66306
VIP-10
p74505
sa(dp74506
g66301
I370
sg66302
I1
sg66303
I5
sg66304
VP48061
p74507
sg66306
VSDF-1
p74508
sa(dp74509
g66301
I314
sg66302
I1
sg66303
I3
sg66304
VP09341
p74510
sg66306
VGRO
p74511
sa(dp74512
g66301
I207
sg66302
I1
sg66303
I3
sg66304
VP01562
p74513
sg66306
VIFN
p74514
sa(dp74515
g66301
I195
sg66302
I1
sg66303
I10
sg66304
VP01563
p74516
sg66306
Vinterferon
p74517
sa(dp74518
g66301
I346
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCXCL9
p74519
sa(dp74520
g66301
I156
sg66302
I2
sg66303
I16
sg66304
VP05112
p74521
sg66306
Vinterleukin IL-4
p74522
sa(dp74523
g66301
I223
sg66302
I4
sg66303
I32
sg66304
VP01375
p74524
sg66306
Vtumor necrosis factor (TNF)-Alfa
p74525
sa(dp74526
g66301
I181
sg66302
I1
sg66303
I5
sg66304
VP40933
p74527
sg66306
VIL-15
p74528
sa(dp74529
g66301
I359
sg66302
I1
sg66303
I6
sg66304
VP02778
p74530
sg66306
VCXCL10
p74531
sa(dp74532
g66301
I323
sg66302
I1
sg66303
I5
sg66304
VP09341
p74533
sg66306
VCXCL1
p74534
sa(dp74535
g66301
I376
sg66302
I1
sg66303
I6
sg66304
VP48061
p74536
sg66306
VCXCL12
p74537
sasg66311
(lp74538
(dp74539
g66301
I0
sg66302
I2
sg66303
I13
sg66314
VC0595936
p74540
sg66306
VAqueous humor
p74541
sa(dp74542
g66301
I15
sg66302
I1
sg66303
I2
sg66314
VC0595936
p74543
sg66306
VAH
p74544
sa(dp74545
g66301
I58
sg66302
I2
sg66303
I19
sg66314
VC1281935
p74546
sg66306
Vtuberculous uveitis
p74547
sa(dp74548
g66301
I223
sg66302
I2
sg66303
I14
sg66314
VC0333516
p74549
sg66306
Vtumor necrosis
p74550
sasa(dp74551
g66296
VAqueous humor (AH) samples from patients with Behcet's disease (BD) (n=29), Vogt-Koyanagi-Harada (VKH) disease (n=21), and HLA-B27-associated uveitis (n=8), and 42 control patients were assayed for the neutrophil chemoattractants CXCL1/GRO-Alfa and CXCL8/IL-8 and the lymphocyte chemoattractants CXCL9/MIG, CXCL10/IP-10 and CXCL12/SDF-1 with the use of a multiplex chemokine assay.
p74552
sg66298
(lp74553
(dp74554
g66301
I331
sg66302
I1
sg66303
I5
sg66304
VP48061
p74555
sg66306
VSDF-1
p74556
sa(dp74557
g66301
I236
sg66302
I1
sg66303
I3
sg66304
VP09341
p74558
sg66306
VGRO
p74559
sa(dp74560
g66301
I314
sg66302
I1
sg66303
I5
sg66304
VP02778
p74561
sg66306
VIP-10
p74562
sa(dp74563
g66301
I296
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCXCL9
p74564
sa(dp74565
g66301
I324
sg66302
I1
sg66303
I6
sg66304
VP48061
p74566
sg66306
VCXCL12
p74567
sa(dp74568
g66301
I123
sg66302
I1
sg66303
I7
sg66304
VP30486
p74569
sg66306
VHLA-B27
p74570
sa(dp74571
g66301
I302
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VMIG
p74572
sa(dp74573
g66301
I230
sg66302
I1
sg66303
I5
sg66304
VP09341
p74574
sg66306
VCXCL1
p74575
sa(dp74576
g66301
I307
sg66302
I1
sg66303
I6
sg66304
VP02778
p74577
sg66306
VCXCL10
p74578
sasg66311
(lp74579
(dp74580
g66301
I0
sg66302
I2
sg66303
I13
sg66314
VC0595936
p74581
sg66306
VAqueous humor
p74582
sa(dp74583
g66301
I15
sg66302
I1
sg66303
I2
sg66314
VC0595936
p74584
sg66306
VAH
p74585
sa(dp74586
g66301
I46
sg66302
I2
sg66303
I16
sg66314
VC0004943
p74587
sg66306
VBehcet's disease
p74588
sa(dp74589
g66301
I142
sg66302
I1
sg66303
I7
sg66314
VC0042164
p74590
sg66306
Vuveitis
p74591
sa(dp74592
g66301
I64
sg66302
I1
sg66303
I2
sg66314
VC0004943
p74593
sg66306
VBD
p74594
sasa(dp74595
g66296
VIn patients with the same disease activity, AH levels of GRO-Alfa and IP-10 were significantly higher in patients with BD than in patients with VKH disease and HLA-B27-associated uveitis (p=0.0474; p&lt;0.001, respectively).
p74596
sg66298
(lp74597
(dp74598
g66301
I160
sg66302
I1
sg66303
I7
sg66304
VP30486
p74599
sg66306
VHLA-B27
p74600
sa(dp74601
g66301
I70
sg66302
I1
sg66303
I5
sg66304
VP02778
p74602
sg66306
VIP-10
p74603
sa(dp74604
g66301
I57
sg66302
I1
sg66303
I8
sg66304
VP09341
p74605
sg66306
VGRO-Alfa
p74606
sasg66311
(lp74607
(dp74608
g66301
I179
sg66302
I1
sg66303
I7
sg66314
VC0042164
p74609
sg66306
Vuveitis
p74610
sasa(dp74611
g66296
VThese data suggest that GRO-Alfa and IP-10 are the predominant CXC chemokines involved in neutrophil and activated T lymphocyte chemoattraction in endogenous uveitis, particularly in BD.
p74612
sg66298
(lp74613
(dp74614
g66301
I24
sg66302
I1
sg66303
I3
sg66304
VP09341
p74615
sg66306
VGRO
p74616
sa(dp74617
g66301
I37
sg66302
I1
sg66303
I5
sg66304
VP02778
p74618
sg66306
VIP-10
p74619
sasg66311
(lp74620
(dp74621
g66301
I158
sg66302
I1
sg66303
I7
sg66314
VC0042164
p74622
sg66306
Vuveitis
p74623
sasa(dp74624
g66296
VThe purpose of this study was to investigate the role and regulation of the CXC chemokine GRO and the interaction between GRO and IL-8 in LPS-induced uveitis in rabbits.
p74625
sg66298
(lp74626
(dp74627
g66301
I90
sg66302
I1
sg66303
I3
sg66304
VP09341
p74628
sg66306
VGRO
p74629
sasg66311
(lp74630
(dp74631
g66301
I138
sg66302
I1
sg66303
I3
sg66314
VC0175697
p74632
sg66306
VLPS
p74633
sa(dp74634
g66301
I150
sg66302
I1
sg66303
I7
sg66314
VC0042164
p74635
sg66306
Vuveitis
p74636
sasa(dp74637
g66296
VTaken together, our results suggest that GRO is an essential mediator for neutrophil infiltration in LPS-induced uveitis in rabbits.
p74638
sg66298
(lp74639
(dp74640
g66301
I41
sg66302
I1
sg66303
I3
sg66304
VP09341
p74641
sg66306
VGRO
p74642
sasg66311
(lp74643
(dp74644
g66301
I113
sg66302
I1
sg66303
I7
sg66314
VC0042164
p74645
sg66306
Vuveitis
p74646
sa(dp74647
g66301
I101
sg66302
I1
sg66303
I3
sg66314
VC0175697
p74648
sg66306
VLPS
p74649
sa(dp74650
g66301
I85
sg66302
I1
sg66303
I12
sg66314
VC0332448
p74651
sg66306
Vinfiltration
p74652
sasa(dp74653
g66296
VNa(+)K(+)ATPase, NKCC1, and alpha-syntrophin were expressed within sensory epithelia and were unaltered in Meniere's disease specimens.
p74654
sg66298
(lp74655
(dp74656
g66301
I17
sg66302
I1
sg66303
I5
sg66304
VP55011
p74657
sg66306
VNKCC1
p74658
sa(dp74659
g66301
I28
sg66302
I1
sg66303
I16
sg66304
g11
sg66306
Valpha-syntrophin
p74660
sa(dp74661
g66301
I0
sg66302
I1
sg66303
I15
sg66304
VP38606
p74662
sg66306
VNa(+)K(+)ATPase
p74663
sasg66311
(lp74664
(dp74665
g66301
I107
sg66302
I2
sg66303
I17
sg66314
VC0025281
p74666
sg66306
VMeniere's disease
p74667
sasa(dp74668
g66296
VAlthough an elevated hemoglobin A1c (HbAc1) level is an independent predictor of worse survival in patients with both digestive cancer and diabetes mellitus, its relationship to short-term prognosis in these patients has not been addressed.
p74669
sg66298
(lp74670
(dp74671
g66301
I37
sg66302
I1
sg66303
I5
sg66304
VP40145
p74672
sg66306
VHbAc1
p74673
sa(dp74674
g66301
I21
sg66302
I2
sg66303
I14
sg66304
g11
sg66306
Vhemoglobin A1c
p74675
sasg66311
(lp74676
(dp74677
g66301
I139
sg66302
I2
sg66303
I17
sg66314
VC0011849
p74678
sg66306
Vdiabetes mellitus
p74679
sa(dp74680
g66301
I118
sg66302
I2
sg66303
I16
sg66314
VC0685938
p74681
sg66306
Vdigestive cancer
p74682
sasa(dp74683
g66296
VWe identified novel driver mutations that developed during adenoma and cancer evolution, particularly in OR1B1 (GPCR signaling pathway) for adenoma evolution, and LAMA1 (PI3K-Akt signaling pathway) and ADCY3 (FGFR signaling pathway) for CRC evolution.
p74684
sg66298
(lp74685
(dp74686
g66301
I163
sg66302
I1
sg66303
I5
sg66304
VP25391
p74687
sg66306
VLAMA1
p74688
sa(dp74689
g66301
I175
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VAkt
p74690
sa(dp74691
g66301
I112
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGPCR
p74692
sa(dp74693
g66301
I170
sg66302
I1
sg66303
I4
sg66304
VP42336
p74694
sg66306
VPI3K
p74695
sa(dp74696
g66301
I105
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VOR1B1
p74697
sa(dp74698
g66301
I237
sg66302
I1
sg66303
I3
sg66304
VP31749
p74699
sg66306
VCRC
p74700
sa(dp74701
g66301
I202
sg66302
I1
sg66303
I5
sg66304
VP40145
p74702
sg66306
VADCY3
p74703
sasg66311
(lp74704
(dp74705
g66301
I59
sg66302
I1
sg66303
I7
sg66314
VC0001430
p74706
sg66306
Vadenoma
p74707
sa(dp74708
g66301
I237
sg66302
I1
sg66303
I3
sg66314
VC1527249
p74709
sg66306
VCRC
p74710
sa(dp74711
g66301
I59
sg66302
I1
sg66303
I7
sg66314
VC0001430
p74712
sg66306
Vadenoma
p74713
sa(dp74714
g66301
I71
sg66302
I1
sg66303
I6
sg66314
VC0006826
p74715
sg66306
Vcancer
p74716
sasa(dp74717
g66296
VRecently, we provided human validation for a cooperating oncogenic role for cAMP in brain tumorigenesis when we found that SNPs in ADCY8 were correlated with glioma (brain tumor) risk in individuals with Neurofibromatosis type 1 (NF1).
p74718
sg66298
(lp74719
(dp74720
g66301
I230
sg66302
I1
sg66303
I3
sg66304
VP21359
p74721
sg66306
VNF1
p74722
sa(dp74723
g66301
I131
sg66302
I1
sg66303
I5
sg66304
VP40145
p74724
sg66306
VADCY8
p74725
sa(dp74726
g66301
I204
sg66302
I3
sg66303
I24
sg66304
VP21359
p74727
sg66306
VNeurofibromatosis type 1
p74728
sasg66311
(lp74729
(dp74730
g66301
I230
sg66302
I1
sg66303
I3
sg66314
VC0027831
p74731
sg66306
VNF1
p74732
sa(dp74733
g66301
I84
sg66302
I2
sg66303
I11
sg66314
VC0006118
p74734
sg66306
Vbrain tumor
p74735
sa(dp74736
g66301
I204
sg66302
I3
sg66303
I24
sg66314
VC0027831
p74737
sg66306
VNeurofibromatosis type 1
p74738
sa(dp74739
g66301
I84
sg66302
I13
sg66303
I80
sg66314
VC0006118
p74740
sg66306
Vbrain tumorigenesis when we found that SNPs in ADCY8 were correlated with glioma
p74741
sasa(dp74742
g66296
VHowever, the cAMP pathway is well-known to be sexually dimorphic, and SNPs in ADCY8 affected glioma risk in a sex-specific fashion, elevating the risk for females while protecting males.
p74743
sg66298
(lp74744
(dp74745
g66301
I78
sg66302
I1
sg66303
I5
sg66304
VP40145
p74746
sg66306
VADCY8
p74747
sasg66311
(lp74748
(dp74749
g66301
I93
sg66302
I1
sg66303
I6
sg66314
VC0017638
p74750
sg66306
Vglioma
p74751
sasa(dp74752
g66296
VHere, we report genetic polymorphisms in the human adenylate cyclase gene adenylate cyclase 8 (ADCY8) that correlate with glioma risk in NF1 in a sex-specific manner, elevating risk in females while reducing risk in males.
p74753
sg66298
(lp74754
(dp74755
g66301
I95
sg66302
I1
sg66303
I5
sg66304
VP40145
p74756
sg66306
VADCY8
p74757
sa(dp74758
g66301
I45
sg66302
I7
sg66303
I48
sg66304
g11
sg66306
Vhuman adenylate cyclase gene adenylate cyclase 8
p74759
sa(dp74760
g66301
I137
sg66302
I1
sg66303
I3
sg66304
VP21359
p74761
sg66306
VNF1
p74762
sasg66311
(lp74763
(dp74764
g66301
I122
sg66302
I1
sg66303
I6
sg66314
VC0017638
p74765
sg66306
Vglioma
p74766
sa(dp74767
g66301
I137
sg66302
I1
sg66303
I3
sg66314
VC0027831
p74768
sg66306
VNF1
p74769
sasa(dp74770
g66296
VOverall, our results establish a sex-specific role for cAMP regulation in human gliomagenesis, specifically identifying ADCY8 as a modifier of glioma risk in NF1.
p74771
sg66298
(lp74772
(dp74773
g66301
I158
sg66302
I1
sg66303
I3
sg66304
VP21359
p74774
sg66306
VNF1
p74775
sa(dp74776
g66301
I120
sg66302
I1
sg66303
I5
sg66304
VP40145
p74777
sg66306
VADCY8
p74778
sasg66311
(lp74779
(dp74780
g66301
I158
sg66302
I1
sg66303
I3
sg66314
VC0027831
p74781
sg66306
VNF1
p74782
sa(dp74783
g66301
I80
sg66302
I1
sg66303
I6
sg66314
VC0017638
p74784
sg66306
Vglioma
p74785
sasa(dp74786
g66296
VThe effect of insulin on the oxidative desaturation of 1-14C palmitic acid to palmitoleic acid (delta 9 desaturase) 1-14C linoleic acid to alpha-linolenic acid (delta 6 desaturase) on rat liver microsomes and 1-14C eicosa-8,11,14-trienoic acid to arachidonic acid (delta 5 desaturase) on rat liver microsomes and hepatoma tissue culture (HTC) cells was studied.
p74787
sg66298
(lp74788
(dp74789
g66301
I265
sg66302
I3
sg66303
I18
sg66304
VP28072
p74790
sg66306
Vdelta 5 desaturase
p74791
sa(dp74792
g66301
I161
sg66302
I3
sg66303
I18
sg66304
VP28072
p74793
sg66306
Vdelta 6 desaturase
p74794
sa(dp74795
g66301
I14
sg66302
I1
sg66303
I7
sg66304
VP01308
p74796
sg66306
Vinsulin
p74797
sasg66311
(lp74798
(dp74799
g66301
I313
sg66302
I1
sg66303
I8
sg66314
VC0023903
p74800
sg66306
Vhepatoma
p74801
sasa(dp74802
g66296
VMethylation of CALCA, CDH1, DAPK1, and EVX2 was more common in squamous cell carcinomas (SCC) compared to adenocarcinomas (ADC).
p74803
sg66298
(lp74804
(dp74805
g66301
I39
sg66302
I1
sg66303
I4
sg66304
VP55085
p74806
sg66306
VEVX2
p74807
sa(dp74808
g66301
I22
sg66302
I1
sg66303
I4
sg66304
VP12830
p74809
sg66306
VCDH1
p74810
sa(dp74811
g66301
I28
sg66302
I1
sg66303
I5
sg66304
VP53355
p74812
sg66306
VDAPK1
p74813
sasg66311
(lp74814
(dp74815
g66301
I89
sg66302
I1
sg66303
I3
sg66314
VC0007137
p74816
sg66306
VSCC
p74817
sa(dp74818
g66301
I63
sg66302
I3
sg66303
I24
sg66314
VC0007137
p74819
sg66306
Vsquamous cell carcinomas
p74820
sa(dp74821
g66301
I106
sg66302
I1
sg66303
I15
sg66314
VC0001418
p74822
sg66306
Vadenocarcinomas
p74823
sa(dp74824
g66301
I123
sg66302
I1
sg66303
I3
sg66314
VC0001418
p74825
sg66306
VADC
p74826
sasa(dp74827
g66296
VOverall, CALCA, DAPK, ESR1, TIMP3, APC and RAR-beta2 promoters were significantly more often hypermethylated in cancers than in controls, while adenocarcinomas were more often hypermethylated above the highest control ratio for APC, TIMP3 and RASSF1A promoters.
p74828
sg66298
(lp74829
(dp74830
g66301
I28
sg66302
I1
sg66303
I5
sg66304
VP35625
p74831
sg66306
VTIMP3
p74832
sa(dp74833
g66301
I35
sg66302
I1
sg66303
I3
sg66304
VP25054
p74834
sg66306
VAPC
p74835
sa(dp74836
g66301
I9
sg66302
I1
sg66303
I5
sg66304
VP06881
p74837
sg66306
VCALCA
p74838
sa(dp74839
g66301
I16
sg66302
I1
sg66303
I4
sg66304
VP53355
p74840
sg66306
VDAPK
p74841
sa(dp74842
g66301
I22
sg66302
I1
sg66303
I4
sg66304
VP03372
p74843
sg66306
VESR1
p74844
sa(dp74845
g66301
I43
sg66302
I2
sg66303
I19
sg66304
VP10276
p74846
sg66306
VRAR-beta2 promoters
p74847
sa(dp74848
g66301
I35
sg66302
I1
sg66303
I3
sg66304
VP25054
p74849
sg66306
VAPC
p74850
sa(dp74851
g66301
I28
sg66302
I1
sg66303
I5
sg66304
VP35625
p74852
sg66306
VTIMP3
p74853
sasg66311
(lp74854
(dp74855
g66301
I112
sg66302
I1
sg66303
I7
sg66314
VC0006826
p74856
sg66306
Vcancers
p74857
sa(dp74858
g66301
I144
sg66302
I1
sg66303
I15
sg66314
VC0001418
p74859
sg66306
Vadenocarcinomas
p74860
sa(dp74861
g66301
I35
sg66302
I1
sg66303
I3
sg66314
VC0033036
p74862
sg66306
VAPC
p74863
sa(dp74864
g66301
I35
sg66302
I1
sg66303
I3
sg66314
VC0033036
p74865
sg66306
VAPC
p74866
sasa(dp74867
g66296
VCombining 4 genes (CALCA, DAPK, ESR1 and APC) yielded a sensitivity of 89% (with all adenocarcinomas identified), equal to cytomorphology (89%) and high-risk human papilloma virus (Hr-HPV; 90%).
p74868
sg66298
(lp74869
(dp74870
g66301
I26
sg66302
I1
sg66303
I4
sg66304
VP53355
p74871
sg66306
VDAPK
p74872
sa(dp74873
g66301
I19
sg66302
I1
sg66303
I5
sg66304
VP06881
p74874
sg66306
VCALCA
p74875
sa(dp74876
g66301
I0
sg66302
I3
sg66303
I17
sg66304
VP01893
p74877
sg66306
VCombining 4 genes
p74878
sa(dp74879
g66301
I41
sg66302
I1
sg66303
I3
sg66304
VP25054
p74880
sg66306
VAPC
p74881
sa(dp74882
g66301
I32
sg66302
I1
sg66303
I4
sg66304
VP03372
p74883
sg66306
VESR1
p74884
sasg66311
(lp74885
(dp74886
g66301
I41
sg66302
I1
sg66303
I3
sg66314
VC0033036
p74887
sg66306
VAPC
p74888
sa(dp74889
g66301
I85
sg66302
I1
sg66303
I15
sg66314
VC0001418
p74890
sg66306
Vadenocarcinomas
p74891
sa(dp74892
g66301
I164
sg66302
I1
sg66303
I9
sg66314
VC0030354
p74893
sg66306
Vpapilloma
p74894
sasa(dp74895
g66296
VThe thyroid tumor was diagnosed as metastasis to the thyroid from lung adenocarcinoma, because it showed mucin production, positive immunoreactivity for carcinoembryonic antigen and negative immunoreactivities for thyroglobulin and calcitonin.
p74896
sg66298
(lp74897
(dp74898
g66301
I153
sg66302
I2
sg66303
I24
sg66304
VP40198
p74899
sg66306
Vcarcinoembryonic antigen
p74900
sa(dp74901
g66301
I214
sg66302
I1
sg66303
I13
sg66304
g11
sg66306
Vthyroglobulin
p74902
sa(dp74903
g66301
I105
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
Vmucin
p74904
sa(dp74905
g66301
I232
sg66302
I1
sg66303
I10
sg66304
VP06881
p74906
sg66306
Vcalcitonin
p74907
sasg66311
(lp74908
(dp74909
g66301
I66
sg66302
I2
sg66303
I19
sg66314
VC0152013
p74910
sg66306
Vlung adenocarcinoma
p74911
sa(dp74912
g66301
I4
sg66302
I2
sg66303
I13
sg66314
VC0040136
p74913
sg66306
Vthyroid tumor
p74914
sa(dp74915
g66301
I35
sg66302
I4
sg66303
I25
sg66314
VC0347023
p74916
sg66306
Vmetastasis to the thyroid
p74917
sasa(dp74918
g66296
VWe searched Medline for clinical trials that assessed disease-modifying drugs for relapsing-remitting multiple sclerosis published from Sept 1, 2008, to Oct 31, 2012.
p74919
sg66298
(lp74920
(dp74921
g66301
I153
sg66302
I2
sg66303
I6
sg66304
VP00480
p74922
sg66306
VOct 31
p74923
sasg66311
(lp74924
(dp74925
g66301
I82
sg66302
I3
sg66303
I38
sg66314
VC0751967
p74926
sg66306
Vrelapsing-remitting multiple sclerosis
p74927
sasa(dp74928
g66296
VSEPT1, SEPT4, and SEPT2 have been found in deposits known as neurofibrillary tangles and glial fibrils in Alzheimer's disease.
p74929
sg66298
(lp74930
(dp74931
g66301
I7
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSEPT4
p74932
sa(dp74933
g66301
I0
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSEPT1
p74934
sa(dp74935
g66301
I18
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSEPT2
p74936
sasg66311
(lp74937
(dp74938
g66301
I61
sg66302
I2
sg66303
I23
sg66314
VC0085400
p74939
sg66306
Vneurofibrillary tangles
p74940
sa(dp74941
g66301
I106
sg66302
I2
sg66303
I19
sg66314
VC1521724
p74942
sg66306
VAlzheimer's disease
p74943
sasa(dp74944
g66296
VFinally, we evaluated the effect of the pro-arousal neuropeptides CRF and Hcrt-1/Ox-A in NPSR-deficient mice.
p74945
sg66298
(lp74946
(dp74947
g66301
I74
sg66302
I1
sg66303
I6
sg66304
VP50336
p74948
sg66306
VHcrt-1
p74949
sasg66311
(lp74950
(dp74951
g66301
I66
sg66302
I1
sg66303
I3
sg66314
VC0022661
p74952
sg66306
VCRF
p74953
sasa(dp74954
g66296
VThe administration of CRF and Hcrt-1/Ox-A, two classic pro-arousal peptides, elicited the same effects in both NPSR(-/-) and wild type mice, ruling out the possibility that adaptive mechanisms occurring at the level of these two systems could have occurred during NPSR(-/-) development to compensate for the lack of NPSR receptors.
p74955
sg66298
(lp74956
(dp74957
g66301
I30
sg66302
I1
sg66303
I6
sg66304
VP50336
p74958
sg66306
VHcrt-1
p74959
sa(dp74960
g66301
I316
sg66302
I2
sg66303
I14
sg66304
g11
sg66306
VNPSR receptors
p74961
sa(dp74962
g66301
I22
sg66302
I1
sg66303
I3
sg66304
VP06850
p74963
sg66306
VCRF
p74964
sasg66311
(lp74965
(dp74966
g66301
I22
sg66302
I1
sg66303
I3
sg66314
VC0022661
p74967
sg66306
VCRF
p74968
sasa(dp74969
g66296
VMoreover, we demonstrated that the deletion of NPSR did not lead to compensatory changes in the vigilance-promoting effects of the CRF and Hcrt-1/Ox-A systems.
p74970
sg66298
(lp74971
(dp74972
g66301
I131
sg66302
I1
sg66303
I3
sg66304
VP06850
p74973
sg66306
VCRF
p74974
sa(dp74975
g66301
I139
sg66302
I1
sg66303
I6
sg66304
VP50336
p74976
sg66306
VHcrt-1
p74977
sasg66311
(lp74978
(dp74979
g66301
I131
sg66302
I1
sg66303
I3
sg66314
VC0022661
p74980
sg66306
VCRF
p74981
sasa(dp74982
g66296
VWe included all RCTs of any calcimimetic agent, cinacalcet HCl (AMG-073, Sensipar), NPS R-467 or NPS R-568 administered to patients with CKD for the treatment of SHPT.
p74983
sg66298
(lp74984
sg66311
(lp74985
(dp74986
g66301
I84
sg66302
I1
sg66303
I3
sg66314
VC0027341
p74987
sg66306
VNPS
p74988
sa(dp74989
g66301
I84
sg66302
I1
sg66303
I3
sg66314
VC0027341
p74990
sg66306
VNPS
p74991
sasa(dp74992
g66296
VRenal osteodystrophy (RO) due to secondary hyperparathyroidism (HPT) in chronic renal failure was an obvious target for studying the effects of NPS R-568.
p74993
sg66298
(lp74994
sg66311
(lp74995
(dp74996
g66301
I33
sg66302
I2
sg66303
I29
sg66314
VC0020503
p74997
sg66306
Vsecondary hyperparathyroidism
p74998
sa(dp74999
g66301
I22
sg66302
I1
sg66303
I2
sg66314
VC0035086
p75000
sg66306
VRO
p75001
sa(dp75002
g66301
I144
sg66302
I1
sg66303
I3
sg66314
VC0027341
p75003
sg66306
VNPS
p75004
sa(dp75005
g66301
I0
sg66302
I2
sg66303
I20
sg66314
VC0035086
p75006
sg66306
VRenal osteodystrophy
p75007
sa(dp75008
g66301
I72
sg66302
I3
sg66303
I21
sg66314
VC0022661
p75009
sg66306
Vchronic renal failure
p75010
sasa(dp75011
g66296
VChanges in BIS (bispectral index) VISTA bilateral monitoring system associated with intraoperative episodes of generalized and focal seizures, during total intravenous anesthesia for resection of a left frontal parasagittal meningioma, are herein described.
p75012
sg66298
(lp75013
sg66311
(lp75014
(dp75015
g66301
I211
sg66302
I2
sg66303
I23
sg66314
VC0751304
p75016
sg66306
Vparasagittal meningioma
p75017
sa(dp75018
g66301
I127
sg66302
I2
sg66303
I14
sg66314
VC0751495
p75019
sg66306
Vfocal seizures
p75020
sa(dp75021
g66301
I168
sg66302
I1
sg66303
I10
sg66314
VC0278134
p75022
sg66306
Vanesthesia
p75023
sasa(dp75024
g66296
VPrevious studies identified a variety of putative target genes from several pathways associated with DNA damage repair, chromatin remodeling complex, PI3K-AKT-mTOR signaling, Notch signaling, cell cycle checkpoint signaling, BRCA-associated complex and Fanconi's anemia susceptibility genes that could be used as biomarkers or therapeutic targets for PARP inhibition.
p75025
sg66298
(lp75026
(dp75027
g66301
I155
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VAKT
p75028
sa(dp75029
g66301
I351
sg66302
I1
sg66303
I4
sg66304
VP09874
p75030
sg66306
VPARP
p75031
sa(dp75032
g66301
I150
sg66302
I1
sg66303
I4
sg66304
VP42336
p75033
sg66306
VPI3K
p75034
sa(dp75035
g66301
I159
sg66302
I1
sg66303
I4
sg66304
VP42345
p75036
sg66306
VmTOR
p75037
sasg66311
(lp75038
(dp75039
g66301
I101
sg66302
I2
sg66303
I10
sg66314
VC0012860
p75040
sg66306
VDNA damage
p75041
sa(dp75042
g66301
I253
sg66302
I2
sg66303
I16
sg66314
VC0015625
p75043
sg66306
VFanconi's anemia
p75044
sasa(dp75045
g66296
VHematologic toxicities, including neutropenia, thrombocytopenia, and anemia, are major adverse effects of PARP inhibitors (PARPis), but the incidence rate and overall risk has not been systematically studied.
p75046
sg66298
(lp75047
(dp75048
g66301
I106
sg66302
I1
sg66303
I4
sg66304
VP09874
p75049
sg66306
VPARP
p75050
sasg66311
(lp75051
(dp75052
g66301
I69
sg66302
I1
sg66303
I6
sg66314
VC0002871
p75053
sg66306
Vanemia
p75054
sa(dp75055
g66301
I87
sg66302
I2
sg66303
I15
sg66314
VC0879626
p75056
sg66306
Vadverse effects
p75057
sasa(dp75058
g66296
VA total of 2,479 patients from 12 RCTs revealed that the incidence of PARPi-associated severe hematologic toxicities was, respectively: neutropenia: 32.9% (95% CI, 20.5%-48.3%); thrombocytopenia: 15.9% (95% CI, 9.5%-25.4%), and anemia: 9.1% (95% CI, 5.1%-15.7%).
p75059
sg66298
(lp75060
sg66311
(lp75061
(dp75062
g66301
I228
sg66302
I1
sg66303
I6
sg66314
VC0002871
p75063
sg66306
Vanemia
p75064
sasa(dp75065
g66296
VExamples of endocrine syndromes are classical carcinoid syndrome caused by serotonin (measured in the urine as its metabolite 5-HIAA), insulinoma syndrome caused by insulin or proinsulin, Zollinger-Ellison syndrome resulting from gastrin secretion, glucagonoma syndrome caused by glucagon, WDHA syndrome caused by vasoactive intestinal peptide, or Cushing's syndrome resulting from ectopic production of adrenocorticotropic hormone or corticotropin-releasing hormone.
p75066
sg66298
(lp75067
(dp75068
g66301
I230
sg66302
I1
sg66303
I7
sg66304
VP01350
p75069
sg66306
Vgastrin
p75070
sa(dp75071
g66301
I176
sg66302
I1
sg66303
I10
sg66304
VP01308
p75072
sg66306
Vproinsulin
p75073
sa(dp75074
g66301
I435
sg66302
I2
sg66303
I31
sg66304
VP06850
p75075
sg66306
Vcorticotropin-releasing hormone
p75076
sa(dp75077
g66301
I135
sg66302
I1
sg66303
I7
sg66304
VP01308
p75078
sg66306
Vinsulin
p75079
sa(dp75080
g66301
I249
sg66302
I1
sg66303
I8
sg66304
VP01275
p75081
sg66306
Vglucagon
p75082
sa(dp75083
g66301
I404
sg66302
I2
sg66303
I27
sg66304
VP01189
p75084
sg66306
Vadrenocorticotropic hormone
p75085
sasg66311
(lp75086
(dp75087
g66301
I135
sg66302
I1
sg66303
I10
sg66314
VC0021670
p75088
sg66306
Vinsulinoma
p75089
sa(dp75090
g66301
I22
sg66302
I1
sg66303
I8
sg66314
VC0039082
p75091
sg66306
Vsyndrome
p75092
sa(dp75093
g66301
I188
sg66302
I2
sg66303
I26
sg66314
VC0043515
p75094
sg66306
VZollinger-Ellison syndrome
p75095
sa(dp75096
g66301
I22
sg66302
I1
sg66303
I9
sg66314
VC0039082
p75097
sg66306
Vsyndromes
p75098
sa(dp75099
g66301
I46
sg66302
I2
sg66303
I18
sg66314
VC0024586
p75100
sg66306
Vcarcinoid syndrome
p75101
sa(dp75102
g66301
I249
sg66302
I2
sg66303
I20
sg66314
VC0017689
p75103
sg66306
Vglucagonoma syndrome
p75104
sa(dp75105
g66301
I290
sg66302
I2
sg66303
I13
sg66314
VC0086768
p75106
sg66306
VWDHA syndrome
p75107
sa(dp75108
g66301
I348
sg66302
I2
sg66303
I18
sg66314
VC0010481
p75109
sg66306
VCushing's syndrome
p75110
sasa(dp75111
g66296
VWe have previously reported and confirmed that vasoactive intestinal peptide (VIP) is a significant stimulator of ACTH and cortisol secretion in at least some patients with Cushing's disease.
p75112
sg66298
(lp75113
(dp75114
g66301
I78
sg66302
I1
sg66303
I3
sg66304
VP01282
p75115
sg66306
VVIP
p75116
sa(dp75117
g66301
I114
sg66302
I1
sg66303
I4
sg66304
VP01189
p75118
sg66306
VACTH
p75119
sa(dp75120
g66301
I47
sg66302
I3
sg66303
I29
sg66304
VP01282
p75121
sg66306
Vvasoactive intestinal peptide
p75122
sasg66311
(lp75123
(dp75124
g66301
I173
sg66302
I2
sg66303
I17
sg66314
VC0221406
p75125
sg66306
VCushing's disease
p75126
sasa(dp75127
g66296
VWe have also found that the hormonal responses to corticotropin-releasing hormone (CRH) in VIP-responsive patients with Cushing's disease were higher than those in VIP non-responders, which suggested a linkage between the actions of CRH and VIP in this disorder.
p75128
sg66298
(lp75129
(dp75130
g66301
I83
sg66302
I1
sg66303
I3
sg66304
VP06850
p75131
sg66306
VCRH
p75132
sa(dp75133
g66301
I50
sg66302
I2
sg66303
I31
sg66304
VP06850
p75134
sg66306
Vcorticotropin-releasing hormone
p75135
sa(dp75136
g66301
I83
sg66302
I1
sg66303
I3
sg66304
VP06850
p75137
sg66306
VCRH
p75138
sa(dp75139
g66301
I91
sg66302
I1
sg66303
I3
sg66304
VP01282
p75140
sg66306
VVIP
p75141
sasg66311
(lp75142
(dp75143
g66301
I120
sg66302
I2
sg66303
I17
sg66314
VC0221406
p75144
sg66306
VCushing's disease
p75145
sasa(dp75146
g66296
VThis study is the first to demonstrate the parallel inhibition by DEX of ACTH and cortisol responses to CRH and VIP in Cushing's disease.
p75147
sg66298
(lp75148
(dp75149
g66301
I73
sg66302
I1
sg66303
I4
sg66304
VP01189
p75150
sg66306
VACTH
p75151
sa(dp75152
g66301
I112
sg66302
I1
sg66303
I3
sg66304
VP01282
p75153
sg66306
VVIP
p75154
sa(dp75155
g66301
I104
sg66302
I1
sg66303
I3
sg66304
VP06850
p75156
sg66306
VCRH
p75157
sasg66311
(lp75158
(dp75159
g66301
I119
sg66302
I2
sg66303
I17
sg66314
VC0221406
p75160
sg66306
VCushing's disease
p75161
sasa(dp75162
g66296
VOf the patients with Cushing's disease, 9 (75%) were responsive to hCRH, 5 (42%) were to VIP, and 3 (25%) were to PHM, showing significant increases in both ACTH and cortisol.
p75163
sg66298
(lp75164
(dp75165
g66301
I89
sg66302
I1
sg66303
I3
sg66304
VP01282
p75166
sg66306
VVIP
p75167
sa(dp75168
g66301
I157
sg66302
I1
sg66303
I4
sg66304
VP01189
p75169
sg66306
VACTH
p75170
sasg66311
(lp75171
(dp75172
g66301
I21
sg66302
I2
sg66303
I17
sg66314
VC0221406
p75173
sg66306
VCushing's disease
p75174
sasa(dp75175
g66296
VIn addition, in the patients with Cushing's disease the coadministration of hCRH with PHM or VIP produced additive increases in both ACTH and cortisol.
p75176
sg66298
(lp75177
(dp75178
g66301
I93
sg66302
I1
sg66303
I3
sg66304
VP01282
p75179
sg66306
VVIP
p75180
sa(dp75181
g66301
I133
sg66302
I1
sg66303
I4
sg66304
VP01189
p75182
sg66306
VACTH
p75183
sasg66311
(lp75184
(dp75185
g66301
I34
sg66302
I2
sg66303
I17
sg66314
VC0221406
p75186
sg66306
VCushing's disease
p75187
sasa(dp75188
g66296
VAbnormalities in hypothalamic-pituitary adrenal axis function were demonstrated by measuring plasma adrenocorticotropin abnormal concentrations following Vasoactive Intestinal Peptide (VIP) and Corticotropin Releasing Hormone (CRH) administration during a phase of remission of Cushing's disease in a 45-year-old female patient.
p75189
sg66298
(lp75190
(dp75191
g66301
I194
sg66302
I3
sg66303
I31
sg66304
VP06850
p75192
sg66306
VCorticotropin Releasing Hormone
p75193
sa(dp75194
g66301
I100
sg66302
I1
sg66303
I19
sg66304
VP01189
p75195
sg66306
Vadrenocorticotropin
p75196
sa(dp75197
g66301
I185
sg66302
I1
sg66303
I3
sg66304
VP01282
p75198
sg66306
VVIP
p75199
sa(dp75200
g66301
I154
sg66302
I3
sg66303
I29
sg66304
VP01282
p75201
sg66306
VVasoactive Intestinal Peptide
p75202
sa(dp75203
g66301
I227
sg66302
I1
sg66303
I3
sg66304
VP06850
p75204
sg66306
VCRH
p75205
sasg66311
(lp75206
(dp75207
g66301
I278
sg66302
I2
sg66303
I17
sg66314
VC0221406
p75208
sg66306
VCushing's disease
p75209
sa(dp75210
g66301
I265
sg66302
I1
sg66303
I9
sg66314
VC0687702
p75211
sg66306
Vremission
p75212
sasa(dp75213
g66296
VWe conclude that the study of ACTH and cortisol response to VIP and CRH may be useful in revealing Cushing's disease even during a remission phase of the disorder.
p75214
sg66298
(lp75215
(dp75216
g66301
I68
sg66302
I1
sg66303
I3
sg66304
VP06850
p75217
sg66306
VCRH
p75218
sa(dp75219
g66301
I30
sg66302
I1
sg66303
I4
sg66304
VP01189
p75220
sg66306
VACTH
p75221
sa(dp75222
g66301
I60
sg66302
I1
sg66303
I3
sg66304
VP01282
p75223
sg66306
VVIP
p75224
sasg66311
(lp75225
(dp75226
g66301
I131
sg66302
I1
sg66303
I9
sg66314
VC0687702
p75227
sg66306
Vremission
p75228
sa(dp75229
g66301
I99
sg66302
I2
sg66303
I17
sg66314
VC0221406
p75230
sg66306
VCushing's disease
p75231
sasa(dp75232
g66296
VHere we introduce a cell culture model of EAD propagation consisting of monolayers of cultured neonatal rat ventricular myocytes treated with anthopleurin-A (AP-A).
p75233
sg66298
(lp75234
(dp75235
g66301
I142
sg66302
I1
sg66303
I14
sg66304
g11
sg66306
Vanthopleurin-A
p75236
sa(dp75237
g66301
I158
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VAP-A
p75238
sasg66311
(lp75239
(dp75240
g66301
I42
sg66302
I1
sg66303
I3
sg66314
VC1864233
p75241
sg66306
VEAD
p75242
sasa(dp75243
g66296
VThe present study provides evidence in support of the hypothesis that AP-A-induced ventricular tachyarrhythmias are due to bradycardia-dependent EAD and triggered activity.
p75244
sg66298
(lp75245
(dp75246
g66301
I70
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VAP-A
p75247
sasg66311
(lp75248
(dp75249
g66301
I145
sg66302
I1
sg66303
I3
sg66314
VC1864233
p75250
sg66306
VEAD
p75251
sa(dp75252
g66301
I123
sg66302
I1
sg66303
I11
sg66314
VC0428977
p75253
sg66306
Vbradycardia
p75254
sasa(dp75255
g66296
VTU alternans was investigated by MAP recordings in six normal dogs, following the administration of anthopleurin-A (AP-A), a drug shown to delay sodium inactivation and to induce bradycardia dependent long QTU, EADs, and TdP.
p75256
sg66298
(lp75257
(dp75258
g66301
I179
sg66302
I5
sg66303
I36
sg66304
VP19525
p75259
sg66306
Vbradycardia dependent long QTU, EADs
p75260
sa(dp75261
g66301
I100
sg66302
I1
sg66303
I14
sg66304
g11
sg66306
Vanthopleurin-A
p75262
sa(dp75263
g66301
I116
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VAP-A
p75264
sasg66311
(lp75265
(dp75266
g66301
I179
sg66302
I1
sg66303
I11
sg66314
VC0428977
p75267
sg66306
Vbradycardia
p75268
sa(dp75269
g66301
I152
sg66302
I1
sg66303
I12
sg66314
VC0544461
p75270
sg66306
Vinactivation
p75271
sasa(dp75272
g66296
VMoreover, a series of recent studies have genetically and functionally linked kalirin signaling to several disorders, including schizophrenia and Alzheimer's disease.
p75273
sg66298
(lp75274
(dp75275
g66301
I78
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
Vkalirin
p75276
sasg66311
(lp75277
(dp75278
g66301
I128
sg66302
I1
sg66303
I13
sg66314
VC0036341
p75279
sg66306
Vschizophrenia
p75280
sa(dp75281
g66301
I146
sg66302
I2
sg66303
I19
sg66314
VC1521724
p75282
sg66306
VAlzheimer's disease
p75283
sasa(dp75284
g66296
VA series of recent studies has improved our understanding of spine dynamics by establishing kalirin-7 as an important regulator of dendritic spine development as well as structural and functional plasticity, providing a model for the molecular control of structural plasticity and implicating kalirin-7 in synaptic pathology in several disorders including schizophrenia and Alzheimer's disease.
p75285
sg66298
(lp75286
(dp75287
g66301
I92
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
Vkalirin-7
p75288
sa(dp75289
g66301
I92
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
Vkalirin-7
p75290
sasg66311
(lp75291
(dp75292
g66301
I356
sg66302
I1
sg66303
I13
sg66314
VC0036341
p75293
sg66306
Vschizophrenia
p75294
sa(dp75295
g66301
I374
sg66302
I2
sg66303
I19
sg66314
VC1521724
p75296
sg66306
VAlzheimer's disease
p75297
sa(dp75298
g66301
I315
sg66302
I1
sg66303
I9
sg66314
VC0677042
p75299
sg66306
Vpathology
p75300
sasa(dp75301
g66296
VHere, we report that inhibition of the cell cycle-dependent kinase 9 (Cdk9) by RNA interference, or the compound flavopiridol, blocked infections with HAdV-C2/5, EKC-causing HAdV-D8/37, and progeny formation in human corneal epithelial and cancer cells.
p75302
sg66298
(lp75303
(dp75304
g66301
I44
sg66302
I3
sg66303
I24
sg66304
VP19525
p75305
sg66306
Vcycle-dependent kinase 9
p75306
sa(dp75307
g66301
I70
sg66302
I1
sg66303
I4
sg66304
VP50750
p75308
sg66306
VCdk9
p75309
sasg66311
(lp75310
(dp75311
g66301
I240
sg66302
I1
sg66303
I6
sg66314
VC0006826
p75312
sg66306
Vcancer
p75313
sa(dp75314
g66301
I135
sg66302
I1
sg66303
I10
sg66314
VC0021311
p75315
sg66306
Vinfections
p75316
sa(dp75317
g66301
I162
sg66302
I1
sg66303
I3
sg66314
VC0014493
p75318
sg66306
VEKC
p75319
sasa(dp75320
g66296
VThe study identifies Cdk9 as a postexposure drug target against adenovirus infections in vitro and suggests that the clinically tested anticancer drug flavopiridol is a candidate for treating adenoviral EKC or adenovirus emergence upon immune suppression.
p75321
sg66298
(lp75322
(dp75323
g66301
I21
sg66302
I1
sg66303
I4
sg66304
VP50750
p75324
sg66306
VCdk9
p75325
sasg66311
(lp75326
(dp75327
g66301
I64
sg66302
I2
sg66303
I21
sg66314
VC0001486
p75328
sg66306
Vadenovirus infections
p75329
sa(dp75330
g66301
I236
sg66302
I2
sg66303
I18
sg66314
VC1840264
p75331
sg66306
Vimmune suppression
p75332
sa(dp75333
g66301
I203
sg66302
I1
sg66303
I3
sg66314
VC0014493
p75334
sg66306
VEKC
p75335
sa(dp75336
g66301
I64
sg66302
I1
sg66303
I10
sg66314
VC0001486
p75337
sg66306
Vadenovirus
p75338
sasa(dp75339
g66296
VWe conclude that: 1) synthetic non-thiazolidinediones can serve as ligands of PPARgamma and PPARdelta; 2) ligand-dependent activation of PPARdelta involves an apparent conformational change and association of the receptor ligand binding domain with CREB-binding protein; 3) PPARgamma activation (but not PPARdelta or PPARalpha activation) is sufficient to potentiate preadipocyte differentiation; 4) non-thiazolidinedione PPARgamma agonists improve hyperglycemia and hypertriglyceridemia in vivo; 5) although PPARalpha activation is sufficient to affect triglyceride metabolism, PPARdelta activation does not appear to modulate glucose or triglyceride levels.
p75340
sg66298
(lp75341
(dp75342
g66301
I92
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
VPPARdelta
p75343
sa(dp75344
g66301
I92
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
VPPARdelta
p75345
sa(dp75346
g66301
I92
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
VPPARdelta
p75347
sa(dp75348
g66301
I317
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
VPPARalpha
p75349
sa(dp75350
g66301
I249
sg66302
I2
sg66303
I20
sg66304
g11
sg66306
VCREB-binding protein
p75351
sa(dp75352
g66301
I92
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
VPPARdelta
p75353
sa(dp75354
g66301
I317
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
VPPARalpha
p75355
sa(dp75356
g66301
I213
sg66302
I4
sg66303
I30
sg66304
g11
sg66306
Vreceptor ligand binding domain
p75357
sasg66311
(lp75358
(dp75359
g66301
I449
sg66302
I1
sg66303
I13
sg66314
VC0020456
p75360
sg66306
Vhyperglycemia
p75361
sasa(dp75362
g66296
VAt present, four loci associated with non-syndromic auditory neuropathy have been mapped: Autosomal recessive deafness-9 [DFNB9; the otoferlin (OTOF) gene] and autosomal recessive deafness-59 [DFNB59; the pejvakin (PJVK) gene], associated with autosomal recessive inheritance; the autosomal dominant auditory neuropathy gene [AUNA1; the diaphanous-3 (DIAPH3) gene]; and AUNX1, linked to chromosome X.
p75363
sg66298
(lp75364
(dp75365
g66301
I122
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VDFNB9
p75366
sasg66311
(lp75367
(dp75368
g66301
I370
sg66302
I1
sg66303
I5
sg66314
VC1845095
p75369
sg66306
VAUNX1
p75370
sa(dp75371
g66301
I110
sg66302
I1
sg66303
I8
sg66314
VC0011053
p75372
sg66306
Vdeafness
p75373
sa(dp75374
g66301
I122
sg66302
I1
sg66303
I5
sg66314
VC1832828
p75375
sg66306
VDFNB9
p75376
sa(dp75377
g66301
I110
sg66302
I1
sg66303
I8
sg66314
VC0011053
p75378
sg66306
Vdeafness
p75379
sa(dp75380
g66301
I193
sg66302
I1
sg66303
I6
sg66314
VC1857744
p75381
sg66306
VDFNB59
p75382
sa(dp75383
g66301
I326
sg66302
I1
sg66303
I5
sg66314
VC1836743
p75384
sg66306
VAUNA1
p75385
sa(dp75386
g66301
I52
sg66302
I2
sg66303
I19
sg66314
VC1852271
p75387
sg66306
Vauditory neuropathy
p75388
sa(dp75389
g66301
I52
sg66302
I2
sg66303
I19
sg66314
VC1852271
p75390
sg66306
Vauditory neuropathy
p75391
sasa(dp75392
g66296
VPresence of antibodies to carbamylated fetal calf serum (CarP-FCS) and fibrinogen (CarP-Fib) was determined by inhouse ELISAs among RA cases in the Leiden Early Arthritis Clinic (n=846) and in the Swedish Epidemiological Investigation of Rheumatoid Arthritis (n=1985) cohorts.
p75393
sg66298
(lp75394
(dp75395
g66301
I57
sg66302
I1
sg66303
I8
sg66304
VP35219
p75396
sg66306
VCarP-FCS
p75397
sa(dp75398
g66301
I71
sg66302
I1
sg66303
I10
sg66304
VP22087
p75399
sg66306
Vfibrinogen
p75400
sa(dp75401
g66301
I83
sg66302
I1
sg66303
I8
sg66304
VP35219
p75402
sg66306
VCarP-Fib
p75403
sasg66311
(lp75404
(dp75405
g66301
I57
sg66302
I1
sg66303
I4
sg66314
VC0263385
p75406
sg66306
VCarP
p75407
sa(dp75408
g66301
I238
sg66302
I2
sg66303
I20
sg66314
VC0003873
p75409
sg66306
VRheumatoid Arthritis
p75410
sa(dp75411
g66301
I57
sg66302
I1
sg66303
I4
sg66314
VC0263385
p75412
sg66306
VCarP
p75413
sa(dp75414
g66301
I161
sg66302
I1
sg66303
I9
sg66314
VC0003864
p75415
sg66306
VArthritis
p75416
sasa(dp75417
g66296
VTo detect the antibodies against human fibrinogen (FIB) Beta67-77 peptide and citrullinated human FIB Beta67-77 peptide in rheumatoid arthritis (RA) and examine their diagnostic values in RA.
p75418
sg66298
(lp75419
(dp75420
g66301
I92
sg66302
I4
sg66303
I27
sg66304
VP22087
p75421
sg66306
Vhuman FIB Beta67-77 peptide
p75422
sa(dp75423
g66301
I51
sg66302
I1
sg66303
I3
sg66304
VP22087
p75424
sg66306
VFIB
p75425
sa(dp75426
g66301
I56
sg66302
I2
sg66303
I17
sg66304
g11
sg66306
VBeta67-77 peptide
p75427
sa(dp75428
g66301
I33
sg66302
I2
sg66303
I16
sg66304
VP22087
p75429
sg66306
Vhuman fibrinogen
p75430
sasg66311
(lp75431
(dp75432
g66301
I123
sg66302
I2
sg66303
I20
sg66314
VC0003873
p75433
sg66306
Vrheumatoid arthritis
p75434
sa(dp75435
g66301
I145
sg66302
I1
sg66303
I2
sg66314
VC0003873
p75436
sg66306
VRA
p75437
sa(dp75438
g66301
I145
sg66302
I1
sg66303
I2
sg66314
VC0003873
p75439
sg66306
VRA
p75440
sasa(dp75441
g66296
VPolymyositis/dermatomyositis, systemic lupus erythematosus and Addison's disease, three conditions regulated by the HLA-B8-DR3 haplotype, were most strongly associated with MG, especially early-onset disease.
p75442
sg66298
(lp75443
(dp75444
g66301
I116
sg66302
I2
sg66303
I20
sg66304
VP30486
p75445
sg66306
VHLA-B8-DR3 haplotype
p75446
sasg66311
(lp75447
(dp75448
g66301
I30
sg66302
I3
sg66303
I28
sg66314
VC0024141
p75449
sg66306
Vsystemic lupus erythematosus
p75450
sa(dp75451
g66301
I63
sg66302
I2
sg66303
I17
sg66314
VC0001403
p75452
sg66306
VAddison's disease
p75453
sa(dp75454
g66301
I0
sg66302
I1
sg66303
I12
sg66314
VC0085655
p75455
sg66306
VPolymyositis
p75456
sa(dp75457
g66301
I13
sg66302
I1
sg66303
I15
sg66314
VC0221056
p75458
sg66306
Vdermatomyositis
p75459
sasa(dp75460
g66296
VThe prevalence of sporadic inclusion body myositis (sIBM) was correlated with the frequency of HLA-DR3.
p75461
sg66298
(lp75462
(dp75463
g66301
I95
sg66302
I1
sg66303
I7
sg66304
VP30486
p75464
sg66306
VHLA-DR3
p75465
sasg66311
(lp75466
(dp75467
g66301
I18
sg66302
I4
sg66303
I32
sg66314
VC0751713
p75468
sg66306
Vsporadic inclusion body myositis
p75469
sa(dp75470
g66301
I52
sg66302
I1
sg66303
I4
sg66314
VC0751713
p75471
sg66306
VsIBM
p75472
sasa(dp75473
g66296
VThe B8-DR3 haplotype fragment conferred the strongest susceptibility (OR 2.9, 95% CI 1.8-4.6), and the B-DR region of other ancestral haplotypes was associated with myositis subgroups.
p75474
sg66298
(lp75475
sg66311
(lp75476
(dp75477
g66301
I165
sg66302
I1
sg66303
I8
sg66314
VC0027121
p75478
sg66306
Vmyositis
p75479
sasa(dp75480
g66296
VMost gastric IFPs were associated with chronic atrophic gastritis while only one ileal polyp was associated with Meckels diverticulum.
p75481
sg66298
(lp75482
(dp75483
g66301
I13
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VIFPs
p75484
sasg66311
(lp75485
(dp75486
g66301
I87
sg66302
I1
sg66303
I5
sg66314
VC0032584
p75487
sg66306
Vpolyp
p75488
sa(dp75489
g66301
I113
sg66302
I2
sg66303
I20
sg66314
VC0025037
p75490
sg66306
VMeckels diverticulum
p75491
sa(dp75492
g66301
I39
sg66302
I3
sg66303
I26
sg66314
VC0017154
p75493
sg66306
Vchronic atrophic gastritis
p75494
sasa(dp75495
g66296
VCBR1, DYRK1A, HMGN1, ITSN1, RCAN1, SON, TMEM50B, and TTC3 were each up-regulated two-fold in Down syndrome samples compared to normal samples; of these, SON and TTC3 were newly reported.
p75496
sg66298
(lp75497
(dp75498
g66301
I21
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VITSN1
p75499
sa(dp75500
g66301
I40
sg66302
I1
sg66303
I7
sg66304
VP56557
p75501
sg66306
VTMEM50B
p75502
sa(dp75503
g66301
I0
sg66302
I1
sg66303
I4
sg66304
VP16152
p75504
sg66306
VCBR1
p75505
sa(dp75506
g66301
I6
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VDYRK1A
p75507
sa(dp75508
g66301
I14
sg66302
I1
sg66303
I5
sg66304
VP05114
p75509
sg66306
VHMGN1
p75510
sasg66311
(lp75511
(dp75512
g66301
I93
sg66302
I2
sg66303
I13
sg66314
VC0013080
p75513
sg66306
VDown syndrome
p75514
sasa(dp75515
g66296
VIn this report we show that high levels of the TTC3 protein, encoded by one of the genes of the Down Syndrome Critical Region (DCR), prevent neurite extension and disrupt Golgi compactness in differentiating primary neurons.
p75516
sg66298
(lp75517
sg66311
(lp75518
(dp75519
g66301
I96
sg66302
I4
sg66303
I29
sg66314
VC1860787
p75520
sg66306
VDown Syndrome Critical Region
p75521
sa(dp75522
g66301
I127
sg66302
I1
sg66303
I3
sg66314
VC1860787
p75523
sg66306
VDCR
p75524
sasa(dp75525
g66296
VTTC3 contains a canonical RING finger motif, a pair of tetratricopeptide motifs, a putative Akt phosphorylation site, and nuclear localization signals, and is encoded by a gene within the Down syndrome (DS) critical region on chromosome 21.
p75526
sg66298
(lp75527
(dp75528
g66301
I92
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VAkt
p75529
sasg66311
(lp75530
(dp75531
g66301
I203
sg66302
I1
sg66303
I2
sg66314
VC0013080
p75532
sg66306
VDS
p75533
sa(dp75534
g66301
I188
sg66302
I2
sg66303
I13
sg66314
VC0013080
p75535
sg66306
VDown syndrome
p75536
sasa(dp75537
g66296
VNonchimeric polytransgenic 152F7 mice encompassing four human chromosome 21 genes (DSCR3, DSCR5, TTC3, and DYRK1A) within the Down syndrome critical region present with learning and memory impairment.
p75538
sg66298
(lp75539
(dp75540
g66301
I90
sg66302
I1
sg66303
I5
sg66304
VP57054
p75541
sg66306
VDSCR5
p75542
sa(dp75543
g66301
I107
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VDYRK1A
p75544
sa(dp75545
g66301
I83
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VDSCR3
p75546
sasg66311
(lp75547
(dp75548
g66301
I126
sg66302
I4
sg66303
I29
sg66314
VC1860787
p75549
sg66306
VDown syndrome critical region
p75550
sa(dp75551
g66301
I182
sg66302
I2
sg66303
I17
sg66314
VC0233794
p75552
sg66306
Vmemory impairment
p75553
sasa(dp75554
g66296
VMultivariate regression analysis revealed that plasma VWF Ag level is an independent predictor of mortality in ARDS pediatric patients.
p75555
sg66298
(lp75556
(dp75557
g66301
I47
sg66302
I3
sg66303
I13
sg66304
VP04275
p75558
sg66306
Vplasma VWF Ag
p75559
sasg66311
(lp75560
(dp75561
g66301
I111
sg66302
I1
sg66303
I4
sg66314
VC0035222
p75562
sg66306
VARDS
p75563
sasa(dp75564
g66296
VPlasma VWF Ag level is an excellent predictive marker for outcome in children with ALI/ARDS.
p75565
sg66298
(lp75566
(dp75567
g66301
I0
sg66302
I3
sg66303
I13
sg66304
VP04275
p75568
sg66306
VPlasma VWF Ag
p75569
sasg66311
(lp75570
(dp75571
g66301
I87
sg66302
I1
sg66303
I4
sg66314
VC0035222
p75572
sg66306
VARDS
p75573
sasa(dp75574
g66296
VIn the multicenter study, patients with direct ARDS also had lower levels of von Willebrand factor antigen and IL-6 and IL-8, markers of endothelial injury and inflammation, respectively.
p75575
sg66298
(lp75576
(dp75577
g66301
I111
sg66302
I1
sg66303
I4
sg66304
VP05231
p75578
sg66306
VIL-6
p75579
sa(dp75580
g66301
I77
sg66302
I4
sg66303
I29
sg66304
VP04275
p75581
sg66306
Vvon Willebrand factor antigen
p75582
sasg66311
(lp75583
(dp75584
g66301
I47
sg66302
I1
sg66303
I4
sg66314
VC0035222
p75585
sg66306
VARDS
p75586
sa(dp75587
g66301
I160
sg66302
I1
sg66303
I12
sg66314
VC0021368
p75588
sg66306
Vinflammation
p75589
sasa(dp75590
g66296
VTo investigate the role of endothelial cell mediators, E-selectin (ES), intercellular adhesion molecule-1 (ICAM-1), tissue factor (TF), and von Willebrand factor (vWF), in the early phase of severe acute pancreatitis (SAP) complicated with respiratory failure [pancreatitis-associated lung injury (PALI)].
p75591
sg66298
(lp75592
(dp75593
g66301
I72
sg66302
I3
sg66303
I33
sg66304
VP05362
p75594
sg66306
Vintercellular adhesion molecule-1
p75595
sa(dp75596
g66301
I140
sg66302
I3
sg66303
I21
sg66304
VP04275
p75597
sg66306
Vvon Willebrand factor
p75598
sa(dp75599
g66301
I163
sg66302
I1
sg66303
I3
sg66304
VP04275
p75600
sg66306
VvWF
p75601
sa(dp75602
g66301
I107
sg66302
I1
sg66303
I6
sg66304
VP05362
p75603
sg66306
VICAM-1
p75604
sa(dp75605
g66301
I27
sg66302
I4
sg66303
I38
sg66304
VP16581
p75606
sg66306
Vendothelial cell mediators, E-selectin
p75607
sasg66311
(lp75608
(dp75609
g66301
I86
sg66302
I1
sg66303
I8
sg66314
VC0001511
p75610
sg66306
Vadhesion
p75611
sa(dp75612
g66301
I240
sg66302
I2
sg66303
I19
sg66314
VC1145670
p75613
sg66306
Vrespiratory failure
p75614
sa(dp75615
g66301
I204
sg66302
I1
sg66303
I12
sg66314
VC0030305
p75616
sg66306
Vpancreatitis
p75617
sa(dp75618
g66301
I198
sg66302
I2
sg66303
I18
sg66314
VC0001339
p75619
sg66306
Vacute pancreatitis
p75620
sasa(dp75621
g66296
VThus, CLC-2 may be a promising and potential novel therapeutic strategy for combating primary open-angle glaucoma.
p75622
sg66298
(lp75623
(dp75624
g66301
I6
sg66302
I1
sg66303
I5
sg66304
VP51788
p75625
sg66306
VCLC-2
p75626
sasg66311
(lp75627
(dp75628
g66301
I86
sg66302
I3
sg66303
I27
sg66314
VC0339573
p75629
sg66306
Vprimary open-angle glaucoma
p75630
sasa(dp75631
g66296
VIn type 2 diabetes mellitus (T2DM) patients, chronic kidney disease (CKD) progression may occur without detectable changes in urinary albumin excretion (UAE) rate.
p75632
sg66298
(lp75633
(dp75634
g66301
I134
sg66302
I1
sg66303
I7
sg66304
VP00441
p75635
sg66306
Valbumin
p75636
sasg66311
(lp75637
(dp75638
g66301
I45
sg66302
I3
sg66303
I22
sg66314
VC1561643
p75639
sg66306
Vchronic kidney disease
p75640
sa(dp75641
g66301
I3
sg66302
I4
sg66303
I24
sg66314
VC0011860
p75642
sg66306
Vtype 2 diabetes mellitus
p75643
sa(dp75644
g66301
I29
sg66302
I1
sg66303
I4
sg66314
VC0011860
p75645
sg66306
VT2DM
p75646
sa(dp75647
g66301
I69
sg66302
I1
sg66303
I3
sg66314
VC1561643
p75648
sg66306
VCKD
p75649
sasa(dp75650
g66296
VTo investigate, for the first time, the impact of systolic pulmonary arterial pressure (PASP) on maximal exercise capacity in adults with mild-to-moderate cystic fibrosis, without PH at rest.
p75651
sg66298
(lp75652
sg66311
(lp75653
(dp75654
g66301
I155
sg66302
I2
sg66303
I15
sg66314
VC0010674
p75655
sg66306
Vcystic fibrosis
p75656
sasa(dp75657
g66296
VAssays of carboxypeptidase B-like activity and C3 in serum from patients with cystic fibrosis and appropriate control subjects failed to demonstrate a deficiency of carboxypeptidase B-like activity or a consistent increase in C3, as was suggested by Conover and associates.
p75658
sg66298
(lp75659
(dp75660
g66301
I10
sg66302
I2
sg66303
I23
sg66304
VP15086
p75661
sg66306
Vcarboxypeptidase B-like
p75662
sa(dp75663
g66301
I10
sg66302
I2
sg66303
I23
sg66304
VP15086
p75664
sg66306
Vcarboxypeptidase B-like
p75665
sasg66311
(lp75666
(dp75667
g66301
I78
sg66302
I2
sg66303
I15
sg66314
VC0010674
p75668
sg66306
Vcystic fibrosis
p75669
sa(dp75670
g66301
I151
sg66302
I4
sg66303
I32
sg66314
VC0398782
p75671
sg66306
Vdeficiency of carboxypeptidase B
p75672
sasa(dp75673
g66296
VDifferences between men and women with cystic fibrosis were apparent, in that women with cystic fibrosis had higher concentrations of both serum carboxypeptidase B-like activity and C3 than either men with cystic fibrosis or control subjects.
p75674
sg66298
(lp75675
(dp75676
g66301
I139
sg66302
I3
sg66303
I24
sg66304
VP15086
p75677
sg66306
Vserum carboxypeptidase B
p75678
sasg66311
(lp75679
(dp75680
g66301
I39
sg66302
I2
sg66303
I15
sg66314
VC0010674
p75681
sg66306
Vcystic fibrosis
p75682
sa(dp75683
g66301
I39
sg66302
I2
sg66303
I15
sg66314
VC0010674
p75684
sg66306
Vcystic fibrosis
p75685
sa(dp75686
g66301
I39
sg66302
I2
sg66303
I15
sg66314
VC0010674
p75687
sg66306
Vcystic fibrosis
p75688
sasa(dp75689
g66296
VThe properties and lysosomal distribution of the enzyme indicated that it was a carboxypeptidase B. Substrate affinity, thermolability, pH stability, the fall and rise in activity with subculture, the cyclical pattern of activity through serial passage and the level of activity were similar for the control and cystic fibrosis enzyme.
p75690
sg66298
(lp75691
(dp75692
g66301
I80
sg66302
I2
sg66303
I18
sg66304
VP15086
p75693
sg66306
Vcarboxypeptidase B
p75694
sa(dp75695
g66301
I312
sg66302
I3
sg66303
I22
sg66304
VP13569
p75696
sg66306
Vcystic fibrosis enzyme
p75697
sasg66311
(lp75698
(dp75699
g66301
I312
sg66302
I2
sg66303
I15
sg66314
VC0010674
p75700
sg66306
Vcystic fibrosis
p75701
sasa(dp75702
g66296
VIn this review the roles identified for different selenoproteins in these steps and how they may promote or inhibit metastatic cancers is discussed.
p75703
sg66298
(lp75704
sg66311
(lp75705
(dp75706
g66301
I127
sg66302
I1
sg66303
I7
sg66314
VC0006826
p75707
sg66306
Vcancers
p75708
sasa(dp75709
g66296
VIndeed, many selenoproteins have antioxidant activity which can attenuate cancer development by minimizing oxidative insult and resultant DNA damage.
p75710
sg66298
(lp75711
(dp75712
g66301
I13
sg66302
I1
sg66303
I14
sg66304
VP55073
p75713
sg66306
Vselenoproteins
p75714
sasg66311
(lp75715
(dp75716
g66301
I138
sg66302
I2
sg66303
I10
sg66314
VC0012860
p75717
sg66306
VDNA damage
p75718
sa(dp75719
g66301
I74
sg66302
I1
sg66303
I6
sg66314
VC0006826
p75720
sg66306
Vcancer
p75721
sasa(dp75722
g66296
VIn this review, we discuss what is currently known about selenoproteins in tumorigenesis with a focus on their contextual roles in cancer development, growth, and progression.
p75723
sg66298
(lp75724
(dp75725
g66301
I57
sg66302
I1
sg66303
I14
sg66304
VP55073
p75726
sg66306
Vselenoproteins
p75727
sasg66311
(lp75728
(dp75729
g66301
I75
sg66302
I1
sg66303
I13
sg66314
VC0007621
p75730
sg66306
Vtumorigenesis
p75731
sa(dp75732
g66301
I131
sg66302
I1
sg66303
I6
sg66314
VC0006826
p75733
sg66306
Vcancer
p75734
sasa(dp75735
g66296
VNew aspects of Se actions in breast cancer have emerged such as the impact of genetic polymorphisms on Se metabolism and response, new functions of selenoproteins, epigenetic modulation of gene expression, and long-term influence of early-life exposure on disease risk.
p75736
sg66298
(lp75737
(dp75738
g66301
I148
sg66302
I1
sg66303
I14
sg66304
VP55073
p75739
sg66306
Vselenoproteins
p75740
sasg66311
(lp75741
(dp75742
g66301
I29
sg66302
I2
sg66303
I13
sg66314
VC0678222
p75743
sg66306
Vbreast cancer
p75744
sasa(dp75745
g66296
VWe observed that both SelS and C99 were colocalized in the membrane fraction of mouse neuroblastoma Neuro2a (N2a) cells.
p75746
sg66298
(lp75747
(dp75748
g66301
I22
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VSelS
p75749
sasg66311
(lp75750
(dp75751
g66301
I80
sg66302
I2
sg66303
I19
sg66314
VC1524043
p75752
sg66306
Vmouse neuroblastoma
p75753
sasa(dp75754
g66296
VThe results suggest that decreased NPY expression in the extended amygdala might be causally linked with the depression induced following type 2 diabetes and that the antidepressant action of imipramine in diabetic mice might be mediated by NPY-NPY Y1 receptor system.
p75755
sg66298
(lp75756
(dp75757
g66301
I35
sg66302
I1
sg66303
I3
sg66304
VP25929
p75758
sg66306
VNPY
p75759
sa(dp75760
g66301
I241
sg66302
I3
sg66303
I19
sg66304
VP25929
p75761
sg66306
VNPY-NPY Y1 receptor
p75762
sasg66311
(lp75763
(dp75764
g66301
I138
sg66302
I3
sg66303
I15
sg66314
VC0011860
p75765
sg66306
Vtype 2 diabetes
p75766
sa(dp75767
g66301
I109
sg66302
I1
sg66303
I10
sg66314
VC0011581
p75768
sg66306
Vdepression
p75769
sasa(dp75770
g66296
VNumerous models of obesity and diabetes are characterized by increased central nervous system (CNS) neuropeptide Y (NPY); in fact, a single intracerebroventricular (icv) administration of NPY in lean fasted rats elevates hepatic VLDL-TG secretion and does so, in large part, via signaling through the CNS NPY Y1 receptor.
p75771
sg66298
(lp75772
(dp75773
g66301
I301
sg66302
I4
sg66303
I19
sg66304
VP25929
p75774
sg66306
VCNS NPY Y1 receptor
p75775
sa(dp75776
g66301
I116
sg66302
I1
sg66303
I3
sg66304
VP25929
p75777
sg66306
VNPY
p75778
sa(dp75779
g66301
I116
sg66302
I1
sg66303
I3
sg66304
VP25929
p75780
sg66306
VNPY
p75781
sa(dp75782
g66301
I100
sg66302
I2
sg66303
I14
sg66304
VP01303
p75783
sg66306
Vneuropeptide Y
p75784
sasg66311
(lp75785
(dp75786
g66301
I31
sg66302
I1
sg66303
I8
sg66314
VC0011849
p75787
sg66306
Vdiabetes
p75788
sa(dp75789
g66301
I19
sg66302
I1
sg66303
I7
sg66314
VC0028754
p75790
sg66306
Vobesity
p75791
sa(dp75792
g66301
I79
sg66302
I1
sg66303
I7
sg66314
VC0027769
p75793
sg66306
Vnervous
p75794
sasa(dp75795
g66296
VWe investigated whether annexin A8 (A-A8), a Ca-binding protein overexpressed in pancreatic cancer, plays a role in cell growth and migration and investigated its association with pancreatic cancer prognosis.
p75796
sg66298
(lp75797
(dp75798
g66301
I45
sg66302
I2
sg66303
I18
sg66304
g11
sg66306
VCa-binding protein
p75799
sasg66311
(lp75800
(dp75801
g66301
I81
sg66302
I2
sg66303
I17
sg66314
VC0235974
p75802
sg66306
Vpancreatic cancer
p75803
sa(dp75804
g66301
I81
sg66302
I2
sg66303
I17
sg66314
VC0235974
p75805
sg66306
Vpancreatic cancer
p75806
sasa(dp75807
g66296
VAlthough Annexin A8 (ANXA8), a member of a superfamily of calcium and phospholipid binding proteins, is physiologically expressed in a tissue-specific manner, recent microarray studies reported that ANXA8 was also ectopically expressed in pancreatic cancers.
p75808
sg66298
(lp75809
(dp75810
g66301
I21
sg66302
I1
sg66303
I5
sg66304
VP13928
p75811
sg66306
VANXA8
p75812
sa(dp75813
g66301
I21
sg66302
I1
sg66303
I5
sg66304
VP13928
p75814
sg66306
VANXA8
p75815
sa(dp75816
g66301
I9
sg66302
I2
sg66303
I10
sg66304
VP13928
p75817
sg66306
VAnnexin A8
p75818
sasg66311
(lp75819
(dp75820
g66301
I239
sg66302
I2
sg66303
I18
sg66314
VC0346647
p75821
sg66306
Vpancreatic cancers
p75822
sasa(dp75823
g66296
VWe investigated the molecular mechanism of expression of ANXA8 in cancer cells and its functional role in pancreatic cancer cells.
p75824
sg66298
(lp75825
(dp75826
g66301
I57
sg66302
I1
sg66303
I5
sg66304
VP13928
p75827
sg66306
VANXA8
p75828
sasg66311
(lp75829
(dp75830
g66301
I66
sg66302
I1
sg66303
I6
sg66314
VC0006826
p75831
sg66306
Vcancer
p75832
sa(dp75833
g66301
I106
sg66302
I2
sg66303
I17
sg66314
VC0235974
p75834
sg66306
Vpancreatic cancer
p75835
sasa(dp75836
g66296
VTo investigate the utility of 26 immunohistochemical markers (CAM 5.2, CK [cytokeratin] 7, CK20, CK17, CK19, MUC1, MUC2, MUC4, MUC5AC, MUC6, p53, DPC4/SMAD4, CDX2, pVHL [von Hippel-Lindau tumor suppressor gene protein], S100P, IMP-3 [insulin-like growth factor 2 messenger RNA binding protein 3], maspin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, PSCA [prostate stem cell antigen], MOC31, CEA [carcinoembryonic antigen], and CA19-9 [cancer antigen 19-9]) in the diagnosis of ductal adenocarcinoma of the pancreas.
p75837
sg66298
(lp75838
(dp75839
g66301
I135
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VMUC6
p75840
sa(dp75841
g66301
I220
sg66302
I1
sg66303
I5
sg66304
VP25815
p75842
sg66306
VS100P
p75843
sa(dp75844
g66301
I328
sg66302
I2
sg66303
I10
sg66304
VP56856
p75845
sg66306
Vclaudin 18
p75846
sa(dp75847
g66301
I91
sg66302
I1
sg66303
I4
sg66304
VP35900
p75848
sg66306
VCK20
p75849
sa(dp75850
g66301
I151
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSMAD4
p75851
sa(dp75852
g66301
I158
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VCDX2
p75853
sa(dp75854
g66301
I317
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
Vclaudin 4
p75855
sa(dp75856
g66301
I227
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VIMP-3
p75857
sa(dp75858
g66301
I115
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VMUC2
p75859
sa(dp75860
g66301
I164
sg66302
I1
sg66303
I4
sg66304
VP40337
p75861
sg66306
VpVHL
p75862
sa(dp75863
g66301
I402
sg66302
I1
sg66303
I3
sg66304
VP40198
p75864
sg66306
VCEA
p75865
sa(dp75866
g66301
I352
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
Vfascin
p75867
sa(dp75868
g66301
I395
sg66302
I1
sg66303
I5
sg66304
VP16422
p75869
sg66306
VMOC31
p75870
sa(dp75871
g66301
I340
sg66302
I2
sg66303
I10
sg66304
VP13928
p75872
sg66306
Vannexin A8
p75873
sa(dp75874
g66301
I360
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VPSCA
p75875
sa(dp75876
g66301
I62
sg66302
I2
sg66303
I7
sg66304
VP01768
p75877
sg66306
VCAM 5.2
p75878
sa(dp75879
g66301
I297
sg66302
I1
sg66303
I6
sg66304
VP36952
p75880
sg66306
Vmaspin
p75881
sa(dp75882
g66301
I141
sg66302
I1
sg66303
I3
sg66304
VP42771
p75883
sg66306
Vp53
p75884
sa(dp75885
g66301
I234
sg66302
I9
sg66303
I60
sg66304
VP01308
p75886
sg66306
Vinsulin-like growth factor 2 messenger RNA binding protein 3
p75887
sa(dp75888
g66301
I71
sg66302
I3
sg66303
I18
sg66304
g11
sg66306
VCK [cytokeratin] 7
p75889
sa(dp75890
g66301
I146
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VDPC4
p75891
sasg66311
(lp75892
(dp75893
g66301
I446
sg66302
I1
sg66303
I6
sg66314
VC0006826
p75894
sg66306
Vcancer
p75895
sa(dp75896
g66301
I62
sg66302
I1
sg66303
I3
sg66314
VC1861821
p75897
sg66306
VCAM
p75898
sa(dp75899
g66301
I488
sg66302
I5
sg66303
I37
sg66314
VC1335302
p75900
sg66306
Vductal adenocarcinoma of the pancreas
p75901
sa(dp75902
g66301
I188
sg66302
I1
sg66303
I5
sg66314
VC0027651
p75903
sg66306
Vtumor
p75904
sasa(dp75905
g66296
VClaudin 18 and annexin A8 are frequently highly overexpressed in infiltrating ductal adenocarcinomas when compared with normal reactive ducts, suggesting a role for these molecules in pancreatic ductal adenocarcinomas.
p75906
sg66298
(lp75907
(dp75908
g66301
I15
sg66302
I2
sg66303
I10
sg66304
VP13928
p75909
sg66306
Vannexin A8
p75910
sa(dp75911
g66301
I0
sg66302
I2
sg66303
I10
sg66304
VP56856
p75912
sg66306
VClaudin 18
p75913
sasg66311
(lp75914
(dp75915
g66301
I85
sg66302
I1
sg66303
I15
sg66314
VC0001418
p75916
sg66306
Vadenocarcinomas
p75917
sa(dp75918
g66301
I85
sg66302
I1
sg66303
I15
sg66314
VC0001418
p75919
sg66306
Vadenocarcinomas
p75920
sa(dp75921
g66301
I65
sg66302
I1
sg66303
I12
sg66314
VC0332448
p75922
sg66306
Vinfiltrating
p75923
sasa(dp75924
g66296
VMultivariate analysis further confirmed that miR-340-low/ROCK1-high expression was an independent prognostic factor of unfavorable survival in pediatric osteosarcoma (for overall survival: p = 0.006, for progression-free survival: p = 0.008).
p75925
sg66298
(lp75926
(dp75927
g66301
I57
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VROCK1
p75928
sa(dp75929
g66301
I45
sg66302
I1
sg66303
I11
sg66304
g11
sg66306
VmiR-340-low
p75930
sasg66311
(lp75931
(dp75932
g66301
I143
sg66302
I2
sg66303
I22
sg66314
VC1332986
p75933
sg66306
Vpediatric osteosarcoma
p75934
sasa(dp75935
g66296
VOur data offer convincing evidence, for the first time, that the combined miR-340 downregulation and ROCK1 upregulation may be linked to tumor progression and adverse prognosis in pediatric osteosarcoma.
p75936
sg66298
(lp75937
(dp75938
g66301
I101
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VROCK1
p75939
sasg66311
(lp75940
(dp75941
g66301
I180
sg66302
I2
sg66303
I22
sg66314
VC1332986
p75942
sg66306
Vpediatric osteosarcoma
p75943
sa(dp75944
g66301
I137
sg66302
I2
sg66303
I17
sg66314
VC0178874
p75945
sg66306
Vtumor progression
p75946
sasa(dp75947
g66296
VWe analyzed the effects of 3 war components-combat exposure (CES), observation of abusive violence (OBS), and participation in abusive violence (PARTC)-and sense of coherence (SOC) on the development of both posttraumatic stress disorder (PTSD) and depression among a sample of war veterans.
p75948
sg66298
(lp75949
sg66311
(lp75950
(dp75951
g66301
I61
sg66302
I1
sg66303
I3
sg66314
VC0265493
p75952
sg66306
VCES
p75953
sa(dp75954
g66301
I90
sg66302
I1
sg66303
I8
sg66314
VC0042693
p75955
sg66306
Vviolence
p75956
sa(dp75957
g66301
I208
sg66302
I3
sg66303
I29
sg66314
VC0038436
p75958
sg66306
Vposttraumatic stress disorder
p75959
sa(dp75960
g66301
I249
sg66302
I1
sg66303
I10
sg66314
VC0011581
p75961
sg66306
Vdepression
p75962
sa(dp75963
g66301
I90
sg66302
I1
sg66303
I8
sg66314
VC0042693
p75964
sg66306
Vviolence
p75965
sa(dp75966
g66301
I239
sg66302
I1
sg66303
I4
sg66314
VC0038436
p75967
sg66306
VPTSD
p75968
sa(dp75969
g66301
I33
sg66302
I2
sg66303
I26
sg66314
VC0265493
p75970
sg66306
Vcomponents-combat exposure
p75971
sasa(dp75972
g66296
VThe expression levels of miR-155 in 38 pairs of cancer tissues and adjacent normal tissues from breast cancer patients were detected using quantitative real-time PCR.
p75973
sg66298
(lp75974
sg66311
(lp75975
(dp75976
g66301
I48
sg66302
I1
sg66303
I6
sg66314
VC0006826
p75977
sg66306
Vcancer
p75978
sa(dp75979
g66301
I96
sg66302
I2
sg66303
I13
sg66314
VC0678222
p75980
sg66306
Vbreast cancer
p75981
sasa(dp75982
g66296
VSoft agar colony formation assay and tumor xenografts showed inhibition of miR-155 could significantly reduce proliferation of cancer cells in vivo and vitro, which confirmed that miR-155 is an effective therapeutic target of breast cancer.
p75983
sg66298
(lp75984
(dp75985
g66301
I75
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-155
p75986
sa(dp75987
g66301
I75
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-155
p75988
sasg66311
(lp75989
(dp75990
g66301
I37
sg66302
I1
sg66303
I5
sg66314
VC0027651
p75991
sg66306
Vtumor
p75992
sa(dp75993
g66301
I127
sg66302
I1
sg66303
I6
sg66314
VC0006826
p75994
sg66306
Vcancer
p75995
sa(dp75996
g66301
I226
sg66302
I2
sg66303
I13
sg66314
VC0678222
p75997
sg66306
Vbreast cancer
p75998
sa(dp75999
g66301
I110
sg66302
I1
sg66303
I13
sg66314
VC0334094
p76000
sg66306
Vproliferation
p76001
sasa(dp76002
g66296
VOur results underscore the importance of miR-155 as a therapeutic target and combination of Doxorubicinol and miR-155-silencing would be a potential way to cure breast cancer.
p76003
sg66298
(lp76004
sg66311
(lp76005
(dp76006
g66301
I161
sg66302
I2
sg66303
I13
sg66314
VC0678222
p76007
sg66306
Vbreast cancer
p76008
sasa(dp76009
g66296
VWe have quantified expression of seven oncomiRs, namely miR-17/92 cluster (miR-17, miR-18a, miR-19a and miR-20a), miR-21, miR-27a and miR-155, in plasma of 137 breast cancer (BC) patients.
p76010
sg66298
(lp76011
(dp76012
g66301
I134
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-155
p76013
sa(dp76014
g66301
I92
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-19a
p76015
sa(dp76016
g66301
I56
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VmiR-17
p76017
sa(dp76018
g66301
I83
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-18a
p76019
sa(dp76020
g66301
I104
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-20a
p76021
sa(dp76022
g66301
I122
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-27a
p76023
sa(dp76024
g66301
I56
sg66302
I2
sg66303
I17
sg66304
g11
sg66306
VmiR-17/92 cluster
p76025
sasg66311
(lp76026
(dp76027
g66301
I175
sg66302
I1
sg66303
I2
sg66314
VC0678222
p76028
sg66306
VBC
p76029
sa(dp76030
g66301
I160
sg66302
I2
sg66303
I13
sg66314
VC0678222
p76031
sg66306
Vbreast cancer
p76032
sasa(dp76033
g66296
VOur results suggested that MIAT acted as a competing endogenous RNA (ceRNA) to regulate the expression of dual specificity phosphatase 7 (DUSP7) by taking up miR-155-5p in breast cancer.
p76034
sg66298
(lp76035
(dp76036
g66301
I158
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-155-5p
p76037
sa(dp76038
g66301
I138
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VDUSP7
p76039
sa(dp76040
g66301
I106
sg66302
I4
sg66303
I30
sg66304
g11
sg66306
Vdual specificity phosphatase 7
p76041
sasg66311
(lp76042
(dp76043
g66301
I172
sg66302
I2
sg66303
I13
sg66314
VC0678222
p76044
sg66306
Vbreast cancer
p76045
sasa(dp76046
g66296
VWe conclude that MIAT promotes breast cancer progression and functions as ceRNA to regulate DUSP7 expression by sponging miR-155-5p in breast cancer.
p76047
sg66298
(lp76048
(dp76049
g66301
I92
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VDUSP7
p76050
sa(dp76051
g66301
I121
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-155-5p
p76052
sasg66311
(lp76053
(dp76054
g66301
I31
sg66302
I2
sg66303
I13
sg66314
VC0678222
p76055
sg66306
Vbreast cancer
p76056
sa(dp76057
g66301
I38
sg66302
I2
sg66303
I18
sg66314
VC0178874
p76058
sg66306
Vcancer progression
p76059
sasa(dp76060
g66296
VFour oncogenic microRNAs (miR-155, miR-19a, miR-181b, and miR-24) and one tumor suppressor microRNA (let-7a) were shown to differentiate between high- and low-risk early breast cancer (EBC) and reflect the surgical tumor removal and adjuvant therapy.
p76061
sg66298
(lp76062
(dp76063
g66301
I35
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-19a
p76064
sa(dp76065
g66301
I44
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VmiR-181b
p76066
sa(dp76067
g66301
I58
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VmiR-24
p76068
sasg66311
(lp76069
(dp76070
g66301
I170
sg66302
I2
sg66303
I13
sg66314
VC0678222
p76071
sg66306
Vbreast cancer
p76072
sa(dp76073
g66301
I74
sg66302
I1
sg66303
I5
sg66314
VC0027651
p76074
sg66306
Vtumor
p76075
sa(dp76076
g66301
I74
sg66302
I1
sg66303
I5
sg66314
VC0027651
p76077
sg66306
Vtumor
p76078
sasa(dp76079
g66296
VThe present study determined the role of postoperative wound fluids (WFs) from patients diagnosed with breast cancer subsequent to breast conserving surgery or breast conserving surgery followed by IORT on the expression of three microRNAs (miRNAs), consisting of miR-21, miR-155 and miR-221, in distinct breast cancer cell lines that represent the general subtypes of breast cancer.
p76080
sg66298
(lp76081
sg66311
(lp76082
(dp76083
g66301
I103
sg66302
I2
sg66303
I13
sg66314
VC0678222
p76084
sg66306
Vbreast cancer
p76085
sa(dp76086
g66301
I103
sg66302
I2
sg66303
I13
sg66314
VC0678222
p76087
sg66306
Vbreast cancer
p76088
sa(dp76089
g66301
I55
sg66302
I2
sg66303
I12
sg66314
VC0043207
p76090
sg66306
Vwound fluids
p76091
sa(dp76092
g66301
I103
sg66302
I2
sg66303
I13
sg66314
VC0678222
p76093
sg66306
Vbreast cancer
p76094
sa(dp76095
g66301
I69
sg66302
I1
sg66303
I3
sg66314
VC0043207
p76096
sg66306
VWFs
p76097
sasa(dp76098
g66296
VAdditionally, it was indicated that both WFs and RT-WF strongly downregulated the expression of miR-21, miR-155 and miR-221 in basal/epithelial and luminal subtypes of breast cancer.
p76099
sg66298
(lp76100
(dp76101
g66301
I41
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VWFs
p76102
sasg66311
(lp76103
(dp76104
g66301
I41
sg66302
I1
sg66303
I3
sg66314
VC0043207
p76105
sg66306
VWFs
p76106
sa(dp76107
g66301
I168
sg66302
I2
sg66303
I13
sg66314
VC0678222
p76108
sg66306
Vbreast cancer
p76109
sasa(dp76110
g66296
VThe expression of three different microRNAs (miR-9, miR-21, and miR-155) in 52 formalin-fixed paraffin-embedded (FFPE) primary cervical cancer tissue samples and 50 FFPE normal cervical tissue samples were evaluated.
p76111
sg66298
(lp76112
sg66311
(lp76113
(dp76114
g66301
I127
sg66302
I2
sg66303
I15
sg66314
VC0302592
p76115
sg66306
Vcervical cancer
p76116
sasa(dp76117
g66296
VMiR-9, miR-21, and miR-155 were significantly overexpressed in cervical cancer tissues compared to normal tissues (P &lt; 0.001).
p76118
sg66298
(lp76119
(dp76120
g66301
I0
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VMiR-9
p76121
sasg66311
(lp76122
(dp76123
g66301
I63
sg66302
I2
sg66303
I15
sg66314
VC0302592
p76124
sg66306
Vcervical cancer
p76125
sasa(dp76126
g66296
VMiR-21 and miR-155 expression combined with the HPV E6/E7 mRNA assay in HPV E6/E7 negative cervical cancer showed increased AUC of 0.7267 and 0.7000, respectively (P = 0.01, P = 0.04), demonstrating their potential as diagnostic tools.
p76127
sg66298
(lp76128
sg66311
(lp76129
(dp76130
g66301
I91
sg66302
I2
sg66303
I15
sg66314
VC0302592
p76131
sg66306
Vcervical cancer
p76132
sasa(dp76133
g66296
VMoreover, miR-21 and miR-155 were predictors showing a 7 fold and 10.3 fold higher risk for HPV E6/E7 negative patients with cervical cancer (P = 0.024 and P = 0.017, respectively) while miR-155 was a predictor showing a 27.9 fold higher risk for HPV E6/E7 positive patients with cervical cancer (P &lt; 0.0001).
p76134
sg66298
(lp76135
sg66311
(lp76136
(dp76137
g66301
I125
sg66302
I2
sg66303
I15
sg66314
VC0302592
p76138
sg66306
Vcervical cancer
p76139
sa(dp76140
g66301
I125
sg66302
I2
sg66303
I15
sg66314
VC0302592
p76141
sg66306
Vcervical cancer
p76142
sasa(dp76143
g66296
VMiR-21 and miR-155 may be helpful in the prediction of both HPV positive and HPV negative cases of cervical cancer.
p76144
sg66298
(lp76145
(dp76146
g66301
I0
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VMiR-21
p76147
sa(dp76148
g66301
I11
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-155
p76149
sasg66311
(lp76150
(dp76151
g66301
I99
sg66302
I2
sg66303
I15
sg66314
VC0302592
p76152
sg66306
Vcervical cancer
p76153
sasa(dp76154
g66296
VThe purpose of this study was to analyze the clinicopathologic significance of expression of EMT-related miRNAs, miR-9 and miR-155, in triple-negative breast cancers (TNBCs).
p76155
sg66298
(lp76156
(dp76157
g66301
I113
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VmiR-9
p76158
sa(dp76159
g66301
I123
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-155
p76160
sa(dp76161
g66301
I93
sg66302
I2
sg66303
I18
sg66304
g11
sg66306
VEMT-related miRNAs
p76162
sasg66311
(lp76163
(dp76164
g66301
I151
sg66302
I2
sg66303
I14
sg66314
VC0006142
p76165
sg66306
Vbreast cancers
p76166
sasa(dp76167
g66296
VThen, based on the experimentally validated miRNA regulations to target genes, 4 candidate miRNAs (miR-24-3p, miR-192-5p, miR-139-5p and miR-155-5p) were identified to potentially contribute to ovarian cancer cell chemoresistance to CDDP through mediating OVCAR-8R cell CDDP resistance-related gene modules, which participated in functions that were closely related to "apoptosis", "cell cycle" and "adhesion".
p76168
sg66298
(lp76169
(dp76170
g66301
I137
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-155-5p
p76171
sa(dp76172
g66301
I122
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-139-5p
p76173
sa(dp76174
g66301
I99
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
VmiR-24-3p
p76175
sa(dp76176
g66301
I110
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-192-5p
p76177
sasg66311
(lp76178
(dp76179
g66301
I400
sg66302
I1
sg66303
I8
sg66314
VC0001511
p76180
sg66306
Vadhesion
p76181
sa(dp76182
g66301
I194
sg66302
I2
sg66303
I14
sg66314
VC1140680
p76183
sg66306
Vovarian cancer
p76184
sasa(dp76185
g66296
VThe renal involvement may present with symptoms arising from interstitial nephritis, mainly distal renal tubular acidosis.
p76186
sg66298
(lp76187
sg66311
(lp76188
(dp76189
g66301
I92
sg66302
I4
sg66303
I29
sg66314
VC1704380
p76190
sg66306
Vdistal renal tubular acidosis
p76191
sa(dp76192
g66301
I61
sg66302
I2
sg66303
I22
sg66314
VC0027707
p76193
sg66306
Vinterstitial nephritis
p76194
sasa(dp76195
g66296
VIn a 29-year-old female patient, with bilateral nephrolithiasis, the diagnosis of primary Sjoegren's syndrome, tubulo-interstitial nephritis, distal renal tubular acidosis, and hypokalemia were established.
p76196
sg66298
(lp76197
sg66311
(lp76198
(dp76199
g66301
I90
sg66302
I2
sg66303
I19
sg66314
VC1527336
p76200
sg66306
VSjoegren's syndrome
p76201
sa(dp76202
g66301
I48
sg66302
I1
sg66303
I15
sg66314
VC0392525
p76203
sg66306
Vnephrolithiasis
p76204
sa(dp76205
g66301
I111
sg66302
I2
sg66303
I29
sg66314
VC0041349
p76206
sg66306
Vtubulo-interstitial nephritis
p76207
sa(dp76208
g66301
I142
sg66302
I4
sg66303
I29
sg66314
VC1704380
p76209
sg66306
Vdistal renal tubular acidosis
p76210
sasa(dp76211
g66296
VTubulo-interstitial nephritis constitutes the most frequent renal lesion and distal tubular acidosis (Type 1) is the most important clinical manifestation of this tubular dysfunction, although the occurrence of chronic renal insufficiency is not an uncommon finding in the presence of distal renal tubular acidosis.
p76212
sg66298
(lp76213
sg66311
(lp76214
(dp76215
g66301
I211
sg66302
I3
sg66303
I27
sg66314
VC0022661
p76216
sg66306
Vchronic renal insufficiency
p76217
sa(dp76218
g66301
I0
sg66302
I2
sg66303
I29
sg66314
VC0041349
p76219
sg66306
VTubulo-interstitial nephritis
p76220
sa(dp76221
g66301
I92
sg66302
I1
sg66303
I8
sg66314
VC0001122
p76222
sg66306
Vacidosis
p76223
sa(dp76224
g66301
I285
sg66302
I4
sg66303
I29
sg66314
VC1704380
p76225
sg66306
Vdistal renal tubular acidosis
p76226
sasa(dp76227
g66296
VRight atrial thrombosis is classified as two type: A (mobile, thin) and B (non mobile and attached to atrial wall) that they are probably of cardiac origin due to local pathology, indwelling catheter, atrial fibrillation, stasis, rheumatological or hematological disease like protein C or S deficiency.
p76228
sg66298
(lp76229
(dp76230
g66301
I276
sg66302
I2
sg66303
I9
sg66304
VP02810
p76231
sg66306
Vprotein C
p76232
sasg66311
(lp76233
(dp76234
g66301
I169
sg66302
I1
sg66303
I9
sg66314
VC0677042
p76235
sg66306
Vpathology
p76236
sa(dp76237
g66301
I222
sg66302
I1
sg66303
I6
sg66314
VC0333138
p76238
sg66306
Vstasis
p76239
sa(dp76240
g66301
I6
sg66302
I2
sg66303
I17
sg66314
VC0340517
p76241
sg66306
Vatrial thrombosis
p76242
sa(dp76243
g66301
I201
sg66302
I2
sg66303
I19
sg66314
VC0004238
p76244
sg66306
Vatrial fibrillation
p76245
sa(dp76246
g66301
I249
sg66302
I2
sg66303
I21
sg66314
VC0018939
p76247
sg66306
Vhematological disease
p76248
sasa(dp76249
g66296
VVenous stasis (e.g., immobilization, congestive heart failure, acute myocardial infarction, obesity), hypercoagulability (e.g., malignancy, inflammatory bowel disease, hyperhomocysteinemia, protein C resistance, antithrombin III, protein C or S deficiency) and endothelial trauma (e.g., surgical trauma, venous trauma, in-dwelling venous instrumentation) are risk factors.
p76250
sg66298
(lp76251
(dp76252
g66301
I212
sg66302
I2
sg66303
I16
sg66304
VP05546
p76253
sg66306
Vantithrombin III
p76254
sa(dp76255
g66301
I190
sg66302
I2
sg66303
I9
sg66304
VP02810
p76256
sg66306
Vprotein C
p76257
sasg66311
(lp76258
(dp76259
g66301
I0
sg66302
I2
sg66303
I13
sg66314
VC0277919
p76260
sg66306
VVenous stasis
p76261
sa(dp76262
g66301
I140
sg66302
I3
sg66303
I26
sg66314
VC0021390
p76263
sg66306
Vinflammatory bowel disease
p76264
sa(dp76265
g66301
I168
sg66302
I1
sg66303
I20
sg66314
VC0598608
p76266
sg66306
Vhyperhomocysteinemia
p76267
sa(dp76268
g66301
I37
sg66302
I3
sg66303
I24
sg66314
VC0018802
p76269
sg66306
Vcongestive heart failure
p76270
sa(dp76271
g66301
I92
sg66302
I1
sg66303
I7
sg66314
VC0028754
p76272
sg66306
Vobesity
p76273
sa(dp76274
g66301
I63
sg66302
I3
sg66303
I27
sg66314
VC0155626
p76275
sg66306
Vacute myocardial infarction
p76276
sa(dp76277
g66301
I128
sg66302
I1
sg66303
I10
sg66314
VC0006826
p76278
sg66306
Vmalignancy
p76279
sa(dp76280
g66301
I102
sg66302
I1
sg66303
I18
sg66314
VC0398623
p76281
sg66306
Vhypercoagulability
p76282
sasa(dp76283
g66296
VTo evaluate the use of selective vs. non-selective cyclo-oxygenase inhibitors (COXIs) for the treatment of chronic non-infectious, non-necrotizing scleritis and episcleritis.
p76284
sg66298
(lp76285
(dp76286
g66301
I51
sg66302
I1
sg66303
I15
sg66304
VP23219
p76287
sg66306
Vcyclo-oxygenase
p76288
sasg66311
(lp76289
(dp76290
g66301
I147
sg66302
I3
sg66303
I26
sg66314
VC1971635
p76291
sg66306
Vscleritis and episcleritis
p76292
sa(dp76293
g66301
I119
sg66302
I1
sg66303
I10
sg66314
VC0009450
p76294
sg66306
Vinfectious
p76295
sasa(dp76296
g66296
VSixty-nine patients with scleritis and episcleritis treated for &gt;=2 months with COXIs were included.
p76297
sg66298
(lp76298
sg66311
(lp76299
(dp76300
g66301
I25
sg66302
I3
sg66303
I26
sg66314
VC1971635
p76301
sg66306
Vscleritis and episcleritis
p76302
sasa(dp76303
g66296
VInitial inflammation control was achieved in 78-81% of scleritis patients and 73-80% episcleritis patients on COXIs (p &gt; .05).
p76304
sg66298
(lp76305
sg66311
(lp76306
(dp76307
g66301
I8
sg66302
I1
sg66303
I12
sg66314
VC0021368
p76308
sg66306
Vinflammation
p76309
sa(dp76310
g66301
I85
sg66302
I1
sg66303
I12
sg66314
VC0014583
p76311
sg66306
Vepiscleritis
p76312
sa(dp76313
g66301
I55
sg66302
I1
sg66303
I9
sg66314
VC0036416
p76314
sg66306
Vscleritis
p76315
sasa(dp76316
g66296
VSelective vs. non-selective COXIs were equally efficacious for the treatment of chronic non-infectious, non-necrotizing scleritis and episcleritis.
p76317
sg66298
(lp76318
sg66311
(lp76319
(dp76320
g66301
I92
sg66302
I1
sg66303
I10
sg66314
VC0009450
p76321
sg66306
Vinfectious
p76322
sa(dp76323
g66301
I120
sg66302
I3
sg66303
I26
sg66314
VC1971635
p76324
sg66306
Vscleritis and episcleritis
p76325
sasa(dp76326
g66296
VHere we show that KIAA0793, containing substantial sequence homology with the catalytic Dbl homology domain of the faciogenital dysplasia gene product (FGD1), is a specific GEF for Cdc42.
p76327
sg66298
(lp76328
(dp76329
g66301
I181
sg66302
I1
sg66303
I5
sg66304
VP60953
p76330
sg66306
VCdc42
p76331
sa(dp76332
g66301
I152
sg66302
I1
sg66303
I4
sg66304
VP98174
p76333
sg66306
VFGD1
p76334
sa(dp76335
g66301
I173
sg66302
I1
sg66303
I3
sg66304
VP10911
p76336
sg66306
VGEF
p76337
sa(dp76338
g66301
I78
sg66302
I4
sg66303
I29
sg66304
g11
sg66306
Vcatalytic Dbl homology domain
p76339
sasg66311
(lp76340
(dp76341
g66301
I152
sg66302
I1
sg66303
I4
sg66314
VC1859974
p76342
sg66306
VFGD1
p76343
sa(dp76344
g66301
I115
sg66302
I2
sg66303
I22
sg66314
VC0175701
p76345
sg66306
Vfaciogenital dysplasia
p76346
sasa(dp76347
g66296
VThe faciogenital dysplasia gene product, FGD1, is a Dbl family member that has recently been shown to function as a CDC42-specific GEF.
p76348
sg66298
(lp76349
(dp76350
g66301
I52
sg66302
I3
sg66303
I17
sg66304
VP10911
p76351
sg66306
VDbl family member
p76352
sa(dp76353
g66301
I41
sg66302
I1
sg66303
I4
sg66304
VP98174
p76354
sg66306
VFGD1
p76355
sa(dp76356
g66301
I116
sg66302
I2
sg66303
I18
sg66304
VP60953
p76357
sg66306
VCDC42-specific GEF
p76358
sasg66311
(lp76359
(dp76360
g66301
I41
sg66302
I1
sg66303
I4
sg66314
VC1859974
p76361
sg66306
VFGD1
p76362
sa(dp76363
g66301
I4
sg66302
I2
sg66303
I22
sg66314
VC0175701
p76364
sg66306
Vfaciogenital dysplasia
p76365
sasa(dp76366
g66296
VThe majority of proteins that contain a DH (Dbl homology) domain were isolated as oncogenes in transfection assays, but two members of the DH family, FGD1 (the product of the faciogenital dysplasia or Aarskog-Scott syndrome locus) and Vav, have been shown to be essential for normal embryonic development.
p76367
sg66298
(lp76368
(dp76369
g66301
I44
sg66302
I1
sg66303
I3
sg66304
VP10911
p76370
sg66306
VDbl
p76371
sa(dp76372
g66301
I235
sg66302
I1
sg66303
I3
sg66304
VP15498
p76373
sg66306
VVav
p76374
sa(dp76375
g66301
I150
sg66302
I1
sg66303
I4
sg66304
VP98174
p76376
sg66306
VFGD1
p76377
sasg66311
(lp76378
(dp76379
g66301
I201
sg66302
I2
sg66303
I22
sg66314
VC0175701
p76380
sg66306
VAarskog-Scott syndrome
p76381
sa(dp76382
g66301
I175
sg66302
I2
sg66303
I22
sg66314
VC0175701
p76383
sg66306
Vfaciogenital dysplasia
p76384
sa(dp76385
g66301
I150
sg66302
I1
sg66303
I4
sg66314
VC1859974
p76386
sg66306
VFGD1
p76387
sasa(dp76388
g66296
VHere we have examined the role of a Dbl-like molecule, the faciogenital dysplasia gene product (FGD1), which when mutated in its Dbl homology domain, cosegregates with the developmental disease Aarskog-Scott syndrome.
p76389
sg66298
(lp76390
(dp76391
g66301
I129
sg66302
I3
sg66303
I19
sg66304
VP10911
p76392
sg66306
VDbl homology domain
p76393
sa(dp76394
g66301
I36
sg66302
I2
sg66303
I17
sg66304
VP10911
p76395
sg66306
VDbl-like molecule
p76396
sa(dp76397
g66301
I96
sg66302
I1
sg66303
I4
sg66304
VP98174
p76398
sg66306
VFGD1
p76399
sasg66311
(lp76400
(dp76401
g66301
I59
sg66302
I2
sg66303
I22
sg66314
VC0175701
p76402
sg66306
Vfaciogenital dysplasia
p76403
sa(dp76404
g66301
I96
sg66302
I1
sg66303
I4
sg66314
VC1859974
p76405
sg66306
VFGD1
p76406
sa(dp76407
g66301
I194
sg66302
I2
sg66303
I22
sg66314
VC0175701
p76408
sg66306
VAarskog-Scott syndrome
p76409
sasa(dp76410
g66296
VNon-survivors (n=29) versus survivors (n=46) were: older (77+/-9.8 vs 68+/-14, p=0.006), had higher New York Heart Association (NYHA) class (2.7+/-0.8 vs 2.3+/-0.8, p=0.037), higher brain natriuretic peptide (1157+/-717 vs 427+/-502 pg/mL, p=0.024, n=18), more coronary artery disease (61% vs 35%, p=0.031), more frequent left ventricular ejection fraction &lt;50% (20.7% vs 4.3%, p=0.026), more functional MR (41% vs 22%, p=0.069), higher mitral E/E(') (12.7+/-4.6 vs 9.8+/-4, p=0.008), higher pulmonary artery systolic pressure (PASP; 52.6+/-18.7 vs 36.7+/-14, p &lt;0.001), more &gt;=3+ tricuspid regurgitation (28% vs 4%, p=0.005) and more right ventricular dysfunction (26% vs 6%, p=0.035).
p76411
sg66298
(lp76412
sg66311
(lp76413
(dp76414
g66301
I261
sg66302
I3
sg66303
I23
sg66314
VC1956346
p76415
sg66306
Vcoronary artery disease
p76416
sa(dp76417
g66301
I644
sg66302
I3
sg66303
I29
sg66314
VC0242707
p76418
sg66306
Vright ventricular dysfunction
p76419
sa(dp76420
g66301
I590
sg66302
I2
sg66303
I23
sg66314
VC0040961
p76421
sg66306
Vtricuspid regurgitation
p76422
sasa(dp76423
g66296
VThe presence of RBBB, IVCD, PASP &gt;= 40 mmHg, left atrium diameter and NYHA functional class were independent predictors of all-cause mortality in DCM patients.
p76424
sg66298
(lp76425
sg66311
(lp76426
(dp76427
g66301
I16
sg66302
I1
sg66303
I4
sg66314
VC0085615
p76428
sg66306
VRBBB
p76429
sa(dp76430
g66301
I22
sg66302
I1
sg66303
I4
sg66314
VC1882112
p76431
sg66306
VIVCD
p76432
sasa(dp76433
g66296
VThe goals of therapy, which should be highlighted in follow-up imaging, include not only reduction of PASP, decrease in pulmonary vascular resistance, and improvements in right ventricular function, cardiac output, and tricuspid regurgitation.
p76434
sg66298
(lp76435
sg66311
(lp76436
(dp76437
g66301
I219
sg66302
I2
sg66303
I23
sg66314
VC0040961
p76438
sg66306
Vtricuspid regurgitation
p76439
sasa(dp76440
g66296
VThe objective of this study was to determine the prognostic significance of CD163(+) cells, interleukin-10 (IL-10), and interferon-gamma (IFN-Gamma) in oral lesions associated with oral squamous cell carcinoma (OSCC).
p76441
sg66298
(lp76442
(dp76443
g66301
I92
sg66302
I1
sg66303
I14
sg66304
VP22301
p76444
sg66306
Vinterleukin-10
p76445
sa(dp76446
g66301
I120
sg66302
I1
sg66303
I16
sg66304
VP01579
p76447
sg66306
Vinterferon-gamma
p76448
sa(dp76449
g66301
I76
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD163
p76450
sa(dp76451
g66301
I138
sg66302
I1
sg66303
I9
sg66304
VP01579
p76452
sg66306
VIFN-Gamma
p76453
sa(dp76454
g66301
I108
sg66302
I1
sg66303
I5
sg66304
VP22301
p76455
sg66306
VIL-10
p76456
sasg66311
(lp76457
(dp76458
g66301
I186
sg66302
I3
sg66303
I23
sg66314
VC0007137
p76459
sg66306
Vsquamous cell carcinoma
p76460
sasa(dp76461
g66296
Vbeta-defensin expression was quantitatively assessed using real-time polymerase chain reactions in OSCC and control cell lines after exposure to interleukin-1beta, tumor necrosis factor-alpha, and interferon-gamma.
p76462
sg66298
(lp76463
(dp76464
g66301
I0
sg66302
I1
sg66303
I13
sg66304
VP59861
p76465
sg66306
Vbeta-defensin
p76466
sa(dp76467
g66301
I145
sg66302
I1
sg66303
I17
sg66304
VP01584
p76468
sg66306
Vinterleukin-1beta
p76469
sa(dp76470
g66301
I164
sg66302
I3
sg66303
I27
sg66304
VP01375
p76471
sg66306
Vtumor necrosis factor-alpha
p76472
sa(dp76473
g66301
I197
sg66302
I1
sg66303
I16
sg66304
VP01579
p76474
sg66306
Vinterferon-gamma
p76475
sasg66311
(lp76476
(dp76477
g66301
I164
sg66302
I2
sg66303
I14
sg66314
VC0333516
p76478
sg66306
Vtumor necrosis
p76479
sasa(dp76480
g66296
VWe investigated the utility of J chain and MEF2B in the diagnosis of CHL, NLPHL, PMBL, T-cell/histiocyte-rich large B-cell lymphoma (TCRLBL), and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and CHL (BCLU, DLBCL/CHL) compared to OCT-2 and BOB.1.
p76481
sg66298
(lp76482
(dp76483
g66301
I292
sg66302
I1
sg66303
I5
sg66304
VP49685
p76484
sg66306
VBOB.1
p76485
sa(dp76486
g66301
I282
sg66302
I1
sg66303
I5
sg66304
VP09086
p76487
sg66306
VOCT-2
p76488
sasg66311
(lp76489
(dp76490
g66301
I87
sg66302
I4
sg66303
I44
sg66314
VC1321547
p76491
sg66306
VT-cell/histiocyte-rich large B-cell lymphoma
p76492
sa(dp76493
g66301
I74
sg66302
I1
sg66303
I5
sg66314
VC1334968
p76494
sg66306
VNLPHL
p76495
sa(dp76496
g66301
I116
sg66302
I2
sg66303
I15
sg66314
VC0079731
p76497
sg66306
VB-cell lymphoma
p76498
sa(dp76499
g66301
I133
sg66302
I1
sg66303
I6
sg66314
VC1321547
p76500
sg66306
VTCRLBL
p76501
sa(dp76502
g66301
I214
sg66302
I4
sg66303
I29
sg66314
VC0079744
p76503
sg66306
Vdiffuse large B-cell lymphoma
p76504
sasa(dp76505
g66296
VJ chain and MEF2B are highly sensitive and specific markers of NLPHL versus CHL, are particularly useful in highlighting LP cells, and, with rare exception, are of greater utility than OCT-2 and BOB.1 in differentiating CHL from NLPHL and other large B-cell lymphomas.
p76506
sg66298
(lp76507
(dp76508
g66301
I12
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VMEF2B
p76509
sa(dp76510
g66301
I195
sg66302
I1
sg66303
I5
sg66304
VP49685
p76511
sg66306
VBOB.1
p76512
sa(dp76513
g66301
I185
sg66302
I1
sg66303
I5
sg66304
VP09086
p76514
sg66306
VOCT-2
p76515
sasg66311
(lp76516
(dp76517
g66301
I251
sg66302
I2
sg66303
I16
sg66314
VC0079731
p76518
sg66306
VB-cell lymphomas
p76519
sa(dp76520
g66301
I63
sg66302
I1
sg66303
I5
sg66314
VC1334968
p76521
sg66306
VNLPHL
p76522
sa(dp76523
g66301
I63
sg66302
I1
sg66303
I5
sg66314
VC1334968
p76524
sg66306
VNLPHL
p76525
sasa(dp76526
g66296
VWe identified several consensus differentially expressed genes and these genes were further confirmed with literature mining; at last, two genes, that is, immunoglobulin J chain and C-X-C motif chemokine ligand 17, were screened as novel gastric cancer associated genes.
p76527
sg66298
(lp76528
(dp76529
g66301
I155
sg66302
I3
sg66303
I22
sg66304
VP01591
p76530
sg66306
Vimmunoglobulin J chain
p76531
sa(dp76532
g66301
I182
sg66302
I5
sg66303
I31
sg66304
VP55773
p76533
sg66306
VC-X-C motif chemokine ligand 17
p76534
sasg66311
(lp76535
(dp76536
g66301
I238
sg66302
I2
sg66303
I14
sg66314
VC0024623
p76537
sg66306
Vgastric cancer
p76538
sasa(dp76539
g66296
VA discovery/validation study on RR-MS responsive to glatiramer acetate identified 8 differentially expressed genes: ITGA2B, ITGB3, CD177, IGJ, IL5RA, MMP8, P2RY12, and S100Beta.
p76540
sg66298
(lp76541
(dp76542
g66301
I143
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VIL5RA
p76543
sa(dp76544
g66301
I168
sg66302
I1
sg66303
I8
sg66304
VP04271
p76545
sg66306
VS100Beta
p76546
sa(dp76547
g66301
I150
sg66302
I1
sg66303
I4
sg66304
VP22894
p76548
sg66306
VMMP8
p76549
sa(dp76550
g66301
I138
sg66302
I1
sg66303
I3
sg66304
VP01591
p76551
sg66306
VIGJ
p76552
sa(dp76553
g66301
I131
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCD177
p76554
sa(dp76555
g66301
I124
sg66302
I1
sg66303
I5
sg66304
VP05106
p76556
sg66306
VITGB3
p76557
sa(dp76558
g66301
I116
sg66302
I1
sg66303
I6
sg66304
VP08514
p76559
sg66306
VITGA2B
p76560
sa(dp76561
g66301
I156
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VP2RY12
p76562
sasg66311
(lp76563
sa(dp76564
g66296
VFor the transcriptome analysis, we found some genes related to Alzheimer's disease (LRP1), an insulin-like growth factor receptor (IGF2R), immunity genes (IGL family and IGJ), two genes related to inflammatory reaction (CXCL5 and CCL3), one gene related to maintenance of cellular morphology (NHS), one gene considered to be a strong apoptosis inductor (LGALS14), and several transcripts of the neuroblastoma breakpoint family (NBPF).
p76565
sg66298
(lp76566
(dp76567
g66301
I220
sg66302
I1
sg66303
I5
sg66304
VP42830
p76568
sg66306
VCXCL5
p76569
sa(dp76570
g66301
I170
sg66302
I1
sg66303
I3
sg66304
VP01591
p76571
sg66306
VIGJ
p76572
sa(dp76573
g66301
I230
sg66302
I1
sg66303
I4
sg66304
VP10147
p76574
sg66306
VCCL3
p76575
sa(dp76576
g66301
I428
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VNBPF
p76577
sa(dp76578
g66301
I395
sg66302
I3
sg66303
I31
sg66304
g11
sg66306
Vneuroblastoma breakpoint family
p76579
sa(dp76580
g66301
I131
sg66302
I1
sg66303
I5
sg66304
VP11717
p76581
sg66306
VIGF2R
p76582
sa(dp76583
g66301
I94
sg66302
I4
sg66303
I35
sg66304
VP01308
p76584
sg66306
Vinsulin-like growth factor receptor
p76585
sa(dp76586
g66301
I84
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VLRP1
p76587
sa(dp76588
g66301
I155
sg66302
I2
sg66303
I10
sg66304
VP15814
p76589
sg66306
VIGL family
p76590
sasg66311
(lp76591
(dp76592
g66301
I63
sg66302
I2
sg66303
I19
sg66314
VC1521724
p76593
sg66306
VAlzheimer's disease
p76594
sa(dp76595
g66301
I197
sg66302
I2
sg66303
I21
sg66314
VC0021368
p76596
sg66306
Vinflammatory reaction
p76597
sa(dp76598
g66301
I293
sg66302
I1
sg66303
I3
sg66314
VC0796085
p76599
sg66306
VNHS
p76600
sa(dp76601
g66301
I395
sg66302
I1
sg66303
I13
sg66314
VC0027819
p76602
sg66306
Vneuroblastoma
p76603
sasa(dp76604
g66296
VUsing principal components analysis, spots containing immunoglobulin J chain, apolipoprotein A-I, procollagen C-endopeptidase enhancer-1 and complement C4-A were associated with lymphoma development (P &lt; 0.0001).
p76605
sg66298
(lp76606
(dp76607
g66301
I54
sg66302
I3
sg66303
I22
sg66304
VP01591
p76608
sg66306
Vimmunoglobulin J chain
p76609
sa(dp76610
g66301
I98
sg66302
I3
sg66303
I38
sg66304
g11
sg66306
Vprocollagen C-endopeptidase enhancer-1
p76611
sa(dp76612
g66301
I141
sg66302
I2
sg66303
I15
sg66304
g11
sg66306
Vcomplement C4-A
p76613
sa(dp76614
g66301
I78
sg66302
I2
sg66303
I18
sg66304
VP02647
p76615
sg66306
Vapolipoprotein A-I
p76616
sasg66311
(lp76617
(dp76618
g66301
I37
sg66302
I1
sg66303
I5
sg66314
VC0015230
p76619
sg66306
Vspots
p76620
sa(dp76621
g66301
I178
sg66302
I1
sg66303
I8
sg66314
VC0024299
p76622
sg66306
Vlymphoma
p76623
sasa(dp76624
g66296
VThe relationship between combined temperature factors showed a linear impact until reaching high temperatures limiting malaria incidence, with a lag 3.25 months.
p76625
sg66298
(lp76626
sg66311
(lp76627
(dp76628
g66301
I119
sg66302
I1
sg66303
I7
sg66314
VC0024530
p76629
sg66306
Vmalaria
p76630
sasa(dp76631
g66296
VExperimental models of malaria have shown that the regulatory molecules, cytotoxic T-lymphocyte attenuator-4 (CTLA-4), lymphocyte activation gene-3 (LAG-3), and programmed death-1 (PD-1) are involved in the functional impairment of T cells during infection.
p76632
sg66298
(lp76633
(dp76634
g66301
I119
sg66302
I3
sg66303
I28
sg66304
VP05154
p76635
sg66306
Vlymphocyte activation gene-3
p76636
sa(dp76637
g66301
I110
sg66302
I1
sg66303
I6
sg66304
VP16410
p76638
sg66306
VCTLA-4
p76639
sa(dp76640
g66301
I149
sg66302
I1
sg66303
I5
sg66304
VP16949
p76641
sg66306
VLAG-3
p76642
sa(dp76643
g66301
I161
sg66302
I2
sg66303
I18
sg66304
VP18621
p76644
sg66306
Vprogrammed death-1
p76645
sa(dp76646
g66301
I73
sg66302
I3
sg66303
I35
sg66304
VP16410
p76647
sg66306
Vcytotoxic T-lymphocyte attenuator-4
p76648
sa(dp76649
g66301
I181
sg66302
I1
sg66303
I4
sg66304
VP18621
p76650
sg66306
VPD-1
p76651
sasg66311
(lp76652
(dp76653
g66301
I23
sg66302
I1
sg66303
I7
sg66314
VC0024530
p76654
sg66306
Vmalaria
p76655
sa(dp76656
g66301
I218
sg66302
I1
sg66303
I10
sg66314
VC0684336
p76657
sg66306
Vimpairment
p76658
sa(dp76659
g66301
I247
sg66302
I1
sg66303
I9
sg66314
VC0009450
p76660
sg66306
Vinfection
p76661
sasa(dp76662
g66296
VWe evaluated the HLA-G 3' untranslated region (3'UTR) polymorphic sites (associated with mRNA stability and target for microRNA binding) and HLA-G tissue expression (heart, colon, and esophagus) in patients presenting Chagas disease, stratified according to the major clinical variants.
p76663
sg66298
(lp76664
(dp76665
g66301
I17
sg66302
I1
sg66303
I5
sg66304
VP17693
p76666
sg66306
VHLA-G
p76667
sasg66311
(lp76668
(dp76669
g66301
I218
sg66302
I2
sg66303
I14
sg66314
VC0041234
p76670
sg66306
VChagas disease
p76671
sasa(dp76672
g66296
VChagas disease patients exhibited differential HLA-G 3'UTR susceptibility allele/genotype/haplotype patterns, according to the major clinical variant (digestive/cardiac/mixed/indeterminate).
p76673
sg66298
(lp76674
(dp76675
g66301
I47
sg66302
I3
sg66303
I26
sg66304
VP17693
p76676
sg66306
VHLA-G 3'UTR susceptibility
p76677
sasg66311
(lp76678
(dp76679
g66301
I0
sg66302
I2
sg66303
I14
sg66314
VC0041234
p76680
sg66306
VChagas disease
p76681
sasa(dp76682
g66296
VWe studied the arthritis association and the spliceo-transcriptome of four different Ltab-Ncr3 haplotypes and showed that higher Ltb and Ncr3 expression, lower Lst1 expression, and the expression of a shorter splice variant of Lst1 correlate with reduced arthritis severity in rats.
p76683
sg66298
(lp76684
(dp76685
g66301
I160
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VLst1
p76686
sa(dp76687
g66301
I129
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VLtb
p76688
sa(dp76689
g66301
I160
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VLst1
p76690
sasg66311
(lp76691
(dp76692
g66301
I15
sg66302
I1
sg66303
I9
sg66314
VC0003864
p76693
sg66306
Varthritis
p76694
sa(dp76695
g66301
I15
sg66302
I1
sg66303
I9
sg66314
VC0003864
p76696
sg66306
Varthritis
p76697
sasa(dp76698
g66296
VThe C825T polymorphism (rs5443) of the Guanine Nucleotide-Binding protein subunit Beta3 (GNB3) gene has been associated with obesity, essential hypertension, atherosclerosis, coronary diseases, and cerebrovascular events, but with some sex-specific effects.
p76699
sg66298
(lp76700
(dp76701
g66301
I39
sg66302
I5
sg66303
I48
sg66304
VP09471
p76702
sg66306
VGuanine Nucleotide-Binding protein subunit Beta3
p76703
sa(dp76704
g66301
I89
sg66302
I1
sg66303
I4
sg66304
VP16520
p76705
sg66306
VGNB3
p76706
sasg66311
(lp76707
(dp76708
g66301
I125
sg66302
I1
sg66303
I7
sg66314
VC0028754
p76709
sg66306
Vobesity
p76710
sa(dp76711
g66301
I158
sg66302
I2
sg66303
I25
sg66314
VC0010054
p76712
sg66306
Vatherosclerosis, coronary
p76713
sa(dp76714
g66301
I134
sg66302
I2
sg66303
I22
sg66314
VC0085580
p76715
sg66306
Vessential hypertension
p76716
sasa(dp76717
g66296
VThe guanine nucleotide-binding protein beta polypeptide 3 (GNB3) 825T allele encodes a product that enhances the activation of heterotrimeric G proteins, which is associated with the occurrence of the splice variant GBeta3 s that could play a role in vascular reactivity and hyperproliferation of smooth muscle cells, that makes such proteins attractive candidate gene products for susceptibility to essential hypertension (EH).
p76718
sg66298
(lp76719
(dp76720
g66301
I201
sg66302
I4
sg66303
I23
sg66304
VP26640
p76721
sg66306
Vsplice variant GBeta3 s
p76722
sa(dp76723
g66301
I4
sg66302
I6
sg66303
I53
sg66304
VP09471
p76724
sg66306
Vguanine nucleotide-binding protein beta polypeptide 3
p76725
sa(dp76726
g66301
I127
sg66302
I3
sg66303
I25
sg66304
g11
sg66306
Vheterotrimeric G proteins
p76727
sa(dp76728
g66301
I59
sg66302
I1
sg66303
I4
sg66304
VP16520
p76729
sg66306
VGNB3
p76730
sasg66311
(lp76731
(dp76732
g66301
I400
sg66302
I2
sg66303
I22
sg66314
VC0085580
p76733
sg66306
Vessential hypertension
p76734
sa(dp76735
g66301
I424
sg66302
I1
sg66303
I2
sg66314
VC0085580
p76736
sg66306
VEH
p76737
sasa(dp76738
g66296
VIn our investigation of how Ang II signals are converted by the AT1R from physiological to pathological outputs, we found that the purinergic P2Y6 receptor (P2Y6R), an inflammation-inducible G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptor (GPCR), promoted Ang II-induced hypertension in mice.
p76739
sg66298
(lp76740
(dp76741
g66301
I28
sg66302
I2
sg66303
I6
sg66304
VP01019
p76742
sg66306
VAng II
p76743
sa(dp76744
g66301
I64
sg66302
I1
sg66303
I4
sg66304
VP30556
p76745
sg66306
VAT1R
p76746
sa(dp76747
g66301
I271
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGPCR
p76748
sa(dp76749
g66301
I28
sg66302
I2
sg66303
I6
sg66304
VP01019
p76750
sg66306
VAng II
p76751
sa(dp76752
g66301
I131
sg66302
I3
sg66303
I24
sg66304
g11
sg66306
Vpurinergic P2Y6 receptor
p76753
sa(dp76754
g66301
I191
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VG protein
p76755
sasg66311
(lp76756
(dp76757
g66301
I302
sg66302
I1
sg66303
I12
sg66314
VC0020538
p76758
sg66306
Vhypertension
p76759
sa(dp76760
g66301
I168
sg66302
I1
sg66303
I12
sg66314
VC0021368
p76761
sg66306
Vinflammation
p76762
sasa(dp76763
g66296
VWe identified the role of regulator of G protein (heterotrimeric guanine nucleotide-binding protein) signaling 5 (RGS5) in blood pressure regulation during pregnancy and preeclampsia.
p76764
sg66298
(lp76765
(dp76766
g66301
I114
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VRGS5
p76767
sa(dp76768
g66301
I39
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VG protein
p76769
sa(dp76770
g66301
I50
sg66302
I4
sg66303
I49
sg66304
VP09471
p76771
sg66306
Vheterotrimeric guanine nucleotide-binding protein
p76772
sasg66311
(lp76773
(dp76774
g66301
I170
sg66302
I1
sg66303
I12
sg66314
VC0032914
p76775
sg66306
Vpreeclampsia
p76776
sasa(dp76777
g66296
VHere, we investigated the expression and function of NR6A1 and its underlying mechanisms in prostate cancer (PCa) patients who underwent radical prostatectomy.
p76778
sg66298
(lp76779
(dp76780
g66301
I53
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VNR6A1
p76781
sasg66311
(lp76782
(dp76783
g66301
I92
sg66302
I2
sg66303
I15
sg66314
VC0600139
p76784
sg66306
Vprostate cancer
p76785
sa(dp76786
g66301
I109
sg66302
I1
sg66303
I3
sg66314
VC0268398
p76787
sg66306
VPCa
p76788
sasa(dp76789
g66296
VA total of 303 cases of prostate cancer after radical prostatectomy were analysed in a tissue microarray (TMA) for NR6A1 immunohistochemistry-based protein expression.
p76790
sg66298
(lp76791
(dp76792
g66301
I115
sg66302
I3
sg66303
I40
sg66304
g11
sg66306
VNR6A1 immunohistochemistry-based protein
p76793
sasg66311
(lp76794
(dp76795
g66301
I24
sg66302
I2
sg66303
I15
sg66314
VC0600139
p76796
sg66306
Vprostate cancer
p76797
sasa(dp76798
g66296
VKnockdown of NR6A1 by small interfering RNA mediated gene silencing and overexpression of NR6A1 through lentivirus were utilized to investigate its potential role in prostate cancer cells.
p76799
sg66298
(lp76800
(dp76801
g66301
I13
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VNR6A1
p76802
sa(dp76803
g66301
I13
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VNR6A1
p76804
sasg66311
(lp76805
(dp76806
g66301
I166
sg66302
I2
sg66303
I15
sg66314
VC0600139
p76807
sg66306
Vprostate cancer
p76808
sasa(dp76809
g66296
VIn addition, gene silencing of NR6A1 resulted in G0/G1 phase cell cycle arrest, and decreased metastatic and invasive potential of prostate cancer cells DU145 and PC3.
p76810
sg66298
(lp76811
(dp76812
g66301
I31
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VNR6A1
p76813
sasg66311
(lp76814
(dp76815
g66301
I131
sg66302
I2
sg66303
I15
sg66314
VC0600139
p76816
sg66306
Vprostate cancer
p76817
sasa(dp76818
g66296
VIn contrast, overexpression of NR6A1 reduced G0/G1 phase cell cycle arrest, and promoted metastatic and invasive potential of prostate cancer cells 22RV1.
p76819
sg66298
(lp76820
(dp76821
g66301
I31
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VNR6A1
p76822
sasg66311
(lp76823
(dp76824
g66301
I126
sg66302
I2
sg66303
I15
sg66314
VC0600139
p76825
sg66306
Vprostate cancer
p76826
sasa(dp76827
g66296
VThe increasing age and number of RTR is likely to be paralleled by an increase of prostate cancer (PCa) incidence.
p76828
sg66298
(lp76829
(dp76830
g66301
I33
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VRTR
p76831
sasg66311
(lp76832
(dp76833
g66301
I82
sg66302
I2
sg66303
I15
sg66314
VC0600139
p76834
sg66306
Vprostate cancer
p76835
sa(dp76836
g66301
I99
sg66302
I1
sg66303
I3
sg66314
VC0268398
p76837
sg66306
VPCa
p76838
sasa(dp76839
g66296
VWe conducted a multicenter retrospective study and reviewed the charts and records of 20 RTRs who had undergone RRP for localized prostate cancer at four French renal transplant centers belonging to the Renal Transplantation Committee of the French Urological Association from April 1996 to April 2007.
p76840
sg66298
(lp76841
(dp76842
g66301
I112
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VRRP
p76843
sasg66311
(lp76844
(dp76845
g66301
I130
sg66302
I2
sg66303
I15
sg66314
VC0600139
p76846
sg66306
Vprostate cancer
p76847
sasa(dp76848
g66296
VIn our study, RRP was a safe procedure to treat localized prostate cancer in RTRs.
p76849
sg66298
(lp76850
sg66311
(lp76851
(dp76852
g66301
I58
sg66302
I2
sg66303
I15
sg66314
VC0600139
p76853
sg66306
Vprostate cancer
p76854
sasa(dp76855
g66296
VIn this study, we examine the expression of RTR in murine placenta and several human placental choriocarcinoma cell lines.
p76856
sg66298
(lp76857
(dp76858
g66301
I44
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VRTR
p76859
sasg66311
(lp76860
(dp76861
g66301
I85
sg66302
I2
sg66303
I25
sg66314
VC0855173
p76862
sg66306
Vplacental choriocarcinoma
p76863
sasa(dp76864
g66296
VRTR mRNA was also expressed in rat choriocarcinoma Rcho-1 cells and in the human placental choriocarcinoma cell lines BeWo, JAR, and JEG-3.
p76865
sg66298
(lp76866
(dp76867
g66301
I0
sg66302
I2
sg66303
I8
sg66304
g11
sg66306
VRTR mRNA
p76868
sasg66311
(lp76869
(dp76870
g66301
I31
sg66302
I2
sg66303
I19
sg66314
VC1882624
p76871
sg66306
Vrat choriocarcinoma
p76872
sa(dp76873
g66301
I81
sg66302
I2
sg66303
I25
sg66314
VC0855173
p76874
sg66306
Vplacental choriocarcinoma
p76875
sasa(dp76876
g66296
VTo evaluate the prognostic significance of PSA nadir (nPSA) and the time to nadir in disease free of recurrence (DFR) in localized carcinoma of prostate treated with radical radiotherapy (RTR).
p76877
sg66298
(lp76878
(dp76879
g66301
I43
sg66302
I2
sg66303
I9
sg66304
VP55786
p76880
sg66306
VPSA nadir
p76881
sasg66311
(lp76882
(dp76883
g66301
I101
sg66302
I1
sg66303
I10
sg66314
VC1458156
p76884
sg66306
Vrecurrence
p76885
sa(dp76886
g66301
I131
sg66302
I3
sg66303
I21
sg66314
VC0600139
p76887
sg66306
Vcarcinoma of prostate
p76888
sa(dp76889
g66301
I43
sg66302
I1
sg66303
I3
sg66314
VC1519176
p76890
sg66306
VPSA
p76891
sasa(dp76892
g66296
VThe present study was aimed to determine the effect of steviol on PC1, CFTR, and Beta-catenin levels in renal epithelial cells with defective PC1 biogenesis and expression (Prkcsh-/- cell) and postnatal Pkd1 homozygous cell (Pkd1-/- cells).
p76893
sg66298
(lp76894
(dp76895
g66301
I71
sg66302
I1
sg66303
I4
sg66304
VP13569
p76896
sg66306
VCFTR
p76897
sa(dp76898
g66301
I203
sg66302
I3
sg66303
I20
sg66304
VP98161
p76899
sg66306
VPkd1 homozygous cell
p76900
sa(dp76901
g66301
I203
sg66302
I1
sg66303
I4
sg66304
VP98161
p76902
sg66306
VPkd1
p76903
sa(dp76904
g66301
I81
sg66302
I1
sg66303
I12
sg66304
VP35222
p76905
sg66306
VBeta-catenin
p76906
sa(dp76907
g66301
I66
sg66302
I1
sg66303
I3
sg66304
VP98161
p76908
sg66306
VPC1
p76909
sasg66311
(lp76910
(dp76911
g66301
I203
sg66302
I1
sg66303
I4
sg66314
VC3149841
p76912
sg66306
VPkd1
p76913
sa(dp76914
g66301
I203
sg66302
I1
sg66303
I4
sg66314
VC3149841
p76915
sg66306
VPkd1
p76916
sa(dp76917
g66301
I66
sg66302
I1
sg66303
I3
sg66314
VC1706595
p76918
sg66306
VPC1
p76919
sa(dp76920
g66301
I66
sg66302
I1
sg66303
I3
sg66314
VC1706595
p76921
sg66306
VPC1
p76922
sasa(dp76923
g66296
VUsing western blot analysis, it was found that steviol treatment at 100myM for 24-48h substantially enhanced and stabilized PC1 C-terminal expression, while decreasing CFTR and Beta-catenin protein expression in both Prkcsh-/- and Pkd1-/- cells.
p76924
sg66298
(lp76925
(dp76926
g66301
I231
sg66302
I1
sg66303
I4
sg66304
VP98161
p76927
sg66306
VPkd1
p76928
sa(dp76929
g66301
I124
sg66302
I2
sg66303
I5
sg66304
VP98161
p76930
sg66306
VPC1 C
p76931
sa(dp76932
g66301
I168
sg66302
I1
sg66303
I4
sg66304
VP13569
p76933
sg66306
VCFTR
p76934
sa(dp76935
g66301
I177
sg66302
I2
sg66303
I20
sg66304
VP35222
p76936
sg66306
VBeta-catenin protein
p76937
sasg66311
(lp76938
(dp76939
g66301
I231
sg66302
I1
sg66303
I4
sg66314
VC3149841
p76940
sg66306
VPkd1
p76941
sa(dp76942
g66301
I124
sg66302
I1
sg66303
I3
sg66314
VC1706595
p76943
sg66306
VPC1
p76944
sasa(dp76945
g66296
VKPT-9274 can attenuate cellular proliferation and induce apoptosis associated with a decrease in active (phosphorylated) PAK4 and Beta-catenin in several Pkd1-null murine cell lines, with a less pronounced effect on the corresponding phenotypically normal cells.
p76946
sg66298
(lp76947
(dp76948
g66301
I130
sg66302
I1
sg66303
I12
sg66304
VP35222
p76949
sg66306
VBeta-catenin
p76950
sa(dp76951
g66301
I121
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VPAK4
p76952
sa(dp76953
g66301
I154
sg66302
I1
sg66303
I9
sg66304
VP98161
p76954
sg66306
VPkd1-null
p76955
sasg66311
(lp76956
(dp76957
g66301
I154
sg66302
I1
sg66303
I4
sg66314
VC3149841
p76958
sg66306
VPkd1
p76959
sa(dp76960
g66301
I23
sg66302
I2
sg66303
I22
sg66314
VC0020507
p76961
sg66306
Vcellular proliferation
p76962
sasa(dp76963
g66296
VGiven the fundamental role of Beta-catenin signaling in intestinal epithelial cell proliferation and the growth-promoting function of protein kinase D1 (PKD1) in these cells, we hypothesized that PKDs mediate cross talk with Beta-catenin signaling.
p76964
sg66298
(lp76965
(dp76966
g66301
I134
sg66302
I3
sg66303
I17
sg66304
g11
sg66306
Vprotein kinase D1
p76967
sa(dp76968
g66301
I30
sg66302
I1
sg66303
I12
sg66304
VP35222
p76969
sg66306
VBeta-catenin
p76970
sa(dp76971
g66301
I196
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VPKDs
p76972
sa(dp76973
g66301
I30
sg66302
I1
sg66303
I12
sg66304
VP35222
p76974
sg66306
VBeta-catenin
p76975
sa(dp76976
g66301
I153
sg66302
I1
sg66303
I4
sg66304
VP98161
p76977
sg66306
VPKD1
p76978
sasg66311
(lp76979
(dp76980
g66301
I134
sg66302
I3
sg66303
I17
sg66314
VC3149841
p76981
sg66306
Vprotein kinase D1
p76982
sa(dp76983
g66301
I83
sg66302
I1
sg66303
I13
sg66314
VC0334094
p76984
sg66306
Vproliferation
p76985
sa(dp76986
g66301
I153
sg66302
I1
sg66303
I4
sg66314
VC3149841
p76987
sg66306
VPKD1
p76988
sasa(dp76989
g66296
VGPCR stimulation also induced the formation of a complex between PKD1 and Beta-catenin, as shown by coimmunoprecipitation that depended on PKD1 catalytic activation, as it was abrogated by cell treatment with PKD family inhibitors.
p76990
sg66298
(lp76991
(dp76992
g66301
I74
sg66302
I1
sg66303
I12
sg66304
VP35222
p76993
sg66306
VBeta-catenin
p76994
sa(dp76995
g66301
I209
sg66302
I2
sg66303
I10
sg66304
VP98161
p76996
sg66306
VPKD family
p76997
sa(dp76998
g66301
I0
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGPCR
p76999
sa(dp77000
g66301
I65
sg66302
I1
sg66303
I4
sg66304
VP98161
p77001
sg66306
VPKD1
p77002
sa(dp77003
g66301
I65
sg66302
I1
sg66303
I4
sg66304
VP98161
p77004
sg66306
VPKD1
p77005
sasg66311
(lp77006
(dp77007
g66301
I65
sg66302
I1
sg66303
I3
sg66314
VC1868682
p77008
sg66306
VPKD
p77009
sa(dp77010
g66301
I65
sg66302
I1
sg66303
I4
sg66314
VC3149841
p77011
sg66306
VPKD1
p77012
sa(dp77013
g66301
I65
sg66302
I1
sg66303
I4
sg66314
VC3149841
p77014
sg66306
VPKD1
p77015
sasa(dp77016
g66296
VUsing transgenic mice that express elevated PKD1 protein in the intestinal epithelium, we detected a marked increase in the localization of Beta-catenin in the nucleus of crypt epithelial cells in the ileum of PKD1 transgenic mice, compared with nontransgenic littermates.
p77017
sg66298
(lp77018
(dp77019
g66301
I44
sg66302
I1
sg66303
I4
sg66304
VP98161
p77020
sg66306
VPKD1
p77021
sa(dp77022
g66301
I140
sg66302
I1
sg66303
I12
sg66304
VP35222
p77023
sg66306
VBeta-catenin
p77024
sa(dp77025
g66301
I44
sg66302
I2
sg66303
I12
sg66304
VP98161
p77026
sg66306
VPKD1 protein
p77027
sasg66311
(lp77028
(dp77029
g66301
I44
sg66302
I1
sg66303
I4
sg66314
VC3149841
p77030
sg66306
VPKD1
p77031
sa(dp77032
g66301
I44
sg66302
I1
sg66303
I4
sg66314
VC3149841
p77033
sg66306
VPKD1
p77034
sasa(dp77035
g66296
VPachyonychia congenita subjects were sampled who exhibited a mutation in KRT6A, KRT6B, KRT6C, KRT16 or KRT17, and the proteins were digested and analyzed by tandem mass spectrometry.
p77036
sg66298
(lp77037
(dp77038
g66301
I73
sg66302
I1
sg66303
I5
sg66304
VP02538
p77039
sg66306
VKRT6A
p77040
sa(dp77041
g66301
I94
sg66302
I1
sg66303
I5
sg66304
VP08779
p77042
sg66306
VKRT16
p77043
sa(dp77044
g66301
I87
sg66302
I1
sg66303
I5
sg66304
VP48668
p77045
sg66306
VKRT6C
p77046
sa(dp77047
g66301
I80
sg66302
I1
sg66303
I5
sg66304
VP08779
p77048
sg66306
VKRT6B
p77049
sasg66311
(lp77050
(dp77051
g66301
I0
sg66302
I2
sg66303
I22
sg66314
VC0265334
p77052
sg66306
VPachyonychia congenita
p77053
sasa(dp77054
g66296
VWe thus performed extensive biomarker measures in these compartments using univariate and multivariate approaches to correlate disease biomarkers with SCORAD and with a combined hyperplasia score [thickness and keratin 16 (K16) mRNA] at baseline and after cyclosporine A treatment in 25 moderate to severe AD patients.
p77055
sg66298
(lp77056
(dp77057
g66301
I223
sg66302
I1
sg66303
I3
sg66304
VP04264
p77058
sg66306
VK16
p77059
sa(dp77060
g66301
I211
sg66302
I2
sg66303
I10
sg66304
VP04264
p77061
sg66306
Vkeratin 16
p77062
sasg66311
(lp77063
(dp77064
g66301
I178
sg66302
I1
sg66303
I11
sg66314
VC0020507
p77065
sg66306
Vhyperplasia
p77066
sasa(dp77067
g66296
VIn addition to increased abundance, KRT16 demonstrated autoantigenicity, since sera from both fracture mice and CRPS patients showed increased autoantibody binding to recombinant kRT16 protein.
p77068
sg66298
(lp77069
(dp77070
g66301
I167
sg66302
I3
sg66303
I25
sg66304
VP08779
p77071
sg66306
Vrecombinant kRT16 protein
p77072
sa(dp77073
g66301
I36
sg66302
I1
sg66303
I5
sg66304
VP08779
p77074
sg66306
VKRT16
p77075
sasg66311
(lp77076
(dp77077
g66301
I112
sg66302
I1
sg66303
I4
sg66314
VC0458219
p77078
sg66306
VCRPS
p77079
sasa(dp77080
g66296
VThe identification of autoantibodies against KRT16 as a biomarker in mice and in humans is a critical step towards these goals, and towards redefining CRPS as having an autoimmune etiology.
p77081
sg66298
(lp77082
(dp77083
g66301
I45
sg66302
I1
sg66303
I5
sg66304
VP08779
p77084
sg66306
VKRT16
p77085
sasg66311
(lp77086
(dp77087
g66301
I169
sg66302
I1
sg66303
I10
sg66314
VC0443146
p77088
sg66306
Vautoimmune
p77089
sa(dp77090
g66301
I151
sg66302
I1
sg66303
I4
sg66314
VC0458219
p77091
sg66306
VCRPS
p77092
sasa(dp77093
g66296
VThese findings were associated with upregulation of mitochondrial Bak and Bcl-2/Bcl-xL, proapoptotic and prosurvival members in the Bcl-2 family, respectively, as well as increased mitochondrial cytochrome c release, caspase activation, and apoptosis in pancreatitis in PKCEpsilon knockout mice.
p77094
sg66298
(lp77095
(dp77096
g66301
I181
sg66302
I4
sg66303
I34
sg66304
VP99999
p77097
sg66306
Vmitochondrial cytochrome c release
p77098
sa(dp77099
g66301
I66
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VBak
p77100
sa(dp77101
g66301
I80
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VBcl-xL
p77102
sa(dp77103
g66301
I74
sg66302
I1
sg66303
I5
sg66304
VP10415
p77104
sg66306
VBcl-2
p77105
sa(dp77106
g66301
I217
sg66302
I1
sg66303
I7
sg66304
VP39880
p77107
sg66306
Vcaspase
p77108
sa(dp77109
g66301
I132
sg66302
I2
sg66303
I12
sg66304
VP10415
p77110
sg66306
VBcl-2 family
p77111
sasg66311
(lp77112
(dp77113
g66301
I254
sg66302
I1
sg66303
I12
sg66314
VC0030305
p77114
sg66306
Vpancreatitis
p77115
sasa(dp77116
g66296
VWe then microinjected a GABAA receptor antagonist, an inhibitor of lactate transport (4CIN), or an inhibitor of lactate dehydrogenase, oxamate (OX), into the VMH prior to inducing hypoglycemia.
p77117
sg66298
(lp77118
(dp77119
g66301
I24
sg66302
I2
sg66303
I14
sg66304
g11
sg66306
VGABAA receptor
p77120
sa(dp77121
g66301
I112
sg66302
I2
sg66303
I21
sg66304
VP49366
p77122
sg66306
Vlactate dehydrogenase
p77123
sasg66311
(lp77124
(dp77125
g66301
I180
sg66302
I1
sg66303
I12
sg66314
VC0020615
p77126
sg66306
Vhypoglycemia
p77127
sasa(dp77128
g66296
VTo assess whether lactate contributes to raising GABA in RH and diabetes, we injected 4CIN or OX into the VMH of RH and diabetic rats before inducing hypoglycemia.
p77129
sg66298
(lp77130
sg66311
(lp77131
(dp77132
g66301
I64
sg66302
I1
sg66303
I8
sg66314
VC0011849
p77133
sg66306
Vdiabetes
p77134
sa(dp77135
g66301
I150
sg66302
I1
sg66303
I12
sg66314
VC0020615
p77136
sg66306
Vhypoglycemia
p77137
sasa(dp77138
g66296
VMechanistically, we show that the protective effect of IL-22 on pancreatitis was mediated via the induction of Bcl-2 and Bcl-X(L), which bind to Beclin-1 and subsequently inhibit autophagosome formation to ameliorate pancreatitis.
p77139
sg66298
(lp77140
(dp77141
g66301
I111
sg66302
I1
sg66303
I5
sg66304
VP10415
p77142
sg66306
VBcl-2
p77143
sa(dp77144
g66301
I55
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VIL-22
p77145
sa(dp77146
g66301
I145
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VBeclin-1
p77147
sa(dp77148
g66301
I121
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VBcl-X(L)
p77149
sasg66311
(lp77150
(dp77151
g66301
I64
sg66302
I1
sg66303
I12
sg66314
VC0030305
p77152
sg66306
Vpancreatitis
p77153
sa(dp77154
g66301
I64
sg66302
I1
sg66303
I12
sg66314
VC0030305
p77155
sg66306
Vpancreatitis
p77156
sasa(dp77157
g66296
VWe used genetically modified rat models to investigate the role of MYL4 in atrial cardiomyopathy.
p77158
sg66298
(lp77159
(dp77160
g66301
I67
sg66302
I1
sg66303
I4
sg66304
VP12829
p77161
sg66306
VMYL4
p77162
sasg66311
(lp77163
(dp77164
g66301
I82
sg66302
I1
sg66303
I14
sg66314
VC0878544
p77165
sg66306
Vcardiomyopathy
p77166
sasa(dp77167
g66296
VExome sequencing and systematic bioinformatic analyses identified a rare missense variant of MYL4 (c.31G&gt;A [p.E11K]) in a large multiplex atrial cardiomyopathy family pedigree.
p77168
sg66298
(lp77169
(dp77170
g66301
I93
sg66302
I1
sg66303
I4
sg66304
VP12829
p77171
sg66306
VMYL4
p77172
sasg66311
(lp77173
(dp77174
g66301
I148
sg66302
I1
sg66303
I14
sg66314
VC0878544
p77175
sg66306
Vcardiomyopathy
p77176
sasa(dp77177
g66296
VMYL4 knockout rats showed a similar atrial cardiomyopathy phenotype, whereas rats with an adjacent 4-amino-acid deletion showed no phenotype.
p77178
sg66298
(lp77179
(dp77180
g66301
I0
sg66302
I1
sg66303
I4
sg66304
VP12829
p77181
sg66306
VMYL4
p77182
sasg66311
(lp77183
(dp77184
g66301
I43
sg66302
I1
sg66303
I14
sg66314
VC0878544
p77185
sg66306
Vcardiomyopathy
p77186
sasa(dp77187
g66296
VLoss-of-function MYL4 gene variants cause progressive atrial cardiomyopathy in humans and rats.
p77188
sg66298
(lp77189
(dp77190
g66301
I17
sg66302
I3
sg66303
I18
sg66304
VP12829
p77191
sg66306
VMYL4 gene variants
p77192
sasg66311
(lp77193
(dp77194
g66301
I61
sg66302
I1
sg66303
I14
sg66314
VC0878544
p77195
sg66306
Vcardiomyopathy
p77196
sasa(dp77197
g66296
VGenome-wide association studies (GWAS) have yielded variants at &gt;30 loci that associate with atrial fibrillation (AF), including rare coding mutations in the sarcomere genes MYH6 and MYL4.
p77198
sg66298
(lp77199
(dp77200
g66301
I186
sg66302
I1
sg66303
I4
sg66304
VP12829
p77201
sg66306
VMYL4
p77202
sa(dp77203
g66301
I177
sg66302
I1
sg66303
I4
sg66304
VP13533
p77204
sg66306
VMYH6
p77205
sasg66311
(lp77206
(dp77207
g66301
I96
sg66302
I2
sg66303
I19
sg66314
VC0004238
p77208
sg66306
Vatrial fibrillation
p77209
sa(dp77210
g66301
I117
sg66302
I1
sg66303
I2
sg66314
VC0004238
p77211
sg66306
VAF
p77212
sasa(dp77213
g66296
VWe imputed these variants into 104,220 individuals down to a minor allele frequency of 0.1% and found a recessive frameshift mutation in MYL4 that causes early-onset atrial fibrillation, several mutations in ABCB4 that increase risk of liver diseases and an intronic variant in GNAS associating with increased thyroid-stimulating hormone levels when maternally inherited.
p77214
sg66298
(lp77215
(dp77216
g66301
I137
sg66302
I1
sg66303
I4
sg66304
VP12829
p77217
sg66306
VMYL4
p77218
sa(dp77219
g66301
I208
sg66302
I1
sg66303
I5
sg66304
VP21439
p77220
sg66306
VABCB4
p77221
sa(dp77222
g66301
I310
sg66302
I2
sg66303
I27
sg66304
VP01222
p77223
sg66306
Vthyroid-stimulating hormone
p77224
sasg66311
(lp77225
(dp77226
g66301
I166
sg66302
I2
sg66303
I19
sg66314
VC0004238
p77227
sg66306
Vatrial fibrillation
p77228
sa(dp77229
g66301
I236
sg66302
I2
sg66303
I14
sg66314
VC0023895
p77230
sg66306
Vliver diseases
p77231
sa(dp77232
g66301
I114
sg66302
I2
sg66303
I19
sg66314
VC0079380
p77233
sg66306
Vframeshift mutation
p77234
sasa(dp77235
g66296
VThe aim of this study is to examine the mitochondrial targeting of NDUFV2 and dissect the pathogenetic mechanism of one human deletion mutation present in patients with early-onset hypertrophic cardiomyopathy and encephalopathy.
p77236
sg66298
(lp77237
(dp77238
g66301
I67
sg66302
I1
sg66303
I6
sg66304
VP19404
p77239
sg66306
VNDUFV2
p77240
sasg66311
(lp77241
(dp77242
g66301
I181
sg66302
I2
sg66303
I27
sg66314
VC0007194
p77243
sg66306
Vhypertrophic cardiomyopathy
p77244
sa(dp77245
g66301
I213
sg66302
I1
sg66303
I14
sg66314
VC0085584
p77246
sg66306
Vencephalopathy
p77247
sasa(dp77248
g66296
VThe deletion mutant mimicking the human early-onset hypertrophic cardiomyopathy and encephalopathy lacked 19-40 residues in NDUFV2 and exhibited a significant reduction in its mitochondrial targeting ability.
p77249
sg66298
(lp77250
(dp77251
g66301
I124
sg66302
I1
sg66303
I6
sg66304
VP19404
p77252
sg66306
VNDUFV2
p77253
sasg66311
(lp77254
(dp77255
g66301
I13
sg66302
I1
sg66303
I6
sg66314
VC0596988
p77256
sg66306
Vmutant
p77257
sa(dp77258
g66301
I52
sg66302
I2
sg66303
I27
sg66314
VC0007194
p77259
sg66306
Vhypertrophic cardiomyopathy
p77260
sa(dp77261
g66301
I84
sg66302
I1
sg66303
I14
sg66314
VC0085584
p77262
sg66306
Vencephalopathy
p77263
sasa(dp77264
g66296
VThe results of human disease cell model established that the impairment of mitochondrial localization of NDUFV2 as a mechanistic basis for early-onset hypertrophic cardiomyopathy and encephalopathy.
p77265
sg66298
(lp77266
(dp77267
g66301
I105
sg66302
I1
sg66303
I6
sg66304
VP19404
p77268
sg66306
VNDUFV2
p77269
sasg66311
(lp77270
(dp77271
g66301
I61
sg66302
I1
sg66303
I10
sg66314
VC0684336
p77272
sg66306
Vimpairment
p77273
sa(dp77274
g66301
I183
sg66302
I1
sg66303
I14
sg66314
VC0085584
p77275
sg66306
Vencephalopathy
p77276
sa(dp77277
g66301
I151
sg66302
I2
sg66303
I27
sg66314
VC0007194
p77278
sg66306
Vhypertrophic cardiomyopathy
p77279
sasa(dp77280
g66296
VA small deletion in the second intron of human NDUFV2 (IVS2+5_+8delGTAA) has been shown to cause hypertrophic cardiomyopathy and encephalomyopathy [Benit, P., Beugnot, R., Chretien, D., Giurgea, I., de Lonlay-Debeney, P., Issartel, J.P., Kerscher, S., Rustin, P., Roetig, A.
p77281
sg66298
(lp77282
(dp77283
g66301
I41
sg66302
I3
sg66303
I31
sg66304
VP19404
p77284
sg66306
Vhuman NDUFV2 (IVS2+5_+8delGTAA)
p77285
sasg66311
(lp77286
(dp77287
g66301
I97
sg66302
I2
sg66303
I27
sg66314
VC0007194
p77288
sg66306
Vhypertrophic cardiomyopathy
p77289
sasa(dp77290
g66296
VWhile mutations in the NDUFS3 gene thus result in Leigh syndrome, a dissimilar clinical phenotype is observed in mutations in the NDUFV2 and NDUFS2 genes, resulting in encephalomyopathy and cardiomyopathy.
p77291
sg66298
(lp77292
(dp77293
g66301
I141
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VNDUFS2 genes
p77294
sa(dp77295
g66301
I130
sg66302
I1
sg66303
I6
sg66304
VP19404
p77296
sg66306
VNDUFV2
p77297
sa(dp77298
g66301
I23
sg66302
I2
sg66303
I11
sg66304
g11
sg66306
VNDUFS3 gene
p77299
sasg66311
(lp77300
(dp77301
g66301
I50
sg66302
I2
sg66303
I14
sg66314
VC0023264
p77302
sg66306
VLeigh syndrome
p77303
sa(dp77304
g66301
I190
sg66302
I1
sg66303
I14
sg66314
VC0878544
p77305
sg66306
Vcardiomyopathy
p77306
sasa(dp77307
g66296
VCombination of denaturing high performance liquid chromatography and sequence analysis allowed us to show that a 4-bp deletion in intron 2 (IVS2+5_+8delGTAA) of the NDUFV2 gene (encoding NADH dehydrogenase ubiquinone flavoprotein 2) causes complex I deficiency and early onset hypertrophic cardiomyopathy with trunk hypotonia in three affected sibs of a consanguineous family.
p77308
sg66298
(lp77309
(dp77310
g66301
I187
sg66302
I5
sg66303
I44
sg66304
VP49366
p77311
sg66306
VNADH dehydrogenase ubiquinone flavoprotein 2
p77312
sa(dp77313
g66301
I165
sg66302
I2
sg66303
I11
sg66304
VP19404
p77314
sg66306
VNDUFV2 gene
p77315
sasg66311
(lp77316
(dp77317
g66301
I316
sg66302
I1
sg66303
I9
sg66314
VC0026827
p77318
sg66306
Vhypotonia
p77319
sa(dp77320
g66301
I277
sg66302
I2
sg66303
I27
sg66314
VC0007194
p77321
sg66306
Vhypertrophic cardiomyopathy
p77322
sa(dp77323
g66301
I240
sg66302
I3
sg66303
I20
sg66314
VC0342776
p77324
sg66306
Vcomplex I deficiency
p77325
sasa(dp77326
g66296
VWhile mutation in a number of genes encoding complex I subunits essentially result in neurological symptoms, this first mutation in NDUFV2 is strikingly associated with cardiomyopathy, as previously observed in the unique case of NDFUS2 mutations.
p77327
sg66298
(lp77328
(dp77329
g66301
I132
sg66302
I1
sg66303
I6
sg66304
VP19404
p77330
sg66306
VNDUFV2
p77331
sasg66311
(lp77332
(dp77333
g66301
I86
sg66302
I2
sg66303
I21
sg66314
VC0235031
p77334
sg66306
Vneurological symptoms
p77335
sa(dp77336
g66301
I169
sg66302
I1
sg66303
I14
sg66314
VC0878544
p77337
sg66306
Vcardiomyopathy
p77338
sasa(dp77339
g66296
VMice were fed a high fat diet to cause diet-induced obesity (DIO) and then administered GALP intranasally for 2 weeks (experimental), or vehicle (control).
p77340
sg66298
(lp77341
sg66311
(lp77342
(dp77343
g66301
I52
sg66302
I1
sg66303
I7
sg66314
VC0028754
p77344
sg66306
Vobesity
p77345
sasa(dp77346
g66296
VGAL and GALP concentrations may be taken as potential biomarkers to predict development of obesity.
p77347
sg66298
(lp77348
(dp77349
g66301
I0
sg66302
I1
sg66303
I3
sg66304
VP16278
p77350
sg66306
VGAL
p77351
sa(dp77352
g66301
I8
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGALP
p77353
sasg66311
(lp77354
(dp77355
g66301
I91
sg66302
I1
sg66303
I7
sg66314
VC0028754
p77356
sg66306
Vobesity
p77357
sasa(dp77358
g66296
VGalanin-like peptide (GALP) has an anti-obesity effect in rats and mice.
p77359
sg66298
(lp77360
(dp77361
g66301
I0
sg66302
I2
sg66303
I20
sg66304
g11
sg66306
VGalanin-like peptide
p77362
sa(dp77363
g66301
I22
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGALP
p77364
sasg66311
(lp77365
(dp77366
g66301
I40
sg66302
I1
sg66303
I7
sg66314
VC0028754
p77367
sg66306
Vobesity
p77368
sasa(dp77369
g66296
VThese results suggest that intranasal administration is an effective route whereby GALP can exert its effect as an anti-obesity drug.
p77370
sg66298
(lp77371
sg66311
(lp77372
(dp77373
g66301
I120
sg66302
I1
sg66303
I7
sg66314
VC0028754
p77374
sg66306
Vobesity
p77375
sasa(dp77376
g66296
VThese results show that GALP stimulates fatty acid Beta-oxidation in liver and lipolysis in adipose tissue, and suggest that the anti-obesity effect of GALP may be due to anorexigenic actions and improvement of lipid metabolism in peripheral tissues via the sympathetic nervous system.
p77377
sg66298
(lp77378
(dp77379
g66301
I24
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGALP
p77380
sa(dp77381
g66301
I24
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGALP
p77382
sasg66311
(lp77383
(dp77384
g66301
I270
sg66302
I1
sg66303
I7
sg66314
VC0027769
p77385
sg66306
Vnervous
p77386
sa(dp77387
g66301
I134
sg66302
I1
sg66303
I7
sg66314
VC0028754
p77388
sg66306
Vobesity
p77389
sasa(dp77390
g66296
VWe conclude that GALP may be of therapeutic value for obesity and life-style-related diseases in the near future.
p77391
sg66298
(lp77392
(dp77393
g66301
I17
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGALP
p77394
sasg66311
(lp77395
(dp77396
g66301
I54
sg66302
I1
sg66303
I7
sg66314
VC0028754
p77397
sg66306
Vobesity
p77398
sasa(dp77399
g66296
VGalanin-like peptide (GALP) shows potential as a therapeutic in the treatment of obesity and related conditions.
p77400
sg66298
(lp77401
(dp77402
g66301
I0
sg66302
I2
sg66303
I20
sg66304
g11
sg66306
VGalanin-like peptide
p77403
sa(dp77404
g66301
I22
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGALP
p77405
sasg66311
(lp77406
(dp77407
g66301
I81
sg66302
I1
sg66303
I7
sg66314
VC0028754
p77408
sg66306
Vobesity
p77409
sasa(dp77410
g66296
VVariations within the gene locus encoding SHP-2 have been associated with increased susceptibility to develop ulcerative colitis and gastric atrophy.
p77411
sg66298
(lp77412
(dp77413
g66301
I42
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSHP-2
p77414
sasg66311
(lp77415
(dp77416
g66301
I133
sg66302
I2
sg66303
I15
sg66314
VC0017154
p77417
sg66306
Vgastric atrophy
p77418
sa(dp77419
g66301
I110
sg66302
I2
sg66303
I18
sg66314
VC0009324
p77420
sg66306
Vulcerative colitis
p77421
sasa(dp77422
g66296
VWhen we considered the host genetic effects alone, gene-gene interactions consistently decreased the risks of gastric cancer and/or atrophic gastritis, including three two-way interactions: PGC rs6912200-PTPN11 rs12229892, PGC rs4711690-IL1B rs1143623 and PTPN11 rs12229892-IL1B rs1143623 and a three-way interaction: PGC rs4711690-PGC rs6912200-PTPN11 rs12229892.
p77423
sg66298
(lp77424
(dp77425
g66301
I190
sg66302
I3
sg66303
I31
sg66304
VP20142
p77426
sg66306
VPGC rs6912200-PTPN11 rs12229892
p77427
sa(dp77428
g66301
I223
sg66302
I3
sg66303
I28
sg66304
VP20142
p77429
sg66306
VPGC rs4711690-IL1B rs1143623
p77430
sa(dp77431
g66301
I318
sg66302
I4
sg66303
I45
sg66304
VP20142
p77432
sg66306
VPGC rs4711690-PGC rs6912200-PTPN11 rs12229892
p77433
sa(dp77434
g66301
I256
sg66302
I3
sg66303
I32
sg66304
g11
sg66306
VPTPN11 rs12229892-IL1B rs1143623
p77435
sasg66311
(lp77436
(dp77437
g66301
I132
sg66302
I2
sg66303
I18
sg66314
VC0017154
p77438
sg66306
Vatrophic gastritis
p77439
sa(dp77440
g66301
I110
sg66302
I2
sg66303
I14
sg66314
VC0024623
p77441
sg66306
Vgastric cancer
p77442
sasa(dp77443
g66296
VInconsistency of reported associations of the G/A polymorphism (rs2301756) in the PTPN11 gene and gastric atrophy prompted us to undertake a meta-analysis.
p77444
sg66298
(lp77445
(dp77446
g66301
I82
sg66302
I2
sg66303
I11
sg66304
g11
sg66306
VPTPN11 gene
p77447
sasg66311
(lp77448
(dp77449
g66301
I98
sg66302
I2
sg66303
I15
sg66314
VC0017154
p77450
sg66306
Vgastric atrophy
p77451
sasa(dp77452
g66296
VAssociations of PTPN11 polymorphism with gastric atrophy in H. pylori (-) and (+) subjects are more readily interpreted in the homozygous and recessive models given that the dominant codominant effects skirted null associations.
p77453
sg66298
(lp77454
(dp77455
g66301
I16
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VPTPN11
p77456
sasg66311
(lp77457
(dp77458
g66301
I41
sg66302
I2
sg66303
I15
sg66314
VC0017154
p77459
sg66306
Vgastric atrophy
p77460
sasa(dp77461
g66296
VEvidence of overall and subgroup decreased risks, strong in seropositive subjects, demonstrates protective effects of the PTPN11 G/A polymorphism from gastric atrophy.
p77462
sg66298
(lp77463
(dp77464
g66301
I122
sg66302
I2
sg66303
I10
sg66304
g11
sg66306
VPTPN11 G/A
p77465
sasg66311
(lp77466
(dp77467
g66301
I151
sg66302
I2
sg66303
I15
sg66314
VC0017154
p77468
sg66306
Vgastric atrophy
p77469
sasa(dp77470
g66296
VThe interaction between Src homology 2 domain-containing protein tyrosine phosphatase (SHP-2) of gastric epithelial cells and cagA from H. pylori plays a crucial role in developments of gastric atrophy and gastric cancer.
p77471
sg66298
(lp77472
(dp77473
g66301
I24
sg66302
I7
sg66303
I61
sg66304
VP12931
p77474
sg66306
VSrc homology 2 domain-containing protein tyrosine phosphatase
p77475
sa(dp77476
g66301
I126
sg66302
I1
sg66303
I4
sg66304
VP05109
p77477
sg66306
VcagA
p77478
sa(dp77479
g66301
I87
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSHP-2
p77480
sasg66311
(lp77481
(dp77482
g66301
I186
sg66302
I2
sg66303
I15
sg66314
VC0017154
p77483
sg66306
Vgastric atrophy
p77484
sa(dp77485
g66301
I206
sg66302
I2
sg66303
I14
sg66314
VC0024623
p77486
sg66306
Vgastric cancer
p77487
sasa(dp77488
g66296
VThis study aimed to investigate the association of haplotype tagging SNPs (htSNPs) in the PTPN11 gene encoding SHP-2 with gastric atrophy and gastric cancer in Chinese population.
p77489
sg66298
(lp77490
(dp77491
g66301
I111
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSHP-2
p77492
sa(dp77493
g66301
I90
sg66302
I2
sg66303
I11
sg66304
g11
sg66306
VPTPN11 gene
p77494
sasg66311
(lp77495
(dp77496
g66301
I122
sg66302
I2
sg66303
I15
sg66314
VC0017154
p77497
sg66306
Vgastric atrophy
p77498
sa(dp77499
g66301
I142
sg66302
I2
sg66303
I14
sg66314
VC0024623
p77500
sg66306
Vgastric cancer
p77501
sasa(dp77502
g66296
VOur study provides the first evidence that rs12423190 polymorphism of the PTPN11 gene is significantly associated with an increased risk of gastric atrophy in H. pylori infected Chinese Han population, suggesting that rs12423190 polymorphism could be used as a useful marker of genetic susceptibility to gastric atrophy among H. pylori infected subjects.
p77503
sg66298
(lp77504
(dp77505
g66301
I74
sg66302
I2
sg66303
I11
sg66304
g11
sg66306
VPTPN11 gene
p77506
sasg66311
(lp77507
(dp77508
g66301
I140
sg66302
I2
sg66303
I15
sg66314
VC0017154
p77509
sg66306
Vgastric atrophy
p77510
sa(dp77511
g66301
I140
sg66302
I2
sg66303
I15
sg66314
VC0017154
p77512
sg66306
Vgastric atrophy
p77513
sasa(dp77514
g66296
VThe present study indicated that overexpression of GRP78 in colon cancer cells could promote cell-matrix adhesion through the upregulation of fibronectin, integrin-Beta1 and phosphorylated FAK.
p77515
sg66298
(lp77516
(dp77517
g66301
I189
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VFAK
p77518
sa(dp77519
g66301
I51
sg66302
I1
sg66303
I5
sg66304
VP11021
p77520
sg66306
VGRP78
p77521
sasg66311
(lp77522
(dp77523
g66301
I60
sg66302
I2
sg66303
I12
sg66314
VC0699790
p77524
sg66306
Vcolon cancer
p77525
sa(dp77526
g66301
I105
sg66302
I1
sg66303
I8
sg66314
VC0001511
p77527
sg66306
Vadhesion
p77528
sasa(dp77529
g66296
VCollectively, our results suggest that berberine-induced AMPK activation inhibits the metastatic potential of colon cancer cells by decreasing integrin Beta1 protein levels and downstream signaling.
p77530
sg66298
(lp77531
(dp77532
g66301
I57
sg66302
I1
sg66303
I4
sg66304
VP54646
p77533
sg66306
VAMPK
p77534
sasg66311
(lp77535
(dp77536
g66301
I110
sg66302
I2
sg66303
I12
sg66314
VC0699790
p77537
sg66306
Vcolon cancer
p77538
sasa(dp77539
g66296
VOn multivariate analysis, the independent predictors of gene expression were hepatitis C (Mx1, OAS2, PKR and IFI16), donor age (IFI16) and recipient gender (IRF7A) (P &lt; .05 for all).
p77540
sg66298
(lp77541
(dp77542
g66301
I101
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPKR
p77543
sa(dp77544
g66301
I95
sg66302
I1
sg66303
I4
sg66304
VP29728
p77545
sg66306
VOAS2
p77546
sa(dp77547
g66301
I90
sg66302
I1
sg66303
I3
sg66304
VP20591
p77548
sg66306
VMx1
p77549
sa(dp77550
g66301
I157
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VIRF7A
p77551
sasg66311
(lp77552
(dp77553
g66301
I77
sg66302
I2
sg66303
I11
sg66314
VC0019196
p77554
sg66306
Vhepatitis C
p77555
sasa(dp77556
g66296
VNo significant difference was observed in the expression of ERRbeta mRNA between endometrial carcinoma (23%, 0.21 +/- 0.16) and normal endometrium (22%, 0.27 +/- 0.15; P &gt; 0.05).
p77557
sg66298
(lp77558
(dp77559
g66301
I60
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VERRbeta mRNA
p77560
sasg66311
(lp77561
(dp77562
g66301
I81
sg66302
I2
sg66303
I21
sg66314
VC0476089
p77563
sg66306
Vendometrial carcinoma
p77564
sasa(dp77565
g66296
VPatients undergoing major open vascular surgery (open abdominal aortic aneurysm [oAAA] repair, aortofemoral bypass, and lower extremity infrainguinal bypass [LEB]) were identified using the Michigan Surgical Quality Collaborative (MSQC) between July 2012 and June 2015.
p77566
sg66298
(lp77567
sg66311
(lp77568
(dp77569
g66301
I54
sg66302
I3
sg66303
I25
sg66314
VC0162871
p77570
sg66306
Vabdominal aortic aneurysm
p77571
sasa(dp77572
g66296
VBeta blocker utilization (&lt;1 month preoperative versus chronic) and POMI rates were prospectively collected for patients undergoing open abdominal aortic aneurysm (AAA) repair (n = 926) and lower extremity bypass (LEB; n = 2,123) from 2003 through 2008.
p77573
sg66298
(lp77574
sg66311
(lp77575
(dp77576
g66301
I167
sg66302
I1
sg66303
I3
sg66314
VC0162871
p77577
sg66306
VAAA
p77578
sa(dp77579
g66301
I140
sg66302
I3
sg66303
I25
sg66314
VC0162871
p77580
sg66306
Vabdominal aortic aneurysm
p77581
sasa(dp77582
g66296
VWe studied 10,081 patients who underwent nonemergent carotid endarterectomy (CEA; n = 5293), lower extremity bypass (LEB; n = 2673), endovascular abdominal aortic aneurysm repair (EVAR; n = 1005), and open infrarenal abdominal aortic aneurysm repair (OAAA; n = 1,110) within the VSGNE from 2003 to 2008.
p77583
sg66298
(lp77584
sg66311
(lp77585
(dp77586
g66301
I146
sg66302
I3
sg66303
I25
sg66314
VC0162871
p77587
sg66306
Vabdominal aortic aneurysm
p77588
sa(dp77589
g66301
I146
sg66302
I3
sg66303
I25
sg66314
VC0162871
p77590
sg66306
Vabdominal aortic aneurysm
p77591
sasa(dp77592
g66296
VWe mailed a survey to the directors of the 8 Canadian vascular surgery training programs, to ascertain the yearly operative volumes of their 3 most recent trainees with respect to 6 index operations: carotid endarterectomy (CEA), types I-IV thoracoabdominal aortic aneurysm (TAA) repair, elective open infrarenal aortic aneurysm (eAAA) repair, ruptured abdominal aortic aneurysm (rAAA) repair, endovascular abdominal aortic aneurysm repair (EVAR) and lower extremity arterial bypass (LEB).
p77593
sg66298
(lp77594
sg66311
(lp77595
(dp77596
g66301
I380
sg66302
I1
sg66303
I4
sg66314
VC0265012
p77597
sg66306
VrAAA
p77598
sa(dp77599
g66301
I344
sg66302
I4
sg66303
I34
sg66314
VC0265012
p77600
sg66306
Vruptured abdominal aortic aneurysm
p77601
sa(dp77602
g66301
I248
sg66302
I3
sg66303
I25
sg66314
VC0162871
p77603
sg66306
Vabdominal aortic aneurysm
p77604
sa(dp77605
g66301
I241
sg66302
I3
sg66303
I32
sg66314
VC0340630
p77606
sg66306
Vthoracoabdominal aortic aneurysm
p77607
sa(dp77608
g66301
I258
sg66302
I2
sg66303
I15
sg66314
VC0003486
p77609
sg66306
Vaortic aneurysm
p77610
sa(dp77611
g66301
I275
sg66302
I1
sg66303
I3
sg66314
VC0162872
p77612
sg66306
VTAA
p77613
sasa(dp77614
g66296
VBetween 1999 and 2002, vascular surgery trainees in Canadian training programs were exposed to the following yearly clinical volumes (expressed as mean [and standard deviation]): CEA 55.4 (33.9), TAA 6.2 (3.8), eAAA 63.8 (30.0), rAAA 13.5 (9.4), EVAR 14.9 (9.6) and LEB 74.5 (34.5).
p77615
sg66298
(lp77616
sg66311
(lp77617
(dp77618
g66301
I196
sg66302
I1
sg66303
I3
sg66314
VC0162872
p77619
sg66306
VTAA
p77620
sasa(dp77621
g66296
VThe range of yearly clinical volumes were: CEA 21-124, TAA 1-18, eAAA 30-133, rAAA 3-45, EVAR 0-34 and LEB 20-143.
p77622
sg66298
(lp77623
sg66311
(lp77624
(dp77625
g66301
I55
sg66302
I1
sg66303
I3
sg66314
VC0162872
p77626
sg66306
VTAA
p77627
sasa(dp77628
g66296
VRisk-adjustment models have not been developed for elective abdominal aortic aneurysm repair (AAA), lower extremity bypass revascularization (LEB), or lower extremity amputation (AMP).
p77629
sg66298
(lp77630
sg66311
(lp77631
(dp77632
g66301
I60
sg66302
I3
sg66303
I25
sg66314
VC0162871
p77633
sg66306
Vabdominal aortic aneurysm
p77634
sa(dp77635
g66301
I94
sg66302
I1
sg66303
I3
sg66314
VC0162871
p77636
sg66306
VAAA
p77637
sa(dp77638
g66301
I70
sg66302
I3
sg66303
I22
sg66314
VC0162871
p77639
sg66306
Vaortic aneurysm repair
p77640
sasa(dp77641
g66296
VPostoperative ileus is accompanied by activation of CGRP, NGF-TrkA, and PAR-2 in DRGs.
p77642
sg66298
(lp77643
(dp77644
g66301
I72
sg66302
I1
sg66303
I5
sg66304
VP55085
p77645
sg66306
VPAR-2
p77646
sa(dp77647
g66301
I58
sg66302
I1
sg66303
I3
sg66304
VP01138
p77648
sg66306
VNGF
p77649
sa(dp77650
g66301
I52
sg66302
I1
sg66303
I4
sg66304
VP80511
p77651
sg66306
VCGRP
p77652
sa(dp77653
g66301
I62
sg66302
I1
sg66303
I4
sg66304
VP06753
p77654
sg66306
VTrkA
p77655
sasg66311
(lp77656
(dp77657
g66301
I0
sg66302
I2
sg66303
I19
sg66314
VC0400877
p77658
sg66306
VPostoperative ileus
p77659
sasa(dp77660
g66296
VThe present study by examining the mRNA and/or protein levels of TrkA and TrkB in the distal colon and in colonic primary afferent neurons in the dorsal root ganglia (DRG) during colitis demonstrated that colitis elicited location-specific changes in the mRNA and protein levels of TrkA and TrkB in colonic primary sensory pathways.
p77661
sg66298
(lp77662
(dp77663
g66301
I65
sg66302
I1
sg66303
I4
sg66304
VP06753
p77664
sg66306
VTrkA
p77665
sa(dp77666
g66301
I74
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTrkB
p77667
sa(dp77668
g66301
I65
sg66302
I1
sg66303
I4
sg66304
VP06753
p77669
sg66306
VTrkA
p77670
sa(dp77671
g66301
I74
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTrkB
p77672
sasg66311
(lp77673
(dp77674
g66301
I179
sg66302
I1
sg66303
I7
sg66314
VC0009319
p77675
sg66306
Vcolitis
p77676
sa(dp77677
g66301
I179
sg66302
I1
sg66303
I7
sg66314
VC0009319
p77678
sg66306
Vcolitis
p77679
sasa(dp77680
g66296
VIn colitis both the TrkA and TrkB protein levels were increased in the L1 and S1 DRGs in a time-dependent manner; however, the level of TrkB mRNA but not TrkA mRNA was increased in these DRGs.
p77681
sg66298
(lp77682
(dp77683
g66301
I29
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VTrkB protein
p77684
sa(dp77685
g66301
I154
sg66302
I2
sg66303
I9
sg66304
VP06753
p77686
sg66306
VTrkA mRNA
p77687
sa(dp77688
g66301
I136
sg66302
I2
sg66303
I9
sg66304
g11
sg66306
VTrkB mRNA
p77689
sa(dp77690
g66301
I20
sg66302
I1
sg66303
I4
sg66304
VP06753
p77691
sg66306
VTrkA
p77692
sa(dp77693
g66301
I78
sg66302
I2
sg66303
I7
sg66304
g11
sg66306
VS1 DRGs
p77694
sasg66311
(lp77695
(dp77696
g66301
I3
sg66302
I1
sg66303
I7
sg66314
VC0009319
p77697
sg66306
Vcolitis
p77698
sasa(dp77699
g66296
VFurther experiments showed that colitis facilitated a retrograde transport of TrkA protein toward and an anterograde transport of TrkA mRNA away from the DRG, which may contribute to the increased TrkA mRNA level in the distal colon during colitis.
p77700
sg66298
(lp77701
(dp77702
g66301
I130
sg66302
I2
sg66303
I9
sg66304
VP06753
p77703
sg66306
VTrkA mRNA
p77704
sa(dp77705
g66301
I130
sg66302
I2
sg66303
I9
sg66304
VP06753
p77706
sg66306
VTrkA mRNA
p77707
sa(dp77708
g66301
I78
sg66302
I2
sg66303
I12
sg66304
VP06753
p77709
sg66306
VTrkA protein
p77710
sasg66311
(lp77711
(dp77712
g66301
I32
sg66302
I1
sg66303
I7
sg66314
VC0009319
p77713
sg66306
Vcolitis
p77714
sa(dp77715
g66301
I32
sg66302
I1
sg66303
I7
sg66314
VC0009319
p77716
sg66306
Vcolitis
p77717
sasa(dp77718
g66296
VDouble staining showed that the expression of TrkA but not TrkB was increased in the specifically labeled colonic afferent neurons in the L1 and S1 DRGs during colitis; this increase in TrkA level was attenuated by pretreatment with resiniferatoxin.
p77719
sg66298
(lp77720
(dp77721
g66301
I46
sg66302
I1
sg66303
I4
sg66304
VP06753
p77722
sg66306
VTrkA
p77723
sa(dp77724
g66301
I145
sg66302
I2
sg66303
I7
sg66304
g11
sg66306
VS1 DRGs
p77725
sa(dp77726
g66301
I59
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTrkB
p77727
sa(dp77728
g66301
I46
sg66302
I1
sg66303
I4
sg66304
VP06753
p77729
sg66306
VTrkA
p77730
sasg66311
(lp77731
(dp77732
g66301
I160
sg66302
I1
sg66303
I7
sg66314
VC0009319
p77733
sg66306
Vcolitis
p77734
sasa(dp77735
g66296
VThese results suggested that colitis-induced primary afferent activation involved retrograde transport of TrkA but not TrkB from the distal colon to primary afferent neurons in DRG.
p77736
sg66298
(lp77737
(dp77738
g66301
I106
sg66302
I1
sg66303
I4
sg66304
VP06753
p77739
sg66306
VTrkA
p77740
sa(dp77741
g66301
I119
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTrkB
p77742
sasg66311
(lp77743
(dp77744
g66301
I29
sg66302
I1
sg66303
I7
sg66314
VC0009319
p77745
sg66306
Vcolitis
p77746
sasa(dp77747
g66296
VIn fact, receptor rearrangements or point mutations convert RET and NTRK1 in dominantly acting transforming genes leading to thyroid tumors, whereas inactivating mutations, associated with Hirschsprung's disease (HSCR) and congenital insensitivity to pain with anhidrosis (CIPA), impair RET and NTRK1 functions, respectively.
p77748
sg66298
(lp77749
(dp77750
g66301
I60
sg66302
I1
sg66303
I3
sg66304
VP07949
p77751
sg66306
VRET
p77752
sa(dp77753
g66301
I60
sg66302
I1
sg66303
I3
sg66304
VP07949
p77754
sg66306
VRET
p77755
sa(dp77756
g66301
I189
sg66302
I2
sg66303
I22
sg66304
VP14138
p77757
sg66306
VHirschsprung's disease
p77758
sa(dp77759
g66301
I213
sg66302
I1
sg66303
I4
sg66304
VP14138
p77760
sg66306
VHSCR
p77761
sasg66311
(lp77762
(dp77763
g66301
I223
sg66302
I6
sg66303
I48
sg66314
VC0020074
p77764
sg66306
Vcongenital insensitivity to pain with anhidrosis
p77765
sa(dp77766
g66301
I189
sg66302
I2
sg66303
I22
sg66314
VC0019569
p77767
sg66306
VHirschsprung's disease
p77768
sa(dp77769
g66301
I125
sg66302
I2
sg66303
I14
sg66314
VC0040136
p77770
sg66306
Vthyroid tumors
p77771
sa(dp77772
g66301
I213
sg66302
I1
sg66303
I4
sg66314
VC2931876
p77773
sg66306
VHSCR
p77774
sa(dp77775
g66301
I273
sg66302
I1
sg66303
I4
sg66314
VC0020074
p77776
sg66306
VCIPA
p77777
sasa(dp77778
g66296
VThus, our results corroborate that therapeutic strategies based on the modulation of CCR1/CCR5-mediated cell migration and/or effector function may contribute to cardiac tissue damage limitation during chronic Chagas disease.
p77779
sg66298
(lp77780
(dp77781
g66301
I85
sg66302
I1
sg66303
I4
sg66304
VP32246
p77782
sg66306
VCCR1
p77783
sa(dp77784
g66301
I90
sg66302
I1
sg66303
I4
sg66304
VP32302
p77785
sg66306
VCCR5
p77786
sasg66311
(lp77787
(dp77788
g66301
I210
sg66302
I2
sg66303
I14
sg66314
VC0041234
p77789
sg66306
VChagas disease
p77790
sasa(dp77791
g66296
VThe results of integrated analysis explored 3 OA-related pathways (rheumatoid arthritis, osteoclast differentiation and ECM-receptor interaction) and 4 candidate genes of OA (BST2, HDAC4, ITGB2 and VCAM1) that may be therapeutic targets.
p77792
sg66298
(lp77793
(dp77794
g66301
I188
sg66302
I1
sg66303
I5
sg66304
VP05107
p77795
sg66306
VITGB2
p77796
sa(dp77797
g66301
I175
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VBST2
p77798
sa(dp77799
g66301
I198
sg66302
I1
sg66303
I5
sg66304
VP19320
p77800
sg66306
VVCAM1
p77801
sa(dp77802
g66301
I120
sg66302
I1
sg66303
I12
sg66304
g11
sg66306
VECM-receptor
p77803
sa(dp77804
g66301
I181
sg66302
I1
sg66303
I5
sg66304
VP56524
p77805
sg66306
VHDAC4
p77806
sasg66311
(lp77807
(dp77808
g66301
I67
sg66302
I2
sg66303
I20
sg66314
VC0003873
p77809
sg66306
Vrheumatoid arthritis
p77810
sasa(dp77811
g66296
VThe patient showed moderate expression of CD18 in neutrophils with a homozygous splice mutation with c.41_c.58+2dup20 of ITGB2 and experienced recurrent severe infections complicated with systemic lupus erythematosus.
p77812
sg66298
(lp77813
(dp77814
g66301
I101
sg66302
I3
sg66303
I25
sg66304
VP05107
p77815
sg66306
Vc.41_c.58+2dup20 of ITGB2
p77816
sa(dp77817
g66301
I42
sg66302
I1
sg66303
I4
sg66304
VP05107
p77818
sg66306
VCD18
p77819
sasg66311
(lp77820
(dp77821
g66301
I188
sg66302
I3
sg66303
I28
sg66314
VC0024141
p77822
sg66306
Vsystemic lupus erythematosus
p77823
sa(dp77824
g66301
I160
sg66302
I1
sg66303
I10
sg66314
VC0021311
p77825
sg66306
Vinfections
p77826
sasa(dp77827
g66296
VShe received hematopoietic stem cell transplantation from a matched elder brother with heterozygous mutation of ITGB2, and has since remained free of infection and systemic lupus erythematosus symptoms without immunosuppression therapy.
p77828
sg66298
(lp77829
(dp77830
g66301
I100
sg66302
I3
sg66303
I17
sg66304
VP05107
p77831
sg66306
Vmutation of ITGB2
p77832
sasg66311
(lp77833
(dp77834
g66301
I150
sg66302
I1
sg66303
I9
sg66314
VC0009450
p77835
sg66306
Vinfection
p77836
sa(dp77837
g66301
I164
sg66302
I3
sg66303
I28
sg66314
VC0024141
p77838
sg66306
Vsystemic lupus erythematosus
p77839
sasa(dp77840
g66296
VUsing mice deficient in all beta2 integrins (CD18 null mice), we demonstrate that expression of these heterodimeric adhesion molecules is critical for arthritis induction in the K/B x N serum transfer model.
p77841
sg66298
(lp77842
(dp77843
g66301
I45
sg66302
I2
sg66303
I9
sg66304
VP05107
p77844
sg66306
VCD18 null
p77845
sa(dp77846
g66301
I102
sg66302
I3
sg66303
I32
sg66304
VP01185
p77847
sg66306
Vheterodimeric adhesion molecules
p77848
sasg66311
(lp77849
(dp77850
g66301
I151
sg66302
I1
sg66303
I9
sg66314
VC0003864
p77851
sg66306
Varthritis
p77852
sa(dp77853
g66301
I116
sg66302
I1
sg66303
I8
sg66314
VC0001511
p77854
sg66306
Vadhesion
p77855
sasa(dp77856
g66296
VUsing null-allele mice and blocking mAbs, we demonstrate specifically that CD11a/CD18 (LFA-1) is absolutely required for the development of arthritis in this model.
p77857
sg66298
(lp77858
(dp77859
g66301
I87
sg66302
I1
sg66303
I5
sg66304
VP20701
p77860
sg66306
VLFA-1
p77861
sa(dp77862
g66301
I81
sg66302
I1
sg66303
I4
sg66304
VP05107
p77863
sg66306
VCD18
p77864
sa(dp77865
g66301
I75
sg66302
I1
sg66303
I5
sg66304
VP20701
p77866
sg66306
VCD11a
p77867
sasg66311
(lp77868
(dp77869
g66301
I27
sg66302
I1
sg66303
I8
sg66314
VC0233660
p77870
sg66306
Vblocking
p77871
sa(dp77872
g66301
I140
sg66302
I1
sg66303
I9
sg66314
VC0003864
p77873
sg66306
Varthritis
p77874
sasa(dp77875
g66296
VThus, key proteins in Alzheimer Disease and Amyotrophic lateral sclerosis (ALS), including amyloid-Beta precursor protein, Tau and superoxide dismutase 1 (SOD1), spread to adjacent cells in their misfolded aggregated forms and exhibit template-directed misfolding to induce further misfolding, disruptions to proteostasis and toxicity.
p77876
sg66298
(lp77877
(dp77878
g66301
I155
sg66302
I1
sg66303
I4
sg66304
VP00441
p77879
sg66306
VSOD1
p77880
sa(dp77881
g66301
I91
sg66302
I3
sg66303
I30
sg66304
VP17342
p77882
sg66306
Vamyloid-Beta precursor protein
p77883
sa(dp77884
g66301
I131
sg66302
I3
sg66303
I22
sg66304
VP00441
p77885
sg66306
Vsuperoxide dismutase 1
p77886
sa(dp77887
g66301
I123
sg66302
I1
sg66303
I3
sg66304
VP49768
p77888
sg66306
VTau
p77889
sasg66311
(lp77890
(dp77891
g66301
I44
sg66302
I3
sg66303
I29
sg66314
VC0002736
p77892
sg66306
VAmyotrophic lateral sclerosis
p77893
sa(dp77894
g66301
I75
sg66302
I1
sg66303
I3
sg66314
VC0002736
p77895
sg66306
VALS
p77896
sa(dp77897
g66301
I22
sg66302
I2
sg66303
I17
sg66314
VC0002395
p77898
sg66306
VAlzheimer Disease
p77899
sa(dp77900
g66301
I91
sg66302
I1
sg66303
I7
sg66314
VC0011560
p77901
sg66306
Vamyloid
p77902
sasa(dp77903
g66296
VThe method is useful for identifying the defective APP-mRNA isoform in LND patients, and in neurodevelopmental and neurodegenerative disorders in which the APP gene is involved in the pathogenesis of diseases such as autism, fragile X syndrome, amyotrophic lateral sclerosis, and Alzheimer's disease, and may pave the way for new strategies applicable to rational antisense drugs design.
p77904
sg66298
(lp77905
(dp77906
g66301
I156
sg66302
I2
sg66303
I8
sg66304
g11
sg66306
VAPP gene
p77907
sa(dp77908
g66301
I51
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VAPP-mRNA
p77909
sasg66311
(lp77910
(dp77911
g66301
I245
sg66302
I3
sg66303
I29
sg66314
VC0002736
p77912
sg66306
Vamyotrophic lateral sclerosis
p77913
sa(dp77914
g66301
I184
sg66302
I1
sg66303
I12
sg66314
VC0699748
p77915
sg66306
Vpathogenesis
p77916
sa(dp77917
g66301
I225
sg66302
I3
sg66303
I18
sg66314
VC0016667
p77918
sg66306
Vfragile X syndrome
p77919
sa(dp77920
g66301
I280
sg66302
I2
sg66303
I19
sg66314
VC1521724
p77921
sg66306
VAlzheimer's disease
p77922
sa(dp77923
g66301
I217
sg66302
I1
sg66303
I6
sg66314
VC0004352
p77924
sg66306
Vautism
p77925
sa(dp77926
g66301
I115
sg66302
I2
sg66303
I27
sg66314
VC0524851
p77927
sg66306
Vneurodegenerative disorders
p77928
sasa(dp77929
g66296
VSeveral findings suggest that the amyloid precursor protein (APP) and the amyloid cascade may play a role in motor neuron disease (MND).
p77930
sg66298
(lp77931
(dp77932
g66301
I34
sg66302
I3
sg66303
I25
sg66304
VP17342
p77933
sg66306
Vamyloid precursor protein
p77934
sa(dp77935
g66301
I61
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VAPP
p77936
sasg66311
(lp77937
(dp77938
g66301
I131
sg66302
I1
sg66303
I3
sg66314
VC0085084
p77939
sg66306
VMND
p77940
sa(dp77941
g66301
I34
sg66302
I1
sg66303
I7
sg66314
VC0011560
p77942
sg66306
Vamyloid
p77943
sa(dp77944
g66301
I109
sg66302
I3
sg66303
I20
sg66314
VC0085084
p77945
sg66306
Vmotor neuron disease
p77946
sa(dp77947
g66301
I34
sg66302
I1
sg66303
I7
sg66314
VC0011560
p77948
sg66306
Vamyloid
p77949
sasa(dp77950
g66296
VConsidering that dementia is one of the most frequent non-motor symptoms in amyotrophic lateral sclerosis (ALS) and that hippocampus is one of the brain areas with greater presence of amyloid-related changes in neurodegenerative diseases, our aim was to analyze the molecular markers of the amyloid cascade of APP in pathology studies of the hippocampus of autopsied patients with ALS and ALS-frontotemporal dementia (FTD).
p77951
sg66298
(lp77952
sg66311
(lp77953
(dp77954
g66301
I76
sg66302
I3
sg66303
I29
sg66314
VC0002736
p77955
sg66306
Vamyotrophic lateral sclerosis
p77956
sa(dp77957
g66301
I184
sg66302
I1
sg66303
I7
sg66314
VC0011560
p77958
sg66306
Vamyloid
p77959
sa(dp77960
g66301
I17
sg66302
I1
sg66303
I8
sg66314
VC0497327
p77961
sg66306
Vdementia
p77962
sa(dp77963
g66301
I107
sg66302
I1
sg66303
I3
sg66314
VC0002736
p77964
sg66306
VALS
p77965
sa(dp77966
g66301
I58
sg66302
I2
sg66303
I14
sg66314
VC0426980
p77967
sg66306
Vmotor symptoms
p77968
sa(dp77969
g66301
I389
sg66302
I2
sg66303
I27
sg66314
VC0338451
p77970
sg66306
VALS-frontotemporal dementia
p77971
sa(dp77972
g66301
I418
sg66302
I1
sg66303
I3
sg66314
VC0338451
p77973
sg66306
VFTD
p77974
sa(dp77975
g66301
I184
sg66302
I1
sg66303
I7
sg66314
VC0011560
p77976
sg66306
Vamyloid
p77977
sa(dp77978
g66301
I317
sg66302
I1
sg66303
I9
sg66314
VC0677042
p77979
sg66306
Vpathology
p77980
sa(dp77981
g66301
I211
sg66302
I2
sg66303
I26
sg66314
VC0524851
p77982
sg66306
Vneurodegenerative diseases
p77983
sa(dp77984
g66301
I107
sg66302
I1
sg66303
I3
sg66314
VC0002736
p77985
sg66306
VALS
p77986
sasa(dp77987
g66296
VImmunohistochemical studies and confocal microscopy were used to analyze the expression of APP, TDP-43, pho-TDP-43, ABeta, APP intracellular cytoplasmatic domain (AICD) peptide, Fe65 protein, and pho-TAU in the hippocampus of seven patients with ALS, two patients with ALS-FTD, and four controls.
p77988
sg66298
(lp77989
(dp77990
g66301
I104
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
Vpho-TDP-43
p77991
sa(dp77992
g66301
I196
sg66302
I1
sg66303
I7
sg66304
VP49768
p77993
sg66306
Vpho-TAU
p77994
sa(dp77995
g66301
I91
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VAPP
p77996
sa(dp77997
g66301
I141
sg66302
I4
sg66303
I35
sg66304
g11
sg66306
Vcytoplasmatic domain (AICD) peptide
p77998
sa(dp77999
g66301
I91
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VAPP
p78000
sa(dp78001
g66301
I178
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VFe65 protein
p78002
sa(dp78003
g66301
I96
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VTDP-43
p78004
sa(dp78005
g66301
I116
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VABeta
p78006
sasg66311
(lp78007
(dp78008
g66301
I273
sg66302
I1
sg66303
I3
sg66314
VC0338451
p78009
sg66306
VFTD
p78010
sa(dp78011
g66301
I246
sg66302
I1
sg66303
I3
sg66314
VC0002736
p78012
sg66306
VALS
p78013
sa(dp78014
g66301
I246
sg66302
I1
sg66303
I3
sg66314
VC0002736
p78015
sg66306
VALS
p78016
sasa(dp78017
g66296
VThese results suggest that Sidt2(-/-) mice had spontaneous nonalcoholic fatty liver disease (NAFLD) accompanied by ERS.
p78018
sg66298
(lp78019
sg66311
(lp78020
(dp78021
g66301
I115
sg66302
I1
sg66303
I3
sg66314
VC0403549
p78022
sg66306
VERS
p78023
sa(dp78024
g66301
I59
sg66302
I4
sg66303
I32
sg66314
VC0400966
p78025
sg66306
Vnonalcoholic fatty liver disease
p78026
sa(dp78027
g66301
I93
sg66302
I1
sg66303
I5
sg66314
VC0400966
p78028
sg66306
VNAFLD
p78029
sasa(dp78030
g66296
VIntraperitoneal and oral glucose tolerance tests in Sidt2 knockout mice indicated glucose intolerance and decreased serum insulin level.
p78031
sg66298
(lp78032
(dp78033
g66301
I116
sg66302
I2
sg66303
I13
sg66304
VP01308
p78034
sg66306
Vserum insulin
p78035
sasg66311
(lp78036
(dp78037
g66301
I33
sg66302
I1
sg66303
I9
sg66314
VC0020963
p78038
sg66306
Vtolerance
p78039
sa(dp78040
g66301
I82
sg66302
I2
sg66303
I19
sg66314
VC0271650
p78041
sg66306
Vglucose intolerance
p78042
sasa(dp78043
g66296
VFor example, CDH15 and PCDH19 are associated with cognitive impairment; CDH5, CDH8, CDH9, CDH10, CDH13, CDH15, PCDH10, PCDH19 and PCDHb4 with autism; CDH7, CDH12, CDH18, PCDH12 and FAT with bipolar disease and schizophrenia; and CDH11, CDH12 and CDH13 with methamphetamine and alcohol dependency.
p78044
sg66298
(lp78045
(dp78046
g66301
I13
sg66302
I1
sg66303
I5
sg66304
VP55291
p78047
sg66306
VCDH15
p78048
sa(dp78049
g66301
I90
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCDH10
p78050
sa(dp78051
g66301
I78
sg66302
I1
sg66303
I4
sg66304
VP55286
p78052
sg66306
VCDH8
p78053
sa(dp78054
g66301
I130
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VPCDHb4
p78055
sa(dp78056
g66301
I229
sg66302
I1
sg66303
I5
sg66304
VP55287
p78057
sg66306
VCDH11
p78058
sa(dp78059
g66301
I156
sg66302
I1
sg66303
I5
sg66304
VP55289
p78060
sg66306
VCDH12
p78061
sa(dp78062
g66301
I156
sg66302
I1
sg66303
I5
sg66304
VP55289
p78063
sg66306
VCDH12
p78064
sa(dp78065
g66301
I163
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCDH18
p78066
sa(dp78067
g66301
I23
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VPCDH19
p78068
sa(dp78069
g66301
I170
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VPCDH12
p78070
sa(dp78071
g66301
I97
sg66302
I1
sg66303
I5
sg66304
VP55290
p78072
sg66306
VCDH13
p78073
sa(dp78074
g66301
I23
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VPCDH19
p78075
sa(dp78076
g66301
I72
sg66302
I1
sg66303
I4
sg66304
VP33151
p78077
sg66306
VCDH5
p78078
sa(dp78079
g66301
I150
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VCDH7
p78080
sa(dp78081
g66301
I97
sg66302
I1
sg66303
I5
sg66304
VP55290
p78082
sg66306
VCDH13
p78083
sa(dp78084
g66301
I84
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VCDH9
p78085
sa(dp78086
g66301
I111
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VPCDH10
p78087
sa(dp78088
g66301
I13
sg66302
I1
sg66303
I5
sg66304
VP55291
p78089
sg66306
VCDH15
p78090
sasg66311
(lp78091
(dp78092
g66301
I142
sg66302
I1
sg66303
I6
sg66314
VC0004352
p78093
sg66306
Vautism
p78094
sa(dp78095
g66301
I277
sg66302
I2
sg66303
I18
sg66314
VC0001973
p78096
sg66306
Valcohol dependency
p78097
sa(dp78098
g66301
I50
sg66302
I2
sg66303
I20
sg66314
VC0338656
p78099
sg66306
Vcognitive impairment
p78100
sa(dp78101
g66301
I210
sg66302
I1
sg66303
I13
sg66314
VC0036341
p78102
sg66306
Vschizophrenia
p78103
sasa(dp78104
g66296
VThe UCNs emitting UV/blue and green/red multiband light were used to activate the photoresponsive Azo and photosensitizer RB molecules; The mesoporous silica shell offered the possibilities to load anticancer drug and conjugate the light triggers; As there are strong charge interaction and hydrogen bonds between Dox and surface silanols of mesoporous silica, the azobenzene molecules worked as "gatekeeper" and "molecular stirrer" to precisely trap and propel the release of Dox under the external stimuli.
p78105
sg66298
(lp78106
sg66311
(lp78107
sa(dp78108
g66296
VUCN1 is significantly reduced in endometrial adenocarcinoma compared to healthy controls.
p78109
sg66298
(lp78110
(dp78111
g66301
I0
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VUCN1
p78112
sasg66311
(lp78113
(dp78114
g66301
I33
sg66302
I2
sg66303
I26
sg66314
VC1153706
p78115
sg66306
Vendometrial adenocarcinoma
p78116
sasa(dp78117
g66296
VUCN1 suppressed migration of endometrial cancer cells in vitro.
p78118
sg66298
(lp78119
sg66311
(lp78120
(dp78121
g66301
I29
sg66302
I2
sg66303
I18
sg66314
VC0476089
p78122
sg66306
Vendometrial cancer
p78123
sasa(dp78124
g66296
VWe demonstrate that UCN1 significantly suppresses the migration of endometrial cancer cells but has no effect on their proliferation.
p78125
sg66298
(lp78126
(dp78127
g66301
I20
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VUCN1
p78128
sasg66311
(lp78129
(dp78130
g66301
I119
sg66302
I1
sg66303
I13
sg66314
VC0334094
p78131
sg66306
Vproliferation
p78132
sa(dp78133
g66301
I67
sg66302
I2
sg66303
I18
sg66314
VC0476089
p78134
sg66306
Vendometrial cancer
p78135
sasa(dp78136
g66296
VThus, loss of UCN1 in endometrial cancer may promote invasion and metastatic spread.
p78137
sg66298
(lp78138
(dp78139
g66301
I14
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VUCN1
p78140
sasg66311
(lp78141
(dp78142
g66301
I53
sg66302
I1
sg66303
I8
sg66314
VC2699153
p78143
sg66306
Vinvasion
p78144
sa(dp78145
g66301
I22
sg66302
I2
sg66303
I18
sg66314
VC0476089
p78146
sg66306
Vendometrial cancer
p78147
sasa(dp78148
g66296
VSeven pathogenic variants leading to NSHL have so far been reported on two mitochondrial genes: MT-RNR1 encoding 12SrRNA and MT-TS1 encoding tRNA for Ser((UCN)) .
p78149
sg66298
(lp78150
(dp78151
g66301
I96
sg66302
I3
sg66303
I24
sg66304
VP43354
p78152
sg66306
VMT-RNR1 encoding 12SrRNA
p78153
sasg66311
(lp78154
sa(dp78155
g66296
VThis study examines the role of FcgammaRIIB in the initiation of allergic rhinitis in mice.
p78156
sg66298
(lp78157
(dp78158
g66301
I32
sg66302
I1
sg66303
I11
sg66304
VP31994
p78159
sg66306
VFcgammaRIIB
p78160
sasg66311
(lp78161
(dp78162
g66301
I65
sg66302
I2
sg66303
I17
sg66314
VC2607914
p78163
sg66306
Vallergic rhinitis
p78164
sasa(dp78165
g66296
VThese results suggest that FcgammaRIIB plays a regulatory role in the initiation of allergic rhinitis that is independent of either mouse strain or type of sensitization.
p78166
sg66298
(lp78167
(dp78168
g66301
I27
sg66302
I1
sg66303
I11
sg66304
VP31994
p78169
sg66306
VFcgammaRIIB
p78170
sasg66311
(lp78171
(dp78172
g66301
I84
sg66302
I2
sg66303
I17
sg66314
VC2607914
p78173
sg66306
Vallergic rhinitis
p78174
sasa(dp78175
g66296
VThis study evaluated the interaction of radiation therapy (RT) and radiofrequency kyphoplasty (RFK) in the treatment of myeloma associated VCF.
p78176
sg66298
(lp78177
sg66311
(lp78178
(dp78179
g66301
I120
sg66302
I1
sg66303
I7
sg66314
VC0026764
p78180
sg66306
Vmyeloma
p78181
sasa(dp78182
g66296
VEighty-six myeloma patients with VCF were treated with RFK followed by radiation therapy (RFK group) or vice versa (RT group).
p78183
sg66298
(lp78184
sg66311
(lp78185
(dp78186
g66301
I11
sg66302
I1
sg66303
I7
sg66314
VC0026764
p78187
sg66306
Vmyeloma
p78188
sasa(dp78189
g66296
VRFK is an effective method for treating VCF in myeloma patients independent of treatment order with regard to radiation therapy.
p78190
sg66298
(lp78191
(dp78192
g66301
I0
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VRFK
p78193
sasg66311
(lp78194
(dp78195
g66301
I47
sg66302
I1
sg66303
I7
sg66314
VC0026764
p78196
sg66306
Vmyeloma
p78197
sasa(dp78198
g66296
VWe investigated the involvement of RFK in cisplatin resistance using human prostate cancer PC3 cells.
p78199
sg66298
(lp78200
(dp78201
g66301
I35
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VRFK
p78202
sasg66311
(lp78203
(dp78204
g66301
I75
sg66302
I2
sg66303
I15
sg66314
VC0600139
p78205
sg66306
Vprostate cancer
p78206
sasa(dp78207
g66296
VThe present study suggests that RFK expression is involved not only in cellular protection from oxidative stress but also in malignant progression of prostate cancer.
p78208
sg66298
(lp78209
(dp78210
g66301
I32
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VRFK
p78211
sasg66311
(lp78212
(dp78213
g66301
I135
sg66302
I4
sg66303
I30
sg66314
VC1739135
p78214
sg66306
Vprogression of prostate cancer
p78215
sa(dp78216
g66301
I96
sg66302
I2
sg66303
I16
sg66314
VC0242606
p78217
sg66306
Voxidative stress
p78218
sasa(dp78219
g66296
VThe anti-cancer effect of ATF-Fc (alone and in combination with trastuzumab) on tumor cells and in a nude mouse tumor model was evaluated by detecting the expression of uPA, urokinase plasminogen activator receptor (uPAR) and HER-2.
p78220
sg66298
(lp78221
(dp78222
g66301
I169
sg66302
I1
sg66303
I3
sg66304
VP00749
p78223
sg66306
VuPA
p78224
sa(dp78225
g66301
I226
sg66302
I1
sg66303
I5
sg66304
VP04626
p78226
sg66306
VHER-2
p78227
sa(dp78228
g66301
I174
sg66302
I4
sg66303
I40
sg66304
VP00747
p78229
sg66306
Vurokinase plasminogen activator receptor
p78230
sa(dp78231
g66301
I216
sg66302
I1
sg66303
I4
sg66304
VP00747
p78232
sg66306
VuPAR
p78233
sa(dp78234
g66301
I26
sg66302
I1
sg66303
I3
sg66304
VP00749
p78235
sg66306
VATF
p78236
sasg66311
(lp78237
(dp78238
g66301
I80
sg66302
I1
sg66303
I5
sg66314
VC0027651
p78239
sg66306
Vtumor
p78240
sa(dp78241
g66301
I80
sg66302
I1
sg66303
I5
sg66314
VC0027651
p78242
sg66306
Vtumor
p78243
sa(dp78244
g66301
I9
sg66302
I1
sg66303
I6
sg66314
VC0006826
p78245
sg66306
Vcancer
p78246
sasa(dp78247
g66296
VThe ability of HMGA1 to regulate the plasminogen activator system may constitute an important mechanism by which HMGA1 promotes cancer progression.
p78248
sg66298
(lp78249
(dp78250
g66301
I15
sg66302
I1
sg66303
I5
sg66304
VP17096
p78251
sg66306
VHMGA1
p78252
sa(dp78253
g66301
I15
sg66302
I1
sg66303
I5
sg66304
VP17096
p78254
sg66306
VHMGA1
p78255
sa(dp78256
g66301
I37
sg66302
I3
sg66303
I28
sg66304
VP00747
p78257
sg66306
Vplasminogen activator system
p78258
sasg66311
(lp78259
(dp78260
g66301
I128
sg66302
I2
sg66303
I18
sg66314
VC0178874
p78261
sg66306
Vcancer progression
p78262
sasa(dp78263
g66296
VKCNJ1 variation is associated with multiple diseases, such as antenatal Bartter syndrome and diabetes.
p78264
sg66298
(lp78265
(dp78266
g66301
I0
sg66302
I1
sg66303
I5
sg66304
VP48048
p78267
sg66306
VKCNJ1
p78268
sasg66311
(lp78269
(dp78270
g66301
I72
sg66302
I2
sg66303
I16
sg66314
VC0004775
p78271
sg66306
VBartter syndrome
p78272
sa(dp78273
g66301
I93
sg66302
I1
sg66303
I8
sg66314
VC0011849
p78274
sg66306
Vdiabetes
p78275
sasa(dp78276
g66296
VNeither diabetes mellitus nor Tempol altered Kir1.1, Kir2.1, Kir6.1, or SUR2B protein levels in renal cortical microvessels.
p78277
sg66298
(lp78278
(dp78279
g66301
I53
sg66302
I1
sg66303
I6
sg66304
VP63252
p78280
sg66306
VKir2.1
p78281
sa(dp78282
g66301
I72
sg66302
I2
sg66303
I13
sg66304
g11
sg66306
VSUR2B protein
p78283
sa(dp78284
g66301
I61
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VKir6.1
p78285
sa(dp78286
g66301
I45
sg66302
I1
sg66303
I6
sg66304
VP48048
p78287
sg66306
VKir1.1
p78288
sasg66311
(lp78289
(dp78290
g66301
I8
sg66302
I2
sg66303
I17
sg66314
VC0011849
p78291
sg66306
Vdiabetes mellitus
p78292
sasa(dp78293
g66296
VTo the extent that the effects of Tempol reflect its antioxidant actions, our observations indicate that oxidative stress contributes to the exaggerated impact of Kir1.1, Kir2.1, and K(ATP) channels on afferent arteriolar tone during diabetes mellitus and that this phenomenon involves posttranslational modulation of channel function.
p78294
sg66298
(lp78295
(dp78296
g66301
I171
sg66302
I1
sg66303
I6
sg66304
VP63252
p78297
sg66306
VKir2.1
p78298
sa(dp78299
g66301
I163
sg66302
I1
sg66303
I6
sg66304
VP48048
p78300
sg66306
VKir1.1
p78301
sasg66311
(lp78302
(dp78303
g66301
I234
sg66302
I2
sg66303
I17
sg66314
VC0011849
p78304
sg66306
Vdiabetes mellitus
p78305
sa(dp78306
g66301
I105
sg66302
I2
sg66303
I16
sg66314
VC0242606
p78307
sg66306
Voxidative stress
p78308
sasa(dp78309
g66296
VFurthermore, results suggested that co-exposure exacerbated the activation of TRPV1 signal pathways, with an enhancement in substance P and calcitonin gene-related peptide production, which contributed to inflammation in asthma by neurogenic inflammation.
p78310
sg66298
(lp78311
(dp78312
g66301
I140
sg66302
I2
sg66303
I15
sg66304
VP06881
p78313
sg66306
Vcalcitonin gene
p78314
sa(dp78315
g66301
I78
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTRPV1
p78316
sasg66311
(lp78317
(dp78318
g66301
I221
sg66302
I1
sg66303
I6
sg66314
VC0004096
p78319
sg66306
Vasthma
p78320
sa(dp78321
g66301
I205
sg66302
I1
sg66303
I12
sg66314
VC0021368
p78322
sg66306
Vinflammation
p78323
sa(dp78324
g66301
I205
sg66302
I1
sg66303
I12
sg66314
VC0021368
p78325
sg66306
Vinflammation
p78326
sasa(dp78327
g66296
VIt is concluded that co-exposure to PM2.5 and FA exacerbated allergic asthma through oxidative stress and enhanced TRPV1 activation.
p78328
sg66298
(lp78329
(dp78330
g66301
I115
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTRPV1
p78331
sasg66311
(lp78332
(dp78333
g66301
I85
sg66302
I2
sg66303
I16
sg66314
VC0242606
p78334
sg66306
Voxidative stress
p78335
sa(dp78336
g66301
I61
sg66302
I2
sg66303
I15
sg66314
VC0155877
p78337
sg66306
Vallergic asthma
p78338
sasa(dp78339
g66296
VIn this review we will summarize recent evidence for an involvement of TRP channels (TRPA1, TRPC4, TRPC6, TRPV1, TRPV4, TRPM2 and TRPM8) expressed in the lung in pathways of toxin sensing and as mediators of lung inflammation and associated diseases like asthma, COPD, lung fibrosis and edema formation.
p78340
sg66298
(lp78341
(dp78342
g66301
I71
sg66302
I2
sg66303
I12
sg66304
VP13686
p78343
sg66306
VTRP channels
p78344
sa(dp78345
g66301
I120
sg66302
I1
sg66303
I5
sg66304
VP10909
p78346
sg66306
VTRPM2
p78347
sa(dp78348
g66301
I130
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTRPM8
p78349
sa(dp78350
g66301
I99
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTRPC6
p78351
sa(dp78352
g66301
I92
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTRPC4
p78353
sa(dp78354
g66301
I106
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTRPV1
p78355
sa(dp78356
g66301
I85
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTRPA1
p78357
sasg66311
(lp78358
(dp78359
g66301
I208
sg66302
I2
sg66303
I17
sg66314
VC0032285
p78360
sg66306
Vlung inflammation
p78361
sa(dp78362
g66301
I255
sg66302
I1
sg66303
I6
sg66314
VC0004096
p78363
sg66306
Vasthma
p78364
sa(dp78365
g66301
I263
sg66302
I1
sg66303
I4
sg66314
VC0024117
p78366
sg66306
VCOPD
p78367
sa(dp78368
g66301
I287
sg66302
I1
sg66303
I5
sg66314
VC0013604
p78369
sg66306
Vedema
p78370
sa(dp78371
g66301
I269
sg66302
I2
sg66303
I13
sg66314
VC0034069
p78372
sg66306
Vlung fibrosis
p78373
sasa(dp78374
g66296
VOur purpose was to investigate the regulatory mechanism of TRPV1 and related cytokines on children bronchial asthma.
p78375
sg66298
(lp78376
(dp78377
g66301
I59
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTRPV1
p78378
sasg66311
(lp78379
(dp78380
g66301
I99
sg66302
I2
sg66303
I16
sg66314
VC0004096
p78381
sg66306
Vbronchial asthma
p78382
sasa(dp78383
g66296
VLogistic regression analysis further demonstrated that TRPV1 mRNA level, EOS, IL-4 and IL-5 may be risk factors for children bronchial asthma.
p78384
sg66298
(lp78385
(dp78386
g66301
I78
sg66302
I1
sg66303
I4
sg66304
VP05112
p78387
sg66306
VIL-4
p78388
sa(dp78389
g66301
I87
sg66302
I1
sg66303
I4
sg66304
VP05113
p78390
sg66306
VIL-5
p78391
sa(dp78392
g66301
I55
sg66302
I2
sg66303
I10
sg66304
g11
sg66306
VTRPV1 mRNA
p78393
sa(dp78394
g66301
I73
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VEOS
p78395
sasg66311
(lp78396
(dp78397
g66301
I125
sg66302
I2
sg66303
I16
sg66314
VC0004096
p78398
sg66306
Vbronchial asthma
p78399
sa(dp78400
g66301
I73
sg66302
I1
sg66303
I3
sg66314
VC1836122
p78401
sg66306
VEOS
p78402
sasa(dp78403
g66296
VThe preliminary regulatory network of TRPV1 and related cytokines on children bronchial asthma established in this study provides certain theoretical basis for pathogenesis and treatment of children bronchial asthma.
p78404
sg66298
(lp78405
(dp78406
g66301
I38
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTRPV1
p78407
sasg66311
(lp78408
(dp78409
g66301
I78
sg66302
I2
sg66303
I16
sg66314
VC0004096
p78410
sg66306
Vbronchial asthma
p78411
sa(dp78412
g66301
I160
sg66302
I1
sg66303
I12
sg66314
VC0699748
p78413
sg66306
Vpathogenesis
p78414
sa(dp78415
g66301
I78
sg66302
I2
sg66303
I16
sg66314
VC0004096
p78416
sg66306
Vbronchial asthma
p78417
sasa(dp78418
g66296
Voleoylethanolamide, sphingosine-1-phosphate, N-palmitoyltaurine) were postulated to be involved in activating the transient receptor potential vanilloid type 1 (TRPV1) receptor, driving TRPV1-dependent pathogenesis in asthma.Our findings suggest that asthma is characterised by a modest systemic metabolic shift in a disease severity-dependent manner, and that steroid treatment significantly affects metabolism.
p78419
sg66298
(lp78420
(dp78421
g66301
I161
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTRPV1
p78422
sa(dp78423
g66301
I114
sg66302
I8
sg66303
I62
sg66304
g11
sg66306
Vtransient receptor potential vanilloid type 1 (TRPV1) receptor
p78424
sasg66311
(lp78425
(dp78426
g66301
I218
sg66302
I1
sg66303
I6
sg66314
VC0004096
p78427
sg66306
Vasthma
p78428
sa(dp78429
g66301
I218
sg66302
I1
sg66303
I6
sg66314
VC0004096
p78430
sg66306
Vasthma
p78431
sa(dp78432
g66301
I202
sg66302
I1
sg66303
I12
sg66314
VC0699748
p78433
sg66306
Vpathogenesis
p78434
sasa(dp78435
g66296
VTo investigate the effects of particulate matter &lt;= 2.5 microns (PM2.5) on asthma-related phenotypes and on lung expression of TRPA1 and TRPV1 proteins in a mouse model of asthma.
p78436
sg66298
(lp78437
(dp78438
g66301
I140
sg66302
I2
sg66303
I14
sg66304
g11
sg66306
VTRPV1 proteins
p78439
sa(dp78440
g66301
I130
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTRPA1
p78441
sasg66311
(lp78442
(dp78443
g66301
I78
sg66302
I1
sg66303
I6
sg66314
VC0004096
p78444
sg66306
Vasthma
p78445
sa(dp78446
g66301
I78
sg66302
I1
sg66303
I6
sg66314
VC0004096
p78447
sg66306
Vasthma
p78448
sasa(dp78449
g66296
VPM2.5 exacerbates effects of asthma in this model, possibly by regulating TRPA1 and TRPV1 and the relevant neurokines.
p78450
sg66298
(lp78451
(dp78452
g66301
I74
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTRPA1
p78453
sa(dp78454
g66301
I84
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VTRPV1
p78455
sasg66311
(lp78456
(dp78457
g66301
I29
sg66302
I1
sg66303
I6
sg66314
VC0004096
p78458
sg66306
Vasthma
p78459
sasa(dp78460
g66296
VOur results show that CM Tln2 is essential for proper Beta1D-integrin expression and that Tln1 can substitute for Tln2 in preserving heart function, but that loss of all Tln forms from the heart-muscle cell leads to myocyte instability and a dilated cardiomyopathy.
p78461
sg66298
(lp78462
(dp78463
g66301
I25
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTln2
p78464
sa(dp78465
g66301
I90
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTln1
p78466
sa(dp78467
g66301
I22
sg66302
I2
sg66303
I7
sg66304
g11
sg66306
VCM Tln2
p78468
sasg66311
(lp78469
(dp78470
g66301
I242
sg66302
I2
sg66303
I22
sg66314
VC0007193
p78471
sg66306
Vdilated cardiomyopathy
p78472
sasa(dp78473
g66296
VThe levels of two miRNAs, hsa-miR-132-5p and hsa-miR-221-5p, were inversely correlated with the expression of CYP1A2 mRNA transcripts in normal human liver tissue samples represented in The Cancer Genome Atlas (TCGA) dataset.
p78474
sg66298
(lp78475
(dp78476
g66301
I26
sg66302
I1
sg66303
I14
sg66304
g11
sg66306
Vhsa-miR-132-5p
p78477
sa(dp78478
g66301
I110
sg66302
I3
sg66303
I23
sg66304
VP05177
p78479
sg66306
VCYP1A2 mRNA transcripts
p78480
sa(dp78481
g66301
I45
sg66302
I1
sg66303
I14
sg66304
g11
sg66306
Vhsa-miR-221-5p
p78482
sasg66311
(lp78483
(dp78484
g66301
I190
sg66302
I1
sg66303
I6
sg66314
VC0006826
p78485
sg66306
VCancer
p78486
sa(dp78487
g66301
I26
sg66302
I1
sg66303
I3
sg66314
VC0393754
p78488
sg66306
Vhsa
p78489
sa(dp78490
g66301
I26
sg66302
I1
sg66303
I3
sg66314
VC0393754
p78491
sg66306
Vhsa
p78492
sasa(dp78493
g66296
VIn situ hybridization and functional experiments in a panel of colorectal cancer cell lines and xenografts further clarified the role of clinical relevant miRNAs.Results: Six miRNAs (miR-92b-3p, miR-188-3p, miR-221-5p, miR-331-3p, miR-425-3p, and miR-497-5p) were identified as strong predictors of survival in the screening cohort.
p78494
sg66298
(lp78495
(dp78496
g66301
I195
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-188-3p
p78497
sa(dp78498
g66301
I231
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-425-3p
p78499
sa(dp78500
g66301
I183
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-92b-3p
p78501
sa(dp78502
g66301
I247
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-497-5p
p78503
sa(dp78504
g66301
I219
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-331-3p
p78505
sa(dp78506
g66301
I207
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-221-5p
p78507
sasg66311
(lp78508
(dp78509
g66301
I63
sg66302
I2
sg66303
I17
sg66314
VC1527249
p78510
sg66306
Vcolorectal cancer
p78511
sasa(dp78512
g66296
VParticularly, CLN1, CLN2 and CLN3 were obtained by adding derivatives C1, C2 or C3 during nanoparticles preparation, while CLN2-Pt were obtained by treating preformed CLN2 with Pt(II).
p78513
sg66298
(lp78514
(dp78515
g66301
I20
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VCLN2
p78516
sa(dp78517
g66301
I20
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VCLN2
p78518
sa(dp78519
g66301
I29
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VCLN3
p78520
sa(dp78521
g66301
I123
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VCLN2-Pt
p78522
sa(dp78523
g66301
I14
sg66302
I1
sg66303
I4
sg66304
VP50897
p78524
sg66306
VCLN1
p78525
sasg66311
(lp78526
(dp78527
g66301
I20
sg66302
I1
sg66303
I4
sg66314
VC1876161
p78528
sg66306
VCLN2
p78529
sa(dp78530
g66301
I20
sg66302
I1
sg66303
I4
sg66314
VC1876161
p78531
sg66306
VCLN2
p78532
sa(dp78533
g66301
I29
sg66302
I1
sg66303
I4
sg66314
VC2931674
p78534
sg66306
VCLN3
p78535
sa(dp78536
g66301
I14
sg66302
I1
sg66303
I4
sg66314
VC1850451
p78537
sg66306
VCLN1
p78538
sa(dp78539
g66301
I20
sg66302
I1
sg66303
I4
sg66314
VC1876161
p78540
sg66306
VCLN2
p78541
sasa(dp78542
g66296
VAs determined by ICP-OES, a content of P and Pt 2.2-fold and 2.5-fold higher in CLN2-Pt than in CLN3 was evidenced.
p78543
sg66298
(lp78544
(dp78545
g66301
I80
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VCLN2-Pt
p78546
sa(dp78547
g66301
I96
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VCLN3
p78548
sa(dp78549
g66301
I17
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VICP-OES
p78550
sasg66311
(lp78551
(dp78552
g66301
I21
sg66302
I1
sg66303
I3
sg66314
VC1838329
p78553
sg66306
VOES
p78554
sa(dp78555
g66301
I80
sg66302
I1
sg66303
I4
sg66314
VC1876161
p78556
sg66306
VCLN2
p78557
sa(dp78558
g66301
I96
sg66302
I1
sg66303
I4
sg66314
VC2931674
p78559
sg66306
VCLN3
p78560
sa(dp78561
g66301
I17
sg66302
I1
sg66303
I3
sg66314
VC0268318
p78562
sg66306
VICP
p78563
sasa(dp78564
g66296
VIn fact, the antiproliferative activity shown by CLN3, CLN2-Pt on the three model cancer cell lines was substantially similar and comparable to that of complex C3 in dmso solution.
p78565
sg66298
(lp78566
(dp78567
g66301
I55
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VCLN2-Pt
p78568
sa(dp78569
g66301
I49
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VCLN3
p78570
sasg66311
(lp78571
(dp78572
g66301
I55
sg66302
I1
sg66303
I4
sg66314
VC1876161
p78573
sg66306
VCLN2
p78574
sa(dp78575
g66301
I49
sg66302
I1
sg66303
I4
sg66314
VC2931674
p78576
sg66306
VCLN3
p78577
sa(dp78578
g66301
I82
sg66302
I1
sg66303
I6
sg66314
VC0006826
p78579
sg66306
Vcancer
p78580
sasa(dp78581
g66296
VSeparate prediction models which could predict consumption of each blood component in intra and postoperative phase of LDLT were derived from among the preoperative Hb, Hct, model for end-stage liver disease (MELD) score, body surface area (BSA), Plt, T. proteins, S. creatinine, B. urea, INR, and serum sodium and chloride.
p78582
sg66298
(lp78583
(dp78584
g66301
I247
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPlt
p78585
sasg66311
(lp78586
(dp78587
g66301
I194
sg66302
I2
sg66303
I13
sg66314
VC0023895
p78588
sg66306
Vliver disease
p78589
sasa(dp78590
g66296
VNo association with vitiligo was found for the MECL1 gene, which encodes a third immunoproteasome subunit and is unlinked to the MHC class II region.
p78591
sg66298
(lp78592
(dp78593
g66301
I129
sg66302
I4
sg66303
I19
sg66304
VP13747
p78594
sg66306
VMHC class II region
p78595
sa(dp78596
g66301
I47
sg66302
I2
sg66303
I10
sg66304
VP40313
p78597
sg66306
VMECL1 gene
p78598
sasg66311
(lp78599
(dp78600
g66301
I20
sg66302
I1
sg66303
I8
sg66314
VC0042900
p78601
sg66306
Vvitiligo
p78602
sasa(dp78603
g66296
VWe report a novel LHX3 mutation, which is associated with combined pituitary hormone deficiency including ACTH deficiency, short neck, and sensorineural hearing loss.
p78604
sg66298
(lp78605
(dp78606
g66301
I58
sg66302
I3
sg66303
I26
sg66304
VP18509
p78607
sg66306
Vcombined pituitary hormone
p78608
sa(dp78609
g66301
I18
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VLHX3
p78610
sa(dp78611
g66301
I106
sg66302
I1
sg66303
I4
sg66304
VP01189
p78612
sg66306
VACTH
p78613
sasg66311
(lp78614
(dp78615
g66301
I139
sg66302
I3
sg66303
I26
sg66314
VC0018784
p78616
sg66306
Vsensorineural hearing loss
p78617
sa(dp78618
g66301
I77
sg66302
I2
sg66303
I18
sg66314
VC0599750
p78619
sg66306
Vhormone deficiency
p78620
sa(dp78621
g66301
I106
sg66302
I2
sg66303
I15
sg66314
VC0342388
p78622
sg66306
VACTH deficiency
p78623
sasa(dp78624
g66296
VSo-called stress hormones, like adrenocorticotropic hormone, cortisol, and antidiuretic hormone, are released concomitant with nausea and vomiting in motion sickness, but do not seem to be involved in the aetiology of motion sickness.
p78625
sg66298
(lp78626
(dp78627
g66301
I32
sg66302
I2
sg66303
I27
sg66304
VP01189
p78628
sg66306
Vadrenocorticotropic hormone
p78629
sasg66311
(lp78630
(dp78631
g66301
I150
sg66302
I2
sg66303
I15
sg66314
VC0026603
p78632
sg66306
Vmotion sickness
p78633
sa(dp78634
g66301
I127
sg66302
I3
sg66303
I19
sg66314
VC0027498
p78635
sg66306
Vnausea and vomiting
p78636
sa(dp78637
g66301
I150
sg66302
I2
sg66303
I15
sg66314
VC0026603
p78638
sg66306
Vmotion sickness
p78639
sasa(dp78640
g66296
VMMP-1/7 serum levels were measured using Luminex xMAP technology in 139 patients- 47 IPF, 36 non-IPF Usual Interstitial Pneumonia (UIP), 14 idiopathic Nonspecific Interstitial Pneumonia (iNSIP), 29 secondary NSIP (secNSIP), 13 stage IV sarcoidosis- and 20 healthy controls, and compared using the Mann-Whitney U test.
p78641
sg66298
(lp78642
(dp78643
g66301
I0
sg66302
I1
sg66303
I5
sg66304
VP03956
p78644
sg66306
VMMP-1
p78645
sasg66311
(lp78646
(dp78647
g66301
I101
sg66302
I3
sg66303
I28
sg66314
VC0085786
p78648
sg66306
VUsual Interstitial Pneumonia
p78649
sa(dp78650
g66301
I151
sg66302
I3
sg66303
I34
sg66314
VC1290344
p78651
sg66306
VNonspecific Interstitial Pneumonia
p78652
sa(dp78653
g66301
I236
sg66302
I1
sg66303
I11
sg66314
VC0036202
p78654
sg66306
Vsarcoidosis
p78655
sa(dp78656
g66301
I131
sg66302
I1
sg66303
I3
sg66314
VC0085786
p78657
sg66306
VUIP
p78658
sasa(dp78659
g66296
VThis activity is regulated by such inhibitors as metalloprvteinase 1 tissue inhibitor and cystatin C. The comparative analysis was applied concerning matrix metalloproteinase 1 precursor; metalloproteinase I tissue inhibitor and cystatin C--indicators of conditions of the "proteolysis-antiproteolysis" system in the bronchoalveolar secretion of patients with chronic obstructive lung disease, bronchial asthma and pneumonia.
p78660
sg66298
(lp78661
(dp78662
g66301
I90
sg66302
I2
sg66303
I10
sg66304
VP01034
p78663
sg66306
Vcystatin C
p78664
sa(dp78665
g66301
I150
sg66302
I8
sg66303
I74
sg66304
VP03956
p78666
sg66306
Vmatrix metalloproteinase 1 precursor; metalloproteinase I tissue inhibitor
p78667
sa(dp78668
g66301
I90
sg66302
I2
sg66303
I10
sg66304
VP01034
p78669
sg66306
Vcystatin C
p78670
sasg66311
(lp78671
(dp78672
g66301
I394
sg66302
I2
sg66303
I16
sg66314
VC0004096
p78673
sg66306
Vbronchial asthma
p78674
sa(dp78675
g66301
I415
sg66302
I1
sg66303
I9
sg66314
VC0032285
p78676
sg66306
Vpneumonia
p78677
sa(dp78678
g66301
I360
sg66302
I4
sg66303
I32
sg66314
VC0024117
p78679
sg66306
Vchronic obstructive lung disease
p78680
sasa(dp78681
g66296
VTo observe the effects of Dureping Injection on the contents of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in the lung tissue of mice with pneumonia of influenza virus infection.
p78682
sg66298
(lp78683
(dp78684
g66301
I64
sg66302
I2
sg66303
I26
sg66304
VP14780
p78685
sg66306
Vmatrix metalloproteinase-9
p78686
sa(dp78687
g66301
I92
sg66302
I1
sg66303
I5
sg66304
VP14780
p78688
sg66306
VMMP-9
p78689
sa(dp78690
g66301
I103
sg66302
I5
sg66303
I46
sg66304
VP01033
p78691
sg66306
Vtissue inhibitor of matrix metalloproteinase-1
p78692
sa(dp78693
g66301
I151
sg66302
I1
sg66303
I6
sg66304
VP01033
p78694
sg66306
VTIMP-1
p78695
sasg66311
(lp78696
(dp78697
g66301
I204
sg66302
I1
sg66303
I9
sg66314
VC0021400
p78698
sg66306
Vinfluenza
p78699
sa(dp78700
g66301
I191
sg66302
I1
sg66303
I9
sg66314
VC0032285
p78701
sg66306
Vpneumonia
p78702
sa(dp78703
g66301
I214
sg66302
I2
sg66303
I15
sg66314
VC0042769
p78704
sg66306
Vvirus infection
p78705
sasa(dp78706
g66296
VWe developed a Korean version of the NPI-Q (KNPI-Q) and compared subitems with those of the Korean version of the NPI (KNPI) in 63 dementia patients; 47 patients had been diagnosed with Alzheimer's disease with dementia, 8 with vascular dementia, and 8 with dementia with Lewy body disease.
p78707
sg66298
(lp78708
(dp78709
g66301
I44
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VKNPI-Q
p78710
sa(dp78711
g66301
I15
sg66302
I5
sg66303
I27
sg66304
g11
sg66306
VKorean version of the NPI-Q
p78712
sasg66311
(lp78713
(dp78714
g66301
I131
sg66302
I1
sg66303
I8
sg66314
VC0497327
p78715
sg66306
Vdementia
p78716
sa(dp78717
g66301
I186
sg66302
I2
sg66303
I19
sg66314
VC1521724
p78718
sg66306
VAlzheimer's disease
p78719
sa(dp78720
g66301
I131
sg66302
I1
sg66303
I8
sg66314
VC0497327
p78721
sg66306
Vdementia
p78722
sa(dp78723
g66301
I131
sg66302
I1
sg66303
I8
sg66314
VC0497327
p78724
sg66306
Vdementia
p78725
sa(dp78726
g66301
I272
sg66302
I3
sg66303
I17
sg66314
VC0752347
p78727
sg66306
VLewy body disease
p78728
sa(dp78729
g66301
I228
sg66302
I2
sg66303
I17
sg66314
VC0011269
p78730
sg66306
Vvascular dementia
p78731
sasa(dp78732
g66296
VAll patients received the Korean version of the Mini-Mental State Examination and the Clinical Dementia Rating within 1 month of the KNPI-Q.
p78733
sg66298
(lp78734
(dp78735
g66301
I133
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VKNPI-Q
p78736
sasg66311
(lp78737
(dp78738
g66301
I95
sg66302
I1
sg66303
I8
sg66314
VC0497327
p78739
sg66306
VDementia
p78740
sasa(dp78741
g66296
VThe KNPI-Q is a reliable and brief instrument that can be employed for screening in the evaluation of neuropsychiatric symptoms of dementia and associated caregiver distress.
p78742
sg66298
(lp78743
(dp78744
g66301
I4
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VKNPI-Q
p78745
sasg66311
(lp78746
(dp78747
g66301
I131
sg66302
I1
sg66303
I8
sg66314
VC0497327
p78748
sg66306
Vdementia
p78749
sasa(dp78750
g66296
VThe cognitive function of each sub-domain, functional impairments, depressive symptoms, and caregiver burden were assessed using the dementia version of Seoul Neuropsychological Screening Battery (SNSB-D), Barthel Index for Daily Living Activities (ADL), Seoul-Instrumental Activities of Daily Living (S-IADL), the Clinical Dementia Rating Sum of Box (CDR-SB), the Global Deterioration Scale (GDS), the Korean version of the Neuropsychiatric Inventory (K-NPI), and the 15-item Geriatric Depression Scale.
p78751
sg66298
(lp78752
(dp78753
g66301
I352
sg66302
I1
sg66303
I6
sg66304
VP51861
p78754
sg66306
VCDR-SB
p78755
sa(dp78756
g66301
I315
sg66302
I6
sg66303
I35
sg66304
VP51861
p78757
sg66306
VClinical Dementia Rating Sum of Box
p78758
sasg66311
(lp78759
(dp78760
g66301
I324
sg66302
I1
sg66303
I8
sg66314
VC0497327
p78761
sg66306
VDementia
p78762
sa(dp78763
g66301
I133
sg66302
I1
sg66303
I8
sg66314
VC0497327
p78764
sg66306
Vdementia
p78765
sa(dp78766
g66301
I487
sg66302
I1
sg66303
I10
sg66314
VC0011581
p78767
sg66306
VDepression
p78768
sa(dp78769
g66301
I67
sg66302
I2
sg66303
I19
sg66314
VC0086132
p78770
sg66306
Vdepressive symptoms
p78771
sasa(dp78772
g66296
VOur primary endpoints were change from baseline to weeks 12 and 24 in the Seoul Neuropsychological Screening Battery-Dementia version (SNSB-D) and the Korean version of neuropsychiatric inventory (K-NPI).
p78773
sg66298
(lp78774
sg66311
(lp78775
(dp78776
g66301
I117
sg66302
I1
sg66303
I8
sg66314
VC0497327
p78777
sg66306
VDementia
p78778
sasa(dp78779
g66296
VThe patients were also evaluated using the Korean version of the Severe Impairment Battery (SIB-Ko), Clinical Dementia Rating (CDR), Global Deterioration Scale (GDS), Barthel Activities of Daily Living (B-ADL), the Korean version of the Instrumental Activities of Daily Living (K-IADL), the Korean version of the Neuropsychiatric Inventory (K-NPI) and the Functional Assessment Staging (FAST).
p78780
sg66298
(lp78781
sg66311
(lp78782
(dp78783
g66301
I72
sg66302
I1
sg66303
I10
sg66314
VC0684336
p78784
sg66306
VImpairment
p78785
sa(dp78786
g66301
I110
sg66302
I1
sg66303
I8
sg66314
VC0497327
p78787
sg66306
VDementia
p78788
sasa(dp78789
g66296
VThe aim of this study is to develop the Korean version of the NPI (K-NPI) and to test its reliability and usefulness in dementia patients.
p78790
sg66298
(lp78791
sg66311
(lp78792
(dp78793
g66301
I120
sg66302
I1
sg66303
I8
sg66314
VC0497327
p78794
sg66306
Vdementia
p78795
sasa(dp78796
g66296
VTotal K-NPI scores correlated positively with dementia severity assessed with the Korean Mini-Mental State Examination.
p78797
sg66298
(lp78798
sg66311
(lp78799
(dp78800
g66301
I46
sg66302
I1
sg66303
I8
sg66314
VC0497327
p78801
sg66306
Vdementia
p78802
sasa(dp78803
g66296
VThe K-NPI, whose reliability and competency are comparable to those of the original version, may be a reliable and useful tool for measuring neuropsychiatric disturbances in Korean dementia patients.
p78804
sg66298
(lp78805
sg66311
(lp78806
(dp78807
g66301
I181
sg66302
I1
sg66303
I8
sg66314
VC0497327
p78808
sg66306
Vdementia
p78809
sasa(dp78810
g66296
VBone and cartilage and their disorders are addressed under the following headings: functions of bone; normal and abnormal bone remodeling; osteopetrosis and osteoporosis; epithelial-mesenchymal interaction, condensation and differentiation; osteoblasts, markers of bone formation, osteoclasts, components of bone, and pathology of bone; chondroblasts, markers of cartilage formation, secondary cartilage, components of cartilage, and pathology of cartilage; intramembranous and endochondral bone formation; RUNX genes and cleidocranial dysplasia (CCD); osterix; histone deacetylase 4 and Runx2; Ligand to receptor activator of NFkappaB (RANKL), RANK, osteoprotegerin, and osteoimmunology; WNT signaling, LRP5 mutations, and beta-catenin; the role of leptin in bone remodeling; collagens, collagenopathies, and osteogenesis imperfecta; FGFs/FGFRs, FGFR3 skeletal dysplasias, craniosynostosis, and other disorders; short limb chondrodysplasias; molecular control of the growth plate in endochondral bone formation and genetic disorders of IHH and PTHR1; ANKH, craniometaphyseal dysplasia, and chondrocalcinosis; transforming growth factor beta, Camurati-Engelmann disease (CED), and Marfan syndrome, types I and II; an ACVR1 mutation and fibrodysplasia ossificans progressiva; MSX1 and MSX2: biology, mutations, and associated disorders; G protein, activation of adenylyl cyclase, GNAS1 mutations, McCune-Albright syndrome, fibrous dysplasia, and Albright hereditary osteodystrophy; FLNA and associated disorders; and morphological development of teeth and their genetic mutations.
p78811
sg66298
(lp78812
(dp78813
g66301
I562
sg66302
I3
sg66303
I21
sg66304
VP56524
p78814
sg66306
Vhistone deacetylase 4
p78815
sa(dp78816
g66301
I704
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VLRP5
p78817
sa(dp78818
g66301
I1217
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VACVR1
p78819
sa(dp78820
g66301
I1284
sg66302
I1
sg66303
I4
sg66304
VP35548
p78821
sg66306
VMSX2
p78822
sa(dp78823
g66301
I1045
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VPTHR1
p78824
sa(dp78825
g66301
I1037
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VIHH
p78826
sa(dp78827
g66301
I627
sg66302
I1
sg66303
I8
sg66304
VP19838
p78828
sg66306
VNFkappaB
p78829
sa(dp78830
g66301
I1275
sg66302
I1
sg66303
I4
sg66304
VP28360
p78831
sg66306
VMSX1
p78832
sa(dp78833
g66301
I1379
sg66302
I1
sg66303
I5
sg66304
VP84996
p78834
sg66306
VGNAS1
p78835
sa(dp78836
g66301
I1171
sg66302
I1
sg66303
I3
sg66304
VP01137
p78837
sg66306
VCED
p78838
sa(dp78839
g66301
I588
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VRunx2
p78840
sa(dp78841
g66301
I847
sg66302
I1
sg66303
I5
sg66304
VP22607
p78842
sg66306
VFGFR3
p78843
sa(dp78844
g66301
I1052
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VANKH
p78845
sa(dp78846
g66301
I1143
sg66302
I2
sg66303
I26
sg66304
VP01137
p78847
sg66306
VCamurati-Engelmann disease
p78848
sa(dp78849
g66301
I1110
sg66302
I4
sg66303
I31
sg66304
VP18075
p78850
sg66306
Vtransforming growth factor beta
p78851
sa(dp78852
g66301
I750
sg66302
I1
sg66303
I6
sg66304
VP41159
p78853
sg66306
Vleptin
p78854
sa(dp78855
g66301
I724
sg66302
I1
sg66303
I12
sg66304
VP35222
p78856
sg66306
Vbeta-catenin
p78857
sa(dp78858
g66301
I1361
sg66302
I2
sg66303
I16
sg66304
VP51828
p78859
sg66306
Vadenylyl cyclase
p78860
sa(dp78861
g66301
I651
sg66302
I1
sg66303
I15
sg66304
g11
sg66306
Vosteoprotegerin
p78862
sa(dp78863
g66301
I637
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VRANKL
p78864
sasg66311
(lp78865
(dp78866
g66301
I1016
sg66302
I2
sg66303
I17
sg66314
VC0019247
p78867
sg66306
Vgenetic disorders
p78868
sa(dp78869
g66301
I157
sg66302
I1
sg66303
I12
sg66314
VC0029456
p78870
sg66306
Vosteoporosis
p78871
sa(dp78872
g66301
I862
sg66302
I1
sg66303
I10
sg66314
VC0334044
p78873
sg66306
Vdysplasias
p78874
sa(dp78875
g66301
I522
sg66302
I2
sg66303
I23
sg66314
VC0008928
p78876
sg66306
Vcleidocranial dysplasia
p78877
sa(dp78878
g66301
I1422
sg66302
I2
sg66303
I17
sg66314
VC0259779
p78879
sg66306
Vfibrous dysplasia
p78880
sa(dp78881
g66301
I810
sg66302
I2
sg66303
I23
sg66314
VC0029434
p78882
sg66306
Vosteogenesis imperfecta
p78883
sa(dp78884
g66301
I547
sg66302
I1
sg66303
I3
sg66314
VC0008928
p78885
sg66306
VCCD
p78886
sa(dp78887
g66301
I1058
sg66302
I2
sg66303
I27
sg66314
VC0265292
p78888
sg66306
Vcraniometaphyseal dysplasia
p78889
sa(dp78890
g66301
I1091
sg66302
I1
sg66303
I17
sg66314
VC0553730
p78891
sg66306
Vchondrocalcinosis
p78892
sa(dp78893
g66301
I318
sg66302
I1
sg66303
I9
sg66314
VC0677042
p78894
sg66306
Vpathology
p78895
sa(dp78896
g66301
I1445
sg66302
I3
sg66303
I34
sg66314
VC2931404
p78897
sg66306
VAlbright hereditary osteodystrophy
p78898
sa(dp78899
g66301
I1037
sg66302
I1
sg66303
I3
sg66314
VC0342384
p78900
sg66306
VIHH
p78901
sa(dp78902
g66301
I1143
sg66302
I2
sg66303
I26
sg66314
VC0011989
p78903
sg66306
VCamurati-Engelmann disease
p78904
sa(dp78905
g66301
I139
sg66302
I1
sg66303
I13
sg66314
VC0029454
p78906
sg66306
Vosteopetrosis
p78907
sa(dp78908
g66301
I1396
sg66302
I2
sg66303
I24
sg66314
VC0242292
p78909
sg66306
VMcCune-Albright syndrome
p78910
sa(dp78911
g66301
I318
sg66302
I1
sg66303
I9
sg66314
VC0677042
p78912
sg66306
Vpathology
p78913
sa(dp78914
g66301
I207
sg66302
I1
sg66303
I12
sg66314
VC0233656
p78915
sg66306
Vcondensation
p78916
sa(dp78917
g66301
I924
sg66302
I1
sg66303
I17
sg66314
VC0343284
p78918
sg66306
Vchondrodysplasias
p78919
sa(dp78920
g66301
I1236
sg66302
I3
sg66303
I37
sg66314
VC0016037
p78921
sg66306
Vfibrodysplasia ossificans progressiva
p78922
sa(dp78923
g66301
I1181
sg66302
I2
sg66303
I15
sg66314
VC0024796
p78924
sg66306
VMarfan syndrome
p78925
sa(dp78926
g66301
I874
sg66302
I1
sg66303
I16
sg66314
VC0010278
p78927
sg66306
Vcraniosynostosis
p78928
sa(dp78929
g66301
I1171
sg66302
I1
sg66303
I3
sg66314
VC0011989
p78930
sg66306
VCED
p78931
sasa(dp78932
g66296
VGenome-wide analysis showed an association of asthma in Russians with the polymorphic loci of gene MUC19 (12q12) encoding gel-forming mucin 19.
p78933
sg66298
(lp78934
(dp78935
g66301
I122
sg66302
I3
sg66303
I20
sg66304
g11
sg66306
Vgel-forming mucin 19
p78936
sa(dp78937
g66301
I94
sg66302
I3
sg66303
I18
sg66304
g11
sg66306
Vgene MUC19 (12q12)
p78938
sasg66311
(lp78939
(dp78940
g66301
I46
sg66302
I1
sg66303
I6
sg66314
VC0004096
p78941
sg66306
Vasthma
p78942
sasa(dp78943
g66296
VSeven polymorphic loci of gene MUC19 (rs1492313, rs2588401, rs2588402, rs2638863, rs2638864, rs1352940, and rs2933373), which are in close linkage disequilibrium among themselves and rs2933346, are associated with asthma with the same p-value (p = 4.96 x 10(-6)).
p78944
sg66298
(lp78945
(dp78946
g66301
I31
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VMUC19
p78947
sasg66311
(lp78948
(dp78949
g66301
I214
sg66302
I1
sg66303
I6
sg66314
VC0004096
p78950
sg66306
Vasthma
p78951
sa(dp78952
g66301
I147
sg66302
I1
sg66303
I14
sg66314
VC0394006
p78953
sg66306
Vdisequilibrium
p78954
sasa(dp78955
g66296
VAccording to our data, the association of polymorphic variants of gene MUC19 with asthma has not been previously identified in any study.
p78956
sg66298
(lp78957
(dp78958
g66301
I71
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VMUC19
p78959
sasg66311
(lp78960
(dp78961
g66301
I82
sg66302
I1
sg66303
I6
sg66314
VC0004096
p78962
sg66306
Vasthma
p78963
sasa(dp78964
g66296
VOur results indicate the important role of polymorphic variants of gene MUC19 in the formation of a predisposition to the development of asthma in individuals of Russian ethnicity.
p78965
sg66298
(lp78966
(dp78967
g66301
I72
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VMUC19
p78968
sasg66311
(lp78969
(dp78970
g66301
I137
sg66302
I1
sg66303
I6
sg66314
VC0004096
p78971
sg66306
Vasthma
p78972
sasa(dp78973
g66296
VTo detect the mucin gene (MUC2, MUC5AC, MUC5B, MUC18 and MUC19) expression in the nasal polyps, allergic rhinitis (AR) and the normal nasal mucosa in human.
p78974
sg66298
(lp78975
(dp78976
g66301
I26
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VMUC2
p78977
sa(dp78978
g66301
I47
sg66302
I1
sg66303
I5
sg66304
VP43121
p78979
sg66306
VMUC18
p78980
sa(dp78981
g66301
I14
sg66302
I2
sg66303
I10
sg66304
g11
sg66306
Vmucin gene
p78982
sa(dp78983
g66301
I57
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VMUC19
p78984
sasg66311
(lp78985
(dp78986
g66301
I96
sg66302
I2
sg66303
I17
sg66314
VC2607914
p78987
sg66306
Vallergic rhinitis
p78988
sa(dp78989
g66301
I115
sg66302
I1
sg66303
I2
sg66314
VC2607914
p78990
sg66306
VAR
p78991
sa(dp78992
g66301
I82
sg66302
I2
sg66303
I12
sg66314
VC0027430
p78993
sg66306
Vnasal polyps
p78994
sasa(dp78995
g66296
VIt indicates that the secretion of MUC19 in allergic rhinitis was on high level.
p78996
sg66298
(lp78997
(dp78998
g66301
I35
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VMUC19
p78999
sasg66311
(lp79000
(dp79001
g66301
I44
sg66302
I2
sg66303
I17
sg66314
VC2607914
p79002
sg66306
Vallergic rhinitis
p79003
sasa(dp79004
g66296
VWe aimed to assess the impact of hypocretin deficiency on attentional functioning by comparing performances on the attention network test (ANT) of narcoleptic patients with hypocretin deficiency (narcolepsy type 1-NT1) versus patients without hypocretin deficiency (narcolepsy type 2-NT2) and healthy controls.
p79005
sg66298
(lp79006
(dp79007
g66301
I33
sg66302
I1
sg66303
I10
sg66304
VP50336
p79008
sg66306
Vhypocretin
p79009
sa(dp79010
g66301
I33
sg66302
I1
sg66303
I10
sg66304
VP50336
p79011
sg66306
Vhypocretin
p79012
sa(dp79013
g66301
I33
sg66302
I1
sg66303
I10
sg66304
VP50336
p79014
sg66306
Vhypocretin
p79015
sasg66311
(lp79016
(dp79017
g66301
I196
sg66302
I1
sg66303
I10
sg66314
VC0027404
p79018
sg66306
Vnarcolepsy
p79019
sa(dp79020
g66301
I196
sg66302
I1
sg66303
I10
sg66314
VC0027404
p79021
sg66306
Vnarcolepsy
p79022
sasa(dp79023
g66296
VA randomized, double-blind prospective trial among recent onset type 1 diabetes patients has been designed using Cyclosporine A and a proton-pump inhibitor, which increases gastrin levels and has been shown to work through the Reg receptor to transform pancreatic duct cells into islets.
p79024
sg66298
(lp79025
(dp79026
g66301
I173
sg66302
I1
sg66303
I7
sg66304
VP01350
p79027
sg66306
Vgastrin
p79028
sa(dp79029
g66301
I227
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VReg receptor
p79030
sasg66311
(lp79031
(dp79032
g66301
I21
sg66302
I1
sg66303
I5
sg66314
VC0456909
p79033
sg66306
Vblind
p79034
sa(dp79035
g66301
I64
sg66302
I3
sg66303
I15
sg66314
VC0011854
p79036
sg66306
Vtype 1 diabetes
p79037
sasa(dp79038
g66296
VIn the A(1)AR agonist area, clinical candidates have been discovered for the following conditions: atrial arrhythmias (tecadenoson, selodenoson and PJ-875); Type II diabetes and insulin sensitizing agents (GR79236, ARA, RPR-749, and CVT-3619); and angina (BAY 68-4986).
p79039
sg66298
(lp79040
(dp79041
g66301
I178
sg66302
I1
sg66303
I7
sg66304
VP01308
p79042
sg66306
Vinsulin
p79043
sasg66311
(lp79044
(dp79045
g66301
I99
sg66302
I2
sg66303
I18
sg66314
VC0085611
p79046
sg66306
Vatrial arrhythmias
p79047
sa(dp79048
g66301
I157
sg66302
I3
sg66303
I16
sg66314
VC0011860
p79049
sg66306
VType II diabetes
p79050
sa(dp79051
g66301
I248
sg66302
I1
sg66303
I6
sg66314
VC0002962
p79052
sg66306
Vangina
p79053
sa(dp79054
g66301
I233
sg66302
I1
sg66303
I3
sg66314
VC0240912
p79055
sg66306
VCVT
p79056
sasa(dp79057
g66296
VThe treatment of type II diabetes using A(1)AR agonists in the clinic has met with limited success due to cardiovascular side effects and a well-defined desensitization of full agonists in human trials (GR79236, ARA, and RPR 749).
p79058
sg66298
(lp79059
sg66311
(lp79060
(dp79061
g66301
I17
sg66302
I3
sg66303
I16
sg66314
VC0011860
p79062
sg66306
Vtype II diabetes
p79063
sasa(dp79064
g66296
VReg protein acts as an autocrine/paracrine growth factor to induce beta-cell replication via the Reg receptor and ameliorates experimental diabetes.
p79065
sg66298
(lp79066
(dp79067
g66301
I97
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VReg receptor
p79068
sa(dp79069
g66301
I0
sg66302
I2
sg66303
I11
sg66304
VP05451
p79070
sg66306
VReg protein
p79071
sasg66311
(lp79072
(dp79073
g66301
I139
sg66302
I1
sg66303
I8
sg66314
VC0011849
p79074
sg66306
Vdiabetes
p79075
sasa(dp79076
g66296
VWe have demonstrated in vitro and in vivo that the exogenous addition of rat and human Reg gene products, Reg/REG proteins, induced beta-cell replication via the Reg receptor and thereby ameliorated experimental diabetes.
p79077
sg66298
(lp79078
(dp79079
g66301
I87
sg66302
I1
sg66303
I3
sg66304
VP05451
p79080
sg66306
VReg
p79081
sa(dp79082
g66301
I81
sg66302
I4
sg66303
I23
sg66304
VP05451
p79083
sg66306
Vhuman Reg gene products
p79084
sa(dp79085
g66301
I162
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VReg receptor
p79086
sa(dp79087
g66301
I110
sg66302
I1
sg66303
I3
sg66304
VP05451
p79088
sg66306
VREG
p79089
sasg66311
(lp79090
(dp79091
g66301
I212
sg66302
I1
sg66303
I8
sg66314
VC0011849
p79092
sg66306
Vdiabetes
p79093
sasa(dp79094
g66296
VFrom the regenerating islet-derived cDNA library we isolated Reg (Regenerating Gene) and demonstrated that Reg protein induces beta-cell replication via the Reg receptor and ameliorates experimental diabetes.
p79095
sg66298
(lp79096
(dp79097
g66301
I107
sg66302
I2
sg66303
I11
sg66304
VP05451
p79098
sg66306
VReg protein
p79099
sa(dp79100
g66301
I61
sg66302
I1
sg66303
I3
sg66304
VP05451
p79101
sg66306
VReg
p79102
sa(dp79103
g66301
I157
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VReg receptor
p79104
sasg66311
(lp79105
(dp79106
g66301
I199
sg66302
I1
sg66303
I8
sg66314
VC0011849
p79107
sg66306
Vdiabetes
p79108
sasa(dp79109
g66296
VGenomic DNA was isolated from patients with hypopituitarism to amplify and sequence eight pituitary specific transcription factors (HESX1, LHX3, LHX4, OTX2, PITX2, POU1F1, PROP1, and SIX6).
p79110
sg66298
(lp79111
(dp79112
g66301
I132
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VHESX1
p79113
sa(dp79114
g66301
I172
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VPROP1
p79115
sa(dp79116
g66301
I145
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VLHX4
p79117
sa(dp79118
g66301
I164
sg66302
I1
sg66303
I6
sg66304
VP28069
p79119
sg66306
VPOU1F1
p79120
sa(dp79121
g66301
I151
sg66302
I1
sg66303
I4
sg66304
VP32243
p79122
sg66306
VOTX2
p79123
sa(dp79124
g66301
I157
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VPITX2
p79125
sa(dp79126
g66301
I139
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VLHX3
p79127
sa(dp79128
g66301
I183
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VSIX6
p79129
sa(dp79130
g66301
I90
sg66302
I4
sg66303
I40
sg66304
VP19883
p79131
sg66306
Vpituitary specific transcription factors
p79132
sasg66311
(lp79133
(dp79134
g66301
I44
sg66302
I1
sg66303
I15
sg66314
VC0020635
p79135
sg66306
Vhypopituitarism
p79136
sasa(dp79137
g66296
VRat insulinoma INS-1E cells and mouse beta-TC3 cells stably expressing Gadd45b were generated.
p79138
sg66298
(lp79139
(dp79140
g66301
I0
sg66302
I3
sg66303
I21
sg66304
VP01308
p79141
sg66306
VRat insulinoma INS-1E
p79142
sa(dp79143
g66301
I71
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VGadd45b
p79144
sasg66311
(lp79145
(dp79146
g66301
I15
sg66302
I1
sg66303
I3
sg66314
VC1533172
p79147
sg66306
VINS
p79148
sa(dp79149
g66301
I4
sg66302
I1
sg66303
I10
sg66314
VC0021670
p79150
sg66306
Vinsulinoma
p79151
sasa(dp79152
g66296
VTo define the genetic landscape of amyotrophic lateral sclerosis (ALS) and assess the contribution of possible oligogenic inheritance, we aimed to comprehensively sequence 17 known ALS genes in 391 ALS patients from the United States.
p79153
sg66298
(lp79154
sg66311
(lp79155
(dp79156
g66301
I66
sg66302
I1
sg66303
I3
sg66314
VC0002736
p79157
sg66306
VALS
p79158
sa(dp79159
g66301
I66
sg66302
I1
sg66303
I3
sg66314
VC0002736
p79160
sg66306
VALS
p79161
sa(dp79162
g66301
I35
sg66302
I3
sg66303
I29
sg66314
VC0002736
p79163
sg66306
Vamyotrophic lateral sclerosis
p79164
sa(dp79165
g66301
I66
sg66302
I1
sg66303
I3
sg66314
VC0002736
p79166
sg66306
VALS
p79167
sasa(dp79168
g66296
VHigh nuclear ATF2 expression was mainly observed in translocation-associated and/or spindle cell sarcomas including synovial sarcoma, desmoplastic small round cell tumor, endometrial stromal sarcoma, gastrointestinal stromal tumor, malignant peripheral nerve sheath tumor, and solitary fibrous tumor.
p79169
sg66298
(lp79170
(dp79171
g66301
I0
sg66302
I3
sg66303
I17
sg66304
VP15336
p79172
sg66306
VHigh nuclear ATF2
p79173
sasg66311
(lp79174
(dp79175
g66301
I134
sg66302
I5
sg66303
I35
sg66314
VC0281508
p79176
sg66306
Vdesmoplastic small round cell tumor
p79177
sa(dp79178
g66301
I171
sg66302
I3
sg66303
I27
sg66314
VC0206630
p79179
sg66306
Vendometrial stromal sarcoma
p79180
sa(dp79181
g66301
I84
sg66302
I3
sg66303
I21
sg66314
VC0205945
p79182
sg66306
Vspindle cell sarcomas
p79183
sa(dp79184
g66301
I116
sg66302
I2
sg66303
I16
sg66314
VC0039101
p79185
sg66306
Vsynovial sarcoma
p79186
sa(dp79187
g66301
I277
sg66302
I3
sg66303
I22
sg66314
VC1266119
p79188
sg66306
Vsolitary fibrous tumor
p79189
sa(dp79190
g66301
I52
sg66302
I1
sg66303
I13
sg66314
VC0040715
p79191
sg66306
Vtranslocation
p79192
sa(dp79193
g66301
I200
sg66302
I4
sg66303
I41
sg66314
VC3179349
p79194
sg66306
Vgastrointestinal stromal tumor, malignant
p79195
sa(dp79196
g66301
I242
sg66302
I4
sg66303
I29
sg66314
VC0751689
p79197
sg66306
Vperipheral nerve sheath tumor
p79198
sasa(dp79199
g66296
VSIRT1 immunoreactivity was reviewed in a series of 164 soft tissue tumors including alveolar soft part sarcoma, angiomyolipoma, clear cell sarcoma, desmoid/fibromatosis, desmoplastic small round cell tumor, Ewing sarcoma, gastrointestinal stromal tumor, glomus tumor, leiomyoma, leiomyosarcoma, lipoma, liposarcoma, malignant peripheral nerve sheath tumor, nodular fasciitis, osteosarcoma, rhabdomyosarcoma, schwannoma, solitary fibrous tumor, synovial sarcoma, undifferentiated pleomorphic sarcoma, and Wilms tumor.
p79200
sg66298
(lp79201
(dp79202
g66301
I0
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSIRT1
p79203
sasg66311
(lp79204
(dp79205
g66301
I444
sg66302
I2
sg66303
I16
sg66314
VC0039101
p79206
sg66306
Vsynovial sarcoma
p79207
sa(dp79208
g66301
I420
sg66302
I3
sg66303
I22
sg66314
VC1266119
p79209
sg66306
Vsolitary fibrous tumor
p79210
sa(dp79211
g66301
I462
sg66302
I3
sg66303
I36
sg66314
VC1704218
p79212
sg66306
Vundifferentiated pleomorphic sarcoma
p79213
sa(dp79214
g66301
I390
sg66302
I1
sg66303
I16
sg66314
VC0035412
p79215
sg66306
Vrhabdomyosarcoma
p79216
sa(dp79217
g66301
I408
sg66302
I1
sg66303
I10
sg66314
VC0027809
p79218
sg66306
Vschwannoma
p79219
sa(dp79220
g66301
I254
sg66302
I2
sg66303
I12
sg66314
VC0017653
p79221
sg66306
Vglomus tumor
p79222
sa(dp79223
g66301
I268
sg66302
I1
sg66303
I9
sg66314
VC0023267
p79224
sg66306
Vleiomyoma
p79225
sa(dp79226
g66301
I156
sg66302
I1
sg66303
I12
sg66314
VC0016048
p79227
sg66306
Vfibromatosis
p79228
sa(dp79229
g66301
I207
sg66302
I2
sg66303
I13
sg66314
VC0553580
p79230
sg66306
VEwing sarcoma
p79231
sa(dp79232
g66301
I112
sg66302
I1
sg66303
I14
sg66314
VC0206633
p79233
sg66306
Vangiomyolipoma
p79234
sa(dp79235
g66301
I376
sg66302
I1
sg66303
I12
sg66314
VC0029463
p79236
sg66306
Vosteosarcoma
p79237
sa(dp79238
g66301
I128
sg66302
I3
sg66303
I18
sg66314
VC0206651
p79239
sg66306
Vclear cell sarcoma
p79240
sa(dp79241
g66301
I148
sg66302
I1
sg66303
I7
sg66314
VC0079218
p79242
sg66306
Vdesmoid
p79243
sa(dp79244
g66301
I120
sg66302
I1
sg66303
I6
sg66314
VC3489413
p79245
sg66306
Vlipoma
p79246
sa(dp79247
g66301
I303
sg66302
I1
sg66303
I11
sg66314
VC0023827
p79248
sg66306
Vliposarcoma
p79249
sa(dp79250
g66301
I170
sg66302
I5
sg66303
I35
sg66314
VC0281508
p79251
sg66306
Vdesmoplastic small round cell tumor
p79252
sa(dp79253
g66301
I84
sg66302
I4
sg66303
I26
sg66314
VC0206657
p79254
sg66306
Valveolar soft part sarcoma
p79255
sa(dp79256
g66301
I222
sg66302
I3
sg66303
I30
sg66314
VC0238198
p79257
sg66306
Vgastrointestinal stromal tumor
p79258
sa(dp79259
g66301
I55
sg66302
I3
sg66303
I18
sg66314
VC0037579
p79260
sg66306
Vsoft tissue tumors
p79261
sa(dp79262
g66301
I504
sg66302
I2
sg66303
I11
sg66314
VC0027708
p79263
sg66306
VWilms tumor
p79264
sa(dp79265
g66301
I279
sg66302
I1
sg66303
I14
sg66314
VC0023269
p79266
sg66306
Vleiomyosarcoma
p79267
sa(dp79268
g66301
I357
sg66302
I2
sg66303
I17
sg66314
VC0410005
p79269
sg66306
Vnodular fasciitis
p79270
sa(dp79271
g66301
I316
sg66302
I5
sg66303
I39
sg66314
VC0751690
p79272
sg66306
Vmalignant peripheral nerve sheath tumor
p79273
sasa(dp79274
g66296
VPathologic diagnosis of CD117-negative GISTs can be facilitated with the application of a panel of immunohistochemical markers, including DOG-1 and WT-1.
p79275
sg66298
(lp79276
(dp79277
g66301
I138
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VDOG-1
p79278
sa(dp79279
g66301
I24
sg66302
I2
sg66303
I20
sg66304
VP10721
p79280
sg66306
VCD117-negative GISTs
p79281
sasg66311
(lp79282
(dp79283
g66301
I39
sg66302
I1
sg66303
I5
sg66314
VC0238198
p79284
sg66306
VGISTs
p79285
sasa(dp79286
g66296
VIn this study, WT-1 immunoreactivity was explored in 97 gastrointestinal stromal tumours (GISTs).
p79287
sg66298
(lp79288
sg66311
(lp79289
(dp79290
g66301
I56
sg66302
I3
sg66303
I32
sg66314
VC0238198
p79291
sg66306
Vgastrointestinal stromal tumours
p79292
sa(dp79293
g66301
I90
sg66302
I1
sg66303
I5
sg66314
VC0238198
p79294
sg66306
VGISTs
p79295
sasa(dp79296
g66296
VThe expression of WT-1 was compared with other immunohistochemical markers of GIST and the association with clinicopathological features was also evaluated.
p79297
sg66298
(lp79298
(dp79299
g66301
I78
sg66302
I1
sg66303
I4
sg66304
VP10721
p79300
sg66306
VGIST
p79301
sasg66311
(lp79302
(dp79303
g66301
I78
sg66302
I1
sg66303
I4
sg66314
VC1847319
p79304
sg66306
VGIST
p79305
sasa(dp79306
g66296
VAll 97 GISTs were positive for WT-1 and the staining intensity was strong in 59 (60.8%), moderate in 28 (28.9%) and weak in 10 cases (10.3%).
p79307
sg66298
(lp79308
sg66311
(lp79309
(dp79310
g66301
I7
sg66302
I1
sg66303
I5
sg66314
VC0238198
p79311
sg66306
VGISTs
p79312
sasa(dp79313
g66296
VAlthough the biological roles of WT-1 in GIST are still unknown, our findings might provide a rationale for immunotherapy targeting WT-1 and a therapeutic solution to the challenge of imatinib-resistant GISTs.
p79314
sg66298
(lp79315
sg66311
(lp79316
(dp79317
g66301
I203
sg66302
I1
sg66303
I5
sg66314
VC0238198
p79318
sg66306
VGISTs
p79319
sa(dp79320
g66301
I41
sg66302
I1
sg66303
I4
sg66314
VC0238198
p79321
sg66306
VGIST
p79322
sasa(dp79323
g66296
VWT-1 immunoreactivity in gastrointestinal stromal tumor (GIST) was currently not known.
p79324
sg66298
(lp79325
sg66311
(lp79326
(dp79327
g66301
I57
sg66302
I1
sg66303
I4
sg66314
VC0238198
p79328
sg66306
VGIST
p79329
sa(dp79330
g66301
I25
sg66302
I3
sg66303
I30
sg66314
VC0238198
p79331
sg66306
Vgastrointestinal stromal tumor
p79332
sasa(dp79333
g66296
VWe, therefore, investigated the expression of WT-1 in GIST in comparison to other soft tissue tumors by immunohistochemistry and Western blot analysis.
p79334
sg66298
(lp79335
sg66311
(lp79336
(dp79337
g66301
I54
sg66302
I1
sg66303
I4
sg66314
VC1847319
p79338
sg66306
VGIST
p79339
sa(dp79340
g66301
I82
sg66302
I3
sg66303
I18
sg66314
VC0037579
p79341
sg66306
Vsoft tissue tumors
p79342
sasa(dp79343
g66296
VWe found that all 28 cases (100%) of GIST are positive for WT-1, diffusely (&gt;75%, 3+) in 13 (46.4%) cases, moderately (26% to 75%, 2+) in 13 (46.4%) cases, and focally (5% to 25%, 1+) in 2 (7.2%) cases.
p79344
sg66298
(lp79345
(dp79346
g66301
I37
sg66302
I1
sg66303
I4
sg66304
VP10721
p79347
sg66306
VGIST
p79348
sasg66311
(lp79349
(dp79350
g66301
I37
sg66302
I1
sg66303
I4
sg66314
VC1847319
p79351
sg66306
VGIST
p79352
sasa(dp79353
g66296
VThe significance of cytoplasmic expression of WT-1 in GIST and some smooth muscle tumors is unclear and warrant further investigation.
p79354
sg66298
(lp79355
sg66311
(lp79356
(dp79357
g66301
I68
sg66302
I3
sg66303
I20
sg66314
VC0206658
p79358
sg66306
Vsmooth muscle tumors
p79359
sa(dp79360
g66301
I54
sg66302
I1
sg66303
I4
sg66314
VC1847319
p79361
sg66306
VGIST
p79362
sasa(dp79363
g66296
VThe potential roles of WT-1 in the diagnosis and treatment of GIST were discussed.
p79364
sg66298
(lp79365
sg66311
(lp79366
(dp79367
g66301
I62
sg66302
I1
sg66303
I4
sg66314
VC1847319
p79368
sg66306
VGIST
p79369
sasa(dp79370
g66296
VThis review will discuss five types of sarcoma that display aberrant tyrosine kinase pathway signaling: gastrointestinal stromal tumor, inflammatory myofibroblastic tumor, congenital fibrosarcoma and mesoblastic nephroma, dermatofibrosarcoma protuberans, and desmoplastic small round cell tumor; one sarcoma predisposition syndrome with specific dysregulation of the ras pathway--neurofibromatosis--will also be discussed.
p79371
sg66298
(lp79372
(dp79373
g66301
I69
sg66302
I2
sg66303
I15
sg66304
VP29401
p79374
sg66306
Vtyrosine kinase
p79375
sa(dp79376
g66301
I367
sg66302
I1
sg66303
I3
sg66304
VP01116
p79377
sg66306
Vras
p79378
sasg66311
(lp79379
(dp79380
g66301
I39
sg66302
I1
sg66303
I7
sg66314
VC1261473
p79381
sg66306
Vsarcoma
p79382
sa(dp79383
g66301
I172
sg66302
I2
sg66303
I23
sg66314
VC0334459
p79384
sg66306
Vcongenital fibrosarcoma
p79385
sa(dp79386
g66301
I200
sg66302
I2
sg66303
I20
sg66314
VC0206628
p79387
sg66306
Vmesoblastic nephroma
p79388
sa(dp79389
g66301
I380
sg66302
I1
sg66303
I17
sg66314
VC0162678
p79390
sg66306
Vneurofibromatosis
p79391
sa(dp79392
g66301
I104
sg66302
I3
sg66303
I30
sg66314
VC0238198
p79393
sg66306
Vgastrointestinal stromal tumor
p79394
sa(dp79395
g66301
I39
sg66302
I1
sg66303
I7
sg66314
VC1261473
p79396
sg66306
Vsarcoma
p79397
sa(dp79398
g66301
I323
sg66302
I1
sg66303
I8
sg66314
VC0039082
p79399
sg66306
Vsyndrome
p79400
sa(dp79401
g66301
I259
sg66302
I5
sg66303
I35
sg66314
VC0281508
p79402
sg66306
Vdesmoplastic small round cell tumor
p79403
sa(dp79404
g66301
I136
sg66302
I3
sg66303
I34
sg66314
VC0334121
p79405
sg66306
Vinflammatory myofibroblastic tumor
p79406
sa(dp79407
g66301
I222
sg66302
I2
sg66303
I31
sg66314
VC0392784
p79408
sg66306
Vdermatofibrosarcoma protuberans
p79409
sasa(dp79410
g66296
VAn additional 80 endometrial cancer patients were studied for RAB32 methylation and MSI status.
p79411
sg66298
(lp79412
(dp79413
g66301
I62
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VRAB32
p79414
sasg66311
(lp79415
(dp79416
g66301
I84
sg66302
I1
sg66303
I3
sg66314
VC0920269
p79417
sg66306
VMSI
p79418
sa(dp79419
g66301
I17
sg66302
I2
sg66303
I18
sg66314
VC0476089
p79420
sg66306
Vendometrial cancer
p79421
sasa(dp79422
g66296
VIn contrast, RAB32 methylation occurred in only 1 of 80 endometrial cancers, including 20 MSI-H, 8 MSI-L and 52 MSS tumors.
p79423
sg66298
(lp79424
(dp79425
g66301
I13
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VRAB32
p79426
sasg66311
(lp79427
(dp79428
g66301
I112
sg66302
I1
sg66303
I3
sg66314
VC0024814
p79429
sg66306
VMSS
p79430
sa(dp79431
g66301
I116
sg66302
I1
sg66303
I6
sg66314
VC0027651
p79432
sg66306
Vtumors
p79433
sa(dp79434
g66301
I90
sg66302
I1
sg66303
I3
sg66314
VC0920269
p79435
sg66306
VMSI
p79436
sa(dp79437
g66301
I56
sg66302
I2
sg66303
I19
sg66314
VC0476089
p79438
sg66306
Vendometrial cancers
p79439
sa(dp79440
g66301
I90
sg66302
I1
sg66303
I3
sg66314
VC0920269
p79441
sg66306
VMSI
p79442
sasa(dp79443
g66296
VWe conclude that although RAB32 methylation is rare in endometrial cancers, it is strongly associated with hMLH1 hypermethylation and MSI in gastric adenocarcinomas.
p79444
sg66298
(lp79445
(dp79446
g66301
I107
sg66302
I1
sg66303
I5
sg66304
VP40692
p79447
sg66306
VhMLH1
p79448
sa(dp79449
g66301
I26
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VRAB32
p79450
sasg66311
(lp79451
(dp79452
g66301
I134
sg66302
I1
sg66303
I3
sg66314
VC0920269
p79453
sg66306
VMSI
p79454
sa(dp79455
g66301
I55
sg66302
I2
sg66303
I19
sg66314
VC0476089
p79456
sg66306
Vendometrial cancers
p79457
sa(dp79458
g66301
I149
sg66302
I1
sg66303
I15
sg66314
VC0001418
p79459
sg66306
Vadenocarcinomas
p79460
sasa(dp79461
g66296
VPanel, consisting of 16 new potential markers for early and differentiated diagnosis of prostatic gland cancer, was identified: BHLHE40, FOXP1, LOC285205, ITGA9, CTDSPL, FGF12, LOC440944/SETD5, VHL, CLCN2, OSBPL10/ZNF860, LMCD1, FAM19A4, CAND2, MAP4, KY and LRRC58.
p79462
sg66298
(lp79463
(dp79464
g66301
I177
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
VLOC440944
p79465
sa(dp79466
g66301
I199
sg66302
I1
sg66303
I5
sg66304
VP51788
p79467
sg66306
VCLCN2
p79468
sa(dp79469
g66301
I245
sg66302
I1
sg66303
I4
sg66304
VP27816
p79470
sg66306
VMAP4
p79471
sa(dp79472
g66301
I238
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCAND2
p79473
sa(dp79474
g66301
I222
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VLMCD1
p79475
sa(dp79476
g66301
I229
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VFAM19A4
p79477
sa(dp79478
g66301
I162
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCTDSPL
p79479
sa(dp79480
g66301
I128
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VBHLHE40
p79481
sa(dp79482
g66301
I187
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSETD5
p79483
sa(dp79484
g66301
I258
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VLRRC58
p79485
sa(dp79486
g66301
I137
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFOXP1
p79487
sa(dp79488
g66301
I194
sg66302
I1
sg66303
I3
sg66304
VP40337
p79489
sg66306
VVHL
p79490
sa(dp79491
g66301
I206
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VOSBPL10
p79492
sa(dp79493
g66301
I170
sg66302
I1
sg66303
I5
sg66304
VP61328
p79494
sg66306
VFGF12
p79495
sa(dp79496
g66301
I155
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VITGA9
p79497
sa(dp79498
g66301
I214
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VZNF860
p79499
sasg66311
(lp79500
(dp79501
g66301
I104
sg66302
I1
sg66303
I6
sg66314
VC0006826
p79502
sg66306
Vcancer
p79503
sa(dp79504
g66301
I194
sg66302
I1
sg66303
I3
sg66314
VC0019562
p79505
sg66306
VVHL
p79506
sasa(dp79507
g66296
VHowever, there is little information about the involvement of MAP4 in human cancer.
p79508
sg66298
(lp79509
(dp79510
g66301
I62
sg66302
I1
sg66303
I4
sg66304
VP27816
p79511
sg66306
VMAP4
p79512
sasg66311
(lp79513
(dp79514
g66301
I76
sg66302
I1
sg66303
I6
sg66314
VC0006826
p79515
sg66306
Vcancer
p79516
sasa(dp79517
g66296
VHere we show that MAP4 serves as a regulator of invasion and migration in esophageal squamous cancer cells.
p79518
sg66298
(lp79519
(dp79520
g66301
I18
sg66302
I1
sg66303
I4
sg66304
VP27816
p79521
sg66306
VMAP4
p79522
sasg66311
(lp79523
(dp79524
g66301
I48
sg66302
I1
sg66303
I8
sg66314
VC2699153
p79525
sg66306
Vinvasion
p79526
sa(dp79527
g66301
I94
sg66302
I1
sg66303
I6
sg66314
VC0006826
p79528
sg66306
Vcancer
p79529
sasa(dp79530
g66296
VThe fusion between echinoderm microtubule-associated protein 4 (EML4) and anaplastic lymphatic tumor kinase (ALK) rearrangement is present in approximately 5% of non-small cell lung cancer (NSCLC) patients.
p79531
sg66298
(lp79532
(dp79533
g66301
I74
sg66302
I4
sg66303
I33
sg66304
g11
sg66306
Vanaplastic lymphatic tumor kinase
p79534
sa(dp79535
g66301
I19
sg66302
I4
sg66303
I43
sg66304
g11
sg66306
Vechinoderm microtubule-associated protein 4
p79536
sa(dp79537
g66301
I64
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VEML4
p79538
sa(dp79539
g66301
I109
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VALK
p79540
sasg66311
(lp79541
(dp79542
g66301
I162
sg66302
I4
sg66303
I26
sg66314
VC0007131
p79543
sg66306
Vnon-small cell lung cancer
p79544
sa(dp79545
g66301
I190
sg66302
I1
sg66303
I5
sg66314
VC0007131
p79546
sg66306
VNSCLC
p79547
sa(dp79548
g66301
I95
sg66302
I1
sg66303
I5
sg66314
VC0027651
p79549
sg66306
Vtumor
p79550
sasa(dp79551
g66296
V#\u80cc#\u666f#\u4e0e#\u76ee#\u7684 #\u68d8#\u76ae#\u52a8#\u7269#\u5fae#\u7ba1#\u76f8#\u5173#\u86cb#\u767d4 (echinoderm microtubule-associated protein 4, EML4) #\u4e0e#\u95f4#\u53d8#\u6027#\u6dcb#\u5df4#\u7624#\u6fc0#\u9176 (anaplastic lymphatic tumor kinase, ALK) #\u91cd#\u6392#\u5f62#\u6210#\u7684#\u878d#\u5408#\u57fa#\u56e0#\u5b58#\u5728#\u4e8e#\u5927#\u7ea65%#\u7684#\u975e#\u5c0f#\u7ec6#\u80de#\u80ba#\u764c (non-small cell lung cancer, NSCLC) #\u60a3#\u8005#\u4e2d, #\u662f#\u7ee7#\u8868#\u76ae#\u751f#\u957f#\u56e0#\u5b50#\u53d7#\u4f53 (epidermal growth factor receptor, EGFR) #\u3001K-ras#\u4e4b#\u540e#\u53c8#\u4e00#\u65b0#\u578b#\u9776#\u70b9#\u57fa#\u56e0#\u3002#\u6709#\u6570#\u636e#\u663e#\u793a#\u643a#\u5e26EML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u7684NSCLC#\u60a3#\u8005#\u63a5#\u53d7ALK#\u6291#\u5236#\u5242#\u6cbb#\u7597#\u540e, #\u5176#\u75be#\u75c5#\u63a7#\u5236#\u7684#\u6709#\u6548#\u7387#\u53ef#\u8fbe80%, #\u63a2#\u7d22#\u548c#\u5efa#\u7acb#\u80fd#\u591f#\u51c6#\u786e#\u5feb#\u901f#\u68c0#\u6d4b#\u51faNSCLC#\u60a3#\u8005EML4-ALK#\u878d#\u5408#\u7a81#\u53d8#\u7684#\u65b9#\u6cd5, #\u662f#\u7b5b#\u9009#\u51fa#\u9002#\u5408#\u6cbb#\u7597#\u7684#\u4f18#\u52bf#\u4eba#\u7fa4#\u7684#\u5173#\u952e#\u3002#\u672c#\u7814#\u7a76#\u5206#\u6790#\u514d#\u75ab#\u7ec4#\u5316#\u6cd5 (immunohistochemistry, IHC) #\u68c0#\u6d4bEML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u7a81#\u53d8#\u7684#\u654f#\u611f#\u5ea6#\u4e0e#\u7279#\u5f02#\u5ea6, #\u8bc4#\u4ef7#\u8be5#\u65b9#\u6cd5#\u51c6#\u786e#\u6027#\u53ca#\u4e34#\u5e8a#\u5e94#\u7528#\u4ef7#\u503c, #\u4ece#\u800c#\u4e3a#\u80ba#\u764c#\u60a3#\u8005"#\u4e2a#\u4f53#\u5316#\u5206#\u5b50#\u6cbb#\u7597"#\u63d0#\u4f9b#\u4f9d#\u636e#\u3002#\u65b9#\u6cd5 #\u901a#\u8fc7Pubmed#\u6570#\u636e#\u5e93#\u68c0#\u7d22#\u6240#\u6709#\u7b26#\u5408#\u68c0#\u7d22#\u6761#\u4ef6#\u7684#\u6587#\u732e, #\u672b#\u6b21#\u68c0#\u7d22#\u65e5#\u671f#\u4e3a2015#\u5e742#\u670825#\u65e5, #\u6839#\u636e#\u7eb3#\u5165#\u548c#\u6392#\u9664#\u6807#\u51c6#\u8fdb#\u884c#\u8fdb#\u4e00#\u6b65#\u7b5b#\u9009, #\u91c7#\u7528#\u8bca#\u65ad#\u8bd5#\u9a8cmeta#\u5206#\u6790#\u65b9#\u6cd5, #\u6bd4#\u8f83#\u7279#\u5f02#\u6027#\u6297#\u4f53#\u514d#\u75ab#\u7ec4#\u5316#\u6cd5#\u4e0e"#\u91d1#\u6807#\u51c6"#\u8367#\u5149#\u539f#\u4f4d#\u6742#\u4ea4 (fluorescence in situ hybridization, FISH) #\u6cd5#\u7684#\u654f#\u611f#\u5ea6#\u3001#\u7279#\u5f02#\u5ea6, #\u4ee5#\u660e#\u786e#\u7279#\u5f02#\u6027#\u6297#\u4f53IHC#\u4f5c#\u4e3a#\u7b5b#\u67e5#\u65b9#\u6cd5#\u7684#\u53ef#\u884c#\u6027#\u3002#\u7ed3#\u679c #\u672c#\u658711#\u7bc7#\u6587#\u732e#\u7eb3#\u5165meta#\u5206#\u6790, EML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u514d#\u75ab#\u7ec4#\u5316#\u7d2f#\u8ba1#\u75c5#\u4f8b3,234#\u4f8b, #\u8bca#\u65ad#\u6bd4#\u503c#\u6bd4 (diagnositic odds ratio, DOR) #\u4e3a1,135.00 (95%CI: 337.10-3,821.46) #\uff1b#\u7efc#\u5408#\u53d7#\u8bd5#\u8005#\u5de5#\u4f5c#\u7279#\u5f81#\u66f2#\u7ebf  (summary receiver operating characteristic curve, SROC) #\u4e0b#\u9762#\u79ef#\u4e3a0.992,3 (SEAUC=0.003,2) , Q*#\u7edf#\u8ba1#\u91cf#\u4e3a0.964,4 (SEQ*=0.008,7) #\u3002#\u7ed3#\u8bba #\u7279#\u5f02#\u6027#\u6297#\u4f53IHC#\u6cd5#\u68c0#\u6d4bEML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u7684#\u65b9#\u6cd5#\u53ef#\u884c, #\u5177#\u6709#\u9ad8#\u7279#\u5f02#\u5ea6#\u548c#\u654f#\u611f#\u5ea6, #\u53ef#\u4f5c#\u4e3a#\u4e00#\u79cd#\u7b80#\u5355#\u5feb#\u901f#\u7684#\u7b5b#\u67e5#\u65b9#\u6cd5, #\u5177#\u6709#\u4e34#\u5e8a#\u5e94#\u7528#\u4ef7#\u503c#\u3002.
p79552
sg66298
(lp79553
(dp79554
g66301
I256
sg66302
I4
sg66303
I32
sg66304
VP01133
p79555
sg66306
Vepidermal growth factor receptor
p79556
sa(dp79557
g66301
I45
sg66302
I3
sg66303
I32
sg66304
VP27816
p79558
sg66306
Vmicrotubule-associated protein 4
p79559
sa(dp79560
g66301
I79
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VEML4
p79561
sa(dp79562
g66301
I140
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VALK
p79563
sa(dp79564
g66301
I79
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VEML4
p79565
sa(dp79566
g66301
I140
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VALK
p79567
sa(dp79568
g66301
I140
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VALK
p79569
sa(dp79570
g66301
I140
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VALK
p79571
sa(dp79572
g66301
I300
sg66302
I1
sg66303
I3
sg66304
VP01116
p79573
sg66306
Vras
p79574
sa(dp79575
g66301
I140
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VALK
p79576
sa(dp79577
g66301
I140
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VALK
p79578
sasg66311
(lp79579
(dp79580
g66301
I191
sg66302
I4
sg66303
I26
sg66314
VC0007131
p79581
sg66306
Vnon-small cell lung cancer
p79582
sa(dp79583
g66301
I126
sg66302
I1
sg66303
I5
sg66314
VC0027651
p79584
sg66306
Vtumor
p79585
sa(dp79586
g66301
I219
sg66302
I1
sg66303
I5
sg66314
VC0007131
p79587
sg66306
VNSCLC
p79588
sasa(dp79589
g66296
VBased on these data, we proposed the set of potential biomarkers for detection of prostate cancer and discrimination between prostate tumors with different malignancy and aggressiveness: BHLHE40, FOXP1, LOC285205, ITGA9, CTDSPL, FGF12, LOC440944/SETD5, VHL, CLCN2, OSBPL10/ZNF860, LMCD1, FAM19A4, CAND2, MAP4, KY, and LRRC58.
p79590
sg66298
(lp79591
(dp79592
g66301
I258
sg66302
I1
sg66303
I5
sg66304
VP51788
p79593
sg66306
VCLCN2
p79594
sa(dp79595
g66301
I318
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VLRRC58
p79596
sa(dp79597
g66301
I281
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VLMCD1
p79598
sa(dp79599
g66301
I187
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VBHLHE40
p79600
sa(dp79601
g66301
I196
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VFOXP1
p79602
sa(dp79603
g66301
I253
sg66302
I1
sg66303
I3
sg66304
VP40337
p79604
sg66306
VVHL
p79605
sa(dp79606
g66301
I246
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VSETD5
p79607
sa(dp79608
g66301
I288
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VFAM19A4
p79609
sa(dp79610
g66301
I229
sg66302
I1
sg66303
I5
sg66304
VP61328
p79611
sg66306
VFGF12
p79612
sa(dp79613
g66301
I221
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCTDSPL
p79614
sa(dp79615
g66301
I304
sg66302
I1
sg66303
I4
sg66304
VP27816
p79616
sg66306
VMAP4
p79617
sa(dp79618
g66301
I214
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VITGA9
p79619
sa(dp79620
g66301
I265
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VOSBPL10
p79621
sa(dp79622
g66301
I297
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VCAND2
p79623
sa(dp79624
g66301
I273
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VZNF860
p79625
sa(dp79626
g66301
I236
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
VLOC440944
p79627
sasg66311
(lp79628
(dp79629
g66301
I82
sg66302
I2
sg66303
I15
sg66314
VC0600139
p79630
sg66306
Vprostate cancer
p79631
sa(dp79632
g66301
I125
sg66302
I2
sg66303
I15
sg66314
VC0033578
p79633
sg66306
Vprostate tumors
p79634
sa(dp79635
g66301
I171
sg66302
I1
sg66303
I14
sg66314
VC0001807
p79636
sg66306
Vaggressiveness
p79637
sa(dp79638
g66301
I156
sg66302
I1
sg66303
I10
sg66314
VC0006826
p79639
sg66306
Vmalignancy
p79640
sa(dp79641
g66301
I253
sg66302
I1
sg66303
I3
sg66314
VC0019562
p79642
sg66306
VVHL
p79643
sasa(dp79644
g66296
VWe also analyzed gene expression of MAP4 in 34 patients with bladder cancer using immunohistochemical staining assay.
p79645
sg66298
(lp79646
(dp79647
g66301
I36
sg66302
I1
sg66303
I4
sg66304
VP27816
p79648
sg66306
VMAP4
p79649
sasg66311
(lp79650
(dp79651
g66301
I61
sg66302
I2
sg66303
I14
sg66314
VC0699885
p79652
sg66306
Vbladder cancer
p79653
sasa(dp79654
g66296
VWe used cAMP elevators and small interfering RNA of MAP4 here, found that both of them can potently inhibit the invasion and the migration of bladder cancer cells by disrupting microtubule (MT) cytoskeleton.
p79655
sg66298
(lp79656
(dp79657
g66301
I52
sg66302
I1
sg66303
I4
sg66304
VP27816
p79658
sg66306
VMAP4
p79659
sasg66311
(lp79660
(dp79661
g66301
I112
sg66302
I1
sg66303
I8
sg66314
VC2699153
p79662
sg66306
Vinvasion
p79663
sa(dp79664
g66301
I142
sg66302
I2
sg66303
I14
sg66314
VC0699885
p79665
sg66306
Vbladder cancer
p79666
sasa(dp79667
g66296
VConsistently, the bladder cancer grade is positively correlated with the protein level of MAP4.
p79668
sg66298
(lp79669
(dp79670
g66301
I90
sg66302
I1
sg66303
I4
sg66304
VP27816
p79671
sg66306
VMAP4
p79672
sasg66311
(lp79673
(dp79674
g66301
I18
sg66302
I2
sg66303
I14
sg66314
VC0699885
p79675
sg66306
Vbladder cancer
p79676
sasa(dp79677
g66296
VOur results indicated that the cAMP/PKA signaling pathway might inhibit bladder cancer cell invasion by targeting MAP4-dependent microtubule dynamics, which could be exploited for the therapy of invasive bladder cancer.
p79678
sg66298
(lp79679
(dp79680
g66301
I114
sg66302
I1
sg66303
I4
sg66304
VP27816
p79681
sg66306
VMAP4
p79682
sa(dp79683
g66301
I36
sg66302
I1
sg66303
I3
sg66304
VP17612
p79684
sg66306
VPKA
p79685
sasg66311
(lp79686
(dp79687
g66301
I87
sg66302
I2
sg66303
I13
sg66314
VC2699153
p79688
sg66306
Vcell invasion
p79689
sa(dp79690
g66301
I72
sg66302
I2
sg66303
I14
sg66314
VC0699885
p79691
sg66306
Vbladder cancer
p79692
sa(dp79693
g66301
I195
sg66302
I3
sg66303
I23
sg66314
VC0859917
p79694
sg66306
Vinvasive bladder cancer
p79695
sasa(dp79696
g66296
VIrritable bowel syndrome symptoms consistently improved after 3 weeks of LFD, and significantly more participants reported symptom relief in response to placebo (80%) than FOS (30%).
p79697
sg66298
(lp79698
sg66311
(lp79699
(dp79700
g66301
I25
sg66302
I1
sg66303
I7
sg66314
VC1457887
p79701
sg66306
Vsymptom
p79702
sa(dp79703
g66301
I0
sg66302
I3
sg66303
I24
sg66314
VC0022104
p79704
sg66306
VIrritable bowel syndrome
p79705
sasa(dp79706
g66296
VChildren with congenital esophageal atresia (EA) and tracheoesophageal fistula (TEF) have chronic respiratory symptoms including recurrent pneumonia, wheezing and persistent cough.
p79707
sg66298
(lp79708
sg66311
(lp79709
(dp79710
g66301
I25
sg66302
I2
sg66303
I18
sg66314
VC0014850
p79711
sg66306
Vesophageal atresia
p79712
sa(dp79713
g66301
I163
sg66302
I2
sg66303
I16
sg66314
VC0562483
p79714
sg66306
Vpersistent cough
p79715
sa(dp79716
g66301
I80
sg66302
I1
sg66303
I3
sg66314
VC0040588
p79717
sg66306
VTEF
p79718
sa(dp79719
g66301
I129
sg66302
I2
sg66303
I19
sg66314
VC0694550
p79720
sg66306
Vrecurrent pneumonia
p79721
sa(dp79722
g66301
I45
sg66302
I1
sg66303
I2
sg66314
VC0014850
p79723
sg66306
VEA
p79724
sa(dp79725
g66301
I150
sg66302
I1
sg66303
I8
sg66314
VC0043144
p79726
sg66306
Vwheezing
p79727
sa(dp79728
g66301
I53
sg66302
I2
sg66303
I25
sg66314
VC0040588
p79729
sg66306
Vtracheoesophageal fistula
p79730
sa(dp79731
g66301
I98
sg66302
I2
sg66303
I20
sg66314
VC0037090
p79732
sg66306
Vrespiratory symptoms
p79733
sasa(dp79734
g66296
VAdult patients experiencing symptoms of cough and recurrent aspiration pneumonia should be evaluated for congenital TEF.
p79735
sg66298
(lp79736
sg66311
(lp79737
(dp79738
g66301
I50
sg66302
I3
sg66303
I30
sg66314
VC0747651
p79739
sg66306
Vrecurrent aspiration pneumonia
p79740
sa(dp79741
g66301
I40
sg66302
I1
sg66303
I5
sg66314
VC0010200
p79742
sg66306
Vcough
p79743
sasa(dp79744
g66296
VOur patient underwent primary repair of OA/TEF malformations, which was later complicated by pneumonia and a recurrent TEF.
p79745
sg66298
(lp79746
sg66311
(lp79747
(dp79748
g66301
I93
sg66302
I1
sg66303
I9
sg66314
VC0032285
p79749
sg66306
Vpneumonia
p79750
sa(dp79751
g66301
I47
sg66302
I1
sg66303
I13
sg66314
VC0000768
p79752
sg66306
Vmalformations
p79753
sasa(dp79754
g66296
VThese findings suggest that a relatively small increase in plasma TNF-Alfa, and decreases in urine TNF-Alfa, GM-CSF, and IL-15 from just before to just after the diagnosis of pneumonia could be markers for an increased risk of PUs in individuals with pneumonia after traumatic SCI.
p79755
sg66298
(lp79756
(dp79757
g66301
I121
sg66302
I1
sg66303
I5
sg66304
VP40933
p79758
sg66306
VIL-15
p79759
sa(dp79760
g66301
I93
sg66302
I2
sg66303
I14
sg66304
VP01375
p79761
sg66306
Vurine TNF-Alfa
p79762
sa(dp79763
g66301
I109
sg66302
I1
sg66303
I6
sg66304
VP04141
p79764
sg66306
VGM-CSF
p79765
sa(dp79766
g66301
I66
sg66302
I1
sg66303
I3
sg66304
VP01375
p79767
sg66306
VTNF
p79768
sasg66311
(lp79769
(dp79770
g66301
I175
sg66302
I1
sg66303
I9
sg66314
VC0032285
p79771
sg66306
Vpneumonia
p79772
sa(dp79773
g66301
I175
sg66302
I1
sg66303
I9
sg66314
VC0032285
p79774
sg66306
Vpneumonia
p79775
sasa(dp79776
g66296
VThe study aimed to investigate the innate cytokine interleukin-15 (IL-15) as a marker of disease severity.A prospective single-centre observational study was conducted in a university-affiliated paediatric teaching hospital, comparing children (0-18 months) hospitalised for viral bronchiolitis, those admitted to the paediatric intensive care unit with severe disease and healthy age-matched controls.
p79777
sg66298
(lp79778
(dp79779
g66301
I67
sg66302
I1
sg66303
I5
sg66304
VP40933
p79780
sg66306
VIL-15
p79781
sa(dp79782
g66301
I42
sg66302
I2
sg66303
I23
sg66304
VP13236
p79783
sg66306
Vcytokine interleukin-15
p79784
sasg66311
(lp79785
(dp79786
g66301
I275
sg66302
I2
sg66303
I19
sg66314
VC0006274
p79787
sg66306
Vviral bronchiolitis
p79788
sasa(dp79789
g66296
VPeripheral blood mononuclear cell (PBMC) IL-15 mRNA expression was significantly higher in those with moderate severity bronchiolitis compared with controls and those with severe disease.
p79790
sg66298
(lp79791
(dp79792
g66301
I11
sg66302
I6
sg66303
I40
sg66304
VP40933
p79793
sg66306
Vblood mononuclear cell (PBMC) IL-15 mRNA
p79794
sasg66311
(lp79795
(dp79796
g66301
I120
sg66302
I1
sg66303
I13
sg66314
VC0006271
p79797
sg66306
Vbronchiolitis
p79798
sasa(dp79799
g66296
VTargets of de-regulated miRNA were differentially expressed in bronchiolitis, including JAK3, STAT5A and NFKB1 on the IL-15 signalling pathway.IL-15 is associated with disease severity in children hospitalised with viral bronchiolitis.
p79800
sg66298
(lp79801
(dp79802
g66301
I88
sg66302
I1
sg66303
I4
sg66304
VP52333
p79803
sg66306
VJAK3
p79804
sa(dp79805
g66301
I118
sg66302
I3
sg66303
I30
sg66304
VP40933
p79806
sg66306
VIL-15 signalling pathway.IL-15
p79807
sa(dp79808
g66301
I105
sg66302
I1
sg66303
I5
sg66304
VP19838
p79809
sg66306
VNFKB1
p79810
sa(dp79811
g66301
I94
sg66302
I1
sg66303
I6
sg66304
VP42229
p79812
sg66306
VSTAT5A
p79813
sasg66311
(lp79814
(dp79815
g66301
I215
sg66302
I2
sg66303
I19
sg66314
VC0006274
p79816
sg66306
Vviral bronchiolitis
p79817
sa(dp79818
g66301
I63
sg66302
I1
sg66303
I13
sg66314
VC0006271
p79819
sg66306
Vbronchiolitis
p79820
sasa(dp79821
g66296
VThe present study aimed to investigate the role of Interleukin 15 (IL-15) in protein degradation in skeletal muscle mediated by the ubiquitin-proteasome pathway (UPP) in a rat model of chronic obstructive pulmonary disease (COPD).
p79822
sg66298
(lp79823
(dp79824
g66301
I132
sg66302
I1
sg66303
I9
sg66304
VP62979
p79825
sg66306
Vubiquitin
p79826
sa(dp79827
g66301
I51
sg66302
I2
sg66303
I14
sg66304
VP40933
p79828
sg66306
VInterleukin 15
p79829
sa(dp79830
g66301
I67
sg66302
I1
sg66303
I5
sg66304
VP40933
p79831
sg66306
VIL-15
p79832
sasg66311
(lp79833
(dp79834
g66301
I185
sg66302
I4
sg66303
I37
sg66314
VC0024117
p79835
sg66306
Vchronic obstructive pulmonary disease
p79836
sa(dp79837
g66301
I224
sg66302
I1
sg66303
I4
sg66314
VC0024117
p79838
sg66306
VCOPD
p79839
sasa(dp79840
g66296
VPatients with SWA were older at seizure diagnosis than those with SA (p=0.04), were less often referred for evaluation of seizures or epilepsy (p=0.04), and were referred faster for VEM, despite SWA were significantly less likely to include motor manifestations (p=0.0004).
p79841
sg66298
(lp79842
sg66311
(lp79843
(dp79844
g66301
I122
sg66302
I1
sg66303
I8
sg66314
VC0036572
p79845
sg66306
Vseizures
p79846
sa(dp79847
g66301
I32
sg66302
I1
sg66303
I7
sg66314
VC0036572
p79848
sg66306
Vseizure
p79849
sa(dp79850
g66301
I134
sg66302
I1
sg66303
I8
sg66314
VC0014544
p79851
sg66306
Vepilepsy
p79852
sa(dp79853
g66301
I241
sg66302
I2
sg66303
I20
sg66314
VC1334804
p79854
sg66306
Vmotor manifestations
p79855
sasa(dp79856
g66296
VWe suggest that patients with SWA have a unique epilepsy syndrome.
p79857
sg66298
(lp79858
sg66311
(lp79859
(dp79860
g66301
I57
sg66302
I1
sg66303
I8
sg66314
VC0039082
p79861
sg66306
Vsyndrome
p79862
sa(dp79863
g66301
I48
sg66302
I1
sg66303
I8
sg66314
VC0014544
p79864
sg66306
Vepilepsy
p79865
sasa(dp79866
g66296
VAchilles tendon (T) and Hoffmann (H) reflexes were evoked during spike and wave activity (SWA) in 6 patients with generalized epilepsy, selected on the basis of their photosensitivity.
p79867
sg66298
(lp79868
sg66311
(lp79869
(dp79870
g66301
I167
sg66302
I1
sg66303
I16
sg66314
VC0393720
p79871
sg66306
Vphotosensitivity
p79872
sa(dp79873
g66301
I114
sg66302
I2
sg66303
I20
sg66314
VC0014548
p79874
sg66306
Vgeneralized epilepsy
p79875
sasa(dp79876
g66296
VPartial epilepsy after shunting manifested itself in 15 patients, but this did not correlate with the side of the shunt or with the side of the SWA in the EEG.
p79877
sg66298
(lp79878
sg66311
(lp79879
(dp79880
g66301
I0
sg66302
I2
sg66303
I16
sg66314
VC0014547
p79881
sg66306
VPartial epilepsy
p79882
sasa(dp79883
g66296
VWe hypothesized that the NDI may be due to of severe hypokalemia induced tubular dysfunction.
p79884
sg66298
(lp79885
sg66311
(lp79886
(dp79887
g66301
I25
sg66302
I1
sg66303
I3
sg66314
VC1563705
p79888
sg66306
VNDI
p79889
sasa(dp79890
g66296
VPreviously, we reported an increase of V1aR mRNA and a decrease of V2R mRNA in the collecting ducts under chronic metabolic acidosis.
p79891
sg66298
(lp79892
(dp79893
g66301
I39
sg66302
I2
sg66303
I9
sg66304
VP37288
p79894
sg66306
VV1aR mRNA
p79895
sa(dp79896
g66301
I67
sg66302
I2
sg66303
I8
sg66304
VP30518
p79897
sg66306
VV2R mRNA
p79898
sasg66311
(lp79899
(dp79900
g66301
I114
sg66302
I2
sg66303
I18
sg66314
VC0220981
p79901
sg66306
Vmetabolic acidosis
p79902
sasa(dp79903
g66296
VPatients with moderate to severe nonproliferative diabetic retinopathy (NPDR) had POBF 18% higher than the control (mean OBF, 943 microL/min).
p79904
sg66298
(lp79905
sg66311
(lp79906
(dp79907
g66301
I26
sg66302
I4
sg66303
I44
sg66314
VC0730278
p79908
sg66306
Vsevere nonproliferative diabetic retinopathy
p79909
sasa(dp79910
g66296
VAmong PRP-treated subjects with PDR, ocular blood flow was 22% below the control (mean OBF, 619 microL/min), and 34% less than moderate to severe nonproliferative diabetic retinopathy.
p79911
sg66298
(lp79912
(dp79913
g66301
I6
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPRP
p79914
sasg66311
(lp79915
(dp79916
g66301
I139
sg66302
I4
sg66303
I44
sg66314
VC0730278
p79917
sg66306
Vsevere nonproliferative diabetic retinopathy
p79918
sa(dp79919
g66301
I32
sg66302
I1
sg66303
I3
sg66314
VC1845050
p79920
sg66306
VPDR
p79921
sasa(dp79922
g66296
VDiabetic patients with no retinopathy or mild NPDR had OBF indistinguishable from the control (785 vs. 797 microL/min).
p79923
sg66298
(lp79924
sg66311
(lp79925
(dp79926
g66301
I26
sg66302
I1
sg66303
I11
sg66314
VC0035309
p79927
sg66306
Vretinopathy
p79928
sasa(dp79929
g66296
VPOBF is unaffected early in diabetic retinopathy, but increases significantly in eyes with moderate to severe NPDR.
p79930
sg66298
(lp79931
sg66311
(lp79932
(dp79933
g66301
I28
sg66302
I2
sg66303
I20
sg66314
VC0011884
p79934
sg66306
Vdiabetic retinopathy
p79935
sa(dp79936
g66301
I103
sg66302
I2
sg66303
I11
sg66314
VC0730278
p79937
sg66306
Vsevere NPDR
p79938
sasa(dp79939
g66296
VThese experimental data represent the largest published assessment of POBF in NPDR.
p79940
sg66298
(lp79941
sg66311
(lp79942
sa(dp79943
g66296
VPOBF in the patients with non-exudative and exudative age related macular degeneration (AMD) was investigated.
p79944
sg66298
(lp79945
sg66311
(lp79946
(dp79947
g66301
I88
sg66302
I1
sg66303
I3
sg66314
VC0242383
p79948
sg66306
VAMD
p79949
sa(dp79950
g66301
I54
sg66302
I4
sg66303
I32
sg66314
VC0242383
p79951
sg66306
Vage related macular degeneration
p79952
sasa(dp79953
g66296
VThe POBF increased but was still below normal levels at the NPDR stage, and then increased to an above normal level in the PPDR/PDR stage of diabetic retinopathy.
p79954
sg66298
(lp79955
sg66311
(lp79956
(dp79957
g66301
I141
sg66302
I2
sg66303
I20
sg66314
VC0011884
p79958
sg66306
Vdiabetic retinopathy
p79959
sa(dp79960
g66301
I61
sg66302
I1
sg66303
I3
sg66314
VC1845050
p79961
sg66306
VPDR
p79962
sasa(dp79963
g66296
VRight before and one month after this fourth vaccine dose, the avidity of IgG antibodies against diphtheria toxin (DT), tetanus toxin (TT), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (Prn) was determined using 1.5 M ammonium thiocyanate as dissociating agent.
p79964
sg66298
(lp79965
(dp79966
g66301
I209
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPrn
p79967
sa(dp79968
g66301
I198
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
Vpertactin
p79969
sa(dp79970
g66301
I115
sg66302
I1
sg66303
I2
sg66304
g11
sg66306
VDT
p79971
sa(dp79972
g66301
I140
sg66302
I2
sg66303
I15
sg66304
g11
sg66306
Vpertussis toxin
p79973
sa(dp79974
g66301
I97
sg66302
I2
sg66303
I16
sg66304
g11
sg66306
Vdiphtheria toxin
p79975
sa(dp79976
g66301
I157
sg66302
I1
sg66303
I2
sg66304
g11
sg66306
VPT
p79977
sasg66311
(lp79978
(dp79979
g66301
I162
sg66302
I2
sg66303
I25
sg66314
VC1704429
p79980
sg66306
Vfilamentous hemagglutinin
p79981
sa(dp79982
g66301
I189
sg66302
I1
sg66303
I3
sg66314
VC1704429
p79983
sg66306
VFHA
p79984
sa(dp79985
g66301
I140
sg66302
I1
sg66303
I9
sg66314
VC0043167
p79986
sg66306
Vpertussis
p79987
sa(dp79988
g66301
I120
sg66302
I1
sg66303
I7
sg66314
VC0039614
p79989
sg66306
Vtetanus
p79990
sa(dp79991
g66301
I97
sg66302
I1
sg66303
I10
sg66314
VC0012546
p79992
sg66306
Vdiphtheria
p79993
sasa(dp79994
g66296
VImmunoglobulin G (IgG) antibodies against pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), tetanus toxoid (TT), and diphtheria toxoid (DT) were measured using commercially available enzyme-linked immunosorbent assays (ELISA).
p79995
sg66298
(lp79996
(dp79997
g66301
I18
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VIgG
p79998
sa(dp79999
g66301
I97
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
Vpertactin
p80000
sa(dp80001
g66301
I108
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPrn
p80002
sa(dp80003
g66301
I0
sg66302
I2
sg66303
I16
sg66304
g11
sg66306
VImmunoglobulin G
p80004
sa(dp80005
g66301
I59
sg66302
I1
sg66303
I2
sg66304
g11
sg66306
VPT
p80006
sa(dp80007
g66301
I42
sg66302
I2
sg66303
I15
sg66304
g11
sg66306
Vpertussis toxin
p80008
sasg66311
(lp80009
(dp80010
g66301
I42
sg66302
I1
sg66303
I9
sg66314
VC0043167
p80011
sg66306
Vpertussis
p80012
sa(dp80013
g66301
I64
sg66302
I2
sg66303
I25
sg66314
VC1704429
p80014
sg66306
Vfilamentous hemagglutinin
p80015
sa(dp80016
g66301
I114
sg66302
I1
sg66303
I7
sg66314
VC0039614
p80017
sg66306
Vtetanus
p80018
sa(dp80019
g66301
I139
sg66302
I1
sg66303
I10
sg66314
VC0012546
p80020
sg66306
Vdiphtheria
p80021
sa(dp80022
g66301
I91
sg66302
I1
sg66303
I3
sg66314
VC1704429
p80023
sg66306
VFHA
p80024
sasa(dp80025
g66296
VWe have developed a magnetic bead-based pentaplex immunoassay (MIA) for the simultaneous detection of IgG antibodies against diphtheria toxin (DT), tetanus toxin (TT), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (Prn).
p80026
sg66298
(lp80027
(dp80028
g66301
I185
sg66302
I1
sg66303
I2
sg66304
g11
sg66306
VPT
p80029
sa(dp80030
g66301
I237
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPrn
p80031
sa(dp80032
g66301
I143
sg66302
I1
sg66303
I2
sg66304
g11
sg66306
VDT
p80033
sa(dp80034
g66301
I226
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
Vpertactin
p80035
sa(dp80036
g66301
I168
sg66302
I2
sg66303
I15
sg66304
g11
sg66306
Vpertussis toxin
p80037
sa(dp80038
g66301
I125
sg66302
I2
sg66303
I16
sg66304
g11
sg66306
Vdiphtheria toxin
p80039
sasg66311
(lp80040
(dp80041
g66301
I148
sg66302
I1
sg66303
I7
sg66314
VC0039614
p80042
sg66306
Vtetanus
p80043
sa(dp80044
g66301
I190
sg66302
I2
sg66303
I25
sg66314
VC1704429
p80045
sg66306
Vfilamentous hemagglutinin
p80046
sa(dp80047
g66301
I168
sg66302
I1
sg66303
I9
sg66314
VC0043167
p80048
sg66306
Vpertussis
p80049
sa(dp80050
g66301
I217
sg66302
I1
sg66303
I3
sg66314
VC1704429
p80051
sg66306
VFHA
p80052
sa(dp80053
g66301
I125
sg66302
I1
sg66303
I10
sg66314
VC0012546
p80054
sg66306
Vdiphtheria
p80055
sasa(dp80056
g66296
VImmunoglobulin G (IgG) antibodies against pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), tetanus toxoid (TT) and diphtheria toxoid (DT) were measured using commercially available ELISA tests.
p80057
sg66298
(lp80058
(dp80059
g66301
I18
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VIgG
p80060
sa(dp80061
g66301
I97
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
Vpertactin
p80062
sa(dp80063
g66301
I108
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPrn
p80064
sa(dp80065
g66301
I0
sg66302
I2
sg66303
I16
sg66304
g11
sg66306
VImmunoglobulin G
p80066
sa(dp80067
g66301
I59
sg66302
I1
sg66303
I2
sg66304
g11
sg66306
VPT
p80068
sa(dp80069
g66301
I42
sg66302
I2
sg66303
I15
sg66304
g11
sg66306
Vpertussis toxin
p80070
sasg66311
(lp80071
(dp80072
g66301
I42
sg66302
I1
sg66303
I9
sg66314
VC0043167
p80073
sg66306
Vpertussis
p80074
sa(dp80075
g66301
I64
sg66302
I2
sg66303
I25
sg66314
VC1704429
p80076
sg66306
Vfilamentous hemagglutinin
p80077
sa(dp80078
g66301
I114
sg66302
I1
sg66303
I7
sg66314
VC0039614
p80079
sg66306
Vtetanus
p80080
sa(dp80081
g66301
I138
sg66302
I1
sg66303
I10
sg66314
VC0012546
p80082
sg66306
Vdiphtheria
p80083
sa(dp80084
g66301
I91
sg66302
I1
sg66303
I3
sg66314
VC1704429
p80085
sg66306
VFHA
p80086
sasa(dp80087
g66296
VAntibody geometric mean concentrations (GMCs) against tetanus (TT), diphtheria (DT), pertussis toxin (PT), filamentous haemagglutinin (FHA) and pertactin (Prn) were measured with commercial ELISA tests in samples taken preceding maternal vaccination and one month afterwards, at delivery and from the cord blood, and in infants before and 1 month after the primary series of 3 pertussis containing hexavalent vaccines.
p80088
sg66298
(lp80089
(dp80090
g66301
I155
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPrn
p80091
sa(dp80092
g66301
I144
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
Vpertactin
p80093
sa(dp80094
g66301
I85
sg66302
I2
sg66303
I15
sg66304
g11
sg66306
Vpertussis toxin
p80095
sa(dp80096
g66301
I102
sg66302
I1
sg66303
I2
sg66304
g11
sg66306
VPT
p80097
sasg66311
(lp80098
(dp80099
g66301
I301
sg66302
I1
sg66303
I4
sg66314
VC0035334
p80100
sg66306
Vcord
p80101
sa(dp80102
g66301
I135
sg66302
I1
sg66303
I3
sg66314
VC1704429
p80103
sg66306
VFHA
p80104
sa(dp80105
g66301
I85
sg66302
I1
sg66303
I9
sg66314
VC0043167
p80106
sg66306
Vpertussis
p80107
sa(dp80108
g66301
I85
sg66302
I1
sg66303
I9
sg66314
VC0043167
p80109
sg66306
Vpertussis
p80110
sa(dp80111
g66301
I68
sg66302
I1
sg66303
I10
sg66314
VC0012546
p80112
sg66306
Vdiphtheria
p80113
sa(dp80114
g66301
I54
sg66302
I1
sg66303
I7
sg66314
VC0039614
p80115
sg66306
Vtetanus
p80116
sa(dp80117
g66301
I107
sg66302
I2
sg66303
I26
sg66314
VC1704429
p80118
sg66306
Vfilamentous haemagglutinin
p80119
sa(dp80120
g66301
I63
sg66302
I1
sg66303
I2
sg66314
VC0039614
p80121
sg66306
VTT
p80122
sa(dp80123
g66301
I80
sg66302
I1
sg66303
I2
sg66314
VC0012546
p80124
sg66306
VDT
p80125
sasa(dp80126
g66296
VImmunoglobulin G (IgG) against tetanus (TT), diphtheria (DT), pertussis toxin (PT), filamentous hemaglutinin (FHA) and pertactin (Prn) were measured using commercial ELISA tests, at baseline, 1 month after maternal vaccination, at delivery, and in infants from cord blood and before and after the primary series (EPI: month 2-3-4) of a pertussis containing vaccine.
p80127
sg66298
(lp80128
(dp80129
g66301
I18
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VIgG
p80130
sa(dp80131
g66301
I79
sg66302
I1
sg66303
I2
sg66304
g11
sg66306
VPT
p80132
sa(dp80133
g66301
I0
sg66302
I2
sg66303
I16
sg66304
g11
sg66306
VImmunoglobulin G
p80134
sa(dp80135
g66301
I62
sg66302
I2
sg66303
I15
sg66304
g11
sg66306
Vpertussis toxin
p80136
sa(dp80137
g66301
I119
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
Vpertactin
p80138
sa(dp80139
g66301
I130
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPrn
p80140
sasg66311
(lp80141
(dp80142
g66301
I62
sg66302
I1
sg66303
I9
sg66314
VC0043167
p80143
sg66306
Vpertussis
p80144
sa(dp80145
g66301
I45
sg66302
I1
sg66303
I10
sg66314
VC0012546
p80146
sg66306
Vdiphtheria
p80147
sa(dp80148
g66301
I62
sg66302
I1
sg66303
I9
sg66314
VC0043167
p80149
sg66306
Vpertussis
p80150
sa(dp80151
g66301
I57
sg66302
I1
sg66303
I2
sg66314
VC0012546
p80152
sg66306
VDT
p80153
sa(dp80154
g66301
I31
sg66302
I1
sg66303
I7
sg66314
VC0039614
p80155
sg66306
Vtetanus
p80156
sa(dp80157
g66301
I84
sg66302
I2
sg66303
I24
sg66314
VC1704429
p80158
sg66306
Vfilamentous hemaglutinin
p80159
sa(dp80160
g66301
I110
sg66302
I1
sg66303
I3
sg66314
VC1704429
p80161
sg66306
VFHA
p80162
sa(dp80163
g66301
I261
sg66302
I1
sg66303
I4
sg66314
VC0035334
p80164
sg66306
Vcord
p80165
sa(dp80166
g66301
I40
sg66302
I1
sg66303
I2
sg66314
VC0039614
p80167
sg66306
VTT
p80168
sa(dp80169
g66301
I313
sg66302
I1
sg66303
I3
sg66314
VC0267963
p80170
sg66306
VEPI
p80171
sasa(dp80172
g66296
VAnti-Pertussis Toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), tetanus toxin (TT) and diphtheria toxin (DT) antibodies were measured by ELISA.
p80173
sg66298
(lp80174
(dp80175
g66301
I100
sg66302
I4
sg66303
I32
sg66304
g11
sg66306
Vdiphtheria toxin (DT) antibodies
p80176
sa(dp80177
g66301
I22
sg66302
I1
sg66303
I2
sg66304
g11
sg66306
VPT
p80178
sa(dp80179
g66301
I71
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPrn
p80180
sa(dp80181
g66301
I60
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
Vpertactin
p80182
sa(dp80183
g66301
I0
sg66302
I2
sg66303
I20
sg66304
g11
sg66306
VAnti-Pertussis Toxin
p80184
sasg66311
(lp80185
(dp80186
g66301
I5
sg66302
I1
sg66303
I9
sg66314
VC0043167
p80187
sg66306
VPertussis
p80188
sa(dp80189
g66301
I54
sg66302
I1
sg66303
I3
sg66314
VC1704429
p80190
sg66306
VFHA
p80191
sa(dp80192
g66301
I77
sg66302
I1
sg66303
I7
sg66314
VC0039614
p80193
sg66306
Vtetanus
p80194
sa(dp80195
g66301
I27
sg66302
I2
sg66303
I25
sg66314
VC1704429
p80196
sg66306
Vfilamentous hemagglutinin
p80197
sa(dp80198
g66301
I100
sg66302
I1
sg66303
I10
sg66314
VC0012546
p80199
sg66306
Vdiphtheria
p80200
sasa(dp80201
g66296
VGeometric mean titers were not different after prebiotic supplementation at 5 months, Ptx (37/44 EU/ml), FHA (78/96 EU/ml), Prn (78/80 EU/ml), Diphtheria (0.40/0.57 IU/ml), Tetanus (0.74/0.99 IU/ml) and Hib (0.35/0.63 myg/ml), and at 12 months Ptx (55/66 EU/ml), FHA (122/119 EU/ml), Prn (116/106 Eu/ml), Diphtheria (0.88/1.11 IU/ml), Tetanus (1.64/1.79 IU/ml) and Hib (2.91/2.55 myg/ml).
p80202
sg66298
(lp80203
(dp80204
g66301
I124
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPrn
p80205
sasg66311
(lp80206
(dp80207
g66301
I173
sg66302
I1
sg66303
I7
sg66314
VC0039614
p80208
sg66306
VTetanus
p80209
sa(dp80210
g66301
I105
sg66302
I1
sg66303
I3
sg66314
VC1704429
p80211
sg66306
VFHA
p80212
sa(dp80213
g66301
I105
sg66302
I1
sg66303
I3
sg66314
VC1704429
p80214
sg66306
VFHA
p80215
sa(dp80216
g66301
I173
sg66302
I1
sg66303
I7
sg66314
VC0039614
p80217
sg66306
VTetanus
p80218
sa(dp80219
g66301
I143
sg66302
I1
sg66303
I10
sg66314
VC0012546
p80220
sg66306
VDiphtheria
p80221
sa(dp80222
g66301
I143
sg66302
I1
sg66303
I10
sg66314
VC0012546
p80223
sg66306
VDiphtheria
p80224
sasa(dp80225
g66296
VThis multiplex immunoassay (MIA) can simultaneously determine levels of specific mouse serum IgG antibodies to P antigens P.69 pertactin (P.69 Prn), filamentous hemagglutinin (FHA), pertussis toxin (Ptx), and combined fimbria type 2 and 3 antigens (Fim2/3) and to diphtheria toxin (Dtx) and tetanus toxin (TT) in a single well.
p80226
sg66298
(lp80227
(dp80228
g66301
I199
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPtx
p80229
sa(dp80230
g66301
I249
sg66302
I1
sg66303
I6
sg66304
VP07333
p80231
sg66306
VFim2/3
p80232
sa(dp80233
g66301
I138
sg66302
I2
sg66303
I8
sg66304
g11
sg66306
VP.69 Prn
p80234
sa(dp80235
g66301
I81
sg66302
I4
sg66303
I26
sg66304
g11
sg66306
Vmouse serum IgG antibodies
p80236
sa(dp80237
g66301
I111
sg66302
I4
sg66303
I25
sg66304
VP01893
p80238
sg66306
VP antigens P.69 pertactin
p80239
sa(dp80240
g66301
I264
sg66302
I2
sg66303
I16
sg66304
g11
sg66306
Vdiphtheria toxin
p80241
sa(dp80242
g66301
I209
sg66302
I7
sg66303
I38
sg66304
VP01893
p80243
sg66306
Vcombined fimbria type 2 and 3 antigens
p80244
sa(dp80245
g66301
I282
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VDtx
p80246
sa(dp80247
g66301
I182
sg66302
I2
sg66303
I15
sg66304
g11
sg66306
Vpertussis toxin
p80248
sasg66311
(lp80249
(dp80250
g66301
I182
sg66302
I1
sg66303
I9
sg66314
VC0043167
p80251
sg66306
Vpertussis
p80252
sa(dp80253
g66301
I264
sg66302
I1
sg66303
I10
sg66314
VC0012546
p80254
sg66306
Vdiphtheria
p80255
sa(dp80256
g66301
I176
sg66302
I1
sg66303
I3
sg66314
VC1704429
p80257
sg66306
VFHA
p80258
sa(dp80259
g66301
I149
sg66302
I2
sg66303
I25
sg66314
VC1704429
p80260
sg66306
Vfilamentous hemagglutinin
p80261
sa(dp80262
g66301
I291
sg66302
I1
sg66303
I7
sg66314
VC0039614
p80263
sg66306
Vtetanus
p80264
sasa(dp80265
g66296
VOur recent study showed reduced G protein Gamma2 subunit (Gng2/GNG2) expression levels in malignant melanoma cells compared with those in benign melanocytic cells in both mice and humans.
p80266
sg66298
(lp80267
(dp80268
g66301
I63
sg66302
I1
sg66303
I4
sg66304
VP59768
p80269
sg66306
VGNG2
p80270
sa(dp80271
g66301
I58
sg66302
I1
sg66303
I4
sg66304
VP59768
p80272
sg66306
VGng2
p80273
sa(dp80274
g66301
I32
sg66302
I4
sg66303
I24
sg66304
VP59768
p80275
sg66306
VG protein Gamma2 subunit
p80276
sasg66311
(lp80277
(dp80278
g66301
I90
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80279
sg66306
Vmalignant melanoma
p80280
sasa(dp80281
g66296
VOur recent study also showed that reduced GNG2 alone augmented proliferation of malignant melanoma cells.
p80282
sg66298
(lp80283
(dp80284
g66301
I42
sg66302
I1
sg66303
I4
sg66304
VP59768
p80285
sg66306
VGNG2
p80286
sasg66311
(lp80287
(dp80288
g66301
I80
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80289
sg66306
Vmalignant melanoma
p80290
sa(dp80291
g66301
I63
sg66302
I1
sg66303
I13
sg66314
VC0334094
p80292
sg66306
Vproliferation
p80293
sasa(dp80294
g66296
VTo our knowledge, however, there is no evidence showing an effect of Gng2/GNG2 alone on metastasis of any cancers including malignant melanoma.
p80295
sg66298
(lp80296
(dp80297
g66301
I69
sg66302
I1
sg66303
I4
sg66304
VP59768
p80298
sg66306
VGng2
p80299
sa(dp80300
g66301
I74
sg66302
I1
sg66303
I4
sg66304
VP59768
p80301
sg66306
VGNG2
p80302
sasg66311
(lp80303
(dp80304
g66301
I106
sg66302
I1
sg66303
I7
sg66314
VC0006826
p80305
sg66306
Vcancers
p80306
sa(dp80307
g66301
I88
sg66302
I1
sg66303
I10
sg66314
VC0027627
p80308
sg66306
Vmetastasis
p80309
sa(dp80310
g66301
I124
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80311
sg66306
Vmalignant melanoma
p80312
sasa(dp80313
g66296
VIn his study, we first prepared GNG2-overexpressed SK-Mel28 human malignant melanoma cells, in which GNG2 protein expression level was undetectably low.
p80314
sg66298
(lp80315
(dp80316
g66301
I32
sg66302
I1
sg66303
I4
sg66304
VP59768
p80317
sg66306
VGNG2
p80318
sa(dp80319
g66301
I101
sg66302
I2
sg66303
I12
sg66304
VP59768
p80320
sg66306
VGNG2 protein
p80321
sasg66311
(lp80322
(dp80323
g66301
I66
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80324
sg66306
Vmalignant melanoma
p80325
sasa(dp80326
g66296
VMigration and invasion activities of the GNG2-overexpressed malignant melanoma cells were suppressed up to 1/10th, with decreased activity of focal adhesion kinase (FAK).
p80327
sg66298
(lp80328
(dp80329
g66301
I165
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VFAK
p80330
sa(dp80331
g66301
I142
sg66302
I3
sg66303
I21
sg66304
g11
sg66306
Vfocal adhesion kinase
p80332
sa(dp80333
g66301
I41
sg66302
I1
sg66303
I4
sg66304
VP59768
p80334
sg66306
VGNG2
p80335
sasg66311
(lp80336
(dp80337
g66301
I60
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80338
sg66306
Vmalignant melanoma
p80339
sa(dp80340
g66301
I120
sg66302
I2
sg66303
I18
sg66314
VC0086439
p80341
sg66306
Vdecreased activity
p80342
sa(dp80343
g66301
I14
sg66302
I1
sg66303
I8
sg66314
VC2699153
p80344
sg66306
Vinvasion
p80345
sa(dp80346
g66301
I148
sg66302
I1
sg66303
I8
sg66314
VC0001511
p80347
sg66306
Vadhesion
p80348
sasa(dp80349
g66296
VTaken together, our results suggest that overexpression of GNG2 alone inhibits metastasis in human malignant melanoma cells with decreased FAK activity.
p80350
sg66298
(lp80351
(dp80352
g66301
I139
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VFAK
p80353
sa(dp80354
g66301
I59
sg66302
I1
sg66303
I4
sg66304
VP59768
p80355
sg66306
VGNG2
p80356
sasg66311
(lp80357
(dp80358
g66301
I79
sg66302
I1
sg66303
I10
sg66314
VC0027627
p80359
sg66306
Vmetastasis
p80360
sa(dp80361
g66301
I99
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80362
sg66306
Vmalignant melanoma
p80363
sasa(dp80364
g66296
VThus, GNG2 might be a candidate of molecular targets of prevention and therapy for metastasis of malignant melanoma.
p80365
sg66298
(lp80366
(dp80367
g66301
I6
sg66302
I1
sg66303
I4
sg66304
VP59768
p80368
sg66306
VGNG2
p80369
sasg66311
(lp80370
(dp80371
g66301
I83
sg66302
I1
sg66303
I10
sg66314
VC0027627
p80372
sg66306
Vmetastasis
p80373
sa(dp80374
g66301
I97
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80375
sg66306
Vmalignant melanoma
p80376
sasa(dp80377
g66296
VOur recent study showed reduced G protein Gamma2 subunit (Gng2/GNG2) expression levels in malignant melanoma cells compared with those in benign melanocytic cells in both mice and humans.
p80378
sg66298
(lp80379
(dp80380
g66301
I63
sg66302
I1
sg66303
I4
sg66304
VP59768
p80381
sg66306
VGNG2
p80382
sa(dp80383
g66301
I58
sg66302
I1
sg66303
I4
sg66304
VP59768
p80384
sg66306
VGng2
p80385
sa(dp80386
g66301
I32
sg66302
I4
sg66303
I24
sg66304
VP59768
p80387
sg66306
VG protein Gamma2 subunit
p80388
sasg66311
(lp80389
(dp80390
g66301
I90
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80391
sg66306
Vmalignant melanoma
p80392
sasa(dp80393
g66296
VAt present, however, there is no evidence showing an effect of Gng2/GNG2 alone on cancer biology.
p80394
sg66298
(lp80395
(dp80396
g66301
I68
sg66302
I1
sg66303
I4
sg66304
VP59768
p80397
sg66306
VGNG2
p80398
sa(dp80399
g66301
I63
sg66302
I1
sg66303
I4
sg66304
VP59768
p80400
sg66306
VGng2
p80401
sasg66311
(lp80402
(dp80403
g66301
I82
sg66302
I1
sg66303
I6
sg66314
VC0006826
p80404
sg66306
Vcancer
p80405
sasa(dp80406
g66296
VThe purpose of this study was to examine the biological significance of GNG2 in human malignant melanoma cells.
p80407
sg66298
(lp80408
(dp80409
g66301
I72
sg66302
I1
sg66303
I4
sg66304
VP59768
p80410
sg66306
VGNG2
p80411
sasg66311
(lp80412
(dp80413
g66301
I86
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80414
sg66306
Vmalignant melanoma
p80415
sasa(dp80416
g66296
VLevels of proliferation and activities of signal transduction molecules were examined in both GNG2-overexpressed and -depleted human malignant melanoma cells.
p80417
sg66298
(lp80418
(dp80419
g66301
I94
sg66302
I1
sg66303
I4
sg66304
VP59768
p80420
sg66306
VGNG2
p80421
sasg66311
(lp80422
(dp80423
g66301
I10
sg66302
I1
sg66303
I13
sg66314
VC0334094
p80424
sg66306
Vproliferation
p80425
sa(dp80426
g66301
I133
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80427
sg66306
Vmalignant melanoma
p80428
sasa(dp80429
g66296
VProliferation of GNG2-overexpressed SK-Mel28 human malignant melanoma cells was suppressed with decreased c-SRC and AKT activities and increased p21(Cip/WAF1) expression level in vitro.
p80430
sg66298
(lp80431
(dp80432
g66301
I153
sg66302
I1
sg66303
I4
sg66304
VP38936
p80433
sg66306
VWAF1
p80434
sa(dp80435
g66301
I106
sg66302
I1
sg66303
I5
sg66304
VP12931
p80436
sg66306
Vc-SRC
p80437
sa(dp80438
g66301
I17
sg66302
I1
sg66303
I4
sg66304
VP59768
p80439
sg66306
VGNG2
p80440
sa(dp80441
g66301
I116
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VAKT
p80442
sa(dp80443
g66301
I145
sg66302
I1
sg66303
I3
sg66304
VP42857
p80444
sg66306
Vp21
p80445
sa(dp80446
g66301
I149
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VCip
p80447
sasg66311
(lp80448
(dp80449
g66301
I51
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80450
sg66306
Vmalignant melanoma
p80451
sa(dp80452
g66301
I0
sg66302
I1
sg66303
I13
sg66314
VC0334094
p80453
sg66306
VProliferation
p80454
sasa(dp80455
g66296
VIn contrast, proliferation of GNG2-depleted A375P human malignant melanoma cells was enhanced with increased c-SRC and AKT activities and decreased p21(Cip/WAF1) expression level in vitro.
p80456
sg66298
(lp80457
(dp80458
g66301
I152
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VCip
p80459
sa(dp80460
g66301
I156
sg66302
I1
sg66303
I4
sg66304
VP38936
p80461
sg66306
VWAF1
p80462
sa(dp80463
g66301
I109
sg66302
I1
sg66303
I5
sg66304
VP12931
p80464
sg66306
Vc-SRC
p80465
sa(dp80466
g66301
I119
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VAKT
p80467
sa(dp80468
g66301
I148
sg66302
I1
sg66303
I3
sg66304
VP42857
p80469
sg66306
Vp21
p80470
sa(dp80471
g66301
I30
sg66302
I1
sg66303
I4
sg66304
VP59768
p80472
sg66306
VGNG2
p80473
sasg66311
(lp80474
(dp80475
g66301
I13
sg66302
I1
sg66303
I13
sg66314
VC0334094
p80476
sg66306
Vproliferation
p80477
sa(dp80478
g66301
I56
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80479
sg66306
Vmalignant melanoma
p80480
sasa(dp80481
g66296
VWe demonstrated for the first time that increased protein expression level of GNG2 alone inhibits proliferation of malignant melanoma cells in vitro and in vivo, suggesting that GNG2 could be a novel molecular target for malignant melanoma therapy.
p80482
sg66298
(lp80483
(dp80484
g66301
I78
sg66302
I1
sg66303
I4
sg66304
VP59768
p80485
sg66306
VGNG2
p80486
sa(dp80487
g66301
I78
sg66302
I1
sg66303
I4
sg66304
VP59768
p80488
sg66306
VGNG2
p80489
sasg66311
(lp80490
(dp80491
g66301
I115
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80492
sg66306
Vmalignant melanoma
p80493
sa(dp80494
g66301
I98
sg66302
I1
sg66303
I13
sg66314
VC0334094
p80495
sg66306
Vproliferation
p80496
sa(dp80497
g66301
I115
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80498
sg66306
Vmalignant melanoma
p80499
sasa(dp80500
g66296
VGng2 transcript expression levels in a malignant melanoma were less than 1/10 of the level in a benign tumor.
p80501
sg66298
(lp80502
(dp80503
g66301
I0
sg66302
I2
sg66303
I15
sg66304
VP59768
p80504
sg66306
VGng2 transcript
p80505
sasg66311
(lp80506
(dp80507
g66301
I96
sg66302
I2
sg66303
I12
sg66314
VC0086692
p80508
sg66306
Vbenign tumor
p80509
sa(dp80510
g66301
I39
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80511
sg66306
Vmalignant melanoma
p80512
sasa(dp80513
g66296
VThe difference in Gng2 transcript expression levels between benign tumors and malignant melanomas was greatest among all of the G protein Gamma subunits examined in this study.
p80514
sg66298
(lp80515
(dp80516
g66301
I18
sg66302
I2
sg66303
I15
sg66304
VP59768
p80517
sg66306
VGng2 transcript
p80518
sa(dp80519
g66301
I128
sg66302
I4
sg66303
I24
sg66304
g11
sg66306
VG protein Gamma subunits
p80520
sasg66311
(lp80521
(dp80522
g66301
I60
sg66302
I2
sg66303
I13
sg66314
VC0086692
p80523
sg66306
Vbenign tumors
p80524
sa(dp80525
g66301
I78
sg66302
I2
sg66303
I19
sg66314
VC0025202
p80526
sg66306
Vmalignant melanomas
p80527
sasa(dp80528
g66296
VMoreover, protein expression levels of Gng2 were decreased in malignant melanomas compared with those in benign melanocytic tumors in RET-mice.
p80529
sg66298
(lp80530
(dp80531
g66301
I39
sg66302
I1
sg66303
I4
sg66304
VP59768
p80532
sg66306
VGng2
p80533
sasg66311
(lp80534
(dp80535
g66301
I124
sg66302
I1
sg66303
I6
sg66314
VC0027651
p80536
sg66306
Vtumors
p80537
sa(dp80538
g66301
I62
sg66302
I2
sg66303
I19
sg66314
VC0025202
p80539
sg66306
Vmalignant melanomas
p80540
sasa(dp80541
g66296
VAnalysis of human malignant melanomas also showed reduced GNG2 protein expression levels in five human malignant melanoma cell lines compared with the expression levels in normal human epithelial melanocytes (NHEM).
p80542
sg66298
(lp80543
(dp80544
g66301
I58
sg66302
I2
sg66303
I12
sg66304
VP59768
p80545
sg66306
VGNG2 protein
p80546
sasg66311
(lp80547
(dp80548
g66301
I18
sg66302
I2
sg66303
I19
sg66314
VC0025202
p80549
sg66306
Vmalignant melanomas
p80550
sa(dp80551
g66301
I18
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80552
sg66306
Vmalignant melanoma
p80553
sasa(dp80554
g66296
VThus, we demonstrated for the first time that Gng2/GNG2 expression levels are reduced in malignant melanoma, suggesting that GNG2 could be a novel biomarker for malignant melanoma.
p80555
sg66298
(lp80556
(dp80557
g66301
I46
sg66302
I1
sg66303
I4
sg66304
VP59768
p80558
sg66306
VGng2
p80559
sa(dp80560
g66301
I51
sg66302
I1
sg66303
I4
sg66304
VP59768
p80561
sg66306
VGNG2
p80562
sa(dp80563
g66301
I51
sg66302
I1
sg66303
I4
sg66304
VP59768
p80564
sg66306
VGNG2
p80565
sasg66311
(lp80566
(dp80567
g66301
I89
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80568
sg66306
Vmalignant melanoma
p80569
sa(dp80570
g66301
I89
sg66302
I2
sg66303
I18
sg66314
VC0025202
p80571
sg66306
Vmalignant melanoma
p80572
sasa(dp80573
g66296
VSeveral DNA repair enzymes are essential for comprehensive neural repair mechanisms after stroke, including PolBeta and NEIL3 for neurogenesis, APE1 for white matter repair, Gadd45b for axonal regeneration, and DNA-PKs for neurovascular remodeling.
p80574
sg66298
(lp80575
(dp80576
g66301
I144
sg66302
I1
sg66303
I4
sg66304
VP27695
p80577
sg66306
VAPE1
p80578
sa(dp80579
g66301
I120
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VNEIL3
p80580
sa(dp80581
g66301
I174
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VGadd45b
p80582
sa(dp80583
g66301
I8
sg66302
I3
sg66303
I18
sg66304
g11
sg66306
VDNA repair enzymes
p80584
sa(dp80585
g66301
I211
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VDNA-PKs
p80586
sasg66311
(lp80587
(dp80588
g66301
I90
sg66302
I1
sg66303
I6
sg66314
VC0038454
p80589
sg66306
Vstroke
p80590
sa(dp80591
g66301
I215
sg66302
I1
sg66303
I3
sg66314
VC0265449
p80592
sg66306
VPKs
p80593
sasa(dp80594
g66296
VThe aims of this study are to determine the expression and the prognostic value of TFF3 in a large series of human endometrial cancer and its relation with ER.
p80595
sg66298
(lp80596
(dp80597
g66301
I83
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTFF3
p80598
sasg66311
(lp80599
(dp80600
g66301
I115
sg66302
I2
sg66303
I18
sg66314
VC0476089
p80601
sg66306
Vendometrial cancer
p80602
sasa(dp80603
g66296
VWe evaluated 328 endometrial carcinomas using TFF3 and ER antibody on paraffin-embedded tissue.
p80604
sg66298
(lp80605
(dp80606
g66301
I46
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTFF3
p80607
sasg66311
(lp80608
(dp80609
g66301
I17
sg66302
I2
sg66303
I22
sg66314
VC0476089
p80610
sg66306
Vendometrial carcinomas
p80611
sasa(dp80612
g66296
V1-TFF3 seems to be a novel pathway in the pathogenesis of type I endometrial carcinomas.
p80613
sg66298
(lp80614
(dp80615
g66301
I0
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
V1-TFF3
p80616
sasg66311
(lp80617
(dp80618
g66301
I42
sg66302
I1
sg66303
I12
sg66314
VC0699748
p80619
sg66306
Vpathogenesis
p80620
sa(dp80621
g66301
I65
sg66302
I2
sg66303
I22
sg66314
VC0476089
p80622
sg66306
Vendometrial carcinomas
p80623
sasa(dp80624
g66296
V2-The strong association of TFF3 and ER in the estrogen-dependent endometrioid carcinoma could explain the reason for its frequent expression by this tumor type.
p80625
sg66298
(lp80626
(dp80627
g66301
I28
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTFF3
p80628
sasg66311
(lp80629
(dp80630
g66301
I66
sg66302
I2
sg66303
I22
sg66314
VC0206687
p80631
sg66306
Vendometrioid carcinoma
p80632
sa(dp80633
g66301
I150
sg66302
I1
sg66303
I5
sg66314
VC0027651
p80634
sg66306
Vtumor
p80635
sasa(dp80636
g66296
V3-TFF3(+) seems to forecast a good prognosis in type I endometrial carcinomas.
p80637
sg66298
(lp80638
(dp80639
g66301
I0
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
V3-TFF3
p80640
sasg66311
(lp80641
(dp80642
g66301
I55
sg66302
I2
sg66303
I22
sg66314
VC0476089
p80643
sg66306
Vendometrial carcinomas
p80644
sasa(dp80645
g66296
VBased on our data, TFF3 expression in endometrial cancer deserves further investigation.
p80646
sg66298
(lp80647
(dp80648
g66301
I19
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTFF3
p80649
sasg66311
(lp80650
(dp80651
g66301
I38
sg66302
I2
sg66303
I18
sg66314
VC0476089
p80652
sg66306
Vendometrial cancer
p80653
sasa(dp80654
g66296
VWe evaluated 401 endometrial carcinomas cases by using four immunomarkers - oestrogen receptor (ER), progesterone receptor (PR), insulin-like growth factor II mRNA - binding protein 3 (IMP3), and intestinal trefoil factor 3 (TFF3)-on a tissue microarray.
p80655
sg66298
(lp80656
(dp80657
g66301
I101
sg66302
I2
sg66303
I21
sg66304
VP06401
p80658
sg66306
Vprogesterone receptor
p80659
sa(dp80660
g66301
I129
sg66302
I9
sg66303
I54
sg66304
VP01344
p80661
sg66306
Vinsulin-like growth factor II mRNA - binding protein 3
p80662
sa(dp80663
g66301
I225
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTFF3
p80664
sa(dp80665
g66301
I76
sg66302
I2
sg66303
I18
sg66304
VP03372
p80666
sg66306
Voestrogen receptor
p80667
sa(dp80668
g66301
I196
sg66302
I4
sg66303
I27
sg66304
g11
sg66306
Vintestinal trefoil factor 3
p80669
sa(dp80670
g66301
I185
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VIMP3
p80671
sa(dp80672
g66301
I124
sg66302
I1
sg66303
I2
sg66304
VP06401
p80673
sg66306
VPR
p80674
sasg66311
(lp80675
(dp80676
g66301
I17
sg66302
I2
sg66303
I22
sg66314
VC0476089
p80677
sg66306
Vendometrial carcinomas
p80678
sasa(dp80679
g66296
VWe recommend using an ER/PR/TFF3/IMP3 immunohistochemical panel in selected cases of endometrial carcinoma where the differential diagnosis is challenging.
p80680
sg66298
(lp80681
(dp80682
g66301
I28
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTFF3
p80683
sa(dp80684
g66301
I33
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VIMP3
p80685
sasg66311
(lp80686
(dp80687
g66301
I85
sg66302
I2
sg66303
I21
sg66314
VC0476089
p80688
sg66306
Vendometrial carcinoma
p80689
sasa(dp80690
g66296
VBy RT-PCR we have confirmed complete FAM107A downregulation in laryngeal cancer cell lines (15/15) and primary tumors (21/21) and this finding was further supported by FAM107A protein immunohistochemistry (15/15).
p80691
sg66298
(lp80692
(dp80693
g66301
I37
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VFAM107A
p80694
sasg66311
(lp80695
(dp80696
g66301
I63
sg66302
I2
sg66303
I16
sg66314
VC0595989
p80697
sg66306
Vlaryngeal cancer
p80698
sa(dp80699
g66301
I103
sg66302
I2
sg66303
I14
sg66314
VC0677930
p80700
sg66306
Vprimary tumors
p80701
sasa(dp80702
g66296
VDownregulated in renal cell carcinoma 1 (DRR1) has important roles in tumor cell growth, neuron survival and spine formation, and was recently shown to bind actin.
p80703
sg66298
(lp80704
(dp80705
g66301
I41
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VDRR1
p80706
sa(dp80707
g66301
I0
sg66302
I6
sg66303
I39
sg66304
g11
sg66306
VDownregulated in renal cell carcinoma 1
p80708
sasg66311
(lp80709
(dp80710
g66301
I17
sg66302
I4
sg66303
I22
sg66314
VC2931882
p80711
sg66306
Vrenal cell carcinoma 1
p80712
sa(dp80713
g66301
I70
sg66302
I1
sg66303
I5
sg66314
VC0027651
p80714
sg66306
Vtumor
p80715
sasa(dp80716
g66296
VIn addition, DRR1 and COMMD1 suppressed the cyclin D1 expression, G1/S transition and cell proliferation of neuroblastoma cells.
p80717
sg66298
(lp80718
(dp80719
g66301
I13
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VDRR1
p80720
sa(dp80721
g66301
I22
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCOMMD1
p80722
sa(dp80723
g66301
I44
sg66302
I2
sg66303
I9
sg66304
VP24385
p80724
sg66306
Vcyclin D1
p80725
sasg66311
(lp80726
(dp80727
g66301
I91
sg66302
I1
sg66303
I13
sg66314
VC0334094
p80728
sg66306
Vproliferation
p80729
sa(dp80730
g66301
I71
sg66302
I1
sg66303
I10
sg66314
VC0599156
p80731
sg66306
Vtransition
p80732
sa(dp80733
g66301
I108
sg66302
I1
sg66303
I13
sg66314
VC0027819
p80734
sg66306
Vneuroblastoma
p80735
sasa(dp80736
g66296
VConsistent with these facts, low expressions of DRR1 were associated with tumorigenesis of human neuroblastoma and its mouse model.
p80737
sg66298
(lp80738
(dp80739
g66301
I48
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VDRR1
p80740
sasg66311
(lp80741
(dp80742
g66301
I74
sg66302
I1
sg66303
I13
sg66314
VC0007621
p80743
sg66306
Vtumorigenesis
p80744
sa(dp80745
g66301
I97
sg66302
I1
sg66303
I13
sg66314
VC0027819
p80746
sg66306
Vneuroblastoma
p80747
sasa(dp80748
g66296
VThis study has thus revealed a novel nuclear complex of F-actin, DRR1 and COMMD1 that is involved in NF-KB degradation and cell cycle suppression in neuroblastoma cells.
p80749
sg66298
(lp80750
(dp80751
g66301
I65
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VDRR1
p80752
sa(dp80753
g66301
I74
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCOMMD1
p80754
sasg66311
(lp80755
(dp80756
g66301
I134
sg66302
I1
sg66303
I11
sg66314
VC0221103
p80757
sg66306
Vsuppression
p80758
sa(dp80759
g66301
I149
sg66302
I1
sg66303
I13
sg66314
VC0027819
p80760
sg66306
Vneuroblastoma
p80761
sasa(dp80762
g66296
VThe aim of the present study was to analyze the expression level of FAM107A gene, a TSG located in 3p21.1, in lung cancer tumors and in tumor adjacent normal lung samples.
p80763
sg66298
(lp80764
(dp80765
g66301
I68
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VFAM107A gene
p80766
sa(dp80767
g66301
I84
sg66302
I4
sg66303
I21
sg66304
g11
sg66306
VTSG located in 3p21.1
p80768
sasg66311
(lp80769
(dp80770
g66301
I122
sg66302
I1
sg66303
I6
sg66314
VC0027651
p80771
sg66306
Vtumors
p80772
sa(dp80773
g66301
I110
sg66302
I2
sg66303
I11
sg66314
VC0684249
p80774
sg66306
Vlung cancer
p80775
sa(dp80776
g66301
I122
sg66302
I1
sg66303
I5
sg66314
VC0027651
p80777
sg66306
Vtumor
p80778
sasa(dp80779
g66296
VPromoter methylation of FAM107A gene was confirmed only in the minority of NSCLCs.
p80780
sg66298
(lp80781
(dp80782
g66301
I24
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VFAM107A gene
p80783
sasg66311
(lp80784
sa(dp80785
g66296
VWe recently characterized a stress and glucocorticoid-regulated gene, down-regulated in renal cell carcinoma - DRR1 (Fam107A).
p80786
sg66298
(lp80787
(dp80788
g66301
I117
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VFam107A
p80789
sa(dp80790
g66301
I111
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VDRR1
p80791
sa(dp80792
g66301
I39
sg66302
I2
sg66303
I29
sg66304
VP48506
p80793
sg66306
Vglucocorticoid-regulated gene
p80794
sasg66311
(lp80795
(dp80796
g66301
I88
sg66302
I3
sg66303
I20
sg66314
VC0007134
p80797
sg66306
Vrenal cell carcinoma
p80798
sasa(dp80799
g66296
VIn human, FAM107A termed TU3A/DRR1 has been reported as a candidate tumor suppressor gene which expression is downregulated in several types of cancer, however no studies have investigated the other family protein, FAM107B.
p80800
sg66298
(lp80801
(dp80802
g66301
I215
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VFAM107B
p80803
sa(dp80804
g66301
I10
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VFAM107A
p80805
sa(dp80806
g66301
I30
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VDRR1
p80807
sa(dp80808
g66301
I25
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTU3A
p80809
sasg66311
(lp80810
(dp80811
g66301
I68
sg66302
I1
sg66303
I5
sg66314
VC0027651
p80812
sg66306
Vtumor
p80813
sa(dp80814
g66301
I144
sg66302
I1
sg66303
I6
sg66314
VC0006826
p80815
sg66306
Vcancer
p80816
sasa(dp80817
g66296
VDown-regulated in renal cell carcinoma 1 (DRR1) is mapped at 3p21.1, and is a candidate tumor suppressor gene.
p80818
sg66298
(lp80819
(dp80820
g66301
I0
sg66302
I6
sg66303
I40
sg66304
g11
sg66306
VDown-regulated in renal cell carcinoma 1
p80821
sa(dp80822
g66301
I42
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VDRR1
p80823
sasg66311
(lp80824
(dp80825
g66301
I88
sg66302
I1
sg66303
I5
sg66314
VC0027651
p80826
sg66306
Vtumor
p80827
sa(dp80828
g66301
I18
sg66302
I4
sg66303
I22
sg66314
VC2931882
p80829
sg66306
Vrenal cell carcinoma 1
p80830
sasa(dp80831
g66296
VDRR1 was poorly expressed in established cancer cell lines, including neuroblastoma cells, whereas strong expression was observed in normal cells.
p80832
sg66298
(lp80833
(dp80834
g66301
I0
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VDRR1
p80835
sasg66311
(lp80836
(dp80837
g66301
I41
sg66302
I1
sg66303
I6
sg66314
VC0006826
p80838
sg66306
Vcancer
p80839
sa(dp80840
g66301
I70
sg66302
I1
sg66303
I13
sg66314
VC0027819
p80841
sg66306
Vneuroblastoma
p80842
sasa(dp80843
g66296
VA neuroblastoma model, MYCN transgenic mice, revealed that DRR1 protein was expressed in the celiac ganglion 2 weeks after birth when neuroblast hyperplasia was also observed; however, there was no longer any expression of DRR1 protein in tumors originating from the ganglion 8 weeks after birth.
p80844
sg66298
(lp80845
(dp80846
g66301
I59
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VDRR1 protein
p80847
sa(dp80848
g66301
I23
sg66302
I1
sg66303
I4
sg66304
VP04198
p80849
sg66306
VMYCN
p80850
sa(dp80851
g66301
I59
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VDRR1 protein
p80852
sasg66311
(lp80853
(dp80854
g66301
I100
sg66302
I1
sg66303
I8
sg66314
VC1258666
p80855
sg66306
Vganglion
p80856
sa(dp80857
g66301
I2
sg66302
I1
sg66303
I13
sg66314
VC0027819
p80858
sg66306
Vneuroblastoma
p80859
sa(dp80860
g66301
I239
sg66302
I1
sg66303
I6
sg66314
VC0027651
p80861
sg66306
Vtumors
p80862
sa(dp80863
g66301
I100
sg66302
I1
sg66303
I8
sg66314
VC1258666
p80864
sg66306
Vganglion
p80865
sa(dp80866
g66301
I145
sg66302
I1
sg66303
I11
sg66314
VC0020507
p80867
sg66306
Vhyperplasia
p80868
sasa(dp80869
g66296
VTogether, our data indicate that DRR1 protein is expressed in normal cells, particularly in the nervous system during embryogenesis, is involved in neuronal cell survival, and is downregulated during neuroblastoma carcinogenesis.
p80870
sg66298
(lp80871
(dp80872
g66301
I33
sg66302
I2
sg66303
I12
sg66304
g11
sg66306
VDRR1 protein
p80873
sasg66311
(lp80874
(dp80875
g66301
I214
sg66302
I1
sg66303
I14
sg66314
VC0596263
p80876
sg66306
Vcarcinogenesis
p80877
sa(dp80878
g66301
I96
sg66302
I1
sg66303
I7
sg66314
VC0027769
p80879
sg66306
Vnervous
p80880
sa(dp80881
g66301
I200
sg66302
I1
sg66303
I13
sg66314
VC0027819
p80882
sg66306
Vneuroblastoma
p80883
sasa(dp80884
g66296
VTU3A, located on 3p21.1, was originally identified as a candidate tumor suppressor gene in renal cell carcinoma (RCC).
p80885
sg66298
(lp80886
(dp80887
g66301
I0
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTU3A
p80888
sasg66311
(lp80889
(dp80890
g66301
I91
sg66302
I3
sg66303
I20
sg66314
VC0007134
p80891
sg66306
Vrenal cell carcinoma
p80892
sa(dp80893
g66301
I66
sg66302
I1
sg66303
I5
sg66314
VC0027651
p80894
sg66306
Vtumor
p80895
sa(dp80896
g66301
I113
sg66302
I1
sg66303
I3
sg66314
VC0007134
p80897
sg66306
VRCC
p80898
sasa(dp80899
g66296
VRecently, down-regulation of TU3A expression has been reported not only in RCC but also in other types of cancers.
p80900
sg66298
(lp80901
(dp80902
g66301
I29
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTU3A
p80903
sasg66311
(lp80904
(dp80905
g66301
I106
sg66302
I1
sg66303
I7
sg66314
VC0006826
p80906
sg66306
Vcancers
p80907
sa(dp80908
g66301
I75
sg66302
I1
sg66303
I3
sg66314
VC0007134
p80909
sg66306
VRCC
p80910
sasa(dp80911
g66296
VFurthermore, we observed promoter hyper-methylation of TU3A in several types of cancer cell lines and primary cancers of the bladder and testis.
p80912
sg66298
(lp80913
(dp80914
g66301
I55
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTU3A
p80915
sasg66311
(lp80916
(dp80917
g66301
I110
sg66302
I1
sg66303
I7
sg66314
VC0006826
p80918
sg66306
Vcancers
p80919
sa(dp80920
g66301
I80
sg66302
I1
sg66303
I6
sg66314
VC0006826
p80921
sg66306
Vcancer
p80922
sasa(dp80923
g66296
VTo our knowledge, the present study is the first to demonstrate the epigenetic inactivation of TU3A in human cancers.
p80924
sg66298
(lp80925
(dp80926
g66301
I95
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTU3A
p80927
sasg66311
(lp80928
(dp80929
g66301
I109
sg66302
I1
sg66303
I7
sg66314
VC0006826
p80930
sg66306
Vcancers
p80931
sa(dp80932
g66301
I79
sg66302
I1
sg66303
I12
sg66314
VC0544461
p80933
sg66306
Vinactivation
p80934
sasa(dp80935
g66296
VThe findings of this study warrant further study to investigate the role of TU3A methylation in cancer development.
p80936
sg66298
(lp80937
(dp80938
g66301
I76
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VTU3A
p80939
sasg66311
(lp80940
(dp80941
g66301
I96
sg66302
I1
sg66303
I6
sg66314
VC0006826
p80942
sg66306
Vcancer
p80943
sasa(dp80944
g66296
VThe aim of this study was to examine the association between GCK, GCKR, FADS1, DGKB/TMEM195 and CDKAL1 gene polymorphisms and the development of gestational diabetes.
p80945
sg66298
(lp80946
(dp80947
g66301
I66
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VGCKR
p80948
sa(dp80949
g66301
I84
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VTMEM195
p80950
sa(dp80951
g66301
I96
sg66302
I2
sg66303
I11
sg66304
g11
sg66306
VCDKAL1 gene
p80952
sa(dp80953
g66301
I61
sg66302
I1
sg66303
I3
sg66304
VP35557
p80954
sg66306
VGCK
p80955
sasg66311
(lp80956
(dp80957
g66301
I145
sg66302
I2
sg66303
I20
sg66314
VC0085207
p80958
sg66306
Vgestational diabetes
p80959
sasa(dp80960
g66296
VBackground Familial hemiplegic migraine type 3 is a monogenic subtype of migraine caused by missense mutations in the neuronal voltage-gated sodium channel gene SCN1A, with 10 different mutations reported so far.
p80961
sg66298
(lp80962
(dp80963
g66301
I118
sg66302
I6
sg66303
I48
sg66304
VP29475
p80964
sg66306
Vneuronal voltage-gated sodium channel gene SCN1A
p80965
sasg66311
(lp80966
(dp80967
g66301
I31
sg66302
I1
sg66303
I8
sg66314
VC0149931
p80968
sg66306
Vmigraine
p80969
sa(dp80970
g66301
I11
sg66302
I3
sg66303
I28
sg66314
VC0338484
p80971
sg66306
VFamilial hemiplegic migraine
p80972
sasa(dp80973
g66296
VResults In both pedigrees, we identified SCN1A mutation p.F1499L, which has been previously associated with familial hemiplegic migraine type 3 and elicited repetitive daily blindness.
p80974
sg66298
(lp80975
(dp80976
g66301
I41
sg66302
I3
sg66303
I23
sg66304
VP35498
p80977
sg66306
VSCN1A mutation p.F1499L
p80978
sasg66311
(lp80979
(dp80980
g66301
I174
sg66302
I1
sg66303
I9
sg66314
VC0456909
p80981
sg66306
Vblindness
p80982
sa(dp80983
g66301
I108
sg66302
I3
sg66303
I28
sg66314
VC0338484
p80984
sg66306
Vfamilial hemiplegic migraine
p80985
sasa(dp80986
g66296
VConclusion Like a substantial proportion of other familial hemiplegic migraine type 3 mutations, p.F1499L affects the intracellular linker between domains III and IV of SCN1A, which seems to be a mutational hot-spot.
p80987
sg66298
(lp80988
(dp80989
g66301
I169
sg66302
I1
sg66303
I5
sg66304
VP35498
p80990
sg66306
VSCN1A
p80991
sasg66311
(lp80992
(dp80993
g66301
I50
sg66302
I3
sg66303
I28
sg66314
VC0338484
p80994
sg66306
Vfamilial hemiplegic migraine
p80995
sasa(dp80996
g66296
VA genetic link between these two diseases is particularly evident in familial hemiplegic migraine: mutations of ATP1A2, SCN1A and CACNA1A genes, identified in this disease, have also been involved in different types of epilepsy and febrile seizures.
p80997
sg66298
(lp80998
(dp80999
g66301
I112
sg66302
I1
sg66303
I6
sg66304
VP50993
p81000
sg66306
VATP1A2
p81001
sa(dp81002
g66301
I120
sg66302
I1
sg66303
I5
sg66304
VP35498
p81003
sg66306
VSCN1A
p81004
sa(dp81005
g66301
I130
sg66302
I2
sg66303
I13
sg66304
VP01893
p81006
sg66306
VCACNA1A genes
p81007
sasg66311
(lp81008
(dp81009
g66301
I232
sg66302
I2
sg66303
I16
sg66314
VC0009952
p81010
sg66306
Vfebrile seizures
p81011
sa(dp81012
g66301
I69
sg66302
I3
sg66303
I28
sg66314
VC0338484
p81013
sg66306
Vfamilial hemiplegic migraine
p81014
sa(dp81015
g66301
I219
sg66302
I1
sg66303
I8
sg66314
VC0014544
p81016
sg66306
Vepilepsy
p81017
sasa(dp81018
g66296
VMutations in three genes (CACNA1A, ATP1A2, and SCN1A) have been found to cause FHM.
p81019
sg66298
(lp81020
(dp81021
g66301
I35
sg66302
I1
sg66303
I6
sg66304
VP50993
p81022
sg66306
VATP1A2
p81023
sa(dp81024
g66301
I47
sg66302
I1
sg66303
I5
sg66304
VP35498
p81025
sg66306
VSCN1A
p81026
sasg66311
(lp81027
(dp81028
g66301
I79
sg66302
I1
sg66303
I3
sg66314
VC1832894
p81029
sg66306
VFHM
p81030
sasa(dp81031
g66296
VAmong these, nine SCN1A gene mutations were reported to cause familial hemiplegic migraine type 3 (FHM3).
p81032
sg66298
(lp81033
(dp81034
g66301
I62
sg66302
I5
sg66303
I35
sg66304
VP35498
p81035
sg66306
Vfamilial hemiplegic migraine type 3
p81036
sa(dp81037
g66301
I99
sg66302
I1
sg66303
I4
sg66304
VP35498
p81038
sg66306
VFHM3
p81039
sa(dp81040
g66301
I18
sg66302
I2
sg66303
I10
sg66304
VP35498
p81041
sg66306
VSCN1A gene
p81042
sasg66311
(lp81043
(dp81044
g66301
I62
sg66302
I5
sg66303
I35
sg66314
VC1864987
p81045
sg66306
Vfamilial hemiplegic migraine type 3
p81046
sa(dp81047
g66301
I99
sg66302
I1
sg66303
I4
sg66314
VC1864987
p81048
sg66306
VFHM3
p81049
sasa(dp81050
g66296
VMethod The clinical manifestations of a Chinese FHM family were recorded and all coding exons and flanking intronic regions of the CACNA1A, ATP1A2, and SCN1A genes were tested for mutations.
p81051
sg66298
(lp81052
(dp81053
g66301
I140
sg66302
I1
sg66303
I6
sg66304
VP50993
p81054
sg66306
VATP1A2
p81055
sa(dp81056
g66301
I152
sg66302
I2
sg66303
I11
sg66304
VP35498
p81057
sg66306
VSCN1A genes
p81058
sasg66311
(lp81059
(dp81060
g66301
I48
sg66302
I1
sg66303
I3
sg66314
VC1832894
p81061
sg66306
VFHM
p81062
sasa(dp81063
g66296
VConclusion The identification of a novel mutation in the SCN1A gene in the Chinese population may further aid in the understanding of FHM genetics.
p81064
sg66298
(lp81065
(dp81066
g66301
I57
sg66302
I2
sg66303
I10
sg66304
VP35498
p81067
sg66306
VSCN1A gene
p81068
sasg66311
(lp81069
(dp81070
g66301
I134
sg66302
I1
sg66303
I3
sg66314
VC1832894
p81071
sg66306
VFHM
p81072
sa(dp81073
g66301
I35
sg66302
I2
sg66303
I14
sg66314
VC2985438
p81074
sg66306
Vnovel mutation
p81075
sasa(dp81076
g66296
VMutations in four genes have been identified in familial hemiplegic migraine (FHM), from which CACNA1A (FHM type 1) and SCN1A (FHM type 3) code for neuronal voltage-gated calcium or sodium channels, respectively, while ATP1A2 (FHM type 2) encodes the Alfa2 isoform of the Na(+),K(+)-ATPase's catalytic subunit, thus classifying FHM primarily as an ion channel/ion transporter pathology.
p81077
sg66298
(lp81078
(dp81079
g66301
I219
sg66302
I1
sg66303
I6
sg66304
VP50993
p81080
sg66306
VATP1A2
p81081
sa(dp81082
g66301
I120
sg66302
I1
sg66303
I5
sg66304
VP35498
p81083
sg66306
VSCN1A
p81084
sa(dp81085
g66301
I283
sg66302
I1
sg66303
I6
sg66304
VP38606
p81086
sg66306
VATPase
p81087
sasg66311
(lp81088
(dp81089
g66301
I78
sg66302
I1
sg66303
I3
sg66314
VC1832894
p81090
sg66306
VFHM
p81091
sa(dp81092
g66301
I78
sg66302
I1
sg66303
I3
sg66314
VC1832894
p81093
sg66306
VFHM
p81094
sa(dp81095
g66301
I376
sg66302
I1
sg66303
I9
sg66314
VC0677042
p81096
sg66306
Vpathology
p81097
sa(dp81098
g66301
I78
sg66302
I1
sg66303
I3
sg66314
VC1832894
p81099
sg66306
VFHM
p81100
sa(dp81101
g66301
I48
sg66302
I3
sg66303
I28
sg66314
VC0338484
p81102
sg66306
Vfamilial hemiplegic migraine
p81103
sa(dp81104
g66301
I78
sg66302
I1
sg66303
I3
sg66314
VC1832894
p81105
sg66306
VFHM
p81106
sa(dp81107
g66301
I78
sg66302
I1
sg66303
I3
sg66314
VC1832894
p81108
sg66306
VFHM
p81109
sasa(dp81110
g66296
VMoreover, three genes (CACNA1A, ATP1A2, and SCN1A) have come from studies performed in individuals with familial hemiplegic migraine (FHM), a monogenic form of migraine with aura.
p81111
sg66298
(lp81112
(dp81113
g66301
I44
sg66302
I1
sg66303
I5
sg66304
VP35498
p81114
sg66306
VSCN1A
p81115
sa(dp81116
g66301
I32
sg66302
I1
sg66303
I6
sg66304
VP50993
p81117
sg66306
VATP1A2
p81118
sasg66311
(lp81119
(dp81120
g66301
I134
sg66302
I1
sg66303
I3
sg66314
VC1832894
p81121
sg66306
VFHM
p81122
sa(dp81123
g66301
I160
sg66302
I3
sg66303
I18
sg66314
VC0154723
p81124
sg66306
Vmigraine with aura
p81125
sa(dp81126
g66301
I104
sg66302
I3
sg66303
I28
sg66314
VC0338484
p81127
sg66306
Vfamilial hemiplegic migraine
p81128
sasa(dp81129
g66296
VThe FHM3 subtype is caused by mutations in SCN1A, which is also the most frequent epilepsy gene encoding the voltage-gated Na+ channel NaV1.1.
p81130
sg66298
(lp81131
(dp81132
g66301
I123
sg66302
I3
sg66303
I18
sg66304
VP37088
p81133
sg66306
VNa+ channel NaV1.1
p81134
sa(dp81135
g66301
I43
sg66302
I1
sg66303
I5
sg66304
VP35498
p81136
sg66306
VSCN1A
p81137
sa(dp81138
g66301
I4
sg66302
I2
sg66303
I12
sg66304
VP35498
p81139
sg66306
VFHM3 subtype
p81140
sasg66311
(lp81141
(dp81142
g66301
I82
sg66302
I1
sg66303
I8
sg66314
VC0014544
p81143
sg66306
Vepilepsy
p81144
sa(dp81145
g66301
I4
sg66302
I1
sg66303
I4
sg66314
VC1864987
p81146
sg66306
VFHM3
p81147
sasa(dp81148
g66296
VThe aim of this study was to explore the clinical, genetic and pathogenetic features of a pure FHM3 family.
p81149
sg66298
(lp81150
(dp81151
g66301
I95
sg66302
I2
sg66303
I11
sg66304
VP35498
p81152
sg66306
VFHM3 family
p81153
sasg66311
(lp81154
(dp81155
g66301
I95
sg66302
I1
sg66303
I4
sg66314
VC1864987
p81156
sg66306
VFHM3
p81157
sasa(dp81158
g66296
VResults and conclusions We identified a novel SCN1A (p.Leu1624Pro) mutation in a pure FHM family with notably early-onset attacks at mean age of 7.
p81159
sg66298
(lp81160
(dp81161
g66301
I46
sg66302
I1
sg66303
I5
sg66304
VP35498
p81162
sg66306
VSCN1A
p81163
sasg66311
(lp81164
(dp81165
g66301
I86
sg66302
I1
sg66303
I3
sg66314
VC1832894
p81166
sg66306
VFHM
p81167
sasa(dp81168
g66296
VL1624P locates in S3 of domain IV, the same domain as two of four known pure FHM3 mutations.
p81169
sg66298
(lp81170
(dp81171
g66301
I77
sg66302
I1
sg66303
I4
sg66304
VP35498
p81172
sg66306
VFHM3
p81173
sasg66311
(lp81174
(dp81175
g66301
I77
sg66302
I1
sg66303
I4
sg66314
VC1864987
p81176
sg66306
VFHM3
p81177
sasa(dp81178
g66296
VSimilar to the known FHM3 mutations, this novel mutation predicts hyperexcitability of GABAergic inhibitory neurons.
p81179
sg66298
(lp81180
(dp81181
g66301
I21
sg66302
I2
sg66303
I14
sg66304
VP35498
p81182
sg66306
VFHM3 mutations
p81183
sasg66311
(lp81184
(dp81185
g66301
I21
sg66302
I1
sg66303
I4
sg66314
VC1864987
p81186
sg66306
VFHM3
p81187
sa(dp81188
g66301
I42
sg66302
I2
sg66303
I14
sg66314
VC2985438
p81189
sg66306
Vnovel mutation
p81190
sasa(dp81191
g66296
VSixty patients with migraine without aura (MO) or with different types of migraine with aura (MA), including sporadic hemiplegic, familial hemiplegic, and probable familial hemiplegic, were screened for mutations in the four genes previously linked with different types of migraine (ATP1A2, CACNA1A, SCN1A, and KCNK18).
p81192
sg66298
(lp81193
(dp81194
g66301
I300
sg66302
I1
sg66303
I5
sg66304
VP35498
p81195
sg66306
VSCN1A
p81196
sa(dp81197
g66301
I283
sg66302
I1
sg66303
I6
sg66304
VP50993
p81198
sg66306
VATP1A2
p81199
sa(dp81200
g66301
I311
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VKCNK18
p81201
sasg66311
(lp81202
(dp81203
g66301
I94
sg66302
I1
sg66303
I2
sg66314
VC0154723
p81204
sg66306
VMA
p81205
sa(dp81206
g66301
I20
sg66302
I3
sg66303
I21
sg66314
VC0338480
p81207
sg66306
Vmigraine without aura
p81208
sa(dp81209
g66301
I20
sg66302
I1
sg66303
I8
sg66314
VC0149931
p81210
sg66306
Vmigraine
p81211
sa(dp81212
g66301
I43
sg66302
I1
sg66303
I2
sg66314
VC0338480
p81213
sg66306
VMO
p81214
sa(dp81215
g66301
I74
sg66302
I3
sg66303
I18
sg66314
VC0154723
p81216
sg66306
Vmigraine with aura
p81217
sasa(dp81218
g66296
VOne novel mutation in SCN1A, encoding Alfa subunit of sodium channel, causing amino acid change M1500V localized to a region encoding inactivation loop between transmembrane domains III and IV of the channel, was detected in a female FHM patient.
p81219
sg66298
(lp81220
(dp81221
g66301
I22
sg66302
I1
sg66303
I5
sg66304
VP35498
p81222
sg66306
VSCN1A
p81223
sasg66311
(lp81224
(dp81225
g66301
I234
sg66302
I1
sg66303
I3
sg66314
VC1832894
p81226
sg66306
VFHM
p81227
sa(dp81228
g66301
I134
sg66302
I1
sg66303
I12
sg66314
VC0544461
p81229
sg66306
Vinactivation
p81230
sa(dp81231
g66301
I4
sg66302
I2
sg66303
I14
sg66314
VC2985438
p81232
sg66306
Vnovel mutation
p81233
sasa(dp81234
g66296
VThe presence of SCN1A mutations and absence of mutations in ATP1A2 or CACNA1A suggest that the Polish patients represent FHM type 3.
p81235
sg66298
(lp81236
(dp81237
g66301
I16
sg66302
I2
sg66303
I15
sg66304
VP35498
p81238
sg66306
VSCN1A mutations
p81239
sa(dp81240
g66301
I60
sg66302
I1
sg66303
I6
sg66304
VP50993
p81241
sg66306
VATP1A2
p81242
sasg66311
(lp81243
(dp81244
g66301
I121
sg66302
I1
sg66303
I3
sg66314
VC1832894
p81245
sg66306
VFHM
p81246
sasa(dp81247
g66296
VMutations of the voltage gated Na(+) channel Na(V)1.1 (SCN1A) are important causes of different genetic epilepsies and can also cause familial hemiplegic migraine (FHM-III).
p81248
sg66298
(lp81249
(dp81250
g66301
I55
sg66302
I1
sg66303
I5
sg66304
VP35498
p81251
sg66306
VSCN1A
p81252
sasg66311
(lp81253
(dp81254
g66301
I104
sg66302
I1
sg66303
I10
sg66314
VC0014544
p81255
sg66306
Vepilepsies
p81256
sa(dp81257
g66301
I164
sg66302
I1
sg66303
I7
sg66314
VC0338484
p81258
sg66306
VFHM-III
p81259
sa(dp81260
g66301
I134
sg66302
I3
sg66303
I28
sg66314
VC0338484
p81261
sg66306
Vfamilial hemiplegic migraine
p81262
sasa(dp81263
g66296
VA mutation causing FHM type 3 (FHM3) has been identified in SCN1A encoding the Nav1.1 Na(+) channel.
p81264
sg66298
(lp81265
(dp81266
g66301
I60
sg66302
I1
sg66303
I5
sg66304
VP35498
p81267
sg66306
VSCN1A
p81268
sa(dp81269
g66301
I19
sg66302
I3
sg66303
I10
sg66304
VP35498
p81270
sg66306
VFHM type 3
p81271
sa(dp81272
g66301
I79
sg66302
I2
sg66303
I12
sg66304
VP35498
p81273
sg66306
VNav1.1 Na(+)
p81274
sa(dp81275
g66301
I31
sg66302
I1
sg66303
I4
sg66304
VP35498
p81276
sg66306
VFHM3
p81277
sasg66311
(lp81278
(dp81279
g66301
I19
sg66302
I3
sg66303
I10
sg66314
VC1864987
p81280
sg66306
VFHM type 3
p81281
sa(dp81282
g66301
I31
sg66302
I1
sg66303
I4
sg66314
VC1864987
p81283
sg66306
VFHM3
p81284
sasa(dp81285
g66296
VIn particular, we investigate the dynamical repertoire from normal spiking (milliseconds) to spreading depression and anoxic depolarization (tens of seconds) and show that FHM3 mutations render gray matter tissue more vulnerable to spreading depression despite opposing effects associated with action potential generation.
p81286
sg66298
(lp81287
(dp81288
g66301
I172
sg66302
I1
sg66303
I4
sg66304
VP35498
p81289
sg66306
VFHM3
p81290
sasg66311
(lp81291
(dp81292
g66301
I172
sg66302
I1
sg66303
I4
sg66314
VC1864987
p81293
sg66306
VFHM3
p81294
sa(dp81295
g66301
I103
sg66302
I1
sg66303
I10
sg66314
VC0011581
p81296
sg66306
Vdepression
p81297
sa(dp81298
g66301
I103
sg66302
I1
sg66303
I10
sg66314
VC0011581
p81299
sg66306
Vdepression
p81300
sasa(dp81301
g66296
VPAR2 gene expression correlated positively with transcript levels of IL-8, IL-1Beta as well mucosal SLPI levels in H. pylori-infected patients (r: 0.47-0.84; p &lt; .0001), whereas no correlation was found with the degree of gastritis.
p81302
sg66298
(lp81303
(dp81304
g66301
I0
sg66302
I1
sg66303
I4
sg66304
VP55085
p81305
sg66306
VPAR2
p81306
sa(dp81307
g66301
I75
sg66302
I1
sg66303
I8
sg66304
VP01584
p81308
sg66306
VIL-1Beta
p81309
sasg66311
(lp81310
(dp81311
g66301
I225
sg66302
I1
sg66303
I9
sg66314
VC0017152
p81312
sg66306
Vgastritis
p81313
sasa(dp81314
g66296
VMucosal levels of Secretory Leukocyte Protease Inhibitor (SLPI) are specifically reduced in relation to H. pylori-induced gastritis.
p81315
sg66298
(lp81316
sg66311
(lp81317
(dp81318
g66301
I122
sg66302
I1
sg66303
I9
sg66314
VC0017152
p81319
sg66306
Vgastritis
p81320
sasa(dp81321
g66296
VIn contrast to other diseases, SLPI seems not to have a regulatory role for Progranulin in H. pylori-mediated gastritis.
p81322
sg66298
(lp81323
sg66311
(lp81324
(dp81325
g66301
I110
sg66302
I1
sg66303
I9
sg66314
VC0017152
p81326
sg66306
Vgastritis
p81327
sasa(dp81328
g66296
VSLPI expression is generally induced during inflammation; however, Helicobacter pylori-mediated gastritis is associated with significantly decreased antral SLPI levels.
p81329
sg66298
(lp81330
(dp81331
g66301
I0
sg66302
I1
sg66303
I4
sg66304
VP03973
p81332
sg66306
VSLPI
p81333
sasg66311
(lp81334
(dp81335
g66301
I44
sg66302
I1
sg66303
I12
sg66314
VC0021368
p81336
sg66306
Vinflammation
p81337
sa(dp81338
g66301
I96
sg66302
I1
sg66303
I9
sg66314
VC0017152
p81339
sg66306
Vgastritis
p81340
sasa(dp81341
g66296
VSLPI expression was retrospectively analysed by immunohistochemistry in 85 paraffin-embedded samples: H. pylori-induced (n=13), non-steroidal anti-inflammatory drug (NSAID)-enhanced (n=18), autoimmune (n=11), lymphocytic gastritis (n=26) and H. pylori-negative controls (n=17).
p81342
sg66298
(lp81343
sg66311
(lp81344
(dp81345
g66301
I190
sg66302
I1
sg66303
I10
sg66314
VC0443146
p81346
sg66306
Vautoimmune
p81347
sa(dp81348
g66301
I209
sg66302
I2
sg66303
I21
sg66314
VC1283271
p81349
sg66306
Vlymphocytic gastritis
p81350
sasa(dp81351
g66296
VIn comparison with the control group, the SLPI expression of antral mucosa in H. pylori-mediated and lymphocytic gastritis was significantly lower (P&lt;0.001), whereas epithelial SLPI expression was not affected in NSAID-enhanced and autoimmune gastritis either in the antrum or corpus, respectively.
p81352
sg66298
(lp81353
(dp81354
g66301
I42
sg66302
I1
sg66303
I4
sg66304
VP03973
p81355
sg66306
VSLPI
p81356
sa(dp81357
g66301
I169
sg66302
I2
sg66303
I15
sg66304
VP12830
p81358
sg66306
Vepithelial SLPI
p81359
sasg66311
(lp81360
(dp81361
g66301
I101
sg66302
I2
sg66303
I21
sg66314
VC1283271
p81362
sg66306
Vlymphocytic gastritis
p81363
sa(dp81364
g66301
I235
sg66302
I2
sg66303
I20
sg66314
VC0017154
p81365
sg66306
Vautoimmune gastritis
p81366
sasa(dp81367
g66296
VBoth the H. pylori-mediated and lymphocytic gastritis revealed a significantly lower expression of SLPI in infiltrating immune cells (P&lt;0.01), whereas immune cells infiltrating the corpus in autoimmune gastritis showed higher SLPI levels than the immune cells of other groups (P&lt;0.03).
p81368
sg66298
(lp81369
(dp81370
g66301
I99
sg66302
I1
sg66303
I4
sg66304
VP03973
p81371
sg66306
VSLPI
p81372
sasg66311
(lp81373
(dp81374
g66301
I32
sg66302
I2
sg66303
I21
sg66314
VC1283271
p81375
sg66306
Vlymphocytic gastritis
p81376
sa(dp81377
g66301
I194
sg66302
I2
sg66303
I20
sg66314
VC0017154
p81378
sg66306
Vautoimmune gastritis
p81379
sa(dp81380
g66301
I107
sg66302
I1
sg66303
I12
sg66314
VC0332448
p81381
sg66306
Vinfiltrating
p81382
sa(dp81383
g66301
I107
sg66302
I1
sg66303
I12
sg66314
VC0332448
p81384
sg66306
Vinfiltrating
p81385
sasa(dp81386
g66296
VAntral SLPI levels were inversely correlated with inflammatory scores of antrum-predominant gastritis.
p81387
sg66298
(lp81388
sg66311
(lp81389
(dp81390
g66301
I92
sg66302
I1
sg66303
I9
sg66314
VC0017152
p81391
sg66306
Vgastritis
p81392
sasa(dp81393
g66296
VPharmacological inhibition of different signaling pathways and genetic knockdown of Notch-2 further revealed JNK as an upstream effector of Notch-2 in TGF-Beta1-mediated renal fibrosis.
p81394
sg66298
(lp81395
(dp81396
g66301
I109
sg66302
I1
sg66303
I3
sg66304
VP53779
p81397
sg66306
VJNK
p81398
sa(dp81399
g66301
I151
sg66302
I1
sg66303
I9
sg66304
VP01137
p81400
sg66306
VTGF-Beta1
p81401
sa(dp81402
g66301
I84
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VNotch-2
p81403
sa(dp81404
g66301
I84
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VNotch-2
p81405
sasg66311
(lp81406
(dp81407
g66301
I170
sg66302
I2
sg66303
I14
sg66314
VC0151650
p81408
sg66306
Vrenal fibrosis
p81409
sasa(dp81410
g66296
VConsistently, we also demonstrated that administration of TSA or a Gamma-secretase inhibitor RO4929097 in the mouse model of unilateral ureteral obstruction significantly ameliorated renal fibrosis through suppression of the JNK/Notch-2 signaling activation.
p81411
sg66298
(lp81412
(dp81413
g66301
I229
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VNotch-2
p81414
sa(dp81415
g66301
I225
sg66302
I1
sg66303
I3
sg66304
VP53779
p81416
sg66306
VJNK
p81417
sasg66311
(lp81418
(dp81419
g66301
I136
sg66302
I2
sg66303
I20
sg66314
VC0041956
p81420
sg66306
Vureteral obstruction
p81421
sa(dp81422
g66301
I183
sg66302
I2
sg66303
I14
sg66314
VC0151650
p81423
sg66306
Vrenal fibrosis
p81424
sa(dp81425
g66301
I206
sg66302
I1
sg66303
I11
sg66314
VC0221103
p81426
sg66306
Vsuppression
p81427
sasa(dp81428
g66296
VAlthough, renal abnormalities are considered an integral part of the HJCYS, published reports on ESRD are scarce.
p81429
sg66298
(lp81430
sg66311
(lp81431
(dp81432
g66301
I69
sg66302
I1
sg66303
I5
sg66314
VC0917715
p81433
sg66306
VHJCYS
p81434
sa(dp81435
g66301
I97
sg66302
I1
sg66303
I4
sg66314
VC0022661
p81436
sg66306
VESRD
p81437
sasa(dp81438
g66296
VHere we show that Notch2 prevents podocyte loss and nephrosis.
p81439
sg66298
(lp81440
(dp81441
g66301
I18
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VNotch2
p81442
sasg66311
(lp81443
(dp81444
g66301
I52
sg66302
I1
sg66303
I9
sg66314
VC0027720
p81445
sg66306
Vnephrosis
p81446
sasa(dp81447
g66296
VAdministration of a Notch2 agonistic monoclonal antibody ameliorates proteinuria and glomerulosclerosis in a mouse model of nephrosis and focal segmental glomerulosclerosis.
p81448
sg66298
(lp81449
(dp81450
g66301
I20
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VNotch2
p81451
sasg66311
(lp81452
(dp81453
g66301
I138
sg66302
I3
sg66303
I34
sg66314
VC0017668
p81454
sg66306
Vfocal segmental glomerulosclerosis
p81455
sa(dp81456
g66301
I85
sg66302
I1
sg66303
I18
sg66314
VC0178664
p81457
sg66306
Vglomerulosclerosis
p81458
sa(dp81459
g66301
I124
sg66302
I1
sg66303
I9
sg66314
VC0027720
p81460
sg66306
Vnephrosis
p81461
sasa(dp81462
g66296
VHence, specific activation of Notch2 rescues damaged podocytes and activating Notch2 may represent a novel clinical strategy for the amelioration of nephrosis and glomerulosclerosis.
p81463
sg66298
(lp81464
(dp81465
g66301
I30
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VNotch2
p81466
sa(dp81467
g66301
I30
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VNotch2
p81468
sasg66311
(lp81469
(dp81470
g66301
I149
sg66302
I1
sg66303
I9
sg66314
VC0027720
p81471
sg66306
Vnephrosis
p81472
sa(dp81473
g66301
I163
sg66302
I1
sg66303
I18
sg66314
VC0178664
p81474
sg66306
Vglomerulosclerosis
p81475
sasa(dp81476
g66296
VTo investigate the effect of both fermented Cordyceps powder (CS) and prednisone on the Notch2/hes-1 signaling activation in the kidney tubules of rats with acute aristolochic acid nephropathy (AAAN).
p81477
sg66298
(lp81478
(dp81479
g66301
I95
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
Vhes-1
p81480
sa(dp81481
g66301
I88
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VNotch2
p81482
sasg66311
(lp81483
(dp81484
g66301
I95
sg66302
I1
sg66303
I3
sg66314
VC0206141
p81485
sg66306
Vhes
p81486
sa(dp81487
g66301
I181
sg66302
I1
sg66303
I11
sg66314
VC0022658
p81488
sg66306
Vnephropathy
p81489
sasa(dp81490
g66296
VThe role of NOTCH2 and JAG1 in formation of proximal nephron structures and podocytes might explain the observed phenotypes of renal dysplasia and proteinuria in patients with Alagille syndrome, and renal tubular acidosis may be the result of JAG1 expression in the collecting ducts.
p81491
sg66298
(lp81492
(dp81493
g66301
I12
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VNOTCH2
p81494
sa(dp81495
g66301
I23
sg66302
I1
sg66303
I4
sg66304
VP78504
p81496
sg66306
VJAG1
p81497
sa(dp81498
g66301
I23
sg66302
I1
sg66303
I4
sg66304
VP78504
p81499
sg66306
VJAG1
p81500
sasg66311
(lp81501
(dp81502
g66301
I127
sg66302
I2
sg66303
I15
sg66314
VC0266313
p81503
sg66306
Vrenal dysplasia
p81504
sa(dp81505
g66301
I199
sg66302
I3
sg66303
I22
sg66314
VC0001126
p81506
sg66306
Vrenal tubular acidosis
p81507
sa(dp81508
g66301
I176
sg66302
I2
sg66303
I17
sg66314
VC0085280
p81509
sg66306
VAlagille syndrome
p81510
sasa(dp81511
g66296
VThe oral pathogenic bacterium involved in human dental caries formation Streptococcus mutans, encodes for two carbonic anhydrase (CA, EC 4.2.1.1) one belonging to the Alfa- and the other one to the Beta-class.
p81512
sg66298
(lp81513
(dp81514
g66301
I110
sg66302
I2
sg66303
I18
sg66304
VP35218
p81515
sg66306
Vcarbonic anhydrase
p81516
sa(dp81517
g66301
I130
sg66302
I1
sg66303
I2
sg66304
VP35218
p81518
sg66306
VCA
p81519
sasg66311
(lp81520
(dp81521
g66301
I48
sg66302
I2
sg66303
I13
sg66314
VC0333519
p81522
sg66306
Vdental caries
p81523
sasa(dp81524
g66296
VStreptococcus mutans, the oral pathogenic bacterium provoking dental caries formation, encodes for a Beta-class carbonic anhydrase (CA, EC 4.2.1.1), SmuCA.
p81525
sg66298
(lp81526
(dp81527
g66301
I101
sg66302
I3
sg66303
I29
sg66304
VP35218
p81528
sg66306
VBeta-class carbonic anhydrase
p81529
sasg66311
(lp81530
(dp81531
g66301
I62
sg66302
I2
sg66303
I13
sg66314
VC0333519
p81532
sg66306
Vdental caries
p81533
sasa(dp81534
g66296
VA carbonic anhydrase (CA, EC 4.2.1.1) denominated PgiCA, belonging to the Gamma-class, from the oral pathogenic bacteria Porphyromonas gingivalis, the main causative agent of periodontitis, was investigated for its inhibition profile with sulfonamides and one sulfamate.
p81535
sg66298
(lp81536
(dp81537
g66301
I22
sg66302
I1
sg66303
I2
sg66304
VP35218
p81538
sg66306
VCA
p81539
sa(dp81540
g66301
I2
sg66302
I2
sg66303
I18
sg66304
VP35218
p81541
sg66306
Vcarbonic anhydrase
p81542
sasg66311
(lp81543
(dp81544
g66301
I175
sg66302
I1
sg66303
I13
sg66314
VC0031099
p81545
sg66306
Vperiodontitis
p81546
sasa(dp81547
g66296
VRecently, an interaction between FIR (FUSE-Binding Protein-Interacting Repressor) and TFIIH/p89/XPB helicase was found to repress c-myc transcription and so might be important for suppressing tumor formation.
p81548
sg66298
(lp81549
(dp81550
g66301
I130
sg66302
I1
sg66303
I5
sg66304
VP12524
p81551
sg66306
Vc-myc
p81552
sa(dp81553
g66301
I96
sg66302
I2
sg66303
I12
sg66304
VP19447
p81554
sg66306
VXPB helicase
p81555
sa(dp81556
g66301
I86
sg66302
I1
sg66303
I5
sg66304
VP32780
p81557
sg66306
VTFIIH
p81558
sasg66311
(lp81559
(dp81560
g66301
I192
sg66302
I1
sg66303
I5
sg66314
VC0027651
p81561
sg66306
Vtumor
p81562
sa(dp81563
g66301
I96
sg66302
I1
sg66303
I3
sg66314
VC0268136
p81564
sg66306
VXPB
p81565
sasa(dp81566
g66296
VIn XPB cells carrying mutant TFIIH, loop formation failed and the serum response was abnormal; RNAi depletion of FIR similarly disabled c-myc regulation.
p81567
sg66298
(lp81568
(dp81569
g66301
I113
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VFIR
p81570
sa(dp81571
g66301
I136
sg66302
I1
sg66303
I5
sg66304
VP12524
p81572
sg66306
Vc-myc
p81573
sa(dp81574
g66301
I29
sg66302
I1
sg66303
I5
sg66304
VP32780
p81575
sg66306
VTFIIH
p81576
sasg66311
(lp81577
(dp81578
g66301
I3
sg66302
I1
sg66303
I3
sg66314
VC0268136
p81579
sg66306
VXPB
p81580
sa(dp81581
g66301
I22
sg66302
I1
sg66303
I6
sg66314
VC0596988
p81582
sg66306
Vmutant
p81583
sasa(dp81584
g66296
VRecently, an interaction between FUSE-binding protein-interacting repressor (FIR) and TFIIH/p89/XPB helicase was found to repress c-myc transcription and might be important for suppressing tumor formation.
p81585
sg66298
(lp81586
(dp81587
g66301
I130
sg66302
I1
sg66303
I5
sg66304
VP12524
p81588
sg66306
Vc-myc
p81589
sa(dp81590
g66301
I77
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VFIR
p81591
sa(dp81592
g66301
I96
sg66302
I2
sg66303
I12
sg66304
VP19447
p81593
sg66306
VXPB helicase
p81594
sa(dp81595
g66301
I86
sg66302
I1
sg66303
I5
sg66304
VP32780
p81596
sg66306
VTFIIH
p81597
sa(dp81598
g66301
I33
sg66302
I3
sg66303
I42
sg66304
g11
sg66306
VFUSE-binding protein-interacting repressor
p81599
sasg66311
(lp81600
(dp81601
g66301
I189
sg66302
I1
sg66303
I5
sg66314
VC0027651
p81602
sg66306
Vtumor
p81603
sa(dp81604
g66301
I96
sg66302
I1
sg66303
I3
sg66314
VC0268136
p81605
sg66306
VXPB
p81606
sasa(dp81607
g66296
VHere, XPB and XPD mutations are shown to block transcription activation by the FUSE Binding Protein (FBP), a regulator of c-myc expression, and repression by the FBP Interacting Repressor (FIR).
p81608
sg66298
(lp81609
(dp81610
g66301
I189
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VFIR
p81611
sa(dp81612
g66301
I101
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VFBP
p81613
sa(dp81614
g66301
I122
sg66302
I1
sg66303
I5
sg66304
VP12524
p81615
sg66306
Vc-myc
p81616
sa(dp81617
g66301
I6
sg66302
I1
sg66303
I3
sg66304
VP19447
p81618
sg66306
VXPB
p81619
sa(dp81620
g66301
I14
sg66302
I1
sg66303
I3
sg66304
VP18074
p81621
sg66306
VXPD
p81622
sa(dp81623
g66301
I79
sg66302
I3
sg66303
I20
sg66304
g11
sg66306
VFUSE Binding Protein
p81624
sa(dp81625
g66301
I162
sg66302
I3
sg66303
I25
sg66304
g11
sg66306
VFBP Interacting Repressor
p81626
sasg66311
(lp81627
(dp81628
g66301
I14
sg66302
I1
sg66303
I3
sg66314
VC0268138
p81629
sg66306
VXPD
p81630
sa(dp81631
g66301
I6
sg66302
I1
sg66303
I3
sg66314
VC0268136
p81632
sg66306
VXPB
p81633
sasa(dp81634
g66296
VThe repression domain of FIR targeted only TFIIH's p89/XPB helicase, required at several stages in transcription, but not factors required for promoter selection.
p81635
sg66298
(lp81636
(dp81637
g66301
I55
sg66302
I2
sg66303
I12
sg66304
VP19447
p81638
sg66306
VXPB helicase
p81639
sa(dp81640
g66301
I25
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VFIR
p81641
sa(dp81642
g66301
I43
sg66302
I1
sg66303
I5
sg66304
VP32780
p81643
sg66306
VTFIIH
p81644
sasg66311
(lp81645
(dp81646
g66301
I55
sg66302
I1
sg66303
I3
sg66314
VC0268136
p81647
sg66306
VXPB
p81648
sasa(dp81649
g66296
VTo investigate the tissue expression and systemic levels of IL-32, as well as its cellular sources, in patients with HS in comparison with healthy donors and patients with two other inflammatory skin diseases: psoriasis and atopic dermatitis (AD).
p81650
sg66298
(lp81651
sg66311
(lp81652
(dp81653
g66301
I243
sg66302
I1
sg66303
I2
sg66314
VC0011615
p81654
sg66306
VAD
p81655
sa(dp81656
g66301
I210
sg66302
I1
sg66303
I9
sg66314
VC0033860
p81657
sg66306
Vpsoriasis
p81658
sa(dp81659
g66301
I195
sg66302
I2
sg66303
I13
sg66314
VC0037274
p81660
sg66306
Vskin diseases
p81661
sa(dp81662
g66301
I224
sg66302
I2
sg66303
I17
sg66314
VC0011615
p81663
sg66306
Vatopic dermatitis
p81664
sasa(dp81665
g66296
VIL-32 was upregulated in patients with HS in both lesional skin and serum when compared with healthy donors and patients with AD or psoriasis.
p81666
sg66298
(lp81667
sg66311
(lp81668
(dp81669
g66301
I132
sg66302
I1
sg66303
I9
sg66314
VC0033860
p81670
sg66306
Vpsoriasis
p81671
sasa(dp81672
g66296
VUsing skin samples from patients with mycosis fungoides (n = 21), healthy volunteers (n = 17), and individuals with atopic dermatitis (n = 17) and psoriasis (n = 9), we found IL32 mRNA expression significantly higher in mycosis fungoides samples than in samples from benign inflammatory skin diseases, and its expression increases with disease progression.
p81673
sg66298
(lp81674
(dp81675
g66301
I175
sg66302
I2
sg66303
I9
sg66304
VP24001
p81676
sg66306
VIL32 mRNA
p81677
sasg66311
(lp81678
(dp81679
g66301
I116
sg66302
I2
sg66303
I17
sg66314
VC0011615
p81680
sg66306
Vatopic dermatitis
p81681
sa(dp81682
g66301
I38
sg66302
I2
sg66303
I17
sg66314
VC0026948
p81683
sg66306
Vmycosis fungoides
p81684
sa(dp81685
g66301
I336
sg66302
I2
sg66303
I19
sg66314
VC0242656
p81686
sg66306
Vdisease progression
p81687
sa(dp81688
g66301
I147
sg66302
I1
sg66303
I9
sg66314
VC0033860
p81689
sg66306
Vpsoriasis
p81690
sa(dp81691
g66301
I38
sg66302
I2
sg66303
I17
sg66314
VC0026948
p81692
sg66306
Vmycosis fungoides
p81693
sa(dp81694
g66301
I287
sg66302
I2
sg66303
I13
sg66314
VC0037274
p81695
sg66306
Vskin diseases
p81696
sasa(dp81697
g66296
VImmunofluorescence staining demonstrated that IL-32 was expressed in AD lesional skin, whereas it was present in neither skin biopsy specimens from healthy donors nor in lesional skin from patients with psoriasis.
p81698
sg66298
(lp81699
sg66311
(lp81700
(dp81701
g66301
I203
sg66302
I1
sg66303
I9
sg66314
VC0033860
p81702
sg66306
Vpsoriasis
p81703
sasa(dp81704
g66296
VIn this study, the expression profile of ASPP2 in choriocarcinoma was examined in comparison with normal placentas and hydatidiform moles, the latter being a type of GTD that carries malignant potential.
p81705
sg66298
(lp81706
(dp81707
g66301
I41
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VASPP2
p81708
sasg66311
(lp81709
(dp81710
g66301
I50
sg66302
I1
sg66303
I15
sg66314
VC0008497
p81711
sg66306
Vchoriocarcinoma
p81712
sa(dp81713
g66301
I119
sg66302
I2
sg66303
I18
sg66314
VC0020217
p81714
sg66306
Vhydatidiform moles
p81715
sasa(dp81716
g66296
VDownregulation of ASPP2 messenger RNA and protein was demonstrated in choriocarcinoma by quantitative PCR and immunohistochemistry.
p81717
sg66298
(lp81718
(dp81719
g66301
I18
sg66302
I5
sg66303
I31
sg66304
g11
sg66306
VASPP2 messenger RNA and protein
p81720
sasg66311
(lp81721
(dp81722
g66301
I70
sg66302
I1
sg66303
I15
sg66314
VC0008497
p81723
sg66306
Vchoriocarcinoma
p81724
sasa(dp81725
g66296
VASPP2-transfected choriocarcinoma cells (JEG-3 and JAR) showed an increase in apoptosis and a decrease in cell migration as detected by TdT-mediated dUTP nick end labeling and wound healing assays, respectively, illustrating the complex action of ASPP2 on cell functions other than programmed cell death.
p81726
sg66298
(lp81727
(dp81728
g66301
I0
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VASPP2
p81729
sa(dp81730
g66301
I0
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VASPP2
p81731
sa(dp81732
g66301
I136
sg66302
I1
sg66303
I3
sg66304
VP04053
p81733
sg66306
VTdT
p81734
sasg66311
(lp81735
(dp81736
g66301
I18
sg66302
I1
sg66303
I15
sg66314
VC0008497
p81737
sg66306
Vchoriocarcinoma
p81738
sasa(dp81739
g66296
VTaken together, we demonstrated a loss of tumor-suppressive ASPP2 in choriocarcinoma with effects on cell migration and apoptosis.
p81740
sg66298
(lp81741
(dp81742
g66301
I60
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VASPP2
p81743
sasg66311
(lp81744
(dp81745
g66301
I69
sg66302
I1
sg66303
I15
sg66314
VC0008497
p81746
sg66306
Vchoriocarcinoma
p81747
sa(dp81748
g66301
I42
sg66302
I1
sg66303
I5
sg66314
VC0027651
p81749
sg66306
Vtumor
p81750
sasa(dp81751
g66296
VNo correlation between erythrocyte TDP concentration and transketolase activity and/or alpha-ETK was observed in ESRD patients, either before or 10 h after administration.
p81752
sg66298
(lp81753
(dp81754
g66301
I57
sg66302
I1
sg66303
I13
sg66304
VP29401
p81755
sg66306
Vtransketolase
p81756
sa(dp81757
g66301
I87
sg66302
I1
sg66303
I9
sg66304
VP51813
p81758
sg66306
Valpha-ETK
p81759
sasg66311
(lp81760
(dp81761
g66301
I113
sg66302
I1
sg66303
I4
sg66314
VC0022661
p81762
sg66306
VESRD
p81763
sasa(dp81764
g66296
VScores for VEGF, TIMP-1, TIMP-3, SLPI and PAI-1 were all increased in OA compared with PM, and higher scores were associated with greater chondropathy.
p81765
sg66298
(lp81766
(dp81767
g66301
I42
sg66302
I1
sg66303
I5
sg66304
VP05121
p81768
sg66306
VPAI-1
p81769
sa(dp81770
g66301
I25
sg66302
I1
sg66303
I6
sg66304
VP35625
p81771
sg66306
VTIMP-3
p81772
sa(dp81773
g66301
I17
sg66302
I1
sg66303
I6
sg66304
VP01033
p81774
sg66306
VTIMP-1
p81775
sa(dp81776
g66301
I33
sg66302
I1
sg66303
I4
sg66304
VP03973
p81777
sg66306
VSLPI
p81778
sasg66311
(lp81779
(dp81780
g66301
I138
sg66302
I1
sg66303
I12
sg66314
VC0007302
p81781
sg66306
Vchondropathy
p81782
sasa(dp81783
g66296
VConcentrations of the plasminogen activators pro-urokinase, tissue plasminogen activator, plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2), plasminogen, and fibrin split product D-dimer in synovial fluid (SF) and blood plasma of 29 patients with rheumatoid arthritis (RA) were compared with the concentrations of 18 patients with spondyloarthropathy (SpA).
p81784
sg66298
(lp81785
(dp81786
g66301
I132
sg66302
I1
sg66303
I5
sg66304
VP05121
p81787
sg66306
VPAI-1
p81788
sa(dp81789
g66301
I60
sg66302
I3
sg66303
I28
sg66304
VP00747
p81790
sg66306
Vtissue plasminogen activator
p81791
sa(dp81792
g66301
I22
sg66302
I1
sg66303
I11
sg66304
VP00747
p81793
sg66306
Vplasminogen
p81794
sa(dp81795
g66301
I22
sg66302
I3
sg66303
I36
sg66304
VP00747
p81796
sg66306
Vplasminogen activators pro-urokinase
p81797
sa(dp81798
g66301
I90
sg66302
I6
sg66303
I40
sg66304
VP00747
p81799
sg66306
Vplasminogen activator inhibitors 1 and 2
p81800
sa(dp81801
g66301
I167
sg66302
I1
sg66303
I6
sg66304
VP22087
p81802
sg66306
Vfibrin
p81803
sa(dp81804
g66301
I142
sg66302
I1
sg66303
I5
sg66304
VP05120
p81805
sg66306
VPAI-2
p81806
sasg66311
(lp81807
(dp81808
g66301
I278
sg66302
I1
sg66303
I2
sg66314
VC0003873
p81809
sg66306
VRA
p81810
sa(dp81811
g66301
I361
sg66302
I1
sg66303
I3
sg66314
VC0949691
p81812
sg66306
VSpA
p81813
sa(dp81814
g66301
I340
sg66302
I1
sg66303
I19
sg66314
VC0949691
p81815
sg66306
Vspondyloarthropathy
p81816
sa(dp81817
g66301
I256
sg66302
I2
sg66303
I20
sg66314
VC0003873
p81818
sg66306
Vrheumatoid arthritis
p81819
sasa(dp81820
g66296
VBesides myeloperoxidase (MPO), which was used as the gold standard in differentiating AML from other type of ALs, the most specific markers for AML in our study were CD14 and CD64 (99.5 and 95.6%).
p81821
sg66298
(lp81822
(dp81823
g66301
I8
sg66302
I1
sg66303
I15
sg66304
VP05164
p81824
sg66306
Vmyeloperoxidase
p81825
sa(dp81826
g66301
I166
sg66302
I1
sg66303
I4
sg66304
VP08571
p81827
sg66306
VCD14
p81828
sa(dp81829
g66301
I25
sg66302
I1
sg66303
I3
sg66304
VP05164
p81830
sg66306
VMPO
p81831
sasg66311
(lp81832
(dp81833
g66301
I86
sg66302
I1
sg66303
I3
sg66314
VC0023467
p81834
sg66306
VAML
p81835
sa(dp81836
g66301
I109
sg66302
I1
sg66303
I3
sg66314
VC0002736
p81837
sg66306
VALs
p81838
sa(dp81839
g66301
I86
sg66302
I1
sg66303
I3
sg66314
VC0023467
p81840
sg66306
VAML
p81841
sasa(dp81842
g66296
VThey were characterized as follows: (1) disease onset with initial signs/symptoms due to intractable otitis media with effusion or granulation, which did not respond to ordinary treatments such as antibiotics and insertion of tympanic ventilation tubes, followed by progressive hearing loss; (2) predominantly female (73%) and older (median age: 68 years); (3) predominantly myeloperoxidase (MPO)-ANCA-positive (60%), followed by proteinase 3 (PR3)-ANCA-positive (19%) and both ANCAs-negative (16%); (4) frequently observed accompanying facial palsy (36%) and hypertrophic pachymeningitis (28%); and (5) disease often involving lung (35%) and kidney (26%) lesions.
p81843
sg66298
(lp81844
(dp81845
g66301
I430
sg66302
I2
sg66303
I12
sg66304
VP63123
p81846
sg66306
Vproteinase 3
p81847
sa(dp81848
g66301
I444
sg66302
I1
sg66303
I3
sg66304
VP63123
p81849
sg66306
VPR3
p81850
sa(dp81851
g66301
I375
sg66302
I1
sg66303
I15
sg66304
VP05164
p81852
sg66306
Vmyeloperoxidase
p81853
sa(dp81854
g66301
I392
sg66302
I1
sg66303
I3
sg66304
VP05164
p81855
sg66306
VMPO
p81856
sasg66311
(lp81857
(dp81858
g66301
I537
sg66302
I2
sg66303
I12
sg66314
VC0015469
p81859
sg66306
Vfacial palsy
p81860
sa(dp81861
g66301
I101
sg66302
I4
sg66303
I26
sg66314
VC0029883
p81862
sg66306
Votitis media with effusion
p81863
sa(dp81864
g66301
I278
sg66302
I2
sg66303
I12
sg66314
VC0011053
p81865
sg66306
Vhearing loss
p81866
sa(dp81867
g66301
I560
sg66302
I2
sg66303
I28
sg66314
VC0948402
p81868
sg66306
Vhypertrophic pachymeningitis
p81869
sasa(dp81870
g66296
VEffects of zolpidem were wide ranging (eg, improvement on the JFK Coma Recovery Scale-Revised, the Unified Parkinson Disease Rating Scale, and the Burke-Fahn-Marsden Dystonia Rating Scale) and generally lasted 1 to 4 hours before the participant returned to baseline.
p81871
sg66298
(lp81872
sg66311
(lp81873
(dp81874
g66301
I66
sg66302
I1
sg66303
I4
sg66314
VC0009421
p81875
sg66306
VComa
p81876
sa(dp81877
g66301
I166
sg66302
I1
sg66303
I8
sg66314
VC0393593
p81878
sg66306
VDystonia
p81879
sa(dp81880
g66301
I107
sg66302
I2
sg66303
I17
sg66314
VC0030567
p81881
sg66306
VParkinson Disease
p81882
sasa(dp81883
g66296
VThe altered tissue steroid concentrations in endometriosis were in line with the expression of various steroidogenic enzymes in the lesions, of which HSD3B2 showed constantly high expression, whereas CYP11A1 expression was low.
p81884
sg66298
(lp81885
(dp81886
g66301
I200
sg66302
I1
sg66303
I7
sg66304
VP05108
p81887
sg66306
VCYP11A1
p81888
sa(dp81889
g66301
I150
sg66302
I1
sg66303
I6
sg66304
VP26439
p81890
sg66306
VHSD3B2
p81891
sasg66311
(lp81892
(dp81893
g66301
I45
sg66302
I1
sg66303
I13
sg66314
VC0014175
p81894
sg66306
Vendometriosis
p81895
sasa(dp81896
g66296
VType III groups together 10 autoimmune diseases (autoimmune thyroid disease, myasthenia and/or thymoma, Sjoegren's syndrome, pernicious anaemia, idiopathic thrombocytopaenic purpura, Addison's disease, insulin-dependent diabetes, vitiligo, autoimmune haemolytic anaemia, systemic lupus erythematosus) for which a genetic predisposition (phenotype HLA B8 and/or DR3 or DR5) seems to be an important factor.
p81897
sg66298
(lp81898
(dp81899
g66301
I202
sg66302
I1
sg66303
I7
sg66304
VP01308
p81900
sg66306
Vinsulin
p81901
sasg66311
(lp81902
(dp81903
g66301
I49
sg66302
I3
sg66303
I26
sg66314
VC0178468
p81904
sg66306
Vautoimmune thyroid disease
p81905
sa(dp81906
g66301
I271
sg66302
I3
sg66303
I28
sg66314
VC0024141
p81907
sg66306
Vsystemic lupus erythematosus
p81908
sa(dp81909
g66301
I183
sg66302
I2
sg66303
I17
sg66314
VC0001403
p81910
sg66306
VAddison's disease
p81911
sa(dp81912
g66301
I202
sg66302
I2
sg66303
I26
sg66314
VC0011854
p81913
sg66306
Vinsulin-dependent diabetes
p81914
sa(dp81915
g66301
I230
sg66302
I1
sg66303
I8
sg66314
VC0042900
p81916
sg66306
Vvitiligo
p81917
sa(dp81918
g66301
I95
sg66302
I1
sg66303
I7
sg66314
VC0040100
p81919
sg66306
Vthymoma
p81920
sa(dp81921
g66301
I28
sg66302
I2
sg66303
I19
sg66314
VC0004364
p81922
sg66306
Vautoimmune diseases
p81923
sa(dp81924
g66301
I77
sg66302
I1
sg66303
I10
sg66314
VC0947912
p81925
sg66306
Vmyasthenia
p81926
sa(dp81927
g66301
I104
sg66302
I2
sg66303
I19
sg66314
VC1527336
p81928
sg66306
VSjoegren's syndrome
p81929
sa(dp81930
g66301
I156
sg66302
I2
sg66303
I25
sg66314
VC0857305
p81931
sg66306
Vthrombocytopaenic purpura
p81932
sa(dp81933
g66301
I125
sg66302
I2
sg66303
I18
sg66314
VC0002892
p81934
sg66306
Vpernicious anaemia
p81935
sa(dp81936
g66301
I240
sg66302
I3
sg66303
I29
sg66314
VC0002880
p81937
sg66306
Vautoimmune haemolytic anaemia
p81938
sasa(dp81939
g66296
VA significant increase in the frequency of HLA DR5 antigen was observed in patients with ARC mainly in purpura thrombocytopenic patients.
p81940
sg66298
(lp81941
(dp81942
g66301
I43
sg66302
I3
sg66303
I15
sg66304
VP30486
p81943
sg66306
VHLA DR5 antigen
p81944
sasg66311
(lp81945
(dp81946
g66301
I103
sg66302
I2
sg66303
I24
sg66314
VC0857305
p81947
sg66306
Vpurpura thrombocytopenic
p81948
sa(dp81949
g66301
I89
sg66302
I1
sg66303
I3
sg66314
VC0001857
p81950
sg66306
VARC
p81951
sasa(dp81952
g66296
VGenome-wide pathway analysis with the dysregulated genes after overexpression of either of the two miRs in MCF-7 breast cancer cell identified the "Cancer"- and "Cell signaling"-related pathway as the top pathway for miR-204 and miR-211, respectively.
p81953
sg66298
(lp81954
(dp81955
g66301
I217
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-204
p81956
sa(dp81957
g66301
I229
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-211
p81958
sasg66311
(lp81959
(dp81960
g66301
I148
sg66302
I1
sg66303
I6
sg66314
VC0006826
p81961
sg66306
VCancer
p81962
sa(dp81963
g66301
I113
sg66302
I2
sg66303
I13
sg66314
VC0678222
p81964
sg66306
Vbreast cancer
p81965
sasa(dp81966
g66296
VIn addition, a high association was observed between miR-204 and miR-211 expression in breast cancer tissue.
p81967
sg66298
(lp81968
(dp81969
g66301
I53
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-204
p81970
sa(dp81971
g66301
I65
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-211
p81972
sasg66311
(lp81973
(dp81974
g66301
I87
sg66302
I2
sg66303
I13
sg66314
VC0678222
p81975
sg66306
Vbreast cancer
p81976
sasa(dp81977
g66296
VTo shed light on their roles of miR-211 in breast cancer, the expression of miR-211 was examined by real-time RT-PCR in breast cancer and normal tissues.
p81978
sg66298
(lp81979
sg66311
(lp81980
(dp81981
g66301
I43
sg66302
I2
sg66303
I13
sg66314
VC0678222
p81982
sg66306
Vbreast cancer
p81983
sa(dp81984
g66301
I43
sg66302
I2
sg66303
I13
sg66314
VC0678222
p81985
sg66306
Vbreast cancer
p81986
sasa(dp81987
g66296
VMiR-211 is significantly downregulated in breast cancer.
p81988
sg66298
(lp81989
(dp81990
g66301
I0
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VMiR
p81991
sasg66311
(lp81992
(dp81993
g66301
I42
sg66302
I2
sg66303
I13
sg66314
VC0678222
p81994
sg66306
Vbreast cancer
p81995
sasa(dp81996
g66296
VMiR-211 re-expression suppressed cell growth, cell cycle, migration, and invasion in triple-negative breast cancer (TNBC) cell line MDA-MB231.
p81997
sg66298
(lp81998
(dp81999
g66301
I0
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VMiR
p82000
sasg66311
(lp82001
(dp82002
g66301
I101
sg66302
I2
sg66303
I13
sg66314
VC0678222
p82003
sg66306
Vbreast cancer
p82004
sa(dp82005
g66301
I73
sg66302
I1
sg66303
I8
sg66314
VC2699153
p82006
sg66306
Vinvasion
p82007
sasa(dp82008
g66296
VThe expression and the functional role of several miRNAs (miR-206, miR-31, miR-27a/b, miR-21, miR-92a, miR-205, miR-125a/b, miR-10b, miR-155, miR-146a/b, miR-335, miR-204, miR-211, miR-7, miR-22, miR-126, and miR-17) in breast cancer has been identified.
p82009
sg66298
(lp82010
(dp82011
g66301
I94
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-92a
p82012
sa(dp82013
g66301
I124
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-10b
p82014
sa(dp82015
g66301
I103
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-205
p82016
sa(dp82017
g66301
I86
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VmiR-21
p82018
sa(dp82019
g66301
I142
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-146a/b
p82020
sa(dp82021
g66301
I58
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-206
p82022
sa(dp82023
g66301
I188
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VmiR-22
p82024
sa(dp82025
g66301
I75
sg66302
I1
sg66303
I9
sg66304
g11
sg66306
VmiR-27a/b
p82026
sa(dp82027
g66301
I154
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-335
p82028
sa(dp82029
g66301
I172
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-211
p82030
sa(dp82031
g66301
I67
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VmiR-31
p82032
sa(dp82033
g66301
I163
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-204
p82034
sa(dp82035
g66301
I112
sg66302
I1
sg66303
I10
sg66304
g11
sg66306
VmiR-125a/b
p82036
sa(dp82037
g66301
I209
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VmiR-17
p82038
sa(dp82039
g66301
I133
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-155
p82040
sa(dp82041
g66301
I196
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-126
p82042
sa(dp82043
g66301
I181
sg66302
I1
sg66303
I5
sg66304
g11
sg66306
VmiR-7
p82044
sasg66311
(lp82045
(dp82046
g66301
I220
sg66302
I2
sg66303
I13
sg66314
VC0678222
p82047
sg66306
Vbreast cancer
p82048
sasa(dp82049
g66296
VQuantitative RT-PCR analysis confirmed that miR-135b, miR-192, miR-194 and miR-211 were significantly up-regulated in radiation-induced mammary cancer compared with spontaneous cancer and normal mammary tissue.
p82050
sg66298
(lp82051
(dp82052
g66301
I54
sg66302
I1
sg66303
I7
sg66304
g11
sg66306
VmiR-192
p82053
sa(dp82054
g66301
I44
sg66302
I1
sg66303
I8
sg66304
g11
sg66306
VmiR-135b
p82055
sasg66311
(lp82056
(dp82057
g66301
I144
sg66302
I1
sg66303
I6
sg66314
VC0006826
p82058
sg66306
Vcancer
p82059
sa(dp82060
g66301
I144
sg66302
I1
sg66303
I6
sg66314
VC0006826
p82061
sg66306
Vcancer
p82062
sasa(dp82063
g66296
VThe HBD/LD ratio in the measles patients two to three days after the onset of rash was significantly lower than that in control subjects (P less than 0.001).
p82064
sg66298
(lp82065
sg66311
(lp82066
(dp82067
g66301
I78
sg66302
I1
sg66303
I4
sg66314
VC0015230
p82068
sg66306
Vrash
p82069
sa(dp82070
g66301
I24
sg66302
I1
sg66303
I7
sg66314
VC0025007
p82071
sg66306
Vmeasles
p82072
sa(dp82073
g66301
I4
sg66302
I1
sg66303
I3
sg66314
VC1840321
p82074
sg66306
VHBD
p82075
sasa(dp82076
g66296
VUC treatment obviously reduced the expression levels of IL-2, IFN-Gamma, NF-KBp65, ICAM-1 and VEGF and increased inhibitory kappa B alpha (IKB-Alfa) expression in the grafts, where no obvious inflammatory cell infiltration or corneal neovascularization was found.
p82077
sg66298
(lp82078
(dp82079
g66301
I56
sg66302
I1
sg66303
I4
sg66304
VP60568
p82080
sg66306
VIL-2
p82081
sa(dp82082
g66301
I83
sg66302
I1
sg66303
I6
sg66304
VP05362
p82083
sg66306
VICAM-1
p82084
sa(dp82085
g66301
I139
sg66302
I1
sg66303
I8
sg66304
VP25963
p82086
sg66306
VIKB-Alfa
p82087
sa(dp82088
g66301
I62
sg66302
I1
sg66303
I9
sg66304
VP01579
p82089
sg66306
VIFN-Gamma
p82090
sasg66311
(lp82091
(dp82092
g66301
I192
sg66302
I3
sg66303
I30
sg66314
VC0302158
p82093
sg66306
Vinflammatory cell infiltration
p82094
sa(dp82095
g66301
I226
sg66302
I2
sg66303
I26
sg66314
VC0085109
p82096
sg66306
Vcorneal neovascularization
p82097
sasa(dp82098
g66296
VIn contrast, none of other patients with MFM had necklace CBs except for one patient with reducing body myopathy.
p82099
sg66298
(lp82100
sg66311
(lp82101
(dp82102
g66301
I104
sg66302
I1
sg66303
I8
sg66314
VC0026848
p82103
sg66306
Vmyopathy
p82104
sasa(dp82105
g66296
VAmong the serums assessed, MMA levels showed a positive correlation to TNSr and KNPQ in the IPD patients with peripheral neuropathy (TNSr r = 0.882, p &lt; 0.001, KNPQ r = 0.710, p = 0.004), while Vitamin B12 and homocysteine showed no statistically significant correlation.
p82106
sg66298
(lp82107
sg66311
(lp82108
(dp82109
g66301
I27
sg66302
I1
sg66303
I3
sg66314
VC0276096
p82110
sg66306
VMMA
p82111
sa(dp82112
g66301
I110
sg66302
I2
sg66303
I21
sg66314
VC0031117
p82113
sg66306
Vperipheral neuropathy
p82114
sasa(dp82115
g66296
VThe serum MMA positively correlated with the severity of neuropathic pain and this can be used as a useful marker in assessment of peripheral neuropathy in Parkinson's disease.
p82116
sg66298
(lp82117
sg66311
(lp82118
(dp82119
g66301
I10
sg66302
I1
sg66303
I3
sg66314
VC0276096
p82120
sg66306
VMMA
p82121
sa(dp82122
g66301
I131
sg66302
I2
sg66303
I21
sg66314
VC0031117
p82123
sg66306
Vperipheral neuropathy
p82124
sa(dp82125
g66301
I57
sg66302
I2
sg66303
I16
sg66314
VC0027796
p82126
sg66306
Vneuropathic pain
p82127
sa(dp82128
g66301
I156
sg66302
I2
sg66303
I19
sg66314
VC0030567
p82129
sg66306
VParkinson's disease
p82130
sasa(dp82131
g66296
VFunctional vitamin B12 deficiency, defined by elevated levels of the B12-dependent metabolites, methylmalonic acid (MMA), and/or homocysteine, despite normal B12 values, may cause neuropathy and is associated with disorders linked to increased oxidative stress.
p82132
sg66298
(lp82133
sg66311
(lp82134
(dp82135
g66301
I244
sg66302
I2
sg66303
I16
sg66314
VC0242606
p82136
sg66306
Voxidative stress
p82137
sa(dp82138
g66301
I11
sg66302
I3
sg66303
I22
sg66314
VC0042847
p82139
sg66306
Vvitamin B12 deficiency
p82140
sa(dp82141
g66301
I116
sg66302
I1
sg66303
I3
sg66314
VC0276096
p82142
sg66306
VMMA
p82143
sa(dp82144
g66301
I180
sg66302
I1
sg66303
I10
sg66314
VC0442874
p82145
sg66306
Vneuropathy
p82146
sa(dp82147
g66301
I96
sg66302
I2
sg66303
I18
sg66314
VC0276096
p82148
sg66306
Vmethylmalonic acid
p82149
sasa(dp82150
g66296
VCDC6 and GDF-9 expressions in 108 gallbladder adenocarcinomas, 15 gallbladder polyps, 35 chronic cholecystitis tissues, and 46 peritumoral tissues were detected using immunohistochemistry (IHC).
p82151
sg66298
(lp82152
(dp82153
g66301
I0
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VCDC6
p82154
sa(dp82155
g66301
I9
sg66302
I1
sg66303
I5
sg66304
VP09466
p82156
sg66306
VGDF-9
p82157
sasg66311
(lp82158
(dp82159
g66301
I66
sg66302
I2
sg66303
I18
sg66314
VC0262493
p82160
sg66306
Vgallbladder polyps
p82161
sa(dp82162
g66301
I46
sg66302
I1
sg66303
I15
sg66314
VC0001418
p82163
sg66306
Vadenocarcinomas
p82164
sa(dp82165
g66301
I89
sg66302
I2
sg66303
I21
sg66314
VC0085694
p82166
sg66306
Vchronic cholecystitis
p82167
sasa(dp82168
g66296
VWe demonstrated that positive CDC6 and GDF-9 expressions were significantly higher in adenocarcinomas than that in peritumoral tissues, polyps, and chronic cholecystitis (p &lt; 0.01).
p82169
sg66298
(lp82170
(dp82171
g66301
I30
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VCDC6
p82172
sa(dp82173
g66301
I39
sg66302
I1
sg66303
I5
sg66304
VP09466
p82174
sg66306
VGDF-9
p82175
sasg66311
(lp82176
(dp82177
g66301
I148
sg66302
I2
sg66303
I21
sg66314
VC0085694
p82178
sg66306
Vchronic cholecystitis
p82179
sa(dp82180
g66301
I136
sg66302
I1
sg66303
I6
sg66314
VC0032584
p82181
sg66306
Vpolyps
p82182
sa(dp82183
g66301
I86
sg66302
I1
sg66303
I15
sg66314
VC0001418
p82184
sg66306
Vadenocarcinomas
p82185
sasa(dp82186
g66296
VPreviously, we identified MFAP4 as a serum biomarker candidate for hepatic fibrosis and cirrhosis in hepatitis C patients.
p82187
sg66298
(lp82188
(dp82189
g66301
I26
sg66302
I1
sg66303
I5
sg66304
VP55083
p82190
sg66306
VMFAP4
p82191
sasg66311
(lp82192
(dp82193
g66301
I67
sg66302
I2
sg66303
I16
sg66314
VC0239946
p82194
sg66306
Vhepatic fibrosis
p82195
sa(dp82196
g66301
I88
sg66302
I1
sg66303
I9
sg66314
VC0023890
p82197
sg66306
Vcirrhosis
p82198
sa(dp82199
g66301
I101
sg66302
I2
sg66303
I11
sg66314
VC0019196
p82200
sg66306
Vhepatitis C
p82201
sasa(dp82202
g66296
VThe aim of the present study was to elucidate the potential of MFAP4 as biomarker for hepatic fibrosis with a focus on the differentiation of no to moderate (F0-F2) and severe fibrosis stages and cirrhosis (F3 and F4, Desmet-Scheuer scoring system).
p82203
sg66298
(lp82204
(dp82205
g66301
I63
sg66302
I1
sg66303
I5
sg66304
VP55083
p82206
sg66306
VMFAP4
p82207
sasg66311
(lp82208
(dp82209
g66301
I196
sg66302
I1
sg66303
I9
sg66314
VC0023890
p82210
sg66306
Vcirrhosis
p82211
sa(dp82212
g66301
I86
sg66302
I2
sg66303
I16
sg66314
VC0239946
p82213
sg66306
Vhepatic fibrosis
p82214
sa(dp82215
g66301
I94
sg66302
I1
sg66303
I8
sg66314
VC0016059
p82216
sg66306
Vfibrosis
p82217
sasa(dp82218
g66296
VLinear and logistic multivariate regression analyses were performed and nonparametric receiver operating characteristic-curves for cirrhosis were used to estimate cut-off points for pMFAP4.
p82219
sg66298
(lp82220
sg66311
(lp82221
(dp82222
g66301
I131
sg66302
I1
sg66303
I9
sg66314
VC0023890
p82223
sg66306
Vcirrhosis
p82224
sasa(dp82225
g66296
VMicrofibrillar-associated protein 4 (MFAP4) is a systemic biomarker that is significantly elevated in samples from patients suffering from hepatic cirrhosis.
p82226
sg66298
(lp82227
(dp82228
g66301
I0
sg66302
I3
sg66303
I35
sg66304
VP55083
p82229
sg66306
VMicrofibrillar-associated protein 4
p82230
sa(dp82231
g66301
I37
sg66302
I1
sg66303
I5
sg66304
VP55083
p82232
sg66306
VMFAP4
p82233
sasg66311
(lp82234
(dp82235
g66301
I124
sg66302
I1
sg66303
I9
sg66314
VC0683278
p82236
sg66306
Vsuffering
p82237
sa(dp82238
g66301
I139
sg66302
I2
sg66303
I17
sg66314
VC0023890
p82239
sg66306
Vhepatic cirrhosis
p82240
sasa(dp82241
g66296
VTropomyosin and MFAP-4 demonstrated high serum levels in patients with hepatic cirrhosis of different causes.
p82242
sg66298
(lp82243
(dp82244
g66301
I0
sg66302
I1
sg66303
I11
sg66304
VP07951
p82245
sg66306
VTropomyosin
p82246
sasg66311
(lp82247
(dp82248
g66301
I71
sg66302
I2
sg66303
I17
sg66314
VC0023890
p82249
sg66306
Vhepatic cirrhosis
p82250
sasa(dp82251
g66296
VA quantitative analysis of MFAP-4 serum levels in a large number of patients showed MFAP-4 as novel candidate biomarker with high diagnostic accuracy for prediction of nondiseased liver versus cirrhosis [area under receiver operating characteristic curve (AUC) = 0.97, P &lt; 0.0001] as well as stage 0 versus stage 4 fibrosis (AUC = 0.84, P &lt; 0.0001), and stages 0 to 3 versus stage 4 fibrosis (AUC = 0.76, P &lt; 0.0001).
p82252
sg66298
(lp82253
sg66311
(lp82254
(dp82255
g66301
I318
sg66302
I1
sg66303
I8
sg66314
VC0016059
p82256
sg66306
Vfibrosis
p82257
sa(dp82258
g66301
I318
sg66302
I1
sg66303
I8
sg66314
VC0016059
p82259
sg66306
Vfibrosis
p82260
sa(dp82261
g66301
I193
sg66302
I1
sg66303
I9
sg66314
VC0023890
p82262
sg66306
Vcirrhosis
p82263
sasa(dp82264
g66296
VLow CRF had PARs of 9.3% and 10.5% for cancer mortality in subjects who had overweight and obesity, respectively.
p82265
sg66298
(lp82266
(dp82267
g66301
I4
sg66302
I1
sg66303
I3
sg66304
VP06850
p82268
sg66306
VCRF
p82269
sasg66311
(lp82270
(dp82271
g66301
I4
sg66302
I1
sg66303
I3
sg66314
VC0022661
p82272
sg66306
VCRF
p82273
sa(dp82274
g66301
I39
sg66302
I1
sg66303
I6
sg66314
VC0006826
p82275
sg66306
Vcancer
p82276
sa(dp82277
g66301
I76
sg66302
I3
sg66303
I22
sg66314
VC1561826
p82278
sg66306
Voverweight and obesity
p82279
sasa(dp82280
g66296
VThe population attributable risks (PARs) were 0.41, 0.40 and 0.38 for total, CVD and cancer mortality, accordingly.
p82281
sg66298
(lp82282
sg66311
(lp82283
(dp82284
g66301
I85
sg66302
I1
sg66303
I6
sg66314
VC0006826
p82285
sg66306
Vcancer
p82286
sa(dp82287
g66301
I77
sg66302
I1
sg66303
I3
sg66314
VC0007222
p82288
sg66306
VCVD
p82289
sasa(dp82290
g66296
VMean EARs for lung cancer were 17.5 cases per 10,000 persons per year (PY) and 10.1 PY.
p82291
sg66298
(lp82292
sg66311
(lp82293
(dp82294
g66301
I14
sg66302
I2
sg66303
I11
sg66314
VC0684249
p82295
sg66306
Vlung cancer
p82296
sasa(dp82297
g66296
VMean EARs for breast cancer were 8.2 PY and 2.8 PY.
p82298
sg66298
(lp82299
sg66311
(lp82300
(dp82301
g66301
I14
sg66302
I2
sg66303
I13
sg66314
VC0678222
p82302
sg66306
Vbreast cancer
p82303
sasa(dp82304
g66296
VIn addition, through activation of G-protein-coupled protease activated receptors (PARs) TF induces cell signaling that is related to cancer, angiogenesis and inflammation.
p82305
sg66298
(lp82306
(dp82307
g66301
I83
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VPARs
p82308
sa(dp82309
g66301
I35
sg66302
I4
sg66303
I46
sg66304
VP63123
p82310
sg66306
VG-protein-coupled protease activated receptors
p82311
sasg66311
(lp82312
(dp82313
g66301
I134
sg66302
I1
sg66303
I6
sg66314
VC0006826
p82314
sg66306
Vcancer
p82315
sa(dp82316
g66301
I159
sg66302
I1
sg66303
I12
sg66314
VC0021368
p82317
sg66306
Vinflammation
p82318
sasa(dp82319
g66296
VPARs are implicated in a wide range of diseases, such as cancer and inflammation.
p82320
sg66298
(lp82321
(dp82322
g66301
I0
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VPARs
p82323
sasg66311
(lp82324
(dp82325
g66301
I57
sg66302
I1
sg66303
I6
sg66314
VC0006826
p82326
sg66306
Vcancer
p82327
sa(dp82328
g66301
I68
sg66302
I1
sg66303
I12
sg66314
VC0021368
p82329
sg66306
Vinflammation
p82330
sasa(dp82331
g66296
VThrombin-induced activation of protease-activated receptors (PARs) represents a link between inflammation and cancer.
p82332
sg66298
(lp82333
(dp82334
g66301
I61
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VPARs
p82335
sa(dp82336
g66301
I31
sg66302
I2
sg66303
I28
sg66304
VP63123
p82337
sg66306
Vprotease-activated receptors
p82338
sa(dp82339
g66301
I0
sg66302
I1
sg66303
I8
sg66304
VP00734
p82340
sg66306
VThrombin
p82341
sasg66311
(lp82342
(dp82343
g66301
I93
sg66302
I1
sg66303
I12
sg66314
VC0021368
p82344
sg66306
Vinflammation
p82345
sa(dp82346
g66301
I110
sg66302
I1
sg66303
I6
sg66314
VC0006826
p82347
sg66306
Vcancer
p82348
sasa(dp82349
g66296
VFrozen tunica vaginalis specimens from patients with adult-onset primary hydrocele testis and control male nonhydrocele patients were subjected to Western blot analysis for the detection of AQP1 and AQP3 proteins.
p82350
sg66298
(lp82351
(dp82352
g66301
I190
sg66302
I1
sg66303
I4
sg66304
VP29972
p82353
sg66306
VAQP1
p82354
sa(dp82355
g66301
I199
sg66302
I2
sg66303
I13
sg66304
g11
sg66306
VAQP3 proteins
p82356
sasg66311
(lp82357
(dp82358
g66301
I73
sg66302
I2
sg66303
I16
sg66314
VC1720771
p82359
sg66306
Vhydrocele testis
p82360
sa(dp82361
g66301
I14
sg66302
I1
sg66303
I9
sg66314
VC0750103
p82362
sg66306
Vvaginalis
p82363
sasa(dp82364
g66296
VAQP1 protein expression in the tunica vaginalis was significantly higher in patients with adult-onset hydrocele testis than in the controls.
p82365
sg66298
(lp82366
(dp82367
g66301
I0
sg66302
I1
sg66303
I4
sg66304
VP29972
p82368
sg66306
VAQP1
p82369
sasg66311
(lp82370
(dp82371
g66301
I38
sg66302
I1
sg66303
I9
sg66314
VC0750103
p82372
sg66306
Vvaginalis
p82373
sa(dp82374
g66301
I102
sg66302
I2
sg66303
I16
sg66314
VC1720771
p82375
sg66306
Vhydrocele testis
p82376
sasa(dp82377
g66296
VThe densities of AQP1-expressing capillaries and lymphatic vessels were similar between the tunica vaginalis of the controls and those of hydrocele patients.
p82378
sg66298
(lp82379
(dp82380
g66301
I17
sg66302
I1
sg66303
I4
sg66304
VP29972
p82381
sg66306
VAQP1
p82382
sasg66311
(lp82383
(dp82384
g66301
I99
sg66302
I1
sg66303
I9
sg66314
VC0750103
p82385
sg66306
Vvaginalis
p82386
sa(dp82387
g66301
I138
sg66302
I1
sg66303
I9
sg66314
VC1720771
p82388
sg66306
Vhydrocele
p82389
sasa(dp82390
g66296
VIn conclusion, overexpression of the AQP1 protein in individual capillary endothelial cells of the tunica vaginalis may contribute to the development of adult-onset primary noncommunicating hydrocele testis as another aquaporin-related disease.
p82391
sg66298
(lp82392
(dp82393
g66301
I218
sg66302
I1
sg66303
I9
sg66304
VP30301
p82394
sg66306
Vaquaporin
p82395
sa(dp82396
g66301
I37
sg66302
I2
sg66303
I12
sg66304
VP29972
p82397
sg66306
VAQP1 protein
p82398
sasg66311
(lp82399
(dp82400
g66301
I190
sg66302
I2
sg66303
I16
sg66314
VC1720771
p82401
sg66306
Vhydrocele testis
p82402
sa(dp82403
g66301
I106
sg66302
I1
sg66303
I9
sg66314
VC0750103
p82404
sg66306
Vvaginalis
p82405
sasa(dp82406
g66296
VThere are very few reports in the published literature of abdominal aortic aneurysm in patient with situs inversus totalis, all of whom underwent open aneurysm repair.
p82407
sg66298
(lp82408
sg66311
(lp82409
(dp82410
g66301
I100
sg66302
I2
sg66303
I14
sg66314
VC0037221
p82411
sg66306
Vsitus inversus
p82412
sa(dp82413
g66301
I58
sg66302
I3
sg66303
I25
sg66314
VC0162871
p82414
sg66306
Vabdominal aortic aneurysm
p82415
sa(dp82416
g66301
I75
sg66302
I1
sg66303
I8
sg66314
VC0002940
p82417
sg66306
Vaneurysm
p82418
sasa(dp82419
g66296
VThe authors describe a case of successfully repaired abdominal aortic aneurysm with a false aneurysm of the right external iliac artery in situs inversus totalis.
p82420
sg66298
(lp82421
sg66311
(lp82422
(dp82423
g66301
I139
sg66302
I2
sg66303
I14
sg66314
VC0037221
p82424
sg66306
Vsitus inversus
p82425
sa(dp82426
g66301
I53
sg66302
I3
sg66303
I25
sg66314
VC0162871
p82427
sg66306
Vabdominal aortic aneurysm
p82428
sa(dp82429
g66301
I86
sg66302
I2
sg66303
I14
sg66314
VC1510412
p82430
sg66306
Vfalse aneurysm
p82431
sasa(dp82432
g66296
VThe surgical management of patients with abdominal aortic aneurysm in situs inversus totalis is discussed.
p82433
sg66298
(lp82434
sg66311
(lp82435
(dp82436
g66301
I41
sg66302
I3
sg66303
I25
sg66314
VC0162871
p82437
sg66306
Vabdominal aortic aneurysm
p82438
sa(dp82439
g66301
I70
sg66302
I2
sg66303
I14
sg66314
VC0037221
p82440
sg66306
Vsitus inversus
p82441
sasa(dp82442
g66296
VCollectively, the MLN CD11b- CD103+ PD-L1High DC subset probably takes up luminal antigens in the intestine, migrates to MLNs, and highly induces regulatory T cells through TGF-Beta activation.
p82443
sg66298
(lp82444
(dp82445
g66301
I121
sg66302
I1
sg66303
I4
sg66304
VP12872
p82446
sg66306
VMLNs
p82447
sa(dp82448
g66301
I18
sg66302
I4
sg66303
I27
sg66304
VP12872
p82449
sg66306
VMLN CD11b- CD103+ PD-L1High
p82450
sa(dp82451
g66301
I173
sg66302
I1
sg66303
I8
sg66304
VP18075
p82452
sg66306
VTGF-Beta
p82453
sasg66311
(lp82454
(dp82455
g66301
I121
sg66302
I1
sg66303
I4
sg66314
VC0026691
p82456
sg66306
VMLNs
p82457
sasa(dp82458
g66296
VFurthermore, Ye were found exclusively associated with CD103(+) DCs in the MLNs from wild-type mice, but not from CCR7(-/-) mice, demonstrating a CCR7 dependent transport of Ye by CD103(+) DCs from LP to the MLNs.
p82459
sg66298
(lp82460
(dp82461
g66301
I55
sg66302
I2
sg66303
I12
sg66304
VP38570
p82462
sg66306
VCD103(+) DCs
p82463
sa(dp82464
g66301
I55
sg66302
I2
sg66303
I12
sg66304
VP38570
p82465
sg66306
VCD103(+) DCs
p82466
sa(dp82467
g66301
I114
sg66302
I1
sg66303
I4
sg66304
VP32248
p82468
sg66306
VCCR7
p82469
sa(dp82470
g66301
I114
sg66302
I1
sg66303
I4
sg66304
VP32248
p82471
sg66306
VCCR7
p82472
sasg66311
(lp82473
(dp82474
g66301
I75
sg66302
I1
sg66303
I4
sg66314
VC0026691
p82475
sg66306
VMLNs
p82476
sa(dp82477
g66301
I75
sg66302
I1
sg66303
I4
sg66314
VC0026691
p82478
sg66306
VMLNs
p82479
sa(dp82480
g66301
I64
sg66302
I1
sg66303
I3
sg66314
VC0268238
p82481
sg66306
VDCs
p82482
sa(dp82483
g66301
I64
sg66302
I1
sg66303
I3
sg66314
VC0268238
p82484
sg66306
VDCs
p82485
sasa(dp82486
g66296
VAlthough extensive studies have demonstrated the importance of the mesenteric lymph nodes (MLNs) and intestinal CD103(+) dendritic cells (DCs) in driving small intestinal tolerance to protein antigen, the structural and immunological basis of colonic tolerance remain poorly understood.
p82487
sg66298
(lp82488
sg66311
(lp82489
(dp82490
g66301
I171
sg66302
I1
sg66303
I9
sg66314
VC0020963
p82491
sg66306
Vtolerance
p82492
sa(dp82493
g66301
I67
sg66302
I3
sg66303
I22
sg66314
VC0026691
p82494
sg66306
Vmesenteric lymph nodes
p82495
sa(dp82496
g66301
I138
sg66302
I1
sg66303
I3
sg66314
VC0268238
p82497
sg66306
VDCs
p82498
sa(dp82499
g66301
I91
sg66302
I1
sg66303
I4
sg66314
VC0026691
p82500
sg66306
VMLNs
p82501
sa(dp82502
g66301
I171
sg66302
I1
sg66303
I9
sg66314
VC0020963
p82503
sg66306
Vtolerance
p82504
sa(dp82505
g66301
I121
sg66302
I2
sg66303
I15
sg66314
VC0268238
p82506
sg66306
Vdendritic cells
p82507
sasa(dp82508
g66296
VDespite tolerance development, CD103(+)CD11b(+) DCs, which are the major migratory DC population in the MLNs, and the tolerance-related retinoic acid-generating enzyme RALDH2 were virtually absent from the ILNs.
p82509
sg66298
(lp82510
(dp82511
g66301
I168
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VRALDH2
p82512
sa(dp82513
g66301
I31
sg66302
I2
sg66303
I20
sg66304
VP38570
p82514
sg66306
VCD103(+)CD11b(+) DCs
p82515
sasg66311
(lp82516
(dp82517
g66301
I8
sg66302
I1
sg66303
I9
sg66314
VC0020963
p82518
sg66306
Vtolerance
p82519
sa(dp82520
g66301
I48
sg66302
I1
sg66303
I3
sg66314
VC0268238
p82521
sg66306
VDCs
p82522
sa(dp82523
g66301
I8
sg66302
I1
sg66303
I9
sg66314
VC0020963
p82524
sg66306
Vtolerance
p82525
sa(dp82526
g66301
I104
sg66302
I1
sg66303
I4
sg66314
VC0026691
p82527
sg66306
VMLNs
p82528
sasa(dp82529
g66296
VHere, we demonstrate that GVHD markedly enhances alloantigen presentation within the mesenteric lymph nodes (mLNs), mediated by donor CD103(+)CD11b(-) dendritic cells (DCs) that migrate from the colon under the influence of CCR7.
p82530
sg66298
(lp82531
(dp82532
g66301
I224
sg66302
I1
sg66303
I4
sg66304
VP32248
p82533
sg66306
VCCR7
p82534
sa(dp82535
g66301
I134
sg66302
I1
sg66303
I16
sg66304
VP38570
p82536
sg66306
VCD103(+)CD11b(-)
p82537
sasg66311
(lp82538
(dp82539
g66301
I85
sg66302
I3
sg66303
I22
sg66314
VC0026691
p82540
sg66306
Vmesenteric lymph nodes
p82541
sa(dp82542
g66301
I168
sg66302
I1
sg66303
I3
sg66314
VC0268238
p82543
sg66306
VDCs
p82544
sa(dp82545
g66301
I26
sg66302
I1
sg66303
I4
sg66314
VC0018133
p82546
sg66306
VGVHD
p82547
sa(dp82548
g66301
I109
sg66302
I1
sg66303
I4
sg66314
VC0026691
p82549
sg66306
VmLNs
p82550
sa(dp82551
g66301
I151
sg66302
I2
sg66303
I15
sg66314
VC0268238
p82552
sg66306
Vdendritic cells
p82553
sasa(dp82554
g66296
VCD103(+) dendritic cells (DCs) continuously migrate from the intestine to the mesenteric lymph nodes (MLNs) and maintain tolerance by driving the development of regulatory T cells (Treg) in the gut.
p82555
sg66298
(lp82556
(dp82557
g66301
I0
sg66302
I1
sg66303
I5
sg66304
VP38570
p82558
sg66306
VCD103
p82559
sasg66311
(lp82560
(dp82561
g66301
I26
sg66302
I1
sg66303
I3
sg66314
VC0268238
p82562
sg66306
VDCs
p82563
sa(dp82564
g66301
I78
sg66302
I3
sg66303
I22
sg66314
VC0026691
p82565
sg66306
Vmesenteric lymph nodes
p82566
sa(dp82567
g66301
I121
sg66302
I1
sg66303
I9
sg66314
VC0020963
p82568
sg66306
Vtolerance
p82569
sa(dp82570
g66301
I102
sg66302
I1
sg66303
I4
sg66314
VC0026691
p82571
sg66306
VMLNs
p82572
sa(dp82573
g66301
I9
sg66302
I2
sg66303
I15
sg66314
VC0268238
p82574
sg66306
Vdendritic cells
p82575
sasa(dp82576
g66296
VTreatment with PBS followed by 1 single dose of VSL#3, 18 h before killing, was associated with a 2-fold increase in CD103(+)CD11c(+) dendritic cells in MLNs and PPs.
p82577
sg66298
(lp82578
(dp82579
g66301
I117
sg66302
I1
sg66303
I13
sg66304
VP38570
p82580
sg66306
VCD103(+)CD11c
p82581
sasg66311
(lp82582
(dp82583
g66301
I162
sg66302
I1
sg66303
I3
sg66314
VC0265259
p82584
sg66306
VPPs
p82585
sa(dp82586
g66301
I15
sg66302
I1
sg66303
I3
sg66314
VC1720830
p82587
sg66306
VPBS
p82588
sa(dp82589
g66301
I153
sg66302
I1
sg66303
I4
sg66314
VC0026691
p82590
sg66306
VMLNs
p82591
sasa(dp82592
g66296
VReduced numbers of Th17 cells, suppressed interleukin (IL)-6 production by intestinal explants, and increased Tregs and CD103-positive regulatory dendritic cells in mesenteric lymph nodes (MLNs) were observed.
p82593
sg66298
(lp82594
(dp82595
g66301
I42
sg66302
I2
sg66303
I18
sg66304
VP60568
p82596
sg66306
Vinterleukin (IL)-6
p82597
sa(dp82598
g66301
I120
sg66302
I1
sg66303
I5
sg66304
VP38570
p82599
sg66306
VCD103
p82600
sasg66311
(lp82601
(dp82602
g66301
I189
sg66302
I1
sg66303
I4
sg66314
VC0026691
p82603
sg66306
VMLNs
p82604
sa(dp82605
g66301
I165
sg66302
I3
sg66303
I22
sg66314
VC0026691
p82606
sg66306
Vmesenteric lymph nodes
p82607
sasa(dp82608
g66296
VThus, oral administration of C. kefyr ameliorated EAE by altering the microflora, accompanied by increased Tregs and CD103-positive regulatory dendritic cells in MLNs and decreased Th17 cells in the intestinal lamina propria.
p82609
sg66298
(lp82610
(dp82611
g66301
I117
sg66302
I1
sg66303
I5
sg66304
VP38570
p82612
sg66306
VCD103
p82613
sasg66311
(lp82614
(dp82615
g66301
I162
sg66302
I1
sg66303
I4
sg66314
VC0026691
p82616
sg66306
VMLNs
p82617
sasa(dp82618
g66296
VThe proportion of CD103 DCs in PPs and MLNs and IL-10-expressing CD4 T cells of PPs and the LP increased after indomethacin treatment.
p82619
sg66298
(lp82620
(dp82621
g66301
I31
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPPs
p82622
sa(dp82623
g66301
I31
sg66302
I1
sg66303
I3
sg66304
g11
sg66306
VPPs
p82624
sa(dp82625
g66301
I48
sg66302
I3
sg66303
I22
sg66304
VP01730
p82626
sg66306
VIL-10-expressing CD4 T
p82627
sa(dp82628
g66301
I39
sg66302
I1
sg66303
I4
sg66304
VP12872
p82629
sg66306
VMLNs
p82630
sa(dp82631
g66301
I18
sg66302
I2
sg66303
I9
sg66304
VP38570
p82632
sg66306
VCD103 DCs
p82633
sasg66311
(lp82634
(dp82635
g66301
I31
sg66302
I1
sg66303
I3
sg66314
VC0265259
p82636
sg66306
VPPs
p82637
sa(dp82638
g66301
I24
sg66302
I1
sg66303
I3
sg66314
VC0268238
p82639
sg66306
VDCs
p82640
sa(dp82641
g66301
I31
sg66302
I1
sg66303
I3
sg66314
VC0265259
p82642
sg66306
VPPs
p82643
sa(dp82644
g66301
I39
sg66302
I1
sg66303
I4
sg66314
VC0026691
p82645
sg66306
VMLNs
p82646
sasa(dp82647
g66296
VThe PP-null mice showed greater indomethacin-induced enteropathy, fewer CD103 DCs in their MLNs, and lower proportion of IL-10-expressing CD4 T cells of their LP than WT mice, regardless of commensal bacteria.
p82648
sg66298
(lp82649
(dp82650
g66301
I72
sg66302
I2
sg66303
I9
sg66304
VP38570
p82651
sg66306
VCD103 DCs
p82652
sa(dp82653
g66301
I121
sg66302
I3
sg66303
I22
sg66304
VP01730
p82654
sg66306
VIL-10-expressing CD4 T
p82655
sasg66311
(lp82656
(dp82657
g66301
I53
sg66302
I1
sg66303
I11
sg66314
VC0021831
p82658
sg66306
Venteropathy
p82659
sa(dp82660
g66301
I91
sg66302
I1
sg66303
I4
sg66314
VC0026691
p82661
sg66306
VMLNs
p82662
sa(dp82663
g66301
I78
sg66302
I1
sg66303
I3
sg66314
VC0268238
p82664
sg66306
VDCs
p82665
sasa(dp82666
g66296
VNaive splenic CD4 T cells co-cultured with CD103 DCs isolated from the MLNs of indomethacin-injected WT mice produced a higher amount of IL-10 compared with those co-cultured with CD103 DCs.
p82667
sg66298
(lp82668
(dp82669
g66301
I14
sg66302
I1
sg66303
I3
sg66304
VP01730
p82670
sg66306
VCD4
p82671
sa(dp82672
g66301
I43
sg66302
I2
sg66303
I9
sg66304
VP38570
p82673
sg66306
VCD103 DCs
p82674
sa(dp82675
g66301
I43
sg66302
I2
sg66303
I9
sg66304
VP38570
p82676
sg66306
VCD103 DCs
p82677
sasg66311
(lp82678
(dp82679
g66301
I71
sg66302
I1
sg66303
I4
sg66314
VC0026691
p82680
sg66306
VMLNs
p82681
sa(dp82682
g66301
I49
sg66302
I1
sg66303
I3
sg66314
VC0268238
p82683
sg66306
VDCs
p82684
sa(dp82685
g66301
I49
sg66302
I1
sg66303
I3
sg66314
VC0268238
p82686
sg66306
VDCs
p82687
sasa(dp82688
g66296
VIn rickets, on the other hand, no PTH/PTHrP receptor gene expression was observed in the growth plate from day 8 of a vitamin D-deficient diet.
p82689
sg66298
(lp82690
(dp82691
g66301
I38
sg66302
I3
sg66303
I19
sg66304
VP12272
p82692
sg66306
VPTHrP receptor gene
p82693
sa(dp82694
g66301
I34
sg66302
I1
sg66303
I3
sg66304
VP01270
p82695
sg66306
VPTH
p82696
sasg66311
(lp82697
(dp82698
g66301
I3
sg66302
I1
sg66303
I7
sg66314
VC0035579
p82699
sg66306
Vrickets
p82700
sasa(dp82701
g66296
VThese results suggest that alterations in the PTH/PTHrP receptor gene expression are associated with rickets but not with TD.
p82702
sg66298
(lp82703
(dp82704
g66301
I50
sg66302
I3
sg66303
I19
sg66304
VP12272
p82705
sg66306
VPTHrP receptor gene
p82706
sa(dp82707
g66301
I46
sg66302
I1
sg66303
I3
sg66304
VP01270
p82708
sg66306
VPTH
p82709
sasg66311
(lp82710
(dp82711
g66301
I101
sg66302
I1
sg66303
I7
sg66314
VC0035579
p82712
sg66306
Vrickets
p82713
sasa(dp82714
g66296
VThe reduction in the PTH/PTHrP receptor gene expression in rickets may be due to the high plasma levels of PTH.
p82715
sg66298
(lp82716
(dp82717
g66301
I21
sg66302
I1
sg66303
I3
sg66304
VP01270
p82718
sg66306
VPTH
p82719
sa(dp82720
g66301
I25
sg66302
I3
sg66303
I19
sg66304
VP12272
p82721
sg66306
VPTHrP receptor gene
p82722
sa(dp82723
g66301
I21
sg66302
I1
sg66303
I3
sg66304
VP01270
p82724
sg66306
VPTH
p82725
sasg66311
(lp82726
(dp82727
g66301
I59
sg66302
I1
sg66303
I7
sg66314
VC0035579
p82728
sg66306
Vrickets
p82729
sasa(dp82730
g66296
VWhat is more important is that the depressed-expression of Cav1.3 paralleled with enhanced-expression of Snapin was documented in atrial samples from atrial fibrillation (AF) patients.
p82731
sg66298
(lp82732
(dp82733
g66301
I105
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VSnapin
p82734
sa(dp82735
g66301
I59
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCav1.3
p82736
sasg66311
(lp82737
(dp82738
g66301
I171
sg66302
I1
sg66303
I2
sg66314
VC0004238
p82739
sg66306
VAF
p82740
sa(dp82741
g66301
I150
sg66302
I2
sg66303
I19
sg66314
VC0004238
p82742
sg66306
Vatrial fibrillation
p82743
sasa(dp82744
g66296
VFurthermore, inactivation of Cav1.3 channels promotes also atrial fibrillation and flutter in knockout mice suggesting that these channels can play a role in stabilizing atrial rhythm.
p82745
sg66298
(lp82746
(dp82747
g66301
I29
sg66302
I2
sg66303
I15
sg66304
g11
sg66306
VCav1.3 channels
p82748
sasg66311
(lp82749
(dp82750
g66301
I59
sg66302
I4
sg66303
I31
sg66314
VC0155709
p82751
sg66306
Vatrial fibrillation and flutter
p82752
sa(dp82753
g66301
I13
sg66302
I1
sg66303
I12
sg66314
VC0544461
p82754
sg66306
Vinactivation
p82755
sasa(dp82756
g66296
VThe significance of the tissue-specific expression of the channel is underpinned by our previous demonstration of atrial fibrillation in a Cav1.3 null mutant mouse model.
p82757
sg66298
(lp82758
(dp82759
g66301
I139
sg66302
I1
sg66303
I6
sg66304
g11
sg66306
VCav1.3
p82760
sasg66311
(lp82761
(dp82762
g66301
I151
sg66302
I1
sg66303
I6
sg66314
VC0596988
p82763
sg66306
Vmutant
p82764
sa(dp82765
g66301
I114
sg66302
I2
sg66303
I19
sg66314
VC0004238
p82766
sg66306
Vatrial fibrillation
p82767
sasa(dp82768
g66296
VMRS studies (MRI 1.5 T unit) were performed in 49 patients with schizophrenia (30 with auditory hallucinations and 19 without auditory hallucinations) and 37 controls.
p82769
sg66298
(lp82770
sg66311
(lp82771
(dp82772
g66301
I87
sg66302
I2
sg66303
I23
sg66314
VC0233762
p82773
sg66306
Vauditory hallucinations
p82774
sa(dp82775
g66301
I64
sg66302
I1
sg66303
I13
sg66314
VC0036341
p82776
sg66306
Vschizophrenia
p82777
sa(dp82778
g66301
I87
sg66302
I2
sg66303
I23
sg66314
VC0233762
p82779
sg66306
Vauditory hallucinations
p82780
sa(dp82781
g66301
I0
sg66302
I1
sg66303
I3
sg66314
VC0025235
p82782
sg66306
VMRS
p82783
sasa(dp82784
g66296
VAs a first step towards understanding the role of OPN in retinal degeneration (RD), we examined changes in OPN expression in a mouse model of RD induced by exposure to a blue light-emitting diode (LED).
p82785
sg66298
(lp82786
(dp82787
g66301
I50
sg66302
I1
sg66303
I3
sg66304
VP10451
p82788
sg66306
VOPN
p82789
sasg66311
(lp82790
(dp82791
g66301
I57
sg66302
I2
sg66303
I20
sg66314
VC0035304
p82792
sg66306
Vretinal degeneration
p82793
sa(dp82794
g66301
I79
sg66302
I1
sg66303
I2
sg66314
VC0035304
p82795
sg66306
VRD
p82796
sa(dp82797
g66301
I79
sg66302
I1
sg66303
I2
sg66314
VC0035304
p82798
sg66306
VRD
p82799
sasa(dp82800
g66296
VSimilarly, those who had retinal disease had higher osteopontin concentrations than those without (16.8+/-2 vs. 12.4+/-3 mg/L; p=0.005).
p82801
sg66298
(lp82802
(dp82803
g66301
I52
sg66302
I1
sg66303
I11
sg66304
VP10451
p82804
sg66306
Vosteopontin
p82805
sasg66311
(lp82806
(dp82807
g66301
I25
sg66302
I2
sg66303
I15
sg66314
VC0035309
p82808
sg66306
Vretinal disease
p82809
sasa(dp82810
g66296
VWe investigated the expression of S100A4 and correlated it with clinical disease activity as well as with the levels of osteopontin (OPN), soluble syndecan-1, and vascular endothelial growth factor (VEGF) in proliferative diabetic retinopathy (PDR).
p82811
sg66298
(lp82812
(dp82813
g66301
I199
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VVEGF
p82814
sa(dp82815
g66301
I34
sg66302
I1
sg66303
I6
sg66304
VP26447
p82816
sg66306
VS100A4
p82817
sa(dp82818
g66301
I163
sg66302
I4
sg66303
I34
sg66304
g11
sg66306
Vvascular endothelial growth factor
p82819
sa(dp82820
g66301
I120
sg66302
I1
sg66303
I11
sg66304
VP10451
p82821
sg66306
Vosteopontin
p82822
sa(dp82823
g66301
I147
sg66302
I1
sg66303
I10
sg66304
VP18827
p82824
sg66306
Vsyndecan-1
p82825
sa(dp82826
g66301
I133
sg66302
I1
sg66303
I3
sg66304
VP10451
p82827
sg66306
VOPN
p82828
sasg66311
(lp82829
(dp82830
g66301
I208
sg66302
I3
sg66303
I34
sg66314
VC0154830
p82831
sg66306
Vproliferative diabetic retinopathy
p82832
sa(dp82833
g66301
I244
sg66302
I1
sg66303
I3
sg66314
VC0154830
p82834
sg66306
VPDR
p82835
sasa(dp82836
g66296
VRecent studies show overexpressed ENAH in several cancer types, and ENAH correlates with tumor invasiveness.
p82837
sg66298
(lp82838
(dp82839
g66301
I34
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VENAH
p82840
sasg66311
(lp82841
(dp82842
g66301
I50
sg66302
I1
sg66303
I6
sg66314
VC0006826
p82843
sg66306
Vcancer
p82844
sa(dp82845
g66301
I89
sg66302
I1
sg66303
I5
sg66314
VC0027651
p82846
sg66306
Vtumor
p82847
sasa(dp82848
g66296
VThis study aimed to investigate the expression and function of ENAH in primary gastric adenocarcinoma, and its prognostic significance.
p82849
sg66298
(lp82850
(dp82851
g66301
I63
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VENAH
p82852
sasg66311
(lp82853
(dp82854
g66301
I79
sg66302
I2
sg66303
I22
sg66314
VC0278701
p82855
sg66306
Vgastric adenocarcinoma
p82856
sasa(dp82857
g66296
VWe found significantly increased mRNA (P = 0.0283) and protein (P = 0.0301) expression of ENAH in gastric cancer tissues.
p82858
sg66298
(lp82859
(dp82860
g66301
I90
sg66302
I1
sg66303
I4
sg66304
g11
sg66306
VENAH
p82861
sasg66311
(lp82862
(dp82863
g66301
I98
sg66302
I2
sg66303
I14
sg66314
VC0024623
p82864
sg66306
Vgastric cancer
p82865
sasa.